﻿FN Clarivate Analytics Web of Science
VR 1.0
PT J
AU Piermarocchi, S
   Tognetto, D
   Piermarocchi, R
   Masetto, M
   Monterosso, G
   Segato, T
   Cavarzeran, F
   Turrini, A
   Peto, T
AF Piermarocchi, Stefano
   Tognetto, Daniele
   Piermarocchi, Rita
   Masetto, Morena
   Monterosso, Gianluca
   Segato, Tatiana
   Cavarzeran, Fabiano
   Turrini, Aida
   Peto, Tunde
CA PAMDI Study Grp
TI Risk Factors and Age-Related Macular Degeneration in a
   Mediterranean-Basin Population: The PAMDI (Prevalence of Age-Related
   Macular Degeneration in Italy) Study - Report 2
SO OPHTHALMIC RESEARCH
LA English
DT Article
DE Age-related macular degeneration; Prevalence of age-related macular
   degeneration; Risk factors of age-related macular degeneration; Food
   frequency questionnaire; Smoking habit; Alcohol consumption; Raman
   spectroscopy; Lutein; Carotenoids
ID CIGARETTE-SMOKING; UNITED-STATES; EYE; MACULOPATHY; PROGRESSION;
   ASSOCIATION; PIGMENT; TROMSO; ADULTS; DIET
AB Aim: To investigate the association of diet and other modifiable risk factors with the prevalence of age-related macular degeneration (ARMD) in rural and urban communities of a Mediterranean population in the northeast of Italy. Methods: A cross-sectional population-based study was conducted among subjects aged over 60 years. A food frequency questionnaire (FFQ) was used to assess the consumption of different food categories, i.e., protective (P), risky (R), lutein-rich (L) and neutral (N). Smoking habit and alcohol intake were also examined. Macular pigment was measured by Raman spectroscopy. Results: P food intake reduced the risk of large drusen (ARM2; OR 0.93; 95% CI 0.89-0.96) within the rural community. In this sub-group, R foods resulted in a slight association with large drusen, though the R/P food ratio was highly correlated with ARM2 (OR 1.21; 95% CI 1.12-1.31). Raman measures showed an age-dependent decrease but did not correlate with lutein intake. Smoking habit showed a positive association with ARM2 among women (OR 2.40; 95% CI 1.54-3.75), whereas alcohol consumption resulted in protective odds (OR 0.72; 95% CI 0.60-0.86). Conclusion: FFQ analysis confirmed the role of P and R foods and the benefit of a Mediterranean diet in ARMD. Moderate alcohol consumption showed a beneficial effect, whereas the deleterious role of a smoking habit was more evident in females. (C) 2015 S. Karger AG, Basel
C1 [Piermarocchi, Stefano; Segato, Tatiana; Cavarzeran, Fabiano] Univ Padua, Padua, Italy.
   [Tognetto, Daniele; Piermarocchi, Rita] Univ Trieste, Trieste, Italy.
   [Masetto, Morena] Abano Terme Hosp, Abano Terme, Italy.
   [Monterosso, Gianluca] Schio Civil Hosp, Schio, Italy.
   [Turrini, Aida] CRA NUT, Res Ctr Food & Nutr, Agr Res Council, Rome, Italy.
   [Peto, Tunde] Moorfields Eye Hosp NHS Fdn Trust, NIHR BMRC, London, England.
   [Peto, Tunde] UCL Inst Ophthalmol, London, England.
C3 University of Padua; University of Trieste; Consiglio per la Ricerca in
   Agricoltura e L'analisi Dell'economia Agraria (CREA); University of
   London; University College London; Moorfields Eye Hospital NHS
   Foundation Trust; University of London; University College London
RP Piermarocchi, S (通讯作者)，Univ Padua, Dept Ophthalmol, Via Giustiniani 2, IT-35128 Padua, Italy.
EM stefano.piermarocchi@unipd.it
RI TURRINI, AIDA/P-2413-2019; Peto, Tunde/G-8812-2018
OI TURRINI, AIDA/0000-0002-2188-9406; Peto, Tunde/0000-0001-6265-0381;
   Tognetto, Daniele/0000-0001-7197-7765
CR Adams MKM, 2012, AM J EPIDEMIOL, V176, P289, DOI 10.1093/aje/kws004
   Andersen MVN, 2008, OPHTHALMOLOGY, V115, P700, DOI 10.1016/j.ophtha.2007.12.013
   [Anonymous], 2013, JAMA, V309, P2005
   [Anonymous], 2009, MMWR MORB MORTAL WKL, V58, P1232
   August CA, 2006, ARCH OPHTHALMOL-CHIC, V124, P529
   Bernstein PS, 2012, INVEST OPHTH VIS SCI, V53, P6178, DOI 10.1167/iovs.12-10275
   Bernstein PS, 2010, VISION RES, V50, P716, DOI 10.1016/j.visres.2009.10.014
   Bernstein PS, 1998, INVEST OPHTH VIS SCI, V39, P2003
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Chang MA, 2008, INVEST OPHTH VIS SCI, V49, P2395, DOI 10.1167/iovs.07-1584
   Chong EWT, 2008, AM J OPHTHALMOL, V145, P707, DOI 10.1016/j.ajo.2007.12.005
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   Erke MG, 2014, ACTA OPHTHALMOL, V92, P662, DOI 10.1111/aos.12346
   Erke MG, 2013, BRIT J OPHTHALMOL, V97, P1036, DOI 10.1136/bjophthalmol-2012-302461
   Evans JR, 2014, OPHTHAL PHYSL OPT, V34, P390, DOI 10.1111/opo.12142
   Feskanich D, 2008, ARCH OPHTHALMOL-CHIC, V126, P519, DOI 10.1001/archopht.126.4.519
   Haan MN, 2006, ARCH OPHTHALMOL-CHIC, V124, P988, DOI 10.1001/archopht.124.7.988
   Hogg RE, 2015, INVEST OPHTH VIS SCI, V56
   Jonasson F, 2003, ARCH OPHTHALMOL-CHIC, V121, P379, DOI 10.1001/archopht.121.3.379
   Klein R, 2004, AM J OPHTHALMOL, V137, P486, DOI 10.1016/j.ajo.2003.11.069
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Kurinij N, 1988, INT C DIET ASS METH
   Merle BMJ, 2015, INVEST OPHTH VIS SCI, V56
   MITCHELL P, 1995, OPHTHALMOLOGY, V102, P1450
   Myers CE, 2014, OPHTHALMOLOGY, V121, P1949, DOI 10.1016/j.ophtha.2014.04.040
   Neelam K, 2005, INVEST OPHTH VIS SCI, V46, P1023, DOI 10.1167/iovs.04-1032
   Piermarocchi S, 2011, OPHTHAL EPIDEMIOL, V18, P129, DOI 10.3109/09286586.2011.574334
   Ross RJ, 2007, EXPERT REV OPHTHALMO, V2, P443, DOI 10.1586/17469899.2.3.443
   Seddon JM, 2005, ARCH OPHTHALMOL-CHIC, V123, P321, DOI 10.1001/archopht.123.3.321
   Seddon JM, 2007, JAMA-J AM MED ASSOC, V297, P1793, DOI 10.1001/jama.297.16.1793
   Thornton J, 2005, EYE, V19, P935, DOI 10.1038/sj.eye.6701978
   VINGERLING JR, 1995, OPHTHALMOLOGY, V102, P205
   Zarbin MA, 2004, ARCH OPHTHALMOL-CHIC, V122, P598, DOI 10.1001/archopht.122.4.598
NR 33
TC 7
Z9 7
U1 0
U2 12
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 0030-3747
EI 1423-0259
J9 OPHTHALMIC RES
JI Ophthalmic Res.
PY 2016
VL 55
IS 3
BP 111
EP 118
DI 10.1159/000441795
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA DD1IF
UT WOS:000369673800001
PM 26666641
DA 2022-11-30
ER

PT J
AU Chandramohan, A
   Stinnett, SS
   Petrowski, JT
   Schuman, SG
   Toth, CA
   Cousins, SW
   Lad, EM
AF Chandramohan, Arthika
   Stinnett, Sandra S.
   Petrowski, John T.
   Schuman, Stefanie G.
   Toth, Cynthia A.
   Cousins, Scott W.
   Lad, Eleonora M.
TI VISUAL FUNCTION MEASURES IN EARLY AND INTERMEDIATE AGE-RELATED MACULAR
   DEGENERATION
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE age-related macular degeneration; visual function testing; low vision;
   microperimetry; low light visual acuity; low light deficit; contrast
   sensitivity
ID TEST-RETEST VARIABILITY; BEAVER-DAM EYE; GEOGRAPHIC ATROPHY;
   LOW-LUMINANCE; CONTRAST SENSITIVITY; COMPUTERIZED METHOD; TESTING
   PROTOCOL; DARK-ADAPTATION; COLOR-VISION; ACUITY LOSS
AB Purpose: The objectives of this study were to evaluate 1) the feasibility of performing computerized tests of low luminance visual acuity (LLVA), cone-specific contrast (Cone Contrast Test [CCT]), contrast sensitivity, and microperimetry and 2) the test-retest repeatability of these outcomes in dry age-related macular degeneration (AMD).
   Methods: This prospective study enrolled 30 subjects at a single site (8 controls, 8 early AMD, and 12 intermediate AMD). Subjects underwent LLVA, contrast sensitivity, CCT, and microperimetry with eye tracking. Low luminance deficit was defined as best-corrected visual acuity minus LLVA in EDTRS letters. Follow-up testing was administered at approximately 1 month.
   Results: There was high test-retest repeatability at one month for all visual function metrics (intraclass correlations >0.7) except log contrast sensitivity (intraclass correlations 0.6). Compared with controls, patients with intermediate AMD showed significant deficits on best-corrected visual acuity, LLVA, low luminance deficit, percent-reduced threshold on microperimetry, and red CCT (P < 0.05), but not on contrast sensitivity, green and blue CCT.
   Conclusion: This pilot study supports the feasibility and reliability of using LLVA, microperimetry, and CCT in early dry AMD. Our data suggest these measures can be used as alternative future clinical trial endpoints. A larger, prospective natural history study of alternative visual function measures in dry AMD is warranted.
C1 [Chandramohan, Arthika; Stinnett, Sandra S.; Petrowski, John T.; Schuman, Stefanie G.; Toth, Cynthia A.; Cousins, Scott W.; Lad, Eleonora M.] Duke Univ, Med Ctr, Dept Ophthalmol, DUMC 3802, Durham, NC 27710 USA.
C3 Duke University
RP Lad, EM (通讯作者)，Duke Univ, Med Ctr, Dept Ophthalmol, DUMC 3802, Durham, NC 27710 USA.
EM nora.lad@duke.edu
RI Toth, Cynthia/L-5534-2019
OI Toth, Cynthia/0000-0002-2324-0854; Stinnett, Sandra/0000-0001-7192-0195
FU NEI [NIH/NEI 5K12 EY016333-08]; NATIONAL EYE INSTITUTE [K12EY016333]
   Funding Source: NIH RePORTER
FX Eleonora Lad was supported by the NEI Clinical Scientist Development
   award NIH/NEI 5K12 EY016333-08.
CR Anastasakis A, 2011, EYE, V25, P245, DOI 10.1038/eye.2010.158
   Beck RW, 2003, AM J OPHTHALMOL, V135, P194, DOI 10.1016/S0002-9394(02)01825-1
   Beckerman H, 2001, QUAL LIFE RES, V10, P571, DOI 10.1023/A:1013138911638
   BRESSLER NM, 1995, OPHTHALMOLOGY, V102, P1206, DOI 10.1016/S0161-6420(95)30889-5
   Bunce C, 2009, AM J OPHTHALMOL, V148, P4, DOI 10.1016/j.ajo.2008.09.032
   Chen FK, 2009, INVEST OPHTH VIS SCI, V50, P3464, DOI 10.1167/iovs.08-2926
   Dimitrov PN, 2011, INVEST OPHTH VIS SCI, V52, P9457, DOI 10.1167/iovs.10-7043
   Faria BM, 2015, RETINA-J RET VIT DIS, V35, P1465, DOI 10.1097/IAE.0000000000000474
   Feigl B, 2004, CURR EYE RES, V29, P327, DOI 10.1080/02713680490516198
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Gregori NZ, 2010, RETINA-J RET VIT DIS, V30, P1046, DOI 10.1097/IAE.0b013e3181d87e04
   HaegerstromPortnoy G, 1997, INVEST OPHTH VIS SCI, V38, P207
   Hogg RE, 2006, PROG RETIN EYE RES, V25, P249, DOI 10.1016/j.preteyeres.2005.11.002
   Holz F G, 1995, Ger J Ophthalmol, V4, P336
   Jackson GR, 2014, OPTOMETRY VISION SCI, V91, P925, DOI 10.1097/OPX.0000000000000247
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P1527
   Klein R, 2008, AM J OPHTHALMOL, V146, P692, DOI 10.1016/j.ajo.2008.05.050
   Klein R, 2013, INVEST OPHTH VIS SCI, V54, DOI 10.1167/iovs.13-12789
   Kovach JL, 2012, J OPHTHALMOL, V2012, DOI 10.1155/2012/786870
   Lesmes LA, 2013, DRUG DISCOV TODAY TH, V2013, pe1
   Lindblad AS, 2009, ARCH OPHTHALMOL-CHIC, V127, P1168, DOI 10.1001/archophthalmol.2009.198
   LOSHIN DS, 1984, ARCH OPHTHALMOL-CHIC, V102, P1303, DOI 10.1001/archopht.1984.01040031053022
   Malek G, 2014, CELL MOL LIFE SCI, V71, P4617, DOI 10.1007/s00018-014-1709-x
   McAlinden C, 2011, OPHTHAL PHYSL OPT, V31, P330, DOI 10.1111/j.1475-1313.2011.00851.x
   Moke PS, 2001, AM J OPHTHALMOL, V132, P903, DOI 10.1016/S0002-9394(01)01256-9
   Neelam K, 2009, SURV OPHTHALMOL, V54, P167, DOI 10.1016/j.survophthal.2008.12.003
   Owsley C, 2006, INVEST OPHTH VIS SCI, V47, P528, DOI 10.1167/iovs.05-1222
   Puell MC, 2012, INVEST OPHTH VIS SCI, V53, P7310, DOI 10.1167/iovs.11-8649
   Rabin J, 2004, VISUAL NEUROSCI, V21, P483, DOI 10.1017/S0952523804213128
   Rabin J, 2011, INVEST OPHTH VIS SCI, V52, P816, DOI 10.1167/iovs.10-6283
   Rein DB, 2009, ARCH OPHTHALMOL-CHIC, V127, P533, DOI 10.1001/archophthalmol.2009.58
   Seddon J, 2001, RETINA-J RET VIT DIS, P1039
   STEINMETZ RL, 1993, BRIT J OPHTHALMOL, V77, P549, DOI 10.1136/bjo.77.9.549
   Sunness JS, 2008, OPHTHALMOLOGY, V115, P1480, DOI 10.1016/j.ophtha.2008.03.009
   Sunness JS, 1997, OPHTHALMOLOGY, V104, P1677, DOI 10.1016/S0161-6420(97)30079-7
   Sunness JS, 1999, OPHTHALMOLOGY, V106, P1768, DOI 10.1016/S0161-6420(99)90340-8
   Weingessel B, 2009, EYE, V23, P1052, DOI 10.1038/eye.2008.237
   Wu ZC, 2015, JAMA OPHTHALMOL, V133, P442, DOI 10.1001/jamaophthalmol.2014.5963
   Wu ZC, 2014, OPHTHALMOLOGY, V121, P1612, DOI 10.1016/j.ophtha.2014.02.005
   Wu ZC, 2013, INVEST OPHTH VIS SCI, V54, P7378, DOI 10.1167/iovs.13-12617
NR 40
TC 37
Z9 37
U1 0
U2 17
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD MAY
PY 2016
VL 36
IS 5
BP 1021
EP 1031
DI 10.1097/IAE.0000000000001002
PG 11
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA DL2RG
UT WOS:000375482100031
PM 26925551
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Friedman, DA
   Lukiw, WJ
   Hill, JM
AF Friedman, Duncan A.
   Lukiw, Walter J.
   Hill, James M.
TI Apolipoprotein E epsilon 4 offers protection against age-related macular
   degeneration
SO MEDICAL HYPOTHESES
LA English
DT Article
ID E GENE; DRUSEN; ASSOCIATION; ATHEROSCLEROSIS; POLYMORPHISMS;
   PATHOGENESIS; CHOLESTEROL; ALLELES
AB Background: In many previous studies, age-related macular degeneration (ARMD) has been linked to a variety of different risk factors. they publications have debated whether apolipoprotein E (apoE) epsilon 4 serves as a potential protective factor in the development of the disease. Other studies have classified the behavior of this protein in different pathologies, including Alzheimer's disease (AD) and cardiovascular disease. The general behavior of the epsilon 4 isoform of ApoE is different than the predominant epsilon 3 isoform.
   Hypothesis: We propose that the general characteristics and molecular behavior of apoE epsilon 4 cause it to be a protective factor against the development of ARMD by preventing cumulative effects of oxidative retinal damage.
   Evaluation of Hypothesis: Review of the literature related to ARMD and ApoE, using OVID as our main database, led to the development of several theories regarding ApoE epsilon 4's behavior compared to epsilon 3 and potential explanation of its protective characteristics.
   Consequences of Hypothesis: We relate these theories to the potential behavior of ApoE epsilon 4 in other situations including choroidal neovascularization, Alzheimer's Disease (AD), cardiovascular disease, herpes simplex virus infection, and smoking.
   Discussion: The potential implications of this theory could be used as a branching point for further studies that examine the role of the different apoE isoforms, in relation to the other risk factors for ARMD. (c) 2006 Elsevier Ltd. All rights reserved.
C1 Louisiana State Univ, Ctr Eye, Hlth Sci Ctr, Dept Ophthalmol, New Orleans, LA 70112 USA.
   Louisiana State Univ, Ctr Neurosci, Hlth Sci Ctr, New Orleans, LA 70112 USA.
   Louisiana State Univ, Dept Pharmacol, Hlth Sci Ctr, New Orleans, LA 70112 USA.
   Louisiana State Univ, Dept Microbiol, Hlth Sci Ctr, New Orleans, LA 70112 USA.
C3 Louisiana State University System; Louisiana State University Health
   Sciences Center New Orleans; Louisiana State University System;
   Louisiana State University Health Sciences Center New Orleans; Louisiana
   State University System; Louisiana State University Health Sciences
   Center New Orleans; Louisiana State University System; Louisiana State
   University Health Sciences Center New Orleans
RP Hill, JM (通讯作者)，Louisiana State Univ, Ctr Eye, Hlth Sci Ctr, Dept Ophthalmol, 2020 Gravier St,Suite B, New Orleans, LA 70112 USA.
EM jhill@lsuhsc.edu
FU NEI NIH HHS [R01 EY006311, EY02377, EY-006311, P30 EY002377] Funding
   Source: Medline; NIA NIH HHS [R01 AG023085, AG-18031, R01 AG023055,
   AG-23055, R01 AG018031] Funding Source: Medline; NATIONAL EYE INSTITUTE
   [R01EY006311, P30EY002377] Funding Source: NIH RePORTER; NATIONAL
   INSTITUTE ON AGING [R01AG018031, R01AG023085, R01AG023055] Funding
   Source: NIH RePORTER
CR Anderson DH, 2004, EXP EYE RES, V78, P243, DOI 10.1016/j.exer.2003.10.011
   Anderson DH, 2001, AM J OPHTHALMOL, V131, P767, DOI 10.1016/S0002-9394(00)00961-2
   Baird PN, 2004, INVEST OPHTH VIS SCI, V45, P1311, DOI 10.1167/iovs.03-1121
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   Dithmar S, 2000, INVEST OPHTH VIS SCI, V41, P2035
   FINE SL, 2000, DRUG THER, V342, P483
   Frank A, 2002, J NEUROL SCI, V203, P173, DOI 10.1016/S0022-510X(02)00286-1
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Gotoh N, 2004, AM J OPHTHALMOL, V138, P567, DOI 10.1016/j.ajo.2004.05.025
   Haddad S, 2006, SURV OPHTHALMOL, V51, P316, DOI 10.1016/j.survophthal.2006.05.001
   Hill JM, 2005, MED HYPOTHESES, V64, P53, DOI 10.1016/j.mehy.2003.12.058
   Johnson LV, 2002, P NATL ACAD SCI USA, V99, P11830, DOI 10.1073/pnas.192203399
   Jun G, 2005, INVEST OPHTH VIS SCI, V46, P3081, DOI 10.1167/iovs.04-1360
   Klaver CCW, 1998, AM J HUM GENET, V63, P200, DOI 10.1086/301901
   Langheinrich AC, 2006, ARTERIOSCL THROM VAS, V26, P347, DOI 10.1161/01.ATV.0000196565.38679.6d
   Li CM, 2006, INVEST OPHTH VIS SCI, V47, P3119, DOI 10.1167/iovs.05-1446
   Lukiw WJ, 2006, EXPERT REV NEUROTHER, V6, P683, DOI 10.1586/14737175.6.5.683
   Lynch JR, 2005, EXP NEUROL, V192, P109, DOI 10.1016/j.expneurol.2004.11.014
   Mahley RW, 2006, P NATL ACAD SCI USA, V103, P5644, DOI 10.1073/pnas.0600549103
   Malek G, 2005, P NATL ACAD SCI USA, V102, P11900, DOI 10.1073/pnas.0503015102
   MARTIDIS A, 2004, OPHTHALMOLOGY, P925
   MOIR RD, 2006, ALZHEIMERS DEMENTIA
   Mullins RF, 2000, FASEB J, V14, P835, DOI 10.1096/fasebj.14.7.835
   Ong JM, 2001, INVEST OPHTH VIS SCI, V42, P1891
   Schmidt S, 2000, MOL VIS, V6, P287
   Schultz DW, 2003, ARCH OPHTHALMOL-CHIC, V121, P679, DOI 10.1001/archopht.121.5.679
   Souied EH, 1998, AM J OPHTHALMOL, V125, P353, DOI 10.1016/S0002-9394(99)80146-9
   Thornton J, 2005, EYE, V19, P935, DOI 10.1038/sj.eye.6701978
   Wong TY, 2006, OPHTHALMOLOGY, V113, P255, DOI 10.1016/j.ophtha.2005.10.048
   Zareparsi S, 2004, INVEST OPHTH VIS SCI, V45, P1306, DOI 10.1167/iovs.03-1253
NR 30
TC 8
Z9 8
U1 0
U2 2
PU CHURCHILL LIVINGSTONE
PI EDINBURGH
PA JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1-3 BAXTERS PLACE,
   LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND
SN 0306-9877
EI 1532-2777
J9 MED HYPOTHESES
JI Med. Hypotheses
PY 2007
VL 68
IS 5
BP 1047
EP 1055
DI 10.1016/j.mehy.2006.09.049
PG 9
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine
GA 157EL
UT WOS:000245701300022
PM 17141963
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Arrigo, A
   Aragona, E
   Battaglia, O
   Saladino, A
   Amato, A
   Borghesan, F
   Pina, A
   Calcagno, F
   Farah, RH
   Bandello, F
   Parodi, MB
AF Arrigo, Alessandro
   Aragona, Emanuela
   Battaglia, Ottavia
   Saladino, Andrea
   Amato, Alessia
   Borghesan, Federico
   Pina, Adelaide
   Calcagno, Francesca
   Farah, Rashid Hassan
   Bandello, Francesco
   Parodi, Maurizio Battaglia
TI Outer retinal tubulation formation and clinical course of advanced
   age-related macular degeneration
SO SCIENTIFIC REPORTS
LA English
DT Article
ID OPTICAL-COHERENCE-TOMOGRAPHY; GEOGRAPHIC ATROPHY
AB Outer retinal tubulations (ORT) are a relatively new finding characterizing outer retinal atrophy. The main aim of the present study was to describe ORT development in advanced age-related macular degeneration (AMD) and to assess its relationship with disease's severity. Patients with advanced AMD characterized either by macular neovascularization or geographic atrophy, showing signs of outer retinal disruption or retinal pigment epithelium atrophy on structural optical coherence tomography (OCT) at the inclusion examination were prospectively recruited. All the patients underwent complete ophthalmologic evaluation, structural OCT scans and fundus autofluorescence imaging. The planned follow-up was of 3-years. Main outcome measures were ORT prevalence, mechanism of ORT formation, mean time needed for complete ORT formation, best-corrected visual acuity (BCVA), definitely decreased autofluorescence (DDAF) area, questionably decreased autofluorescence (QDAF) area, retinal layer thickness, foveal sparing, number of intravitreal injections. We also assessed the possible role of external limiting membrane (ELM) and Muller cells in ORT pathogenesis. Seventy eyes (70 patients) were included; 43 showed dry AMD evolving to geographic atrophy, while 27 displayed the features of wet AMD. Baseline BCVA was 0.5 +/- 0.5 LogMAR, decreasing to 0.9 +/- 0.5 LogMAR at the 3-year follow-up (p<0.01). We detected completely formed ORT in 26/70 eyes (37%), subdivided as follows: 20 eyes (77%) wet AMD and 6 eyes (23%) dry AMD (p<0.01). ORT took 18 +/- 8 months (range 3-35 months) to develop fully. We described the steps leading to ORT development, characterized by progressive involvement of, and damage to the photoreceptors, the ELM and the RPE. Eyes displaying ORT were associated with a smaller QDAF area, less retinal layers damage and lower rate of foveal sparing than eyes free of ORT (p<0.01). We also described pigment accumulations simulating ORT, which were detected in 16/70 eyes (23%), associated with a greater loss of foveal sparing, increased DDAF area and smaller QDAF area at the 3-year follow-up (p<0.01). In conclusion, this study provided a description of the steps leading to ORT development in AMD. ELM and Muller cells showed a role in ORT pathogenesis. Furthermore, we described a subtype of pigment hypertrophy mimicking ORT, evaluating its clinical utility.
C1 [Arrigo, Alessandro; Aragona, Emanuela; Battaglia, Ottavia; Saladino, Andrea; Amato, Alessia; Borghesan, Federico; Pina, Adelaide; Calcagno, Francesca; Farah, Rashid Hassan; Bandello, Francesco; Parodi, Maurizio Battaglia] IRCCS San Raffaele Sci Inst, Dept Ophthalmol, Via Olgettina 60, I-20132 Milan, Italy.
C3 Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele
RP Arrigo, A (通讯作者)，IRCCS San Raffaele Sci Inst, Dept Ophthalmol, Via Olgettina 60, I-20132 Milan, Italy.
EM alessandro.arrigo@hotmail.com
OI bandello, francesco/0000-0003-3238-9682; Battaglia Parodi,
   Maurizio/0000-0002-0385-7961
FU Alimera Sciences (Alpharetta, Georgia, USA); Allergan Inc (Irvine,
   California, USA); Farmila-Thea (Clermont-Ferrand, France); Bayer
   Shering-Pharma (Berlin, Germany); Bausch And Lomb (Rochester, New York,
   USA); Genentech (San Francisco, California, USA); Hoffmann-La-Roche
   (Basel, Switzerland); NovagaliPharma (Evry, France); Novartis (Basel,
   Switzerland); Sanofi-Aventis (Paris, France); Thrombogenics (Heverlee,
   Belgium); Zeiss (Dublin, USA)
FX Francesco Bandello consultant for: Alcon (Fort Worth, Texas, USA),
   Alimera Sciences (Alpharetta, Georgia, USA), Allergan Inc (Irvine,
   California, USA), Farmila-Thea (Clermont-Ferrand, France), Bayer
   Shering-Pharma (Berlin, Germany), Bausch And Lomb (Rochester, New York,
   USA), Genentech (San Francisco, California, USA), Hoffmann-La-Roche
   (Basel, Switzerland), NovagaliPharma (Evry, France), Novartis (Basel,
   Switzerland), Sanofi-Aventis (Paris, France), Thrombogenics (Heverlee,
   Belgium), Zeiss (Dublin, USA). All other authors have no disclosures to
   declare.
CR Al-Halafi AM, 2015, EYE VISION, V2, DOI 10.1186/s40662-015-0018-2
   Braimah IZ, 2017, RETINA-J RET VIT DIS, V37, P578, DOI 10.1097/IAE.0000000000001220
   Dirani A, 2015, RETINA-J RET VIT DIS, V35, P1166, DOI 10.1097/IAE.0000000000000439
   Dolz-Marco R, 2017, OPHTHALMOLOGY, V124, P1353, DOI 10.1016/j.ophtha.2017.03.043
   Ervin AM, 2019, TRANSL VIS SCI TECHN, V8, DOI 10.1167/tvst.8.2.16
   Fleckenstein M, 2018, OPHTHALMOLOGY, V125, P369, DOI 10.1016/j.ophtha.2017.08.038
   Goldberg NR, 2013, RETINA-J RET VIT DIS, V33, P1871, DOI 10.1097/IAE.0b013e318296b12f
   Guymer RH, 2020, OPHTHALMOLOGY, V127, P394, DOI 10.1016/j.ophtha.2019.09.035
   Haensli C, 2021, RETINA-J RET VIT DIS, V41, P1940, DOI 10.1097/IAE.0000000000003135
   Hariri A, 2015, OPHTHALMOLOGY, V122, P407, DOI 10.1016/j.ophtha.2014.08.035
   Holz FG, 2017, OPHTHALMOLOGY, V124, P464, DOI 10.1016/j.ophtha.2016.12.002
   Jaffe GJ., 2020, OPHTHALMOL RETINA, VS2468, P30490
   Janse van Rensburg E., 2021, RETINA-J RET VIT DIS
   Jung JJ, 2012, ARCH OPHTHALMOL-CHIC, V130, P1618, DOI 10.1001/archophthalmol.2012.1902
   Kuehlewein L, 2016, RETINA-J RET VIT DIS, V36, P1216, DOI 10.1097/IAE.0000000000000870
   Lee JY, 2014, OPHTHALMOLOGY, V121, P2423, DOI 10.1016/j.ophtha.2014.06.013
   Litts KM, 2016, INVEST OPHTH VIS SCI, V57, P2647, DOI 10.1167/iovs.16-19262
   Preti RC, 2018, RETINA-J RET VIT DIS, V38, P1518, DOI 10.1097/IAE.0000000000001810
   Reichenbach A, 2020, GLIA, V68, P768, DOI 10.1002/glia.23727
   Sadda SR, 2018, OPHTHALMOLOGY, V125, P537, DOI 10.1016/j.ophtha.2017.09.028
   Schaal KB, 2015, RETINA-J RET VIT DIS, V35, P1339, DOI 10.1097/IAE.0000000000000471
   Zweifel SA, 2009, ARCH OPHTHALMOL-CHIC, V127, P1596, DOI 10.1001/archophthalmol.2009.326
NR 22
TC 1
Z9 1
U1 0
U2 1
PU NATURE PORTFOLIO
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
SN 2045-2322
J9 SCI REP-UK
JI Sci Rep
PD JUL 19
PY 2021
VL 11
IS 1
AR 14735
DI 10.1038/s41598-021-94310-5
PG 12
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA TM9BG
UT WOS:000675840600049
PM 34282240
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Dulull, NK
   Dias, DA
   Thrimawithana, TR
   Kwa, FAA
AF Dulull, Nabeela K.
   Dias, Daniel A.
   Thrimawithana, Thilini R.
   Kwa, Faith A. A.
TI L-Sulforaphane Confers Protection Against Oxidative Stress in an In
   Vitro Model of Age-Related Macular Degeneration
SO CURRENT MOLECULAR PHARMACOLOGY
LA English
DT Article
DE Age-related macular degeneration; glutathione-S-transferase;
   L-Sulforaphane; metabolomic profiling; oxidative stress; retinal pigment
   epithelium
ID PIGMENT EPITHELIAL-CELLS; ENDOTHELIAL-CELLS; CANCER CHEMOPREVENTION;
   GENE-EXPRESSION; FATTY-ACIDS; GROWTH; TRICHOSTATIN; ACTIVATION; VEGF;
   HOMOCYSTEINE
AB Background: In age-related macular degeneration, oxidative damage and abnormal neovascularization in the retina are caused by the upregulation of vascular endothelium growth factor and reduced expression of Glutathione-S-transferase genes. Current treatments are only palliative. Compounds from cruciferous vegetables (e.g. L-Sulforaphane) have been found to restore normal gene expression levels in diseases including cancer via the activity of histone deacetylases and DNA methyl-transferases, thus retarding disease progression.
   Objective: To examine L-Sulforaphane as a potential treatment to ameliorate aberrant levels of gene expression and metabolites observed in age-related macular degeneration.
   Method: The in vitro oxidative stress model of AMD was based on the exposure of Adult Retinal Pigment Epithelium-19 cell line to 200 mu M hydrogen peroxide. The effects of L-Sulforaphane on cell proliferation were determined by MTS assay. The role of GSTM1, VEGFA, DNMT1 and HDAC6 genes in modulating these effects was investigated using quantitative real-time polymerase chain reaction. The metabolic profiling of L-Sulforaphane-treated cells via gas-chromatography mass-spectrometry was established. Significant differences between control and treatment groups were validated using one-way ANOVA, student t-test and post-hoc Bonferroni statistical tests (p<0.05).
   Results: L-Sulforaphane induced a dose-dependent increase in cell proliferation in the presence of hydrogen peroxide by upregulating Glutathione-S-Transferase mu l gene expression. Metabolic profiling revealed that L-Sulforaphane increased levels of 2-monopalmitoglycerol, 9, 12, 15,-(Z-Z-Z)-Octadecatrienoic acid, 2-[Bis(trimethylsilyl)amino]ethyl bis(trimethylsilyl)-phosphate and nonanoic acid but decreased beta-alanine levels in the absence or presence of hydrogen peroxide, respectively.
   Conclusion: This study supports the use of L-Sulforaphane to promote regeneration of retinal cells under oxidative stress conditions.
C1 [Dulull, Nabeela K.; Dias, Daniel A.; Kwa, Faith A. A.] RMIT Univ, Sch Hlth & Biomed Sci, Discipline Lab Med, Bundoora, Vic 3083, Australia.
   [Thrimawithana, Thilini R.] RMIT Univ, Sch Hlth & Biomed Sci, Discipline Pharm, Bundoora, Vic 3083, Australia.
C3 Royal Melbourne Institute of Technology (RMIT); Royal Melbourne
   Institute of Technology (RMIT)
RP Kwa, FAA (通讯作者)，RMIT Univ, Sch Hlth & Biomed Sci, Bldg 201,Level 9,Room 14D,West Campus, Bundoora, Vic 3083, Australia.
EM faith.kwa@rmit.edu.au
OI Dias, Daniel/0000-0003-0129-3178; Kwa, Faith/0000-0002-9702-0563
FU School of Health and Biomedical Sciences, Royal Melbourne Institute of
   Technology University, Australia
FX This work was funded by the School of Health and Biomedical Sciences,
   Royal Melbourne Institute of Technology University, Australia. We would
   like to thank Dr. Narin Osman (Discipline of Human Biosciences, RMIT
   University, Australia) for purchasing the ARPE-19 cell culture. We would
   also like to acknowledge Dr. Ee Ken Choong of The University of
   Melbourne (Australia) for his advice on the graphical representation of
   data and thank Ms. Jane Yong Lin Wu of Temasek Polytechnic (Singapore)
   for her technical support.
CR Addo E., 2016, OCULAR DRUG DELIVERY, P11, DOI [10.1007/978-3-319-47691-9_2, DOI 10.1007/978-3-319-47691-9_2]
   AlQathama A, 2015, NAT PROD REP, V32, P1170, DOI 10.1039/c4np00130c
   Ardeljan D, 2013, PROG RETIN EYE RES, V37, P68, DOI 10.1016/j.preteyeres.2013.07.003
   Asakage Masahiro, 2006, Angiogenesis, V9, P83, DOI 10.1007/s10456-006-9034-0
   Balaiya S, 2012, MOL VIS, V18, P114
   Banescu C, 2014, OXID MED CELL LONGEV, V2014, DOI 10.1155/2014/875861
   Berger SL, 2016, CSH PERSPECT BIOL, V8, DOI 10.1101/cshperspect.a019463
   Biosystems A, 2008, BIOSYSTEMS GUIDE PER, P1
   Chan N, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0120587
   Chen YH, 2010, MOL INTERV, V10, P271, DOI 10.1124/mi.10.5.4
   Cho E, 2001, AM J CLIN NUTR, V73, P209
   Cho SG, 2001, J BIOL CHEM, V276, P12749, DOI 10.1074/jbc.M005561200
   Coleman HR, 2008, LANCET, V372, P1835, DOI 10.1016/S0140-6736(08)61759-6
   D'Urso A, 2014, TRENDS GENET, V30, P230, DOI 10.1016/j.tig.2014.04.004
   Davis R, 2009, ONCOL REP, V22, P1473, DOI 10.3892/or_00000589
   Deroanne CF, 2002, ONCOGENE, V21, P427, DOI 10.1038/sj.onc.1205108
   Di Paola R, 2011, BIOCHEM PHARMACOL, V82, P1478, DOI 10.1016/j.bcp.2011.07.074
   Dunn KC, 1996, EXP EYE RES, V62, P155, DOI 10.1006/exer.1996.0020
   Fernandes RO, 2015, MOL CELL BIOCHEM, V401, P61, DOI 10.1007/s11010-014-2292-z
   Ganai SA, 2016, BIOMED PHARMACOTHER, V81, P250, DOI 10.1016/j.biopha.2016.04.022
   Gopinath B, 2013, AM J CLIN NUTR, V98, P129, DOI 10.3945/ajcn.112.057091
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Han ZX, 2017, GENESIS, V55, DOI 10.1002/dvg.23022
   Hunter A, 2012, INVEST OPHTH VIS SCI, V53, P2089, DOI 10.1167/iovs.11-8449
   Huo XC, 2015, CELL PHYSIOL BIOCHEM, V35, P1787, DOI 10.1159/000373990
   Jayakody SA, 2015, PROG RETIN EYE RES, V46, P31, DOI 10.1016/j.preteyeres.2015.01.003
   Kaczynska A, 2017, BREAST CANCER-TOKYO, V24, P271, DOI 10.1007/s12282-016-0700-9
   Kang FW, 2012, ONCOL REP, V28, P193, DOI 10.3892/or.2012.1784
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Kauppinen A, 2012, IMMUNOL LETT, V147, P29, DOI 10.1016/j.imlet.2012.05.005
   Kelly SP, 2011, EYE, V25, P710, DOI 10.1038/eye.2011.89
   Kelsey NA, 2010, MOLECULES, V15, P7792, DOI 10.3390/molecules15117792
   Khan JC, 2006, BRIT J OPHTHALMOL, V90, P75, DOI 10.1136/bjo.2005.073643
   Khan MA, 2015, EVID-BASED COMPL ALT, V2015, DOI 10.1155/2015/412149
   Kleinman ME, 2014, INVEST OPHTH VIS SCI, V55
   Kong L, 2016, NEUROCHEM INT, V100, P52, DOI 10.1016/j.neuint.2016.08.011
   Kovacs K, 2015, INVEST OPHTH VIS SCI, V56, P6523, DOI 10.1167/iovs.15-16793
   Kwa FAA, 2014, DRUG DISCOV TODAY, V19, P1387, DOI 10.1016/j.drudis.2014.03.026
   Lee YJ, 2011, J KOREAN MED SCI, V26, P1474, DOI 10.3346/jkms.2011.26.11.1474
   Li B, 2015, INT J MOL MED, V36, P53, DOI 10.3892/ijmm.2015.2199
   Licznerska B, 2015, PHYTOTHER RES, V29, P93, DOI 10.1002/ptr.5232
   Liu AH, 2010, J LIPID RES, V51, P3217, DOI 10.1194/jlr.M007518
   Marazita MC, 2016, REDOX BIOL, V7, P78, DOI 10.1016/j.redox.2015.11.011
   Marin-Castano ME, 2006, INVEST OPHTH VIS SCI, V47, P4098, DOI 10.1167/iovs.05-1230
   Meeran SM, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011457
   Mukherjee PK, 2004, P NATL ACAD SCI USA, V101, P8491, DOI 10.1073/pnas.0402531101
   Nazmy EA, 2017, CAN J PHYSIOL PHARM, V95, P420, DOI 10.1139/cjpp-2016-0447
   Nita M, 2016, OXID MED CELL LONGEV, V2016, DOI 10.1155/2016/3164734
   Nowak JZ, 2006, PHARMACOL REP, V58, P353
   Pascolini D, 2012, BRIT J OPHTHALMOL, V96, P614, DOI 10.1136/bjophthalmol-2011-300539
   Por ED, 2016, J OCUL PHARMACOL TH, V32, P415, DOI 10.1089/jop.2016.0038
   Prasad PS, 2010, MATURITAS, V66, P46, DOI 10.1016/j.maturitas.2010.02.006
   Pushpoth S, 2013, INVEST OPHTH VIS SCI, V54
   Rasoulinejad SA, 2015, CASP J INTERN MED, V6, P141
   Ritz SA, 2007, AM J PHYSIOL-LUNG C, V292, pL33, DOI 10.1152/ajplung.00170.2006
   Rochtchina E, 2007, AM J OPHTHALMOL, V143, P344, DOI 10.1016/j.ajo.2006.08.032
   Rosa MF, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/627201
   Safa FK, 2014, IRAN J BASIC MED SCI, V17, P332
   Sparrrow JR, 2010, CURR MOL MED, V10, P802
   Tamba M, 1999, INT J RADIAT BIOL, V75, P1177
   Tan JSL, 2009, ARCH OPHTHALMOL-CHIC, V127, P656, DOI 10.1001/archophthalmol.2009.76
   Thimmulappa RK, 2002, CANCER RES, V62, P5196
   Thornton J, 2005, EYE, V19, P935, DOI 10.1038/sj.eye.6701978
   Tortorella SM, 2015, ANTIOXID REDOX SIGN, V22, P1382, DOI 10.1089/ars.2014.6097
   Wang LP, 2015, ONCOTARGET, V6, P25917, DOI 10.18632/oncotarget.4542
   Wang YC, 2017, ONCOL REP, V37, P2905, DOI 10.3892/or.2017.5565
   Williams R, 2016, FOOD CHEM, V197, P761, DOI 10.1016/j.foodchem.2015.11.015
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Xie MY, 2014, MOL VIS, V20, P1411
   Yang YQ, 2009, HYPERTENSION, V54, P1360, DOI 10.1161/HYPERTENSIONAHA.109.139428
   Yao H, 2008, INT J CANCER, V123, P1255, DOI 10.1002/ijc.23647
   Ye L, 2013, OXID MED CELL LONGEV, V2013, DOI 10.1155/2013/413024
NR 72
TC 10
Z9 10
U1 0
U2 9
PU BENTHAM SCIENCE PUBL LTD
PI SHARJAH
PA EXECUTIVE STE Y-2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB
   EMIRATES
SN 1874-4672
EI 1874-4702
J9 CURR MOL PHARMACOL
JI Curr. Molec. Pharmacol.
PY 2018
VL 11
IS 3
BP 237
EP 253
DI 10.2174/1874467211666180125163009
PG 17
WC Biochemistry & Molecular Biology; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Pharmacology & Pharmacy
GA GU6US
UT WOS:000445452800007
PM 29376497
DA 2022-11-30
ER

PT J
AU Arjamaa, O
   Nikinmaa, M
   Salminen, A
   Kaarniranta, K
AF Arjamaa, Olli
   Nikinmaa, Mikko
   Salminen, Antero
   Kaarniranta, Kai
TI Regulatory role of HIF-1 alpha in the pathogenesis of age-related
   macular degeneration (AMD)
SO AGEING RESEARCH REVIEWS
LA English
DT Review
DE AMD; Hypoxia; Inflammation; Oxidative stress
ID HYPOXIA-INDUCIBLE FACTOR; COMPLEMENT-FACTOR-H; RETINAL-PIGMENT
   EPITHELIUM; HSP90 MOLECULAR CHAPERONE; FACTOR-KAPPA-B; OXIDATIVE STRESS;
   INNATE IMMUNITY; FACTOR 1-ALPHA; NADPH OXIDASE; RISK-FACTORS
AB Age-related macular degeneration (AMD) is a leading cause of irreversible blindness in the elderly throughout the world. AMD is attributed to a complex interaction of genetic and environmental factors. It is characterized by degeneration involving the retinal photoreceptors, retinal pigment epithelium (RPE), and Bruch's membrane, as well as alterations in choroidal capillaries. Aging and age-associated degenerative diseases, such as AMD, are intimately associated with decreased levels of tissue oxygenation and hypoxia that may induce accumulation of detrimental RPE-associated deposits, inflammation and neovascularization processes in retina. Hypoxia-inducible factor (HIF) is the master regulator for hypoxia-induced cellular adaptation that is involved in NF-kappa B signaling and the autophagic protein clearance system. In this review, we discuss role of HIF in AMD pathology and as a possible therapeutic target. (C) 2009 Elsevier Ireland Ltd. All rights reserved.
C1 [Kaarniranta, Kai] Univ Kuopio, Dept Ophthalmol, Inst Clin Med, FIN-70211 Kuopio, Finland.
   [Arjamaa, Olli; Nikinmaa, Mikko] Univ Turku, Dept Biol, Ctr Excellence Evolutionary Genet & Physiol, FIN-20014 Turku, Finland.
   [Salminen, Antero] Univ Kuopio, Inst Clin Med, Dept Neurol, FIN-70211 Kuopio, Finland.
   [Salminen, Antero] Kuopio Univ Hosp, Dept Neurol, FIN-70211 Kuopio, Finland.
   [Kaarniranta, Kai] Kuopio Univ Hosp, Dept Ophthalmol, FIN-70211 Kuopio, Finland.
C3 University of Eastern Finland; University of Turku; University of
   Eastern Finland; Kuopio University Hospital; Kuopio University Hospital
RP Kaarniranta, K (通讯作者)，Univ Kuopio, Dept Ophthalmol, Inst Clin Med, FIN-70211 Kuopio, Finland.
EM kaarnira@messi.uku.fi
RI Nikinmaa, Mikko/AAZ-2803-2021
OI Nikinmaa, Mikko/0000-0003-0593-1018; Kaarniranta,
   Kai/0000-0003-2600-8679
FU Academy of Finland; Kuopio University Hospital; Finnish Eye Foundation;
   Finnish Funding Agency for Technology and Innovation
FX This study was funded by the Academy of Finland, the EVO fund of the
   Kuopio University Hospital, the Finnish Eye Foundation and the Finnish
   Funding Agency for Technology and Innovation. We thank Dr. Ewen
   MacDonald for checking the language.
CR Al-Shabrawey M, 2008, INVEST OPHTH VIS SCI, V49, P3239, DOI 10.1167/iovs.08-1755
   Algvere PV, 2003, ACTA OPHTHALMOL SCAN, V81, P427, DOI 10.1034/j.1600-0420.2003.00157.x
   Ambati J, 2003, SURV OPHTHALMOL, V48, P257, DOI 10.1016/S0039-6257(03)00030-4
   Anderson DH, 2002, AM J OPHTHALMOL, V134, P411, DOI 10.1016/S0002-9394(02)01624-0
   ARJAMAA O, 2009, AM J PHYSIOL, V286, pR257
   Arjamaa O, 2006, EXP EYE RES, V83, P473, DOI 10.1016/j.exer.2006.01.016
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   BelAiba RS, 2007, MOL BIOL CELL, V18, P4691, DOI 10.1091/mbc.E07-04-0391
   Bellot G, 2009, MOL CELL BIOL, V29, P2570, DOI 10.1128/MCB.00166-09
   Berra E, 2006, EMBO REP, V7, P41, DOI 10.1038/sj.embor.7400598
   Berra E, 2003, EMBO J, V22, P4082, DOI 10.1093/emboj/cdg392
   Berra E, 2000, BIOCHEM PHARMACOL, V60, P1171, DOI 10.1016/S0006-2952(00)00423-8
   Bertout JA, 2008, NAT REV CANCER, V8, P967, DOI 10.1038/nrc2540
   Bonello S, 2007, ARTERIOSCL THROM VAS, V27, P755, DOI 10.1161/01.ATV.0000258979.92828.bc
   Boon CJE, 2008, AM J HUM GENET, V82, P516, DOI 10.1016/j.ajhg.2007.11.007
   BOULTON M, 1993, J PHOTOCH PHOTOBIO B, V19, P201, DOI 10.1016/1011-1344(93)87085-2
   Boulton M, 2001, EYE, V15, P384, DOI 10.1038/eye.2001.141
   Brahimi-Horn MC, 2007, FEBS LETT, V581, P3582, DOI 10.1016/j.febslet.2007.06.018
   BRESSLER NM, 1988, SURV OPHTHALMOL, V32, P375, DOI 10.1016/0039-6257(88)90052-5
   Buch H, 2005, ACTA OPHTHALMOL SCAN, V83, P409, DOI 10.1111/J.1600-0420.2005.00492.x
   Calzada MJ, 2007, CLIN TRANSL ONCOL, V9, P278, DOI 10.1007/s12094-007-0055-y
   Cash TP, 2007, FREE RADICAL BIO MED, V43, P1219, DOI 10.1016/j.freeradbiomed.2007.07.001
   Cherniack NS, 2004, J APPL PHYSIOL, V96, P352, DOI 10.1152/japplphysiol.00755.2003
   Chowdhury R, 2008, CHEM SOC REV, V37, P1308, DOI 10.1039/b701676j
   Chung HY, 2009, AGEING RES REV, V8, P18, DOI 10.1016/j.arr.2008.07.002
   Cockman ME, 2000, J BIOL CHEM, V275, P25733, DOI 10.1074/jbc.M002740200
   Crabb JW, 2002, P NATL ACAD SCI USA, V99, P14682, DOI 10.1073/pnas.222551899
   Decanini A, 2007, AM J OPHTHALMOL, V143, P607, DOI 10.1016/j.ajo.2006.12.006
   Donoso LA, 2006, SURV OPHTHALMOL, V51, P137, DOI 10.1016/j.survophthal.2005.12.001
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Ema M, 1997, P NATL ACAD SCI USA, V94, P4273, DOI 10.1073/pnas.94.9.4273
   Ennis S, 2008, LANCET, V372, P1828, DOI 10.1016/S0140-6736(08)61348-3
   Epstein ACR, 2001, CELL, V107, P43, DOI 10.1016/S0092-8674(01)00507-4
   Eskelinen EL, 2008, INT REV CEL MOL BIO, V266, P207, DOI 10.1016/S1937-6448(07)66005-5
   Fahling M, 2009, ACTA PHYSIOL, V195, P205, DOI 10.1111/j.1748-1716.2008.01894.x
   Fandrey J, 2006, CARDIOVASC RES, V71, P642, DOI 10.1016/j.cardiores.2006.05.005
   Forooghian F, 2007, BRIT J OPHTHALMOL, V91, DOI 10.1136/bjo.2007.123125
   Francis PJ, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0001197
   Frede S, 2007, METHOD ENZYMOL, V435, P405, DOI 10.1016/S0076-6879(07)35021-0
   Frede S, 2006, BIOCHEM J, V396, P517, DOI 10.1042/BJ20051839
   Frede S, 2009, J IMMUNOL, V182, P6470, DOI 10.4049/jimmunol.0802378
   Gehrs KM, 2006, ANN MED, V38, P450, DOI 10.1080/07853890600946724
   Grunwald JE, 2005, INVEST OPHTH VIS SCI, V46, P1033, DOI 10.1167/iovs.04-1050
   Gu YZ, 1998, GENE EXPRESSION, V7, P205
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Hardarson SH, 2006, INVEST OPHTH VIS SCI, V47, P5011, DOI 10.1167/iovs.06-0039
   Heidbreder M, 2003, FASEB J, V17, P1541, DOI 10.1096/fj.02-0963fje
   Heidbreder M, 2007, BIOCHEM BIOPH RES CO, V352, P437, DOI 10.1016/j.bbrc.2006.11.027
   Hickey MM, 2006, CURR TOP DEV BIOL, V76, P217, DOI 10.1016/S0070-2153(06)76007-0
   Hirsila M, 2003, J BIOL CHEM, V278, P30772, DOI 10.1074/jbc.M304982200
   Hirvela H, 1996, OPHTHALMOLOGY, V103, P871, DOI 10.1016/S0161-6420(96)30593-9
   Hjelmeland LM, 1999, MOL VIS, V5
   Holz F.G., 2004, AGE RELATED MACULAR, P24
   Holz FG, 2007, AM J OPHTHALMOL, V143, P463, DOI 10.1016/j.ajo.2006.11.041
   Howes KA, 2004, INVEST OPHTH VIS SCI, V45, P3713, DOI 10.1167/iovs.04-0404
   Huang LE, 1998, P NATL ACAD SCI USA, V95, P7987, DOI 10.1073/pnas.95.14.7987
   HUTCHINSON AK, 1993, ARCH OPHTHALMOL-CHIC, V111, P734, DOI 10.1001/archopht.1993.01090060020010
   Inoue Y, 2007, BRIT J OPHTHALMOL, V91, P1720, DOI 10.1136/bjo.2006.111583
   Iwai K, 1999, P NATL ACAD SCI USA, V96, P12436, DOI 10.1073/pnas.96.22.12436
   Iyer NV, 1998, GENOMICS, V52, P159, DOI 10.1006/geno.1998.5416
   Jaakkola P, 2001, SCIENCE, V292, P468, DOI 10.1126/science.1059796
   Jaakkola PM, 2009, AUTOPHAGY, V5, P410, DOI 10.4161/auto.5.3.7823
   Jiang BH, 1996, J BIOL CHEM, V271, P17771, DOI 10.1074/jbc.271.30.17771
   Johnson LV, 2001, EXP EYE RES, V73, P887, DOI 10.1006/exer.2001.1094
   Kaarniranta K, 2005, NEUROSCI LETT, V382, P185, DOI 10.1016/j.neulet.2005.03.009
   Kaarniranta K, 2009, J MOL MED, V87, P117, DOI 10.1007/s00109-008-0418-z
   Kaarniranta K, 2009, AGEING RES REV, V8, P128, DOI 10.1016/j.arr.2009.01.001
   Kaelin WG, 2008, MOL CELL, V30, P393, DOI 10.1016/j.molcel.2008.04.009
   Kaluz S, 2006, J CELL BIOCHEM, V97, P207, DOI 10.1002/jcb.20633
   Kamura T, 2000, P NATL ACAD SCI USA, V97, P10430, DOI 10.1073/pnas.190332597
   Kang KH, 2009, TRENDS MOL MED, V15, P191, DOI 10.1016/j.molmed.2009.03.005
   Ke QD, 2006, MOL PHARMACOL, V70, P1469, DOI 10.1124/mol.106.027029
   Kenneth NS, 2008, BIOCHEM J, V414, P19, DOI 10.1042/BJ20081055
   Kietzmann T, 2003, THROMB HAEMOSTASIS, V89, P666
   KILLINGSWORTH MC, 1990, EYE, V4, P613, DOI 10.1038/eye.1990.86
   Kivirikko KI, 1998, MATRIX BIOL, V16, P357, DOI 10.1016/S0945-053X(98)90009-9
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Kociok N, 2007, GRAEF ARCH CLIN EXP, V245, P258, DOI 10.1007/s00417-006-0355-x
   Kong XG, 2006, MOL CELL BIOL, V26, P2019, DOI 10.1128/MCB.26.6.2019-2028.2006
   Kurz T, 2009, AUTOPHAGY, V5, P494, DOI 10.4161/auto.5.4.7961
   Kvanta A, 1996, INVEST OPHTH VIS SCI, V37, P1929
   Lando D, 2002, SCIENCE, V295, P858, DOI 10.1126/science.1068592
   Lee SM, 2006, CANCER LETT, V242, P231, DOI 10.1016/j.canlet.2005.11.001
   Lisy K, 2008, CELL DEATH DIFFER, V15, P642, DOI 10.1038/sj.cdd.4402315
   Lisztwan J, 1999, GENE DEV, V13, P1822, DOI 10.1101/gad.13.14.1822
   Loane E, 2008, BRIT J OPHTHALMOL, V92, P1163, DOI 10.1136/bjo.2007.135566
   Madrid LV, 2000, MOL CELL BIOL, V20, P1626, DOI 10.1128/MCB.20.5.1626-1638.2000
   Mahon PC, 2001, GENE DEV, V15, P2675, DOI 10.1101/gad.924501
   Maller JB, 2007, NAT GENET, V39, P1200, DOI 10.1038/ng2131
   MARSHALL J, 1987, EYE-T OPHTH SOC UK, V1, P282, DOI 10.1038/eye.1987.47
   Martin G, 2004, GRAEF ARCH CLIN EXP, V242, P321, DOI 10.1007/s00417-003-0838-y
   Martinez-Vicente M, 2005, EXP GERONTOL, V40, P622, DOI 10.1016/j.exger.2005.07.005
   Mayer MP, 1999, CURR BIOL, V9, pR322, DOI 10.1016/S0960-9822(99)80203-6
   Meri S, 2007, ANN NY ACAD SCI, V1109, P93, DOI 10.1196/annals.1398.011
   Metelitsina TI, 2008, INVEST OPHTH VIS SCI, V49, P358, DOI 10.1167/iovs.07-0526
   Minet E, 2000, FEBS LETT, V468, P53, DOI 10.1016/S0014-5793(00)01181-9
   Montezuma Sandra R, 2007, Semin Ophthalmol, V22, P229, DOI 10.1080/08820530701745140
   Morimoto RI, 2008, GENE DEV, V22, P1427, DOI 10.1101/gad.1657108
   Mottet D, 2003, J BIOL CHEM, V278, P31277, DOI 10.1074/jbc.M300763200
   Mottet D, 2003, J CELL PHYSIOL, V194, P30, DOI 10.1002/jcp.10176
   Mullins RF, 2000, FASEB J, V14, P835, DOI 10.1096/fasebj.14.7.835
   Mylonis I, 2006, J BIOL CHEM, V281, P33095, DOI 10.1074/jbc.M605058200
   Neckers Len, 2003, Current Opinion in Oncology, V15, P419, DOI 10.1097/00001622-200311000-00003
   Ng TK, 2008, INVEST OPHTH VIS SCI, V49, P3312, DOI 10.1167/iovs.07-1517
   Nordgaard CL, 2008, INVEST OPHTH VIS SCI, V49, P2848, DOI 10.1167/iovs.07-1352
   Ohh M, 2000, NAT CELL BIOL, V2, P423, DOI 10.1038/35017054
   OTROCK ZK, 2009, CRIT REV ONCOL HEMAT
   Park KH, 2009, MOL VIS, V15, P200
   PAULEIKHOFF D, 1990, AM J OPHTHALMOL, V109, P38, DOI 10.1016/S0002-9394(14)75576-X
   Pearl LH, 2008, BIOCHEM J, V410, P439, DOI 10.1042/BJ20071640
   Pearl LH, 2006, ANNU REV BIOCHEM, V75, P271, DOI 10.1146/annurev.biochem.75.103004.142738
   PENFOLD PL, 1985, GRAEF ARCH CLIN EXP, V223, P69, DOI 10.1007/BF02150948
   Pillunat LE, 1999, EUR J OPHTHALMOL, V9, pS44, DOI 10.1177/112067219900901S15
   Pournaras CJ, 2008, PROG RETIN EYE RES, V27, P284, DOI 10.1016/j.preteyeres.2008.02.002
   Pugh CW, 2003, NAT MED, V9, P677, DOI 10.1038/nm0603-677
   Rankin EB, 2008, CELL DEATH DIFFER, V15, P678, DOI 10.1038/cdd.2008.21
   Rapino C, 2005, AGING CELL, V4, P177, DOI 10.1111/j.1474-9726.2005.00161.x
   Richter K, 2001, J BIOL CHEM, V276, P33689, DOI 10.1074/jbc.M103832200
   Rissanen E, 2006, J EXP BIOL, V209, P994, DOI 10.1242/jeb.02103
   Rius J, 2008, NATURE, V453, P807, DOI 10.1038/nature06905
   RYHANEN T, 2008, J CELL MOL MED
   Ryhanen T, 2008, EUR J PHARMACOL, V584, P229, DOI 10.1016/j.ejphar.2008.02.010
   Salminen A, 2008, CELL MOL LIFE SCI, V65, P1049, DOI 10.1007/s00018-008-7461-3
   SALMINEN A, 2009, TRENDS MOL MED
   Sarkar D, 2006, CANCER LETT, V236, P13, DOI 10.1016/j.canlet.2005.04.009
   Schlingemann RO, 2004, GRAEF ARCH CLIN EXP, V242, P91, DOI 10.1007/s00417-003-0828-0
   Schnitzer SE, 2005, FEBS LETT, V579, P529, DOI 10.1016/j.febslet.2004.12.023
   Scroggins BT, 2007, MOL CELL, V25, P151, DOI 10.1016/j.molcel.2006.12.008
   Seddon JM, 2005, ARCH OPHTHALMOL-CHIC, V123, P321, DOI 10.1001/archopht.123.3.321
   Seitsonen S, 2006, MOL VIS, V12, P796
   Seitsonen SP, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003833
   Semenza GL, 2000, GENE DEV, V14, P1983
   SEMENZA GL, 1992, MOL CELL BIOL, V12, P5447, DOI 10.1128/MCB.12.12.5447
   Semenza GL, 2003, NAT REV CANCER, V3, P721, DOI 10.1038/nrc1187
   Semenza GL, 2007, SCIENCE, V318, P62, DOI 10.1126/science.1147949
   SEREGARD S, 1994, GRAEF ARCH CLIN EXP, V232, P325, DOI 10.1007/BF00175983
   Shimada H, 2007, GRAEF ARCH CLIN EXP, V245, P295, DOI 10.1007/s00417-006-0367-6
   Sizemore N, 1999, MOL CELL BIOL, V19, P4798
   Smith TG, 2008, BRIT J HAEMATOL, V141, P325, DOI 10.1111/j.1365-2141.2008.07029.x
   Smith W, 1996, ARCH OPHTHALMOL-CHIC, V114, P1518, DOI 10.1001/archopht.1996.01100140716016
   Sparrow JR, 2003, ADV EXP MED BIOL, V533, P205
   Spilsbury K, 2000, AM J PATHOL, V157, P135, DOI 10.1016/S0002-9440(10)64525-7
   Stockmann C, 2006, CLIN EXP PHARMACOL P, V33, P968, DOI 10.1111/j.1440-1681.2006.04474.x
   Suter M, 2000, J BIOL CHEM, V275, P39625, DOI 10.1074/jbc.M007049200
   Tanimoto K, 2000, EMBO J, V19, P4298, DOI 10.1093/emboj/19.16.4298
   Taylor CT, 2008, J PHYSIOL-LONDON, V586, P4055, DOI 10.1113/jphysiol.2008.157669
   Terman A, 2004, INT J BIOCHEM CELL B, V36, P1400, DOI 10.1016/j.biocel.2003.08.009
   Tian H, 1997, GENE DEV, V11, P72, DOI 10.1101/gad.11.1.72
   Tolppanen AM, 2009, MOL VIS, V15, P762
   Treinin M, 2003, PHYSIOL GENOMICS, V14, P17, DOI 10.1152/physiolgenomics.00179.2002
   Trick GL, 2005, PROG RETIN EYE RES, V24, P259, DOI 10.1016/j.preteyeres.2004.08.001
   Ushio-Fukai M, 2008, CANCER LETT, V266, P37, DOI 10.1016/j.canlet.2008.02.044
   van Leeuwen R, 2003, INVEST OPHTH VIS SCI, V44, P3771, DOI 10.1167/iovs.03-0121
   van Uden P, 2008, BIOCHEM J, V412, P477, DOI 10.1042/BJ20080476
   Wang AL, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004160
   WANG GL, 1995, P NATL ACAD SCI USA, V92, P5510, DOI 10.1073/pnas.92.12.5510
   Wangsa-Wirawan ND, 2003, ARCH OPHTHALMOL-CHIC, V121, P547, DOI 10.1001/archopht.121.4.547
   Winkler BS, 1999, MOL VIS, V5
   Wu WC, 2007, EXP EYE RES, V85, P721, DOI 10.1016/j.exer.2007.08.005
   Xing C, 2008, GENES IMMUN, V9, P231, DOI 10.1038/gene.2008.10
   Yamada Y, 2006, EXP EYE RES, V82, P840, DOI 10.1016/j.exer.2005.10.005
   Yates JRW, 2007, NEW ENGL J MED, V357, P553, DOI 10.1056/NEJMoa072618
   Yu DY, 2005, EXP EYE RES, V80, P745, DOI 10.1016/j.exer.2005.01.018
   Yuan G, 2008, J CELL PHYSIOL, V217, P674, DOI 10.1002/jcp.21537
   Zhang HF, 2008, J BIOL CHEM, V283, P10892, DOI 10.1074/jbc.M800102200
   Zhang P, 2007, OPHTHALMOLOGICA, V221, P411, DOI 10.1159/000107502
   Zhao W, 2008, GRAEF ARCH CLIN EXP, V246, P1413, DOI 10.1007/s00417-008-0858-8
   Zinkernagel AS, 2007, J MOL MED, V85, P1339, DOI 10.1007/s00109-007-0282-2
NR 170
TC 113
Z9 114
U1 2
U2 15
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 1568-1637
EI 1872-9649
J9 AGEING RES REV
JI Ageing Res. Rev.
PD OCT
PY 2009
VL 8
IS 4
BP 349
EP 358
DI 10.1016/j.arr.2009.06.002
PG 10
WC Cell Biology; Geriatrics & Gerontology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology; Geriatrics & Gerontology
GA 498EU
UT WOS:000270120800009
PM 19589398
DA 2022-11-30
ER

PT J
AU Shu, DY
   Butcher, E
   Saint-Geniez, M
AF Shu, Daisy Y.
   Butcher, Erik
   Saint-Geniez, Magali
TI EMT and EndMT: Emerging Roles in Age-Related Macular Degeneration
SO INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
LA English
DT Review
DE age-related macular degeneration; epithelial-mesenchymal transition;
   endothelial-mesenchymal transition; subretinal fibrosis; transforming
   growth factor-beta
ID RETINAL-PIGMENT EPITHELIUM; GROWTH-FACTOR-BETA; TO-MESENCHYMAL
   TRANSITION; PLASMINOGEN-ACTIVATOR INHIBITOR-1; NONLETHAL OXIDANT INJURY;
   BRUCHS MEMBRANE; CHOROIDAL NEOVASCULARIZATION; INTRAVITREAL
   METHOTREXATE; EXTRACELLULAR-MATRIX; SUBRETINAL FIBROSIS
AB Epithelial-mesenchymal transition (EMT) and endothelial-mesenchymal transition (EndMT) are physiological processes required for normal embryogenesis. However, these processes can be hijacked in pathological conditions to facilitate tissue fibrosis and cancer metastasis. In the eye, EMT and EndMT play key roles in the pathogenesis of subretinal fibrosis, the end-stage of age-related macular degeneration (AMD) that leads to profound and permanent vision loss. Predominant in subretinal fibrotic lesions are matrix-producing mesenchymal cells believed to originate from the retinal pigment epithelium (RPE) and/or choroidal endothelial cells (CECs) through EMT and EndMT, respectively. Recent evidence suggests that EMT of RPE may also be implicated during the early stages of AMD. Transforming growth factor-beta (TGF beta) is a key cytokine orchestrating both EMT and EndMT. Investigations in the molecular mechanisms underpinning EMT and EndMT in AMD have implicated a myriad of contributing factors including signaling pathways, extracellular matrix remodelling, oxidative stress, inflammation, autophagy, metabolism and mitochondrial dysfunction. Questions arise as to differences in the mesenchymal cells derived from these two processes and their distinct mechanistic contributions to the pathogenesis of AMD. Detailed discussion on the AMD microenvironment highlights the synergistic interactions between RPE and CECs that may augment the EMT and EndMT processes in vivo. Understanding the differential regulatory networks of EMT and EndMT and their contributions to both the dry and wet forms of AMD can aid the development of therapeutic strategies targeting both RPE and CECs to potentially reverse the aberrant cellular transdifferentiation processes, regenerate the retina and thus restore vision.
C1 [Shu, Daisy Y.; Butcher, Erik; Saint-Geniez, Magali] Schepens Eye Res Inst Massachusetts Eye & Ear, Boston, MA 02114 USA.
   [Shu, Daisy Y.; Saint-Geniez, Magali] Harvard Med Sch, Dept Ophthalmol, Boston, MA 02114 USA.
   [Butcher, Erik] Harvard Univ, Harvard John A Paulson Sch Engn & Appl Sci, Cambridge, MA 02138 USA.
C3 Harvard University; Harvard Medical School; Harvard University
RP Saint-Geniez, M (通讯作者)，Schepens Eye Res Inst Massachusetts Eye & Ear, Boston, MA 02114 USA.; Saint-Geniez, M (通讯作者)，Harvard Med Sch, Dept Ophthalmol, Boston, MA 02114 USA.
EM Daisy_Shu@MEEI.HARVARD.EDU; Erik_Butcher@MEEI.HARVARD.EDU;
   magali_saintgeniez@meei.harvard.edu
RI ; Shu, Daisy Y./D-1187-2018
OI Butcher, Erik/0000-0001-5595-589X; Shu, Daisy Y./0000-0002-5382-6450
FU U.S. Department of Defense [VR180132]; National Eye Institute
   [P30EYE003790]
FX This research was funded by U.S. Department of Defense: VR180132, Iraty
   Award: N/A, National Eye Institute: P30EYE003790.
CR Abu El-Asrar AM, 2015, EXP EYE RES, V132, P179, DOI 10.1016/j.exer.2015.01.023
   Ambati J, 2013, NAT REV IMMUNOL, V13, P438, DOI 10.1038/nri3459
   Nieto MA, 2016, CELL, V166, P21, DOI 10.1016/j.cell.2016.06.028
   Annes JP, 2003, J CELL SCI, V116, P217, DOI 10.1242/jcs.00229
   Zamarripa DA, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-13621-8
   Bai YJ, 2014, MOL VIS, V20, P1258
   Bastiaans J, 2013, INVEST OPHTH VIS SCI, V54, P8306, DOI 10.1167/iovs.13-12383
   Basu A, 2009, INVEST OPHTH VIS SCI, V50, P4974, DOI 10.1167/iovs.09-3619
   Behzadian MA, 2001, INVEST OPHTH VIS SCI, V42, P853
   Benedicto I, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15374
   Boles NC, 2020, STEM CELL REP, V14, P631, DOI 10.1016/j.stemcr.2020.03.009
   Bu SC, 2014, RETINA-J RET VIT DIS, V34, P2317, DOI 10.1097/IAE.0000000000000349
   Cai H, 2006, CURR EYE RES, V31, P181, DOI 10.1080/02713680500514628
   Cao YA, 2014, INVEST OPHTH VIS SCI, V55, P7321, DOI 10.1167/iovs.14-15167
   Chan ESL, 2010, NAT REV RHEUMATOL, V6, P175, DOI 10.1038/nrrheum.2010.5
   Chau KY, 2007, EYE, V21, P1511, DOI [10.1038/sj.eye.6702722, 10.1038/sj.eye.6702722x]
   Che D, 2016, INT J MOL MED, V38, P1815, DOI 10.3892/ijmm.2016.2768
   Chen HC, 2012, LAB INVEST, V92, P676, DOI 10.1038/labinvest.2011.201
   Chen X, 2014, CURR MOL MED, V14, P523, DOI 10.2174/1566524014666140331230411
   Chen XY, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0096365
   Cicha I, 2009, BIOFACTORS, V35, P200, DOI 10.1002/biof.30
   ClinicalTrials.gov U.S. National Library Medicine, US NAT LIB MED GUA 1
   CONNOR TB, 1989, J CLIN INVEST, V83, P1661, DOI 10.1172/JCI114065
   Cui Jing, 2009, J Ocul Biol Dis Infor, V2, P12, DOI 10.1007/s12177-009-9015-9
   Cui L, 2019, ANN TRANSL MED, V7, DOI 10.21037/atm.2019.11.90
   Cui W, 2014, INT J OPHTHALMOL-CHI, V7, P194, DOI 10.3980/j.issn.2222-3959.2014.02.02
   Curcio C.A., 2013, RETINA-J RET VIT DIS, VVolume 1, P465
   DAS A, 1992, OPHTHALMOLOGY, V99, P1368
   Das S, 2009, BMC CELL BIOL, V10, DOI 10.1186/1471-2121-10-94
   Del Priore LV, 1998, ARCH OPHTHALMOL-CHIC, V116, P335, DOI 10.1001/archopht.116.3.335
   Del Priore LV, 2002, CURR EYE RES, V25, P79
   Elner SG, 2003, EXP EYE RES, V76, P585, DOI 10.1016/S0014-4835(03)00028-9
   Espinosa-Heidmann DG, 2005, EXP EYE RES, V80, P369, DOI 10.1016/j.exer.2004.10.005
   Feher J, 2006, NEUROBIOL AGING, V27, P983, DOI 10.1016/j.neurobiolaging.2005.05.012
   Feng ZL, 2015, GRAEF ARCH CLIN EXP, V253, P875, DOI 10.1007/s00417-014-2922-x
   Ferrington DA, 2017, REDOX BIOL, V13, P255, DOI 10.1016/j.redox.2017.05.015
   Frenkel S, 2008, BRIT J OPHTHALMOL, V92, P383, DOI 10.1136/bjo.2007.127928
   Friedlander M, 2007, J CLIN INVEST, V117, P576, DOI 10.1172/JCI31030
   Friedman E, 2000, AM J OPHTHALMOL, V130, P658, DOI 10.1016/S0002-9394(00)00643-7
   Fritsche LG, 2013, NAT GENET, V45, P433, DOI 10.1038/ng.2578
   Fukushima A, 2020, BIOCHEM BIOPHYS REP, V22, DOI 10.1016/j.bbrep.2020.100760
   Furihata T, 2015, FLUIDS BARRIERS CNS, V12, DOI 10.1186/s12987-015-0003-0
   Gabbiani G, 2003, J PATHOL, V200, P500, DOI 10.1002/path.1427
   Gangaputra S, 2009, OPHTHALMOLOGY, V116, P2188, DOI 10.1016/j.ophtha.2009.04.020
   GAUDRIC A, 1987, AM J OPHTHALMOL, V104, P364, DOI 10.1016/0002-9394(87)90226-1
   Ghosh S, 2018, INVEST OPHTH VIS SCI, V59, P104, DOI 10.1167/iovs.18-24132
   Gnanaguru G, 2016, INVEST OPHTH VIS SCI, V57, P4704, DOI 10.1167/iovs.15-18663
   Golestaneh N, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2016.453
   GROSSNIKLAUS HE, 1994, OPHTHALMOLOGY, V101, P1099
   Grossniklaus HE, 1998, ARCH OPHTHALMOL-CHIC, V116, P745, DOI 10.1001/archopht.116.6.745
   Guerra F, 2017, FRONT ONCOL, V7, DOI 10.3389/fonc.2017.00295
   Guidry C, 2002, INVEST OPHTH VIS SCI, V43, P267
   Gullapalli VK, 2005, EXP EYE RES, V80, P235, DOI 10.1016/j.exer.2004.09.006
   Heller JP, 2014, TRANSL VIS SCI TECHN, V3, DOI 10.1167/tvst.3.4.4
   Hirasawa M, 2011, MOL VIS, V17, P1222
   Hirsch L, 2015, CYTOKINE, V71, P394, DOI 10.1016/j.cyto.2014.11.014
   Horiguchi M, 2012, J BIOCHEM, V152, P321, DOI 10.1093/jb/mvs089
   Hou X, 2009, GRAEF ARCH CLIN EXP, V247, P1477, DOI 10.1007/s00417-009-1135-1
   Hu BJ, 2014, INT J MOL SCI, V15, P1606, DOI 10.3390/ijms15011606
   Hyttinen JMT, 2018, CELL MOL LIFE SCI, V75, P2991, DOI 10.1007/s00018-018-2843-7
   Iacovelli J, 2016, INVEST OPHTH VIS SCI, V57, P1038, DOI 10.1167/iovs.15-17758
   Inoki I, 2001, FASEB J, V15, P219, DOI 10.1096/fj.01-0332fje
   Ishikawa K, 2016, EXP EYE RES, V142, P19, DOI 10.1016/j.exer.2015.03.009
   Ishikawa K, 2015, SCI REP-UK, V5, DOI 10.1038/srep16386
   Ishikawa M, 2015, EXP EYE RES, V133, P3, DOI 10.1016/j.exer.2015.02.017
   Jo YJ, 2011, INVEST OPHTH VIS SCI, V52, P6089, DOI 10.1167/iovs.10-5189
   Johnson LV, 2000, EXP EYE RES, V70, P441, DOI 10.1006/exer.1999.0798
   Kaarniranta K, 2020, PROG RETIN EYE RES, V79, DOI 10.1016/j.preteyeres.2020.100858
   Kaarniranta K, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19082317
   Kaarniranta K, 2013, AUTOPHAGY, V9, P973, DOI 10.4161/auto.24546
   Kalluri R, 2009, J CLIN INVEST, V119, P1420, DOI 10.1172/JCI39104
   Karunadharma PP, 2010, INVEST OPHTH VIS SCI, V51, P5470, DOI 10.1167/iovs.10-5429
   Kaufhold S, 2014, J EXP CLIN CANC RES, V33, DOI 10.1186/s13046-014-0062-0
   Kechagia JZ, 2019, NAT REV MOL CELL BIO, V20, P457, DOI 10.1038/s41580-019-0134-2
   Kenney MC, 2010, INVEST OPHTH VIS SCI, V51, P4289, DOI 10.1167/iovs.09-4778
   Kim M, 2015, CELL REP, V11, P270, DOI 10.1016/j.celrep.2015.03.015
   Kimoto K, 2004, INVEST OPHTH VIS SCI, V45, P2431, DOI 10.1167/iovs.03-1276
   Klaassen I, 2015, EXP EYE RES, V133, P37, DOI 10.1016/j.exer.2014.10.016
   Koh JY, 2019, MOL BRAIN, V12, DOI 10.1186/s13041-019-0439-2
   Kokudo T, 2008, J CELL SCI, V121, P3317, DOI 10.1242/jcs.028282
   Kovacic JC, 2012, CIRCULATION, V125, P1795, DOI 10.1161/CIRCULATIONAHA.111.040352
   Kozlowski MR, 2012, MED HYPOTHESES, V78, P505, DOI 10.1016/j.mehy.2012.01.018
   Krstic J, 2015, OXID MED CELL LONGEV, V2015, DOI 10.1155/2015/654594
   Kuiper EJ, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002675
   Kurup SK, 2010, ACTA OPHTHALMOL, V88, pe145, DOI 10.1111/j.1755-3768.2009.01560.x
   KVANTA A, 1994, OPHTHALMIC RES, V26, P361, DOI 10.1159/000267502
   Lam JD, 2017, DIABETES, V66, P1950, DOI 10.2337/db16-1035
   Lambert V, 2003, INVEST OPHTH VIS SCI, V44, P2791, DOI 10.1167/iovs.02-1179
   Lambert V, 2001, FASEB J, V15, P1021, DOI 10.1096/fj.00-0393com
   Lampugnani MG, 2012, CSH PERSPECT MED, V2, DOI 10.1101/cshperspect.a006528
   Lebrun Jean-Jacques, 2012, ISRN Mol Biol, V2012, P381428, DOI 10.5402/2012/381428
   Lee WH, 2016, SCI REP-UK, V6, DOI 10.1038/srep27903
   Li GB, 2015, CELL PHYSIOL BIOCHEM, V35, P1773, DOI 10.1159/000373989
   Liebner S, 2004, J CELL BIOL, V166, P359, DOI 10.1083/jcb.200403050
   Lilien J, 2005, CURR OPIN CELL BIOL, V17, P459, DOI 10.1016/j.ceb.2005.08.009
   Little K, 2018, EBIOMEDICINE, V38, P283, DOI 10.1016/j.ebiom.2018.11.029
   Liu YQ, 2010, INVEST OPHTH VIS SCI, V51, P3372, DOI 10.1167/iovs.09-4321
   Lopez D, 2009, ARCH BIOCHEM BIOPHYS, V482, P77, DOI 10.1016/j.abb.2008.11.016
   Lopez PF, 1996, INVEST OPHTH VIS SCI, V37, P855
   Luo K, 2017, CSH PERSPECT BIOL, V9, DOI 10.1101/cshperspect.a022137
   Luo XT, 2018, DIS MODEL MECH, V11, DOI 10.1242/dmm.032060
   Lutty G, 1999, MOL VIS, V5
   Maminishkis A, 2006, INVEST OPHTH VIS SCI, V47, P3612, DOI 10.1167/iovs.05-1622
   Marin-Castano ME, 2006, INVEST OPHTH VIS SCI, V47, P4098, DOI 10.1167/iovs.05-1230
   Marin-Castano ME, 2005, INVEST OPHTH VIS SCI, V46, P3331, DOI 10.1167/iovs.04-1224
   Marneros AG, 2005, AM J PATHOL, V167, P1451, DOI 10.1016/S0002-9440(10)61231-X
   MARSHALL GE, 1992, BRIT J OPHTHALMOL, V76, P607, DOI 10.1136/bjo.76.10.607
   Martino F, 2018, FRONT PHYSIOL, V9, DOI 10.3389/fphys.2018.00824
   Matoba R, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0181481
   McLenachan Samuel, 2017, Biochem Biophys Rep, V10, P178, DOI 10.1016/j.bbrep.2017.03.008
   McLeod DS, 2009, INVEST OPHTH VIS SCI, V50, P4982, DOI 10.1167/iovs.09-3639
   Medici D, 2012, SEMIN CANCER BIOL, V22, P379, DOI 10.1016/j.semcancer.2012.04.004
   Mochizuki M, 2013, PROG RETIN EYE RES, V33, P10, DOI 10.1016/j.preteyeres.2012.10.002
   MOORE DJ, 1995, INVEST OPHTH VIS SCI, V36, P1290
   Mullins RF, 2000, FASEB J, V14, P835, DOI 10.1096/fasebj.14.7.835
   Mylavarapu S, 2019, FRONT ONCOL, V9, DOI 10.3389/fonc.2019.00054
   Nackman GB, 1997, SURGERY, V122, P39, DOI 10.1016/S0039-6060(97)90262-2
   Nelson WJ, 2004, SCIENCE, V303, P1483, DOI 10.1126/science.1094291
   Neve A, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/756078
   Niessen CM, 2007, J INVEST DERMATOL, V127, P2525, DOI 10.1038/sj.jid.5700865
   Nita M, 2014, MED SCI MONITOR, V20, P1003, DOI 10.12659/MSM.889887
   Nordgaard CL, 2006, INVEST OPHTH VIS SCI, V47, P815, DOI 10.1167/iovs.05-0976
   Nordgaard CL, 2008, INVEST OPHTH VIS SCI, V49, P2848, DOI 10.1167/iovs.07-1352
   Ohlmann A, 2016, HISTOCHEM CELL BIOL, V146, P769, DOI 10.1007/s00418-016-1461-4
   Okada Y, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0167200
   Ozkaya A, 2018, SAUDI J OPHTHALMOL, V32, P269, DOI 10.1016/j.sjopt.2018.08.002
   Park JA, 2016, J CELL SCI, V129, P3375, DOI 10.1242/jcs.187922
   Park JA, 2015, NAT MATER, V14, P1040, DOI [10.1038/NMAT4357, 10.1038/nmat4357]
   PAULEIKHOFF D, 1990, OPHTHALMOLOGY, V97, P171
   Penn JS, 2003, INVEST OPHTH VIS SCI, V44, P5423, DOI 10.1167/iovs.02-0804
   PEPPER MS, 1992, J CELL PHYSIOL, V153, P129, DOI 10.1002/jcp.1041530117
   Perez L, 2017, CYTOKINE GROWTH F R, V33, P41, DOI 10.1016/j.cytogfr.2016.09.002
   PFEFFER BA, 1994, EXP EYE RES, V59, P323, DOI 10.1006/exer.1994.1114
   Phillips SJ, 2003, CURR EYE RES, V26, P81, DOI 10.1076/ceyr.26.2.81.14508
   Phuong TTT, 2017, J PHYSIOL-LONDON, V595, P6869, DOI 10.1113/JP275052
   Piera-Velazquez S, 2019, PHYSIOL REV, V99, P1281, DOI 10.1152/physrev.00021.2018
   Pierro L, 2012, CLIN OPHTHALMOL, V6, P219, DOI 10.2147/OPTH.S27656
   Plantner JJ, 1998, EXP EYE RES, V67, P637, DOI 10.1006/exer.1998.0552
   Pratt CH, 2008, MOL VIS, V14, P1414
   Radeke MJ, 2015, GENOME MED, V7, DOI 10.1186/s13073-015-0183-x
   Rafii S, 2016, NATURE, V529, P316, DOI 10.1038/nature17040
   RAMRATTAN RS, 1994, INVEST OPHTH VIS SCI, V35, P2857
   Recalde S, 2011, INVEST OPHTH VIS SCI, V52, P7090, DOI 10.1167/iovs.11-7300
   Robertson IB, 2016, CSH PERSPECT BIOL, V8, DOI 10.1101/cshperspect.a021907
   Rosales MAB, 2019, LIFE SCI ALLIANCE, V2, DOI [10.26508/lsa.201800212, 10.26508/lsa.201900436]
   Sadaka A, 2016, CLIN OPHTHALMOL, V10, P1811, DOI 10.2147/OPTH.S111893
   Saika S, 2006, LAB INVEST, V86, P106, DOI 10.1038/labinvest.3700375
   Saika S, 2004, LAB INVEST, V84, P1245, DOI 10.1038/labinvest.3700156
   Saika S, 2001, DEV BIOL, V240, P419, DOI 10.1006/dbio.2001.0480
   Saint-Geniez M, 2009, P NATL ACAD SCI USA, V106, P18751, DOI 10.1073/pnas.0905010106
   Saito A, 2013, J BIOCHEM, V153, P493, DOI 10.1093/jb/mvt032
   Saito Y, 1998, RETINA-J RET VIT DIS, V18, P103, DOI 10.1097/00006982-199818020-00002
   Saitoh M, 2018, J BIOCHEM, V164, P257, DOI 10.1093/jb/mvy047
   Sanford LP, 1997, DEVELOPMENT, V124, P2659
   SARKS JP, 1988, EYE, V2, P552, DOI 10.1038/eye.1988.106
   SARKS SH, 1976, BRIT J OPHTHALMOL, V60, P324, DOI 10.1136/bjo.60.5.324
   Satish S, 2018, OXID MED CELL LONGEV, V2018, DOI 10.1155/2018/9248640
   Schiff L, 2019, COMMUN BIOL, V2, DOI 10.1038/s42003-019-0406-6
   Scott LE, 2019, FRONT CELL DEV BIOL, V7, DOI 10.3389/fcell.2019.00135
   Sharma S, 2019, J CELL MOL MED, V23, P761, DOI 10.1111/jcmm.13972
   Shu DY, 2017, PROG RETIN EYE RES, V60, P44, DOI 10.1016/j.preteyeres.2017.08.001
   Shukal D, 2020, EXP EYE RES, V197, DOI 10.1016/j.exer.2020.108072
   Siemerink MJ, 2010, DEV OPHTHALMOL, V46, P4, DOI 10.1159/000320006
   Sinha D, 2016, EXP EYE RES, V144, P46, DOI 10.1016/j.exer.2015.08.018
   Siren V, 1999, OPHTHALMIC RES, V31, P184, DOI 10.1159/000055531
   Sonoda S, 2009, NAT PROTOC, V4, P662, DOI 10.1038/nprot.2009.33
   Spencer C, 2017, J CELL MOL MED, V21, P2542, DOI 10.1111/jcmm.13175
   Steen B, 1998, INVEST OPHTH VIS SCI, V39, P2194
   Stefansson E, 2011, PROG RETIN EYE RES, V30, P72, DOI 10.1016/j.preteyeres.2010.09.003
   Stone RC, 2016, CELL TISSUE RES, V365, P495, DOI 10.1007/s00441-016-2464-0
   Sugioka K, 2013, EXP EYE RES, V115, P13, DOI 10.1016/j.exer.2013.06.020
   Sun JX, 2018, ANGIOGENESIS, V21, P635, DOI 10.1007/s10456-018-9614-9
   Sun K, 2007, MOL VIS, V13, P2310
   Suzuki M, 2007, MOL VIS, V13, P772
   Swaney JS, 2008, EXP EYE RES, V87, P367, DOI 10.1016/j.exer.2008.07.005
   Takahashi E, 2016, BIOCHEM BIOPH RES CO, V470, P569, DOI 10.1016/j.bbrc.2016.01.104
   Tamiya S, 2016, EXP EYE RES, V142, P26, DOI 10.1016/j.exer.2015.02.008
   Tamiya S, 2010, INVEST OPHTH VIS SCI, V51, P2755, DOI 10.1167/iovs.09-4725
   TANIHARA H, 1993, INVEST OPHTH VIS SCI, V34, P413
   Terluk MR, 2015, J NEUROSCI, V35, P7304, DOI 10.1523/JNEUROSCI.0190-15.2015
   Tezel TH, 2004, INVEST OPHTH VIS SCI, V45, P3337, DOI 10.1167/iovs.04-0193
   Tezel TH, 1997, GRAEF ARCH CLIN EXP, V235, P41, DOI 10.1007/BF01007836
   Tezel TH, 1999, INVEST OPHTH VIS SCI, V40, P467
   THOMAS MA, 1994, OPHTHALMOLOGY, V101, P1384
   Toops KA, 2014, EXP EYE RES, V124, P74, DOI 10.1016/j.exer.2014.05.003
   Tosi GM, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19113363
   Tosi GM, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-26442-0
   Tschumperlin DJ, 2020, PHARMACOL THERAPEUT, V212, DOI 10.1016/j.pharmthera.2020.107575
   Tseng WA, 2013, INVEST OPHTH VIS SCI, V54, P110, DOI 10.1167/iovs.12-10655
   Udar N, 2009, INVEST OPHTH VIS SCI, V50, P2966, DOI 10.1167/iovs.08-2646
   Umazume K, 2014, AM J PATHOL, V184, P1419, DOI 10.1016/j.ajpath.2014.01.022
   Umazume K, 2013, INVEST OPHTH VIS SCI, V54, P1150, DOI 10.1167/iovs.12-10418
   Wang H, 2003, INVEST OPHTH VIS SCI, V44, P2199, DOI 10.1167/iovs.02-0435
   Welch-Reardon KM, 2015, ARTERIOSCL THROM VAS, V35, P303, DOI 10.1161/ATVBAHA.114.303220
   Wu T, 2020, CELL SIGNAL, V70, DOI 10.1016/j.cellsig.2020.109571
   Yamada Y, 2008, J NEUROCHEM, V105, P1187, DOI 10.1111/j.1471-4159.2008.05211.x
   Zanzottera EC, 2015, INVEST OPHTH VIS SCI, V56, P3269, DOI 10.1167/iovs.15-16432
   Zarranz-Ventura J, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0065434
   Zhang H, 2012, INT J OPHTHALMOL-CHI, V5, P307, DOI 10.3980/j.issn.2222-3959.2012.03.11
   Zhang M, 2018, DIS MODEL MECH, V11, DOI 10.1242/dmm.032698
   Zhang RS, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0146808
   Zhao Z, 2016, AM J CANCER RES, V6, P2162
   Zou J, 2017, BIOSCIENCE REP, V37, DOI 10.1042/BSR20171049
NR 203
TC 72
Z9 72
U1 3
U2 10
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 1422-0067
J9 INT J MOL SCI
JI Int. J. Mol. Sci.
PD JUN
PY 2020
VL 21
IS 12
AR 4271
DI 10.3390/ijms21124271
PG 26
WC Biochemistry & Molecular Biology; Chemistry, Multidisciplinary
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry
GA ML5JS
UT WOS:000549502900001
PM 32560057
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Liutkeviciene, R
   Lesauskaite, V
   Zaliuniene, D
   Zaliaduonyte-Peksiene, D
   Cimbalas, A
   Jasinskas, V
   Gustiene, O
   Simonyte, S
   Tamosiunas, A
AF Liutkeviciene, Rasa
   Lesauskaite, Vaiva
   Zaliuniene, Dalia
   Zaliaduonyte-Peksiene, Diana
   Cimbalas, Andrius
   Jasinskas, Vytautas
   Gustiene, Olivija
   Simonyte, Sandrita
   Tamosiunas, Abdonas
TI Early Age-Related Macular Degeneration in Patients with Myocardial
   Infarction
SO CURRENT EYE RESEARCH
LA English
DT Article
DE Age-related macular degeneration; Myocardial infarction; Prevalence;
   Population; Age
ID CORONARY-HEART-DISEASE; BODY-MASS INDEX; RISK-FACTORS; APOLIPOPROTEIN-E;
   CARDIOVASCULAR-DISEASE; SERUM-CHOLESTEROL; BRUCHS MEMBRANE;
   FAMILY-HISTORY; TERM INCIDENCE; ASSOCIATION
AB Purpose: To investigate the prevalence of early age-related macular degeneration (AMD) in patients with acute myocardial infarction (MI).
   Methods: Enrolled in the study were 262 acute MI patients (MI group), aged 40-64 years, as well as 1,155 non-MI persons, aged 40-64 years, from a random sample (reference group) of the Kaunas population.
   Results: The prevalence of early AMD in the random sample was 7.3%, while in MI patients, the prevalence was 54.5% (P < 0.001). For all age groups, the prevalence of early AMD was significantly (P < 0.005) higher in MI patients than in reference-group persons. In the reference group, the prevalence of early AMD increased significantly with age, whereas no such trend was observed in the MI group. At the 45- to 54-year-olds, the prevalence was significantly higher in males than in females (9.9% vs. 3.7%; P < 0.05) in the reference group, while overall, the prevalence of early AMD in the males and females of the much larger reference group was 8.6% versus 6.2%, respectively (P > 0.05). It increased more with age for females (3.7% and 10.8% at the age 45-54 and 55-64 years, P < 0.05, respectively) while in males, frequency of AMD did not differ significantly between latter age groups (9.9% vs. 11.6%; P > 0.05).
   Conclusions: We conclude that the prevalence of early AMD is significantly higher in patients with MI than in a random sample of the population.
C1 [Liutkeviciene, Rasa; Zaliuniene, Dalia; Jasinskas, Vytautas] Lithuanian Univ Hlth Sci, Med Acad, Dept Ophthalmol, Kaunas, Lithuania.
   [Lesauskaite, Vaiva; Simonyte, Sandrita; Tamosiunas, Abdonas] Lithuanian Univ Hlth Sci, Med Acad, Inst Cardiol, Kaunas, Lithuania.
   [Zaliaduonyte-Peksiene, Diana; Gustiene, Olivija] Lithuanian Univ Hlth Sci, Med Acad, Dept Cardiol, Kaunas, Lithuania.
   [Cimbalas, Andrius] Vilnius Univ, Fac Med, Vilnius, Lithuania.
C3 Lithuanian University of Health Sciences; Lithuanian University of
   Health Sciences; Lithuanian University of Health Sciences; Vilnius
   University
RP Liutkeviciene, R (通讯作者)，Lithuanian Univ Hlth Sci, Med Acad, Dept Ophthalmol, Eiveniu 2, Kaunas, Lithuania.
EM rliutkeviciene@gmail.com
RI Tamosiunas, Abdonas/AAD-4274-2021
OI Lesauskaite, Vaiva/0000-0003-2736-3111
CR Age-Related Eye Dis Study Res Grp, 2001, AM J OPHTHALMOL, V132, P668
   Al-Azzawi F, 2009, MATURITAS, V63, P135, DOI 10.1016/j.maturitas.2009.03.009
   Ali M, 2009, WORLD HLTH STAT
   Brook RD, 2000, AM J HYPERTENS, V13, p112S, DOI 10.1016/S0895-7061(00)00228-4
   Buch H, 2005, ACTA OPHTHALMOL SCAN, V83, P409, DOI 10.1111/J.1600-0420.2005.00492.x
   *CDC, 2004, MMWR-MORBID MORTAL W, V53, P1069
   Chakravarthy U, 2007, OPHTHALMOLOGY, V114, P1157, DOI 10.1016/j.ophtha.2006.09.022
   Chakravarthy U, 2010, BMC OPHTHALMOL, V10, DOI 10.1186/1471-2415-10-31
   Chau KY, 2003, J HUM HYPERTENS, V17, P119
   Chen Zhengming, 2002, Semin Vasc Med, V2, P243, DOI 10.1055/s-2002-35392
   Cho EY, 2001, ANN EPIDEMIOL, V11, P328, DOI 10.1016/S1047-2797(01)00217-4
   Davignon J, 1999, CLIN CHIM ACTA, V286, P115, DOI 10.1016/S0009-8981(99)00097-2
   Domarkiene Stanislava, 2003, Medicina (Kaunas), V39, P1193
   Duan YK, 2007, OPHTHALMOLOGY, V114, P732, DOI 10.1016/j.ophtha.2006.07.045
   Evans JR, 2001, PROG RETIN EYE RES, V20, P227, DOI 10.1016/S1350-9462(00)00023-9
   Fiotti N, 2005, GENET MED, V7, P272, DOI 10.1097/01.GIM.0000159903.69597.73
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Giovannucci E, 2008, ARCH INTERN MED, V168, P1174, DOI 10.1001/archinte.168.11.1174
   Guo L, 1999, INVEST OPHTH VIS SCI, V40, P2676
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Hamdi HK, 2002, BIOCHEM BIOPH RES CO, V295, P668, DOI 10.1016/S0006-291X(02)00728-3
   Hu FB, 1997, NEW ENGL J MED, V337, P1491, DOI 10.1056/NEJM199711203372102
   Hyman Leslie, 2002, Curr Opin Ophthalmol, V13, P171
   Johnson LV, 2000, EXP EYE RES, V70, P441, DOI 10.1006/exer.1999.0798
   Kanda A, 2008, BRIT J OPHTHALMOL, V92, P448, DOI 10.1136/bjo.2007.131581
   Kaplan RC, 2008, ATHEROSCLEROSIS, V201, P130, DOI 10.1016/j.atherosclerosis.2008.01.003
   Kardys I, 2006, J AM COLL CARDIOL, V47, P1568, DOI 10.1016/j.jacc.2005.11.076
   Klein R, 2006, OPHTHALMOLOGY, V113, P373, DOI 10.1016/j.ophtha.2005.12.013
   Klein R, 2004, AM J OPHTHALMOL, V137, P486, DOI 10.1016/j.ajo.2003.11.069
   Klein R, 2003, OPHTHALMOLOGY, V110, P636, DOI 10.1016/S0161-6420(02)01448-3
   Klein R, 2010, ARCH OPHTHALMOL-CHIC, V128, P750, DOI 10.1001/archophthalmol.2010.92
   Kumar A, 2008, INDIAN J CLIN BIOCHE, V23, P296, DOI 10.1007/s12291-008-0067-6
   LAROSA JC, 1990, CIRCULATION, V81, P1721, DOI 10.1161/01.CIR.81.5.1721
   Libby P, 2009, J AM COLL CARDIOL, V54, P2129, DOI 10.1016/j.jacc.2009.09.009
   Mahley RW, 2000, ANNU REV GENOM HUM G, V1, P507, DOI 10.1146/annurev.genom.1.1.507
   MANSON JE, 1987, JAMA-J AM MED ASSOC, V257, P353, DOI 10.1001/jama.257.3.353
   Milton RC, 2005, OPHTHALMOLOGY, V112, P533, DOI 10.1016/j.ophtha.2004.10.047
   Oguido APMT, 2008, ARQ BRAS OFTALMOL, V71, P375, DOI 10.1590/S0004-27492008000300013
   Miyazaki M, 2003, BRIT J OPHTHALMOL, V87, P469, DOI 10.1136/bjo.87.4.469
   Nangia V, 2011, RETINA-J RET VIT DIS, V31, P1179, DOI 10.1097/IAE.0b013e3181f57ff2
   Obisesan TO, 1998, J AM GERIATR SOC, V46, P1
   Owen CG, 2003, BRIT J OPHTHALMOL, V87, P312, DOI 10.1136/bjo.87.3.312
   Parekh N, 2007, ARCH OPHTHALMOL-CHIC, V125, P661, DOI 10.1001/archopht.125.5.661
   Piehler Armin P, 2007, Tidsskr Nor Laegeforen, V127, P2930
   Pitsavos C, 2002, TOB CONTROL, V11, P220, DOI 10.1136/tc.11.3.220
   Price JF, 1997, EUR HEART J, V18, P719
   Rao VS, 2010, INT J VASC MED, V2010, DOI DOI 10.1155/2010/389235
   Robman L, 2004, OPHTHAL EPIDEMIOL, V11, P161, DOI 10.1080/09286580490514469
   Rochtchina E, 2007, AM J OPHTHALMOL, V143, P344, DOI 10.1016/j.ajo.2006.08.032
   SanGiovanni JP, 2007, ARCH OPHTHALMOL-CHIC, V125, P671, DOI 10.1001/archopht.125.5.671
   Sarangarajan R, 2005, OPHTHALMIC RES, V37, P136, DOI 10.1159/000085533
   Schaumberg DA, 2001, ARCH OPHTHALMOL-CHIC, V119, P1259
   Seddon JM, 2004, JAMA-J AM MED ASSOC, V291, P704, DOI 10.1001/jama.291.6.704
   Seddon JM, 2003, ARCH OPHTHALMOL-CHIC, V121, P785, DOI 10.1001/archopht.121.6.785
   Smith W, 1998, AUST NZ J OPHTHALMOL, V26, P203, DOI 10.1111/j.1442-9071.1998.tb01311.x
   Snow KK, 2002, AM J OPHTHALMOL, V134, P842, DOI 10.1016/S0002-9394(02)01755-5
   Souied EH, 1998, AM J OPHTHALMOL, V125, P353, DOI 10.1016/S0002-9394(99)80146-9
   Squire IB, 2004, J CARD FAIL, V10, P328, DOI 10.1016/j.cardfail.2003.11.003
   STAMLER J, 1993, CIRCULATION, V88, P1954, DOI 10.1161/01.CIR.88.4.1954
   STAMPFER MJ, 1992, JAMA-J AM MED ASSOC, V268, P877, DOI 10.1001/jama.268.7.877
   SUMMERS KM, 1993, CLIN EXP PHARMACOL P, V20, P320, DOI 10.1111/j.1440-1681.1993.tb01694.x
   Sun C, 2009, OPHTHALMOLOGY, V116, P1913, DOI 10.1016/j.ophtha.2009.03.046
   Tan JSL, 2007, OPHTHALMOLOGY, V114, P1143, DOI 10.1016/j.ophtha.2006.09.033
   Thornton J, 2005, EYE, V19, P935, DOI 10.1038/sj.eye.6701978
   Thygesen K, 2007, EUR HEART J, V28, P2525
   TunstallPedoe H, 1996, CIRCULATION, V93, P1981, DOI 10.1161/01.CIR.93.11.1981
   van Leeuwen R, 2004, AM J OPHTHALMOL, V137, P750, DOI 10.1016/S0002-9394(03)01089-4
   VINGERLING JR, 1995, BRIT MED J, V310, P1570, DOI 10.1136/bmj.310.6994.1570
   Wong TY, 2007, OPHTHALMOLOGY, V114, P86, DOI 10.1016/j.ophtha.2006.06.039
   Yarnell J, 2003, INT J EPIDEMIOL, V32, P71, DOI 10.1093/ije/dyg038
   Zarbin MA, 2004, ARCH OPHTHALMOL-CHIC, V122, P598, DOI 10.1001/archopht.122.4.598
NR 72
TC 5
Z9 5
U1 0
U2 3
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0271-3683
EI 1460-2202
J9 CURR EYE RES
JI Curr. Eye Res.
PD FEB
PY 2012
VL 37
IS 2
BP 94
EP 100
DI 10.3109/02713683.2011.629069
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 877JL
UT WOS:000299174600002
PM 22070427
DA 2022-11-30
ER

PT J
AU Michikawa, T
   Ishida, S
   Nishiwaki, Y
   Kikuchi, Y
   Tsuboi, T
   Hosoda, K
   Ishigami, A
   Iwasawa, S
   Nakano, M
   Takebayashi, T
AF Michikawa, Takehiro
   Ishida, Susumu
   Nishiwaki, Yuji
   Kikuchi, Yuriko
   Tsuboi, Tazuru
   Hosoda, Kanae
   Ishigami, Ai
   Iwasawa, Satoko
   Nakano, Makiko
   Takebayashi, Toru
TI Serum antioxidants and age-related macular degeneration among older
   Japanese
SO ASIA PACIFIC JOURNAL OF CLINICAL NUTRITION
LA English
DT Article
DE serum antioxidants; Age-related Macular Degeneration (AMD); diet; aged;
   Japan
ID BLUE MOUNTAINS EYE; BETA-CAROTENE; ALPHA-TOCOPHEROL; VITAMIN-E; DIETARY
   ANTIOXIDANTS; MACULOPATHY; SUPPLEMENTATION; PREVALENCE; POPULATION;
   DISEASE
AB From the perspective of human nutrition, the prevention of age-related macular degeneration (AMD) through diet control is feasible and desirable. We investigated the relationship between serum antioxidants and AMD in the community-dwelling older Japanese eating a typical Japanese diet. In this study, 722 subjects aged 65 years or older (297 males and 425 females) who had gradable fundus photographs were included. The subjects were divided into three groups of early or late AMD or non-maculopathy. Serum antioxidants (alpha-, gammatocopherols, retinol, beta-cryptoxanthin, alpha-, beta-carotenes, lycopene, and lutein and zeaxanthin) were measured with high-performance liquid chromatography. To clarify the combined effect as the group of the antioxidants, we defined the carotene family (alpha-, beta-carotenes and lycopene) and carotenoid family (betacryptoxanthin, alpha-, beta-carotenes, lycopene, lutein and zeaxanthin). Tertiles of each serum antioxidant were obtained and the prevalence of early or late AMD was compared with univariate or multivariate analysis. The overall prevalence of early AMD was 4.4% (95% confidence interval: 3.1-6.2) and late AMD was 1.1% (0.5-2.2). Only alpha-tocopherol and beta-cryptoxanthin were related to late AMD as single antioxidants. On the other hand, the carotene and carotenoid families as a combination of antioxidants were protectively associated with late AMD. No relationship was found between serum antioxidants and early AMD. Our findings support the hypothesis that a combination of serum antioxidants obtained from the traditional Japanese diet is protective for late AMD, but not for early AMD.
C1 [Nishiwaki, Yuji] Keio Univ, Dept Prevent Med & Publ Hlth, Sch Med, Shinjuku Ku, Tokyo 1608582, Japan.
   [Ishida, Susumu] Keio Univ, Dept Ophthalmol, Sch Med, Tokyo 1608582, Japan.
C3 Keio University; Keio University
RP Nishiwaki, Y (通讯作者)，Keio Univ, Dept Prevent Med & Publ Hlth, Sch Med, Shinjuku Ku, 35 Shinanomachi, Tokyo 1608582, Japan.
EM nisiwaki@sc.itc.keio.ac.jp
RI ISHIDA, SUSUMU/D-7067-2012; Takebayashi, Toru/K-7526-2013; Takebayashi,
   Toru/AAB-9356-2019; Nakano, Makiko/L-3795-2013
OI Takebayashi, Toru/0000-0002-8268-8026; Takebayashi,
   Toru/0000-0002-8268-8026; 
FU Uehara Memorial Foundation
FX This study was supported by the Uehara Memorial Foundation. We extend
   our thanks all those involved in the Kurabuchi study.
CR Beatty S, 1999, BRIT J OPHTHALMOL, V83, P867, DOI 10.1136/bjo.83.7.867
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Bohm F, 1997, J AM CHEM SOC, V119, P621, DOI 10.1021/ja962512c
   Cho EY, 2004, ARCH OPHTHALMOL-CHIC, V122, P883, DOI 10.1001/archopht.122.6.883
   Chong EWT, 2007, BMJ-BRIT MED J, V335, P755, DOI 10.1136/bmj.39350.500428.47
   Delcourt C, 1999, ARCH OPHTHALMOL-CHIC, V117, P1384, DOI 10.1001/archopht.117.10.1384
   Evans J, 1996, BRIT J OPHTHALMOL, V80, P9, DOI 10.1136/bjo.80.1.9
   Fine SL, 2000, NEW ENGL J MED, V342, P483, DOI 10.1056/NEJM200002173420707
   Imamura Y, 2006, P NATL ACAD SCI USA, V103, P11282, DOI 10.1073/pnas.0602131103
   Ito Y, 2003, CANCER SCI, V94, P57, DOI 10.1111/j.1349-7006.2003.tb01352.x
   Ito Y, 1999, INT J VITAM NUTR RES, V69, P385, DOI 10.1024/0300-9831.69.6.385
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Kawasaki R, 2008, OPHTHALMOLOGY, V115, P1735, DOI 10.1016/j.ophtha.2008.02.012
   Mares JA, 2004, ARCH OPHTHALMOL-CHIC, V122, P628, DOI 10.1001/archopht.122.4.628
   Mares JA, 2006, ARCH OPHTHALMOL-CHIC, V124, P1339, DOI 10.1001/archopht.124.9.1339
   Moeller SM, 2006, ARCH OPHTHALMOL-CHIC, V124, P1151, DOI 10.1001/archopht.124.8.1151
   Oshima Y, 2001, BRIT J OPHTHALMOL, V85, P1153, DOI 10.1136/bjo.85.10.1153
   Pomerleau J, 2003, BRIT J NUTR, V89, P827, DOI 10.1079/BJN2003841
   Smith W, 1997, AM J OPHTHALMOL, V124, P838, DOI 10.1016/S0002-9394(14)71702-7
   SOMMER A, 1991, NEW ENGL J MED, V325, P1412, DOI 10.1056/NEJM199111143252004
   Stahl W, 1998, FEBS LETT, V427, P305, DOI 10.1016/S0014-5793(98)00434-7
   Stahl W, 2003, MOL ASPECTS MED, V24, P345, DOI 10.1016/S0098-2997(03)00030-X
   Tan JSL, 2008, OPHTHALMOLOGY, V115, P334, DOI 10.1016/j.ophtha.2007.03.083
   Taylor HR, 2002, BMJ-BRIT MED J, V325, P11, DOI 10.1136/bmj.325.7354.11
   Teikari JM, 1998, ACTA OPHTHALMOL SCAN, V76, P224, DOI 10.1034/j.1600-0420.1998.760220.x
   Trichopoulos D, 2000, ASIA PAC J CLIN NUTR, V9, pS4, DOI 10.1046/j.1440-6047.2000.00174.x
   Truscott TG, 1996, J PHOTOCH PHOTOBIO B, V35, P233, DOI 10.1016/S1011-1344(96)07299-5
   van Leeuwen R, 2005, JAMA-J AM MED ASSOC, V294, P3101, DOI 10.1001/jama.294.24.3101
   WEST S, 1994, ARCH OPHTHALMOL-CHIC, V112, P222, DOI 10.1001/archopht.1994.01090140098031
   Zarbin MA, 2004, ARCH OPHTHALMOL-CHIC, V122, P598, DOI 10.1001/archopht.122.4.598
NR 30
TC 34
Z9 36
U1 1
U2 9
PU H E C PRESS, HEALTHY EATING CLUB PTY LTD
PI MCKINNON
PA PO BOX 4121, MCKINNON, VIC 3204, AUSTRALIA
SN 0964-7058
EI 1440-6047
J9 ASIA PAC J CLIN NUTR
JI Asia Pac. J. Clin. Nutr.
PY 2009
VL 18
IS 1
BP 1
EP 7
PG 7
WC Nutrition & Dietetics
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Nutrition & Dietetics
GA 431EC
UT WOS:000265043100002
PM 19329388
DA 2022-11-30
ER

PT J
AU de Guimaraes, TAC
   Georgiou, M
   Bainbridge, JWB
   Michaelides, M
AF de Guimaraes, Thales Antonio Cabral
   Georgiou, Michalis
   Bainbridge, James W. B.
   Michaelides, Michel
TI Gene therapy for neovascular age-related macular degeneration:
   rationale, clinical trials and future directions
SO BRITISH JOURNAL OF OPHTHALMOLOGY
LA English
DT Review
DE angiogenesis; clinical trial; degeneration; genetics; retina
AB Age-related macular degeneration (AMD) is one of the leading causes of irreversible blindness in the developed world. Antivascular endothelial growth factor therapy has transformed the management and outcome of neovascular AMD (nAMD), although the need for repeated intravitreal injections-even lifelong-and the related complications, high drug costs, frequent clinic visits and repeated imaging have resulted in an enormous burden both to healthcare systems and patients. The application of gene therapy approaches for sustained delivery of a range of antiangiogenic proteins has the promise of helping to address these aforementioned challenges. A number of early phase clinical trials of gene therapy in nAMD have provided encouraging results, with many more ongoing or anticipated. There remain significant areas of controversy, including regarding the optimal treatment targets, routes of administration and potential safety concerns. In this review we aim to provide an update of the current status of gene therapy for nAMD and briefly discuss future prospects.
C1 [de Guimaraes, Thales Antonio Cabral; Georgiou, Michalis; Bainbridge, James W. B.; Michaelides, Michel] UCL, UCL Inst Ophthalmol, London, England.
   [de Guimaraes, Thales Antonio Cabral; Georgiou, Michalis; Bainbridge, James W. B.; Michaelides, Michel] Moorfields Eye Hosp, London EC1V 9EL, England.
C3 University of London; University College London; University of London;
   University College London; Moorfields Eye Hospital NHS Foundation Trust
RP Michaelides, M (通讯作者)，Moorfields Eye Hosp, London EC1V 9EL, England.
EM michel.michaelides@ucl.ac.uk
RI Cabral de Guimarães, Thales Antônio/AAD-9236-2022
OI Michaelides, Michel/0000-0002-1552-7046; Bainbridge,
   James/0000-0003-1318-8201; Cabral de Guimaraes, Thales
   Antonio/0000-0002-7936-6851; Georgiou, Michalis/0000-0001-6397-8071
FU National Institute for Health Research Biomedical Research Centre at
   Moorfields Eye Hospital NHS Foundation Trust; UCL Institute of
   Ophthalmology; Fight for Sight; Moorfields Eye Hospital Special
   Trustees; Moorfields Eye Charity; Retina UK; Foundation Fighting
   Blindness (USA); Wellcome Trust [099173/Z/12/Z]
FX This work has been supported by grants from the National Institute for
   Health Research Biomedical Research Centre at Moorfields Eye Hospital
   NHS Foundation Trust and UCL Institute of Ophthalmology, Fight for
   Sight, Moorfields Eye Hospital Special Trustees, Moorfields Eye Charity,
   Retina UK, the Foundation Fighting Blindness (USA), and the Wellcome
   Trust (099173/Z/12/Z). The views expressed are those of the authors and
   not necessarily those of the NHS, the UCL, the NIHR or the Department of
   Health.
CR Ali RR, 1998, HUM GENE THER, V9, P81, DOI 10.1089/hum.1998.9.1-81
   Allocca M, 2007, J VIROL, V81, P11372, DOI 10.1128/JVI.01327-07
   Andrae J, 2008, GENE DEV, V22, P1276, DOI 10.1101/gad.1653708
   [Anonymous], 2019, AAO 2019 DAILY
   Apte RS, 2019, CELL, V176, P1248, DOI 10.1016/j.cell.2019.01.021
   Arbabi A, 2019, J OCUL PHARMACOL TH, V35, P79, DOI 10.1089/jop.2018.0087
   Arcondeguy T, 2013, NUCLEIC ACIDS RES, V41, P7997, DOI 10.1093/nar/gkt539
   Askou AL, 2012, J GENE MED, V14, P632, DOI 10.1002/jgm.2678
   Augustin HG, 2009, NAT REV MOL CELL BIO, V10, P165, DOI 10.1038/nrm2639
   Bainbridge JWB, 2015, NEW ENGL J MED, V372, P1887, DOI 10.1056/NEJMoa1414221
   Binley K, 2012, HUM GENE THER, V23, P980, DOI 10.1089/hum.2012.008
   Bruewer AR, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0060218
   Campochiaro PA, 2006, HUM GENE THER, V17, P167, DOI 10.1089/hum.2006.17.167
   Campochiaro PA, 2017, HUM GENE THER, V28, P99, DOI 10.1089/hum.2016.117
   Cashman SM, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019078
   Constable IJ, 2016, EBIOMEDICINE, V14, P168, DOI 10.1016/j.ebiom.2016.11.016
   Dalkara D, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3005708
   Dalkara D, 2009, MOL THER, V17, P2096, DOI 10.1038/mt.2009.181
   Day TP, 2014, ADV EXP MED BIOL, V801, P687, DOI 10.1007/978-1-4614-3209-8_86
   Dehghanian Fariba, 2014, Avicenna Journal of Medical Biotechnology, V6, P192
   DEVRIES C, 1992, SCIENCE, V255, P989, DOI 10.1126/science.1312256
   Ding K, 2019, J CLIN INVEST, V129, P4901, DOI 10.1172/JCI129085
   Dong JY, 1996, HUM GENE THER, V7, P2101, DOI 10.1089/hum.1996.7.17-2101
   Falk MK, 2013, AM J OPHTHALMOL, V155, P89, DOI 10.1016/j.ajo.2012.06.031
   Ferrara N, 2004, ENDOCR REV, V25, P581, DOI 10.1210/er.2003-0027
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Garba AO, 2010, OPHTHALMOL EYE DIS, V2, P75, DOI 10.4137/OED.S4878
   Grimm D, 2017, HUM GENE THER, V28, P1075, DOI 10.1089/hum.2017.172
   Grishanin R, 2019, MOL THER, V27, P118, DOI 10.1016/j.ymthe.2018.11.003
   Habot-Wilner Z, 2019, ACTA OPHTHALMOL, V97, P460, DOI 10.1111/aos.14042
   Haller JA, 2013, OPHTHALMOLOGY, V120, pS3, DOI 10.1016/j.ophtha.2013.01.057
   Harper SJ, 2008, NAT REV CANCER, V8, P880, DOI 10.1038/nrc2505
   Heier JS, 2017, LANCET, V390, P50, DOI 10.1016/S0140-6736(17)30979-0
   Hellstrom M, 2009, GENE THER, V16, P521, DOI 10.1038/gt.2008.178
   Hussain RM, 2017, OSLI RETINA, V48, P780, DOI 10.3928/23258160-20170928-01
   Hussain RM, 2017, EXPERT OPIN EMERG DR, V22, P235, DOI 10.1080/14728214.2017.1362390
   Jin GM, 2018, BRIT J OPHTHALMOL, V102, P625, DOI 10.1136/bjophthalmol-2017-310368
   Jung JH, 2019, DRUG DISCOV TODAY, V24, P1654, DOI 10.1016/j.drudis.2019.03.027
   Juttner J, 2019, NAT NEUROSCI, V22, P1345, DOI 10.1038/s41593-019-0431-2
   Kaiser PK, 2010, AM J OPHTHALMOL, V150, P33, DOI 10.1016/j.ajo.2010.02.006
   Keel S, 2017, JAMA OPHTHALMOL, V135, P1242, DOI 10.1001/jamaophthalmol.2017.4182
   KENDALL RL, 1993, P NATL ACAD SCI USA, V90, P10705, DOI 10.1073/pnas.90.22.10705
   Kim J, 2019, SCI ADV, V5, DOI 10.1126/sciadv.aau6732
   Kumar-Singh R, 2019, EXP EYE RES, V184, P266, DOI 10.1016/j.exer.2019.05.006
   Kumaran N, 2018, BRIT MED BULL, V126, P13, DOI 10.1093/bmb/ldy005
   Lai K, 2015, EXPERT REV CLIN PHAR, V8, P135, DOI 10.1586/17512433.2015.990379
   Lee J, 2014, INVEST OPHTH VIS SCI, V55, P2191, DOI 10.1167/iovs.14-13897
   Lewis RA, 2007, J CATARACT REFR SURG, V33, P1217, DOI 10.1016/j.jcrs.2007.03.051
   Li JQ, 2020, BRIT J OPHTHALMOL, V104, P1077, DOI 10.1136/bjophthalmol-2019-314422
   Li QH, 2008, MOL VIS, V14, P1760
   MacLaren RE, 2014, LANCET, V383, P1129, DOI 10.1016/S0140-6736(13)62117-0
   MAGLIONE D, 1991, P NATL ACAD SCI USA, V88, P9267, DOI 10.1073/pnas.88.20.9267
   Maguire MG, 2016, OPHTHALMOLOGY, V123, P1751, DOI 10.1016/j.ophtha.2016.03.045
   Mingozzi F, 2011, CURR GENE THER, V11, P321, DOI 10.2174/156652311796150354
   Peden MC, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017140
   Petrs-Silva H, 2011, MOL THER, V19, P293, DOI 10.1038/mt.2010.234
   Pihlmann M, 2012, J GENE MED, V14, P328, DOI 10.1002/jgm.2623
   Planul A, 2017, ANNU REV VIS SCI, V3, P121, DOI 10.1146/annurev-vision-102016-061413
   Rabinowitz JE, 2002, J VIROL, V76, P791, DOI 10.1128/JVI.76.2.791-801.2002
   Rakic JM, 2003, INVEST OPHTH VIS SCI, V44, P3186, DOI 10.1167/iovs.02-1092
   Rakoczy EP, 2015, LANCET, V386, P2395, DOI 10.1016/S0140-6736(15)00345-1
   Rasmussen H, 2001, Hum Gene Ther, V12, P2029
   REGENXBIO, 2019, REGENXBIO ANN ADD PO
   REGENXBIO, 2020, REGENXBIO REP CONT P
   Reid CA, 2017, INVEST OPHTH VIS SCI, V58, P6429, DOI 10.1167/iovs.17-22281
   Rosen Lee S, 2002, Cancer Control, V9, P36
   Saharinen P, 2004, TRENDS IMMUNOL, V25, P387, DOI 10.1016/j.it.2004.05.003
   Singer MA, 2012, OPHTHALMOLOGY, V119, P1175, DOI 10.1016/j.ophtha.2011.12.016
   Spilsbury K, 2000, AM J PATHOL, V157, P135, DOI 10.1016/S0002-9440(10)64525-7
   Stieger K, 2008, MOL THER, V16, P916, DOI 10.1038/mt.2008.41
   Takahashi H, 2005, CLIN SCI, V109, P227, DOI 10.1042/CS20040370
   TERMAN BI, 1992, BIOCHEM BIOPH RES CO, V187, P1579, DOI 10.1016/0006-291X(92)90483-2
   Testa F, 2013, OPHTHALMOLOGY, V120, P1283, DOI 10.1016/j.ophtha.2012.11.048
   Tetz M, 2012, OPHTHALMOLOGICA, V227, P183, DOI 10.1159/000336045
   Trapani I, 2019, GENES-BASEL, V10, DOI 10.3390/genes10040287
   Trapani I, 2014, EMBO MOL MED, V6, P194, DOI 10.1002/emmm.201302948
   Ucuzian AA, 2010, J BURN CARE RES, V31, P158, DOI 10.1097/BCR.0b013e3181c7ed82
   Weleber RG, 2016, OPHTHALMOLOGY, V123, P1606, DOI 10.1016/j.ophtha.2016.03.003
   Wilde C, 2017, EYE, V31, P1042, DOI 10.1038/eye.2017.30
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Wykoff CC, 2020, PHASE 1 STUDY INTRAV
   Xia XB, 2008, MOL VIS, V14, P1965
   Xue K, 2017, EYE, V31, P1308, DOI 10.1038/eye.2017.158
   Yeh S, 2019, RETINA-J RET VIT DIS, V39, P1880, DOI 10.1097/IAE.0000000000002279
   Yin L, 2011, INVEST OPHTH VIS SCI, V52, P2775, DOI 10.1167/iovs.10-6250
   Zaiss AK, 2005, CURR GENE THER, V5, P323, DOI 10.2174/1566523054065039
NR 86
TC 23
Z9 23
U1 0
U2 6
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0007-1161
EI 1468-2079
J9 BRIT J OPHTHALMOL
JI Br. J. Ophthalmol.
PD FEB
PY 2021
VL 105
IS 2
BP 151
EP 157
DI 10.1136/bjophthalmol-2020-316195
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA QB6HE
UT WOS:000614238600003
PM 32269060
OA Green Published, hybrid
DA 2022-11-30
ER

PT J
AU Chew, EY
AF Chew, Emily Y.
TI Nutrition, Genes, and Age-Related Macular Degeneration: What Have We
   Learned from the Trials?
SO OPHTHALMOLOGICA
LA English
DT Article
DE Age-related macular degeneration; Clinical trials; Genetics
ID EYE DISEASE; NATIONAL-HEALTH; ANTIOXIDANTS; ZINC; CFH; ASSOCIATIONS;
   ZEAXANTHIN; LUTEIN; NO
AB The Age-Related Eye Disease Study (AREDS) and AREDS2 provided evidence for treating persons with age-related macular degeneration (AMD) with antioxidant vitamins and minerals to reduce the risk of development of late AMD. The AREDS2 data suggest that the beta-carotene in the original AREDS supplements be replaced by lutein and zeaxanthin, providing a safer drug for those who are smokers or former smokers. Even though consuming fish reduced the risk of AMD in observational studies, the AREDS2 results showed that omega-3 long-chain polyunsaturated fatty acids (docosahexaenoic acid/eicosapentaenoic acid) had no beneficial effect on AMD. Despite the major progress in the discovery of gene variants associated with AMD, the use of genetic testing to predict disease has not been clinically useful. The use of genetic testing prior to AMD therapies such as administering AREDS supplements is not recommended by the American Academy of Ophthalmology and other organizations. (C) 2017 S. Karger AG, Basel
C1 [Chew, Emily Y.] NEI, NIH, Bldg 10 CRC Room 3-2531,10 Ctr Dr,MSC 1204, Bethesda, MD 20892 USA.
C3 National Institutes of Health (NIH) - USA; NIH National Eye Institute
   (NEI)
RP Chew, EY (通讯作者)，NEI, NIH, Bldg 10 CRC Room 3-2531,10 Ctr Dr,MSC 1204, Bethesda, MD 20892 USA.
EM echew@nei.nih.gov
RI Mitchell, Paul/P-1498-2014
OI Chew, Emily/0000-0003-0999-9802
FU National Eye Institute/National Institutes of Health, Department of
   Health and Human Services, Bethesda, MD, USA [HHS-N-260-2005-00007-C,
   NO1-EY-5-0007]; Office of Dietary Supplements, National Center for
   Complementary and Alternative Medicine; National Institute on Aging;
   National Heart, Lung, and Blood Institute; National Institute of
   Neurological Disorders and Stroke; NATIONAL EYE INSTITUTE [ZIAEY000489]
   Funding Source: NIH RePORTER
FX The AREDS2 clinical trial was supported by the intramural program funds
   and contracts from the National Eye Institute/National Institutes of
   Health, Department of Health and Human Services, Bethesda, MD, USA
   (contract HHS-N-260-2005-00007-C; ADB contract NO1-EY-5-0007). Funds
   were generously contributed to these contracts by the following NIH
   institutes: Office of Dietary Supplements, National Center for
   Complementary and Alternative Medicine; National Institute on Aging;
   National Heart, Lung, and Blood Institute, and National Institute of
   Neurological Disorders and Stroke.
CR Augood C, 2008, AM J CLIN NUTR, V88, P398, DOI 10.1093/ajcn/88.2.398
   Awh CC, 2015, OPHTHALMOLOGY, V122, P162, DOI 10.1016/j.ophtha.2014.07.049
   Awh CC, 2013, OPHTHALMOLOGY, V120, P2317, DOI 10.1016/j.ophtha.2013.07.039
   Bonds DE, 2014, JAMA INTERN MED, V174, P763, DOI 10.1001/jamainternmed.2014.328
   Chew EY, 2015, JAMA-J AM MED ASSOC, V314, P791, DOI 10.1001/jama.2015.9677
   Chew EY, 2014, OPHTHALMOLOGY, V121, P2173, DOI 10.1016/j.ophtha.2014.05.008
   Chew EY, 2014, JAMA OPHTHALMOL, V132, P142, DOI 10.1001/jamaophthalmol.2013.7376
   Chew EY, 2013, OPHTHALMOLOGY, V120, P1604, DOI 10.1016/j.ophtha.2013.01.021
   Chew EY, 2013, JAMA-J AM MED ASSOC, V309, P2005, DOI 10.1001/jama.2013.4997
   Chew EY, 2012, OPHTHALMOLOGY, V119, P2282, DOI 10.1016/j.ophtha.2012.05.027
   Csaky K.G., 2017, J VITR DIS, V1, P75, DOI [10.1177/2474126416680671, DOI 10.1177/2474126416680671]
   GOLDBERG J, 1988, AM J EPIDEMIOL, V128, P700, DOI 10.1093/oxfordjournals.aje.a115023
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Mares-Perlman JA, 2001, AM J EPIDEMIOL, V153, P424, DOI 10.1093/aje/153.5.424
   Moeller SM, 2006, ARCH OPHTHALMOL-CHIC, V124, P1151, DOI 10.1001/archopht.124.8.1151
   SanGiovanni JP, 2007, ARCH OPHTHALMOL-CHIC, V125, P1225, DOI 10.1001/archopht.125.9.1225
   SanGiovanni JP, 2009, AM J CLIN NUTR, V90, P1601, DOI 10.3945/ajcn.2009.27594
   Seddon JM, 2003, ARCH OPHTHALMOL-CHIC, V121, P1728, DOI 10.1001/archopht.121.12.1728
   SEDDON JM, 1994, JAMA-J AM MED ASSOC, V272, P1413, DOI 10.1001/jama.272.18.1413
   Stone EM, 2015, JAMA OPHTHALMOL, V133, P598, DOI 10.1001/jamaophthalmol.2015.0369
   Stone EM, 2012, OPHTHALMOLOGY, V119, P2408, DOI 10.1016/j.ophtha.2012.05.047
   Tan JSL, 2008, OPHTHALMOLOGY, V115, P334, DOI 10.1016/j.ophtha.2007.03.083
   Wittes J, 2015, OPHTHALMOLOGY, V122, P3, DOI 10.1016/j.ophtha.2014.10.023
NR 23
TC 11
Z9 11
U1 0
U2 11
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 0030-3755
EI 1423-0267
J9 OPHTHALMOLOGICA
JI Ophthalmologica
PY 2017
VL 238
IS 1-2
BP 1
EP 5
DI 10.1159/000473865
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA FC1MB
UT WOS:000406600200001
PM 28478452
OA Bronze, Green Accepted
DA 2022-11-30
ER

PT J
AU Dugel, PU
   Novack, RL
   Csaky, KG
   Richmond, PP
   Birch, DG
   Kubota, R
AF Dugel, Pravin U.
   Novack, Roger L.
   Csaky, Karl G.
   Richmond, Preston P.
   Birch, David G.
   Kubota, Ryo
TI PHASE II, RANDOMIZED, PLACEBO-CONTROLLED, 90-DAY STUDY OF EMIXUSTAT
   HYDROCHLORIDE IN GEOGRAPHIC ATROPHY ASSOCIATED WITH DRY AGE-RELATED
   MACULAR DEGENERATION
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
ID VISUAL CYCLE MODULATOR; FUNDUS AUTOFLUORESCENCE; VERTEBRATE RETINA;
   LIPOFUSCIN; COMPONENT; PROGRESSION; DISEASE; A2E; ELECTRORETINOGRAM;
   PATHOGENESIS
AB Purpose:
   This study assessed the safety, tolerability, and pharmacodynamics of emixustat hydrochloride (ACU-4429), a novel visual cycle modulator, in subjects with geographic atrophy associated with dry age-related macular degeneration.
   Methods:
   Subjects were randomly assigned to oral emixustat (2, 5, 7, or 10 mg once daily) or placebo (3:1 ratio) for 90 days. Recovery of rod photoreceptor sensitivity after a photobleach was measured by electroretinography. Safety evaluations included analysis of adverse events and ophthalmic examinations.
   Results:
   Seventy-two subjects (54 emixustat and 18 placebo) were evaluated. Emixustat suppressed rod photoreceptor sensitivity in a dose-dependent manner. Suppression plateaued by Day 14 and was reversible within 7 days to 14 days after drug cessation. Most systemic adverse events were not considered treatment related. Dose-related ocular adverse events (chromatopsia, 57% emixustat vs. 17% placebo and delayed dark adaptation, 48% emixustat vs. 6% placebo) were mild to moderate in severity, and the majority resolved on study or within 7 days to 14 days after study drug cessation. Reversibility of these adverse events with long-term administration, however, is undetermined.
   Conclusion:
   In this Phase II study, emixustat produced a dose-dependent reversible effect on rod function that is consistent with the proposed mechanism of action. These results support further testing of emixustat for the treatment of geographic atrophy associated with dry age-related macular degeneration.
C1 [Dugel, Pravin U.] Retinal Consultants Arizona, Phoenix, AZ 85064 USA.
   [Novack, Roger L.] Retina Vitreous Associates Med Grp, Beverly Hills, CA USA.
   [Csaky, Karl G.] Texas Retina Associates, Dallas, TX USA.
   [Richmond, Preston P.] Cent Florida Retina, Orlando, FL USA.
   [Birch, David G.] Retina Fdn Southwest, Dallas, TX USA.
   [Kubota, Ryo] Acucela Inc, Seattle, WA USA.
C3 Retina Vitreous Associates Medical Group; Retina Foundation of the
   Southwest
RP Dugel, PU (通讯作者)，Retinal Consultants Arizona, 1101 E Missouri Ave, Phoenix, AZ 85064 USA.
EM pdugel@gmail.com
FU Acucela Inc.; NATIONAL EYE INSTITUTE [R01EY009076] Funding Source: NIH
   RePORTER
FX Supported by Acucela Inc. The sponsor participated in design and conduct
   of the study; data collection, management, and analysis; interpretation
   of the data; and preparation, review, and approval of the manuscript.
CR Bermann M, 2001, EXP EYE RES, V72, P191
   BONTING SL, 1961, EXP EYE RES, V1, P14, DOI 10.1016/S0014-4835(61)80004-3
   BROWN KT, 1961, J PHYSIOL-LONDON, V158, P257, DOI 10.1113/jphysiol.1961.sp006768
   Choudhry N, 2010, SEMIN OPHTHALMOL, V25, P206, DOI 10.3109/08820538.2010.518121
   de Jong PTVM, 2006, NEW ENGL J MED, V355, P1474, DOI 10.1056/NEJMra062326
   Donoso LA, 2006, SURV OPHTHALMOL, V51, P137, DOI 10.1016/j.survophthal.2005.12.001
   ELDRED GE, 1993, NATURE, V361, P724, DOI 10.1038/361724a0
   FERRIS FL, 1982, AM J OPHTHALMOL, V94, P91, DOI 10.1016/0002-9394(82)90197-0
   Finnemann SC, 2002, P NATL ACAD SCI USA, V99, P3842, DOI 10.1073/pnas.052025899
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Golczak M, 2005, P NATL ACAD SCI USA, V102, P8162, DOI 10.1073/pnas.0503318102
   Golczak M, 2008, J BIOL CHEM, V283, P9543, DOI 10.1074/jbc.M708982200
   Holz FG, 2007, AM J OPHTHALMOL, V143, P463, DOI 10.1016/j.ajo.2006.11.041
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Kanda A, 2008, BRIT J OPHTHALMOL, V92, P448, DOI 10.1136/bjo.2007.131581
   Klein ML, 2010, OPHTHALMOLOGY, V117, P1554, DOI 10.1016/j.ophtha.2009.12.012
   Klein R, 2011, ARCH OPHTHALMOL-CHIC, V129, P75, DOI 10.1001/archophthalmol.2010.318
   Kubota R, 2014, RETINA-J RET VIT DIS, V34, P603, DOI 10.1097/01.iae.0000434565.80060.f8
   Kubota R, 2012, RETINA-J RET VIT DIS, V32, P183, DOI 10.1097/IAE.0b013e318217369e
   Lamb LE, 2004, PHOTOCHEM PHOTOBIOL, V79, P127, DOI 10.1562/0031-8655(2004)079<0127:AACOOL>2.0.CO;2
   Lindblad AS, 2009, ARCH OPHTHALMOL-CHIC, V127, P1168, DOI 10.1001/archophthalmol.2009.198
   Maeda A, 2006, MOL PHARMACOL, V70, P1220, DOI 10.1124/mol.106.026823
   Marmor MF, 2009, DOC OPHTHALMOL, V118, P69, DOI 10.1007/s10633-008-9155-4
   Pascolini D, 2012, BRIT J OPHTHALMOL, V96, P614, DOI 10.1136/bjophthalmol-2011-300539
   Radu RA, 2003, P NATL ACAD SCI USA, V100, P4742, DOI 10.1073/pnas.0737855100
   Rein DB, 2009, ARCH OPHTHALMOL-CHIC, V127, P533, DOI 10.1001/archophthalmol.2009.58
   Resnikoff S, 2004, B WORLD HEALTH ORGAN, V82, P844
   Schmitz-Valckenberg S, 2004, INVEST OPHTH VIS SCI, V45, P4470, DOI 10.1167/iovs.03-1311
   Schmitz-Valckenberg S, 2006, INVEST OPHTH VIS SCI, V47, P2648, DOI 10.1167/iovs.05-0892
   Schmitz-Valckenberg S, 2009, SURV OPHTHALMOL, V54, P96, DOI 10.1016/j.survophthal.2008.10.004
   Schmitz-Valckenberg S, 2009, INVEST OPHTH VIS SCI, V50, P3915, DOI 10.1167/iovs.08-2484
   Seddon J, 2013, EPIDEMIOLOGY RISK FA, V5th, P1134
   Sparrow JR, 2010, J LIPID RES, V51, P247, DOI 10.1194/jlr.R000687
   Sparrow JR, 2002, INVEST OPHTH VIS SCI, V43, P1222
   Suter M, 2000, J BIOL CHEM, V275, P39625, DOI 10.1074/jbc.M007049200
NR 35
TC 42
Z9 46
U1 0
U2 7
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD JUN
PY 2015
VL 35
IS 6
BP 1173
EP 1183
DI 10.1097/IAE.0000000000000606
PG 11
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA CJ7KJ
UT WOS:000355673600017
PM 25932553
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Maugeri, A
   Barchitta, M
   Mazzone, MG
   Giuliano, F
   Agodi, A
AF Maugeri, Andrea
   Barchitta, Martina
   Mazzone, Maria Grazia
   Giuliano, Francesco
   Agodi, Antonella
TI Complement System and Age-Related Macular Degeneration: Implications of
   Gene-Environment Interaction for Preventive and Personalized Medicine
SO BIOMED RESEARCH INTERNATIONAL
LA English
DT Review
ID C-REACTIVE-PROTEIN; DECAY-ACCELERATING FACTOR; FACTOR-H POLYMORPHISM;
   GENOME-WIDE ASSOCIATION; BODY-MASS INDEX; FACTOR-I GENE;
   CIGARETTE-SMOKING; ALTERNATIVE PATHWAY; FACTOR-B; GEOGRAPHIC ATROPHY
AB Age-related macular degeneration (AMD) is the most common cause of visual loss in developed countries, with a significant economic and social burden on public health. Although genome-wide and gene-candidate studies have been enabled to identify genetic variants in the complement system associated with AMD pathogenesis, the effect of gene-environment interaction is still under debate. In this review we provide an overview of the role of complement system and its genetic variants inAMD, summarizing the consequences of the interaction between genetic and environmental risk factors on AMD onset, progression, and therapeutic response. Finally, we discuss the perspectives of current evidence in the field of genomics driven personalized medicine and public health.
C1 [Maugeri, Andrea; Barchitta, Martina; Agodi, Antonella] Univ Catania, Dept Med & Surg Sci & Adv Technol GF Ingrassia, Via S Sofia 87, I-95123 Catania, Italy.
   [Mazzone, Maria Grazia; Giuliano, Francesco] SIFI SpA, Res & Dev Dept, Via Ercole Patti 36, I-95025 Catania, Italy.
C3 University of Catania
RP Agodi, A (通讯作者)，Univ Catania, Dept Med & Surg Sci & Adv Technol GF Ingrassia, Via S Sofia 87, I-95123 Catania, Italy.
EM agodia@unict.it
RI Agodi, Antonella/B-3501-2011; Maugeri, Andrea/K-1018-2017; Barchitta,
   Martina/A-1362-2015; Agodi, Antonella/AIF-3938-2022; Barchitta,
   Martina/AFV-8723-2022
OI Agodi, Antonella/0000-0002-4405-8162; Maugeri,
   Andrea/0000-0003-2655-8574; Barchitta, Martina/0000-0002-0905-5003;
   Agodi, Antonella/0000-0002-4405-8162; 
FU Department of Medical and Surgical Sciences and Advanced Technologies
   "GF Ingrassia," University of Catania, Italy (Piano Triennale di
   Sviluppo delle Attivita di Ricerca Scientifica del Dipartimento 2016-18)
FX This research was funded by the Department of Medical and Surgical
   Sciences and Advanced Technologies "GF Ingrassia," University of
   Catania, Italy (Piano Triennale di Sviluppo delle Attivita di Ricerca
   Scientifica del Dipartimento 2016-18).
CR Abedi F, 2013, OPHTHALMOLOGY, V120, P1641, DOI 10.1016/j.ophtha.2013.01.014
   Agarwal A, 2015, CLIN OPHTHALMOL, V9, P1001, DOI [10.2147/OPTH.S59725, 10.2147/OPTH.S74959]
   Agbeko RS, 2010, PEDIATR CRIT CARE ME, V11, P561, DOI 10.1097/PCC.0b013e3181d900ba
   Ambati J, 2012, NEURON, V75, P26, DOI 10.1016/j.neuron.2012.06.018
   Awh CC, 2015, OPHTHALMOLOGY, V122, P162, DOI 10.1016/j.ophtha.2014.07.049
   Bao B, 2010, AM J CLIN NUTR, V91, P1634, DOI 10.3945/ajcn.2009.28836
   Barbour TD, 2016, NEPHROL DIAL TRANSPL, V31, P717, DOI 10.1093/ndt/gfu317
   Barchitta M, 2016, DIS MARKERS, V2016, DOI 10.1155/2016/8486406
   Blaum BS, 2015, NAT CHEM BIOL, V11, P77, DOI [10.1038/NCHEMBIO.1696, 10.1038/nchembio.1696]
   Bressler SB, 2009, OPHTHALMOLOGY, V116, pS1, DOI 10.1016/j.ophtha.2009.06.045
   Brodbeck WG, 1996, J IMMUNOL, V156, P2528
   Buitendijk GHS, 2014, INVEST OPHTH VIS SCI, V55, P6167, DOI 10.1167/iovs.14-15142
   Buitendijk GHS, 2013, OPHTHALMOLOGY, V120, P2644, DOI 10.1016/j.ophtha.2013.07.053
   Chakravarthy U, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.04.015
   Chen GH, 2015, SCI REP-UK, V5, DOI 10.1038/srep14517
   Chen H, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0042464
   Chen W, 2010, P NATL ACAD SCI USA, V107, P7401, DOI 10.1073/pnas.0912702107
   Chew EY, 2014, OPHTHALMOLOGY, V121, P2173, DOI 10.1016/j.ophtha.2014.05.008
   Chew EY, 2013, JAMA-J AM MED ASSOC, V309, P2005, DOI 10.1001/jama.2013.4997
   Clark SJ, 2015, J CLIN MED, V4, P18, DOI 10.3390/jcm4010018
   Crabb JW, 2002, P NATL ACAD SCI USA, V99, P14682, DOI 10.1073/pnas.222551899
   DeAngelis MM, 2007, ARCH OPHTHALMOL-CHIC, V125, P49, DOI 10.1001/archopht.125.1.49
   Deban L, 2008, J IMMUNOL, V181, P8433, DOI 10.4049/jimmunol.181.12.8433
   Delcourt C, 2001, Ophthalmic Epidemiol, V8, P237, DOI 10.1076/opep.8.4.237.1613
   Delcourt C, 2011, INVEST OPHTH VIS SCI, V52, P5955, DOI 10.1167/iovs.10-6235
   Despriet DDG, 2006, JAMA-J AM MED ASSOC, V296, P301, DOI 10.1001/jama.296.3.301
   DISCIPIO RG, 1992, J IMMUNOL, V149, P2592
   Duvvari MR, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0094165
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Ennis S, 2010, EUR J HUM GENET, V18, P15, DOI 10.1038/ejhg.2009.113
   Esparza-Gordillo J, 2004, IMMUNOGENETICS, V56, P77, DOI 10.1007/s00251-004-0660-7
   Evans JR, 2005, BRIT J OPHTHALMOL, V89, P550, DOI 10.1136/bjo.2004.049726
   Fagerness JA, 2009, EUR J HUM GENET, V17, P100, DOI 10.1038/ejhg.2008.140
   Farkas I, 2002, J PHYSIOL-LONDON, V539, P537, DOI 10.1113/jphysiol.2001.013381
   Ferrara D, 2015, JAMA OPHTHALMOL, V133, P785, DOI 10.1001/jamaophthalmol.2015.0814
   Finnemann SC, 2002, P NATL ACAD SCI USA, V99, P3842, DOI 10.1073/pnas.052025899
   Francis Peter James, 2011, Trans Am Ophthalmol Soc, V109, P115
   Fritsche LG, 2016, NAT GENET, V48, P134, DOI 10.1038/ng.3448
   Fritsche LG, 2013, NAT GENET, V45, P433, DOI 10.1038/ng.2578
   Geerlings MJ, 2017, MOL IMMUNOL, V84, P65, DOI 10.1016/j.molimm.2016.11.016
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   Grassmann F, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0037979
   Grunwald JE, 2012, OPHTHALMOLOGY, V119, P1634, DOI 10.1016/j.ophtha.2012.02.013
   Gu JY, 2009, MOL CELL PROTEOMICS, V8, P1338, DOI 10.1074/mcp.M800453-MCP200
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Hagstrom SA, 2013, OPHTHALMOLOGY, V120, P593, DOI 10.1016/j.ophtha.2012.11.037
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Harris CL, 2005, J BIOL CHEM, V280, P2569, DOI 10.1074/jbc.M410179200
   Harris CL, 2007, J IMMUNOL, V178, P352, DOI 10.4049/jimmunol.178.1.352
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Helgason H, 2013, NAT GENET, V45, P1371, DOI 10.1038/ng.2740
   Ho L, 2011, ARCH OPHTHALMOL-CHIC, V129, P758, DOI 10.1001/archophthalmol.2011.141
   Hong N, 2016, ACTA OPHTHALMOL, V94, P334, DOI 10.1111/aos.13049
   Howard KP, 2014, INVEST OPHTH VIS SCI, V55, P2592, DOI 10.1167/iovs.13-13763
   Huang Y, 2006, J BIOL CHEM, V281, P27398, DOI 10.1074/jbc.M603690200
   HUSLER T, 1995, J BIOL CHEM, V270, P3483
   Jarva H, 1999, J IMMUNOL, V163, P3957
   Johnson EJ, 2005, NUTR REV, V63, P9, DOI 10.1301/nr.2004.janr.9-15
   Johnson LV, 2000, EXP EYE RES, V70, P441, DOI 10.1006/exer.1999.0798
   Johnson LV, 2001, EXP EYE RES, V73, P887, DOI 10.1006/exer.2001.1094
   Jozsi M, 2008, TRENDS IMMUNOL, V29, P380, DOI 10.1016/j.it.2008.04.008
   Kaemmerer E, 2007, INVEST OPHTH VIS SCI, V48, P1342, DOI 10.1167/iovs.06-0549
   Kaiser PK, 2007, AM J OPHTHALMOL, V144, P850, DOI 10.1016/j.ajo.2007.08.012
   Kalf RRJ, 2014, GENET MED, V16, P85, DOI 10.1038/gim.2013.80
   Kavanagh D, 2013, SEMIN NEPHROL, V33, P508, DOI 10.1016/j.semnephrol.2013.08.003
   Kawa MP, 2014, J IMMUNOL RES, V2014, DOI 10.1155/2014/483960
   KEW RR, 1985, J CLIN INVEST, V75, P1000, DOI 10.1172/JCI111760
   Khandhadia S, 2012, IMMUNOBIOLOGY, V217, P127, DOI 10.1016/j.imbio.2011.07.019
   Kim DD, 2006, CLIN IMMUNOL, V118, P127, DOI 10.1016/j.clim.2005.10.014
   Klein B E, 2001, Ophthalmic Epidemiol, V8, P251, DOI 10.1076/opep.8.4.251.1612
   Klein ML, 2008, OPHTHALMOLOGY, V115, P1019, DOI 10.1016/j.ophtha.2008.01.036
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Klein R, 2007, AM J OPHTHALMOL, V143, P473, DOI 10.1016/j.ajo.2006.11.058
   Kloeckener-Gruissem B, 2011, INVEST OPHTH VIS SCI, V52, P4694, DOI 10.1167/iovs.10-6080
   Kondo N, 2010, EUR J HUM GENET, V18, P634, DOI 10.1038/ejhg.2009.243
   Kopp A, 2012, BIOMOLECULES, V2, P46, DOI 10.3390/biom2010046
   Langford-Smith A, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00025
   Lechanteur YTE, 2015, JAMA OPHTHALMOL, V133, P533, DOI 10.1001/jamaophthalmol.2015.18
   Liao X, 2016, ARCH GERONTOL GERIAT, V64, P123, DOI 10.1016/j.archger.2016.01.011
   Lin H, 2017, OPHTHAL EPIDEMIOL, V24, P311, DOI 10.1080/09286586.2017.1290259
   Liszewski MK, 2015, J INTERN MED, V277, P294, DOI 10.1111/joim.12338
   LOCKERT DH, 1995, J BIOL CHEM, V270, P19723, DOI 10.1074/jbc.270.34.19723
   LOKKI ML, 1991, IMMUNOGENETICS, V34, P242, DOI 10.1007/BF00215259
   Lublin D M, 2005, Immunohematology, V21, P39
   Machalinska A, 2009, OPHTHALMIC RES, V42, P54, DOI 10.1159/000219686
   Maller JB, 2007, NAT GENET, V39, P1200, DOI 10.1038/ng2131
   Manderson AP, 2004, ANNU REV IMMUNOL, V22, P431, DOI 10.1146/annurev.immunol.22.012703.104549
   MARESPERLMAN JA, 1995, ARCH OPHTHALMOL-CHIC, V113, P743, DOI 10.1001/archopht.1995.01100060069034
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Maugeri A., ACTA OPHTHALMOLOGICA
   McKay GJ, 2011, HUM MUTAT, V32, P1407, DOI 10.1002/humu.21577
   McRae JL, 2005, J IMMUNOL, V174, P6250, DOI 10.4049/jimmunol.174.10.6250
   MEDOF ME, 1984, J EXP MED, V160, P1558, DOI 10.1084/jem.160.5.1558
   MERI S, 1990, IMMUNOLOGY, V71, P1
   Merle BMJ, 2016, AM J CLIN NUTR, V103, P1135, DOI 10.3945/ajcn.115.117606
   Merle BMJ, 2015, AM J CLIN NUTR, V102, P1196, DOI 10.3945/ajcn.115.111047
   Mihlan M, 2009, CELL DEATH DIFFER, V16, P1630, DOI 10.1038/cdd.2009.103
   Mihlan M, 2009, MOL IMMUNOL, V46, P335, DOI 10.1016/j.molimm.2008.10.029
   Miller JW, 2013, AM J OPHTHALMOL, V155, P1, DOI 10.1016/j.ajo.2012.10.018
   Montes T, 2009, P NATL ACAD SCI USA, V106, P4366, DOI 10.1073/pnas.0812584106
   Morgan BP, 1997, CLIN EXP IMMUNOL, V107, P1, DOI 10.1046/j.1365-2249.1997.d01-890.x
   Mossakowska D, 1999, EUR J IMMUNOL, V29, P1955, DOI 10.1002/(SICI)1521-4141(199906)29:06<1955::AID-IMMU1955>3.3.CO;2-F
   Mullins RF, 2000, FASEB J, V14, P835, DOI 10.1096/fasebj.14.7.835
   Munch IC, 2016, ACTA OPHTHALMOL, V94, P657, DOI 10.1111/aos.13198
   Myers CE, 2014, OPHTHALMOLOGY, V121, P1949, DOI 10.1016/j.ophtha.2014.04.040
   Nan R, 2011, J MOL BIOL, V408, P714, DOI 10.1016/j.jmb.2011.03.006
   Nan R, 2008, J MOL BIOL, V384, P1341, DOI 10.1016/j.jmb.2008.10.030
   Neuner B, 2009, ADDICT BEHAV, V34, P938, DOI 10.1016/j.addbeh.2009.05.015
   NICHOLSONWELLER A, 1982, J IMMUNOL, V129, P184
   Nishida N, 2006, P NATL ACAD SCI USA, V103, P19737, DOI 10.1073/pnas.0609791104
   Nozaki M, 2006, P NATL ACAD SCI USA, V103, P2328, DOI 10.1073/pnas.0408835103
   PERKINS SJ, 1991, BIOCHEMISTRY-US, V30, P2847, DOI 10.1021/bi00225a017
   Perkins SJ, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00126
   Reynolds R, 2013, OPHTHALMOLOGY, V120, P1020, DOI 10.1016/j.ophtha.2012.10.020
   ROLLINS SA, 1990, J IMMUNOL, V144, P3478
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   ROSS GD, 1982, J IMMUNOL, V129, P2051
   Ryu E, 2010, MOL VIS, V16, P2811
   Saksens NTM, 2016, JAMA OPHTHALMOL, V134, P287, DOI 10.1001/jamaophthalmol.2015.5592
   SanGiovanni JP, 2008, ARCH OPHTHALMOL-CHIC, V126, P1274, DOI 10.1001/archopht.126.9.1274
   SanGiovanni JP, 2009, AM J CLIN NUTR, V90, P1601, DOI 10.3945/ajcn.2009.27594
   Sarks S, 2007, INVEST OPHTH VIS SCI, V48, P968, DOI 10.1167/iovs.06-0443
   Schaumberg DA, 2007, ARCH OPHTHALMOL-CHIC, V125, P55, DOI 10.1001/archopht.125.1.55
   Schmidt S, 2006, AM J HUM GENET, V78, P852, DOI 10.1086/503822
   Scholl HPN, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002593
   Schwartz SG, 2011, J OPHTHALMOL, V2011, DOI 10.1155/2011/252549
   Scott WK, 2007, OPHTHALMOLOGY, V114, P1151, DOI 10.1016/j.ophtha.2006.08.054
   Scripsema NK, 2015, J OPHTHALMOL, V2015, DOI 10.1155/2015/865179
   Seddon JM, 2004, JAMA-J AM MED ASSOC, V291, P704, DOI 10.1001/jama.291.6.704
   Seddon JM, 2003, ARCH OPHTHALMOL-CHIC, V121, P1728, DOI 10.1001/archopht.121.12.1728
   Seddon JM, 2003, ARCH OPHTHALMOL-CHIC, V121, P785, DOI 10.1001/archopht.121.6.785
   SEDDON JM, 1994, JAMA-J AM MED ASSOC, V272, P1413, DOI 10.1001/jama.272.18.1413
   Seddon JM, 2001, ARCH OPHTHALMOL-CHIC, V119, P1191, DOI 10.1001/archopht.119.8.1191
   Seddon JM, 2006, HUM HERED, V61, P157, DOI 10.1159/000094141
   Seddon JM, 2006, ARCH OPHTHALMOL-CHIC, V124, P995, DOI 10.1001/archopht.124.7.995
   Seddon JM, 2016, BRIT J OPHTHALMOL, V100, P1731, DOI 10.1136/bjophthalmol-2016-308624
   Seddon JM, 2013, NAT GENET, V45, P1366, DOI 10.1038/ng.2741
   Sepp T, 2006, INVEST OPHTH VIS SCI, V47, P536, DOI 10.1167/iovs.05-1143
   Seya T, 1999, INT J BIOCHEM CELL B, V31, P1255, DOI 10.1016/S1357-2725(99)00092-8
   SEYA T, 1991, MOL IMMUNOL, V28, P1137
   Simone B, 2013, HEALTH POLICY, V110, P214, DOI 10.1016/j.healthpol.2013.01.015
   Sivaprasad S, 2007, ARCH OPHTHALMOL-CHIC, V125, P515, DOI 10.1001/archopht.125.4.515
   Sofat R, 2012, INT J EPIDEMIOL, V41, P250, DOI 10.1093/ije/dyr204
   Spencer KL, 2007, HUM MOL GENET, V16, P1986, DOI 10.1093/hmg/ddm146
   Thakkinstian A, 2006, HUM MOL GENET, V15, P2784, DOI 10.1093/hmg/ddl220
   Thakkinstian A, 2012, AM J EPIDEMIOL, V176, P361, DOI 10.1093/aje/kws031
   Thornton J, 2005, EYE, V19, P935, DOI 10.1038/sj.eye.6701978
   Tian J, 2012, INVEST OPHTH VIS SCI, V53, P4262, DOI 10.1167/iovs.11-8542
   Tian Y, 2015, ACTA OPHTHALMOL, V93, P141, DOI 10.1111/aos.12535
   Tomany SC, 2004, ARCH OPHTHALMOL-CHIC, V122, P750, DOI 10.1001/archopht.122.5.750
   Tomany SC, 2004, OPHTHALMOLOGY, V111, P1280, DOI 10.1016/j.ophtha.2003.11.010
   Tomany SC, 2003, OPHTHALMOLOGY, V110, P1526, DOI 10.1016/S0161-6420(03)00539-6
   Tong Y, 2010, MOL VIS, V16, P1958
   Tortajada A, 2009, HUM MOL GENET, V18, P3452, DOI 10.1093/hmg/ddp289
   Troutbeck R, 2012, CLIN EXP OPHTHALMOL, V40, P18, DOI 10.1111/j.1442-9071.2011.02581.x
   van de Ven JPH, 2013, NAT GENET, V45, P813, DOI 10.1038/ng.2640
   VandenLangenberg GM, 1998, AM J EPIDEMIOL, V148, P204, DOI 10.1093/oxfordjournals.aje.a009625
   Vives-Bauza C, 2008, J BIOL CHEM, V283, P24770, DOI 10.1074/jbc.M800706200
   Wagner E. K., 2016, SCI REPORTS, V6
   Wagner E, 2010, NAT REV DRUG DISCOV, V9, P43, DOI 10.1038/nrd3011
   Wang JJ, 2014, OPHTHALMOLOGY, V121, P667, DOI 10.1016/j.ophtha.2013.10.017
   Wang JJ, 2009, AM J EPIDEMIOL, V169, P633, DOI 10.1093/aje/kwn358
   Wang JY, 2008, J IMMUNOL, V181, P712, DOI 10.4049/jimmunol.181.1.712
   Wang Q, 2016, INT J OPHTHALMOL-CHI, V9, P298, DOI 10.18240/ijo.2016.02.23
   Wang X, 2014, GENE, V538, P306, DOI 10.1016/j.gene.2014.01.032
   Wang X, 2013, INT J OPHTHALMOL-CHI, V6, P861, DOI 10.3980/j.issn.2222-3959.2013.06.21
   Weismann D, 2011, NATURE, V478, P76, DOI 10.1038/nature10449
   Wu J, 2009, NAT IMMUNOL, V10, P728, DOI 10.1038/ni.1755
   Wu MX, 2016, OPHTHALMIC RES, V55, P135, DOI 10.1159/000442257
   Yates JRW, 2007, NEW ENGL J MED, V357, P553, DOI 10.1056/NEJMoa072618
   Yehoshua Z, 2014, OPHTHALMOLOGY, V121, P693, DOI 10.1016/j.ophtha.2013.09.044
   Ying GS, 2013, OPHTHALMOLOGY, V120, P122, DOI 10.1016/j.ophtha.2012.07.042
   Yu QQ, 2015, GENE, V561, P249, DOI 10.1016/j.gene.2015.02.039
   Yu Y, 2014, HUM MOL GENET, V23, P5283, DOI 10.1093/hmg/ddu226
   Zhan XW, 2013, NAT GENET, V45, P1375, DOI 10.1038/ng.2758
   Zhang MX, 2015, GENET MOL RES, V14, P12567, DOI 10.4238/2015.October.16.24
   Zhou JL, 2006, P NATL ACAD SCI USA, V103, P16182, DOI 10.1073/pnas.0604255103
   Zhou J, 2009, INVEST OPHTH VIS SCI, V50, P1392, DOI 10.1167/iovs.08-2868
   Zipfel PF, 2009, IMMUNOL LETT, V126, P1, DOI 10.1016/j.imlet.2009.07.005
   Zipfel PF, 2009, NAT REV IMMUNOL, V9, P729, DOI 10.1038/nri2620
NR 181
TC 21
Z9 21
U1 0
U2 3
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 2314-6133
EI 2314-6141
J9 BIOMED RES INT
JI Biomed Res. Int.
PY 2018
VL 2018
AR 7532507
DI 10.1155/2018/7532507
PG 13
WC Biotechnology & Applied Microbiology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biotechnology & Applied Microbiology; Research & Experimental Medicine
GA GT0MC
UT WOS:000444134900001
PM 30225264
OA Green Submitted, Green Published, gold
DA 2022-11-30
ER

PT J
AU Blasiak, J
   Synowiec, E
   Salminen, A
   Kaarniranta, K
AF Blasiak, Janusz
   Synowiec, Ewelina
   Salminen, Antero
   Kaarniranta, Kai
TI Genetic Variability in DNA Repair Proteins in Age-Related Macular
   Degeneration
SO INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
LA English
DT Review
DE age-related macular degeneration; AMD; DNA repair; genetic polymorphism
ID BASE EXCISION-REPAIR; SYNDROME GROUP-B; LUNG-CANCER RISK; SINGLE
   NUCLEOTIDE POLYMORPHISMS; HOGG1 SER(326)CYS POLYMORPHISM; CELL
   REACTIVATION ASSAY; COMPLEMENT FACTOR-H; HUMAN MUTY HOMOLOG;
   COLORECTAL-CANCER; BREAST-CANCER
AB The pathogenesis of age-related macular degeneration (AMD) is complex and involves interactions between environmental and genetic factors, with oxidative stress playing an important role inducing damage in biomolecules, including DNA. Therefore, genetic variability in the components of DNA repair systems may influence the ability of the cell to cope with oxidative stress and in this way contribute to the pathogenesis of AMD. However, few reports have been published on this subject so far. We demonstrated that the c.977C>G polymorphism (rs1052133) in the hOGG1 gene and the c.972G>C polymorphism (rs3219489) in the MUTYH gene, the products of which play important roles in the repair of oxidatively damaged DNA, might be associated with the risk of AMD. Oxidative stress may promote misincorporation of uracil into DNA, where it is targeted by several DNA glycosylases. We observed that the g.4235T>C (rs2337395) and c.-32A>G (rs3087404) polymorphisms in two genes encoding such glycosylases, UNG and SMUG1, respectively, could be associated with the occurrence of AMD. Polymorphisms in some other DNA repair genes, including XPD (ERCC2), XRCC1 and ERCC6 (CSB) have also been reported to be associated with AMD. These data confirm the importance of the cellular reaction to DNA damage, and this may be influenced by variability in DNA repair genes, in AMD pathogenesis.
C1 [Blasiak, Janusz; Synowiec, Ewelina] Univ Lodz, Fac Biol & Environm Protect, Dept Mol Genet, PL-90236 Lodz, Poland.
   [Salminen, Antero] Univ Eastern Finland, Inst Clin Med, Dept Neurol, FI-70211 Kuopio, Finland.
   [Salminen, Antero] Kuopio Univ Hosp, Dept Neurol, FI-70211 Kuopio, Finland.
   [Kaarniranta, Kai] Univ Eastern Finland, Inst Clin Med, Dept Ophthalmol, FI-70211 Kuopio, Finland.
   [Kaarniranta, Kai] Kuopio Univ Hosp, Dept Ophthalmol, FI-70211 Kuopio, Finland.
C3 University of Lodz; University of Eastern Finland; Kuopio University
   Hospital; University of Eastern Finland; University of Eastern Finland;
   Kuopio University Hospital; University of Eastern Finland
RP Blasiak, J (通讯作者)，Univ Lodz, Fac Biol & Environm Protect, Dept Mol Genet, Pomorska 141-143, PL-90236 Lodz, Poland.
EM jblasiak@biol.uni.lodz.pl; ewelinas@biol.uni.lodz.pl;
   antero.salminen@uef.fi; Kai.Kaarniranta@kuh.fi
OI Blasiak, Janusz/0000-0001-9539-9584; Synowiec,
   Ewelina/0000-0002-0730-4491; Kaarniranta, Kai/0000-0003-2600-8679
CR Akbari M, 2007, NEUROSCIENCE, V145, P1201, DOI 10.1016/j.neuroscience.2006.10.010
   Ali M, 2008, GASTROENTEROLOGY, V135, P499, DOI 10.1053/j.gastro.2008.04.035
   Ames BN, 2001, MUTAT RES-FUND MOL M, V475, P7, DOI 10.1016/S0027-5107(01)00070-7
   An Q, 2005, EMBO J, V24, P2205, DOI 10.1038/sj.emboj.7600689
   Baas DC, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013786
   Barnes DE, 2004, ANNU REV GENET, V38, P445, DOI 10.1146/annurev.genet.38.072902.092448
   Berntsson SG, 2011, J NEURO-ONCOL, V105, P531, DOI 10.1007/s11060-011-0614-5
   Blount BC, 1997, P NATL ACAD SCI USA, V94, P3290, DOI 10.1073/pnas.94.7.3290
   Bojanowski Christine M, 2005, Trans Am Ophthalmol Soc, V103, P37
   Boldogh I, 2001, NUCLEIC ACIDS RES, V29, P2802, DOI 10.1093/nar/29.13.2802
   Boorstein RJ, 2001, J BIOL CHEM, V276, P41991, DOI 10.1074/jbc.M106953200
   Campalans A, 2005, DNA REPAIR, V4, P826, DOI 10.1016/j.dnarep.2005.04.014
   Chang CH, 2009, ANTICANCER RES, V29, P5121
   Chen W, 2010, P NATL ACAD SCI USA, V107, P7401, DOI 10.1073/pnas.0912702107
   Chevillard S, 1998, ONCOGENE, V16, P3083, DOI 10.1038/sj.onc.1202096
   Chiu CF, 2008, ORAL ONCOL, V44, P582, DOI 10.1016/j.oraloncology.2007.07.006
   Choi JY, 2003, BREAST CANCER RES TR, V79, P59, DOI 10.1023/A:1023305826726
   Christen WG, 2009, ARCH INTERN MED, V169, P335, DOI 10.1001/archinternmed.2008.574
   Christiansen M, 2003, NUCLEIC ACIDS RES, V31, P963, DOI 10.1093/nar/gkg164
   Clarkson SG, 2005, DNA REPAIR, V4, P1068, DOI 10.1016/j.dnarep.2005.07.001
   Conrad DF, 2010, NATURE, V464, P704, DOI 10.1038/nature08516
   Ding XY, 2009, PROG RETIN EYE RES, V28, P1, DOI 10.1016/j.preteyeres.2008.10.001
   Duell EJ, 2001, CANCER EPIDEM BIOMAR, V10, P217
   Duthie SJ, 2002, J NUTR, V132, p2444S, DOI 10.1093/jn/132.8.2444S
   Dybdahl M, 1999, CANCER EPIDEM BIOMAR, V8, P77
   Endres M, 2004, J CLIN INVEST, V113, P1711, DOI 10.1172/JCI200420926
   Fanciulli M, 2010, CLIN GENET, V77, P201, DOI 10.1111/j.1399-0004.2009.01342.x
   Faure H, 1998, FREE RADICAL RES, V28, P377, DOI 10.3109/10715769809070806
   Fenech M, 2012, MUTAT RES-FUND MOL M, V733, P21, DOI 10.1016/j.mrfmmm.2011.11.003
   Gabriel HE, 2006, AM J CLIN NUTR, V83, P835, DOI 10.1093/ajcn/83.4.835
   Ginsberg G, 2011, MUTAT RES-REV MUTAT, V727, P1, DOI 10.1016/j.mrrev.2011.02.001
   Goode EL, 2002, CANCER EPIDEM BIOMAR, V11, P1513
   Gorgun E, 2010, INVEST OPHTH VIS SCI, V51, P4732, DOI 10.1167/iovs.09-4842
   Gu J, 2005, CLIN CANCER RES, V11, P1408, DOI 10.1158/1078-0432.CCR-04-1101
   Gu YS, 2002, J BIOL CHEM, V277, P11135, DOI 10.1074/jbc.M108618200
   Hamajima Nobuyuki, 2002, Asian Pac J Cancer Prev, V3, P197
   Han L, 2012, P NATL ACAD SCI USA, V109, P4604, DOI 10.1073/pnas.1120743109
   Hardy J, 2010, NEURON, V68, P201, DOI 10.1016/j.neuron.2010.10.014
   Hashiguchi K, 2004, NUCLEIC ACIDS RES, V32, P5596, DOI 10.1093/nar/gkh863
   Haug T, 1998, NUCLEIC ACIDS RES, V26, P1449, DOI 10.1093/nar/26.6.1449
   Hill JW, 2007, CANCER DETECT PREV, V31, P237, DOI 10.1016/j.cdp.2007.05.001
   Ho L, 2011, ARCH OPHTHALMOL-CHIC, V129, P758, DOI 10.1001/archophthalmol.2011.141
   Hu YY, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035220
   Huang XX, 2012, MOL GENET METAB, V106, P127, DOI 10.1016/j.ymgme.2012.02.017
   Hung RJ, 2005, AM J EPIDEMIOL, V162, P925, DOI 10.1093/aje/kwi318
   Ishida T, 1999, CYTOGENET CELL GENET, V85, P232, DOI 10.1159/000015299
   Jiang Z, 2010, BREAST CANCER RES TR, V123, P203, DOI 10.1007/s10549-010-0751-0
   Johnson AB, 2007, MUTAT RES-FUND MOL M, V618, P149, DOI 10.1016/j.mrfmmm.2006.10.007
   Kasahara M, 2008, J EXP CLIN CANC RES, V27, DOI 10.1186/1756-9966-27-49
   Kavli B, 2005, J EXP MED, V201, P2011, DOI 10.1084/jem.20050042
   Kavli B, 2002, J BIOL CHEM, V277, P39926, DOI 10.1074/jbc.M207107200
   Khandhadia S, 2012, ADV EXP MED BIOL, V724, P15, DOI 10.1007/978-1-4614-0653-2_2
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Krokan HE, 2002, ONCOGENE, V21, P8935, DOI 10.1038/sj.onc.1205996
   Krokan HE, 2001, PROG NUCLEIC ACID RE, V68, P365
   Laczmanska I, 2006, ENVIRON MOL MUTAGEN, V47, P666, DOI 10.1002/em.20253
   Laine JP, 2006, EMBO J, V25, P387, DOI 10.1038/sj.emboj.7600933
   Lee JM, 2001, INT J CANCER, V95, P240, DOI 10.1002/1097-0215(20010720)95:4<240::AID-IJC1041>3.0.CO;2-1
   Lehmann AR, 2001, GENE DEV, V15, P15, DOI 10.1101/gad.859501
   Li Yongliang, 2006, International Journal of Occupational Medicine and Environmental Health, V19, P45, DOI 10.2478/v10001-006-0006-9
   Liao SG, 2012, J CANCER RES CLIN, V138, P1689, DOI 10.1007/s00432-012-1246-7
   Licht CL, 2003, AM J HUM GENET, V73, P1217, DOI 10.1086/380399
   Lin ZN, 2008, HUM MUTAT, V29, P113, DOI 10.1002/humu.20610
   Liu MM, 2011, INVEST OPHTH VIS SCI, V52, P3129, DOI 10.1167/iovs.10-6735
   Ma HX, 2009, CANCER LETT, V273, P172, DOI 10.1016/j.canlet.2008.08.002
   Marian C, 2011, EUR J CLIN NUTR, V65, P683, DOI 10.1038/ejcn.2011.29
   Masaoka A, 2003, BIOCHEMISTRY-US, V42, P5003, DOI 10.1021/bi0273213
   Miyaishi A, 2009, J EXP CLIN CANC RES, V28, DOI 10.1186/1756-9966-28-10
   Naccarati A, 2007, MUTAT RES-REV MUTAT, V635, P118, DOI 10.1016/j.mrrev.2007.02.001
   Nilsen H, 1997, NUCLEIC ACIDS RES, V25, P750, DOI 10.1093/nar/25.4.750
   Nohmi T, 2005, MUTAT RES-FUND MOL M, V591, P60, DOI 10.1016/j.mrfmmm.2005.03.033
   Pabalan N, 2010, BREAST CANCER RES TR, V124, P531, DOI 10.1007/s10549-010-0863-6
   Qiao YW, 2002, CARCINOGENESIS, V23, P295, DOI 10.1093/carcin/23.2.295
   Qiao YW, 2002, MUTAT RES-FUND MOL M, V509, P165, DOI 10.1016/S0027-5107(02)00219-1
   Ratnasinghe D, 2001, CANCER EPIDEM BIOMAR, V10, P119
   Ricceri F, 2012, MUTAT RES-FUND MOL M, V736, P117, DOI 10.1016/j.mrfmmm.2011.07.013
   Seker H, 2001, CANCER RES, V61, P7430
   Shields PG, 2000, J CLIN ONCOL, V18, P2309, DOI 10.1200/JCO.2000.18.11.2309
   Shinmura K, 2001, ANTIOXID REDOX SIGN, V3, P597, DOI 10.1089/15230860152542952
   Slyskova J, 2007, MUTAT RES-GEN TOX EN, V634, P101, DOI 10.1016/j.mrgentox.2007.06.012
   Sousa MML, 2007, MOL ASPECTS MED, V28, P276, DOI 10.1016/j.mam.2007.04.006
   Stern MC, 2001, CANCER EPIDEM BIOMAR, V10, P125
   Stevnsner T, 2002, ONCOGENE, V21, P8675, DOI 10.1038/sj.onc.1205994
   Stevnsner T, 2008, MECH AGEING DEV, V129, P441, DOI 10.1016/j.mad.2008.04.009
   Synowiec E., 2012, RETINA UNPUB
   Synowiec E, 2012, EXP EYE RES, V98, P58, DOI 10.1016/j.exer.2012.02.008
   Takao M, 1999, NUCLEIC ACIDS RES, V27, P3638, DOI 10.1093/nar/27.18.3638
   Takezaki T, 2002, INT J CANCER, V99, P624, DOI 10.1002/ijc.10400
   Tao H, 2008, CANCER SCI, V99, P355, DOI 10.1111/j.1349-7006.2007.00694.x
   Tong Y, 2010, MOL VIS, V16, P1958
   TROELSTRA C, 1993, NUCLEIC ACIDS RES, V21, P419, DOI 10.1093/nar/21.3.419
   Tuimala J, 2002, CARCINOGENESIS, V23, P1003, DOI 10.1093/carcin/23.6.1003
   Tuo JS, 2006, P NATL ACAD SCI USA, V103, P9256, DOI 10.1073/pnas.0603485103
   Tuo JS, 2003, FASEB J, V17, P668, DOI 10.1096/fj.02-0851com
   Vineis P, 2009, JNCI-J NATL CANCER I, V101, P24, DOI 10.1093/jnci/djn437
   Vogel U, 2005, CANCER DETECT PREV, V29, P209, DOI 10.1016/j.cdp.2005.01.001
   Vogel U, 2001, CARCINOGENESIS, V22, P899, DOI 10.1093/carcin/22.6.899
   Wang AL, 2008, MOL VIS, V14, P644
   Wang YH, 2011, ANTICANCER RES, V31, P3939
   Weiss JM, 2005, MOL CARCINOGEN, V42, P127, DOI 10.1002/mc.20067
   Xue HP, 2011, AM J EPIDEMIOL, V173, P363, DOI 10.1093/aje/kwq378
   Yin G, 2012, J EPIDEMIOL, V22, P64, DOI 10.2188/jea.JE20110059
   Yuan H, 2011, GENET MOL RES, V10, P3356, DOI 10.4238/2011.November.22.6
   Zhan P, 2010, J THORAC ONCOL, V5, P1337, DOI 10.1097/JTO.0b013e3181e7fe2a
   Zhang HJ, 2011, ANTICANCER RES, V31, P3945
   Zhang Xuhui, 2012, BMC Res Notes, V5, P263, DOI 10.1186/1756-0500-5-263
   Zhang Y, 2011, INT J COLORECTAL DIS, V26, P1257, DOI 10.1007/s00384-011-1222-8
NR 107
TC 24
Z9 24
U1 0
U2 13
PU MDPI AG
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
SN 1422-0067
J9 INT J MOL SCI
JI Int. J. Mol. Sci.
PD OCT
PY 2012
VL 13
IS 10
BP 13378
EP 13397
DI 10.3390/ijms131013378
PG 20
WC Biochemistry & Molecular Biology; Chemistry, Multidisciplinary
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry
GA 031YE
UT WOS:000310677800070
PM 23202958
OA Green Submitted, gold, Green Published
DA 2022-11-30
ER

PT J
AU Major, JC
   Wykoff, CC
   Mariani, AF
   Chen, E
   Croft, DE
   Brown, DM
AF Major, James C., Jr.
   Wykoff, Charles C.
   Mariani, Angeline F.
   Chen, Eric
   Croft, Daniel E.
   Brown, David M.
TI COMPARISON OF SPECTRAL-DOMAIN AND TIME-DOMAIN OPTICAL COHERENCE
   TOMOGRAPHY IN THE DETECTION OF NEOVASCULAR AGE-RELATED MACULAR
   DEGENERATION ACTIVITY
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE OCT; ocular coherence tomography; spectral domain; time domain; AMD;
   comparison; neovascular; age-related macular degeneration; identifying;
   exudative disease
ID RANIBIZUMAB
AB Purpose: To compare the sensitivity of commonly used time-domain (TD-OCT) and spectral-domain optical coherence tomography platforms and scanning modalities in the management of neovascular age-related macular degeneration in a population with a high prevalence of exudative disease activity.
   Methods: Fifty consecutive patients within the prospective SAVE (Super-dose Anti-Vascular Endothelial growth factor) trial, which analyzed the utility of 2.0 mg intravitreal ranibizumab for the treatment of recalcitrant neovascular age-related macular degeneration, were enrolled in a comparison trial of 3 different optical coherence tomography (OCT) platforms. Stratus TD-OCT radial scan (Carl Zeiss Meditec, Inc) was compared with 3 Heidelberg Spectralis Heidelberg Retinal Angiograph+OCT (Heidelberg Engineering) acquisition settings (radial, 7-line raster, volumetric) and 2 Cirrus high definition (HD)-OCT (Carl Zeiss Meditec, Inc) acquisition settings (5-line raster, volumetric).
   Results: Using every imaging platform and acquisition setting, evidence of exudative disease activity was positively identified in 163 of 191 patient visits (85.3%). Intraretinal cysts were identified in 83 of 191 visits (43.5%), and subretinal fluid was identified in 116 of 191 visits (60.7%). Of these positive visits, the Stratus TD-OCT radial scanning technology demonstrated a significantly lower rate of detection (71.8%) when compared with the Spectralis HRA+OCT spectral domain scanning modalities (radial 87.1%, P < 0.001; 7-line raster 92.0%, P < 0.001; volumetric 94.5%, P < 0.001) or the Cirrus HD-OCT spectral domain scanning modalities (5-line raster 81.6%, P = 0.001; volumetric 92.0%, P < 0.001). Intraretinal cysts and subretinal fluid were identified in 83 visits (43.5%) and 116 visits (60.7%), respectively, with 36 eyes (18.8%) having fluid in both locations. No individual imaging modality demonstrated a diagnostic advantage for detecting subretinal fluid versus intraretinal cysts (e.g., Cirrus volume detected 86.7% of intraretinal cysts and 88.8% of subretinal fluid, P = 0.33).
   Conclusion: In this neovascular age-related macular degeneration patient population, spectral-domain ocular coherence tomography was a superior diagnostic tool when compared with TD-OCT, with each spectral domain platform and acquisition setting identifying significantly more exudative disease activity. The two spectral domain platforms (Cirrus and Spectralis) were not directly compared because identical image acquisition parameters were not used. No individual imaging modality demonstrated a diagnostic advantage for detecting subretinal fluid versus intraretinal cysts.
C1 Retina Consultants Houston, Weill Cornell Med Coll, Houston, TX 77030 USA.
   Methodist Hosp, Houston, TX 77030 USA.
C3 Cornell University; The Methodist Hospital System; The Methodist
   Hospital - Houston
RP Brown, DM (通讯作者)，Retina Consultants Houston, 6560 Fannin St,Suite 750, Houston, TX 77030 USA.
EM dmbmd@houstonretina.com
CR Cukras C, 2010, EYE, V24, P775, DOI 10.1038/eye.2009.211
   Forooghian F, 2008, INVEST OPHTH VIS SCI, V49, P4290, DOI 10.1167/iovs.08-2113
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Gupta V, 2008, AM J OPHTHALMOL, V145, P1018, DOI 10.1016/j.ajo.2008.01.021
   Ho J, 2009, OPHTHALMOLOGY, V116, P1960, DOI 10.1016/j.ophtha.2009.03.034
   HUANG D, 1991, SCIENCE, V254, P1178, DOI 10.1126/science.1957169
   Keane PA, 2009, AM J OPHTHALMOL, V148, P242, DOI 10.1016/j.ajo.2009.03.004
   Kiernan DF, 2010, AM J OPHTHALMOL, V150, P138, DOI 10.1016/j.ajo.2010.04.019
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Martin DF, 2012, OPHTHALMOLOGY
   Sayanagi K, 2009, OPHTHALMOLOGY, V116, P947, DOI 10.1016/j.ophtha.2008.11.002
   Wykoff CC, 2013, OPHTHAL SURG LAS IM, V44, P121, DOI 10.3928/23258160-20130313-04
NR 12
TC 15
Z9 16
U1 0
U2 4
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD JAN
PY 2014
VL 34
IS 1
BP 48
EP 54
DI 10.1097/IAE.0b013e3182965743
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA AI6CZ
UT WOS:000336958700009
PM 23764967
DA 2022-11-30
ER

PT J
AU Hirashima, T
   Moriya, T
   Bun, T
   Utsumi, T
   Hirose, M
   Oh, H
AF Hirashima, Takafumi
   Moriya, Takeshi
   Bun, Toshitaka
   Utsumi, Takao
   Hirose, Miou
   Oh, Hideyasu
TI OPTICAL COHERENCE TOMOGRAPHY FINDINGS AND SURGICAL OUTCOMES OF TISSUE
   PLASMINOGEN ACTIVATOR-ASSISTED VITRECTOMY FOR SUBMACULAR HEMORRHAGE
   SECONDARY TO AGE-RELATED MACULAR DEGENERATION
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE age-related macular degeneration; ellipsoid layer; OCT findings;
   plasminogen activator-assisted vitrectomy; submacular hemorrhage
ID SUBRETINAL HEMORRHAGE; PNEUMATIC DISPLACEMENT; NATURAL-HISTORY; VISUAL
   PROGNOSIS; INJECTION; MANAGEMENT; GAS; EYES; REMOVAL
AB Purpose:To study the relationship between morphologic findings using spectral domain optical coherence tomography and surgical outcomes in patients with submacular hemorrhage (SMH) secondary to age-related macular degeneration.Methods:Medical charts of nine eyes of nine patients who underwent tissue plasminogen activator-assisted vitrectomy for SMH secondary to age-related macular degeneration were retrospectively reviewed. The preoperative height and lateral width of both SMH and pigment epithelial detachment documented with optical coherence tomography, were measured. The status of ellipsoid layers was also analyzed.Results:Complete displacement of SMH from the fovea was achieved in all nine eyes. The preoperative status of the ellipsoid layer under the fovea was detectable in four eyes and absent in the remaining five eyes. Postoperative best-corrected visual acuity was significantly better in eyes with preoperative detectable ellipsoid layers (P < 0.01). Eyes with preoperative SMH heights <400 m also exhibited better best-corrected visual acuity (P < 0.05). There was no significant correlation between postoperative best-corrected visual acuity and the specific features of pigment epithelial detachment, including height, lateral width, and number.Conclusion:The preoperative presence of detectable ellipsoid layers and a lower height of SMH may predict good visual prognosis. In contrast, no specific features of pigment epithelial detachment correlated with postoperative best-corrected visual acuity.
C1 [Hirashima, Takafumi; Moriya, Takeshi; Bun, Toshitaka; Utsumi, Takao; Hirose, Miou; Oh, Hideyasu] Hyogo Kenritsu Amagasaki Hosp, Dept Ophthalmol, Amagasaki, Hyogo 6600828, Japan.
RP Oh, H (通讯作者)，Hyogo Kenritsu Amagasaki Hosp, Dept Ophthalmol, Higashidaimotsu Cho1-1-1, Amagasaki, Hyogo 6600828, Japan.
EM hideyasu@kuhp.kyoto-u.ac.jp
CR Avery RL, 1996, RETINA-J RET VIT DIS, V16, P183, DOI 10.1097/00006982-199616030-00001
   BENNETT SR, 1990, AM J OPHTHALMOL, V109, P33, DOI 10.1016/S0002-9394(14)75575-8
   Chang W, 2014, AM J OPHTHALMOL, V157, P1250, DOI 10.1016/j.ajo.2014.02.007
   Chen CY, 2007, RETINA-J RET VIT DIS, V27, P321, DOI 10.1097/01.iae.0000237586.48231.75
   Cheung CMG, 2013, GRAEF ARCH CLIN EXP, V251, P19, DOI 10.1007/s00417-012-2029-1
   ELBABA F, 1986, OPHTHALMOLOGY, V93, P1581
   GLATT H, 1982, AM J OPHTHALMOL, V94, P762, DOI 10.1016/0002-9394(82)90301-4
   Hassan AS, 1999, OPHTHALMOLOGY, V106, P1900, DOI 10.1016/S0161-6420(99)90399-8
   Hattenbach LO, 2001, OPHTHALMOLOGY, V108, P1485, DOI 10.1016/S0161-6420(01)00648-0
   Haupert CL, 2001, AM J OPHTHALMOL, V131, P208, DOI 10.1016/S0002-9394(00)00734-0
   Hayashi H, 2009, AM J OPHTHALMOL, V148, P83, DOI 10.1016/j.ajo.2009.01.017
   Hillenkamp J, 2010, GRAEF ARCH CLIN EXP, V248, P5, DOI 10.1007/s00417-009-1158-7
   IBANEZ HE, 1995, ARCH OPHTHALMOL-CHIC, V113, P62, DOI 10.1001/archopht.1995.01100010064022
   Kamei M, 1996, AM J OPHTHALMOL, V121, P267, DOI 10.1016/S0002-9394(14)70274-0
   Kapran Z, 2013, OSLI RETINA, V44, P471, DOI 10.3928/23258160-20130909-09
   Kim JH, 2014, OPHTHALMOLOGY, V121, P926, DOI 10.1016/j.ophtha.2013.11.004
   Landa G, 2011, RETINA-J RET VIT DIS, V31, P364, DOI 10.1097/IAE.0b013e3181e91132
   Lim JI, 1995, OPHTHALMOLOGY, V240, P717
   Maheshwary AS, 2010, AM J OPHTHALMOL, V150, P63, DOI 10.1016/j.ajo.2010.01.039
   Ohji M, 1998, ARCH OPHTHALMOL-CHIC, V116, P1326, DOI 10.1001/archopht.116.10.1326
   Olivier S, 2004, OPHTHALMOLOGY, V111, P1201, DOI 10.1016/j.ophtha.2003.10.020
   Ota M, 2008, AM J OPHTHALMOL, V145, P273, DOI 10.1016/j.ajo.2007.09.019
   Papavasileiou E, 2013, RETINA-J RET VIT DIS, V33, P846, DOI 10.1097/IAE.0b013e318271f278
   Pauleikhoff D, 2002, GRAEF ARCH CLIN EXP, V240, P533, DOI 10.1007/s00417-002-0505-8
   POLINER LS, 1986, OPHTHALMOLOGY, V93, P543
   Sandberg MA, 2005, INVEST OPHTH VIS SCI, V46, P3349, DOI 10.1167/iovs.04-1383
   Sandhu SS, 2010, CLIN OPHTHALMOL, V4, P637
   Schulze SD, 2002, GRAEFES ARCH CLIN EX, V109, P723
   Scupola A, 1999, OPHTHALMOLOGICA, V213, P97, DOI 10.1159/000027400
   Spaide RF, 2013, RETINA-J RET VIT DIS, V33, P1800, DOI 10.1097/IAE.0b013e31829c3765
   Staurenghi G, 2014, OPHTHALMOLOGY, V121, P1572, DOI 10.1016/j.ophtha.2014.02.023
   Submacular Surgery Trials (SST) Research Group, 2004, AM J OPHTHALMOL, V111, P2007
   TOTH CA, 1991, ARCH OPHTHALMOL-CHIC, V109, P723, DOI 10.1001/archopht.1991.01080050139046
   Treumer F, 2010, BRIT J OPHTHALMOL, V94, P48, DOI 10.1136/bjo.2009.164707
   Ueda-Arakawa N, 2012, JPN J OPHTHALMOL, V56, P589, DOI 10.1007/s10384-012-0191-y
   VANDER JF, 1992, OPHTHALMIC SURG LAS, V23, P361
NR 36
TC 11
Z9 11
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD OCT
PY 2015
VL 35
IS 10
BP 1969
EP 1978
DI 10.1097/IAE.0000000000000574
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA CS6US
UT WOS:000362219000007
PM 26079475
DA 2022-11-30
ER

PT J
AU Chen, L
   Messinger, JD
   Kar, D
   Duncan, JL
   Curcio, CA
AF Chen, Ling
   Messinger, Jeffrey D.
   Kar, Deepayan
   Duncan, Jacque L.
   Curcio, Christine A.
TI Biometrics, Impact, and Significance of Basal Linear Deposit and
   Subretinal Drusenoid Deposit in Age-Related Macular Degeneration
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
DE age-related macular degeneration; basal linear deposit;
   clinicopathologic correlation; drusen; histopathology; histology;
   neovascularization; optical coherence tomography; photoreceptors;
   subretinal drusenoid deposit
ID OPTICAL COHERENCE TOMOGRAPHY; RETINAL-PIGMENT EPITHELIUM; EARLY
   CHOROIDAL NEOVASCULARIZATION; INDOCYANINE GREEN ANGIOGRAPHY;
   VISIBLE-LIGHT OCT; CLINICOPATHOLOGICAL CORRELATION; GEOGRAPHIC ATROPHY;
   BRUCHS MEMBRANE; PROGRESSION; MORPHOLOGY
AB PURPOSE. Basal linear deposit (BLinD) is a thin layer of soft drusen material. To elucidate the biology of extracellular deposits conferring age-related macular degeneration (AMD) progression risk and inform multimodal clinical imaging based on optical coherence tomography (OCT), we examined lipid content and regional prevalence of BLinD, soft drusen, pre-BLinD, and subretinal drusenoid deposit (SDD) in AMD and non-AMD aged eyes. We estimated BLinD volume and illustrated its relation to type 1 macular neovascularization (MNV).
   METHODS. Donor eyes were classified as early to intermediate AMD (n = 25) and age-matched controls (n = 54). In high-resolution histology, we assessed BLinD/soft drusen thickness at 836 and 1716 locations in AMD and control eyes, respectively. BLinD volume was estimated using solid geometry in donor eyes, one clinically characterized.
   RESULTS. BLinD, drusen, type 1 MNV, and fluid occupy the sub-RPE-basal laminar space. BLinD volume in a 3-mm diameter circle may be as much as 0.0315 mm(3). Osmophilic lipid was more concentrated in BLinD/drusen than SDD. In the fovea, BLinD/drusen was prevalent in AMD eyes; pre-BLinD was prevalent in control eyes. SDD was low in the fovea and high in perifovea, especially in AMD eyes.
   CONCLUSIONS. Although invisible, BLinD may presage type 1 MNV. BLinD volume approaches the criterion OCT drusen volume of 0.03 mm(3) for AMD progression risk. BLinD culminates years of subfoveal lipid accumulation. SDD is detected relatively late in life, with currently unknown precursors. Deposit topography suggests one outer retinal lipid recycling system serving specialized cone and rod physiology, and its dysregulation in AMD is due to impaired transfer to the circulation.
C1 [Chen, Ling] Chongqing Med Univ, Affiliated Hosp 1, Chongqing Key Lab Ophthalmol, Chongqing, Peoples R China.
   [Chen, Ling] Chongqing Eye Inst, Chongqing, Peoples R China.
   [Chen, Ling; Messinger, Jeffrey D.; Kar, Deepayan; Curcio, Christine A.] Univ Alabama Birmingham, Sch Med, Dept Ophthalmol & Visual Sci, Birmingham, AL USA.
   [Duncan, Jacque L.] Univ Calif San Francisco, Dept Ophthalmol, San Francisco, CA USA.
C3 Chongqing Medical University; University of Alabama System; University
   of Alabama Birmingham; University of California System; University of
   California San Francisco
RP Curcio, CA (通讯作者)，Univ Alabama Birmingham, Dept Ophthalmol & Visual Sci, EyeSight Fdn Alabama Vis Res Labs, Sch Med, 1670 Univ Blvd Room 360, Birmingham, AL 35294 USA.
EM christinecurcio@uabmc.edu
RI Kar, Deepayan/AAX-8374-2020
OI Kar, Deepayan/0000-0003-2176-7430
FU Macula Foundation, New York; National Institutes of Health [R01EY06019];
   EyeSight Foundation of Alabama; International Retinal Research
   Foundation; Edward N. and Della L. Thome Foundation; Arnold and Mabel
   Beckman Initiative for Macular Research
FX Supported by The Macula Foundation, New York; an anonymous donor to
   University of Alabama at Birmingham; and Heidelberg Engineering. The
   Project MACULA website and the recovery of human donor eyes for research
   has been supported by National Institutes of Health grant R01EY06019,
   EyeSight Foundation of Alabama, International Retinal Research
   Foundation, the Edward N. and Della L. Thome Foundation, the Arnold and
   Mabel Beckman Initiative for Macular Research, and institutional support
   from Research to Prevent Blindness. The recovery of the clinically
   documented case was made possible by the Foundation Fighting Blindness.
   Purchase of the slide scanner was made possible by the Carl G. and
   Pauline Buck Trust.
CR Abdelfattah NS, 2016, INVEST OPHTH VIS SCI, V57, P1839, DOI 10.1167/iovs.15-18572
   Anderson DMG, 2020, J AM SOC MASS SPECTR, V31, P2426, DOI 10.1021/jasms.0c00119
   [Anonymous], 2020, EYE 1119, DOI DOI 10.1038/S41433-020-01293-0
   Arnold JJ, 1997, AM J OPHTHALMOL, V124, P344, DOI 10.1016/S0002-9394(14)70826-8
   Balaratnasingam C, 2016, INVEST OPHTH VIS SCI, V57, P5479, DOI 10.1167/iovs.16-19816
   Bloom SM, 2021, RETINA-J RET VIT DIS, V41, P181, DOI 10.1097/IAE.0000000000002792
   BRESSLER SB, 1983, RETINA-J RET VIT DIS, V3, P7, DOI 10.1097/00006982-198300310-00002
   Burgess S, 2017, OPHTHALMOLOGY, V124, P1165, DOI 10.1016/j.ophtha.2017.03.042
   Chen L, 2020, RETINA-J RET VIT DIS, V40, P1644, DOI 10.1097/IAE.0000000000002893
   Chen L, 2020, OPHTHALMOLOGY, V127, P931, DOI 10.1016/j.ophtha.2020.01.040
   Chen L, 2020, RETINA-J RET VIT DIS, V40, P618, DOI 10.1097/IAE.0000000000002657
   Chen L, 2018, INVEST OPHTH VIS SCI, V59, P5237, DOI 10.1167/iovs.18-25124
   Chen L, 2018, CLIN EXP OPHTHALMOL, V46, P908, DOI 10.1111/ceo.13306
   Chen L, 2020, INT CONF UNMAN AIRCR, P188, DOI 10.1109/ICUAS48674.2020.9213964
   Chong SP, 2018, BIOMED OPT EXPRESS, V9, P1477, DOI 10.1364/BOE.9.001477
   Cohen SY, 2007, BRIT J OPHTHALMOL, V91, P1173, DOI 10.1136/bjo.2007.115501
   Curcio C. A., 2018, INVEST OPHTHALMOL VI, V59, pAMD182
   CURCIO CA, 1993, INVEST OPHTH VIS SCI, V34, P3278
   Curcio CA, 1999, ARCH OPHTHALMOL-CHIC, V117, P329, DOI 10.1001/archopht.117.3.329
   CURCIO CA, 1990, J COMP NEUROL, V292, P497, DOI 10.1002/cne.902920402
   Curcio Christine A, 2018, Invest Ophthalmol Vis Sci, V59, pAMD160, DOI 10.1167/iovs.18-24882
   Curcio CA, 2013, RETINA-J RET VIT DIS, V33, P265, DOI 10.1097/IAE.0b013e31827e25e0
   Curcio CA, 2011, INVEST OPHTH VIS SCI, V52, P3943, DOI 10.1167/iovs.10-6377
   Curcio CA, 2010, J LIPID RES, V51, P451, DOI 10.1194/jlr.R002238
   Curcio CA, 2009, PROG RETIN EYE RES, V28, P393, DOI 10.1016/j.preteyeres.2009.08.001
   Garcia CAD, 2014, OSLI RETINA, V45, P18, DOI 10.3928/23258160-20131217-01
   Dinculescu A, 2015, INVEST OPHTH VIS SCI, V56, P6971, DOI 10.1167/iovs.15-17166
   Dolz-Marco R, 2018, OPHTHALMOLOGY, V125, P1287, DOI 10.1016/j.ophtha.2018.02.036
   Ebrahimi KB, 2013, J PATHOL, V229, P729, DOI 10.1002/path.4128
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Flaxman SR, 2017, LANCET GLOB HEALTH, V5, pE1221, DOI 10.1016/S2214-109X(17)30393-5
   Freeman SR, 2010, RETINA-J RET VIT DIS, V30, P431, DOI 10.1097/IAE.0b013e3181bd2f94
   Freund KB, 2010, RETINA-J RET VIT DIS, V30, P1333, DOI 10.1097/IAE.0b013e3181e7976b
   FRIEDMAN E, 1966, ARCH OPHTHALMOL-CHIC, V75, P334
   Fritsche LG, 2016, NAT GENET, V48, P134, DOI 10.1038/ng.3448
   Gass JDM, STEREOSCOPIC ATLAS M, V4th
   GREEN WR, 1993, OPHTHALMOLOGY, V100, P1519
   Greferath U, 2016, OPHTHALMOLOGY, V123, P1320, DOI 10.1016/j.ophtha.2016.02.009
   Gregori G, 2011, OPHTHALMOLOGY, V118, P1373, DOI 10.1016/j.ophtha.2010.11.013
   Grossniklaus HE, 2005, ARCH OPHTHALMOL-CHIC, V123, P914
   Guymer RH, 2020, OPHTHALMOLOGY, V127, P394, DOI 10.1016/j.ophtha.2019.09.035
   Guymer RH, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0083759
   GUYTON JR, 1988, J HISTOCHEM CYTOCHEM, V36, P1319, DOI 10.1177/36.10.2458408
   Jung JJ, 2014, AM J OPHTHALMOL, V158, P769, DOI 10.1016/j.ajo.2014.07.006
   KILLINGSWORTH MC, 1995, GRAEF ARCH CLIN EXP, V233, P313, DOI 10.1007/BF00200479
   Kim JH, 2020, RETINA-J RET VIT DIS, V40, P1124, DOI 10.1097/IAE.0000000000002489
   Klein R, 2007, OPHTHALMOLOGY, V114, P253, DOI 10.1016/j.ophtha.2006.10.040
   Lee AY, 2020, TRANSL VIS SCI TECHN, V9, DOI 10.1167/tvst.9.2.62
   Lee B, 2020, TRANSL VIS SCI TECHN, V9, DOI 10.1167/tvst.9.7.12
   Lei JQ, 2017, GRAEF ARCH CLIN EXP, V255, P1551, DOI 10.1007/s00417-017-3693-y
   LEUREDUPREE AE, 1981, INVEST OPHTH VIS SCI, V21, P1
   Li ML, 2019, OPHTHALMOL RETINA, V3, P99, DOI 10.1016/j.oret.2018.08.008
   Li ML, 2019, RETINA-J RET VIT DIS, V39, P802, DOI 10.1097/IAE.0000000000002461
   Li ML, 2018, OPHTHALMOLOGY, V125, P276, DOI 10.1016/j.ophtha.2017.08.019
   Marmorstein LY, 2007, HUM MOL GENET, V16, P2423, DOI 10.1093/hmg/ddm199
   Mehta Nitish, 2021, Retin Cases Brief Rep, V15, P391, DOI 10.1097/ICB.0000000000000817
   MIMOUN G, 1990, J FR OPHTALMOL, V13, P511
   Najeeb BH, 2020, RETINA-J RET VIT DIS, V40, P2255, DOI 10.1097/IAE.0000000000002774
   Nassisi M, 2019, OPHTHALMOLOGY, V126, P1667, DOI 10.1016/j.ophtha.2019.05.016
   Oak ASW, 2014, RETINA-J RET VIT DIS, V34, P825, DOI 10.1097/IAE.0000000000000121
   Owsley C, 2016, OPHTHALMOLOGY, V123, P344, DOI 10.1016/j.ophtha.2015.09.041
   Pilgrim MG, 2017, INVEST OPHTH VIS SCI, V58, DOI 10.1167/iovs.16-21060
   Pollreisz A, 2021, INVEST OPHTHALMOL VI, V61, P2356
   Pollreisz A, 2020, INVEST OPHTH VIS SCI, V61, DOI 10.1167/iovs.61.8.13
   Ruberti JW, 2003, INVEST OPHTH VIS SCI, V44, P1753, DOI 10.1167/iovs.02-0496
   Rudolf M, 2008, INVEST OPHTH VIS SCI, V49, P1200, DOI 10.1167/iovs.07-1466
   Rudolf M, 2019, INVEST OPHTH VIS SCI, V60, P461, DOI 10.1167/iovs.18-25786
   Rudolf M, 2018, CURR EYE RES, V43, P135, DOI 10.1080/02713683.2017.1370118
   SARKS JP, 1988, EYE, V2, P552, DOI 10.1038/eye.1988.106
   Sarks JP, 1997, EYE, V11, P515, DOI 10.1038/eye.1997.137
   SARKS SH, 1980, T OPHTHAL SOC UK, V100, P414
   Sarks SH, 2006, AGE RELATED MACULAR, P1041
   Sarks S, 2007, INVEST OPHTH VIS SCI, V48, P968, DOI 10.1167/iovs.06-0443
   Shirazi MF, 2020, BIOMED OPT EXPRESS, V11, P4520, DOI 10.1364/BOE.393906
   Spaide RF, 2003, RETINA-J RET VIT DIS, V23, P595, DOI 10.1097/00006982-200310000-00001
   Spaide RF, 2020, OPHTHALMOLOGY, V127, P616, DOI 10.1016/j.ophtha.2019.11.004
   Spaide RF, 2018, SURV OPHTHALMOL, V63, P782, DOI 10.1016/j.survophthal.2018.05.005
   Spaide RF, 2018, RETINA-J RET VIT DIS, V38, P891, DOI 10.1097/IAE.0000000000001732
   Spaide RF, 2010, RETINA-J RET VIT DIS, V30, P1441, DOI 10.1097/IAE.0b013e3181ee5ce8
   Staurenghi G, 2014, OPHTHALMOLOGY, V121, P1572, DOI 10.1016/j.ophtha.2014.02.023
   Steinberg JS, 2013, INVEST OPHTH VIS SCI, V54, P4054, DOI 10.1167/iovs.12-11538
   Storti F, 2019, ELIFE, V8, DOI 10.7554/eLife.45100
   Sura AA, 2020, INVEST OPHTH VIS SCI, V61, DOI 10.1167/iovs.61.13.19
   Thomas SE, 2016, J LIPID RES, V57, P1865, DOI 10.1194/jlr.M070193
   Tong YH, 2016, RETINA-J RET VIT DIS, V36, pS127, DOI 10.1097/IAE.0000000000001325
   Vachali PP, 2013, ARCH BIOCHEM BIOPHYS, V539, P181, DOI 10.1016/j.abb.2013.07.008
   Vavvas DG, 2016, EBIOMEDICINE, V5, P198, DOI 10.1016/j.ebiom.2016.01.033
   Wang JJ, 2007, OPHTHALMOLOGY, V114, P92, DOI 10.1016/j.ophtha.2006.07.017
   Yannuzzi LA, 2001, RETINA-J RET VIT DIS, V21, P416, DOI 10.1097/00006982-200110000-00003
   Yehoshua Z, 2011, OPHTHALMOLOGY, V118, P2434, DOI 10.1016/j.ophtha.2011.05.008
   Yi K, 2009, BRIT J OPHTHALMOL, V93, P176, DOI 10.1136/bjo.2008.137356
   Zanzottera EC, 2015, INVEST OPHTH VIS SCI, V56, P3253, DOI 10.1167/iovs.15-16431
   Zarubina AV, 2016, OPHTHALMOLOGY, V123, P1090, DOI 10.1016/j.ophtha.2015.12.034
   Zeng GF, 2007, BLOOD, V109, P1345, DOI 10.1182/blood-2006-07-037952
   Zhang TW, 2019, BIOMED OPT EXPRESS, V10, P2918, DOI 10.1364/BOE.10.002918
   Zhang YH, 2014, AM J OPHTHALMOL, V158, P584, DOI 10.1016/j.ajo.2014.05.038
   Zheng WC, 2015, J LIPID RES, V56, P81, DOI 10.1194/jlr.M053439
   Zweifel SA, 2010, OPHTHALMOLOGY, V117, P303, DOI 10.1016/j.ophtha.2009.07.014
NR 98
TC 13
Z9 13
U1 3
U2 6
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD JAN
PY 2021
VL 62
IS 1
AR 33
DI 10.1167/iovs.62.1.33
PG 15
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA QQ5KI
UT WOS:000624561900009
PM 33512402
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Labuz, G
   Zielinska, A
   Kessler, LJ
   Rayamajhi, A
   Komar, K
   Khoramnia, R
   Auffarth, GU
AF Labuz, Grzegorz
   Zielinska, Agnieszka
   Kessler, Lucy J.
   Rayamajhi, Asu
   Komar, Katarzyna
   Khoramnia, Ramin
   Auffarth, Gerd U.
TI Two-Photon Vision in Age-Related Macular Degeneration: A Translational
   Study
SO DIAGNOSTICS
LA English
DT Article
DE two-photon vision; AMD; normal aging; microperimetry; retinal
   sensitivity
ID RETINAL SENSITIVITY; MICROPERIMETRY
AB The recently introduced term "two-photon vision" relates to the visual perception resulting from a simultaneous absorption of two photons by photoreceptors. In this study, we determined two-photon retinal sensitivity in age-related macular degeneration (AMD) and compared it that in normal aging. Microperimetry was performed with visible (white) light and infrared (IR) light, which was perceived as green in the two-photon stimulation. In total, 45 subjects were included with one (better) eye studied. Furthermore, best-corrected visual acuity (VA) and ocular straylight were assessed. AMD resulted in decreased median (interquartile range) logMAR VA, i.e., 0.15 (0.05; 0.24), which in normal eyes was -0.02 (-0.06; 0.02). The two groups showed comparable straylight levels. Sensitivity to IR light was significantly lower in the AMD group (p < 0.001): 8.3 (7.4, 9.3) dB than in controls 10.7 (9.7, 11.2) dB. AMD also significantly affected visible light sensitivity (p < 0.001): 14.0 (11.0; 15.5) dB vs. 18.0 (16.3; 18.9) dB. Notably, the two-photon approach yielded a lower data spread. In conclusion, AMD considerably impairs retinal sensitivity measured in the single- and two-photon realm. However, two-photon-vision microperimetry may improve the testing accuracy and offer an additional diagnostic parameter (beyond VA measurements) for retinal function assessment.
C1 [Labuz, Grzegorz; Kessler, Lucy J.; Rayamajhi, Asu; Khoramnia, Ramin; Auffarth, Gerd U.] Univ Hosp Heidelberg, David J Apple Ctr Vis Res, Dept Ophthalmol, Neuenheimer Feld 400, D-69120 Heidelberg, Germany.
   [Zielinska, Agnieszka; Komar, Katarzyna] Nicolaus Copernicus Univ Torun, Fac Phys Astron & Informat, Inst Phys, Grudziadzka 5, PL-87100 Torun, Poland.
   [Rayamajhi, Asu] Karlsruhe Inst Technol Kit, Light Technol Inst LTI, Engesserstr 13,Bldg 30-34, D-76131 Karlsruhe, Germany.
   [Komar, Katarzyna] Int Ctr Translat Eye Res, Skierniewicka 10A, PL-01230 Warsaw, Poland.
   [Komar, Katarzyna] Polish Acad Sci, Inst Phys Chem, Dept Phys Chem Biol Syst, Kasprzaka 44-52, PL-01224 Warsaw, Poland.
C3 Ruprecht Karls University Heidelberg; Nicolaus Copernicus University;
   Helmholtz Association; Karlsruhe Institute of Technology; Polish Academy
   of Sciences; Institute of Physical Chemistry of the Polish Academy of
   Sciences
RP Labuz, G (通讯作者)，Univ Hosp Heidelberg, David J Apple Ctr Vis Res, Dept Ophthalmol, Neuenheimer Feld 400, D-69120 Heidelberg, Germany.
EM grzegorz.labuz@med.uni-heidelberg.de; azielinska@fizyka.umk.pl;
   lucyjoanne.kessler@med.uni-heidelberg.de; asu.rayamajhi@kit.edu;
   kkomar@fizyka.umk.pl; ramin.khoramnia@med.uni-heidelberg.de;
   gerd.auffarth@med.uni-heidelberg.de
RI Khoramnia, Ramin/AAR-8358-2020; Zielińska, Agnieszka/A-4278-2017
OI Khoramnia, Ramin/0000-0002-6237-7773; Zielińska,
   Agnieszka/0000-0003-1528-0028; Auffarth, Gerd/0000-0002-6927-5251;
   Kessler, Lucy Joanne/0000-0002-5322-9875
FU Klaus Tschira Foundation [00.290.2016]; National Science Centre
   [2016/23/B/ST2/00752]; International Centre for Translational Eye
   Research within the International Research Agendas Programme of the
   Foundation for Polish Science - European Union under the European
   Regional Development Fund [MAB/2019/12]
FX This work was supported by a research grant from the Klaus Tschira
   Foundation (00.290.2016 to G.U.A.). K.K. reports support from National
   Science Centre (2016/23/B/ST2/00752) and the International Centre for
   Translational Eye Research (MAB/2019/12) within the International
   Research Agendas Programme of the Foundation for Polish Science
   co-financed by the European Union under the European Regional
   Development Fund.
CR Alexander P, 2012, EYE, V26, P678, DOI 10.1038/eye.2012.7
   Alfaro D.V, 2015, AGE RELATED MACULAR, V2nd
   Cassels NK, 2018, SURV OPHTHALMOL, V63, P40, DOI 10.1016/j.survophthal.2017.05.007
   CIE, 1932, COMM INT ECL P
   Curcio CA, 1996, INVEST OPHTH VIS SCI, V37, P1236
   Dinc UA, 2008, EUR J OPHTHALMOL, V18, P595, DOI 10.1177/112067210801800416
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   GRIFFIN DR, 1947, J OPT SOC AM, V37, P546, DOI 10.1364/JOSA.37.000546
   Holz F.G., 2012, AGE RELATED MACULAR
   Kaufman PL, 2011, ADLERS PHYSL EYE
   Kessler LJ, 2022, DIAGNOSTICS, V12, DOI 10.3390/diagnostics12020333
   Labuz G, 2022, SCI REP-UK, V12, DOI 10.1038/s41598-022-05718-6
   Labuz G, 2021, RETINA-J RET VIT DIS, V41, P1302, DOI 10.1097/IAE.0000000000003032
   Labuz G, 2020, TRANSL VIS SCI TECHN, V9, DOI 10.1167/tvst.9.8.7
   Meleppat RK, 2021, SCI REP-UK, V11, DOI 10.1038/s41598-021-95320-z
   Montolio FGJ, 2012, INVEST OPHTH VIS SCI, V53, P7010, DOI 10.1167/iovs.12-10268
   Munk MR, 2013, AM J OPHTHALMOL, V156, P633, DOI 10.1016/j.ajo.2013.05.037
   Owsley C, 2007, OPHTHALMOLOGY, V114, P1728, DOI 10.1016/j.ophtha.2006.12.023
   Palczewska G, 2014, P NATL ACAD SCI USA, V111, pE5445, DOI 10.1073/pnas.1410162111
   Prins N., 2016, PSYCHOPHYSICS PRACTI
   Ruminski D, 2019, BIOMED OPT EXPRESS, V10, P4551, DOI 10.1364/BOE.10.004551
   Sabour-Pickett S, 2013, J OPHTHALMOL, V2013, DOI 10.1155/2013/268438
   Takahashi A, 2016, AM J OPHTHALMOL, V168, P260, DOI 10.1016/j.ajo.2016.06.006
   van den Berg TJTP, 2013, Z MED PHYS, V23, P6, DOI 10.1016/j.zemedi.2012.10.009
   Zielinska A, 2021, INVEST OPHTH VIS SCI, V62, DOI 10.1167/iovs.62.15.23
NR 25
TC 0
Z9 0
U1 2
U2 3
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2075-4418
J9 DIAGNOSTICS
JI Diagnostics
PD MAR
PY 2022
VL 12
IS 3
AR 760
DI 10.3390/diagnostics12030760
PG 12
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA 0E7NR
UT WOS:000776864200001
PM 35328313
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Jiang, PF
   Tan, HY
   Peng, QH
AF Jiang Pengfei
   Tan Hanyu
   Peng Qinghu
TI Ranibizumab and conbercept for treating wet age-related macular
   degeneration in China A systematic review and meta-analysis
SO MEDICINE
LA English
DT Review
DE conbercept; meta-analysis; ranibizumab; wet age-related macular
   degeneration
ID TRIAL
AB Background: This study aimed to evaluate the therapeutic effects of ranibizumab and conbercept on wet age-related macular degeneration. Methods: Randomized controlled trials comparing ranibizumab and conbercept in the treatment of wet age-related macular degeneration were searched in the PubMed, Medline, EMbase, Cochrane Library, China National Knowledge Infrastructure, Wanfang databases, and Weipu Journal. Two reviewers independently extracted the data and assessed the methodological quality. Data analysis was performed using Rev Man 5.3 software for statistical analysis. Results: A total of 16 randomized controlled trials, including 1018 patients, were included, and the results showed that the effect of ranibizumab on uncorrected visual acuity was not significantly different from that of conbercept (Mean difference [MD] = -.03, 95% Confidence interval [CI] [-.10-.05], P = .47), and there was no significant difference between the two drugs in the effect on best-corrected visual acuity (MD = .00, 95% CI [-.02-.03], P = .73). The effect of conbercept on intraocular pressure was better than that of ranibizumab (MD = 1.61, 95% CI [1.05-2.17], P < .001). The effect of ranibizumab on central macular thickness was not significantly different from that of conbercept (MD = 1.31, 95% CI [-3.81-6.43], P = .62). Conbercept had a better inhibitory effect on choroidal neovascularization than ranibizumab (MD = .49, 95% CI [.32-.76], P = .001). Conclusion: The effects of ranibizumab on uncorrected visual acuity, best corrected visual acuity, and central macular thickness were not significantly different from those of conbercept. Conbercept is associated with a lower risk of increased intraocular pressure and regression of choroidal neovascularization compared with ranibizumab.
C1 [Jiang Pengfei; Tan Hanyu; Peng Qinghu] Hunan Univ Chinese Med, Changsha 410208, Hunan, Peoples R China.
C3 Hunan University of Chinese Medicine
RP Peng, QH (通讯作者)，Hunan Univ Chinese Med, Changsha 410208, Hunan, Peoples R China.
EM pqh410007@126.com
FU Domestic First-Class Discipline Construction Project of Chinese Medicine
   of Hunan University of Chinese Medicine; Hunan Engineering Technology
   Research Center for the Prevention and Treatment of torhinolaryngologic
   Diseases and Protection of Visual Function with Chinese Medicine; Hunan
   Provincial Key Laboratory for the Prevention and Treatment of
   Ophthalmology and Otolaryngology Diseases with Traditional Chinese
   Medicine
FX This work was supported by the Domestic First-Class Discipline
   Construction Project of Chinese Medicine of Hunan University of Chinese
   Medicine, Hunan Engineering Technology Research Center for the
   Prevention and Treatment of torhinolaryngologic Diseases and Protection
   of Visual Function with Chinese Medicine, and Hunan Provincial Key
   Laboratory for the Prevention and Treatment of Ophthalmology and
   Otolaryngology Diseases with Traditional Chinese Medicine.
CR Black JRM, 2016, GENET MED, V18, P283, DOI 10.1038/gim.2015.70
   Cai XA., 2016, INT EYE SCI, V16, P1501
   Constable IJ, 2016, EBIOMEDICINE, V14, P168, DOI 10.1016/j.ebiom.2016.11.016
   Deng LH., 2018, MED SCI J CENT S CHI, V46, P657
   Fan Q., 2018, INT EYE SCI, V18, P1451
   Gillies MC, 2019, JAMA OPHTHALMOL, V137, P372, DOI 10.1001/jamaophthalmol.2018.6776
   Holz FG, 2015, BRIT J OPHTHALMOL, V99, P220, DOI 10.1136/bjophthalmol-2014-305327
   Hu BZ, 2018, CHINA CONTIN MED ED, V10, P132
   Lei JP., 2018, CHINA URBAN RURAL EN, V12, P127
   Liang XD., 2019, J GUANGDONG MED COLL, V37, P207
   Liu GH, 2018, J CLIN MED, V5, P98
   Lv P., 2016, J COMMUNITY MED, V14, P30
   Ma H, 2019, DRUGS CLIN PRACT, V24, P92
   Mulyukov Z, 2018, CPT-PHARMACOMET SYST, V7, P660, DOI 10.1002/psp4.12322
   Niu JY., 2016, GUANGXI MED, V38, P641
   Ou C, 2019, EVID-BASED COMPL ALT, V2019, DOI 10.1155/2019/6020846
   Peden MC, 2015, OPHTHALMOLOGY, V122, P803, DOI 10.1016/j.ophtha.2014.11.018
   Shi XW, 2019, HENAN MED RES JANUAR, V28, P98
   Shu BJ., 2018, J CLIN MED PRACT, V22, P93
   Souied EH, 2015, RETINA-J RET VIT DIS, V35, P1743, DOI 10.1097/IAE.0000000000000548
   Wang LP, 2018, DRUG DES DEV THER, V12, P3625, DOI 10.2147/DDDT.S176021
   Wykoff CC, 2015, OPHTHALMOLOGY, V122, P2514, DOI 10.1016/j.ophtha.2015.08.009
   Xue BQ, 2019, N PHARM, V16, P155
   Yang JH., 2018, J N SICHUAN MED COLL, V33, P108
   Yang W, 2018, MICROSC RES TECHNIQ, V81, P384, DOI 10.1002/jemt.22989
   Yuzawa M, 2015, OPHTHALMOLOGY, V122, P571, DOI 10.1016/j.ophtha.2014.09.024
   Zhang CH., 2016, J CLIN MED, V3, P10428
   Zhang JX, 2018, BMC OPHTHALMOL, V18, DOI 10.1186/s12886-018-0807-1
   Zhang LL., 2017, J CHANGZHI MED COLL, V3, P209
NR 29
TC 0
Z9 0
U1 10
U2 13
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0025-7974
EI 1536-5964
J9 MEDICINE
JI Medicine (Baltimore)
PD DEC 3
PY 2021
VL 100
IS 48
AR e27774
DI 10.1097/MD.0000000000027774
PG 7
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA XH9CB
UT WOS:000725722600059
PM 35049171
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Guymer, RH
   Tao, LWW
   Goh, JK
   Liew, D
   Ischenko, O
   Robman, LD
   Aung, K
   Cipriani, T
   Cain, M
   Richardson, AJ
   Baird, PN
   Langham, R
AF Guymer, Robyn H.
   Tao, Lingwei W.
   Goh, Jonathan K.
   Liew, Danny
   Ischenko, Olga
   Robman, Liubov D.
   Aung, KhinZaw
   Cipriani, Tania
   Cain, Melinda
   Richardson, Andrea J.
   Baird, Paul N.
   Langham, Robyn
TI Identification of Urinary Biomarkers for Age-Related Macular
   Degeneration
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
ID C-REACTIVE PROTEIN; MONOCYTE CHEMOATTRACTANT PROTEIN-1; INFLAMMATION;
   MACULOPATHY; PROTEOMICS; DRUSEN; MARKERS; SYSTEM; KIDNEY; GENE
AB PURPOSE. Age-related macular degeneration (AMD) can be considered as a chronic low-grade systemic inflammatory disease. This study was undertaken to test the associations of AMD with the urinary proinflammatory cytokines transforming growth factor (TGF)-beta 1, macrophage chemoattractant protein (MCP)-1 and C3a-desArg, as potential noninvasive biomarkers for monitoring AMD.
   METHODS. A cross-sectional study of 103 AMD cases, comprising early AMD (n = 51), geographic atrophy (GA; n = 19), or choroidal neovascularization (CNV; 33), and 54 unrelated controls, aged 73 +/- 9 years, who attended the Royal Victorian Eye and Ear Hospital and private practice in Victoria, Australia. AMD status was determined from the bilateral retinal digital photographs and through angiography and optical coherence tomography images when confirmation of CNV was needed. Serum and urine cytokine levels were measured by immunoassay and the rs1061170 (Y402H) single-nucleotide polymorphism of the complement factor H (CFH) gene was determined.
   RESULTS. Multivariate logistic regression analyses demonstrated significant associations of urinary TGF-beta 1 levels (odds ratio [95% confidence interval]: OR = 1.24 [1.02-1.50]; P < 0.031) and MCP-1 levels (OR = 1.07 [1.02-1.12]; P < 0.008), in early AMD, and also MCP-1 levels with GA (OR = 1.10 [1.03-1.17]; P < 0.003). There was no correlation between urinary and serum cytokine levels. Individuals with one or more copies of the C allele (Y402H) were 2.5 times more likely to have urinary MCP-1 above median levels (P < 0.040).
   CONCLUSIONS. This study demonstrates a novel finding of an association between elevated urinary cytokines TGF-beta 1 and MCP-1 and AMD. Further development of a urinary biomarker profile could provide a practical tool for detection of early AMD, progression monitoring, and assessment of treatment efficacy. (Invest Ophthalmol Vis Sci. 2011;52:4639-4644) DOI:10.1167/iovs.10-7120
C1 [Guymer, Robyn H.; Tao, Lingwei W.; Goh, Jonathan K.; Robman, Liubov D.; Aung, KhinZaw; Cipriani, Tania; Cain, Melinda; Richardson, Andrea J.; Baird, Paul N.] Univ Melbourne, Royal Victorian Eye & Ear Hosp, CERA, Melbourne, Vic 3002, Australia.
   [Liew, Danny] Univ Melbourne, Royal Melbourne Hosp, Dept Med, Melbourne, Vic 3050, Australia.
   [Ischenko, Olga; Langham, Robyn] St Vincents Hosp, Dept Nephrol, Fitzroy, Vic 3065, Australia.
C3 Royal Victorian Eye & Ear Hospital; University of Melbourne; Royal
   Melbourne Hospital; University of Melbourne; St Vincent's Hospital
   Melbourne
RP Guymer, RH (通讯作者)，Univ Melbourne, Royal Victorian Eye & Ear Hosp, CERA, 32 Gisborne St, Melbourne, Vic 3002, Australia.
EM rhg@unimelb.edu.au
RI Robman, Liubov/N-9075-2013
OI Baird, Paul/0000-0002-1305-3502; Guymer, Robyn/0000-0002-9441-4356;
   Liew, Danny/0000-0002-0131-623X
FU National Health and Medical Research Council of Australia; Macular
   Society
FX Supported by the National Health and Medical Research Council of
   Australia through a Practitioner Fellowship to RHG and The Macular
   Society. CERA receives Operational Infrastructure Support from the
   Victorian Government.
CR Adachi J, 2006, GENOME BIOL, V7, DOI 10.1186/gb-2006-7-9-r80
   Ambati J, 2003, NAT MED, V9, P1390, DOI 10.1038/nm950
   Anderson DH, 2002, AM J OPHTHALMOL, V134, P411, DOI 10.1016/S0002-9394(02)01624-0
   Baird PN, 2006, INVEST OPHTH VIS SCI, V47, P4194, DOI 10.1167/iovs.05-1285
   Basile DP, 1999, CURR OPIN NEPHROL HY, V8, P21, DOI 10.1097/00041552-199901000-00005
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Boekhoorn SS, 2007, ARCH OPHTHALMOL-CHIC, V125, P1396, DOI 10.1001/archopht.125.10.1396
   Decramer S, 2008, MOL CELL PROTEOMICS, V7, P1850, DOI 10.1074/mcp.R800001-MCP200
   Grassi MA, 2007, ARCH OPHTHALMOL-CHIC, V125, P93, DOI 10.1001/archopht.125.1.93
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Huang SJ, 2003, RETINA-J RET VIT DIS, V23, P429, DOI 10.1097/00006982-200306000-00036
   Jonas JB, 2010, ARCH OPHTHALMOL-CHIC, V128, P1281, DOI 10.1001/archophthalmol.2010.227
   Klein R, 2005, AM J OPHTHALMOL, V140, P35, DOI 10.1016/j.ajo.2005.01.051
   Nussenblatt RB, 2007, AM J OPHTHALMOL, V144, P618, DOI 10.1016/j.ajo.2007.06.025
   Ohlsson S, 2009, MEDIAT INFLAMM, V2009, DOI 10.1155/2009/584916
   Pang JX, 2002, J PROTEOME RES, V1, P161, DOI 10.1021/pr015518w
   PENFOLD PL, 1985, GRAEF ARCH CLIN EXP, V223, P69, DOI 10.1007/BF02150948
   ROBMAN L, OPHTHALMOLOGY, V117, P1982
   Seddon JM, 2005, ARCH OPHTHALMOL-CHIC, V123, P774, DOI 10.1001/archopht.123.6.774
   Seddon JM, 2004, JAMA-J AM MED ASSOC, V291, P704, DOI 10.1001/jama.291.6.704
   Shaw EA, 2007, NEPHROL DIAL TRANSPL, V22, P104, DOI 10.1093/ndt/gfl607
   Sivaprasad S, 2007, ARCH OPHTHALMOL-CHIC, V125, P515, DOI 10.1001/archopht.125.4.515
   Tam FWK, 2009, CYTOKINE, V47, P37, DOI 10.1016/j.cyto.2009.04.001
   Wada T, 2000, KIDNEY INT, V58, P1492, DOI 10.1046/j.1523-1755.2000.00311.x
   Wu KHC, 2007, INVEST OPHTH VIS SCI, V48, P1983, DOI 10.1167/iovs.06-0223
   Xing C, 2008, GENES IMMUN, V9, P231, DOI 10.1038/gene.2008.10
   Xu HP, 2009, PROG RETIN EYE RES, V28, P348, DOI 10.1016/j.preteyeres.2009.06.001
   Yamamoto T, 2008, PROTEOMICS, V8, P2156, DOI 10.1002/pmic.200800138
NR 28
TC 33
Z9 36
U1 0
U2 3
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD JUN
PY 2011
VL 52
IS 7
BP 4639
EP 4644
DI 10.1167/iovs.10-7120
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 800BP
UT WOS:000293332500095
PM 21498607
DA 2022-11-30
ER

PT J
AU Zhang, J
   Xing, ZH
   Ma, MM
   Wang, N
   Cai, YD
   Chen, L
   Xu, X
AF Zhang, Jian
   Xing, ZhiHao
   Ma, Mingming
   Wang, Ning
   Cai, Yu-Dong
   Chen, Lei
   Xu, Xun
TI Gene Ontology and KEGG Enrichment Analyses of Genes Related to
   Age-Related Macular Degeneration
SO BIOMED RESEARCH INTERNATIONAL
LA English
DT Article
ID GENOME-WIDE ASSOCIATION; FACTOR-H POLYMORPHISM; QUALITY-OF-LIFE;
   SUSCEPTIBILITY LOCI; KYOTO ENCYCLOPEDIA; OXIDATIVE DAMAGE; PREDICTION;
   RISK; CLASSIFIER; IMPAIRMENT
AB Identifying disease genes is one of the most important topics in biomedicine and may facilitate studies on the mechanisms underlying disease. Age-related macular degeneration (AMD) is a serious eye disease; it typically affects older adults and results in a loss of vision due to retina damage. In this study, we attempt to develop an effective method for distinguishing AMD-related genes. Gene ontology and KEGG enrichment analyses of known AMD-related genes were performed, and a classification system was established. In detail, each gene was encoded into a vector by extracting enrichment scores of the gene set, including it and its direct neighbors in STRING, and gene ontology terms or KEGG pathways. Then certain feature-selection methods, including minimum redundancy maximum relevance and incremental feature selection, were adopted to extract key features for the classification system. As a result, 720 GO terms and 11 KEGG pathways were deemed the most important factors for predicting AMD-related genes.
C1 [Zhang, Jian; Ma, Mingming; Wang, Ning; Xu, Xun] Shanghai Jiao Tong Univ, Shanghai Peoples Hosp 1, Sch Med, Dept Ophthalmol, Shanghai 200080, Peoples R China.
   [Zhang, Jian; Ma, Mingming; Wang, Ning; Xu, Xun] Shanghai Jiao Tong Univ, Shanghai Peoples Hosp 1, Sch Med, Shanghai Key Lab Ocular Fundus Dis, Shanghai 200080, Peoples R China.
   [Xing, ZhiHao] Shanghai Jiao Tong Univ, Inst Hlth Sci, Sch Med, Shanghai 200025, Peoples R China.
   [Xing, ZhiHao] Chinese Acad Sci, Shanghai Inst Biol Sci, Key Lab Stem Cell Biol, Shanghai 200025, Peoples R China.
   [Cai, Yu-Dong] Shanghai Univ, Inst Syst Biol, Shanghai 200444, Peoples R China.
   [Chen, Lei] Shanghai Maritime Univ, Coll Informat Engn, Shanghai 201306, Peoples R China.
C3 Shanghai Jiao Tong University; Shanghai Jiao Tong University; Shanghai
   Jiao Tong University; Chinese Academy of Sciences; Shanghai Institutes
   for Biological Sciences, CAS; Shanghai University; Shanghai Maritime
   University
RP Chen, L (通讯作者)，Shanghai Maritime Univ, Coll Informat Engn, Shanghai 201306, Peoples R China.
EM chen_leil@163.com; drxuxun@tom.com
RI Xing, Zhihao/AAH-6061-2020; Chen, Lei/A-2275-2011
OI Chen, Lei/0000-0003-3068-1583
FU National Basic Research Program of China [2011CB510101]; Doctoral
   Innovation Fund of Shanghai Jiaotong University School of Medicine
   [BXJ201337, BXJ201234]; National Natural Science Foundation of China
   [81100679, 81273424, 31371335, 61202021]
FX This paper was supported by the National Basic Research Program of China
   (2011CB510101), Doctoral Innovation Fund of Shanghai Jiaotong University
   School of Medicine (BXJ201337 and BXJ201234), and National Natural
   Science Foundation of China (81100679, 81273424, 31371335, and
   61202021).
CR Al-Ubaidi MR, 2013, INVEST OPHTH VIS SCI, V54, P8119, DOI 10.1167/iovs.13-13536
   Ambati J, 2013, NAT REV IMMUNOL, V13, P438, DOI 10.1038/nri3459
   Anderson DH, 2010, PROG RETIN EYE RES, V29, P95, DOI 10.1016/j.preteyeres.2009.11.003
   Arakawa S, 2011, NAT GENET, V43, P1001, DOI 10.1038/ng.938
   Baldi P, 2000, BIOINFORMATICS, V16, P412, DOI 10.1093/bioinformatics/16.5.412
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   Carmona-Saez P, 2007, GENOME BIOL, V8, DOI 10.1186/gb-2007-8-1-r3
   Chakravarthy U, 2010, BMC OPHTHALMOL, V10, DOI 10.1186/1471-2415-10-31
   Chen L, 2014, MOL BIOSYST, V10, P868, DOI 10.1039/c3mb70490d
   Chen L, 2013, CURR BIOINFORM, V8, P545, DOI 10.2174/1574893611308050004
   Chen L, 2013, CURR BIOINFORM, V8, P200, DOI 10.2174/1574893611308020008
   Chen L, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035254
   Chen L, 2010, BMC BIOINFORMATICS, V11, DOI 10.1186/1471-2105-11-293
   Chen L, 2010, J COMPUT CHEM, V31, P1766, DOI 10.1002/jcc.21467
   Chen L, 2009, J COMPUT CHEM, V30, P2248, DOI 10.1002/jcc.21230
   Chen W, 2010, P NATL ACAD SCI USA, V107, P7401, DOI 10.1073/pnas.0912702107
   Cramer H., 1946, MATH METHODS STAT
   Dewan A, 2006, SCIENCE, V314, P989, DOI 10.1126/science.1133807
   Dryja T. P., 1998, SCIENCE, V279
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Fagerness JA, 2009, EUR J HUM GENET, V17, P100, DOI 10.1038/ejhg.2008.140
   Forrester JV, 2003, NAT MED, V9, P1350, DOI 10.1038/nm1103-1350
   Fritsche LG, 2013, NAT GENET, V45, P433, DOI 10.1038/ng.2578
   Fritsche LG, 2010, HUM MOL GENET, V19, P4694, DOI 10.1093/hmg/ddq399
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   Gorin MB, 2012, MOL ASPECTS MED, V33, P467, DOI 10.1016/j.mam.2012.04.004
   Green W Richard, 2005, Retina, V25, P1519, DOI 10.1097/00006982-200507001-00015
   Harris MA, 2006, NUCLEIC ACIDS RES, V34, pD322, DOI 10.1093/nar/gkj021
   Harrison KM, 2008, PUBLIC HEALTH REP, V123, P618, DOI 10.1177/003335490812300512
   He ZS, 2010, LECT NOTES OPER RES, V13, P35
   Hollyfield JG, 2008, NAT MED, V14, P194, DOI 10.1038/nm1709
   Holzinger A, 2013, BMC BIOINFORMATICS, V14, DOI 10.1186/1471-2105-14-191
   Hu P, 2013, P NATL ACAD SCI USA, V110, pE4069, DOI 10.1073/pnas.1307574110
   Huang T, 2012, BIOCHIMIE, V94, P1017, DOI 10.1016/j.biochi.2011.12.024
   Huang T, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025297
   Hughes AE, 2006, NAT GENET, V38, P1173, DOI 10.1038/ng1890
   Iyengar SK, 2004, AM J HUM GENET, V74, P20, DOI 10.1086/380912
   JULIANO RL, 1993, J CELL BIOL, V120, P577, DOI 10.1083/jcb.120.3.577
   Kanehisa M, 2000, NUCLEIC ACIDS RES, V28, P27, DOI 10.1093/nar/28.1.27
   Kawasaki R, 2010, OPHTHALMOLOGY, V117, P921, DOI 10.1016/j.ophtha.2009.10.007
   Keerthi SS, 2001, NEURAL COMPUT, V13, P637, DOI 10.1162/089976601300014493
   Kendall M.G., 1973, ADV THEORY STAT, V2
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Kohavi R, P 14 INT JOINT C ART, P1137
   Li BQ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0043927
   Liutkeviciene R., 2013, OPHTHALMIC GENETICS
   Lu L, 2010, MOL DIVERS, V14, P81, DOI 10.1007/s11030-009-9149-5
   MATTHEWS BW, 1975, BIOCHIM BIOPHYS ACTA, V405, P442, DOI 10.1016/0005-2795(75)90109-9
   Meyer-Ruesenberg B, 2010, KLIN MONATSBL AUGENH, V227, P646, DOI 10.1055/s-0029-1245118
   Mitchell J, 2006, HEALTH QUAL LIFE OUT, V4, DOI 10.1186/1477-7525-4-97
   Neale BM, 2010, P NATL ACAD SCI USA, V107, P7395, DOI 10.1073/pnas.0912019107
   Pascolini D, 2004, OPHTHAL EPIDEMIOL, V11, P67, DOI 10.1076/opep.11.2.67.28158
   Peng HC, 2005, IEEE T PATTERN ANAL, V27, P1226, DOI 10.1109/TPAMI.2005.159
   Platt  J., 1998, FAST TRAINING SUPPOR
   Priya RR, 2012, OPHTHALMOLOGY, V119, P2526, DOI 10.1016/j.ophtha.2012.06.042
   Shen JK, 2007, HISTOL HISTOPATHOL, V22, P1301, DOI 10.14670/HH-22.1301
   Shugay M, 2013, BIOINFORMATICS, V29, P2539, DOI 10.1093/bioinformatics/btt445
   Swaroop A, 2009, ANNU REV GENOM HUM G, V10, P19, DOI 10.1146/annurev.genom.9.081307.164350
   Thornton J, 2005, EYE, V19, P935, DOI 10.1038/sj.eye.6701978
   Weeks DE, 2004, AM J HUM GENET, V75, P174, DOI 10.1086/422476
   Whitcup SM, 2013, INT J INFLAMM, V2013, DOI 10.1155/2013/348092
   Witten I., DATA MINING PRACTICA
   Yan CH, 2004, BIOINFORMATICS, V20, P371, DOI 10.1093/bioinformatics/bth920
   Yang ZL, 2006, SCIENCE, V314, P992, DOI 10.1126/science.1133811
   Yates JRW, 2007, NEW ENGL J MED, V357, P553, DOI 10.1056/NEJMoa072618
   Zhang Y, 2008, BMC GENOMICS, V9, DOI [10.1186/1471-2164-9-S2-S27, 10.1186/1471-2164-9-203]
   Zhou X., 2010, BMC BIOINFORMATICS, V11
NR 67
TC 21
Z9 22
U1 0
U2 8
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 2314-6133
EI 2314-6141
J9 BIOMED RES INT
JI Biomed Res. Int.
PY 2014
VL 2014
AR 450386
DI 10.1155/2014/450386
PG 10
WC Biotechnology & Applied Microbiology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biotechnology & Applied Microbiology; Research & Experimental Medicine
GA AN1XJ
UT WOS:000340377000001
OA gold, Green Published, Green Submitted
DA 2022-11-30
ER

PT J
AU Ghazi, NG
AF Ghazi, Nicola G.
TI Bevacizumab for neovascular age-related macular degeneration (ABC
   trial): multicenter randomized double-masked study
SO EXPERT REVIEW OF CLINICAL PHARMACOLOGY
LA English
DT Article
DE anti-VEGF; Avastin (R); bevacizumab; intravitreal injections; Lucentis
   (R); neovascular age-related macular degeneration; NVAMD; ranibizumab;
   VEGF
AB The ABC trial is the first multicenter, randomized clinical trial that addresses the safety and efficacy of bevacizumab (Avastin (R), Genentech, Inc., CA, USA) in the treatment of neovascular age-related macular degeneration. The trial showed that an initial loading dose of three intravitreal injections of Avastin 1.25 mg at 6-week intervals, followed by a 6-weekly variable retreatment regimen, according to strict functional and anatomic criteria for up to 1 year, is safe and effective. The results are in line with those reported previously in the pivotal ranibizumab (Lucentis (R), Genentech, Inc.) trials following monthly intravitreal injections. The trial also exemplifies the paradigm shift in primary end point selection and patient expectation that the arrival of anti-VEGF agents, such as Lucentis and Avastin, has allowed for. Instead of visual stabilization and retardation of visual loss, patients and physicians now expect visual improvement following treatment. Such expectation was almost unrealistic prior to the availability of these agents.
C1 [Ghazi, Nicola G.] King Khalid Eye Specialist Hosp, POB 7191, Riyadh 11462, Saudi Arabia.
C3 King Khaled Eye Specialist Hospital
RP Ghazi, NG (通讯作者)，King Khalid Eye Specialist Hosp, POB 7191, Riyadh 11462, Saudi Arabia.
EM nghazi@kkesh.med.sa
RI Ghazi, Nicola/AAH-4169-2020
OI Ghazi, Nicola/0000-0001-9255-8025
CR [Anonymous], 1999, Arch Ophthalmol, V117, P1329
   Arnold J, 2001, AM J OPHTHALMOL, V131, P541
   Avery RL, 2006, OPHTHALMOLOGY, V113, P363, DOI 10.1016/j.ophtha.2005.11.019
   Boyer DS, 2009, OPHTHALMOLOGY, V116, P1731, DOI 10.1016/j.ophtha.2009.05.024
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Chong NV, 2009, EYE, V23, P1250, DOI 10.1038/eye.2009.84
   Fung AE, 2006, BRIT J OPHTHALMOL, V90, P1344, DOI 10.1136/bjo.2006.099598
   Fung AE, 2007, AM J OPHTHALMOL, V143, P566, DOI 10.1016/j.ajo.2007.01.028
   Funk M, 2009, INVEST OPHTH VIS SCI, V50, P1025, DOI 10.1167/iovs.08-2510
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Hu CC, 2010, STROKE, V41, P613, DOI 10.1161/STROKEAHA.109.571000
   Klettner AK, 2009, GRAEF ARCH CLIN EXP, V247, P1601, DOI 10.1007/s00417-009-1136-0
   Lalwani GA, 2009, AM J OPHTHALMOL, V148, P43, DOI 10.1016/j.ajo.2009.01.024
   Michels S, 2005, OPHTHALMOLOGY, V112, P1035, DOI 10.1016/j.ophtha.2005.02.007
   Mordenti J, 1999, TOXICOL PATHOL, V27, P536, DOI 10.1177/019262339902700507
   Mordenti J, 1999, TOXICOL SCI, V52, P101, DOI 10.1093/toxsci/52.1.101
   Nishijima K, 2007, AM J PATHOL, V171, P53, DOI 10.2353/ajpath.2007.061237
   Peters S, 2007, AM J OPHTHALMOL, V143, P995, DOI 10.1016/j.ajo.2007.03.007
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Saint-Geniez M, 2006, INVEST OPHTH VIS SCI, V47, P3135, DOI 10.1167/iovs.05-1229
   Schouten JSAG, 2009, GRAEF ARCH CLIN EXP, V247, P1, DOI 10.1007/s00417-008-0952-y
   Spaide RF, 2006, RETINA-J RET VIT DIS, V26, P383, DOI 10.1097/00006982-200604000-00001
   Spitzer MS, 2006, BRIT J OPHTHALMOL, V90, P1316, DOI 10.1136/bjo.2006.095190
   Subramanian ML, 2009, AM J OPHTHALMOL, V148, P875, DOI 10.1016/j.ajo.2009.07.009
   Tufail A, 2010, BMJ-BRIT MED J, V340, DOI 10.1136/bmj.c2459
   Wickremasinghe SS, 2008, OPHTHALMOLOGY, V115, P1911, DOI 10.1016/j.ophtha.2008.05.007
   Wong TY, 2009, AM J OPHTHALMOL, V148, P327, DOI 10.1016/j.ajo.2009.05.012
   Wong TY, 2006, ANN INTERN MED, V145, P98, DOI 10.7326/0003-4819-145-2-200607180-00007
   ZIEMSSEN F, 2009, MED AGING, V26, P295
NR 29
TC 2
Z9 2
U1 0
U2 1
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 1751-2433
EI 1751-2441
J9 EXPERT REV CLIN PHAR
JI Expert Rev. Clin. Pharmacol.
PY 2010
VL 3
IS 6
BP 747
EP 752
DI 10.1586/ECP.10.58
PG 6
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA VB9IK
UT WOS:000423377100012
PM 22111778
DA 2022-11-30
ER

PT J
AU Francone, A
   Yun, L
   Kothari, N
   Cheng, I
   Farajzadeh, M
   Govetto, A
   Hubschman, JP
AF Francone, Anibal
   Yun, Lisa
   Kothari, Nikisha
   Cheng, Iris
   Farajzadeh, Matthew
   Govetto, Andrea
   Hubschman, Jean-Pierre
TI LAMELLAR MACULAR HOLES IN THE PRESENCE OF AGE-RELATED MACULAR
   DEGENERATION
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE age-related macular degeneration; anti-vascular endothelial growth
   factor; choroidal neovascularization; degenerative lamellar macular
   hole; epiretinal proliferation; geographic atrophy; lamellar macular
   holes; macular holes; optical coherence tomography; tractional lamellar
   macular hole
ID OPTICAL COHERENCE TOMOGRAPHY; CLASSIFICATION; MACULOPATHY; TRACTION;
   PSEUDOHOLES; INTERFACE; MICROGLIA; DIAGNOSIS; RETINA
AB Purpose: To investigate whether age-related macular degeneration (AMD) has an influence on the prevalence and anatomical characteristics of lamellar macular holes (LMHs). Methods: Clinical records and spectral-domain optical coherence tomography images of 756 eyes of 423 consecutive patients diagnosed with AMD were reviewed and analyzed. Spectral-domain optical coherence tomography was used to identify degenerative or tractional LMH subtypes and assess their morphology. The clinical and optical coherence tomography findings of AMD eyes with LMH were compared with those of a control group of eyes with LMH without AMD from a previously published report. Results: Lamellar macular holes were identified in 25 eyes of 23 patients (3.3%; 25 of 756). Seventeen of 25 eyes (68%) presented with degenerative LMH and underlying late neovascular AMD. Mean best-corrected visual acuity was worse in eyes with AMD and LMH eyes than in those with AMD and no LMH (20/230 vs. 20/98; P = 0.02). The mean outer diameter was greater in the group with degenerative LMH with concomitant AMD than in the control group of degenerative LMH without AMD (1,323.9 +/- 999.1 mu m vs. 905.9 +/- 356.8 mu m, respectively; P = 0.01). Conclusion: The incidence of degenerative LMH increased in advanced forms of AMD, whereas the presence of tractional LMH subtype may be unrelated to AMD evolution.
C1 [Francone, Anibal; Yun, Lisa; Kothari, Nikisha; Cheng, Iris; Farajzadeh, Matthew; Hubschman, Jean-Pierre] Univ Calif Los Angeles, Stein Eye Inst, Retina Div, 100 Stein Plaza, Los Angeles, CA 90095 USA.
   [Govetto, Andrea] Fatebenefratelli Oftalm Hosp, Ophthalmol Dept, Milan, Italy.
C3 University of California System; University of California Los Angeles
RP Hubschman, JP (通讯作者)，Univ Calif Los Angeles, Stein Eye Inst, Retina Div, 100 Stein Plaza, Los Angeles, CA 90095 USA.
EM jphubschman@gmail.com
FU Research to Prevent Blindness (RPB) New York, NY
FX Supported by an unrestricted institutional grant from the Research to
   Prevent Blindness (RPB) (J.-P. H.) New York, NY, and by a donation from
   the Hess Foundation, New York, NY.
CR Acquistapace A, 2017, GRAEF ARCH CLIN EXP, V255, P2331, DOI 10.1007/s00417-017-3806-7
   Adler R, 1999, MOL VIS, V5
   Bhattacharya S, 2012, INVEST OPHTH VIS SCI, V53, P8350, DOI 10.1167/iovs.12-10495
   Bhutto I, 2012, MOL ASPECTS MED, V33, P295, DOI 10.1016/j.mam.2012.04.005
   BIRD AC, 1995, AM J OPHTHALMOL, V119, P543, DOI 10.1016/S0002-9394(14)70212-0
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Bottoni F, 2008, BRIT J OPHTHALMOL, V92, P635, DOI 10.1136/bjo.2007.127597
   Bottoni F, 2013, GRAEF ARCH CLIN EXP, V251, P467, DOI 10.1007/s00417-012-2044-2
   Chi ZL, 2010, ADV EXP MED BIOL, V703, P127, DOI 10.1007/978-1-4419-5635-4_9
   Compera D, 2018, BRIT J OPHTHALMOL, V102, P84, DOI 10.1136/bjophthalmol-2016-310128
   Curcio CA, 1999, ARCH OPHTHALMOL-CHIC, V117, P329, DOI 10.1001/archopht.117.3.329
   DOREY CK, 1989, INVEST OPHTH VIS SCI, V30, P1691
   Duker JS, 2013, OPHTHALMOLOGY, V120, P2611, DOI 10.1016/j.ophtha.2013.07.042
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Frangieh G T, 1981, Retina, V1, P311, DOI 10.1097/00006982-198101040-00008
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   GAO H, 1992, INVEST OPHTH VIS SCI, V33, P1
   Gass J D, 1975, Trans Am Ophthalmol Soc, V73, P231
   GASS JDM, 1976, ARCH OPHTHALMOL-CHIC, V94, P793, DOI 10.1001/archopht.1976.03910030391008
   Gaudric A, 1999, ARCH OPHTHALMOL-CHIC, V117, P744
   Govetto A, 2017, AM J OPHTHALMOL, V175, P99, DOI 10.1016/j.ajo.2016.12.006
   Govetto A, 2016, AM J OPHTHALMOL, V164, P99, DOI 10.1016/j.ajo.2016.02.008
   Gupta N, 2003, EXP EYE RES, V76, P463, DOI 10.1016/S0014-4835(02)00332-9
   Haouchine B, 2004, AM J OPHTHALMOL, V138, P732, DOI 10.1016/j.ajo.2004.06.088
   Haouchine B, 2001, OPHTHALMOLOGY, V108, P15, DOI 10.1016/S0161-6420(00)00519-4
   HOGAN M J, 1972, Transactions of the American Academy of Ophthalmology and Oto-Laryngology, V76, P64
   Kent DL, 2014, MOL VIS, V20, P46
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   Ko J, 2017, ACTA OPHTHALMOL, V95, pE221, DOI 10.1111/aos.13245
   Kurihara T, 2012, J CLIN INVEST, V122, P4213, DOI 10.1172/JCI65157
   Liesenborghs I, 2018, ACTA OPHTHALMOL, V96, P729, DOI 10.1111/aos.13671
   McLeod DS, 2009, INVEST OPHTH VIS SCI, V50, P4982, DOI 10.1167/iovs.09-3639
   Meuer SM, 2015, OPHTHALMOLOGY, V122, P787, DOI 10.1016/j.ophtha.2014.10.014
   PROVIS JM, 1995, GLIA, V14, P243, DOI 10.1002/glia.440140402
   SARKS SH, 1976, BRIT J OPHTHALMOL, V60, P324, DOI 10.1136/bjo.60.5.324
   Seddon JM, 2006, OPHTHALMOLOGY, V113, P260, DOI 10.1016/j.ophtha.2005.11.001
   Segal O, 2015, ISR MED ASSOC J, V17, P750
   Sobrin L, 2014, PROG RETIN EYE RES, V40, P1, DOI 10.1016/j.preteyeres.2013.12.004
   Sunness JS, 1999, MOL VIS, V5
   Takahashi H, 2000, AM J OPHTHALMOL, V130, P677, DOI 10.1016/S0002-9394(00)00626-7
   Tao LW, 2016, CLIN EXP OPHTHALMOL, V44, P422, DOI 10.1111/ceo.12685
   Theodossiadis P, 2010, EUR J OPHTHALMOL, V20, P1086, DOI 10.1177/112067211002000613
   Witkin AJ, 2006, OPHTHALMOLOGY, V113, P388, DOI 10.1016/j.ophtha.2005.10.047
NR 43
TC 2
Z9 2
U1 1
U2 2
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD JUN
PY 2020
VL 40
IS 6
BP 1079
EP 1086
DI 10.1097/IAE.0000000000002532
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA LW6LN
UT WOS:000539255800014
PM 31145390
OA Green Published, hybrid
DA 2022-11-30
ER

PT J
AU Hussain, N
   Das, T
   Khanna, R
   Sumasri, K
   Ram, LSM
AF Hussain, Nazimul
   Das, Taraprasad
   Khanna, Rohit
   Sumasri, Kallukuri
   ram, Lakshmana Samud Mohan Ram
TI Verteporfin therapy for neovascular age-related macular degeneration in
   Indian eyes
SO JAPANESE JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE age-related macular degeneration; choroidal neovascularization;
   photodynamic therapy; subfoveal; verteporfin
ID PHOTODYNAMIC THERAPY
AB Purpose: To determine visual outcome after a 12-month follow-up period of verteporfin therapy for subfoveal choroidal neovascularization (CNV) secondary to age-related macular degeneration (AMD) in Indian patients.
   Methods: Twenty-five patients (26 eyes) who completed a 12-month follow-up after photodynamic therapy for subfoveal CNV secondary to AMD were included in the study. The follow-up schedule was every month for 2 months and then every 3 months thereafter until 12 months. Improvement in visual acuity. was defined as a >= 10-lettcr gain, and deterioration as a >= 10-letter loss in the Early Treatment Diabetic Retinopathy Study chart at 4m.
   Results: The mean age of the 25 patients was 62.3 +/- 9 years. There were 17 male patients (68%). The mean initial letter acuity was 28. 4 +/- 14.1, and the final letter acuity was 25.5 +/- 18.4 at 12 months. Initial visual acuity was >= 20/40 in seven eyes, 20/50-20/80 in nine eyes, and 20/100-20/200 in ten eyes; seven eyes had a >= 10-letter gain, and three eyes had a >= 10-letter loss. At the end of 12 months, six eyes had a >= 10-letter gain and ten eyes had a >= 10-letter loss.
   Conclusion: Photodynamic therapy appears to preserve the vision in subfoveal CNV secondary to AMD in the eyes of Indian patients.
C1 LV Prasad Eye Inst, Smt Kanuri Santhamma Retina Vitreous Ctr, Hyderabad 500034, Andhra Pradesh, India.
   LV Prasad Eye Inst, ICARE, Hyderabad, Andhra Pradesh, India.
C3 L. V. Prasad Eye Institute; L. V. Prasad Eye Institute
RP Hussain, N (通讯作者)，LV Prasad Eye Inst, Smt Kanuri Santhamma Retina Vitreous Ctr, LV Prasad Marg,Banjara Hills, Hyderabad 500034, Andhra Pradesh, India.
EM nazimul@lvpei.org
RI Hussain, Nazimul/Q-7563-2019
OI Hussain, Nazimul/0000-0001-6920-5168
CR Arnold J, 2001, AM J OPHTHALMOL, V131, P541
   Axer-Siegel R, 2004, AM J OPHTHALMOL, V137, P258, DOI 10.1016/j.ajo.2003.08.009
   Blumenkranz MS, 2001, ARCH OPHTHALMOL-CHIC, V119, P198
   Bressler NM, 2002, ARCH OPHTHALMOL-CHIC, V120, P1443
   Bressler NM, 2005, RETINA-J RET VIT DIS, V25, P119
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   Greve MDJ, 2005, ARCH OPHTHALMOL-CHIC, V123, P448
   Hussain Nazimul, 2004, Indian Journal of Ophthalmology, V52, P227
   Hussain Nazimul, 2005, Indian Journal of Ophthalmology, V53, P101
   Rubin GS, 2002, RETINA-J RET VIT DIS, V22, P536, DOI 10.1097/00006982-200210000-00002
   Tano Y, 2003, AM J OPHTHALMOL, V136, P1049, DOI 10.1016/S0002-9394(03)00576-2
NR 11
TC 5
Z9 5
U1 0
U2 0
PU SPRINGER JAPAN KK
PI TOKYO
PA SHIROYAMA TRUST TOWER 5F, 4-3-1 TORANOMON, MINATO-KU, TOKYO, 105-6005,
   JAPAN
SN 0021-5155
EI 1613-2246
J9 JPN J OPHTHALMOL
JI Jpn. J. Ophthalmol.
PD NOV-DEC
PY 2006
VL 50
IS 6
BP 524
EP 528
DI 10.1007/s10384-006-0367-4
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 120XS
UT WOS:000243120700005
PM 17180526
DA 2022-11-30
ER

PT J
AU Kaikaryte, K
   Gedvilaite, G
   Vilkeviciute, A
   Kriauciuniene, L
   Mockute, R
   Cebatoriene, D
   Zemaitiene, R
   Balciuniene, VJ
   Liutkeviciene, R
AF Kaikaryte, Kriste
   Gedvilaite, Greta
   Vilkeviciute, Alvita
   Kriauciuniene, Loresa
   Mockute, Ruta
   Cebatoriene, Dzastina
   Zemaitiene, Reda
   Balciuniene, Vilma Jurate
   Liutkeviciene, Rasa
TI SIRT1: Genetic Variants and Serum Levels in Age-Related Macular
   Degeneration
SO LIFE-BASEL
LA English
DT Article
DE age-related macular degeneration (AMD); SIRT1; rs3818292; rs3758391;
   rs7895833; SIRT1 levels
ID PROTEIN; EXPRESSION; APOPTOSIS; CATARACT; PATHWAYS; CELLS; P53
AB Background: The aim of this paper was to determine the frequency of SIRT1 rs3818292, rs3758391, rs7895833 single nucleotide polymorphism genotypes and SIRT1 serum levels associated with age-related macular degeneration (AMD) in the Lithuanian population. Methods: Genotyping of SIRT1 rs3818292, rs3758391 and rs7895833 was performed using RT-PCR. SIRT1 serum level was determined using the ELISA method. Results: We found that rs3818292 and rs7895833 were associated with an increased risk of developing exudative AMD. Additional sex-differentiated analysis revealed only rs7895833 was associated with an increased risk of developing exudative AMD in women after strict Bonferroni correction. The analysis also revealed that individuals carrying rs3818292, rs3758391 and rs7895833 haplotype G-T-G are associated with increased odds of exudative AMD. Still, the rare haplotypes were associated with the decreased odds of exudative AMD. After performing an analysis of serum SIRT1 levels and SIRT1 genetic variant, we found that carriers of the SIRT1 rs3818292 minor allele G had higher serum SIRT1 levels than the AA genotype. In addition, individuals carrying at least one SIRT1 rs3758391 T allele also had elevated serum SIRT1 levels compared with individuals with the wild-type CC genotype. Conclusions: Our study showed that the SIRT1 polymorphisms rs3818292 and rs7895833 and rs3818292-rs3758391-rs7895833 haplotype G-T-G could be associated with the development of exudative AMD. Also, two SNPs (rs3818292 and rs3758391) are associated with elevated SIRT1 levels.
C1 [Kaikaryte, Kriste; Gedvilaite, Greta; Vilkeviciute, Alvita; Kriauciuniene, Loresa; Liutkeviciene, Rasa] Lithuanian Univ Hlth Sci, Med Acad, Neurosci Inst, Lab Ophthalmol, Eiveniu 2, LT-50161 Kaunas, Lithuania.
   [Kriauciuniene, Loresa; Mockute, Ruta; Cebatoriene, Dzastina; Zemaitiene, Reda; Balciuniene, Vilma Jurate; Liutkeviciene, Rasa] Lithuanian Univ Hlth Sci, Med Acad, Dept Ophthalmol, Eiveniu 2 Str, LT-50161 Kaunas, Lithuania.
C3 Lithuanian University of Health Sciences; Lithuanian University of
   Health Sciences
RP Kaikaryte, K (通讯作者)，Lithuanian Univ Hlth Sci, Med Acad, Neurosci Inst, Lab Ophthalmol, Eiveniu 2, LT-50161 Kaunas, Lithuania.
EM kriste.kaikaryte@lsmuni.lt; greta.gedvilaite@lsmuni.lt;
   alvita.vilkeviciute@lsmuni.lt; loresa.kriauciuniene@lsmuni.lt;
   rutikess@gmail.com; dzastina.cebatoriene@lsmuni.lt;
   reda.zemaitiene@lsmuni.lt; jurate.balciuniene@lsmu.lt;
   rasa.liutkeviciene@lsmuni.lt
OI Gedvilaite, Greta/0000-0001-7469-8825; Vilkeviciute,
   Alvita/0000-0002-0427-5568
CR Age-Related Eye Dis Study Res Grp, 2001, AM J OPHTHALMOL, V132, P668
   AMES A, 1992, J NEUROSCI, V12, P4234
   Anekonda Thimmappa S, 2008, BMC Res Notes, V1, P122, DOI 10.1186/1756-0500-1-122
   [Anonymous], RS3758391 REFSNP REP
   [Anonymous], US
   [Anonymous], RS3818292 REFSNP REP
   [Anonymous], RS7895833 REFSNP REP
   Balaiya S, 2013, MOL VIS, V19, P2385
   Balaiya S, 2012, MOL VIS, V18, P114
   Ban N, 2013, EXP GERONTOL, V48, P1212, DOI 10.1016/j.exger.2013.04.010
   Bhattacharya S, 2012, INVEST OPHTH VIS SCI, V53, P8350, DOI 10.1167/iovs.12-10495
   Brochier C, 2013, J NEUROSCI, V33, P8621, DOI 10.1523/JNEUROSCI.5214-12.2013
   Chen ZQ, 2015, MEDICINE, V94, DOI 10.1097/MD.0000000000002238
   Cheng HL, 2003, P NATL ACAD SCI USA, V100, P10794, DOI 10.1073/pnas.1934713100
   Ferrara N, 2006, RETINA-J RET VIT DIS, V26, P859, DOI 10.1097/01.iae.0000242842.14624.e7
   Fletcher AE, 2010, OPHTHALMIC RES, V44, P191, DOI 10.1159/000316476
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Han J, 2013, CELL CYCLE, V12, P263, DOI 10.4161/cc.23056
   Jaliffa C, 2009, INVEST OPHTH VIS SCI, V50, P3562, DOI 10.1167/iovs.08-2817
   Kaeberlein M, 1999, GENE DEV, V13, P2570, DOI 10.1101/gad.13.19.2570
   Klein R, 2004, AM J OPHTHALMOL, V137, P486, DOI 10.1016/j.ajo.2003.11.069
   Kubota S, 2011, INVEST OPHTH VIS SCI, V52, P9142, DOI 10.1167/iovs.11-8041
   Kubota S, 2010, AM J PATHOL, V177, P1725, DOI 10.2353/ajpath.2010.100098
   Kurihara T, 2010, DEVELOPMENT, V137, P1563, DOI 10.1242/dev.049015
   Lee SH, 2000, J BIOL CHEM, V275, P33679, DOI 10.1074/jbc.M004994200
   Lesauskaite V, 2008, MEDICINA-LITHUANIA, V44, P386, DOI 10.3390/medicina44050050
   Lin H, 2019, GENOME BIOL, V20, DOI 10.1186/s13059-019-1847-4
   Lin TJ, 2011, J CATARACT REFR SURG, V37, P1270, DOI 10.1016/j.jcrs.2011.02.027
   Liutkeviciene R, 2019, GENE, V686, P8, DOI 10.1016/j.gene.2018.11.004
   Liutkeviciene R, 2017, GENE, V636, P30, DOI 10.1016/j.gene.2017.09.022
   Liutkeviciene R, 2010, MEDICINA-LITHUANIA, V46, P89, DOI 10.3390/medicina46020013
   Maeda S, 2011, CLIN EXP NEPHROL, V15, P381, DOI 10.1007/s10157-011-0418-0
   Maloney SC, 2013, RETINA-J RET VIT DIS, V33, P862, DOI 10.1097/IAE.0b013e31826af556
   McBurney MW, 2003, MOL CELL BIOL, V23, P38, DOI 10.1128/MCB.23.1.38-54.2003
   Mimura T, 2013, EXP EYE RES, V116, P17, DOI 10.1016/j.exer.2013.07.017
   Neverauskiene J., 2003, INT J OPHTHALMOL-CHI, V3, P225
   Niven JE, 2008, J EXP BIOL, V211, P1792, DOI 10.1242/jeb.017574
   Ozawa Y, 2010, OPHTHALMIC RES, V44, P199, DOI 10.1159/000316484
   Potente M, 2007, GENE DEV, V21, P2644, DOI 10.1101/gad.435107
   Razi S, 2017, J GERONTOL A-BIOL, V72, P870, DOI 10.1093/gerona/glx018
   Sidorova-Darmos E, 2014, FRONT AGING NEUROSCI, V6, DOI 10.3389/fnagi.2014.00333
   Sole X, 2006, BIOINFORMATICS, V22, P1928, DOI 10.1093/bioinformatics/btl268
   Tao TT, 2022, BMC ENDOCR DISORD, V22, DOI 10.1186/s12902-022-00965-0
   Winkler BS, 1999, MOL VIS, V5
   Wojcik M, 2009, MINI-REV MED CHEM, V9, P386, DOI 10.2174/1389557510909030386
   Yang JQ, 2009, J BIOL CHEM, V284, P27042, DOI 10.1074/jbc.M109.047340
   Zarbin MA, 2004, ARCH OPHTHALMOL-CHIC, V122, P598, DOI 10.1001/archopht.122.4.598
   Zheng TY, 2011, CURR EYE RES, V36, P449, DOI 10.3109/02713683.2011.559301
   Zuo L, 2013, INVEST OPHTH VIS SCI, V54, P5097, DOI 10.1167/iovs.13-12157
NR 49
TC 0
Z9 0
U1 1
U2 1
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2075-1729
J9 LIFE-BASEL
JI Life-Basel
PD MAY
PY 2022
VL 12
IS 5
AR 753
DI 10.3390/life12050753
PG 17
WC Biology; Microbiology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Life Sciences & Biomedicine - Other Topics; Microbiology
GA 1O7RS
UT WOS:000801525000001
PM 35629418
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Rahman, EZ
   Singer, MA
AF Rahman, E. Z.
   Singer, M. A.
TI Brolucizumab as treatment of wet age-related maculopathy
SO DRUGS OF TODAY
LA English
DT Article
DE Brolucizumab; Wet age-related macular degeneration; Vascular endothelial
   growth factor (VEGF) inhibitors; Ophthalmic drugs
AB Given the success in stabilizing vision with current anti-vascular endothelial growth factor (VEGF) options, one main target for future anti-VEGF drug development includes creating medications with longer durations of action. Achieving this goal will decrease the number of overall injections and follow-up visits required to ensure better patient compliance. The smallest anti-VEGF created so far is brolucizumab (Beovu; Novartis). It is a 26-kDa IgG single-chain antibody fragment that delivers 11 times more anti-VEGF per injection than aflibercept. Brolucizumab was approved by the U.S. Food and Drug Administration (FDA) in late 2019 for the treatment of wet age-related macular degeneration, and has been also approved for the same indication in Japan and the European Union in 2020. In this article, we compare brolucizumab to current FDA-approved anti-VEGF treatments, address the studies associated with brolucizumab, discuss brolucizumab's side effects, and conclude with recommendations.
C1 [Rahman, E. Z.; Singer, M. A.] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA.
   [Singer, M. A.] Med Ctr Ophthalmol Associates, 9157 Huebner Rd, San Antonio, TX 78240 USA.
C3 University of Texas System; University of Texas Health San Antonio
RP Singer, MA (通讯作者)，Med Ctr Ophthalmol Associates, 9157 Huebner Rd, San Antonio, TX 78240 USA.
EM msinger11@me.com
CR American Society of Retina Specialists (ASRS), 2020, MEMB UPD NOV APP SAF
   [Anonymous], 2020, OCCL RET VASC SOLL I
   [Anonymous], 2018, RTH258 C001 CLIN STU
   [Anonymous], 2018, RTH258 C002 CLIN STU
   Boulanger-Scemama E, 2015, J FR OPHTALMOL, V38, P620, DOI 10.1016/j.jfo.2014.11.015
   Dugel P.U., 2018, AM AC OPHTH ANN M OC
   Dugel PU, 2020, OPHTHALMOLOGY, V127, P72, DOI 10.1016/j.ophtha.2019.04.017
   Holz FG, 2016, EYE, V30, P1063, DOI 10.1038/eye.2016.90
   Jaffe G.J., 2018, ANN M ASS RES VIS OP
   Yannuzzi NA, 2019, CLIN OPHTHALMOL, V13, P1323, DOI 10.2147/OPTH.S184706
NR 10
TC 3
Z9 3
U1 0
U2 2
PU PROUS SCIENCE, SAU-THOMSON REUTERS
PI BARCELONA
PA 398 PROVENCA, 08025 BARCELONA, SPAIN
SN 1699-3993
EI 1699-4019
J9 DRUG TODAY
JI Drugs Today
PD NOV
PY 2020
VL 56
IS 11
BP 699
EP 704
DI 10.1358/dot.2020.56.11.3199812
PG 6
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA OW3ZT
UT WOS:000592829800001
PM 33332477
DA 2022-11-30
ER

PT J
AU Klein, R
   Knudtson, MD
   Lee, KE
   Klein, BEK
AF Klein, Ronald
   Knudtson, Michael D.
   Lee, Kristine E.
   Klein, Barbara E. K.
TI Serum Cystatin C Level, Kidney Disease Markers, and Incidence of
   Age-Related Macular Degeneration The Beaver Dam Eye Study
SO ARCHIVES OF OPHTHALMOLOGY
LA English
DT Article
ID HEMOLYTIC-UREMIC SYNDROME; COMPLEMENT FACTOR-H; VISUAL-ACUITY;
   MEMBRANOPROLIFERATIVE GLOMERULONEPHRITIS; ENDOTHELIAL DYSFUNCTION;
   PIGMENT EPITHELIUM; OXIDATIVE STRESS; MACULOPATHY; GENE; INFLAMMATION
AB Objective: To examine the associations of the serum cystatin C level and chronic kidney disease with the incidence of age-related macular degeneration (AMD) over 15 years.
   Methods: In this population-based cohort study of 4926 individuals aged 43 to 86 years at baseline, 3779 participated in 1 or more follow-up examinations. Age-related macular degeneration was determined by grading photographs of the macula. Individuals were defined as having mild or moderate to severe chronic kidney disease based on a value of more than 45 mL/min/1.73 m(2) to 60 mL/min/1.73 m(2) or less and 45 mL/min/1.73 m(2) or less, respectively, according to the Modification of Diet in Renal Disease Study equation.
   Results: While controlling for age and other risk factors, the level of serum cystatin C at baseline was associated with the incidence of early AMD (odds ratio per log standard deviation [95% confidence interval], 1.16 [1.01-1.35]) and exudative AMD (1.42 [1.03-1.96]) but not geographic atrophy (0.89 [0.56-1.41]) or progression of AMD (1.02 [0.88-1.18]). Mild chronic kidney disease was associated with the 15-year cumulative incidence of early AMD (odds ratio per log standard deviation, 1.36 [95% confidence interval, 1.00-1.86]) but not the incidence of other AMD end points.
   Conclusion: There is a relationship between the level of serum cystatin C and chronic kidney disease with the incidence of AMD. The underlying biological processes remain to be determined.
C1 [Klein, Ronald; Knudtson, Michael D.; Lee, Kristine E.; Klein, Barbara E. K.] Univ Wisconsin, Sch Med & Publ Hlth, Dept Ophthalmol & Visual Sci, Madison, WI 53706 USA.
C3 University of Wisconsin System; University of Wisconsin Madison
RP Klein, R (通讯作者)，Univ Wisconsin, Sch Med & Publ Hlth, Dept Ophthalmol & Visual Sci, Madison, WI 53706 USA.
OI Klein, Ronald/0000-0002-4428-6237
FU National Eye Institute [EY06594]; National Institute of Diabetes and
   Digestive and Kidney Diseases [DK073217]; National Institutes of Health;
   Senior Scientific Investigator Awards from Research to Prevent
   Blindness; NATIONAL EYE INSTITUTE [U10EY006594] Funding Source: NIH
   RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY
   DISEASES [R01DK073217] Funding Source: NIH RePORTER
FX This study was supported by grants EY06594 (Drs R. Klein and B. E. K.
   Klein) from the National Eye Institute and DK073217 (Dr R. Klein) from
   the National Institute of Diabetes and Digestive and Kidney Diseases,
   National Institutes of Health and in part by Senior Scientific
   Investigator Awards (Drs R. Klein and B. E. K. Klein) from Research to
   Prevent Blindness.
CR ABRAHAMSON M, 1994, METHOD ENZYMOL, V244, P685
   ABRAHAMSON M, 1986, J BIOL CHEM, V261, P1282
   Abrera-Abeleda MA, 2006, J MED GENET, V43, P582, DOI 10.1136/jmg.2005.038315
   Alexander JJ, 2007, J AM SOC NEPHROL, V18, P1157, DOI 10.1681/ASN.2006101125
   Alexander JJ, 2005, J AM SOC NEPHROL, V16, P52, DOI 10.1681/ASN.2004090778
   Anderson DH, 2002, AM J OPHTHALMOL, V134, P411, DOI 10.1016/S0002-9394(02)01624-0
   [Anonymous], [No title captured]
   [Anonymous], 2002, AM J KIDNEY DIS S1, V39, pS1
   BARKA T, 1994, ANAT REC, V239, P343, DOI 10.1002/ar.1092390312
   BARRETT AJ, 1986, BIOMED BIOCHIM ACTA, V45, P1363
   BLUMENKRANZ MS, 1986, OPHTHALMOLOGY, V93, P552
   Buddles MRH, 2000, AM J HUM GENET, V66, P1721, DOI 10.1086/302877
   Caprioli J, 2003, HUM MOL GENET, V12, P3385, DOI 10.1093/hmg/ddg363
   COCKCROFT DW, 1976, NEPHRON, V16, P31, DOI 10.1159/000180580
   Cohn DH, 2000, AM J HUM GENET, V67, P647, DOI 10.1086/303051
   Decanini A, 2007, AM J OPHTHALMOL, V143, P607, DOI 10.1016/j.ajo.2006.12.006
   Dragon-Durey MA, 2004, J AM SOC NEPHROL, V15, P787, DOI 10.1097/01.ASN.0000115702.28859.A7
   Ferreras M, 2000, FEBS LETT, V486, P247, DOI 10.1016/S0014-5793(00)02249-3
   Filler G, 2005, CLIN BIOCHEM, V38, P1, DOI 10.1016/j.clinbiochem.2004.09.025
   Fox CS, 2004, J AM SOC NEPHROL, V15, P2457, DOI 10.1097/01.ASN.0000135972.13396.6F
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Hosmer DW, 1989, APPL LOGISTIC REGRES, P238
   Im E, 2005, MOL BIOL CELL, V16, P3488, DOI 10.1091/mbc.E04-11-1029
   KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868
   Klein R, 1998, AM J EPIDEMIOL, V147, P103
   Klein R, 1997, OPHTHALMOLOGY, V104, P7, DOI 10.1016/S0161-6420(97)30368-6
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Klein R, 2001, OPHTHALMOLOGY, V108, P1757, DOI 10.1016/S0161-6420(01)00769-2
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1310
   Klein R, 1996, OPHTHALMOLOGY, V103, P1169, DOI 10.1016/S0161-6420(96)30526-5
   Klein R, 2002, OPHTHALMOLOGY, V109, P1767, DOI 10.1016/S0161-6420(02)01146-6
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   Klein R, 1999, OPHTHALMOLOGY, V106, P1056, DOI 10.1016/S0161-6420(99)90255-5
   KLEIN R, 1995, BEAVER DAM EYE STUDY, V2
   KLEIN R, 1999, BEAVER DAM EYE STUDY, V3
   Klein R, 2007, OPHTHALMOLOGY, V114, P253, DOI 10.1016/j.ophtha.2006.10.040
   Klein R, 2006, AM J OPHTHALMOL, V142, P539, DOI 10.1016/j.ajo.2006.06.015
   Knight EL, 2004, KIDNEY INT, V65, P1416, DOI 10.1111/j.1523-1755.2004.00517.x
   Knudtson MD, 2006, ARCH OPHTHALMOL-CHIC, V124, P243, DOI 10.1001/archopht.124.2.243
   Landray MJ, 2004, AM J KIDNEY DIS, V43, P244, DOI 10.1053/j.ajkd.2003.10.037
   Levey AS, 1999, ANN INTERN MED, V130, P461, DOI 10.7326/0003-4819-130-6-199903160-00002
   Liew G, 2008, J AM SOC NEPHROL, V19, P806, DOI 10.1681/ASN.2007080844
   LINTON KLP, 1991, AM J EPIDEMIOL, V134, P1438, DOI 10.1093/oxfordjournals.aje.a116049
   Marneros AG, 2004, EMBO J, V23, P89, DOI 10.1038/sj.emboj.7600014
   Mezzano D, 2001, KIDNEY INT, V60, P1844, DOI 10.1046/j.1523-1755.2001.00998.x
   Neary JJ, 2002, J AM SOC NEPHROL, V13, P2052, DOI 10.1097/01.ASN.0000022006.49966.F8
   Neumann HPH, 2003, J MED GENET, V40, P676, DOI 10.1136/jmg.40.9.676
   Oberg BP, 2004, KIDNEY INT, V65, P1009, DOI 10.1111/j.1523-1755.2004.00465.x
   Paraoan L, 2003, EXP EYE RES, V76, P753, DOI 10.1016/S0014-4835(03)00061-7
   Perez-Caballero D, 2001, AM J HUM GENET, V68, P478, DOI 10.1086/318201
   Pow DV, 2005, MACULAR DEGENERATION, P123, DOI 10.1007/3-540-26977-0_8
   Saunders RE, 2006, HUM MUTAT, V27, P21, DOI 10.1002/humu.20268
   Thompson CL, 2007, HUM MOL GENET, V16, P2135, DOI 10.1093/hmg/ddm164
   Tsao YP, 2006, LIFE SCI, V79, P545, DOI 10.1016/j.lfs.2006.01.041
   Tsukaguchi H, 2000, J AM SOC NEPHROL, V11, P1674, DOI 10.1681/ASN.V1191674
   TURK V, 1991, FEBS LETT, V285, P213, DOI 10.1016/0014-5793(91)80804-C
   Vollmer M, 1998, AM J HUM GENET, V63, P1724, DOI 10.1086/302162
   Wasselius J, 2001, INVEST OPHTH VIS SCI, V42, P1901
   Ying LH, 1999, AM J HUM GENET, V65, P1538, DOI 10.1086/302673
   Zatterstrom UK, 2000, CELL STRUCT FUNCT, V25, P97
   Zurdel J, 2002, BRIT J OPHTHALMOL, V86, P214, DOI 10.1136/bjo.86.2.214
NR 61
TC 41
Z9 42
U1 0
U2 3
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 515 N STATE ST, CHICAGO, IL 60610-0946 USA
SN 0003-9950
J9 ARCH OPHTHALMOL-CHIC
JI Arch. Ophthalmol.
PD FEB
PY 2009
VL 127
IS 2
BP 193
EP 199
DI 10.1001/archophthalmol.2008.551
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 405DR
UT WOS:000263203400010
PM 19204238
OA Green Accepted, Bronze
DA 2022-11-30
ER

PT J
AU Barral, S
   Francis, PJ
   Schultz, DW
   Schain, MB
   Haynes, C
   Majewski, J
   Ott, J
   Acott, T
   Weleber, RG
   Klein, ML
AF Barral, Sandra
   Francis, Peter J.
   Schultz, Dennis W.
   Schain, Mitchell B.
   Haynes, Chad
   Majewski, Jacek
   Ott, Jurg
   Acott, Ted
   Weleber, Richard G.
   Klein, Michael L.
TI Expanded genome scan in extended families with age-related macular
   degeneration
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
ID COMPLEMENT FACTOR-H; SUSCEPTIBILITY LOCI; MACULOPATHY; POLYMORPHISM;
   ASSOCIATION; VARIANT; GENE; LINKAGE; REGIONS; 10Q26
AB PURPOSE. To investigate further the genetic contribution to age-related macular degeneration (AMD), increasing the power of a previous analysis and reproducing the original findings.
   METHODS. A large cohort of families with this condition was assembled, and an expanded genome scan was performed with 556 microsatellite markers. In 2003, the results were reported of a genome-wide linkage analysis of 70 of these pedigrees. Members of 51 new families have now been ascertained and many of the original pedigrees expanded. Parametric and non-parametric linkage analyses were performed with a denser map of markers. In addition, analyses were performed with the sample stratified by age at ascertainment and by two major advanced phenotypes for the disease: neovascular AMD ( choroidal neovascularization) and geographic atrophy.
   RESULTS. The results corroborate the macular degeneration susceptibility loci consistently reported by the authors and others in genome-wide scans. New loci were identified, including the finding of a two-point HLOD of 3.70 at 6q25.2.
   CONCLUSIONS. The results suggest that the use of families enriched in predisposition to AMD has legitimacy. Genetic analyses of a genome-wide scan performed on our large cohort of families add further confirmatory evidence that susceptibility loci lie on 1q, 3p, 9q, and 10q. Furthermore, new loci have been identified, including a locus on 6q.
C1 Oregon Hlth & Sci Univ, Casey Eye Inst, Macular Degenerat Ctr, Portland, OR 97239 USA.
   Rockefeller Univ, Lab Stat Genet, New York, NY 10021 USA.
C3 Oregon Health & Science University; Rockefeller University
RP Klein, ML (通讯作者)，Oregon Hlth & Sci Univ, Casey Eye Inst, Macular Degenerat Ctr, 3375 SW Terwilliger Blvd, Portland, OR 97239 USA.
EM kleinm@ohsu.edu
FU NCRR NIH HHS [5M01-RR000334] Funding Source: Medline; NEI NIH HHS
   [EY12203] Funding Source: Medline; NHGRI NIH HHS [HG00008] Funding
   Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000334]
   Funding Source: NIH RePORTER; NATIONAL EYE INSTITUTE [R01EY012203]
   Funding Source: NIH RePORTER
CR Abecasis GR, 2004, AM J HUM GENET, V74, P482, DOI 10.1086/382786
   Allikmets R, 2000, AM J HUM GENET, V67, P487, DOI 10.1086/303018
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Fisher SA, 2005, HUM MOL GENET, V14, P2257, DOI 10.1093/hmg/ddi230
   Gorin Michael B, 2005, Ophthalmic Genet, V26, P57, DOI 10.1080/13816810590969914
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Hamdi HK, 2002, BIOCHEM BIOPH RES CO, V295, P668, DOI 10.1016/S0006-291X(02)00728-3
   Hammond CJ, 2002, OPHTHALMOLOGY, V109, P730, DOI 10.1016/S0161-6420(01)01049-1
   Iyengar SK, 2004, AM J HUM GENET, V74, P20, DOI 10.1086/380912
   Jakobsdottir J, 2005, AM J HUM GENET, V77, P389, DOI 10.1086/444437
   Jun G, 2005, INVEST OPHTH VIS SCI, V46, P3081, DOI 10.1167/iovs.04-1360
   Klein Michael L, 2003, Ophthalmol Clin North Am, V16, P567, DOI 10.1016/S0896-1549(03)00063-4
   Klein R, 2004, AM J OPHTHALMOL, V137, P486, DOI 10.1016/j.ajo.2003.11.069
   Klein R, 1997, OPHTHALMOLOGY, V104, P7, DOI 10.1016/S0161-6420(97)30368-6
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Majewski J, 2003, AM J HUM GENET, V73, P540, DOI 10.1086/377701
   O'Connell JR, 1998, AM J HUM GENET, V63, P259, DOI 10.1086/301904
   Schick JH, 2003, AM J HUM GENET, V72, P1412, DOI 10.1086/375500
   Schmidt S, 2000, MOL VIS, V6, P287
   Schultz Dennis W, 2005, Ophthalmic Genet, V26, P101, DOI 10.1080/13816810590968023
   Schultz DW, 2003, HUM MOL GENET, V12, P3315, DOI 10.1093/hmg/ddg348
   Seddon JM, 2003, AM J HUM GENET, V73, P780, DOI 10.1086/378505
   Stone EM, 2004, NEW ENGL J MED, V351, P346, DOI 10.1056/NEJMoa040833
   Tou JS, 2004, FASEB J, V18, P1297, DOI 10.1096/fj.04-1862fje
   Ulgen A, 2004, HUM HERED, V57, P39, DOI 10.1159/000077388
   Weeks DE, 2000, HUM MOL GENET, V9, P1329, DOI 10.1093/hmg/9.9.1329
   Weeks DE, 2004, AM J HUM GENET, V75, P174, DOI 10.1086/422476
   Weeks DE, 2001, AM J OPHTHALMOL, V132, P682, DOI 10.1016/S0002-9394(01)01214-4
   Zareparsi S, 2005, AM J HUM GENET, V77, P149, DOI 10.1086/431426
   Zareparsi S, 2005, HUM MOL GENET, V14, P1449, DOI 10.1093/hmg/ddi154
NR 31
TC 13
Z9 13
U1 0
U2 2
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD DEC
PY 2006
VL 47
IS 12
BP 5453
EP 5459
DI 10.1167/iovs.06-0655
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 110TW
UT WOS:000242404900045
PM 17122136
DA 2022-11-30
ER

PT J
AU de Guimaraes, TAC
   Varela, MD
   Georgiou, M
   Michaelides, M
AF de Guimaraes, Thales Antonio Cabral
   Varela, Malena Daich
   Georgiou, Michalis
   Michaelides, Michel
TI Treatments for dry age-related macular degeneration: therapeutic
   avenues, clinical trials and future directions
SO BRITISH JOURNAL OF OPHTHALMOLOGY
LA English
DT Review
DE genetics; angiogenesis; degeneration; retina; macula
ID GEOGRAPHIC ATROPHY SECONDARY; CILIARY NEUROTROPHIC FACTOR; COMPLEMENT
   INHIBITION; RETINAL DEGENERATION; OXIDATIVE STRESS; GENE-THERAPY;
   MACULOPATHY; BRIMONIDINE; DELIVERY; AGONISTS
AB Age-related macular degeneration (AMD) is the leading cause of irreversible blindness in the developed world. The identification of the central role of vascular endothelial growth factor (VEGF) in the pathogenesis of neovascular AMD and the introduction of anti-VEGF agents as gold-standard treatment, have drastically changed its prognosis-something yet to be seen in dry AMD. Several therapeutic avenues with a wide variability of targets are currently being investigated in dry AMD. The approaches being investigated to reduce the rate of disease progression include, (1) drugs with antioxidative properties, (2) inhibitors of the complement cascade, (3) neuroprotective agents, (4) visual cycle inhibitors, (5) gene therapy and (6) cell-based therapies. A number of early phase clinical trials have provided promising results, with many more ongoing and anticipated in the near future. In this review, we aim to provide an update of the interventional trials to date and future prospects for the treatment of dry AMD.
C1 [de Guimaraes, Thales Antonio Cabral; Varela, Malena Daich; Georgiou, Michalis; Michaelides, Michel] UCL, Inst Ophthalmol, London, England.
   [de Guimaraes, Thales Antonio Cabral; Varela, Malena Daich; Georgiou, Michalis; Michaelides, Michel] Moorfields Eye Hosp NHS Fdn Trust, London EC1V 2PD, England.
C3 University of London; University College London; University of London;
   University College London; Moorfields Eye Hospital NHS Foundation Trust
RP Michaelides, M (通讯作者)，Moorfields Eye Hosp NHS Fdn Trust, London EC1V 2PD, England.
EM michel.michaelides@ucl.ac.uk
RI Cabral de Guimarães, Thales Antônio/AAD-9236-2022
OI Daich Varela, Malena/0000-0003-4960-4510; Cabral de Guimaraes, Thales
   Antonio/0000-0002-7936-6851
FU National Institute for Health Research Biomedical Research Centre at
   Moorfields Eye Hospital NHS Foundation Trust and UCL Institute of
   Ophthalmology; Moorfields Eye Charity; Retina UK; Foundation Fighting
   Blindness (USA); Wellcome Trust [099173/Z/12/Z]
FX This work has been supported by grants from the National Institute for
   Health Research Biomedical Research Centre at Moorfields Eye Hospital
   NHS Foundation Trust and UCL Institute of Ophthalmology, Moorfields Eye
   Charity, Retina UK, the Foundation Fighting Blindness (USA) and The
   Wellcome Trust [099173/Z/12/Z]. For the purpose of open access, the
   author has applied a CC BY public copyright licence to any Author
   Accepted Manuscript version arising from this submission.
CR Anderson DH, 2002, AM J OPHTHALMOL, V134, P411, DOI 10.1016/S0002-9394(02)01624-0
   [Anonymous], 2019, GLOBENEWSWIRE
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Brahmajoti, 2016, INVEST OPHTHALMOL VI, V57
   Camardo J, 2003, TRANSPL P, V35, p18S, DOI 10.1016/S0041-1345(03)00356-7
   Campagne MV, 2014, J PATHOL, V232, P151, DOI 10.1002/path.4266
   Cashman SM, 2015, J GENE MED, V17, P229, DOI 10.1002/jgm.2865
   Cashman SM, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019078
   Charters, 2020, OPHTHALMOLOGY TIMES
   Chew EY, 2014, JAMA OPHTHALMOL, V132, P142, DOI 10.1001/jamaophthalmol.2013.7376
   Chew EY, 2013, JAMA-J AM MED ASSOC, V309, P2005, DOI 10.1001/jama.2013.4997
   Chirco KR, 2016, EXP EYE RES, V146, P393, DOI 10.1016/j.exer.2015.09.003
   Cho E, 2001, AM J CLIN NUTR, V73, P209
   Cruess AF, 2008, PHARMACOECONOMICS, V26, P57, DOI 10.2165/00019053-200826010-00006
   Csaky KG, 2020, INVEST OPHTH VIS SCI, V61
   Datta S, 2017, PROG RETIN EYE RES, V60, P201, DOI 10.1016/j.preteyeres.2017.03.002
   de Guimaraes TAC, 2021, BRIT J OPHTHALMOL, V105, P151, DOI 10.1136/bjophthalmol-2020-316195
   DeAngelis MM, 2017, HUM MOL GENET, V26, pR45, DOI 10.1093/hmg/ddx228
   Ding XY, 2009, PROG RETIN EYE RES, V28, P1, DOI 10.1016/j.preteyeres.2008.10.001
   Donello JE, 2001, J PHARMACOL EXP THER, V296, P216
   Dugel, 2020, CLIN TRIAL DOWNLOAD
   Ebrahimi KB, 2011, J LIPIDS, V2011, DOI 10.1155/2011/802059
   Efficacy Cgov, 2016, SAF TOL STUD RN6G SU
   Ellis S, 2020, INVEST OPHTH VIS SCI, V61
   Evans JR, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000254.pub3
   Feigl B, 2009, PROG RETIN EYE RES, V28, P63, DOI 10.1016/j.preteyeres.2008.11.004
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Flaxman SR, 2017, LANCET GLOB HEALTH, V5, pE1221, DOI 10.1016/S2214-109X(17)30393-5
   Freeman, 2019, BRIMONIDINE DRUG DEL
   Fritsche LG, 2013, NAT GENET, V45, P433, DOI 10.1038/ng.2578
   Gehrs KM, 2010, ARCH OPHTHALMOL-CHIC, V128, P349, DOI 10.1001/archophthalmol.2010.18
   Guymer RH, 2019, OPHTHALMOLOGY, V126, P829, DOI 10.1016/j.ophtha.2018.09.015
   Hillmen P, 2006, NEW ENGL J MED, V355, P1233, DOI 10.1056/NEJMoa061648
   Ho AC, 2017, AM J OPHTHALMOL, V179, P67, DOI 10.1016/j.ajo.2017.04.006
   Holz FG, 2018, JAMA OPHTHALMOL, V136, P666, DOI 10.1001/jamaophthalmol.2018.1544
   IVERIC bio, 2020, IVERIC BIO ANN POS Z
   Jaffe GJ, 2021, OPHTHALMOLOGY, V128, P576, DOI 10.1016/j.ophtha.2020.08.027
   Jobling AI, 2015, FASEB J, V29, P696, DOI 10.1096/fj.14-262444
   Kashani AH, 2018, SCI TRANSL MED, V10, DOI 10.1126/scitranslmed.aao4097
   Katschke KJ, 2012, J BIOL CHEM, V287, P12886, DOI 10.1074/jbc.M112.345082
   Kaufman Y, 2011, J BIOL CHEM, V286, P7958, DOI 10.1074/jbc.M110.178640
   Kauper K, 2012, INVEST OPHTH VIS SCI, V53, P7484, DOI 10.1167/iovs.12-9970
   Kim S, 2019, BMC HEALTH SERV RES, V19, DOI 10.1186/s12913-019-4666-0
   Klein R, 1998, AM J EPIDEMIOL, V147, P103
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   Krupin T, 2011, AM J OPHTHALMOL, V151, P671, DOI 10.1016/j.ajo.2010.09.026
   Kumar-Singh R, 2019, EXP EYE RES, V184, P266, DOI 10.1016/j.exer.2019.05.006
   Kuppermann BD, 2021, RETINA-J RET VIT DIS, V41, P144, DOI 10.1097/IAE.0000000000002789
   Lachmann PJ, 2019, IMMUNOBIOLOGY, V224, P511, DOI 10.1016/j.imbio.2019.05.003
   Lafuente MP, 2001, INVEST OPHTH VIS SCI, V42, P2074
   Lawson EC, 2016, ADV EXP MED BIOL, V854, P431, DOI 10.1007/978-3-319-17121-0_57
   Liao DS, 2020, OPHTHALMOLOGY, V127, P186, DOI 10.1016/j.ophtha.2019.07.011
   Loyet KM, 2014, J PHARMACOL EXP THER, V351, P527, DOI 10.1124/jpet.114.215921
   Lund RD, 2007, STEM CELLS, V25, P602, DOI 10.1634/stemcells.2006-0308
   Ma L, 2011, J BIOL CHEM, V286, P7966, DOI 10.1074/jbc.M110.178657
   Maga TK, 2010, HUM MUTAT, V31, pE1445, DOI 10.1002/humu.21256
   Mata NL, 2013, RETINA-J RET VIT DIS, V33, P498, DOI 10.1097/IAE.0b013e318265801d
   Merin S, 2008, J OCUL PHARMACOL TH, V24, P80, DOI 10.1089/jop.2007.0022
   Mullins RE, 2011, INVEST OPHTH VIS SCI, V52, P1606, DOI 10.1167/iovs.10-6476
   Mullins RF, 2011, EXP EYE RES, V93, P565, DOI 10.1016/j.exer.2011.06.015
   News Healio, 2020, NEWS HEALIO
   News Healio, 2016, NEWS HEALIO
   Oveson BC, 2011, J NEUROCHEM, V116, P144, DOI 10.1111/j.1471-4159.2010.07092.x
   Pardue MT, 2018, PROG RETIN EYE RES, V65, P50, DOI 10.1016/j.preteyeres.2018.02.002
   Parsons CG, 2015, NEUROPHARMACOLOGY, V92, P158, DOI 10.1016/j.neuropharm.2014.12.038
   Phillips MJ, 2008, INVEST OPHTH VIS SCI, V49, P2148, DOI 10.1167/iovs.07-1012
   Qian CX, 2018, AAO RETINA SUBDAY 1
   Radu RA, 2005, INVEST OPHTH VIS SCI, V46, P4393, DOI 10.1167/iovs.05-0820
   Rajagopalan L, 2019, INVEST OPHTH VIS SCI, V60
   Rammes G, 2015, NEUROPHARMACOLOGY, V92, P170, DOI 10.1016/j.neuropharm.2014.12.037
   Rosenfeld PJ, 2018, OPHTHALMOL RETINA, V2, P1028, DOI 10.1016/j.oret.2018.03.001
   Rosenfeld PJ, 2018, OPHTHALMOLOGY, V125, P1556, DOI 10.1016/j.ophtha.2018.03.059
   Sadda SR, 2018, OPHTHALMOLOGY, V125, P537, DOI 10.1016/j.ophtha.2017.09.028
   SanGiovanni JP, 2009, AM J CLIN NUTR, V90, P1601, DOI 10.3945/ajcn.2009.27594
   Schwartz SD, 2015, LANCET, V385, P509, DOI 10.1016/S0140-6736(14)61376-3
   Shaw LT, 2020, EXPERT OPIN INV DRUG, V29, P547, DOI 10.1080/13543784.2020.1763953
   Shibagaki K, 2015, EXP EYE RES, V139, P64, DOI 10.1016/j.exer.2015.07.007
   Sieving PA, 2006, P NATL ACAD SCI USA, V103, P3896, DOI 10.1073/pnas.0600236103
   Smith W, 1996, ARCH OPHTHALMOL-CHIC, V114, P1518, DOI 10.1001/archopht.1996.01100140716016
   Stealth BioTherapeutics, 2019, STEALTH BIOTH ANN PO
   Szeto HH, 2014, BRIT J PHARMACOL, V171, P2029, DOI 10.1111/bph.12461
   Tanito M, 2010, EXP EYE RES, V91, P111, DOI 10.1016/j.exer.2010.04.012
   Wen R, 2012, PROG RETIN EYE RES, V31, P136, DOI 10.1016/j.preteyeres.2011.11.005
   Whitmore SS, 2015, PROG RETIN EYE RES, V45, P1, DOI 10.1016/j.preteyeres.2014.11.005
   WoldeMussie E, 2001, INVEST OPHTH VIS SCI, V42, P2849
   Wong WT, 2013, INVEST OPHTH VIS SCI, V54, P2941, DOI 10.1167/iovs.13-11650
   Wong WT, 2010, INVEST OPHTH VIS SCI, V51, P6131, DOI 10.1167/iovs.10-5637
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Yehoshua Z, 2014, OPHTHALMOLOGY, V121, P693, DOI 10.1016/j.ophtha.2013.09.044
   Yoles E, 1999, INVEST OPHTH VIS SCI, V40, P65
   Zeng SM, 2016, J PATHOL, V238, P446, DOI 10.1002/path.4669
NR 91
TC 28
Z9 28
U1 0
U2 6
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0007-1161
EI 1468-2079
J9 BRIT J OPHTHALMOL
JI Br. J. Ophthalmol.
PD MAR
PY 2022
VL 106
IS 3
BP 297
EP 304
DI 10.1136/bjophthalmol-2020-318452
EA MAR 2021
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA ZH4UL
UT WOS:000726872800001
PM 33741584
OA hybrid, Green Published
DA 2022-11-30
ER

PT J
AU Huang, LZ
   Li, YJ
   Xie, XF
   Zhang, JJ
   Cheng, CY
   Yamashiro, K
   Chen, LJ
   Ma, XY
   Cheung, CMG
   Wang, YS
   Zhang, CF
   Bai, YJ
   Hou, J
   Chen, XL
   Qi, Y
   Li, SS
   Sun, YY
   Mei, JP
   Cheng, Y
   Yu, WZ
   Hu, XB
   Zhuang, FF
   Fan, L
   Lu, Y
   Sun, XH
   Zhu, XJ
   Shen, DF
   Chan, CC
   Zhao, MW
   Yoshimura, N
   Pang, CP
   Wong, TY
   Khor, CC
   Zhang, K
   Zhou, P
   Li, XX
AF Huang, Lv-Zhen
   Li, Ying-Jie
   Xie, Xue-Feng
   Zhang, Jing-Jing
   Cheng, Ching-Yu
   Yamashiro, Kenji
   Chen, Li-Jia
   Ma, Xiao-Yun
   Cheung, Chui Ming G.
   Wang, Yu-Sheng
   Zhang, Chun-Fang
   Bai, Yu-Jing
   Hou, Jing
   Chen, Xiao-Li
   Qi, Yun
   Li, Shan-Shan
   Sun, Yao-Yao
   Mei, Jun-Pu
   Cheng, Yong
   Yu, Wen-Zhen
   Hu, Xiong-Bing
   Zhuang, Feng-Feng
   Fan, Lei
   Lu, Yi
   Sun, Xing-Huai
   Zhu, Xiang-Jia
   Shen, De-Fen
   Chan, Chi-Chao
   Zhao, Ming-Wei
   Yoshimura, Nagahisa
   Pang, Chi Pui
   Wong, Tien Yin
   Khor, Chiea Chuen
   Zhang, Kang
   Zhou, Peng
   Li, Xiao-Xin
TI Whole-exome sequencing implicates UBE3D in age-related macular
   degeneration in East Asian populations
SO NATURE COMMUNICATIONS
LA English
DT Article
ID GENOME-WIDE ASSOCIATION; UBIQUITIN-PROTEASOME-SYSTEM; EXPRESSION;
   DISEASE; LOCI
AB Age-related macular degeneration (AMD) is a leading cause of irreversible central blindness among the elderly worldwide. We use exome sequencing to analyse nonsynonymous single-nucleotide variants (SNVs) across the whole genome of 216 neovascular AMD cases and 1,553 controls. As a follow-up validation, we evaluate 3,772 neovascular AMD cases and 6,942 controls from five independent cohorts in the East Asian population. Here we show strong evidence of an association at a novel, missense SNV, rs7739323, which is located in the ubiquitin protein ligase E3D (UBE3D) gene (P-meta = 1.46 x 10(-9), odds ratio (OR) = 0.74, 95% confidence interval (CI): 0.63-0.88). Furthermore, ablation of the UBE3D protein lead to an abnormal amount of pigment granules deposited in retinal pigment epithelium microvilli area and an abnormal response on electroretinography (ERG) in UBE3D(+/-) heterozygous mice. Our findings indicate that the ubiquitin-proteasome system may play a role in the pathogenesis of neovascular AMD.
C1 [Huang, Lv-Zhen; Zhang, Jing-Jing; Bai, Yu-Jing; Hou, Jing; Chen, Xiao-Li; Qi, Yun; Li, Shan-Shan; Sun, Yao-Yao; Cheng, Yong; Yu, Wen-Zhen; Zhao, Ming-Wei; Khor, Chiea Chuen; Li, Xiao-Xin] Minist Educ China, Key Lab Vis Loss & Restorat, Beijing 100044, Peoples R China.
   [Huang, Lv-Zhen; Zhang, Jing-Jing; Bai, Yu-Jing; Hou, Jing; Chen, Xiao-Li; Qi, Yun; Li, Shan-Shan; Sun, Yao-Yao; Cheng, Yong; Yu, Wen-Zhen; Zhao, Ming-Wei; Li, Xiao-Xin] Peking Univ, Peoples Hosp, Dept Ophthalmol, Beijing 100044, Peoples R China.
   [Huang, Lv-Zhen; Zhang, Jing-Jing; Bai, Yu-Jing; Hou, Jing; Chen, Xiao-Li; Qi, Yun; Li, Shan-Shan; Sun, Yao-Yao; Yu, Wen-Zhen; Hu, Xiong-Bing; Zhao, Ming-Wei; Li, Xiao-Xin] Beijing Key Lab Diag & Therapy Retinal & Choroid, Beijing 100044, Peoples R China.
   [Li, Ying-Jie] Chinese Acad Med Sci, Peking Union Med Coll, Canc Inst & Hosp, Dept Abdominal Surg Oncol, Beijing 100021, Peoples R China.
   [Xie, Xue-Feng] BGI Shenzhen, Shenzhen 518083, Peoples R China.
   [Cheng, Ching-Yu; Cheung, Chui Ming G.; Mei, Jun-Pu; Wong, Tien Yin] Singapore Eye Res Inst, Singapore 169856, Singapore.
   [Cheng, Ching-Yu; Wong, Tien Yin] Duke Natl Univ Singapore, Grad Sch Med, Singapore, Singapore.
   [Zhang, Chun-Fang; Wong, Tien Yin] Natl Univ Singapore, Dept Ophthalmol, Singapore 119228, Singapore.
   [Cheng, Ching-Yu; Wong, Tien Yin] Natl Univ Hlth Syst, Singapore 119228, Singapore.
   [Cheng, Ching-Yu; Cheung, Chui Ming G.; Wang, Yu-Sheng; Wong, Tien Yin] Singapore Natl Eye Ctr, Singapore 168751, Singapore.
   [Yamashiro, Kenji; Yoshimura, Nagahisa] Kyoto Univ, Grad Sch Med, Dept Ophthalmol & Visual Sci, Kyoto 6068507, Japan.
   [Chen, Li-Jia; Pang, Chi Pui] Chinese Univ Hong Kong, Dept Ophthalmol & Visual Sci, Hong Kong 999077, Hong Kong, Peoples R China.
   [Ma, Xiao-Yun] Guanghua Integrat Med Hosp, Dept Ophthalmol, Shanghai 200052, Peoples R China.
   [Wang, Yu-Sheng] Fourth Mil Med Univ, Xijing Hosp, Dept Ophthalmol, Xian 710032, Peoples R China.
   [Zhang, Chun-Fang] Peking Univ, Peoples Hosp, Dept Clin Epidemiol, Beijing 100044, Peoples R China.
   [Hu, Xiong-Bing; Zhuang, Feng-Feng] Beijing View Solid Biotechnol, Beijing 100034, Peoples R China.
   [Fan, Lei; Lu, Yi; Sun, Xing-Huai; Zhu, Xiang-Jia; Zhou, Peng] Fudan Univ, Shanghai Med Coll, Shanghai 200032, Peoples R China.
   [Lu, Yi; Sun, Xing-Huai; Zhu, Xiang-Jia; Zhou, Peng] Fudan Univ, Eye & ENT Hosp, Dept Ophthalmol, Shanghai 200433, Peoples R China.
   [Shen, De-Fen; Chan, Chi-Chao] NEI, NIH, Bethesda, MD 20892 USA.
   [Khor, Chiea Chuen] Genome Inst Singapore, Div Human Genet, Singapore 138672, Singapore.
   [Khor, Chiea Chuen] Natl Univ Singapore, Saw Swee Hock Sch Publ Hlth, Singapore 117549, Singapore.
   [Khor, Chiea Chuen] Natl Univ Hlth Syst, Singapore 117549, Singapore.
   [Zhang, Kang] Inst Genom Med, La Jolla, CA 92093 USA.
   [Zhang, Kang] Shiley Eye Ctr, La Jolla, CA 92093 USA.
   [Zhang, Kang] Univ Calif San Diego, La Jolla, CA 92093 USA.
   [Zhou, Peng] Pkwy Hlth Hongqiao Med Ctr, Shanghai 201101, Peoples R China.
C3 Ministry of Education, China; Peking University; Chinese Academy of
   Medical Sciences - Peking Union Medical College; Cancer Institute &
   Hospital - CAMS; Peking Union Medical College; Beijing Genomics
   Institute (BGI); National University of Singapore; Singapore National
   Eye Center; National University of Singapore; National University of
   Singapore; National University of Singapore; Singapore National Eye
   Center; Kyoto University; Chinese University of Hong Kong; Air Force
   Military Medical University; Peking University; Fudan University; Fudan
   University; National Institutes of Health (NIH) - USA; NIH National Eye
   Institute (NEI); Agency for Science Technology & Research (A*STAR);
   A*STAR - Genome Institute of Singapore (GIS); National University of
   Singapore; National University of Singapore; University of California
   System; University of California San Diego
RP Li, XX (通讯作者)，Minist Educ China, Key Lab Vis Loss & Restorat, Beijing 100044, Peoples R China.
EM zhaomingwei@medmail.com.cn; drzhoupeng@gmail.com; drlixiaoxin@163.com
RI Chen, Li Jia/I-5078-2014; zhuang, Fengfeng/A-5822-2018; Zhang,
   Kang/Y-2740-2019; Cheng, Ching-Yu/Y-2229-2019; Wong, Tien
   Yin/AAC-9724-2020; Zhou, Peng/C-6054-2008
OI Chen, Li Jia/0000-0003-3500-5840; zhuang, Fengfeng/0000-0001-7888-0827;
   Zhang, Kang/0000-0002-4549-1697; Cheng, Ching-Yu/0000-0003-0655-885X;
   Wong, Tien Yin/0000-0002-8448-1264; Zhou, Peng/0000-0002-1744-5167;
   Yamashiro, Kenji/0000-0001-9354-8558; Cheung, Chui Ming
   Gemmy/0000-0003-3358-3516; Khor, Chiea Chuen/0000-0002-1128-4729
FU National Basic Research Program of China (973 Program) [2011CB510200];
   National Natural Science Foundation of China [81200669, 81100666,
   81102003, 81270989, 81100653]; Research Fund for Science and Technology
   Program of Beijing [Z121100005312006]; Doctoral Program of Higher
   Education of China [20120071120089]; Zhuo-Xue Project of Fudan
   University; National Medical Research Council (NMRC) [0796/2003,
   IRG07nov013, IRG09nov014, NMRC 1176/2008, NIG/1003/2009, STaR/0003/2008,
   CG/SERI/2010, CSA/033/2012]; Biomedical Research Council in Singapore
   [BMRC 08/1/35/19/550, 09/1/35/19/616, 10/1/35/19/671]; BrightFocus
   Foundation, USA [M2011068]; NMRC, Singapore [CSA/033/2012]; NATIONAL EYE
   INSTITUTE [ZIAEY000418] Funding Source: NIH RePORTER; Veterans Affairs
   [I01BX001898] Funding Source: NIH RePORTER
FX This work was supported by the National Basic Research Program of China
   (973 Program, no. 2011CB510200), the National Natural Science Foundation
   of China (nos. 81200669, 81100666, 81102003, 81270989 and 81100653), and
   the Research Fund for Science and Technology Program of Beijing (no.
   Z121100005312006), the Doctoral Program of Higher Education of China
   (no. 20120071120089) and the Zhuo-Xue Project of Fudan University (to
   P.Z.). This work was also supported by the National Medical Research
   Council (NMRC grants 0796/2003, IRG07nov013, IRG09nov014, NMRC
   1176/2008, NIG/1003/2009, STaR/0003/2008, CG/SERI/2010 and
   CSA/033/2012), and Biomedical Research Council (BMRC 08/1/35/19/550,
   09/1/35/19/616 and 10/1/35/19/671) in Singapore; the BrightFocus
   Foundation (M2011068), USA. C.-Y.C. is supported by an award from NMRC
   (CSA/033/2012), Singapore.
CR Albert TJ, 2007, NAT METHODS, V4, P903, DOI 10.1038/NMETH1111
   Balastik M, 2008, P NATL ACAD SCI USA, V105, P12016, DOI 10.1073/pnas.0802261105
   Bilguvar K, 2010, NATURE, V467, P207, DOI 10.1038/nature09327
   Chen YH, 2010, MOL INTERV, V10, P271, DOI 10.1124/mi.10.5.4
   Ciechanover A, 2003, NEURON, V40, P427, DOI 10.1016/S0896-6273(03)00606-8
   Cipriani V, 2012, HUM MOL GENET, V21, P4138, DOI 10.1093/hmg/dds225
   Clemons TE, 2003, ARCH OPHTHALMOL-CHIC, V121, P211
   Fritsche LG, 2013, NAT GENET, V45, P433, DOI 10.1038/ng.2578
   Haas AL, 1997, FASEB J, V11, P1257
   Hegde AN, 2004, PROG NEUROBIOL, V73, P311, DOI 10.1016/j.pneurobio.2004.05.005
   Holliday EG, 2013, PLOS ONE, V8, DOI [10.1371/journal.pone.0082305, 10.1371/journal.pone.0053830]
   Japanese Study Group of Polypoidal Choroidal Vasculopathy, 2005, Nippon Ganka Gakkai Zasshi, V109, P417
   Jones A, 2011, P NATL ACAD SCI USA, V108, P14578, DOI 10.1073/pnas.1102853108
   Kaarniranta K, 2011, J ALZHEIMERS DIS, V24, P615, DOI 10.3233/JAD-2011-101908
   Kaneko H, 2011, NATURE, V471, P325, DOI 10.1038/nature09830
   Kiezun A, 2012, NAT GENET, V44, P623, DOI 10.1038/ng.2303
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   Lencz T, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3739
   Liu ZZ, 2014, ADV EXP MED BIOL, V801, P237, DOI 10.1007/978-1-4614-3209-8_31
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Metzker ML, 2010, NAT REV GENET, V11, P31, DOI 10.1038/nrg2626
   Naj AC, 2013, ANN HUM GENET, V77, P215, DOI 10.1111/ahg.12011
   Nath D, 2009, NATURE, V458, P421, DOI 10.1038/458421a
   Norton N, 2011, AM J HUM GENET, V88, P273, DOI 10.1016/j.ajhg.2011.01.016
   Ohno-Matsui K, 2011, PROG RETIN EYE RES, V30, P217, DOI 10.1016/j.preteyeres.2011.02.004
   Qi Y, 2014, INVEST OPHTH VIS SCI, V55, P5466, DOI 10.1167/iovs.14-14380
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Sanders SS, 2011, CLIN GENET, V79, P132, DOI 10.1111/j.1399-0004.2010.01585.x
   Singleton AB, 2011, LANCET NEUROL, V10, P942, DOI 10.1016/S1474-4422(11)70196-X
   Sobrin L, 2012, OPHTHALMOLOGY, V119, P1874, DOI 10.1016/j.ophtha.2012.03.014
   SOMMER T, 1993, NATURE, V365, P176, DOI 10.1038/365176a0
   Sommer T, 2014, BBA-MOL CELL RES, V1843, P1, DOI 10.1016/j.bbamcr.2013.09.009
   Takeda A, 2009, NATURE, V460, P225, DOI 10.1038/nature08151
   van Wijk SJL, 2010, FASEB J, V24, P981, DOI 10.1096/fj.09-136259
   Wu MC, 2011, AM J HUM GENET, V89, P82, DOI 10.1016/j.ajhg.2011.05.029
   Zhou P, 2011, FASEB J, V25, P3489, DOI 10.1096/fj.11-189258
NR 36
TC 30
Z9 35
U1 1
U2 28
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2041-1723
J9 NAT COMMUN
JI Nat. Commun.
PD APR
PY 2015
VL 6
AR 6687
DI 10.1038/ncomms7687
PG 6
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA CH0GU
UT WOS:000353698500001
PM 25872646
OA gold
DA 2022-11-30
ER

PT J
AU Szaflik, JP
   Janik-Papis, K
   Synowiec, E
   Ksiazek, D
   Zaras, M
   Wozniak, K
   Szaflik, J
   Blasiak, J
AF Szaflik, Jacek P.
   Janik-Papis, Katarzyna
   Synowiec, Ewelina
   Ksiazek, Dominika
   Zaras, Magdalena
   Wozniak, Katarzyna
   Szaflik, Jerzy
   Blasiak, Janusz
TI DNA damage and repair in age-related macular degeneration
SO MUTATION RESEARCH-FUNDAMENTAL AND MOLECULAR MECHANISMS OF MUTAGENESIS
LA English
DT Article
DE Age-related macular degeneration; AMD; DNA damage; DNA repair; Oxidative
   stress
ID BASE EXCISION-REPAIR; DOUBLE-STRAND BREAKS; MITOCHONDRIAL-DNA;
   ESCHERICHIA-COLI; COMET ASSAY; SUBSTRATE-SPECIFICITY;
   GEL-ELECTROPHORESIS; EPITHELIAL-CELLS; ACTION SPECTRA; BLUE-LIGHT
AB Age-related macular degeneration (AMD) is a retinal degenerative disease that is the main cause of vision loss in individuals over the age of 55 in the Western world. Clinically relevant AMD results from damage to the retinal pigment epithelial (RPE) cells thought to be mainly caused by oxidative stress The stress also affects the DNA of RPE cells. which promotes genome instability in these cells. These effects may coincide with the decrease in the efficacy of DNA repair with age. Therefore individuals with DNA repair impaired more than average for a given age may be more susceptible to AMD if oxidative stress affects their RPE cells. This maybe helpful in AMD risk assessment In the present work we determined the level of basal (measured in the alkaline cornet assay) endogenous and endogenous oxidative DNA damage, the Susceptibility to exogenous mutagens and the efficacy of DNA repair in lymphocytes of 100 AMD patients and 110 age-matched individuals without visual disturbances. The cells taken from AMD patients displayed a higher extent of basal endogenous DNA damage without differences between patients of dry and wet forms of the disease DNA double-strand breaks did not contribute to the observed DNA damage as checked by the neutral comet assay and pulsed field gel electrophoresis The extent of oxidative modification to DNA bases was grater in AMD patients than in the controls, as probed by DNA repair enzymes NTH1 and Fpg. Lymphocytes from AMD patients displayed a higher sensitivity to hydrogen peroxide and UV radiation and repaired lesions induced by these factors less effectively than the cells from the control individuals. We postulate that the impaired efficacy of DNA repair may combine with enhanced sensitivity of RPE cells to blue and UV lights, contributing to the pathogenesis of AMD (C) 2009 Elsevier B.V. All rights reserved
C1 [Janik-Papis, Katarzyna; Synowiec, Ewelina; Ksiazek, Dominika; Wozniak, Katarzyna; Blasiak, Janusz] Univ Lodz, Dept Mol Genet, PL-90237 Lodz, Poland.
   [Szaflik, Jacek P.; Zaras, Magdalena; Szaflik, Jerzy] Med Univ Warsaw, Dept Ophthalmol, PL-03710 Warsaw, Poland.
   [Szaflik, Jacek P.; Zaras, Magdalena; Szaflik, Jerzy] Samodzielny Publ Szpital Okulisty, PL-03710 Warsaw, Poland.
C3 University of Lodz; Medical University of Warsaw
RP Blasiak, J (通讯作者)，Univ Lodz, Dept Mol Genet, Banacha 12-16, PL-90237 Lodz, Poland.
RI Janik-Superson, Katarzyna/ABA-2571-2021
OI Janik-Superson, Katarzyna/0000-0001-9692-7238; Szaflik,
   Jerzy/0000-0002-7601-1326; Synowiec, Ewelina/0000-0002-0730-4491;
   Blasiak, Janusz/0000-0001-9539-9584
FU Ministry of Science and Higher Education [402 071 32/2210]
FX This work was supported by the grant number 402 071 32/2210 of Ministry
   of Science and Higher Education. We thank Anna Krzyzanowska, Alicja
   Malinowska and Monika Kicinska for technical assistance.
CR Alexander P, 1967, Symp Soc Exp Biol, V21, P29
   Andreassen PR, 2006, CARCINOGENESIS, V27, P883, DOI 10.1093/carcin/bgi319
   ASHBY J, 1995, MUTAGENESIS, V10, P85, DOI 10.1093/mutage/10.2.85
   Barron MJ, 2001, INVEST OPHTH VIS SCI, V42, P3016
   Baynes JW, 2002, ANN NY ACAD SCI, V959, P360, DOI 10.1111/j.1749-6632.2002.tb02107.x
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Blasiak J, 2004, MUTAT RES-FUND MOL M, V554, P297, DOI 10.1016/j.mrfmmm.2004.05.011
   Blasiak J, 2004, MUTAT RES-FUND MOL M, V554, P139, DOI 10.1016/j.mrfmmm.2004.04.001
   Blasiak J, 2003, MUTAT RES-GEN TOX EN, V535, P25, DOI 10.1016/S1383-5718(02)00289-9
   Bogenhagen DF, 2001, PROG NUCLEIC ACID RE, V68, P257
   BOITEUX S, 1992, BIOCHEMISTRY-US, V31, P106, DOI 10.1021/bi00116a016
   BRASH DE, 1988, PHOTOCHEM PHOTOBIOL, V48, P59
   Campisi J, 2007, NAT REV MOL CELL BIO, V8, P729, DOI 10.1038/nrm2233
   Chan CM, 2008, MOL VIS, V14, P2528
   COLLINS AR, 1993, CARCINOGENESIS, V14, P1733, DOI 10.1093/carcin/14.9.1733
   Dandona L, 1998, ARCH OPHTHALMOL-CHIC, V116, P545, DOI 10.1001/archopht.116.4.514
   David-Cordonnier MH, 2000, J BIOL CHEM, V275, P11865, DOI 10.1074/jbc.275.16.11865
   de Souza-Pinto NC, 2008, DNA REPAIR, V7, P1098, DOI 10.1016/j.dnarep.2008.03.011
   Essers J, 2006, CURR OPIN CELL BIOL, V18, P240, DOI 10.1016/j.ceb.2006.03.004
   Faghri S, 2008, J MED GENET, V45, P609, DOI 10.1136/jmg.2008.058743
   Falik-Zaccai TC, 2008, AM J MED GENET A, V146A, P1423, DOI 10.1002/ajmg.a.32309
   Feret A, 2007, GERIATR NURS, V28, P387, DOI 10.1016/j.gerinurse.2007.03.003
   Foray N, 1999, INT J RADIAT BIOL, V75, P1589, DOI 10.1080/095530099139197
   Godley BF, 2005, J BIOL CHEM, V280, P21061, DOI 10.1074/jbc.M502194200
   Heuser VD, 2008, CELL BIOL INT, V32, P1223, DOI 10.1016/j.cellbi.2008.07.005
   Howell N, 1999, INT REV CYTOL, V186, P49
   IMLAY JA, 1988, SCIENCE, V240, P640, DOI 10.1126/science.2834821
   JONES CA, 1987, RADIAT RES, V110, P244, DOI 10.2307/3576902
   Klaude M, 1996, MUTAT RES-DNA REPAIR, V363, P89, DOI 10.1016/0921-8777(95)00063-1
   KLEIN R, 1995, INVEST OPHTH VIS SCI, V36, P182
   Klein R, 1997, OPHTHALMOLOGY, V104, P7, DOI 10.1016/S0161-6420(97)30368-6
   Kowald A, 2001, BIOL SIGNAL RECEPT, V10, P162
   Ksiazek K, 2008, BIOCHEM BIOPH RES CO, V373, P335, DOI 10.1016/j.bbrc.2008.06.026
   KUEFNER MA, 2009, INVEST RADIOL    MAY
   Kuo LJ, 2008, IN VIVO, V22, P305
   Lieber MR, 2004, NAT REV MOL CELL BIO, V5, P69, DOI 10.1038/nrm1281
   LINDAHL T, 1993, NATURE, V362, P709, DOI 10.1038/362709a0
   LOBER G, 1977, PHOTOCHEM PHOTOBIOL, V25, P215, DOI 10.1111/j.1751-1097.1977.tb06902.x
   Michikawa Y, 1999, SCIENCE, V286, P774, DOI 10.1126/science.286.5440.774
   Mostoslavsky R, 2008, FRONT BIOSCI-LANDMRK, V13, P6966, DOI 10.2741/3203
   Nieborowska-Skorska M, 2006, CELL CYCLE, V5, P994, DOI 10.4161/cc.5.9.2722
   ORR WC, 1994, SCIENCE, V263, P1128, DOI 10.1126/science.8108730
   PEAK JG, 1995, PHOTOCHEM PHOTOBIOL, V61, P484, DOI 10.1111/j.1751-1097.1995.tb02349.x
   PEAK MJ, 1989, PHOTODERMATOLOGY, V6, P1
   Pflaum M, 1998, MUTAT RES-DNA REPAIR, V408, P137, DOI 10.1016/S0921-8777(98)00029-9
   SETLOW RB, 1994, MUTAT RES, V307, P365, DOI 10.1016/0027-5107(94)90310-7
   Singh NP, 1997, MUTAT RES-DNA REPAIR, V383, P167, DOI 10.1016/S0921-8777(96)00056-0
   SINGH NP, 1988, EXP CELL RES, V175, P184, DOI 10.1016/0014-4827(88)90265-0
   TCHOU J, 1991, P NATL ACAD SCI USA, V88, P4690, DOI 10.1073/pnas.88.11.4690
   Tice RR, 2000, ENVIRON MOL MUTAGEN, V35, P206, DOI 10.1002/(SICI)1098-2280(2000)35:3<206::AID-EM8>3.0.CO;2-J
   WAGNER L, 1994, ELECTROPHORESIS, V15, P1078, DOI 10.1002/elps.11501501161
   Wang AL, 2008, MOL VIS, V14, P644
   Xu G, 2008, MECH AGEING DEV, V129, P366, DOI 10.1016/j.mad.2008.03.001
   Zarbin MA, 2004, ARCH OPHTHALMOL-CHIC, V122, P598, DOI 10.1001/archopht.122.4.598
NR 54
TC 35
Z9 36
U1 1
U2 18
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0027-5107
EI 1873-135X
J9 MUTAT RES-FUND MOL M
JI Mutat. Res.-Fundam. Mol. Mech. Mutagen.
PD OCT 2
PY 2009
VL 669
IS 1-2
BP 169
EP 176
DI 10.1016/j.mrfmmm.2009.06.008
PG 8
WC Biotechnology & Applied Microbiology; Genetics & Heredity; Toxicology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biotechnology & Applied Microbiology; Genetics & Heredity; Toxicology
GA 510CO
UT WOS:000271065800023
PM 19559717
DA 2022-11-30
ER

PT J
AU Udar, N
   Atilano, SR
   Memarzadeh, M
   Boyer, DS
   Chwa, M
   Lu, S
   Maguen, B
   Langberg, J
   Coskun, P
   Wallace, DC
   Nesburn, AB
   Khatibi, N
   Hertzog, D
   Le, K
   Hwang, D
   Kenney, MC
AF Udar, Nitin
   Atilano, Shari R.
   Memarzadeh, Masood
   Boyer, David S.
   Chwa, Marilyn
   Lu, Stephanie
   Maguen, Barak
   Langberg, Jonathan
   Coskun, Pinar
   Wallace, Douglas C.
   Nesburn, Anthony B.
   Khatibi, Nikan
   Hertzog, Dieter
   Le, Khoi
   Hwang, Daniel
   Kenney, M. Cristina
TI Mitochondrial DNA Haplogroups Associated with Age-Related Macular
   Degeneration
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
ID FACTOR-H POLYMORPHISM; PARKINSONS-DISEASE; ALZHEIMER-DISEASE;
   SKELETAL-MUSCLE; RISK-FACTORS; COMPLEMENT; MTDNA; GENE; MACULOPATHY;
   POPULATION
AB PURPOSE. To examine the mtDNA control regions in normal and age-related macular degeneration (AMD) retinas. To identify the mtDNA variations associated with AMD.
   METHODS. Retinas from 10 normal and 11 AMD globes were isolated and analyzed for mtDNA rearrangements by long extension-polymerase chain reaction (LX-PCR) and for the nature and frequency of single-nucleotide polymorphisms (SNPs) in the mtDNA control region by direct sequencing. Blood DNA was extracted from 99 AMD and 92 age-matched control subjects. The sequence variations that define haplogroups H, I, J, K, T, V, X, and U were characterized by PCR, restriction enzyme digestion, and/or sequencing.
   RESULTS. LX-PCR of retinal mtDNAs revealed high levels of rearrangements in the patients with AMD and the control subjects, consistent with the decline in mitochondrial function with age. However, the AMD retinas had higher oxidized DNA levels and a higher number of SNPs than controls (P = 0.02). The control region SNPs T16126C and A73G, commonly found in haplogroups J and T, were more frequent in the AMD retinas than in normal retinas. The associations between AMD and haplogroups J and T were confirmed and extended by analysis of blood DNA. SNPs at position a T16126C (J; odds ratio [OR] = 3.66), T16126C+G13368A (JT; OR = 10.27), A4917G + A73G (T4; OR = 5), and T3197C + A12308G (U5; OR = infinity), were all strongly associated with AMD.
   CONCLUSIONS. AMD retinas exhibited increased mtDNA control region SNPs compared to normal retinas. This correlated with an increased frequency of mtDNA SNPs associated with haplogroups J, T and U in patients with AMD. These results implicate mitochondrial alterations in the etiology of AMD. ( Invest Ophthalmol Vis Sci. 2009; 50: 2966-2974) DOI:10.1167/iovs.08-2646
C1 [Kenney, M. Cristina] Univ Calif Irvine, Med Ctr, Dept Ophthalmol, Orange, CA 92868 USA.
   [Boyer, David S.] Retina Vitreous Associates Med Grp, Beverly Hills, CA USA.
   [Coskun, Pinar; Wallace, Douglas C.] Univ Calif Irvine, Dept Biol Chem, Ctr Mol & Mitochondrial Med & Genet, Irvine, CA 92717 USA.
   [Coskun, Pinar; Wallace, Douglas C.] Univ Calif Irvine, Dept Ecol & Evolutionary Biol, Ctr Mol & Mitochondrial Med & Genet, Irvine, CA 92717 USA.
   [Coskun, Pinar; Wallace, Douglas C.] Univ Calif Irvine, Dept Pediat, Ctr Mol & Mitochondrial Med & Genet, Irvine, CA 92717 USA.
   [Nesburn, Anthony B.] Cedars Sinai Med Ctr, Los Angeles, CA 90048 USA.
   [Khatibi, Nikan] Kansas City Med Sch, Kansas City, MO USA.
   [Hertzog, Dieter] Loma Linda Med Ctr, Loma Linda, CA USA.
   [Le, Khoi] Dartmouth Hitchcock Med Ctr, Hanover, NH USA.
C3 University of California System; University of California Irvine; Retina
   Vitreous Associates Medical Group; University of California System;
   University of California Irvine; University of California System;
   University of California Irvine; University of California System;
   University of California Irvine; Cedars Sinai Medical Center; Loma Linda
   University; Dartmouth College
RP Kenney, MC (通讯作者)，Univ Calif Irvine, Med Ctr, Dept Ophthalmol, 101 City Dr, Orange, CA 92868 USA.
EM mkenney@uci.edu
OI Atilano, Shari/0000-0002-7729-7864; Udar, Nitin/0000-0001-8533-9190
FU Discovery Eye Foundation; Lincy Foundation; Henry L. Guenther
   Foundation; Iris and B. Gerald Cantor Foundation; Gilbert Foundation;
   Research to Prevent Blindness
FX Supported by the Discovery Eye Foundation, the Lincy Foundation, the
   Henry L. Guenther Foundation, the Iris and B. Gerald Cantor Foundation,
   the Gilbert Foundation, and Research to Prevent Blindness.
CR Andrews R, 2006, BRIT J OPHTHALMOL, V90, P488, DOI 10.1136/bjo.2005.084335
   Atilano SR, 2005, INVEST OPHTH VIS SCI, V46, P1256, DOI 10.1167/iovs.04-1395
   Brown MD, 1997, AM J HUM GENET, V60, P381
   Canter JA, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002091
   Castro MG, 2006, INT J CARDIOL, V112, P202, DOI 10.1016/j.ijcard.2005.09.008
   Chagnon P, 1999, AM J MED GENET, V85, P20, DOI 10.1002/(SICI)1096-8628(19990702)85:1<20::AID-AJMG6>3.0.CO;2-K
   Conley YP, 2005, HUM MOL GENET, V14, P1991, DOI 10.1093/hmg/ddi204
   Coskun PE, 2004, P NATL ACAD SCI USA, V101, P10726, DOI 10.1073/pnas.0403649101
   Dewan A, 2007, CURR OPIN GENET DEV, V17, P228, DOI 10.1016/j.gde.2007.04.004
   Donoso LA, 2006, SURV OPHTHALMOL, V51, P137, DOI 10.1016/j.survophthal.2005.12.001
   Dunaief JL, 2002, ARCH OPHTHALMOL-CHIC, V120, P1435, DOI 10.1001/archopht.120.11.1435
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Fesahat F, 2007, CELL MOL NEUROBIOL, V27, P329, DOI 10.1007/s10571-006-9126-9
   Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309
   Gu GY, 2002, J NEUROPATH EXP NEUR, V61, P634, DOI 10.1093/jnen/61.7.634
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Hamdi HK, 2003, FRONT BIOSCI-LANDMRK, V8, pE305, DOI 10.2741/1019
   Hassani-Kumleh H, 2006, CELL MOL NEUROBIOL, V26, P119, DOI 10.1007/s10571-006-9026-z
   Hofmann S, 1997, GENOMICS, V39, P8, DOI 10.1006/geno.1996.4474
   Huerta C, 2005, J NEUROL SCI, V236, P49, DOI 10.1016/j.jns.2005.04.016
   Jessie BC, 2001, EXP GERONTOL, V37, P169, DOI 10.1016/S0531-5565(01)00153-X
   Jones MM, 2007, ARCH OPHTHALMOL-CHIC, V125, P1235, DOI 10.1001/archopht.125.9.1235
   Khusnutdinova E, 2008, ANN NY ACAD SCI, V1147, P1, DOI 10.1196/annals.1427.001
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Melov S, 1997, NUCLEIC ACIDS RES, V25, P974, DOI 10.1093/nar/25.5.974
   MELOV S, 1995, NUCLEIC ACIDS RES, V23, P4122, DOI 10.1093/nar/23.20.4122
   Mishmar D, 2003, P NATL ACAD SCI USA, V100, P171, DOI 10.1073/pnas.0136972100
   Montiel-Sosa F, 2006, GENE, V368, P21, DOI 10.1016/j.gene.2005.09.015
   Moshfeghi DM, 2007, RETINA-J RET VIT DIS, V27, P269, DOI 10.1097/IAE.0b013e31802e3e9b
   Muller-Eberhard H J, 1980, Adv Immunol, V29, P1, DOI 10.1016/S0065-2776(08)60042-5
   Narayanan R, 2007, OPHTHALMOLOGY, V114, P1327, DOI 10.1016/j.ophtha.2006.10.035
   Reynier P, 1999, EUR J HUM GENET, V7, P404, DOI 10.1038/sj.ejhg.5200293
   Roquet W, 2004, BRIT J OPHTHALMOL, V88, P638, DOI 10.1136/bjo.2003.017632
   Rozen S, 2000, Methods Mol Biol, V132, P365
   Ruiz-Pesini E, 2004, SCIENCE, V303, P223, DOI 10.1126/science.1088434
   Seddon JM, 2006, OPHTHALMOLOGY, V113, P260, DOI 10.1016/j.ophtha.2005.11.001
   Shastry BS, 2006, OPHTHALMOLOGICA, V220, P291, DOI 10.1159/000094617
   Subrarnaniam V, 2008, BBA-BIOENERGETICS, V1777, P666, DOI 10.1016/j.bbabio.2008.03.015
   Tanimoto S, 2007, NEUROSCI LETT, V414, P71, DOI 10.1016/j.neulet.2006.12.011
   Tomany SC, 2004, OPHTHALMOLOGY, V111, P1280, DOI 10.1016/j.ophtha.2003.11.010
   Torroni A, 1996, GENETICS, V144, P1835
   TORRONI A, 1993, AM J HUM GENET, V53, P563
   van der Walt JM, 2004, NEUROSCI LETT, V365, P28, DOI 10.1016/j.neulet.2004.04.051
   van der Walt JM, 2003, AM J HUM GENET, V72, P804, DOI 10.1086/373937
   WALLACE DC, 1994, J BIOENERG BIOMEMBR, V26, P241, DOI 10.1007/BF00763096
   Wallace DC, 2005, ANNU REV GENET, V39, P359, DOI 10.1146/annurev.genet.39.110304.095751
   WALLACE DC, 1992, ANNU REV BIOCHEM, V61, P1175, DOI 10.1146/annurev.bi.61.070192.005523
   Wang AL, 2008, MOL VIS, V14, P644
   Yang ZL, 2006, SCIENCE, V314, P992, DOI 10.1126/science.1133811
   Yoshida T, 2007, MOL VIS, V13, P545
NR 50
TC 92
Z9 94
U1 0
U2 6
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD JUN
PY 2009
VL 50
IS 6
BP 2966
EP 2974
DI 10.1167/iovs.08-2646
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 450ME
UT WOS:000266403800059
PM 19151382
DA 2022-11-30
ER

PT J
AU Baatz, H
   Darawsha, R
   Ackermann, H
   Scharioth, GB
   de Ortueta, D
   Pavlidis, M
   Hattenbach, LO
AF Baatz, Holger
   Darawsha, Raed
   Ackermann, Hanns
   Scharioth, Gabor B.
   de Ortueta, Diego
   Pavlidis, Mitrofanis
   Hattenbach, Lars O.
TI Phacoemulsification does not induce neovascular age-related macular
   degeneration
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
ID INTRAOCULAR-LENS IMPLANTATION; BLUE MOUNTAINS EYE; QUALITY-OF-LIFE;
   CATARACT-SURGERY; VISUAL FUNCTION; BEAVER DAM; MACULOPATHY; EXTRACTION;
   EDEMA; RISK
AB PURPOSE. To investigate whether cataract surgery by phaco-emulsification induces progression of early age-related macular degeneration (AMD) to neovascular AMD.
   METHODS. Retrospective case-control study. Included were consecutive patients who had undergone phacoemulsification from January 2000 to February 2006 at the Recklinghausen Eye Centre, who had a preexisting diagnosis of early AMD and who were followed up for at least 1 year after surgery (n = 1152 eyes of 696 patients). The control group comprised phakic patients diagnosed with early AMD from January 2000 to February 2006, who did not undergo eye surgery and were followed up for at least 1 year (n = 334 eyes of 202 patients).
   RESULTS. At baseline, control eyes had significantly better visual acuity than those of patients who were going to have cataract surgery (0.30/0.35 +/- 0.34 vs. 0.40/0.49 +/- 0.34, respectively; median/mean +/- SD; P < 0.001, Mann-Whitney rank sum test). After 1 year, visual acuity in the control group was worse than in surgical eyes (0.30/0.39 +/- 0.38 vs. 0.20/0.26 +/- 0.30, respectively; median/mean +/- SD; P < 0.001, Mann-Whitney rank sum test). In the cataract surgery group, neovascular AMD developed in 28 (2.43%) of 1152 eyes in the first postoperative year. In the control group, it developed in 6 (1.74%) of 344 eyes within 1 year. There was no significant difference between the groups in the incidence of neovascular AMD (P = 0.57, odds ratio 1.30, 95% CI 0.52-3.24, logistic regression analysis, adjusted for age and baseline visual acuity).
   CONCLUSIONS. The results indicate that cataract surgery in eyes with early AMD is not a causative factor in neovascular AMD.
C1 [Baatz, Holger; Darawsha, Raed; Scharioth, Gabor B.; de Ortueta, Diego; Pavlidis, Mitrofanis] Recklinghausen Eye Ctr, Recklinghausen, Germany.
   [Ackermann, Hanns] Goethe Univ Frankfurt, Inst Biostat, Frankfurt, Germany.
   [Hattenbach, Lars O.] Klinikum Stadt Ludwigshafen, Dept Ophthalmol, D-6700 Ludwigshafen, Germany.
C3 Goethe University Frankfurt; Ludwigshafen Hospital
RP Baatz, H (通讯作者)，Augenzentrum Recklinghausen, Erlbruch 34-36, D-45657 Recklinghausen, Germany.
EM holger.baatz@augenzentrum.org
RI Hattenbach, Lars-Olof/AAC-5621-2020; de Ortueta, Diego/J-2084-2019
OI Hattenbach, Lars-Olof/0000-0002-5275-8118; de Ortueta,
   Diego/0000-0001-9977-5460
CR Armbrecht AM, 2003, J CATARACT REFR SURG, V29, P686, DOI 10.1016/S0886-3350(02)01650-4
   Armbrecht AM, 2000, BRIT J OPHTHALMOL, V84, P1343, DOI 10.1136/bjo.84.12.1343
   BLAIR CJ, 1979, AM J OPHTHALMOL, V87, P77, DOI 10.1016/0002-9394(79)90195-8
   COOK RJ, 1995, BRIT MED J, V310, P452, DOI 10.1136/bmj.310.6977.452
   COX DR, 1972, J R STAT SOC B, V34, P187
   Freeman EE, 2003, AM J OPHTHALMOL, V135, P849, DOI 10.1016/S0002-9394(02)02253-5
   Glazer-Hockstein C, 2006, RETINA-J RET VIT DIS, V26, P1, DOI 10.1097/00006982-200601000-00001
   HALPERIN M, 1971, J CHRON DIS, V24, P125, DOI 10.1016/0021-9681(71)90106-8
   Jackson TL, 2001, OPHTHALMOLOGICA, V215, P271, DOI 10.1159/000050873
   Kaiserman I, 2007, OPHTHALMOLOGY, V114, P278, DOI 10.1016/j.ophtha.2006.10.019
   KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868
   Klein R, 1998, ARCH OPHTHALMOL-CHIC, V116, P506, DOI 10.1001/archopht.116.4.506
   Klein R, 2002, ARCH OPHTHALMOL-CHIC, V120, P1551, DOI 10.1001/archopht.120.11.1551
   Klein R, 2007, OPHTHALMOLOGY, V114, P253, DOI 10.1016/j.ophtha.2006.10.040
   Livingston P M, 1995, Ophthalmic Epidemiol, V2, P151, DOI 10.3109/09286589509057097
   Lundqvist B, 2006, J CATARACT REFR SURG, V32, P1944, DOI 10.1016/j.jcrs.2006.06.023
   Lundstrom M, 2002, BRIT J OPHTHALMOL, V86, P1330, DOI 10.1136/bjo.86.12.1330
   MANTEL NATHAN, 1966, CANCERCHEMOTHERAP REP, V50, P163
   Mason JO, 2006, RETINA-J RET VIT DIS, V26, P356, DOI 10.1097/00006982-200603000-00018
   Mentes J, 2003, OPHTHALMOLOGICA, V217, P408, DOI 10.1159/000073070
   Pollack A, 1996, OPHTHALMOLOGY, V103, P1546, DOI 10.1016/S0161-6420(96)30464-8
   Shuttleworth GN, 1998, BRIT J OPHTHALMOL, V82, P611, DOI 10.1136/bjo.82.6.611
   Sutter FKP, 2007, INVEST OPHTH VIS SCI, V48, P1472, DOI 10.1167/iovs.06-0766
   Ursell PG, 1999, J CATARACT REFR SURG, V25, P1492, DOI 10.1016/S0886-3350(99)00196-0
   Usui T, 2004, INVEST OPHTH VIS SCI, V45, P368, DOI 10.1167/iovs.03-0106
   Vote BJ, 2004, CLIN EXP OPHTHALMOL, V32, P397, DOI 10.1111/j.1442-9071.2004.00845.x
   Wang JJ, 2007, OPHTHALMOLOGY, V114, P92, DOI 10.1016/j.ophtha.2006.07.017
   Wang JJ, 2003, OPHTHALMOLOGY, V110, P1960, DOI 10.1016/S0161-6420(03)00816-9
NR 28
TC 45
Z9 49
U1 0
U2 0
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD MAR
PY 2008
VL 49
IS 3
BP 1079
EP 1083
DI 10.1167/iovs.07-0557
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 271TZ
UT WOS:000253812900035
PM 18326733
DA 2022-11-30
ER

PT J
AU Yang, ZL
   Camp, NJ
   Sun, H
   Tong, ZZ
   Gibbs, D
   Cameron, DJ
   Chen, HY
   Zhao, Y
   Pearson, E
   Li, X
   Chien, J
   DeWan, A
   Harmon, J
   Bernstein, PS
   Shridhar, V
   Zabriskie, NA
   Hoh, J
   Howes, K
   Zhang, K
AF Yang, Zhenglin
   Camp, Nicola J.
   Sun, Hui
   Tong, Zongzhong
   Gibbs, Daniel
   Cameron, D. Joshua
   Chen, Haoyu
   Zhao, Yu
   Pearson, Erik
   Li, Xi
   Chien, Jeremy
   DeWan, Andrew
   Harmon, Jennifer
   Bernstein, Paul S.
   Shridhar, Viji
   Zabriskie, Norman A.
   Hoh, Josephine
   Howes, Kimberly
   Zhang, Kang
TI A variant of the HTRA1 gene increases susceptibility to age-related
   macular degeneration
SO SCIENCE
LA English
DT Article
ID COMPLEMENT FACTOR-H; CIGARETTE-SMOKING; RISK; POLYMORPHISM; CFH;
   ASSOCIATION; MACULOPATHY; LOC387715; DISEASE
AB Age-related macular degeneration (AMD) is the most common cause of irreversible vision loss in the developed world and has a strong genetic predisposition. A locus at human chromosome 10q26 affects the risk of AMD, but the precise gene(s) have not been identified. We genotyped 581 AMD cases and 309 normal controls in a Caucasian cohort in Utah. We demonstrate that a single-nucleotide polymorphism, rs11200638, in the promoter region of HTRA1 is the most likely causal variant for AMD at 10q26 and is estimated to confer a population attributable risk of 49.3%. The HTRA1 gene encodes a secreted serine protease. Preliminary analysis of lymphocytes and retinal pigment epithelium from four AMD patients revealed that the risk allele was associated with elevated expression levels of HTRA1 mRNA and protein. We also found that drusen in the eyes of AMD patients were strongly immunolabeled with HTRA1 antibody. Together, these findings support a key role for HTRA1 in AMD susceptibility and identify a potential new pathway for AMD pathogenesis.
C1 Univ Utah, Sch Med, Moran Eye Ctr, Dept Ophthalmol & Visual Sci, Salt Lake City, UT 84132 USA.
   Univ Utah, Sch Med, Eccles Inst Human Genet, Program Human Mol Biol & Genet, Salt Lake City, UT 84132 USA.
   Sichuan Prov Peoples Hosp, Chengdu 610071, Sichuan, Peoples R China.
   Univ Utah, Sch Med, Dept Biomed Informat, Div Genet Epidemiol, Salt Lake City, UT 84108 USA.
   Univ Calif Los Angeles, Sch Med, Dept Physiol, Los Angeles, CA 90095 USA.
   Univ Calif Los Angeles, Sch Med, Jules Stein Eye Inst, Los Angeles, CA 90095 USA.
   Mayo Clin, Coll Med, Dept Lab Med & Expt Pathol, Rochester, MN 55905 USA.
   Yale Univ, Dept Epidemiol & Publ Hlth, New Haven, CT 06520 USA.
C3 Utah System of Higher Education; University of Utah; Utah System of
   Higher Education; University of Utah; Sichuan Provincial People's
   Hospital; Utah System of Higher Education; University of Utah;
   University of California System; University of California Los Angeles;
   University of California Los Angeles Medical Center; David Geffen School
   of Medicine at UCLA; University of California System; University of
   California Los Angeles; University of California Los Angeles Medical
   Center; David Geffen School of Medicine at UCLA; Mayo Clinic; Yale
   University
RP Zhang, K (通讯作者)，Univ Utah, Sch Med, Moran Eye Ctr, Dept Ophthalmol & Visual Sci, Salt Lake City, UT 84132 USA.
EM kzhang@hmbg.utah.edu
RI Chu, Kai On/E-2325-2016; Chen, Haoyu/A-7432-2013; Chien,
   Jeremy/AID-8939-2022; Zhang, Kang/Y-2740-2019; Seal, Sudipta/A-7698-2012
OI Chen, Haoyu/0000-0003-0676-4610; Zhang, Kang/0000-0002-4549-1697; Chien,
   Jeremy/0000-0003-4744-8374; DeWan, Andrew/0000-0002-7679-8704
FU NATIONAL CANCER INSTITUTE [K07CA098364] Funding Source: NIH RePORTER;
   NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000064] Funding Source: NIH
   RePORTER; NATIONAL EYE INSTITUTE [R01EY015771, P30EY014800, R01EY014428,
   R01EY014448] Funding Source: NIH RePORTER
CR Attebo K, 1996, OPHTHALMOLOGY, V103, P357
   Dewan A, 2006, SCIENCE, V314, P989, DOI 10.1126/science.1133807
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Fisher SA, 2005, HUM MOL GENET, V14, P2257, DOI 10.1093/hmg/ddi230
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   Grau S, 2006, J BIOL CHEM, V281, P6124, DOI 10.1074/jbc.M500361200
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Jakobsdottir J, 2005, AM J HUM GENET, V77, P389, DOI 10.1086/444437
   Klaver CCW, 1998, ARCH OPHTHALMOL-CHIC, V116, P1646, DOI 10.1001/archopht.116.12.1646
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Li M, 2006, NAT GENET, V38, P1049, DOI 10.1038/ng1871
   Magnusson KP, 2006, PLOS MED, V3, P109, DOI 10.1371/journal.pmed.0030005
   Maller J, 2006, NAT GENET, V38, P1055, DOI 10.1038/ng1873
   Oka C, 2004, DEVELOPMENT, V131, P1041, DOI 10.1242/dev.00999
   Rivera A, 2005, HUM MOL GENET, V14, P3227, DOI 10.1093/hmg/ddi353
   Schmidt S, 2006, AM J HUM GENET, V78, P852, DOI 10.1086/503822
   Seddon JM, 1996, JAMA-J AM MED ASSOC, V276, P1141, DOI 10.1001/jama.276.14.1141
NR 18
TC 609
Z9 654
U1 8
U2 68
PU AMER ASSOC ADVANCEMENT SCIENCE
PI WASHINGTON
PA 1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA
SN 0036-8075
J9 SCIENCE
JI Science
PD NOV 10
PY 2006
VL 314
IS 5801
BP 992
EP 993
DI 10.1126/science.1133811
PG 2
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA 103OG
UT WOS:000241896000053
PM 17053109
DA 2022-11-30
ER

PT J
AU Afarid, M
   Azimi, A
   Malekzadeh, M
AF Afarid, Mehrdad
   Azimi, Ali
   Malekzadeh, Mahyar
TI Evaluation of serum interferons in patients with age-related macular
   degeneration
SO JOURNAL OF RESEARCH IN MEDICAL SCIENCES
LA English
DT Article
DE Immune system; interferon; macular degeneration
ID NEUROTROPHIC FACTOR; IFN-BETA; GAMMA; THERAPY; ALPHA
AB Background: Environmental, genetic, and immunological factors may play a role in the pathogenesis of age-related macular degeneration (AMD). In an attempt to better understand the pathogenesis of AMD, in this study, we evaluated the serum interferon (IFN) levels in patients with AMD and compared it with persons without AMD. Materials and Methods: In this case-control study, 42 patients with AMD and 42 healthy individuals (without AMD) were enrolled as the case and control groups, respectively. The two groups were matched regarding their age and sex. We classified the case group as dry-type and wet-type AMD. Blood samples were obtained and the serum was collected and frozen at -20 degrees C. Alpha-, beta-, and gamma-IFN levels were measured using the sandwich ELISA method and compared between and within the groups. Results: The mean beta IFN levels in both case and control groups were 46.88 +/- 27.25 pg/ml and 34.90 +/- 18.81 pg/ml (P = 0.021), respectively. Regarding gamma and alpha IFN, the serum levels were not detectable in most of the patients and no significant difference was detected between the case and control groups. Conclusion: We found that serum beta IFN levels are higher in patients with AMD. This finding may have diagnostic, therapeutic, and prognostic value in AMD patients and can be a beginning for further evaluation.
C1 [Afarid, Mehrdad; Azimi, Ali] Shiraz Univ Med Sci Shiraz Iran, Poostchi Ophthalmol Res Ctr, Shiraz Med Sch, Dept Ophthalmol, Shiraz, Iran.
   [Malekzadeh, Mahyar] Shiraz Univ Med Sci, Sch Med, Shiraz Inst Canc Res, Shiraz, Iran.
C3 Shiraz University of Medical Science
RP Azimi, A (通讯作者)，Shiraz Univ Med Sci Shiraz Iran, Poostchi Ophthalmol Res Ctr, Shiraz Med Sch, Dept Ophthalmol, Shiraz, Iran.
EM ali.azimi1385@gmail.com
RI Malekzadeh, Mahyar/B-5031-2012; Afarid, Mehrdad/K-6921-2016; Azimi,
   Ali/B-1634-2019
OI Malekzadeh, Mahyar/0000-0003-1581-0471; Afarid,
   Mehrdad/0000-0003-2348-9163; Azimi, Ali/0000-0001-7744-5858
FU Shiraz Institute for Cancer Research
FX The authors would like to thank all the participants who patiently took
   part in our study. The present article was extracted from the thesis
   written by Ali Azimi, which was under the supervision of Dr. Mehrdad
   Afarid. We also would like to thank Ms. Roustaei for statistical
   analysis, Poustchi Ophthalmology Research Center and Shiraz Institute
   for Cancer Research for supporting this study.
CR Afarid M, 2016, INDIAN J OPHTHALMOL, V64, P376, DOI 10.4103/0301-4738.185605
   Afarid M, 2016, J NEUROL SCI, V363, P43, DOI 10.1016/j.jns.2016.02.024
   Afarid M, 2015, INT J OPHTHALMOL-CHI, V8, P991, DOI 10.3980/j.issn.2222-3959.2015.05.25
   Ambati J, 2012, NEURON, V75, P26, DOI 10.1016/j.neuron.2012.06.018
   Amberger M, 2007, CLIN EXP RHEUMATOL, V25, pS52
   Amirpour N, 2013, INT J PREVENTIVE MED, V4, P1243
   Bertolotto A, 2015, CYTOKINE GROWTH F R, V26, P241, DOI 10.1016/j.cytogfr.2014.12.002
   Bertolotto A, 2014, NEUROL SCI, V35, P307, DOI 10.1007/s10072-013-1616-1
   Deuter CME, 2006, RETINA-J RET VIT DIS, V26, P786, DOI 10.1097/01.iae.0000244265.75771.71
   Frederick Paul A, 2014, Curr Ophthalmol Rep, V2, P14
   Gattoni A, 2006, Clin Ter, V157, P377
   Gul A, 2007, DRUGS, V67, P2013, DOI 10.2165/00003495-200767140-00004
   Johnson HM, 2015, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00667
   Kauppinen A, 2016, CELL MOL LIFE SCI, V73, P1765, DOI 10.1007/s00018-016-2147-8
   Kim YH, 2009, GRAEF ARCH CLIN EXP, V247, P651, DOI 10.1007/s00417-009-1049-y
   Lin CM, 2016, AM J TRANSPLANT, V16, P3121, DOI 10.1111/ajt.13865
   Liu BY, 2010, MOL VIS, V16, P184
   Luckoff A, 2016, EMBO MOL MED, V8, P670, DOI 10.15252/emmm.201505994
   Lyn-Cook BD, 2014, MOL IMMUNOL, V61, P38, DOI 10.1016/j.molimm.2014.05.001
   Marneros AG, 2007, FASEB J, V21, P3809, DOI 10.1096/fj.07-8422com
   McCannel CA., 2016, 2016 2017 BASIC CLIN
   Mei FJ, 2006, J NEUROL SCI, V246, P71, DOI 10.1016/j.jns.2006.02.008
   Mo FM, 2010, INVEST OPHTH VIS SCI, V51, P4226, DOI 10.1167/iovs.09-3910
   Ornek K, 2012, J RES MED SCI, V17, P582
   Parmeggiani F, 2013, MEDIAT INFLAMM, V2013, DOI 10.1155/2013/435607
   Reddy U, 2006, COCHRANE DB SYST REV, V1
   Renner I, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0114288
   Seaman William, INTERFERON BETA RECO
   Sun T, 2013, ONCOL RES, V21, P227, DOI 10.3727/096504014X13890370410285
   Thirion M, 2007, CLIN EXP RHEUMATOL, V25, P791
   Yang DSF, 2008, BRIT J HOSP MED, V69, P575, DOI 10.12968/hmed.2008.69.10.31317
NR 31
TC 4
Z9 4
U1 0
U2 0
PU WOLTERS KLUWER MEDKNOW PUBLICATIONS
PI MUMBAI
PA WOLTERS KLUWER INDIA PVT LTD , A-202, 2ND FLR, QUBE, C T S  NO 1498A-2
   VILLAGE MAROL, ANDHERI EAST, MUMBAI, 400059, INDIA
SN 1735-1995
EI 1735-7136
J9 J RES MED SCI
JI J. Res. Med. Sci.
PD MAR
PY 2019
VL 24
AR 24
DI 10.4103/jrms.JRMS_363_18
PG 5
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA IA8IF
UT WOS:000469801700006
PM 31007694
DA 2022-11-30
ER

PT J
AU Ikram, MK
   Mitchell, P
   Klein, R
   Sharrett, AR
   Couper, DJ
   Wong, TY
AF Ikram, M. Kamran
   Mitchell, Paul
   Klein, Ronald
   Sharrett, A. Rickey
   Couper, David J.
   Wong, Tien Y.
TI Age-Related Macular Degeneration and Long-Term Risk of Stroke Subtypes
SO STROKE
LA English
DT Article
DE age-related macular degeneration; cerebral infarction; intracerebral
   hemorrhage; retinal imaging
AB Background and Purpose-We examined the relationship of age-related macular degeneration (AMD) with incident stroke, including stroke subtypes of cerebral infarction and intracerebral hemorrhage.
   Methods-We included 12 216 participants with retinal photographs taken at the third examination visit (1993-1995) from the Atherosclerosis Risk in Communities (ARIC) Study, a population-based cohort study in middle-aged persons. Images were evaluated for AMD signs according to a standardized protocol. Incident events of stroke and its subtypes were identified and validated through case record review over time.
   Results-AMD was diagnosed in 591 participants, of whom 576 had early and 15 late AMD. After a mean follow-up of 13.0 years (SD, 3.3), 619 persons developed an incident stroke, including 548 cerebral infarction and 57 intracerebral hemorrhages. Participants with any AMD were at an increased risk of stroke (multivariable adjusted hazard ratio, 1.51; 95% CI, 1.11-2.06) with a stronger association for intracerebral hemorrhage (hazard ratio, 2.64; 95% CI, 1.18-5.87) than cerebral infarction (hazard ratio, 1.42; 95% CI, 1.01-1.99).
   Conclusions-Persons with AMD are at an increased risk of both cerebral infarction and intracerebral hemorrhage. These data provide further insight into common pathophysiological processes between AMD and stroke subtypes. (Stroke. 2012;43:1681-1683.)
C1 [Ikram, M. Kamran; Wong, Tien Y.] Singapore Natl Eye Ctr, Singapore Eye Res Inst, Singapore 168751, Singapore.
   [Ikram, M. Kamran; Wong, Tien Y.] Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Ophthalmol, Singapore 117595, Singapore.
   [Ikram, M. Kamran] Erasmus MC, Dept Ophthalmol, Rotterdam, Netherlands.
   [Mitchell, Paul] Univ Sydney, Ctr Vis Res, Dept Ophthalmol, Sydney, NSW 2006, Australia.
   [Mitchell, Paul] Univ Sydney, Westmead Millennium Inst, Dept Ophthalmol, Sydney, NSW 2006, Australia.
   [Klein, Ronald] Univ Wisconsin, Sch Med & Publ Hlth, Dept Ophthalmol & Visual Sci, Madison, WI USA.
   [Sharrett, A. Rickey] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Epidemiol, Baltimore, MD USA.
   [Couper, David J.] Univ N Carolina, Dept Biostat, Chapel Hill, NC USA.
C3 National University of Singapore; Singapore National Eye Center;
   National University of Singapore; Erasmus University Rotterdam; Erasmus
   MC; University of Sydney; University of Sydney; Westmead Institute for
   Medical Research; University of Wisconsin System; University of
   Wisconsin Madison; Johns Hopkins University; Johns Hopkins Bloomberg
   School of Public Health; University of North Carolina; University of
   North Carolina Chapel Hill
RP Ikram, MK (通讯作者)，Singapore Natl Eye Ctr, Singapore Eye Res Inst, 11 3rd Hosp Ave, Singapore 168751, Singapore.
EM kamran_ikram@nuhs.edu.sg
RI Wong, Tien Yin/AAC-9724-2020; Mitchell, Paul/P-1498-2014
OI Wong, Tien Yin/0000-0002-8448-1264; Ikram, Mohammad
   Kamran/0000-0003-0173-9571; Klein, Ronald/0000-0002-4428-6237; Couper,
   David/0000-0002-4313-9235
FU National Heart, Lung, and Blood Institute [HHSN268201100005C,
   HHSN268201100006C, HHSN268201100007C, HHSN268201100008C,
   HHSN2682011-00009C, HHSN268201100010C, HHSN268201100011C,
   HHSN268201100012C]
FX The Atherosclerosis Risk in Communities Study is carried out as a
   collaborative study supported by National Heart, Lung, and Blood
   Institute contracts (HHSN268201100005C, HHSN268201100006C,
   HHSN268201100007C, HHSN268201100008C, HHSN2682011-00009C,
   HHSN268201100010C, HHSN268201100011C, and HHSN268201100012C).
CR Baker ML, 2008, STROKE, V39, P1371, DOI 10.1161/STROKEAHA.107.496091
   Hu CC, 2010, STROKE, V41, P613, DOI 10.1161/STROKEAHA.109.571000
   Klein R, 2003, OPHTHALMOLOGY, V110, P25, DOI 10.1016/S0161-6420(02)01565-8
   Lim LS, 2011, AM J OPHTHALMOL, V152, P329, DOI 10.1016/j.ajo.2011.05.040
   Sun C, 2009, OPHTHALMOLOGY, V116, P1913, DOI 10.1016/j.ophtha.2009.03.046
   Tan JSL, 2008, BRIT J OPHTHALMOL, V92, P509, DOI 10.1136/bjo.2007.131706
   Wieberdink RG, 2011, STROKE, V42, P2138, DOI 10.1161/STROKEAHA.111.616359
   Wong TY, 2010, STROKE, V41, P575, DOI 10.1161/STROKEAHA.109.574475
   Wong TY, 2006, ANN INTERN MED, V145, P98, DOI 10.7326/0003-4819-145-2-200607180-00007
NR 9
TC 37
Z9 37
U1 0
U2 3
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0039-2499
J9 STROKE
JI Stroke
PD JUN
PY 2012
VL 43
IS 6
BP 1681
EP 1683
DI 10.1161/STROKEAHA.112.654632
PG 3
WC Clinical Neurology; Peripheral Vascular Disease
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Neurosciences & Neurology; Cardiovascular System & Cardiology
GA 948SV
UT WOS:000304523800049
PM 22535267
OA Green Accepted, Green Published, Green Submitted, Bronze
DA 2022-11-30
ER

PT J
AU Luke, C
   Alteheld, N
   Aisenbrey, S
   Luke, M
   Bartz-Schmidt, KU
   Walter, P
   Kirchhof, B
AF Luke, C
   Alteheld, N
   Aisenbrey, S
   Luke, M
   Bartz-Schmidt, KU
   Walter, P
   Kirchhof, B
TI Electro-oculographic findings after 360 degrees retinotomy and macular
   translocation for subfoveal choroidal neovascularisation in age-related
   macular degeneration
SO GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Article
ID LASER PHOTOCOAGULATION; RETINAL-DETACHMENT; FOVEAL TRANSLOCATION;
   PHOTODYNAMIC THERAPY; ELECTRO-OCULOGRAM; CLINICAL-TRIALS; VISUAL-ACUITY;
   SILICONE OIL; RABBIT EYE; MANAGEMENT
AB Purpose. To evaluate potential electro-oculographic changes after 360degrees retinotomy and macular translocation for subfoveal choroidal neovascularisation in patients with age-related macular degeneration (AMD) in a randomised comparative (self-controlled) trial. Methods. A consecutive series of 30 patients suffering from subfoveal choroidal neovascularisation secondary to age-related macular degeneration underwent 360degrees retinotomy and macular translocation. The EOG served as the main parameter of the study and was recorded 1 day prior to the translocation surgery and no earlier than 21 days after the silicone oil removal. Results. Postoperatively, a statistically significant decrease in mean dark trough by 64% was found for treated eyes (P<0.001). The mean dark trough of the fellow eye remained stable after surgery (P=0.33). The postoperative difference between the treated und untreated eyes proved to be statistically significant (P<0.001). The Arden ratio remained stable in the treated and untreated eyes with mean values of 204% (P=0.81) and 213% (P=0.18), respectively. A significant correlation between the reduction of the dark trough and the visual acuity at the 1-year follow-up was found. Conclusions. A persistent decrease in the corneofundal potential is associated with 360degrees retinotomy and macular translocation for exudative AMD. This indicates a substantial postoperative malfunction of retinal pigment epithelial cells and an impaired photoreceptor regeneration. The impeded recovery of the RPE-photoreceptor complex can be interpreted as the result of the surgical trauma on the basis of prediseased RPE. A severe postoperative decrease in dark trough forecasts an incomplete recovery of visual acuity.
C1 Univ Cologne, Dept Vitreoretinal Surg, Ctr Ophthalmol, D-50924 Cologne, Germany.
   Univ Tubingen, Dept Ophthalmol, D-72074 Tubingen, Germany.
C3 University of Cologne; Eberhard Karls University of Tubingen; Eberhard
   Karls University Hospital
RP Luke, C (通讯作者)，Univ Cologne, Dept Vitreoretinal Surg, Ctr Ophthalmol, Joseph Stelzmann Str 9, D-50924 Cologne, Germany.
RI Walter, Peter/L-5982-2018
OI Walter, Peter/0000-0001-8745-6593
CR Aisenbrey S, 2002, ARCH OPHTHALMOL-CHIC, V120, P451
   ALEXANDRIDIS E, 1975, NETZHAUTFUNKTION NAC, P98
   Arden G B, 1962, Br J Ophthalmol, V46, P449, DOI 10.1136/bjo.46.8.449
   ARMALY MF, 1962, ARCH OPHTHALMOL-CHIC, V68, P390, DOI 10.1001/archopht.1962.00960030394013
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   BRESSLER NM, 1987, ARCH OPHTHALMOL-CHIC, V105, P209
   CONSTABLE I, 1982, AUST J OPHTHALMOL, V10, P5, DOI 10.1111/j.1442-9071.1982.tb00355.x
   de Juan E, 1998, AM J OPHTHALMOL, V125, P635, DOI 10.1016/S0002-9394(98)00018-X
   ELENIUS V, 1973, ARCH OPHTHALMOL-CHIC, V90, P60, DOI 10.1001/archopht.1973.01000050062013
   FERRIS FL, 1982, AM J OPHTHALMOL, V94, P91, DOI 10.1016/0002-9394(82)90197-0
   FISHER SK, 1998, RETINAL PIGMENT EPIT, P406
   FOULDS W. S., 1966, INVEST OPHTHALHOL, V5, P93
   FRANCOIS J, 1978, OPHTHALMOLOGICA, V176, P133, DOI 10.1159/000308705
   FRUMAR KD, 1985, RETINA-J RET VIT DIS, V5, P16, DOI 10.1097/00006982-198500510-00004
   Fujikado T, 1998, AM J OPHTHALMOL, V125, P647, DOI 10.1016/S0002-9394(98)00021-X
   GASS JDM, 1973, ARCH OPHTHALMOL-CHIC, V90, P206
   HAWKINS BS, 1993, ARCH OPHTHALMOL-CHIC, V111, P1200
   Imai K, 1998, AM J OPHTHALMOL, V125, P627, DOI 10.1016/S0002-9394(98)00023-3
   KRASTEL H, 1980, OPHTHALMOLOGICA, V181, P47, DOI 10.1159/000309024
   LEE PF, 1969, ANN OPHTHALMOL, V1, P15
   Leibowitz H M, 1980, Surv Ophthalmol, V24, P335
   Lewis GP, 2000, INVEST OPHTH VIS SCI, V41, P1542
   LINDSEY P, 1983, INVEST OPHTHALMOL  S, V24, P242
   LOBES LA, 1978, BRIT J OPHTHALMOL, V62, P223, DOI 10.1136/bjo.62.4.223
   Luke C, 2001, BRIT J OPHTHALMOL, V85, P928, DOI 10.1136/bjo.85.8.928
   MACHEMER R, 1993, GRAEF ARCH CLIN EXP, V231, P635, DOI 10.1007/BF00921957
   MACHEMER R, 1993, GRAEF ARCH CLIN EXP, V231, P629, DOI 10.1007/BF00921956
   MAGUIRE MG, 1994, ARCH OPHTHALMOL-CHIC, V112, P480
   MARCUS M, 1983, ANN OPHTHALMOL, V15, P235
   Marmor MF, 1998, DOC OPHTHALMOL, V95, P91, DOI 10.1023/A:1001788731171
   MARMOR MF, 1993, ARCH OPHTHALMOL-CHIC, V111, P601, DOI 10.1001/archopht.1993.01090050035023
   MARMOR MF, 1979, RETINAL PIGMENT EPIT, P226
   MEREDITH TA, 1985, BRIT J OPHTHALMOL, V69, P254, DOI 10.1136/bjo.69.4.254
   Miller JW, 1999, ARCH OPHTHALMOL-CHIC, V117, P1161
   MOMIROV D, 1983, OPHTHALMOLOGICA, V186, P183, DOI 10.1159/000309284
   Ninomiya Y, 1996, AM J OPHTHALMOL, V122, P613, DOI 10.1016/S0002-9394(14)70479-9
   OBER RR, 1983, RETINA-J RET VIT DIS, V3, P77, DOI 10.1097/00006982-198300320-00002
   SCHMIDT B, 1970, GRAEFES ARCH OPHTHAL, V180, P20
   STERNBERG P, 1991, ARCH OPHTHALMOL-CHIC, V109, P1232
   Walter P, 1999, GRAEF ARCH CLIN EXP, V237, P962, DOI 10.1007/s004170050331
NR 40
TC 9
Z9 10
U1 0
U2 1
PU SPRINGER-VERLAG
PI NEW YORK
PA 175 FIFTH AVE, NEW YORK, NY 10010 USA
SN 0721-832X
J9 GRAEF ARCH CLIN EXP
JI Graefes Arch. Clin. Exp. Ophthalmol.
PD SEP
PY 2003
VL 241
IS 9
BP 710
EP 715
DI 10.1007/s00417-003-0709-6
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 734CF
UT WOS:000186037100004
PM 12937992
DA 2022-11-30
ER

PT J
AU Kim, K
   Kim, JM
   Kim, D
   Yu, SY
   Kim, ES
AF Kim, Kiyoung
   Kim, Jae Min
   Kim, Do Gyun
   Yu, Seung-Young
   Kim, Eung Suk
TI Five-Year Follow-Up of Unaffected Fellow Eyes in Patients with
   Polypoidal Choroidal Vasculopathy
SO OPHTHALMOLOGICA
LA English
DT Article
DE Age-related macular degeneration; Choroidal neovascularization; Fellow
   eyes; Polypoidal choroidal vasculopathy
ID AGE-RELATED MACULOPATHY; MACULAR DEGENERATION; JAPANESE PATIENTS;
   THICKNESS
AB Purpose: To evaluate the incidence and risk factors of neovascular age-related macular degeneration (nAMD) including polypoidal choroidal vasculopathy (PCV) or any type of choroidal neovascularization (CNV) in fellow eyes of unilateral PCV. Methods: This retrospective study included 48 patients with unilateral PCV. For the initial PCV diagnosis, optical coherence tomography and indocyanine green angiography were performed, and patients with and without neovascularization were compared. Results: Of 48 fellow eyes, 10 (20.8%) had drusen, 9 (18.8%) had retinal pigment epitheliopathy, 9 (18.8%) had irregular retinal pigment epithelium (RPE) elevation, 13 (27.1%) had choroidal vascular dilation, 12 (25%) had choroidal vascular hyperpermeability, and 9 (18.8%) had branching vascular network (BVN) at baseline. The development of nAMD was noted in 8 eyes (17%). The subfoveal choroidal thickness (p = 0.001), irregular RPE elevation (p < 0.001), choroidal vascular dilation (p < 0.001), choroidal vascular hyperpermeability (p < 0.001), and BVN (p < 0.001) in fellow eyes were significantly correlated with development of PCV. After multivariate analysis, BVN (p = 0.045, odds ratio = 24.66) in the fellow eye was the only significant risk factor for the development of nAMD. Conclusions: PCV or CNV developed in 17% of fellow eyes during the 5 years. Unilateral PCV with contralateral BVN requires careful monitoring for future development of PCV or CNV in fellow eyes.
C1 [Kim, Kiyoung; Kim, Jae Min; Yu, Seung-Young; Kim, Eung Suk] Kyung Hee Univ, Dept Ophthalmol, Med Ctr, Seoul, South Korea.
   [Kim, Do Gyun] Hanyang Univ, Coll Med, Myongji Hosp, Dept Ophthalmol, Goyang, South Korea.
C3 Kyung Hee University; Hanyang University; Myongji Hospital
RP Kim, ES (通讯作者)，Kyung Hee Univ Hosp, Dept Ophthalmol, 23 Kyungheedae Ro, Seoul, South Korea.
EM eungyi@khu.ac.kr
RI KIM, KIYOUNG/GWM-6103-2022
CR Balaratnasingam C, 2016, RETINA-J RET VIT DIS, V36, P1, DOI 10.1097/IAE.0000000000000774
   BURGESS DB, 1993, ARCH OPHTHALMOL-CHIC, V111, P1189
   Byeon SH, 2008, JPN J OPHTHALMOL, V52, P57, DOI 10.1007/s10384-007-0498-2
   Cheung CMG, 2019, EYE, V33, P14, DOI 10.1038/s41433-018-0158-4
   Cheung CMG, 2018, OPHTHALMOLOGY, V125, P708, DOI 10.1016/j.ophtha.2017.11.019
   Chung SE, 2011, OPHTHALMOLOGY, V118, P840, DOI 10.1016/j.ophtha.2010.09.012
   Ciardella AP, 2004, SURV OPHTHALMOL, V49, P25, DOI 10.1016/j.survophthal.2003.10.007
   Cheung CM, 2018, OPHTHALMOL RETINA, V2, P1196, DOI 10.1016/j.oret.2018.06.014
   Iida T, 1999, RETINA-J RET VIT DIS, V19, P508, DOI 10.1097/00006982-199911000-00005
   Khan S, 2012, RETINA-J RET VIT DIS, V32, P1057, DOI 10.1097/IAE.0b013e31823beb14
   Kim SW, 2011, RETINA-J RET VIT DIS, V31, P1904, DOI 10.1097/IAE.0b013e31821801c5
   Kim YT, 2012, BRIT J OPHTHALMOL, V96, P1217, DOI 10.1136/bjophthalmol-2012-301644
   Klein R, 2007, OPHTHALMOLOGY, V114, P253, DOI 10.1016/j.ophtha.2006.10.040
   Koizumi H, 2011, GRAEF ARCH CLIN EXP, V249, P1123, DOI 10.1007/s00417-011-1620-1
   Lee J, 2018, ROUTL STUD INT BUS W, P1
   Li Y, 2014, OPHTHALMOLOGY, V121, P2290, DOI 10.1016/j.ophtha.2014.06.016
   Lo Giudice G, 2008, EUR J OPHTHALMOL, V18, P652, DOI 10.1177/112067210801800429
   Maruko I, 2007, AM J OPHTHALMOL, V144, P15, DOI 10.1016/j.ajo.2007.03.047
   Mukesh BN, 2004, OPHTHALMOLOGY, V111, P1176, DOI 10.1016/j.ophtha.2003.08.042
   Ozawa S, 2009, RETINA-J RET VIT DIS, V29, P793, DOI 10.1097/IAE.0b013e3181a3b7d9
   Pang CE, 2015, RETINA-J RET VIT DIS, V35, P1, DOI 10.1097/IAE.0000000000000331
   Sasahara M, 2006, AM J OPHTHALMOL, V142, P601, DOI 10.1016/j.ajo.2006.05.051
   Sasaki M, 2014, OPTOMETRY VISION SCI, V91, P849, DOI 10.1097/OPX.0000000000000317
   Sho K, 2003, ARCH OPHTHALMOL-CHIC, V121, P1392, DOI 10.1001/archopht.121.10.1392
   Spaide RF, 1996, RETINA-J RET VIT DIS, V16, P203, DOI 10.1097/00006982-199616030-00004
   Ueta T, 2008, AM J OPHTHALMOL, V146, P96, DOI 10.1016/j.ajo.2008.03.002
   Uyama M, 2000, BRIT J OPHTHALMOL, V84, P1018, DOI 10.1136/bjo.84.9.1018
   Warrow DJ, 2013, RETINA-J RET VIT DIS, V33, P1659, DOI 10.1097/IAE.0b013e3182953df4
   Wong CW, 2016, PROG RETIN EYE RES, V53, P107, DOI 10.1016/j.preteyeres.2016.04.002
   Yanagi Y, 2017, INVEST OPHTH VIS SCI, V58, P3488, DOI 10.1167/iovs.16-21167
NR 30
TC 3
Z9 3
U1 0
U2 1
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 0030-3755
EI 1423-0267
J9 OPHTHALMOLOGICA
JI Ophthalmologica
PD MAY
PY 2020
VL 243
IS 3
BP 172
EP 177
DI 10.1159/000501212
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA LO2CU
UT WOS:000533434600002
PM 31553990
DA 2022-11-30
ER

PT J
AU Hong, SP
   Park, H
   Kwon, JS
   Yoo, E
AF Hong, Seung Pyo
   Park, HaeYean
   Kwon, Jae-Sung
   Yoo, Eunyoung
TI Effectiveness of eccentric viewing training for daily visual activities
   for individuals with age-related macular degeneration: A systematic
   review and meta-analysis
SO NEUROREHABILITATION
LA English
DT Review
DE Age-related macular degeneration; eccentric viewing training;
   meta-analysis; occupational therapy
ID PUBLICATION BIAS; IMPAIRMENT; FALLS; RISK
AB BACKGROUND: Eccentric viewing training can be successfully applied in the clinical setting based on positive evidence. Nonetheless, published research should be integrated to provide a conclusive perspective of the efficacy of eccentric viewing training.
   OBJECTIVE: Meta-analysis was conducted to examine effectiveness of eccentric viewing training on daily visual activities for individuals with age-related macular degeneration (AMD).
   METHODS: The papers used in this study were located through PubMed, Ovid, ProQuest, EBSCOhost, RISS, and KMbase on studies published between January, 1990 and December, 2012. The keywords for searching were "age-related macular degeneration" and "eccentric viewing", "eccentric fixation", "peripheral vision" or "preferred retinal loci". The effect sizes were calculated using Comprehensive Meta-Analysis 2.0 and interpreted according to Cohen's criteria.
   RESULTS: A total of 258 studies were found, among which five papers suited the main selection criteria for final analysis. The entire effect size was 0.660 (95% CI, 0.232 similar to 1.088), indicating a moderate effect size of the eccentric viewing training for individuals with AMD in their daily visual activities (p < 0.05).
   CONCLUSIONS: The results of this study demonstrated the clinical effectiveness of eccentric viewing training for individuals with AMD. This result should be interpreted cautiously, though, given the possibility of publication bias.
C1 [Hong, Seung Pyo] Dongnam Hlth Coll, Dept Occupat Therapy, Suwon, South Korea.
   [Park, HaeYean] Florida Int Univ, Dept Occupat Therapy, Miami, FL 33199 USA.
   [Kwon, Jae-Sung] Cheongju Univ, Dept Occupat Therapy, Cheongju, South Korea.
   [Yoo, Eunyoung] Yonsei Univ, Dept Occupat Therapy, Wonju, South Korea.
C3 State University System of Florida; Florida International University;
   Cheongju University; Yonsei University
RP Yoo, E (通讯作者)，Yonsei Univ, Dept Occupat Therapy, 234 Maeji Ri, Heungup Myon, Kangwon Do, South Korea.
EM splash@yonsei.ac.kr
FU Dongnam Health College research foundation
FX The study was funded by Dongnam Health College research foundation in
   2011.
CR BEOM HAN， SANG, 2009, [Journal of The Korean Ophthalmological Society, 대한안과학회지], V50, P280
   Brody BL, 2001, OPHTHALMOLOGY, V108, P1893, DOI 10.1016/S0161-6420(01)00754-0
   COCHRAN WG, 1954, BIOMETRICS, V10, P417, DOI 10.2307/3001616
   Cohen J., 1988, STAT POWER ANAL SOCI, V2nd
   Collins J., 1990, LOW VIS AH 2 C MELB, P168
   CUMMINGS RW, 1985, AM J OPTOM PHYS OPT, V62, P833
   de Boer MR, 2004, J BONE MINER RES, V19, P1539, DOI 10.1359/JBMR.040504
   Frennesson C, 1995, DOC OPHTHALMOL, V91, P9, DOI 10.1007/BF01204619
   Friberg T. R., 2000, CLIN ADVISOR, V3, P58
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Girdler S, 2008, OTJR-OCCUP PART HEAL, V28, P110, DOI 10.3928/15394492-20080601-05
   GOODRICH GL, 1986, AM J OPTOM PHYS OPT, V63, P119
   Goodrich GL, 2000, VISION REHABILITATIO, P230
   Holocomb J G, 1976, J Am Optom Assoc, V47, P1438
   Ivers RQ, 2002, INJ PREV, V8, P259, DOI 10.1136/ip.8.3.259-a
   Jung J. H., 2010, THESIS CHUNGANG U
   LEGGE GE, 1985, VISION RES, V25, P253, DOI 10.1016/0042-6989(85)90118-X
   Nilsson UL, 2003, VISION RES, V43, P1777, DOI 10.1016/S0042-6989(03)00219-0
   NOORDEN GKV, 1962, AM J OPHTHALMOL, V53, P642, DOI 10.1016/0002-9394(62)91987-6
   Palmer S, 2010, BRIT J OPHTHALMOL, V94, P494, DOI 10.1136/bjo.2008.152231
   Qiu F, 2009, CLIN EXP OPTOM, V92, P90, DOI 10.1111/j.1444-0938.2008.00343.x
   Reeves BC, 2004, BRIT J OPHTHALMOL, V88, P1443, DOI 10.1136/bjo.2003.037457
   Rosenthal R., 1980, EVALUATION ED, V4, P18
   Schultz-Krohn W., 2012, PEDRETTIS OCCUPATION, P1169
   SIMES RJ, 1987, STAT MED, V6, P11, DOI 10.1002/sim.4780060104
   Sutton AJ, 2000, BMJ-BRIT MED J, V320, P1574, DOI 10.1136/bmj.320.7249.1574
   Tarita-Nistor L, 2009, VISUAL NEUROSCI, V26, P487, DOI 10.1017/S0952523809990265
   Trombly C., 1999, AOTA EVIDENCE BASED
   Vukicevic M., 2005, INT C SERIES, V1282, P544, DOI DOI 10.1016/j.ics.2005.04.024
   Vukicevic M, 2009, J VISUAL IMPAIR BLIN, V103, P277, DOI 10.1177/0145482X0910300506
   Watkins, 2007, FDN CLIN RES APPL PR
   Whittaker, 2007, LOW VISION REHABILIT
   박종화, 2009, [Journal of The Korean Ophthalmological Society, 대한안과학회지], V50, P572
   김연덕, 2007, [Journal of The Korean Ophthalmological Society, 대한안과학회지], V48, P111
NR 34
TC 2
Z9 4
U1 0
U2 16
PU IOS PRESS
PI AMSTERDAM
PA NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS
SN 1053-8135
EI 1878-6448
J9 NEUROREHABILITATION
JI Neurorehabilitation
PY 2014
VL 34
IS 3
BP 587
EP 595
DI 10.3233/NRE-141055
PG 9
WC Clinical Neurology; Rehabilitation
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC Neurosciences & Neurology; Rehabilitation
GA AJ7YQ
UT WOS:000337918400019
PM 24463233
DA 2022-11-30
ER

PT J
AU McGuinness, MB
   Finger, RP
   Wu, ZC
   Luu, CD
   Chen, FK
   Arnold, JJ
   Chakravarthy, U
   Heriot, WJ
   Runciman, J
   Guymer, RH
AF McGuinness, Myra B.
   Finger, Robert P.
   Wu, Zhichao
   Luu, Chi D.
   Chen, Fred K.
   Arnold, Jenifer J.
   Chakravarthy, Usha
   Heriot, Wilson J.
   Runciman, Jim
   Guymer, Robyn H.
CA LEAD Study Grp
TI Properties of the Impact of Vision Impairment and Night Vision
   Questionnaires Among People With Intermediate Age-Related Macular
   Degeneration
SO TRANSLATIONAL VISION SCIENCE & TECHNOLOGY
LA English
DT Article
DE age-related macular degeneration; night vision; patient-reported
   outcomes; vision-related quality of life; visual impairment
ID QUALITY-OF-LIFE; VISUAL FUNCTION; LOW LUMINANCE
AB Purpose: To explore the psychometric properties of the Impact of Vision Impairment (IVI-28) and Night Vision Questionnaires (NVQ-10) among people with intermediate age-related macular degeneration (iAMD).
   Methods: Baseline responses were collected from 288 participants (aged 50-88 years, 74% female) in the Laser intervention in Early stages of Age-related macular Degeneration (LEAD) study in Australia and Northern Ireland. Psychometric properties (discrimination, ordering of thresholds, person separation, item miss-fit, and differential item functioning according to sex) were explored using grouped rating scale and partial credit models. Spearman's correlation was estimated to assess the association with measures of visual function (mean mesopic microperimetric sensitivity, best-corrected visual acuity, low-luminance visual acuity, and low-luminance deficit). The psychometric properties were then explored following recalibration of the instruments.
   Results: In this homogenous population, ceiling effects caused by relatively high levels of functional vision were evident for both instruments. The IVI-28 and NVQ-10 displayed suboptimal discrimination between levels of functional vision in iAMD and poor targeting among people with iAMD. The correlation between ability scores and measures of visual function was mild. In general, the NVQ-10 showed superior psychometric properties to the IVI-28 among these participants. No significant improvement in reliability could be gained following recalibration.
   Conclusions: Both instruments were designed for populations with more severe visual loss and poorly discriminate in this cohort of iAMD.
   Translational Relevance: New instruments that can capture the subtle changes in functional vision that occur early in AMD are required to aid evaluation of emerging interventions for iAMD.
C1 [McGuinness, Myra B.; Finger, Robert P.; Wu, Zhichao; Luu, Chi D.; Guymer, Robyn H.] Ctr Eye Res Australia, East Melbourne, Australia.
   [Finger, Robert P.] Univ Bonn, Dept Ophthalmol, Bonn, Germany.
   [Wu, Zhichao; Luu, Chi D.; Guymer, Robyn H.] Univ Melbourne, Dept Surg, Ophthalmol, Melbourne, Vic, Australia.
   [Chen, Fred K.] Univ Western Australia, Ctr Ophthalmol & Visual Sci, Crawley, Australia.
   [Chen, Fred K.] Royal Perth Hosp, Dept Ophthalmol, Perth, WA, Australia.
   [Arnold, Jenifer J.] Marsden Eye Res, Sydney, NSW, Australia.
   [Chakravarthy, Usha] Belfast Hlth & Social Care Trust, Belfast, Antrim, North Ireland.
   [Heriot, Wilson J.] Retinol Inst, Glen Iris, Australia.
   [Runciman, Jim] Adelaide Eye & Retinal Ctr, Adelaide, SA, Australia.
C3 Centre for Eye Research Australia; University of Bonn; University of
   Melbourne; University of Western Australia; Royal Perth Hospital;
   University of Western Australia
RP McGuinness, MB (通讯作者)，Ctr Eye Res, Melbourne, Vic, Australia.; McGuinness, MB (通讯作者)，Level 7,Peter Howson Wing,32 Gisborne St, East Melbourne, Vic 3002, Australia.
EM myra.mcguinness@unimelb.edu.au
RI McGuinness, Myra/G-4900-2017
OI McGuinness, Myra/0000-0002-5422-040X; Chen, Fred/0000-0003-2809-9930
FU National Health & Medical Research Council (NHMRC) of Australia
   [1027624]; BUPA Health Foundation (Australia); Ellex Medical Lasers,
   Ltd. (Australia); NHMRC Principal Research Fellowship [1103013]; NHMRC
   [1104985]; NHMRC (Centre for Research Excellence) [529923]; NHMRC (Early
   Career Fellowship) [1054712]; NHMRC (Career Development Fellowship)
   [1142962]
FX The Laser intervention in Early stages of Agerelated macular
   Degeneration (LEAD) Study was supported by grants from the National
   Health & Medical Research Council (NHMRC) of Australia Project grant
   (1027624, RG and CL), the BUPA Health Foundation (Australia), and Ellex
   Medical Lasers, Ltd. (Australia) who also provided the investigational
   devices. RG is funded by a NHMRC Principal Research Fellowship 1103013.
   ZW received funding from NHMRC (Fellowship Grant 1104985). CERA received
   operational infrastructure support from the Victorian government and the
   NHMRC (Centre for Research Excellence grant 529923). FC received funding
   from NHMRC (Early Career Fellowship 1054712 and Career Development
   Fellowship 1142962).
CR Clemons TE, 2003, ARCH OPHTHALMOL-CHIC, V121, P211
   Colenbrander A., 2003, VISUAL IMPAIRMENT RE, V5, P115, DOI DOI 10.1080/1388235039048919
   Fenwick EK, 2017, BRIT J OPHTHALMOL, V101, P591, DOI 10.1136/bjophthalmol-2016-308541
   Fenwick EK, 2017, QUAL LIFE RES, V26, P479, DOI 10.1007/s11136-016-1395-2
   Finger RP, 2019, OPHTHALMOLOGICA, V241, P61, DOI 10.1159/000491402
   Finger RP, 2011, INVEST OPHTH VIS SCI, V52, P8241, DOI 10.1167/iovs.11-7858
   Fraser RG, 2016, INVEST OPHTH VIS SCI, V57, P5436, DOI 10.1167/iovs.16-19295
   Goldstein JE, 2018, TRANSL VIS SCI TECHN, V7, DOI 10.1167/tvst.7.6.38
   Gothwal VK, 2009, J CATARACT REFR SURG, V35, P1961, DOI 10.1016/j.jcrs.2009.05.058
   Guymer RH, 2019, OPHTHALMOLOGY, V126, P829, DOI 10.1016/j.ophtha.2018.09.015
   Khadka J, 2013, OPTOMETRY VISION SCI, V90, P720, DOI 10.1097/OPX.0000000000000001
   Lamoureux EL, 2008, OPHTHAL EPIDEMIOL, V15, P105, DOI 10.1080/09286580701840354
   Lamoureux EL, 2007, INVEST OPHTH VIS SCI, V48, P1001, DOI 10.1167/iovs.06-0361
   Lamoureux EL, 2006, INVEST OPHTH VIS SCI, V47, P4732, DOI 10.1167/iovs.06-0220
   Lek JJ, 2017, OPHTHALMOL RETINA, V1, P227, DOI 10.1016/j.oret.2016.12.001
   Linacre John M, 2002, J Appl Meas, V3, P85
   Massof RW, 2007, OPTOMETRY VISION SCI, V84, P763, DOI 10.1097/OPX.0b013e3181339efd
   Neely D, 2017, RETINA-J RET VIT DIS, V37, P1329, DOI 10.1097/IAE.0000000000001454
   Nguyen CT, 2018, INVEST OPHTH VIS SCI, V59, DOI 10.1167/iovs.17-23084
   Owsley C, 2006, INVEST OPHTH VIS SCI, V47, P528, DOI 10.1167/iovs.05-1222
   Owsley C, 2016, BMC OPHTHALMOL, V16, DOI 10.1186/s12886-016-0274-5
   Pesudovs K, 2007, OPTOMETRY VISION SCI, V84, P663, DOI 10.1097/OPX.0b013e318141fe75
   Senthil MP, 2017, SURV OPHTHALMOL, V62, P546, DOI 10.1016/j.survophthal.2016.12.011
   Stelmack JA, 2004, INVEST OPHTH VIS SCI, V45, P3919, DOI 10.1167/iovs.04-0208
   Taylor DJ, 2016, BMJ OPEN, V6, DOI 10.1136/bmjopen-2016-011504
   Thylefors B, 2002, OPHTHALMIC EPIDEMIOL, V9, P83, DOI 10.1076/opep.9.2.83.1523
   US Department of Health and Human Services Food and Drug Administration, 2009, GUID IND PAT REP OUT
   Wu M., 2016, ED MEASUREMENT APPL, P207
   Wu ZC, 2016, BRIT J OPHTHALMOL, V100, P395, DOI 10.1136/bjophthalmol-2015-306621
   Wu ZC, 2015, JAMA OPHTHALMOL, V133, P442, DOI 10.1001/jamaophthalmol.2014.5963
   Yazdanie M, 2017, OPHTHALMOLOGY, V124, P1332, DOI 10.1016/j.ophtha.2017.05.005
   Ying GS, 2008, OPHTHALMOLOGY, V115, P1876, DOI 10.1016/j.ophtha.2008.05.023
   Ying GS, 2011, OPHTHALMOLOGY, V118, P332, DOI 10.1016/j.ophtha.2010.06.030
NR 33
TC 9
Z9 9
U1 0
U2 1
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 2164-2591
J9 TRANSL VIS SCI TECHN
JI Transl. Vis. Sci. Technol.
PD SEP
PY 2019
VL 8
IS 5
AR 3
DI 10.1167/tvst.8.5.3
PG 11
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA IX7NF
UT WOS:000485870300002
PM 31588369
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Zhuang, J
   Madden, DJ
   Cunha, P
   Badea, A
   Davis, SW
   Potter, GG
   Lad, EM
   Cousins, SW
   Chen, NK
   Allen, K
   Maciejewski, AJ
   Fernandez, XD
   Diaz, MT
   Whitson, HE
AF Zhuang, Jie
   Madden, David J.
   Cunha, Priscila
   Badea, Alexandra
   Davis, Simon W.
   Potter, Guy G.
   Lad, Eleonora M.
   Cousins, Scott W.
   Chen, Nan-Kuei
   Allen, Kala
   Maciejewski, Abigail J.
   Fernandez, Xuan Duong
   Diaz, Michele T.
   Whitson, Heather E.
TI Cerebral white matter connectivity, cognition, and age-related macular
   degeneration
SO NEUROIMAGE-CLINICAL
LA English
DT Article
DE AMD; DTI; White matter connectivity; Quantitative anisotropy (QA);
   Verbal fluency
ID FUNCTIONAL CONNECTIVITY; ALZHEIMERS-DISEASE; DIFFUSION MRI; IMPAIRMENT;
   PATHWAYS; DEMENTIA; CONNECTOMETRY; FASCICLE; NETWORKS; ANATOMY
AB Age-related macular degeneration (AMD) is a common retina disease associated with cognitive impairment in older adults. The mechanism(s) that account for the link between AMD and cognitive decline remain unclear. Here we aim to shed light on this issue by investigating whether relationships between cognition and white matter in the brain differ by AMD status. In a direct group comparison of brain connectometry maps from diffusion weighted images, AMD patients showed significantly weaker quantitative anisotropy (QA) than healthy controls, predominantly in the splenium and left optic radiation. The QA of these tracts, however, did not correlate with the visual acuity measure, indicating that this group effect is not directly driven by visual loss. The AMD and control groups did not differ significantly in cognitive performance. Across all participants, better cognitive performance (e.g. verbal fluency) is associated with stronger connectivity strength in white matter tracts including the splenium and the left inferior fronto-occipital fasciculus/inferior longitudinal fasciculus. However, there were significant interactions between group and cognitive performance (verbal fluency, memory), suggesting that the relation between QA and cognitive performance was weaker in AMD patients than in controls. This may be explained by unmeasured determinants of performance that are more common or impactful in AMD or by a recruitment bias whereby the AMD group had higher cognitive reserve. In general, our findings suggest that neural degeneration in the brain might occur in parallel to AMD in the eyes, although the participants studied here do not (yet) exhibit overt cognitive declines per standard assessments.
C1 [Zhuang, Jie] Shanghai Univ Sport, Sch Psychol, Shanghai, Peoples R China.
   [Zhuang, Jie; Madden, David J.; Cunha, Priscila; Badea, Alexandra; Davis, Simon W.; Chen, Nan-Kuei; Allen, Kala; Maciejewski, Abigail J.; Fernandez, Xuan Duong] Duke Univ, Med Ctr, Brain Imaging & Anal Ctr, Durham, NC USA.
   [Madden, David J.; Potter, Guy G.] Duke Univ, Med Ctr, Dept Psychiat & Behav Sci, Durham, NC USA.
   [Davis, Simon W.] Duke Univ, Med Ctr, Dept Neurol, Durham, NC USA.
   [Lad, Eleonora M.; Cousins, Scott W.; Whitson, Heather E.] Duke Univ, Sch Med, Dept Ophthalmol, Durham, NC 27708 USA.
   [Cousins, Scott W.] Johns Hopkins Univ, Sch Med, Dept Otolaryngol, Baltimore, MD 21205 USA.
   [Cousins, Scott W.] Univ Massachusetts, Dept Commun Disorders, Amherst, MA 01003 USA.
   [Chen, Nan-Kuei] Univ Arizona, Dept Biomed Engn, Tucson, AZ USA.
   [Diaz, Michele T.] Penn State Univ, Dept Psychol & Linguist, University Pk, PA 16802 USA.
   [Whitson, Heather E.] Duke Univ, Ctr Study Aging & Human Dev, Durham, NC USA.
   [Whitson, Heather E.] Durham VA Med Ctr, Geriatr Res Educ & Clin Ctr, Durham, NC USA.
   [Whitson, Heather E.] Duke Univ, Sch Med, Dept Med, Durham, NC 27706 USA.
C3 Shanghai University of Sport; Duke University; Duke University; Duke
   University; Duke University; Johns Hopkins University; University of
   Massachusetts System; University of Massachusetts Amherst; University of
   Arizona; Pennsylvania Commonwealth System of Higher Education (PCSHE);
   Pennsylvania State University; Pennsylvania State University -
   University Park; Duke University; Geriatric Research Education &
   Clinical Center; US Department of Veterans Affairs; Veterans Health
   Administration (VHA); Durham VA Medical Center; Duke University
RP Zhuang, J (通讯作者)，Shanghai Univ Sport, Sch Psychol, Shanghai, Peoples R China.; Whitson, HE (通讯作者)，Duke Univ, Sch Med, Dept Ophthalmol, Durham, NC 27708 USA.
EM jie.zhuang@duke.edu; heather.whitson@duke.edu
RI ; Chen, Nan-kuei/E-7791-2016
OI Madden, David/0000-0003-2815-6552; Chen, Nan-kuei/0000-0001-6564-4219;
   Whitson, Heather/0000-0002-8417-4846
FU NIH [R01 AG043438, R01 AG039684, R01 AG034138]; Duke University Medical
   Center Institutional Review Board
FX This research was funded by NIH grant R01 AG043438 to HEW, R01 AG039684
   to DJM, and R01 AG034138 to MTD. This manuscript has not been published
   elsewhere, nor is it currently under consideration for publication
   elsewhere. This research has been approved by the Duke University
   Medical Center Institutional Review Board. All authors have reviewed the
   contents of the manuscript, approved its contents, and validated the
   accuracy of the data. The authors declare no conflicts of interest.
CR Baker ML, 2009, ARCH OPHTHALMOL-CHIC, V127, P667, DOI 10.1001/archophthalmol.2009.30
   Benton A. L., 1977, NEUROSENSORY CTR COM
   BRESSLER NM, 1988, SURV OPHTHALMOL, V32, P375, DOI 10.1016/0039-6257(88)90052-5
   Catani M, 2005, ANN NEUROL, V57, P8, DOI 10.1002/ana.20319
   Clemons TE, 2006, ARCH OPHTHALMOL-CHIC, V124, P537
   Dayan M, 2015, BRAIN STRUCT FUNCT, V220, P291, DOI 10.1007/s00429-013-0655-y
   DeBuc DC, 2018, FRONT PHYSIOL, V9, DOI 10.3389/fphys.2018.01721
   Dick AS, 2012, BRAIN, V135, P3529, DOI 10.1093/brain/aws222
   Friederici AD, 2009, TRENDS COGN SCI, V13, P175, DOI 10.1016/j.tics.2009.01.001
   FULD PA, 1990, J CLIN EXP NEUROPSYC, V12, P520, DOI 10.1080/01688639008400998
   Glasser MF, 2008, CEREB CORTEX, V18, P2471, DOI 10.1093/cercor/bhn011
   Hardy J, 2002, SCIENCE, V297, P353, DOI 10.1126/science.1072994
   Iverson GL, 2001, ARCH CLIN NEUROPSYCH, V16, P183, DOI 10.1016/S0887-6177(00)00060-3
   Kaiser P., 2009, T AM OPHTHAL SOC
   Klaver CCW, 1999, AM J EPIDEMIOL, V150, P963
   Knyazeva MG, 2013, NEURAL PLAST, V2013, DOI 10.1155/2013/639430
   Liu Y, 2007, BRAIN, V130, P2085, DOI 10.1093/brain/awm121
   Liu ZX, 2010, PROC SPIE, V7628, DOI 10.1117/12.844748
   Makris N, 2005, CEREB CORTEX, V15, P854, DOI 10.1093/cercor/bhh186
   Meyer L, 2014, NEUROPSYCHOLOGIA, V61, P190, DOI 10.1016/j.neuropsychologia.2014.06.014
   MONSCH AU, 1992, ARCH NEUROL-CHICAGO, V49, P1253, DOI 10.1001/archneur.1992.00530360051017
   National Eye Institute, 2011, FACTS AG REL MAC DEG
   OLDFIELD RC, 1971, NEUROPSYCHOLOGIA, V9, P97, DOI 10.1016/0028-3932(71)90067-4
   Papoutsi M, 2011, NEUROIMAGE, V58, P656, DOI 10.1016/j.neuroimage.2011.06.036
   Parker GJM, 2005, NEUROIMAGE, V24, P656, DOI 10.1016/j.neuroimage.2004.08.047
   Petrides M, 2002, EUR J NEUROSCI, V16, P291, DOI 10.1046/j.1460-9568.2001.02090.x
   Pham TQ, 2006, GERONTOLOGY, V52, P353, DOI 10.1159/000094984
   Rauschecker JP, 2009, NAT NEUROSCI, V12, P718, DOI 10.1038/nn.2331
   Rolheiser T, 2011, J NEUROSCI, V31, P16949, DOI 10.1523/JNEUROSCI.2725-11.2011
   Rozzini L, 2014, AM J ALZHEIMERS DIS, V29, P256, DOI 10.1177/1533317513517032
   Sager Mark A, 2006, WMJ, V105, P25
   Saur D, 2010, NEUROIMAGE, V49, P3187, DOI 10.1016/j.neuroimage.2009.11.009
   Saur D, 2008, P NATL ACAD SCI USA, V105, P18035, DOI 10.1073/pnas.0805234105
   Schmahmann J.D., 2009, FIBER PATHWAYS BRAIN, P1, DOI [10.1093/acprof:oso9780195104233.001.0001, DOI 10.1093/ACPROF:OSO9780195104233.001.0001]
   Stelmack JA, 2004, INVEST OPHTH VIS SCI, V45, P3919, DOI 10.1167/iovs.04-0208
   Swanson MR, 2017, DEVELOPMENTAL SCI, V20, DOI 10.1111/desc.12360
   Szlyk JP, 2009, INVEST OPHTH VIS SCI, V50, P4487, DOI 10.1167/iovs.08-2258
   Szlyk JP, 2004, J VISUAL IMPAIR BLIN, V98, P261
   Tun PA, 2006, AGE AGEING, V35, P629, DOI 10.1093/ageing/afl095
   Turken AU, 2011, FRONT SYST NEUROSCI, V5, DOI 10.3389/fnsys.2011.00001
   Whitson HE, 2018, J AM GERIATR SOC, V66, P2052, DOI 10.1111/jgs.15506
   Whitson HE, 2010, ARCH GERONTOL GERIAT, V50, P209, DOI 10.1016/j.archger.2009.03.010
   Wong FCK, 2011, J NEUROSCI, V31, P8780, DOI 10.1523/JNEUROSCI.0999-11.2011
   Wong TY, 2002, AM J OPHTHALMOL, V134, P828
   Woo SJ, 2012, OPHTHALMOLOGY, V119, P2094, DOI 10.1016/j.ophtha.2012.04.026
   Yeatman JD, 2011, J COGNITIVE NEUROSCI, V23, P3304, DOI 10.1162/jocn_a_00061
   Yeh FC, 2016, NEUROIMAGE, V125, P162, DOI 10.1016/j.neuroimage.2015.10.053
   Yeh FC, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0080713
   Yeh FC, 2013, NEUROIMAGE-CLIN, V2, P912, DOI 10.1016/j.nicl.2013.06.014
   Zhuang J, 2018, NEUROBIOL AGING, V63, P65, DOI 10.1016/j.neurobiolaging.2017.11.003
NR 50
TC 2
Z9 3
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 2213-1582
J9 NEUROIMAGE-CLIN
JI NeuroImage-Clin.
PY 2021
VL 30
AR 102594
DI 10.1016/j.nicl.2021.102594
EA MAR 2021
PG 9
WC Neuroimaging
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC Neurosciences & Neurology
GA TE9JP
UT WOS:000670322900006
PM 33662707
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Baas, DC
   Ho, L
   Ennis, S
   Merriam, JE
   Tanck, MWT
   Uitterlinden, AG
   de Jong, PTVM
   Cree, AJ
   Griffiths, HL
   Rivadeneira, F
   Hofman, A
   van Duijn, C
   Smith, RT
   Barile, GR
   Gorgels, TGMF
   Vingerling, JR
   Klaver, CCW
   Lotery, AJ
   Allikmets, R
   Bergen, AAB
AF Baas, Dominique C.
   Ho, Lintje
   Ennis, Sarah
   Merriam, Joanna E.
   Tanck, Michael W. T.
   Uitterlinden, Andre G.
   de Jong, Paulus T. V. M.
   Cree, Angela J.
   Griffiths, Helen L.
   Rivadeneira, Fernando
   Hofman, Albert
   van Duijn, Cornelia
   Smith, R. Theodore
   Barile, Gaetano R.
   Gorgels, Theo G. M. F.
   Vingerling, Johannes R.
   Klaver, Caroline C. W.
   Lotery, Andrew J.
   Allikmets, Rando
   Bergen, Arthur A. B.
TI The Complement Component 5 Gene and Age-Related Macular Degeneration
SO OPHTHALMOLOGY
LA English
DT Article
ID FACTOR-H POLYMORPHISM; GEOGRAPHIC ATROPHY; GENOTYPING ERRORS; SERPING1
   GENE; ASSOCIATION; DRUSEN; VARIANT; RISK; HAPLOTYPE; COMMON
AB Objective: To investigate the association between variants in the complement component 5 (C5) gene and age-related macular degeneration (AMD).
   Design: Separate and combined data from 3 large AMD case-control studies and a prospective population-based study (The Rotterdam Study).
   Participants: A total of 2599 AMD cases and 3458 ethnically matched controls.
   Methods: Fifteen single nucleotide polymorphisms (SNPs) spanning the C5 gene were initially genotyped in 375 cases and 199 controls from The Netherlands (The Amsterdam/Rotterdam-Netherlands [AMRO-NL] study population). Replication testing of selected SNPs was performed in the Rotterdam Study (NL) and study populations from Southampton, United Kingdom (UK), and New York, United States (US).
   Main Outcome Measures: Early and late stages of prevalent and incident AMD, graded according to (a modification of) the international grading and classification system of AMD.
   Results: Significant allelic or genotypic associations between 8 C5 SNPs and AMD were found in the AMRO-NL study and this risk seemed to be independent of CFH Y402H, LOC387715 A69S, age, and gender. None of these findings could be confirmed consistently in 3 replication populations.
   Conclusions: Although the complement pathway, including C5, plays a crucial role in AMD, and the C5 protein is present in drusen, no consistent significant associations between C5 SNPs and AMD were found in any of these studies. The implications for genetic screening of AMD are discussed.
   Financial Disclosure(s): The authors have no proprietary or commercial interest in any of the materials discussed in this article. Ophthalmology 2010; 117: 500-511 (C) 2010 by the American Academy of Ophthalmology.
C1 [Baas, Dominique C.; de Jong, Paulus T. V. M.; Gorgels, Theo G. M. F.; Bergen, Arthur A. B.] Inst Royal Netherlands Acad Arts & Sci KNAW, Netherlands Inst Neurosci NIN, Dept Clin & Mol Ophthalmogenet, Amsterdam, Netherlands.
   [Ho, Lintje; Uitterlinden, Andre G.; Rivadeneira, Fernando; Hofman, Albert; van Duijn, Cornelia; Vingerling, Johannes R.; Klaver, Caroline C. W.] Erasmus MC, Dept Epidemiol & Biostat, Rotterdam, Netherlands.
   [Ho, Lintje; Vingerling, Johannes R.; Klaver, Caroline C. W.] Erasmus MC, Dept Ophthalmol, Rotterdam, Netherlands.
   [Ennis, Sarah] Univ Southampton, Dept Human Genet Div, Southampton, Hants, England.
   [Merriam, Joanna E.; Smith, R. Theodore; Barile, Gaetano R.; Allikmets, Rando] Columbia Univ, Dept Ophthalmol Pathol & Cell Biol, New York, NY USA.
   [Tanck, Michael W. T.] Univ Amsterdam, Acad Med Ctr, Dept Epidemiol & Biostat, NL-1105 AZ Amsterdam, Netherlands.
   [Uitterlinden, Andre G.; Rivadeneira, Fernando; Hofman, Albert; van Duijn, Cornelia] Erasmus MC, Dept Internal Med, Rotterdam, Netherlands.
   [de Jong, Paulus T. V. M.; Bergen, Arthur A. B.] Univ Amsterdam, Acad Med Ctr, Dept Ophthalmol, NL-1105 AZ Amsterdam, Netherlands.
   [Cree, Angela J.; Griffiths, Helen L.; Lotery, Andrew J.] Univ Southampton, Southampton Gen Hosp, Clin Neurosci Div Mp 806, Southampton, Hants, England.
   [Bergen, Arthur A. B.] Univ Amsterdam, Acad Med Ctr, Dept Clin Genet, NL-1105 AZ Amsterdam, Netherlands.
C3 Royal Netherlands Academy of Arts & Sciences; Netherlands Institute for
   Neuroscience (NIN-KNAW); Erasmus University Rotterdam; Erasmus MC;
   Erasmus University Rotterdam; Erasmus MC; University of Southampton;
   Columbia University; University of Amsterdam; Academic Medical Center
   Amsterdam; Erasmus University Rotterdam; Erasmus MC; University of
   Amsterdam; Academic Medical Center Amsterdam; University of Southampton;
   University of Amsterdam; Academic Medical Center Amsterdam; Vrije
   Universiteit Amsterdam
RP Bergen, AAB (通讯作者)，Meibergdreef 47, NL-1105 BA Amsterdam, Netherlands.
EM a.bergen@nin.knaw.nl
RI Bergen, Arthur/J-3637-2013; Allikmets, Rando/ABD-4533-2021; Rivadeneira,
   Fernando/O-5385-2015; Klaver, Caroline C.W./A-2013-2016
OI Rivadeneira, Fernando/0000-0001-9435-9441; Van Duijn,
   Cornelia/0000-0002-2374-9204; Tanck, Michael/0000-0001-9828-4459; Baas,
   Dominique C./0000-0003-0989-9828; Klaver, Caroline/0000-0002-2355-5258;
   Lotery, Andrew/0000-0001-5541-4305; Cree, Angela/0000-0002-1987-8900;
   Bergen, Arthur/0000-0002-6333-9576; smith, theodore/0000-0002-1693-943X
FU Merck; Nederlandse Vereniging ter Voorkoming van Blindheid; Netherlands
   Organisation of Scientific Research NWO Investments [175.010.2005.011,
   911-03-012]; Research Institute for Diseases in the Elderly
   [014-93-015]; Netherlands Genomics Initiative (NGI)/Netherlands
   Organisation for Scientific Research (NWO) [050-060-810]; Erasmus
   Medical Center; Erasmus University, Rotterdam; Netherlands Organization
   for the Health Research and Development (ZonMw); Research Institute for
   Diseases in the Elderly (RIDE); Ministry of Education, Culture and
   Science; Ministry for Health, Welfare and Sports, the European
   Commission (DG XII); Municipality of Rotterdam; National Eye Institute
   [EY13435, EY017404]; Macula Vision Research Foundation; Kaplen
   Foundation; Wigdeon Point Charitable Foundation; Department of
   Ophthalmology, Columbia University; Research to Prevent Blindness, Inc;
   National Institute for Health Research [NF-SI-0507-10094] Funding
   Source: researchfish; NATIONAL EYE INSTITUTE [R24EY017404, R01EY013435]
   Funding Source: NIH RePORTER
FX This study was in part financed by an unrestricted research grant from
   Merck and the Nederlandse Vereniging ter Voorkoming van Blindheid (both
   to A. A. B.).; The generation and management of genome-wide association
   study genotype data for the Rotterdam Study is supported by the
   Netherlands Organisation of Scientific Research NWO Investments (nr.
   175.010.2005.011, 911-03-012). This study is funded by the Research
   Institute for Diseases in the Elderly (014-93-015; RIDE2), the
   Netherlands Genomics Initiative (NGI)/Netherlands Organisation for
   Scientific Research (NWO) project nr. 050-060-810, and funding from the
   Erasmus Medical Center and Erasmus University, Rotterdam, Netherlands
   Organization for the Health Research and Development (ZonMw), the
   Research Institute for Diseases in the Elderly (RIDE), the Ministry of
   Education, Culture and Science, the Ministry for Health, Welfare and
   Sports, the European Commission (DG XII), and the Municipality of
   Rotterdam.; The US study is supported in part by the grants from the
   National Eye Institute EY13435 and EY017404; the Macula Vision Research
   Foundation; Kaplen Foundation; Wigdeon Point Charitable Foundation and
   an unrestricted grant to the Department of Ophthalmology, Columbia
   University, from Research to Prevent Blindness, Inc.
CR Age-Related Eye Dis Study Res Grp, 2001, AM J OPHTHALMOL, V132, P668
   Allikmets R, 2009, NEW ENGL J MED, V360, P2252
   Anderson DH, 2002, AM J OPHTHALMOL, V134, P411, DOI 10.1016/S0002-9394(02)01624-0
   Attia J, 2009, JAMA-J AM MED ASSOC, V301, P191, DOI 10.1001/jama.2008.946
   Baird PN, 2006, HUM MUTAT, V27, P337, DOI 10.1002/humu.20288
   Baird PN, 2004, INVEST OPHTH VIS SCI, V45, P1311, DOI 10.1167/iovs.03-1121
   Barrett JC, 2005, BIOINFORMATICS, V21, P263, DOI 10.1093/bioinformatics/bth457
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Burton PR, 2007, NATURE, V447, P661, DOI 10.1038/nature05911
   Chen W, 2009, EXP EYE RES, V89, P292, DOI 10.1016/j.exer.2008.10.017
   Coleman HR, 2008, LANCET, V372, P1835, DOI 10.1016/S0140-6736(08)61759-6
   Colhoun HM, 2003, LANCET, V361, P865, DOI 10.1016/S0140-6736(03)12715-8
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   Crabb JW, 2002, P NATL ACAD SCI USA, V99, P14682, DOI 10.1073/pnas.222551899
   de Jong PTVM, 2006, NEW ENGL J MED, V355, P1474, DOI 10.1056/NEJMra062326
   Despriet DDG, 2008, INVEST OPHTH VIS SCI, V49, P364, DOI 10.1167/iovs.07-0656
   Dewan A, 2006, SCIENCE, V314, P989, DOI 10.1126/science.1133807
   Edwards AO, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003813
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Ennis S, 2008, LANCET, V372, P1828, DOI 10.1016/S0140-6736(08)61348-3
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   GERARD C, 1994, ANNU REV IMMUNOL, V12, P775, DOI 10.1146/annurev.iy.12.040194.004015
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   Gotoh N, 2006, HUM GENET, V120, P139, DOI 10.1007/s00439-006-0187-0
   Gressner O, 2007, CLIN BIOCHEM, V40, P771, DOI 10.1016/j.clinbiochem.2007.02.001
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Hillebrandt S, 2005, NAT GENET, V37, P835, DOI 10.1038/ng1599
   Hofman A, 2007, EUR J EPIDEMIOL, V22, P819, DOI 10.1007/s10654-007-9199-x
   Johnson LV, 2000, EXP EYE RES, V70, P441, DOI 10.1006/exer.1999.0798
   Johnson LV, 2001, EXP EYE RES, V73, P887, DOI 10.1006/exer.2001.1094
   Kang SJ, 2004, GENET EPIDEMIOL, V26, P132, DOI 10.1002/gepi.10301
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Lau LI, 2006, INVEST OPHTH VIS SCI, V47, P3242, DOI 10.1167/iovs.05-1532
   Lommatzsch A, 2008, GRAEF ARCH CLIN EXP, V246, P803, DOI 10.1007/s00417-007-0749-4
   Lommatzsch A, 2007, GRAEF ARCH CLIN EXP, V245, P1713, DOI 10.1007/s00417-007-0649-7
   Lotery AJ, 2006, HUM MUTAT, V27, P568, DOI 10.1002/humu.20344
   Maller JB, 2007, NAT GENET, V39, P1200, DOI 10.1038/ng2131
   Miller MB, 2008, ADV GENET, V60, P141, DOI 10.1016/S0065-2660(07)00406-3
   Mullins RF, 2000, FASEB J, V14, P835, DOI 10.1096/fasebj.14.7.835
   Nozaki M, 2006, P NATL ACAD SCI USA, V103, P2328, DOI 10.1073/pnas.0408835103
   Okamoto H, 2006, MOL VIS, V12, P156
   Park KH, 2009, MOL VIS, V15, P200
   Purcell S, 2007, AM J HUM GENET, V81, P559, DOI 10.1086/519795
   Richards JB, 2008, LANCET, V371, P1505, DOI 10.1016/S0140-6736(08)60599-1
   Scholl HPN, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002593
   Trikalinos TA, 2006, AM J EPIDEMIOL, V163, P300, DOI 10.1093/aje/kwj046
   Walport MJ, 2001, NEW ENGL J MED, V344, P1058, DOI 10.1056/NEJM200104053441406
   Walport MJ, 2001, NEW ENGL J MED, V344, P1140, DOI 10.1056/NEJM200104123441506
   Yang ZL, 2008, NEW ENGL J MED, V359, P1456, DOI 10.1056/NEJMoa0802437
   Yang ZL, 2006, SCIENCE, V314, P992, DOI 10.1126/science.1133811
   Yates JRW, 2007, NEW ENGL J MED, V357, P553, DOI 10.1056/NEJMoa072618
   Zareparsi S, 2005, HUM MOL GENET, V14, P1449, DOI 10.1093/hmg/ddi154
NR 54
TC 29
Z9 34
U1 2
U2 4
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0161-6420
EI 1549-4713
J9 OPHTHALMOLOGY
JI Ophthalmology
PD MAR
PY 2010
VL 117
IS 3
BP 500
EP 511
DI 10.1016/j.ophtha.2009.08.032
PG 12
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 563BQ
UT WOS:000275101000014
PM 20022638
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Deng, YH
   Qiao, LF
   Du, MY
   Qu, C
   Wan, L
   Li, J
   Huang, LL
AF Deng, Yanhui
   Qiao, Lifeng
   Du, Mingyan
   Qu, Chao
   Wan, Ling
   Li, Jie
   Huang, Lulin
TI Age-related macular degeneration: Epidemiology, genetics,
   pathophysiology, diagnosis, and targeted therapy
SO GENES & DISEASES
LA English
DT Review
DE Age-related macular degeneration; Diagnosis; Genetics; Mechanism; Target
   treatment
ID COMPLEMENT FACTOR-H; OPTICAL COHERENCE TOMOGRAPHY; PIGMENT
   EPITHELIAL-CELLS; SIMPLIFIED SEVERITY SCALE; OCULAR BLOOD-FLOW;
   CHOROIDAL NEOVASCULARIZATION; APOLIPOPROTEIN-E; CIGARETTE-SMOKING;
   IN-VITRO; DIETARY ANTIOXIDANTS
AB Age-related macular degeneration (AMD) is a complex eye disorder and is the leading cause of incurable blindness worldwide in the elderly. Clinically, AMD initially affects the central area of retina known as the macula and it is classified as early stage to late stage (advanced AMD). The advanced AMD is classified into the nonexudative or atrophic form (dry AMD) and the exudative or neovascular form (wet AMD). More severe vision loss is typically associated with the wet form. Multiple genetic factors, lipid metabolism, oxidative stress and aging, play a role in the etiology of AMD. Dysregulation in genetic to AMD is established to 46%-71% of disease contribution, with CFH and ARMS2/HTRA1 to be the two most notable risk loci among the 103 identified AMD associated loci so far. Chronic cigarette smoking is the most proven consistently risk living habits for AMD. Deep learning algorithm has been developed based on image recognition to distinguish wet AMD and normal macula with high accuracy. Currently, anti-vascular endothelial growth factor (VEGF) therapy is highly effective at treating wet AMD. Several new generation AMD drugs and iPSC-derived RPE cell therapy are in the clinical trial stage and are promising to improve AMD treatment in the near future. Copyright (C) 2021, Chongqing Medical University. Production and hosting by Elsevier B.V.
C1 [Deng, Yanhui; Du, Mingyan; Huang, Lulin] Univ Elect Sci & Technol China, Sch Med, Sichuan Prov Peoples Hosp, Key Lab Human Dis Gene Study Sichuan Prov,Dept Cl, Chengdu 610072, Sichuan, Peoples R China.
   [Deng, Yanhui; Du, Mingyan] Chinese Acad Med Sci, Sichuan Acad Med Sci, Res Unit Blindness Prevent, Chengdu 610072, Sichuan, Peoples R China.
   [Qiao, Lifeng; Qu, Chao; Wan, Ling; Li, Jie] Univ Elect Sci & Technol China, Sch Med, Sichuan Prov Peoples Hosp, Dept Ophthalmol, Chengdu 610072, Sichuan, Peoples R China.
   [Huang, Lulin] Chinese Acad Sci, Inst Chengdu Biol, Sichuan Translat Med Hosp, Chengdu 610041, Sichuan, Peoples R China.
C3 Sichuan Provincial People's Hospital; University of Electronic Science &
   Technology of China; Chinese Academy of Medical Sciences - Peking Union
   Medical College; Sichuan Provincial People's Hospital; Sichuan
   Provincial People's Hospital; University of Electronic Science &
   Technology of China; Chinese Academy of Sciences
RP Huang, LL (通讯作者)，32 First Ring Rd West 2, Chengdu 610072, Sichuan, Peoples R China.
EM huangluling@yeah.net
FU National Natural Science Foundation of China [81670895, 81970839,
   81700841]; Department of Science and Technology of Sichuan Province,
   China [21ZDYF0551, 2016FZ0091]
FX This research was supported by the National Natural Science Foundation
   of China (No. 81670895 and 81970839 to L.H., 81700841 to J.L.) and the
   Department of Science and Technology of Sichuan Province, China (No.
   21ZDYF0551 to L.H; 2016FZ0091 to Ling Wan).
CR Agnieszka Kubicka-Trzaska, 2010, Klin Oczna, V112, P289
   Akyurt A, 2002, KLIN MONATSBL AUGENH, V219, P50, DOI 10.1055/s-2002-23501
   Alexander P, 2015, EYE, V29, P992, DOI 10.1038/eye.2015.89
   Anastasopoulos E, 2018, OPHTHAL EPIDEMIOL, V25, P457, DOI 10.1080/09286586.2018.1512634
   Anderson DH, 2001, AM J OPHTHALMOL, V131, P767, DOI 10.1016/S0002-9394(00)00961-2
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   Bhatwadekar AD, 2013, DIABETES, V62, P273, DOI 10.2337/db12-0172
   Bhutto IA, 2008, ARCH OPHTHALMOL-CHIC, V126, P670, DOI 10.1001/archopht.126.5.670
   Boltz A, 2010, INVEST OPHTH VIS SCI, V51, P4220, DOI 10.1167/iovs.09-4968
   BOULTON ME, 1982, BIRTH DEFECTS-ORIG, V18, P101
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Busik JV, 2009, J EXP MED, V206, P2897, DOI 10.1084/jem.20090889
   Cahill MT, 2003, ARCH OPHTHALMOL-CHIC, V121, P132
   Calippe B, 2017, IMMUNITY, V46, P261, DOI 10.1016/j.immuni.2017.01.006
   Campagne MV, 2014, J PATHOL, V232, P151, DOI 10.1002/path.4266
   Campochiaro P A, 1999, Mol Vis, V5, P34
   Cassels NK, 2018, SURV OPHTHALMOL, V63, P40, DOI 10.1016/j.survophthal.2017.05.007
   Chakravarthy U, 2010, BMC OPHTHALMOL, V10, DOI 10.1186/1471-2415-10-31
   Chappelow AV, 2008, DRUGS, V68, P1029, DOI 10.2165/00003495-200868080-00002
   Chen FK, 2010, BRIT J OPHTHALMOL, V94, P1337, DOI 10.1136/bjo.2009.172593
   Cheung CMG, 2019, RETINA-J RET VIT DIS, V39, P1655, DOI 10.1097/IAE.0000000000002228
   Cheung N, 2012, AM J OPHTHALMOL, V153, P193, DOI 10.1016/j.ajo.2011.11.022
   Chhablani JK, 2010, AM J OPHTHALMOL, V150, P754, DOI 10.1016/j.ajo.2010.07.021
   Chiu CJ, 2009, BRIT J OPHTHALMOL, V93, P1241, DOI 10.1136/bjo.2008.143412
   Choi JK, 2011, ARCH OPHTHALMOL-CHIC, V129, P196, DOI 10.1001/archophthalmol.2010.355
   Chong EWT, 2008, AM J OPHTHALMOL, V145, P707, DOI 10.1016/j.ajo.2007.12.005
   Choudhury F, 2011, AM J OPHTHALMOL, V152, P385, DOI 10.1016/j.ajo.2011.02.025
   Cicinelli MV, 2020, RETINA-J RET VIT DIS, V40, P499, DOI 10.1097/IAE.0000000000002452
   Cicinelli MV, 2018, SURV OPHTHALMOL, V63, P236, DOI 10.1016/j.survophthal.2017.06.005
   Ciulla TA, 2001, BRIT J OPHTHALMOL, V85, P510, DOI 10.1136/bjo.85.5.510
   Clark SJ, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01778
   Constable IJ, 2016, EBIOMEDICINE, V14, P168, DOI 10.1016/j.ebiom.2016.11.016
   da Cruz L, 2018, NAT BIOTECHNOL, V36, P1, DOI 10.1038/nbt.4114
   Davis MD, 2005, ARCH OPHTHALMOL-CHIC, V123, P1484
   Dias JRD, 2011, BRIT J OPHTHALMOL, V95, P1631, DOI 10.1136/bjo.2010.186361
   DeAngelis MM, 2008, OPHTHALMOLOGY, V115, P1209, DOI 10.1016/j.ophtha.2007.10.032
   DeAngelis MM, 2007, ARCH OPHTHALMOL-CHIC, V125, P49, DOI 10.1001/archopht.125.1.49
   Del Priore LV, 2002, INVEST OPHTH VIS SCI, V43, P3312
   Despriet DDG, 2006, JAMA-J AM MED ASSOC, V296, P301, DOI 10.1001/jama.296.3.301
   Dewan A, 2006, SCIENCE, V314, P989, DOI 10.1126/science.1133807
   Dugel PU, 2020, OPHTHALMOLOGY, V127, P72, DOI 10.1016/j.ophtha.2019.04.017
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Eiriksdottir G, 2006, ATHEROSCLEROSIS, V186, P222, DOI 10.1016/j.atherosclerosis.2005.12.012
   Ennis S, 2008, LANCET, V372, P1828, DOI 10.1016/S0140-6736(08)61348-3
   Ennis S, 2010, EUR J HUM GENET, V18, P15, DOI 10.1038/ejhg.2009.113
   Esparza-Gordillo J, 2004, IMMUNOGENETICS, V56, P77, DOI 10.1007/s00251-004-0660-7
   FEENEYBURNS L, 1984, INVEST OPHTH VIS SCI, V25, P195
   Ferrington DA, 2016, PROG RETIN EYE RES, V51, P69, DOI 10.1016/j.preteyeres.2015.09.002
   Ferris FL, 2005, ARCH OPHTHALMOL-CHIC, V123, P1570
   Fine SL, 2000, NEW ENGL J MED, V342, P483, DOI 10.1056/NEJM200002173420707
   Fischer T, 2015, ORVOSI HETILAP, V156, P358, DOI 10.1556/OH.2015.30017
   FLOOD MT, 1980, INVEST OPHTH VIS SCI, V19, P1309
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   FRIEDMAN E, 1989, OPHTHALMOLOGY, V96, P104
   FRIEDMAN E, 1995, OPHTHALMOLOGY, V102, P640, DOI 10.1016/S0161-6420(95)30974-8
   Friedman E, 1997, AM J OPHTHALMOL, V124, P677, DOI 10.1016/S0002-9394(14)70906-7
   Fritsche LG, 2008, NAT GENET, V40, P892, DOI 10.1038/ng.170
   Fritsche LG, 2014, ANNU REV GENOM HUM G, V15, P151, DOI 10.1146/annurev-genom-090413-025610
   Gelfand BD, 2016, TRENDS MOL MED, V22, P656, DOI 10.1016/j.molmed.2016.06.009
   Gliem M, 2015, INVEST OPHTH VIS SCI, V56, P2664, DOI 10.1167/iovs.14-15733
   Golestaneh N, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2016.453
   Goodman Denise M, 2012, JAMA, V308, P1702, DOI 10.1001/jama.2012.4091
   Gouras P, 1996, VISION RES, V36, P4121, DOI 10.1016/S0042-6989(96)00180-0
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Hamilton WS, 2007, LANCET, V370, P1480, DOI 10.1016/S0140-6736(07)61627-4
   Hanus J, 2015, AGEING RES REV, V24, P286, DOI 10.1016/j.arr.2015.09.002
   Heier JS, 2017, LANCET, V390, P50, DOI 10.1016/S0140-6736(17)30979-0
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Hikichi T, 2019, INVEST OPHTH VIS SCI, V60, P1088, DOI 10.1167/iovs.18-24522
   Ho L, 2011, ARCH OPHTHALMOL-CHIC, V129, P758, DOI 10.1001/archophthalmol.2011.141
   Holash J, 2002, P NATL ACAD SCI USA, V99, P11393, DOI 10.1073/pnas.172398299
   Houston T, 2001, AM FAM PHYSICIAN, V63, P225
   HU DN, 1982, BIRTH DEFECTS-ORIG, V18, P67
   Huang LL, 2016, NAT GENET, V48, P640, DOI 10.1038/ng.3546
   Hughes AE, 2007, PLOS MED, V4, P1993, DOI 10.1371/journal.pmed.0040355
   Humphries JM, 2003, J AGR FOOD CHEM, V51, P1322, DOI 10.1021/jf026073e
   Hyttinen JMT, 2017, AGEING RES REV, V36, P64, DOI 10.1016/j.arr.2017.03.006
   Hyttinen JMT, 2011, REJUV RES, V14, P651, DOI 10.1089/rej.2011.1220
   Igarashi T, 2010, HUM GENE THER, V21, P631, DOI 10.1089/hum.2009.153
   Ishida BY, 2004, J LIPID RES, V45, P263, DOI 10.1194/jlr.M300306-JLR200
   Jia YL, 2014, OPHTHALMOLOGY, V121, P1435, DOI 10.1016/j.ophtha.2014.01.034
   Johnson LV, 2001, EXP EYE RES, V73, P887, DOI 10.1006/exer.2001.1094
   Jonas JB, 2014, LANCET GLOB HEALTH, V2, pE65, DOI 10.1016/S2214-109X(13)70163-3
   Kaiser PK, 2013, OPHTHALMOLOGY, V120, pS11, DOI 10.1016/j.ophtha.2013.01.061
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1439, DOI 10.1001/archopht.119.10.1439
   Kaur I, 2010, INVEST OPHTH VIS SCI, V51, P59, DOI 10.1167/iovs.09-4135
   Kawasaki R, 2010, OPHTHALMOLOGY, V117, P921, DOI 10.1016/j.ophtha.2009.10.007
   Kermany DS, 2018, CELL, V172, P1122, DOI 10.1016/j.cell.2018.02.010
   KEW RR, 1985, J CLIN INVEST, V75, P1000, DOI 10.1172/JCI111760
   Khanani AM, 2020, JAMA OPHTHALMOL, V138, P964, DOI 10.1001/jamaophthalmol.2020.2699
   Khandhadia S, 2010, EXPERT REV MOL MED, V12, DOI 10.1017/S146239941000164X
   Klein R, 2006, OPHTHALMOLOGY, V113, P373, DOI 10.1016/j.ophtha.2005.12.013
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Klein R, 2011, ARCH OPHTHALMOL-CHIC, V129, P75, DOI 10.1001/archophthalmol.2010.318
   Klein R, 2009, ARCH OPHTHALMOL-CHIC, V127, P193, DOI 10.1001/archophthalmol.2008.551
   Kunimoto D, 2019, OSLI RETINA, V50, pE10, DOI 10.3928/23258160-20190129-13
   Lai LJ, 2007, J BIOMED SCI, V14, P313, DOI 10.1007/s11373-007-9153-7
   Lappas A, 2004, GRAEF ARCH CLIN EXP, V242, P638, DOI 10.1007/s00417-003-0764-z
   Laude A, 2010, PROG RETIN EYE RES, V29, P19, DOI 10.1016/j.preteyeres.2009.10.001
   Lauer N, 2011, J IMMUNOL, V187, P4374, DOI 10.4049/jimmunol.1002488
   Li CM, 2006, INVEST OPHTH VIS SCI, V47, P3119, DOI 10.1167/iovs.05-1446
   LI LX, 1988, EXP EYE RES, V47, P911, DOI 10.1016/0014-4835(88)90073-5
   Li W, 2016, DRUG DES DEV THER, V10, P3415, DOI 10.2147/DDDT.S115801
   Li XX, 2014, OPHTHALMOLOGY, V121, P1740, DOI 10.1016/j.ophtha.2014.03.026
   Liew G, 2016, OPHTHALMOLOGY, V123, P1874, DOI 10.1016/j.ophtha.2016.05.043
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   LOPEZ R, 1987, INVEST OPHTH VIS SCI, V28, P1131
   Ludwig PE, 2019, INT J RETINA VITR, V5, DOI 10.1186/s40942-019-0158-y
   Ma J, 2017, OPHTHALMOL EYE DIS, V9, DOI 10.1177/1179172116686075
   Machemer R, 1998, AM J OPHTHALMOL, V125, P698, DOI 10.1016/S0002-9394(98)00020-8
   MacLachlan TK, 2011, MOL THER, V19, P326, DOI 10.1038/mt.2010.258
   Mandai M, 2017, NEW ENGL J MED, V376, P1038, DOI 10.1056/NEJMoa1608368
   Manjunath V, 2011, AM J OPHTHALMOL, V152, P663, DOI 10.1016/j.ajo.2011.03.008
   Merle BMJ, 2017, INVEST OPHTH VIS SCI, V58, P4569, DOI 10.1167/iovs.17-21673
   Merle BMJ, 2014, INVEST OPHTH VIS SCI, V55, P2010, DOI 10.1167/iovs.14-13916
   Milton RC, 2005, OPHTHALMOLOGY, V112, P533, DOI 10.1016/j.ophtha.2004.10.047
   Mori F, 2001, BRIT J OPHTHALMOL, V85, P531, DOI 10.1136/bjo.85.5.531
   Mori K, 2001, AM J PATHOL, V159, P313, DOI 10.1016/S0002-9440(10)61697-5
   Moult E, 2014, OSLI RETINA, V45, P496, DOI 10.3928/23258160-20141118-03
   Naj AC, 2013, ANN HUM GENET, V77, P215, DOI 10.1111/ahg.12011
   Neale BM, 2010, P NATL ACAD SCI USA, V107, P7395, DOI 10.1073/pnas.0912019107
   Ng EWM, 2006, NAT REV DRUG DISCOV, V5, P123, DOI 10.1038/nrd1955
   Nidhi B, 2013, INDIAN J OPHTHALMOL, V61, P722, DOI 10.4103/0301-4738.120218
   Nozaki M, 2006, P NATL ACAD SCI USA, V103, P2328, DOI 10.1073/pnas.0408835103
   Park DH, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01007
   Pechan P, 2009, GENE THER, V16, P10, DOI 10.1038/gt.2008.115
   Polito A, 2011, BRIT J OPHTHALMOL, V95, P74, DOI 10.1136/bjo.2009.170381
   Raisler BJ, 2002, P NATL ACAD SCI USA, V99, P8909, DOI 10.1073/pnas.122247299
   Rakoczy EP, 2015, LANCET, V386, P2395, DOI 10.1016/S0140-6736(15)00345-1
   Rastogi N, 2016, SURV OPHTHALMOL, V61, P422, DOI 10.1016/j.survophthal.2015.10.003
   Reibaldi M, 2016, AM J OPHTHALMOL, V161, P78, DOI 10.1016/j.ajo.2015.09.031
   Reichel E, 1999, OPHTHALMOLOGY, V106, P1908, DOI 10.1016/S0161-6420(99)90400-1
   Rickman CB, 2013, INVEST OPHTH VIS SCI, V54, pORSF68, DOI 10.1167/iovs.13-12757
   Rivera A, 2005, HUM MOL GENET, V14, P3227, DOI 10.1093/hmg/ddi353
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Schaumberg DA, 2007, ARCH OPHTHALMOL-CHIC, V125, P55, DOI 10.1001/archopht.125.1.55
   Schmidt S, 2006, AM J HUM GENET, V78, P852, DOI 10.1086/503822
   Schmidt S, 2005, MOL VIS, V11, P941
   Schmidt S, 2000, MOL VIS, V6, P287
   Schmidt-Erfurth U, 2017, EYE, V31, P26, DOI 10.1038/eye.2016.227
   Schmitz-Valckenberg S, 2009, SURV OPHTHALMOL, V54, P96, DOI 10.1016/j.survophthal.2008.10.004
   Schuman SG, 2009, OPHTHALMOLOGY, V116, P488, DOI 10.1016/j.ophtha.2008.10.006
   Schwartz SD, 2012, LANCET, V379, P713, DOI 10.1016/S0140-6736(12)60028-2
   Scott WK, 2007, OPHTHALMOLOGY, V114, P1151, DOI 10.1016/j.ophtha.2006.08.054
   Seddon JM, 2004, JAMA-J AM MED ASSOC, V291, P704, DOI 10.1001/jama.291.6.704
   Seddon JM, 2007, JAMA-J AM MED ASSOC, V297, P1793, DOI 10.1001/jama.297.16.1793
   Seddon JM, 2006, HUM HERED, V61, P157, DOI 10.1159/000094141
   Seddon JM, 2010, OPHTHALMOLOGY, V117, P1560, DOI 10.1016/j.ophtha.2009.11.020
   Sepp T, 2006, INVEST OPHTH VIS SCI, V47, P536, DOI 10.1167/iovs.05-1143
   Sobrin L, 2014, PROG RETIN EYE RES, V40, P1, DOI 10.1016/j.preteyeres.2013.12.004
   Soderberg AC, 2012, BRIT J OPHTHALMOL, V96, P714, DOI 10.1136/bjophthalmol-2011-300721
   Song PG, 2017, J GLOB HEALTH, V7, DOI 10.7189/jogh.07.020703
   Sparrow JR, 2003, VISION RES, V43, P2983, DOI 10.1016/S0042-6989(03)00475-9
   Srinivasan S, 2017, EYE, V31, P1176, DOI 10.1038/eye.2017.47
   Stanzel BV, 2012, INVEST OPHTH VIS SCI, V53, P490, DOI 10.1167/iovs.11-8260
   Strunnikova NV, 2010, HUM MOL GENET, V19, P2468, DOI 10.1093/hmg/ddq129
   Sui GY, 2013, BRIT J OPHTHALMOL, V97, P389, DOI 10.1136/bjophthalmol-2012-302281
   Swenor BK, 2010, OPHTHALMOLOGY, V117, P2395, DOI 10.1016/j.ophtha.2010.03.058
   Thumann G, 2009, BIOMATERIALS, V30, P287, DOI 10.1016/j.biomaterials.2008.09.039
   Thumann GP-DM, 2015, CLIN DEV, V26, P97
   Treder M, 2018, GRAEF ARCH CLIN EXP, V256, P259, DOI 10.1007/s00417-017-3850-3
   Tserentsoodol N, 2006, MOL VIS, V12, P1319
   Tufail AF, 2007, GRAEFES ARCH CLIN EX, V245, P1409
   Varma R, 2016, JAMA OPHTHALMOL, V134, P571, DOI 10.1001/jamaophthalmol.2016.0588
   Wang GF, 2010, HUM GENET, V127, P595, DOI 10.1007/s00439-010-0805-8
   Wang JJ, 2014, OPHTHALMOLOGY, V121, P667, DOI 10.1016/j.ophtha.2013.10.017
   Wang JJ, 2009, AM J EPIDEMIOL, V169, P633, DOI 10.1093/aje/kwn358
   Wang YF, 2016, NUTRIENTS, V8, DOI 10.3390/nu8100663
   Weikel KA, 2012, MOL ASPECTS MED, V33, P318, DOI 10.1016/j.mam.2012.03.005
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Yang ZL, 2006, SCIENCE, V314, P992, DOI 10.1126/science.1133811
   Yang ZL, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1000836
   Yeung L, 2018, RETINA-J RET VIT DIS, V38, P263, DOI 10.1097/IAE.0000000000001556
   Zhang M, 2008, MOL VIS, V14, P37
   Zhang M, 2009, PHARM RES-DORDR, V26, P204, DOI 10.1007/s11095-008-9718-9
   Zhou JL, 2006, P NATL ACAD SCI USA, V103, P16182, DOI 10.1073/pnas.0604255103
   Zhu W, 2016, NUTRIENTS, V8, DOI 10.3390/nu8110743
NR 178
TC 15
Z9 16
U1 10
U2 19
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 2352-4820
EI 2352-3042
J9 GENES DIS
JI Genes Dis.
PD JAN
PY 2022
VL 9
IS 1
BP 62
EP 79
DI 10.1016/j.gendis.2021.02.009
EA DEC 2021
PG 18
WC Biochemistry & Molecular Biology; Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Genetics & Heredity
GA XW9EE
UT WOS:000735912200008
PM 35005108
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Eter, N
   Krohne, TU
   Holz, FG
AF Eter, Nicole
   Krohne, Tim U.
   Holz, Frank G.
TI New pharmacologic approaches to therapy for age-related macular
   degeneration
SO BIODRUGS
LA English
DT Review
ID INTRAVITREAL TRIAMCINOLONE ACETONIDE; SUBFOVEAL CHOROIDAL
   NEOVASCULARIZATION; COHERENCE TOMOGRAPHY FINDINGS; BEVACIZUMAB AVASTIN
   TREATMENT; EPITHELIUM-DERIVED FACTOR; GROWTH-FACTOR VEGF; PHOTODYNAMIC
   THERAPY; OCULAR NEOVASCULARIZATION; ANGIOSTATIC STEROIDS; ANECORTAVE
   ACETATE
AB As a result of a better understanding of molecular mechanisms, a variety of new pharmacologic treatments. have recently been developed for patients with age-related macular degeneration (AMD). Efficacy and tolerability have been demonstrated for drugs targeting vascular endothelial growth factor (VEGF), a key player in the pathogenesis of choroidal neovascularization. Both pegaptanib (anti-VEGF aptamer) and ranibizumab (anti-VEGF antibody fragment), applied at 4- to 6-week intervals into the vitreous, modified the natural course of the disease in phase III clinical studies. Corticosteroids with anti-angiogenic properties also represent a treatment option for wet AMD. Both intravitreal triamcinolone and anecortave acetate, administered juxtasclerally, are currently being pursued.
   The combination of different treatment strategies and potential synergistic effects offers new perspectives. While photodynamic therapy (PDT) combined with intravitreal triamcinolone is already frequently applied, other combinations (e.g. anti-VEGF drugs with PDT or antifibrotic agents) appear to be attractive alternatives. Pigment epithelium-derived factor represents another potential target, as well as inhibitors of matrix-metalloproteinases. With the advent of gene therapy, the use of small interfering RNA (siRNA) is also on the horizon.
   Prophylactic measures are still limited. The combination of vitamins C and E, beta-carotene, and zinc as used in the AREDS (Age-Related Eye Disease Study) reduces risk for conversion from early- to late-stage disease in patients with high-risk features, at least to some extent. Lutein and zeaxanthin dietary supplements for improvement of macular pigment density need to be investigated in future longitudinal trials.
C1 Univ Bonn, Med Ctr, Dept Ophthalmol, D-53127 Bonn, Germany.
C3 University of Bonn
RP Eter, N (通讯作者)，Univ Bonn, Med Ctr, Dept Ophthalmol, Ernst Abbe Str 2, D-53127 Bonn, Germany.
EM eter@uni-bonn.de
RI Krohne, Tim/D-1497-2013; Krohne, Tim/AAG-4412-2020
OI Krohne, Tim/0000-0003-2280-925X; 
CR Augustin AJ, 2002, OPHTHALMOLOGE, V99, P299, DOI 10.1007/s00347-002-0629-6
   Avery RL, 2006, OPHTHALMOLOGY, V113, P363, DOI 10.1016/j.ophtha.2005.11.019
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   Beatty S, 2001, INVEST OPHTH VIS SCI, V42, P439
   BenEzra D, 1997, INVEST OPHTH VIS SCI, V38, P1954
   Berendschot TTJM, 2000, INVEST OPHTH VIS SCI, V41, P3322
   Bird A, 1996, BRIT J OPHTHALMOL, V80, P2, DOI 10.1136/bjo.80.1.2
   Blanco-Colio LM, 2003, KIDNEY INT, V63, P12, DOI 10.1046/j.1523-1755.2003.00744.x
   Blinder K, 2003, RETINA-J RET VIT DIS, V23, P14
   Bone RA, 2003, J NUTR, V133, P992, DOI 10.1093/jn/133.4.992
   BROUTYBOYE D, 1980, SCIENCE, V208, P516, DOI 10.1126/science.6154315
   Chang TS, 1999, CAN J OPHTHALMOL, V34, P266
   Christen WG, 2001, ARCH OPHTHALMOL-CHIC, V119, P1143, DOI 10.1001/archopht.119.8.1143
   Ciulla TA, 2003, RETINA-J RET VIT DIS, V23, P808, DOI 10.1097/00006982-200312000-00011
   Ciulla TA, 2001, ARCH OPHTHALMOL-CHIC, V119, P399, DOI 10.1001/archopht.119.3.399
   Clark AF, 1999, INVEST OPHTH VIS SCI, V40, P2158
   CRUM R, 1985, SCIENCE, V230, P1375, DOI 10.1126/science.2416056
   CSAKY KG, 2004, INVEST OPHTHALMOL  S, V45
   Curcio CA, 2005, EXP EYE RES, V81, P731, DOI 10.1016/j.exer.2005.04.012
   Curcio CA, 2001, INVEST OPHTH VIS SCI, V42, P265
   DAMICO D, 2004, INVEST OPHTHALMOL  S, V45
   De Luca LM, 1996, NUTR REV, V54, P178, DOI 10.1111/j.1753-4887.1996.tb03926.x
   ENGLER CB, 1993, ACTA OPHTHALMOL, V71, P27
   EY C, 2005, OPHTHALMOL VIS SCI S, V46
   EZEKOWITZ RAB, 1992, NEW ENGL J MED, V326, P1456, DOI 10.1056/NEJM199205283262203
   Falsini B, 2003, OPHTHALMOLOGY, V110, P51, DOI 10.1016/S0161-6420(02)01547-6
   Ferrara N, 2005, BIOCHEM BIOPH RES CO, V333, P328, DOI 10.1016/j.bbrc.2005.05.132
   Fish G, 2003, OPHTHALMOLOGY, V110, P979, DOI 10.1016/S0161-6420(03)00085-X
   FLAMM P, 1987, KLIN MONATSBL AUGENH, V190, P59, DOI 10.1055/s-2008-1050331
   Folkman J, 1974, Adv Cancer Res, V19, P331, DOI 10.1016/S0065-230X(08)60058-5
   FOTSIS T, 1995, J NUTR, V125, pS790, DOI 10.1093/jn/125.suppl_3.790S
   FUNG WE, 1991, AM J OPHTHALMOL, V112, P349, DOI 10.1016/S0002-9394(14)76743-1
   Garrett KL, 2001, J GENE MED, V3, P373, DOI 10.1002/jgm.197
   Gasparini G, 2001, LANCET ONCOL, V2, P733, DOI 10.1016/S1470-2045(01)00587-3
   Genaidy M, 2002, RETINA-J RET VIT DIS, V22, P772, DOI 10.1097/00006982-200212000-00014
   Gillies MC, 2003, ARCH OPHTHALMOL-CHIC, V121, P667, DOI 10.1001/archopht.121.5.667
   GOLDBERG J, 1988, AM J EPIDEMIOL, V128, P700, DOI 10.1093/oxfordjournals.aje.a115023
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   GRUBER BL, 1995, BLOOD, V86, P2488
   Guyer DR, 1997, ARCH OPHTHALMOL-CHIC, V115, P865
   Hall NF, 2001, BRIT MED J, V323, P375, DOI 10.1136/bmj.323.7309.375
   Hammond BR, 1997, INVEST OPHTH VIS SCI, V38, P1795
   Hammond BR, 2000, INVEST OPHTH VIS SCI, V41, P1492
   Harris A, 1996, ACTA OPHTHALMOL SCAN, V74, P569
   Harris A, 2003, BRIT J OPHTHALMOL, V87, P753, DOI 10.1136/bjo.87.6.753
   HEIER JS, 2004, INVEST OPHTHALMOL  S, V45
   HEIER JS, 2006, OPHTHALMOLOGY
   Higgins RD, 2000, INVEST OPHTH VIS SCI, V41, P1507
   Holash J, 2002, P NATL ACAD SCI USA, V99, P11393, DOI 10.1073/pnas.172398299
   HOLEKAMP NM, 2001, P 34 ANN SCI M RET S, P66
   Holz F., 1993, GER J OPHTHALMOL, V2, P391
   Holz FG, 2003, OPHTHALMOLOGE, V100, P97, DOI 10.1007/s00347-002-0761-3
   HOLZ FG, 2004, AGE RELATED MACULAR, P73
   HRUBY K, 1977, WIEN KLIN WOCHENSCHR, V89, P439
   Iturralde D, 2006, RETINA-J RET VIT DIS, V26, P279, DOI 10.1097/00006982-200603000-00005
   Jonas JB, 2003, BRIT J OPHTHALMOL, V87, P462, DOI 10.1136/bjo.87.4.462
   Kaminski M S, 1993, J Am Optom Assoc, V64, P862
   KARCIOGLU ZA, 1982, SURV OPHTHALMOL, V27, P114, DOI 10.1016/0039-6257(82)90195-3
   KARL S, 2004, P GERM SOC OPHTH DOG
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Konner Jason, 2004, Clin Colorectal Cancer, V4 Suppl 2, pS81
   Krzystolik MG, 2002, ARCH OPHTHALMOL-CHIC, V120, P338
   Lambert V, 2001, FASEB J, V15, P1021, DOI 10.1096/fj.00-0393com
   Landrum JT, 1997, EXP EYE RES, V65, P57, DOI 10.1006/exer.1997.0309
   Lutty G, 1999, MOL VIS, V5
   Maguire MG, 2001, INVEST OPHTH VIS SCI, V42, pS233
   Majji AB, 1999, INVEST OPHTH VIS SCI, V40, P1477
   Malek G, 2003, AM J PATHOL, V162, P413, DOI 10.1016/S0002-9440(10)63836-9
   McNatt LG, 1999, J OCUL PHARMACOL TH, V15, P413, DOI 10.1089/jop.1999.15.413
   MCNATT LG, 1992, J STEROID BIOCHEM, V42, P687, DOI 10.1016/0960-0760(92)90109-V
   Michels S, 2005, OPHTHALMOLOGY, V112, P1035, DOI 10.1016/j.ophtha.2005.02.007
   MILLER JW, 1995, INVEST OPHTH VIS SCI, V36, pS401
   MOON S, 2002, INVEST OPHTHALMOL  S
   Mori K, 2002, INVEST OPHTH VIS SCI, V43, P1994
   Mori K, 2002, INVEST OPHTH VIS SCI, V43, P2428
   Nakajima M, 2001, INVEST OPHTH VIS SCI, V42, P2110
   NEWSOME DA, 1988, ARCH OPHTHALMOL-CHIC, V106, P192
   OIKAWA T, 1988, CANCER LETT, V43, P85, DOI 10.1016/0304-3835(88)90218-2
   Pauleikhoff D, 2001, OPHTHALMOLOGE, V98, P511, DOI 10.1007/s003470170110
   PAULEIKHOFF D, 1990, AM J OPHTHALMOL, V109, P211, DOI 10.1016/S0002-9394(14)75989-6
   Penn JS, 2001, INVEST OPHTH VIS SCI, V42, P283
   *PFIZER INC, TREATM RES MACUGEN P
   PROIA AD, 1993, EXP EYE RES, V57, P693, DOI 10.1006/exer.1993.1177
   Rasmussen H, 2001, Hum Gene Ther, V12, P2029
   Rechtman E, 2004, BRIT J OPHTHALMOL, V88, P344, DOI 10.1136/bjo.2003.027177
   Reich S, 2003, MOL VIS, V9, P210
   Renno RZ, 2002, INVEST OPHTH VIS SCI, V43, P1574
   Rosenfeld PJ, 2005, OPHTHAL SURG LAS IM, V36, P336, DOI 10.3928/1542-8877-20050701-15
   Rosenfeld PJ, 2005, OPHTHAL SURG LAS IM, V36, P331, DOI 10.3928/1542-8877-20050701-14
   ROTH D, 2002, INVEST OPHTHALMOL  S, V43
   Russell S, 2003, OPHTHALMOLOGY, V110, P2372, DOI 10.1016/j.ophtha.2003.08.020
   Saishin Y, 2003, J CELL PHYSIOL, V195, P241, DOI 10.1002/jcp.10246
   Schmidt-Erfurth U, 2005, DEV OPHTHALMOL, V38, P120, DOI 10.1159/000082772
   Schmidt-Erfurth U, 2005, EUR J OPHTHALMOL, V15, P482, DOI 10.1177/112067210501500411
   Schmidt-Erfurth U, 2003, INVEST OPHTH VIS SCI, V44, P4473, DOI 10.1167/iovs.02-1115
   Schutt F, 2002, OPHTHALMOLOGE, V99, P301, DOI 10.1007/s00347-002-0605-1
   Seigel D, 2002, ARCH OPHTHALMOL-CHIC, V120, P100
   Shalinsky DR, 1999, ANN NY ACAD SCI, V878, P236, DOI 10.1111/j.1749-6632.1999.tb07689.x
   Slakter JS, 2006, OPHTHALMOLOGY, V113, P3, DOI 10.1016/j.ophtha.2005.10.019
   Spaide RF, 2005, OPHTHALMOLOGY, V112, P301, DOI 10.1016/j.ophtha.2004.08.012
   Spaide RF, 2003, OPHTHALMOLOGY, V110, P1517, DOI 10.1016/S0161-6420(03)00544-X
   Spaide RF, 1999, RETINA-J RET VIT DIS, V19, P141, DOI 10.1097/00006982-199902000-00010
   Spaide RF, 2006, RETINA-J RET VIT DIS, V26, P275, DOI 10.1097/00006982-200603000-00004
   SPANDAU U, 2002, INVEST OPHTHALMOL  S
   Spilsbury K, 2000, AM J PATHOL, V157, P135, DOI 10.1016/S0002-9440(10)64525-7
   Steen B, 1998, INVEST OPHTH VIS SCI, V39, P2194
   Stellmach V, 2001, P NATL ACAD SCI USA, V98, P2593, DOI 10.1073/pnas.031252398
   Tolentino MJ, 2004, RETINA-J RET VIT DIS, V24, P132, DOI 10.1097/00006982-200402000-00018
   Uyama M, 2000, BRIT J OPHTHALMOL, V84, P1018, DOI 10.1136/bjo.84.9.1018
   Vane JR, 2003, THROMB RES, V110, P255, DOI 10.1016/S0049-3848(03)00379-7
   VEILLARD N, 2002, CELL MOL LIFE SCI, V51, P1771
   Wilson HL, 2004, AM J OPHTHALMOL, V137, P615, DOI 10.1016/j.ajo.2003.10.025
   YANG R, 2005, INVEST OPHTHLAMOL  S, V45
   YANNUZZI LA, 1992, ARCH OPHTHALMOL-CHIC, V110, P1701
NR 114
TC 30
Z9 34
U1 0
U2 13
PU ADIS INT LTD
PI NORTHCOTE
PA 5 THE WAREHOUSE WAY, NORTHCOTE 0627, AUCKLAND, NEW ZEALAND
SN 1173-8804
EI 1179-190X
J9 BIODRUGS
JI Biodrugs
PY 2006
VL 20
IS 3
BP 167
EP 179
DI 10.2165/00063030-200620030-00004
PG 13
WC Oncology; Immunology; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Immunology; Pharmacology & Pharmacy
GA 058AO
UT WOS:000238636700004
PM 16724865
DA 2022-11-30
ER

PT J
AU Damasceno, NA
   Damasceno, EF
   Silva, FQ
   Singh, RP
AF Damasceno, Nadyr A.
   Damasceno, Eduardo F.
   Silva, Fabiana Q.
   Singh, Rishi P.
TI Outer Retinal Tubulation and Neovascular Age-Related Macular
   Degeneration: A Review of the Pathogenesis and Clinical Implications
SO OPHTHALMIC SURGERY LASERS & IMAGING RETINA
LA English
DT Review
ID OPTICAL COHERENCE TOMOGRAPHY; GEOGRAPHIC ATROPHY; RANIBIZUMAB;
   AFLIBERCEPT; THERAPY
AB Outer retinal tubulation (ORT) is a retinal finding that can mimic intraretinal fluid and has been identified with spectral-domain optical coherence tomography in patients with age-related macular degeneration (AMD). The purpose of this review is to summarize the findings related to the pathogenesis of ORT and its clinical implications. Studies reporting the pathogenesis and the clinical implications of ORT in patients with AMD were identified and summarized. A total of 18 studies were included in this review. The body of evidence to date regarding ORT in patients with AMD indicates that ORT is a structure associated with advanced macular diseases that does not require anti-vascular endothelial growth factor treatment.
C1 [Damasceno, Nadyr A.] Hosp Naval Marcilio Dias, Ophthalmol Dept, Rio De Janeiro, Brazil.
   [Damasceno, Nadyr A.; Damasceno, Eduardo F.] Univ Fed Fluminense, Ophthalmol Dept, Niteroi, RJ, Brazil.
   [Damasceno, Nadyr A.; Silva, Fabiana Q.; Singh, Rishi P.] Cleveland Clin, Cole Eye Inst, Cleveland, OH 44106 USA.
C3 Universidade Federal Fluminense; Cleveland Clinic Foundation
RP Singh, RP (通讯作者)，9500 Euclid Ave,Desk i32, Cleveland, OH 44195 USA.
EM SINGHR@ccf.org
RI Damasceno, Nadyr A/O-8385-2017; Silva, Fabiana/GWU-9143-2022
OI Damasceno, Nadyr A/0000-0003-2899-6658; 
FU Apellis; Alcon; Regeneron; Genentech
FX Dr. Singh is a consultant for Regeneron, Genentech, Shire, Optos, and
   Zeiss and has received research funding from Apellis, Alcon, Regeneron,
   and Genentech. The remaining authors report no relevant financial
   disclosures.
CR Coscas F, 2015, INVEST OPHTH VIS SCI, V56, P4129, DOI 10.1167/iovs.15-16735
   Dirani A, 2015, RETINA-J RET VIT DIS, V35, P1166, DOI 10.1097/IAE.0000000000000439
   Dolz-Marco R, 2017, OPHTHALMOLOGY, V124, P1353, DOI 10.1016/j.ophtha.2017.03.043
   Espina M, 2016, BRIT J OPHTHALMOL, V100, P819, DOI 10.1136/bjophthalmol-2015-307141
   Faria-Correia F, 2013, OPHTHALMOLOGICA, V229, P147, DOI 10.1159/000346854
   Giachetti Filho Richard Geraldo, 2016, Int J Retina Vitreous, V2, P6, DOI 10.1186/s40942-016-0029-8
   Gildener-Leapman JR, 2015, OSLI RETINA, V46, P345, DOI 10.3928/23258160-20150323-08
   Goldberg NR, 2013, RETINA-J RET VIT DIS, V33, P1871, DOI 10.1097/IAE.0b013e318296b12f
   Gregori NZ, 2010, RETINA-J RET VIT DIS, V30, P1046, DOI 10.1097/IAE.0b013e3181d87e04
   Hariri A, 2015, OPHTHALMOLOGY, V122, P407, DOI 10.1016/j.ophtha.2014.08.035
   Iaculli C, 2015, RETINA-J RET VIT DIS, V35, P1979, DOI 10.1097/IAE.0000000000000609
   Jaffe GJ, 2015, AM J OPHTHALMOL, V160, P1226, DOI 10.1016/j.ajo.2015.08.024
   Lee JY, 2014, OPHTHALMOLOGY, V121, P2423, DOI 10.1016/j.ophtha.2014.06.013
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Litts KM, 2017, RETINA-J RET VIT DIS, V37, P978, DOI 10.1097/IAE.0000000000001265
   Litts KM, 2016, INVEST OPHTH VIS SCI, V57, P2647, DOI 10.1167/iovs.16-19262
   Litts KM, 2015, INVEST OPHTH VIS SCI, V56, P2243, DOI 10.1167/iovs.14-15838
   Massamba N, 2017, GRAEF ARCH CLIN EXP, V255, P61, DOI 10.1007/s00417-016-3423-x
   Moussa K, 2013, RETINA-J RET VIT DIS, V33, P1590, DOI 10.1097/IAE.0b013e31828d6052
   Schaal KB, 2015, RETINA-J RET VIT DIS, V35, P1339, DOI 10.1097/IAE.0000000000000471
   Wolff B, 2012, J OPHTHALMOL, V2012, DOI 10.1155/2012/542417
   Wolff B, 2011, ACTA OPHTHALMOL, V89, pE496, DOI 10.1111/j.1755-3768.2011.02144.x
   Zweifel SA, 2009, ARCH OPHTHALMOL-CHIC, V127, P1596, DOI 10.1001/archophthalmol.2009.326
NR 23
TC 1
Z9 1
U1 0
U2 6
PU SLACK INC
PI THOROFARE
PA 6900 GROVE RD, THOROFARE, NJ 08086 USA
SN 2325-8160
EI 2325-8179
J9 OSLI RETINA
JI Ophthalmic Surg. Lasers Imag. Retin.
PD NOV
PY 2018
VL 49
IS 11
BP 870
EP 876
DI 10.3928/23258160-20181101-08
PG 7
WC Ophthalmology; Surgery
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology; Surgery
GA HB7FY
UT WOS:000451244100017
PM 30457646
DA 2022-11-30
ER

PT J
AU Oliveira, MA
   Farinha, C
   Rodrigues, TM
   Martins, A
   Cachulo, MD
   Marques, JP
   Pires, I
   Silva, R
AF Oliveira, Mariana A.
   Farinha, Claudia
   Rodrigues, Tiago M.
   Martins, Amelia
   Cachulo, Maria da Luz
   Marques, Joao Pedro
   Pires, Isabel
   Silva, Rufino
TI Macular atrophy development in neovascular age-related macular
   degeneration during first year of treatment: Incidence and risk factors
SO EUROPEAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE Atrophy; intravitreal injection; anti-VEGF; neovascular age-related
   macular degeneration; ranibizumab; aflibercept
ID PIGMENT EPITHELIAL ATROPHY; GEOGRAPHIC ATROPHY; GROWTH; VEGF;
   RANIBIZUMAB; PROGRESSION; OUTCOMES; DISEASE; FORM; EYE
AB Purpose:
   To assess the development of macular atrophy, according to the new Classification of Atrophy Meetings criteria, in patients with treatment-naive neovascular age-related macular degeneration during the first year of treatment with ranibizumab or aflibercept, and to determine baseline factors predictive of atrophy development.
   Methods:
   Retrospective subanalysis of three prospective clinical trials that included eyes with treatment-naive neovascular age-related macular degeneration. Multimodal evaluation was performed with spectral-domain optical coherence tomography, fluorescein angiography, fundus autofluorescence and color fundus photography at baseline and after 12 months of treatment. The main outcome was the macular atrophy type, classified according to Classification of Atrophy Meeting criteria. Logistic regression models were built to test predictors of macular atrophy development.
   Results:
   A total of 85 eyes of 85 patients (63% female; mean age: 78.5 +/- 6.3 years old) were included. After 12 months of antiangiogenic therapy, all four Classification of Atrophy Meeting types of macular atrophy developed de novo. The atrophy type with highest incidence at end of follow-up was incomplete retinal pigment epithelium and outer retinal atrophy (63.6%; 95% confidence interval: 45.9%-86.0%). A significant association was observed between development at 12 months and the presence of incomplete retinal pigment epithelium and outer retinal atrophy at baseline (odds ratio (95% confidence interval): 22.4 (1.6, 323.5)). The number of injections was predictive of complete outer retinal atrophy development at end of follow-up (odds ratio (95% confidence interval) 1.5 (1.1, 2.1), p = 0.011).
   Conclusion:
   Predictors of atrophy development have the potential to change treatment practices. Further research is warranted.
C1 [Oliveira, Mariana A.; Farinha, Claudia; Rodrigues, Tiago M.; Martins, Amelia; Cachulo, Maria da Luz; Marques, Joao Pedro; Pires, Isabel; Silva, Rufino] Ctr Hosp & Univ Coimbra, Dept Ophthalmol, Coimbra, Portugal.
   [Farinha, Claudia; Cachulo, Maria da Luz; Marques, Joao Pedro; Pires, Isabel; Silva, Rufino] Assoc Innovat & Biomed Res Light & Image, Coimbra, Portugal.
   [Farinha, Claudia; Cachulo, Maria da Luz; Marques, Joao Pedro; Pires, Isabel; Silva, Rufino] Univ Coimbra, Fac Med, Coimbra, Portugal.
   [Rodrigues, Tiago M.] Inst Mol & Clin Ophthalmol Basel IOB, Basel, Switzerland.
C3 Universidade de Coimbra; Centro Hospitalar e Universitario de Coimbra
   (CHUC); Universidade de Coimbra; Universidade de Coimbra
RP Oliveira, MA (通讯作者)，CHUC, Dept Ophthalmol, CRIO, 8th Floor, P-3000075 Coimbra, Portugal.
EM mariana.alg.oliveira@gmail.com
RI Silva, Rufino M/J-2817-2012; Marques, João Pedro/J-3584-2012; Farinha,
   Claudia/R-1392-2017
OI Silva, Rufino M/0000-0001-8676-0833; Marques, João
   Pedro/0000-0002-1014-0483; Farinha, Claudia/0000-0003-4596-0913; Pires,
   Isabel/0000-0002-5764-0178; Almeida Oliveira,
   Mariana/0000-0002-4414-7990
CR Abdelfattah NS, 2016, RETINA-J RET VIT DIS, V36, P1843, DOI 10.1097/IAE.0000000000001059
   Chakravarthy U, 2013, LANCET, V382, P1258, DOI 10.1016/S0140-6736(13)61501-9
   Danis RP, 2013, INVEST OPHTH VIS SCI, V54, P4548, DOI 10.1167/iovs.13-11804
   Gillies MC, 2015, OPHTHALMOLOGY, V122, P1837, DOI 10.1016/j.ophtha.2015.05.010
   Grunwald JE, 2017, OPHTHALMOLOGY, V124, P97, DOI 10.1016/j.ophtha.2016.09.012
   Grunwald JE, 2015, OPHTHALMOLOGY, V122, P809, DOI 10.1016/j.ophtha.2014.11.007
   Grunwald JE, 2014, OPHTHALMOLOGY, V121, P150, DOI 10.1016/j.ophtha.2013.08.015
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Kurihara T, 2012, J CLIN INVEST, V122, P4213, DOI 10.1172/JCI65157
   Lois N, 2013, RETINA-J RET VIT DIS, V33, P13, DOI 10.1097/IAE.0b013e3182657fff
   Maguire MG, 2016, OPHTHALMOLOGY, V123, P1751, DOI 10.1016/j.ophtha.2016.03.045
   Mantel I, 2018, RETINA, V39, P906
   Mantel I, 2019, BRIT J OPHTHALMOL, V103, P900, DOI 10.1136/bjophthalmol-2018-312430
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Munk MR, 2016, ACTA OPHTHALMOL, V94, pE757, DOI 10.1111/aos.13157
   Nunes RP, 2013, OSLI RETINA, V44, P344, DOI 10.3928/23258160-20130715-06
   Rofagha S, 2013, OPHTHALMOLOGY, V120, P2292, DOI 10.1016/j.ophtha.2013.03.046
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rosenfeld PJ, 2011, OPHTHALMOLOGY, V118, P523, DOI 10.1016/j.ophtha.2010.07.011
   Sadda SR, 2018, OPHTHALMOLOGY, V125, P878, DOI 10.1016/j.ophtha.2017.12.026
   Sadda SR, 2018, OPHTHALMOLOGY, V125, P537, DOI 10.1016/j.ophtha.2017.09.028
   Saint-Geniez M, 2009, P NATL ACAD SCI USA, V106, P18751, DOI 10.1073/pnas.0905010106
   Schmitz-Valckenberg S, 2011, INVEST OPHTH VIS SCI, V52, P7640, DOI 10.1167/iovs.11-7457
   Spaide RF, 2013, RETINA-J RET VIT DIS, V33, P1800, DOI 10.1097/IAE.0b013e31829c3765
   Sunness JS, 1999, OPHTHALMOLOGY, V106, P1768, DOI 10.1016/S0161-6420(99)90340-8
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Young M, 2014, RETINA-J RET VIT DIS, V34, P1308, DOI 10.1097/IAE.0000000000000081
NR 27
TC 1
Z9 1
U1 0
U2 2
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 1120-6721
EI 1724-6016
J9 EUR J OPHTHALMOL
JI Eur. J. Ophthalmol.
PD MAR
PY 2021
VL 31
IS 2
BP 521
EP 528
AR 1120672120908718
DI 10.1177/1120672120908718
EA FEB 2020
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA SB1ZQ
UT WOS:000517410000001
PM 32103681
DA 2022-11-30
ER

PT J
AU Dietzel, M
   Zeimer, M
   Heimes, B
   Claes, B
   Pauleikhoff, D
   Hense, HW
AF Dietzel, Martha
   Zeimer, Meike
   Heimes, Britta
   Claes, Birte
   Pauleikhoff, Daniel
   Hense, Hans-Werner
TI Determinants of Macular Pigment Optical Density and Its Relation to
   Age-Related Maculopathy: Results from the Muenster Aging and Retina
   Study (MARS)
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
ID SERUM CONCENTRATIONS; LUTEIN; AUTOFLUORESCENCE; CAROTENOIDS; POPULATION;
   ZEAXANTHIN; DEGENERATION; AMD; PHOTOMETRY; MELANIN
AB PURPOSE. The controversial protective effect of macular pigment (MP), consisting of lutein (L) and zeaxantin (Z), in age-related maculopathy (ARM) and its late-stage, age-related macular degeneration (AMD) is discussed. Determinants of MP optical density (MPOD) and its relation to ARM were investigated.
   METHODS. MPOD was accessed at eccentricities of 0.5 degrees and 2.0 degrees from the fovea in 369 participants in the 2.6-year follow-up examination of the prospective Muenster Aging and Retina Study using dual-wavelength analysis of autofluorescence images. ARM was graded from standardized fundus photographs according to the International Classification System.
   RESULTS. MPOD at 0.5 degrees and 2.0 degrees between pairs and within single eyes was strongly correlated (P < 0.001). Smoking and body mass index showed moderately inverse associations with MPOD at 2.0 degrees, and age was positively related to MPOD at both eccentricities. Serum L, measured at the baseline examination, was significantly associated with MPOD measured at follow-up. Likewise, use of L/Z-containing supplements raised MPOD. Crude mean MPOD increased with ascending stage of ARM. However, adjustment for influential factors and exclusion of L supplement users removed differences of mean MPOD between ARM stages. Considering further the accompanying eye, study eyes with ARM had significantly higher MPOD when the contralateral eye had AMD.
   CONCLUSIONS. MPOD levels showed a high degree of intraindividual concordance and interindividual variability. Long-standing serum L levels, and in particular L supplementation, were the strongest determinants of MPOD. The hypothetical inverse association between MPOD and ARM stage was not confirmed. (Invest Ophthalmol Vis Sci. 2011;52:3452-3457) DOI: 10.1167/iovs.10-6713
C1 [Dietzel, Martha; Claes, Birte; Hense, Hans-Werner] Univ Munster, Inst Epidemiol & Social Med, Munster, Germany.
   [Dietzel, Martha; Zeimer, Meike; Heimes, Britta; Pauleikhoff, Daniel] St Franziskus Hosp, Dept Ophthalmol, Munster, Germany.
C3 University of Munster; St. Franziskus-Hospital
RP Hense, HW (通讯作者)，Univ Hosp Muenster, Inst Epidemiol & Social Med, Domagkstr 3, D-48129 Munster, Germany.
EM hense@uni-muenster.de
OI Heimes-Bussmann, Britta/0000-0003-3898-1679
FU Deutsche Forschungsgemeinschaft [HE 2293/5-1, HE 2293/5-2, HE 2293/5-3];
   University of Muenster; Pro Retina Foundation; Jackstaedt Foundation
FX Supported in part by grants from Deutsche Forschungsgemeinschaft HE
   2293/5-1, 5-2, 5-3; the Intramural IMF fund of the University of
   Muenster; the Pro Retina Foundation; and the Jackstaedt Foundation.
CR Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   Berendschot TT, 2005, EXP EYE RES, V81, P602, DOI 10.1016/j.exer.2005.03.019
   Berendschot TTJM, 2002, INVEST OPHTH VIS SCI, V43, P1928
   Bernstein PS, 2002, OPHTHALMOLOGY, V109, P1780, DOI 10.1016/S0161-6420(02)01173-9
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Bone RA, 1997, EXP EYE RES, V64, P211, DOI 10.1006/exer.1996.0210
   Bone RA, 2001, INVEST OPHTH VIS SCI, V42, P235
   Broekmans WMR, 2002, AM J CLIN NUTR, V76, P595, DOI 10.1093/ajcn/76.3.595
   Curran-Celentano J, 2001, AM J CLIN NUTR, V74, P796
   Dasch B, 2005, GRAEF ARCH CLIN EXP, V243, P1028, DOI 10.1007/s00417-005-1176-z
   Delori FC, 2006, J OPT SOC AM A, V23, P521, DOI 10.1364/JOSAA.23.000521
   Delori FC, 2001, J OPT SOC AM A, V18, P1212, DOI 10.1364/JOSAA.18.001212
   DELORI FC, 1995, INVEST OPHTH VIS SCI, V36, P718
   Hammond BR, 2002, INVEST OPHTH VIS SCI, V43, P47
   Hammond BR, 2000, INVEST OPHTH VIS SCI, V41, P1492
   Hammond BR, 1997, J OPT SOC AM A, V14, P1187, DOI 10.1364/JOSAA.14.001187
   Jahn C, 2005, GRAEF ARCH CLIN EXP, V243, P222, DOI 10.1007/s00417-004-0995-7
   Kanis MJ, 2008, INVEST OPHTH VIS SCI, V49, P2077, DOI 10.1167/iovs.07-1181
   Kanis MJ, 2007, GRAEF ARCH CLIN EXP, V245, P767, DOI 10.1007/s00417-006-0478-0
   Koh HH, 2004, EXP EYE RES, V79, P21, DOI 10.1016/j.exer.2004.03.001
   LaRowe TL, 2008, OPHTHALMOLOGY, V115, P876, DOI 10.1016/j.ophtha.2007.06.015
   Liew SHM, 2005, INVEST OPHTH VIS SCI, V46, P4430, DOI 10.1167/iovs.05-0519
   Lima VC, 2010, INVEST OPHTH VIS SCI, V51, P5840, DOI 10.1167/iovs.09-4695
   Loane E, 2008, BRIT J OPHTHALMOL, V92, P1163, DOI 10.1136/bjo.2007.135566
   Mares-Perlman JA, 2001, AM J EPIDEMIOL, V153, P424, DOI 10.1093/aje/153.5.424
   Nolan JM, 2007, EXP EYE RES, V84, P61, DOI 10.1016/j.exer.2006.08.016
   Nolan JM, 2010, OPHTHALMIC RES, V44, P131, DOI 10.1159/000315531
   Obana A, 2008, OPHTHALMOLOGY, V115, P147, DOI 10.1016/j.ophtha.2007.02.028
   OLSON JA, 1984, J NATL CANCER I, V73, P1439
   Robson AG, 2003, VISION RES, V43, P1765, DOI 10.1016/S0042-6989(03)00280-3
   Trieschmann M, 2006, GRAEF ARCH CLIN EXP, V244, P1565, DOI 10.1007/s00417-006-0289-3
   Trieschmann M, 2003, GRAEF ARCH CLIN EXP, V241, P1006, DOI 10.1007/s00417-003-0796-4
   Trieschmann M, 2007, EXP EYE RES, V84, P718, DOI 10.1016/j.exer.2006.12.010
   van Leeuwen R, 2003, EUR J EPIDEMIOL, V18, P845, DOI 10.1023/A:1025643303914
   van Leeuwen R, 2003, ARCH OPHTHALMOL-CHIC, V121, P519, DOI 10.1001/archopht.121.4.519
   Wustemeyer H, 2002, GRAEF ARCH CLIN EXP, V240, P666, DOI 10.1007/s00417-002-0515-6
NR 36
TC 40
Z9 42
U1 0
U2 5
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD MAY
PY 2011
VL 52
IS 6
BP 3452
EP 3457
DI 10.1167/iovs.10-6713
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 800CF
UT WOS:000293335400002
PM 21296816
DA 2022-11-30
ER

PT J
AU Panthier, C
   Querques, G
   Zerbib, J
   Souied, EH
AF Panthier, Christophe
   Querques, Giuseppe
   Zerbib, Jennyfer
   Souied, Eric H.
TI Spontaneous Combined Full-Thickness Retinal and Pigment Epithelium
   Macular Hole in Age-Related Macular Degeneration
SO OPHTHALMIC SURGERY LASERS & IMAGING RETINA
LA English
DT Article
ID INJECTION
AB The authors describe a case of combined full-thickness retinal and pigment epithelium macular hole that spontaneously developed in the right eye of an 86-year-old woman with age-related macular degeneration (AMD). One year prior, the patient had been diagnosed with drusenoid pigment epithelium detachment (PED) in the right eye and geographic atrophy in the left eye. Full-thickness macular hole associated with PED and spontaneous rip of the retinal pigment epithelium (RPE) associated with macular hole have been previously reported in eyes with exudative AMD. However, the authors are unaware of any report of spontaneous full-thickness retinal and pigment epithelium hole at the macula in AMD. The pathogenic mechanisms of this unusual macular hole, which involves the full retinal thickness and RPE, may include stretching forces at the vitreomacular interface and pushing from within the PED.
C1 [Panthier, Christophe; Querques, Giuseppe; Zerbib, Jennyfer; Souied, Eric H.] Univ Paris 12, Dept Ophthalmol, Ctr Hosp Intercommunal Creteil, F-94000 Creteil, France.
C3 Universite Paris-Est-Creteil-Val-de-Marne (UPEC); CHI Creteil
RP Querques, G (通讯作者)，Univ Paris 12, Dept Ophthalmol, Ctr Hosp Intercommunal Creteil, 40 Ave Verdun, F-94000 Creteil, France.
EM giuseppe.querques@hotmail.it
OI Querques, Giuseppe/0000-0002-3292-9581
CR Bressler Neil M, 2004, JAMA, V291, P1900, DOI 10.1001/jama.291.15.1900
   Cabazon S., 2010, INT OPHTHALMOL, V30, P739
   Emerson GG, 2005, AM J OPHTHALMOL, V140, P316, DOI 10.1016/j.ajo.2005.01.028
   GASS JDM, 1988, ARCH OPHTHALMOL-CHIC, V106, P629, DOI 10.1001/archopht.1988.01060130683026
   Klein R, 1997, OPHTHALMOLOGY, V104, P7, DOI 10.1016/S0161-6420(97)30368-6
   Mojana F, 2008, AM J OPHTHALMOL, V146, P218, DOI 10.1016/j.ajo.2008.04.027
   Querques G, 2009, ACTA OPHTHALMOL, V87, P235, DOI 10.1111/j.1755-3768.2008.01226.x
   Querques G, 2009, AM J OPHTHALMOL, V147, P375, DOI 10.1016/j.ajo.2008.10.008
   Zayit-Soudry S, 2007, SURV OPHTHALMOL, V52, P227, DOI 10.1016/j.survophthal.2007.02.008
NR 9
TC 4
Z9 4
U1 0
U2 0
PU SLACK INC
PI THOROFARE
PA 6900 GROVE RD, THOROFARE, NJ 08086 USA
SN 2325-8160
EI 2325-8179
J9 OSLI RETINA
JI Ophthalmic Surg. Lasers Imag. Retin.
PD MAR-APR
PY 2013
VL 44
IS 2
BP 208
EP 210
DI 10.3928/23258160-20130213-01
PG 3
WC Ophthalmology; Surgery
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology; Surgery
GA 172PS
UT WOS:000321017200022
PM 23413892
DA 2022-11-30
ER

PT J
AU Kabasawa, S
   Mori, K
   Horie-Inoue, K
   Gehlbach, PL
   Inoue, S
   Awata, T
   Katayama, S
   Yoneya, S
AF Kabasawa, Sho
   Mori, Keisuke
   Horie-Inoue, Kuniko
   Gehlbach, Peter L.
   Inoue, Satoshi
   Awata, Takuya
   Katayama, Shigehiro
   Yoneya, Shin
TI Associations of Cigarette Smoking But Not Serum Fatty Acids with
   Age-related Macular Degeneration in a Japanese Population
SO OPHTHALMOLOGY
LA English
DT Article
ID POLYPOIDAL CHOROIDAL VASCULOPATHY; EICOSAPENTAENOIC ACID; PHOTODYNAMIC
   THERAPY; FISH CONSUMPTION; 5-YEAR INCIDENCE; HEART-DISEASE;
   RISK-FACTORS; WHITE MEN; MACULOPATHY; PREVALENCE
AB Purpose: To assess modifiable environmental risk factors and protective factors for age-related macular degeneration (AMD) in a native Japanese population.
   Design: A case-control study.
   Participants: We included 422 case-control samples composed of 279 consecutive AMD cases and 143 controls.
   Methods: Information regarding systemic conditions and lifestyle were documented in each subject by standardized questionnaire including age, gender, smoking history, body mass index (BMI), and history of cardiovascular disease, hypertension, and diabetes. Serum fatty acids profiles were analyzed by gas chromatography performed on blood samples taken from each study participant. Logistic regression and multiple comparison analyses were utilized in this study.
   Main Outcome Measures: Population-specific information assessing systemic conditions, lifestyle, and serum fatty acid profiles.
   Results: Among environmental factors analyzed cigarette smoking showed the most significant association with development of all AMD (P<0.00001; odds ratio [OR], 4.06; 95% confidence interval [CI], 2.22-7.43), typical neovascular AMD (P<0.0001, OR, 4.59; 95% CI, 2.29-9.18), and polypoidal choroidal vasculopathy (P<0.001; OR, 4.87; 95% CI, 1.96-12.1). Hypertension and BMI showed a mild association with AMD. Although male prevalence was significantly higher in all case groups than in controls with conventional Scheffe correction, there was no association of gender with AMD development when logistic regression analysis was used to adjust for cigarette smoking. There was no difference in fatty acid profiles, except for a mild association of eicosapentaenoic acid concentration in the all AMD group.
   Conclusions: In the Japanese population studied, cigarette smoking influenced the risk of AMD but fractionated serum fatty acid levels did not. Although prior reports indicate a male predominance in Japanese patients with AMD, this study demonstrates that cigarette smoking accounts for this confounding bias. In addition, our population-specific data do not demonstrate significant differences in serum fatty acid composition, including omega-3 and omega-6 long chain polyunsaturated fatty acids, in Japanese patients with and without AMD. These results are consistent with the high proportion of smokers in aged Japanese men and the high fish oil intake in this population.
   Financial Disclosure(s): The authors have no proprietary or commercial interest in any of the materials discussed in this article. Ophthalmology 2011; 118: 1082-1088 (C) 2011 by the American Academy of Ophthalmology.
C1 [Kabasawa, Sho; Mori, Keisuke; Yoneya, Shin] Saitama Med Univ, Dept Ophthalmol, Iruma, Saitama 3500495, Japan.
   [Horie-Inoue, Kuniko; Inoue, Satoshi] Saitama Med Univ, Res Ctr Genom Med, Div Gene Regulat & Signal Transduct, Iruma, Saitama 3500495, Japan.
   [Gehlbach, Peter L.] Johns Hopkins Univ, Sch Med, Dept Ophthalmol, Baltimore, MD 21205 USA.
   [Awata, Takuya; Katayama, Shigehiro] Saitama Med Univ, Dept Med, Div Endocrinol & Diabet, Iruma, Saitama 3500495, Japan.
C3 Saitama Medical University; Saitama Medical University; Johns Hopkins
   University; Saitama Medical University
RP Mori, K (通讯作者)，Saitama Med Univ, Dept Ophthalmol, 38 Morohongo, Iruma, Saitama 3500495, Japan.
EM keisuke@saitama-med.ac.jp
OI Awata, Takuya/0000-0003-2622-8129
FU Medical Research Center, Saitama Medical University [20-1-2-02]; Eye
   Research Foundation for the Aged; Ministry of Education, Culture and
   Science in Japan [21592242]
FX Supported in part by an Institutional Grant (20-1-2-02) from the Medical
   Research Center, Saitama Medical University (KM), a Grant from the Eye
   Research Foundation for the Aged (KM) and a grant-in-aid for scientific
   research (21592242) from the Ministry of Education, Culture and Science
   in Japan (KM).
CR Anand R, 2000, OPHTHALMOLOGY, V107, P2224
   Ando M, 1999, J AM SOC NEPHROL, V10, P2177
   Bird AC, 2003, EYE, V17, P457, DOI 10.1038/sj.eye.6700562
   Chan WM, 2006, JPN J OPHTHALMOL, V50, P161, DOI 10.1007/s10384-005-0259-z
   Chen San-Ni, 1993, Journal of the Formosan Medical Association, V92, P823
   Chong EWT, 2009, ARCH OPHTHALMOL-CHIC, V127, P674, DOI 10.1001/archophthalmol.2009.60
   Chong EWT, 2008, ARCH OPHTHALMOL-CHIC, V126, P826, DOI 10.1001/archopht.126.6.826
   Gomi F, 2008, BRIT J OPHTHALMOL, V92, P70, DOI 10.1136/bjo.2007.122283
   Gomi F, 2008, OPHTHALMOLOGY, V115, P141, DOI 10.1016/j.ophtha.2007.02.031
   Gotoh N, 2008, CLIN EXP OPHTHALMOL, V36, P437, DOI 10.1111/j.1442-9071.2008.01791.x
   Gotoh N, 2009, AM J OPHTHALMOL, V147, P1037, DOI 10.1016/j.ajo.2008.12.036
   Heeschen C, 2001, NAT MED, V7, P833, DOI 10.1038/89961
   HIRAI A, 1982, THROMB RES, V28, P285, DOI 10.1016/0049-3848(82)90112-8
   Hu FB, 2002, JAMA-J AM MED ASSOC, V287, P1815, DOI 10.1001/jama.287.14.1815
   Japanese Study Group of Polypoidal Choroidal Vasculopathy, 2005, Nippon Ganka Gakkai Zasshi, V109, P417
   Kawasaki R, 2008, OPHTHALMOLOGY, V115, P1376, DOI 10.1016/j.ophtha.2007.11.015
   KLEIN BE, 1982, ARCH OPHTHALMOL-CHIC, V100, P571
   Klein R, 2004, AM J OPHTHALMOL, V137, P486, DOI 10.1016/j.ajo.2003.11.069
   Klein R, 1997, OPHTHALMOLOGY, V104, P7, DOI 10.1016/S0161-6420(97)30368-6
   Klein R, 2008, ARCH OPHTHALMOL-CHIC, V126, P115, DOI 10.1001/archopht.126.1.115
   Koh AHC, 2002, ANN ACAD MED SINGAP, V31, P399
   Kondo N, 2008, INVEST OPHTH VIS SCI, V49, P1101, DOI 10.1167/iovs.07-1145
   KROMHOUT D, 1985, NEW ENGL J MED, V312, P1205, DOI 10.1056/NEJM198505093121901
   Kubo N, 1990, REPORT NATIONWIDE CL, P121
   Ladas ID, 2004, EYE, V18, P455, DOI 10.1038/sj.eye.6700706
   Leibowitz H M, 1980, Surv Ophthalmol, V24, P335
   Maruko I, 2007, AM J OPHTHALMOL, V144, P15, DOI 10.1016/j.ajo.2007.03.047
   MARUO T, 1991, JPN J OPHTHALMOL, V35, P268
   Milton RC, 2005, OPHTHALMOLOGY, V112, P533, DOI 10.1016/j.ophtha.2004.10.047
   MITCHELL P, 1995, OPHTHALMOLOGY, V102, P1450
   Miyazaki M, 2005, INVEST OPHTH VIS SCI, V46, P1907, DOI 10.1167/iovs.04-0923
   Mori K, 2007, INVEST OPHTH VIS SCI, V48, P5315, DOI 10.1167/iovs.07-0426
   Mori K, 2007, J HUM GENET, V52, P636, DOI 10.1007/s10038-007-0162-1
   Mori K, 2010, OPHTHALMOLOGY, V117, P928, DOI 10.1016/j.ophtha.2009.10.001
   NOZAKI S, 1992, INT J VITAM NUTR RES, V62, P256
   Ohida T, 2001, JAMA-J AM MED ASSOC, V285, P2643, DOI 10.1001/jama.285.20.2643
   SanGiovanni JP, 2007, ARCH OPHTHALMOL-CHIC, V125, P671, DOI 10.1001/archopht.125.5.671
   SanGiovanni JP, 2009, AM J CLIN NUTR, V90, P1601, DOI 10.3945/ajcn.2009.27594
   SanGiovanni JP, 2005, PROG RETIN EYE RES, V24, P87, DOI 10.1016/j.preteyeres.2004.06.002
   SCHACHAT AP, 1995, ARCH OPHTHALMOL-CHIC, V113, P728, DOI 10.1001/archopht.1995.01100060054032
   Seddon JM, 2006, OPHTHALMOLOGY, V113, P260, DOI 10.1016/j.ophtha.2005.11.001
   Sekikawa A, 2008, J AM COLL CARDIOL, V52, P417, DOI 10.1016/j.jacc.2008.03.047
   Sekikawa A, 2007, AM J EPIDEMIOL, V165, P617, DOI 10.1093/aje/kwk053
   Sho K, 2003, ARCH OPHTHALMOL-CHIC, V121, P1392, DOI 10.1001/archopht.121.10.1392
   SISCOVICK DS, 1995, JAMA-J AM MED ASSOC, V274, P1363, DOI 10.1001/jama.274.17.1363
   Suner IJ, 2004, INVEST OPHTH VIS SCI, V45, P311, DOI 10.1167/iovs.03-0733
   TAMURA Y, 1986, PROG LIPID RES, V25, P461, DOI 10.1016/0163-7827(86)90092-5
   Tan JSL, 2009, ARCH OPHTHALMOL-CHIC, V127, P656, DOI 10.1001/archophthalmol.2009.76
   Uyama M, 2002, AM J OPHTHALMOL, V133, P639, DOI 10.1016/S0002-9394(02)01404-6
   Uyama M, 1999, ARCH OPHTHALMOL-CHIC, V117, P1035
   Uyama M, 1992, INT C SERIES, V982, P947
   Yannuzzi LA, 1999, ARCH OPHTHALMOL-CHIC, V117, P1503
   Yasuda M, 2009, OPHTHALMOLOGY, V116, P2135, DOI 10.1016/j.ophtha.2009.04.017
   Yoshida T, 2007, MOL VIS, V13, P545
   Yuzawa M, 1997, INT OPHTHALMOL, V21, P1, DOI 10.1023/A:1005845521424
   Zhang JJ, 1999, PREV MED, V28, P520, DOI 10.1006/pmed.1998.0472
NR 56
TC 40
Z9 44
U1 0
U2 7
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0161-6420
EI 1549-4713
J9 OPHTHALMOLOGY
JI Ophthalmology
PD JUN
PY 2011
VL 118
IS 6
BP 1082
EP 1088
DI 10.1016/j.ophtha.2010.10.012
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 771JJ
UT WOS:000291152700013
PM 21514959
DA 2022-11-30
ER

PT J
AU Hwang, DK
   Hsu, CC
   Chang, KJ
   Chao, D
   Sun, CH
   Jheng, YC
   Yarmishyn, AA
   Wu, JC
   Tsai, CY
   Wang, ML
   Peng, CH
   Chien, KH
   Kao, CL
   Lin, TC
   Woung, LC
   Chen, SJ
   Chiou, SH
AF Hwang, De-Kuang
   Hsu, Chih-Chien
   Chang, Kao-Jung
   Chao, Daniel
   Sun, Chuan-Hu
   Jheng, Ying-Chun
   Yarmishyn, Aliaksandr A.
   Wu, Jau-Ching
   Tsai, Ching-Yao
   Wang, Mong-Lien
   Peng, Chi-Hsien
   Chien, Ke-Hung
   Kao, Chung-Lan
   Lin, Tai-Chi
   Woung, Lin-Chung
   Chen, Shih-Jen
   Chiou, Shih-Hwa
TI Artificial intelligence-based decision-making for age-related macular
   degeneration
SO THERANOSTICS
LA English
DT Article
DE deep learning; convolutional neural network; artificial intelligence
   (AI); AI-based website; telemedicine; cloud website
ID OPTICAL COHERENCE TOMOGRAPHY; HOME
AB Artificial intelligence (AI) based on convolutional neural networks (CNNs) has a great potential to enhance medical workflow and improve health care quality. Of particular interest is practical implementation of such AI-based software as a cloud-based tool aimed for telemedicine, the practice of providing medical care from a distance using electronic interfaces.
   Methods: In this study, we used a dataset of labeled 35,900 optical coherence tomography (OCT) images obtained from age-related macular degeneration (AMD) patients and used them to train three types of CNNs to perform AMD diagnosis.
   Results: Here, we present an AI-and cloud-based telemedicine interaction tool for diagnosis and proposed treatment of AMD. Through deep learning process based on the analysis of preprocessed optical coherence tomography (OCT) imaging data, our AI-based system achieved the same image discrimination rate as that of retinal specialists in our hospital. The AI platform's detection accuracy was generally higher than 90% and was significantly superior (p < 0.001) to that of medical students (69.4% and 68.9%) and equal (p = 0.99) to that of retinal specialists (92.73% and 91.90%). Furthermore, it provided appropriate treatment recommendations comparable to those of retinal specialists.
   Conclusions: We therefore developed a website for realistic cloud computing based on this AI platform, available at https://www.ym.edu.tw/similar to AI-OCT/. Patients can upload their OCT images to the website to verify whether they have AMD and require treatment. Using an AI-based cloud service represents a real solution for medical imaging diagnostics and telemedicine.
C1 [Hwang, De-Kuang; Hsu, Chih-Chien; Lin, Tai-Chi; Chen, Shih-Jen; Chiou, Shih-Hwa] Taipei Vet Gen Hosp, Dept Ophthalmol, Taipei, Taiwan.
   [Hwang, De-Kuang; Hsu, Chih-Chien; Kao, Chung-Lan; Lin, Tai-Chi; Chiou, Shih-Hwa] Natl Yang Ming Univ, Inst Clin Med, Taipei, Taiwan.
   [Hwang, De-Kuang; Hsu, Chih-Chien; Chang, Kao-Jung; Wu, Jau-Ching; Tsai, Ching-Yao; Wang, Mong-Lien; Kao, Chung-Lan; Lin, Tai-Chi; Woung, Lin-Chung; Chen, Shih-Jen; Chiou, Shih-Hwa] Natl Yang Ming Univ, Sch Med, Taipei, Taiwan.
   [Chao, Daniel] Univ Calif San Diego, Shiley Eye Inst, Clin Ophthalmol, San Diego, CA 92103 USA.
   [Sun, Chuan-Hu; Jheng, Ying-Chun; Yarmishyn, Aliaksandr A.; Wang, Mong-Lien; Chiou, Shih-Hwa] Taipei Vet Gen Hosp, Dept Med Res, Taipei, Taiwan.
   [Jheng, Ying-Chun] Natl Yang Ming Univ, Dept Phys Therapy & Assist Technol, Taipei, Taiwan.
   [Tsai, Ching-Yao; Woung, Lin-Chung] Taipei City Hosp, Dept Ophthalmol, Taipei, Taiwan.
   [Wang, Mong-Lien] Natl Yang Ming Univ, Inst Environm Hlth, Taipei, Taiwan.
   [Peng, Chi-Hsien] Shin Kong Wu Ho Mem Hosp, Dept Ophthalmol, Taipei, Taiwan.
   [Peng, Chi-Hsien] Fu Jen Catholic Univ, Taipei, Taiwan.
   [Chien, Ke-Hung] Triserv Gen Hosp, Dept Ophthalmol, Taipei, Taiwan.
   [Chien, Ke-Hung] Natl Def Med Ctr, Taipei, Taiwan.
   [Chien, Ke-Hung] Natl Yang Ming Univ, Inst Pharmacol, Taipei, Taiwan.
   [Kao, Chung-Lan; Chiou, Shih-Hwa] Taipei Vet Gen Hosp, Dept Phys Med & Rehabil, Taipei, Taiwan.
   [Chiou, Shih-Hwa] Acad Sinica, Genom Res Ctr, Taipei, Taiwan.
   [Wu, Jau-Ching] Taipei Vet Gen Hosp, Neurol Inst, Dept Neurosurg, Taipei, Taiwan.
C3 Taipei Veterans General Hospital; National Yang Ming Chiao Tung
   University; National Yang Ming Chiao Tung University; University of
   California System; University of California San Diego; Taipei Veterans
   General Hospital; National Yang Ming Chiao Tung University; Taipei City
   Hospital; National Yang Ming Chiao Tung University; Shin Kong Wu Ho Su
   Memorial Hospital; Fu Jen Catholic University; Tri-Service General
   Hospital; National Defense Medical Center; National Yang Ming Chiao Tung
   University; Taipei Veterans General Hospital; Academia Sinica - Taiwan;
   Taipei Veterans General Hospital
RP Chiou, SH (通讯作者)，Taipei Vet Gen Hosp, Dept Med Res, Taipei, Taiwan.; Chiou, SH (通讯作者)，Acad Sinica, Genom Res Ctr, Taipei, Taiwan.; Chiou, SH (通讯作者)，Natl Yang Ming Univ, Inst Clin Med, Sch Med, Inst Pharmacol, Taipei, Taiwan.
EM shchiou@vghtpe.gov.tw
RI Wu, Jau-Ching/AAU-4009-2021; Hwang, DK De-Kuang/J-3931-2016
OI Wu, Jau-Ching/0000-0002-6996-3409; Hwang, DK
   De-Kuang/0000-0001-6346-8485; WOUNG, LIN-CHUNG/0000-0002-0700-7606;
   Chang, Kao-Jung/0000-0002-2238-7387
FU Ministry of Science and Technology (MOST) [105-2633-B-009-003,
   105-3011-B010-001, 106-2633-B-009-001, 106-2319-B-001-003,
   106-2119-M-010-001, 106-3114-B-010-002, 107-2633-B-009-003]; Academia
   Sinica; MOST [MOST 104-0210-01-09-02, 105-0210-01-13-01,
   106-0210-01-15-02, 107-0210-01-19-01]; Taipei Veterans General Hospital
   [V104E14-001-MY3-2, V105C-077, V106E-004-2, V106C-001, V107C-139,
   V107E-002-2]; Department of Health Cancer Center Research of Excellence
   [MOHW105-TDU-B211-134003, MOHW105-TDU-B-211-133017,
   MOHW106-TDU-B-211-113001, MOHW107-TDU-B-211-123001]; NRPB Human iPSC
   Alliance-Core Service [MOST 105-2325-B-010-005]; VGH; TSGH; NDMC; AS
   Joint Research Program [VTA105-V1-5-1, VTA107-V1-5-1]; NTUH Joint
   Research Program [VN106-02, VN107-16]; National Health Research
   Institutes, Taiwan [NHRI-EX10610621BI, NHRI-EX107-10621BI]; Cancer
   Progression Research Center, National Yang-Ming University; "Aiming for
   the SPROUT Project-Center for Intelligent Drug Systems and Smart
   Bio-devices (IDS2B)" of National Chiao Tung University from the Featured
   Areas Research Center Program within the framework of the Higher
   Education Sprout Project, Ministry of Edu
FX This study was funded by the Ministry of Science and Technology (MOST)
   (105-2633-B-009-003, 105-3011-B010-001, 106-2633-B-009-001,
   106-2319-B-001-003, 106-2119-M-010-001, 106-3114-B-010-002, and
   107-2633-B-009-003), Academia Sinica and MOST (MOST 104-0210-01-09-02,
   105-0210-01-13-01, 106-0210-01-15-02, and 107-0210-01-19-01), Taipei
   Veterans General Hospital (V104E14-001-MY3-2, V105C-077, V106E-004-2,
   V106C-001, V107C-139, and V107E-002-2), the Department of Health Cancer
   Center Research of Excellence (MOHW105-TDU-B211-134003,
   MOHW105-TDU-B-211-133017, MOHW106-TDU-B-211-113001, and
   MOHW107-TDU-B-211-123001), NRPB Human iPSC Alliance-Core Service (MOST
   105-2325-B-010-005), VGH, TSGH, NDMC, AS Joint Research Program
   (VTA105-V1-5-1, and VTA107-V1-5-1), VGH, NTUH Joint Research Program
   (VN106-02. VN107-16), and National Health Research Institutes
   (NHRI-EX10610621BI, and NHRI-EX107-10621BI), Taiwan. This work was also
   financially supported by the "Cancer Progression Research Center,
   National Yang-Ming University" and "Aiming for the SPROUT Project-Center
   for Intelligent Drug Systems and Smart Bio-devices (IDS2B)" of National
   Chiao Tung University from the Featured Areas Research Center Program
   within the framework of the Higher Education Sprout Project by the
   Ministry of Education (MOE) in Taiwan." Furthermore, special thanks to
   IEI x QNAP team's contribution in deploying a reliable AI server and
   proceeding AI model to make a fabulous success in this study.
CR Chew EY, 2016, RETINA-J RET VIT DIS, V36, P1542, DOI 10.1097/IAE.0000000000000940
   Christiansen EM, 2018, CELL, V173, P792, DOI 10.1016/j.cell.2018.03.040
   Fung AE, 2007, AM J OPHTHALMOL, V143, P566, DOI 10.1016/j.ajo.2007.01.028
   Griebel L, 2015, BMC MED INFORM DECIS, V15, DOI 10.1186/s12911-015-0145-7
   HEE MR, 1995, AM J OPHTHALMOL, V120, P65, DOI 10.1016/S0002-9394(14)73760-2
   Hjelm NM, 2005, J TELEMED TELECARE, V11, P60, DOI 10.1258/1357633053499886
   HUANG D, 1991, SCIENCE, V254, P1178, DOI 10.1126/science.1957169
   Kermany DS, 2018, CELL, V172, P1122, DOI 10.1016/j.cell.2018.02.010
   Lee CS, 2017, BIOMED OPT EXPRESS, V8, P3440, DOI 10.1364/BOE.8.003440
   McDonnell ME, 2018, CURR DIABETES REP, V18, DOI 10.1007/s11892-018-1015-3
   Mitchell P, 2010, BRIT J OPHTHALMOL, V94, P2, DOI 10.1136/bjo.2009.159160
   Prahs P, 2018, GRAEF ARCH CLIN EXP, V256, P91, DOI 10.1007/s00417-017-3839-y
   Schlegl T, 2018, OPHTHALMOLOGY, V125, P549, DOI 10.1016/j.ophtha.2017.10.031
   Surendran Thandalam Sundararajan, 2014, J Diabetes Sci Technol, V8, P262
   Wittenborn JS, 2017, JAMA OPHTHALMOL, V135, P452, DOI 10.1001/jamaophthalmol.2017.0255
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Zhao R, 2017, BIOMED OPT EXPRESS, V8, P5049, DOI 10.1364/BOE.8.005049
NR 17
TC 68
Z9 74
U1 6
U2 38
PU IVYSPRING INT PUBL
PI LAKE HAVEN
PA PO BOX 4546, LAKE HAVEN, NSW 2263, AUSTRALIA
SN 1838-7640
J9 THERANOSTICS
JI Theranostics
PY 2019
VL 9
IS 1
BP 232
EP 245
DI 10.7150/thno.28447
PG 14
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine
GA HF0DC
UT WOS:000453827100004
PM 30662564
OA Green Published, Green Submitted, gold
DA 2022-11-30
ER

PT J
AU Wood, JM
   Black, AA
   Mallon, K
   Kwan, AS
   Owsley, C
AF Wood, Joanne M.
   Black, Alex A.
   Mallon, Kerry
   Kwan, Anthony S.
   Owsley, Cynthia
TI Effects of Age-Related Macular Degeneration on Driving Performance
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
DE age-related macular degeneration; driving performance; motion
   sensitivity
ID VISUAL IMPAIRMENT; OLDER DRIVERS; HABITS; ADULTS; SENSITIVITY;
   INVOLVEMENT; MACULOPATHY; CATARACT; INJURIES; SAFETY
AB PURPOSE: To explore differences in driving performance of older adults with age-related macular degeneration (AMD) and age-matched controls, and to identify the visual determinants of driving performance in this population.
   METHODS: Participants included 33 older drivers with AMD (mean age [M] = 76.6 +/- 6.1 years; better eye Age-Related Eye Disease Study grades: early [61%] and intermediate [39%]) and 50 age-matched controls (M = 74.6 +/- 5.0 years). Visual tests included visual acuity, contrast sensitivity, visual fields, and motion sensitivity. On-road driving performance was assessed in a dual-brake vehicle by an occupational therapist (masked to drivers' visual status). Outcome measures included driving safety ratings (scale of 1-10, where higher values represented safer driving), types of driving behavior errors, locations at which errors were made, and number of critical errors (CE) requiring an instructor intervention.
   RESULTS: Drivers with AMD were rated as less safe than controls (4.8 vs. 6.2; P = 0.012); safety ratings were associated with AMD severity (early: 5.5 versus intermediate: 3.7), even after adjusting for age. Drivers with AMD had higher CE rates than controls (1.42 vs. 0.36, respectively; rate ratio 3.05, 95% confidence interval 1.47-6.36, P = 0.003) and exhibited more observation, lane keeping, and gap selection errors and made more errors at traffic light-controlled intersections (P < 0.05). Only motion sensitivity was significantly associated with driving safety in the AMD drivers (P = 0.005).
   CONCLUSIONS: Drivers with early and intermediate AMD can exhibit impairments in their driving performance, particularly during complex driving situations; motion sensitivity was most strongly associated with driving performance. These findings have important implications for assessing the driving ability of older drivers with visual impairment.
C1 [Wood, Joanne M.; Black, Alex A.; Mallon, Kerry] Queensland Univ Technol, Sch Optometry & Vis Sci, Brisbane, Qld, Australia.
   [Kwan, Anthony S.] Queensland Eye Inst, Brisbane, Qld, Australia.
   [Kwan, Anthony S.] Univ Queensland, Brisbane, Qld, Australia.
   [Owsley, Cynthia] Univ Alabama Birmingham, Dept Ophthalmol, Birmingham, AL 35294 USA.
C3 Queensland University of Technology (QUT); Queensland Eye Institute;
   University of Queensland; University of Alabama System; University of
   Alabama Birmingham
RP Wood, JM (通讯作者)，Queensland Univ Technol, Sch Optometry & Vis Sci, Victoria Pk Rd, Kelvin Grove, Qld 4059, Australia.
EM j.wood@qut.edu.au
RI Black, Alex/I-9727-2012
OI Black, Alex/0000-0002-8671-5167
FU National Health and Medical Research Council (Melbourne, Australia)
   [100845]; National Institutes of Health (Bethesda, MD, USA)
   [R01EY18966]; Research to Prevent Blindness (New York, NY, USA);
   Eyesight Foundation of Alabama (Birmingham, AL, USA); NATIONAL EYE
   INSTITUTE [R01EY018966] Funding Source: NIH RePORTER
FX Supported by grants from National Health and Medical Research Council
   100845 (Melbourne, Australia), National Institutes of Health R01EY18966
   (Bethesda, MD, USA), Research to Prevent Blindness (New York, NY, USA),
   and the Eyesight Foundation of Alabama (Birmingham, AL, USA).
CR BAILEY IL, 1976, AM J OPTOM PHYS OPT, V53, P740
   Ball K, 1998, ACCIDENT ANAL PREV, V30, P313, DOI 10.1016/S0001-4575(97)00102-4
   Bronstad PM, 2016, CLIN EXP OPTOM, V99, P435, DOI 10.1111/cxo.12432
   Bronstad PM, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0136517
   Bronstad PM, 2013, JAMA OPHTHALMOL, V131, P303, DOI 10.1001/jamaophthalmol.2013.1443
   DeCarlo DK, 2003, OPTOMETRY VISION SCI, V80, P207, DOI 10.1097/00006324-200303000-00010
   ELLIOTT DB, 1991, CLIN VISION SCI, V6, P471
   Ferris FL, 2005, ARCH OPHTHALMOL-CHIC, V123, P1570
   FOLSTEIN MF, 1983, ARCH GEN PSYCHIAT, V40, P812
   Holopigian K, 1997, OPTOMETRY VISION SCI, V74, P152, DOI 10.1097/00006324-199703000-00026
   Maguire MG, 2016, OPHTHALMOLOGY, V123, P1751, DOI 10.1016/j.ophtha.2016.03.045
   Mangione CM, 1999, AM J OPHTHALMOL, V128, P45, DOI 10.1016/S0002-9394(99)00169-5
   MCCLOSKEY LW, 1994, AGE AGEING, V23, P267, DOI 10.1093/ageing/23.4.267
   McGwin G, 2013, BRIT J OPHTHALMOL, V97, P1173, DOI 10.1136/bjophthalmol-2013-303601
   Moore LW, 2005, APPL NURS RES, V18, P110, DOI 10.1016/j.apnr.2004.06.014
   Nelson-Quigg JM, 2000, INVEST OPHTH VIS SCI, V41, P2212
   Owsley C, 1999, J GERONTOL A-BIOL, V54, pM203, DOI 10.1093/gerona/54.4.M203
   Owsley C, 1999, SURV OPHTHALMOL, V43, P535, DOI 10.1016/S0039-6257(99)00035-1
   Owsley C, 2001, ARCH OPHTHALMOL-CHIC, V119, P881
   Owsley C, 2008, J VISUAL IMPAIR BLIN, V102, P621, DOI 10.1177/0145482X0810201007
   Scilley K, 2002, OPHTHALMOLOGY, V109, P1235, DOI 10.1016/S0161-6420(02)01060-6
   Seiple W, 2013, OPTOMETRY VISION SCI, V90, P45, DOI 10.1097/OPX.0b013e3182794775
   Sengupta S, 2014, OPHTHALMOLOGY, V121, P727, DOI 10.1016/j.ophtha.2013.09.042
   SZLYK JP, 1995, ARCH OPHTHALMOL-CHIC, V113, P1033, DOI 10.1001/archopht.1995.01100080085033
   Taylor HR, 2005, MED J AUSTRALIA, V182, P565, DOI 10.5694/j.1326-5377.2005.tb06815.x
   Wang JJ, 2000, CLIN EXP OPHTHALMOL, V28, P268, DOI 10.1046/j.1442-9071.2000.00315.x
   Wood JM, 2006, BRIT J OPHTHALMOL, V90, P1277, DOI 10.1136/bjo.2006.096057
   Wood JM, 2005, J NEUROL NEUROSUR PS, V76, P176, DOI 10.1136/jnnp.2004.047118
   Wood JM, 2002, HUM FACTORS, V44, P482, DOI 10.1518/0018720024497664
   Wood JM, 2001, OPTOMETRY VISION SCI, V78, P343, DOI 10.1097/00006324-200105000-00018
   Wood JM, 2008, J AM GERIATR SOC, V56, P986, DOI 10.1111/j.1532-5415.2008.01709.x
   Wood JM, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0158318
   Wood JM, 2013, ACCIDENT ANAL PREV, V50, P1161, DOI 10.1016/j.aap.2012.09.009
   Wood JM, 2011, INVEST OPHTH VIS SCI, V52, P5088, DOI 10.1167/iovs.10-6644
   Wood JM, 2009, J AM GERIATR SOC, V57, P2062, DOI 10.1111/j.1532-5415.2009.02498.x
   Wood JM, 2009, INVEST OPHTH VIS SCI, V50, P482, DOI 10.1167/iovs.08-1942
NR 36
TC 24
Z9 25
U1 0
U2 15
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD JAN
PY 2018
VL 59
IS 1
BP 273
EP 279
DI 10.1167/iovs.17-22751
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC Ophthalmology
GA FX1ZL
UT WOS:000425855900032
PM 29340641
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Capuano, V
   Souied, EH
   Miere, A
   Jung, C
   Costanzo, E
   Querques, G
AF Capuano, Vittorio
   Souied, Eric H.
   Miere, Alexandra
   Jung, Camille
   Costanzo, Eliana
   Querques, Giuseppe
TI Choroidal maps in non-exudative age-related macular degeneration
SO BRITISH JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID OPTICAL COHERENCE TOMOGRAPHY; RETICULAR PSEUDODRUSEN; GEOGRAPHIC
   ATROPHY; THICKNESS; PROGRESSION; VOLUME; MACULOPATHY
AB Purpose To compare choroidal thickness maps (CMs) in patients with non-exudative age-related macular degeneration (AMD) and control subjects using swept source optical coherence tomography (Swept-OCT).
   Methods CMs were automatically measured in the different Early Treatment of Diabetic Retinopathy Study (ETDRS) sectors in eyes with early non-exudative AMD (early AMD) (large soft drusen: group 1; reticular pseudodrusen: group 2 and variable combination of large soft drusen and reticular pseudodrusen: group 3), late non-exudative AMD/geographic atrophy (GA) (late AMD) (group 4) and control subjects (group 5). Fundus autofluorescence (FAF) images were overlaid to sectorial CMs in late-AMD group (group 4).
   Results A total of 90 eyes (90 patients, 79.7 +/- 8.34 years old) were included. CMs were significantly reduced in early-AMD group 2 and 3 and late-AMD group 4 compared with control subjects in group 5 and early-AMD group 1 (large soft drusen alone) for each ETDRS sectors (p<0.05). No difference in CMs was found by comparing group 2 with 3 and group 2 and 3 with group 4. No statistical differences in CMs were found among ETDRS sectors with >50% absence of FAF ('Hypo FAF' sectors) resulting from retinal atrophy versus <= 50% absence of FAF ('hyper/iso FAF' sectors owing to >50% preserved retina) in late-AMD group (group 4) (p=0.328).
   Conclusions CMs appeared thinner in early nonexudative AMD with intermediate distribution of reticular pseudodrusen versus control subjects and early non-exudative AMD with drusen alone. Same results were found in the group with variable combination of large soft drusen and reticular pseudodrusen. In GA eyes, a choroidal thinning could be detected independently of the retinal pigmented epithelium status.
C1 [Capuano, Vittorio; Souied, Eric H.; Miere, Alexandra; Costanzo, Eliana; Querques, Giuseppe] Univ Paris Est Creteil, Ctr Hosp Intercommunal Creteil, Dept Ophthalmol, Creteil, France.
   [Souied, Eric H.; Jung, Camille; Querques, Giuseppe] Univ Paris Est, Grp Rech Clin Macula, Creteil, France.
   [Jung, Camille] Ctr Hop Intercommunal Creteil, Ctr Ressources Biol, F-94000 Creteil, France.
   [Jung, Camille] Ctr Hop Intercommunal Creteil, Ctr Rech Clin, F-94000 Creteil, France.
C3 Universite Paris-Est-Creteil-Val-de-Marne (UPEC); CHI Creteil;
   Universite Paris-Est-Creteil-Val-de-Marne (UPEC); Universite
   Paris-Est-Creteil-Val-de-Marne (UPEC); CHI Creteil; Universite
   Paris-Est-Creteil-Val-de-Marne (UPEC); CHI Creteil
RP Querques, G (通讯作者)，Ctr Hosp Intercommunal Creteil, Dept Ophthalmol, 40 Ave Verdun, F-94000 Creteil, France.
EM giuseppe.querques@hotmail.it
RI Miere, Alexandra/AIC-4074-2022; Costanzo, Eliana/AAA-7690-2020
OI Miere, Alexandra/0000-0003-4123-8210; JUNG, Camille/0000-0001-8486-8939;
   Querques, Giuseppe/0000-0002-3292-9581
CR Adi M, 2014, RETINA, V34, P306
   [Anonymous], 1991, OPHTHALMOLOGY, V98, P786
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   DELORI FC, 1995, INVEST OPHTH VIS SCI, V36, P718
   Forte R, 2012, ACTA OPHTHALMOL, V90, pE281, DOI 10.1111/j.1755-3768.2011.02331.x
   Hirata M, 2011, INVEST OPHTH VIS SCI, V52, P4971, DOI 10.1167/iovs.11-7729
   Holz FG, 2007, AM J OPHTHALMOL, V143, P463, DOI 10.1016/j.ajo.2006.11.041
   HUANG D, 1991, SCIENCE, V254, P1178, DOI 10.1126/science.1957169
   Lee MY, 2012, BRIT J OPHTHALMOL, V96, P1222, DOI 10.1136/bjophthalmol-2011-301207
   Lindner M, 2015, INVEST OPHTH VIS SCI, V56, P875, DOI 10.1167/iovs.14-14933
   Mansouri K, 2013, OPHTHALMOLOGY, V120, P2508, DOI 10.1016/j.ophtha.2013.07.040
   Querques G, 2011, RETINA-J RET VIT DIS, V31, P518, DOI 10.1097/IAE.0b013e3181f04974
   Querques G, 2012, INVEST OPHTH VIS SCI, V53, P1264, DOI 10.1167/iovs.11-9063
   Schmitz-Valckenberg S, 2010, OPHTHALMOLOGY, V117, P1169, DOI 10.1016/j.ophtha.2009.10.044
   Shao L, 2013, INVEST OPHTH VIS SCI, V54, P230, DOI 10.1167/iovs.12-10351
   Sigler EJ, 2013, INVEST OPHTH VIS SCI, V54, P6307, DOI 10.1167/iovs.13-12653
   Spaide RF, 2008, AM J OPHTHALMOL, V146, P496, DOI 10.1016/j.ajo.2008.05.032
   Sunness JS, 1999, MOL VIS, V5
   Ueda-Arakawa N, 2014, AM J OPHTHALMOL, V157, P994, DOI 10.1016/j.ajo.2014.01.018
   Wang JJ, 2007, OPHTHALMOLOGY, V114, P92, DOI 10.1016/j.ophtha.2006.07.017
   Yiu G, 2015, AM J OPHTHALMOL, V159, P617, DOI 10.1016/j.ajo.2014.12.010
   Zweifel SA, 2010, OPHTHALMOLOGY, V117, P303, DOI 10.1016/j.ophtha.2009.07.014
NR 22
TC 20
Z9 20
U1 0
U2 1
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0007-1161
EI 1468-2079
J9 BRIT J OPHTHALMOL
JI Br. J. Ophthalmol.
PD MAY
PY 2016
VL 100
IS 5
BP 677
EP 682
DI 10.1136/bjophthalmol-2015-307169
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA DL0OT
UT WOS:000375333000019
PM 26347526
DA 2022-11-30
ER

PT J
AU Shin, JY
   Son, A
   Kim, H
   Kim, Y
   Yu, HG
AF Shin, Joo Young
   Son, Areum
   Kim, Hyunsoo
   Kim, Youngsoo
   Yu, Hyeong Gon
TI Carboxymethyl-lysine-modified Plasma Proteins in Age-related Macular
   Degeneration
SO BIOTECHNOLOGY AND BIOPROCESS ENGINEERING
LA English
DT Article
DE age-related macular degeneration; drusen; plasma protein; carboxymethyl
   lysine; advanced glycation end products
ID GLYCATION END-PRODUCTS; GROWTH-FACTOR EXPRESSION; PROTEOMIC ANALYSIS;
   AQUEOUS-HUMOR; INCREASE; PENTOSIDINE; PROGRESSION; BIOMARKERS;
   CLUSTERIN; RECEPTOR
AB To identify increased or decreased levels of carboxymethyl lysine (CML)-modified proteins in the plasma of age-related macular degeneration (AMD) patients and age-matched controls for the identification of possible plasma biomarkers of AMD and its progression. Plasma samples from patients with wet AMD with choroidal neovascularization (wAMD group) (n = 10), intermediate dry AMD (dAMD group) (n = 10), and age-matched controls (control group) (n = 10) were immunoprecipitated to select peptides with CML modification. LC-MS/MS was used to identify proteins in each group with CML modification. Among the identified CML enriched proteins, 6 commonly abundant proteins were identified in the plasma. There was no significant difference in amount of these proteins among the three groups, except CML-modified albumin, which was significantly decreased with progressed AMD (P = 0.0015). Five proteins were identified in the control group only, and 10 other proteins were identified in the dAMD group, and 4 other proteins in the wAMD group. Proteins involved in inflammatory responses and immunologic response were found to contain CML in the less advanced dAMD group. In the more advanced wAMD group, intracellular proteins associated with transcription or molecular activation associated with angiogenesis or blood vessel formation were found to be altered with CML. Proteins involved in inflammatory and immunologic response were CML-modified in earlier dry AMD while proteins associated with angiogenesis and blood vessel formation were CML-modified in advanced wet AMD, suggesting the possible role of oxidative change of proteins with different functions as the pathophysiology of the development and progression of AMD.
C1 [Shin, Joo Young; Yu, Hyeong Gon] Seoul Natl Univ, Dept Ophthalmol, Coll Med, Seoul, South Korea.
   [Shin, Joo Young] VHS Med Ctr, Dept Ophthalmol, Seoul, South Korea.
   [Son, Areum; Kim, Hyunsoo; Kim, Youngsoo] Seoul Natl Univ, Coll Med, Dept Biomed Sci, Seoul, South Korea.
C3 Seoul National University (SNU); Veterans Health Service Medical Center;
   Seoul National University (SNU)
RP Yu, HG (通讯作者)，Seoul Natl Univ, Dept Ophthalmol, Coll Med, Seoul, South Korea.
EM hgonyu@snu.ac.kr
RI Kim, Youngsoo/D-6046-2012
OI Kim, Hyunsoo/0000-0002-8441-3376
FU Seoul National University Hospital Research Fund [0320120250]
FX This research was supported by a grant (0320120250) from Seoul National
   University Hospital Research Fund in 2012.
CR An E, 2006, J PROTEOME RES, V5, P2599, DOI 10.1021/pr060121j
   Baynes JW, 2001, EXP GERONTOL, V36, P1527, DOI 10.1016/S0531-5565(01)00138-3
   De Toledo M, 2001, ONCOGENE, V20, P7307, DOI 10.1038/sj.onc.1204921
   Goh SY, 2008, J CLIN ENDOCR METAB, V93, P1143, DOI 10.1210/jc.2007-1817
   Gu JY, 2010, ADV EXP MED BIOL, V664, P411, DOI 10.1007/978-1-4419-1399-9_47
   Hammes HP, 1999, INVEST OPHTH VIS SCI, V40, P1855
   Handa JT, 1999, INVEST OPHTH VIS SCI, V40, P775
   Howes KA, 2004, INVEST OPHTH VIS SCI, V45, P3713, DOI 10.1167/iovs.04-0404
   Ishibashi T, 1998, ARCH OPHTHALMOL-CHIC, V116, P1629, DOI 10.1001/archopht.116.12.1629
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1439, DOI 10.1001/archopht.119.10.1439
   Khachigian LM, 1999, CIRC RES, V84, P1258, DOI 10.1161/01.RES.84.11.1258
   Kim TW, 2012, J PROTEOME RES, V11, P4034, DOI 10.1021/pr300080s
   Koss MJ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0096895
   Kuroki M, 1996, J CLIN INVEST, V98, P1667, DOI 10.1172/JCI118962
   Lu M, 1998, J CLIN INVEST, V101, P1219, DOI 10.1172/JCI1277
   Matsuda A, 2003, ONCOGENE, V22, P3307, DOI 10.1038/sj.onc.1206406
   Myagmar BE, 2005, BIOCHEM BIOPH RES CO, V329, P1046, DOI 10.1016/j.bbrc.2005.02.069
   Ni JQ, 2009, MOL CELL PROTEOMICS, V8, P1921, DOI 10.1074/mcp.M900127-MCP200
   Rikiyama T, 2003, BBA-GENE STRUCT EXPR, V1629, P15, DOI 10.1016/S0167-4781(03)00156-8
   Sakaguchi H, 2002, EXP EYE RES, V74, P547, DOI 10.1006/exer.2002.1186
   Saras J, 1997, J BIOL CHEM, V272, P24333, DOI 10.1074/jbc.272.39.24333
   Thambisetty M, 2010, ARCH GEN PSYCHIAT, V67, P739, DOI 10.1001/archgenpsychiatry.2010.78
   Yamada Y, 2006, EXP EYE RES, V82, P840, DOI 10.1016/j.exer.2005.10.005
   Yao JQ, 2013, PROTEOM CLIN APPL, V7, P550, DOI 10.1002/prca.201200012
NR 24
TC 1
Z9 1
U1 0
U2 0
PU KOREAN SOC BIOTECHNOLOGY & BIOENGINEERING
PI SEOUL
PA KOREAN SCIENCE TECHNOLOGY CENTER, #704 YEOGSAM-DONG, KANGNAM-KU, SEOUL
   135-703, SOUTH KOREA
SN 1226-8372
EI 1976-3816
J9 BIOTECHNOL BIOPROC E
JI Biotechnol. Bioprocess Eng.
PD FEB
PY 2017
VL 22
IS 1
BP 52
EP 59
DI 10.1007/s12257-016-0504-y
PG 8
WC Biotechnology & Applied Microbiology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biotechnology & Applied Microbiology
GA EP4CY
UT WOS:000397329400008
DA 2022-11-30
ER

PT J
AU Keel, S
   Xie, J
   Foreman, J
   van Wijngaarden, P
   Taylor, HR
   Dirani, M
AF Keel, Stuart
   Xie, Jing
   Foreman, Joshua
   van Wijngaarden, Peter
   Taylor, Hugh R.
   Dirani, Mohamed
TI Prevalence of Age-Related Macular Degeneration in Australia The
   Australian National Eye Health Survey
SO JAMA OPHTHALMOLOGY
LA English
DT Article
ID VISUAL IMPAIRMENT; INDIGENOUS AUSTRALIANS; MACULOPATHY; POPULATION;
   CLASSIFICATION
AB IMPORTANCE Age-related macular degeneration (AMD) is a leading cause of irreversible blindness among the elderly population globally. Currently, knowledge of the epidemiology of AMD in Australia remains scarce because of a paucity of recent population-based data.
   OBJECTIVE To examine the prevalence of AMD in Australia.
   DESIGN, SETTING, AND PARTICIPANTS In this population-based, cross-sectional survey performed from March 11, 2015, to April 18, 2016, a sample of 3098 nonindigenous Australians 50 years and older and 1738 indigenous Australians 40 years and older from 30 geographic areas across Australia were examined.
   MAIN OUTCOMES AND MEASURES Any AMD, early AMD, intermediate AMD, and late AMD graded according to the Beckman clinical classification system.
   RESULTS A total of 4836 individuals were examined, including 3098 nonindigenous Australian (64.1%; 58.9% female vs 41.1% male; age range, 40-92 years; mean [SD] age, 55.0 [10.0] years) and 1738 indigenous Australians (35.9%; 53.6% female vs 46.4% male; age range, 50-98 years; mean [SD] age, 66.6 [9.7] years). A total of 4589 (94.9%, 2946 nonindigenous and 1643 indigenous) participants had retinal photographs in at least 1 eye that were gradable for AMD. The weighted prevalence of early AMD was 14.8%(95% CI, 11.7%-18.6%) and of intermediate AMD was 10.5%(95% CI, 8.3%-13.1%) among nonindigenous Australians. In indigenous Australians, the weighted prevalence of early AMD was 13.8% (95% CI, 9.7%-19.3%) and of intermediate AMD was 5.7%(96% CI, 4.7%-7.0%). Late AMD was found in 0.96%(95% CI, 0.59%-1.55%) of nonindigenous participants (atrophic, 0.72%; neovascular, 0.24%). The prevalence of late AMD increased to 6.7% in participants 80 years or older and was higher in men (1.4% vs 0.61%, P = .02). Only 3 (0.17% [95% CI, 0.04%-0.63%]) indigenous participants had late (atrophic) AMD. Age-related macular degeneration was attributed as the main cause of vision loss (< 6/12 in the better eye) in 23 of 208 nonindigenous Australians (11.1%) and 2 of 183 indigenous Australians (1.1%).
   CONCLUSIONS AND RELEVANCE In line with data from other white populations, AMD is a prominent cause of vision loss in the nonindigenous Australian population. An increased provision of low vision rehabilitation services may be required to cope with the projected increase in AMD in Australia.
C1 [Keel, Stuart; Xie, Jing; Foreman, Joshua; van Wijngaarden, Peter; Dirani, Mohamed] Royal Victorian Eye & Ear Hosp, Ctr Eye Res Australia, Melbourne, Vic, Australia.
   [Foreman, Joshua; van Wijngaarden, Peter] Univ Melbourne, Dept Surg, Melbourne, Vic, Australia.
   [Taylor, Hugh R.] Univ Melbourne, Indigenous Eye Hlth Unit, Melbourne Sch Populat & Global Hlth, Melbourne, Vic, Australia.
C3 Centre for Eye Research Australia; Royal Victorian Eye & Ear Hospital;
   University of Melbourne; University of Melbourne
RP Keel, S (通讯作者)，Royal Victorian Eye & Ear Hosp, Ctr Eye Res Australia, 32 Gisborne St, East Melbourne, Vic 3002, Australia.
EM stuart.keel@unimelb.edu.au
RI xie, jing/GRY-1689-2022
OI van Wijngaarden, Peter/0000-0002-8800-7834; Foreman,
   Joshua/0000-0002-3685-4054; /0000-0001-6694-3587
FU Department of Health of the Australian Government; Peggy and Leslie
   Cranbourne Foundation; Novartis Australia; OPSM; Carl Zeiss; Designs for
   Vision; Royal Flying Doctor Service; Optometry Australia; Brien Holden
   Vision Institute; National Health and Medical Research Council
   [1090466]; Australian Postgraduate Award scholarship
FX The National Eye Health Survey was funded by the Department of Health of
   the Australian Government and also received financial contributions from
   the Peggy and Leslie Cranbourne Foundation and Novartis Australia.
   In-kind support was received from industry and sector partners, OPSM,
   Carl Zeiss, Designs for Vision, the Royal Flying Doctor Service,
   Optometry Australia, and the Brien Holden Vision Institute. Dr Dirani is
   supported by National Health and Medical Research Council Career
   Development Fellowship 1090466. Mr Foreman is supported by an Australian
   Postgraduate Award scholarship.
CR Australian Government Department of Health, 2014, IMPL PLAN NAT FRAM A
   Australian Institute of Health and Welfare, 2011, 2010 NAT DRUG STRAT
   Australian Institute of Health and Welfare, 2014, MOR LIF EXP IND AUST
   Australian Institute of Health and Welfare, 2005, VIS PROBL AM OLD AUS
   Avery RL, 2006, OPHTHALMOLOGY, V113, P363, DOI 10.1016/j.ophtha.2005.11.019
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Bressler SB, 2008, ARCH OPHTHALMOL-CHIC, V126, P241, DOI 10.1001/archophthalmol.2007.53
   Cahill MT, 2005, OPHTHALMOLOGY, V112, P152, DOI 10.1016/j.ophtha.2004.06.036
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   Ferrara N, 2006, RETINA-J RET VIT DIS, V26, P859, DOI 10.1097/01.iae.0000242842.14624.e7
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Foreman J, 2017, OPHTHAL EPIDEMIOL, P1
   Foreman J, 2017, CLIN EXP OPHTHALMOL, V45, P336, DOI 10.1111/ceo.12892
   General Assembly of the World Medical Association, 2014, J Am Coll Dent, V81, P14
   Gupta OP, 2007, CURR OPIN OPHTHALMOL, V18, P201, DOI 10.1097/ICU.0b013e32810c8df4
   Hassell JB, 2006, BRIT J OPHTHALMOL, V90, P593, DOI 10.1136/bjo.2005.086595
   JAMPOL LM, 1992, ARCH OPHTHALMOL-CHIC, V110, P1699, DOI 10.1001/archopht.1992.01080240039024
   Jonasson F, 2003, ARCH OPHTHALMOL-CHIC, V121, P379, DOI 10.1001/archopht.121.3.379
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Kawasaki R, 2008, OPHTHALMOLOGY, V115, P1735, DOI 10.1016/j.ophtha.2008.02.012
   Klein R, 2006, OPHTHALMOLOGY, V113, P373, DOI 10.1016/j.ophtha.2005.12.013
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Klein R, 1999, OPHTHALMOLOGY, V106, P1056, DOI 10.1016/S0161-6420(99)90255-5
   Landers J, 2010, BRIT J OPHTHALMOL, V94, P1140, DOI 10.1136/bjo.2009.168146
   Leveziel N, 2010, M S-MED SCI, V26, P509
   MITCHELL P, 1995, OPHTHALMOLOGY, V102, P1450
   Mitchell P., 2011, EYES FUTURE CLEAR OU, P1
   Pascolini D, 2004, OPHTHAL EPIDEMIOL, V11, P67, DOI 10.1076/opep.11.2.67.28158
   Regillo CD, 2015, AM J OPHTHALMOL, V160, P1014, DOI 10.1016/j.ajo.2015.07.034
   Smith W, 2001, OPHTHALMOLOGY, V108, P697, DOI 10.1016/S0161-6420(00)00580-7
   Taylor HR, 2010, MED J AUSTRALIA, V192, P312, DOI 10.5694/j.1326-5377.2010.tb03529.x
   VanNewkirk MR, 2001, OPHTHALMOLOGY, V108, P960, DOI 10.1016/S0161-6420(01)00554-1
   VanNewkirk MR, 2000, OPHTHALMOLOGY, V107, P1593, DOI 10.1016/S0161-6420(00)00175-5
   Varma R, 2004, OPHTHALMOLOGY, V111, P1288, DOI 10.1016/j.ophtha.2004.01.023
   VINGERLING JR, 1995, OPHTHALMOLOGY, V102, P205
   Wang JJ, 2000, CLIN EXP OPHTHALMOL, V28, P268, DOI 10.1046/j.1442-9071.2000.00315.x
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
NR 37
TC 24
Z9 25
U1 0
U2 5
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 2168-6165
EI 2168-6173
J9 JAMA OPHTHALMOL
JI JAMA Ophthalmol.
PD NOV
PY 2017
VL 135
IS 11
BP 1242
EP 1249
DI 10.1001/jamaophthalmol.2017.4182
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA FM2ER
UT WOS:000414798100021
PM 29049463
OA Bronze, Green Published
DA 2022-11-30
ER

PT J
AU Bhavsar, A
   Bressler, NM
   Burdan, A
   Costello, CV
   Haynes, LA
   Ho, AC
   Koester, J
   Lim, JI
   Reaves, A
   Rosenfeld, PJ
   Singerman, LJ
   Slakter, JS
AF Bhavsar, A
   Bressler, NM
   Burdan, A
   Costello, CV
   Haynes, LA
   Ho, AC
   Koester, J
   Lim, JI
   Reaves, A
   Rosenfeld, PJ
   Singerman, LJ
   Slakter, JS
CA VAM Study Writing Comm
TI Verteporfin therapy in age-related macular degeneration (VAM): An
   open-label multicenter photodynamic therapy study of 4,435 patients
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE age-related macular degeneration; choroidal neovascularization;
   photodynamic therapy; verteporfin; Visudyne (R)
ID SUBFOVEAL CHOROIDAL NEOVASCULARIZATION; RANDOMIZED CLINICAL-TRIALS;
   INFUSION-ASSOCIATED PAIN
AB Purpose: To provide broad clinical experience and to gather safety data on photodynamic therapy with verteporfin (Visudyne, Novartis AG, Basel, Switzerland), also termed verteporfin therapy, in patients with predominantly classic subfoveal choroidal neovascularization (CNV) secondary to age-related macular degeneration (AMD). The Verteporfin in Age-related Macular Degeneration (VAM) Study was designed to provide expanded access to verteporfin therapy after beneficial results for these cases were reported but before regulatory approval in North America.
   Methods: This open-label multicenter study from September 1999 through June 2000 enrolled among 222 centers patients 50 years or older in the United States, or 40 years or older in Canada, with age-related macular degeneration and subfoveal CNV with a lesion composition that was predominantly classic CNV on fluorescein angiography. Corrected visual acuity with habitual eyewear in the office setting was 20/40 to 20/200, inclusive. All patients received verteporfin therapy and returned for follow-up every 3 months. At those follow-up examinations, additional courses of treatment were recommended if any fluorescein leakage from CNV was identified. Safety information was collected from patient self-reporting, questioning (in person and by telephone), and physician evaluation. Safety was assessed by evaluating the effect of treatment on corrected distance visual acuity and by evaluating adverse events.
   Results: A total of 4,435 patients were enrolled of whom 4,051 (91%) completed the study after receiving 6,701 treatments. Most patients received only one treatment in VAM before regulatory approval of verteporfin in the United States and Canada. Three hundred patients (6.8%) experienced an adverse event considered by the treating ophthalmologist to be associated with treatment, including 115 (2.6%) with abnormal or decreased vision, of whom 25 (0.6%) experienced acute severe visual acuity decrease, and 14 (0.3%) with transient infusion-related back pain. Patients were advised to avoid exposure to direct sunlight for 24 hours; however, after verteporfin administration only 2 (0.05%) reported a photosensitivity reaction. An additional course of verteporfin therapy was administered to 1,739 of 2,314 patients (75.2%) who had a month 3 examination that was not their close-out visit and 177 of 266 (66.5%) who had a month 6 examination that was not their close-out visit.
   Conclusions: Verteporfin therapy exhibited no additional or new safety concerns. The therapy associated with a low incidence of adverse events when expanded access was provided in a large, open-label, multicenter study, including a low incidence (0.05%) of reported photosensitivity reactions despite a short photosensitivity protection period (24 hours) following verteporfin administration.
RP Bressler, NM (通讯作者)，Suite 115,550 N Broadway, Baltimore, MD 21205 USA.
EM nmboffice@jhmi.edu
RI Bhavsar, Abdhish/AHC-3614-2022
OI Bhavsar, Abdhish/0000-0002-3316-7152
CR Arnold J, 2001, OPHTHALMOLOGY, V108, P841
   Arnold J, 2001, AM J OPHTHALMOL, V131, P541
   Blumenkranz MS, 2001, ARCH OPHTHALMOL-CHIC, V119, P198
   Borodoker N, 2002, AM J OPHTHALMOL, V133, P211, DOI 10.1016/S0002-9394(01)01341-1
   Bressler NM, 2002, ARCH OPHTHALMOL-CHIC, V120, P1307
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   Miller JW, 1999, ARCH OPHTHALMOL-CHIC, V117, P1161
   Spaide RF, 2003, AM J OPHTHALMOL, V135, P549, DOI 10.1016/S0002-9394(02)01983-9
   *TREATM AG REL MAC, 2004, IN PRESS RETINA
NR 9
TC 22
Z9 23
U1 0
U2 3
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD AUG
PY 2004
VL 24
IS 4
BP 512
EP 520
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 847QY
UT WOS:000223411200003
PM 15300071
DA 2022-11-30
ER

PT J
AU Fisher, SA
   Abecasis, GR
   Yashar, BM
   Zareparsi, S
   Swaroop, A
   Iyengar, SK
   Klein, BEK
   Klein, R
   Lee, KE
   Majewski, J
   Schultz, DW
   Klein, ML
   Seddon, JM
   Santangelo, SL
   Weeks, DE
   Conley, YP
   Mah, TS
   Schmidt, S
   Haines, JL
   Pericak-Vance, MA
   Gorin, MB
   Schulz, HL
   Pardi, F
   Lewis, CM
   Weber, BHF
AF Fisher, SA
   Abecasis, GR
   Yashar, BM
   Zareparsi, S
   Swaroop, A
   Iyengar, SK
   Klein, BEK
   Klein, R
   Lee, KE
   Majewski, J
   Schultz, DW
   Klein, ML
   Seddon, JM
   Santangelo, SL
   Weeks, DE
   Conley, YP
   Mah, TS
   Schmidt, S
   Haines, JL
   Pericak-Vance, MA
   Gorin, MB
   Schulz, HL
   Pardi, F
   Lewis, CM
   Weber, BHF
TI Meta-analysis of genome scans of age-related macular degeneration
SO HUMAN MOLECULAR GENETICS
LA English
DT Article
ID BEAVER DAM EYE; STARGARDT-DISEASE GENE; COMPLEX HUMAN-DISEASES;
   SUSCEPTIBILITY LOCI; FAMILIAL AGGREGATION; LINKAGE ANALYSIS; EXTENDED
   FAMILIES; BIPOLAR DISORDER; OXIDATIVE STRESS; APOLIPOPROTEIN-E
AB A genetic contribution to the development of age-related macular degeneration (AMD) is well established. Several genome-wide linkage studies have identified a number of putative susceptibility loci for AMD but only a few of these regions have been replicated in independent studies. Here, we perform a meta-analysis of six AMD genome screens using the genome-scan meta-analysis method, which allows linkage results from several studies to be combined, providing greater power to identify regions that show only weak evidence for linkage in individual studies. Results from non-parametric analysis for a broad AMD clinical phenotype (including two studies with quantitative traits) were extracted. For each study, 120 genomic bins of similar to 30 cM were defined and ranked according to maximum evidence for linkage within each bin. Bin ranks were weighted according to study size and summed across all studies; the summed rank (SR) for each bin was assessed empirically for significance using permutation methods. A high SR indicates a region with consistent evidence for linkage across studies. The strongest evidence for an AMD susceptibility locus was found on chromosome 10q26 where genome-wide significant linkage was observed (P=0.00025). Several other regions met the empirical significance criteria for bins likely to contain linked loci including adjacent pairs of bins on chromosomes 1q, 2p, 3p and 16. Several of the regions identified here showed only weak evidence for linkage in the individual studies. These results will help prioritize regions for future positional and functional candidate gene studies in AMD.
C1 Univ London Kings Coll, Guys Kings & St Thomas Sch Med, Dept Med & Mol Genet, London SE1 9RT, England.
   Univ Michigan, Dept Biostat, Ann Arbor, MI 48109 USA.
   Univ Michigan, Dept Ophthalmol & Visual Sci, Ann Arbor, MI 48109 USA.
   Univ Michigan, Dept Human Genet, Ann Arbor, MI 48109 USA.
   Case Western Reserve Univ, Dept Epidemiol & Biostat, Cleveland, OH 44106 USA.
   Univ Wisconsin, Sch Med, Dept Ophthalmol & Visual Sci, Madison, WI USA.
   Rockefeller Univ, Lab Stat Genet, New York, NY 10021 USA.
   Oregon Hlth & Sci Univ, Casey Eye Inst, Macular Degenerat Ctr, Dept Ophthalmol, Portland, OR USA.
   Harvard Univ, Sch Publ Hlth, Sch Med, Boston, MA 02115 USA.
   Massachusetts Eye & Ear Infirm, Ophthalmol Epidemiol Unit, Boston, MA 02114 USA.
   Massachusetts Gen Hosp, Dept Psychiat, Psychiat & Neurodev Genet Unit, Charlestown, MA USA.
   Univ Pittsburgh, Grad Sch Publ Hlth, Dept Human Genet, Pittsburgh, PA 15261 USA.
   Univ Pittsburgh, Grad Sch Publ Hlth, Dept Biostat, Pittsburgh, PA 15261 USA.
   Univ Pittsburgh, Sch Nursing, Pittsburgh, PA 15261 USA.
   Univ Pittsburgh, Sch Med, Dept Ophthalmol, Pittsburgh, PA 15261 USA.
   Duke Univ, Med Ctr, Ctr Human Genet, Dept Med, Durham, NC USA.
   Vanderbilt Univ, Med Ctr, Ctr Human Genet Res, Nashville, TN USA.
   Univ Wurzburg, Bioctr, Inst Human Genet, Wurzburg, Germany.
   Univ Regensburg, Inst Human Genet, D-8400 Regensburg, Germany.
C3 University of London; King's College London; University of Michigan
   System; University of Michigan; University of Michigan System;
   University of Michigan; University of Michigan System; University of
   Michigan; Case Western Reserve University; University of Wisconsin
   System; University of Wisconsin Madison; Rockefeller University; Oregon
   Health & Science University; Harvard University; Harvard Medical School;
   Harvard T.H. Chan School of Public Health; Harvard University;
   Massachusetts Eye & Ear Infirmary; Harvard University; Massachusetts
   General Hospital; Pennsylvania Commonwealth System of Higher Education
   (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of
   Higher Education (PCSHE); University of Pittsburgh; Pennsylvania
   Commonwealth System of Higher Education (PCSHE); University of
   Pittsburgh; Pennsylvania Commonwealth System of Higher Education
   (PCSHE); University of Pittsburgh; Duke University; Vanderbilt
   University; University of Wurzburg; University of Regensburg
RP Fisher, SA (通讯作者)，Univ London Kings Coll, Guys Hosp, Guys Kings & St Thomas Sch Med, Dept Med & Mol Genet, 8th Floor,Guys Tower, London SE1 9RT, England.
EM sheila.fisher@genetics.kcl.ac.uk
RI Weeks, Daniel E/B-2995-2012; Lewis, Cathryn M/A-5225-2010; Haines,
   Jonathan/C-3374-2012; /S-1190-2019; Abecasis, Goncalo R/B-7840-2010;
   Lewis, Cathryn/M-8766-2019
OI Weeks, Daniel E/0000-0001-9410-7228; Lewis, Cathryn
   M/0000-0002-8249-8476; Haines, Jonathan/0000-0002-4351-4728;
   /0000-0001-7488-250X; Lewis, Cathryn/0000-0002-8249-8476; Swaroop,
   Anand/0000-0002-1975-1141; Weber, Bernhard H.F./0000-0002-8808-7723;
   Abecasis, Goncalo/0000-0003-1509-1825; Yashar, Beverly
   M./0000-0003-0807-3258
FU NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR003655, M01RR000095]
   Funding Source: NIH RePORTER; NATIONAL EYE INSTITUTE [R01EY012203,
   U10EY011309, R01EY008247, P30EY010572, R01EY012118, R01EY011309,
   R01EY012562, U10EY006594, R01EY009859, R01EY003279, U10EY012118,
   F32EY014085, R01EY010605, R03EY015216] Funding Source: NIH RePORTER;
   NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM028356,
   R37GM028356] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING
   [P60AG011268] Funding Source: NIH RePORTER; NCRR NIH HHS [RR03655, M01
   RR-00095] Funding Source: Medline; NEI NIH HHS [EY015288, EY03279,
   EY08247, EY10572, EY10605, EY11309, EY12118, EY12562, F32-EY014085,
   EY015216, EY012203, R01-EY 09859, R01-EY10605, R01-EY11309, U10-EY11309,
   U10-EY06594, R01-U10-EY06594] Funding Source: Medline; NHGRI NIH HHS
   [HG00008] Funding Source: Medline; NHLBI NIH HHS [HL07567] Funding
   Source: Medline; NIA NIH HHS [AG11268] Funding Source: Medline; NIGMS
   NIH HHS [GM28356] Funding Source: Medline
CR Abecasis GR, 2004, AM J HUM GENET, V74, P482, DOI 10.1086/382786
   Abecasis GR, 2002, NAT GENET, V30, P97, DOI 10.1038/ng786
   Allikmets R, 2000, AM J HUM GENET, V67, P487, DOI 10.1086/303018
   Allikmets R, 1997, SCIENCE, V277, P1805, DOI 10.1126/science.277.5333.1805
   Altmuller J, 2001, AM J HUM GENET, V69, P936, DOI 10.1086/324069
   Baird PN, 2004, INVEST OPHTH VIS SCI, V45, P1311, DOI 10.1167/iovs.03-1121
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   Blasi MA, 2001, OPHTHALMOLOGICA, V215, P51, DOI 10.1159/000050826
   Chiodini BD, 2003, ARTERIOSCL THROM VAS, V23, P1863, DOI 10.1161/01.ATV.0000093281.10213.DB
   Cordell HJ, 2001, ANN HUM GENET, V65, P491, DOI 10.1017/S0003480001008831
   DeJong PTVM, 1997, AM J OPHTHALMOL, V124, P862, DOI 10.1016/S0002-9394(14)71715-5
   Demenais F, 2003, HUM MOL GENET, V12, P1865, DOI 10.1093/hmg/ddg195
   EDWARDS AO, 2005, SCI EXPRESS
   Fine SL, 2000, NEW ENGL J MED, V342, P483, DOI 10.1056/NEJM200002173420707
   Fisher SA, 2003, ARTHRITIS RHEUM-US, V48, P1200, DOI 10.1002/art.10945
   Gudbjartsson DF, 2000, NAT GENET, V25, P12, DOI 10.1038/75514
   Guymer RH, 2001, ARCH OPHTHALMOL-CHIC, V119, P745, DOI 10.1001/archopht.119.5.745
   HAINES JL, 2005, SCI EXPRESS
   Hammond CJ, 2002, OPHTHALMOLOGY, V109, P730, DOI 10.1016/S0161-6420(01)01049-1
   Iyengar SK, 2004, AM J HUM GENET, V74, P20, DOI 10.1086/380912
   Kenealy SJ, 2004, MOL VIS, V10, P57
   Klaver CCW, 1998, AM J HUM GENET, V63, P200, DOI 10.1086/301901
   Klaver CCW, 1998, ARCH OPHTHALMOL-CHIC, V116, P1646, DOI 10.1001/archopht.116.12.1646
   Klein ML, 1998, ARCH OPHTHALMOL-CHIC, V116, P1082, DOI 10.1001/archopht.116.8.1082
   Klein R, 2004, AM J OPHTHALMOL, V137, P486, DOI 10.1016/j.ajo.2003.11.069
   Klein R, 1997, OPHTHALMOLOGY, V104, P7, DOI 10.1016/S0161-6420(97)30368-6
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1310
   KLEIN RJ, 2005, SCI EXPRESS
   Koivukoski L, 2004, HUM MOL GENET, V13, P2325, DOI 10.1093/hmg/ddh237
   Kruglyak L, 1996, AM J HUM GENET, V58, P1347
   LANDER E, 1995, NAT GENET, V11, P241, DOI 10.1038/ng1195-241
   Levinson DF, 2003, AM J HUM GENET, V73, P17, DOI 10.1086/376548
   Lewis CM, 2003, AM J HUM GENET, V73, P34, DOI 10.1086/376549
   Majewski J, 2003, AM J HUM GENET, V73, P540, DOI 10.1086/377701
   Marazita ML, 2004, AM J HUM GENET, V75, P161, DOI 10.1086/422475
   MEYERS SM, 1995, AM J OPHTHALMOL, V120, P757, DOI 10.1016/S0002-9394(14)72729-1
   Risch N, 1996, SCIENCE, V273, P1516, DOI 10.1126/science.273.5281.1516
   Rivera A, 2000, AM J HUM GENET, V67, P800, DOI 10.1086/303090
   SANTANGELO SL, 2005, INVEST OPHTH VIS SCI, V43, pB758
   SARKS SH, 1976, BRIT J OPHTHALMOL, V60, P324, DOI 10.1136/bjo.60.5.324
   Schick JH, 2003, AM J HUM GENET, V72, P1412, DOI 10.1086/375500
   Schultz DW, 2003, HUM MOL GENET, V12, P3315, DOI 10.1093/hmg/ddg348
   Seddon JM, 2005, ARCH OPHTHALMOL-CHIC, V123, P321, DOI 10.1001/archopht.123.3.321
   Seddon JM, 2003, AM J HUM GENET, V73, P780, DOI 10.1086/378505
   Seddon JM, 1997, AM J OPHTHALMOL, V123, P199, DOI 10.1016/S0002-9394(14)71036-0
   Shroyer NF, 2001, HUM MOL GENET, V10, P2671, DOI 10.1093/hmg/10.23.2671
   van Heel DA, 2004, HUM MOL GENET, V13, P763, DOI 10.1093/hmg/ddh090
   Webster AR, 2001, INVEST OPHTH VIS SCI, V42, P1179
   Weeks DE, 2000, HUM MOL GENET, V9, P1329, DOI 10.1093/hmg/9.9.1329
   Weeks DE, 2004, AM J HUM GENET, V75, P174, DOI 10.1086/422476
   Weeks DE, 2001, AM J OPHTHALMOL, V132, P682, DOI 10.1016/S0002-9394(01)01214-4
   Wise LH, 1999, ANN HUM GENET, V63, P263, DOI 10.1046/j.1469-1809.1999.6330263.x
   YOUNG RW, 1987, SURV OPHTHALMOL, V31, P291, DOI 10.1016/0039-6257(87)90115-9
   Zareparsi S, 2004, INVEST OPHTH VIS SCI, V45, P1306, DOI 10.1167/iovs.03-1253
   Zintzaras E, 2005, GENET EPIDEMIOL, V28, P123, DOI 10.1002/gepi.20048
NR 55
TC 177
Z9 187
U1 0
U2 5
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0964-6906
J9 HUM MOL GENET
JI Hum. Mol. Genet.
PD AUG 1
PY 2005
VL 14
IS 15
BP 2257
EP 2264
DI 10.1093/hmg/ddi230
PG 8
WC Biochemistry & Molecular Biology; Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Genetics & Heredity
GA 948OG
UT WOS:000230725000017
PM 15987700
OA Green Published, Green Submitted
DA 2022-11-30
ER

PT J
AU Bhatt, P
   Fnu, G
   Bhatia, D
   Shahid, A
   Sutariya, V
AF Bhatt, Priyanka
   Fnu, Gulimirerouzi
   Bhatia, Deepak
   Shahid, Amna
   Sutariya, Vijaykumar
TI Nanodelivery of Resveratrol-Loaded PLGA Nanoparticles for Age-Related
   Macular Degeneration
SO AAPS PHARMSCITECH
LA English
DT Article
DE resveratrol; PLGA nanoparticles; sustained release; intravitreal ocular
   delivery; anti-VEGF
ID DELIVERY; PROGRESS; CELLS; DNA
AB Age-related macular degeneration, precisely neovascular form, is the leading cause of vision loss and the key treatment includes intravitreal injections of anti-vascular endothelial growth factor (anti-VEGF) agents. A method to increase local concentration of drug at posterior segment of the eye and to reduce the frequency of intravitreal injections is an unmet need. Resveratrol, a naturally occurring antioxidant and anti-inflammatory polyphenol, was loaded in PLGA polymeric nanoparticles to study their sustained release property and effectiveness in reducing expression of VEGF protein in vitro. Nanoparticles were characterized using FTIR, DSC, size, encapsulation efficiency, TEM, and in vitro drug release studies. Using MTT assay, the cytotoxicity of formulation was evaluated on ARPE-19 cells. The cellular uptake and VEGF expression levels were also evaluated in in vitro settings. The optimized formulation had a particle size of 102.7 nm with - 47.30 mV of zeta potential. Entrapment efficiency was found to be 65.21%. The cell viability results suggested compatibility of developed formulation. Cellular uptake and VEGF expression levels for the formulated nanoparticles specified that the developed formulation showed potential cellular uptake and had displayed anti-angiogenic property by inhibiting VEGF expression in vitro. The results showed successful development of resveratrol-loaded nanoparticles which may be used for neovascular AMD treatment alone or in combination with anti-VEGF agents.
C1 [Bhatt, Priyanka; Fnu, Gulimirerouzi; Shahid, Amna; Sutariya, Vijaykumar] Univ S Florida, Taneja Coll Pharm, Dept Pharmaceut Sci, 12901 Bruce B Downs Blvd,MDC30, Tampa, FL 33612 USA.
   [Bhatia, Deepak] Bernard J Dunn Sch Pharm, Dept Pharmacogen, 8095 Innovat Pk Dr, Fairfax, VA 22031 USA.
C3 State University System of Florida; University of South Florida
RP Sutariya, V (通讯作者)，Univ S Florida, Taneja Coll Pharm, Dept Pharmaceut Sci, 12901 Bruce B Downs Blvd,MDC30, Tampa, FL 33612 USA.
EM vsutariy@usf.edu
FU High Tech Corridor Matching Grant Program [FHT 17-20]; Param Bhakti
   Healthcare and Research Services LLC
FX Necessary funds for this work were provided by the High Tech Corridor
   Matching Grant Program (FHT 17-20) with Param Bhakti Healthcare and
   Research Services LLC.
CR Abu-Amero KK, 2016, NUTRIENTS, V8, DOI 10.3390/nu8040200
   Al Gwairi O, 2016, J OPHTHALMOL, V2016, DOI 10.1155/2016/2913612
   Alshetaili AS, 2018, TROP J PHARM RES, V17, P1263, DOI 10.4314/tjpr.v17i7.6
   Bhatt P, 2019, AAPS PHARMSCITECH, V20, DOI 10.1208/s12249-019-1474-0
   Bhatt P, 2018, INT J PHARMACEUT, V536, P95, DOI 10.1016/j.ijpharm.2017.11.048
   Bhatt P, 2016, CANCER RES, V76, DOI 10.1158/1538-7445.AM2016-2065
   Bhatt P, 2015, DRUG DELIV, V22, P849, DOI 10.3109/10717544.2014.898348
   Chung SW, 2010, ARCH BIOCHEM BIOPHYS, V501, P79, DOI 10.1016/j.abb.2010.05.003
   Dib B, 2015, BBA-MOL CELL RES, V1853, P2897, DOI 10.1016/j.bbamcr.2015.08.012
   Diyana I., 2017, INT J OPHTHALMOL CLI, V4, P1, DOI [10.23937/2378-346X/1410082, DOI 10.23937/2378-346X/1410082]
   Halasz K, 2019, CURR DRUG DELIV, V16, P153, DOI 10.2174/1567201815666181017095708
   Hoare TR, 2008, POLYMER, V49, P1993, DOI 10.1016/j.polymer.2008.01.027
   Huo MR, 2017, J CONTROL RELEASE, V245, P81, DOI 10.1016/j.jconrel.2016.11.013
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Kim KL, 2017, INVEST OPHTH VIS SCI, V58, P3592, DOI 10.1167/iovs.17-21416
   King RE, 2005, CHEM-BIOL INTERACT, V151, P143, DOI 10.1016/j.cbi.2004.11.003
   LANGCAKE P, 1977, EXPERIENTIA, V33, P151, DOI 10.1007/BF02124034
   Lynn Savannah A, 2018, F1000Res, V7, P1107, DOI 10.12688/f1000research.15409.1
   Nagineni CN, 2014, AGING DIS, V5, P88, DOI 10.14366/AD.2014.050088
   Nickla DL, 2010, PROG RETIN EYE RES, V29, P144, DOI 10.1016/j.preteyeres.2009.12.002
   Nowak JZ, 2006, PHARMACOL REP, V58, P353
   Oake A., 2019, SURFACE MODIFICATION, P1
   Patel J, 2018, J MICROENCAPSUL, V35, P204, DOI 10.1080/02652048.2018.1453560
   Patil SV, 2016, RSC ADV, V6, P110206, DOI 10.1039/c6ra23614f
   Pennington KL, 2016, EYE VISION, V3, DOI 10.1186/s40662-016-0063-5
   Pernis AB, 2002, J CLIN INVEST, V109, P1279, DOI 10.1172/JCI200215786
   Rhone M, 2008, NUTR REV, V66, P465, DOI 10.1111/j.1753-4887.2008.00078.x
   Sadat S.M., 2016, J BIOMATER NANOBIOTE, V7, P91, DOI DOI 10.4236/JBNB.2016.72011
   Shahiwala A, 2018, IN VITRO INV VIVO TO
   Shang Q, 2015, RSC ADV, V5, P75025, DOI 10.1039/c5ra12262g
   Yewale C, 2018, J DRUG DELIV SCI TEC, V45, P334, DOI 10.1016/j.jddst.2018.03.027
   Zhang C, 2004, COLLOID SURFACE B, V39, P69, DOI 10.1016/j.colsurfb.2004.09.002
NR 32
TC 22
Z9 22
U1 5
U2 26
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 1530-9932
J9 AAPS PHARMSCITECH
JI AAPS PharmSciTech
PD OCT 21
PY 2020
VL 21
IS 8
AR 291
DI 10.1208/s12249-020-01836-4
PG 9
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA OG3GX
UT WOS:000581778200001
PM 33085055
DA 2022-11-30
ER

PT J
AU Rouvas, A
   Liarakos, VS
   Theodossiadis, P
   Papathanassiou, M
   Petrou, P
   Ladas, I
   Vergados, I
AF Rouvas, Alexandros
   Liarakos, Vasilios S.
   Theodossiadis, Panagiotis
   Papathanassiou, Miltiadis
   Petrou, Petros
   Ladas, Ioannis
   Vergados, Ioannis
TI The Effect of Intravitreal Ranibizumab on the Fellow Untreated Eye with
   Subfoveal Scarring due to Exudative Age-Related Macular Degeneration
SO OPHTHALMOLOGICA
LA English
DT Article
DE Ranibizumab; Lucentis; Anti-VEGF; Age-related macular degeneration;
   Choroidal neovascularization scar; Fellow eye; VEGF
ID ENDOTHELIAL GROWTH-FACTOR; PHARMACOKINETICS; EXPRESSION; VEGF;
   MEMBRANES; CELLS
AB Aim: Our purpose was to evaluate the possible effect of intravitreal ranibizumab on the fellow untreated eye with choroidal neovascularization (CNV) and subfoveal scarring associated with age-related macular degeneration (AMD). Methods: A retrospective observational study was conducted. One hundred eighty-seven ranibizumab-treated patients diagnosed as having subfoveal CNV scarring in the untreated eye were compared with a control group of untreated unilateral subfoveal CNV scarring. Inclusion criteria concerning treated eyes in the ranibizumab group complied with the MARINA and ANCHOR studies. Demographic data, clinical course, visual acuity, fluorescein angiography and optical coherence tomography findings were evaluated. Results: Clinical improvement was confirmed in 24% of the patients in the ranibizumab group and in only 12.9% of the controls. Improvement was noted as early as 2-4 months (2.83 +/- 0.75 months) after the initiation of treatment in the fellow eye compared with 33.25 +/- 9.43 months in the control group (p = 0.01; Mann-Whitney U test). Kaplan-Meier curves demonstrate the positive impact of ranibizumab on the visual acuity of the fellow untreated eye (p = 0.016; Log-Rank test). Conclusions: Ranibizumab might induce some therapeutic effect in selected cases of end-stage CNV scarring, which needs to be further examined. The VEGF levels in the compartments of the fellow eye of patients with age-related macular degeneration treated with ranibizumab need to be further evaluated. Copyright (c) 2009 S. Karger AG, Basel
C1 [Rouvas, Alexandros; Liarakos, Vasilios S.; Theodossiadis, Panagiotis; Papathanassiou, Miltiadis; Petrou, Petros; Vergados, Ioannis] Univ Athens, Attikon Univ Hosp, Dept Ophthalmol 2, GR-12462 Athens, Greece.
   [Ladas, Ioannis] Univ Athens, G Gennimatas Hosp, Dept Ophthalmol 1, GR-12462 Athens, Greece.
C3 National & Kapodistrian University of Athens; University Hospital
   Attikon; National & Kapodistrian University of Athens
RP Rouvas, A (通讯作者)，Univ Athens, Attikon Univ Hosp, Dept Ophthalmol 2, Rimini 1, GR-12462 Athens, Greece.
EM v_liarakos@yahoo.com
CR AVERY RL, 2006, OPHTHALMOLOGY, P113
   Bakri SJ, 2007, OPHTHALMOLOGY, V114, P2179, DOI 10.1016/j.ophtha.2007.09.012
   Bakri SJ, 2007, OPHTHALMOLOGY, V114, P855, DOI 10.1016/j.ophtha.2007.01.017
   BRESSLER NM, 1988, SURV OPHTHALMOL, V32, P375, DOI 10.1016/0039-6257(88)90052-5
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Gaudreault J, 2005, INVEST OPHTH VIS SCI, V46, P726, DOI 10.1167/iovs.04-0601
   Gaudreault J, 2007, RETINA-J RET VIT DIS, V27, P1260, DOI 10.1097/IAE.0b013e318134eecd
   Gerhardinger C, 1998, AM J PATHOL, V152, P1453
   Haughney PC, 2005, INVEST OPHTH VIS SCI, P46
   Kim I, 1999, INVEST OPHTH VIS SCI, V40, P2115
   Kvanta A, 1996, INVEST OPHTH VIS SCI, V37, P1929
   Lai TYY, 2007, GRAEF ARCH CLIN EXP, V245, P1877, DOI 10.1007/s00417-007-0679-1
   Leibowitz H M, 1980, Surv Ophthalmol, V24, P335
   Lopez PF, 1996, INVEST OPHTH VIS SCI, V37, P855
   Mennel S, 2007, ACTA OPHTHALMOL SCAN, V85, P689, DOI 10.1111/j.1600-0420.2007.00926.x
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Shima DT, 1996, INVEST OPHTH VIS SCI, V37, P1334
   SHIMA DT, 1995, MOL MED, V1, P182, DOI 10.1007/BF03401566
   Tolentino MJ, 1996, ARCH OPHTHALMOL-CHIC, V114, P964, DOI 10.1001/archopht.1996.01100140172010
   Zarbin MA, 1998, EUR J OPHTHALMOL, V8, P199, DOI 10.1177/112067219800800401
NR 20
TC 24
Z9 25
U1 0
U2 2
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 0030-3755
EI 1423-0267
J9 OPHTHALMOLOGICA
JI Ophthalmologica
PY 2009
VL 223
IS 6
BP 383
EP 389
DI 10.1159/000228590
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 513WE
UT WOS:000271354000007
PM 19602910
DA 2022-11-30
ER

PT J
AU Rim, TH
   Lee, CS
   Lee, SC
   Kim, S
   Kim, SS
AF Rim, Tyler Hyungtaek
   Lee, Christopher Seungkyu
   Lee, Sung Chul
   Kim, Sangah
   Kim, Sung Soo
CA Korean Ophthalmological Soc
TI Association between Previous Cataract Surgery and Age-Related Macular
   Degeneration
SO SEMINARS IN OPHTHALMOLOGY
LA English
DT Article
DE Age-related macular degeneration; cataract; cataract surgery; KNHANES;
   national survey
ID BLUE MOUNTAINS EYE; QUALITY-OF-LIFE; LENS OPACITIES; RISK-FACTORS;
   BEAVER DAM; MACULOPATHY; PATHOGENESIS; INFLAMMATION; EXTRACTION; DISEASE
AB Purpose: To assess the association between age-related macular degeneration (AMD) and previous cataract surgery. Methods: We studied 17,987 randomly selected participants from the Korea National Health and Nutrition Examination Survey who were aged >= 40 years and underwent additional ophthalmologic examinations in 2008-12. The associations between previous cataract surgery and early/late AMD were identified using multivariate logistic regression analysis of data from right or left eyes. Clustered multivariate logistic regression analysis was performed using both eyes to assess inter-eye correlation in same subject. Previous cataract surgery and cataract subtypes were based on slit-lamp examination without pupil dilation. Early and late AMD diagnoses were based on non-mydriatic digital retinal image. Results: By univariate logistic regression, both early and late AMD prevalence were higher in subjects with pseudophakia/aphakia compared to subjects with cataract as a reference group, or subjects with phakic eye (including clear lens) as a reference group. In univariate logistic regression, both early and late AMD prevalence were higher in eyes with cataract or pseudo/aphakia compared to eyes with clear lens. However, after adjusting for age with multivariate logistic regression, all statistically significant differences in AMD prevalence among subgroups disappeared. Conclusions: We found no association between the previous cataract surgery and increased early/late AMD risk in our representative, large, national patient database. This suggests that increasing age, and not cataract surgery history, is predictive of AMD risk. These findings are limited by cross-sectional study and need to be replicated by other longitudinal observational studies.
C1 [Rim, Tyler Hyungtaek; Lee, Christopher Seungkyu; Lee, Sung Chul; Kim, Sangah; Kim, Sung Soo] Yonsei Univ, Severance Hosp, Dept Ophthalmol, Coll Med, Seoul, South Korea.
   [Kim, Sung Soo] Yonsei Univ, Yonsei Healthcare Big Data Based Knowledge Integr, Coll Med, Seoul, South Korea.
   [Kim, Sung Soo] Yonsei Univ, Inst Convergence Sci, Coll Med, Seoul, South Korea.
C3 Yonsei University; Yonsei University Health System; Yonsei University;
   Yonsei University Health System; Yonsei University; Yonsei University
   Health System
RP Kim, SS (通讯作者)，Yonsei Univ, Coll Med, Dept Ophthalmol, Severance Hosp,Inst Vis Res, 50 Yonsei Ro, Seoul 03722, South Korea.
EM semekim@yuhs.ac
OI Kim, Sangah/0000-0002-8511-2903; Lee, Christopher/0000-0001-5054-9470;
   Rim, Tyler Hyungtaek/0000-0001-6465-2620; Kim, Sung
   Soo/0000-0002-0574-7993; Kim, Sung Soo/0000-0003-3049-9554; , Sung
   Chul/0000-0001-9438-2385
CR Armbrecht AM, 2000, BRIT J OPHTHALMOL, V84, P1343, DOI 10.1136/bjo.84.12.1343
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   BLAIR CJ, 1979, AM J OPHTHALMOL, V87, P77, DOI 10.1016/0002-9394(79)90195-8
   Buch H, 2005, ACTA OPHTHALMOL SCAN, V83, P409, DOI 10.1111/J.1600-0420.2005.00492.x
   Casparis H, 2012, COCHRANE DB SYST REV, V6
   Chew EY, 2009, OPHTHALMOLOGY, V116, P297, DOI 10.1016/j.ophtha.2008.09.019
   Colak E, 2012, BIOCHEM MEDICA, V22, P39
   Cugati S, 2006, OPHTHALMOLOGY, V113, P2020, DOI 10.1016/j.ophtha.2006.05.047
   Dong LM, 2009, ARCH OPHTHALMOL-CHIC, V127, P1412, DOI 10.1001/archophthalmol.2009.152
   Donoso LA, 2006, SURV OPHTHALMOL, V51, P137, DOI 10.1016/j.survophthal.2005.12.001
   Freeman EE, 2003, AM J OPHTHALMOL, V135, P849, DOI 10.1016/S0002-9394(02)02253-5
   HILLER R, 1986, AM J EPIDEMIOL, V124, P916, DOI 10.1093/oxfordjournals.aje.a114481
   Hooper CY, 2009, CLIN EXP OPHTHALMOL, V37, P570, DOI 10.1111/j.1442-9071.2009.02095.x
   Klein R, 2002, ARCH OPHTHALMOL-CHIC, V120, P1551, DOI 10.1001/archopht.120.11.1551
   LIU IY, 1989, AM J PUBLIC HEALTH, V79, P765, DOI 10.2105/AJPH.79.6.765
   Lundstrom M, 2002, BRIT J OPHTHALMOL, V86, P1330, DOI 10.1136/bjo.86.12.1330
   Pollack A, 1996, OPHTHALMOLOGY, V103, P1546, DOI 10.1016/S0161-6420(96)30464-8
   Shuttleworth GN, 1998, BRIT J OPHTHALMOL, V82, P611, DOI 10.1136/bjo.82.6.611
   SPERDUTO RD, 1981, ARCH OPHTHALMOL-CHIC, V99, P1004
   Wang JJ, 2003, OPHTHALMOLOGY, V110, P1960, DOI 10.1016/S0161-6420(03)00816-9
   Wang TJ, 2012, OPHTHAL EPIDEMIOL, V19, P137, DOI 10.3109/09286586.2012.680531
   WEST SK, 1989, ARCH OPHTHALMOL-CHIC, V107, P875, DOI 10.1001/archopht.1989.01070010897038
   Writing C, 2014, OPHTHALMOLOGY
NR 23
TC 10
Z9 11
U1 0
U2 2
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0882-0538
EI 1744-5205
J9 SEMIN OPHTHALMOL
JI Semin. Ophthalmol.
PY 2017
VL 32
IS 4
BP 466
EP 473
DI 10.3109/08820538.2015.1119861
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA FA4HM
UT WOS:000405404400014
PM 27128789
DA 2022-11-30
ER

PT J
AU Majewski, J
   Schultz, DW
   Weleber, RG
   Schain, MB
   Edwards, AO
   Matise, TC
   Acott, TS
   Ott, J
   Klein, ML
AF Majewski, J
   Schultz, DW
   Weleber, RG
   Schain, MB
   Edwards, AO
   Matise, TC
   Acott, TS
   Ott, J
   Klein, ML
TI Age-related macular degeneration - a genome scan in extended families
SO AMERICAN JOURNAL OF HUMAN GENETICS
LA English
DT Article
ID LINKAGE ANALYSIS; MACULOPATHY; SUSCEPTIBILITY; PROGRAM; LOCI
AB We performed a genomewide scan and genetic linkage analysis, to identify loci associated with age-related macular degeneration (AMD). We collected 70 families, ranging from small nuclear families to extended multigenerational pedigrees and consisting of a total of 344 affected and 217 unaffected members available for genotyping. We performed linkage analyses using parametric and allele-sharing models. We performed the analyses on the complete pedigrees but also subdivided the families into nuclear pedigrees. Finally, to dissect potential genetic factors responsible for differences in disease manifestation, we stratified the sample by two major AMD phenotypes (neovascular AMD and geographic atrophy) and by age of affected family members at the time of our evaluation. We have previously demonstrated linkage between AMD and 1q25-31 in a single large family. In the combined sample, we have detected the following loci with scores exceeding a cutoff under at least one LOD = 2 of the models considered: 1q31 (HLOD = 2.07 at D1S518), 3p13 (HLOD = 2.19 at D3S1304/D3S4545), 4q32 (HLOD = 2.66 at D4S2368, for the subset of families with predominantly dry AMD), 9q33 (LODzir = 2.01 at D9S930/D9S934), and 10q26 (HLOD = 3.06 at D10S1230). Using correlation analysis, we have found a statistically significant correlation between LOD scores at 3p13 and 10q26, providing evidence for epistatic interactions between the loci and, hence, a complex basis of AMD. Our study has identified new loci that should be considered in future mapping and mutational analyses of AMD and has strengthened the evidence in support of loci suggested by other studies.
C1 Oregon Hlth Sci Univ, Dept Ophthalmol, Macular Degenerat Ctr, Casey Eye Inst, Portland, OR 97201 USA.
   Rockefeller Univ, Lab Stat Genet, New York, NY 10021 USA.
   Oregon Hlth Sci Univ, Dept Mol & Med Genet, Portland, OR 97201 USA.
   Oregon Hlth Sci Univ, Dept Biochem & Mol Biol, Portland, OR 97201 USA.
   Univ Texas, SW Med Ctr, Dept Ophthalmol, Dallas, TX USA.
C3 Oregon Health & Science University; Rockefeller University; Oregon
   Health & Science University; Oregon Health & Science University;
   University of Texas System; University of Texas Dallas; University of
   Texas Southwestern Medical Center Dallas
RP Klein, ML (通讯作者)，Oregon Hlth Sci Univ, Dept Ophthalmol, Macular Degenerat Ctr, Casey Eye Inst, 3375 SW Terwilliger Blvd, Portland, OR 97201 USA.
FU NEI NIH HHS [EY 12203, R01 EY012203, EY 03279, R01 EY008247, R01
   EY003279, EY 08247, P30 EY010572, EY 10572] Funding Source: Medline;
   NHGRI NIH HHS [HG00008, R01 HG000008] Funding Source: Medline; NATIONAL
   EYE INSTITUTE [R01EY008247, R01EY003279, R01EY012203, P30EY010572]
   Funding Source: NIH RePORTER
CR Allikmets R, 1997, SCIENCE, V277, P1805, DOI 10.1126/science.277.5333.1805
   Badner JA, 1998, AM J HUM GENET, V63, P880, DOI 10.1086/302007
   Broman KW, 1998, AM J HUM GENET, V63, P861, DOI 10.1086/302011
   COTTINGHAM RW, 1993, AM J HUM GENET, V53, P252
   Cox NJ, 1999, NAT GENET, V21, P213, DOI 10.1038/6002
   Evans J, 1996, BRIT J OPHTHALMOL, V80, P9, DOI 10.1136/bjo.80.1.9
   Gudbjartsson DF, 2000, NAT GENET, V25, P12, DOI 10.1038/75514
   HAINES JL, 2002, ASS RES VIS OPHTH M
   IYENGAR SK, 2002, ASS RES VIS OPHTH M
   Kent WJ, 2002, GENOME RES, V12, P996, DOI 10.1101/gr.229102
   Klein ML, 1998, ARCH OPHTHALMOL-CHIC, V116, P1082, DOI 10.1001/archopht.116.8.1082
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Klein R, 2002, OPHTHALMOLOGY, V109, P1767, DOI 10.1016/S0161-6420(02)01146-6
   LANDER E, 1995, NAT GENET, V11, P241, DOI 10.1038/ng1195-241
   Li YJ, 2002, AM J HUM GENET, V70, P985, DOI 10.1086/339815
   Majewski J, 2001, AM J HUM GENET, V69, P853, DOI 10.1086/323419
   McPeek MS, 1999, GENET EPIDEMIOL, V16, P225, DOI 10.1002/(SICI)1098-2272(1999)16:3<225::AID-GEPI1>3.0.CO;2-#
   O'Connell JR, 1998, AM J HUM GENET, V63, P259, DOI 10.1086/301904
   Ott J., 1999, ANAL HUMAN GENETIC L
   TERWILLIGER JD, 1994, HDB HUMAN GENETIC LI
   Weeks DE, 2000, HUM MOL GENET, V9, P1329, DOI 10.1093/hmg/9.9.1329
   Weeks DE, 2001, AM J OPHTHALMOL, V132, P682, DOI 10.1016/S0002-9394(01)01214-4
   Whittemore AS, 2001, AM J HUM GENET, V68, P457, DOI 10.1086/318186
   WILLIAMSON JA, 1995, GENET EPIDEMIOL, V12, P163, DOI 10.1002/gepi.1370120205
NR 24
TC 145
Z9 152
U1 0
U2 4
PU UNIV CHICAGO PRESS
PI CHICAGO
PA 1427 E 60TH ST, CHICAGO, IL 60637-2954 USA
SN 0002-9297
J9 AM J HUM GENET
JI Am. J. Hum. Genet.
PD SEP
PY 2003
VL 73
IS 3
BP 540
EP 550
DI 10.1086/377701
PG 11
WC Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Genetics & Heredity
GA 718FG
UT WOS:000185134000007
PM 12900797
OA Bronze, Green Published
DA 2022-11-30
ER

PT J
AU Abdin, AD
   Suffo, S
   Asi, F
   Langenbucher, A
   Seitz, B
AF Abdin, Alaa Din
   Suffo, Shady
   Asi, Fatima
   Langenbucher, Achim
   Seitz, Berthold
TI Intravitreal ranibizumab versus aflibercept following treat and extend
   protocol for neovascular age-related macular degeneration
SO GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Article
DE Neovascular age-related macular degeneration; Ranibizumab; Aflibercept;
   Treat and extend
ID VEGF; BEVACIZUMAB; OUTCOMES; THERAPY; NEED
AB Purpose To assess the morphological and functional outcome and stability of the "treat and extend" protocol using aflibercept compared to ranibizumab for the treatment of eyes with neovascular age-related macular degeneration.
   Patients and methods This retrospective study included 100 eyes of 94 patients with primary onset neovascular age-related macular degeneration followed up for 12months. We studied two groups of eyes: group 1, 50 eyes treated with 0.5mg/0.05mL ranibizumab and group 2, 50 eyes treated with 2.0mg/0.05mL aflibercept. During the first year, all eyes received 3 aflibercept or ranibizumab injections monthly as upload phase. Then, eyes were treated with a treat and extend algorithm. Main outcome measures included: best corrected visual acuity (BCVA), central macular thickness (CMT), and the number of injections. In addition, we compared recurrence rates between the two groups.
   Results BCVA (log MAR) in group 1 vs group 2 was 0.54 +/- 0.31 vs 0.49 +/- 0.30 (p=0.38) before treatment and 0.49 +/- 0.33 vs 0.47 +/- 0.32 (p=0.85) after treatment. The visual improvement (decimal) was 0.05 +/- 0.13 vs 0.04 +/- 0.12 (p=0.91). CMT in group 1 vs group 2 was 375.6 +/- 98.3 mu m vs 369.6 +/- 103.7 mu m (p=0.73) before treatment and 306.3 +/- 71.8 mu m vs 294.8 +/- 96 mu m (p=0.54) after treatment. The decrease in CMT was 69.3 +/- 93 mu m vs 74.8 +/- 96 mu m (p=0.77). The number of injections/eye after upload phase in group 1 vs group 2 was 5.88 +/- 1.4 vs 6.16 +/- 1.3 (p=0.25). Finally, major recurrence rates were statistically significantly different between the two groups (2% vs 6%, p=0.04).
   Conclusions Significant differences regarding BCVA, central macular thickness, and the number of injections were not found between aflibercept and ranibizumab during the first year following the treat and extend protocol. However, the significantly higher major recurrence rates in the aflibercept group after extending the treatment interval to 10 weeks might suggest that aflibercept should better not to be used in longer than 8 weeks intervals during the first year of treatment.
C1 [Abdin, Alaa Din; Suffo, Shady; Asi, Fatima; Seitz, Berthold] Saarland Univ, Dept Ophthalmol, Med Ctr, UKS, KirrbergerStr 100,Bldg 22, D-66421 Homburg, Saar, Germany.
   [Langenbucher, Achim] Saarland Univ, Inst Expt Ophthalmol, Homburg, Saar, Germany.
C3 Universitatsklinikum des Saarlandes; Universitatsklinikum des Saarlandes
RP Abdin, AD (通讯作者)，Saarland Univ, Dept Ophthalmol, Med Ctr, UKS, KirrbergerStr 100,Bldg 22, D-66421 Homburg, Saar, Germany.
EM alaadin.abdin@uks.eu
RI Seitz, Berthold/AAB-8546-2019
OI Seitz, Berthold/0000-0001-9701-8204; Abdin, Alaadin/0000-0001-8190-7277
CR Abdin AD, 2020, OPHTHALMOLOGE, V117, P50, DOI 10.1007/s00347-019-0911-5
   Augustin AJ, 2009, EXPERT OPIN THER TAR, V13, P641, DOI 10.1517/14728220902942322
   Beck RW, 2003, AM J OPHTHALMOL, V135, P194, DOI 10.1016/S0002-9394(02)01825-1
   Berg K, 2015, OPHTHALMOLOGY, V122, P146, DOI 10.1016/j.ophtha.2014.07.041
   Chakravarthy U, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.04.015
   Ferrara N, 2003, NAT MED, V9, P669, DOI 10.1038/nm0603-669
   Ferrara N, 2006, RETINA-J RET VIT DIS, V26, P859, DOI 10.1097/01.iae.0000242842.14624.e7
   Freund KB, 2015, RETINA-J RET VIT DIS, V35, P1489, DOI 10.1097/IAE.0000000000000627
   Gillies MC, 2016, OPHTHALMOLOGY, V123, P2545, DOI 10.1016/j.ophtha.2016.08.016
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Holz FG, 2015, BRIT J OPHTHALMOL, V99, P220, DOI 10.1136/bjophthalmol-2014-305327
   Jeng KW, 2014, RETINA-J RET VIT DIS, V34, P1796, DOI 10.1097/IAE.0000000000000182
   Lad EM, 2014, AM J OPHTHALMOL, V158, P537, DOI 10.1016/j.ajo.2014.05.014
   Mantel I, 2013, GRAEF ARCH CLIN EXP, V251, P697, DOI 10.1007/s00417-012-2090-9
   Rasmussen A, 2013, OPHTHALMOLOGY, V120, P2630, DOI 10.1016/j.ophtha.2013.05.018
   Rayess N, 2015, AM J OPHTHALMOL, V159, P3, DOI 10.1016/j.ajo.2014.09.011
   Rush RB, 2014, RETINA-J RET VIT DIS, V34, P846, DOI 10.1097/IAE.0000000000000033
   Schmidt-Erfurth U, 2014, BRIT J OPHTHALMOL, V98, P1144, DOI 10.1136/bjophthalmol-2014-305702
   Schmidt-Erfurth U, 2014, OPHTHALMOLOGY, V121, P193, DOI 10.1016/j.ophtha.2013.08.011
   Spaide R, 2007, AM J OPHTHALMOL, V143, P679, DOI 10.1016/j.ajo.2007.02.024
   Stewart MW, 2008, BRIT J OPHTHALMOL, V92, P667, DOI 10.1136/bjo.2007.134874
   Stewart MW, 2014, EXPERT REV CLIN PHAR, V7, P167, DOI 10.1586/17512433.2014.884458
   Stewart MW, 2012, CLIN OPHTHALMOL, V6, P1175, DOI 10.2147/OPTH.S33372
   Stewart MW, 2012, NAT REV DRUG DISCOV, V11, P269, DOI 10.1038/nrd3700
NR 24
TC 8
Z9 9
U1 0
U2 1
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 0721-832X
EI 1435-702X
J9 GRAEF ARCH CLIN EXP
JI Graefes Arch. Clin. Exp. Ophthalmol.
PD AUG
PY 2019
VL 257
IS 8
BP 1671
EP 1677
DI 10.1007/s00417-019-04360-9
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA IJ3MX
UT WOS:000475809900011
PM 31144055
DA 2022-11-30
ER

PT J
AU Xu, J
   Zhu, DH
   He, SK
   Spee, C
   Ryan, SJ
   Hinton, DR
AF Xu, Jing
   Zhu, Danhong
   He, Shikun
   Spee, Christine
   Ryan, Stephen J.
   Hinton, David R.
TI Transcriptional regulation of bone morphogenetic protein 4 by tumor
   necrosis factor and its relationship with age-related macular
   degeneration
SO FASEB JOURNAL
LA English
DT Article
DE choroidal neovascularization; CNV; c-Jun NH(2)-terminal kinase; JNK;
   specificity protein 1; Sp1; phosphorylation
ID INDUCED CHOROIDAL NEOVASCULARIZATION; ENDOTHELIAL GROWTH-FACTOR; PIGMENT
   EPITHELIAL-CELLS; TNF-ALPHA; SP1 PHOSPHORYLATION; GENE-TRANSCRIPTION;
   SIGNALING PATHWAY; MOUSE EMBRYO; EXPRESSION; BMP4
AB Bone morphogenetic protein-4 (BMP4) may be involved in the molecular switch that determines which late form of age-related macular degeneration (AMD) an individual develops. BMP4 expression is high in retinal pigment epithelium (RPE) cells in late, dry AMD patients, while BMP4 expression is low in the wet form of the disease, characterized by choroidal neovascularization (CNV). Here, we sought to determine the mechanism by which BMP4 is down-regulated in CNV. BMP4 expression was decreased within laser-induced CNV lesions in mice at a time when tumor necrosis factor (TNF) expression was high (7 d postlaser) and was reexpressed in RPE when TNF levels declined (14 d postlaser). We found that TNF, an important angiogenic stimulus, significantly down-regulates BMP4 expression in cultured human fetal RPE cells, ARPE-19 cells, and RPE cells in murine posterior eye cup explants. We identified two specificity protein 1 (Sp1) binding sites in the BMP4 promoter that are required for basal expression of BMP4 and its down-regulation by TNF. Through c-Jun NH(2)-terminal kinase (JNK) activation, TNF modulates Sp1 phosphorylation, thus decreasing its affinity to the BMP4 promoter. The down-regulation of BMP4 expression by TNF in CNV and mechanisms established might be useful for defining novel targets for AMD therapy.-Xu, J., Zhu, D., He, S., Spee, C., Ryan, S. J., Hinton, D. R. Transcriptional regulation of bone morphogenetic protein 4 by tumor necrosis factor and its relationship with age-related macular degeneration. FASEB J. 25, 2221-2233 (2011). www.fasebj.org
C1 [Xu, Jing] Univ So Calif, Keck Sch Med, Grad Program Neurosci, Los Angeles, CA 90089 USA.
   [He, Shikun; Hinton, David R.] Univ So Calif, Keck Sch Med, Dept Pathol, Los Angeles, CA 90089 USA.
   [Zhu, Danhong; He, Shikun; Spee, Christine; Ryan, Stephen J.; Hinton, David R.] Univ So Calif, Keck Sch Med, Dept Ophthalmol, Los Angeles, CA 90089 USA.
   [Xu, Jing; Zhu, Danhong; He, Shikun; Spee, Christine; Ryan, Stephen J.; Hinton, David R.] Doheny Eye Inst, Los Angeles, CA 90033 USA.
C3 University of Southern California; University of Southern California;
   University of Southern California; Doheny Eye Institute
RP Hinton, DR (通讯作者)，Univ So Calif, Keck Sch Med, Dept Pathol & Ophthalmol, 2011 Zonal Ave,HMR 209, Los Angeles, CA 90089 USA.
EM dhinton@hsc.usc.edu
FU U.S. National Institutes of Health [EY01545, EY03040]; Arnold and Mabel
   Beckman Foundation; Research to Prevent Blindness Inc. (New York, NY,
   USA); NATIONAL EYE INSTITUTE [R01EY001545] Funding Source: NIH RePORTER
FX The authors thank Dr. Ram Kannan, Dr. Jeannie Chen, and Dr. Harold
   Kochounian for discussion and comments on this manuscript. The authors
   thank Ernesto Barron and Eric Barron for assistance with figure
   preparation. This research was supported by U.S. National Institutes of
   Health grants EY01545 and EY03040, the Arnold and Mabel Beckman
   Foundation, and an unrestricted grant to the Department of Ophthalmology
   from Research to Prevent Blindness Inc. (New York, NY, USA).
CR Afonso V, 2006, FREE RADICAL BIO MED, V41, P709, DOI 10.1016/j.freeradbiomed.2006.05.014
   An E, 2006, J PROTEOME RES, V5, P2599, DOI 10.1021/pr060121j
   An EY, 2008, MOL VIS, V14, P2292
   Anderson HDI, 2004, J BIOL CHEM, V279, P963, DOI 10.1074/jbc.M309552200
   Armstrong SA, 1997, J BIOL CHEM, V272, P13489, DOI 10.1074/jbc.272.21.13489
   Bakrania P, 2008, AM J HUM GENET, V82, P304, DOI 10.1016/j.ajhg.2007.09.023
   Bandyopadhyay A, 2006, PLOS GENET, V2, P2116, DOI 10.1371/journal.pgen.0020216
   Bilsland AE, 2006, CANCER RES, V66, P1363, DOI 10.1158/0008-5472.CAN-05-1941
   Bonello MR, 2004, J BIOL CHEM, V279, P2377, DOI 10.1074/jbc.M308254200
   Bramlage CP, 2006, ARTHRITIS RES THER, V8, DOI 10.1186/ar1923
   Chang B, 2001, BMC GENET, V2, DOI 10.1186/1471-2156-2-18
   Chappelow AV, 2008, DRUGS, V68, P1029, DOI 10.2165/00003495-200868080-00002
   Chen GQ, 2002, SCIENCE, V296, P1634, DOI 10.1126/science.1071924
   Chu SJ, 2005, GENE, V348, P1, DOI 10.1016/j.gene.2005.01.013
   Chuang JY, 2008, MOL BIOL CELL, V19, P1139, DOI 10.1091/mbc.E07-09-0881
   Chun RF, 1998, J VIROL, V72, P2615, DOI 10.1128/JVI.72.4.2615-2629.1998
   Das M, 2007, P NATL ACAD SCI USA, V104, P15759, DOI 10.1073/pnas.0707782104
   de Jong PTVM, 2006, NEW ENGL J MED, V355, P1474, DOI 10.1056/NEJMra062326
   Denson LA, 2001, J CLIN INVEST, V107, P1451, DOI 10.1172/JCI10994
   Ding XY, 2009, PROG RETIN EYE RES, V28, P1, DOI 10.1016/j.preteyeres.2008.10.001
   Dunn KC, 1996, EXP EYE RES, V62, P155, DOI 10.1006/exer.1996.0020
   FOJAS DB, 2001, EMBO J, V20, P5737
   Furuta Y, 1998, GENE DEV, V12, P3764, DOI 10.1101/gad.12.23.3764
   Garcia-Layana A, 2009, OPHTHALMIC RES, V42, P205, DOI 10.1159/000232946
   Gehrs KM, 2006, ANN MED, V38, P450, DOI 10.1080/07853890600946724
   Hangai M, 2006, J NEUROIMMUNOL, V171, P45, DOI 10.1016/j.jneuroim.2005.09.018
   Hangai M, 2001, INVEST OPHTH VIS SCI, V42, P1617
   Higuchi H, 2004, J BIOL CHEM, V279, P51, DOI 10.1074/jbc.M309476200
   Holtkamp GM, 2001, PROG RETIN EYE RES, V20, P29, DOI 10.1016/S1350-9462(00)00017-3
   Horiguchi M, 2000, CYTOKINE, V12, P526, DOI 10.1006/cyto.1999.0577
   Huang J, 2009, DEVELOPMENT, V136, P1741, DOI 10.1242/dev.034082
   Jin M, 2004, INVEST OPHTH VIS SCI, V45, P323, DOI 10.1167/iovs.03-0355
   Kane R, 2008, MOL VIS, V14, P1138
   Kiyono M, 2006, ONCOGENE, V25, P7131, DOI 10.1038/sj.onc.1209700
   Kiyono M, 2003, MOL CELL BIOL, V23, P4627, DOI 10.1128/MCB.23.13.4627-4636.2003
   Koga T, 2007, AM J PHYSIOL-LUNG C, V293, pL693, DOI 10.1152/ajplung.00491.2006
   Lawson KA, 1999, GENE DEV, V13, P424, DOI 10.1101/gad.13.4.424
   LEE JJ, ONCOGENE, V29, P561
   Lichtlen P, 2010, INVEST OPHTH VIS SCI, V51, P4738, DOI 10.1167/iovs.09-4890
   Lopez PF, 1996, INVEST OPHTH VIS SCI, V37, P855
   Markomichelakis NN, 2005, AM J OPHTHALMOL, V139, P537, DOI 10.1016/j.ajo.2004.09.058
   Mathura JR, 2000, INVEST OPHTH VIS SCI, V41, P592
   Milanini-Mongiat J, 2002, J BIOL CHEM, V277, P20631, DOI 10.1074/jbc.M201753200
   Muller F, 2007, DEVELOPMENT, V134, P3483, DOI 10.1242/dev.02884
   Oh H, 1999, INVEST OPHTH VIS SCI, V40, P1891
   Olson JL, 2007, ARCH OPHTHALMOL-CHIC, V125, P1221, DOI 10.1001/archopht.125.9.1221
   Park KM, 2009, J BIOL CHEM, V284, P27557, DOI 10.1074/jbc.M109.034504
   Plikus MV, 2008, NATURE, V451, P340, DOI 10.1038/nature06457
   Schlingemann RO, 2004, GRAEF ARCH CLIN EXP, V242, P91, DOI 10.1007/s00417-003-0828-0
   Shi X, 2006, EXP EYE RES, V83, P1325, DOI 10.1016/j.exer.2006.07.007
   Shimizu T, 1998, BONE, V23, P127, DOI 10.1016/S8756-3282(98)00086-6
   Singhatanadgit W, 2006, INT J BIOCHEM CELL B, V38, P1794, DOI 10.1016/j.biocel.2006.05.005
   Sonoda S, 2009, NAT PROTOC, V4, P662, DOI 10.1038/nprot.2009.33
   Sreekumar PG, 2008, INVEST OPHTH VIS SCI, V49, P1210, DOI 10.1167/iovs.07-0667
   Tan NY, 2009, MOL CELL BIOL, V29, P2483, DOI 10.1128/MCB.01828-08
   Theodossiadis PG, 2009, AM J OPHTHALMOL, V147, P825, DOI 10.1016/j.ajo.2008.12.004
   Thompson DL, 2003, MOL CELL BIOL, V23, P2277, DOI 10.1128/MCB.23.7.2277-2286.2003
   Trousse F, 2001, J NEUROSCI, V21, P1292
   vandenWijngaard A, 1996, BIOCHEM BIOPH RES CO, V219, P789, DOI 10.1006/bbrc.1996.0312
   Wajant H, 2003, CELL DEATH DIFFER, V10, P45, DOI 10.1038/sj.cdd.4401189
   Weaver M, 2000, DEVELOPMENT, V127, P2695
   Weston CR, 2003, GENE DEV, V17, P1271, DOI 10.1101/gad.1087303
   Wordinger RJ, 2007, EXP BIOL MED, V232, P979, DOI 10.3181/0510-MR-345
   Yang P, 2005, INVEST OPHTH VIS SCI, V46, P1755, DOI 10.1167/iovs.04-1039
   Zhu DH, 2009, AGING-US, V1, P740, DOI 10.18632/aging.100078
   Zhu DH, 2009, J BIOL CHEM, V284, P9529, DOI 10.1074/jbc.M809393200
   Zhu GH, 2002, ONCOGENE, V21, P8477, DOI 10.1038/sj.onc.1206030
   Zhu NL, 2007, GENE, V393, P70, DOI 10.1016/j.gene.2007.01.016
NR 68
TC 17
Z9 19
U1 1
U2 5
PU FEDERATION AMER SOC EXP BIOL
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA
SN 0892-6638
J9 FASEB J
JI Faseb J.
PD JUL
PY 2011
VL 25
IS 7
BP 2221
EP 2233
DI 10.1096/fj.10-178350
PG 13
WC Biochemistry & Molecular Biology; Biology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other
   Topics; Cell Biology
GA 785PY
UT WOS:000292242200014
PM 21411747
OA Green Published
DA 2022-11-30
ER

PT J
AU Burgansky-Eliash, Z
   Barash, H
   Nelson, D
   Grinvald, A
   Sorkin, A
   Loewenstein, A
   Barak, A
AF Burgansky-Eliash, Zvia
   Barash, Hila
   Nelson, Darin
   Grinvald, Amiram
   Sorkin, Alina
   Loewenstein, Anat
   Barak, Adiel
TI Retinal Blood Flow Velocity in Patients with Age-Related Macular
   Degeneration
SO CURRENT EYE RESEARCH
LA English
DT Article
DE Age-related macular degeneration; imaging; retinal blood flow velocity;
   retinal physiology; RFI
ID CARDIOVASCULAR RISK-FACTORS; ENDOTHELIAL GROWTH-FACTOR;
   BLUE-MOUNTAINS-EYE; CHOROIDAL NEOVASCULARIZATION; INTRAVITREAL
   INJECTION; BEVACIZUMAB AVASTIN(R); DIABETIC-RETINOPATHY; BEAVER DAM;
   MACULOPATHY; ATHEROSCLEROSIS
AB Purpose/Aim of the study: To study changes in retinal blood flow velocity in patients with early and neovascular age-related macular degeneration (AMD). We used the Retinal Function Imager (RFI, Optical Imaging Ltd., Rehovot, Israel), a noninvasive diagnostic approach for measuring blood flow velocity.
   Materials and Methods: Sixty eyes of 43 AMD patients and 53 eyes of 35 healthy individuals over the age of 50 were recruited for this study. All patients were scanned by the RFI with analysis of blood flow velocity of secondary and tertiary branches of arteries and veins. Differences among groups were assessed by mixed linear models.
   Results: The average velocity in AMD patients was significantly lower compared to controls in arteries (3.6 +/- 1.4 versus 4.3 +/- 1.0 mm/sec, p=0.009) but not in veins (2.6 +/- 0.9 versus 3.1 +/- 0.6 mm/sec, p = 0.08). When comparing the velocity between low-and high-grade AMD eyes, venous velocity was slower in the high grade AMD eyes only in the "narrow'' group of vessels.
   Conclusions: Decreased blood flow velocity in retinal arteries in patients with AMD was found. Despite the fact that AMD is essentially a choroidal disease, retinal vessels show a functional abnormality, which may suggest that the vascular abnormality in this disease is more generalized.
C1 [Burgansky-Eliash, Zvia] Edith Wolfson Med Ctr, Dept Ophthalmol, Holon, Israel.
   [Burgansky-Eliash, Zvia; Barash, Hila; Loewenstein, Anat; Barak, Adiel] Tel Aviv Univ, Sackler Sch Med, IL-69978 Tel Aviv, Israel.
   [Nelson, Darin; Sorkin, Alina] Opt Imaging Ltd, Rehovot, Israel.
   [Grinvald, Amiram] Weizmann Inst Sci, Dept Neurobiol, IL-76100 Rehovot, Israel.
   [Loewenstein, Anat; Barak, Adiel] Sourasky Med Ctr, Dept Ophthalmol, Tel Aviv, Israel.
C3 Tel Aviv University; Sackler Faculty of Medicine; Weizmann Institute of
   Science; Tel Aviv University; Sackler Faculty of Medicine; Tel Aviv
   Sourasky Medical Center
RP Barak, A (通讯作者)，Sourasky Med Ctr, Dept Ophthalmol, Tel Aviv, Israel.
EM adielbarak@gmail.com
RI GRINVALD, AMIRAM/AAH-9919-2019
FU Optical Imaging, Ltd.
FX Patents and inventor (AG), all other authors report no conflicts of
   interest. The authors alone are responsible for the content and writing
   of the paper. Funding was provided by Optical Imaging, Ltd.
CR Anand R, 2000, OPHTHALMOLOGY, V107, P2224
   Barak A, 2012, EUR J OPHTHALMOL, V22, P423, DOI 10.5301/ejo.5000074
   Beutelspacher SC, 2011, ACTA OPHTHALMOL, V89, pE479, DOI 10.1111/j.1755-3768.2011.02136.x
   Bhutto IA, 2010, EXP EYE RES, V90, P155, DOI 10.1016/j.exer.2009.10.004
   Blaauwgeers HGT, 1999, AM J PATHOL, V155, P421, DOI 10.1016/S0002-9440(10)65138-3
   Boltz A, 2010, INVEST OPHTH VIS SCI, V51, P4220, DOI 10.1167/iovs.09-4968
   Bonnin P, 2010, ACTA OPHTHALMOL, V88, P641, DOI 10.1111/j.1755-3768.2009.01526.x
   Burgansky-Eliash Z, 2010, RETINA-J RET VIT DIS, V30, P765, DOI 10.1097/IAE.0b013e3181c596c6
   Chaine G, 1998, BRIT J OPHTHALMOL, V82, P996, DOI 10.1136/bjo.82.9.996
   Cheung N, 2007, BRIT J OPHTHALMOL, V91, P430, DOI 10.1136/bjo.2006.106054
   Ciulla TA, 1999, AM J OPHTHALMOL, V128, P75, DOI 10.1016/S0002-9394(99)00061-6
   Ciulla TA, 2001, ACTA OPHTHALMOL SCAN, V79, P108, DOI 10.1034/j.1600-0420.2001.079002108.x
   Feigl B, 2007, EYE, V21, P689, DOI 10.1038/sj.eye.6702389
   Feigl B, 2007, CLIN EXP OPTOM, V90, P263, DOI 10.1111/j.1444-0938.2007.00152.x
   Feigl B, 2009, PROG RETIN EYE RES, V28, P63, DOI 10.1016/j.preteyeres.2008.11.004
   Ferris FL, 2005, ARCH OPHTHALMOL-CHIC, V123, P1570
   Fine SL, 2005, AM J OPHTHALMOL, V139, P405, DOI 10.1016/j.ajo.2004.11.050
   Fontaine O, 2011, INVEST OPHTH VIS SCI, V52, P7400, DOI 10.1167/iovs.10-6646
   FRIEDMAN E, 1995, OPHTHALMOLOGY, V102, P640, DOI 10.1016/S0161-6420(95)30974-8
   GOLDBERG J, 1988, AM J EPIDEMIOL, V128, P700, DOI 10.1093/oxfordjournals.aje.a115023
   GRINVALD A, 1986, NATURE, V324, P361, DOI 10.1038/324361a0
   Grisanti S, 2008, PROG RETIN EYE RES, V27, P372, DOI 10.1016/j.preteyeres.2008.05.002
   Grunwald JE, 1998, INVEST OPHTH VIS SCI, V39, P385
   Grunwald JE, 2005, INVEST OPHTH VIS SCI, V46, P1033, DOI 10.1167/iovs.04-1050
   HAYREH SS, 1990, EYE, V4, P273, DOI 10.1038/eye.1990.39
   Hirvela H, 1996, OPHTHALMOLOGY, V103, P871, DOI 10.1016/S0161-6420(96)30593-9
   KAHN HA, 1977, AM J EPIDEMIOL, V106, P33, DOI 10.1093/oxfordjournals.aje.a112429
   KLEIN R, 1993, OPHTHALMOLOGY, V100, P406
   Klein R, 2013, OPHTHALMOLOGY, V120, P1012, DOI 10.1016/j.ophtha.2012.11.003
   Klein R, 2010, ARCH OPHTHALMOL-CHIC, V128, P750, DOI 10.1001/archophthalmol.2010.92
   Maguire MG, 1997, ARCH OPHTHALMOL-CHIC, V115, P741
   McLeod DS, 2009, INVEST OPHTH VIS SCI, V50, P4982, DOI 10.1167/iovs.09-3639
   McLeod DS, 2002, INVEST OPHTH VIS SCI, V43, P1986
   Medeiros NE, 2001, INVEST OPHTH VIS SCI, V42, P795
   Metelitsina TI, 2008, INVEST OPHTH VIS SCI, V49, P358, DOI 10.1167/iovs.07-0526
   Micieli JA, 2012, ACTA OPHTHALMOL, V90, pE13, DOI 10.1111/j.1755-3768.2011.02209.x
   Nagaoka T, 2006, ARCH OPHTHALMOL-CHIC, V124, P665, DOI 10.1001/archopht.124.5.665
   Noma H, 2009, BRIT J OPHTHALMOL, V93, P630, DOI 10.1136/bjo.2008.146597
   OHNISHI Y, 1994, AM J OPHTHALMOL, V117, P24, DOI 10.1016/S0002-9394(14)73011-9
   Pauleikhoff D, 1999, ARCH OPHTHALMOL-CHIC, V117, P1353, DOI 10.1001/archopht.117.10.1353
   Pauleikhoff D, 1992, Ger J Ophthalmol, V1, P12
   Rosenfeld Philip J, 2006, Ophthalmol Clin North Am, V19, P361
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Sato E, 2006, EYE, V20, P697, DOI 10.1038/sj.eye.6701951
   Sato E, 2006, GRAEF ARCH CLIN EXP, V244, P963, DOI 10.1007/s00417-005-0201-6
   Smith W, 1998, ARCH OPHTHALMOL-CHIC, V116, P583, DOI 10.1001/archopht.116.5.583
   Snow K K, 1999, Ophthalmic Epidemiol, V6, P125, DOI 10.1076/opep.6.2.125.1558
   Tan JSL, 2007, OPHTHALMOLOGY, V114, P1143, DOI 10.1016/j.ophtha.2006.09.033
   Toklu Y, 2011, ACTA OPHTHALMOL, V89, pE41, DOI 10.1111/j.1755-3768.2010.02075.x
   Tomany SC, 2004, OPHTHALMOLOGY, V111, P1280, DOI 10.1016/j.ophtha.2003.11.010
   van Leeuwen R, 2003, INVEST OPHTH VIS SCI, V44, P3771, DOI 10.1167/iovs.03-0121
   VANDERKOOI JM, 1991, AM J PHYSIOL, V260, pC1131, DOI 10.1152/ajpcell.1991.260.6.C1131
   VINGERLING JR, 1995, AM J EPIDEMIOL, V142, P404, DOI 10.1093/oxfordjournals.aje.a117648
   Vingerling JR, 1996, ARCH OPHTHALMOL-CHIC, V114, P1193, DOI 10.1001/archopht.1996.01100140393005
   Wickremasinghe SS, 2012, CLIN EXP OPHTHALMOL, V40, P59, DOI 10.1111/j.1442-9071.2011.02613.x
   Wilkinson-Berka JL, 2004, CURR PHARM DESIGN, V10, P3331, DOI 10.2174/1381612043383142
   Ziemssen Focke, 2009, International Ophthalmology, V29, P213, DOI 10.1007/s10792-008-9221-7
NR 57
TC 31
Z9 35
U1 0
U2 11
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0271-3683
EI 1460-2202
J9 CURR EYE RES
JI Curr. Eye Res.
PD MAR
PY 2014
VL 39
IS 3
BP 304
EP 311
DI 10.3109/02713683.2013.840384
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA AD1YS
UT WOS:000333030200010
PM 24147793
DA 2022-11-30
ER

PT J
AU Schwartz, SG
   Agarwal, A
   Kovach, JL
   Gallins, PJ
   Cade, W
   Postel, EA
   Wang, GF
   Ayala-Haedo, J
   Spencer, KM
   Haines, JL
   Pericak-Vance, MA
   Scott, WK
AF Schwartz, Stephen G.
   Agarwal, Anita
   Kovach, Jaclyn L.
   Gallins, Paul J.
   Cade, William
   Postel, Eric A.
   Wang, Gaofeng
   Ayala-Haedo, Juan
   Spencer, Kylee M.
   Haines, Jonathan L.
   Pericak-Vance, Margaret A.
   Scott, William K.
TI THE ARMS2 A69S VARIANT AND BILATERAL ADVANCED AGE-RELATED MACULAR
   DEGENERATION
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE age-related macular degeneration; ARMS2; choroidal neovascularization;
   genotypes; geographic atrophy
ID COMPLEMENT-FACTOR-H; CHROMOSOME 10Q26; LOC387715 A69S; FACTOR-B;
   POLYMORPHISM; HTRA1; RISK; SUSCEPTIBILITY; ASSOCIATION; INCREASES
AB Purpose: To identify genetic associations between specific risk genes and bilateral advanced age-related macular degeneration (AMD) in a retrospective, observational case series of 1,003 patients: 173 patients with geographic atrophy in at least 1 eye and 830 patients with choroidal neovascularization in at least 1 eye.
   Methods: Patients underwent clinical examination and fundus photography. The images were subsequently graded using a modified grading system adapted from the Age-Related Eye Disease Study. Genetic analysis was performed to identify genotypes at 4 AMD-associated variants (ARMS2 A69S, CFH Y402H, C3 R102G, and CFB R32Q) in these patients.
   Results: There were no statistically significant relationships between clinical findings and genotypes at CFH, C3, and CFB. The genotype at ARMS2 correlated with bilateral advanced AMD using a variety of comparisons: unilateral geographic atrophy versus bilateral geographic atrophy (P = 0.08), unilateral choroidal neovascularization versus bilateral choroidal neovascularization (P = 9.0 x 10(-8)), and unilateral late AMD versus bilateral late AMD (P = 5.9 x 10(-8)).
   Conclusion: In this series, in patients with geographic atrophy or choroidal neovascularization in at least 1 eye, the ARMS2 A69S substitution strongly associated with geographic atrophy or choroidal neovascularization in the fellow eye. The ARMS2 A69S substitution may serve as a marker for bilateral advanced AMD. RETINA 32:1486-1491, 2012
C1 [Schwartz, Stephen G.; Kovach, Jaclyn L.] Univ Miami, Miller Sch Med, Bascom Palmer Eye Inst, Miami, FL 33136 USA.
   [Agarwal, Anita] Vanderbilt Univ, Vanderbilt Eye Inst, Nashville, TN USA.
   [Gallins, Paul J.; Cade, William; Wang, Gaofeng; Ayala-Haedo, Juan; Pericak-Vance, Margaret A.; Scott, William K.] Univ Miami, Miller Sch Med, John P Hussman Inst Human Genom, Miami, FL 33136 USA.
   [Postel, Eric A.] Duke Univ, Ctr Eye, Durham, NC USA.
   [Spencer, Kylee M.; Haines, Jonathan L.] Vanderbilt Univ, Ctr Human Genet Res, Nashville, TN USA.
C3 Bascom Palmer Eye Institute; University of Miami; Vanderbilt University;
   University of Miami; Duke University; Vanderbilt University
RP Schwartz, SG (通讯作者)，311 9th St N,100, Naples, FL 34102 USA.
EM sschwartz2@med.miami.edu
RI Haines, Jonathan/C-3374-2012
OI Haines, Jonathan/0000-0002-4351-4728; Scott, William/0000-0001-9336-6404
FU National Institutes of Health grant [7R01EY012118]; National Institutes
   of Health Center Grant [P30-EY014801]; Research to Prevent Blindness,
   New York, NY; NATIONAL EYE INSTITUTE [P30EY014801, R01EY012118] Funding
   Source: NIH RePORTER
FX Partially supported by the National Institutes of Health grant
   7R01EY012118, National Institutes of Health Center Grant P30-EY014801,
   and by an unrestricted grant to the University of Miami from Research to
   Prevent Blindness, New York, NY.
CR Ambati J, 2003, SURV OPHTHALMOL, V48, P257, DOI 10.1016/S0039-6257(03)00030-4
   Andreoli MT, 2009, AM J OPHTHALMOL, V148, P869, DOI 10.1016/j.ajo.2009.07.002
   Chan Chi-Chao, 2007, Trans Am Ophthalmol Soc, V105, P92
   Chen HY, 2008, VISION RES, V48, P690, DOI 10.1016/j.visres.2007.10.014
   Chowers I, 2008, MOL VIS, V14, P2263
   Cruess AF, 2008, PHARMACOECONOMICS, V26, P57, DOI 10.2165/00019053-200826010-00006
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Friedrich U, 2011, HUM MOL GENET, V20, P1387, DOI 10.1093/hmg/ddr020
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Jakobsdottir J, 2005, AM J HUM GENET, V77, P389, DOI 10.1086/444437
   Kanda A, 2007, P NATL ACAD SCI USA, V104, P16227, DOI 10.1073/pnas.0703933104
   Kanda A, 2010, MOL VIS, V16, P1317
   Klein ML, 2010, OPHTHALMOLOGY, V117, P1554, DOI 10.1016/j.ophtha.2009.12.012
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Kortvely E, 2010, INVEST OPHTH VIS SCI, V51, P79, DOI 10.1167/iovs.09-3850
   Leveziel N, 2010, INVEST OPHTH VIS SCI, V51, P2620, DOI 10.1167/iovs.09-4423
   Maller JB, 2007, NAT GENET, V39, P1200, DOI 10.1038/ng2131
   Pai ASI, 2009, ARCH OPHTHALMOL-CHIC, V127, P1339, DOI 10.1001/archophthalmol.2009.239
   Resnikoff S, 2004, B WORLD HEALTH ORGAN, V82, P844
   Schmidt S, 2006, AM J HUM GENET, V78, P852, DOI 10.1086/503822
   Schmidt S, 2000, MOL VIS, V6, P287
   Scholl HPN, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007418
   Seddon JM, 2010, OPHTHALMOLOGY, V117, P1560, DOI 10.1016/j.ophtha.2009.11.020
   Seitsonen SP, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003833
   Shuler RK, 2008, AM J OPHTHALMOL, V145, P303, DOI 10.1016/j.ajo.2007.09.027
   Spencer KL, 2008, HUM MOL GENET, V17, P1821, DOI 10.1093/hmg/ddn075
   Spencer KL, 2007, HUM MOL GENET, V16, P1986, DOI 10.1093/hmg/ddm146
   Tedeschi-Blok N, 2007, OPHTHALMOLOGY, V114, P99, DOI 10.1016/j.ophtha.2006.07.043
   Tuo J, 2008, OPHTHALMOLOGY, V115, P1891, DOI 10.1016/j.ophtha.2008.05.021
   Wang GF, 2010, ARCH OPHTHALMOL-CHIC, V128, P1491, DOI 10.1001/archophthalmol.2010.256
   Wang GF, 2009, INVEST OPHTH VIS SCI, V50, P3084, DOI 10.1167/iovs.08-3240
   Yang ZL, 2006, SCIENCE, V314, P992, DOI 10.1126/science.1133811
   Yang ZL, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1000836
   Yates JRW, 2007, NEW ENGL J MED, V357, P553, DOI 10.1056/NEJMoa072618
NR 36
TC 19
Z9 21
U1 0
U2 4
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0275-004X
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD SEP
PY 2012
VL 32
IS 8
BP 1486
EP 1491
DI 10.1097/IAE.0b013e318240a540
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 004HN
UT WOS:000308672300008
PM 22481475
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Pandi, SPS
   Rajendran, A
   Krishnan, SR
   Anto, MJ
   Gardiner, T
   Chakravarthy, U
   Veerappan, M
AF Pandi, Sudha Priya Soundara
   Rajendran, Anand
   Krishnan, Santhi Radha
   Anto, Minu Jenifer
   Gardiner, Tom
   Chakravarthy, Usha
   Veerappan, Muthukkaruppan
TI Characterization of age-related macular degeneration in Indian donor
   eyes
SO INDIAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE Age-related macular degeneration; donor eyes; fundus images;
   histopathology; retinal pigment epithelium
AB Purpose: The purpose of this study was to test the reliability of fundus stereomicroscopy in postmortem eyes to assign severity of age-related macular degeneration (AMD) using the Minnesota grading and confirmation by histology using Alabama and Sarks grading scales and to assess the incidence of AMD pathology in donor eyes from a South Indian population. Methods: Eyes (199) from 153 donors (55-95 years) after obtaining fundus images were processed for histology. Fundus images were graded according to the Minnesota grading system based on drusen size, area of depigmentation, and atrophy. At least one eye from each donor displaying the AMD phenotypes were subjected to histological examination. The fundus grading was correlated with histology and the stages of AMD assigned for early AMD by the Alabama AMD grading system and for both early and advanced AMD by the Sarks classification. Results: Stereoscopic examination of the fundus found that 10 of the 153 donors had features of early AMD and 3 advanced AMD. Following histological examination, one of the early AMD eyes was reclassified as advanced AMD. Early AMD features that were observed on histology included soft drusen (>63 mu m), basal laminar deposits, photoreceptor outer segment degeneration, disorganization of retinal pigment epithelium (RPE), Bruch's membrane thickening. Advanced AMD features observed in histology are extensive atrophy of RPE, choroidal neovascularization and disciform scar formation. Conclusion: Identification of either early or advanced AMD using stereomicroscopic assessment (SMA) showed high sensitivity and specificity. However, misclassification between AMD stages can occur when only SMA is used.
C1 [Pandi, Sudha Priya Soundara; Anto, Minu Jenifer; Veerappan, Muthukkaruppan] Aravind Med Res Fdn, Dr G Venkataswamy Eye Res Inst, Dept Stem Cell Biol, Madurai, Tamil Nadu, India.
   [Rajendran, Anand] Aravind Eye Hosp, Vitreoretinal Serv, Chennai, Tamil Nadu, India.
   [Krishnan, Santhi Radha] Aravind Eye Hosp, Dept Pathol, Madurai, Tamil Nadu, India.
   [Krishnan, Santhi Radha] Postgrad Inst Ophthalmol, Madurai, Tamil Nadu, India.
   [Anto, Minu Jenifer] Bharathiyar Univ, Dept Human Genet & Mol Biol, Coimbatore, Tamil Nadu, India.
   [Pandi, Sudha Priya Soundara; Gardiner, Tom; Chakravarthy, Usha] Queens Univ Belfast, Ctr Vis Sci, Belfast, Antrim, North Ireland.
   [Pandi, Sudha Priya Soundara] Univ Southampton, Fac Med, Clin & Expt Sci, Southampton, Hants, England.
C3 Bharathiar University; Queens University Belfast; University of
   Southampton
RP Veerappan, M (通讯作者)，Aravind Med Res Fdn, Dr G Venkataswamy Eye Res Inst, Madurai 625020, Tamil Nadu, India.
EM muthu@aravind.org
RI Veerappan, Muthukkaruppan/AAE-8516-2022
OI Soundara Pandi, Sudha Priya/0000-0002-0308-0742; Jenifer,
   Minu/0000-0002-7819-8884; Gardiner, Tom/0000-0003-4907-2630
FU ALCON Research Fellowship
FX ALCON Research Fellowship to Sudha Priya Soundara Pandi
CR Age-Related Eye Dis Study Res Grp, 2001, AM J OPHTHALMOL, V132, P668
   Bressler Neil M, 2002, J Am Board Fam Pract, V15, P142
   Curcio CA, 1998, INVEST OPHTH VIS SCI, V39, P1085
   Ding XY, 2009, PROG RETIN EYE RES, V28, P1, DOI 10.1016/j.preteyeres.2008.10.001
   Fine SL, 2000, NEW ENGL J MED, V342, P483, DOI 10.1056/NEJM200002173420707
   Hageman G.S., 1995, ORIANIZATION RETINA
   Hawkins BS, 1999, MOL VIS, V5
   Klein R, 2004, AM J OPHTHALMOL, V137, P486, DOI 10.1016/j.ajo.2003.11.069
   Krishnaiah S, 2005, INVEST OPHTH VIS SCI, V46, P4442, DOI 10.1167/iovs.05-0853
   Krishnan T, 2010, INVEST OPHTH VIS SCI, V51, P701, DOI 10.1167/iovs.09-4114
   Nowak JZ, 2006, PHARMACOL REP, V58, P353
   Olsen TW, 2004, INVEST OPHTH VIS SCI, V45, P4484, DOI 10.1167/iovs.04-0342
   SARKS SH, 1976, BRIT J OPHTHALMOL, V60, P324, DOI 10.1136/bjo.60.5.324
   Stone EM, 1999, NAT GENET, V22, P199, DOI 10.1038/9722
   Stone EM, 2001, HUM MOL GENET, V10, P2285, DOI 10.1093/hmg/10.20.2285
   Tanaka N, 2006, MOL THER, V13, P609, DOI 10.1016/j.ymthe.2005.08.024
   Zeiss CJ, 2010, VET PATHOL, V47, P396, DOI 10.1177/0300985809359598
NR 17
TC 0
Z9 0
U1 0
U2 1
PU WOLTERS KLUWER MEDKNOW PUBLICATIONS
PI MUMBAI
PA WOLTERS KLUWER INDIA PVT LTD , A-202, 2ND FLR, QUBE, C T S  NO 1498A-2
   VILLAGE MAROL, ANDHERI EAST, MUMBAI, 400059, INDIA
SN 0301-4738
EI 1998-3689
J9 INDIAN J OPHTHALMOL
JI Indian J. Ophthalmol.
PD MAR
PY 2021
VL 69
IS 3
BP 642
EP 646
DI 10.4103/ijo.IJO_291_20
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA QQ3ZW
UT WOS:000624463600038
PM 33595493
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Kuroda, Y
   Tsujikawa, A
   Ooto, S
   Yamashiro, K
   Oishi, A
   Nakanishi, H
   Kumagai, K
   Hata, M
   Arichika, S
   Ellabban, AA
   Yoshimura, N
AF Kuroda, Yoshimasa
   Tsujikawa, Akitaka
   Ooto, Sotaro
   Yamashiro, Kenji
   Oishi, Akio
   Nakanishi, Hideo
   Kumagai, Kyoko
   Hata, Masayuki
   Arichika, Shigeta
   Ellabban, Abdallah A.
   Yoshimura, Nagahisa
TI Association of Focal Choroidal Excavation With Age-Related Macular
   Degeneration
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
DE focal choroidal excavation; exudative age-related macular degeneration;
   sweptsource optical coherence tomography
ID OPTICAL COHERENCE TOMOGRAPHY; CENTRAL SEROUS CHORIORETINOPATHY; VASCULAR
   HYPERPERMEABILITY; THICKNESS; VASCULOPATHY; NEOVASCULARIZATION; EYES;
   VOLUME
AB PURPOSE. To study the prevalence, tomographic features, and clinical characteristics of focal choroidal excavation (FCE) in eyes with exudative age-related macular degeneration (AMD).
   METHODS. We examined 243 consecutive eyes with exudative AMD with a prototype sweptsource optical coherence tomography (OCT) system. Three-dimensional images of the macular area, covering 6 x 6 mm(2) , were reconstructed by segmentation of the outer surface of the retinal pigment epithelium.
   RESULTS. Three-dimensional swept-source OCT revealed 15 excavations in 12 eyes (4.9%); 10 had a single excavation and 2 had multiple excavations (2 and 3 excavations, respectively). In multiaveraged scans, unusual choroidal tissue was found beneath 5 excavations, bridging the excavation with the outer choroidal boundary. Additionally, the suprachoroidal space was observed beneath 7 excavations-the outer choroidal boundary appeared to be pulled inward by this bridging tissue. In 9 excavations, color fundus photographs showed pigmentary disturbance. Fourteen excavations (93.3%) were located within or adjacent to the choroidal neovascularization area. Compared with eyes without FCE, in eyes with FCE, the mean age was significantly higher (P = 0.040) and mean visual acuity was significantly better (P = 0.014). In addition, polypoidal lesions were observed in 8 of 12 eyes with FCE, but they appeared to have a limited effect on either the rate of FCE (P = 0.44) or the clinical characteristics of the eyes.
   CONCLUSIONS. While FCE may be partially related to the choroidal neovascularization associated with exudative AMD, other factors may also influence this association.
C1 [Kuroda, Yoshimasa; Tsujikawa, Akitaka; Ooto, Sotaro; Yamashiro, Kenji; Oishi, Akio; Nakanishi, Hideo; Kumagai, Kyoko; Hata, Masayuki; Arichika, Shigeta; Ellabban, Abdallah A.; Yoshimura, Nagahisa] Kyoto Univ, Grad Sch Med, Dept Ophthalmol & Visual Sci, Kyoto 6068507, Japan.
   [Ellabban, Abdallah A.] Suez Canal Univ, Fac Med, Dept Ophthalmol, Ismailia, Egypt.
C3 Kyoto University; Egyptian Knowledge Bank (EKB); Suez Canal University
RP Tsujikawa, A (通讯作者)，Kyoto Univ, Grad Sch Med, Dept Ophthalmol & Visual Sci, Sakyo Ku, Kyoto 6068507, Japan.
EM tujikawa@kuhp.kyoto-u.ac.jp
RI Oishi, Akio/AAE-9996-2020
OI Oishi, Akio/0000-0002-0977-9458; Ellabban, Abdallah/0000-0002-6033-2969;
   Yamashiro, Kenji/0000-0001-9354-8558; Tsujikawa,
   Akitaka/0000-0003-0779-7799
FU Japan Society for the Promotion of Science (JSPS), Tokyo, Japan
   [21592256]; Japan National Society for the Prevention of Blindness,
   Tokyo, Japan
FX Supported, in part, by the Japan Society for the Promotion of Science
   (JSPS), Tokyo, Japan (Grant-in-Aid for Scientific Research 21592256) and
   the Japan National Society for the Prevention of Blindness, Tokyo,
   Japan.
CR Abe Sachi, 2010, Retin Cases Brief Rep, V4, P373, DOI 10.1097/ICB.0b013e3181babe7e
   Bressler Neil M, 2004, JAMA, V291, P1900, DOI 10.1001/jama.291.15.1900
   Chan WM, 2007, AM J OPHTHALMOL, V143, P977, DOI 10.1016/j.ajo.2007.02.039
   Chen JC, 2012, CAN J OPHTHALMOL, V47, pE56, DOI 10.1016/j.jcjo.2012.07.006
   Chong NHV, 2005, AM J PATHOL, V166, P241, DOI 10.1016/S0002-9440(10)62248-1
   Chung SE, 2011, OPHTHALMOLOGY, V118, P840, DOI 10.1016/j.ophtha.2010.09.012
   de Bruin DM, 2008, INVEST OPHTH VIS SCI, V49, P4545, DOI 10.1167/iovs.07-1553
   Ellabban AA, 2013, AM J OPHTHALMOL, V156, P673, DOI 10.1016/j.ajo.2013.05.010
   Ellabban AA, 2012, AM J OPHTHALMOL, V153, P1133, DOI 10.1016/j.ajo.2011.12.013
   Esmaeelpour M, 2010, INVEST OPHTH VIS SCI, V51, P5260, DOI 10.1167/iovs.10-5196
   Ferrara D, 2014, OPHTHALMOLOGY, V121, P719, DOI 10.1016/j.ophtha.2013.10.014
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P532
   Grunwald JE, 2005, INVEST OPHTH VIS SCI, V46, P1033, DOI 10.1167/iovs.04-1050
   Hirata M, 2011, INVEST OPHTH VIS SCI, V52, P4971, DOI 10.1167/iovs.11-7729
   Ikuno Y, 2010, INVEST OPHTH VIS SCI, V51, P2173, DOI 10.1167/iovs.09-4383
   Jampol LM, 2006, RETINA-J RET VIT DIS, V26, P1072, DOI 10.1097/01.iae.0000248819.86737.a5
   Jirarattanasopa P, 2012, INVEST OPHTH VIS SCI, V53, P3663, DOI 10.1167/iovs.12-9619
   Katome T, 2012, CASE REP OPHTHALM, V3, P96, DOI 10.1159/000337880
   Kobayashi W, 2012, CLIN OPHTHALMOL, V6, P1373, DOI 10.2147/OPTH.S33879
   Koizumi H, 2011, GRAEF ARCH CLIN EXP, V249, P1123, DOI 10.1007/s00417-011-1620-1
   Kumano Y, 2013, OPTOMETRY VISION SCI, V90, pE110, DOI 10.1097/OPX.0b013e31828736f3
   Lalwani GA, 2009, AM J OPHTHALMOL, V148, P43, DOI 10.1016/j.ajo.2009.01.024
   Lee JH, 2014, AM J OPHTHALMOL, V157, P710, DOI 10.1016/j.ajo.2013.12.011
   Margolis R, 2011, ARCH OPHTHALMOL-CHIC, V129, P1320, DOI 10.1001/archophthalmol.2011.148
   Maruko I, 2007, AM J OPHTHALMOL, V144, P15, DOI 10.1016/j.ajo.2007.03.047
   Metelitsina TI, 2008, INVEST OPHTH VIS SCI, V49, P358, DOI 10.1167/iovs.07-0526
   Obata R, 2013, RETINA-J RET VIT DIS, V33, P1201, DOI 10.1097/IAE.0b013e31827b6452
   Pauleikhoff D, 1999, ARCH OPHTHALMOL-CHIC, V117, P1353, DOI 10.1001/archopht.117.10.1353
   Sasahara M, 2006, AM J OPHTHALMOL, V142, P601, DOI 10.1016/j.ajo.2006.05.051
   Say EAT, 2013, OPHTHAL SURG LAS IM, V44, P409, DOI 10.3928/23258160-20130715-12
   SPAIDE RF, 1995, RETINA-J RET VIT DIS, V15, P100, DOI 10.1097/00006982-199515020-00003
   Wakabayashi T, 2010, BRIT J OPHTHALMOL, V94, P611, DOI 10.1136/bjo.2009.163535
   Wakabayashi Y, 2010, ACTA OPHTHALMOL, V88, pe87, DOI 10.1111/j.1755-3768.2010.01895.x
   Xu HF, 2014, OPHTHALMOLOGY, V121, P246, DOI 10.1016/j.ophtha.2013.08.014
   Yasuno Y, 2007, OPT EXPRESS, V15, P6121, DOI 10.1364/OE.15.006121
NR 35
TC 24
Z9 26
U1 0
U2 1
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD SEP
PY 2014
VL 55
IS 9
BP 6046
EP 6054
DI 10.1167/iovs.14-14723
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA AQ9DX
UT WOS:000343146900075
PM 25190653
DA 2022-11-30
ER

PT J
AU Arevalo, JF
   Lasave, AF
   Wu, L
   Acon, D
   Berrocal, MH
   Diaz-Llopis, M
   Gallego-Pinazo, R
   Serrano, MA
   Alezzandrini, AA
   Rojas, S
   Maia, M
   Lujan, S
AF Arevalo, J. Fernando
   Lasave, Andres F.
   Wu, Lihteh
   Acon, Dhariana
   Berrocal, Maria H.
   Diaz-Llopis, Manuel
   Gallego-Pinazo, Roberto
   Serrano, Martin A.
   Alezzandrini, Arturo A.
   Rojas, Sergio
   Maia, Mauricio
   Lujan, Silvio
CA Pan-Amer Collaborative Retina
TI INTRAVITREAL BEVACIZUMAB FOR CHOROIDAL NEOVASCULARIZATION IN AGE-RELATED
   MACULAR DEGENERATION 5-Year Results of The Pan-American Collaborative
   Retina Study Group
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE aflibercept; bevacizumab; choroidal neovascularization; ranibizumab;
   vascular endothelial growth factor
ID CLINICAL-PRACTICE; RANIBIZUMAB; TACHYPHYLAXIS; TRIAL; VERTEPORFIN;
   INJECTION
AB Purpose: To report the long-term anatomical and functional outcomes of patients with choroidal neovascularization secondary to age-related macular degeneration treated with intravitreal bevacizumab (IVB).
   Methods: Retrospective case series. Patients diagnosed with subfoveal choroidal neovascularization secondary to age-related macular degeneration that were treated with at least 1 intravitreal injection of 1.25 mg of IVB and had a minimum follow-up of 60 months. Patients underwent best-corrected Snellen visual acuity testing, optical coherence tomography, and ophthalmoscopic examination at baseline and follow-up visits.
   Results: Two hundred and forty-seven consecutive patients (292 eyes) were included. The mean number of IVB injections per eye was 10.9 +/- 6.4. At 5 years, the BCVA decreased from 20/150 (logMAR 0.9 +/- 0.6) at baseline to 20/250 (logMAR 1.1 +/- 0.7) (P = <0.0001). The mean CMT decreased from 343.1+ 122.3 mm at baseline to 314.7 +/- 128.8 mm at 60 months of follow-up (P = 0.009). Geographic atrophy (GA) was observed at baseline in 47 (16%) of 292 eyes. By 5 years, GA developed or progressed in 124 (42.5%) of 292 eyes (P < 0.0001).
   Conclusion: The early visual gains obtained from IVB were not maintained at 5 years of follow-up. In addition, IVB may play a role in the development or progression of GA.
C1 [Arevalo, J. Fernando] Johns Hopkins Univ, Sch Med, Wilmer Eye Inst, Retina Div, Baltimore, MD 21287 USA.
   [Arevalo, J. Fernando] King Khalid Eye Specialist Hosp, Vitreoretinal & Uveitis Div, Riyadh, Saudi Arabia.
   [Lasave, Andres F.] Clin Privada Ojos, Retina & Vitreous Serv, Mar Del Plata, Buenos Aires, Argentina.
   [Wu, Lihteh; Acon, Dhariana] Inst Cirugia Ocular, San Jose, Costa Rica.
   [Berrocal, Maria H.] Univ Puerto Rico, San Juan, PR 00936 USA.
   [Diaz-Llopis, Manuel; Gallego-Pinazo, Roberto] Univ Valencia, Hosp La Fe, E-46003 Valencia, Spain.
   [Serrano, Martin A.] Ctr Caracas, Clin Oftalmol, Caracas, Venezuela.
   [Serrano, Martin A.] Arevalo Coutinho Fdn Res Ophthalmol, Caracas, Venezuela.
   [Alezzandrini, Arturo A.] Univ Buenos Aires, Fac Med, OFTALMOS, Buenos Aires, DF, Argentina.
   [Rojas, Sergio] Fundac Hosp Nuestra Senora Luz, Mexico City, DF, Mexico.
   [Maia, Mauricio] Fed Univ Sao Paulo UNIFESP, Dept Ophthalmol & Visual Sci, Retina Div, Sao Paulo, Brazil.
   [Lujan, Silvio] MACULA D&T Diagnst, Tratamiento & Rehabil Visual, Lima, Peru.
C3 Johns Hopkins University; Johns Hopkins Medicine; King Khaled Eye
   Specialist Hospital; University of Puerto Rico; Hospital Universitari i
   Politecnic La Fe; University of Valencia; University of Buenos Aires;
   Universidade Federal de Sao Paulo (UNIFESP)
RP Arevalo, JF (通讯作者)，Johns Hopkins Univ, Sch Med, Wilmer Eye Inst, 600 N Wolfe St,Maumenee 708, Baltimore, MD 21287 USA.
EM arevalojf@jhmi.edu
RI Maia, Mauricio/I-5892-2015
OI Maia, Mauricio/0000-0002-7034-8091; Arevalo Suarez, Fernando
   Antonio/0000-0002-4114-5949; Lasave, Andres/0000-0002-9602-9769
FU SECOND SIGHT LLC; Springer SBM LLC; ALCON LABORATORIES; EyEngineering
   Inc; DORC International B.V.; Bayer AG
FX SECOND SIGHT LLC (C)(L); Springer SBM LLC (P); ALCON LABORATORIES
   (C)(L); EyEngineering Inc (C); DORC International B.V. (C)(L); Bayer AG
   (C). None of the remaining authors have any financial/conflicting
   interests to disclose.
CR Anothaisintawee T, 2012, CLINICOECONOMIC OUTC, V4, P361, DOI 10.2147/CEOR.S37458
   Berg K, 2015, OPHTHALMOLOGY, V122, P146, DOI 10.1016/j.ophtha.2014.07.041
   Blumenkranz MS, 2001, ARCH OPHTHALMOL-CHIC, V119, P198
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   Chakravarthy U, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.04.015
   Dakin HA, 2014, BMJ OPEN, V4, DOI 10.1136/bmjopen-2014-005094
   Forooghian F, 2009, RETINA-J RET VIT DIS, V29, P723, DOI 10.1097/IAE.0b013e3181a2c1c3
   Gasperini JL, 2012, BRIT J OPHTHALMOL, V96, P14, DOI 10.1136/bjo.2011.204685
   Grunwald JE, 2014, OPHTHALMOLOGY, V121, P150, DOI 10.1016/j.ophtha.2013.08.015
   Hutton D, 2014, HEALTH AFFAIR, V33, P931, DOI 10.1377/hlthaff.2013.0832
   Kodjikian L, 2013, OPHTHALMOLOGY, V120, P2300, DOI 10.1016/j.ophtha.2013.06.020
   Krebs I, 2013, BRIT J OPHTHALMOL, V97, P266, DOI 10.1136/bjophthalmol-2012-302391
   Lalwani GA, 2009, AM J OPHTHALMOL, V148, P43, DOI 10.1016/j.ajo.2009.01.024
   Marques IR, 2013, OPHTHALMOLOGICA, V229, P158, DOI 10.1159/000343709
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Muniraju R, 2013, OPHTHALMOLOGICA, V230, P27, DOI 10.1159/000350238
   Rasmussen A, 2014, CURR OPIN OPHTHALMOL, V25, P158, DOI 10.1097/ICU.0000000000000050
   Rasmussen A, 2013, OPHTHALMOLOGY, V120, P2630, DOI 10.1016/j.ophtha.2013.05.018
   Regillo CD, 2008, AM J OPHTHALMOL, V145, P239, DOI 10.1016/j.ajo.2007.10.004
   Rofagha S, 2013, OPHTHALMOLOGY, V120, P2292, DOI 10.1016/j.ophtha.2013.03.046
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rosenfeld PJ, 2005, OPHTHAL SURG LAS IM, V36, P331, DOI 10.3928/1542-8877-20050701-14
   Schaal S, 2008, OPHTHALMOLOGY, V115, P2199, DOI 10.1016/j.ophtha.2008.07.007
   Schmidt-Erfurth U, 2014, OPHTHALMOLOGY, V121, P193, DOI 10.1016/j.ophtha.2013.08.011
   Silva R, 2013, OPHTHALMOLOGY, V120, P130, DOI 10.1016/j.ophtha.2012.07.026
   Singer MA, 2012, OPHTHALMOLOGY, V119, P1175, DOI 10.1016/j.ophtha.2011.12.016
   Tufail A, 2014, OPHTHALMOLOGY, V121, P1092, DOI 10.1016/j.ophtha.2013.11.031
   Zhu MD, 2015, GRAEF ARCH CLIN EXP, V253, P1217, DOI 10.1007/s00417-014-2799-8
NR 29
TC 37
Z9 37
U1 0
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD MAY
PY 2016
VL 36
IS 5
BP 859
EP 867
DI 10.1097/IAE.0000000000000827
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA DL2RG
UT WOS:000375482100009
PM 26529555
DA 2022-11-30
ER

PT J
AU Javitt, JC
   Zhou, ZY
   Maguire, MG
   Fine, SL
   Willke, RJ
AF Javitt, JC
   Zhou, ZY
   Maguire, MG
   Fine, SL
   Willke, RJ
TI Incidence of exudative age-related macular degeneration among elderly
   Americans
SO OPHTHALMOLOGY
LA English
DT Article
ID VISUAL IMPAIRMENT; CHOROIDAL NEOVASCULARIZATION; 5-YEAR INCIDENCE; EYE
   CARE; PREVALENCE; BLINDNESS; OUTCOMES; CLAIMS; MACULOPATHY; POPULATION
AB Purpose: To estimate the 3-year incidence of exudative age-related macular degeneration (AMD) and its treatment by laser photocoagulation in elderly Americans.
   Design: Population-based cohort study using insurance claims data.
   Participants: A random 5% sample of Medicare beneficiaries, age 65 and older.
   Methods: Incidence of exudative AMD and of laser photocoagulation for this condition was assessed based on four categories of ascertainment criteria that included procedure and diagnosis codes associated with exudative AMD, choroidal neovascularization, and its treatment.
   Main Outcome Measures: Incidence of AMD and of associated laser photocoagulation.
   Results: Overall, the 3-year incidence of exudative AMD is estimated to be between 9.4 per 1000 and 11.4 per 1000 Americans age 65 and older (depending on ascertainment criteria), based on those diagnosed and treated by ophthalmologists for the condition. These estimates bracket the measured incidence of exudative AMD in the Beaver Dam Eye Study and lie within its 95% confidence interval. The 3-year incidence of exudative AMD with attendant laser photocoagulation was 2.3 per 1000. Women were found to have a slightly higher incidence of AMD than men using all ascertainment criteria (P < 0.001), and white Americans were found to have a fivefold-to-sixfold higher ascertainment criteria than black Americans (P < 0.001).
   Conclusions: The reported incidence of exudative AMD identified in the population of Medicare beneficiaries suggests that measurements on incidence for this condition derived from the Beaver Dam Eye Study can be generalized to the U.S. population. (C) 2003 by the American Academy of Ophthalmology.
C1 Johns Hopkins Univ, Wilmer Ophthalmol Inst, Baltimore, MD 21218 USA.
   Pfizer Inc, Peapack, NJ USA.
   Univ Penn, Scheie Eye Inst, Philadelphia, PA 19104 USA.
C3 Johns Hopkins University; Johns Hopkins Medicine; Pfizer; University of
   Pennsylvania
RP Javitt, JC (通讯作者)，4733 Bethesda Ave,Suite 720, Bethesda, MD 20814 USA.
RI Javitt, Jonathan/AAJ-5574-2021
OI Javitt, Jonathan/0000-0003-2371-1609
FU NEI NIH HHS [EY06594] Funding Source: Medline
CR BRESSLER NM, 1995, ARCH OPHTHALMOL-CHIC, V113, P301, DOI 10.1001/archopht.1995.01100030055022
   Coleman AL, 1997, SURV OPHTHALMOL, V42, P271, DOI 10.1016/S0039-6257(97)00095-7
   Ellwein LB, 1996, OPHTHALMOLOGY, V103, P1732, DOI 10.1016/S0161-6420(96)30433-8
   JAVITT JC, 1991, ARCH OPHTHALMOL-CHIC, V109, P1079, DOI 10.1001/archopht.1991.01080080039023
   JAVITT JC, 1993, ARCH OPHTHALMOL-CHIC, V111, P605, DOI 10.1001/archopht.1993.01090050039024
   Klein R, 1997, OPHTHALMOLOGY, V104, P7, DOI 10.1016/S0161-6420(97)30368-6
   Maguire MG, 1997, ARCH OPHTHALMOL-CHIC, V115, P741
   MITCHELL JB, 1994, MED CARE, V32, pJS38
   Munoz B, 2000, ARCH OPHTHALMOL-CHIC, V118, P819, DOI 10.1001/archopht.118.6.819
   PIERAMICI DJ, 1994, ARCH OPHTHALMOL-CHIC, V112, P1043, DOI 10.1001/archopht.1994.01090200049020
   SOMMER A, 1991, NEW ENGL J MED, V325, P1412, DOI 10.1056/NEJM199111143252004
   TIELSCH JM, 1995, NEW ENGL J MED, V332, P1205, DOI 10.1056/NEJM199505043321806
   VanNewkirk MR, 2000, OPHTHALMOLOGY, V107, P1593, DOI 10.1016/S0161-6420(00)00175-5
NR 13
TC 83
Z9 85
U1 0
U2 5
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0161-6420
J9 OPHTHALMOLOGY
JI Ophthalmology
PD AUG
PY 2003
VL 110
IS 8
BP 1534
EP 1539
DI 10.1016/S0161-6420(03)00495-0
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 710VK
UT WOS:000184703400012
PM 12917168
DA 2022-11-30
ER

PT J
AU Sengupta, S
   Nguyen, AM
   van Landingham, SW
   Solomon, SD
   Do, DV
   Ferrucci, L
   Friedman, DS
   Ramulu, PY
AF Sengupta, Sabyasachi
   Nguyen, Angeline M.
   van Landingham, Suzanne W.
   Solomon, Sharon D.
   Do, Diana V.
   Ferrucci, Luigi
   Friedman, David S.
   Ramulu, Pradeep Y.
TI Evaluation of real-world mobility in age-related macular degeneration
SO BMC OPHTHALMOLOGY
LA English
DT Article
DE Age-related macular degeneration; Physical activity; Mobility
ID PHYSICAL-ACTIVITY; LIFE-SPACE; OLDER PATIENTS; RISK; ASSOCIATION;
   IMPAIRMENT; DEPRESSION; MORTALITY; DISEASE; HOME
AB Background: Previous research has suggested an association between poor vision and decreased mobility, including restricted levels of physical activity and travel away from home. We sought to determine the impact of age-related macular degeneration (AMD) on these measures of mobility.
   Methods: Fifty-seven AMD patients with bilateral, or severe unilateral, visual impairment were compared to 59 controls with normal vision. All study subjects were between the ages of 60 and 80. Subjects wore accelerometers and cellular network-based tracking devices over 7 days of normal activity. Number of steps taken, time spent in moderate-to-vigorous physical activity (MVPA), number of excursions from home, and time spent away from home were the primary outcome measures.
   Results: In multivariate negative binomial regression models adjusted for age, gender, race, comorbidities, and education, AMD participants took fewer steps than controls (18% fewer steps per day, p = 0.01) and spent significantly less time in MVPA (35% fewer minutes, p < 0.001). In multivariate logistic regression models adjusting for age, sex, race, cognition, comorbidities, and grip strength, AMD subjects showed an increased likelihood of not leaving their home on a given day (odds ratio = 1.36, p = 0.04), but did not show a significant difference in the magnitude of time spent away from home (9% fewer minutes, p = 0.11).
   Conclusion: AMD patients with poorer vision engage in significantly less physical activity and take fewer excursions away from the home. Further studies identifying the factors mediating the relationship between vision loss and mobility are needed to better understand how to improve mobility among AMD patients.
C1 [Sengupta, Sabyasachi; Nguyen, Angeline M.; van Landingham, Suzanne W.; Solomon, Sharon D.; Friedman, David S.; Ramulu, Pradeep Y.] Johns Hopkins Univ, Wilmer Eye Inst, Baltimore, MD 21287 USA.
   [Do, Diana V.] Univ Nebraska Med Ctr, Truhlsen Eye Inst, Omaha, NE USA.
   [Ferrucci, Luigi] NIA, Longitudinal Studies Sect, Clin Res Branch, NIH, Bethesda, MD 20892 USA.
   [Friedman, David S.] Johns Hopkins Bloomberg Sch Publ Hlth, Baltimore, MD USA.
   [Friedman, David S.; Ramulu, Pradeep Y.] Johns Hopkins Univ, Dana Ctr Prevent Ophthalmol, Baltimore, MD USA.
C3 Johns Hopkins University; Johns Hopkins Medicine; University of Nebraska
   System; University of Nebraska Medical Center; National Institutes of
   Health (NIH) - USA; NIH National Institute on Aging (NIA); Johns Hopkins
   University; Johns Hopkins Bloomberg School of Public Health; Johns
   Hopkins University
RP Ramulu, PY (通讯作者)，Johns Hopkins Univ, Wilmer Eye Inst, 600 North Wolfe St,Maumenee B-110, Baltimore, MD 21287 USA.
EM pramulu@jhmi.edu
RI Sengupta, Sabyasachi/Y-4936-2019
OI Sengupta, Sabyasachi/0000-0001-7441-5856; Friedman,
   David/0000-0002-2055-5797
FU Dennis W. Jahnigen Memorial Award; NIH [EY018595, EY022976]; Research to
   Prevent Blindness Robert and Helen Schaub Special Scholar Award;
   Intramural Research Program of the NIH (National Institute on Aging);
   Doris Duke Charitable Research Foundation Clinical Research Fellowship;
   NATIONAL EYE INSTITUTE [K23EY018595, R01EY022976] Funding Source: NIH
   RePORTER
FX This research was supported in part by the Dennis W. Jahnigen Memorial
   Award, NIH Grants EY018595 and EY022976, the Research to Prevent
   Blindness Robert and Helen Schaub Special Scholar Award, the Intramural
   Research Program of the NIH (National Institute on Aging), and the Doris
   Duke Charitable Research Foundation Clinical Research Fellowship. All
   funding organizations had no role in the design or conduct of this
   research. Sabyasachi Sengupta and Pradeep Ramulu had full access to all
   of the data in the study and take responsibility for the integrity of
   the data and the accuracy of the data analysis.
CR [Anonymous], 2008, REP
   Atienza AA, 2011, MED SCI SPORT EXER, V43, P815, DOI 10.1249/MSS.0b013e3181fdfc32
   BAILEY IL, 1991, INVEST OPHTH VIS SCI, V32, P422
   Boyle PA, 2010, J AM GERIATR SOC, V58, P1925, DOI 10.1111/j.1532-5415.2010.03058.x
   Brody BL, 2001, OPHTHALMOLOGY, V108, P1893, DOI 10.1016/S0161-6420(01)00754-0
   Busse A, 2002, J CLIN EPIDEMIOL, V55, P909, DOI 10.1016/S0895-4356(02)00449-3
   CAMPBELL MK, 1993, J GERONTOL, V48, pS230, DOI 10.1093/geronj/48.4.S230
   Chowdhury PP, 2014, ETHNIC DIS, V24, P92
   Colley RC, 2011, J SPORT SCI, V29, P783, DOI 10.1080/02640414.2011.557744
   ELLIOTT DB, 1990, OPHTHAL PHYSL OPT, V10, P21, DOI 10.1111/j.1475-1313.1990.tb01100.x
   FARMER ME, 1988, AM J EPIDEMIOL, V128, P1340, DOI 10.1093/oxfordjournals.aje.a115087
   Findl O, 2003, J CATARACT REFR SURG, V29, P106, DOI 10.1016/S0886-3350(02)01509-2
   Freeman EE, 2006, INVEST OPHTH VIS SCI, V47, P514, DOI 10.1167/iovs.05-0934
   Haeuber E, 2004, ARCH PHYS MED REHAB, V85, P1997, DOI 10.1016/j.apmr.2003.11.035
   Hallemans A, 2009, GAIT POSTURE, V30, P55, DOI 10.1016/j.gaitpost.2009.02.018
   James BD, 2011, AM J GERIAT PSYCHIAT, V19, P961, DOI 10.1097/JGP.0b013e318211c219
   Kono A, 2007, ARCH GERONTOL GERIAT, V45, P233, DOI 10.1016/j.archger.2006.10.013
   LIANG KY, 1986, BIOMETRIKA, V73, P13, DOI 10.1093/biomet/73.1.13
   Locher JL, 2005, SOC SCI MED, V60, P747, DOI 10.1016/j.socscimed.2004.06.023
   Mackey DC, 2014, J AM GERIATR SOC, V62, P1288, DOI 10.1111/jgs.12892
   Montorio I, 1996, Int Psychogeriatr, V8, P103, DOI 10.1017/S1041610296002505
   Oliver M, 2011, J PHYS ACT HEALTH, V8, P296, DOI 10.1123/jpah.8.2.296
   Penedo FJ, 2004, CANCER INVEST, V22, P51, DOI 10.1081/CNV-120027580
   Popescu ML, 2011, INVEST OPHTH VIS SCI, V52, P7168, DOI 10.1167/iovs.11-7564
   Ramulu PY, 2012, J PHYS ACT HEALTH, V9, P809, DOI 10.1123/jpah.9.6.809
   Ramulu PY, 2012, OPHTHALMOLOGY, V119, P1159, DOI 10.1016/j.ophtha.2012.01.013
   Ramulu PY, 2009, OPHTHALMOLOGY, V116, P1846, DOI 10.1016/j.ophtha.2009.03.033
   Sengupta S, 2014, OPHTHALMOLOGY, V121, P727, DOI 10.1016/j.ophtha.2013.09.042
   Sherrod CE, 2014, JAMA OPHTHALMOL, V132, P1239, DOI 10.1001/jamaophthalmol.2014.2213
   Shimada H, 2010, ARCH GERONTOL GERIAT, V50, P140, DOI 10.1016/j.archger.2009.02.015
   van Landingham SW, 2012, OPHTHALMOLOGY, V119, P2486, DOI 10.1016/j.ophtha.2012.06.034
   Vogel T, 2009, INT J CLIN PRACT, V63, P303, DOI 10.1111/j.1742-1241.2008.01957.x
   WEST SK, 1993, CURR EYE RES, V12, P123, DOI 10.3109/02713689308999480
   Willis JR, 2012, ARCH OPHTHALMOL-CHIC, V130, P329, DOI 10.1001/archopthalmol.2011.1773
   Xue QL, 2008, AM J EPIDEMIOL, V167, P240, DOI 10.1093/aje/kwm270
NR 36
TC 30
Z9 32
U1 1
U2 6
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1471-2415
J9 BMC OPHTHALMOL
JI BMC Ophthalmol.
PD JAN 30
PY 2015
VL 15
AR 9
DI 10.1186/1471-2415-15-9
PG 11
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA CA6SG
UT WOS:000349045300001
PM 25636376
OA Green Published, gold, Green Submitted
DA 2022-11-30
ER

PT J
AU Cohen, SY
   Dubois, L
   Grenet, T
   Nghiem-Buffet, S
   Jung, C
   Fajnkuchen, F
   Delahaye-Mazza, C
   Quentel, G
   Tadayoni, R
AF Cohen, Salomon Y.
   Dubois, Lise
   Grenet, Typhaine
   Nghiem-Buffet, Sylvia
   Jung, Camille
   Fajnkuchen, Franck
   Delahaye-Mazza, Corinne
   Quentel, Gabriel
   Tadayoni, Ramin
TI PERIPAPILLARY RETINAL PIGMENT EPITHELIUM CHANGES IN AGE-RELATED MACULAR
   DEGENERATION
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE age-related macular degeneration; fundus autofluorescence; peripapillary
   changes
ID 488 NM-EXCITATION; FUNDUS AUTOFLUORESCENCE;
   CHOROIDAL-NEOVASCULARIZATION; RETICULAR PSEUDODRUSEN; MACULOPATHY;
   CLASSIFICATION; PREVALENCE; EYES
AB Purpose:To describe peripapillary retinal pigment epithelium changes observed in patients with age-related macular degeneration (AMD) and evaluate their prevalence.Methods:This study is a prospective, monocentric, comparative case series including 104 consecutive patients with AMD, and 34 patients who are more than 60 years old and consulting for other conditions (control group). Color and fundus autofluorescence images centered on the optic disk were taken and graded by 2 independent readers from 0 to 4: 0, absent; 1, uneven background; 2, focal hyperautofluorescent dots and spots; 3, light reticular pattern; 4, dense reticular pattern. Statistical analysis was performed to correlate the presence of peripapillary retinal pigment epithelium changes with age, sex, and AMD subtype.Results:Peripapillary retinal pigment epithelium changes were observed in 76/104 AMD eyes (73.0%) and were significantly more frequent than in eyes with other conditions (14/34, 41.1%, P = 0.002), whereas groups did not differ for age (P = 0.14). Grade 2 peripapillary retinal pigment epithelium changes were more frequently observed in patients with AMD than in controls (41.3 vs. 17.6%, P = 0.013). No differences were found between patients with AMD having peripapillary retinal pigment epithelium changes and other patients for age distribution (P = 0.14), sex ratio (P = 0.34), or AMD type (P = 0.57).Conclusion:Peripapillary retinal pigment epithelium changes were more frequent in patients with AMD than in controls, and when present, they were of higher grade. Peripapillary retinal pigment epithelium changes significance is not yet understood and needs further evaluation.
C1 [Cohen, Salomon Y.; Dubois, Lise; Grenet, Typhaine; Nghiem-Buffet, Sylvia; Fajnkuchen, Franck; Delahaye-Mazza, Corinne; Quentel, Gabriel] Ophthalm Ctr Imaging & Laser, 11 Rue Antoine Bourdelle, F-75015 Paris, France.
   [Cohen, Salomon Y.] Intercity Hosp, Dept Ophthalmol, Creteil, France.
   [Cohen, Salomon Y.] Univ Paris Est, Creteil, France.
   [Jung, Camille] Intercity Hosp, Ctr Clin & Biol Res, Creteil, France.
   [Tadayoni, Ramin] Lariboisiere Hosp, AP HP, Dept Ophthalmol, Paris, France.
   [Tadayoni, Ramin] Univ Paris 07, Paris, France.
C3 Universite Paris-Est-Creteil-Val-de-Marne (UPEC); CHI Creteil;
   Universite Paris-Est-Creteil-Val-de-Marne (UPEC); Universite
   Paris-Est-Creteil-Val-de-Marne (UPEC); CHI Creteil; Assistance Publique
   Hopitaux Paris (APHP); Hopital Universitaire Lariboisiere-Fernand-Widal
   - APHP; UDICE-French Research Universities; Universite Paris Cite;
   UDICE-French Research Universities; Universite Paris Cite
RP Cohen, SY (通讯作者)，Ophthalm Ctr Imaging & Laser, 11 Rue Antoine Bourdelle, F-75015 Paris, France.
EM sycsyc75@gmail.com
OI JUNG, Camille/0000-0001-8486-8939
CR Age-Related Eye Dis Study Res Grp, 2001, AM J OPHTHALMOL, V132, P668
   Augood CA, 2006, ARCH OPHTHALMOL-CHIC, V124, P529, DOI 10.1001/archopht.124.4.529
   Bessho K, 2009, GRAEF ARCH CLIN EXP, V247, P729, DOI 10.1007/s00417-008-1033-y
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Chebil A, 2014, J FR OPHTALMOL, V37, P635, DOI 10.1016/j.jfo.2014.07.007
   Dandekar SS, 2005, ARCH OPHTHALMOL-CHIC, V123, P1507, DOI 10.1001/archopht.123.11.1507
   DelaPaz MA, 1997, AM J OPHTHALMOL, V124, P331, DOI 10.1016/S0002-9394(14)70825-6
   Deli A, 2013, INT OPHTHALMOL, V33, P635, DOI 10.1007/s10792-013-9749-z
   Delori FC, 2000, INVEST OPHTH VIS SCI, V41, P496
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Holz FG, 2001, INVEST OPHTH VIS SCI, V42, P1051
   HUMPHREY WT, 1984, AM J OPHTHALMOL, V98, P717, DOI 10.1016/0002-9394(84)90686-X
   Klaver CCW, 2001, INVEST OPHTH VIS SCI, V42, P2237
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   Kumar N, 2013, OPHTHALMOLOGY, V120, P334, DOI 10.1016/j.ophtha.2012.07.076
   LEWIS H, 1985, OPHTHALMOLOGY, V92, P1485
   McBain VA, 2007, BRIT J OPHTHALMOL, V91, P491, DOI 10.1136/bjo.2006.095109
   MITCHELL P, 1995, OPHTHALMOLOGY, V102, P1450
   Postel EA, 2005, AM J OPHTHALMOL, V139, P820, DOI 10.1016/j.ajo.2004.12.029
   Querques G, 2011, RETINA-J RET VIT DIS, V31, P518, DOI 10.1097/IAE.0b013e3181f04974
   Reznicek L, 2012, INVEST OPHTH VIS SCI, V53, P2193, DOI 10.1167/iovs.11-8483
   Shuler RK, 2008, OPHTHALMOLOGY, V115, P520, DOI 10.1016/j.ophtha.2007.06.021
   Solbach U, 1997, RETINA-J RET VIT DIS, V17, P385
   Vaclavik V, 2008, OPHTHALMOLOGY, V115, P342, DOI 10.1016/j.ophtha.2007.04.023
   vonRuckmann A, 1997, INVEST OPHTH VIS SCI, V38, P478
   Zweifel SA, 2010, OPHTHALMOLOGY, V117, P303, DOI 10.1016/j.ophtha.2009.07.014
NR 26
TC 3
Z9 3
U1 0
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD MAR
PY 2016
VL 36
IS 3
BP 458
EP 464
DI 10.1097/IAE.0000000000000741
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA DG1MW
UT WOS:000371833200004
PM 26267678
DA 2022-11-30
ER

PT J
AU Wang, YF
   Wang, MX
   Han, Y
   Zhang, R
   Ma, L
AF Wang, Yafeng
   Wang, Mingxu
   Han, Yue
   Zhang, Rui
   Ma, Le
TI ABCA1 rs1883025 polymorphism and risk of age-related macular
   degeneration
SO GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Article
DE Age-related macular degeneration; ABCA1; Polymorphism
ID POLYPOIDAL CHOROIDAL VASCULOPATHY; GENOME-WIDE ASSOCIATION;
   GENETIC-VARIANTS; EXPRESSION; DRUSEN; SUSCEPTIBILITY; EFFLUX; TIMP3;
   LOCI
AB To evaluate the association of the ABCA1 rs1883025 polymorphism and susceptibility to age-related macular degeneration (AMD).
   A systematic search of the PubMed, EMBASE, and ISI web of science databases was performed to identify eligible published studies without language restrictions up to September 2015. Pooled odds ratios (ORs) with 95 % confidence intervals (CIs) were estimated under different genetic models using meta-analytic methods. Stratified analysis and sensitivity analysis were performed to explore potential sources of heterogeneity.
   A total of 12 articles with 25,445 cases and 36,460 controls were eligible in this meta-analysis. The ABCA1 rs1883025 variant showed significant association with the lower risk of overall AMD under the allelic model (OR= 0.81, 95 % CI=0.74-0.89). Stratified analysis based on ethnicity demonstrated a strong association between rs1883025 polymorphism and AMD in the Caucasian population, but not in Asian population. For late AMD, the ABCA1 rs1883025 variant was observed to have a significant association with the lower risk of this disease (OR = 0.81, 95 % CI, 0.72-0.91). In early-stage AMD, significant associations of the rs1883025 polymorphism with lower risk of early AMD were observed in different genetic models (OR ranging from 0.45 to 0.65, all P < 0.05).
   The present meta-analysis indicated that the T allelic in rs1883025 variant was significantly associated with the risk of developing AMD, particularly at the early stage. The associations of the ABCA1 locus with AMD risk in various populations need further exploration.
C1 [Wang, Yafeng; Wang, Mingxu; Han, Yue; Zhang, Rui; Ma, Le] Xi An Jiao Tong Univ, Hlth Sci Ctr, Sch Publ Hlth, 76 Yanta West Rd, Xian 710061, Shaanxi, Peoples R China.
C3 Xi'an Jiaotong University
RP Ma, L (通讯作者)，Xi An Jiao Tong Univ, Hlth Sci Ctr, Sch Publ Hlth, 76 Yanta West Rd, Xian 710061, Shaanxi, Peoples R China.
EM male@mail.xjtu.edu.cn
RI wang, yafeng/J-4829-2017
FU National Natural Science Foundation of China [NSFC-81202198,
   NSFC-81473059]
FX NSFC provided financial support in the form of the National Natural
   Science Foundation of China (NSFC-81202198, NSFC-81473059). The sponsor
   had no role in the design or conduct of this research.
CR Augustin AJ, 2009, EXPERT OPIN THER TAR, V13, P641, DOI 10.1517/14728220902942322
   Blasiak J, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/768026
   Chen W, 2010, P NATL ACAD SCI USA, V107, P7401, DOI 10.1073/pnas.0912702107
   Dietzel M, 2014, GRAEF ARCH CLIN EXP, V252, P1273, DOI 10.1007/s00417-014-2690-7
   Duncan KG, 2009, BRIT J OPHTHALMOL, V93, P1116, DOI 10.1136/bjo.2008.144006
   Ebrahimi KB, 2014, ADV EXP MED BIOL, V801, P259, DOI 10.1007/978-1-4614-3209-8_33
   Fauser S, 2011, INVEST OPHTH VIS SCI, V52, P5525, DOI 10.1167/iovs.10-6827
   Huang C, 2013, MOL VIS, V19, P1211
   Ishida BY, 2006, BRIT J OPHTHALMOL, V90, P616, DOI 10.1136/bjo.2005.085076
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Kaemmerer E, 2007, INVEST OPHTH VIS SCI, V48, P1342, DOI 10.1167/iovs.06-0549
   Koskela A, 2014, MOL VIS, V20, P760
   Langmann T, 2003, CLIN CHEM, V49, P230, DOI 10.1373/49.2.230
   Li FT, 2014, OPHTHALMIC RES, V51, P210, DOI 10.1159/000357978
   Lucas A D, 2001, Expert Rev Mol Med, V3, P1, DOI 10.1017/S1462399401003696
   Merle BMJ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0079848
   Neale BM, 2010, P NATL ACAD SCI USA, V107, P7395, DOI 10.1073/pnas.0912019107
   Peter I, 2011, AM J OPHTHALMOL, V152, P1005, DOI 10.1016/j.ajo.2011.05.016
   Sobrin L, 2012, OPHTHALMOLOGY, V119, P1874, DOI 10.1016/j.ophtha.2012.03.014
   Stroup DF, 2000, JAMA-J AM MED ASSOC, V283, P2008, DOI 10.1001/jama.283.15.2008
   Tang CR, 2009, J BIOL CHEM, V284, P32336, DOI 10.1074/jbc.M109.047472
   Wang AL, 2009, AUTOPHAGY, V5, P563, DOI 10.4161/auto.5.4.8163
   Wang D, 2015, OPHTHALMIC GENET
   Wang HQ, 2014, VACCINE, V32, P4806, DOI 10.1016/j.vaccine.2014.05.061
   Yu Y, 2011, HUM MOL GENET, V20, P3699, DOI 10.1093/hmg/ddr270
   Yu Y, 2011, INVEST OPHTH VIS SCI, V52, P4663, DOI 10.1167/iovs.10-7070
   Yvan-Charvet L, 2010, ARTERIOSCL THROM VAS, V30, P139, DOI 10.1161/ATVBAHA.108.179283
   Zhang XZ, 2013, EXP EYE RES, V108, P16, DOI 10.1016/j.exer.2012.12.005
NR 28
TC 9
Z9 9
U1 0
U2 11
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 0721-832X
EI 1435-702X
J9 GRAEF ARCH CLIN EXP
JI Graefes Arch. Clin. Exp. Ophthalmol.
PD FEB
PY 2016
VL 254
IS 2
BP 323
EP 332
DI 10.1007/s00417-015-3211-z
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA DD5ZU
UT WOS:000370004300014
PM 26608582
DA 2022-11-30
ER

PT J
AU Lee, AY
   Butt, T
   Chew, E
   Agron, E
   Clemons, TE
   Egan, CA
   Lee, CS
   Tufail, A
AF Lee, Aaron Y.
   Butt, Thomas
   Chew, Emily
   Agron, Elvira
   Clemons, Traci E.
   Egan, Catherine A.
   Lee, Cecilia S.
   Tufail, Adnan
CA UK EMR AMD Res Grp
TI Cost-effectiveness of age-related macular degeneration study supplements
   in the UK: combined trial and real-world outcomes data
SO BRITISH JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE age-related macular degeneration; supplements; cost-effectiveness;
   health economics
ID EYE DISEASE; PREVALENCE; AFLIBERCEPT; THERAPY; UTILITY
AB Aims To evaluate the cost-effectiveness of Age-Related Eye Disease Study (AREDS) 1 & 2 supplements in patients with either bilateral intermediate age-related macular degeneration, AREDS category 3, or unilateral neovascular age-related macular degeneration AMD (nAMD), AREDS category 4.
   Methods A patient-level health state transition model based on levels of visual acuity in the better-seeing eye was constructed to simulate the costs and consequences of patients taking AREDS vitamin supplements. Setting: UK National Health Service (NHS). The model was populated with data from AREDS and real-world outcomes and resource use from a prospective multicentre national nAMD database study containing 92 976 ranibizumab treatment episodes.
   Interventions Two treatment approaches were compared: immediate intervention with AREDS supplements or no supplements. Main outcome measures: quality-adjusted life years (QALYs) and healthcare costs were accrued for each strategy, and incremental costs and QALYs were calculated for the lifetime of the patient. One-way and probabilistic sensitivity analyses were employed to test the uncertainty of the model.
   Results For AREDS category 3, the incremental cost-effectiveness ratio was 30197. For AREDS category 4 compared with no intervention, AREDS supplements are more effective (10.59 vs 10.43 QALYs) and less costly (52074 pound vs 54 900) over the lifetime of the patient.
   Conclusions The recommendation to publicly fund AREDS supplements to category 3 patients would depend on the healthcare system willingness to pay. In contrast, initiating AREDS supplements in AREDS category 4 patients is both cost saving and more effective than no supplement use and should therefore be considered in public health policy.
C1 [Lee, Aaron Y.; Lee, Cecilia S.] Univ Washington, Dept Ophthalmol, Seattle, WA 98195 USA.
   [Butt, Thomas; Egan, Catherine A.; Tufail, Adnan] UCL, Inst Ophthalmol, London, England.
   [Chew, Emily] NIH, Div Epidemiol & Clin Res, Bldg 10, Bethesda, MD 20892 USA.
   [Agron, Elvira] NEI, Div Epidemiol & Clin Applicat, Bethesda, MD 20892 USA.
   [Clemons, Traci E.] EMMES Corp, Rockville, MD USA.
   [Egan, Catherine A.; Tufail, Adnan] Moorfields Eye Hosp, London, England.
C3 University of Washington; University of Washington Seattle; University
   of London; University College London; National Institutes of Health
   (NIH) - USA; National Institutes of Health (NIH) - USA; NIH National Eye
   Institute (NEI); Emmes Corporation; University of London; University
   College London; Moorfields Eye Hospital NHS Foundation Trust
RP Tufail, A (通讯作者)，Moorfields Eye Hosp NHS Trust, 162 City Rd, London SE1 4TT, England.
EM adnan.tufail@moorfields.nhs.uk
RI Lee, Aaron/AAT-2839-2020; Butt, Thomas/AAH-7882-2019; Lee,
   Cecilia/K-2569-2014
OI Butt, Thomas/0000-0002-0387-4550; Tufail, Adnan/0000-0001-6131-7640;
   Lee, Aaron/0000-0002-7452-1648; Lee, Cecilia/0000-0003-1994-7213
FU Macular Society; National Eye Institute/National Institutes of Health
   (NEI/NIH), Department of Health and Human Services, Bethesda, Maryland
   [HHS3N3260320053000073C]; ADB Contract [N013EY3530007]; NEI
   [K23EY024921]; Research to Prevent Blindness; Department of Health's
   NIHR Biomedical Research Centre for Ophthalmology at Moorfields Eye
   Hospital; UCL Institute of Ophthalmology; Novartis Pharmaceuticals;
   NATIONAL EYE INSTITUTE [K23EY024921, ZIAEY000489] Funding Source: NIH
   RePORTER
FX The health economic work was funded by the Macular Society. The data
   used in this analysis from the AREDS study was supported by the
   intramural programme funds and contracts from the National Eye
   Institute/National Institutes of Health (NEI/NIH), Department of Health
   and Human Services, Bethesda, Maryland. Contract No.
   HHS3N3260320053000073C. ADB Contract No. N013EY3530007. CSL was
   supported by NEI K23EY024921. Dr AYL was supported by Research to
   Prevent Blindness. CAE and AT received a proportion of funding from the
   Department of Health's NIHR Biomedical Research Centre for Ophthalmology
   at Moorfields Eye Hospital and UCL Institute of Ophthalmology. The
   collection of UK AMD EMR data used in the analysis was supported in part
   by unrestricted research award by Novartis Pharmaceuticals.
CR [Anonymous], 2008, RAN PEG TREATM AG RE
   Aronow ME, 2014, CURR OPIN OPHTHALMOL, V25, P186, DOI 10.1097/ICU.0000000000000046
   Aslam Tariq, 2014, Clin Ophthalmol, V8, P2045, DOI 10.2147/OPTH.S63937
   Bressler NM, 2003, ARCH OPHTHALMOL-CHIC, V121, P1621
   Brown GC, 2000, ARCH OPHTHALMOL-CHIC, V118, P47
   Butt T, 2015, BMJ OPEN, V5, DOI 10.1136/bmjopen-2014-006535
   Chew EY, 2014, JAMA OPHTHALMOL, V132, P142, DOI 10.1001/jamaophthalmol.2013.7376
   Chew EY, 2013, JAMA-J AM MED ASSOC, V309, P2005, DOI 10.1001/jama.2013.4997
   Chew EY, 2012, OPHTHALMOLOGY, V119, P2282, DOI 10.1016/j.ophtha.2012.05.027
   Evans JR, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000254.pub3
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Gillies MC, 2016, OPHTHALMOLOGY, V123, P2545, DOI 10.1016/j.ophtha.2016.08.016
   Health and Social Care Information Centre, HOSP EP STAT 2011 12
   Hopley C, 2004, BRIT J OPHTHALMOL, V88, P450, DOI 10.1136/bjo.2003.035279
   Kassoff A, 1999, CONTROL CLIN TRIALS, V20, P573
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Klok Rogier M, 2004, Expert Rev Pharmacoecon Outcomes Res, V4, P599, DOI 10.1586/14737167.4.6.599
   Lee AY, 2015, BRIT J OPHTHALMOL, V99, P1045, DOI 10.1136/bjophthalmol-2014-306229
   National Institute for Health and Care Excellence, RAN TREATM DIAB MAC
   National Institute for Health and Care Excellence, 2013, AFL SOL INJ TREAT WE
   National Institute for Health and Care Excellence (NICE), 2013, GUID METH TECHN APPR
   Owen CG, 2012, BRIT J OPHTHALMOL, V96, P752, DOI 10.1136/bjophthalmol-2011-301109
   Rein DB, 2007, OPHTHALMOLOGY, V114, P1319, DOI 10.1016/j.ophtha.2006.10.041
   Rofagha S, 2013, OPHTHALMOLOGY, V120, P2292, DOI 10.1016/j.ophtha.2013.03.046
   Rudnicka AR, 2012, OPHTHALMOLOGY, V119, P571, DOI 10.1016/j.ophtha.2011.09.027
   Schmidt-Erfurth U, 2014, OPHTHALMOLOGY, V121, P193, DOI 10.1016/j.ophtha.2013.08.011
   Tamura H, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0133628
   The National Institute for Health and Care Excellence, AFL SOL INJ TREAT WE
   Wilde C, 2017, EYE, V31, P1042, DOI 10.1038/eye.2017.30
NR 29
TC 7
Z9 7
U1 0
U2 10
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0007-1161
EI 1468-2079
J9 BRIT J OPHTHALMOL
JI Br. J. Ophthalmol.
PD APR
PY 2018
VL 102
IS 4
BP 465
EP 472
DI 10.1136/bjophthalmol-2017-310939
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA GC4DD
UT WOS:000429732500009
PM 28835423
OA Green Submitted, Green Accepted
DA 2022-11-30
ER

PT J
AU Abdelfattah, NS
   Zhang, HY
   Boyer, DS
   Sadda, SR
AF Abdelfattah, Nizar Saleh
   Zhang, Hongyang
   Boyer, David S.
   Sadda, Srinivas R.
TI PROGRESSION OF MACULAR ATROPHY IN PATIENTS WITH NEOVASCULAR AGE-RELATED
   MACULAR DEGENERATION UNDERGOING ANTIVASCULAR ENDOTHELIAL GROWTH FACTOR
   THERAPY
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE aflibercept; bevacizumab; choroidal neovascularization; geographic
   atrophy; macular degeneration; neovascular AMD; optical coherence
   tomography; ranibizumab; treat-and-extend protocol; wet macular
   degeneration
ID BEAVER DAM EYE; GEOGRAPHIC ATROPHY; FUNDUS AUTOFLUORESCENCE;
   RISK-FACTORS; MACULOPATHY; DISEASE; TRIALS
AB Purpose:To define the frequency and quantify the progression of macular atrophy (MA) in patients with neovascular age-related macular degeneration undergoing treatment with antivascular endothelial growth factor therapy for >2 years.Methods:Fifty-four eyes of 46 patients (86.7 6.8 years, 53.7% women) diagnosed with wet age-related macular degeneration were included in this retrospective study. Eyes that received photodynamic therapy or laser treatment were excluded. All eyes were imaged at baseline and after 2 years with the Cirrus spectral domain optical coherence tomography using a 512 x 128 macular cube scan protocol centered on the fovea. Optical coherence tomography en face fundus images were obtained for each 3-dimensional data set using the U.S. Food and Drug Administration-cleared Advanced RPE Analysis software, which automatically identifies atrophic areas by segmenting regions of increased reflectivity in en face choroidal slab images. Segmentation errors were manually corrected by trained Doheny Image Reading Center graders using a standardized grading protocol. The prevalence rates of atrophy at baseline and at 2-years follow-up and enlargement rates were computed. Baseline demographic factors and types and numbers of antivascular endothelial growth factor injections received over time were correlated with the development and enlargement of atrophy.Results:Macular atrophy was noted at baseline in 32 (59.3%) eyes and progressed in all eyes over the next 2 years. Among the 28 eyes without atrophy at baseline, MA developed by 2 years in 6 eyes (21.4% of eyes without MA at baseline). Of note, 22 eyes (40.7% of overall cohort) never developed atrophy during the course of the study. Among eyes with atrophy at baseline, the annual growth rate of MA was found to be 0.89 +/- 0.93 mm(2). A multiple regression analysis was performed to evaluate the influence of gender, age, smoking status, medication injected, and number of injections on MA. Except for the number of total injections (R-2 = 0.3, P < 0.01), the studied variables could not significantly predict development or progression of MA (F [0.73, 13] = 0.378, P = 0.86, R-2 = 0.05). However, the study was not powered to detect small effects.Conclusion:Macular atrophy is a frequent finding in eyes with wet age-related macular degeneration both before and after antivascular endothelial growth factor therapy. The frequency of new optical coherence tomography-defined atrophy (21% at 2 years) after starting therapy was close to the rates reported in CATT, IVAN, and HARBOR. The rate of MA enlargement was positively correlated with the number of injections, but did not appear to be greater than that reported for atrophy in the absence of choroidal neovascularization.
C1 [Abdelfattah, Nizar Saleh; Zhang, Hongyang; Sadda, Srinivas R.] Doheny Eye Inst, Doheny Image Reading Ctr, Los Angeles, CA USA.
   [Abdelfattah, Nizar Saleh; Zhang, Hongyang; Sadda, Srinivas R.] David Geffen Sch Med, Dept Ophthalmol, UCLA, Los Angeles, CA USA.
   [Zhang, Hongyang] Guangdong Gen Hosp, Dept Ophthalmol, Guangzhou, Peoples R China.
   [Boyer, David S.] Retina Vitreous Associates Med Grp, Beverly Hills, CA USA.
C3 Doheny Eye Institute; University of California System; University of
   California Los Angeles; University of California Los Angeles Medical
   Center; David Geffen School of Medicine at UCLA; Guangdong Academy of
   Medical Sciences & Guangdong General Hospital; Retina Vitreous
   Associates Medical Group
RP Sadda, SR (通讯作者)，Doheny Eye Inst, Doheny Image Reading Ctr, Los Angeles, CA USA.
EM ssadda@doheny.org
RI Abdelfattah, Nizar Saleh/H-6908-2019
OI Abdelfattah, Nizar Saleh/0000-0002-9396-3054
FU Carl Zeiss Meditec; Optos; Allergan; Genentech
FX D. S. Boyer is a consultant for Aerpio, Alcon, Allergan, Bayer,
   Genentech, GS, KalVista, Neurotech, Nicox, Novartis, Ohr, Santaris,
   Santen, ThromboGenics, and Regeneron Pharmaceuticals. He receives
   honoraria from Alcon, Allergan, Genentech, Novartis, and Regeneron. S.
   R. Sadda is a consultant for Carl Zeiss Meditec, Optos, Allergan,
   Genentech, Alcon, Novartis, and Roche. He receives research funding from
   Carl Zeiss Meditec, Optos, Allergan, and Genentech. He also receives
   honoraria from Carl Zeiss Meditec, Optos, and Allergan. The remaining
   authors have no financial/conflicting interests to disclose.
CR Bhisitkul RB, 2015, AM J OPHTHALMOL, V159, P915, DOI 10.1016/j.ajo.2015.01.032
   Busbee BG, 2013, OPHTHALMOLOGY, V120, P1046, DOI 10.1016/j.ophtha.2012.10.014
   Chakravarthy U, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.04.015
   Chen Q, 2013, BIOMED OPT EXPRESS, V4, P2729, DOI 10.1364/BOE.4.002729
   Davis MD, 2005, ARCH OPHTHALMOL-CHIC, V123, P1484
   Domalpally A, 2013, OPHTHALMOLOGY, V120, P2666, DOI 10.1016/j.ophtha.2013.07.047
   Feuer WJ, 2013, JAMA OPHTHALMOL, V131, P110, DOI 10.1001/jamaophthalmol.2013.572
   Fleckenstein M, 2011, INVEST OPHTH VIS SCI, V52, P6552, DOI 10.1167/iovs.11-7298
   Grunwald JE, 2015, OPHTHALMOLOGY, V122, P809, DOI 10.1016/j.ophtha.2014.11.007
   Hirvela H, 1996, OPHTHALMOLOGY, V103, P871, DOI 10.1016/S0161-6420(96)30593-9
   Holz FG, 2007, AM J OPHTHALMOL, V143, P463, DOI 10.1016/j.ajo.2006.11.041
   Hwang JC, 2006, INVEST OPHTH VIS SCI, V47, P2655, DOI 10.1167/iovs.05-1027
   KLEIN R, 1993, OPHTHALMOLOGY, V100, P406
   Klein R, 2008, AM J OPHTHALMOL, V146, P692, DOI 10.1016/j.ajo.2008.05.050
   Lois N, 2013, RETINA-J RET VIT DIS, V33, P13, DOI 10.1097/IAE.0b013e3182657fff
   Lujan BJ, 2009, OPHTHAL SURG LAS IM, V40, P96, DOI 10.3928/15428877-20090301-16
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   McBain VA, 2011, RETINA-J RET VIT DIS, V31, P1043, DOI 10.1097/IAE.0b013e3181fe54c7
   Pirbhai A, 2005, AM J OPHTHALMOL, V139, P455, DOI 10.1016/j.ajo.2004.09.077
   SARKS JP, 1988, EYE, V2, P552, DOI 10.1038/eye.1988.106
   Scholl HPN, 2003, GRAEF ARCH CLIN EXP, V241, P39, DOI 10.1007/s00417-002-0602-8
   Sunness JS, 2007, OPHTHALMOLOGY, V114, P271, DOI 10.1016/j.ophtha.2006.09.016
   Sunness JS, 2006, RETINA-J RET VIT DIS, V26, P666, DOI 10.1097/00006982-200607000-00013
   Sunness JS, 1999, INVEST OPHTH VIS SCI, V40, P1761
   VINGERLING JR, 1995, OPHTHALMOLOGY, V102, P205
   Yehoshua Z, 2011, OPHTHALMOLOGY, V118, P679, DOI 10.1016/j.ophtha.2010.08.018
NR 26
TC 41
Z9 43
U1 1
U2 5
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD OCT
PY 2016
VL 36
IS 10
BP 1843
EP 1850
DI 10.1097/IAE.0000000000001059
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA DZ6US
UT WOS:000385998600017
PM 27135213
DA 2022-11-30
ER

PT J
AU Kumar, S
   Berriochoa, Z
   Jones, AD
   Fu, YB
AF Kumar, Sandeep
   Berriochoa, Zachary
   Jones, Alex D.
   Fu, Yingbin
TI Detecting Abnormalities in Choroidal Vasculature in a Mouse Model of
   Age-related Macular Degeneration by Time-course Indocyanine Green
   Angiography
SO JOVE-JOURNAL OF VISUALIZED EXPERIMENTS
LA English
DT Article
DE Medicine; Issue 84; Indocyanine Green Angiography; ICGA; choroid
   vasculature; age-related macular degeneration; AMD; Polypoidal Choroidal
   Vasculopathy; PCV; confocal scanning laser ophthalmoscope; IV-ICGA;
   time-course ICGA; tail-vein injection
ID ANIMAL-MODELS; VASCULOPATHY; VIDEOANGIOGRAPHY
AB Indocyanine Green Angiography (or ICGA) is a technique performed by ophthalmologists to diagnose abnormalities of the choroidal and retinal vasculature of various eye diseases such as age-related macular degeneration (AMD). ICGA is especially useful to image the posterior choroidal vasculature of the eye due to its capability of penetrating through the pigmented layer with its infrared spectrum. ICGA time course can be divided into early, middle, and late phases. The three phases provide valuable information on the pathology of eye problems. Although time-course ICGA by intravenous (IV) injection is widely used in the clinic for the diagnosis and management of choroid problems, ICGA by intraperitoneal injection (IP) is commonly used in animal research. Here we demonstrated the technique to obtain high-resolution ICGA time-course images in mice by tail-vein injection and confocal scanning laser ophthalmoscopy. We used this technique to image the choroidal lesions in a mouse model of age-related macular degeneration. Although it is much easier to introduce ICG to the mouse vasculature by IP, our data indicate that it is difficult to obtain reproducible ICGA time course images by IP-ICGA. In contrast, ICGA via tail vein injection provides high quality ICGA time-course images comparable to human studies. In addition, we showed that ICGA performed on albino mice gives clearer pictures of choroidal vessels than that performed on pigmented mice. We suggest that time-course IV-ICGA should become a standard practice in AMD research based on animal models.
C1 [Kumar, Sandeep; Berriochoa, Zachary; Jones, Alex D.; Fu, Yingbin] Univ Utah, Hlth Sci Ctr, Dept Ophthalmol & Visual Sci, Salt Lake City, UT 84112 USA.
   [Fu, Yingbin] Univ Utah, Hlth Sci Ctr, Dept Neurobiol & Anat, Salt Lake City, UT 84112 USA.
C3 Utah System of Higher Education; University of Utah; Utah System of
   Higher Education; University of Utah
RP Fu, YB (通讯作者)，Univ Utah, Hlth Sci Ctr, Dept Ophthalmol & Visual Sci, Salt Lake City, UT 84112 USA.
EM yingbin.fu@hsc.utah.edu
OI kumar, sandeep/0000-0002-2918-8276
FU NIH [1R01EY022901]; Career Development Award from Research to Prevent
   Blindness (RPB); C.M.Reeves & M.A. Reeves Foundation; E. Matilda Ziegler
   Foundation for the Blind; Knights Templar Eye Foundation; RPB; NATIONAL
   EYE INSTITUTE [R01EY022901] Funding Source: NIH RePORTER
FX This work was supported by NIH grant 1R01EY022901, the Career
   Development Award from Research to Prevent Blindness (RPB), C.M.Reeves &
   M.A. Reeves Foundation, E. Matilda Ziegler Foundation for the Blind,
   Knights Templar Eye Foundation, and an unrestricted grant to the
   Department of Ophthalmology at the University of Utah from RPB. We thank
   Balamurali Ambati for technical assistance on the Spectralis
   Multi-Modality Imaging System and Tao Zhang for discussions and comments
   on the manuscript.
CR Alex Anne F, 2013, Methods Mol Biol, V935, P41, DOI 10.1007/978-1-62703-080-9_3
   [Anonymous], 2006, AGE RELATED MACULAR
   Ciardella Antonio P, 2002, Ophthalmol Clin North Am, V15, P537, DOI 10.1016/S0896-1549(02)00053-6
   Ciardella AP, 2004, SURV OPHTHALMOL, V49, P25, DOI 10.1016/j.survophthal.2003.10.007
   Coppens G, 2011, Bull Soc Belge Ophtalmol, P39
   DESTRO M, 1989, OPHTHALMOLOGY, V96, P846
   Ding XY, 2009, PROG RETIN EYE RES, V28, P1, DOI 10.1016/j.preteyeres.2008.10.001
   Duane T. D., 2002, DUANES CLIN OPHTHALM
   Fischer M Dominik, 2013, Methods Mol Biol, V935, P79, DOI 10.1007/978-1-62703-080-9_5
   Grossniklaus HE, 2010, PROG RETIN EYE RES, V29, P500, DOI 10.1016/j.preteyeres.2010.05.003
   GUYER DR, 1992, OPHTHALMOLOGY, V99, P287
   Imamura Y, 2010, SURV OPHTHALMOL, V55, P501, DOI 10.1016/j.survophthal.2010.03.004
   Janssen A, 2008, INVEST OPHTH VIS SCI, V49, P2812, DOI 10.1167/iovs.07-1444
   Jian YF, 2013, J BIOMED OPT, V18, DOI 10.1117/1.JBO.18.5.056007
   Jones A, 2011, P NATL ACAD SCI USA, V108, P14578, DOI 10.1073/pnas.1102853108
   KUCK H, 1993, RETINA-J RET VIT DIS, V13, P36, DOI 10.1097/00006982-199313010-00009
   Pennesi ME, 2012, MOL ASPECTS MED, V33, P487, DOI 10.1016/j.mam.2012.06.003
   Rakoczy PE, 2006, EXP EYE RES, V82, P741, DOI 10.1016/j.exer.2005.10.012
   REGILLO CD, 1994, OPHTHALMOLOGY, V101, P280
   Sasahara M, 2006, AM J OPHTHALMOL, V142, P601, DOI 10.1016/j.ajo.2006.05.051
   SCHEIDER A, 1992, AM J OPHTHALMOL, V113, P45, DOI 10.1016/S0002-9394(14)75752-6
   SCHEIDER A, 1989, AM J OPHTHALMOL, V108, P458, DOI 10.1016/S0002-9394(14)73325-2
   Seeliger MW, 2005, VISION RES, V45, P3512, DOI 10.1016/j.visres.2005.08.014
   Silva RM, 2005, GRAEF ARCH CLIN EXP, V243, P973, DOI 10.1007/s00417-005-1139-4
   SPAIDE RF, 1995, RETINA-J RET VIT DIS, V15, P100, DOI 10.1097/00006982-199515020-00003
   Tsujikawa A, 2007, AM J OPHTHALMOL, V143, P102, DOI 10.1016/j.ajo.2006.08.025
   YANNUZZI LA, 1992, RETINA-J RET VIT DIS, V12, P191, DOI 10.1097/00006982-199212030-00003
   Yannuzzi LA, 2000, OPHTHALMOLOGY, V107, P767, DOI 10.1016/S0161-6420(99)00173-6
   Yannuzzi LA, 2011, AM J OPHTHALMOL, V151, P745, DOI 10.1016/j.ajo.2011.01.043
NR 29
TC 6
Z9 6
U1 0
U2 4
PU JOURNAL OF VISUALIZED EXPERIMENTS
PI CAMBRIDGE
PA 1 ALEWIFE CENTER, STE 200, CAMBRIDGE, MA 02140 USA
SN 1940-087X
J9 JOVE-J VIS EXP
JI J. Vis. Exp.
PD FEB
PY 2014
IS 84
AR e51061
DI 10.3791/51061
PG 7
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA CA0JL
UT WOS:000348604100034
PM 24637497
OA Green Published, Green Accepted
DA 2022-11-30
ER

PT J
AU Brader, HS
   Ying, GS
   Martin, ER
   Maguire, MG
AF Brader, Hilary Smolen
   Ying, Gui-shuang
   Martin, E. Revell
   Maguire, Maureen G.
CA Complications Age-Related Macular
TI Characteristics of Incident Geographic Atrophy in the Complications of
   Age-Related Macular Degeneration Prevention Trial
SO OPHTHALMOLOGY
LA English
DT Article
ID OPTICAL COHERENCE TOMOGRAPHY; FUNDUS AUTOFLUORESCENCE IMAGES; BEAVER DAM
   EYE; VISUAL-ACUITY; 5-YEAR INCIDENCE; NATURAL-HISTORY; CLINICAL-TRIALS;
   LARGE DRUSEN; PROGRESSION; MACULOPATHY
AB Objective: To characterize the size, location, conformation, and features of incident geographic atrophy (GA) as detected by annual stereoscopic color photographs and fluorescein angiograms (FAs).
   Design: Retrospective cohort study within a larger clinical trial.
   Participants: Patients with bilateral large drusen in whom GA developed during the course of the Complications of Age-related Macular Degeneration Prevention Trial (CAPT).
   Methods: Annual stereoscopic color photographs and FAs were reviewed from 114 CAPT patients in whom GA developed in the untreated eye during 5 to 6 years of follow-up. Geographic atrophy was defined according to the Revised GA Criteria for identifying early GA.(23) Color-optimized fundus photographs were viewed concurrently with the FAs during grading.
   Main Outcome Measures: Size and distance from the fovea of individual GA lesions, number of areas of atrophy, and change in visual acuity (VA) when GA first developed in an eye.
   Results: At presentation, the median total GA area was 0.26 mm(2) (0.1 disc area). Geographic atrophy presented as a single lesion in 89 (78%) eyes. The median distance from the fovea was 395 mu m. Twenty percent of incident GA lesions were subfoveal and an additional 18% were within 250 mu m of the foveal center. Development of GA was associated with a mean decrease of 7 letters from the baseline VA level compared with 1 letter among matched early age-related macular degeneration eyes without GA. Geographic atrophy that formed in areas previously occupied by drusenoid pigment epithelial detachments on average were larger (0.53 vs. 0.20 mm(2); P = 0.0001), were more central (50 vs. 500 mu m from the center of the fovea; P<0.0001), and were associated with significantly worse visual outcome (20/50 vs. 20/25; P = 0.0003) than GA with other drusen types as precursors.
   Conclusions: Incident GA most often appears on color fundus photographs and FAs as a small, singular, parafoveal lesion, although a large minority of lesions are subfoveal or multifocal at initial detection. The characteristics of incident GA vary with precursor drusen types. These data can facilitate design of future clinical trials of therapies for GA.
C1 [Brader, Hilary Smolen; Ying, Gui-shuang; Martin, E. Revell; Maguire, Maureen G.] Univ Penn, Sch Med, Dept Ophthalmol, Philadelphia, PA 19104 USA.
C3 University of Pennsylvania
RP Brader, HS (通讯作者)，Univ Penn, CAPT Coordinating Ctr, 3535 Market St,Suite 700, Philadelphia, PA 19104 USA.
RI Mitchell, Paul/P-1498-2014
FU National Eye Institute, National Institutes of Health, Bethesda,
   Maryland [EY012211, EY012261, EY012279]; Research to Prevent Blindness,
   Inc., New York, New York; Doris Duke Charitable Foundation, New York,
   New York; NATIONAL EYE INSTITUTE [U10EY012279, U10EY012261] Funding
   Source: NIH RePORTER
FX Supported by the National Eye Institute, National Institutes of Health,
   Bethesda, Maryland (grant nos.: EY012211, EY012261, and EY012279); an
   unrestricted grant from Research to Prevent Blindness, Inc., New York,
   New York; and a grant from the Doris Duke Charitable Foundation, New
   York, New York to the University of Pennsylvania to fund Clinical
   Research Fellow Hilary Smolen Brader.
CR Age-Related Eye Dis Study Res Grp, 2001, AM J OPHTHALMOL, V132, P668
   [Anonymous], 1991, OPHTHALMOLOGY, V98, P741
   [Anonymous], 2000, AG REL EYE DIS STUD
   Bearelly S, 2010, ADV EXP MED BIOL, V664, P395, DOI 10.1007/978-1-4419-1399-9_45
   Brader HS, 2011, INVEST OPHTH VIS SCI, V52, P9218, DOI 10.1167/iovs.11-7493
   Brar M, 2009, AM J OPHTHALMOL, V148, P439, DOI 10.1016/j.ajo.2009.04.022
   CASSWELL AG, 1985, BRIT J OPHTHALMOL, V69, P397, DOI 10.1136/bjo.69.6.397
   Complications Age-Related Macular, 2008, OPHTHALMOLOGY, V115, P1474, DOI 10.1016/j.ophtha.2008.03.008
   Cukras C, 2010, OPHTHALMOLOGY, V117, P489, DOI 10.1016/j.ophtha.2009.12.002
   Davis MD, 2005, ARCH OPHTHALMOL-CHIC, V123, P1484
   Dreyhaupt J, 2005, OPHTHAL EPIDEMIOL, V12, P353, DOI 10.1080/09286580591005723
   Fleckenstein M, 2010, INVEST OPHTH VIS SCI, V51, P3846, DOI 10.1167/iovs.09-4533
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Gerth C, 2003, ARCH OPHTHALMOL-CHIC, V121, P1404, DOI 10.1001/archopht.121.10.1404
   Hartmann KI, 2011, RETINA-J RET VIT DIS, V31, P1323, DOI 10.1097/IAE.0b013e31820a6850
   Holz FG, 2001, INVEST OPHTH VIS SCI, V42, P1051
   Holz FG, 2007, AM J OPHTHALMOL, V143, P463, DOI 10.1016/j.ajo.2006.11.041
   Hubbard LD, 2008, INVEST OPHTH VIS SCI, V49, P3269, DOI 10.1167/iovs.07-1267
   Khanifar AA, 2012, RETINA-J RET VIT DIS, V32, P1884, DOI 10.1097/IAE.0b013e3182509778
   Klaver CCW, 2001, INVEST OPHTH VIS SCI, V42, P2237
   Klein ML, 2008, OPHTHALMOLOGY, V115, P1026, DOI 10.1016/j.ophtha.2007.08.030
   KLEIN R, 1995, INVEST OPHTH VIS SCI, V36, P182
   Klein R, 1997, OPHTHALMOLOGY, V104, P7, DOI 10.1016/S0161-6420(97)30368-6
   Klein R, 2002, OPHTHALMOLOGY, V109, P1767, DOI 10.1016/S0161-6420(02)01146-6
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   Klein R, 2008, AM J OPHTHALMOL, V146, P692, DOI 10.1016/j.ajo.2008.05.050
   Klein R, 2007, OPHTHALMOLOGY, V114, P253, DOI 10.1016/j.ophtha.2006.10.040
   Klein R, 2011, ARCH OPHTHALMOL-CHIC, V129, P75, DOI 10.1001/archophthalmol.2010.318
   MAGUIRE P, 1986, AM J OPHTHALMOL, V102, P621, DOI 10.1016/0002-9394(86)90535-0
   Meleth AD, 2011, INVEST OPHTH VIS SCI, V52, P1119, DOI 10.1167/iovs.10-6075
   Midena E, 2007, BRIT J OPHTHALMOL, V91, P1499, DOI 10.1136/bjo.2007.119685
   Mitchell P, 2002, OPHTHALMOLOGY, V109, P1092, DOI 10.1016/S0161-6420(02)01055-2
   PACH J, 1989, ANN OPHTHALMOL, V21, P454
   Park DW, 2006, OPHTHALMOLOGY, V113, P1974, DOI 10.1016/j.ophtha.2006.08.015
   Roquet W, 2004, BRIT J OPHTHALMOL, V88, P638, DOI 10.1136/bjo.2003.017632
   Sayegh RG, 2011, OPHTHALMOLOGY, V118, P1844, DOI 10.1016/j.ophtha.2011.01.043
   SCHATZ H, 1989, OPHTHALMOLOGY, V96, P1541
   Schmitz-Valckenberg S, 2002, GRAEF ARCH CLIN EXP, V240, P73, DOI 10.1007/s00417-001-0413-3
   Schmitz-Valckenberg S, 2006, INVEST OPHTH VIS SCI, V47, P2648, DOI 10.1167/iovs.05-0892
   Schmitz-Valckenberg S, 2011, INVEST OPHTH VIS SCI, V52, P1, DOI 10.1167/iovs.10-5619
   Sunness JS, 2008, J VISUAL IMPAIR BLIN, V102, P600
   Sunness JS, 2007, OPHTHALMOLOGY, V114, P271, DOI 10.1016/j.ophtha.2006.09.016
   Sunness JS, 1999, MOL VIS, V5
   Sunness JS, 1997, OPHTHALMOLOGY, V104, P1677, DOI 10.1016/S0161-6420(97)30079-7
   Sunness JS, 1999, OPHTHALMOLOGY, V106, P1768, DOI 10.1016/S0161-6420(99)90340-8
   vonRuckmann A, 1997, INVEST OPHTH VIS SCI, V38, P478
NR 46
TC 17
Z9 17
U1 0
U2 6
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0161-6420
EI 1549-4713
J9 OPHTHALMOLOGY
JI Ophthalmology
PD SEP
PY 2013
VL 120
IS 9
BP 1871
EP 1879
DI 10.1016/j.ophtha.2013.01.049
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 213HG
UT WOS:000324045800042
PM 23622873
OA Green Accepted
DA 2022-11-30
ER

PT J
AU DeCroos, FC
   Toth, CA
   Stinnett, SS
   Heydary, CS
   Burns, R
   Jaffe, GJ
AF DeCroos, Francis Char
   Toth, Cynthia A.
   Stinnett, Sandra S.
   Heydary, Cynthia S.
   Burns, Russell
   Jaffe, Glenn J.
CA CATT Res Grp
TI Optical Coherence Tomography Grading Reproducibility during the
   Comparison of Age-related Macular Degeneration Treatments Trials
SO OPHTHALMOLOGY
LA English
DT Article
ID INTRAVITREAL BEVACIZUMAB AVASTIN; RANIBIZUMAB; AGREEMENT; EDEMA
AB Objective: To report reading center reproducibility during grading of Stratus optical coherence tomography (OCT) (Carl Zeiss Meditec, Dublin, CA) images obtained during the Comparison of Age-Related Macular Degeneration Treatments Trials (CATT).
   Design: Prospective, clinical trial.
   Participants: Independent reading teams reevaluated 270 OCT scans randomly sampled from the first 2 years of CATT enrollment. To assess temporal drift, a cohort of 23 scans submitted during the initial portion of the CATT study was longitudinally followed with serial reproducibility analysis.
   Intervention: The CATT readers performed standardized grading of OCT images. A reader team, composed of 2 independent readers and a senior reader, evaluated each scan. Grading included the CATT OCT end points of total thickness at the foveal center point and intraretinal fluid (IRF), subretinal fluid (SRF), and subretinal pigment epithelium (RPE) fluid. Independent reading teams masked to the results of initial grading reevaluated scans to determine the reproducibility of qualitative grading and measurements.
   Main Outcome Measures: Categorical grading agreement was reported using percent agreement and kappa statistic, and measurement agreement was reported using intraclass correlations and paired differences.
   Results: Reading center teams reproducibly graded IRF (percent agreement = 73%, kappa = 0.48; 95% confidence interval [CI], 0.38-0.58), SRF (percent agreement = 90%; kappa = 0.80; 95% CI, 0.73-0.87), and sub-RPE fluid (percent agreement 88%; kappa = 0.75; 95% CI, 0.67-0.83). For independent reading center team measurements of total thickness at the foveal center point, the intraclass correlation was 0.99 (95% CI, 0.99-0.99), and the mean paired difference between reading center teams was 4 mu m (95% limits of agreement, -55 to 47 mu m). There was no qualitative or quantitative grading drift.
   Conclusions: The standardized protocols used to evaluate OCT scans from the CATT study were reproducible. The methods used are suitable to monitor OCT imaging data from a large, neovascular age-related macular degeneration, interventional, multicenter study.
   Financial Disclosure(s): The author(s) have no proprietary or commercial interest in any materials discussed in this article. Ophthalmology 2012;119:2549-2557 (C) 2012 by the American Academy of Ophthalmology.
C1 [DeCroos, Francis Char; Jaffe, Glenn J.] Wills Eye Inst Mid Atlantic Retina, Philadelphia, PA USA.
   [DeCroos, Francis Char; Toth, Cynthia A.; Stinnett, Sandra S.; Heydary, Cynthia S.; Burns, Russell] Duke Univ, Ctr Eye, Durham, NC USA.
C3 Duke University
RP Jaffe, GJ (通讯作者)，Duke Eye Ctr, DUMC Box 3802, Durham, NC 27710 USA.
EM jaffe001@mc.duke.edu
RI Toth, Cynthia/L-5534-2019; toth, cynthia a/F-5614-2011
OI Toth, Cynthia/0000-0002-2324-0854; Stinnett, Sandra/0000-0001-7192-0195
FU National Institutes of Health [5U10EYO17825]; Heed Foundation; NATIONAL
   EYE INSTITUTE [U10EY017825, U10EY017823] Funding Source: NIH RePORTER
FX National Institutes of Health 5U10EYO17825. This work also was supported
   in part by the Heed Foundation.
CR Ahlers C, 2005, EUR J OPHTHALMOL, V15, P774, DOI 10.1177/112067210501500619
   [Anonymous], 1991, OPHTHALMOLOGY, V98, P786
   Avery RL, 2006, OPHTHALMOLOGY, V113, P363, DOI 10.1016/j.ophtha.2005.11.019
   Boyer D, 2010, OPHTHALMOLOGY, V117, P1860, DOI 10.1016/j.ophtha.2010.02.022
   Coscas F, 2007, AM J OPHTHALMOL, V144, P592, DOI 10.1016/j.ajo.2007.06.014
   Crewson PE, 2005, AM J ROENTGENOL, V184, P1391, DOI 10.2214/ajr.184.5.01841391
   Dadgostar H, 2009, OPHTHALMOLOGY, V116, P1740, DOI 10.1016/j.ophtha.2009.05.033
   Domalpally A, 2009, ARCH OPHTHALMOL-CHIC, V127, P1461, DOI 10.1001/archophthalmol.2009.277
   Falkner-Radler CI, 2010, OPHTHALMOLOGY, V117, P798, DOI 10.1016/j.ophtha.2009.08.034
   FEINSTEIN AR, 1990, J CLIN EPIDEMIOL, V43, P543, DOI 10.1016/0895-4356(90)90158-L
   Fung AE, 2007, AM J OPHTHALMOL, V143, P566, DOI 10.1016/j.ajo.2007.01.028
   Glassman AR, 2009, INVEST OPHTH VIS SCI, V50, P560, DOI 10.1167/iovs.08-1881
   Gupta OP, 2010, OPHTHALMOLOGY, V117, P2134, DOI 10.1016/j.ophtha.2010.02.032
   Haller JA, 2010, OPHTHALMOLOGY, V117, P1134, DOI 10.1016/j.ophtha.2010.03.032
   Hee MR, 1996, OPHTHALMOLOGY, V103, P1260, DOI 10.1016/S0161-6420(96)30512-5
   HEE MR, 1995, ARCH OPHTHALMOL-CHIC, V113, P1019, DOI 10.1001/archopht.1995.01100080071031
   Jaffe GJ, 2004, AM J OPHTHALMOL, V137, P156, DOI 10.1016/S0002-9394(03)00792-X
   Kaiser PK, 2007, OPHTHALMOLOGY, V114, P1868, DOI 10.1016/j.ophtha.2007.04.030
   Keane PA, 2009, AM J OPHTHALMOL, V148, P242, DOI 10.1016/j.ajo.2009.03.004
   KOCH GG, 1977, BIOMETRICS, V33, P133, DOI 10.2307/2529309
   Krebs I, 2010, OPHTHALMOLOGY, V117, P1577, DOI 10.1016/j.ophtha.2010.04.032
   LANDIS JR, 1977, BIOMETRICS, V33, P159, DOI 10.2307/2529310
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Rich RM, 2006, RETINA-J RET VIT DIS, V26, P495, DOI 10.1097/01.iae.0000225766.75009.3a
   Ritter M, 2011, BRIT J OPHTHALMOL, V95, P381, DOI 10.1136/bjo.2009.175976
   Rogers AH, 2002, AM J OPHTHALMOL, V134, P566, DOI 10.1016/S0002-9394(02)01566-0
   Rothenbuehler SP, 2009, AM J OPHTHALMOL, V147, P831, DOI 10.1016/j.ajo.2008.12.005
   Sayanagi K, 2009, OPHTHALMOLOGY, V116, P947, DOI 10.1016/j.ophtha.2008.11.002
   Srinivasan VJ, 2006, OPHTHALMOLOGY, V113, P2054, DOI 10.1016/j.ophtha.2006.05.046
   Ting TD, 2002, ARCH OPHTHALMOL-CHIC, V120, P731
   Wilkins JR, 1996, OPHTHALMOLOGY, V103, P2142, DOI 10.1016/S0161-6420(96)30377-1
   Wojtkowski M, 2004, AM J OPHTHALMOL, V138, P412, DOI 10.1016/j.ajo.2004.04.049
   Zhang N, 2007, AM J OPHTHALMOL, V144, P37, DOI 10.1016/j.ajo.2007.03.056
NR 33
TC 50
Z9 51
U1 0
U2 12
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0161-6420
EI 1549-4713
J9 OPHTHALMOLOGY
JI Ophthalmology
PD DEC
PY 2012
VL 119
IS 12
BP 2549
EP 2557
DI 10.1016/j.ophtha.2012.06.040
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 049AL
UT WOS:000311954300018
PM 22939114
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Scholl, HPN
   Fleckenstein, M
   Charbel Issa, P
   Keilhauer, C
   Holz, FG
   Weber, BHF
AF Scholl, Hendrik P. N.
   Fleckenstein, Monika
   Charbel Issa, Peter
   Keilhauer, Claudia
   Holz, Frank G.
   Weber, Bernhard H. F.
TI An update on the genetics of age-related macular degeneration
SO MOLECULAR VISION
LA English
DT Review
ID COMPLEMENT FACTOR-H; RETINAL-PIGMENT EPITHELIUM; FUNDUS AUTOFLUORESCENCE
   PATTERNS; STARGARDT-DISEASE GENE; BODY-MASS INDEX; GEOGRAPHIC ATROPHY;
   RISK-FACTORS; FAMILIAL AGGREGATION; ALLELIC VARIATION; GENOMEWIDE-SCAN
AB Age-related macular degeneration (AMD) is a genetically complex disorder of the photoreceptor-RPE-Bruch's membrane-choriocapillaris complex. Family and twin studies have shown that the susceptibility for this disease is genetically influenced. The heritability has been estimated to be up to 71%. Linkage and association studies have identified several chromosomal regions that are likely to contain susceptibility loci with strongest evidence found on chromosome 1q31 and 10q26. Variants in the complement factor H (CFH) gene have been shown by several independent studies to be associated with an increased risk for AMD in Caucasian populations. These findings imply that the innate immune system may play a significant role in AMD pathogenesis. The LOC387715/HTRA1 locus within 10q26 has been identified as a second major locus contributing to AMD pathogenesis. The two late forms of AMD, choroidal neovascularization and geographic atrophy, have not been found to be different in risk allele distribution. Variants within CFH and LOC387715/HTRA1 may contribute to the increased risk of late AMD largely through their impact on precursors, such as drusen and/or other RPE/Bruch's membrane changes. Considering variants at CFH, LOC387715/HTRA1 and complement component 2-complement factor B (C2-FB), high-risk homozygotes at all three loci may have a 250-fold increased risk compared to baseline. However, the identification of genetic factors has not resulted in therapeutic strategies to modify the disease so far and additional genetic and environmental factors are yet to be discovered in order to influence the onset and the progression of AMD.
C1 Univ Bonn, Dept Ophthalmol, D-53127 Bonn, Germany.
   Univ Wurzburg, Dept Ophthalmol, Wurzburg, Germany.
   Univ Regensburg, Inst Human Genet, D-8400 Regensburg, Germany.
C3 University of Bonn; University of Wurzburg; University of Regensburg
RP Scholl, HPN (通讯作者)，Univ Bonn, Hosp Eye, Ernst Abbe Str 2, D-53127 Bonn, Germany.
EM hendrik.scholl@ukb.unibonn.de
RI Issa, Peter Charbel/O-2580-2019; Issa, Peter Charbel/F-9603-2011; Issa,
   Peter Charbel/E-8935-2018
OI Issa, Peter Charbel/0000-0002-0351-6673; Issa, Peter
   Charbel/0000-0002-0351-6673; Weber, Bernhard H.F./0000-0002-8808-7723
CR Abecasis GR, 2004, AM J HUM GENET, V74, P482, DOI 10.1086/382786
   Allikmets R, 1997, NAT GENET, V17, P122, DOI 10.1038/ng0997-122b
   Allikmets R, 2000, AM J HUM GENET, V67, P487, DOI 10.1086/303018
   Allikmets R, 1997, SCIENCE, V277, P1805, DOI 10.1126/science.277.5333.1805
   Ambati J, 2003, SURV OPHTHALMOL, V48, P257, DOI 10.1016/S0039-6257(03)00030-4
   Anand R, 2000, OPHTHALMOLOGY, V107, P2224
   Andersen Nis, 2004, Int J Circumpolar Health, V63 Suppl 2, P320
   Assink JJM, 2005, OPHTHALMOLOGY, V112, P482, DOI 10.1016/j.ophtha.2004.10.035
   Baum L, 2003, OPHTHALMOLOGICA, V217, P111, DOI 10.1159/000068553
   Bindewald A, 2005, INVEST OPHTH VIS SCI, V46, P3309, DOI 10.1167/iovs.04-0430
   Bindewald A, 2005, BRIT J OPHTHALMOL, V89, P874, DOI 10.1136/bjo.2004.057794
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Conley YP, 2006, HUM MOL GENET, V15, P3206, DOI 10.1093/hmg/ddl396
   de Cordoba SR, 2004, MOL IMMUNOL, V41, P355, DOI 10.1016/j.molimm.2004.02.005
   de Jong PTVM, 2006, NEW ENGL J MED, V355, P1474, DOI 10.1056/NEJMra062326
   DeJong PTVM, 1997, AM J OPHTHALMOL, V124, P862, DOI 10.1016/S0002-9394(14)71715-5
   DELORI FC, 1995, INVEST OPHTH VIS SCI, V36, P718
   Despriet DDG, 2006, JAMA-J AM MED ASSOC, V296, P301, DOI 10.1001/jama.296.3.301
   Dewan A, 2006, SCIENCE, V314, P989, DOI 10.1126/science.1133807
   Donoso LA, 2006, SURV OPHTHALMOL, V51, P137, DOI 10.1016/j.survophthal.2005.12.001
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   ELDRED GE, 1988, EXP EYE RES, V47, P71, DOI 10.1016/0014-4835(88)90025-5
   Fisher SA, 2005, HUM MOL GENET, V14, P2257, DOI 10.1093/hmg/ddi230
   FLECKENSTEIN M, ARVO ANN M 2006 APR
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P532
   Fuse N, 2000, JPN J OPHTHALMOL, V44, P245, DOI 10.1016/S0021-5155(00)00150-7
   GASS JDM, 1973, ARCH OPHTHALMOL-CHIC, V90, P206
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   Gorin MB, 1999, MOL VIS, V5, pU31
   Grassi MA, 2006, HUM MUTAT, V27, P921, DOI 10.1002/humu.20359
   GREGOR Z, 1978, BRIT J OPHTHALMOL, V62, P547, DOI 10.1136/bjo.62.8.547
   Guymer RH, 2001, ARCH OPHTHALMOL-CHIC, V119, P745, DOI 10.1001/archopht.119.5.745
   Haddad S, 2006, SURV OPHTHALMOL, V51, P316, DOI 10.1016/j.survophthal.2006.05.001
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   HEIBA IM, 1994, GENET EPIDEMIOL, V11, P571
   Holz FG, 2001, INVEST OPHTH VIS SCI, V42, P1051
   Holz FG, 2004, AM J OPHTHALMOL, V137, P504, DOI 10.1016/j.ajo.2003.11.026
   Holz FG, 1999, GRAEF ARCH CLIN EXP, V237, P145, DOI 10.1007/s004170050209
   Hsu WM, 2004, OPHTHALMOLOGY, V111, P62, DOI 10.1016/j.ophtha.2003.05.011
   Hughes AE, 2006, NAT GENET, V38, P1173, DOI 10.1038/ng1890
   HYMAN LG, 1983, AM J EPIDEMIOL, V118, P213, DOI 10.1093/oxfordjournals.aje.a113629
   Issa PC, 2005, OPHTHALMOLOGE, V102, P1036, DOI 10.1007/s00347-005-1269-4
   Iyengar SK, 2004, AM J HUM GENET, V74, P20, DOI 10.1086/380912
   Jakobsdottir J, 2005, AM J HUM GENET, V77, P389, DOI 10.1086/444437
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1439, DOI 10.1001/archopht.119.10.1439
   Klaver CCW, 1998, ARCH OPHTHALMOL-CHIC, V116, P1646, DOI 10.1001/archopht.116.12.1646
   Klein ML, 1998, ARCH OPHTHALMOL-CHIC, V116, P1082, DOI 10.1001/archopht.116.8.1082
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Kuroiwa S, 1999, BRIT J OPHTHALMOL, V83, P613, DOI 10.1136/bjo.83.5.613
   Li M, 2006, NAT GENET, V38, P1049, DOI 10.1038/ng1871
   Lim JI, 1998, RETINA-J RET VIT DIS, V18, P435
   Magnusson KP, 2006, PLOS MED, V3, P109, DOI 10.1371/journal.pmed.0030005
   Majewski J, 2003, AM J HUM GENET, V73, P540, DOI 10.1086/377701
   Maller J, 2006, NAT GENET, V38, P1055, DOI 10.1038/ng1873
   Munoz B, 2000, ARCH OPHTHALMOL-CHIC, V118, P819, DOI 10.1001/archopht.118.6.819
   Oppermann M, 2006, CLIN EXP IMMUNOL, V144, P342, DOI 10.1111/j.1365-2249.2006.03071.x
   Oshima Y, 2001, BRIT J OPHTHALMOL, V85, P1153, DOI 10.1136/bjo.85.10.1153
   Rivera A, 2005, HUM MOL GENET, V14, P3227, DOI 10.1093/hmg/ddi353
   Rivera A, 2000, AM J HUM GENET, V67, P800, DOI 10.1086/303090
   SCHACHAT AP, 1995, ARCH OPHTHALMOL-CHIC, V113, P728, DOI 10.1001/archopht.1995.01100060054032
   Schick JH, 2003, AM J HUM GENET, V72, P1412, DOI 10.1086/375500
   Schmidt S, 2003, INVEST OPHTH VIS SCI, V44, P2868, DOI 10.1167/iovs.02-0957
   Schmitz-Valckenberg S, 2006, INVEST OPHTH VIS SCI, V47, P2648, DOI 10.1167/iovs.05-0892
   SCHOLL HPN, ARVO ANN M 2006 APR
   Seddon JM, 2005, ARCH OPHTHALMOL-CHIC, V123, P321, DOI 10.1001/archopht.123.3.321
   Seddon JM, 2003, AM J HUM GENET, V73, P780, DOI 10.1086/378505
   Seddon JM, 2003, ARCH OPHTHALMOL-CHIC, V121, P785, DOI 10.1001/archopht.121.6.785
   Seddon JM, 1996, JAMA-J AM MED ASSOC, V276, P1141, DOI 10.1001/jama.276.14.1141
   Seddon JM, 1997, AM J OPHTHALMOL, V123, P199, DOI 10.1016/S0002-9394(14)71036-0
   Seddon JM, 2006, HUM HERED, V61, P157, DOI 10.1159/000094141
   Shastry BS, 2006, OPHTHALMOLOGICA, V220, P291, DOI 10.1159/000094617
   SHCMIDT S, 2006, AM J HUM GENET, V78, P852
   Sho K, 2003, ARCH OPHTHALMOL-CHIC, V121, P1392, DOI 10.1001/archopht.121.10.1392
   Shroyer NF, 2001, HUM MOL GENET, V10, P2671, DOI 10.1093/hmg/10.23.2671
   Smith W, 2001, OPHTHALMOLOGY, V108, P697, DOI 10.1016/S0161-6420(00)00580-7
   Souied EH, 2005, MOL VIS, V11, P1135
   Souied EH, 2000, INVEST OPHTH VIS SCI, V41, P244
   Stone EM, 1999, NAT GENET, V22, P199, DOI 10.1038/9722
   Stone EM, 1998, NAT GENET, V20, P328, DOI 10.1038/3798
   Stone EM, 2004, NEW ENGL J MED, V351, P346, DOI 10.1056/NEJMoa040833
   Thornton J, 2005, EYE, V19, P935, DOI 10.1038/sj.eye.6701978
   Tomany SC, 2004, OPHTHALMOLOGY, V111, P1280, DOI 10.1016/j.ophtha.2003.11.010
   Uyama M, 2000, BRIT J OPHTHALMOL, V84, P1018, DOI 10.1136/bjo.84.9.1018
   van Leeuwen R, 2005, JAMA-J AM MED ASSOC, V294, P3101, DOI 10.1001/jama.294.24.3101
   Varma R, 2004, OPHTHALMOLOGY, V111, P1288, DOI 10.1016/j.ophtha.2004.01.023
   VONRUCKMANN A, 1995, BRIT J OPHTHALMOL, V79, P407, DOI 10.1136/bjo.79.5.407
   Webster AR, 2001, INVEST OPHTH VIS SCI, V42, P1179
   Weeks DE, 2004, AM J HUM GENET, V75, P174, DOI 10.1086/422476
   Yang ZL, 2006, SCIENCE, V314, P992, DOI 10.1126/science.1133811
   Yates JRW, 2000, J MED GENET, V37, P83, DOI 10.1136/jmg.37.2.83
   Zarbin MA, 2004, ARCH OPHTHALMOL-CHIC, V122, P598, DOI 10.1001/archopht.122.4.598
   Zareparsi S, 2005, AM J HUM GENET, V77, P149, DOI 10.1086/431426
   Zipfel PF, 2006, SEMIN THROMB HEMOST, V32, P146, DOI 10.1055/s-2006-939770
NR 94
TC 121
Z9 126
U1 0
U2 10
PU MOLECULAR VISION
PI ATLANTA
PA C/O JEFF BOATRIGHT, LAB B, 5500 EMORY EYE CENTER, 1327 CLIFTON RD, N E,
   ATLANTA, GA 30322 USA
SN 1090-0535
J9 MOL VIS
JI Mol. Vis.
PD FEB 7
PY 2007
VL 13
IS 20-24
BP 196
EP 205
PG 10
WC Biochemistry & Molecular Biology; Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Ophthalmology
GA 139YF
UT WOS:000244468100004
PM 17327825
DA 2022-11-30
ER

PT J
AU Kurashige, Y
   Otani, A
   Sasahara, M
   Yodoi, Y
   Tamura, H
   Tsuikawa, A
   Yoshimura, N
AF Kurashige, Yumiko
   Otani, Atsushi
   Sasahara, Manabu
   Yodoi, Yuko
   Tamura, Hiroshi
   Tsuikawa, Akitaka
   Yoshimura, Nagahisa
TI Two-year results of photodynamic therapy for polypoidal choroidal
   vasculopathy
SO AMERICAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID MACULAR DEGENERATION; JAPANESE PATIENTS; VERTEPORFIN; NEOVASCULARIZATION
AB PURPOSE: To report on the two-year visual outcomes of indocyanine green angiography-guided photodynamic therapy (PDT) for polypoidal choroidal vasculopathy (PCV) patients.
   DESIGN: Retrospective case study.
   METHODS: A retrospective analysis that examined the clinical and angiographic data related to 41 eyes of 38 PCV patients (25 males, 13 females; average age standard deviation [SD], 72.9 +/- 7.4 years) with follow-up periods of 24 months or more.
   RESULTS: The average number of PDT treatments was 1.65. After the 12-month follow-up, 12 eyes required retreatment. Although the mean visual acuity (VA) +/- SD before PDT (0.55 +/- 0.38 logarithm of the minimum angle of resolution units) improved to 0.46 +/- 0.41 at 12 months after the initial PDT, at 24 months, it declined significantly to 0.59 +/- 0.44 (P = .0018). Although only seven of 41 eyes exhibited VA deterioration at the 12-month follow-up examination, a decreased VA was noted in 18 eyes during the period starting from the 12-month follow-up until the final examination. The cases were bilateral in 11 (61.1%) of the 18 eyes. At the final examination, the mean VA of the bilateral cases but not the unilateral cases was significantly lower than that observed for the initial VA.
   CONCLUSIONS: PDT is an effective treatment against CV over the short-term for both unilateral and bilateral cases. However, the VA prognosis may not the same after 12 months, especially for those PCV patients who have exudative age-related macular degeneration in contralateral eye.
C1 [Kurashige, Yumiko; Otani, Atsushi; Sasahara, Manabu; Yodoi, Yuko; Tamura, Hiroshi; Tsuikawa, Akitaka; Yoshimura, Nagahisa] Kyoto Univ, Grad Sch Med, Dept Ophthalmol & Visual Sci, Sakyo Ku, Kyoto 6068507, Japan.
C3 Kyoto University
RP Otani, A (通讯作者)，Kyoto Univ, Grad Sch Med, Dept Ophthalmol, Sakyo Ku, 54 Shogoin Kawahara Cho, Kyoto 6068507, Japan.
EM otan@kuhp.kyoto-u.ac.jp
RI TAMURA, Hiroshi/H-1855-2011
OI TAMURA, Hiroshi/0000-0002-7740-2732; Tsujikawa,
   Akitaka/0000-0003-0779-7799
CR BURGESS DB, 1993, ARCH OPHTHALMOL-CHIC, V111, P1189
   Chakravarthy U, 2007, OPHTHALMOLOGY, V114, P1157, DOI 10.1016/j.ophtha.2006.09.022
   Chan WM, 2004, OPHTHALMOLOGY, V111, P1576, DOI 10.1016/j.ophtha.2003.12.056
   Chen J, 2008, CHINESE J ORG CHEM, V28, P123
   Costa RA, 2005, PROG RETIN EYE RES, V24, P560, DOI 10.1016/j.preteyeres.2005.01.001
   Eandi CM, 2007, RETINA-J RET VIT DIS, V27, P825, DOI 10.1097/IAE.0b013e31804b3f70
   Kikuchi M, 2007, OPHTHALMOLOGY, V114, P1722, DOI 10.1016/j.ophtha.2006.12.021
   LEE MW, EYE IN PRESS
   Lee SC, 2004, OPHTHALMOLOGICA, V218, P193, DOI 10.1159/000076844
   Otani A, 2007, AM J OPHTHALMOL, V144, P7, DOI 10.1016/j.ajo.2007.03.014
   Quaranta M, 2002, AM J OPHTHALMOL, V134, P277, DOI 10.1016/S0002-9394(02)01516-7
   Silva RM, 2005, GRAEF ARCH CLIN EXP, V243, P973, DOI 10.1007/s00417-005-1139-4
   SPAIDE RF, 1995, RETINA-J RET VIT DIS, V15, P100, DOI 10.1097/00006982-199515020-00003
   Spaide RF, 2002, RETINA-J RET VIT DIS, V22, P529, DOI 10.1097/00006982-200210000-00001
   Tano Y, 2003, AM J OPHTHALMOL, V136, P1049, DOI 10.1016/S0002-9394(03)00576-2
   Tedeschi-Blok N, 2007, OPHTHALMOLOGY, V114, P99, DOI 10.1016/j.ophtha.2006.07.043
   Tong JP, 2006, AM J OPHTHALMOL, V141, P456, DOI 10.1016/j.ajo.2005.10.012
   Uyama M, 2002, AM J OPHTHALMOL, V133, P639, DOI 10.1016/S0002-9394(02)01404-6
   Uyama M, 2000, BRIT J OPHTHALMOL, V84, P1018, DOI 10.1136/bjo.84.9.1018
   Yannuzzi LA, 1997, ARCH OPHTHALMOL-CHIC, V115, P478, DOI 10.1001/archopht.1997.01100150480005
   YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001
   Yodoi Y, 2007, INVEST OPHTH VIS SCI, V48, P5464, DOI 10.1167/iovs.07-0093
   Yuzawa M, 2003, JPN J OPHTHALMOL, V47, P379, DOI 10.1016/S0021-5155(03)00042-X
   YUZAWA M, 1991, JPN J OPHTHALMOL, V35, P87
NR 24
TC 83
Z9 92
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0002-9394
J9 AM J OPHTHALMOL
JI Am. J. Ophthalmol.
PD OCT
PY 2008
VL 146
IS 4
BP 513
EP 519
DI 10.1016/j.ajo.2008.05.025
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 355XH
UT WOS:000259742200007
PM 18614133
DA 2022-11-30
ER

PT J
AU Singh, A
   Falk, MK
   Hviid, TVF
   Sorensen, TL
AF Singh, Amardeep
   Falk, Mads K.
   Hviid, Thomas V. F.
   Sorensen, Torben L.
TI Increased Expression of CD200 on Circulating CD11b+ Monocytes in
   Patients with Neovascular Age-related Macular Degeneration
SO OPHTHALMOLOGY
LA English
DT Article
ID MICROGLIAL ACTIVATION; SUBRETINAL MICROGLIA; ALZHEIMERS-DISEASE;
   INFLAMMATION; RECEPTOR; ACCUMULATION; MACROPHAGE; CELLS; MODEL;
   NEURODEGENERATION
AB Objective: Dysregulation of retinal microglial activity has been implicated in the pathogenesis of neovascular age-related macular degeneration. Microglia activity can be regulated through the membrane protein CD200 and its corresponding receptor, the CD200 receptor (CD200R). Because both the ligand and the receptor are expressed on a broad spectrum of cell types, we set out to study the expression of CD200 and CD200R on CD11b+ monocytes, granulocytes, and subsets of T lymphocytes.
   Design: Prospective, case-control study.
   Participants: The study population consisted of 62 patients with neovascular age-related macular degeneration (AMD) and 44 age-matched controls without AMD.
   Methods: The participants were aged 60 years or older, had no history of immune dysfunction or cancer, and were not receiving immune-modulating therapy. All participants were subjected to a structured interview, and detailed retinal imaging was performed: fundus autofluorescence imaging, digital color fundoscopy, and spectral-domain optical coherence tomography. Fluorescein and indocyanine green angiography were performed in patients with suspected neovascular AMD. Visual acuity was measured in both eyes. Fresh venous blood was obtained and stained with monoclonal antibodies and analyzed using flow cytometry within 6 hours of phlebotomy.
   Main Outcome Measures: The percentage of CD11b+ monocytes, granulocytes, and CD4+/CD8+ T lymphocytes positive for CD200 or CD200R in patients and controls, respectively.
   Results: Patients with neovascular AMD had a higher percentage of CD11b+CD200+ monocytes and CD200+ monocytes compared with controls. Multiple regression analysis revealed that the intergroup differences observed were independent of age. Moreover, an age-related increment in CD200 expression on monocytes was observed in controls with healthy eyes, but not in patients with neovascular AMD. We did not find any differences in CD200 and CD200R expression between patients with subretinal fibrosis and patients without subretinal fibrosis.
   Conclusions: The surface expression of CD200 on circulating CD11b+ monocytes was found to be increased in patients with neovascular AMD compared with controls with healthy eyes. This novel finding supports the notion that altered regulation of the inflammatory response plays an integral role in the pathogenesis of AMD.
C1 [Singh, Amardeep; Falk, Mads K.; Sorensen, Torben L.] Copenhagen Univ Hosp Roskilde, Clin Eye Res Unit, Dept Ophthalmol, Copenhagen, Denmark.
   [Singh, Amardeep; Falk, Mads K.; Hviid, Thomas V. F.; Sorensen, Torben L.] Univ Copenhagen, Copenhagen, Denmark.
   [Hviid, Thomas V. F.] Copenhagen Univ Hosp Roskilde, Ctr Immune Regulat & Reprod Immunol, Dept Clin Biochem, Copenhagen, Denmark.
C3 University of Copenhagen
RP Singh, A (通讯作者)，Copenhagen Univ Hosp Roskilde, Clin Eye Res Unit, Dept Ophthalmol, Kogevej 7-13, DK-4000 Roskilde, Denmark.
EM asingh@dadlnet.dk
RI Sørensen, Torben Lykke L/N-1417-2014; Singh, Amardeep/ABI-4544-2020
OI Sørensen, Torben Lykke L/0000-0002-6790-0199; 
FU Region Zealand's Research Fund; Velux Foundation; Danish Eye Research
   Foundation; Danish Eye Health Society (Vaern om Synet); Beckett
   Foundation; Synoptik Foundation
FX This study was funded by Region Zealand's Research Fund, the Velux
   Foundation, the Danish Eye Research Foundation, the Danish Eye Health
   Society (Vaern om Synet), the Beckett Foundation, and the Synoptik
   Foundation. The sponsor or funding organization had no role in the
   design or conduct of this research.
CR Burgisser P, 2007, CYTOM PART A, V71A, P632, DOI 10.1002/cyto.a.20414
   Carter DA, 2004, CURR EYE RES, V28, P427, DOI 10.1080/02713680490503778
   Chakravarthy U, 2010, BMJ-BRIT MED J, V340, DOI 10.1136/bmj.c981
   Chan-Ling T, 2011, EXP EYE RES, V92, P361, DOI 10.1016/j.exer.2011.02.009
   Chitnis T, 2007, AM J PATHOL, V170, P1695, DOI 10.2353/ajpath.2007.060677
   Combadiere C, 2007, J CLIN INVEST, V117, P2920, DOI 10.1172/JCI31692
   DASTGHEIB K, 1994, ARCH OPHTHALMOL-CHIC, V112, P813, DOI 10.1001/archopht.1994.01090180111045
   Dick AD, 2003, J LEUKOCYTE BIOL, V74, P161, DOI 10.1189/jlb.1102535
   Dick AD, 2001, INVEST OPHTH VIS SCI, V42, P170
   Dimeloe S, 2012, THORAX, V67, P574, DOI 10.1136/thoraxjnl-2011-200651
   Ding JD, 2011, P NATL ACAD SCI USA, V108, pE279, DOI 10.1073/pnas.1100901108
   DOSQUET C, 1992, NOUV REV FR HEMATOL, V34, pS55
   Falk MK, 2013, AM J OPHTHALMOL, V155, P89, DOI 10.1016/j.ajo.2012.06.031
   Freedman ND, 2008, LANCET ONCOL, V9, P649, DOI 10.1016/S1470-2045(08)70154-2
   GEHRMANN J, 1995, BRAIN RES REV, V20, P269, DOI 10.1016/0165-0173(94)00015-H
   Grossniklaus HE, 2002, MOL VIS, V8, P119
   Hoek RM, 2000, SCIENCE, V290, P1768, DOI 10.1126/science.290.5497.1768
   Issa PC, 2011, GRAEF ARCH CLIN EXP, V249, P163, DOI 10.1007/s00417-010-1568-6
   Kaiser Peter K, 2009, Trans Am Ophthalmol Soc, V107, P311
   Kamei M, 2007, INVEST OPHTH VIS SCI, V48, P1801, DOI 10.1167/iovs.06-0699
   Kaur C, 2001, MICROSC RES TECHNIQ, V54, P2, DOI 10.1002/jemt.1114
   Kettenmann H, 2011, PHYSIOL REV, V91, P461, DOI 10.1152/physrev.00011.2010
   Krauthausen M, 2011, AM J PATHOL, V179, P2346, DOI 10.1016/j.ajpath.2011.07.041
   Langmann T, 2007, J LEUKOCYTE BIOL, V81, P1345, DOI 10.1189/jlb.0207114
   Lebson L, 2010, J NEUROSCI, V30, P9651, DOI 10.1523/JNEUROSCI.0329-10.2010
   LOPEZ PF, 1991, AM J OPHTHALMOL, V112, P647, DOI 10.1016/S0002-9394(14)77270-8
   Luo XG, 2010, NEUROCHEM RES, V35, P540, DOI 10.1007/s11064-009-0094-6
   Ma WX, 2013, NEUROBIOL AGING, V34, P943, DOI 10.1016/j.neurobiolaging.2012.06.010
   Ma WX, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007945
   Meuth SG, 2008, J NEUROIMMUNOL, V194, P62, DOI 10.1016/j.jneuroim.2007.11.013
   Mishra MK, 2012, AM J PATHOL, V181, P642, DOI 10.1016/j.ajpath.2012.05.011
   Ohno-Matsui K, 2011, PROG RETIN EYE RES, V30, P217, DOI 10.1016/j.preteyeres.2011.02.004
   Omri S, 2011, AM J PATHOL, V179, P942, DOI 10.1016/j.ajpath.2011.04.018
   PATARROYO M, 1989, LANCET, V2, P1139
   Prasad K, 2006, CARDIOVASC DRUG REV, V24, P33, DOI 10.1111/j.1527-3466.2006.00033.x
   Provis JM, 1996, PERSPECT DEV NEUROBI, V3, P213
   Raoul W, 2010, J NEUROINFLAMM, V7, DOI 10.1186/1742-2094-7-87
   Scali C, 2002, NEUROBIOL AGING, V23, P523, DOI 10.1016/S0197-4580(01)00346-3
   Schuetz E, 2004, CURR DRUG TARGETS, V5, P619, DOI 10.2174/1389450043345164
   Seddon JM, 2006, OPHTHALMOLOGY, V113, P260, DOI 10.1016/j.ophtha.2005.11.001
   Seddon JM, 2011, OPHTHALMOLOGY, V118, P2203, DOI 10.1016/j.ophtha.2011.04.029
   Singh A, 2012, AM J OPHTHALMOL, V154, P193, DOI 10.1016/j.ajo.2012.01.036
   Telander DG, 2011, SEMIN OPHTHALMOL, V26, P192, DOI 10.3109/08820538.2011.570849
   Varnum MM, 2012, ARCH IMMUNOL THER EX, V60, P251, DOI 10.1007/s00005-012-0181-2
   Walker DG, 2009, EXP NEUROL, V215, P5, DOI 10.1016/j.expneurol.2008.09.003
   Walter L, 2009, SEMIN IMMUNOPATHOL, V31, P513, DOI 10.1007/s00281-009-0180-5
   Wright GJ, 2003, J IMMUNOL, V171, P3034, DOI 10.4049/jimmunol.171.6.3034
   Xu HP, 2008, AGING CELL, V7, P58, DOI 10.1111/j.1474-9726.2007.00351.x
   Xu HP, 2007, GLIA, V55, P1189, DOI 10.1002/glia.20535
   Xu HP, 2009, PROG RETIN EYE RES, V28, P348, DOI 10.1016/j.preteyeres.2009.06.001
   Zhang S, 2011, J NEUROINFLAMM, V8, DOI 10.1186/1742-2094-8-154
NR 51
TC 31
Z9 32
U1 0
U2 12
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0161-6420
EI 1549-4713
J9 OPHTHALMOLOGY
JI Ophthalmology
PD MAY
PY 2013
VL 120
IS 5
BP 1029
EP 1037
DI 10.1016/j.ophtha.2012.11.002
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 140VE
UT WOS:000318683400022
PM 23410964
DA 2022-11-30
ER

PT J
AU Gourier, HCY
   Chong, NV
AF Gourier, Hanae C. Y.
   Chong, N. Victor
TI Can Novel Treatment of Age-Related Macular Degeneration Be Developed by
   Better Understanding of Sorsby's Fundus Dystrophy
SO JOURNAL OF CLINICAL MEDICINE
LA English
DT Review
DE Sorsby's fundus dystrophy; age-related macular degeneration; Bruch's
   membrane; TIMP-3; choroidal neovascularisation; geographic atrophy
ID RETINAL-PIGMENT EPITHELIUM; LACKING TISSUE INHIBITOR; TIMP-3
   MESSENGER-RNA; METALLOPROTEINASES-3 TIMP3; BRUCHS MEMBRANE; MUTATION;
   CHORIOCAPILLARIS; LOCALIZATION; PATHOGENESIS; EXPRESSION
AB Sorsby's Fundus Dystrophy (SFD) is a rare autosomal dominant maculopathy that shares many clinical features with Age-Related Macular Degeneration (AMD). It is caused by a mutation in a single gene, TIMP-3, which accumulates in Bruch's membrane (BM). BM thickening and TIMP-3 accumulation can also be found in AMD. From our understanding of the pathophysiology of SFD we hypothesize that BM thickening could be responsible for making the elastic layer vulnerable to invasion by choriocapillaris, thereby leading to choroidal neovascularization in some cases of AMD, whilst in others it could deprive the retinal pigment epithelium of its blood supply, thereby causing geographic atrophy.
C1 [Gourier, Hanae C. Y.; Chong, N. Victor] Oxford Univ Hosp, Oxford Eye Hosp, Oxford OX3 9DU, England.
RP Chong, NV (通讯作者)，Oxford Univ Hosp, Oxford Eye Hosp, Oxford OX3 9DU, England.
EM hanae.gourier@gmail.com; victor@eretina.org
RI Chong, Victor/Q-6565-2018
OI Chong, Victor/0000-0002-7693-522X
CR Ardeljan D, 2013, EUR J HUM GENET, V21, P1152, DOI 10.1038/ejhg.2013.14
   Balaskas K, 2013, EYE, V27, P101, DOI 10.1038/eye.2012.221
   Blaauwgeers HGT, 1999, AM J PATHOL, V155, P421, DOI 10.1016/S0002-9440(10)65138-3
   Brew K, 2010, BBA-MOL CELL RES, V1803, P55, DOI 10.1016/j.bbamcr.2010.01.003
   CAPON MRC, 1989, OPHTHALMOLOGY, V96, P1769
   Chen W, 2010, P NATL ACAD SCI USA, V107, P7401, DOI 10.1073/pnas.0912702107
   Chong NHV, 2000, INVEST OPHTH VIS SCI, V41, P898
   Chong NHV, 2005, AM J PATHOL, V166, P241, DOI 10.1016/S0002-9440(10)62248-1
   Chong NHV, 2003, AM J OPHTHALMOL, V136, P954, DOI 10.1016/S0002-9394(03)00482-3
   Della NG, 1996, INVEST OPHTH VIS SCI, V37, P1921
   Ebrahem Q, 2011, INVEST OPHTH VIS SCI, V52, P6117, DOI 10.1167/iovs.10-5899
   Fariss RN, 1998, BRIT J OPHTHALMOL, V82, P1329, DOI 10.1136/bjo.82.11.1329
   Fariss RN, 1997, AM J PATHOL, V150, P323
   Felbor U, 1996, J MED GENET, V33, P233, DOI 10.1136/jmg.33.3.233
   FELBOR U, 1995, HUM MOL GENET, V4, P2415, DOI 10.1093/hmg/4.12.2415
   Fritsche LG, 2013, NAT GENET, V45, P433, DOI 10.1038/ng.2578
   HENKIND P, 1983, T OPHTHAL SOC UK, V103, P444
   Holz FG, 2004, AM J OPHTHALMOL, V137, P504, DOI 10.1016/j.ajo.2003.11.026
   Issa PC, 2011, GRAEF ARCH CLIN EXP, V249, P163, DOI 10.1007/s00417-010-1568-6
   Jacobson SG, 2002, ARCH OPHTHALMOL-CHIC, V120, P376
   Janssen A, 2008, INVEST OPHTH VIS SCI, V49, P2812, DOI 10.1167/iovs.07-1444
   Kamei M, 1999, INVEST OPHTH VIS SCI, V40, P2367
   Knupp C, 2002, J STRUCT BIOL, V137, P31, DOI 10.1006/jsbi.2002.4449
   KORTE GE, 1984, INVEST OPHTH VIS SCI, V25, P1135
   Langton KP, 2000, J BIOL CHEM, V275, P27027
   Langton KP, 2005, HUM MOL GENET, V14, P3579, DOI 10.1093/hmg/ddi385
   LECO KJ, 1994, J BIOL CHEM, V269, P9352
   Lin RJ, 2006, AM J OPHTHALMOL, V142, P839, DOI 10.1016/j.ajo.2006.06.003
   McLeod DS, 2009, INVEST OPHTH VIS SCI, V50, P4982, DOI 10.1167/iovs.09-3639
   POLKINGHORNE PJ, 1989, OPHTHALMOLOGY, V96, P1763
   Qi JH, 2003, NAT MED, V9, P407, DOI 10.1038/nm846
   Sivaprasad S, 2005, INVEST OPHTH VIS SCI, V46, P3046, DOI 10.1167/iovs.04-1277
   Sivaprasad S, 2008, AM J OPHTHALMOL, V146, P228, DOI 10.1016/j.ajo.2008.03.024
   Skeie JM, 2008, INVEST OPHTH VIS SCI, V49, P5574, DOI 10.1167/iovs.08-1984
   SORSBY A, 1949, BRIT J OPHTHALMOL, V33, P67, DOI 10.1136/bjo.33.2.67
   Spraul CW, 1999, SURV OPHTHALMOL, V44, pS10, DOI 10.1016/S0039-6257(99)00086-7
   Stohr H, 2012, ADV EXP MED BIOL, V723, P261, DOI 10.1007/978-1-4614-0631-0_34
   WEBER BHF, 1994, NAT GENET, V8, P352, DOI 10.1038/ng1294-352
NR 38
TC 8
Z9 9
U1 0
U2 2
PU MDPI AG
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
SN 2077-0383
J9 J CLIN MED
JI J. Clin. Med.
PD MAY
PY 2015
VL 4
IS 5
BP 874
EP 883
DI 10.3390/jcm4050874
PG 10
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA CT9MV
UT WOS:000363142200006
PM 26239453
OA Green Published, Green Submitted, gold
DA 2022-11-30
ER

PT J
AU Merle, BMJ
   Silver, RE
   Rosner, B
   Seddon, JM
AF Merle, Benedicte M. J.
   Silver, Rachel E.
   Rosner, Bernard
   Seddon, Johanna M.
TI Dietary folate, B vitamins, genetic susceptibility and progression to
   advanced nonexudative age-related macular degeneration with geographic
   atrophy: a prospective cohort study
SO AMERICAN JOURNAL OF CLINICAL NUTRITION
LA English
DT Article
DE folate; B vitamins; geographic atrophy; macular degeneration; genetics
ID PLASMA HOMOCYSTEINE; FOLIC-ACID; MACULOPATHY; LUTEIN; RISK; EPIGENETICS;
   CAROTENOIDS; PREVALENCE; METABOLISM; ZEAXANTHIN
AB Background: There is growing evidence of the importance of nutrition in age-related macular degeneration (AMD), but few studies have explored associations with folate and B vitamins. No effective therapeutic strategy for geographic atrophy (GA) is available, and prevention could be of great value.
   Objective: We investigated associations between dietary folate, B vitamins, and progression to GA and whether these associations might be modified by genetic susceptibility.
   Design: Among 2525 subjects (4663 eyes) in the Age-Related Eye Disease Study, 405 subjects (528 eyes) progressed to GA over 13 y. Folate and B vitamins were log transformed and calorie adjusted separately for men and women. Ten loci in 7 AMD genes [complement factor H, age-related maculopathy susceptibility 2/high-temperature requirement A serine peptidase 1, complement component 2, complement component 3, complement factor B, collagen type VIII alpha 1, and RAD51 paralog B] were examined. Survival analysis was used to assess associations between incident GA and dietary intake of folate and B vitamins. Interaction effects between these nutrients and genetic variation on AMD risk were also evaluated. Subjects with at least one eye free of advanced AMD at baseline were included in these analyses.
   Results: There was a reduced risk of progression to GAwith increasing intake of thiamin, riboflavin, and folate after adjusting for age, sex, and total energy intake (P-trend = 0.01, 0.03, and 0.001, respectively). After adjustment for demographic, behavioral, ocular, and genetic covariates, trends remained statistically significant for folate (P-trend = 0.007) and were borderline for thiamin (P-trend = 0.05). Riboflavin did not retain statistical significance (P-trend = 0.20). Folate was significantly associated with lower risk of incident GA among subjects homozygous for the complement component 3 (C3) R102G rs2230199 nonrisk genotype (CC) (HR = 0.43; 95% CI: 0.27, 0.70; P = 0.0005) but not subjects carrying the risk allele (G) (P = 0.76). Neither folate nor any B vitamin was significantly associated with neovascular AMD.
   Conclusions: High folate intake was associated with a reduced risk of progression to GA. This relation could be modified by genetic susceptibility, particularly related to the C3 genotype. This trial was registered at clinicaltrials. gov as NCT00594672.
C1 [Merle, Benedicte M. J.; Silver, Rachel E.; Seddon, Johanna M.] Tufts Med Ctr, New England Eye Ctr, Ophthalm Epidemiol & Genet Serv, Boston, MA USA.
   [Rosner, Bernard] Harvard Univ, Sch Med, Channing Div Network Med, Boston, MA USA.
   [Seddon, Johanna M.] Tufts Univ, Sch Med, Dept Ophthalmol, Boston, MA 02111 USA.
   [Seddon, Johanna M.] Tufts Univ, Sackler Sch Grad Biomed Sci, Boston, MA 02111 USA.
C3 Tufts Medical Center; Harvard University; Harvard Medical School; Tufts
   University; Tufts University
RP Seddon, JM (通讯作者)，Tufts Med Ctr, New England Eye Ctr, Ophthalm Epidemiol & Genet Serv, Boston, MA USA.; Seddon, JM (通讯作者)，Tufts Univ, Sch Med, Dept Ophthalmol, Boston, MA 02111 USA.; Seddon, JM (通讯作者)，Tufts Univ, Sackler Sch Grad Biomed Sci, Boston, MA 02111 USA.
EM jseddon@tuftsmedicalcenter.org
RI Merle, Benedicte MJ/F-1247-2015; Mitchell, Paul/P-1498-2014; Merle,
   Benedicte MJ/AAQ-5021-2021
OI Merle, Benedicte MJ/0000-0003-1332-0954; Merle, Benedicte
   MJ/0000-0003-1332-0954
FU Fondation Dalloz-Institut de France; Philippe Foundation; Jean-Walter
   Zellidja-Academie Francaise; NIH [RO1-EY11309, RO1-EY022445];
   Massachusetts Lions Eye Research Fund; Research to Prevent Blindness;
   Foundation Fighting Blindness; American Macular Degeneration Foundation;
   Age-Related Macular Degeneration Research Fund; Ophthalmic Epidemiology
   and Genetics Service; Tufts Medical Center; Tufts University School of
   Medicine; NATIONAL EYE INSTITUTE [R01EY011309, R01EY022445] Funding
   Source: NIH RePORTER
FX Supported by grants from Fondation Dalloz-Institut de France, Philippe
   Foundation, and Jean-Walter Zellidja-Academie Francaise (to BMJM);
   grants from the NIH (RO1-EY11309) and the Massachusetts Lions Eye
   Research Fund, unrestricted grants from Research to Prevent Blindness,
   Foundation Fighting Blindness, American Macular Degeneration Foundation,
   and Age-Related Macular Degeneration Research Fund, Ophthalmic
   Epidemiology and Genetics Service, Tufts Medical Center, Tufts
   University School of Medicine (to JMS); and grant RO1-EY022445 from the
   NIH (to BR). The funding sources had no role as relates to the
   following: design and conduct of the study; collection, management,
   analysis, and interpretation of the data; preparation, review, or
   approval of the manuscript; and decision to submit the manuscript for
   publication.
CR [Anonymous], 1999, CONTROL CLIN TRIALS, DOI 10.1016/S0197-2456(99)00031-8
   Augood CA, 2006, ARCH OPHTHALMOL-CHIC, V124, P529, DOI 10.1001/archopht.124.4.529
   BLAND JM, 1995, BRIT MED J, V310, P170, DOI 10.1136/bmj.310.6973.170
   Chew EY, 2013, JAMA-J AM MED ASSOC, V309, P2005, DOI 10.1001/jama.2013.4997
   Choi SW, 2010, ADV NUTR, V1, P8, DOI 10.3945/an.110.1004
   Christen WG, 2009, ARCH INTERN MED, V169, P335, DOI 10.1001/archinternmed.2008.574
   Delcourt C, 2006, INVEST OPHTH VIS SCI, V47, P2329, DOI 10.1167/iovs.05-1235
   Fenech M, 2012, MUTAT RES-FUND MOL M, V733, P21, DOI 10.1016/j.mrfmmm.2011.11.003
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Fritsche LG, 2013, NAT GENET, V45, P433, DOI 10.1038/ng.2578
   Glynn RJ, 2012, OPHTHAL EPIDEMIOL, V19, P159, DOI 10.3109/09286586.2012.674614
   Gopinath B, 2013, AM J CLIN NUTR, V98, P129, DOI 10.3945/ajcn.112.057091
   Grassmann F, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0126636
   Heuberger RA, 2002, AM J CLIN NUTR, V76, P897, DOI 10.1093/ajcn/76.4.897
   Holz FG, 2014, OPHTHALMOLOGY, V121, P1079, DOI 10.1016/j.ophtha.2013.11.023
   Kamburoglu G, 2006, GRAEF ARCH CLIN EXP, V244, P565, DOI 10.1007/s00417-005-0108-2
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Klein ML, 2010, OPHTHALMOLOGY, V117, P1554, DOI 10.1016/j.ophtha.2009.12.012
   Klein R, 2008, AM J OPHTHALMOL, V146, P692, DOI 10.1016/j.ajo.2008.05.050
   Klein R, 2007, OPHTHALMOLOGY, V114, P253, DOI 10.1016/j.ophtha.2006.10.040
   Kronenberg G, 2009, CURR MOL MED, V9, P315, DOI 10.2174/156652409787847146
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Ma L, 2012, BRIT J NUTR, V107, P350, DOI 10.1017/S0007114511004260
   Mattson MP, 2003, TRENDS NEUROSCI, V26, P137, DOI 10.1016/S0166-2236(03)00032-8
   Park LK, 2012, P NUTR SOC, V71, P75, DOI 10.1017/S0029665111003302
   Purcell S, 2007, AM J HUM GENET, V81, P559, DOI 10.1086/519795
   Reynolds R, 2013, OPHTHALMOLOGY, V120, P1020, DOI 10.1016/j.ophtha.2012.10.020
   Rochtchina E, 2007, AM J OPHTHALMOL, V143, P344, DOI 10.1016/j.ajo.2006.08.032
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Seddon JM, 2006, OPHTHALMOLOGY, V113, P260, DOI 10.1016/j.ophtha.2005.11.001
   Seddon JM, 2006, AM J OPHTHALMOL, V141, P201, DOI 10.1016/j.ajo.2005.07.059
   SEDDON JM, 1994, JAMA-J AM MED ASSOC, V272, P1413, DOI 10.1001/jama.272.18.1413
   Seddon JM, 2015, INVEST OPHTH VIS SCI, V56, P2192, DOI 10.1167/iovs.14-15841
   Seddon JM, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0087047
   Seddon JM, 2010, MOL VIS, V16, P2412
   Sobrin L, 2014, PROG RETIN EYE RES, V40, P1, DOI 10.1016/j.preteyeres.2013.12.004
   Ulrey CL, 2005, HUM MOL GENET, V14, pR139, DOI 10.1093/hmg/ddi100
   United States Department of Agriculture (USDA), 2010, DIET GUID AM
   Van den Veyver IB, 2002, ANNU REV NUTR, V22, P255, DOI 10.1146/annurev.nutr.22.010402.102932
   Yu Y, 2012, INVEST OPHTH VIS SCI, V53, P1548, DOI 10.1167/iovs.11-8657
   Zampatti S, 2014, NUTR RES, V34, P95, DOI 10.1016/j.nutres.2013.10.011
NR 41
TC 28
Z9 29
U1 0
U2 15
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0002-9165
EI 1938-3207
J9 AM J CLIN NUTR
JI Am. J. Clin. Nutr.
PD APR
PY 2016
VL 103
IS 4
BP 1135
EP 1144
DI 10.3945/ajcn.115.117606
PG 10
WC Nutrition & Dietetics
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Nutrition & Dietetics
GA DI3VI
UT WOS:000373426400023
PM 26961928
OA Green Published, Bronze
DA 2022-11-30
ER

PT J
AU Kumar, A
   Gopalakrishnan, K
   Sinha, S
AF Kumar, Atul
   Gopalakrishnan, Kiran
   Sinha, Subijoy
TI COMBINATION PHOTODYNAMIC THERAPY AND INTRAVITREAL RANIBIZUMAB IN
   NEOVASCULAR AGE-RELATED MACULAR DEGENERATION IN A NORTH INDIAN
   POPULATION A Pilot Study
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE age-related macular degeneration (AMD); choroidal neovascularization;
   intravitreal ranibizumab; photodynamic therapy; verteporfin; combination
   therapy
ID CHOROIDAL NEOVASCULARIZATION; VERTEPORFIN; PREVALENCE; TRIAMCINOLONE;
   MACULOPATHY
AB Purpose: To evaluate photodynamic therapy (PDT) with verteporfin along with intravitreal ranibizumab in treatment of neovascular age-related macular degeneration.
   Methods: This prospective interventional care series included 16 patients (17 eyes) of choroidal neovascularization secondary to neovascular age-related macular degeneration who were treated with PDT with verteporfin followed by an injection of 0.5 mg ranibizumab on the same day. The main outcome measures were best corrected visual acuity as recorded by both Snellen and Early Treatment Diabetic Retinopathy Study (ETDRS) charts (logMAR), contrast sensitivity (Pelli-Robson Chart), retreatment frequency, and frequency of side effects.
   Results: Seventeen eyes underwent PDT with verteporfin and intravitreal 0.5 mg ranibizumab, following PDT. Patients were followed up every month for a total period of 6 months. Initial visual acuity ranged from CF to 20/32 and final acuity ranged from CF to 20/20. Visual acuity stabilized (gain/loss <2 lines) in 14 out of 17 eyes (82.35%) and improved in 3 out of 17(17.65%). Contrast sensitivity improved in 15 out of 17 eyes (82.24%) There were no cases of ocular/systemic adverse events. Retreatment was required in only 2 out of 17 cases (11.76%) with a single injection of intravitreal ranibizumab.
   Conclusion: The combination of PDT with intravitreal ranibizumab improves contrast sensitivity and stabilizes vision and reduces the number of retreatments, without significant ocular/systemic risks. RETINA 28:1296-1301, 2008
C1 [Kumar, Atul; Gopalakrishnan, Kiran; Sinha, Subijoy] All India Inst Med Sci, Dr Rajendra Prasad Ctr Ophthalm Sci, New Delhi 110029, India.
C3 All India Institute of Medical Sciences (AIIMS) New Delhi; Dr. Rajendra
   Prasad Centre for Ophthalmic Sciences
RP Kumar, A (通讯作者)，D-66,Malcha Marg, New Delhi, India.
EM akum66mm@yahoo.co.in
RI Gopalakrishnan, Kiran/AAL-1487-2021
CR Arnold J, 2001, AM J OPHTHALMOL, V131, P541
   Blick SKA, 2007, DRUGS, V67, P1199, DOI 10.2165/00003495-200767080-00007
   Boyer DS, 2007, OPHTHALMOLOGY, V114, P246, DOI 10.1016/j.ophtha.2006.10.045
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Dhalla MS, 2006, RETINA-J RET VIT DIS, V26, P988, DOI 10.1097/01.iae.0000247164.70376.91
   Ferrara N, 2006, RETINA-J RET VIT DIS, V26, P859, DOI 10.1097/01.iae.0000242842.14624.e7
   Fung AE, 2007, AM J OPHTHALMOL, V143, P566, DOI 10.1016/j.ajo.2007.01.028
   Heier JS, 2006, ARCH OPHTHALMOL-CHIC, V124, P1532, DOI 10.1001/archopht.124.11.1532
   Hussain Nazimul, 2006, Indian Journal of Ophthalmology, V54, P247
   Hussain N, 2006, JPN J OPHTHALMOL, V50, P524, DOI 10.1007/s10384-006-0367-4
   Kaiser PK, 2007, CURR MED RES OPIN, V23, P477, DOI 10.1185/030079907X167624
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Kumar Atul, 2007, Indian Journal of Ophthalmology, V55, P207
   Miller JW, 1999, ARCH OPHTHALMOL-CHIC, V117, P1161
   Nirmalan PK, 2004, ARCH OPHTHALMOL-CHIC, V122, P581, DOI 10.1001/archopht.122.4.581
   Regillo CD, 2008, AM J OPHTHALMOL, V145, P239, DOI 10.1016/j.ajo.2007.10.004
   Rosenfeld Philip J, 2006, Ophthalmol Clin North Am, V19, P361
   Spaide R, 2007, AM J OPHTHALMOL, V143, P679, DOI 10.1016/j.ajo.2007.02.024
   VINGERLING JR, 1995, OPHTHALMOLOGY, V102, P205
NR 19
TC 5
Z9 6
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD OCT
PY 2008
VL 28
IS 9
BP 1296
EP 1301
DI 10.1097/IAE.0b013e3181814482
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 366IM
UT WOS:000260474200019
PM 18667951
DA 2022-11-30
ER

PT J
AU Fragiotta, S
   Parravano, M
   Sacconi, R
   Costanzo, E
   De Geronimo, D
   Prascina, F
   Capuano, V
   Souied, EH
   Han, IC
   Mullins, R
   Querques, G
AF Fragiotta, Serena
   Parravano, Mariacristina
   Sacconi, Riccardo
   Costanzo, Eliana
   De Geronimo, Daniele
   Prascina, Francesco
   Capuano, Vittorio
   Souied, Eric H.
   Han, Ian C.
   Mullins, Robert
   Querques, Giuseppe
TI Sub-retinal pigment epithelium tubules in non-neovascular age-related
   macular degeneration
SO SCIENTIFIC REPORTS
LA English
DT Article
ID OUTER RETINAL TUBULATION; OPTICAL-COHERENCE-TOMOGRAPHY;
   CLINICOPATHOLOGICAL CORRELATION; EVOLUTION; ATROPHY; DRUSEN
AB To describe a novel optical coherence tomography (OCT) signature resembling sub-retinal pigment epithelium (RPE) tubules (SRT) in non-neovascular age-related macular degeneration (AMD). Patients suffering from non-neovascular AMD with complete medical records and multimodal imaging were retrospectively revised in three different tertiary care centers. Multimodal imaging included color fundus photograph, spectral-domain OCT (Spectralis, Heidelberg Engineering, Germany), fundus autofluorescence, OCT angiography (RTVue XR Avanti, Optovue, Inc., Fremont, CA). A total of 7 eyes of 7 patients with drusenoid pigment epithelium detachment (PED) were consecutively analyzed. The sub-RPE tubules appeared as ovoidal structures with a hyperreflective contour and hyporeflective interior appreciable in the sub-RPE-basal lamina (BL) space on OCT B-scan. The anatomical location of the sub-RPE formations was lying above the Bruch's membrane in 5/7 cases (71.4%) or floating in the sub-RPE-BL space in 2/7 cases (28.6%). En-face OCTA revealed a curvilinear tubulation-like structure corresponding to SRT without flow signal. Sub-RPE tubules represent a newly identified OCT signature observed in eyes with drusenoid PED. The presumed origin may include a variant of calcified structure or alternatively activated RPE cells with some residual BL or basal laminar deposits attracted to BrM for craving oxygen.
C1 [Fragiotta, Serena] UniCamillus St Camillus Int Univ Hlth Sci, Rome, Italy.
   [Parravano, Mariacristina; Costanzo, Eliana; De Geronimo, Daniele] IRCCS Fdn Bietti, Rome, Italy.
   [Sacconi, Riccardo; Prascina, Francesco; Querques, Giuseppe] Univ Vita Salute, Dept Ophthalmol, IRCCS Osped San Raffaele, Via Olgettina 60, I-20132 Milan, Italy.
   [Capuano, Vittorio; Souied, Eric H.] Ctr Hosp Intercommunal Creteil, Creteil, France.
   [Han, Ian C.; Mullins, Robert] Univ Iowa, Carver Coll Med, Inst Vis Res, Dept Ophthalmol & Visual Sci, Iowa City, IA USA.
C3 IRCCS - Fondazione "G.B. Bietti" per lo Studio e la Ricerca in
   Oftalmologia; Vita-Salute San Raffaele University; IRCCS Ospedale San
   Raffaele; Universite Paris-Est-Creteil-Val-de-Marne (UPEC); CHI Creteil;
   University of Iowa
RP Querques, G (通讯作者)，Univ Vita Salute, Dept Ophthalmol, IRCCS Osped San Raffaele, Via Olgettina 60, I-20132 Milan, Italy.
EM giuseppe.querques@hotmail.it
FU Italian Ministry of Health; Puma Foundation; Fondazione Roma
FX The research for this paper was financially supported by Italian
   Ministry of Health and Fondazione Roma. The authors gratefully
   acknowledge Puma Foundation for its support. The funders had no role in
   study design, data collection and analysis, decision to publish, or
   preparation of the manuscript.
CR Ach T, 2015, INVEST OPHTH VIS SCI, V56, P3242, DOI 10.1167/iovs.14-16274
   Balaratnasingam C, 2017, OPHTHALMOLOGY, V124, P644, DOI 10.1016/j.ophtha.2016.12.034
   BARTHEL LK, 1990, J HISTOCHEM CYTOCHEM, V38, P1383, DOI 10.1177/38.9.2201738
   BRESSLER NM, 1994, RETINA-J RET VIT DIS, V14, P130, DOI 10.1097/00006982-199414020-00006
   Cao DF, 2021, INVEST OPHTH VIS SCI, V62, DOI 10.1167/iovs.62.10.34
   Cheung CMG, 2021, OPHTHALMOLOGY, V128, P443, DOI 10.1016/j.ophtha.2020.08.006
   Cukras C, 2010, OPHTHALMOLOGY, V117, P489, DOI 10.1016/j.ophtha.2009.12.002
   Curcio CA, 2017, INVEST OPHTH VIS SCI, V58, P211, DOI 10.1167/iovs.17-21872
   Dolz-Marco R, 2018, AM J OPHTHALMOL, V191, P23, DOI 10.1016/j.ajo.2018.03.038
   Dolz-Marco R, 2017, OPHTHALMOLOGY, V124, P1353, DOI 10.1016/j.ophtha.2017.03.043
   Fragiotta S, 2020, GRAEF ARCH CLIN EXP, V258, P491, DOI 10.1007/s00417-019-04565-y
   Fragiotta S, 2019, INVEST OPHTH VIS SCI, V60, P3100, DOI 10.1167/iovs.19-26589
   Green W R, 1977, Trans Am Ophthalmol Soc, V75, P180
   Guidry C, 2002, INVEST OPHTH VIS SCI, V43, P267
   Jung JJ, 2012, ARCH OPHTHALMOL-CHIC, V130, P1618, DOI 10.1001/archophthalmol.2012.1902
   Li ML, 2019, RETINA-J RET VIT DIS, V39, P802, DOI 10.1097/IAE.0000000000002461
   Litts KM, 2017, RETINA-J RET VIT DIS, V37, P978, DOI 10.1097/IAE.0000000000001265
   Litts KM, 2015, JAMA OPHTHALMOL, V133, P609, DOI 10.1001/jamaophthalmol.2015.126
   Mullins RF, 2014, AM J PATHOL, V184, P3142, DOI 10.1016/j.ajpath.2014.07.017
   Ooto S, 2014, JAMA OPHTHALMOL, V132, P806, DOI 10.1001/jamaophthalmol.2014.1871
   Pilgrim Matthew G, 2021, Ophthalmol Sci, V1, P100053, DOI 10.1016/j.xops.2021.100053
   Pollreisz A, 2020, INVEST OPHTH VIS SCI, V61, DOI 10.1167/iovs.61.8.13
   Preti RC, 2018, RETINA-J RET VIT DIS, V38, P1518, DOI 10.1097/IAE.0000000000001810
   Querques G, 2015, RETINA-J RET VIT DIS, V35, P1735, DOI 10.1097/IAE.0000000000000553
   Querques G, 2014, OPHTHALMOLOGY, V121, P173, DOI 10.1016/j.ophtha.2013.06.024
   Sadda SR, 2018, OPHTHALMOLOGY, V125, P537, DOI 10.1016/j.ophtha.2017.09.028
   Schaal KB, 2015, RETINA-J RET VIT DIS, V35, P1339, DOI 10.1097/IAE.0000000000000471
   Tan ACS, 2018, SCI TRANSL MED, V10, DOI 10.1126/scitranslmed.aat4544
   Tan ACS, 2017, INVEST OPHTH VIS SCI, V58, P2349, DOI 10.1167/iovs.16-21237
   Thompson RB, 2015, P NATL ACAD SCI USA, V112, P1565, DOI 10.1073/pnas.1413347112
   Zanzottera EC, 2016, RETINA-J RET VIT DIS, V36, pS12, DOI 10.1097/IAE.0000000000001276
   Zanzottera EC, 2015, INVEST OPHTH VIS SCI, V56, P3253, DOI 10.1167/iovs.15-16431
   Zanzottera EC, 2015, INVEST OPHTH VIS SCI, V56, P3269, DOI 10.1167/iovs.15-16432
   Zweifel SA, 2009, ARCH OPHTHALMOL-CHIC, V127, P1596, DOI 10.1001/archophthalmol.2009.326
NR 34
TC 0
Z9 0
U1 0
U2 0
PU NATURE PORTFOLIO
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
SN 2045-2322
J9 SCI REP-UK
JI Sci Rep
PD SEP 7
PY 2022
VL 12
IS 1
AR 15198
DI 10.1038/s41598-022-19193-6
PG 11
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA 4L4WQ
UT WOS:000852630800055
PM 36071082
OA Green Published, gold, Green Submitted
DA 2022-11-30
ER

PT J
AU Hassan, M
   Afridi, R
   Sadiq, MA
   Soliman, MK
   Agarwal, A
   Sepah, YJ
   Do, DV
   Nguyen, QD
AF Hassan, Muhammad
   Afridi, Rubbia
   Sadiq, Mohammad Ali
   Soliman, Mohamed Kamel
   Agarwal, Aniruddha
   Sepah, Yasir Jamal
   Do, Diana V.
   Quan Dong Nguyen
TI The role of Aflibercept in the management of age-related macular
   degeneration
SO EXPERT OPINION ON BIOLOGICAL THERAPY
LA English
DT Article
DE Age-related macular degeneration; aflibercept; anti-vegf therapy;
   clinical trials; view; marina; anchor; catt; vegf
ID ENDOTHELIAL GROWTH-FACTOR; FACTOR TRAP-EYE; INTRAVITREAL AFLIBERCEPT;
   CHOROIDAL NEOVASCULARIZATION; VEGF TRAP; RANIBIZUMAB; BEVACIZUMAB;
   INHIBITION; INJECTION; MODEL
AB Introduction: During the past decade, significant advances have occurred in the management of neovascular age-related macular degeneration (NV-AMD). The advent of anti-vascular endothelial growth factor (anti-VEGF) therapy has shifted the treatment goal of NV-AMD from merely salvaging vision to improving visual acuity and maintaining a good quality of life. Aflibercept (AFL) is a significant addition to the arsenal of anti-VEGF therapies against the NV-AMD. In the index review, pharmacology and efficacy of AFL has been reviewed.
   Areas Covered: An extensive literature search was performed to identify preclinical and clinical studies performed to illustrate the role of AFL in NV-AMD. Randomized clinical trials evaluating other anti-VEGF agents were also included for comparison. Additionally, studies where AFL was employed to treat anti-VEGF-resistant cases agents have been reviewed.
   Expert Opinion: AFL is an effective agent in the management of NV-AMD and its efficacy has been found to be comparable to ranibizumab (RBZ). Additionally, AFL is a good alternative agent in patients with NV-AMD resistant to RBZ and bevacizumab (BVZ), and can potentially lessen the treatment burden. As more research is conducted, the role of AFL in varying dosing regimens, as monotherapy and in combination with other agents, will become further defined.
C1 [Hassan, Muhammad; Afridi, Rubbia; Sadiq, Mohammad Ali; Soliman, Mohamed Kamel; Agarwal, Aniruddha; Sepah, Yasir Jamal; Do, Diana V.; Quan Dong Nguyen] Univ Nebraska Med Ctr, OIRRC, Stanley M Truhlsen Eye Inst, 985540 Nebraska Med Ctr, Omaha, NE 68198 USA.
   [Soliman, Mohamed Kamel] Assiut Univ, Dept Ophthalmol, Assiut, Egypt.
C3 University of Nebraska System; University of Nebraska Medical Center;
   Egyptian Knowledge Bank (EKB); Assiut University
RP Nguyen, QD (通讯作者)，Univ Nebraska Med Ctr, OIRRC, Stanley M Truhlsen Eye Inst, 985540 Nebraska Med Ctr, Omaha, NE 68198 USA.
EM quan.nguyen@unmc.edu
RI Soliman, Mohamed/M-4243-2019
OI Soliman, Mohamed/0000-0003-1671-8925
CR AIELLO LP, 1995, P NATL ACAD SCI USA, V92, P10457, DOI 10.1073/pnas.92.23.10457
   Al-Halafi Ali M, 2014, Oman J Ophthalmol, V7, P112, DOI 10.4103/0974-620X.142591
   Arnold J, 2001, AM J OPHTHALMOL, V131, P541
   Bhavsar KV, 2014, SAUDI J OPHTHALMOL, V28, P129, DOI 10.1016/j.sjopt.2014.03.001
   Bhisitkul RB, 2015, AM J OPHTHALMOL, V159, P915, DOI 10.1016/j.ajo.2015.01.032
   Blumenkranz MS, 2001, ARCH OPHTHALMOL-CHIC, V119, P198
   Brown D.M., 2009, OPHTHALMOLOGY, V116, pe5
   Brown DM, 2013, OPHTHALMOLOGY, V120, P349, DOI 10.1016/j.ophtha.2012.08.008
   Brown DM, 2011, OPHTHALMOLOGY, V118, P1089, DOI 10.1016/j.ophtha.2011.02.039
   Cao JT, 2010, INVEST OPHTH VIS SCI, V51, P6009, DOI 10.1167/iovs.09-4956
   Chakravarthy U, 2013, LANCET, V382, P1258, DOI 10.1016/S0140-6736(13)61501-9
   Chang AA, 2014, OPHTHALMOLOGY, V121, P188, DOI 10.1016/j.ophtha.2013.08.035
   Elshout M, 2014, GRAEF ARCH CLIN EXP, V252, P1911, DOI 10.1007/s00417-014-2641-3
   FERRIS FL, 1984, ARCH OPHTHALMOL-CHIC, V102, P1640
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Grewal DS, 2014, EYE, V28, P895, DOI 10.1038/eye.2014.101
   Grunwald JE, 2015, OPHTHALMOLOGY, V122, P809, DOI 10.1016/j.ophtha.2014.11.007
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Heier JS, 2011, OPHTHALMOLOGY, V118, P1098, DOI 10.1016/j.ophtha.2011.03.020
   Huo XC, 2015, CELL PHYSIOL BIOCHEM, V35, P1787, DOI 10.1159/000373990
   Kawashima Y, 2015, GRAEF ARCH CLIN EXP, V253, P1471, DOI 10.1007/s00417-014-2838-5
   Klein R, 2004, AM J OPHTHALMOL, V137, P486, DOI 10.1016/j.ajo.2003.11.069
   Krohne TU, 2012, AM J OPHTHALMOL, V154, P682, DOI 10.1016/j.ajo.2012.03.047
   Lee SH, 2015, ANN SURG TREAT RES, V89, P1, DOI 10.4174/astr.2015.89.1.1
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   McKibbin M, 2015, EYE, V29, pS1, DOI 10.1038/eye.2015.77
   Meyer CH, 2011, RETINA-J RET VIT DIS, V31, P1877, DOI 10.1097/IAE.0b013e318217373c
   Miller JW, 2013, OPHTHALMOLOGY, V120, P106, DOI 10.1016/j.ophtha.2012.07.038
   Miller JW, 2013, AM J OPHTHALMOL, V155, P1, DOI 10.1016/j.ajo.2012.10.018
   Nguyen QD, 2006, OPHTHALMOLOGY, V113, P1522, DOI 10.1016/j.ophtha.2006.05.055
   Nguyen QD, 2009, OPHTHALMOLOGY, V116, P2175, DOI 10.1016/j.ophtha.2009.04.023
   Nork TM, 2011, ARCH OPHTHALMOL-CHIC, V129, P1042, DOI 10.1001/archophthalmol.2011.210
   Oliveira HB, 2010, EUR J OPHTHALMOL, V20, P48, DOI 10.1177/112067211002000106
   Papadopoulos N, 2012, ANGIOGENESIS, V15, P171, DOI 10.1007/s10456-011-9249-6
   Rakic JM, 2003, INVEST OPHTH VIS SCI, V44, P3186, DOI 10.1167/iovs.02-1092
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Saishin Y, 2003, J CELL PHYSIOL, V195, P241, DOI 10.1002/jcp.10246
   Sarao V, 2016, RETINA-J RET VIT DIS, V36, P770, DOI 10.1097/IAE.0000000000000751
   Schmidt-Erfurth U, 2014, OPHTHALMOLOGY, V121, P193, DOI 10.1016/j.ophtha.2013.08.011
   Semeraro F, 2013, DRUG DES DEV THER, V7, P711, DOI 10.2147/DDDT.S40215
   Singh RP, 2015, CLIN OPHTHALMOL, V9, P1759, DOI 10.2147/OPTH.S87043
   Stewart MW, 2008, BRIT J OPHTHALMOL, V92, P667, DOI 10.1136/bjo.2007.134874
   Thomas M, 2013, CLIN OPHTHALMOL, V7, P495, DOI 10.2147/OPTH.S29974
   Veikkola T, 2000, CANCER RES, V60, P203
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Wykoff CC, 2014, BRIT J OPHTHALMOL, V98, P951, DOI 10.1136/bjophthalmol-2013-304736
   Wykoff CC, 2013, OPHTHALMOLOGY, V120, P1945, DOI 10.1016/j.ophtha.2013.06.030
NR 48
TC 7
Z9 7
U1 0
U2 7
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 1471-2598
EI 1744-7682
J9 EXPERT OPIN BIOL TH
JI Expert Opin. Biol. Ther.
PD MAY
PY 2016
VL 16
IS 5
BP 699
EP 709
DI 10.1517/14712598.2016.1167182
PG 11
WC Biotechnology & Applied Microbiology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biotechnology & Applied Microbiology; Research & Experimental Medicine
GA DK0KC
UT WOS:000374600700010
PM 26982640
DA 2022-11-30
ER

PT J
AU Jaffe, GJ
   Martin, DF
   Toth, CA
   Daniel, E
   Maguire, MG
   Ying, GS
   Grunwald, JE
   Huang, JY
AF Jaffe, Glenn J.
   Martin, Daniel F.
   Toth, Cynthia A.
   Daniel, Ebenezer
   Maguire, Maureen G.
   Ying, Gui-Shuang
   Grunwald, Juan E.
   Huang, Jiayan
CA Comparison Age-related Macular
TI Macular Morphology and Visual Acuity in the Comparison of Age-related
   Macular Degeneration Treatments Trials
SO OPHTHALMOLOGY
LA English
DT Article
ID OPTICAL COHERENCE TOMOGRAPHY; RANIBIZUMAB; BEVACIZUMAB
AB Objective: To describe the effects of treatment for 1 year with ranibizumab or bevacizumab on macular morphology and the association of macular morphology with visual acuity (VA) in eyes with neovascular age-related macular degeneration (AMD).
   Design: Prospective cohort study within a randomized clinical trial.
   Participants: Participants in the Comparison of Age-related Macular Degeneration Treatments Trials.
   Methods: Participants were assigned randomly to treatment with ranibizumab or bevacizumab on a monthly or as-needed schedule. Optical coherence tomography (OCT), fluorescein angiography (FA), color fundus photography (FP), and VA testing were performed periodically throughout 52 weeks. Masked readers graded images. General linear models were applied to evaluate effects of time and treatment on outcomes.
   Main Outcome Measures: Fluid type and location and thickness by OCT, size, and lesion composition on FP, FA, and VA.
   Results: Intraretinal fluid (IRF), subretinal fluid (SRF), subretinal pigment epithelium fluid, and retinal, subretinal, and subretinal tissue complex thickness decreased in all treatment groups. A higher proportion of eyes treated monthly with ranibizumab had fluid resolution at 4 weeks, and the difference persisted through 52 weeks. At 52 weeks, there was little association between the presence of fluid of any type (without regard to fluid location) and the mean VA. However, at all time points, eyes with residual IRF, especially foveal IRF, had worse mean VA (9 letters) than those without IRF. Eyes with abnormally thin (<120 mu m) or thick (>212 mu m) retinas had worse VA than those with normal thickness (120-212 mu m). At week 52, eyes with larger neovascular lesions or with foveal scar had worse VA than eyes without these features.
   Conclusions: Anti-vascular endothelial growth factor (VEGF) therapy reduced lesion activity and improved VA in all treatment groups. At all time points, eyes with residual IRF had worse VA than those without. Eyes with abnormally thin or thick retinas, residual large lesions, and scar also had worse VA. Monthly ranibizumab dosing yielded more eyes with no fluid and an abnormally thin retina, although the long-term significance is unknown. These results have important treatment implications in eyes undergoing anti-VEGF therapy for neovascular AMD. (c) 2013 by the American Academy of Ophthalmology.
C1 [Jaffe, Glenn J.; Toth, Cynthia A.] Duke Univ, Dept Ophthalmol, Durham, NC 27710 USA.
   [Martin, Daniel F.] Cleveland Clin, Cole Eye Inst, Cleveland, OH 44106 USA.
   [Daniel, Ebenezer; Maguire, Maureen G.; Ying, Gui-Shuang; Grunwald, Juan E.; Huang, Jiayan] Univ Penn, Dept Ophthalmol, Philadelphia, PA 19104 USA.
C3 Duke University; Cleveland Clinic Foundation; University of Pennsylvania
RP Jaffe, GJ (通讯作者)，Duke Univ, Dept Ophthalmol, Box 3802,Erwin Rd, Durham, NC 27710 USA.
EM jaffe001@mc.duke.edu
RI Toth, Cynthia/L-5534-2019; Ciulla, Thomas/AAA-1299-2020
OI Toth, Cynthia/0000-0002-2324-0854; Ciulla, Thomas/0000-0001-5557-6777;
   Vavvas, Demetrios/0000-0002-8622-6478; Folk, James/0000-0002-6271-2906;
   Daniel, Ebenezer/0000-0002-2027-2316; Losordo,
   Douglas/0000-0002-6857-7506
FU National Eye Institute, National Institutes of Health, Department of
   Health and Human Services, Bethesda, Maryland [U10 EY017823, U10
   EY017825, U10 EY017826, U10 EY017828]; NATIONAL EYE INSTITUTE
   [U10EY017825] Funding Source: NIH RePORTER
FX Supported by cooperative agreements U10 EY017823, U10 EY017825, U10
   EY017826, and U10 EY017828 from the National Eye Institute, National
   Institutes of Health, Department of Health and Human Services, Bethesda,
   Maryland. The funding organization participated in the design and
   conduct of the study and review of the manuscript.
CR Beck RW, 2003, AM J OPHTHALMOL, V135, P194, DOI 10.1016/S0002-9394(02)01825-1
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Chan A, 2006, ARCH OPHTHALMOL-CHIC, V124, P193, DOI 10.1001/archopht.124.2.193
   CLEVELAND WS, 1979, J AM STAT ASSOC, V74, P829, DOI 10.2307/2286407
   DeCroos FC, 2012, OPHTHALMOLOGY, V119, P2549, DOI 10.1016/j.ophtha.2012.06.040
   Gamulescu Maria-Andreea, 2010, International Ophthalmology, V30, P261, DOI 10.1007/s10792-009-9318-7
   Grunwald JE, 2012, OPHTHALMOLOGY, V119, P1634, DOI 10.1016/j.ophtha.2012.02.013
   Kaiser PK, 2007, OPHTHALMOLOGY, V114, P1868, DOI 10.1016/j.ophtha.2007.04.030
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Ting TD, 2002, ARCH OPHTHALMOL-CHIC, V120, P731
   Ying GS, 2013, OPHTHALMOLOGY, V120, P122, DOI 10.1016/j.ophtha.2012.07.042
NR 13
TC 186
Z9 191
U1 1
U2 47
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0161-6420
J9 OPHTHALMOLOGY
JI Ophthalmology
PD SEP
PY 2013
VL 120
IS 9
BP 1860
EP 1870
DI 10.1016/j.ophtha.2013.01.073
PG 11
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 213HG
UT WOS:000324045800041
PM 23642377
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Carneiro, AM
   Falcao, MS
   Brandao, EM
   Falcao-Reis, FM
AF Carneiro, Angela M.
   Falcao, Manuel S.
   Brandao, Elisete M.
   Falcao-Reis, Fernando M.
TI INTRAVITREAL BEVACIZUMAB FOR NEOVASCULAR AGE-RELATED MACULAR
   DEGENERATION WITH OR WITHOUT PRIOR TREATMENT WITH PHOTODYNAMIC THERAPY
   One-Year Results
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE AMD; anti-VEGF therapy; Avastin; choroidal neovascularization;
   intravitreal bevacizumab; PDT
ID SUBFOVEAL CHOROIDAL NEOVASCULARIZATION; UNITED-STATES; VERTEPORFIN;
   RANIBIZUMAB; AVASTIN; PREVALENCE; SECONDARY; OCCULT; TRIAL
AB Purpose: The purpose of this study was to elucidate the effect of prior photodynamic therapy (PDT) on the efficacy of intravitreal bevacizumab for the treatment of neovascular age-related macular degeneration.
   Methods: One hundred and nine eyes of 102 patients with neovascular age-related macular degeneration were evaluated-80 eyes without prior treatment (group 1) and 29 with prior PDT (group 2). Best-corrected visual acuity, ocular coherence tomography, and funduscopy were assessed monthly.
   Results were evaluated at 1, 3, 6, and 12 months. Results: One hundred and one eyes completed a 12-month evaluation. At 12 months, best-corrected visual acuity increased 5.6 letters with treatment (P = 0.001): +5.7 letters in group 1 and +5.4 in group 2 (P = 0.92). Overall, visual acuity improved >= 15 letters in 22.5% of eyes: 24.0% of naive eyes versus 18.5% with prior PDT (P = 0.56). Best-corrected visual acuity loss >= 15 letters occurred in 6 eyes, 5 with naive lesions. An overall reduction in ocular coherence tomography central retinal thickness was observed at all time points. Mean number of injections per eye per year was 5.6, 6.13 in group 1 versus 4.22 in group 2 (P = 0.01). Two retinal pigment epithelial tears, one subretinal macular hemorrhage, and two strokes occurred in naive lesions.
   Conclusion: The authors showed similar efficacy for intravitreal bevacizumab independently of prior PDT treatment. Eyes with prior PDT needed a statistically significantly lower number of injections to control their lesions. RETINA 30:85-92,2010
C1 [Carneiro, Angela M.; Falcao, Manuel S.; Brandao, Elisete M.; Falcao-Reis, Fernando M.] Hosp Sao Joao, Dept Ophthalmol, P-4200319 Oporto, Portugal.
   [Carneiro, Angela M.; Falcao, Manuel S.; Falcao-Reis, Fernando M.] Univ Porto, Fac Med, P-4100 Oporto, Portugal.
C3 Sao Joao Hospital; Universidade do Porto
RP Carneiro, AM (通讯作者)，Hosp Sao Joao, Dept Ophthalmol, Al Prof Hernani Monteiro, P-4200319 Oporto, Portugal.
EM angelacarneiro@netcabo.pt
RI Carneiro, Angela/N-9680-2013; Falcao/AAQ-8509-2020
OI Carneiro, Angela/0000-0002-3370-7243; Falcao/0000-0003-4718-0910;
   Falcao-Reis, Fernando/0000-0002-5995-9430
FU Sociedade Portuguesa de Oftalmologia and Hospital de Sao Joao
FX Supported by Sociedade Portuguesa de Oftalmologia and Hospital de Sao
   Joao.
CR [Anonymous], 1999, ARCH OPHTHALMOL, V117, P1329
   Arnold J, 2001, AM J OPHTHALMOL, V131, P541
   AVERY RL, 2006, OPHTHALMOLOGY, V13
   Bashshur ZF, 2008, AM J OPHTHALMOL, V145, P249, DOI 10.1016/j.ajo.2007.09.031
   Bashshur ZF, 2007, ARCH OPHTHALMOL-CHIC, V125, P1357, DOI 10.1001/archopht.125.10.1357
   Blumenkranz MS, 2001, ARCH OPHTHALMOL-CHIC, V119, P198
   Bressler NM, 2003, ARCH OPHTHALMOL-CHIC, V121, P1621
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   Falkenstein IA, 2007, RETINA-J RET VIT DIS, V27, P701, DOI 10.1097/IAE.0b013e3180654240
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Fung AE, 2007, AM J OPHTHALMOL, V143, P566, DOI 10.1016/j.ajo.2007.01.028
   Goff MJ, 2007, RETINA-J RET VIT DIS, V27, P432, DOI 10.1097/IAE.0b013e318042b53f
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Grunewald M, 2006, CELL, V124, P175, DOI 10.1016/j.cell.2005.10.036
   HEIER JS, 2006, OPHTHALMOLOGY, V113
   Klein R, 2004, AM J OPHTHALMOL, V137, P486, DOI 10.1016/j.ajo.2003.11.069
   Ladas ID, 2007, RETINA-J RET VIT DIS, V27, P891, DOI 10.1097/IAE.0b013e3180ca9ad9
   Ladewig MS, 2008, GRAEF ARCH CLIN EXP, V246, P17, DOI 10.1007/s00417-007-0654-x
   Michels S, 2005, OPHTHALMOLOGY, V112, P1035, DOI 10.1016/j.ophtha.2005.02.007
   Regillo CD, 2008, AM J OPHTHALMOL, V145, P239, DOI 10.1016/j.ajo.2007.10.004
   Rich RM, 2006, RETINA-J RET VIT DIS, V26, P495, DOI 10.1097/01.iae.0000225766.75009.3a
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rosenfeld PJ, 2005, OPHTHAL SURG LAS IM, V36, P331, DOI 10.3928/1542-8877-20050701-14
   SACU S, 2009, EYE             0123
   Spaide RF, 2006, RETINA-J RET VIT DIS, V26, P383, DOI 10.1097/00006982-200604000-00001
   Wachtlin J, 2003, GRAEF ARCH CLIN EXP, V241, P518, DOI 10.1007/s00417-003-0650-8
   Zlateva GP, 2007, RETINA-J RET VIT DIS, V27, P1292, DOI 10.1097/01.iae.0000300915.81866.b8
NR 28
TC 15
Z9 15
U1 0
U2 3
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0275-004X
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD JAN
PY 2010
VL 30
IS 1
BP 85
EP 92
DI 10.1097/IAE.0b013e3181c700a9
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 607ZX
UT WOS:000278547300011
PM 20010320
DA 2022-11-30
ER

PT J
AU Cruess, AF
   Giacomantonio, N
AF Cruess, Alan F.
   Giacomantonio, Nicholas
TI Cardiac Issues of Noncardiac Drugs: The Rising Story of Avastin in
   Age-Related Macular Degeneration
SO OPHTHALMOLOGICA
LA English
DT Review
DE Intravitreal anti-VEGF therapies; Safety; Wet age-related macular
   degeneration
ID INTRAVITREAL BEVACIZUMAB; MYOCARDIAL-INFARCTION; RISK-FACTORS; DISEASE
AB Emerging safety data, accompanied with recent demographic trends, point to the need for an in-depth review and consideration of potential consequences that might arise from continuing use of bevacizumab (Avastin (R)) to treat elderly patients presenting with wet age-related macular degeneration (AMD). Although it is expected that lower doses of Avastin used for intravitreal administration and an intact blood-retina barrier would reduce the systemic exposure of the drug, both animal and human studies suggest that this may not be the case. In addition, emerging real-world and clinical trial data continue to point toward compromises in both cardio- and cerebrovascular safety with Avastin. Thus, clinicians are urged to adopt the highest possible standard of care in the treatment of an already fragile AMD population. Furthermore, postmarketing surveillance and pharmacovigilance with intravitreal anti-VEGF inhibitors should remain a priority. (C) 2013 S. Karger AG, Basel
C1 [Cruess, Alan F.; Giacomantonio, Nicholas] Dalhousie Univ, Capital Hlth, Halifax, NS, Canada.
C3 Dalhousie University
RP Cruess, AF (通讯作者)，Dept Ophthalmol & Visual Sci, Room 2035,2W Victoria,1276 South Pk St, Halifax, NS B3H 2Y9, Canada.
EM alan.cruess@dal.ca
CR Ambati J, 2003, SURV OPHTHALMOL, V48, P257, DOI 10.1016/S0039-6257(03)00030-4
   [Anonymous], 2011, AVASTIN PRODUCT MONO
   Bakri SJ, 2007, OPHTHALMOLOGY, V114, P855, DOI 10.1016/j.ophtha.2007.01.017
   Barros-Pereira R, 2011, ASS RES VIS OPHTH AN
   Boyer DS, 2009, OPHTHALMOLOGY, V116, P1731, DOI 10.1016/j.ophtha.2009.05.024
   Carneiro AM, 2012, ACTA OPHTHALMOL, V90, pE25, DOI 10.1111/j.1755-3768.2011.02240.x
   Carneiro AM, 2011, OPHTHALMOLOGICA, V225, P211, DOI 10.1159/000323943
   Chakravarthy U, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.04.015
   Chen HX, 2009, NAT REV CLIN ONCOL, V6, P465, DOI 10.1038/nrclinonc.2009.94
   Curtis LH, 2010, ARCH OPHTHALMOL-CHIC, V128, P1273, DOI 10.1001/archophthalmol.2010.223
   Duan YK, 2007, OPHTHALMOLOGY, V114, P732, DOI 10.1016/j.ophtha.2006.07.045
   Ferrara N, 2006, RETINA-J RET VIT DIS, V26, P859, DOI 10.1097/01.iae.0000242842.14624.e7
   Georgopoulos M, 2009, BRIT J OPHTHALMOL, V93, P457, DOI 10.1136/bjo.2008.138479
   Gower EW, 2011, ARVO M, V52, P6644
   Health Canada, 2012, REP EYE INFL END TOX
   Health Canada, 2012, REP SEV INF END LEAD
   Hogg RE, 2008, OPHTHALMOLOGY, V115, P1046, DOI 10.1016/j.ophtha.2007.07.031
   Holland S, 2009, 72 ANN M CAN OPHTH S
   Hong T, 2011, SURV OPHTHALMOL, V56, P184, DOI 10.1016/j.survophthal.2010.08.007
   Kim H, 2009, MOL VIS, V15
   Lee DS, 2009, CAN MED ASSOC J, V181, pE55, DOI 10.1503/cmaj.081629
   Lee S, 2007, CELL, V130, P691, DOI 10.1016/j.cell.2007.06.054
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Pollack A, 2011, NY TIMES
   Rasier R, 2009, EYE, V23, P1714, DOI 10.1038/eye.2008.360
   Tan JSL, 2007, OPHTHALMOLOGY, V114, P1143, DOI 10.1016/j.ophtha.2006.09.033
   Wong TY, 2007, OPHTHALMOLOGY, V114, P86, DOI 10.1016/j.ophtha.2006.06.039
NR 28
TC 6
Z9 6
U1 0
U2 4
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 0030-3755
EI 1423-0267
J9 OPHTHALMOLOGICA
JI Ophthalmologica
PY 2014
VL 231
IS 2
BP 75
EP 79
DI 10.1159/000355569
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 296AE
UT WOS:000330156700002
PM 24217407
OA hybrid
DA 2022-11-30
ER

PT J
AU Gower, EW
   Cassard, SD
   Bass, EB
   Schein, OD
   Bressler, NM
AF Gower, Emily W.
   Cassard, Sandra D.
   Bass, Eric B.
   Schein, Oliver D.
   Bressler, Neil M.
TI A COST-EFFECTIVENESS ANALYSIS OF THREE TREATMENTS FOR AGE-RELATED
   MACULAR DEGENERATION
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE cost effectiveness; age-related macular degeneration; ranabizumab;
   pegaptanib; treatment; photodynamic therapy
ID HEALTH-STATE PREFERENCES; SUBFOVEAL CHOROIDAL NEOVASCULARIZATION;
   PHOTODYNAMIC THERAPY; VERTEPORFIN THERAPY; RANIBIZUMAB; METHODOLOGY;
   PEGAPTANIB; VISION; TRIAL; CARE
AB Purpose: The purpose of this study was to evaluate the cost effectiveness of pegaptanib sodium and ranibizumab injections compared with photodynamic therapy (PDT) with verteporfin for the treatment of choroidal neovascularization secondary to age-related macular degeneration.
   Methods: The analyses were performed using outcomes data from the pivotal trials for each treatment and the medicare reimbursable costs for each treatment and associated medical procedures. A multistate transition model with 3-month cycles was created to compare incremental medical costs associated with pegaptanib or ranibizumab versus PDT for patients with starting vision of 20/40, 20/80, and 20/200 Snellen equivalent.
   Results: Two-year medical treatment costs ranged from $3,100 to $54,100 depending on treatment and lesion type. Photodynamic therapy was less costly and more effective than pegaptanib for predominantly classic and minimally classic lesions. Ranibizumab was not only more effective but also more costly than PDT for all lesion types.
   Conclusion: Compared with PDT, pegaptanib is inferior in both cost and effectiveness, whereas ranibizumab has a greater effectiveness. Because ranibizumab does not meet 1 of the common thresholds for being considered cost effective (<$50,000 per quality-adjusted life year), there is rationale to seek other therapies that are more cost effective.
   RETINA 30: 212-221, 2010
C1 [Gower, Emily W.; Cassard, Sandra D.; Schein, Oliver D.; Bressler, Neil M.] Wilmer Eye Inst, Dept Ophthalmol, Baltimore, MD 21287 USA.
   [Bass, Eric B.] Johns Hopkins Univ, Sch Med, Dept Internal Med, Baltimore, MD USA.
C3 Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins
   University
RP Gower, EW (通讯作者)，Wilmer Eye Inst, Dept Ophthalmol, 600 N Wolfe St,Wilmer 116, Baltimore, MD 21287 USA.
EM egower1@jhmi.edu
OI Bass, Eric/0000-0001-9106-527X
FU Research to Prevent Blindness; Acucela; Bausch and Lomb; Carl Zeiss
   Meditec; Genentech; Notal Vision Inc.; Novartis; Othera; Regeneron;
   TargeGen; Novartis Ophthalmics
FX Dr. Gower's effort is supported in part by a Special Scholars' award
   from Research to Prevent Blindness. The authors' employer, The Johns
   Hopkins University, received an unrestricted gift from Novartis
   Ophthalmics, which was used to support this analysis. Dr. Bressler's
   employer, the Johns Hopkins University (JHU), but not Dr. Bressler,
   receives funding from Acucela, Bausch and Lomb, Carl Zeiss Meditec,
   Genentech, Notal Vision Inc., Novartis, Othera, Regeneron, and TargeGen
   for sponsored projects by the Department of Ophthalmology for effort of
   Dr. Bressler. Dr. Bressler receives salary support for these sponsored
   projects; the terms of these projects are negotiated and administered by
   JHU's Office of Research Administration. Under the School's policy,
   support for the costs of research, administered by the institution, do
   not constitute a conflict of interest.
CR *AM AC OPHTH, 2001, PREF PRACT PATT AG R
   [Anonymous], 1991, Arch Ophthalmol, V109, P1220
   Arnold JJ, 2004, AM J OPHTHALMOL, V137, P683, DOI 10.1016/j.ajo.2003.11.059
   Bhavsar AR, 2007, AM J OPHTHALMOL, V144, P454, DOI 10.1016/j.ajo.2007.04.011
   Blumenkranz MS, 2001, ARCH OPHTHALMOL-CHIC, V119, P198
   Bressler NM, 2002, ARCH OPHTHALMOL-CHIC, V120, P1443
   Bressler NM, 2002, AM J OPHTHALMOL, V133, P168, DOI 10.1016/S0002-9394(01)01237-5
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   Brown GC, 2005, AM J OPHTHALMOL, V140, P679, DOI 10.1016/j.ajo.2005.04.061
   Brown MM, 2008, OPHTHALMOLOGY, V115, P1039, DOI 10.1016/j.ophtha.2007.08.033
   Brown Melissa M, 2005, Curr Opin Ophthalmol, V16, P191, DOI 10.1097/01.icu.0000164166.55550.68
   Brown MM, 2003, SURV OPHTHALMOL, V48, P204, DOI 10.1016/S0039-6257(02)00457-5
   Brown MM, 2002, ARCH OPHTHALMOL-CHIC, V120, P481
   Busbee Brandon G., 2004, International Ophthalmology Clinics, V44, P155, DOI 10.1097/00004397-200404440-00012
   Clemons TE, 2003, ARCH OPHTHALMOL-CHIC, V121, P211
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   Earnshaw SR, 2007, CLIN THER, V29, P2096, DOI 10.1016/j.clinthera.2007.09.001
   FROBERG DG, 1989, J CLIN EPIDEMIOL, V42, P345, DOI 10.1016/0895-4356(89)90039-5
   FROBERG DG, 1989, J CLIN EPIDEMIOL, V42, P585, DOI 10.1016/0895-4356(89)90155-8
   FROBERG DG, 1989, J CLIN EPIDEMIOL, V42, P459, DOI 10.1016/0895-4356(89)90136-4
   FROBERG DG, 1989, J CLIN EPIDEMIOL, V42, P675, DOI 10.1016/0895-4356(89)90011-5
   Gold MR., 1996, COST EFFECTIVENESS H
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Greve MDJ, 2005, ARCH OPHTHALMOL-CHIC, V123, P448
   Hurley Susan F, 2008, Cost Eff Resour Alloc, V6, P12, DOI 10.1186/1478-7547-6-12
   Javitt JC, 2008, VALUE HEALTH, V11, P563, DOI 10.1111/j.1524-4733.2007.00283.x
   Regillo CD, 2008, AM J OPHTHALMOL, V145, P239, DOI 10.1016/j.ajo.2007.10.004
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Sharma S, 2005, CAN J OPHTHALMOL, V40, P369, DOI 10.1016/S0008-4182(05)80079-1
   Sharma S, 2001, OPHTHALMOLOGY, V108, P2051, DOI 10.1016/S0161-6420(01)00764-3
   Smiddy WE, 2007, OPHTHALMOLOGY, V114, P847, DOI 10.1016/j.ophtha.2006.10.038
   STERNBERG P, 1991, ARCH OPHTHALMOL-CHIC, V109, P1242
   STERNBERG P, 1991, ARCH OPHTHALMOL-CHIC, V109, P1232
   *VISION CLIN TRAIL, 2006, OPHTHALMOLOGY, V113
NR 36
TC 19
Z9 20
U1 0
U2 9
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD FEB
PY 2010
VL 30
IS 2
BP 212
EP 221
DI 10.1097/IAE.0b013e3181babd8e
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 607ZY
UT WOS:000278547400003
PM 19940805
DA 2022-11-30
ER

PT J
AU Altinkaynak, H
   Kars, ME
   Kurkcuoglu, PZ
   Ugurlu, N
AF Altinkaynak, Hasan
   Kars, Meltem Ece
   Kurkcuoglu, Piraye Zeynep
   Ugurlu, Nagihan
TI Blood coagulation parameters after intravitreal injection of aflibercept
   in patients with neovascular age-related macular degeneration
SO INTERNATIONAL OPHTHALMOLOGY
LA English
DT Article
DE Activated partial thromboplastin time; Age-related macular degeneration;
   Aflibercept; Arterial thrombotic events; Prothrombin time
ID PARTIAL THROMBOPLASTIN TIME; ENDOTHELIAL GROWTH-FACTOR; ADVERSE EVENTS;
   INCREASED RISK; RANIBIZUMAB; ANGIOGENESIS; BEVACIZUMAB; OCCLUSION; EYE
AB PurposeThe aim of this study was to evaluate the effect of intravitreal injection of aflibercept (IVA) on blood coagulation tests in neovascular age-related macular degeneration (AMD) patients.MethodsThirty-four patients with neovascular AMD (study group) and 32 healthy individuals (control group) were enrolled. Prothrombin time (PT) and activated partial thromboplastin time (aPTT) were measured at different times in patients with neovascular AMD.ResultsThe levels of PT and aPTT after IVA were decreased at 1month after the first injection and 1month after the second injection compared to the baseline measurement in the study group.ConclusionsIVA may cause a decrease in the levels of PT and aPTT at 1month after the first injection and 1month after the second injection although these results are not statistically significant in our study.
C1 [Altinkaynak, Hasan] Ankara Ataturk Educ & Res Hosp, Dept Ophthalmol, Ankara, Turkey.
   [Kars, Meltem Ece; Ugurlu, Nagihan] Yildirim Beyazit Univ, Ankara Ataturk Educ & Res Hosp, Dept Ophthalmol, Ankara, Turkey.
   [Kurkcuoglu, Piraye Zeynep] World Eye Hosp, Dept Ophthalmol, Ankara, Turkey.
C3 Ankara Ataturk Training & Research Hospital; Ankara Ataturk Training &
   Research Hospital; Yildirim Beyazit University
RP Altinkaynak, H (通讯作者)，Ankara Ataturk Educ & Res Hosp, Dept Ophthalmol, Ankara, Turkey.
EM altinkaynak167@yahoo.com
RI Altinkaynak, Hasan/V-6058-2017; Kars, Meltem Ece/GLU-1436-2022
OI Kars, Meltem Ece/0000-0001-5922-5608
CR Attebo K, 1996, OPHTHALMOLOGY, V103, P357
   Campochiaro PA, 2015, OPHTHALMOLOGY, V122, P538, DOI 10.1016/j.ophtha.2014.08.031
   Campochiaro PA, 2010, OPHTHALMOLOGY, V117, P1102, DOI 10.1016/j.ophtha.2010.02.021
   Costagliola C, 2012, EXPERT OPIN BIOL TH, V12, P1299, DOI 10.1517/14712598.2012.707176
   Ehlers JP, 2011, RETINA-J RET VIT DIS, V31, P1856, DOI 10.1097/IAE.0b013e31820d59a5
   Evoy KE, 2013, ANN PHARMACOTHER, V47, P819, DOI 10.1345/aph.1R705
   Favaloro EJ, 2008, SEMIN THROMB HEMOST, V34, P612, DOI 10.1055/s-0028-1104540
   Ferrara N, 2004, ENDOCR REV, V25, P581, DOI 10.1210/er.2003-0027
   Ferrara N, 2001, AM J PHYSIOL-CELL PH, V280, pC1358, DOI 10.1152/ajpcell.2001.280.6.C1358
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Hu CC, 2010, STROKE, V41, P613, DOI 10.1161/STROKEAHA.109.571000
   KLEIN R, 1995, INVEST OPHTH VIS SCI, V36, P182
   Korte W, 2000, AM J CLIN PATHOL, V113, P123, DOI 10.1309/G98J-ANA9-RMNC-XLYU
   Legnani C, 2006, BRIT J HAEMATOL, V134, P227, DOI 10.1111/j.1365-2141.2006.06130.x
   Lippi G, 2008, SEMIN THROMB HEMOST, V34, P604, DOI 10.1055/s-0028-1104539
   Molenaar PJ, 2011, CLIN CHEM LAB MED, V49, P1479, DOI 10.1515/CCLM.2011.615
   Munoz B, 2000, ARCH OPHTHALMOL-CHIC, V118, P819, DOI 10.1001/archopht.118.6.819
   Ng EWM, 2005, CAN J OPHTHALMOL, V40, P352, DOI 10.1016/S0008-4182(05)80078-X
   Ozkan B, 2012, CAN J OPHTHALMOL, V47, P264, DOI 10.1016/j.jcjo.2012.03.016
   Qian J, 2011, ACTA OPHTHALMOL, V89, pE332, DOI 10.1111/j.1755-3768.2011.02151.x
   Sang DN, 2008, DIABETOLOGIA, V51, P1570, DOI 10.1007/s00125-008-1078-9
   Scappaticci FA, 2007, JNCI-J NATL CANCER I, V99, P1232, DOI 10.1093/jnci/djm086
   Schmid MK, 2015, BRIT J OPHTHALMOL, V99, P141, DOI 10.1136/bjophthalmol-2014-305149
   Schmidt-Erfurth U, 2014, OPHTHALMOLOGY, V121, P193, DOI 10.1016/j.ophtha.2013.08.011
   Senthil M, 2014, THROMB RES, V134, P165, DOI 10.1016/j.thromres.2014.04.022
   Stewart MW, 2012, MAYO CLIN PROC, V87, P77, DOI 10.1016/j.mayocp.2011.10.001
   Sun C, 2009, OPHTHALMOLOGY, V116, P1913, DOI 10.1016/j.ophtha.2009.03.046
   Tan JSL, 2008, BRIT J OPHTHALMOL, V92, P509, DOI 10.1136/bjo.2007.131706
   THOMPSON SG, 1995, NEW ENGL J MED, V332, P635, DOI 10.1056/NEJM199503093321003
   Tripodi A, 2006, J THROMB HAEMOST, V4, P750, DOI 10.1111/j.1538-7836.2006.01857.x
   Tripodi A, 2004, BLOOD, V104, P3631, DOI 10.1182/blood-2004-03-1042
   Ueta T, 2014, OPHTHALMOLOGY, V121, P2193, DOI 10.1016/j.ophtha.2014.05.022
   von Hanno T, 2010, ACTA OPHTHALMOL, V88, P263, DOI 10.1111/j.1755-3768.2008.01406.x
   Wroblewski JJ, 2009, ARCH OPHTHALMOL-CHIC, V127, P374, DOI 10.1001/archophthalmol.2009.14
   Yi ZHZ, 2015, CURR EYE RES, V40, P1166, DOI 10.3109/02713683.2014.990638
   Yoshida I, 2014, GRAEF ARCH CLIN EXP, V252, P1483, DOI 10.1007/s00417-014-2717-0
   Zakarija A, 2005, CURR OPIN ONCOL, V17, P578, DOI 10.1097/01.cco.0000183672.15133.ab
NR 37
TC 2
Z9 2
U1 0
U2 2
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0165-5701
EI 1573-2630
J9 INT OPHTHALMOL
JI Int. Ophthalmol.
PD DEC
PY 2018
VL 38
IS 6
BP 2397
EP 2402
DI 10.1007/s10792-017-0741-x
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA HC3BQ
UT WOS:000451676200020
PM 29027065
DA 2022-11-30
ER

PT J
AU Montserrat-de la Paz, S
   Naranjo, MC
   Bermudez, B
   Lopez, S
   Abia, R
   Muriana, FJG
AF Montserrat-de la Paz, S.
   Naranjo, M. C.
   Bermudez, B.
   Lopez, S.
   Abia, R.
   Muriana, F. J. G.
TI Dietary fatty acids and lipoproteins on progression of age-related
   macular degeneration
SO GRASAS Y ACEITES
LA English
DT Article
DE Age-related macular degeneration; Dietary fats; Fatty acids;
   Lipoproteins; Olive oil; Retina
ID ENDOTHELIAL GROWTH-FACTOR; FISH INTAKE; OXIDATIVE STRESS; BRUCHS
   MEMBRANE; EYE DISEASE; ASSOCIATION; RISK; MOUSE; OMEGA-3-FATTY-ACIDS;
   ATHEROSCLEROSIS
AB Age-related macular degeneration (AMD) is a medical condition of central loss vision and blindness. Numerous studies have revealed that changes on certain dietary fatty acids (FAs) could have useful for AMD management. This review summarizes the effects of dietary omega-3 long-chain PUFAs, MUFAs, and SFAs, and lipoproteins on AMD. Findings are consistent with the beneficial role of dietary omega-3 long-chain PUFAs, while the effects of dietary MUFAs and SFAs appeared to be ambiguous with respect to the possible protection from MUFAs and to the possible adverse impact from SFAs on AMD. Some of the pathological mechanisms associated with lipoproteins on AMD share those observed previously in cardiovascular diseases. It was also noticed that the effects of FAs in the diet and lipoprotein on AMD could be modulated by genetic variants. From a population health perspective, the findings of this review are in favour of omega-3 long-chain FAs recommendations in a preventive and therapeutic regimen to attain lower AMD occurrence and progression rates. Additional long-term and short-term nutrigenomic studies are required to clearly establish the role and the relevance of interaction of dietary FAs, lipoproteins, and genes in the genesis and progression of AMD.
C1 [Montserrat-de la Paz, S.; Naranjo, M. C.; Lopez, S.; Abia, R.; Muriana, F. J. G.] CSIC, Inst Grasa, Lab Cellular & Mol Nutr, Ctra Utrera Km 1, Seville 41013, Spain.
   [Bermudez, B.] Univ Seville, Sch Biol, Dept Cell Biol, C Prof Garcia Gonzalez S-N, E-41012 Seville, Spain.
C3 Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto
   de la Grasa (IG); University of Sevilla
RP Montserrat-de la Paz, S (通讯作者)，CSIC, Inst Grasa, Lab Cellular & Mol Nutr, Ctra Utrera Km 1, Seville 41013, Spain.
EM delapaz@us.es
RI Muriana, Francisco José García/S-1825-2016; la Paz, Sergio
   Montserrat-de/Z-3447-2019; Lopez, Sergio/G-3300-2016
OI la Paz, Sergio Montserrat-de/0000-0001-5400-3192; Lopez,
   Sergio/0000-0001-5952-3568; Naranjo, MC/0000-0002-1516-8098; MURIANA,
   FRANCISCO/0000-0002-9018-4792; Bermudez, Beatriz/0000-0002-7429-6567
FU Spanish Ministry of Science and Innovation, MICINN [AGL2011-29008]; FPI
   fellowship of MICINN [BES-2012-056104]; "V Own Research Plan"
   (University of Seville); Spanish Research Council (CSIC)/Juan de la
   Cierva
FX This study was supported by the research Grant AGL2011-29008 (Spanish
   Ministry of Science and Innovation, MICINN). S.M. has the benefit of a
   FPI fellowship (BES-2012-056104) of MICINN. B.B. and S.L. acknowledge
   financial support from "V Own Research Plan" (University of Seville) and
   the Spanish Research Council (CSIC)/Juan de la Cierva, respectively.
CR Acar N, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035102
   Ananth S, 2014, BBA-MOL BASIS DIS, V1842, P603, DOI 10.1016/j.bbadis.2014.01.010
   Baltmr A, 2014, J OPHTHALMOL, V2014, DOI 10.1155/2014/459136
   Bjelakovic G, 2012, COCHRANE DB SYST REV, DOI [10.1002/14651858.CD007176.pub2, 10.1590/1516-3180.20151332T1]
   Celkova L, 2015, J CLIN MED, V4, P172, DOI 10.3390/jcm4010172
   Chew EY, 2013, JAMA-J AM MED ASSOC, V309, P2005, DOI 10.1001/jama.2013.4997
   Chiras D, 2015, CRIT REV CL LAB SCI, V52, P12, DOI 10.3109/10408363.2014.968703
   Chiu CJ, 2014, AM J OPHTHALMOL, V158, P118, DOI 10.1016/j.ajo.2014.04.016
   Cho E, 2001, AM J CLIN NUTR, V73, P209
   Chong EWT, 2009, ARCH OPHTHALMOL-CHIC, V127, P674, DOI 10.1001/archophthalmol.2009.60
   Chong EWT, 2008, ARCH OPHTHALMOL-CHIC, V126, P826, DOI 10.1001/archopht.126.6.826
   Christen WG, 2011, ARCH OPHTHALMOL-CHIC, V129, P921, DOI 10.1001/archophthalmol.2011.34
   Clemons Traci E, 2005, Ophthalmology, V112, P533
   Curcio CA, 2009, PROG RETIN EYE RES, V28, P393, DOI 10.1016/j.preteyeres.2009.08.001
   Dasari B, 2011, BMC OPHTHALMOL, V11, DOI 10.1186/1471-2415-11-22
   Delcourt C, 2007, EUR J CLIN NUTR, V61, P1341, DOI 10.1038/sj.ejcn.1602685
   Demeestere D, 2015, DRUG DISCOV TODAY, V20, P928, DOI 10.1016/j.drudis.2015.05.003
   DiBattista AM, 2015, BBA-MOL CELL RES, V1853, P904, DOI 10.1016/j.bbamcr.2015.01.015
   Ersoy L, 2014, INVEST OPHTH VIS SCI, V55, P1842, DOI 10.1167/iovs.13-13420
   Espinosa-Heidmann DG, 2004, INVEST OPHTH VIS SCI, V45, P260, DOI 10.1167/iovs.03-0910
   Evans JR, 2014, OPHTHAL PHYSL OPT, V34, P390, DOI 10.1111/opo.12142
   Fritsche LG, 2013, NAT GENET, V45, P433, DOI 10.1038/ng.2578
   Fujihara M, 2009, EXP EYE RES, V88, P1115, DOI 10.1016/j.exer.2009.01.017
   Gorusupudi A, 2016, J LIPID RES, V57, P499, DOI 10.1194/jlr.P065540
   Haab O., 1888, SIEBIENTER PERIODISC, P429
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Johnson LV, 2002, P NATL ACAD SCI USA, V99, P11830, DOI 10.1073/pnas.192203399
   Kishan AU, 2011, SURV OPHTHALMOL, V56, P195, DOI 10.1016/j.survophthal.2010.08.008
   Klein R, 2007, ARCH OPHTHALMOL-CHIC, V125, P534, DOI 10.1001/archopht.125.4.534
   Klein R, 2013, OPHTHALMOLOGY, V120, P1012, DOI 10.1016/j.ophtha.2012.11.003
   Kliffen M, 2000, BRIT J OPHTHALMOL, V84, P1415, DOI 10.1136/bjo.84.12.1415
   Lee Y, 2015, INVEST OPHTH VIS SCI, V56, P8403, DOI 10.1167/iovs.15-16936
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Lopez S, 2014, BBA-BIOMEMBRANES, V1838, P1638, DOI 10.1016/j.bbamem.2014.01.007
   MARESPERLMAN JA, 1995, ARCH OPHTHALMOL-CHIC, V113, P743, DOI 10.1001/archopht.1995.01100060069034
   Merle BMJ, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0130816
   Merle BMJ, 2014, INVEST OPHTH VIS SCI, V55, P2010, DOI 10.1167/iovs.14-13916
   Millen AE, 2015, JAMA OPHTHALMOL, V133, P1171, DOI 10.1001/jamaophthalmol.2015.2715
   Montserrat-de la Paz S, 2016, FOOD FUNCT, V7, P1345, DOI [10.1039/c6fo00136j, 10.1039/C6FO00136J]
   Mullins RF, 2000, FASEB J, V14, P835, DOI 10.1096/fasebj.14.7.835
   Neale BM, 2010, P NATL ACAD SCI USA, V107, P7395, DOI 10.1073/pnas.0912019107
   Nita M, 2014, MEDIAT INFLAMM, V2014, DOI 10.1155/2014/930671
   Omenn GS, 2007, EUR J CANCER PREV, V16, P184, DOI 10.1097/01.cej.0000215612.98132.18
   Parekh N, 2009, ARCH OPHTHALMOL-CHIC, V127, P1483, DOI 10.1001/archophthalmol.2009.130
   Pascolini D, 2012, BRIT J OPHTHALMOL, V96, P614, DOI 10.1136/bjophthalmol-2011-300539
   Promsote W, 2014, MOL VIS, V20, P73
   Rasoulinejad SA, 2015, CASP J INTERN MED, V6, P141
   Rezende FA, 2014, AM J OPHTHALMOL, V158, P1071, DOI 10.1016/j.ajo.2014.07.036
   Robman L, 2007, CAN J OPHTHALMOL, V42, P720, DOI 10.3129/i07-116
   Rudolf M, 2005, BRIT J OPHTHALMOL, V89, P1627, DOI 10.1136/bjo.2005.071183
   Saade C, 2014, CLIN EXP OPHTHALMOL, V42, P865, DOI 10.1111/ceo.12353
   SanGiovanni JP, 2005, PROG RETIN EYE RES, V24, P87, DOI 10.1016/j.preteyeres.2004.06.002
   Seddon JM, 2003, ARCH OPHTHALMOL-CHIC, V121, P1728, DOI 10.1001/archopht.121.12.1728
   Seddon JM, 2001, ARCH OPHTHALMOL-CHIC, V119, P1191, DOI 10.1001/archopht.119.8.1191
   Smith W, 2000, ARCH OPHTHALMOL-CHIC, V118, P401, DOI 10.1001/archopht.118.3.401
   Sonoda S, 2009, NAT PROTOC, V4, P662, DOI 10.1038/nprot.2009.33
   Souied EH, 2013, OPHTHALMOLOGY, V120, P1619, DOI 10.1016/j.ophtha.2013.01.005
   Sui GY, 2013, BRIT J OPHTHALMOL, V97, P389, DOI 10.1136/bjophthalmol-2012-302281
   Tan JSL, 2009, ARCH OPHTHALMOL-CHIC, V127, P656, DOI 10.1001/archophthalmol.2009.76
   Verhoeff F H, 1937, Trans Am Ophthalmol Soc, V35, P262
   Wang K, 2014, SCI REP-UK, V4, DOI 10.1038/srep07601
   Wang L, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010329
   Wang Y., 2015, J NANOMATER, V2015, P1, DOI DOI 10.1038/SREP18296
   Weikel KA, 2012, MOL ASPECTS MED, V33, P318, DOI 10.1016/j.mam.2012.03.005
   Weikel KA, 2012, INVEST OPHTH VIS SCI, V53, P622, DOI 10.1167/iovs.11-8545
   Whitcup SM, 2013, INT J INFLAMM, V2013, DOI 10.1155/2013/348092
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
NR 67
TC 1
Z9 1
U1 1
U2 9
PU CONSEJO SUPERIOR INVESTIGACIONES CIENTIFICAS-CSIC
PI MADRID
PA VITRUVIO 8, 28006 MADRID, SPAIN
SN 0017-3495
EI 1988-4214
J9 GRASAS ACEITES
JI Grasas Aceites
PD APR-JUN
PY 2017
VL 68
IS 2
AR e187
DI 10.3989/gya.0830162
PG 7
WC Chemistry, Applied; Food Science & Technology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Chemistry; Food Science & Technology
GA EY1GZ
UT WOS:000403715500001
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Jin, EZ
   Bai, YJ
   Huang, LZ
   Zhao, M
   Zhang, CF
   Zhao, MW
   Li, XX
AF Jin, Enzhong
   Bai, Yujing
   Huang, Lvzhen
   Zhao, Min
   Zhang, Chunfang
   Zhao, Mingwei
   Li, Xiaoxin
TI Evidence of a novel gene HERPUD1 in polypoidal choroidal vasculopathy
SO INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL PATHOLOGY
LA English
DT Article
DE HERPUD1; single-nucleotide polymorphism (SNP); amyloid beta; polypoidal
   choroidal vasculopathy; angiogenesis
ID PIGMENT EPITHELIAL-CELLS; MACULAR DEGENERATION; AMYLOID-BETA; CLINICAL
   CHARACTERISTICS; MATRIX METALLOPROTEINASES; CHINESE PATIENTS; ER-STRESS;
   PROTEIN; RPE; ANGIOGENESIS
AB Polypoidal choroidal vasculopathy (PCV) is an exudative maculopathy, with clinical features distinct from neovascular age-related macular degeneration (nAMD) which is the leading cause of irreversible blindness in the elderly. Our studies focused on the genetic background and function of a novel gene HERPUD1 in PCV. HERPUD1 has been reported to increase the level of amyloid beta (A beta), which is a component of drusen deposits underlying the retinal pigment epithelium (RPE) layer. To verify the genetic functional associations of HERPUD1 with PCV, exome sequencing of HERPUD1 was performed in unrelated Chinese individuals, including nAMD patients, PCV patients and control subjects. Immunohistochemistry assays for HERPUD1 were performed in the subretinal membranes of PCV patients. The relationship between HERPUD1 and amyloid beta precursor was determined using real-time PCR in HERPUD1-overexpressing RPE cells. The gene expression patterns of angiogenesis cytokines and chemokines in both A beta-treated RPE cells and in Brown Norway rats that received A beta subretinal injections were determined. We showed that HERPUD1 rs2217332 is significant associated with Chinese PCV, and HERPUD1 was expressed in PCV subretinal membranes. Besides, Plasma A beta 42 protein was significantly higher in PCV patients compared to nAMD and control subjects. A beta could upregulate angiogenic factors, chemokines and matrix metalloproteinases both in RPE cells and in a rat model of subretinal A beta injection. The imbalance of the cytokines may be one of the mechanisms for the formation and development of PCV. Our results strongly suggest that HERPUD1 is highly associated with PCV patients.
C1 [Jin, Enzhong; Bai, Yujing; Huang, Lvzhen; Zhao, Min; Zhao, Mingwei; Li, Xiaoxin] Peking Univ, Dept Ophthalmol, Peoples Hosp, Beijing 100044, Peoples R China.
   [Jin, Enzhong; Bai, Yujing; Huang, Lvzhen; Zhao, Min; Zhao, Mingwei; Li, Xiaoxin] Minist Educ, Key Lab Vis Loss & Restorat, Beijing 100044, Peoples R China.
   [Jin, Enzhong; Bai, Yujing; Huang, Lvzhen; Zhao, Min; Zhao, Mingwei; Li, Xiaoxin] Beijing Key Lab Diag & Therapy Retinal & Choroid, Beijing 100044, Peoples R China.
   [Zhang, Chunfang] Peking Univ, Clin Epidemiol & Biostat, Peoples Hosp, Beijing 100044, Peoples R China.
C3 Peking University; Peking University
RP Zhao, MW (通讯作者)，Peking Univ, Dept Ophthalmol, Peoples Hosp, Key Lab Vis Loss & Restorat,Minist Educ, 11 Xizhimen South St, Beijing 100044, Peoples R China.
EM zhaomingwei64@163.com
OI Jin, Enzhong/0000-0003-1450-5846; Zhao, Min/0000-0003-0521-9186
FU National Basic Research Program of China (973 Program) [2011CB510200];
   Beijing Nova Program [Z13-1102000413004]; National Natural Science
   Foundation of China [81470651, 812-00690, 81100666]; Peking University
   People's Hospital Research and Development Fund [RDB2012-24]
FX This work was supported by the National Basic Research Program of China
   (973 Program, 2011CB510200), Beijing Nova Program (Z13-1102000413004),
   the National Natural Science Foundation of China Grant (81470651,
   812-00690, 81100666) and the Peking University People's Hospital
   Research and Development Fund (RDB2012-24). The funders had no role in
   the study design, data collection and analysis, decision to publish or
   preparation of the manuscript.
CR Alge-Priglinger CS, 2009, INVEST OPHTH VIS SCI, V50, P5495, DOI 10.1167/iovs.08-3193
   Belal C, 2012, HUM MOL GENET, V21, P963, DOI 10.1093/hmg/ddr502
   Binder S, 2007, PROG RETIN EYE RES, V26, P516, DOI 10.1016/j.preteyeres.2007.02.002
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Bruban J, 2009, AGING CELL, V8, P162, DOI 10.1111/j.1474-9726.2009.00456.x
   Byeon SH, 2008, JPN J OPHTHALMOL, V52, P57, DOI 10.1007/s10384-007-0498-2
   Cai JY, 2000, PROG RETIN EYE RES, V19, P205, DOI 10.1016/S1350-9462(99)00009-9
   Cao RH, 2010, P NATL ACAD SCI USA, V107, P856, DOI 10.1073/pnas.0911661107
   Chigurupati S, 2009, J BIOL CHEM, V284, P18323, DOI 10.1074/jbc.M109.020891
   Coleman HR, 2008, LANCET, V372, P1835, DOI 10.1016/S0140-6736(08)61759-6
   Das A, 2003, PROG RETIN EYE RES, V22, P721, DOI 10.1016/j.preteyeres.2003.08.001
   Dentchev T, 2003, MOL VIS, V9, P184
   Doyle SL, 2012, NAT MED, V18, P791, DOI 10.1038/nm.2717
   Dunn KC, 1996, EXP EYE RES, V62, P155, DOI 10.1006/exer.1996.0020
   Eichler W, 2006, CURR PHARM DESIGN, V12, P2645, DOI 10.2174/138161206777698729
   Eilken HM, 2010, CURR OPIN CELL BIOL, V22, P617, DOI 10.1016/j.ceb.2010.08.010
   Goel S, 2011, PHYSIOL REV, V91, P1071, DOI 10.1152/physrev.00038.2010
   Grossniklaus HE, 2010, PROG RETIN EYE RES, V29, P500, DOI 10.1016/j.preteyeres.2010.05.003
   Hedlund EM, 2009, P NATL ACAD SCI USA, V106, P17505, DOI 10.1073/pnas.0908026106
   Hou J, 2011, GRAEF ARCH CLIN EXP, V249, P975, DOI 10.1007/s00417-010-1575-7
   Huang LZ, 2010, INVEST OPHTH VIS SCI, V51, P3193, DOI 10.1167/iovs.09-3779
   Imamura Y, 2010, SURV OPHTHALMOL, V55, P501, DOI 10.1016/j.survophthal.2010.03.004
   Ingber DE, 2002, CIRC RES, V91, P877, DOI 10.1161/01.RES.0000039537.73816.E5
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Jones A, 2011, P NATL ACAD SCI USA, V108, P14578, DOI 10.1073/pnas.1102853108
   Kessenbrock K, 2010, CELL, V141, P52, DOI 10.1016/j.cell.2010.03.015
   Koh AHC, 2013, RETINA-J RET VIT DIS, V33, P686, DOI 10.1097/IAE.0b013e3182852446
   Kondo N, 2008, INVEST OPHTH VIS SCI, V49, P1101, DOI 10.1167/iovs.07-1145
   Ladas ID, 2004, EYE, V18, P455, DOI 10.1038/sj.eye.6700706
   Lafaut BA, 2000, GRAEF ARCH CLIN EXP, V238, P752, DOI 10.1007/s004170000180
   Laude A, 2010, PROG RETIN EYE RES, V29, P19, DOI 10.1016/j.preteyeres.2009.10.001
   Lim TH, 2010, EYE, V24, P483, DOI 10.1038/eye.2009.323
   Liu RT, 2013, INVEST OPHTH VIS SCI, V54, P2225, DOI 10.1167/iovs.12-10849
   Liu Y, 2007, GRAEF ARCH CLIN EXP, V245, P1441, DOI 10.1007/s00417-007-0575-8
   Maruko I, 2007, AM J OPHTHALMOL, V144, P15, DOI 10.1016/j.ajo.2007.03.047
   Marutani T, 2011, BBA-GEN SUBJECTS, V1810, P790, DOI 10.1016/j.bbagen.2011.04.017
   Nagineni CN, 2003, J CELL PHYSIOL, V197, P453, DOI 10.1002/jcp.10378
   Nakashizuka H, 2008, INVEST OPHTH VIS SCI, V49, P4729, DOI 10.1167/iovs.08-2134
   Novack GD, 2008, ANNU REV PHARMACOL, V48, P61, DOI 10.1146/annurev.pharmtox.48.060607.174028
   Ohno-Matsui K, 2011, PROG RETIN EYE RES, V30, P217, DOI 10.1016/j.preteyeres.2011.02.004
   Orimo A, 2005, CELL, V121, P335, DOI 10.1016/j.cell.2005.02.034
   Page-McCaw A, 2007, NAT REV MOL CELL BIO, V8, P221, DOI 10.1038/nrm2125
   Rosenbaum JT, 2012, NEW ENGL J MED, V367, P768, DOI 10.1056/NEJMcibr1204973
   Sai X, 2002, J BIOL CHEM, V277, P12915, DOI 10.1074/jbc.M112372200
   Sai XR, 2003, FEBS LETT, V553, P151, DOI 10.1016/S0014-5793(03)01009-3
   Scassellati-Sforzolini B, 2001, RETINA-J RET VIT DIS, V21, P121, DOI 10.1097/00006982-200104000-00004
   Sho K, 2003, ARCH OPHTHALMOL-CHIC, V121, P1392, DOI 10.1001/archopht.121.10.1392
   Stahl A, 2009, GRAEF ARCH CLIN EXP, V247, P767, DOI 10.1007/s00417-009-1058-x
   Stone EM, 2007, ANNU REV MED, V58, P477, DOI 10.1146/annurev.med.58.111405.133335
   Takahashi Kanji, 2008, Nippon Ganka Gakkai Zasshi, V112, P1076
   Yannuzzi LA, 1999, ARCH OPHTHALMOL-CHIC, V117, P1503
   YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001
   Yoshida T, 2005, J CLIN INVEST, V115, P2793, DOI 10.1172/JCI24635
   Zhuo JM, 2010, J ALZHEIMERS DIS, V20, P569, DOI 10.3233/JAD-2010-1394
NR 54
TC 10
Z9 10
U1 0
U2 1
PU E-CENTURY PUBLISHING CORP
PI MADISON
PA 40 WHITE OAKS LN, MADISON, WI 53711 USA
SN 1936-2625
J9 INT J CLIN EXP PATHO
JI Int. J. Clin. Exp. Pathol.
PY 2015
VL 8
IS 11
BP 13928
EP 13944
PG 17
WC Oncology; Pathology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Pathology
GA DA9OX
UT WOS:000368140100014
PM 26823705
DA 2022-11-30
ER

PT J
AU Stoller, GL
   Kokame, GT
   Dreyer, RF
   Shapiro, H
   Tuomi, LL
AF Stoller, Glenn L.
   Kokame, Gregg T.
   Dreyer, Richard F.
   Shapiro, Howard
   Tuomi, Lisa L.
TI Patterns of Early and Delayed Visual Response to Ranibizumab Treatment
   for Neovascular Age-Related Macular Degeneration
SO JAMA OPHTHALMOLOGY
LA English
DT Article
ID 2.0 MG RANIBIZUMAB; VERTEPORFIN; EFFICACY; SAFETY
AB IMPORTANCE Understanding the range of temporal responses to ranibizumab is critical for the assessment of individualized treatment regimens for neovascular age-related macular degeneration.
   OBJECTIVE To examine patterns of visual and anatomical response to ranibizumab treatment.
   DESIGN, SETTING, AND PARTICIPANTS This study is a retrospective subanalysis of HARBOR (a phase 3, double-masked, multicenter, randomized, active treatment-controlled study of the efficacy and safety of 0.5 mg and 2.0 mg ranibizumab administered monthly or on an as-needed basis (PRN) in patients with subfoveal neovascular age-related macular degeneration). A total of 1097 patients with neovascular age-related macular degeneration were randomized to intravitreal ranibizumab, 0.5 or 2.0 mg, administered monthly or as needed (PRN) with monthly monitoring. Of the 1097 patients, 1057 were included in the analysis for early responders (best-corrected visual acuity [BCVA] obtained at baseline and month 3), and 988 patients were included in the analysis for delayed responders (BCVA obtained at baseline, month 3, and month 12). The HARBOR study began July 7, 2009, with the primary 12-month end point completed on August 5, 2011, ongoing to 24 months. Data analysis for the subgroup was performed from January 4, 2013, through December 17, 2015.
   INTERVENTIONS Patients were categorized based on BCVA outcomes as early 15-letter responders (gained >= 15 letters from baseline at month 3) or delayed 15-letter responders (did not gain >= 15 letters from baseline at month 3 but did so at month 12).
   MAIN OUTCOMES AND MEASURES Changes from baseline in BCVA and central foveal thickness (CFT).
   RESULTS In total, 266 early and 135 delayed 15-letter responders were identified. In the 0.5-mg monthly, 0.5-mg PRN, 2.0-mg monthly, and 2.0-mg PRN treatment groups, 63 (24.0%) of 263, 65 (24.6%) of 264, 68 (25.7%) of 265, and 70 (26.4%) of 265 patients were early responders, respectively, and 40 (16.3%) of 246, 31 (12.6%) of 247, 35 (14.1%) of 248, and 29 (11.7%) of 247 patients were delayed responders, respectively. By month 12, early vs delayed responders in the PRN treatment groups received 7.5 vs 7.4 ranibizumab injections, respectively (P=.84). More than 80% of early responders receiving PRN treatment maintained 15-letter or greater gains at month 24. At baseline, early vs delayed responders had worse BCVA (49.8 vs 55.4 letters; P<.001) and greater CFT (374.9 vs 339.0 mu m; P=.02), although anatomical results were comparable by month 3 (CFT, 187.7 vs 188.9 mu m).
   CONCLUSIONS AND RELEVANCE Improvement of 15 letters or more from baseline occurred in 266 (25.2%) of 1057 patients within 3 months of beginning ranibizumab treatment, whereas an additional 135 (13.7%) of 988 patients achieved this gain by 12 months. The 2 cohorts had similar anatomical temporal response patterns. PRN treatment with monthly monitoring was effective in maintaining early vision gains and allowing delayed vision gains. These results suggest that vision improvement can continue in some patients after macular edema resolves and CFT decreases stabilize.
C1 [Stoller, Glenn L.] Ophthalm Consultants Long Isl, 360 Merrick Rd, Lynbrook, NY 11563 USA.
   [Kokame, Gregg T.] Retina Ctr Pali Momi, Aiea, HI USA.
   [Kokame, Gregg T.] Univ Hawaii, Retina Consultants Hawaii, Sch Med, Honolulu, HI 96822 USA.
   [Dreyer, Richard F.] Retina Northwest, Portland, OR USA.
   [Shapiro, Howard; Tuomi, Lisa L.] Genentech Inc, San Francisco, CA 94080 USA.
C3 University of Hawaii System; Roche Holding; Genentech
RP Stoller, GL (通讯作者)，Ophthalm Consultants Long Isl, 360 Merrick Rd, Lynbrook, NY 11563 USA.
EM gstoller@ocli.net
FU Genentech Inc
FX Genentech Inc provided support for the study and participated in the
   study design; conducting the study; data collection, management,
   analysis and interpretation; preparation, review, and approval of the
   manuscript; and decision to submit the manuscript for publication.
CR Boyer DS, 2009, OPHTHALMOLOGY, V116, P1731, DOI 10.1016/j.ophtha.2009.05.024
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   Browning DJ, 2008, OPHTHALMOLOGY, V115, P1366, DOI 10.1016/j.ophtha.2007.12.004
   Busbee BG, 2013, OPHTHALMOLOGY, V120, P1046, DOI 10.1016/j.ophtha.2012.10.014
   Chakravarthy U, 2013, LANCET, V382, P1258, DOI 10.1016/S0140-6736(13)61501-9
   Chakravarthy U, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.04.015
   Chong V, 2016, EYE, V30, P270, DOI 10.1038/eye.2015.217
   Hariprasad SM, 2012, J OPHTHALMOL, V2012, DOI 10.1155/2012/690641
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Ho AC, 2014, OPHTHALMOLOGY, V121, P2181, DOI 10.1016/j.ophtha.2014.05.009
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Regillo CD, 2008, AM J OPHTHALMOL, V145, P239, DOI 10.1016/j.ajo.2007.10.004
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Schmidt-Erfurth U, 2014, OPHTHALMOLOGY, V121, P193, DOI 10.1016/j.ophtha.2013.08.011
NR 16
TC 14
Z9 14
U1 0
U2 1
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 2168-6165
EI 2168-6173
J9 JAMA OPHTHALMOL
JI JAMA Ophthalmol.
PD MAY
PY 2016
VL 134
IS 5
BP 545
EP 553
DI 10.1001/jamaophthalmol.2016.0379
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA DL7CB
UT WOS:000375796100018
PM 27010625
OA Bronze
DA 2022-11-30
ER

PT J
AU Nita, M
   Strzalka-Mrozik, B
   Grzybowski, A
   Mazurek, U
   Romaniuk, W
AF Nita, Malgorzata
   Strzalka-Mrozik, Barbara
   Grzybowski, Andrzej
   Mazurek, Urszula
   Romaniuk, Wanda
TI Age-related macular degeneration and changes in the extracellular matrix
SO MEDICAL SCIENCE MONITOR
LA English
DT Review
DE AMD; Extracellular Matrix; Metalloproteinases; Tissue Inhibitors of
   Metalloproteinases; Collagen; Bruch's Membrane; Elastin
ID RETINAL-PIGMENT EPITHELIUM; COMPLEMENT FACTOR-H; CHOROIDAL NEOVASCULAR
   MEMBRANES; ENDOTHELIAL GROWTH-FACTOR; POSTERIOR CAPSULE OPACIFICATION;
   NONLETHAL OXIDANT INJURY; BASAL LAMINAR DEPOSIT; HUMAN BRUCHS MEMBRANE;
   COLLAGEN-IV ISOFORMS; SMOOTH-MUSCLE-CELL
AB Age-related macular degeneration (AMD) is the leading cause of permanent, irreversible, central blindness (scotoma in the central visual field that makes reading and writing impossible, stereoscopic vision, recognition of colors and details) in patients over the age of 50 years in European and North America countries, and an important role is attributed to disorders in the regulation of the extracellular matrix (ECM). The main aim of this article is to present the crucial processes that occur on the level of Bruch's membrane, with special consideration of the metalloproteinase substrates, metalloproteinase, and tissue inhibitor of metalloproteinase (TIMP). A comprehensive review of the literature was performed through MEDLINE and PubMed searches, covering the years 2005-2012, using the following keywords: AMD, extracellular matrix, metalloproteinases, tissue inhibitors of metalloproteinases, Bruch's membrane, collagen, elastin.
   In the pathogenesis of AMD, a significant role is played by collagen type I and type IV; elastin; fibulin-3, -5, and -6; matrix metalloproteinase (MMP)-2, MMP-9, MMP-14, and MMP-1; and TIMP-3. Other important mechanisms include: ARMS2 and HTR1 proteins, the complement system, the urokinase plasminogen activator system, and pro-renin receptor activation.
   Continuous rebuilding of the extracellular matrix occurs in both early and advanced AMD, simultaneously with the dysfunction of retinal pigment epithelium (RPE) cells and endothelial cells. The pathological degradation or accumulation of ECM structural components are caused by impairment or hyperactivity of specific MMPs/TIMPs complexes, and is also endangered by the influence of other mechanisms connected with both genetic and environmental factors.
C1 [Nita, Malgorzata] Domest & Specialized Med Ctr Dilmed, Katowice, Poland.
   [Strzalka-Mrozik, Barbara; Mazurek, Urszula] Med Univ Silesia, Dept Mol Biol, Sosnowiec, Poland.
   [Grzybowski, Andrzej] Poznan City Hosp, Dept Ophthalmol, Poznan, Poland.
   [Grzybowski, Andrzej] Univ Warmia & Mazury, Dept Ophthalmol, Olsztyn, Poland.
   [Romaniuk, Wanda] Med Univ Silesia, Independent Publ Clin Hosp, Dept Ophthalmol, Katowice, Poland.
C3 Medical University Silesia; University of Warmia & Mazury; Medical
   University Silesia
RP Grzybowski, A (通讯作者)，Poznan City Hosp, Dept Ophthalmol, Poznan, Poland.
EM ae.grzybowski@gmail.com
RI Grzybowski, A/E-4486-2010
OI Grzybowski, A/0000-0002-3724-2391; Mazurek, Urszula/0000-0003-1181-4934;
   STRZALKA-MROZIK, BARBARA/0000-0001-9854-2569
CR Alcazar O, 2007, INVEST OPHTH VIS SCI, V48, P5662, DOI 10.1167/iovs.07-0392
   Alcazar O, 2009, MOL CELL PROTEOMICS, V8, P2201, DOI 10.1074/mcp.M900203-MCP200
   Alcazar O, 2009, EXP EYE RES, V89, P638, DOI 10.1016/j.exer.2009.06.014
   ALEXANDER JP, 1990, INVEST OPHTH VIS SCI, V31, P2520
   ANDERSON DH, 1990, INVEST OPHTH VIS SCI, V31, P81
   Anderson DH, 2002, AM J OPHTHALMOL, V134, P411, DOI 10.1016/S0002-9394(02)01624-0
   Andreasen PA, 1997, INT J CANCER, V72, P1, DOI 10.1002/(SICI)1097-0215(19970703)72:1<1::AID-IJC1>3.0.CO;2-Z
   Augustin AJ, 2009, EXPERT OPIN THER TAR, V13, P641, DOI 10.1517/14728220902942322
   Bader BL, 2005, MOL CELL BIOL, V25, P6846, DOI 10.1128/MCB.25.15.6846-6856.2005
   Bai XY, 2009, MATRIX BIOL, V28, P194, DOI 10.1016/j.matbio.2009.02.004
   Baker AH, 1998, J CLIN INVEST, V101, P1478, DOI 10.1172/JCI1584
   BANDA MJ, 1983, J EXP MED, V157, P1184, DOI 10.1084/jem.157.4.1184
   BANDA MJ, 1980, J EXP MED, V152, P1563, DOI 10.1084/jem.152.6.1563
   Bazan NG, 2006, TRENDS NEUROSCI, V29, P263, DOI 10.1016/j.tins.2006.03.005
   Bhutto IA, 2006, EXP EYE RES, V82, P99, DOI 10.1016/j.exer.2005.05.007
   Booij JC, 2010, PROG RETIN EYE RES, V29, P1, DOI 10.1016/j.preteyeres.2009.08.003
   Bressler NM, 2009, OPHTHALMOLOGY, V116, pS15, DOI 10.1016/j.ophtha.2009.06.048
   BRESSLER NM, 1995, ARCH OPHTHALMOL-CHIC, V113, P301, DOI 10.1001/archopht.1995.01100030055022
   BRESSLER SB, 1990, ARCH OPHTHALMOL-CHIC, V108, P1442, DOI 10.1001/archopht.1990.01070120090035
   CHAKRAVARTI S, 1990, J BIOL CHEM, V265, P10597
   Chang C, 2001, TRENDS CELL BIOL, V11, pS37, DOI 10.1016/S0962-8924(01)02122-5
   Chau KY, 2007, EYE, V21, P1511, DOI [10.1038/sj.eye.6702722, 10.1038/sj.eye.6702722x]
   Chen L, 2003, BRIT J OPHTHALMOL, V87, P212, DOI 10.1136/bjo.87.2.212
   Chen SJ, 2001, BRIT J OPHTHALMOL, V85, P1411, DOI 10.1136/bjo.85.12.1411
   Chong NHV, 2005, AM J PATHOL, V166, P241, DOI 10.1016/S0002-9440(10)62248-1
   Chronopoulos A, 2011, CURR EYE RES, V36, P747, DOI 10.3109/02713683.2011.585735
   Comer Grant M, 2004, Curr Opin Ophthalmol, V15, P508, DOI 10.1097/01.icu.0000143685.60479.3b
   Crabb JW, 2002, P NATL ACAD SCI USA, V99, P14682, DOI 10.1073/pnas.222551899
   Cruess AF, 2009, ACTA OPHTHALMOL, V87, P118, DOI 10.1111/j.1755-3768.2008.01218.x
   Curcio CA, 2005, EXP EYE RES, V80, P761, DOI 10.1016/j.exer.2004.09.017
   Curcio CA, 1999, ARCH OPHTHALMOL-CHIC, V117, P329, DOI 10.1001/archopht.117.3.329
   DAS A, 1990, ARCH OPHTHALMOL-CHIC, V108, P421, DOI 10.1001/archopht.1990.01070050119045
   de Cordoba SR, 2004, MOL IMMUNOL, V41, P355, DOI 10.1016/j.molimm.2004.02.005
   de Jong PTVM, 2006, NEW ENGL J MED, V355, P1474, DOI 10.1056/NEJMra062326
   De Luca A, 2003, J HISTOCHEM CYTOCHEM, V51, P1279, DOI 10.1177/002215540305101004
   Deryugina EI, 1998, CANCER RES, V58, P3743
   Des Parkin J, 2011, HUM MUTAT, V32, P127, DOI 10.1002/humu.21401
   Despriet DDG, 2009, OPHTHALMOLOGY, V116, P474, DOI 10.1016/j.ophtha.2008.09.055
   Dewan A, 2006, SCIENCE, V314, P989, DOI 10.1126/science.1133807
   Dhaliwal BS, 1999, CLIN CHIM ACTA, V286, P191, DOI 10.1016/S0009-8981(99)00101-1
   Donoso LA, 2006, SURV OPHTHALMOL, V51, P137, DOI 10.1016/j.survophthal.2005.12.001
   Dorrell M, 2007, SURV OPHTHALMOL, V52, pS3, DOI 10.1016/j.survophthal.2006.10.017
   Ebrahem Q, 2006, P NATL ACAD SCI USA, V103, P13480, DOI 10.1073/pnas.0601552103
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Ekblom M, 1998, ANN NY ACAD SCI, V857, P194, DOI 10.1111/j.1749-6632.1998.tb10117.x
   Ellerbroek SM, 1999, BIOESSAYS, V21, P940, DOI 10.1002/(SICI)1521-1878(199911)21:11<940::AID-BIES6>3.0.CO;2-J
   Elliot SJ, 2010, EXP EYE RES, V90, P10, DOI 10.1016/j.exer.2009.09.001
   Elner SG, 2003, EXP EYE RES, V76, P585, DOI 10.1016/S0014-4835(03)00028-9
   Erickson AC, 2000, J HISTOCHEM CYTOCHEM, V48, P1291, DOI 10.1177/002215540004801001
   Espinosa-Heidmann DG, 2006, INVEST OPHTH VIS SCI, V47, P729, DOI 10.1167/iovs.05-0719
   Evans JR, 2001, PROG RETIN EYE RES, V20, P227, DOI 10.1016/S1350-9462(00)00023-9
   Favor J, 2007, GENETICS, V175, P725, DOI 10.1534/genetics.106.064733
   Ferris FL, 2005, ARCH OPHTHALMOL-CHIC, V123, P1570
   Fine SL, 2000, NEW ENGL J MED, V342, P483, DOI 10.1056/NEJM200002173420707
   Fisher SA, 2007, HUM MUTAT, V28, P406, DOI 10.1002/humu.20464
   Friedman E, 2000, AM J OPHTHALMOL, V130, P658, DOI 10.1016/S0002-9394(00)00643-7
   Fritsche LG, 2008, NAT GENET, V40, P892, DOI 10.1038/ng.170
   Fu L, 2007, HUM MOL GENET, V16, P2411, DOI 10.1093/hmg/ddm198
   Gasque P, 2000, IMMUNOPHARMACOLOGY, V49, P171, DOI 10.1016/S0162-3109(00)80302-1
   Gautieri A, 2009, BIOPHYS J, V97, P857, DOI 10.1016/j.bpj.2009.04.059
   George SJ, 1998, CURR OPIN LIPIDOL, V9, P413, DOI 10.1097/00041433-199810000-00005
   Ghosh S, 2000, J BIOL CHEM, V275, P23869, DOI 10.1074/jbc.M000935200
   Gohring W, 1998, EUR J BIOCHEM, V255, P60, DOI 10.1046/j.1432-1327.1998.2550060.x
   Gould DB, 2007, HUM MOL GENET, V16, P798, DOI 10.1093/hmg/ddm024
   Green W R, 1999, Mol Vis, V5, P27
   GREEN WR, 1993, OPHTHALMOLOGY, V100, P1519
   Grossniklaus HE, 2002, MOL VIS, V8, P119
   Gu XR, 2003, J BIOL CHEM, V278, P42027, DOI 10.1074/jbc.M305460200
   Gumbiner BM, 1996, CELL, V84, P345, DOI 10.1016/S0092-8674(00)81279-9
   Guymer R, 1999, PROG RETIN EYE RES, V18, P59, DOI 10.1016/S1350-9462(98)00012-3
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   HAGEMAN GS, 1995, INVEST OPHTH VIS SCI, V36, P432
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Hammer T, 2001, ARCH OPHTHALMOL-CHIC, V119, P1023, DOI 10.1001/archopht.119.7.1023
   HEWITT AT, 1989, INVEST OPHTH VIS SCI, V30, P478
   Hillenkamp J, 2004, INVEST OPHTH VIS SCI, V45, P1493, DOI 10.1167/iovs.03-0765
   Hollyfield JG, 2008, NAT MED, V14, P194, DOI 10.1038/nm1709
   HOSODA Y, 1993, OPHTHALMIC RES, V25, P289, DOI 10.1159/000267327
   Hussain AA, 2002, J OPT SOC AM A, V19, P166, DOI 10.1364/JOSAA.19.000166
   Hyman L, 2000, ARCH OPHTHALMOL-CHIC, V118, P351, DOI 10.1001/archopht.118.3.351
   Imai H, 2007, CURR EYE RES, V32, P903, DOI 10.1080/02713680701604749
   Iozzo RV, 1998, ANNU REV BIOCHEM, V67, P609, DOI 10.1146/annurev.biochem.67.1.609
   ISHIBASHI T, 1994, J CATARACT REFR SURG, V20, P643, DOI 10.1016/S0886-3350(13)80655-4
   ISHIBASHI T, 1995, OPHTHALMIC RES, V27, P208, DOI 10.1159/000267707
   Iyengar SK, 2004, AM J HUM GENET, V74, P20, DOI 10.1086/380912
   Johnson LR, 2000, IEEE ANN HIST COMPUT, V22, P70
   Jonas JB, 2003, GRAEF ARCH CLIN EXP, V241, P125, DOI 10.1007/s00417-002-0615-3
   JONES SE, 1994, FEBS LETT, V352, P171, DOI 10.1016/0014-5793(94)00951-1
   Jozsi M, 2008, TRENDS IMMUNOL, V29, P380, DOI 10.1016/j.it.2008.04.008
   Kamei M, 1999, INVEST OPHTH VIS SCI, V40, P2367
   KARWATOWSKI WSS, 1995, BRIT J OPHTHALMOL, V79, P944, DOI 10.1136/bjo.79.10.944
   Khoshnoodi J, 2008, MICROSC RES TECHNIQ, V71, P357, DOI 10.1002/jemt.20564
   Kijlstra A, 2005, OCUL IMMUNOL INFLAMM, V13, P3, DOI 10.1080/09273940590909185
   Kimura N, 1998, EXP CELL RES, V241, P36, DOI 10.1006/excr.1998.4016
   Klein ML, 1998, ARCH OPHTHALMOL-CHIC, V116, P1082, DOI 10.1001/archopht.116.8.1082
   Klein R, 2004, AM J OPHTHALMOL, V137, P486, DOI 10.1016/j.ajo.2003.11.069
   Klein R, 1997, OPHTHALMOLOGY, V104, P7, DOI 10.1016/S0161-6420(97)30368-6
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Klein Ronald, 2003, Ophthalmology, V110, P1273, DOI 10.1016/S0161-6420(03)00599-2
   Klenotic PA, 2004, J BIOL CHEM, V279, P30469, DOI 10.1074/jbc.M403026200
   Kohfeldt E, 1998, J MOL BIOL, V282, P99, DOI 10.1006/jmbi.1998.2004
   Kondo N, 2008, INVEST OPHTH VIS SCI, V49, P1101, DOI 10.1167/iovs.07-1145
   Kortvely E, 2010, INVEST OPHTH VIS SCI, V51, P79, DOI 10.1167/iovs.09-3850
   Kwak N, 2000, INVEST OPHTH VIS SCI, V41, P3158
   Lee SH, 2007, NAT MED, V13, P567, DOI 10.1038/nm1583
   Leu ST, 2002, EXP EYE RES, V74, P141, DOI 10.1006/exer.2001.1112
   LIOTTA LA, 1991, CELL, V64, P327, DOI 10.1016/0092-8674(91)90642-C
   Marin-Castano ME, 2006, INVEST OPHTH VIS SCI, V47, P4098, DOI 10.1167/iovs.05-1230
   Marin-Castano ME, 2005, INVEST OPHTH VIS SCI, V46, P3331, DOI 10.1167/iovs.04-1224
   Marini JC, 2007, HUM MUTAT, V28, P209, DOI 10.1002/humu.20429
   Marmorstein LHY, 2002, P NATL ACAD SCI USA, V99, P13067, DOI 10.1073/pnas.202491599
   MARSHALL GE, 1992, BRIT J OPHTHALMOL, V76, P607, DOI 10.1136/bjo.76.10.607
   McCarty CA, 2001, ARCH OPHTHALMOL-CHIC, V119, P1455
   McConnell V, 2005, Ulster Med J, V74, P82
   Mckee KK, 2007, J BIOL CHEM, V282, P21437, DOI 10.1074/jbc.M702963200
   MCLEOD DS, 1994, INVEST OPHTH VIS SCI, V35, P3799
   McLeod DS, 2002, INVEST OPHTH VIS SCI, V43, P1986
   MIETTINEN A, 1986, J EXP MED, V163, P1064, DOI 10.1084/jem.163.5.1064
   Miner JH, 2008, MICROSC RES TECHNIQ, V71, P349, DOI 10.1002/jemt.20563
   Moore DJ, 2001, INVEST OPHTH VIS SCI, V42, P2970
   MOSES MA, 1991, J CELL BIOCHEM, V47, P230, DOI 10.1002/jcb.240470308
   Mullins RF, 1997, OPHTHALMOLOGY, V104, P288, DOI 10.1016/S0161-6420(97)30322-4
   Mullins RF, 2000, FASEB J, V14, P835, DOI 10.1096/fasebj.14.7.835
   Nackman GB, 1997, SURGERY, V122, P39, DOI 10.1016/S0039-6060(97)90262-2
   Nagase H, 2006, CARDIOVASC RES, V69, P562, DOI 10.1016/j.cardiores.2005.12.002
   Nagase H, 1999, J BIOL CHEM, V274, P21491, DOI 10.1074/jbc.274.31.21491
   Nagase H, 1997, BIOL CHEM, V378, P151
   Nasir MA, 1997, BRIT J OPHTHALMOL, V81, P481, DOI 10.1136/bjo.81.6.481
   NEWSOME DA, 1987, AM J OPHTHALMOL, V104, P373, DOI 10.1016/0002-9394(87)90227-3
   Ng KP, 2008, MOL CELL PROTEOMICS, V7, P1397, DOI 10.1074/mcp.M700525-MCP200
   Nguyen M, 2001, INT J BIOCHEM CELL B, V33, P960, DOI 10.1016/S1357-2725(01)00007-3
   Nishi O, 1996, BRIT J OPHTHALMOL, V80, P63, DOI 10.1136/bjo.80.1.63
   Ortega N, 2002, J CELL SCI, V115, P4201, DOI 10.1242/jcs.00106
   PAULEIKHOFF D, 1990, OPHTHALMOLOGY, V97, P171
   Pauleikhoff D., 1994, Ophthalmologe, V91, P730
   PAULEIKHOFF D, 1990, AM J OPHTHALMOL, V109, P38, DOI 10.1016/S0002-9394(14)75576-X
   Poschl E, 2004, DEVELOPMENT, V131, P1619, DOI 10.1242/dev.01037
   Praddaude F, 2009, EXP EYE RES, V89, P109, DOI 10.1016/j.exer.2009.02.020
   Reale E, 2009, CELLS TISSUES ORGANS, V190, P170, DOI 10.1159/000187632
   Renganathan K, 2008, ADV EXP MED BIOL, V613, P261, DOI 10.1007/978-0-387-74904-4_30
   Ritch R, 2001, SURV OPHTHALMOL, V45, P265, DOI 10.1016/S0039-6257(00)00196-X
   Rivera A, 2005, HUM MOL GENET, V14, P3227, DOI 10.1093/hmg/ddi353
   ROBERTS JM, 1990, EXP EYE RES, V50, P165, DOI 10.1016/0014-4835(90)90227-L
   Ruiz-Moreno JM, 2008, CLIN OPHTHALMOL, V2, P71
   Saika S, 1998, EXP EYE RES, V66, P283, DOI 10.1006/exer.1997.0434
   Saika S, 1998, JPN J OPHTHALMOL, V42, P368, DOI 10.1016/S0021-5155(98)00033-1
   SanGiovanni JP, 2005, PROG RETIN EYE RES, V24, P87, DOI 10.1016/j.preteyeres.2004.06.002
   Sarks SH, 1999, BRIT J OPHTHALMOL, V83, P358, DOI 10.1136/bjo.83.3.358
   Sarks SH, 2001, MED RETINA, VII, P1064
   Sarks S, 2007, INVEST OPHTH VIS SCI, V48, P968, DOI 10.1167/iovs.06-0443
   Sarraf D, 1999, RETINA-J RET VIT DIS, V19, P513, DOI 10.1097/00006982-199911000-00006
   Schittny JC, 1989, CURR OPIN CELL BIOL, V1, P983, DOI 10.1016/0955-0674(89)90069-0
   SchlotzerSchrehardt U, 1997, INVEST OPHTH VIS SCI, V38, P970
   Schultz DW, 2003, HUM MOL GENET, V12, P3315, DOI 10.1093/hmg/ddg348
   Schwarzbauer J, 1999, CURR BIOL, V9, pR242, DOI 10.1016/S0960-9822(99)80153-5
   Schwesinger C, 2001, AM J PATHOL, V158, P1161, DOI 10.1016/S0002-9440(10)64063-1
   Sebag J, 2000, EUR J OPHTHALMOL, V10, P1
   Shah GK, 2009, RETINA-J RET VIT DIS, V29, P133, DOI 10.1097/IAE.0b013e3181960a28
   SHERAIDAH G, 1993, OPHTHALMOLOGY, V100, P47
   Sheridan C, 2004, GRAEF ARCH CLIN EXP, V242, P68, DOI 10.1007/s00417-003-0800-z
   Sheridan CM, 2000, EXP EYE RES, V71, pS119
   Sivaprasad S, 2005, CLIN EXP OPHTHALMOL, V33, P518, DOI 10.1111/j.1442-9071.2005.01074.x
   Smith W, 2001, OPHTHALMOLOGY, V108, P697, DOI 10.1016/S0161-6420(00)00580-7
   Smyth N, 1999, J CELL BIOL, V144, P151, DOI 10.1083/jcb.144.1.151
   Snow K K, 1999, Ophthalmic Epidemiol, V6, P125, DOI 10.1076/opep.6.2.125.1558
   Spaide RF, 1999, RETINA-J RET VIT DIS, V19, P141, DOI 10.1097/00006982-199902000-00010
   Sparrow JR, 2005, EXP EYE RES, V80, P595, DOI 10.1016/j.exer.2005.01.007
   Spilsbury K, 2000, AM J PATHOL, V157, P135, DOI 10.1016/S0002-9440(10)64525-7
   Spraul CW, 1999, SURV OPHTHALMOL, V44, pS10, DOI 10.1016/S0039-6257(99)00086-7
   Starita C, 1996, EXP EYE RES, V62, P565, DOI 10.1006/exer.1996.0066
   Steen B, 1998, INVEST OPHTH VIS SCI, V39, P2194
   Stillwell W, 2003, CHEM PHYS LIPIDS, V126, P1, DOI 10.1016/S0009-3084(03)00101-4
   Stohr H, 1995, GENOME RES, V5, P483, DOI 10.1101/gr.5.5.483
   Stone EM, 1999, NAT GENET, V22, P199, DOI 10.1038/9722
   Stone EM, 2004, NEW ENGL J MED, V351, P346, DOI 10.1056/NEJMoa040833
   Sweeney SM, 2008, J BIOL CHEM, V283, P21187, DOI 10.1074/jbc.M709319200
   Timpl R, 1996, BIOESSAYS, V18, P123, DOI 10.1002/bies.950180208
   Tummalapalli CM, 1999, J CELL BIOCHEM, V75, P515, DOI 10.1002/(SICI)1097-4644(19991201)75:3<515::AID-JCB15>3.3.CO;2-3
   Umeda S, 2005, FASEB J, V19, P1683, DOI 10.1096/fj.04-3525fje
   Van Agtmael T, 2010, CELL TISSUE RES, V339, P167, DOI 10.1007/s00441-009-0866-y
   VANDERSCHAFT TL, 1992, OPHTHALMOLOGY, V99, P278
   VANDERSCHAFT TL, 1994, GRAEF ARCH CLIN EXP, V232, P40, DOI 10.1007/BF00176436
   VINDING T, 1990, ACTA OPHTHALMOL, V68, P410
   Visse R, 2003, CIRC RES, V92, P827, DOI 10.1161/01.RES.0000070112.80711.3D
   Volonghi I, 2010, CURR MED CHEM, V17, P1317, DOI 10.2174/092986710790936293
   Wang GF, 2009, INVEST OPHTH VIS SCI, V50, P3084, DOI 10.1167/iovs.08-3240
   Wang JJ, 2003, ARCH OPHTHALMOL-CHIC, V121, P658, DOI 10.1001/archopht.121.5.658
   Warburton S, 2005, MOL VIS, V11, P1122
   White DJ, 2004, INT J BIOCHEM CELL B, V36, P1405, DOI 10.1016/j.biocel.2003.08.016
   Witmer AN, 2003, PROG RETIN EYE RES, V22, P1, DOI 10.1016/S1350-9462(02)00043-5
   WRIGHT JK, 1991, BIOCHIM BIOPHYS ACTA, V1094, P207, DOI 10.1016/0167-4889(91)90010-U
   Wu C, 1997, HISTOL HISTOPATHOL, V12, P233
   Xu HP, 2009, PROG RETIN EYE RES, V28, P348, DOI 10.1016/j.preteyeres.2009.06.001
   YAMAMOTO T, 1989, BRIT J OPHTHALMOL, V73, P162, DOI 10.1136/bjo.73.3.162
   Yang ZL, 2006, SCIENCE, V314, P992, DOI 10.1126/science.1133811
   Yeow KM, 2002, MATRIX BIOL, V21, P75, DOI 10.1016/S0945-053X(01)00180-9
   Zarbin MA, 2004, ARCH OPHTHALMOL-CHIC, V122, P598, DOI 10.1001/archopht.122.4.598
   Zhang YW, 2010, EXP EYE RES, V90, P374, DOI 10.1016/j.exer.2009.09.018
   Zhou JL, 2006, P NATL ACAD SCI USA, V103, P16182, DOI 10.1073/pnas.0604255103
   Zhou J, 2009, INVEST OPHTH VIS SCI, V50, P1392, DOI 10.1167/iovs.08-2868
   Zhuge Y, 2001, J BIOL CHEM, V276, P16248, DOI 10.1074/jbc.M010190200
   Zipfel PF, 2009, IMMUNOL LETT, V126, P1, DOI 10.1016/j.imlet.2009.07.005
   Zipfel PF, 2006, MOL IMMUNOL, V43, P97, DOI 10.1016/j.molimm.2005.06.015
NR 204
TC 70
Z9 74
U1 1
U2 19
PU INT SCIENTIFIC LITERATURE, INC
PI SMITHTOWN
PA 361 FOREST LANE, SMITHTOWN, NY 11787 USA
SN 1643-3750
J9 MED SCI MONITOR
JI Med. Sci. Monitor
PD JUN 18
PY 2014
VL 20
BP 1003
EP 1016
PG 14
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine
GA AK6UT
UT WOS:000338563500001
PM 24938626
OA Green Published
DA 2022-11-30
ER

PT J
AU Ogino, K
   Tsujikawa, A
   Yamashiro, K
   Ooto, S
   Oishi, A
   Nakata, I
   Miyake, M
   Takahashi, A
   Ellabban, AA
   Yoshimura, N
AF Ogino, Ken
   Tsujikawa, Akitaka
   Yamashiro, Kenji
   Ooto, Sotaro
   Oishi, Akio
   Nakata, Isao
   Miyake, Masahiro
   Takahashi, Ayako
   Ellabban, Abdallah A.
   Yoshimura, Nagahisa
TI Multimodal evaluation of macular function in age-related macular
   degeneration
SO JAPANESE JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE Age-related macular degeneration; Drusenoid pigment epithelial
   detachment; Drusen; Focal macular electroretinography; Microperimetry
ID PIGMENT EPITHELIAL DETACHMENT; RETINAL VEIN OCCLUSION; MEDIATED
   MULTIFOCAL ELECTRORETINOGRAM; TOMOGRAPHIC HYPERREFLECTIVE FOCI; SCANNING
   LASER OPHTHALMOSCOPE; INTRAVITREAL BEVACIZUMAB; PHOTODYNAMIC THERAPY;
   PEGAPTANIB SODIUM; FUNDUS PERIMETRY; SOFT DRUSEN
AB To evaluate macular function using multimodality in eyes with age-related macular degeneration (AMD) at various stages.
   Macular function in 20 control eyes (20 subjects), 17 eyes (17 patients) with large drusen, 18 eyes (18 patients) with drusenoid pigment epithelial detachment (PED), and 19 eyes (19 patients) with neovascular AMD was examined using a Landolt chart for visual acuity; retinal sensitivity was measured by microperimetry; and focal macular electroretinography (fmERG) was performed. In all of these eyes, retinal morphology was examined using optical coherence tomography.
   Eyes with neovascular AMD showed morphologic changes in the neurosensory retina as well as marked deterioration of macular function in all parameters measured with a Landolt chart, fmERG, and microperimetry. Eyes with large drusen showed only minimal morphologic changes in the neurosensory retina. In this large drusen group, although retinal sensitivity at the central point was significantly decreased (P = 0.0063), the other parameters of macular function were well preserved. In eyes with drusenoid PED, the structure of the neurosensory retina was well preserved, while the foveal thickness was significantly increased (P = 0.013). The macular function of these eyes was significantly deteriorated, with the VA, amplitude of the a-wave and b-wave, and retinal sensitivity being markedly decreased. In addition, the area of PED correlated with the latency of the a-wave and b-wave and with the retinal sensitivity within the central 4A degrees or 8A degrees region.
   Multimodal evaluation demonstrated a significant decrease in macular function in drusenoid PED and in neovascular AMD.
C1 [Ogino, Ken; Tsujikawa, Akitaka; Yamashiro, Kenji; Ooto, Sotaro; Oishi, Akio; Nakata, Isao; Miyake, Masahiro; Takahashi, Ayako; Ellabban, Abdallah A.; Yoshimura, Nagahisa] Kyoto Univ, Dept Ophthalmol & Visual Sci, Grad Sch Med, Sakyo Ku, Kyoto 6068507, Japan.
C3 Kyoto University
RP Tsujikawa, A (通讯作者)，Kyoto Univ, Dept Ophthalmol & Visual Sci, Grad Sch Med, Sakyo Ku, Kyoto 6068507, Japan.
EM tujikawa@kuhp.kyoto-u.ac.jp
RI Miyake, Masahiro/V-1261-2019; Oishi, Akio/AAE-9996-2020
OI Miyake, Masahiro/0000-0001-7410-3764; Oishi, Akio/0000-0002-0977-9458;
   Tsujikawa, Akitaka/0000-0003-0779-7799; Yamashiro,
   Kenji/0000-0001-9354-8558; Ellabban, Abdallah/0000-0002-6033-2969
CR Bolz M, 2010, BRIT J OPHTHALMOL, V94, P185, DOI 10.1136/bjo.2008.143974
   Bolz M, 2009, OPHTHALMOLOGY, V116, P914, DOI 10.1016/j.ophtha.2008.12.039
   Bressler Neil M, 2004, JAMA, V291, P1900, DOI 10.1001/jama.291.15.1900
   Calabrese A, 2011, INVEST OPHTH VIS SCI, V52, P2417, DOI 10.1167/iovs.09-5056
   CASSWELL AG, 1985, BRIT J OPHTHALMOL, V69, P397, DOI 10.1136/bjo.69.6.397
   Cukras C, 2010, OPHTHALMOLOGY, V117, P489, DOI 10.1016/j.ophtha.2009.12.002
   Dinc UA, 2008, EUR J OPHTHALMOL, V18, P595, DOI 10.1177/112067210801800416
   Falsini B, 1999, GRAEF ARCH CLIN EXP, V237, P193, DOI 10.1007/s004170050218
   Falsini B, 2000, INVEST OPHTH VIS SCI, V41, P1498
   Feigl B, 2007, EYE, V21, P689, DOI 10.1038/sj.eye.6702389
   Feigl B, 2005, EYE, V19, P431, DOI 10.1038/sj.eye.6701503
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Gallego-Pinazo R, 2011, CLIN OPHTHALMOL, V5, P161, DOI 10.2147/OPTH.S15832
   Gerth C, 2006, ARCH OPHTHALMOL-CHIC, V124, P345, DOI 10.1001/archopht.124.3.345
   HARTNETT ME, 1992, GRAEF ARCH CLIN EXP, V230, P11, DOI 10.1007/BF00166756
   Hautamaki A, 2014, ACTA OPHTHALMOL, V92, P51, DOI 10.1111/j.1755-3768.2012.02556.x
   Ishibashi T, 2013, JPN J OPHTHALMOL, V57, P417, DOI 10.1007/s10384-013-0255-7
   Iwama D, 2010, CLIN EXP OPHTHALMOL, V38, P483, DOI 10.1111/j.1442-9071.2010.02294.x
   Krishnan R, 2010, CAN J OPHTHALMOL, V45, P83, DOI 10.3129/i09-187
   Landa G, 2011, RETINA-J RET VIT DIS, V31, P364, DOI 10.1097/IAE.0b013e3181e91132
   Lee Na Young, 2008, Korean J Ophthalmol, V22, P194, DOI 10.3341/kjo.2008.22.3.194
   Li J, 2001, BRIT J OPHTHALMOL, V85, P287, DOI 10.1136/bjo.85.3.287
   Midena E, 2007, BRIT J OPHTHALMOL, V91, P1499, DOI 10.1136/bjo.2007.119685
   Midena Edoardo, 2004, Semin Ophthalmol, V19, P55, DOI 10.1080/08820530490882896
   Miyake Y, 1998, Nagoya J Med Sci, V61, P79
   Nishihara H, 2008, INVEST OPHTH VIS SCI, V49, P3121, DOI 10.1167/iovs.08-1835
   Ogino K, 2012, RETINA-J RET VIT DIS, V32, P77, DOI 10.1097/IAE.0b013e318217ffc7
   Ogino K, 2011, INVEST OPHTH VIS SCI, V52, P8047, DOI 10.1167/iovs.11-8143
   Ogino K, 2011, INVEST OPHTH VIS SCI, V52, P3514, DOI 10.1167/iovs.10-7142
   Ozdemir H, 2012, ACTA OPHTHALMOL, V90, P71, DOI 10.1111/j.1755-3768.2009.01838.x
   Parisi V, 2007, RETINA-J RET VIT DIS, V27, P879, DOI 10.1097/IAE.0b013e318042d6aa
   Piccardi M, 2009, OPHTHALMIC RES, V41, P194, DOI 10.1159/000217723
   Querques G, 2009, EUR J OPHTHALMOL, V19, P890, DOI 10.1177/112067210901900535
   Resnikoff S, 2004, B WORLD HEALTH ORGAN, V82, P844
   Ritter M, 2010, EYE, V24, P962, DOI 10.1038/eye.2009.265
   Rohrschneider K, 2005, AM J OPHTHALMOL, V139, P125, DOI 10.1016/j.ajo.2004.08.060
   Roquet W, 2004, BRIT J OPHTHALMOL, V88, P638, DOI 10.1136/bjo.2003.017632
   Springer C, 2005, OPHTHALMOLOGY, V112, P848, DOI 10.1016/j.ophtha.2004.11.051
   Sulzbacher F, 2012, INVEST OPHTH VIS SCI, V53, P6448, DOI 10.1167/iovs.11-9162
   Tezel TH, 1996, OPHTHALMOLOGY, V103, P1829, DOI 10.1016/S0161-6420(96)30419-3
   Yodoi Y, 2007, AM J OPHTHALMOL, V143, P984, DOI 10.1016/j.ajo.2007.01.026
   Yoshida Y, 2013, JPN J OPHTHALMOL, V57, P283, DOI 10.1007/s10384-013-0234-z
   Yoshizawa C, 2013, JPN J OPHTHALMOL, V57, P68, DOI 10.1007/s10384-012-0206-8
NR 43
TC 7
Z9 8
U1 0
U2 8
PU SPRINGER JAPAN KK
PI TOKYO
PA CHIYODA FIRST BLDG EAST, 3-8-1 NISHI-KANDA, CHIYODA-KU, TOKYO, 101-0065,
   JAPAN
SN 0021-5155
EI 1613-2246
J9 JPN J OPHTHALMOL
JI Jpn. J. Ophthalmol.
PD MAR
PY 2014
VL 58
IS 2
BP 155
EP 165
DI 10.1007/s10384-013-0295-z
PG 11
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA AD1WW
UT WOS:000333025400006
PM 24327061
OA Green Submitted
DA 2022-11-30
ER

PT J
AU Moschos, MM
   Laios, K
   Androudi, S
   Ladas, DS
   Chatziralli, IP
AF Moschos, Marilita M.
   Laios, Konstantinos
   Androudi, Sofia
   Ladas, Dimitrios S.
   Chatziralli, Irini P.
TI Anti-platelet effects of vitamin supplements in age-related macular
   degeneration: an in vitro study
SO CUTANEOUS AND OCULAR TOXICOLOGY
LA English
DT Article
DE AMD; anti-inflammatory; anti-angiogenic; vitamin; resveratrol
ID PLATELET-ACTIVATING-FACTOR; ANTIOXIDANTS; CAROTENOIDS
AB Objective: The purpose of this experimental study was to investigate the role of vitamin supplements (Ocuvite, Vitalux Omega, and Nutrof Total) as possible inhibitors of the onset of age-related macular degeneration (AMD).Materials and methods: The anti-aggregating effect of each vitamin was determined against four accumulative factors namely, platelet activating factor (PAF), adenosine diphosphate (ADP), thrombin receptor-activating peptide (TRAP), and arachidonic acid (AA) in the platelet rich plasma (PRP) of healthy volunteers.Results: Ocuvite, Vitalux Omega, and Nutrof Total were more potent inhibitors against PAF and ADP compared to TRAP and AA. Among the three vitamins, Nutrof Total displayed more potent inhibitions against TRAP and AA, while against PAF and ADP all the three vitamins revealed similar IC50 values.Conclusions: The vitamins Ocuvite, Vitalux Omega, and Nutrof Total have anti-aggregating effects and therefore can be used against AMD in healthy volunteers.
C1 [Moschos, Marilita M.; Laios, Konstantinos; Ladas, Dimitrios S.; Chatziralli, Irini P.] Univ Athens, Dept Ophthalmol 1, Lab Electrophysiol, Athens, Greece.
   [Androudi, Sofia] Univ Thessaly, Dept Ophthalmol, Larisa, Greece.
C3 National & Kapodistrian University of Athens; University of Thessaly
RP Moschos, MM (通讯作者)，6 Ikarias St, Athens 14578, Greece.
EM moschosmarilita@yahoo.fr
RI Chatziralli, Irini/AAG-4779-2020; Laios, Konstantinos/GLN-6029-2022;
   Androudi, Sofia/AAB-7618-2021
OI Chatziralli, Irini/0000-0001-8523-1024; Androudi,
   Sofia/0000-0002-5303-7793
CR Ambati J, 2003, SURV OPHTHALMOL, V48, P257, DOI 10.1016/S0039-6257(03)00030-4
   Gachet C, 2001, INT J HEMATOL, V74, P375, DOI 10.1007/BF02982079
   Grover AK, 2014, MOL CELL BIOCHEM, V388, P173, DOI 10.1007/s11010-013-1908-z
   Iroku-Malize Tochi, 2016, FP Essent, V445, P24
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Krishnadev N, 2010, CURR OPIN OPHTHALMOL, V21, P184, DOI 10.1097/ICU.0b013e32833866ee
   Lancon A, 2016, MOLECULES, V21, DOI 10.3390/molecules21030304
   Ma L, 2011, BR J NUTR, V8, P1
   Moschos Marilita M, 2014, Med Hypothesis Discov Innov Ophthalmol, V3, P83
   Moschos MM, 2014, CUTAN OCUL TOXICOL, V33, P235, DOI 10.3109/15569527.2013.835818
   Nitoda E, 2012, EXPERT OPIN THER TAR, V16, P1027, DOI 10.1517/14728222.2012.712961
   Pratt S, 1999, J Am Optom Assoc, V70, P39
   Schmidl D, 2015, ACTA OPHTHALMOL, V93, P105, DOI 10.1111/aos.12650
   SEDDON JM, 1994, JAMA-J AM MED ASSOC, V272, P1413, DOI 10.1001/jama.272.18.1413
   SNODDERLY DM, 1995, AM J CLIN NUTR, V62, P1448
   Tan JSL, 2008, OPHTHALMOLOGY, V115, P334, DOI 10.1016/j.ophtha.2007.03.083
NR 16
TC 0
Z9 1
U1 1
U2 2
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 1556-9527
EI 1556-9535
J9 CUTAN OCUL TOXICOL
JI Cutan. Ocul. Toxicol.
PY 2018
VL 37
IS 3
BP 207
EP 209
DI 10.1080/15569527.2017.1409754
PG 3
WC Ophthalmology; Toxicology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology; Toxicology
GA GM4RK
UT WOS:000438110100001
PM 29171298
DA 2022-11-30
ER

PT J
AU Shi, JNV
   Wielaard, J
   Smith, RT
   Sajda, P
AF Shi, Jianing V.
   Wielaard, Jim
   Smith, R. Theodore
   Sajda, Paul
TI Decoding simulated neurodynamics predicts the perceptual consequences of
   age-related macular degeneration
SO JOURNAL OF VISION
LA English
DT Article
DE computational modeling; low vision; visual cortex
ID LATERAL GENICULATE-NUCLEUS; PRIMARY VISUAL-CORTEX; BLIND SPOT;
   ORIENTATION SELECTIVITY; STRIATE CORTEX; GEOGRAPHIC ATROPHY; FACE
   RECOGNITION; DECISION-MAKING; GANGLION-CELLS; HUMAN BRAIN
AB Age-related macular degeneration (AMD) is the major cause of blindness in the developed world. Though substantial work has been done to characterize the disease, it is difficult to predict how the state of an individual's retina will ultimately affect their high-level perceptual function. In this paper, we describe an approach that couples retinal imaging with computational neural modeling of early visual processing to generate quantitative predictions of an individual's visual perception. Using a patient population with mild to moderate AMD, we show that we are able to accurately predict subject-specific psychometric performance by decoding simulated neurodynamics that are a function of scotomas derived from an individual's fundus image. On the population level, we find that our approach maps the disease on the retina to a representation that is a substantially better predictor of high-level perceptual performance than traditional clinical metrics such as drusen density and coverage. In summary, our work identifies possible new metrics for evaluating the efficacy of treatments for AMD at the level of the expected changes in high-level visual perception and, in general, typifies how computational neural models can be used as a framework to characterize the perceptual consequences of early visual pathologies.
C1 [Shi, Jianing V.; Smith, R. Theodore; Sajda, Paul] Columbia Univ, Dept Biomed Engn, New York, NY 10027 USA.
   [Wielaard, Jim; Smith, R. Theodore] Columbia Univ, Dept Ophthalmol, New York, NY 10027 USA.
C3 Columbia University; Columbia University
RP Sajda, P (通讯作者)，Columbia Univ, Dept Biomed Engn, 351 Engn Terrace,MC8904, New York, NY 10027 USA.
EM psajda@columbia.edu
OI smith, theodore/0000-0002-1693-943X
FU NGA NURI [HM1582-07-1-2002]; NIH [R01EY015520]; New York Community
   Trust; NATIONAL EYE INSTITUTE [R01EY015520] Funding Source: NIH RePORTER
FX This work was supported by NGA NURI Grant HM1582-07-1-2002, NIH Grant
   R01EY015520, and the New York Community Trust. We thank Marios
   Philiastides for assistance in the statistical analysis and Mihai
   Busuioc for assistance with the psychophysics experiments.
CR Beausencourt E, 2000, OPHTHALMOLOGY, V107, P375, DOI 10.1016/S0161-6420(99)00056-1
   Benardete EA, 1999, VISUAL NEUROSCI, V16, P355, DOI 10.1017/S0952523899162151
   BLASDEL GG, 1983, J NEUROSCI, V3, P1389
   BLASDEL GG, 1992, J NEUROSCI, V12, P3115, DOI 10.1523/JNEUROSCI.12-08-03115.1992
   BRESSLER NM, 1988, SURV OPHTHALMOL, V32, P375, DOI 10.1016/0039-6257(88)90052-5
   BRESSLER NM, 1988, RETINA-J RET VIT DIS, V8, P109, DOI 10.1097/00006982-198808020-00005
   BRESSLER SB, 1990, ARCH OPHTHALMOL-CHIC, V108, P1442, DOI 10.1001/archopht.1990.01070120090035
   Brindlay G., 1969, J PHYSL, V1968, P479
   Britten K., 1992, J NEUROSCI, V12, P1157
   BULLIMORE MA, 1991, INVEST OPHTH VIS SCI, V32, P2020
   Chen YZ, 2006, NAT NEUROSCI, V9, P1412, DOI 10.1038/nn1792
   CONNOLLY M, 1984, J COMP NEUROL, V226, P544, DOI 10.1002/cne.902260408
   CRONER LJ, 1995, VISION RES, V35, P7, DOI 10.1016/0042-6989(94)E0066-T
   Dakin SC, 2002, CURR BIOL, V12, pR476, DOI 10.1016/S0960-9822(02)00960-0
   Delori FC, 2000, INVEST OPHTH VIS SCI, V41, P496
   DERRINGTON AM, 1984, J PHYSIOL-LONDON, V357, P219, DOI 10.1113/jphysiol.1984.sp015498
   DiCarlo JJ, 2007, TRENDS COGN SCI, V11, P333, DOI 10.1016/j.tics.2007.06.010
   Elsner AE, 1996, VISION RES, V36, P191, DOI 10.1016/0042-6989(95)00100-E
   FREUND TF, 1989, J COMP NEUROL, V289, P315, DOI 10.1002/cne.902890211
   Goffaux V, 2006, J EXP PSYCHOL HUMAN, V32, P1023, DOI 10.1037/0096-1523.32.4.1023
   Graf ABA, 2011, NAT NEUROSCI, V14, P239, DOI 10.1038/nn.2733
   Green DM., 1966, SIGNAL DETECTION THE
   Gross CG, 2002, NEUROSCIENTIST, V8, P512, DOI 10.1177/107385802237175
   HICKS TP, 1983, J PHYSIOL-LONDON, V337, P183, DOI 10.1113/jphysiol.1983.sp014619
   Hoel P. G., 1971, INTRO STAT THEORY
   Humayun MS, 2003, VISION RES, V43, P2573, DOI 10.1016/S0042-6989(03)00457-7
   KAWABATA N, 1982, PERCEPT MOTOR SKILL, V55, P95, DOI 10.2466/pms.1982.55.1.95
   KAWABATA N, 1984, PERCEPT PSYCHOPHYS, V36, P151, DOI 10.3758/BF03202675
   KIRKPATRICK JNP, 1995, EYE, V9, P48, DOI 10.1038/eye.1995.7
   Klaver CCW, 1998, ARCH OPHTHALMOL-CHIC, V116, P653, DOI 10.1001/archopht.116.5.653
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   Malpeli JG, 1996, J COMP NEUROL, V375, P363
   Mata ML, 2005, J NEUROPHYSIOL, V93, P919, DOI 10.1152/jn.00668.2004
   McClure ME, 2000, BRIT J OPHTHALMOL, V84, P244, DOI 10.1136/bjo.84.3.244
   McLaughlin D, 2000, P NATL ACAD SCI USA, V97, P8087, DOI 10.1073/pnas.110135097
   McManus JNJ, 2008, J NEUROPHYSIOL, V99, P2086, DOI 10.1152/jn.00871.2007
   MURAKAMI I, 1995, VISION RES, V35, P1041, DOI 10.1016/0042-6989(94)00201-V
   Palmer C, 2007, J NEUROSCI, V27, P8122, DOI 10.1523/JNEUROSCI.1940-07.2007
   Philiastides MG, 2006, J NEUROSCI, V26, P8965, DOI 10.1523/JNEUROSCI.1655-06.2006
   Philiastides MG, 2006, CEREB CORTEX, V16, P509, DOI 10.1093/cercor/bhi130
   QUICK RF, 1974, KYBERNETIK, V16, P65, DOI 10.1007/BF00271628
   Quiroga RQ, 2007, J NEUROPHYSIOL, V98, P1997, DOI 10.1152/jn.00125.2007
   Quiroga RQ, 2005, NATURE, V435, P1102, DOI 10.1038/nature03687
   RAMACHANDRAN VS, 1992, SCI AM, V266, P86, DOI 10.1038/scientificamerican0592-86
   Remky A, 2005, BRIT J OPHTHALMOL, V89, P464, DOI 10.1136/bjo.2004.050260
   Ringach DL, 2002, J NEUROSCI, V22, P5639
   SHAPLEY R, 1990, ANNU REV PSYCHOL, V41, P635, DOI 10.1146/annurev.ps.41.020190.003223
   Shi JN, 2010, J MACH LEARN RES, V11, P713
   SMIDDY WE, 1984, OPHTHALMOLOGY, V91, P271
   Smith RT, 2006, INVEST OPHTH VIS SCI, V47, P5495, DOI 10.1167/iovs.05-1318
   Smith RT, 2009, AM J OPHTHALMOL, V148, P733, DOI 10.1016/j.ajo.2009.06.028
   Smith RT, 2005, ARCH OPHTHALMOL-CHIC, V123, P200, DOI 10.1001/archopht.123.2.200
   SPEAR P, 1984, J NEUROPHYSIOL, V72, P402
   Sunness JS, 1999, OPHTHALMOLOGY, V106, P910, DOI 10.1016/S0161-6420(99)00509-6
   Sunness JS, 1999, INVEST OPHTH VIS SCI, V40, P1761
   Tripathy SP, 1996, VISION RES, V36, P1585, DOI 10.1016/0042-6989(95)02200-7
   TRIPATHY SP, 1994, VISION RES, V34, P1127, DOI 10.1016/0042-6989(94)90295-X
   Troje NF, 1996, VISION RES, V36, P1761, DOI 10.1016/0042-6989(95)00230-8
   vonRuckmann A, 1997, INVEST OPHTH VIS SCI, V38, P478
   Wielaard J, 2006, J NEUROPHYSIOL, V96, P2739, DOI 10.1152/jn.00346.2006
   Wielaard J, 2006, CEREB CORTEX, V16, P1531, DOI 10.1093/cercor/bhj090
   Wormald R., 2003, COCHRANE REV, V2, P3
   Zrenner E, 2002, SCIENCE, V295, P1022, DOI 10.1126/science.1067996
   Zur D, 2003, VISION RES, V43, P971, DOI 10.1016/S0042-6989(03)00038-5
NR 65
TC 1
Z9 1
U1 0
U2 3
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 1534-7362
J9 J VISION
JI J. Vision
PY 2011
VL 11
IS 14
AR 4
DI 10.1167/11.14.4
PG 19
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 869YC
UT WOS:000298635300004
PM 22144563
OA Green Accepted, Green Submitted, gold
DA 2022-11-30
ER

PT J
AU Chen, HY
   Liu, K
   Chen, LJ
   Hou, P
   Chen, WQ
   Pang, CP
AF Chen, Haoyu
   Liu, Ke
   Chen, Li Jia
   Hou, Ping
   Chen, Weiqi
   Pang, Chi Pui
TI Genetic associations in polypoidal choroidal vasculopathy: A systematic
   review and meta-analysis
SO MOLECULAR VISION
LA English
DT Review
ID COMPLEMENT FACTOR-H; AGE-RELATED MACULOPATHY; MACULAR DEGENERATION;
   LOC387715/HTRA1 VARIANTS; PHOTODYNAMIC THERAPY; JAPANESE POPULATION;
   VISUAL PROGNOSIS; LESION SIZE; POLYMORPHISMS; SUSCEPTIBILITY
AB Purpose: To investigate the genetic associations of polypoidal choroidal vasculopathy (PCV), the genetic difference between PCV and age-related macular degeneration (AMD), and the genotype-phenotype correlation of PCV.
   Methods: A systematic review and meta-analysis were performed. Published articles about genetic associations of PCV identified from a literature search were reviewed. The following data from individual studies were extracted and analyzed: 1) comparison of genetic polymorphisms between PCV and controls; 2) comparison of genetic polymorphisms between PCV and AMD; and 3) comparison of phenotypes between different genotype groups.
   Results: A total of 33 articles fulfilled the inclusion criteria. With meta-analyses, variants in four genes were found to be significantly associated with PCV: LOC387715 rs10490924 (n=9, allelic odds ratio [ OR]=2.27, p<0.00001), HTRA1 rs11200638 (n=4, OR=2.72, p<0.00001), CFH rs1061170 (n=4, OR=1.72, p<0.00001), CFH rs800292 (n=5, OR=2.10, p<0.00001), and C2 rs547154 (n=3, OR=0.56, p=0.01). LOC387715 rs10490924 was the only variant showing a significant difference between PCV and wet AMD (n=5, OR=0.66, p<0.00001). The risk genotypes of rs10490924 were associated with larger lesion size, greater chance of vitreous hemorrhage, and worse therapeutic response in PCV.
   Conclusions: LOC387715 rs10490924 was associated with PCV and its clinical manifestations, and showed a discrepant distribution between PCV and AMD. Variants in HTRA1, CFH, and C2 were also associated with PCV.
C1 [Chen, Haoyu; Hou, Ping; Chen, Weiqi; Pang, Chi Pui] Shantou Univ, Joint Shantou Int Eye Ctr, Shantou 515041, Guangdong, Peoples R China.
   [Chen, Haoyu; Hou, Ping; Chen, Weiqi; Pang, Chi Pui] Chinese Univ Hong Kong, Shantou 515041, Guangdong, Peoples R China.
   [Chen, Haoyu; Liu, Ke; Chen, Li Jia; Pang, Chi Pui] Chinese Univ Hong Kong, Dept Ophthalmol & Visual Sci, Hong Kong, Hong Kong, Peoples R China.
C3 Shantou University; Chinese University of Hong Kong
RP Chen, HY (通讯作者)，Shantou Univ, Joint Shantou Int Eye Ctr, N Dongxia Rd, Shantou 515041, Guangdong, Peoples R China.
EM drchenhaoyu@gmail.com
RI Chu, Kai On/E-2325-2016; Chen, Haoyu/A-7432-2013; Chen, Li
   Jia/I-5078-2014; Pang, Chi P/I-5388-2014
OI Chen, Haoyu/0000-0003-0676-4610; Chen, Li Jia/0000-0003-3500-5840; 
FU National Nature Science Foundation of China [30901646, 81170853];
   Guangdong Science and Technology Project [2011B031300013]; Guangdong
   Medical Research Foundation [B2010230]; Science and Technology Project
   of Shantou City, China [2009-70]
FX This study was supported by the National Nature Science Foundation of
   China (30901646 and 81170853), Guangdong Science and Technology Project
   (2011B031300013), Guangdong Medical Research Foundation (B2010230), and
   Science and Technology Project of Shantou City, China (2009-70).
CR Bessho H, 2011, MOL VIS, V17, P977
   Bessho H, 2009, MOL VIS, V15, P1107
   Dewan A, 2006, SCIENCE, V314, P989, DOI 10.1126/science.1133807
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Ennis S, 2008, LANCET, V372, P1828, DOI 10.1016/S0140-6736(08)61348-3
   Fuse N, 2011, AM J OPHTHALMOL, V151, P550, DOI 10.1016/j.ajo.2010.08.048
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   Goto Asako, 2009, J Ocul Biol Dis Infor, V2, P164
   Gotoh N, 2004, AM J OPHTHALMOL, V138, P567, DOI 10.1016/j.ajo.2004.05.025
   Gotoh N, 2008, CLIN EXP OPHTHALMOL, V36, P437, DOI 10.1111/j.1442-9071.2008.01791.x
   Gotoh N, 2010, JPN J OPHTHALMOL, V54, P609, DOI 10.1007/s10384-010-0865-2
   Gotoh N, 2009, AM J OPHTHALMOL, V147, P1037, DOI 10.1016/j.ajo.2008.12.036
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Hayashi H, 2010, INVEST OPHTH VIS SCI, V51, P5914, DOI 10.1167/iovs.10-5554
   Jakobsdottir J, 2005, AM J HUM GENET, V77, P389, DOI 10.1086/444437
   Jones A, 2011, P NATL ACAD SCI USA, V108, P14578, DOI 10.1073/pnas.1102853108
   Kanda A, 2007, P NATL ACAD SCI USA, V104, P16227, DOI 10.1073/pnas.0703933104
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Kondo N, 2008, INVEST OPHTH VIS SCI, V49, P1101, DOI 10.1167/iovs.07-1145
   Kondo N, 2007, AM J OPHTHALMOL, V144, P608, DOI 10.1016/j.ajo.2007.06.003
   Kondo N, 2009, MOL VIS, V15, P1819
   Kondo N, 2009, OPHTHALMOLOGY, V116, P304, DOI 10.1016/j.ophtha.2008.11.011
   Laude A, 2010, PROG RETIN EYE RES, V29, P19, DOI 10.1016/j.preteyeres.2009.10.001
   Lee KY, 2008, INVEST OPHTH VIS SCI, V49, P2613, DOI 10.1167/iovs.07-0860
   Li M, 2010, MOL VIS, V16, P231
   Lima LH, 2011, OPHTHALMIC GENET, V32, P80, DOI 10.3109/13816810.2010.544362
   Lima LH, 2010, OPHTHALMOLOGY, V117, P1567, DOI 10.1016/j.ophtha.2009.12.018
   Maller JB, 2007, NAT GENET, V39, P1200, DOI 10.1038/ng2131
   Nakanishi H, 2010, INVEST OPHTH VIS SCI, V51, P6183, DOI 10.1167/iovs.09-4948
   Nakata I, 2011, OPHTHALMOLOGY, V118, P1408, DOI 10.1016/j.ophtha.2010.12.011
   Nakata I, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019108
   Park DH, 2012, RETINA-J RET VIT DIS, V32, P299, DOI 10.1097/IAE.0b013e318225290f
   Park DH, 2012, JPN J OPHTHALMOL, V56, P60, DOI 10.1007/s10384-011-0089-0
   Rivera A, 2005, HUM MOL GENET, V14, P3227, DOI 10.1093/hmg/ddi353
   Sakurada Y, 2008, AM J OPHTHALMOL, V145, P1058, DOI 10.1016/j.ajo.2008.02.007
   Sakurada Y, 2011, OPHTHALMOLOGY, V118, P1402, DOI 10.1016/j.ophtha.2010.12.010
   Sakurada Y, 2010, RETINA-J RET VIT DIS, V30, P1616, DOI 10.1097/IAE.0b013e3181e587e3
   Sakurada Y, 2009, RETINA-J RET VIT DIS, V29, P1522, DOI 10.1097/IAE.0b013e3181af0d72
   Sng CCA, 2011, OPHTHALMIC RES, V45, P191, DOI 10.1159/000321387
   SPAIDE RF, 1995, RETINA-J RET VIT DIS, V15, P100, DOI 10.1097/00006982-199515020-00003
   Tanaka K, 2011, INVEST OPHTH VIS SCI, V52, P7441, DOI 10.1167/iovs.11-7546
   Tsujikawa A, 2011, AM J OPHTHALMOL, V151, P961, DOI 10.1016/j.ajo.2011.01.002
   Wu KF, 2012, CURR EYE RES, V37, P68, DOI 10.3109/02713683.2011.618289
   Yamashiro K, 2011, INVEST OPHTH VIS SCI, V52, P8780, DOI 10.1167/iovs.11-8205
   Yang ZL, 2006, SCIENCE, V314, P992, DOI 10.1126/science.1133811
   YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001
   Zareparsi S, 2005, AM J HUM GENET, V77, P149, DOI 10.1086/431426
   Zhang XZ, 2011, INVEST OPHTH VIS SCI, V52, P8063, DOI 10.1167/iovs.11-7820
NR 49
TC 47
Z9 52
U1 0
U2 6
PU MOLECULAR VISION
PI ATLANTA
PA C/O JEFF BOATRIGHT, LAB B, 5500 EMORY EYE CENTER, 1327 CLIFTON RD, N E,
   ATLANTA, GA 30322 USA
SN 1090-0535
J9 MOL VIS
JI Mol. Vis.
PD APR 4
PY 2012
VL 18
IS 87-88
BP 816
EP 829
PG 14
WC Biochemistry & Molecular Biology; Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Ophthalmology
GA 947KE
UT WOS:000304428100001
PM 22509112
DA 2022-11-30
ER

PT J
AU Karadimas, P
   Bouzas, EA
AF Karadimas, P
   Bouzas, EA
TI Fundus autofluorescence imaging in serous and drusenoid pigment
   epithelial detachments associated with age-related macular degeneration
SO AMERICAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID OPHTHALMOSCOPE
AB PURPOSE: To investigate the fundus autofluorescence (FAF) imaging findings in patients with serous and drusenoid pigment epithelial detachment (PED) associated with age-related macular degeneration (AMD).
   DESIGN: Observational case series.
   METHODS: Fourteen eyes of 13 consecutive patients with serous (n = 10) and drusenoid (n = 4) PED were prospectively included.
   RESULTS: In all cases of serous vascularized (n = 7) and avascular (n = 3) PED, the FAF signal was increased, corresponding to the area of detachment. In drusenoid PED, the FAF was either increased or decreased. The decreased signal was recorded in cases associated with pigmented clumping.
   CONCLUSIONS: These findings are useful for a more detailed phenotyping of patients with PED associated with AMD. FAF may derive not only from lipofuscin, but also from other sources, such as sub retinal pigment epithelium fluid.
C1 Henry Dunant Hosp, Dept Ophthalmol 1, Med Retina Unit, Athens 11526, Greece.
C3 Henry Dunant Hospital
RP Karadimas, P (通讯作者)，Henry Dunant Hosp, Dept Ophthalmol 1, Med Retina Unit, 107 Mesog Ave, Athens 11526, Greece.
EM t_karadimas@yahoo.com
CR DELORI FC, 1995, INVEST OPHTH VIS SCI, V36, P718
   GASS JDM, 1997, STEREOSCOPIC ATLAS M, P82
   Lois N, 2002, AM J OPHTHALMOL, V133, P341, DOI 10.1016/S0002-9394(01)01404-0
   Pauleikhoff D, 2002, GRAEF ARCH CLIN EXP, V240, P533, DOI 10.1007/s00417-002-0505-8
   Scholl HPN, 2004, INVEST OPHTH VIS SCI, V45, P574, DOI 10.1167/iovs.03-0495
   VONRUCKMANN A, 1995, BRIT J OPHTHALMOL, V79, P407, DOI 10.1136/bjo.79.5.407
   vonRuckmann A, 1997, INVEST OPHTH VIS SCI, V38, P478
NR 7
TC 21
Z9 27
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0002-9394
J9 AM J OPHTHALMOL
JI Am. J. Ophthalmol.
PD DEC
PY 2005
VL 140
IS 6
BP 1163
EP 1165
DI 10.1016/j.ajo.2005.07.037
PG 3
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 000QA
UT WOS:000234475900043
PM 16376680
DA 2022-11-30
ER

PT J
AU Klein, R
   Myers, CE
   Lee, KE
   Gangnon, RE
   Sivakumaran, TA
   Iyengar, SK
   Klein, BEK
AF Klein, Ronald
   Myers, Chelsea E.
   Lee, Kristine E.
   Gangnon, Ronald E.
   Sivakumaran, Theru A.
   Iyengar, Sudha K.
   Klein, Barbara E. K.
TI Small Drusen and Age-Related Macular Degeneration: The Beaver Dam Eye
   Study
SO JOURNAL OF CLINICAL MEDICINE
LA English
DT Article
DE age-related macular degeneration; epidemiology; genetic risk; incidence;
   retinal drusen; risk factors; size and area
ID VISUAL-ACUITY; 5-YEAR INCIDENCE; NATURAL-HISTORY; SEVERITY SCALE;
   MACULOPATHY; PROGRESSION; POPULATION; PERIOD; CLASSIFICATION; PREVALENCE
AB We tested the hypothesis that large areas of small hard drusen (diameter <63 mu m) and intermediate drusen (diameter 63-124 mu m) are associated with the incidence of age-related macular degeneration (AMD). Eyes of 3344 older adults with at least two consecutive visits spaced five years apart over a 20-year period were included. A 6-level severity scale, including no drusen, four levels of increasing area (from minimal (<2596 mu m(2) to large (>9086 mu m(2))) of only small hard drusen, and intermediate drusen, was used. The five-year incidence of AMD was 3% in eyes at the start of the interval with no, minimal, small, and moderate areas of only small drusen and 5% and 25% for eyes with large area of only small drusen and intermediate drusen, respectively. Compared to eyes with a moderate area of small drusen, the odds ratio (OR) of developing AMD in eyes with a large area of only small drusen was 1.8 (p < 0.001). Compared to eyes with large area of only small drusen, eyes with intermediate drusen had an OR of 5.5 (p < 0.001) of developing AMD. Our results are consistent with our hypothesis that large areas of only small drusen are associated with the incidence of AMD.
C1 [Klein, Ronald; Myers, Chelsea E.; Lee, Kristine E.; Klein, Barbara E. K.] Univ Wisconsin, Sch Med & Publ Hlth, Dept Ophthalmol & Visual Sci, Madison, WI 53726 USA.
   [Gangnon, Ronald E.] Univ Wisconsin, Sch Med & Publ Hlth, Dept Biostat & Med Informat, Madison, WI 53726 USA.
   [Gangnon, Ronald E.] Univ Wisconsin, Sch Med & Publ Hlth, Dept Populat Hlth Sci, Madison, WI 53726 USA.
   [Sivakumaran, Theru A.; Iyengar, Sudha K.] Case Western Reserve Univ, Dept Epidemiol & Biostat, Cleveland, OH 44106 USA.
   [Sivakumaran, Theru A.] Univ Kentucky, Coll Med, Dept Pathol & Lab Med, Lexington, KY 40536 USA.
C3 University of Wisconsin System; University of Wisconsin Madison;
   University of Wisconsin System; University of Wisconsin Madison;
   University of Wisconsin System; University of Wisconsin Madison; Case
   Western Reserve University; University of Kentucky
RP Klein, R (通讯作者)，Univ Wisconsin, Sch Med & Publ Hlth, Dept Ophthalmol & Visual Sci, Madison, WI 53726 USA.
EM kleinr@epi.ophth.wisc.edu; myers@epi.ophth.wisc.edu;
   klee@epi.ophth.wisc.edu; ronald@biostat.wisc.edu; sth248@uky.edu;
   ski@case.edu; kleinb@epi.ophth.wisc.edu
RI /S-1190-2019
OI /0000-0001-7488-250X
FU National Institutes of Health [EY06594]; Research to Prevent Blindness,
   New York, NY; NATIONAL EYE INSTITUTE [U10EY006594] Funding Source: NIH
   RePORTER
FX This study was supported by National Institutes of Health grant EY06594
   (Barbara E. K. Klein and Ronald Klein) and, in part, by Research to
   Prevent Blindness, New York, NY. No funds were received for covering the
   costs to publish in open access. The funding sponsors had no role in the
   design of the study; in the collection, analyses, or interpretation of
   data; in the writing of the manuscript, and in the decision to publish
   results. The content is solely the responsibility of the authors and
   does not necessarily reflect the official views of the National Eye
   Institute or the National Institutes of Health.
CR [Anonymous], [No title captured]
   Ardeljan D, 2013, PROG RETIN EYE RES, V37, P68, DOI 10.1016/j.preteyeres.2013.07.003
   Buitendijk GHS, 2013, OPHTHALMOLOGY, V120, P2644, DOI 10.1016/j.ophtha.2013.07.053
   Davis MD, 2005, ARCH OPHTHALMOL-CHIC, V123, P1484
   Dietzel M, 2014, GRAEF ARCH CLIN EXP, V252, P1273, DOI 10.1007/s00417-014-2690-7
   Ferris FL, 2005, ARCH OPHTHALMOL-CHIC, V123, P1570
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   GASS JDM, 1973, ARCH OPHTHALMOL-CHIC, V90, P206
   GRAGOUDAS ES, 1976, ARCH OPHTHALMOL-CHIC, V94, P755, DOI 10.1001/archopht.1976.03910030365003
   Klaver CCW, 2001, INVEST OPHTH VIS SCI, V42, P2237
   Klein BE, 2010, BEAVER DAM EYE STUDY
   Klein ML, 2010, OPHTHALMOLOGY, V117, P1554, DOI 10.1016/j.ophtha.2009.12.012
   Klein R, 1997, OPHTHALMOLOGY, V104, P7, DOI 10.1016/S0161-6420(97)30368-6
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Klein R, 2001, OPHTHALMOLOGY, V108, P1757, DOI 10.1016/S0161-6420(01)00769-2
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1310
   Klein R, 1996, OPHTHALMOLOGY, V103, P1169, DOI 10.1016/S0161-6420(96)30526-5
   Klein R, 2002, OPHTHALMOLOGY, V109, P1767, DOI 10.1016/S0161-6420(02)01146-6
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   Klein R, 1995, BEAVER DAM EYE STUDY
   KLEIN R, 1991, BEAVER DAM EYE STUDY
   Klein R, 1999, BEAVER DAM EYE STUDY
   Klein R, 2007, OPHTHALMOLOGY, V114, P253, DOI 10.1016/j.ophtha.2006.10.040
   Klein R, 2006, AM J OPHTHALMOL, V142, P539, DOI 10.1016/j.ajo.2006.06.015
   Klein R, 2014, OPHTHAL EPIDEMIOL, V21, P14, DOI 10.3109/09286586.2013.867512
   Klein R, 2013, OPHTHALMOLOGY, V120, P1210, DOI 10.1016/j.ophtha.2012.11.041
   Klein R, 2013, JAMA OPHTHALMOL, V131, P383, DOI 10.1001/jamaophthalmol.2013.713
   LINTON KLP, 1991, AM J EPIDEMIOL, V134, P1438, DOI 10.1093/oxfordjournals.aje.a116049
   Mitchell P, 2002, OPHTHALMOLOGY, V109, P1092, DOI 10.1016/S0161-6420(02)01055-2
   Munch IC, 2010, INVEST OPHTH VIS SCI, V51, P2317, DOI 10.1167/iovs.09-4482
   Rudolf M, 2008, INVEST OPHTH VIS SCI, V49, P1200, DOI 10.1167/iovs.07-1466
   Rudolf M, 2014, BRIT J OPHTHALMOL, V98, P698, DOI 10.1136/bjophthalmol-2013-304226
   SARKS SH, 1980, T OPHTHAL SOC UK, V100, P414
   Seddon JM, 2006, OPHTHALMOLOGY, V113, P260, DOI 10.1016/j.ophtha.2005.11.001
   Seddon JM, 2013, INVEST OPHTH VIS SCI, V54, DOI 10.1167/iovs.13-13234
   VANDERSCHAFT TL, 1992, OPHTHALMOLOGY, V99, P278
   Yehoshua Z, 2011, OPHTHALMOLOGY, V118, P2434, DOI 10.1016/j.ophtha.2011.05.008
NR 37
TC 11
Z9 11
U1 0
U2 2
PU MDPI AG
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
SN 2077-0383
J9 J CLIN MED
JI J. Clin. Med.
PD MAR
PY 2015
VL 4
IS 3
BP 425
EP 440
DI 10.3390/jcm4030425
PG 16
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA CT9KT
UT WOS:000363136600005
PM 25905023
OA Green Accepted, Green Published, gold
DA 2022-11-30
ER

PT J
AU Gopinath, B
   Liew, G
   Burlutsky, G
   Mitchell, P
AF Gopinath, Bamini
   Liew, Gerald
   Burlutsky, George
   Mitchell, Paul
TI Physical Activity and the 15-Year Incidence of Age-Related Macular
   Degeneration
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
DE age-related macular degeneration; physical activity; Blue Mountains Eye
   Study; incidence
ID LONG-TERM INCIDENCE; CARDIORESPIRATORY FITNESS; 10-YEAR INCIDENCE;
   BLOOD-PRESSURE; RISK-FACTORS; ASSOCIATION; MACULOPATHY; PREVALENCE;
   QUESTIONNAIRE; CONSUMPTION
AB PURPOSE. There is uncertainty in the published literature as to whether physical activity should be advocated for age-related macular degeneration (AMD) prevention. We aimed to assess prospectively the association between physical activity and the 15-year incidence of AMD in older adults.
   METHODS. We assessed AMD from retinal photographs. Participants provided details of walking exercise and the performance of moderate or vigorous activities, which were used to calculate metabolic equivalents (METs).
   RESULTS. After adjusting for age, adults aged >= 75 years in the highest tertile (the most physically active) compared to those in the lowest tertile (least physically active) were 79% less likely to have incident late AMD over the 15 years (odds ratio [OR], 0.21; 95% confidence intervals [CI], 0.05-0.95). However, after further adjusting for sex, body mass index, smoking, fish consumption, and white cell count, this association was no longer statistically significant (OR, 0.26; 95% CI, 0.06-1.28). Significant associations were not found in those aged < 75 or with the 15-year cumulative incidence of early AMD.
   CONCLUSIONS. Physical activity did not influence the risk of AMD over 15 years in older adults, independent of diet, smoking, white cell count, and body mass index.
C1 Univ Sydney, Dept Ophthalmol, Ctr Vis Res, Sydney, NSW 2006, Australia.
   Univ Sydney, Westmead Millennium Inst, Sydney, NSW 2006, Australia.
C3 University of Sydney; University of Sydney; Westmead Institute for
   Medical Research
RP Gopinath, B (通讯作者)，Westmead Millennium Inst, Ctr Vis Res, Westmead, NSW 2145, Australia.
EM bamini.gopinath@sydney.edu.au
RI Mitchell, Paul/P-1498-2014; Liew, Gerald/AAB-6870-2022; Gopinath,
   Bamini/K-4286-2019
OI Gopinath, Bamini/0000-0003-3573-359X
FU Australian National Health and Medical Research Council [974159, 991407,
   211069, 262120]; Westmead Millennium Institute; Macular Disease
   Foundation Australia; Blackmores Dr Paul Beaumont Fellowship
FX Supported by Australian National Health and Medical Research Council
   Grants 974159, 991407, 211069, and 262120 (Blue Mountain Eye Study), and
   Westmead Millennium Institute (Blue Mountain Eye Study), and by a
   Macular Disease Foundation Australia and Blackmores Dr Paul Beaumont
   Fellowship (BG). The authors alone are responsible for the content and
   writing of the paper.
CR [Anonymous], 2012, OPHTHALMOLOGY, V26, P26
   Astrup A, 2001, Public Health Nutr, V4, P499
   Attebo K, 1996, OPHTHALMOLOGY, V103, P357
   Australian Institute of Health National Heart Foundation & Risk Factor Prevalence Study Management Committee, 1980, RISK FACT PREV STUD
   Chew EY, 2013, JAMA-J AM MED ASSOC, V309, P2005, DOI 10.1001/jama.2013.4997
   Christen WG, 2009, ARCH INTERN MED, V169, P335, DOI 10.1001/archinternmed.2008.574
   Clemons Traci E, 2005, Ophthalmology, V112, P533
   Craig CL, 2003, MED SCI SPORT EXER, V35, P1381, DOI 10.1249/01.MSS.0000078924.61453.FB
   Gopinath B, 2014, BRIT J NUTR, V111, P1673, DOI 10.1017/S000711451300408X
   Gopinath B, 2013, AM J CLIN NUTR, V98, P129, DOI 10.3945/ajcn.112.057091
   Guymer RH, 2006, MED J AUSTRALIA, V184, P455, DOI 10.5694/j.1326-5377.2006.tb00318.x
   Johnson EJ, 2005, NUTR REV, V63, P9, DOI 10.1301/nr.2004.janr.9-15
   KLEIN BEK, 1989, INVEST OPHTH VIS SCI, V30, P304
   Knudtson MD, 2006, BRIT J OPHTHALMOL, V90, P1461, DOI 10.1136/bjo.2006.103796
   Kodama S, 2009, JAMA-J AM MED ASSOC, V301, P2024, DOI 10.1001/jama.2009.681
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   MacAuley D, 1996, J EPIDEMIOL COMMUN H, V50, P258, DOI 10.1136/jech.50.3.258
   Mares JA, 2011, ARCH OPHTHALMOL-CHIC, V129, P470, DOI 10.1001/archophthalmol.2010.314
   Michels S, 2005, OPHTHALMOLOGY, V112, P1035, DOI 10.1016/j.ophtha.2005.02.007
   MITCHELL P, 1995, OPHTHALMOLOGY, V102, P1450
   Moeller SM, 2006, ARCH OPHTHALMOL-CHIC, V124, P1151, DOI 10.1001/archopht.124.8.1151
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   SanGiovanni JP, 2008, ARCH OPHTHALMOL-CHIC, V126, P1274, DOI 10.1001/archopht.126.9.1274
   SanGiovanni JP, 2007, ARCH OPHTHALMOL-CHIC, V125, P1225, DOI 10.1001/archopht.125.9.1225
   SanGiovanni JP, 2009, AM J CLIN NUTR, V90, P1601, DOI 10.3945/ajcn.2009.27594
   Seddon JM, 2004, JAMA-J AM MED ASSOC, V291, P704, DOI 10.1001/jama.291.6.704
   Seddon JM, 2003, ARCH OPHTHALMOL-CHIC, V121, P785, DOI 10.1001/archopht.121.6.785
   Shankar A, 2007, AM J EPIDEMIOL, V165, P375, DOI 10.1093/aje/kwk022
   Smith W, 1998, ARCH OPHTHALMOL-CHIC, V116, P583, DOI 10.1001/archopht.116.5.583
   Smith W, 1998, AUST NZ J PUBL HEAL, V22, P456, DOI 10.1111/j.1467-842X.1998.tb01414.x
   Tan JSL, 2007, ARCH OPHTHALMOL-CHIC, V125, P1089, DOI 10.1001/archopht.125.8.1089
   Tan JSL, 2009, ARCH OPHTHALMOL-CHIC, V127, P656, DOI 10.1001/archophthalmol.2009.76
   Wang JJ, 2007, OPHTHALMOLOGY, V114, P92, DOI 10.1016/j.ophtha.2006.07.017
   Wang JJ, 2009, AM J EPIDEMIOL, V169, P633, DOI 10.1093/aje/kwn358
   Wei M, 1999, ANN INTERN MED, V130, P89, DOI 10.7326/0003-4819-130-2-199901190-00002
   Wells JCK, 2008, INT J OBESITY, V32, P1042, DOI 10.1038/ijo.2008.37
   Williams PT, 2009, INVEST OPHTH VIS SCI, V50, P101, DOI 10.1167/iovs.08-2165
   YANNUZZI LA, 1992, ARCH OPHTHALMOL-CHIC, V110, P1701
NR 38
TC 22
Z9 22
U1 0
U2 16
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD DEC
PY 2014
VL 55
IS 12
BP 7799
EP 7803
DI 10.1167/iovs.14-15575
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA AX9KR
UT WOS:000347222300010
PM 25389200
DA 2022-11-30
ER

PT J
AU Choi, J
   Moon, JW
   Shin, HJ
AF Choi, Jaekyung
   Moon, Jun Woong
   Shin, Hyun Jin
TI Chronic Kidney Disease, Early Age-related Macular Degeneration, and
   Peripheral Retinal Drusen
SO OPHTHALMIC EPIDEMIOLOGY
LA English
DT Article
DE Age-related macular degeneration; Peripheral retinal drusen; Chronic
   kidney disease; Epidemiology; Macula
ID COMPLEMENT FACTOR-H; RISK; ASSOCIATIONS; EYE; INFLAMMATION; MACULOPATHY;
   FOUNDATION; PHENOTYPES; GENOTYPES; GENETICS
AB Purpose: To evaluate the association between chronic kidney disease (CKD) and early age-related macular degeneration (AMD) and peripheral retinal drusen in Korean adults 50 years and older.
   Methods: This study included 3008 participants aged 50-87 years. Early AMD was assessed from retinal photographs based on modified Wisconsin AMD grading system and peripheral retinal drusen were assessed with a standardized examination. We defined CKD as estimated glomerular filtration rate of 60mL/min/1.73m(2) and below according to the Modification of Diet in Renal Disease equation. Logistic regression was used to examine the association between early AMD, peripheral retinal drusen, and CKD.
   Results: There were 88 subjects with early AMD and 42 subjects with peripheral retinal drusen. After adjusting for age, gender, body mass index, smoking status, hypertension, and diabetes mellitus, a significant association was found between CKD and peripheral retinal drusen as well as early AMD. Subjects with CKD were more likely to have early AMD (OR, 1.68; 95% CI, 1.04-2.72) and peripheral retinal drusen (OR, 2.01; 95% CI, 1.02-3.99) than those without CKD.
   Conclusions: CKD was associated with peripheral retinal drusen as well as early AMD in Korean adults 50 years and older.
C1 [Choi, Jaekyung] Konkuk Univ, Dept Family Med, Med Ctr, Sch Med, Seoul, South Korea.
   [Moon, Jun Woong; Shin, Hyun Jin] Konkuk Univ, Dept Ophthalmol, Med Ctr, Sch Med, Seoul, South Korea.
C3 Konkuk University; Konkuk University Medical Center; Konkuk University;
   Konkuk University Medical Center
RP Choi, J (通讯作者)，Konkuk Univ, Dept Family Med, Med Ctr, Sch Med, 4-12 Hwayang Dong, Seoul, South Korea.
EM cjk@kuh.ac.kr
RI Shin, Hyunjin/ABF-6057-2021
FU Konkuk University
FX This work was supported by Konkuk University in 2011. There are no
   commercial or financial relationships relevant to the results and
   conclusions of this paper for any of the authors. The funding
   organizations had no role in the design or conduct of this research.
CR Alexander JJ, 2007, J AM SOC NEPHROL, V18, P1157, DOI 10.1681/ASN.2006101125
   Alexander JJ, 2005, J AM SOC NEPHROL, V16, P52, DOI 10.1681/ASN.2004090778
   Boon CJF, 2009, MOL IMMUNOL, V46, P1573, DOI 10.1016/j.molimm.2009.02.013
   Choi JK, 2011, ARCH OPHTHALMOL-CHIC, V129, P196, DOI 10.1001/archophthalmol.2010.355
   Coleman HR, 2008, LANCET, V372, P1835, DOI 10.1016/S0140-6736(08)61759-6
   Cong RH, 2008, ANN EPIDEMIOL, V18, P647, DOI 10.1016/j.annepidem.2008.04.002
   de Cordoba SR, 2008, CLIN EXP IMMUNOL, V151, P1, DOI 10.1111/j.1365-2249.2007.03574.x
   Donoso LA, 2010, SURV OPHTHALMOL, V55, P227, DOI 10.1016/j.survophthal.2009.11.001
   Dragon-Durey MA, 2004, J AM SOC NEPHROL, V15, P787, DOI 10.1097/01.ASN.0000115702.28859.A7
   Droz I, 2008, BRIT J OPHTHALMOL, V92, P513, DOI 10.1136/bjo.2007.127811
   Freedman BI, 2007, ARCH INTERN MED, V167, P1113, DOI 10.1001/archinte.167.11.1113
   Friedman E, 2000, AM J OPHTHALMOL, V130, P658, DOI 10.1016/S0002-9394(00)00643-7
   Hallan SI, 2006, BMJ-BRIT MED J, V333, P1047, DOI 10.1136/bmj.39001.657755.BE
   Hollyfield JG, 2008, NAT MED, V14, P194, DOI 10.1038/nm1709
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Kawasaki R, 2010, OPHTHALMOLOGY, V117, P921, DOI 10.1016/j.ophtha.2009.10.007
   Klein R, 2004, AM J OPHTHALMOL, V137, P486, DOI 10.1016/j.ajo.2003.11.069
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   Klein R, 2009, ARCH OPHTHALMOL-CHIC, V127, P193, DOI 10.1001/archophthalmol.2008.551
   Laude A, 2010, PROG RETIN EYE RES, V29, P19, DOI 10.1016/j.preteyeres.2009.10.001
   Levey AS, 2003, ANN INTERN MED, V139, P137, DOI 10.7326/0003-4819-139-2-200307150-00013
   Liew G, 2008, J AM SOC NEPHROL, V19, P806, DOI 10.1681/ASN.2007080844
   Lim JI, 1998, RETINA-J RET VIT DIS, V18, P435
   Munch IC, 2010, INVEST OPHTH VIS SCI, V51, P2317, DOI 10.1167/iovs.09-4482
   Nitsch D, 2009, OPHTHAL EPIDEMIOL, V16, P181, DOI 10.1080/09286580902863064
   Postel EA, 2005, AM J OPHTHALMOL, V139, P820, DOI 10.1016/j.ajo.2004.12.029
   Ross RJ, 2007, EXPERT REV OPHTHALMO, V2, P443, DOI 10.1586/17469899.2.3.443
   Scholl HPN, 2007, MOL VIS, V13, P196
   Seddon JM, 2003, ARCH OPHTHALMOL-CHIC, V121, P785, DOI 10.1001/archopht.121.6.785
   Seddon JM, 2009, INVEST OPHTH VIS SCI, V50, P586, DOI 10.1167/iovs.08-2514
   Thompson CL, 2007, HUM MOL GENET, V16, P2135, DOI 10.1093/hmg/ddm164
   van Leeuwen R, 2003, INVEST OPHTH VIS SCI, V44, P3771, DOI 10.1167/iovs.03-0121
   Vassalotti JA, 2007, AM J KIDNEY DIS, V50, P169, DOI 10.1053/j.ajkd.2007.06.013
   World Health Organization Regional Office for the Western Pacific, 2000, AS PAC PERSP RED OB
   Yamagata K, 2007, KIDNEY INT, V71, P159, DOI 10.1038/sj.ki.5002017
   Yates JRW, 2007, NEW ENGL J MED, V357, P553, DOI 10.1056/NEJMoa072618
   Zipfel PF, 2006, MOL IMMUNOL, V43, P97, DOI 10.1016/j.molimm.2005.06.015
NR 37
TC 12
Z9 13
U1 0
U2 4
PU INFORMA HEALTHCARE
PI LONDON
PA TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND
SN 0928-6586
J9 OPHTHAL EPIDEMIOL
JI Ophthalmic Epidemiol.
PD DEC
PY 2011
VL 18
IS 6
BP 259
EP 263
DI 10.3109/09286586.2011.602509
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 843DW
UT WOS:000296653500002
PM 22053834
DA 2022-11-30
ER

PT J
AU Canter, JA
   Olson, LM
   Spencer, K
   Schnetz-Boutaud, N
   Anderson, B
   Hauser, MA
   Schmidt, S
   Postel, EA
   Agarwal, A
   Pericak-Vance, MA
   Sternberg, P
   Haines, JL
AF Canter, Jeffrey A.
   Olson, Lana M.
   Spencer, Kylee
   Schnetz-Boutaud, Nathalie
   Anderson, Brent
   Hauser, Michael A.
   Schmidt, Silke
   Postel, Eric A.
   Agarwal, Anita
   Pericak-Vance, Margaret A.
   Sternberg, Paul, Jr.
   Haines, Jonathan L.
TI Mitochondrial DNA Polymorphism A4917G Is Independently Associated with
   Age-Related Macular Degeneration
SO PLOS ONE
LA English
DT Article
AB The objective of this study was to determine if MTND2* LHON4917G (4917G), a specific non-synonymous polymorphism in the mitochondrial genome previously associated with neurodegenerative phenotypes, is associated with increased risk for age-related macular degeneration (AMD). A preliminary study of 393 individuals (293 cases and 100 controls) ascertained at Vanderbilt revealed an increased occurrence of 4917G in cases compared to controls (15.4% vs. 9.0%, p = 0.11). Since there was a significant age difference between cases and controls in this initial analysis, we extended the study by selecting Caucasian pairs matched at the exact age at examination. From the 1547 individuals in the Vanderbilt/Duke AMD population association study (including 157 in the preliminary study), we were able to match 560 (280 cases and 280 unaffected) on exact age at examination. This study population was genotyped for 4917G plus specific AMD-associated nuclear genome polymorphisms in CFH, LOC387715 and ApoE. Following adjustment for the listed nuclear genome polymorphisms, 4917G independently predicts the presence of AMD (OR = 2.16, 95% CI 1.20-3.91, p = 0.01). In conclusion, a specific mitochondrial polymorphism previously implicated in other neurodegenerative phenotypes (4917G) appears to convey risk for AMD independent of recently discovered nuclear DNA polymorphisms.
C1 [Canter, Jeffrey A.; Olson, Lana M.; Spencer, Kylee; Schnetz-Boutaud, Nathalie; Anderson, Brent; Haines, Jonathan L.] Vanderbilt Univ, Med Ctr, Dept Mol Physiol & Biophys, Ctr Human Genet Res, Nashville, TN 37203 USA.
   [Agarwal, Anita; Sternberg, Paul, Jr.] Vanderbilt Univ, Med Ctr, Dept Ophthalmol, Nashville, TN USA.
   [Hauser, Michael A.; Schmidt, Silke] Duke Univ, Med Ctr, Ctr Human Genet, Durham, NC USA.
   [Postel, Eric A.] Duke Univ, Med Ctr, Duke Eye Ctr, Durham, NC USA.
   [Pericak-Vance, Margaret A.] Univ Miami, Miller Sch Med, Inst Human Genom, Miami, FL USA.
C3 Vanderbilt University; Vanderbilt University; Duke University; Duke
   University; University of Miami
RP Canter, JA (通讯作者)，Vanderbilt Univ, Med Ctr, Dept Mol Physiol & Biophys, Ctr Human Genet Res, Nashville, TN 37203 USA.
EM jeff.canter@vanderbilt.edu
RI Haines, Jonathan/C-3374-2012
OI Haines, Jonathan/0000-0002-4351-4728
FU Vanderbilt University Medical Center Clinical Research Center [M01
   RR00095];  [EY12118]; NATIONAL CENTER FOR RESEARCH RESOURCES
   [M01RR000095] Funding Source: NIH RePORTER; NATIONAL EYE INSTITUTE
   [U10EY012118, R01EY012118] Funding Source: NIH RePORTER
FX This study was supported by grant EY12118 (to M. A. P.-V and J.L.H.) and
   by the Vanderbilt University Medical Center Clinical Research Center
   (grant M01 RR00095).
CR ANDERSON S, 1981, NATURE, V290, P457, DOI 10.1038/290457a0
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   CANN RL, 1984, GENETICS, V106, P479
   Canter JA, 2008, PHARMACOGENOMICS J, V8, P71, DOI 10.1038/sj.tpj.6500470
   *CDCP, 2004, PREV VIS IMP SEL EY
   DiMauro S, 2003, NEW ENGL J MED, V348, P2656, DOI 10.1056/NEJMra022567
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Hammond CJ, 2002, OPHTHALMOLOGY, V109, P730, DOI 10.1016/S0161-6420(01)01049-1
   Hulgan T, 2005, AIDS, V19, P1341, DOI 10.1097/01.aids.0000180786.02930.a1
   Klaver CCW, 1998, ARCH OPHTHALMOL-CHIC, V116, P1646, DOI 10.1001/archopht.116.12.1646
   Liang FQ, 2004, EXP EYE RES, V78, P1069, DOI 10.1016/j.exer.2004.02.003
   Ohia SE, 2005, MUTAT RES-FUND MOL M, V579, P22, DOI 10.1016/j.mrfmmm.2005.03.025
   Postel EA, 2005, AM J OPHTHALMOL, V139, P820, DOI 10.1016/j.ajo.2004.12.029
   Ruiz-Pesini E, 2000, AM J HUM GENET, V67, P682, DOI 10.1086/303040
   Schmidt S, 2006, AM J HUM GENET, V78, P852, DOI 10.1086/503822
   Schmidt Silke, 2002, Ophthalmic Genet, V23, P209, DOI 10.1076/opge.23.4.209.13883
   Swaroop A, 2007, HUM MOL GENET, V16, pR174, DOI 10.1093/hmg/ddm212
   Torroni A, 1996, GENETICS, V144, P1835
   van der Walt JM, 2003, AM J HUM GENET, V72, P804, DOI 10.1086/373937
   Wallace DC, 1999, GENE, V238, P211, DOI 10.1016/S0378-1119(99)00295-4
   WALLACE DC, 1994, P NATL ACAD SCI USA, V91, P8739, DOI 10.1073/pnas.91.19.8739
   Wallace DC, 1999, SCIENCE, V283, P1482, DOI 10.1126/science.283.5407.1482
NR 22
TC 79
Z9 84
U1 0
U2 2
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD MAY 7
PY 2008
VL 3
IS 5
AR e2091
DI 10.1371/journal.pone.0002091
PG 4
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA 382YX
UT WOS:000261642400014
PM 18461138
OA Green Published, Green Submitted, gold
DA 2022-11-30
ER

PT J
AU Ebrahem, Q
   Renganathan, K
   Sears, J
   Vasanji, A
   Gu, XR
   Lu, L
   Salomon, RG
   Crabb, JW
   Anand-Apte, B
AF Ebrahem, Quteba
   Renganathan, Kutralanathan
   Sears, Jonathan
   Vasanji, Amit
   Gu, Xiaorong
   Lu, Liang
   Salomon, Robert G.
   Crabb, John W.
   Anand-Apte, Bela
TI Carboxyethylpyrrole oxidative protein modifications stimulate
   neovascularization: Implications for age-related macular degeneration
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
   AMERICA
LA English
DT Article
DE oxidation
ID GLYCATION END-PRODUCTS; ENDOTHELIAL GROWTH-FACTOR; FACTOR-H
   POLYMORPHISM; OXIDIZED PHOSPHOLIPIDS; COMPLEMENT; ANGIOGENESIS;
   PATHOGENESIS; MEMBRANE; FAMILY; GENE
AB Choroidal neovascularization (CNV), the advanced stage of age-related macular degeneration (AMD), accounts for > 80% of vision loss in AMD. Carboxyethylpyrrole (CEP) protein modifications, uniquely generated from oxidation of docosahexaenoate-containing lipids, are more abundant in Bruch's membrane from AMD eyes. We tested the hypothesis that CEP protein adducts stimulate angiogenesis and possibly contribute to CNV in AMD. Human serum albumin (HSA) or acetyl-Gly-Lys-O-methyl ester (dipeptide) were chemically modified to yield CEP-modified HSA (CEP-HSA) or CEP-dipeptide. The in vivo angiogenic properties of CEP-HSA and CEP-dipeptide were demonstrated by using the chick chorioallantoic membrane and rat corneal micropocket assays. Low picomole amounts of CEP-HSA and CEP-dipeptide stimulated neovascularization. Monoclonal anti-CEP antibody neutralized limbal vessel growth stimulated by CEP-HSA, whereas anti-VEGF antibody was found to only partially neutralize vessel growth. Subretinal injections of CEP-modified mouse serum albumin exacerbated laser-induced CNV in mice. In vitro treatments of human retinal pigment epithelial cells with CEP-dipeptide or CEP-HSA did not induce increased VEGF secretion. Overall, these results suggest that CEP-induced angiogenesis utilizes VEGF-independent pathways and that anti-CEP therapeutic modalities might be of value in limiting CNV in AMD.
C1 Case Western Reserve Univ, Cleveland Clin Fdn, Cleveland Clin Lerner Coll Med, Dept Ophthalmol,Cole Eye Inst, Cleveland, OH 44195 USA.
   Case Western Reserve Univ, Cleveland Clin Fdn, Lerner Res Inst, Cleveland, OH 44195 USA.
   Case Western Reserve Univ, Dept Chem, Cleveland, OH 44195 USA.
C3 Case Western Reserve University; Cleveland Clinic Foundation; Case
   Western Reserve University; Cleveland Clinic Foundation; Case Western
   Reserve University
RP Anand-Apte, B (通讯作者)，Case Western Reserve Univ, Cleveland Clin Fdn, Cleveland Clin Lerner Coll Med, Dept Ophthalmol,Cole Eye Inst, 9500 Euclid Ave, Cleveland, OH 44195 USA.
EM anandab@ccf.org
RI renganathan, Kutralanathan/F-8580-2010; Salomon, Robert G/C-3463-2008
OI renganathan, Kutralanathan/0000-0001-9001-2934; Salomon,
   Robert/0000-0001-9456-3557
FU NATIONAL CANCER INSTITUTE [R01CA106415] Funding Source: NIH RePORTER;
   NATIONAL EYE INSTITUTE [R24EY015638, F32EY006603, R01EY006603,
   R01EY014239, R01EY016490] Funding Source: NIH RePORTER; NATIONAL
   INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM021249] Funding Source: NIH
   RePORTER; NCI NIH HHS [R01 CA106415, CA106415] Funding Source: Medline;
   NEI NIH HHS [EY06603, EY014239, R01 EY006603, R01 EY016490, EY015638,
   R24 EY015638, F32 EY006603, EY016490, R01 EY014239] Funding Source:
   Medline; NIGMS NIH HHS [R01 GM021249, GM21249] Funding Source: Medline
CR [Anonymous], 1991, Ophthalmology, V98, P757
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   Bok D, 2005, P NATL ACAD SCI USA, V102, P7053, DOI 10.1073/pnas.0502819102
   Bora PS, 2005, J IMMUNOL, V174, P491, DOI 10.4049/jimmunol.174.1.491
   Campochiaro PA, 2000, J CELL PHYSIOL, V184, P301, DOI 10.1002/1097-4652(200009)184:3<301::AID-JCP3>3.0.CO;2-H
   Crabb JW, 2002, P NATL ACAD SCI USA, V99, P14682, DOI 10.1073/pnas.222551899
   CRABB JW, 1997, AMINO ACID ANAL
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   FLIESLER SJ, 1983, PROG LIPID RES, V22, P79
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Gu XR, 2003, J BIOL CHEM, V278, P42027, DOI 10.1074/jbc.M305460200
   Gu XR, 2003, J ORG CHEM, V68, P3749, DOI 10.1021/jo026721t
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Handa JT, 1999, INVEST OPHTH VIS SCI, V40, P775
   Hirata C, 1997, BIOCHEM BIOPH RES CO, V236, P712, DOI 10.1006/bbrc.1997.7036
   Hoffmann S, 2000, INVEST OPHTH VIS SCI, V41, P2389
   Hoffmann S, 2002, GRAEF ARCH CLIN EXP, V240, P996, DOI 10.1007/s00417-002-0568-6
   Ishibashi T, 1998, ARCH OPHTHALMOL-CHIC, V116, P1629, DOI 10.1001/archopht.116.12.1629
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Kaur K, 1997, CHEM RES TOXICOL, V10, P1387, DOI 10.1021/tx970112c
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Malek G, 2005, P NATL ACAD SCI USA, V102, P11900, DOI 10.1073/pnas.0503015102
   Ng EWM, 2005, CAN J OPHTHALMOL, V40, P352, DOI 10.1016/S0008-4182(05)80078-X
   NGUYEN M, 1994, MICROVASC RES, V47, P31, DOI 10.1006/mvre.1994.1003
   Okamoto T, 2002, MICROVASC RES, V63, P186, DOI 10.1006/mvre.2001.2371
   Podrez EA, 2002, J BIOL CHEM, V277, P38517, DOI 10.1074/jbc.M205924200
   Podrez EA, 2002, J BIOL CHEM, V277, P38503, DOI 10.1074/jbc.M203318200
   Rosenfeld PJ, 2005, OPHTHALMOLOGY, V112, P1048, DOI 10.1016/j.ophtha.2005.01.043
   Seddon JM, 1996, JAMA-J AM MED ASSOC, V276, P1141, DOI 10.1001/jama.276.14.1141
   STERNBERG P, 1991, ARCH OPHTHALMOL-CHIC, V109, P1242
   STERNBERG P, 1991, ARCH OPHTHALMOL-CHIC, V109, P1232
   Subbanagounder G, 2002, VASC PHARMACOL, V38, P201, DOI 10.1016/S1537-1891(02)00170-2
   Sun MJ, 2002, J ORG CHEM, V67, P3575, DOI 10.1021/jo0105383
   Tobe T, 1998, AM J PATHOL, V153, P1641, DOI 10.1016/S0002-9440(10)65753-7
   Winkler BS, 1999, MOL VIS, V5
   WU JT, 1993, J CLIN LAB ANAL, V7, P252, DOI 10.1002/jcla.1860070503
NR 38
TC 94
Z9 98
U1 0
U2 4
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027-8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD SEP 5
PY 2006
VL 103
IS 36
BP 13480
EP 13484
DI 10.1073/pnas.0601552103
PG 5
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA 084DR
UT WOS:000240512700041
PM 16938854
OA Bronze, Green Published
DA 2022-11-30
ER

PT J
AU Giocanti-Auregan, A
   Chbat, E
   Darugar, A
   Morel, C
   Morin, B
   Conrath, J
   Devin, F
AF Giocanti-Auregan, Audrey
   Chbat, Elige
   Darugar, Adil
   Morel, Christophe
   Morin, Bruno
   Conrath, John
   Devin, Francois
TI Influence of new societal factors on neovascular age-related macular
   degeneration outcomes
SO BMC OPHTHALMOLOGY
LA English
DT Article
DE Age-related macular degeneration; Economic burden; Societal factors;
   Retinal disease
ID MACULOPATHY; DEPRESSION; PREVALENCE; EYE; RANIBIZUMAB; EDUCATION;
   ANXIETY; PAIN
AB Background: To assess the impact of unstudied societal factors for neovascular age-related macular degeneration (nAMD) on functional outcomes after anti-VEGFs.
   Methods: Charts of 94 nAMD patients treated in the Monticelli-Paradis Centre, Marseille, France, were reviewed. Phone interviews were conducted to assess societal factors, including transportation, living status, daily reading and social security scheme (SSS). Primary outcome was the impact of family support and disease burden on functional improvement in nAMD.
   Results: Between baseline and month 24 (M24), 42.4% of the variability in best-corrected visual acuity (BCVA) was explained by the cumulative effect of the following societal factors: intermittent out-patient follow-up, marital status, daily reading, transportation type, commuting time. No isolated societal factor significantly correlated with ETDRS BCVA severity at M24. A trend to correlation was observed between the EDTRS score at M24 and the SSS (P = 0.076), economic burden (P = 0.075), time between diagnosis and treatment initiation (P = 0.070). A significant correlation was found for the disease burdensome on the patient (P = 0.034) and low vision rehabilitation (P = 0.014).
   Conclusions: Societal factors could influence functional outcomes in nAMD patients treated with anti-VEGFs. They could contribute to the healing process or sustain disease progression.
C1 [Giocanti-Auregan, Audrey] Avicenne Hosp, Dept Ophthalmol, DHU Vis & Handicaps, 125 Rue Stalingrad, F-93000 Bobigny, France.
   [Giocanti-Auregan, Audrey] Univ Paris 06, Sorbonne Univ, UPMC, CNRS,INSERM,Inst Vis, 17 Rue Moreau, F-75012 Paris, France.
   [Chbat, Elige; Morel, Christophe; Morin, Bruno; Conrath, John; Devin, Francois] Ophthalmol Ctr Paradis Marseille, 433 Rue Paradis, F-13008 Marseille, France.
   [Darugar, Adil] Hop La Pitie Salpetriere, Ophthalmol, DHU Vis & Handicaps, 47-83 Bd Hop, F-75013 Paris, France.
   [Darugar, Adil] Oise Ophthalmol, 6 Ave Poteau, F-60300 Chamant, France.
C3 Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire
   Avicenne - APHP; Centre National de la Recherche Scientifique (CNRS);
   Institut National de la Sante et de la Recherche Medicale (Inserm);
   UDICE-French Research Universities; Sorbonne Universite; Universite
   Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital
   Universitaire Pitie-Salpetriere - APHP; UDICE-French Research
   Universities; Sorbonne Universite
RP Giocanti-Auregan, A (通讯作者)，Avicenne Hosp, Dept Ophthalmol, DHU Vis & Handicaps, 125 Rue Stalingrad, F-93000 Bobigny, France.; Giocanti-Auregan, A (通讯作者)，Univ Paris 06, Sorbonne Univ, UPMC, CNRS,INSERM,Inst Vis, 17 Rue Moreau, F-75012 Paris, France.
EM audreygiocanti@yahoo.fr
FU AVOPH (association for Vision in ophthalmology-Avicenne hospital)
FX AVOPH (association for Vision in ophthalmology-Avicenne hospital).
CR Anand A, 2014, CURR GENOMICS, V15, P266, DOI 10.2174/1389202915666140516204512
   Aoki A, 2016, SCI REP-UK, V6, DOI 10.1038/srep20723
   Cackett P, 2008, BRIT J OPHTHALMOL, V92, P1312, DOI 10.1136/bjo.2007.136077
   Cohen SY, 2013, GRAEF ARCH CLIN EXP, V251, P2499, DOI 10.1007/s00417-013-2338-z
   Dawson SR, 2014, BMC OPHTHALMOL, V14, DOI 10.1186/1471-2415-14-78
   Descalzi G, 2015, TRENDS NEUROSCI, V38, P237, DOI 10.1016/j.tins.2015.02.001
   Espahbodi F, 2015, IRAN J PSYCHIATRY BE, V9, DOI 10.17795/ijpbs227
   Hamano T, 2015, OPHTHAL EPIDEMIOL, V22, P308, DOI 10.3109/09286586.2015.1056537
   Hykin P, 2016, CLIN OPHTHALMOL, V10, P87, DOI 10.2147/OPTH.S92627
   Kawasaki R, 2010, OPHTHALMOLOGY, V117, P921, DOI 10.1016/j.ophtha.2009.10.007
   Keilhauer CN, 2011, OPHTHALMIC GENET, V32, P237, DOI 10.3109/13816810.2011.592177
   Kelly CSP, 2003, BRIT MED J, V326, P1458
   Kiecolt-Glaser JK, 2002, ANNU REV PSYCHOL, V53, P83, DOI 10.1146/annurev.psych.53.100901.135217
   Klaver CCW, 2001, INVEST OPHTH VIS SCI, V42, P2237
   Klein R, 1999, PROG RETIN EYE RES, V18, P371, DOI 10.1016/S1350-9462(98)00025-1
   MITCHELL P, 1995, OPHTHALMOLOGY, V102, P1450
   Ojeda B, 2017, CURR MED RES OPIN, P1
   Orban T, 2015, FASEB J, V29, P4579, DOI 10.1096/fj.15-275289
   Ruiz-Moreno JM, 2008, CURR MED RES OPIN, V24, P2103, DOI [10.1185/03007990802214300 , 10.1185/03007990802214300]
   Seddon JM, 2009, INVEST OPHTH VIS SCI, V50, P2044, DOI 10.1167/iovs.08-3064
   Senra H, 2017, AM J OPHTHALMOL, V177, P213, DOI 10.1016/j.ajo.2017.03.005
   Sharma P, 2016, J APPL PHYSIOL, V120, P114, DOI 10.1152/japplphysiol.00122.2015
   Thornton J, 2005, EYE, V19, P935, DOI 10.1038/sj.eye.6701978
   VonKorff M, 1996, BRIT J PSYCHIAT, V168, P101, DOI 10.1192/S0007125000298474
   Wang SB, 2015, BRIT J OPHTHALMOL, V99, P365, DOI 10.1136/bjophthalmol-2014-305793
   Wong T, 2008, OPHTHALMOLOGY, V115, P116, DOI 10.1016/j.ophtha.2007.03.008
   Zimmet P, 2001, NATURE, V414, P782, DOI 10.1038/414782a
NR 27
TC 1
Z9 1
U1 0
U2 4
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1471-2415
J9 BMC OPHTHALMOL
JI BMC Ophthalmol.
PD FEB 1
PY 2018
VL 18
AR 22
DI 10.1186/s12886-018-0690-9
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA FU9XA
UT WOS:000424209300001
PM 29385989
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Koss, MJ
   Hoffmann, J
   Nguyen, N
   Pfister, M
   Mischak, H
   Mullen, W
   Husi, H
   Rejdak, R
   Koch, F
   Jankowski, J
   Krueger, K
   Bertelmann, T
   Klein, J
   Schanstra, JP
   Siwy, J
AF Koss, Michael Janusz
   Hoffmann, Janosch
   Nguyen, Nauke
   Pfister, Marcel
   Mischak, Harald
   Mullen, William
   Husi, Holger
   Rejdak, Robert
   Koch, Frank
   Jankowski, Joachim
   Krueger, Katharina
   Bertelmann, Thomas
   Klein, Julie
   Schanstra, Joost P.
   Siwy, Justyna
TI Proteomics of Vitreous Humor of Patients with Exudative Age-Related
   Macular Degeneration
SO PLOS ONE
LA English
DT Article
ID AQUEOUS-HUMOR; PROTEINS; NEOVASCULARIZATION; RHEOPHERESIS; TRANSFERRIN;
   EXPRESSION; BIOMARKERS; DISCOVERY; FLUID
AB Background: There is absence of specific biomarkers and an incomplete understanding of the pathophysiology of exudative age-related macular degeneration (AMD).
   Methods and Findings: Eighty-eight vitreous samples (73 from patients with treatment naive AMD and 15 control samples from patients with idiopathic floaters) were analyzed with capillary electrophoresis coupled to mass spectrometry in this retrospective case series to define potential candidate protein markers of AMD. Nineteen proteins were found to be upregulated in vitreous of AMD patients. Most of the proteins were plasma derived and involved in biological (ion) transport, acute phase inflammatory reaction, and blood coagulation. A number of proteins have not been previously associated to AMD including alpha-1-antitrypsin, fibrinogen alpha chain and prostaglandin H2-D isomerase. Alpha-1-antitrypsin was validated in vitreous of an independent set of AMD patients using Western blot analysis. Further systems biology analysis of the data indicated that the observed proteomic changes may reflect upregulation of immune response and complement activity.
   Conclusions: Proteome analysis of vitreous samples from patients with AMD, which underwent an intravitreal combination therapy including a core vitrectomy, steroids and bevacizumab, revealed apparent AMD-specific proteomic changes. The identified AMD-associated proteins provide some insight into the pathophysiological changes associated with AMD.
C1 [Koss, Michael Janusz; Nguyen, Nauke; Koch, Frank] Goethe Univ Frankfurt, Dept Ophthalmol, D-60054 Frankfurt, Germany.
   [Koss, Michael Janusz; Pfister, Marcel] Doheny Eye Inst, Los Angeles, CA 90033 USA.
   [Koss, Michael Janusz] Heidelberg Univ, Dept Ophthalmol, Heidelberg, Germany.
   [Hoffmann, Janosch; Mischak, Harald; Klein, Julie; Schanstra, Joost P.; Siwy, Justyna] Mosa Diagnost, Hannover, Germany.
   [Mischak, Harald; Mullen, William; Husi, Holger] Univ Glasgow, BHF Glasgow Cardiovasc Res Ctr, Glasgow, Lanark, Scotland.
   [Rejdak, Robert] Lublin Univ, Dept Gen Ophthalmol, Lublin, Poland.
   [Jankowski, Joachim; Krueger, Katharina; Siwy, Justyna] Charite, Dept Nephrol Endocrinol & Transplantat Med, D-13353 Berlin, Germany.
   [Bertelmann, Thomas] Philipps Univ, Dept Ophthalmol, Marburg, Germany.
   [Schanstra, Joost P.] Inst Cardiovasc & Metab Dis, INSERM, U1048, Toulouse, France.
   [Schanstra, Joost P.] Univ Toulouse 3, F-31062 Toulouse, France.
C3 Goethe University Frankfurt; Doheny Eye Institute; Ruprecht Karls
   University Heidelberg; University of Glasgow; Free University of Berlin;
   Humboldt University of Berlin; Charite Universitatsmedizin Berlin;
   Philipps University Marburg; Institut National de la Sante et de la
   Recherche Medicale (Inserm); Universite de Toulouse; Universite Toulouse
   III - Paul Sabatier
RP Koss, MJ (通讯作者)，Goethe Univ Frankfurt, Dept Ophthalmol, D-60054 Frankfurt, Germany.
EM Michael.koss@me.com
RI Mullen, William/GWC-8078-2022; Schanstra, Joost P/X-7724-2018; Klein,
   Julie/ABE-2622-2020; Klein, Julie/M-7088-2017
OI Schanstra, Joost P/0000-0002-7471-372X; Klein,
   Julie/0000-0002-3279-0559; Klein, Julie/0000-0002-3279-0559; Mischak,
   Harald/0000-0003-0323-0306; Mullen, William/0000-0002-5685-1563; Rejdak,
   Robert/0000-0003-3321-2723; Siwy, Justyna/0000-0003-1407-2534
FU Adolf Messer Stiftung in Konigstein, Hessen, Germany
FX The study was financed in part by the Adolf Messer Stiftung in
   Konigstein, Hessen, Germany; No additional external funding was received
   for this study. http://www.adolf-messer-stiftung.de/. The funders had no
   role in study design, data collection and analysis, decision to publish,
   or preparation of the manuscript.
CR Adamis AP, 1996, ARCH OPHTHALMOL-CHIC, V114, P66, DOI 10.1001/archopht.1996.01100130062010
   Angi M, 2012, MEDIAT INFLAMM, V2012, DOI 10.1155/2012/148039
   Augustin AJ, 2007, RETINA-J RET VIT DIS, V27, P133, DOI 10.1097/IAE.0b013e3180323de7
   BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x
   Bennett KL, 2011, J PROTEOMICS, V74, P151, DOI 10.1016/j.jprot.2010.10.002
   Boehm N, 2012, BRAIN BEHAV IMMUN, V26, P96, DOI 10.1016/j.bbi.2011.07.241
   Chowdhury UR, 2011, INVEST OPHTH VIS SCI, V52, P6443, DOI 10.1167/iovs.11-7409
   Chowers I, 2006, INVEST OPHTH VIS SCI, V47, P2135, DOI 10.1167/iovs.05-1135
   Cryan LM, 2008, PROTEOM CLIN APPL, V2, P762, DOI 10.1002/prca.200780094
   Ecker SM, 2012, MOL VIS, V18, P1658
   Ecker SM, 2011, MOL VIS, V17, P2856
   Evans JR, 2001, PROG RETIN EYE RES, V20, P227, DOI 10.1016/S1350-9462(00)00023-9
   Funk M, 2009, OPHTHALMOLOGY, V116, P2393, DOI 10.1016/j.ophtha.2009.05.039
   Garcia-Ramirez M, 2007, DIABETOLOGIA, V50, P1294, DOI 10.1007/s00125-007-0627-y
   Grossniklaus HE, 2004, AM J OPHTHALMOL, V137, P496, DOI 10.1016/j.ajo.2003.09.042
   Grus FH, 2007, PROTEOM CLIN APPL, V1, P876, DOI 10.1002/prca.200700105
   Jantos-Siwy J, 2009, J PROTEOME RES, V8, P268, DOI 10.1021/pr800401m
   Kim SJ, 2006, CURR EYE RES, V31, P231, DOI 10.1080/02713680600557030
   Kim TW, 2012, J PROTEOME RES, V11, P4034, DOI 10.1021/pr300080s
   Kisic B, 2012, OXID MED CELL LONGEV, V2012, DOI 10.1155/2012/467130
   Klingel R, 2002, THER APHER, V6, P271, DOI 10.1046/j.1526-0968.2002.00418.x
   Klingel R, 2010, THER APHER DIAL, V14, P276, DOI 10.1111/j.1744-9987.2010.00807.x
   Koch FH, 2011, ARCH OPHTHALMOL-CHIC, V129, P1599, DOI 10.1001/archophthalmol.2011.341
   Koss MJ, 2010, OPHTHALMOLOGICA, V224, P72, DOI 10.1159/000235724
   Metzger J, 2013, GUT, V62, P122, DOI 10.1136/gutjnl-2012-302047
   Mischak H, 2007, PROTEOM CLIN APPL, V1, P792, DOI 10.1002/prca.200700043
   Mischak H, 2013, CLIN BIOCHEM, V46, P432, DOI 10.1016/j.clinbiochem.2012.09.025
   Mischak H, 2011, PROTEOM CLIN APPL, V5, P9, DOI 10.1002/prca.201000058
   Morohoshi K, 2012, EXP MOL PATHOL, V93, P193, DOI 10.1016/j.yexmp.2012.03.007
   Morohoshi K, 2012, EXP MOL PATHOL, V92, P64, DOI 10.1016/j.yexmp.2011.09.017
   Neuhoff NV, 2004, RAPID COMMUN MASS SP, V18, P149, DOI 10.1002/rcm.1294
   Noma H, 2008, EYE, V22, P42, DOI 10.1038/sj.eye.6702498
   Pfister M, 2012, OPHTHALMOLOGE Z DTSC
   Spaide RF, 2006, AM J OPHTHALMOL, V141, P149, DOI 10.1016/j.ajo.2005.07.025
   Stefansson E, 2006, ACTA OPHTHALMOL SCAN, V84, P718, DOI 10.1111/j.1600-0420.2006.00778.x
   Stefansson E, 2009, GRAEF ARCH CLIN EXP, V247, P147, DOI 10.1007/s00417-008-0980-7
   Theodorescu D, 2006, LANCET ONCOL, V7, P230, DOI 10.1016/S1470-2045(06)70584-8
   Walia S, 2010, SEMIN OPHTHALMOL, V25, P289, DOI 10.3109/08820538.2010.518912
   Wohlrab W, 2004, HYALURONSAEURE HAUT
   Wysokinski D, 2013, EXP EYE RES, V106, P14, DOI 10.1016/j.exer.2012.10.003
   Yamane K, 2003, MOL CELL PROTEOMICS, V2, P1177, DOI 10.1074/mcp.M300038-MCP200
   Zurbig P, 2006, ELECTROPHORESIS, V27, P2111, DOI 10.1002/elps.200500827
NR 42
TC 56
Z9 59
U1 0
U2 18
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD MAY 14
PY 2014
VL 9
IS 5
AR e96895
DI 10.1371/journal.pone.0096895
PG 11
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA AI4TJ
UT WOS:000336857400043
PM 24828575
OA Green Published, gold, Green Accepted, Green Submitted
DA 2022-11-30
ER

PT J
AU Raman, R
   Biswas, S
   Vaitheeswaran, K
   Sharma, T
AF Raman, R.
   Biswas, S.
   Vaitheeswaran, K.
   Sharma, T.
TI Macular pigment optical density in wet age-related macular degeneration
   among Indians
SO EYE
LA English
DT Article
DE macular pigment; age-related macular degeneration; carotenoids; lutein;
   zeaxanthin; ultraviolet
ID HETEROCHROMATIC FLICKER PHOTOMETRY; CIGARETTE-SMOKING; EYE DISEASE;
   DIABETIC-RETINOPATHY; SERUM CONCENTRATIONS; RISK-FACTORS; CAROTENOIDS;
   LUTEIN; MACULOPATHY; ZEAXANTHIN
AB Purpose To estimate the value of macular pigment optical density (MPOD) in adult south Indian population with wet age-related macular degeneration (AMD).
   Methods A total of 33 patients with wet AMD and 29 age-matched controls >50 years of age underwent MPOD measurement with the macular densitometer. The patients were also tested for their dietary intake of carotenoids, smoking history, and lifetime UV exposure.
   Results The mean MPOD values in the Indian population with wet AMD was 0.23 (95% CI: 0.18-0.29) vs control was 0.43 (95% CI: 0.37-0.49), P<0.0001, at 0.51 eccentricity. Ex-smokers had a lower MPOD than nonsmokers (0.16 (0.09-0.23) vs 0.28 (0.22-0.34), P = 0.026) and the lowest level of carotenoids intake had 48% lower MPOD than the highest level (0.14 (0.08-0.21) vs 0.33 (0.24-0.43), P = 0.012). There was no significant age-related decline or gender variation in MPOD.
   Conclusion This study establishes the MPOD in adult Indian population with wet AMD, with a lack of macular pigment in association with wet AMD. Eye (2012) 26, 1052-1057; doi:10.1038/eye.2012.86; published online 25 May 2012
C1 [Raman, R.; Sharma, T.] Sankara Nethralaya, Shri Bhagwan Mahavir Vitreoretinal Serv, Madras 600006, Tamil Nadu, India.
   [Biswas, S.] Elite Sch Optometry, Madras, Tamil Nadu, India.
   [Vaitheeswaran, K.] Dept Prevent Ophthalmol, Madras, Tamil Nadu, India.
RP Raman, R (通讯作者)，Sankara Nethralaya, Shri Bhagwan Mahavir Vitreoretinal Serv, 18 Coll Rd, Madras 600006, Tamil Nadu, India.
EM rajivpgraman@gmail.com
RI Biswas, Sayantan/AAR-8256-2021; Raman, Rajiv/A-7234-2009; Biswas,
   Sayantan/AAQ-6183-2021
OI Biswas, Sayantan/0000-0001-6011-0365; Raman, Rajiv/0000-0001-5842-0233;
   Biswas, Sayantan/0000-0001-6011-0365
CR Beatty S, 1999, BRIT J OPHTHALMOL, V83, P867, DOI 10.1136/bjo.83.7.867
   Beatty S, 2001, INVEST OPHTH VIS SCI, V42, P439
   Berendschot TTJM, 2000, INVEST OPHTH VIS SCI, V41, P3322
   Berendschot TTJM, 2002, INVEST OPHTH VIS SCI, V43, P1928
   Bernstein PS, 2002, OPHTHALMOLOGY, V109, P1780, DOI 10.1016/S0161-6420(02)01173-9
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Bone RA, 2003, J NUTR, V133, P992, DOI 10.1093/jn/133.4.992
   Bone RA, 2001, INVEST OPHTH VIS SCI, V42, P235
   Bressler Neil M, 2002, J Am Board Fam Pract, V15, P142
   Burke JD, 2005, J NUTR, V135, P1208, DOI 10.1093/jn/135.5.1208
   Ciulla TA, 2004, AM J OPHTHALMOL, V138, P582, DOI 10.1016/j.ajo.2004.05.057
   Curran-Celentano J, 2001, AM J CLIN NUTR, V74, P796
   DeAngelis MM, 2007, ARCH OPHTHALMOL-CHIC, V125, P49, DOI 10.1001/archopht.125.1.49
   Hammond BR, 1996, VISION RES, V36, P3003, DOI 10.1016/0042-6989(96)00008-9
   Hammond BR, 1997, INVEST OPHTH VIS SCI, V38, P1795
   Hebert JR, 1998, PUBLIC HEALTH NUTR, V1, P123, DOI 10.1079/PHN19980019
   Jahn C, 2005, GRAEF ARCH CLIN EXP, V243, P222, DOI 10.1007/s00417-004-0995-7
   Kohner EM, 1998, ARCH OPHTHALMOL-CHIC, V116, P297, DOI 10.1001/archopht.116.3.297
   Krishnaiah S, 2005, INVEST OPHTH VIS SCI, V46, P4442, DOI 10.1167/iovs.05-0853
   Krishnan T, 2010, INVEST OPHTH VIS SCI, V51, P701, DOI 10.1167/iovs.09-4114
   Leffondre K, 2002, AM J EPIDEMIOL, V156, P813, DOI 10.1093/aje/kwf122
   Loane E, 2008, SURV OPHTHALMOL, V53, P68, DOI 10.1016/j.survophthal.2007.10.008
   Mares JA, 2006, AM J CLIN NUTR, V84, P1107
   McCarty CA, 1996, B WORLD HEALTH ORGAN, V74, P353
   MITCHELL P, 1995, OPHTHALMOLOGY, V102, P1450
   Moeller SM, 2006, ARCH OPHTHALMOL-CHIC, V124, P1151, DOI 10.1001/archopht.124.8.1151
   Mozaffarieh M, 2003, NUTR J, V2, DOI 10.1186/1475-2891-2-20
   Narendran V, 2002, BRIT J OPHTHALMOL, V86, P1014, DOI 10.1136/bjo.86.9.1014
   Nolan JM, 2007, INVEST OPHTH VIS SCI, V48, P571, DOI 10.1167/iovs.06-0864
   Nolan JM, 2007, EXP EYE RES, V84, P61, DOI 10.1016/j.exer.2006.08.016
   Obana A, 2008, OPHTHALMOLOGY, V115, P147, DOI 10.1016/j.ophtha.2007.02.028
   Rajan S Irudaya, 2003, J Aging Soc Policy, V15, P11, DOI 10.1300/J031v15n02_02
   Raman R, 2011, INVEST OPHTH VIS SCI, V52, P7910, DOI 10.1167/iovs.11-7636
   SanGiovanni JP, 2007, ARCH OPHTHALMOL-CHIC, V125, P1225, DOI 10.1001/archopht.125.9.1225
   Schmidt S, 2006, AM J HUM GENET, V78, P852, DOI 10.1086/503822
   Snodderly DM, 2004, INVEST OPHTH VIS SCI, V45, P531, DOI 10.1167/iovs.03-0762
   SNODDERLY DM, 1995, AM J CLIN NUTR, V62, P1448
   Stringham JM, 2008, EXP EYE RES, V87, P445, DOI 10.1016/j.exer.2008.08.005
   VINGERLING JR, 1995, OPHTHALMOLOGY, V102, P205
   Wenzel AJ, 2007, OPHTHAL PHYSL OPT, V27, P329, DOI 10.1111/j.1475-1313.2007.00495.x
   Wooten BR, 1999, INVEST OPHTH VIS SCI, V40, P2481
NR 41
TC 6
Z9 6
U1 0
U2 5
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0950-222X
EI 1476-5454
J9 EYE
JI Eye
PD AUG
PY 2012
VL 26
IS 8
BP 1052
EP 1057
DI 10.1038/eye.2012.86
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 991TW
UT WOS:000307726000007
PM 22627475
OA Bronze, Green Published
DA 2022-11-30
ER

PT J
AU Fu, DJ
   Keenan, TD
   Faes, L
   Lim, E
   Wagner, SK
   Moraes, G
   Huemer, J
   Kern, C
   Patel, PJ
   Balaskas, K
   Sim, DA
   Bunce, C
   Stratton, I
   Keane, PA
AF Fu, Dun Jack
   Keenan, Tiarnan D.
   Faes, Livia
   Lim, Ernest
   Wagner, Siegfried K.
   Moraes, Gabriella
   Huemer, Josef
   Kern, Christoph
   Patel, Praveen J.
   Balaskas, Konstantinos
   Sim, Dawn A.
   Bunce, Catey
   Stratton, Irene
   Keane, Pearse A.
TI Insights From Survival Analyses During 12 Years of Anti-Vascular
   Endothelial Growth Factor Therapy for Neovascular Age-Related Macular
   Degeneration
SO JAMA OPHTHALMOLOGY
LA English
DT Article
ID REAL-WORLD; OUTCOMES; AFLIBERCEPT; RANIBIZUMAB; TREAT; EYE; AMD
AB Question Can the limitations of current visual outcomes reporting standards of retrospective ophthalmology studies be overcome? Findings In this cohort study of 7802 patients, those with neovascular age-related macular degeneration beginning antivascular endothelial growth factor therapy were most likely to experience a positive visual outcome within the first 2.0 years after injection that is typically maintained for 1.1 years, with deterioration to poor vision within 8.7 years. Meaning Survival analyses can provide long-term prognostic information that may overcome the limitations of current reporting practices and should therefore be considered in analyses of real-world data.
   This cohort study uses data from a tertiary eye center to assess the potential usefulness of survival analyses of 12 years of anti-vascular endothelial growth factor therapy for neovascular age-related macular degeneration.
   Importance Although multiple imputation models for missing data and the use of mixed-effects models generally provide better outcome estimates than using only observed data or last observation carried forward in clinical trials, such approaches usually cannot be applied to visual outcomes from retrospective analyses of clinical practice settings, also called real-world outcomes. Objective To explore the potential usefulness of survival analysis techniques for retrospective clinical practice visual outcomes. Design, Setting, and Participants This retrospective cohort study covered a 12-year observation period at a tertiary eye center. Of 10 744 eyes with neovascular age-related macular degeneration receiving anti-vascular endothelial growth factor (VEGF) therapy between October 28, 2008, and February 1, 2020, 7802 eyes met study criteria (treatment-naive, first-treated eyes starting anti-VEGF therapy). Eyes were excluded from the analysis if they received photodynamic therapy or macular laser, any previous anti-VEGF therapy, treatment with anti-VEGF agents other than ranibizumab or aflibercept, or had an unknown date or visual acuity (VA) value at first injection. Main Outcomes and Measures Kaplan-Meier estimates and Cox proportional hazards modeling were used to consider VA reaching an Early Treatment Diabetic Retinopathy Study (ETDRS) letter score of 70 (Snellen equivalent, 20/40) or better, duration of VA sustained at or better than 70 (20/40), and VA declining to 35 (20/200) or worse. Results A total of 7802 patients (mean [SD] age, 78.7 [8.8] years; 4776 women [61.2%]; and 4785 White [61.3%]) were included in the study. The median time to attaining a VA letter score greater than or equal to 70 (20/40) was 2.0 years (95% CI, 1.87-2.32) after the first anti-VEGF injection. Predictive features were baseline VA (hazard ratio [HR], 1.43 per 5 ETDRS letter score or 1 line; 95% CI, 1.40-1.46), baseline age (HR, 0.88 per 5 years; 95% CI, 0.86-0.90), and injection number (HR, 1.12; 95% CI, 1.10-1.15). Of the 4439 of 7802 patients (57%) attaining this outcome, median time sustained at an ETDRS letter score of 70 (20/40) or better was 1.1 years (95% CI, 1.1-1.2). Conclusions and Relevance In this cohort study, patients with neovascular age-related macular degeneration beginning anti-VEGF therapy were more likely to experience positive visual outcomes within the first 2.0 years after treatment, typically maintaining this outcome for 1.1 years but then deteriorating to poor vision within 8.7 years. These findings demonstrate the potential usefulness of the proposed analyses. This data set, combined with the statistical approach for retrospective analyses, may provide long-term prognostic information for patients newly diagnosed with this condition.
C1 [Fu, Dun Jack; Faes, Livia; Lim, Ernest; Wagner, Siegfried K.; Moraes, Gabriella; Huemer, Josef; Kern, Christoph; Patel, Praveen J.; Balaskas, Konstantinos; Sim, Dawn A.; Keane, Pearse A.] Moorfields Eye Hosp Natl Hlth Serv NHS Fdn Trust, London, England.
   [Fu, Dun Jack; Faes, Livia; Lim, Ernest; Wagner, Siegfried K.; Moraes, Gabriella; Huemer, Josef; Kern, Christoph; Patel, Praveen J.; Balaskas, Konstantinos; Sim, Dawn A.; Keane, Pearse A.] UCL, Inst Ophthalmol, London, England.
   [Keenan, Tiarnan D.] NEI, Dept Epidemiol & Clin Applicat, NIH, Bethesda, MD 20892 USA.
   [Faes, Livia] Eye Clin Cantonal Hosp Lucerne, Luzern, Switzerland.
   [Huemer, Josef] Hanusch Hosp, Vienna Inst Res Ocular Surg, A Karl Landsteiner Inst, Vienna, Austria.
   [Kern, Christoph] Univ Hosp Munich, Dept Ophthalmol, Munich, Germany.
   [Sim, Dawn A.; Keane, Pearse A.] Kings Coll London, Sch Populat Hlth & Environm Sci, London, England.
   [Bunce, Catey] Gloucestershire Retinal Res Grp, Gloucester, England.
   [Stratton, Irene] Moorfields Eye Hosp, Natl Inst Hlth & Res Biomed Ctr, London, England.
C3 University of London; University College London; Moorfields Eye Hospital
   NHS Foundation Trust; University of London; University College London;
   National Institutes of Health (NIH) - USA; NIH National Eye Institute
   (NEI); WGKK - Hanusch Hospital; University of Munich; University of
   London; King's College London; University of London; University College
   London; Moorfields Eye Hospital NHS Foundation Trust
RP Keane, PA (通讯作者)，Moorfields Eye Hosp NHS Fdn Trust, NIHR Biomed Res Ctr Ophthalmol, 162 City Rd, London EC1V 2PD, England.
EM pearse.keane1@nhs.net
RI Balaskas, Konstantinos/ABD-5979-2020
OI Balaskas, Konstantinos/0000-0002-7690-6277; stratton,
   irene/0000-0003-1172-7865; Keane, Pearse/0000-0002-9239-745X; Lim,
   Ernest/0000-0002-6972-0511
FU Moorfields Eye Charity Career Development Award [R190028A]; UK Research
   & Innovation Future Leaders Fellowship [MR/T019050/1]; MRC [MC_PC_19005,
   MR/T000953/1] Funding Source: UKRI; UKRI [MR/T019050/1] Funding Source:
   UKRI
FX This study was supported by grant R190028A from the Moorfields Eye
   Charity Career Development Award and MR/T019050/1 from the UK Research &
   Innovation Future Leaders Fellowship.
CR Altman DG, 1991, PRACTICAL STAT MED R
   American Academy of Ophthalmology, 2017, VIS REH PREF PRACT P
   ANDERSEN PK, 1982, ANN STAT, V10, P1100, DOI 10.1214/aos/1176345976
   Barthelmes D, 2018, RETINA-J RET VIT DIS, V38, P20, DOI 10.1097/IAE.0000000000001496
   Bell ML, 2014, BMC MED RES METHODOL, V14, DOI 10.1186/1471-2288-14-118
   Berg K, 2017, ACTA OPHTHALMOL, V95, P796, DOI 10.1111/aos.13522
   Bland JM, 1998, BRIT MED J, V317, P1572, DOI 10.1136/bmj.317.7172.1572
   Bochicchio S, 2019, OPHTHALMOL RETINA, V3, P27, DOI 10.1016/j.oret.2018.08.003
   Brijesh T, 2016, AM J OPHTHALMOL, V162, P200, DOI 10.1016/j.ajo.2015.11.002
   Bron AM, 2010, CLIN OPHTHALMOL, V4, P1361, DOI 10.2147/OPTH.S15359
   Brynskov T, 2020, ACTA OPHTHALMOL, V98, P132, DOI 10.1111/aos.14183
   Bunce C, 2016, BRIT J OPHTHALMOL, V100, P291, DOI 10.1136/bjophthalmol-2015-307821
   Calvo P, 2015, J OPHTHALMOL, V2015, DOI 10.1155/2015/820605
   Chandra S, 2020, EYE, V34, P1888, DOI 10.1038/s41433-020-0764-9
   Clark TG, 2003, BRIT J CANCER, V89, P232, DOI 10.1038/sj.bjc.6601118
   Donoso LA, 2006, SURV OPHTHALMOL, V51, P137, DOI 10.1016/j.survophthal.2005.12.001
   Eleftheriadou M, 2018, OPHTHALMOL THER, V7, P361, DOI 10.1007/s40123-018-0139-5
   Essex RW, 2016, OPHTHALMOLOGY, V123, P2393, DOI 10.1016/j.ophtha.2016.07.012
   Fasler K, 2019, BMJ OPEN, V9, DOI 10.1136/bmjopen-2018-027441
   Ferreira A, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0133968
   Garweg JG, 2018, GRAEF ARCH CLIN EXP, V256, P823, DOI 10.1007/s00417-018-3907-y
   Gillies M, 2020, AM J OPHTHALMOL, V210, P116, DOI 10.1016/j.ajo.2019.10.007
   Gillies MC, 2019, JAMA OPHTHALMOL, V137, P372, DOI 10.1001/jamaophthalmol.2018.6776
   Gillies MC, 2017, OPHTHALMOLOGY, V124, pE31, DOI 10.1016/j.ophtha.2016.05.054
   Gillies MC, 2015, OPHTHALMOLOGY, V122, P1837, DOI 10.1016/j.ophtha.2015.05.010
   Gupta OP, 2010, OPHTHALMOLOGY, V117, P2134, DOI 10.1016/j.ophtha.2010.02.032
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Inoue M, 2016, AM J OPHTHALMOL, V169, P95, DOI 10.1016/j.ajo.2016.06.021
   International Council of Ophthalmology, 2002, 29 INT C OPHTH APR 2
   Jackson Rod, 2006, Evid Based Nurs, V9, P68, DOI 10.1136/ebn.9.3.68
   Jampol LM, 2020, JAMA OPHTHALMOL, V138, P5, DOI 10.1001/jamaophthalmol.2019.4782
   Javidi S, 2020, J OPHTHALMOL, V2020, DOI 10.1155/2020/3207614
   KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868
   Kung FF, 2020, OPHTHALMOL RETINA, V4, P1047, DOI 10.1016/j.oret.2020.05.005
   Lachin JM, 2016, CLIN TRIALS, V13, P161, DOI 10.1177/1740774515602688
   Lamoureux EL, 2004, ARCH OPHTHALMOL-CHIC, V122, P84, DOI 10.1001/archopht.122.1.84
   Lee AY, 2017, BRIT J OPHTHALMOL, V101, P1683, DOI 10.1136/bjophthalmol-2016-309818
   Lotery A, 2017, EYE, V31, P1697, DOI 10.1038/eye.2017.143
   Mason AJ, 2020, BMC MED RES METHODOL, V20, DOI 10.1186/s12874-020-00930-2
   Mathis T, 2017, ANN EYE SCI, V2(3), P14
   Mehta H, 2018, PROG RETIN EYE RES, V65, P127, DOI 10.1016/j.preteyeres.2017.12.002
   Miller ML, 2020, BMC MED RES METHODOL, V20, DOI 10.1186/s12874-020-00936-w
   MOONS KGM, 2009, BMJ-BRIT MED J, V338, DOI DOI 10.1136/BMJ.B375
   Revicki DA, 1999, PHARMACOECONOMICS, V15, P423, DOI 10.2165/00019053-199915050-00001
   Rodrigues IA, 2016, AM J OPHTHALMOL, V168, P1, DOI 10.1016/j.ajo.2016.04.012
   RStudio Team, 2015, INT DEV ENV R
   Spaide RF, 2020, OPHTHALMOLOGY, V127, P616, DOI 10.1016/j.ophtha.2019.11.004
   Starr MR, 2020, RETINA-J RET VIT DIS, V40, P1665, DOI 10.1097/IAE.0000000000002668
   Tufail A, 2014, OPHTHALMOLOGY, V121, P1092, DOI 10.1016/j.ophtha.2013.11.031
   US Food & Administration, DRUG APPR PACK LUC R
   Vandenbroucke JP, 2014, INT J SURG, V12, P1500, DOI 10.1016/j.ijsu.2014.07.014
   Wolff B, 2020, CLIN EXP OPHTHALMOL, V48, P636, DOI 10.1111/ceo.13742
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   World Medical Association, 2013, JAMA-J AM MED ASSOC, V310, P2191, DOI [DOI 10.1001/JAMA.2013.281053, 10.1001/jama.2013.281053]
NR 54
TC 16
Z9 16
U1 0
U2 1
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 2168-6165
EI 2168-6173
J9 JAMA OPHTHALMOL
JI JAMA Ophthalmol.
PD JAN
PY 2021
VL 139
IS 1
BP 57
EP 67
DI 10.1001/jamaophthalmol.2020.5044
EA NOV 2020
PG 11
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA PX1MC
UT WOS:000592736300001
PM 33211064
OA Green Published
DA 2022-11-30
ER

PT J
AU Schneider, EW
   Fowler, SC
AF Schneider, Eric W.
   Fowler, Samuel C.
TI Optical coherence tomography angiography in the management of
   age-related macular degeneration
SO CURRENT OPINION IN OPHTHALMOLOGY
LA English
DT Review
DE age-related macular degeneration; choroidal neovascularization;
   geographic atrophy; optical coherence tomography angiography
ID CHOROIDAL NEOVASCULARIZATION; SPECTRAL-DOMAIN; FLUORESCEIN ANGIOGRAPHY;
   SWEPT-SOURCE; OCT-ANGIOGRAPHY; TYPE-1 NEOVASCULARIZATION; GEOGRAPHIC
   ATROPHY; ULTRAHIGH-SPEED; CHORIOCAPILLARIS; SECONDARY
AB Purpose of reviewOptical coherence tomography angiography (OCT-A) provides rapid, flow-based imaging of the retinal and choroidal vasculature in a noninvasive manner. This review contrasts this novel technique with conventional angiography and discusses its current uses and limitations in the management of age-related macular degeneration (AMD).Recent findingsInitial work with OCT-A has focused on its ability to identify choriocapillaris flow alterations in dry AMD and to sensitively detect choroidal neovascular membranes (CNVs) in neovascular AMD. Reduced choriocapillaris flow beyond the borders of geographic atrophy seen on OCT-A suggests a primary vascular cause in geographic atrophy. Longitudinal OCT-A analysis of CNV morphology has demonstrated the transition from an immature to mature CNV phenotype following treatment. Current clinical applications of OCT-A include identification of asymptomatic CNV and monitoring for CNV development in the setting of an acquired vitelliform lesion.SummaryOCT-A remains a promising diagnostic tool but one still very much in evolution. Larger studies will be needed to more accurately describe its sensitivity and specificity for CNV detection and to better characterize longitudinal CNV morphologic changes. Anticipated hardware and software updates including swept-source light sources, automated montaging, and manual adjustment of interscan timing should enhance the capabilities of OCT-A in the management of AMD.
C1 [Schneider, Eric W.; Fowler, Samuel C.] Tennessee Retina PC, 345 23rd Ave N Suite 350, Nashville, TN 37215 USA.
RP Schneider, EW (通讯作者)，Tennessee Retina PC, 345 23rd Ave N Suite 350, Nashville, TN 37215 USA.
EM ericschneider79@gmail.com
FU Carl Zeiss Meditec, Inc.
FX E.S.: Speaker Fees - Carl Zeiss Meditec, Inc.
CR Ahmed D, 2017, RETINA
   Al-Sheikh M, 2017, RETINA, V38, P220
   [Anonymous], 1993, Arch Ophthalmol, V111, P1200
   Balaratnasingam C, 2016, AM J OPHTHALMOL, V172, P28, DOI 10.1016/j.ajo.2016.09.008
   Biesemeier A, 2014, NEUROBIOL AGING, V35, P2562, DOI 10.1016/j.neurobiolaging.2014.05.003
   Choi W, 2015, OPHTHALMOLOGY, V122, P2532, DOI 10.1016/j.ophtha.2015.08.029
   Cicinelli MV, 2017, BRIT J OPHTHALMOL, V101, P1193, DOI 10.1136/bjophthalmol-2016-309481
   Corbelli E, 2017, INVEST OPHTH VIS SCI, V58, P5201, DOI 10.1167/iovs.17-22508
   Coscas GJ, 2015, RETINA-J RET VIT DIS, V35, P2219, DOI 10.1097/IAE.0000000000000766
   Couturier A, 2015, RETINA-J RET VIT DIS, V35, P2384, DOI 10.1097/IAE.0000000000000859
   de Carlo TE, 2015, OPHTHALMOLOGY, V122, P1228, DOI 10.1016/j.ophtha.2015.01.029
   Dias JRD, 2018, OPHTHALMOLOGY, V125, P255, DOI 10.1016/j.ophtha.2017.08.030
   Eandi CM, 2017, INVEST OPHTH VIS SCI, V58, P3690, DOI 10.1167/iovs.17-21941
   El Ameen A, 2015, RETINA-J RET VIT DIS, V35, P2212, DOI 10.1097/IAE.0000000000000773
   Farecki ML, 2017, GRAEF ARCH CLIN EXP, V255, P913, DOI 10.1007/s00417-017-3588-y
   Faridi A, 2017, OPHTHALMOL RETINA, V1, P294, DOI 10.1016/j.oret.2017.02.007
   Gong JW, 2016, J OPHTHALMOL, V2016, DOI 10.1155/2016/7521478
   Huang D, 2016, DEV OPHTHALMOL, V56, P6, DOI 10.1159/000442770
   Huang D, 2015, RETINA-J RET VIT DIS, V35, P2260, DOI 10.1097/IAE.0000000000000846
   Hughes EH, 2005, AM J OPHTHALMOL, V139, P344, DOI 10.1016/j.ajo.2004.07.058
   Inoue M, 2016, INVEST OPHTH VIS SCI, V57, pOCT314, DOI 10.1167/iovs.15-18900
   Johnson R. N, 2013, RETINA
   Kim DY, 2013, P NATL ACAD SCI USA, V110, P14354, DOI 10.1073/pnas.1307315110
   Kuehlewein L, 2015, RETINA-J RET VIT DIS, V35, P2229, DOI 10.1097/IAE.0000000000000835
   Kuehlewein L, 2015, AM J OPHTHALMOL, V160, P739, DOI 10.1016/j.ajo.2015.06.030
   Lane M, 2016, INVEST OPHTH VIS SCI, V57, pOCT585, DOI 10.1167/iovs.15-18915
   Liakopoulos S, 2008, INVEST OPHTH VIS SCI, V49, P5048, DOI 10.1167/iovs.08-1877
   Lumbroso B, 2015, RETINA-J RET VIT DIS, V35, P2242, DOI 10.1097/IAE.0000000000000879
   Lupidi M, 2015, INVEST OPHTH VIS SCI, V56, P7638, DOI 10.1167/iovs.15-17603
   Malamos P, 2017, CURR EYE RES, V42, P1689, DOI 10.1080/02713683.2017.1356336
   Mase T, 2016, INVEST OPHTH VIS SCI, V57, pOCT504, DOI 10.1167/iovs.15-18877
   Matsunaga D, 2014, OSLI RETINA, V45, P510, DOI 10.3928/23258160-20141118-04
   Mendis KR, 2010, INVEST OPHTH VIS SCI, V51, P5864, DOI 10.1167/iovs.10-5333
   Miere A, 2017, RETINA
   Miller AR, 2017, INVEST OPHTH VIS SCI, V58, P1499, DOI 10.1167/iovs.16-20969
   Miura M, 2011, INVEST OPHTH VIS SCI, V52, P2689, DOI 10.1167/iovs.10-6282
   Morgan JIW, 2016, OPHTHAL PHYSL OPT, V36, P218, DOI 10.1111/opo.12289
   Nesper PL, 2017, AM J OPHTHALMOL, V174, P42, DOI 10.1016/j.ajo.2016.10.005
   Novais EA, 2016, AM J OPHTHALMOL, V164, P80, DOI 10.1016/j.ajo.2016.01.011
   Palejwala NV, 2015, RETINA-J RET VIT DIS, V35, P2204, DOI 10.1097/IAE.0000000000000867
   Povazay B, 2007, J BIOMED OPT, V12, DOI 10.1117/1.2773728
   Querques G, 2016, BRIT J OPHTHALMOL, V100, P1724, DOI 10.1136/bjophthalmol-2016-308370
   Roisman L, 2016, OPHTHALMOLOGY, V123, P1309, DOI 10.1016/j.ophtha.2016.01.044
   Rosenfeld PJ, 2016, DEV OPHTHALMOL, V56, P18, DOI 10.1159/000442773
   Sacconi R, 2017, RETINA
   Schneider EW, 2014, INVEST OPHTH VIS SCI, V55, P542, DOI 10.1167/iovs.13-13034
   Seddon JM, 2016, JAMA OPHTHALMOL, V134, P1272, DOI 10.1001/jamaophthalmol.2016.3519
   Spaide RF, 2016, AM J OPHTHALMOL, V170, P58, DOI 10.1016/j.ajo.2016.07.023
   Spaide RF, 2015, AM J OPHTHALMOL, V160, P6, DOI 10.1016/j.ajo.2015.04.012
   Spaide RF, 2015, JAMA OPHTHALMOL, V133, P45, DOI 10.1001/jamaophthalmol.2014.3616
   Sulzbacher F, 2017, ACTA OPHTHALMOL, V95, P414, DOI 10.1111/aos.13364
   Zhang AQ, 2015, J BIOMED OPT, V20, DOI 10.1117/1.JBO.20.10.100901
NR 52
TC 20
Z9 20
U1 0
U2 7
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1040-8738
EI 1531-7021
J9 CURR OPIN OPHTHALMOL
JI Curr. Opin. Ophthalmol.
PD MAY
PY 2018
VL 29
IS 3
BP 217
EP 225
DI 10.1097/ICU.0000000000000469
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA GC0AF
UT WOS:000429436700005
PM 29538181
DA 2022-11-30
ER

PT J
AU Hernandez-Zimbron, LF
   Zamora-Alvarado, R
   Ochoa-De la Paz, L
   Velez-Montoya, R
   Zenteno, E
   Gulias-Canizo, R
   Quiroz-Mercado, H
   Gonzalez-Salinas, R
AF Fernando Hernandez-Zimbron, Luis
   Zamora-Alvarado, Ruben
   Ochoa-De la Paz, Lenin
   Velez-Montoya, Raul
   Zenteno, Edgar
   Gulias-Canizo, Rosario
   Quiroz-Mercado, Hugo
   Gonzalez-Salinas, Roberto
TI Age-Related Macular Degeneration: New Paradigms for Treatment and
   Management of AMD
SO OXIDATIVE MEDICINE AND CELLULAR LONGEVITY
LA English
DT Review
ID RETINAL-PIGMENT EPITHELIUM; ENDOTHELIAL GROWTH-FACTOR;
   CENTRAL-NERVOUS-SYSTEM; MULLER GLIA; OXIDATIVE STRESS; NEURAL
   REGENERATION; ALZHEIMERS-DISEASE; NEURONAL-ACTIVITY; CURRENT KNOWLEDGE;
   MICROGLIAL CELLS
AB Age-related macular degeneration (AMD) is a well-characterized and extensively studied disease. It is currently considered the leading cause of visual disability among patients over 60 years. The hallmark of early AMD is the formation of drusen, pigmentary changes at the macula, and mild to moderate vision loss. There are two forms of AMD: the "dry" and the "wet" form that is less frequent but is responsible for 90% of acute blindness due to AMD. Risk factors have been associated with AMD progression, and they are taking relevance to understand how AMD develops: (1) advanced age and the exposition to environmental factors inducing high levels of oxidative stress damaging the macula and (2) this damage, which causes inflammation inducing a vicious cycle, altogether causing central vision loss. There is neither a cure nor treatment to prevent AMD. However, there are some treatments available for the wet form of AMD. This article will review some molecular and cellular mechanisms associated with the onset of AMD focusing on feasible treatments for each related factor in the development of this pathology such as vascular endothelial growth factor, oxidative stress, failure of the clearance of proteins and organelles, and glial cell dysfunction in AMD.
C1 [Fernando Hernandez-Zimbron, Luis; Zamora-Alvarado, Ruben; Ochoa-De la Paz, Lenin; Velez-Montoya, Raul; Gulias-Canizo, Rosario; Quiroz-Mercado, Hugo; Gonzalez-Salinas, Roberto] Asociac Evitar Ceguera, Res Dept, Mexico City, DF, Mexico.
   [Ochoa-De la Paz, Lenin; Zenteno, Edgar] Univ Nacl Autonoma Mexico, Sch Med, Biochem Dept, Mexico City 04510, DF, Mexico.
   [Velez-Montoya, Raul] Asociac Evitar Ceguera, Retina Dept, Mexico City, DF, Mexico.
C3 Universidad Nacional Autonoma de Mexico
RP Hernandez-Zimbron, LF (通讯作者)，Asociac Evitar Ceguera, Res Dept, Mexico City, DF, Mexico.
EM lfhernandez@unam.mx
RI Gonzalez-Salinas, Roberto/I-3127-2016; Gulias-Cañizo,
   Rosario/AAN-1417-2020
OI Gonzalez-Salinas, Roberto/0000-0001-6654-5191; Gulias-Cañizo,
   Rosario/0000-0001-5732-9913; HERNANDEZ ZIMBRON, LUIS
   FERNANDO/0000-0002-5098-367X; Zenteno, Edgar/0000-0001-5603-4072;
   Ochoa-de la Paz, Lenin/0000-0002-7561-0853
FU Asociacion Para Evitar la Ceguera en Mexico IAP
FX This work was supported by generous funding from Asociacion Para Evitar
   la Ceguera en Mexico IAP. The authors thank Ann H. Milam Ph.D. for the
   permission to use their images shown in Figure 1.
CR Alghisi GC, 2006, ENDOTHELIUM-J ENDOTH, V13, P113, DOI 10.1080/10623320600698037
   Ashraf M, 2017, EYE, V31, P1523, DOI 10.1038/eye.2017.81
   Balasingam V, 1996, GLIA, V18, P11, DOI 10.1002/(SICI)1098-1136(199609)18:1<11::AID-GLIA2>3.0.CO;2-6
   Becker Silke, 2012, Cells, V1, P851, DOI 10.3390/cells1040851
   Bhutto IA, 2008, ARCH OPHTHALMOL-CHIC, V126, P670, DOI 10.1001/archopht.126.5.670
   Blackshaw S, 2004, PLOS BIOL, V2, P1411, DOI 10.1371/journal.pbio.0020247
   Blasiak J, 2011, FRONT BIOSCI-LANDMRK, V16, P1551, DOI 10.2741/3804
   Bola C, 2014, GRAEF ARCH CLIN EXP, V252, P699, DOI 10.1007/s00417-014-2604-8
   Bonds DE, 2014, JAMA INTERN MED, V174, P763, DOI 10.1001/jamainternmed.2014.328
   Bringmann A, 2006, PROG RETIN EYE RES, V25, P397, DOI 10.1016/j.preteyeres.2006.05.003
   Bringmann A, 2012, OPHTHALMOLOGICA, V227, P1, DOI 10.1159/000328979
   Bringmann A, 2009, PROG RETIN EYE RES, V28, P423, DOI 10.1016/j.preteyeres.2009.07.001
   Buchholz DE, 2009, STEM CELLS, V27, P2427, DOI 10.1002/stem.189
   Buffo A, 2010, BIOCHEM PHARMACOL, V79, P77, DOI 10.1016/j.bcp.2009.09.014
   Byeon SH, 2010, INVEST OPHTH VIS SCI, V51, P1190, DOI 10.1167/iovs.09-4144
   Cao XG, 2011, PATHOL INT, V61, P528, DOI 10.1111/j.1440-1827.2011.02695.x
   Carr AJ, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0008152
   Catala Angel, 2011, Front Biosci (Schol Ed), V3, P52, DOI 10.2741/s131
   Cejkova J., 2015, GLOBAL J RES ANAL, V4
   Chan CM, 2015, INT J MOL SCI, V16, P5789, DOI 10.3390/ijms16035789
   Chen YH, 2011, ARCH OPHTHALMOL-CHIC, V129, P344, DOI 10.1001/archophthalmol.2011.10
   Cho MS, 2012, STEM CELL RES, V9, P101, DOI 10.1016/j.scr.2012.05.002
   Dahl G, 2006, IUBMB LIFE, V58, P409, DOI 10.1080/15216540600794526
   Dang YL, 2015, CLIN INTERV AGING, V10, P255, DOI 10.2147/CIA.S73705
   Das AV, 2006, DEV BIOL, V299, P283, DOI 10.1016/j.ydbio.2006.07.029
   Davalos D, 2005, NAT NEUROSCI, V8, P752, DOI 10.1038/nn1472
   Del Debbio CB, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012425
   Dentchev T, 2003, MOL VIS, V9, P184
   Dmitriev AV, 1999, VISUAL NEUROSCI, V16, P1157, DOI 10.1017/S095252389916615X
   Dong A, 2009, J CELL PHYSIOL, V219, P544, DOI 10.1002/jcp.21698
   Du J, 2013, J PHARM PHARMACOL, V65, P1753, DOI 10.1111/jphp.12108
   Falkner-Radler CI, 2011, BRIT J OPHTHALMOL, V95, P370, DOI 10.1136/bjo.2009.176305
   Fischer AJ, 2001, NAT NEUROSCI, V4, P247, DOI 10.1038/85090
   Fischer AJ, 2014, GLIA, V62, P1608, DOI 10.1002/glia.22703
   Fontainhas AM, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0015973
   Galluzzi L, 2016, NAT REV NEUROSCI, V17, P467, DOI 10.1038/nrn.2016.51
   Garba AO, 2010, OPHTHALMOL EYE DIS, V2, P75, DOI 10.4137/OED.S4878
   Giannelli SG, 2011, STEM CELLS, V29, P344, DOI 10.1002/stem.579
   Gohdo T, 2001, OPHTHALMIC RES, V33, P298, DOI 10.1159/000055684
   GRAEBER MB, 1988, J NEUROCYTOL, V17, P209, DOI 10.1007/BF01674208
   Gu YH, 2016, OPHTHALMIC RES, V55, P70, DOI 10.1159/000441501
   Hahn P, 2003, ARCH OPHTHALMOL-CHIC, V121, P1099, DOI 10.1001/archopht.121.8.1099
   HALLIWELL B, 1991, AM J MED, V91, pS14, DOI 10.1016/0002-9343(91)90279-7
   Handa JT, 2012, MOL ASPECTS MED, V33, P418, DOI 10.1016/j.mam.2012.03.006
   Hanisch UK, 2007, NAT NEUROSCI, V10, P1387, DOI 10.1038/nn1997
   Hanus J, 2016, BRIT J OPHTHALMOL, V100, P122, DOI 10.1136/bjophthalmol-2015-306972
   Hayes S, 2007, DEV BIOL, V312, P300, DOI 10.1016/j.ydbio.2007.09.046
   HernandezZimbron L. F., 2016, UPDATE ON DEMENTIA
   Hill-Bator A, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/292139
   Ho TC, 2006, APOPTOSIS, V11, P1899, DOI 10.1007/s10495-006-9403-6
   Hollyfield JG, 2008, NAT MED, V14, P194, DOI 10.1038/nm1709
   Iacovelli J, 2016, INVEST OPHTH VIS SCI, V57, P1038, DOI 10.1167/iovs.15-17758
   Iglesias R, 2009, J NEUROSCI, V29, P7092, DOI 10.1523/JNEUROSCI.6062-08.2009
   Jadhav AP, 2009, PROG RETIN EYE RES, V28, P249, DOI 10.1016/j.preteyeres.2009.05.002
   Jarrett SG, 2012, MOL ASPECTS MED, V33, P399, DOI 10.1016/j.mam.2012.03.009
   Javitt NB, 2009, CURR OPIN OPHTHALMOL, V20, P151, DOI 10.1097/ICU.0b013e32832af468
   Jayaram H, 2014, STEM CELL TRANSL MED, V3, P323, DOI 10.5966/sctm.2013-0112
   Jeitner TM, 2011, CURR MED CHEM, V18, P1515
   Johnson LV, 2000, EXP EYE RES, V70, P441, DOI 10.1006/exer.1999.0798
   Kamao H, 2014, STEM CELL REP, V2, P205, DOI 10.1016/j.stemcr.2013.12.007
   Karlstetter M, 2010, IMMUNOBIOLOGY, V215, P685, DOI 10.1016/j.imbio.2010.05.010
   Karunadharma PP, 2010, INVEST OPHTH VIS SCI, V51, P5470, DOI 10.1167/iovs.10-5429
   Kauppinen A, 2016, CELL MOL LIFE SCI, V73, P1765, DOI 10.1007/s00018-016-2147-8
   Kleinman ME, 2008, NATURE, V452, P591, DOI 10.1038/nature06765
   Koch S, 2011, BIOCHEM J, V437, P169, DOI 10.1042/BJ20110301
   Kokkinaki M, 2011, STEM CELLS, V29, P825, DOI 10.1002/stem.635
   Komatsu M, 2006, NATURE, V441, P880, DOI 10.1038/nature04723
   Langmann T, 2007, J LEUKOCYTE BIOL, V81, P1345, DOI 10.1189/jlb.0207114
   Larsen KE, 2002, HISTOL HISTOPATHOL, V17, P897, DOI 10.14670/HH-17.897
   Lawrence JM, 2007, STEM CELLS, V25, P2033, DOI 10.1634/stemcells.2006-0724
   Leach JK, 2001, CANCER RES, V61, P3894
   Lee JE, 2008, INVEST OPHTH VIS SCI, V49, P4169, DOI 10.1167/iovs.08-2076
   Li Y, 2012, DEV CELL, V23, P1189, DOI 10.1016/j.devcel.2012.10.027
   Liu J, 2016, SCI REP-UK, V6, DOI 10.1038/srep20639
   Liu W, 2011, LIFE SCI, V89, P141, DOI 10.1016/j.lfs.2011.05.011
   Loffler K, 2015, GLIA, V63, P1809, DOI 10.1002/glia.22846
   Marneros AG, 2005, AM J PATHOL, V167, P1451, DOI 10.1016/S0002-9440(10)61231-X
   Mehrpour M, 2010, CELL RES, V20, P748, DOI 10.1038/cr.2010.82
   Menzies FM, 2015, NAT REV NEUROSCI, V16, P345, DOI 10.1038/nrn3961
   Milisav I, 2015, MOLECULES, V20, P22718, DOI 10.3390/molecules201219865
   Mitter S. K., 2012, ADV EXPT MED BIOL, V723
   Mitter SK, 2014, AUTOPHAGY, V10, P1989, DOI 10.4161/auto.36184
   Mu YL, 2014, INT J CLIN EXP MED, V7, P3843
   Nagai N, 2014, J NUTR BIOCHEM, V25, P1218, DOI 10.1016/j.jnutbio.2014.05.015
   Newman EA, 2003, J NEUROSCI, V23, P1659, DOI 10.1523/jneurosci.23-05-01659.2003
   Newman EA, 2001, J NEUROSCI, V21, P2215, DOI 10.1523/JNEUROSCI.21-07-02215.2001
   Newman EA, 1998, J NEUROSCI, V18, P4022
   Nimmerjahn A, 2005, SCIENCE, V308, P1314, DOI 10.1126/science.1110647
   Olsson AK, 2006, NAT REV MOL CELL BIO, V7, P359, DOI 10.1038/nrm1911
   Ooto S, 2004, P NATL ACAD SCI USA, V101, P13654, DOI 10.1073/pnas.0402129101
   Osakada F, 2009, J PHARMACOL SCI, V109, P168, DOI 10.1254/jphs.08R19FM
   Pankratov Y, 2006, PFLUG ARCH EUR J PHY, V452, P589, DOI 10.1007/s00424-006-0061-x
   Parmeggiani F, 2012, MEDIAT INFLAMM, V2012, DOI 10.1155/2012/546786
   Petrovski G., AUTOPHAGY PRINCIPLES, P157
   Pollak J, 2013, DEVELOPMENT, V140, P2619, DOI 10.1242/dev.091355
   Ransohoff RM, 2010, NATURE, V468, P253, DOI 10.1038/nature09615
   Ratnayaka JA, 2015, EYE, V29, P1013, DOI 10.1038/eye.2015.100
   Renganathan K, 2008, ADV EXP MED BIOL, V613, P261, DOI 10.1007/978-0-387-74904-4_30
   Richer S, 2014, NUTRIENTS, V6, P4404, DOI 10.3390/nu6104404
   Roesch K, 2008, J COMP NEUROL, V509, P225, DOI 10.1002/cne.21730
   Saitoh Y, 2011, J PHOTOCH PHOTOBIO B, V102, P69, DOI 10.1016/j.jphotobiol.2010.09.006
   Salminen A, 2013, PROG NEUROBIOL, V106, P33, DOI 10.1016/j.pneurobio.2013.06.002
   Salvi SM, 2006, POSTGRAD MED J, V82, P581, DOI 10.1136/pgmj.2005.040857
   Sanges D, 2013, CELL REP, V4, P271, DOI 10.1016/j.celrep.2013.06.015
   SanGiovanni JP, 2007, ARCH OPHTHALMOL-CHIC, V125, P1225, DOI 10.1001/archopht.125.9.1225
   Santos AM, 2008, J COMP NEUROL, V506, P224, DOI 10.1002/cne.21538
   SAWADA M, 1995, INT J DEV NEUROSCI, V13, P253, DOI 10.1016/0736-5748(94)00076-F
   Schmidl D, 2015, ACTA OPHTHALMOL, V93, P105, DOI 10.1111/aos.12650
   Schwartz SD, 2016, INVEST OPHTH VIS SCI, V57, DOI 10.1167/iovs.15-18681
   Schwartz SD, 2015, LANCET, V385, P509, DOI 10.1016/S0140-6736(14)61376-3
   Schwartz SD, 2012, LANCET, V379, P713, DOI 10.1016/S0140-6736(12)60028-2
   Shaw PX, 2016, AIMS MOL SCI, V3, P196, DOI 10.3934/molsci.2016.2.196
   Shaw PX, 2012, P NATL ACAD SCI USA, V109, P13757, DOI 10.1073/pnas.1121309109
   Shaw PX, 2000, J CLIN INVEST, V105, P1731, DOI 10.1172/JCI8472
   Soura V, 2012, BIOCHEM J, V441, P579, DOI 10.1042/BJ20110749
   Stout CE, 2002, J BIOL CHEM, V277, P10482, DOI 10.1074/jbc.M109902200
   Sun YD, 2012, ANN NUTR METAB, V60, P293, DOI 10.1159/000338444
   Takahashi K, 2006, CELL, V126, P663, DOI 10.1016/j.cell.2006.07.024
   Uckermann O, 2006, J NEUROSCI RES, V83, P538, DOI 10.1002/jnr.20760
   Uno K, 2006, BRIT J OPHTHALMOL, V90, P48, DOI 10.1136/bjo.2005.074005
   Vaajasaari H, 2011, MOL VIS, V17, P558
   Velez-Montoya R, 2014, RETINA-J RET VIT DIS, V34, P423, DOI 10.1097/IAE.0000000000000036
   Velez-Montoya R, 2013, RETINA-J RET VIT DIS, V33, P1487, DOI 10.1097/IAE.0b013e318271f265
   Wagner L, 2017, GLIA, V65, P1059, DOI 10.1002/glia.23144
   Wake H, 2011, NEURON GLIA BIOL, V7, P47, DOI 10.1017/S1740925X12000063
   Wan J, 2007, BIOCHEM BIOPH RES CO, V363, P347, DOI 10.1016/j.bbrc.2007.08.178
   Wang MH, 2011, J NEUROINFLAMM, V8, DOI 10.1186/1742-2094-8-173
   Wei L, 2012, CELL REP, V2, P1151, DOI 10.1016/j.celrep.2012.10.013
   Weissman T, 2003, CEREB CORTEX, V13, P550, DOI 10.1093/cercor/13.6.550
   Whitcup SM, 2013, INT J INFLAMM, V2013, DOI 10.1155/2013/348092
   Wu NL, 2011, J AGR FOOD CHEM, V59, P8391, DOI 10.1021/jf200931t
   Wurm A, 2008, J NEUROCHEM, V104, P386, DOI 10.1111/j.1471-4159.2007.04992.x
   Wurm A, 2006, GLIA, V54, P411, DOI 10.1002/glia.20391
   Xu HP, 2009, PROG RETIN EYE RES, V28, P348, DOI 10.1016/j.preteyeres.2009.06.001
   Yonekawa Y, 2015, J CLIN MED, V4, P343, DOI 10.3390/jcm4020343
   Yu JY, 2007, SCIENCE, V318, P1917, DOI 10.1126/science.1151526
   Zelinka CP, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0044477
   Zhang D, 2010, MOL NEUROBIOL, V41, P232, DOI 10.1007/s12035-010-8098-4
   Zhao TB, 2011, NATURE, V474, P212, DOI 10.1038/nature10135
NR 139
TC 118
Z9 124
U1 1
U2 22
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 1942-0900
EI 1942-0994
J9 OXID MED CELL LONGEV
JI Oxidative Med. Cell. Longev.
PY 2018
VL 2018
AR 8374647
DI 10.1155/2018/8374647
PG 14
WC Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology
GA FV8CO
UT WOS:000424812700001
PM 29484106
OA Green Submitted, Green Published, gold
DA 2022-11-30
ER

PT J
AU Sharma, HE
   Mathewson, PA
   Lane, M
   Shah, P
   Glover, N
   Palmer, H
   Haque, MS
   Denniston, AK
   Tsaloumas, MD
AF Sharma, Hannah E.
   Mathewson, Priscilla A.
   Lane, Mark
   Shah, Peter
   Glover, Nicholas
   Palmer, Helen
   Haque, M. Sayeed
   Denniston, Alastair K.
   Tsaloumas, Marie D.
TI The role of social deprivation in severe neovascular age-related macular
   degeneration
SO BRITISH JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID SOCIOECONOMIC-STATUS; VISUAL IMPAIRMENT; MACULOPATHY; POPULATION;
   GLAUCOMA; SERVICE; HEALTH; SIGHT; EYE
AB Background/aims Advances in therapy have improved outcomes for patients with neovascular age-related macular degeneration (nAMD). Prompt access to treatment is a priority and may be used as a key performance indicator. In this study, we investigate how social deprivation may impact on access to services, treatment and visual impairment registration.
   Methods Patients were identified retrospectively through the Certificate of Visual Impairment system for the University Hospitals Birmingham Medical Retina service. The Index of Multiple Deprivation (IMD) 2007 score was calculated for each patient. The impact of deprivation, age, gender and ethnicity on key stages in the care pathway was assessed.
   Results 120 patients were identified. Patients with greater social deprivation were under-represented, had worse visual acuity at first presentation (correlation of the better-seeing eye with IMD 0.225 (p=0.013)) and had sight-impairment registration earlier (correlation -0.246; p=0.007). Deprivation did not affect time to first appointment, and was not associated with a higher rate of non-attendance.
   Conclusions The late presentation and under-representation of patients with greater social deprivation is a serious concern. Our study strongly suggests that this vulnerable group is encountering barriers in accessing treatment in nAMD, and that these occur prior to entry into the Hospital Eye Service.
C1 [Sharma, Hannah E.; Mathewson, Priscilla A.; Lane, Mark; Shah, Peter; Glover, Nicholas; Palmer, Helen; Denniston, Alastair K.; Tsaloumas, Marie D.] Univ Hosp Birmingham NHS Fdn Trust, Dept Ophthalmol, Queen Elizabeth Hosp Birmingham, Birmingham B15 2WB, W Midlands, England.
   [Shah, Peter] Moorfields Eye Hosp NHS Fdn Trust, NIHR Biomed Res Ctr Ophthalmol, London, England.
   [Shah, Peter] UCL Inst Ophthalmol, London, England.
   [Shah, Peter] Wolverhampton Univ, Sch Hlth & Wellbeing, Ctr Hlth & Social Care Improvement, Wolverhampton WV1 1DJ, W Midlands, England.
   [Haque, M. Sayeed] Univ Birmingham, Dept Primary Care & Clin Sci, Birmingham, W Midlands, England.
   [Denniston, Alastair K.] Univ Birmingham, Coll Med & Dent Sci, Acad Unit Ophthalmol, Birmingham, W Midlands, England.
C3 University of Birmingham; University of London; University College
   London; Moorfields Eye Hospital NHS Foundation Trust; University of
   London; University College London; University of Wolverhampton;
   University of Birmingham; University of Birmingham
RP Denniston, AK (通讯作者)，Univ Hosp Birmingham NHS Fdn Trust, Dept Ophthalmol, Queen Elizabeth Hosp Birmingham, Mindelsohn Way, Birmingham B15 2WB, W Midlands, England.
EM a.denniston@bham.ac.uk
RI Haque, Mohammad S/B-9160-2018; Denniston, Alastair/ABD-1238-2020
OI Denniston, Alastair/0000-0001-7849-0087
FU Academy of Medical Sciences (AMS) [AMS-SGCL5-Denniston] Funding Source:
   researchfish
CR Acharya N, 2009, BRIT J OPHTHALMOL, V93, P627, DOI 10.1136/bjo.2008.147231
   Anand R, 2000, OPHTHALMOLOGY, V107, P2224
   Bachmann MO, 2003, DIABETIC MED, V20, P921, DOI 10.1046/j.1464-5491.2003.01050.x
   Barry RJ, 2005, BRIT J OPHTHALMOL, V89, P995, DOI 10.1136/bjo.2004.059915
   Bunce C, 2006, BMC PUBLIC HEALTH, V6, DOI 10.1186/1471-2458-6-58
   Cackett P, 2008, BRIT J OPHTHALMOL, V92, P1312, DOI 10.1136/bjo.2007.136077
   Chua PY, 2013, EUR J OPHTHALMOL, V23, P831, DOI 10.5301/ejo.5000302
   Cross V, 2007, EYE, V21, P912, DOI 10.1038/sj.eye.6702461
   Department of Health, 2012, IMPR OUTC SUPP TRA 2
   Durnian JM, 2010, EYE, V24, P112, DOI 10.1038/eye.2009.32
   Eayres D, 2012, W MIDLANDS KEY HLTH, P1
   General Household Survey, AN OPHTH DAT 1990 91
   GRAHAM PA, 1968, BRIT J PREV SOC MED, V22, P238
   Hamilton W, 2002, BRIT J GEN PRACT, V52, P317
   Jackson CA, 2012, DIABETOLOGIA, V55, P2938, DOI 10.1007/s00125-012-2667-1
   KAHN HA, 1977, AM J EPIDEMIOL, V106, P33, DOI 10.1093/oxfordjournals.aje.a112429
   Klein R, 1999, OPHTHALMOLOGY, V106, P1056, DOI 10.1016/S0161-6420(99)90255-5
   McCarty CA, 2001, ARCH OPHTHALMOL-CHIC, V119, P1455
   Minassian DC, 2011, BRIT J OPHTHALMOL, V95, P1433, DOI 10.1136/bjo.2010.195370
   Mitry D, 2010, INVEST OPHTH VIS SCI, V51, P4963, DOI 10.1167/iovs.10-5400
   Nessim M, 2010, BRIT J OPHTHALMOL, V94, P1304, DOI 10.1136/bjo.2009.160721
   Ng WS, 2010, BRIT J OPHTHALMOL, V94, P85, DOI 10.1136/bjo.2008.153312
   ROBINSON R, 1994, BRIT J OPHTHALMOL, V78, P736, DOI 10.1136/bjo.78.10.736
   Rosenfeld PJ, 2006, OPHTHALMOLOGY, V113, P623, DOI 10.1016/j.ophtha.2006.01.027
   Sanchez-Santos MT, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0072656
   TIELSCH JM, 1991, ARCH OPHTHALMOL-CHIC, V109, P637, DOI 10.1001/archopht.1991.01080050051027
   Williams GP, 2007, EYE, V21, P522, DOI 10.1038/sj.eye.6702256
   Xu L, 2006, BRIT J OPHTHALMOL, V90, P1087, DOI 10.1136/bjo.2006.096123
NR 28
TC 12
Z9 12
U1 0
U2 6
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0007-1161
EI 1468-2079
J9 BRIT J OPHTHALMOL
JI Br. J. Ophthalmol.
PD DEC
PY 2014
VL 98
IS 12
BP 1625
EP 1628
DI 10.1136/bjophthalmol-2014-304959
PG 4
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA AU0AB
UT WOS:000345284300005
PM 24997180
DA 2022-11-30
ER

PT J
AU Sharma, P
   Mittal, S
AF Sharma, Puneet
   Mittal, Sachin
TI Nanotechnology: revolutionizing the delivery of drugs to treat
   age-related macular degeneration
SO EXPERT OPINION ON DRUG DELIVERY
LA English
DT Article
DE AMD; vegf; nanotechnology; delivery; aseptic manufacturing; regulatory
ID INTRAVITREAL INJECTION; PLGA NANOPARTICLES; CONTROLLED-RELEASE;
   POSTERIOR SEGMENT; SUSTAINED-RELEASE; ANTI-VEGF; BEVACIZUMAB; EYE;
   PHARMACOKINETICS; RANIBIZUMAB
AB Introduction: Age-related macular degeneration (AMD) is a progressive retinal disease that degrades the eye's ability to grasp visual acuity. The antivascular endothelial growth factor (VEGF) therapies have made significant strides in improving the quality of life, and there is a continued opportunity to improve delivery, outcomes, and patient convenience and compliance. The treatments available could gain better clinical outcome from novel therapeutics through nanotechnology application.
   Areas covered: This review summarizes AMD biology and the pathophysiology of the disease along with the successes and limitations of available therapies. It further discusses the promising nanotechnology modalities that could become the cornerstone of future AMD research for improving delivery and reducing frequency of administration thus, enabling development of novel therapeutics.
   Expert opinion: The robust translation from preclinical work to clinical outcome for AMD remains an unmet need. Continuing to investigate in deeper understanding of biology and advancing high-quality targets into the clinic in combination with the application of advanced nanotechnology to design patient-centric offerings for both dry and wet AMD is needed. Because of the lack of regulatory precedence, and challenging manufacturing and supply chain need, the future of nano-enabled technologies is challenging but presents exciting treatment options for AMD.
C1 [Sharma, Puneet] GSK Consumer, Cent Tech, Lincoln, NE USA.
   [Mittal, Sachin] Merck & Co Inc, Pharmaceut Sci, Kenilworth, NJ USA.
C3 Merck & Company
RP Sharma, P (通讯作者)，GSK Consumer Healthcare, 10401 Highway 6, Lincoln, NE 68517 USA.
EM puneet.z.sharma@gsk.com
CR Abrishami M, 2009, RETINA-J RET VIT DIS, V29, P699, DOI 10.1097/IAE.0b013e3181a2f42a
   Ahmad I, 2019, MAT SCI ENG C-MATER, V100, P959, DOI 10.1016/j.msec.2019.03.060
   Amrite AC, 2005, J PHARM PHARMACOL, V57, P1555, DOI 10.1211/jpp.57.12.0005
   Anderson DH, 2002, AM J OPHTHALMOL, V134, P411, DOI 10.1016/S0002-9394(02)01624-0
   Anderson JM, 1997, ADV DRUG DELIVER REV, V28, P5, DOI 10.1016/S0169-409X(97)00048-3
   [Anonymous], 2017, NANOTECHNOLOGY GUIDA
   [Anonymous], 2014, NANOTECHNOLOGY GUIDA
   [Anonymous], 2018, NANOTECHNOLOGY GUIDA
   Augustin AJ, 2007, RETINA-J RET VIT DIS, V27, P133, DOI 10.1097/IAE.0b013e3180323de7
   Bakri SJ, 2007, OPHTHALMOLOGY, V114, P855, DOI 10.1016/j.ophtha.2007.01.017
   Berg K, 2015, OPHTHALMOLOGY, V122, P146, DOI 10.1016/j.ophtha.2014.07.041
   Bhutto I, 2012, MOL ASPECTS MED, V33, P295, DOI 10.1016/j.mam.2012.04.005
   Bitounis Dimitrios, 2012, ISRN Pharm, V2012, P738432, DOI 10.5402/2012/738432
   Boas U, 2004, CHEM SOC REV, V33, P43, DOI 10.1039/b309043b
   Bozzuto G, 2015, INT J NANOMED, V10, P975, DOI 10.2147/IJN.S68861
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Cano M, 2010, VISION RES, V50, P652, DOI 10.1016/j.visres.2009.08.018
   Chakravarthy U, 2010, BMC OPHTHALMOL, V10, DOI 10.1186/1471-2415-10-31
   Chan HK, 2011, ADV DRUG DELIVER REV, V63, P406, DOI 10.1016/j.addr.2011.03.011
   Chauhan AS, 2018, MOLECULES, V23, DOI 10.3390/molecules23040938
   Chew EY, 2013, JAMA-J AM MED ASSOC, V309, P2005, DOI 10.1001/jama.2013.4997
   Cholkar K., 2013, EYE ANATOMY PHYSL BA
   Cholkar K, 2015, AAPS PHARMSCITECH, V16, P610, DOI 10.1208/s12249-014-0244-2
   Chopra P, 2012, J CONTROL RELEASE, V160, P96, DOI 10.1016/j.jconrel.2012.01.032
   Chowdhary RK, 2003, J PHARM PHARM SCI, V6, P13
   Christian P, 2008, ECOTOXICOLOGY, V17, P326, DOI 10.1007/s10646-008-0213-1
   Crabb JW, 2002, P NATL ACAD SCI USA, V99, P14682, DOI 10.1073/pnas.222551899
   Davis BM, 2014, SMALL, V10, P1575, DOI 10.1002/smll.201303433
   de Jong PTVM, 2006, NEW ENGL J MED, V355, P1474, DOI 10.1056/NEJMra062326
   de la Fuente M, 2010, ADV DRUG DELIVER REV, V62, P100, DOI 10.1016/j.addr.2009.11.026
   Diebold Y, 2010, PROG RETIN EYE RES, V29, P596, DOI 10.1016/j.preteyeres.2010.08.002
   Din FU, 2017, INT J NANOMED, V12, P7291, DOI 10.2147/IJN.S146315
   Dobrovolskaia MA, 2008, MOL PHARMACEUT, V5, P487, DOI 10.1021/mp800032f
   DRESSELHAUS MS, 2000, PH CH MAT L, V23, P331
   Dugel PU, 2017, OPHTHALMOLOGY, V124, P1296, DOI 10.1016/j.ophtha.2017.03.057
   Duncan R, 2011, MOL PHARMACEUT, V8, P2101, DOI 10.1021/mp200394t
   Durairaj C, 2009, INVEST OPHTH VIS SCI, V50, P4887, DOI 10.1167/iovs.09-3565
   Eandi CM, 2016, EUR J PHARMACOL, V787, P78, DOI 10.1016/j.ejphar.2016.03.002
   Edelhauser HF, 2010, INVEST OPHTH VIS SCI, V51, P5403, DOI 10.1167/iovs.10-5392
   Ehrlich R, 2008, CLIN INTERV AGING, V3, P473
   ELDEM T, 1991, PHARMACEUT RES, V8, P47, DOI 10.1023/A:1015874121860
   Elsaid N, 2016, MOL PHARMACEUT, V13, P2923, DOI 10.1021/acs.molpharmaceut.6b00335
   Fasano M, 2005, IUBMB LIFE, V57, P787, DOI 10.1080/15216540500404093
   Ferrara N, 2006, RETINA-J RET VIT DIS, V26, P859, DOI 10.1097/01.iae.0000242842.14624.e7
   Gaudana R, 2010, AAPS J, V12, P348, DOI 10.1208/s12248-010-9183-3
   Gaudreault J, 2005, INVEST OPHTH VIS SCI, V46, P726, DOI 10.1167/iovs.04-0601
   Gaudreault J, 2007, RETINA-J RET VIT DIS, V27, P1260, DOI 10.1097/IAE.0b013e318134eecd
   Grabnar PA, 2011, J MICROENCAPSUL, V28, P323, DOI 10.3109/02652048.2011.569763
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Green MR, 2006, ANN ONCOL, V17, P1263, DOI 10.1093/annonc/mdl104
   Grimaudo MA, 2018, MOL PHARMACEUT, V15, P571, DOI 10.1021/acs.molpharmaceut.7b00939
   Gupta R.B., 2006, NANOPARTICLE TECHNOL
   Hatz K, 2017, EUR J OPHTHALMOL, V27, P470, DOI 10.5301/ejo.5000886
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Holtze C, 2013, J PHYS D APPL PHYS, V46, DOI 10.1088/0022-3727/46/11/114008
   Holz FG, 2016, OPHTHALMOLOGY, V123, P1080, DOI 10.1016/j.ophtha.2015.12.030
   Hoshikawa A, 2017, J DRUG DELIV SCI TEC, V38, P45, DOI 10.1016/j.jddst.2017.01.004
   Iezzi R, 2012, BIOMATERIALS, V33, P979, DOI 10.1016/j.biomaterials.2011.10.010
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Jiang SB, 2018, INT J OPHTHALMOL-CHI, V11, P1038, DOI 10.18240/ijo.2018.06.23
   Johnson LV, 2001, EXP EYE RES, V73, P887, DOI 10.1006/exer.2001.1094
   Jonas JB, 2009, OPHTHALMIC RES, V41, P21, DOI 10.1159/000162113
   Kabanov AV, 2009, ANGEW CHEM INT EDIT, V48, P5418, DOI 10.1002/anie.200900441
   Kaminskas LM, 2012, NANOMED-NANOTECHNOL, V8, P103, DOI 10.1016/j.nano.2011.05.013
   Kim KM, 2014, INT J NANOMED, V9, P29, DOI 10.2147/IJN.S57922
   Klein ML, 2008, OPHTHALMOLOGY, V115, P1026, DOI 10.1016/j.ophtha.2007.08.030
   Kompella UB, 2013, PROG RETIN EYE RES, V36, P172, DOI 10.1016/j.preteyeres.2013.04.001
   Kouchakzadeh H, 2010, AAPS PHARMSCITECH, V11, P1206, DOI 10.1208/s12249-010-9487-8
   Kovach JL, 2012, J OPHTHALMOL, V2012, DOI 10.1155/2012/786870
   Kumar-Singh R, 2019, EXP EYE RES, V184, P266, DOI 10.1016/j.exer.2019.05.006
   Kumari A, 2010, COLLOID SURFACE B, V75, P1, DOI 10.1016/j.colsurfb.2009.09.001
   Lambert NG, 2016, PROG RETIN EYE RES, V54, P64, DOI 10.1016/j.preteyeres.2016.04.003
   Li FF, 2012, OPEN OPHTHALMOL J, V6, P54, DOI 10.2174/1874364101206010054
   Li S., 2002, BIODEGRADATION ALIPH, P71
   Li TH, 2015, PHOTOCH PHOTOBIO SCI, V14, P972, DOI 10.1039/c4pp00412d
   Li YL, 2015, CHEM REV, V115, P8564, DOI 10.1021/cr500131f
   Li ZX, 2012, CHEM SOC REV, V41, P2590, DOI 10.1039/c1cs15246g
   Lin TC, 2015, J CHIN MED ASSOC, V78, P635, DOI 10.1016/j.jcma.2015.07.008
   Liu JX, 2019, INT J NANOMED, V14, P8819, DOI 10.2147/IJN.S217038
   Liu K, 2019, AM J OPHTHALMOL, V197, P156, DOI 10.1016/j.ajo.2018.08.026
   Liu R, 2014, J MATER CHEM A, V2, P17286, DOI 10.1039/c4ta04036h
   Lu BT, 2019, POLYMERS-BASEL, V11, DOI 10.3390/polym11020304
   Lu Y, 2014, INT J OPHTHALMOL-CHI, V7, P1, DOI 10.3980/j.issn.2222-3959.2014.01.01
   de Redin IL, 2018, INT J PHARMACEUT, V541, P214, DOI 10.1016/j.ijpharm.2018.02.003
   Luschmann C, 2014, CORNEA, V33, P77, DOI 10.1097/ICO.0b013e3182a7f3bf
   Mandai M, 2017, NEW ENGL J MED, V376, P1038, DOI 10.1056/NEJMoa1608368
   Mandal A, 2017, EXPERT OPIN DRUG DEL, V14, P385, DOI 10.1080/17425247.2016.1214565
   Marano RJ, 2005, GENE THER, V12, P1544, DOI 10.1038/sj.gt.3302579
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   McCannel CA, 2011, RETINA-J RET VIT DIS, V31, P654, DOI 10.1097/IAE.0b013e31820a67e4
   Mehnert W, 2001, ADV DRUG DELIVER REV, V47, P165, DOI 10.1016/S0169-409X(01)00105-3
   Miele E, 2009, INT J NANOMED, V4, P99
   Mishra DK, 2018, NANOMED-NANOTECHNOL, V14, P2023, DOI 10.1016/j.nano.2018.05.021
   Mu HJ, 2018, DRUG DELIV, V25, P1372, DOI 10.1080/10717544.2018.1474967
   Narayan R, 2018, PHARMACEUTICS, V10, DOI 10.3390/pharmaceutics10030118
   Narvekar P, 2019, ASSAY DRUG DEV TECHN, V17, P167, DOI 10.1089/adt.2019.920
   Neufeld G, 1999, FASEB J, V13, P9, DOI 10.1096/fasebj.13.1.9
   Noh G, 2018, PHARMACEUTICS, V10, DOI 10.3390/pharmaceutics10040208
   Oh JK, 2008, PROG POLYM SCI, V33, P448, DOI 10.1016/j.progpolymsci.2008.01.002
   Paliwal R, 2014, AAPS PHARMSCITECH, V15, P1527, DOI 10.1208/s12249-014-0177-9
   Pandit J, 2017, ARTIF CELL NANOMED B, V45, P1397, DOI 10.1080/21691401.2016.1243545
   Paolicelli P, 2009, EXPERT OPIN DRUG DEL, V6, P239, DOI 10.1517/17425240902762818
   Qiu FF, 2019, MOL PHARMACEUT, V16, P1958, DOI 10.1021/acs.molpharmaceut.8b01319
   Rastoin O, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21134627
   RAVIOLA G, 1977, EXP EYE RES, V25, P27, DOI 10.1016/S0014-4835(77)80009-2
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Saad WS, 2016, NANO TODAY, V11, P212, DOI 10.1016/j.nantod.2016.04.006
   Salvi SM, 2006, POSTGRAD MED J, V82, P581, DOI 10.1136/pgmj.2005.040857
   Sanchez-Lopez E, 2018, SMALL, V14, DOI 10.1002/smll.201701808
   Savin CL, 2019, MAT SCI ENG C-MATER, V98, P843, DOI 10.1016/j.msec.2019.01.036
   Schmidt-Erfurth U, 2000, SURV OPHTHALMOL, V45, P195, DOI 10.1016/S0039-6257(00)00158-2
   Sene A, 2015, TRENDS MOL MED, V21, P43, DOI 10.1016/j.molmed.2014.10.005
   Shi Z., 2020, SMART MAT MED
   Shimazaki H, 2011, INVEST OPHTH VIS SCI, V52, P7289, DOI 10.1167/iovs.11-7983
   Sousa F, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-03959-4
   Suda K, 2017, J CONTROL RELEASE, V266, P301, DOI 10.1016/j.jconrel.2017.09.036
   Suen WLL, 2013, J CONTROL RELEASE, V167, P21, DOI 10.1016/j.jconrel.2013.01.004
   Tarhini M, 2017, INT J PHARMACEUT, V522, P172, DOI 10.1016/j.ijpharm.2017.01.067
   Thornton J, 2005, EYE, V19, P935, DOI 10.1038/sj.eye.6701978
   Trivedi R, 2010, NANOMEDICINE-UK, V5, P485, DOI [10.2217/nnm.10.10, 10.2217/NNM.10.10]
   Ugurlu N, 2019, J BIOMED NANOTECHNOL, V15, P830, DOI 10.1166/jbn.2019.2716
   Ulbrich K, 2009, EUR J PHARM BIOPHARM, V71, P251, DOI 10.1016/j.ejpb.2008.08.021
   Urtti A, 2006, ADV DRUG DELIVER REV, V58, P1131, DOI 10.1016/j.addr.2006.07.027
   Urtti A, 2019, SMALL, V15, DOI 10.1002/smll.201805199
   Vakalis N, 2015, SCI REP-UK, V5, DOI 10.1038/srep08627
   Varshochian R, 2015, J BIOMED MATER RES A, V103, P3148, DOI 10.1002/jbm.a.35446
   Vicario-de-la-Torre M, 2017, GELS-BASEL, V3, DOI 10.3390/gels3020016
   Wang Yaning, 2004, Angiogenesis, V7, P335, DOI 10.1007/s10456-004-8272-2
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Wu W, 2016, INT J PHARMACEUT, V513, P238, DOI 10.1016/j.ijpharm.2016.09.013
   Xie BB, 2015, INT J PHARMACEUT, V490, P375, DOI 10.1016/j.ijpharm.2015.05.071
   Xu RZ, 2011, BIOCONJUGATE CHEM, V22, P870, DOI 10.1021/bc1002295
   Xu ZP, 2006, CHEM ENG SCI, V61, P1027, DOI 10.1016/j.ces.2005.06.019
   Yadav M, 2020, DRUG DELIV TRANSL RE, V10, P919, DOI 10.1007/s13346-020-00733-4
   Yan J, 2018, J PHOTOCH PHOTOBIO B, V183, P133, DOI 10.1016/j.jphotobiol.2018.04.033
   Yang H, 2003, J BIOMAT SCI-POLYM E, V14, P1043, DOI 10.1163/156856203769231556
   Yanga YL, 2013, P NATL ACAD SCI USA, V110, P12018, DOI 10.1073/pnas.1301331110
   Yerlikaya F, 2013, J PHARM SCI-US, V102, P3748, DOI 10.1002/jps.23686
   Zhang XP, 2018, BIOMED PHARMACOTHER, V107, P1056, DOI 10.1016/j.biopha.2018.08.092
   Zhou ZY, 2013, INT J PHARMACEUT, V452, P173, DOI 10.1016/j.ijpharm.2013.04.075
   Zielinska A., 2020, MOLECULES, V25, P16
NR 141
TC 4
Z9 4
U1 7
U2 17
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 1742-5247
EI 1744-7593
J9 EXPERT OPIN DRUG DEL
JI Expert Opin. Drug Deliv.
PD AUG 3
PY 2021
VL 18
IS 8
BP 1131
EP 1149
DI 10.1080/17425247.2021.1888925
EA APR 2021
PG 19
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA TR7DD
UT WOS:000640141900001
PM 33691548
DA 2022-11-30
ER

PT J
AU Eller, AW
   Gorovoy, IR
   Mayercik, VA
AF Eller, Andrew W.
   Gorovoy, Ian R.
   Mayercik, Vera A.
TI Yellow Corneal Ring Associated with Vitamin Supplementation for
   Age-Related Macular Degeneration
SO OPHTHALMOLOGY
LA English
DT Article
ID BETA-CAROTENE; CONFOCAL MICROSCOPY; WILSONS-DISEASE; LUNG-CANCER;
   DEPOSITION; DIAGNOSIS; ARGYROSIS; THERAPY
AB Purpose: To report the first described cases of peripheral yellow corneal rings secondary to vitamin supplementation for age-related macular degeneration (ARMD).
   Design: Retrospective single-center case series.
   Participants: The eyes of 4 patients taking vitamin supplementation for ARMD were examined at the University of Pittsburgh Medical Center Department of Ophthalmology between January 2010 and April 2011.
   Methods: We reviewed the medical records of 4 patients with peripheral corneal rings receiving vitamin supplementation for ARMD.
   Main Outcome Measures: The presence of peripheral yellow corneal rings, skin findings, and serum carotene levels.
   Results: Each patient had circumferential, yellow, peripheral corneal rings and exhibited subtle yellowing of the skin most notable on the palms. Serum carotene levels were normal in 2 of the 3 patients and markedly elevated in the last patient in whom it was measured.
   Conclusions: It is unclear at this time how to counsel patients with this ocular finding. We suspect that these rings are more common than generally appreciated because they may have a subtle appearance or be misdiagnosed as arcus senilis. We suggest that a formal study be performed on a cohort of patients taking vitamin supplementation for macular degeneration that specifically screens for yellow rings and measures serum carotene levels when they are identified.
C1 [Eller, Andrew W.; Gorovoy, Ian R.; Mayercik, Vera A.] Univ Pittsburgh, Sch Med, Dept Ophthalmol, Retina Serv,UPMC Eye Ctr, Pittsburgh, PA 15261 USA.
C3 Pennsylvania Commonwealth System of Higher Education (PCSHE); University
   of Pittsburgh
RP Eller, AW (通讯作者)，203 Lothrop St,Room 822, Pittsburgh, PA 15213 USA.
EM elleraw@upmc.edu
FU National Institutes of Health CORE [P30 EY008098]; Eye and Ear
   Foundation of Pittsburgh, PA; Research to Prevent Blindness (New York,
   NY); NATIONAL EYE INSTITUTE [P30EY008098] Funding Source: NIH RePORTER
FX Supported in part by National Institutes of Health CORE Grant P30
   EY008098, Eye and Ear Foundation of Pittsburgh, PA, and an Unrestricted
   Grant from Research to Prevent Blindness (New York, NY).
CR Aggarwal A, 2009, BRIT MED J, V339, pb3494
   Ala A, 2007, LANCET, V369, P397, DOI 10.1016/S0140-6736(07)60196-2
   BENDICH A, 1989, AM J CLIN NUTR, V49, P358, DOI 10.1093/ajcn/49.2.358
   BLUHM R, 1990, JAMA-J AM MED ASSOC, V264, P1141, DOI 10.1001/jama.264.9.1141
   Diplock AT, 1998, BRIT J NUTR, V80, pS77, DOI 10.1079/BJN19980106
   FLEMING CR, 1977, ANN INTERN MED, V86, P285, DOI 10.7326/0003-4819-86-3-285
   Garron L K, 1976, Trans Am Ophthalmol Soc, V74, P295
   Goldblum D, 1998, POSTGRAD MED J, V74, P642, DOI 10.1136/pgmj.74.877.642
   HEINONEN OP, 1994, NEW ENGL J MED, V330, P1029
   Karthik SV, 2006, PEDIATR DERMATOL, V23, P571, DOI 10.1111/j.1525-1470.2006.00312.x
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Kuhlwein A, 1980, Z Hautkr, V55, P817
   Leo MA, 1997, AM J CLIN NUTR, V66, P1461, DOI 10.1093/ajcn/66.6.1461
   Leung A K, 1987, Adv Pediatr, V34, P223
   Lopez JD, 2003, CORNEA, V22, P573, DOI 10.1097/00003226-200308000-00017
   Merle U, 2007, GUT, V56, P115, DOI 10.1136/gut.2005.087262
   Nishimura Toshio, 1993, Journal of Dermatology (Tokyo), V20, P287
   Omenn GS, 1996, NEW ENGL J MED, V334, P1150, DOI 10.1056/NEJM199605023341802
   Palamar M, 2010, ARCH OPHTHALMOL-CHIC, V128, P503, DOI 10.1001/archophthalmol.2010.37
   POHFITZPATRICK MB, 1984, J AM ACAD DERMATOL, V11, P111, DOI 10.1016/S0190-9622(84)70143-5
   Probst LE, 1996, CORNEA, V15, P94
   Rahmami B, 2003, ARCH OPHTHALMOL-CHIC, V121, P403, DOI 10.1001/archopht.121.3.400
   Roberts EA, 2008, HEPATOLOGY, V47, P2089, DOI 10.1002/hep.22261
   ROUSSEAU A, 1983, J AM ACAD DERMATOL, V8, P123, DOI 10.1016/S0190-9622(83)80288-6
   Sanchez-Pulgarin M, 2010, CORNEA, V29, P580, DOI 10.1097/ICO.0b013e3181b532fa
   SCHOENBERGER M, 1979, ARCH OPHTHALMOL-CHIC, V97, P1914
   Tietz NW, 2000, CLIN GUIDE LAB TESTS, P116
   Van Arnum SD, 1998, KIRK OTHMER ENCY CHE, V25, P99
   Webber SK, 2001, CORNEA, V20, P217, DOI 10.1097/00003226-200103000-00023
   ZIEGLER RG, 1989, J NUTR, V119, P116, DOI 10.1093/jn/119.1.116
NR 30
TC 6
Z9 9
U1 0
U2 4
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0161-6420
J9 OPHTHALMOLOGY
JI Ophthalmology
PD MAY
PY 2012
VL 119
IS 5
BP 1011
EP 1016
DI 10.1016/j.ophtha.2011.10.032
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 933XM
UT WOS:000303399800018
PM 22330962
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Takeda, A
   Baffi, JZ
   Kleinman, ME
   Cho, WG
   Nozaki, M
   Yamada, K
   Kaneko, H
   Albuquerque, RJC
   Dridi, S
   Saito, K
   Raisler, BJ
   Budd, SJ
   Geisen, P
   Munitz, A
   Ambati, BK
   Green, MG
   Ishibashi, T
   Wright, JD
   Humbles, AA
   Gerard, CJ
   Ogura, Y
   Pan, YZ
   Smith, JR
   Grisanti, S
   Hartnett, ME
   Rothenberg, ME
   Ambati, J
AF Takeda, Atsunobu
   Baffi, Judit Z.
   Kleinman, Mark E.
   Cho, Won Gil
   Nozaki, Miho
   Yamada, Kiyoshi
   Kaneko, Hiroki
   Albuquerque, Romulo J. C.
   Dridi, Sami
   Saito, Kuniharu
   Raisler, Brian J.
   Budd, Steven J.
   Geisen, Pete
   Munitz, Ariel
   Ambati, Balamurali K.
   Green, Martha G.
   Ishibashi, Tatsuro
   Wright, John D.
   Humbles, Alison A.
   Gerard, Craig J.
   Ogura, Yuichiro
   Pan, Yuzhen
   Smith, Justine R.
   Grisanti, Salvatore
   Hartnett, M. Elizabeth
   Rothenberg, Marc E.
   Ambati, Jayakrishna
TI CCR3 is a target for age-related macular degeneration diagnosis and
   therapy
SO NATURE
LA English
DT Article
ID ENDOTHELIAL GROWTH-FACTOR; RETINAL-PIGMENT EPITHELIUM; EXPERIMENTAL
   CHOROIDAL NEOVASCULARIZATION; GENE-EXPRESSION PROFILES; MAST-CELLS;
   EOSINOPHIL RECRUITMENT; VISUAL FUNCTION; EOTAXIN; VEGF; MODEL
AB Age-related macular degeneration (AMD), a leading cause of blindness worldwide, is as prevalent as cancer in industrialized nations. Most blindness in AMD results from invasion of the retina by choroidal neovascularisation (CNV). Here we show that the eosinophil/mast cell chemokine receptor CCR3 is specifically expressed in choroidal neovascular endothelial cells in humans with AMD, and that despite the expression of its ligands eotaxin-1, -2 and -3, neither eosinophils nor mast cells are present in human CNV. Genetic or pharmacological targeting of CCR3 or eotaxins inhibited injury-induced CNV in mice. CNV suppression by CCR3 blockade was due to direct inhibition of endothelial cell proliferation, and was uncoupled from inflammation because it occurred in mice lacking eosinophils or mast cells, and was independent of macrophage and neutrophil recruitment. CCR3 blockade was more effective at reducing CNV than vascular endothelial growth factor A (VEGF-A) neutralization, which is in clinical use at present, and, unlike VEGF-A blockade, is not toxic to the mouse retina. In vivo imaging with CCR3-targeting quantum dots located spontaneous CNV invisible to standard fluorescein angiography in mice before retinal invasion. CCR3 targeting might reduce vision loss due to AMD through early detection and therapeutic angioinhibition.
C1 [Takeda, Atsunobu; Baffi, Judit Z.; Kleinman, Mark E.; Cho, Won Gil; Nozaki, Miho; Yamada, Kiyoshi; Kaneko, Hiroki; Albuquerque, Romulo J. C.; Dridi, Sami; Saito, Kuniharu; Raisler, Brian J.; Green, Martha G.; Ambati, Jayakrishna] Univ Kentucky, Dept Ophthalmol & Visual Sci, Lexington, KY 40506 USA.
   [Albuquerque, Romulo J. C.; Raisler, Brian J.; Ambati, Jayakrishna] Univ Kentucky, Dept Physiol, Lexington, KY 40506 USA.
   [Nozaki, Miho; Ogura, Yuichiro] Nagoya City Univ, Grad Sch Med Sci, Dept Ophthalmol & Visual Sci, Nagoya, Aichi 4678601, Japan.
   [Budd, Steven J.; Geisen, Pete; Wright, John D.; Hartnett, M. Elizabeth] Univ N Carolina, Dept Ophthalmol, Chapel Hill, NC 27599 USA.
   [Munitz, Ariel; Rothenberg, Marc E.] Univ Cincinnati, Cincinnati Childrens Hosp, Med Ctr, Div Allergy & Immunol,Dept Pediat, Cincinnati, OH 45229 USA.
   [Ambati, Balamurali K.] Univ Utah, Sch Med, Dept Ophthalmol & Visual Sci, Moran Eye Ctr, Salt Lake City, UT 84132 USA.
   [Ambati, Balamurali K.] Vet Affairs Salt Lake City Healthcare Syst, Dept Ophthalmol, Salt Lake City, UT 84148 USA.
   [Ishibashi, Tatsuro] Kyushu Univ, Grad Sch Med Sci, Dept Ophthalmol, Fukuoka 8128582, Japan.
   [Humbles, Alison A.; Gerard, Craig J.] Harvard Univ, Sch Med, Childrens Hosp, Dept Med, Boston, MA 02215 USA.
   [Pan, Yuzhen; Smith, Justine R.] Oregon Hlth & Sci Univ, Casey Eye Inst, Portland, OR 97239 USA.
   [Grisanti, Salvatore] Med Univ Lubeck, Dept Ophthalmol, D-23538 Lubeck, Germany.
C3 University of Kentucky; University of Kentucky; Nagoya City University;
   University of North Carolina; University of North Carolina Chapel Hill;
   Cincinnati Children's Hospital Medical Center; University System of
   Ohio; University of Cincinnati; Utah System of Higher Education;
   University of Utah; US Department of Veterans Affairs; Kyushu
   University; Harvard University; Boston Children's Hospital; Harvard
   Medical School; Oregon Health & Science University; University of Lubeck
RP Ambati, J (通讯作者)，Univ Kentucky, Dept Ophthalmol & Visual Sci, Lexington, KY 40506 USA.
EM jamba2@email.uky.edu
RI Smith, Justine/Y-9044-2019; Dridi, Sami/Q-8207-2019; Kaneko,
   Hiroki/O-7695-2015; Pan, YZ/GVS-2269-2022; Kaneko, Hiroki/AHA-2461-2022
OI Smith, Justine/0000-0002-4756-5493; Kaneko, Hiroki/0000-0003-0731-6465;
   Kaneko, Hiroki/0000-0003-0731-6465; Kleinman, Mark/0000-0001-8557-7949
FU National Eye Institute/National Institutes of Health (NIH) [EY015422,
   EY018350, EY018836]; Doris Duke Distinguished Clinical Scientist Award;
   Burroughs Wellcome Fund Clinical Scientist Awar; Macula Vision Research
   Foundation; E. Matilda Ziegler Foundation for the Blind; American Health
   Assistance Foundation; NIH [EY017182, EY017950, AI45898, DK076893,
   AI039759, EY017011, EY015130, EY010572]; VA Merit Award and the
   Department of Defense; RPB Career Development Award; NATIONAL EYE
   INSTITUTE [R01EY018836, R01EY017011, R56EY015130, R01EY015422,
   R01EY018350, R01EY017182, R01EY015130, P30EY010572, R01EY017950] Funding
   Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS
   DISEASES [R01AI045898, R01AI039759, R37AI045898] Funding Source: NIH
   RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY
   DISEASES [R01DK076893] Funding Source: NIH RePORTER
FX Acknowledgements We thank R. King, L. Xu, M. McConnell, K. Emerson, G.
   R. Pattison and M. Mingler for technical assistance, J. M. Farber for
   the gift of a reagent, R. J. Kryscio for statistical guidance, and B.
   Appukuttan, M. W. Fannon, R. Mohan, A. P. Pearson, A. M. Rao, G. S. Rao
   and K. Ambati for discussions. J. A. was supported by National Eye
   Institute/National Institutes of Health (NIH) grants EY015422, EY018350
   and EY018836, the Doris Duke Distinguished Clinical Scientist Award, the
   Burroughs Wellcome Fund Clinical Scientist Award in Translational
   Research, the Macula Vision Research Foundation, the E. Matilda Ziegler
   Foundation for the Blind, the Dr. E. Vernon Smith and Eloise C. Smith
   Macular Degeneration Endowed Chair, the Lew R. Wassermann Merit &
   Physician Scientist Awards ( Research to Prevent Blindness, RPB), the
   American Health Assistance Foundation, and a departmental unrestricted
   grant from the RPB. J. Z. B. was supported by the University of Kentucky
   Physician Scientist Award. M. E. K. was supported by the International
   Retinal Research Foundation Dr. Charles Kelman Postdoctoral Scholar
   Award. R. J. C. A. was supported by Fight for Sight. B. K. A. was
   supported by NIH grants EY017182 and EY017950, the VA Merit Award and
   the Department of Defense. M. E. R. was supported by NIH grants AI45898
   and DK076893. C. J. G. was supported by NIH grant AI039759. M. E. H. was
   supported by NIH grants EY017011 and EY015130 and a RPB departmental
   unrestricted grant. J. R. S. was supported by NIH grant EY010572, and
   RPB Career Development Award and a departmental unrestricted grant.
CR Ambati J, 2003, NAT MED, V9, P1390, DOI 10.1038/nm950
   Ambati J, 2003, SURV OPHTHALMOL, V48, P257, DOI 10.1016/S0039-6257(03)00030-4
   Blanchard C, 2006, J CLIN INVEST, V116, P536, DOI 10.1172/JCI26679
   BRESSLER SB, 1990, ARCH OPHTHALMOL-CHIC, V108, P1442, DOI 10.1001/archopht.1990.01070120090035
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Carmeliet P, 1996, NATURE, V380, P435, DOI 10.1038/380435a0
   Famiglietti EV, 2003, BRAIN RES, V969, P195, DOI 10.1016/S0006-8993(02)03766-6
   Ferrara N, 1996, NATURE, V380, P439, DOI 10.1038/380439a0
   Fulkerson PC, 2005, BLOOD, V106, P436, DOI 10.1182/blood-2005-02-0489
   Fulkerson PC, 2004, P NATL ACAD SCI USA, V101, P1987, DOI 10.1073/pnas.0308544100
   Geisen P, 2006, EXP EYE RES, V82, P608, DOI 10.1016/j.exer.2005.08.021
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Green W R, 1977, Trans Am Ophthalmol Soc, V75, P180
   Grossniklaus HE, 2005, ARCH OPHTHALMOL-CHIC, V123, P914
   Heissig B, 2005, J EXP MED, V202, P739, DOI 10.1084/jem.20050959
   Humbles AA, 2002, P NATL ACAD SCI USA, V99, P1479, DOI 10.1073/pnas.261462598
   Humbles AA, 2004, SCIENCE, V305, P1776, DOI 10.1126/science.1100283
   Ip MS, 2008, OPHTHALMOLOGY, V115, P1837, DOI 10.1016/j.ophtha.2008.08.012
   JOSE PJ, 1994, J EXP MED, V179, P881, DOI 10.1084/jem.179.3.881
   Justice JP, 2003, AM J PHYSIOL-LUNG C, V284, pL169, DOI 10.1152/ajplung.00260.2002
   KITAMURA Y, 1978, BLOOD, V52, P447
   Kleinman ME, 2008, NATURE, V452, P591, DOI 10.1038/nature06765
   Maguire MG, 1997, ARCH OPHTHALMOL-CHIC, V115, P741
   Marneros AG, 2005, AM J PATHOL, V167, P1451, DOI 10.1016/S0002-9440(10)61231-X
   Nishijima K, 2007, AM J PATHOL, V171, P53, DOI 10.2353/ajpath.2007.061237
   Nozaki M, 2006, P NATL ACAD SCI USA, V103, P2328, DOI 10.1073/pnas.0408835103
   Nozaki M, 2006, J CLIN INVEST, V116, P422, DOI 10.1172/JCI26316
   Peterson LJ, 2007, EXP EYE RES, V84, P737, DOI 10.1016/j.exer.2006.12.012
   Pope SM, 2005, J IMMUNOL, V175, P5341, DOI 10.4049/jimmunol.175.8.5341
   Puxeddu A, 2005, INT J BIOCHEM CELL B, V37, P628, DOI 10.1016/j.biocel.2004.09.001
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rothenberg ME, 2006, ANNU REV IMMUNOL, V24, P147, DOI 10.1146/annurev.immunol.24.021605.090720
   Rothenberg ME, 1997, J EXP MED, V185, P785, DOI 10.1084/jem.185.4.785
   Saint-Geniez M, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003554
   Sakurai E, 2003, INVEST OPHTH VIS SCI, V44, P2743, DOI 10.1167/iovs.02-1246
   Sakurai E, 2003, INVEST OPHTH VIS SCI, V44, P3578, DOI 10.1167/iovs.03-0097
   Salcedo R, 2001, J IMMUNOL, V166, P7571, DOI 10.4049/jimmunol.166.12.7571
   Sayanagi K, 2009, BRIT J OPHTHALMOL, V93, P622, DOI 10.1136/bjo.2008.151977
   Smith JR, 2007, INVEST OPHTH VIS SCI, V48, P2676, DOI 10.1167/iovs.06-0598
   St Croix B, 2000, SCIENCE, V289, P1197
   Teixeira MM, 1997, J CLIN INVEST, V100, P1657, DOI 10.1172/JCI119690
   Tobe T, 1998, AM J PATHOL, V153, P1641, DOI 10.1016/S0002-9440(10)65753-7
   Wenzel SE, 2009, NEW ENGL J MED, V360, P1026, DOI 10.1056/NEJMe0900334
   Yodoi Y, 2009, AM J OPHTHALMOL, V147, P816, DOI 10.1016/j.ajo.2008.11.020
   Zamora DO, 2007, MOL VIS, V13, P2058
   Zhang L, 1997, SCIENCE, V276, P1268, DOI 10.1126/science.276.5316.1268
   Zhou JH, 2005, MOL VIS, V11, P414
NR 47
TC 188
Z9 212
U1 0
U2 40
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0028-0836
EI 1476-4687
J9 NATURE
JI Nature
PD JUL 9
PY 2009
VL 460
IS 7252
BP 225
EP U87
DI 10.1038/nature08151
PG 7
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA 467RV
UT WOS:000267761000034
PM 19525930
OA Green Accepted, Green Submitted
DA 2022-11-30
ER

PT J
AU Vogel, RN
   Davis, DB
   Kimura, BH
   Rathinavelu, S
   Graves, GS
   Szabo, A
   Han, DP
AF Vogel, Ryan N.
   Davis, Drew B.
   Kimura, Brad H.
   Rathinavelu, Senthil
   Graves, Gabrielle S.
   Szabo, Aniko
   Han, Dennis P.
TI NEOVASCULAR AGE-RELATED MACULAR DEGENERATION WITH ADVANCED VISUAL LOSS
   TREATED WITH ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY Clinical
   Outcome and Prognostic Indicators
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE age-related macular degeneration; anti-vascular endothelial growth
   factor; intravitreal; choroidal neovascularization; visual acuity
ID VERTEPORFIN PHOTODYNAMIC THERAPY; INTRAVITREAL BEVACIZUMAB; SUBGROUP
   ANALYSIS; RANIBIZUMAB; ACUITY; MORPHOLOGY; INJECTION; EFFICACY; REGIMEN;
   SAFETY
AB Purpose: To describe visual outcome and prognostic indicators in neovascular age-related macular degeneration with advanced visual loss at the initiation of anti-vascular endothelial growth factor therapy.
   Methods: A retrospective chart review was performed on a consecutive series of 1,410 patients with neovascular age-related macular degeneration treated with anti-vascular endothelial growth factor therapy at the Medical College of Wisconsin. Subjects were included if at the initiation of therapy they had 20/200 or worse visual acuity (VA) with no other visually limiting eye disease and a minimum follow-up of 6 months. The change in VA at 6 months and 12 months was assessed compared with baseline. Visual improvement/ worsening was defined as at least +/- 0.3 logMAR (equivalent to 15 ETDRS [Early Treatment Diabetic Retinopathy Study] letters) change. Other factors for analysis included number of injections received, drug type, and various clinical and imaging findings.
   Results: One hundred thirty-one cases met the study criteria, and 97 were followed for 12 months. Baseline VA was 1.38 logMAR (20/480 Snellen equivalent). Mean VA change (logMAR) consisted of an improvement of 0.23 (P, 0.0001) at 6 months and 0.17 (P = 0.003) at 12 months. At 12 months, VA improved in 45% and worsened in 20%. Among subjects with baseline VA worse than 20/400, VA improved in 57% and worsened in 20%. On univariate analysis at either the 6 months or 12 months follow-up, visual improvement was associated with retinal hemorrhage (P = 0.03) and subretinal fluid (P = 0.02), whereas visual worsening was associated with retinal pigment epithelial detachment (P = 0.04) and intraretinal fluid (P = 0.01). With multivariate analysis, visual improvement was predicted by both a larger number of injections received (P = 0.001) and a poorer baseline VA (P = 0.001). Injection medication type did not influence outcome.
   Conclusion: Statistically significant visual improvement was observed in association with anti-vascular endothelial growth factor therapy in patients with severe neovascular age-related macular degeneration, even in patients whose initial VA was worse than that studied in large anti-vascular endothelial growth factor clinical trials. Numerous clinically discernable or potentially modifiable factors may influence outcome in such patients.
C1 [Vogel, Ryan N.; Davis, Drew B.; Kimura, Brad H.; Rathinavelu, Senthil; Graves, Gabrielle S.; Han, Dennis P.] Med Coll Wisconsin, Inst Eye, 925 North 87th St, Milwaukee, WI 53226 USA.
   [Szabo, Aniko] Med Coll Wisconsin, Inst Hlth & Soc, Milwaukee, WI 53226 USA.
C3 Medical College of Wisconsin; Medical College of Wisconsin
RP Han, DP (通讯作者)，Med Coll Wisconsin, Inst Eye, 925 North 87th St, Milwaukee, WI 53226 USA.
EM dhan@mcw.edu
FU Research to Prevent Blindness, Inc, New York, NY; Clinical and
   Translational Science Award (CTSA) program of the National Center for
   Advancing Translational Sciences [8UL1TR000055]; VitreoRetinal Surgery
   Foundation, Minneapolis, MN; Jack A. and Elaine D. Klieger Professorship
FX Supported in part by an unrestricted grant from Research to Prevent
   Blindness, Inc, New York, NY; by grant 8UL1TR000055 from the Clinical
   and Translational Science Award (CTSA) program of the National Center
   for Advancing Translational Sciences; by the VitreoRetinal Surgery
   Foundation, Minneapolis, MN; and by the Jack A. and Elaine D. Klieger
   Professorship (D. Han, MD).
CR Abedi F, 2014, RETINA-J RET VIT DIS, V34, P1531, DOI 10.1097/IAE.0000000000000134
   Abraham P, 2010, AM J OPHTHALMOL, V150, P315, DOI 10.1016/j.ajo.2010.04.011
   Antoszyk AN, 2008, AM J OPHTHALMOL, V145, P862, DOI 10.1016/j.ajo.2007.12.029
   Avery PJ, 2011, CLIN PHARMACOL THER, V90, P701, DOI 10.1038/clpt.2011.186
   Boyer DS, 2007, OPHTHALMOLOGY, V114, P246, DOI 10.1016/j.ophtha.2006.10.045
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   Busbee BG, 2013, OPHTHALMOLOGY, V120, P1046, DOI 10.1016/j.ophtha.2012.10.014
   Chakravarthy U, 2006, OPHTHALMOLOGY, V113, P1508, DOI 10.1016/j.ophtha.2006.02.064
   Chakravarthy U, 2013, LANCET, V382, P1258, DOI 10.1016/S0140-6736(13)61501-9
   Chakravarthy U, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.04.015
   Chrapek O, 2015, J OPHTHALMOL, V2015, DOI 10.1155/2015/867479
   Ehrlich R, 2008, RETINA-J RET VIT DIS, V28, P1302, DOI 10.1097/IAE.0b013e3181803c2a
   Ferrara N, 2006, RETINA-J RET VIT DIS, V26, P859, DOI 10.1097/01.iae.0000242842.14624.e7
   FINE SL, 1982, ARCH OPHTHALMOL-CHIC, V100, P912
   Fish G, 2003, OPHTHALMOLOGY, V110, P979, DOI 10.1016/S0161-6420(03)00085-X
   Fong DS, 2010, OPHTHALMOLOGY, V117, P298, DOI 10.1016/j.ophtha.2009.07.023
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Galbinur T, 2009, BRIT J OPHTHALMOL, V93, P1351, DOI 10.1136/bjo.2009.158931
   Golbaz I, 2011, INVEST OPHTH VIS SCI, V52, P1599, DOI 10.1167/iovs.09-5018
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Heier JS, 2006, ARCH OPHTHALMOL-CHIC, V124, P1532, DOI 10.1001/archopht.124.11.1532
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Holekamp NM, 2014, AM J OPHTHALMOL, V157, P825, DOI 10.1016/j.ajo.2013.12.018
   Holz FG, 2011, OPHTHALMOLOGY, V118, P663, DOI 10.1016/j.ophtha.2010.12.019
   Jaffe GJ, 2013, OPHTHALMOLOGY, V120, P1860, DOI 10.1016/j.ophtha.2013.01.073
   Kaiser PK, 2007, AM J OPHTHALMOL, V144, P850, DOI 10.1016/j.ajo.2007.08.012
   Kiss CG, 2009, INVEST OPHTH VIS SCI, V50, P2376, DOI 10.1167/iovs.08-2017
   Koch R, 2015, BMC OPHTHALMOL, V15, DOI 10.1186/s12886-015-0123-y
   Kodjikian L, 2013, OPHTHALMOLOGY, V120, P2300, DOI 10.1016/j.ophtha.2013.06.020
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Martin DF, 2002, RETINA-J RET VIT DIS, V22, P143
   Novack GD, 2008, ANNU REV PHARMACOL, V48, P61, DOI 10.1146/annurev.pharmtox.48.060607.174028
   Parodi MB, 2012, ARCH OPHTHALMOL-CHIC, V130, P934, DOI 10.1001/archophthalmol.2011.2617
   Regillo CD, 2008, AM J OPHTHALMOL, V145, P239, DOI 10.1016/j.ajo.2007.10.004
   Ristau T, 2013, J CLIN EXP OPHTHALMO, V4, P1
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Schmidt-Erfurth U, 2015, OPHTHALMOLOGY, V122, P822, DOI 10.1016/j.ophtha.2014.11.017
   Schmidt-Erfurth U, 2014, OPHTHALMOLOGY, V121, P193, DOI 10.1016/j.ophtha.2013.08.011
   Schmidt-Erfurth U, 2011, OPHTHALMOLOGY, V118, P831, DOI 10.1016/j.ophtha.2010.09.004
   Shah AR, 2007, AM J OPHTHALMOL, V143, P83, DOI 10.1016/j.ajo.2006.09.043
   Shah AR, 2009, OPHTHALMOLOGY, V116, P1901, DOI 10.1016/j.ophtha.2009.03.055
   Simader C, 2014, OPHTHALMOLOGY, V121, P1237, DOI 10.1016/j.ophtha.2013.12.029
   Sorensen TL, 2011, ACTA OPHTHALMOL, V89, pE97, DOI 10.1111/j.1755-3768.2010.01899.x
   TIMBERLAKE GT, 1987, INVEST OPHTH VIS SCI, V28, P1268
   Veritti D, 2012, OPHTHALMOLOGICA, V227, P11, DOI 10.1159/000337154
   Ying GS, 2013, OPHTHALMOLOGY, V120, P122, DOI 10.1016/j.ophtha.2012.07.042
NR 48
TC 5
Z9 5
U1 0
U2 3
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD FEB
PY 2017
VL 37
IS 2
BP 257
EP 264
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA EK1FO
UT WOS:000393671400014
PM 27429385
DA 2022-11-30
ER

PT J
AU Dossarps, D
   Martine, L
   Berdeaux, O
   Sibille, E
   Bron, AM
   Creuzot-Garcher, CP
   Bretillon, L
   Masson, EAY
AF Dossarps, Denis
   Martine, Lucy
   Berdeaux, Olivier
   Sibille, Estelle
   Bron, Alain M.
   Creuzot-Garcher, Catherine P.
   Bretillon, Lionel
   Masson, Elodie A. Y.
TI Plasmatic Ganglioside Profile and Age-Related Macular Degeneration: A
   Case-Control Study
SO OPHTHALMIC RESEARCH
LA English
DT Article
DE Ganglioside; Glycosphingolipid; Ceramide; Age-related macular
   degeneration; Plasma; Lipids; Liquid chromatography coupled to mass
   spectrometry
ID LIQUID-CHROMATOGRAPHY; QUANTITATIVE-ANALYSIS; MASS-SPECTROMETRY; GD2
   GANGLIOSIDE; SERUM; CANCER; NEUROBLASTOMA; PATHOGENESIS; SANDHOFF
AB Purpose: Gangliosides are glycosphingolipids that are particularly abundant in the nervous system, including the retina. However, their precise role in this tissue and its pathologies remain poorly understood. The objective of the present study was to characterize the ganglioside profile of human plasma and to determine whether it is affected in age-related macular degeneration (AMD). Methods: Eighty-three subjects were included: control subjects (n = 25), atrophic AMD patients (n = 27) and exudative AMD patients (n = 31). For each subject, gangliosides were extracted from plasma and analyzed by liquid chromatography coupled to mass spectrometry. Results: GM3 appeared to be by far the major ganglioside of human plasma, associated with GD3. No specific ganglioside class was detected in the plasma of AMD patients. Fourteen molecular species of GM3 and 9 species of GD3, accounting for the variability of the ceramide moiety of the ganglioside molecule, were identified and characterized. Analyses revealed no significant differences in the proportion of these species between control, atrophic and exudative AMD patient groups. Total GM3 levels did not differ either. Conclusion: Although gangliosides are considered important for the retina's structure and function, it seems that circulating gangliosides are not associated with the retinal damage occurring during the course of AMD. (C) 2016 S. Karger AG, Basel
C1 [Dossarps, Denis; Bron, Alain M.; Creuzot-Garcher, Catherine P.] Univ Bourgogne Franche Comte, Ctr Hosp Univ Dijon, Dept Ophthalmol, Dijon, France.
   [Martine, Lucy; Berdeaux, Olivier; Sibille, Estelle; Bron, Alain M.; Creuzot-Garcher, Catherine P.; Bretillon, Lionel; Masson, Elodie A. Y.] Univ Bourgogne Franche Comte, INRA, CNRS, Ctr Sci Gout & Alimentat, Dijon, France.
C3 CHU Dijon Bourgogne; INRAE; Institut Agro; AgroSup Dijon; Centre
   National de la Recherche Scientifique (CNRS); Universite de Bourgogne
RP Creuzot-Garcher, CP (通讯作者)，Dijon Univ Hosp, Dept Ophthalmol, 14 Rue Gaffarel, FR-21000 Dijon, France.
EM catherine.creuzot-garcher@chu-dijon.fr
RI Bron, Alain/AAP-8010-2020
OI Bron, Alain/0000-0002-7265-931X; MASSON, Elodie/0000-0001-6312-0913;
   Bretillon, Lionel/0000-0002-6957-100X
FU Direction de la recherche clinique (Centre Hospitalier Universitaire de
   Dijon); Universite de Bourgogne Franche-Comte; INRA; Conseil Regional de
   Bourgogne; FEDER
FX This work was funded by the Direction de la recherche clinique (Centre
   Hospitalier Universitaire de Dijon), Universite de Bourgogne
   Franche-Comte, INRA, Conseil Regional de Bourgogne and FEDER.
CR Augustin AJ, 2009, EXPERT OPIN THER TAR, V13, P641, DOI 10.1517/14728220902942322
   Birkle S, 2003, BIOCHIMIE, V85, P455, DOI 10.1016/S0300-9084(03)00006-3
   Crook MA, 2001, DIABETES CARE, V24, P316, DOI 10.2337/diacare.24.2.316
   Czaplicki D, 2009, ACTA BIOCHIM POL, V56, P423
   Denny CA, 2007, J NEUROCHEM, V101, P1294, DOI 10.1111/j.1471-4159.2007.04525.x
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P532
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Kolter T, 2006, BBA-BIOMEMBRANES, V1758, P2057, DOI 10.1016/j.bbamem.2006.05.027
   KUNDU SK, 1985, ARCH BIOCHEM BIOPHYS, V238, P388, DOI 10.1016/0003-9861(85)90179-1
   LADISCH S, 1985, LANCET, V1, P136
   Lin L, 2012, PROTEOMICS, V12, P2238, DOI 10.1002/pmic.201200016
   Masson EAY, 2015, J LIPID RES, V56, P1821, DOI 10.1194/jlr.D060764
   Merrill AH, 2005, METHODS, V36, P207, DOI 10.1016/j.ymeth.2005.01.009
   PANZETTA P, 1980, J NEUROCHEM, V35, P100, DOI 10.1111/j.1471-4159.1980.tb12494.x
   Perez CA, 2002, CANCER J, V8, P55, DOI 10.1097/00130404-200201000-00010
   PORTOUKALIAN J, 1993, INT J CANCER, V53, P948
   Sango K, 2008, OPHTHALMIC RES, V40, P241, DOI 10.1159/000127831
   Sato T, 2008, OBES RES CLIN PRACT, V2, P231, DOI 10.1016/j.orcp.2008.06.001
   SENN HJ, 1989, EUR J BIOCHEM, V181, P657, DOI 10.1111/j.1432-1033.1989.tb14773.x
   Shui GH, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019731
   Wagener R, 1996, J LIPID RES, V37, P1823
   Yu R. K., 2007, COMPREHENSIVE GLYCOS, P73, DOI 10.1016/B978-044451967-2/00003-9
   YU RK, 1972, J LIPID RES, V13, P680
   Yu RK, 2012, NEUROCHEM RES, V37, P1230, DOI 10.1007/s11064-012-0744-y
   Zamfir AD, 2013, ANAL BIOANAL CHEM, V405, P7321, DOI 10.1007/s00216-013-7173-x
   Zaprianova E, 2001, NEUROCHEM RES, V26, P95, DOI 10.1023/A:1011027125744
   Zarbin MA, 2004, ARCH OPHTHALMOL-CHIC, V122, P598, DOI 10.1001/archopht.122.4.598
NR 27
TC 2
Z9 2
U1 0
U2 10
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 0030-3747
EI 1423-0259
J9 OPHTHALMIC RES
JI Ophthalmic Res.
PY 2016
VL 56
IS 1
BP 41
EP 48
DI 10.1159/000444059
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA DN1FR
UT WOS:000376812200007
PM 27035458
DA 2022-11-30
ER

PT J
AU Smit, C
   Wiertz-Arts, K
   van de Garde, EMW
AF Smit, Cornelis
   Wiertz-Arts, Karin
   van de Garde, Ewoudt M. W.
TI Intravitreal aflibercept versus intravitreal ranibizumab in patients
   with age-related macular degeneration: a comparative effectiveness study
SO JOURNAL OF COMPARATIVE EFFECTIVENESS RESEARCH
LA English
DT Article
DE aflibercept; age-related macular degeneration; anti-VEGF treatment;
   comparative effectiveness research; ranibizumab
ID TREATMENT PATTERNS; VEGF TRAP; RE NATA; BEVACIZUMAB; INJECTION
AB Aim: A hospital-wide, unselected switch of ranibizumab to aflibercept in treatment of age-related macular degeneration (AMD) allowed us to compare the clinical effectiveness of these agents. Method: In a single-center before-after, observational study design new AMD-patients started with aflibercept treatment in 2013-2014 were compared with a control group of AMD-patients on ranibizumab before the switch. Results: The mean difference in visual acuity (in logMAR units) after 1 year was comparable (+0.012 [aflibercept, n=37] vs +0.17 [ranibizumab, n=30], p=0.154). However, the aflibercept-group did receive more intravitreal injections (5.8vs 4.7 injections, p=0.004) and were treated longer (265.7vs 197.7days; p=0.011). Conclusion: With no difference in clinical effectiveness, longer treatment intervals for aflibercept should be investigated.
C1 [Smit, Cornelis; van de Garde, Ewoudt M. W.] St Antonius Hosp, Dept Pharm, Nieuwegein, Netherlands.
   [Wiertz-Arts, Karin] St Antonius Hosp, Dept Ophthalmol, Nieuwegein, Netherlands.
C3 St. Antonius Hospital Utrecht; St. Antonius Hospital Utrecht
RP van de Garde, EMW (通讯作者)，St Antonius Hosp, Dept Pharm, Nieuwegein, Netherlands.
EM e.van.de.garde@antoniusziekenhuis.nl
RI Smit, Cornelis/AAK-8756-2020
OI Smit, Cornelis/0000-0002-1357-9248
CR Bohni SC, 2015, BMC OPHTHALMOL, V15, DOI 10.1186/s12886-015-0101-4
   Cho H, 2013, BRIT J OPHTHALMOL, V97, P1032, DOI 10.1136/bjophthalmol-2013-303344
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Holladay JT, 1997, J REFRACT SURG, V13, P388
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Johnston SS, 2013, ADV THER, V30, P1111, DOI 10.1007/s12325-013-0078-4
   Lotery AJ, 2015, EYE, V29, P380, DOI 10.1038/eye.2014.308
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Mori R, 2017, OPHTHALMOLOGICA, V238, P17, DOI 10.1159/000468950
   Ohnaka M, 2017, GRAEF ARCH CLIN EXP, V255, P657, DOI 10.1007/s00417-016-3507-7
   Reich O, 2015, RISK MANAG HEALTHC P, V8, P55, DOI 10.2147/RMHP.S80536
   Sox HC, 2009, ANN INTERN MED, V151, P203, DOI 10.7326/0003-4819-151-3-200908040-00125
   Stewart MW, 2008, BRIT J OPHTHALMOL, V92, P667, DOI 10.1136/bjo.2007.134874
   Takayama K, 2017, OPHTHALMOLOGICA, V237, P105, DOI 10.1159/000461785
   Yancopoulos GD, 2010, CELL, V143, P13, DOI 10.1016/j.cell.2010.09.028
   Yuzawa M, 2015, OPHTHALMOLOGY, V122, P571, DOI 10.1016/j.ophtha.2014.09.024
NR 16
TC 2
Z9 2
U1 0
U2 1
PU FUTURE MEDICINE LTD
PI LONDON
PA UNITEC HOUSE, 3RD FLOOR, 2 ALBERT PLACE, FINCHLEY CENTRAL, LONDON, N3
   1QB, ENGLAND
SN 2042-6305
EI 2042-6313
J9 J COMP EFFECT RES
JI J. Comp. Eff. Res.
PD JUN
PY 2018
VL 7
IS 6
BP 561
EP 567
DI 10.2217/cer-2017-0099
PG 7
WC Health Care Sciences & Services
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Health Care Sciences & Services
GA GL3RL
UT WOS:000437057400005
PM 29855194
OA Green Submitted
DA 2022-11-30
ER

PT J
AU Kim, YH
   Lee, B
   Kang, E
   Oh, J
AF Kim, Young Ho
   Lee, Boram
   Kang, Edward
   Oh, Jaeryung
TI Comparison of Regional Differences in the Choroidal Thickness between
   Patients with Pachychoroid Neovasculopathy and Classic Exudative
   Age-related Macular Degeneration
SO CURRENT EYE RESEARCH
LA English
DT Article
DE Age-related macular degeneration; pachychoroid neovasculopathy;
   peripapillary choroidal thickness; regional choroidal differences;
   subfoveal choroidal thickness
ID CENTRAL SEROUS CHORIORETINOPATHY; BRUCHS MEMBRANE; DISEASE; EYES
AB Purpose: To compare the regional differences in the choroidal thickness (CT) between patients with pachychoroid neovasculopathy (PNV) and classic exudative age-related macular degeneration (ceAMD).
   Materials and Methods: We included both eyes of patients with unilateral macular neovascularization (MNV) due to ceAMD or PNV. Unilateral eyes of normal subjects were also included as a normal control group. The regional difference in CT was defined as a difference between the macular and extramacular areas, and calculated as the ratio of subfoveal CT (SFCT) to nasal peripapillary CT (PCT).
   Results: In normal subjects, the choroid was 2.25 +/- 0.10 times thicker at the macula than at the extramacular area. The SFCT and PCT were significantly affected by age (P P < .001, respectively), whereas the regional difference in CT were independent of age (P = .076). Analysis of covariance including age, sex, and MNV group showed that regional difference in CT were significantly affected by sex, nasal peripapillary CT, and MNV group (P = .023, P < .001, and P < .001, respectively). The estimated marginal mean of the regional difference in CT was significantly smaller in the ceAMD group (1.671 +/- 0.103) than in the normal control (2.250 +/- 0.095, P = .003) and PNV groups (2.0880 +/- 0.086, P < .001).
   Conclusions: Regional differences in CT were consistent with aging. However, the difference varied with the presence of PNV or ceAMD. Measurement of regional differences in CT provides additional information for characterizing the choroid in patients with MNV.
C1 [Kim, Young Ho; Lee, Boram; Kang, Edward; Oh, Jaeryung] Korea Univ, Coll Med, Dept Ophthalmol, Seoul, South Korea.
C3 Korea University; Korea University Medicine (KU Medicine)
RP Oh, J (通讯作者)，Korea Univ Med, Dept Ophthalmol, 73 Goryeodae Ro, Seoul 02841, South Korea.
EM ojr4991@korea.ac.kr
RI Kim, Young Ho/ABH-7801-2020; Kang, Edward/V-4367-2019; Oh,
   Jaeryung/ABD-3090-2021
OI Kim, Young Ho/0000-0002-5281-1185; Kang, Edward/0000-0001-7482-8757; Oh,
   Jaeryung/0000-0002-1036-6562
FU Korea Medical Device Development Fund - Korea government (the Ministry
   of Science and ICT); Ministry of Trade, Industry and Energy; Ministry of
   Health Welfare; Ministry of Food and Drug Safety [9991007076,
   KMDF_RnD_202011B20-02]
FX This work was supported by the Korea Medical Device Development Fund
   grant funded by the Korea government (the Ministry of Science and ICT,
   the Ministry of Trade, Industry and Energy, the Ministry of Health &
   Welfare, the Ministry of Food and Drug Safety) [NTIS Number: 9991007076,
   KMDF_RnD_202011B20-02].
CR Abdolrahimzadeh S, 2017, CURR EYE RES, V42, P1468, DOI 10.1080/02713683.2017.1347692
   Balaratnasingam C, 2016, RETINA-J RET VIT DIS, V36, P1, DOI 10.1097/IAE.0000000000000774
   Borrelli E, 2018, AM J OPHTHALMOL, V196, P34, DOI 10.1016/j.ajo.2018.08.014
   Cheung CMG, 2019, EYE, V33, P14, DOI 10.1038/s41433-018-0158-4
   Chong NHV, 2005, AM J PATHOL, V166, P241, DOI 10.1016/S0002-9440(10)62248-1
   Chung SE, 2011, OPHTHALMOLOGY, V118, P840, DOI 10.1016/j.ophtha.2010.09.012
   Dansingani KK, 2016, RETINA-J RET VIT DIS, V36, P499, DOI 10.1097/IAE.0000000000000742
   Ferreira JT, 2017, AM J OPHTHALMOL, V176, P15, DOI 10.1016/j.ajo.2016.12.023
   Flores-Moreno I, 2013, BRIT J OPHTHALMOL, V97, P1010, DOI 10.1136/bjophthalmol-2012-302836
   FREUND KB, 1993, AM J OPHTHALMOL, V115, P786, DOI 10.1016/S0002-9394(14)73649-9
   Fung AT, 2012, RETINA-J RET VIT DIS, V32, P1829, DOI 10.1097/IAE.0b013e3182680a66
   Hayreh SS, 2004, INVEST OPHTH VIS SCI, V45, P749, DOI 10.1167/iovs.03-0469
   HAYREH SS, 1975, BRIT J OPHTHALMOL, V59, P631, DOI 10.1136/bjo.59.11.631
   Hirata M, 2011, INVEST OPHTH VIS SCI, V52, P4971, DOI 10.1167/iovs.11-7729
   Huang W., 2020, CURR EYE RES
   Joachim N, 2014, INVEST OPHTH VIS SCI, V55, P4421, DOI 10.1167/iovs.14-14476
   Kawasaki R, 2010, OPHTHALMOLOGY, V117, P921, DOI 10.1016/j.ophtha.2009.10.007
   Kim SW, 2011, RETINA-J RET VIT DIS, V31, P1904, DOI 10.1097/IAE.0b013e31821801c5
   Lee J, 2019, RETINA-J RET VIT DIS, V39, P670, DOI 10.1097/IAE.0000000000002019
   Lee M, 2018, INVEST OPHTH VIS SCI, V59, P4896, DOI 10.1167/iovs.18-25018
   Li XQ, 2011, INVEST OPHTH VIS SCI, V52, P8438, DOI 10.1167/iovs.11-8108
   Mansouri K, 2013, OPHTHALMOLOGY, V120, P2508, DOI 10.1016/j.ophtha.2013.07.040
   Margolis R, 2009, AM J OPHTHALMOL, V147, P811, DOI 10.1016/j.ajo.2008.12.008
   Miyake M, 2015, SCI REP-UK, V5, DOI 10.1038/srep16204
   Nassisi M, 2019, GRAEF ARCH CLIN EXP, V257, P2079, DOI 10.1007/s00417-019-04403-1
   Nickla DL, 2010, PROG RETIN EYE RES, V29, P144, DOI 10.1016/j.preteyeres.2009.12.002
   Oh Jaeryung, 2013, Korean J Ophthalmol, V27, P172, DOI 10.3341/kjo.2013.27.3.172
   Pang CE, 2015, RETINA-J RET VIT DIS, V35, P1, DOI 10.1097/IAE.0000000000000331
   Pauleikhoff D, 2005, RETINA-J RET VIT DIS, V25, P1065, DOI 10.1097/00006982-200512000-00016
   Sayin N, 2015, INDIAN J OPHTHALMOL, V63, P445, DOI 10.4103/0301-4738.159884
   Sizmaz S, 2013, BRIT J OPHTHALMOL, V97, P601, DOI 10.1136/bjophthalmol-2012-302393
   Spaide RF, 2008, AM J OPHTHALMOL, V146, P496, DOI 10.1016/j.ajo.2008.05.032
   Spaide RF, 2020, OPHTHALMOLOGY, V127, P616, DOI 10.1016/j.ophtha.2019.11.004
   Spaide RF, 2018, RETINA-J RET VIT DIS, V38, P891, DOI 10.1097/IAE.0000000000001732
   Spaide RF, 2018, RETINA-J RET VIT DIS, V38, P708, DOI 10.1097/IAE.0000000000001689
   Spraul CW, 1999, SURV OPHTHALMOL, V44, pS10, DOI 10.1016/S0039-6257(99)00086-7
   Touhami S, 2020, INVEST OPHTH VIS SCI, V61, DOI 10.1167/iovs.61.3.38
   Usui S, 2012, INVEST OPHTH VIS SCI, V53, P2300, DOI 10.1167/iovs.11-8383
   Vujosevic S, 2012, RETINA-J RET VIT DIS, V32, P1781, DOI 10.1097/IAE.0b013e31825db73d
   Wang W, 2020, INVEST OPHTH VIS SCI, V61, DOI 10.1167/iovs.61.4.29
   Xu J, 2013, OPHTHALMOLOGY, V120, P2023, DOI 10.1016/j.ophtha.2013.03.009
   Yun C, 2016, GRAEF ARCH CLIN EXP, V254, P427, DOI 10.1007/s00417-015-3054-7
   Yun C, 2015, RETINA-J RET VIT DIS, V35, P1860, DOI 10.1097/IAE.0000000000000539
NR 43
TC 3
Z9 3
U1 0
U2 4
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0271-3683
EI 1460-2202
J9 CURR EYE RES
JI Curr. Eye Res.
PD SEP 2
PY 2021
VL 46
IS 9
BP 1398
EP 1405
DI 10.1080/02713683.2021.1887269
EA FEB 2021
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA TY9BU
UT WOS:000621295600001
PM 33550884
DA 2022-11-30
ER

PT J
AU Kefauver, SC
AF Kefauver, S. C.
TI EMIXUSTAT HYDROCHLORIDE Retinoid isomerohydrolase (RPE65) inhibitor,
   Treatment of age-related macular degeneration.
SO DRUGS OF THE FUTURE
LA English
DT Article
DE Age-related macular degeneration; Vision loss; Vascular endothelial
   growth factor; Emixustat hydrochloride; ACU-4429
ID BODY-MASS INDEX; VISUAL CYCLE; CIGARETTE-SMOKING; RISK-FACTORS;
   VITAMIN-C; ASSOCIATIONS; RANIBIZUMAB; PATHOGENESIS; ACU-4429; VARIANT
AB Age-related macular degeneration (AMD) is one of the leading causes of vision loss worldwide, especially in elderly populations, which are expected to nearly triple in the next few decades. As recent as 10 years ago there were no treatment options for either the early or advanced stages of wet (neovascular, exudative) and dry (geographic atrophy, non-exudative) AMD, but development has since advanced rapidly on a number of fronts. Vascular endothelial growth factor (VEGF) antagonists have been largely successful in the prevention or delay of blindness due to wet AMD. While anti-VEGF therapy has greatly improved treatment of wet AMD, there is still a large unmet therapeutic need concerning dry AMD. Considerable progress has been made in improving our understanding of the epidemiology and pathogenesis of AMD, but the intermediate and advanced forms of dry AMD still have no approved therapeutic treatments. Emixustat hydrochloride (ACU-4429), a novel modulator of the visual cycle, has shown promise for the treatment of dry AMD by suppressing the production and accumulation of toxic retinoid by-products, and thus preserving the overall health of ageing ocular tissues. It has shown considerable promise, with favorable safety and efficacy profiles in preclinical and phase I studies, and is currently in phase II/III studies.
C1 Thomson Reuters, Barcelona, Spain.
C3 Clarivate
RP Kefauver, SC (通讯作者)，Thomson Reuters, Barcelona, Spain.
EM shawn.kefauver@thomsonreuters.com
RI Kefauver, Shawn Carlisle/AAK-8461-2020
OI Kefauver, Shawn Carlisle/0000-0002-1687-1965
CR Al-Fayoumi S., 2012, ANNU MEET ASSOC RES
   Andreoli MT, 2009, AM J OPHTHALMOL, V148, P869, DOI 10.1016/j.ajo.2009.07.002
   [Anonymous], 1991, Arch Ophthalmol, V109, P1109
   [Anonymous], 1986, Arch Ophthalmol, V104, P694
   [Anonymous], [No title captured], Patent No. 2011512321
   [Anonymous], [No title captured], Patent No. 103553945
   [Anonymous], [No title captured], Patent No. 2012214852
   [Anonymous], [No title captured], Patent No. 2012122938
   [Anonymous], [No title captured], Patent No. 2013197096
   [Anonymous], [No title captured], Patent No. 2009045479
   [Anonymous], [No title captured], Patent No. 7982071
   [Anonymous], [No title captured], Patent No. 2009326074
   [Anonymous], [No title captured], Patent No. 2091955
   [Anonymous], [No title captured], Patent No. 8829244
   Bavik C., 2009, ANNU MEET ASSOC RES
   Birch D.G., 2012, ANNU MEET ASSOC RES
   Bloch SB, 2012, AM J OPHTHALMOL, V153, P209, DOI 10.1016/j.ajo.2011.10.016
   Brechner RJ, 2011, AM J OPHTHALMOL, V151, P887, DOI 10.1016/j.ajo.2010.11.017
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Chew EY, 2013, OPHTHALMOLOGY, V120, P1604, DOI 10.1016/j.ophtha.2013.01.021
   Chew EY, 2012, OPHTHALMOLOGY, V119, P2282, DOI 10.1016/j.ophtha.2012.05.027
   Chopdar A, 2003, BRIT MED J, V326, P485, DOI 10.1136/bmj.326.7387.485
   Curtis LH, 2010, ARCH OPHTHALMOL-CHIC, V128, P1273, DOI 10.1001/archophthalmol.2010.223
   David R., 2010, 30TH ANNU MEET SOC V
   Dixon JA, 2009, EXPERT OPIN INV DRUG, V18, P1573, DOI 10.1517/13543780903201684
   Dugel P.U., 2013, ANNU MEET ASSOC RES
   Ferris FL, 2005, ARCH OPHTHALMOL-CHIC, V123, P1570
   Francis PJ, 2007, HUM HERED, V63, P212, DOI 10.1159/000100046
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Henry S.H., 2012, ANNU MEET ASSOC RES
   Henry SH, 2014, INVEST OPHTH VIS SCI, V55
   Holz FG, 2007, AM J OPHTHALMOL, V143, P463, DOI 10.1016/j.ajo.2006.11.041
   HUANG D, 1991, SCIENCE, V254, P1178, DOI 10.1126/science.1957169
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Kawasaki R, 2010, OPHTHALMOLOGY, V117, P921, DOI 10.1016/j.ophtha.2009.10.007
   Kubota R., 2009, ANNU MEET ASSOC RES
   Kubota R, 2014, RETINA-J RET VIT DIS, V34, P603, DOI 10.1097/01.iae.0000434565.80060.f8
   Kubota R, 2012, RETINA-J RET VIT DIS, V32, P183, DOI 10.1097/IAE.0b013e318217369e
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Maller J, 2006, NAT GENET, V38, P1055, DOI 10.1038/ng1873
   Mata N., 2013, 10ST INT SYMP OCULAR
   Mata N., 2013, RETINAL PHYSICIAN, V10, P20
   McConnell V, 2005, Ulster Med J, V74, P82
   Mcgee D.H., 2009, ANNU MEET ASSOC RES
   Milton RC, 2005, OPHTHALMOLOGY, V112, P533, DOI 10.1016/j.ophtha.2004.10.047
   Mitchell P, 1998, OPHTHALMOLOGY, V105, P1359, DOI 10.1016/S0161-6420(98)98013-7
   Nowak JZ, 2006, PHARMACOL REP, V58, P353
   Peeters A, 2008, ARCH OPHTHALMOL-CHIC, V126, P1554, DOI 10.1001/archopht.126.11.1554
   Podoll T., 2012, INVEST OPHTH VIS SCI, V53, P5353
   Podoll T, 2013, INVEST OPHTH VIS SCI, V54
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   SanGiovanni JP, 2007, ARCH OPHTHALMOL-CHIC, V125, P1225, DOI 10.1001/archopht.125.9.1225
   Schmucker C, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0042701
   Schmucker C, 2011, BRIT J OPHTHALMOL, V95, P308, DOI 10.1136/bjo.2009.178574
   Schutt F, 2002, OPHTHALMOLOGE, V99, P301, DOI 10.1007/s00347-002-0605-1
   Seddon JM, 1996, JAMA-J AM MED ASSOC, V276, P1141, DOI 10.1001/jama.276.14.1141
   SEDDON JM, 1994, JAMA-J AM MED ASSOC, V272, P1413, DOI 10.1001/jama.272.18.1413
   Seddon JM, 2006, ARCH OPHTHALMOL-CHIC, V124, P995, DOI 10.1001/archopht.124.7.995
   Seddon Johanna M., 2004, International Ophthalmology Clinics, V44, P17, DOI 10.1097/00004397-200404440-00004
   Seddon JM, 2010, MOL VIS, V16, P2412
   Smith W, 2001, OPHTHALMOLOGY, V108, P697, DOI 10.1016/S0161-6420(00)00580-7
   SNODDERLY DM, 1995, AM J CLIN NUTR, V62, P1448
   Sobrin L, 2011, AM J OPHTHALMOL, V151, P345, DOI 10.1016/j.ajo.2010.08.015
   Tan JSL, 2007, OPHTHALMOLOGY, V114, P1143, DOI 10.1016/j.ophtha.2006.09.033
   Travis GH, 2007, ANNU REV PHARMACOL, V47, P469, DOI 10.1146/annurev.pharmtox.47.120505.105225
   Wormald R, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD002030.pub3
   Yu Y, 2011, HUM MOL GENET, V20, P3699, DOI 10.1093/hmg/ddr270
   Zarbin MA, 2004, ARCH OPHTHALMOL-CHIC, V122, P598, DOI 10.1001/archopht.122.4.598
NR 71
TC 1
Z9 1
U1 0
U2 12
PU PROUS SCIENCE, SAU-THOMSON REUTERS
PI BARCELONA
PA 398 PROVENCA, 08025 BARCELONA, SPAIN
SN 0377-8282
EI 2013-0368
J9 DRUG FUTURE
JI Drug Future
PD SEP
PY 2014
VL 39
IS 9
BP 615
EP 625
DI 10.1358/dof.2014.039.09.2207181
PG 11
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA AQ7QJ
UT WOS:000343014000002
DA 2022-11-30
ER

PT J
AU Hirani, A
   Grover, A
   Lee, YW
   Pathak, Y
   Sutariya, V
AF Hirani, Anjali
   Grover, Aditya
   Lee, Yong W.
   Pathak, Yashwant
   Sutariya, Vijaykumar
TI Triamcinolone acetonide nanoparticles incorporated in thermoreversible
   gels for age-related macular degeneration
SO PHARMACEUTICAL DEVELOPMENT AND TECHNOLOGY
LA English
DT Article
DE Age-related macular degeneration; PLGA nanoparticles; triamcinolone
   acetonide; thermoreversible gel; VEGF
ID DRUG-DELIVERY; CHOROIDAL NEOVASCULARIZATION; INTRAVITREAL INJECTION;
   PLGA NANOPARTICLES; SUSTAINED DELIVERY; PARTICLE-SIZE; IN-VITRO;
   PHARMACOKINETICS; CORTICOSTEROIDS; DEXAMETHASONE
AB Age-related macular degeneration (AMD) is one of the leading causes of blindness in the US affecting millions yearly. It is characterized by intraocular neovascularization, inflammation and retinal damage which can be ameliorated through intraocular injections of glucocorticoids. However, the complications that arise from repetitive injections as well as the difficulty posed by targeting the posterior segment of the eye make this interesting territory for the development of novel drug delivery systems (DDS). In the present study, we described the development of a DDS composed of triamcinolone acetonide-encapsulated PEGylated PLGA nanoparticles (NP) incorporated into PLGA-PEG-PLGA thermoreversible gel and its use against VEGF expression characteristic of AMD. We found that the NP with mean size of 208 +/- 1.0nm showed uniform size distribution and exhibited sustained release of the drug. We also demonstrated that the polymer can be injected as a solution and transition to a gel phase based on the biological temperature of the eye. Additionally, the proposed DDS was non-cytotoxic to ARPE-19 cells and significantly reduced VEGF expression by 43.5 +/- 3.9% as compared to a 1.53 +/- 11.1% reduction with triamcinolone. These results suggest the proposed DDS will contribute to the development of novel therapeutic strategies for AMD.
C1 [Hirani, Anjali; Grover, Aditya; Pathak, Yashwant; Sutariya, Vijaykumar] Univ S Florida, USF Coll Pharm, Dept Pharmaceut Sci, Tampa, FL 33612 USA.
   [Hirani, Anjali; Lee, Yong W.] Virginia Tech Wake Forest Univ, Sch Biomed Engn & Sci, Blacksburg, VA USA.
C3 State University System of Florida; University of South Florida;
   Virginia Polytechnic Institute & State University
RP Sutariya, V (通讯作者)，Univ S Florida, Coll Pharm, Dept Pharmaceut Sci, 12901 Bruce B Downs Blvd MDC 30, Tampa, FL 33612 USA.
EM vsutariy@health.usf.edu
RI pathak, yashwant/AAN-3177-2021
CR Bala I, 2004, CRIT REV THER DRUG, V21, P387, DOI 10.1615/CritRevTherDrugCarrierSyst.v21.i5.20
   Bourges JL, 2003, INVEST OPHTH VIS SCI, V44, P3562, DOI 10.1167/iovs.02-1068
   Bu HZ, 2007, CURR DRUG METAB, V8, P91, DOI 10.2174/138920007779815977
   Budhian A, 2007, INT J PHARM, V336, P367, DOI 10.1016/j.ijpharm.2006.11.061
   Buschini E, 2011, PROG NEUROBIOL, V95, P14, DOI 10.1016/j.pneurobio.2011.05.011
   Bylsma Guy W, 2005, Clin Exp Optom, V88, P322
   Carroll RT, 2010, J DRUG TARGET, V18, P665, DOI 10.3109/10611861003639796
   Choi BG, 2010, BIOMATERIALS, V31, P9266, DOI 10.1016/j.biomaterials.2010.08.067
   Ciulla TA, 2001, ARCH OPHTHALMOL-CHIC, V119, P399, DOI 10.1001/archopht.119.3.399
   Duvvuri S, 2005, J CONTROL RELEASE, V108, P282, DOI 10.1016/j.jconrel.2005.09.002
   Fernandez-Robredo P, 2014, J OPHTHALMOL, V2014, DOI 10.1155/2014/510285
   Ferrara N, 2003, NAT MED, V9, P669, DOI 10.1038/nm0603-669
   Gambhire S, 2013, INT J PHARM PHARM SC, V5, P27
   Gaudana R, 2010, AAPS J, V12, P348, DOI 10.1208/s12248-010-9183-3
   Geldenhuys W, 2011, J DRUG TARGET, V19, P837, DOI 10.3109/1061186X.2011.589435
   Gomez-Graete C, 2007, INT J PHARMACEUT, V331, P153, DOI 10.1016/j.ijpharm.2006.11.028
   Gopal Lekha, 2007, Indian Journal of Ophthalmology, V55, P431
   HAWKINS BS, 1993, ARCH OPHTHALMOL-CHIC, V111, P1200
   Kadam RS, 2012, INT J PHARMACEUT, V434, P140, DOI 10.1016/j.ijpharm.2012.05.025
   Kreppel F, 2008, MOL THER, V16, P16, DOI 10.1038/sj.mt.6300321
   Li FF, 2012, OPEN OPHTHALMOL J, V6, P54, DOI 10.2174/1874364101206010054
   Majithiya RJ, 2006, AAPS PHARMSCITECH, V7
   McGhee CNJ, 2002, DRUG SAFETY, V25, P33, DOI 10.2165/00002018-200225010-00004
   Moghimipour E., 2013, RES J PHARM BIOL CHE, V4, P101
   Nirmal H.B., 2010, INT J PHARMTECH RES, V2, P1398
   Nowak JZ, 2006, PHARMACOL REP, V58, P353
   Park D, 2013, MACROMOL BIOSCI, V13, P464, DOI 10.1002/mabi.201200384
   Park YG, 2012, J OPHTHALMOL, V2012, DOI 10.1155/2012/637316
   Patel Ashaben, 2013, World J Pharmacol, V2, P47
   Patel SP, 2014, J DRUG DELIV, V2014, DOI 10.1155/2014/401747
   Peyman GA, 2009, RETINA-J RET VIT DIS, V29, P875, DOI 10.1097/IAE.0b013e3181a94f01
   Regatieri C, 2012, AGE RELATED MACULAR, P83
   Sabzevari A, 2013, EUR J PHARM BIOPHARM, V84, P63, DOI 10.1016/j.ejpb.2012.12.010
   Sherif Z, 2002, OPHTHALMOLOGICA, V216, P305, DOI 10.1159/000066189
   Spaide RF, 2003, OPHTHALMOLOGY, V110, P1517, DOI 10.1016/S0161-6420(03)00544-X
   Suen WLL, 2013, J CONTROL RELEASE, V167, P21, DOI 10.1016/j.jconrel.2013.01.004
   Sutariya V, 2013, PHARM DEV TECHNOL, V18, P957, DOI 10.3109/10837450.2011.647035
   Tamboli V, 2013, COLLOID POLYM SCI, V291, P1235, DOI 10.1007/s00396-012-2854-0
   Thrimawithana TR, 2011, DRUG DELIV LETT, V1, P40
   Urtti A, 2006, ADV DRUG DELIVER REV, V58, P1131, DOI 10.1016/j.addr.2006.07.027
   Vodithala S., 2010, INT J BIOPHARM, V1, P39
   Wang YS, 2002, GRAEF ARCH CLIN EXP, V240, P42, DOI 10.1007/s00417-001-0398-y
   Wu WS, 2006, J INVEST DERMATOL, V126, P1264, DOI 10.1038/sj.jid.5700274
   Yasukawa T, 2004, PROG RETIN EYE RES, V23, P253, DOI 10.1016/j.preteyeres.2004.02.003
   Yoncheva K, 2000, PHARMAZIE, V55, P148
   Zhang WS, 2004, J CONTROL RELEASE, V99, P241, DOI 10.1016/j.jconrel.2004.07.001
   Zhou HY, 2013, INT J OPHTHALMOL-CHI, V6, P390, DOI 10.3980/j.issn.2222-3959.2013.03.25
NR 47
TC 32
Z9 34
U1 0
U2 35
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 1083-7450
EI 1097-9867
J9 PHARM DEV TECHNOL
JI Pharm. Dev. Technol.
PD JAN 2
PY 2016
VL 21
IS 1
BP 61
EP 67
DI 10.3109/10837450.2014.965326
PG 7
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA DB7LR
UT WOS:000368697300008
PM 25259682
DA 2022-11-30
ER

PT J
AU Kim, KL
   Han, JM
   Kim, MS
   Park, SJ
   Kim, SW
   Kim, JH
   Kim, M
   Lee, CS
   Kang, HG
   Lee, JY
   Woo, SJ
AF Kim, Kyoung Lae
   Han, Jeong Mo
   Kim, Min Seok
   Park, Sang Jun
   Kim, Seong-Woo
   Kim, Jae Hui
   Kim, Min
   Lee, Christopher Seungkyu
   Kang, Hyun Goo
   Lee, Joo Yong
   Woo, Se Joon
TI MACULAR HOLE ASSOCIATED WITH AGE-RELATED MACULAR DEGENERATION
   Pathogenesis and Surgical Outcomes
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE age-related macular degeneration; macular hole; mechanism; optical
   coherence tomography; vitrectomy
ID OPTICAL COHERENCE TOMOGRAPHY; VITREOMACULAR ADHESION; VITRECTOMY;
   INTERFACE; INJECTION
AB Purpose: To ascertain the pathogenesis of macular hole (MH) associated with age-related macular degeneration (AMD) and its surgical outcomes. Methods: Patients with full-thickness MH associated with AMD (higher grades than intermediate) were enrolled. The mechanism of MH formation and closure rate after vitrectomy (surgical outcome) were determined using optical coherence tomography imaging. Results: The mechanism of MH formation (35 eyes) associated with AMD was classified into four types: vitreomacular traction (42.9%), gradual retinal thinning caused by subretinal drusen or pigment epithelial detachment (22.9%), massive subretinal hemorrhage (20.0%), and combined (14.3%). In the 41 eyes that underwent vitrectomy, the logarithm of the minimum angle of resolution best-corrected visual acuity improved from 0.82 (0.10-2.30) preoperative to 0.69 (0.10-2.30) postoperative (P = 0.001). Successful closure of the MH was achieved in 33 eyes (80.5%) after vitrectomy. No significant association was observed between the closure rate of MH after vitrectomy and mechanism of MH formation (P = 0.083). Conclusion: The mechanism of MH formation associated with AMD was classified into four types and was not related to its surgical outcome. Considering visual improvement and surgical outcome after vitrectomy in our study, active surgical treatment can be considered for MH associated with AMD.
C1 [Kim, Kyoung Lae; Kim, Min Seok; Park, Sang Jun; Woo, Se Joon] Seoul Natl Univ Bundang Hosp, Seoul Natl Univ Coll Med, Dept Ophthalmol, Gyeonggi Do, South Korea.
   [Kim, Kyoung Lae] Gangwon Natl Univ Hosp, Gangwon Natl Univ Coll Med, Dept Ophthalmol, Gangwon Do, South Korea.
   [Han, Jeong Mo] Seoul Natl Univ Hosp, Seoul Natl Univ Coll Med, Dept Ophthalmol, Seoul, South Korea.
   [Han, Jeong Mo] Kong Eye Hosp, Seoul, South Korea.
   [Kim, Seong-Woo] Korea Univ Med, Korea Univ Guro Hosp, Dept Ophthalmol, Seoul, South Korea.
   [Kim, Jae Hui] Kims Eye Hosp, Dept Ophthalmol, Seoul, South Korea.
   [Kim, Min; Kang, Hyun Goo] Yonsei Univ Coll Med, Gangnam Severance Hosp, Dept Ophthalmol, Seoul, South Korea.
   [Lee, Christopher Seungkyu] Yonsei Univ Coll Med, Severance Hosp, Inst Vis Res, Dept Ophthalmol, Seoul, South Korea.
   [Lee, Joo Yong] Univ Ulsan, Asan Med Ctr, Dept Ophthalmol, Coll Med, Seoul, South Korea.
C3 Seoul National University (SNU); Seoul National University Hospital;
   Korea University; Korea University Medicine (KU Medicine); Yonsei
   University; Yonsei University Health System; Yonsei University; Yonsei
   University Health System; University of Ulsan; Asan Medical Center
RP Woo, SJ (通讯作者)，Seoul Natl Univ Bundang Hosp, Seoul Natl Univ Coll Med, Dept Ophthalmol, 82 Gumi Ro,173Beon Gil, Seongnam Si 13620, Gyeonggi Do, South Korea.
EM sejoon1@snu.ac.kr
RI ; Kang, Hyun Goo/C-5569-2018
OI Lee, Christopher/0000-0001-5054-9470; Kang, Hyun
   Goo/0000-0001-8359-9618; Kim, Min/0000-0003-1873-6959
CR Berinstein DM, 2000, OPHTHALMOLOGY, V107, P2233, DOI 10.1016/S0161-6420(00)00417-6
   Clemens CR, 2010, J OCUL PHARMACOL TH, V26, P297, DOI 10.1089/jop.2009.0140
   Duker JS, 2013, OPHTHALMOLOGY, V120, P2611, DOI 10.1016/j.ophtha.2013.07.042
   Ferris FL, 2005, ARCH OPHTHALMOL-CHIC, V123, P1570
   Jackson TL, 2013, OPHTHALMOLOGY, V120, P629, DOI 10.1016/j.ophtha.2012.09.003
   Johnson Mark W, 2012, Retina, V32 Suppl 2, pS174, DOI 10.1097/IAE.0b013e31825bef62
   JOHNSON RN, 1988, OPHTHALMOLOGY, V95, P917
   Krebs I, 2007, AM J OPHTHALMOL, V144, P741, DOI 10.1016/j.ajo.2007.07.024
   Kumar Vinod, 2012, Retin Cases Brief Rep, V6, P109, DOI 10.1097/ICB.0b013e31820a2f30
   Kumawat D, 2019, RETINA-J RET VIT DIS, V39, P1236, DOI 10.1097/IAE.0000000000002448
   Mitchell P, 2018, LANCET, V392, P1147, DOI 10.1016/S0140-6736(18)31550-2
   Moisseiev E, 2010, CASE REP OPHTHALM, V1, P36, DOI 10.1159/000319827
   Mojana F, 2008, AM J OPHTHALMOL, V146, P218, DOI 10.1016/j.ajo.2008.04.027
   Mukherjee C, 2015, OPEN OPHTHALMOL J, V9, P177, DOI 10.2174/1874364101509010177
   Oshima Y, 2015, BMC OPHTHALMOL, V15, DOI 10.1186/s12886-015-0021-3
   Rao P, 2017, OPHTHALMOL RETINA, V1, P158, DOI 10.1016/j.oret.2016.09.014
   Regatieri Caio V, 2012, Retin Cases Brief Rep, V6, P125, DOI 10.1097/ICB.0b013e3182160952
   Ringeisen Alexander L, 2019, Int Ophthalmol Clin, V59, P127, DOI 10.1097/IIO.0000000000000248
   Sadda SR, 2018, OPHTHALMOLOGY, V125, P537, DOI 10.1016/j.ophtha.2017.09.028
   Sakaguchi H, 2012, CLIN OPHTHALMOL, V6, P1281, DOI 10.2147/OPTH.S34629
   SEBAG J, 1987, GRAEF ARCH CLIN EXP, V225, P89, DOI 10.1007/BF02160337
   Solomon SD, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005139.pub3
   Storch MW, 2017, INDIAN J OPHTHALMOL, V65, P632, DOI 10.4103/ijo.IJO_818_16
   Tanner V, 2001, BRIT J OPHTHALMOL, V85, P1092, DOI 10.1136/bjo.85.9.1092
   Velez-Montoya R, 2014, RETINA-J RET VIT DIS, V34, P423, DOI 10.1097/IAE.0000000000000036
   Veloso CE, 2015, OPHTHALMOLOGY, V122, P1569, DOI 10.1016/j.ophtha.2015.04.028
   Wan Michael J, 2009, Retin Cases Brief Rep, V3, P86, DOI 10.1097/ICB.0b013e31815f3cd2
   Yamamoto Kaori, 2011, Nippon Ganka Gakkai Zasshi, V115, P20
   Zhao PP, 2018, J OPHTHALMOL, V2018, DOI 10.1155/2018/7389412
NR 29
TC 0
Z9 0
U1 0
U2 2
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD OCT
PY 2021
VL 41
IS 10
BP 2079
EP 2087
DI 10.1097/IAE.0000000000003148
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA WN5GS
UT WOS:000711796500011
PM 34543242
DA 2022-11-30
ER

PT J
AU Zeng, JX
   Chen, YH
   Tong, ZZ
   Zhou, XR
   Zhao, CO
   Wang, K
   Hughes, G
   Kasuga, D
   Bedell, M
   Lee, C
   Ferreyra, H
   Kozak, I
   Haw, W
   Guan, JA
   Shaw, R
   Stevenson, W
   Weishaar, PD
   Nelson, MH
   Tang, LS
   Zhang, K
AF Zeng, Jiexi
   Chen, Yuhong
   Tong, Zongzhong
   Zhou, Xinrong
   Zhao, Chao
   Wang, Kevin
   Hughes, Guy
   Kasuga, Daniel
   Bedell, Matthew
   Lee, Clara
   Ferreyra, Henry
   Kozak, Igor
   Haw, Weldon
   Guan, Jean
   Shaw, Robert
   Stevenson, William
   Weishaar, Paul D.
   Nelson, Mark H.
   Tang, Luosheng
   Zhang, Kang
TI Lack of association of CFD polymorphisms with advanced age-related
   macular degeneration
SO MOLECULAR VISION
LA English
DT Article
ID COMPLEMENT FACTOR-D; GEOGRAPHIC ATROPHY; FACTOR-H; MACULOPATHY; PATHWAY;
   DISEASE; RISK; GENE; EYE; SUSCEPTIBILITY
AB Purpose: Age-related macular degeneration (AMD) is the most common cause of irreversible central vision loss worldwide. Research has linked AMD susceptibility with dysregulation of the complement cascade. Typically, complement factor H (CFH), complement factor B (CFB), complement component 2 (C2), and complement component 3 (C3) are associated with AMD. In this paper, we investigated the association between complement factor D (CFD), another factor of the complement system, and advanced AMD in a Caucasian population.
   Methods: Six single nucleotide polymorphisms (SNPs), rs1683564, rs35186399, rs1683563, rs3826945, rs34337649, and rs1651896, across the region covering CFD, were chosen for this study. One hundred and seventy-eight patients with advanced AMD and 161 age-matched normal controls were genotyped. Potential positive signals were further tested in another independent 445 advanced AMD patients and 190 controls. chi(2) tests were performed to compare the allele frequencies between case and control groups.
   Results: None of the six SNPs of CFD was found to be significantly associated with advanced AMD in our study.
   Conclusions: Our findings suggest that CFD may not play a major role in the genetic susceptibility to AMD because no association was found between the six SNPs analyzed in the CFD region and advanced AMD.
C1 [Zeng, Jiexi; Chen, Yuhong; Zhou, Xinrong; Zhao, Chao; Wang, Kevin; Hughes, Guy; Kasuga, Daniel; Bedell, Matthew; Lee, Clara; Ferreyra, Henry; Kozak, Igor; Haw, Weldon; Guan, Jean; Shaw, Robert; Zhang, Kang] Univ Calif San Diego, IGM, La Jolla, CA 92093 USA.
   [Zeng, Jiexi; Chen, Yuhong; Zhou, Xinrong; Zhao, Chao; Wang, Kevin; Hughes, Guy; Kasuga, Daniel; Bedell, Matthew; Lee, Clara; Ferreyra, Henry; Kozak, Igor; Haw, Weldon; Guan, Jean; Shaw, Robert; Zhang, Kang] Univ Calif San Diego, Shiley Eye Ctr, La Jolla, CA 92093 USA.
   [Zeng, Jiexi; Tang, Luosheng] Cent S Univ, Xiangya Hosp 2, Dept Ophthalmol, Changsha, Hunan, Peoples R China.
   [Chen, Yuhong] Fudan Univ, Shanghai Med Sch, Eye & ENT Hosp, Dept Ophthalmol & Vis Sci, Shanghai 200433, Peoples R China.
   [Zeng, Jiexi; Chen, Yuhong; Tong, Zongzhong; Zhao, Chao; Zhang, Kang] Univ Utah, Sch Med, Moran Eye Ctr, Dept Ophthalmol & Visual Sci, Salt Lake City, UT USA.
   [Stevenson, William; Weishaar, Paul D.] Vitreo Retinal Consultants & Surg, Wichita, KS USA.
   [Nelson, Mark H.] N Carolina Macular Consultants, Winston Salem, NC USA.
C3 University of California System; University of California San Diego;
   University of California System; University of California San Diego;
   Central South University; Fudan University; Utah System of Higher
   Education; University of Utah
RP Zhang, K (通讯作者)，Univ Calif San Diego, IGM, MC0838 Skaggs SSPPS,Room 4272,9500 Gilman Dr, La Jolla, CA 92093 USA.
EM kangzhang@ucsd.edu
RI Zhang, Kang/Y-2740-2019; Kozak, Igor/AAC-4645-2019; Mohammed,
   Imran/J-8271-2012
OI Zhang, Kang/0000-0002-4549-1697; Mohammed, Imran/0000-0002-8412-0768
FU NIH; VA; Foundation Fighting Blindness; Macula Vision Research
   Foundation; Ruth and Milton Steinbach Fund; Research to Prevent
   Blindness; BWF
FX We thank all the participating AMD patients and their families. K.Z. is
   supported by grants from NIH, VA Merit Award, Foundation Fighting
   Blindness, the Macula Vision Research Foundation, Ruth and Milton
   Steinbach Fund, Research to Prevent Blindness, BWF Clinical Scientist
   Award in Translational Research. K.Z. has full access to all the data in
   the study and takes responsibility for the integrity of the data and the
   accuracy of the data analysis.
CR Anderson DH, 2010, PROG RETIN EYE RES, V29, P95, DOI 10.1016/j.preteyeres.2009.11.003
   Andreoli MT, 2009, AM J OPHTHALMOL, V148, P869, DOI 10.1016/j.ajo.2009.07.002
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Brantley MA, 2007, OPHTHALMOLOGY, V114, P2168, DOI 10.1016/j.ophtha.2007.09.008
   Bressler SB, 2008, ARCH OPHTHALMOL-CHIC, V126, P241, DOI 10.1001/archophthalmol.2007.53
   Cameron DJ, 2007, CELL CYCLE, V6, P1122, DOI 10.4161/cc.6.9.4157
   Chappelow AV, 2008, DRUGS, V68, P1029, DOI 10.2165/00003495-200868080-00002
   Despriet DDG, 2009, OPHTHALMOLOGY, V116, P474, DOI 10.1016/j.ophtha.2008.09.055
   Dewan A, 2007, CURR OPIN GENET DEV, V17, P228, DOI 10.1016/j.gde.2007.04.004
   Dewan A, 2006, SCIENCE, V314, P989, DOI 10.1126/science.1133807
   Gehrs KM, 2010, ARCH OPHTHALMOL-CHIC, V128, P349, DOI 10.1001/archophthalmol.2010.18
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Hecker LA, 2010, HUM MOL GENET, V19, P209, DOI 10.1093/hmg/ddp472
   Katta S, 2009, J GENET, V88, P425, DOI 10.1007/s12041-009-0064-4
   Kaur I, 2010, INVEST OPHTH VIS SCI, V51, P59, DOI 10.1167/iovs.09-4135
   Khan JC, 2006, BRIT J OPHTHALMOL, V90, P75, DOI 10.1136/bjo.2005.073643
   Klein R, 2003, OPHTHALMOLOGY, V110, P636, DOI 10.1016/S0161-6420(02)01448-3
   Milton RC, 2005, OPHTHALMOLOGY, V112, P533, DOI 10.1016/j.ophtha.2004.10.047
   Montezuma Sandra R, 2007, Semin Ophthalmol, V22, P229, DOI 10.1080/08820530701745140
   Nussenblatt RB, 2009, CURR OPIN INVEST DR, V10, P434
   Patel N, 2008, EYE, V22, P768, DOI 10.1038/sj.eye.6702844
   Rohrer B, 2007, INVEST OPHTH VIS SCI, V48, P5282, DOI 10.1167/iovs.07-0282
   Scholl HPN, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002593
   Seddon JM, 2003, ARCH OPHTHALMOL-CHIC, V121, P785, DOI 10.1001/archopht.121.6.785
   Seddon JM, 2009, INVEST OPHTH VIS SCI, V50, P2044, DOI 10.1167/iovs.08-3064
   Sprong T, 2006, BLOOD, V107, P4865, DOI 10.1182/blood-2005-07-2820
   Stahl GL, 2003, AM J PATHOL, V162, P449, DOI 10.1016/S0002-9440(10)63839-4
   van Leeuwen R, 2003, EUR J EPIDEMIOL, V18, P845, DOI 10.1023/A:1025643303914
   Volanakis JE, 1996, PROTEIN SCI, V5, P553
   Yang ZL, 2006, SCIENCE, V314, P992, DOI 10.1126/science.1133811
   Zanke B, 2010, CAN J OPHTHALMOL, V45, P22, DOI 10.3129/i09-209
NR 31
TC 9
Z9 17
U1 0
U2 4
PU MOLECULAR VISION
PI ATLANTA
PA C/O JEFF BOATRIGHT, LAB B, 5500 EMORY EYE CENTER, 1327 CLIFTON RD, N E,
   ATLANTA, GA 30322 USA
SN 1090-0535
J9 MOL VIS
JI Mol. Vis.
PD NOV 3
PY 2010
VL 16
IS 243
BP 2273
EP 2278
PG 6
WC Biochemistry & Molecular Biology; Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Ophthalmology
GA 688EL
UT WOS:000284832500001
PM 21139680
DA 2022-11-30
ER

PT J
AU Gonzalez, EG
   Teichman, J
   Lillakas, L
   Markowitz, SN
   Steinbach, MJ
AF Gonzalez, Esther G.
   Teichman, Joshua
   Lillakas, Linda
   Markowitz, Samuel N.
   Steinbach, Martin J.
TI Fixation stability using radial gratings in patients with age-related
   macular degeneration
SO CANADIAN JOURNAL OF OPHTHALMOLOGY-JOURNAL CANADIEN D OPHTALMOLOGIE
LA English
DT Article
ID PREFERRED RETINAL LOCI; SCANNING LASER OPHTHALMOSCOPE; LOCATION;
   TARGETS; SCOTOMA; DISEASE; FOVEA; MICROSACCADES; FUNDUS; ACUITY
AB Background: The fixation stability of patients with macular atrophy is generally worse than that of people without pathology.
   Methods: The effects of 2 types of high-contrast fixation stimuli on fixation stability were compared between patients with longstanding age-related macular degeneration (AMD) and control subjects with normal vision. One stimulus was a 9-cycle square-wave radial grating measuring 5 degrees in diameter and the other a white 0.5 degrees disc. A video-based infrared eye tracker with remote optics was used to record eye position while participants fixated the stimuli in primary position of gaze for 6 to 7 s. Fixation stability was measured with a bivariate contour ellipse area (BCEA).
   Results: For patients with AMD, fixation stability for the radial grating was largely independent of visual acuity, whereas fixation stability for the disc diminished with acuity. For the control observers, there were no differences in fixation stability for the 2 kinds of stimuli.
   Interpretation: In clinical and research settings, radial gratings can be useful targets for fixation for patients with macular disease since they provide enough visual information to help maintain fixation stability. These findings have important implications for the design of clinical tests and procedures such as perimetry, multifocal electroretinography, and optical coherence tomography for patients with macular atrophies.
C1 Toronto Western Hosp, Toronto Western Res Inst, Vis Sci Res Program, Toronto, ON M5T 2S8, Canada.
   York Univ, Ctr Vis Res, Toronto, ON M3J 2R7, Canada.
   Univ Toronto, Dept Ophthalmol & Vis Sci, Toronto, ON, Canada.
   Univ Toronto, Inst Med Sci, Toronto, ON, Canada.
C3 University of Toronto; University Toronto Affiliates; University Health
   Network Toronto; York University - Canada; University of Toronto;
   University of Toronto
RP Gonzalez, EG (通讯作者)，Toronto Western Hosp, Toronto Western Res Inst, Vis Sci Res Program, 399 Bathurst St,FP 6-212, Toronto, ON M5T 2S8, Canada.
EM gonzalez@yorku.ca
CR Altpeter E, 2000, VISION RES, V40, P1539, DOI 10.1016/S0042-6989(00)00059-6
   ANSTIS SM, 1974, VISION RES, V14, P589, DOI 10.1016/0042-6989(74)90049-2
   Bellmann C, 2004, OPHTHALMOLOGY, V111, P2265, DOI 10.1016/j.ophtha.2004.06.019
   BRIDGEMAN B, 1980, VISION RES, V20, P813, DOI 10.1016/0042-6989(80)90013-9
   Crossland MD, 2002, OPTOMETRY VISION SCI, V79, P735, DOI 10.1097/00006324-200211000-00011
   Crossland MD, 2005, OPHTHALMOLOGY, V112, P1579, DOI 10.1016/j.ophtha.2005.03.027
   Crossland MD, 2004, VISION RES, V44, P1537, DOI 10.1016/j.visres.2004.01.006
   CUMMINGS RW, 1985, AM J OPTOM PHYS OPT, V62, P833
   Deruaz A, 2002, VISION RES, V42, P2947, DOI 10.1016/S0042-6989(02)00354-1
   Duchowski A. T., 2007, EYE TRACKING METHODO, V2nd, P51
   Fletcher DC, 1997, OPHTHALMOLOGY, V104, P632, DOI 10.1016/S0161-6420(97)30260-7
   HEINEN SJ, 1992, VISION RES, V32, P365, DOI 10.1016/0042-6989(92)90145-9
   HOWARD IP, 1982, HUMAN VISUAL ORIENTA, P3
   KOSNIK W, 1988, PSYCHOL AGING, V3, P37, DOI 10.1037/h0090402
   KOSNIK W, 1987, PSYCHOL AGING, V2, P302, DOI 10.1037/0882-7974.2.3.302
   KOSNIK W, 1986, INVEST OPHTH VIS SCI, V27, P1720
   Lei H, 1997, INVEST OPHTH VIS SCI, V38, P1812
   MACKEBEN M, 1998, VIS 96 P 5 INT C LOW, P119
   Mackeben M., 1999, PERIMETRY UPDATE 199, P307
   NOORDEN GKV, 1962, AM J OPHTHALMOL, V53, P642, DOI 10.1016/0002-9394(62)91987-6
   Rohrschneider K, 1998, OPHTHALMOLOGE, V95, P706, DOI 10.1007/s003470050339
   Rohrschneider K, 2004, INVEST OPHTH VIS SCI, V45, P3257, DOI 10.1167/iovs.03-1157
   SANSBURY RV, 1973, J OPT SOC AM, V63, P612, DOI 10.1364/JOSA.63.000612
   SCHUCHARD RA, 1992, CLIN VISION SCI, V7, P511
   Somani S, 2004, CAN J OPHTHALMOL, V39, P517, DOI 10.1016/S0008-4182(04)80141-8
   STEINMAN RM, 1965, J OPT SOC AM, V55, P1158, DOI 10.1364/JOSA.55.001158
   Timberlake GT, 2005, OPTOMETRY VISION SCI, V82, P177
   TIMBERLAKE GT, 1986, INVEST OPHTH VIS SCI, V27, P1137
   WEBB RH, 1987, APPL OPTICS, V26, P1492, DOI 10.1364/AO.26.001492
   WHITE JM, 1990, INVEST OPHTH VIS SCI, V31, P1149
   WHITTAKER SG, 1988, INVEST OPHTH VIS SCI, V29, P268
   WINTERSON BJ, 1976, VISION RES, V16, P1387, DOI 10.1016/0042-6989(76)90156-5
   Yu LH, 2004, IEEE T BIO-MED ENG, V51, P1765, DOI 10.1109/TBME.2004.831523
NR 33
TC 28
Z9 28
U1 1
U2 8
PU CANADIAN OPHTHAL SOC
PI OTTAWA
PA 1525 CARLING AVE SUITE 610, OTTAWA, ONTARIO K1Z 8R9, CANADA
SN 0008-4182
EI 1715-3360
J9 CAN J OPHTHALMOL
JI Can. J. Opthalmol.-J. Can. Opthalmol.
PD JUN
PY 2006
VL 41
IS 3
BP 333
EP 339
DI 10.1139/I06-019
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 054AX
UT WOS:000238348900007
PM 16767189
DA 2022-11-30
ER

PT J
AU Zhang, ZY
   Bao, XL
   Cong, YY
   Fan, B
   Li, GY
AF Zhang, Zi-Yuan
   Bao, Xiao-Li
   Cong, Yun-Yi
   Fan, Bin
   Li, Guang-Yu
TI Autophagy in Age-Related Macular Degeneration: A Regulatory Mechanism of
   Oxidative Stress
SO OXIDATIVE MEDICINE AND CELLULAR LONGEVITY
LA English
DT Review
ID RETINAL-PIGMENT EPITHELIUM; DNA-DAMAGE RESPONSE; MOLECULAR-MECHANISMS;
   CELLS; RPE; MTOR; PROTEINS; PATHWAY; TARGET; COMPLEMENT
AB Age-related macular degeneration (AMD) is a leading cause of severe visual loss and irreversible blindness in the elderly population worldwide. Retinal pigment epithelial (RPE) cells are the major site of pathological alterations in AMD. They are responsible for the phagocytosis of shed photoreceptor outer segments (POSs) and clearance of cellular waste under physiological conditions. Age-related, cumulative oxidative stimuli contribute to the pathogenesis of AMD. Excessive oxidative stress induces RPE cell degeneration and incomplete digestion of POSs, leading to the continuous accumulation of cellular waste (such as lipofuscin). Autophagy is a major system of degradation of damaged or unnecessary proteins. However, degenerative RPE cells in AMD patients cannot perform autophagy sufficiently to resist oxidative damage. Increasing evidence supports the idea that enhancing the autophagic process can properly alleviate oxidative injury in AMD and protect RPE and photoreceptor cells from degeneration and death, although overactivated autophagy may lead to cell death at early stages of retinal degenerative diseases. The crosstalk among the NFE2L2, PGC-1, p62, AMPK, and PI3K/Akt/mTOR pathways may play a crucial role in improving disturbed autophagy and mitigating the progression of AMD. In this review, we discuss how autophagy prevents oxidative damage in AMD, summarize potential neuroprotective strategies for therapeutic interventions, and provide an overview of these neuroprotective mechanisms.
C1 [Zhang, Zi-Yuan; Bao, Xiao-Li; Cong, Yun-Yi; Fan, Bin; Li, Guang-Yu] Second Hosp Jilin Univ, Dept Ophthalmol, Changchun 130000, Peoples R China.
C3 Jilin University
RP Li, GY (通讯作者)，Second Hosp Jilin Univ, Dept Ophthalmol, Changchun 130000, Peoples R China.
EM liguangyu@aliyun.com
OI Bao, Xiao-Li/0000-0002-3124-1152
FU Natural Science Foundation of Jilin Province [20200801043GH,
   20200201379JC, 20190201083JC]; Science and Technology Project of
   Education Department of Jilin Province [JJKH20190046KJ, JJKH20190049KJ]
FX We thank LetPub (http://www.letpub.com) for its linguistic assistance
   during the preparation of this manuscript. This work was supported by
   grants from the Natural Science Foundation of Jilin Province (Nos.
   20200801043GH, 20200201379JC, and 20190201083JC) and the Science and
   Technology Project of Education Department of Jilin Province (Nos.
   JJKH20190046KJ and JJKH20190049KJ).
CR Abokyi S, 2020, OXID MED CELL LONGEV, V2020, DOI 10.1155/2020/7901270
   Ao J, 2018, CLIN EXP OPHTHALMOL, V46, P670, DOI 10.1111/ceo.13121
   Argun M, 2014, EYE, V28, P752, DOI 10.1038/eye.2014.50
   Baldelli S, 2013, BBA-GEN SUBJECTS, V1830, P4137, DOI 10.1016/j.bbagen.2013.04.006
   Bhattarai N, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21062066
   Blasiak J, 2020, CELL MOL LIFE SCI, V77, P789, DOI 10.1007/s00018-019-03420-x
   Blasiak J, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20010210
   Blasiak J, 2017, OXID MED CELL LONGEV, V2017, DOI 10.1155/2017/5293258
   Blasiak J, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/768026
   BOSCH E, 1993, J HISTOCHEM CYTOCHEM, V41, P253, DOI 10.1177/41.2.8419462
   Boya P, 2016, PROG RETIN EYE RES, V55, P206, DOI 10.1016/j.preteyeres.2016.08.001
   Brown EE, 2019, REDOX BIOL, V24, DOI 10.1016/j.redox.2019.101201
   Cai JJ, 2019, EXP CELL RES, V374, P231, DOI 10.1016/j.yexcr.2018.11.028
   Carroll MV, 2011, ADV DRUG DELIVER REV, V63, P965, DOI 10.1016/j.addr.2011.06.005
   Celkova L, 2015, J CLIN MED, V4, P172, DOI 10.3390/jcm4010172
   Chan CM, 2019, J BIOMED SCI, V26, DOI 10.1186/s12929-019-0531-z
   Chang CC, 2018, OXID MED CELL LONGEV, V2018, DOI 10.1155/2018/9015765
   Chen CL, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19051416
   Chen Y, 2013, J BIOL CHEM, V288, P7506, DOI 10.1074/jbc.M112.439935
   Cho MJ, 2019, EXP MOL MED, V51, DOI 10.1038/s12276-019-0327-y
   Coffe V, 2006, NEUROCHEM RES, V31, P103, DOI 10.1007/s11064-005-9236-7
   Crooke A, 2017, J PINEAL RES, V63, DOI 10.1111/jpi.12430
   Czarny P, 2015, INT J MOL SCI, V16, P2641, DOI 10.3390/ijms16022641
   Datta S, 2017, PROG RETIN EYE RES, V60, P201, DOI 10.1016/j.preteyeres.2017.03.002
   Diot A, 2016, MAMM GENOME, V27, P381, DOI 10.1007/s00335-016-9651-x
   Dolz-Marco R, 2018, AM J OPHTHALMOL, V191, P23, DOI 10.1016/j.ajo.2018.03.038
   Eamegdool SS, 2020, FREE RADICAL BIO MED, V146, P357, DOI 10.1016/j.freeradbiomed.2019.11.018
   Felszeghy S, 2019, REDOX BIOL, V20, P1, DOI 10.1016/j.redox.2018.09.011
   Hernandez-Zimbron LF, 2018, OXID MED CELL LONGEV, V2018, DOI 10.1155/2018/8374647
   Filomeni G, 2015, CELL DEATH DIFFER, V22, P377, DOI 10.1038/cdd.2014.150
   Fleckenstein M, 2010, INVEST OPHTH VIS SCI, V51, P3846, DOI 10.1167/iovs.09-4533
   Gammone MA, 2019, NUTRIENTS, V11, DOI 10.3390/nu11010046
   Garcia-Prat L, 2016, NATURE, V529, P37, DOI 10.1038/nature16187
   Golestaneh N, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2016.453
   Golestaneh N, 2016, J TRANSL MED, V14, DOI 10.1186/s12967-016-1101-8
   Gouras P, 2016, GRAEF ARCH CLIN EXP, V254, P1221, DOI 10.1007/s00417-016-3342-x
   Guo CY, 2013, NEURAL REGEN RES, V8, P2003, DOI 10.3969/j.issn.1673-5374.2013.21.009
   Hallam D, 2017, STEM CELLS, V35, P2305, DOI 10.1002/stem.2708
   Hanus J, 2015, AGEING RES REV, V24, P286, DOI 10.1016/j.arr.2015.09.002
   Hara K, 2002, CELL, V110, P177, DOI 10.1016/S0092-8674(02)00833-4
   Hyttinen JMT, 2018, CELL MOL LIFE SCI, V75, P2991, DOI 10.1007/s00018-018-2843-7
   Hyttinen JMT, 2017, AGEING RES REV, V36, P64, DOI 10.1016/j.arr.2017.03.006
   Hyttinen JMT, 2011, REJUV RES, V14, P651, DOI 10.1089/rej.2011.1220
   Islam FMA, 2014, OPHTHALMOLOGY, V121, P1428, DOI 10.1016/j.ophtha.2014.01.002
   Jain A, 2010, J BIOL CHEM, V285, P22576, DOI 10.1074/jbc.M110.118976
   Jiao XL, 2014, CHINESE MED J-PEKING, V127, P1749, DOI 10.3760/cma.j.issn.0366-6999.20140129
   Johansson I, 2015, AUTOPHAGY, V11, P1636, DOI 10.1080/15548627.2015.1061170
   Kaarniranta K, 2020, PROG RETIN EYE RES, V79, DOI 10.1016/j.preteyeres.2020.100858
   Kaarniranta K, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20102374
   Kaarniranta K, 2019, BIOCHIMIE, V159, P49, DOI 10.1016/j.biochi.2018.07.010
   Kaarniranta K, 2017, CELL BIOL TOXICOL, V33, P113, DOI 10.1007/s10565-016-9371-8
   Kaarniranta K, 2011, J ALZHEIMERS DIS, V24, P615, DOI 10.3233/JAD-2011-101908
   Kaarniranta K, 2009, AGEING RES REV, V8, P128, DOI 10.1016/j.arr.2009.01.001
   Kang R, 2011, CELL DEATH DIFFER, V18, P571, DOI 10.1038/cdd.2010.191
   Kannan R, 2016, BBA-GEN SUBJECTS, V1860, P258, DOI 10.1016/j.bbagen.2015.05.016
   Kansanen E, 2013, REDOX BIOL, V1, P45, DOI 10.1016/j.redox.2012.10.001
   Karlsson M, 2013, EXP EYE RES, V116, P359, DOI 10.1016/j.exer.2013.10.014
   Kauppinen A, 2016, CELL MOL LIFE SCI, V73, P1765, DOI 10.1007/s00018-016-2147-8
   Keeling E, 2018, CELLS-BASEL, V7, DOI 10.3390/cells7020016
   Khristov V, 2018, METHODS MOL BIOL, V1722, P223, DOI 10.1007/978-1-4939-7553-2_15
   Kim Y, 2016, NUTRIENTS, V8, DOI 10.3390/nu8010017
   Kim YC, 2015, J CLIN INVEST, V125, P25, DOI 10.1172/JCI73939
   Kinnunen K, 2012, ACTA OPHTHALMOL, V90, P299, DOI 10.1111/j.1755-3768.2011.02179.x
   Klettner A, 2013, INT J BIOCHEM CELL B, V45, P1457, DOI 10.1016/j.biocel.2013.04.013
   Kozhevnikova OS, 2018, BIOGERONTOLOGY, V19, P223, DOI 10.1007/s10522-018-9751-y
   Kumar R, 2011, J ETHNOPHARMACOL, V136, P260, DOI 10.1016/j.jep.2011.04.040
   Kunchithapautham K, 2007, AUTOPHAGY, V3, P433, DOI 10.4161/auto.4294
   Kuo C, 2020, ACTA DIABETOL, V57, P13, DOI 10.1007/s00592-019-01352-3
   Kurz T, 2009, AUTOPHAGY, V5, P494, DOI 10.4161/auto.5.4.7961
   Lamark T, 2017, ESSAYS BIOCHEM, V61, P609, DOI 10.1042/EBC20170035
   Lee J, 2012, BIOCHEM J, V441, P523, DOI 10.1042/BJ20111451
   Lei L, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18040728
   Li CP, 2013, BIOCHEM BIOPH RES CO, V438, P739, DOI 10.1016/j.bbrc.2013.07.097
   LI S, 2016, IEEE T TRANSPORTATIO, V2, P2, DOI DOI 10.18280/IJHT.340207
   Li Y, 2019, TISSUE CELL, V61, P98, DOI 10.1016/j.tice.2019.09.008
   Lin W, 2018, IN VITRO CELL DEV-AN, V54, P355, DOI 10.1007/s11626-018-0243-9
   Liu J, 2016, SCI REP-UK, V6, DOI 10.1038/srep20639
   Liu YL, 2018, FRONT AGING NEUROSCI, V10, DOI 10.3389/fnagi.2018.00389
   Lohr HR, 2006, EXP EYE RES, V83, P380, DOI 10.1016/j.exer.2006.01.014
   Lu TX, 2018, J ALLERGY CLIN IMMUN, V141, P1202, DOI 10.1016/j.jaci.2017.08.034
   Fanjul-Moles ML, 2016, OXID MED CELL LONGEV, V2016, DOI 10.1155/2016/7420637
   McHarg S, 2015, MOL IMMUNOL, V67, P43, DOI 10.1016/j.molimm.2015.02.032
   Meyer JG, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-51777-7
   Mitter SK, 2014, AUTOPHAGY, V10, P1989, DOI 10.4161/auto.36184
   Mohr AM, 2015, SEMIN LIVER DIS, V35, P3, DOI 10.1055/s-0034-1397344
   Motohashi H, 2004, P NATL ACAD SCI USA, V101, P6379, DOI 10.1073/pnas.0305902101
   Myeku N, 2011, J BIOL CHEM, V286, P22426, DOI 10.1074/jbc.M110.149252
   Naso F, 2020, EMBO J, V39, DOI 10.15252/embj.2019102468
   Ney PA, 2015, BBA-MOL CELL RES, V1853, P2775, DOI 10.1016/j.bbamcr.2015.02.022
   Pawlowska E, 2019, OXID MED CELL LONGEV, V2019, DOI 10.1155/2019/9682318
   Perusek L, 2015, J BIOL CHEM, V290, P29035, DOI 10.1074/jbc.M115.682310
   Piippo N, 2014, BBA-MOL CELL RES, V1843, P3038, DOI 10.1016/j.bbamcr.2014.09.015
   Pool FM, 2020, NPJ AGING MECH DIS, V6, DOI 10.1038/s41514-019-0039-5
   Rajapakse D, 2017, OXID MED CELL LONGEV, V2017, DOI 10.1155/2017/6926485
   Rigacci S, 2015, ONCOTARGET, V6, P35344, DOI 10.18632/oncotarget.6119
   Roginska D, 2017, OXID MED CELL LONGEV, V2017, DOI 10.1155/2017/5306790
   Rozing MP, 2020, PROG RETIN EYE RES, V76, DOI 10.1016/j.preteyeres.2019.100825
   Saito Y, 2018, REDOX BIOL, V19, P354, DOI 10.1016/j.redox.2018.09.004
   Saxton RA, 2017, CELL, V168, P960, DOI [10.1016/j.cell.2017.03.035, 10.1016/j.cell.2017.02.004]
   Schaaf MBE, 2016, FASEB J, V30, P3961, DOI 10.1096/fj.201600698R
   Sheu SJ, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0213932
   Singh AK, 2017, MOL NEUROBIOL, V54, P5815, DOI 10.1007/s12035-016-0129-3
   Sinha D, 2016, EXP EYE RES, V144, P46, DOI 10.1016/j.exer.2015.08.018
   Stepicheva NA, 2019, ADV EXP MED BIOL, V1185, P45, DOI 10.1007/978-3-030-27378-1_8
   Sun Y, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-0794-4
   Szatmari-Toth M, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20040926
   Tang BR, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0103364
   Tokarz P, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17060898
   Uchiki T, 2012, AGING CELL, V11, P1, DOI 10.1111/j.1474-9726.2011.00752.x
   Viiri J, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0069563
   Wakabayashi N, 2003, NAT GENET, V35, P238, DOI 10.1038/ng1248
   Wang L, 2016, ADV EXP MED BIOL, V854, P17, DOI 10.1007/978-3-319-17121-0_3
   Wang L, 2014, BBA-MOL CELL RES, V1843, P1248, DOI 10.1016/j.bbamcr.2014.03.016
   Wang LF, 2007, J BIOL CHEM, V282, P20036, DOI 10.1074/jbc.M702376200
   Wang SB, 2019, OXID MED CELL LONGEV, V2019, DOI 10.1155/2019/3632169
   Wang XC, 2014, DNA CELL BIOL, V33, P198, DOI 10.1089/dna.2013.2164
   Wang XY, 2016, NEUROBIOL AGING, V47, P168, DOI 10.1016/j.neurobiolaging.2016.07.025
   Wang YJ, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17010073
   Wei QQ, 2019, DISCOV MED, V27, P189
   Wei QQ, 2018, DRUG DES DEV THER, V12, P2715, DOI 10.2147/DDDT.S176349
   Widomska J, 2020, NUTRIENTS, V12, DOI 10.3390/nu12051333
   Yang C, 2019, EXP EYE RES, V189, DOI 10.1016/j.exer.2019.107849
   Zhang CX, 2019, HUM MOL GENET, V28, P3355, DOI 10.1093/hmg/ddz171
   Zhang J, 2015, CELL DEATH DIS, V6, DOI 10.1038/cddis.2015.330
   Zhang LM, 2019, TOXICOL LETT, V311, P105, DOI 10.1016/j.toxlet.2019.05.001
   Zhang M, 2018, DIS MODEL MECH, V11, DOI 10.1242/dmm.032698
   Zhang TZ, 2014, BIOCHEM BIOPH RES CO, V450, P966, DOI 10.1016/j.bbrc.2014.06.082
   Zhao C, 2011, J CLIN INVEST, V121, P369, DOI 10.1172/JCI44303
   Zhao ZY, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019456
   Zhu K, 2017, INVEST OPHTH VIS SCI, V58, P6113, DOI 10.1167/iovs.17-22465
   Zhu LX, 2020, J CELL PHYSIOL, V235, P7392, DOI 10.1002/jcp.29641
NR 131
TC 31
Z9 31
U1 6
U2 20
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 1942-0900
EI 1942-0994
J9 OXID MED CELL LONGEV
JI Oxidative Med. Cell. Longev.
PD AUG 8
PY 2020
VL 2020
AR 2896036
DI 10.1155/2020/2896036
PG 13
WC Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology
GA NF8HG
UT WOS:000563533200002
PM 32831993
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Molins, B
   Romero-Vazquez, S
   Fuentes-Prior, P
   Adan, A
   Dick, AD
AF Molins, Blanca
   Romero-Vazquez, Sara
   Fuentes-Prior, Pablo
   Adan, Alfredo
   Dick, Andrew D.
TI C-Reactive Protein as a Therapeutic Target in Age-Related Macular
   Degeneration
SO FRONTIERS IN IMMUNOLOGY
LA English
DT Review
DE C-reactive protein; macular degeneration; aging; inflammation; retina
ID COMPLEMENT FACTOR-H; RISK-FACTORS; CIGARETTE-SMOKING; PENTAMERIC
   SYMMETRY; ACTIVATED PLATELETS; ENDOTHELIAL-CELLS; HUMAN NEUTROPHILS;
   BRUCHS MEMBRANE; HUMAN RETINA; INFLAMMATION
AB Age-related macular degeneration (AMD), a retinal degenerative disease, is the leading cause of central vision loss among the elderly population in developed countries and an increasing global burden. The major risk is aging, compounded by other environmental factors and association with genetic variants for risk of progression. Although the etiology of AMD is not yet clearly understood, several pathogenic pathways have been proposed, including dysfunction of the retinal pigment epithelium, inflammation, and oxidative stress. The identification of AMD susceptibility genes encoding complement factors and the presence of complement and other inflammatory mediators in drusen, the hallmark deposits of AMD, support the concept that local inflammation and immune-mediated processes play a key role in AMD pathogenesis that may be accelerated through systemic immune activation. In this regard, increased levels of circulating C-reactive protein (CRP) have been associated with higher risk of AMD. Besides being a risk marker for AMD, CRP may also play a role in the progression of the disease as it has been identified in drusen, and we have recently found that its monomeric form (mCRP) induces blood retinal barrier disruption in vitro. In this review, we will address recent evidence that links CRP and AMD pathogenesis, which may open new therapeutic opportunities to prevent the progression of AMD.
C1 [Molins, Blanca; Romero-Vazquez, Sara; Adan, Alfredo] Hosp Clin Barcelona, Inst Invest Biomed Agusti Pi & Sunyer IDIBAPS, Barcelona, Spain.
   [Fuentes-Prior, Pablo] Biomed Res Inst St Pau IIB St Pau, Mol Bases Dis, Barcelona, Spain.
   [Fuentes-Prior, Pablo] Univ Autonoma Barcelona, Bellaterra, Spain.
   [Dick, Andrew D.] Univ Bristol, Acad Unit Ophthalmol, Sch Clin Sci, Bristol, Avon, England.
   [Dick, Andrew D.] Univ Bristol, Acad Unit Ophthalmol, Sch Cellular & Mol Med, Bristol, Avon, England.
   [Dick, Andrew D.] UCL, Moorfields Eye Hosp, Inst Ophthalmol, NIHR,Biomed Res Ctr, London, England.
C3 University of Barcelona; Hospital Clinic de Barcelona; IDIBAPS;
   Autonomous University of Barcelona; University of Bristol; University of
   Bristol; University of London; King's College London; University College
   London; Moorfields Eye Hospital NHS Foundation Trust
RP Molins, B (通讯作者)，Hosp Clin Barcelona, Inst Invest Biomed Agusti Pi & Sunyer IDIBAPS, Barcelona, Spain.
EM bmolins@clinic.ub.es
OI Dick, Andrew/0000-0002-0742-3159; Fuentes-Prior,
   Pablo/0000-0002-6618-3204
FU Ministry of Science and Innovation of Spain, "Instituto de Salud Carlos
   III," "Fondo de Investigacion Sanitaria" [RD16/0008]
FX This work was supported by the Ministry of Science and Innovation of
   Spain, "Instituto de Salud Carlos III," "Fondo de Investigacion
   Sanitaria" (RD16/0008).
CR Age-Related Eye Dis Study Res Grp, 2001, AM J OPHTHALMOL, V132, P668
   Ahmed UK, 2016, J BIOL CHEM, V291, P11939, DOI 10.1074/jbc.M115.702746
   Ambati J, 2013, NAT REV IMMUNOL, V13, P438, DOI 10.1038/nri3459
   Anderson DH, 2002, AM J OPHTHALMOL, V134, P411, DOI 10.1016/S0002-9394(02)01624-0
   Bhutto IA, 2011, BRIT J OPHTHALMOL, V95, P1323, DOI 10.1136/bjo.2010.199216
   Biro A, 2007, IMMUNOLOGY, V121, P40, DOI 10.1111/j.1365-2567.2007.02535.x
   Black S, 2004, J BIOL CHEM, V279, P48487, DOI 10.1074/jbc.R400025200
   Braig D, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms14188
   Chang MK, 2002, P NATL ACAD SCI USA, V99, P13043, DOI 10.1073/pnas.192399699
   Chirco KR, 2016, J PATHOL, V240, P173, DOI 10.1002/path.4766
   Choi JK, 2011, ARCH OPHTHALMOL-CHIC, V129, P196, DOI 10.1001/archophthalmol.2010.355
   Christen WG, 1996, JAMA-J AM MED ASSOC, V276, P1147, DOI 10.1001/jama.276.14.1147
   Christopeit T, 2009, ANAL BIOCHEM, V391, P39, DOI 10.1016/j.ab.2009.04.037
   Cipriani V, 2017, JAMA OPHTHALMOL, V135, P909, DOI 10.1001/jamaophthalmol.2017.2191
   Clark SJ, 2014, J IMMUNOL, V193, P4962, DOI 10.4049/jimmunol.1401613
   Clark SJ, 2010, J BIOL CHEM, V285, P30192, DOI 10.1074/jbc.M110.103986
   Crabb JW, 2002, P NATL ACAD SCI USA, V99, P14682, DOI 10.1073/pnas.222551899
   Curcio CA, 2009, PROG RETIN EYE RES, V28, P393, DOI 10.1016/j.preteyeres.2009.08.001
   Demontis F, 2013, DIS MODEL MECH, V6, P1339, DOI 10.1242/dmm.012559
   Dick AD, 2017, EYE, V31, P87, DOI 10.1038/eye.2016.177
   Donoso LA, 2006, SURV OPHTHALMOL, V51, P137, DOI 10.1016/j.survophthal.2005.12.001
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Eisenhardt SU, 2009, CIRC RES, V105, P128, DOI 10.1161/CIRCRESAHA.108.190611
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Fritsche LG, 2016, NAT GENET, V48, P134, DOI 10.1038/ng.3448
   Giannakis E, 2003, EUR J IMMUNOL, V33, P962, DOI 10.1002/eji.200323541
   Habersberger J, 2012, CARDIOVASC RES, V96, P64, DOI 10.1093/cvr/cvs237
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Hakobyan S, 2008, J BIOL CHEM, V283, P30451, DOI 10.1074/jbc.M803648200
   Hecker LA, 2010, HUM MOL GENET, V19, P209, DOI 10.1093/hmg/ddp472
   Holmes C, 2009, NEUROLOGY, V73, P768, DOI 10.1212/WNL.0b013e3181b6bb95
   Jakobsdottir J, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002199
   Ji SR, 2007, FASEB J, V21, P284, DOI 10.1096/fj.06-6722com
   Johnson PT, 2006, P NATL ACAD SCI USA, V103, P17456, DOI 10.1073/pnas.0606234103
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1439, DOI 10.1001/archopht.119.10.1439
   Kawa MP, 2014, J IMMUNOL RES, V2014, DOI 10.1155/2014/483960
   Keenan TDL, 2015, INVEST OPHTH VIS SCI, V56, P4870, DOI 10.1167/iovs.15-17009
   Khan JC, 2006, BRIT J OPHTHALMOL, V90, P75, DOI 10.1136/bjo.2005.073643
   Khreiss T, 2005, CIRC RES, V97, P690, DOI 10.1161/01.RES.0000183881.11739.CB
   Khreiss T, 2004, CIRCULATION, V109, P2016, DOI 10.1161/01.CIR.0000125527.41598.68
   Khreiss T, 2002, J BIOL CHEM, V277, P40775, DOI 10.1074/jbc.M205378200
   Kim Y, 2014, P NATL ACAD SCI USA, V111, P16082, DOI 10.1073/pnas.1403814111
   Klein R, 2004, AM J OPHTHALMOL, V137, P486, DOI 10.1016/j.ajo.2003.11.069
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Klein R, 2011, ARCH OPHTHALMOL-CHIC, V129, P75, DOI 10.1001/archophthalmol.2010.318
   Laine M, 2007, J IMMUNOL, V178, P3831, DOI 10.4049/jimmunol.178.6.3831
   Lambert NG, 2016, PROG RETIN EYE RES, V54, P64, DOI 10.1016/j.preteyeres.2016.04.003
   Langford-Smith A, 2014, J INNATE IMMUN, V6, P407, DOI 10.1159/000356513
   Lauer N, 2011, J IMMUNOL, V187, P4374, DOI 10.4049/jimmunol.1002488
   McGwin G, 2005, BRIT J OPHTHALMOL, V89, P1166, DOI 10.1136/bjo.2005.067397
   Mikolajek H, 2011, J MOL RECOGNIT, V24, P371, DOI 10.1002/jmr.1090
   Miller JW, 2013, AM J OPHTHALMOL, V155, P1, DOI 10.1016/j.ajo.2012.10.018
   Molins B, 2008, ARTERIOSCL THROM VAS, V28, P2239, DOI 10.1161/ATVBAHA.108.174359
   Molins B, 2017, AM J PHYSIOL-CELL PH, V312, pC244, DOI 10.1152/ajpcell.00057.2016
   Molins B, 2016, SCI REP-UK, V6, DOI 10.1038/srep22889
   Molins B, 2011, CARDIOVASC RES, V92, P328, DOI 10.1093/cvr/cvr226
   Mullins RF, 2000, FASEB J, V14, P835, DOI 10.1096/fasebj.14.7.835
   Mullins RF, 2014, AM J PATHOL, V184, P3142, DOI 10.1016/j.ajpath.2014.07.017
   Nitsch D, 2008, OPHTHALMOLOGY, V115, P1904, DOI 10.1016/j.ophtha.2008.06.035
   Nussenblatt RB, 2014, AM J OPHTHALMOL, V158, P5, DOI 10.1016/j.ajo.2014.03.014
   Okemefuna AI, 2010, J BIOL CHEM, V285, P1053, DOI 10.1074/jbc.M109.044529
   Potempa Lawrence A, 2015, Biophys Rep, V1, P18
   Ridker PM, 2008, NEW ENGL J MED, V359, P2195, DOI 10.1056/NEJMoa0807646
   Ridker PM, 2002, NEW ENGL J MED, V347, P1557, DOI 10.1056/NEJMoa021993
   Ristau T, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0093459
   Rofagha S, 2013, OPHTHALMOLOGY, V120, P2292, DOI 10.1016/j.ophtha.2013.03.046
   SanGiovanni JP, 2007, ARCH OPHTHALMOL-CHIC, V125, P671, DOI 10.1001/archopht.125.5.671
   Seddon JM, 2006, NUTRITION, V22, P441, DOI 10.1016/j.nut.2005.12.004
   Seddon JM, 2005, ARCH OPHTHALMOL-CHIC, V123, P321, DOI 10.1001/archopht.123.3.321
   Seddon JM, 2004, JAMA-J AM MED ASSOC, V291, P704, DOI 10.1001/jama.291.6.704
   Seddon JM, 1996, JAMA-J AM MED ASSOC, V276, P1141, DOI 10.1001/jama.276.14.1141
   Seddon JM, 2010, OPHTHALMOLOGY, V117, P1560, DOI 10.1016/j.ophtha.2009.11.020
   Seth A, 2008, INVEST OPHTH VIS SCI, V49, P743, DOI 10.1167/iovs.07-1072
   Shaw AC, 2013, NAT REV IMMUNOL, V13, P875, DOI 10.1038/nri3547
   Singh SK, 2017, J BIOL CHEM, V292, P3129, DOI 10.1074/jbc.M116.773176
   Skeie JM, 2010, INVEST OPHTH VIS SCI, V51, P5336, DOI 10.1167/iovs.10-5322
   Tan JSL, 2007, OPHTHALMOLOGY, V114, P1143, DOI 10.1016/j.ophtha.2006.09.033
   Thiele JR, 2014, CIRCULATION, V130, P35, DOI 10.1161/CIRCULATIONAHA.113.007124
   Thompson D, 1999, STRUCTURE, V7, P169, DOI 10.1016/S0969-2126(99)80023-9
   Tomany SC, 2004, OPHTHALMOLOGY, V111, P1280, DOI 10.1016/j.ophtha.2003.11.010
   van Leeuwen R, 2003, EUR J EPIDEMIOL, V18, P845, DOI 10.1023/A:1025643303914
   Vine AK, 2005, OPHTHALMOLOGY, V112, P2076, DOI 10.1016/j.ophtha.2005.07.004
   VOLANAKI.JE, 1971, P SOC EXP BIOL MED, V136, P612
   VOLANAKIS JE, 1979, NATURE, V281, P155, DOI 10.1038/281155a0
   Weismann D, 2011, NATURE, V478, P76, DOI 10.1038/nature10449
   Whitcup SM, 2013, INT J INFLAMM, V2013, DOI 10.1155/2013/348092
   Winkler BS, 1999, MOL VIS, V5
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Yates JRW, 2007, NEW ENGL J MED, V357, P553, DOI 10.1056/NEJMoa072618
   Zarbin MA, 2004, ARCH OPHTHALMOL-CHIC, V122, P598, DOI 10.1001/archopht.122.4.598
NR 91
TC 22
Z9 22
U1 0
U2 13
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 1664-3224
J9 FRONT IMMUNOL
JI Front. Immunol.
PD APR 19
PY 2018
VL 9
AR 808
DI 10.3389/fimmu.2018.00808
PG 9
WC Immunology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Immunology
GA GD3TO
UT WOS:000430426900002
PM 29725335
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Guven, M
   Batar, B
   Mutlu, T
   Bostanci, M
   Mete, M
   Aras, C
   Unal, M
AF Guven, Mehmet
   Batar, Bahadir
   Mutlu, Tuba
   Bostanci, Merve
   Mete, Meltem
   Aras, Cengiz
   Unal, Mustafa
TI Toll-Like Receptors 2 and 4 Polymorphisms in Age-Related Macular
   Degeneration
SO CURRENT EYE RESEARCH
LA English
DT Article
DE Age-related macular degeneration; TLR polymorphism
ID POLYPOIDAL CHOROIDAL VASCULOPATHY; PATTERN-RECOGNITION RECEPTORS;
   RETINAL-PIGMENT EPITHELIUM; IMMUNE-SYSTEM; TLR4; NEOVASCULARIZATION;
   SUSCEPTIBILITY; HYALURONAN; ACTIVATION; EXPRESSION
AB Purpose: Age-related macular degeneration (AMD) is a complex disorder with multifactorial etiology, caused by a combination of genetic and environmental factors. Innate immunity appears to play a key role in the pathogenesis of AMD. The purpose of this study was to determine whether common variation in the human toll-like receptors (TLRs) 2 and 4 alters the risk of AMD.Patients and methods: A total of 183 patients with AMD and 200 disease-free control subjects were enrolled. The genotyping of polymorphisms TLR2 (TLR2-Arg753Gln: rs5743708) and TLR4 (TLR4-Asp299Gly: rs4986790; TLR4-Thr399Ile: rs4986791) were done using real-time PCR.Results: TLR2 Arg753Gln genotype had approximately four times greater risk of AMD compared with TLR2 Arg753Arg genotype (OR=3.88; 95% CI: 1.76-8.75, p=0.001). TLR2 Arg753Gln genotype was significantly higher in the patients with dry-type AMD (16%) and wet-type AMD (18%) than in the control (5%) subjects (p=0.005 and p=0.0008, respectively). There were no significant differences in the distribution of TLR4-Asp299Gly and TLR4-Thr399Ile genotypes between AMD patients and controls (p>0.05).Conclusion: Our results suggest that TLR2 polymorphism may contribute to the pathogenesis of AMD.
C1 [Guven, Mehmet; Batar, Bahadir; Mutlu, Tuba; Bostanci, Merve; Mete, Meltem] Istanbul Univ, Cerrahpasa Fac Med, Dept Med Biol, Istanbul, Turkey.
   [Aras, Cengiz] Istanbul Univ, Cerrahpasa Fac Med, Dept Ophthalmol, Istanbul, Turkey.
   [Unal, Mustafa] Akdeniz Univ, Fac Med, Dept Ophthalmol, TR-07058 Antalya, Turkey.
C3 Istanbul University; Istanbul University - Cerrahpasa; Istanbul
   University; Istanbul University - Cerrahpasa; Akdeniz University
RP Unal, M (通讯作者)，Akdeniz Univ, Fac Med, Dept Ophthalmol, TR-07058 Antalya, Turkey.
EM mustafaunalmd@gmail.com
RI Batar, Bahadir/F-4724-2018; GUVEN, MEHMET/C-9833-2019
OI GUVEN, MEHMET/0000-0002-8749-1708; Mutlu, Tuba/0000-0003-3601-6074;
   METE, Meltem/0000-0002-9297-8254
FU University of Istanbul; Akdeniz University Scientific Research Projects
   Unit
FX The authors report no conflicts of interest. The authors alone are
   responsible for the content and writing of the paper. This study was
   supported by the Research Fund of The University of Istanbul. MU was
   supported by Akdeniz University Scientific Research Projects Unit.
CR Allikmets R, 2009, NEW ENGL J MED, V360, P2252
   Andreakos E, 2004, IMMUNOL REV, V202, P250, DOI 10.1111/j.0105-2896.2004.00202.x
   Arbour NC, 2000, NAT GENET, V25, P187, DOI 10.1038/76048
   Balistreri CR, 2009, J CLIN IMMUNOL, V29, P406, DOI 10.1007/s10875-009-9297-5
   Berdeli A, 2005, J MOL MED, V83, P535, DOI 10.1007/s00109-005-0677-x
   Buwitt-Beckmann U, 2006, J BIOL CHEM, V281, P9049, DOI 10.1074/jbc.M512525200
   Chen YH, 2010, MOL INTERV, V10, P271, DOI 10.1124/mi.10.5.4
   Cheng Y, 2014, GENET MOL RES, V13, P302, DOI 10.4238/2014.January.17.15
   Cho YE, 2009, INVEST OPHTH VIS SCI, V50, P5614, DOI 10.1167/iovs.09-3688
   Cosan F, 2009, CLIN RHEUMATOL, V28, P1385, DOI 10.1007/s10067-009-1252-6
   Coscas G, 2014, AM J OPHTHALMOL, V158, P309, DOI 10.1016/j.ajo.2014.05.004
   Dalgic N, 2011, HUM IMMUNOL, V72, P440, DOI 10.1016/j.humimm.2011.02.001
   Despriet DDG, 2008, INVEST OPHTH VIS SCI, V49, P364, DOI 10.1167/iovs.07-0656
   Ebrahem Q, 2006, P NATL ACAD SCI USA, V103, P13480, DOI 10.1073/pnas.0601552103
   Edwards AO, 2008, INVEST OPHTH VIS SCI, V49, P1652, DOI 10.1167/iovs.07-1378
   Frederick Paul A, 2014, Curr Ophthalmol Rep, V2, P14
   Fujimoto T, 2010, INVEST OPHTH VIS SCI, V51, P4694, DOI 10.1167/iovs.09-4464
   Gorin MB, 1999, MOL VIS, V5, pU31
   Gounarides J, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0111472
   Hollyfield JG, 1997, EXP EYE RES, V65, P603, DOI 10.1006/exer.1997.0369
   Iwasaki A, 2010, SCIENCE, V327, P291, DOI 10.1126/science.1183021
   Jiang D, 2007, ANNU REV CELL DEV BI, V23, P435, DOI 10.1146/annurev.cellbio.23.090506.123337
   Kaarniranta K, 2009, J MOL MED, V87, P117, DOI 10.1007/s00109-008-0418-z
   Karaca N, 2013, J EUR ACAD DERMATOL, V27, pe85, DOI 10.1111/j.1468-3083.2012.04514.x
   Kaur I, 2006, INVEST OPHTH VIS SCI, V47, P3729, DOI 10.1167/iovs.05-1430
   Kawai T, 2010, NAT IMMUNOL, V11, P373, DOI 10.1038/ni.1863
   Kent DL, 2014, MOL VIS, V20, P46
   Klaver CCW, 2003, DEV OPHTHALMOL, V37, P155
   Klettner A, 2013, ACTA OPHTHALMOL, V91, pE211, DOI 10.1111/aos.12031
   Miyake K, 2007, SEMIN IMMUNOL, V19, P3, DOI 10.1016/j.smim.2006.12.002
   Ozato K, 2002, BIOTECHNIQUES, P66
   Schroder NW, 2005, LANCET INFECT DIS, V5, P156, DOI 10.1016/S1473-3099(05)70023-2
   Sharma NK, 2014, MOL CELL BIOCHEM, V393, P1, DOI 10.1007/s11010-014-2040-4
   Sng CCA, 2011, OPHTHALMIC RES, V45, P191, DOI 10.1159/000321387
   Song GG, 2013, MOL BIOL REP, V40, P5129, DOI 10.1007/s11033-013-2616-1
   Yang ZL, 2008, NEW ENGL J MED, V359, P1456, DOI 10.1056/NEJMoa0802437
   Zarbin MA, 2004, ARCH OPHTHALMOL-CHIC, V122, P598, DOI 10.1001/archopht.122.4.598
   Zareparsi S, 2005, HUM MOL GENET, V14, P1449, DOI 10.1093/hmg/ddi154
   Zhu Y, 2013, MOL VIS, V19, P1826
NR 39
TC 9
Z9 9
U1 0
U2 3
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0271-3683
EI 1460-2202
J9 CURR EYE RES
JI Curr. Eye Res.
PY 2016
VL 41
IS 6
BP 856
EP 861
DI 10.3109/02713683.2015.1067326
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA DO6ZJ
UT WOS:000377931700015
PM 26398587
DA 2022-11-30
ER

PT J
AU Pieroni, CG
   Witkin, AJ
   Ko, TH
   Fujimoto, JG
   Chan, A
   Schuman, JS
   Ishikawa, H
   Reichel, E
   Duker, JS
AF Pieroni, CG
   Witkin, AJ
   Ko, TH
   Fujimoto, JG
   Chan, A
   Schuman, JS
   Ishikawa, H
   Reichel, E
   Duker, JS
TI Ultrahigh resolution optical coherence tomography in non-exudative age
   related macular degeneration
SO BRITISH JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID RETINAL-PIGMENT EPITHELIUM; CHOROIDAL NEOVASCULARIZATION; PHOTODYNAMIC
   THERAPY; TAP; VERTEPORFIN; PROGRESSION; PATHOLOGY; DRUSEN
AB Aim: To describe the appearance of the non-exudative forms of age related macular degeneration (AMD) as imaged by ultrahigh resolution optical coherence tomography (UHR-OCT).
   Methods: A UHR-OCT ophthalmic imaging system, which utilises a femtosecond laser light source capable of,3 mm axial resolution, was employed to obtain retinal cross sectional images of patients with non-exudative AMD. Observational studies of the resulting retinal images were performed.
   Results: 52 eyes of 42 patients with the clinical diagnosis of non-exudative AMD were imaged using the UHR-OCT system. 47 of the 52 (90%) eyes had the clinical diagnosis of drusen and/or retinal pigment epithelial (RPE) changes. In these patients, three patterns of drusen were apparent on UHR-OCT: (1) distinct RPE excrescences, (2) a saw toothed pattern of the RPE, and (3) nodular drusen. On UHR-OCT, three eyes (6%) with a clinical diagnosis of non-exudative AMD had evidence of fluid under the retina or RPE. Two of these three patients had findings suspicious for subclinical choroidal neovascularisation on UHR-OCT.
   Conclusion: With the increased resolution of UHR-OCT compared to standard OCT, the involvement of the outer retinal layers are more clearly defined. UHR-OCT may allow for the detection of early exudative changes not visible clinically or by angiography.
C1 Tufts Univ, New England Med Ctr, New England Eye Ctr, Boston, MA 02111 USA.
   MIT, Dept Elect Engn & Comp Sci, Cambridge, MA 02139 USA.
   MIT, Elect Res Lab, Cambridge, MA 02139 USA.
   Univ Pittsburgh, Sch Med, Dept Ophthalmol, UPMC Eye Ctr, Pittsburgh, PA USA.
C3 Tufts Medical Center; Tufts University; Massachusetts Institute of
   Technology (MIT); Massachusetts Institute of Technology (MIT);
   Pennsylvania Commonwealth System of Higher Education (PCSHE); University
   of Pittsburgh
RP Reichel, E (通讯作者)，Tufts Univ, New England Med Ctr, New England Eye Ctr, 750 Washington St,Box 450, Boston, MA 02111 USA.
EM ereichel@tufts-nemc.org
RI Schuman, Joel S/K-7304-2012; Schuman, Joel S/M-2389-2019; Ishikawa,
   Hiroshi/ABC-6293-2020
OI Schuman, Joel S/0000-0002-8885-3766; Schuman, Joel
   S/0000-0002-8885-3766; Ishikawa, Hiroshi/0000-0001-6310-5748
FU NATIONAL EYE INSTITUTE [R01EY011289, R01EY013178, P30EY013078] Funding
   Source: NIH RePORTER; NEI NIH HHS [R01 EY013178, R01 EY011289, R01
   EY013178-04, P30 EY013078, R01 EY011289-16, P30 EY013078-04,
   R01-EY11289-16, R01-EY13178, P30-EY13078] Funding Source: Medline
CR *AM NAT STAND I, 1993, SAF LAS
   Anger EM, 2004, EXP EYE RES, V78, P1117, DOI 10.1016/j.exer.2004.01.011
   [Anonymous], 1991, Arch Ophthalmol, V109, P1109
   Barbazetto I, 2003, ARCH OPHTHALMOL-CHIC, V121, P1253
   Blinder KJ, 2003, AM J OPHTHALMOL, V136, P407, DOI 10.1016/S0002-9394(03)00223-X
   Blumenkranz MS, 2001, ARCH OPHTHALMOL-CHIC, V119, P198
   Bressler NM, 2002, ARCH OPHTHALMOL-CHIC, V120, P1307
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   BRESSLER SB, 1990, ARCH OPHTHALMOL-CHIC, V108, P1442, DOI 10.1001/archopht.1990.01070120090035
   Bressler SB, 2004, ARCH OPHTHALMOL-CHIC, V122, P325, DOI 10.1001/archopht.122.3.325
   Drexler W, 2003, ARCH OPHTHALMOL-CHIC, V121, P695, DOI 10.1001/archopht.121.5.695
   Drexler W, 2001, NAT MED, V7, P502, DOI 10.1038/86589
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   GREEN WR, 1993, OPHTHALMOLOGY, V100, P1519
   HAWKINS BS, 1990, ARCH OPHTHALMOL-CHIC, V108, P816
   Hee MR, 1996, OPHTHALMOLOGY, V103, P1260, DOI 10.1016/S0161-6420(96)30512-5
   HEE MR, 1995, ARCH OPHTHALMOL-CHIC, V113, P325, DOI 10.1001/archopht.1995.01100030081025
   HUANG D, 1991, SCIENCE, V254, P1178, DOI 10.1126/science.1957169
   Klaver CCW, 1998, ARCH OPHTHALMOL-CHIC, V116, P653, DOI 10.1001/archopht.116.5.653
   Klein R, 1997, OPHTHALMOLOGY, V104, P7, DOI 10.1016/S0161-6420(97)30368-6
   Klein R, 2002, OPHTHALMOLOGY, V109, P1767, DOI 10.1016/S0161-6420(02)01146-6
   Ko TH, 2004, OPHTHALMOLOGY, V111, P2033, DOI 10.1016/j.ophtha.2004.05.021
   Pons ME, 2005, OPHTHALMOLOGY, V112, P1079, DOI 10.1016/j.ophtha.2004.11.061
   SARKS JP, 1994, EYE, V8, P269, DOI 10.1038/eye.1994.57
   SARKS SH, 1973, BRIT J OPHTHALMOL, V57, P951, DOI 10.1136/bjo.57.12.951
   SWANSON EA, 1993, OPT LETT, V18, P1864, DOI 10.1364/OL.18.001864
   Zacks DN, 2004, ARCH OPHTHALMOL-CHIC, V122, P406, DOI 10.1001/archopht.122.3.406
NR 27
TC 75
Z9 78
U1 0
U2 4
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0007-1161
EI 1468-2079
J9 BRIT J OPHTHALMOL
JI Br. J. Ophthalmol.
PD FEB
PY 2006
VL 90
IS 2
BP 191
EP 197
DI 10.1136/bjo.2005.076612
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 003ZH
UT WOS:000234721300018
PM 16424532
OA Green Published, Green Accepted
DA 2022-11-30
ER

PT J
AU Dorschmann, P
   Klettner, A
AF Doerschmann, Philipp
   Klettner, Alexa
TI Fucoidans as Potential Therapeutics for Age-Related Macular
   Degeneration-Current Evidence from In Vitro Research
SO INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
LA English
DT Review
DE fucoidan; age-related macular degeneration (AMD); retinal pigment
   epithelium (RPE); vascular endothelial growth factor (VEGF); Saccharina
   latissima; Laminaria hyperborea; oxidative stress; sulfated fucan; brown
   seaweed
AB Age-related macular degeneration (AMD) is the major reason for blindness in the industrialized world with limited treatment options. Important pathogenic pathways in AMD include oxidative stress and vascular endothelial growth factor (VEGF) secretion. Due to their bioactivities, fucoidans have recently been suggested as potential therapeutics. This review gives an overview of the recent developments in this field. Recent studies have characterized several fucoidans from different species, with different molecular characteristics and different extraction methods, in regard to their ability to reduce oxidative stress and inhibit VEGF in AMD-relevant in vitro systems. As shown in these studies, fucoidans exhibit a species dependency in their bioactivity. Additionally, molecular properties such as molecular weight and fucose content are important issues. Fucoidans from Saccharina latissima and Laminaria hyperborea were identified as the most promising candidates for further development. Further research is warranted to establish fucoidans as potential therapeutics for AMD.
C1 [Doerschmann, Philipp; Klettner, Alexa] Univ Med Ctr Schleswig Holstein UKSH, Dept Ophthalmol, Campus Kiel, D-24105 Kiel, Germany.
C3 University of Kiel; Schleswig Holstein University Hospital
RP Klettner, A (通讯作者)，Univ Med Ctr Schleswig Holstein UKSH, Dept Ophthalmol, Campus Kiel, D-24105 Kiel, Germany.
EM philipp.doerschmann@uksh.de; alexakarina.klettner@uksh.de
OI Klettner, Alexa/0000-0002-2709-1059
FU EU InterReg-Deutschland-Denmark; European Fund of Regional Development,
   project FucoSan [122-1.1 20]; Helmut Ecker Stiftung [01/20]
FX This study was partly funded by EU InterReg-Deutschland-Denmark and the
   European Fund of Regional Development, project FucoSan, grant number
   122-1.1 20, and by Helmut Ecker Stiftung, grant number 01/20.
CR Abu R, 2013, INT J BIOL MACROMOL, V59, P305, DOI 10.1016/j.ijbiomac.2013.04.035
   Ale MT, 2011, MAR DRUGS, V9, P2106, DOI 10.3390/md9102106
   Bhutto I, 2012, MOL ASPECTS MED, V33, P295, DOI 10.1016/j.mam.2012.04.005
   Bittkau KS, 2020, ALGAL RES, V45, DOI 10.1016/j.algal.2019.101759
   Bittkau KS, 2019, MAR DRUGS, V17, DOI 10.3390/md17080441
   Bourne RRA, 2017, LANCET GLOB HEALTH, V5, pE888, DOI 10.1016/S2214-109X(17)30293-0
   Cai H, 2006, MOL VIS, V12, P1
   Chappelow AV, 2008, DRUGS, V68, P1029, DOI 10.2165/00003495-200868080-00002
   Chen HJ, 2016, CANCER LETT, V382, P44, DOI 10.1016/j.canlet.2016.08.020
   Cho M, 2014, CARBOHYD POLYM, V113, P507, DOI 10.1016/j.carbpol.2014.07.055
   Cohen SY, 2007, BRIT J OPHTHALMOL, V91, P1173, DOI 10.1136/bjo.2007.115501
   Curcio CA, 2011, BRIT J OPHTHALMOL, V95, P1638, DOI 10.1136/bjophthalmol-2011-300344
   Datta S, 2017, PROG RETIN EYE RES, V60, P201, DOI 10.1016/j.preteyeres.2017.03.002
   Dithmer M, 2017, MAR DRUGS, V15, DOI 10.3390/md15070193
   Dithmer M, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0089150
   Dorschmann P, 2019, MAR DRUGS, V17, DOI 10.3390/md17100548
   Dorschmann P, 2019, MAR DRUGS, V17, DOI 10.3390/md17050258
   Dorschmann P, 2020, MAR DRUGS, V18, DOI 10.3390/md18060282
   Dunn KC, 1996, EXP EYE RES, V62, P155, DOI 10.1006/exer.1996.0020
   Ferrara N, 1996, Curr Opin Nephrol Hypertens, V5, P35, DOI 10.1097/00041552-199601000-00008
   Ford KM, 2011, INVEST OPHTH VIS SCI, V52, P9478, DOI 10.1167/iovs.11-8353
   Fuh G, 2006, J BIOL CHEM, V281, P6625, DOI 10.1074/jbc.M507783200
   Gerber HP, 1998, J BIOL CHEM, V273, P30336, DOI 10.1074/jbc.273.46.30336
   Green RW, 1999, MOL VIS, V5
   Halling B., 2015, J NUTR HLTH, V2, P1, DOI DOI 10.15744/2393-9060.2.205
   Hanus J, 2015, AGEING RES REV, V24, P286, DOI 10.1016/j.arr.2015.09.002
   He Y, 2019, INT J OPHTHALMOL-CHI, V12, P375, DOI 10.18240/ijo.2019.03.04
   Heesterbeek TJ, 2020, OPHTHAL PHYSL OPT, V40, P140, DOI 10.1111/opo.12675
   Huang TH, 2015, MAR DRUGS, V13, P1882, DOI 10.3390/md13041882
   Imbs TI, 2020, INT J BIOL MACROMOL, V142, P778, DOI 10.1016/j.ijbiomac.2019.10.018
   Irhimeh MR, 2005, METHOD FIND EXP CLIN, V27, P705, DOI 10.1358/mf.2005.27.10.948919
   Jayawardena TU, 2020, MAR DRUGS, V18, DOI 10.3390/md18040212
   Jayawardena TU, 2019, INT J BIOL MACROMOL, V131, P614, DOI 10.1016/j.ijbiomac.2019.03.105
   Kaarniranta K, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20102374
   Kadena K, 2018, MAR DRUGS, V16, DOI 10.3390/md16080254
   Kamba T, 2006, AM J PHYSIOL-HEART C, V290, pH560, DOI 10.1152/ajpheart.00133.2005
   Kannan R, 2006, MOL VIS, V12, P1649
   Kim SA, 2020, BIOCHEM BIOPH RES CO, V522, P240, DOI 10.1016/j.bbrc.2019.11.085
   King A, 2004, PHOTOCHEM PHOTOBIOL, V79, P470, DOI 10.1562/LE-03-17.1
   Klettner A., 2013, VASCULAR ENDOTHELIAL, P117
   Klettner A, 2019, METHODS MOL BIOL, V1834, P109, DOI 10.1007/978-1-4939-8669-9_8
   Klettner A, 2016, MAR DRUGS, V14, DOI 10.3390/md14020031
   Klettner A, 2015, MOL VIS, V21, P736
   Klettner A, 2013, ACTA OPHTHALMOL, V91, pE211, DOI 10.1111/aos.12031
   Klettner Alexa, 2012, Front Biosci (Schol Ed), V4, P392
   Klettner A, 2009, GRAEF ARCH CLIN EXP, V247, P1487, DOI 10.1007/s00417-009-1139-x
   Klettner AK, 2020, RETINAL PIGMENT EPITHELIUM IN HEALTH AND DISEASE, P295, DOI 10.1007/978-3-030-28384-1_17
   Koh HSA, 2020, FRONT PHARMACOL, V11, DOI 10.3389/fphar.2020.00831
   Koinzer S, 2015, CURR EYE RES, V40, P853, DOI 10.3109/02713683.2014.961613
   Kopplin G, 2018, ACS APPL BIO MATER, V1, P1880, DOI 10.1021/acsabm.8b00436
   Kurihara T, 2012, J CLIN INVEST, V122, P4213, DOI 10.1172/JCI65157
   Lahrsen E, 2018, CARBOHYD POLYM, V192, P208, DOI 10.1016/j.carbpol.2018.03.056
   Lange CAK, 2012, OPHTHALMOLOGICA, V227, P115, DOI 10.1159/000331418
   Lee SH, 2012, CARBOHYD POLYM, V89, P599, DOI 10.1016/j.carbpol.2012.03.056
   Li B, 2008, MOLECULES, V13, P1671, DOI 10.3390/molecules13081671
   Li XX, 2015, MOL MED REP, V11, P3746, DOI 10.3892/mmr.2015.3224
   Li Y, 2019, ANIMALS-BASEL, V9, DOI 10.3390/ani9121108
   Liu F, 2012, PHYTOMEDICINE, V19, P797, DOI 10.1016/j.phymed.2012.03.015
   Marneros AG, 2005, AM J PATHOL, V167, P1451, DOI 10.1016/S0002-9440(10)61231-X
   Marudhupandi T, 2014, Pak J Biol Sci, V17, P402, DOI 10.3923/pjbs.2014.402.407
   Middleton S, 2010, VET CLIN N AM-FOOD A, V26, P557, DOI 10.1016/j.cvfa.2010.09.002
   Miller JW, 2016, INVEST OPHTH VIS SCI, V57, P6911, DOI 10.1167/iovs.16-21201
   Miller JW, 2013, OPHTHALMOLOGY, V120, P106, DOI 10.1016/j.ophtha.2012.07.038
   Morya VK, 2012, APPL MICROBIOL BIOT, V93, P71, DOI 10.1007/s00253-011-3666-8
   Nagamine T, 2015, MAR DRUGS, V13, P48, DOI 10.3390/md13010048
   Narazaki M, 2008, BLOOD, V111, P4126, DOI 10.1182/blood-2007-09-112474
   Neupane S, 2020, J CHROMATOGR A, V1612, DOI 10.1016/j.chroma.2019.460658
   Nishijima K, 2007, AM J PATHOL, V171, P53, DOI 10.2353/ajpath.2007.061237
   Nowak JZ, 2013, PHARMACOL REP, V65, P288, DOI 10.1016/S1734-1140(13)71005-3
   Oh JY, 2020, MOLECULES, V25, DOI 10.3390/molecules25102361
   Oliveira C, 2019, CARBOHYD POLYM, V223, DOI 10.1016/j.carbpol.2019.115034
   Park HY, 2011, FOOD CHEM TOXICOL, V49, P1745, DOI 10.1016/j.fct.2011.04.020
   Park J, 2017, INT IMMUNOPHARMACOL, V43, P91, DOI 10.1016/j.intimp.2016.12.006
   Pennesi ME, 2012, MOL ASPECTS MED, V33, P487, DOI 10.1016/j.mam.2012.06.003
   Pomin VH, 2016, BIOORGAN MED CHEM, V24, P3965, DOI 10.1016/j.bmc.2016.07.037
   Pozharitskaya ON, 2020, MAR DRUGS, V18, DOI 10.3390/md18050275
   Pozharitskaya ON, 2019, MAR DRUGS, V17, DOI 10.3390/md17120687
   Pozharitskaya ON, 2018, MAR DRUGS, V16, DOI 10.3390/md16040132
   Provis JM, 1997, EXP EYE RES, V65, P555, DOI 10.1006/exer.1997.0365
   Ren DD, 2019, INT J BIOL MACROMOL, V140, P188, DOI 10.1016/j.ijbiomac.2019.08.002
   Rizzolo LJ, 2014, EXP EYE RES, V126, P16, DOI 10.1016/j.exer.2013.12.018
   Rofagha S, 2013, OPHTHALMOLOGY, V120, P2292, DOI 10.1016/j.ophtha.2013.03.046
   Rohrer B, 2016, ADV EXP MED BIOL, V854, P793, DOI 10.1007/978-3-319-17121-0_106
   Rohwer K, 2019, MAR DRUGS, V17, DOI 10.3390/md17090538
   Rui X, 2017, BMC COMPLEM ALTERN M, V17, DOI 10.1186/s12906-017-1885-y
   Rusche B, 2003, ALTEX-ALTERN TIEREXP, V20, P63
   Sanjeewa KKA, 2019, CARBOHYD POLYM, V224, DOI 10.1016/j.carbpol.2019.115195
   Schmidt-Erfurth U, 2017, OPHTHALMOLOGICA, V237, P185, DOI 10.1159/000458539
   Schmidt-Erfurth U, 2014, BRIT J OPHTHALMOL, V98, P1144, DOI 10.1136/bjophthalmol-2014-305702
   Schnichels S, 2021, PROG RETIN EYE RES, V81, DOI 10.1016/j.preteyeres.2020.100880
   Schwesinger C, 2001, AM J PATHOL, V158, P1161, DOI 10.1016/S0002-9440(10)64063-1
   Sim SY, 2019, NUTR RES, V65, P54, DOI 10.1016/j.nutres.2019.02.002
   Somasundaran S, 2020, CLIN EXP OPHTHALMOL, V48, P1043, DOI 10.1111/ceo.13834
   Strauss O, 2005, PHYSIOL REV, V85, P845, DOI 10.1152/physrev.00021.2004
   Nguyen TT, 2020, MAR DRUGS, V18, DOI 10.3390/md18060296
   Tode J, 2018, TRANSL VIS SCI TECHN, V7, DOI 10.1167/tvst.7.3.2
   Ustyuzhanina NE, 2014, GLYCOBIOLOGY, V24, P1265, DOI 10.1093/glycob/cwu063
   Wada M, 2001, CURR EYE RES, V23, P226, DOI 10.1076/ceyr.23.3.226.5467
   Wang J, 2008, INT J BIOL MACROMOL, V42, P127, DOI 10.1016/j.ijbiomac.2007.10.003
   Wang YQ, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19124050
   Watkins WM, 2013, EXP EYE RES, V116, P240, DOI 10.1016/j.exer.2013.09.014
   Yang WZ, 2013, EXP EYE RES, V115, P96, DOI 10.1016/j.exer.2013.06.011
   Ye J, 2020, MAR DRUGS, V18, DOI 10.3390/md18060328
   Zhang E, 2020, PAK J PHARM SCI, V33, P1, DOI 10.36721/PJPS.2020.33.1.REG.001-009.1
   Zhang Y, 2018, CELL PHYSIOL BIOCHEM, V46, P1704, DOI 10.1159/000489246
NR 105
TC 7
Z9 9
U1 0
U2 6
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 1422-0067
J9 INT J MOL SCI
JI Int. J. Mol. Sci.
PD DEC
PY 2020
VL 21
IS 23
AR 9272
DI 10.3390/ijms21239272
PG 19
WC Biochemistry & Molecular Biology; Chemistry, Multidisciplinary
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry
GA PD8EN
UT WOS:000597911400001
PM 33291752
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Miceli, MV
   Jazwinski, SM
AF Miceli, MV
   Jazwinski, SM
TI Nuclear gene expression changes due to mitochondrial dysfunction in
   ARPE-19 cells: Implications for age-related macular degeneration
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
ID RETINAL-PIGMENT EPITHELIUM; CHOROIDAL NEOVASCULAR MEMBRANES; BRUCHS
   MEMBRANE; SUPEROXIDE-DISMUTASE; MESSENGER-RNA; DRUSEN; MACULOPATHY;
   VITRONECTIN; EYE; MANIFESTATIONS
AB PURPOSE. To measure changes in nuclear gene expression resulting from mitochondrial dysfunction in retinal pigment epithelial cells.
   METHODS. ARPE-19 retinal pigment epithelial cells were depleted of their mitochondrial ( mt) DNA by passaging in a low concentration of ethidium bromide. Loss of mitochondrial DNA was determined by uridine auxotrophy and quantitative real-time polymerase chain reaction of isolated DNA. Loss of mitochondrial membrane potential was estimated by uptake of JC-1. Changes in nuclear gene expression were determined by quantitative real-time reverse transcription-polymerase chain reaction of isolated total RNA from ethidium-bromide-treated and untreated cells. Morphologic and phenotypic changes were determined by phase-contrast microscopy, sensitivity to the oxidant tert-butyl hydroperoxide (tBH), and invasion assay.
   RESULTS. ARPE-19 cells became auxotrophic for growth on uridine after eight passages in 50 ng/mL ethidium bromide. Quantitative PCR revealed almost complete loss of mitochondrial DNA (rho(0) cells). Uptake of JC-1 was reduced in the rho(0) cells, indicating reduction of mitochondrial membrane potential. Quantitative RT-PCR measured increased expression of genes coding for drusen components, lipid transport, extracellular matrix components, and responses to inflammation in the rho(0) cells. The rho(0) cells also exhibited an increased sensitivity to killing by tBH and increased migration and invasion through solubulized basement membrane - coated tissue culture inserts.
   CONCLUSIONS. ARPE-19 cells respond to loss of mitochondrial function by changes in nuclear gene expression that resemble changes observed in age-related macular degeneration. The results lead to the hypothesis that loss of mitochondrial function with age and resultant changes in nuclear gene expression may explain some of the changes in the macula that are associated with the known clinical manifestations of age-related macular degeneration.
C1 Louisiana State Univ, Hlth Sci Ctr, Dept Biochem & Mol Biol, New Orleans, LA 70112 USA.
C3 Louisiana State University System; Louisiana State University Health
   Sciences Center New Orleans
RP Miceli, MV (通讯作者)，Louisiana State Univ, Hlth Sci Ctr, Dept Biochem & Mol Biol, 1901 Perdido St,Box P7-2, New Orleans, LA 70112 USA.
EM mmicel@lsuhsc.edu
CR Anandatheerthavarada HK, 2003, J CELL BIOL, V161, P41, DOI 10.1083/jcb.200207030
   Anderson DH, 2002, AM J OPHTHALMOL, V134, P411, DOI 10.1016/S0002-9394(02)01624-0
   Anderson DH, 2001, AM J OPHTHALMOL, V131, P767, DOI 10.1016/S0002-9394(00)00961-2
   Barja G, 2004, TRENDS NEUROSCI, V27, P595, DOI 10.1016/j.tins.2004.07.005
   Biswas G, 1999, EMBO J, V18, P522, DOI 10.1093/emboj/18.3.522
   Blackburn J, 2003, INVEST OPHTH VIS SCI, V44, P4613, DOI 10.1167/iovs.03-0112
   BOK D, 1971, J CELL BIOL, V49, P664, DOI 10.1083/jcb.49.3.664
   Borghouts C, 2004, GENETICS, V166, P765, DOI 10.1534/genetics.166.2.765
   BRESSLER NM, 1994, RETINA-J RET VIT DIS, V14, P130, DOI 10.1097/00006982-199414020-00006
   Bressler NM, 2003, ARCH OPHTHALMOL-CHIC, V121, P1621
   Butow RA, 2004, MOL CELL, V14, P1, DOI 10.1016/S1097-2765(04)00179-0
   Butow RA, 2002, CELL DEATH DIFFER, V9, P1043, DOI 10.1038/sj.cdd.4401083
   Chomyn A, 2003, BIOCHEM BIOPH RES CO, V304, P519, DOI 10.1016/S0006-291X(03)00625-9
   COSSARIZZA A, 1993, BIOCHEM BIOPH RES CO, V197, P40, DOI 10.1006/bbrc.1993.2438
   Crabb JW, 2002, P NATL ACAD SCI USA, V99, P14682, DOI 10.1073/pnas.222551899
   Curcio CA, 2001, INVEST OPHTH VIS SCI, V42, P265
   Dunaief JL, 2002, ARCH OPHTHALMOL-CHIC, V120, P1435, DOI 10.1001/archopht.120.11.1435
   Duncan KG, 2002, BIOCHEM BIOPH RES CO, V292, P1017, DOI 10.1006/bbrc.2002.6756
   Dunn KC, 1996, EXP EYE RES, V62, P155, DOI 10.1006/exer.1996.0020
   ELDRED GE, 1993, RETINAL DEGENERATION, P15
   ELNER SG, 1992, EXP EYE RES, V55, P21, DOI 10.1016/0014-4835(92)90087-9
   Elner Susan G, 2002, Trans Am Ophthalmol Soc, V100, P273
   Feher J, 2003, OPHTHALMOLOGICA, V217, P351, DOI 10.1159/000071351
   Finnemann SC, 2003, EMBO J, V22, P4143, DOI 10.1093/emboj/cdg416
   Gray JX, 1996, J IMMUNOL, V157, P5438
   Green W R, 1999, Mol Vis, V5, P27
   Hageman GS, 1999, FASEB J, V13, P477, DOI 10.1096/fasebj.13.3.477
   HAYES KC, 1989, INVEST OPHTH VIS SCI, V30, P225
   Heckenlively JR, 2003, RETINA-J RET VIT DIS, V23, P518, DOI 10.1097/00006982-200308000-00012
   HOGAN M J, 1972, Transactions of the American Academy of Ophthalmology and Oto-Laryngology, V76, P64
   Isashiki Y, 1998, ACTA OPHTHALMOL SCAN, V76, P6, DOI 10.1034/j.1600-0420.1998.760103.x
   Kamei M, 1999, INVEST OPHTH VIS SCI, V40, P2367
   Kimoto K, 2004, INVEST OPHTH VIS SCI, V45, P2431, DOI 10.1167/iovs.03-1276
   Kimura K, 2000, AM J OPHTHALMOL, V130, P769, DOI 10.1016/S0002-9394(00)00552-3
   King M P, 1996, Methods Enzymol, V264, P304, DOI 10.1016/S0076-6879(96)64029-4
   Kirchman PA, 1999, GENETICS, V152, P179
   Kitaoka T, 1997, CURR EYE RES, V16, P396, DOI 10.1076/ceyr.16.4.396.10685
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Kvanta A, 2000, CURR EYE RES, V21, P684, DOI 10.1076/0271-3683(200009)21:3;1-R;FT684
   Kwak N, 2000, INVEST OPHTH VIS SCI, V41, P3158
   Liang FQ, 2003, EXP EYE RES, V76, P397, DOI 10.1016/S0014-4835(03)00023-X
   Lopez PF, 1996, INVEST OPHTH VIS SCI, V37, P855
   Malek G, 2003, AM J PATHOL, V162, P413, DOI 10.1016/S0002-9440(10)63836-9
   Miceli MV, 1997, INVEST OPHTH VIS SCI, V38, P1588
   Miceli MV, 2005, EXP CELL RES, V302, P270, DOI 10.1016/j.yexcr.2004.09.006
   MICELI MV, 1991, INVEST OPHTH VIS SCI, V32, P2847
   Mitsuhiro MRKH, 2003, ACTA OPHTHALMOL SCAN, V81, P630, DOI 10.1111/j.1395-3907.2003.00170.x
   MULLIE MA, 1985, ARCH OPHTHALMOL-CHIC, V103, P1825, DOI 10.1001/archopht.1985.01050120059020
   Newsome DA, 1995, J TRACE ELEM EXP MED, V8, P193
   Omori K, 2002, MATRIX BIOL, V21, P337, DOI 10.1016/S0945-053X(02)00013-6
   Ozaki S, 1999, BIOCHEM BIOPH RES CO, V258, P524, DOI 10.1006/bbrc.1999.0672
   Rakic JM, 2003, INVEST OPHTH VIS SCI, V44, P1732, DOI 10.1167/iovs.02-0809
   SARKS SH, 1976, BRIT J OPHTHALMOL, V60, P324, DOI 10.1136/bjo.60.5.324
   SARKS SH, 1982, AUST J OPHTHALMOL, V10, P91, DOI 10.1111/j.1442-9071.1982.tb00366.x
   SCHEIFFARTH OF, 1988, GRAEF ARCH CLIN EXP, V226, P357, DOI 10.1007/BF02172967
   Spraul CW, 1999, SURV OPHTHALMOL, V44, pS10, DOI 10.1016/S0039-6257(99)00086-7
   Strunnikova N, 2004, INVEST OPHTH VIS SCI, V45, P3767, DOI 10.1167/iovs.04-0311
   Traven A, 2001, J BIOL CHEM, V276, P4020, DOI 10.1074/jbc.M006807200
   Tyni T, 2002, PEDIATR RES, V52, P595, DOI 10.1203/01.PDR.0000030874.20888.2D
   van Leeuwen R, 2003, EUR J EPIDEMIOL, V18, P845, DOI 10.1023/A:1025643303914
   VANDERSCHAFT TL, 1993, BRIT J OPHTHALMOL, V77, P657, DOI 10.1136/bjo.77.10.657
   YOUNG RW, 1969, J CELL BIOL, V42, P392, DOI 10.1083/jcb.42.2.392
   YOUNG RW, 1987, SURV OPHTHALMOL, V31, P291, DOI 10.1016/0039-6257(87)90115-9
   Zarbin MA, 1998, EUR J OPHTHALMOL, V8, P199, DOI 10.1177/112067219800800401
NR 64
TC 46
Z9 47
U1 0
U2 4
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD MAY
PY 2005
VL 46
IS 5
BP 1765
EP 1773
DI 10.1167/iovs.04-1327
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 920RO
UT WOS:000228708000034
PM 15851580
DA 2022-11-30
ER

PT J
AU Wang, FH
   Yuan, YZ
   Wang, L
   Ye, XF
   Zhao, JK
   Shen, MX
   Zhang, Q
   Xu, D
   Qin, GY
   Zhang, W
   Yuan, F
   Chang, Q
   Zhao, PQ
   Wang, F
   Sun, XD
AF Wang, Fenghua
   Yuan, Yuanzhi
   Wang, Ling
   Ye, Xiaofeng
   Zhao, Jingke
   Shen, Mengxi
   Zhang, Qi
   Xu, Ding
   Qin, Guoyou
   Zhang, Wei
   Yuan, Fei
   Chang, Qing
   Zhao, Peiquan
   Wang, Fang
   Sun, Xiaodong
TI One-Year Outcomes of 1 Dose versus 3 Loading Doses Followed by Pro Re
   Nata Regimen Using Ranibizumab for Neovascular Age-Related Macular
   Degeneration: The ARTIS Trial
SO JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID SAFETY OUTCOMES; BEVACIZUMAB; EFFICACY; THERAPY; LIFE
AB Purpose. To compare the functional and anatomical outcomes of one dose and three loading doses followed by the pro re nata (PRN) regimen in Chinese neovascular age-related macular degeneration (nvAMD) (including polypoidal choroidal vasculopathy (PCV)) patients. Methods. In this multicenter, prospective, open-label, controlled, 12-month study (ClinicalTrials.gov: NCT02810808), patients were randomized (1 : 1) to 1 dose + PRN (PRN group) or 3 loading doses + PRN (LD group) using intravitreal ranibizumab treatment. Best-corrected visual acuity (BCVA) and central retinal thickness (CRT) were evaluated. The main outcome was the change in BCVA. The noninferiority limit was 5 letters. Results. Forty-five patients in the PRN group and 49 patients in the LD group finished 12-month follow-up. Each group included 4 PCV patients. The mean change in BCVA from baseline was 7.8 letters in the PRN group, compared with 10.9 letters in the LD group (P=0.344). There were no significant differences between two groups in the mean change of CRT (-159.3 mu m vs. -120.5 mu m) at month 12. The mean number of injections during the 12-month follow-up was 6.0 in the PRN group and 6.8 in the LD group. The proportion of patients who gained an improvement in visual acuity by 15 or more letters was 28.9% in the PRN group and 44.9% in the LD group (P=0.066). Conclusion. One dose + PRN showed noninferior visual gains than 3 loading doses + PRN regimen using ranibizumab in Chinese nvAMD and PCV patients. Number of injections in the PRN group was similar as that in the LD group but remained a potential risk of vision instability during one-year follow-up using OCT-guided retreatment criteria.
C1 [Wang, Fenghua; Zhao, Jingke; Shen, Mengxi; Sun, Xiaodong] Shanghai Jiao Tong Univ, Sch Med, Dept Ophthalmol, Shanghai Gen Hosp,Shanghai Peoples Hosp 1, Shanghai, Peoples R China.
   [Wang, Fenghua; Sun, Xiaodong] Shanghai Engn Ctr Visual Sci & Photomed, Shanghai, Peoples R China.
   [Yuan, Yuanzhi; Yuan, Fei] Fudan Univ, Zhongshan Hosp, Dept Ophthalmol, Shanghai, Peoples R China.
   [Wang, Ling; Ye, Xiaofeng; Chang, Qing] Fudan Univ, Eye & ENT Hosp, Dept Ophthalmol, Shanghai, Peoples R China.
   [Zhang, Qi; Zhao, Peiquan] Shanghai Jiao Tong Univ, Sch Med, Xinhua Hosp, Dept Ophthalmol, Shanghai, Peoples R China.
   [Xu, Ding; Wang, Fang] Tongji Univ, Shanghai Peoples Hosp 10, Sch Med, Dept Ophthalmol, Shanghai, Peoples R China.
   [Qin, Guoyou; Zhang, Wei] Fudan Univ, Sch Publ Hlth, Dept Biostat, Shanghai, Peoples R China.
   [Qin, Guoyou; Zhang, Wei] Fudan Univ, Key Lab Publ Hlth Safety, Shanghai, Peoples R China.
   [Chang, Qing] Fudan Univ, Eye & ENT Hosp, Shanghai Key Lab Visual Impairment & Restorat, Shanghai, Peoples R China.
   [Sun, Xiaodong] Shanghai Key Lab Fundus Dis, Shanghai, Peoples R China.
C3 Shanghai Jiao Tong University; Fudan University; Fudan University;
   Shanghai Jiao Tong University; Tongji University; Fudan University;
   Fudan University; Fudan University
RP Sun, XD (通讯作者)，Shanghai Jiao Tong Univ, Sch Med, Dept Ophthalmol, Shanghai Gen Hosp,Shanghai Peoples Hosp 1, Shanghai, Peoples R China.; Sun, XD (通讯作者)，Shanghai Engn Ctr Visual Sci & Photomed, Shanghai, Peoples R China.; Yuan, F (通讯作者)，Fudan Univ, Zhongshan Hosp, Dept Ophthalmol, Shanghai, Peoples R China.; Chang, Q (通讯作者)，Fudan Univ, Eye & ENT Hosp, Dept Ophthalmol, Shanghai, Peoples R China.; Zhao, PQ (通讯作者)，Shanghai Jiao Tong Univ, Sch Med, Xinhua Hosp, Dept Ophthalmol, Shanghai, Peoples R China.; Wang, F (通讯作者)，Tongji Univ, Shanghai Peoples Hosp 10, Sch Med, Dept Ophthalmol, Shanghai, Peoples R China.; Chang, Q (通讯作者)，Fudan Univ, Eye & ENT Hosp, Shanghai Key Lab Visual Impairment & Restorat, Shanghai, Peoples R China.; Sun, XD (通讯作者)，Shanghai Key Lab Fundus Dis, Shanghai, Peoples R China.
EM yuan.fei@zs-hospital.sh.cn; qngchang@aliyun.com; zhaopeiquan@126.com;
   dreyemilwang_122@163.com; xdsun@sjtu.edu.cn
RI Shen, Mengxi/ABC-6941-2021
OI Shen, Mengxi/0000-0002-1336-1695; Yuan, Yuan-zhi/0000-0002-5240-3915
FU Shanghai Creative Key Medical Research [1341195400]; Shanghai Municipal
   Education Commission-Gaofeng Clinical Medicine Grant Support [20152229];
   Frontier Project of Hospital Development Center [SHDC12016105];
   Translational Medicine Innovation Fund of Shanghai Jiao Tong University
   School of Medicine [15ZH4005]; National Natural Science Foundation of
   China [81730026, 81470640]; Science and Technology Commission of
   Shanghai Municipality [16411952900, 16dz2251500]; Biomedical Engineering
   Program of Shanghai Jiaotong University [YG2016ZD03]
FX This study was supported by the Shanghai Creative Key Medical Research
   (1341195400), Shanghai Municipal Education Commission-Gaofeng Clinical
   Medicine Grant Support (20152229), Frontier Project of Hospital
   Development Center (SHDC12016105), Translational Medicine Innovation
   Fund of Shanghai Jiao Tong University School of Medicine (15ZH4005),
   National Natural Science Foundation of China (81730026), Science and
   Technology Commission of Shanghai Municipality (16411952900), National
   Natural Science Foundation of China (81470640), Science and Technology
   Commission of Shanghai Municipality (16dz2251500), and Biomedical
   Engineering Program of Shanghai Jiaotong University (YG2016ZD03).
CR Bressler Neil M, 2004, JAMA, V291, P1900, DOI 10.1001/jama.291.15.1900
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Busbee BG, 2013, OPHTHALMOLOGY, V120, P1046, DOI 10.1016/j.ophtha.2012.10.014
   [中华医学会眼科学分会眼底病学组中国老年性黄斑变性临床指南与临床路径制订委员会 Chinese Ophthalmological Society Chines], 2013, [中华眼底病杂志, Chinese Journal of Ocular Fundus Diseases], V29, P343
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Gupta B, 2011, BRIT J OPHTHALMOL, V95, P386, DOI 10.1136/bjo.2010.179499
   Kataja M, 2018, BRIT J OPHTHALMOL, V102, P959, DOI 10.1136/bjophthalmol-2017-311055
   Kodjikian L, 2013, OPHTHALMOLOGY, V120, P2300, DOI 10.1016/j.ophtha.2013.06.020
   Lalwani GA, 2009, AM J OPHTHALMOL, V148, P43, DOI 10.1016/j.ajo.2009.01.024
   Liu Y, 2007, GRAEF ARCH CLIN EXP, V245, P1441, DOI 10.1007/s00417-007-0575-8
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Menon G, 2013, EYE, V27, P959, DOI 10.1038/eye.2013.93
   Miere A, 2019, RETINA-J RET VIT DIS, V39, P548, DOI 10.1097/IAE.0000000000001964
   Mitchell P, 2011, CURR MED RES OPIN, V27, P1465, DOI 10.1185/03007995.2011.585394
   Rakic JM, 2013, CLIN OPHTHALMOL, V7, P1849, DOI 10.2147/OPTH.S49385
   Resnikoff S, 2002, B WORLD HEALTH ORGAN, V82, P844
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Takayama K, 2017, OPHTHALMOLOGICA, V237, P105, DOI 10.1159/000461785
   Tufail A, 2014, OPHTHALMOLOGY, V121, P1092, DOI 10.1016/j.ophtha.2013.11.031
   Yadav S, 2017, BRIT J OPHTHALMOL, V101, P1377, DOI 10.1136/bjophthalmol-2016-310074
NR 20
TC 7
Z9 8
U1 0
U2 2
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 2090-004X
EI 2090-0058
J9 J OPHTHALMOL
JI J. Ophthalmol.
PD OCT 10
PY 2019
VL 2019
AR 7530458
DI 10.1155/2019/7530458
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA JH8LO
UT WOS:000493019900002
PM 31687203
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Koulisis, N
   Moysidis, SN
   Govindaraju, VK
   Dersch, AM
   Jr, AC
   Covert, DJ
   Dadgostar, H
   Dass, AB
   Drenser, KA
   Engstrom, RE
   Faia, LJ
   Garretson, BR
   Guerami, AH
   Hanscom, TA
   Mahmoud, TH
   Margherio, AR
   Oh, KT
   Randhawa, S
   Raphaelian, PV
   Rhoades, WR
   Ruby, AJ
   Sanfilippo, CJ
   Sneed, SR
   Trese, MT
   Wolfe, JD
   Williams, GA
   Yedavally, S
   Hassan, TS
AF Koulisis, Nicole
   Moysidis, Stavros N.
   Govindaraju, Viren K.
   Dersch, Anne Merrylees
   Jr, Antonio Capone
   Covert, Douglas J.
   Dadgostar, Hajir
   Dass, A. Bawa
   Drenser, Kimberly A.
   Engstrom, Robert E., Jr.
   Faia, Lisa J.
   Garretson, Bruce R.
   Guerami, Amir H.
   Hanscom, Thomas A.
   Mahmoud, Tamer H.
   Margherio, Alan R.
   Oh, Kean T.
   Randhawa, Sandeep
   Raphaelian, Paul, V
   Rhoades, William R.
   Ruby, Alan J.
   Sanfilippo, Christian J.
   Sneed, Scott R.
   Trese, Michael T.
   Wolfe, Jeremy D.
   Williams, George A.
   Yedavally, Sunita
   Hassan, Tarek S.
TI CLINICAL OUTCOMES AND TREATMENT COURSE OF EYES WITH NEOVASCULAR
   AGE-RELATED MACULAR DEGENERATION FOLLOWING THE DEVELOPMENT OF
   ENDOPHTHALMITIS
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE endophthalmitis; neovascular age-related macular degeneration;
   intravitreal anti-vascular endothelial growth factor F; VEGF;
   intravitreal injections; bevacizumab; ranibizumab; aflibercept;
   dexamethasone; laser; photodynamic therapy; optical coherence
   tomography; multimodal imaging; tap and inject; vitrectomy; vancomycin;
   ceftazidime; dexamethasone
AB Purpose: To evaluate the clinical course of patients with neovascular age-related macular degeneration (nAMD) after developing endophthalmitis during their treatment with intravitreal injections. Methods: Multicenter, retrospective series. Results: From April 2013 to October 2018, 196,598 intravitreal anti-vascular endothelial growth factor (VEGF) injections were performed, with 75 cases of endophthalmitis (incidence 0.0381%). There was no association between intravitreal anti-VEGF drug (P = 0.29), anesthetic method (P = 0.26), povidone concentration (P = 0.22), or any intraprocedure variable and endophthalmitis incidence. Seventy-two patients (96%) were treated with intravitreal tap and inject , while 3 underwent immediate pars plana vitrectomy. After endophthalmitis resolution, 17 patients (22.7%) were not re-treated for nAMD (in 10 cases due to inactive disease; follow-up, 115 +/- 8.4 weeks). Patients required less frequent anti-VEGF injections after infection (7.4 +/- 0.61 weeks vs. 11.5 +/- 1.8 weeks; P = 0.004). Preinfection logarithm of the minimum angle of resolution visual acuity was 0.585 +/- 0.053 (similar to 20/77). It worsened with endophthalmitis (1.67 +/- 0.08, similar to 20/935; P < 0.001) and again on postendophthalmitis treatment day 1 (1.94 +/- 0.064; count fingers; P < 0.001), but improved after reinitiating nAMD therapy (1.02 +/- 0.11; similar to 20/209; P < 0.001). Better visual acuity on postendophthalmitis week 1 (P = 0.002) and reinitiation of nAMD treatment (P = 0.008) were associated with better final visual acuity, and streptococcal culture with worse visual acuity (P = 0.028). The postendophthalmitis treatment interval was associated with the anti-VEGF drug used (aflibercept = ranibizumab > bevacizumab; P < 0.001). Conclusion: Patients with nAMD required fewer injections after endophthalmitis, suggesting a biological change in disease activity. Neovascular age-related macular degeneration became quiescent in 13.3% of eyes. Most achieved better outcomes with anti-VEGF reinitiation.
C1 [Koulisis, Nicole; Moysidis, Stavros N.; Govindaraju, Viren K.; Dersch, Anne Merrylees; Jr, Antonio Capone; Covert, Douglas J.; Dass, A. Bawa; Drenser, Kimberly A.; Faia, Lisa J.; Garretson, Bruce R.; Mahmoud, Tamer H.; Margherio, Alan R.; Oh, Kean T.; Randhawa, Sandeep; Raphaelian, Paul, V; Rhoades, William R.; Ruby, Alan J.; Sneed, Scott R.; Trese, Michael T.; Wolfe, Jeremy D.; Williams, George A.; Yedavally, Sunita; Hassan, Tarek S.] Oakland Univ, Dept Ophthalmol, Associated Retinal Consultants PC, William Beaumont Sch Med, Royal Oak, MI 48073 USA.
   [Koulisis, Nicole] Univ Southern Calif, Dept Ophthalmol, USC Roski Eye Inst, Keck Sch Med, Los Angeles, CA 90007 USA.
   [Moysidis, Stavros N.; Dadgostar, Hajir; Engstrom, Robert E., Jr.; Guerami, Amir H.; Hanscom, Thomas A.; Sanfilippo, Christian J.] Retina Partners, Los Angeles, CA USA.
C3 Oakland University; University of Southern California
RP Hassan, TS (通讯作者)，Oakland Univ, William Beaumont Sch Med, Associated Retinal Consultants Pc, Royal Oak, MI 48073 USA.
EM tsahassan@yahoo.com
OI Wolfe, Jeremy/0000-0003-2781-7152
FU Alliance for Vision Research, Southfield, MI; Heed Ophthalmic
   Foundation; Ronald G. Michels Foundation
FX D Supported by an unrestricted research grant from the Alliance for
   Vision Research, Southfield, MI 48034, and by the generous support of
   the Heed Ophthalmic Foundation and the Ronald G. Michels Foundation. The
   sponsors had no role in the design or conduct of this research.
CR [Anonymous], 1995, Arch Ophthalmol, V113, P1479
   [Anonymous], 2010, WORLD POP AG 2009
   Arnett JJ., 2019, RETINA-J RET VIT DIS, V10, P1097
   Blasiak J, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/768026
   Borkar DS, 2018, AM J OPHTHALMOL, V194, P1, DOI 10.1016/j.ajo.2018.06.022
   Fliesler SJ, 2010, J LIPID RES, V51, P3399, DOI 10.1194/jlr.R010538
   Fritsche LG, 2016, NAT GENET, V48, P134, DOI 10.1038/ng.3448
   Gemenetzi M, 2016, EYE, V30, P1, DOI 10.1038/eye.2015.203
   Jaffe GJ, 2019, OPHTHALMOLOGY, V126, P252, DOI 10.1016/j.ophtha.2018.08.035
   Kally Peter M, 2017, Retin Cases Brief Rep, V11, P316, DOI 10.1097/ICB.0000000000000352
   Kataja M, 2018, BRIT J OPHTHALMOL, V102, P959, DOI 10.1136/bjophthalmol-2017-311055
   Kertes PJ, 2019, OPHTHALMOLOGY, V126, P841, DOI 10.1016/j.ophtha.2019.01.013
   Khurana RN, 2019, AM J OPHTHALMOL, V200, P161, DOI 10.1016/j.ajo.2019.01.005
   Kiss S, 2018, CLIN OPHTHALMOL, V12, P1625, DOI 10.2147/OPTH.S169143
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Meredith TA, 2015, OPHTHALMOLOGY, V122, P817, DOI 10.1016/j.ophtha.2014.10.027
   Nudleman E, 2016, CLIN OPHTHALMOL, V10, P1053, DOI 10.2147/OPTH.S109894
   Okada M, 2018, AM J OPHTHALMOL, V192, P184, DOI 10.1016/j.ajo.2018.05.026
   Parmeggiani F, 2012, MEDIAT INFLAMM, V2012, DOI 10.1155/2012/546786
   Pennington KL, 2016, EYE VISION, V3, DOI 10.1186/s40662-016-0063-5
   Pikuleva IA, 2014, PROG RETIN EYE RES, V41, P64, DOI 10.1016/j.preteyeres.2014.03.002
   Rao P, 2018, OPHTHALMOLOGY, V125, P522, DOI 10.1016/j.ophtha.2017.10.010
   Rayess N, 2019, RETINA-J RET VIT DIS, V39, P2070, DOI 10.1097/IAE.0000000000002300
   Regillo CD, 2008, AM J OPHTHALMOL, V145, P239, DOI 10.1016/j.ajo.2007.10.004
   Stefansson E, 2011, PROG RETIN EYE RES, V30, P72, DOI 10.1016/j.preteyeres.2010.09.003
   Stem MS, 2019, OPHTHALMOL RETINA, V3, P3, DOI 10.1016/j.oret.2018.09.013
   Storey P, 2014, OPHTHALMOLOGY, V121, P283, DOI 10.1016/j.ophtha.2013.08.037
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Ying GS, 2018, OPHTHALMOL RETINA, V2, P525, DOI 10.1016/j.oret.2017.10.003
NR 30
TC 2
Z9 2
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD JUN
PY 2021
VL 41
IS 6
BP 1242
EP 1250
DI 10.1097/IAE.0000000000002998
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA SO2SL
UT WOS:000658826900014
PM 33079789
DA 2022-11-30
ER

PT J
AU Zhao, M
   Mantel, I
   Gelize, E
   Li, XX
   Xie, XY
   Arboleda, A
   Seminel, M
   Levy-Boukris, R
   Dernigoghossian, M
   Prunotto, A
   Andrieu-Soler, C
   Rivolta, C
   Canonica, J
   Naud, MC
   Lechner, S
   Farman, N
   Bravo-Osuna, I
   Herrero-Vanrell, R
   Jaisser, F
   Behar-Cohen, F
AF Zhao, Min
   Mantel, Irmela
   Gelize, Emmanuelle
   Li, Xinxin
   Xie, Xiaoyue
   Arboleda, Alejandro
   Seminel, Marie
   Levy-Boukris, Rinath
   Dernigoghossian, Marilyn
   Prunotto, Andrea
   Andrieu-Soler, Charlotte
   Rivolta, Carlo
   Canonica, Jeremie
   Naud, Marie-Christine
   Lechner, Sebastian
   Farman, Nicolette
   Bravo-Osuna, Irene
   Herrero-Vanrell, Rocio
   Jaisser, Frederic
   Behar-Cohen, Francine
TI Mineralocorticoid receptor antagonism limits experimental choroidal
   neovascularization and structural changes associated with neovascular
   age-related macular degeneration
SO NATURE COMMUNICATIONS
LA English
DT Article
ID ENDOTHELIAL-GROWTH-FACTOR; CENTRAL SEROUS CHORIORETINOPATHY; DECORIN;
   ANGIOGENESIS; CELLS; MACROPHAGES; SPIRONOLACTONE; INFLAMMATION;
   RANIBIZUMAB; BEVACIZUMAB
AB Choroidal neovascularization (CNV) is a major cause of visual impairment in patients suffering from wet age-related macular degeneration (AMD), particularly when refractory to intraocular anti-VEGF injections. Here we report that treatment with the oral mineralocorticoid receptor (MR) antagonist spironolactone reduces signs of CNV in patients refractory to anti-VEGF treatment. In animal models of wet AMD, pharmacological inhibition of the MR pathway or endothelial-specific deletion of MR inhibits CNV through VEGF-independent mechanisms, in part through upregulation of the extracellular matrix protein decorin. Intravitreal injections of spironolactone-loaded microspheres and systemic delivery lead to similar reductions in CNV. Together, our work suggests MR inhibition as a novel therapeutic option for wet AMD patients unresponsive to anti-VEGF drugs.
C1 [Zhao, Min; Gelize, Emmanuelle; Li, Xinxin; Xie, Xiaoyue; Arboleda, Alejandro; Seminel, Marie; Levy-Boukris, Rinath; Dernigoghossian, Marilyn; Naud, Marie-Christine; Behar-Cohen, Francine] INSERM, Ctr Rech Cordeliers, Team 17, UMR S 1138, F-75006 Paris, France.
   [Zhao, Min; Gelize, Emmanuelle; Li, Xinxin; Xie, Xiaoyue; Arboleda, Alejandro; Seminel, Marie; Levy-Boukris, Rinath; Dernigoghossian, Marilyn; Naud, Marie-Christine; Lechner, Sebastian; Farman, Nicolette; Jaisser, Frederic; Behar-Cohen, Francine] Sorbonne Univ, Univ Pierre & Marie Curie, Ctr Rech Cordeliers, UMR S 1138, F-75006 Paris, France.
   [Zhao, Min; Gelize, Emmanuelle; Li, Xinxin; Xie, Xiaoyue; Arboleda, Alejandro; Seminel, Marie; Levy-Boukris, Rinath; Dernigoghossian, Marilyn; Naud, Marie-Christine; Lechner, Sebastian; Farman, Nicolette; Jaisser, Frederic; Behar-Cohen, Francine] Paris Descartes Univ, Sorbonne Paris Cite, Ctr Rech Cordeliers, UMR S 1138, F-75006 Paris, France.
   [Mantel, Irmela; Canonica, Jeremie] Univ Lausanne, Jules Gonin Eye Hosp, Fdn Asile Aveugles, Dept Ophthalmol, CH-1004 Lausanne, Switzerland.
   [Arboleda, Alejandro] Univ Miami, Miller Sch Med, Bascom Palmer Eye Inst, Ophthalm Biophys Ctr,Dept Ophthalmol, Miami, FL 33136 USA.
   [Prunotto, Andrea; Rivolta, Carlo] Univ Lausanne, Unit Med Genet, Dept Computat Biol, CH-1011 Lausanne, Switzerland.
   [Andrieu-Soler, Charlotte] Univ Montpellier, CNRS, IGMM, F-34293 Montpellier 5, France.
   [Rivolta, Carlo] Univ Leicester, Dept Genet & Genome Biol, Leicester LE1 7RH, Leics, England.
   [Lechner, Sebastian; Farman, Nicolette; Jaisser, Frederic] INSERM, Ctr Rech Cordeliers, Team 1, UMR S 1138, F-75006 Paris, France.
   [Bravo-Osuna, Irene; Herrero-Vanrell, Rocio] Univ Complutense Madrid, Dept Pharm & Pharmaceut Technol, E-28040 Madrid, Spain.
   [Bravo-Osuna, Irene; Herrero-Vanrell, Rocio] Univ Complutense Madrid, Fac Pharm, Inst Univ Farm Ind, E-28040 Madrid, Spain.
   [Bravo-Osuna, Irene; Herrero-Vanrell, Rocio] Fdn Invest HCSC, Inst Invest Sanitaria San Carlos IdISSC, Madrid 28040, Spain.
   [Behar-Cohen, Francine] Hotel Dieu Paris, AP HP, F-75004 Paris, France.
C3 Institut National de la Sante et de la Recherche Medicale (Inserm);
   UDICE-French Research Universities; Sorbonne Universite; Universite
   Paris Cite; Institut National de la Sante et de la Recherche Medicale
   (Inserm); UDICE-French Research Universities; Sorbonne Universite;
   Universite Paris Cite; Institut National de la Sante et de la Recherche
   Medicale (Inserm); UDICE-French Research Universities; Sorbonne
   Universite; Universite Paris Cite; University of Lausanne; Bascom Palmer
   Eye Institute; University of Miami; University of Lausanne; Centre
   National de la Recherche Scientifique (CNRS); Universite de Montpellier;
   University of Leicester; Institut National de la Sante et de la
   Recherche Medicale (Inserm); UDICE-French Research Universities;
   Sorbonne Universite; Universite Paris Cite; Complutense University of
   Madrid; Complutense University of Madrid; Assistance Publique Hopitaux
   Paris (APHP); Hopital Universitaire Hotel-Dieu - APHP; UDICE-French
   Research Universities; Universite Paris Cite
RP Behar-Cohen, F (通讯作者)，INSERM, Ctr Rech Cordeliers, Team 17, UMR S 1138, F-75006 Paris, France.; Behar-Cohen, F (通讯作者)，Sorbonne Univ, Univ Pierre & Marie Curie, Ctr Rech Cordeliers, UMR S 1138, F-75006 Paris, France.; Behar-Cohen, F (通讯作者)，Paris Descartes Univ, Sorbonne Paris Cite, Ctr Rech Cordeliers, UMR S 1138, F-75006 Paris, France.; Behar-Cohen, F (通讯作者)，Hotel Dieu Paris, AP HP, F-75004 Paris, France.
EM Francine.behar@gmail.com
RI Jaisser, Frederic/P-4287-2017; bravo-osuna, irene/M-3469-2015; Zhao,
   Min/AAX-7664-2020
OI Jaisser, Frederic/0000-0001-9051-1901; bravo-osuna,
   irene/0000-0003-3133-7872; Zhao, Min/0000-0002-5418-7275; Prunotto,
   Andrea/0000-0003-1235-1740; Rivolta, Carlo/0000-0002-0733-9950;
   Andrieu-Soler, Charlotte/0000-0002-3287-6117
FU INSERM; Agence Nationale de la Recherche [ANR Mineraloret
   ANR-11-BSV1-0022, ROCK-SUR-MeR ANR-15-CE18-0032]; Swiss National Science
   Foundation [156260]; MINECO/AEI/FEDER, UE [MAT2013-43127-R,
   MAT2017-83858-C2-1]; Fondation pour la Recherche Medicale (FRM Visual
   System 2013) [DVS20131228894]
FX We thank INSERM, the Agence Nationale de la Recherche (ANR Mineraloret
   ANR-11-BSV1-0022, and ROCK-SUR-MeR ANR-15-CE18-0032), the Fondation pour
   la Recherche Medicale (FRM Visual System 2013, DVS20131228894) and the
   Swiss National Science Foundation (grant #156260 to C.R.) for financial
   support. This research was also supported by grants from MAT2013-43127-R
   and MAT2017-83858-C2-1 MINECO/AEI/FEDER, UE. We thank Christophe Klein
   from Center d'Histologie, d'Imagerieet de Cytometrie, and Georges
   Zadigue from Center d'Explorations Fonctionnelles of Center de Recherche
   des Cordeliers for their technical support. We thank Maeva
   Dupuis-Deniaud, MDSTAT Consulting Lyon, France for her assistance in the
   statistical analysis.
CR Arnold JJ, 2016, BMC OPHTHALMOL, V16, DOI 10.1186/s12886-016-0207-3
   Ba J, 2015, DRUG DES DEV THER, V9, DOI 10.2147/DDDT.S86269
   Barrera-Chimal J, 2018, KIDNEY INT, V93, P1344, DOI 10.1016/j.kint.2017.12.016
   Barrera-Chimal J, 2017, J AM SOC NEPHROL, V28, P1216, DOI 10.1681/ASN.2016040477
   Berka JLW, 2009, CIRC RES, V104, P124, DOI 10.1161/CIRCRESAHA.108.176008
   Bhutto I, 2012, MOL ASPECTS MED, V33, P295, DOI 10.1016/j.mam.2012.04.005
   Bousquet E, 2015, RETINA-J RET VIT DIS, V35, P2505, DOI 10.1097/IAE.0000000000000614
   Campochiaro PA, 2015, PROG RETIN EYE RES, V49, P67, DOI 10.1016/j.preteyeres.2015.06.002
   Cao JH, 2014, OPHTHALMOLOGY, V121, P1871, DOI 10.1016/j.ophtha.2014.04.012
   Celkova L, 2015, J CLIN MED, V4, P172, DOI 10.3390/jcm4010172
   Clausen BE, 1999, TRANSGENIC RES, V8, P265, DOI 10.1023/A:1008942828960
   Combadiere C, 2007, J CLIN INVEST, V117, P2920, DOI 10.1172/JCI31692
   CRUM R, 1985, SCIENCE, V230, P1375, DOI 10.1126/science.2416056
   Daruich A, 2016, TRANSL VIS SCI TECHN, V5, DOI 10.1167/tvst.5.2.2
   Daruich A, 2015, PROG RETIN EYE RES, V48, P82, DOI 10.1016/j.preteyeres.2015.05.003
   Du SS, 2013, EXP EYE RES, V116, P151, DOI 10.1016/j.exer.2013.08.019
   Fraccarollo D, 2011, CIRCULATION, V123, P400, DOI 10.1161/CIRCULATIONAHA.110.983023
   Framme C, 2010, INVEST OPHTH VIS SCI, V51, P1671, DOI 10.1167/iovs.09-4496
   Frikeche J, 2016, EXP EYE RES, V151, P142, DOI 10.1016/j.exer.2016.08.015
   Fujii M, 2012, J STEROID BIOCHEM, V129, P145, DOI 10.1016/j.jsbmb.2011.12.014
   Funder JW, 2017, J ENDOCRINOL, V234, pT17, DOI 10.1530/JOE-17-0119
   Gergely R, 2017, RETINA-J RET VIT DIS, V37, P1084, DOI 10.1097/IAE.0000000000001303
   Gewaily D, 2015, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD007324.pub3
   Grossniklaus HE, 2010, PROG RETIN EYE RES, V29, P500, DOI 10.1016/j.preteyeres.2010.05.003
   Grunin M, 2014, ADV EXP MED BIOL, V801, P199, DOI 10.1007/978-1-4614-3209-8_26
   Gubbiotti MA, 2016, MATRIX BIOL, V55, P7, DOI 10.1016/j.matbio.2016.09.009
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Hussain RM, 2017, EXPERT OPIN EMERG DR, V22, P235, DOI 10.1080/14728214.2017.1362390
   Jaisser F, 2016, PHARMACOL REV, V68, P49, DOI 10.1124/pr.115.011106
   Jarvelainen H, 2015, MATRIX BIOL, V43, P15, DOI 10.1016/j.matbio.2015.01.023
   Jung JJ, 2014, AM J OPHTHALMOL, V158, P769, DOI 10.1016/j.ajo.2014.07.006
   Kaneko H, 2011, NATURE, V471, P325, DOI 10.1038/nature09830
   Kapoor KG, 2017, OPHTHALMOL THER, V6, P141, DOI 10.1007/s40123-016-0075-1
   Keenan TDL, 2012, INVEST OPHTH VIS SCI, V53, P7528, DOI 10.1167/iovs.12-10797
   Kolkhof P, 2017, J ENDOCRINOL, V234, pT125, DOI 10.1530/JOE-16-0600
   Maguire MG, 2016, OPHTHALMOLOGY, V123, P1751, DOI 10.1016/j.ophtha.2016.03.045
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Michel F, 2004, CIRCULATION, V109, P1933, DOI 10.1161/01.CIR.0000127112.36796.9B
   Miller JW, 2016, INVEST OPHTH VIS SCI, V57, P6911, DOI 10.1167/iovs.16-21201
   Miller JW, 2013, OPHTHALMOLOGY, V120, P106, DOI 10.1016/j.ophtha.2012.07.038
   Mitchell P, 2018, LANCET, V392, P1147, DOI 10.1016/S0140-6736(18)31550-2
   Miternique-Grosse A, 2006, J HYPERTENS, V24, P2207, DOI 10.1097/01.hjh.0000249698.26983.4e
   Mohan R, 2011, PLOS ONE, V6, DOI [10.1371/journal.pone.0026432, 10.1371/journal.pone.0026846]
   Mueller KB, 2015, HYPERTENSION, V66, P988, DOI 10.1161/HYPERTENSIONAHA.115.06172
   Neill T, 2016, ADV DRUG DELIVER REV, V97, P174, DOI 10.1016/j.addr.2015.10.016
   Neill T, 2012, J BIOL CHEM, V287, P5492, DOI 10.1074/jbc.M111.283499
   Nelimarkka L, 2001, AM J PATHOL, V158, P345, DOI 10.1016/S0002-9440(10)63975-2
   Olsen TW, 2004, OPHTHALMOLOGY, V111, P250, DOI 10.1016/j.ophtha.2003.05.030
   Rezar-Dreindl S, 2016, INVEST OPHTH VIS SCI, V57, P4144, DOI 10.1167/iovs.16-19772
   Rush RB, 2014, AM J OPHTHALMOL, V158, P337, DOI 10.1016/j.ajo.2014.05.007
   Schafer N, 2013, EUR HEART J, V34, P3515, DOI 10.1093/eurheartj/eht095
   Schonherr E, 2004, J VASC RES, V41, P499, DOI 10.1159/000081806
   Usher MG, 2010, J CLIN INVEST, V120, P3350, DOI 10.1172/JCI41080
   Wang XL, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-10124-4
   Wang YD, 2010, NATURE, V465, P483, DOI 10.1038/nature09002
   Wendling O, 2009, GENESIS, V47, P14, DOI 10.1002/dvg.20448
   Whitcup SM, 2018, INVEST OPHTH VIS SCI, V59, P1, DOI 10.1167/iovs.17-22259
   Whitmore SS, 2015, PROG RETIN EYE RES, V45, P1, DOI 10.1016/j.preteyeres.2014.11.005
   Witmer AN, 2003, PROG RETIN EYE RES, V22, P1, DOI 10.1016/S1350-9462(02)00043-5
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Xaus J, 2001, BLOOD, V98, P2124, DOI 10.1182/blood.V98.7.2124
   Yang SQ, 2016, DRUG DES DEV THER, V10, P1857, DOI 10.2147/DDDT.S97653
   Yuan XL, 2010, MOL CELL PROTEOMICS, V9, P1031, DOI 10.1074/mcp.M900523-MCP200
   Zhang SX, 2007, PROG RETIN EYE RES, V26, P1, DOI 10.1016/j.preteyeres.2006.09.002
   Zhao M, 2017, J CONTROL RELEASE, V266, P187, DOI 10.1016/j.jconrel.2017.09.029
   Zhao M, 2012, J CLIN INVEST, V122, P2672, DOI 10.1172/JCI61427
   Zhao M, 2010, FASEB J, V24, P3405, DOI 10.1096/fj.09-154344
NR 67
TC 29
Z9 29
U1 0
U2 15
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2041-1723
J9 NAT COMMUN
JI Nat. Commun.
PD JAN 21
PY 2019
VL 10
AR 369
DI 10.1038/s41467-018-08125-6
PG 13
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA HI0WL
UT WOS:000456165100006
PM 30664640
OA Green Published, gold, Green Accepted
DA 2022-11-30
ER

PT J
AU Semoun, O
   Guigui, B
   Tick, S
   Coscas, G
   Soubrane, G
   Souied, EH
AF Semoun, O.
   Guigui, B.
   Tick, S.
   Coscas, G.
   Soubrane, G.
   Souied, E. H.
TI Infrared features of classic choroidal neovascularisation in exudative
   age-related macular degeneration
SO BRITISH JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID PHOTODYNAMIC THERAPY; MACULOPATHY; PREVALENCE; MEMBRANES; BLINDNESS; EYE
AB Aim: Wet age-related macular degeneration (AMD) represents a heterogeneous group of phenotypes, all defined by fluorescein angiography features (FA). Imaging of wet AMD is extensively described in literature, including colour pictures, FA, indocyanine green angiography (ICG) and optical coherence tomography (OCT). The purpose of this study was to describe features of infrared (IR) pictures of a homogeneous subgroup of classic choroidal neovascularisation (CNV) associated with wet AMD,
   Methods: We analysed 22 eyes of 22 consecutive patients with classic CNV. All patients underwent a complete ophthalmological examination including colour fundus photography, infrared picture, fluorescein angiography, indocyanine green angiography and an optical coherence tomography.
   Results: Infrared pictures revealed a whitish ring surrounding the neovascular lesion in all eyes (22/22). The whitish ring corresponded in all cases to the borders of the CNV defined on the early phase of FA and ICG pictures. The ring had an "O-shape'' in 15/22 cases (68%) and a "U-shape'' in 7/22 cases (32%).
   Conclusion: Analysis of infrared pictures in classic CNV constantly revealed a whitish ring that is correlated to the limits of the lesion. IR picture is a non invasive imaging of the macula, but the specificity of the features needs to be investigated in further studies.
C1 [Semoun, O.; Guigui, B.; Tick, S.; Coscas, G.; Soubrane, G.; Souied, E. H.] Univ Paris 12, Fac Med Henri Mondor, Ctr Hosp Intercommunal Creteil, Serv Univ Ophtalmol Creteil, Creteil, France.
C3 Assistance Publique Hopitaux Paris (APHP); Universite
   Paris-Est-Creteil-Val-de-Marne (UPEC); Hopital Universitaire
   Henri-Mondor - APHP; CHI Creteil
RP Souied, EH (通讯作者)，CHIC Serv Ophtalmol, 70 Ave Verdun, F-94010 Creteil, France.
EM eric.souied@chicreteil.fr
CR BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Blumenkranz MS, 2001, ARCH OPHTHALMOL-CHIC, V119, P198
   Cohen SY, 2007, BRIT J OPHTHALMOL, V91, P1173, DOI 10.1136/bjo.2007.115501
   FERRIS FL, 1984, ARCH OPHTHALMOL-CHIC, V102, P1640
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Gelisken F, 1998, JPN J OPHTHALMOL, V42, P300, DOI 10.1016/S0021-5155(98)00010-0
   GROSSNIKLAUS HE, 1994, OPHTHALMOLOGY, V101, P1099
   Hartnett ME, 1996, OPHTHALMOLOGY, V103, P58, DOI 10.1016/S0161-6420(96)30731-8
   Hee MR, 1996, OPHTHALMOLOGY, V103, P1260, DOI 10.1016/S0161-6420(96)30512-5
   KAHN HA, 1977, AM J EPIDEMIOL, V106, P17, DOI 10.1093/oxfordjournals.aje.a112428
   KAHN HA, 1973, PUBLICATION NIH, V73, P427
   KLEIN BE, 1982, ARCH OPHTHALMOL-CHIC, V100, P571
   Klein R, 1997, OPHTHALMOLOGY, V104, P7, DOI 10.1016/S0161-6420(97)30368-6
   LOPEZ PF, 1993, OPHTHALMOLOGY, V100, P415
   Resnikoff S, 2004, B WORLD HEALTH ORGAN, V82, P844
   SOMMER A, 1991, NEW ENGL J MED, V325, P1412, DOI 10.1056/NEJM199111143252004
   Soubrane G, 2004, J FR OPHTALMOL, V27, P79, DOI 10.1016/S0181-5512(04)96098-6
   *VERT ROUNDT 2000, 2002, RETINA, V22, P6
NR 18
TC 22
Z9 22
U1 0
U2 7
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0007-1161
EI 1468-2079
J9 BRIT J OPHTHALMOL
JI Br. J. Ophthalmol.
PD FEB
PY 2009
VL 93
IS 2
BP 182
EP 185
DI 10.1136/bjo.2008.145235
PG 4
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 399XZ
UT WOS:000262833900011
PM 18984656
DA 2022-11-30
ER

PT J
AU Rovner, BW
   Casten, RJ
   Leiby, BE
   Tasman, WS
AF Rovner, Barry W.
   Casten, Robin J.
   Leiby, Benjamin E.
   Tasman, William S.
TI Activity loss is associated with cognitive decline in age-related
   macular degeneration
SO ALZHEIMERS & DEMENTIA
LA English
DT Article
DE Activity loss; Cognitive decline; Vision loss
ID QUALITY-OF-LIFE; CHRONIC DISEASE SCORE; ALZHEIMERS-DISEASE; INFORMANT
   QUESTIONNAIRE; VISUAL IMPAIRMENT; VISION IMPAIRMENT; PHYSICAL-ACTIVITY;
   ELDERLY IQCODE; OLDER ADULTS; DEMENTIA
AB Background/Methods: The objective of this study was to determine whether relinquishing cognitive, physical, and social activities is associated with an increased risk of cognitive decline in patients with age-related macular degeneration (AMD). We conducted a 3-year longitudinal study of 206 nondemented patients with AMD.
   Results: Twenty-three subjects (14.4%) declined cognitively. Age, sex, education, decline in visual acuity, and number of dropped activities were associated with cognitive decline; each additional dropped activity increased the risk by 58%. Subjects who relinquished three activities were 3.87 times (95% confidence interval, 1.95-7.76) more likely to become demented than subjects who relinquished no activities; those who relinquished five activities were 9.54 times (95% confidence interval, 3.05-30.43) more likely. A multivariate model demonstrated that number of dropped activities was a powerful predictor of cognitive decline after controlling for relevant risk factors, particularly for Subjects younger than 80 years of age.
   Conclusions: Relinquishing valued activities is associated with an increased risk of cognitive decline in older patients with vision loss caused by AMD. These data suggest the importance of promoting optimal cognitive and physical health in patients with AMD and perhaps other chronic diseases. (C) 2009 The Alzheimer's Association. All rights reserved.
C1 [Rovner, Barry W.] Thomas Jefferson Univ, Jefferson Med Coll, Dept Psychiat, Philadelphia, PA 19107 USA.
   [Rovner, Barry W.] Thomas Jefferson Univ, Jefferson Med Coll, Dept Neurol, Philadelphia, PA 19107 USA.
   [Casten, Robin J.] Thomas Jefferson Univ, Jefferson Med Coll, Dept Psychiat & Human Behav, Philadelphia, PA 19107 USA.
   [Leiby, Benjamin E.] Thomas Jefferson Univ, Jefferson Med Coll, Dept Pharmacol & Expt Therapeut, Div Biostat, Philadelphia, PA 19107 USA.
   [Tasman, William S.] Thomas Jefferson Univ, Jefferson Med Coll, Wills Eye Inst, Dept Ophthalmol, Philadelphia, PA 19107 USA.
C3 Jefferson University; Jefferson University; Jefferson University;
   Jefferson University; Jefferson University
RP Rovner, BW (通讯作者)，Thomas Jefferson Univ, Jefferson Med Coll, Dept Psychiat, Philadelphia, PA 19107 USA.
EM barry.rovner@jefferson.edu
FU NIMH [RO 1 MH61331]; Farber Institute for Neurosciences of Thomas
   Jefferson University; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND
   KIDNEY DISEASES [T32DK060455] Funding Source: NIH RePORTER; NATIONAL
   INSTITUTE OF MENTAL HEALTH [R01MH061331] Funding Source: NIH RePORTER
FX This work was supported by NIMH grant RO 1 MH61331 and the Farber
   Institute for Neurosciences of Thomas Jefferson University.
CR Backman L, 2003, J GERONTOL B-PSYCHOL, V58, pP228, DOI 10.1093/geronb/58.4.P228
   Bassuk SS, 1999, ANN INTERN MED, V131, P165, DOI 10.7326/0003-4819-131-3-199908030-00002
   Bennett DA, 2006, LANCET NEUROL, V5, P406, DOI 10.1016/S1474-4422(06)70417-3
   Bird TD, 2005, NEW ENGL J MED, V352, P862, DOI 10.1056/NEJMp058027
   Breitner JCS, 2006, J GERIATR PSYCH NEUR, V19, P129, DOI 10.1177/0891988706291081
   Burke D, 2007, BRIT J PSYCHIAT, V190, P371, DOI 10.1192/bjp.bp.106.033407
   Carter RE, 2005, BIOSTATISTICS, V6, P39, DOI 10.1093/biostatistics/kxh016
   Chia EM, 2006, ARCH OPHTHALMOL-CHIC, V124, P1465, DOI 10.1001/archopht.124.10.1465
   CLARK DO, 1995, MED CARE, V33, P783, DOI 10.1097/00005650-199508000-00004
   Clemons TE, 2006, ARCH OPHTHALMOL-CHIC, V124, P537
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   Crews JE, 2004, AM J PUBLIC HEALTH, V94, P823, DOI 10.2105/AJPH.94.5.823
   Dandona L, 1998, ARCH OPHTHALMOL-CHIC, V116, P545, DOI 10.1001/archopht.116.4.514
   DZURILLA TJ, 2000, PROBLEM SOLVING THER, P95
   FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6
   Gandy S, 2005, J CLIN INVEST, V115, P1121, DOI 10.1172/JCI200525100
   Hendrie Hugh C, 2006, Alzheimers Dement, V2, P12, DOI 10.1016/j.jalz.2005.11.004
   HINTON DR, 1986, NEW ENGL J MED, V315, P485, DOI 10.1056/NEJM198608213150804
   HOLLADAY JT, 1991, AM J OPHTHALMOL, V111, P372, DOI 10.1016/S0002-9394(14)72328-1
   JORM AF, 1994, PSYCHOL MED, V24, P145, DOI 10.1017/S003329170002691X
   Jorm AF, 2004, INT PSYCHOGERIATR, V16, P275, DOI 10.1017/S1041610204000390
   Klaver CCW, 1999, AM J EPIDEMIOL, V150, P963
   Lee BK, 2007, ARCH GEN PSYCHIAT, V64, P810, DOI 10.1001/archpsyc.64.7.810
   LINDENBERGER U, 1994, PSYCHOL AGING, V9, P339, DOI 10.1037/0882-7974.9.3.339
   Mangione CM, 1999, AM J OPHTHALMOL, V128, P45, DOI 10.1016/S0002-9394(99)00169-5
   Massof RW, 2001, VISION RES, V41, P397, DOI 10.1016/S0042-6989(00)00249-2
   Mungas D, 2001, ARCH NEUROL-CHICAGO, V58, P1243, DOI 10.1001/archneur.58.8.1243
   PARMELEE PA, 1991, J GERONTOL, V46, pP15, DOI 10.1093/geronj/46.1.P15
   Reyes-Ortiz CA, 2005, J AM GERIATR SOC, V53, P681, DOI 10.1111/j.1532-5415.2005.53219.x
   Rockwood K, 2007, ALZHEIMERS DEMENT, V3, pS38, DOI 10.1016/j.jalz.2007.01.003
   Rovner BW, 2007, ARCH GEN PSYCHIAT, V64, P886, DOI 10.1001/archpsyc.64.8.886
   RUBIN GS, 1994, OPTOMETRY VISION SCI, V71, P750, DOI 10.1097/00006324-199412000-00005
   Schmidt Silke, 2002, Ophthalmic Genet, V23, P209, DOI 10.1076/opge.23.4.209.13883
   Seeman TE, 2001, HEALTH PSYCHOL, V20, P243, DOI 10.1037//0278-6133.20.4.243
   Stelmack J, 2001, OPTOMETRY VISION SCI, V78, P335, DOI 10.1097/00006324-200105000-00017
   Sturman MT, 2005, ARCH NEUROL-CHICAGO, V62, P1750, DOI 10.1001/archneur.62.11.1750
   Verghese J, 2003, NEW ENGL J MED, V348, P2508, DOI 10.1056/NEJMoa022252
   VONKORFF M, 1992, J CLIN EPIDEMIOL, V45, P197, DOI 10.1016/0895-4356(92)90016-G
   Wang JYJ, 2006, NEUROLOGY, V66, P911, DOI 10.1212/01.wnl.0000192165.99963.2a
   WILLIAMS JBW, 1988, ARCH GEN PSYCHIAT, V45, P742
   Wilson RS, 2002, JAMA-J AM MED ASSOC, V287, P742, DOI 10.1001/jama.287.6.742
   WYOSHIDA T, 2005, J CLIN INVEST, V115, P2793
NR 42
TC 27
Z9 27
U1 0
U2 5
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1552-5260
EI 1552-5279
J9 ALZHEIMERS DEMENT
JI Alzheimers. Dement.
PD JAN
PY 2009
VL 5
IS 1
BP 12
EP 17
DI 10.1016/j.jalz.2008.06.001
PG 6
WC Clinical Neurology
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC Neurosciences & Neurology
GA 392ZW
UT WOS:000262341700005
PM 19118805
OA Green Submitted, Green Accepted
DA 2022-11-30
ER

PT J
AU Falk, MK
   Kemp, H
   Sorensen, TL
AF Falk, Mads Kruger
   Kemp, Henrik
   Sorensen, Torben Lykke
TI Four-Year Treatment Results of Neovascular Age-Related Macular
   Degeneration With Ranibizumab and Causes for Discontinuation of
   Treatment
SO AMERICAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID INTRAVITREAL BEVACIZUMAB; DOSING REGIMEN; THERAPY
AB PURPOSE: To evaluate 4-year treatment results of neovascular age-related macular degeneration with ranibizumab using a variable dosing regimen.
   DESIGN: Retrospective, single-center chart review.
   METHODS: This was a retrospective single-center study that included 855 patients with neovascular age-related macular degeneration receiving treatment with ranibizumab during a 4-year period. Included in the study were patients with a minimum follow-up of 15 months and all patients who terminated treatment regardless of follow-up.
   RESULTS: A total of 1321 patients were treated over the 4-year period, and 855 patients were eligible for inclusion. Of those, 456 patients were still receiving active treatment, whereas 399 patients had discontinued treatment. Overall treatment results showed a significant decrease in vision from 53.2 Early Treatment Diabetic Retinopathy Study letters (range, 1 to 85 letters) to 50.5 letters (range, 1 to 87 letters; P < .001). Mean follow-up was 23.3 months (range, 4 to 48 months). The reason for discontinuing treatment in 181 patients was no signs of activity, whereas 113 patients were judged to be nontreatable. Thirty-six patients declined further treatment for various reasons.
   CONCLUSIONS: This report shows that when follow-up extends beyond 2 to 3 years, visual acuity does seem to decrease. Our data show that different responder groups can be identified: bad or nonresponders (approximately 15% of all patients) and good responders (approximately 21% of all patients). These 2 groups in general can be identified within the first 2 years of treatment, whereas the third group of regular responders (approximately 64% of all patients) require continuous monitoring and treatment for years. (Am J Ophthalmol 2013;155:89-95. (C) 2013 by Elsevier Inc. All rights reserved.)
C1 [Falk, Mads Kruger; Kemp, Henrik; Sorensen, Torben Lykke] Univ Copenhagen, Hosp Roskilde, Dept Ophthalmol, DK-4000 Roskilde, Denmark.
   [Falk, Mads Kruger; Sorensen, Torben Lykke] Univ Copenhagen, Fac Hlth & Med Sci, DK-4000 Roskilde, Denmark.
C3 University of Copenhagen; University of Copenhagen
RP Falk, MK (通讯作者)，Univ Copenhagen, Hosp Roskilde, Dept Ophthalmol, Kogevej 7-13, DK-4000 Roskilde, Denmark.
EM mfal@regionsjaelland.dk
RI Sørensen, Torben Lykke L/N-1417-2014
OI Sørensen, Torben Lykke L/0000-0002-6790-0199
CR Biarnes M, 2011, EUR J OPHTHALMOL, V21, P282, DOI 10.5301/EJO.2010.5766
   Bloch SB, ACTA OPHTHALMOL
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   Fung AE, 2007, AM J OPHTHALMOL, V143, P566, DOI 10.1016/j.ajo.2007.01.028
   Heimes B, 2011, GRAEF ARCH CLIN EXP, V249, P639, DOI 10.1007/s00417-010-1524-5
   Hjelmqvist L, J OPHTHALMO IN PRESS
   Kumar A, 2011, BRIT J OPHTHALMOL, V95, P530, DOI 10.1136/bjo.2009.171868
   Luu ST, 2010, CLIN EXP OPHTHALMOL, V38, P659, DOI 10.1111/j.1442-9071.2010.02309.x
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Querques G, 2010, BRIT J OPHTHALMOL, V94, P292, DOI 10.1136/bjo.2009.170670
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rothenbuehler SP, 2009, AM J OPHTHALMOL, V147, P831, DOI 10.1016/j.ajo.2008.12.005
   Singer MA, 2012, OPHTHALMOLOGY, V119, P1175, DOI 10.1016/j.ophtha.2011.12.016
   Tano Y, 2011, ACTA OPHTHALMOL, V89, P208, DOI 10.1111/j.1755-3768.2010.02065.x
   Tao Y, 2010, J OCUL PHARMACOL TH, V26, P79, DOI 10.1089/jop.2009.0095
NR 15
TC 74
Z9 76
U1 0
U2 11
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0002-9394
J9 AM J OPHTHALMOL
JI Am. J. Ophthalmol.
PD JAN
PY 2013
VL 155
IS 1
BP 89
EP 95
DI 10.1016/j.ajo.2012.06.031
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 066ML
UT WOS:000313224800008
PM 23022167
DA 2022-11-30
ER

PT J
AU Stefansson, E
   Geirsdottir, A
   Sigurdsson, H
AF Stefansson, Einar
   Geirsdottir, Asbjorg
   Sigurdsson, Haraldur
TI Metabolic physiology in age related macular degeneration
SO PROGRESS IN RETINAL AND EYE RESEARCH
LA English
DT Article
DE Age related macular degeneration; Oxygen; Vascular endothelial growth
   factor; Neovascularization; Subretinal hemorrhage; Edema; Retina;
   Pigment epithelial detachment; Vitreous humour; Posterior hyaloid;
   Vitrectomy; Posterior vitreous detachment; Fick's law; Vitreolysis
ID OCULAR BLOOD-FLOW; ENDOTHELIAL GROWTH-FACTOR; POSTERIOR VITREOMACULAR
   ADHESION; EXPERIMENTAL RETINAL-DETACHMENT; INDOCYANINE GREEN
   ANGIOGRAPHY; FACTOR MESSENGER-RNA; CHOROIDAL NEOVASCULARIZATION;
   PHARMACOLOGICAL VITREOLYSIS; OXYGEN DISTRIBUTION; PIGMENT EPITHELIUM
AB Ischemia and hypoxia have been implicated in the pathophysiology of age related macular degeneration (AMD). This has mostly been based on studies on choroidal perfusion, which is not the only contributor to retinal hypoxia found in AMD eyes. Other features of AMD may also interfere with retinal oxygen metabolism including confluent drusen, serous or hemorrhagic retinal detachment, retinal edema and vitreoretinal adhesion. Each of these features contributes to retinal hypoxia: the drusen and retinal elevation by increasing the distance between the choriocapillaris and retina: vitreoretinal adhesion by reducing diffusion and convection of oxygen towards and vascular endothelial growth factor (VEGF) away from hypoxic retinal areas. Hypoxia-inducible-factor is known to exist in subretinal neovascularization and hypoxia is the main stimulus for the production of VEGF. Each feature may not by itself create enough hypoxia and VEGF accumulation to stimulate wet AMD, but they may combine to do so.
   Choroidal ischemia in AMD has been demonstrated by many researchers, using different technologies. Choroidal ischemia obviously decreases oxygen delivery to the outer retina.
   Confluent drusen, thickening of Bruch's membrane and any detachment of retina or retinal pigment epithelium, increases the distance between the choriocapillaris and the retina and thereby reduces the oxygen flux from the choroid to the outer retina according to Fick's law of diffusion. Retinal elevation and choroidal ischemia may combine forces to reduce choroidal oxygen delivery to the outer retina, produce retinal hypoxia. Hypoxia leads to production of VEGF leading to neovascularization and tissue edema. A vicious cycle may develop, where VEGF production increases effusion, retinal detachment and edema, further increasing hypoxia and VEGF production.
   Adhesion of the viscous posterior vitreous cortex to the retina maintains a barrier to diffusion and convection currents in the vitreous cavity according to the laws of Fick's. Stokes-Einstein and Hagen-Poiseuille. If the vitreous is detached from the surface of the retina, the low viscosity fluid transports oxygen and nutrients towards an ischemic area of the retina, and cytokines away from the retina, at a faster rate than through attached vitreous gel. Vitreoretinal adhesion can exacerbate retinal hypoxia and accumulation of cytokines, such as VEGF. Vitreoretinal traction can also cause hypoxia by retinal elevation.
   Conceivably, the basic features of AMD, drusen, choroidal ischemia, and vitreoretinal adhesion are independently determined by genetics and environment and may combine in variable proportions. If the resulting hypoxia and consequent VEGF accumulation crosses a threshold, this will trigger effusion and neovascularization. (C) 2010 Elsevier Ltd. All rights reserved.
C1 [Stefansson, Einar; Geirsdottir, Asbjorg; Sigurdsson, Haraldur] Univ Iceland, Natl Univ Hosp, IS-101 Reykjavik, Iceland.
C3 Landspitali National University Hospital; University of Iceland
RP Stefansson, E (通讯作者)，Univ Iceland, Natl Univ Hosp, IS-101 Reykjavik, Iceland.
EM einarste@landspitali.is
CR Aaberg TM, 1999, AM J OPHTHALMOL, V128, P231
   Abdelsalam A, 1999, SURV OPHTHALMOL, V44, P1, DOI 10.1016/S0039-6257(99)00072-7
   AHMED J, 1993, INVEST OPHTH VIS SCI, V34, P516
   AIELLO LP, 1995, ARCH OPHTHALMOL-CHIC, V113, P1538, DOI 10.1001/archopht.1995.01100120068012
   Algvere PV, 2006, ACTA OPHTHALMOL SCAN, V84, P4, DOI 10.1111/j.1600-0420.2005.00627.x
   Algvere PV, 2003, ACTA OPHTHALMOL SCAN, V81, P427, DOI 10.1034/j.1600-0420.2003.00157.x
   BIRD AC, 1993, BRIT J OPHTHALMOL, V77, P614, DOI 10.1136/bjo.77.10.614
   Blaauwgeers HGT, 1999, AM J PATHOL, V155, P421, DOI 10.1016/S0002-9440(10)65138-3
   Boltz A, 2010, INVEST OPHTH VIS SCI, V51, P4220, DOI 10.1167/iovs.09-4968
   BRAUN RD, 1995, INVEST OPHTH VIS SCI, V36, P542
   Bressler SB, 2009, OPHTHALMOLOGY, V116, pS1, DOI 10.1016/j.ophtha.2009.06.045
   Campochiaro PA, 2004, EXPERT OPIN BIOL TH, V4, P1395, DOI 10.1517/14712598.4.9.1395
   CHEN JC, 1992, INVEST OPHTH VIS SCI, V33, P334
   Chen SJ, 2001, BRIT J OPHTHALMOL, V85, P1411, DOI 10.1136/bjo.85.12.1411
   Ciulla TA, 1999, AM J OPHTHALMOL, V128, P75, DOI 10.1016/S0002-9394(99)00061-6
   Ciulla TA, 2002, BRIT J OPHTHALMOL, V86, P209, DOI 10.1136/bjo.86.2.209
   Ciulla TA, 2001, ACTA OPHTHALMOL SCAN, V79, P108, DOI 10.1034/j.1600-0420.2001.079002108.x
   Curcio CA, 2009, PROG RETIN EYE RES, V28, P393, DOI 10.1016/j.preteyeres.2009.08.001
   Ding XY, 2009, PROG RETIN EYE RES, V28, P1, DOI 10.1016/j.preteyeres.2008.10.001
   Dorey CK, 1996, ARCH OPHTHALMOL-CHIC, V114, P1210, DOI 10.1001/archopht.1996.01100140410008
   Feigl B, 2007, EYE, V21, P689, DOI 10.1038/sj.eye.6702389
   FEIGL B, 2007, CLIN EXP OPHTHALM S1, V35, pA85
   Feigl B, 2007, CLIN NEUROPHYSIOL, V118, P887, DOI 10.1016/j.clinph.2006.12.012
   Feigl B, 2007, CLIN OPHTHALMOL, V1, P167
   Feigl B, 2009, PROG RETIN EYE RES, V28, P63, DOI 10.1016/j.preteyeres.2008.11.004
   Figueroa M, 2006, AM J OPHTHALMOL, V141, P863, DOI 10.1016/j.ajo.2005.11.049
   FRIEDMAN E, 1995, OPHTHALMOLOGY, V102, P640, DOI 10.1016/S0161-6420(95)30974-8
   FRIEDMAN E, 1963, ARCH OPHTHALMOL-CHIC, V69, P220
   Friedman E, 2008, AM J OPHTHALMOL, V146, P348, DOI 10.1016/j.ajo.2008.05.017
   GISLADOTTIR S, 2009, GRAEFES ARCH CLIN EX
   Goldberg MF, 1998, OPHTHALMIC SURG LAS, V29, P385
   Grunwald JE, 1998, INVEST OPHTH VIS SCI, V39, P385
   Grunwald JE, 2005, INVEST OPHTH VIS SCI, V46, P1033, DOI 10.1167/iovs.04-1050
   Harris A, 1999, PROG RETIN EYE RES, V18, P669
   HAUGH LM, 1990, ANN BIOMED ENG, V18, P19, DOI 10.1007/BF02368415
   HAYASHI K, 1985, OPHTHALMOLOGICA, V190, P30, DOI 10.1159/000309489
   Hosal BM, 1998, EUR J OPHTHALMOL, V8, P234, DOI 10.1177/112067219800800406
   Inoue Y, 2007, BRIT J OPHTHALMOL, V91, P1720, DOI 10.1136/bjo.2006.111583
   Klein R, 2004, AM J OPHTHALMOL, V137, P486, DOI 10.1016/j.ajo.2003.11.069
   Krebs I, 2007, AM J OPHTHALMOL, V144, P741, DOI 10.1016/j.ajo.2007.07.024
   Kubasiak LA, 2002, P NATL ACAD SCI USA, V99, P12825, DOI 10.1073/pnas.202474099
   Lee SJ, 2009, AM J OPHTHALMOL, V147, P621, DOI 10.1016/j.ajo.2008.10.003
   Lengyel I, 2004, INVEST OPHTH VIS SCI, V45, P2886, DOI 10.1167/iovs.03-1083
   Levy AP, 1996, J BIOL CHEM, V271, P25492, DOI 10.1074/jbc.271.41.25492
   Levy AP, 1996, J BIOL CHEM, V271, P2746, DOI 10.1074/jbc.271.5.2746
   Lewis G, 1999, AM J OPHTHALMOL, V128, P165, DOI 10.1016/S0002-9394(99)00103-8
   Lewis GP, 2004, AM J OPHTHALMOL, V137, P1085, DOI 10.1016/j.ajo.2004.01.045
   LINSENMEIER RA, 1992, J GEN PHYSIOL, V99, P177, DOI 10.1085/jgp.99.2.177
   Linsenmeier RA, 2000, INVEST OPHTH VIS SCI, V41, P3117
   Liu LX, 2002, BIOCHEM BIOPH RES CO, V291, P908, DOI 10.1006/bbrc.2002.6551
   Lutty G, 1999, MOL VIS, V5
   McLeod DS, 2009, INVEST OPHTH VIS SCI, V50, P4982, DOI 10.1167/iovs.09-3639
   Mendrinos E, 2009, ACTA OPHTHALMOL, V87, P290, DOI 10.1111/j.1755-3768.2008.01247.x
   Mervin K, 1999, AM J OPHTHALMOL, V128, P155, DOI 10.1016/S0002-9394(99)00104-X
   Metelitsina TI, 2008, INVEST OPHTH VIS SCI, V49, P358, DOI 10.1167/iovs.07-0526
   Metelitsina TI, 2006, BRIT J OPHTHALMOL, V90, P342, DOI 10.1136/bjo.2005.082974
   Mojana F, 2008, AM J OPHTHALMOL, V146, P218, DOI 10.1016/j.ajo.2008.04.027
   MOORE DJ, 1995, INVEST OPHTH VIS SCI, V36, P1290
   Mori F, 2001, BRIT J OPHTHALMOL, V85, P1399, DOI 10.1136/bjo.85.12.1399
   Mori F, 2001, BRIT J OPHTHALMOL, V85, P531, DOI 10.1136/bjo.85.5.531
   Mori Fumihiko, 2003, Nippon Ganka Gakkai Zasshi, V107, P674
   Pauleikhoff D, 1999, ARCH OPHTHALMOL-CHIC, V117, P1353, DOI 10.1001/archopht.117.10.1353
   Pemp B, 2008, CAN J OPHTHALMOL, V43, P295, DOI 10.3129/i08-049
   PIGUET B, 1992, AM J OPHTHALMOL, V113, P657, DOI 10.1016/S0002-9394(14)74790-7
   Pournaras CJ, 2006, INVEST OPHTH VIS SCI, V47, P1581, DOI 10.1167/iovs.05-0434
   Quiram PA, 2007, RETINA-J RET VIT DIS, V27, P1090, DOI 10.1097/IAE.0b013e3180654229
   Robison CD, 2009, AM J OPHTHALMOL, V148, P79, DOI 10.1016/j.ajo.2009.01.014
   Roos MW, 2007, COMPUT BIOL MED, V37, P890, DOI 10.1016/j.compbiomed.2006.09.005
   Ross RD, 1998, AM J OPHTHALMOL, V125, P71, DOI 10.1016/S0002-9394(99)80237-2
   Ryan SJ, 2001, RETINA, P1005
   Sakai T, 2001, INVEST OPHTH VIS SCI, V42, pS446
   SAKAUE H, 1989, JPN J OPHTHALMOL, V33, P199
   Sandhu R, 2007, EYE, V21, P506, DOI 10.1038/sj.eye.6702242
   SARKS SH, 1980, T OPHTHAL SOC UK, V100, P414
   Sarks S, 2007, INVEST OPHTH VIS SCI, V48, P968, DOI 10.1167/iovs.06-0443
   Schmetterer L, 1998, GRAEF ARCH CLIN EXP, V236, P160, DOI 10.1007/s004170050058
   SCHULZE S, 2008, ACTA OPHTHALMOL
   Sebag J, 2007, GRAEF ARCH CLIN EXP, V245, P576, DOI 10.1007/s00417-006-0394-3
   Sebag J, 2002, RETINA-J RET VIT DIS, V22, P1, DOI 10.1097/00006982-200202000-00001
   Sebag J, 2009, BRIT J OPHTHALMOL, V93, P989, DOI 10.1136/bjo.2009.157313
   Sebag J, 2009, RETINA-J RET VIT DIS, V29, P871, DOI 10.1097/IAE.0b013e3181ac7b3c
   Sebag J, 1998, RETINA-J RET VIT DIS, V18, P1
   Sheridan CM, 2009, GRAEF ARCH CLIN EXP, V247, P1361, DOI 10.1007/s00417-009-1133-3
   Shui YB, 2009, ARCH OPHTHALMOL-CHIC, V127, P475, DOI 10.1001/archophthalmol.2008.621
   Solomon SD, 2009, RETINA-J RET VIT DIS, V29, P1080, DOI 10.1097/IAE.0b013e3181b1baeb
   Sowter HM, 2001, CANCER RES, V61, P6669
   Spaide RF, 2003, RETINA-J RET VIT DIS, V23, P595, DOI 10.1097/00006982-200310000-00001
   Spraul CW, 1996, INVEST OPHTH VIS SCI, V37, P2724
   Starita C, 1997, INVEST OPHTH VIS SCI, V38, P762
   STEFANSSON E, 1990, GRAEF ARCH CLIN EXP, V228, P120, DOI 10.1007/BF00935719
   STEFANSSON E, 1990, INVEST OPHTH VIS SCI, V31, P284
   STEFANSSON E, 1981, OCULAR OXYGENATION N
   Stefansson E, 2006, SURV OPHTHALMOL, V51, P364, DOI 10.1016/j.survophthal.2006.04.005
   SUBCZYNSKI WK, 1991, BIOCHEMISTRY-US, V30, P8578, DOI 10.1021/bi00099a013
   SUBCZYNSKI WK, 1992, BIOPHYS J, V63, P573, DOI 10.1016/S0006-3495(92)81612-0
   SUBCZYNSKI WK, 1989, P NATL ACAD SCI USA, V86, P4474, DOI 10.1073/pnas.86.12.4474
   SUBCZYNSKI WK, 1992, J GEN PHYSIOL, V100, P69, DOI 10.1085/jgp.100.1.69
   Uretmen O, 2003, OPHTHALMOLOGICA, V217, P137, DOI 10.1159/000068559
   Verhoeff F H, 1937, Trans Am Ophthalmol Soc, V35, P262
   Vinores SA, 2000, ADV EXP MED BIOL, V476, P129
   Wang SF, 2007, INVEST OPHTH VIS SCI, V48, P1335, DOI 10.1167/iovs.06-0842
   Wangsa-Wirawan ND, 2003, ARCH OPHTHALMOL-CHIC, V121, P547, DOI 10.1001/archopht.121.4.547
   YANCEY CM, 1989, INVEST OPHTH VIS SCI, V30, P600
   YANCEY CM, 1988, INVEST OPHTH VIS SCI, V29, P700
NR 104
TC 107
Z9 118
U1 0
U2 24
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 1350-9462
EI 1873-1635
J9 PROG RETIN EYE RES
JI Prog. Retin. Eye Res.
PD JAN
PY 2011
VL 30
IS 1
BP 72
EP 80
DI 10.1016/j.preteyeres.2010.09.003
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 710WQ
UT WOS:000286548100004
PM 20951826
DA 2022-11-30
ER

PT J
AU Feher, J
   Kovacs, I
   Artico, M
   Cavallotti, C
   Papale, A
   Gabrieli, CB
AF Feher, Janos
   Kovacs, Illes
   Artico, Marco
   Cavallotti, Carlo
   Papale, Antonio
   Gabrieli, Corrado Balacco
TI Mitochondrial alterations of retinal pigment epithelium in age-related
   macular degeneration
SO NEUROBIOLOGY OF AGING
LA English
DT Article
DE retinal pigment epithelium; mitochondria; lipofuscin; peroxisomes;
   age-related macular degeneration; electron microscopy; morphometry
ID ACTIVATED RECEPTORS ALPHA; FATTY-ACIDS; OXIDATIVE STRESS;
   SKELETAL-MUSCLE; GENE-EXPRESSION; BETA-OXIDATION; DNA DAMAGE;
   LIPOFUSCIN; DYSFUNCTION; APOPTOSIS
AB Mitochondrial dysfunctions have been implicated in the pathophysiology of several age-related diseases including age-related macular degeneration (AMD), a progressive neurodegenerative disease affecting primarily the retinal pigment epithelium (RPE). The aims of our electron microscopic and morphometric studies were to reveal qualitative and quantitative alterations of mitochondria in human RPE from AMD and from age- and sex-matched controls. With increasing age a significant decrease in number and area of mitochondria, as well as loss of cristae and matrix density were found in both AMD and control specimens. These decreases were significantly greater in AMD than in normal aging. Alterations of mitochondria were accompanied by proliferation of peroxisomes and lipofuscin granules in both AMD and control specimens, although the difference between groups was significant only for peroxisomes. Unexpectedly, morphometric data showed that the RPE alterations seen in AMD may also develop in normal aging, 10-15 years after appearing in AMD patients. These findings suggest that (i) the severity of mitochondrial and peroxisomal alterations are different between AMD and normal aging, and (ii) the timing of damage to RPE may be critical for the development of AMD. We conclude that besides the well-documented age-related changes in mitochondrial DNA, alterations of mitochondrial membranes may also play a role in the pathogenesis of AMD. These membranes could be a new target for treatment of AMD and other age-related diseases. (c) 2005 Elsevier Inc. All rights reserved.
C1 Univ Roma La Sapienza, Ophthalm Neurosci Program, Dept Ophthalmol, I-00187 Rome, Italy.
   Semmelweis Univ, Dept Ophthalmol, Ophthalm Neurosci Program, H-1085 Budapest, Hungary.
   Univ Roma La Sapienza, Fac Pharm, Ophthalm Neurosci Program, I-00187 Rome, Italy.
   Univ Roma La Sapienza, Dept Cardiovasc & Resp Sci, Ophthalm Neurosci Program, I-00187 Rome, Italy.
C3 Sapienza University Rome; Semmelweis University; Sapienza University
   Rome; Sapienza University Rome
RP Feher, J (通讯作者)，Univ Roma La Sapienza, Ophthalm Neurosci Program, Dept Ophthalmol, Via Lombardia 23-C, I-00187 Rome, Italy.
EM j.feher@libero.it
RI cavallotti, carlo/F-6593-2013
OI Kovacs, Illes/0000-0001-5763-0482
CR Andrews RM, 1999, BRIT J OPHTHALMOL, V83, P231, DOI 10.1136/bjo.83.2.231
   ATAMNA H, 2001, SCI WORLD J S3, V1, P81
   Barreau E, 1996, INVEST OPHTH VIS SCI, V37, P384
   Barron MJ, 2001, INVEST OPHTH VIS SCI, V42, P3016
   BATTELLI D, 1992, BIOCHIM BIOPHYS ACTA, V1117, P33, DOI 10.1016/0304-4165(92)90158-Q
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   BEAUMONT K, 1988, BIOCHEM PHARMACOL, V37, P1009, DOI 10.1016/0006-2952(88)90502-3
   Ben-Shachar D, 2002, J NEUROCHEM, V83, P1241, DOI 10.1046/j.1471-4159.2002.01263.x
   Bergmann M, 2004, FASEB J, V18, P562, DOI 10.1096/fj.03-0289fje
   Binienda Zbigniew, 2003, Current Medicinal Chemistry - Central Nervous System Agents, V3, P275, DOI 10.2174/1568015033477659
   Bird AC, 2003, EYE, V17, P457, DOI 10.1038/sj.eye.6700562
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Brunk UT, 2002, EUR J BIOCHEM, V269, P1996, DOI 10.1046/j.1432-1033.2002.02869.x
   Campbell AM, 2002, BBA-BIOMEMBRANES, V1567, P123, DOI 10.1016/S0005-2736(02)00607-7
   Cotman CW, 2002, NEUROBIOL AGING, V23, P809, DOI 10.1016/S0197-4580(02)00073-8
   Crompton M, 2004, AGING CELL, V3, P3, DOI 10.1046/j.1474-9728.2003.00073.x
   Del Priore LV, 2002, INVEST OPHTH VIS SCI, V43, P3312
   DENTON RM, 1975, MOL CELL BIOCHEM, V9, P27, DOI 10.1007/BF01731731
   Dunaief JL, 2002, ARCH OPHTHALMOL-CHIC, V120, P1435, DOI 10.1001/archopht.120.11.1435
   Ershov AV, 2000, J NEUROSCI RES, V60, P328, DOI 10.1002/(SICI)1097-4547(20000501)60:3<328::AID-JNR7>3.0.CO;2-5
   Feher J, 2005, OPHTHALMOLOGICA, V219, P154, DOI 10.1159/000085248
   Feher J, 2003, OPHTHALMOLOGICA, V217, P351, DOI 10.1159/000071351
   Finnemann SC, 2002, P NATL ACAD SCI USA, V99, P3842, DOI 10.1073/pnas.052025899
   Forman BM, 1997, P NATL ACAD SCI USA, V94, P4312, DOI 10.1073/pnas.94.9.4312
   Fox DA, 2003, EUR J OPHTHALMOL, V13, pS44
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Furuno T, 2001, BIOCHEM PHARMACOL, V62, P1037, DOI 10.1016/S0006-2952(01)00745-6
   Gabbita SP, 1998, BBA-BIOMEMBRANES, V1372, P163, DOI 10.1016/S0005-2736(98)00040-6
   Gosker HR, 2000, AM J CLIN NUTR, V71, P1033
   Haimovici R, 2002, GRAEF ARCH CLIN EXP, V240, P90, DOI 10.1007/s00417-001-0417-z
   Hansson M, 2003, BBA-MOL CELL RES, V1593, P283, DOI 10.1016/S0167-4889(02)00398-1
   Hatch GM, 2004, BIOCHEM CELL BIOL, V82, P99, DOI 10.1139/o03-074
   Hettema EH, 2000, BBA-MOL CELL BIOL L, V1486, P18, DOI 10.1016/S1388-1981(00)00045-7
   Hiltunen JK, 2000, BBA-MOL CELL BIOL L, V1484, P117, DOI 10.1016/S1388-1981(00)00013-5
   Hirai K, 2001, J NEUROSCI, V21, P3017, DOI 10.1523/JNEUROSCI.21-09-03017.2001
   Hollyfield JG, 2003, ADV EXP MED BIOL, V533, P83
   Jackson GR, 2002, AGEING RES REV, V1, P381, DOI 10.1016/S1568-1637(02)00007-7
   James AM, 2002, J BIOMED SCI, V9, P475, DOI 10.1159/000064721
   Jin GF, 2001, CURR EYE RES, V23, P11, DOI 10.1076/ceyr.23.1.11.5423
   Katz ML, 1999, INVEST OPHTH VIS SCI, V40, P175
   KELLER H, 1993, P NATL ACAD SCI USA, V90, P2160, DOI 10.1073/pnas.90.6.2160
   Kelley DE, 2002, DIABETES, V51, P2944, DOI 10.2337/diabetes.51.10.2944
   Kennedy CJ, 1995, EYE, V9, P763, DOI 10.1038/eye.1995.192
   Kersten S, 2000, NATURE, V405, P421, DOI 10.1038/35013000
   Klaver CCW, 1998, ARCH OPHTHALMOL-CHIC, V116, P653, DOI 10.1001/archopht.116.5.653
   Kliewer SA, 1997, P NATL ACAD SCI USA, V94, P4318, DOI 10.1073/pnas.94.9.4318
   Kroemer G, 2000, NAT MED, V6, P513, DOI 10.1038/74994
   Kuksa V, 2003, VISION RES, V43, P2959, DOI 10.1016/S0042-6989(03)00482-6
   Liang FQ, 2003, EXP EYE RES, V76, P397, DOI 10.1016/S0014-4835(03)00023-X
   Marmorstein AD, 2002, INVEST OPHTH VIS SCI, V43, P2435
   Midena E, 1997, INVEST OPHTH VIS SCI, V38, P469
   Murata T, 2000, INVEST OPHTH VIS SCI, V41, P2309
   Nagy L, 1998, CELL, V93, P229, DOI 10.1016/S0092-8674(00)81574-3
   Papadopoulos V., 2003, Annales Pharmaceutiques Francaises, V61, P30
   Paradies G, 1997, FEBS LETT, V406, P136, DOI 10.1016/S0014-5793(97)00264-0
   Pepe S, 2000, CLIN EXP PHARMACOL P, V27, P745, DOI 10.1046/j.1440-1681.2000.03326.x
   PEPE S, 1999, AM J PHYSIOL, V276, P149, DOI [DOI 10.1152/AJPHEART.1999.276.1.H149, 10.1152/ajpheart.1999.276.1.H149]
   Rakoczy PE, 2002, AM J PATHOL, V161, P1515, DOI 10.1016/S0002-9440(10)64427-6
   Remky A, 2001, BRIT J OPHTHALMOL, V85, P1432, DOI 10.1136/bjo.85.12.1432
   ROBISON WG, 1975, INVEST OPHTH VISUAL, V14, P866
   Rottenberg H, 1997, BIOCHEM BIOPH RES CO, V240, P68, DOI 10.1006/bbrc.1997.7605
   Schon EA, 2003, J CLIN INVEST, V111, P303, DOI 10.1172/JCI200317741
   Shaban H, 2002, EXP EYE RES, V75, P99, DOI 10.1006/exer.2001.1192
   Shamsi FA, 2001, INVEST OPHTH VIS SCI, V42, P3041
   SHIGENAGA MK, 1994, P NATL ACAD SCI USA, V91, P10771, DOI 10.1073/pnas.91.23.10771
   Sparrow JR, 2003, VISION RES, V43, P2983, DOI 10.1016/S0042-6989(03)00475-9
   Sprecher H, 2000, BBA-MOL CELL BIOL L, V1486, P219, DOI 10.1016/S1388-1981(00)00077-9
   Sugrue MM, 2001, BIOL SIGNAL RECEPT, V10, P176
   Sundelin S, 1998, CURR EYE RES, V17, P851, DOI 10.1076/ceyr.17.8.851.5146
   Suter M, 2000, J BIOL CHEM, V275, P39625, DOI 10.1074/jbc.M007049200
   Szabo I, 2004, PFLUG ARCH EUR J PHY, V448, P304, DOI 10.1007/s00424-004-1259-4
   Toescu EC, 2000, CELL CALCIUM, V28, P329, DOI 10.1054/ceca.2000.0167
   TOLENTINO MJ, 1994, VISION RES, V34, P409, DOI 10.1016/0042-6989(94)90099-X
   Tyni T, 2002, PEDIATR RES, V52, P595, DOI 10.1203/01.PDR.0000030874.20888.2D
   Varma R, 2004, OPHTHALMOLOGY, V111, P1288, DOI 10.1016/j.ophtha.2004.01.023
   von Ruckmann A, 1998, KLIN MONATSBL AUGENH, V213, P32, DOI 10.1055/s-2008-1034940
   Winkler BS, 1999, MOL VIS, V5
   Wolf G, 2003, NUTR REV, V61, P342, DOI 10.1301/nr.2003.oct.342-346
   Zammit VA, 1998, LIPIDS, V33, P371, DOI 10.1007/s11745-998-0217-7
   Zingsheim H. P., 1976, METHODS MEMBRANE BIO, P1
NR 80
TC 251
Z9 260
U1 2
U2 18
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0197-4580
EI 1558-1497
J9 NEUROBIOL AGING
JI Neurobiol. Aging
PD JUL
PY 2006
VL 27
IS 7
BP 983
EP 993
DI 10.1016/j.neurobiolaging.2005.05.012
PG 11
WC Geriatrics & Gerontology; Neurosciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Geriatrics & Gerontology; Neurosciences & Neurology
GA 049JP
UT WOS:000238012700010
PM 15979212
DA 2022-11-30
ER

PT J
AU Fang, IM
   Lin, YC
   Yang, CH
   Yang, CM
   Chen, MS
AF Fang, I-M
   Lin, Y-C
   Yang, C-H
   Yang, C-M
   Chen, M-S
TI Effects of intravitreal gas with or without tissue plasminogen activator
   on submacular haemorrhage in age-related macular degeneration
SO EYE
LA English
DT Article
DE age-related macular degeneration; tissue plasminogen activator;
   submacular haemorrhage; pneumatic displacement
ID EXPERIMENTAL SUBRETINAL HEMORRHAGE; PNEUMATIC DISPLACEMENT; RETINAL
   TOXICITY; NATURAL-HISTORY; INJECTION; MANAGEMENT; RABBITS; EYES
AB Purpose To compare the anatomic and functional outcomes of treating thick submacular haemorrhage with intravitreal gas injection with and without tissue plasminogen activator (t-PA) in patients with age-related macular degeneration.
   Methods A review of age-related macular degeneration patients with submacular haemorrhage who underwent intravitreal gas injection with and without t-PA at a tertiary referral centre was conducted. Main outcome measures were best and final postoperative visual acuity.
   Results A total of 53 eyes of 53 patients were included, 28 eyes received intravitreal t-PA and gas injection (t-PA and gas group) and 25 eyes received intravitreal gas injection alone (gas-alone group). Incidence of best visual acuity improvement was significantly higher in the t-PA and gas group than in the gas-alone group (60.7 vs 32.0%; P = 0.037). However, subgroup analysis demonstrated that the difference was significant only in eyes with haemorrhage duration of more than 14 days (46.2 vs 8.3%; P = 0.035). Incidence of final visual acuity improvement was not significantly different between the two groups (42.9 vs 28.0%; P = 0.39). The complications of vitreous haemorrhage and endophthalmitis were similar between the two groups. Multiple logistic regression analysis demonstrated that shorter haemorrhage duration (<14 days) was the main factor predictive of best visual acuity improvement OR = 9.02, P = 0.015). Whether t-PA was used was of borderline significance (OR = 4.96, P = 0.046).
   Abstract
   Conclusions Intravitreal t-PA was valuable for submacular haemorrhage only in eyes with relatively old haemorrhage. For eyes with recent onset of haemorrhage, t-PA is suggested only if initial gas injection failed to displace submacular haemorrhage.
C1 [Fang, I-M; Lin, Y-C; Yang, C-H; Yang, C-M; Chen, M-S] Natl Taiwan Univ Hosp, Dept Ophthalmol, Taipei, Taiwan.
   [Fang, I-M] Taipei City Hosp, Zhongxiao Branch, Dept Ophthalmol, Taipei, Taiwan.
C3 National Taiwan University; National Taiwan University Hospital; Taipei
   City Hospital
RP Yang, CH (通讯作者)，Natl Taiwan Univ Hosp, Dept Ophthalmol, 7 Chung Shan S Rd, Taipei, Taiwan.
EM chyangoph@ntu.edu.tw
RI Yang, Chung-May/AAV-3737-2020; Yang, Chang-Hao/AAR-3759-2021
OI YANG, CHANG-HAO/0000-0002-4328-8716; YANG, CHUNG-MAY/0000-0003-4082-420X
CR Avery RL, 1996, RETINA-J RET VIT DIS, V16, P183, DOI 10.1097/00006982-199616030-00001
   BENNETT SR, 1990, AM J OPHTHALMOL, V109, P33, DOI 10.1016/S0002-9394(14)75575-8
   Berrocal MH, 1996, AM J OPHTHALMOL, V122, P486, DOI 10.1016/S0002-9394(14)72107-5
   Boone DE, 1996, RETINA-J RET VIT DIS, V16, P518, DOI 10.1097/00006982-199616060-00009
   Borrillo JL, 2001, CURR OPIN OPHTHALMOL, V12, P207, DOI 10.1097/00055735-200106000-00011
   Chaudhry NA, 1999, OPHTHALMIC SURG LAS, V30, P176
   Chen SN, 2003, OPHTHALMOLOGY, V110, P704, DOI 10.1016/S0161-6420(02)01979-6
   Daneshvar H, 1999, CAN J OPHTHALMOL, V34, P385
   GLATT H, 1982, AM J OPHTHALMOL, V94, P762, DOI 10.1016/0002-9394(82)90301-4
   Handwerger BA, 2001, ARCH OPHTHALMOL-CHIC, V119, P28
   Hassan AS, 1999, OPHTHALMOLOGY, V106, P1900, DOI 10.1016/S0161-6420(99)90399-8
   Hattenbach LO, 2001, OPHTHALMOLOGY, V108, P1485, DOI 10.1016/S0161-6420(01)00648-0
   Haupert CL, 2001, AM J OPHTHALMOL, V131, P208, DOI 10.1016/S0002-9394(00)00734-0
   Heriot W, 1996, AM AC OPHTH ANN VITR
   Hesse L, 1999, GRAEF ARCH CLIN EXP, V237, P273, DOI 10.1007/s004170050232
   Hrach CJ, 2000, ARCH OPHTHALMOL-CHIC, V118, P659
   IRVINE WD, 1991, ARCH OPHTHALMOL-CHIC, V109, P718, DOI 10.1001/archopht.1991.01080050134044
   Johnson M W, 2000, Curr Opin Ophthalmol, V11, P201, DOI 10.1097/00055735-200006000-00009
   JOHNSON MW, 1991, RETINA-J RET VIT DIS, V11, P250, DOI 10.1097/00006982-199111020-00011
   JOHNSON MW, 1992, OPHTHALMOLOGY, V99, P515
   JOHNSON MW, 1990, ARCH OPHTHALMOL-CHIC, V108, P259, DOI 10.1001/archopht.1990.01070040111042
   Kamei M, 1996, AM J OPHTHALMOL, V121, P267, DOI 10.1016/S0002-9394(14)70274-0
   Kamei M, 1999, AM J OPHTHALMOL, V128, P739, DOI 10.1016/S0002-9394(99)00239-1
   Krepler K, 2000, RETINA-J RET VIT DIS, V20, P251, DOI 10.1097/00006982-200003000-00005
   LEWIS H, 1994, AM J OPHTHALMOL, V118, P559, DOI 10.1016/S0002-9394(14)76571-7
   Meier P, 1999, OPHTHALMOLOGE, V96, P643, DOI 10.1007/s003470050467
   Ohji M, 1998, ARCH OPHTHALMOL-CHIC, V116, P1326, DOI 10.1001/archopht.116.10.1326
   Scupola A, 1999, OPHTHALMOLOGICA, V213, P97, DOI 10.1159/000027400
   TAKEUCHI A, 1994, INVEST OPHTH VIS SCI, V35, P3792
   Tennant Matthew T S, 2002, Ophthalmol Clin North Am, V15, P445, DOI 10.1016/S0896-1549(02)00049-4
   TOTH CA, 1991, ARCH OPHTHALMOL-CHIC, V109, P723, DOI 10.1001/archopht.1991.01080050139046
   Vote BJ, 2004, RETINA-J RET VIT DIS, V24, P808, DOI 10.1097/00006982-200410000-00024
   Wirostko W J, 2000, Curr Opin Ophthalmol, V11, P195, DOI 10.1097/00055735-200006000-00008
NR 33
TC 24
Z9 24
U1 0
U2 0
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0950-222X
EI 1476-5454
J9 EYE
JI Eye
PD FEB
PY 2009
VL 23
IS 2
BP 397
EP 406
DI 10.1038/sj.eye.6703017
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 406US
UT WOS:000263321000026
PM 17975562
OA Bronze
DA 2022-11-30
ER

PT J
AU Pawlowska, E
   Szczepanska, J
   Koskela, A
   Kaarniranta, K
   Blasiak, J
AF Pawlowska, Elzbieta
   Szczepanska, Joanna
   Koskela, Ali
   Kaarniranta, Kai
   Blasiak, Janusz
TI Dietary Polyphenols in Age-Related Macular Degeneration: Protection
   against Oxidative Stress and Beyond
SO OXIDATIVE MEDICINE AND CELLULAR LONGEVITY
LA English
DT Review
ID AUTOPHAGY; CELLS; RPE
AB Age-related macular degeneration (AMD) is a multifactorial disease of the retina featured by degeneration and loss of photoreceptors and retinal pigment epithelium (RPE) cells with oxidative stress playing a role in its pathology. Although systematic reviews do not support the protective role of diet rich in antioxidants against AMD, dietary polyphenols (DPs) have been reported to have beneficial effects on vision. Some of them, such as quercetin and cyanidin-3-glucoside, can directly scavenge reactive oxygen species (ROS) due to the presence of two hydroxyl groups in their B ring structure. Apart from direct ROS scavenging, DPs can lower oxidative stress in several other pathways. Many DPs induce NRF2 (nuclear factor, erythroid 2-like 2) activation and expression of phase II enzymes that are under transcriptional control of this factor. DPs can inhibit A2E photooxidation in RPE cells, which is a source of oxidative stress. Anti-inflammatory action of DPs in RPE cells is associated with regulation of various interleukins and signaling pathways, including IL-6/JAK2 (Janus kinase 2)/STAT3. Some DPs can improve impaired cellular waste clearance, including AMD-specific deficient phagocytosis of the A beta 42 peptide and autophagy.
C1 [Pawlowska, Elzbieta] Med Univ Lodz, Dept Orthodont, Pomorska 251, PL-92216 Lodz, Poland.
   [Szczepanska, Joanna] Med Univ Lodz, Dept Pediat Dent, Pomorska 251, PL-92216 Lodz, Poland.
   [Koskela, Ali; Kaarniranta, Kai] Univ Eastern Finland, Dept Ophthalmol, Kuopio 70211, Finland.
   [Koskela, Ali; Kaarniranta, Kai] Kuopio Univ Hosp, Dept Ophthalmol, Kuopio 70029, Finland.
   [Blasiak, Janusz] Univ Lodz, Dept Mol Genet, Fac Biol & Environm Protect, Pomorska 141-143, PL-90236 Lodz, Poland.
C3 Medical University Lodz; Medical University Lodz; University of Eastern
   Finland; Kuopio University Hospital; University of Eastern Finland;
   University of Lodz
RP Blasiak, J (通讯作者)，Univ Lodz, Dept Mol Genet, Fac Biol & Environm Protect, Pomorska 141-143, PL-90236 Lodz, Poland.
EM janusz.blasiak@biol.uni.lodz.pl
OI Pawlowska, Elzbieta/0000-0002-5373-4783; Szczepanska,
   JOANNA/0000-0001-9912-5345; Blasiak, Janusz/0000-0001-9539-9584
CR Al-Janabi A, 2018, EYE, V32, P981, DOI 10.1038/s41433-018-0066-7
   Blasiak Janusz, 2013, Front Biosci (Schol Ed), V5, P412
   Bradley DT, 2011, EYE, V25, P683, DOI 10.1038/eye.2011.37
   Cao XG, 2010, EXP EYE RES, V91, P15, DOI 10.1016/j.exer.2010.03.016
   Carneiro A, 2017, OXID MED CELL LONGEV, V2017, DOI 10.1155/2017/2435963
   Carpentier S, 2009, CRIT REV FOOD SCI, V49, P313, DOI 10.1080/10408390802066979
   Chan CM, 2008, MOL VIS, V14, P2528
   Chang CH, 2017, PHARM BIOL, V55, P571, DOI 10.1080/13880209.2016.1263344
   Chang YC, 2014, FRONT AGING NEUROSCI, V6, DOI 10.3389/fnagi.2014.00191
   Charteris DG, 2002, EYE, V16, P369, DOI 10.1038/sj.eye.6700194
   Chen CL, 2012, ACTA OPHTHALMOL, V90, pe389, DOI 10.1111/j.1755-3768.2012.02426.x
   Chen R, 2014, MOL VIS, V20, P242
   Chen X, 2003, CLIN CANCER RES, V9, P3115
   Chew EY, 2014, JAMA OPHTHALMOL, V132, P142, DOI 10.1001/jamaophthalmol.2013.7376
   Chew EY, 2013, OPHTHALMOLOGY, V120, P1604, DOI 10.1016/j.ophtha.2013.01.021
   Chou WW, 2012, CELL IMMUNOL, V273, P79, DOI 10.1016/j.cellimm.2011.11.003
   Chung KT, 1998, CRIT REV FOOD SCI, V38, P421, DOI 10.1080/10408699891274273
   Crespy V, 2003, AM J PHYSIOL-GASTR L, V284, pG980, DOI 10.1152/ajpgi.00223.2002
   Datta S, 2017, PROG RETIN EYE RES, V60, P201, DOI 10.1016/j.preteyeres.2017.03.002
   DECSI T, 2019, THE AMERICAN JOURNAL, V94, p1914s, DOI DOI 10.3945/ajcn.110.000893
   Evans JR, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000253.pub3
   Falavarjani KG, 2013, EYE, V27, P787, DOI 10.1038/eye.2013.107
   FERRETTI C, 1988, Pharmacological Research Communications, V20, P150, DOI 10.1016/S0031-6989(88)80280-7
   Ford KM, 2011, INVEST OPHTH VIS SCI, V52, P9478, DOI 10.1167/iovs.11-8353
   Gehrs KM, 2006, ANN MED, V38, P450, DOI 10.1080/07853890600946724
   Gemenetzi M, 2017, EYE, V31, P1, DOI 10.1038/eye.2016.208
   Guo Y, 2015, J NUTR BIOCHEM, V26, P201, DOI 10.1016/j.jnutbio.2014.10.008
   HANDELMAN GJ, 1988, INVEST OPHTH VIS SCI, V29, P850
   Hanneken A, 2006, INVEST OPHTH VIS SCI, V47, P3164, DOI 10.1167/iovs.04-1369
   Harasym J, 2014, NUTRITION, V30, P511, DOI 10.1016/j.nut.2013.08.019
   HUANG F, 2002, TOXICOLOGY, V31, P176, DOI DOI 10.1002/TOX.22032
   Huang WH, 2006, BIOSCI BIOTECH BIOCH, V70, P2371, DOI 10.1271/bbb.50698
   Hytti M, 2017, J NUTR BIOCHEM, V42, P37, DOI 10.1016/j.jnutbio.2016.12.014
   Hytti M, 2015, EXP EYE RES, V132, P208, DOI 10.1016/j.exer.2015.02.001
   Ishige K, 2001, FREE RADICAL BIO MED, V30, P433, DOI 10.1016/S0891-5849(00)00498-6
   Ishikado A, 2013, FREE RADICAL BIO MED, V65, P1506, DOI 10.1016/j.freeradbiomed.2012.12.006
   Kaarniranta K, 2013, AUTOPHAGY, V9, P973, DOI 10.4161/auto.24546
   KALT W, 2002, JOURNAL OF AGRICULTU, V56, P705, DOI DOI 10.1021/JF071998L
   Kalt W, 2010, J AGR FOOD CHEM, V58, P4001, DOI 10.1021/jf903038r
   Kauppinen A, 2016, CELL MOL LIFE SCI, V73, P1765, DOI 10.1007/s00018-016-2147-8
   Khurana S, 2013, NUTRIENTS, V5, P3779, DOI 10.3390/nu5103779
   Kim J, 2018, FOOD FUNCT, V9, P2171, DOI 10.1039/c7fo01958k
   King RE, 2005, CHEM-BIOL INTERACT, V151, P143, DOI 10.1016/j.cbi.2004.11.003
   Kook D, 2008, INVEST OPHTH VIS SCI, V49, P1712, DOI 10.1167/iovs.07-0477
   Koskela A, 2016, NUTRIENTS, V8, DOI 10.3390/nu8050284
   Koskela A, 2014, MOL VIS, V20, P760
   Kumar A, 2015, FUTURE MED CHEM, V7, P2065, DOI 10.4155/fmc.15.132
   Lamb TD, 2004, PROG RETIN EYE RES, V23, P307, DOI 10.1016/j.preteyeres.2004.03.001
   Lancon A, 2016, MOLECULES, V21, DOI 10.3390/molecules21030304
   Lee BL, 2016, NUTR RES, V36, P1402, DOI 10.1016/j.nutres.2016.11.008
   Li Y, 2013, TOXICOL APPL PHARM, V272, P726, DOI 10.1016/j.taap.2013.07.029
   Maher P, 2005, INVEST OPHTH VIS SCI, V46, P4796, DOI 10.1167/iovs.05-0397
   Maher P, 2008, EXP EYE RES, V86, P366, DOI 10.1016/j.exer.2007.11.009
   Mandal MNA, 2009, FREE RADICAL BIO MED, V46, P672, DOI 10.1016/j.freeradbiomed.2008.12.006
   Mares JA, 2011, ARCH OPHTHALMOL-CHIC, V129, P470, DOI 10.1001/archophthalmol.2010.314
   Matsumoto H, 2003, J AGR FOOD CHEM, V51, P3560, DOI 10.1021/jf034132y
   MEDINAREMON A, 2002, JOURNAL OF CLINICAL, V83, P114, DOI DOI 10.1111/BCP.12986
   Milbury PE, 2007, INVEST OPHTH VIS SCI, V48, P2343, DOI 10.1167/iovs.06-0452
   Mitter SK, 2014, AUTOPHAGY, V10, P1989, DOI 10.4161/auto.36184
   Molins B, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00808
   Moosavi F, 2016, DRUG DES DEV THER, V10, P23, DOI 10.2147/DDDT.S96936
   NAGINENI C, 2002, AGING AND DISEASE, V5, P88, DOI DOI 10.14366/AD.2014.050088
   Niture SK, 2014, FREE RADICAL BIO MED, V66, P36, DOI 10.1016/j.freeradbiomed.2013.02.008
   Oliver VF, 2015, EPIGENETICS-US, V10, P698, DOI 10.1080/15592294.2015.1060388
   Park HJ, 2006, EXP DERMATOL, V15, P589, DOI 10.1111/j.1600-0625.2006.00449.x
   PARK S, 2002, THE JOURNAL OF PHARM, V69, P334, DOI DOI 10.1111/JPHP.12691
   Querques G, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0149219
   Reboul E, 2007, BRIT J NUTR, V97, P440, DOI 10.1017/S0007114507352604
   Reuland DJ, 2013, FREE RADICAL BIO MED, V56, P102, DOI 10.1016/j.freeradbiomed.2012.11.016
   Richer S, 2013, NUTRIENTS, V5, P1989, DOI 10.3390/nu5061989
   Sampath C, 2016, PHYTOMEDICINE, V23, P200, DOI 10.1016/j.phymed.2015.12.013
   SAVOLAINEN H, 2002, JOURNAL OF APPLIED T, V12, P191, DOI DOI 10.1002/JAT.2550120307
   Scapagnini G, 2011, MOL NEUROBIOL, V44, P192, DOI 10.1007/s12035-011-8181-5
   Sheu SJ, 2010, J OCUL PHARMACOL TH, V26, P231, DOI 10.1089/jop.2009.0137
   Sobrin L, 2014, PROG RETIN EYE RES, V40, P1, DOI 10.1016/j.preteyeres.2013.12.004
   Sparrow JR, 2012, PROG RETIN EYE RES, V31, P121, DOI 10.1016/j.preteyeres.2011.12.001
   Subramani M, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-12496-z
   Sulaiman RS, 2014, EXP EYE RES, V129, P161, DOI 10.1016/j.exer.2014.10.002
   SUN M, 2002, THE JOURNAL OF BIOLO, V281, P4222, DOI DOI 10.1074/jbc.M509769200
   TIRUPULA K, 2002, PHOTOCHEMISTRY AND P, V85, P463, DOI DOI 10.1111/J.1751-1097.2008.00533.X
   Toomey CB, 2018, PROG RETIN EYE RES, V62, P38, DOI 10.1016/j.preteyeres.2017.09.001
   Tsao R, 2010, NUTRIENTS, V2, P1231, DOI 10.3390/nu2121231
   Veltmann M, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0147312
   Wang J, 2018, MOL MED REP, V17, P648, DOI 10.3892/mmr.2017.7916
   Wang TG, 2018, BMJ-BRIT MED J, V360, DOI 10.1136/bmj.j5644
   Wang Y, 2017, J FUNCT FOODS, V33, P103, DOI 10.1016/j.jff.2017.02.034
   Wang Y, 2017, EXP EYE RES, V160, P45, DOI 10.1016/j.exer.2017.04.010
   Wang Y, 2015, J SCI FOOD AGR, V95, P936, DOI 10.1002/jsfa.6765
   Warwick A, 2018, EYE, V32, P849, DOI 10.1038/eye.2017.245
   Woo JM, 2012, MOL VIS, V18, P901
   Xie XB, 2017, MOL VIS, V23, P520
   Xu JY, 2010, INVEST OPHTH VIS SCI, V51, P6665, DOI 10.1167/iovs.10-5698
   Yang P, 2006, INVEST OPHTH VIS SCI, V47, P4598, DOI 10.1167/iovs.06-0140
   Yoon SM, 2016, ARCH PHARM RES, V39, P21, DOI 10.1007/s12272-015-0683-7
   Zhan J, 2016, CURR MOL MED, V16, P487, DOI 10.2174/1566524016666160429121606
   Zhao SM, 2020, J SCI FOOD AGR, V100, P5111, DOI 10.1002/jsfa.8882
   Zhao Z, 2014, FOOD CHEM TOXICOL, V74, P216, DOI 10.1016/j.fct.2014.10.001
   Zhu W, 2015, DRUG DES DEV THER, V9, P5337, DOI 10.2147/DDDT.S84979
   Zhuang Pei, 2011, Eye Sci, V26, P23, DOI 10.3969/j.issn.1000-4432.2011.01.006
NR 99
TC 50
Z9 53
U1 1
U2 9
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 1942-0900
EI 1942-0994
J9 OXID MED CELL LONGEV
JI Oxidative Med. Cell. Longev.
PY 2019
VL 2019
AR 9682318
DI 10.1155/2019/9682318
PG 13
WC Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology
GA HT8QV
UT WOS:000464830600001
PM 31019656
OA Green Published, Green Submitted, gold
DA 2022-11-30
ER

PT J
AU Sho, K
   Takahashi, K
   Yamada, H
   Wada, M
   Nagai, Y
   Otsuji, T
   Nishikawa, M
   Mitsuma, Y
   Yamazaki, Y
   Matsumura, M
   Uyama, M
AF Sho, K
   Takahashi, K
   Yamada, H
   Wada, M
   Nagai, Y
   Otsuji, T
   Nishikawa, M
   Mitsuma, Y
   Yamazaki, Y
   Matsumura, M
   Uyama, M
TI Polypoidal choroidal vasculopathy - Incidence, demographic features, and
   clinical characteristics
SO ARCHIVES OF OPHTHALMOLOGY
LA English
DT Article
ID PIGMENT EPITHELIAL DETACHMENTS; CLINICOPATHOLOGICAL CORRELATION; MACULAR
   DEGENERATION; BLACK-WOMEN; NEOVASCULARIZATION; IPCV
AB Objective: To clarify the incidence, demographic features, and clinical characteristics of polypoidal choroidal vasculopathy (PCV) in Japanese patients.
   Methods: Consecutive patients with presumed neovascular age-related macular degeneration (AMD) who met the eligibility criteria were examined between January 1, 1999, and October 3 1, 2001. All patients underwent complete ophthalmologic examination and fluorescein and indocyanine green angiography.
   Results: Among 471 eyes of 418 patients who met the criteria, 110 eyes (23%) of 100 patients were diagnosed as having PCV and 361 eyes (77%) of 318 patients as having neovascular AMD. Mean age of patients with PCV was 68.4 years, with a male preponderance (63% of patients) involvement was mostly unilateral (90% of patients), and polypoidal vascular lesions were located mainly in the macula (85% of eyes). Retinal manifestations of PCV were characterized by serous macular detachment (52% of eyes), submacular hemorrhage (30% of eyes), and retinal pigment epithelium degeneration (10% of eyes). There were few subretinal fibrovascular proliferations (7% of eyes). Mean visual acuity was 0.31 in eyes with PCV and 0.18 in eyes with AMD. The incidence of severe visual loss (0.2 or worse) was 35% in PCV and 53% in AMD.
   Conclusions: The incidence of PCV in Japanese patients is high, and the incidence and demographic features vary in different ethnic groups. The clinical manifestations of PCV and AMD resemble each other; however, PCV is characterized by low incidence of subretinal fibrovascular proliferation, slow progression of vascular abnormality, and minimal association with conventional choroidal neovascularization. These factors seem to lead to a more favorable visual outcome in PCV compared with neovascular AMD.
C1 Kansai Med Univ, Dept Ophthalmol, Moriguchi, Osaka 570, Japan.
C3 Kansai Medical University
RP Uyama, M (通讯作者)，13-8 Ohkamedani Naizencho, Kyoto 6120047, Japan.
CR Ahuja RM, 2000, BRIT J OPHTHALMOL, V84, P479, DOI 10.1136/bjo.84.5.479
   BRESSLER NM, 1988, SURV OPHTHALMOL, V32, P375, DOI 10.1016/0039-6257(88)90052-5
   CAPONE A, 1994, ARCH OPHTHALMOL-CHIC, V112, P1091, DOI 10.1001/archopht.1994.01090200097029
   GASS JDM, 1997, STEREOSCOPIC ATLAS M, V1, P250
   KLEINER RC, 1990, RETINA-J RET VIT DIS, V10, P9, DOI 10.1097/00006982-199001010-00002
   Kwok AKH, 2002, BRIT J OPHTHALMOL, V86, P892, DOI 10.1136/bjo.86.8.892
   Lafaut BA, 2000, RETINA-J RET VIT DIS, V20, P650, DOI 10.1097/00006982-200011000-00010
   Lafaut BA, 2000, GRAEF ARCH CLIN EXP, V238, P752, DOI 10.1007/s004170000180
   MACCUMBER MW, 1994, RETINA-J RET VIT DIS, V14, P143, DOI 10.1097/00006982-199414020-00007
   Moorthy RS, 1998, OPHTHALMOLOGY, V105, P1380, DOI 10.1016/S0161-6420(98)98016-2
   Okubo A, 2002, BRIT J OPHTHALMOL, V86, P1093, DOI 10.1136/bjo.86.10.1093
   PERKOVICH BT, 1990, RETINA-J RET VIT DIS, V10, P18, DOI 10.1097/00006982-199001010-00003
   PIERAMICI DJ, 1994, ARCH OPHTHALMOL-CHIC, V112, P1043, DOI 10.1001/archopht.1994.01090200049020
   Rosa RH, 2002, ARCH OPHTHALMOL-CHIC, V120, P502
   Ross RD, 1996, RETINA-J RET VIT DIS, V16, P105, DOI 10.1097/00006982-199616020-00003
   Scassellati-Sforzolini B, 2001, RETINA-J RET VIT DIS, V21, P121, DOI 10.1097/00006982-200104000-00004
   SPAIDE RF, 1995, RETINA-J RET VIT DIS, V15, P100, DOI 10.1097/00006982-199515020-00003
   Spraul CW, 1997, KLIN MONATSBL AUGENH, V210, P405, DOI 10.1055/s-2008-1035085
   STERN RM, 1985, AM J OPHTHALMOL, V100, P560, DOI 10.1016/0002-9394(85)90682-8
   Tateiwa H, 2002, GRAEF ARCH CLIN EXP, V240, P354, DOI 10.1007/s00417-002-0459-x
   Terasaki H, 2002, BRIT J OPHTHALMOL, V86, P321, DOI 10.1136/bjo.86.3.321
   Uyama M, 2002, AM J OPHTHALMOL, V133, P639, DOI 10.1016/S0002-9394(02)01404-6
   Uyama M, 1999, ARCH OPHTHALMOL-CHIC, V117, P1035
   Yannuzzi LA, 1999, ARCH OPHTHALMOL-CHIC, V117, P1503
   Yannuzzi LA, 1998, ARCH OPHTHALMOL-CHIC, V116, P382
   Yannuzzi LA, 1997, ARCH OPHTHALMOL-CHIC, V115, P478, DOI 10.1001/archopht.1997.01100150480005
   YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001
   Yannuzzi LA, 2000, OPHTHALMOLOGY, V107, P767, DOI 10.1016/S0161-6420(99)00173-6
NR 28
TC 338
Z9 365
U1 2
U2 8
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 515 N STATE ST, CHICAGO, IL 60610 USA
SN 0003-9950
J9 ARCH OPHTHALMOL-CHIC
JI Arch. Ophthalmol.
PD OCT
PY 2003
VL 121
IS 10
BP 1392
EP 1396
DI 10.1001/archopht.121.10.1392
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 732FL
UT WOS:000185930100005
PM 14557174
DA 2022-11-30
ER

PT J
AU Bro, T
   Derebecka, M
   Jorstad, OK
   Grzybowski, A
AF Bro, Tomas
   Derebecka, Magdalena
   Jorstad, Oystein Kalsnes
   Grzybowski, Andrzej
TI Off-label use of bevacizumab for wet age-related macular degeneration in
   Europe
SO GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Article
DE Bevacizumab; Avastin; Wet AMD; Intravitreal injections; Off-label;
   Health economics
ID RANIBIZUMAB
AB Purpose To analyse current off-label use of bevacizumab for wet age-related macular degeneration (AMD) in Europe. Methods The study was conducted as a combined survey and literature review. It included the 22 most populous countries in Europe. In each country, ophthalmologists with particular knowledge about off-label treatment responded to a questionnaire. Results Answers were obtained from twenty European countries. The off-label use of bevacizumab for wet AMD greatly differed between nations; the bevacizumab proportion varied from non-existent (0%) to very high (97%). There were also large disparities within single countries (e.g. 0-80%), which were attributable to differences in regional decision-making. Both governmental institutions and national ophthalmological societies expressed highly diverging opinions on the use of off-label treatment. Intravitreal administration of bevacizumab had been a matter of legal dispute in several countries. The question about responsibility for off-label therapy mainly remained unanswered. Conclusions There was a highly varying utilization of bevacizumab between European countries. Despite an intention of a consistent approach to medical regulations, Europe has not yet reached a professional or political consensus on the ophthalmic off-label use of bevacizumab.
C1 [Bro, Tomas] Acad Hlth & Care Reg Jonkoping, Futurum, Jonkoping, Sweden.
   [Bro, Tomas] Hoglandssjukhuset, Ogonmottagningen, S-57581 Eksjo, Sweden.
   [Derebecka, Magdalena] Reg Hosp Elblag, Dept Ophthalmol, Elblag, Poland.
   [Jorstad, Oystein Kalsnes] Oslo Univ Hosp, Dept Ophthalmol, Oslo, Norway.
   [Jorstad, Oystein Kalsnes] Univ Oslo, Fac Med, Oslo, Norway.
   [Grzybowski, Andrzej] Univ Warmia & Mazury, Olsztyn, Poland.
   [Grzybowski, Andrzej] Inst Res Ophthalmol, Poznan, Poland.
C3 Futurum; University of Oslo; University of Oslo; University of Warmia &
   Mazury
RP Bro, T (通讯作者)，Acad Hlth & Care Reg Jonkoping, Futurum, Jonkoping, Sweden.; Bro, T (通讯作者)，Hoglandssjukhuset, Ogonmottagningen, S-57581 Eksjo, Sweden.
EM tomas.bro@med.lu.se
OI Bro, Tomas/0000-0003-0185-4326; Jorstad, Oystein
   Kalsnes/0000-0003-1259-0653; Grzybowski, Andrzej/0000-0002-3724-2391
FU Lund University; Futurum-Akademin for vard och halsa Region Jonkopings
   lan [FUTURUM-808791]
FX Open access funding provided by Lund University. This study was funded
   by Futurum-Akademin for vard och halsa Region Jonkopings lan (grant
   number FUTURUM-808791).
CR Aronson JK, 2017, BRIT J CLIN PHARMACO, V83, P2615, DOI 10.1111/bcp.13394
   Berg K, 2015, OPHTHALMOLOGY, V122, P146, DOI 10.1016/j.ophtha.2014.07.041
   Bundesausschuss G, 2018, ANL 4 ZUM ABSCHN K A
   Chakravarthy U, 2013, LANCET, V382, P1258, DOI 10.1016/S0140-6736(13)61501-9
   Chakravarthy U, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.04.015
   COHEN D, 2015, BMJ-BRIT MED J, V350, DOI [DOI 10.1136/BMJ.H1654, DOI 10.1136/bmj.h1654]
   COHEN D, 2014, BMJ-BRIT MED J, V348, DOI DOI 10.1136/BMJ.G2006
   Cohen D, 2018, BMJ-BRIT MED J, V362, DOI 10.1136/bmj.k4035
   Cohen SY, 2015, ANAL LIT SYNTHESE BE
   Conseil d'Etat, 2017, N 392459
   Council for Choices in Health Care in Finland, 2015, TREATM WET AGE REL M
   Council of the European Union, 2006, OFFICIAL J EUROPEAN
   den Exter A, 2014, CASEBOOK EUROPEAN UN
   Elshout M, 2018, ACTA OPHTHALMOL, V96, P770, DOI 10.1111/aos.13824
   German Ophthalmological Society & Retinological Society & Association of Ophthalmologists in Germany, 2007, STAT GERM OPHTH SOC
   Hake C-M, 2018, PRISLAPP KLAR LABEL
   Jorstad OK, 2017, ACTA OPHTHALMOL, V95, P460, DOI 10.1111/aos.13480
   Kodjikian L, 2013, OPHTHALMOLOGY, V120, P2300, DOI 10.1016/j.ophtha.2013.06.020
   Krebs I, 2013, BRIT J OPHTHALMOL, V97, P266, DOI 10.1136/bjophthalmol-2012-302391
   Kristiansen IS, 2020, ACTA OPHTHALMOL, V98, P279, DOI 10.1111/aos.14262
   Lakemedelsforsakringen, 2018, TAG ATT UTG ERS LAK
   Lakemedelsverket, 2016, INFORM FRAN LAKEMEDE, V27, P13
   Low A, 2019, BRIT J OPHTHALMOL, V103, P442, DOI 10.1136/bjophthalmol-2018-312691
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Martin W, 2018, OPHTHALMO CHIRURG, V30, P255
   Messori Andrea, 2014, Recenti Prog Med, V105, P137, DOI 10.1701/1459.16117
   National Health Fund, 2017, TREATM NEOV WET FORM
   National institute for health and care excellens, 2018, NICE GUID AG REL MAC
   Nederlands Oogheelkundig Gezelschap, 2014, RICHTL LEEFT MAC
   Norsk oftamologisk forening, 2017, NASJ KVAL OFT
   Parikh R, 2019, OPHTHALMOL RETINA, V3, P16, DOI 10.1016/j.oret.2018.08.002
   PTO, 2017, POS NAT CONS OPHTH U
   Salzer J, 2016, NEUROLOGY, V87, P2074, DOI 10.1212/WNL.0000000000003331
   Schauwvlieghe AME, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0153052
   Seregard S, 2011, OGONBLICK, P3
   Shalaby AK, 2016, EYE, V30, P1404, DOI 10.1038/eye.2016.154
   Sivertsen MS, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-20525-8
   Societa Oftalmologica Italiana, 2012, DOC CTS SOI AV
   Stanca HT, 2019, EXP THER MED, V18, P4993, DOI 10.3892/etm.2019.7858
   Styrgruppen for Svenska Makularegistret, 2017, RSRAPP ALLM 2016 SVE
   Tandvards- och lakemedelsformansverket (The Dental and Pharaceutical Benefits Agency), 2017, ANDR TANDV LAK ALLM
   The American Society of Retina Specialists, 2018, GLOB TRENDS RET SURV
   The Royal College of Ophthalmologists, 2018, NEW NICE AG REL MAC
   The Royal College of Ophthalmologists, 2018, ROYAL COLL OPHTH IS
   Tick S, 2018, J FR OPHTALMOL, V41, P862, DOI 10.1016/j.jfo.2018.06.002
   Tuuminen R, 2019, ACTA OPHTHALMOL, V97, pE808, DOI 10.1111/aos.14031
   Weda M, 2017, STUDY LABEL USE MEDI
NR 48
TC 23
Z9 25
U1 0
U2 4
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 0721-832X
EI 1435-702X
J9 GRAEF ARCH CLIN EXP
JI Graefes Arch. Clin. Exp. Ophthalmol.
PD MAR
PY 2020
VL 258
IS 3
BP 503
EP 511
DI 10.1007/s00417-019-04569-8
EA DEC 2019
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA KN4JG
UT WOS:000504890600001
PM 31889214
OA Green Published, hybrid
DA 2022-11-30
ER

PT J
AU Wysokinski, D
   Danisz, K
   Pawlowska, E
   Dorecka, M
   Romaniuk, D
   Robaszkiewicz, J
   Szaflik, M
   Szaflik, J
   Blasiak, J
   Szaflik, JP
AF Wysokinski, Daniel
   Danisz, Katarzyna
   Pawlowska, Elzbieta
   Dorecka, Mariola
   Romaniuk, Dorota
   Robaszkiewicz, Jacek
   Szaflik, Marta
   Szaflik, Jerzy
   Blasiak, Janusz
   Szaflik, Jacek P.
TI Transferrin receptor levels and polymorphism of its gene in age-related
   macular degeneration
SO ACTA BIOCHIMICA POLONICA
LA English
DT Article
DE AMD; gene polymorphism; iron; oxidative stress; TFRC; transferrin
   receptor
ID BEAVER DAM EYE; RISK-FACTORS; IRON HOMEOSTASIS; TERM INCIDENCE; DISEASE;
   SMOKING; MACULOPATHY; TOXICITY; UPDATE; HERITABILITY
AB The aim of the present study was to investigate the association of age related macular degeneration (AMD) risk with some aspects of iron homeostasis: iron concentration in serum, level of soluble transferrin receptor (sTfR), and transferrin receptor (TFRC) genetic variability. Four hundred and ninety one AMD patients and 171 controls were enrolled in the study. Restriction fragment length polymorphism PCR was employed to genotype polymorphisms of the TFRC gene, and colorimetric assays were used to determine the level of iron and sTfR. Multiple logistic regression was applied for all genotype/allelerelated analyses and the ANOVA test for iron and sTfR serum level comparison. We found that the genotypes and alleles of the c.-253G>A polymorphism of the TFRC gene were associated with AMD risk and this association was modulated by smoking status, AMD family history, living environment (rural/urban), body mass index and age. The levels of sTfR was higher in AMD patients than controls, whereas concentrations of iron did not differ in these two groups. No association was found between AMD occurrence and the p.Gly142Ser polymorphism of the TRFC gene. The results obtained suggest that transferrin receptor and variability of its gene may influence AMD risk.
C1 [Wysokinski, Daniel; Danisz, Katarzyna; Blasiak, Janusz] Univ Lodz, Dept Mol Genet, PL-90131 Lodz, Poland.
   [Pawlowska, Elzbieta] Med Univ Lodz, Dept Orthodont, Lodz, Poland.
   [Dorecka, Mariola; Romaniuk, Dorota] Med Univ Silesia, Dept Ophthalmol, Katowice, Poland.
   [Robaszkiewicz, Jacek; Szaflik, Marta] Laser Eye Microsurg Ctr, Warsaw, Poland.
   [Szaflik, Marta] Med Univ Warsaw, Szpital Dzieciatka Jezus, Dept Ophthalmol, Warsaw, Poland.
   [Szaflik, Jerzy; Szaflik, Jacek P.] Med Univ Warsaw, Dept Ophthalmol, Warsaw, Poland.
   [Szaflik, Jerzy; Szaflik, Jacek P.] Samodzielny Publ Klin Szpital Okulistyczny, Warsaw, Poland.
C3 University of Lodz; Medical University Lodz; Medical University Silesia;
   Medical University of Warsaw; Medical University of Warsaw
RP Szaflik, JP (通讯作者)，Med Univ Warsaw, Dept Ophthalmol, Warsaw, Poland.
EM szaflik@ophthalmology.pl
OI Pawlowska, Elzbieta/0000-0002-5373-4783; Dorecka,
   Mariola/0000-0003-1768-9628; Blasiak, Janusz/0000-0001-9539-9584;
   Szaflik, Jerzy/0000-0002-7601-1326
FU Polish Ministry of Science and Higher Education [N N402 248 336]
FX This work was supported by grant N N402 248 336 from Polish Ministry of
   Science and Higher Education.
CR Ambati J, 2003, SURV OPHTHALMOL, V48, P257, DOI 10.1016/S0039-6257(03)00030-4
   Anand R, 2000, OPHTHALMOLOGY, V107, P2224
   Bao W, 2012, BMC MED, V10, DOI 10.1186/1741-7015-10-119
   Blasiak J, 2011, FRONT BIOSCI-LANDMRK, V16, P1551, DOI 10.2741/3804
   Brissot P, 2012, BBA-GEN SUBJECTS, V1820, P403, DOI 10.1016/j.bbagen.2011.07.014
   Buch H, 2005, ACTA OPHTHALMOL SCAN, V83, P409, DOI 10.1111/J.1600-0420.2005.00492.x
   Chen H, 2009, INVEST OPHTH VIS SCI, V50, P1895, DOI 10.1167/iovs.08-2850
   Chiu CJ, 2001, INVEST OPHTH VIS SCI, V52, P9099
   Coleman HR, 2008, LANCET, V372, P1835, DOI 10.1016/S0140-6736(08)61759-6
   Cong RH, 2008, ANN EPIDEMIOL, V18, P647, DOI 10.1016/j.annepidem.2008.04.002
   Ding XY, 2009, PROG RETIN EYE RES, V28, P1, DOI 10.1016/j.preteyeres.2008.10.001
   Eaton JW, 2002, FREE RADICAL BIO MED, V32, P833, DOI 10.1016/S0891-5849(02)00772-4
   Edison ES, 2008, EUR J HAEMATOL, V81, P411, DOI 10.1111/j.1600-0609.2008.01143.x
   Feret A, 2007, GERIATR NURS, V28, P387, DOI 10.1016/j.gerinurse.2007.03.003
   Finger RP, 2011, BRIT J OPHTHALMOL, V95, P1061, DOI 10.1136/bjo.2010.194712
   Frank R N, 2000, Trans Am Ophthalmol Soc, V98, P109
   Ganesh SK, 2009, NAT GENET, V41, P1191, DOI 10.1038/ng.466
   Hammond CJ, 2002, OPHTHALMOLOGY, V109, P730, DOI 10.1016/S0161-6420(01)01049-1
   He XN, 2007, PROG RETIN EYE RES, V26, P649, DOI 10.1016/j.preteyeres.2007.07.004
   Hentze MW, 2004, CELL, V117, P285, DOI 10.1016/S0092-8674(04)00343-5
   Hogg RE, 2006, PROG RETIN EYE RES, V25, P249, DOI 10.1016/j.preteyeres.2005.11.002
   Jacobs A, 1976, Ciba Found Symp, P91
   Jia SP, 2008, J PHYS CHEM B, V112, P4461, DOI 10.1021/jp711528z
   Jomova K, 2011, TOXICOLOGY, V283, P65, DOI 10.1016/j.tox.2011.03.001
   Kaarniranta K, 2011, J ALZHEIMERS DIS, V24, P615, DOI 10.3233/JAD-2011-101908
   Kakhlon O, 2002, FREE RADICAL BIO MED, V33, P1037, DOI 10.1016/S0891-5849(02)01006-7
   Klein BEK, 1998, ARCH OPHTHALMOL-CHIC, V116, P219, DOI 10.1001/archopht.116.2.219
   KLEIN ML, 1994, ARCH OPHTHALMOL-CHIC, V112, P932, DOI 10.1001/archopht.1994.01090190080025
   Klein R, 2003, OPHTHALMOLOGY, V110, P636, DOI 10.1016/S0161-6420(02)01448-3
   Kohgo Y, 2008, INT J HEMATOL, V88, P7, DOI 10.1007/s12185-008-0120-5
   Fernandez-Real JM, 2010, EUR J CLIN INVEST, V40, P600, DOI 10.1111/j.1365-2362.2010.02306.x
   McConnell V, 2005, Ulster Med J, V74, P82
   Milton RC, 2005, OPHTHALMOLOGY, V112, P533, DOI 10.1016/j.ophtha.2004.10.047
   Montezuma Sandra R, 2007, Semin Ophthalmol, V22, P229, DOI 10.1080/08820530701745140
   Munoz M, 2009, WORLD J GASTROENTERO, V15, P4617, DOI 10.3748/wjg.15.4617
   Nadadur SS, 2008, INDIAN J MED RES, V128, P533
   Njajou OT, 2006, HUM HERED, V61, P222, DOI 10.1159/000094777
   Owen CG, 2012, BRIT J OPHTHALMOL, V96, P752, DOI 10.1136/bjophthalmol-2011-301109
   Ponka P, 1999, INT J BIOCHEM CELL B, V31, P1111, DOI 10.1016/S1357-2725(99)00070-9
   Sanfilippo PG, 2010, SURV OPHTHALMOL, V55, P561, DOI 10.1016/j.survophthal.2010.07.003
   SanGiovanni JP, 2007, ARCH OPHTHALMOL-CHIC, V125, P671, DOI 10.1001/archopht.125.5.671
   Scholl HPN, 2007, MOL VIS, V13, P196
   Seddon JM, 2006, HUM HERED, V61, P157, DOI 10.1159/000094141
   Seddon JM, 2006, ARCH OPHTHALMOL-CHIC, V124, P995, DOI 10.1001/archopht.124.7.995
   Shahid H, 2012, BRIT J OPHTHALMOL, V96, P427, DOI 10.1136/bjophthalmol-2011-300193
   Tan JSL, 2007, ARCH OPHTHALMOL-CHIC, V125, P1089, DOI 10.1001/archopht.125.8.1089
   Theil EC, 2009, CHEM REV, V109, P4568, DOI 10.1021/cr900052g
   Tomany SC, 2004, OPHTHALMOLOGY, V111, P1280, DOI 10.1016/j.ophtha.2003.11.010
   Ullah AZD, 2012, NUCLEIC ACIDS RES, V40, pW65, DOI 10.1093/nar/gks364
   Vojnikovic B, 2007, COLLEGIUM ANTROPOL, V31, P43
   Wang JJ, 2008, OPHTHALMOLOGY, V115, P693, DOI 10.1016/j.ophtha.2007.05.038
   Wong RW, 2007, RETINA-J RET VIT DIS, V27, P997, DOI 10.1097/IAE.0b013e318074c290
   Wysokinski D, 2013, EXP EYE RES, V106, P14, DOI 10.1016/j.exer.2012.10.003
   Wysokinski D, 2011, TOHOKU J EXP MED, V223, P253, DOI 10.1620/tjem.223.253
   Yuan HY, 2006, NUCLEIC ACIDS RES, V34, pW635, DOI 10.1093/nar/gkl236
NR 55
TC 13
Z9 13
U1 0
U2 3
PU ACTA BIOCHIMICA POLONICA
PI WARSAW
PA PASTEURA 3, 02-093 WARSAW, POLAND
SN 0001-527X
EI 1734-154X
J9 ACTA BIOCHIM POL
JI Acta Biochim. Pol.
PY 2015
VL 62
IS 2
BP 177
EP 184
DI 10.18388/abp.2014_843
PG 8
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology
GA CM0JF
UT WOS:000357363500003
PM 25915522
OA Green Submitted, gold
DA 2022-11-30
ER

PT J
AU Ohno-Matsui, K
AF Ohno-Matsui, Kyoko
TI Parallel findings in age-related macular degeneration and Alzheimer's
   disease
SO PROGRESS IN RETINAL AND EYE RESEARCH
LA English
DT Article
DE Age-related macular degeneration; Alzheimer's disease; Drusen; Amyloid
   beta; Senile plaque; Complement activation
ID ENDOTHELIAL GROWTH-FACTOR; COMPLEMENT FACTOR-H; GLYCATION END-PRODUCTS;
   AMYLOID-BETA PEPTIDE; RETINAL-PIGMENT EPITHELIUM; TRANSGENIC MOUSE
   MODEL; OXIDATIVE STRESS; A-BETA; APOLIPOPROTEIN-E; MONOCLONAL-ANTIBODY
AB Age is a common risk factor for Alzheimer's disease (AD) and age-related macular degeneration (AMD). Because of the increasing age of the population, these two age-related diseases have recently received a great deal of attention. In addition to age as a risk factor, AD and AMD have many characteristics in common. An important characteristic common to both diseases is the presence of amyloid beta (A beta) in the senile plaques of the AD brain and in the drusen of AMD patients. We have focused on the role of A beta as a key regulator of the progression from drusen to AMD, and our results have shown that A beta causes an imbalance of angiogenesis-related factors in the retinal pigment epithelial (RPE) cells. Mice that lack the A beta-degrading enzyme neprilysin develop RPE degeneration, and the sub-RPE deposits that are formed have features similar to those of AMD in humans. These data suggest that a common pathogenic mechanism might exist between AMD and AD. Thus, therapeutic approaches that have targeted A beta in patients with AD can also be applied to AMD. In this review, we summarise recent findings on the shared characteristics and perspectives between AMD and AD, beginning with the mechanism of A beta deposition and including a discussion of A beta-targeted therapeutic approaches for both AD and AMD. (C) 2011 Elsevier Ltd. All rights reserved.
C1 Tokyo Med & Dent Univ, Dept Ophthalmol & Visual Sci, Bunkyo Ku, Tokyo 1138510, Japan.
C3 Tokyo Medical & Dental University (TMDU)
RP Ohno-Matsui, K (通讯作者)，Tokyo Med & Dent Univ, Dept Ophthalmol & Visual Sci, Bunkyo Ku, 1-5-45 Yushima, Tokyo 1138510, Japan.
EM k.ohno.oph@tmd.ac.jp
CR ABRAHAM CR, 1988, CELL, V52, P487, DOI 10.1016/0092-8674(88)90462-X
   AKIYAMA H, 1991, J NEUROIMMUNOL, V32, P19, DOI 10.1016/0165-5728(91)90067-H
   Akiyama H, 2000, NEUROBIOL AGING, V21, P383, DOI 10.1016/S0197-4580(00)00124-X
   Anderson DH, 2004, EXP EYE RES, V78, P243, DOI 10.1016/j.exer.2003.10.011
   Anderson DH, 2001, AM J OPHTHALMOL, V131, P767, DOI 10.1016/S0002-9394(00)00961-2
   Anderson DH, 2010, PROG RETIN EYE RES, V29, P95, DOI 10.1016/j.preteyeres.2009.11.003
   Anderton BH, 1997, PHILOS T ROY SOC B, V352, P1781, DOI 10.1098/rstb.1997.0162
   Anthony JC, 2000, NEUROLOGY, V54, P2066, DOI 10.1212/WNL.54.11.2066
   Atwood CS, 2002, PEPTIDES, V23, P1343, DOI 10.1016/S0196-9781(02)00070-0
   Baker ML, 2009, ARCH OPHTHALMOL-CHIC, V127, P667, DOI 10.1001/archophthalmol.2009.30
   BARANY M, 1985, LANCET, V1, P517
   BAUER J, 1991, FEBS LETT, V285, P111, DOI 10.1016/0014-5793(91)80737-N
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   Bonifati DM, 2007, MOL IMMUNOL, V44, P999, DOI 10.1016/j.molimm.2006.03.007
   Boscolo E, 2007, INT J MOL MED, V19, P581
   BREITNER JCS, 1995, NEUROBIOL AGING, V16, P523, DOI 10.1016/0197-4580(95)00049-K
   Brennan LA, 2009, EXP EYE RES, V88, P195, DOI 10.1016/j.exer.2008.05.018
   BRESSLER SB, 1990, ARCH OPHTHALMOL-CHIC, V108, P1442, DOI 10.1001/archopht.1990.01070120090035
   Bruban J, 2009, AGING CELL, V8, P162, DOI 10.1111/j.1474-9726.2009.00456.x
   Bryleva EY, 2010, P NATL ACAD SCI USA, V107, P3081, DOI 10.1073/pnas.0913828107
   Butovsky O, 2006, P NATL ACAD SCI USA, V103, P11784, DOI 10.1073/pnas.0604681103
   Butterfield DA, 2004, BRAIN PATHOL, V14, P426
   Cameron B, 2010, NEUROBIOL DIS, V37, P503, DOI 10.1016/j.nbd.2009.10.006
   Carmi Y, 2009, J IMMUNOL, V183, P4705, DOI 10.4049/jimmunol.0901511
   Chakravarthy U, 2010, BMC OPHTHALMOL, V10, DOI 10.1186/1471-2415-10-31
   Chen L, 2002, OCUL IMMUNOL INFLAMM, V10, P27, DOI 10.1076/ocii.10.1.27.10328
   Chi ZL, 2010, ADV EXP MED BIOL, V703, P127, DOI 10.1007/978-1-4419-5635-4_9
   Chong EWT, 2008, ARCH OPHTHALMOL-CHIC, V126, P826, DOI 10.1001/archopht.126.6.826
   Chong EWT, 2007, BMJ-BRIT MED J, V335, P755, DOI 10.1136/bmj.39350.500428.47
   Chong NHV, 2005, AM J PATHOL, V166, P241, DOI 10.1016/S0002-9440(10)62248-1
   Christen WG, 2009, OPHTHALMOLOGY, V116, P2386, DOI 10.1016/j.ophtha.2009.05.031
   Combadiere C, 2007, J CLIN INVEST, V117, P2920, DOI 10.1172/JCI31692
   Corcoran JPT, 2004, EUR J NEUROSCI, V20, P896, DOI 10.1111/j.1460-9568.2004.03563.x
   CORIA F, 1988, LAB INVEST, V58, P454
   Darvesh AS, 2010, EXPERT REV NEUROTHER, V10, P729, DOI 10.1586/ERN.10.42
   Dawson DW, 1999, SCIENCE, V285, P245, DOI 10.1126/science.285.5425.245
   Dei R, 2002, ACTA NEUROPATHOL, V104, P113, DOI 10.1007/s00401-002-0523-y
   Dentchev T, 2003, MOL VIS, V9, P184
   Desai BS, 2009, J NEURAL TRANSM, V116, P587, DOI 10.1007/s00702-009-0226-9
   Dewan A, 2006, SCIENCE, V314, P989, DOI 10.1126/science.1133807
   Ding JD, 2008, VISION RES, V48, P339, DOI 10.1016/j.visres.2007.07.025
   Donoso LA, 2006, SURV OPHTHALMOL, V51, P137, DOI 10.1016/j.survophthal.2005.12.001
   DOWSON JH, 1982, BRIT J PSYCHIAT, V140, P142, DOI 10.1192/bjp.140.2.142
   Dutescu RM, 2009, GRAEF ARCH CLIN EXP, V247, P1213, DOI 10.1007/s00417-009-1060-3
   Edwards Albert O., 2007, Angiogenesis, V10, P119, DOI 10.1007/s10456-007-9064-2
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Eikelenboom P, 1996, NEUROBIOL AGING, V17, P673
   EIKELENBOOM P, 1982, ACTA NEUROPATHOL, V57, P239, DOI 10.1007/BF00685397
   Ershov AV, 2000, J NEUROSCI RES, V60, P328, DOI 10.1002/(SICI)1097-4547(20000501)60:3<328::AID-JNR7>3.0.CO;2-5
   Faller P, 2009, CHEMBIOCHEM, V10, P2837, DOI 10.1002/cbic.200900321
   Fariss RN, 1998, BRIT J OPHTHALMOL, V82, P1329, DOI 10.1136/bjo.82.11.1329
   FEENEY L, 1978, INVEST OPHTH VIS SCI, V17, P583
   FEENEYBURNS L, 1984, INVEST OPHTH VIS SCI, V25, P195
   Fotuhi M, 2009, NAT CLIN PRACT NEURO, V5, P140, DOI 10.1038/ncpneuro1044
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Fu HJ, 2010, CNS NEUROL DISORD-DR, V9, P197, DOI 10.2174/187152710791012017
   FUKUCHI K, 1998, FRONT BIOSCI, V21, P327
   Gehrs KM, 2006, ANN MED, V38, P450, DOI 10.1080/07853890600946724
   GLENNER GG, 1984, BIOCHEM BIOPH RES CO, V120, P885, DOI 10.1016/S0006-291X(84)80190-4
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   GOLLIN PA, 1992, NEUROREPORT, V3, P201, DOI 10.1097/00001756-199202000-00020
   Good PF, 1996, AM J PATHOL, V149, P21
   Green WR, 1999, AGE RELATED MACULAR, P81
   Haass C, 2007, NAT REV MOL CELL BIO, V8, P101, DOI 10.1038/nrm2101
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   HAGEMAN GS, 1999, MOL VIS, V3, P28
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Hamilton G, 2007, NEUROMOL MED, V9, P331, DOI 10.1007/s12017-007-8013-y
   HARDY JA, 1992, SCIENCE, V256, P184, DOI 10.1126/science.1566067
   HARRINGTON CR, 1993, BIOCHIM BIOPHYS ACTA, V1158, P120, DOI 10.1016/0304-4165(93)90005-S
   Hashimoto T, 2002, EMBO J, V21, P1524, DOI 10.1093/emboj/21.7.1524
   Hebert LE, 2003, ARCH NEUROL-CHICAGO, V60, P1119, DOI 10.1001/archneur.60.8.1119
   Higuchi M, 2005, NAT NEUROSCI, V8, P527, DOI 10.1038/nn1422
   Hillmen P, 2004, NEW ENGL J MED, V350, P552, DOI 10.1056/NEJMoa031688
   Hirtz D, 2007, NEUROLOGY, V68, P326, DOI 10.1212/01.wnl.0000252807.38124.a3
   Huttunen HJ, 2008, NEURODEGENER DIS, V5, P212, DOI 10.1159/000113705
   Inoue I, 1998, BIOCHEM BIOPH RES CO, V246, P370, DOI 10.1006/bbrc.1998.8622
   Isas JM, 2010, INVEST OPHTH VIS SCI, V51, P1304, DOI 10.1167/iovs.09-4207
   Ishibashi T, 1998, ARCH OPHTHALMOL-CHIC, V116, P1629, DOI 10.1001/archopht.116.12.1629
   ISHII T, 1976, ACTA NEUROPATHOL, V36, P243, DOI 10.1007/BF00685368
   ISSEMANN I, 1990, NATURE, V347, P645, DOI 10.1038/347645a0
   IWAMOTO N, 1994, NEUROSCI LETT, V177, P23, DOI 10.1016/0304-3940(94)90035-3
   Iwata N, 2002, J NEUROSCI RES, V70, P493, DOI 10.1002/jnr.10390
   Iwata N, 2001, SCIENCE, V292, P1550, DOI 10.1126/science.1059946
   Janssen BJC, 2007, J BIOL CHEM, V282, P29241, DOI 10.1074/jbc.M704587200
   Jick H, 2000, LANCET, V356, P1627, DOI 10.1016/S0140-6736(00)03155-X
   Johnson LV, 2001, EXP EYE RES, V73, P887, DOI 10.1006/exer.2001.1094
   Johnson LV, 2002, P NATL ACAD SCI USA, V99, P11830, DOI 10.1073/pnas.192203399
   Johnson PT, 2006, P NATL ACAD SCI USA, V103, P17456, DOI 10.1073/pnas.0606234103
   Jucker M, 1996, MOL CHEM NEUROPATHOL, V28, P209, DOI 10.1007/BF02815224
   Kalaria RN, 1998, MOL BRAIN RES, V62, P101, DOI 10.1016/S0169-328X(98)00190-9
   Kam JH, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013127
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Kayed R, 2003, SCIENCE, V300, P486, DOI 10.1126/science.1079469
   KELLER H, 1993, ANN NY ACAD SCI, V684, P157, DOI 10.1111/j.1749-6632.1993.tb32279.x
   Khandhadia S, 2010, EXPERT REV MOL MED, V12, DOI 10.1017/S146239941000164X
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Klunk WE, 2004, ANN NEUROL, V55, P306, DOI 10.1002/ana.20009
   Koronyo-Hamaoui M, 2011, NEUROIMAGE, V54, pS204, DOI 10.1016/j.neuroimage.2010.06.020
   Kurji KH, 2010, INVEST OPHTH VIS SCI, V51, P1151, DOI 10.1167/iovs.09-3622
   Landa G, 2011, J OCUL PHARMACOL TH, V27, P77, DOI 10.1089/jop.2010.0109
   Landa G, 2008, CURR EYE RES, V33, P1011, DOI 10.1080/02713680802484637
   Le Fur I, 2010, NEUROBIOL AGING, V31, P165, DOI 10.1016/j.neurobiolaging.2008.03.003
   Lee CS, 2009, ARTERIOSCL THROM VAS, V29, P472, DOI 10.1161/ATVBAHA.108.176230
   Lengyel I, 2007, EXP EYE RES, V84, P772, DOI 10.1016/j.exer.2006.12.015
   Li YK, 2003, J NEUROSCI, V23, P1605
   Liang FQ, 2003, EXP EYE RES, V76, P397, DOI 10.1016/S0014-4835(03)00023-X
   Liu BQ, 2009, AM J PATHOL, V175, P2099, DOI 10.2353/ajpath.2009.090159
   LOEFFLER KU, 1993, INVEST OPHTH VIS SCI, V34, P2600
   Luchsinger JA, 2004, LANCET NEUROL, V3, P579, DOI 10.1016/S1474-4422(04)00878-6
   Luibl V, 2006, J CLIN INVEST, V116, P378, DOI 10.1172/JCI25843
   Ma KN, 2010, INVEST OPHTH VIS SCI, V51, P6776, DOI 10.1167/iovs.10-5887
   Ma WC, 2007, INVEST OPHTH VIS SCI, V48, P1355, DOI 10.1167/iovs.06-0738
   Ma WX, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007945
   Malek G, 2003, AM J PATHOL, V162, P413, DOI 10.1016/S0002-9440(10)63836-9
   Mandrekar-Colucci S, 2010, CNS NEUROL DISORD-DR, V9, P156, DOI 10.2174/187152710791012071
   Martins IJ, 2009, J NEUROCHEM, V111, P1275, DOI 10.1111/j.1471-4159.2009.06408.x
   MCGEER PL, 1989, NEUROSCI LETT, V107, P341, DOI 10.1016/0304-3940(89)90843-4
   MCGEER PL, 1992, RES IMMUNOL, V143, P621, DOI 10.1016/0923-2494(92)80045-M
   Miller LM, 2006, J STRUCT BIOL, V155, P30, DOI 10.1016/j.jsb.2005.09.004
   Moos T, 2000, CELL MOL NEUROBIOL, V20, P77, DOI 10.1023/A:1006948027674
   MORI H, 1987, SCIENCE, V235, P1641, DOI 10.1126/science.3029875
   Morikis D, 1998, PROTEIN SCI, V7, P619, DOI 10.1002/pro.5560070311
   Mullins RF, 2000, FASEB J, V14, P835, DOI 10.1096/fasebj.14.7.835
   Murata T, 2000, INVEST OPHTH VIS SCI, V41, P2309
   NEWSOME DA, 1987, AM J OPHTHALMOL, V104, P373, DOI 10.1016/0002-9394(87)90227-3
   Ni Z, 2009, OPHTHALMOLOGICA, V223, P401, DOI 10.1159/000228926
   Ning A, 2008, INVEST OPHTH VIS SCI, V49, P5136, DOI 10.1167/iovs.08-1849
   Nishiyama E, 1997, BRAIN RES, V750, P20, DOI 10.1016/S0006-8993(96)01329-7
   Nozaki M, 2006, P NATL ACAD SCI USA, V103, P2328, DOI 10.1073/pnas.0408835103
   NUKINA N, 1988, NEUROSCI LETT, V87, P240, DOI 10.1016/0304-3940(88)90455-7
   Ohno-Matsui K, 2001, J CELL PHYSIOL, V189, P323, DOI 10.1002/jcp.10026
   Parisi V, 2001, CLIN NEUROPHYSIOL, V112, P1860, DOI 10.1016/S1388-2457(01)00620-4
   Penfold PL, 2001, PROG RETIN EYE RES, V20, P385, DOI 10.1016/S1350-9462(00)00025-2
   Perez SE, 2009, INVEST OPHTH VIS SCI, V50, P793, DOI 10.1167/iovs.08-2384
   PERLMUTTER LS, 1992, J NEUROSCI RES, V33, P549, DOI 10.1002/jnr.490330407
   Prakasam A, 2010, J ALZHEIMERS DIS, V20, P1243, DOI 10.3233/JAD-2010-100210
   Priller C, 2006, J NEUROSCI, V26, P7212, DOI 10.1523/JNEUROSCI.1450-06.2006
   Querfurth HW, 2010, NEW ENGL J MED, V362, P329, DOI 10.1056/NEJMra0909142
   Reichwald J, 2009, J NEUROINFLAMM, V6, DOI 10.1186/1742-2094-6-35
   Reynolds R, 2009, INVEST OPHTH VIS SCI, V50, P5818, DOI 10.1167/iovs.09-3928
   Ricchieri G L, 1983, Acta Neurol (Napoli), V5, P103
   Ricklin D, 2008, ADV EXP MED BIOL, V632, P273, DOI 10.1007/978-0-387-78952-1_20
   Ricklin D, 2007, NAT BIOTECHNOL, V25, P1265, DOI 10.1038/nbt1342
   Rofstad EK, 2000, CANCER RES, V60, P4932
   Rogala E, 2001, ANTICANCER RES, V21, P4259
   ROGERS J, 1992, P NATL ACAD SCI USA, V89, P10016, DOI 10.1073/pnas.89.21.10016
   Rohrer B, 2010, ADV EXP MED BIOL, V703, P137, DOI 10.1007/978-1-4419-5635-4_10
   Roychaudhuri R, 2009, J BIOL CHEM, V284, P4749, DOI 10.1074/jbc.R800036200
   Russo R, 2005, FEBS LETT, V579, P6027, DOI 10.1016/j.febslet.2005.09.054
   Saido TC, 2006, NEUROSCI RES, V54, P235, DOI 10.1016/j.neures.2005.12.015
   Scholl HPN, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002593
   Schrader M, 2006, BBA-MOL CELL RES, V1763, P1755, DOI 10.1016/j.bbamcr.2006.09.006
   Shen Y, 1998, BRAIN RES, V796, P187, DOI 10.1016/S0006-8993(98)00346-1
   SHIRAHAMA T, 1982, AM J PATHOL, V107, P41
   Shirotani K, 2001, J BIOL CHEM, V276, P21895, DOI 10.1074/jbc.M008511200
   Smith MA, 2000, BBA-MOL BASIS DIS, V1502, P139, DOI 10.1016/S0925-4439(00)00040-5
   Song F, 2009, BRAIN RES REV, V61, P69, DOI 10.1016/j.brainresrev.2009.05.003
   Spencer KL, 2008, HUM MOL GENET, V17, P1821, DOI 10.1093/hmg/ddn075
   STONE WL, 1979, EXP EYE RES, V28, P387, DOI 10.1016/0014-4835(79)90114-3
   Strohmeyer R, 2000, MOL BRAIN RES, V81, P7, DOI 10.1016/S0169-328X(00)00149-2
   Szekely CA, 2010, CNS NEUROL DISORD-DR, V9, P132, DOI 10.2174/187152710791012026
   Tarkowski E, 2002, NEUROBIOL AGING, V23, P237, DOI 10.1016/S0197-4580(01)00285-8
   Terai K, 2001, NEUROSCIENCE, V104, P299, DOI 10.1016/S0306-4522(01)00095-1
   Terni B, 2010, BRAIN PATHOL, V20, P222, DOI 10.1111/j.1750-3639.2009.00266.x
   TOMBRANTINK J, 1991, EXP EYE RES, V53, P411, DOI 10.1016/0014-4835(91)90248-D
   Tsai KJ, 2009, NEUROSCIENCE, V159, P638, DOI 10.1016/j.neuroscience.2008.12.045
   Umeda S, 2005, FASEB J, V19, P1683, DOI 10.1096/fj.04-3525fje
   Urieli-Shoval S, 2000, CURR OPIN HEMATOL, V7, P64, DOI 10.1097/00062752-200001000-00012
   VANDERSCHAFT TL, 1993, BRIT J OPHTHALMOL, V77, P657, DOI 10.1136/bjo.77.10.657
   VITEK MP, 1994, P NATL ACAD SCI USA, V91, P4766, DOI 10.1073/pnas.91.11.4766
   Voronov E, 2003, P NATL ACAD SCI USA, V100, P2645, DOI 10.1073/pnas.0437939100
   Walsh DM, 2007, J NEUROCHEM, V101, P1172, DOI 10.1111/j.1471-4159.2006.04426.x
   Wang JY, 2008, J IMMUNOL, V181, P712, DOI 10.4049/jimmunol.181.1.712
   Wang JY, 2009, J CELL PHYSIOL, V220, P119, DOI 10.1002/jcp.21742
   Wang L, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010329
   Watson GS, 2005, AM J GERIAT PSYCHIAT, V13, P950, DOI 10.1176/appi.ajgp.13.11.950
   Wilson HL, 2004, AM J OPHTHALMOL, V137, P615, DOI 10.1016/j.ajo.2003.10.025
   Wolozin B, 2004, CNS DRUG REV, V10, P127
   Wong TY, 2006, OPHTHALMOLOGY, V113, P255, DOI 10.1016/j.ophtha.2005.10.048
   Wyss-Coray T, 2002, NEURON, V35, P419, DOI 10.1016/S0896-6273(02)00794-8
   Yamakawa K, 2000, BIOCHEM BIOPH RES CO, V271, P571, DOI 10.1006/bbrc.2000.2665
   Yan SD, 1996, NATURE, V382, P685, DOI 10.1038/382685a0
   Yang SP, 2004, NEUROBIOL AGING, V25, P283, DOI 10.1016/S0197-4580(03)00111-8
   Yang ZL, 2006, SCIENCE, V314, P992, DOI 10.1126/science.1133811
   Yasojima K, 1999, AM J PATHOL, V154, P927, DOI 10.1016/S0002-9440(10)65340-0
   Yasuda M, 2009, OPHTHALMOLOGY, V116, P2135, DOI 10.1016/j.ophtha.2009.04.017
   Yates JRW, 2007, NEW ENGL J MED, V357, P553, DOI 10.1056/NEJMoa072618
   Yoshida T, 2005, J CLIN INVEST, V115, P2793, DOI 10.1172/JCI24635
   Zamiri Parisa, 2007, Chem Immunol Allergy, V92, P86, DOI 10.1159/000099259
   Zanjani H, 2005, ALZ DIS ASSOC DIS, V19, P55, DOI 10.1097/01.wad.0000165506.60370.94
   Zetterberg M, 2008, AM J MED GENET B, V147B, P720, DOI 10.1002/ajmg.b.30668
NR 192
TC 190
Z9 199
U1 2
U2 28
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 1350-9462
EI 1873-1635
J9 PROG RETIN EYE RES
JI Prog. Retin. Eye Res.
PD JUL
PY 2011
VL 30
IS 4
BP 217
EP 238
DI 10.1016/j.preteyeres.2011.02.004
PG 22
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 791OC
UT WOS:000292673500001
PM 21440663
DA 2022-11-30
ER

PT J
AU Wang, T
   Xia, J
   Yuan, M
   Wu, XH
   Zhu, Y
   Chen, C
   Bergunder, SJ
   Liu, ZZ
   Chen, WB
   Huang, K
   Lin, HT
AF Wang, Ting
   Xia, Jun
   Yuan, Meng
   Wu, Xiaohang
   Zhu, Yi
   Chen, Chuan
   Bergunder, Sean J.
   Liu, Zhenzhen
   Chen, Wenben
   Huang, Kai
   Lin, Haotian
TI Hypertension affects the treatment of wet age-related macular
   degeneration
SO ACTA OPHTHALMOLOGICA
LA English
DT Article
DE wet age&#8208; related macular degeneration; hypertension; anti&#8208;
   VEGF treatment; vitrectomy
AB Purpose Due to population ageing as well as the high prevalence of hypertension and age-related macular degeneration (AMD) in elderly individuals, and the relationship between hypertension and AMD is unclear. Our research aimed to investigate the association between hypertension, wet AMD (wAMD) and the treatment strategy of wAMD patients affected by hypertension.
   Methods Data of wAMD patients at Zhongshan Ophthalmic Center, Sun Yat-sen University, between 1 January 2002 and 30 June 2019, were extracted from the electronic healthcare information system. wAMD patients were divided into subgroups by hypertension status, age, sex, the need for vitrectomy surgery and the number of anti-VEGF drug intravitreal injections that these were divided in 1-3 vs. >3 (available time from 1 January 2012 to 30 June 2019).
   Results A total of 3096 wAMD patients (41.7% female, 58.3% male) with an age range of 50-96 years (68.7 (SD 9.42) years) were included. wAMD was significantly associated with hypertension (p < 0.001). After adjustment for sex and age, Cox regression model showed a significant association between hypertension in wAMD patients and the number of injections (RR = 1.31, 95% CI: 1.13-1.50, p < 0.001). There was no significant association between hypertension and the need for vitrectomy (p = 0.82).
   Conclusions wet AMD was associated with hypertension status, and after the regular series of three injections, wAMD patients with hypertension were more likely to receive anti-VEGF drug intravitreal injections than those without hypertension. These results may facilitate prospective research on the prevention of wAMD and contribute to the management of wAMD patients.
C1 [Wang, Ting; Yuan, Meng; Wu, Xiaohang; Liu, Zhenzhen; Chen, Wenben; Lin, Haotian] Sun Yat Sen Univ, Zhongshan Ophthalm Ctr, State Key Lab Ophthalmol, Guangzhou, Peoples R China.
   [Xia, Jun] Sun Yat Sen Univ, Key Lab Machine Intelligence & Adv Comp, Guangzhou, Peoples R China.
   [Zhu, Yi] Univ Miami, Miller Sch Med, Dept Mol & Cellular Pharmacol, Miami, FL 33136 USA.
   [Chen, Chuan] Univ Miami, Miller Sch Med, Sylvester Comprehens Canc Ctr, Miami, FL 33136 USA.
   [Bergunder, Sean J.] R&D Ctr Ophthalm Cutting Edge Technol & Med Devic, Jihua Lab, Foshan, Guangdong, Peoples R China.
   [Lin, Haotian] Sun Yat Sen Univ, Ctr Precis Med, Guangzhou, Peoples R China.
C3 Sun Yat Sen University; Sun Yat Sen University; University of Miami;
   University of Miami; Ji Hua Laboratory; Sun Yat Sen University
RP Lin, HT (通讯作者)，Sun Yat Sen Univ, Zhongshan Ophthalm Ctr, Xian Lie South Rd 54, Guangzhou 510060, Peoples R China.
EM haot.lin@hotmail.com
FU National Key R&D Program of China [2018YFC0116500] Funding Source:
   Medline
CR [Anonymous], 2015, RETINAVITREOUS PANEL
   Bourne RRA, 2013, LANCET GLOB HEALTH, V1, pE339, DOI 10.1016/S2214-109X(13)70113-X
   Cascella R, 2014, J OPHTHALMOL, V2014, DOI 10.1155/2014/582842
   Cheung CMG, 2014, J INTERN MED, V276, P140, DOI 10.1111/joim.12227
   Choudhury F, 2011, AM J OPHTHALMOL, V152, P385, DOI 10.1016/j.ajo.2011.02.025
   Drummond GR, 2019, NAT REV IMMUNOL, V19, P517, DOI 10.1038/s41577-019-0160-5
   Kim SJ, 2015, SCI REP-UK, V5, DOI 10.1038/srep11872
   Kitagawa Y, 2016, OPHTHALMOLOGY, V123, P1278, DOI 10.1016/j.ophtha.2016.01.035
   Klaver CCW, 2001, INVEST OPHTH VIS SCI, V42, P2237
   Klein Ronald, 2003, Ophthalmology, V110, P1273, DOI 10.1016/S0161-6420(03)00599-2
   Klein R, 2013, OPHTHALMOLOGY, V120, P1012, DOI 10.1016/j.ophtha.2012.11.003
   Kulkarni PS, 1999, INVEST OPHTH VIS SCI, V40, P721
   Li Y, 2019, FASEB J, V33, P8555, DOI 10.1096/fj.201900060R
   Metelitsina TI, 2008, INVEST OPHTH VIS SCI, V49, P358, DOI 10.1167/iovs.07-0526
   Metelitsina TI, 2006, BRIT J OPHTHALMOL, V90, P342, DOI 10.1136/bjo.2005.082974
   Otani A, 2001, DIABETES, V50, P867, DOI 10.2337/diabetes.50.4.867
   Park SJ, 2014, OPHTHALMOLOGY, V121, P1756, DOI 10.1016/j.ophtha.2014.03.022
   Pons M, 2011, AM J PATHOL, V178, P2665, DOI 10.1016/j.ajpath.2011.02.006
   Tomany SC, 2004, OPHTHALMOLOGY, V111, P1280, DOI 10.1016/j.ophtha.2003.11.010
   Treumer F, 2017, GRAEF ARCH CLIN EXP, V255, P1115, DOI 10.1007/s00417-017-3620-2
   van Leeuwen R, 2003, INVEST OPHTH VIS SCI, V44, P3771, DOI 10.1167/iovs.03-0121
   Whelton PK, 2018, CIRCULATION, V138, pE484, DOI 10.1161/CIR.0000000000000596
   Wong T, 2007, LANCET, V369, P425, DOI 10.1016/S0140-6736(07)60198-6
   Wong TY, 2004, NEW ENGL J MED, V351, P2310, DOI 10.1056/NEJMra032865
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
NR 25
TC 0
Z9 0
U1 2
U2 8
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1755-375X
EI 1755-3768
J9 ACTA OPHTHALMOL
JI Acta Ophthalmol.
PD DEC
PY 2021
VL 99
IS 8
BP 871
EP 876
DI 10.1111/aos.14791
EA MAR 2021
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA WW9GS
UT WOS:000635081300001
PM 33787087
OA Green Published
DA 2022-11-30
ER

PT J
AU Kim, JB
   Lad, EM
AF Kim, Joon-Bom
   Lad, Eleonora M.
TI Therapeutic Options Under Development for Nonneovascular Age-Related
   Macular Degeneration and Geographic Atrophy
SO DRUGS & AGING
LA English
DT Review
ID COMPLEMENT ACTIVATION; ALZHEIMERS-DISEASE; CLINICAL-TRIAL;
   BETA-CAROTENE; DRUSEN; RISK; BRIMONIDINE; CELLS; PHOTOBIOMODULATION;
   IRRADIATION
AB Age-related macular degeneration (AMD) is a chronic, multifactorial disease and a leading cause of irreversible blindness in the elderly population in the Western Hemisphere. Among the two major subtypes of AMD, the prevalence of the nonneovascular (dry) type is approximately 85-90% and the neovascular (wet) type is 10-15%. Healthy lifestyle and nutritional supplements of anti-oxidative micronutrients have been shown to delay the progression of dry AMD and lower the risk of development of wet AMD, and anti-vascular endothelial growth factor (anti-VEGF) injections have been shown to improve visual acuity for wet AMD patients. However, to date, there is no approved treatment for geographic atrophy (GA), a debilitating late stage of dry AMD. Thus, this represents a large unmet need in this patient population. This review focuses on the current management and treatment of nonneovascular AMD, the drugs and devices that have been under investigation for the treatment of GA, and the latest clinical trial results. A few therapeutic options have shown initial promising clinical trial results, but failed to show efficacy in larger trials, while others are awaiting future clinical trial results and long-term follow-up to evaluate safety and efficacy.
C1 [Kim, Joon-Bom; Lad, Eleonora M.] Duke Univ, Duke Eye Ctr, Dept Ophthalmol, 2351 Erwin Rd, Durham, NC 27705 USA.
C3 Duke University
RP Lad, EM (通讯作者)，Duke Univ, Duke Eye Ctr, Dept Ophthalmol, 2351 Erwin Rd, Durham, NC 27705 USA.
EM nora.lad@duke.edu
CR Albarracin R, 2011, INVEST OPHTH VIS SCI, V52, P3582, DOI 10.1167/iovs.10-6664
   Aronow ME, 2014, CURR OPIN OPHTHALMOL, V25, P186, DOI 10.1097/ICU.0000000000000046
   Bavik C, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0124940
   Booij JC, 2010, PROG RETIN EYE RES, V29, P1, DOI 10.1016/j.preteyeres.2009.08.003
   BRESSLER NM, 1988, SURV OPHTHALMOL, V32, P375, DOI 10.1016/0039-6257(88)90052-5
   Brown EE, 2018, ADV EXP MED BIOL, V1074, P11, DOI 10.1007/978-3-319-75402-4_2
   Chew EY, 2013, JAMA-J AM MED ASSOC, V309, P2005, DOI 10.1001/jama.2013.4997
   Chiu CJ, 2014, AM J OPHTHALMOL, V158, P118, DOI 10.1016/j.ajo.2014.04.016
   Cousins SW, 2016, INVEST OPHTH VIS SCI, V57
   da Cruz L, 2018, NAT BIOTECHNOL, V36, P1, DOI 10.1038/nbt.4114
   Ding JD, 2008, VISION RES, V48, P339, DOI 10.1016/j.visres.2007.07.025
   Diniz B, 2013, INVEST OPHTH VIS SCI, V54, P5087, DOI 10.1167/iovs.12-11239
   Druesne-Pecollo N, 2010, INT J CANCER, V127, P172, DOI 10.1002/ijc.25008
   Dugel P, 2020, RETINA PHYS, P17
   Dugel PU., 2020, RETIN PHYS, V17, P16
   Eells JT, 2004, MITOCHONDRION, V4, P559, DOI 10.1016/j.mito.2004.07.033
   Eells JT, 2003, P NATL ACAD SCI USA, V100, P3439, DOI 10.1073/pnas.0534746100
   Erke MG, 2012, OPHTHALMOLOGY, V119, P1737, DOI 10.1016/j.ophtha.2012.03.016
   Freeman WR, 2019, INVEST OPHTH VIS SCI, V60
   Fuhrmann S, 2003, J COMP NEUROL, V461, P111, DOI 10.1002/cne.10701
   Fujimoto JG, 2000, NEOPLASIA, V2, P9, DOI 10.1038/sj.neo.7900071
   Garrity ST, 2018, INVEST OPHTH VIS SCI, V59, pAMD48, DOI 10.1167/iovs.18-24158
   Gass J D, 1971, Trans Am Acad Ophthalmol Otolaryngol, V75, P580
   Ghosn C, 2017, INVEST OPHTH VIS SCI, V58
   Gkotsi D, 2014, EXP EYE RES, V122, P50, DOI 10.1016/j.exer.2014.02.023
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   Grossman N, 1998, LASER SURG MED, V22, P212, DOI 10.1002/(SICI)1096-9101(1998)22:4<212::AID-LSM5>3.0.CO;2-S
   Guymer RH, 2019, OPHTHALMOLOGY, V126, P829, DOI 10.1016/j.ophtha.2018.09.015
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Holz FG, 2018, JAMA OPHTHALMOL, V136, P666, DOI 10.1001/jamaophthalmol.2018.1544
   Holz FG, 2014, OPHTHALMOLOGY, V121, P1079, DOI 10.1016/j.ophtha.2013.11.023
   Issa PC, 2014, INVEST OPHTH VIS SCI, V55
   Jobling AI, 2015, FASEB J, V29, P696, DOI 10.1096/fj.14-262444
   Johnson LV, 2000, EXP EYE RES, V70, P441, DOI 10.1006/exer.1999.0798
   Johnson LV, 2001, EXP EYE RES, V73, P887, DOI 10.1006/exer.2001.1094
   Johnson LV, 2002, P NATL ACAD SCI USA, V99, P11830, DOI 10.1073/pnas.192203399
   Kaiser P, 2019, AM SOC RET SPEC ANN
   Karu T, 1999, J PHOTOCH PHOTOBIO B, V49, P1, DOI 10.1016/S1011-1344(98)00219-X
   KARU T, 1995, J PHOTOCH PHOTOBIO B, V27, P219, DOI 10.1016/1011-1344(94)07078-3
   Kashani AH, 2020, OPHTHALMOL RETINA, V4, P264, DOI 10.1016/j.oret.2019.09.017
   Kashani AH, 2018, SCI TRANSL MED, V10, DOI 10.1126/scitranslmed.aao4097
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Kauper K, 2012, INVEST OPHTH VIS SCI, V53, P7484, DOI 10.1167/iovs.12-9970
   Kenney CM, 2018, ASS RES VIS OPHTH AN
   Klein R, 2002, AM J EPIDEMIOL, V156, P589, DOI 10.1093/aje/kwf092
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Klein Ronald, 2003, Ophthalmology, V110, P1273, DOI 10.1016/S0161-6420(03)00599-2
   Klein R, 2010, ARCH OPHTHALMOL-CHIC, V128, P750, DOI 10.1001/archophthalmol.2010.92
   Kuppermann B, 2019, RETINA PHYS, V28
   Landa G, 2008, CURR EYE RES, V33, P1011, DOI 10.1080/02713680802484637
   Liao DS, 2020, OPHTHALMOLOGY, V127, P186, DOI 10.1016/j.ophtha.2019.07.011
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Luibl V, 2006, J CLIN INVEST, V116, P378, DOI 10.1172/JCI25843
   Machalinska A, 2009, OPHTHALMIC RES, V42, P54, DOI 10.1159/000219686
   Maller J, 2006, NAT GENET, V38, P1055, DOI 10.1038/ng1873
   Mandai M, 2017, NEW ENGL J MED, V376, P1038, DOI 10.1056/NEJMoa1608368
   MARESPERLMAN JA, 1995, ARCH OPHTHALMOL-CHIC, V113, P743, DOI 10.1001/archopht.1995.01100060069034
   Markowitz SN, 2020, RETINA-J RET VIT DIS, V40, P1471, DOI 10.1097/IAE.0000000000002632
   Mihai DM, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.314
   Mullins RF, 2001, EYE, V15, P390, DOI 10.1038/eye.2001.142
   Ophthalmics A LLC, 2020, BAUSCH HLTH ACQUIRE
   Park DW, 2006, OPHTHALMOLOGY, V113, P1974, DOI 10.1016/j.ophtha.2006.08.015
   Parsons CG, 2015, NEUROPHARMACOLOGY, V92, P158, DOI 10.1016/j.neuropharm.2014.12.038
   Querques G, 2018, GRAEF ARCH CLIN EXP, V256, P1, DOI 10.1007/s00417-017-3848-x
   Quiroz Mercado H, 2018, ASS RES VIS OPHTH AP
   Ralston JPG, 2010, INVESTIG OPHTHALMOL, V51, P913
   Ramirez C, 2016, J OCUL PHARMACOL TH, V32, P102, DOI 10.1089/jop.2015.0083
   Riemann CD, 2020, INVEST OPHTH VIS SCI, V61
   Rosenfeld PJ, 2018, OPHTHALMOL RETINA, V2, P1028, DOI 10.1016/j.oret.2018.03.001
   Rosenfeld PJ, 2018, OPHTHALMOLOGY, V125, P1556, DOI 10.1016/j.ophtha.2018.03.059
   Saylor M, 2009, ARCH OPHTHALMOL-CHIC, V127, P402, DOI 10.1001/archophthalmol.2009.9
   Scholl HPN, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002593
   Schwartz SD, 2016, INVEST OPHTH VIS SCI, V57, DOI 10.1167/iovs.15-18681
   Schwartz SD, 2015, LANCET, V385, P509, DOI 10.1016/S0140-6736(14)61376-3
   Schwartz SD, 2012, LANCET, V379, P713, DOI 10.1016/S0140-6736(12)60028-2
   Song WK, 2015, STEM CELL REP, V4, P860, DOI 10.1016/j.stemcr.2015.04.005
   Tang J, 2013, INVEST OPHTH VIS SCI, V54, P3681, DOI 10.1167/iovs.12-11018
   Virgili G, 2015, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006537.pub3
   Wang JJ, 2014, OPHTHALMOLOGY, V121, P667, DOI 10.1016/j.ophtha.2013.10.017
   Wong-Riley MTT, 2005, J BIOL CHEM, V280, P4761, DOI 10.1074/jbc.M409650200
   Yang P, 2019, INVEST OPHTH VIS SCI, V60
   Yaspan BL, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aaf1443
   Yates JRW, 2007, NEW ENGL J MED, V357, P553, DOI 10.1056/NEJMoa072618
   Yehoshua Z, 2014, OPHTHALMOLOGY, V121, P693, DOI 10.1016/j.ophtha.2013.09.044
NR 86
TC 3
Z9 3
U1 1
U2 3
PU ADIS INT LTD
PI NORTHCOTE
PA 5 THE WAREHOUSE WAY, NORTHCOTE 0627, AUCKLAND, NEW ZEALAND
SN 1170-229X
EI 1179-1969
J9 DRUG AGING
JI Drugs Aging
PD JAN
PY 2021
VL 38
IS 1
BP 17
EP 27
DI 10.1007/s40266-020-00822-6
EA DEC 2020
PG 11
WC Geriatrics & Gerontology; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Geriatrics & Gerontology; Pharmacology & Pharmacy
GA PY3YQ
UT WOS:000601484400001
PM 33355716
DA 2022-11-30
ER

PT J
AU Serra, R
   Coscas, F
   Pinna, A
   Cabral, D
   Coscas, G
   Souied, EH
AF Serra, Rita
   Coscas, Florence
   Pinna, Antonio
   Cabral, Diogo
   Coscas, Gabriel
   Souied, Eric H.
TI Fractal analysis of polypoidal choroidal neovascularisation in
   age-related macular degeneration
SO BRITISH JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE Retina
ID COHERENCE TOMOGRAPHY ANGIOGRAPHY; OCT ANGIOGRAPHY; BLOOD-FLOW;
   VASCULOPATHY; QUANTIFICATION
AB Aim To describe optical coherence tomography angiography (OCTA) features of polypoidal choroidal neovascularisation (PCNV) secondary to age-related macular degeneration. Methods A retrospective consecutive series of 51 patients with a diagnosis of PCNV, based on clinical and multimodal imaging, was analysed. All patients with PCNV underwent a comprehensive ophthalmological examination, including fluorescein and indocyanine green angiography, structural optical coherence tomography (OCT) and OCTA. Two blinded retinal specialists carefully reviewed OCTA slabs in order to assess the morphological patterns of PCNV lesions. Furthermore, fractal analysis of PCNV en face images on OCTA, including vascular perfusion density (VPD), fractal dimension (FD) and lacunarity (LAC), was performed. Results Fifty-one PCNV eyes were included in the study. In all, the branching vascular network appeared hyper-reflective. Polyps showed two different patterns: in 34/51 (67%) eyes, they corresponded to hypo-reflective structures, whereas in the remaining 17 (33%) eyes, they appeared as hyper-reflective lesions. In all PCNV eyes, mean VPD, FD and LAC were 0.76 +/- 0.17%, 1.46 +/- 0.12 and 2.4 +/- 0.87, respectively. No significant difference was found between PCNVs showing a different OCTA pattern, in terms of quantitative OCTA parameters. Conclusion Fractal analysis provides quantitative parameters demonstrating that PCNVs with different OCTA patterns share the same neovascular architecture and branching complexity. These new findings improve our ability to interpret OCTA slabs, opening new areas of discussion about this type of neovascular lesion.
C1 [Serra, Rita] Univ Sassari, Dept Surg & Biomed Sci, Sassari, Italy.
   [Serra, Rita] Cittadella Univ Cagliari, Ist Ric Genet & Biomed IRGB, CNR, I-09042 Cagliari, Italy.
   [Serra, Rita; Coscas, Florence; Coscas, Gabriel] Ctr Ophtalmol Odeon, 113 Bd St Germain, Paris, France.
   [Serra, Rita; Coscas, Florence; Coscas, Gabriel; Souied, Eric H.] Univ Paris Est Creteil, Dept Ophthalmol, Ctr Hospitalier Intercommunal Creteil, Creteil, France.
   [Pinna, Antonio] Univ Sassari, Dept Med Surg & Expt Sci, Sassari, Italy.
   [Cabral, Diogo] Inst Oftalmologia Dr Gama Pinto, Lisbon, Portugal.
C3 University of Sassari; Consiglio Nazionale delle Ricerche (CNR);
   Istituto di Ricerca Genetica e Biomedica (IRGB-CNR); Universite
   Paris-Est-Creteil-Val-de-Marne (UPEC); CHI Creteil; University of
   Sassari
RP Coscas, F (通讯作者)，Univ Paris Est, Ctr Hospitalier Intercommunal Creteil, 40 Ave Verdun, F-94010 Creteil, France.
EM coscas.f@gmail.com
RI Pinna, Antonio/H-5067-2018
OI Pinna, Antonio/0000-0003-3052-2662; SERRA, RITA/0000-0002-6341-1435
CR Akaza Eriko, 2006, Nippon Ganka Gakkai Zasshi, V110, P288
   Al-Sheikh M, 2018, RETINA-J RET VIT DIS, V38, P220, DOI 10.1097/IAE.0000000000001628
   Ampornpruet Atchara, 2005, Journal of the Medical Association of Thailand, V88, pS51
   Anantharaman G, 2018, INDIAN J OPHTHALMOL, V66, P896, DOI 10.4103/ijo.IJO_1136_17
   Bo QY, 2019, JAMA OPHTHALMOL, V137, P642, DOI 10.1001/jamaophthalmol.2019.0449
   Chen YT, 2018, LASER SURG MED, V50, P427, DOI 10.1002/lsm.22801
   Chi YT, 2017, JAMA OPHTHALMOL, V135, P1310, DOI 10.1001/jamaophthalmol.2017.4360
   Ciardella AP, 2004, SURV OPHTHALMOL, V49, P25, DOI 10.1016/j.survophthal.2003.10.007
   Coscas F, 2019, BRIT J OPHTHALMOL, V103, P1342, DOI 10.1136/bjophthalmol-2018-313065
   Durbin MK, 2017, JAMA OPHTHALMOL, V135, P370, DOI 10.1001/jamaophthalmol.2017.0080
   Faridi A, 2017, OPHTHALMOL RETINA, V1, P294, DOI 10.1016/j.oret.2017.02.007
   Forte R, 2020, BRIT J OPHTHALMOL, V104, P1057, DOI 10.1136/bjophthalmol-2019-315189
   HOPEROSS M, 1994, OPHTHALMOLOGY, V101, P529
   Huang CH, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-018-37384-y
   Ichiyama Y, 2017, RETINA-J RET VIT DIS, V37, P724, DOI 10.1097/IAE.0000000000001576
   Kim JY, 2016, GRAEF ARCH CLIN EXP, V254, P1505, DOI 10.1007/s00417-015-3228-3
   Laude A, 2010, PROG RETIN EYE RES, V29, P19, DOI 10.1016/j.preteyeres.2009.10.001
   Lindner M, 2016, INVEST OPHTH VIS SCI, V57, P6342, DOI 10.1167/iovs.16-19741
   Maruko Ichiro, 2019, Retin Cases Brief Rep, V13, P88, DOI 10.1097/ICB.0000000000000542
   Matsunaga DR, 2015, OSLI RETINA, V46, P796, DOI 10.3928/23258160-20150909-03
   Nagiel A, 2015, JAMA OPHTHALMOL, V133, P629, DOI 10.1001/jamaophthalmol.2015.0668
   OTSU N, 1979, IEEE T SYST MAN CYB, V9, P62, DOI 10.1109/TSMC.1979.4310076
   Otsuji T, 2000, OPHTHALMIC SURG LAS, V31, P210
   Palkar AH, 2019, TAIWAN J OPHTHALMOL, V9, P72, DOI 10.4103/tjo.tjo_35_18
   Rebhun CB, 2017, TRANSL VIS SCI TECHN, V6, DOI 10.1167/tvst.6.6.4
   Sato T, 2007, RETINA-J RET VIT DIS, V27, P589, DOI 10.1097/01.iae.0000249386.63482.05
   Serra R, 2021, RETINA-J RET VIT DIS, V41, P93, DOI 10.1097/IAE.0000000000002807
   Serra R, 2020, RETINA-J RET VIT DIS, V40, P1224, DOI 10.1097/IAE.0000000000002604
   SPAIDE RF, 1995, RETINA-J RET VIT DIS, V15, P100, DOI 10.1097/00006982-199515020-00003
   Spaide RF, 2020, OPHTHALMOLOGY, V127, P616, DOI 10.1016/j.ophtha.2019.11.004
   Spaide RF, 2018, PROG RETIN EYE RES, V64, P1, DOI 10.1016/j.preteyeres.2017.11.003
   Spaide RF, 2015, RETINA-J RET VIT DIS, V35, P2163, DOI 10.1097/IAE.0000000000000765
   Srour M, 2016, BRIT J OPHTHALMOL, V100, P1489, DOI 10.1136/bjophthalmol-2015-307892
   Tanaka K, 2017, BRIT J OPHTHALMOL, V101, P51, DOI 10.1136/bjophthalmol-2016-309264
   Tomiyasu T, 2016, INVEST OPHTH VIS SCI, V57, pOCT324, DOI 10.1167/iovs.15-18898
   Wang M, 2016, INVEST OPHTH VIS SCI, V57, pOCT526, DOI 10.1167/iovs.15-18955
   YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001
NR 37
TC 5
Z9 6
U1 0
U2 2
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0007-1161
EI 1468-2079
J9 BRIT J OPHTHALMOL
JI Br. J. Ophthalmol.
PD OCT
PY 2021
VL 105
IS 10
BP 1421
EP 1426
DI 10.1136/bjophthalmol-2020-317011
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA UZ8JS
UT WOS:000702446300020
PM 32892164
OA Green Published, hybrid
DA 2022-11-30
ER

PT J
AU Morohoshi, K
   Goodwin, AM
   Ohbayashi, M
   Ono, SJ
AF Morohoshi, Kei
   Goodwin, Anne M.
   Ohbayashi, Masaharu
   Ono, Santa Jeremy
TI Autoimmunity in retinal degeneration: Autoimmune retinopathy and
   age-related macular degeneration
SO JOURNAL OF AUTOIMMUNITY
LA English
DT Article
DE Autaimmune retinopathy; Retinal degeneration; Age-related macular
   degeneration; Autoantibody profile; Antigen microarray; Mouse models
ID CHLAMYDIA-PNEUMONIAE INFECTION; CANCER-ASSOCIATED RETINOPATHY;
   CREATINE-KINASE ISOENZYMES; CHOROIDAL NEOVASCULARIZATION; BRAIN-TYPE;
   PIGMENT EPITHELIUM; NIGHT BLINDNESS; CHICKEN RETINA; ANIMAL-MODEL;
   DRUSEN
AB Autoantibody production is associated with a variety of ocular disorders, including autoimmune retinopathy (AIR) and age-related macular degeneration (AMD). A breakdown of immunologic tolerance (ocular immune privilege), including the blood-retinal barrier, anti-immune and anti-inflammatory proteins, and anterior chamber-associated immune deviation may play important roles in these disorders. Although the exact triggers for ocular autoimmunity are unknown, autoimmune targeting of retinal tissue is clearly associated with and may contribute to the pathogenesis of both AIR and AMD. Autoantibody production has long been associated with AIR, a collection of disorders that includes cancer-associated retinopathy, melanoma-associated retinopathy and non-paraneoplastic autoimmune retinopathy. A growing body of evidence indicates that AMD pathogenesis, too, involves ocular inflammation and autoimmunity. Identification and quantification of autoantibodies produced in patients with AIR and AMD may assist with diagnosis, prognosis, and choice of treatments. Animal models that allow investigation of ocular autoimmunity will also be needed to better understand the disease processes and to develop novel therapies. In this review we discuss ocular immune privilege and potential mechanisms of autoimmunity in the eye. We describe how autoimmunity relates to the pathogenesis of AIR and AMD. We explain how the antigen microarray technique is used to detect autoantibodies in patient serum samples, and discuss how current animal models for AMD can be used to investigate autoimmune pathogenesis. Finally, we outline unanswered questions and exciting areas of future study related to autoimmune retinal degeneration. (C) 2009 Elsevier Ltd. All rights reserved.
C1 [Ono, Santa Jeremy] Emory Univ, Sch Med, Off Provost, Dobbs Ocular Immunol Labs,Emory Eye Ctr, Atlanta, GA 30322 USA.
   [Morohoshi, Kei; Ohbayashi, Masaharu; Ono, Santa Jeremy] Emory Univ, Sch Med, Dept Ophthalmol, Atlanta, GA 30322 USA.
   [Goodwin, Anne M.] Massachusetts Coll Liberal Arts, Dept Biol, N Adams, MA 01247 USA.
C3 Emory University; Emory University; Massachusetts System of Public
   Higher Education; Massachusetts College Liberal Arts
RP Ono, SJ (通讯作者)，Emory Univ, Sch Med, Off Provost, Dobbs Ocular Immunol Labs,Emory Eye Ctr, 201 Dowman Dr,Suite 404, Atlanta, GA 30322 USA.
EM sjono@emory.edu
OI Morohoshi, Kei/0000-0002-2891-9073
FU R. Howard Dobbs, Jr. Foundation; Special Trustees of Moorfields Eye
   Hospital
FX We are grateful to Jinchun Zhou and Quan-Zhen Li for carrying out the
   antigen microarray and to Yun Lian for help with data analysis in the
   Microarray Core Facility, University of Texas Southwestern Medical
   Center. This study was supported by the R. Howard Dobbs, Jr. Foundation
   and the Special Trustees of Moorfields Eye Hospital.
CR Adamus G, 1997, INVEST OPHTH VIS SCI, V38, P283
   Adamus G, 1998, J AUTOIMMUN, V11, P671, DOI 10.1006/jaut.1998.0239
   Adamus G, 1996, CLIN IMMUNOL IMMUNOP, V78, P120, DOI 10.1006/clin.1996.0021
   Adamus Grazyna, 2004, BMC Ophthalmol, V4, P5, DOI 10.1186/1471-2415-4-5
   Adamus Grazyna, 2002, Int Rev Immunol, V21, P209, DOI 10.1080/08830180212068
   Adamus G, 2009, AUTOIMMUN REV, V8, P410, DOI 10.1016/j.autrev.2009.01.002
   Ahn BY, 2006, PROTEOMICS, V6, P1200, DOI 10.1002/pmic.200500457
   ALEXANDER KR, 1992, INVEST OPHTH VIS SCI, V33, P477
   Ambati J, 2003, NAT MED, V9, P1390, DOI 10.1038/nm950
   Arawaka S, 1998, INT J MOL MED, V1, P597
   Bazhin AV, 2009, INT J CANCER, V124, P140, DOI 10.1002/ijc.23909
   Becker MD, 2000, OCUL IMMUNOL INFLAMM, V8, P93, DOI 10.1076/0927-3948(200006)8:2;1-0;FT093
   BERSON EL, 1988, AM J OPHTHALMOL, V106, P307, DOI 10.1016/0002-9394(88)90366-2
   Blank M, 2008, J AUTOIMMUN, V30, P1, DOI 10.1016/j.jaut.2007.11.015
   Bora NS, 2006, J IMMUNOL, V177, P1872, DOI 10.4049/jimmunol.177.3.1872
   Bora PS, 2005, J IMMUNOL, V174, P491, DOI 10.4049/jimmunol.174.1.491
   Caspi Rachel R, 2003, Curr Protoc Immunol, VChapter 15, DOI 10.1002/0471142735.im1506s53
   Caspi RR, 2006, IMMUNOL REV, V213, P23, DOI 10.1111/j.1600-065X.2006.00439.x
   Caspi RR, 1997, EYE, V11, P209, DOI 10.1038/eye.1997.53
   Chan CC, 2008, OPHTHALMIC RES, V40, P124, DOI 10.1159/000119862
   Crabb JW, 2002, P NATL ACAD SCI USA, V99, P14682, DOI 10.1073/pnas.222551899
   Cunha-Vaz JG, 2004, EXP EYE RES, V78, P715, DOI 10.1016/S0014-4835(03)00213-6
   de Jong PTVM, 2006, NEW ENGL J MED, V355, P1474, DOI 10.1056/NEJMra062326
   de Kozak Y, 1992, Reg Immunol, V4, P168
   DOBI ET, 1989, ARCH OPHTHALMOL-CHIC, V107, P264, DOI 10.1001/archopht.1989.01070010270035
   Ebrahem Q, 2006, P NATL ACAD SCI USA, V103, P13480, DOI 10.1073/pnas.0601552103
   Egwuagu CE, 1997, J IMMUNOL, V159, P3109
   Frisancho-Kiss S, 2006, J IMMUNOL, V176, P6411, DOI 10.4049/jimmunol.176.11.6411
   Gershwin ME, 2008, J AUTOIMMUN, V30, P105, DOI 10.1016/j.jaut.2007.12.006
   Goldstein SM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1641
   Gu JY, 2009, MOL CELL PROTEOMICS, V8, P1338, DOI 10.1074/mcp.M800453-MCP200
   Gu XR, 2003, J BIOL CHEM, V278, P42027, DOI 10.1074/jbc.M305460200
   Guy J, 1999, ARCH OPHTHALMOL-CHIC, V117, P471
   Guymer R, 2007, CLIN EXP OPHTHALMOL, V35, P89, DOI 10.1111/j.1442-9071.2006.01392.x
   HAAS P, 2009, EYE
   Hageman GS, 1999, MOL VIS, V5
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Heckenlively JR, 2008, SEMIN IMMUNOPATHOL, V30, P127, DOI 10.1007/s00281-008-0114-7
   Heckenlively JR, 1999, AM J OPHTHALMOL, V127, P565, DOI 10.1016/S0002-9394(98)00446-2
   Heckenlively JR, 2000, ARCH OPHTHALMOL-CHIC, V118, P1525
   Hollyfield JG, 2008, NAT MED, V14, P194, DOI 10.1038/nm1709
   Imamura Y, 2006, P NATL ACAD SCI USA, V103, P11282, DOI 10.1073/pnas.0602131103
   Jager MJ, 2007, J CLIN INVEST, V117, P3182, DOI 10.1172/JCI34070
   Joachim SC, 2007, GRAEF ARCH CLIN EXP, V245, P619, DOI 10.1007/s00417-006-0429-9
   Johnson LV, 2000, EXP EYE RES, V70, P441, DOI 10.1006/exer.1999.0798
   Kalayoglu MV, 2005, GRAEF ARCH CLIN EXP, V243, P1080, DOI 10.1007/s00417-005-1169-y
   Kalayoglu MV, 2003, ARCH OPHTHALMOL-CHIC, V121, P478, DOI 10.1001/archopht.121.4.478
   Kikuchi T, 2000, J NEUROIMMUNOL, V103, P26, DOI 10.1016/S0165-5728(99)00163-0
   Li HS, 2008, AUTOIMMUN REV, V7, P168, DOI 10.1016/j.autrev.2007.11.010
   Mackay IR, 2008, J AUTOIMMUN, V30, P5, DOI 10.1016/j.jaut.2007.11.009
   Mantel I, 2008, EXP MOL PATHOL, V84, P90, DOI 10.1016/j.yexmp.2007.10.006
   Miller DM, 2004, AM J OPHTHALMOL, V138, P323, DOI 10.1016/j.ajo.2004.03.018
   MILLER H, 1986, INVEST OPHTH VIS SCI, V27, P1644
   Mullins RF, 2000, FASEB J, V14, P835, DOI 10.1096/fasebj.14.7.835
   NEUMANN DA, 1991, CLIN EXP IMMUNOL, V86, P405
   Niederkorn Jerry Y, 2007, Chem Immunol Allergy, V92, P27, DOI 10.1159/000099251
   Niederkorn JY, 2006, NAT IMMUNOL, V7, P354, DOI 10.1038/ni1328
   Njoku DB, 2009, J AUTOIMMUN, V32, P52, DOI 10.1016/j.jaut.2008.11.003
   Ohguro HN, 1999, INVEST OPHTH VIS SCI, V40, P82
   Okunuki Y, 2008, MOL VIS, V14, P1094
   Patel N, 2005, IMMUNOLOGY, V115, P422, DOI 10.1111/j.1365-2567.2005.02173.x
   PENFOLD PL, 1990, GRAEF ARCH CLIN EXP, V228, P270, DOI 10.1007/BF00920033
   POLANS AS, 1993, INVEST OPHTH VIS SCI, V34, P81
   RAO NA, 1989, INVEST OPHTH VIS SCI, V30, P2348
   Resnikoff S, 2004, B WORLD HEALTH ORGAN, V82, P844
   Robman L, 2007, INVEST OPHTH VIS SCI, V48, P4007, DOI 10.1167/iovs.06-1434
   Rose NR, 2008, AUTOIMMUNITY, V41, P419, DOI 10.1080/08916930802031686
   Rosenberg M, 2001, LEBENSM-WISS TECHNOL, V34, P279, DOI 10.1006/fstl.2001.0754
   Russell SR, 2000, AM J OPHTHALMOL, V129, P205, DOI 10.1016/S0002-9394(99)00345-1
   Ryan S J, 1979, Trans Am Ophthalmol Soc, V77, P707
   SAWYER RA, 1976, AM J OPHTHALMOL, V81, P606, DOI 10.1016/0002-9394(76)90125-2
   Shen D, 2009, BRIT J OPHTHALMOL, V93, P405, DOI 10.1136/bjo.2008.145383
   Shiraga S, 2002, J NEUROIMMUNOL, V132, P72, DOI 10.1016/S0165-5728(02)00314-4
   Shoenfeld Y, 2008, J AUTOIMMUN, V31, P325, DOI 10.1016/j.jaut.2008.08.004
   Silverstein AM, 2003, NAT IMMUNOL, V4, P931, DOI 10.1038/ni1003-931
   Skeie JM, 2009, EYE, V23, P747, DOI 10.1038/eye.2008.206
   THIRKILL CE, 1993, ARCH OPHTHALMOL-CHIC, V111, P974, DOI 10.1001/archopht.1993.01090070094026
   Tobe T, 1998, AM J PATHOL, V153, P1641, DOI 10.1016/S0002-9440(10)65753-7
   Tuo JS, 2007, INVEST OPHTH VIS SCI, V48, P3827, DOI 10.1167/iovs.07-0051
   Tuo JS, 2004, PROG RETIN EYE RES, V23, P229, DOI 10.1016/j.preteyeres.2004.02.001
   Umeda S, 2005, FASEB J, V19, P1683, DOI 10.1096/fj.04-3525fje
   WALLIMANN T, 1986, P NATL ACAD SCI USA, V83, P3816, DOI 10.1073/pnas.83.11.3816
   WEGMANN G, 1991, DIFFERENTIATION, V46, P77, DOI 10.1111/j.1432-0436.1991.tb00868.x
   Weleber RG, 2005, AM J OPHTHALMOL, V139, P780, DOI 10.1016/j.ajo.2004.12.104
   WHITCUP SM, 1993, CLIN IMMUNOL IMMUNOP, V67, P143, DOI 10.1006/clin.1993.1057
   Whitcup SM, 1998, AM J OPHTHALMOL, V126, P230, DOI 10.1016/S0002-9394(98)00149-4
   Whittingham S, 2008, J AUTOIMMUN, V31, P197, DOI 10.1016/j.jaut.2008.04.004
   Wittstock M, 2003, EUR NEUROL, V50, P172, DOI 10.1159/000073059
   Xing C, 2008, GENES IMMUN, V9, P231, DOI 10.1038/gene.2008.10
   Zamiri Parisa, 2007, Chem Immunol Allergy, V92, P86, DOI 10.1159/000099259
NR 92
TC 61
Z9 64
U1 0
U2 9
PU ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD
PI LONDON
PA 24-28 OVAL RD, LONDON NW1 7DX, ENGLAND
SN 0896-8411
EI 1095-9157
J9 J AUTOIMMUN
JI J. Autoimmun.
PD NOV-DEC
PY 2009
VL 33
IS 3-4
SI SI
BP 247
EP 254
DI 10.1016/j.jaut.2009.09.003
PG 8
WC Immunology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Immunology
GA 534KZ
UT WOS:000272896800012
PM 19846275
DA 2022-11-30
ER

PT J
AU Gu, XR
   Meer, SG
   Miyagi, M
   Rayborn, ME
   Hollyfield, JG
   Crabb, JW
   Salomon, RG
AF Gu, XR
   Meer, SG
   Miyagi, M
   Rayborn, ME
   Hollyfield, JG
   Crabb, JW
   Salomon, RG
TI Carboxyethylpyrrole protein adducts and autoantibodies, biomarkers for
   age-related macular degeneration
SO JOURNAL OF BIOLOGICAL CHEMISTRY
LA English
DT Article
ID OXIDIZED PHOSPHOLIPIDS; PATHOGENESIS; OXIDATION; DRUSEN; PRODUCTS;
   FAMILY
AB Age-related macular degeneration (AMD) is a slow, progressive disease with both genetic and environmental risk factors. Free radical-induced oxidation of docosahexaenoate (DHA)-containing lipids generates omega-(2-carboxyethyl)pyrrole (CEP) protein adducts that are more abundant in ocular tissues from AMD than normal human donors. To understand better the role of oxidative damage in AMD, we have synthesized CEP-modified proteins, produced anti-CEP antibodies, and initiated analysis of CEP immunoreactivity and autoantibodies in human plasma. A highly selective rabbit polyclonal anti-CEP antibody was raised that binds CEP 1000 times more strongly than carboxypropylpyrrole, a close structural analogue. The CEP adduct uniquely indicates oxidative modification from DHA derivatives because CEP protein modifications cannot arise from any other common polyunsaturated fatty acid. Immunocytochemistry localized CEP to photoreceptor rod outer segments and retinal pigment epithelium in mouse retina and demonstrated more intense CEP immunoreactivity in photoreceptors from a human AMD donor compared with healthy human retina. The mean level of anti-CEP immunoreactivity in AMD human plasma (n = 19 donors) was 1.5-fold higher (p = 0.004) than in age-matched controls (n = 19 donors). Sera from AMD patients demonstrated mean titers of anti-CEP autoantibody 2.3-fold higher than controls (p = 0.02). Of individuals (n = 13) exhibiting both antigen and autoantibody levels above the mean for non-AMD controls, 92% had AMD. These results suggest that together CEP immunoreactivity and autoantibody titer may have diagnostic utility in predicting AMD susceptibility.
C1 Cleveland Clin Fdn, Cole Eye Inst i31, Cleveland, OH 44195 USA.
   Case Western Reserve Univ, Dept Chem, Cleveland, OH 44106 USA.
C3 Cleveland Clinic Foundation; Case Western Reserve University
RP Crabb, JW (通讯作者)，Cleveland Clin Fdn, Cole Eye Inst i31, 9500 Euclid Ave, Cleveland, OH 44195 USA.
EM crabbj@ccf.org; rgs@po.cwru.edu
RI Salomon, Robert G/C-3463-2008
OI Salomon, Robert/0000-0001-9456-3557
FU NATIONAL EYE INSTITUTE [R01EY014240, R01EY002362, R01EY014239,
   R56EY014240] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND
   BLOOD INSTITUTE [R01HL053315] Funding Source: NIH RePORTER; NATIONAL
   INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM021249] Funding Source: NIH
   RePORTER; NEI NIH HHS [EY 14239, EY 14240, EY 6603, EY 2362] Funding
   Source: Medline; NHLBI NIH HHS [HL 53315] Funding Source: Medline; NIGMS
   NIH HHS [GM 21249] Funding Source: Medline
CR Abdelsalam A, 1999, SURV OPHTHALMOL, V44, P1, DOI 10.1016/S0039-6257(99)00072-7
   ALVAREZ RA, 1994, INVEST OPHTH VIS SCI, V35, P402
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   Crabb JW, 2002, P NATL ACAD SCI USA, V99, P14682, DOI 10.1073/pnas.222551899
   Crabb JW, 1998, J BIOL CHEM, V273, P20712, DOI 10.1074/jbc.273.33.20712
   DECAPRIO AP, 1987, MOL PHARMACOL, V32, P542
   Evans JR, 2001, PROG RETIN EYE RES, V20, P227, DOI 10.1016/S1350-9462(00)00023-9
   FLIESLER SJ, 1983, PROG LIPID RES, V22, P79
   Gu XR, 2003, J ORG CHEM, V68, P3749, DOI 10.1021/jo026721t
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Johnson LV, 2000, EXP EYE RES, V70, P441, DOI 10.1006/exer.1999.0798
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Kaur K, 1997, CHEM RES TOXICOL, V10, P1387, DOI 10.1021/tx970112c
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   MACDONALD RC, 1991, BIOCHIM BIOPHYS ACTA, V1061, P297, DOI 10.1016/0005-2736(91)90295-J
   Miyagi M, 2002, MOL CELL PROTEOMICS, V1, P293, DOI 10.1074/mcp.M100034-MCP200
   Penfold PL, 2001, PROG RETIN EYE RES, V20, P385, DOI 10.1016/S1350-9462(00)00025-2
   Podrez EA, 2002, J BIOL CHEM, V277, P38517, DOI 10.1074/jbc.M205924200
   Podrez EA, 2002, J BIOL CHEM, V277, P38503, DOI 10.1074/jbc.M203318200
   Salomon RG, 2000, BBA-MOL CELL BIOL L, V1485, P225, DOI 10.1016/S1388-1981(00)00038-X
   Sayre LM, 1996, CHEM RES TOXICOL, V9, P1194, DOI 10.1021/tx960094j
   Seddon JM, 1996, JAMA-J AM MED ASSOC, V276, P1141, DOI 10.1001/jama.276.14.1141
   SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7
   STEINBRECHER UP, 1987, J BIOL CHEM, V262, P3603
   Stone EM, 2001, HUM MOL GENET, V10, P2285, DOI 10.1093/hmg/10.20.2285
   Subbanagounder G, 2002, VASC PHARMACOL, V38, P201, DOI 10.1016/S1537-1891(02)00170-2
   Sun MJ, 2002, J ORG CHEM, V67, P3575, DOI 10.1021/jo0105383
   WANG N, 1992, CURR EYE RES, V11, P783, DOI 10.3109/02713689209000751
   West KA, 2001, EXP EYE RES, V73, P479, DOI 10.1006/exer.2001.1058
NR 29
TC 246
Z9 257
U1 0
U2 8
PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
PI ROCKVILLE
PA 11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES
SN 0021-9258
EI 1083-351X
J9 J BIOL CHEM
JI J. Biol. Chem.
PD OCT 24
PY 2003
VL 278
IS 43
BP 42027
EP 42035
DI 10.1074/jbc.M305460200
PG 9
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology
GA 733FP
UT WOS:000185989500058
PM 12923198
OA hybrid
DA 2022-11-30
ER

PT J
AU Ozdemir, H
   Karacorlu, SA
   Karacorlu, M
AF Ozdemir, H
   Karacorlu, SA
   Karacorlu, M
TI Early optical coherence tomography changes after photodynamic therapy in
   patients with age-related macular degeneration
SO AMERICAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID SUBFOVEAL CHOROIDAL NEOVASCULARIZATION
AB PURPOSE: To evaluate early changes after photodynamic therapy (PDT) in patients with age-related macular degeneration (AMD) by optical coherence tomography (OCT).
   DESIGN: Prospective interventional case series.
   METHODS: PDT was performed on 20 eyes of 20 patients who presented with subfoveal choroidal neovascularization (CNV) attributable to AMD. OCT was used to evaluate changes at 2, 12, and 24 hours and at 3, 7, 15, and 30 days after therapy.
   RESULTS: In the first 24 hours, OCT showed an increase in the subretinal fluid (SF) in all eyes and an increase in intraretinal fluid (IF) in 13 eyes. On the 15th day and the 30th day after therapy, reduction of SF and IF was observed in almost all eyes.
   CONCLUSIONS: Serial OCT evaluation of patients with subfoveal CNV attributable to AMD suggests that the initial response after PDT is an increase in SF and IF.
C1 Istanbul Retina Inst Inc, TR-34349 Istanbul, Turkey.
C3 Istanbul Retina Enstitusu
RP Karacorlu, M (通讯作者)，Istanbul Retina Inst Inc, Hakki Yeten Caddesi 8,K 7, TR-34349 Istanbul, Turkey.
EM retina@pobox.com
RI Karaçorlu, Murat/AFK-0782-2022; Karaçorlu, Murat/AAF-7763-2022
CR Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   Costa RA, 2003, RETINA-J RET VIT DIS, V23, P159, DOI 10.1097/00006982-200304000-00004
   Rogers AH, 2002, AM J OPHTHALMOL, V134, P566, DOI 10.1016/S0002-9394(02)01566-0
   Sahni J, 2005, BRIT J OPHTHALMOL, V89, P316, DOI 10.1136/bjo.2004.043364
   Salinas-Alaman A, 2005, AM J OPHTHALMOL, V140, P23, DOI 10.1016/j.ajo.2005.01.044
NR 5
TC 26
Z9 27
U1 0
U2 4
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0002-9394
EI 1879-1891
J9 AM J OPHTHALMOL
JI Am. J. Ophthalmol.
PD MAR
PY 2006
VL 141
IS 3
BP 574
EP 576
DI 10.1016/j.ajo.2005.09.031
PG 3
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 022LS
UT WOS:000236057900029
PM 16490515
DA 2022-11-30
ER

PT J
AU Chirco, KR
   Whitmore, SS
   Wang, K
   Potempa, LA
   Halder, JA
   Stone, EM
   Tucker, BA
   Mullins, RF
AF Chirco, Kathleen R.
   Whitmore, S. Scott
   Wang, Kai
   Potempa, Lawrence A.
   Halder, Jennifer A.
   Stone, Edwin M.
   Tucker, Budd A.
   Mullins, Robert F.
TI Monomeric C-reactive protein and inflammation in age-related macular
   degeneration
SO JOURNAL OF PATHOLOGY
LA English
DT Article
DE age-related macular degeneration; C-reactive protein; inflammation;
   microvasculature; choroid; ICAM-1
ID COMPLEMENT FACTOR-H; RETINAL-PIGMENT EPITHELIUM; MEMBRANE ATTACK
   COMPLEX; ENDOTHELIAL-CELLS; HUMAN CHORIOCAPILLARIS; ACTIVATED PLATELETS;
   ADHESION MOLECULE-1; GENE-EXPRESSION; HUMAN EYES; RISK
AB Age-related macular degeneration (AMD) is a devastating disease characterized by central vision loss in elderly individuals. Previous studies have suggested a link between elevated levels of total C-reactive protein (CRP) in the choroid, CFH genotype, and AMD status; however, the structural form of CRP present in the choroid, its relationship to CFH genotype, and its functional consequences have not been assessed. In this report, we studied genotyped human donor eyes (n = 60) and found that eyes homozygous for the high-risk CFH (Y402H) allele had elevated monomeric CRP (mCRP) within the choriocapillaris and Bruch's membrane, compared to those with the low-risk genotype. Treatment of choroidal endothelial cells in vitro with mCRP increased migration rate and monolayer permeability compared to treatment with pentameric CRP (pCRP) or medium alone. Organ cultures treated with mCRP exhibited dramatically altered expression of inflammatory genes as assessed by RNA sequencing, including ICAM-1 and CA4, both of which were confirmed at the protein level. Our data indicate that mCRP is the more abundant form of CRP in human choroid, and that mCRP levels are elevated in individuals with the high-risk CFH genotype. Moreover, pro-inflammatory mCRP significantly affects endothelial cell phenotypes in vitro and ex vivo, suggesting a role for mCRP in choroidal vascular dysfunction in AMD. Copyright (C) 2016 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.
C1 [Chirco, Kathleen R.; Whitmore, S. Scott; Wang, Kai; Halder, Jennifer A.; Stone, Edwin M.; Tucker, Budd A.; Mullins, Robert F.] Univ Iowa, Stephen A Wynn Inst Vis Res, Iowa City, IA USA.
   [Chirco, Kathleen R.; Whitmore, S. Scott; Halder, Jennifer A.; Stone, Edwin M.; Tucker, Budd A.; Mullins, Robert F.] Univ Iowa, Dept Ophthalmol & Visual Sci, Iowa City, IA USA.
   [Wang, Kai] Univ Iowa, Dept Biostat, Iowa City, IA USA.
   [Potempa, Lawrence A.] Roosevelt Univ, Coll Pharm, Schaumburg, IL USA.
C3 University of Iowa; University of Iowa; University of Iowa
RP Mullins, RF (通讯作者)，Univ Iowa, Dept Ophthalmol & Visual Sci, Iowa City, IA USA.; Mullins, RF (通讯作者)，Stephen A Wynn Inst Vis Res, 375 Newton Rd, Iowa City, IA 52242 USA.
EM Robert-Mullins@uiowa.edu
RI Mullins, Robert F/I-6717-2013
OI Stone, Edwin M./0000-0003-3343-4414; Whitmore, S.
   Scott/0000-0003-0161-9625; Mullins, Robert/0000-0002-5006-0891; Tucker,
   Budd/0000-0003-2178-1742
FU NATIONAL EYE INSTITUTE [R01EY024605] Funding Source: NIH RePORTER;
   NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008629] Funding
   Source: NIH RePORTER; NEI NIH HHS [R01 EY024605] Funding Source:
   Medline; NIGMS NIH HHS [T32 GM008629] Funding Source: Medline
CR Ablonczy Z, 2014, FASEB J, V28, P2369, DOI 10.1096/fj.13-248021
   Anderson DH, 2002, AM J OPHTHALMOL, V134, P411, DOI 10.1016/S0002-9394(02)01624-0
   Bhutto IA, 2011, BRIT J OPHTHALMOL, V95, P1323, DOI 10.1136/bjo.2010.199216
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Biro A, 2007, IMMUNOLOGY, V121, P40, DOI 10.1111/j.1365-2567.2007.02535.x
   Black S, 2004, J BIOL CHEM, V279, P48487, DOI 10.1074/jbc.R400025200
   Chen M, 2015, J LEUKOCYTE BIOL, V98, P713, DOI 10.1189/jlb.3RI0615-239R
   Chew EY, 2014, JAMA OPHTHALMOL, V132, P272, DOI 10.1001/jamaophthalmol.2013.6636
   Chirco KR, 2016, EXP EYE RES, V146, P393, DOI 10.1016/j.exer.2015.09.003
   Crabb JW, 2002, P NATL ACAD SCI USA, V99, P14682, DOI 10.1073/pnas.222551899
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Eisenhardt SU, 2009, CIRC RES, V105, P128, DOI 10.1161/CIRCRESAHA.108.190611
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Fritsche LG, 2016, NAT GENET, V48, P134, DOI 10.1038/ng.3448
   Gabay C, 1999, NEW ENGL J MED, V340, P448, DOI 10.1056/NEJM199902113400607
   GANTER U, 1989, EMBO J, V8, P3773, DOI 10.1002/j.1460-2075.1989.tb08554.x
   Gao JY, 2015, MEDIAT INFLAMM, V2015, DOI 10.1155/2015/690243
   Grossniklaus HE, 2002, MOL VIS, V8, P119
   Habersberger J, 2012, CARDIOVASC RES, V96, P64, DOI 10.1093/cvr/cvs237
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Ji SR, 2009, FASEB J, V23, P1806, DOI 10.1096/fj.08-116962
   Johnson PT, 2006, P NATL ACAD SCI USA, V103, P17456, DOI 10.1073/pnas.0606234103
   Juel HB, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0132800
   Karaca I, 2003, CURR MED RES OPIN, V19, P187, DOI 10.1185/030079903125001686
   Kassoff A, 1999, CONTROL CLIN TRIALS, V20, P573
   Khreiss T, 2004, CIRCULATION, V109, P2016, DOI 10.1161/01.CIR.0000125527.41598.68
   Kim D, 2013, GENOME BIOL, V14, DOI 10.1186/gb-2013-14-4-r36
   Kim IK, 2008, MOL VIS, V14, P1487
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Lauer N, 2011, J IMMUNOL, V187, P4374, DOI 10.4049/jimmunol.1002488
   Li H, 2014, MOL MED REP, V9, P427, DOI 10.3892/mmr.2013.1833
   Liao Y, 2014, BIOINFORMATICS, V30, P923, DOI 10.1093/bioinformatics/btt656
   Liu GQ, 2011, ARTERIOSCL THROM VAS, V31, P1342, DOI 10.1161/ATVBAHA.110.222208
   Love MI, 2014, GENOME BIOL, V15, DOI 10.1186/s13059-014-0550-8
   Martini JF, 2000, MOL ENDOCRINOL, V14, P1536, DOI 10.1210/me.14.10.1536
   MCLEOD DS, 1995, AM J PATHOL, V147, P642
   Molins B, 2011, CARDIOVASC RES, V92, P328, DOI 10.1093/cvr/cvr226
   Montalvo V, 2007, CURR EYE RES, V32, P917, DOI 10.1080/02713680701656343
   MORLEY JJ, 1982, ANN NY ACAD SCI, V389, P406, DOI 10.1111/j.1749-6632.1982.tb22153.x
   Mullins RF, 2006, MOL VIS, V12, P224
   Mullins RE, 2011, INVEST OPHTH VIS SCI, V52, P1606, DOI 10.1167/iovs.10-6476
   Mullins RF, 2014, AM J PATHOL, V184, P3142, DOI 10.1016/j.ajpath.2014.07.017
   Mullins RF, 2011, EXP EYE RES, V93, P565, DOI 10.1016/j.exer.2011.06.015
   Nagy JA, 2008, ANGIOGENESIS, V11, P109, DOI 10.1007/s10456-008-9099-z
   Nozaki M, 2006, P NATL ACAD SCI USA, V103, P2328, DOI 10.1073/pnas.0408835103
   POTEMPA LA, 1983, MOL IMMUNOL, V20, P1165, DOI 10.1016/0161-5890(83)90140-2
   POTEMPA LA, 1987, MOL IMMUNOL, V24, P531, DOI 10.1016/0161-5890(87)90028-9
   Potempa LA, 1999, US Patent, Patent No. 5874238
   Potempa Lawrence A, 2015, Biophys Rep, V1, P18
   Robman L, 2010, OPHTHALMOLOGY, V117, P1982, DOI 10.1016/j.ophtha.2010.02.003
   Schroeder A, 2006, BMC MOL BIOL, V7, DOI 10.1186/1471-2199-7-3
   Seddon JM, 2005, ARCH OPHTHALMOL-CHIC, V123, P774, DOI 10.1001/archopht.123.6.774
   Seddon JM, 2004, JAMA-J AM MED ASSOC, V291, P704, DOI 10.1001/jama.291.6.704
   Seddon JM, 2010, OPHTHALMOLOGY, V117, P1560, DOI 10.1016/j.ophtha.2009.11.020
   Skeie JM, 2010, INVEST OPHTH VIS SCI, V51, P5336, DOI 10.1167/iovs.10-5322
   Slevin M, 2010, BRAIN PATHOL, V20, P151, DOI 10.1111/j.1750-3639.2008.00256.x
   Songstad AE, 2015, INVEST OPHTH VIS SCI, V56, P8258, DOI 10.1167/iovs.15-17073
   Stitt AW, 2011, PROG RETIN EYE RES, V30, P149, DOI 10.1016/j.preteyeres.2011.02.001
   Trapnell C, 2012, NAT PROTOC, V7, P562, DOI 10.1038/nprot.2012.016
   Vavvas DG, 2016, EBIOMEDICINE, V5, P198, DOI 10.1016/j.ebiom.2016.01.033
   Waheed A, 2014, SUBCELL BIOCHEM, V75, P157, DOI 10.1007/978-94-007-7359-2_9
   Wang HW, 2001, BIOCHEM BIOPH RES CO, V288, P75, DOI 10.1006/bbrc.2001.5733
   Wang MY, 2011, FASEB J, V25, P3186, DOI 10.1096/fj.11-182741
   Whitcup SM, 2013, INT J INFLAMM, V2013, DOI 10.1155/2013/348092
   Whitmore SS, 2013, MOL VIS, V19, P2274
   Wu Y, 2015, BIOL CHEM, V396, P1181, DOI 10.1515/hsz-2015-0149
   Yuan XL, 2010, MOL CELL PROTEOMICS, V9, P1031, DOI 10.1074/mcp.M900523-MCP200
NR 68
TC 34
Z9 34
U1 0
U2 4
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0022-3417
EI 1096-9896
J9 J PATHOL
JI J. Pathol.
PD OCT
PY 2016
VL 240
IS 2
BP 173
EP 183
DI 10.1002/path.4766
PG 11
WC Oncology; Pathology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Pathology
GA EA5VB
UT WOS:000386691000006
PM 27376713
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Mitchell, P
AF Mitchell, Paul
TI A systematic review of the efficacy and safety outcomes of anti-VEGF
   agents used for treating neovascular age-related macular degeneration:
   comparison of ranibizumab and bevacizumab
SO CURRENT MEDICAL RESEARCH AND OPINION
LA English
DT Review
DE Age-related macular degeneration; AMD; Avastin; Bevacizumab; Lucentis;
   Ranibizumab; VEGF
ID VERTEPORFIN PHOTODYNAMIC THERAPY; ENDOTHELIAL GROWTH-FACTOR; RANDOMIZED
   CLINICAL-TRIAL; VISION-RELATED FUNCTION; INTRAVITREAL BEVACIZUMAB;
   CHOROIDAL NEOVASCULARIZATION; DIABETIC-RETINOPATHY; AVASTIN;
   TRIAMCINOLONE; MULTICENTER
AB Objective:
   To systematically review ocular and systemic events in treatment of wet age-related macular degeneration (AMD) with anti-vascular endothelial growth factor antibodies, ranibizumab and bevacizumab, and to provide a detailed perspective of their differences on clinical use, efficacy and safety.
   Research design and methods:
   This review was based on a 2010 PubMed literature search performed using two separate terms: 'lucentis' OR 'ranibizumab' AND 'age-related macular degeneration' OR 'AMD' or 'avastin' OR 'bevacizumab' AND 'age-related macular degeneration' OR 'AMD'. A clinical diagnosis of wet AMD was defined by the authors of the trial reports. Clinical studies that met Level I or Level II evidence criteria were considered for review.
   Findings:
   Eight large, randomized, controlled trials of ranibizumab (Level I) included 1485 patients (range 162-716) and four open-label studies of ranibizumab (Level II) included 4484 patients (range 32-4300). Six studies (one Level I, five Level II) of bevacizumab included 424 patients (range 28-165). All demonstrated improvements in visual acuity. Only one study (Level II) compared the efficacy of ranibizumab and bevacizumab. Adverse ocular and systemic safety events occurring during the study were prospectively recorded for ranibizumab, irrespective of their suspected relationship to study treatments. Only three of six bevacizumab studies reported details of adverse ocular or systemic events. There was extensive Level I and Level II evidence to support both the efficacy and safety of ranibizumab in wet AMD. Data suggest that bevacizumab provides efficacy in wet AMD, but the safety profile of intravitreal bevacizumab remains to be established.
   Conclusion:
   In contrast to ranibizumab, current safety data for bevacizumab are incomplete and not yet robust. If the medical community remains committed to using intravitreal bevacizumab, it is critical to establish that it has an acceptable safety profile, supported by evidence-based medicine. Considerable further research is warranted to achieve this.
C1 [Mitchell, Paul] Univ Sydney, Dept Ophthalmol, Sydney, NSW 2006, Australia.
C3 University of Sydney
RP Mitchell, P (通讯作者)，Westmead Hosp, Eye Clin B4A, Hawkesbury Rd, Westmead, NSW 2145, Australia.
EM paul.mitchell@sydney.edu.au
RI Mitchell, Paul/P-1498-2014
FU Novartis Pharmaceuticals Corporation
FX Alpha-Plus Medical Communications Ltd provided editorial support in the
   production of this manuscript; this support was sponsored by Novartis
   Pharmaceuticals Corporation.
CR AIELLO LP, 1994, NEW ENGL J MED, V331, P1480, DOI 10.1056/NEJM199412013312203
   Alexander SL, 2007, OPHTHALMOLOGY, V114, P2174, DOI 10.1016/j.ophtha.2007.09.017
   Antoszyk AN, 2008, AM J OPHTHALMOL, V145, P862, DOI 10.1016/j.ajo.2007.12.029
   Avery RL, 2006, OPHTHALMOLOGY, V113, P1695, DOI 10.1016/j.ophtha.2006.05.064
   Bakri SJ, 2007, OPHTHALMOLOGY, V114, P855, DOI 10.1016/j.ophtha.2007.01.017
   Bashshur ZF, 2007, ARCH OPHTHALMOL-CHIC, V125, P1357, DOI 10.1001/archopht.125.10.1357
   Boyd SR, 2002, ARCH OPHTHALMOL-CHIC, V120, P1644
   Boyer DS, 2009, OPHTHALMOLOGY, V116, P1731, DOI 10.1016/j.ophtha.2009.05.024
   Bressler NM, 2009, ARCH OPHTHALMOL-CHIC, V127, P13, DOI 10.1001/archophthalmol.2008.562
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   Chakravarthy U, 2006, OPHTHALMOLOGY, V113, P1508, DOI 10.1016/j.ophtha.2006.02.064
   Chang TS, 2007, ARCH OPHTHALMOL-CHIC, V125, P1460, DOI 10.1001/archopht.125.11.1460
   Chen Y, 1999, J MOL BIOL, V293, P865, DOI 10.1006/jmbi.1999.3192
   Curtis LH, 2010, ARCH OPHTHALMOL-CHIC, V128, P1273, DOI 10.1001/archophthalmol.2010.223
   D'Amico DJ, 2006, OPHTHALMOLOGY, V113, P992, DOI 10.1016/j.ophtha.2006.02.027
   Dafer Rima M, 2007, Semin Ophthalmol, V22, P201, DOI 10.1080/08820530701543024
   Dib E, 2008, INVEST OPHTH VIS SCI, V49, P1097, DOI 10.1167/iovs.07-1225
   Emerson MV, 2008, CLIN OPHTHALMOL, V2, P377
   Ferrara N, 2006, RETINA-J RET VIT DIS, V26, P859, DOI 10.1097/01.iae.0000242842.14624.e7
   Fung AE, 2006, BRIT J OPHTHALMOL, V90, P1344, DOI 10.1136/bjo.2006.099598
   Gehrs KM, 2006, ANN MED, V38, P450, DOI 10.1080/07853890600946724
   *GEN, 2010, AV PRESCR INF
   *GEN, GEN REP INTR INFL RE
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Hahn R, 2007, OPHTHALMOLOGE, V104, P588, DOI 10.1007/s00347-007-1547-4
   *HEALTHCANADA, REP EYE INFL END TOX
   Heier JS, 2006, ARCH OPHTHALMOL-CHIC, V124, P1532, DOI 10.1001/archopht.124.11.1532
   Heier JS, 2006, OPHTHALMOLOGY, V113, P633, DOI 10.1016/j.ophtha.2005.10.052
   HOLLAND S, 2009, CANADIAN OPHTHALMOLO
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Kahook MY, 2010, RETINA-J RET VIT DIS, V30, P887, DOI 10.1097/IAE.0b013e3181d50cea
   Kliffen M, 1997, BRIT J OPHTHALMOL, V81, P154, DOI 10.1136/bjo.81.2.154
   Kvanta A, 1996, INVEST OPHTH VIS SCI, V37, P1929
   Lazic R, 2007, OPHTHALMOLOGY, V114, P1179, DOI 10.1016/j.ophtha.2007.03.006
   Lewington S, 2002, LANCET, V360, P1903, DOI 10.1016/S0140-6736(02)11911-8
   Liew G, 2007, NEW ENGL J MED, V356, P747
   Lynch SS, 2007, ANN PHARMACOTHER, V41, P614, DOI 10.1345/aph.1H316
   McGimpsey SJ, 2008, BRIT J OPHTHALMOL, V92, P436, DOI 10.1136/bjo.2007.125070
   Mitchell P, 2010, BRIT J OPHTHALMOL, V94, P2, DOI 10.1136/bjo.2009.159160
   Nomoto H, 2009, INVEST OPHTH VIS SCI, V50, P4807, DOI 10.1167/iovs.08-3148
   Novartis, 2006, LUC PRESCR INF
   Oxford Centre for Evidence-based Medicine, 2009, LEV EV
   Potter MJ, 2010, BRIT J OPHTHALMOL, V94, P174, DOI 10.1136/bjo.2008.155531
   Regillo CD, 2008, AM J OPHTHALMOL, V145, P239, DOI 10.1016/j.ajo.2007.10.004
   Resnikoff S, 2004, B WORLD HEALTH ORGAN, V82, P844
   Rosenfeld Philip J, 2006, Ophthalmol Clin North Am, V19, P361
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rosenfeld PJ, 2006, OPHTHALMOLOGY, V113, P623, DOI 10.1016/j.ophtha.2006.01.027
   Ross JS, 2009, ARCH INTERN MED, V169, P1976, DOI 10.1001/archinternmed.2009.394
   Roth DB, 2009, OPHTHALMOLOGY, V116, P1226, DOI 10.1016/j.ophtha.2009.02.011
   Sacu S, 2009, EYE, V23, P2223, DOI 10.1038/eye.2008.423
   Schmidt-Erfurth U, 2010, EXPERT OPIN DRUG SAF, V9, P149, DOI 10.1517/14740330903418422
   SCHMUCKER C, 2009, TREATMENT AGE RELATE
   Schmucker C, 2010, GRAEF ARCH CLIN EXP, V248, P451, DOI 10.1007/s00417-009-1249-5
   SHARMA S, 2010, 28 ANN M AM SOC RET
   Subramanian ML, 2009, AM J OPHTHALMOL, V148, P875, DOI 10.1016/j.ajo.2009.07.009
   SUBRAMANIAN ML, 2010, ANN M ASS RES VIS OP
   Tan JSL, 2008, BRIT J OPHTHALMOL, V92, P509, DOI 10.1136/bjo.2007.131706
   Tan JSL, 2007, OPHTHALMOLOGY, V114, P1143, DOI 10.1016/j.ophtha.2006.09.033
   Tano Y, 2010, ACTA OPHTHALMOL, V88, P309, DOI 10.1111/j.1755-3768.2009.01843.x
   Tufail A, 2010, BMJ-BRIT MED J, V340, DOI 10.1136/bmj.c2459
   *US PHARM CONV INC, 2005, USP 28 NF 23, pCH788
   Weigert G, 2008, BRIT J OPHTHALMOL, V92, P356, DOI 10.1136/bjo.2007.125823
   Wong TY, 2007, LANCET, V370, P204, DOI 10.1016/S0140-6736(07)61104-0
NR 65
TC 73
Z9 78
U1 0
U2 23
PU INFORMA HEALTHCARE
PI LONDON
PA TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND
SN 0300-7995
J9 CURR MED RES OPIN
JI Curr. Med. Res. Opin.
PD JUL
PY 2011
VL 27
IS 7
BP 1465
EP 1475
DI 10.1185/03007995.2011.585394
PG 11
WC Medicine, General & Internal; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine; Research & Experimental Medicine
GA 777YY
UT WOS:000291662300019
PM 21623685
DA 2022-11-30
ER

PT J
AU Hollander, AI
   Mullins, RF
   Orozco, LD
   Voigt, AP
   Chen, HH
   Strunz, T
   Grassmann, F
   Haines, JL
   Kuiper, JJW
   Tumminia, S
   Allikmets, R
   Hageman, GS
   Stambolian, D
   Klaver, CCW
   Boeke, JD
   Chen, H
   Honigberg, L
   Katti, S
   Frazer, KA
   Weber, BHF
   Gorin, MB
AF den Hollander, Anneke I.
   Mullins, Robert F.
   Orozco, Luz D.
   Voigt, Andrew P.
   Chen, Hsu-Hsin
   Strunz, Tobias
   Grassmann, Felix
   Haines, Jonathan L.
   Kuiper, Jonas J. W.
   Tumminia, Santa J.
   Allikmets, Rando
   Hageman, Gregory S.
   Stambolian, Dwight
   Klaver, Caroline C. W.
   Boeke, Jef D.
   Chen, Hao
   Honigberg, Lee
   Katti, Suresh
   Frazer, Kelly A.
   Weber, Bernhard H. F.
   Gorin, Michael B.
TI Systems genomics in age-related macular degeneration
SO EXPERIMENTAL EYE RESEARCH
LA English
DT Article
DE Age-related macular degeneration; Omics; Systems genomics; Single cell
   sequencing; Expression quantitative trait locus; Complement system;
   iPSc-RPE; Induced pluripotent stem cells; Clinical trial
ID COMPLEMENT FACTOR-H; LOW-FREQUENCY VARIANTS; RARE GENETIC-VARIANTS;
   HIGH-RISK; WIDE ASSOCIATION; CFI GENE; ACTIVATION; CELLS; POLYMORPHISM;
   DRUSEN
AB Genomic studies in age-related macular degeneration (AMD) have identified genetic variants that account for the majority of AMD risk. An important next step is to understand the functional consequences and downstream effects of the identified AMD-associated genetic variants. Instrumental for this next step are 'omics' technologies, which enable high-throughput characterization and quantification of biological molecules, and subsequent integration of genomics with these omics datasets, a field referred to as systems genomics.Single cell sequencing studies of the retina and choroid demonstrated that the majority of candidate AMD genes identified through genomic studies are expressed in non-neuronal cells, such as the retinal pigment epithelium (RPE), glia, myeloid and choroidal cells, highlighting that many different retinal and choroidal cell types contribute to the pathogenesis of AMD. Expression quantitative trait locus (eQTL) studies in retinal tissue have identified putative causal genes by demonstrating a genetic overlap between gene regulation and AMD risk. Linking genetic data to complement measurements in the systemic circulation has aided in understanding the effect of AMD-associated genetic variants in the complement system, and supports that protein QTL (pQTL) studies in plasma or serum samples may aid in understanding the effect of genetic variants and pinpointing causal genes in AMD. A recent epigenomic study fine-mapped AMD causal variants by determing regulatory regions in RPE cells differentiated from induced pluripotent stem cells (iPSC-RPE). Another approach that is being employed to pinpoint causal AMD genes is to produce synthetic DNA assemblons representing risk and protective haplotypes, which are then delivered to cellular or animal model systems.Pinpointing causal genes and understanding disease mechanisms is crucial for the next step towards clinical translation. Clinical trials targeting proteins encoded by the AMD-associated genomic loci C3, CFB, CFI, CFH, and ARMS2/HTRA1 are currently ongoing, and a phase III clinical trial for C3 inhibition recently showed a modest reduction of lesion growth in geographic atrophy. The EYERISK consortium recently developed a genetic test for AMD that allows genotyping of common and rare variants in AMD-associated genes. Polygenic risk scores (PRS) were applied to quantify AMD genetic risk, and may aid in predicting AMD progression.In conclusion, genomic studies represent a turning point in our exploration of AMD. The results of those studies now serve as a driving force for several clinical trials. Expanding to omics and systems genomics will further decipher function and causality from the associations that have been reported, and will enable the development of therapies that will lessen the burden of AMD.
C1 [den Hollander, Anneke I.; Klaver, Caroline C. W.] Radboud Univ Nijmegen, Dept Ophthalmol, Med Ctr, Nijmegen, Netherlands.
   [den Hollander, Anneke I.] AbbVie, Genom Res Ctr, Cambridge, MA USA.
   [Mullins, Robert F.; Voigt, Andrew P.] Univ Iowax, Med Ctr, Iowa City, IA USA.
   [Mullins, Robert F.; Voigt, Andrew P.] Univ Iowa, Carver Coll Med, Dept Ophthalmol & Visual Sci, Iowa City, IA USA.
   [Orozco, Luz D.; Chen, Hsu-Hsin; Chen, Hao; Honigberg, Lee] Genentech Inc, South San Francisco, CA USA.
   [Strunz, Tobias; Weber, Bernhard H. F.] Univ Regensburg, Inst Human Genet, Regensburg, Germany.
   [Grassmann, Felix] Hlth & Med Univ, Potsdam, Germany.
   [Haines, Jonathan L.] Case Western Reserve Univ, Dept Populat & Quantitat Hlth Sci, Cleveland, OH USA.
   [Haines, Jonathan L.] Case Western Reserve Univ, Cleveland Inst Computat Biol, Cleveland, OH USA.
   [Kuiper, Jonas J. W.] Univ Med Ctr Utrecht, Dept Ophthalmol, Utrecht, Netherlands.
   [Kuiper, Jonas J. W.] Univ Med Ctr Utrecht, Ctr Translat Immunol, Utrecht, Netherlands.
   [Tumminia, Santa J.] NEI, Bethesda, MD USA.
   [Allikmets, Rando] Columbia Univ, Dept Ophthalmol, New York, NY USA.
   [Allikmets, Rando] Columbia Univ, Dept Pathol & Cell Biol, New York, NY USA.
   [Hageman, Gregory S.] Univ Utah, Sharon Eccles Steele Ctr Translat Med, John A Moran Eye Ctr, Dept Ophthalmol & Visual Sci, Salt Lake City, UT USA.
   [Stambolian, Dwight] Univ Penn, Perelman Sch Med, Dept Ophthalmol & Human Genet, Philadelphia, PA USA.
   [Klaver, Caroline C. W.] Erasmus MC, Dept Ophthalmol & Epidemiol, Rotterdam, Netherlands.
   [Klaver, Caroline C. W.] Inst Mol & Clin Ophthalmol, Basel, Switzerland.
   [Boeke, Jef D.] NYU Langone Hlth, Inst Syst Genet, New York, NY USA.
   [Boeke, Jef D.] NYU Langone Hlth, Dept Biochem & Mol Pharmacol, New York, NY USA.
   [Boeke, Jef D.] NYU Tandon Sch Engn, Dept Biomed Engn, Brooklyn, NY USA.
   [Katti, Suresh] Gemini Therapeut, Cambridge, MA USA.
   [Frazer, Kelly A.] Univ Calif San Diego, Dept Pediat, La Jolla, CA USA.
   [Frazer, Kelly A.] Univ Calif San Diego, Inst Genom Med, La Jolla, CA USA.
   [Weber, Bernhard H. F.] Univ Hosp Regensburg, Inst Clin Human Genet, Regensburg, Germany.
   [Gorin, Michael B.] Univ Calif Los Angeles, Dept Ophthalmol & Human Genet, Los Angeles, CA USA.
   [den Hollander, Anneke I.] AbbVie, Genom Res Ctr, Cambridge Res Ctr, 200 Sidney St, Cambridge, MA 02139 USA.
C3 Radboud University Nijmegen; AbbVie; University of Iowa; Roche Holding;
   Genentech; University of Regensburg; Case Western Reserve University;
   Case Western Reserve University; Utrecht University; Utrecht University
   Medical Center; Utrecht University; Utrecht University Medical Center;
   National Institutes of Health (NIH) - USA; NIH National Eye Institute
   (NEI); Columbia University; Columbia University; Utah System of Higher
   Education; University of Utah; University of Pennsylvania; Pennsylvania
   Medicine; Erasmus University Rotterdam; Erasmus MC; NYU Langone Medical
   Center; NYU Langone Medical Center; New York University; New York
   University Tandon School of Engineering; University of California
   System; University of California San Diego; University of California
   System; University of California San Diego; University of Regensburg;
   University of California System; University of California Los Angeles;
   AbbVie
RP Hollander, AI (通讯作者)，Radboud Univ Nijmegen, Dept Ophthalmol, Med Ctr, Nijmegen, Netherlands.; Hollander, AI (通讯作者)，AbbVie, Genom Res Ctr, Cambridge, MA USA.; Hollander, AI (通讯作者)，AbbVie, Genom Res Ctr, Cambridge Res Ctr, 200 Sidney St, Cambridge, MA 02139 USA.
EM anneke.denhollander@abbvie.com
FU NIH [EY024605, EY022310, EY030614, R01 EY014800, R24 EY017404, R01
   EY031209, R01EY031663]; NIH/NEI [R01EY028203, R01EY028954, R01EY029315,
   P30EY019007]; Foundation Fighting Blindness Program Project award
   [PPA-1218-0751-COLU]; Research to Prevent Blindness (RPB); Columbia
   University, New York, NY, USA; Voyant Biotherapeutics LLC; Perceive
   Biotherapeutics Inc.; Research to Prevent Blindness, New York, NY;
   Support Sight Foundation (TSSF); Harold and Pauline Price Foundation
FX RFM: NIH grant EY024605. JLH: NIH R01 grants EY022310; EY030614. RA:
   NIH/NEI grants R01EY028203, R01EY028954, R01EY029315, P30EY019007,
   Foundation Fighting Blindness Program Project award PPA-1218-0751-COLU,
   and Unrestricted funds from the Research to Prevent Blindness (RPB) to
   the Department of Ophthalmology, Columbia University, New York, NY, USA.
   GSH: NIH (R01 EY014800, R24 EY017404), charitable donations made to the
   Sharon Eccles Steele Center for Translational Medicine, Voyant
   Biotherapeutics LLC, Perceive Biotherapeutics Inc. and an unrestricted
   grant from Research to Prevent Blindness, New York, NY, to the
   Department of Ophthalmology and Visual Sciences, University of Utah. DS:
   NIH R01 EY031209 and Support Sight Foundation (TSSF). KAF: NIH grant
   R01EY031663. MBG: Harold and Pauline Price Foundation, unrestricted
   grant to the Dept of Ophthalmology UCLA by Research to Prevent
   Blindness, NY NY, and The William & Margaret Fern Holmes Family
   Foundation.
CR Adriaens M E, 2018, Biophys Rev, V10, P1053, DOI 10.1007/s12551-018-0435-2
   Ajana S, 2021, OPHTHALMOLOGY, V128, P587, DOI 10.1016/j.ophtha.2020.08.031
   Biggs R., 2021, 13 INT C COMPLEMENT
   Biggs R, 2020, INVEST OPHTH VIS SCI, V61
   Borras C, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-50420-9
   Brosh R, 2021, P NATL ACAD SCI USA, V118, DOI 10.1073/pnas.2023952118
   Buitendijk GHS, 2014, INVEST OPHTH VIS SCI, V55, P6167, DOI 10.1167/iovs.14-15142
   Chen W, 2010, P NATL ACAD SCI USA, V107, P7401, DOI 10.1073/pnas.0912702107
   Chen XY, 2020, CURR EYE RES, V45, P1390, DOI 10.1080/02713683.2020.1740744
   Cipriani V, 2021, AM J HUM GENET, V108, P1385, DOI 10.1016/j.ajhg.2021.05.015
   Cipriani V, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-14499-3
   Clark BS, 2019, NEURON, V102, P1111, DOI 10.1016/j.neuron.2019.04.010
   Colijn JM, 2021, OPHTHALMOLOGY, V128, P1039, DOI 10.1016/j.ophtha.2020.11.024
   Cowan CS, 2020, CELL, V182, P1623, DOI 10.1016/j.cell.2020.08.013
   Dalvi S, 2019, ADV EXP MED BIOL, V1186, P1, DOI 10.1007/978-3-030-28471-8_1
   de Breuk A, 2021, JAMA OPHTHALMOL, V139, P1218, DOI 10.1001/jamaophthalmol.2021.4102
   de Breuk A, 2021, OPHTHALMOLOGY, V128, P1604, DOI 10.1016/j.ophtha.2020.07.037
   de Jong S, 2022, HUM MOL GENET, V31, P455, DOI 10.1093/hmg/ddab256
   de Jong S, 2021, PROG RETIN EYE RES, V84, DOI 10.1016/j.preteyeres.2021.100952
   de Jong S, 2020, HUM MOL GENET, V29, P2313, DOI 10.1093/hmg/ddaa114
   De Koning-Backus APM, 2019, AM J OPHTHALMOL, V198, P70, DOI 10.1016/j.ajo.2018.09.036
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Fernandez-Godino R, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-28143-0
   Ferrara D, 2015, JAMA OPHTHALMOL, V133, P785, DOI 10.1001/jamaophthalmol.2015.0814
   Fritsche L.G., 2013, NAT GENET, V45, P433
   Fritsche LG, 2016, NAT GENET, V48, P134, DOI 10.1038/ng.3448
   Galloway CA, 2017, P NATL ACAD SCI USA, V114, pE8214, DOI 10.1073/pnas.1710430114
   Gaziano JM, 2016, J CLIN EPIDEMIOL, V70, P214, DOI 10.1016/j.jclinepi.2015.09.016
   Geerlings MJ, 2017, MOL IMMUNOL, V84, P65, DOI 10.1016/j.molimm.2016.11.016
   Giambartolomei C, 2014, PLOS GENET, V10, DOI 10.1371/journal.pgen.1004383
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   Grassmann F, 2019, JAMA OPHTHALMOL, V137, P867, DOI 10.1001/jamaophthalmol.2019.1318
   Grassmann F, 2017, GENOME MED, V9, DOI 10.1186/s13073-017-0418-0
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Hallam TM, 2020, INVEST OPHTH VIS SCI, V61, DOI 10.1167/iovs.61.6.18
   Hecker LA, 2010, HUM MOL GENET, V19, P209, DOI 10.1093/hmg/ddp472
   Heesterbeek TJ, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-43144-3
   Helgason H, 2013, NAT GENET, V45, P1371, DOI 10.1038/ng.2740
   Hughes AE, 2006, NAT GENET, V38, P1173, DOI 10.1038/ng1890
   Java A, 2020, TRANSL VIS SCI TECHN, V9, DOI 10.1167/tvst.9.9.37
   Johnson LV, 2011, P NATL ACAD SCI USA, V108, P18277, DOI 10.1073/pnas.1109703108
   Kavanagh D, 2015, HUM MOL GENET, V24, P3861, DOI 10.1093/hmg/ddv091
   Keenan TDL, 2015, INVEST OPHTH VIS SCI, V56, P4870, DOI 10.1167/iovs.15-17009
   Khanani AM, 2021, AM J OPHTHALMOL, V232, P49, DOI 10.1016/j.ajo.2021.06.017
   Kiel C, 2020, CELLS-BASEL, V9, DOI 10.3390/cells9102257
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Landowski M, 2019, P NATL ACAD SCI USA, V116, P3703, DOI 10.1073/pnas.1814014116
   Laurent J.M., 2019, BIOCHEMISTRY-US, V4, P46
   Laurent JM, 2019, PRECIS CLIN MED, V2, P1, DOI 10.1093/pcmedi/pby019
   Lauwen S, 2017, INVEST OPHTH VIS SCI, V58, pBIO88, DOI 10.1167/iovs.17-21809
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Lores-Motta L, 2021, AM J HUM GENET, V108, P1367, DOI 10.1016/j.ajhg.2021.06.002
   Lukowski SW, 2019, EMBO J, V38, DOI 10.15252/embj.2018100811
   Lutty GA, 2020, EXP EYE RES, V192, DOI 10.1016/j.exer.2020.107939
   Lyu YF, 2021, SCI REP-UK, V11, DOI 10.1038/s41598-021-95122-3
   Macosko EZ, 2015, CELL, V161, P1202, DOI 10.1016/j.cell.2015.05.002
   Maturi R.K., 2021, AM ACAD OPHTHALMOL
   McClellan J, 2010, CELL, V141, P210, DOI 10.1016/j.cell.2010.03.032
   Menon M, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-12780-8
   Mullins RE, 2011, INVEST OPHTH VIS SCI, V52, P1606, DOI 10.1167/iovs.10-6476
   Neale BM, 2010, P NATL ACAD SCI USA, V107, P7395, DOI 10.1073/pnas.0912019107
   Orozco LD, 2020, CELL REP, V30, P1246, DOI 10.1016/j.celrep.2019.12.082
   Panopoulos AD, 2017, STEM CELL REP, V8, P1086, DOI 10.1016/j.stemcr.2017.03.012
   Pappas CM, 2021, HUM GENOMICS, V15, DOI 10.1186/s40246-021-00359-8
   Payer LM, 2017, P NATL ACAD SCI USA, V114, pE3984, DOI 10.1073/pnas.1704117114
   Peng YR, 2019, CELL, V176, P1222, DOI 10.1016/j.cell.2019.01.004
   Peterson RE, 2019, CELL, V179, P589, DOI 10.1016/j.cell.2019.08.051
   Pickrell JK, 2014, AM J HUM GENET, V94, P559, DOI 10.1016/j.ajhg.2014.03.004
   Pilgrim MG, 2017, INVEST OPHTH VIS SCI, V58, DOI 10.1167/iovs.16-21060
   Porcu E, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-10936-0
   Radu RA, 2014, J BIOL CHEM, V289, P9113, DOI 10.1074/jbc.M114.548669
   Ramon y Cajal S, 1972, STRUCTURE RETINA
   Ratnapriya R, 2019, NAT GENET, V51, P606, DOI 10.1038/s41588-019-0351-9
   Raychaudhuri S, 2011, NAT GENET, V43, P1232, DOI 10.1038/ng.976
   Schick T, 2017, EYE, V31, P810, DOI 10.1038/eye.2016.328
   Seddon JM, 2005, ARCH OPHTHALMOL-CHIC, V123, P321, DOI 10.1001/archopht.123.3.321
   Seddon JM, 2020, INVEST OPHTH VIS SCI, V61, DOI 10.1167/iovs.61.14.32
   Seddon JM, 2013, NAT GENET, V45, P1366, DOI 10.1038/ng.2741
   Shekhar K, 2016, CELL, V166, P1308, DOI 10.1016/j.cell.2016.07.054
   Smailhodzic D, 2012, OPHTHALMOLOGY, V119, P339, DOI 10.1016/j.ophtha.2011.07.056
   Smith EN, 2019, STEM CELL REP, V12, P1342, DOI 10.1016/j.stemcr.2019.04.012
   Sridhar A, 2020, CELL REP, V30, P1644, DOI 10.1016/j.celrep.2020.01.007
   Strunz T, 2020, CELLS-BASEL, V9, DOI 10.3390/cells9102267
   Strunz T, 2020, PLOS GENET, V16, DOI 10.1371/journal.pgen.1008934
   Strunz T, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-58510-9
   Sudlow C, 2015, PLOS MED, V12, DOI 10.1371/journal.pmed.1001779
   Sun BB, 2018, NATURE, V558, P73, DOI 10.1038/s41586-018-0175-2
   Taylor RL, 2019, OPHTHALMOLOGY, V126, P1410, DOI 10.1016/j.ophtha.2019.03.013
   Tellier A, 2021, INVEST OPHTH VIS SCI, V62
   Thanassoulis G, 2009, JAMA-J AM MED ASSOC, V301, P2386, DOI 10.1001/jama.2009.812
   Tom I, 2020, P NATL ACAD SCI USA, V117, P9952, DOI 10.1073/pnas.1917608117
   Toomey CB, 2015, P NATL ACAD SCI USA, V112, pE3040, DOI 10.1073/pnas.1424391112
   Tran NM, 2019, NEURON, V104, P1039, DOI 10.1016/j.neuron.2019.11.006
   Tzoumas N, 2021, SURV OPHTHALMOL, V66, P378, DOI 10.1016/j.survophthal.2020.10.008
   van de Ven JPH, 2013, NAT GENET, V45, P813, DOI 10.1038/ng.2640
   Voigt AP, 2019, EXP EYE RES, V184, P234, DOI 10.1016/j.exer.2019.05.001
   Voigt AP, 2021, HUM MOL GENET, V30, P1543, DOI 10.1093/hmg/ddab140
   Voigt AP, 2020, EXP EYE RES, V200, DOI 10.1016/j.exer.2020.108204
   Voigt AP, 2019, P NATL ACAD SCI USA, V116, P24100, DOI 10.1073/pnas.1914143116
   Wagner EK, 2016, SCI REP-UK, V6, DOI 10.1038/srep31531
   Weismann D, 2011, NATURE, V478, P76, DOI 10.1038/nature10449
   Westenskow PD, 2012, INVEST OPHTH VIS SCI, V53, P6282, DOI 10.1167/iovs.12-9721
   Williams BL, 2021, P NATL ACAD SCI USA, V118, DOI 10.1073/pnas.2103617118
   Yan Q, 2018, HUM MOL GENET, V27, P929, DOI 10.1093/hmg/ddy002
   Yan WJ, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-66092-9
   Yates JRW, 2007, NEW ENGL J MED, V357, P553, DOI 10.1056/NEJMoa072618
   Yu Y, 2011, HUM MOL GENET, V20, P3699, DOI 10.1093/hmg/ddr270
   Zhan XW, 2013, NAT GENET, V45, P1375, DOI 10.1038/ng.2758
   Zheng ZY, 2020, NUCLEIC ACIDS RES, V48, pD983, DOI 10.1093/nar/gkz888
NR 110
TC 0
Z9 0
U1 2
U2 2
PU ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD
PI LONDON
PA 24-28 OVAL RD, LONDON NW1 7DX, ENGLAND
SN 0014-4835
EI 1096-0007
J9 EXP EYE RES
JI Exp. Eye Res.
PD DEC
PY 2022
VL 225
AR 109248
DI 10.1016/j.exer.2022.109248
PG 13
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 5Z0LD
UT WOS:000879669200005
PM 36108770
OA hybrid, Green Published
DA 2022-11-30
ER

PT J
AU Honda, S
   Imai, H
   Yamashiro, K
   Kurimoto, Y
   Kanamori-Matsui, N
   Kagotani, Y
   Tamura, Y
   Yamamoto, H
   Ohoto, S
   Takagi, H
   Uenishi, M
   Negi, A
AF Honda, Shigeru
   Imai, Hisanori
   Yamashiro, Kenji
   Kurimoto, Yasuo
   Kanamori-Matsui, Noriko
   Kagotani, Yasuaki
   Tamura, Yasushi
   Yamamoto, Hiroyuki
   Ohoto, Sotaro
   Takagi, Hitoshi
   Uenishi, Mamoru
   Negi, Akira
TI Comparative Assessment of Photodynamic Therapy for Typical Age-Related
   Macular Degeneration and Polypoidal Choroidal Vasculopathy: A
   Multicenter Study in Hyogo Prefecture, Japan
SO OPHTHALMOLOGICA
LA English
DT Article
DE Photodynamic therapy; Age-related macular degeneration; Polypoidal
   choroidal vasculopathy
ID RETINAL ANGIOMATOUS PROLIFERATION; INTRAVITREAL BEVACIZUMAB;
   CLINICAL-TRIAL; VERTEPORFIN; NEOVASCULARIZATION
AB Purpose: We aimed to evaluate the effects of photodynamic therapy (PDT) on different phenotypes of age-related macular degenerations (AMD): typical AMD (tAMD) and polypoidal choroidal vasculopathy (PCV). Procedures: 246 eyes from 242 patients ( tAMD: 139, PCV: 107 eyes) were recruited. Gender, age, best-corrected visual acuity (BCVA) before treatment, greatest linear dimension before treatment, lesion phenotype and PDT frequency were evaluated for predicting the BCVA at 12 months after PDT using stepwise multiple regression analyses. Additionally, 125 eyes with tAMD and 97 eyes with PCV followed up for more than 12 months after the final PDT were compared for the recurrence period. Results: In the stepwise analysis, a younger age, better pre-treatment BCVA, lower PDT frequency, lesions with PCV and a smaller pretreatment greatest linear dimension were all significantly beneficial for a better BCVA at 12 months after PDT. PCV showed a significantly lower PDT frequency and greater improvement in the BCVA than tAMD. The recurrence period of PCV was significantly later than that of tAMD. Conclusions: The phenotype of AMD is significantly correlated with its prognosis after PDT. PCV showed a significantly better response to PDT in terms of BCVA improvement and effect durability. Copyright (C) 2009 S. Karger AG, Basel
C1 [Honda, Shigeru; Imai, Hisanori; Negi, Akira] Kobe Univ, Grad Sch Med, Dept Surg, Div Ophthalmol,Chuo Ku, Kobe, Hyogo 6500017, Japan.
   [Yamashiro, Kenji; Kurimoto, Yasuo] Kobe City Gen Hosp, Dept Ophthalmol, Kobe, Hyogo, Japan.
   [Uenishi, Mamoru] Mitsubishi Kobe Hosp, Dept Ophthalmol, Kobe, Hyogo, Japan.
   [Kanamori-Matsui, Noriko; Kagotani, Yasuaki] Ono Municipal Hosp, Dept Ophthalmol, Ono, Hokkaido, Japan.
   [Tamura, Yasushi; Yamamoto, Hiroyuki] Nippon Steel Hirohata Hosp, Dept Ophthalmol, Himeji, Hyogo, Japan.
   [Ohoto, Sotaro; Takagi, Hitoshi] Hyogo Kenritsu Amagasaki Hosp, Dept Ophthalmol, Amagasaki, Hyogo, Japan.
C3 Kobe University; Kobe City Medical Center General Hospital
RP Honda, S (通讯作者)，Kobe Univ, Grad Sch Med, Dept Surg, Div Ophthalmol,Chuo Ku, 7-5-2 Kusunoki Cho, Kobe, Hyogo 6500017, Japan.
EM sighonda@med.kobe-u.ac.jp
RI Honda, Shigeru/W-4761-2019
OI Yamashiro, Kenji/0000-0001-9354-8558; Imai, Hisanori/0000-0001-8879-3604
CR Ahmad K, 2007, LANCET INFECT DIS, V7, P10, DOI 10.1016/S1473-3099(06)70670-3
   Akaza E, 2007, JPN J OPHTHALMOL, V51, P270, DOI 10.1007/s10384-007-0452-3
   Arnold J, 2001, OPHTHALMOLOGY, V108, P841
   Arnold J, 2001, AM J OPHTHALMOL, V131, P541
   Bhavsar A, 2004, RETINA-J RET VIT DIS, V24, P512
   Blinder KJ, 2003, OPHTHALMOLOGY, V110, P667, DOI 10.1016/S0161-6420(02)01998-X
   Boscia F, 2006, GRAEF ARCH CLIN EXP, V244, P1224, DOI 10.1007/s00417-005-0205-2
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   Brown DM, 2007, AM J OPHTHALMOL, V144, P627, DOI 10.1016/j.ajo.2007.06.039
   Chan WM, 2004, OPHTHALMOLOGY, V111, P1576, DOI 10.1016/j.ophtha.2003.12.056
   Chan WM, 2003, OPHTHALMOLOGY, V110, P2395, DOI 10.1016/S0161-6420(03)00788-7
   Ciardella AP, 2004, SURV OPHTHALMOL, V49, P25, DOI 10.1016/j.survophthal.2003.10.007
   Cleary CA, 2008, EYE, V22, P82, DOI 10.1038/sj.eye.6702936
   Gomi F, 2008, BRIT J OPHTHALMOL, V92, P70, DOI 10.1136/bjo.2007.122283
   Gomi F, 2008, OPHTHALMOLOGY, V115, P141, DOI 10.1016/j.ophtha.2007.02.031
   Kondo N, 2008, INVEST OPHTH VIS SCI, V49, P1101, DOI 10.1167/iovs.07-1145
   Krebs I, 2008, GRAEF ARCH CLIN EXP, V246, P237, DOI 10.1007/s00417-007-0651-0
   Ladewig MS, 2008, GRAEF ARCH CLIN EXP, V246, P17, DOI 10.1007/s00417-007-0654-x
   Leibowitz H M, 1980, Surv Ophthalmol, V24, P335
   Maruko I, 2007, AM J OPHTHALMOL, V144, P15, DOI 10.1016/j.ajo.2007.03.047
   Nakajima M, 2004, JPN J OPHTHALMOL, V48, P249, DOI 10.1007/s10384-003-0057-4
   Potter MJ, 2007, BRIT J OPHTHALMOL, V91, P753, DOI 10.1136/bjo.2006.110239
   SEGATO T, 1993, AGING-CLIN EXP RES, V5, P165, DOI 10.1007/BF03324151
   Spaide RF, 2002, AM J OPHTHALMOL, V134, P62, DOI 10.1016/S0002-9394(02)01452-6
   SPAIDE RF, 1995, RETINA-J RET VIT DIS, V15, P100, DOI 10.1097/00006982-199515020-00003
   Tano Y, 2003, AM J OPHTHALMOL, V136, P1049, DOI 10.1016/S0002-9394(03)00576-2
   Uyama M, 1999, ARCH OPHTHALMOL-CHIC, V117, P1035
   Yannuzzi LA, 2001, RETINA-J RET VIT DIS, V21, P416, DOI 10.1097/00006982-200110000-00003
   Yannuzzi LA, 1997, ARCH OPHTHALMOL-CHIC, V115, P478, DOI 10.1001/archopht.1997.01100150480005
   YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001
NR 30
TC 40
Z9 45
U1 0
U2 3
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 0030-3755
EI 1423-0267
J9 OPHTHALMOLOGICA
JI Ophthalmologica
PY 2009
VL 223
IS 5
BP 333
EP 338
DI 10.1159/000221837
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 491IA
UT WOS:000269570900008
PM 19478533
DA 2022-11-30
ER

PT J
AU Anand, A
   Sharma, K
   Chen, W
   Sharma, NK
AF Anand, Akshay
   Sharma, Kaushal
   Chen, Wei
   Sharma, Neel Kamal
TI Using Current Data to Define New Approach in Age Related Macular
   Degeneration: Need to Accelerate Translational Research
SO CURRENT GENOMICS
LA English
DT Article
DE Age related macular degeneration; Mitochondrial genes; Epigenetics; SNP;
   Biomarkers; Translational research; Bio-informatics
ID GENOME-WIDE ASSOCIATION; COMPLEMENT FACTOR-H; MITOCHONDRIAL-DNA;
   GEOGRAPHIC ATROPHY; CLINICAL-RESEARCH; GENETIC RISK; VARIANTS;
   POLYMORPHISM; SUSCEPTIBILITY; RANIBIZUMAB
AB Age related macular degeneration (AMD) is one of the major retinal degenerative disease of ageing whose complex genetic basis remains undeciphered. The involvement of various other factors like mitochondrial genes, cytoskeletal proteins and the role of epigenetics has been described in this review. Several population based AMD genetic studies have been carried out worldwide. Despite the increased publication of reports, clinical translation still eludes this davastating disease. We suggest models to address roadblocks in clinical translation hoping that these would be beneficial to drive AMD research towards innovative biomarkers and therapeutics Therefore, addressing the need large autopsy studies and combining it with efficient use of bioinformatic tools, statistical modeling and probing SNP-biomarker association are key to time bound resolution of this disease.
C1 [Anand, Akshay; Sharma, Kaushal] Post Grad Inst Med Educ & Res, Dept Neurol, Neurosci Res Lab, Chandigarh, India.
   [Chen, Wei] Univ Pittsburgh, Div Pulm Med Allergy & Immunol, Pittsburgh, PA 15224 USA.
   [Sharma, Neel Kamal] NEI, Neurobiol Neurodegenerat & Repair Lab, Bethesda, MD USA.
C3 Post Graduate Institute of Medical Education & Research (PGIMER),
   Chandigarh; Pennsylvania Commonwealth System of Higher Education
   (PCSHE); University of Pittsburgh; National Institutes of Health (NIH) -
   USA; NIH National Eye Institute (NEI)
RP Anand, A (通讯作者)，Post Grad Inst Med Educ & Res, Dept Neurol, Neurosci Res Lab, Chandigarh, India.
EM akshay1anand@rediffmail.com
RI Chen, Wei/AAX-5994-2020
OI Chen, Wei/0000-0001-7196-8703
CR AAMC, 2006, PROM TRANSL CLIN SCI
   Adamo JE, 2012, ACAD MED, V87, P279, DOI 10.1097/ACM.0b013e318244838a
   Almeida LN, 2012, GRAEF ARCH CLIN EXP, V250, P185, DOI 10.1007/s00417-011-1807-5
   Anand A, 2014, SCI REP-UK, V4, DOI 10.1038/srep04114
   Anand A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0049905
   Arakawa S, 2011, NAT GENET, V43, P1001, DOI 10.1038/ng.938
   Assink JJM, 2005, OPHTHALMOLOGY, V112, P482, DOI 10.1016/j.ophtha.2004.10.035
   Barron MJ, 2001, INVEST OPHTH VIS SCI, V42, P3016
   BEGG CB, 1988, J ROY STAT SOC A STA, V151, P419, DOI 10.2307/2982993
   Bollati V, 2009, MECH AGEING DEV, V130, P234, DOI 10.1016/j.mad.2008.12.003
   Boon CJE, 2008, AM J HUM GENET, V82, P516, DOI 10.1016/j.ajhg.2007.11.007
   Bornstein P, 2009, J CELL COMMUN SIGNAL, V3, P189, DOI 10.1007/s12079-009-0060-8
   Bowler RP, 2013, OMICS, V17, P619, DOI 10.1089/omi.2013.0038
   Canter JA, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002091
   Chakravarthy U, 2010, BMC OPHTHALMOL, V10, DOI 10.1186/1471-2415-10-31
   Chen W, 2010, P NATL ACAD SCI USA, V107, P7401, DOI 10.1073/pnas.0912702107
   Chew EY, 2013, JAMA-J AM MED ASSOC, V309, P2005, DOI 10.1001/jama.2013.4997
   Chong EWT, 2009, ARCH OPHTHALMOL-CHIC, V127, P674, DOI 10.1001/archophthalmol.2009.60
   Cipriani V, 2012, HUM MOL GENET, V21, P4138, DOI 10.1093/hmg/dds225
   Clarke JJ, 2012, ENVIRON MOL MUTAGEN, V53, P631, DOI 10.1002/em.21733
   Committee on Improving the Quality of Cancer Care. Addressing the Challenges of an Aging Population Board on Health Care Services Institute of Medicine, 2013, DELIVERING HIGH QUAL
   de Jong PTVM, 2006, NEW ENGL J MED, V355, P1474, DOI 10.1056/NEJMra062326
   Delcourt C, 2006, INVEST OPHTH VIS SCI, V47, P2329, DOI 10.1167/iovs.05-1235
   DICKERSIN K, 1992, JAMA-J AM MED ASSOC, V267, P374, DOI 10.1001/jama.267.3.374
   DOSSO AA, 1992, OPHTHALMOLOGICA, V205, P24, DOI 10.1159/000310307
   Du W, 2013, ONCOGENE, V32, P3319, DOI 10.1038/onc.2012.359
   EASTERBROOK PJ, 1991, LANCET, V337, P867, DOI 10.1016/0140-6736(91)90201-Y
   Eckmiller MS, 2004, PROG RETIN EYE RES, V23, P495, DOI 10.1016/j.preteyeres.2004.04.005
   Elrakaiby M., 2014, OMICS IN PRESS
   Fritsche LG, 2013, NAT GENET, V45, P433, DOI 10.1038/ng.2578
   Gaudreault J, 2005, INVEST OPHTH VIS SCI, V46, P726, DOI 10.1167/iovs.04-0601
   Gaudreault J, 2007, RETINA-J RET VIT DIS, V27, P1260, DOI 10.1097/IAE.0b013e318134eecd
   Gehrs KM, 2010, ARCH OPHTHALMOL-CHIC, V128, P349, DOI 10.1001/archophthalmol.2010.18
   Gredilla R, 2010, EXP GERONTOL, V45, P478, DOI 10.1016/j.exger.2010.01.017
   Gungor K, 2014, OMICS, V18, P275, DOI 10.1089/omi.2014.0040
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Holliday EG, 2013, PLOS ONE, V8, DOI [10.1371/journal.pone.0082305, 10.1371/journal.pone.0053830]
   Hu YN, 2013, AM J HUM GENET, V92, P547, DOI 10.1016/j.ajhg.2013.03.003
   Jarrett SG, 2008, PROG RETIN EYE RES, V27, P596, DOI 10.1016/j.preteyeres.2008.09.001
   Jomary C, 2006, INVEST OPHTH VIS SCI, V47, P1620, DOI 10.1167/iovs.05-1176
   Jones MM, 2007, ARCH OPHTHALMOL-CHIC, V125, P1235, DOI 10.1001/archopht.125.9.1235
   Kaneko H, 2011, NATURE, V471, P325, DOI 10.1038/nature09830
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1439, DOI 10.1001/archopht.119.10.1439
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Kenney MC, 2010, INVEST OPHTH VIS SCI, V51, P4289, DOI 10.1167/iovs.09-4778
   Klaver CCW, 1998, ARCH OPHTHALMOL-CHIC, V116, P1646, DOI 10.1001/archopht.116.12.1646
   Klein ML, 2011, ARCH OPHTHALMOL-CHIC, V129, P1543, DOI 10.1001/archophthalmol.2011.216
   KLEIN ML, 1994, ARCH OPHTHALMOL-CHIC, V112, P932, DOI 10.1001/archopht.1994.01090190080025
   Klein R, 2007, OPHTHAL EPIDEMIOL, V14, P184, DOI 10.1080/09286580701344381
   MacPherson H, 2004, COMPLEMENT THER MED, V12, P136, DOI 10.1016/j.ctim.2004.07.043
   Mantel I, 2014, OPHTHALMIC GENET, V35, P12, DOI 10.3109/13816810.2013.766217
   Marchenko GN, 2001, GENE, V265, P87, DOI 10.1016/S0378-1119(01)00360-2
   MELROSE MA, 1985, OPHTHALMIC SURG LAS, V16, P648
   MEYERS SM, 1988, ARCH OPHTHALMOL-CHIC, V106, P651
   Mullins RF, 2011, BMC MED GENET, V12, DOI 10.1186/1471-2350-12-58
   Munoz B, 2005, ARCH OPHTHALMOL-CHIC, V123, P1575, DOI 10.1001/archopht.123.11.1575
   Murillo H, 2006, ACAD MED, V81, P107, DOI 10.1097/00001888-200602000-00002
   Naj AC, 2013, ANN HUM GENET, V77, P215, DOI 10.1111/ahg.12011
   Ozdemir V, 2014, OMICS, V18, P211, DOI 10.1089/omi.2014.0029
   PIGUET B, 1993, BRIT J OPHTHALMOL, V77, P400, DOI 10.1136/bjo.77.7.400
   Primakoff P, 2000, TRENDS GENET, V16, P83, DOI 10.1016/S0168-9525(99)01926-5
   Ryu E, 2010, MOL VIS, V16, P2811
   Sabbadini RA, 2011, BRIT J PHARMACOL, V162, P1225, DOI 10.1111/j.1476-5381.2010.01118.x
   SanGiovanni JP, 2007, ARCH OPHTHALMOL-CHIC, V125, P1225, DOI 10.1001/archopht.125.9.1225
   SanGiovanni JP, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005508
   Seddon JM, 1997, AM J OPHTHALMOL, V123, P199, DOI 10.1016/S0002-9394(14)71036-0
   Seddon JM, 2006, ARCH OPHTHALMOL-CHIC, V124, P995, DOI 10.1001/archopht.124.7.995
   Seddon JM, 2013, JAMA OPHTHALMOL, V131, P448, DOI 10.1001/jamaophthalmol.2013.2578
   Seddon JM, 2009, INVEST OPHTH VIS SCI, V50, P2044, DOI 10.1167/iovs.08-3064
   Seddon JM, 2013, FARADAY DISCUSS, V161, P9, DOI 10.1039/c2fd90045a
   Sepp T, 2006, INVEST OPHTH VIS SCI, V47, P536, DOI 10.1167/iovs.05-1143
   Sharma NK, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0070193
   Sharma NK, 2013, GENE, V523, P106, DOI 10.1016/j.gene.2013.03.052
   Sharma NK, 2012, CURR NEUROVASC RES, V9, P256
   Sharma NK, 2012, DNA CELL BIOL, V31, P1618, DOI 10.1089/dna.2012.1786
   Sobrin L, 2012, OPHTHALMOLOGY, V119, P1874, DOI 10.1016/j.ophtha.2012.03.014
   Sundaresan P, 2012, INVEST OPHTH VIS SCI, V53, P7492, DOI 10.1167/iovs.12-10073
   Thakkinstian A, 2012, AM J EPIDEMIOL, V176, P361, DOI 10.1093/aje/kws031
   Thaler S, 2010, ACTA OPHTHALMOL, V88, pE170, DOI 10.1111/j.1755-3768.2010.01927.x
   Thomas DC, 2004, INT J EPIDEMIOL, V33, P21, DOI 10.1093/ije/dyh048
   Thornton J, 2005, EYE, V19, P935, DOI 10.1038/sj.eye.6701978
   Tian J, 2012, INVEST OPHTH VIS SCI, V53, P4262, DOI 10.1167/iovs.11-8542
   Tunis SR, 2003, JAMA-J AM MED ASSOC, V290, P1624, DOI 10.1001/jama.290.12.1624
   Wight TN, 2005, ARTERIOSCL THROM VAS, V25, P12, DOI 10.1161/01.ATV.0000150043.43083.aa
   Yang ZL, 2008, NEW ENGL J MED, V359, P1456, DOI 10.1056/NEJMoa0802437
   Yu Y, 2011, HUM MOL GENET, V20, P3699, DOI 10.1093/hmg/ddr270
   Zareparsi S, 2005, AM J HUM GENET, V77, P149, DOI 10.1086/431426
   Zerhouni E, 2003, SCIENCE, V302, P63, DOI 10.1126/science.1091867
   Zhao C, 2011, J CLIN INVEST, V121, P369, DOI 10.1172/JCI44303
NR 89
TC 8
Z9 8
U1 0
U2 5
PU BENTHAM SCIENCE PUBL LTD
PI SHARJAH
PA EXECUTIVE STE Y-2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB
   EMIRATES
SN 1389-2029
EI 1875-5488
J9 CURR GENOMICS
JI Curr. Genomics
PY 2014
VL 15
IS 4
BP 266
EP 277
DI 10.2174/1389202915666140516204512
PG 12
WC Biochemistry & Molecular Biology; Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Genetics & Heredity
GA AT9CJ
UT WOS:000345225300003
PM 25132797
OA Green Published, Green Submitted
DA 2022-11-30
ER

PT J
AU Zarbin, MA
AF Zarbin, MA
TI Current concepts in the pathogenesis of age-related macular degeneration
SO ARCHIVES OF OPHTHALMOLOGY
LA English
DT Review
ID ENDOTHELIAL GROWTH-FACTOR; RETINAL-PIGMENT EPITHELIUM; GLYCATION
   END-PRODUCTS; EXPERIMENTAL CHOROIDAL NEOVASCULARIZATION; IMMUNE-MEDIATED
   PROCESSES; OCULAR BLOOD-FLOW; BRUCHS MEMBRANE; GEOGRAPHIC ATROPHY;
   TISSUE INHIBITOR; MATRIX METALLOPROTEINASES
AB Objective: To review and synthesize information concerning the pathogenesis of age-related macular degeneration (AMD).
   Methods: Review of the English-language literature.
   Results: Five concepts relevant to the cell biology of AMD are as follows: (1) AMD involves aging changes plus additional pathological changes (ie, AMD is not just an aging change); (2) in aging and AMD, oxidative stress causes retinal pigment epithelial (RPE) and, possibly, choriocapillaris injury; (3) in AMD (and perhaps in aging), RPE and, possibly, choriocapillaris injury results in a chronic inflammatory response within the Bruch membrane and the choroid; (4) in AMD, RPE and, possibly, choriocapillaris injury and inflammation lead to formation of an abnormal extracellular matrix (ECM), which causes altered diffusion of nutrients to the retina and RPE, possibly precipitating further RPE and retinal damage; and (5) the abnormal ECM results in altered RPE-choriocapillaris behavior leading ultimately to atrophy of the retina, RPE, and choriocapillaris and/or choroidal new vessel growth. In this sequence of events, both the environment and multiple genes can alter a patient's susceptibility to AMD. Implicit in this characterization of AMD pathogenesis is the concept that there is linear progression from one stage of the disease to the next. This assumption may be incorrect, and different biochemical pathways leading to geographic atrophy and/or choroidal new vessels may operate simultaneously.
   Conclusions: Better knowledge of AMD cell biology will lead to better treatments for AMD at all stages of the disease. Many unanswered questions regarding AMD pathogenesis remain. Multiple animal models and in vitro models of specific aspects of AMD are needed to make rapid progress in developing effective therapies for different stages of the disease.
C1 Univ Med & Dent New Jersey, New Jersey Med Sch, Inst Ophthalmol & Vis Sci, Newark, NJ 07103 USA.
C3 Rutgers State University New Brunswick; Rutgers State University Medical
   Center
RP Zarbin, MA (通讯作者)，Univ Med & Dent New Jersey, New Jersey Med Sch, Inst Ophthalmol & Vis Sci, 90 Bergen St,Suite 6100, Newark, NJ 07103 USA.
EM zarbin@njmsa.umdnj.edu
OI Zarbin, Marco/0000-0002-7811-7132
CR Abdelsalam A, 1999, SURV OPHTHALMOL, V44, P1, DOI 10.1016/S0039-6257(99)00072-7
   Ahir A, 2002, INVEST OPHTH VIS SCI, V43, P458
   AHMED J, 1993, INVEST OPHTH VIS SCI, V34, P516
   Akiyama H, 2000, NEUROBIOL AGING, V21, P383, DOI 10.1016/S0197-4580(00)00124-X
   ALEXANDER JP, 1990, INVEST OPHTH VIS SCI, V31, P2520
   Allikmets R, 1997, SCIENCE, V277, P1805, DOI 10.1126/science.277.5333.1805
   Ambati J, 2003, NAT MED, V9, P1390, DOI 10.1038/nm950
   Anand R, 2000, OPHTHALMOLOGY, V107, P2224
   Anderson DH, 2002, AM J OPHTHALMOL, V134, P411, DOI 10.1016/S0002-9394(02)01624-0
   Anderson DH, 2001, AM J OPHTHALMOL, V131, P767, DOI 10.1016/S0002-9394(00)00961-2
   Asahara T, 1998, CIRC RES, V83, P233, DOI 10.1161/01.RES.83.3.233
   Bailey TA, 2001, EXP EYE RES, V73, P851, DOI 10.1006/exer.2001.1089
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   Beatty S, 2001, INVEST OPHTH VIS SCI, V42, P439
   Benner JD, 2002, ARCH OPHTHALMOL-CHIC, V120, P586, DOI 10.1001/archopht.120.5.586
   Benson AB, 2000, CLIN CANCER RES, V6, P3870
   Berendschot TTJM, 2002, INVEST OPHTH VIS SCI, V43, P1928
   Bohr V A, 1998, J Investig Dermatol Symp Proc, V3, P11
   Bone RA, 2001, INVEST OPHTH VIS SCI, V42, P235
   BOULTON M, 1993, J PHOTOCH PHOTOBIO B, V19, P201, DOI 10.1016/1011-1344(93)87085-2
   BRESSLER NM, 1994, RETINA-J RET VIT DIS, V14, P130, DOI 10.1097/00006982-199414020-00006
   Bressler NM, 2002, AM J OPHTHALMOL, V133, P168, DOI 10.1016/S0002-9394(01)01237-5
   Burns R P, 1980, Trans Am Ophthalmol Soc, V78, P206
   Cai JY, 1999, INVEST OPHTH VIS SCI, V40, P959
   Cai JY, 2000, PROG RETIN EYE RES, V19, P205, DOI 10.1016/S1350-9462(99)00009-9
   Campochiaro P A, 1999, Mol Vis, V5, P34
   CASTORINA C, 1992, NEUROCHEM RES, V17, P599, DOI 10.1007/BF00968789
   CHANDRASEKHAR S, 1983, P NATL ACAD SCI-BIOL, V80, P4747, DOI 10.1073/pnas.80.15.4747
   CHEN JC, 1992, INVEST OPHTH VIS SCI, V33, P334
   Chen SJ, 2001, BRIT J OPHTHALMOL, V85, P1411, DOI 10.1136/bjo.85.12.1411
   CHOW CK, 1986, J AM COLL NUTR, V5, P305
   CHURCH DF, 1985, ENVIRON HEALTH PERSP, V64, P111, DOI 10.2307/3430003
   Ciulla TA, 1999, AM J OPHTHALMOL, V128, P75, DOI 10.1016/S0002-9394(99)00061-6
   Ciulla TA, 2002, BRIT J OPHTHALMOL, V86, P209, DOI 10.1136/bjo.86.2.209
   COHEN SM, 1994, BRIT J OPHTHALMOL, V78, P791, DOI 10.1136/bjo.78.10.791
   Coudray C, 1997, BIOL TRACE ELEM RES, V57, P183, DOI 10.1007/BF02778201
   Crabb JW, 2002, P NATL ACAD SCI USA, V99, P14682, DOI 10.1073/pnas.222551899
   Curcio CA, 1999, ARCH OPHTHALMOL-CHIC, V117, P329, DOI 10.1001/archopht.117.3.329
   DAS A, 1990, ARCH OPHTHALMOL-CHIC, V108, P421, DOI 10.1001/archopht.1990.01070050119045
   DASTGHEIB K, 1994, ARCH OPHTHALMOL-CHIC, V112, P813, DOI 10.1001/archopht.1994.01090180111045
   Davies S., 1998, IOVS, V39, pS129
   Dawson DW, 1999, SCIENCE, V285, P245, DOI 10.1126/science.285.5425.245
   Del Priore LV, 2001, AM J OPHTHALMOL, V131, P472, DOI 10.1016/S0002-9394(00)00850-3
   DELAPAZ M, 1992, INVEST OPHTH VIS SCI, V33, P3497
   DelaPaz MA, 1997, INVEST OPHTH VIS SCI, V38, P1060
   Delcourt C, 1999, ARCH OPHTHALMOL-CHIC, V117, P1384, DOI 10.1001/archopht.117.10.1384
   Delcourt C, 1999, OPHTHALMOLOGY, V106, P215, DOI 10.1016/S0161-6420(99)90059-3
   Delori FC, 2000, INVEST OPHTH VIS SCI, V41, P496
   DUGUID IGM, 1992, CURR EYE RES, V11, P153, DOI 10.3109/02713689208999526
   DYLEWSKI DP, 1983, NEUROBIOL AGING, V4, P89, DOI 10.1016/0197-4580(83)90059-3
   ELNER SG, 1992, LAB INVEST, V66, P200
   Evans J, 1996, BRIT J OPHTHALMOL, V80, P9, DOI 10.1136/bjo.80.1.9
   Farboud B, 1999, MOL VIS, V5, pU1
   FARKAS TG, 1971, AM J OPHTHALMOL, V71, P1206, DOI 10.1016/0002-9394(71)90964-0
   FAURY G, 1995, J VASC RES, V32, P112, DOI 10.1159/000159084
   FEENEYBURNS L, 1985, AM J OPHTHALMOL, V100, P686, DOI 10.1016/0002-9394(85)90625-7
   FEENEYBURNS L, 1984, INVEST OPHTH VIS SCI, V25, P195
   Felbor U, 1997, INVEST OPHTH VIS SCI, V38, P1054
   Finnemann SC, 2002, P NATL ACAD SCI USA, V99, P3842, DOI 10.1073/pnas.052025899
   Fish G, 2003, OPHTHALMOLOGY, V110, P979, DOI 10.1016/S0161-6420(03)00085-X
   Frank RN, 1999, AM J OPHTHALMOL, V127, P694, DOI 10.1016/S0002-9394(99)00032-X
   Frank RN, 1997, OPHTHALMIC RES, V29, P341, DOI 10.1159/000268032
   Friedman DS, 1999, OPHTHALMOLOGY, V106, P1049, DOI 10.1016/S0161-6420(99)90267-1
   FRIEDMAN E, 1963, ARCH OPHTHALMOL-CHIC, V69, P220
   FRIEDRICHSON T, 1995, CURR EYE RES, V14, P693, DOI 10.3109/02713689508998497
   FULOP T, 1986, BIOCHEM BIOPH RES CO, V141, P92, DOI 10.1016/S0006-291X(86)80339-4
   GASS JDM, 1973, ARCH OPHTHALMOL-CHIC, V90, P206
   GASS JDM, 1997, STEREOSCOPIC ATLAS M, P70
   GOTTSCH JD, 1990, INVEST OPHTH VIS SCI, V31, P1674
   Green W R, 1977, Trans Am Ophthalmol Soc, V75, P180
   GREEN WR, 1993, OPHTHALMOLOGY, V100, P1519
   GRINDLE CFJ, 1978, T OPHTHAL SOC UK, V98, P172
   Grunwald JE, 1998, ARCH OPHTHALMOL-CHIC, V116, P150
   Grunwald JE, 1998, INVEST OPHTH VIS SCI, V39, P385
   Guo L, 1999, INVEST OPHTH VIS SCI, V40, P2676
   GURNE DH, 1991, OPHTHALMOLOGY, V98, P602
   GUYER DR, 1986, ARCH OPHTHALMOL-CHIC, V104, P702, DOI 10.1001/archopht.1986.01050170092029
   Guymer R, 1999, PROG RETIN EYE RES, V18, P59, DOI 10.1016/S1350-9462(98)00012-3
   Hageman GS, 1999, FASEB J, V13, P477, DOI 10.1096/fasebj.13.3.477
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Haimovici R, 2001, INVEST OPHTH VIS SCI, V42, P1592
   Hammes HP, 1999, INVEST OPHTH VIS SCI, V40, P1855
   Hammond BR, 1996, VISION RES, V36, P2001, DOI 10.1016/0042-6989(95)00290-1
   Hammond BR, 1996, VISION RES, V36, P3003, DOI 10.1016/0042-6989(96)00008-9
   Hammond BR, 1996, EXP EYE RES, V62, P293, DOI 10.1006/exer.1996.0035
   Hammond BR, 1997, OPTOMETRY VISION SCI, V74, P499, DOI 10.1097/00006324-199707000-00017
   Hammond CJ, 2002, OPHTHALMOLOGY, V109, P730, DOI 10.1016/S0161-6420(01)01049-1
   Hanahan D, 1997, SCIENCE, V277, P48, DOI 10.1126/science.277.5322.48
   Handa JT, 1999, INVEST OPHTH VIS SCI, V40, P775
   Hangai M, 2001, INVEST OPHTH VIS SCI, V42, P1617
   Hangai M, 2001, HUM GENE THER, V12, P1311, DOI 10.1089/104303401750270968
   HARMAN D, 1956, J GERONTOL, V11, P298, DOI 10.1093/geronj/11.3.298
   Hawkins BS, 1999, MOL VIS, V5
   HERIOT WJ, 1984, OPHTHALMOLOGY, V91, P1603
   Hernandez E, 1999, INVEST OPHTH VIS SCI, V40, pS927
   HEWITT AT, 1989, INVEST OPHTH VIS SCI, V30, P478
   HOGAN MJ, 1967, ARCH OPHTHALMOL-CHIC, V77, P410, DOI 10.1001/archopht.1967.00980020412022
   Hogan MJ, 1971, HISTOLOGY HUMAN EYE
   Holz FG, 2001, INVEST OPHTH VIS SCI, V42, P1051
   HOLZ FG, 1994, ARCH OPHTHALMOL-CHIC, V112, P402, DOI 10.1001/archopht.1994.01090150132035
   Holz FG, 1999, INVEST OPHTH VIS SCI, V40, P737
   Honda S, 2001, INVEST OPHTH VIS SCI, V42, P2419
   Hu QB, 1996, EXP CELL RES, V224, P251, DOI 10.1006/excr.1996.0135
   Hussain AA, 2002, J OPT SOC AM A, V19, P166, DOI 10.1364/JOSAA.19.000166
   HUTCHINSON AK, 1993, ARCH OPHTHALMOL-CHIC, V111, P734, DOI 10.1001/archopht.1993.01090060020010
   Ishibashi T, 1998, ARCH OPHTHALMOL-CHIC, V116, P1629, DOI 10.1001/archopht.116.12.1629
   ISHIBASHI T, 1985, ARCH OPHTHALMOL-CHIC, V103, P708
   ISHIBASHI T, 1986, AM J OPHTHALMOL, V101, P342, DOI 10.1016/0002-9394(86)90830-5
   JACOBSON SG, 1995, NAT GENET, V11, P27, DOI 10.1038/ng0995-27
   Johnson LV, 2000, EXP EYE RES, V70, P441, DOI 10.1006/exer.1999.0798
   Johnson LV, 2001, EXP EYE RES, V73, P887, DOI 10.1006/exer.2001.1094
   Johnson LV, 2002, P NATL ACAD SCI USA, V99, P11830, DOI 10.1073/pnas.192203399
   Kamei M, 1999, INVEST OPHTH VIS SCI, V40, P2367
   Kaplan HJ, 1999, NAT MED, V5, P292, DOI 10.1038/6509
   KARCIOGLU ZA, 1982, SURV OPHTHALMOL, V27, P114, DOI 10.1016/0039-6257(82)90195-3
   KARWATOWSKI WSS, 1995, BRIT J OPHTHALMOL, V79, P944, DOI 10.1136/bjo.79.10.944
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   KATZ ML, 1994, INVEST OPHTH VIS SCI, V35, P3613
   Kennedy CJ, 1995, EYE, V9, P763, DOI 10.1038/eye.1995.192
   KILLINGSWORTH MC, 1987, GRAEF ARCH CLIN EXP, V225, P406, DOI 10.1007/BF02334166
   KILLINGSWORTH MC, 1990, EYE, V4, P613, DOI 10.1038/eye.1990.86
   Kim I, 1999, INVEST OPHTH VIS SCI, V40, P2115
   King GL, 1996, ENDOCRIN METAB CLIN, V25, P255, DOI 10.1016/S0889-8529(05)70324-8
   Klein R, 1997, OPHTHALMOLOGY, V104, P7, DOI 10.1016/S0161-6420(97)30368-6
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Klein R, 1999, PROG RETIN EYE RES, V18, P371, DOI 10.1016/S1350-9462(98)00025-1
   KLEIN R, 1993, OPHTHALMOLOGY, V100, P406
   Kliffen M, 1997, BRIT J OPHTHALMOL, V81, P154, DOI 10.1136/bjo.81.2.154
   KORTE GE, 1989, INT REV CYTOL, V114, P221
   Krzystolik MG, 2002, ARCH OPHTHALMOL-CHIC, V120, P338
   Kuntz CA, 1996, INVEST OPHTH VIS SCI, V37, P1772
   Kvanta A, 2000, CURR EYE RES, V21, P684, DOI 10.1076/0271-3683(200009)21:3;1-R;FT684
   Kvanta A, 1996, INVEST OPHTH VIS SCI, V37, P1929
   Lanchoney DM, 1998, ARCH OPHTHALMOL-CHIC, V116, P1045, DOI 10.1001/archopht.116.8.1045
   Landrum J T, 1997, Adv Pharmacol, V38, P537
   Langton KP, 1998, J BIOL CHEM, V273, P16778, DOI 10.1074/jbc.273.27.16778
   LaVail MM, 1998, INVEST OPHTH VIS SCI, V39, P592
   Leu ST, 2002, EXP EYE RES, V74, P141, DOI 10.1006/exer.2001.1112
   LILES MR, 1991, ARCH OPHTHALMOL-CHIC, V109, P1285, DOI 10.1001/archopht.1991.01080090111033
   Lip PL, 2001, OPHTHALMOLOGY, V108, P705, DOI 10.1016/S0161-6420(00)00663-1
   LOEFFLER KU, 1992, ARCH OPHTHALMOL-CHIC, V110, P15
   LOFFLER KU, 1986, GRAEF ARCH CLIN EXP, V224, P493, DOI 10.1007/BF02154735
   Lois N, 2002, AM J OPHTHALMOL, V133, P341, DOI 10.1016/S0002-9394(01)01404-0
   Lopez PF, 1996, INVEST OPHTH VIS SCI, V37, P855
   Lu M, 1998, J CLIN INVEST, V101, P1219, DOI 10.1172/JCI1277
   Lutty G, 1999, MOL VIS, V5
   LYDA W, 1957, AM J OPHTHALMOL, V44, P362, DOI 10.1016/0002-9394(57)93133-1
   Maillard LC, 1912, CR HEBD ACAD SCI, V154, P66
   Maisonpierre PC, 1997, SCIENCE, V277, P55, DOI 10.1126/science.277.5322.55
   Malek G, 2003, AM J PATHOL, V162, P413, DOI 10.1016/S0002-9440(10)63836-9
   Marmorstein AD, 2002, INVEST OPHTH VIS SCI, V43, P2435
   Marshall J., 1998, RETINAL PIGMENT EPIT, P669
   MCLEOD DS, 1994, INVEST OPHTH VIS SCI, V35, P3799
   McLeod DS, 2002, INVEST OPHTH VIS SCI, V43, P1986
   MOORE DJ, 1995, INVEST OPHTH VIS SCI, V36, P1290
   Moore DJ, 2001, INVEST OPHTH VIS SCI, V42, P2970
   Mori K, 2002, INVEST OPHTH VIS SCI, V43, P1994
   Mori K, 2002, INVEST OPHTH VIS SCI, V43, P2428
   Mousa SA, 1999, J CELL BIOCHEM, V74, P135, DOI 10.1002/(SICI)1097-4644(19990701)74:1<135::AID-JCB15>3.0.CO;2-#
   Mullins RF, 2000, INVEST OPHTH VIS SCI, V41, pS24
   Mullins RF, 1997, OPHTHALMOLOGY, V104, P288, DOI 10.1016/S0161-6420(97)30322-4
   Mullins RF, 2000, FASEB J, V14, P835, DOI 10.1096/fasebj.14.7.835
   Munch G, 1998, J NEURAL TRANSM, V105, P439, DOI 10.1007/s007020050069
   MURANO S, 1991, MOL CELL BIOL, V11, P3905, DOI 10.1128/MCB.11.8.3905
   Murata T, 2000, INVEST OPHTH VIS SCI, V41, P2309
   Nasir MA, 1997, BRIT J OPHTHALMOL, V81, P481, DOI 10.1136/bjo.81.6.481
   Nauck M, 1998, EUR J PHARMACOL, V341, P309, DOI 10.1016/S0014-2999(97)01464-7
   Nelson KC, 1999, INVEST OPHTH VIS SCI, V40, P1927
   NEWSOME DA, 1987, CURR EYE RES, V6, P1211, DOI 10.3109/02713688709025231
   Noji Y, 2001, CLIN CHEM LAB MED, V39, P380, DOI 10.1515/CCLM.2001.060
   Oh H, 1999, INVEST OPHTH VIS SCI, V40, P1891
   Oh H, 1999, J BIOL CHEM, V274, P15732, DOI 10.1074/jbc.274.22.15732
   Ohno-Matsui K, 2001, J CELL PHYSIOL, V189, P323, DOI 10.1002/jcp.10026
   Okubo A, 1999, INVEST OPHTH VIS SCI, V40, P443
   Otani A, 1999, INVEST OPHTH VIS SCI, V40, P1912
   PACKER L, 1993, ANN NY ACAD SCI, V691, P48, DOI 10.1111/j.1749-6632.1993.tb26156.x
   PandaJonas S, 1996, AM J OPHTHALMOL, V121, P181, DOI 10.1016/S0002-9394(14)70583-5
   PAULEIKHOFF D, 1990, OPHTHALMOLOGY, V97, P171
   Pauleikhoff D, 1999, INVEST OPHTH VIS SCI, V40, pS920
   Pauleikhoff D, 1999, ARCH OPHTHALMOL-CHIC, V117, P1353, DOI 10.1001/archopht.117.10.1353
   PAULEIKHOFF D, 1990, AM J OPHTHALMOL, V109, P211, DOI 10.1016/S0002-9394(14)75989-6
   Pauleikhoff D., 1994, Ophthalmologe, V91, P730
   PENFOLD P, 1984, AUST J OPHTHALMOL, V12, P23
   PENFOLD PL, 1987, GRAEF ARCH CLIN EXP, V225, P70, DOI 10.1007/BF02155808
   Penfold PL, 1997, INVEST OPHTH VIS SCI, V38, P2125
   Penfold PL, 2000, CLIN EXP IMMUNOL, V121, P458, DOI 10.1046/j.1365-2249.2000.01316.x
   PENFOLD PL, 1985, GRAEF ARCH CLIN EXP, V223, P69, DOI 10.1007/BF02150948
   PENFOLD PL, 1990, GRAEF ARCH CLIN EXP, V228, P270, DOI 10.1007/BF00920033
   Piguet B, 1996, OPHTHALMIC GENET, V17, P175, DOI 10.3109/13816819609057891
   RAMRATTAN RS, 1994, INVEST OPHTH VIS SCI, V35, P2857
   Ranson NT, 2002, BRIT J OPHTHALMOL, V86, P527, DOI 10.1136/bjo.86.5.527
   Rasmussen H, 2001, Hum Gene Ther, V12, P2029
   RASOAMANANTENA P, 1994, EXP CELL RES, V213, P121, DOI 10.1006/excr.1994.1181
   REMULLA JFC, 1995, BRIT J OPHTHALMOL, V79, P558, DOI 10.1136/bjo.79.6.558
   RIKANS LE, 1988, BIOCHIM BIOPHYS ACTA, V966, P269, DOI 10.1016/0304-4165(88)90076-1
   Robert L, 1998, GERONTOLOGY, V44, P307, DOI 10.1159/000022034
   Robert L, 1998, PATHOL BIOL, V46, P491
   Ruiz A, 1996, BIOCHEM BIOPH RES CO, V226, P467, DOI 10.1006/bbrc.1996.1379
   RUNGGERBRANDLE E, 1987, INVEST OPHTH VIS SCI, V28, P2026
   Sakaguchi H, 2002, EXP EYE RES, V74, P547, DOI 10.1006/exer.2002.1186
   Sakai N, 1996, J AM CHEM SOC, V118, P1559, DOI 10.1021/ja953480g
   Samiec PS, 1998, FREE RADICAL BIO MED, V24, P699, DOI 10.1016/S0891-5849(97)00286-4
   SARKS JP, 1988, EYE, V2, P552, DOI 10.1038/eye.1988.106
   Sarks JP, 1997, EYE, V11, P515, DOI 10.1038/eye.1997.137
   SARKS JP, 1994, EYE, V8, P269, DOI 10.1038/eye.1994.57
   SARKS SH, 1976, BRIT J OPHTHALMOL, V60, P324, DOI 10.1136/bjo.60.5.324
   Sarks SH, 1999, BRIT J OPHTHALMOL, V83, P358, DOI 10.1136/bjo.83.3.358
   SARKS SH, 1982, AUST J OPHTHALMOL, V10, P91, DOI 10.1111/j.1442-9071.1982.tb00366.x
   SATO TN, 1995, NATURE, V376, P70, DOI 10.1038/376070a0
   SCHATZ H, 1989, OPHTHALMOLOGY, V96, P1541
   Schmidt AM, 2000, BBA-MOL CELL RES, V1498, P99, DOI 10.1016/S0167-4889(00)00087-2
   Schutt F, 2000, INVEST OPHTH VIS SCI, V41, P2303
   Schwesinger C, 2001, AM J PATHOL, V158, P1161, DOI 10.1016/S0002-9440(10)64063-1
   Seddon JM, 1997, AM J OPHTHALMOL, V123, P199, DOI 10.1016/S0002-9394(14)71036-0
   SEDDON JM, 1994, JAMA-J AM MED ASSOC, V272, P1413, DOI 10.1001/jama.272.18.1413
   Seo MS, 1999, AM J PATHOL, V154, P1743, DOI 10.1016/S0002-9440(10)65430-2
   SEREGARD S, 1994, GRAEF ARCH CLIN EXP, V232, P325, DOI 10.1007/BF00175983
   SHERAIDAH G, 1993, OPHTHALMOLOGY, V100, P47
   SIPOS EP, 1994, ANN NY ACAD SCI, V732, P263, DOI 10.1111/j.1749-6632.1994.tb24741.x
   Smith W, 1999, OPHTHALMOLOGY, V106, P761, DOI 10.1016/S0161-6420(99)90164-1
   Spaide RF, 1999, RETINA-J RET VIT DIS, V19, P141, DOI 10.1097/00006982-199902000-00010
   SPERDUTO RD, 1993, ARCH OPHTHALMOL-CHIC, V111, P104
   Spilsbury K, 2000, AM J PATHOL, V157, P135, DOI 10.1016/S0002-9440(10)64525-7
   Starita C, 1997, INVEST OPHTH VIS SCI, V38, P762
   Starita C, 1996, EXP EYE RES, V62, P565, DOI 10.1006/exer.1996.0066
   STARITA C, 1995, AM J MED GENET, V57, P235, DOI 10.1002/ajmg.1320570224
   Steen B, 1998, INVEST OPHTH VIS SCI, V39, P2194
   Stone EM, 1999, NAT GENET, V22, P199, DOI 10.1038/9722
   Stone EM, 2001, HUM MOL GENET, V10, P2285, DOI 10.1093/hmg/10.20.2285
   Stone EM, 1998, NAT GENET, V20, P328, DOI 10.1038/3798
   Streilein JW, 2002, VISION RES, V42, P487, DOI 10.1016/S0042-6989(01)00185-7
   Sundelin S, 1998, CURR EYE RES, V17, P851, DOI 10.1076/ceyr.17.8.851.5146
   Sundelin SP, 2001, FREE RADICAL BIO MED, V30, P74, DOI 10.1016/S0891-5849(00)00444-5
   Sundelin SP, 2001, FREE RADICAL BIO MED, V31, P217, DOI 10.1016/S0891-5849(01)00573-1
   Sunness JS, 1999, OPHTHALMOLOGY, V106, P910, DOI 10.1016/S0161-6420(99)00509-6
   Sunness JS, 1999, MOL VIS, V5
   Takahashi T, 2000, AM J OPHTHALMOL, V130, P774, DOI 10.1016/S0002-9394(00)00772-8
   TARABOLETTI G, 1995, J NATL CANCER I, V87, P293, DOI 10.1093/jnci/87.4.293
   TATE DJ, 1993, INVEST OPHTH VIS SCI, V34, P2348
   TINKLER JH, 1995, NAT MED, V1, P98
   TOMBRANTINK J, 1989, INVEST OPHTH VIS SCI, V30, P1700
   TORCZYNSKI E, 1976, AM J OPHTHALMOL, V81, P428, DOI 10.1016/0002-9394(76)90298-1
   TSO MOM, 1985, OPHTHALMOLOGY, V92, P628
   VandenLangenberg GM, 1998, AM J EPIDEMIOL, V148, P204, DOI 10.1093/oxfordjournals.aje.a009625
   VANDERSCHAFT TL, 1993, BRIT J OPHTHALMOL, V77, P657, DOI 10.1136/bjo.77.10.657
   VANDEWOUDE MFJ, 1987, J AM COLL NUTR, V6, P307, DOI 10.1080/07315724.1987.10720192
   VERZAR F, 1957, GERONTOLOGY, V1, P363, DOI 10.1159/000210714
   Vingerling JR, 1995, EPIDEMIOL REV, V17, P347, DOI 10.1093/oxfordjournals.epirev.a036198
   VINGERLING JR, 1995, OPHTHALMOLOGY, V102, P205
   Wallace DC, 1997, SCI AM, V277, P40, DOI 10.1038/scientificamerican0897-40
   Wallace DC, 1999, SCIENCE, V283, P1482, DOI 10.1126/science.283.5407.1482
   Wallace Douglas C., 1998, Biofactors, V7, P187
   Wassell J, 1999, J BIOL CHEM, V274, P23828, DOI 10.1074/jbc.274.34.23828
   WEBER BHF, 1994, NAT GENET, V8, P352, DOI 10.1038/ng1294-352
   WEITER JJ, 1988, AM J OPHTHALMOL, V106, P286, DOI 10.1016/0002-9394(88)90363-7
   WEITER JJ, 1986, INVEST OPHTH VIS SCI, V27, P145
   Wells JA, 1996, BRIT J OPHTHALMOL, V80, P363, DOI 10.1136/bjo.80.4.363
   WEST S, 1994, ARCH OPHTHALMOL-CHIC, V112, P222, DOI 10.1001/archopht.1994.01090140098031
   Winkler BS, 1999, MOL VIS, V5
   Yates JRW, 2000, J MED GENET, V37, P83, DOI 10.1136/jmg.37.2.83
   Ye SQ, 2002, J BIOMED SCI, V9, P384, DOI 10.1159/000064547
   Yu CE, 1997, AM J HUM GENET, V60, P330
   ZARBIN MA, 1999, AGE RELATED MACULAR, P363
NR 263
TC 795
Z9 857
U1 3
U2 112
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 0003-9950
EI 1538-3601
J9 ARCH OPHTHALMOL-CHIC
JI Arch. Ophthalmol.
PD APR
PY 2004
VL 122
IS 4
BP 598
EP 614
DI 10.1001/archopht.122.4.598
PG 17
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 812GT
UT WOS:000220828700020
PM 15078679
OA Bronze
DA 2022-11-30
ER

PT J
AU Meredith, EL
   Mainolfi, N
   Poor, S
   Qiu, YB
   Miranda, K
   Powers, J
   Liu, DL
   Ma, FP
   Solovay, C
   Rao, C
   Johnson, L
   Ji, N
   Artman, G
   Hardegger, L
   Hanks, S
   Shen, SY
   Woolfenden, A
   Fassbender, E
   Sivak, JM
   Zhang, YQ
   Long, D
   Cepeda, R
   Liu, F
   Hosagrahara, VP
   Lee, W
   Tarsa, P
   Anderson, K
   Elliott, J
   Jaffee, B
AF Meredith, Erik L.
   Mainolfi, Nello
   Poor, Stephen
   Qiu, Yubin
   Miranda, Karl
   Powers, James
   Liu, Donglei
   Ma, Fupeng
   Solovay, Catherine
   Rao, Chang
   Johnson, Leland
   Ji, Nan
   Artman, Gerald
   Hardegger, Leo
   Hanks, Shawn
   Shen, Siyuan
   Woolfenden, Amber
   Fassbender, Elizabeth
   Sivak, Jeremy M.
   Zhang, Yiqin
   Long, Debby
   Cepeda, Rosemarie
   Liu, Fang
   Hosagrahara, Vinayak P.
   Lee, Wendy
   Tarsa, Peter
   Anderson, Karen
   Elliott, Jason
   Jaffee, Bruce
TI Discovery of Oral VEGFR-2 Inhibitors with Prolonged Ocular Retention
   That Are Efficacious in Models of Wet Age-Related Macular Degeneration
SO JOURNAL OF MEDICINAL CHEMISTRY
LA English
DT Article
ID ENDOTHELIAL GROWTH-FACTOR; CHOROIDAL NEOVASCULARIZATION; RANIBIZUMAB;
   KINASE; PAZOPANIB; RECEPTOR
AB The benefit of intravitreal anti-VEGF therapy in treating wet age-related macular degeneration (AMD) is well established. Identification of VEGFR-2 inhibitors with optimal ADME properties for an ocular indication provides opportunities for dosing routes beyond intravitreal injection. We employed a high throughput in vivo screening strategy with rodent models of choroidal neovascularization and iterative compound design to identify VEGFR-2 inhibitors with potential to benefit wet AMD patients. These compounds demonstrate preferential ocular tissue distribution and efficacy after oral administration while minimizing systemic exposure.
C1 [Meredith, Erik L.; Mainolfi, Nello; Miranda, Karl; Powers, James; Liu, Donglei; Ma, Fupeng; Solovay, Catherine; Rao, Chang; Johnson, Leland; Ji, Nan; Artman, Gerald; Hardegger, Leo; Elliott, Jason] Novartis Inst BioMed Res, Global Discovery Chem, Cambridge, MA 02139 USA.
   [Poor, Stephen; Qiu, Yubin; Hanks, Shawn; Shen, Siyuan; Woolfenden, Amber; Fassbender, Elizabeth; Sivak, Jeremy M.; Zhang, Yiqin; Long, Debby; Cepeda, Rosemarie; Liu, Fang; Anderson, Karen; Jaffee, Bruce] Novartis Inst BioMed Res, Ophthalmol, Cambridge, MA 02139 USA.
   [Hosagrahara, Vinayak P.; Lee, Wendy] Novartis Inst BioMed Res, Metab & Pharmacokinet, Cambridge, MA 02139 USA.
   [Tarsa, Peter] Novartis Inst BioMed Res, Chem & Pharmaceut Profiling, Cambridge, MA 02139 USA.
C3 Novartis; Novartis; Novartis; Novartis
RP Meredith, EL (通讯作者)，Novartis Inst BioMed Res, Global Discovery Chem, 100 Technol Sq, Cambridge, MA 02139 USA.
EM erik.meredith@novartis.com
RI Sivak, Jeremy/AAA-3467-2022
OI Sivak, Jeremy/0000-0002-8776-223X; Tarsa, Peter/0000-0002-0578-7944
CR AIELLO LP, 1994, NEW ENGL J MED, V331, P1480, DOI 10.1056/NEJM199412013312203
   Amparo F, 2013, INVEST OPHTH VIS SCI, V54, P537, DOI 10.1167/iovs.12-11032
   Bates DO, 1997, AM J PHYSIOL-HEART C, V273, pH687, DOI 10.1152/ajpheart.1997.273.2.H687
   Bold G., 2008, PCT Int. Appl., Patent No. [WO 2008009487, 2008009487]
   Bold G., 2006, PCT Int. Appl., Patent No. [WO 2006059234, 2006059234]
   Boyer Stephen J., 2002, Current Topics in Medicinal Chemistry, V2, P973, DOI 10.2174/1568026023393273
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Connolly TJ, 2005, ORG PROCESS RES DEV, V9, P80, DOI 10.1021/op0498114
   Diago T, 2008, MAYO CLIN PROC, V83, P231
   Ferrara N, 1997, ENDOCR REV, V18, P4, DOI 10.1210/er.18.1.4
   Gao H, 2004, VISION RES, V44, P349, DOI 10.1016/j.visres.2003.09.027
   Ji N, 2010, TETRAHEDRON LETT, V51, P6799, DOI 10.1016/j.tetlet.2010.10.073
   Johnson L, 2013, SYNTHESIS-STUTTGART, V45, P171, DOI 10.1055/s-0032-1317935
   Jones KA, 2009, METHODS MOL BIOL, V565, P209, DOI 10.1007/978-1-60327-258-2_10
   Keefe D, 2011, ONCOLOGIST, V16, P432, DOI 10.1634/theoncologist.2010-0271
   Kemt M., 2008, ACTA OPHTHALMOL, V86, P456
   Kutchinsky J, 2003, ASSAY DRUG DEV TECHN, V1, P685, DOI 10.1089/154065803770381048
   Kwak N, 2000, INVEST OPHTH VIS SCI, V41, P3158
   Lopez PF, 1996, INVEST OPHTH VIS SCI, V37, P855
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Matsumoto T, 2001, Sci STKE, V2001, pre21, DOI 10.1126/stke.2001.112.re21
   Musumeci F, 2012, J MED CHEM, V55, P10797, DOI 10.1021/jm301085w
   Nguyen QD, 2006, AM J OPHTHALMOL, V142, P961, DOI 10.1016/j.ajo.2006.06.068
   Schenone S, 2007, CURR MED CHEM, V14, P2495, DOI 10.2174/092986707782023622
   Seelen W, 2003, TETRAHEDRON LETT, V44, P4491, DOI 10.1016/S0040-4039(03)00988-2
   SHALABY F, 1995, NATURE, V376, P62, DOI 10.1038/376062a0
   Takahashi K, 2009, ARCH OPHTHALMOL-CHIC, V127, P494, DOI 10.1001/archophthalmol.2009.27
   TERMAN BI, 1992, BIOCHEM BIOPH RES CO, V187, P1579, DOI 10.1016/0006-291X(92)90483-2
   Wan ZK, 2007, J ORG CHEM, V72, P10194, DOI 10.1021/jo7020373
   Zhou LP, 2007, J PHARM SCI-US, V96, P3052, DOI 10.1002/jps.20913
NR 30
TC 22
Z9 23
U1 0
U2 12
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0022-2623
EI 1520-4804
J9 J MED CHEM
JI J. Med. Chem.
PD DEC 10
PY 2015
VL 58
IS 23
BP 9273
EP 9286
DI 10.1021/acs.jmedchem.5b01227
PG 14
WC Chemistry, Medicinal
WE Science Citation Index Expanded (SCI-EXPANDED); Index Chemicus (IC)
SC Pharmacology & Pharmacy
GA CY3WG
UT WOS:000366340000014
PM 26568411
OA Green Published
DA 2022-11-30
ER

PT J
AU Pollmann, S
   Rosenblum, L
   Linnhoff, S
   Porracin, E
   Geringswald, F
   Herbik, A
   Renner, K
   Hoffmann, MB
AF Pollmann, Stefan
   Rosenblum, Lisa
   Linnhoff, Stefanie
   Porracin, Eleonora
   Geringswald, Franziska
   Herbik, Anne
   Renner, Katja
   Hoffmann, Michael B.
TI Preserved Contextual Cueing in Realistic Scenes in Patients with
   Age-Related Macular Degeneration
SO BRAIN SCIENCES
LA English
DT Article
DE visual search; vision loss; incidental learning; macular degeneration;
   fovea
ID VISUAL-SEARCH; MEMORY
AB Foveal vision loss has been shown to reduce efficient visual search guidance due to contextual cueing by incidentally learned contexts. However, previous studies used artificial (T- among L-shape) search paradigms that prevent the memorization of a target in a semantically meaningful scene. Here, we investigated contextual cueing in real-life scenes that allow explicit memory of target locations in semantically rich scenes. In contrast to the contextual cueing deficits in artificial scenes, contextual cueing in patients with age-related macular degeneration (AMD) did not differ from age-matched normal-sighted controls. We discuss this in the context of visuospatial working-memory demands for which both eye movement control in the presence of central vision loss and memory-guided search may compete. Memory-guided search in semantically rich scenes may depend less on visuospatial working memory than search in abstract displays, potentially explaining intact contextual cueing in the former but not the latter. In a practical sense, our findings may indicate that patients with AMD are less deficient than expected after previous lab experiments. This shows the usefulness of realistic stimuli in experimental clinical research.
C1 [Pollmann, Stefan; Rosenblum, Lisa; Linnhoff, Stefanie; Porracin, Eleonora; Geringswald, Franziska] Otto von Guericke Univ, Dept Expt Psychol, Postfach 4120, D-39016 Magdeburg, Germany.
   [Pollmann, Stefan; Hoffmann, Michael B.] Otto von Guericke Univ, Ctr Behav Brain Sci, D-39016 Magdeburg, Germany.
   [Pollmann, Stefan] Capital Normal Univ, Beijing Key Lab Learning & Cognit, Beijing 100048, Peoples R China.
   [Pollmann, Stefan] Capital Normal Univ, Sch Psychol, Beijing 100048, Peoples R China.
   [Geringswald, Franziska] Aix Marseille Univ, Lab Neurosci Cognit, UMR 7291, F-13331 Marseille, France.
   [Geringswald, Franziska] CNRS, F-13331 Marseille, France.
   [Herbik, Anne; Hoffmann, Michael B.] Otto von Guericke Univ, Dept Ophthalmol, D-39016 Magdeburg, Germany.
   [Renner, Katja] Eye Clin Johannispl, D-04103 Leipzig, Germany.
C3 Otto von Guericke University; Otto von Guericke University; Capital
   Normal University; Capital Normal University; Centre National de la
   Recherche Scientifique (CNRS); CNRS - National Institute for Biology
   (INSB); UDICE-French Research Universities; Aix-Marseille Universite;
   Centre National de la Recherche Scientifique (CNRS); Otto von Guericke
   University
RP Pollmann, S (通讯作者)，Otto von Guericke Univ, Dept Expt Psychol, Postfach 4120, D-39016 Magdeburg, Germany.; Pollmann, S (通讯作者)，Otto von Guericke Univ, Ctr Behav Brain Sci, D-39016 Magdeburg, Germany.; Pollmann, S (通讯作者)，Capital Normal Univ, Beijing Key Lab Learning & Cognit, Beijing 100048, Peoples R China.; Pollmann, S (通讯作者)，Capital Normal Univ, Sch Psychol, Beijing 100048, Peoples R China.
EM stefan.pollmann@ovgu.de; erosenblum94@gmail.com;
   stefanie.linnhoff@med.ovgu.de; eleonora.porracin@gmail.com;
   franziska.geringswald@gmail.com; anne.herbik@ovgu.de;
   renner@augen-leipzig.de; michael.hoffmann@med.ovgu.de
RI Pollmann, Stefan/AAH-5584-2020
OI Pollmann, Stefan/0000-0001-5840-5658; Linnhoff,
   Stefanie/0000-0001-6241-2949; Rosenblum, Lisa/0000-0003-4155-4029
FU Deutsche Forschungsgemeinschaft [PO548/14-2]
FX This work was supported by a grant of the Deutsche
   Forschungsgemeinschaft (PO548/14-2) to S.P.
CR Annac E, 2013, J VISION, V13, DOI 10.1167/13.13.6
   BIEDERMA.I, 1972, SCIENCE, V177, P77, DOI 10.1126/science.177.4043.77
   Boucart M, 2013, VISION RES, V86, P35, DOI 10.1016/j.visres.2013.04.006
   Boucart M, 2013, INVEST OPHTH VIS SCI, V54, P1950, DOI 10.1167/iovs.12-9680
   Brockmole JR, 2006, VIS COGN, V13, P99, DOI 10.1080/13506280500165188
   Chun MM, 1998, COGNITIVE PSYCHOL, V36, P28, DOI 10.1006/cogp.1998.0681
   Colagiuri B, 2016, PSYCHON B REV, V23, P1996, DOI 10.3758/s13423-016-1063-0
   Dienes Z, 2014, FRONT PSYCHOL, V5, DOI 10.3389/fpsyg.2014.00781
   Geringswald F, 2016, J VISION, V16, DOI 10.1167/16.2.6
   Geringswald F, 2015, J EXP PSYCHOL LEARN, V41, P1485, DOI 10.1037/xlm0000117
   Geringswald F, 2013, J VISION, V13, DOI 10.1167/13.3.28
   Geringswald F, 2012, FRONT HUM NEUROSCI, V6, DOI 10.3389/fnhum.2012.00134
   Geyer T, 2012, FRONT HUM NEUROSCI, V6, DOI 10.3389/fnhum.2012.00272
   Geyer T, 2010, J EXP PSYCHOL HUMAN, V36, P515, DOI 10.1037/a0017448
   JASP Team, 2020, JASP VERS 0 14
   Jiang YV., 2019, SPATIAL LEARNING ATT, P59, DOI [10.1007/7657_2019_19, DOI 10.1007/7657_2019_19]
   Manginelli AA, 2013, ATTEN PERCEPT PSYCHO, V75, P1103, DOI 10.3758/s13414-013-0466-5
   Manginelli AA, 2012, EXP PSYCHOL, V59, P47, DOI 10.1027/1618-3169/a000125
   Peirce JW, 2009, FRONT NEUROINFORM, V2, DOI 10.3389/neuro.11.010.2008
   Pollmann S, 2020, TRANSL VIS SCI TECHN, V9, DOI 10.1167/tvst.9.8.15
   Pollmann S, 2019, BRIT J PSYCHOL, V110, P372, DOI 10.1111/bjop.12311
   Smith ND, 2011, OPHTHAL PHYSL OPT, V31, P225, DOI 10.1111/j.1475-1313.2011.00836.x
   Vadillo MA, 2016, PSYCHON B REV, V23, P87, DOI 10.3758/s13423-015-0892-6
   Vo MLH, 2013, COGNITION, V126, P198, DOI 10.1016/j.cognition.2012.09.017
   Wagenmakers EJ, 2018, PSYCHON B REV, V25, P58, DOI [10.3758/s13423-017-1323-7, 10.3758/s13423-017-1343-3]
NR 25
TC 0
Z9 0
U1 1
U2 5
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2076-3425
J9 BRAIN SCI
JI Brain Sci.
PD DEC
PY 2020
VL 10
IS 12
AR 941
DI 10.3390/brainsci10120941
PG 12
WC Neurosciences
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC Neurosciences & Neurology
GA PK2BS
UT WOS:000602256800001
PM 33297319
OA Green Published, gold, Green Submitted
DA 2022-11-30
ER

PT J
AU Yamamoto-Rodriguez, L
   Zarbin, MA
   Casaroli-Marano, RP
AF Yamamoto-Rodriguez, Liria
   Zarbin, Marco A.
   Casaroli-Marano, Ricardo P.
TI New frontiers and clinical implications in the pathophysiology of
   age-related macular degeneration
SO MEDICINA CLINICA
LA English
DT Review
DE Inflammation; Oxidative stress; Drusen; Inflammasomes; Complement
   pathway; VEGF
ID GEOGRAPHIC ATROPHY; OXIDATIVE STRESS; BETA; ANGIOGENESIS; INFLAMMATION;
   GALECTIN-1; COMPLEMENT; PROTEIN; DRUSEN; VEGF
AB Age-related macular degeneration (AMD) involves progressive degeneration of the central retina, termed the macula, which provides high-acuity vision needed to recognize faces, drive, etc. AMD is the leading cause of blindness in the aging population. A plethora of paradigm-shifting perspectives regarding AMD's multifaceted pathophysiology is emerging. This review will endeavor to gather novel insights and attempts to identify translational implications and new areas of research. The concept of aberrant inflammation being at the center of age-related diseases, particularly AMD, is being received with increasing credence. Retinal angiogenesis, at the forefront of the neovascular complications of AMD (nAMD), is now being understood as an imbalance between trophic factors released by retinal cells secretome. Additionally, mechanisms involving oxidative stress and inflammatory complement pathways have also been identified, along with genetic and other risk factors that play a key role in AMD's onset and progression. Associations have been drawn with AMD and other degenerative deposit diseases such as Alzheimer's disease, atherosclerosis, and glomerulonephritis, which are providing further insight into this maculopathy. (C) 2020 Elsevier Espafia, S.L.U. All rights reserved.
C1 [Yamamoto-Rodriguez, Liria; Casaroli-Marano, Ricardo P.] Univ Barcelona, Sch Med FMCS, Dept Surg, Barcelona, Spain.
   [Yamamoto-Rodriguez, Liria; Casaroli-Marano, Ricardo P.] Univ Barcelona, Hosp Clin Barcelona, Barcelona, Spain.
   [Zarbin, Marco A.] Rutgers State Univ, Rutgers New Jersey Med Sch, Inst Ophthalmol & Visual Sci, Newark, NJ USA.
   [Casaroli-Marano, Ricardo P.] Inst Biomed Res IIB St Pau SGR1113, Barcelona, Spain.
   [Casaroli-Marano, Ricardo P.] BST, Barcelona, Spain.
C3 University of Barcelona; University of Barcelona; Hospital Clinic de
   Barcelona; Rutgers State University Newark; Rutgers State University New
   Brunswick; Rutgers State University Medical Center
RP Casaroli-Marano, RP (通讯作者)，Univ Barcelona, Sch Med FMCS, Dept Surg, Barcelona, Spain.; Casaroli-Marano, RP (通讯作者)，Univ Barcelona, Hosp Clin Barcelona, Barcelona, Spain.; Casaroli-Marano, RP (通讯作者)，Inst Biomed Res IIB St Pau SGR1113, Barcelona, Spain.; Casaroli-Marano, RP (通讯作者)，BST, Barcelona, Spain.
EM rcasaroli@ub.edu
OI Zarbin, Marco/0000-0002-7811-7132
CR Al-Zamil WM, 2017, CLIN INTERV AGING, V12, P1313, DOI 10.2147/CIA.S143508
   Araujo RS, 2018, BIOCHIMIE, V155, P104, DOI 10.1016/j.biochi.2018.06.019
   Blasiak J, 2017, OXID MED CELL LONGEV, V2017, DOI 10.1155/2017/5293258
   Boon CJF, 2013, PROG RETIN EYE RES, V37, P90, DOI 10.1016/j.preteyeres.2013.08.003
   Cabral Thiago, 2017, Int J Retina Vitreous, V3, P31, DOI 10.1186/s40942-017-0084-9
   Campagne MV, 2016, IMMUNOBIOLOGY, V221, P733, DOI 10.1016/j.imbio.2015.11.007
   Campagne MV, 2014, J PATHOL, V232, P151, DOI 10.1002/path.4266
   Campbell M, 2013, J MOL MED, V91, P1059, DOI 10.1007/s00109-013-1050-0
   Chen M, 2015, J LEUKOCYTE BIOL, V98, P713, DOI 10.1189/jlb.3RI0615-239R
   Chirco KR, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00539
   Croci DO, 2014, CELL, V156, P744, DOI 10.1016/j.cell.2014.01.043
   Curcio CA, 2001, INVEST OPHTH VIS SCI, V42, P265
   Curcio CA, 2010, J LIPID RES, V51, P451, DOI 10.1194/jlr.R002238
   Datta S, 2017, PROG RETIN EYE RES, V60, P201, DOI 10.1016/j.preteyeres.2017.03.002
   Devarajan G, 2016, CURR EYE RES, V41, P1235, DOI 10.3109/02713683.2015.1109129
   Farnoodian M, 2015, PHYSL REP, V3, P1
   Farnoodian M, 2018, AM J PHYSIOL-CELL PH, V314, pC456, DOI 10.1152/ajpcell.00259.2017
   Farnoodian M, 2017, CLIN SCI, V131, P1763, DOI 10.1042/CS20170066
   Ferris FL, 2005, ARCH OPHTHALMOL-CHIC, V123, P1570
   Fleckenstein M, 2018, OPHTHALMOLOGY, V125, P369, DOI 10.1016/j.ophtha.2017.08.038
   Fritsche LG, 2015, NAT GENET, V35, P30
   Layana AG, 2017, NUTRIENTS, V9, DOI 10.3390/nu9101120
   GREEN WR, 1993, OPHTHALMOLOGY, V100, P1519
   Gupta V, 2016, CELL MOL LIFE SCI, V73, P4279, DOI 10.1007/s00018-016-2295-x
   Handa JT, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-11262-1
   Handa JT, 2017, BBA-MOL CELL BIOL L, V1862, P430, DOI 10.1016/j.bbalip.2016.07.013
   Ishikawa M, 2015, J OPHTHALMOL, V2015, DOI 10.1155/2015/138070
   Kanda A, 2015, SCI REP, V5, P1
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Kauppinen A, 2016, CELL MOL LIFE SCI, V73, P1765, DOI 10.1007/s00018-016-2147-8
   Kijlstra A, 2015, OPHTHALMIC RES, V54, P64, DOI 10.1159/000432401
   Liu N, 2016, SCI REP-UK, V6, DOI [10.1038/srep36276, 10.1038/srep33819]
   Fanjul-Moles ML, 2016, OXID MED CELL LONGEV, V2016, DOI 10.1155/2016/7420637
   Luo GH, 2016, SCI REP-UK, V6, P1, DOI [10.1038/srep35231, 10.1038/s41598-016-0027-y]
   Marazita MC, 2016, REDOX BIOL, V7, P78, DOI 10.1016/j.redox.2015.11.011
   Oak ASW, 2014, RETINA-J RET VIT DIS, V34, P825, DOI 10.1097/IAE.0000000000000121
   Ong SR, 2018, EYE, V32, P1296, DOI 10.1038/s41433-018-0081-8
   Ooi KGJ, 2019, SURV OPHTHALMOL, V64, P401, DOI 10.1016/j.survophthal.2019.01.013
   Pennington KL, 2016, EYE VISION, V3, DOI 10.1186/s40662-016-0063-5
   Pikuleva IA, 2014, PROG RETIN EYE RES, V41, P64, DOI 10.1016/j.preteyeres.2014.03.002
   Roizenblatt M, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19113688
   SARKS JP, 1994, EYE, V8, P269, DOI 10.1038/eye.1994.57
   Shaw PX, 2016, AIMS MOL SCI, V3, P196, DOI 10.3934/molsci.2016.2.196
   Sunness JS, 2008, OPHTHALMOLOGY, V115, P1480, DOI 10.1016/j.ophtha.2008.03.009
   Sunness JS, 2005, AM J OPHTHALMOL, V140, P1085, DOI 10.1016/j.ajo.2005.07.040
   Sunness JS, 1997, OPHTHALMOLOGY, V104, P1677, DOI 10.1016/S0161-6420(97)30079-7
   Thornton J, 2005, EYE, V19, P935, DOI 10.1038/sj.eye.6701978
   Toomey CB, 2018, PROG RETIN EYE RES, V62, P38, DOI 10.1016/j.preteyeres.2017.09.001
   Waltl I, 2018, CURR EYE RES, V43, P368, DOI 10.1080/02713683.2017.1403632
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Wu J, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0089600
   Xu QY, 2018, LIPIDS HEALTH DIS, V17, DOI 10.1186/s12944-017-0647-7
   Yang N, 2017, EXP EYE RES, V159, P1, DOI 10.1016/j.exer.2017.02.015
   Zarbin MA, 2004, ARCH OPHTHALMOL-CHIC, V122, P598, DOI 10.1001/archopht.122.4.598
   Zarbin MA, 2014, DEV OPHTHALMOL, V53, P1, DOI 10.1159/000358536
   Zarbin MA, 2010, RETINA-J RET VIT DIS, V30, P1350, DOI 10.1097/IAE.0b013e3181f57e30
   Zhao YH, 2015, MOL NEUROBIOL, V52, P533, DOI 10.1007/s12035-014-8886-3
NR 57
TC 2
Z9 2
U1 0
U2 3
PU ELSEVIER ESPANA SLU
PI BARCELONA
PA AV JOSEP TARRADELLAS, 20-30, 1ERA PLANTA, BARCELONA, CP-08029, SPAIN
SN 0025-7753
EI 1578-8989
J9 MED CLIN-BARCELONA
JI Med. Clin.
PD JUN 26
PY 2020
VL 154
IS 12
BP 496
EP 504
DI 10.1016/j.medcli.2020.01.023
PG 9
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA LZ5LQ
UT WOS:000541265800005
PM 32197861
DA 2022-11-30
ER

PT J
AU Bennis, A
   Gorgels, TGMF
   ten Brink, JB
   van der Spek, PJ
   Bossers, K
   Heine, VM
   Bergen, AA
AF Bennis, Anna
   Gorgels, Theo G. M. F.
   ten Brink, Jacoline B.
   van der Spek, Peter J.
   Bossers, Koen
   Heine, Vivi M.
   Bergen, Arthur A.
TI Comparison of Mouse and Human Retinal Pigment Epithelium Gene Expression
   Profiles: Potential Implications for Age-Related Macular Degeneration
SO PLOS ONE
LA English
DT Article
ID OXIDATIVE STRESS; STEM-CELLS; SUPEROXIDE-DISMUTASE; HUMAN RPE; ZINC;
   MODEL; DRUSEN; MICE; INFLAMMATION; PATHOGENESIS
AB Background
   The human retinal pigment epithelium (RPE) plays an important role in the pathogenesis of age related macular degeneration (AMD). AMD is the leading cause of blindness worldwide. There is currently no effective treatment available. Preclinical studies in AMD mouse models are essential to develop new therapeutics. This requires further in-depth knowledge of the similarities and differences between mouse and human RPE.
   Methods
   We performed a microarray study to identify and functionally annotate RPE specific gene expression in mouse and human RPE. We used a meticulous method to determine C57BL/6J mouse RPE signature genes, correcting for possible RNA contamination from its adjacent layers: the choroid and the photoreceptors. We compared the signature genes, gene expression profiles and functional annotations of the mouse and human RPE.
   Results
   We defined sets of mouse (64), human (171) and mouse-human interspecies (22) RPE signature genes. Not unexpectedly, our gene expression analysis and comparative functional annotation suggested that, in general, the mouse and human RPE are very similar. For example, we found similarities for general features, like "organ development" and "disorders related to neurological tissue". However, detailed analysis of the molecular pathways and networks associated with RPE functions, suggested also multiple species-specific differences, some of which may be relevant for the development of AMD. For example, CFHR1, most likely the main complement regulator in AMD pathogenesis was highly expressed in human RPE, but almost absent in mouse RPE. Furthermore, functions assigned to mouse and human RPE expression profiles indicate (patho-) biological differences related to AMD, such as oxidative stress, Bruch's membrane, immune-regulation and outer blood retina barrier.
   Conclusion
   These differences may be important for the development of new therapeutic strategies and translational studies in age-related macular degeneration.
C1 [Bennis, Anna; ten Brink, Jacoline B.; Bergen, Arthur A.] Univ Amsterdam, Acad Med Ctr, Dept Clin Genet, NL-1105 AZ Amsterdam, Netherlands.
   [Bennis, Anna; Gorgels, Theo G. M. F.; Bergen, Arthur A.] Royal Netherlands Acad Arts & Sci, Netherlands Inst Neurosci NIN KNAW, Amsterdam, Netherlands.
   [Gorgels, Theo G. M. F.] Maastricht Univ, Univ Eye, Ctr Med, Clin Maastricht, Maastricht, Netherlands.
   [van der Spek, Peter J.] Erasmus Univ, Med Ctr, Dept Bioinformat, Rotterdam, Netherlands.
   [Bossers, Koen] Royal Netherlands Acad Arts & Sci, Netherlands Inst Neurosci, Lab Neuroregenerat, Amsterdam, Netherlands.
   [Heine, Vivi M.] Vrije Univ Amsterdam, Med Ctr, Dept Pediat Child Neurol, Amsterdam, Netherlands.
   [Heine, Vivi M.] Vrije Univ Amsterdam, Ctr Neurogen & Cognit Res, Dept Complex Trait Genet, Amsterdam, Netherlands.
   [Bergen, Arthur A.] Univ Amsterdam, Acad Med Ctr, Dept Ophthalmol, NL-1105 AZ Amsterdam, Netherlands.
C3 University of Amsterdam; Academic Medical Center Amsterdam; Vrije
   Universiteit Amsterdam; Royal Netherlands Academy of Arts & Sciences;
   Netherlands Institute for Neuroscience (NIN-KNAW); Maastricht
   University; Maastricht University Medical Centre (MUMC); Erasmus
   University Rotterdam; Erasmus MC; Royal Netherlands Academy of Arts &
   Sciences; Netherlands Institute for Neuroscience (NIN-KNAW); Vrije
   Universiteit Amsterdam; Vrije Universiteit Amsterdam; University of
   Amsterdam; Academic Medical Center Amsterdam
RP Bergen, AA (通讯作者)，Univ Amsterdam, Acad Med Ctr, Dept Clin Genet, Meibergdreef 9, NL-1105 AZ Amsterdam, Netherlands.
EM aabergen@amc.uva.nl
RI Heine, Vivi M/F-1741-2011
OI Heine, Vivi M/0000-0003-4416-3875; Bergen, Arthur/0000-0002-6333-9576
FU General Dutch Foundation Preventing Blindness; foundation
   Blinden-Penning; National Foundation for Blindness and Low Vision
   (LSBS); National Foundation of Macular Degeneration (MD); Netherlands
   Eye Foundation (Oogvereniging); Gelderse Foundation for the Blind;
   Retina Netherlands Foundation; Foundation Winckel-Sweep; Rotterdam
   Foundation for the Blind (RvB); Hague Foundation "Care for the Blind"
   [2011-6]
FX This study was supported by grants from the General Dutch Foundation
   Preventing Blindness, the foundation Blinden-Penning, the National
   Foundation for Blindness and Low Vision (LSBS); The National Foundation
   of Macular Degeneration (MD); The Netherlands Eye Foundation
   (Oogvereniging); The Gelderse Foundation for the Blind; Retina
   Netherlands Foundation; The Foundation Winckel-Sweep; The Rotterdam
   Foundation for the Blind (RvB); and The Hague Foundation "Care for the
   Blind" (all coordinated through the UitZicht platform, project 2011-6).
   The funders had no role in study design, data collection and analysis,
   decision to publish, or preparation of the manuscript.
CR Ambati J, 2003, NAT MED, V9, P1390, DOI 10.1038/nm950
   Anderson DH, 2002, AM J OPHTHALMOL, V134, P411, DOI 10.1016/S0002-9394(02)01624-0
   Anderson DH, 2010, PROG RETIN EYE RES, V29, P95, DOI 10.1016/j.preteyeres.2009.11.003
   Bailey TA, 2004, INVEST OPHTH VIS SCI, V45, P675, DOI 10.1167/iovs.03-0351
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   Behndig A, 1998, INVEST OPHTH VIS SCI, V39, P471
   Booij JC, 2010, PROG RETIN EYE RES, V29, P1, DOI 10.1016/j.preteyeres.2009.08.003
   Booij Judith C, 2010, PLoS One, V5, pe9341, DOI 10.1371/journal.pone.0009341
   Booij JC, 2009, BMC GENOMICS, V10, DOI 10.1186/1471-2164-10-164
   Buschini E, 2015, CLIN OPHTHALMOL, V9, P563, DOI 10.2147/OPTH.S59724
   Campa C, 2011, CURR DRUG TARGETS, V12, P173, DOI 10.2174/138945011794182674
   Chavali VRM, 2011, HUM MOL GENET, V20, P2000, DOI 10.1093/hmg/ddr080
   Chew EY, 2013, JAMA-J AM MED ASSOC, V309, P2005, DOI 10.1001/jama.2013.4997
   Chew EY, 2012, OPHTHALMOLOGY, V119, P2282, DOI 10.1016/j.ophtha.2012.05.027
   Coffey PJ, 2007, P NATL ACAD SCI USA, V104, P16651, DOI 10.1073/pnas.0705079104
   de Jong PTVM, 2006, NEW ENGL J MED, V355, P1474, DOI 10.1056/NEJMra062326
   Dufner-Beattie J, 2007, HUM MOL GENET, V16, P1391, DOI 10.1093/hmg/ddm088
   Ervin JF, 2007, J NEUROPATH EXP NEUR, V66, P1093, DOI 10.1097/nen.0b013e31815c196a
   Flinn JM, 2014, METALLOMICS, V6, P1223, DOI 10.1039/c4mt00058g
   Fritsche LG, 2010, HUM MOL GENET, V19, P4694, DOI 10.1093/hmg/ddq399
   Hageman GS, 2006, ANN MED, V38, P592, DOI 10.1080/07853890601097030
   Hawkins BS, 1999, MOL VIS, V5
   Hollyfield JG, 2008, NAT MED, V14, P194, DOI 10.1038/nm1709
   Hughes AE, 2006, NAT GENET, V38, P1173, DOI 10.1038/ng1890
   Imamura Y, 2006, P NATL ACAD SCI USA, V103, P11282, DOI 10.1073/pnas.0602131103
   Janssen SF, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0083345
   Janssen SF, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0044973
   Justilien V, 2007, INVEST OPHTH VIS SCI, V48, P4407, DOI 10.1167/iovs.07-0432
   Karunadharma PP, 2010, INVEST OPHTH VIS SCI, V51, P5470, DOI 10.1167/iovs.10-5429
   Kaur C, 2008, PROG RETIN EYE RES, V27, P622, DOI 10.1016/j.preteyeres.2008.09.003
   Kimura K, 2000, AM J OPHTHALMOL, V130, P769, DOI 10.1016/S0002-9394(00)00552-3
   Kondo N, 2009, MOL VIS, V15, P1819
   Lengyel I, 2007, EXP EYE RES, V84, P772, DOI 10.1016/j.exer.2006.12.015
   Leung KW, 2008, INVEST OPHTH VIS SCI, V49, P1221, DOI 10.1167/iovs.07-0781
   Luo C, 2011, MOL VIS, V17, P1588
   Maeda T, 2013, J BIOL CHEM, V288, P34484, DOI 10.1074/jbc.M113.518571
   Mattapallil MJ, 2012, INVEST OPHTH VIS SCI, V53, P2921, DOI 10.1167/iovs.12-9662
   NEWSOME DA, 1990, INVEST OPHTH VIS SCI, V31, P2508
   NEWSOME DA, 1988, ARCH OPHTHALMOL-CHIC, V106, P192
   Nita M, 2014, MEDIAT INFLAMM, V2014, DOI 10.1155/2014/930671
   Nozaki M, 2006, P NATL ACAD SCI USA, V103, P2328, DOI 10.1073/pnas.0408835103
   Pennesi ME, 2012, MOL ASPECTS MED, V33, P487, DOI 10.1016/j.mam.2012.06.003
   Rizzolo LJ, 2014, EXP EYE RES, V126, P16, DOI 10.1016/j.exer.2013.12.018
   Schlingemann RO, 2004, GRAEF ARCH CLIN EXP, V242, P91, DOI 10.1007/s00417-003-0828-0
   Schmidl D, 2015, ACTA OPHTHALMOL, V93, P105, DOI 10.1111/aos.12650
   Schwartz SD, 2012, LANCET, V379, P713, DOI 10.1016/S0140-6736(12)60028-2
   Seo SJ, 2012, EXP EYE RES, V101, P60, DOI 10.1016/j.exer.2012.05.013
   Shu XH, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027433
   Smailhodzic D, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0112682
   Smyth, 2004, STAT APPL GENET MOL, V3, P1, DOI DOI 10.2202/1544-6115.1027
   Stanzel BV, 2014, STEM CELL REP, V2, P64, DOI 10.1016/j.stemcr.2013.11.005
   Strauss O, 2005, PHYSIOL REV, V85, P845, DOI 10.1152/physrev.00021.2004
   Strunnikova NV, 2010, HUM MOL GENET, V19, P2468, DOI 10.1093/hmg/ddq129
   Tokarz P, 2013, BIOGERONTOLOGY, V14, P461, DOI 10.1007/s10522-013-9463-2
   Wang J, 2013, NUCLEIC ACIDS RES, V41, pW77, DOI 10.1093/nar/gkt439
NR 55
TC 32
Z9 33
U1 0
U2 5
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD OCT 30
PY 2015
VL 10
IS 10
AR e0141597
DI 10.1371/journal.pone.0141597
PG 23
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA CV0EH
UT WOS:000363920800059
PM 26517551
OA Green Submitted, gold, Green Published
DA 2022-11-30
ER

PT J
AU Aktas, S
   Sagdik, HM
   Tetikoglu, ME
   Aktas, H
   Ozcura, F
   Ucar, F
   Alisik, M
   Ergin, M
AF Aktas, Serdar
   Sagdik, Haci Murat
   Tetikoglu, Mehm Et
   Aktas, Hatice
   Ozcura, Fatih
   Ucar, Fatma
   Alisik, Murat
   Ergin, Merve
TI Dynamic thiol/disulfide homeostasis in patients with age-related macular
   degeneration
SO ARQUIVOS BRASILEIROS DE OFTALMOLOGIA
LA English
DT Article
DE Macular degeneration; Sulfhydryl compounds; Disulfides; Oxidative
   stress; Malondialdehyde
ID MALONDIALDEHYDE LEVELS; SUPEROXIDE-DISMUTASE; OXIDATIVE STRESS;
   PREVALENCE; MALONALDEHYDE; HOMOCYSTEINE; MACULOPATHY; PRODUCTS;
   CATALASE; THIOLS
AB Purpose: We evaluated dynamic thiol/disulfide homeostasis (TDH), malondialdehyde (MDA) levels, and catalase (CAT) activity in patients with age-related macular degeneration (AMD). All analyzes were conducted on plasma samples.
   Methods: Thirty-two patients with AMD and 38 age-matched healthy controls were included. Native thiol, total thiol, and disulfide levels and TDH status were determined using a novel, automated assay. MDA levels and CAT activity were determined. Percentages were compared using the chi-squared test. The Student's t-test and Mann-Whitney U-test were used to compare quantitative variables.
   Results: Native thiol levels were significantly lower (p=0.004) in patients with AMD (272.02 +/- 52.41 mu mol/l) than in healthy individuals (307.82 +/- 47.18 mu mol/l), whereas disulfide levels were significantly higher (p<0.001) in patients with AMD than in controls (21.64 +/- 5.59 vs. 14.48 +/- 5.37 mu mol/L). Dynamic TDH was also significantly lower (p<0.001) in patients with AMD than in controls (13.41 +/- 4.3 vs. 25.41 +/- 14.52 mu mol/l). No significant differences were evident in total thiol or MDA levels. Mean CAT activity was significantly higher (p=0.043) in patients with AMD compared with controls (0.035 vs. 0.018 k/ml).
   Conclusions: The antioxidant/oxidant balance demonstrated by dynamic TDH is shifted to the oxidative side in patients with AMD.
C1 [Aktas, Serdar; Sagdik, Haci Murat; Tetikoglu, Mehm Et; Ozcura, Fatih] Dumlupinar Univ, Dept Ophthalmol, Sch Med, TR-43270 Kutahya, Turkey.
   [Aktas, Hatice] DPU Evliya Celebi Training & Res Hosp, Clin Ophthalmol, Kutahya, Turkey.
   [Ucar, Fatma] Diskapi Yildirim Beyazit Training & Res Hosp, Dept Clin Biochem, Ankara, Turkey.
   [Alisik, Murat; Ergin, Merve] Ataturk Training & Res Hosp, Dept Clin Biochem, Ankara, Turkey.
C3 Dumlupinar University; Kutahya Evliya Celebi Training & Research
   Hospital; Diskapi Yildirim Beyazit Training & Research Hospital; Ankara
   Ataturk Training & Research Hospital
RP Aktas, S (通讯作者)，Dumlupinar Univ, Dept Ophthalmol, Sch Med, TR-43270 Kutahya, Turkey.
EM serdaraktas77@gmail.com
RI Ozcura, Fatih/F-8640-2011; Alisik, Murat/O-6114-2019
OI Ozcura, Fatih/0000-0001-6482-180X; Alisik, Murat/0000-0003-0434-3206
CR Aebi H.I., 1974, METHOD ENZYMATIC ANA, DOI DOI 10.1016/B978-0-12-091302-2.50032-3
   Ates O, 2009, TOHOKU J EXP MED, V217, P17, DOI 10.1620/tjem.217.17
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   Coral K, 2006, EYE, V20, P203, DOI 10.1038/sj.eye.6701853
   Danis RP, 2015, CLIN OPHTHALMOL, V9, P2159, DOI 10.2147/OPTH.S92359
   Deneke SM, 2000, CURR TOP CELL REGUL, V36, P151
   Erel O, 2014, CLIN BIOCHEM, V47, P326, DOI 10.1016/j.clinbiochem.2014.09.026
   ESTERBAUER H, 1990, METHOD ENZYMOL, V186, P407
   ESTERBAUER H, 1991, FREE RADICAL BIO MED, V11, P81, DOI 10.1016/0891-5849(91)90192-6
   Gordois A, 2010, GLOBAL EC COST VISUA
   HALLIWELL B, 1985, MOL ASPECTS MED, V8, P89, DOI 10.1016/0098-2997(85)90001-9
   HARMAN D, 1981, P NATL ACAD SCI-BIOL, V78, P7124, DOI 10.1073/pnas.78.11.7124
   Javadzadeh A, 2010, MOL VIS, V16, P2578
   Jia LH, 2011, AGING CLIN EXP RES, V23, P264, DOI 10.1007/BF03324965
   Jiang SN, 2005, INVEST OPHTH VIS SCI, V46, P1054, DOI 10.1167/iovs.04-0949
   Kemp M, 2008, FREE RADICAL BIO MED, V44, P921, DOI 10.1016/j.freeradbiomed.2007.11.008
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   MITCHELL P, 1995, OPHTHALMOLOGY, V102, P1450
   Moran LK, 2001, CURR MED CHEM, V8, P763, DOI 10.2174/0929867013372904
   Moriarty SE, 2003, FREE RADICAL BIO MED, V35, P1582, DOI 10.1016/j.freeradbiomed.2003.09.006
   ORR WC, 1994, SCIENCE, V263, P1128, DOI 10.1126/science.8108730
   Schutt F, 2003, INVEST OPHTH VIS SCI, V44, P3663, DOI 10.1167/iovs.03-0172
   Sen CK, 2000, CURR TOP CELL REGUL, V36, P1
   TATE DJ, 1995, INVEST OPHTH VIS SCI, V36, P1271
   WHO, 2011, GLOBAL HLTH AGING
   Wlodek L, 2002, POL J PHARMACOL, V54, P215
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Yorgun MA, 2016, CURR EYE RES, V41, P1584, DOI 10.3109/02713683.2016.1141965
NR 28
TC 4
Z9 4
U1 0
U2 0
PU CONSEL BRASIL OFTALMOLOGIA
PI SAO PAULO
PA ALAMEDA SANTOS 1343, 11 ANDAR CJ 1110, CERQUEIRA CESAR, SAO PAULO, SP
   00000, BRAZIL
SN 0004-2749
EI 1678-2925
J9 ARQ BRAS OFTALMOL
JI Arq. Bras. Oftalmol.
PD JUL-AUG
PY 2017
VL 80
IS 4
BP 234
EP 237
DI 10.5935/0004-2749.20170057
PG 4
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA FI2UI
UT WOS:000411799900007
PM 28954023
OA gold
DA 2022-11-30
ER

PT J
AU Kim, K
   Park, SW
   Kim, JH
   Lee, SH
   Kim, D
   Koo, T
   Kim, KE
   Kim, JH
   Kim, JS
AF Kim, Kyoungmi
   Park, Sung Wook
   Kim, Jin Hyoung
   Lee, Seung Hwan
   Kim, Daesik
   Koo, Taeyoung
   Kim, Kwang-eun
   Kim, Jeong Hun
   Kim, Jin-Soo
TI Genome surgery using Cas9 ribonucleoproteins for the treatment of
   age-related macular degeneration
SO GENOME RESEARCH
LA English
DT Article
ID CRISPR-CAS9 NUCLEASES; MOUSE MODEL; GENE; SPECIFICITIES; ENDONUCLEASES;
   MUSCLE; CPF1
AB RNA-guided genome surgery using CRISPR-Cas9 nucleases has shown promise for the treatment of diverse genetic diseases. Yet, the potential of such nucleases for therapeutic applications in nongenetic diseases is largely unexplored. Here, we focus on age-related macular degeneration (AMD), a leading cause of blindness in adults, which is associated with retinal overexpression of, rather than mutations in, the VEGFA gene. Subretinal injection of preassembled, Vegfa gene-specific Cas9 ribonucleoproteins (RNPs) into the adult mouse eye gave rise to mutagenesis at the target site in the retinal pigment epithelium. Furthermore, Cas9 RNPs effectively reduced the area of laser-induced choroidal neovascularization (CNV) in a mouse model of AMD. Genome-wide profiling of Cas9 off-target effects via Digenome-seq showed that off-target mutations were rarely induced in the human genome. Because Cas9 RNPs can function immediately after in vivo delivery and are rapidly degraded by endogenous proteases, their activities are unlikely to be hampered by antibody-and cell-mediated adaptive immune systems. Our results demonstrate that in vivo genome editing with Cas9 RNPs has the potential for the local treatment for nongenetic degenerative diseases, expanding the scope of RNA-guided genome surgery to a new dimension.
C1 [Kim, Kyoungmi; Lee, Seung Hwan; Kim, Daesik; Koo, Taeyoung; Kim, Kwang-eun; Kim, Jin-Soo] Inst for Basic Sci Korea, Ctr Genome Engn, Seoul 08826, South Korea.
   [Park, Sung Wook; Kim, Jeong Hun] Seoul Natl Univ, Coll Med, Dept Biomed Sci, Seoul 03080, South Korea.
   [Park, Sung Wook; Kim, Jin Hyoung; Kim, Jeong Hun] Seoul Natl Univ Hosp, Biomed Res Inst, FARB Lab, Seoul 03082, South Korea.
   [Kim, Daesik; Kim, Kwang-eun; Kim, Jin-Soo] Seoul Natl Univ, Dept Chem, Seoul 08826, South Korea.
   [Kim, Jeong Hun] Seoul Natl Univ, Coll Med, Dept Ophthalmol, Seoul 03080, South Korea.
C3 Institute for Basic Science - Korea (IBS); Seoul National University
   (SNU); Seoul National University (SNU); Seoul National University
   Hospital; Seoul National University (SNU); Seoul National University
   (SNU)
RP Kim, K; Kim, JS (通讯作者)，Inst for Basic Sci Korea, Ctr Genome Engn, Seoul 08826, South Korea.; Kim, JS (通讯作者)，Seoul Natl Univ, Dept Chem, Seoul 08826, South Korea.
EM steph25@snu.ac.kr; jskim01@snu.ac.kr
RI KIM, Jin-Soo/M-6918-2013; Kim, Kyoungmi/AAR-3964-2020; Kim,
   Daesik/AFH-7798-2022; Park, Sung Wook/D-5541-2012
OI KIM, Jin-Soo/0000-0003-4847-1306; Kim, Kyoungmi/0000-0003-0941-806X;
   Park, Sung Wook/0000-0001-8151-6663; Kim, Jeong Hun/0000-0003-2957-1766;
   Kim, Kwang-eun/0000-0002-5355-1979
FU Institute for Basic Science [IBS-R021-D1]; Pioneer Research Program of
   the National Research Foundation of Korea (NRF)/MEST [2012-0009544]; Bio
   & Medical Technology Development Program of the National Research
   Foundation; MSIP [NRF-2015M3A9E6028949]
FX This work was supported by the Institute for Basic Science (IBS-R021-D1
   to J.-S.K.), the Pioneer Research Program of the National Research
   Foundation of Korea (NRF)/MEST (2012-0009544 to Je.H.K.), the Bio &
   Medical Technology Development Program of the National Research
   Foundation, and MSIP (NRF-2015M3A9E6028949 to Je.H.K.). We thank
   Sunghyun Kim for Digenome-seq analysis.
CR Bae S, 2014, BIOINFORMATICS, V30, P1473, DOI 10.1093/bioinformatics/btu048
   Calcedo R, 2015, HUM GENE THER METHOD, V26, P103, DOI 10.1089/hgtb.2015.082
   Chew WL, 2016, NAT METHODS, V13, P868, DOI 10.1038/nmeth.3993
   Cho SW, 2014, GENOME RES, V24, P132, DOI 10.1101/gr.162339.113
   Deng WL, 2015, P NATL ACAD SCI USA, V112, P11870, DOI 10.1073/pnas.1515692112
   Fernandez-Godino R, 2016, NAT PROTOC, V11, P1206, DOI 10.1038/nprot.2016.065
   Fu YF, 2014, NAT BIOTECHNOL, V32, P279, DOI 10.1038/nbt.2808
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Kim D., 2015, NAT METHODS, V12, P1
   Kim D, 2016, NAT BIOTECHNOL, V34, P863, DOI 10.1038/nbt.3609
   Kim D, 2016, GENOME RES, V26, P406, DOI 10.1101/gr.199588.115
   Kim S, 2014, GENOME RES, V24, P1012, DOI 10.1101/gr.171322.113
   Kleinstiver BP, 2016, NATURE, V529, P490, DOI 10.1038/nature16526
   Krzywinski M, 2009, GENOME RES, V19, P1639, DOI 10.1101/gr.092759.109
   Kurihara T, 2012, J CLIN INVEST, V122, P4213, DOI 10.1172/JCI65157
   Lambert V, 2013, NAT PROTOC, V8, P2197, DOI 10.1038/nprot.2013.135
   LEUNG DW, 1989, SCIENCE, V246, P1306, DOI 10.1126/science.2479986
   Long CZ, 2016, SCIENCE, V351, P400, DOI 10.1126/science.aad5725
   Maeder ML, 2016, MOL THER, V24, P430, DOI 10.1038/mt.2016.10
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Nelson CE, 2016, SCIENCE, V351, P403, DOI 10.1126/science.aad5143
   Park J, 2015, BIOINFORMATICS, V31, P4014, DOI 10.1093/bioinformatics/btv537
   Park SW, 2015, ONCOTARGET, V6, P35263, DOI 10.18632/oncotarget.5894
   Park SW, 2015, JOVE-J VIS EXP, DOI 10.3791/53030
   Ran FA, 2015, NATURE, V520, P186, DOI 10.1038/nature14299
   Schmidt-Erfurth U, 2014, OPHTHALMOLOGY, V121, P193, DOI 10.1016/j.ophtha.2013.08.011
   Schumann K, 2015, P NATL ACAD SCI USA, V112, P10437, DOI 10.1073/pnas.1512503112
   Shankar G, 2007, NAT BIOTECHNOL, V25, P555, DOI 10.1038/nbt1303
   Slaymaker IM, 2016, SCIENCE, V351, P84, DOI 10.1126/science.aad5227
   Tabebordbar M, 2016, SCIENCE, V351, P407, DOI 10.1126/science.aad5177
   Woo JW, 2015, NAT BIOTECHNOL, V33, P1162, DOI 10.1038/nbt.3389
   Yin H, 2014, NAT BIOTECHNOL, V32, P551, DOI 10.1038/nbt.2884
   Zetsche B, 2015, CELL, V163, P759, DOI 10.1016/j.cell.2015.09.038
   Zuris JA, 2015, NAT BIOTECHNOL, V33, P73, DOI 10.1038/nbt.3081
NR 34
TC 94
Z9 103
U1 2
U2 51
PU COLD SPRING HARBOR LAB PRESS, PUBLICATIONS DEPT
PI COLD SPRING HARBOR
PA 1 BUNGTOWN RD, COLD SPRING HARBOR, NY 11724 USA
SN 1088-9051
EI 1549-5469
J9 GENOME RES
JI Genome Res.
PD MAR
PY 2017
VL 27
IS 3
BP 419
EP 426
DI 10.1101/gr.219089.116
PG 8
WC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology;
   Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology;
   Genetics & Heredity
GA EN0IR
UT WOS:000395694000008
PM 28209587
OA hybrid, Green Published
DA 2022-11-30
ER

PT J
AU Blasiak, J
   Reiter, RJ
   Kaarniranta, K
AF Blasiak, Janusz
   Reiter, Russel J.
   Kaarniranta, Kai
TI Melatonin in Retinal Physiology and Pathology: The Case of Age-Related
   Macular Degeneration
SO OXIDATIVE MEDICINE AND CELLULAR LONGEVITY
LA English
DT Review
ID ARYLALKYLAMINE N-ACETYLTRANSFERASE; OXIDATIVE STRESS; CIRCADIAN CLOCK;
   LIPID-PEROXIDATION; DNA-DAMAGE; PHOTORECEPTOR CELLS; PIGMENT EPITHELIUM;
   VITAMIN-E; TRYPTOPHAN-HYDROXYLASE; MESSENGER-RNA
AB Melatonin, an indoleamine, is synthesized mainly in the pineal gland in a circadian fashion, but it is produced in many other organs, including the retina, which seems to be especially important as the eye is a primary recipient of circadian signals. Melatonin displays strong antioxidative properties, which predispose it to play a protective role in many human pathologies associated with oxidative stress, including premature aging and degenerative disease. Therefore, melatonin may play a role in age-related macular degeneration (AMD), a disease affecting photoreceptors, and retinal pigment epithelium (RPE) with an established role of oxidative stress in its pathogenesis. Several studies have shown that melatonin could exert the protective effect against damage to RPE cells evoked by reactive oxygen species (ROS), but it has also been reported to increase ROS-induced damage to photoreceptors and RPE. Melatonin behaves like synthetic mitochondria-targeted antioxidants, which concentrate in mitochondria at relatively high levels; thus, melatonin may prevent mitochondrial damage in AMD. The retina contains telomerase, an enzyme implicated in maintaining the length of telomeres, and oxidative stress inhibits telomere synthesis, while melatonin overcomes this effect. These features support considering melatonin as a preventive and therapeutic agent in the treatment of AMD.
C1 [Blasiak, Janusz] Univ Lodz, Dept Mol Genet, Pomorska 141-143, PL-90236 Lodz, Poland.
   [Reiter, Russel J.] Univ Texas Hlth Sci Ctr San Antonio, Dept Cellular & Struct Biol, San Antonio, TX 78229 USA.
   [Kaarniranta, Kai] Univ Eastern Finland, Dept Ophthalmol, Kuopio 70211, Finland.
   [Kaarniranta, Kai] Kuopio Univ Hosp, Dept Ophthalmol, Kuopio 70029, Finland.
C3 University of Lodz; University of Texas System; University of Texas
   Health San Antonio; University of Eastern Finland; Kuopio University
   Hospital; University of Eastern Finland
RP Blasiak, J (通讯作者)，Univ Lodz, Dept Mol Genet, Pomorska 141-143, PL-90236 Lodz, Poland.
EM jblasiak@biol.uni.lodz.pl
OI Blasiak, Janusz/0000-0001-9539-9584; Kaarniranta,
   Kai/0000-0003-2600-8679
FU Academy of Finland [296840]; Finnish Eye Foundation; Kuopio University
   Hospital VTR Grant [5503743]
FX This study was supported by the Academy of Finland (296840), the Finnish
   Eye Foundation, and the Kuopio University Hospital VTR Grant (5503743).
CR Acuna-Castroviejo D, 2014, CELL MOL LIFE SCI, V71, P2997, DOI 10.1007/s00018-014-1579-2
   Akbari M, 2015, DNA REPAIR, V32, P172, DOI 10.1016/j.dnarep.2015.04.029
   Akiyama M, 2013, CANCER LETT, V340, P82, DOI 10.1016/j.canlet.2013.07.003
   Alarma-Estrany P, 2007, PHARMACOL THERAPEUT, V113, P507, DOI 10.1016/j.pharmthera.2006.11.003
   Amadio M, 2016, PHARMACOL RES, V103, P253, DOI 10.1016/j.phrs.2015.11.027
   Andersen LPH, 2016, CLIN DRUG INVEST, V36, P169, DOI 10.1007/s40261-015-0368-5
   Baba K, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0037799
   Bar Christian, 2016, F1000Res, V5, DOI 10.12688/f1000research.7020.1
   Baranov PY, 2014, TISSUE ENG PT A, V20, P1465, DOI [10.1089/ten.tea.2013.0361, 10.1089/ten.TEA.2013.0361]
   Blasiak J, 2013, INT J MOL SCI, V14, P2996, DOI 10.3390/ijms14022996
   Blasiak J, 2012, INT J MOL SCI, V13, P13378, DOI 10.3390/ijms131013378
   Blasiak J, 2011, FRONT BIOSCI-LANDMRK, V16, P1551, DOI 10.2741/3804
   Brainard GC, 2001, J NEUROSCI, V21, P6405
   Bubenik GA, 2011, J PHYSIOL PHARMACOL, V62, P13
   Cantu-Medellin N, 2013, NITRIC OXIDE-BIOL CH, V34, P19, DOI 10.1016/j.niox.2013.02.081
   Chaurasia SS, 2006, J NEUROCHEM, V99, P1142, DOI 10.1111/j.1471-4159.2006.04154.x
   Chaurasia SS, 2006, MOL VIS, V12, P215
   Chen W, 2000, MOL BRAIN RES, V81, P43, DOI 10.1016/S0169-328X(00)00160-1
   Coon SL, 2002, J CLIN ENDOCR METAB, V87, P4699, DOI 10.1210/jc.2002-020683
   Coto-Montes A, 2012, MOL CELL ENDOCRINOL, V361, P12, DOI 10.1016/j.mce.2012.04.009
   DeBruyne JP, 2006, NEURON, V50, P465, DOI 10.1016/j.neuron.2006.03.041
   Erren TC, 2015, NEUROENDOCRINOL LETT, V36, P187
   Feher J, 2006, NEUROBIOL AGING, V27, P983, DOI 10.1016/j.neurobiolaging.2005.05.012
   Fernandez A, 2015, J PINEAL RES, V59, P292, DOI 10.1111/jpi.12264
   Ferrington DA, 2016, EXP EYE RES, V145, P269, DOI 10.1016/j.exer.2016.01.018
   Fischer TW, 2008, EXP DERMATOL, V17, P713, DOI 10.1111/j.1600-0625.2008.00767.x
   Fox NE, 1998, FREE RADICAL BIO MED, V24, P900, DOI 10.1016/S0891-5849(97)00369-9
   Fritsche LG, 2014, ANNU REV GENOM HUM G, V15, P151, DOI 10.1146/annurev-genom-090413-025610
   Frost LS, 2014, EXP EYE RES, V124, P56, DOI 10.1016/j.exer.2014.04.010
   Garhofer G, 2002, CURR EYE RES, V24, P109, DOI 10.1076/ceyr.24.2.109.8164
   Gatfield D, 2007, SCIENCE, V316, P1135, DOI 10.1126/science.1144165
   Greco A, 2016, AM J MED, V129, DOI 10.1016/j.amjmed.2016.03.038
   Guajardo MH, 2003, J PINEAL RES, V35, P276, DOI 10.1034/j.1600-079X.2003.00087.x
   Haque R, 2011, J NEUROCHEM, V119, P6, DOI 10.1111/j.1471-4159.2011.07397.x
   Haque R, 2010, J NEUROCHEM, V113, P1296, DOI 10.1111/j.1471-4159.2010.06698.x
   Hayasaka N, 2002, J NEUROSCI, V22, P1600, DOI 10.1523/JNEUROSCI.22-05-01600.2002
   Hiragaki S, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0106819
   Iuvone PM, 2014, ADV EXP MED BIOL, V801, P765, DOI 10.1007/978-1-4614-3209-8_96
   Iuvone PM, 1999, ADV EXP MED BIOL, V460, P31
   Ivanova TN, 2008, BRAIN RES, V1207, P111, DOI 10.1016/j.brainres.2008.02.025
   Ivanova TN, 2003, BRAIN RES, V973, P56, DOI 10.1016/S0006-8993(03)02540-X
   Ivanova TN, 2003, BRAIN RES, V991, P96, DOI 10.1016/j.brainres.2003.08.003
   Jiang TT, 2016, OXID MED CELL LONGEV, V2016, DOI 10.1155/2016/3528274
   Kaarniranta Kai, 2010, Front Biosci (Elite Ed), V2, P1374
   Kaemmerer E, 2007, INVEST OPHTH VIS SCI, V48, P1342, DOI 10.1167/iovs.06-0549
   Karbowski M, 2003, CELL DEATH DIFFER, V10, P870, DOI 10.1038/sj.cdd.4401260
   Karunadharma PP, 2010, INVEST OPHTH VIS SCI, V51, P5470, DOI 10.1167/iovs.10-5429
   Kashyap MV, 2013, IN VIVO, V27, P685
   Katz ML, 2002, ARCH GERONTOL GERIAT, V34, P359, DOI 10.1016/S0167-4943(02)00012-2
   Kauppinen A, 2016, CELL MOL LIFE SCI, V73, P1765, DOI 10.1007/s00018-016-2147-8
   Kaur C, 2008, PROG RETIN EYE RES, V27, P622, DOI 10.1016/j.preteyeres.2008.09.003
   Kaur C, 2008, CLIN OPHTHALMOL, V2, P879, DOI 10.2147/opth.s3361
   Khandhadia S, 2010, EXPERT REV MOL MED, V12, DOI 10.1017/S146239941000164X
   Kijlstra A, 2015, OPHTHALMIC RES, V54, P64, DOI 10.1159/000432401
   Kim JY, 2013, CELL, V154, P365, DOI 10.1016/j.cell.2013.06.012
   Kohle C, 2007, BIOCHEM PHARMACOL, V73, P1853, DOI 10.1016/j.bcp.2007.01.009
   Koskela A, 2016, NUTRIENTS, V8, DOI 10.3390/nu8050284
   Kovacs J, 2000, J CLIN ENDOCR METAB, V85, P666, DOI 10.1210/jc.85.2.666
   Lambert NG, 2016, PROG RETIN EYE RES, V54, P64, DOI 10.1016/j.preteyeres.2016.04.003
   Lambros ML, 2016, ADV EXP MED BIOL, V854, P67, DOI 10.1007/978-3-319-17121-0_10
   Lau BWM, 2007, J MOL NEUROSCI, V32, P160, DOI 10.1007/s12031-007-0031-6
   Lee MC, 2001, EXP NEUROL, V172, P407, DOI 10.1006/exnr.2001.7793
   Liang FQ, 2004, EXP EYE RES, V78, P1069, DOI 10.1016/j.exer.2004.02.003
   Liang J, 2004, NEUROREPORT, V15, P1497, DOI 10.1097/01.wnr.0000131007.59315.66
   Litts KM, 2015, INVEST OPHTH VIS SCI, V56, P2243, DOI 10.1167/iovs.14-15838
   Liu SM, 2015, J PINEAL RES, V59, P508, DOI 10.1111/jpi.12282
   Fanjul-Moles ML, 2016, OXID MED CELL LONGEV, V2016, DOI 10.1155/2016/7420637
   Ma Q, 2012, PHARMACOL REV, V64, P1055, DOI 10.1124/pr.110.004333
   Mainster MA, 2010, SURV OPHTHALMOL, V55, P272, DOI 10.1016/j.survophthal.2009.07.006
   Manchester LC, 2015, J PINEAL RES, V59, P403, DOI 10.1111/jpi.12267
   Marchiafava PL, 1999, J PINEAL RES, V26, P184, DOI 10.1111/j.1600-079X.1999.tb00582.x
   Margrain TH, 2004, PROG RETIN EYE RES, V23, P523, DOI 10.1016/j.preteyeres.2004.05.001
   Martinez-Aguila A, 2016, J PHARMACOL EXP THER, V357, P293, DOI 10.1124/jpet.115.231456
   Matsunaga H, 1999, INVEST OPHTH VIS SCI, V40, P197
   Michelson G, 2002, RETINA-J RET VIT DIS, V22, P336, DOI 10.1097/00006982-200206000-00013
   Min XJ, 2011, CURR EYE RES, V36, P135, DOI 10.3109/02713683.2010.525679
   Moreno MC, 2004, FREE RADICAL BIO MED, V37, P803, DOI 10.1016/j.freeradbiomed.2004.06.001
   Munoz E, 2003, CHRONOBIOL INT, V20, P371, DOI 10.1081/CBI-120022525
   Nishi T, 2015, BMJ OPEN, V5, DOI 10.1136/bmjopen-2015-007930
   Nita M, 2016, OXID MED CELL LONGEV, V2016, DOI 10.1155/2016/3164734
   Olinski R, 2016, MUTAT RES-REV MUTAT, V767, P59, DOI 10.1016/j.mrrev.2016.02.001
   Opresko P.L., 2016, AGEING RES REV
   Organisciak DT, 2000, INVEST OPHTH VIS SCI, V41, P3694
   Perepechaeva ML, 2014, B EXP BIOL MED+, V157, P424, DOI 10.1007/s10517-014-2582-1
   Peschke E, 2015, J PINEAL RES, V59, P1, DOI 10.1111/jpi.12240
   Peters JL, 2005, J PINEAL RES, V38, P209, DOI 10.1111/j.1600-079X.2004.00195.x
   Pinazo-Duran MD, 2014, J OPHTHALMOL, V2014, DOI 10.1155/2014/901686
   Plafker SM, 2012, INT REV CEL MOL BIO, V298, P135, DOI 10.1016/B978-0-12-394309-5.00004-3
   POEGGELER B, 1993, J PINEAL RES, V14, P151, DOI 10.1111/j.1600-079X.1993.tb00498.x
   Poljsak B, 2013, OXID MED CELL LONGEV, V2013, DOI 10.1155/2013/956792
   Pozdeyev N, 2006, J NEUROSCI, V26, P9153, DOI 10.1523/JNEUROSCI.1384-06.2006
   Pujol-Lereis LM, 2016, ADV EXP MED BIOL, V854, P87, DOI 10.1007/978-3-319-17121-0_13
   PULIDO O, 1986, EXP GERONTOL, V21, P23, DOI 10.1016/0531-5565(86)90014-8
   Ramis MR, 2015, CURR MED CHEM, V22, P2690, DOI 10.2174/0929867322666150619104143
   Rastmanesh R, 2011, MED HYPOTHESES, V76, P79, DOI 10.1016/j.mehy.2010.08.036
   Reibaldi M, 2016, AM J OPHTHALMOL, V161, P78, DOI 10.1016/j.ajo.2015.09.031
   Reiter RJ, 2007, ADV MED SCI-POLAND, V52, P11
   Reiter RJ, 2014, PHYSIOLOGY, V29, P325, DOI 10.1152/physiol.00011.2014
   Reiter RJ, 2014, CURR PHARM DESIGN, V20, P4788
   Reppert SM, 2002, NATURE, V418, P935, DOI 10.1038/nature00965
   Rosen R, 2009, MOL VIS, V15, P1673
   Rosen RB, 2012, MOL VIS, V18, P1640
   Rowe-Rendleman C, 2004, BRAIN RES BULL, V62, P549, DOI 10.1016/S0361-9230(03)00072-8
   Ruan GX, 2006, P NATL ACAD SCI USA, V103, P9703, DOI 10.1073/pnas.0601940103
   Rufiange M, 2002, INVEST OPHTH VIS SCI, V43, P2491
   Rufiange Marianne, 2002, Documenta Ophthalmologica, V104, P231, DOI 10.1023/A:1015265812018
   Sakamoto K, 2004, J NEUROCHEM, V90, P1019, DOI 10.1111/j.1471-4159.2004.02571.x
   Savaskan E, 2007, CURR ALZHEIMER RES, V4, P47, DOI 10.2174/156720507779939823
   Sehgal A, 2008, NEURON, V57, P8, DOI 10.1016/j.neuron.2007.12.018
   Sengupta A, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024483
   Shaw PX, 2012, P NATL ACAD SCI USA, V109, P13757, DOI 10.1073/pnas.1121309109
   Shay JW, 2016, CANCER DISCOV, V6, P584, DOI 10.1158/2159-8290.CD-16-0062
   Siu AW, 1999, J PINEAL RES, V27, P122, DOI 10.1111/j.1600-079X.1999.tb00606.x
   Siu AW, 2006, J PINEAL RES, V40, P101, DOI 10.1111/j.1600-079X.2005.00304.x
   Siu AW, 1998, J PINEAL RES, V24, P239, DOI 10.1111/j.1600-079X.1998.tb00539.x
   Sivakumar V, 2008, BRAIN PATHOL, V18, P71, DOI 10.1111/j.1750-3639.2007.00104.x
   Sparrrow JR, 2010, CURR MOL MED, V10, P802
   Stehle JH, 2011, J PINEAL RES, V51, P17, DOI 10.1111/j.1600-079X.2011.00856.x
   Sugawara T, 1998, INVEST OPHTH VIS SCI, V39, P2458
   Suzuki M, 2007, MOL VIS, V13, P772
   Tan DX, 2015, MOLECULES, V20, P18886, DOI 10.3390/molecules201018886
   Tan DX, 2003, J PINEAL RES, V34, P75, DOI 10.1034/j.1600-079X.2003.02111.x
   Terluk MR, 2015, J NEUROSCI, V35, P7304, DOI 10.1523/JNEUROSCI.0190-15.2015
   Terman A, 2010, ANTIOXID REDOX SIGN, V12, P503, DOI 10.1089/ars.2009.2598
   Torres F, 2015, J PINEAL RES, V58, P362, DOI 10.1111/jpi.12222
   Tosini G, 1996, SCIENCE, V272, P419, DOI 10.1126/science.272.5260.419
   Tosini G, 2006, CHRONOBIOL INT, V23, P381, DOI 10.1080/07420520500482066
   Tosini G, 2008, BIOESSAYS, V30, P624, DOI 10.1002/bies.20777
   Tosini G, 2007, FASEB J, V21, P3866, DOI 10.1096/fj.07-8371com
   Tosini G, 2012, EXP EYE RES, V103, P82, DOI 10.1016/j.exer.2012.08.009
   Tsilimbaris MK, 2016, J OPHTHALMOL, V2016, DOI 10.1155/2016/4367631
   VONZGLINICKI T, 1995, EXP CELL RES, V220, P186, DOI 10.1006/excr.1995.1305
   Wan TT, 2015, BIOMED PHARMACOTHER, V74, P145, DOI 10.1016/j.biopha.2015.08.002
   Wiechmann AF, 1999, J PINEAL RES, V27, P116, DOI 10.1111/j.1600-079X.1999.tb00605.x
   Wiechmann AF, 2008, PROG RETIN EYE RES, V27, P137, DOI 10.1016/j.preteyeres.2007.10.001
   Xin ZL, 2015, J PINEAL RES, V58, P375, DOI 10.1111/jpi.12227
   Xu LL, 2016, MOL VIS, V22, P275
   Yang G, 2007, ONCOGENE, V26, P1492, DOI 10.1038/sj.onc.1209905
   Yi CX, 2005, ANN NY ACAD SCI, V1057, P384, DOI 10.1196/annals.1356.029
   Yilmaz T, 2002, EUR J OPHTHALMOL, V12, P443, DOI 10.1177/112067210201200601
   Yoshida A, 2015, J PHOTOCH PHOTOBIO B, V151, P48, DOI 10.1016/j.jphotobiol.2015.07.001
   Zmijewski MA, 2009, MOL CELL ENDOCRINOL, V307, P211, DOI 10.1016/j.mce.2009.04.010
NR 142
TC 30
Z9 33
U1 3
U2 4
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 1942-0900
EI 1942-0994
J9 OXID MED CELL LONGEV
JI Oxidative Med. Cell. Longev.
PY 2016
VL 2016
AR 6819736
DI 10.1155/2016/6819736
PG 12
WC Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology
GA DW2VT
UT WOS:000383500600001
PM 27688828
OA Green Published, gold, Green Submitted
DA 2022-11-30
ER

PT J
AU Lopez-Miguel, A
   Coco-Martin, MB
   Martinez-Fernandez, R
   Gomez-Ramirez, AM
   Garcia-Ayuso, D
   Sobrado-Calvo, P
   Maldonado, MJ
AF Lopez-Miguel, Alberto
   Coco-Martin, Marfa B.
   Martinez-Fernandez, Rosa
   Gomez-Ramirez, Ana M.
   Garcia-Ayuso, Diego
   Sobrado-Calvo, Paloma
   Maldonado, Miguel J.
TI Patient-Reported Outcomes in Spanish Patients Diagnosed with Bilateral
   Age-Related Macular Degeneration
SO OPHTHALMOLOGICA
LA English
DT Article
DE Age-related macular degeneration; National Eye Institute Visual Function
   Questionnaire, 25 items; Patient-reported outcomes; Short-Form General
   Health Survey, 12 items
ID QUALITY-OF-LIFE; QUESTIONNAIRE; RELIABILITY; VALIDITY; IMPACT;
   POPULATION
AB Purpose: To evaluate the patient-reported outcomes (PRO) in age-related macular degeneration (AMD) patients by using instruments for eliciting health status and vision specific issues. Methods: PRO were assessed using the 25-item National Eye Institute Visual Function Questionnaire (NEIVFQ-25) and the Short-Form General Health Survey (SF-12). Results: The mean age and corrected distance visual acuity (CDVA) in the better eye of the AMD patients were 82.53 +/- 5.17 years and 0.82 +/- 0.43 logMAR, respectively. The overall NEIVFQ-25 composite score was 57.89. SF-12 physical and mental component summary scores were 37.28 and 57.25, respectively. There were significant correlations (p <= 0.05) between CDVA and the following NEIVFQ-25 subscales: general (r = -0.73), near (r = -0.40) and distance vision (r = -0.60), role limitations (r = -0.40), social function (r = -0.48) and mental health (r = -0.38). Conclusions: Visual function is severely affected in AMD patients. It hampers their daily living without, however, deeply disturbing their social function. This may help them retain adequate mental health despite their poor physical status. Copyright (C) 2013 S. Karger AG, Basel
C1 [Lopez-Miguel, Alberto; Coco-Martin, Marfa B.; Maldonado, Miguel J.] Univ Valladolid, IOBA Eye Inst, Valladolid, Spain.
   [Martinez-Fernandez, Rosa; Gomez-Ramirez, Ana M.; Garcia-Ayuso, Diego; Sobrado-Calvo, Paloma] Univ Murcia, Fac Med, Dept Ophthalmol, Murcia, Spain.
C3 Universidad de Valladolid; University of Murcia
RP Coco-Martin, MB (通讯作者)，Edificio IOBA Paseo Belen 17, ES-47011 Valladolid, Spain.
EM bego@ioba.med.uva.es
RI Gomez-Ramirez, Ana María/AAB-4677-2019; García-Ayuso,
   Diego/AAC-4954-2020; López-Miguel, Alberto/K-6117-2014
OI Gomez-Ramirez, Ana María/0000-0001-7953-7289; García-Ayuso,
   Diego/0000-0002-7639-5366; López-Miguel, Alberto/0000-0001-9429-1571;
   Maldonado, Miguel J./0000-0002-1021-3275; Coco-Martin, Maria
   Begona/0000-0001-9977-429X
FU RETICS [D07/0062/0013]
FX This work was supported by RETICS D07/0062/0013 (Oftalmologia).
CR [Anonymous], 2005, REFL PAP REG GUID US
   Baker RS, 2006, OPHTHALMOLOGY, V113, P1363, DOI 10.1016/j.ophtha.2006.01.073
   Bradley C, 2001, LANCET, V357, P7, DOI 10.1016/S0140-6736(00)03562-5
   Bradley C, 1999, QUAL LIFE RES, V8, P79, DOI 10.1023/A:1026485130100
   Cahill MT, 2005, OPHTHALMOLOGY, V112, P152, DOI 10.1016/j.ophtha.2004.06.036
   Chiang A, 2011, CURR OPIN OPHTHALMOL, V22, P199, DOI 10.1097/ICU.0b013e32834597d9
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   Crossland MD, 2006, VISION RES, V46, P590, DOI 10.1016/j.visres.2005.05.015
   Escobar-Bravo MA, 2012, ARCH GERONTOL GERIAT, V54, P109, DOI 10.1016/j.archger.2011.01.008
   FDA Ctr Drug Evaluation Res, 2006, HEALTH QUAL LIFE OUT, V4, DOI 10.1186/1477-7525-4-79
   Fine SL, 2000, NEW ENGL J MED, V342, P483, DOI 10.1056/NEJM200002173420707
   Globe DR, 2002, OPHTHALMOLOGY, V109, P1793, DOI 10.1016/S0161-6420(02)01124-7
   Hassell JB, 2006, BRIT J OPHTHALMOL, V90, P593, DOI 10.1136/bjo.2005.086595
   Klein R, 2011, ARCH OPHTHALMOL-CHIC, V129, P75, DOI 10.1001/archophthalmol.2010.318
   Lamoureux EL, 2007, INVEST OPHTH VIS SCI, V48, P1476, DOI 10.1167/iovs.06-0610
   Mackenzie PJ, 2002, OPHTHALMOLOGY, V109, P720, DOI 10.1016/S0161-6420(01)01021-1
   Mangione CM, 2001, ARCH OPHTHALMOL-CHIC, V119, P1050, DOI 10.1001/archopht.119.7.1050
   Marella M, 2010, INVEST OPHTH VIS SCI, V51, P2878, DOI 10.1167/iovs.09-4494
   Mathew RS, 2011, OPHTHAL PHYSL OPT, V31, P375, DOI 10.1111/j.1475-1313.2011.00848.x
   Meleth AD, 2011, CURR OPIN OPHTHALMOL, V22, P190, DOI 10.1097/ICU.0b013e32834594b0
   Midena E, 1997, INVEST OPHTH VIS SCI, V38, P469
   Mitchell J, 2008, AM J OPHTHALMOL, V146, P447, DOI 10.1016/j.ajo.2008.04.031
   Mitchell J, 2006, HEALTH QUAL LIFE OUT, V4, DOI 10.1186/1477-7525-4-97
   Piqueras OM, 2011, GAC SANIT, V25, P50, DOI 10.1016/j.gaceta.2010.09.001
   Orr P, 2011, INVEST OPHTH VIS SCI, V52, P3354, DOI 10.1167/iovs.10-5645
   Revicki DA, 2010, INVEST OPHTH VIS SCI, V51, P712, DOI 10.1167/iovs.09-3766
   Ruiz-Moreno JM, 2008, CURR MED RES OPIN, V24, P2103, DOI [10.1185/03007990802214300 , 10.1185/03007990802214300]
   Schmier JK, 2006, OPHTHAL EPIDEMIOL, V13, P137, DOI 10.1080/09286580600573049
   Stelmack JA, 2003, J VISUAL IMPAIR BLIN, V97, P521, DOI 10.1177/0145482X0309700904
   Ware JE, 1996, MED CARE, V34, P220, DOI 10.1097/00005650-199603000-00003
   Wiliams RA, 1998, ARCH OPHTHALMOL-CHIC, V116, P514
   Wolffsohn JS, 2000, AM J OPHTHALMOL, V130, P793, DOI 10.1016/S0002-9394(00)00610-3
NR 32
TC 1
Z9 1
U1 0
U2 5
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 0030-3755
EI 1423-0267
J9 OPHTHALMOLOGICA
JI Ophthalmologica
PY 2013
VL 230
IS 2
BP 69
EP 75
DI 10.1159/000351652
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 210ZI
UT WOS:000323873500003
PM 23886949
DA 2022-11-30
ER

PT J
AU Tarita-Nistor, L
   Gonzalez, EG
   Markowitz, SN
   Steinbach, MJ
AF Tarita-Nistor, Luminita
   Gonzalez, Esther G.
   Markowitz, Samuel N.
   Steinbach, Martin J.
TI Binocular interactions in patients with age-related macular
   degeneration: Acuity summation and rivalry
SO VISION RESEARCH
LA English
DT Article
DE age-related macular degeneration; acuity; rivalry; binocular
   interactions
ID VISUAL-ACUITY; CONTRAST SENSITIVITY; PERIPHERAL FIELD; FACE RECOGNITION;
   VISION; INHIBITION; PERFORMANCE; IMPAIRMENT; MOBILITY; YOUNG
AB This study examined two aspects of binocular function in patients with age-related macular degeneration (AMD): summation/inhibition of visual acuity and rivalry. The performance of 17 patients with AMD was compared with that of 17 elderly controls and 21 young people. Monocular and binocular acuities were measured using a multiple-E optotype test. Binocular ratios, defined as the better-eye acuity divided by the binocular acuity, were calculated. We also measured eye dominance during rivalry (proportion of time the participants reported perceiving the input to each eye) and rivalry rates (number of alternations per minute). The results showed that while overall binocular ratios were similar for the three groups, the frequency distributions of people who experienced inhibition, equality or summation were different for the young and AMD groups. In the rivalry test, patients experienced more piecemeal perception than the elderly and young controls, but time dominance from the better-seeing eye was comparable for the three groups. Rivalry rates decreased with age and further with pathology. Moreover, rivalry time dominance of the worse-seeing eye was negatively correlated with interocular acuity differences for the AMD group. (c) 2006 Elsevier Ltd. All rights reserved.
C1 York Univ, Ctr Vis Res, Toronto, ON M3J 2R7, Canada.
   Toronto Western Hosp, Vis Sci Res Program, Toronto, ON M5T 2S8, Canada.
   Univ Toronto, Dept Ophthalmol, Toronto, ON M5S 1A1, Canada.
C3 York University - Canada; University of Toronto; University Toronto
   Affiliates; University Health Network Toronto; University of Toronto
RP Steinbach, MJ (通讯作者)，York Univ, Ctr Vis Res, Toronto, ON M3J 2R7, Canada.
EM mjs@yorku.ca
CR Azen SP, 2002, INVEST OPHTH VIS SCI, V43, P1742
   BLAKE R, 1973, PERCEPT PSYCHOPHYS, V14, P161, DOI 10.3758/BF03198631
   BLAKE R, 1992, VISUAL NEUROSCI, V8, P469, DOI 10.1017/S0952523800004971
   Blake R, 2002, NAT REV NEUROSCI, V3, P13, DOI 10.1038/nrn701
   BULLIMORE MA, 1991, INVEST OPHTH VIS SCI, V32, P2020
   CAGENELLO R, 1993, J OPT SOC AM A, V10, P1841, DOI 10.1364/JOSAA.10.001841
   CAMPBELL FW, 1965, NATURE, V208, P191, DOI 10.1038/208191a0
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   DEBELSUNCE S, 1991, INVEST OPHTH VIS SCI, V32, P2645
   EDWARDS MG, 1999, OPHTHALMOLOGY
   ELLIOTT DB, 1995, OPHTHAL PHYSL OPT, V15, P553, DOI 10.1016/0275-5408(95)00025-9
   Ergun E, 2003, OPHTHALMOLOGY, V110, P65, DOI 10.1016/S0161-6420(02)01566-X
   FAHLE M, 1991, BIOL CYBERN, V66, P1, DOI 10.1007/BF00196447
   Faubert J, 2002, CAN J EXP PSYCHOL, V56, P164, DOI 10.1037/h0087394
   Faubert J, 2000, J AM GERIATR SOC, V48, P375, DOI 10.1111/j.1532-5415.2000.tb04693.x
   FRISEN L, 1988, J PHYSIOL-LONDON, V402, P773, DOI 10.1113/jphysiol.1988.sp017233
   Gagnon RWC, 2003, CURR EYE RES, V27, P315, DOI 10.1076/ceyr.27.5.315.17225
   GILCHRIST J, 1987, OPHTHAL PHYSL OPT, V7, P373
   Gonzalez EG., 2004, U HLTH NETW RES DAY
   HARRIS JP, 1973, PERCEPTION, V2, P235, DOI 10.1068/p020235
   HARRIS MJ, 1985, OPHTHALMOLOGY, V92, P1550
   Hassan SE, 2002, OPTOMETRY VISION SCI, V79, P697, DOI 10.1097/00006324-200211000-00007
   He S, 2001, VISION RES, V41, P835, DOI 10.1016/S0042-6989(00)00315-1
   HERAVIAN JS, 1990, OPHTHAL PHYSL OPT, V10, P257, DOI 10.1111/j.1475-1313.1990.tb00861.x
   HOME R, 1978, VISION RES, V18, P579, DOI 10.1016/0042-6989(78)90206-7
   HOROWITZ MW, 1949, J EXP PSYCHOL, V39, P581, DOI 10.1037/h0056892
   HOWARD IP, 2002, SEEING DEPTH BASIC M, V1
   LEGGE GE, 1984, VISION RES, V24, P373, DOI 10.1016/0042-6989(84)90063-4
   LEVELT WJM, 1966, BRIT J PSYCHOL, V57, P225, DOI 10.1111/j.2044-8295.1966.tb01023.x
   LEVITT H, 1971, J ACOUST SOC AM, V49, P467, DOI 10.1121/1.1912375
   LIU L, 1992, VISION RES, V32, P1471, DOI 10.1016/0042-6989(92)90203-U
   Pardhan S, 2003, CURR EYE RES, V26, P297, DOI 10.1076/ceyr.26.4.297.15430
   PARDHAN S, 1990, OPTOMETRY VISION SCI, V67, P688, DOI 10.1097/00006324-199009000-00006
   Pardhan S, 1997, CURR EYE RES, V16, P252, DOI 10.1076/ceyr.16.3.252.15407
   Pardhan S, 1996, CURR EYE RES, V15, P315, DOI 10.3109/02713689609007626
   Pardhan S, 2000, CURR EYE RES, V20, P35, DOI 10.1076/0271-3683(200001)20:1;1-H;FT035
   PARDHAN S, 1990, OPHTHAL PHYSL OPT, V10, P33, DOI 10.1016/0275-5408(90)90127-K
   Quillen DA, 2001, ARCH OPHTHALMOL-CHIC, V119, P1725
   REGAN D, 1992, OPHTHAL PHYSL OPT, V12, P425, DOI 10.1016/0275-5408(92)90171-R
   ROSS JE, 1985, BRIT J OPHTHALMOL, V69, P51, DOI 10.1136/bjo.69.1.51
   Rosser DA, 2003, INVEST OPHTH VIS SCI, V44, P3278, DOI 10.1167/iovs.02-1100
   Rubin GS, 2000, INVEST OPHTH VIS SCI, V41, P3327
   SHAPIRO M, 1971, AMBLYOPIA
   Sobel KV, 2003, VISION RES, V43, P1533, DOI 10.1016/S0042-6989(03)00178-0
   Tejeria L, 2002, BRIT J OPHTHALMOL, V86, P1019, DOI 10.1136/bjo.86.9.1019
   Tong F, 2001, NATURE, V411, P195, DOI 10.1038/35075583
   Ukai K, 2003, PERCEPT MOTOR SKILL, V97, P393, DOI 10.2466/pms.2003.97.2.393
   Valberg A, 2002, J OPT SOC AM A, V19, P223, DOI 10.1364/JOSAA.19.000223
   Westheimer G, 2003, OPTOMETRY VISION SCI, V80, P745, DOI 10.1097/00006324-200311000-00010
   Wildsoet C, 1998, OPHTHAL PHYSL OPT, V18, P263, DOI 10.1046/j.1475-1313.1998.00370.x
NR 50
TC 27
Z9 28
U1 0
U2 10
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0042-6989
EI 1878-5646
J9 VISION RES
JI Vision Res.
PD AUG
PY 2006
VL 46
IS 16
BP 2487
EP 2498
DI 10.1016/j.visres.2006.01.035
PG 12
WC Neurosciences; Ophthalmology; Psychology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Neurosciences & Neurology; Ophthalmology; Psychology
GA 062DH
UT WOS:000238924300003
PM 16545856
OA Bronze
DA 2022-11-30
ER

PT J
AU Agosta, E
   Lazzeri, S
   Orlandi, P
   Figus, M
   Fioravanti, A
   Di Desidero, T
   Sartini, MS
   Nardi, M
   Danesi, R
   Bocci, G
AF Agosta, Elisa
   Lazzeri, Stefano
   Orlandi, Paola
   Figus, Michele
   Fioravanti, Anna
   Di Desidero, Teresa
   Sartini, Maria Sole
   Nardi, Marco
   Danesi, Romano
   Bocci, Guido
TI Pharmacogenetics of antiangiogenic and antineovascular therapies of
   age-related macular degeneration
SO PHARMACOGENOMICS
LA English
DT Review
DE age-related macular degeneration; angiogenesis; CFH; genetics;
   pharmacogenetics; VEGF-A
ID ENDOTHELIAL GROWTH-FACTOR; COMPLEMENT FACTOR-H; CHOROIDAL
   NEOVASCULARIZATION SECONDARY; HTRA1 PROMOTER POLYMORPHISM; FACTOR GENE
   POLYMORPHISMS; RETINA STUDY-GROUP; PHOTODYNAMIC THERAPY;
   APOLIPOPROTEIN-E; GENOMEWIDE-SCAN; INTRAVITREAL RANIBIZUMAB
AB Age-related macular degeneration (AMD), the most common age-related disease causing irreversible visual loss in industrialized countries, is a complex and multifactorial illness. Researchers have found components of the complement alternative pathway inside drusen and Bruch's membrane of AMD patients, underlying a possible important role of complement factor H in the pathogenesis of AMD. The neovascular (wet) AMD is the most destructive form and it is characterized by invasion of new blood vessels into subretinal spaces with subsequent exudation and bleeding, resulting in scarring of the macular region and loss of the central vision. The hallmark of the neovascular form is the choroidal neovascularization, where VEGF-A has an important role in the pathogenesis of the disease. SNPs of these genes have recently been investigated as potential pharmacogenetic markers of the antiangiogenic and antineovascular therapy of AMD, which includes verteporfin photodynamic therapy and anti-VEGF-A drugs, such as pegaptanib, bevacizumab and ranibizumab. The CFH rs1061170 CT and TT genotypes have been associated with an improvement of visual acuity in bevacizumab or ranibizumab treated patients, whereas patients harboring VEGF-A rs699946 G allele responded better to bevacizumab-based therapy if compared with patients carrying the A allele. In conclusion, the discovery of pharmacogenetic markers for the personalization of the antiangiogenic and/or antineovascular therapy could be, in the future, a key issue in ophthalmology to obtain a personalization of the therapy and to avoid unnecessary costs and adverse drug reactions.
C1 [Agosta, Elisa; Orlandi, Paola; Fioravanti, Anna; Di Desidero, Teresa; Danesi, Romano; Bocci, Guido] Univ Pisa, Dept Internal Med, Div Pharmacol, I-56125 Pisa, Italy.
   [Lazzeri, Stefano; Figus, Michele; Sartini, Maria Sole; Nardi, Marco] Univ Pisa, Ophthalmol Unit, I-56125 Pisa, Italy.
C3 University of Pisa; University of Pisa
RP Bocci, G (通讯作者)，Univ Pisa, Dept Internal Med, Div Pharmacol, Via Roma 55, I-56125 Pisa, Italy.
EM guido.bocci@med.unipi.it
RI Figus, Michele/AAA-9808-2019; Bocci, Guido/AAC-7515-2022; Danesi,
   Romano/J-7239-2018; Danesi, Romano/AAC-9410-2019; Figus,
   Michele/AAD-6850-2020
OI Figus, Michele/0000-0003-2243-9033; Danesi, Romano/0000-0002-4414-8934;
   Danesi, Romano/0000-0002-4414-8934; Di Desidero,
   Teresa/0000-0002-5487-071X; nardi, marco/0000-0003-3422-9498
FU University of Pisa
FX The present work was supported by academic funding from the University
   of Pisa to G Bocci. The authors have no other relevant affiliations or
   financial involvement with any organization or entity with a financial
   interest in or financial conflict with the subject matter or materials
   discussed in the manuscript apart from those disclosed.
CR Abraham P, 2010, AM J OPHTHALMOL, V150, P315, DOI 10.1016/j.ajo.2010.04.011
   Anderson DH, 2002, AM J OPHTHALMOL, V134, P411, DOI 10.1016/S0002-9394(02)01624-0
   [Anonymous], 1999, Arch Ophthalmol, V117, P1329
   Arevalo JF, 2008, RETINA-J RET VIT DIS, V28, P1387, DOI 10.1097/IAE.0b013e3181884ff4
   Arnold J, 2001, AM J OPHTHALMOL, V131, P541
   Avery RL, 2006, OPHTHALMOLOGY, V113, P363, DOI 10.1016/j.ophtha.2005.11.019
   Bhisitkul RB, 2006, BRIT J OPHTHALMOL, V90, P1542, DOI 10.1136/bjo.2006.098426
   Bocci G, 2011, PHARMACOGENOMICS, V12, P1077, DOI [10.2217/pgs.11.75, 10.2217/PGS.11.75]
   Boekhoorn SS, 2008, OPHTHALMOLOGY, V115, P1899, DOI 10.1016/j.ophtha.2008.06.026
   Brantley MA, 2009, EYE, V23, P626, DOI 10.1038/eye.2008.28
   Brantley MA, 2007, OPHTHALMOLOGY, V114, P2168, DOI 10.1016/j.ophtha.2007.09.008
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   Chowers I, 2008, MOL VIS, V14, P2263
   Chowers I, 2008, MOL VIS, V14, P1829
   Churchill AJ, 2006, HUM MOL GENET, V15, P2955, DOI 10.1093/hmg/ddl238
   Curtis LH, 2012, AM J OPHTHALMOL, V153, P1116, DOI 10.1016/j.ajo.2011.11.032
   D'Amico DJ, 2006, OPHTHALMOLOGY, V113, P992, DOI 10.1016/j.ophtha.2006.02.027
   de Jong PTVM, 2006, NEW ENGL J MED, V355, P1474, DOI 10.1056/NEJMra062326
   DeAngelis MM, 2008, OPHTHALMOLOGY, V115, P1209, DOI 10.1016/j.ophtha.2007.10.032
   Dewan A, 2006, SCIENCE, V314, P989, DOI 10.1126/science.1133807
   Dithmar S, 2001, ARCH OPHTHALMOL-CHIC, V119, P1643, DOI 10.1001/archopht.119.11.1643
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Fang AM, 2009, MOL VIS, V15, P2710
   Feng X, 2009, OPHTHALMOLOGY, V116
   Ferrara N, 2003, NAT MED, V9, P669, DOI 10.1038/nm0603-669
   Folk JC, 2010, NEW ENGL J MED, V363, P1648, DOI 10.1056/NEJMct1000495
   Francis PJ, 2008, HUM MOL GENET, V17, P2673, DOI 10.1093/hmg/ddn167
   Frank RN, 1997, OPHTHALMIC RES, V29, P341, DOI 10.1159/000268032
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Fritsche LG, 2008, NAT GENET, V40, P892, DOI 10.1038/ng.170
   Galan A, 2010, OPHTHALMOLOGY, V117, P1769, DOI 10.1016/j.ophtha.2010.01.030
   Goverdhan SV, 2008, EYE, V22, P849, DOI 10.1038/sj.eye.6702830
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Grau S, 2006, J BIOL CHEM, V281, P6124, DOI 10.1074/jbc.M500361200
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Holz FG, 2011, OPHTHALMOLOGY, V118, P663, DOI 10.1016/j.ophtha.2010.12.019
   Hughes AE, 2007, PLOS MED, V4, P1993, DOI 10.1371/journal.pmed.0040355
   Imai Daisuke, 2010, J Ocul Biol Dis Infor, V3, P53, DOI 10.1007/s12177-010-9055-1
   Immonen I, 2010, OPHTHALMOLOGY, V117, P103, DOI 10.1016/j.ophtha.2009.06.037
   Iyengar SK, 2004, AM J HUM GENET, V74, P20, DOI 10.1086/380912
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Janik-Papis K, 2009, EXP MOL PATHOL, V87, P234, DOI 10.1016/j.yexmp.2009.09.005
   Johnson LV, 2001, EXP EYE RES, V73, P887, DOI 10.1006/exer.2001.1094
   Kanda A, 2007, P NATL ACAD SCI USA, V104, P16227, DOI 10.1073/pnas.0703933104
   Kaur I, 2008, INVEST OPHTH VIS SCI, V49, P1771, DOI 10.1167/iovs.07-0560
   Kenealy SJ, 2004, MOL VIS, V10, P57
   Keyt BA, 1996, J BIOL CHEM, V271, P7788, DOI 10.1074/jbc.271.13.7788
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Kliffen M, 1997, BRIT J OPHTHALMOL, V81, P154, DOI 10.1136/bjo.81.2.154
   Kloeckener-Gruissem B, 2011, INVEST OPHTH VIS SCI, V52, P4694, DOI 10.1167/iovs.10-6080
   Konopatskaya O, 2006, MOL VIS, V12, P626
   Kortvely E, 2010, INVEST OPHTH VIS SCI, V51, P79, DOI 10.1167/iovs.09-3850
   Kvanta A, 1996, INVEST OPHTH VIS SCI, V37, P1929
   Lalwani GA, 2009, AM J OPHTHALMOL, V148, P43, DOI 10.1016/j.ajo.2009.01.024
   Lee AY, 2009, BRIT J OPHTHALMOL, V93, P610, DOI 10.1136/bjo.2008.150995
   Lin JM, 2008, AM J OPHTHALMOL, V145, P1045, DOI 10.1016/j.ajo.2008.01.027
   Lu F, 2007, VISION RES, V47, P3120, DOI 10.1016/j.visres.2007.08.010
   Ly DH, 2000, SCIENCE, V287, P2486, DOI 10.1126/science.287.5462.2486
   MAHLEY RW, 1988, SCIENCE, V240, P622, DOI 10.1126/science.3283935
   Majewski J, 2003, AM J HUM GENET, V73, P540, DOI 10.1086/377701
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   McKay GJ, 2011, HUM MUTAT, V32, P1407, DOI 10.1002/humu.21577
   McKibbin M, 2012, BRIT J OPHTHALMOL, V96, P208, DOI 10.1136/bjo.2010.193680
   Miyake K, 2008, J HUM GENET, V53, P174, DOI 10.1007/s10038-007-0231-5
   Montezuma Sandra R, 2007, Semin Ophthalmol, V22, P229, DOI 10.1080/08820530701745140
   Mordenti J, 1999, TOXICOL PATHOL, V27, P536, DOI 10.1177/019262339902700507
   Nakata I, 2011, JPN J OPHTHALMOL, V55, P435, DOI 10.1007/s10384-011-0061-z
   Nischler C, 2011, ACTA OPHTHALMOL, V89, pE344, DOI 10.1111/j.1755-3768.2010.02080.x
   Oka C, 2004, DEVELOPMENT, V131, P1041, DOI 10.1242/dev.00999
   Ong JM, 2001, INVEST OPHTH VIS SCI, V42, P1891
   Parmeggiani F, 2008, INVEST OPHTH VIS SCI, V49, P3100, DOI 10.1167/iovs.07-1654
   Parmeggiani F, 2007, PHARMACOGENET GENOM, V17, P1039, DOI 10.1097/FPC.0b013e3282f12a4e
   Parmeggiani Francesco, 2009, Recent Pat DNA Gene Seq, V3, P114
   Parmeggiani F, 2009, PHARMACOGENOMICS, V10, P81, DOI 10.2217/14622416.10.1.81
   Pasqualetti G, 2007, PHARMACOGENOMICS, V8, P49, DOI 10.2217/14622416.8.1.49
   Patel PJ, 2008, TRIALS, V9, DOI 10.1186/1745-6215-9-56
   Perrin RM, 2005, DIABETOLOGIA, V48, P2422, DOI 10.1007/s00125-005-1951-8
   Polak MB, 2008, J FR OPHTALMOL, V31, P537
   Prasad PS, 2010, MATURITAS, V66, P46, DOI 10.1016/j.maturitas.2010.02.006
   Rakic JM, 2003, INVEST OPHTH VIS SCI, V44, P3186, DOI 10.1167/iovs.02-1092
   Rivera A, 2005, HUM MOL GENET, V14, P3227, DOI 10.1093/hmg/ddi353
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rosenfeld PJ, 2005, OPHTHALMOLOGY, V112, P1048, DOI 10.1016/j.ophtha.2005.01.043
   Salam A, 2011, ACTA OPHTHALMOL, V89, P405, DOI 10.1111/j.1755-3768.2010.02079.x
   Schmidt Silke, 2002, Ophthalmic Genet, V23, P209, DOI 10.1076/opge.23.4.209.13883
   Schmidt-Erfurth U, 2011, OPHTHALMOLOGY, V118, P831, DOI 10.1016/j.ophtha.2010.09.004
   Scholl HPN, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002593
   Seddon JM, 2003, AM J HUM GENET, V73, P780, DOI 10.1086/378505
   Seddon JM, 2010, OPHTHALMOLOGY, V117, P1560, DOI 10.1016/j.ophtha.2009.11.020
   Seitsonen SP, 2007, EUR J OPHTHALMOL, V17, P943, DOI 10.1177/112067210701700612
   SHALABY F, 1995, NATURE, V376, P62, DOI 10.1038/376062a0
   Simonelli F, 2001, OPHTHALMIC RES, V33, P325, DOI 10.1159/000055688
   Sivaprasad S, 2006, EYE, V20, P867, DOI 10.1038/sj.eye.6702176
   Soker S, 1998, CELL, V92, P735, DOI 10.1016/S0092-8674(00)81402-6
   Spaide RF, 2006, RETINA-J RET VIT DIS, V26, P383, DOI 10.1097/00006982-200604000-00001
   Steinbrook R, 2006, NEW ENGL J MED, V355, P1409, DOI 10.1056/NEJMp068185
   Teper SJ, 2010, MOL VIS, V16, P2598
   Tocharus J, 2004, DEV GROWTH DIFFER, V46, P257
   Tong Y, 2010, MOL VIS, V16, P1958
   Tsuchihashi T, 2011, OPHTHALMOLOGY, V118, P93, DOI 10.1016/j.ophtha.2010.04.007
   Tufail A, 2010, BMJ-BRIT MED J, V340, DOI 10.1136/bmj.c2459
   Waheed Nadia K., 2004, International Ophthalmology Clinics, V44, P11, DOI 10.1097/00004397-200404430-00004
   Wang GF, 2009, INVEST OPHTH VIS SCI, V50, P3084, DOI 10.1167/iovs.08-3240
   Weeks DE, 2004, AM J HUM GENET, V75, P174, DOI 10.1086/422476
   Wickremasinghe SS, 2011, INVEST OPHTH VIS SCI, V52, P4072, DOI 10.1167/iovs.10-6550
   Witmer AN, 2003, PROG RETIN EYE RES, V22, P1, DOI 10.1016/S1350-9462(02)00043-5
   Wolf CR, 2000, BRIT MED J, V320, P987, DOI 10.1136/bmj.320.7240.987
   Wu L, 2008, GRAEF ARCH CLIN EXP, V246, P81, DOI 10.1007/s00417-007-0660-z
   Yang ZL, 2006, SCIENCE, V314, P992, DOI 10.1126/science.1133811
   Yoshida T, 2007, MOL VIS, V13, P545
   Zareparsi S, 2004, INVEST OPHTH VIS SCI, V45, P1306, DOI 10.1167/iovs.03-1253
NR 113
TC 21
Z9 23
U1 0
U2 10
PU FUTURE MEDICINE LTD
PI LONDON
PA UNITEC HOUSE, 3RD FLOOR, 2 ALBERT PLACE, FINCHLEY CENTRAL, LONDON, N3
   1QB, ENGLAND
SN 1462-2416
EI 1744-8042
J9 PHARMACOGENOMICS
JI Pharmacogenomics
PD JUL
PY 2012
VL 13
IS 9
BP 1037
EP 1053
DI 10.2217/PGS.12.77
PG 17
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA 977EB
UT WOS:000306638100013
PM 22838951
DA 2022-11-30
ER

PT J
AU Kose, C
   Sevik, U
   Gencalioglu, O
AF Koese, Cemal
   Sevik, Ugur
   Gencalioglu, Okyay
TI Automatic segmentation of age-related macular degeneration in retinal
   fundus images
SO COMPUTERS IN BIOLOGY AND MEDICINE
LA English
DT Article
DE medical image processing; retina; optic disk; macula; age-related
   macular degenerations; segmentation; diagnosis
ID OPTIC DISC; DIAGNOSIS
AB Every year an increasing number of people are affected by age-related macular degeneration (ARMD). Consequently, vast amount of information is accumulated in medical databases and manual classification of this information is becoming more and more difficult. Therefore, there is an increasing interest in developing automated evaluation methods to follow up the diseases. In this paper, we have presented an automatic method for segmenting the ARMD in retinal fundus images. Previously used direct segmentation techniques, generating unsatisfactory results in some cases, are more complex and costly than our inverse method. This is because of the fact that the texture of unhealthy areas of macula is quite irregular and varies from eye to eye. Therefore, a simple inverse segmentation method is proposed to exploit the homogeneity of healthy areas of the macula rather than unhealthy areas. This method first extracts healthy areas of the macula by employing a simple region growing method. Then, blood vessels are also extracted and classified as healthy regions. In order to produce the final segmented image, the inverse image of the segmented image is generated as unhealthy region of the macula. The performance of the method is examined on various qualities of retinal fundus images. The segmentation method without any user involvement provides over 90% segmentation accuracy. Segmented images with reference invariants are also compared with consecutive images of the same patient to follow up the changes in the disease. (C) 2008 Elsevier Ltd. All rights reserved.
C1 [Koese, Cemal; Sevik, Ugur] Karadeniz Tech Univ, Dept Comp Engn, Fac Engn, TR-61080 Trabzon, Turkey.
   [Gencalioglu, Okyay] Karadeniz Tech Univ, Fac Med, TR-61080 Trabzon, Turkey.
C3 Karadeniz Technical University; Karadeniz Technical University
RP Kose, C (通讯作者)，Karadeniz Tech Univ, Dept Comp Engn, Fac Engn, TR-61080 Trabzon, Turkey.
EM ckose@ktu.edu.tr; usevik@ktu.edu.tr; okyaygenc@meds.ktu.edu.tr
RI Şevik, Uğur/E-5056-2013; KÖSE, Cemal/V-9731-2017
OI Şevik, Uğur/0000-0002-2056-9988; KÖSE, Cemal/0000-0002-5982-4771
CR Al-Rawi M, 2007, COMPUT BIOL MED, V37, P262, DOI 10.1016/j.compbiomed.2006.03.003
   Chrastek R, 2005, MED IMAGE ANAL, V9, P297, DOI 10.1016/j.media.2004.12.004
   FOLKESSON J, 2005, P SPIE
   HART WE, 1994, AUTOMATIC SEGMENTATI
   Huh S, 2002, COMPUT BIOL MED, V32, P311, DOI 10.1016/S0010-4825(02)00023-9
   Kom G, 2007, COMPUT BIOL MED, V37, P37, DOI 10.1016/j.compbiomed.2005.12.004
   Kose C, 2006, LECT NOTES COMPUT SC, V4109, P74
   Lalonde M, 2001, IEEE T MED IMAGING, V20, P1193, DOI 10.1109/42.963823
   Letteboer MMJ, 2004, ACAD RADIOL, V11, P1125, DOI 10.1016/j.acra.2004.05.020
   Li HQ, 2001, 2001 INTERNATIONAL CONFERENCE ON IMAGE PROCESSING, VOL II, PROCEEDINGS, P837, DOI 10.1109/ICIP.2001.958624
   Lynch JA, 2000, PROC SPIE, V3979, P925, DOI 10.1117/12.387758
   MENDELS F, 1999, ENG MED BIOL 1999 21, V2, P1139
   Mohamed SS, 2007, BIOMED ENG ONLINE, V6, DOI 10.1186/1475-925X-6-10
   MOON N, 2002, LNCS
   Nattkemper TW, 2003, COMPUT BIOL MED, V33, P31, DOI 10.1016/S0010-4825(02)00060-4
   Osareh A, 2002, INT C PATT RECOG, P743, DOI 10.1109/ICPR.2002.1044865
   Pakin SK, 2002, P SOC PHOTO-OPT INS, V4684, P155, DOI 10.1117/12.467113
   PITAS I, 1990, VENETSANOPOULOS NONL
   Rapantzikos K, 2003, MED IMAGE ANAL, V7, P95, DOI 10.1016/S1361-8415(02)00093-2
   Rapantzikos K, 2001, 2001 INTERNATIONAL CONFERENCE ON IMAGE PROCESSING, VOL III, PROCEEDINGS, P1055, DOI 10.1109/ICIP.2001.958308
   Sinthanayothin C, 1999, BRIT J OPHTHALMOL, V83, P902, DOI 10.1136/bjo.83.8.902
   Soliz P, 2002, P SOC PHOTO-OPT INS, V4681, P159, DOI 10.1117/12.466917
   Song JT, 2005, LECT NOTES COMPUT SC, V3645, P492
   Stammberger T, 1999, MAGN RESON IMAGING, V17, P1033, DOI 10.1016/S0730-725X(99)00040-5
   Stewart CV, 2005, LECT NOTES COMPUT SC, V3765, P31
   Tamez-Pena JG, 1999, PROC SPIE, V3661, P300, DOI 10.1117/12.348585
   Tolba M.F., 2003, INT C ENT INF SYST I, V2, P165
   Vermeer KA, 2004, COMPUT BIOL MED, V34, P209, DOI 10.1016/S0010-4825(03)00055-6
   Villeger A, 2006, LECT NOTES COMPUT SC, V4179, P909
   Walter T, 2002, IEEE T MED IMAGING, V21, P1236, DOI 10.1109/TMI.2002.806290
   Xu JA, 2006, COMPUT BIOL MED, V36, P921, DOI 10.1016/j.compbiomed.2005.05.001
NR 31
TC 57
Z9 58
U1 0
U2 8
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0010-4825
EI 1879-0534
J9 COMPUT BIOL MED
JI Comput. Biol. Med.
PD MAY
PY 2008
VL 38
IS 5
BP 611
EP 619
DI 10.1016/j.compbiomed.2008.02.008
PG 9
WC Biology; Computer Science, Interdisciplinary Applications; Engineering,
   Biomedical; Mathematical & Computational Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Life Sciences & Biomedicine - Other Topics; Computer Science;
   Engineering; Mathematical & Computational Biology
GA 306AE
UT WOS:000256218200008
PM 18402931
DA 2022-11-30
ER

PT J
AU Cho, YK
   Lee, SM
   Kang, YJ
   Kang, YM
   Jeon, IC
   Park, DH
AF Cho, Yeon-Kyoung
   Lee, Seung-Min
   Kang, Yeong-Ji
   Kang, Yeong-Mo
   Jeon, In-Chul
   Park, Dae-Hun
TI The Age-Related Macular Degeneration (AMD)-Preventing Mechanism of
   Natural Products
SO PROCESSES
LA English
DT Review
DE age-related macular degeneration (AMD); natural products; preventing
   mechanism; dry AMD
ID PIGMENT EPITHELIAL-CELLS; OXIDATIVE STRESS; ARPE-19 CELLS; DIETARY
   ANTIOXIDANTS; ENDOGENOUS ADJUVANTS; LIPID-PEROXIDATION; VISUAL FUNCTION;
   BETA-CAROTENE; UP-REGULATION; NITRIC-OXIDE
AB Age-related macular degeneration (AMD) is related to central visual loss in elderly people and, based on the increment in the percentage of the aging population, the number of people suffering from AMD could increase. AMD is initiated by retinal pigment epithelium (RPE) cell death, finally leading to neovascularization in the macula lutea. AMD is an uncurable disease, but the symptom can be suppressed. The current therapy of AMD can be classified into four types: device-based treatment, anti-inflammatory drug treatment, anti-vascular endothelial growth factor treatment, and natural product treatment. All these therapies have adverse effects, however early AMD therapy used with products has several advantages, as it can prevent RPE cell apoptosis in safe doses. Cell death (apoptosis) is caused by various factors, such as oxidative stress, inflammation, carbonyl stress, and a deficiency in essential components for cells, and RPE cell death is related to oxidative stress, inflammation, and carbonyl stress. Some natural products have anti-oxidative effects, anti-inflammation effects, and/or anti-carbonylation effects. The AMD preventive mechanism of natural products varies, with some natural products activating one or more anti-apoptotic pathways, such as the Nrf2/HO-1 anti-oxidative pathway, the anti-inflammasome pathway, and the anti-carbonyl pathway. As AMD drug candidates from natural products effectively inhibit RPE cell death, they have the potential to be developed as drugs for preventing early (dry) AMD.
C1 [Cho, Yeon-Kyoung; Kang, Yeong-Ji; Kang, Yeong-Mo; Jeon, In-Chul] Dongshin Univ, Coll Hlth & Welf, Naju 58245, South Korea.
   [Lee, Seung-Min] Kangwon Natl Univ, Sch Vet Med, Chunchon 24341, South Korea.
   [Park, Dae-Hun] Dongshin Univ, Oriental Med, Naju 58245, South Korea.
C3 Dongshin University; Kangwon National University; Dongshin University
RP Jeon, IC (通讯作者)，Dongshin Univ, Coll Hlth & Welf, Naju 58245, South Korea.; Park, DH (通讯作者)，Dongshin Univ, Oriental Med, Naju 58245, South Korea.
EM yktender@naver.com; smin0515@gmail.com; yjkang0426@naver.com;
   didiaos@naver.com; icjeon@dsu.ac.kr; dhj1221@hanmail.net
OI Park, Dae-Hun/0000-0002-3972-3690
CR Al-Zamil WM, 2017, CLIN INTERV AGING, V12, P1313, DOI 10.2147/CIA.S143508
   Anderson DH, 2002, AM J OPHTHALMOL, V134, P411, DOI 10.1016/S0002-9394(02)01624-0
   Anderson OA, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0067263
   Anwer MS, 2004, HEPATOLOGY, V39, P581, DOI 10.1002/hep.20090
   Arnhold S, 2007, GRAEF ARCH CLIN EXP, V245, P414, DOI 10.1007/s00417-006-0382-7
   Augustin AJ, 2009, EXPERT OPIN THER TAR, V13, P641, DOI 10.1517/14728220902942322
   Aung KH, 2020, FRONT PHARMACOL, V11, DOI 10.3389/fphar.2020.566699
   Bai NS, 2010, J AGR FOOD CHEM, V58, P5363, DOI 10.1021/jf100332w
   Bazan NG, 2006, ADV EXP MED BIOL, V572, P531
   Bhutto I, 2012, MOL ASPECTS MED, V33, P295, DOI 10.1016/j.mam.2012.04.005
   Borlinghaus J, 2014, MOLECULES, V19, P12591, DOI 10.3390/molecules190812591
   BRESNICK GH, 1983, OPHTHALMOLOGY, V90, P1301
   Bressler SB, 2009, OPHTHALMOLOGY, V116, pS1, DOI 10.1016/j.ophtha.2009.06.045
   Broz P, 2016, NAT REV IMMUNOL, V16, P407, DOI 10.1038/nri.2016.58
   Cao X, 2010, BRAIN RES, V1347, P142, DOI 10.1016/j.brainres.2010.05.072
   Chen C, 2017, MOL MED REP, V15, P2289, DOI 10.3892/mmr.2017.6252
   Chen WP, 2021, OXID MED CELL LONGEV, V2021, DOI 10.1155/2021/4053276
   Chen X, 2018, BIOMED PHARMACOTHER, V101, P87, DOI 10.1016/j.biopha.2018.02.054
   Chew EY, 2014, JAMA OPHTHALMOL, V132, P142, DOI 10.1001/jamaophthalmol.2013.7376
   Chichili GR, 2006, BRIT J NUTR, V96, P643, DOI 10.1079/BJN20061843
   Cho YK, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms222111837
   Collin T., 1999, ACUTE CHRONIC INFLAM, P50
   Crouch RK, 2015, PROG MOL BIOL TRANSL, V134, P449, DOI 10.1016/bs.pmbts.2015.06.005
   da Cruz L, 2018, NAT BIOTECHNOL, V36, P1, DOI 10.1038/nbt.4114
   de Guimaraes TAC, 2022, BRIT J OPHTHALMOL, V106, P297, DOI 10.1136/bjophthalmol-2020-318452
   Degenhardt T.P., 2005, MAILLARD REACTION FO, P3
   Dong X, 2011, MOL VIS, V17, P2040
   Eldred GE, 1995, GERONTOLOGY, V41, P15
   Evereklioglu C, 2003, DOC OPHTHALMOL, V106, P129, DOI 10.1023/A:1022512402811
   Falavarjani KG, 2013, EYE, V27, P787, DOI 10.1038/eye.2013.107
   Fernandez-Albarral JA, 2021, J CLIN MED, V10, DOI 10.3390/jcm10214801
   Franzone F, 2021, EXP THER MED, V22, DOI 10.3892/etm.2021.10222
   FUTTERMAN S, 1964, INVEST OPHTH VISUAL, V3, P441
   Gordon S, 2010, IMMUNITY, V32, P593, DOI 10.1016/j.immuni.2010.05.007
   Guan SP, 2013, BRIT J PHARMACOL, V168, P1707, DOI 10.1111/bph.12054
   HAM WT, 1978, INVEST OPHTH VIS SCI, V17, P1029
   Heitmar R, 2019, NUTRIENTS, V11, DOI 10.3390/nu11030649
   Hsu YA, 2021, CURR ISSUES MOL BIOL, V43, P716, DOI 10.3390/cimb43020052
   Idelson M, 2018, STEM CELL REP, V11, P681, DOI 10.1016/j.stemcr.2018.07.009
   Imamura Y, 2006, P NATL ACAD SCI USA, V103, P11282, DOI 10.1073/pnas.0602131103
   Itoh K, 1999, GENE DEV, V13, P76, DOI 10.1101/gad.13.1.76
   Jarrett SG, 2012, MOL ASPECTS MED, V33, P399, DOI 10.1016/j.mam.2012.03.009
   Jin XL, 2018, J IMMUNOL RES, V2018, DOI 10.1155/2018/5604610
   Jonas JB, 2017, ASIA-PAC J OPHTHALMO, V6, P493, DOI 10.22608/APO.2017251
   Justilien V, 2007, INVEST OPHTH VIS SCI, V48, P4407, DOI 10.1167/iovs.07-0432
   Kapugi M, 2019, ORTHOP NURS, V38, P336, DOI 10.1097/NOR.0000000000000595
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Kauppinen A, 2012, IMMUNOL LETT, V147, P29, DOI 10.1016/j.imlet.2012.05.005
   Kensler TW, 2007, ANNU REV PHARMACOL, V47, P89, DOI 10.1146/annurev.pharmtox.46.120604.141046
   Khandhadia S, 2012, ADV EXP MED BIOL, V724, P15, DOI 10.1007/978-1-4614-0653-2_2
   Khandhadia S, 2010, EXPERT REV MOL MED, V12, DOI 10.1017/S146239941000164X
   Khurana RN, 2021, AM J OPHTHALMOL, V227, P222, DOI [10.1016/i.aio.2021.03.033, 10.1016/j.ajo.2021.03.033]
   Kim DH, 2020, MOLECULES, V25, DOI 10.3390/molecules25071737
   Kim SS, 2012, J NUTR BIOCHEM, V23, P1314, DOI 10.1016/j.jnutbio.2011.07.012
   Klein R, 2014, OPHTHAL EPIDEMIOL, V21, P14, DOI 10.3109/09286586.2013.867512
   Klein R, 2013, INVEST OPHTH VIS SCI, V54, DOI 10.1167/iovs.13-12789
   Kong JM, 2003, PHYTOCHEMISTRY, V64, P923, DOI 10.1016/S0031-9422(03)00438-2
   Lambros ML, 2016, ADV EXP MED BIOL, V854, P67, DOI 10.1007/978-3-319-17121-0_10
   Lederman M, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0087751
   Lee BH, 2013, J AGR FOOD CHEM, V61, P1288, DOI 10.1021/jf305067n
   Lee BL, 2016, NUTR RES, V36, P1402, DOI 10.1016/j.nutres.2016.11.008
   Lee BW, 2011, TOXICOL APPL PHARM, V252, P47, DOI 10.1016/j.taap.2011.01.018
   Lee SY, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-62749-7
   Liu HJ, 2017, MOL MED REP, V16, P2069, DOI 10.3892/mmr.2017.6838
   Liu YX, 2015, J AGR FOOD CHEM, V63, P9295, DOI 10.1021/acs.jafc.5b04341
   Loboda A, 2016, CELL MOL LIFE SCI, V73, P3221, DOI 10.1007/s00018-016-2223-0
   Long EK, 2010, FREE RADICAL BIO MED, V49, P1, DOI 10.1016/j.freeradbiomed.2010.03.015
   Lund RD, 2006, CLONING STEM CELLS, V8, P189, DOI 10.1089/clo.2006.8.189
   Mainster MA, 2000, OPHTHALMIC SURG LAS, V31, P359
   Marti R, 2016, CANCERS, V8, DOI 10.3390/cancers8060058
   Matsuura T, 2017, OXID MED CELL LONGEV, V2017, DOI 10.1155/2017/9548767
   Mayne ST, 2003, J NUTR, V133, p933S, DOI 10.1093/jn/133.3.933S
   Militao GCG, 2004, PHARMAZIE, V59, P965
   Mitsuishi Y, 2012, FRONT ONCOL, V2, DOI 10.3389/fonc.2012.00200
   Morizur L, 2020, MOL CELL NEUROSCI, V107, DOI 10.1016/j.mcn.2020.103523
   Mosser DM, 2003, J LEUKOCYTE BIOL, V73, P209, DOI 10.1189/jlb.0602325
   Mu YL, 2014, INT J CLIN EXP MED, V7, P3843
   Musolino C, 2017, MEDIAT INFLAMM, V2017, DOI 10.1155/2017/1852517
   Nazari H, 2015, PROG RETIN EYE RES, V48, P1, DOI 10.1016/j.preteyeres.2015.06.004
   NEWSOME DA, 1990, INVEST OPHTH VIS SCI, V31, P2508
   Ni TM, 2019, BIOSCIENCE REP, V39, DOI 10.1042/BSR20190689
   O'Neill HC, 2020, CURR STEM CELL RES T, V15, P89, DOI 10.2174/1574888X15666191218094020
   Oeverhaus M, 2019, OPHTHALMOLOGE, V116, P164, DOI 10.1007/s00347-017-0643-3
   Otani A, 2004, J CLIN INVEST, V114, P765, DOI 10.1172/JCI200421686
   Ouyang XL, 2020, BIOMED PHARMACOTHER, V130, DOI 10.1016/j.biopha.2020.110577
   Satoh Takumi, 2017, F1000Res, V6, P2138, DOI 10.12688/f1000research.12111.1
   Shah ZA, 2010, J CEREBR BLOOD F MET, V30, P1951, DOI 10.1038/jcbfm.2010.53
   Shi Y, 2002, EUR J IMMUNOL, V32, P155, DOI 10.1002/1521-4141(200201)32:1<155::AID-IMMU155>3.0.CO;2-P
   Shi Y, 2000, P NATL ACAD SCI USA, V97, P14590, DOI 10.1073/pnas.260497597
   Silva MD, 2018, MOLECULES, V23, DOI 10.3390/molecules23071803
   Sommerburg O, 1998, BRIT J OPHTHALMOL, V82, P907, DOI 10.1136/bjo.82.8.907
   Son TG, 2010, J NEUROCHEM, V112, P1316, DOI 10.1111/j.1471-4159.2009.06552.x
   Sparrow JR, 2003, J BIOL CHEM, V278, P18207, DOI 10.1074/jbc.M300457200
   Steinmetz JD, 2021, LANCET GLOB HEALTH, V9, pE144, DOI 10.1016/S2214-109X(20)30489-7
   Sun HJ, 2020, PHARMACOLOGY, V105, P28, DOI 10.1159/000502614
   Takahashi K, 2006, CELL, V126, P663, DOI 10.1016/j.cell.2006.07.024
   Takeuchi O, 2010, CELL, V140, P805, DOI 10.1016/j.cell.2010.01.022
   Tan JSL, 2008, OPHTHALMOLOGY, V115, P334, DOI 10.1016/j.ophtha.2007.03.083
   TATE DJ, 1995, INVEST OPHTH VIS SCI, V36, P1271
   Thitilertdecha P, 2015, INT J PHARMACEUT, V478, P39, DOI 10.1016/j.ijpharm.2014.11.004
   Totan Y, 2001, BRIT J OPHTHALMOL, V85, P1426, DOI 10.1136/bjo.85.12.1426
   Tu G, 2016, MOL MED REP, V13, P2320, DOI 10.3892/mmr.2016.4797
   Wan WC, 2021, J INFLAMM RES, V14, P3129, DOI 10.2147/JIR.S306456
   Wang K, 2017, EXP CELL RES, V357, P335, DOI 10.1016/j.yexcr.2017.05.030
   Wang Y, 2017, EXP EYE RES, V160, P45, DOI 10.1016/j.exer.2017.04.010
   Warden C, 2020, EXP EYE RES, V193, DOI 10.1016/j.exer.2020.107974
   Winsor N, 2019, CELL MICROBIOL, V21, DOI 10.1111/cmi.13079
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Wu YL, 2010, P NATL ACAD SCI USA, V107, P7275, DOI 10.1073/pnas.0913112107
   Yang M, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21134658
   Yin DZ, 1996, FREE RADICAL BIO MED, V21, P871, DOI 10.1016/0891-5849(96)00175-X
   Yu CC, 2012, FREE RADICAL BIO MED, V52, P660, DOI 10.1016/j.freeradbiomed.2011.11.021
   Zhang H, 2014, FREE RADICAL BIO MED, V69, P219, DOI 10.1016/j.freeradbiomed.2014.01.025
   Zhang JM, 2007, INT ANESTHESIOL CLIN, V45, P27, DOI 10.1097/AIA.0b013e318034194e
   Zhang ZJ, 2012, J AGR FOOD CHEM, V60, P8171, DOI 10.1021/jf301511m
   Zhao HL, 2019, INT J MOL MED, V43, P936, DOI 10.3892/ijmm.2018.4027
   Zhao XM, 2012, BRAIN RES, V1482, P13, DOI 10.1016/j.brainres.2012.09.010
   Zhu C, 2017, BIOMED PHARMACOTHER, V88, P124, DOI 10.1016/j.biopha.2016.11.089
   Zor RK, 2020, THER ADV OPHTHALMOL, V12, DOI 10.1177/2515841420951682
NR 119
TC 0
Z9 0
U1 9
U2 11
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2227-9717
J9 PROCESSES
JI Processes
PD APR
PY 2022
VL 10
IS 4
AR 678
DI 10.3390/pr10040678
PG 14
WC Engineering, Chemical
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Engineering
GA 0S5XU
UT WOS:000786347100001
OA gold
DA 2022-11-30
ER

PT J
AU Lai, TYY
   Chan, WM
   Liu, DT
   Lam, DS
AF Lai, Timothy Y. Y.
   Chan, Wai-Man
   Liu, David T.
   Lam, Dennis S.
TI Ranibizumab for retinal angiomatous proliferation in neovascular
   age-related macular degeneration
SO GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Article
DE retinal angiomatous proliferation; age-related macular degeneration;
   ranibizumab; anti-VEGF
ID INTRAVITREAL TRIAMCINOLONE; PHOTODYNAMIC THERAPY
AB Background To report the efficacy of intravitreal injection of ranibizumab (Lucentis) in the treatment of retinal angiomatous proliferation (RAP) in neovascular age-related macular degeneration (AMD).
   Methods Case review of four consecutive patients who received 3 injections at monthly intervals of intravitreal ranibizumab injections for RAP. The serial changes in best-corrected visual acuity (BCVA), optical coherence tomography (OCT), fluorescein angiography (FA), and indocyanine green angiography (ICGA) are presented.
   Results The baseline mean logMAR BCVA was 0.89 (Snellen equivalent of 20/155). After three injections of ranibizumab, all four patients had visual improvement and the mean logMAR BCVA improved to 0.59 (Snellen equivalent of 20/78). The mean visual improvement was 3.0 lines. All patients also had complete resolution of subretinal fluid after treatment, and the mean OCT central foveal thickness reduced from 438 mu m at baseline to 169 mu m at 3 months. Follow-up FA and ICGA at 3 months showed absence of leakage in three patients with minimal leakage in the remaining patient. One patient had recurrence of RAP at 8 months after commencement of treatment, and repeat ranibizumab injection resulted in resolution of the subretinal fluid and pigment epithelial detachment and visual improvement.
   Conclusions Intravitreal ranibizumab injections appeared to be an effective treatment for RAP, resulting in visual gain and reduction in macular thickness. Further long-term studies to evaluate the efficacy of intravitreal ranibizumab in RAP are warranted.
C1 Chinese Univ Hong Kong, Hong Kong Eye Hosp, Dept Ophthalmol & Visual Sci, Hong Kong, Hong Kong, Peoples R China.
C3 Chinese University of Hong Kong
RP Lai, TYY (通讯作者)，Chinese Univ Hong Kong, Hong Kong Eye Hosp, Dept Ophthalmol & Visual Sci, 147K Argyle St, Hong Kong, Hong Kong, Peoples R China.
EM tyylai@cuhk.edu.hk
RI Lai, Timothy Y Y/AAC-2120-2020; Lam, Dennis/AAL-1211-2020
OI Lai, Timothy Y Y/0000-0002-7832-6428; 
CR Bottoni F, 2005, ARCH OPHTHALMOL-CHIC, V123, P1644, DOI 10.1001/archopht.123.12.1644
   Bottoni F, 2006, GRAEF ARCH CLIN EXP, V244, P1528, DOI 10.1007/s00417-006-0311-9
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Donati MC, 2006, OPHTHALMOLOGICA, V220, P31, DOI 10.1159/000089272
   Freund KB, 2006, ARCH OPHTHALMOL-CHIC, V124, P487, DOI 10.1001/archopht.124.4.487
   Fung AE, 2007, AM J OPHTHALMOL, V143, P566, DOI 10.1016/j.ajo.2007.01.028
   Joeres S, 2007, GRAEFES ARCH CLIN EX
   Meyerle CB, 2007, RETINA-J RET VIT DIS, V27, P451, DOI 10.1097/IAE.0b013e318030ea80
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Yannuzzi LA, 2001, RETINA-J RET VIT DIS, V21, P416, DOI 10.1097/00006982-200110000-00003
NR 10
TC 36
Z9 39
U1 0
U2 1
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0721-832X
EI 1435-702X
J9 GRAEF ARCH CLIN EXP
JI Graefes Arch. Clin. Exp. Ophthalmol.
PD DEC
PY 2007
VL 245
IS 12
BP 1877
EP 1880
DI 10.1007/s00417-007-0679-1
PG 4
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 232HX
UT WOS:000251010600019
PM 17901972
DA 2022-11-30
ER

PT J
AU Theelen, T
   Berendschot, TTJM
   Hoyng, CB
   Boon, CJF
   Klevering, BJ
AF Theelen, Thomas
   Berendschot, Tos T. J. M.
   Hoyng, Carel B.
   Boon, Camiel J. F.
   Klevering, B. Jeroen
TI Near-infrared reflectance imaging of neovascular age-related macular
   degeneration
SO GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Article
DE Age-related maculopathy; Choroidal neovascularization; Confocal laser
   scanning ophthalmoscopy; Near-infrared reflectance; Fluorescein
   angiography
ID OPTICAL COHERENCE TOMOGRAPHY; OCCULT CHOROIDAL NEOVASCULARIZATION; HUMAN
   OCULAR FUNDUS; MULLER CELLS; CLINICOPATHOLOGICAL CORRELATION;
   PHOTODYNAMIC THERAPY; SPECTRAL REFLECTANCE; POLARIMETRY; PREVALENCE;
   AGREEMENT
AB To evaluate various types of neovascular age-related macular degeneration (AMD) by near-infrared fundus reflectance (NIR) as compared to fundus fluorescein angiography (FFA) and to test NIR for assessment of leakage due to choroidal neovascularization (CNV).
   Thirty-three patients with neovascular AMD (cases) and 20 age-matched patients with non-exudative AMD and healthy subjects (controls) were examined with a confocal scanning laser ophthalmoscope (Heidelberg Retina Angiograph 2). NIR images of neovascular AMD were qualitatively compared to the corresponding FFA and to age-matched controls. CNV membranes and exudation areas were manually segmented on FFA and NIR and analyzed quantitatively.
   Of all cases included, five eyes had classic CNV, six had minimal classic lesions, 15 occult CNV's and seven eyes had retinal angiomatous proliferation (RAP). A dark halo on NIR was found in all cases and showed high correspondence to leakage on FFA (r (2) = 0.93; p < 0,0005). In classic CNV and minimal classic CNV, the classic part of the lesion on FFA revealed strong correlation to a dark core surrounded by a bright reflecting ring on NIR (r (2) = 0.88; p < 0.0005). Occult parts on FFA of minimal classic CNV and occult CNV lesions appeared as poorly demarcated, jagged areas of increased NIR. RAP was characterized by speckled NIR located at the intraretinal neovascular complex.
   NIR imaging in neovascular AMD revealed characteristic alterations depending on the type of CNV. These changes may reflect histological differences of the lesions. Leakage caused local darkening of NIR, presumably originating from increased light-scattering and absorbance by fluid accumulation and sub-cellular structure alterations.
C1 [Theelen, Thomas; Hoyng, Carel B.; Boon, Camiel J. F.; Klevering, B. Jeroen] Radboud Univ Nijmegen, Med Ctr, Dept Ophthalmol 400, NL-6500 HB Nijmegen, Netherlands.
   [Berendschot, Tos T. J. M.] Univ Eye Clin Maastricht, Maastricht, Netherlands.
C3 Radboud University Nijmegen; Maastricht University; Maastricht
   University Medical Centre (MUMC)
RP Theelen, T (通讯作者)，Radboud Univ Nijmegen, Med Ctr, Dept Ophthalmol 400, POB 9101, NL-6500 HB Nijmegen, Netherlands.
EM t.theelen@ohk.umcn.nl
RI Klevering, B.J./L-4434-2015; Hoyng, C.B./H-8050-2014; Theelen,
   Thomas/A-3192-2012; Berendschot, Tos TJM/M-8509-2016; Boon,
   CJF/P-7534-2014
OI Theelen, Thomas/0000-0001-9067-1171; Berendschot, Tos
   TJM/0000-0002-8101-939X; Boon, CJF/0000-0002-6737-7932
CR Berendschot TTJM, 2003, PROG RETIN EYE RES, V22, P171, DOI 10.1016/S1350-9462(02)00060-5
   Bringmann A, 2006, PROG RETIN EYE RES, V25, P397, DOI 10.1016/j.preteyeres.2006.05.003
   Campochiaro PA, 2000, J CELL PHYSIOL, V184, P301, DOI 10.1002/1097-4652(200009)184:3<301::AID-JCP3>3.0.CO;2-H
   Cheney E, 1994, NUMERICAL MATH COMPU, V3rd
   Coscas F, 2007, AM J OPHTHALMOL, V144, P592, DOI 10.1016/j.ajo.2007.06.014
   DELORI FC, 1989, APPL OPTICS, V28, P1061, DOI 10.1364/AO.28.001061
   Elsner AE, 1996, VISION RES, V36, P191, DOI 10.1016/0042-6989(95)00100-E
   Elsner AE, 2007, J OPT SOC AM A, V24, P1468, DOI 10.1364/JOSAA.24.001468
   Franze K, 2007, P NATL ACAD SCI USA, V104, P8287, DOI 10.1073/pnas.0611180104
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Hartnett ME, 1996, OPHTHALMOLOGY, V103, P58, DOI 10.1016/S0161-6420(96)30731-8
   Holz FG, 2003, OPHTHALMOLOGY, V110, P400, DOI 10.1016/S0161-6420(02)01770-0
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Kaiser RS, 2002, RETINA-J RET VIT DIS, V22, P683, DOI 10.1097/00006982-200212000-00001
   Klaver CCW, 1998, ARCH OPHTHALMOL-CHIC, V116, P653, DOI 10.1001/archopht.116.5.653
   Klein R, 2007, OPHTHALMOLOGY, V114, P253, DOI 10.1016/j.ophtha.2006.10.040
   Kunze C, 1999, OPHTHALMOLOGY, V106, P1830, DOI 10.1016/S0161-6420(99)90364-0
   Lafaut BA, 2000, BRIT J OPHTHALMOL, V84, P239, DOI 10.1136/bjo.84.3.239
   Lafaut BA, 2000, BRIT J OPHTHALMOL, V84, P1269, DOI 10.1136/bjo.84.11.1269
   Liakopoulos S, 2008, INVEST OPHTH VIS SCI, V49, P5048, DOI 10.1167/iovs.08-1877
   Miura M, 2002, RETINA-J RET VIT DIS, V22, P300, DOI 10.1097/00006982-200206000-00008
   Miura M, 2008, INVEST OPHTH VIS SCI, V49, P2661, DOI 10.1167/iovs.07-0501
   Reichenbach A, 2007, GRAEF ARCH CLIN EXP, V245, P627, DOI 10.1007/s00417-006-0516-y
   Schmidt-Erfurth UM, 2007, PROG RETIN EYE RES, V26, P437, DOI 10.1016/j.preteyeres.2007.03.002
   Semoun O, 2009, BRIT J OPHTHALMOL, V93, P182, DOI 10.1136/bjo.2008.145235
   Smith RT, 2005, BRIT J OPHTHALMOL, V89, P87, DOI 10.1136/bjo.2004.042937
   van Velthoven MEJ, 2006, GRAEF ARCH CLIN EXP, V244, P1119, DOI 10.1007/s00417-005-0209-y
   vandeKraats J, 1996, VISION RES, V36, P2229, DOI 10.1016/0042-6989(96)00001-6
   VANNORREN D, 1986, VISION RES, V26, P313, DOI 10.1016/0042-6989(86)90028-3
   Weinberger AWA, 2006, INVEST OPHTH VIS SCI, V47, P3098, DOI 10.1167/iovs.05-1104
   Wojtkowski M, 2005, OPHTHALMOLOGY, V112, P1734, DOI 10.1016/j.ophtha.2005.05.023
   Zhang N, 2007, AM J OPHTHALMOL, V144, P37, DOI 10.1016/j.ajo.2007.03.056
NR 32
TC 29
Z9 29
U1 0
U2 2
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0721-832X
J9 GRAEF ARCH CLIN EXP
JI Graefes Arch. Clin. Exp. Ophthalmol.
PD DEC
PY 2009
VL 247
IS 12
BP 1625
EP 1633
DI 10.1007/s00417-009-1148-9
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 518YZ
UT WOS:000271733500006
PM 19641931
OA hybrid, Green Published
DA 2022-11-30
ER

PT J
AU Ristau, T
   Ersoy, L
   Lechanteur, Y
   den Hollander, AI
   Daha, MR
   Hahn, M
   Hoyng, CB
   Fauser, S
AF Ristau, Tina
   Ersoy, Lebriz
   Lechanteur, Yara
   den Hollander, Anneke I.
   Daha, Mohamed R.
   Hahn, Moritz
   Hoyng, Carel B.
   Fauser, Sascha
TI Allergy Is a Protective Factor Against Age-Related Macular Degeneration
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
DE age-related macular degeneration; allergy; risk factor
ID SYSTEMIC COMPLEMENT ACTIVATION; NLRP3 INFLAMMASOME ACTIVATION; RISK;
   COMPONENTS; VARIANT; ASTHMA; CELLS
AB PURPOSE. To investigate the role of allergy on AMD.
   METHODS. Age-related macular degeneration staging was performed for 3585 individuals (1878 from Cologne, Germany, and 1707 from Nijmegen, The Netherlands). Interviewer-assisted questionnaires were evaluated for the factors smoking, use of corticosteroids, and history of allergy, including causative allergens. Serum complement component C3d and C3 levels were measured and the C3d:C3 ratio was calculated. Associations of allergy with AMD/late AMD were assessed by logistic regression analysis; C3d:C3 ratio was compared between groups.
   RESULTS. The discovery cohort from Cologne included 864 AMD patients and 1014 controls; 495 patients had late AMD. Positive history of allergy showed strong protective effects on the phenotype AMD (OR 0.52; P = 3.42 x 10(-9)) and late AMD (OR 0.32; P x 2.57 X 10(-13)). Subclassification in allergy-provoking agents showed significant protective effects in all groups. After adjustment for age, sex, smoking, and corticosteroid use, protective effects for AMD (OR 0.75; P = 0.018) and late AMD (OR 0.49; P = 2.87 x 10(-5)) were confirmed. Although the C3d: C3 ratio was higher in AMD/late AMD patients (both P < 0.001), there was no association with allergy in AMD (P = 0.22). The protective effect of allergy on AMD was confirmed in the replication cohort from Nijmegen (P = 0.002 for AMD; P = 0.0001 for late AMD).
   CONCLUSIONS. Allergy has a protective effect on the development of AMD independent of the provoking allergen, which cannot be explained by complement activation. Further investigations are necessary to elucidate the molecular mechanisms underlying the protective effect of allergy on AMD.
C1 [Ristau, Tina; Ersoy, Lebriz; Fauser, Sascha] Univ Hosp Cologne, Dept Ophthalmol, D-50924 Cologne, Germany.
   [Lechanteur, Yara; den Hollander, Anneke I.; Hoyng, Carel B.] Radboud Univ Nijmegen, Dept Ophthalmol, Med Ctr, NL-6525 ED Nijmegen, Netherlands.
   [Daha, Mohamed R.] Leiden Univ, Dept Nephrol, Med Ctr, Leiden, Netherlands.
   [Hahn, Moritz] Univ Cologne, Inst Med Stat Informat & Epidemiol, D-50931 Cologne, Germany.
C3 University of Cologne; Radboud University Nijmegen; Leiden University;
   Leiden University Medical Center (LUMC); Leiden University - Excl LUMC;
   University of Cologne
RP Fauser, S (通讯作者)，Univ Hosp Cologne, Dept Ophthalmol, Kerpener Str 62, D-50924 Cologne, Germany.
EM sascha.fauser@uk-koeln.de
RI Lechanteur, Yara/ABB-6875-2020; Hollander, Anneke den/N-4911-2014;
   Lehtimäki, Terho/AAD-1094-2022; Hoyng, C.B./H-8050-2014
OI Lechanteur, Yara/0000-0003-0951-4625; Lehtimäki,
   Terho/0000-0002-2555-4427; 
FU Retinovit Foundation, Germany
FX Supported by the Retinovit Foundation, Germany. The sponsor or funding
   organization had no role in the design or conduct of this research. The
   authors alone are responsible for the content and writing of the paper.
CR Ambati J, 2013, NAT REV IMMUNOL, V13, P438, DOI 10.1038/nri3459
   Baumann R, 2013, AM J RHINOL ALLERGY, V27, P266, DOI 10.2500/ajra.2013.27.3913
   Besnard AG, 2011, ALLERGY, V66, P1047, DOI 10.1111/j.1398-9995.2011.02586.x
   Doyle SL, 2012, NAT MED, V18, P791, DOI 10.1038/nm.2717
   Eisenbarth SC, 2008, NATURE, V453, P1122, DOI 10.1038/nature06939
   Fattah MA, 2010, INDIAN J PEDIATR, V77, P771, DOI 10.1007/s12098-010-0117-y
   Gerard NP, 2002, CURR OPIN IMMUNOL, V14, P705, DOI 10.1016/S0952-7915(02)00410-7
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   Hecker LA, 2010, HUM MOL GENET, V19, P209, DOI 10.1093/hmg/ddp472
   Joachim SC, 2007, GRAEF ARCH CLIN EXP, V245, P619, DOI 10.1007/s00417-006-0429-9
   Klein R, 2008, ARCH OPHTHALMOL-CHIC, V126, P840, DOI 10.1001/archopht.126.6.840
   Laumonnier Y, 2011, CURR ALLERGY ASTHM R, V11, P122, DOI 10.1007/s11882-010-0171-6
   Mo FM, 2010, INVEST OPHTH VIS SCI, V51, P4226, DOI 10.1167/iovs.09-3910
   O'Garra A, 2007, NAT REV IMMUNOL, V7, P425, DOI 10.1038/nri2097
   Reynolds R, 2009, INVEST OPHTH VIS SCI, V50, P5818, DOI 10.1167/iovs.09-3928
   Rosenwasser LJ, 2011, CURR ALLERGY ASTHM R, V11, P178, DOI 10.1007/s11882-011-0179-6
   Scholl HPN, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002593
   Smailhodzic D, 2012, OPHTHALMOLOGY, V119, P339, DOI 10.1016/j.ophtha.2011.07.056
   Sun YY, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035415
   Tarallo V, 2012, CELL, V149, P847, DOI 10.1016/j.cell.2012.03.036
   Tschopp J, 2010, NAT REV IMMUNOL, V10, P210, DOI 10.1038/nri2725
   Tseng WA, 2013, INVEST OPHTH VIS SCI, V54, P110, DOI 10.1167/iovs.12-10655
   van de Ven JPH, 2013, NAT GENET, V45, P813, DOI 10.1038/ng.2640
   Yates JRW, 2007, NEW ENGL J MED, V357, P553, DOI 10.1056/NEJMoa072618
NR 24
TC 31
Z9 31
U1 0
U2 8
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD JAN
PY 2014
VL 55
IS 1
BP 210
EP 214
DI 10.1167/iovs.13-13248
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA AB6DG
UT WOS:000331877200023
PM 24235017
DA 2022-11-30
ER

PT J
AU Churchill, AJ
   Carter, JG
   Lovell, HC
   Ramsden, C
   Turner, SJ
   Yeung, A
   Escardo, J
   Atan, D
AF Churchill, Amanda J.
   Carter, James G.
   Lovell, Helen C.
   Ramsden, Conor
   Turner, Steven J.
   Yeung, Anna
   Escardo, Julia
   Atan, Denize
TI VEGF polymorphisms are associated with neovascular age-related macular
   degeneration
SO HUMAN MOLECULAR GENETICS
LA English
DT Article
ID ENDOTHELIAL GROWTH-FACTOR; FACTOR-H POLYMORPHISM; FACTOR GENE; HAPLOTYPE
   RECONSTRUCTION; DIABETIC-RETINOPATHY; RISK; TRANSCRIPTION; ANGIOGENESIS;
   ANTIOXIDANTS; MACULOPATHY
AB Age-related macular degeneration (AMD) is the most common cause of blindness in the elderly. Linkage has been shown to the vascular endothelial growth factor (VEGF) gene and ocular levels of VEGF are raised in individuals with the neovascular form of disease. To examine the role of VEGF further, we conducted a case-control study where 45 individuals with neovascular AMD and 94 age-matched controls were genotyped for 14 single nucleotide polymorphisms (SNPs) in the VEGF promoter and gene. The single SNP +674 CC genotype was significantly associated with AMD (OR=2.40, 95%CI 1.09-5.26, P=0.027). Haplotype analysis of SNPs +674, +4618, +5092, +9162 and +9512 revealed that CTCCT and TCACC were associated with AMD (OR=15.77, 95% CI 1.91-130.24, P=0.0161 and OR=9.95, 95%CI 3.22-30.74, P=0.000053, respectively). The haplotype TCACT was associated with the control group (P=0.0001832). Furthermore, haplotype analysis of promoter SNPs revealed that possession of the -460T, -417T, -172C, -165C, -160C, -152G, -141A, -116A, +405C haplotype was strongly associated with AMD (OR=18.24, 95%CI 2.25-148.25, P=0.0074). This is the most extensive analysis of the VEGF gene in AMD, demonstrating a clear association with the exudative form of disease, thereby creating the possibility for predictive testing. Smoking, high fat intake and hypertension are negative environmental risk factors in AMD, whereas increased consumption of dietary antioxidants can have a protective effect. Identification of those at risk in the population would allow individual counselling with lifestyle advice to reduce the risks of blindness.
C1 Bristol Eye Hosp, Bristol BS1 2LX, Avon, England.
   Birmingham Womans Hosp NHS Trust, W Midlands Reg Genet Lab, Birmingham B15 2TG, W Midlands, England.
   Univ Bristol, Bristol BS1 2LX, Avon, England.
C3 Bristol Eye Hospital; Birmingham Women's Hospital; University of Bristol
RP Churchill, AJ (通讯作者)，Bristol Eye Hosp, Lower Maudlin St, Bristol BS1 2LX, Avon, England.
EM a.j.churchill@bristol.ac.uk
RI Atan, Denize/B-5536-2019
OI Atan, Denize/0000-0003-1217-4852; Carter, James/0000-0003-1860-9677
CR AHMAD Z, 2006, RETINAL THICKENING C
   Allikmets R, 1997, SCIENCE, V277, P1805, DOI 10.1126/science.277.5333.1805
   Awata T, 2002, DIABETES, V51, P1635, DOI 10.2337/diabetes.51.5.1635
   *BIOB, 2004, TRANSPLORER VERS 1 4
   Box NF, 1998, MAMM GENOME, V9, P50, DOI 10.1007/s003359900678
   Churchill AJ, 1998, BRIT J OPHTHALMOL, V82, P373, DOI 10.1136/bjo.82.4.373
   Del Bo R, 2005, ANN NEUROL, V57, P373, DOI 10.1002/ana.20390
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   FINKENZELLER G, 1992, CANCER RES, V52, P4821
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2006, INVEST OPHTH VIS SCI, V47, P329, DOI 10.1167/iovs.05-0116
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   HEIER JS, 2006, RANDOMIZED CONTROLLE
   Hogg R, 2004, CURR EYE RES, V29, P387, DOI 10.1080/02713680490517890
   Holz FG, 2006, INTERNIST, V47, P192, DOI 10.1007/s00108-005-1545-z
   Ke XY, 2003, BIOINFORMATICS, V19, P287, DOI 10.1093/bioinformatics/19.2.287
   Khan JC, 2006, BRIT J OPHTHALMOL, V90, P75, DOI 10.1136/bjo.2005.073643
   Klaver CCW, 1998, AM J HUM GENET, V63, P200, DOI 10.1086/301901
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Kliffen M, 1997, BRIT J OPHTHALMOL, V81, P154, DOI 10.1136/bjo.81.2.154
   Krippl P, 2003, INT J CANCER, V106, P468, DOI 10.1002/ijc.11238
   Ku KT, 2005, ORAL ONCOL, V41, P497, DOI 10.1016/j.oraloncology.2004.12.009
   Lee JH, 2005, P NATL ACAD SCI USA, V102, P18902, DOI 10.1073/pnas.0509069102
   Lin CC, 2003, UROLOGY, V62, P374, DOI 10.1016/S0090-4295(03)00268-1
   Lu H, 2005, CANCER RES, V65, P5015, DOI 10.1158/0008-5472.CAN-04-2786
   Metelitsina TI, 2006, BRIT J OPHTHALMOL, V90, P342, DOI 10.1136/bjo.2005.082974
   MILLER SA, 1988, NUCLEIC ACIDS RES, V16, P1215, DOI 10.1093/nar/16.3.1215
   Papaoglou D, 2005, FERTIL STERIL, V83, P959, DOI 10.1016/j.fertnstert.2004.12.017
   Perrin RM, 2005, DIABETOLOGIA, V48, P2422, DOI 10.1007/s00125-005-1951-8
   Powell B, 2003, MOL VIS, V9, P460
   Ray D, 2004, DIABETES, V53, P861, DOI 10.2337/diabetes.53.3.861
   RUNNEBAUM, 1995, LANCET, V345, P1250
   RUNNEBAUM IB, 1995, LANCET, V345, P994, DOI 10.1016/S0140-6736(95)90745-9
   Ryuto M, 1996, J BIOL CHEM, V271, P28220, DOI 10.1074/jbc.271.45.28220
   SCHULLER C, 1994, EMBO J, V13, P4382, DOI 10.1002/j.1460-2075.1994.tb06758.x
   *SEATTL SNPS, 2005, SEATTL SNPS NHLBI PR
   Seo JS, 2005, RHEUMATOLOGY, V44, P1299, DOI 10.1093/rheumatology/kei013
   Sorbera LA, 2003, DRUG FUTURE, V28, P541, DOI 10.1358/dof.2003.028.06.738510
   Stephens M, 2003, AM J HUM GENET, V73, P1162, DOI 10.1086/379378
   Stephens M, 2001, AM J HUM GENET, V68, P978, DOI 10.1086/319501
   Stevens A, 2003, CANCER RES, V63, P812
   Stone EM, 2004, NEW ENGL J MED, V351, P346, DOI 10.1056/NEJMoa040833
   Suganthalakshmi B, 2006, MOL VIS, V12, P336
   Summers AM, 2005, NEPHROL DIAL TRANSPL, V20, P2427, DOI 10.1093/ndt/gfi029
   TISCHER E, 1991, J BIOL CHEM, V266, P11947
   Uitenbroek DG., 1997, SISA BINOMIAL
   van Leeuwen R, 2005, JAMA-J AM MED ASSOC, V294, P3101, DOI 10.1001/jama.294.24.3101
   Vannay A, 2005, PEDIATR RES, V57, P396, DOI 10.1203/01.PDR.0000153867.80238.E0
   VINGERLING JR, 1995, OPHTHALMOLOGY, V102, P205
   Warren RS, 1996, J BIOL CHEM, V271, P29483, DOI 10.1074/jbc.271.46.29483
   Watson CJ, 2000, CYTOKINE, V12, P1232, DOI 10.1006/cyto.2000.0692
   Zareparsi S, 2005, HUM MOL GENET, V14, P1449, DOI 10.1093/hmg/ddi154
NR 54
TC 146
Z9 158
U1 0
U2 7
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0964-6906
EI 1460-2083
J9 HUM MOL GENET
JI Hum. Mol. Genet.
PD OCT 1
PY 2006
VL 15
IS 19
BP 2955
EP 2961
DI 10.1093/hmg/ddl238
PG 7
WC Biochemistry & Molecular Biology; Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Genetics & Heredity
GA 086TO
UT WOS:000240696100012
PM 16940309
OA Bronze
DA 2022-11-30
ER

PT J
AU Sheybani, A
   Kymes, S
   Schlief, S
   Apte, R
AF Sheybani, Arsham
   Kymes, Steven
   Schlief, Shelley
   Apte, Rajendra
TI VASCULAR EVENTS IN PATIENTS WITH AGE-RELATED MACULAR DEGENERATION
   TREATED WITH INTRAOCULAR BEVACIZUMAB
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE avastin; complications; lucentis; macular degeneration
ID CHOROIDAL NEOVASCULARIZATION SECONDARY; ARTERIAL THROMBOEMBOLIC EVENTS;
   EYE DISEASE; AVASTIN; RANIBIZUMAB; THERAPY
AB Purpose: The purpose of this study was to determine the incidence of vascular events in patients treated with intraocular injections of bevacizumab.
   Methods: The subjects were 769 persons (mean age, 79.9 years; range, 47-97 years) from the Barnes Retina Institute in St. Louis. Patients received at least one intraocular injection of bevacizumab for the treatment of neovascular age-related macular degeneration. The study endpoints included myocardial infarction, cerebrovascular accident, thromboembolic disease, new hypertension, bleeding, and death.
   Results: There were events in 74 patients (9.6%; 95% confidence interval, 7.5-11.7%) over a mean follow-up of 13.2 months (range, 1-23 months). Among other events, 15 patients (2.0%; 95% confidence interval, 1-3%) had a nonlethal myocardial infarction, 27 patients (3.5%; 95% confidence interval, 2.2-4.8%) had an episode of new or increased blood pressure, and 19 patients (2.5%; 95% confidence interval, 1.4-3.6%) died. There was no correlation between the number of bevacizumab injections and incidence of any event.
   Conclusion: Intraocular bevacizumab may be safe for intraocular use from a systemic standpoint. RETINA 29:1404-1408, 2009
C1 [Sheybani, Arsham; Kymes, Steven; Schlief, Shelley; Apte, Rajendra] Washington Univ, Sch Med, Dept Ophthalmol & Visual Sci, St Louis, MO 63110 USA.
   [Sheybani, Arsham] Washington Univ, Dept Internal Med, St Louis, MO 63110 USA.
C3 Washington University (WUSTL); Washington University (WUSTL)
RP Apte, R (通讯作者)，Washington Univ, St Louis Sch Med, 660 S Euclid Ave,Box 8096, St Louis, MO 63110 USA.
EM apte@vision.wustl.edu
CR Alexander SL, 2007, OPHTHALMOLOGY, V114, P2174, DOI 10.1016/j.ophtha.2007.09.017
   Avery RL, 2006, OPHTHALMOLOGY, V113, P363, DOI 10.1016/j.ophtha.2005.11.019
   Bressler NM, 2003, ARCH OPHTHALMOL-CHIC, V121, P1621
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Caprioni Francesco, 2007, Future Oncol, V3, P141, DOI 10.2217/14796694.3.2.141
   Chobanian AV, 2007, NEW ENGL J MED, V357, P789, DOI 10.1056/NEJMcp071137
   Clemons TE, 2004, ARCH OPHTHALMOL-CHIC, V122, P716
   Duan YK, 2007, OPHTHALMOLOGY, V114, P732, DOI 10.1016/j.ophtha.2006.07.045
   FERRIS FL, 1984, ARCH OPHTHALMOL-CHIC, V102, P1640
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Fung AE, 2006, BRIT J OPHTHALMOL, V90, P1344, DOI 10.1136/bjo.2006.099598
   Geitzenauer W, 2006, KLIN MONATSBL AUGENH, V223, P822, DOI 10.1055/s-2006-926875
   Klein R, 1998, AM J EPIDEMIOL, V147, P103
   Lazic R, 2007, GRAEF ARCH CLIN EXP, V245, P68, DOI 10.1007/s00417-006-0466-4
   MARESPERLMAN JA, 1995, ARCH OPHTHALMOL-CHIC, V113, P743, DOI 10.1001/archopht.1995.01100060069034
   Michels S, 2005, OPHTHALMOLOGY, V112, P1035, DOI 10.1016/j.ophtha.2005.02.007
   Moshfeghi AA, 2006, OPHTHALMOLOGY, V113, P2002, DOI 10.1016/j.ophtha.2006.05.070
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Scappaticci FA, 2007, JNCI-J NATL CANCER I, V99, P1232, DOI 10.1093/jnci/djm086
   Schaumberg DA, 2001, ARCH OPHTHALMOL-CHIC, V119, P1259
   Spaide RF, 2006, RETINA-J RET VIT DIS, V26, P383, DOI 10.1097/00006982-200604000-00001
   YANNUZZI LA, 1992, ARCH OPHTHALMOL-CHIC, V110, P1701
   Yoganathan P, 2006, RETINA-J RET VIT DIS, V26, P994, DOI 10.1097/01.iae.0000244380.34082.67
NR 23
TC 9
Z9 9
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD NOV-DEC
PY 2009
VL 29
IS 10
BP 1404
EP 1408
DI 10.1097/IAE.0b013e3181b32d13
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 519SH
UT WOS:000271787600003
PM 19898178
DA 2022-11-30
ER

PT J
AU Salinas-Alaman, A
   Garcia-Layana, A
   Maldonado, MJ
   Sainz-Gomez, C
   Alvarez-Vidal, A
AF Salinas-Alaman, A
   Garcia-Layana, A
   Maldonado, MJ
   Sainz-Gomez, C
   Alvarez-Vidal, A
TI Using optical coherence tomography to monitor photodynamic therapy in
   age related macular degeneration
SO AMERICAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID SUBFOVEAL CHOROIDAL NEOVASCULARIZATION; FLUORESCEIN ANGIOGRAPHY;
   VERTEPORFIN THERAPY; EDEMA; MEMBRANES; TAP; MACULOPATHY; PREVALENCE
AB PURPOSE: To evaluate the role of optical coherence tomography (OCT) in determining choroidal neovascularization (CNV) activity before and after photodynamic therapy (PDT) in patients with age,related macular degeneration (ARMD).
   DESIGN: Prospective observational case series.
   METHODS. SETTING: Institutional study. PATIENT POPULATION: Fifty-three patients (62 eyes) with ARMD. OBSERVATION PROCEDURE: Prospective observational case study. MAIN OUTCOME MEASURES: Presence or absence of leakage on fluorescein angiography, presence of intraretinal or sub-retinal fluid on OCT, and macular and choroidal neovascular complex thickness on OCT.
   RESULTS: The macular thickness decreased significantly after PDT (P = .001). However, no significant changes in CNV thickness were measured after PDT (P = .567). Once the diagnosis of ARMD was established before treatment, OCT had a sensitivity of 96.77% for detecting CNV activity. After treatment, OCT had a good sensitivity (95.65%) and a moderate specificity (59.01%) in determining CNV activity, which resulted in a diagnostic efficiency (proportion of correct results) of 82.95%.
   CONCLUSIONS: OCT appears to be useful for indicating CNV activity. Therefore, it may serve as a complementary technique for deciding the need for PDT and re-treatment in patients with ARMD.
C1 Univ Navarra, Univ Clin, Dept Ophthalmol, E-31080 Pamplona, Spain.
C3 University of Navarra
RP Salinas-Alaman, A (通讯作者)，Univ Navarra, Univ Clin, Dept Ophthalmol, Avda Pio XII,36, E-31080 Pamplona, Spain.
EM asalinas@unav.es
OI Maldonado, Miguel J./0000-0002-1021-3275
CR Antcliff RJ, 2000, OPHTHALMOLOGY, V107, P593, DOI 10.1016/S0161-6420(99)00087-1
   Arnold J, 2001, AM J OPHTHALMOL, V131, P541
   Barbazetto I, 2003, ARCH OPHTHALMOL-CHIC, V121, P1253
   Blinder KJ, 2003, AM J OPHTHALMOL, V136, P407, DOI 10.1016/S0002-9394(03)00223-X
   Blumenkranz MS, 2001, ARCH OPHTHALMOL-CHIC, V119, P198
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   Costa RA, 2003, RETINA-J RET VIT DIS, V23, P159, DOI 10.1097/00006982-200304000-00004
   Friedman SM, 2000, AM J OPHTHALMOL, V130, P839, DOI 10.1016/S0002-9394(00)00605-X
   Hee MR, 1996, OPHTHALMOLOGY, V103, P1260, DOI 10.1016/S0161-6420(96)30512-5
   HEE MR, 1995, ARCH OPHTHALMOL-CHIC, V113, P1019, DOI 10.1001/archopht.1995.01100080071031
   Holz FG, 2003, OPHTHALMOLOGY, V110, P400, DOI 10.1016/S0161-6420(02)01770-0
   HUANG D, 1991, SCIENCE, V254, P1178, DOI 10.1126/science.1957169
   Kaiser RS, 2002, RETINA-J RET VIT DIS, V22, P683, DOI 10.1097/00006982-200212000-00001
   Kang SW, 2004, AM J OPHTHALMOL, V137, P313, DOI 10.1016/j.ajo.2003.09.016
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Moshfeghi DM, 2003, AM J OPHTHALMOL, V135, P343, DOI 10.1016/S0002-9394(02)01936-0
   PULIAFITO CA, 1995, OPHTHALMOLOGY, V102, P217
   Rogers AH, 2002, AM J OPHTHALMOL, V134, P566, DOI 10.1016/S0002-9394(02)01566-0
   Sanchez-Tocino H, 2002, INVEST OPHTH VIS SCI, V43, P1588
   Schmidt-Erfurth U, 2002, INVEST OPHTH VIS SCI, V43, P830
   Schneeberg AE, 2003, OPHTHALMOLOGE, V100, P960, DOI 10.1007/s00347-003-0822-2
   Schnurrbusch UEK, 2001, BRIT J OPHTHALMOL, V85, P1086, DOI 10.1136/bjo.85.9.1086
   VINGERLING JR, 1995, OPHTHALMOLOGY, V102, P205
   YANNUZZI LA, 1986, OPHTHALMOLOGY, V93, P611
NR 24
TC 65
Z9 70
U1 0
U2 9
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0002-9394
EI 1879-1891
J9 AM J OPHTHALMOL
JI Am. J. Ophthalmol.
PD JUL
PY 2005
VL 140
IS 1
BP 23
EP 28
DI 10.1016/j.ajo.2005.01.044
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 949IN
UT WOS:000230778700004
PM 15922284
DA 2022-11-30
ER

PT J
AU Takahashi, M
   Sato, T
   Kishi, S
AF Takahashi, Maki
   Sato, Taku
   Kishi, Shoji
TI Intravitreal Bevacizumab for Age-Related Macular Degeneration with Good
   Visual Acuity
SO JAPANESE JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE age-related macular degeneration; anti-VEGF therapy; choroidal
   neovascularization; good visual acuity; intravitreal bevacizumab
   injection
ID RANIBIZUMAB; PHARMACOKINETICS; PEGAPTANIB
AB Purpose: To retrospectively study the efficacy of intravitreal bevacizumab (IVB) for exudative age-related macular degeneration (AMD) in patients with good visual acuity (VA).
   Methods: Fifteen eyes of 15 patients (mean age, 69.0 +/- 11.3 years) with AMD whose VA was 0.6 or better were treated with IVB 1.25 mg/0.05 ml. The patients were followed for 12 to 29 months (mean, 17.4 +/- 4.9 months).
   Results: Best-corrected visual acuity (BCVA) ranged from 0.6 to 1.2 (mean, 0.89 +/- 0.21) at baseline and was stable in 13 of 15 eyes (86.7%) when BCVA was 0.6 or better at the end of follow-up. The VA levels did not differ significantly (P = 0.42; paired t test) between baseline and the final examination. Two of the 15 eyes underwent photodynamic therapy during follow-up. The mean central retinal thickness significantly decreased from 278.4 +/- 71.9 mu m at baseline to 240.00 +/- 58.5 mu m at 3 months after the first IVB treatment (P = 0.02; Wilcoxon signed rank test). During follow-up, a mean of two injections was administered, and 47% of patients required only one injection. No adverse events developed.
   Conclusion: IVB was effective for maintaining good vision in exudative AMD in 15 eyes for at least 12 months. Jpn J Ophthalmol 2010;54:565-570 (C) Japanese Ophthalmological Society 2010
C1 [Takahashi, Maki; Sato, Taku; Kishi, Shoji] Gunma Univ, Sch Med, Dept Ophthalmol, Maebashi, Gunma 3718511, Japan.
C3 Gunma University
RP Takahashi, M (通讯作者)，Gunma Univ, Sch Med, Dept Ophthalmol, 3-39-15 Showamachi, Maebashi, Gunma 3718511, Japan.
EM maki-t@wg7.so-net.ne.jp
CR Arnold J, 2001, AM J OPHTHALMOL, V131, P541
   Arnold JJ, 2004, AM J OPHTHALMOL, V137, P683, DOI 10.1016/j.ajo.2003.11.059
   Avery RL, 2006, OPHTHALMOLOGY, V113, P363, DOI 10.1016/j.ophtha.2005.11.019
   Bakri SJ, 2007, OPHTHALMOLOGY, V114, P2179, DOI 10.1016/j.ophtha.2007.09.012
   Bakri SJ, 2007, OPHTHALMOLOGY, V114, P855, DOI 10.1016/j.ophtha.2007.01.017
   Bashshur ZF, 2008, AM J OPHTHALMOL, V145, P249, DOI 10.1016/j.ajo.2007.09.031
   Blinder KJ, 2003, AM J OPHTHALMOL, V136, P407, DOI 10.1016/S0002-9394(03)00223-X
   Blumenkranz MS, 2001, ARCH OPHTHALMOL-CHIC, V119, P198
   Boyer DS, 2007, OPHTHALMOLOGY, V114, P246, DOI 10.1016/j.ophtha.2006.10.045
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Chakravarthy U, 2006, OPHTHALMOLOGY, V113, P1508, DOI 10.1016/j.ophtha.2006.02.064
   FINE SL, 1982, ARCH OPHTHALMOL-CHIC, V100, P912
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Lalwani GA, 2009, AM J OPHTHALMOL, V148, P43, DOI 10.1016/j.ajo.2009.01.024
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Tano Y, 2003, AM J OPHTHALMOL, V136, P1049, DOI 10.1016/S0002-9394(03)00576-2
NR 17
TC 10
Z9 11
U1 0
U2 1
PU SPRINGER JAPAN KK
PI TOKYO
PA SHIROYAMA TRUST TOWER 5F, 4-3-1 TORANOMON, MINATO-KU, TOKYO, 105-6005,
   JAPAN
SN 0021-5155
EI 1613-2246
J9 JPN J OPHTHALMOL
JI Jpn. J. Ophthalmol.
PD NOV
PY 2010
VL 54
IS 6
BP 565
EP 570
DI 10.1007/s10384-010-0864-3
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 709VK
UT WOS:000286469300007
PM 21191717
DA 2022-11-30
ER

PT J
AU Toulouie, S
   Chang, S
   Pan, JL
   Snyder, K
   Yiu, G
AF Toulouie, Sara
   Chang, Sean
   Pan, Julia
   Snyder, Kiersten
   Yiu, Glenn
TI Relationship of Retinal Vessel Caliber with Age-Related Macular
   Degeneration
SO JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID VASCULAR CALIBER; MICROVASCULAR ABNORMALITIES; ATHEROSCLEROSIS RISK;
   CHOROIDAL THICKNESS; GEOGRAPHIC ATROPHY; BLOOD-PRESSURE; ASSOCIATION;
   PREVALENCE; EYE; CHORIOCAPILLARIS
AB Purpose. Evaluate the relationship between retinal vascular caliber and age-related macular degeneration (AMD) severity or progression. Methods. A retrospective secondary analysis of 1172 fundus photographs and clinical data from the prospective Age-Related Eye Disease Study (AREDS). Central retinal artery equivalent (CRAE), central retinal vein equivalent (CRVE), and arteriole-to-venule ratio (AVR) were measured using the Parr-Hubbard-Knudtson formula. Univariate and multivariate regressions were used to determine the association of CRAE, CRVE, and AVR with age, sex, smoking status, presence of cilioretinal artery, and AMD severity at baseline and 5 years using the 9-step AMD severity score. Results. Only CRAE and CRVE were higher in men (P < 0.001), current smokers (P < 0.001), and the eyes with a cilioretinal artery (P=0.009-0.043). AMD severity was greater in older patients (P=0.001), current smokers (P=0.012), the eyes without a cilioretinal artery (P=0.001), and lower AVR (P=0.034) on multivariate regression but was not influenced by CRAE or CRVE (P=0.240-0.500). Choroidal neovascularization (CNV) presence was associated with older age (P=0.003) and absence of a cilioretinal artery (P=0.009), while central geographic atrophy (CGA) was associated with narrower CRAE (P=0.002) and possibly AVR (P=0.046). None of the retinal vessel parameters were predictive of AMD severity score or new onset of CNV or CGA at 5 years. Conclusion. A lower arteriole-to-venule ratio may be associated with AMD severity, with narrower arterioles seen in the eyes with geographic atrophy, suggesting a role of the retinal vasculature in AMD pathophysiology.
C1 [Toulouie, Sara; Chang, Sean; Pan, Julia; Snyder, Kiersten; Yiu, Glenn] Univ Calif Sacramento, Dept Ophthalmol & Vis Sci, Sacramento, CA 95817 USA.
   [Toulouie, Sara] Calif Northstate Univ, Coll Med, Elk Grove, CA USA.
C3 California State University System; California State University
   Sacramento
RP Yiu, G (通讯作者)，Univ Calif Sacramento, Dept Ophthalmol & Vis Sci, Sacramento, CA 95817 USA.
EM stoulouie@ucdavis.edu; sscchang@ucdavis.edu; jhopan@ucdavis.edu;
   kierstensnyder@gwmail.gwu.edu; gyiu@ucdavis.edu
OI Chang, Sean/0000-0001-6301-6593
FU Brightfocus Foundation [Nih R01 Ey032238, Nih R21 Ey031108]; Macula
   Society; National Eye Institute (NIH) [HHSNOI-EY-0-2127]
FX The authors thank Dr. Nicola Ferrier from the School of Engineering and
   Department of Ophthalmology and Visual Sciences at the University of
   Wisconsin-Madison for use of the IVAN software. Dr. Yiu is supported by
   Nih R01 Ey032238 and Nih R21 Ey031108, the Brightfocus Foundation, and
   the Macula Society. The AREDS study was supported by the National Eye
   Institute (NIH) (HHSNOI-EY-0-2127).
CR Bild DE, 2002, AM J EPIDEMIOL, V156, P871, DOI 10.1093/aje/kwf113
   Byon I, 2021, RETINA-J RET VIT DIS, V41, P393, DOI 10.1097/IAE.0000000000002906
   Chen L, 2021, INVEST OPHTH VIS SCI, V62, DOI 10.1167/iovs.62.1.33
   Corvi F, 2021, RETINA-J RET VIT DIS, V41, P686, DOI 10.1097/IAE.0000000000002990
   Curcio Christine A, 2018, Invest Ophthalmol Vis Sci, V59, pAMD182, DOI 10.1167/iovs.18-24883
   Dervenis N, 2020, BRIT J OPHTHALMOL, V104, P1246, DOI 10.1136/bjophthalmol-2019-315212
   Downie E, 2015, INVEST OPHTH VIS SCI, V56
   Ferrier N.J., 2004, IVAN VESSEL MEASUREM
   Gangaputra S, 2012, AM J OPHTHALMOL, V153, P434, DOI 10.1016/j.ajo.2011.08.028
   Giannaccare G, 2020, RETINA-J RET VIT DIS, V40, P960, DOI 10.1097/IAE.0000000000002459
   Heitmar Rebekka, 2015, J Optom, V8, P252, DOI 10.1016/j.optom.2014.07.002
   Hubbard LD, 1999, OPHTHALMOLOGY, V106, P2269, DOI 10.1016/S0161-6420(99)90525-0
   Invernizzi A, 2018, INVEST OPHTH VIS SCI, V59, P3836, DOI 10.1167/iovs.18-23960
   Jabs DA, 2018, INVEST OPHTH VIS SCI, V59, P904, DOI 10.1167/iovs.17-23334
   Jeganathan VSE, 2008, AM J OPHTHALMOL, V146, P954, DOI 10.1016/j.ajo.2008.07.006
   Kassoff A, 1999, CONTROL CLIN TRIALS, V20, P573
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Keenan TD, 2020, RETINA-J RET VIT DIS, V40, P632, DOI 10.1097/IAE.0000000000002434
   KLEIN BEK, 1992, OPHTHALMOLOGY, V99, P546
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1310
   Knudtson MD, 2003, CURR EYE RES, V27, P143, DOI 10.1076/ceyr.27.3.143.16049
   Kurt MM, 2018, RETINA-J RET VIT DIS, V38, P1120, DOI 10.1097/IAE.0000000000001682
   Lee B, 2018, INVEST OPHTH VIS SCI, V59, P5246, DOI 10.1167/iovs.17-23600
   Lee SC, 2020, AM J OPHTHALMOL, V212, P7, DOI 10.1016/j.ajo.2019.11.031
   Leontidis G, 2016, COMPUT BIOL MED, V72, P65, DOI 10.1016/j.compbiomed.2016.03.006
   Leung H, 2003, INVEST OPHTH VIS SCI, V44, P2900, DOI 10.1167/iovs.02-1114
   Mosher A, 2006, AM J OPHTHALMOL, V142, P875, DOI 10.1016/j.ajo.2006.05.056
   Moult EM, 2020, RETINA-J RET VIT DIS, V40, P428, DOI 10.1097/IAE.0000000000002556
   Parr J C, 1974, Trans Ophthalmol Soc N Z, V26, P55
   PARR JC, 1974, AM J OPHTHALMOL, V77, P472, DOI 10.1016/0002-9394(74)90457-7
   PARR JC, 1974, AM J OPHTHALMOL, V77, P478, DOI 10.1016/0002-9394(74)90458-9
   Pauli TW, 2012, INVEST OPHTH VIS SCI, V53, P5117, DOI 10.1167/iovs.12-9643
   Scharf JM, 2020, INVEST OPHTH VIS SCI, V61, DOI 10.1167/iovs.61.11.11
   Sharrett AR, 1999, AM J EPIDEMIOL, V150, P263
   Shi YY, 2021, AM J OPHTHALMOL, V224, P321, DOI 10.1016/j.ajo.2020.12.015
   Snyder K, 2018, JAMA OPHTHALMOL, V136, P1008, DOI 10.1001/jamaophthalmol.2018.2650
   Sun C, 2009, SURV OPHTHALMOL, V54, P74, DOI 10.1016/j.survophthal.2008.10.003
   Ting DSW, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-08276-4
   Toto L, 2017, BRIT J OPHTHALMOL, V101, P774, DOI 10.1136/bjophthalmol-2016-309160
   Trinh M, 2019, TRANSL VIS SCI TECHN, V8, DOI 10.1167/tvst.8.4.20
   Velaga SB, 2020, RETINA-J RET VIT DIS, V40, P612, DOI 10.1097/IAE.0000000000002667
   Wong SS, 2017, AM J OPHTHALMOL, V184, P108, DOI 10.1016/j.ajo.2017.10.005
   Wong TY, 2003, OPHTHALMOLOGY, V110, P658, DOI 10.1016/S0161-6420(02)01931-0
   Wu ZC, 2020, OPHTHALMOL RETINA, V4, P568, DOI 10.1016/j.oret.2019.12.011
   Yanagi M, 2014, INVEST OPHTH VIS SCI, V55, P405, DOI 10.1167/iovs.13-12512
   Yang K, 2012, GRAEF ARCH CLIN EXP, V250, P741, DOI 10.1007/s00417-011-1824-4
   Yiu G, 2020, INVEST OPHTH VIS SCI, V61, DOI 10.1167/iovs.61.2.32
   Yiu G, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-41509-2
   Yiu G, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-14715-z
   Yiu G, 2015, AM J OPHTHALMOL, V159, P617, DOI 10.1016/j.ajo.2014.12.010
NR 51
TC 0
Z9 0
U1 1
U2 1
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 2090-004X
EI 2090-0058
J9 J OPHTHALMOL
JI J. Ophthalmol.
PD JUL 31
PY 2022
VL 2022
AR 8210599
DI 10.1155/2022/8210599
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 3Q1RB
UT WOS:000838010300006
PM 35957743
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Wang, E
   Kalloniatis, M
   Ly, A
AF Wang, Elisa
   Kalloniatis, Michael
   Ly, Angelica
TI Assessment of patient education materials for age-related macular
   degeneration
SO OPHTHALMIC AND PHYSIOLOGICAL OPTICS
LA English
DT Article
DE actionability; AMD; macular degeneration; patient education materials;
   PEMAT; understandability
ID HEALTH; INFORMATION; UNDERSTANDABILITY; ACTIONABILITY; INTERNET;
   QUALITY; TOOL
AB Purpose Age-related macular degeneration (AMD) is a leading cause of vision loss. It is helpful for patients living with AMD to understand the prognosis, risk factors and management of their condition. Online education materials are a popular and promising channel for conveying this knowledge to patients with AMD. However, the quality of these materials-particularly with respect to qualities such as 'understandability' and 'actionability'-is not yet known. This study assessed a collection of online materials about AMD based on these qualities of 'understandability' and 'actionability'. Methods Online education materials about AMD were sourced through Google from six English-speaking nations: Australia, New Zealand, USA, UK, Ireland and Canada. Three Australian/New Zealand trained and registered optometrists participated in the grading of the 'understandability' and 'actionability' of online education materials using the Patient Education Materials Assessment Tool (PEMAT). Results This study analysed a total of 75 online materials. The mean 'understandability' score was 74% (range: 38%-94%). The 'understandability' PEMAT criterion U11 (calling for a summary of the key points) scored most poorly across all materials. The mean 'actionability' score was 49% (range: 0%-83%). The 'actionability' PEMAT criterion A26 (using 'visual aids' to make instructions easier to act on) scored most poorly across all materials. Conclusion Most education materials about AMD are easy to understand, but difficult to act on, because of a lack of meaningful visual aids. We propose future enhancements to AMD education materials-including the use of summaries, visual aids and a habit tracker-to help patients with AMD improve their understanding of disease prognosis, risk factors and eye assessment schedule requirements.
C1 [Wang, Elisa; Kalloniatis, Michael; Ly, Angelica] Univ New South Wales Sydney, Ctr Eye Hlth, Kensington, NSW, Australia.
   [Wang, Elisa; Kalloniatis, Michael; Ly, Angelica] Univ New South Wales Sydney, Sch Optometry & Vis Sci, Kensington, NSW, Australia.
C3 University of New South Wales Sydney; University of New South Wales
   Sydney
RP Ly, A (通讯作者)，Univ New South Wales Sydney, Ctr Eye Hlth, Kensington, NSW, Australia.
EM a.ly@unsw.edu.au
OI Ly, Angelica/0000-0001-7881-1522; Kalloniatis,
   Michael/0000-0002-5264-4639; Wang, Elisa/0000-0002-0592-9383
FU Australian Government Research Training Program Scholarship; Guide Dogs
   NSW/ACT
FX Australian Government Research Training Program Scholarship; Guide Dogs
   NSW/ACT
CR Ab Hamid MR, 2021, NUTR FOOD SCI, V51, P621, DOI 10.1108/NFS-04-2020-0155
   Abdelmseih M., 2016, J CLIN EXP OPHTHALMO, V7, P30
   Bach-Faig A, 2011, PUBLIC HEALTH NUTR, V14, P2274, DOI 10.1017/S1368980011002515
   BECKER MH, 1975, MED CARE, V13, P10, DOI 10.1097/00005650-197501000-00002
   Burrows PJ, 1999, ADV HEALTH SCI EDUC, V4, P145, DOI 10.1023/A:1009826701445
   Cajita MI, 2017, J CARDIOVASC NURS, V32, P156, DOI 10.1097/JCN.0000000000000324
   Castles FG., 2010, ENGLISH SPEAKING COU
   CHAIKEN S, 1980, J PERS SOC PSYCHOL, V39, P752, DOI 10.1037/0022-3514.39.5.752
   Chen YY, 2018, J MED INTERNET RES, V20, DOI 10.2196/jmir.9370
   Flaxman SR, 2017, LANCET GLOB HEALTH, V5, pE1221, DOI 10.1016/S2214-109X(17)30393-5
   Fortuna J, 2020, BMC OPHTHALMOL, V20, DOI 10.1186/s12886-020-01664-x
   Gopinath B, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0122548
   Heesterbeek TJ, 2020, OPHTHAL PHYSL OPT, V40, P140, DOI 10.1111/opo.12675
   John AM, 2015, J AAPOS, V19, P430, DOI 10.1016/j.jaapos.2015.07.286
   Kane SJ, 2019, PUBLIC HEALTH NURS, V36, P379, DOI 10.1111/phn.12577
   Kanerva N, 2014, PUBLIC HEALTH NUTR, V17, P1697, DOI 10.1017/S1368980013002395
   Keane MT, 2008, COMMUN ACM, V51, P49, DOI 10.1145/1314215.1314224
   Klein R, 2007, OPHTHALMOLOGY, V114, P253, DOI 10.1016/j.ophtha.2006.10.040
   Kloosterboer A, 2021, SEMIN OPHTHALMOL, V36, P400, DOI 10.1080/08820538.2021.1893761
   Lipari M, 2019, AM J HEALTH-SYST PH, V76, P182, DOI 10.1093/ajhp/zxy021
   Petty R.E., 1986, COMMUN PERSUATION
   Sarabandi A, 2021, CLIN EXP OPTOM, V104, P215, DOI 10.1111/cxo.13121
   Schalnus R, 2010, OPHTHALMOLOGICA, V224, P30, DOI 10.1159/000233233
   Shoemaker SJ, 2014, PATIENT EDUC COUNS, V96, P395, DOI 10.1016/j.pec.2014.05.027
   Shuyler KS, 2003, J MED INTERNET RES, V5, DOI 10.2196/jmir.5.4.e24
   Taylor DJ, 2020, EYE, V34, P461, DOI 10.1038/s41433-019-0445-8
   Taylor DJ, 2018, OPHTHAL PHYSL OPT, V38, P98, DOI 10.1111/opo.12419
   Toms Elaine G, 2007, Health Informatics J, V13, P223, DOI 10.1177/1460458207079901
   Vishnevetsky J, 2018, PATIENT EDUC COUNS, V101, P490, DOI 10.1016/j.pec.2017.09.003
   Yoo P, 2016, CAN J OPHTHALMOL, V51, pE1, DOI 10.1016/j.jcjo.2015.09.010
NR 30
TC 0
Z9 0
U1 0
U2 1
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0275-5408
EI 1475-1313
J9 OPHTHAL PHYSL OPT
JI Ophthalmic Physiol. Opt.
PD JUL
PY 2022
VL 42
IS 4
BP 839
EP 848
DI 10.1111/opo.12991
EA MAY 2022
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 1V5WQ
UT WOS:000791393700001
PM 35521818
OA Green Published
DA 2022-11-30
ER

PT J
AU Bro, T
   Hagg, S
AF Bro, Tomas
   Hagg, Staffan
TI Worth changing? Clinical effects of switching treatment in neovascular
   age-related macular degeneration from intravitreal ranibizumab and
   aflibercept to bevacizumab in a region in southern Sweden
SO EUROPEAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE Age-related macular degeneration; retina; legal aspects of medical;
   surgical therapy; socioeconomics and education in medicine;
   ophthalmology; practice management; CME; health economics
ID ANTI-VEGF AGENTS; CHOROIDAL NEOVASCULARIZATION; TACHYPHYLAXIS;
   VERTEPORFIN; EYE
AB Purpose: To examine the clinical effects of switching intravitreal drug treatment from the approved vascular endothelial growth factor inhibitors, ranibizumab and aflibercept, to off label use of bevacizumab in patients with wet age-related macular degeneration. Methods: This retrospective study scrutinized medical records of patients with wet age-related macular degeneration who switched therapy to bevacizumab due to a policy decision. Best corrected visual acuity, central retinal thickness, and number of injections before and 1 year after the switch was compared. The non-inferiority margin of best corrected visual acuity was five Early Treatment Diabetic Retinopathy Study letters. Results: A switch from ranibizumab was evaluable in 93 eyes and from aflibercept in 19 eyes. Neither of the groups had a significant non-inferior visual acuity 16 month after the switch. Mean best corrected visual acuity in Early Treatment Diabetic Retinopathy Study letters was 63.8 (95% confidence interval: 61.3-66.4) before and 62.2 (95% confidence interval: 59.3-65.1) after in the ranibizumab group and 68.2 (95% confidence interval: 63.3-73.1) before and 67.7 (95% confidence interval: 62.8-72.6) after in the aflibercept group. Mean central retinal thickness in micrometers decreased from 254 (95% confidence interval: 247-261) to 250 (95% confidence interval: 225-275) in the ranibizumab group and from 265 (95% confidence interval: 255-276) to 262 (95% confidence interval: 251-273) in the aflibercept group. The treatment was changed again after the switch in 18% of the patients in the ranibizumab group and 19% in the aflibercept group and these subjects were excluded from the analyses. Conclusion: In patients with neovascular age-related macular degeneration, a switch from ranibizumab or aflibercept to bevacizumab seems possible without a significant decrease in visual acuity in most patients.
C1 [Bro, Tomas] Hoglandssjukhuset, Eye Unit, S-57581 Eksjo, Sweden.
   [Bro, Tomas; Hagg, Staffan] Futurum, Jonkoping, Sweden.
   [Hagg, Staffan] Linkoping Univ, Dept Med & Hlth Sci, Linkoping, Sweden.
C3 Futurum; Linkoping University
RP Bro, T (通讯作者)，Hoglandssjukhuset, Eye Unit, S-57581 Eksjo, Sweden.
EM tomas.bro@med.lu.se
OI Bro, Tomas/0000-0003-0185-4326
FU Futurum - Akademin for vard och halsa Region Jonkopings lan
   [FUTURUM-808791]
FX The author(s) disclosed receipt of the following financial support for
   the research, authorship, and/or publication of this article: this study
   was funded by Futurum - Akademin for vard och halsa Region Jonkopings
   lan (grant number FUTURUM-808791).
CR Almony A, 2011, CAN J OPHTHALMOL, V46, P182, DOI 10.3129/i10-095
   Andreoli Michael T, 2015, Digit J Ophthalmol, V21, P1, DOI 10.5693/djo.01.2015.04.002
   Bressler NM, 2002, ARCH OPHTHALMOL-CHIC, V120, P1443
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Doguizi S, 2015, INT J OPHTHALMOL-CHI, V8, P846, DOI 10.3980/j.issn.2222-3959.2015.04.37
   Eghoj MS, 2012, BRIT J OPHTHALMOL, V96, P21, DOI 10.1136/bjo.2011.203893
   Ehlken C, 2014, EYE, V28, P538, DOI 10.1038/eye.2014.64
   Freund KB, 2015, RETINA-J RET VIT DIS, V35, P1489, DOI 10.1097/IAE.0000000000000627
   Freund KB, 2010, RETINA-J RET VIT DIS, V30, P1333, DOI 10.1097/IAE.0b013e3181e7976b
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Hutton D, 2014, HEALTH AFFAIR, V33, P931, DOI 10.1377/hlthaff.2013.0832
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Moja L, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD011230.pub2
   Penn JS, 2008, PROG RETIN EYE RES, V27, P331, DOI 10.1016/j.preteyeres.2008.05.001
   Pinheiro-Costa J, 2014, OPHTHALMOLOGICA, V232, P149, DOI 10.1159/000363422
   Regillo CD, 2008, AM J OPHTHALMOL, V145, P239, DOI 10.1016/j.ajo.2007.10.004
   Region Jonkopings lan, 2015, 20152324 RJL
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   VanderBeek BL, 2015, JAMA OPHTHALMOL, V133, P1159, DOI 10.1001/jamaophthalmol.2015.2556
   Waizel M, 2016, EUR J OPHTHALMOL, V26, P469, DOI 10.5301/ejo.5000781
   World Health Organization, 2012, GLOB DAT VIS IMP 201
   Zeiss, 2015, CIRRUS HD OCT US MAN
NR 22
TC 1
Z9 1
U1 0
U2 2
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 1120-6721
EI 1724-6016
J9 EUR J OPHTHALMOL
JI Eur. J. Ophthalmol.
PD JAN
PY 2021
VL 31
IS 1
BP 144
EP 148
AR 1120672119883602
DI 10.1177/1120672119883602
EA OCT 2019
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA QC0TA
UT WOS:000492132900001
PM 31642333
DA 2022-11-30
ER

PT J
AU Thi, HCT
   Despretz, P
   Boucart, M
AF Thi Ha Chau Tran
   Despretz, Pascal
   Boucart, Muriel
TI Scene Perception in Age-Related Macular Degeneration: The Effect of
   Contrast
SO OPTOMETRY AND VISION SCIENCE
LA English
DT Article
DE age-related macular degeneration; scene perception; low vision; scotoma;
   contrast sensitivity
ID GEOGRAPHIC ATROPHY; NATURAL SCENES; FUNDUS AUTOFLUORESCENCE; RAPID
   CATEGORIZATION; OBJECT RECOGNITION; IMAGE-ENHANCEMENT; FACE RECOGNITION;
   VISUAL FUNCTION; OLDER-ADULTS; VISION
AB Purpose. To investigate the effect of contrast on scene perception in people with age-related macular degeneration (AMD) and to examine the relationship between task performance and macular function.
   Methods. Nineteen patients with AMD and visual acuity below 20/50 were compared with 16 normally sighted, age-matched controls. Complete ophthalmologic examination (visual acuity, intraocular pressure measurement, and funduscopy) was performed in both patients and controls. In addition, Pelli-Robson contrast sensitivity, fluorescein angiography, and visual field size were assessed in the AMD study patients. The stimuli were photographs of natural scenes containing or lacking an animal (the target). For each scene, the contrast of the original photograph was divided by 2, 4, and 8 to yield versions with a residual contrast of 50, 25, and 12.5%, respectively. The four levels of contrast were presented randomly and participants were asked to press a key when they saw an animal.
   Results. AMD patients exhibited a larger drop in target detection performance with the decrease in contrast than controls. We found a correlation between visual acuity and performance when the contrast was reduced to 50, 25, and 12.5% of the original value but not in the normal contrast condition. There were no correlations between letter contrast sensitivity, visual field lesion size, and performance.
   Conclusions. Our results suggest that optimal, stable contrast conditions would facilitate object recognition in everyday life for people with AMD. (Optom Vis Sci 2012;89:419-425)
C1 [Thi Ha Chau Tran; Despretz, Pascal; Boucart, Muriel] Univ Lille Nord France, Lab Neurosci & Pathol Fonct, CNRS, F-59037 Lille, France.
   [Thi Ha Chau Tran] Univ Catholique Lille, Serv Ophtalmol, Hop St Vincent de Paul, Lille, France.
C3 Centre National de la Recherche Scientifique (CNRS); Universite de Lille
   - ISITE; Universite de Lille; Universite Catholique de Lille
RP Boucart, M (通讯作者)，Univ Lille Nord France, Lab Neurosci & Pathol Fonct, Hop Roger Salengro, CNRS,Serv Explorat Fonct Vis, F-59037 Lille, France.
EM m-boucart@chru-lille.fr
RI TRAN, Thi Ha Chau/AAF-2162-2020
OI TRAN, Thi Ha Chau/0000-0001-9066-7092
FU Programme Interdisciplinaire Longevite-Vieillissement; French Centre
   National de la Recherche Scientifique
FX This study was supported by a "Programme Interdisciplinaire
   Longevite-Vieillissement" grant by the French Centre National de la
   Recherche Scientifique (to MB).
CR Avidan G, 2002, J NEUROPHYSIOL, V87, P3102, DOI 10.1152/jn.2002.87.6.3102
   Black AA, 2011, OPTOMETRY VISION SCI, V88, P1275, DOI 10.1097/OPX.0b013e31822f4d6a
   Boucart M, 2008, VISUAL NEUROSCI, V25, P685, DOI 10.1017/S0952523808080826
   Brody BL, 2001, OPHTHALMOLOGY, V108, P1893, DOI 10.1016/S0161-6420(01)00754-0
   BULLIMORE MA, 1991, INVEST OPHTH VIS SCI, V32, P2020
   Cahill MT, 2005, OPHTHALMOLOGY, V112, P152, DOI 10.1016/j.ophtha.2004.06.036
   Cheung SH, 2005, VISUAL NEUROSCI, V22, P187, DOI 10.1017/S0952523805222071
   Elliott SL, 2010, J VISION, V10, DOI 10.1167/10.4.4
   Fletcher DC, 2006, OPTOMETRY VISION SCI, V83, P178, DOI 10.1097/01.opx.0000204510.08026.7f
   Hahn GA, 2009, GRAEF ARCH CLIN EXP, V247, P43, DOI 10.1007/s00417-008-0919-z
   Hart PM, 1999, BRIT J OPHTHALMOL, V83, P1115, DOI 10.1136/bjo.83.10.1115
   Hassan SE, 2002, OPTOMETRY VISION SCI, V79, P697, DOI 10.1097/00006324-200211000-00007
   Hogervorst MA, 2008, OPTOMETRY VISION SCI, V85, P951, DOI 10.1097/OPX.0b013e3181886fc7
   Holz FG, 2007, AM J OPHTHALMOL, V143, P463, DOI 10.1016/j.ajo.2006.11.041
   Lawton TA, 1998, VISION RES, V38, P153, DOI 10.1016/S0042-6989(97)00140-5
   Mace MJM, 2010, ANIM COGN, V13, P405, DOI 10.1007/s10071-009-0290-4
   Mace MJM, 2005, EUR J NEUROSCI, V21, P2007, DOI 10.1111/j.1460-9568.2005.04029.x
   Mace MJM, 2005, NEUROREPORT, V16, P349
   MacMillan N. A., 1991, DETECTION THEORY USE
   Mangione CM, 2001, ARCH OPHTHALMOL-CHIC, V119, P1050, DOI 10.1001/archopht.119.7.1050
   Medeiros NE, 2001, INVEST OPHTH VIS SCI, V42, P795
   Mei M, 2007, INVEST OPHTH VIS SCI, V48, P3419, DOI 10.1167/iovs.06-0731
   OWSLEY C, 1987, BRIT J OPHTHALMOL, V71, P791, DOI 10.1136/bjo.71.10.791
   OWSLEY C, 1983, VISION RES, V23, P689, DOI 10.1016/0042-6989(83)90210-9
   PELI E, 1991, INVEST OPHTH VIS SCI, V32, P2337
   Pokorny J, 1997, J OPT SOC AM A, V14, P2477, DOI 10.1364/JOSAA.14.002477
   Qiu F, 2009, CLIN EXP OPTOM, V92, P90, DOI 10.1111/j.1444-0938.2008.00343.x
   Rubin GS, 2001, INVEST OPHTH VIS SCI, V42, P64
   Schmitz-Valckenberg S, 2004, INVEST OPHTH VIS SCI, V45, P4470, DOI 10.1167/iovs.03-1311
   Soubrane G, 2007, ARCH OPHTHALMOL-CHIC, V125, P1249, DOI 10.1001/archopht.125.9.1249
   STRASBURGER H, 1991, PERCEPT PSYCHOPHYS, V49, P495, DOI 10.3758/BF03212183
   Sunness JS, 2008, OPHTHALMOLOGY, V115, P1480, DOI 10.1016/j.ophtha.2008.03.009
   Szabo SM, 2008, J AM GERIATR SOC, V56, P800, DOI 10.1111/j.1532-5415.2008.01666.x
   TANNER WP, 1954, PSYCHOL REV, V61, P401, DOI 10.1037/h0058700
   Tejeria L, 2002, BRIT J OPHTHALMOL, V86, P1019, DOI 10.1136/bjo.86.9.1019
   Tran THC, 2011, J FR OPHTALMOL, V34, P723, DOI 10.1016/j.jfo.2011.04.014
   TULUNAYKEESEY U, 1988, J OPT SOC AM A, V5, P2191, DOI 10.1364/JOSAA.5.002191
   WHITTAKER SG, 1993, OPTOMETRY VISION SCI, V70, P54, DOI 10.1097/00006324-199301000-00010
   Wood JM, 2009, INVEST OPHTH VIS SCI, V50, P482, DOI 10.1167/iovs.08-1942
   WURM LH, 1993, J EXP PSYCHOL HUMAN, V19, P899, DOI 10.1037/0096-1523.19.4.899
NR 40
TC 10
Z9 10
U1 0
U2 12
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1040-5488
EI 1538-9235
J9 OPTOMETRY VISION SCI
JI Optom. Vis. Sci.
PD APR
PY 2012
VL 89
IS 4
BP 419
EP 425
DI 10.1097/OPX.0b013e31824c3a21
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 923RO
UT WOS:000302636600008
PM 22407253
OA Green Submitted
DA 2022-11-30
ER

PT J
AU Cervantes-Castaneda, RA
   Banin, E
   Hemo, I
   Shpigel, M
   Averbukh, E
   Chowers, I
AF Cervantes-Castaneda, R. A.
   Banin, E.
   Hemo, I.
   Shpigel, M.
   Averbukh, E.
   Chowers, I.
TI Lack of benefit of early awareness to age-related macular degeneration
SO EYE
LA English
DT Article
DE age-related macular degeneration; early awareness; visual acuity; lesion
   size
ID SUBRETINAL NEOVASCULARIZATION; CHOROIDAL NEOVASCULARIZATION;
   CLINICAL-TRIAL; VISION LOSS; MEMBRANES; THERAPY; VERTEPORFIN; FEATURES;
   TAP
AB Aims To assess the rate of early awareness to the presence of age-related macular degeneration (AMD) and whether it enables early detection of transition to neovascular AMD (NVAMD) as compared with patients whose first presentation to an ophthalmologist is already at the neovascular stage of disease.
   Methods A retrospective analysis of 268 eyes of 268 consecutive patients with newly diagnosed NVAMD that were treated in a tertiary referral centre was performed. Patients were classified into those who were unaware (Group 1), or aware ( Group 2), of the fact that they had AMD before diagnosis of NVAMD. Visual acuity, lesion size and composition, and demographics were compared between both groups.
   Results In all, 185 patients (69%) and 83 patients (31%) were classified to Groups 1 and 2, respectively. Patients in Groups 1 and 2 had similar demographic characteristics, presenting visual acuity and lesion size, and lesion compositions. Group 1 patients were more likely to have a positive history for smoking (41 vs 26% in Group 2, P = 0.03), whereas Group 2 patients were more likely to have positive family history for AMD ( 20 vs 10%, P = 0.02).
   Conclusions These data suggest that current screening methods fail to identify the majority of patients with AMD before the development of NVAMD. The findings also demonstrate that in the routine clinical setting, prior awareness of AMD may not facilitate early detection of treatable choroidal neovascularization lesions.
C1 [Cervantes-Castaneda, R. A.; Banin, E.; Hemo, I.; Shpigel, M.; Averbukh, E.; Chowers, I.] Hadassah Hebrew Univ Med Ctr, Dept Ophthalmol, IL-91120 Jerusalem, Israel.
C3 Hebrew University of Jerusalem
RP Chowers, I (通讯作者)，Hadassah Hebrew Univ Med Ctr, Dept Ophthalmol, POB 12000, IL-91120 Jerusalem, Israel.
EM chowers@md.huji.ac.il
CR ACHARD OA, 1995, AM J OPHTHALMOL, V120, P322, DOI 10.1016/S0002-9394(14)72162-2
   *AM AC OPHTH, 2003, PREF PRACT PATT AG R
   Arden GB, 2004, BRIT J OPHTHALMOL, V88, P1180, DOI 10.1136/bjo.2003.033480
   Avery RL, 2006, OPHTHALMOLOGY, V113, P363, DOI 10.1016/j.ophtha.2005.11.019
   Blinder KJ, 2003, AM J OPHTHALMOL, V136, P407, DOI 10.1016/S0002-9394(03)00223-X
   Blumenkranz MS, 2001, ARCH OPHTHALMOL-CHIC, V119, P198
   Bressler Neil M, 2002, J Am Board Fam Pract, V15, P142
   FINE SL, 1985, OPHTHALMOLOGY, V92, P603
   Fink W, 2004, J BIOMED OPT, V9, P149, DOI 10.1117/1.1625952
   Goldstein M, 2005, RETINA-J RET VIT DIS, V25, P296
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   GREY RHB, 1979, BRIT J OPHTHALMOL, V63, P85, DOI 10.1136/bjo.63.2.85
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   KLEIN ML, 1989, OPHTHALMOLOGY, V96, P1416
   Lee PP, 2003, OPHTHALMOLOGY, V110, P1952, DOI 10.1016/S0161-6420(03)00817-0
   Loewenstein A, 2003, OPHTHALMOLOGY, V110, P966, DOI 10.1016/S0161-6420(03)00074-5
   Olsen TW, 2004, OPHTHALMOLOGY, V111, P250, DOI 10.1016/j.ophtha.2003.05.030
   Rosenfeld PJ, 2005, OPHTHAL SURG LAS IM, V36, P331, DOI 10.3928/1542-8877-20050701-14
   ROY MS, 1985, OPHTHALMOLOGICA, V191, P215, DOI 10.1159/000309590
   Sloan FA, 2004, HEALTH SERV RES, V39, P1429, DOI 10.1111/j.1475-6773.2004.00297.x
   VANDER JF, 1989, OPHTHALMOLOGY, V96, P1422
   Zaidi FH, 2004, EYE, V18, P503, DOI 10.1038/sj.eye.6700708
   2005, RETINA, V25, P119
NR 23
TC 9
Z9 9
U1 0
U2 6
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0950-222X
J9 EYE
JI Eye
PD JUN
PY 2008
VL 22
IS 6
BP 777
EP 781
DI 10.1038/sj.eye.6702691
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 312HL
UT WOS:000256659800006
PM 17220824
OA Bronze
DA 2022-11-30
ER

PT J
AU Williams, MA
   Mckay, GJ
   Chakravarthy, U
AF Williams, Michael A.
   Mckay, Gareth J.
   Chakravarthy, Usha
TI Complement inhibitors for age-related macular degeneration
SO COCHRANE DATABASE OF SYSTEMATIC REVIEWS
LA English
DT Review
ID FACTOR-H POLYMORPHISM; RISK; DRUSEN; SYSTEM; OLDER
AB Background
   Given the relatively high prevalence of age-related macular degeneration (AMD) and the increased incidence of AMD as populations age, the results of trials of novel treatments are awaited with much anticipation. The complement cascade describes a series of proteolytic reactions occurring throughout the body that generate proteins with a variety of roles including the initiation and promotion of immune reactions against foreign materials or micro-organisms. The complement cascade is normally tightly regulated, but much evidence implicates complement overactivity in AMD and so it is a logical therapeutic target in the treatment of AMD.
   Objectives
   To assess the effects and safety of complement inhibitors in the prevention or treatment of advanced AMD.
   Search methods
   We searched CENTRAL (which contains the Cochrane Eyes and Vision Group Trials Register) (The Cochrane Library 2013, Issue 11), Ovid MEDLINE, Ovid MEDLINE In-Process and Other Non-Indexed Citations, Ovid MEDLINE Daily, Ovid OLDMEDLINE (January 1946 to November 2013), EMBASE (January 1980 to November 2013), Allied and Complementary Medicine Database (AMED) (January 1985 to November 2013), Latin American and Caribbean Literature on Health Sciences (LILACS) (January 1982 to November 2013), OpenGrey (System for Information on Grey Literature in Europe) (www.opengrey.eu/), Web of Science Conference Proceedings Citation Index - Science (CPCI-S) (January 1990 to November 2013), the metaRegister of Controlled Trials (mRCT) (www.controlled-trials.com), ClinicalTrials.gov (www.clinicaltrials.gov) and the WHO International Clinical Trials Registry Platform (ICTRP) (www.who.int/ictrp/search/en). We did not use any date or language restrictions in the electronic searches for trials. We last searched the electronic databases on 21 November 2013. We also performed handsearching of proceedings, from 2012 onwards, of meetings and conferences of specific professional organisations.
   Selection criteria
   We planned to include randomised controlled trials (RCTs) with parallel treatment groups which investigated either the prevention or treatment of advanced AMD by inhibition of the complement cascade.
   Data collection and analysis
   Two authors (MW and GMcK) independently evaluated all the titles and abstracts resulting from the searches. We contacted companies running clinical trials which had not yet reported results to request information. Since no trials met our inclusion criteria, we undertook no assessment of quality or meta-analysis.
   Main results
   We identified and screened 317 references but there were no published RCTs that met the inclusion criteria. We identified two ongoing studies: one phase I study and one phase II study.
   Authors' conclusions
   There is insufficient information at present to generate evidence-based recommendations on the potential safety and efficacy of complement inhibitors for prevention or treatment of AMD. However we anticipate the results of ongoing trials.
C1 [Williams, Michael A.] Royal Victoria Hosp, Med Ophthalmol Eye & Ear Clin, Belfast BT12 6BA, Antrim, North Ireland.
   [Mckay, Gareth J.] Queens Univ Belfast, Ctr Publ Hlth, Belfast, Antrim, North Ireland.
   [Chakravarthy, Usha] Queens Univ Belfast, Ctr Vision & Vasc Sci, Belfast, Antrim, North Ireland.
C3 Queens University Belfast; Queens University Belfast
RP Williams, MA (通讯作者)，Royal Victoria Hosp, Med Ophthalmol Eye & Ear Clin, Grosvenor Rd, Belfast BT12 6BA, Antrim, North Ireland.
EM m.williams@qub.ac.uk
RI McKay, Gareth/AAZ-2601-2020
OI McKay, Gareth/0000-0001-8197-6280; Chakravarthy,
   Usha/0000-0002-2606-3734; Williams, Michael/0000-0002-5051-5921
FU Dunhill Medical Trust/Royal College of Physicians Clinical Research
   Fellowship, UK; Alzheimer's Research Trust Emergency Grant, UK; Medical
   Research Council [MC_CF023241] Funding Source: researchfish
FX External sources; Dunhill Medical Trust/Royal College of Physicians
   Clinical Research Fellowship, UK.; Supported MA Williams; Alzheimer's
   Research Trust Emergency Grant, UK.; Supported MA Williams
CR [Anonymous], 2009, NAT REV DRUG DISCOV, V8, P922, DOI 10.1038/nrd3063
   Augood CA, 2006, ARCH OPHTHALMOL-CHIC, V124, P529, DOI 10.1001/archopht.124.4.529
   Bora PS, 2005, J IMMUNOL, V174, P491, DOI 10.4049/jimmunol.174.1.491
   Buttner-Mainik A, 2011, PLANT BIOTECHNOL J, V9, P373, DOI 10.1111/j.1467-7652.2010.00552.x
   Chakravarthy U, 2010, BMC OPHTHALMOL, V10, DOI 10.1186/1471-2415-10-31
   Crabb JW, 2002, P NATL ACAD SCI USA, V99, P14682, DOI 10.1073/pnas.222551899
   de Cordoba SR, 2004, MOL IMMUNOL, V41, P355, DOI 10.1016/j.molimm.2004.02.005
   Deeks JJ, 2011, COCHRANE HANDBOOK FO
   Despriet DDG, 2006, JAMA-J AM MED ASSOC, V296, P301, DOI 10.1001/jama.296.3.301
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Evans JR, 2004, OPHTHALMOLOGY, V111, P513, DOI 10.1016/j.ophtha.2003.07.012
   Glanville JM, 2006, J MED LIBR ASSOC, V94, P130
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Haines JL, 2007, P NATL ACAD SCI USA, V104, P16725, DOI 10.1073/pnas.0708151104
   Heneka MT, 2007, J NEUROIMMUNOL, V184, P69, DOI 10.1016/j.jneuroim.2006.11.017
   HIGGINS JPT, 2011, COCHRANE HDB SYSTEMA, V0001
   Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557
   Hogg RE, 2007, OPHTHALMOLOGY, V114, P1027
   Issa PC, 2011, GRAEF ARCH CLIN EXP, V249, P163, DOI 10.1007/s00417-010-1568-6
   Johnson LR, 2000, IEEE ANN HIST COMPUT, V22, P70
   Johnson LV, 2002, P NATL ACAD SCI USA, V99, P11830, DOI 10.1073/pnas.192203399
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Khandhadia S, 2012, IMMUNOBIOLOGY, V217, P127, DOI 10.1016/j.imbio.2011.07.019
   Kirkham JJ, 2010, BMJ-BRIT MED J, V340, pc365, DOI DOI 10.1136/BMJ.C365
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Markiewski MM, 2007, AM J PATHOL, V171, P715, DOI 10.2353/ajpath.2007.070166
   Owen CG, 2003, BRIT J OPHTHALMOL, V87, P312, DOI 10.1136/bjo.87.3.312
   Patel N, 2008, EYE, V22, P768, DOI 10.1038/sj.eye.6702844
   Ricklin D, 2007, NAT BIOTECHNOL, V25, P1265, DOI 10.1038/nbt1342
   Riley RD, 2011, BMJ-BRIT MED J, V342, P594
   Schwartz SG, 2011, J OPHTHALMOL, V2011, DOI 10.1155/2011/252549
   Seddon JM, 1997, AM J OPHTHALMOL, V123, P199, DOI 10.1016/S0002-9394(14)71036-0
   Sivaprasad S, 2006, EYE, V20, P867, DOI 10.1038/sj.eye.6702176
   Sterne JAC, 2011, COCHRANE HANDBOOK FO
   Tamamis P, 2012, CHEM BIOL DRUG DES, V79, P703, DOI 10.1111/j.1747-0285.2012.01324.x
   The Nordic Cochrane Centre The Cochrane Collaboration, 2012, REVIEW MANAGER REVMA
   Thornton J, 2005, EYE, V19, P935, DOI 10.1038/sj.eye.6701978
   Troutbeck R, 2012, CLIN EXP OPHTHALMOL, V40, P18, DOI 10.1111/j.1442-9071.2011.02581.x
   Williams MA, 2011, COCHRANE DATABASE OF, DOI [10.1002/14651858.CD009300, DOI 10.1002/14651858.CD009300]
NR 41
TC 18
Z9 18
U1 0
U2 9
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1469-493X
EI 1361-6137
J9 COCHRANE DB SYST REV
JI Cochrane Database Syst Rev.
PY 2014
IS 1
AR CD009300
DI 10.1002/14651858.CD009300.pub2
PG 22
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA 301BT
UT WOS:000330508400012
PM 24431152
OA Green Published
DA 2022-11-30
ER

PT J
AU Radvay, X
   Duhoux, S
   Koenig-Supiot, F
   Vital-Durand, F
AF Radvay, Xavier
   Duhoux, Stephanie
   Koenig-Supiot, Francoise
   Vital-Durand, Francois
TI Balance training and visual rehabilitation of age-related macular
   degeneration patients
SO JOURNAL OF VESTIBULAR RESEARCH-EQUILIBRIUM & ORIENTATION
LA English
DT Article
DE AMD; postural sway; aging; rehabilitation; gaze control; reading
ID PREFERRED RETINAL LOCI; STABILITY; STRATEGIES; LOCATION; PROGRAM;
   VISION; WOMEN; GAZE
AB Patients with Age-Related Macular Degeneration (AMD) experience a large scotoma precluding central vision. In addition, 2/3 of these patients present visuomotor and balance deficits resulting in clumsiness and increased risk of falls. On the basis of previous work demonstrating that visual, vestibular and somatosensory functions involved in balance control can be rehabilitated by training, we attempted to improve these functions by balance training. We measured the impact of balance training on several visuomotor functions and reading speed.
   We compared balance status of 54 AMD patients to 55 normal controls. Sixteen of these patients and 14 controls subsequently received balance training sessions on a postural platform (Multitest (R)) stressing sensorimotor coordination by selectively inhibiting or disturbing either, visual, vestibular or somatosensory input. Producing a conflict between two inputs reinforces the use of the third.
   We assessed postural sway, pointing accuracy, reading performance and, for the patients, the effect of low vision training and balance training on the shift from several spontaneous Preferred Retinal Loci ( PRLs) to one or more Trained Retinal Loci ( TRL). Even after a limited number of sessions of cross-modal balance training, the results show a significant improvement for the vestibular input and fixation stability. A decrease of visual dependency was observed only in the control group. Apart from these improvements, pointing accuracy and reading speed were not significantly improved compared to controls, leading to the conclusion that more training sessions may be necessary to gain more significant improvement of visuo-motor functions.
C1 [Radvay, Xavier; Duhoux, Stephanie; Koenig-Supiot, Francoise; Vital-Durand, Francois] INSERM 846, Stem Cell & Brain Res Inst, F-69500 Bron, France.
   [Radvay, Xavier; Vital-Durand, Francois] Ecole Prat Hautes Etud, Paris, France.
   [Duhoux, Stephanie; Koenig-Supiot, Francoise] Univ Lyon, F-69000 Lyon, France.
C3 Institut National de la Sante et de la Recherche Medicale (Inserm);
   UDICE-French Research Universities; PSL Research University Paris; Ecole
   Pratique des Hautes Etudes (EPHE)
RP Vital-Durand, F (通讯作者)，INSERM 846, Stem Cell & Brain Res Inst, 18 Ave Doyen Lepine, F-69500 Bron, France.
EM vital@lyon.inserm.fr
CR *ANAES, 2001, TRAIT DEG MAC LIEE A
   BALOH RW, 1993, EXP BRAIN RES, V95, P509
   Borger LL, 1999, J VESTIBUL RES-EQUIL, V9, P197
   Brabyn J, 2001, OPTOMETRY VISION SCI, V78, P264, DOI 10.1097/00006324-200105000-00008
   BRODIE SE, 1987, INVEST OPHTH VIS SCI, V28, P736
   Camicioli R, 1997, ARCH NEUROL-CHICAGO, V54, P976, DOI 10.1001/archneur.1997.00550200040008
   Carter ND, 2001, BRIT J SPORT MED, V35, P348, DOI 10.1136/bjsm.35.5.348
   Crossland MD, 2005, OPHTHALMOLOGY, V112, P1579, DOI 10.1016/j.ophtha.2005.03.027
   Crossland MD, 2004, VISION RES, V44, P1537, DOI 10.1016/j.visres.2004.01.006
   Deruaz A, 2002, VISION RES, V42, P2947, DOI 10.1016/S0042-6989(02)00354-1
   Diard J. P., 1998, Revue Internationale des Services de Sante des Forces Armees, V71, P225
   Duret F, 1999, VISION RES, V39, P873, DOI 10.1016/S0042-6989(98)00179-5
   ELLIOTT DB, 1995, OPHTHAL PHYSL OPT, V15, P553, DOI 10.1016/0275-5408(95)00025-9
   Gauchard GC, 2003, NEUROSCI RES, V45, P409, DOI 10.1016/S0168-0102(03)00008-7
   Gauchard GC, 2001, GERONTOLOGY, V47, P263, DOI 10.1159/000052810
   Goodrich G., 2004, VIS IMPAIR RES, V6, P135, DOI [10.1080/13882350490903690, DOI 10.1080/13882350490903690]
   GUEZ JE, 1993, VISION RES, V33, P1271, DOI 10.1016/0042-6989(93)90213-G
   Hahn GA, 2006, BRIT J OPHTHALMOL, V90, P480, DOI 10.1136/bjo.2005.087379
   HEIN A, 1979, SCIENCE, V204, P1321, DOI 10.1126/science.313076
   HORAK FB, 1989, NEUROBIOL AGING, V10, P727, DOI 10.1016/0197-4580(89)90010-9
   Hue OA, 2004, AGING CLIN EXP RES, V16, P356
   Ionescu E, 2006, INT J PEDIATR OTORHI, V70, P1457, DOI 10.1016/j.ijporl.2006.03.012
   Isableu B, 2003, EXP BRAIN RES, V150, P208, DOI 10.1007/s00221-003-1446-0
   JOHNSON CA, 1980, AM J OPHTHALMOL, V89, P731, DOI 10.1016/0002-9394(80)90296-2
   Keshner EA, 2004, J VESTIBUL RES-EQUIL, V14, P307
   Lei H, 1997, INVEST OPHTH VIS SCI, V38, P1812
   LORD SR, 1991, AGE AGEING, V20, P175, DOI 10.1093/ageing/20.3.175
   Lord SR, 1996, AGE AGEING, V25, P292, DOI 10.1093/ageing/25.4.292
   Lord SR, 1996, ARCH PHYS MED REHAB, V77, P232, DOI 10.1016/S0003-9993(96)90103-3
   MACKEBEN M, VISION REHABILITATIO, P158
   MARENDAZ C, 1989, PERCEPTION, V18, P739, DOI 10.1068/p180739
   McGibbon CA, 2004, J VESTIBUL RES-EQUIL, V14, P467
   Nilsson UL, 1998, OPTOMETRY VISION SCI, V75, P873, DOI 10.1097/00006324-199812000-00009
   Singh R, 1991, Indian J Ophthalmol, V39, P127
   SKINNER HB, 1984, CLIN ORTHOP RELAT R, P208
   Sober SJ, 2005, NAT NEUROSCI, V8, P490, DOI 10.1038/nn1427
   TOUPET M, EXPERTA MED, P143
   WHITE JM, 1990, INVEST OPHTH VIS SCI, V31, P1149
NR 38
TC 22
Z9 24
U1 1
U2 6
PU IOS PRESS
PI AMSTERDAM
PA NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS
SN 0957-4271
EI 1878-6464
J9 J VESTIBUL RES-EQUIL
JI J. Vestib. Res.-Equilib. Orientat.
PY 2007
VL 17
IS 4
BP 183
EP 193
PG 11
WC Neurosciences; Otorhinolaryngology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Neurosciences & Neurology; Otorhinolaryngology
GA 320QG
UT WOS:000257249500004
PM 18525144
DA 2022-11-30
ER

PT J
AU Gerendas, BS
   Sadeghipour, A
   Michl, M
   Goldbach, F
   Mylonas, G
   Gruber, A
   Alten, T
   Leingang, O
   Sacu, S
   Bogunovic, H
   Schmidt-Erfurth, U
AF Gerendas, Bianca S.
   Sadeghipour, Amir
   Michl, Martin
   Goldbach, Felix
   Mylonas, Georgios
   Gruber, Anastasha
   Alten, Thomas
   Leingang, Oliver
   Sacu, Stefan
   Bogunovic, Hrvoje
   Schmidt-Erfurth, Ursula
TI VALIDATION OF AN AUTOMATED FLUID ALGORITHM ON REAL-WORLD DATA OF
   NEOVASCULAR AGE-RELATED MACULAR DEGENERATION OVER FIVE YEARS
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE deep learning; fluid monitoring; neovascular AMD; OCT; real-world
   management
ID OPTICAL COHERENCE TOMOGRAPHY; VISUAL-ACUITY; RETINAL FLUID; OUTCOMES;
   QUANTIFICATION; IDENTIFICATION; RANIBIZUMAB; BIOMARKERS; MANAGEMENT;
   THERAPY
AB Background/Purpose: To apply an automated deep learning automated fluid algorithm on data from real-world management of patients with neovascular age-related macular degeneration for quantification of intraretinal/subretinal fluid volumes in optical coherence tomography images. Methods: Data from the Vienna Imaging Biomarker Eye Study (VIBES, 2007-2018) were analyzed. Databases were filtered for treatment-naive neovascular age-related macular degeneration with a baseline optical coherence tomography and at least one follow-up and 1,127 eyes included. Visual acuity and optical coherence tomography at baseline, Months 1 to 3/Years 1 to 5, age, sex, and treatment number were included. Artificial intelligence and certified manual grading were compared in a subanalysis of 20%. Main outcome measures were fluid volumes. Results: Intraretinal/subretinal fluid volumes were maximum at baseline (intraretinal fluid: 21.5/76.6/107.1 nL; subretinal fluid 13.7/86/262.5 nL in the 1/3/6-mm area). Intraretinal fluid decreased to 5 nL at M1-M3 (1-mm) and increased to 11 nL (Y1) and 16 nL (Y5). Subretinal fluid decreased to a mean of 4 nL at M1-M3 (1-mm) and remained stable below 7 nL until Y5. Intraretinal fluid was the only variable that reflected VA change over time. Comparison with human expert readings confirmed an area under the curve of >0.9. Conclusion: The Vienna Fluid Monitor can precisely quantify fluid volumes in optical coherence tomography images from clinical routine over 5 years. Automated tools will introduce precision medicine based on fluid guidance into real-world management of exudative disease, improving clinical outcomes while saving resources.
C1 [Gerendas, Bianca S.; Sadeghipour, Amir; Michl, Martin; Goldbach, Felix; Mylonas, Georgios; Alten, Thomas; Leingang, Oliver; Sacu, Stefan; Bogunovic, Hrvoje; Schmidt-Erfurth, Ursula] Med Univ Vienna, Dept Ophthalmol & Optometry, Vienna, Austria.
   [Sadeghipour, Amir] RetInSight GmbH, Elisabethstr, Vienna, Austria.
   [Gruber, Anastasha] Med Univ Vienna, Dept Med Stat, Vienna, Austria.
C3 Medical University of Vienna; Medical University of Vienna
RP Schmidt-Erfurth, U (通讯作者)，Med Univ Vienna, Dept Ophthalmol, Waehringer Guertel 18-20, A-1090 Vienna, Austria.
EM ursula.schmidt-erfurth@meduniwien.ac.at
CR Bogunovic H, 2019, IEEE T MED IMAGING, V38, P1858, DOI 10.1109/TMI.2019.2901398
   Chakravarthy U, 2021, EYE, V35, P2983, DOI 10.1038/s41433-020-01354-4
   Chakravarthy U, 2016, OPHTHALMOLOGY, V123, P1731, DOI 10.1016/j.ophtha.2016.04.005
   Cohen SY, 2013, RETINA-J RET VIT DIS, V33, P474, DOI 10.1097/IAE.0b013e31827b6324
   Daien V, 2019, BMC OPHTHALMOL, V19, DOI 10.1186/s12886-019-1208-9
   De Fauw J, 2018, NAT MED, V24, P1342, DOI 10.1038/s41591-018-0107-6
   DeCroos FC, 2012, OPHTHALMOLOGY, V119, P2549, DOI 10.1016/j.ophtha.2012.06.040
   Evans RN, 2020, JAMA OPHTHALMOL, V138, P1043, DOI 10.1001/jamaophthalmol.2020.3001
   Finger RP, 2013, ACTA OPHTHALMOL, V91, P540, DOI 10.1111/j.1755-3768.2012.02493.x
   Gerendas BS, 2017, VISION RES, V139, P204, DOI 10.1016/j.visres.2017.03.008
   Gillies MC, 2013, INVEST OPHTH VIS SCI, V54, P5754, DOI 10.1167/iovs.13-11993
   Holz FG, 2020, RETINA-J RET VIT DIS, V40, P1673, DOI 10.1097/IAE.0000000000002670
   Holz FG, 2016, BRIT J OPHTHALMOL, V100, P1623, DOI 10.1136/bjophthalmol-2015-308166
   Hsu J, 2020, OPHTHALMOLOGY, V127, P1189, DOI 10.1016/j.ophtha.2020.03.034
   Jaffe GJ, 2019, OPHTHALMOLOGY, V126, P252, DOI 10.1016/j.ophtha.2018.08.035
   Keenan TDL, 2021, AM J OPHTHALMOL, V224, P267, DOI 10.1016/j.ajo.2020.12.012
   Keenan TDL, 2021, OPHTHALMOLOGY, V128, P100, DOI [10.1016/j.opatha.2020.06.038, 10.1016/j.ophtha.2020.06.038]
   Kiss S, 2020, OPHTHALMOLOGY, V127, P1179, DOI 10.1016/j.ophtha.2020.02.027
   Lange C, 2009, GRAEF ARCH CLIN EXP, V247, P137, DOI 10.1007/s00417-008-0926-0
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Mehta H, 2018, PROG RETIN EYE RES, V65, P127, DOI 10.1016/j.preteyeres.2017.12.002
   Michl M, 2022, BRIT J OPHTHALMOL, V106, P113, DOI 10.1136/bjophthalmol-2020-317416
   Moraes G, 2021, OPHTHALMOLOGY, V128, P693, DOI 10.1016/j.ophtha.2020.09.025
   Pawloff M, 2022, RETINA-J RET VIT DIS, V42, P831, DOI 10.1097/IAE.0000000000003385
   Roberts PK, 2020, JAMA OPHTHALMOL, V138, P945, DOI 10.1001/jamaophthalmol.2020.2457
   Rosenfeld PJ, 2016, INVEST OPHTH VIS SCI, V57, pOCT14, DOI 10.1167/iovs.16-19969
   Schlegl T, 2018, OPHTHALMOLOGY, V125, P549, DOI 10.1016/j.ophtha.2017.10.031
   Schmidt-Erfurth U, 2020, OPHTHALMOLOGY, V127, P1211, DOI 10.1016/j.ophtha.2020.03.010
   Schmidt-Erfurth U, 2018, PROG RETIN EYE RES, V67, P1, DOI 10.1016/j.preteyeres.2018.07.004
   Schmidt-Erfurth U, 2018, OPHTHALMOL RETINA, V2, P24, DOI 10.1016/j.oret.2017.03.015
   Schmidt-Erfurth U, 2016, PROG RETIN EYE RES, V50, P1, DOI 10.1016/j.preteyeres.2015.07.007
   Schmidt-Erfurth U, 2014, BRIT J OPHTHALMOL, V98, P1144, DOI 10.1136/bjophthalmol-2014-305702
   Sharma S, 2016, OPHTHALMOLOGY, V123, P865, DOI 10.1016/j.ophtha.2015.12.002
   Toth CA, 2015, RETINA-J RET VIT DIS, V35, P1303, DOI 10.1097/IAE.0000000000000483
   Trivizki O, 2020, AM J OPHTHALMOL, V219, P222, DOI 10.1016/j.ajo.2020.06.028
   Wilson M, 2021, JAMA OPHTHALMOL, V139, P964, DOI 10.1001/jamaophthalmol.2021.2273
NR 36
TC 0
Z9 0
U1 1
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD SEP
PY 2022
VL 42
IS 9
BP 1673
EP 1682
DI 10.1097/IAE.0000000000003557
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 3W9IM
UT WOS:000842662100008
PM 35994584
DA 2022-11-30
ER

PT J
AU Wu, JL
   Sun, XD
AF Wu, Jiali
   Sun, Xiaodong
TI Construction of a ferroptosis-associated circRNA-miRNA-mRNA network in
   age-related macular degeneration
SO EXPERIMENTAL EYE RESEARCH
LA English
DT Article
DE Age-related macular degeneration; Ferroptosis; circRNA; miRNA
ID NLRP3 INFLAMMASOME; UP-REGULATION; IRON; CANCER; ANGIOGENESIS;
   METASTASIS; AUTOPHAGY; STRESS; CELLS
AB Age-related macular degeneration (AMD) is a leading cause of severe vision impairment in the aging population. However, the underlying molecular mechanism remains unclear. Ferroptosis is a novel non-apoptotic programmed cell death pathway, that contributes to AMD. In addition, non-coding RNA-led epigenetic profile was identified in the regulation of AMD progression. Considering that non-coding RNAs are vital regulators of ferroptosis-related genes in various pathological events, we explored and constructed a ferroptosis-associated circRNA-miRNA-mRNA network in AMD. Differential expression of fourteen ferroptosis-associated genes were identified based on our microarray analysis and the FerrDb tool at the threshold of P < 0.05 and log(2)|fold change| & GE; 1, which were subsequently validated by the public datasets. We further screened eight miRNAs via public datasets and the miRNet database. Based on these eight miRNAs, 23 circRNAs were mined using the Starbase tool. Taking all these together, we obtained a ferroptosis-related network with 414 pairs of circRNA-miRNA-mRNA, which are potential targets in future AMD treatments.
C1 [Wu, Jiali; Sun, Xiaodong] Shanghai Jiao Tong Univ, Shanghai Gen Hosp, Sch Med, Dept Ophthalmol, Shanghai, Peoples R China.
   [Wu, Jiali; Sun, Xiaodong] Natl Clin Res Ctr Ophthalm Dis, Shanghai, Peoples R China.
   [Sun, Xiaodong] Shanghai Key Lab Fundus Dis, Shanghai, Peoples R China.
   [Sun, Xiaodong] Shanghai Engn Ctr Visual Sci & Photomed, Shanghai, Peoples R China.
C3 Shanghai Jiao Tong University
RP Sun, XD (通讯作者)，Wujin Rd 85, Shanghai 200080, Peoples R China.
EM xdsun@sjtu.edu.cn
FU National Natural Science Foundation of China [82171076]; Shanghai
   Hospital Development Center [SHDC2020CR5014]
FX Supported by the National Natural Science Foundation of China (82171076)
   . Supported by Shanghai Hospital Development Center (SHDC2020CR5014) .
CR Ambati J, 2012, NEURON, V75, P26, DOI 10.1016/j.neuron.2012.06.018
   Ashraf M, 2017, EYE, V31, P1523, DOI 10.1038/eye.2017.81
   Battaglia AM, 2020, CELLS-BASEL, V9, DOI 10.3390/cells9061505
   Buhler A, 2013, EXP EYE RES, V115, P73, DOI 10.1016/j.exer.2013.06.014
   Chen HY, 2021, FRONT MOL BIOSCI, V8, DOI 10.3389/fmolb.2021.756085
   Coffman LG, 2009, P NATL ACAD SCI USA, V106, P570, DOI 10.1073/pnas.0812010106
   Donato L, 2020, ANTIOXIDANTS-BASEL, V9, DOI 10.3390/antiox9040307
   Hernandez-Zimbron LF, 2018, OXID MED CELL LONGEV, V2018, DOI 10.1155/2018/8374647
   Glorie LLF, 2012, AM J PHYSIOL-RENAL, V303, pF681, DOI 10.1152/ajprenal.00075.2012
   Hadziahmetovic M, 2011, INVEST OPHTH VIS SCI, V52, P959, DOI 10.1167/iovs.10-6207
   Hahn P, 2003, ARCH OPHTHALMOL-CHIC, V121, P1099, DOI 10.1001/archopht.121.8.1099
   He ZW, 2019, J EXP CLIN CANC RES, V38, DOI 10.1186/s13046-019-1065-7
   Hong YK, 2021, BMC CANCER, V21, DOI 10.1186/s12885-021-08559-0
   Huang RR, 2017, AUTOPHAGY, V13, P1722, DOI 10.1080/15548627.2017.1356975
   Ildefonso CJ, 2016, ADV EXP MED BIOL, V854, P59, DOI 10.1007/978-3-319-17121-0_9
   Jiang ZM, 2019, CANCER CELL INT, V19, DOI 10.1186/s12935-019-0977-9
   Jin Y, 2021, FRONT CELL DEV BIOL, V9, DOI 10.3389/fcell.2021.685120
   Kaarniranta K, 2020, PROG RETIN EYE RES, V79, DOI 10.1016/j.preteyeres.2020.100858
   Keller CW, 2021, AUTOPHAGY, V17, P1244, DOI 10.1080/15548627.2020.1756678
   Lei B, 2020, J EXP CLIN CANC RES, V39, DOI 10.1186/s13046-020-01571-5
   Li CY, 2022, MOL MED REP, V25, DOI 10.3892/mmr.2021.12577
   Li D, 2021, J CELL MOL MED, V25, P3610, DOI 10.1111/jcmm.16458
   Li LB, 2019, CELLS-BASEL, V8, DOI 10.3390/cells8020198
   Li Q, 2021, INT J GEN MED, V14, P10117, DOI 10.2147/IJGM.S343233
   Li XR, 2021, INT J MOL MED, V47, DOI 10.3892/ijmm.2021.4894
   Li YF, 2015, J BIOL CHEM, V290, P11918, DOI 10.1074/jbc.M115.645903
   Li Y, 2020, J BREAST CANCER, V23, P355, DOI 10.4048/jbc.2020.23.e47
   Liang XL, 2021, MOL THER-ONCOLYTICS, V23, P501, DOI 10.1016/j.omto.2021.11.002
   Lin XT, 2021, MOL THER, V29, P244, DOI 10.1016/j.ymthe.2020.09.005
   Liu F, 2018, INT J CLIN EXP PATHO, V11, P5901
   Liu P, 2019, PHYTOMEDICINE, V64, DOI 10.1016/j.phymed.2019.152925
   Lux A, 2007, BRIT J OPHTHALMOL, V91, P1318, DOI 10.1136/bjo.2006.113902
   Mahoney-Sanchez L, 2021, PROG NEUROBIOL, V196, DOI 10.1016/j.pneurobio.2020.101890
   Mitchell P, 2018, LANCET, V392, P1147, DOI 10.1016/S0140-6736(18)31550-2
   Newman AM, 2012, GENOME MED, V4, DOI [10.1186/PREACCEPT-1418491035586234, 10.1186/gm315]
   Ren ZY, 2021, FRONT GENET, V12, DOI 10.3389/fgene.2021.672904
   Rinaldi C, 2021, LIFE-BASEL, V11, DOI 10.3390/life11080767
   Roggia MF, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0098864
   Scimone C, 2021, EXP EYE RES, V209, DOI 10.1016/j.exer.2021.108641
   Shang AQ, 2020, AGING-US, V12, P8352, DOI 10.18632/aging.103145
   Su LJ, 2019, OXID MED CELL LONGEV, V2019, DOI 10.1155/2019/5080843
   Suarez-Barrio C, 2021, BIOMOLECULES, V11, DOI 10.3390/biom11070954
   Takashi Y, 2020, FREE RADICAL BIO MED, V161, P60, DOI 10.1016/j.freeradbiomed.2020.09.027
   Tarallo V, 2012, CELL, V149, P847, DOI 10.1016/j.cell.2012.03.036
   Totsuka K, 2019, EXP EYE RES, V181, P316, DOI 10.1016/j.exer.2018.08.019
   Wallsh JO, 2021, CELLS-BASEL, V10, DOI 10.3390/cells10051049
   Wang S, 2021, PEERJ, V9, DOI 10.7717/peerj.11233
   Wang Y., 2021, FRONT MOL BIOSCI, V8, DOI 10.3389/fmolb.2021.692530
   Wang YF, 2018, CANCER BIOL THER, V19, P1162, DOI 10.1080/15384047.2018.1491497
   Wong RW, 2007, RETINA-J RET VIT DIS, V27, P997, DOI 10.1097/IAE.0b013e318074c290
   Wu JL, 2019, DRUG DES DEV THER, V13, P2413, DOI 10.2147/DDDT.S206355
   Wu ZH, 2021, CELL DEATH DISCOV, V7, DOI 10.1038/s41420-021-00473-5
   Wu ZW, 2022, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.783362
   Xu CC, 2021, FRONT GENET, V12, DOI 10.3389/fgene.2021.697043
   Yan N, 2020, FRONT NEUROSCI-SWITZ, V13, DOI 10.3389/fnins.2019.01443
   Yan SS, 2020, CANCER LETT, V488, P18, DOI 10.1016/j.canlet.2020.04.021
   Yang M, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21197279
   Yang WS, 2016, TRENDS CELL BIOL, V26, P165, DOI 10.1016/j.tcb.2015.10.014
   Yang WJ, 2020, AGING-US, V12, P23996, DOI 10.18632/aging.104081
   Yang XC, 2022, ANN TRANSL MED, V10, DOI 10.21037/atm-21-6265
   Zhang LW, 2019, CURR EYE RES, V44, P1226, DOI 10.1080/02713683.2019.1625407
   Zhang PF, 2018, INFLAMMATION, V41, P143, DOI 10.1007/s10753-017-0672-8
   Zhang W, 2021, CANCER GENE THER, V28, P279, DOI 10.1038/s41417-020-00218-z
   Zhang Z, 2021, FRONT MED-LAUSANNE, V8, DOI 10.3389/fmed.2021.675842
   Zhao TT, 2021, AGING DIS, V12, P529, DOI 10.14336/AD.2020.0912
   Zhao XH, 2021, FRONT CELL DEV BIOL, V9, DOI 10.3389/fcell.2021.639851
   Zheng Y, 2021, FRONT CARDIOVASC MED, V8, DOI 10.3389/fcvm.2021.747449
   Zhu HS, 2022, FEBS OPEN BIO, V12, P412, DOI 10.1002/2211-5463.13348
NR 68
TC 0
Z9 0
U1 1
U2 1
PU ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD
PI LONDON
PA 24-28 OVAL RD, LONDON NW1 7DX, ENGLAND
SN 0014-4835
EI 1096-0007
J9 EXP EYE RES
JI Exp. Eye Res.
PD NOV
PY 2022
VL 224
AR 109234
DI 10.1016/j.exer.2022.109234
PG 11
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 4Y0BE
UT WOS:000861199100003
PM 36044964
DA 2022-11-30
ER

PT J
AU Xie, RT
   Wang, B
   Zuo, SK
   Du, M
   Wang, XH
   Yu, Y
   Yan, H
AF Xie, Ruotian
   Wang, Bei
   Zuo, Shengkai
   Du, Mei
   Wang, Xiaohong
   Yu, Ying
   Yan, Hua
TI Protective effects of CRTH2 suppression in dry age-related macular
   degeneration
SO BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
LA English
DT Article
DE Age-related macular degeneration; Chemoattractant receptor-homologous;
   molecule expressed on T helper type 2 cells; Sodium iodate
ID VISUAL-ACUITY; STRESS; APOPTOSIS; RECEPTOR; IMPACT
AB Age-related macular degeneration (AMD) is the leading cause of central vision loss in the elderly. Oxidative stress-induced retinal pigment epithelium (RPE) cell apoptosis is a crucial pathogenic hallmark in AMD. Chemoattractant receptor-homologous molecule expressed on T helper type 2 cells (CRTH2), a prostaglandin (PG) D2 receptor, has been implicated in various pathophysiological events, especially inflammation and stress-induced cell apoptosis. However, its specific role in AMD is not fully understood. Here we studied the effect of CRTH2 on AMD. Our results showed that when stimulated by H2O2, CRTH2 mRNA expression in cells tended to increase. Flow cytometry revealed that the CRTH2 inhibitor could protect the RPE from apoptosis. After NaIO3 injection, a larger area of retinal degeneration was observed in wild-type mice than in CRTH2(-/-) mice. Optical coherence tomography (OCT) and Hematoxylin and Eosin (H&E) staining of retinal sections showed that sodium iodate-induced loss of photoreceptor cells was reduced in CRTH2(-/-) mice after treatment; TUNEL-positive cells were mostly found in the outer nuclear layer. In the control group, NaIO3 stimulation increased the number of TUNEL-positive cells, whereas the percentage of TUNEL-positive cells was significantly lower in CRTH2(-/-) mice. Similarly, the CRTH2 receptor inhibitor CAY10471 similarly inhibited sodium iodate-induced retinal damage. Our results suggest that targeting CRTH2 is a promising therapeutic strategy for the treatment of progressive retinal degeneration in AMD. (C) 2022 Elsevier Inc. All rights reserved.
C1 [Xie, Ruotian; Wang, Bei; Zuo, Shengkai; Du, Mei; Wang, Xiaohong; Yu, Ying; Yan, Hua] Tianjin Med Univ, Tianjin, Peoples R China.
   [Xie, Ruotian; Yan, Hua] Tianjin Med Univ, Dept Ophthalmol, Gen Hosp, Tianjin, Peoples R China.
   [Yan, Hua] Nankai Univ, Sch Med, Tianjin, Peoples R China.
C3 Tianjin Medical University; Tianjin Medical University; Nankai
   University
RP Yan, H (通讯作者)，Nankai Univ, Gen Hosp, Dept Ophthalmol, Sch Med,Tianjin Med Univ, Tianjin 300052, Peoples R China.
EM zyyyanhua@tmu.edu.cn
RI Zuo, Shengkai/GVO-9978-2022
OI Wang, Bei/0000-0001-5587-5451; Wang, Xiaohong/0000-0001-8628-243X
FU National Natural Science Foundation of China [81900883];
   Beijing-Tianjin-Hebei Special Project [19JCZDJC64300, 20JCZXJC00180]
FX This work was supported by National Natural Science Foundation of China
   [grant number 81900883]; Beijing-Tianjin-Hebei Special Project [grant
   number 19JCZDJC64300(Z), 20JCZXJC00180].
CR Akuffo KO, 2017, INVEST OPHTH VIS SCI, V58, P5347, DOI 10.1167/iovs.16-21192
   Al-Zamil WM, 2017, CLIN INTERV AGING, V12, P1313, DOI 10.2147/CIA.S143508
   Bhutto I, 2012, MOL ASPECTS MED, V33, P295, DOI 10.1016/j.mam.2012.04.005
   Brody BL, 2001, OPHTHALMOLOGY, V108, P1893, DOI 10.1016/S0161-6420(01)00754-0
   Chew Emily Y, 2013, Ophthalmology, V120, P1604, DOI 10.1016/j.ophtha.2013.01.021
   Chou R, 2016, JAMA-J AM MED ASSOC, V315, P915, DOI 10.1001/jama.2016.0783
   Cui Z, 2021, HYPERTENSION, V78, P1527, DOI 10.1161/HYPERTENSIONAHA.121.17548
   Datta S, 2017, PROG RETIN EYE RES, V60, P201, DOI 10.1016/j.preteyeres.2017.03.002
   Dou GR, 2012, FREE RADICAL BIO MED, V53, P1111, DOI 10.1016/j.freeradbiomed.2012.06.042
   Duarri A, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms221910497
   Eguchi N, 1999, P NATL ACAD SCI USA, V96, P726, DOI 10.1073/pnas.96.2.726
   Enzbrenner A, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22179218
   Flaxman SR, 2017, LANCET GLOB HEALTH, V5, pE1221, DOI 10.1016/S2214-109X(17)30393-5
   GREEN WR, 1985, OPHTHALMOLOGY, V92, P615
   HOGAN M J, 1972, Transactions of the American Academy of Ophthalmology and Oto-Laryngology, V76, P64
   Holz FG, 2018, JAMA OPHTHALMOL, V136, P666, DOI 10.1001/jamaophthalmol.2018.1544
   Jang KH, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2016.437
   Kaarniranta K, 2020, PROG RETIN EYE RES, V79, DOI 10.1016/j.preteyeres.2020.100858
   Li JQ, 2020, BRIT J OPHTHALMOL, V104, P1077, DOI 10.1136/bjophthalmol-2019-314422
   Quan JH, 2020, TOXICOLOGY, V442, DOI 10.1016/j.tox.2020.152540
   RINGVOLD A, 1981, EXP EYE RES, V33, P361, DOI 10.1016/S0014-4835(81)80088-7
   Salminen A, 2010, MOL MED, V16, P535, DOI 10.2119/molmed.2010.00070
   Stahl A, 2020, DTSCH ARZTEBL INT, V117, P513, DOI 10.3238/arztebl.2020.0513
   Taylor H R, 1990, Trans Am Ophthalmol Soc, V88, P163
   Taylor HR, 1990, T AM OPHTHAL SOC, V88, P173
   Wang BW, 2020, SIGNAL TRANSDUCT TAR, V5, DOI 10.1038/s41392-020-0122-1
   Wang J, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-017-02794-5
   Winkler B S, 1999, Mol Vis, V5, P32
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Xue LZ, 2005, J IMMUNOL, V175, P6531, DOI 10.4049/jimmunol.175.10.6531
   Yao J, 2013, INT J MOL SCI, V14, P10355, DOI 10.3390/ijms140510355
   Yue L, 2012, BONE, V51, P338, DOI 10.1016/j.bone.2012.06.003
   Zhang LM, 2019, TOXICOL LETT, V311, P105, DOI 10.1016/j.toxlet.2019.05.001
   Zuo SK, 2018, EMBO MOL MED, V10, DOI 10.15252/emmm.201708237
NR 34
TC 0
Z9 0
U1 2
U2 2
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0006-291X
EI 1090-2104
J9 BIOCHEM BIOPH RES CO
JI Biochem. Biophys. Res. Commun.
PD OCT 8
PY 2022
VL 624
BP 8
EP 15
DI 10.1016/j.bbrc.2022.07.003
PG 8
WC Biochemistry & Molecular Biology; Biophysics
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Biophysics
GA 4L7NU
UT WOS:000852817200002
PM 35932581
DA 2022-11-30
ER

PT J
AU Mu, YL
   Zhao, ML
   Su, GM
AF Mu, Yalin
   Zhao, Manli
   Su, Guangming
TI Stem cell-based therapies for age-related macular degeneration: current
   status and prospects
SO INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL MEDICINE
LA English
DT Review
DE Stem cell; age-related macular degeneration; retinal pigment epithelium;
   clinical trial
ID RETINAL-PIGMENT EPITHELIUM; IN-VITRO DIFFERENTIATION; RAT MODEL;
   AUTOLOGOUS TRANSPLANTATION; SUBRETINAL TRANSPLANTATION;
   DOPAMINERGIC-NEURONS; VISUAL FUNCTION; GANGLION-CELLS; ES CELLS;
   GENERATION
AB Age-related macular degeneration (AMD) is one of the major causes of irreversible blindness both in developed and developing countries. During the past decades, the managements of neovascular AMD (wet AMD) have dramatically progressed. However, still no effective treatment for non-neovascular AMD (dry AMD) which was characterized by geographic macular atrophy. Recent advances in stem cell sciences have demonstrated that retinal pigment epithelium (RPE) cells can be generated from several types of stem cells (including embryonic stem cells, induced pluripotent stem cells, mesenchymal stem cells, et al) by cell co-culturing or defined factors. Additionally, studies also showed that visual function could be recovered by transplantation of these cells into subretinal space in vivo. Moreover, the United States Food and Drug Administration already approved several clinical trials to evaluate the efficiencies of stem cell based cell transplantation for dry AMD patients. Till now, a few patients enrolled in these studies achieved promising outcomes. This review will summarize recent advances in stem cell based RPE differentiation, transplantation, and the preliminary results of clinical trials. The obstacles and prospects in this field will also be discussed.
C1 [Mu, Yalin; Zhao, Manli; Su, Guangming] Henan Univ Sci & Technol, Yellow River Hosp, Dept Ophthalmol, Sanmenxia City, Henan Province, Peoples R China.
C3 Henan University of Science & Technology
RP Mu, YL (通讯作者)，Henan Univ Sci & Technol, Yellow River Hosp, Dept Ophthalmol, Sanmenxia City, Henan Province, Peoples R China.
EM muyalinsmx@163.com
CR Arnhold S, 2007, GRAEF ARCH CLIN EXP, V245, P414, DOI 10.1007/s00417-006-0382-7
   Aruta C, 2011, PIGM CELL MELANOMA R, V24, P233, DOI 10.1111/j.1755-148X.2010.00793.x
   Bernardos RL, 2007, J NEUROSCI, V27, P7028, DOI 10.1523/JNEUROSCI.1624-07.2007
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   Buchholz DE, 2009, STEM CELLS, V27, P2427, DOI 10.1002/stem.189
   Carr AJ, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0008152
   Castanheira P, 2008, ARQ BRAS OFTALMOL, V71, P644, DOI 10.1590/S0004-27492008000500007
   Cho MS, 2008, P NATL ACAD SCI USA, V105, P3392, DOI 10.1073/pnas.0712359105
   Cho MS, 2012, STEM CELL RES, V9, P101, DOI 10.1016/j.scr.2012.05.002
   Cicero SA, 2009, P NATL ACAD SCI USA, V106, P6685, DOI 10.1073/pnas.0901596106
   Colquitt JL, 2008, HEALTH TECHNOL ASSES, V12, P1
   Comyn O, 2010, CURR OPIN NEUROL, V23, P4, DOI 10.1097/WCO.0b013e3283352f96
   Eiraku M, 2011, NATURE, V472, P51, DOI 10.1038/nature09941
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Gong LH, 2008, CLIN EXP OPHTHALMOL, V36, P666, DOI 10.1111/j.1442-9071.2008.01857.x
   Gonzales CR, 2005, RETINA-J RET VIT DIS, V25, P815
   Gualdoni S, 2010, STEM CELLS, V28, P1048, DOI 10.1002/stem.423
   Guan Y, 2013, CURR MOL MED, V13, P1419
   Haruta M, 2004, INVEST OPHTH VIS SCI, V45, P1020, DOI 10.1167/iovs.03-1034
   Hill AJ, 2009, STEM CELLS DEV, V18, P399, DOI 10.1089/scd.2008.0084
   Hirami Y, 2009, NEUROSCI LETT, V458, P126, DOI 10.1016/j.neulet.2009.04.035
   Hu YT, 2008, INVEST OPHTH VIS SCI, V49, P3185, DOI 10.1167/iovs.07-1299
   Huang C, 2012, J CELL BIOCHEM, V113, P590, DOI 10.1002/jcb.23383
   Huang LB, 2013, OCUL IMMUNOL INFLAMM, V21, P276, DOI 10.3109/09273948.2013.791925
   Ikeda H, 2005, P NATL ACAD SCI USA, V102, P11331, DOI 10.1073/pnas.0500010102
   Inoue Y, 2007, EXP EYE RES, V85, P234, DOI 10.1016/j.exer.2007.04.007
   Jin ZB, 2009, J GENET, V88, P417, DOI 10.1007/s12041-009-0063-5
   Jonas JB, 2010, ACTA OPHTHALMOL, V88, pe131, DOI 10.1111/j.1755-3768.2009.01564.x
   Kawasaki H, 2002, P NATL ACAD SCI USA, V99, P1580, DOI 10.1073/pnas.032662199
   Kawasaki H, 2000, NEURON, V28, P31, DOI 10.1016/S0896-6273(00)00083-0
   Klein R, 2008, OPHTHALMOLOGY, V115, P1460, DOI 10.1016/j.ophtha.2008.01.026
   Klein R, 2006, AM J OPHTHALMOL, V142, P539, DOI 10.1016/j.ajo.2006.06.015
   Klimanskaya I, 2004, CLONING STEM CELLS, V6, P217, DOI 10.1089/1536230042323420
   Kokkinaki M, 2011, STEM CELLS, V29, P825, DOI 10.1002/stem.635
   Kumar A, 2005, INDIAN J MED PAED S3, V26, P12
   Lakowski J, 2010, HUM MOL GENET, V19, P4545, DOI 10.1093/hmg/ddq378
   Lamba DA, 2006, P NATL ACAD SCI USA, V103, P12769, DOI 10.1073/pnas.0601990103
   Lamba DA, 2009, CELL STEM CELL, V4, P73, DOI 10.1016/j.stem.2008.10.015
   Levkovitch-Verbin H, 2010, INVEST OPHTH VIS SCI, V51, P6394, DOI 10.1167/iovs.09-4310
   Lu B, 2009, STEM CELLS, V27, P2126, DOI 10.1002/stem.149
   Lund RD, 2006, CLONING STEM CELLS, V8, P189, DOI 10.1089/clo.2006.8.189
   Ma ZZ, 2009, INVEST OPHTH VIS SCI, V50, P2975, DOI 10.1167/iovs.08-2573
   Machalinska A, 2013, INVEST OPHTH VIS SCI, V54, P8292, DOI 10.1167/iovs.13-12221
   Meyer JS, 2011, STEM CELLS, V29, P1206, DOI 10.1002/stem.674
   Osakada F, 2009, J CELL SCI, V122, P3169, DOI 10.1242/jcs.050393
   Otani A, 2004, J CLIN INVEST, V114, P765, DOI 10.1172/JCI200421686
   Parameswaran S, 2010, STEM CELLS, V28, P695, DOI 10.1002/stem.320
   Park HYL, 2012, BRAIN RES, V1469, P10, DOI 10.1016/j.brainres.2012.06.006
   Parmeggiani F, 2012, MEDIAT INFLAMM, V2012, DOI 10.1155/2012/546786
   Schwartz SD, 2012, LANCET, V379, P713, DOI 10.1016/S0140-6736(12)60028-2
   Siqueira RC, 2011, RETINA-J RET VIT DIS, V31, P1207, DOI 10.1097/IAE.0b013e3181f9c242
   Siqueira RC, 2010, ARQ BRAS OFTALMOL, V73, P474, DOI 10.1590/S0004-27492010000500019
   Song WT, 2013, STEM CELL RES THER, V4, DOI 10.1186/scrt305
   Takahashi K, 2006, CELL, V126, P663, DOI 10.1016/j.cell.2006.07.024
   Tomita M, 2002, STEM CELLS, V20, P279, DOI 10.1634/stemcells.20-4-279
   Tropepe V, 2000, SCIENCE, V287, P2032, DOI 10.1126/science.287.5460.2032
   Tzameret A, 2014, EXP EYE RES, V118, P135, DOI 10.1016/j.exer.2013.10.023
   VINGERLING JR, 1995, OPHTHALMOLOGY, V102, P205
   Wang SM, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009200
   West EL, 2012, STEM CELLS, V30, P1424, DOI 10.1002/stem.1123
   West EL, 2010, STEM CELLS, V28, P1997, DOI 10.1002/stem.520
   Xu W, 2013, CELL MOL NEUROBIOL, V33, P1171, DOI 10.1007/s10571-013-9983-y
   Xu W, 2013, ARQ BRAS OFTALMOL, V76, P105, DOI 10.1590/S0004-27492013000200010
   Zhang TR, 2009, INVEST OPHTH VIS SCI, V50, P2982, DOI 10.1167/iovs.08-2131
   Zhang Y, 2010, INVEST OPHTH VIS SCI, V51, P3742, DOI 10.1167/iovs.08-3314
   Zhu Y, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0054552
NR 66
TC 18
Z9 18
U1 0
U2 11
PU E-CENTURY PUBLISHING CORP
PI MADISON
PA 40 WHITE OAKS LN, MADISON, WI 53711 USA
SN 1940-5901
J9 INT J CLIN EXP MED
JI Int. J. Clin. Exp. Med.
PY 2014
VL 7
IS 11
BP 3843
EP 3852
PG 10
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine
GA AZ6BC
UT WOS:000348302100003
PM 25550892
DA 2022-11-30
ER

PT J
AU Wang, YJ
   Hanus, JW
   Abu-Asab, MS
   Shen, DF
   Ogilvy, A
   Ou, JX
   Chu, XK
   Shi, GP
   Li, W
   Wang, SS
   Chan, CC
AF Wang, Yujuan
   Hanus, Jakub W.
   Abu-Asab, Mones S.
   Shen, Defen
   Ogilvy, Alexander
   Ou, Jingxing
   Chu, Xi K.
   Shi, Guangpu
   Li, Wei
   Wang, Shusheng
   Chan, Chi-Chao
TI NLRP3 Upregulation in Retinal Pigment Epithelium in Age-Related Macular
   Degeneration
SO INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
LA English
DT Article
DE retina; oxidative stress; inflammation; autophagy; mitochondria
ID INFLAMMASOME ACTIVATION; OXIDATIVE STRESS; CELLS; EXPRESSION;
   MECHANISMS; AUTOPHAGY; CALCIUM; DISEASE; MODELS; IMPACT
AB Inflammation and oxidative stress are involved in age-related macular degeneration (AMD) and possibly associated with an activation of neuronal apoptosis inhibitor protein/class II transcription activator of the Major Histocompatibility Complex (MHC)/heterokaryon incompatibility/telomerase-associated protein 1, leucine-rich repeat or nucleotide-binding domain, leucine-rich repeat-containing family, and pyrin domain-containing 3 (NLRP3) inflammasome. In the present study, we used a translational approach to address this hypothesis. In patients with AMD, we observed increased mRNA levels of NLRP3, pro-interleukin-1 beta (IL-1 beta) and pro-IL-18 in AMD lesions of the retinal pigment epithelium (RPE) and photoreceptor. In vitro, a similar increase was evoked by oxidative stress or lipopolysaccharide (LPS) stimulation in the adult retinal pigment epithelium (ARPE-19) cell line, and the increase was reduced in siRNA transfected cells to knockdown NLRP3. Ultrastructural studies of ARPE-19 cells showed a swelling of the cytoplasm, mitochondrial damage, and occurrence of autophagosome-like structures. NLRP3 positive dots were detected within autophagosome-like structures or in the extracellular space. Next, we used a mouse model of AMD, Ccl2/Cx3cr1 double knockout on rd8 background (DKO rd8) to ascertain the in vivo relevance. Ultrastructural studies of the RPE of these mice showed damaged mitochondria, autophagosome-like structures, and cytoplasmic vacuoles, which are reminiscent of the pathology seen in stressed ARPE-19 cells. The data suggest that the NLRP3 inflammasome may contribute in AMD pathogenesis.
C1 [Wang, Yujuan; Shen, Defen; Chu, Xi K.; Chan, Chi-Chao] NEI, Immunopathol Sect, Immunol Lab, NIH, Bethesda, MD 20892 USA.
   [Wang, Yujuan] Sun Yat Sen Univ, Zhongshan Ophthalm Ctr, State Key Lab Ophthalmol, Guangzhou 510060, Guangdong, Peoples R China.
   [Hanus, Jakub W.; Wang, Shusheng] Tulane Univ, Dept Cell & Mol Biol, New Orleans, LA 70118 USA.
   [Abu-Asab, Mones S.; Ogilvy, Alexander; Chan, Chi-Chao] NEI, Histopathol Core, NIH, Bethesda, MD 20892 USA.
   [Ou, Jingxing; Li, Wei] NEI, Unit Retinal Neurophysiol, NIH, Bethesda, MD 20892 USA.
   [Shi, Guangpu] NEI, Expt Immunol Sect, Immunol Lab, NIH, Bethesda, MD 20892 USA.
C3 National Institutes of Health (NIH) - USA; NIH National Eye Institute
   (NEI); Sun Yat Sen University; Tulane University; National Institutes of
   Health (NIH) - USA; NIH National Eye Institute (NEI); National
   Institutes of Health (NIH) - USA; NIH National Eye Institute (NEI);
   National Institutes of Health (NIH) - USA; NIH National Eye Institute
   (NEI)
RP Chan, CC (通讯作者)，NEI, Immunopathol Sect, Immunol Lab, NIH, Bethesda, MD 20892 USA.; Chan, CC (通讯作者)，NEI, Histopathol Core, NIH, Bethesda, MD 20892 USA.
EM yujuanwang2013@gmail.com; jhanus@tulane.edu; mones@nei.nih.gov;
   defen.shen@gmail.com; ogilvy.alexander@gmail.com; ouj@nei.nih.gov;
   xi.kathy.chu@gmail.com; shig@nei.nih.gov; liwei2@nei.nih.gov;
   swang1@tulane.edu; chanc@nei.nih.gov
FU National Eye Institute; NATIONAL EYE INSTITUTE [ZICEY000461] Funding
   Source: NIH RePORTER
FX The National Eye Institute Intramural Research Program provided the
   funding and supported the study. Nicholas Popp provided editing
   assistance.
CR Ambati J, 2012, NEURON, V75, P26, DOI 10.1016/j.neuron.2012.06.018
   Ardeljan D, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0095900
   Ardeljan D, 2013, PROG RETIN EYE RES, V37, P68, DOI 10.1016/j.preteyeres.2013.07.003
   Behrends C, 2010, NATURE, V466, P68, DOI 10.1038/nature09204
   Cao XG, 2010, EXP EYE RES, V91, P15, DOI 10.1016/j.exer.2010.03.016
   Chen M, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0061381
   Chen SD, 2014, EXPERT REV OPHTHALMO, V9, P285, DOI 10.1586/17469899.2014.939171
   Chu XK, 2013, BIOENGINEERED, V4, P130, DOI 10.4161/bioe.22949
   Chung JY, 2008, J HISTOCHEM CYTOCHEM, V56, P1033, DOI 10.1369/jhc.2008.951863
   Colak E, 2012, AGING CLIN EXP RES, V24, P588, DOI 10.3275/8593
   Coleman HR, 2008, LANCET, V372, P1835, DOI 10.1016/S0140-6736(08)61759-6
   de Jong PTVM, 2006, NEW ENGL J MED, V355, P1474, DOI 10.1056/NEJMra062326
   Ding XY, 2009, INVEST OPHTH VIS SCI, V50, P4957, DOI 10.1167/iovs.09-3381
   Dong Z, 2006, ANNU REV PATHOL-MECH, V1, P405, DOI 10.1146/annurev.pathol.1.110304.100218
   Doyle SL, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3007616
   Doyle SL, 2012, NAT MED, V18, P791, DOI 10.1038/nm.2717
   Ebrahimi KB, 2011, J LIPIDS, V2011, DOI 10.1155/2011/802059
   Fowler BJ, 2014, SCIENCE, V346, P1000, DOI 10.1126/science.1261754
   Fujihara M, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003119
   Gee KR, 2000, CELL CALCIUM, V27, P97, DOI 10.1054/ceca.1999.0095
   Ijima R, 2014, INVEST OPHTH VIS SCI, V55, DOI 10.1167/iovs.14-15367
   Kauppinen A, 2012, IMMUNOL LETT, V147, P29, DOI 10.1016/j.imlet.2012.05.005
   Kerur N, 2013, INVEST OPHTH VIS SCI, V54, P7395, DOI 10.1167/iovs.13-12500
   Kishan AU, 2011, SURV OPHTHALMOL, V56, P195, DOI 10.1016/j.survophthal.2010.08.008
   Klein R, 2011, ARCH OPHTHALMOL-CHIC, V129, P75, DOI 10.1001/archophthalmol.2010.318
   Klettner A, 2013, INT J BIOCHEM CELL B, V45, P1457, DOI 10.1016/j.biocel.2013.04.013
   Lemasters JJ, 2009, BBA-BIOENERGETICS, V1787, P1395, DOI 10.1016/j.bbabio.2009.06.009
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Marneros AG, 2013, CELL REP, V4, P945, DOI 10.1016/j.celrep.2013.08.002
   Mattapallil MJ, 2012, INVEST OPHTH VIS SCI, V53, P2921, DOI 10.1167/iovs.12-9662
   Medzhitov R, 2008, NATURE, V454, P428, DOI 10.1038/nature07201
   Murakami T, 2012, P NATL ACAD SCI USA, V109, P11282, DOI 10.1073/pnas.1117765109
   NAGINENI CN, 1994, CLIN DIAGN LAB IMMUN, V1, P569, DOI 10.1128/CDLI.1.5.569-577.1994
   Ogilvy AJ, 2014, ULTRASTRUCT PATHOL, V38, P335, DOI 10.3109/01913123.2014.927406
   Oh H, 1999, INVEST OPHTH VIS SCI, V40, P1891
   Parekh AB, 2008, CELL CALCIUM, V44, P6, DOI 10.1016/j.ceca.2007.12.006
   Popp N., 2013, J CLIN EXP OPHTHALMO, V4
   Ramkumar HL, 2013, J NUTR, V143, P1129, DOI 10.3945/jn.112.169649
   Rutar M, 2011, INVEST OPHTH VIS SCI, V52, P5347, DOI 10.1167/iovs.10-7119
   Shen DF, 2011, INVEST OPHTH VIS SCI, V52, P2897, DOI 10.1167/iovs.10-6114
   Shen J., 2014, J CELL PHYSL, V229, P947
   Shi CS, 2012, NAT IMMUNOL, V13, P255, DOI 10.1038/ni.2215
   Strowig T, 2012, NATURE, V481, P278, DOI 10.1038/nature10759
   Tarallo V, 2012, CELL, V149, P847, DOI 10.1016/j.cell.2012.03.036
   Tseng WA, 2013, INVEST OPHTH VIS SCI, V54, P110, DOI 10.1167/iovs.12-10655
   Tuo JS, 2007, INVEST OPHTH VIS SCI, V48, P3827, DOI 10.1167/iovs.07-0051
   Tuo JS, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-59
   Tuo JS, 2012, NEUROBIOL AGING, V33, DOI 10.1016/j.neurobiolaging.2011.01.009
   von Ahlfen S, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0001261
   Wang Y, 2011, EYE, V25, P127, DOI 10.1038/eye.2010.196
   Wang YJ, 2013, ASN NEURO, V5, DOI 10.1042/AN20130028
   Wang YJ, 2012, APOPTOSIS, V17, P1144, DOI 10.1007/s10495-012-0750-1
   Xu HP, 2009, PROG RETIN EYE RES, V28, P348, DOI 10.1016/j.preteyeres.2009.06.001
   Zhou RB, 2011, NATURE, V469, P221, DOI 10.1038/nature09663
NR 54
TC 24
Z9 25
U1 0
U2 8
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
SN 1422-0067
J9 INT J MOL SCI
JI Int. J. Mol. Sci.
PD JAN
PY 2016
VL 17
IS 1
AR 73
DI 10.3390/ijms17010073
PG 15
WC Biochemistry & Molecular Biology; Chemistry, Multidisciplinary
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry
GA DK0DW
UT WOS:000374583800070
PM 26760997
OA Green Submitted, gold, Green Published
DA 2022-11-30
ER

PT J
AU Lin, JM
   Wan, L
   Tsai, YY
   Lin, HJ
   Tsai, YS
   Lee, CC
   Tsai, CH
   Tsai, FJ
   Tseng, SH
AF Lin, Jane-Ming
   Wan, Lei
   Tsai, Yi-Yu
   Lin, Hui-Ju
   Tsai, Yushin
   Lee, Cheng-Chun
   Tsai, Chang-Hai
   Tsai, Fuu-Jen
   Tseng, Sung-Huei
TI HTRA1 polymorphism in dry and wet age-related macular degeneration
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE HTRA1; polymorphism; age-related macular degeneration; Taiwan;
   prevalence
ID PROMOTER POLYMORPHISM; JAPANESE POPULATION; ADULT-POPULATION;
   UNITED-STATES; RISK-FACTORS; BEIJING EYE; MACULOPATHY; PREVALENCE; GENE;
   PATHOGENESIS
AB Purpose: To investigate HTRA1 polymorphisms in unrelated Taiwan Chinese patients with age-related macular degeneration (AMD) and control subjects without AMD.
   Methods: A total of 95 unrelated Taiwan Chinese patients with AMD and 90 age- and sex-matched control subjects were enrolled in the study. Genomic DNA was prepared from peripheral blood obtained from all patients with AMD and control subjects. Polymerase chain reactions were used to analyze two HTRA1 single-nucleotide polymorphisms (rs11200638 [G/A] and rs10490924 [G/T]).
   Results: Of the 95 participants with AMD, dry AMD was diagnosed in 52 patients and wet AMD in 43 patients. Both rs11200638 (G/A) and rs10490924 (G/T) were significantly associated with all AMD (rs11200638: P = 6.7 X 10(-7) for an additive allele-dosage model, ORhet = 1.97 [0.81, 4.81], ORhom = 8.59 [3.28, 22.49], A allele: 73% in all AMD versus 47% in controls; rs10490924: P 9.2 X 10(-6), ORhet = 1.86 [0.79, 4.35], ORhom = 5.08 [2.21, 11.70], T allele: 73% in all AMD versus 50% in controls). In terms of significance of association, rs11200638 was the most significantly associated variant. Subtype analysis including dry and wet AMD also revealed similar results. Haplotype analysis demonstrated that AT was significantly associated with wet and all AMD (P = 0.011 and 0.004, respectively), whereas GG was significantly associated with the control group when compared with all AMD (P = 0.035).
   Conclusions: The study demonstrated that both single-nucleotide polymorphisms were significantly associated with dry and wet AMD and rs11200638 was the most significantly associated variant in a Taiwan Chinese population.
C1 [Lin, Jane-Ming; Tsai, Yi-Yu; Lin, Hui-Ju] China Med Univ Hosp, Dept Ophthalmol, Taichung, Taiwan.
   [Wan, Lei; Tsai, Chang-Hai; Tsai, Fuu-Jen] China Med Univ Hosp, Dept Med Genet, Taichung, Taiwan.
   [Wan, Lei; Lee, Cheng-Chun; Tsai, Chang-Hai; Tsai, Fuu-Jen] China Med Univ Hosp, Dept Med Res, Taichung, Taiwan.
   [Tsai, Yushin; Tsai, Fuu-Jen] China Med Univ, Grad Inst Chinese Med Sci, Taichung, Taiwan.
   [Tseng, Sung-Huei] Natl Cheng Kung Univ Hosp, Dept Ophthalmol, Tainan, Taiwan.
   [Wan, Lei; Tsai, Chang-Hai; Tsai, Fuu-Jen] Asia Univ, Dept Biotechnol & Bioinformat, Taichung, Taiwan.
C3 China Medical University Taiwan; China Medical University Hospital -
   Taiwan; China Medical University Taiwan; China Medical University
   Hospital - Taiwan; China Medical University Taiwan; China Medical
   University Hospital - Taiwan; China Medical University Taiwan; National
   Cheng Kung University; National Cheng Kung University Hospital; Asia
   University Taiwan
RP Tsai, FJ (通讯作者)，China Med Univ Hosp, Dept Med Genet, 2 Yuh Der Road, Taichung, Taiwan.
EM d0704@mail.cmuh.org.tw
RI Wan, Lei/F-4719-2010; Tsai, Fuu-Jen/J-4140-2015
OI Wan, Lei/0000-0002-9525-3232
CR Augood CA, 2006, ARCH OPHTHALMOL-CHIC, V124, P529, DOI 10.1001/archopht.124.4.529
   Bird AC, 2003, EYE, V17, P457, DOI 10.1038/sj.eye.6700562
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Clausen T, 2002, MOL CELL, V10, P443, DOI 10.1016/S1097-2765(02)00658-5
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   De Luca A, 2003, J HISTOCHEM CYTOCHEM, V51, P1279, DOI 10.1177/002215540305101004
   Dewan A, 2006, SCIENCE, V314, P989, DOI 10.1126/science.1133807
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Fuse N, 2000, JPN J OPHTHALMOL, V44, P245, DOI 10.1016/S0021-5155(00)00150-7
   Hamdi HK, 2002, BIOCHEM BIOPH RES CO, V295, P668, DOI 10.1016/S0006-291X(02)00728-3
   Klein R, 2007, OPHTHALMOLOGY, V114, P253, DOI 10.1016/j.ophtha.2006.10.040
   Li YB, 2006, AM J OPHTHALMOL, V142, P788, DOI 10.1016/j.ajo.2006.06.001
   Ly DH, 2000, SCIENCE, V287, P2486, DOI 10.1126/science.287.5462.2486
   Marx J, 2006, SCIENCE, V311, P1704, DOI 10.1126/science.311.5768.1704
   Miyazaki M, 2005, INVEST OPHTH VIS SCI, V46, P1907, DOI 10.1167/iovs.04-0923
   Nowak JZ, 2006, PHARMACOL REP, V58, P353
   Oshima Y, 2001, BRIT J OPHTHALMOL, V85, P1153, DOI 10.1136/bjo.85.10.1153
   Tan JSL, 2007, OPHTHALMOLOGY, V114, P1143, DOI 10.1016/j.ophtha.2006.09.033
   Tocharus J, 2004, DEV GROWTH DIFFER, V46, P257
   Tsai CY, 2005, JPN J OPHTHALMOL, V49, P166, DOI 10.1007/s10384-004-0164-x
   Xu L, 2006, BRIT J OPHTHALMOL, V90, P1087, DOI 10.1136/bjo.2006.096123
   Yang ZL, 2006, SCIENCE, V314, P992, DOI 10.1126/science.1133811
   Yoshida T, 2007, MOL VIS, V13, P545
   Zarbin MA, 2004, ARCH OPHTHALMOL-CHIC, V122, P598, DOI 10.1001/archopht.122.4.598
NR 24
TC 19
Z9 20
U1 0
U2 3
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD FEB
PY 2008
VL 28
IS 2
BP 309
EP 313
DI 10.1097/IAE.0b013e31814cef3a
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 266TV
UT WOS:000253460800015
PM 18301036
DA 2022-11-30
ER

PT J
AU Lores-Motta, L
   de Jong, E
   den Hollander, A
AF Lores-Motta, Laura
   de Jong, Eiko K.
   den Hollander, Anneke I.
TI Exploring the Use of Molecular Biomarkers for Precision Medicine in
   Age-Related Macular Degeneration
SO MOLECULAR DIAGNOSIS & THERAPY
LA English
DT Review
ID ENDOTHELIAL GROWTH-FACTOR; COMPLEMENT FACTOR-H; ANTI-VEGF TREATMENT;
   INTRAVITREAL RANIBIZUMAB TREATMENT; TEST OPHTHALMOLOGY 2015; RISK ALLELE
   NUMBER; GEOGRAPHIC ATROPHY; AREDS SUPPLEMENTS; PLASMA-LEVELS;
   GENE-THERAPY
AB Precision medicine aims to improve patient care by adjusting medication to each patient's individual needs. Age-related macular degeneration (AMD) is a heterogeneous eye disease in which several pathways are involved, and the risk factors driving the disease differ per patient. As a consequence, precision medicine holds promise for improved management of this disease, which is nowadays a main cause of vision loss in the elderly. In this review, we provide an overview of the studies that have evaluated the use of molecular biomarkers to predict response to treatment in AMD. We predominantly focus on genetic biomarkers, but also include studies that examined circulating or eye fluid biomarkers in treatment response. This involves studies on treatment response to dietary supplements, response to anti-vascular endothelial growth factor, and response to complement inhibitors. In addition, we highlight promising new therapies that have been or are currently being tested in clinical trials and discuss the molecular studies that can help identify the most suitable patients for these upcoming therapeutic approaches.
C1 [Lores-Motta, Laura; de Jong, Eiko K.; den Hollander, Anneke I.] Radboud Univ Nijmegen, Med Ctr, Donders Inst Brain Cognit & Behav, Dept Ophthalmol, Philips van Leydenlaan 15, NL-6525 EX Nijmegen, Netherlands.
   [den Hollander, Anneke I.] Radboud Univ Nijmegen, Med Ctr, Donders Inst Brain Cognit & Behav, Dept Human Genet, Nijmegen, Netherlands.
C3 Philips; Radboud University Nijmegen; Radboud University Nijmegen
RP den Hollander, A (通讯作者)，Radboud Univ Nijmegen, Med Ctr, Donders Inst Brain Cognit & Behav, Dept Ophthalmol, Philips van Leydenlaan 15, NL-6525 EX Nijmegen, Netherlands.; den Hollander, A (通讯作者)，Radboud Univ Nijmegen, Med Ctr, Donders Inst Brain Cognit & Behav, Dept Human Genet, Nijmegen, Netherlands.
EM anneke.denhollander@radboudumc.nl
RI Hollander, Anneke den/N-4911-2014
OI Lores-Motta, Laura/0000-0002-2423-9126
FU European Research Council under the European Union's Seventh Framework
   Programme (FP)/ERC Grant [310644]; European Research Council under the
   European Union's Horizon Research and Innovation Programme/ERC Grant
   [737607]; European Union's Seventh Framework Programme for research,
   technological development and demonstration [317472]
FX The research leading to these results has received funding from the
   European Research Council under the European Union's Seventh Framework
   Programme (FP/2007-2013)/ERC Grant Agreement n. 310644 (MACULA). The
   research leading to these results has received funding from the European
   Research Council under the European Union's Horizon 2020 Research and
   Innovation Programme/ERC Grant Agreement n. 737607 (MACULA2). This
   project has received funding from the European Union's Seventh Framework
   Programme for research, technological development and demonstration
   under Grant agreement no. 317472 (EyeTN).
CR Abedi F, 2013, OPHTHALMOLOGY, V120, P1641, DOI 10.1016/j.ophtha.2013.01.014
   Abedi F, 2013, OPHTHALMOLOGY, V120, P115, DOI 10.1016/j.ophtha.2012.10.006
   Age-Related Eye Disease Study 2 Research Group, 2013, JAMA, V309, P2005, DOI 10.1001/jama.2013.4997
   Amoaku WM, 2015, EYE, V29, P721, DOI 10.1038/eye.2015.48
   Anderson DH, 2010, PROG RETIN EYE RES, V29, P95, DOI 10.1016/j.preteyeres.2009.11.003
   Ansari M, 2013, HUM MOL GENET, V22, P4857, DOI 10.1093/hmg/ddt336
   Arnall JR, 2019, J ONCOL PHARM PRACT, V25, P179, DOI 10.1177/1078155217738324
   Assel MJ, 2018, OPHTHALMOLOGY, V125, P391, DOI 10.1016/j.ophtha.2017.09.008
   Awh CC, 2015, OPHTHALMOLOGY, V122, pE62, DOI 10.1016/j.ophtha.2015.03.028
   Awh CC, 2015, OPHTHALMOLOGY, V122, P162, DOI 10.1016/j.ophtha.2014.07.049
   Awh CC, 2013, OPHTHALMOLOGY, V120, P2317, DOI 10.1016/j.ophtha.2013.07.039
   Bakbak B, 2016, CURR EYE RES, V41, P862, DOI 10.3109/02713683.2015.1067325
   Bardak H, 2016, GENET MOL RES, V15, DOI 10.4238/gmr15048774
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   Betteridge DJ, 2000, METABOLISM, V49, P3, DOI 10.1016/S0026-0495(00)80077-3
   Boltz A, 2012, OPHTHALMOLOGY, V119, P1615, DOI 10.1016/j.ophtha.2012.02.001
   Brantley MA, 2007, OPHTHALMOLOGY, V114, P2168, DOI 10.1016/j.ophtha.2007.09.008
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   Campochiaro PA, 2006, HUM GENE THER, V17, P167, DOI 10.1089/hum.2006.17.167
   Campochiaro PA, 2017, HUM GENE THER, V28, P99, DOI 10.1089/hum.2016.117
   Caprioli J, 2006, BLOOD, V108, P1267, DOI 10.1182/blood-2005-10-007252
   Cashman SM, 2015, J GENE MED, V17, P229, DOI 10.1002/jgm.2865
   Chakravarthy U, 2013, LANCET, V382, P1258, DOI 10.1016/S0140-6736(13)61501-9
   Chakravarthy U, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.04.015
   Chakravarthy U, 2010, BMC OPHTHALMOL, V10, DOI 10.1186/1471-2415-10-31
   Chalam KV, 2014, J OPHTHALMOL, V2014, DOI 10.1155/2014/502174
   Chang W, 2013, MOL VIS, V19, P702
   Chaudhary V, 2016, OPHTHALMOLOGICA, V236, P88, DOI 10.1159/000446819
   Chen GH, 2015, SCI REP-UK, V5, DOI 10.1038/srep14517
   Chen H, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0042464
   Chew EY, 2015, OPHTHALMOLOGY, V122, P212, DOI 10.1016/j.ophtha.2014.10.012
   Chew EY, 2014, OPHTHALMOLOGY, V121, P2173, DOI 10.1016/j.ophtha.2014.05.008
   Constable IJ, 2017, AM J OPHTHALMOL, V177, P150, DOI 10.1016/j.ajo.2017.02.018
   Constable IJ, 2016, EBIOMEDICINE, V14, P168, DOI 10.1016/j.ebiom.2016.11.016
   Cruz-Gonzalez F, 2016, INT J OPHTHALMOL-CHI, V9, P1304, DOI 10.18240/ijo.2016.09.12
   Cruz-Gonzalez F, 2014, GRAEF ARCH CLIN EXP, V252, P469, DOI 10.1007/s00417-014-2585-7
   Cyranoski D, 2017, NATURE, V543, DOI 10.1038/nature.2017.22412
   Dikmetas O, 2013, MOL VIS, V19, P2571
   Veloso CED, 2014, OPHTHALMIC RES, V51, P1, DOI 10.1159/000354328
   Dunkelberger JR, 2010, CELL RES, V20, P34, DOI 10.1038/cr.2009.139
   Falcao DA, 2008, SCAND J IMMUNOL, V68, P445, DOI 10.1111/j.1365-3083.2008.02152.x
   FERRIS FL, 1984, ARCH OPHTHALMOL-CHIC, V102, P1640
   Filleur S, 2009, J CELL BIOCHEM, V106, P769, DOI 10.1002/jcb.22072
   Flaxman SR, 2017, LANCET GLOB HEALTH, V5, pE1221, DOI 10.1016/S2214-109X(17)30393-5
   Francis PJ, 2008, MOL VIS, V14, P1395
   Francis Peter James, 2011, Trans Am Ophthalmol Soc, V109, P115
   Fritsche LG, 2016, NAT GENET, V48, P134, DOI 10.1038/ng.3448
   Fukumori Y, 1989, INT IMMUNOL, V1, P85, DOI 10.1093/intimm/1.1.85
   Gage BF, 2017, JAMA-J AM MED ASSOC, V318, P1115, DOI 10.1001/jama.2017.11469
   Garber K, 2015, NAT BIOTECHNOL, V33, P890, DOI 10.1038/nbt0915-890
   Garcia-Layana A, 2017, CLIN INTERV AGING, V12, P1579, DOI 10.2147/CIA.S142685
   Geerlings MJ, 2017, MOL IMMUNOL, V84, P65, DOI 10.1016/j.molimm.2016.11.016
   Geerlings MJ, 2017, JAMA OPHTHALMOL, V135, P39, DOI 10.1001/jamaophthalmol.2016.4604
   Gemenetzi M, 2017, EYE, V31, P1, DOI 10.1038/eye.2016.208
   Guymer R, 2015, GRAEF ARCH CLIN EXP, V253, P1347, DOI 10.1007/s00417-015-2970-x
   Habibi I, 2016, KLIN MONATSBL AUGENH, V233, P465, DOI 10.1055/s-0041-111801
   Habibi I, 2013, OPHTHALMIC RES, V49, P177, DOI 10.1159/000345068
   Hagstrom SA, 2015, OPHTHALMOLOGY, V122, P1563, DOI 10.1016/j.ophtha.2015.04.024
   Hagstrom SA, 2014, OPHTHALMOLOGY, V121, P1663, DOI 10.1016/j.ophtha.2014.02.025
   Hagstrom SA, 2014, JAMA OPHTHALMOL, V132, P521, DOI 10.1001/jamaophthalmol.2014.109
   Hagstrom SA, 2013, OPHTHALMOLOGY, V120, P593, DOI 10.1016/j.ophtha.2012.11.037
   Hautamaki A, 2014, OPHTHALMOLOGY, V121, P973, DOI 10.1016/j.ophtha.2013.11.035
   Hautamaki A, 2013, RETINA-J RET VIT DIS, V33, P1815, DOI 10.1097/IAE.0b013e318285cf92
   He YL, 1999, MOL ENDOCRINOL, V13, P537, DOI 10.1210/me.13.4.537
   Hecker LA, 2010, HUM MOL GENET, V19, P209, DOI 10.1093/hmg/ddp472
   Heier JS, 2017, LANCET, V390, P50, DOI 10.1016/S0140-6736(17)30979-0
   Henricks LM, 2017, ANN ONCOL, V28, P2915, DOI 10.1093/annonc/mdx411
   Hermann MM, 2014, OPHTHALMOLOGY, V121, P905, DOI 10.1016/j.ophtha.2013.10.047
   Ho AC, 2017, AM J OPHTHALMOL, V179, P67, DOI 10.1016/j.ajo.2017.04.006
   Holz FG, 2014, OPHTHALMOLOGY, V121, P1079, DOI 10.1016/j.ophtha.2013.11.023
   Hong N, 2016, ACTA OPHTHALMOL, V94, P334, DOI 10.1111/aos.13049
   Hu ZZ, 2015, BRIT J OPHTHALMOL, V99, P593, DOI 10.1136/bjophthalmol-2014-305488
   Imai Daisuke, 2010, J Ocul Biol Dis Infor, V3, P53, DOI 10.1007/s12177-010-9055-1
   Jacob M, 2019, MASS SPECTROM REV, V38, P221, DOI 10.1002/mas.21548
   Kang Haeng Ku, 2012, Korean J Ophthalmol, V26, P414, DOI 10.3341/kjo.2012.26.6.414
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Kersten E, 2018, SURV OPHTHALMOL, V63, P9, DOI 10.1016/j.survophthal.2017.05.003
   Kitchens JW, 2013, CLIN OPHTHALMOL, V7, P1987, DOI 10.2147/OPTH.S39635
   Klaver CCW, 1998, ARCH OPHTHALMOL-CHIC, V116, P653, DOI 10.1001/archopht.116.5.653
   Klein ML, 2008, OPHTHALMOLOGY, V115, P1019, DOI 10.1016/j.ophtha.2008.01.036
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Kloeckener-Gruissem B, 2011, INVEST OPHTH VIS SCI, V52, P4694, DOI 10.1167/iovs.10-6080
   Kubicka-Trzaska A, 2012, ACTA OPHTHALMOL, V90, pE21, DOI 10.1111/j.1755-3768.2011.02237.x
   Kuriyan AE, 2017, NEW ENGL J MED, V376, P1047, DOI 10.1056/NEJMoa1609583
   Kuroda Y, 2015, OPHTHALMOLOGY, V122, P2303, DOI 10.1016/j.ophtha.2015.06.053
   Lai TYY, 2009, RETINA-J RET VIT DIS, V29, P1218, DOI 10.1097/IAE.0b013e3181b32c45
   Lazzeri S, 2016, PHARMACOGENOMICS, V17, P27, DOI 10.2217/pgs.15.153
   Le Meur G, 2018, MOL THER, V26, P256, DOI 10.1016/j.ymthe.2017.09.014
   Lechner J, 2016, IMMUN AGEING, V13, DOI 10.1186/s12979-016-0060-5
   Lee AY, 2009, BRIT J OPHTHALMOL, V93, P610, DOI 10.1136/bjo.2008.150995
   LEUNG DW, 1989, SCIENCE, V246, P1306, DOI 10.1126/science.2479986
   Lores-Motta L, 2018, OPHTHALMOLOGY, V125, P1064, DOI 10.1016/j.ophtha.2017.12.023
   Lores-Motta L, 2016, PHARMACOGENET GENOM, V26, P20, DOI 10.1097/FPC.0000000000000180
   Lotery AJ, 2013, OPHTHALMOLOGY, V120, P2637, DOI 10.1016/j.ophtha.2013.07.046
   Machalinska A, 2009, OPHTHALMIC RES, V42, P54, DOI 10.1159/000219686
   Mandai M, 2017, NEW ENGL J MED, V376, P1038, DOI 10.1056/NEJMoa1608368
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Matsumiya W, 2014, PHARMACOGENOMICS, V15, P833, DOI [10.2217/PGS.14.51, 10.2217/pgs.14.51]
   McKibbin M, 2012, BRIT J OPHTHALMOL, V96, P208, DOI 10.1136/bjo.2010.193680
   McLeod DS, 2009, INVEST OPHTH VIS SCI, V50, P4982, DOI 10.1167/iovs.09-3639
   Medina FM, 2019, OPHTHALMIC RES, V61, P168, DOI 10.1159/000475995
   Medina FM, 2015, OPHTHALMIC RES, V54, P169, DOI 10.1159/000439172
   Menghini M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0042014
   Nakata I, 2011, JPN J OPHTHALMOL, V55, P435, DOI 10.1007/s10384-011-0061-z
   Nassar K, 2015, GRAEF ARCH CLIN EXP, V253, P699, DOI 10.1007/s00417-014-2738-8
   Nischler C, 2011, ACTA OPHTHALMOL, V89, pE344, DOI 10.1111/j.1755-3768.2010.02080.x
   Nozaki M, 2006, P NATL ACAD SCI USA, V103, P2328, DOI 10.1073/pnas.0408835103
   Odaibo SG, 2015, OPHTHALMOLOGY, V122, pE58, DOI 10.1016/j.ophtha.2015.02.040
   OREILLY MS, 1994, CELL, V79, P315, DOI 10.1016/0092-8674(94)90200-3
   OReilly MS, 1997, CELL, V88, P277, DOI 10.1016/S0092-8674(00)81848-6
   Orlin A, 2012, RETINA-J RET VIT DIS, V32, P4, DOI 10.1097/IAE.0b013e31822a2c7c
   Park JH, 2011, P NATL ACAD SCI USA, V108, P18026, DOI 10.1073/pnas.1114759108
   Park UC, 2014, RETINA-J RET VIT DIS, V34, P288, DOI 10.1097/IAE.0b013e3182979e1e
   Paun CC, 2016, SCI REP-UK, V6, DOI 10.1038/srep26568
   Pearlman J, 2015, OPHTHALMOLOGY, V122, pE60, DOI 10.1016/j.ophtha.2015.01.031
   Piermarocchi S, 2015, ACTA OPHTHALMOL, V93, pE451, DOI 10.1111/aos.12587
   Pirmohamed M, 2013, NEW ENGL J MED, V369, P2294, DOI 10.1056/NEJMoa1311386
   Pons M, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016722
   Rakoczy EP, 2015, LANCET, V386, P2395, DOI 10.1016/S0140-6736(15)00345-1
   Reynolds R, 2009, INVEST OPHTH VIS SCI, V50, P5818, DOI 10.1167/iovs.09-3928
   Riaz M, 2016, SCI REP-UK, V6, DOI 10.1038/srep37924
   Ristau T, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0093459
   Rivera A, 2005, HUM MOL GENET, V14, P3227, DOI 10.1093/hmg/ddi353
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Sardell RJ, 2016, INVEST OPHTH VIS SCI, V57, P6107, DOI 10.1167/iovs.16-19519
   Schick T, 2017, EYE, V31, P810, DOI 10.1038/eye.2016.328
   Scholl HPN, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002593
   Schwartz SD, 2015, LANCET, V385, P509, DOI 10.1016/S0140-6736(14)61376-3
   Schwartz SD, 2012, LANCET, V379, P713, DOI 10.1016/S0140-6736(12)60028-2
   Seddon JM, 2005, ARCH OPHTHALMOL-CHIC, V123, P321, DOI 10.1001/archopht.123.3.321
   Seddon JM, 2016, BRIT J OPHTHALMOL, V100, P1731, DOI 10.1136/bjophthalmol-2016-308624
   Seddon JM, 2015, INVEST OPHTH VIS SCI, V56, P2192, DOI 10.1167/iovs.14-15841
   Shah AR, 2016, AM J OPHTHALMOL, V163, P154, DOI 10.1016/j.ajo.2015.11.033
   Sharma NK, 2013, DNA CELL BIOL, V32, P549, DOI 10.1089/dna.2013.2072
   Shibuya M, 2013, J BIOCHEM, V153, P13, DOI 10.1093/jb/mvs136
   Silva AS, 2012, MOL VIS, V18, P2288
   Sivaprasad S, 2007, ARCH OPHTHALMOL-CHIC, V125, P515, DOI 10.1001/archopht.125.4.515
   Smailhodzic D, 2012, OPHTHALMOLOGY, V119, P2304, DOI 10.1016/j.ophtha.2012.05.040
   Smailhodzic D, 2012, OPHTHALMOLOGY, V119, P339, DOI 10.1016/j.ophtha.2011.07.056
   Song WK, 2015, STEM CELL REP, V4, P860, DOI 10.1016/j.stemcr.2015.04.005
   Stanton CM, 2011, INVEST OPHTH VIS SCI, V52, P8828, DOI 10.1167/iovs.11-7933
   Teper SJ, 2010, MOL VIS, V16, P2598
   Thompson Michael A, 2017, Am J Manag Care, V23, pSP425
   Tian J, 2012, PHARMACOGENOMICS, V13, P779, DOI [10.2217/PGS.12.53, 10.2217/pgs.12.53]
   Triebwasser MP, 2015, INVEST OPHTH VIS SCI, V56, P6873, DOI 10.1167/iovs.15-17432
   Tsilimbaris MK, 2016, J OPHTHALMOL, V2016, DOI 10.1155/2016/4367631
   Valverde-Megias A, 2017, GRAEF ARCH CLIN EXP, V255, P2091, DOI 10.1007/s00417-017-3748-0
   van Asten F, 2014, OPHTHAL EPIDEMIOL, V21, P347, DOI 10.3109/09286586.2014.949010
   van de Ven JPH, 2013, NAT GENET, V45, P813, DOI 10.1038/ng.2640
   Vavvas DG, 2018, P NATL ACAD SCI USA, V115, pE696, DOI 10.1073/pnas.1718059115
   Verhoef TI, 2016, PHARMACOGENOMICS J, V16, P478, DOI 10.1038/tpj.2016.41
   Wagner EK, 2016, SCI REP-UK, V6, DOI 10.1038/srep31531
   Wang VM, 2012, MOL VIS, V18, P2578
   Weinshilboum RM, 2017, MAYO CLIN PROC, V92, P1711, DOI 10.1016/j.mayocp.2017.09.001
   Wickremasinghe SS, 2011, INVEST OPHTH VIS SCI, V52, P4072, DOI 10.1167/iovs.10-6550
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Wu MX, 2017, BRIT J OPHTHALMOL, V101, P976, DOI 10.1136/bjophthalmol-2016-309418
   Yamashiro K, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-09632-0
   Yaspan BL, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aaf1443
   Yehoshua Z, 2014, OPHTHALMOLOGY, V121, P693, DOI 10.1016/j.ophtha.2013.09.044
   Yildiz BK, 2016, OPHTHALMIC RES, V56, P132, DOI 10.1159/000446186
   Yuan DQ, 2013, OPHTHALMOLOGICA, V230, P227, DOI 10.1159/000355068
   Zhao L, 2013, CURR MOL MED, V13, P929, DOI 10.2174/15665240113139990048
   Zhou YL, 2017, BMC OPHTHALMOL, V17, DOI 10.1186/s12886-017-0487-2
NR 165
TC 17
Z9 17
U1 0
U2 7
PU ADIS INT LTD
PI NORTHCOTE
PA 5 THE WAREHOUSE WAY, NORTHCOTE 0627, AUCKLAND, NEW ZEALAND
SN 1177-1062
EI 1179-2000
J9 MOL DIAGN THER
JI Mol. Diagn. Ther.
PD JUN
PY 2018
VL 22
IS 3
BP 315
EP 343
DI 10.1007/s40291-018-0332-1
PG 29
WC Genetics & Heredity; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Genetics & Heredity; Pharmacology & Pharmacy
GA GG0KK
UT WOS:000432367000004
PM 29700787
OA Green Published, hybrid
DA 2022-11-30
ER

PT J
AU Mozetic, V
   Pacheco, RL
   Latorraca, CDC
   Lee, FCYO
   Gomes, JVB
   Riera, R
AF Mozetic, Vania
   Pacheco, Rafael Leite
   Cruz Latorraca, Carolina de Oliveira
   Yu Ogasawara Lee, Fernanda Chin
   Borges Gomes, Joao Victor
   Riera, Rachel
TI What do Cochrane systematic reviews say about interventions for
   age-related macular degeneration?
SO SAO PAULO MEDICAL JOURNAL
LA English
DT Review
DE Cochrane reviews; Age-related macular degeneration; Systematic reviews;
   Overview
AB BACKGROUND: Age-related macular degeneration (AMD) is the third largest cause of blindness worldwide, accounting for 8.7% of all cases. A considerable number of preventive or therapeutic interventions have been used for AMD.
   OBJECTIVE: This study presents a critical view of the interventions that have been assessed through Cochrane systematic reviews.
   DESIGN AND SETTING: Review of systematic reviews, conducted in the Discipline of Evidence-Based Medicine, Escola Paulista de Medicina (EPM), Universidade Federal de Sao Paulo (UNIFESP).
   METHODS: Review of Cochrane systematic reviews about interventions for AMD.
   RESULTS: The 18 systematic reviews included assessed the effects of surgical techniques, laser/photo/radiotherapy, intravitreal injections, systemic drugs and phytotherapy/vitamins/supplements.
   CONCLUSION: The Cochrane systematic reviews found evidence that use of bevacizumab, ranibizumab, pegaptanib, laser photocoagulation, photodynamic therapy and multivitamin compounds may present some benefits for treating AMD. There was insufficient evidence for supporting the use of macular translocation, submacular surgery, steroid implantation, radiotherapy, intravitreal aflibercept, interferon alfa, statins or omega-3 fatty acids for treating AMD; or the use of multivitamin antioxidant vitamins or mineral supplementation for preventing AMD. Future randomized controlled trials are imperative to reduce the uncertainty in several clinical questions regarding AMD.
C1 [Mozetic, Vania; Pacheco, Rafael Leite; Cruz Latorraca, Carolina de Oliveira; Yu Ogasawara Lee, Fernanda Chin; Borges Gomes, Joao Victor; Riera, Rachel] Cochrane Brazil, Sao Paulo, SP, Brazil.
   [Mozetic, Vania] Inst Dante Pazzanese Cardiol, Sao Paulo, SP, Brazil.
   [Pacheco, Rafael Leite] Ctr Univ Sao Camilo, Sao Paulo, SP, Brazil.
   [Pacheco, Rafael Leite; Cruz Latorraca, Carolina de Oliveira] Univ Fed Sao Paulo, Evidence Based Hlth Program, UNIFESP, Sao Paulo, SP, Brazil.
   [Yu Ogasawara Lee, Fernanda Chin; Borges Gomes, Joao Victor; Riera, Rachel] Univ Fed Sao Paulo, UNIFESP, EPM, Sao Paulo, SP, Brazil.
   [Borges Gomes, Joao Victor] Hosp Sirio Libanes, Ctr Hlth Technol Assessment, Sao Paulo, SP, Brazil.
C3 Instituto Dante Pazzanese de Cardiologia; Centro Universitario Sao
   Camilo; Universidade Federal de Sao Paulo (UNIFESP); Universidade
   Federal de Sao Paulo (UNIFESP); Hospital Sirio Libanes
RP Pacheco, RL (通讯作者)，Univ Fed Sao Paulo, UNIFESP, Programa Posgrad Saude Baseada Evidencias, Rua Botucatu 740-3 Andar, BR-04023900 Sao Paulo, SP, Brazil.
EM rleitepacheco@hotmail.com
RI Riera, Rachel/K-8839-2015; Pacheco, Rafael L/Q-5393-2018
OI Riera, Rachel/0000-0002-9522-1871; Mozetic, Vania/0000-0002-6243-1530;
   Gomes, Joao Victor/0000-0002-4769-6661; Chin Yu Ogasawara Lee,
   Fernanda/0000-0002-5320-3755; Pacheco, Rafael Leite/0000-0001-7487-8471;
   Latorraca, Carolina/0000-0001-9146-4684
CR Atkins D, 2004, BMJ-BRIT MED J, V328, P1490
   Brandl C, 2016, OPHTHALMOLOGE, V113, P735, DOI 10.1007/s00347-016-0341-6
   Eandi CM, 2008, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006928.pub2
   Evans J. R., 2017, COCHRANE DB SYST REV, V7, DOI DOI 10.1002/14651858.CD000254.PUB4
   Evans JR, 2017, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000253.pub4
   Evans JR, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001775.pub2
   Evans JR, 2010, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004004.pub3
   Gehlbach P, 2016, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006927.pub5
   Geltzer A, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005022.pub3
   Giansanti F, 2009, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006931.pub2
   Gupta A, 2018, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD011140.pub2
   Lawrenson JG, 2015, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD010015.pub3
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Moja L, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD011230.pub2
   Reddy U, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005138.pub2
   Sarwar S, 2016, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD011346.pub2
   Solomon SD, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005139.pub3
   Virgili G, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004763.pub2
   Virgili G, 2015, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006537.pub3
   Williams MA, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD009300.pub2
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Wormald R, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD002030.pub3
NR 22
TC 2
Z9 2
U1 2
U2 3
PU ASSOCIACAO PAULISTA MEDICINA
PI SAO PAULO
PA AV BRIG LUIS ANTONIO, 278-7 ANDAR, SAO PAULO, CEP01318-901, BRAZIL
SN 1516-3180
J9 SAO PAULO MED J
JI Sao Paulo Med. J.
PD NOV-DEC
PY 2019
VL 137
IS 6
BP 530
EP 542
DI 10.1590/1516-3180.2019.010317092019
PG 13
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA LG7JU
UT WOS:000528273300010
PM 32159640
OA gold
DA 2022-11-30
ER

PT J
AU Srinivasan, PP
   Kim, LA
   Mettu, PS
   Cousins, SW
   Comer, GM
   Izatt, JA
   Farsiu, S
AF Srinivasan, Pratul P.
   Kim, Leo A.
   Mettu, Priyatham S.
   Cousins, Scott W.
   Comer, Grant M.
   Izatt, Joseph A.
   Farsiu, Sina
TI Fully automated detection of diabetic macular edema and dry age-related
   macular degeneration from optical coherence tomography images
SO BIOMEDICAL OPTICS EXPRESS
LA English
DT Article
ID NERVE-FIBER LAYER; RETINAL LAYERS; OCT IMAGES; SEGMENTATION; THICKNESS;
   CLASSIFICATION; BOUNDARIES; DIAGNOSIS; SCANS; SHAPE
AB We present a novel fully automated algorithm for the detection of retinal diseases via optical coherence tomography (OCT) imaging. Our algorithm utilizes multiscale histograms of oriented gradient descriptors as feature vectors of a support vector machine based classifier. The spectral domain OCT data sets used for cross-validation consisted of volumetric scans acquired from 45 subjects: 15 normal subjects, 15 patients with dry age-related macular degeneration (AMD), and 15 patients with diabetic macular edema (DME). Our classifier correctly identified 100% of cases with AMD, 100% cases with DME, and 86.67% cases of normal subjects. This algorithm is a potentially impactful tool for the remote diagnosis of ophthalmic diseases. (C)2014 Optical Society of America
C1 [Srinivasan, Pratul P.; Izatt, Joseph A.; Farsiu, Sina] Duke Univ, Dept Biomed Engn, Durham, NC 27708 USA.
   [Srinivasan, Pratul P.; Farsiu, Sina] Duke Univ, Dept Comp Sci, Durham, NC 27708 USA.
   [Kim, Leo A.] Harvard Univ, Massachusetts Eye & Ear Infirm, Schepens Eye Res Inst, Boston, MA 02114 USA.
   [Mettu, Priyatham S.; Cousins, Scott W.; Izatt, Joseph A.; Farsiu, Sina] Duke Univ, Med Ctr, Dept Ophthalmol, Durham, NC 27710 USA.
   [Comer, Grant M.] Univ Michigan, Kellogg Eye Ctr, Ann Arbor, MI 48105 USA.
   [Farsiu, Sina] Duke Univ, Dept Elect & Comp Engn, Durham, NC 27708 USA.
C3 Duke University; Duke University; Harvard University; Massachusetts Eye
   & Ear Infirmary; Schepens Eye Research Institute; Duke University;
   University of Michigan System; University of Michigan; Duke University
RP Srinivasan, PP (通讯作者)，Duke Univ, Dept Biomed Engn, Durham, NC 27708 USA.
EM pratul.srinivasan@duke.edu
RI Izatt, Joseph/C-9067-2014; Kim, Leo/Y-3323-2018
OI Izatt, Joseph/0000-0003-1993-2249; Kim, Leo/0000-0001-9106-6416; Farsiu,
   Sina/0000-0003-4872-2902
FU NIH [R01 EY022691]; U.S. Army Medical Research Acquisition Activity
   Contract [W81XWH-12-1-0397]; Duke University Pratt Undergraduate
   Fellowship Program; Juvenile Diabetes Research Foundation; NEI
   [K12-EY16335, K12 EY016333-08]; Massachusetts Lions Eye Research Fund;
   NATIONAL EYE INSTITUTE [R01EY022691, K12EY016335] Funding Source: NIH
   RePORTER
FX This research was supported by the NIH R01 EY022691 (SF), the U.S. Army
   Medical Research Acquisition Activity Contract W81XWH-12-1-0397 (JAI),
   the Duke University Pratt Undergraduate Fellowship Program (PPS), the
   Juvenile Diabetes Research Foundation (GMC), the NEI K12-EY16335 (LAK),
   the NEI K12 EY016333-08 (PSM), and the Massachusetts Lions Eye Research
   Fund (LAK). We would like to thank Professors Magali Saint-Geniez and
   Kevin McHugh of Harvard University for their collaboration and
   invaluable feedback.
CR Albarrak A, 2013, P 2013 INT C MED IM, P59
   Anantrasirichai N, 2013, I S BIOMED IMAGING, P1332
   Antony BJ, 2013, BIOMED OPT EXPRESS, V4, P2712, DOI 10.1364/BOE.4.002712
   BURT PJ, 1983, IEEE T COMMUN, V31, P532, DOI 10.1109/TCOM.1983.1095851
   Carass A, 2014, BIOMED OPT EXPRESS, V5, P1062, DOI 10.1364/BOE.5.001062
   Chiu SJ, 2012, BIOMED OPT EXPRESS, V3, P1127, DOI 10.1364/BOE.3.001127
   Chiu SJ, 2012, INVEST OPHTH VIS SCI, V53, P53, DOI 10.1167/iovs.11-7640
   Chiu SJ, 2010, OPT EXPRESS, V18, P19413, DOI 10.1364/OE.18.019413
   CORTES C, 1995, MACH LEARN, V20, P273, DOI 10.1007/BF00994018
   Dabov K, 2007, IEEE T IMAGE PROCESS, V16, P2080, DOI 10.1109/TIP.2007.901238
   Dalal N., 2005, CVPR
   DeBuc DC, 2009, J BIOMED OPT, V14, DOI 10.1117/1.3268773
   Douglas JY, 2012, PROG RETIN EYE RES, V31, P481, DOI 10.1016/j.preteyeres.2012.04.005
   Fang LY, 2012, BIOMED OPT EXPRESS, V3, P927, DOI 10.1364/BOE.3.000927
   Farsiu S, 2014, OPHTHALMOLOGY, V121, P162, DOI 10.1016/j.ophtha.2013.07.013
   Fernandez DC, 2005, OPT EXPRESS, V13, P10200, DOI 10.1364/OPEX.13.010200
   Fernandez DC, 2005, IEEE T MED IMAGING, V24, P929, DOI 10.1109/TMI.2005.848655
   Gregori G, 2011, OPHTHALMOLOGY, V118, P1373, DOI 10.1016/j.ophtha.2010.11.013
   HEE MR, 1995, ARCH OPHTHALMOL-CHIC, V113, P325, DOI 10.1001/archopht.1995.01100030081025
   Ishikawa H, 2005, INVEST OPHTH VIS SCI, V46, P2012, DOI 10.1167/iovs.04-0335
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Koprowski R, 2013, BIOMED ENG ONLINE, V12, DOI 10.1186/1475-925X-12-117
   Kuo AN, 2013, AM J OPHTHALMOL, V156, P304, DOI 10.1016/j.ajo.2013.03.012
   Lang A, 2013, BIOMED OPT EXPRESS, V4, P1133, DOI 10.1364/BOE.4.001133
   Lee JY, 2013, INVEST OPHTH VIS SCI, V54, P7595, DOI 10.1167/iovs.13-11762
   Liu YY, 2011, INVEST OPHTH VIS SCI, V52, P8316, DOI 10.1167/iovs.10-7012
   Mayer MA, 2012, BIOMED OPT EXPRESS, V3, P572, DOI 10.1364/BOE.3.000572
   Mayer MA, 2010, BIOMED OPT EXPRESS, V1, P1358, DOI 10.1364/BOE.1.001358
   Medeiros FA, 2005, AM J OPHTHALMOL, V139, P44, DOI 10.1016/j.ajo.2004.08.069
   Mishra A, 2009, OPT EXPRESS, V17, P23719, DOI 10.1364/OE.17.023719
   Mujat M, 2005, OPT EXPRESS, V13, P9480, DOI 10.1364/OPEX.13.009480
   Paunescu LA, 2004, INVEST OPHTH VIS SCI, V45, P1716, DOI 10.1167/iovs.03-0514
   Rickman CB, 2013, INVEST OPHTH VIS SCI, V54, pORSF68, DOI 10.1167/iovs.13-12757
   Shahidi M, 2005, AM J OPHTHALMOL, V139, P1056, DOI 10.1016/j.ajo.2005.01.012
   Somfai GM, 2014, BMC BIOINFORMATICS, V15, DOI 10.1186/1471-2105-15-106
   Srinivasan PP, 2014, BIOMED OPT EXPRESS, V5, P348, DOI 10.1364/BOE.5.000348
   Tan O, 2008, OPHTHALMOLOGY, V115, P949, DOI 10.1016/j.ophtha.2007.08.011
   Vermeer KA, 2011, BIOMED OPT EXPRESS, V2, P1743, DOI 10.1364/BOE.2.001743
   Yang Q, 2011, BIOMED OPT EXPRESS, V2, P2493, DOI 10.1364/BOE.2.002493
   Zhang YG, 2014, EURASIP J ADV SIG PR, DOI 10.1186/1687-6180-2014-17
NR 40
TC 223
Z9 233
U1 0
U2 33
PU OPTICAL SOC AMER
PI WASHINGTON
PA 2010 MASSACHUSETTS AVE NW, WASHINGTON, DC 20036 USA
SN 2156-7085
J9 BIOMED OPT EXPRESS
JI Biomed. Opt. Express
PD OCT 1
PY 2014
VL 5
IS 10
BP 3568
EP 3577
DI 10.1364/BOE.5.003568
PG 10
WC Biochemical Research Methods; Optics; Radiology, Nuclear Medicine &
   Medical Imaging
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Optics; Radiology, Nuclear Medicine &
   Medical Imaging
GA AQ9BI
UT WOS:000343135200025
PM 25360373
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Choi, S
   Park, SM
   Jee, D
AF Choi, Seulggie
   Park, Sang Min
   Jee, Donghyun
TI Utility values for age-related macular degeneration patients in Korea
SO PLOS ONE
LA English
DT Article
ID QUALITY-OF-LIFE; DIABETIC-RETINOPATHY; RESOURCE UTILIZATION; BURDEN;
   IMPACT; IMPAIRMENT; PREVALENCE
AB Purpose
   Age-related macular degeneration (AMD) is one of the most important causes of blindness globally and may lead to decreased quality of life. Utility values for AMD patients according to sociodemographic and clinical characteristics have been little-studied, particularly among Asian populations.
   Methods
   A total of 1,283 AMD patients were identified from the Korean National Health and Nutrition Examination Survey from 2008 to 2012. A 45-degree digital retinal image for each eye was used to identify AMD patients. The utility values, calculated by the three level version of EuroQol-5D, of AMD patients according to sociodemographic and clinical characteristics were determined. The Kruskal-Wallis test was used to identify factors associated with reduced utility values among AMD patients.
   Results
   The mean utility value for AMD patients was 0.8765. Patients who were older (mean utility value 0.8339), were women (0.8488), had lower education levels (0.8287), were not employed (0.8467), and had lower household income (0.8022) had lower utility values (all p values <0.001). Utility values did not significantly differ according to AMD subtype (p value 0.729), likely due to the lack of enough power as only 48 patients had late AMD. Patients with lower best-eye visual acuity (BEVA) had lower utility values compared to those with high BEVA, even among those with high worst-eye visual acuity (WEVA) (p value <0.001).
   Conclusion
   Sociodemographic factors and visual acuity are important factors in determining the quality of life among AMD patients. Preserving BEVA, regardless of WEVA, may be associated with improved quality of life.
C1 [Choi, Seulggie; Park, Sang Min] Seoul Natl Univ, Dept Biomed Sci, Grad Sch, Seoul, South Korea.
   [Park, Sang Min] Seoul Natl Univ Hosp, Dept Family Med, Seoul, South Korea.
   [Jee, Donghyun] Catholic Univ Korea, St Vincents Hosp, Coll Med, Div Vitreous & Retina,Dept Ophthalmol, Suwon, South Korea.
C3 Seoul National University (SNU); Seoul National University (SNU); Seoul
   National University Hospital; Catholic University of Korea
RP Jee, D (通讯作者)，Catholic Univ Korea, St Vincents Hosp, Coll Med, Div Vitreous & Retina,Dept Ophthalmol, Suwon, South Korea.
EM donghyunjee@catholic.ac.kr
RI Park, Sang Min/V-9194-2019
FU Korea Health Technology R&D Project through the Korea Health Industry
   Development Institute (KHIDI) - Ministry of Health & Welfare, Republic
   of Korea [HI17C1234]
FX This study was supported by a grant from the Korea Health Technology R&D
   Project through the Korea Health Industry Development Institute (KHIDI),
   funded by the Ministry of Health & Welfare, Republic of Korea (Grant
   number: HI17C1234, URL: http://www.khidi.or.kr/eps). The funders had no
   role in study design, data collection and analysis, decision to publish,
   or preparation of the manuscript.
CR Augood CA, 2006, ARCH OPHTHALMOL-CHIC, V124, P529, DOI 10.1001/archopht.124.4.529
   Brown GC, 2000, ARCH OPHTHALMOL-CHIC, V118, P47
   Brown MM, 2002, ARCH OPHTHALMOL-CHIC, V120, P481
   Dawson SR, 2014, BMC OPHTHALMOL, V14, DOI 10.1186/1471-2415-14-78
   Eong KGA, 2012, EYE, V26, P379, DOI 10.1038/eye.2011.218
   Espallargues M, 2005, INVEST OPHTH VIS SCI, V46, P4016, DOI 10.1167/iovs.05-0072
   KRAMAROW EA, 1995, DEMOGRAPHY, V32, P335, DOI 10.2307/2061684
   La TY, 2014, CURR EYE RES, V39, P1232, DOI 10.3109/02713683.2014.907431
   Lamoureux EL, 2008, OPHTHAL EPIDEMIOL, V15, P105, DOI 10.1080/09286580701840354
   Lee BS, 2008, OPHTHALMOLOGY, V115, P898, DOI 10.1016/j.ophtha.2007.06.008
   Lim LS, 2013, ASIA-PAC J OPHTHALMO, V2, P32, DOI 10.1097/APO.0b013e31827ff5bc
   Lotery A, 2007, BRIT J OPHTHALMOL, V91, P1303, DOI 10.1136/bjo.2007.116939
   Mitchell J, 2006, HEALTH QUAL LIFE OUT, V4, DOI 10.1186/1477-7525-4-97
   Sahel JA, 2007, ARCH OPHTHALMOL-CHIC, V125, P945, DOI 10.1001/archopht.125.7.945
   Saw SM, 2005, J GLAUCOMA, V14, P455, DOI 10.1097/01.ijg.0000185434.08051.82
   Seong SC, 2017, INT J EPIDEMIOL, V46, P799, DOI 10.1093/ije/dyw253
   Shah VA, 2004, OPHTHAL EPIDEMIOL, V11, P43, DOI 10.1076/opep.11.1.43.26436
   Soubrane G, 2007, ARCH OPHTHALMOL-CHIC, V125, P1249, DOI 10.1001/archopht.125.9.1249
   Taylor DJ, 2016, BMJ OPEN, V6, DOI 10.1136/bmjopen-2016-011504
   Tung TH, 2005, DIABETES RES CLIN PR, V68, P265, DOI 10.1016/j.diabres.2004.10.003
   Wiliams RA, 1998, ARCH OPHTHALMOL-CHIC, V116, P514
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
NR 22
TC 2
Z9 2
U1 0
U2 3
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JUL 31
PY 2018
VL 13
IS 7
AR e0201399
DI 10.1371/journal.pone.0201399
PG 10
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA GO7ZJ
UT WOS:000440300500033
PM 30063734
OA Green Published, gold, Green Submitted
DA 2022-11-30
ER

PT J
AU Chen, CY
   Wong, TY
   Heriot, WJ
AF Chen, Christine Y.
   Wong, Tien Y.
   Heriot, Wilson J.
TI Intravitreal bevacizumab (Avastin) for neovascular age-related macular
   degeneration: A short-term study
SO AMERICAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
AB PURPOSE: To report the short-term study of intravitreal bevacizurnab (Avastin) in the treatment of neovascular age,related macular degeneration (AMD).
   DESIGN: Interventional, consecutive, prospective case series.
   METHODS: One hundred and two eyes of 102 patients with neovascular AMD received monthly intravitreal bevacizumab (Avastin) (1.25 mg) until resolution of macular edema, subretinal fluid, and/or pigment epithelial detachment. Outcome measures included visual acuity (VA) and central retinal thickness as defined from optical coherence tomography (OCT).
   RESULTS: Mean VA was 20/80 and OCT central retinal thickness was 251.0 +/- 74.6 mu m before injection and improved to 20/63 and 214.9 +/- 41.7 mu m at six weeks (P < .001), 20/50 and 204.8 +/- 33.6 mu m at 10 weeks (P < .001), and remained stable at 20/50 and 210 mu m after 14 weeks (P < .05). No significant ocular or systemic side effects were observed.
   CONCLUSIONS: Intravitreal bevacizumab (Avastin) appears to be beneficial and well tolerated in the treatment of neovascular AMD in the short term. Further comparative evaluation against other antivascular endothelial growth factor (VEGF) agents and dosing schedule is warranted.
C1 Eye Surg Assoc, Cabrini Med Ctr, Malvern, Vic 3144, Australia.
   Univ Melbourne, Ctr Eye Res Australia, Melbourne, Vic, Australia.
   Royal Victorian Eye & Ear Hosp, Melbourne, Vic, Australia.
C3 Cabrini Health; Centre for Eye Research Australia; University of
   Melbourne; Royal Victorian Eye & Ear Hospital
RP Heriot, WJ (通讯作者)，Eye Surg Assoc, Cabrini Med Ctr, Malvern, Vic 3144, Australia.
EM wilson@eyesurgery.com.au
RI Wong, Tien Yin/AAC-9724-2020
OI Wong, Tien Yin/0000-0002-8448-1264
CR Avery RL, 2006, OPHTHALMOLOGY, V113, P363, DOI 10.1016/j.ophtha.2005.11.019
   Rich RM, 2006, RETINA-J RET VIT DIS, V26, P495, DOI 10.1097/01.iae.0000225766.75009.3a
   Rosenfeld PJ, 2005, OPHTHAL SURG LAS IM, V36, P331, DOI 10.3928/1542-8877-20050701-14
   Spaide RF, 2006, RETINA-J RET VIT DIS, V26, P383, DOI 10.1097/00006982-200604000-00001
   2006, PRELIMINARY RESULTS
NR 5
TC 77
Z9 88
U1 0
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0002-9394
J9 AM J OPHTHALMOL
JI Am. J. Ophthalmol.
PD MAR
PY 2007
VL 143
IS 3
BP 510
EP 512
DI 10.1016/j.ajo.2006.10.004
PG 3
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 141CZ
UT WOS:000244555700021
PM 17317398
DA 2022-11-30
ER

PT J
AU Haddad, S
   Chen, CA
   Santangelo, SL
   Seddon, JM
AF Haddad, Stephen
   Chen, Clara A.
   Santangelo, Susan L.
   Seddon, Johanna M.
TI The genetics of age-related macular degeneration: A review of progress
   to date
SO SURVEY OF OPHTHALMOLOGY
LA English
DT Review
DE age-related macular degeneration (AMD); age-related maculopathy (ARM);
   genetics; heritability; linkage; macula; retina
ID COMPLEMENT FACTOR-H; BEAVER DAM EYE; APOLIPOPROTEIN-E GENE; C-REACTIVE
   PROTEIN; STARGARDT-DISEASE GENE; NONFAMILIAL JAPANESE PATIENTS;
   DIETARY-FAT; ALLELIC VARIATION; CANDIDATE GENE; CHOROIDAL
   NEOVASCULARIZATION
AB Age-related macular degeneration (AMD) is the leading cause of vision loss and blindness among older adults in the USA and throughout the developed world. Etiological research suggests that AMD is a complex disease, caused by the actions and interactions of multiple genes and environmental factors. Familial aggregation studies, twin studies, and segregation analyses have provided strong evidence for the heritability of AMD, and linkage and association studies have been conducted to localize the disease-causing genes. Whole genome linkage scans have implicated nearly every chromosome in the human genome, with the most replicated signals residing on 1q25-31 and 10q26. Association studies have identified a major risk variant within the complement factor H gene (CFH), and recent reports suggest that PLEKHA1/LOC387715 and the BF/C2 regions may be major risk loci for AMD as well. Several other genes have had at least one positive association finding and deserve further exploration. Among these, apolipoprotein E (APOE) may be a minor risk locus. Additional genes will likely be identified, and future studies should explore the potential interactions of these genes with other genes as well as environmental factors.
C1 Massachusetts Eye & Ear Infirm, Epidemiol Unit, Boston, MA 02114 USA.
   Massachusetts Eye & Ear Infirm, Psychiat & Neurodev Genet Unit, Boston, MA 02114 USA.
   Harvard Univ, Sch Med, Dept Psychiat, Boston, MA 02115 USA.
   Harvard Univ, Sch Med, Dept Ophthalmol, Boston, MA 02115 USA.
   Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA.
C3 Harvard University; Massachusetts Eye & Ear Infirmary; Harvard
   University; Massachusetts Eye & Ear Infirmary; Harvard University;
   Harvard Medical School; Harvard University; Harvard Medical School;
   Harvard University; Harvard T.H. Chan School of Public Health
RP Seddon, JM (通讯作者)，Massachusetts Eye & Ear Infirm, Epidemiol Unit, 243 Charles St, Boston, MA 02114 USA.
EM Johanna_Seddon@meei.harvard.edu
FU NEI NIH HHS [R01 EY011309] Funding Source: Medline
CR Abecasis GR, 2004, AM J HUM GENET, V74, P482, DOI 10.1086/382786
   Age-Related Eye Dis Study Res Grp, 2001, AM J OPHTHALMOL, V132, P668
   Akimoto A, 2001, GRAEF ARCH CLIN EXP, V239, P66, DOI 10.1007/PL00007900
   Allikmets R, 1999, HUM GENET, V104, P449, DOI 10.1007/s004390050986
   Allikmets R, 2000, AM J HUM GENET, V67, P487, DOI 10.1086/303018
   Allikmets R, 1997, SCIENCE, V277, P1805, DOI 10.1126/science.277.5333.1805
   Ayyagari R, 2001, Ophthalmic Genet, V22, P233, DOI 10.1076/opge.22.4.233.2219
   Baird PN, 2004, AM J OPHTHALMOL, V138, P665, DOI 10.1016/j.ajo.2004.04.053
   Baird PN, 2004, INVEST OPHTH VIS SCI, V45, P1311, DOI 10.1167/iovs.03-1121
   Baum L, 2003, OPHTHALMOLOGICA, V217, P111, DOI 10.1159/000068553
   Bernstein PS, 2002, INVEST OPHTH VIS SCI, V43, P466
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Blackmore TK, 1998, INFECT IMMUN, V66, P1427, DOI 10.1128/IAI.66.4.1427-1431.1998
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   Cho E, 2001, AM J CLIN NUTR, V73, P209
   Christen WG, 1996, JAMA-J AM MED ASSOC, V276, P1147, DOI 10.1001/jama.276.14.1147
   Clark AG, 2004, GENET EPIDEMIOL, V27, P321, DOI 10.1002/gepi.20025
   Conley YP, 2005, HUM MOL GENET, V14, P1991, DOI 10.1093/hmg/ddi204
   Cruickshanks KJ, 1997, ARCH OPHTHALMOL-CHIC, V115, P242, DOI 10.1001/archopht.1997.01100150244015
   Davis MD, 2005, ARCH OPHTHALMOL-CHIC, V123, P1484
   de Cordoba SR, 2004, MOL IMMUNOL, V41, P355, DOI 10.1016/j.molimm.2004.02.005
   De La Paz MA, 1999, OPHTHALMOLOGY, V106, P1531, DOI 10.1016/S0161-6420(99)90449-9
   DelaPaz MA, 1997, INVEST OPHTH VIS SCI, V38, P1060
   Donoso LA, 2006, SURV OPHTHALMOL, V51, P137, DOI 10.1016/j.survophthal.2005.12.001
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Esfandiary H, 2005, BRIT J OPHTHALMOL, V89, P470, DOI 10.1136/bjo.2004.047340
   FARAONE SV, 1992, RES DESIGNS METHODS, P93
   FEARON DT, 1978, P NATL ACAD SCI USA, V75, P1971, DOI 10.1073/pnas.75.4.1971
   Fiotti N, 2005, GENET MED, V7, P272, DOI 10.1097/01.GIM.0000159903.69597.73
   Fisher SA, 2005, HUM MOL GENET, V14, P2257, DOI 10.1093/hmg/ddi230
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Fuse N, 2000, JPN J OPHTHALMOL, V44, P245, DOI 10.1016/S0021-5155(00)00150-7
   Giannakis E, 2003, EUR J IMMUNOL, V33, P962, DOI 10.1002/eji.200323541
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   Gotoh N, 2004, AM J OPHTHALMOL, V138, P567, DOI 10.1016/j.ajo.2004.05.025
   Gottfredsdottir MS, 1999, ACTA OPHTHALMOL SCAN, V77, P422, DOI 10.1034/j.1600-0420.1999.770413.x
   Goverdhan SV, 2005, INVEST OPHTH VIS SCI, V46, P1726, DOI 10.1167/iovs.04-0928
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Grizzard WS, 2003, OPHTHAL EPIDEMIOL, V10, P315, DOI 10.1076/opep.10.5.315.17317
   GURNE DH, 1991, OPHTHALMOLOGY, V98, P602
   Guymer RH, 2002, CLIN EXP OPHTHALMOL, V30, P419, DOI 10.1046/j.1442-9071.2002.00572.x
   Guymer RH, 2001, ARCH OPHTHALMOL-CHIC, V119, P745, DOI 10.1001/archopht.119.5.745
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2006, INVEST OPHTH VIS SCI, V47, P329, DOI 10.1167/iovs.05-0116
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Hamdi HK, 2002, BIOCHEM BIOPH RES CO, V295, P668, DOI 10.1016/S0006-291X(02)00728-3
   Hammond CJ, 2002, OPHTHALMOLOGY, V109, P730, DOI 10.1016/S0161-6420(01)01049-1
   Hayashi M, 2004, Ophthalmic Genet, V25, P111
   HEIBA IM, 1994, GENET EPIDEMIOL, V11, P51, DOI 10.1002/gepi.1370110106
   Ikeda T, 2001, AM J OPHTHALMOL, V132, P191, DOI 10.1016/S0002-9394(01)00975-8
   Iyengar SK, 2004, AM J HUM GENET, V74, P20, DOI 10.1086/380912
   Jakobsdottir J, 2005, AM J HUM GENET, V77, P389, DOI 10.1086/444437
   Johnson LV, 2004, NEW ENGL J MED, V351, P320, DOI 10.1056/NEJMp048131
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Kenealy SJ, 2004, MOL VIS, V10, P57
   KILLINGSWORTH MC, 1990, EYE, V4, P613, DOI 10.1038/eye.1990.86
   Kimura K, 2000, AM J OPHTHALMOL, V130, P769, DOI 10.1016/S0002-9394(00)00552-3
   Klaver CCW, 1998, AM J HUM GENET, V63, P200, DOI 10.1086/301901
   Klaver CCW, 1998, ARCH OPHTHALMOL-CHIC, V116, P1646, DOI 10.1001/archopht.116.12.1646
   Klein BEK, 2001, AM J EPIDEMIOL, V154, P207, DOI 10.1093/aje/154.3.207
   Klein ML, 1998, ARCH OPHTHALMOL-CHIC, V116, P1082, DOI 10.1001/archopht.116.8.1082
   KLEIN ML, 1994, ARCH OPHTHALMOL-CHIC, V112, P932, DOI 10.1001/archopht.1994.01090190080025
   Klein R, 2005, AM J OPHTHALMOL, V140, P35, DOI 10.1016/j.ajo.2005.01.051
   Klein R, 1997, OPHTHALMOLOGY, V104, P7, DOI 10.1016/S0161-6420(97)30368-6
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Kramer F, 2000, EUR J HUM GENET, V8, P286, DOI 10.1038/sj.ejhg.5200447
   Kuehn MH, 2001, INVEST OPHTH VIS SCI, V42, P3123
   Kuroiwa S, 1999, BRIT J OPHTHALMOL, V83, P613, DOI 10.1136/bjo.83.5.613
   Lotery AJ, 2000, INVEST OPHTH VIS SCI, V41, P1291
   Magnusson KP, 2006, PLOS MED, V3, P109, DOI 10.1371/journal.pmed.0030005
   Majewski J, 2003, AM J HUM GENET, V73, P540, DOI 10.1086/377701
   MARESPERLMAN JA, 1995, ARCH OPHTHALMOL-CHIC, V113, P743, DOI 10.1001/archopht.1995.01100060069034
   MEYERS SM, 1995, AM J OPHTHALMOL, V120, P757, DOI 10.1016/S0002-9394(14)72729-1
   MEYERS SM, 1988, ARCH OPHTHALMOL-CHIC, V106, P651
   MOLD C, 1984, J IMMUNOL, V133, P882
   Mullins RF, 2000, FASEB J, V14, P835, DOI 10.1096/fasebj.14.7.835
   *NAT ADV EYE COUNC, NIH PUBL
   Pang CP, 2000, OPHTHALMOLOGICA, V214, P289, DOI 10.1159/000027506
   PIGUET B, 1993, BRIT J OPHTHALMOL, V77, P400, DOI 10.1136/bjo.77.7.400
   Reich DE, 2001, NATURE, V411, P199, DOI 10.1038/35075590
   Rivera A, 2005, HUM MOL GENET, V14, P3227, DOI 10.1093/hmg/ddi353
   Rivera A, 2000, AM J HUM GENET, V67, P800, DOI 10.1086/303090
   Santangelo Susan L, 2005, Ophthalmic Genet, V26, P61, DOI 10.1080/13816810490967944
   Sauer CG, 2001, BRIT J OPHTHALMOL, V85, P969, DOI 10.1136/bjo.85.8.969
   SCHACHAT AP, 1994, ARCH OPHTHALMOL-CHIC, V112, P500
   Schick JH, 2003, AM J HUM GENET, V72, P1412, DOI 10.1086/375500
   Schmidt S, 2006, AM J HUM GENET, V78, P852, DOI 10.1086/503822
   Schmidt S, 2005, MOL VIS, V11, P941
   Schmidt S, 2004, BMC GENET, V5, DOI 10.1186/1471-2156-5-18
   Schmidt S, 2003, INVEST OPHTH VIS SCI, V44, P2868, DOI 10.1167/iovs.02-0957
   Schmidt S, 2000, MOL VIS, V6, P287
   Schmidt Silke, 2002, Ophthalmic Genet, V23, P209, DOI 10.1076/opge.23.4.209.13883
   Schultz DW, 2003, ARCH OPHTHALMOL-CHIC, V121, P679, DOI 10.1001/archopht.121.5.679
   Schultz DW, 2003, HUM MOL GENET, V12, P3315, DOI 10.1093/hmg/ddg348
   Seddon JM, 2006, OPHTHALMOLOGY, V113, P260, DOI 10.1016/j.ophtha.2005.11.001
   Seddon JM, 2005, ARCH OPHTHALMOL-CHIC, V123, P774, DOI 10.1001/archopht.123.6.774
   Seddon JM, 2005, ARCH OPHTHALMOL-CHIC, V123, P321, DOI 10.1001/archopht.123.3.321
   Seddon JM, 2004, JAMA-J AM MED ASSOC, V291, P704, DOI 10.1001/jama.291.6.704
   Seddon JM, 2003, ARCH OPHTHALMOL-CHIC, V121, P1728, DOI 10.1001/archopht.121.12.1728
   Seddon JM, 2003, AM J HUM GENET, V73, P780, DOI 10.1086/378505
   Seddon JM, 2003, ARCH OPHTHALMOL-CHIC, V121, P785, DOI 10.1001/archopht.121.6.785
   Seddon JM, 2001, OPHTHALMOLOGY, V108, P2060, DOI 10.1016/S0161-6420(01)00777-1
   Seddon JM, 1996, JAMA-J AM MED ASSOC, V276, P1141, DOI 10.1001/jama.276.14.1141
   Seddon JM, 1997, AM J OPHTHALMOL, V123, P199, DOI 10.1016/S0002-9394(14)71036-0
   SEDDON JM, 1994, JAMA-J AM MED ASSOC, V272, P1413, DOI 10.1001/jama.272.18.1413
   Seddon JM, 2001, ARCH OPHTHALMOL-CHIC, V119, P1191, DOI 10.1001/archopht.119.8.1191
   SEDDON JM, 2006, IN PRESS HUMAN HERED
   SEDDON JM, 1994, INVEST OPHTH VIS SCI, V25, P2003
   SEDDON JM, 2006, MED RETINA, V2, P1017
   SEDDON JM, 1996, AM J HUM GENET S, V59, P388
   Sepp T, 2006, INVEST OPHTH VIS SCI, V47, P536, DOI 10.1167/iovs.05-1143
   Shastry BS, 1999, OPHTHALMOLOGICA, V213, P165, DOI 10.1159/000027413
   Shroyer NF, 2001, HUM MOL GENET, V10, P2671, DOI 10.1093/hmg/10.23.2671
   SILVESTRI G, 1994, EYE, V8, P564, DOI 10.1038/eye.1994.138
   Simonelli F, 2001, OPHTHALMIC RES, V33, P325, DOI 10.1159/000055688
   Smith W, 2000, ARCH OPHTHALMOL-CHIC, V118, P401, DOI 10.1001/archopht.118.3.401
   Snow K K, 1999, Ophthalmic Epidemiol, V6, P125, DOI 10.1076/opep.6.2.125.1558
   SOMMER A, 1991, NEW ENGL J MED, V325, P1412, DOI 10.1056/NEJM199111143252004
   Souied EH, 1998, AM J OPHTHALMOL, V125, P353, DOI 10.1016/S0002-9394(99)80146-9
   Souied EH, 2005, MOL VIS, V11, P1135
   Souied EH, 2000, INVEST OPHTH VIS SCI, V41, P244
   Stone EM, 1999, NAT GENET, V22, P199, DOI 10.1038/9722
   Stone EM, 1998, NAT GENET, V20, P328, DOI 10.1038/3798
   Stone EM, 2004, NEW ENGL J MED, V351, P346, DOI 10.1056/NEJMoa040833
   Thylefors B, 1998, AM J OPHTHALMOL, V125, P90, DOI 10.1016/S0002-9394(99)80239-6
   Tomany SC, 2004, OPHTHALMOLOGY, V111, P1280, DOI 10.1016/j.ophtha.2003.11.010
   Tou JS, 2004, FASEB J, V18, P1297, DOI 10.1096/fj.04-1862fje
   Webster AR, 2001, INVEST OPHTH VIS SCI, V42, P1179
   Weeks DE, 2000, HUM MOL GENET, V9, P1329, DOI 10.1093/hmg/9.9.1329
   Weeks DE, 2004, AM J HUM GENET, V75, P174, DOI 10.1086/422476
   Weeks DE, 2001, AM J OPHTHALMOL, V132, P682, DOI 10.1016/S0002-9394(01)01214-4
   Wong TY, 2006, OPHTHALMOLOGY, V113, P255, DOI 10.1016/j.ophtha.2005.10.048
   Zareparsi S, 2005, AM J HUM GENET, V77, P149, DOI 10.1086/431426
   Zareparsi S, 2005, HUM MOL GENET, V14, P1449, DOI 10.1093/hmg/ddi154
   Zareparsi S, 2004, INVEST OPHTH VIS SCI, V45, P1306, DOI 10.1167/iovs.03-1253
   Zurdel J, 2002, BRIT J OPHTHALMOL, V86, P214, DOI 10.1136/bjo.86.2.214
NR 138
TC 224
Z9 243
U1 0
U2 16
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0039-6257
EI 1879-3304
J9 SURV OPHTHALMOL
JI Surv. Ophthalmol.
PD JUL-AUG
PY 2006
VL 51
IS 4
BP 316
EP 363
DI 10.1016/j.survophthal.2006.05.001
PG 48
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 068HN
UT WOS:000239364100003
PM 16818082
DA 2022-11-30
ER

PT J
AU Ahmed, D
   Stattin, M
   Haas, AM
   Kickinger, S
   Gabriel, M
   Graf, A
   Krepler, K
   Ansari-Shahrezaei, S
AF Ahmed, Daniel
   Stattin, Martin
   Haas, Anna-Maria
   Kickinger, Stefan
   Gabriel, Maximilian
   Graf, Alexandra
   Krepler, Katharina
   Ansari-Shahrezaei, Siamak
TI The Diagnostic Capability of Swept Source OCT Angiography in
   Treatment-Naive Exudative Neovascular Age-Related Macular Degeneration
SO JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
AB Purpose. To evaluate the capability of swept source-optical coherence tomography angiography (SS-OCTA) in the detection and localization of treatment-naive macular neovascularization (MNV) secondary to exudative neovascular age-related macular degeneration (nAMD). Methods. In this prospective, observational case series, 158 eyes of 142 patients were diagnosed with exudative nAMD using fluorescein (FA) and indocyanine green angiography (ICGA) and evaluated by SS-OCTA in a tertiary retina center (Rudolf Foundation Hospital Vienna, Austria). The main outcome measure was the sensitivity of SS-OCTA compared to the standard multimodal imaging approach. Secondary outcome measure was the anatomic analysis of MNV in relation to the retinal pigment epithelium. Results. En-face SS-OCTA confirmed a MNV in 126 eyes (sensitivity: 79.8%), leaving 32 eyes (20.2%) undetected. In 23 of these 32 eyes (71.9%), abnormal flow in cross-sectional SS-OCTA B-scans was identified, giving an overall SS-OCTA sensitivity of 94.3%. Eyes with a pigment epithelium detachment (PED) >= 300 mu m had a smaller probability for correct MNV detection (p=0.015). Type 1 MNV showed a trend (p=0.051) towards smaller probability for the correct detection compared to all other subtypes. Other relevant factors for the nondetection of MNV in SS-OCTA were image artifacts present in 3 of 32 eyes (9.4%). SS-OCTA confirmed the anatomic localization of 93 in 126 MNVs as compared to FA (sensitivity: 73.8%). There was no influence of age, gender, pseudophakia, visual acuity, central foveal thickness, or subfoveal choroidal thickness on the detection rate of MNV. Conclusions. SS-OCTA remains inferior to dye-based angiography in the detection rate of exudative nAMD consistent with type 1 MNV and a PED >= 300 mu m. The capability to combine imaging modalities and distinguish the respective MNV subtype improves its diagnostic value.
C1 [Ahmed, Daniel; Stattin, Martin; Haas, Anna-Maria; Kickinger, Stefan; Gabriel, Maximilian; Krepler, Katharina; Ansari-Shahrezaei, Siamak] Rudolf Fdn Hosp, Karl Landsteiner Inst Retinal Res & Imaging, Juchgasse 25, A-1030 Vienna, Austria.
   [Ahmed, Daniel; Stattin, Martin; Haas, Anna-Maria; Krepler, Katharina; Ansari-Shahrezaei, Siamak] Rudolf Fdn Hosp, Dept Ophthalmol, Juchgasse 25, A-1030 Vienna, Austria.
   [Gabriel, Maximilian; Ansari-Shahrezaei, Siamak] Med Univ Graz, Dept Ophthalmol, Auenbruggerpl 1, A-8036 Graz, Austria.
   [Graf, Alexandra] Med Univ Vienna, Ctr Med Stat Informat & Intelligent Syst, Spitalgasse 23, A-1090 Vienna, Austria.
C3 Medical University of Graz; Medical University of Vienna
RP Ansari-Shahrezaei, S (通讯作者)，Rudolf Fdn Hosp, Karl Landsteiner Inst Retinal Res & Imaging, Juchgasse 25, A-1030 Vienna, Austria.; Ansari-Shahrezaei, S (通讯作者)，Rudolf Fdn Hosp, Dept Ophthalmol, Juchgasse 25, A-1030 Vienna, Austria.; Ansari-Shahrezaei, S (通讯作者)，Med Univ Graz, Dept Ophthalmol, Auenbruggerpl 1, A-8036 Graz, Austria.
EM daniel.ahmed@wienkav.at; martin.stattin@wienkav.at;
   anna-maria.haas@wienkav.at; stefan.kickinger@hotmail.com;
   maximilian.gabriel@medunigraz.at; alexandra.graf@meduniwien.ac.at;
   katharina.krepler@wienkav.at; siamak.ansari-shahrezaei@wienkav.at
OI Graf, Alexandra/0000-0003-0035-2658; Gabriel,
   Maximilian/0000-0002-3329-5779; Ansari Shahrezaei,
   Siamak/0000-0001-8032-4686
CR Ahmed D, 2018, RETINA-J RET VIT DIS, V38, P2143, DOI 10.1097/IAE.0000000000001832
   Cheung CMG, 2019, RETINA-J RET VIT DIS, V39, P1655, DOI 10.1097/IAE.0000000000002228
   Cole ED, 2016, RETINA-J RET VIT DIS, V36, pS83, DOI 10.1097/IAE.0000000000001338
   Corvi F, 2021, GRAEF ARCH CLIN EXP, V259, P291, DOI 10.1007/s00417-020-04821-6
   Corvi F, 2020, RETINA-J RET VIT DIS, V40, P873, DOI 10.1097/IAE.0000000000002471
   Dansingani KK, 2018, CLIN EXP OPHTHALMOL, V46, P189, DOI 10.1111/ceo.13114
   Do DV, 2013, CURR OPIN OPHTHALMOL, V24, P244, DOI 10.1097/ICU.0b013e32835fd7dd
   Endersid C, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0210505
   Falavarjani KG, 2017, BRIT J OPHTHALMOL, V101, P564, DOI 10.1136/bjophthalmol-2016-309104
   Faridi A, 2017, OPHTHALMOL RETINA, V1, P294, DOI 10.1016/j.oret.2017.02.007
   Freund KB, 2008, RETINA-J RET VIT DIS, V28, P201, DOI 10.1097/IAE.0b013e3181669504
   Freund KB, 2010, RETINA-J RET VIT DIS, V30, P1333, DOI 10.1097/IAE.0b013e3181e7976b
   Fujita A, 2020, RETINA-J RET VIT DIS, V40, P2296, DOI 10.1097/IAE.0000000000002760
   Haas AM, 2021, ACTA OPHTHALMOL, V99, pE260, DOI 10.1111/aos.14572
   Hartnett ME, 1996, OPHTHALMOLOGY, V103, P2042, DOI 10.1016/S0161-6420(96)30389-8
   Holz FG, 2017, OPHTHALMOLOGY, V124, P464, DOI 10.1016/j.ophtha.2016.12.002
   Inoue M, 2016, INVEST OPHTH VIS SCI, V57, pOCT314, DOI 10.1167/iovs.15-18900
   Jia YL, 2012, OPT EXPRESS, V20, P4710, DOI 10.1364/OE.20.004710
   Kashani AH, 2017, PROG RETIN EYE RES, V60, P66, DOI 10.1016/j.preteyeres.2017.07.002
   Li ML, 2019, OPHTHALMOL RETINA, V3, P99, DOI 10.1016/j.oret.2018.08.008
   Makita S, 2006, OPT EXPRESS, V14, P7821, DOI 10.1364/OE.14.007821
   Miller AR, 2017, INVEST OPHTH VIS SCI, V58, P1499, DOI 10.1167/iovs.16-20969
   Motulsky EH, 2018, OSLI RETINA, V49, P878, DOI 10.3928/23258160-20181101-09
   Mrejen S, 2019, RETINA-J RET VIT DIS, V39, P1973, DOI 10.1097/IAE.0000000000002244
   Novais EA, 2016, AM J OPHTHALMOL, V164, P80, DOI 10.1016/j.ajo.2016.01.011
   Perrott-Reynolds R, 2019, EYE, V33, P274, DOI 10.1038/s41433-018-0229-6
   Spaide RF, 2020, OPHTHALMOLOGY, V127, P616, DOI 10.1016/j.ophtha.2019.11.004
   Spaide RF, 2018, RETINA-J RET VIT DIS, V38, P891, DOI 10.1097/IAE.0000000000001732
   Spaide RF, 2018, PROG RETIN EYE RES, V64, P1, DOI 10.1016/j.preteyeres.2017.11.003
   Stanga PE, 2016, DEV OPHTHALMOL, V56, P13, DOI 10.1159/000442771
   Su GL, 2017, CLIN OPHTHALMOL, V11, P889, DOI 10.2147/OPTH.S135479
   Tan ACS, 2018, RETINA-J RET VIT DIS, V38, P1759, DOI 10.1097/IAE.0000000000002016
   Told R, 2016, SCI REP-UK, V6, DOI 10.1038/srep38132
   Told R, 2018, INVEST OPHTH VIS SCI, V59, P2393, DOI 10.1167/iovs.17-22902
   Wang R, 2019, BMC OPHTHALMOL, V19, DOI 10.1186/s12886-019-1163-5
   Yeo JH, 2019, J CLIN MED, V8, DOI 10.3390/jcm8091272
   Zhang QQ, 2017, INVEST OPHTH VIS SCI, V58, P1506, DOI 10.1167/iovs.16-20977
NR 37
TC 1
Z9 1
U1 0
U2 1
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 2090-004X
EI 2090-0058
J9 J OPHTHALMOL
JI J. Ophthalmol.
PD FEB 16
PY 2021
VL 2021
AR 6695918
DI 10.1155/2021/6695918
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA QR5QV
UT WOS:000625272400002
PM 34513087
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Flaxel, C
   Schain, MB
   Hamon, SC
   Francis, PJ
AF Flaxel, Christina
   Schain, Mitchell B.
   Hamon, Sara C.
   Francis, Peter J.
TI PROSPECTIVE RANDOMIZED CONTROLLED TRIAL OF COMBINATION RANIBIZUMAB
   (LUCENTIS) AND BROMFENAC (XIBROM) FOR NEOVASCULAR AGE-RELATED MACULAR
   DEGENERATION A Pilot Study
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE AMD; VEGF; treatment; ranibizumab; nonsteroidal antiinflammatory agent;
   bromfenac; clinical trial
ID THERAPY; 0.09-PERCENT; DISEASES; EDEMA; VEGF
AB Purpose: To evaluate whether bromfenac eyedrops and ranibizumab intravitreal injections would provide added efficacy over ranibizumab alone.
   Methods: This was a single-site, multiinvestigator, prospective, open-label, interventional, Phase II study of patients with new or recurrent exudative/neovascular age-related macular degeneration. Thirty eyes were enrolled consecutively and were randomized in a ratio of 2: 1 to combination therapy with intravitreal ranibizumab and topical bromfenac, and ranibizumab alone. All patients received ranibizumab monthly therapy for 4 months then as needed monthly in accordance with standard of care. Patients receiving bromfenac self-administered 1 drop twice a day for 12 months. Patients were followed for 12 months.
   Results: There were no safety concerns with the combination therapy. No statistically significant differences were identified in Early Treatment Diabetic Retinopathy Study best-corrected visual acuity or the number of injections required. However, the mean 12-month change in central macular thickness in the combination group was -81.56 mu m while in the ranibizumab group alone the change was -42.50 mu m (P = 0.03). The proportion of eyes experiencing a decrease in CMT of 50 mu m or more was also significantly higher in those receiving combination therapy (P = 0.046).
   Conclusion: This pilot study is the first to prospectively identify a biologic signal that may indicate combination therapy with an easily administered well-tolerated eyedrop and ranibizumab is efficacious for the treatment of neovascular age-related macular degeneration. Further studies are warranted to validate this finding. RETINA 32: 417-423, 2012
C1 [Flaxel, Christina; Schain, Mitchell B.; Francis, Peter J.] Oregon Hlth & Sci Univ, Macular Degenerat Ctr, Casey Eye Inst, Portland, OR 97239 USA.
   [Hamon, Sara C.] Rockefeller Univ, Dept Stat Genet, New York, NY 10021 USA.
C3 Oregon Health & Science University; Rockefeller University
RP Francis, PJ (通讯作者)，Oregon Hlth & Sci Univ, Macular Degenerat Ctr, Casey Eye Inst, 3375 SW Terwilliger Blvd, Portland, OR 97239 USA.
EM francisp@ohsu.edu
FU Genentech Inc, San Francisco, CA; Foundation Fighting Blindness;
   Research to Prevent Blindness USA
FX Study was supported by an individual investigator award from the
   Genentech Inc, San Francisco, CA (P. J. F.), and by the Career
   Development Awards from the Foundation Fighting Blindness (P. J. F.) and
   the Research to Prevent Blindness USA (P.J.F.).
CR Augustin AJ, 2009, EXPERT OPIN THER TAR, V13, P641, DOI 10.1517/14728220902942322
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57
   Browning DJ, 2007, OPHTHALMOLOGY, V114, P525, DOI 10.1016/j.ophtha.2006.06.052
   Chang TS, 2007, ARCH OPHTHALMOL-CHIC, V125, P1460, DOI 10.1001/archopht.125.11.1460
   Constable I, 2005, EXPERT OPIN BIOL TH, V5, P1373, DOI 10.1517/14712598.5.10.1373
   DAMICO DJ, 1994, NEW ENGL J MED, V331, P95, DOI 10.1056/NEJM199407143310207
   Donoso LA, 2010, SURV OPHTHALMOL, V55, P227, DOI 10.1016/j.survophthal.2009.11.001
   Eichler W, 2006, CURR PHARM DESIGN, V12, P2645, DOI 10.2174/138161206777698729
   Eter N, 2006, BIODRUGS, V20, P167, DOI 10.2165/00063030-200620030-00004
   Ferrara N, 2006, RETINA-J RET VIT DIS, V26, P859, DOI 10.1097/01.iae.0000242842.14624.e7
   Heier JS, 2009, RETINA-J RET VIT DIS, V29, P1310, DOI 10.1097/IAE.0b013e3181b094e6
   Jones J, 2009, EXPERT OPIN PHARMACO, V10, P2379, DOI 10.1517/14656560903188425
   Kim SJ, 2010, EXP EYE RES, V91, P537, DOI 10.1016/j.exer.2010.07.011
   Kiss CG, 2009, INVEST OPHTH VIS SCI, V50, P2376, DOI 10.1167/iovs.08-2017
   NLME: Linear and Nonlinear Mixed Effects Models, 2008, NLME LINEAR NONLINEA, P1
   Ozkiris A, 2010, EXPERT OPIN THER PAT, V20, P103, DOI 10.1517/13543770902762885
   Rajappa M, 2010, ADV CLIN CHEM, V50, P103, DOI 10.1016/S0065-2423(10)50006-4
   Rosenfeld Philip J, 2006, Ophthalmol Clin North Am, V19, P361
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Team RDC, 2009, R LANG ENV STAT COMP
   Warren KA, 2010, RETINA-J RET VIT DIS, V30, P260, DOI 10.1097/IAE.0b013e3181b8628e
   Zweifel SA, 2009, RETINA-J RET VIT DIS, V29, P1527, DOI 10.1097/IAE.0b013e3181b32f4c
NR 23
TC 30
Z9 33
U1 0
U2 4
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0275-004X
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD MAR
PY 2012
VL 32
IS 3
BP 417
EP 423
DI 10.1097/IAE.0b013e318229b0af
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 900RU
UT WOS:000300907200002
PM 21862953
DA 2022-11-30
ER

PT J
AU Thibaut, M
   Boucart, M
   Tran, THC
AF Thibaut, Miguel
   Boucart, Muriel
   Thi Ha Chau Tran
TI Object search in neovascular age-related macular degeneration: the
   crowding effect
SO CLINICAL AND EXPERIMENTAL OPTOMETRY
LA English
DT Article
DE anti-VEGF; neovascular age-related macular degeneration; object
   perception; visual search
ID INTRAVITREAL RANIBIZUMAB; SCENE PERCEPTION; VISION; PEOPLE;
   CATEGORIZATION; IDENTIFICATION; PERFORMANCE; PREVALENCE; ATTENTION;
   IMPACT
AB Background Visual search, an activity that relies on central vision, is frequent in daily life. This study investigates the effect of spacing between items in an object search task in participants with central vision loss. Methods Patients with neovascular age-related macular degeneration (AMD), age-matched controls, and young controls were included. The stimuli were displays of four, six and nine objects randomly presented in a 'crowded' (spacing 1.5 degrees) or 'uncrowded' (spacing 6 degrees) condition. For each of 96 trials, participants were asked to search for a predefined target that remained on the screen until the response was recorded. Accuracy, search time, and eye movements (number of fixations and scan path ratio) were recorded. Results Compared to older controls, accuracy decreased by 31 per cent and search time increased by 61 per cent in AMD participants. Ageing also affected performance with a lower accuracy by 13.5 per cent and longer search times by 46 per cent in older compared to younger controls. Increasing the spacing between elements increased accuracy by 21 per cent in AMD participants but it had no effect in older and younger controls. Performance was not related to visual acuity or to duration of neovascular AMD, but search time was correlated to the lesion size in the 'crowded' condition. Conclusions Object search is ubiquitous in daily life activities. When visual acuity is irrevocably reduced, increasing the spacing between elements can reliably improve object search performance in patients.
C1 [Thibaut, Miguel; Boucart, Muriel] Univ Lille, SCALab, Natl Ctr Sci Res, Lille, France.
   [Thi Ha Chau Tran] Catholic Univ Lille, Ophthalmol Dept, Lille Catholic Hosp, Lille, France.
C3 Universite de Lille - ISITE; Universite de Lille
RP Thi, HCT (通讯作者)，Catholic Univ Lille, Ophthalmol Dept, Lille Catholic Hosp, Lille, France.
EM tran.hachau@ghicl.net
RI TRAN, Thi Ha Chau/AAF-2162-2020
OI TRAN, Thi Ha Chau/0000-0001-9066-7092
CR Altaweel MM, 2015, OPHTHALMOLOGY, V122, P391, DOI 10.1016/j.ophtha.2014.08.020
   Bellmann C, 2004, OPHTHALMOLOGY, V111, P2265, DOI 10.1016/j.ophtha.2004.06.019
   Blackmore-Wright S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0080325
   Boucart M, 2015, INVEST OPHTH VIS SCI, V56, P6832, DOI 10.1167/iovs.15-16758
   Boucart M, 2013, INVEST OPHTH VIS SCI, V54, P1950, DOI 10.1167/iovs.12-9680
   Boulanger-Scemama E, 2016, J FR OPHTALMOL, V39, P668, DOI 10.1016/j.jfo.2016.06.001
   BOUMA H, 1970, NATURE, V226, P177, DOI 10.1038/226177a0
   Brockmole JR, 2006, Q J EXP PSYCHOL, V59, P1177, DOI 10.1080/17470210600665996
   Buckle M, 2015, EYE, V29, P403, DOI 10.1038/eye.2014.296
   Calabrese A, 2010, INVEST OPHTH VIS SCI, V51, P1247, DOI 10.1167/iovs.09-3682
   Cohen SY, 2012, RETINA-J RET VIT DIS, V32, P1480, DOI 10.1097/IAE.0b013e318240a516
   Corveleyn X, 2018, OPTOMETRY VISION SCI, V95, P171, DOI 10.1097/OPX.0000000000001189
   Crabb DP, 2017, BEHAV BRAIN SCI, V40, P23, DOI 10.1017/S0140525X16000054
   Crossland MD, 2004, VISION RES, V44, P1537, DOI 10.1016/j.visres.2004.01.006
   Crossland MD, 2011, RETINA-J RET VIT DIS, V31, P2109, DOI 10.1097/IAE.0b013e31820d3fba
   Danis RP, 2015, CLIN OPHTHALMOL, V9, P2159, DOI 10.2147/OPTH.S92359
   Eckstein MP, 2011, J VISION, V11, DOI 10.1167/11.5.14
   Fragiotta S, 2018, OPTOMETRY VISION SCI, V95, P384, DOI 10.1097/OPX.0000000000001201
   Gaffney AJ, 2014, OPHTHAL PHYSL OPT, V34, P427, DOI 10.1111/opo.12132
   Geringswald F, 2013, J VISION, V13, DOI 10.1167/13.3.28
   Grunwald JE, 2015, OPHTHALMOLOGY, V122, P809, DOI 10.1016/j.ophtha.2014.11.007
   Hahn S, 2018, AGING NEUROPSYCHOL C, V25, P535, DOI 10.1080/13825585.2017.1344185
   Klein R, 2011, ARCH OPHTHALMOL-CHIC, V129, P75, DOI 10.1001/archophthalmol.2010.318
   Kuyk TK, 2005, VISION RES, V45, P3224, DOI 10.1016/j.visres.2005.07.019
   Lenoble Q, 2015, OPTOMETRY VISION SCI, V92, P986, DOI 10.1097/OPX.0000000000000694
   Mack SC, 2011, J VISION, V11, DOI 10.1167/11.9.9
   MacKeben M, 2011, INVEST OPHTH VIS SCI, V52, P7603, DOI 10.1167/iovs.10-6728
   Mangione CM, 1998, ARCH OPHTHALMOL-CHIC, V116, P1496, DOI 10.1001/archopht.116.11.1496
   MATCHAR DB, 2006, MEASURING QUALITY LI
   Querques G, 2012, GRAEF ARCH CLIN EXP, V250, P479, DOI 10.1007/s00417-011-1831-5
   Sarwar S, 2016, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD011346.pub2
   Senra H, 2016, GRAEF ARCH CLIN EXP, V254, P1873, DOI 10.1007/s00417-016-3384-0
   Solomon SD, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005139.pub3
   Stormer VS, 2013, J COGNITIVE NEUROSCI, V25, P188, DOI 10.1162/jocn_a_00303
   Taylor DJ, 2017, INVEST OPHTH VIS SCI, V58, P1887, DOI 10.1167/iovs.16-21122
   Taylor DJ, 2016, BMJ OPEN, V6, DOI 10.1136/bmjopen-2016-011504
   Tran THC, 2017, J OPHTHALMOL, V2017, DOI 10.1155/2017/8984313
   Tran THC, 2014, OPTOMETRY VISION SCI, V91, P1012, DOI 10.1097/OPX.0000000000000313
   Thi HCT, 2011, OPHTHAL SURG LAS IM, V42, P498, DOI 10.3928/15428877-20110804-04
   Thi HCT, 2012, OPTOMETRY VISION SCI, V89, P419, DOI 10.1097/OPX.0b013e31824c3a21
   Thi HCT, 2011, INVEST OPHTH VIS SCI, V52, P1655, DOI 10.1167/iovs.10-6003
   Thi HCT, 2010, INVEST OPHTH VIS SCI, V51, P6868, DOI 10.1167/iovs.10-5517
   Thibaut M, 2016, J FR OPHTALMOL, V39, P82, DOI 10.1016/j.jfo.2015.08.010
   Thibaut M, 2018, CLIN EXP OPTOM, V101, P372, DOI 10.1111/cxo.12644
   Thibaut M, 2015, OPHTHAL PHYSL OPT, V35, P336, DOI 10.1111/opo.12201
   Thibaut M, 2014, VISION RES, V98, P46, DOI 10.1016/j.visres.2014.03.004
   Tran THC, 2012, J FR OPHTALMOL, V35, P58, DOI 10.1016/j.jfo.2011.08.002
   Wallace JM, 2017, J VISION, V17, DOI 10.1167/17.1.33
   Yuzawa M, 2013, CLIN OPHTHALMOL, V7, P1325, DOI 10.2147/OPTH.S45248
NR 49
TC 3
Z9 3
U1 0
U2 3
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 0816-4622
EI 1444-0938
J9 CLIN EXP OPTOM
JI Clin. Exp. Optom.
PD SEP
PY 2020
VL 103
IS 5
BP 648
EP 655
DI 10.1111/cxo.12982
EA NOV 2019
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA NE0US
UT WOS:000494926700001
PM 31698519
OA Green Submitted
DA 2022-11-30
ER

PT J
AU Enseleit, F
   Michels, S
   Sudano, I
   Stahel, M
   Zweifel, S
   Schlager, O
   Becker, M
   Winnik, S
   Nagele, M
   Flammer, AJ
   Neidhart, M
   Graf, N
   Matter, CM
   Seifert, B
   Luscher, TF
   Ruschitzka, F
AF Enseleit, Frank
   Michels, Stephan
   Sudano, Isabella
   Stahel, Marc
   Zweifel, Sandrine
   Schlager, Oliver
   Becker, Matthias
   Winnik, Stephan
   Nagele, Matthias
   Flammer, Andreas J.
   Neidhart, Michel
   Graf, Nicole
   Matter, Christian M.
   Seifert, Burkhardt
   Luscher, Thomas F.
   Ruschitzka, Frank
TI SAVE-AMD: Safety of VEGF Inhibitors in Age-Related Macular Degeneration
SO OPHTHALMOLOGICA
LA English
DT Article
DE Age-related macular degeneration; Endothelial function; Vascular
   endothelial growth factor; Clinical trial; Ranibizumab; Bevacizumab
ID ENDOTHELIAL GROWTH-FACTOR; VERTEPORFIN PHOTODYNAMIC THERAPY;
   MYOCARDIAL-INFARCTION; INTRAVITREAL BEVACIZUMAB; METHODOLOGICAL ISSUES;
   ARTERIAL STIFFNESS; RANIBIZUMAB; RISK; PHARMACOKINETICS; DYSFUNCTION
AB Objective: To determine whether intraocular treatment with vascular endothelial growth factor (VEGF) inhibitors change systemic endothelial function (EF) in patients with neovascular age-related macular degeneration (AMD). Methods: In this prospective, randomized, 2-center, double-masked controlled interventional trial, patients with neovascular and dry AMD were enrolled. Eligible neovascular AMD patients received 2 intravitreal loading doses of either ranibizumab 0.5 mg or bevacizumab 1.25 mg at 4-week intervals and were subsequently followed every 4 weeks and treated according to a pro re nata regime for up to 1 year. Patients with dry AMD served as controls. The primary endpoint was the change in EF assessed by flow-mediated dilatation (FMD) after 2 months of treatment with VEGF inhibitors in patients with AMD compared to patients with dry AMD. FMD was assessed with B-mode high-resolution ultrasonography of the left brachial artery. Results: 24 patients with neovascular AMD and 26 patients with dry ADM were included in the trial. Treatment with VEGF inhibitors did not significantly change FMD (from 4.7 +/- 2.4 to 3.9 +/- 1.9% after 8 weeks, p = 0.07, and to 5.1 +/- 2.0% after 1 year; p = 0.93 vs. baseline, respectively). Conclusions: EF did not significantly differ between patients with neovascular AMD treated with intravitreal VEGF inhibition and patients with dry AMD. (C) 2017 The Author(s) Published by S. Karger AG, Basel
C1 [Michels, Stephan; Stahel, Marc; Becker, Matthias] City Hosp Triemli Zurich, Dept Ophthalmol, Zurich, Switzerland.
   [Enseleit, Frank; Sudano, Isabella; Schlager, Oliver; Winnik, Stephan; Nagele, Matthias; Flammer, Andreas J.; Matter, Christian M.; Luscher, Thomas F.; Ruschitzka, Frank] Univ Heart Ctr, Dept Cardiol, Zurich, Switzerland.
   [Zweifel, Sandrine] Univ Hosp Zurich, Dept Ophthalmol, Zurich, Switzerland.
   [Neidhart, Michel] Univ Hosp Zurich, Clin Rheumatol, Zurich, Switzerland.
   [Seifert, Burkhardt] Univ Zurich, Biostat Dept, Epidemiol Biostat & Prevent Inst, Zurich, Switzerland.
   [Graf, Nicole] Graf Biostat, Winterthur, Switzerland.
C3 Triemli Hospital; University of Zurich; University Zurich Hospital;
   University of Zurich; University Zurich Hospital; University of Zurich
RP Enseleit, F (通讯作者)，Univ Heart Ctr, Ramistr 100, CH-8091 Zurich, Switzerland.
EM frank.enseleit@usz.ch
RI Becker, Matthias/A-8733-2014; Zweifel, Sandrine/AAX-5045-2020; Flammer,
   Andreas/AAJ-1328-2021; , isabella/AAK-5483-2020
OI Seifert, Burkhardt/0000-0002-5829-2478; Winnik,
   Stephan/0000-0002-1277-5132; Neidhart, Michel/0000-0002-9656-5967
FU Swiss National Science Foundation [32003B_130840]; Swiss Heart
   Foundation; Werner H. Spross Foundation for Ophthalmology; Bandung
   Foundation; Austrian Science Fund - FWF (Erwin Schrodinger Stipendium)
   [J3559-B23]
FX Funded by a Swiss National Science Foundation Grant (32003B_130840), the
   Swiss Heart Foundation, the Werner H. Spross Foundation for
   Ophthalmology, the Bandung Foundation, and the Austrian Science Fund -
   FWF (Erwin Schrodinger Stipendium J3559-B23 to O. Schlager). The funding
   sources had no influence on the design and conduct of the study;
   collection, management, analysis, and interpretation of the data; and
   preparation, review, or approval of the manuscript. The foundation for
   research of the Department of Ophthalmology at the City Hospital Triemli
   Zurich has received reimbursement for research, consultancy work, and
   presentations of Stephan Michels on behalf of Novartis and Bayer. T.F.
   Luscher has received educational and research grants from Bayer Health
   Care, Berlin, Germany, and Pfizer Inc., New York, NY, USA, unrelated to
   this project. The other authors report no conflict of interest in
   connection with this paper.
CR Algvere PV, 2008, ACTA OPHTHALMOL, V86, P482, DOI 10.1111/j.1600-0420.2007.01113.x
   ALTMAN R, 1994, BMJ-BRIT MED J, V308, P81, DOI 10.1136/bmj.308.6921.81
   Bakri SJ, 2007, OPHTHALMOLOGY, V114, P855, DOI 10.1016/j.ophtha.2007.01.017
   Bashshur ZF, 2006, AM J OPHTHALMOL, V142, P1, DOI 10.1016/j.ajo.2006.02.037
   Bloch SB, 2012, AM J OPHTHALMOL, V153, P209, DOI 10.1016/j.ajo.2011.10.016
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   Casparis H, 2014, RETINA-J RET VIT DIS, V34, P12, DOI 10.1097/IAE.0b013e31829f74b0
   Chakravarthy U, 2014, INVEST OPHTH VIS SCI, V55
   Chakravarthy U, 2013, LANCET, V382, P1258, DOI 10.1016/S0140-6736(13)61501-9
   Chakravarthy U, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.04.015
   Chenevard R, 2003, CIRCULATION, V107, P405, DOI 10.1161/01.CIR.0000051361.69808.3A
   Davis MD, 2005, ARCH OPHTHALMOL-CHIC, V123, P1484
   Deanfield J, 2005, J HYPERTENS, V23, P7, DOI 10.1097/00004872-200501000-00004
   Duan YK, 2007, OPHTHALMOLOGY, V114, P732, DOI 10.1016/j.ophtha.2006.07.045
   Enseleit F, 2009, BR J CARDIOL, V16, pS3
   Faita F, 2011, J HYPERTENS, V29, P85, DOI 10.1097/HJH.0b013e32833fc938
   Ferrara N, 2005, BIOCHEM BIOPH RES CO, V333, P328, DOI 10.1016/j.bbrc.2005.05.132
   Gaudreault J, 2005, INVEST OPHTH VIS SCI, V46, P726, DOI 10.1167/iovs.04-0601
   Gemignani V, 2008, ULTRASOUND MED BIOL, V34, P385, DOI 10.1016/j.ultrasmedbio.2007.08.006
   Gemignani V, 2007, IEEE T MED IMAGING, V26, P393, DOI 10.1109/TMI.2006.891477
   Heier JS, 2006, ARCH OPHTHALMOL-CHIC, V124, P1532, DOI 10.1001/archopht.124.11.1532
   Inai T, 2004, AM J PATHOL, V165, P35, DOI 10.1016/S0002-9440(10)63273-7
   Infanger M, 2007, CARDIOVASC PATHOL, V16, P291, DOI 10.1016/j.carpath.2007.04.001
   Kamba T, 2006, AM J PHYSIOL-HEART C, V290, pH560, DOI 10.1152/ajpheart.00133.2005
   Kemp A, 2013, RETINA-J RET VIT DIS, V33, P920, DOI 10.1097/IAE.0b013e318276e07b
   Kodjikian L, 2013, OPHTHALMOLOGY, V120, P2300, DOI 10.1016/j.ophtha.2013.06.020
   Krebs I, 2013, BRIT J OPHTHALMOL, V97, P266, DOI 10.1136/bjophthalmol-2012-302391
   Lalwani GA, 2009, AM J OPHTHALMOL, V148, P43, DOI 10.1016/j.ajo.2009.01.024
   Laurent S, 2006, EUR HEART J, V27, P2588, DOI 10.1093/eurheartj/ehl254
   Levey AS, 1999, ANN INTERN MED, V130, P461, DOI 10.7326/0003-4819-130-6-199903160-00002
   Mancia G, 2007, EUR HEART J, V28, P1462, DOI [10.1093/eurheartj/ehm236, 10.1093/eurheartj/eht151]
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   MELLION BT, 1983, MOL PHARMACOL, V23, P653
   Moja L, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD011230.pub2
   Pannier BM, 2002, AM J HYPERTENS, V15, P743, DOI 10.1016/S0895-7061(02)02962-X
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rosengart TK, 1999, CIRCULATION, V100, P468, DOI 10.1161/01.CIR.100.5.468
   Schachinger V, 2000, CIRCULATION, V101, P1899, DOI 10.1161/01.CIR.101.16.1899
   Semeraro F, 2014, EXPERT OPIN DRUG SAF, V13, P785, DOI 10.1517/14740338.2014.911284
   Solomon SD, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005139.pub3
   Sudano I, 2010, CIRCULATION, V122, P1789, DOI 10.1161/CIRCULATIONAHA.110.956490
   Tufail A, 2010, BMJ-BRIT MED J, V340, DOI 10.1136/bmj.c2459
   Tziros C, 2006, CURR DRUG TARGETS, V7, P1243, DOI 10.2174/138945006778559111
   Ueta T, 2009, OPHTHALMOLOGY, V116, P362, DOI 10.1016/j.ophtha.2008.09.046
   Williams B, 2012, J HYPERTENS, V30, pS13, DOI 10.1097/HJH.0b013e328353e523
   Winnik S, 2013, INT J CARDIOL, V168, P2453, DOI 10.1016/j.ijcard.2013.03.010
   Wong TY, 2007, LANCET, V370, P204, DOI 10.1016/S0140-6736(07)61104-0
   Wong TY, 2006, ANN INTERN MED, V145, P98, DOI 10.7326/0003-4819-145-2-200607180-00007
   YANNUZZI LA, 1992, ARCH OPHTHALMOL-CHIC, V110, P1701
   Yashkin AP, 2016, OPHTHALMOLOGY, V123, P2225, DOI 10.1016/j.ophtha.2016.06.053
   Zlokovic BV, 2006, NAT MED, V12, P390, DOI 10.1038/nm0406-390
NR 52
TC 9
Z9 9
U1 0
U2 1
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 0030-3755
EI 1423-0267
J9 OPHTHALMOLOGICA
JI Ophthalmologica
PY 2017
VL 238
IS 4
BP 205
EP 216
DI 10.1159/000478665
PG 12
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA FK9LQ
UT WOS:000413833100004
PM 28866675
OA hybrid, Green Published, Green Accepted
DA 2022-11-30
ER

PT J
AU Chen, JS
   Adelman, RA
AF Chen, Jessica S.
   Adelman, Ron A.
TI Hyperacuity Exam Screens for Choroidal Neovascularization in Age-Related
   Macular Degeneration on a Mobile Device
SO OPHTHALMIC SURGERY LASERS & IMAGING RETINA
LA English
DT Article
ID ENDOTHELIAL GROWTH-FACTOR; DIAGNOSTIC-ACCURACY; METAANALYSIS;
   PREVALENCE; OUTCOMES
AB BACKGROUND AND OBJECTIVE: Timely treatment of age-related macular degeneration (AMD) is integral in improving outcomes. To catch choroidal neovascularization as soon as possible, patients should monitor vision at home. The objective of this study is to explore the Hyperacuity App (HAC) as a screen for progression of disease in AMD.
   PATIENTS AND METHODS: A cross-sectional, single-center study was performed with 33 subjects. Consent was obtained and patient information was protected in accordance with the protocol approved by the Yale Human Research Protection Program. A masked retinal subspecialist then graded the spectral-domain optical coherence tomography (SD-OCT) taken the same day to determine which patients required treatment. Further data about the patient were obtained through chart review.
   RESULTS: The HAC was shown to have 92.3% sensitivity and 61.5% specificity in distinguishing between patients who required treatment and those who did not require treatment.
   CONCLUSION: The HAC is a potential screen for choroidal neovascularization in AMD.
C1 [Chen, Jessica S.; Adelman, Ron A.] Yale Sch Med, New Haven, CT USA.
C3 Yale University
RP Chen, JS (通讯作者)，123 York St,Apt 3G, New Haven, CT 06511 USA.
EM jessica.chen@yale.edu
CR AMSLER M, 1947, OPHTHALMOLOGICA, V114, P248, DOI 10.1159/000300476
   [Anonymous], AG REL MAC DEG SUMM
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   Faes L, 2014, EYE, V28, P788, DOI 10.1038/eye.2014.104
   Lim JH, 2012, AM J OPHTHALMOL, V153, P678, DOI 10.1016/j.ajo.2011.09.013
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Olsen TW, 2004, OPHTHALMOLOGY, V111, P250, DOI 10.1016/j.ophtha.2003.05.030
   Peden MC, 2015, OPHTHALMOLOGY, V122, P803, DOI 10.1016/j.ophtha.2014.11.018
   Potamitis T, 2000, EYE, V14, P302, DOI 10.1038/eye.2000.77
   Raymond SM., APPLE IPAD 2 LCD DIS
   SCHUCHARD RA, 1993, ARCH OPHTHALMOL-CHIC, V111, P776, DOI 10.1001/archopht.1993.01090060064024
   Wang YZ, 2013, INVEST OPHTH VIS SCI, V54, P5497, DOI 10.1167/iovs.13-12037
   Wilde C, 2015, EYE, V29, P602, DOI 10.1038/eye.2015.44
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Wu ZC, 2015, JAMA OPHTHALMOL, V133, P442, DOI 10.1001/jamaophthalmol.2014.5963
   Zaidi FH, 2004, EYE, V18, P503, DOI 10.1038/sj.eye.6700708
NR 16
TC 2
Z9 2
U1 0
U2 5
PU SLACK INC
PI THOROFARE
PA 6900 GROVE RD, THOROFARE, NJ 08086 USA
SN 2325-8160
EI 2325-8179
J9 OSLI RETINA
JI Ophthalmic Surg. Lasers Imag. Retin.
PD AUG
PY 2016
VL 47
IS 8
BP 708
EP 715
DI 10.3928/23258160-20160808-03
PG 8
WC Ophthalmology; Surgery
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology; Surgery
GA EJ3GQ
UT WOS:000393101000003
PM 27548447
DA 2022-11-30
ER

PT J
AU Major, JC
   Wykoff, CC
   Croft, DE
   Wang, R
   Mariani, AF
   Lehmann, AE
   Brown, DM
AF Major, James C., Jr.
   Wykoff, Charles C.
   Croft, Daniel E.
   Wang, Rui
   Mariani, Angeline F.
   Lehmann, Anna E.
   Brown, David M.
TI Aflibercept for pigment epithelial detachment for previously treated
   neovascular age-related macular degeneration
SO CANADIAN JOURNAL OF OPHTHALMOLOGY-JOURNAL CANADIEN D OPHTALMOLOGIE
LA English
DT Article
ID OPTICAL COHERENCE TOMOGRAPHY; OCCULT CHOROIDAL NEOVASCULARIZATION;
   INTRAVITREAL RANIBIZUMAB; TRAP-EYE; BEVACIZUMAB; TEARS; VEGF
AB Objective: Assess the efficacy of intravitreal aflibercept on pigment epithelial detachments (RED) associated with previously treated patients with neovascular age-related macular degeneration (AMD).
   Design: Retrospective study.
   Participants: Sixty eyes.
   Methods: Patients with persistent RED who were treated with intravitreal aflibercept (2.0 mg) with >2 previous injections of bevacizumab (1.25 mg) or ranibizumab (0.5 mg) were analyzed.
   Results: Mean number of prior injections was 24.8 during a mean of 32 months of management (range 3-77 months). Baseline mean FED height was 258 mu m (range 80-687 mu m), which decreased at 1, 6, and 12 months upon switching to aflibercept to 226 pm (-14%, range 34-701 mu m), 215 pm (-18%, range 0-666 mu m), and 208 mu m (-22%, range 0-752 pm), respectively. The majority of eyes experienced a decrease in FED height after switching to aflibercept: 50/58 (86%), 38/47 (81%), and 37/47 (79%) at months 1, 6, and 12, respectively. Reduction in FED height was weakly correlated with improved visual acuity (R-2 = 0.11).
   Conclusions: Intravitreal aflibercept resulted in significant reduction in FED height in previously treated eyes with neovascular AMD.
C1 [Major, James C., Jr.; Wykoff, Charles C.; Brown, David M.] Houston Methodist Hosp, Retina Consultants Houston, Weill Cornell Med Coll, Houston, TX USA.
   [Croft, Daniel E.; Wang, Rui; Mariani, Angeline F.; Lehmann, Anna E.] Retina Consultants Houston, Houston, TX 77030 USA.
C3 Cornell University; The Methodist Hospital System; The Methodist
   Hospital - Houston
RP Wykoff, CC (通讯作者)，Retina Consultants Houston, 6560 FanninSt,Suite 750, Houston, TX 77030 USA.
EM ccwmd@houstonretina.com
OI Wang, Rui/0000-0002-0900-7714
CR Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Chan CK, 2010, RETINA-J RET VIT DIS, V30, P203, DOI 10.1097/IAE.0b013e3181babda5
   Chen E, 2007, RETINA-J RET VIT DIS, V27, P445, DOI 10.1097/01.iae.0000249574.89437.40
   Coscas F, 2007, AM J OPHTHALMOL, V144, P592, DOI 10.1016/j.ajo.2007.06.014
   Cunningham ET, 2011, OPHTHALMOLOGY, V118, P2447, DOI 10.1016/j.ophtha.2011.05.026
   Freeman WR, 2011, RETINA-J RET VIT DIS, V31, P1812, DOI 10.1097/IAE.0b013e31821987a4
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Kalouda P, 2015, SEMIN OPHTHALMOL, V30, P6, DOI 10.3109/08820538.2013.807852
   Lalwani GA, 2009, AM J OPHTHALMOL, V148, P43, DOI 10.1016/j.ajo.2009.01.024
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Nagiel A, 2013, AM J OPHTHALMOL, V156, P981, DOI 10.1016/j.ajo.2013.06.024
   Nguyen QD, 2009, OPHTHALMOLOGY, V116, P2141, DOI 10.1016/j.ophtha.2009.04.030
   Patel KH, 2013, EYE, V27, P664, DOI 10.1038/eye.2013.31
   Pepple K, 2011, SEMIN OPHTHALMOL, V26, P198, DOI 10.3109/08820538.2011.570850
   Ritter M, 2010, EYE, V24, P962, DOI 10.1038/eye.2009.265
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Stewart MW, 2012, RETINA-J RET VIT DIS, V32, P434, DOI 10.1097/IAE.0B013E31822C290F
NR 19
TC 16
Z9 16
U1 0
U2 2
PU CANADIAN OPHTHAL SOC
PI OTTAWA
PA 1525 CARLING AVE SUITE 610, OTTAWA, ONTARIO K1Z 8R9, CANADA
SN 0008-4182
EI 1715-3360
J9 CAN J OPHTHALMOL
JI Can. J. Opthalmol.-J. Can. Opthalmol.
PD OCT
PY 2015
VL 50
IS 5
BP 373
EP 377
DI 10.1016/j.jcjo.2014.12.012
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA CW0UN
UT WOS:000364705100022
PM 26455973
DA 2022-11-30
ER

PT J
AU Olsen, TW
   Feng, X
AF Olsen, TW
   Feng, X
TI The Minnesota Grading System of eye bank eyes for age-related macular
   degeneration
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
ID VISUAL IMPAIRMENT; MACULOPATHY; PREVALENCE; POPULATION; RNA
AB PURPOSE. The Minnesota Grading System (MGS) is a method to evaluate human eye bank eyes and determine the level of age-related macular degeneration (AMD), by using criteria and definitions from the Age-Related Eye Disease Study (AREDS).
   METHODS. Donor eyes ( 108 pairs) from the Minnesota Lions Eye Bank were cut circumferentially at the pars plana to remove the anterior segment. A 1000 +/- 2.5-mum ruby sphere was placed on the optic nerve as a size reference. A digital, high-resolution, color macular photograph was taken through a dissecting microscope. The neurosensory retina was removed from one globe of the pair. The underlying retinal pigment epithelium was rephotographed, localizing the fovea with a proportional triangle. A grid was superimposed in the macular photographs and images were graded according to AREDS criteria. Twenty pairs were dissected bilaterally and graded for symmetry.
   RESULTS. Eighty-eight globes were graded into one of four MGS categories. Nineteen (95%) of 20 globes had symmetric grades.
   CONCLUSIONS. The MGS provides a methodology to grade donor tissue from eye bank eyes to correspond to the AREDS classification system. Donor tissue may be used for subsequent molecular analysis, including genomics and proteomics.
C1 Univ Minnesota, Dept Ophthalmol, Minneapolis, MN 55455 USA.
C3 University of Minnesota System; University of Minnesota Twin Cities
RP Olsen, TW (通讯作者)，Univ Minnesota, Dept Ophthalmol, MMC Box 493,420 Delaware St SE, Minneapolis, MN 55455 USA.
EM olsen010@umn.edu
FU NATIONAL EYE INSTITUTE [R03EY014176] Funding Source: NIH RePORTER;
   NATIONAL INSTITUTE ON AGING [R01AG025392] Funding Source: NIH RePORTER;
   NEI NIH HHS [EY014176] Funding Source: Medline; NIA NIH HHS [R01
   AG025392, AG025392] Funding Source: Medline
CR Age-Related Eye Dis Study Res Grp, 2001, AM J OPHTHALMOL, V132, P668
   [Anonymous], 1991, OPHTHALMOLOGY, V98, P807
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Buch H, 2001, OPHTHALMOLOGY, V108, P2347, DOI 10.1016/S0161-6420(01)00823-5
   Crabb JW, 2002, P NATL ACAD SCI USA, V99, P14682, DOI 10.1073/pnas.222551899
   Curcio CA, 1998, INVEST OPHTH VIS SCI, V39, P1085
   Derham BK, 1999, PROG RETIN EYE RES, V18, P463, DOI 10.1016/S1350-9462(98)00030-5
   Gillespie JW, 2002, AM J PATHOL, V160, P449, DOI 10.1016/S0002-9440(10)64864-X
   HYMAN LG, 1983, AM J EPIDEMIOL, V118, P213, DOI 10.1093/oxfordjournals.aje.a113629
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Klaver CCW, 1998, ARCH OPHTHALMOL-CHIC, V116, P653, DOI 10.1001/archopht.116.5.653
   KLEIN BE, 1982, ARCH OPHTHALMOL-CHIC, V100, P571
   KLEIN R, 1995, INVEST OPHTH VIS SCI, V36, P182
   Klein R, 1997, OPHTHALMOLOGY, V104, P7, DOI 10.1016/S0161-6420(97)30368-6
   Klein R, 2003, OPHTHALMOLOGY, V110, P25, DOI 10.1016/S0161-6420(02)01565-8
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   Leibowitz H M, 1980, Surv Ophthalmol, V24, P335
   Louie JL, 2002, EXP EYE RES, V75, P271, DOI 10.1006/exer.2002.2022
   Malik KF, 2003, INVEST OPHTH VIS SCI, V44, P2730, DOI 10.1167/iovs.02-1120
   Masuda N, 1999, NUCLEIC ACIDS RES, V27, P4436, DOI 10.1093/nar/27.22.4436
   MITCHELL P, 1995, OPHTHALMOLOGY, V102, P1450
   OShea JG, 1996, MED J AUSTRALIA, V165, P561, DOI 10.5694/j.1326-5377.1996.tb138643.x
   Soto C, 2001, FEBS LETT, V498, P204, DOI 10.1016/S0014-5793(01)02486-3
   Wisniewski T, 1998, AMYLOID, V5, P212
NR 25
TC 58
Z9 61
U1 0
U2 0
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD DEC
PY 2004
VL 45
IS 12
BP 4484
EP 4490
DI 10.1167/iovs.04-0342
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 873GZ
UT WOS:000225269200034
PM 15557458
DA 2022-11-30
ER

PT J
AU Dang, YL
   Zhang, C
   Zhu, Y
AF Dang, Yalong
   Zhang, Chun
   Zhu, Yu
TI Stem cell therapies for age-related macular degeneration: the past,
   present, and future
SO CLINICAL INTERVENTIONS IN AGING
LA English
DT Review
DE stem cell; age-related macular degeneration; retinal pigment epithelium;
   cell reprogramming; clinical trial
ID RETINAL-PIGMENT EPITHELIUM; IN-VITRO DIFFERENTIATION; RAT MODEL; BRUCHS
   MEMBRANE; CHOROIDAL NEOVASCULARIZATION; SUBRETINAL TRANSPLANTATION;
   DIRECTED DIFFERENTIATION; TRANSLOCATION SURGERY; HUMAN FIBROBLASTS;
   VISUAL FUNCTION
AB In the developed world, age-related macular degeneration (AMD) is one of the major causes of irreversible blindness in the elderly. Although management of neovascular AMD (wet AMD) has dramatically progressed, there is still no effective treatment for nonneovascular AMD (dry AMD), which is characterized by retinal pigment epithelial (RPE) cell death (or dysfunction) and microenvironmental disruption in the retina. Therefore, RPE replacement and microenvironmental regulation represent viable treatments for dry AMD. Recent advances in cell biology have demonstrated that RPE cells can be easily generated from several cell types (pluripotent stem cells, multipotent stem cells, or even somatic cells) by spontaneous differentiation, coculturing, defined factors or cell reprogramming, respectively. Additionally, in vivo studies also showed that the restoration of visual function could be obtained by transplanting functional RPE cells into the subretinal space of recipient. More importantly, clinical trials approved by the US government have shown promising prospects in RPE transplantation. However, key issues such as implantation techniques, immune rejection, and xeno-free techniques are still needed to be further investigated. This review will summarize recent advances in cell transplantation for dry AMD. The obstacles and prospects in this field will also be discussed.
C1 [Dang, Yalong; Zhang, Chun] Peking Univ, Hosp 3, Dept Ophthalmol, Beijing 100871, Peoples R China.
   [Dang, Yalong; Zhang, Chun] Peking Univ, Hosp 3, Clin Stem Cell Res Ctr, Beijing 100871, Peoples R China.
   [Dang, Yalong; Zhu, Yu] Zhengzhou Univ, Affiliated Hosp 1, Dept Ophthalmol, Zhengzhou, Henan, Peoples R China.
C3 Peking University; Peking University; Zhengzhou University
RP Zhang, C (通讯作者)，Peking Univ, Hosp 3, Clin Stem Cell Res Ctr 2, Dept Ophthalmol, Beijing 100871, Peoples R China.
EM zhangcl@yahoo.com
RI Dang, Yalong/Q-4156-2017
OI Dang, Yalong/0000-0003-2194-6375
FU International Cooperation Project of Henan Province [2013GH11]; National
   Natural Science Foundation of China [81371017]; Key Project of Science
   Research of Henan Province Education Committee [13A320427]
FX This study was supported by the International Cooperation Project of
   Henan Province (2013GH11), the National Natural Science Foundation of
   China (No 81371017), and the Key Project of Science Research of Henan
   Province Education Committee (No 13A320427).
CR Afshari FT, 2009, EYE, V23, P1890, DOI 10.1038/eye.2008.411
   Afshari FT, 2010, BRAIN, V133, P448, DOI 10.1093/brain/awp319
   Arnhold S, 2007, GRAEF ARCH CLIN EXP, V245, P414, DOI 10.1007/s00417-006-0382-7
   Aruta C, 2011, PIGM CELL MELANOMA R, V24, P233, DOI 10.1111/j.1755-148X.2010.00793.x
   Bernardos RL, 2007, J NEUROSCI, V27, P7028, DOI 10.1523/JNEUROSCI.1624-07.2007
   Binder S, 2004, INVEST OPHTH VIS SCI, V45, P4151, DOI 10.1167/iovs.04-0118
   Brandl C, 2014, NEUROMOL MED, V16, P551, DOI 10.1007/s12017-014-8308-8
   Buchholz DE, 2013, STEM CELL TRANSL MED, V2, P384, DOI 10.5966/sctm.2012-0163
   Buchholz DE, 2009, STEM CELLS, V27, P2427, DOI 10.1002/stem.189
   Carr AJ, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0008152
   Cavelti-Weder C, 2014, METHODS MOL BIOL, V1150, P247, DOI 10.1007/978-1-4939-0512-6_17
   Chanda S, 2014, STEM CELL REP, V3, P282, DOI 10.1016/j.stemcr.2014.05.020
   Chen FK, 2010, BRIT J OPHTHALMOL, V94, P1337, DOI 10.1136/bjo.2009.172593
   Cho MS, 2012, STEM CELL RES, V9, P101, DOI 10.1016/j.scr.2012.05.002
   Cicero SA, 2009, P NATL ACAD SCI USA, V106, P6685, DOI 10.1073/pnas.0901596106
   de Juan E, 1998, AM J OPHTHALMOL, V125, P635, DOI 10.1016/S0002-9394(98)00018-X
   Del Priore LV, 1998, ARCH OPHTHALMOL-CHIC, V116, P335, DOI 10.1001/archopht.116.3.335
   Del Priore LV, 2003, INVEST OPHTH VIS SCI, V44, P4044, DOI 10.1167/iovs.02-1175
   Eiraku M, 2011, NATURE, V472, P51, DOI 10.1038/nature09941
   Falkner-Radler CI, 2011, BRIT J OPHTHALMOL, V95, P370, DOI 10.1136/bjo.2009.176305
   Fang IM, 2009, EXP EYE RES, V88, P12, DOI 10.1016/j.exer.2008.09.019
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Gelisken F, 2007, GRAEF ARCH CLIN EXP, V245, P1085, DOI 10.1007/s00417-006-0524-y
   Gong LH, 2008, CLIN EXP OPHTHALMOL, V36, P666, DOI 10.1111/j.1442-9071.2008.01857.x
   Guan Y, 2013, CURR MOL MED, V13, P1419
   Gullapalli Vamsi K, 2004, Trans Am Ophthalmol Soc, V102, P123
   GULLAPALLI VK, 2004, T AM OPHTHAL SOC, V102, P137
   Haruta M, 2004, INVEST OPHTH VIS SCI, V45, P1020, DOI 10.1167/iovs.03-1034
   HE S, 1993, GRAEF ARCH CLIN EXP, V231, P737, DOI 10.1007/BF00919290
   Hill AJ, 2009, STEM CELLS DEV, V18, P399, DOI 10.1089/scd.2008.0084
   Hirami Y, 2009, NEUROSCI LETT, V458, P126, DOI 10.1016/j.neulet.2009.04.035
   Hu QR, 2010, STEM CELLS, V28, P1981, DOI 10.1002/stem.531
   Huang C, 2012, J CELL BIOCHEM, V113, P590, DOI 10.1002/jcb.23383
   Huang LB, 2013, OCUL IMMUNOL INFLAMM, V21, P276, DOI 10.3109/09273948.2013.791925
   Huang PY, 2014, CELL STEM CELL, V14, P370, DOI 10.1016/j.stem.2014.01.003
   Idelson M, 2009, CELL STEM CELL, V5, P396, DOI 10.1016/j.stem.2009.07.002
   Ikeda H, 2005, P NATL ACAD SCI USA, V102, P11331, DOI 10.1073/pnas.0500010102
   Inoue Y, 2007, EXP EYE RES, V85, P234, DOI 10.1016/j.exer.2007.04.007
   Jonas JB, 2010, ACTA OPHTHALMOL, V88, pe131, DOI 10.1111/j.1755-3768.2009.01564.x
   Joussen AM, 2003, GRAEF ARCH CLIN EXP, V241, P966, DOI 10.1007/s00417-003-0792-8
   Joussen AM, 2006, AM J OPHTHALMOL, V142, P17, DOI 10.1016/j.ajo.2006.01.090
   Kamao H, 2014, STEM CELL REP, V2, P205, DOI 10.1016/j.stemcr.2013.12.007
   Karow M, 2014, JOVE-J VIS EXP, DOI 10.3791/51433
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Kawasaki H, 2002, P NATL ACAD SCI USA, V99, P1580, DOI 10.1073/pnas.032662199
   Klein R, 2008, OPHTHALMOLOGY, V115, P1460, DOI 10.1016/j.ophtha.2008.01.026
   Klein R, 2006, AM J OPHTHALMOL, V142, P539, DOI 10.1016/j.ajo.2006.06.015
   Klimanskaya I, 2004, CLONING STEM CELLS, V6, P217, DOI 10.1089/1536230042323420
   Kokkinaki M, 2011, STEM CELLS, V29, P825, DOI 10.1002/stem.635
   Krohne TU, 2012, STEM CELL TRANSL MED, V1, P96, DOI 10.5966/sctm.2011-0057
   Kumar A, 2005, INDIAN J MED PAED S3, V26, P12
   Lai CC, 2000, INVEST OPHTH VIS SCI, V41, P3134
   Lai JC, 2002, ARCH OPHTHALMOL-CHIC, V120, P1317, DOI 10.1001/archopht.120.10.1317
   Lamba DA, 2006, P NATL ACAD SCI USA, V103, P12769, DOI 10.1073/pnas.0601990103
   Levkovitch-Verbin H, 2010, INVEST OPHTH VIS SCI, V51, P6394, DOI 10.1167/iovs.09-4310
   Lu B, 2009, STEM CELLS, V27, P2126, DOI 10.1002/stem.149
   Lund RD, 2006, CLONING STEM CELLS, V8, P189, DOI 10.1089/clo.2006.8.189
   Machalinska A, 2013, INVEST OPHTH VIS SCI, V54, P8292, DOI 10.1167/iovs.13-12221
   MACHEMER R, 1993, GRAEF ARCH CLIN EXP, V231, P635, DOI 10.1007/BF00921957
   MacLaren RE, 2007, OPHTHALMOLOGY, V114, P561, DOI 10.1016/j.ophtha.2006.06.049
   Martin MJ, 2005, NAT MED, V11, P228, DOI 10.1038/nm1181
   Meyer JS, 2009, P NATL ACAD SCI USA, V106, P16698, DOI 10.1073/pnas.0905245106
   Osakada F, 2009, J CELL SCI, V122, P3169, DOI 10.1242/jcs.050393
   Osakada F, 2009, NAT PROTOC, V4, P811, DOI 10.1038/nprot.2009.51
   Otani A, 2004, J CLIN INVEST, V114, P765, DOI 10.1172/JCI200421686
   Park HYL, 2012, BRAIN RES, V1469, P10, DOI 10.1016/j.brainres.2012.06.006
   Park Un Chul, 2011, Clin Exp Reprod Med, V38, P216, DOI 10.5653/cerm.2011.38.4.216
   Parmeggiani F, 2012, MEDIAT INFLAMM, V2012, DOI 10.1155/2012/546786
   Raya A, 2009, NATURE, V460, P53, DOI 10.1038/nature08129
   Sakami S, 2008, MECH DEVELOP, V125, P106, DOI 10.1016/j.mod.2007.10.001
   Sakamoto N, 2007, BLOOD, V110, P501, DOI 10.1182/blood-2007-01-066522
   Schwartz SD, 2012, LANCET, V379, P713, DOI 10.1016/S0140-6736(12)60028-2
   Siqueira RC, 2011, RETINA-J RET VIT DIS, V31, P1207, DOI 10.1097/IAE.0b013e3181f9c242
   Siqueira RC, 2010, ARQ BRAS OFTALMOL, V73, P474, DOI 10.1590/S0004-27492010000500019
   Song WT, 2013, STEM CELL RES THER, V4, DOI 10.1186/scrt305
   Sun K, 2007, MOL VIS, V13, P2310
   Takahashi K, 2006, CELL, V126, P663, DOI 10.1016/j.cell.2006.07.024
   Takasato M, 2014, SEMIN NEPHROL, V34, P462, DOI 10.1016/j.semnephrol.2014.06.012
   Takeuchi K, 2012, EYE, V26, P52, DOI 10.1038/eye.2011.302
   Tezel TH, 2004, INVEST OPHTH VIS SCI, V45, P3337, DOI 10.1167/iovs.04-0193
   Tezel TH, 1999, INVEST OPHTH VIS SCI, V40, P467
   Tomita M, 2002, STEM CELLS, V20, P279, DOI 10.1634/stemcells.20-4-279
   Tropepe V, 2000, SCIENCE, V287, P2032, DOI 10.1126/science.287.5460.2032
   Tzameret A, 2014, EXP EYE RES, V118, P135, DOI 10.1016/j.exer.2013.10.023
   Vaajasaari H, 2011, MOL VIS, V17, P558
   VINGERLING JR, 1995, OPHTHALMOLOGY, V102, P205
   Vugler A, 2008, EXP NEUROL, V214, P347, DOI 10.1016/j.expneurol.2008.09.007
   Wang SM, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009200
   Wapinski OL, 2013, CELL, V155, P621, DOI 10.1016/j.cell.2013.09.028
   Westenskow PD, 2012, INVEST OPHTH VIS SCI, V53, P6282, DOI 10.1167/iovs.12-9721
   Xu W, 2013, CELL MOL NEUROBIOL, V33, P1171, DOI 10.1007/s10571-013-9983-y
   Xu W, 2013, ARQ BRAS OFTALMOL, V76, P105, DOI 10.1590/S0004-27492013000200010
   Yang N, 2013, NAT BIOTECHNOL, V31, P434, DOI 10.1038/nbt.2564
   Yu JY, 2007, SCIENCE, V318, P1917, DOI 10.1126/science.1151526
   Zhang KJ, 2014, PROTEIN CELL, V5, P48, DOI 10.1007/s13238-013-0011-2
   Zhang Y, 2010, INVEST OPHTH VIS SCI, V51, P3742, DOI 10.1167/iovs.08-3314
   Zhang YS, 2012, J ASSIST REPROD GEN, V29, P735, DOI 10.1007/s10815-012-9802-2
   Zhu Y, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0054552
NR 98
TC 21
Z9 29
U1 2
U2 47
PU DOVE MEDICAL PRESS LTD
PI ALBANY
PA PO BOX 300-008, ALBANY, AUCKLAND 0752, NEW ZEALAND
EI 1178-1998
J9 CLIN INTERV AGING
JI Clin. Interv. Aging
PY 2015
VL 10
BP 255
EP 264
DI 10.2147/CIA.S73705
PG 10
WC Geriatrics & Gerontology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Geriatrics & Gerontology
GA AY8DW
UT WOS:000347785600001
PM 25609937
OA Green Published, gold, Green Submitted
DA 2022-11-30
ER

PT J
AU Uddin, D
   Jeffrey, BG
   Flynn, O
   Wong, W
   Wiley, H
   Keenan, T
   Chew, E
   Cukras, C
AF Uddin, Durin
   Jeffrey, Brett G.
   Flynn, Oliver
   Wong, Wai
   Wiley, Henry
   Keenan, Tiarnan
   Chew, Emily
   Cukras, Catherine
TI Repeatability of Scotopic Sensitivity and Dark Adaptation Using a
   Medmont Dark-Adapted Chromatic Perimeter in Age-related Macular
   Degeneration
SO TRANSLATIONAL VISION SCIENCE & TECHNOLOGY
LA English
DT Article
DE dark adaptation; repeatability; scotopic sensitivities; retina;
   age-related macular degeneration
ID RETINITIS-PIGMENTOSA; LOW LUMINANCE; ROD; QUESTIONNAIRE; AGREEMENT; CONE
AB Purpose: Functional studies of rods in age-related macular degeneration using the Medmont Dark-Adapted Chromatic Perimeter (DACP) have demonstrated impairments in scotopic sensitivities and dark adaptation (DA). We investigated the intersession repeatability of scotopic sensitivity and DA parameters including the rod intercept time recorded from the Medmont DACP.
   Methods: Scotopic thresholds (14 test points) and DA using a 30% photobleach (eight test points) were measured on two separate days from participants 50 years of age or older with a range of age-related macular degeneration severity at loci superior and inferior to the fovea. Repeatability coefficients were calculated for prebleach scotopic sensitivity, and for DA parameters including rod intercept time.
   Results: Twelve participants (mean age, 79.7 +/- 8.1 years) repeated Medmont DACP testing within 50 days. Repeatability coefficients for prebleach scotopic sensitivity to long wavelength (red, 625 nm) and short wavelength (cyan, 505 nm) were 5.9 dB and 7.2 dB, respectively. The DA curve- derived repeatability coefficients for cone threshold was 3.9 dB, final threshold 5.3 dB, with an R value of 0.075 decades/min, rod intercept time 7.6 minutes, and RITslope 0.54 min/degree.
   Conclusions: This study establishes repeatability coefficients for scotopic thresholds and multiple DA parameters obtained with the Medmont DACP in patients with age-relatedmacular degeneration. These repeatability coefficients will serve as the basis for determining clinically meaningful change in rod function in future clinical trials.
   Translational Relevance: Measures of repeatability parameters of scotopic thresholds and DA are essential to the accurate interpretation of results in future studies and trials using these measures.
C1 [Uddin, Durin; Jeffrey, Brett G.; Flynn, Oliver; Wong, Wai; Wiley, Henry; Keenan, Tiarnan; Chew, Emily; Cukras, Catherine] NEI, NIH, Bethesda, MD 20892 USA.
C3 National Institutes of Health (NIH) - USA; NIH National Eye Institute
   (NEI)
RP Cukras, C (通讯作者)，NEI, Div Epidemiol & Clin Res, NIH, Bethesda, MD 20892 USA.; Cukras, C (通讯作者)，NEI, Ophthalm Genet & Visual Funct Branch, NIH, Bethesda, MD 20892 USA.
EM cukrasc@nei.nih.gov
FU National Eye Institute Intramural Research Program, National Institutes
   of Health (NIH), Bethesda, Maryland; NIH Medical Research Scholars
   Program; NIH; Doris Duke Charitable Foundation; American Association for
   Dental Research; Colgate-Palmolive Company; Genentech; Elsevier
FX Supported by the National Eye Institute Intramural Research Program,
   National Institutes of Health (NIH), Bethesda, Maryland; and the NIH
   Medical Research Scholars Program, a public-private partnership
   supported jointly by the NIH and generous contributions to the
   Foundation for the NIH from the Doris Duke Charitable Foundation, the
   American Association for Dental Research, the Colgate-Palmolive Company,
   Genentech, Elsevier, and other private donors.
CR Bennett LD, 2019, INVEST OPHTH VIS SCI, V60, P1122, DOI 10.1167/iovs.18-25473
   Bennett LD, 2017, TRANSL VIS SCI TECHN, V6, DOI 10.1167/tvst.6.4.15
   Bland JM, 1999, STAT METHODS MED RES, V8, P135, DOI 10.1191/096228099673819272
   BLAND JM, 1986, LANCET, V1, P307, DOI 10.1016/s0140-6736(86)90837-8
   Chen CZ, 2004, DOC OPHTHALMOL, V109, P1
   CHEN JC, 1992, INVEST OPHTH VIS SCI, V33, P334
   Christoforidis J, 2011, GRAEF ARCH CLIN EXP, V249, P1345, DOI 10.1007/s00417-011-1706-9
   Cideciyan AV, 2018, INVEST OPHTH VIS SCI, V59, P4558, DOI 10.1167/iovs.18-24931
   Crossland MD, 2011, BMC OPHTHALMOL, V11, DOI 10.1186/1471-2415-11-5
   Curcio CA, 2000, INVEST OPHTH VIS SCI, V41, P2015
   Curcio CA, 1996, INVEST OPHTH VIS SCI, V37, P1236
   Dimitrov PN, 2008, INVEST OPHTH VIS SCI, V49, P55, DOI 10.1167/iovs.06-1048
   Dimitrov PN, 2011, INVEST OPHTH VIS SCI, V52, P9457, DOI 10.1167/iovs.10-7043
   DRUM B, 1987, APPL OPTICS, V26, P1415, DOI 10.1364/AO.26.001415
   Flamendorf J, 2015, OPHTHALMOLOGY, V122, P2053, DOI 10.1016/j.ophtha.2015.06.023
   Flynn OJ, 2018, INVEST OPHTH VIS SCI, V59, P2411, DOI 10.1167/iovs.17-22874
   HOLZ FG, 1994, BRIT J OPHTHALMOL, V78, P79, DOI 10.1136/bjo.78.1.79-a
   Jackson GR, 2002, AGEING RES REV, V1, P381, DOI 10.1016/S1568-1637(02)00007-7
   Jackson GR, 1999, VISION RES, V39, P3975, DOI 10.1016/S0042-6989(99)00092-9
   Jackson GR, 1998, VISION RES, V38, P3655, DOI 10.1016/S0042-6989(98)00044-3
   Jackson GR, 2014, INVEST OPHTH VIS SCI, V55, DOI 10.1167/iovs.13-13745
   Jackson Gregory R, 2008, J Ocul Biol Dis Infor, V1, P7, DOI 10.1007/s12177-008-9002-6
   Krezel AK, 2015, BRIT J OPHTHALMOL, V99, P1560, DOI 10.1136/bjophthalmol-2014-306544
   LAMB TD, 1981, VISION RES, V21, P1773, DOI 10.1016/0042-6989(81)90211-X
   Mackenzie PJ, 2002, OPHTHALMOLOGY, V109, P720, DOI 10.1016/S0161-6420(01)01021-1
   McGuigan DB, 2016, INVEST OPHTH VIS SCI, V57, P3118, DOI 10.1167/iovs.16-19302
   Nebbioso M, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/671529
   Nguyen CT, 2018, INVEST OPHTH VIS SCI, V59, DOI 10.1167/iovs.17-23084
   Owsley C, 2000, INVEST OPHTH VIS SCI, V41, P267
   Owsley C, 2006, INVEST OPHTH VIS SCI, V47, P528, DOI 10.1167/iovs.05-1222
   Owsley C, 2001, OPHTHALMOLOGY, V108, P1196, DOI 10.1016/S0161-6420(01)00580-2
   Owsley C, 2016, OPHTHALMOLOGY, V123, P344, DOI 10.1016/j.ophtha.2015.09.041
   Owsley C, 2014, INVEST OPHTH VIS SCI, V55, P4776, DOI 10.1167/iovs.14-14502
   Pfau M, 2017, INVEST OPHTH VIS SCI, V58, P158, DOI 10.1167/iovs.17-21454
   Pfau M, 2020, RETINA-J RET VIT DIS, V40, P169, DOI 10.1097/IAE.0000000000002337
   Pfau M, 2018, EYE, V32, P1819, DOI 10.1038/s41433-018-0183-3
   Pfau M, 2018, BRIT J OPHTHALMOL, V102, P1054, DOI 10.1136/bjophthalmol-2017-311012
   Pfau M, 2017, OPHTHALMOLOGICA, V237, P42, DOI 10.1159/000453079
   Scilley K, 2002, OPHTHALMOLOGY, V109, P1235, DOI 10.1016/S0161-6420(02)01060-6
   Tan RS, 2018, TRANSL VIS SCI TECHN, V7, DOI 10.1167/tvst.7.3.3
   Vaz S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0073990
   Welker Susanne G, 2018, Invest Ophthalmol Vis Sci, V59, pAMD152, DOI 10.1167/iovs.18-23878
   Wu ZC, 2016, BRIT J OPHTHALMOL, V100, P395, DOI 10.1136/bjophthalmol-2015-306621
   Yazdanie M, 2017, OPHTHALMOLOGY, V124, P1332, DOI 10.1016/j.ophtha.2017.05.005
NR 44
TC 3
Z9 3
U1 1
U2 2
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 2164-2591
J9 TRANSL VIS SCI TECHN
JI Transl. Vis. Sci. Technol.
PD JUN
PY 2020
VL 9
IS 7
AR 31
DI 10.1167/tvst.9.7.31
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA QG6VM
UT WOS:000617722500006
PM 32832236
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Ding, JD
   Kelly, U
   Landowski, M
   Toomey, CB
   Groelle, M
   Miller, C
   Smith, SG
   Klingeborn, M
   Singhapricha, T
   Jiang, HX
   Frank, MM
   Rickman, CB
AF Ding, Jin-Dong
   Kelly, Una
   Landowski, Michael
   Toomey, Christopher B.
   Groelle, Marybeth
   Miller, Chelsey
   Smith, Stephanie G.
   Klingeborn, Mikael
   Singhapricha, Terry
   Jiang, Haixiang
   Frank, Michael M.
   Rickman, Catherine Bowes
TI Expression of Human Complement Factor H Prevents Age-Related Macular
   Degeneration-Like Retina Damage and Kidney Abnormalities in Aged Cfh
   Knockout Mice
SO AMERICAN JOURNAL OF PATHOLOGY
LA English
DT Article
ID DENSE DEPOSIT DISEASE; MEMBRANOPROLIFERATIVE GLOMERULONEPHRITIS; BRUCHS
   MEMBRANE; TRANSGENIC MICE; MODEL; GENE; POLYMORPHISM; MACULOPATHY;
   ACTIVATION; DEFICIENT
AB Complement factor H (CFH) is an important regulatory protein in the alternative pathway of the complement system, and CFH polymorphisms increase the genetic risk of age-related macular degeneration dramatically. These same human CFH variants have also been associated with dense deposit disease. To mechanistically study the function of CFH in the pathogenesis of these diseases, we created transgenic mouse lines using human CFH bacterial artificial chromosomes expressing full-length human CFH variants and crossed these to Cfh knockout (Cfh(-/-)) mice. Human CFH protein inhibited cleavage of mouse complement component 3 and factor B in plasma and in retinal pigment epithelium/choroid/sclera, establishing that human CFH regulates activation of the mouse alternative pathway. One of the mouse tines, which express relatively higher levels of CFH, demonstrated functional and structural protection of the retina owing to the Cfh deletion. Impaired visual function, detected as a deficit in the scotopic electroretinographic response, was improved in this transgenic mouse Line compared with Cfh(-/-) mice, and transgenics had a thicker outer nuclear Layer and Less sub retinal pigment epithelium deposit accumulation. In addition, expression of human CFH also completely protected the mice from developing kidney abnormalities associated with loss of CFH. These humanized CFH mice present a valuable model for study of the molecular mechanisms of age-related macular degeneration and dense deposit disease and for testing therapeutic targets.
C1 [Ding, Jin-Dong; Kelly, Una; Landowski, Michael; Toomey, Christopher B.; Groelle, Marybeth; Miller, Chelsey; Smith, Stephanie G.; Klingeborn, Mikael; Singhapricha, Terry; Rickman, Catherine Bowes] Duke Univ, Med Ctr, Dept Ophthalmol, Durham, NC 27710 USA.
   [Toomey, Christopher B.; Rickman, Catherine Bowes] Duke Univ, Med Ctr, Dept Cell Biol, Durham, NC 27710 USA.
   [Jiang, Haixiang; Frank, Michael M.] Duke Univ, Med Ctr, Dept Pediat, Durham, NC 27710 USA.
C3 Duke University; Duke University; Duke University
RP Rickman, CB (通讯作者)，Duke Univ, Med Ctr, Box 3802, Durham, NC 27710 USA.
EM bowes007@duke.edu
RI Klingeborn, Mikael/AAC-2471-2019; Ding, Jindong/B-3324-2008
OI Klingeborn, Mikael/0000-0003-2907-0371; Ding,
   Jindong/0000-0003-0427-0369; Bowes Rickman,
   Catherine/0000-0002-8555-9596; Landowski, Michael/0000-0003-0151-0689
FU NIH [EY019038, P30 EY005722]; Edward N. & Della L. Thome Memorial
   Foundation Award; Foundation Fighting Blindness; NATIONAL EYE INSTITUTE
   [R01EY019038, P30EY005722] Funding Source: NIH RePORTER; NATIONAL
   INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007754, T32GM007171] Funding
   Source: NIH RePORTER
FX Supported by funding from NIH grants EY019038 (C.B.R.) and P30 EY005722,
   Edward N. & Della L. Thome Memorial Foundation Award (C.B.R.), and the
   Foundation Fighting Blindness (C.B.R.).
CR Abrera-Abeleda MA, 2006, J MED GENET, V43, P582, DOI 10.1136/jmg.2005.038315
   Amaratunga A, 1996, J BIOL CHEM, V271, P5628, DOI 10.1074/jbc.271.10.5628
   Anand R, 2000, OPHTHALMOLOGY, V107, P2224
   Ansari M, 2013, HUM MOL GENET, V22, P4857, DOI 10.1093/hmg/ddt336
   Appel GB, 2005, J AM SOC NEPHROL, V16, P1392, DOI 10.1681/ASN.2005010078
   Clark SJ, 2010, J BIOL CHEM, V285, P30192, DOI 10.1074/jbc.M110.103986
   Coffey PJ, 2007, P NATL ACAD SCI USA, V104, P16651, DOI 10.1073/pnas.0705079104
   Curcio CA, 2005, EXP EYE RES, V80, P761, DOI 10.1016/j.exer.2004.09.017
   de Jong PTVM, 2006, NEW ENGL J MED, V355, P1474, DOI 10.1056/NEJMra062326
   Ding JD, 2008, VISION RES, V48, P339, DOI 10.1016/j.visres.2007.07.025
   Ding JD, 2011, P NATL ACAD SCI USA, V108, pE279, DOI 10.1073/pnas.1100901108
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Fakhouri F, 2010, KIDNEY INT, V78, P279, DOI 10.1038/ki.2010.132
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   GOURAS P, 1970, INVEST OPHTH VISUAL, V9, P557
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Herrmann R, 2010, J NEUROSCI, V30, P3239, DOI 10.1523/JNEUROSCI.4775-09.2010
   Holers VM, 2008, IMMUNOL REV, V223, P300, DOI 10.1111/j.1600-065X.2008.00641.x
   Jackson GR, 2004, INVEST OPHTH VIS SCI, V45, P3271, DOI 10.1167/iovs.04-0019
   Jackson GR, 1999, VISION RES, V39, P3975, DOI 10.1016/S0042-6989(99)00092-9
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Johnson M, 2007, CURR EYE RES, V32, P791, DOI 10.1080/02713680701550660
   Kam JH, 2013, AM J PATHOL, V183, P480, DOI 10.1016/j.ajpath.2013.04.008
   Kelly U, 2010, J IMMUNOL, V185, P5486, DOI 10.4049/jimmunol.0903596
   Kelly U, 2009, INVEST OPHTH VIS SCI, V50, P1540, DOI 10.1167/iovs.08-2782
   Klein R, 2004, AM J OPHTHALMOL, V137, P486, DOI 10.1016/j.ajo.2003.11.069
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Lim JH, 2012, OXID MED CELL LONGEV, V2012, DOI 10.1155/2012/171383
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Mattapallil MJ, 2012, INVEST OPHTH VIS SCI, V53, P2921, DOI 10.1167/iovs.12-9662
   MEISLER MH, 1992, TRENDS GENET, V8, P341, DOI 10.1016/0168-9525(92)90278-C
   Morgan B. P., 1999, COMPLEMENT REGULATOR
   Pickering MC, 2007, J EXP MED, V204, P1249, DOI 10.1084/jem.20070301
   Pickering MC, 2002, NAT GENET, V31, P424, DOI 10.1038/ng912
   Prosser BE, 2007, J EXP MED, V204, P2277, DOI 10.1084/jem.20071069
   Rickman CB, 2013, INVEST OPHTH VIS SCI, V54, pORSF68, DOI 10.1167/iovs.13-12757
   Smith RJH, 2007, J AM SOC NEPHROL, V18, P2447, DOI 10.1681/ASN.2007030356
   Ufret-Vincenty RL, 2010, INVEST OPHTH VIS SCI, V51, P5878, DOI 10.1167/iovs.09-4457
   Walker PD, 2007, CURR OPIN NEPHROL HY, V16, P204, DOI 10.1097/MNH.0b013e3280bdc0f4
   Williams JAE, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0068616
   Yang XW., 2005, CURRENT PROTOCOLS NE, V31, P5, DOI [10.1002/0471142301.ns0520s31, DOI 10.1002/0471142301.NS0520S31]
   Yu W, 1999, SCIENCE, V285, P1080, DOI 10.1126/science.285.5430.1080
NR 43
TC 39
Z9 40
U1 0
U2 8
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0002-9440
EI 1525-2191
J9 AM J PATHOL
JI Am. J. Pathol.
PD JAN
PY 2015
VL 185
IS 1
BP 29
EP 42
DI 10.1016/j.ajpath.2014.08.026
PG 14
WC Pathology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pathology
GA AX4ES
UT WOS:000346887200005
PM 25447048
OA hybrid, Green Published
DA 2022-11-30
ER

PT J
AU Wu, A
   Lu, RH
   Lee, E
AF Wu, Andres
   Lu, Renhao
   Lee, Esak
TI Tissue engineering in age-related macular degeneration: a mini-review
SO JOURNAL OF BIOLOGICAL ENGINEERING
LA English
DT Review
DE Age-related macular degeneration (AMD); Tissue-engineered models;
   Microfluidic devices; 3D cell culture; 2D cell culture; Non-exudative
   ('dry) AMD; Exudative ('wet) AMD; Retinal pigment epithelium; Bruchs
   membrane; Drusen; Macular neovascularization; Macular atrophy
ID RETINAL-PIGMENT EPITHELIUM; IN-VITRO; CHOROIDAL NEOVASCULARIZATION;
   DRUSEN; TRANSPLANTATION; EYE; CULTURE; DIFFERENTIATION; TRANSLOCATION;
   COMPLEMENT
AB Age-related macular degeneration (AMD) is a progressive, degenerative disease of the macula, leading to severe visual loss in the elderly population. There are two types of AMD: non-exudative ('dry') AMD and exudative ('wet') AMD. Non-exudative AMD is characterized by drusen formation and macular atrophy, while the blood vessels are not leaky. Exudative AMD is a more advanced form of the disease, featured with abnormal blood vessel growth and vascular leakage. Even though anti-angiogenic therapies have been effective in treating wet AMD by normalizing blood vessels, there is no treatment available to prevent or treat dry AMD. Currently, the mechanisms of drusen formation and macular atrophy in the dry AMD are poorly understood, in part because the currently available in vivo models of AMD could not decouple and isolate the complex biological and biophysical factors in the macular region for a detailed mechanism study, including the complement system, angiogenesis factors, extracellular matrix, etc. In the present review article, we describe the biological background of AMD and the key cells and structures in AMD, including retinal epithelium, photoreceptor, Bruch's membrane, and choriocapillaris. We also discuss pre-clinical animal models of AMD and in vivo tissue-engineered approaches, including cell suspension injection and organoid-derived cell sheet transplantation. We also discuss in vitro tissue-engineered models for AMD research. Specifically, we evaluate and compare currently available two- and three-dimensional AMD tissue-engineered models that mimic key anatomical players in AMD progression, including pathophysiological characteristics in Bruch's membrane, photoreceptor, and choriocapillaris. Finally, we discuss the limitation of current AMD models and future directions.
C1 [Wu, Andres; Lu, Renhao; Lee, Esak] Cornell Univ, Nancy E & Peter C Meinig Sch Biomed Engn, Ithaca, NY 14853 USA.
   [Wu, Andres] Cornell Univ, Ann S Bowers Coll Comp & Informat Sci, Ithaca, NY 14853 USA.
C3 Cornell University; Cornell University
RP Lee, E (通讯作者)，Cornell Univ, Nancy E & Peter C Meinig Sch Biomed Engn, Ithaca, NY 14853 USA.
EM el767@cornell.edu
OI Lee, Esak/0000-0002-5328-6677
FU National Institutes of Health [AI166772, CA252162]; Cornell University
   Start-up fund; Meinig Family Investigator fund; Academic Integration at
   Cornell; Adam Rachel Broder fund for Cancer Research (Cornell)
FX A.W., R.L., and E.L. were supported by National Institutes of Health
   (AI166772, CA252162), the Cornell University Start-up fund, the Meinig
   Family Investigator fund, Multi-Investigator Seed Grant provided by
   Academic Integration at Cornell, and Adam Rachel Broder fund for Cancer
   Research (Cornell).
CR Achberger K, 2019, ELIFE, V8, DOI 10.7554/eLife.46188
   Anderson DH, 2010, PROG RETIN EYE RES, V29, P95, DOI 10.1016/j.preteyeres.2009.11.003
   Apte RS, 2021, NEW ENGL J MED, V385, P539, DOI 10.1056/NEJMcp2102061
   Assawachananont J, 2014, STEM CELL REP, V2, P662, DOI 10.1016/j.stemcr.2014.03.011
   Balaratnasingam C, 2016, INVEST OPHTH VIS SCI, V57, P5479, DOI 10.1167/iovs.16-19816
   Bandello F, 2017, RECENT ADV MANAGEMEN, V6
   Binder S, 2004, INVEST OPHTH VIS SCI, V45, P4151, DOI 10.1167/iovs.04-0118
   Binder S, 2002, AM J OPHTHALMOL, V133, P215, DOI 10.1016/S0002-9394(01)01373-3
   Booij JC, 2010, RES DYNAMIC NATURE B, V29, P18
   Chakradhar S, 2016, NAT MED, V22, P116, DOI 10.1038/nm0216-116
   Chen L-J, 2017, KAJI HJSR MICROFLUID, V7, P9
   Chen L, 2020, RETINA-J RET VIT DIS, V40, P618, DOI 10.1097/IAE.0000000000002657
   Christoforidis JB, 2011, CURR DRUG TARGETS, V12, P221
   Churm R, 2019, CLIN EXP OPHTHALMOL, V47, P1055, DOI 10.1111/ceo.13578
   Cowan CS, 2020, CELL, V182, P1623, DOI 10.1016/j.cell.2020.08.013
   Curcio CA, 2000, INVEST OPHTH VIS SCI, V41, P2015
   Curcio CA, 1999, ARCH OPHTHALMOL-CHIC, V117, P329, DOI 10.1001/archopht.117.3.329
   Curcio Christine A, 2018, Invest Ophthalmol Vis Sci, V59, pAMD160, DOI 10.1167/iovs.18-24882
   Curcio CA, 2013, RETINA-J RET VIT DIS, V33, P265, DOI 10.1097/IAE.0b013e31827e25e0
   Curcio CA, 2011, BRIT J OPHTHALMOL, V95, P1638, DOI 10.1136/bjophthalmol-2011-300344
   De Cilla S, 2020, AFLIBERCEPT RANIBIZU
   Edelman JL, 2000, CASTRO MRJEER QUANTI, V71, P533
   Edwards Albert O., 2007, Angiogenesis, V10, P119, DOI 10.1007/s10456-007-9064-2
   Evans JB, 2013, NAT REV DRUG DISCOV, V12, P501, DOI 10.1038/nrd4038
   Farjood F, 2018, LAB CHIP, V18, P3413, DOI 10.1039/c8lc00659h
   Farnoodian M, 2018, J OPHTHAL VIS RES, V13, P470, DOI 10.4103/jovr.jovr_67_18
   Fernandez-Godino R, 2016, NAT PROTOC, V11, P1206, DOI 10.1038/nprot.2016.065
   Fliesler AJ., 1983, ANDERSON REJPILR CHE, V22, P131
   Fritsche LG, 2016, NAT GENET, V48, P134, DOI 10.1038/ng.3448
   Gehrs KM, 2010, ARCH OPHTHALMOL-CHIC, V128, P349, DOI 10.1001/archophthalmol.2010.18
   Giddabasappa A, 2016, EXP EYE RES, V145, P373, DOI 10.1016/j.exer.2016.02.010
   Grebe R, 2019, EXP EYE RES, V181, P252, DOI 10.1016/j.exer.2019.02.018
   Hadziahmetovic M, 2021, FRONT CELL DEV BIOL, V8, DOI 10.3389/fcell.2020.612812
   Hawkins BT, 2005, PHARMACOL REV, V57, P173, DOI 10.1124/pr.57.2.4
   Hera R, 2005, AM J OPHTHALMOL, V139, P589, DOI 10.1016/j.ajo.2004.11.064
   Hildebrand GD, 2011, PEDIATRIC RETINA, P39, DOI 10.1007/978-3-642-12041-1_2
   Hung SSC, 2016, PROG RETIN EYE RES, V53, P1, DOI 10.1016/j.preteyeres.2016.05.001
   Hurst J, 2020, SCHNICHELS SJFIN ORG, V14, P1150
   Jemni-Damer N, 2020, FRONT BIOENG BIOTECH, V8, DOI 10.3389/fbioe.2020.588014
   Jeon CJ, 1998, J NEUROSCI, V18, P8936
   Jeong HS, 2019, J CELL PHYSIOL, V234, P3837, DOI 10.1002/jcp.27156
   Johnson LV., 2011, CELL CULTURE MODEL M, V108
   Jun SJ, 2019, EXP EYE RES, V181, P346, DOI 10.1016/j.exer.2018.09.023
   Jung YH, 2018, ADV MATER, V30, DOI 10.1002/adma.201803550
   Keenan TDL, 2021, ADV EXP MED BIOL, V1256, P1, DOI 10.1007/978-3-030-66014-7_1
   Kernt M, 2010, BRIT J OPHTHALMOL, V94, P1533, DOI 10.1136/bjo.2010.182162
   Kundu J, 2016, ACTA BIOMATER, V31, P61, DOI 10.1016/j.actbio.2015.11.028
   Leclaire MD, 2019, GRAEF ARCH CLIN EXP, V257, P931, DOI 10.1007/s00417-019-04253-x
   Lee E, 2016, CURR OPIN CHEM ENG, V11, P20, DOI 10.1016/j.coche.2015.12.001
   Limb GA, 2002, INVEST OPHTH VIS SCI, V43, P864
   LOPEZ R, 1987, INVEST OPHTH VIS SCI, V28, P1131
   Lutty GA, 2020, EXP EYE RES, V192, DOI 10.1016/j.exer.2020.107939
   Ma WX, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007945
   MacLeod RA, 1999, DREXLER HGJIJOC WIDE, P563
   McUsic AC, 2012, PLGA SCAFFOLDS, V33, p1396 1405
   Mullins RE, 2011, INVEST OPHTH VIS SCI, V52, P1606, DOI 10.1167/iovs.10-6476
   Muniz A, 2014, INVEST OPHTH VIS SCI, V55, P198, DOI 10.1167/iovs.13-11740
   Murphy AR, 2020, ACTA BIOMATER, V104, P1, DOI 10.1016/j.actbio.2020.01.013
   Nebel C, 2017, BIOCHEM BIOPH RES CO, V484, P681, DOI 10.1016/j.bbrc.2017.01.176
   Pan WW, 2021, COMMUN BIOL, V4, DOI 10.1038/s42003-021-01765-3
   Pandi SPS., 2021, TEELING JLJEER PROGR, V203
   Pertile G, 2002, AM J OPHTHALMOL, V134, P560, DOI 10.1016/S0002-9394(02)01641-0
   Pfeffer BA, 2014, EXP EYE RES, V126, P1, DOI 10.1016/j.exer.2014.07.010
   Picaud S., 2019, PRIMATE MODEL UNDERS, V116
   Pilgrim MG, 2017, INVEST OPHTH VIS SCI, V58, DOI 10.1167/iovs.16-21060
   Rosenfeld PJ, 2021, AM J OPHTHALMOL
   Salimiaghdam N, 2019, AGE RELATED MACULAR, V13
   Sawa M, OPHTHALMOLOGY CHANGE, V240, P16
   Schnichels S, 2021, PROG RETIN EYE RES, V81, DOI 10.1016/j.preteyeres.2020.100880
   Scimone C, 2020, ANTIOXIDANTS-BASEL, V9, DOI 10.3390/antiox9111154
   Shokoohmand A, 2017, NOVEL 3D CULTURED MO, V17
   Singh D, 2018, BIOMATERIALS, V154, P158, DOI 10.1016/j.biomaterials.2017.10.052
   Sonoda S, 2009, NAT PROTOC, V4, P662, DOI 10.1038/nprot.2009.33
   Spaide RF, 2019, AM J OPHTHALMOL, V207, P395, DOI 10.1016/j.ajo.2019.04.035
   Su D, 2016, RETINA-J RET VIT DIS, V36, pS40, DOI 10.1097/IAE.0000000000001268
   Tolentino MJ, 2004, RETINA-J RET VIT DIS, V24, P132, DOI 10.1097/00006982-200402000-00018
   van Meurs JC, 2004, BRIT J OPHTHALMOL, V88, P110, DOI 10.1136/bjo.88.1.110
   Villanueva M Teresa, 2019, Nat Rev Drug Discov, V18, P172, DOI 10.1038/d41573-019-00017-8
   Wang Pengrui, 2018, Bioprinting, V12, pe00029, DOI 10.1016/j.bprint.2018.e00029
   Wang XL, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-10124-4
   Weigel AL, 2002, MED MICROARRAY ANAL, V33
   Yehoshua Z, 2011, SEMIN OPHTHALMOL, V26, P167, DOI 10.3109/08820538.2011.577132
   Yiu G, 2020, INVEST OPHTH VIS SCI, V61, DOI 10.1167/iovs.61.2.32
   Yiu G, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-14715-z
NR 84
TC 0
Z9 0
U1 4
U2 4
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1754-1611
J9 J BIOL ENG
JI J. Biol. Eng.
PD MAY 16
PY 2022
VL 16
IS 1
AR 11
DI 10.1186/s13036-022-00291-y
PG 12
WC Biochemical Research Methods; Biotechnology & Applied Microbiology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology
GA 1H4LG
UT WOS:000796515000001
PM 35578246
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Wong, KH
   Nam, HY
   Lew, SY
   Naidu, M
   David, P
   Kamalden, TA
   Hadie, SNH
   Lim, LW
AF Wong, Kah-Hui
   Nam, Hui-Yin
   Lew, Sze-Yuen
   Naidu, Murali
   David, Pamela
   Kamalden, Tengku Ain
   Hadie, Siti Nurma Hanim
   Lim, Lee-Wei
TI Discovering the Potential of Natural Antioxidants in Age-Related Macular
   Degeneration: A Review
SO PHARMACEUTICALS
LA English
DT Article
DE age-related macular degeneration; oxidative damage; retina;
   angiogenesis; antioxidants
ID VERTEPORFIN PHOTODYNAMIC THERAPY; PIGMENT EPITHELIAL-CELLS; SUBFOVEAL
   CHOROIDAL NEOVASCULARIZATION; INTRAVITREAL BEVACIZUMAB AVASTIN;
   NF-KAPPA-B; OXIDATIVE STRESS; BLUE-LIGHT; RETINAL DEGENERATION;
   GEOGRAPHIC ATROPHY; HYDROGEN-PEROXIDE
AB Age-related macular degeneration (AMD) is a multifactorial disease associated with anatomical changes in the inner retina. Despite tremendous advances in clinical care, there is currently no cure for AMD. This review aims to evaluate the published literature on the therapeutic roles of natural antioxidants in AMD. A literature search of PubMed, Web of Science and Google Scholar for peer-reviewed articles published between 1 January 2011 and 31 October 2021 was undertaken. A total of 82 preclinical and 18 clinical studies were eligible for inclusion in this review. We identified active compounds, carotenoids, extracts and polysaccharides, flavonoids, formulations, vitamins and whole foods with potential therapeutic roles in AMD. We evaluated the integral cellular signaling pathways including the activation of antioxidant pathways and angiogenesis pathways orchestrating their mode of action. In conclusion, we examined the therapeutic roles of natural antioxidants in AMD which warrant further study for application in clinical practice. Our current understanding is that natural antioxidants have the potential to improve or halt the progression of AMD, and tailoring therapeutics to the specific disease stages may be the key to preventing irreversible vision loss.
C1 [Wong, Kah-Hui; Lew, Sze-Yuen; Naidu, Murali; David, Pamela] Univ Malaya, Fac Med, Dept Anat, Kuala Lumpur 50603, Malaysia.
   [Wong, Kah-Hui; Lim, Lee-Wei] Univ Hong Kong, Neuromodulat Lab, Sch Biomed Sci, Li Ka Shing Fac Med,Pokfulam, 21 Sassoon Rd, Hong Kong, Peoples R China.
   [Nam, Hui-Yin] Univ Malaya, Tissue Engn Grp, Dept Orthopaed Surg NOCERAL, Fac Med, Kuala Lumpur 50603, Malaysia.
   [Kamalden, Tengku Ain] Univ Malaya, Fac Med, Dept Ophthalmol, UM Eye Res Ctr, Kuala Lumpur 50603, Malaysia.
   [Hadie, Siti Nurma Hanim] Univ Sains Malaysia, Dept Anat, Sch Med Sci, Hlth Campus, Kota Baharu 16150, Kelantan, Malaysia.
C3 Universiti Malaya; University of Hong Kong; Universiti Malaya;
   Universiti Malaya; Universiti Sains Malaysia
RP Wong, KH (通讯作者)，Univ Malaya, Fac Med, Dept Anat, Kuala Lumpur 50603, Malaysia.; Wong, KH; Lim, LW (通讯作者)，Univ Hong Kong, Neuromodulat Lab, Sch Biomed Sci, Li Ka Shing Fac Med,Pokfulam, 21 Sassoon Rd, Hong Kong, Peoples R China.
EM wkahhui@um.edu.my; huiyin26@yahoo.com; szeyuenlew@gmail.com;
   murali_naidu@um.edu.my; rosiepamela@um.edu.my; taftkamalden@um.edu.my;
   snurma@usm.my; limlw@hku.hk
RI DAVID, ROSIE PAMELA/B-9602-2010; Lim, Lee Wei/M-3245-2019; Hadie, Siti
   Nurma Hanim/L-7296-2016; KAMALDEN, TENGKU AIN FATHLUN
   TENGKU/B-9941-2010; Nam, Hui Yin/F-5013-2013; Kah-Hui, Wong/C-1048-2010
OI Hadie, Siti Nurma Hanim/0000-0001-9046-9379; KAMALDEN, TENGKU AIN
   FATHLUN TENGKU/0000-0001-9810-5334; Kah-Hui, Wong/0000-0002-8292-4498;
   Lim, Lee Wei/0000-0001-6692-6285; Wong, Kah Hui/0000-0001-5669-8987;
   Lew, Sze Yuen/0000-0002-5402-6869
CR Abokyi S, 2020, OXID MED CELL LONGEV, V2020, DOI 10.1155/2020/7901270
   Adijanto J, 2014, EXP EYE RES, V126, P77, DOI 10.1016/j.exer.2014.01.015
   Akuffo KO, 2017, INVEST OPHTH VIS SCI, V58, P5347, DOI 10.1167/iovs.16-21192
   Al-Zamil WM, 2017, CLIN INTERV AGING, V12, P1313, DOI 10.2147/CIA.S143508
   Allegrini D, 2021, J MED FOOD, DOI 10.1089/jmf.2020.0199
   Alshamrani M, 2019, AAPS PHARMSCITECH, V20, DOI 10.1208/s12249-019-1404-1
   [Anonymous], 1993, Arch Ophthalmol, V111, P104
   Antoszyk AN, 2008, AM J OPHTHALMOL, V145, P862, DOI 10.1016/j.ajo.2007.12.029
   Iloki-Assanga SB, 2015, BMC COMPLEM ALTERN M, V15, DOI 10.1186/s12906-015-0765-6
   Betts Brandi S, 2011, ISRN Ophthalmol, V2011, P184295, DOI 10.5402/2011/184295
   Bhutto I, 2012, MOL ASPECTS MED, V33, P295, DOI 10.1016/j.mam.2012.04.005
   Birch DG, 2007, INT J NANOMED, V2, P65, DOI 10.2147/nano.2007.2.1.65
   Biswas L, 2020, EXP EYE RES, V191, DOI 10.1016/j.exer.2020.107931
   Blumenkranz MS, 2001, ARCH OPHTHALMOL-CHIC, V119, P198
   Bosch-Morell F, 2020, NEURAL REGEN RES, V15, P2207, DOI 10.4103/1673-5374.284978
   Bracha P, 2017, EXPERT OPIN BIOL TH, V17, P1113, DOI 10.1080/14712598.2017.1346079
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   Broadhead GK, 2019, GRAEF ARCH CLIN EXP, V257, P31, DOI 10.1007/s00417-018-4163-x
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   Bucheli P, 2011, OPTOMETRY VISION SCI, V88, P257, DOI 10.1097/OPX.0b013e318205a18f
   Carneiro A, 2017, OXID MED CELL LONGEV, V2017, DOI 10.1155/2017/6469138
   Chang CH, 2017, PHARM BIOL, V55, P571, DOI 10.1080/13880209.2016.1263344
   Chang YC, 2014, FRONT AGING NEUROSCI, V6, DOI 10.3389/fnagi.2014.00191
   Chen LJ, 2020, J FORMOS MED ASSOC, V119, P569, DOI 10.1016/j.jfma.2019.04.012
   Chen PJ, 2019, J CELL BIOCHEM, V120, P1028, DOI 10.1002/jcb.27599
   Chen YX, 2019, RETINA-J RET VIT DIS, V39, P1985, DOI 10.1097/IAE.0000000000002292
   Cheng LB, 2014, INT J MOL SCI, V15, P18762, DOI 10.3390/ijms151018762
   Cheng YP, 2016, CHINESE J PHYSIOL, V59, P202, DOI 10.4077/CJP.2016.BAE404
   Cheung CMG, 2014, OPHTHALMOLOGY, V121, P1598, DOI 10.1016/j.ophtha.2014.02.004
   Chew EY, 2014, JAMA OPHTHALMOL, V132, P142, DOI 10.1001/jamaophthalmol.2013.7376
   Chew EY, 2013, JAMA-J AM MED ASSOC, V309, P2005, DOI 10.1001/jama.2013.4997
   Cho EY, 2008, AM J CLIN NUTR, V87, P1837, DOI 10.1093/ajcn/87.6.1837
   Chong V, 2016, EYE, V30, P270, DOI 10.1038/eye.2015.217
   Chua B, 2006, ARCH OPHTHALMOL-CHIC, V124, P981, DOI 10.1001/archopht.124.7.981
   Cornebise C, 2020, MOLECULES, V25, DOI 10.3390/molecules25235564
   Costa RA, 2007, GRAEF ARCH CLIN EXP, V245, P1273, DOI 10.1007/s00417-007-0557-x
   Courtaut F, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22126590
   Csaky K, 2017, INVEST OPHTH VIS SCI, V58, P3456, DOI 10.1167/iovs.17-22339
   Delcourt C, 1999, ARCH OPHTHALMOL-CHIC, V117, P1384, DOI 10.1001/archopht.117.10.1384
   Di Marco S, 2019, ANTIOXIDANTS-BASEL, V8, DOI 10.3390/antiox8070224
   Dithmer M, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0089150
   Dorschmann P, 2019, MAR DRUGS, V17, DOI 10.3390/md17100548
   Dorschmann P, 2019, MAR DRUGS, V17, DOI 10.3390/md17050258
   Dorschmann P, 2020, MAR DRUGS, V18, DOI 10.3390/md18060282
   Du MB, 2020, EVID-BASED COMPL ALT, V2020, DOI 10.1155/2020/3805967
   Du YY, 2020, OXID MED CELL LONGEV, V2020, DOI 10.1155/2020/2684672
   Dubey SK, 2021, INT J PHARMACEUT, V600, DOI 10.1016/j.ijpharm.2021.120499
   Due WW, 2018, OXID MED CELL LONGEV, V2018, DOI 10.1155/2018/1610751
   Dunn EN, 2017, OSLI RETINA, V48, P100, DOI 10.3928/23258160-20170130-02
   Emoto Y, 2013, IN VIVO, V27, P583
   Falavarjani KG, 2013, RETINA-J RET VIT DIS, V33, P971, DOI 10.1097/IAE.0b013e31826f0675
   Falsini B, 2010, INVEST OPHTH VIS SCI, V51, P6118, DOI 10.1167/iovs.09-4995
   Feng TT, 2015, INT J CLIN EXP PATHO, V8, P9126
   Fung FY, 2017, SINGAP MED J, V58, P115, DOI 10.11622/smedj.2017016
   Gao YJ, 2017, AGING DIS, V8, P778, DOI 10.14336/AD.2017.0725
   Georgiou Tassos, 2014, PharmaNutrition, V2, P8, DOI 10.1016/j.phanu.2013.10.001
   Golestaneh N, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2016.453
   Gomi F, 2008, BRIT J OPHTHALMOL, V92, P70, DOI 10.1136/bjo.2007.122283
   Gross SJ, 2021, ANGIOGENESIS, V24, P789, DOI 10.1007/s10456-021-09791-9
   Grzybowski A, 2018, OPHTHALMOLOGICA, V239, P181, DOI 10.1159/000486145
   Hadziahmetovic M, 2021, FRONT CELL DEV BIOL, V8, DOI 10.3389/fcell.2020.612812
   Hammond BR, 2014, INVEST OPHTH VIS SCI, V55, P8583, DOI 10.1167/iovs.14-15573
   Hariton E, 2018, BJOG-INT J OBSTET GY, V125, P1716, DOI 10.1111/1471-0528.15199
   He HJ, 2019, J CELL MOL MED, V23, P3495, DOI 10.1111/jcmm.14246
   Hellinen L, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-50324-8
   Holekamp N, 2020, OPHTHALMOLOGY, V127, P769, DOI 10.1016/j.ophtha.2019.12.009
   Hsieh FC, 2018, OXID MED CELL LONGEV, V2018, DOI 10.1155/2018/4814928
   Huang WY, 2018, J AGR FOOD CHEM, V66, P1638, DOI 10.1021/acs.jafc.7b06135
   Husain D, 1996, ARCH OPHTHALMOL-CHIC, V114, P978, DOI 10.1001/archopht.1996.01100140186012
   Hytti M, 2017, J NUTR BIOCHEM, V42, P37, DOI 10.1016/j.jnutbio.2016.12.014
   Hytti M, 2015, EXP EYE RES, V132, P208, DOI 10.1016/j.exer.2015.02.001
   Ibuki M, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21238940
   Ibuki M, 2020, FRONT PHARMACOL, V11, DOI 10.3389/fphar.2020.00174
   Ibuki M, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20205049
   Ishihara T, 2018, NUTRIENTS, V10, DOI 10.3390/nu10050593
   Ito A, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0235213
   Jaffe GJ, 2017, OPHTHALMOLOGY, V124, P224, DOI 10.1016/j.ophtha.2016.10.010
   Jeung IC, 2016, INT J MED SCI, V13, P139, DOI 10.7150/ijms.13861
   Jin GM, 2019, CLIN EXP OPHTHALMOL, V47, P1019, DOI 10.1111/ceo.13580
   Jin M, 2018, CURR MOL MED, V18, P622, DOI 10.2174/1566524019666190107155311
   Jitsanong T, 2011, TOXICOL IN VITRO, V25, P167, DOI 10.1016/j.tiv.2010.10.014
   Joachim N, 2014, INVEST OPHTH VIS SCI, V55, P4421, DOI 10.1167/iovs.14-14476
   John PA, 2013, NAT PROD COMMUN, V8, P711
   Johra FT, 2020, ANTIOXIDANTS-BASEL, V9, DOI 10.3390/antiox9111046
   Kaiser PK, 2009, OPHTHALMOLOGY, V116, P747, DOI 10.1016/j.ophtha.2008.12.057
   Kamoshita M, 2016, SCI REP-UK, V6, DOI 10.1038/srep30226
   Kanavi MR, 2014, MOLECULES, V19, P17578, DOI 10.3390/molecules191117578
   Kang NR, 2019, EVID-BASED COMPL ALT, V2019, DOI 10.1155/2019/5710289
   Karimi P, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21082949
   Kassoff A, 1999, CONTROL CLIN TRIALS, V20, P573
   Kaszubski P, 2016, OPHTHALMIC RES, V55, P185, DOI 10.1159/000443209
   Khan RA, 2018, SAUDI PHARM J, V26, P739, DOI 10.1016/j.jsps.2018.02.015
   Kim DH, 2020, MOLECULES, V25, DOI 10.3390/molecules25071737
   Kim HR, 2021, NUTRIENTS, V13, DOI 10.3390/nu13010025
   Kim KA, 2015, J AGR FOOD CHEM, V63, P7750, DOI 10.1021/acs.jafc.5b02578
   King RE, 2005, CHEM-BIOL INTERACT, V151, P143, DOI 10.1016/j.cbi.2004.11.003
   Kita T, 2008, BIOSCI BIOTECH BIOCH, V72, P1789, DOI 10.1271/bbb.80075
   Koyama Y, 2019, ANTIOXIDANTS-BASEL, V8, DOI 10.3390/antiox8040079
   Kurutas EB, 2016, NUTR J, V15, DOI 10.1186/s12937-016-0186-5
   Kyosseva SV, 2016, OPHTHALMOL EYE DIS, V8, P23, DOI 10.4137/OED.S32200
   Lai TYY, 2008, BRIT J OPHTHALMOL, V92, P661, DOI 10.1136/bjo.2007.135103
   Lashay Alireza, 2016, Med Hypothesis Discov Innov Ophthalmol, V5, P32
   Lee BL, 2016, NUTR RES, V36, P1402, DOI 10.1016/j.nutres.2016.11.008
   Lee HS, 2014, MOLECULES, V19, P12150, DOI 10.3390/molecules190812150
   Lee Y, 2015, INVEST OPHTH VIS SCI, V56, P8403, DOI 10.1167/iovs.15-16936
   Lew SY, 2020, BMC COMPLEMENT MED, V20, DOI 10.1186/s12906-020-03132-x
   Lew SY, 2020, FOOD SCI TECH-BRAZIL, V40, P264, DOI 10.1590/fst.09919
   Li S, 2018, INT J OPHTHALMOL-CHI, V11, P970, DOI 10.18240/ijo.2018.06.12
   Li S, 2021, OXID MED CELL LONGEV, V2021, DOI 10.1155/2021/7654143
   Li S, 2019, INT J BIOL SCI, V15, P2016, DOI 10.7150/ijbs.30536
   Li S, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19061736
   Li YM, 2021, TRIALS, V22, DOI 10.1186/s13063-021-05025-x
   Li YB, 2006, AM J OPHTHALMOL, V142, P788, DOI 10.1016/j.ajo.2006.06.001
   Lim TH, 2020, JAMA OPHTHALMOL, V138, P935, DOI 10.1001/jamaophthalmol.2020.2443
   Lima Veronica Castro, 2016, Int J Retina Vitreous, V2, P19
   Liu L, 2015, INT J OPHTHALMOL-CHI, V8, P11, DOI 10.3980/j.issn.2222-3959.2015.01.02
   Loughman J., 2010, J OPTOM, V3, P74
   Luo X, 2018, FRONT PHARMACOL, V9, DOI 10.3389/fphar.2018.00240
   Maccarone R, 2008, INVEST OPHTH VIS SCI, V49, P1254, DOI 10.1167/iovs.07-0438
   Malek G, 2018, EXPERT OPIN DRUG DIS, V13, P359, DOI 10.1080/17460441.2018.1430136
   Marangoni D, 2013, J TRANSL MED, V11, DOI 10.1186/1479-5876-11-228
   Marco Fabiana Di, 2013, Am J Neurodegener Dis, V2, P208
   Martinez-Solis I, 2019, PLANTA MED, V85, P1292, DOI 10.1055/a-0947-5712
   Masuda T, 2017, OXID MED CELL LONGEV, V2017, DOI 10.1155/2017/9208489
   Mehta H, 2018, PROG RETIN EYE RES, V65, P127, DOI 10.1016/j.preteyeres.2017.12.002
   Millan-Linares MC, 2019, J FOOD BIOCHEM, V43, DOI 10.1111/jfbc.12995
   Muangnoi C, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20133367
   Muraoka Y, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0036135
   Nadeau JH, 2019, NAT REV DRUG DISCOV, V18, P255, DOI 10.1038/s41573-018-0009-9
   Nakano-Okuno M, 2014, STEM CELL REV REP, V10, P743, DOI 10.1007/s12015-014-9536-x
   Namdari M, 2017, BIOMED PHARMACOTHER, V87, P321, DOI 10.1016/j.biopha.2016.12.099
   Narimatsu T, 2015, EXP EYE RES, V132, P48, DOI 10.1016/j.exer.2015.01.003
   Nashine S, 2020, NUTRIENTS, V12, DOI 10.3390/nu12010159
   Nashine S, 2019, AGING-US, V11, P1177, DOI 10.18632/aging.101820
   Neal SE, 2020, INVEST OPHTH VIS SCI, V61, DOI 10.1167/iovs.61.4.32
   Newman DK, 2016, EYE, V30, P202, DOI 10.1038/eye.2015.251
   Nikkhah H, 2018, J OPHTHAL VIS RES, V13, P158, DOI 10.4103/jovr.jovr_50_18
   Ogawa K, 2014, BMC COMPLEM ALTERN M, V14, DOI 10.1186/1472-6882-14-120
   Organisciak DT, 2013, MOL VIS, V19, P1433
   Orhan C, 2021, OXID MED CELL LONGEV, V2021, DOI 10.1155/2021/6672525
   Osada H, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0178627
   Paimela T, 2011, PHARMACOL RES, V64, P501, DOI 10.1016/j.phrs.2011.05.027
   Palkar AH, 2019, TAIWAN J OPHTHALMOL, V9, P72, DOI 10.4103/tjo.tjo_35_18
   Pan HT, 2020, J INT MED RES, V48, DOI 10.1177/0300060520931618
   Park C, 2019, CUTAN OCUL TOXICOL, V38, P298, DOI 10.1080/15569527.2019.1613425
   Park DW, 2021, ANTIOXIDANTS-BASEL, V10, DOI 10.3390/antiox10040613
   Park SI, 2017, J PHARM PHARMACOL, V69, P334, DOI 10.1111/jphp.12691
   Patel C, 2020, EXP EYE RES, V195, DOI 10.1016/j.exer.2020.108031
   Pelkonen L, 2017, MOL PHARMACEUT, V14, P605, DOI 10.1021/acs.molpharmaceut.6b00782
   Pennesi ME, 2012, MOL ASPECTS MED, V33, P487, DOI 10.1016/j.mam.2012.06.003
   Phang MWL, 2021, CHIN MED-UK, V16, DOI 10.1186/s13020-020-00414-x
   Piccardi M, 2012, EVID-BASED COMPL ALT, V2012, DOI 10.1155/2012/429124
   Pikuleva IA, 2014, PROG RETIN EYE RES, V41, P64, DOI 10.1016/j.preteyeres.2014.03.002
   Plafker SM, 2012, INT REV CEL MOL BIO, V298, P135, DOI 10.1016/B978-0-12-394309-5.00004-3
   Pocrnich CE, 2009, CAN J OPHTHALMOL, V44, P431, DOI 10.3129/i09-109
   Qian TW, 2018, EUR J CLIN INVEST, V48, DOI 10.1111/eci.12840
   Qiu G, 2006, EXP EYE RES, V83, P141, DOI 10.1016/j.exer.2005.11.014
   Radomska-Lesniewska DM, 2019, CENT EUR J IMMUNOL, V44, P181, DOI 10.5114/ceji.2019.87070
   Rastoin O, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21134627
   Reinke MH, 1999, OPHTHALMOLOGY, V106, P1915, DOI 10.1016/S0161-6420(99)90401-3
   Rezaie T, 2012, INVEST OPHTH VIS SCI, V53, P7847, DOI 10.1167/iovs.12-10793
   Rho J., 2021, ANIMAL MODELS MED BI, DOI [10.5772/intechopen.96601, DOI 10.5772/INTECHOPEN.96601]
   Riazi A, 2017, ITAL J MED, V11, P196, DOI 10.4081/itjm.2016.758
   Rimpela AK, 2018, ADV DRUG DELIVER REV, V126, P23, DOI 10.1016/j.addr.2017.12.008
   Rivero-Montejo SD, 2021, AGRICULTURE-BASEL, V11, DOI 10.3390/agriculture11020134
   Rohwer K, 2019, MAR DRUGS, V17, DOI 10.3390/md17090538
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rudolf M, 2008, INVEST OPHTH VIS SCI, V49, P1200, DOI 10.1167/iovs.07-1466
   Samuel W, 2017, MOL VIS, V23, P60
   Saviranta NMM, 2011, FOOD RES INT, V44, P109, DOI 10.1016/j.foodres.2010.10.056
   Schnurrbusch UEK, 2005, ARCH OPHTHALMOL-CHIC, V123, P1347, DOI 10.1001/archopht.123.10.1347
   Schwikkard S, 2019, J NAT PROD, V82, P1227, DOI 10.1021/acs.jnatprod.8b00989
   Scott LJ, 2000, DRUG AGING, V16, P139, DOI 10.2165/00002512-200016020-00005
   Seddon JM, 2006, ARCH OPHTHALMOL-CHIC, V124, P995, DOI 10.1001/archopht.124.7.995
   Shah M, 2019, PHARM RES-DORDR, V36, DOI 10.1007/s11095-019-2588-5
   Shanmuganathan S, 2018, VASC PHARMACOL, V108, P23, DOI 10.1016/j.vph.2018.04.005
   Shaw PX, 2016, AIMS MOL SCI, V3, P196, DOI 10.3934/molsci.2016.2.196
   Silvan JM, 2016, FOOD FUNCT, V7, P1067, DOI [10.1039/c5fo01368b, 10.1039/C5FO01368B]
   Singer MA, 2012, OPHTHALMOLOGY, V119, P1175, DOI 10.1016/j.ophtha.2011.12.016
   Song DL, 2016, EXP EYE RES, V145, P1, DOI 10.1016/j.exer.2015.10.005
   Srivastava R, 2010, Pharmacogn Rev, V4, P200, DOI 10.4103/0973-7847.70919
   Subermaniam K, 2020, SAUDI J BIOL SCI, V27, P1435, DOI 10.1016/j.sjbs.2020.04.042
   Subramani M, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-12496-z
   Sudhalkar A, 2015, INDIAN J OPHTHALMOL, V63, P899, DOI 10.4103/0301-4738.176025
   Sun S, 2017, STEM CELL RES THER, V8, DOI 10.1186/s13287-017-0584-4
   Supanji S, 2021, CLIN OPHTHALMOL, V15, P1101, DOI 10.2147/OPTH.S298310
   Tang LJ, 2018, BIOMED PHARMACOTHER, V103, P829, DOI 10.1016/j.biopha.2018.04.104
   Terheyden JH, 2020, TRIALS, V21, DOI 10.1186/s13063-020-04595-6
   Pham TNM, 2021, NUTRIENTS, V13, DOI 10.3390/nu13020359
   Tolentino M, 2011, SURV OPHTHALMOL, V56, P95, DOI 10.1016/j.survophthal.2010.08.006
   Tsujikawa A, 2010, JPN J OPHTHALMOL, V54, P310, DOI 10.1007/s10384-010-0813-1
   Tu G, 2016, MOL MED REP, V13, P2320, DOI 10.3892/mmr.2016.4797
   Tzekov R, 2006, INVEST OPHTH VIS SCI, V47, P377, DOI 10.1167/iovs.05-0838
   Ueta T, 2009, OPHTHALMOLOGY, V116, P362, DOI 10.1016/j.ophtha.2008.09.046
   Upadhyay M, 2020, REDOX BIOL, V37, DOI 10.1016/j.redox.2020.101623
   van den Bergh H, 2001, Semin Ophthalmol, V16, P181, DOI 10.1076/soph.16.4.181.10299
   Velilla S, 2013, J OPHTHALMOL, V2013, DOI 10.1155/2013/895147
   Vieira LC, 2020, PLANTA MED, V86, P1286, DOI 10.1055/a-1223-2525
   Wang HB, 2016, MOL VIS, V22, P189
   Wang J, 2020, J DRUG DELIV SCI TEC, V55, DOI 10.1016/j.jddst.2019.101377
   Wang SS, 2013, EXPERT OPIN THER PAT, V23, P269, DOI 10.1517/13543776.2013.751972
   Wang Y, 2017, J FUNCT FOODS, V33, P103, DOI 10.1016/j.jff.2017.02.034
   Wang Y, 2015, MOLECULES, V20, P22395, DOI 10.3390/molecules201219785
   Wei QQ, 2018, EXP THER MED, V16, P1187, DOI 10.3892/etm.2018.6305
   Wilkinson JT, 2011, DRUGS, V71, P2421, DOI 10.2165/11596840-000000000-00000
   Wong P, 2017, MOL VIS, V23, P718
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Wu HH, 2020, BIOMED PHARMACOTHER, V126, DOI 10.1016/j.biopha.2020.110050
   Wu J, 2015, JAMA OPHTHALMOL, V133, P1415, DOI 10.1001/jamaophthalmol.2015.3590
   Wu ZC, 2015, JAMA OPHTHALMOL, V133, P442, DOI 10.1001/jamaophthalmol.2014.5963
   Xin G, 2020, ACS APPL MATER INTER, V12, P57710, DOI 10.1021/acsami.0c17296
   Xu XY, 2020, BMC PUBLIC HEALTH, V20, DOI 10.1186/s12889-020-8445-y
   Yang L, 2019, CURR MOL MED, V19, P434, DOI 10.2174/1566524019666190425195706
   Yang M, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21134658
   Yiu G, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-14715-z
   Yonekawa Y, 2015, CSH PERSPECT MED, V5, DOI 10.1101/cshperspect.a017178
   Yoon SM, 2016, ARCH PHARM RES, V39, P21, DOI 10.1007/s12272-015-0683-7
   Yuan HD, 2016, MOLECULES, V21, DOI 10.3390/molecules21050559
   Yuan ZL, 2020, OXID MED CELL LONGEV, V2020, DOI 10.1155/2020/7962393
   Zhao BC, 2020, MOL MED REP, V21, P220, DOI 10.3892/mmr.2019.10827
   Zhao Z, 2014, FOOD CHEM TOXICOL, V74, P216, DOI 10.1016/j.fct.2014.10.001
   Zhou HY, 2011, INVEST OPHTH VIS SCI, V52, P4338, DOI 10.1167/iovs.10-6519
   Zhu W, 2015, DRUG DES DEV THER, V9, P5337, DOI 10.2147/DDDT.S84979
   Ziemssen F, 2020, J OPHTHALMOL, V2020, DOI 10.1155/2020/8652370
NR 224
TC 3
Z9 3
U1 8
U2 12
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 1424-8247
J9 PHARMACEUTICALS-BASE
JI Pharmaceuticals
PD JAN
PY 2022
VL 15
IS 1
AR 101
DI 10.3390/ph15010101
PG 50
WC Chemistry, Medicinal; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA ZC5RM
UT WOS:000757577100001
PM 35056157
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Wang, Q
AF Wang, Qin
TI Association of TLR3 gene polymorphisms with age-related macular
   degeneration
SO INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL MEDICINE
LA English
DT Article
DE Age-related macular degeneration (AMD); toll-like receptor 3 (TLR3)
   gene; haplotypes
ID TOLL-LIKE RECEPTOR-3; PIGMENT EPITHELIAL-CELLS; CHOROIDAL
   NEOVASCULARIZATION; GEOGRAPHIC ATROPHY; VISUAL IMPAIRMENT;
   UNITED-STATES; PREVALENCE; MACULOPATHY; POPULATION; EYE
AB Purpose: In this study, we selected rs3775291 and rs3775296 polymorphisms of from toll-like receptor 3 (TLR3) gene to investigate their association with the susceptibility of age-related macular degeneration (ARMD or AMD). Haplotypes of the two polymorphisms were also detected in AMD patients. Methods: A hospital-based multiple- center case-control study was designed. 110 AMD cases and 108 healthy controls were enrolled in this study chi(2) test was applied to count and analyze the genotype and allele frequencies in case and control groups. The relationship between TLR3 polymorphisms and the susceptibility of AMD was presented by odds ratios (ORs) and 95% confidence intervals (CIs). Results: The genotype distributions of TLR3 rs3775291 and rs3775296 polymorphisms in control group were in accordance with Hardy-Weinberg equilibrium (HWE) (P>0.05). The distributions of rs3775291 polymorphism AG genotype in case and control groups had statistically significant differences (P<0.05), and AG genotype could increase the onset risk of AMD by 1.89 times when compared with GG genotype (OR=1.89, 95% CI=1.09-3.28). In addition, rs3775296 polymorphism TT genotype was related to the occurrence of AMD (OR=4.70, 95% CI=1.26-17.46), and T allele could also increase the risk of AMD (OR=1.64, 95% CI=1.06-2.55). Linkage disequilibrium (LD) and haplotype analysis suggested that rs3775291 and rs3775296 polymorphisms formed 4 haplotypes, and the distribution differences of one of them, namely T-A haplotype, between case and control groups were statistically significant (P<0.05). Conclusions: TLR3 polymorphisms can increase the onset risk of AMD.
C1 [Wang, Qin] Qianxinanzhou Peoples Hosp, Dept Ophthalmol, 95 Yanan Rd, Xingyi 562400, Guizhou, Peoples R China.
RP Wang, Q (通讯作者)，Qianxinanzhou Peoples Hosp, Dept Ophthalmol, 95 Yanan Rd, Xingyi 562400, Guizhou, Peoples R China.
EM wangqwinq@sina.com
CR Ambati J, 2003, SURV OPHTHALMOL, V48, P257, DOI 10.1016/S0039-6257(03)00030-4
   Cho YE, 2009, INVEST OPHTH VIS SCI, V50, P5614, DOI 10.1167/iovs.09-3688
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   de Jong PTVM, 2006, NEW ENGL J MED, V355, P1474, DOI 10.1056/NEJMra062326
   Edwards AO, 2008, INVEST OPHTH VIS SCI, V49, P1652, DOI 10.1167/iovs.07-1378
   Evans J, 1996, BRIT J OPHTHALMOL, V80, P9, DOI 10.1136/bjo.80.1.9
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Kassoff A, 1999, CONTROL CLIN TRIALS, V20, P573
   Klaver CCW, 1998, ARCH OPHTHALMOL-CHIC, V116, P1646, DOI 10.1001/archopht.116.12.1646
   Klein R, 2004, AM J OPHTHALMOL, V137, P486, DOI 10.1016/j.ajo.2003.11.069
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Kleinman ME, 2012, MOL THER, V20, P101, DOI 10.1038/mt.2011.212
   Monique L, 2006, J MOL NEUROSCI, V29, P185, DOI 10.1385/JMN/29:03:185
   Li YB, 2006, AM J OPHTHALMOL, V142, P788, DOI 10.1016/j.ajo.2006.06.001
   Maloney SC, 2010, OPHTHALMIC RES, V44, P237, DOI 10.1159/000313989
   Pascolini D, 2004, OPHTHAL EPIDEMIOL, V11, P67, DOI 10.1076/opep.11.2.67.28158
   Sng CCA, 2011, OPHTHALMIC RES, V45, P191, DOI 10.1159/000321387
   Spaide RF, 2003, RETINA-J RET VIT DIS, V23, P595, DOI 10.1097/00006982-200310000-00001
   Sundelin S, 1998, CURR EYE RES, V17, P851, DOI 10.1076/ceyr.17.8.851.5146
   Takeda K, 2003, ANNU REV IMMUNOL, V21, P335, DOI 10.1146/annurev.immunol.21.120601.141126
   Wornle M, 2011, INVEST OPHTH VIS SCI, V52, P6536, DOI 10.1167/iovs.10-6993
   Yang ZL, 2008, NEW ENGL J MED, V359, P1456, DOI 10.1056/NEJMoa0802437
   Yates JRW, 2000, J MED GENET, V37, P83, DOI 10.1136/jmg.37.2.83
   Zhou P, 2011, FASEB J, V25, P3489, DOI 10.1096/fj.11-189258
   Zhu Y, 2013, MOL VIS, V19, P1826
NR 25
TC 0
Z9 0
U1 0
U2 2
PU E-CENTURY PUBLISHING CORP
PI MADISON
PA 40 WHITE OAKS LN, MADISON, WI 53711 USA
SN 1940-5901
J9 INT J CLIN EXP MED
JI Int. J. Clin. Exp. Med.
PY 2016
VL 9
IS 2
BP 4610
EP 4614
PG 5
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine
GA DK1EL
UT WOS:000374655200507
DA 2022-11-30
ER

PT J
AU Parravano, M
   Oddone, F
   Tedeschi, M
   Chiaravalloti, A
   Perillo, L
   Boccassini, B
   Varano, M
AF Parravano, Mariacristina
   Oddone, Francesco
   Tedeschi, Massimiliano
   Chiaravalloti, Adele
   Perillo, Loredana
   Boccassini, Barbara
   Varano, Monica
TI RETINAL FUNCTIONAL CHANGES MEASURED BY MICROPERIMETRY IN NEOVASCULAR
   AGE-RELATED MACULAR DEGENERATION TREATED WITH RANIBIZUMAB 24-Month
   Results
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE age-related macular degeneration; antivascular endothelial growth
   factor; choroidal neovascular membrane; CNV; ranibizumab
ID SCANNING LASER MICROPERIMETRY; ANTI-VEGF ANTIBODY; VISUAL-ACUITY;
   OPHTHALMOSCOPE; BEVACIZUMAB; SELECTION; DISEASES; EDEMA
AB Purpose: The purpose of this study was to assess long-term functional and structural retinal changes in patients with neovascular age-related macular degeneration treated with intravitreal 0.5 mg ranibizumab.
   Methods: Eighteen patients with neovascular age-related macular degeneration have been evaluated in this retrospective 24-month follow-up study. All patients have been treated with 3 injections of 0.5 mg ranibizumab 1 month apart and retreated according to predefined criteria. At baseline, all patients were subjected to visual acuity, fluorescein angiography, MP1 microperimetry, and Stratus optical coherence tomography. Although visual acuity and optical coherence tomography were repeated 28 6 2 days after each injection, MP1 was performed at 6, 12, and 24 months.
   Results: Seventeen of 18 and 14 of 18 patients completed 12 and 24 months of follow-up, respectively. Mean retinal sensitivity significantly improved from 3.89 +/- 3.0 dB to 7.33 +/- 4.11 dB at 24 months (P = 0.024). Mean visual acuity improved from 48.67 +/- 8.59 to 59.17 +/- 16.45 at 24 months (P = 0.049). Visual acuity improved to >= 15 letters in 33.3% (6 of 18) of patients and,15 letters in 44.4% (8 of 18); 22.2% (4 of 18) of patients lost,15 letters at 24 months. Five of 13 patients (38.5%) with either an instable or relatively instable fixation at baseline showed improvement of fixation stability at 24 months. Central retinal thickness significantly decreased from 310.5 +/- 85.7 to 232.9 +/- 60.1 at 24 months (P = 0.0001).
   Conclusion: Intravitreal injections of 0.5 mg ranibizumab determine progressive improvement of retinal sensitivity until 24 months, although visual acuity levels off after 6 months, suggesting that microperimetry may give additional information about macular function not given by visual acuity alone. RETINA 30:1017-1024, 2010
C1 [Parravano, Mariacristina; Oddone, Francesco; Tedeschi, Massimiliano; Chiaravalloti, Adele; Perillo, Loredana; Boccassini, Barbara; Varano, Monica] Fdn GB Bietti, IRCCS, I-00198 Rome, Italy.
C3 IRCCS - Fondazione "G.B. Bietti" per lo Studio e la Ricerca in
   Oftalmologia
RP Parravano, M (通讯作者)，Fdn GB Bietti, IRCCS, ViaLivenza 3, I-00198 Rome, Italy.
EM criparra@tin.it
RI Varano, Monica/K-8573-2016; Oddone, Francesco/K-8876-2016
OI Oddone, Francesco/0000-0002-2504-0004; Varano,
   Monica/0000-0002-6530-1563
CR Andersen IVN, 1996, ACTA OPHTHALMOL SCAN, V74, P135
   Bressler NM, 2003, ARCH OPHTHALMOL-CHIC, V121, P1621
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Chen FK, 2009, INVEST OPHTH VIS SCI, V50, P3464, DOI 10.1167/iovs.08-2926
   Chen Y, 1999, J MOL BIOL, V293, P865, DOI 10.1006/jmbi.1999.3192
   DAMICO DJ, 1994, NEW ENGL J MED, V331, P95, DOI 10.1056/NEJM199407143310207
   Ferrara N, 2004, NAT REV DRUG DISCOV, V3, P391, DOI 10.1038/nrd1381
   Ferrara N, 2000, RECENT PROG HORM RES, V55, P15
   FERRIS FL, 1982, AM J OPHTHALMOL, V94, P91, DOI 10.1016/0002-9394(82)90197-0
   FREUND KB, 1993, AM J OPHTHALMOL, V115, P786, DOI 10.1016/S0002-9394(14)73649-9
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Fujii GY, 2002, OPHTHALMOLOGY, V109, P1737, DOI 10.1016/S0161-6420(02)01120-X
   Fung AE, 2007, AM J OPHTHALMOL, V143, P566, DOI 10.1016/j.ajo.2007.01.028
   Gardner TW, 2002, SURV OPHTHALMOL, V47, pS253, DOI 10.1016/S0039-6257(02)00387-9
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Kaiser PK, 2007, OPHTHALMOLOGY, V114, P1868, DOI 10.1016/j.ophtha.2007.04.030
   KLEIN R, 1999, AGE RELATED MACULAR, P31
   Lalwani GA, 2009, AM J OPHTHALMOL, V148, P43, DOI 10.1016/j.ajo.2009.01.024
   Larsson J, 2005, AM J OPHTHALMOL, V139, P802, DOI 10.1016/j.ajo.2004.12.054
   LEIBOWITZ HM, 1980, SURV OPHTHALMOL, V24, pS335
   MIDENA E, 2007, PERIMETRY FUNDUS INT, P229
   Midena Edoardo, 2004, Semin Ophthalmol, V19, P55, DOI 10.1080/08820530490882896
   NUSSENBLATT RB, 1987, OPHTHALMOLOGY, V94, P1134
   Parravano M, 2009, RETINA-J RET VIT DIS, V29, P329, DOI 10.1097/IAE.0b013e31819093e6
   Prager F, 2008, RETINA-J RET VIT DIS, V28, P682, DOI 10.1097/IAE.0b013e318161dc70
   PULIAFITO CA, 1995, OPHTHALMOLOGY, V102, P217
   Rohrschneider K, 2005, AM J OPHTHALMOL, V139, P125, DOI 10.1016/j.ajo.2004.08.060
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Schneider U, 1996, GRAEF ARCH CLIN EXP, V234, P612, DOI 10.1007/BF00185293
   SCHNEIDER U, 1993, KLIN MONATSBL AUGENH, V203, P212, DOI 10.1055/s-2008-1045670
   Springer C, 2005, OPHTHALMOLOGY, V112, P848, DOI 10.1016/j.ophtha.2004.11.051
   Tezel TH, 1996, OPHTHALMOLOGY, V103, P1829, DOI 10.1016/S0161-6420(96)30419-3
   Varano M, 1998, Semin Ophthalmol, V13, P203, DOI 10.3109/08820539809056054
   Vujosevic S, 2006, INVEST OPHTH VIS SCI, V47, P3044, DOI 10.1167/iovs.05-1141
NR 35
TC 36
Z9 36
U1 0
U2 3
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD JUL-AUG
PY 2010
VL 30
IS 7
BP 1017
EP 1024
DI 10.1097/IAE.0b013e3181cfd3c6
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 622CE
UT WOS:000279635600004
PM 20224469
DA 2022-11-30
ER

PT J
AU Incorvaia, C
   Campa, C
   Parmeggiani, F
   Menzione, M
   D'Angelo, S
   Della Corte, M
   Rinaldi, M
   Romano, M
   Dell'Omo, R
   Costagliola, C
AF Incorvaia, Carlo
   Campa, Claudio
   Parmeggiani, Francesco
   Menzione, Massimo
   D'Angelo, Sergio
   Della Corte, Michele
   Rinaldi, Michele
   Romano, Mary
   Dell'Omo, Roberto
   Costagliola, Ciro
TI 12-month retrospective study and review of photodynamic therapy with
   verteporfin for subfoveal choroidal neovascularization in age-related
   macular degeneration
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Review
DE age-related macular degeneration; photodynamic therapy with verteporfin;
   subfoveal choroidal neovascularization
ID INTRAVITREAL TRIAMCINOLONE; TRIPLE THERAPY; LESION SIZE; TAP;
   RANIBIZUMAB; SECONDARY; PDT
AB Purpose: To evaluate the 12-month visual outcome of photodynamic therapy with verteporfin (PDT-V) for patients with subfoveal choroidal neovascularization (CNV) secondary to age-related macular degeneration and to verify the predictive role of visual and angiographic factors.
   Methods: This retrospective, interventional, consecutive case series study included subjects with different forms of subfoveal CNV. All patients received PDT-V according to Treatment of Age-Related Macular Degeneration With Photodynamic Therapy/Visudyne in Photodynamic Therapy guidelines. A review of medical and angiographic records was performed.
   Results: Two hundred sixteen patients were divided into 4 study groups: group I, 60 eyes with classic CNV; group II, 56 eyes with predominantly classic CNV; group III, 42 eyes with minimally classic CNV; and group IV, 58 eyes with occult CNV. In groups I and II, best-corrected visual acuity (BCVA) was moderately decreased, without reaching a statistically noticeable level during the entire follow-up; lesion size reduction only reached significance in group I. Groups III and IV showed evident worsening of BCVA (P < 0.05), despite concomitant reduction in CNV size (statistically remarkable only for occult CNV). All study groups exhibited a significant correlation between higher baseline BCVA and better final visual outcome. In groups II and IV, smaller baseline CNV sizes also favorably influenced final BCVA.
   Conclusions: Standardized PDT-V minimizes deterioration of central vision only in patients with classic and predominantly classic CNV. Irrespective of the CNV type, better BCVA at presentation represents a good predictive sign. In predominantly classic and occult lesions, minor initial CNV dimension is also a positive prognostic element.
C1 [Incorvaia, Carlo; Campa, Claudio; Parmeggiani, Francesco; Menzione, Massimo] Univ Ferrara, Dept Ophthalmol, I-44100 Ferrara, Italy.
   [Menzione, Massimo; Della Corte, Michele; Rinaldi, Michele; Romano, Mary] Univ Naples Federico II, Eye Clin, Naples, Italy.
   [Dell'Omo, Roberto; Costagliola, Ciro] Univ Molise, Dept Hlth Sci, Campobasso, Italy.
C3 University of Ferrara; University of Naples Federico II; University of
   Molise
RP Campa, C (通讯作者)，Univ Ferrara, Dipartimento Discipline Medico Chirurgiche Commun, Sez Clin Oculist, Corso giovecca 203, I-44100 Ferrara, Italy.
EM claudio.campa@yahoo.com
RI campa, claudio/B-3992-2013; Costagliola, Ciro/G-5707-2012; dell'Omo,
   Roberto/K-7328-2016
OI Costagliola, Ciro/0000-0001-8477-6188; dell'Omo,
   Roberto/0000-0002-7663-8874; DELLA CORTE, MICHELE/0000-0003-1320-1883;
   D'Angelo, Sergio/0000-0003-1118-3845
CR Arias L, 2006, OPHTHALMOLOGY, V113, P2243, DOI 10.1016/j.ophtha.2006.04.039
   Armbrecht AM, 2004, BRIT J OPHTHALMOL, V88, P1270, DOI 10.1136/bjo.2003.038604
   Arnold J, 2001, AM J OPHTHALMOL, V131, P541
   Augustin AJ, 2007, RETINA-J RET VIT DIS, V27, P133, DOI 10.1097/IAE.0b013e3180323de7
   Axer-Siegel R, 2004, AM J OPHTHALMOL, V137, P258, DOI 10.1016/j.ajo.2003.08.009
   Azab M, 2004, RETINA-J RET VIT DIS, V24, P1
   Barbazetto I, 2003, ARCH OPHTHALMOL-CHIC, V121, P1253
   Barnes RM, 2004, EYE, V18, P809, DOI 10.1038/sj.eye.6701329
   Bhavsar A, 2004, RETINA-J RET VIT DIS, V24, P512
   Blinder KJ, 2003, AM J OPHTHALMOL, V136, P407, DOI 10.1016/S0002-9394(03)00223-X
   Bradley John, 2007, Angiogenesis, V10, P141, DOI 10.1007/s10456-007-9069-x
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   BRESSLER SB, 1994, ARCH OPHTHALMOL-CHIC, V112, P1176
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   *CERT ROUNDT PART, 2005, RETINA, V25, P119
   Chakravarthy U, 2006, BRIT J OPHTHALMOL, V90, P1188, DOI 10.1136/bjo.2005.082255
   Dhalla MS, 2006, RETINA-J RET VIT DIS, V26, P988, DOI 10.1097/01.iae.0000247164.70376.91
   Ergun E, 2006, AM J OPHTHALMOL, V142, P10, DOI 10.1016/j.ajo.2006.02.048
   Essex RW, 2003, CLIN EXP OPHTHALMOL, V31, P476, DOI 10.1046/j.1442-9071.2003.00714.x
   Frennesson CI, 2004, ACTA OPHTHALMOL SCAN, V82, P645, DOI 10.1111/j.1600-0420.2004.00368.x
   Greve MDJ, 2005, ARCH OPHTHALMOL-CHIC, V123, P448
   HAWKINS BS, 1993, ARCH OPHTHALMOL-CHIC, V111, P1200
   Kaiser PK, 2006, AM J OPHTHALMOL, V142, P660, DOI 10.1016/j.ajo.2006.05.061
   Klein R, 2004, AM J OPHTHALMOL, V137, P486, DOI 10.1016/j.ajo.2003.11.069
   Liggett PE, 2006, AM J OPHTHALMOL, V142, P1072, DOI 10.1016/j.ajo.2006.07.029
   Maguire MG, 1999, AGE RELATED MACULAR, P17
   Michels S, 2003, INVEST OPHTH VIS SCI, V44, P2147, DOI 10.1167/iovs.02-0604
   Nicolo M, 2006, RETINA-J RET VIT DIS, V26, P58, DOI 10.1097/00006982-200601000-00010
   POTTER MJ, 2006, EYE
   Resnikoff S, 2004, B WORLD HEALTH ORGAN, V82, P844
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Schmidt-Erfurth U, 2000, SURV OPHTHALMOL, V45, P195, DOI 10.1016/S0039-6257(00)00158-2
   Schmidt-Erfurth U, 2002, INVEST OPHTH VIS SCI, V43, P830
   Sivaprasad S, 2006, EYE, V20, P43, DOI 10.1038/sj.eye.6701787
   STERNBERG P, 1991, ARCH OPHTHALMOL-CHIC, V109, P1242
   Tano Y, 2003, AM J OPHTHALMOL, V136, P1049, DOI 10.1016/S0002-9394(03)00576-2
   TAP and VIP Study Group, 2002, RETINA, V22, P6
   Wachtlin J, 2005, GRAEF ARCH CLIN EXP, V243, P438, DOI 10.1007/s00417-004-1071-z
   Wickens J, 2006, DRUG SAFETY, V29, P189, DOI 10.2165/00002018-200629030-00003
NR 39
TC 17
Z9 18
U1 0
U2 5
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD FEB
PY 2008
VL 28
IS 2
BP 289
EP 297
DI 10.1097/IAE.0b013e31813ffe90
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 266TV
UT WOS:000253460800013
PM 18301052
OA Green Submitted
DA 2022-11-30
ER

PT J
AU Ahluwalia, A
   Shen, LBL
   Chen, EM
   Sun, MY
   Park, MM
   Young, BK
   Del Priore, LV
AF Ahluwalia, Aneesha
   Shen, Liangbo L.
   Chen, Evan M.
   Sun, Mengyuan
   Park, Michael M.
   Young, Benjamin K.
   Del Priore, Lucian V.
TI Geographic atrophy severity and mortality in age-related macular
   degeneration
SO GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Article
DE Mortality; Geographic atrophy; Age-related macular degeneration; Area of
   atrophy; Systemic disease
ID FUNDUS AUTOFLUORESCENCE IMAGES; VISUAL IMPAIRMENT; EYE DISEASE;
   CARDIOVASCULAR MORTALITY; OXIDATIVE STRESS; PROGRESSION; RISK; Y402H;
   INTERVENTION; ASSOCIATIONS
AB Purpose To examine the association between geographic atrophy (GA) disease characteristics and mortality risk. Methods We manually delineated color fundus photographs of 209 Age-Related Eye Disease Study (AREDS) participants with GA secondary to age-related macular degeneration to identify total area of atrophy, GA effective radius growth rate, disease laterality, and the presence of foveal center involvement. Associations between GA characteristics and mortality were assessed with Cox proportional hazards models adjusted for health status indicators. Results During a median follow-up of 6.8 years, 48 (23.0%) participants with GA died. In adjusted models, accounting for age, sex, and health status, participants with total GA area in the highest quartile had a significantly increased risk of all-cause mortality compared to those with total GA area in the lowest quartile (hazard ratio [HR], 3.42; 95% confidence interval [CI], 1.32-8.86; P = 0.011). GA effective radius growth rate, bilateral disease, and the presence of foveal center involvement were not significantly associated with mortality. In a multivariable model, including health status indicators and all GA characteristics, total area of atrophy in the highest quartile remained significantly associated with mortality (HR, 4.65; 95% CI, 1.29-16.70; P = 0.019). Conclusions More extensive GA, as indicated by a greater total area of atrophy, was associated with an increased risk of all-cause mortality in our cohort. The extent of GA may reflect the extent of underlying disease processes that contribute to greater mortality risk, further suggesting that GA may be part of a systemic rather than purely ocular disease process.
C1 [Ahluwalia, Aneesha; Shen, Liangbo L.; Chen, Evan M.; Park, Michael M.; Del Priore, Lucian V.] Yale Sch Med, Dept Ophthalmol & Visual Sci, 40 Temple St,Suite 1B, New Haven, CT 06510 USA.
   [Sun, Mengyuan] Yale Univ, Dept Mol Biophys & Biochem, New Haven, CT USA.
   [Young, Benjamin K.] Univ Michigan, Sch Med, Kellogg Eye Ctr, Ann Arbor, MI 48109 USA.
C3 Yale University; Yale University; University of Michigan System;
   University of Michigan
RP Del Priore, LV (通讯作者)，Yale Sch Med, Dept Ophthalmol & Visual Sci, 40 Temple St,Suite 1B, New Haven, CT 06510 USA.
EM lucian.delpriore@yale.edu
OI Shen, Liangbo/0000-0002-1823-0854
FU Richard K. Gershon, MD, Student Research Fellowship; National Eye
   Institute (NEI) [P30 EY026878]
FX Research reported in this publication was supported by the Richard K.
   Gershon, MD, Student Research Fellowship (recipient: AA) and P30
   EY026878 fromthe National Eye Institute (NEI) (recipient: Yale Vision
   Science Core). The sponsors or funding organizations had no role in the
   design or conduct of this research.
CR Bressler Neil M, 2004, JAMA, V291, P1900, DOI 10.1001/jama.291.15.1900
   Brody BL, 2001, OPHTHALMOLOGY, V108, P1893, DOI 10.1016/S0161-6420(01)00754-0
   Caire J, 2014, JAMA OPHTHALMOL, V132, P528, DOI 10.1001/jamaophthalmol.2013.8175
   Cascella R, 2014, J OPHTHALMOL, V2014, DOI 10.1155/2014/582842
   Cheung CMG, 2014, J INTERN MED, V276, P140, DOI 10.1111/joim.12227
   Choi HG, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-20374-5
   Cleland SC, 2021, OPHTHALMOL RETINA, V5, P41, DOI 10.1016/j.oret.2020.07.006
   Clemons TE, 2004, ARCH OPHTHALMOL-CHIC, V122, P716
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   Crabb JW, 2014, CSH PERSPECT MED, V4, DOI 10.1101/cshperspect.a017194
   Cugati S, 2007, ARCH OPHTHALMOL-CHIC, V125, P917, DOI 10.1001/archopht.125.7.917
   CUMMINGS SR, 1995, NEW ENGL J MED, V332, P767, DOI 10.1056/NEJM199503233321202
   Domalpally A, 2016, OPHTHALMOLOGY, V123, P2401, DOI 10.1016/j.ophtha.2016.06.025
   Fisher DE, 2015, OPHTHALMOLOGY, V122, P382, DOI 10.1016/j.ophtha.2014.08.006
   Fleckenstein M, 2014, INVEST OPHTH VIS SCI, V55, P2911, DOI 10.1167/iovs.13-13409
   Grassmann F, 2019, JAMA OPHTHALMOL, V137, P867, DOI 10.1001/jamaophthalmol.2019.1318
   Hanus J, 2015, AGEING RES REV, V24, P286, DOI 10.1016/j.arr.2015.09.002
   Holz FG, 2007, AM J OPHTHALMOL, V143, P463, DOI 10.1016/j.ajo.2006.11.041
   Holz FG, 2014, OPHTHALMOLOGY, V121, P1079, DOI 10.1016/j.ophtha.2013.11.023
   Kassoff A, 1999, CONTROL CLIN TRIALS, V20, P573
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Khanifar AA, 2012, RETINA-J RET VIT DIS, V32, P1884, DOI 10.1097/IAE.0b013e3182509778
   Klein ML, 2008, OPHTHALMOLOGY, V115, P1026, DOI 10.1016/j.ophtha.2007.08.030
   Klein R, 2002, OPHTHALMOLOGY, V109, P1767, DOI 10.1016/S0161-6420(02)01146-6
   Knudtson MD, 2006, ARCH OPHTHALMOL-CHIC, V124, P243, DOI 10.1001/archopht.124.2.243
   Litwinska Z, 2019, FRONT AGING NEUROSCI, V11, DOI 10.3389/fnagi.2019.00286
   Machalinska A, 2012, ACTA OPHTHALMOL, V90, P695, DOI 10.1111/j.1755-3768.2011.02295.x
   Mailman MD, 2007, NAT GENET, V39, P1181, DOI 10.1038/ng1007-1181
   Marsiglia M, 2013, INVEST OPHTH VIS SCI, V54, P7362, DOI 10.1167/iovs.12-11073
   McCarty CA, 2001, BRIT J OPHTHALMOL, V85, P322, DOI 10.1136/bjo.85.3.322
   McGuinness MB, 2017, EYE, V31, P1345, DOI 10.1038/eye.2017.139
   McGuinness MB, 2017, OPHTHAL EPIDEMIOL, V24, P141, DOI 10.1080/09286586.2016.1259422
   Mooijaart SP, 2007, EXP GERONTOL, V42, P1116, DOI 10.1016/j.exger.2007.08.001
   Niazi S, 2019, ACTA OPHTHALMOL, V97, P558, DOI 10.1111/aos.14072
   Papudesu C, 2018, OPHTHALMOLOGY, V125, P512, DOI 10.1016/j.ophtha.2017.10.028
   Pathai S, 2013, AGEING RES REV, V12, P490, DOI 10.1016/j.arr.2012.11.002
   Pedula KL, 2015, J AM GERIATR SOC, V63, P910, DOI 10.1111/jgs.13405
   Pennington KL, 2016, EYE VISION, V3, DOI 10.1186/s40662-016-0063-5
   Pequignot R, 2019, J AM GERIATR SOC, V67, P546, DOI 10.1111/jgs.15731
   Pikuleva IA, 2014, PROG RETIN EYE RES, V41, P64, DOI 10.1016/j.preteyeres.2014.03.002
   Reuter S, 2010, FREE RADICAL BIO MED, V49, P1603, DOI 10.1016/j.freeradbiomed.2010.09.006
   Sepp T, 2006, INVEST OPHTH VIS SCI, V47, P536, DOI 10.1167/iovs.05-1143
   Shankar A, 2007, AM J EPIDEMIOL, V165, P375, DOI 10.1093/aje/kwk022
   Shen LB, 2018, OPHTHALMOL RETINA, V2, P914, DOI 10.1016/j.oret.2018.01.019
   Shen LBL, 2022, BRIT J OPHTHALMOL, V106, P689, DOI 10.1136/bjophthalmol-2020-317636
   Shen LL, 2021, OPHTHALMOL RETINA, V5, P868, DOI 10.1016/j.oret.2020.12.002
   Shen LL, 2021, OPHTHALMOL RETINA, V5, P761, DOI 10.1016/j.oret.2020.11.003
   Shen LL, 2020, OPHTHALMOL RETINA, V4, P899, DOI 10.1016/j.oret.2020.03.020
   Shen LBL, 2019, RETINA-J RET VIT DIS, V39, P1829, DOI 10.1097/IAE.0000000000002480
   Wang JCC, 2015, MOL VIS, V21, P264
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Wood JM, 2011, INVEST OPHTH VIS SCI, V52, P5088, DOI 10.1167/iovs.10-6644
   Xin XL, 2018, RETINA-J RET VIT DIS, V38, P497, DOI 10.1097/IAE.0000000000001741
   Yehoshua Z, 2011, OPHTHALMOLOGY, V118, P679, DOI 10.1016/j.ophtha.2010.08.018
NR 54
TC 0
Z9 0
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 0721-832X
EI 1435-702X
J9 GRAEF ARCH CLIN EXP
JI Graefes Arch. Clin. Exp. Ophthalmol.
PD SEP
PY 2021
VL 259
IS 9
BP 2643
EP 2651
DI 10.1007/s00417-021-05145-9
EA MAR 2021
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA UD4CF
UT WOS:000630616000001
PM 33742280
DA 2022-11-30
ER

PT J
AU Alexander, P
   Mushtaq, F
   Osmond, C
   Amoaku, W
AF Alexander, P.
   Mushtaq, F.
   Osmond, C.
   Amoaku, W.
TI Microperimetric changes in neovascular age-related macular degeneration
   treated with ranibizumab
SO EYE
LA English
DT Article
DE microperimetry; wet macular degeneration; choroidal neovascular membrane
ID INTRAVITREAL RANIBIZUMAB; BEVACIZUMAB; SENSITIVITY; MACULOPATHY; EYE
AB Purpose To assess the value of microperimetry in eyes with neovascular age-related macular degeneration previously treated with ranibizumab and now in the maintenance phase of therapy.
   Methods A total of 21 eyes (14 patients) were included. Microperimetry was performed using the Macular Integrity Assessment Device on at least three occasions for each eye. Intravitreal ranibizumab was administered if visual acuity (VA) or optical coherence tomography (OCT) showed signs of active disease.
   Results Five eyes showed no change in VA or OCT findings, and required no intravitreal injections. In these eyes, mean threshold sensitivity (TS) decreased by 13% (paired t-test, P = 0.05) during the study period, but fixation stability (FS) was unchanged. In all, 16 eyes showed signs of disease activity, and therefore required ranibizumab injections during the study. In these eyes, VA, central retinal thickness (CRT), FS, and TS remained unchanged during follow-up. Peak TS was noted when CRT was 210 mu m; above or below 210 mu m, there was a gradual reduction in TS.
   Conclusion This study has provided novel information on the relationship between macular sensitivity, CRT, and VA in the maintenance phase of ranibizumab therapy. Patients with stable VA and CRT may still have deteriorating retinal sensitivity. This is usually a late manifestation and may indicate subclinical CNV activity. Eye (2012) 26, 678-683; doi: 10.1038/eye.2012.7; published online 10 February 2012
C1 [Mushtaq, F.; Amoaku, W.] Univ Nottingham, Queens Med Ctr, Div Ophthalmol & Vis Sci, Nottingham NG7 2UH, England.
   [Alexander, P.] Univ Nottingham Hosp, Queens Med Ctr, Dept Ophthalmol, Nottingham NG7 2UH, England.
   [Osmond, C.] Univ Southampton, Southampton Gen Hosp, MRC Lifecourse Epidemiol Unit, Southampton, Hants, England.
C3 University of Nottingham; University of Nottingham; University of
   Southampton
RP Amoaku, W (通讯作者)，Univ Nottingham, Queens Med Ctr, Div Ophthalmol & Vis Sci, Nottingham NG7 2UH, England.
EM wma@nottingham.ac.uk
OI Osmond, Clive/0000-0002-9054-4655; Amoaku, Winfried/0000-0001-5028-7984
FU MRC [MC_UP_A620_1017] Funding Source: UKRI; Medical Research Council
   [MC_UP_A620_1017, MC_UU_12011/3] Funding Source: Medline
CR Bolz M, 2010, BRIT J OPHTHALMOL, V94, P185, DOI 10.1136/bjo.2008.143974
   Ergun E, 2003, OPHTHALMOLOGY, V110, P65, DOI 10.1016/S0161-6420(02)01566-X
   Franzco FKC, 2009, CLIN EXP OPHTHALMOL, V37, P275, DOI 10.1111/j.1442-9071.2009.01915.x
   Hartmann KI, 2011, RETINA-J RET VIT DIS, V31, P1323, DOI 10.1097/IAE.0b013e31820a6850
   Hatef E, 2011, AM J OPHTHALMOL, V152, P400, DOI 10.1016/j.ajo.2011.02.024
   Klein R, 1997, OPHTHALMOLOGY, V104, P7, DOI 10.1016/S0161-6420(97)30368-6
   Klein R, 1999, OPHTHALMOLOGY, V106, P1056, DOI 10.1016/S0161-6420(99)90255-5
   Landa G, 2011, RETINA-J RET VIT DIS, V31, P364, DOI 10.1097/IAE.0b013e3181e91132
   Lang GK, 2007, OPHTHALMOLOGY
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   McClure ME, 2000, BRIT J OPHTHALMOL, V84, P244, DOI 10.1136/bjo.84.3.244
   Midena E, 2007, BRIT J OPHTHALMOL, V91, P1499, DOI 10.1136/bjo.2007.119685
   Midena Edoardo, 2004, Semin Ophthalmol, V19, P55, DOI 10.1080/08820530490882896
   Midena E, 2010, OPHTHALMOLOGY, V117, P1571, DOI 10.1016/j.ophtha.2009.12.044
   Okada K, 2009, CLIN OPHTHALMOL, V3, P483
   Ozdemir H, 2012, ACTA OPHTHALMOL, V90, P71, DOI 10.1111/j.1755-3768.2009.01838.x
   Parravano M, 2010, RETINA-J RET VIT DIS, V30, P1017, DOI 10.1097/IAE.0b013e3181cfd3c6
   Prager F, 2008, RETINA-J RET VIT DIS, V28, P682, DOI 10.1097/IAE.0b013e318161dc70
   Querques G, 2008, J FR OPHTALMOL, V31, P515, DOI 10.1016/S0181-5512(08)72469-0
   Ritter M, 2010, EYE, V24, P962, DOI 10.1038/eye.2009.265
   Royal College of Ophthalmologists, 2009, AG REL MAC DEG GUID
   Squirrell DM, 2010, RETINA-J RET VIT DIS, V30, P436, DOI 10.1097/IAE.0b013e3181bd2f29
   Uppal G, 2011, INVEST OPHTH VIS SCI, V52, P6486, DOI 10.1167/iovs.10-5879
NR 23
TC 17
Z9 18
U1 0
U2 4
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0950-222X
EI 1476-5454
J9 EYE
JI Eye
PD MAY
PY 2012
VL 26
IS 5
BP 678
EP 683
DI 10.1038/eye.2012.7
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 941BP
UT WOS:000303937400008
PM 22322998
OA Green Published, Bronze
DA 2022-11-30
ER

PT J
AU Wood, A
   Guggenheim, JA
AF Wood, Ashley
   Guggenheim, Jeremy A.
TI Refractive Error Has Minimal Influence on the Risk of Age-Related
   Macular Degeneration: A Mendelian Randomization Study
SO AMERICAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID INSTRUMENTS; MECHANISMS; DISEASE; MYOPIA
AB PURPOSE: To test the hypothesis that refractive errors such as myopia and hyperopia cause an increased risk of age-related macular degeneration (AMD) and to quantify the degree of risk.
   DESIGN: Two-sample Mendelian randomization analysis of data from a genome-wide association study.
   PARTICIPANTS: As instrumental variables for refractive error, 126 genome-wide significant genetic variants identified by the Consortium for Refractive Error and Myopia and 23andMe Inc. were chosen. The association with refractive error for the 126 variants was obtained from a published study for a sample of 95,505 European ancestry participants from UK Biobank. Association with AMD for the 126 genetic variants was determined from a genome-wide association study (GWAS) published by the International Age-related Macular Degeneration Genomics consortium of 33,526 (16,144 cases and 17,832 controls) European ancestry participants.
   METHODS: Two-sample Mendelian randomization (MR) analysis was used to assess the causal role of refractive error on AMD risk, using the 126 genetic variants associated with refractive error as instrumental variables, under the assumption that the relationship between refractive error and AMD risk is linear. Main outcome measurement: the risk AMD was caused by a 1-diopter (D) change in refractive error.
   RESULTS: MR analysis suggested that refractive error had very limited influence on the risk of AMD. Specifically, 1 D more hyperopic refractive error was associated with an odds ratio (OR) of 1.080 (95% confidence interval [CI], 1.021-1.142; P = 0.007) increased risk of AMD. MR-Egger, MR pleiotropy residual sum and outlier, weighted median, and Phenoscanner-based sensitivity analyses detected minimal evidence to suggest that this result was biased by horizontal pleiotropy.
   CONCLUSIONS: Under the assumption of a linear relationship between refractive error and the risk of AMD, myopia and hyperopia only minimally influence the causal risk for AMD. Thus, inconsistently reported strong associations between refractive error and AMD are likely to be the result of noncausal factors such as stochastic variation, confounding, or selection bias. (C) 2019 Elsevier Inc. All rights reserved.
C1 [Wood, Ashley; Guggenheim, Jeremy A.] Cardiff Univ, Sch Optometry & Vis Sci, Cardiff, S Glam, Wales.
C3 Cardiff University
RP Wood, A (通讯作者)，Cardiff Univ, Sch Optometry & Vis Sci, Cardiff, S Glam, Wales.
EM wooda2@cardiff.ac.uk
OI Guggenheim, Jeremy/0000-0001-5164-340X
FU UK Biobank Resource application [17351]
FX This research was supported by UK Biobank Resource application 17351.
CR Ambati J, 2012, NEURON, V75, P26, DOI 10.1016/j.neuron.2012.06.018
   Anand R, 2000, OPHTHALMOLOGY, V107, P2224
   Bowden J, 2016, GENET EPIDEMIOL, V40, P304, DOI 10.1002/gepi.21965
   Bowden J, 2015, INT J EPIDEMIOL, V44, P512, DOI 10.1093/ije/dyv080
   Brion MJA, 2013, INT J EPIDEMIOL, V42, P1497, DOI 10.1093/ije/dyt179
   Burgess S, 2018, ANNU REV GENOM HUM G, V19, P303, DOI 10.1146/annurev-genom-083117-021731
   Burgess S, 2017, OPHTHALMOLOGY, V124, P1165, DOI 10.1016/j.ophtha.2017.03.042
   Burgess S, 2013, GENET EPIDEMIOL, V37, P658, DOI 10.1002/gepi.21758
   Burgess S, 2013, J COMP EFFECT RES, V2, P209, DOI [10.2217/CER.13.14, 10.2217/cer.13.14]
   Chakravarthy U, 2010, BMC OPHTHALMOL, V10, DOI 10.1186/1471-2415-10-31
   Chamie J, 2005, WORLD POPULATION PRO
   Cheung CMG, 2012, ARCH OPHTHALMOL-CHIC, V130, P480, DOI 10.1001/archophthalmol.2011.376
   Fraser-Bell S, 2010, AM J OPHTHALMOL, V149, P735, DOI 10.1016/j.ajo.2009.11.013
   Fritsche LG, 2016, NAT GENET, V48, P134, DOI 10.1038/ng.3448
   Hartwig FP, 2016, INT J EPIDEMIOL, V45, P1717, DOI 10.1093/ije/dyx028
   Ikram MK, 2003, INVEST OPHTH VIS SCI, V44, P3778, DOI 10.1167/iovs.03-0120
   Jonas JB, 2010, OPHTHALMOLOGY, V117, P2234, DOI 10.1016/j.ophtha.2009.12.006
   Lawlor DA, 2008, STAT MED, V27, P1133, DOI 10.1002/sim.3034
   Lawrenson JG, 2013, BMC PUBLIC HEALTH, V13, DOI 10.1186/1471-2458-13-564
   Lee JY, 2013, INVEST OPHTH VIS SCI, V54, P7812, DOI 10.1167/iovs.13-12284
   Li Y, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0090897
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   MALTZMAN BA, 1979, ANN OPHTHALMOL, V11, P1197
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Milton RC, 2005, OPHTHALMOLOGY, V112, P533, DOI 10.1016/j.ophtha.2004.10.047
   Mojarrad NG, 2018, OPHTHAL PHYSL OPT, V38, P492, DOI 10.1111/opo.12579
   Morgan IG, 2012, LANCET, V379, P1739, DOI 10.1016/S0140-6736(12)60272-4
   Nickla DL, 2010, PROG RETIN EYE RES, V29, P144, DOI 10.1016/j.preteyeres.2009.12.002
   Pallikaris IG, 2006, AM J OPHTHALMOL, V141, P611, DOI 10.1016/j.ajo.2005.11.010
   Pan CW, 2013, OPHTHALMOLOGY, V120, P2058, DOI 10.1016/j.ophtha.2013.03.028
   Pan CW, 2013, OPHTHALMOLOGY, V120, P284, DOI 10.1016/j.ophtha.2012.07.065
   Pezzullo L, 2018, BMC HEALTH SERV RES, V18, DOI 10.1186/s12913-018-2836-0
   Plotnikov D, 2019, BR J OPHTHALMOL, DOI [10.1136/bjophthalmol-2018-313640, DOI 10.1136/BJOPHTHALMOL-1-2018-313640]
   Quartilho A, 2016, EYE, V30, P602, DOI 10.1038/eye.2015.288
   Quigley MG, 2018, INVEST OPHTH VIS SCI, V59, P3852, DOI 10.1167/iovs.17-23696
   R Core Team, 2022, R LANG ENV STAT COMP
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Saw SM, 2005, OPHTHAL PHYSL OPT, V25, P381, DOI 10.1111/j.1475-1313.2005.00298.x
   Simpson ARH, 2012, SURV OPHTHALMOL, V57, P498, DOI 10.1016/j.survophthal.2012.01.011
   Staley JR, 2017, GENET EPIDEMIOL, V41, P341, DOI 10.1002/gepi.22041
   Staley JR, 2016, BIOINFORMATICS, V32, P3207, DOI 10.1093/bioinformatics/btw373
   Swanson SA, 2018, EUR J EPIDEMIOL, V33, P723, DOI 10.1007/s10654-018-0396-6
   Tedja MS, 2018, NAT GENET, V50, P834, DOI 10.1038/s41588-018-0127-7
   Vansteelandt S, 2018, BIOSTATISTICS, V19, P426, DOI 10.1093/biostatistics/kxx050
   Verbanck M, 2018, NAT GENET, V50, P693, DOI 10.1038/s41588-018-0099-7
   Viechtbauer W, 2010, J STAT SOFTW, V36, P1, DOI 10.18637/jss.v036.i03
   Wang HD, 2016, LANCET, V388, P1459, DOI 10.1016/S0140-6736(16)31012-1
   Xu L, 2007, OPHTHALMOLOGY, V114, P121, DOI 10.1016/j.ophtha.2006.05.071
   Yavorska OO, 2017, INT J EPIDEMIOL, V46, P1734, DOI 10.1093/ije/dyx034
   Yonekawa Y, 2015, J CLIN MED, V4, P343, DOI 10.3390/jcm4020343
NR 50
TC 6
Z9 6
U1 2
U2 9
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0002-9394
EI 1879-1891
J9 AM J OPHTHALMOL
JI Am. J. Ophthalmol.
PD OCT
PY 2019
VL 206
BP 87
EP 93
DI 10.1016/j.ajo.2019.03.018
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA JL8VM
UT WOS:000495805400009
PM 30905725
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Kaarniranta, K
   Pawlowska, E
   Szczepanska, J
   Jablkowska, A
   Blasiak, J
AF Kaarniranta, Kai
   Pawlowska, Elzbieta
   Szczepanska, Joanna
   Jablkowska, Aleksandra
   Blasiak, Janusz
TI Can vitamin D protect against age-related macular degeneration or slow
   its progression?
SO ACTA BIOCHIMICA POLONICA
LA English
DT Review
DE dietary vitamin D; age-related macular degeneration; autophagy;
   inflammation; immune response
ID RETINAL-PIGMENT EPITHELIUM; CARCINOMA-CELL-LINES; DNA-DAMAGE RESPONSE;
   1-ALPHA,25-DIHYDROXYVITAMIN D-3; D DEFICIENCY; D-RECEPTOR; 1,25(OH)(2)
   VITAMIN-D-3; ELEVATED EXPRESSION; NLRP3 INFLAMMASOME; PROMOTER ACTIVITY
AB Dietary vitamin D plays an important role in maintaining proper vision. Age-related macular degeneration (AMD) is a complex eye disease with unknown pathogenesis. Studies on dietary supplementation and AMD occurrence and progression have produced conflicting results. In its advanced stage, AMD may be associated with apoptosis, pyroptosis or necroptosis of retinal cells. Vitamin D has been reported to play a role in modulating each of these programmed death pathways. Vitamin D is a modulator of the immune system and it acts synergistically with two members of the regulators of complement activation family H and I, whose specific variants are the most important genetic factors for AMD pathogenesis. Angiogenesis is an essential component of the neovascular form of AMD, the most devastating type of the disease and vitamin D is reputed to possess antiangiogenic properties. Cellular DNA damage response is weakened in AMD patients and so it is another process that can be modulated by vitamin D. Finally, impaired autophagy is claimed to play a role in AMD and emerging evidence suggests that vitamin D can influence autophagy. Therefore, several pathways of vitamin D metabolism and AMD pathogenesis overlap, suggesting that vitamin D could modulate the course of AMD.
C1 [Kaarniranta, Kai] Univ Eastern Finland, Dept Ophthalmol, Kuopio 70211, Finland.
   [Kaarniranta, Kai] Kuopio Univ Hosp, Dept Ophthalmol, Kuopio 70029, Finland.
   [Pawlowska, Elzbieta] Med Univ Lodz, Dept Orthodont, PL-92216 Lodz, Poland.
   [Szczepanska, Joanna] Med Univ Lodz, Dept Pediat Dent, PL-92216 Lodz, Poland.
   [Jablkowska, Aleksandra] W Bieganski Hosp, Dept Infect & Liver Dis, PL-91347 Lodz, Poland.
   [Blasiak, Janusz] Univ Lodz, Fac Biol & Environm Protect, Dept Mol Genet, PL-90236 Lodz, Poland.
C3 University of Eastern Finland; Kuopio University Hospital; University of
   Eastern Finland; Medical University Lodz; Medical University Lodz;
   University of Lodz
RP Blasiak, J (通讯作者)，Univ Lodz, Fac Biol & Environm Protect, Dept Mol Genet, PL-90236 Lodz, Poland.
EM janusz.blasiak@biol.uni.lodz.pl
OI Szczepanska, JOANNA/0000-0001-9912-5345; Pawlowska,
   Elzbieta/0000-0002-5373-4783; Blasiak, Janusz/0000-0001-9539-9584
FU Kuopio University Hospital [5503743]; Finnish Eye Foundation; Academy of
   Finland [296840]
FX This work was supported by the Kuopio University Hospital (grant no.
   5503743), the Finnish Eye Foundation and the Academy of Finland (grant
   no. 296840).
CR Ahn J, 2016, VITAM HORM, V100, P321, DOI 10.1016/bs.vh.2015.10.012
   Al Mheid I, 2017, J AM COLL CARDIOL, V70, P89, DOI 10.1016/j.jacc.2017.05.031
   Al-Hussaini H, 2008, MOL VIS, V14, P1784
   Albert DM, 2007, INVEST OPHTH VIS SCI, V48, P2327, DOI 10.1167/iovs.06-1210
   Alsalem JA, 2014, INVEST OPHTH VIS SCI, V55, P2140, DOI 10.1167/iovs.13-13019
   Annweiler C, 2016, MATURITAS, V88, P101, DOI 10.1016/j.maturitas.2016.04.002
   Aoki A, 2016, SCI REP-UK, V6, DOI 10.1038/srep20723
   Aryan Nona, 2016, Open Neurol J, V10, P83, DOI 10.2174/1874205X01610010083
   Bergsbaken T, 2009, NAT REV MICROBIOL, V7, P99, DOI 10.1038/nrmicro2070
   Blasiak J, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20010210
   Blasiak J, 2017, OXID MED CELL LONGEV, V2017, DOI 10.1155/2017/5293258
   Blasiak J, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/768026
   Blasiak J, 2013, INT J MOL SCI, V14, P2996, DOI 10.3390/ijms14022996
   Blasiak Janusz, 2013, Front Biosci (Schol Ed), V5, P412
   Blasiak J, 2012, INT J MOL SCI, V13, P13378, DOI 10.3390/ijms131013378
   Blasiak J, 2011, FRONT BIOSCI-LANDMRK, V16, P1291, DOI 10.2741/3789
   BOSCH E, 1993, J HISTOCHEM CYTOCHEM, V41, P253, DOI 10.1177/41.2.8419462
   Brandstetter C, 2016, J PHOTOCH PHOTOBIO B, V161, P177, DOI 10.1016/j.jphotobiol.2016.05.018
   Broadhead GK, 2015, NUTR REV, V73, P448, DOI 10.1093/nutrit/nuv005
   Celkova L, 2015, J CLIN MED, V4, P172, DOI 10.3390/jcm4010172
   Chang YC, 2015, TOXICOL IN VITRO, V29, P1358, DOI 10.1016/j.tiv.2015.05.014
   Chatterjee M, 2001, MUTAT RES-FUND MOL M, V475, P69, DOI 10.1016/S0027-5107(01)00080-X
   Chew EY, 2017, OPHTHALMOLOGICA, V238, P1, DOI 10.1159/000473865
   Chew EY, 2014, JAMA OPHTHALMOL, V132, P272, DOI 10.1001/jamaophthalmol.2013.6636
   Chew EY, 2012, OPHTHALMOLOGY, V119, P2282, DOI 10.1016/j.ophtha.2012.05.027
   Chirumbolo S, 2017, CLIN THER, V39, P894, DOI 10.1016/j.clinthera.2017.03.021
   Christakos S, 2011, MOL CELL ENDOCRINOL, V347, P25, DOI 10.1016/j.mce.2011.05.038
   Cougnard-Greoire A, 2015, J NUTR, V145, P1865, DOI 10.3945/jn.115.214387
   Cugati S, 2007, ARCH OPHTHALMOL-CHIC, V125, P917, DOI 10.1001/archopht.125.7.917
   Dawoud NM, 2016, SKIN PHARMACOL PHYS, V29, P76, DOI 10.1159/000443839
   Day S, 2012, ARCH OPHTHALMOL-CHIC, V130, P1070, DOI 10.1001/archophthalmol.2012.439
   de Jongh RT, 2017, MOL CELL ENDOCRINOL, V453, P144, DOI 10.1016/j.mce.2017.06.005
   Decuypere JP, 2011, CELL CALCIUM, V50, P242, DOI 10.1016/j.ceca.2011.04.001
   Duque G, 2017, AUSTRALAS J AGEING, V36, P8, DOI 10.1111/ajag.12408
   EBELING PR, 1992, J CLIN ENDOCR METAB, V75, P176, DOI 10.1210/jc.75.1.176
   Ekmekcioglu C, 2017, INT J ENV RES PUB HE, V14, DOI 10.3390/ijerph14020127
   Everitt AV, 2006, CLIN INTERV AGING, V1, P11, DOI 10.2147/ciia.2006.1.1.11
   Fedirko V, 2010, CANCER EPIDEM BIOMAR, V19, P280, DOI 10.1158/1055-9965.EPI-09-0448
   Ferrington DA, 2006, EXP EYE RES, V83, P638, DOI 10.1016/j.exer.2006.03.003
   Ferrington DA, 2016, EXP EYE RES, V145, P269, DOI 10.1016/j.exer.2016.01.018
   Field S, 2013, DERM-ENDOCRINOL, V5, DOI 10.4161/derm.25244
   Gaksch M, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0170791
   Gallagher JC, 2013, ENDOCRIN METAB CLIN, V42, P319, DOI 10.1016/j.ecl.2013.02.004
   Gedlicka C, 2006, J ORAL PATHOL MED, V35, P472, DOI 10.1111/j.1600-0714.2006.00407.x
   Geraci S, 2017, AM J PHYSIOL-RENAL, DOI [10.1152/ajpre-nal.00329.2015, DOI 10.1152/AJPRE-NAL.00329.2015]
   Golan S, 2011, EYE, V25, P1122, DOI 10.1038/eye.2011.174
   GOLDBERG J, 1988, AM J EPIDEMIOL, V128, P700, DOI 10.1093/oxfordjournals.aje.a115023
   Pardo VG, 2013, AGEING RES REV, V12, P76, DOI 10.1016/j.arr.2012.06.001
   Graffe A, 2012, J AM GERIATR SOC, V60, P1367, DOI 10.1111/j.1532-5415.2012.04015.x
   Grubler MR, 2017, REV ENDOCR METAB DIS, V18, P259, DOI 10.1007/s11154-017-9417-0
   Hager G, 2004, ACTA OTO-LARYNGOL, V124, P90, DOI 10.1080/00016480310015353
   Hager G, 2001, ACTA OTO-LARYNGOL, V121, P103
   Haussler MR, 2013, CALCIFIED TISSUE INT, V92, P77, DOI 10.1007/s00223-012-9619-0
   Haussler MR, 2012, REV ENDOCR METAB DIS, V13, P57, DOI 10.1007/s11154-011-9199-8
   He Y, 2016, TRENDS BIOCHEM SCI, V41, P1012, DOI 10.1016/j.tibs.2016.09.002
   Heaney RP, 2008, CLIN J AM SOC NEPHRO, V3, P1535, DOI 10.2215/CJN.01160308
   Hill TR, 2017, THER ADV MUSCULOSKEL, V9, P89, DOI 10.1177/1759720X17692502
   Hill TR, 2013, P NUTR SOC, V72, P372, DOI 10.1017/S0029665113002036
   Hisa T, 1996, ARCH DERMATOL RES, V288, P262, DOI 10.1007/s004030050058
   Hjelmeland LM, 2011, INVEST OPHTH VIS SCI, V52, P1622, DOI 10.1167/iovs.10-6765
   HORST RL, 1990, ENDOCRINOLOGY, V126, P1053, DOI 10.1210/endo-126-2-1053
   Hoyer-Hansen M, 2007, MOL CELL, V25, P193, DOI 10.1016/j.molcel.2006.12.009
   Hutchinson JN, 2014, HUM HERED, V78, P59, DOI 10.1159/000362814
   Hyttinen JMT, 2017, AGEING RES REV, V36, P64, DOI 10.1016/j.arr.2017.03.006
   Itty S, 2014, RETINA-J RET VIT DIS, V34, P1779, DOI 10.1097/IAE.0000000000000178
   Jarrett SG, 2012, MOL ASPECTS MED, V33, P399, DOI 10.1016/j.mam.2012.03.009
   Jee D, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0149294
   Kaarniranta K, 2017, CELL BIOL TOXICOL, V33, P113, DOI 10.1007/s10565-016-9371-8
   Kaarniranta K, 2013, AUTOPHAGY, V9, P973, DOI 10.4161/auto.24546
   Kallay E, 2002, FOOD CHEM TOXICOL, V40, P1191, DOI 10.1016/S0278-6915(02)00030-3
   Kanaki T, 2016, REV ENDOCR METAB DIS, V17, P433, DOI 10.1007/s11154-016-9392-x
   Katoh M, 2013, INT J MOL MED, V32, P763, DOI 10.3892/ijmm.2013.1444
   Kauppinen A, 2016, CELL MOL LIFE SCI, V73, P1765, DOI 10.1007/s00018-016-2147-8
   KERNACKI KA, 1994, J OCUL PHARMACOL, V10, P281, DOI 10.1089/jop.1994.10.281
   Kim EC, 2014, INVEST OPHTH VIS SCI, V55, P4823, DOI 10.1167/iovs.14-14763
   Kim HJ, 2017, ANN LAB MED, V37, P34, DOI 10.3343/alm.2017.37.1.34
   Kinyamu HK, 1996, J BONE MINER RES, V11, P1400
   Kozlowski MR, 2015, CURR EYE RES, V40, P501, DOI 10.3109/02713683.2014.935440
   Kwa FAA, 2014, DRUG DISCOV TODAY, V19, P1387, DOI 10.1016/j.drudis.2014.03.026
   Lee V, 2012, NEUROBIOL AGING, V33, P2382, DOI 10.1016/j.neurobiolaging.2011.12.002
   Li YJ, 2015, CELL PHYSIOL BIOCHEM, V35, P1663, DOI 10.1159/000373980
   Liao SM, 2017, MOL VIS, V23, P318
   Liu MM, 2012, HUM GENOMICS, V6, DOI 10.1186/1479-7364-6-13
   Lyzogubov VV, 2016, AM J PATHOL, V186, P2088, DOI 10.1016/j.ajpath.2016.03.021
   MACLAUGHLIN J, 1985, J CLIN INVEST, V76, P1536, DOI 10.1172/JCI112134
   Maguire O, 2010, CANCER BIOL THER, V10, P351, DOI 10.4161/cbt.10.4.12617
   Mangin M, 2014, INFLAMM RES, V63, P803, DOI 10.1007/s00011-014-0755-z
   Mason RS, 2010, J STEROID BIOCHEM, V121, P164, DOI 10.1016/j.jsbmb.2010.03.082
   McKay GJ, 2017, OPHTHALMOLOGY, V124, P90, DOI 10.1016/j.ophtha.2016.09.007
   Millen AE, 2017, J NUTR HEALTH AGING, V21, P772, DOI 10.1007/s12603-016-0827-6
   Millen AE, 2015, JAMA OPHTHALMOL, V133, P1171, DOI 10.1001/jamaophthalmol.2015.2715
   Millen AE, 2011, ARCH OPHTHALMOL-CHIC, V129, P481, DOI 10.1001/archophthalmol.2011.48
   Mitter SK, 2012, ADV EXP MED BIOL, V723, P83, DOI 10.1007/978-1-4614-0631-0_12
   Mizushima N, 2007, GENE DEV, V21, P2861, DOI 10.1101/gad.1599207
   Morrison Margaux A., 2011, Human Genomics, V5, P538
   Nebbioso M, 2017, CRIT REV FOOD SCI, V57, P559, DOI 10.1080/10408398.2014.893504
   Need AG, 2008, J BONE MINER RES, V23, P1859, DOI 10.1359/JBMR.080607
   Osborn MP, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0072737
   Pahl L, 2013, EXP EYE RES, V116, P234, DOI 10.1016/j.exer.2013.09.012
   Parekh N, 2007, ARCH OPHTHALMOL-CHIC, V125, P661, DOI 10.1001/archopht.125.5.661
   Pawlowska E, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17040372
   Penna G, 2000, J IMMUNOL, V164, P2405, DOI 10.4049/jimmunol.164.5.2405
   Piotrowska A, 2016, ACTA BIOCHIM POL, V63, P17, DOI 10.18388/abp.2015_1104
   Pludowski P, 2018, J STEROID BIOCHEM, V175, P125, DOI 10.1016/j.jsbmb.2017.01.021
   Pludowski P, 2013, ENDOKRYNOL POL, V64, P319, DOI 10.5603/EP.2013.0012
   Prietl B, 2013, NUTRIENTS, V5, P2502, DOI 10.3390/nu5072502
   Reibaldi M, 2016, AM J OPHTHALMOL, V161, P78, DOI 10.1016/j.ajo.2015.09.031
   Reichrath J, 2016, REV ENDOCR METAB DIS, V17, P405, DOI 10.1007/s11154-016-9353-4
   Reichrath J, 2012, DERM-ENDOCRINOL, V4, DOI 10.4161/derm.21312
   Riachy R, 2002, ENDOCRINOLOGY, V143, P4809, DOI 10.1210/en.2002-220449
   Sarma A, 2011, PROTEIN CELL, V2, P291, DOI 10.1007/s13238-011-1038-x
   Seddon JM, 2003, ARCH OPHTHALMOL-CHIC, V121, P1728, DOI 10.1001/archopht.121.12.1728
   Seddon JM, 2011, OPHTHALMOLOGY, V118, P1386, DOI 10.1016/j.ophtha.2010.12.020
   Sharma LK, 2017, NUTRITION, V34, P76, DOI 10.1016/j.nut.2016.09.014
   Shen L, 2015, NUTR J, V14, DOI 10.1186/s12937-015-0063-7
   Shibutani ST, 2015, NAT IMMUNOL, V16, P1014, DOI 10.1038/ni.3273
   SHOKRAVI MT, 1995, INVEST OPHTH VIS SCI, V36, P83
   Sikora E, 2014, CURR VASC PHARMACOL, V12, P698
   SINGH A, 2014, DAN MED J, V61
   Stevens R, 2015, CLIN NUTR ESPEN, V10, pE112, DOI 10.1016/j.clnesp.2015.03.080
   Suh HW, 2017, CURR MED CHEM, V24, P898, DOI 10.2174/0929867323666161202151856
   Suzuki T, 2000, CURR EYE RES, V20, P127, DOI 10.1076/0271-3683(200002)20:2;1-D;FT127
   Suzuki T, 2000, INVEST OPHTH VIS SCI, V41, P154
   Synowiec E, 2012, EXP EYE RES, V98, P58, DOI 10.1016/j.exer.2012.02.008
   Szaflik JP, 2009, MUTAT RES-FUND MOL M, V669, P169, DOI 10.1016/j.mrfmmm.2009.06.008
   Tulk SE, 2015, J CELL BIOCHEM, V116, P711, DOI 10.1002/jcb.24985
   Underwood BR, 2010, HUM MOL GENET, V19, P3413, DOI 10.1093/hmg/ddq253
   Uro M, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0130879
   Wang JR, 2008, J BIOL CHEM, V283, P25596, DOI 10.1074/jbc.M801716200
   Wang JJ, 2007, OPHTHALMOLOGY, V114, P92, DOI 10.1016/j.ophtha.2006.07.017
   Wong G, 2004, J STEROID BIOCHEM, V89-90, P567, DOI 10.1016/j.jsbmb.2004.03.072
   Wu SP, 2011, DISCOV MED, V11, P325
   Xiong YY, 2016, EXP MOL PATHOL, V100, P386, DOI 10.1016/j.yexmp.2016.03.003
   Xu GH, 2014, PROTEIN CELL, V5, P728, DOI 10.1007/s13238-014-0077-5
   Yu B, 2018, SCI SIGNAL, V11, DOI 10.1126/scisignal.aag3315
   Yuk JM, 2013, MOL CELLS, V36, P393, DOI 10.1007/s10059-013-0298-0
   Zhou BBS, 2000, NATURE, V408, P433, DOI 10.1038/35044005
NR 137
TC 5
Z9 5
U1 1
U2 6
PU ACTA BIOCHIMICA POLONICA
PI WARSAW
PA PASTEURA 3, 02-093 WARSAW, POLAND
SN 0001-527X
EI 1734-154X
J9 ACTA BIOCHIM POL
JI Acta Biochim. Pol.
PY 2019
VL 66
IS 2
BP 147
EP 158
DI 10.18388/abp.2018_2810
PG 12
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology
GA IR8HD
UT WOS:000481681700004
PM 31210463
OA gold
DA 2022-11-30
ER

PT J
AU Williams, MA
   Silvestri, V
   Craig, D
   Passmore, AP
   Silvestri, G
AF Williams, Michael A.
   Silvestri, Vittorio
   Craig, David
   Passmore, A. Peter
   Silvestri, Giuliana
TI The Prevalence of Age-Related Macular Degeneration in Alzheimer's
   Disease
SO JOURNAL OF ALZHEIMERS DISEASE
LA English
DT Article
DE Alzheimer's disease; amyloid-beta; macular degeneration; retinal drusen
ID AMYLOID-BETA; FOLLOW-UP; MACULOPATHY; DRUSEN; NEURODEGENERATION;
   POPULATION; ROTTERDAM; RISK; EYE
AB Background: Age-related macular degeneration (AMD) and Alzheimer's disease (AD) share several features, including the presence of extracellular abnormal deposits associated with neuronal degeneration, drusen, and plaques, respectively. Investigation of any association of AMD and specifically AD is worthwhile but has rarely been done.
   Objectives: The aim of this study was to determine the prevalence of AMD in subjects with AD in comparison with an age-matched cognitively normal cohort.
   Methods: Cases were defined as those diagnosed with AD using standardized criteria as part of their clinical care, while controls were cognitively intact individuals aged 65 years or more. Dilated retinal photographs were taken, and a range of potentially confounding factors measured including APOE genotype. AMD features were recorded and AMD grades given.
   Results: Data was collected on 322 controls and 258 cases. While AMD was associated with AD, and the proportion of cases of advanced AMD in AD cases was twice that of controls, when corrected the association was lost. AD was associated with age, the presence of an APOE allele, and smoking, while being 'generally unwell recently' was associated with a reduced risk of AD.
   Conclusion: AD and AMD are both associated with age, but our study does not find evidence they are associated with each other. However the retina offers an opportunity to non-invasively image neuronal tissue, and more sophisticated imaging techniques may shed light on ocular biomarkers of AD.
C1 [Williams, Michael A.] Queens Univ Belfast, Royal Victoria Hosp, Ctr Med Educ, Belfast BT12 6BJ, Antrim, North Ireland.
   [Silvestri, Vittorio] Queens Univ Belfast, Cent Angiog Resource Facil, Ctr Med Expt, Inst Clin Sci A, Belfast BT12 6BJ, Antrim, North Ireland.
   [Craig, David] Northern Hlth & Social Care Trust, Antrim, Antrim, North Ireland.
   [Passmore, A. Peter] Queens Univ Belfast, Royal Victoria Hosp, Sch Med Dent & Biomed Sci, Ctr Publ Hlth,Inst Clin Sci, Belfast BT12 6BJ, Antrim, North Ireland.
   [Silvestri, Giuliana] Queens Univ Belfast, Ctr Med Expt, Inst Clin Sci A, Belfast BT12 6BJ, Antrim, North Ireland.
C3 Queens University Belfast; Queens University Belfast; Queens University
   Belfast; Queens University Belfast
RP Williams, MA (通讯作者)，Queens Univ Belfast, Royal Victoria Hosp, Ctr Med Educ, Mulhouse Bldg,Mulhouse Rd, Belfast BT12 6BJ, Antrim, North Ireland.
EM m.williams@qub.ac.uk
OI Williams, Michael/0000-0002-5051-5921
FU Dunhill Medical Trust / Royal College of Physicians Research Fellowship;
   Alzheimer's Research Trust Emergency Grant
FX Dr. MA Williams was supported by a Dunhill Medical Trust / Royal College
   of Physicians Research Fellowship, and by an Alzheimer's Research Trust
   Emergency Grant.
CR Anderson DH, 2004, EXP EYE RES, V78, P243, DOI 10.1016/j.exer.2003.10.011
   Augood CA, 2006, ARCH OPHTHALMOL-CHIC, V124, P529, DOI 10.1001/archopht.124.4.529
   Baumritter A CC, 2007, ASS RES VISION OPHTH
   Bonifati DM, 2007, MOL IMMUNOL, V44, P999, DOI 10.1016/j.molimm.2006.03.007
   Dentchev T, 2003, MOL VIS, V9, P184
   Guo L, 2010, CURR ALZHEIMER RES, V7, P3, DOI 10.2174/156720510790274491
   Kaarniranta K, 2011, J ALZHEIMERS DIS, V24, P615, DOI 10.3233/JAD-2011-101908
   Keenan TDL, 2014, JAMA OPHTHALMOL, V132, P63, DOI 10.1001/jamaophthalmol.2013.5696
   Klaver CCW, 1999, AM J EPIDEMIOL, V150, P963
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   KLEIN R, 1992, BEAVER DAM EYE STUDY, V99, P933
   Kovacs Katalin A, 2007, Ideggyogy Sz, V60, P169
   Luibl V, 2006, J CLIN INVEST, V116, P378, DOI 10.1172/JCI25843
   MCKHANN G, 1984, NEUROLOGY, V34, P939, DOI 10.1212/WNL.34.7.939
   Ohno-Matsui K, 2011, PROG RETIN EYE RES, V30, P217, DOI 10.1016/j.preteyeres.2011.02.004
   Roca-Santiago H.M., 2006, Arch Soc Esp Oftalmol, V81, P73
   SCHACHAT AP, 1995, ARCH OPHTHALMOL-CHIC, V113, P728, DOI 10.1001/archopht.1995.01100060054032
   Sparrow JM, 1997, EYE, V11, P315, DOI 10.1038/eye.1997.67
   Tomany SC, 2004, OPHTHALMOLOGY, V111, P1280, DOI 10.1016/j.ophtha.2003.11.010
   van Leeuwen R, 2003, ARCH OPHTHALMOL-CHIC, V121, P519, DOI 10.1001/archopht.121.4.519
   Williams MA, 2009, AGE AGEING, V38, P648, DOI 10.1093/ageing/afp136
   Yoshida T, 2005, J CLIN INVEST, V115, P2793, DOI 10.1172/JCI24635
NR 22
TC 32
Z9 34
U1 0
U2 9
PU IOS PRESS
PI AMSTERDAM
PA NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS
SN 1387-2877
EI 1875-8908
J9 J ALZHEIMERS DIS
JI J. Alzheimers Dis.
PY 2014
VL 42
IS 3
BP 909
EP 914
DI 10.3233/JAD-140243
PG 6
WC Neurosciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Neurosciences & Neurology
GA AP7DC
UT WOS:000342237000020
PM 25024309
DA 2022-11-30
ER

PT J
AU Klein, BEK
   Howard, KP
   Lee, KE
   Iyengar, SK
   Sivakumaran, TA
   Klein, R
AF Klein, Barbara E. K.
   Howard, Kerri P.
   Lee, Kristine E.
   Iyengar, Sudha K.
   Sivakumaran, Theru A.
   Klein, Ronald
TI The Relationship of Cataract and Cataract Extraction to Age-related
   Macular Degeneration: The Beaver Dam Eye Study
SO OPHTHALMOLOGY
LA English
DT Article
ID BLUE MOUNTAINS EYE; VISUAL-ACUITY; RISK-FACTORS; 5-YEAR INCIDENCE;
   MACULOPATHY; PREVALENCE; SURGERY; POPULATION; ASSOCIATION; PROGRESSION
AB Objective: To examine the associations of cataract and cataract surgery with early and late age-related macular degeneration (AMD) over a 20-year interval.
   Design: Longitudinal population-based study of age-related eye diseases.
   Participants: Beaver Dam Eye Study participants.
   Methods: Persons aged 43 to 86 years participated in the baseline examination in 1988-1990. Participants were followed up at 5-year intervals after the baseline examination. Examinations consisted of ocular examination with lens and fundus photography, medical history, measurements of blood pressure, height, and weight. Values of risk variables were updated, and incidences of early and late AMD were calculated for each 5-year interval. Odds ratios were computed using discrete linear logistic regression modeling with generalized estimating equation methods to account for correlation between the eyes and multiple intervals.
   Main Outcome Measures: Age-related macular degeneration.
   Results: After adjusting for age and sex, neither cataract nor cataract surgery was associated with increased odds for developing early AMD. Further adjusting for high-risk gene alleles (CFH and ARMS2) and other possible risk factors did not materially affect the odds ratio (OR). However, cataract surgery was associated with incidence of late AMD (OR 1.93; 95% confidence interval [CI], 1.28-2.90). This OR was not materially altered by further adjusting for high-risk alleles (CFH Y402H, ARMS2) or other risk factors. The OR for late AMD was higher for cataract surgery performed 5 or more years prior compared with less than 5 years prior.
   Conclusions: These data strongly support the past findings of an association of cataract surgery with late AMD independent of other risk factors, including high-risk genetic status, and suggest the importance of considering these findings when counseling patients regarding cataract surgery. These findings should provide further impetus for the search for measures to prevent or delay the development of age-related cataract.
   Financial Disclosure(s): The author(s) have no proprietary or commercial interest in any materials discussed in this article. Ophthalmology 2012;119:1628-1633 (C) 2012 by the American Academy of Ophthalmology.
C1 [Klein, Barbara E. K.; Howard, Kerri P.; Lee, Kristine E.; Klein, Ronald] Univ Wisconsin, Sch Med & Publ Hlth, Dept Ophthalmol & Visual Sci, Madison, WI 53726 USA.
   [Iyengar, Sudha K.; Sivakumaran, Theru A.] Case Western Reserve Univ, Dept Epidemiol & Biostat, Cleveland, OH 44106 USA.
   [Sivakumaran, Theru A.] Cincinnati Childrens Hosp Med Ctr, Div Human Genet, Cincinnati, OH USA.
C3 University of Wisconsin System; University of Wisconsin Madison; Case
   Western Reserve University; Cincinnati Children's Hospital Medical
   Center
RP Klein, BEK (通讯作者)，Univ Wisconsin, Sch Med & Publ Hlth, Dept Ophthalmol & Visual Sci, 610 N Walnut St,4th Floor WARF, Madison, WI 53726 USA.
EM kleinb@epi.ophth.wisc.edu
RI /S-1190-2019
OI /0000-0001-7488-250X; Klein, Ronald/0000-0002-4428-6237
FU National Institutes of Health [EY06594]; Research to Prevent Blindness,
   New York, NY; National Eye Institute; NATIONAL EYE INSTITUTE
   [U10EY006594] Funding Source: NIH RePORTER
FX This study was supported by National Institutes of Health Grant EY06594
   (B. E. K. Klein and R. Klein) and, in part, by Research to Prevent
   Blindness (R. Klein and B. E. K. Klein, Senior Scientific Investigator
   Awards), New York, NY. The National Eye Institute provided funding for
   the entire study, including the collection and analyses of data; R. P.
   B. provided additional support for data analyses. Neither funding
   organization had a role in the design or conduct of this research.
CR Agresti A., 2007, INTRO CATEGORICAL DA, P99
   Chakravarthy U, 2010, BMC OPHTHALMOL, V10, DOI 10.1186/1471-2415-10-31
   Chan CK, 2007, RETINA-J RET VIT DIS, V27, P541, DOI 10.1097/IAE.0b013e3180cc2612
   Cheung CMG, 2012, ARCH OPHTHALMOL-CHIC, V130, P480, DOI 10.1001/archophthalmol.2011.376
   Chew EY, 2009, OPHTHALMOLOGY, V116, P297, DOI 10.1016/j.ophtha.2008.09.019
   CRUICKSHANKS KJ, 1992, AM J PUBLIC HEALTH, V82, P1658, DOI 10.2105/AJPH.82.12.1658
   Day S, 2011, AM J OPHTHALMOL, V152, P1014, DOI 10.1016/j.ajo.2011.05.008
   Freeman EE, 2003, AM J OPHTHALMOL, V135, P849, DOI 10.1016/S0002-9394(02)02253-5
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Hosmer DW, 1989, APPL LOGISTIC REGRES, P238
   JAVITT JC, 1995, OPHTHALMOLOGY, V102, P1583
   Jonasson F, 2011, OPHTHALMOLOGY, V118, P825, DOI 10.1016/j.ophtha.2010.08.044
   KLEIN BEK, 1990, OPHTHALMOLOGY, V97, P1428
   Klein R, 1997, OPHTHALMOLOGY, V104, P7, DOI 10.1016/S0161-6420(97)30368-6
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Klein R, 2001, OPHTHALMOLOGY, V108, P1757, DOI 10.1016/S0161-6420(01)00769-2
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1310
   Klein R, 1996, OPHTHALMOLOGY, V103, P1169, DOI 10.1016/S0161-6420(96)30526-5
   Klein R, 2002, ARCH OPHTHALMOL-CHIC, V120, P1551, DOI 10.1001/archopht.120.11.1551
   Klein R, 2002, OPHTHALMOLOGY, V109, P1767, DOI 10.1016/S0161-6420(02)01146-6
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   Klein R, 2006, AM J OPHTHALMOL, V142, P539, DOI 10.1016/j.ajo.2006.06.015
   McCarty CA, 2001, ARCH OPHTHALMOL-CHIC, V119, P1455
   MITCHELL P, 1995, OPHTHALMOLOGY, V102, P1450
   Shah CP, 2011, OPHTHALMOLOGY, V118, P2028, DOI 10.1016/j.ophtha.2011.02.034
   THYLEFORS B, 1995, B WORLD HEALTH ORGAN, V73, P115
   VINGERLING JR, 1995, OPHTHALMOLOGY, V102, P205
   Wang JJ, 2003, OPHTHALMOLOGY, V110, P1960, DOI 10.1016/S0161-6420(03)00816-9
   Xu L, 2011, GRAEF ARCH CLIN EXP, V249, P981, DOI 10.1007/s00417-010-1571-y
NR 29
TC 46
Z9 50
U1 0
U2 12
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0161-6420
J9 OPHTHALMOLOGY
JI Ophthalmology
PD AUG
PY 2012
VL 119
IS 8
BP 1628
EP 1633
DI 10.1016/j.ophtha.2012.01.050
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 982YA
UT WOS:000307080100021
PM 22578823
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Ravera, V
   Giani, A
   Pellegrini, M
   Oldani, M
   Invernizzi, A
   Carini, E
   Cigada, M
   Bottoni, F
   Staurenghi, G
AF Ravera, Vittoria
   Giani, Andrea
   Pellegrini, Marco
   Oldani, Marta
   Invernizzi, Alessandro
   Carini, Elisa
   Cigada, Mario
   Bottoni, Ferdinando
   Staurenghi, Giovanni
TI COMPARISON AMONG DIFFERENT DIAGNOSTIC METHODS IN THE STUDY OF TYPE AND
   ACTIVITY OF CHOROIDAL NEOVASCULAR MEMBRANES IN AGE-RELATED MACULAR
   DEGENERATION
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE AMD; CNV; multiimaging
ID OPTICAL COHERENCE TOMOGRAPHY; INDOCYANINE GREEN ANGIOGRAPHY;
   PHOTODYNAMIC THERAPY; RETICULAR PSEUDODRUSEN; VISUAL-ACUITY;
   VERTEPORFIN; AUTOFLUORESCENCE; RANIBIZUMAB; SUBTYPES; TAP
AB Purpose: To determine interobserver and intraobserver agreement in classifying the subtypes of choroidal neovascularization (CNV) and the decision of retreatment in patients affected by exudative age-related macular degeneration. Different imaging techniques were evaluated individually and compared with multiimaging.
   Methods: Fifty-two patients with naive CNV in age-related macular degeneration were evaluated after 3 monthly intravitreal injections of ranibizumab. Choroidal neovascularization subtype and activity were evaluated using spectral domain optical coherence tomography, infrared light, fundus autofluorescence, fluorescein angiography (FA), and indocyanine green angiography (ICGA). The evaluation was performed independently by 10 different retina specialists, 2 for each test. Other two operators analyzed all the information available together.
   Results: The interobserver k regarding the types of CNV was 0.69 for multiimaging, 0.63 for spectral domain optical coherence tomography, 0.43 for FA, and 0.46 for ICGA. The k values for interobserver for retreatment decision were 0.77 for multiimaging, 0.88 for spectral domain optical coherence tomography, 0.61 for infrared, 0.37 for fundus autofluorescence, 0.25 for FA, and 0.23 for ICGA. Fluorescein angiography, spectral domain optical coherence tomography, ICGA, and infrared showed good association with multiimaging on defining CNV activity (P = 0.0003, P, 0.0001, P = 0.01, and P = 0.05, respectively).
   Conclusion: Optical coherence tomography and infrared evaluations of CNV activity were reproducible and strongly associated with multiimaging, whereas FA and ICGA evaluations showed poor reproducibility.
C1 [Ravera, Vittoria; Giani, Andrea; Pellegrini, Marco; Oldani, Marta; Invernizzi, Alessandro; Cigada, Mario; Bottoni, Ferdinando; Staurenghi, Giovanni] Univ Milan, Dept Biomed & Clin Sci Luigi Sacco, Luigi Sacco Hosp, ASST Fatebenefratelli Sacco,Eye Clin, Milan, Italy.
   [Carini, Elisa] ASST Fatebenefratelli Sacco, Milan, Italy.
C3 University of Milan; Luigi Sacco Hospital
RP Staurenghi, G (通讯作者)，Univ Milan, Eye Clin, Luigi Sacco Hosp, Via GB Grassi 74, I-20157 Milan, Italy.
EM giovanni.staurenghi@unimi.it
OI pellegrini, marco/0000-0002-3550-591X
CR Barbazetto I, 2003, ARCH OPHTHALMOL-CHIC, V121, P1253
   Bindewald A, 2005, INVEST OPHTH VIS SCI, V46, P3309, DOI 10.1167/iovs.04-0430
   Blinder KJ, 2003, AM J OPHTHALMOL, V136, P407, DOI 10.1016/S0002-9394(03)00223-X
   BRESSLER NM, 1988, SURV OPHTHALMOL, V32, P375, DOI 10.1016/0039-6257(88)90052-5
   Framme C, 2012, ACTA OPHTHALMOL, V90, P49, DOI 10.1111/j.1755-3768.2010.01940.x
   Freund KB, 2008, RETINA-J RET VIT DIS, V28, P201, DOI 10.1097/IAE.0b013e3181669504
   GASS JDM, 1994, AM J OPHTHALMOL, V118, P285, DOI 10.1016/S0002-9394(14)72951-4
   Gess AJ, 2011, SEMIN OPHTHALMOL, V26, P225, DOI 10.3109/08820538.2011.582533
   Giani A, 2011, INVEST OPHTH VIS SCI, V52, P5579, DOI 10.1167/iovs.10-6617
   Giani A, 2011, RETINA-J RET VIT DIS, V31, P942, DOI 10.1097/IAE.0b013e31820a68cc
   Grossniklaus HE, 1998, AM J OPHTHALMOL, V126, P59, DOI 10.1016/S0002-9394(98)00145-7
   Hartnett ME, 1996, OPHTHALMOLOGY, V103, P58, DOI 10.1016/S0161-6420(96)30731-8
   Hartnett ME, 1996, OPHTHALMOLOGY, V103, P2042, DOI 10.1016/S0161-6420(96)30389-8
   Hawkins BS, 1999, MOL VIS, V5
   Heimes B, 2008, GRAEF ARCH CLIN EXP, V246, P1229, DOI 10.1007/s00417-008-0854-z
   Holz FG, 2003, OPHTHALMOLOGY, V110, P400, DOI 10.1016/S0161-6420(02)01770-0
   Lalwani GA, 2009, AM J OPHTHALMOL, V148, P43, DOI 10.1016/j.ajo.2009.01.024
   Liakopoulos S, 2008, INVEST OPHTH VIS SCI, V49, P5048, DOI 10.1167/iovs.08-1877
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Miller JW, 1999, ARCH OPHTHALMOL-CHIC, V117, P1161
   Mitchell P, 2010, BRIT J OPHTHALMOL, V94, P2, DOI 10.1136/bjo.2009.159160
   Pauleikhoff D, 2005, RETINA-J RET VIT DIS, V25, P1065, DOI 10.1097/00006982-200512000-00016
   Polito A, 2006, ANN ACAD MED SINGAP, V35, P420
   Querques G, 2010, RETINA-J RET VIT DIS, V30, P222, DOI 10.1097/IAE.0b013e3181bceef0
   Ravera V, 2016, RETINA-J RET VIT DIS, V36, P2274, DOI 10.1097/IAE.0000000000001152
   Semoun O, 2009, BRIT J OPHTHALMOL, V93, P182, DOI 10.1136/bjo.2008.145235
   STERNBERG P, 1991, ARCH OPHTHALMOL-CHIC, V109, P1232
   Sulzbacher F, 2011, AM J OPHTHALMOL, V152, P799, DOI 10.1016/j.ajo.2011.04.011
   Suzuki M, 2014, AM J OPHTHALMOL, V157, P1005, DOI 10.1016/j.ajo.2014.01.025
   Ting TD, 2002, ARCH OPHTHALMOL-CHIC, V120, P731
   Ueda-Arakawa N, 2013, AM J OPHTHALMOL, V155, P260, DOI 10.1016/j.ajo.2012.08.011
   Yannuzzi LA, 2011, AM J OPHTHALMOL, V151, P745, DOI 10.1016/j.ajo.2011.01.043
   Zweifel SA, 2010, OPHTHALMOLOGY, V117, P303, DOI 10.1016/j.ophtha.2009.07.014
NR 33
TC 5
Z9 5
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD FEB
PY 2019
VL 39
IS 2
BP 281
EP 287
DI 10.1097/IAE.0000000000001960
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA IQ4RW
UT WOS:000480739100008
PM 29232336
DA 2022-11-30
ER

PT J
AU Moult, EM
   Alibhai, AY
   Rebhun, C
   Lee, B
   Ploner, S
   Schottenhamml, J
   Husvogt, L
   Baumal, CR
   Witkin, AJ
   Maier, A
   Duker, JS
   Rosenfeld, PJ
   Waheed, NK
   Fujimoto, JG
AF Moult, Eric M.
   Alibhai, Agha Yasin
   Rebhun, Carl
   Lee, ByungKun
   Ploner, Stefan
   Schottenhamml, Julia
   Husvogt, Lennart
   Baumal, Caroline R.
   Witkin, Andre J.
   Maier, Andreas
   Duker, Jay S.
   Rosenfeld, Phillip J.
   Waheed, Nadia K.
   Fujimoto, James G.
TI SPATIAL DISTRIBUTION OF CHORIOCAPILLARIS IMPAIRMENT IN EYES WITH
   CHOROIDAL NEOVASCULARIZATION SECONDARY TO AGE-RELATED MACULAR
   DEGENERATION A Quantitative OCT Angiography Study
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE choriocapillaris; CNV; OCTA; AMD; blood flow; choroid
ID OPTICAL COHERENCE TOMOGRAPHY; SWEPT-SOURCE; MOTION CORRECTION;
   SPECTRAL-DOMAIN; AMPLITUDE-DECORRELATION; GEOGRAPHIC ATROPHY;
   ULTRAHIGH-SPEED; PENETRATION; ARTIFACTS; RETINA
AB Purpose: To develop an optical coherence tomography angiography (OCTA)-based framework for quantitatively analyzing the spatial distribution of choriocapillaris (CC) impairment around choroidal neovascularization (CNV) secondary to age-related macular degeneration. Methods: In a retrospective, cross-sectional study, 400-kHz swept-source OCTA images from 7 eyes of 6 patients with CNV secondary to age-related macular degeneration were quantitatively analyzed using custom software. A lesion-centered zonal OCTA analysis technique-which portioned the field-of-view into zones relative to CNV boundaries-was developed to quantify the spatial dependence of CC flow deficits. Results: Quantitative, lesion-centered zonal analysis of CC OCTA images revealed highest flow-deficit percentages near CNV boundaries, decreasing in zones farther from the boundaries. Optical coherence tomography angiography using shorter (1.5 ms) interscan times revealed more severe flow deficits than OCTA using longer (3.0 ms) interscan times; however, spatial trends were similar for both interscan times. A detailed description of the OCTA processing steps and parameters was provided so as to elucidate their influence on quantitative measurements. Conclusion: Impairment of the CC, assessed by flow-deficit percentages, was most prominent closest to CNV boundaries. The lesion-centered zonal analysis technique enabled quantitative CC measurements relative to focal lesions. Understanding how processing steps, imaging/processing parameters, and artifacts can affect quantitative CC measurements is important for longitudinal, OCTA-based studies of disease progression, and treatment response.
C1 [Moult, Eric M.; Lee, ByungKun; Fujimoto, James G.] MIT, Dept Elect Engn & Comp Sci, Res Lab Elect, Cambridge, MA 02139 USA.
   [Alibhai, Agha Yasin; Rebhun, Carl; Baumal, Caroline R.; Witkin, Andre J.; Duker, Jay S.; Waheed, Nadia K.] Tufts Med Ctr, New England Eye Ctr, Boston, MA 02111 USA.
   [Ploner, Stefan; Schottenhamml, Julia; Husvogt, Lennart; Maier, Andreas] Friedrich Alexander Univ Erlangen Nurnberg FAU, Dept Comp Sci, Pattern Recognit Lab, Erlangen, Germany.
   [Rosenfeld, Phillip J.] Univ Miami, Miller Sch Med, Dept Ophthalmol, Bascom Palmer Eye Inst, Miami, FL 33136 USA.
C3 Massachusetts Institute of Technology (MIT); Tufts Medical Center;
   University of Erlangen Nuremberg; Bascom Palmer Eye Institute;
   University of Miami
RP Fujimoto, JG (通讯作者)，Dept Elect Engn & Comp Sci, Res Lab Elect, 77 Massachusetts Ave, Cambridge, MA 02139 USA.
EM jgfuji@mit.edu
RI Maier, Andreas/AAV-6505-2021
OI Maier, Andreas/0000-0002-9550-5284
FU NIH [5-R01-EY011289-31]
FX NIH 5-R01-EY011289-31, Macula Vision Research Foundation (MVRF),
   Champalimaud Vision Award, Beckman-Argyros Award in Vision Research,
   Massachusetts Lions Clubs.
CR Agemy SA, 2015, RETINA-J RET VIT DIS, V35, P2353, DOI 10.1097/IAE.0000000000000862
   Al-Sheikh M, 2017, INVEST OPHTH VIS SCI, V58, P2063, DOI 10.1167/iovs.16-21289
   Bhutto I, 2012, MOL ASPECTS MED, V33, P295, DOI 10.1016/j.mam.2012.04.005
   Biesemeier A, 2014, NEUROBIOL AGING, V35, P2562, DOI 10.1016/j.neurobiolaging.2014.05.003
   Borrelli E, 2017, INVEST OPHTH VIS SCI, V58, P4792, DOI 10.1167/iovs.17-22360
   Braaf B, 2012, OPT EXPRESS, V20, P20516, DOI 10.1364/OE.20.020516
   Camino A, 2017, BIOMED OPT EXPRESS, V8, P3053, DOI 10.1364/BOE.8.003053
   Camino A, 2016, BIOMED OPT EXPRESS, V7, P3905, DOI 10.1364/BOE.7.003905
   Campbell JP, 2017, SCI REP-UK, V7, DOI 10.1038/srep42201
   Chakravarthy U, 2013, LANCET, V382, P1258, DOI 10.1016/S0140-6736(13)61501-9
   Chiu SJ, 2010, OPT EXPRESS, V18, P19413, DOI 10.1364/OE.18.019413
   Choi W, 2015, OPHTHALMOLOGY, V122, P2532, DOI 10.1016/j.ophtha.2015.08.029
   Cole ED, 2017, OPHTHALMOL RETINA, V1, P435, DOI 10.1016/j.oret.2017.01.019
   Gao SS, 2016, INVEST OPHTH VIS SCI, V57, pOCT27, DOI 10.1167/iovs.15-19043
   Gorczynska I, 2017, SPIE P, V1004510, P1004510
   Gorczynska I, 2016, BIOMED OPT EXPRESS, V7, P911, DOI 10.1364/BOE.7.000911
   Grunwald JE, 2014, OPHTHALMOLOGY, V121, P150, DOI 10.1016/j.ophtha.2013.08.015
   HAYASHI K, 1985, OPHTHALMOLOGICA, V190, P30, DOI 10.1159/000309489
   Hong YJ, 2013, INVEST OPHTH VIS SCI, V54, P3621, DOI 10.1167/iovs.12-11184
   Jaillon F, 2012, OPT EXPRESS, V20, P385, DOI 10.1364/OE.20.000385
   Jia YL, 2014, OPHTHALMOLOGY, V121, P1435, DOI 10.1016/j.ophtha.2014.01.034
   Jia YL, 2012, OPT EXPRESS, V20, P4710, DOI 10.1364/OE.20.004710
   Kashani AH, 2017, PROG RETIN EYE RES, V60, P66, DOI 10.1016/j.preteyeres.2017.07.002
   Kraus MF, 2014, BIOMED OPT EXPRESS, V5, P2591, DOI 10.1364/BOE.5.002591
   Kraus MF, 2012, BIOMED OPT EXPRESS, V3, P1182, DOI 10.1364/BOE.3.001182
   Kuehlewein L, 2015, AM J OPHTHALMOL, V160, P739, DOI 10.1016/j.ajo.2015.06.030
   Kurokawa K, 2017, BIOMED OPT EXPRESS, V8, P1803, DOI 10.1364/BOE.8.001803
   Lane M, 2016, INVEST OPHTH VIS SCI, V57, pOCT585, DOI 10.1167/iovs.15-18915
   Lois N, 2013, RETINA-J RET VIT DIS, V33, P13, DOI 10.1097/IAE.0b013e3182657fff
   McLeod DS, 2009, INVEST OPHTH VIS SCI, V50, P4982, DOI 10.1167/iovs.09-3639
   MCLEOD DS, 1994, INVEST OPHTH VIS SCI, V35, P3799
   Miller AR, 2017, INVEST OPHTH VIS SCI, V58, P1499, DOI 10.1167/iovs.16-20969
   Mo S, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0169385
   Moreira-Neto CA, 2018, J OPHTHALMOL, V2018, DOI 10.1155/2018/8125267
   Moult E, 2014, OSLI RETINA, V45, P496, DOI 10.3928/23258160-20141118-03
   Moult EM, 2016, RETINA-J RET VIT DIS, V36, pS2, DOI 10.1097/IAE.0000000000001287
   Novais EA, 2016, AM J OPHTHALMOL, V164, P80, DOI 10.1016/j.ajo.2016.01.011
   OLVER JM, 1990, EYE, V4, P262, DOI 10.1038/eye.1990.38
   Povazay B, 2007, J BIOMED OPT, V12, DOI 10.1117/1.2773728
   Rebhun CB, 2018, OPHTHALMOL RETINA, V2, P306, DOI 10.1016/j.oret.2017.08.013
   Schottenhamml J, 2017, OCT OCTA SEGMENTATIO, P645
   Seddon JM, 2016, JAMA OPHTHALMOL, V134, P1272, DOI 10.1001/jamaophthalmol.2016.3519
   Spaide RF, 2008, AM J OPHTHALMOL, V146, P496, DOI 10.1016/j.ajo.2008.05.032
   Spaide RF, 2018, PROG RETIN EYE RES, V64, P1, DOI 10.1016/j.preteyeres.2017.11.003
   Spaide RF, 2018, RETINA-J RET VIT DIS, V38, P79, DOI 10.1097/IAE.0000000000001517
   Spaide RF, 2016, AM J OPHTHALMOL, V170, P58, DOI 10.1016/j.ajo.2016.07.023
   Spaide RF, 2015, RETINA-J RET VIT DIS, V35, P2163, DOI 10.1097/IAE.0000000000000765
   Uji A, 2017, JAMA OPHTHALMOL, V135, P1197, DOI 10.1001/jamaophthalmol.2017.3904
   Uji A, 2017, OPHTHALMOLOGY, V124, P944, DOI 10.1016/j.ophtha.2017.02.006
   Unterhuber A, 2005, OPT EXPRESS, V13, P3252, DOI 10.1364/OPEX.13.003252
   Zhang AQ, 2015, BIOMED OPT EXPRESS, V6, P4130, DOI 10.1364/BOE.6.004130
   Zhang M, 2016, BIOMED OPT EXPRESS, V7, P816, DOI 10.1364/BOE.7.000816
   Zhang QQ, 2018, INVEST OPHTH VIS SCI, V59, P203, DOI 10.1167/iovs.17-22953
NR 53
TC 21
Z9 22
U1 0
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD MAR
PY 2020
VL 40
IS 3
BP 428
EP 445
DI 10.1097/IAE.0000000000002556
PG 18
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA LA1RI
UT WOS:000523731700006
PM 31415449
OA Green Accepted, Green Submitted
DA 2022-11-30
ER

PT J
AU Hashemi, S
   Faramarzi, MA
   Falavarjani, KG
   Abdollahi, M
AF Hashemi, Saba
   Faramarzi, Mohammad Ali
   Falavarjani, Khalil Ghasemi
   Abdollahi, Mohammad
TI Bevacizumab for choroidal neovascularization secondary to age-related
   macular degeneration and pathological myopia
SO EXPERT OPINION ON BIOLOGICAL THERAPY
LA English
DT Article
DE age-related macular degeneration; anti-VEGF; bevacizumab; choroidal
   neovascularization; pathological myopia; VEGF
ID INTRAVITREAL PEGAPTANIB SODIUM; ENDOTHELIAL GROWTH-FACTOR; ANTI-VEGF
   AGENTS; PHOTODYNAMIC THERAPY; PROGNOSTIC-FACTORS; ADVERSE EVENTS;
   FOLLOW-UP; INJECTION; PATHOGENESIS; TRIAMCINOLONE
AB Introduction: Many retinal specialists have utilized intravitreal bevacizumab as an anti-VEGF to treat choroidal neovascularization (CNV), secondary to age-related macular degeneration (AMD) and pathological myopia, with favorable results. Bevacizumab is currently approved only for the systemic treatment of colon carcinoma, whereas it is widely used off-label for treating ocular neovascular diseases.
   Areas covered: In this review, after thorough search, 33 relevant studies conducted in the last 4 years were found. These articles comprised 14 studies about use of bevacizumab alone or in combination with other therapeutic agents to treat exudative AMD, and 19 studies on the use of myopic CNV.
   Expert opinion: Although bevacizumab is widely used as an anti-VEGF agent for the treatment of exudative AMD, data on its systemic side effects are limited because of studies' short follow-up periods, absence of appropriate controls, limitation in reporting outcomes, and lack of controlled clinical trials in Phase III. Some safety studies demonstrated no difference between bevacizumab and ranibizumab in occurrence of heart attacks or stroke. Conducting proper randomized clinical trials with long-term follow-up is crucial to make sure about efficacy and safety of bevacizumab.
C1 [Hashemi, Saba; Faramarzi, Mohammad Ali] Univ Tehran Med Sci, Dept Pharmaceut Biotechnol, Fac Pharm, Tehran 1417614411, Iran.
   [Hashemi, Saba; Faramarzi, Mohammad Ali] Biotechnol Res Ctr, Tehran, Iran.
   [Falavarjani, Khalil Ghasemi] Iran Univ Med Sci, Rassoul Akram Hosp, Eye Res Ctr, Tehran, Iran.
   [Abdollahi, Mohammad] Univ Tehran Med Sci, Fac Pharm, Tehran 1417614411, Iran.
   [Abdollahi, Mohammad] Pharmaceut Sci Res Ctr, Tehran 1417614411, Iran.
C3 Tehran University of Medical Sciences; Iran University of Medical
   Sciences; Tehran University of Medical Sciences; Tehran University of
   Medical Sciences
RP Abdollahi, M (通讯作者)，Univ Tehran Med Sci, Fac Pharm, Tehran 1417614411, Iran.
EM Mohammad@Tums.Ac.Ir
RI Abdollahi, Mohammad/B-9232-2008; Falavarjani, Khalil Ghasemi/I-4029-2019
OI Abdollahi, Mohammad/0000-0003-0123-1209; Faramarzi, Mohammad
   Ali/0000-0002-8822-453X; Ghasemi Falavarjani, Khalil/0000-0001-5221-1844
CR Abdollahi Mohammad, 2004, J Infus Nurs, V27, P386, DOI 10.1097/00129804-200411000-00004
   Akin Z, 2013, THESCIENTIFICWORLDJO, V2013
   Ambati J, 2003, SURV OPHTHALMOL, V48, P257, DOI 10.1016/S0039-6257(03)00030-4
   Axer-Siegel R, 2012, RETINA-J RET VIT DIS, V32, P1811, DOI 10.1097/IAE.0b013e31825db771
   Baba T, 2010, BRIT J OPHTHALMOL, V94, P864, DOI 10.1136/bjo.2009.166025
   Desco MC, 2011, RETINA-J RET VIT DIS, V31, P475, DOI 10.1097/IAE.0b013e3181f201a6
   Carneiro AM, 2010, RETINA-J RET VIT DIS, V30, P85, DOI 10.1097/IAE.0b013e3181c700a9
   Chakravarthy U, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.04.015
   Chen CH, 2011, J OCUL PHARMACOL TH, V27, P395, DOI 10.1089/jop.2011.0023
   Cheung LK, 2013, PHARMACOTHERAPY, V33, P838, DOI 10.1002/phar.1264
   Coppens G, 2010, Bull Soc Belge Ophtalmol, P39
   Costagliola C, 2012, EXPERT OPIN BIOL TH, V12, P1299, DOI 10.1517/14712598.2012.707176
   Ehlken C, 2014, EYE, V28, P538, DOI 10.1038/eye.2014.64
   el Matri L, 2010, GRAEF ARCH CLIN EXP, V248, P779, DOI 10.1007/s00417-010-1302-4
   El-Mollayess GM, 2013, RETINA-J RET VIT DIS, V33, P1828, DOI 10.1097/IAE.0b013e3182877a0d
   El-Mollayess GM, 2012, AM J OPHTHALMOL, V153, P481, DOI 10.1016/j.ajo.2011.08.018
   El-Mollayess GM, 2011, SEMIN OPHTHALMOL, V26, P69, DOI 10.3109/08820538.2010.545100
   Falavarjani KG, 2013, EYE, V27, P787, DOI 10.1038/eye.2013.107
   Finger RP, 2014, SURV OPHTHALMOL, V59, P1, DOI 10.1016/j.survophthal.2013.03.009
   Foster PJ, 2014, EYE, V28, P202, DOI 10.1038/eye.2013.280
   Freund KB., 2014, CURR OPHTHALMOL REP, V2, P6
   Gharbiya M, 2012, BRIT J OPHTHALMOL, V96, P1068, DOI 10.1136/bjophthalmol-2012-301639
   Giansanti F, 2012, RETINA-J RET VIT DIS, V32, P1547, DOI 10.1097/IAE.0b013e3182411cee
   Gohel PS, 2008, AM J MED, V121, P279, DOI 10.1016/j.amjmed.2007.10.020
   Gunther JB, 2009, SURV OPHTHALMOL, V54, P372, DOI 10.1016/j.survophthal.2009.02.004
   Guo XM, 2010, ARCH OPHTHALMOL-CHIC, V128, P1473, DOI 10.1001/archophthalmol.2010.270
   Gupta B, 2010, EYE, V24, P203, DOI 10.1038/eye.2009.201
   Hara R, 2010, GRAEF ARCH CLIN EXP, V248, P931, DOI 10.1007/s00417-010-1343-8
   Iacono P, 2011, RETINA-J RET VIT DIS, V31, P1841, DOI 10.1097/IAE.0b013e31821800a4
   Ikuno Y, 2010, INVEST OPHTH VIS SCI, V51, P3721, DOI 10.1167/iovs.09-3493
   Inhoffen W, 2012, OPHTHALMOLOGE, V109, P749, DOI 10.1007/s00347-011-2498-3
   Introini U, 2012, EYE, V26, P976, DOI 10.1038/eye.2012.75
   Issa PC, 2011, GRAEF ARCH CLIN EXP, V249, P163, DOI 10.1007/s00417-010-1568-6
   Iwata E, 2012, INVEST OPHTH VIS SCI, V53, P4185, DOI 10.1167/iovs.11-9335
   Jonas JB, 2010, ACTA OPHTHALMOL, V88, P630, DOI 10.1111/j.1755-3768.2008.01502.x
   Joussen AM, 2009, DTSCH ARZTEBL INT, V65, P3
   Kaiser PK, 2012, GRAEF ARCH CLIN EXP, V250, P1563, DOI 10.1007/s00417-012-2123-4
   Kato A., 2014, TAIWAN J OPHTHALMOL, V4, P3
   Kitagawa Takako, 2013, Nippon Ganka Gakkai Zasshi, V117, P727
   Kitagawa Takako, 2013, Nippon Ganka Gakkai Zasshi, V117, P344
   Kodjikian L, 2013, OPHTHALMOLOGY, V120, P2300, DOI 10.1016/j.ophtha.2013.06.020
   Law V, 2014, NUCLEIC ACIDS RES, V42, pD1091, DOI 10.1093/nar/gkt1068
   Leveziel N, 2013, AM J OPHTHALMOL, V155, P913, DOI 10.1016/j.ajo.2012.11.021
   Leydolt C, 2010, ACTA OPHTHALMOL, V88, P594, DOI 10.1111/j.1755-3768.2008.01485.x
   Liang IC, 2014, INT OPHTHALMOL, V34, P971, DOI 10.1007/s10792-014-9907-y
   Loh BK, 2010, ANN ACAD MED SINGAP, V39, P493
   Luthert PJ., 2011, DIAGN HISTOPATHOL, V17, P10, DOI [10.1016/j.mpdhp.2010.10.004, DOI 10.1016/J.MPDHP.2010.10.004]
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Milani P, 2012, CLIN OPHTHALMOL, V6, P1885, DOI 10.2147/OPTH.S34649
   Nakanishi H, 2011, EYE, V25, P375, DOI 10.1038/eye.2010.226
   Neelam K, 2012, PROG RETIN EYE RES, V31, P495, DOI 10.1016/j.preteyeres.2012.04.001
   Ng DS, 2012, CLIN EXP OPHTHALMOL, V40, pE98, DOI 10.1111/j.1442-9071.2011.02684.x
   Nguyen QD, 2005, BRIT J OPHTHALMOL, V89, DOI 10.1136/bjo.2005.066431
   Nowak JZ, 2006, PHARMACOL REP, V58, P353
   Parodi MB, 2013, RETINA-J RET VIT DIS, V33, P593, DOI 10.1097/IAE.0b013e31826b6731
   Parodi MB, 2010, ARCH OPHTHALMOL-CHIC, V128, P437, DOI 10.1001/archophthalmol.2009.408
   Patel KH, 2013, EYE, V27, P664, DOI 10.1038/eye.2013.31
   Peiretti E, 2012, CAN J OPHTHALMOL, V47, P28, DOI 10.1016/j.jcjo.2011.12.009
   Ratnamala U, 2011, INVEST OPHTH VIS SCI, V52, P6814, DOI 10.1167/iovs.10-6815
   Rinaldi M, 2013, RETINA-J RET VIT DIS, V33, P397, DOI 10.1097/IAE.0b013e318261a73c
   Ruiz-Moreno JM, 2012, ACTA OPHTHALMOL, V90, pE82, DOI 10.1111/j.1755-3768.2010.02070.x
   Ruiz-Moreno JM, 2011, GRAEF ARCH CLIN EXP, V249, P595, DOI 10.1007/s00417-010-1599-z
   Ruiz-Moreno JM, 2010, RETINA-J RET VIT DIS, V30, P1609, DOI 10.1097/IAE.0b013e3181e22659
   Ruiz-Moreno JM, 2010, GRAEF ARCH CLIN EXP, V248, P937, DOI 10.1007/s00417-010-1340-y
   Rush RB, 2013, RETINA, V34, P846
   Saviano S, 2014, INT J OPHTHALMOL-CHI, V7, P335, DOI 10.3980/j.issn.2222-3959.2014.02.26
   Sayanagi K, 2011, J CLIN EXPT OPHTHALM, V2, P165
   Shienbaum G, 2012, AM J OPHTHALMOL, V153, P468, DOI 10.1016/j.ajo.2011.08.011
   Tao Y, 2010, J OCUL PHARMACOL TH, V26, P79, DOI 10.1089/jop.2009.0095
   Thulliez M, 2014, JAMA OPHTHALMOL
   Voykov B, 2010, GRAEF ARCH CLIN EXP, V248, P543, DOI 10.1007/s00417-009-1285-1
   Walia S, 2013, INT J PHARM RES, V3, P59
   Wang EQ, 2013, RETINA-J RET VIT DIS, V33, P1375, DOI 10.1097/IAE.0b013e31827d260a
   Wang JH, 2012, GRAEF ARCH CLIN EXP, V250, P1717, DOI 10.1007/s00417-012-2159-5
   Wolf S, 2014, OPHTHALMOLOGY, V121, P682, DOI 10.1016/j.ophtha.2013.10.023
   Wong TY, 2014, AM J OPHTHALMOL, V157, P9, DOI 10.1016/j.ajo.2013.08.010
   Yoshizawa C, 2013, JPN J OPHTHALMOL, V57, P68, DOI 10.1007/s10384-012-0206-8
   Zachary I, 2001, AM J PHYSIOL-CELL PH, V280, pC1375, DOI 10.1152/ajpcell.2001.280.6.C1375
   Zhang XY, 2014, INT J OPHTHALMOL-CHI, V7, P355, DOI 10.3980/j.issn.2222-3959.2014.02.30
   Zhu Y, 2014, COCHRANE DATABASE SY
NR 80
TC 11
Z9 12
U1 0
U2 20
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 1471-2598
EI 1744-7682
J9 EXPERT OPIN BIOL TH
JI Expert Opin. Biol. Ther.
PD DEC
PY 2014
VL 14
IS 12
BP 1837
EP 1848
DI 10.1517/14712598.2014.967210
PG 12
WC Biotechnology & Applied Microbiology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biotechnology & Applied Microbiology; Research & Experimental Medicine
GA AU4TT
UT WOS:000345605000011
PM 25283631
DA 2022-11-30
ER

PT J
AU Schmid-Kubista, KE
   Glittenberg, CG
   Cezanne, M
   Holzmann, K
   Neumaier-Ammerer, B
   Binder, S
AF Schmid-Kubista, Katharina E.
   Glittenberg, Carl G.
   Cezanne, Melanie
   Holzmann, Klaus
   Neumaier-Ammerer, Beatrix
   Binder, Susanne
TI Daytime levels of melatonin in patients with age-related macular
   degeneration
SO ACTA OPHTHALMOLOGICA
LA English
DT Article
DE age-related macular degeneration; antioxidant; circadian rhythm;
   melatonin; visual acuity
ID ENDOTHELIAL GROWTH-FACTOR; PIGMENT EPITHELIAL-CELLS; LIGHT; DAMAGE;
   TRANSMITTANCE; SECRETION; MECHANISM
AB Melatonin (N-acetyl-5-methoxytryptamine) (MT) is a hormone that acts as an antioxidant. It is produced by the pineal gland and within the retina; its release is blocked by light entering the eye. We examined whether MT daytime levels differ between pseudophakic patients with age-related macular degeneration (ARMD) and pseudophakic subjects without any ocular pathology of the same age.
   A prospective, cross-sectional, observational study was performed. Pseudophakic patients of the same age group were included. Patients underwent complete ophthalmic examinations and blood sampling between 08:00 and 10:00 hr. MT daytime value in the serum was the main outcome measure.
   Sixty-nine pseudophakic patients were included. Fifty patients with exudative and non-exudative ARMD were in the study group while 19 patients were controls. Patients with ARMD had significantly higher daytime levels of MT (P = 0.003). There were significant differences in MT daytime levels between the exudative and non-exudative forms (P = 0.009). MT values also correlated with the best-corrected visual acuity (r = -0.285, P = 0.019).
   These data indicate that pseudophakic patients with ARMD produce more MT during the day compared to pseudophakic subjects without ARMD. This may be caused by the reduced visual acuity in patients with ARMD, whereby less light reaches the photoreceptors, allowing MT secretion to continue during the day. Because MT also acts as an antioxidant and daytime levels are higher in patients with ARMD, these results might be interpreted as a rescue factor.
C1 [Schmid-Kubista, Katharina E.; Glittenberg, Carl G.; Neumaier-Ammerer, Beatrix; Binder, Susanne] Rudolf Fdn Clin, Ludwig Boltzmann Inst Retinol & Biomicroscop Lase, Dept Ophthalmol, A-1030 Vienna, Austria.
   [Cezanne, Melanie] Med Univ Vienna, Dept Anaesthesiol, Vienna, Austria.
   [Holzmann, Klaus] Med Univ Vienna, Inst Canc Res, Dept Med 1, Vienna, Austria.
C3 Ludwig Boltzmann Institute; Medical University of Vienna; Medical
   University of Vienna
RP Schmid-Kubista, KE (通讯作者)，Rudolf Fdn Clin, Ludwig Boltzmann Inst Retinol & Biomicroscop Lase, Dept Ophthalmol, Juchgasse 25, A-1030 Vienna, Austria.
EM katharina.schmid-kubista@wienkav.at
RI Holzmann, Klaus/I-4437-2019
OI Holzmann, Klaus/0000-0003-4077-3377
FU ELISA
FX The abstract was presented at the ARVO Meeting, 30 April to 4 May 2006
   in Fort Lauderdale, Florida, USA [Invest Ophthalmol Vis Sci 2006 ; 47:
   E-Abstract 5910]. We also thank Josef Schmid MD for financial support of
   the ELISA kit.
CR BLAZYNSKI C, 1991, J NEUROCHEM, V57, P685
   Cai JY, 2000, PROG RETIN EYE RES, V19, P205, DOI 10.1016/S1350-9462(99)00009-9
   Charman WN, 2003, OPHTHAL PHYSL OPT, V23, P181, DOI 10.1046/j.1475-1313.2003.00105.x
   Ferrari E, 2000, EXP GERONTOL, V35, P1239, DOI 10.1016/S0531-5565(00)00160-1
   Fourtillan JB, 2001, AM J PHYSIOL-ENDOC M, V280, pE11, DOI 10.1152/ajpendo.2001.280.1.E11
   Frank RN, 1996, AM J OPHTHALMOL, V122, P393, DOI 10.1016/S0002-9394(14)72066-5
   Holekamp NM, 2002, AM J OPHTHALMOL, V134, P220, DOI 10.1016/S0002-9394(02)01549-0
   Iuvone PM, 2005, PROG RETIN EYE RES, V24, P433, DOI 10.1016/j.preteyeres.2005.01.003
   Kvanta A, 1996, INVEST OPHTH VIS SCI, V37, P1929
   Liang FQ, 2004, EXP EYE RES, V78, P1069, DOI 10.1016/j.exer.2004.02.003
   Liang FQ, 2003, EXP EYE RES, V76, P397, DOI 10.1016/S0014-4835(03)00023-X
   Lopez PF, 1996, INVEST OPHTH VIS SCI, V37, P855
   NASH MS, 1995, INVEST OPHTH VIS SCI, V36, P95
   Ohashi Y, 1999, BIOL PSYCHIAT, V45, P1646, DOI 10.1016/S0006-3223(98)00255-8
   Ohno-Matsui K, 2001, J CELL PHYSIOL, V189, P323, DOI 10.1002/jcp.10026
   Rufiange M, 2002, INVEST OPHTH VIS SCI, V43, P2491
   Skene DJ, 2003, EXP GERONTOL, V38, P199, DOI 10.1016/S0531-5565(02)00198-5
   Sugawara T, 1998, INVEST OPHTH VIS SCI, V39, P2458
   Tosini G, 2003, J NEUROENDOCRINOL, V15, P364, DOI 10.1046/j.1365-2826.2003.00973.x
   WEALE RA, 1988, J PHYSIOL-LONDON, V395, P577, DOI 10.1113/jphysiol.1988.sp016935
   WEALE RA, 1982, BRIT J OPHTHALMOL, V66, P31, DOI 10.1136/bjo.66.1.31
   Wiechmann AF, 1999, MOL BRAIN RES, V63, P297, DOI 10.1016/S0169-328X(98)00292-7
   Winkler BS, 1999, MOL VIS, V5
   Wright KP, 1997, BRAIN RES, V747, P78, DOI 10.1016/S0006-8993(96)01268-1
   Yi CX, 2005, ANN NY ACAD SCI, V1057, P384, DOI 10.1196/annals.1356.029
   Zeitzer JM, 1999, AM J MED, V107, P432, DOI 10.1016/S0002-9343(99)00266-1
NR 26
TC 14
Z9 15
U1 0
U2 2
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1755-375X
EI 1755-3768
J9 ACTA OPHTHALMOL
JI Acta Ophthalmol.
PD FEB
PY 2009
VL 87
IS 1
BP 89
EP 93
DI 10.1111/j.1755-3768.2008.01173.x
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 399UZ
UT WOS:000262826100014
PM 18494741
DA 2022-11-30
ER

PT J
AU Brown, MM
   Brown, GC
   Stein, JD
   Roth, Z
   Campanella, J
   Beauchamp, GR
AF Brown, MM
   Brown, GC
   Stein, JD
   Roth, Z
   Campanella, J
   Beauchamp, GR
TI Age-related macular degeneration: economic burden and value-based
   medicine analysis
SO CANADIAN JOURNAL OF OPHTHALMOLOGY-JOURNAL CANADIEN D OPHTALMOLOGIE
LA English
DT Article
DE age factor; cost of illness; economics; macular clegeneration; quality
   of life
ID QUALITY-OF-LIFE; UTILITY ANALYSIS; PROSTATE-CANCER; HEALTH STATES; SCALE
AB Age-related macular degeneration (AMD) is a major public health problem. It can be estimated that 17 100 new cases of neovascular (wet) AMD and 180 000 new cases of geographic-atrophy (dry) AMD occur in Canada annually. In addition to having a devastating effect on patients' lives, the condition causes significant adverse consequences for the economy. The deleterious effect of AMD on quality of life is markedly underestimated by ophthalmologists who treat patients with AMD, by nonophthalmic physicians and by the public. In fact, patients with different degrees of severity of AMD have a perceived impairment of their quality of life that is 96% to 750% greater than the impairment estimated by treating ophthalmologists. Mild AMD causes a 17% decrease in the quality of life of the average patient, a decrease similar to that encountered with symptomatic human immunodeficiency virus infection or moderate cardiac angina. Moderate AMD produces a 40% decrease in quality of life, a decrease similar to that associated with permanent renal dialysis or severe cardiac angina. Very severe AMD causes a 63% decrement in quality of life, a decrease similar to that encountered with advanced prostatic cancer with uncontrollable pain or a severe stroke that leaves a person bedridden, incontinent and requiring constant nursing care. The adverse economic consequences of AMD include an annual $2.6 billion negative impact on Canada's gross domestic product. The return on investment is high for both current AMD therapies and research into new treatment modalities.
C1 Ctr Value Based Med, Flourtown, PA 19031 USA.
   Univ Penn, Sch Med, Dept Ophthalmol, Philadelphia, PA 19104 USA.
   Univ Penn, Leonard Davis Inst Hlth Econ, Philadelphia, PA 19104 USA.
   Eye Res Inst, Philadelphia, PA USA.
   Thomas Jefferson Univ, Jefferson Med Coll, Wills Eye Hosp, Retina Serv, Philadelphia, PA 19107 USA.
   NYU, Sch Med, New York, NY USA.
   Texas SW Sch Med, Dallas, TX USA.
C3 University of Pennsylvania; University of Pennsylvania; Jefferson
   University; New York University
RP Brown, MM (通讯作者)，Ctr Value Based Med, Box 335, Flourtown, PA 19031 USA.
EM mbrown@valuebasechnedicine.com
RI Brown, Martin M/B-3288-2009
OI Stein, Joshua/0000-0003-2937-6987
CR [Anonymous], 1991, Arch Ophthalmol, V109, P1109
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Blumenkranz MS, 2001, ARCH OPHTHALMOL-CHIC, V119, P198
   Bosch JL, 1996, MED DECIS MAKING, V16, P217, DOI 10.1177/0272989X9601600305
   Bressler NM, 2002, ARCH OPHTHALMOL-CHIC, V120, P1307
   Brown CD, 2000, PROC BRIGHTON CROP, V1-3, P85
   Brown GC, 2000, J DIABETES COMPLICAT, V14, P18, DOI 10.1016/S1056-8727(00)00061-1
   Brown GC, 2000, ARCH OPHTHALMOL-CHIC, V118, P47
   Brown GC, 2000, CAN J OPHTHALMOL, V35, P27
   Brown MM, 2003, OPHTHALMOLOGY, V110, P1076, DOI 10.1016/S0161-6420(03)00254-9
   Brown MM, 2003, SURV OPHTHALMOL, V48, P204, DOI 10.1016/S0039-6257(02)00457-5
   Brown MM, 2001, OPHTHALMOLOGY, V108, P643, DOI 10.1016/S0161-6420(00)00635-7
   Brown MM, 2005, EVIDENCE BASED VALUE
   Busbee BG, 2003, RETINA-J RET VIT DIS, V23, P279, DOI 10.1097/00006982-200306000-00001
   CASE KE, 1996, PRINCIPLES EC, P61
   Casten Robin J, 2004, Curr Opin Ophthalmol, V15, P181, DOI 10.1097/01.icu.0000120710.35941.3f
   Chapman GB, 1998, MED DECIS MAKING, V18, P278, DOI 10.1177/0272989X9801800304
   DRUMMOND MF, 2000, METHODS EC EVALUATIO, P139
   Duncan PW, 2000, NEUROPHARMACOLOGY, V39, P835, DOI 10.1016/S0028-3908(00)00003-4
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   FROBERG DG, 1989, J CLIN EPIDEMIOL, V42, P459, DOI 10.1016/0895-4356(89)90136-4
   FRYBACK DG, 1993, MED DECIS MAKING, V13, P89, DOI 10.1177/0272989X9301300202
   Gold M.R., 1996, COST EFFECTIVENESS H, P82
   HOUSER M, 2003, PITTSBURGH TRIB 0223
   Kaplan RM, 1998, INT J QUAL HEALTH C, V10, P509, DOI 10.1093/intqhc/10.6.509
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Klein R, 2002, OPHTHALMOLOGY, V109, P1767, DOI 10.1016/S0161-6420(02)01146-6
   KRAHN MD, 1994, JAMA-J AM MED ASSOC, V272, P773, DOI 10.1001/jama.272.10.773
   Kuntz KM, 1996, CIRCULATION, V94, P957, DOI 10.1161/01.CIR.94.5.957
   LAWTON MP, 1969, GERONTOLOGIST, V9, P179, DOI 10.1093/geront/9.3_Part_1.179
   Lunde I M, 1993, Scand J Prim Health Care, V11, P98, DOI 10.3109/02813439308994910
   Mangione CM, 2001, ARCH OPHTHALMOL-CHIC, V119, P1050, DOI 10.1001/archopht.119.7.1050
   MCLEOD RS, 1991, GASTROENTEROLOGY, V101, P1307, DOI 10.1016/0016-5085(91)90081-U
   Miyamoto J M, 1985, Med Decis Making, V5, P191, DOI 10.1177/0272989X8500500208
   OLEARY JF, 1995, MED DECIS MAKING, V15, P132, DOI 10.1177/0272989X9501500205
   *RAND CORP, RAND 36 IT HLTH SURV
   Rothwell PM, 1997, BMJ-BRIT MED J, V314, P1580, DOI 10.1136/bmj.314.7094.1580
   SACKETT DL, 1978, J CHRON DIS, V31, P697, DOI 10.1016/0021-9681(78)90072-3
   Samsa GP, 1998, AM HEART J, V136, P703, DOI 10.1016/S0002-8703(98)70019-5
   Schrader GD, 1997, PSYCHOTHER PSYCHOSOM, V66, P258, DOI 10.1159/000289144
   Sharma S, 1997, CAN J OPHTHALMOL, V32, P359
   Stein J D, 2002, J Clin Hypertens (Greenwich), V4, P181, DOI 10.1111/j.1524-6175.2002.00970.x
   Stein JD, 2003, BRIT J OPHTHALMOL, V87, P8, DOI 10.1136/bjo.87.1.8
   STEINBERG EP, 1994, ARCH OPHTHALMOL-CHIC, V112, P630, DOI 10.1001/archopht.1994.01090170074026
   Tengs TO, 2002, MED DECIS MAKING, V22, P475, DOI 10.1177/0272989X02238300
   Tengs TO, 2001, STROKE, V32, P964, DOI 10.1161/01.STR.32.4.964
   Tosteson ANA, 2001, OSTEOPOROSIS INT, V12, P1042, DOI 10.1007/s001980170015
   United States Central Intelligence Agency, WORLD FACTB
   *US DEP COMM, BEA NAT EC ACC
   [No title captured]
NR 50
TC 105
Z9 107
U1 0
U2 19
PU CANADIAN OPHTHAL SOC
PI OTTAWA
PA 1525 CARLING AVE SUITE 610, OTTAWA, ONTARIO K1Z 8R9, CANADA
SN 0008-4182
EI 1715-3360
J9 CAN J OPHTHALMOL
JI Can. J. Opthalmol.-J. Can. Opthalmol.
PD JUN
PY 2005
VL 40
IS 3
BP 277
EP 287
DI 10.1016/S0008-4182(05)80070-5
PG 11
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 941RH
UT WOS:000230231400003
PM 15947797
DA 2022-11-30
ER

PT J
AU Nesmith, BLW
   Ihnen, M
   Schaal, S
AF Nesmith, Brooke L. W.
   Ihnen, Mark
   Schaal, Shlomit
TI POOR RESPONDERS TO BEVACIZUMAB PHARMACOTHERAPY IN AGE-RELATED MACULAR
   DEGENERATION AND IN DIABETIC MACULAR EDEMA DEMONSTRATE INCREASED RISK
   FOR OBSTRUCTIVE SLEEP APNEA
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE obstructive sleep apnea; age-related macular degeneration; diabetic
   macular edema; poor responders; bevacizumab
ID ENDOTHELIAL GROWTH-FACTOR; BERLIN QUESTIONNAIRE; UNITED-STATES;
   INTRAVITREAL BEVACIZUMAB; HIGH PREVALENCE; RANIBIZUMAB; DISEASE;
   THERAPY; ADULTS; NONRESPONDERS
AB Purpose: To investigate the risk for obstructive sleep apnea (OSA) in patients with exudative age-related macular degeneration (AMD) or diabetic macular edema with poor response to anti-vascular endothelial growth factor therapy with bevacizumab (Avastin).
   Methods: Age-related macular degeneration group was categorized into nonexudative, exudative, or poor response exudative. Diabetic macular edema group included patients with nonproliferative diabetic retinopathy and cystoid macular edema. Patients were categorized based on the number of intravitreal injections of bevacizumab received. Both groups were compared with age-matched controls. Patients completed a screening questionnaire to assess the risk for OSA, the main outcome measure.
   Results: Of 103 patients with AMD, 56 (54.37%) had nonexudative AMD and 47 (45.63%) had exudative AMD, of which 14 (29.79%) had poor response exudative AMD and were at a significantly higher risk of OSA (P < 0.05). Of 30 diabetic macular edema patients with cystoid macular edema, 4 (19%) received 1 injection, 18 (81.82%) received 2 or more consecutive injections, and 16 (72.73%) received 3 or more consecutive injections. Risk for OSA increased significantly with increasing number of injections (P < 0.05).
   Conclusion: Patients with exudative AMD and diabetic macular edema with poor response to anti-vascular endothelial growth factor therapy have a significantly higher risk of OSA compared with age-matched controls and should be screened to assess the risk of OSA.
C1 [Nesmith, Brooke L. W.; Ihnen, Mark; Schaal, Shlomit] Univ Louisville, Dept Ophthalmol & Visual Sci, Louisville, KY 40202 USA.
C3 University of Louisville
RP Schaal, S (通讯作者)，Univ Louisville, Dept Ophthalmol & Visual Sci, 301 E Muhammad Ali Blvd, Louisville, KY 40202 USA.
EM s.schaal@louisville.edu
FU Research to Prevent Blindness, Inc, New York, NY
FX Supported in part by an unrestricted grant from Research to Prevent
   Blindness, Inc, New York, NY.
CR Abedi F, 2013, OPHTHALMOLOGY, V120, P115, DOI 10.1016/j.ophtha.2012.10.006
   Ahmadi N, 2008, SLEEP BREATH, V12, P39, DOI 10.1007/s11325-007-0125-y
   Berg S, 2008, CLIN RESPIR J, V2, P197, DOI 10.1111/j.1752-699X.2008.00076.x
   Best MW, 2013, SLEEP BREATH, V17, P1221, DOI 10.1007/s11325-013-0827-2
   Bilgin G, 2013, J NEURO-OPHTHALMOL, V33, P232, DOI 10.1097/WNO.0b013e31828eecbd
   Botros N, 2009, AM J MED, V122, P1122, DOI 10.1016/j.amjmed.2009.04.026
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Cohen SY, 2012, RETINA-J RET VIT DIS, V32, P1480, DOI 10.1097/IAE.0b013e318240a516
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   Ding J, 2012, CURR DIABETES REP, V12, P346, DOI 10.1007/s11892-012-0283-6
   Elman MJ, 2012, OPHTHALMOLOGY, V119, P2312, DOI 10.1016/j.ophtha.2012.08.022
   Epstein LJ, 2009, J CLIN SLEEP MED, V5, P263
   Ferrara N, 2006, RETINA-J RET VIT DIS, V26, P859, DOI 10.1097/01.iae.0000242842.14624.e7
   Fong DS, 2004, DIABETES CARE, V27, P2540, DOI 10.2337/diacare.27.10.2540
   Forooghian F, 2009, RETINA-J RET VIT DIS, V29, P723, DOI 10.1097/IAE.0b013e3181a2c1c3
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P532
   Glacet-Bernard A, 2010, ARCH OPHTHALMOL-CHIC, V128, P1533, DOI 10.1001/archophthalmol.2010.272
   Hariprasad SM, 2008, BRIT J OPHTHALMOL, V92, P89, DOI 10.1136/bjo.2007.122416
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Kempen JH, 2004, ARCH OPHTHALMOL-CHIC, V122, P552
   King H, 1998, DIABETES CARE, V21, P1414, DOI 10.2337/diacare.21.9.1414
   Krebs I, 2013, BRIT J OPHTHALMOL, V97, P1443, DOI 10.1136/bjophthalmol-2013-303513
   Lalwani GA, 2009, AM J OPHTHALMOL, V148, P43, DOI 10.1016/j.ajo.2009.01.024
   Lanzetta P, 2013, BRIT J OPHTHALMOL, V97, P1497, DOI 10.1136/bjophthalmol-2013-303394
   Lee Won, 2008, Expert Rev Respir Med, V2, P349, DOI 10.1586/17476348.2.3.349
   Leveque TK, 2007, SLEEP BREATH, V11, P253, DOI 10.1007/s11325-007-0112-3
   Lux A, 2007, BRIT J OPHTHALMOL, V91, P1318, DOI 10.1136/bjo.2006.113902
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Mason RH, 2012, RETINA-J RET VIT DIS, V32, P1791, DOI 10.1097/IAE.0b013e318259568b
   Mitchell P, 2011, OPHTHALMOLOGY, V118, P615, DOI 10.1016/j.ophtha.2011.01.031
   Mojon DS, 1999, OPHTHALMOLOGY, V106, P1009, DOI 10.1016/S0161-6420(99)00525-4
   Netzer NC, 1999, ANN INTERN MED, V131, P485, DOI 10.7326/0003-4819-131-7-199910050-00002
   Orlin A, 2012, RETINA-J RET VIT DIS, V32, P4, DOI 10.1097/IAE.0b013e31822a2c7c
   Otsuji T, 2013, CLIN OPHTHALMOL, V7, P1487, DOI 10.2147/OPTH.S46317
   Pack AI, 2009, PROG CARDIOVASC DIS, V51, P434, DOI 10.1016/j.pcad.2009.01.002
   Rajendram R, 2012, ARCH OPHTHALMOL-CHIC, V130, P972, DOI 10.1001/archophthalmol.2012.393
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rosenfeld PJ, 2011, OPHTHALMOLOGY, V118, P523, DOI 10.1016/j.ophtha.2010.07.011
   Schaal S, 2008, OPHTHALMOLOGY, V115, P2199, DOI 10.1016/j.ophtha.2008.07.007
   Sforza E, 2011, SLEEP MED, V12, P142, DOI 10.1016/j.sleep.2010.09.004
   Shah NA, 2010, SLEEP BREATH, V14, P131, DOI 10.1007/s11325-009-0298-7
   Shams Naveed, 2006, Ophthalmol Clin North Am, V19, P335
   Shamsuzzaman ASM, 2003, JAMA-J AM MED ASSOC, V290, P1906, DOI 10.1001/jama.290.14.1906
   Strollo PJ, 1996, NEW ENGL J MED, V334, P99, DOI 10.1056/NEJM199601113340207
   Witmer AN, 2003, PROG RETIN EYE RES, V22, P1, DOI 10.1016/S1350-9462(02)00043-5
   Yuan A, 2011, SEMIN OPHTHALMOL, V26, P149, DOI 10.3109/08820538.2011.570846
   Yuzawa M, 2013, CLIN OPHTHALMOL, V7, P1325, DOI 10.2147/OPTH.S45248
NR 47
TC 30
Z9 31
U1 0
U2 5
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD DEC
PY 2014
VL 34
IS 12
BP 2423
EP 2430
DI 10.1097/IAE.0000000000000247
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA AU9KK
UT WOS:000345911300018
PM 25062438
DA 2022-11-30
ER

PT J
AU Venkatesh, P
   Sagar, P
   Chawla, R
   Gogia, V
   Vohra, R
   Sharma, YR
AF Venkatesh, Pradeep
   Sagar, Pradeep
   Chawla, Rohan
   Gogia, Varun
   Vohra, Rajibal
   Sharma, Yog Raj
TI Evaluation of fundus autofluorescence patterns in age-related macular
   degeneration
SO INTERNATIONAL JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE age-related macular degeneration; fundus autofluorescence; lipofuscin;
   choroidal neovascularization
ID GEOGRAPHIC ATROPHY; PREVALENCE; PROGRESSION; MACULOPATHY; DISEASE;
   LIPOFUSCIN; IMPACT; EYE
AB AIM: To study the various morphological patterns of fundus autofluorescence (FAF) images in patients with age -related macular degeneration (AMD) in Indian population.
   METHODS: Totally 179 eyes of 104 patients with clinical diagnosis of AMD were recruited into the study. Autofluorescence images were captured using confocal scanning laser ophthalmoscope and the patterns of FAF were classified.
   RESULTS: Of 179 eyes, 27 (15.08%) were early AMD, 58 (32.41%) were intermediate AMD, 94 eyes (52.51%) were late AMD. Of 94 eyes with late AMD, 79 (84.04%) were neovascular AMD and 15 (15.96%) were central geographic atrophy. In eyes with early and intermediate AMD, 9 patterns of FAF were noted. Six patterns (normal, minimal change, focal increased, patchy increased, linear, reticular) were similar to that in the published classification. Two patterns (lacelike and speckled) described in the published classification were not found. Three new patterns (focal hypo -fluorescence, patchy hypo-fluorescence, mixed focal hypo-fluorescence and hyper-fluorescence) were detected. In eyes with neovascular AMD, 6 morphological patterns of FAF were noted. Two patterns (mixed hypo -fluorescence and hyper-fluorescence, central hypo -fluorescence with hyper-fluorescent rim) were similar to that in published classification. Two patterns (normal, near normal or normal background fluorescence in the centre of hypo-fluorescent area) described in the published classification were not found. Four new patterns (minimal change, hypo -fluorescent patch, central hypo fluorescence with surrounding reticular, bull's eye) were recognized. In eye with central geographic atrophy 5 morphological patterns were noted and these were similar to that in published classification.
   CONCLUSION: Phenotypic differences in the pattern of FAF exist in the study population compared to existing classification systems.
C1 [Venkatesh, Pradeep; Sagar, Pradeep; Chawla, Rohan; Gogia, Varun; Vohra, Rajibal; Sharma, Yog Raj] All India Inst Med Sci, Dept Ophthalmol, Dr Rajendra Prasad Ctr Ophthalm Sci, New Delhi 110029, India.
C3 All India Institute of Medical Sciences (AIIMS) New Delhi; Dr. Rajendra
   Prasad Centre for Ophthalmic Sciences
RP Venkatesh, P (通讯作者)，All India Inst Med Sci, Dr Rajendra Prasad Ctr Ophthalm Sci, Room 477, New Delhi 110029, India.
EM venkyprao@yahoo.com
CR Batioglu F, 2015, SEMIN OPHTHALMOL, V30, P65, DOI 10.3109/08820538.2013.810285
   Batioglu F, 2014, OPTOMETRY VISION SCI, V91, P950, DOI 10.1097/OPX.0000000000000321
   Bindewald A, 2005, INVEST OPHTH VIS SCI, V46, P3309, DOI 10.1167/iovs.04-0430
   FEENEY L, 1978, INVEST OPHTH VIS SCI, V17, P583
   Gobel AP, 2016, GRAEF ARCH CLIN EXP, V254, P59, DOI 10.1007/s00417-015-3012-4
   Holz FG, 2001, INVEST OPHTH VIS SCI, V42, P1051
   Holz FG, 2007, AM J OPHTHALMOL, V143, P463, DOI 10.1016/j.ajo.2006.11.041
   Jeong YJ, 2014, EYE, V28, P209, DOI 10.1038/eye.2013.275
   Katz ML, 1996, MECH AGEING DEV, V92, P159, DOI 10.1016/S0047-6374(96)01817-9
   Katz ML, 1996, INVEST OPHTH VIS SCI, V92, P159
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Krishnan T, 2010, INVEST OPHTH VIS SCI, V51, P701, DOI 10.1167/iovs.09-4114
   Kumar N, 2013, OPHTHALMOLOGY, V120, P334, DOI 10.1016/j.ophtha.2012.07.076
   MITCHELL P, 1995, OPHTHALMOLOGY, V102, P1450
   Peng Q, 2013, GENET MOL RES, V12, P6140, DOI 10.4238/2013.December.2.11
   Sparrow JR, 2014, J CLIN MED, V3, P1302, DOI 10.3390/jcm3041302
   Vidinova CN, 2013, KLIN MONATSBL AUGENH, V230, P1135, DOI 10.1055/s-0032-1328636
   VINGERLING JR, 1995, OPHTHALMOLOGY, V102, P205
   vonRuckmann A, 1997, INVEST OPHTH VIS SCI, V38, P478
   Yehoshua Z, 2015, OSLI RETINA, V46, P413, DOI 10.3928/23258160-20150422-03
NR 20
TC 1
Z9 1
U1 0
U2 4
PU IJO PRESS
PI XI AN
PA NO 269 YOUYI EAST RD, XI AN, 710054, PEOPLES R CHINA
SN 2222-3959
EI 2227-4898
J9 INT J OPHTHALMOL-CHI
JI Int. J. Ophthalmol.
PD DEC 18
PY 2016
VL 9
IS 12
BP 1779
EP 1784
DI 10.18240/ijo.2016.12.13
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA EG5ZF
UT WOS:000391122700013
PM 28003979
OA Green Published, gold, Green Submitted
DA 2022-11-30
ER

PT J
AU Qiu, F
   Leat, SJ
AF Qiu, Feng
   Leat, Susan J.
TI Functional deficits in early stage age-related maculopathy
SO CLINICAL AND EXPERIMENTAL OPTOMETRY
LA English
DT Article
DE age-related maculopathy; ARM; contour interaction; contrast sensitivity;
   crowding
ID BEAVER DAM EYE; MEDIATED MULTIFOCAL ELECTRORETINOGRAM; MACULAR
   DEGENERATION; CONTRAST SENSITIVITY; CONTOUR INTERACTION; VISUAL-ACUITY;
   PSYCHOPHYSICAL EVIDENCE; FLICKER SENSITIVITY; GRADING SYSTEM; LOW-VISION
AB It is of interest to examine paracentral functional deficits in early age-related maculopathy (ARM), as histopathological studies indicate that this is where the earliest changes occur. The purpose of this study is to detect the sensory functional deficits at chosen retinal areas around the fovea and at the fovea itself in patients with early age-related maculopathy and to determine the type of functional losses that are more pronounced in early ARM.
   Ten participants with early ARM and 10 age-matched controls took part. Crowded and uncrowded visual acuity and static and transient contrast sensitivity were measured in the same selected eye of each participant at eight predetermined retinal locations plus the fovea in patients with early ARM and controls. All measurements were made using computer-generated targets.
   A significant difference between the controls and subjects with ARM was found in low spatial frequency static contrast sensitivity (p = 0.05) but not for transient contrast sensitivity (p = 0.586). Visual acuity (uncrowded VA and crowded VA) showed a borderline difference (p = 0.072 and p = 0.084, respectively). Compared to controls, there was no evidence of increased contour interaction effects in early ARM (p = 0.595).
   The subjects with very early ARM showed significant loss of low spatial frequency static contrast sensitivity before the loss of high contrast VA, indicating that static contrast sensitivity may be one of the earliest functional losses in early ARM and this loss was found to extend across the central 10 degrees of the retina.
C1 [Qiu, Feng; Leat, Susan J.] Univ Waterloo, Sch Optometry, Waterloo, ON N2L 3G1, Canada.
C3 University of Waterloo
RP Qiu, F (通讯作者)，Univ Waterloo, Sch Optometry, 200 Univ Ave W, Waterloo, ON N2L 3G1, Canada.
EM leat@uwaterloo.ca
OI Leat, Susan/0000-0002-7082-035X
CR Bellmann C, 2004, OPHTHALMOLOGY, V111, P2265, DOI 10.1016/j.ophtha.2004.06.019
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   BROWN B, 1986, AM J OPTOM PHYS OPT, V63, P450
   BROWN B, 1984, AM J OPTOM PHYS OPT, V61, P265
   Brown B, 1987, CLIN EXP OPTOM, V70, P145
   Brown B, 1987, CLIN EXP OPTOM, V70, P112
   Cacho I, 2007, OPTOMETRY VISION SCI, V84, P487, DOI 10.1097/OPX.0b013e318073c2f2
   CHENG AS, 1993, OPTOMETRY VISION SCI, V70, P89, DOI 10.1097/00006324-199302000-00001
   Cruickshanks KJ, 1997, ARCH OPHTHALMOL-CHIC, V115, P242, DOI 10.1001/archopht.1997.01100150244015
   Curcio CA, 1996, INVEST OPHTH VIS SCI, V37, P1236
   EMSLEY HH, 1952, VISUAL OPTICS, P43
   ENOCH JM, 1978, INVEST OPHTH VIS SCI, V17, P208
   Falsini B, 2000, INVEST OPHTH VIS SCI, V41, P1498
   Feigl B, 2004, CURR EYE RES, V29, P327, DOI 10.1080/02713680490516198
   Flom M., 1991, PROBL OPTOM, V3, P237
   Gerth C, 2006, ARCH OPHTHALMOL-CHIC, V124, P345, DOI 10.1001/archopht.124.3.345
   Gonzalez EG, 2006, CAN J OPHTHALMOL, V41, P333, DOI 10.1139/I06-019
   Irving EL, 2006, INVEST OPHTH VIS SCI, V47, P2478, DOI 10.1167/iovs.05-1311
   JACOBS RJ, 1979, VISION RES, V19, P1187, DOI 10.1016/0042-6989(79)90183-4
   Jones Bryan W, 2005, Clin Exp Optom, V88, P282
   KELLY DH, 1977, OPT ACTA, V24, P107, DOI 10.1080/713819495
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   KLEINER RC, 1988, ARCH OPHTHALMOL-CHIC, V106, P55
   Knudtson MD, 2004, INVEST OPHTH VIS SCI, V45, P2135, DOI 10.1167/iovs.03-1085
   KULIKOWSKI JJ, 1973, J PHYSIOL-LONDON, V232, P149, DOI 10.1113/jphysiol.1973.sp010261
   KULIKOWSKI JJ, 1971, VISION RES, V11, P261, DOI 10.1016/0042-6989(71)90190-8
   Leat SJ, 1999, INVEST OPHTH VIS SCI, V40, P504
   LEAT SJ, 1990, OPHTHAL PHYSL OPT, V10, P8, DOI 10.1111/j.1475-1313.1990.tb01098.x
   Leat SJ, 1999, OPTOMETRY VISION SCI, V76, P198, DOI 10.1097/00006324-199904000-00023
   Leibowitz H M, 1980, Surv Ophthalmol, V24, P335
   Li J, 2001, BRIT J OPHTHALMOL, V85, P287, DOI 10.1136/bjo.85.3.287
   Loewenstein A, 2003, OPHTHALMOLOGY, V110, P966, DOI 10.1016/S0161-6420(03)00074-5
   LOSHIN DS, 1984, ARCH OPHTHALMOL-CHIC, V102, P1303, DOI 10.1001/archopht.1984.01040031053022
   Lovie-Kitchin Jan, 2005, Clin Exp Optom, V88, P292
   MAYER MJ, 1992, INVEST OPHTH VIS SCI, V33, P3136
   MAYER MJ, 1994, INVEST OPHTH VIS SCI, V35, P1138
   Mei M, 2007, INVEST OPHTH VIS SCI, V48, P3419, DOI 10.1167/iovs.06-0731
   Midena E, 1997, INVEST OPHTH VIS SCI, V38, P469
   MILLODOT M, 1966, BRIT J PHYSIOL OPT, V23, P75
   Mones J, 2005, EYE, V19, P1142, DOI 10.1038/sj.eye.6701717
   Owsley C, 2000, INVEST OPHTH VIS SCI, V41, P267
   Owsley C, 2007, OPHTHALMOLOGY, V114, P1728, DOI 10.1016/j.ophtha.2006.12.023
   Pardhan S, 1997, NEURO-OPHTHALMOLOGY, V18, P59, DOI 10.3109/01658109709044118
   Phipps JA, 1999, AUST NZ J OPHTHALMOL, V27, P265, DOI 10.1046/j.1440-1606.1999.00193.x
   Phipps JA, 2003, INVEST OPHTH VIS SCI, V44, P2277, DOI 10.1167/iovs.02-0769
   PLANT GD, 1991, SPATIAL VISION, V10, P43
   ROBERTSON KM, 1995, CAN J OPTOM, V57, P26
   Rohrschneider K, 2004, INVEST OPHTH VIS SCI, V45, P3257, DOI 10.1167/iovs.03-1157
   SJOSTRAND J, 1979, ACTA OPHTHALMOL, V57, P832
   STANGOS N, 1995, OPHTHALMOLOGICA, V209, P194, DOI 10.1159/000310612
   SUNNESS JS, 1985, ARCH OPHTHALMOL-CHIC, V103, P811
   SWANN PG, 1991, OPHTHAL PHYSL OPT, V11, P59, DOI 10.1016/0275-5408(91)90012-8
   Tyler CW, 1997, SPATIAL VISION, V10, P479, DOI 10.1163/156856897X00410
   VanNewkirk MR, 2000, OPHTHALMOLOGY, V107, P1593, DOI 10.1016/S0161-6420(00)00175-5
   Wang JJ, 2003, ARCH OPHTHALMOL-CHIC, V121, P658, DOI 10.1001/archopht.121.5.658
   Wang Q, 1996, INVEST OPHTH VIS SCI, V37, P2234
   Wang YZ, 2002, INVEST OPHTH VIS SCI, V43, P2055
   Wassle H, 2004, NAT REV NEUROSCI, V5, P747, DOI 10.1038/nrn1497
   Wilcox D T, 1989, J Am Optom Assoc, V60, P504
   [No title captured]
NR 61
TC 11
Z9 11
U1 0
U2 3
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0816-4622
EI 1444-0938
J9 CLIN EXP OPTOM
JI Clin. Exp. Optom.
PD MAR
PY 2009
VL 92
IS 2
BP 90
EP 98
DI 10.1111/j.1444-0938.2008.00343.x
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 412US
UT WOS:000263750300003
PM 19016808
OA Bronze
DA 2022-11-30
ER

PT J
AU Edwards, G
   Olson, CG
   Euritt, CP
   Koulen, P
AF Edwards, Genea
   Olson, Caroline G.
   Euritt, Carlyn P.
   Koulen, Peter
TI Molecular Mechanisms Underlying the Therapeutic Role of Vitamin E in
   Age-Related Macular Degeneration
SO FRONTIERS IN NEUROSCIENCE
LA English
DT Review
DE age-related macular degeneration (AMD); antioxidant; retina; tocopherol;
   tocotrienol; vitamin E
ID TOCOPHEROL TRANSFER PROTEIN; RETINAL-PIGMENT EPITHELIUM; ENDOTHELIAL
   GROWTH-FACTOR; PHOTORECEPTOR OUTER SEGMENT; ALPHA-TOCOPHEROL;
   E-DEFICIENCY; E SUPPLEMENTATION; OXIDATIVE STRESS; KINASE-C;
   EXPERIMENTAL GALACTOSEMIA
AB The eye is particularly susceptible to oxidative stress and disruption of the delicate balance between oxygen-derived free radicals and antioxidants leading to many degenerative diseases. Attention has been called to all isoforms of vitamin E, with alpha-tocopherol being the most common form. Though similar in structure, each is diverse in antioxidant activity. Preclinical reports highlight vitamin E's influence on cell physiology and survival through several signaling pathways by activating kinases and transcription factors relevant for uptake, transport, metabolism, and cellular action to promote neuroprotective effects. In the clinical setting, population-based studies on vitamin E supplementation have been inconsistent at times and follow-up studies are needed. Nonetheless, vitamin E's health benefits outweigh the controversies. The goal of this review is to recognize the importance of vitamin E's role in guarding against gradual central vision loss observed in age-related macular degeneration (AMD). The therapeutic role and molecular mechanisms of vitamin E's function in the retina, clinical implications, and possible toxicity are collectively described in the present review.
C1 [Edwards, Genea; Olson, Caroline G.; Euritt, Carlyn P.; Koulen, Peter] Univ Missouri Kansas City, Vis Res Ctr, Sch Med, Dept Ophthalmol, Kansas City, MO USA.
C3 University of Missouri System; University of Missouri Kansas City
RP Koulen, P (通讯作者)，Univ Missouri Kansas City, Vis Res Ctr, Sch Med, Dept Ophthalmol, Kansas City, MO USA.
EM koulenp@umkc.edu
OI Edwards, Genea/0000-0002-5790-5391
CR Abdel-Aal EM, 2013, NUTRIENTS, V5, P1169, DOI 10.3390/nu5041169
   ABDO KM, 1986, FOOD CHEM TOXICOL, V24, P1043, DOI 10.1016/0278-6915(86)90287-5
   Aeschimann W, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-05148-9
   ALVAREZ F, 1983, HEPATOLOGY, V3, P410
   Ambati J, 2013, NAT REV IMMUNOL, V13, P438, DOI 10.1038/nri3459
   AMEMIYA T, 1981, A GRAEF ARCH KLIN EX, V216, P103, DOI 10.1007/BF00414577
   Amorim NCM, 2022, BRIT J NUTR, V127, P1224, DOI 10.1017/S0007114521001963
   Aydemir Orhan, 2004, International Ophthalmology, V25, P283, DOI 10.1007/s10792-005-2034-z
   Aydemir Orhan, 2004, Pathophysiology, V11, P167, DOI 10.1016/j.pathophys.2004.08.001
   Betti M, 2006, FREE RADICAL BIO MED, V41, P464, DOI 10.1016/j.freeradbiomed.2006.04.012
   BHAT R, 1986, PEDIATRICS, V78, P866
   Bhutto I, 2012, MOL ASPECTS MED, V33, P295, DOI 10.1016/j.mam.2012.04.005
   BISHARA S, 1982, BRIT J OPHTHALMOL, V66, P767, DOI 10.1136/bjo.66.12.767
   Block KI, 2007, CANCER TREAT REV, V33, P407, DOI 10.1016/j.ctrv.2007.01.005
   Brigelius-Flohe R, 2007, GENES NUTR, V2, P249, DOI 10.1007/s12263-007-0055-0
   Brown BG, 2001, NEW ENGL J MED, V345, P1583, DOI 10.1056/NEJMoa011090
   Brown EE, 2019, REDOX BIOL, V24, DOI 10.1016/j.redox.2019.101201
   Bursell SE, 1999, DIABETES CARE, V22, P1245, DOI 10.2337/diacare.22.8.1245
   Callanan D, 1998, JAMA-J AM MED ASSOC, V279, P1702, DOI 10.1001/jama.279.21.1702-b
   Campbell M, 2013, ADV EXP MED BIOL, V763, P70
   CATIGNANI GL, 1977, BIOCHIM BIOPHYS ACTA, V497, P349, DOI 10.1016/0304-4165(77)90192-1
   Chapy H, 2015, BRIT J PHARMACOL, V172, P4714, DOI 10.1111/bph.13246
   Chen J, 2012, NAT MED, V18, P658, DOI 10.1038/nm.2761
   Cheung MC, 2001, ARTERIOSCL THROM VAS, V21, P1320, DOI 10.1161/hq0801.095151
   Chew EY, 2012, OPHTHALMOLOGY, V119, P2282, DOI 10.1016/j.ophtha.2012.05.027
   Cho EY, 2008, AM J CLIN NUTR, V87, P1837, DOI 10.1093/ajcn/87.6.1837
   Chowers I, 2001, EYE, V15, P525, DOI 10.1038/eye.2001.167
   Copp RP, 1999, BRAIN RES, V822, P80, DOI 10.1016/S0006-8993(99)01090-2
   Crabb JW, 2002, P NATL ACAD SCI USA, V99, P14682, DOI 10.1073/pnas.222551899
   Cunha-Vaz J, 2011, EUR J OPHTHALMOL, V21, pS3, DOI 10.5301/EJO.2010.6049
   Curcio CA, 2011, BRIT J OPHTHALMOL, V95, P1638, DOI 10.1136/bjophthalmol-2011-300344
   De Groef L, 2018, J OCUL PHARMACOL TH, V34, P129, DOI 10.1089/jop.2016.0180
   Dentchev T, 2003, MOL VIS, V9, P184
   Domanico Daniela, 2015, Med Hypothesis Discov Innov Ophthalmol, V4, P64
   DOREY CK, 1989, INVEST OPHTH VIS SCI, V30, P1691
   Doyle C, 2006, CA-CANCER J CLIN, V56, P323, DOI 10.3322/canjclin.56.6.323
   Dunaief JL, 2002, ARCH OPHTHALMOL-CHIC, V120, P1435, DOI 10.1001/archopht.120.11.1435
   Duncan KG, 1999, OPHTHALMIC RES, V31, P399, DOI 10.1159/000055564
   Duncan RS, 2022, FRONT PHARMACOL, V12, DOI 10.3389/fphar.2021.798938
   Engin KN, 2007, EUR J OPHTHALMOL, V17, P528, DOI 10.1177/112067210701700408
   Evans HM, 1925, P NATL ACAD SCI USA, V11, P373, DOI 10.1073/pnas.11.7.373
   Evans HM, 1922, SCIENCE, V56, P650, DOI 10.1126/science.56.1458.650
   FALLOR MK, 1984, J TOXICOL-CUTAN OCUL, V3, P337, DOI 10.3109/15569528409036286
   FARNSWORTH CC, 1976, BIOCHIM BIOPHYS ACTA, V443, P556, DOI 10.1016/0005-2736(76)90473-9
   Feng ZH, 2010, J NUTR BIOCHEM, V21, P1222, DOI 10.1016/j.jnutbio.2009.10.010
   Finnemann SC, 2002, P NATL ACAD SCI USA, V99, P3842, DOI 10.1073/pnas.052025899
   Fleissig E, 2021, AM J OPHTHALMOL, V222, P202, DOI 10.1016/j.ajo.2020.08.028
   Fletcher EL, 2014, OPTOMETRY VISION SCI, V91, P878, DOI 10.1097/OPX.0000000000000322
   FRAUNFELDER FW, 1995, BRIT J OPHTHALMOL, V79, P54, DOI 10.1136/bjo.79.1.54
   Glenn JV, 2009, BBA-GEN SUBJECTS, V1790, P1109, DOI 10.1016/j.bbagen.2009.04.016
   Golumbic C., 1941, J AM CHEM SOC, V63, P1279, DOI [10.1021/ja01850a037, DOI 10.1021/JA01850A037]
   Goss-Sampson MA, 1998, FREE RADICAL BIO MED, V25, P457, DOI 10.1016/S0891-5849(98)00096-3
   Grassi G, 2018, EUR HEART J, V39, P57, DOI 10.1093/eurheartj/ehx664
   Guajardo M, 1999, MOL CELL BIOCHEM, V197, P173, DOI 10.1023/A:1006926605402
   Guler H., 2022, MED REC, V4, P7
   HANDELMAN GJ, 1994, AM J CLIN NUTR, V59, P1025, DOI 10.1093/ajcn/59.5.1025
   HAYES KC, 1974, INVEST OPHTH VISUAL, V13, P499
   HAYES KC, 1974, AM J CLIN NUTR, V27, P1130, DOI 10.1093/ajcn/27.8.1130
   Hayton SM, 2003, CLIN NEUROPHYSIOL, V114, P2124, DOI 10.1016/S1388-2457(03)00214-1
   He F, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21134777
   HERRMANN RK, 1984, INVEST OPHTH VIS SCI, V25, P429
   Hosomi A, 1998, NEUROSCI LETT, V256, P159, DOI 10.1016/S0304-3940(98)00785-X
   Hosoya K, 2014, HANDBOOK OF NUTRITION, DIET, AND THE EYE, P321, DOI 10.1016/B978-0-12-401717-7.00032-0
   Hughes A., 1985, PROG RET RES, V4, P243, DOI [10.1016/0278-4327(85)90011-2, DOI 10.1016/0278-4327(85)90011-2]
   HURLEY LS, 1983, J NUTR, V113, P1875, DOI 10.1093/jn/113.9.1875
   ITO T, 1995, ARCH BIOCHEM BIOPHYS, V316, P864, DOI 10.1006/abbi.1995.1116
   Ittermann T, 2014, THYROID, V24, P1473, DOI 10.1089/thy.2014.0190
   Kaempf-Rotzoll DE, 2003, PLACENTA, V24, P439, DOI 10.1053/plac.2002.0966
   Kaempf-Rotzoll DE, 2002, BIOL REPROD, V67, P599, DOI 10.1095/biolreprod67.2.599
   Kagan DB, 2012, CLIN OPHTHALMOL, V6, P1471, DOI 10.2147/OPTH.S35139
   Kassoff A, 1999, CONTROL CLIN TRIALS, V20, P573
   Kauppinen A, 2016, CELL MOL LIFE SCI, V73, P1765, DOI 10.1007/s00018-016-2147-8
   Kim JH, 2010, AM J PATHOL, V176, P1517, DOI 10.2353/ajpath.2010.090398
   Kim SR, 2006, EXP EYE RES, V82, P828, DOI 10.1016/j.exer.2005.10.004
   KITAGAWA M, 1989, J NUTR SCI VITAMINOL, V35, P133, DOI 10.3177/jnsv.35.133
   Knickelbein Jared E, 2015, Int Ophthalmol Clin, V55, P63, DOI 10.1097/IIO.0000000000000073
   Kowanetz M, 2006, CLIN CANCER RES, V12, P5018, DOI 10.1158/1078-0432.CCR-06-1520
   Kowluru RA, 1996, DIABETES, V45, P1233, DOI 10.2337/diabetes.45.9.1233
   Kowluru RA, 1999, FREE RADICAL BIO MED, V26, P371, DOI 10.1016/S0891-5849(98)00210-X
   Kowluru RA, 2001, DIABETES, V50, P1938, DOI 10.2337/diabetes.50.8.1938
   KUNISAKI M, 1995, AM J PHYSIOL-ENDOC M, V269, pE239, DOI 10.1152/ajpendo.1995.269.2.E239
   Kunisaki M, 1998, BIOFACTORS, V7, P55, DOI 10.1002/biof.5520070109
   Kyosseva SV, 2016, OPHTHALMOL EYE DIS, V8, P23, DOI 10.4137/OED.S32200
   Lamb LE, 2004, PHOTOCHEM PHOTOBIOL, V79, P127, DOI 10.1562/0031-8655(2004)079<0127:AACOOL>2.0.CO;2
   Lawenda BD, 2008, JNCI-J NATL CANCER I, V100, P773, DOI 10.1093/jnci/djn148
   Le NK, 2020, J STROKE CEREBROVASC, V29, DOI 10.1016/j.jstrokecerebrovasdis.2020.104747
   Liu BY, 2011, J TRANSL MED, V9, DOI 10.1186/1479-5876-9-111
   Liu ML, 2002, J CARDIOVASC PHARM, V39, P714, DOI 10.1097/00005344-200205000-00012
   Lloret A, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20040879
   Lloyd J K, 1973, Clin Endocrinol Metab, V2, P127, DOI 10.1016/S0300-595X(73)80030-1
   London A, 2013, NAT REV NEUROL, V9, P44, DOI 10.1038/nrneurol.2012.227
   Lonn E, 2005, JAMA-J AM MED ASSOC, V293, P1338, DOI 10.1001/jama.293.11.1338
   Ma HW, 2014, P NATL ACAD SCI USA, V111, P3602, DOI 10.1073/pnas.1317041111
   Mabalirajan U, 2009, J APPL PHYSIOL, V107, P1285, DOI 10.1152/japplphysiol.00459.2009
   MARTIN MM, 1977, AM J CLIN NUTR, V30, P1629, DOI 10.1093/ajcn/30.10.1629
   McIntyre BS, 2000, LIPIDS, V35, P171, DOI 10.1007/BF02664767
   Medicine, 2000, I MED US PAN DIET AN
   MILLAY RH, 1988, OPHTHALMOLOGY, V95, P930
   Miller ER, 2005, ANN INTERN MED, V142, P37, DOI 10.7326/0003-4819-142-1-200501040-00110
   Mitta VP, 2013, JAMA OPHTHALMOL, V131, P507, DOI 10.1001/jamaophthalmol.2013.2303
   Miyazawa T, 2004, ANN NY ACAD SCI, V1031, P401, DOI 10.1196/annals.1331.057
   Miyazawa T, 2008, ASIA PAC J CLIN NUTR, V17, P253
   MORAN J, 1987, EXP EYE RES, V45, P769, DOI 10.1016/S0014-4835(87)80094-5
   MULLER DPR, 1992, EYE, V6, P221, DOI 10.1038/eye.1992.43
   Naegele MP, 2018, EUR HEART J, V39, P47, DOI 10.1093/eurheartj/ehx565
   Napolitano G, 2019, NUTRIENTS, V11, DOI 10.3390/nu11122900
   Ng L, 2010, J NEUROSCI, V30, P3347, DOI 10.1523/JNEUROSCI.5267-09.2010
   Nussenblatt RB, 2006, AM J OPHTHALMOL, V141, P193, DOI 10.1016/j.ajo.2005.07.036
   Ohira A, 2003, INVEST OPHTH VIS SCI, V44, P1230, DOI 10.1167/iovs.02-0191
   Olcott HS, 1937, J AM CHEM SOC, V59, P1008, DOI 10.1021/ja01285a013
   Omarova S, 2012, J CLIN INVEST, V122, P3012, DOI 10.1172/JCI63816
   OUAHCHI K, 1995, NAT GENET, V9, P141, DOI 10.1038/ng0295-141
   PASCOE GA, 1987, ARCH BIOCHEM BIOPHYS, V253, P287, DOI 10.1016/0003-9861(87)90181-0
   Pastori D, 2013, J AM HEART ASSOC, V2, DOI 10.1161/JAHA.113.000364
   PEARCE BC, 1992, J MED CHEM, V35, P3595, DOI 10.1021/jm00098a002
   Pennesi ME, 2012, MOL ASPECTS MED, V33, P487, DOI 10.1016/j.mam.2012.06.003
   Peyman GA, 2009, RETINA-J RET VIT DIS, V29, P875, DOI 10.1097/IAE.0b013e3181a94f01
   Podszun M, 2014, NUTR RES REV, V27, P215, DOI 10.1017/S0954422414000146
   Rakoczy PE, 2006, EXP EYE RES, V82, P741, DOI 10.1016/j.exer.2005.10.012
   Rego AC, 1998, TOXICOLOGY, V128, P113, DOI 10.1016/S0300-483X(98)00054-7
   ROBISON WG, 1979, INVEST OPHTH VIS SCI, V18, P683
   ROBISON WG, 1980, INVEST OPHTH VIS SCI, V19, P1030
   Rodriguez IR, 2010, J LIPID RES, V51, P2847, DOI 10.1194/jlr.R004820
   Rotzoll DE, 2008, EUR J OBSTET GYN R B, V140, P183, DOI 10.1016/j.ejogrb.2008.03.013
   Saishin Y, 2003, J CELL PHYSIOL, V195, P210, DOI 10.1002/jcp.10238
   Sarks SH, 1999, BRIT J OPHTHALMOL, V83, P358, DOI 10.1136/bjo.83.3.358
   Sen CK, 2006, LIFE SCI, V78, P2088, DOI 10.1016/j.lfs.2005.12.001
   Shin JI, 2013, NAT REV IMMUNOL, V13, DOI 10.1038/nri3459-c1
   Singh U, 2005, ANNU REV NUTR, V25, P151, DOI 10.1146/annurev.nutr.24.012003.132446
   Snodderly D. Max, 1995, American Journal of Clinical Nutrition, V62, p1448S, DOI 10.1093/ajcn/62.6.1448S
   Song BL, 2006, J BIOL CHEM, V281, P25054, DOI 10.1074/jbc.M605575200
   Sparrow JR, 2012, MOL ASPECTS MED, V33, P436, DOI 10.1016/j.mam.2012.03.007
   Sparrow JR, 2003, J BIOL CHEM, V278, P18207, DOI 10.1074/jbc.M300457200
   STEPHENS RJ, 1988, EXP EYE RES, V47, P237, DOI 10.1016/0014-4835(88)90007-3
   Stocker A, 1999, IUBMB LIFE, V48, P49, DOI 10.1080/713803478
   Sunness JS, 1997, OPHTHALMOLOGY, V104, P1677, DOI 10.1016/S0161-6420(97)30079-7
   Tachikawa M, 2007, MOL VIS, V13, P2041
   Takeda M, 1996, LIFE SCI, V58, P631, DOI 10.1016/0024-3205(95)02331-3
   TAKEDA M, 1994, THYROID, V4, P467, DOI 10.1089/thy.1994.4.467
   Tam KW, 2013, FOOD CHEM, V138, P1015, DOI 10.1016/j.foodchem.2012.09.147
   Tamura T, 2020, AM J RESP CELL MOL, V62, P810, DOI 10.1165/rcmb.2019-0404LE
   Tanito M, 2002, INVEST OPHTH VIS SCI, V43, P1162
   Tanito M, 2004, LIPIDS, V39, P469, DOI 10.1007/s11745-004-1252-0
   Tanito M, 2007, INVEST OPHTH VIS SCI, V48, P396, DOI 10.1167/iovs.06-0872
   Taylor HR, 2002, BMJ-BRIT MED J, V325, P11, DOI 10.1136/bmj.325.7354.11
   Thakur V, 2010, BIOCHEMISTRY-US, V49, P9339, DOI 10.1021/bi100960b
   Timothy NH, 2004, INVEST OPHTH VIS SCI, V45, pU404
   Tisi A, 2021, CELLS-BASEL, V10, DOI 10.3390/cells10010064
   Titchenell PM, 2012, BIOCHEM J, V446, P455, DOI 10.1042/BJ20111961
   TRABER MG, 1989, AM J CLIN NUTR, V49, P517, DOI 10.1093/ajcn/49.3.517
   TSAI AC, 1978, AM J CLIN NUTR, V31, P831, DOI 10.1093/ajcn/31.5.831
   Tserentsoodol N, 2006, MOL VIS, V12, P1319
   Upadhyay J, 2009, BIOINFORMATION, V3, P326, DOI 10.6026/97320630003326
   Viana M., 1996, PREV VIT DIABET, V39, P1046, DOI [10.1007/BF00400652, DOI 10.1007/BF00400652]
   Violi F, 2010, CIRCULATION, V121, P1033, DOI 10.1161/CIRCULATIONAHA.109.880211
   Wahid S, 2014, J PHARM BIOALLIED SC, V6, P185, DOI 10.4103/0975-7406.130955
   Winkler BS, 1999, MOL VIS, V5
   Xu X, 2004, CURR EYE RES, V28, P251, DOI 10.1076/ceyr.28.4.251.27834
   Yamaoka S, 2008, FREE RADICAL RES, V42, P602, DOI 10.1080/10715760802189864
   Yang SF, 2016, J OPHTHALMOL, V2016, DOI 10.1155/2016/4915916
   Yang Y, 2016, SCI REP-UK, V6, DOI 10.1038/srep30933
   Yargicoglu P, 2003, ACTA OPHTHALMOL SCAN, V81, P181, DOI 10.1034/j.1600-0420.2003.00040.x
   Yin JG, 2011, J CELL PHYSIOL, V226, P2025, DOI 10.1002/jcp.22532
   Zapata GL, 2008, VET J, V177, P266, DOI 10.1016/j.tvjl.2007.04.005
   Zhou J, 2009, INVEST OPHTH VIS SCI, V50, P1392, DOI 10.1167/iovs.08-2868
   Ziegler M, 2020, ANTIOXIDANTS-BASEL, V9, DOI 10.3390/antiox9100935
   Zimmer S, 2000, J BIOL CHEM, V275, P25672, DOI 10.1074/jbc.M000851200
   Zingg JM, 2019, IUBMB LIFE, V71, P456, DOI 10.1002/iub.1986
   Zingg JM, 2015, J NUTR SCI VITAMINOL, V61, pS76, DOI 10.3177/jnsv.61.S76
NR 169
TC 1
Z9 1
U1 2
U2 2
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
EI 1662-453X
J9 FRONT NEUROSCI-SWITZ
JI Front. Neurosci.
PD MAY 4
PY 2022
VL 16
AR 890021
DI 10.3389/fnins.2022.890021
PG 15
WC Neurosciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Neurosciences & Neurology
GA 1I8HK
UT WOS:000797467600001
PM 35600628
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Uretmen, O
   Akkin, C
   Erakgum, T
   Killi, R
AF Uretmen, O
   Akkin, C
   Erakgum, T
   Killi, R
TI Color Doppler imaging of choroidal circulation in patients with
   asymmetric age-related macular degeneration
SO OPHTHALMOLOGICA
LA English
DT Article
DE age-related macular degeneration; choroidal blood flow; color Doppler
   imaging; choroidal neovascularisation
ID OCULAR BLOOD-FLOW; RETINAL-PIGMENT EPITHELIUM; BRUCH MEMBRANE CHANGE;
   RISK-FACTORS; DISCIFORM DEGENERATION; PERFUSION ABNORMALITY; FELLOW
   EYES; 2ND EYE; DRUSEN; MACULOPATHY
AB We aimed at evaluating the possible role of choroidal perfusion abnormalities in the development of choroidal neovascularisation (CNV) in patients with age-related macular degeneration (AMD). Twenty-six patients who had non-exudative AMD in the first eye and CNV secondary to AMD in the fellow eye were enrolled. Blood flow velocities, vessel pulsatilities and resistivities were measured from ophthalmic artery, nasal and temporal posterior ciliary arteries using colour Doppler imaging. Systolic and diastolic velocities were lower in eyes with CNV for all vessels, except for the systolic velocity of the nasal posterior ciliary artery (p >0.05). Pulsatility and resistivity indices were higher in eyes with CNV for all vessels. This difference was statistically significant for the resistivity index of the nasal and temporal posterior ciliary arteries (p = 0.032 and p = 0.021, respectively) and the pulsatility index of the nasal posterior ciliary artery (p = 0.035). We have shown that in patients with AMD choroidal blood flow is more impaired in the eyes with CNV than in the fellow eyes.
C1 Ege Univ, Sch Med, Dept Ophthalmol, TR-35100 Izmir, Turkey.
   Ege Univ, Sch Med, Dept Radiol, TR-35100 Izmir, Turkey.
C3 Ege University; Ege University
RP Uretmen, O (通讯作者)，Ege Univ, Sch Med, Dept Ophthalmol, TR-35100 Izmir, Turkey.
RI akkın, cezmi/ABG-4054-2021
CR Boker T, 1993, Ger J Ophthalmol, V2, P10
   BRESSLER NM, 1989, ARCH OPHTHALMOL-CHIC, V107, P847, DOI 10.1001/archopht.1989.01070010869032
   BRESSLER NM, 1988, SURV OPHTHALMOL, V32, P375, DOI 10.1016/0039-6257(88)90052-5
   BRESSLER NM, 1988, RETINA-J RET VIT DIS, V8, P109, DOI 10.1097/00006982-198808020-00005
   BRESSLER SB, 1990, ARCH OPHTHALMOL-CHIC, V108, P1442, DOI 10.1001/archopht.1990.01070120090035
   BRESSLER SB, 1982, AM J OPHTHALMOL, V93, P157, DOI 10.1016/0002-9394(82)90410-X
   Chaine G, 1998, BRIT J OPHTHALMOL, V82, P996, DOI 10.1136/bjo.82.9.996
   CHANDRA SR, 1974, AM J OPHTHALMOL, V78, P579, DOI 10.1016/S0002-9394(14)76293-2
   CHEN JC, 1992, INVEST OPHTH VIS SCI, V33, P334
   Ciulla TA, 1998, SURV OPHTHALMOL, V43, P134, DOI 10.1016/S0039-6257(98)00014-9
   Ciulla TA, 1999, AM J OPHTHALMOL, V128, P75, DOI 10.1016/S0002-9394(99)00061-6
   EISNER A, 1992, INVEST OPHTH VIS SCI, V33, P3091
   FARKAS TG, 1971, AM J OPHTHALMOL, V71, P1196, DOI 10.1016/0002-9394(71)90963-9
   FARKAS TG, 1971, AM J OPHTHALMOL, V71, P1206, DOI 10.1016/0002-9394(71)90964-0
   FEENEYBURNS L, 1985, AM J OPHTHALMOL, V100, P686, DOI 10.1016/0002-9394(85)90625-7
   FRIEDMAN E, 1989, OPHTHALMOLOGY, V96, P104
   FRIEDMAN E, 1995, OPHTHALMOLOGY, V102, P640, DOI 10.1016/S0161-6420(95)30974-8
   Friedman E, 1997, AM J OPHTHALMOL, V124, P677, DOI 10.1016/S0002-9394(14)70906-7
   GASS JDM, 1973, ARCH OPHTHALMOL-CHIC, V90, P206
   GASS JDM, 1967, AM J OPHTHALMOL, V63, P617
   GRAGOUDAS ES, 1976, ARCH OPHTHALMOL-CHIC, V94, P755, DOI 10.1001/archopht.1976.03910030365003
   GREGOR Z, 1977, BRIT J OPHTHALMOL, V61, P141, DOI 10.1136/bjo.61.2.141
   GRINDLE CFJ, 1978, T OPHTHAL SOC UK, V98, P172
   Grunwald JE, 1998, INVEST OPHTH VIS SCI, V39, P385
   Harris A, 1999, PROG RETIN EYE RES, V18, P669
   HOGAN M J, 1972, Transactions of the American Academy of Ophthalmology and Oto-Laryngology, V76, P64
   HOLZ FG, 1994, OPHTHALMOLOGY, V101, P1522
   HYMAN LG, 1983, AM J EPIDEMIOL, V118, P213, DOI 10.1093/oxfordjournals.aje.a113629
   Klein H, 1998, GLYCOCONJUGATE J, V15, P147, DOI 10.1023/A:1006964105349
   KLEIN R, 1993, OPHTHALMOLOGY, V100, P406
   LAVIN MJ, 1991, BRIT J OPHTHALMOL, V75, P133, DOI 10.1136/bjo.75.3.133
   Leibowitz H M, 1980, Surv Ophthalmol, V24, P335
   MAINSTER MA, 1983, OPHTHALMOLOGY, V90, P945
   MAYER MJ, 1994, INVEST OPHTH VIS SCI, V35, P1138
   Mitchell P, 1998, OPHTHALMOLOGY, V105, P1359, DOI 10.1016/S0161-6420(98)98013-7
   Mori F, 2001, BRIT J OPHTHALMOL, V85, P531, DOI 10.1136/bjo.85.5.531
   Pauleikhoff D, 1999, ARCH OPHTHALMOL-CHIC, V117, P1353, DOI 10.1001/archopht.117.10.1353
   PAULEIKHOFF D, 1990, AM J OPHTHALMOL, V109, P211, DOI 10.1016/S0002-9394(14)75989-6
   PIGUET B, 1992, AM J OPHTHALMOL, V113, P657, DOI 10.1016/S0002-9394(14)74790-7
   Pollack A, 1998, OPHTHALMIC SURG LAS, V29, P286
   PRUNTE C, 1988, GRAEF ARCH CLIN EXP, V226, P55, DOI 10.1007/BF02172719
   REMULLA JFC, 1995, BRIT J OPHTHALMOL, V79, P558, DOI 10.1136/bjo.79.6.558
   Ross RD, 1998, AM J OPHTHALMOL, V125, P71, DOI 10.1016/S0002-9394(99)80237-2
   Sandberg MA, 1998, OPHTHALMOLOGY, V105, P441, DOI 10.1016/S0161-6420(98)93025-1
   SARKS JP, 1988, EYE, V2, P552, DOI 10.1038/eye.1988.106
   SARKS SH, 1976, BRIT J OPHTHALMOL, V60, P324, DOI 10.1136/bjo.60.5.324
   Sarraf D, 1999, RETINA-J RET VIT DIS, V19, P513, DOI 10.1097/00006982-199911000-00006
   SMIDDY WE, 1984, OPHTHALMOLOGY, V91, P271
   STRAHLMAN ER, 1983, ARCH OPHTHALMOL-CHIC, V101, P1191
   TEETERS VW, 1973, AM J OPHTHALMOL, V76, P1
   TSO MOM, 1983, OPHTHALMOLOGY, V90, P952
   WEST SK, 1989, ARCH OPHTHALMOL-CHIC, V107, P875, DOI 10.1001/archopht.1989.01070010897038
   YANNUZZI LA, 1992, ARCH OPHTHALMOL-CHIC, V110, P1701
   ZHAO J, 1995, INT OPHTHALMOL, V19, P1, DOI 10.1007/BF00156412
NR 54
TC 21
Z9 23
U1 0
U2 0
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 0030-3755
J9 OPHTHALMOLOGICA
JI Ophthalmologica
PD MAR-APR
PY 2003
VL 217
IS 2
BP 137
EP 142
DI 10.1159/000068559
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 653VT
UT WOS:000181458300010
PM 12592053
DA 2022-11-30
ER

PT J
AU Ebeling, MC
   Geng, ZH
   Stahl, MR
   Kapphahn, RJ
   Roehrich, H
   Montezuma, SR
   Ferrington, DA
   Dutton, JR
AF Ebeling, Mara C.
   Geng, Zhaohui
   Stahl, Madilyn R.
   Kapphahn, Rebecca J.
   Roehrich, Heidi
   Montezuma, Sandra R.
   Ferrington, Deborah A.
   Dutton, James R.
TI Testing Mitochondrial-Targeted Drugs in iPSC-RPE from Patients with
   Age-Related Macular Degeneration
SO PHARMACEUTICALS
LA English
DT Article
DE human-induced pluripotent stem cells; retinal pigment epithelium;
   age-related macular degeneration; personalized drug testing
ID RETINAL-PIGMENT EPITHELIUM; OXIDATIVE STRESS; BEST-DISEASE; EYE DISEASE;
   METFORMIN; PATHOGENESIS; MODEL; MECHANISM; CELLS
AB Age-related macular degeneration (AMD) is the leading cause of blindness in the elderly. No universally effective treatments exist for atrophic or "dry" AMD, which results from loss of the retinal pigment epithelium (RPE) and photoreceptors and accounts for approximate to 80% of all AMD patients. Prior studies provide evidence for the involvement of mitochondrial dysfunction in AMD pathology. This study used induced pluripotent stem cell (iPSC) RPE derived from five AMD patients to test the efficacy of three drugs (AICAR (5-Aminoimidazole-4-carboxamide ribonucleotide), Metformin, trehalose) that target key processes in maintaining optimal mitochondrial function. The patient iPSC-RPE lines were used in a proof-of-concept drug screen, utilizing an analysis of RPE mitochondrial function following acute and extended drug exposure. Results show considerable variability in drug response across patient cell lines, supporting the need for a personalized medicine approach for treating AMD. Furthermore, our results demonstrate the feasibility of using iPSC-RPE from AMD patients to develop a personalized drug treatment regime and provide a roadmap for the future clinical management of AMD.
C1 [Ebeling, Mara C.; Stahl, Madilyn R.; Kapphahn, Rebecca J.; Montezuma, Sandra R.; Ferrington, Deborah A.] Univ Minnesota, Dept Ophthalmol & Visual Neurosci, Minneapolis, MN 55455 USA.
   [Geng, Zhaohui; Ferrington, Deborah A.; Dutton, James R.] Univ Minnesota, Stem Cell Inst, Minneapolis, MN 55455 USA.
   [Geng, Zhaohui; Dutton, James R.] Univ Minnesota, Dept Genet Cell Biol & Dev, Minneapolis, MN 55455 USA.
   [Roehrich, Heidi] Univ Minnesota, Histol Core Vis Res, Minneapolis, MN 55455 USA.
C3 University of Minnesota System; University of Minnesota Twin Cities;
   University of Minnesota System; University of Minnesota Twin Cities;
   University of Minnesota System; University of Minnesota Twin Cities;
   University of Minnesota System; University of Minnesota Twin Cities
RP Ferrington, DA (通讯作者)，Univ Minnesota, Dept Ophthalmol & Visual Neurosci, Minneapolis, MN 55455 USA.; Ferrington, DA; Dutton, JR (通讯作者)，Univ Minnesota, Stem Cell Inst, Minneapolis, MN 55455 USA.; Dutton, JR (通讯作者)，Univ Minnesota, Dept Genet Cell Biol & Dev, Minneapolis, MN 55455 USA.
EM ebeli017@umn.edu; gengx@umn.edu; stahl154@umn.edu; kapph001@umn.edu;
   rohri002@umn.edu; smontezu@umn.edu; ferri013@umn.edu; dutto015@umn.edu
OI Ferrington, Deborah/0000-0003-2561-7464; , Heidi/0000-0002-2232-9494
CR Andreux PA, 2013, NAT REV DRUG DISCOV, V12, P465, DOI 10.1038/nrd4023
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   Blitzer AL, 2021, JAMA OPHTHALMOL, V139, P302, DOI 10.1001/jamaophthalmol.2020.6331
   Brown EE, 2019, INVEST OPHTH VIS SCI, V60, P1470, DOI 10.1167/iovs.18-26422
   Cai H, 2019, EXP EYE RES, V185, DOI 10.1016/j.exer.2019.04.009
   Cerniauskas E, 2020, STEM CELL TRANSL MED, V9, P1585, DOI 10.1002/sctm.20-0211
   Chang YC, 2014, FRONT AGING NEUROSCI, V6, DOI 10.3389/fnagi.2014.00191
   Chew EY, 2013, OPHTHALMOLOGY, V120, P1604, DOI 10.1016/j.ophtha.2013.01.021
   Chew EY, 2013, JAMA-J AM MED ASSOC, V309, P2005, DOI 10.1001/jama.2013.4997
   Crombie DE, 2017, SLAS DISCOV, V22, P1016, DOI 10.1177/2472555217696797
   Davis MD, 2005, ARCH OPHTHALMOL-CHIC, V123, P1484
   Duong TT, 2018, STEM CELL RES, V27, P140, DOI 10.1016/j.scr.2018.01.009
   Ebeling MC, 2021, CELLS-BASEL, V10, DOI 10.3390/cells10040789
   Ebeling MC, 2020, REDOX BIOL, V34, DOI 10.1016/j.redox.2020.101552
   Elanzew A, 2020, FRONT BIOENG BIOTECH, V8, DOI 10.3389/fbioe.2020.580352
   Elitt MS, 2018, HUM MOL GENET, V27, pR89, DOI 10.1093/hmg/ddy186
   Feher J, 2006, NEUROBIOL AGING, V27, P983, DOI 10.1016/j.neurobiolaging.2005.05.012
   Ferrington DA, 2021, ADV EXP MED BIOL, V1256, P237, DOI 10.1007/978-3-030-66014-7_10
   Ferrington DA, 2017, REDOX BIOL, V13, P255, DOI 10.1016/j.redox.2017.05.015
   Galloway CA, 2017, P NATL ACAD SCI USA, V114, pE8214, DOI 10.1073/pnas.1710430114
   Geng ZH, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0173575
   Ghavami S, 2014, PROG NEUROBIOL, V112, P24, DOI 10.1016/j.pneurobio.2013.10.004
   Golestaneh N, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2016.453
   Golestaneh N, 2016, J TRANSL MED, V14, DOI 10.1186/s12967-016-1101-8
   Gong J, 2020, STEM CELL TRANSL MED, V9, P364, DOI 10.1002/sctm.19-0321
   Hallam D, 2017, STEM CELLS, V35, P2305, DOI 10.1002/stem.2708
   Herzig S, 2018, NAT REV MOL CELL BIO, V19, P121, DOI 10.1038/nrm.2017.95
   Kanow MA, 2017, ELIFE, V6, DOI 10.7554/eLife.28899
   Karim MR, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0231212
   Karunadharma PP, 2010, INVEST OPHTH VIS SCI, V51, P5470, DOI 10.1167/iovs.10-5429
   Kauppinen A, 2016, CELL MOL LIFE SCI, V73, P1765, DOI 10.1007/s00018-016-2147-8
   Kim J, 2016, EXP MOL MED, V48, DOI 10.1038/emm.2016.16
   Kulkarni AS, 2020, CELL METAB, V32, P15, DOI 10.1016/j.cmet.2020.04.001
   Lee JH, 2020, YONSEI MED J, V61, P816, DOI 10.3349/ymj.2020.61.9.816
   Lee SJ, 2021, FASEB J, V35, DOI 10.1096/fj.202001939RR
   Lin HJ, 2011, INVEST OPHTH VIS SCI, V52, P3521, DOI 10.1167/iovs.10-6163
   Matoba R, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0181481
   McNeish J, 2015, CELL STEM CELL, V17, P8, DOI 10.1016/j.stem.2015.06.013
   Miyagishima KJ, 2016, STEM CELL TRANSL MED, V5, P1562, DOI 10.5966/sctm.2016-0037
   Nordgaard CL, 2008, INVEST OPHTH VIS SCI, V49, P2848, DOI 10.1167/iovs.07-1352
   Palmieri M, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms14338
   Polinati PP, 2015, INVEST OPHTH VIS SCI, V56, P3371, DOI 10.1167/iovs.14-14007
   Regent F, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-47123-6
   Saini JS, 2017, CELL STEM CELL, V20, P635, DOI 10.1016/j.stem.2016.12.015
   Schafer N, 2020, ANTIOXIDANTS-BASEL, V9, DOI 10.3390/antiox9090793
   Singh R, 2013, HUM MOL GENET, V22, P593, DOI 10.1093/hmg/dds469
   Strauss O, 2005, PHYSIOL REV, V85, P845, DOI 10.1152/physrev.00021.2004
   Swaroop A, 2009, ANNU REV GENOM HUM G, V10, P19, DOI 10.1146/annurev.genom.9.081307.164350
   Terluk MR, 2015, J NEUROSCI, V35, P7304, DOI 10.1523/JNEUROSCI.0190-15.2015
   Truong V, 2021, SLAS TECHNOL, V26, P287, DOI 10.1177/2472630320972110
   Vial G, 2019, FRONT ENDOCRINOL, V10, DOI 10.3389/fendo.2019.00294
   Wang Y, 2019, CELL REP, V29, P1511, DOI 10.1016/j.celrep.2019.09.070
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Xu L, 2018, P NATL ACAD SCI USA, V115, P10475, DOI 10.1073/pnas.1802724115
   Zhang M, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-59244-4
   Zhao X, 2020, OXID MED CELL LONGEV, V2020, DOI 10.1155/2020/2524174
   Zhou GC, 2001, J CLIN INVEST, V108, P1167, DOI 10.1172/JCI13505
NR 57
TC 2
Z9 2
U1 1
U2 1
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 1424-8247
J9 PHARMACEUTICALS-BASE
JI Pharmaceuticals
PD JAN
PY 2022
VL 15
IS 1
AR 62
DI 10.3390/ph15010062
PG 18
WC Chemistry, Medicinal; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA ZC2NB
UT WOS:000757362100001
PM 35056119
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Cuellar-Partida, G
   Craig, JE
   Burdon, KP
   Wang, JJ
   Vote, BJ
   Souzeau, E
   McAllister, IL
   Isaacs, T
   Lake, S
   Mackey, DA
   Constable, IJ
   Mitchell, P
   Hewitt, AW
   MacGregor, S
AF Cuellar-Partida, Gabriel
   Craig, Jamie E.
   Burdon, Kathryn P.
   Wang, Jie Jin
   Vote, Brendan J.
   Souzeau, Emmanuelle
   McAllister, Ian L.
   Isaacs, Timothy
   Lake, Stewart
   Mackey, David A.
   Constable, Ian J.
   Mitchell, Paul
   Hewitt, Alex W.
   MacGregor, Stuart
TI Assessment of polygenic effects links primary open-angle glaucoma and
   age-related macular degeneration
SO SCIENTIFIC REPORTS
LA English
DT Article
ID GENOME-WIDE ASSOCIATION; COMMON VARIANTS; DISEASES; INFLAMMATION;
   PREVALENCE; GENDER; ABCA1; RISK; LOCI; AMD
AB Primary open-angle glaucoma (POAG) and age-related macular degeneration (AMD) are leading causes of irreversible blindness. Several loci have been mapped using genome-wide association studies. Until very recently, there was no recognized overlap in the genetic contribution to AMD and POAG. At genome-wide significance level, only ABCA1 harbors associations to both diseases. Here, we investigated the genetic architecture of POAG and AMD using genome-wide array data. We estimated the heritability for POAG (h(g)(2) = 0.42 +/- 0.09) and AMD (h(g)(2) = 0.71 +/- 0.08). Removing known loci for POAG and AMD decreased the h(g)(2) estimates to 0.36 and 0.24, respectively. There was evidence for a positive genetic correlation between POAG and AMD (r(g) = 0.47 +/- 0.25) which remained after removing known loci (r(g) = 0.64 +/- 0.31). We also found that the genetic correlation between sexes for POAG was likely to be less than 1 (r(g) = 0.33 +/- 0.24), suggesting that differences of prevalence among genders may be partly due to heritable factors.
C1 [Cuellar-Partida, Gabriel; MacGregor, Stuart] QIMR Berghofer Med Res Inst, Stat Genet, Brisbane, Qld 4006, Australia.
   [Craig, Jamie E.; Souzeau, Emmanuelle; Lake, Stewart] Flinders Univ S Australia, Dept Ophthalmol, Adelaide, SA 5001, Australia.
   [Burdon, Kathryn P.; Mackey, David A.; Hewitt, Alex W.] Univ Tasmania, Menzies Inst Med Res, Hobart, Tas 7001, Australia.
   [Wang, Jie Jin; Mitchell, Paul] Univ Sydney, Dept Ophthalmol, Ctr Vis Res, Sydney, NSW 2145, Australia.
   [Wang, Jie Jin; Mitchell, Paul] Univ Sydney, Westmead Inst Med Res, Sydney, NSW 2145, Australia.
   [Vote, Brendan J.] Launceston Eye Inst, Launceston, Tas 7249, Australia.
   [McAllister, Ian L.; Isaacs, Timothy; Mackey, David A.; Constable, Ian J.] Univ Western Australia, Ctr Ophthalmol & Visual Sci, Lions Eye Inst, Perth, WA 6009, Australia.
   [Hewitt, Alex W.] Univ Melbourne, Royal Victorian Eye & Ear Hosp, Ctr Eye Res Australia, East Melbourne, Vic 3002, Australia.
C3 QIMR Berghofer Medical Research Institute; Flinders University South
   Australia; University of Tasmania; Menzies Institute for Medical
   Research; University of Sydney; University of Sydney; Westmead Institute
   for Medical Research; Lions Eye Institute; University of Western
   Australia; Centre for Eye Research Australia; Royal Victorian Eye & Ear
   Hospital; University of Melbourne
RP Cuellar-Partida, G; MacGregor, S (通讯作者)，QIMR Berghofer Med Res Inst, Stat Genet, Brisbane, Qld 4006, Australia.
EM Gabriel.Cuellar@qimrberghofer.edu.au;
   StuartMacGregor@qimrberghofer.edu.au
RI Souzeau, Emmanuelle/AAB-5608-2022; Mackey, David A/H-5340-2014; Burdon,
   Kathryn/AAD-2334-2022; lake, stewart/AAH-6265-2021; Burdon,
   Kathryn/A-5026-2009; Partida, Gabriel Cuellar/C-6686-2017; Mitchell,
   Paul/P-1498-2014; Wang, Jie Jin/P-1499-2014; Macgregor,
   Stuart/C-6442-2009; wang, jie/GRS-0942-2022
OI Souzeau, Emmanuelle/0000-0002-2015-6577; Mackey, David
   A/0000-0001-7914-4709; Burdon, Kathryn/0000-0001-8217-1249; lake,
   stewart/0000-0003-0078-3319; Burdon, Kathryn/0000-0001-8217-1249;
   Partida, Gabriel Cuellar/0000-0001-7648-4097; Wang, Jie
   Jin/0000-0001-9491-4898; Macgregor, Stuart/0000-0001-6731-8142;
   constable, ian/0000-0002-2140-6478; Hewitt, Alex/0000-0002-5123-5999;
   Craig, Jamie/0000-0001-9955-9696
FU Center for Inherited Diseases Research [HHSN268201200008I]; NIH/NEI
   [1X01HG006934-01, EY022310]; University of Queensland; QIMR Berghofer
   Medical Research Institute; Australian Research Council; National Health
   and Medical Research Council (NHMRC) of Australia [1023911]; Ophthalmic
   Research Institute of Australia; BrightFocus Foundation; Ramaciotti
   Establishment Grant; NHMRC; National Health and Medical Research Council
   ( NHMRC), Australia [974159, 211069, 457349, 512423, 302010, 571013];
   NATIONAL EYE INSTITUTE [R01EY022310] Funding Source: NIH RePORTER
FX We thank the International AMD Genomics Consortium for carrying out the
   genotyping of the participants in this study. Genotyping for
   International AMD Genomics Consortium was funded through The Center for
   Inherited Diseases Research (HHSN268201200008I), as well as NIH/NEI
   grants 1X01HG006934-01 (to Goncalo R. Abecasis) and EY022310 (to
   Jonathan L. Haines). GCP thanks the University of Queensland and QIMR
   Berghofer Medical Research Institute for scholarship support. SM is
   supported by an Australian Research Council Future Fellowship. The UWA,
   LEI & Flinders group acknowledges financial support for participant
   recruitment and sample processing provided by the National Health and
   Medical Research Council (NHMRC) of Australia (#1023911), the Ophthalmic
   Research Institute of Australia, the BrightFocus Foundation and a
   Ramaciotti Establishment Grant. KPB, JEC and AWH are supported by NHMRC
   Fellowships. The authors acknowledge the support of B. Usher-Ridge, L.
   Palmer, L. Ma and DL Lim in patient recruitment and data collection. The
   Westmead/Sydney samples were collected in three studies that were
   supported by the National Health and Medical Research Council ( NHMRC),
   Australia: Grant IDs 974159, 211069, 457349 and 512423 supported the
   Blue Mountains Eye Study that provided population-based controls; Grant
   ID 302010 supported the Cataract Surgery and Risk of Age-related Macular
   Degeneration study that provided clinic-based early and late AMD cases
   and controls; and Grant ID 571013 supported the Genes and environment in
   late AMD study that provided clinic-based late AMD cases. The NHMRC had
   no role in the design or conduct of these studies.
CR Altshuler DM, 2012, NATURE, V491, P56, DOI 10.1038/nature11632
   Bailey JNC, 2013, HUM MOL GENET, V22, pR59, DOI 10.1093/hmg/ddt396
   Black JRM, 2016, GENET MED, V18, P283, DOI 10.1038/gim.2015.70
   Bodh Sonam A, 2011, Oman J Ophthalmol, V4, P3, DOI 10.4103/0974-620X.77655
   Bulik-Sullivan B, 2015, NAT GENET, V47, P1236, DOI 10.1038/ng.3406
   Bulik-Sullivan BK, 2015, NAT GENET, V47, P291, DOI 10.1038/ng.3211
   Burdon KP, 2011, NAT GENET, V43, P574, DOI 10.1038/ng.824
   Cascio C, 2015, STEROIDS, V103, P31, DOI 10.1016/j.steroids.2015.08.002
   Chen YH, 2014, NAT GENET, V46, P1115, DOI 10.1038/ng.3078
   Cohen LP, 2014, CSH PERSPECT MED, V4, DOI 10.1101/cshperspect.a017236
   Craig JE, 2009, GENOME RES, V19, P2075, DOI 10.1101/gr.094680.109
   Fritsche LG, 2016, NAT GENET, V48, P134, DOI 10.1038/ng.3448
   Fritsche LG, 2014, ANNU REV GENOM HUM G, V15, P151, DOI 10.1146/annurev-genom-090413-025610
   Fritsche LG, 2013, NAT GENET, V45, P433, DOI 10.1038/ng.2578
   Gharahkhani P, 2014, NAT GENET, V46, P1120, DOI 10.1038/ng.3079
   Hall JB, 2015, BMC BIOINFORMATICS, V16, DOI 10.1186/s12859-015-0760-4
   Joachim N, 2015, OPHTHALMOLOGY, V122, P2482, DOI 10.1016/j.ophtha.2015.08.002
   Lee SH, 2012, BIOINFORMATICS, V28, P2540, DOI 10.1093/bioinformatics/bts474
   Lee SH, 2011, AM J HUM GENET, V88, P294, DOI 10.1016/j.ajhg.2011.02.002
   Newman-Casey PA, 2014, JAMA OPHTHALMOL, V132, P298, DOI 10.1001/jamaophthalmol.2013.7618
   Pasquale LR, 2013, MOL VIS, V19, P1471
   Rudnicka AR, 2006, INVEST OPHTH VIS SCI, V47, P4254, DOI 10.1167/iovs.06-0299
   Souzeau E, 2012, CLIN EXP OPHTHALMOL, V40, P569, DOI 10.1111/j.1442-9071.2011.02742.x
   Stanton CM, 2014, ADV EXP MED BIOL, V801, P251, DOI 10.1007/978-1-4614-3209-8_32
   Telander DG, 2011, SEMIN OPHTHALMOL, V26, P192, DOI 10.3109/08820538.2011.570849
   Tham YC, 2014, OPHTHALMOLOGY, V121, P2081, DOI 10.1016/j.ophtha.2014.05.013
   Thorleifsson G, 2010, NAT GENET, V42, P906, DOI 10.1038/ng.661
   Vohra R, 2013, SURV OPHTHALMOL, V58, P311, DOI 10.1016/j.survophthal.2012.08.010
   Wang Y, 2011, EYE, V25, P127, DOI 10.1038/eye.2010.196
   Wei X, 2012, MED HYPOTHESES, V79, P377, DOI 10.1016/j.mehy.2012.05.041
   Wiggs JL, 2012, PLOS GENET, V8, P413, DOI 10.1371/journal.pgen.1002654
   Yang JA, 2011, AM J HUM GENET, V88, P76, DOI 10.1016/j.ajhg.2010.11.011
   Yang JA, 2010, NAT GENET, V42, P565, DOI 10.1038/ng.608
NR 33
TC 16
Z9 16
U1 0
U2 5
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2045-2322
J9 SCI REP-UK
JI Sci Rep
PD MAY 31
PY 2016
VL 6
AR 26885
DI 10.1038/srep26885
PG 6
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA DN2FH
UT WOS:000376879000001
PM 27241461
OA gold, Green Published, Green Submitted
DA 2022-11-30
ER

PT J
AU Ciulla, TA
   Danis, RP
   Klein, SB
   Malinovsky, VE
   Soni, PS
   Pratt, LA
   Pugh, NO
   Morphis, JG
   Bloch, C
   Cameron, J
AF Ciulla, TA
   Danis, RP
   Klein, SB
   Malinovsky, VE
   Soni, PS
   Pratt, LA
   Pugh, NO
   Morphis, JG
   Bloch, C
   Cameron, J
TI Proton therapy for exudative age-related macular degeneration: A
   randomized, sham-controlled clinical trial
SO AMERICAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
AB PURPOSE: To examine the effect of proton beam irradiation on subfoveal choroidal neovascular membranes (CNVM) associated with age,related macular degeneration (AMD).
   DESIGN: Randomized, prospective, sham-controlled, double-masked treatment trial.
   METHODS: Thirty-seven subjects with subfoveal CNVM due to AMD were randomly assigned to 16-Gy proton irradiation delivered in two fractions 24 hours apart or to sham control treatment. Recruitment was halted at 37 subjects for ethical reasons regarding randomization to sham treatment when Food and Drug Administration approval of Visudyne was anticipated.
   RESULTS: Proton irradiation was associated with a trend toward stabilization of visual acuity, but this association did not reach statistical significance. No correlations were found within the fluorescein angiography data, including greatest linear dimension of CNVM total size, area of active leakage, area of associated subretinal hemorrhage, and intensity.
   CONCLUSIONS: With the acceptance of photodynamic therapy, future studies will require more complex design and larger sample size to determine whether radiation can play either a primary or adjunctive role in treating these lesions.
C1 Indiana Univ, Sch Med, Midwest Eye Inst, Dept Ophthalmol,Retina Serv, Indianapolis, IN 46280 USA.
C3 Indiana University System; Indiana University-Purdue University
   Indianapolis
RP Ciulla, TA (通讯作者)，Indiana Univ, Sch Med, Midwest Eye Inst, Dept Ophthalmol,Retina Serv, 201 Penn Pkwy, Indianapolis, IN 46280 USA.
RI Bloch, Charles/AAG-3137-2019; Ciulla, Thomas/AAA-1299-2020
OI Bloch, Charles/0000-0002-8035-0056; Ciulla, Thomas/0000-0001-5557-6777
CR Flaxel CJ, 2000, EYE, V14, P155, DOI 10.1038/eye.2000.46
NR 1
TC 34
Z9 34
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0002-9394
J9 AM J OPHTHALMOL
JI Am. J. Ophthalmol.
PD DEC
PY 2002
VL 134
IS 6
BP 905
EP 906
DI 10.1016/S0002-9394(02)01821-4
PG 2
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 624BA
UT WOS:000179738600016
PM 12470761
DA 2022-11-30
ER

PT J
AU Lu, L
   Gu, XR
   Hong, L
   Laird, J
   Jaffe, K
   Choi, J
   Crabb, J
   Salomon, RG
AF Lu, Liang
   Gu, Xiaorong
   Hong, Li
   Laird, James
   Jaffe, Keeve
   Choi, Jaewoo
   Crabb, John
   Salomon, Robert G.
TI Synthesis and structural characterization of
   carboxyethylpyrrole-modified proteins: mediators of age-related macular
   degeneration
SO BIOORGANIC & MEDICINAL CHEMISTRY
LA English
DT Article
DE Age-related macular degeneration; Carboxyethylpyrrole; Organic
   synthesis; Protein modification; Lipid oxidation; Angiogenesis;
   Biomarkers
ID MEMBRANES; NEOVASCULARIZATION; FEATURES; ADDUCTS
AB Protein modifications in which the e-amino group of lysyl residues is incorporated into a 2-(omega-carboxy-ethyl)pyrrole (CEP) are mediators of age-related macular degeneration (AMD). They promote both angiogenesis into the retina ('wet AMD') and geographic retinal atrophy ('dry AMD'). Blood levels of CEPs are biomarkers for clinical prognosis of the disease. To enable mechanistic studies of their role in promoting AMD, for example, through the activation of B- and T-cells, interaction with receptors, or binding with complement proteins, we developed an efficient synthesis of CEP derivatives, that is especially effective for proteins. The structures of tryptic peptides derived from CEP-modified proteins were also determined. A key finding is that 4,7-dioxoheptanoic acid 9-fluorenylmethyl ester reacts with primary amines to provide 9-fluorenylmethyl esters of CEP-modified proteins that can be deprotected in situ with 1,8-diazabicyclo[5.4.0]undec-7-ene without causing protein denaturation. The introduction of multiple CEP-modifications with a wide variety of CEP: protein ratios is readily achieved using this strategy. (C) 2009 Elsevier Ltd. All rights reserved.
C1 [Lu, Liang; Hong, Li; Laird, James; Choi, Jaewoo; Salomon, Robert G.] Case Western Reserve Univ, Dept Chem, Cleveland, OH 44106 USA.
   [Gu, Xiaorong; Crabb, John] Cleveland Clin Fdn, Cole Eye Inst, Cleveland, OH 44195 USA.
   [Jaffe, Keeve] Frantz Biomarkers LLC, Mentor, OH 44060 USA.
C3 Case Western Reserve University; Cleveland Clinic Foundation
RP Salomon, RG (通讯作者)，Case Western Reserve Univ, Dept Chem, Cleveland, OH 44106 USA.
EM rgs@case.edu
RI Salomon, Robert G/C-3463-2008
OI Salomon, Robert/0000-0001-9456-3557
FU National Institutes of Health [GM21249, HL53315]; State of Ohio Third
   Frontier BRTT Award [TECH05-064]; NATIONAL HEART, LUNG, AND BLOOD
   INSTITUTE [R01HL053315] Funding Source: NIH RePORTER; NATIONAL INSTITUTE
   OF GENERAL MEDICAL SCIENCES [R01GM021249] Funding Source: NIH RePORTER
FX We are grateful for support of this work by National Institutes of
   Health Grants GM21249 and HL53315, and by a State of Ohio Third Frontier
   BRTT Award TECH05-064. We also thank Suresh P. Annangudi for preparing
   compound 13.
CR Aulak KS, 2001, P NATL ACAD SCI USA, V98, P12056, DOI 10.1073/pnas.221269198
   BAUDOUIN C, 1992, JPN J OPHTHALMOL, V36, P443
   BOGA C, 1986, SYNTHESIS-STUTTGART, P212
   Bok D, 2002, P NATL ACAD SCI USA, V99, P14619, DOI 10.1073/pnas.242607899
   BUCHI G, 1969, J ORG CHEM, V34, P1122
   Chen CD, 1998, TETRAHEDRON, V54, P9067, DOI 10.1016/S0040-4020(98)00544-4
   Crabb JW, 2002, P NATL ACAD SCI USA, V99, P14682, DOI 10.1073/pnas.222551899
   Crabb JW, 1998, J BIOL CHEM, V273, P20712, DOI 10.1074/jbc.273.33.20712
   DECAPRIO AP, 1987, MOL PHARMACOL, V32, P542
   Ebrahem Q, 2006, P NATL ACAD SCI USA, V103, P13480, DOI 10.1073/pnas.0601552103
   FERRIS FL, 1983, AM J EPIDEMIOL, V118, P132, DOI 10.1093/oxfordjournals.aje.a113624
   Greenberg ME, 2008, J BIOL CHEM, V283, P2385, DOI 10.1074/jbc.M707348200
   Gu XR, 2003, J BIOL CHEM, V278, P42027, DOI 10.1074/jbc.M305460200
   Gu XR, 2003, J ORG CHEM, V68, P3749, DOI 10.1021/jo026721t
   Hollyfield JG, 2008, NAT MED, V14, P194, DOI 10.1038/nm1709
   JACKSON AH, 1980, COMPREHENSIVE ORGANI, V4, P275
   Kaur K, 1997, CHEM RES TOXICOL, V10, P1387, DOI 10.1021/tx970112c
   Kruijff B. D., 1997, NATURE, V386, P129
   Krzystolik MG, 2002, ARCH OPHTHALMOL-CHIC, V120, P338
   LOPEZ PF, 1991, AM J OPHTHALMOL, V112, P647, DOI 10.1016/S0002-9394(14)77270-8
   Miyagi M, 2002, MOL CELL PROTEOMICS, V1, P293, DOI 10.1074/mcp.M100034-MCP200
   Renganathan K, 2005, INVEST OPHTHALMOL VI, V46
   Sayre LM, 1996, CHEM RES TOXICOL, V9, P1194, DOI 10.1021/tx960094j
   SCHNECK JO, 2000, CURRENT PROTOCOLS IM
   Sheppeck JE, 2000, TETRAHEDRON LETT, V41, P5329, DOI 10.1016/S0040-4039(00)00853-4
   SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7
   Stone EM, 2001, HUM MOL GENET, V10, P2285, DOI 10.1093/hmg/10.20.2285
   West KA, 2001, EXP EYE RES, V73, P479, DOI 10.1006/exer.2001.1058
NR 28
TC 24
Z9 26
U1 0
U2 5
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0968-0896
EI 1464-3391
J9 BIOORGAN MED CHEM
JI Bioorg. Med. Chem.
PD NOV 1
PY 2009
VL 17
IS 21
BP 7548
EP 7561
DI 10.1016/j.bmc.2009.09.009
PG 14
WC Biochemistry & Molecular Biology; Chemistry, Medicinal; Chemistry,
   Organic
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Pharmacology & Pharmacy; Chemistry
GA 508BZ
UT WOS:000270903100019
PM 19786352
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Jackson, TL
   Soare, C
   Petrarca, C
   Simpson, A
   Neffendorf, JE
   Petrarca, R
   Muldrew, A
   Peto, T
   Chakravarthy, U
   Membrey, L
   Haynes, R
   Costen, M
   Steel, D
   Desai, R
AF Jackson, Timothy L.
   Soare, Cristina
   Petrarca, Caroline
   Simpson, Andrew
   Neffendorf, James E.
   Petrarca, Robert
   Muldrew, Alyson
   Peto, Tunde
   Chakravarthy, Usha
   Membrey, Luke
   Haynes, Richard
   Costen, Mark
   Steel, David
   Desai, Riti
CA MERLOT Study Grp
TI Evaluation of Month-24 Efficacy and Safety of Epimacular Brachytherapy
   for Previously Treated Neovascular Age-Related Macular Degeneration The
   MERLOT Randomized Clinical Trial
SO JAMA OPHTHALMOLOGY
LA English
DT Article
ID STEREOTACTIC RADIOTHERAPY; RANIBIZUMAB; PREVALENCE
AB This randomized clinical trial describes the second-year results of the ophthalmological device trial of epimacular brachytherapy, a proposed second-line therapy for neovascular age-related macular degeneration.
   Question Does epimacular brachytherapy reduce the number of anti-vascular endothelial growth factor injections that patients with chronic, active neovascular age-related macular degeneration require without sacrificing their visual acuity? Findings In this randomized clinical trial of 363 participants with neovascular age-related macular degeneration, epimacular brachytherapy did not reduce the frequency of anti-vascular endothelial growth factor injections and was associated with worse visual acuity at month 24 compared with as-needed ranibizumab monotherapy. Meaning These findings do not support the addition of epimacular brachytherapy to anti-vascular endothelial growth factor treatment for neovascular age-related macular degeneration.
   Importance Although anti-vascular endothelial growth factor (VEGF) treatment offers better outcomes than the natural history of neovascular age-related macular degeneration (ARMD), a less burdensome, less expensive, and more durable treatment is needed. Objective To assess the efficacy and safety of epimacular brachytherapy (EMB) for chronic, active, neovascular ARMD. Design, Setting, and Participants The Macular Epiretinal Brachytherapy vs Ranibizumab (Lucentis) Only Treatment (MERLOT) pivotal device trial was conducted at 24 National Health Service hospitals across the UK. Patients who had neovascular ARMD and received intravitreal ranibizumab were enrolled between November 10, 2009, and January 30, 2012. Eligible patients were randomized 2:1 and were stratified by lens status and angiographic lesion type to receive either EMB plus as-needed ranibizumab or as-needed ranibizumab monotherapy. Participants were followed up monthly for 24 months and then assessed at a final visit at month 36. Masking of participants and clinicians was not possible, but best-corrected visual acuity (BCVA) and imaging were analyzed by masked assessors. Analysis followed the intent-to-treat approach. Interventions Pars plana vitrectomy with 24 Gy EMB plus as-needed ranibizumab vs as-needed ranibizumab monotherapy. Main Outcomes and Measures Coprimary outcomes were the number of as-needed ranibizumab injections and the mean change in Early Treatment Diabetic Retinopathy Study (ETDRS) BCVA with a noninferiority margin of -5 ETDRS letters. Secondary outcomes were the percentage of participants losing fewer than 15 ETDRS letters and gaining 0 or more or 15 or more ETDRS letters and the mean change in angiographic total lesion size, choroidal neovascularization size, and foveal thickness on optical coherence tomography. Results Of 363 participants, 329 (90.6%) completed 24 months of follow-up (222 participants in the EMB group and 107 in the ranibizumab group). The mean (SD) age of the combined groups was 76.5 (7.4) years. The mean (SD) number of ranibizumab injections was 9.3 (6.7) in the EMB group and 8.3 (4.5) in the ranibizumab group, with a difference of 1.0 injection (95% CI, -0.3 to 2.3; P = .13). The mean (SD) BCVA change was -11.2 (15.7) ETDRS letters in the EMB group and -1.4 (10.9) ETDRS letters in the ranibizumab group, with a difference of 9.8 ETDRS letters (95% CI, -6.7 to -12.9). In the EMB group, 65.6% of participants (160 of 244) lost fewer than 15 ETDRS letters vs 86.6% (103 of 119) in the ranibizumab group, with a difference of 21% (95% CI, 12.4%-29.5%; P < .001). Microvascular abnormalities occurred in 20 of 207 eyes (9.7%) in the EMB group and 1 of 97 eyes (1.0%) in the ranibizumab group. These abnormalities occurred outside the foveal center, and there were no unexpected safety concerns. Conclusions and Relevance The MERLOT trial found that despite the acceptable safety of EMB, it did not reduce the number of ranibizumab injections and was associated with worse visual acuity than anti-VEGF treatment alone; these results do not support EMB use as an adjunct treatment for chronic, active neovascular ARMD.
C1 [Jackson, Timothy L.; Petrarca, Caroline; Simpson, Andrew; Neffendorf, James E.; Petrarca, Robert] Kings Coll London, Fac Life Sci & Med, London, England.
   [Jackson, Timothy L.; Soare, Cristina; Simpson, Andrew; Neffendorf, James E.; Petrarca, Robert; Desai, Riti] Kings Coll Hosp London, Dept Ophthalmol, London, England.
   [Muldrew, Alyson; Chakravarthy, Usha] Queens Univ Belfast, Cent Angiog Reading Ctr, NetwORC UK, Belfast, Antrim, North Ireland.
   [Peto, Tunde] Moorfields Eye Hosp, Reading Ctr, London, England.
   [Membrey, Luke] Maidstone Hlth Author, Dept Ophthalmol, Maidstone, Kent, England.
   [Haynes, Richard] Bristol Eye Hosp, Dept Ophthalmol, Bristol, Avon, England.
   [Costen, Mark] Hull & East Yorkshire Eye Hosp, Dept Ophthalmol, Kingston Upon Hull, N Humberside, England.
   [Steel, David] Sunderland Eye Infirm, Vitreoretinal Unit, Sunderland, England.
   [Steel, David] Newcastle Univ, Inst Genet Med, Newcastle Upon Tyne, Tyne & Wear, England.
C3 University of London; King's College London; King's College Hospital NHS
   Foundation Trust; King's College Hospital; Queens University Belfast;
   University of London; University College London; Moorfields Eye Hospital
   NHS Foundation Trust; Bristol Eye Hospital; Newcastle University - UK
RP Jackson, TL (通讯作者)，Kings Coll Hosp London, Kings Coll London, Fac Life Sci & Med, London SE5 9R5, England.
EM t.jackson1@nhs.net
OI Soare, Maria-Cristina/0000-0002-4533-0105; Desai,
   Riti/0000-0001-6425-0648; Jackson, Timothy/0000-0001-7618-1555
FU NIHR Comprehensive Clinical Research Network; NeoVista; MRC
   [MC_U137686853, MC_UU_12026/5, MC_U137686861] Funding Source: UKRI
FX This study was funded by the NIHR Comprehensive Clinical Research
   Network (all participating sites) and by an unrestricted research grant
   from NeoVista (Prof Jackson).
CR ALTMAN R, 1994, BMJ-BRIT MED J, V308, P81, DOI 10.1136/bmj.308.6921.81
   CHAKRAVARTHY U, 1993, BRIT J OPHTHALMOL, V77, P265, DOI 10.1136/bjo.77.5.265
   Chen YY, 2018, INT OPHTHALMOL, V38, P293, DOI 10.1007/s10792-017-0462-1
   Dugel PU, 2013, OPHTHALMOLOGY, V120, P317, DOI 10.1016/j.ophtha.2012.07.068
   Dugel PU, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.01.014
   Holz FG, 2013, BRIT J OPHTHALMOL, V97, P1161, DOI 10.1136/bjophthalmol-2013-303232
   Jackson TL, 2013, EYE, V27, P644, DOI 10.1038/eye.2013.12
   Jackson TL, 2016, OPHTHALMOLOGY, V123, P1287, DOI 10.1016/j.ophtha.2016.02.028
   Jackson TL, 2015, RETINA-J RET VIT DIS, V35, P194, DOI 10.1097/IAE.0000000000000283
   Jackson TL, 2015, OPHTHALMOLOGY, V122, P138, DOI 10.1016/j.ophtha.2014.07.043
   Jackson TL, 2013, OPHTHALMOLOGY, V120, P1893, DOI 10.1016/j.ophtha.2013.02.016
   Jackson TL, 2013, OPHTHALMOLOGY, V120, P1597, DOI 10.1016/j.ophtha.2013.01.074
   Kakinoki M, 2012, INVEST OPHTH VIS SCI, V53, P5877, DOI 10.1167/iovs.12-10164
   Kirwan JF, 2003, EYE, V17, P207, DOI 10.1038/sj.eye.6700306
   Maguire MG, 2016, OPHTHALMOLOGY, V123, P1751, DOI 10.1016/j.ophtha.2016.03.045
   MedDRA, WELC ICH MEDDRA
   Neffendorf JE, 2016, TRIALS, V17, DOI 10.1186/s13063-016-1676-7
   Owen CG, 2012, BRIT J OPHTHALMOL, V96, P752, DOI 10.1136/bjophthalmol-2011-301109
   Petrarca Robert, 2014, Retina, V34, P874, DOI 10.1097/IAE.0000000000000026
   Rofagha S, 2013, OPHTHALMOLOGY, V120, P2292, DOI 10.1016/j.ophtha.2013.03.046
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Schmidt-Erfurth U, 2014, OPHTHALMOLOGY, V121, P193, DOI 10.1016/j.ophtha.2013.08.011
   Tufail A, 2014, OPHTHALMOLOGY, V121, P1092, DOI 10.1016/j.ophtha.2013.11.031
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   World Medical Association, 2013, JAMA-J AM MED ASSOC, V310, P2191, DOI [DOI 10.1001/JAMA.2013.281053, 10.1001/jama.2013.281053]
NR 25
TC 2
Z9 2
U1 0
U2 2
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 2168-6165
EI 2168-6173
J9 JAMA OPHTHALMOL
JI JAMA Ophthalmol.
PD AUG
PY 2020
VL 138
IS 8
BP 835
EP 842
DI 10.1001/jamaophthalmol.2020.2309
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA NE8LE
UT WOS:000562855500005
PM 32644148
OA Bronze, Green Published
DA 2022-11-30
ER

PT J
AU Day, S
   Acquah, K
   Lee, PP
   Mruthyunjaya, P
   Sloan, FA
AF Day, Shelley
   Acquah, Kofi
   Lee, Paul P.
   Mruthyunjaya, Prithvi
   Sloan, Frank A.
TI Medicare Costs for Neovascular Age-Related Macular Degeneration,
   1994-2007
SO AMERICAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID QUALITY-OF-LIFE; PROPENSITY SCORE; VISUAL IMPAIRMENT; UNITED-STATES;
   RANIBIZUMAB; BEVACIZUMAB; PREVALENCE; TRENDS
AB PURPOSE: To assess changes in Medicare payments for neovascular age-related macular degeneration (AMD) since introduction of anti-vascular endothelial growth factor (VEGF) therapies.
   DESIGN: Retrospective, longitudinal cohort study.
   METHODS: Using the Medicare 5% sample, beneficiaries with new diagnoses of neovascular AMD in 1994 (N = 2497), 2000 (N = 3927), and 2006 (N = 6041) were identified using International Classification of Diseases (ICD-9-CM). The total first-year health care and eye care costs were calculated for each beneficiary. Propensity score matching was used to match individuals in the 2000 and 2006 cohorts with the 1994 cohort on age, sex, race, Charlson Comorbidity Index, and low vision/blindness.
   RESULTS: The number of beneficiaries newly diagnosed with neovascular AMD more than doubled between the 1994 and 2006 cohorts. Overall yearly Part B payments per beneficiary increased significantly from $3567 for the 1994 to $5991 for the 2006 cohort (P < .01) in constant 2008 dollars. Payments for eye care alone doubled from $1504 for the 1994 cohort to $3263 for the 2006 cohort (P < .01). Most of the increase in payments for eye care in 2006 reflected payments for anti-VEGF injections, which were $1609 over 1 year. Mean annual numbers of visits and imaging studies also increased significantly between the 1994 and 2006 cohort. Results were similar in the matched sample.
   CONCLUSIONS: The introduction of anti-VEGF intravitreal injections has offered remarkable clinical benefits for patients with neovascular AMD, but these benefits have come at the cost of an increased financial burden of providing care for these patients. (Am J Ophthalmol 2011;152:1014-1020. (C) 2011 by Elsevier Inc. All rights reserved.)
C1 [Acquah, Kofi; Sloan, Frank A.] Duke Univ, Dept Econ, Durham, NC 27708 USA.
   [Day, Shelley; Lee, Paul P.; Mruthyunjaya, Prithvi; Sloan, Frank A.] Duke Univ, Dept Ophthalmol, Duke Eye Ctr, Durham, NC 27708 USA.
C3 Duke University; Duke University
RP Sloan, FA (通讯作者)，Duke Univ, Dept Econ, Box 90097,236 Social Sci Bldg, Durham, NC 27708 USA.
EM fsloan@duke.edu
OI Lee, Paul/0000-0002-3338-136X; Day Ghafoori,
   Shelley/0000-0001-6674-7877; mruthyunjaya, prithvi/0000-0003-1087-9736
FU National Institute on Aging, Bethesda, Maryland [2R37-AG-17473-05A1];
   Alcon; National Institutes of Health; Washington University; NATIONAL
   INSTITUTE ON AGING [R37AG017473, R01AG017473] Funding Source: NIH
   RePORTER
FX ALL AUTHORS HAVE COMPLETED AND SUBMITTED THE ICMJE FORM FOR DISCLOSURE
   OF POTENTIAL CONFLICTS OF Interest. Publication of this article was
   partially supported by the National Institute on Aging, Bethesda,
   Maryland (grant 2R37-AG-17473-05A1). The sponsor had no role in the
   design or conduct of this study. Shelley Day has served as a consultant
   for Genentech. Paul Lee has served as a consultant for Allergan, Pfizer,
   and Genentech, and he has received financial support from Alcon, the
   National Institutes of Health, and the Washington University Award.
   Involved in design of the study (S.D., F.S., P.M., P.L.); conduct of the
   study (S.D., K.A., F.S.); collection, management, analysis, and
   interpretation of the data (S.D., K.A., F.S., P.L., P.M.); and
   preparation, review, or approval of the manuscript (S.D., K.A., F.S.,
   P.L., P.M.). The Duke University Institutional Review Board approved
   this study.
CR Austin PC, 2007, STAT MED, V26, P734, DOI 10.1002/sim.2580
   Brechner RJ, 2011, AM J OPHTHALMOL, V151, P887, DOI 10.1016/j.ajo.2010.11.017
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   Brown MM, 2008, OPHTHALMOLOGY, V115, P1039, DOI 10.1016/j.ophtha.2007.08.033
   CHARLSON ME, 1987, J CHRON DIS, V40, P373, DOI 10.1016/0021-9681(87)90171-8
   Coleman AL, 2008, OPHTHALMOLOGY, V115, P18, DOI 10.1016/j.ophtha.2007.04.016
   Coleman AL, 2010, AM J OPHTHALMOL, V150, P683, DOI 10.1016/j.ajo.2010.05.030
   D'Agostino RB, 1998, STAT MED, V17, P2265, DOI 10.1002/(SICI)1097-0258(19981015)17:19<2265::AID-SIM918>3.0.CO;2-B
   Evans JR, 2004, OPHTHALMOLOGY, V111, P513, DOI 10.1016/j.ophtha.2003.07.012
   Fong DS, 2010, OPHTHALMOLOGY, V117, P298, DOI 10.1016/j.ophtha.2009.07.023
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Gower EW, 2010, RETINA-J RET VIT DIS, V30, P212, DOI 10.1097/IAE.0b013e3181babd8e
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Klein R, 2010, ARCH OPHTHALMOL-CHIC, V128, P750, DOI 10.1001/archophthalmol.2010.92
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Normand SLT, 2001, J CLIN EPIDEMIOL, V54, P387, DOI 10.1016/S0895-4356(00)00321-8
   Ramulu PY, 2010, ARCH OPHTHALMOL-CHIC, V128, P1335, DOI 10.1001/archophthalmol.2010.224
   Rein DB, 2006, ARCH OPHTHALMOL-CHIC, V124, P1754, DOI 10.1001/archopht.124.12.1754
   Resnikoff S, 2004, B WORLD HEALTH ORGAN, V82, P844
   ROSENBAUM PR, 1983, BIOMETRIKA, V70, P41, DOI 10.1093/biomet/70.1.41
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Salm M, 2006, AM J OPHTHALMOL, V142, P976, DOI 10.1016/j.ajo.2006.07.057
   Schmier JK, 2009, ARCH OPHTHALMOL-CHIC, V127, P900, DOI 10.1001/archophthalmol.2009.122
   Sloan FA, 2004, HEALTH SERV RES, V39, P1429, DOI 10.1111/j.1475-6773.2004.00297.x
   Smiddy WE, 2009, OPHTHALMOLOGY, V116, P481, DOI 10.1016/j.ophtha.2008.10.029
   Talic I, 2022, LEARN INSTR, V81, DOI [10.1016/j.learninstruc.2022.101594, 10.1016/j.ajo.2004.02.011]
NR 26
TC 53
Z9 55
U1 0
U2 13
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0002-9394
J9 AM J OPHTHALMOL
JI Am. J. Ophthalmol.
PD DEC
PY 2011
VL 152
IS 6
BP 1014
EP 1020
DI 10.1016/j.ajo.2011.05.008
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 857JN
UT WOS:000297714900016
PM 21843875
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Talks, J
   Daien, V
   Finger, RP
   Eldem, B
   Sakamoto, T
   Cardillo, JA
   Mitchell, P
   Wong, TY
   Korobelnik, JF
AF Talks, James
   Daien, Vincent
   Finger, Robert P.
   Eldem, Bora
   Sakamoto, Taiji
   Cardillo, Jose Augusto
   Mitchell, Paul
   Wong, Tien Yin
   Korobelnik, Jean-Francois
TI The use of real-world evidence for evaluating anti-vascular endothelial
   growth factor treatment of neovascular age-related macular degeneration
SO SURVEY OF OPHTHALMOLOGY
LA English
DT Review
DE clinical practice; effectiveness; neovascular age-related macular
   degeneration; noninterventional; ophthalmology; real-life; real-world;
   retinal disease
ID VISUAL-ACUITY OUTCOMES; INTRAVITREAL BEVACIZUMAB AVASTIN; SHORT-TERM
   EFFICACY; ANTI-VEGF TREATMENT; MYOCARDIAL-INFARCTION; RANIBIZUMAB
   TREATMENT; CLINICAL-RESEARCH; REGISTRY TRIAL; AFLIBERCEPT; AMD
AB Randomized controlled trials are the gold standard in medical research, providing evidence of the efficacy of a treatment in well-defined patient populations. By contrast, real-world studies explore the effectiveness of treatments in routine clinical practice, often with diverse patient populations. Although both randomized controlled trials and real-world studies contribute to the understanding of the benefits and risks of therapies, they generate different types of data and serve complementary purposes. Real-world studies evaluating the management of neovascular age-related macular degeneration have shown that visual outcomes achieved with anti-vascular endothelial growth factor in clinical practice often differ from those derived from clinical trials, highlighting the importance of assessing such outcomes in real-world studies. Benefits include finding variations in treatment provision, leading to: service improvements; the understanding of the need for continued and higher than previously provided treatment frequency; and new treatment regimens such as treat-and-extend. There is potential for the scope of real-world studies to be expanded to include other patient outcomes, such as quality of life, thus providing decision-makers with additional information to complement the data collected in randomized controlled trials. Physicians, patients, and regulators stand to gain much from further development and the conduct of real-world studies. We provide an overview of the importance of real-world evidence in the management of neovascular age-related macular degeneration with anti-vascular endothelial growth factor therapy, describe sources of real-world evidence, and assess the relative strengths and limitations of randomized controlled trials and real-world studies. (C) 2019 Published by Elsevier Inc.
C1 [Talks, James] Newcastle Tyne Hosp NHS Fdn Trust, Newcastle Upon Tyne, Tyne & Wear, England.
   [Daien, Vincent] Univ Hosp Montpellier, Montpellier, France.
   [Finger, Robert P.] Univ Augenklin Bonn, Bonn, Germany.
   [Eldem, Bora] Hacettepe Univ, Ankara, Turkey.
   [Sakamoto, Taiji] Kagoshima Univ, Grad Sch Med & Dent Sci, Kagoshima, Japan.
   [Cardillo, Jose Augusto] Univ Sao Paulo, Sao Paulo, Brazil.
   [Mitchell, Paul] Sydney West Retina, Sydney, NSW, Australia.
   [Wong, Tien Yin] Natl Univ Singapore, Singapore Natl Eye Ctr, Duke NUS Med Sch, Singapore, Singapore.
   [Korobelnik, Jean-Francois] CHU Bordeaux, Serv Ophtalmol, Bordeaux, France.
   [Korobelnik, Jean-Francois] Univ Bordeaux, Populat Hlth Res Ctr, Team LEHA, UMR 1219, F-33000 Bordeaux, France.
C3 Newcastle Upon Tyne Hospitals NHS Foundation Trust; Universite de
   Montpellier; CHU de Montpellier; University of Bonn; Hacettepe
   University; Kagoshima University; Universidade de Sao Paulo; National
   University of Singapore; Singapore National Eye Center; CHU Bordeaux;
   UDICE-French Research Universities; Universite de Bordeaux
RP Talks, J (通讯作者)，Newcastle Tyne Hosp NHS Fdn Trust, Royal Victoria Hosp, Queen Victoria Rd, Newcastle Upon Tyne NE1 4LP, Tyne & Wear, England.
EM James.Talks@nuth.nhs.uk
RI DAIEN, Vincent/Z-5516-2019; Wong, Tien Yin/AAC-9724-2020
OI DAIEN, Vincent/0000-0001-5675-0861; Wong, Tien Yin/0000-0002-8448-1264;
   Talks, James/0000-0001-6126-6476
FU Bayer Consumer Health AG, Pharmaceuticals, Basel
FX Bayer Consumer Health AG, Pharmaceuticals, Basel, organized the author
   meetings and provided funding for editorial support with the preparation
   of the manuscript.
CR Abedi F, 2013, OPHTHALMOLOGY, V120, P115, DOI 10.1016/j.ophtha.2012.10.006
   Arias L, 2009, EYE, V23, P326, DOI 10.1038/sj.eye.6703053
   Arnold JJ, 2015, OPHTHALMOLOGY, V122, P1212, DOI 10.1016/j.ophtha.2015.02.009
   Australian Institute of Health and Welfare. Australian Government, NAT DEATH IND
   Avery RL, 2006, OPHTHALMOLOGY, V113, P363, DOI 10.1016/j.ophtha.2005.11.019
   Barthelmes D, 2016, BRIT J OPHTHALMOL, V100, P1640, DOI 10.1136/bjophthalmol-2015-308090
   Bertelsen M, 2012, BMJ-BRIT MED J, V345, DOI 10.1136/bmj.e7885
   Buitendijk GHS, 2013, OPHTHALMOLOGY, V120, P2644, DOI 10.1016/j.ophtha.2013.07.053
   CAMPBELL RJ, 2012, BMJ-BRIT MED J, V344, DOI DOI 10.1136/BMJ.E4203
   Carlsson AC, 2013, BMC PUBLIC HEALTH, V13, DOI 10.1186/1471-2458-13-670
   Chen CY, 2007, AM J OPHTHALMOL, V143, P510, DOI 10.1016/j.ajo.2006.10.004
   Cheung CMG, 2017, OPHTHALMOLOGY, V124, P1305, DOI 10.1016/j.ophtha.2017.03.056
   Chong V, 2016, EYE, V30, P270, DOI 10.1038/eye.2015.217
   Chong YH, 2017, OPHTHALMOLOGY, V124, P336, DOI 10.1016/j.ophtha.2016.11.016
   Daien V, 2017, OPHTHALMIC RES, V58, P67, DOI 10.1159/000456721
   Daien V, 2015, OPHTHALMOLOGY, V122, P1633, DOI 10.1016/j.ophtha.2015.04.017
   Dakin HA, 2014, BMJ OPEN, V4, DOI 10.1136/bmjopen-2014-005094
   Dreyer NA, 2010, AM J MANAG CARE, V16, P467
   Erie JC, 2016, OPHTHALMOLOGY, V123, P1257, DOI 10.1016/j.ophtha.2016.02.015
   Esen F, 2016, AM J OPHTHALMOL, V169, P68, DOI 10.1016/j.ajo.2016.06.019
   Eye Disease Case-Control Study Group, 1996, ARCH OPHTHALMOL-CHIC, V114, P545, DOI DOI 10.1001/ARCHOPHT.1996.01100130537006
   Falk MK, 2013, AM J OPHTHALMOL, V155, P89, DOI 10.1016/j.ajo.2012.06.031
   Finger RP, 2014, OPHTHALMOLOGY, V121, P1246, DOI 10.1016/j.ophtha.2013.12.032
   Finger RP, 2014, SURV OPHTHALMOL, V59, P1, DOI 10.1016/j.survophthal.2013.03.009
   Food and Drug Administration, US REAL WORLD EV SUP
   Frobert O, 2010, AM HEART J, V160, P1042, DOI 10.1016/j.ahj.2010.08.040
   Gangnon RE, 2015, JAMA OPHTHALMOL, V133, P125, DOI 10.1001/jamaophthalmol.2014.4252
   Garrison LP, 2007, VALUE HEALTH, V10, P326, DOI 10.1111/j.1524-4733.2007.00186.x
   Gillies MC, 2017, OPHTHALMOLOGY, V124, pE31, DOI 10.1016/j.ophtha.2016.05.054
   Gillies MC, 2015, OPHTHALMOLOGY, V122, P1837, DOI 10.1016/j.ophtha.2015.05.010
   Gillies MC, 2016, OPHTHALMOLOGY, V123, P1751
   Godwin Marshall, 2003, BMC Med Res Methodol, V3, P28, DOI 10.1186/1471-2288-3-28
   Greenfield S, 2012, J COMP EFFECT RES, V1, P263, DOI 10.2217/CER.12.23
   Grimes DA, 2002, LANCET, V359, P248, DOI 10.1016/S0140-6736(02)07451-2
   Grimes DA, 2002, LANCET, V359, P57, DOI 10.1016/S0140-6736(02)07283-5
   Grimes DA, 2002, LANCET, V359, P145, DOI 10.1016/S0140-6736(02)07373-7
   Hagstrom SA, 2013, OPHTHALMOLOGY
   Hagstrom SA, 2014, JAMA OPHTHALMOL, V132, P521, DOI 10.1001/jamaophthalmol.2014.109
   Ho PM, 2008, CIRCULATION, V118, P1675, DOI 10.1161/CIRCULATIONAHA.107.721357
   Holz FG, 2016, EYE, V30, P1063, DOI 10.1038/eye.2016.90
   Holz FG, 2013, BRIT J OPHTHALMOL, V97, P1161, DOI 10.1136/bjophthalmol-2013-303232
   Hosokawa M, 2017, JPN J OPHTHALMOL, V61, P150, DOI 10.1007/s10384-016-0492-7
   Hosokawa M, 2015, BRIT J OPHTHALMOL, V99, P1087, DOI 10.1136/bjophthalmol-2014-305275
   Iida T, 2016, 10 C AS PAC VITR SOC
   Ijiri S, 2015, GRAEF ARCH CLIN EXP, V253, P351, DOI 10.1007/s00417-014-2707-2
   Inoue M, 2014, RETINA-J RET VIT DIS, V34, P2178, DOI 10.1097/IAE.0000000000000229
   International Consortium for Health Outcomes Measurement, MAC DEG DAT COLL REF
   James S, 2015, NAT REV CARDIOL, V12, P312, DOI 10.1038/nrcardio.2015.33
   Joachim N, 2017, BRIT J OPHTHALMOL, V101, P1185, DOI 10.1136/bjophthalmol-2016-309729
   Joachim N, 2015, OPHTHALMOLOGY, V122, P2482, DOI 10.1016/j.ophtha.2015.08.002
   Johnson KE, 2016, TRIALS, V17, DOI 10.1186/s13063-016-1158-y
   Johnston RL, 2017, ADV THER, V34, P703, DOI 10.1007/s12325-017-0483-1
   Kim LN, 2016, RETINA-J RET VIT DIS, V36, P1418, DOI 10.1097/IAE.0000000000001142
   Kim L, 2014, EPIDEMIOL HEALTH, V36, DOI 10.4178/epih/e2014008
   Klein R, 2006, AM J OPHTHALMOL, V142, P539, DOI 10.1016/j.ajo.2006.06.015
   Koizumi H, 2015, BRIT J OPHTHALMOL, V99, P1284, DOI 10.1136/bjophthalmol-2014-306432
   Lalwani GA, 2009, AM J OPHTHALMOL, V148, P43, DOI 10.1016/j.ajo.2009.01.024
   Lauer MS, 2013, NEW ENGL J MED, V369, P1579, DOI 10.1056/NEJMp1310102
   Lee AY, 2015, BRIT J OPHTHALMOL, V99, P1045, DOI 10.1136/bjophthalmol-2014-306229
   Liew G, 2016, EYE, V30, P1462, DOI 10.1038/eye.2016.149
   Lim JH, 2012, AM J OPHTHALMOL, V153, P678, DOI 10.1016/j.ajo.2011.09.013
   Lyall DAM, 2012, EYE, V26, P1517, DOI 10.1038/eye.2012.199
   Maguire MG, 2016, OPHTHALMOLOGY, V123, P1751, DOI 10.1016/j.ophtha.2016.03.045
   Mahajan Rajiv, 2015, Int J Appl Basic Med Res, V5, P82, DOI 10.4103/2229-516X.157148
   Mantel I, 2018, SURV OPHTHALMOL, V63, P638, DOI 10.1016/j.survophthal.2018.02.004
   Mehta H, 2018, PROG RETIN EYE RES, V65, P127, DOI 10.1016/j.preteyeres.2017.12.002
   Menghini M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0042014
   Mitchell P, 1996, OPHTHALMOLOGY, V103, P1661, DOI 10.1016/S0161-6420(96)30449-1
   Muether PS, 2011, GRAEF ARCH CLIN EXP, V249, P633, DOI 10.1007/s00417-010-1520-9
   Ng WY, 2015, AM J OPHTHALMOL, V159, P557, DOI 10.1016/j.ajo.2014.12.005
   Oishi A, 2015, AM J OPHTHALMOL, V159, P853, DOI 10.1016/j.ajo.2015.01.018
   Parke DW, 2017, OPHTHALMOLOGE, V114, pS1, DOI 10.1007/s00347-016-0265-1
   Pimentel MA, 2016, JAMA OPHTHALMOL, V134, P1001, DOI 10.1001/jamaophthalmol.2016.2166
   Pushpoth S, 2012, BRIT J OPHTHALMOL, V96, P1469, DOI 10.1136/bjophthalmol-2012-302167
   Rofagha S, 2013, OPHTHALMOLOGY, V120, P2292, DOI 10.1016/j.ophtha.2013.03.046
   Rostron E, 2012, EYE, V26, P933, DOI 10.1038/eye.2012.61
   Rothwell PM, 2005, LANCET, V365, P82, DOI 10.1016/S0140-6736(04)17670-8
   Royal College of Ophthalmologists, MAX CAP AMD SERV
   Saito M, 2017, JPN J OPHTHALMOL, V61, P74, DOI 10.1007/s10384-016-0478-5
   Schulz KF, 2002, LANCET, V359, P431, DOI 10.1016/S0140-6736(02)07605-5
   Sherman RE, 2016, NEW ENGL J MED, V375, P2293, DOI 10.1056/NEJMsb1609216
   Singal AG, 2014, CLIN TRANSL GASTROEN, V5, DOI 10.1038/ctg.2013.13
   Soh SE, 2010, AM J OPHTHALMOL, V150, P3, DOI 10.1016/j.ajo.2010.03.008
   Song XS, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0113843
   Stanley K, 2007, CIRCULATION, V115, P1164, DOI 10.1161/CIRCULATIONAHA.105.594945
   Talks JS, 2017, EYE, V31, P1613, DOI 10.1038/eye.2017.86
   Talks JS, 2016, OPHTHALMOLOGY, V123, P337, DOI 10.1016/j.ophtha.2015.09.039
   Thorpe KE, 2009, J CLIN EPIDEMIOL, V62, P464, DOI [10.1016/j.jclinepi.2008.12.011, 10.1503/cmaj.090523]
   Treweek S, 2009, TRIALS, V10, DOI 10.1186/1745-6215-10-37
   Vaze A, 2014, RETINA-J RET VIT DIS, V34, P1774, DOI 10.1097/IAE.0000000000000173
   Virgili G, 2017, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD007419.pub5
   VISION 2020 UK, UK EYE SURV INF MEMB
   Wang JJ, 2007, OPHTHALMOLOGY, V114, P92, DOI 10.1016/j.ophtha.2006.07.017
   Yamamoto A, 2015, OPHTHALMOLOGY, V122, P1866, DOI 10.1016/j.ophtha.2015.05.024
   Yang K, 2011, OPHTHALMOLOGY, V118, P1395, DOI 10.1016/j.ophtha.2010.12.030
   You QS, 2012, OPHTHALMOLOGY, V119, P2519, DOI 10.1016/j.ophtha.2012.06.043
NR 96
TC 18
Z9 19
U1 0
U2 10
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0039-6257
EI 1879-3304
J9 SURV OPHTHALMOL
JI Surv. Ophthalmol.
PD SEP-OCT
PY 2019
VL 64
IS 5
BP 707
EP 719
DI 10.1016/j.survophthal.2019.02.008
PG 13
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA IP9MZ
UT WOS:000480375600011
PM 30797883
DA 2022-11-30
ER

PT J
AU Miura, M
   Elsner, AE
   Beausencourt, E
   Kunze, C
   Hartnett, ME
   Lashkari, K
   Trempe, CL
AF Miura, M
   Elsner, AE
   Beausencourt, E
   Kunze, C
   Hartnett, ME
   Lashkari, K
   Trempe, CL
TI Grading of infrared confocal scanning laser tomography and video
   displays of digitized color slides in exudative age-related macular
   degeneration
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE age-related macular degeneration; choroidal neovascularization; confocal
   scanning laser tomography; infrared laser; pigment epithelial
   detachment; retinal imaging
ID HUMAN OCULAR FUNDUS; OPHTHALMOSCOPE; MACULOPATHY; PREVALENCE; EYES
AB Purpose: To detect and localize exudative lesions in exudative age-related macular degeneration and to compare images obtained from infrared scanning laser tomography and video displays of digitized color slides in detection and localization of exudation.
   Methods: In a prospective study, 11 eyes of 11 patients with exudative age-related macular degeneration were studied. From 32 images with infrared scanning laser tomography, confocal images were chosen in the following focal planes: anterior to the retina, the retinal surface, and the deep retina. Using the fluorescein angiogram as a standard, three retinal specialists rank-ordered the ability to discern the lesion in these confocal images, the summary of confocal images, and video displays of digitized color slides that were adjusted to the same resolution as that of the confocal images (approximately 23 mum per pixel).
   Results: For choroidal neovascularization, both the retinal surface image and the summary image were rated superior to video displays of digitized color slides (P < 0.004). The confocal images were ranked in the following fashion: best, retinal surface; next, deep retina; and then, anterior to the retina (P < 0.01). For pigment epithelial detachment, all three confocal images and summary images were superior to video displays of digitized color slides (P < 0.002). There were no significant differences among the confocal images (P = 0.95).
   Conclusion: Infrared confocal imaging was superior to video displays of digitized color slides for visualization of both pigment epithelial detachment and choroidal neovascularization. This technique could have an impact on epidemiologic studies.
C1 Schepens Eye Res Inst, Boston, MA 02114 USA.
   Harvard Univ, Sch Med, Dept Ophthalmol, Boston, MA USA.
   Schepens Retina Associates, Boston, MA USA.
   Leopold Franzens Univ, Dept Ophthalmol, Innsbruck, Austria.
C3 Harvard University; Schepens Eye Research Institute; Harvard University;
   Harvard Medical School; University of Innsbruck
RP Elsner, AE (通讯作者)，Schepens Eye Res Inst, 20 Staniford St, Boston, MA 02114 USA.
OI Lashkari, Kameran/0000-0003-3855-0246
FU NEI NIH HHS [EYO12178, R01 EY007624, EYO07624] Funding Source: Medline;
   NATIONAL EYE INSTITUTE [R44EY012178, R29EY007624, R43EY012178,
   R01EY007624] Funding Source: NIH RePORTER
CR BARTSCH DU, 1989, AM J OPHTHALMOL, V108, P277, DOI 10.1016/0002-9394(89)90118-9
   Beausencourt E, 2000, OPHTHALMOLOGY, V107, P375, DOI 10.1016/S0161-6420(99)00056-1
   BECKMAN C, 1995, BRIT J OPHTHALMOL, V79, P900, DOI 10.1136/bjo.79.10.900
   BRESSLER NM, 1989, ARCH OPHTHALMOL-CHIC, V107, P847, DOI 10.1001/archopht.1989.01070010869032
   DELORI FC, 1989, APPL OPTICS, V28, P1061, DOI 10.1364/AO.28.001061
   DREHER AW, 1991, AM J OPHTHALMOL, V111, P221, DOI 10.1016/S0002-9394(14)72263-9
   Elsner AE, 1996, VISION RES, V36, P191, DOI 10.1016/0042-6989(95)00100-E
   ELSNER AE, 1986, J OPT SOC AM A, V3, P916, DOI 10.1364/JOSAA.3.000916
   Hartnett ME, 1996, OPHTHALMOLOGY, V103, P58, DOI 10.1016/S0161-6420(96)30731-8
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   Kunze C, 1999, OPHTHALMOLOGY, V106, P1830, DOI 10.1016/S0161-6420(99)90364-0
   MANIVANNAN A, 1994, BRIT J OPHTHALMOL, V78, P84, DOI 10.1136/bjo.78.2.84
   Miura M, 2000, INVEST OPHTH VIS SCI, V41, pS162
   MIURA M, 2001, OSA, P28
   STERNBERG P, 1991, ARCH OPHTHALMOL-CHIC, V109, P1220
   YANNUZZI LA, 1986, OPHTHALMOLOGY, V93, P611
NR 17
TC 14
Z9 15
U1 1
U2 3
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0275-004X
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD JUN
PY 2002
VL 22
IS 3
BP 300
EP 308
DI 10.1097/00006982-200206000-00008
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 569GX
UT WOS:000176594200008
PM 12055463
DA 2022-11-30
ER

PT J
AU Calvo-Gonzalez, C
   Reche-Frutos, J
   Donate-Lopez, J
   Garcia-Feijoo, J
   Leila, M
   Fernandez-Perez, C
   Garcia-Sanchez, J
AF Calvo-Gonzalez, C.
   Reche-Frutos, J.
   Donate-Lopez, J.
   Garcia-Feijoo, J.
   Leila, M.
   Fernandez-Perez, C.
   Garcia-Sanchez, J.
TI Combined Pegaptanib sodium (Macugen) and photodynamic therapy in
   predominantly classic juxtafoveal choroidal neovascularisation in age
   related macular degeneration
SO BRITISH JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID INTRAVITREAL BEVACIZUMAB; VERTEPORFIN THERAPY
AB Aims: This prospective, open label, non-comparative, observational case series evaluates 6-month results of Pegaptanib Sodium (Macugen(R)) and Photodynamic Therapy (PDT) in predominantly classic juxtafoveal choroidal neovascularisation (CNV) in age-related macular degeneration (AMD) in seven eyes of seven patients.
   Results: Best corrected visual acuity (BCVA) diminished with a mean of five letters. Initial area of CNV increased significantly from 1.4 mm(2) to 2.7 mm(2). There was a significant increase in the greatest linear dimension (GLD) from 1280.3 mu m to 2065.7 mu m at the 24-week follow-up.
   Conclusion: Predominantly classic juxtafoveal CNVs are highly aggressive lesions that demonstrate poor response despite combined therapy using PDT and Macugen.
C1 [Calvo-Gonzalez, C.; Reche-Frutos, J.; Donate-Lopez, J.; Garcia-Feijoo, J.; Fernandez-Perez, C.; Garcia-Sanchez, J.] Hosp Univ Clin San Carlos, Madrid, Spain.
RP Calvo-Gonzalez, C (通讯作者)，C Profesor Martin Lagos S-N, Madrid 28040, Spain.
EM calvo_glez@yahoo.es
RI Pérez, Cristina Fernández/I-2220-2015; Donate-Lopez, Juan/AAB-5144-2019;
   Pérez, Cristina Fernández/K-8078-2019; GARCIA FEIJOO, JULIAN/G-9762-2017
OI Pérez, Cristina Fernández/0000-0001-9853-6257; Donate-Lopez,
   Juan/0000-0002-9944-6736; Pérez, Cristina Fernández/0000-0001-9853-6257;
   GARCIA FEIJOO, JULIAN/0000-0002-7772-5718
CR Augustin AJ, 2006, EUR J OPHTHALMOL, V16, P824, DOI 10.1177/112067210601600607
   Blair MP, 2004, RETINA-J RET VIT DIS, V24, P501, DOI 10.1097/00006982-200408000-00001
   Dhalla MS, 2006, RETINA-J RET VIT DIS, V26, P988, DOI 10.1097/01.iae.0000247164.70376.91
   Lazic R, 2007, OPHTHALMOLOGY, V114, P1179, DOI 10.1016/j.ophtha.2007.03.006
NR 4
TC 8
Z9 8
U1 0
U2 4
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0007-1161
EI 1468-2079
J9 BRIT J OPHTHALMOL
JI Br. J. Ophthalmol.
PD JAN
PY 2008
VL 92
IS 1
BP 74
EP 75
DI 10.1136/bjo.2007.128942
PG 2
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 247CM
UT WOS:000252054700017
PM 18156376
DA 2022-11-30
ER

PT J
AU Kato, A
   Yasukawa, T
   Suga, K
   Hirano, Y
   Nozaki, M
   Yoshida, M
   Ogura, Y
AF Kato, Aki
   Yasukawa, Tsutomu
   Suga, Keiji
   Hirano, Yoshio
   Nozaki, Miho
   Yoshida, Munenori
   Ogura, Yuichiro
TI Intravitreal Ranibizumab for Patients with Neovascular Age-Related
   Macular Degeneration with Good Baseline Visual Acuity
SO OPHTHALMOLOGICA
LA English
DT Article
DE Good baseline visual acuity; Intravitreal ranibizumab; Neovascular
   age-related macular degeneration; Single-dose regimen
ID POLYPOIDAL CHOROIDAL VASCULOPATHY; PHOTODYNAMIC THERAPY; VEGF-TRAP;
   BEVACIZUMAB; AFLIBERCEPT; VERTEPORFIN; EFFICACY; ANTIBODY; SAFETY; EYES
AB Purpose: To report the 1-year results of intravitreal ranibizunnab (IVR) injections for neovascular age-related macular degeneration (nAMD) in patients with good baseline visual acuity (VA). Methods: Thirty-six eyes of 36 patients with nAMD with best-corrected VAs (BCVAs) >0.6 (equal to 0.22 in the logarithm of the minimum angle of resolution unit) were enrolled. IVR was the primary treatment; additional treatment was administered as needed. BCVAs and central retinal thickness (CRT) were measured periodically. Results: The mean number of injections at month 12 was 3.3. The mean BCVAs were 0.11 +/- 0.02 at baseline and 0.12 +/- 0.03 at month 12, which did not significantly differ. The mean CRT significantly improved from 320 15 to 254 12 pm at month 12 (p < 0.01). Photodynamic therapy was applied in 2 cases because of frequent recurrences. Conclusions: IVR maintained VA and improved morphological changes in wet AMD with good baseline VA. (C) 2014 S. Karger AG, Basel
C1 [Kato, Aki; Yasukawa, Tsutomu; Suga, Keiji; Hirano, Yoshio; Nozaki, Miho; Yoshida, Munenori; Ogura, Yuichiro] Nagoya City Univ, Grad Sch Med Sci, Dept Ophthalmol & Visual Sci, Nagoya, Aichi 4678601, Japan.
C3 Nagoya City University
RP Kato, A (通讯作者)，Nagoya City Univ, Grad Sch Med Sci, Dept Ophthalmol & Visual Sci, Mizuho Ku, 1 Kawasumi, Nagoya, Aichi 4678601, Japan.
EM akikato@med.nagoya-cu.ac.jp
OI Hirano, Yoshio/0000-0002-9173-0839
FU Japanese Society; Ministry of Health, Labor and Welfare of Japan;
   Grants-in-Aid for Scientific Research [25462758] Funding Source: KAKEN
FX The authors were supported by a Grant-in Aid for Scientific Research (B)
   from the Japanese Society for the Promotion of Science and a Grant-in
   Aid for Scientific Research from the Ministry of Health, Labor and
   Welfare of Japan.
CR Bakall B, 2013, AM J OPHTHALMOL, V156, P15, DOI 10.1016/j.ajo.2013.02.017
   Bressler Neil M, 2004, JAMA, V291, P1900, DOI 10.1001/jama.291.15.1900
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Busbee BG, 2013, OPHTHALMOLOGY, V120, P1046, DOI 10.1016/j.ophtha.2012.10.014
   Chakravarthy U, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.04.015
   Cho H, 2013, BRIT J OPHTHALMOL, V97, P1032, DOI 10.1136/bjophthalmol-2013-303344
   Ferrara N, 2003, NAT MED, V9, P669, DOI 10.1038/nm0603-669
   Fung AE, 2007, AM J OPHTHALMOL, V143, P566, DOI 10.1016/j.ajo.2007.01.028
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Holash J, 2002, P NATL ACAD SCI USA, V99, P11393, DOI 10.1073/pnas.172398299
   Ikemori S, 2012, J CLIN EXP OPHTHALMO, V3, P4
   Kawasaki R, 2008, OPHTHALMOLOGY, V115, P1376, DOI 10.1016/j.ophtha.2007.11.015
   Koh A, 2012, RETINA-J RET VIT DIS, V32, P1453, DOI 10.1097/IAE.0b013e31824f91e8
   Lalwani GA, 2009, AM J OPHTHALMOL, V148, P43, DOI 10.1016/j.ajo.2009.01.024
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Mori R, 2013, JPN J OPHTHALMOL, V57, P365, DOI 10.1007/s10384-013-0245-9
   Muller YA, 1998, STRUCTURE, V6, P1153, DOI 10.1016/S0969-2126(98)00116-6
   Presta LG, 1997, CANCER RES, V57, P4593
   Raja MSA, 2010, BRIT J OPHTHALMOL, V94, P1543, DOI 10.1136/bjo.2009.174763
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Saito M, 2012, RETINA-J RET VIT DIS, V32, P1250, DOI 10.1097/IAE.0b013e318236e503
   Tano Y, 2008, OPHTHALMOLOGY, V115, P585, DOI 10.1016/j.ophtha.2007.10.018
   Tsuchihashi Takashi, 2010, Nippon Ganka Gakkai Zasshi, V114, P7
   Williams TA, 2011, EYE, V25, P1617, DOI 10.1038/eye.2011.224
   Yasuda M, 2009, OPHTHALMOLOGY, V116, P2135, DOI 10.1016/j.ophtha.2009.04.017
NR 25
TC 4
Z9 4
U1 1
U2 6
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 0030-3755
EI 1423-0267
J9 OPHTHALMOLOGICA
JI Ophthalmologica
PY 2015
VL 233
IS 1
BP 27
EP 34
DI 10.1159/000368249
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA CA5ST
UT WOS:000348968800005
PM 25412682
DA 2022-11-30
ER

PT J
AU Shaban, H
   Richter, C
AF Shaban, H
   Richter, C
TI A2E and blue light in the retina: The paradigm of age-related macular
   degeneration
SO BIOLOGICAL CHEMISTRY
LA English
DT Review
DE A2E; antioxidants; apoptosis; carotenoids; mitochondria; retinoids
ID LYSOSOMAL DEGRADATIVE FUNCTIONS; N-RETINYLIDENE ETHANOLAMINE; LIPOFUSCIN
   FLUOROPHORE; PIGMENT EPITHELIUM; MITOCHONDRIAL DECAY; INDUCED APOPTOSIS;
   DAMAGE; CELLS; ABCR; PROTECTION
AB The photoreceptors in the retina, designed to initiate the cascade of events which link the incoming light to the sensation of 'vision', are susceptible to damage by light, particularly blue light. The damage can lead to cell death and diseases. The turnover of retinal, an essential element of the visual process, is the basis of the events that lead to damage. Free retinal, absorbing in the blue region of the visible spectrum, is phototoxic, and is a precursor of the (photo)toxic compound A2E, which specifically targets cytochrome oxidase and thereby induces cell death by apoptosis. Cell death induced by A2E in the dark is prevented by negatively charged phospholipids. The blue light-filtering molecules lutein and zeaxanthin are tailor-made substances protecting the retina. In vitro, they protect cytochrome oxidase against the permanent damage caused by A2E in combination with light. These novel findings should enable us to prevent or cure the dry form of age-related macular degeneration, the leading cause of severe visual impairment in humans living in developed countries.
C1 Swiss Fed Inst Technol, Inst Biochem, CH-8092 Zurich, Switzerland.
C3 ETH Zurich
RP Richter, C (通讯作者)，Swiss Fed Inst Technol, Inst Biochem, Univ Str 16, CH-8092 Zurich, Switzerland.
RI shaban, Hamdy/C-1939-2014; Shaban, Hamdy/ABD-5617-2021
OI shaban, Hamdy/0000-0003-3760-6113; Shaban, Hamdy/0000-0003-3760-6113
CR AMES BN, 1995, BBA-MOL BASIS DIS, V1271, P165, DOI 10.1016/0925-4439(95)00024-X
   BERGER JW, 1999, AGE RELATED MACULAR
   Bermann M, 2001, EXP EYE RES, V72, P191
   Cai JY, 2000, PROG RETIN EYE RES, V19, P205, DOI 10.1016/S1350-9462(99)00009-9
   CHEN LB, 1988, ANNU REV CELL BIOL, V4, P155, DOI 10.1146/annurev.cb.04.110188.001103
   CRUICKSHANKS KJ, 1993, ARCH OPHTHALMOL-CHIC, V111, P514, DOI 10.1001/archopht.1993.01090040106042
   Eldred GE, 1995, GERONTOLOGY, V41, P15
   ELDRED GE, 1993, NATURE, V361, P724, DOI 10.1038/361724a0
   FEENEY L, 1978, INVEST OPHTH VIS SCI, V17, P583
   GORGELS TGMF, 1995, INVEST OPHTH VIS SCI, V36, P851
   Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309
   Grimm C, 2000, NAT GENET, V25, P63, DOI 10.1038/75614
   Hagen TM, 1998, ANN NY ACAD SCI, V854, P214, DOI 10.1111/j.1749-6632.1998.tb09904.x
   HAM WT, 1976, NATURE, V260, P153, DOI 10.1038/260153a0
   Hengartner MO, 2000, NATURE, V407, P770, DOI 10.1038/35037710
   Holz FG, 1999, INVEST OPHTH VIS SCI, V40, P737
   Holz FG, 1999, OPHTHALMOLOGE, V96, P781, DOI 10.1007/s003470050496
   ISHIBASHI T, 1986, AM J OPHTHALMOL, V101, P342, DOI 10.1016/0002-9394(86)90830-5
   Junghans A, 2001, ARCH BIOCHEM BIOPHYS, V391, P160, DOI 10.1006/abbi.2001.2411
   Krogmeier JR, 2001, J MICROSC-OXFORD, V202, P386, DOI 10.1046/j.1365-2818.2001.00855.x
   Liu JH, 2000, J BIOL CHEM, V275, P29354, DOI 10.1074/jbc.M910191199
   Mata NL, 2000, P NATL ACAD SCI USA, V97, P7154, DOI 10.1073/pnas.130110497
   Mata NL, 2001, INVEST OPHTH VIS SCI, V42, P1685
   Michaelides M, 2001, EYE, V15, P148, DOI 10.1038/eye.2001.49
   PARISH EJ, 1998, RRD ORG CHEM 1, V2, P95
   Reme CE, 1998, PROG RETIN EYE RES, V17, P443, DOI 10.1016/S1350-9462(98)00009-3
   Ren RXF, 1997, J AM CHEM SOC, V119, P3619, DOI 10.1021/ja9700414
   RICHTER C, 1993, FEBS LETT, V325, P104, DOI 10.1016/0014-5793(93)81423-W
   Richter C, 2001, CELL DEATH DIFFER, V8, P207, DOI 10.1038/sj.cdd.4400849
   Sakai N, 1996, J AM CHEM SOC, V118, P1559, DOI 10.1021/ja953480g
   Schalch W, 1992, EXS, V62, P280
   SEDDON JM, 1994, JAMA-J AM MED ASSOC, V272, P1413, DOI 10.1001/jama.272.18.1413
   Seko Y, 2001, GRAEF ARCH CLIN EXP, V239, P47, DOI 10.1007/s004170000220
   Shaban H, 2001, ARCH BIOCHEM BIOPHYS, V394, P111, DOI 10.1006/abbi.2001.2535
   SHABAN H, 2002, IN PRESS EXP EYE RES
   SHOFFNER JM, 1994, ANNU REV NUTR, V14, P535, DOI 10.1146/annurev.nu.14.070194.002535
   Sparrow JR, 1999, INVEST OPHTH VIS SCI, V40, P2988
   Sparrow JR, 2001, INVEST OPHTH VIS SCI, V42, P1356
   Sparrow JR, 2000, INVEST OPHTH VIS SCI, V41, P1981
   SPERDUTO RD, 1993, ARCH OPHTHALMOL-CHIC, V111, P104
   Sun H, 2001, J BIOL CHEM, V276, P11766, DOI 10.1074/jbc.M010152200
   SUN H, 2001, SCI AM           OCT, P61
   Sundelin SP, 2001, FREE RADICAL BIO MED, V31, P217, DOI 10.1016/S0891-5849(01)00573-1
   Suter M, 2000, J BIOL CHEM, V275, P39625, DOI 10.1074/jbc.M007049200
   Taylor H R, 1990, Trans Am Ophthalmol Soc, V88, P163
   Weng J, 1999, CELL, V98, P13, DOI 10.1016/S0092-8674(00)80602-9
   Winkler BS, 1999, MOL VIS, V5
   YOUNG RW, 1969, J CELL BIOL, V42, P392, DOI 10.1083/jcb.42.2.392
NR 48
TC 46
Z9 66
U1 1
U2 20
PU WALTER DE GRUYTER GMBH
PI BERLIN
PA GENTHINER STRASSE 13, D-10785 BERLIN, GERMANY
SN 1431-6730
EI 1437-4315
J9 BIOL CHEM
JI Biol. Chem.
PD MAR-APR
PY 2002
VL 383
IS 3-4
BP 537
EP 545
DI 10.1515/BC.2002.054
PG 9
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology
GA 551PV
UT WOS:000175570800017
PM 12033441
DA 2022-11-30
ER

PT J
AU Yu, HH
   Yuan, L
   Yang, YH
   Ma, SH
   Peng, LH
   Wang, Y
   Zhang, C
   Li, T
AF Yu, Honghua
   Yuan, Ling
   Yang, Yahan
   Ma, Suihong
   Peng, Lianghong
   Wang, Yong
   Zhang, Chu
   Li, Tao
TI Increased serum IgA concentration and plasmablast frequency in patients
   with age-related macular degeneration
SO IMMUNOBIOLOGY
LA English
DT Article
DE IgA; Plasmablast; Age-related macular degeneration
ID FACTOR-H POLYMORPHISM; RISK-FACTORS; COMPLEMENT; TRANSCRIPTS;
   ACTIVATION; PATHWAY; CELLS
AB Age-related macular degeneration (AMD) is the leading cause of blindness among senior citizens of developed countries, with currently unknown etiology. Despite the close associations between AMD development and inhibitory complement factor H mutations, the first step of complement activation, which is the antibody response in AMD patients, has not been studied. Here, we obtained blood and tear samples from AMD patients and Non-AMD controls. We found that compared to Non-AMD controls, AMD subjects had increased IgA titers in serum and tear, and had elevated levels of circulating antibody-secreting plasmablasts. The increase in antibody titer was limited to the IgA isotype, since no significant differences were observed in IgM and IgG isotypes between AMD patients and Non-AMD controls. Interestingly, this increased antibody response in AMID patients was correlated with disease severity, as late AMD patients had increased IgA titers in serum and tear, as well as elevated plasmablast frequency after staphylococcal enterotoxin B stimulation, compared to early AMD patients. Together, our results implicated a role of overreactive IgA responses in AMD pathogenesis. (C) 2016 Elsevier GmbH. All rights reserved.
C1 [Yu, Honghua; Yang, Yahan; Li, Tao] Sun Yat Sen Univ, Zhongshan Ophthalm Ctr, State Key Lab Ophthalmol, Guangzhou 510275, Guangdong, Peoples R China.
   [Yu, Honghua; Peng, Lianghong; Wang, Yong; Zhang, Chu] PLA, Guangzhou Mil Command, Gen Hosp, Dept Ophthalmol, Guangzhou 510010, Guangdong, Peoples R China.
   [Yuan, Ling] Kunming Med Coll, Affiliated Hosp 1, Dept Ophthalmol, Kunming 650031, Peoples R China.
   [Ma, Suihong] Guangzhou 1 Peoples Hosp, Guangzhou 510180, Guangdong, Peoples R China.
C3 Sun Yat Sen University; Southern Theater Command General Hospital;
   Kunming Medical University; South China University of Technology
RP Li, T (通讯作者)，Sun Yat Sen Univ, Zhongshan Ophthalm Ctr, State Key Lab Ophthalmol, Guangzhou 510275, Guangdong, Peoples R China.; Ma, SH (通讯作者)，Guangzhou 1 Peoples Hosp, Guangzhou 510180, Guangdong, Peoples R China.
EM suihongma@sina.com; taoligz@126.com
OI Li, Tao/0000-0001-8064-871X; Yu, Honghua/0000-0002-0782-346X
FU Science and Technology Program of Guangzhou, China [1563000152];
   National Natural Science Foundation of China [81260151]; Applied Basic
   Research Foundation of the Department of Science and Technology of
   Yunnan Province [201 1FB062]; Science and Technology Foundation of the
   Department of Health of Yunnan Province [2012ws0015]
FX This work was supported by grant 1563000152 from Science and Technology
   Program of Guangzhou, China (H. Yu), grant 81260151 from the National
   Natural Science Foundation of China (L. Yuan), grant 201 1FB062 from the
   Applied Basic Research Foundation of the Department of Science and
   Technology of Yunnan Province (L. Yuan), and grant 2012ws0015 from the
   Science and Technology Foundation of the Department of Health of Yunnan
   Province (L. Yuan).
CR Anderson DH, 2004, EXP EYE RES, V78, P243, DOI 10.1016/j.exer.2003.10.011
   Avalos AM, 2009, J IMMUNOL, V183, P6262, DOI 10.4049/jimmunol.0901941
   Castigli E, 2005, J EXP MED, V201, P35, DOI 10.1084/jem.20032000
   Cerutti A, 2011, ANNU REV IMMUNOL, V29, P273, DOI 10.1146/annurev-immunol-031210-101317
   Cherepanoff S, 2006, CLIN EXP OPHTHALMOL, V34, P590, DOI 10.1111/j.1442-9071.2006.01281.x
   de Jong PTVM, 2006, NEW ENGL J MED, V355, P1474, DOI 10.1056/NEJMra062326
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Evans JR, 2001, PROG RETIN EYE RES, V20, P227, DOI 10.1016/S1350-9462(00)00023-9
   Haas P, 2011, ACTA OPHTHALMOL, V89, P335, DOI 10.1111/j.1755-3768.2009.01697.x
   Harwood NE, 2010, ANNU REV IMMUNOL, V28, P185, DOI 10.1146/annurev-immunol-030409-101216
   He B, 2007, IMMUNITY, V26, P812, DOI 10.1016/j.immuni.2007.04.014
   HIEMSTRA PS, 1987, EUR J IMMUNOL, V17, P321, DOI 10.1002/eji.1830170304
   ISLAM KB, 1991, INT IMMUNOL, V3, P1099, DOI 10.1093/intimm/3.11.1099
   ITOH K, 1995, J IMMUNOL, V154, P4341
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Klein R, 2010, ARCH OPHTHALMOL-CHIC, V128, P750, DOI 10.1001/archophthalmol.2010.92
   Kulkarni A.D., 2005, ADV DRUG DELIV REV, P1994
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Litinskiy MB, 2002, NAT IMMUNOL, V3, P822, DOI 10.1038/ni829
   Macpherson AJ, 2008, MUCOSAL IMMUNOL, V1, P11, DOI 10.1038/mi.2007.6
   Maller JB, 2007, NAT GENET, V39, P1200, DOI 10.1038/ng2131
   Monteiro RC, 2003, ANNU REV IMMUNOL, V21, P177, DOI 10.1146/annurev.immunol.21.120601.141011
   Morita R, 2011, IMMUNITY, V34, P108, DOI 10.1016/j.immuni.2010.12.012
   Morohoshi K, 2012, EXP MOL PATHOL, V92, P64, DOI 10.1016/j.yexmp.2011.09.017
   Nassar K., 2014, GRAEFES ARCH CLIN EX, P1
   NILSSON L, 1991, INT IMMUNOL, V3, P1107, DOI 10.1093/intimm/3.11.1107
   Ricklin D, 2010, NAT IMMUNOL, V11, P785, DOI 10.1038/ni.1923
   Rickman CB, 2013, INVEST OPHTH VIS SCI, V54, pORSF68, DOI 10.1167/iovs.13-12757
   SHOCKETT P, 1991, J IMMUNOL, V147, P4374
   Tamm SA, 2001, OCUL IMMUNOL INFLAMM, V9, P75, DOI 10.1076/ocii.9.2.75.3972
   Tangye SG, 2002, J IMMUNOL, V169, P4298, DOI 10.4049/jimmunol.169.8.4298
   Taylor PR, 2000, J EXP MED, V192, P359, DOI 10.1084/jem.192.3.359
   Wang Lei, 2010, Proceedings of the 2010 IEEE AUTOTESTCON, DOI 10.1109/AUTEST.2010.5613631
   Zakaria N, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0036451
NR 35
TC 3
Z9 3
U1 0
U2 7
PU ELSEVIER GMBH
PI MUNICH
PA HACKERBRUCKE 6, 80335 MUNICH, GERMANY
SN 0171-2985
J9 IMMUNOBIOLOGY
JI Immunobiology
PD MAY
PY 2016
VL 221
IS 5
BP 650
EP 656
DI 10.1016/j.imbio.2016.01.004
PG 7
WC Immunology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Immunology
GA DI6ZB
UT WOS:000373647700007
PM 26827241
DA 2022-11-30
ER

PT J
AU Raoul, W
   Auvynet, C
   Camelo, S
   Guillonneau, X
   Feumi, C
   Combadiere, C
   Sennlaub, F
AF Raoul, William
   Auvynet, Constance
   Camelo, Serge
   Guillonneau, Xavier
   Feumi, Charles
   Combadiere, Christophe
   Sennlaub, Florian
TI CCL2/CCR2 and CX3CL1/CX3CR1 chemokine axes and their possible
   involvement in age-related macular degeneration
SO JOURNAL OF NEUROINFLAMMATION
LA English
DT Review
ID EXPERIMENTAL CHOROIDAL NEOVASCULARIZATION; MONOCYTE CHEMOATTRACTANT
   PROTEIN-1; ENDOTHELIAL GROWTH-FACTOR; FACTOR-H POLYMORPHISM; RETINAL
   MICROGLIA; SUBRETINAL MICROGLIA; FRACTALKINE RECEPTOR; ANIMAL-MODEL;
   EXPRESSION; MICE
AB The causes of age-related macular degeneration (AMD) are not well understood. Due to demographic shifts in the industrialized world a growing number of people will develop AMD in the coming decades. To develop treatments it is essential to characterize the disease's pathogenic process. Over the past few years, numerous studies have focused on the role of chemotactic cytokines, also known as chemokines. Certain chemokines, such as CCL2 and CX3CL1, appear to be crucial in subretinal microglia and macrophage accumulation observed in AMD, and participate in the development of retinal degeneration as well as in choroidal neovascularization. This paper reviews the possible implications of CCL2 and CX3CL1 signaling in AMD. Expression patterns, single nucleotide polymorphisms (SNPs) association studies, chemokine and chemokine receptor knockout models are discussed. Future AMD treatments could target chemokines and/or their receptors.
C1 [Auvynet, Constance; Combadiere, Christophe] INSERM, UMR S945, Lab Immunol Cellulaire, F-75013 Paris, France.
   [Raoul, William; Auvynet, Constance; Camelo, Serge; Guillonneau, Xavier; Feumi, Charles; Sennlaub, Florian] Ctr Rech Cordeliers, INSERM, UMR S 872, F-75006 Paris, France.
   [Raoul, William; Auvynet, Constance; Camelo, Serge; Guillonneau, Xavier; Feumi, Charles; Sennlaub, Florian] Univ Paris 06, UMR S 872, F-75006 Paris, France.
   [Raoul, William; Auvynet, Constance; Camelo, Serge; Guillonneau, Xavier; Feumi, Charles; Sennlaub, Florian] Univ Paris 05, UMR S 872, F-75006 Paris, France.
   [Combadiere, Christophe] UPMC, UMR S945, F-75006 Paris, France.
   [Combadiere, Christophe] Grp Hosp Pitie Salpetriere, AP HP, Serv Immunol, F-75013 Paris, France.
   [Sennlaub, Florian] Hop Hotel Dieu, AP HP, Serv Ophtalmol, F-75001 Paris, France.
C3 Institut National de la Sante et de la Recherche Medicale (Inserm);
   Institut National de la Sante et de la Recherche Medicale (Inserm);
   UDICE-French Research Universities; Sorbonne Universite; Universite
   Paris Cite; UDICE-French Research Universities; Sorbonne Universite;
   Universite Paris Cite; UDICE-French Research Universities; Universite
   Paris Cite; UDICE-French Research Universities; Sorbonne Universite;
   Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire
   Pitie-Salpetriere - APHP; UDICE-French Research Universities; Sorbonne
   Universite; Assistance Publique Hopitaux Paris (APHP); Hopital
   Universitaire Hotel-Dieu - APHP; UDICE-French Research Universities;
   Universite Paris Cite
RP Combadiere, C (通讯作者)，INSERM, UMR S945, Lab Immunol Cellulaire, F-75013 Paris, France.
EM christophe.combadiere@upmc.fr; florian.sennlaub@inserm.fr
RI guillonneau, xavier/AAF-9495-2021; Raoul, William/H-2118-2018;
   Combadiere, Christophe/I-5639-2013; Sennlaub, Florian/F-2756-2017;
   Guillonneau, xavier/E-3995-2017
OI guillonneau, xavier/0000-0001-7379-3935; Raoul,
   William/0000-0002-5040-3372; Combadiere, Christophe/0000-0002-1755-4531;
   Sennlaub, Florian/0000-0003-4412-1341; Guillonneau,
   xavier/0000-0001-7379-3935; Camelo, Serge/0000-0001-8733-8503
FU ANR [AO5120DD]; European Grant "Innochem" [LSHB-CT-2005-518167]; ANR
   "Maladies Neurologiques et Maladies Psychiatriques" [R08098DS]; ERC
   [ERC-2007 St.G. 210345]; Assistance Publique-Hopitaux de Paris; INSERM
FX This work was supported by grants from INSERM, ANR "blanc" (AO5120DD),
   European Grant "Innochem" (LSHB-CT-2005-518167), ANR "Maladies
   Neurologiques et Maladies Psychiatriques" (R08098DS) and ERC starting
   Grant (ERC-2007 St.G. 210345). C. C. and F. S. are recipients of a
   contract "Interface" from Assistance Publique-Hopitaux de Paris. We
   thank Christopher Murray for critical review of the manuscript.
CR Ambati J, 2003, NAT MED, V9, P1390, DOI 10.1038/nm950
   Bazan JF, 1997, NATURE, V385, P640, DOI 10.1038/385640a0
   Bellander BM, 2004, J NEUROTRAUM, V21, P605, DOI 10.1089/089771504774129937
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Cardona AE, 2006, NAT NEUROSCI, V9, P917, DOI 10.1038/nn1715
   Chan CC, 2008, OPHTHALMIC RES, V40, P124, DOI 10.1159/000119862
   CHARO IF, 1994, P NATL ACAD SCI USA, V91, P2752, DOI 10.1073/pnas.91.7.2752
   Checchin D, 2006, INVEST OPHTH VIS SCI, V47, P3595, DOI 10.1167/iovs.05-1522
   Chen HY, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002339
   Cohen SY, 2007, BRIT J OPHTHALMOL, V91, P354, DOI 10.1136/bjo.2006.101022
   Combadiere C, 2003, CIRCULATION, V107, P1009, DOI 10.1161/01.CIR.0000057548.68243.42
   Combadiere C, 2008, CIRCULATION, V117, P1649, DOI 10.1161/CIRCULATIONAHA.107.745091
   Combadiere C, 2007, J CLIN INVEST, V117, P2920, DOI 10.1172/JCI31692
   Daoudi M, 2004, J BIOL CHEM, V279, P19649, DOI 10.1074/jbc.M313457200
   Despriet DDG, 2008, INVEST OPHTH VIS SCI, V49, P364, DOI 10.1167/iovs.07-0656
   DEVOS AF, 1994, INVEST OPHTH VIS SCI, V35, P3873
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Eltayeb S, 2007, J NEUROINFLAMM, V4, DOI 10.1186/1742-2094-4-14
   Espinosa-Heidmann DG, 2003, INVEST OPHTH VIS SCI, V44, P3586, DOI 10.1167/iovs.03-0038
   FARKAS TG, 1971, AM J OPHTHALMOL, V71, P1196, DOI 10.1016/0002-9394(71)90963-9
   Geissmann F, 2003, IMMUNITY, V19, P71, DOI 10.1016/S1074-7613(03)00174-2
   Gupta N, 2003, EXP EYE RES, V76, P463, DOI 10.1016/S0014-4835(02)00332-9
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Hakobyan S, 2008, J BIOL CHEM, V283, P30451, DOI 10.1074/jbc.M803648200
   Higgins GT, 2003, INVEST OPHTH VIS SCI, V44, P1775, DOI 10.1167/iovs.02-0742
   Ishibashi T, 1997, GRAEF ARCH CLIN EXP, V235, P159, DOI 10.1007/BF00941723
   Johnson LV, 2001, EXP EYE RES, V73, P887, DOI 10.1006/exer.2001.1094
   Joly S, 2009, AM J PATHOL, V174, P2310, DOI 10.2353/ajpath.2009.090023
   Jonas JB, 2010, ARCH OPHTHALMOL-CHIC, V128, P1281, DOI 10.1001/archophthalmol.2010.227
   Jung S, 2000, MOL CELL BIOL, V20, P4106, DOI 10.1128/MCB.20.11.4106-4114.2000
   Klein R, 2004, AM J OPHTHALMOL, V137, P486, DOI 10.1016/j.ajo.2003.11.069
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Klein R, 2007, OPHTHALMOLOGY, V114, P253, DOI 10.1016/j.ophtha.2006.10.040
   Liang KJ, 2009, INVEST OPHTH VIS SCI, V50, P4444, DOI 10.1167/iovs.08-3357
   Luhmann UFO, 2009, INVEST OPHTH VIS SCI, V50, P5934, DOI 10.1167/iovs.09-3462
   Luibl V, 2006, J CLIN INVEST, V116, P378, DOI 10.1172/JCI25843
   Luster AD, 1998, NEW ENGL J MED, V338, P436, DOI 10.1056/NEJM199802123380706
   Ma WX, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007945
   Matsubara T, 1999, INVEST OPHTH VIS SCI, V40, P3186
   McDermott DH, 2003, J CLIN INVEST, V111, P1241, DOI 10.1172/JCI200316790
   Mullins RF, 2000, FASEB J, V14, P835, DOI 10.1096/fasebj.14.7.835
   Nakazawa T, 2007, P NATL ACAD SCI USA, V104, P2425, DOI 10.1073/pnas.0608167104
   Ng TF, 2001, INVEST OPHTH VIS SCI, V42, P3301
   Nozaki M, 2006, P NATL ACAD SCI USA, V103, P2328, DOI 10.1073/pnas.0408835103
   Ormsby RJ, 2008, INVEST OPHTH VIS SCI, V49, P1763, DOI 10.1167/iovs.07-1297
   Penfold PL, 1997, INVEST OPHTH VIS SCI, V38, P2125
   Ramkumar HL, 2010, PROG RETIN EYE RES, V29, P169, DOI 10.1016/j.preteyeres.2010.02.002
   Ransohoff RM, 2009, IMMUNITY, V31, P711, DOI 10.1016/j.immuni.2009.09.010
   Raoul W, 2008, OPHTHAL RES, V40, P115, DOI 10.1159/000119860
   Raoul W, 2008, J NEUROIMMUNOL, V198, P56, DOI 10.1016/j.jneuroim.2008.04.014
   Rogue RS, 1999, BRAIN RES, V836, P110, DOI 10.1016/S0006-8993(99)01625-X
   Rudolf M, 2008, EXP EYE RES, V87, P402, DOI 10.1016/j.exer.2008.07.010
   Sakurai E, 2003, INVEST OPHTH VIS SCI, V44, P3578, DOI 10.1167/iovs.03-0097
   SARKS SH, 1976, BRIT J OPHTHALMOL, V60, P324, DOI 10.1136/bjo.60.5.324
   Silverman MD, 2003, INVEST OPHTH VIS SCI, V44, P1608, DOI 10.1167/iovs.02-0233
   Tsutsumi C, 2003, J LEUKOCYTE BIOL, V74, P25, DOI 10.1189/jlb.0902436
   Tuo JS, 2007, INVEST OPHTH VIS SCI, V48, P3827, DOI 10.1167/iovs.07-0051
   Tuo JS, 2004, FASEB J, V18, pA934
   van Leeuwen R, 2003, ARCH OPHTHALMOL-CHIC, V121, P519, DOI 10.1001/archopht.121.4.519
   VANDERSCHAFT TL, 1993, BRIT J OPHTHALMOL, V77, P657, DOI 10.1136/bjo.77.10.657
   Xu HP, 2008, AGING CELL, V7, P58, DOI 10.1111/j.1474-9726.2007.00351.x
   Xu HP, 2009, PROG RETIN EYE RES, V28, P348, DOI 10.1016/j.preteyeres.2009.06.001
   Xu Q, 2006, J NEUROSCI, V26, P4985, DOI 10.1523/JNEUROSCI.5476-05.2006
   Yamada K, 2007, INVEST OPHTH VIS SCI, V48, P1839, DOI 10.1167/iovs.06-1085
   YANG X, BR J OPHTHALMOL
   Yi XJ, 1997, GRAEF ARCH CLIN EXP, V235, P313, DOI 10.1007/BF01739641
   ZWEIFEL SA, 2010, OPHTHALMOLOGY
NR 68
TC 68
Z9 71
U1 0
U2 11
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1742-2094
J9 J NEUROINFLAMM
JI J. Neuroinflamm.
PD DEC 2
PY 2010
VL 7
AR 87
DI 10.1186/1742-2094-7-87
PG 7
WC Immunology; Neurosciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Immunology; Neurosciences & Neurology
GA 696VP
UT WOS:000285469800001
PM 21126357
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Gildener-Leapman, JR
   Srivistava, S
   Ehlers, JP
   Kaiser, PK
AF Gildener-Leapman, Juliana R.
   Srivistava, Sunil
   Ehlers, Justis P.
   Kaiser, Peter K.
TI Prevalence of Outer Retinal Tubulation After Anti-VEGF Therapy for
   Age-Related Macular Degeneration
SO OPHTHALMIC SURGERY LASERS & IMAGING RETINA
LA English
DT Article
ID OPTICAL-COHERENCE-TOMOGRAPHY; RANIBIZUMAB; BEVACIZUMAB
AB BACKGROUND AND OBJECTIVE: To assess whether there is a correlation between anti-vascular endothelial growth factor (VEGF) therapy and the incidence of outer retinal tubulation (ORT) in patients with exudative age-related macular degeneration (AMD).
   PATIENTS AND METHODS: A retrospective review of all patients at the Cole Eye Institute who received anti-VEGF injections for exudative AMD and underwent optical coherence tomography (OCT) evaluation was performed. A total of 543 patients were identified and included in the study. The number of treatments and the change in Snellen visual acuity from the time of diagnosis until the development of ORT were tabulated.
   RESULTS: Seventy individuals with ORT were identified. The data analyzed showed a wide variation in the number of treatments until the development of ORT and did not show a significant correlation between ORT incidence and decreased visual acuity.
   CONCLUSION: Although a correlation was found between the increased incidence of ORT and length of anti-VEGF treatment, there was no evidence of decreased visual acuity, which suggests that the ORT might be benign.
C1 [Gildener-Leapman, Juliana R.] Case Western Reserve Univ, Sch Med, Dept Ophthalmol, Cleveland, OH USA.
   [Srivistava, Sunil; Ehlers, Justis P.; Kaiser, Peter K.] Cole Eye Inst, Cleveland, OH 44195 USA.
C3 Case Western Reserve University
RP Kaiser, PK (通讯作者)，Cole Eye Inst, 9500 Euclid Ave,Desk I3, Cleveland, OH 44195 USA.
EM pkkaiser@gmail.com
OI Kaiser, Peter/0000-0001-5126-045X
FU Research to Prevent Blindness
FX Dr. Kaiser is a consultant for Alcon, Novartis, Genentech, Bayer, and
   Regeneron and received a grant from Research to Prevent Blindness. The
   remaining authors report no relevant financial disclosures.
CR Fujimoto JG, 2000, NEOPLASIA, V2, P9, DOI 10.1038/sj.neo.7900071
   Harper RA, 2010, BASIC OPHTHALMOLOGY, P76
   Holladay JT, 1997, J REFRACT SURG, V13, P388
   Hooper CY, 2003, CLIN EXP OPHTHALMOL, V31, P376, DOI 10.1046/j.1442-9071.2003.00683.x
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rosenfeld PJ, 2005, OPHTHAL SURG LAS IM, V36, P331, DOI 10.3928/1542-8877-20050701-14
   Zweifel SA, 2009, ARCH OPHTHALMOL-CHIC, V127, P1596, DOI 10.1001/archophthalmol.2009.326
NR 8
TC 8
Z9 9
U1 0
U2 2
PU SLACK INC
PI THOROFARE
PA 6900 GROVE RD, THOROFARE, NJ 08086 USA
SN 2325-8160
EI 2325-8179
J9 OSLI RETINA
JI Ophthalmic Surg. Lasers Imag. Retin.
PD MAR
PY 2015
VL 46
IS 3
BP 345
EP 348
DI 10.3928/23258160-20150323-08
PG 4
WC Ophthalmology; Surgery
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology; Surgery
GA CO6UH
UT WOS:000359291400009
PM 25856821
DA 2022-11-30
ER

PT J
AU Murphy, C
   Johnson, AP
   Koenekoop, RK
   Seiple, W
   Overbury, O
AF Murphy, Caitlin
   Johnson, Aaron P.
   Koenekoop, Robert K.
   Seiple, William
   Overbury, Olga
TI The Relationship Between Cognitive Status and Known Single Nucleotide
   Polymorphisms in Age-Related Macular Degeneration
SO FRONTIERS IN AGING NEUROSCIENCE
LA English
DT Article
DE age-related macular degeneration; mild cognitive impairment; low vision;
   genetics; complement factor H; age-related maculopathy susceptibility
   gene 2; fatty acid desaturase 1
ID FACTOR-H POLYMORPHISM; ALZHEIMERS-DISEASE; COMPLEMENT ACTIVATION;
   CARDIOVASCULAR-HEALTH; DOCOSAHEXAENOIC ACID; VISUAL IMPAIRMENT;
   CATARACT-SURGERY; RISK ALLELES; DEMENTIA; ASSOCIATION
AB Recent literature has reported a higher occurrence of cognitive impairment among individuals with Age-related Macular Degeneration (AMD) compared to older adults with normal vision. This pilot study explored potential links between single nucleotide polymorphisms (SNPs) in AMD and cognitive status. Individuals with AMD (N = 21) and controls (N = 18) were genotyped for the SNPs CFHY402H, ARMS2A69S and FADS1 rs174547. Cognitive status was evaluated using the Montreal Cognitive Assessment. The two groups differed significantly on which subscales were most difficult. The control group had difficulty with delayed recall while those with AMD had difficulty on delayed recall in addition to abstraction and orientation. Homozygous carriers of the FADS1 rs174547 SNP had significantly lower scores than heterozygotes or non-carriers on the MoCA. The results suggest that the FADS1 SNP may play a role in visual impairment/cognitive impairment comorbidity as reflected in the poorer cognitive scores among homozygotes with AMD compared to those carrying only one, or no copies of the SNP.
C1 [Murphy, Caitlin; Overbury, Olga] Univ Montreal, Low Vis Lab, Sch Optometry, Montreal, PQ, Canada.
   [Murphy, Caitlin; Johnson, Aaron P.] Concordia Univ, Dept Psychol, Concordia Vis Labs, Montreal, PQ, Canada.
   [Murphy, Caitlin; Johnson, Aaron P.] Ctr Ouest Ile Montreal, Ctr Integre Univ Sante & Serv Sociaux Ctr Ouest I, Ctr Readaptat Lethbridge Layton Mackay, Ctr Interdisciplinary Res Rehabil Greater Montrea, Montreal, PQ, Canada.
   [Koenekoop, Robert K.] McGill Univ Hlth Ctr, Fac Med, Paediat Surg & Human Genet & Ophthalmol, Montreal, PQ, Canada.
   [Seiple, William] Lighthouse Guild, Arlene R Gordon Res Inst, New York, NY USA.
   [Seiple, William] NYU, Sch Med, New York, NY USA.
   [Overbury, Olga] Lady Davis Inst Med Res, Montreal, PQ, Canada.
C3 Universite de Montreal; Concordia University - Canada; Universite de
   Montreal; McGill University; New York University; Lady Davis Institute;
   McGill University
RP Murphy, C (通讯作者)，Univ Montreal, Low Vis Lab, Sch Optometry, Montreal, PQ, Canada.; Murphy, C (通讯作者)，Concordia Univ, Dept Psychol, Concordia Vis Labs, Montreal, PQ, Canada.; Murphy, C (通讯作者)，Ctr Ouest Ile Montreal, Ctr Integre Univ Sante & Serv Sociaux Ctr Ouest I, Ctr Readaptat Lethbridge Layton Mackay, Ctr Interdisciplinary Res Rehabil Greater Montrea, Montreal, PQ, Canada.
EM caitlin.murphy@mail.concordia.ca
RI Koenekoop, Robert/AAT-6676-2021
FU Common Infrastructures program of the Vision Health Research Network
   (VHRN) of the Fonds de Recherche du Quebec en Sante (FRQS); Canadian
   National Institute for the Blind Ross C. Purse Doctoral Fellowship; FRQS
   Doctoral Fellowship; VHRN/FRQS Bourse de Doctorat en Sciences de la
   Vision
FX This work was supported by the Common Infrastructures program of the
   Vision Health Research Network (VHRN) of the Fonds de Recherche du
   Quebec en Sante (FRQS) and doctoral fellowships: The Canadian National
   Institute for the Blind Ross C. Purse Doctoral Fellowship, the FRQS
   Doctoral Fellowship and the VHRN/FRQS Bourse de Doctorat en Sciences de
   la Vision.
CR Alzheimer A, 1995, Clin Anat, V8, P429
   Anderson DH, 2004, EXP EYE RES, V78, P243, DOI 10.1016/j.exer.2003.10.011
   Anstey KJ, 2006, J INT NEUROPSYCH SOC, V12, P632, DOI 10.1017/S1355617706060954
   Areds Research Group, 2006, ARCH OPHTHALMOL, V124, P537, DOI [10.1001/archopht.124.4.537, DOI 10.1001/ARCHOPHT.124.4.537]
   Augood C, 2008, AM J CLIN NUTR, V88, P398, DOI 10.1093/ajcn/88.2.398
   Baker ML, 2009, ARCH OPHTHALMOL-CHIC, V127, P667, DOI 10.1001/archophthalmol.2009.30
   Burton PR, 2007, NATURE, V447, P661, DOI 10.1038/nature05911
   Busse A, 2002, J CLIN EPIDEMIOL, V55, P909, DOI 10.1016/S0895-4356(02)00449-3
   Cakiner-Egilmez Tulay, 2008, Insight, V33, P20
   Chen NH, 2019, J NEUROSCI, V39, P3529, DOI 10.1523/JNEUROSCI.2126-18.2019
   Chung SD, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0120003
   Clay OJ, 2009, J AGING HEALTH, V21, P547, DOI 10.1177/0898264309333326
   Cohen JC, 2004, SCIENCE, V305, P869, DOI 10.1126/science.1099870
   Coussa RG, 2015, INVEST OPHTH VIS SCI, V56, P8297, DOI 10.1167/iovs.15-17104
   CRAIG J, 2008, NAT ED, V1, P184
   Dag E, 2014, EUR REV MED PHARMACO, V18, P3025
   Demirci S, 2015, TURK J MED SCI, V45, P1115, DOI 10.3906/sag-1406-135
   Dumont J, 2011, J NUTR, V141, P1247, DOI 10.3945/jn.111.140392
   Duponsel N., 2010, OPTOM VIS SCI, V87
   Ebermann I, 2009, EUR J HUM GENET, V17, P80, DOI 10.1038/ejhg.2008.143
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Fauser S, 2011, INVEST OPHTH VIS SCI, V52, P5525, DOI 10.1167/iovs.10-6827
   Freemantle E, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0042696
   Fritsche LG, 2008, NAT GENET, V40, P892, DOI 10.1038/ng.170
   Gatta LB, 2008, DEMENT GERIATR COGN, V26, P169, DOI 10.1159/000151050
   Gauthier S, 2006, LANCET, V367, P1262, DOI 10.1016/S0140-6736(06)68542-5
   Guo L, 2010, CURR ALZHEIMER RES, V7, P3, DOI 10.2174/156720510790274491
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2006, INVEST OPHTH VIS SCI, V47, P329, DOI 10.1167/iovs.05-0116
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Hall TA, 2005, J AM GERIATR SOC, V53, P2140, DOI 10.1111/j.1532-5415.2005.00499.x
   Harrabi H, 2015, INVEST OPHTH VIS SCI, V56, P1217, DOI 10.1167/iovs.14-15370
   Hellstrand S, 2012, J LIPID RES, V53, P1183, DOI 10.1194/jlr.P023721
   Hoops S, 2009, NEUROLOGY, V73, P1738, DOI 10.1212/WNL.0b013e3181c34b47
   IBM Corporation, 2011, IBM SPSS STAT OSX
   Jakobsdottir J, 2005, AM J HUM GENET, V77, P389, DOI 10.1086/444437
   JASP Team T, 2017, JASP VERS 0 8 1 2 CO
   Jefferis JM, 2012, AGE AGEING, V41, P565, DOI 10.1093/ageing/afs042
   Johnson LV, 2002, P NATL ACAD SCI USA, V99, P11830, DOI 10.1073/pnas.192203399
   Jonna G, 2013, OPHTHALMOLOGY, V120, P1106, DOI 10.1016/j.ophtha.2013.01.041
   Kaarniranta K, 2011, J ALZHEIMERS DIS, V24, P615, DOI 10.3233/JAD-2011-101908
   Katta S, 2009, J GENET, V88, P425, DOI 10.1007/s12041-009-0064-4
   Keenan TDL, 2014, JAMA OPHTHALMOL, V132, P63, DOI 10.1001/jamaophthalmol.2013.5696
   Klaver CCW, 1999, AM J EPIDEMIOL, V150, P963
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Klein R, 2007, OPHTHALMOLOGY, V114, P253, DOI 10.1016/j.ophtha.2006.10.040
   Koenekoop RK, 2003, AM J OPHTHALMOL, V136, P678, DOI 10.1016/S0002-9394(03)00331-3
   Kristiansson K, 2008, GENOME BIOL, V9, DOI 10.1186/gb-2008-9-8-109
   LINDENBERGER U, 1994, PSYCHOL AGING, V9, P339, DOI 10.1037/0882-7974.9.3.339
   Lohmueller KE, 2003, NAT GENET, V33, P177, DOI 10.1038/ng1071
   Lopez OL, 2003, ARCH NEUROL-CHICAGO, V60, P1385, DOI 10.1001/archneur.60.10.1385
   Martinelli N, 2008, AM J CLIN NUTR, V88, P941, DOI 10.1093/ajcn/88.4.941
   Merino DM, 2011, MOL GENET METAB, V103, P171, DOI 10.1016/j.ymgme.2011.02.012
   Mick P, 2017, INNOV AGING S1, V1, P732, DOI DOI 10.1093/geroni/igx004.2643
   Micklisch S, 2017, J NEUROINFLAMM, V14, DOI 10.1186/s12974-016-0776-3
   Morimoto S. S., 2015, HHS PUBLIC ACCESS AU, V44, P138, DOI [10.3928/00485713-20140306-05, DOI 10.3928/00485713-20140306-05]
   Nasreddine ZS, 2005, J AM GERIATR SOC, V53, P695, DOI 10.1111/j.1532-5415.2005.53221.x
   Neale BM, 2010, P NATL ACAD SCI USA, V107, P7395, DOI 10.1073/pnas.0912019107
   NIH, 2017, DBSNP
   Ohno-Matsui K, 2011, PROG RETIN EYE RES, V30, P217, DOI 10.1016/j.preteyeres.2011.02.004
   Orr SK, 2008, CURR OPIN INVEST DR, V9, P735
   Pham TQ, 2006, GERONTOLOGY, V52, P353, DOI 10.1159/000094984
   Potter GG, 2007, NEUROLOGIST, V13, P105, DOI 10.1097/01.nrl.0000252947.15389.a9
   Proitsi P, 2012, NEUROBIOL AGING, V33, DOI 10.1016/j.neurobiolaging.2011.12.036
   Renaud J, 2013, CLIN INTERV AGING, V8, P931, DOI 10.2147/CIA.S27717
   Rousselet GA, 2017, EUR J NEUROSCI, V46, P1738, DOI 10.1111/ejn.13610
   Roy-Gagnon MH, 2011, HUM GENET, V129, P521, DOI 10.1007/s00439-010-0945-x
   Rozzini L, 2007, INT J GERIATR PSYCH, V22, P1217, DOI 10.1002/gps.1816
   Rozzini L, 2014, AM J ALZHEIMERS DIS, V29, P256, DOI 10.1177/1533317513517032
   Serini S, 2011, CHEM RES TOXICOL, V24, P2093, DOI 10.1021/tx200314p
   Shpanskaya K., 2018, SCI REP, V8, P1, DOI 10.1038/s41598-017-17765-5
   Smailhodzic D, 2012, OPHTHALMOLOGY, V119, P2304, DOI 10.1016/j.ophtha.2012.05.040
   Smailhodzic D, 2012, OPHTHALMOLOGY, V119, P339, DOI 10.1016/j.ophtha.2011.07.056
   Summers MJ, 2012, NEUROPSYCHOLOGY, V26, P498, DOI 10.1037/a0028576
   Terai K, 2001, NEUROSCIENCE, V104, P299, DOI 10.1016/S0306-4522(01)00095-1
   Tsai DC, 2015, OPHTHALMOLOGY, V122, P2327, DOI 10.1016/j.ophtha.2015.07.033
   Tuo JS, 2009, AM J PATHOL, V175, P799, DOI 10.2353/ajpath.2009.090089
   Uauy R, 2006, NUTR REV, V64, pS24, DOI 10.1301/nr.2006.may.S24-S33
   Valentijn SAM, 2005, J AM GERIATR SOC, V53, P374, DOI 10.1111/j.1532-5415.2005.53152.x
   Weiser MJ, 2016, NUTRIENTS, V8, DOI 10.3390/nu8020099
   Whitson HE, 2011, AGING CLIN EXP RES, V23, P343, DOI 10.1007/BF03325233
   Whitson HE, 2010, ARCH GERONTOL GERIAT, V50, P209, DOI 10.1016/j.archger.2009.03.010
   Wittich W, 2014, BRIT J VISUAL IMPA, V32, P249, DOI 10.1177/0264619614540162
   Wittich W, 2010, J VISUAL IMPAIR BLIN, V104, P360, DOI 10.1177/0145482X1010400606
   Wong TY, 2002, AM J OPHTHALMOL, V134, P828
   Woo SJ, 2012, OPHTHALMOLOGY, V119, P2094, DOI 10.1016/j.ophtha.2012.04.026
   Wortmann M, 2012, ALZHEIMERS RES THER, V4, DOI 10.1186/alzrt143
   Zeggini E, 2005, NAT GENET, V37, P1320, DOI 10.1038/ng1670
   Zhao LQ, 2016, NEUROBIOL AGING, V42, P69, DOI 10.1016/j.neurobiolaging.2016.02.011
   Zheng DD, 2018, JAMA OPHTHALMOL, V136, P989, DOI 10.1001/jamaophthalmol.2018.2493
   Zhou LX, 2016, CLIN INTERV AGING, V11, P215, DOI 10.2147/CIA.S102213
   2012, WORLD MAL REP 2012, P1
NR 92
TC 1
Z9 1
U1 0
U2 1
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 1663-4365
J9 FRONT AGING NEUROSCI
JI Front. Aging Neurosci.
PD OCT 16
PY 2020
VL 12
AR 586691
DI 10.3389/fnagi.2020.586691
PG 9
WC Geriatrics & Gerontology; Neurosciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Geriatrics & Gerontology; Neurosciences & Neurology
GA OK5PR
UT WOS:000584702800001
PM 33178008
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Freeman, EE
   Munoz, B
   Bressler, SB
   West, SK
AF Freeman, EE
   Munoz, B
   Bressler, SB
   West, SK
TI Hormone replacement therapy, reproductive factors, and age-related
   macular degeneration: The Salisbury eye evaluation project
SO OPHTHALMIC EPIDEMIOLOGY
LA English
DT Article
DE age-related macular degeneration; drusen; estrogen; hormone replacement
   therapy; reproduction
ID POSTMENOPAUSAL WOMEN; VISUAL IMPAIRMENT; ESTROGEN-RECEPTOR; MACULOPATHY;
   POPULATION; CATARACTS; RISK; BETA
AB Purpose: To evaluate a potential relationship between hormone replacement therapy (HRT), reproductive factors and age-related macular degeneration (AMD).
   Methods: 1,458 female participants (age 65-84) from the Salisbury Eye Evaluation study were available for this cross-sectional analysis. AMD outcomes were identified by reading center assessment of fundus photographs.
   Results: Women who currently used HRT had a lower adjusted odds of large drusen (> 125 mu m) (OR = 0.5, 95% CI 0.2-1.0). Use of HRT was not statistically significantly associated with the prevalence of early AMD or advanced AMD, although the odds ratios were all much less than 1. Women who had had an increased number of births had a greater prevalence of large drusen (test of linear trend, p = 0.03).
   Conclusions: Current use of HRT was associated with a lower odds of large drusen, which may be predictive of advanced AMD. No statistically significant correlations were found between HRT or reproductive factors and early or advanced AMD.
C1 Johns Hopkins Univ Hosp, Wilmer Eye Inst, Dana Ctr Prevent Ophthalmol, Baltimore, MD 21287 USA.
   Johns Hopkins Univ Hosp, Wilmer Eye Inst, Retinal Vasc Ctr, Baltimore, MD 21287 USA.
   Johns Hopkins Univ Hosp, Wilmer Eye Inst, Wilmer Photograph Reading Ctr, Baltimore, MD 21287 USA.
C3 Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins
   University; Johns Hopkins Medicine; Johns Hopkins University; Johns
   Hopkins Medicine
RP Freeman, EE (通讯作者)，Johns Hopkins Univ Hosp, Wilmer Eye Inst, Dana Ctr Prevent Ophthalmol, Room 129,600 N Wolfe St, Baltimore, MD 21287 USA.
EM efreeman@jhsph.edu
OI Freeman, Ellen/0000-0002-1403-8427
CR Akcay T, 2000, J TOXICOL ENV HEAL A, V59, P1, DOI 10.1080/009841000157023
   BRESSLER NM, 1989, ARCH OPHTHALMOL-CHIC, V107, P847, DOI 10.1001/archopht.1989.01070010869032
   David W, 2000, APPL LOGISTIC REGRES, P26, DOI 10.1002/0471722146
   EVANS J, 1998, EPIDEMIOLOGY EYE DIS
   GRIFIN JE, 1992, TXB ENDOCRINE PHYSL
   HYMAN L, 1992, PRINCIPLES PRACTICE, P1
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Klein B E, 1994, Trans Am Ophthalmol Soc, V92, P289
   Klein BEK, 2000, AM J OPHTHALMOL, V130, P322, DOI 10.1016/S0002-9394(00)00474-8
   Munaut C, 2001, BRIT J OPHTHALMOL, V85, P877, DOI 10.1136/bjo.85.7.877
   Munoz B, 2000, ARCH OPHTHALMOL-CHIC, V118, P819, DOI 10.1001/archopht.118.6.819
   Ogueta SB, 1999, INVEST OPHTH VIS SCI, V40, P1906
   Peters AL, 1996, JAMA-J AM MED ASSOC, V276, P1246, DOI 10.1001/jama.276.15.1246
   Snow KK, 2002, AM J OPHTHALMOL, V134, P842, DOI 10.1016/S0002-9394(02)01755-5
   SPENCER G, 1988, CURRENT POPULATION P, V25
   SUBBIAH MTR, 1993, J CLIN ENDOCR METAB, V77, P1095, DOI 10.1210/jc.77.4.1095
   TAYLOR HR, 1989, AUST NZ J OPHTHALMOL, V17, P81, DOI 10.1111/j.1442-9071.1989.tb00492.x
   VINGERLING JR, 1995, BRIT MED J, V310, P1570, DOI 10.1136/bmj.310.6994.1570
   Wang JJ, 2003, ARCH OPHTHALMOL-CHIC, V121, P658, DOI 10.1001/archopht.121.5.658
   WEST SK, 1988, INVEST OPHTH VIS SCI, V29, P73
   West SK, 1997, INVEST OPHTH VIS SCI, V38, P72
   YANNUZZI LA, 1992, ARCH OPHTHALMOL-CHIC, V110, P1701
NR 22
TC 26
Z9 27
U1 0
U2 2
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 325 CHESTNUT ST, SUITE 800, PHILADELPHIA, PA 19106 USA
SN 0928-6586
J9 OPHTHAL EPIDEMIOL
JI Ophthalmic Epidemiol.
PD FEB
PY 2005
VL 12
IS 1
BP 37
EP 45
DI 10.1080/09286580490907779
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 911HU
UT WOS:000227994000006
PM 15848919
DA 2022-11-30
ER

PT J
AU Triebwasser, MP
   Roberson, EDO
   Yu, Y
   Schramm, EC
   Wagner, EK
   Raychaudhuri, S
   Seddon, JM
   Atkinson, JP
AF Triebwasser, Michael P.
   Roberson, Elisha D. O.
   Yu, Yi
   Schramm, Elizabeth C.
   Wagner, Erin K.
   Raychaudhuri, Soumya
   Seddon, Johanna M.
   Atkinson, John P.
TI Rare Variants in the Functional Domains of Complement Factor H Are
   Associated With Age-Related Macular Degeneration
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
DE macular degeneration; rare genetic variants; sequencing
ID HEMOLYTIC-UREMIC SYNDROME; INTEGRATIVE GENOMICS VIEWER; DNA-SEQUENCING
   DATA; HIGH-RISK; CFH; GENES; C3; POLYMORPHISM; RECOGNITION; FRAMEWORK
AB PURPOSE. Age-related macular degeneration (AMD) has a substantial genetic risk component, as evidenced by the risk from common genetic variants uncovered in the first genome-wide association studies. More recently, it has become apparent that rare genetic variants also play an independent role in AMD risk. We sought to determine if rare variants in complement factor H (CFH) played a role in AMD risk.
   METHODS. We had previously collected DNA from a large population of patients with advanced age-related macular degeneration (A-AMD) and controls for targeted deep sequencing of candidate AMD risk genes. In this analysis, we tested for an increased burden of rare variants in CFH in 1665 cases and 752 controls from this cohort.
   RESULTS. We identified 65 missense, nonsense, or splice-site mutations with a minor allele frequency <= 1%. Rare variants with minor allele frequency <= 1% (odds ratio [OR] = 1.5, P = 4.4 x 10(-2)), 0.5% (OR = 1.6, P = 2.6 x 10(-2)), and all singletons (OR = 2.3, P = 3.3 x 10(-2)) were enriched in A-AMD cases. Moreover, we observed loss-of-function rare variants (nonsense, splice-site, and loss of a conserved cysteine) in 10 cases and serum levels of FH were decreased in all 5 with an available sample (haploinsufficiency). Further, rare variants in the major functional domains of CFH were increased in cases (OR = 3.2; P = 1.4 x 10(-3)) and the magnitude of the effect correlated with the disruptive nature of the variant, location in an active site, and inversely with minor allele frequency.
   CONCLUSIONS. In this large A-AMD cohort, rare variants in the CFH gene were enriched and tended to be located in functional sites or led to low serum levels. These data, combined with those indicating a similar, but even more striking, increase in rare variants found in CFI, strongly implicate complement activation in A-AMD etiopathogenesis as CFH and CFI interact to inhibit the alternative pathway.
C1 [Triebwasser, Michael P.; Roberson, Elisha D. O.; Schramm, Elizabeth C.; Atkinson, John P.] Washington Univ, Sch Med, Dept Internal Med, Div Rheumatol, St Louis, MO 63110 USA.
   [Roberson, Elisha D. O.] Washington Univ, Sch Med, Dept Genet, St Louis, MO 63110 USA.
   [Yu, Yi; Wagner, Erin K.; Seddon, Johanna M.] Tufts Med Ctr, New England Eye Ctr, Ophthalm Epidemiol & Genet Serv, Boston, MA USA.
   [Wagner, Erin K.; Seddon, Johanna M.] Tufts Univ, Sch Med, Dept Ophthalmol, Sackler Sch Grad Med Sci, Boston, MA 02111 USA.
   [Raychaudhuri, Soumya] Broad Inst, Program Med & Populat Genet, Cambridge, MA USA.
   [Raychaudhuri, Soumya] Brigham & Womens Hosp, Div Genet, Partners HealthCare Ctr Personalized Genet Med, Boston, MA 02115 USA.
   [Raychaudhuri, Soumya] Brigham & Womens Hosp, Div Rheumatol Immunol & Allergy, Boston, MA 02115 USA.
   [Raychaudhuri, Soumya] Univ Manchester, Fac Med & Human Sci, Manchester, Lancs, England.
   [Raychaudhuri, Soumya] Karolinska Inst, Dept Med, Solna, Sweden.
C3 Washington University (WUSTL); Washington University (WUSTL); Tufts
   Medical Center; Tufts University; Harvard University; Massachusetts
   Institute of Technology (MIT); Broad Institute; Harvard University;
   Brigham & Women's Hospital; Partners Healthcare System; Harvard
   University; Brigham & Women's Hospital; University of Manchester;
   Karolinska Institutet
RP Atkinson, JP (通讯作者)，Washington Univ, Sch Med, Dept Internal Med, Div Rheumatol, St Louis, MO 63110 USA.
EM jatkinso@dom.wustl.edu
RI Roberson, Elisha/ABC-1810-2020; Roberson, Elisha D.O./J-1747-2012
OI Roberson, Elisha/0000-0001-5921-2399; Roberson, Elisha
   D.O./0000-0001-5921-2399; Raychaudhuri, Soumya/0000-0002-1901-8265
FU NEI NIH HHS [R01-EY11309, R01 EY011309] Funding Source: Medline; NHGRI
   NIH HHS [1U01HG007690-01, U01 HG007690] Funding Source: Medline; NHLBI
   NIH HHS [F30HL103072, U54 HL112303, F30 HL103072] Funding Source:
   Medline; NIAID NIH HHS [R01 AI041592, R01-AI041592] Funding Source:
   Medline; NIAMS NIH HHS [R01 AR063759, P30 AR048335, 1R01AR063759-01A1,
   P30 AR48335] Funding Source: Medline; NIGMS NIH HHS [U01 GM092691,
   5U01GM092691-04] Funding Source: Medline; NATIONAL EYE INSTITUTE
   [R01EY011309] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND
   BLOOD INSTITUTE [F30HL103072, U54HL112303] Funding Source: NIH RePORTER;
   NATIONAL HUMAN GENOME RESEARCH INSTITUTE [U01HG007690] Funding Source:
   NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES
   [R01AI041592] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF
   ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR063759,
   P30AR048335] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL
   MEDICAL SCIENCES [U01GM092691] Funding Source: NIH RePORTER
CR Ambati J, 2013, NAT REV IMMUNOL, V13, P438, DOI 10.1038/nri3459
   Anderson DH, 2010, PROG RETIN EYE RES, V29, P95, DOI 10.1016/j.preteyeres.2009.11.003
   Ansari M, 2013, HUM MOL GENET, V22, P4857, DOI 10.1093/hmg/ddt336
   Bradley DT, 2011, EYE, V25, P683, DOI 10.1038/eye.2011.37
   Clark SJ, 2013, J IMMUNOL, V190, P2049, DOI 10.4049/jimmunol.1201751
   Cruchaga C, 2014, NATURE, V505, P550, DOI 10.1038/nature12825
   DePristo MA, 2011, NAT GENET, V43, P491, DOI 10.1038/ng.806
   Duvvari MR, 2015, MOL VIS, V21, P285
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Fagerness JA, 2009, EUR J HUM GENET, V17, P100, DOI 10.1038/ejhg.2008.140
   Forneris F, 2010, SCIENCE, V330, P1816, DOI 10.1126/science.1195821
   Fritsche LG, 2013, NAT GENET, V45, P433, DOI 10.1038/ng.2578
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Helgason H, 2013, NAT GENET, V45, P1371, DOI 10.1038/ng.2740
   Hoffman JD, 2014, INVEST OPHTH VIS SCI, V55, P4455, DOI 10.1167/iovs.13-13684
   Jozsi M, 2006, J AM SOC NEPHROL, V17, P170, DOI 10.1681/ASN.2005080868
   Kavanagh D, 2008, ANNU REV MED, V59, P293, DOI 10.1146/annurev.med.59.060106.185110
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Lachmann PJ, 2009, ADV IMMUNOL, V104, P115, DOI 10.1016/S0065-2776(08)04004-2
   Li H, 2009, BIOINFORMATICS, V25, P1754, DOI 10.1093/bioinformatics/btp324
   Maller J, 2006, NAT GENET, V38, P1055, DOI 10.1038/ng1873
   Maller JB, 2007, NAT GENET, V39, P1200, DOI 10.1038/ng2131
   McKenna A, 2010, GENOME RES, V20, P1297, DOI 10.1101/gr.107524.110
   Noris M, 2010, CLIN J AM SOC NEPHRO, V5, P1844, DOI 10.2215/CJN.02210310
   Noris M, 2009, NEW ENGL J MED, V361, P1676, DOI 10.1056/NEJMra0902814
   Pechtl IC, 2011, J BIOL CHEM, V286, P11082, DOI 10.1074/jbc.M110.211839
   Raychaudhuri S, 2011, NAT GENET, V43, P1232, DOI 10.1038/ng.976
   Reynolds R, 2009, INVEST OPHTH VIS SCI, V50, P5818, DOI 10.1167/iovs.09-3928
   Robinson JT, 2011, NAT BIOTECHNOL, V29, P24, DOI 10.1038/nbt.1754
   de Cordoba SR, 2014, SEMIN THROMB HEMOST, V40, P422, DOI 10.1055/s-0034-1375296
   Schramm EC, 2014, MOL IMMUNOL, V61, P118, DOI 10.1016/j.molimm.2014.06.032
   Seddon JM, 2013, NAT GENET, V45, P1366, DOI 10.1038/ng.2741
   Seddon JM, 2009, INVEST OPHTH VIS SCI, V50, P2044, DOI 10.1167/iovs.08-3064
   Sobrin L, 2014, PROG RETIN EYE RES, V40, P1, DOI 10.1016/j.preteyeres.2013.12.004
   Thorvaldsdottir H, 2013, BRIEF BIOINFORM, V14, P178, DOI 10.1093/bib/bbs017
   Wu MC, 2011, AM J HUM GENET, V89, P82, DOI 10.1016/j.ajhg.2011.05.029
   Yates JRW, 2007, NEW ENGL J MED, V357, P553, DOI 10.1056/NEJMoa072618
   Yu Y, 2014, HUM MOL GENET, V23, P5283, DOI 10.1093/hmg/ddu226
   Zhan XW, 2013, NAT GENET, V45, P1375, DOI 10.1038/ng.2758
   Zipfel PF, 2009, NAT REV IMMUNOL, V9, P729, DOI 10.1038/nri2620
NR 42
TC 47
Z9 47
U1 0
U2 3
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD OCT
PY 2015
VL 56
IS 11
BP 6873
EP 6878
DI 10.1167/iovs.15-17432
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA DB0YQ
UT WOS:000368235100089
PM 26501415
OA Green Published
DA 2022-11-30
ER

PT J
AU Kourlas, H
   Schiller, DS
AF Kourlas, H
   Schiller, DS
TI Pegaptanib sodium for the treatment of neovascular age-related macular
   degeneration: A review
SO CLINICAL THERAPEUTICS
LA English
DT Review
DE pegaptanib; neovascular age-related macular degeneration; vascular
   endothelial growth factor; VEGF
ID PHOTODYNAMIC THERAPY; PATHOGENESIS; VERTEPORFIN
AB Objective: This article reviews available information on the new selective vascular endothelial growth factor aptamer pegaptanib in the treatment of neovascular age-related macular degeneration (ARMD). The pharmacology, pharmacokinetics, pharmacodynamics, contraindications, and drug-interaction potential of pegaptanib are discussed, and the results of clinical trials evaluating its efficacy and tolerability are summarized.
   Methods: Relevant articles were identified through searches of MEDLINE (1966-June 2005) and International Pharmaceutical Abstracts (1970-June 2005). The search terms included pegaptanib sodium, Macugen, age-related macular degeneration, and choroidal neovascularization. The reference lists of identified articles were reviewed for additional publications, and further information was obtained from the manufacturer of pegaptanib. Included studies were review articles and Phase 11, 111, and IV clinical trials, with preference given to available Phase III studies.
   Results: Only 1 research group has evaluated the tolerability and efficacy of pegaptanib in patients with neovascular ARMD. The VEGF Inhibition Study in Ocular Neovascularization involved 2 concurrent randomized trials of intravitreous injections of pegaptanib 0.3 mg (n = 294), 1 mg (n = 300), and 3 mg (n = 296) compared with sham injections (n = 296) every 6 weeks for 54 weeks in patients with neovascular ARMD. Assessments were conducted at 6, 12, 18, 24, 30, 42, 48, and 54 weeks. The primary end point was the proportion of patients losing < 15 letters on the study eye chart at 54 weeks. This end point was achieved in 70%, 71%, and 65% of patients who received pegaptanib 0.3 (P < 0.001), 1 (P < 0.001), and 3 mg (P = 0.03), respectively, compared with 55% of those receiving the sham injections. Significant improvements in visual acuity with pegaptanib compared with the sham-injection group were seen at all time points (0.3 and 1 mg: P < 0.002; 3 mg: P < 0.05). The sham-injection group was twice as likely to have severe vision loss (loss of 30 letters or 6 lines on the eye chart) compared with those receiving pegaptanib 0.3 or 1 mg (P < 0.001). Adverse events reported significantly more often in the pegaptanib group compared with the sham-injection group included vitreous floaters (33% vs 28%, respectively; P < 0.001), vitreous opacities (18% vs 10%; P < 0.001), and anterior-chamber inflammation (14% vs 6%; P = 0.001). Injection-related adverse events during the first year of pegaptanib treatment included endophthalmitis in 12 (1.3%) patients, retinal detachment in 6 (0.7%) patients, and traumatic injury to the lens in 5 (0.6%) patients.
   Conclusions: There are few published clinical data on pegaptanib. In 2 clinical comparisons with sham injections, pegaptanib was well tolerated and effective in slowing the decline in visual acuity in patients with neovascular ARMD. This agent may be considered an option for the treatment of neovascular ARMD.
C1 Long Isl Univ, Div Pharm Practice, Arnold & Marie Schwartz Coll Pharm & Hlth Sci, Brooklyn, NY 11201 USA.
C3 Long Island University-Brooklyn Campus
RP Kourlas, H (通讯作者)，Long Isl Univ, Div Pharm Practice, Arnold & Marie Schwartz Coll Pharm & Hlth Sci, 75 DeKalb Ave, Brooklyn, NY 11201 USA.
EM helen.kourlas@liu.edu
CR Ambati J, 2003, SURV OPHTHALMOL, V48, P257, DOI 10.1016/S0039-6257(03)00030-4
   ARROYO J, 2005, AGE RELATED MACULAR
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Bressler NM, 2002, ARCH OPHTHALMOL-CHIC, V120, P1443
   Bressler NM, 2005, RETINA-J RET VIT DIS, V25, P119
   Ferris FL, 2004, NEW ENGL J MED, V351, P2863, DOI 10.1056/NEJMe048316
   FLEMING T, 2005, 2005 DRUG TOPICS RED, P473
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   HEIER JS, 2005, INVEST OPHTH VIS SCI, V46, P1393
   Hopley C, 2004, BRIT J OPHTHALMOL, V88, P982, DOI 10.1136/bjo.2003.039131
   Hyman L, 2000, ARCH OPHTHALMOL-CHIC, V118, P351, DOI 10.1001/archopht.118.3.351
   Jonas JB, 2005, EYE, V19, P163, DOI 10.1038/sj.eye.6701438
   KUO CJ, 2005, UPTODATE
   Lois N, 2004, COMP OPHTHALMOL UPDA, V5, P143
   MACUGEN, 2004, PEGAPTANIB SODIUM
   Michels S, 2005, OPHTHALMOLOGY, V112, P1035, DOI 10.1016/j.ophtha.2005.02.007
   MIELER W, 2005, INVEST OPHTH VIS SCI, V46, P1380
   Mordenti J, 1999, TOXICOL PATHOL, V27, P14, DOI 10.1177/019262339902700104
   Ng EWM, 2005, CAN J OPHTHALMOL, V40, P352, DOI 10.1016/S0008-4182(05)80078-X
   Russell S, 2003, OPHTHALMOLOGY, V110, P2372, DOI 10.1016/j.ophtha.2003.08.020
   Smith DH, 2004, BRIT J OPHTHALMOL, V88, P1107, DOI 10.1136/bjo.2003.023986
   Tanner V, 1998, EYE, V12, P751, DOI 10.1038/eye.1998.191
   van Wijngaarden P, 2005, JAMA-J AM MED ASSOC, V293, P1509, DOI 10.1001/jama.293.12.1509
   Vinores SA, 2003, CURR OPIN MOL THER, V5, P673
   Zarbin MA, 2004, ARCH OPHTHALMOL-CHIC, V122, P598, DOI 10.1001/archopht.122.4.598
NR 25
TC 59
Z9 73
U1 1
U2 15
PU ELSEVIER
PI BRIDGEWATER
PA 685 ROUTE 202-206, BRIDGEWATER, NJ 08807 USA
SN 0149-2918
EI 1879-114X
J9 CLIN THER
JI Clin. Ther.
PD JAN
PY 2006
VL 28
IS 1
BP 36
EP 44
DI 10.1016/j.clinthera.2006.01.009
PG 9
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA 013WM
UT WOS:000235440700004
PM 16490578
DA 2022-11-30
ER

PT J
AU Zengin, MO
   Karti, O
   Karahan, E
   Kusbeci, T
AF Zengin, Mehmet Ozgur
   Karti, Omer
   Karahan, Eyyup
   Kusbeci, Tuncay
TI An Evaluation of the Relationship Between Clinically Unilateral
   Pseudoexfoliation Syndrome and Age-Related Macular Degeneration
SO OPHTHALMIC SURGERY LASERS & IMAGING RETINA
LA English
DT Article
ID OPTICAL COHERENCE TOMOGRAPHY; SUBFOVEAL CHOROIDAL THICKNESS; BLOOD-FLOW;
   EXFOLIATION SYNDROME; ASSOCIATION; RIGIDITY; GLAUCOMA; EYES
AB BACKGROUND AND OBJECTIVE: To evaluate the relationship between age-related macular degeneration (AMD) and clinically unilateral pseudoexfoliation syndrome (XFS).
   PATIENTS AND METHODS: Seventy-six patients (152 eyes) with bilateral AMD and clinically unilateral XFS were included. Eyes with AMD were divided into three stages (early, intermediate, and late), based on the Beckman Initiative for Macular Research Classification Committee of fundus findings. The distribution of AMD lesions was assessed in both groups, and the subfoveal choroidal thickness (SFCT) was measured using enhanced depth imaging spectral-domain optical coherence tomography (SD-OCT).
   RESULTS: There were significantly more early and intermediate-stage AMD cases in eyes with XFS than in non-XFS fellow eyes (P < .05), In contrast, there were significantly fewer wet AMD cases In XFS eyes than in non-XFS fellow eyes (P < .05). SFCT in all AMD stages was significantly lower in eyes with XFS (P < .05).
   CONCLUSION: XFS was associated with a lower prevalence of wet AMD. Further studies are required to elucidate this association.
C1 [Zengin, Mehmet Ozgur; Karti, Omer; Kusbeci, Tuncay] Bozyaka Training & Res Hosp, Dept Ophthalmol, Izmir, Turkey.
   [Karahan, Eyyup] Van Training & Res Hosp, Van, Turkey.
C3 Izmir Bozyaka Training & Research Hospital; Van Training & Research
   Hospital
RP Karti, O (通讯作者)，Saim Cikrikci Cad 59, Bozyaka Izmir, Turkey.
EM kartiomer@gmail.com
RI Kusbeci, Tuncay/AAO-1012-2020; Zengin, MO/B-2222-2014; karahan,
   eyyup/U-2977-2017; karti, omer/ABB-9922-2020
OI Kusbeci, Tuncay/0000-0002-5169-4140
CR AASVED H, 1975, ACTA OPHTHALMOL, V53, P879
   Chung SE, 2011, OPHTHALMOLOGY, V118, P840, DOI 10.1016/j.ophtha.2010.09.012
   Cursiefen C, 2001, ACTA OPHTHALMOL SCAN, V79, P476, DOI 10.1034/j.1600-0420.2001.790509.x
   Dayanir Volkan, 2009, International Ophthalmology, V29, P27, DOI 10.1007/s10792-008-9193-7
   Detorakis ET, 2005, CORNEA, V24, P688, DOI 10.1097/01.ico.0000154232.18618.e0
   Eroglu FC, 2015, EYE, V29, P791, DOI 10.1038/eye.2015.34
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   FRIEDMAN E, 1989, OPHTHALMOLOGY, V96, P104
   Grammenandi E, 2010, CLIN EXP OPHTHALMOL, V38, P444, DOI 10.1111/j.1442-9071.2010.02275.x
   Grunwald JE, 1998, INVEST OPHTH VIS SCI, V39, P385
   Jonas JB, 2014, RETINA-J RET VIT DIS, V34, P1149, DOI 10.1097/IAE.0000000000000035
   Jones W, 1992, J Am Optom Assoc, V63, P643
   Kim SW, 2011, RETINA-J RET VIT DIS, V31, P1904, DOI 10.1097/IAE.0b013e31821801c5
   Kivela T, 1997, INVEST OPHTH VIS SCI, V38, P2008
   Kling F, 2001, J FR OPHTALMOL, V24, P7
   Kozobolis VP, 1999, ARCH OPHTHALMOL-CHIC, V117, P664
   Lee JY, 2013, INVEST OPHTH VIS SCI, V54, P7812, DOI 10.1167/iovs.13-12284
   Manjunath V, 2011, AM J OPHTHALMOL, V152, P663, DOI 10.1016/j.ajo.2011.03.008
   Margolis R, 2009, AM J OPHTHALMOL, V147, P811, DOI 10.1016/j.ajo.2008.12.008
   Mitchell P, 1999, ARCH OPHTHALMOL-CHIC, V117, P1319, DOI 10.1001/archopht.117.10.1319
   Mitchell P, 1997, AM J OPHTHALMOL, V124, P685, DOI 10.1016/S0002-9394(14)70908-0
   NETLAND PA, 1995, OPHTHALMOLOGY, V102, P878, DOI 10.1016/S0161-6420(95)30939-6
   Ocakoglu O, 2004, ACTA OPHTHALMOL SCAN, V82, P49, DOI 10.1046/j.1600-0420.2003.00196.x
   Pallikaris IG, 2006, AM J OPHTHALMOL, V141, P611, DOI 10.1016/j.ajo.2005.11.010
   PRINCE AM, 1987, ARCH OPHTHALMOL-CHIC, V105, P1076
   Rahman W, 2013, GRAEF ARCH CLIN EXP, V251, P1483, DOI 10.1007/s00417-012-2199-x
   REPO LP, 1995, OPHTHALMOLOGY, V102, P1199, DOI 10.1016/S0161-6420(95)30890-1
   Ritch R, 2001, SURV OPHTHALMOL, V45, P265, DOI 10.1016/S0039-6257(00)00196-X
   SchlotzerSchrehardt U, 1997, INVEST OPHTH VIS SCI, V38, P970
   SCHLOTZERSCHREHARDT U, 1991, ARCH OPHTHALMOL-CHIC, V109, P565, DOI 10.1001/archopht.1991.01080040133044
   Shimizu K, 1988, Acta Ophthalmol Suppl, V184, P112
   Sigler EJ, 2013, INVEST OPHTH VIS SCI, V54, P6307, DOI 10.1167/iovs.13-12653
   TAYLOR HR, 1979, T OPHTHAL SOC UK, V99, P302
   Turan-Vural E, 2015, OPHTHALMOLOGICA, V233, P204, DOI 10.1159/000371899
   Wood A, 2011, AM J OPHTHALMOL, V152, P1030, DOI 10.1016/j.ajo.2011.05.021
NR 35
TC 4
Z9 5
U1 0
U2 2
PU SLACK INC
PI THOROFARE
PA 6900 GROVE RD, THOROFARE, NJ 08086 USA
SN 2325-8160
EI 2325-8179
J9 OSLI RETINA
JI Ophthalmic Surg. Lasers Imag. Retin.
PD JAN
PY 2018
VL 49
IS 1
BP 12
EP 19
DI 10.3928/23258160-20171215-02
PG 8
WC Ophthalmology; Surgery
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology; Surgery
GA FS7PP
UT WOS:000419990200002
PM 29304261
DA 2022-11-30
ER

PT J
AU Oeverhaus, M
   zu Westrup, VM
   Dietzel, M
   Hense, HW
   Pauleikhoff, D
AF Oeverhaus, Michael
   zu Westrup, Verena Meyer
   Dietzel, Martha
   Hense, Hans-Werner
   Pauleikhoff, Daniel
TI Genetic Polymorphisms and the Phenotypic Characterization of Individuals
   with Early Age-Related Macular Degeneration
SO OPHTHALMOLOGICA
LA English
DT Article
DE Single nucleotide polymorphisms; SD-OCT; Early age-related macular
   degeneration; Drusen; Microperimetry; Phenotyping; Genetic
   polymorphisms; Risk factors; Phenotypic differences
ID OPTICAL COHERENCE TOMOGRAPHY; RISK-FACTORS; FUNDUS AUTOFLUORESCENCE;
   MACULOPATHY; PROGRESSION; DRUSEN; RETINA; EYE; ASSOCIATION;
   MICROPERIMETRY
AB Purpose: While the importance of risk polymorphisms for the pathogenesis of age-related macular degeneration (AMD) is well established, their impact on morphological and functional phenotypes is largely unclear. We aimed to characterize individual phenotypes in patients who were either homozygous for a risk allele in the CFH gene, ARMS2 gene, or both as compared to non-carriers. Methods: Patients with early AMD (n = 85) were assessed during a follow-up examination of a prospective study (MARS) with multi-modal diagnostics including SD-OCT and microperimetry. Results: Compared to non-carriers, OCT scans revealed lower retinal thickness in patients homozygous for CFH or ARMS2, which was caused by a significantly reduced photoreceptor layer. The number and ultrastructure of drusen were also significantly different. Conclusions: These findings indicate that patients with risk alleles demonstrate distinct phenotypic differences of morphology and function as compared to non-carriers. In particular in the CFH group, a loss of photoreceptors occurred concomitantly with reduced retinal sensitivity. Further studies might help to better understand the pathophysiology. (C) 2017 S. Karger AG, Basel
C1 [Oeverhaus, Michael; Dietzel, Martha; Pauleikhoff, Daniel] St Franziskus Hosp, Dept Ophthalmol, Munster, Germany.
   [zu Westrup, Verena Meyer; Hense, Hans-Werner] Univ Munster, Fac Med, Inst Epidemiol & Social Med, Munster, Germany.
   [Oeverhaus, Michael] Univ Hosp Essen, Dept Ophthalmol, Hufelandstr 55, DE-45147 Essen, Germany.
   [Dietzel, Martha] Maximilians Eye Clin, Nurnberg, Germany.
C3 St. Franziskus-Hospital; University of Munster; University of Duisburg
   Essen
RP Oeverhaus, M (通讯作者)，Univ Hosp Essen, Dept Ophthalmol, Hufelandstr 55, DE-45147 Essen, Germany.
EM michael.oeverhaus@uk-essen.de
RI Oeverhaus, Michael/AAA-5356-2019; Oeverhaus, Michael/AAK-3084-2021
OI Oeverhaus, Michael/0000-0003-0807-7689
FU Deutsche Forschungsgesellschaft [HE PA 357/7-1]; Intramural
   International Monetary Fund of the University of Munster; Pro Retina
   Foundation; Jackstadt Foundation
FX This study was supported in part by Deutsche Forschungsgesellschaft
   Grants HE PA 357/7-1; the Intramural International Monetary Fund of the
   University of Munster; the Pro Retina Foundation; and the Jackstadt
   Foundation.
CR BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Capoluongo E, 2012, NEUROBIOL AGING, V33, DOI 10.1016/j.neurobiolaging.2012.03.008
   Chakravarthy U, 2013, OPHTHALMOLOGY, V120, P342, DOI 10.1016/j.ophtha.2012.08.004
   Chakravarthy U, 2010, BMC OPHTHALMOL, V10, DOI 10.1186/1471-2415-10-31
   Chavali VRM, 2015, J CLIN MED, V4, P304, DOI 10.3390/jcm4020304
   Chew EY, 2014, JAMA OPHTHALMOL, V132, P142, DOI 10.1001/jamaophthalmol.2013.7376
   Dasch B, 2005, ARCH OPHTHALMOL-CHIC, V123, P1501, DOI 10.1001/archopht.123.11.1501
   Dasch B, 2005, GRAEF ARCH CLIN EXP, V243, P1028, DOI 10.1007/s00417-005-1176-z
   Dietzel M, 2010, OPHTHALMOLOGE, V107, P1103, DOI 10.1007/s00347-010-2141-8
   Dietzel M, 2014, GRAEF ARCH CLIN EXP, V252, P1273, DOI 10.1007/s00417-014-2690-7
   Dietzel M, 2011, INVEST OPHTH VIS SCI, V52, P3452, DOI 10.1167/iovs.10-6713
   Farwick A, 2009, EYE, V23, P2238, DOI 10.1038/eye.2008.426
   Farwick A, 2010, INVEST OPHTH VIS SCI, V51, P731, DOI 10.1167/iovs.09-3953
   Gangnon RE, 2012, ARCH OPHTHALMOL-CHIC, V130, P1169, DOI 10.1001/archophthalmol.2012.693
   HUANG D, 1991, SCIENCE, V254, P1178, DOI 10.1126/science.1957169
   Joachim N, 2015, OPHTHALMOLOGY, V122, P2482, DOI 10.1016/j.ophtha.2015.08.002
   Katta S, 2009, J GENET, V88, P425, DOI 10.1007/s12041-009-0064-4
   Khanifar AA, 2008, OPHTHALMOLOGY, V115, P1883, DOI 10.1016/j.ophtha.2008.04.041
   Klaver CCW, 2001, INVEST OPHTH VIS SCI, V42, P2237
   Landa G, 2012, OPHTHALMIC RES, V47, P81, DOI 10.1159/000324988
   Landa G, 2011, RETINA-J RET VIT DIS, V31, P364, DOI 10.1097/IAE.0b013e3181e91132
   Lechanteur YTE, 2015, JAMA OPHTHALMOL, V133, P533, DOI 10.1001/jamaophthalmol.2015.18
   Lu LN, 2016, MEDICINE, V95, DOI 10.1097/MD.0000000000002967
   Maguire MG, 2016, JAMA OPHTHALMOL, V134, P674, DOI 10.1001/jamaophthalmol.2016.0669
   Margolis R, 2009, AM J OPHTHALMOL, V147, P811, DOI 10.1016/j.ajo.2008.12.008
   Midena E, 2007, BRIT J OPHTHALMOL, V91, P1499, DOI 10.1136/bjo.2007.119685
   Munch IC, 2010, INVEST OPHTH VIS SCI, V51, P2317, DOI 10.1167/iovs.09-4482
   Owsley C, 2016, CURR EYE RES, V41, P266, DOI 10.3109/02713683.2015.1011282
   PAULEIKHOFF D, 1992, OPHTHALMOLOGY, V99, P1548
   Piermarocchi S, 2015, ACTA OPHTHALMOL, V93, pE451, DOI 10.1111/aos.12587
   Rahman W, 2011, INVEST OPHTH VIS SCI, V52, P2267, DOI 10.1167/iovs.10-6024
   Resnikoff S, 2004, B WORLD HEALTH ORGAN, V82, P844
   Rogala J, 2015, INVEST OPHTH VIS SCI, V56, P1689, DOI 10.1167/iovs.14-16221
   Schaumberg DA, 2007, ARCH OPHTHALMOL-CHIC, V125, P55, DOI 10.1001/archopht.125.1.55
   Scholl HPN, 2004, INVEST OPHTH VIS SCI, V45, P574, DOI 10.1167/iovs.03-0495
   Scilley K, 2002, OPHTHALMOLOGY, V109, P1235, DOI 10.1016/S0161-6420(02)01060-6
   Seddon JM, 2005, ARCH OPHTHALMOL-CHIC, V123, P321, DOI 10.1001/archopht.123.3.321
   Seddon JM, 2015, INVEST OPHTH VIS SCI, V56, P2192, DOI 10.1167/iovs.14-15841
   Seddon JM, 2011, OPHTHALMOLOGY, V118, P2203, DOI 10.1016/j.ophtha.2011.04.029
   Skerka C, 2007, MOL IMMUNOL, V44, P3398, DOI 10.1016/j.molimm.2007.02.012
   Spaide RF, 2008, AM J OPHTHALMOL, V146, P496, DOI 10.1016/j.ajo.2008.05.032
   Spaide RF, 2011, RETINA-J RET VIT DIS, V31, P1609, DOI 10.1097/IAE.0b013e3182247535
   Wachter A, 2004, OPHTHALMOLOGE, V101, P50, DOI 10.1007/s00347-003-0868-1
   Wu ZC, 2014, OPHTHALMOLOGY, V121, P1445, DOI 10.1016/j.ophtha.2014.01.025
   Xu YT, 2012, INT J OPHTHALMOL-CHI, V5, P125, DOI 10.3980/j.issn.2222-3959.2012.02.02
NR 45
TC 7
Z9 7
U1 0
U2 5
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 0030-3755
EI 1423-0267
J9 OPHTHALMOLOGICA
JI Ophthalmologica
PY 2017
VL 238
IS 1-2
BP 6
EP 16
DI 10.1159/000468949
PG 11
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA FC1MB
UT WOS:000406600200002
PM 28558370
DA 2022-11-30
ER

PT J
AU Stattin, M
   Forster, J
   Daniel, A
   Graf, A
   Krepler, K
   Ansari-Shahrezaei, S
AF Stattin, Martin
   Forster, Julia
   Daniel, Ahmed
   Graf, Alexandra
   Krepler, Katharina
   Ansari-Shahrezaei, Siamak
TI Relationship between Neovascular Density in Swept Source-Optical
   Coherence Tomography Angiography and Signs of Activity in Exudative
   Age-Related Macular Degeneration
SO JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID CHOROIDAL NEOVASCULARIZATION; CNV
AB Purpose. To assess the relationship between signs of activity in exudative neovascular age-related macular degeneration (nAMD) following anti-vascular endothelial growth factor (anti-VEGF) treatment and morphology of choroidal neovascularization (CNV) based on neovascular density as imaged using swept source-optical coherence tomography angiography (SS-OCTA) in a qualitative manner. Methods. A single-cohort retrospective data analysis from one tertiary eye care center. Seventy-seven eyes of 72 patients were included and their charts reviewed which had been started on intravitreal injections with anti-VEGF for nAMD at least one year prior to enrollment. Clinically active disease was evaluated by slit-lamp fundus examination and spectral domain-OCT B-scans. Morphological appearance in SS-OCTA was characterized based on 5 different criteria and subsequently divided into 3 groups: predominantly hyperdense, minimally hyperdense, and hypodense lesions. Results. Fifty-eight eyes (75%) were considered clinically active and 19 eyes (25%) clinically inactive. CNV was depicted in 71 eyes (92%) by SS-OCTA and separated accordingly into predominantly hyperdense (32%), minimally hyperdense (34%), and hypodense lesions (34%). A borderline significant difference in the probability of neovascular activity for predominantly hyperdense lesions compared to hypodense lesions was detected (p=0.05). Conclusions. Hyperdense choroidal neovascularization based on qualitative assessment of flow density showed a significant relation to active disease. Inactivity could not be matched adequately. This study demonstrated the potential usefulness of SS-OCTA for guidance of treatment in age-related macular degeneration.
C1 [Stattin, Martin; Forster, Julia; Daniel, Ahmed; Krepler, Katharina; Ansari-Shahrezaei, Siamak] Karl Landsteiner Inst Retinal Res & Imaging, Vienna, Austria.
   [Stattin, Martin; Daniel, Ahmed; Krepler, Katharina; Ansari-Shahrezaei, Siamak] Rudolf Fdn Hosp, Dept Ophthalmol, Juchgasse 25, A-1030 Vienna, Austria.
   [Graf, Alexandra] Med Univ Vienna, Ctr Med Stat Informat & Intelligent Syst, Spitalgasse 23, A-1090 Vienna, Austria.
   [Ansari-Shahrezaei, Siamak] Med Univ Graz, Dept Ophthalmol, Auenbruggerpl 1, A-8036 Graz, Austria.
C3 Medical University of Vienna; Medical University of Graz
RP Ansari-Shahrezaei, S (通讯作者)，Karl Landsteiner Inst Retinal Res & Imaging, Vienna, Austria.; Ansari-Shahrezaei, S (通讯作者)，Rudolf Fdn Hosp, Dept Ophthalmol, Juchgasse 25, A-1030 Vienna, Austria.; Ansari-Shahrezaei, S (通讯作者)，Med Univ Graz, Dept Ophthalmol, Auenbruggerpl 1, A-8036 Graz, Austria.
EM martin.stattin@wienkav.at; julia.forster@horn.lknoe.at;
   daniel.ahmed@wienkav.at; alexandra.graf@meduniwien.ac.at;
   katharina.krepler@wienkav.at; siamak.ansari-shahrezaei@wienkav.at
OI Ansari Shahrezaei, Siamak/0000-0001-8032-4686; Graf,
   Alexandra/0000-0003-0035-2658
CR Ahmed D, 2018, RETINA-J RET VIT DIS, V38, P2143, DOI 10.1097/IAE.0000000000001832
   Al-Sheikh M, 2018, RETINA-J RET VIT DIS, V38, P220, DOI 10.1097/IAE.0000000000001628
   Coscas GJ, 2015, RETINA-J RET VIT DIS, V35, P2219, DOI 10.1097/IAE.0000000000000766
   Farecki ML, 2017, GRAEF ARCH CLIN EXP, V255, P913, DOI 10.1007/s00417-017-3588-y
   Gong JW, 2016, J OPHTHALMOL, V2016, DOI 10.1155/2016/7521478
   Grossniklaus HE, 2004, AM J OPHTHALMOL, V137, P496, DOI 10.1016/j.ajo.2003.09.042
   Ichiyama Y, 2017, RETINA-J RET VIT DIS, V37, P724, DOI 10.1097/IAE.0000000000001576
   Jia YL, 2014, OPHTHALMOLOGY, V121, P1435, DOI 10.1016/j.ophtha.2014.01.034
   Liang MC, 2016, RETINA-J RET VIT DIS, V36, P2265, DOI 10.1097/IAE.0000000000001102
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Lumbroso B, 2015, RETINA-J RET VIT DIS, V35, P2242, DOI 10.1097/IAE.0000000000000879
   Makita S, 2006, OPT EXPRESS, V14, P7821, DOI 10.1364/OE.14.007821
   Miere A, 2015, RETINA-J RET VIT DIS, V35, P2275, DOI 10.1097/IAE.0000000000000819
   Muakkassa NW, 2015, RETINA-J RET VIT DIS, V35, P2252, DOI 10.1097/IAE.0000000000000836
   Novais EA, 2016, AM J OPHTHALMOL, V164, P80, DOI 10.1016/j.ajo.2016.01.011
   Phasukkijwatana N, 2017, BRIT J OPHTHALMOL, V101, P597, DOI 10.1136/bjophthalmol-2016-308815
   Querques G, 2013, INVEST OPHTH VIS SCI, V54, P6886, DOI 10.1167/iovs.13-11665
   Rispoli M, 2018, OSLI RETINA, V49, P918, DOI 10.3928/23258160-20181203-02
   Roberts PK, 2017, RETINA-J RET VIT DIS, V37, P1492, DOI 10.1097/IAE.0000000000001400
   Sambhav K, 2017, SURV OPHTHALMOL, V62, P838, DOI 10.1016/j.survophthal.2017.05.006
   Savastano MC, 2015, RETINA-J RET VIT DIS, V35, P2196, DOI 10.1097/IAE.0000000000000635
   Spaide RF, 2017, RETINA-J RET VIT DIS, V37, P609, DOI 10.1097/IAE.0000000000001575
   Wirth MA, 2017, ACTA OPHTHALMOL, V95, P428, DOI 10.1111/aos.13226
   YANNUZZI LA, 1986, OPHTHALMOLOGY, V93, P611
NR 24
TC 4
Z9 4
U1 0
U2 0
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 2090-004X
EI 2090-0058
J9 J OPHTHALMOL
JI J. Ophthalmol.
PD JUL 9
PY 2019
VL 2019
AR 4806061
DI 10.1155/2019/4806061
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA IK7LX
UT WOS:000476772100001
PM 31360542
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Pinna, A
   Porcu, T
   D'Amico-Ricci, G
   Dore, S
   Boscia, F
   Paliogiannis, P
   Carru, C
   Zinellu, A
AF Pinna, Antonio
   Porcu, Tiziana
   D'Amico-Ricci, Giuseppe
   Dore, Stefano
   Boscia, Francesco
   Paliogiannis, Panagiotis
   Carru, Ciriaco
   Zinellu, Angelo
TI Complete Blood Cell Count-Derived Inflammation Biomarkers in Men with
   Age-Related Macular Degeneration
SO OCULAR IMMUNOLOGY AND INFLAMMATION
LA English
DT Article
DE age-related macular degeneration; complete blood cell count;
   inflammation biomarkers
ID FACTOR-H POLYMORPHISM; NEUTROPHIL/LYMPHOCYTE RATIO; LYMPHOCYTE RATIO;
   DISEASE-ACTIVITY; RISK; ASSOCIATION; MACULOPATHY; MARKERS; VARIANT;
   CANCER
AB Purpose: To investigate the role of some blood count-derived inflammation biomarkers in age-related macular degeneration (AMD). Methods: Seventy-nine men with late-stage AMD and 79 male age-matched cataract controls without AMD were recruited in March-December, 2016. A blood sample was taken. The following blood cell count-derived indexes were evaluated: neutrophil/lymphocyte ratio (NLR), derived NLR [dNLR = neutrophils/(white blood cells - neutrophils)], platelet/lymphocyte ratio (PLR), monocyte/lymphocyte ratio (MLR), (neutrophils x monocytes)/lymphocyte ratio (SIRI), and (neutrophils x monocytes x platelets)/lymphocyte ratio (AISI). Results: AMD patients had significantly lower median values of white blood cells, monocytes, neutrophils, platelets, and mean platelet volume (MPV). Regarding the combined indexes, only AISI was significantly lower in AMD patients than in controls. Receiver operating characteristics curve analysis revealed that the ability of AISI and MPV to predict AMD is poor. Conclusion: Results suggests that NLR, dNLR, PLR, MLR, SIRI, and AISI are unreliable disease biomarkers in men with AMD. Larger scale studies are necessary to confirm these findings.
C1 [Pinna, Antonio; Porcu, Tiziana; Dore, Stefano; Boscia, Francesco] Univ Sassari, Dept Med Surg & Expt Sci, Sassari, Italy.
   [Pinna, Antonio; Dore, Stefano; Boscia, Francesco; Carru, Ciriaco] Univ Sassari, Azienda Osped, Sassari, Italy.
   [D'Amico-Ricci, Giuseppe; Paliogiannis, Panagiotis; Carru, Ciriaco; Zinellu, Angelo] Univ Sassari, Dept Biomed Sci, Sassari, Italy.
C3 University of Sassari; University of Sassari; University of Sassari
RP Pinna, A (通讯作者)，Univ Sassari, Dept Med Surg & Expt Sci, Sassari, Italy.; Pinna, A (通讯作者)，Univ Sassari, Ophthalmol Unit, Dept Med Surg & Expt Sci, Viale San Pietro 43 A, I-07100 Sassari, Italy.
EM apinna@uniss.it
RI Boscia, Francesco/AAC-7729-2022; Carru, Ciriaco/AAI-9996-2021;
   Paliogiannis, Panagiotis/M-6870-2016; Ricci, Giuseppe
   D'Amico/O-6051-2019; Pinna, Antonio/H-5067-2018
OI Paliogiannis, Panagiotis/0000-0001-5485-6056; Ricci, Giuseppe
   D'Amico/0000-0002-9022-4790; Pinna, Antonio/0000-0003-3052-2662;
   Zinellu, Angelo/0000-0002-8396-0968; Carru, Ciriaco/0000-0002-6985-4907;
   dore, stefano/0000-0001-6439-8028
CR Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   Despriet DDG, 2006, JAMA-J AM MED ASSOC, V296, P301, DOI 10.1001/jama.296.3.301
   Dolan RD, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-16955-5
   Dolan RD, 2017, CRIT REV ONCOL HEMAT, V116, P134, DOI 10.1016/j.critrevonc.2017.06.002
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Fu HT, 2015, CLIN LAB, V61, P269, DOI 10.7754/Clin.Lab.2014.140927
   Gopinath B, 2013, AM J CLIN NUTR, V98, P129, DOI 10.3945/ajcn.112.057091
   Hong N, 2016, ACTA OPHTHALMOL, V94, P334, DOI 10.1111/aos.13049
   Hu ZD, 2014, CLIN BIOCHEM, V47, P287, DOI 10.1016/j.clinbiochem.2014.08.022
   Ilhan N, 2015, OCUL IMMUNOL INFLAMM, V23, P287, DOI 10.3109/09273948.2014.921715
   INHOFFEN W, 1990, GRAEF ARCH CLIN EXP, V228, P316, DOI 10.1007/BF00920054
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Khan JC, 2006, BRIT J OPHTHALMOL, V90, P75, DOI 10.1136/bjo.2005.073643
   KLEIN R, 1993, OPHTHALMOLOGY, V100, P406
   Kurtul Bengi Ece, 2016, Korean J Ophthalmol, V30, P377
   Mertoglu C, 2017, DIABETES METAB SYND, V11, pS127, DOI 10.1016/j.dsx.2016.12.021
   Mullins RF, 2000, FASEB J, V14, P835, DOI 10.1096/fasebj.14.7.835
   Nathan C, 2006, NAT REV IMMUNOL, V6, P173, DOI 10.1038/nri1785
   Paliogiannis P, 2018, EUR RESPIR REV, V27, DOI 10.1183/16000617.0113-2017
   Pinna A, 2007, INVEST OPHTH VIS SCI, V48, P2747, DOI 10.1167/iovs.06-1064
   Qi Q, 2016, CANCER-AM CANCER SOC, V122, P2158, DOI 10.1002/cncr.30057
   Schmidl D, 2015, ACTA OPHTHALMOL, V93, P105, DOI 10.1111/aos.12650
   Sengul EA, 2017, INT J OPHTHALMOL-CHI, V10, P754, DOI 10.18240/ijo.2017.05.16
   Shankar A, 2007, AM J EPIDEMIOL, V165, P375, DOI 10.1093/aje/kwk022
   Tarallo V, 2012, CELL, V149, P847, DOI 10.1016/j.cell.2012.03.036
   Tasoglu O, 2017, MEDICINE, V96, DOI 10.1097/MD.0000000000006073
   Ulu SM, 2013, DIABETES TECHNOL THE, V15, P942, DOI 10.1089/dia.2013.0097
   Wu KHC, 2007, INVEST OPHTH VIS SCI, V48, P1983, DOI 10.1167/iovs.06-0223
   Xu HP, 2009, PROG RETIN EYE RES, V28, P348, DOI 10.1016/j.preteyeres.2009.06.001
   Yang ZL, 2006, SCIENCE, V314, P992, DOI 10.1126/science.1133811
   Yasuda M, 2009, OPHTHALMOLOGY, V116, P2135, DOI 10.1016/j.ophtha.2009.04.017
   Yates JRW, 2007, NEW ENGL J MED, V357, P553, DOI 10.1056/NEJMoa072618
NR 33
TC 16
Z9 16
U1 0
U2 0
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0927-3948
EI 1744-5078
J9 OCUL IMMUNOL INFLAMM
JI Ocul. Immunol. Inflamm.
PD AUG 18
PY 2019
VL 27
IS 6
BP 932
EP 936
DI 10.1080/09273948.2018.1485960
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA IU5II
UT WOS:000483620000012
PM 29953308
DA 2022-11-30
ER

PT J
AU Koo, T
   Park, SW
   Jo, DH
   Kim, D
   Kim, JH
   Cho, HY
   Kim, J
   Kim, JH
   Kim, JS
AF Koo, Taeyoung
   Park, Sung Wook
   Jo, Dong Hyun
   Kim, Daesik
   Kim, Jin Hyoung
   Cho, Hee-Yeon
   Kim, Jeungeun
   Kim, Jeong Hun
   Kim, Jin-Soo
TI CRISPR-LbCpf1 prevents choroidal neovascularization in a mouse model of
   age-related macular degeneration
SO NATURE COMMUNICATIONS
LA English
DT Article
ID ENDOTHELIAL GROWTH-FACTOR; CRISPR-CAS; CPF1; SPECIFICITIES; CELLS;
   ENDONUCLEASE; EXPRESSION; NUCLEASES; INJECTION; EFFICACY
AB LbCpf1, derived from Lachnospiraceae bacterium ND2006, is a CRISPR RNA-guided endonuclease and holds promise for therapeutic applications. Here we show that LbCpf1 can be used for therapeutic gene editing in a mouse model of age-related macular degeneration (AMD). The intravitreal delivery of LbCpf1, targeted to two angiogenesis-associated genes encoding vascular endothelial growth factor A (Vegfa) and hypoxia inducing factor 1a (Hif1a), using adeno-associated virus, led to efficient gene disruption with no apparent off-target effects in the retina and retinal pigment epithelium (RPE) cells. Importantly, LbCpf1 targeted to Vegfa or Hif1a in RPE cells reduced the area of laser-induced choroidal neovascularization as efficiently as aflibercept, an anti-VEGF drug currently used in the clinic, without inducing cone dysfunction. Unlike aflibercept, LbCpf1 targeted to Vegfa or Hif1a achieved a long-term therapeutic effect on CNV, potentially avoiding repetitive injections. Taken together, these results indicate that LbCpf1-mediated in vivo genome editing to ablate pathologic angiogenesis provides an effective strategy for the treatment of AMD and other neovascularization-associated diseases.
C1 [Koo, Taeyoung; Cho, Hee-Yeon; Kim, Jin-Soo] Ctr Genome Engn, Inst Basic Sci, Seoul 151747, South Korea.
   [Koo, Taeyoung; Kim, Jin-Soo] Univ Sci & Technol, Dept Basic Sci, Daejeon 34113, South Korea.
   [Park, Sung Wook; Jo, Dong Hyun; Kim, Jin Hyoung; Kim, Jeong Hun] Seoul Natl Univ Hosp, Biomed Res Inst, FARB Lab, Seoul 03082, South Korea.
   [Park, Sung Wook; Kim, Jeong Hun] Seoul Natl Univ, Coll Med, Dept Biomed Sci, Seoul, South Korea.
   [Park, Sung Wook; Kim, Jeong Hun] Seoul Natl Univ, Coll Med, Dept Ophthalmol, Seoul 03080, South Korea.
   [Kim, Daesik; Kim, Jeungeun; Kim, Jin-Soo] Seoul Natl Univ, Dept Chem, Seoul 151747, South Korea.
C3 Institute for Basic Science - Korea (IBS); University of Science &
   Technology (UST); Seoul National University (SNU); Seoul National
   University Hospital; Seoul National University (SNU); Seoul National
   University (SNU); Seoul National University (SNU)
RP Kim, JS (通讯作者)，Ctr Genome Engn, Inst Basic Sci, Seoul 151747, South Korea.; Kim, JS (通讯作者)，Univ Sci & Technol, Dept Basic Sci, Daejeon 34113, South Korea.; Kim, JH (通讯作者)，Seoul Natl Univ Hosp, Biomed Res Inst, FARB Lab, Seoul 03082, South Korea.; Kim, JH (通讯作者)，Seoul Natl Univ, Coll Med, Dept Biomed Sci, Seoul, South Korea.; Kim, JH (通讯作者)，Seoul Natl Univ, Coll Med, Dept Ophthalmol, Seoul 03080, South Korea.; Kim, JS (通讯作者)，Seoul Natl Univ, Dept Chem, Seoul 151747, South Korea.
EM steph25@snu.ac.kr; jskim01@snu.ac.kr
RI Jo, Dong Hyun/D-5962-2012; Kim, Daesik/AFH-7798-2022; KIM,
   Jin-Soo/M-6918-2013; Park, Sung Wook/D-5541-2012
OI Jo, Dong Hyun/0000-0002-6320-6829; KIM, Jin-Soo/0000-0003-4847-1306;
   Park, Sung Wook/0000-0001-8151-6663; Kim, Jeong Hun/0000-0003-2957-1766
FU Basic Science Research Program through the National Research Foundation
   of Korea (NRF) - Ministry of Education [2017R1A6A3A04004741]; Pioneer
   Research Program of NRF/MEST [2012-0009544]; Bio & Medical Technology
   Development Program of the National Research Foundation; MSIP
   [NRF-2015M3A9E6028949]; Institute for Basic Science [IBS-R021-D1]
FX This work was supported by the Basic Science Research Program through
   the National Research Foundation of Korea (NRF) funded by the Ministry
   of Education [2017R1A6A3A04004741 to D.H.J.], the Pioneer Research
   Program of NRF/MEST [2012-0009544 to J.H.K.], the Bio & Medical
   Technology Development Program of the National Research Foundation and
   MSIP [NRF-2015M3A9E6028949 to J.H.K.], and Institute for Basic Science
   [IBS-R021-D1 to J.-S.K.].
CR Amoaku WM, 2015, EYE, V29, P1397, DOI 10.1038/eye.2015.159
   Bainbridge JWB, 2008, NEW ENGL J MED, V358, P2231, DOI 10.1056/NEJMoa0802268
   Barrangou R, 2007, SCIENCE, V315, P1709, DOI 10.1126/science.1138140
   Bemelmans AP, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0061618
   Byrne LC, 2015, MOL THER, V23, P290, DOI 10.1038/mt.2014.181
   Cheung LK, 2013, PHARMACOTHERAPY, V33, P838, DOI 10.1002/phar.1264
   Cho SW, 2013, NAT BIOTECHNOL, V31, P230, DOI 10.1038/nbt.2507
   Cong L, 2013, SCIENCE, V339, P819, DOI 10.1126/science.1231143
   Dai Wei-Jing, 2016, Mol Ther Nucleic Acids, V5, pe349, DOI 10.1038/mtna.2016.58
   Fellmann C, 2017, NAT REV DRUG DISCOV, V16, P89, DOI 10.1038/nrd.2016.238
   Ferrara N, 2010, NAT MED, V16, P1107, DOI 10.1038/nm1010-1107
   Fonfara I, 2016, NATURE, V532, P517, DOI 10.1038/nature17945
   Funk M, 2009, OPHTHALMOLOGY, V116, P2393, DOI 10.1016/j.ophtha.2009.05.039
   Gresh J, 2003, VISUAL NEUROSCI, V20, P211, DOI 10.1017/S0952523803202108
   Hanout M, 2013, BIOMED RES INT, V2013, DOI 10.1155/2013/830837
   Hauswirth WW, 2008, HUM GENE THER, V19, P979, DOI 10.1089/hum.2008.107
   Huang XG, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-00140-3
   Hung SSC, 2016, INVEST OPHTH VIS SCI, V57, P3470, DOI 10.1167/iovs.16-19316
   Hur JK, 2016, NAT BIOTECHNOL, V34, P807, DOI 10.1038/nbt.3596
   Jinek M, 2013, ELIFE, V2, DOI 10.7554/eLife.00471
   Jinek M, 2012, SCIENCE, V337, P816, DOI 10.1126/science.1225829
   Kim D, 2016, NAT BIOTECHNOL, V34, P863, DOI 10.1038/nbt.3609
   Kim D, 2016, GENOME RES, V26, P406, DOI 10.1101/gr.199588.115
   Kim D, 2015, NAT METHODS, V12, P237, DOI [10.1038/NMETH.3284, 10.1038/nmeth.3284]
   Kim E, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms14500
   Kim HK, 2017, NAT METHODS, V14, P153, DOI [10.1038/NMETH.4104, 10.1038/nmeth.4104]
   Kleinstiver BP, 2016, NAT BIOTECHNOL, V34, P869, DOI 10.1038/nbt.3620
   Koo T, 2017, BRIEF FUNCT GENOMICS, V16, P38, DOI 10.1093/bfgp/elw032
   Kurihara T, 2012, J CLIN INVEST, V122, P4213, DOI 10.1172/JCI65157
   Lei B, 2009, MOL VIS, V15, P1374
   Maguire AM, 2008, NEW ENGL J MED, V358, P2240, DOI 10.1056/NEJMoa0802315
   Mali P, 2013, SCIENCE, V339, P823, DOI 10.1126/science.1232033
   Nathwani AC, 2011, MOL THER, V19, P876, DOI 10.1038/mt.2010.274
   Ochakovski GA, 2017, FRONT NEUROSCI-SWITZ, V11, DOI 10.3389/fnins.2017.00174
   Park SJ, 2016, INVEST OPHTH VIS SCI, V57, P2612, DOI 10.1167/iovs.16-19204
   Raczy C, 2013, BIOINFORMATICS, V29, P2041, DOI 10.1093/bioinformatics/btt314
   Sanchez-Rivera FJ, 2015, NAT REV CANCER, V15, P387, DOI 10.1038/nrc3950
   Sawada O, 2010, RETINA-J RET VIT DIS, V30, P1034, DOI 10.1097/IAE.0b013e3181ce74c8
   Shih CS, 2009, NEUROMOL MED, V11, P43, DOI 10.1007/s12017-009-8059-0
   Sugano E, 2016, GENE THER, V23, P158, DOI 10.1038/gt.2015.99
   Toth E, 2016, BIOL DIRECT, V11, DOI 10.1186/s13062-016-0147-0
   Weinberger D, 2017, CURR EYE RES, V42, P1545, DOI 10.1080/02713683.2017.1349154
   Yiu G, 2016, INVEST OPHTH VIS SCI, V57, P5490, DOI 10.1167/iovs.16-20296
   Yu WH, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms14716
   Zetsche B, 2017, NAT BIOTECHNOL, V35, P31, DOI 10.1038/nbt.3737
   Zetsche B, 2015, CELL, V163, P759, DOI 10.1016/j.cell.2015.09.038
NR 46
TC 52
Z9 53
U1 3
U2 18
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2041-1723
J9 NAT COMMUN
JI Nat. Commun.
PD MAY 10
PY 2018
VL 9
AR 1855
DI 10.1038/s41467-018-04175-y
PG 8
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA GF2LS
UT WOS:000431772000003
PM 29748595
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Priya, RR
   Chew, EY
   Swaroop, A
AF Priya, Rinki Ratna
   Chew, Emily Y.
   Swaroop, Anand
TI Genetic Studies of Age-related Macular Degeneration Lessons, Challenges,
   and Opportunities for Disease Management
SO OPHTHALMOLOGY
LA English
DT Article
ID COMPLEMENT FACTOR-H; MOLECULAR-GENETICS; ASSOCIATION; RISK;
   SUSCEPTIBILITY; VARIANTS; LOCI; CFH; PATHOGENESIS; POLYMORPHISM
AB Background: Age-related macular degeneration (AMD) is a common cause of visual impairment in individuals >55 years of age worldwide. The varying clinical phenotypes of AMD result from contributions of genetic, epigenetic, and nongenetic (environmental) factors. Genetic studies of AMD have come of age as a direct result of tremendous gains from the human genome project, genome-wide association studies, and identification of numerous susceptibility loci. These findings have implicated immune response, high-density lipoprotein cholesterol metabolism, extracellular matrix, and angiogenesis signaling pathways in disease pathophysiology.
   Main Outcome Measures: Herein, we address how the wealth of genetic findings in AMD is expected to impact the practice of medicine, providing opportunities for improved risk assessment, molecular diagnosis, preventive, and therapeutic intervention.
   Conclusions: We propose that the potential of using genetic variants for monitoring treatment response (pharmacogenetics) may usher in a new era of personalized medicine in the clinical management of AMD.
   Financial Disclosure(s): Proprietary or commercial disclosures may be found after the references. Ophthalmology 2012;119:2526-2536 (C) 2012 by the American Academy of Ophthalmology.
C1 [Swaroop, Anand] NEI, Neurobiol Neurodegenerat & Repair Lab, NIH, Bethesda, MD 20892 USA.
C3 National Institutes of Health (NIH) - USA; NIH National Eye Institute
   (NEI)
RP Swaroop, A (通讯作者)，NEI, Neurobiol Neurodegenerat & Repair Lab, NIH, MSC0610,6 Ctr Dr, Bethesda, MD 20892 USA.
EM swaroopa@nei.nih.gov
OI Swaroop, Anand/0000-0002-1975-1141; Ratnapriya,
   Rinki/0000-0002-0469-4631
FU National Eye Institute of the National Institutes of Health; NATIONAL
   EYE INSTITUTE [ZIAEY000475] Funding Source: NIH RePORTER
FX Supported by the intramural program of the National Eye Institute of the
   National Institutes of Health.
CR Allikmets R, 2000, AM J HUM GENET, V67, P487, DOI 10.1086/303018
   Baillie JK, 2011, NATURE, V479, P534, DOI 10.1038/nature10531
   Brantley MA, 2007, OPHTHALMOLOGY, V114, P2168, DOI 10.1016/j.ophtha.2007.09.008
   Chen W, 2010, P NATL ACAD SCI USA, V107, P7401, DOI 10.1073/pnas.0912702107
   Chen YH, 2011, ARCH OPHTHALMOL-CHIC, V129, P344, DOI 10.1001/archophthalmol.2011.10
   Christen WG, 2009, ARCH INTERN MED, V169, P335, DOI 10.1001/archinternmed.2008.574
   Cirulli ET, 2010, NAT REV GENET, V11, P415, DOI 10.1038/nrg2779
   DeAngelis MM, 2011, SEMIN OPHTHALMOL, V26, P77, DOI 10.3109/08820538.2011.577129
   Feng XF, 2009, OPHTHALMOLOGY, V116, P1908, DOI 10.1016/j.ophtha.2009.03.011
   Ferris FL, 2005, ARCH OPHTHALMOL-CHIC, V123, P1570
   Francis PJ, 2009, J MED GENET, V46, P300, DOI 10.1136/jmg.2008.062737
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Gorin MB, 2007, ARCH OPHTHALMOL-CHIC, V125, P21, DOI 10.1001/archopht.125.1.21
   Goverdhan SV, 2008, EYE, V22, P849, DOI 10.1038/sj.eye.6702830
   Haddad S, 2006, SURV OPHTHALMOL, V51, P316, DOI 10.1016/j.survophthal.2006.05.001
   Jakobsdottir J, 2009, PLOS GENET, V5, DOI 10.1371/journal.pgen.1000337
   Jun GG, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025775
   Kanda A, 2008, BRIT J OPHTHALMOL, V92, P448, DOI 10.1136/bjo.2007.131581
   Kaneko H, 2011, NATURE, V471, P325, DOI 10.1038/nature09830
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Klaver CCW, 1998, AM J HUM GENET, V63, P200, DOI 10.1086/301901
   Klein ML, 2008, OPHTHALMOLOGY, V115, P1019, DOI 10.1016/j.ophtha.2008.01.036
   Klein ML, 2011, ARCH OPHTHALMOL-CHIC, V129, P1543, DOI 10.1001/archophthalmol.2011.216
   Klein R, 2006, OPHTHALMOLOGY, V113, P373, DOI 10.1016/j.ophtha.2005.12.013
   Klein R, 2004, AM J OPHTHALMOL, V137, P486, DOI 10.1016/j.ajo.2003.11.069
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Kraft P, 2009, NEW ENGL J MED, V360, P1701, DOI 10.1056/NEJMp0810107
   Krishnadev N, 2010, CURR OPIN OPHTHALMOL, V21, P184, DOI 10.1097/ICU.0b013e32833866ee
   Lee AY, 2009, BRIT J OPHTHALMOL, V93, P610, DOI 10.1136/bjo.2008.150995
   Maller J, 2006, NAT GENET, V38, P1055, DOI 10.1038/ng1873
   Martin L, 2012, J CLIN INVEST, V122, P1589, DOI 10.1172/JCI60020
   McCarthy MI, 2008, NAT REV GENET, V9, P356, DOI 10.1038/nrg2344
   McKibbin M, 2012, BRIT J OPHTHALMOL, V96, P208, DOI 10.1136/bjo.2010.193680
   Orlin A, 2012, RETINA-J RET VIT DIS, V32, P4, DOI 10.1097/IAE.0b013e31822a2c7c
   Rivera A, 2005, HUM MOL GENET, V14, P3227, DOI 10.1093/hmg/ddi353
   SanGiovanni JP, 2008, ARCH OPHTHALMOL-CHIC, V126, P1274, DOI 10.1001/archopht.126.9.1274
   Schaumberg DA, 2007, ARCH OPHTHALMOL-CHIC, V125, P55, DOI 10.1001/archopht.125.1.55
   Schmidt Silke, 2002, Ophthalmic Genet, V23, P209, DOI 10.1076/opge.23.4.209.13883
   Schu M.C., 2012, ARVO M, V53, P2259
   Schultz DW, 2003, HUM MOL GENET, V12, P3315, DOI 10.1093/hmg/ddg348
   Seddon JM, 2007, JAMA-J AM MED ASSOC, V297, P1793, DOI 10.1001/jama.297.16.1793
   Seitsonen SP, 2007, EUR J OPHTHALMOL, V17, P943, DOI 10.1177/112067210701700612
   Silveira AC, 2010, VISION RES, V50, P698, DOI 10.1016/j.visres.2009.09.016
   Smith W, 2001, OPHTHALMOLOGY, V108, P697, DOI 10.1016/S0161-6420(00)00580-7
   Stone EM, 2001, HUM MOL GENET, V10, P2285, DOI 10.1093/hmg/10.20.2285
   Swaroop A, 2009, ANNU REV GENOM HUM G, V10, P19, DOI 10.1146/annurev.genom.9.081307.164350
   Tarallo V, 2012, CELL, V149, P847, DOI 10.1016/j.cell.2012.03.036
   Teper SJ, 2010, MOL VIS, V16, P2598
   Weeks DE, 2004, AM J HUM GENET, V75, P174, DOI 10.1086/422476
   Yu Y, 2011, HUM MOL GENET, V20, P3699, DOI 10.1093/hmg/ddr270
   Zanke B, 2010, CAN J OPHTHALMOL, V45, P22, DOI 10.3129/i09-209
   Zarbin MA, 2004, ARCH OPHTHALMOL-CHIC, V122, P598, DOI 10.1001/archopht.122.4.598
NR 52
TC 59
Z9 60
U1 0
U2 12
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0161-6420
EI 1549-4713
J9 OPHTHALMOLOGY
JI Ophthalmology
PD DEC
PY 2012
VL 119
IS 12
BP 2526
EP 2536
DI 10.1016/j.ophtha.2012.06.042
PG 11
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 049AL
UT WOS:000311954300016
PM 23009893
OA Green Submitted, Green Accepted
DA 2022-11-30
ER

PT J
AU De Bats, F
   Nitenberg, CV
   Fantino, B
   Denis, P
   Kodjikian, L
AF De Bats, F.
   Nitenberg, C. Vannier
   Fantino, B.
   Denis, P.
   Kodjikian, L.
TI Age-Related Macular Degeneration Screening Using a Nonmydriatic Digital
   Color Fundus Camera and Telemedicine
SO OPHTHALMOLOGICA
LA English
DT Article
DE Age-related macular degeneration; Screening; Telemedicine
ID MACULOPATHY; PREVALENCE; EYE; ROTTERDAM
AB Purpose: To investigate the use of a nonmydriatic digital color fundus camera and telemedicine as screening tools for age-related macular degeneration (AMD). Methods: Nonmydriatic color fundus photography was performed on patients consulting health examination centers and transmitted by telemedicine to an ophthalmology department. Rates for different grades of AMD were calculated and also statistically related to the presence or absence of risk factors. Results: Among the 1,022 patients screened, a total of 1,363 color fundus photographs were interpreted, with 80% gradable images, allowing a diagnosis of AMD in 178 photographs. Among all the gradable images, 83.7% had no AMD (grade 0). The rates of AMD at grades 1, 2, 3 and 4 were 8%, 5.6%, 2.3% and 0.4%, respectively. A statistical odds ratio was found between the presence of AMD on fundus photographs and age, familial history of AMD or prior cataract surgery. Conclusions: Nonmydriatic color fundus photography and telemedicine succeeded in screening for AMD. (C) 2013 S. Karger AG, Basel
C1 [De Bats, F.; Denis, P.; Kodjikian, L.] Univ Lyon, Croix Rousse Univ Hosp, Dept Ophthalmol, Lyon, France.
   [Nitenberg, C. Vannier] Hlth Examinat Ctr French Hlth Insurance Rhone, Lyon, France.
   [Fantino, B.] Univ Hosp Angers, Dept Internal Med & Clin Gerontol, Angers, France.
   [Fantino, B.] Reg Hlth Agcy Lorraine, Nancy, France.
C3 CHU Lyon; Universite d'Angers; Centre Hospitalier Universitaire d'Angers
RP Kodjikian, L (通讯作者)，Croix Rousse Univ Hosp, Dept Ophthalmol, 103 Grande Rue Croix Rousse, FR-69004 Lyon, France.
EM laurent.kodjikian@chu-lyon.fr
CR [Anonymous], 2001, TRAIT DEG MAC LIEE A
   Augood CA, 2006, ARCH OPHTHALMOL-CHIC, V124, P529, DOI 10.1001/archopht.124.4.529
   Beynat J, 2009, DIABETES METAB, V35, P49, DOI 10.1016/j.diabet.2008.07.002
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Delcourt C, 2001, Ophthalmic Epidemiol, V8, P237, DOI 10.1076/opep.8.4.237.1613
   Ferris FL, 2005, ARCH OPHTHALMOL-CHIC, V123, P1570
   Klein R, 2004, ARCH OPHTHALMOL-CHIC, V122, P1642, DOI 10.1001/archopht.122.11.1642
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Le Tien V, 2008, AM J OPHTHALMOL, V146, P520, DOI 10.1016/j.ajo.2008.05.031
   MITCHELL P, 1995, OPHTHALMOLOGY, V102, P1450
   Pirbhai A, 2005, AM J OPHTHALMOL, V139, P455, DOI 10.1016/j.ajo.2004.09.077
   Rattner A, 2006, NAT REV NEUROSCI, V7, P860, DOI 10.1038/nrn2007
   van Leeuwen R, 2003, ARCH OPHTHALMOL-CHIC, V121, P519, DOI 10.1001/archopht.121.4.519
   VINGERLING JR, 1995, OPHTHALMOLOGY, V102, P205
   2006, DIABETES METAB, V32, P643
NR 15
TC 27
Z9 27
U1 0
U2 4
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 0030-3755
EI 1423-0267
J9 OPHTHALMOLOGICA
JI Ophthalmologica
PY 2014
VL 231
IS 3
BP 172
EP 176
DI 10.1159/000356695
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA AD3ES
UT WOS:000333121700008
PM 24356326
DA 2022-11-30
ER

PT J
AU Baba, T
   Miyazaki, D
   Inata, K
   Uotani, R
   Miyake, H
   Sasaki, S
   Shimizu, Y
   Inoue, Y
   Nakamura, K
AF Baba, Takashi
   Miyazaki, Dai
   Inata, Kodai
   Uotani, Ryu
   Miyake, Hitomi
   Sasaki, Shin-ichi
   Shimizu, Yumiko
   Inoue, Yoshitsugu
   Nakamura, Kazuomi
TI Role of IL-4 in bone marrow driven dysregulated angiogenesis and
   age-related macular degeneration
SO ELIFE
LA English
DT Article
ID ANTIINFLAMMATORY CYTOKINE; ENDOTHELIAL-CELLS; EPITHELIAL-CELLS;
   GROWTH-FACTOR; INTERLEUKIN-4; INFLAMMATION; INHIBITION;
   NEOVASCULARIZATION; PATHOGENESIS; EXPRESSION
AB Age-associated sterile inflammation can cause dysregulated choroidal neovascularization (CNV) as age-related macular degeneration (AMD). Intraocular fluid screening of 234 AMD patients identified high levels of IL-4. The purpose of this study was to determine the functional role of IL-4 in CNV formation using murine CNV model. Our results indicate that the IL-4/IL-4 receptors (IL4Rs) controlled tube formation and global proangiogenic responses of bone marrow cells. CCR2(+) bone marrow cells were recruited to form very early CNV lesions. IL-4 rapidly induces CCL2, which enhances recruitment of CCR2(+) bone marrow cells. This in vivo communication, like quorum-sensing, was followed by the induction of IL-4 by the bone marrow cells during the formation of mature CNVs. For CNV development, IL-4 in bone marrow cells are critically required, and IL-4 directly promotes CNV formation mainly by IL-4R. The IL-4/IL-4R alpha axis contributes to pathological angiogenesis through communications with bone marrow cells leading to retinal degeneration.
C1 [Baba, Takashi; Miyazaki, Dai; Inata, Kodai; Uotani, Ryu; Miyake, Hitomi; Sasaki, Shin-ichi; Shimizu, Yumiko; Inoue, Yoshitsugu] Tottori Univ, Fac Med, Div Ophthalmol & Visual Sci, Yonago, Tottori, Japan.
   [Nakamura, Kazuomi] Tottori Univ, Fac Med, Dept Biomed Sci, Div Pathol Biochem, Yonago, Tottori, Japan.
C3 Tottori University; Tottori University
RP Baba, T; Miyazaki, D (通讯作者)，Tottori Univ, Fac Med, Div Ophthalmol & Visual Sci, Yonago, Tottori, Japan.
EM babatakashi8@gmail.com; miyazaki-ttr@umin.ac.jp
OI Baba, Takashi/0000-0001-7318-9420
FU  [JP16K15733];  [JP25670733]
FX Japan Society for the Promotion of Science JP16K15733 Takashi Babar
   Japan Society for the Promotion of Science JP25670733 Takashi Babar The
   funders had no role in study design, data collection and interpretation,
   or the decision to submit the work for publication.
CR Adao-Novaes J, 2009, J NEUROSCI RES, V87, P2167, DOI 10.1002/jnr.22026
   Antonioli L, 2018, NAT REV IMMUNOL, V18, P537, DOI 10.1038/s41577-018-0040-4
   Beck M, 2016, AM J OPHTHALMOL, V167, P10, DOI 10.1016/j.ajo.2016.04.003
   Caballero S, 2007, DIABETES, V56, P960, DOI 10.2337/db06-1254
   Cao XG, 2011, PATHOL INT, V61, P528, DOI 10.1111/j.1440-1827.2011.02695.x
   Chen CC, 2015, CELL, V161, P277, DOI 10.1016/j.cell.2015.02.016
   Chitnis T, 2017, J CLIN INVEST, V127, P3577, DOI 10.1172/JCI90609
   Chono I, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-32725-3
   Clement M, 2014, P NATL ACAD SCI USA, V111, pE1101, DOI 10.1073/pnas.1314505111
   Copland DA, 2018, INVEST OPHTH VIS SCI, V59, pAMD83, DOI 10.1167/iovs.18-23893
   DeCicco-Skinner KL, 2014, JOVE-J VIS EXP, DOI 10.3791/51312
   Feng CY, 2017, MOL VIS, V23, P765
   Gao F, 2016, ANGIOGENESIS, V19, P107, DOI 10.1007/s10456-016-9497-6
   Grant MB, 2002, NAT MED, V8, P607, DOI 10.1038/nm0602-607
   Grochot-Przeczek A, 2013, ANGIOGENESIS VASCULA, DOI [10.1007/978-3-7091-1428-5, DOI 10.1007/978-3-7091-1428-5]
   Haas CS, 2006, ARTHRITIS RHEUM, V54, P2402, DOI 10.1002/art.22034
   Kiyota T, 2010, FASEB J, V24, P3093, DOI 10.1096/fj.10-155317
   Koeberle PD, 2004, NEUROSCIENCE, V125, P903, DOI 10.1016/S0306-4522(03)00398-1
   Kotowicz K, 2004, CLIN EXP ALLERGY, V34, P445, DOI 10.1111/j.1365-2222.2004.01902.x
   da Silva AGLS, 2008, J NEUROIMMUNOL, V196, P82, DOI 10.1016/j.jneuroim.2008.03.003
   Lee YW, 2010, BIOMOL THER, V18, P135, DOI 10.4062/biomolther.2010.18.2.135
   Lee YW, 2004, MOL MED, V10, P19, DOI 10.2119/2004-00024.Lee
   Leung KW, 2009, MOL IMMUNOL, V46, P1374, DOI 10.1016/j.molimm.2008.12.001
   Luckoff A, 2016, EMBO MOL MED, V8, P670, DOI 10.15252/emmm.201505994
   Merchand-Reyes G, 2019, J IMMUNOL, V203, P3216, DOI 10.4049/jimmunol.1900059
   Miyazaki D, 2017, EXP EYE RES, V161, P143, DOI 10.1016/j.exer.2017.06.017
   Pearson JD, 2010, MICROVASC RES, V79, P162, DOI 10.1016/j.mvr.2009.12.004
   Rohde E, 2006, STEM CELLS, V24, P357, DOI 10.1634/stemcells.2005-0072
   Sasaki M, 2010, J HEPATOL, V53, P318, DOI 10.1016/j.jhep.2010.03.008
   Sasaki S, 2012, INVEST OPHTH VIS SCI, V53, P3424, DOI 10.1167/iovs.11-7913
   Schatteman GC, 2003, ADV EXP MED BIOL, V522, P9
   Schmeisser A, 2001, CARDIOVASC RES, V49, P671, DOI 10.1016/S0008-6363(00)00270-4
   Sennlaub F, 2013, EMBO MOL MED, V5, P1775, DOI 10.1002/emmm.201302692
   Skaria T, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0156002
   Volpert OV, 1998, J EXP MED, V188, P1039, DOI 10.1084/jem.188.6.1039
   Wang QR, 1998, IN VITRO CELL DEV-AN, V34, P443
   Wu WK, 2015, AM J PATHOL, V185, P2324, DOI 10.1016/j.ajpath.2015.04.013
   Yoshida S, 2003, J LEUKOCYTE BIOL, V73, P137, DOI 10.1189/jlb.0302117
   Zhao WH, 2006, J NEUROCHEM, V99, P1176, DOI 10.1111/j.1471-4159.2006.04172.x
   Zhou YD, 2017, INT J OPHTHALMOL-CHI, V10, P1902, DOI 10.18240/ijo.2017.12.18
NR 40
TC 7
Z9 7
U1 1
U2 3
PU ELIFE SCIENCES PUBLICATIONS LTD
PI CAMBRIDGE
PA SHERATON HOUSE, CASTLE PARK, CAMBRIDGE, CB3 0AX, ENGLAND
SN 2050-084X
J9 ELIFE
JI eLife
PD MAY 5
PY 2020
VL 9
AR e54527
DI 10.7554/eLife.54257
PG 22
WC Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Life Sciences & Biomedicine - Other Topics
GA LL8TX
UT WOS:000531828000001
PM 32366355
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Liu, YY
   Fortmann, SD
   Shen, JK
   Wielechowski, E
   Tretiakova, A
   Yoo, S
   Kozarsky, K
   Wang, JX
   Wilson, JM
   Campochiaro, PA
AF Liu, Yuanyuan
   Fortmann, Seth D.
   Shen, Jikui
   Wielechowski, Erik
   Tretiakova, Anna
   Yoo, Stephen
   Kozarsky, Karen
   Wang, Jiangxia
   Wilson, James M.
   Campochiaro, Peter A.
TI AAV8-antiVEGFfab Ocular Gene Transfer for Neovascular Age-Related
   Macular Degeneration
SO MOLECULAR THERAPY
LA English
DT Article
ID EPITHELIUM-DERIVED FACTOR; ENDOTHELIAL GROWTH-FACTOR; INHIBITS CHOROIDAL
   NEOVASCULARIZATION; RANDOMIZED CLINICAL-TRIAL; SUBRETINAL
   NEOVASCULARIZATION; RETINAL NEOVASCULARIZATION; ADENOASSOCIATED VIRUSES;
   PROLONGED BLOCKADE; VEGF; RANIBIZUMAB
AB Sustained suppression of VEGF is needed in many patients with neovascular age-related macular degeneration (NVAMD), and gene transfer of a VEGF-neutralizing protein is a promising approach to achieve it. Initial clinical trials testing this approach have shown encouraging signals, but evidence of robust transgene expression and consistent antiangiogenic and antipermeability activity has been lacking. In this study, we demonstrate expression of an anti-human VEGF antibody fragment (antiVEGFfab) after subretinal injection of AAV8-antiVEGFfab. In transgenic mice expressing human VEGF in retina (rho/VEGF mice), a model of type 3 choroidal neovascularization (NV), eyes injected with >= 1 x 10(7) gene copies (GC) of AAV8-antiVEGFfab had significantly less mean area of NV than null vector-injected eyes. A dose-dependent response was observed with modest reduction of NV with <= 3 x 10(7), >50% reduction with >= 1 x 10(8) GC and almost complete elimination of NV with 3 x 10(9) or 1 x 10(10) GC. In Tet/opsin/VEGF mice, in which doxycycline-induced high expression of VEGF leads to severe vascular leakage and exudative retinal detachment (RD), reduction of total RD by 70%-80% occurred with 3 x 10(9) or 1 x 10(10) GC of AAV8-antiVEGFfab, an effect that was sustained for at least a month. These data strongly support initiating clinical trials testing subretinal injection of AAV8-antiVEGFfab in patients with NVAMD.
C1 [Liu, Yuanyuan; Fortmann, Seth D.; Shen, Jikui; Campochiaro, Peter A.] Johns Hopkins Univ, Sch Med, Dept Ophthalmol, Baltimore, MD 21205 USA.
   [Liu, Yuanyuan; Fortmann, Seth D.; Shen, Jikui; Campochiaro, Peter A.] Johns Hopkins Univ, Sch Med, Dept Neurosci, Baltimore, MD 21205 USA.
   [Wielechowski, Erik; Tretiakova, Anna; Wilson, James M.] Univ Penn, Sch Med, Dept Med, Philadelphia, PA 19104 USA.
   [Wielechowski, Erik; Tretiakova, Anna; Wilson, James M.] Univ Penn, Sch Med, Dept Pediat, Philadelphia, PA 19104 USA.
   [Yoo, Stephen; Kozarsky, Karen] REGENXBIO Inc, Rockville, MD USA.
   [Wang, Jiangxia] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Biostat, Johns Hopkins Biostat Ctr, Baltimore, MD USA.
   [Liu, Yuanyuan] Tianjin Med Univ, Dept Ophthalmol, Gen Hosp, Tianjin, Peoples R China.
   [Tretiakova, Anna] Pfizer Inc, Rare Dis Res Unit, 610 Main St, Cambridge, MA 02139 USA.
   [Kozarsky, Karen] Vector BioPartners, Bala Cynwyd, PA USA.
C3 Johns Hopkins University; Johns Hopkins University; University of
   Pennsylvania; University of Pennsylvania; Johns Hopkins University;
   Johns Hopkins Bloomberg School of Public Health; Tianjin Medical
   University; Pfizer
RP Campochiaro, PA (通讯作者)，Johns Hopkins Sch Med, Dept Ophthalmol, 600 N Wolfe St, Baltimore, MD 21287 USA.; Campochiaro, PA (通讯作者)，Johns Hopkins Sch Med, Dept Neurosci, 600 N Wolfe St, Baltimore, MD 21287 USA.
EM pcampo@jhmi.edu
RI Wilson, James M/F-9220-2011; liu, yuanyuan/GWZ-5838-2022
OI Wilson, James M/0000-0002-9630-3131; Fortmann, Seth/0000-0002-9554-8751
FU REGENXBIO; Wilmer Biostatistics Core Grant [EY01765]; NATIONAL EYE
   INSTITUTE [P30EY001765] Funding Source: NIH RePORTER
FX The study was funded by REGENXBIO and Wilmer Biostatistics Core Grant
   EY01765. Vector used in this study was obtained from the Gene Therapy
   Program Vector Core of the University of Pennsylvania.
CR Bainbridge JWB, 2002, GENE THER, V9, P320, DOI 10.1038/sj.gt.3301680
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Calcedo R, 2009, J INFECT DIS, V199, P381, DOI 10.1086/595830
   Campochiaro PA, 2006, HUM GENE THER, V17, P167, DOI 10.1089/hum.2006.17.167
   Constable IJ, 2016, EBIOMEDICINE, V14, P168, DOI 10.1016/j.ebiom.2016.11.016
   Fang JM, 2005, NAT BIOTECHNOL, V23, P584, DOI 10.1038/nbt1087
   Gao GP, 2002, P NATL ACAD SCI USA, V99, P11854, DOI 10.1073/pnas.182412299
   Gehlbach P, 2003, GENE THER, V10, P637, DOI 10.1038/sj.gt.3301931
   Heier JS, 2017, LANCET, V390, P50, DOI 10.1016/S0140-6736(17)30979-0
   Honda M, 2000, GENE THER, V7, P978, DOI 10.1038/sj.gt.3301203
   Iwase T, 2013, J CONTROL RELEASE, V172, P625, DOI 10.1016/j.jconrel.2013.10.008
   Kotterman MA, 2015, GENE THER, V22, P116, DOI 10.1038/gt.2014.115
   Lai CC, 2001, INVEST OPHTH VIS SCI, V42, P2401
   Lai CM, 2005, MOL THER, V12, P659, DOI 10.1016/j.ymthe.2005.04.022
   Maguire MG, 2016, OPHTHALMOLOGY, V123, P1751, DOI 10.1016/j.ophtha.2016.03.045
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Miki A, 2010, J CELL PHYSIOL, V224, P262, DOI 10.1002/jcp.22129
   Mori K, 2002, INVEST OPHTH VIS SCI, V43, P1994
   Mori K, 2001, J CELL PHYSIOL, V188, P253, DOI 10.1002/jcp.1114
   Ohno-Matsui K, 2002, AM J PATHOL, V160, P711, DOI 10.1016/S0002-9440(10)64891-2
   Okamoto N, 1997, AM J PATHOL, V151, P281
   Rakoczy EP, 2015, LANCET, V386, P2395, DOI 10.1016/S0140-6736(15)00345-1
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rota R, 2004, J GENE MED, V6, P992, DOI 10.1002/jgm.586
   Singer MA, 2012, OPHTHALMOLOGY, V119, P1175, DOI 10.1016/j.ophtha.2011.12.016
   Takahashi K, 2003, FASEB J, V17, P896, DOI 10.1096/fj.02-0824fje
   Tobe T, 1998, INVEST OPHTH VIS SCI, V39, P180
   Ueno S, 2008, J CELL PHYSIOL, V217, P13, DOI 10.1002/jcp.21445
   Vandenberghe LH, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3002103
   Yannuzzi LA, 2001, RETINA-J RET VIT DIS, V21, P416, DOI 10.1097/00006982-200110000-00003
NR 30
TC 23
Z9 25
U1 1
U2 3
PU CELL PRESS
PI CAMBRIDGE
PA 50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA
SN 1525-0016
EI 1525-0024
J9 MOL THER
JI Mol. Ther.
PD FEB 7
PY 2018
VL 26
IS 2
BP 542
EP 549
DI 10.1016/j.ymthe.2017.12.002
PG 8
WC Biotechnology & Applied Microbiology; Genetics & Heredity; Medicine,
   Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biotechnology & Applied Microbiology; Genetics & Heredity; Research &
   Experimental Medicine
GA FW3KW
UT WOS:000425206300020
PM 29292162
OA Green Published, hybrid
DA 2022-11-30
ER

PT J
AU Geerlings, MJ
   de Jong, EK
   den Hollander, AI
AF Geerlings, Maartje J.
   de Jong, Eiko K.
   den Hollander, Anneke I.
TI The complement system in age-related macular degeneration: A review of
   rare genetic variants and implications for personalized treatment
SO MOLECULAR IMMUNOLOGY
LA English
DT Review
DE Age-related macular degeneration; Complement system; Alternative
   pathway; Rare genetic variants
ID HEMOLYTIC-UREMIC SYNDROME; GENOME-WIDE ASSOCIATION; FACTOR-H
   POLYMORPHISM; FACTOR-I; HIGH-RISK; FUNCTIONAL-CHARACTERIZATION;
   MEMBRANOPROLIFERATIVE GLOMERULONEPHRITIS; SUSCEPTIBILITY LOCI; C3
   MUTATION; CFI GENE
AB Age-related macular degeneration (AMD) is a progressive retinal disease and the major cause of irreversible vision loss in the elderly. Numerous studies have found both common and rare genetic variants in the complement pathway to play a role in the pathogenesis of AMD. In this review we provide an overview of rare variants identified in AMD patients, and summarize the functional consequences of rare genetic variation in complement genes on the complement system. Finally, we discuss the relevance of this work in light of ongoing clinical trials that study the effectiveness of complement inhibitors against AMD. (C) 2016 The Authors. Published by Elsevier Ltd.
C1 [Geerlings, Maartje J.; de Jong, Eiko K.; den Hollander, Anneke I.] Radboud Univ Nijmegen, Med Ctr, Dept Ophthalmol, Donders Inst Brain Cognit & Behav, Nijmegen, Netherlands.
   [den Hollander, Anneke I.] Radboud Univ Nijmegen, Med Ctr, Dept Human Genet, Donders Inst Brain Cognit & Behav, Nijmegen, Netherlands.
C3 Radboud University Nijmegen; Radboud University Nijmegen
RP den Hollander, AI (通讯作者)，Radboud Univ Nijmegen, Med Ctr, Dept Ophthalmol, POB 9101, NL-6500 HB Nijmegen, Netherlands.
EM anneke.denhollander@radboudumc.nl
RI Geerlings, Maartje/P-8309-2015; de Jong, Eiko/P-3407-2015; Hollander,
   Anneke den/N-4911-2014; Geerlings, Maartje/P-3338-2019
OI Geerlings, Maartje/0000-0003-1164-3573; de Jong,
   Eiko/0000-0001-6520-0407; Geerlings, Maartje/0000-0003-1164-3573
FU European Research Council under the European Union's Seventh Framework
   Programme (FP)/ERC Grant [310644]
FX The authors would like to thank the International Age-Related Macular
   Degeneration Genomics'Consortium (IAMDGC) for sharing minor allele
   frequencies and odd-ratio's of rare variants in the CFH, CFI, C3 and C9
   genes identified in Fritsche et al 2016, and A. Kwong, X. Zhan, A.
   Swaroop and G.R. Abecasis for sharing their dataset of rare variants in
   the CFH, CFI andC3genes identified in Zhan et al. 2013. The research
   leading to these results has received funding from the European Research
   Council under the European Union's Seventh Framework Programme
   (FP/2007-2013)/ERC Grant Agreement n. 310644 (MACULA).
CR Abecasis GR, 2004, AM J HUM GENET, V74, P482, DOI 10.1086/382786
   Agarwal A, 2015, CLIN OPHTHALMOL, V9, P1001, DOI [10.2147/OPTH.S59725, 10.2147/OPTH.S74959]
   Albuquerque JAT, 2012, J IMMUNOL, V189, P3242, DOI 10.4049/jimmunol.1201418
   Alexander P, 2014, MOL VIS, V20, P1253
   Bienaime F, 2010, KIDNEY INT, V77, P339, DOI 10.1038/ki.2009.472
   Boon CJE, 2008, AM J HUM GENET, V82, P516, DOI 10.1016/j.ajhg.2007.11.007
   Brackman D, 2011, NEPHROL DIAL TRANSPL, V26, P3399, DOI 10.1093/ndt/gfr422
   Bresin E, 2013, J AM SOC NEPHROL, V24, P475, DOI 10.1681/ASN.2012090884
   Caprioli J, 2006, BLOOD, V108, P1267, DOI 10.1182/blood-2005-10-007252
   Cayci FS, 2012, PEDIATR NEPHROL, V27, P2327, DOI 10.1007/s00467-012-2283-9
   Chakravarthy U, 2010, BMC OPHTHALMOL, V10, DOI 10.1186/1471-2415-10-31
   Chakravarthy U, 2010, BMJ-BRIT MED J, V340, DOI 10.1136/bmj.c981
   Chan MR, 2009, AM J KIDNEY DIS, V53, P321, DOI 10.1053/j.ajkd.2008.06.027
   Cheng CY, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7063
   Chew EY, 2015, JAMA-J AM MED ASSOC, V314, P791, DOI 10.1001/jama.2015.9677
   Chew EY, 2014, JAMA OPHTHALMOL, V132, P142, DOI 10.1001/jamaophthalmol.2013.7376
   Dragon-Durey MA, 2004, J AM SOC NEPHROL, V15, P787, DOI 10.1097/01.ASN.0000115702.28859.A7
   Duvvari MR, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0152047
   Duvvari MR, 2015, MOL VIS, V21, P285
   Duvvari MR, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0094165
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Fagerness JA, 2009, EUR J HUM GENET, V17, P100, DOI 10.1038/ejhg.2008.140
   Fakhouri F, 2010, J AM SOC NEPHROL, V21, P859, DOI 10.1681/ASN.2009070706
   Fakhouri F, 2008, BLOOD, V112, P4542, DOI 10.1182/blood-2008-03-144691
   Falcao DA, 2008, SCAND J IMMUNOL, V68, P445, DOI 10.1111/j.1365-3083.2008.02152.x
   Ferreira VP, 2009, J IMMUNOL, V182, P7009, DOI 10.4049/jimmunol.0804031
   Fremeaux-Bacchi V, 2004, J MED GENET, V41, DOI 10.1136/jmg.2004.019083
   Fremeaux-Bacchi V, 2008, BLOOD, V112, P4948, DOI 10.1182/blood-2008-01-133702
   Fritsche LG, 2016, NAT GENET, V48, P134, DOI 10.1038/ng.3448
   Fritsche LG, 2014, ANNU REV GENOM HUM G, V15, P151, DOI 10.1146/annurev-genom-090413-025610
   Fritsche LG, 2013, NAT GENET, V45, P433, DOI 10.1038/ng.2578
   Fukumori Y, 1989, INT IMMUNOL, V1, P85, DOI 10.1093/intimm/1.1.85
   Geerlings MJ., 2016, JAMA OPHTHALMOL, P4604
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Hammond CJ, 2002, OPHTHALMOLOGY, V109, P730, DOI 10.1016/S0161-6420(01)01049-1
   Heinen Stefan, 2006, Hum Mutat, V27, P292, DOI 10.1002/humu.9408
   Helgason H, 2013, NAT GENET, V45, P1371, DOI 10.1038/ng.2740
   Hoffman JD, 2014, INVEST OPHTH VIS SCI, V55, P4455, DOI 10.1167/iovs.13-13684
   Horiuchi T, 1998, J IMMUNOL, V160, P1509
   Hughes AE, 2006, NAT GENET, V38, P1173, DOI 10.1038/ng1890
   Iyengar SK, 2004, AM J HUM GENET, V74, P20, DOI 10.1086/380912
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Johnson LV, 2001, EXP EYE RES, V73, P887, DOI 10.1006/exer.2001.1094
   Johnson SA, 2010, MOL IMMUNOL, V47, P1585, DOI 10.1016/j.molimm.2009.12.001
   Jozsi M, 2006, J AM SOC NEPHROL, V17, P170, DOI 10.1681/ASN.2005080868
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Kavanagh D, 2008, MOL IMMUNOL, V45, P95, DOI 10.1016/j.molimm.2007.05.004
   Kavanagh D, 2015, HUM MOL GENET, V24, P3861, DOI 10.1093/hmg/ddv091
   Klaver CCW, 1998, ARCH OPHTHALMOL-CHIC, V116, P1646, DOI 10.1001/archopht.116.12.1646
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Majewski J, 2003, AM J HUM GENET, V73, P540, DOI 10.1086/377701
   Maller JB, 2007, NAT GENET, V39, P1200, DOI 10.1038/ng2131
   Manolio TA, 2009, NATURE, V461, P747, DOI 10.1038/nature08494
   Manuelian T, 2003, J CLIN INVEST, V111, P1181, DOI 10.1172/JCI200316651
   Martinez-Barricarte R, 2015, MOL IMMUNOL, V66, P263, DOI 10.1016/j.molimm.2015.03.248
   McCarthy MI, 2008, NAT REV GENET, V9, P356, DOI 10.1038/nrg2344
   MEYERS SM, 1995, AM J OPHTHALMOL, V120, P757, DOI 10.1016/S0002-9394(14)72729-1
   Miller E., 2012, 719 WASH U
   Miyake M, 2015, JPN J OPHTHALMOL, V59, P273, DOI 10.1007/s10384-015-0394-0
   Mohlin FC, 2015, MOL IMMUNOL, V65, P367, DOI 10.1016/j.molimm.2015.02.013
   Mullins RF, 2001, EYE, V15, P390, DOI 10.1038/eye.2001.142
   Neumann HPH, 2003, J MED GENET, V40, P676, DOI 10.1136/jmg.40.9.676
   Nilsson SC, 2007, MOL IMMUNOL, V44, P1835, DOI 10.1016/j.molimm.2006.10.005
   Nilsson SC, 2010, EUR J IMMUNOL, V40, P172, DOI 10.1002/eji.200939280
   Nishiguchi KM, 2012, INVEST OPHTH VIS SCI, V53, P508, DOI 10.1167/iovs.11-8425
   Pechtl IC, 2011, J BIOL CHEM, V286, P11082, DOI 10.1074/jbc.M110.211839
   Perez-Caballero D, 2001, AM J HUM GENET, V68, P478, DOI 10.1086/318201
   Pras E, 2015, J MED GENET, V52, P484, DOI 10.1136/jmedgenet-2015-103130
   Ratnapriya R, 2014, HUM MOL GENET, V23, P5827, DOI 10.1093/hmg/ddu276
   Raychaudhuri S, 2011, NAT GENET, V43, P1232, DOI 10.1038/ng.976
   Recalde S, 2016, J AM SOC NEPHROL, V27, P1305, DOI 10.1681/ASN.2015050580
   Roumenina LT, 2012, BLOOD, V119, P4182, DOI 10.1182/blood-2011-10-383281
   Saksens NTM, 2016, JAMA OPHTHALMOL, V134, P287, DOI 10.1001/jamaophthalmol.2015.5592
   Sanchez-Corral P, 2002, AM J HUM GENET, V71, P1285, DOI 10.1086/344515
   Schramm EC, 2015, BLOOD, V125, P2359, DOI 10.1182/blood-2014-10-609073
   Seddon JM, 2005, ARCH OPHTHALMOL-CHIC, V123, P321, DOI 10.1001/archopht.123.3.321
   Seddon JM, 2003, AM J HUM GENET, V73, P780, DOI 10.1086/378505
   Seddon JM, 1997, AM J OPHTHALMOL, V123, P199, DOI 10.1016/S0002-9394(14)71036-0
   Seddon JM, 2013, NAT GENET, V45, P1366, DOI 10.1038/ng.2741
   Sellier-Leclerc AL, 2007, J AM SOC NEPHROL, V18, P2392, DOI 10.1681/ASN.2006080811
   Servais A, 2012, KIDNEY INT, V82, P454, DOI 10.1038/ki.2012.63
   Shen JK, 2007, HISTOL HISTOPATHOL, V22, P1301, DOI 10.14670/HH-22.1301
   Stahl AL, 2008, BLOOD, V111, P5307, DOI 10.1182/blood-2007-08-106153
   Szarvas N, 2016, MOL IMMUNOL, V71, P10, DOI 10.1016/j.molimm.2016.01.003
   Tomany SC, 2004, OPHTHALMOLOGY, V111, P1280, DOI 10.1016/j.ophtha.2003.11.010
   Tortajada A, 2012, KIDNEY INT, V81, P56, DOI 10.1038/ki.2011.291
   Triebwasser MP, 2015, INVEST OPHTH VIS SCI, V56, P6873, DOI 10.1167/iovs.15-17432
   van de Ven JPH, 2013, NAT GENET, V45, P813, DOI 10.1038/ng.2640
   van de Ven JPH, 2012, ARCH OPHTHALMOL-CHIC, V130, P1038, DOI 10.1001/archophthalmol.2012.265
   van Doorn KJ, 2013, CLIN KIDNEY J, V6, P216, DOI 10.1093/ckj/sfs190
   Volokhina E, 2012, PEDIATR NEPHROL, V27, P1519, DOI 10.1007/s00467-012-2183-z
   Volz C, 2015, EUR J PHARM BIOPHARM, V95, P158, DOI 10.1016/j.ejpb.2015.02.020
   Vyse TJ, 1996, J CLIN INVEST, V97, P925, DOI 10.1172/JCI118515
   Wagner EK, 2016, SCI REP-UK, V6, DOI 10.1038/srep31531
   Weeks DE, 2004, AM J HUM GENET, V75, P174, DOI 10.1086/422476
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Yates JRW, 2007, NEW ENGL J MED, V357, P553, DOI 10.1056/NEJMoa072618
   Yehoshua Z, 2014, OPHTHALMOLOGY, V121, P693, DOI 10.1016/j.ophtha.2013.09.044
   Yu Y, 2014, HUM MOL GENET, V23, P5283, DOI 10.1093/hmg/ddu226
   Zhan XW, 2013, NAT GENET, V45, P1375, DOI 10.1038/ng.2758
NR 103
TC 111
Z9 113
U1 0
U2 11
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0161-5890
J9 MOL IMMUNOL
JI Mol. Immunol.
PD APR
PY 2017
VL 84
SI SI
BP 65
EP 76
DI 10.1016/j.molimm.2016.11.016
PG 12
WC Biochemistry & Molecular Biology; Immunology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Immunology
GA ET3TE
UT WOS:000400201600010
PM 27939104
OA Green Published, hybrid
DA 2022-11-30
ER

PT J
AU Zhan, XW
   Larson, DE
   Wang, CL
   Koboldt, DC
   Sergeev, YV
   Fulton, RS
   Fulton, LL
   Fronick, CC
   Branham, KE
   Bragg-Gresham, J
   Jun, G
   Hu, YN
   Kang, HM
   Liu, DJ
   Othman, M
   Brooks, M
   Ratnapriya, R
   Boleda, A
   Grassmann, F
   von Strachwitz, C
   Olson, LM
   Buitendijk, GHS
   Hofman, A
   van Duijn, CM
   Cipriani, V
   Moore, AT
   Shahid, H
   Jiang, YD
   Conley, YP
   Morgan, DJ
   Kim, IK
   Johnson, MP
   Cantsilieris, S
   Richardson, AJ
   Guymer, RH
   Luo, HR
   Ouyang, H
   Licht, C
   Pluthero, FG
   Zhang, MM
   Zhang, K
   Baird, PN
   Blangero, J
   Klein, ML
   Farrer, LA
   DeAngelis, MM
   Weeks, DE
   Gorin, MB
   Yates, JRW
   Klaver, CCW
   Pericak-Vance, MA
   Haines, JL
   Weber, BHF
   Wilson, RK
   Heckenlively, JR
   Chew, EY
   Stambolian, D
   Mardis, ER
   Swaroop, A
   Abecasis, GR
AF Zhan, Xiaowei
   Larson, David E.
   Wang, Chaolong
   Koboldt, Daniel C.
   Sergeev, Yuri V.
   Fulton, Robert S.
   Fulton, Lucinda L.
   Fronick, Catrina C.
   Branham, Kari E.
   Bragg-Gresham, Jennifer
   Jun, Goo
   Hu, Youna
   Kang, Hyun Min
   Liu, Dajiang
   Othman, Mohammad
   Brooks, Matthew
   Ratnapriya, Rinki
   Boleda, Alexis
   Grassmann, Felix
   von Strachwitz, Claudia
   Olson, Lana M.
   Buitendijk, Gabrielle H. S.
   Hofman, Albert
   van Duijn, Cornelia M.
   Cipriani, Valentina
   Moore, Anthony T.
   Shahid, Humma
   Jiang, Yingda
   Conley, Yvette P.
   Morgan, Denise J.
   Kim, Ivana K.
   Johnson, Matthew P.
   Cantsilieris, Stuart
   Richardson, Andrea J.
   Guymer, Robyn H.
   Luo, Hongrong
   Ouyang, Hong
   Licht, Christoph
   Pluthero, Fred G.
   Zhang, Mindy M.
   Zhang, Kang
   Baird, Paul N.
   Blangero, John
   Klein, Michael L.
   Farrer, Lindsay A.
   DeAngelis, Margaret M.
   Weeks, Daniel E.
   Gorin, Michael B.
   Yates, John R. W.
   Klaver, Caroline C. W.
   Pericak-Vance, Margaret A.
   Haines, Jonathan L.
   Weber, Bernhard H. F.
   Wilson, Richard K.
   Heckenlively, John R.
   Chew, Emily Y.
   Stambolian, Dwight
   Mardis, Elaine R.
   Swaroop, Anand
   Abecasis, Goncalo R.
TI Identification of a rare coding variant in complement 3 associated with
   age-related macular degeneration
SO NATURE GENETICS
LA English
DT Article
ID HEMOLYTIC-UREMIC SYNDROME; GENOME-WIDE ASSOCIATION; FACTOR-H
   POLYMORPHISM; COMMON DISEASES; SEQUENCING DATA; EYE DISEASE; FACTOR-B;
   RISK; SUSCEPTIBILITY; MUTATIONS
AB Macular degeneration is a common cause of blindness in the elderly. To identify rare coding variants associated with a large increase in risk of age-related macular degeneration (AMD), we sequenced 2,335 cases and 789 controls in 10 candidate loci (57 genes). To increase power, we augmented our control set with ancestry-matched exome-sequenced controls. An analysis of coding variation in 2,268 AMD cases and 2,268 ancestry-matched controls identified 2 large-effect rare variants: previously described p. Arg1210Cys encoded in the CFH gene (case frequency (f(case)) = 0.51%; control frequency (f(control)) = 0.02%; odds ratio (OR) = 23.11) and newly identified p. Lys155Gln encoded in the C3 gene (f(case) = 1.06%; f(control) = 0.39%; OR = 2.68). The variants suggest decreased inhibition of C3 by complement factor H, resulting in increased activation of the alternative complement pathway, as a key component of disease biology.
C1 [Zhan, Xiaowei; Wang, Chaolong; Bragg-Gresham, Jennifer; Jun, Goo; Hu, Youna; Kang, Hyun Min; Liu, Dajiang; Abecasis, Goncalo R.] Univ Michigan, Sch Publ Hlth, Dept Biostat, Ctr Stat Genet, Ann Arbor, MI 48109 USA.
   [Larson, David E.; Koboldt, Daniel C.; Fulton, Robert S.; Fulton, Lucinda L.; Fronick, Catrina C.; Wilson, Richard K.; Mardis, Elaine R.] Washington Univ, Sch Med, Genome Inst, St Louis, MO USA.
   [Wang, Chaolong] Harvard Univ, Sch Publ Hlth, Dept Biostat, Boston, MA 02115 USA.
   [Sergeev, Yuri V.] NEI, Ophthalm Genet & Visual Funct Branch, Bethesda, MD 20892 USA.
   [Branham, Kari E.; Othman, Mohammad; Heckenlively, John R.] Univ Michigan, Kellogg Eye Ctr, Dept Ophthalmol & Visual Sci, Ann Arbor, MI 48109 USA.
   [Brooks, Matthew; Ratnapriya, Rinki; Boleda, Alexis; Swaroop, Anand] NEI, US Natl Inst Hlth, Neurobiol Neurodegenerat & Repair Lab, Bethesda, MD 20892 USA.
   [Grassmann, Felix; Weber, Bernhard H. F.] Univ Regensburg, Inst Human Genet, D-93053 Regensburg, Germany.
   [von Strachwitz, Claudia] Southwest Eye Ctr, Stuttgart, Germany.
   [Olson, Lana M.; Haines, Jonathan L.] Vanderbilt Univ, Sch Med, Ctr Human Genet Res, Nashville, TN 37212 USA.
   [Olson, Lana M.; Haines, Jonathan L.] Vanderbilt Univ, Sch Med, Dept Mol Physiol & Biophys, Nashville, TN 37212 USA.
   [Buitendijk, Gabrielle H. S.; Klaver, Caroline C. W.] Erasmus MC, Dept Ophthalmol, Rotterdam, Netherlands.
   [Buitendijk, Gabrielle H. S.; Hofman, Albert; van Duijn, Cornelia M.; Klaver, Caroline C. W.] Erasmus MC, Dept Epidemiol, Rotterdam, Netherlands.
   [Hofman, Albert] Netherlands Genom Initiat, Netherlands Consortium Hlth Aging, The Hague, Netherlands.
   [Cipriani, Valentina; Moore, Anthony T.; Yates, John R. W.] UCL, UCL Inst Ophthalmol, London, England.
   [Cipriani, Valentina; Moore, Anthony T.; Yates, John R. W.] Moorfields Eye Hosp, London, England.
   [Shahid, Humma; Yates, John R. W.] Univ Cambridge, Cambridge Inst Med Res, Dept Med Genet, Cambridge, England.
   [Shahid, Humma] Cambridge Univ Hosp Natl Hlth Serv NHS Fdn Trust, Cambridge, England.
   [Jiang, Yingda; Weeks, Daniel E.] Univ Pittsburgh, Grad Sch Publ Hlth, Dept Biostat, Pittsburgh, PA 15261 USA.
   [Conley, Yvette P.] Univ Pittsburgh, Grad Sch Publ Hlth, Dept Hlth Promot & Dev, Pittsburgh, PA USA.
   [Morgan, Denise J.; DeAngelis, Margaret M.] Univ Utah, John A Moran Eye Ctr, Dept Ophthalmol & Visual Sci, Salt Lake City, UT USA.
   [Kim, Ivana K.] Harvard Univ, Massachusetts Eye & Ear Infirm, Sch Med, Retina Serv, Boston, MA USA.
   [Kim, Ivana K.] Harvard Univ, Massachusetts Eye & Ear Infirm, Sch Med, Boston, MA USA.
   [Johnson, Matthew P.; Blangero, John] Texas Biomed Res Inst, San Antonio, TX USA.
   [Cantsilieris, Stuart; Richardson, Andrea J.; Guymer, Robyn H.; Baird, Paul N.] Univ Melbourne, Royal Victorian Eye & Ear Hosp, Ctr Eye Res Australia, East Melbourne, Vic, Australia.
   [Luo, Hongrong; Ouyang, Hong; Zhang, Mindy M.; Zhang, Kang] Univ Calif San Diego, Dept Ophthalmol, Shiley Eye Ctr, La Jolla, CA 92093 USA.
   [Luo, Hongrong; Ouyang, Hong; Zhang, Mindy M.; Zhang, Kang] Univ Calif San Diego, Inst Genom Med, La Jolla, CA 92093 USA.
   [Licht, Christoph] Hosp Sick Children, Dept Pediat, Toronto, ON M5G 1X8, Canada.
   [Pluthero, Fred G.] Hosp Sick Children, Cell Biol Program, Toronto, ON M5G 1X8, Canada.
   [Klein, Michael L.] Oregon Hlth & Sci Univ, Casey Eye Inst, Macular Degenerat Ctr, Portland, OR 97201 USA.
   [Farrer, Lindsay A.] Boston Univ, Sch Med, Dept Med, Sect Biomed Genet, Boston, MA 02118 USA.
   [Farrer, Lindsay A.] Boston Univ, Sch Publ Hlth, Boston, MA 02118 USA.
   [Farrer, Lindsay A.] Boston Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02118 USA.
   [Farrer, Lindsay A.] Boston Univ, Sch Publ Hlth, Dept Biostat, Boston, MA USA.
   [Farrer, Lindsay A.] Boston Univ, Sch Med, Dept Neurol, Boston, MA 02118 USA.
   [Farrer, Lindsay A.] Boston Univ, Sch Med, Dept Ophthalmol, Boston, MA 02118 USA.
   [Weeks, Daniel E.] Univ Pittsburgh, Grad Sch Publ Hlth, Dept Human Genet, Pittsburgh, PA 15261 USA.
   [Gorin, Michael B.] Univ Calif Los Angeles, David Geffen Sch Med, Jules Stein Eye Inst, Dept Ophthalmol, Los Angeles, CA 90095 USA.
   [Pericak-Vance, Margaret A.] Univ Miami, Miller Sch Med, John P Hussman Inst Human Genom, Miami, FL 33136 USA.
   [Chew, Emily Y.] NEI, US Natl Inst Hlth, Div Epidemiol & Clin Applicat, Bethesda, MD 20892 USA.
   [Stambolian, Dwight] Univ Penn, Sch Med, Dept Ophthalmol & Human Genet, Philadelphia, PA 19104 USA.
C3 University of Michigan System; University of Michigan; Washington
   University (WUSTL); Harvard University; Harvard T.H. Chan School of
   Public Health; National Institutes of Health (NIH) - USA; NIH National
   Eye Institute (NEI); University of Michigan System; University of
   Michigan; National Institutes of Health (NIH) - USA; NIH National Eye
   Institute (NEI); University of Regensburg; Vanderbilt University;
   Vanderbilt University; Erasmus University Rotterdam; Erasmus MC; Erasmus
   University Rotterdam; Erasmus MC; University of London; University
   College London; University of London; University College London;
   Moorfields Eye Hospital NHS Foundation Trust; University of Cambridge;
   Pennsylvania Commonwealth System of Higher Education (PCSHE); University
   of Pittsburgh; Pennsylvania Commonwealth System of Higher Education
   (PCSHE); University of Pittsburgh; Utah System of Higher Education;
   University of Utah; Harvard University; Harvard Medical School;
   Massachusetts Eye & Ear Infirmary; Harvard University; Harvard Medical
   School; Massachusetts Eye & Ear Infirmary; Texas Biomedical Research
   Institute; Centre for Eye Research Australia; Royal Victorian Eye & Ear
   Hospital; University of Melbourne; University of California System;
   University of California San Diego; University of California System;
   University of California San Diego; University of Toronto; University
   Toronto Affiliates; Hospital for Sick Children (SickKids); University of
   Toronto; University Toronto Affiliates; Hospital for Sick Children
   (SickKids); Oregon Health & Science University; Boston University;
   Boston University; Boston University; Boston University; Boston
   University; Boston University; Pennsylvania Commonwealth System of
   Higher Education (PCSHE); University of Pittsburgh; University of
   California System; University of California Los Angeles; University of
   California Los Angeles Medical Center; David Geffen School of Medicine
   at UCLA; University of Miami; National Institutes of Health (NIH) - USA;
   NIH National Eye Institute (NEI); University of Pennsylvania
RP Abecasis, GR (通讯作者)，Univ Michigan, Sch Publ Hlth, Dept Biostat, Ctr Stat Genet, Ann Arbor, MI 48109 USA.
EM goncalo@umich.edu
RI Branham, Kari/AAA-8336-2022; Haines, Jonathan/C-3374-2012; Pluthero,
   Fred/T-8593-2019; Weeks, Daniel E/B-2995-2012; Jun, Goo/M-5235-2016;
   Farrer, Lindsay/AAS-1035-2020; Blangero, John/ABA-7175-2021; Jun,
   Goo/F-1941-2017; luo, hongrong/B-2714-2015; Wilson, Richard
   K./AAF-4139-2019; Mardis, Elaine/W-2202-2019; Cipriani,
   Valentina/A-8549-2012; DeAngelis, e/J-7863-2015; Zhang,
   Kang/Y-2740-2019; Klaver, Caroline C.W./A-2013-2016
OI Haines, Jonathan/0000-0002-4351-4728; Weeks, Daniel
   E/0000-0001-9410-7228; Jun, Goo/0000-0003-0891-0204; Jun,
   Goo/0000-0003-0891-0204; luo, hongrong/0000-0001-7994-1193; Wilson,
   Richard K./0000-0002-1992-1358; Cipriani, Valentina/0000-0002-0839-9955;
   Zhang, Kang/0000-0002-4549-1697; Larson, David/0000-0001-7934-5906;
   Baird, Paul/0000-0002-1305-3502; Farrer, Lindsay/0000-0001-5533-4225;
   Ouyang, Hong/0000-0002-7622-7733; Klaver, Caroline/0000-0002-2355-5258;
   Swaroop, Anand/0000-0002-1975-1141; Pluthero, Fred/0000-0002-0451-5840;
   Grassmann, Felix/0000-0003-1390-7528; Ratnapriya,
   Rinki/0000-0002-0469-4631; Guymer, Robyn/0000-0002-9441-4356; Van Duijn,
   Cornelia/0000-0002-2374-9204; Kim, Ivana/0000-0003-0310-6129; Branham,
   Kari/0000-0002-2492-254X; Wang, Chaolong/0000-0003-3945-1012; Liu,
   Dajiang/0000-0001-6553-858X; Conley, Yvette/0000-0002-1784-6067
FU US National Institutes of Health (National Eye Institute, National Human
   Genome Research Institute) [EY022005, HG007022, HG005552, EY016862,
   U54HG003079, EY09859]; Medical Research Council, UK [G0000067]; Deutsche
   Forschungsgemeinschaft [WE1259/19-2]; Thome Memorial Foundation; Harold
   and Pauline Price Foundation; Medical Research Council [MR/K006584/1,
   G0000067] Funding Source: researchfish; National Institute for Health
   Research [NF-SI-0507-10204] Funding Source: researchfish; NATIONAL EYE
   INSTITUTE [R01EY022005, R01EY021532, ZIAEY000476, R01EY009859,
   ZIAEY000475, R01EY016862, R01EY012118] Funding Source: NIH RePORTER;
   NATIONAL HUMAN GENOME RESEARCH INSTITUTE [U01HG006513, U54HG003079,
   R01HG007022, RC2HG005552] Funding Source: NIH RePORTER; NATIONAL
   INSTITUTE OF MENTAL HEALTH [R01MH084698] Funding Source: NIH RePORTER;
   MRC [G0000067] Funding Source: UKRI
FX We thank all study participants for their generous volunteering. We
   thank B. Li, W. Chen, C. Sidore, T. Teslovich, L. Fritsche and M.
   Boehnke for useful discussion and suggestions. This project was
   supported by grants from the US National Institutes of Health (National
   Eye Institute, National Human Genome Research Institute; grants
   EY022005, HG007022, HG005552, EY016862, U54HG003079 and EY09859); the
   Medical Research Council, UK (grant G0000067); the Deutsche
   Forschungsgemeinschaft (grant WE1259/19-2); the Alcon Research
   Institute; The UK Department of Health's National Institute for Health
   Research (NIHR) Biomedical Research Centre for Ophthalmology at
   Moorfields Eye Hospital and the UCL Institute of Ophthalmology; Research
   to Prevent Blindness (New York); the Thome Memorial Foundation; the
   Harold and Pauline Price Foundation; and the National Health and Medical
   Research Council of Australia (NHMRC) Clinical Research Excellence
   (grant 529923, NHMRC practitioner fellowship 529905 and NHMRC Senior
   Research Fellowship 1028444). The study was also supported by the
   Intramural Research Program (Computational Medicine Initiative) of the
   National Eye Institute. The Centre for Eye Research Australia (CERA)
   receives operational infrastructure support from the Victorian
   Government. The views expressed in the publication are those of the
   authors and not necessarily those of their employers or the funders.
CR Altshuler DM, 2012, NATURE, V491, P56, DOI 10.1038/nature11632
   Anand R, 2000, OPHTHALMOLOGY, V107, P2224
   Arakawa S, 2011, NAT GENET, V43, P1001, DOI 10.1038/ng.938
   Burton PR, 2007, NATURE, V447, P661, DOI 10.1038/nature05911
   Chen W, 2010, P NATL ACAD SCI USA, V107, P7401, DOI 10.1073/pnas.0912702107
   Chew EY, 2012, OPHTHALMOLOGY, V119, P2282, DOI 10.1016/j.ophtha.2012.05.027
   Cox D.R., 1989, MONOGRAPHS STAT APPL, V2nd ed.
   Dewan A, 2006, SCIENCE, V314, P989, DOI 10.1126/science.1133807
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Fagerness JA, 2009, EUR J HUM GENET, V17, P100, DOI 10.1038/ejhg.2008.140
   Ferreira VP, 2009, J IMMUNOL, V182, P7009, DOI 10.4049/jimmunol.0804031
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Fritsche LG, 2008, NAT GENET, V40, P892, DOI 10.1038/ng.170
   Fritsche LG, 2013, NAT GENET, V45, P433, DOI 10.1038/ng.2578
   Fu WQ, 2013, NATURE, V493, P216, DOI 10.1038/nature11690
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Helgason H, 2013, NAT GENET, V45, P1371, DOI 10.1038/ng.2740
   Heurich M, 2011, P NATL ACAD SCI USA, V108, P8761, DOI 10.1073/pnas.1019338108
   HIRJI KF, 1987, J AM STAT ASSOC, V82, P1110, DOI 10.2307/2289388
   Jakobsdottir J, 2005, AM J HUM GENET, V77, P389, DOI 10.1086/444437
   Jozsi M, 2006, J AM SOC NEPHROL, V17, P170, DOI 10.1681/ASN.2005080868
   Jun G, 2012, AM J HUM GENET, V91, P839, DOI 10.1016/j.ajhg.2012.09.004
   Kanda A, 2007, P NATL ACAD SCI USA, V104, P16227, DOI 10.1073/pnas.0703933104
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Li BS, 2008, AM J HUM GENET, V83, P311, DOI 10.1016/j.ajhg.2008.06.024
   Li H, 2009, BIOINFORMATICS, V25, P1754, DOI 10.1093/bioinformatics/btp324
   Li JZ, 2008, SCIENCE, V319, P1100, DOI 10.1126/science.1153717
   Maller JB, 2007, NAT GENET, V39, P1200, DOI 10.1038/ng2131
   Manuelian T, 2003, J CLIN INVEST, V111, P1181, DOI 10.1172/JCI200316651
   Mathieson I, 2012, NAT GENET, V44, P243, DOI 10.1038/ng.1074
   McKenna A, 2010, GENOME RES, V20, P1297, DOI 10.1101/gr.107524.110
   Nejentsev S, 2009, SCIENCE, V324, P387, DOI 10.1126/science.1167728
   Price AL, 2010, AM J HUM GENET, V86, P832, DOI 10.1016/j.ajhg.2010.04.005
   Priya RR, 2012, OPHTHALMOLOGY, V119, P2526, DOI 10.1016/j.ophtha.2012.06.042
   Raychaudhuri S, 2011, NAT GENET, V43, P1232, DOI 10.1038/ng.976
   Rivera A, 2005, HUM MOL GENET, V14, P3227, DOI 10.1093/hmg/ddi353
   ROSENBAUM PR, 1983, BIOMETRIKA, V70, P41, DOI 10.1093/biomet/70.1.41
   Sanchez-Corral P, 2002, AM J HUM GENET, V71, P1285, DOI 10.1086/344515
   Swaroop A, 2009, ANNU REV GENOM HUM G, V10, P19, DOI 10.1146/annurev.genom.9.081307.164350
   Tennessen JA, 2012, SCIENCE, V337, P64, DOI 10.1126/science.1219240
   Wu MC, 2011, AM J HUM GENET, V89, P82, DOI 10.1016/j.ajhg.2011.05.029
   Yates JRW, 2007, NEW ENGL J MED, V357, P553, DOI 10.1056/NEJMoa072618
NR 43
TC 128
Z9 129
U1 0
U2 28
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 1061-4036
EI 1546-1718
J9 NAT GENET
JI Nature Genet.
PD NOV
PY 2013
VL 45
IS 11
BP 1375
EP +
DI 10.1038/ng.2758
PG 7
WC Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Genetics & Heredity
GA 244JL
UT WOS:000326384100020
PM 24036949
OA Green Accepted, Green Submitted
DA 2022-11-30
ER

PT J
AU Wang, J
   Zibetti, C
   Shang, P
   Sripathi, SR
   Zhang, PW
   Cano, M
   Hoang, T
   Xia, SL
   Ji, HK
   Merbs, SL
   Zack, DJ
   Handa, JT
   Sinha, D
   Blackshaw, S
   Qian, J
AF Wang, Jie
   Zibetti, Cristina
   Shang, Peng
   Sripathi, Srinivasa R.
   Zhang, Pingwu
   Cano, Marisol
   Thanh Hoang
   Xia, Shuli
   Ji, Hongkai
   Merbs, Shannath L.
   Zack, Donald J.
   Handa, James T.
   Sinha, Debasish
   Blackshaw, Seth
   Qian, Jiang
TI ATAC-Seq analysis reveals a widespread decrease of chromatin
   accessibility in age-related macular degeneration
SO NATURE COMMUNICATIONS
LA English
DT Article
ID HISTONE DEACETYLASE INHIBITORS; RETINAL-PIGMENT EPITHELIUM; BODY-MASS
   INDEX; GENE-EXPRESSION; DNA METHYLATION; COMPREHENSIVE ANALYSIS; IL17RC
   PROMOTER; MECHANISMS; CELLS; HYPOMETHYLATION
AB Age-related macular degeneration (AMD) is a significant cause of vision loss in the elderly. The extent to which epigenetic changes regulate AMD progression is unclear. Here we globally profile chromatin accessibility using ATAC-Seq in the retina and retinal pigmented epithelium (RPE) from AMD and control patients. Global decreases in chromatin accessibility occur in the RPE with early AMD, and in the retina of advanced disease, suggesting that dysfunction in the RPE drives disease onset. Footprints of photoreceptor and RPE-specific transcription factors are enriched in differentially accessible regions (DARs). Genes associated with DARs show altered expression in AMD. Cigarette smoke treatment of RPE cells recapitulates chromatin accessibility changes seen in AMD, providing an epigenetic link between a known risk factor for AMD and AMD pathology. Finally, overexpression of HDAC11 is partially responsible for the observed reduction in chromatin accessibility, suggesting that HDAC11 may be a potential new therapeutic target for AMD.
C1 [Wang, Jie; Shang, Peng; Sripathi, Srinivasa R.; Zhang, Pingwu; Cano, Marisol; Merbs, Shannath L.; Zack, Donald J.; Handa, James T.; Sinha, Debasish; Blackshaw, Seth; Qian, Jiang] Johns Hopkins Univ, Sch Med, Dept Ophthalmol, Baltimore, MD 21205 USA.
   [Zibetti, Cristina; Thanh Hoang; Blackshaw, Seth] Johns Hopkins Univ, Sch Med, Solomon H Snyder Dept Neurosci, Baltimore, MD 21205 USA.
   [Xia, Shuli; Blackshaw, Seth] Johns Hopkins Univ, Sch Med, Dept Neurol, Baltimore, MD 21205 USA.
   [Xia, Shuli] Johns Hopkins Univ, Sch Med, Hugo W Moser Res Inst Kennedy Krieger, Baltimore, MD 21205 USA.
   [Ji, Hongkai] Johns Hopkins Bloomberg, Sch Publ Hlth, Dept Biostat, Baltimore, MD 21205 USA.
   [Blackshaw, Seth] Johns Hopkins Univ, Sch Med, Ctr Human Syst Biol, Baltimore, MD 21205 USA.
   [Blackshaw, Seth] Johns Hopkins Univ, Sch Med, Inst Cell Engn, Baltimore, MD 21205 USA.
   [Shang, Peng; Sinha, Debasish] Univ Pittsburgh, Sch Med, Dept Ophthalmol, Pittsburgh, PA 15224 USA.
   [Shang, Peng; Sinha, Debasish] Univ Pittsburgh, Sch Med, Dept Cell Biol, Pittsburgh, PA 15224 USA.
   [Shang, Peng; Sinha, Debasish] Univ Pittsburgh, Sch Med, Dept Dev Biol, Pittsburgh, PA 15224 USA.
C3 Johns Hopkins University; Johns Hopkins University; Johns Hopkins
   University; Johns Hopkins University; Johns Hopkins University; Johns
   Hopkins Bloomberg School of Public Health; Johns Hopkins University;
   Johns Hopkins University; Pennsylvania Commonwealth System of Higher
   Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth
   System of Higher Education (PCSHE); University of Pittsburgh;
   Pennsylvania Commonwealth System of Higher Education (PCSHE); University
   of Pittsburgh
RP Blackshaw, S; Qian, J (通讯作者)，Johns Hopkins Univ, Sch Med, Dept Ophthalmol, Baltimore, MD 21205 USA.; Blackshaw, S (通讯作者)，Johns Hopkins Univ, Sch Med, Solomon H Snyder Dept Neurosci, Baltimore, MD 21205 USA.; Blackshaw, S (通讯作者)，Johns Hopkins Univ, Sch Med, Dept Neurol, Baltimore, MD 21205 USA.; Blackshaw, S (通讯作者)，Johns Hopkins Univ, Sch Med, Ctr Human Syst Biol, Baltimore, MD 21205 USA.; Blackshaw, S (通讯作者)，Johns Hopkins Univ, Sch Med, Inst Cell Engn, Baltimore, MD 21205 USA.
EM sblack@jhmi.edu; jiang.qian@jhmi.edu
RI Zibetti, Cristina/V-7566-2019
OI Zibetti, Cristina/0000-0003-4922-1245; Wang, Jie/0000-0002-7491-7001;
   /0000-0002-3780-5641
FU NIH [R01EY024580, R01EY023188, R01EY020560, R01EY027691]; Macular
   Degeneration Foundation [R01NS091165]; RPB/IRRF Catalyst Award for
   Innovative Research Approaches for AMD; NATIONAL EYE INSTITUTE
   [R01EY020560] Funding Source: NIH RePORTER
FX This work was supported by NIH grants R01EY024580 (to J.Q.), R01EY023188
   (to S.L.M. and J.Q.), R01EY020560 (to S.B.), R01EY027691, Macular
   Degeneration Foundation (to J.T.H.), R01NS091165 (to S.X.), and RPB/IRRF
   Catalyst Award for Innovative Research Approaches for AMD (D.S.). We
   thank Akrit Sodhi, Jeff Mumm, and Albert Jun for insightful discussions.
CR Ambati J, 2012, NEURON, V75, P26, DOI 10.1016/j.neuron.2012.06.018
   Anders S, 2015, BIOINFORMATICS, V31, P166, DOI 10.1093/bioinformatics/btu638
   Bhise NS, 2013, INT J NANOMED, V8, P4641, DOI 10.2147/IJN.S53830
   Bhutto I, 2012, MOL ASPECTS MED, V33, P295, DOI 10.1016/j.mam.2012.04.005
   Blackshaw S, 2004, PLOS BIOL, V2, P1411, DOI 10.1371/journal.pbio.0020247
   Blackshaw S, 2001, CELL, V107, P579, DOI 10.1016/S0092-8674(01)00574-8
   Bolger AM, 2014, BIOINFORMATICS, V30, P2114, DOI 10.1093/bioinformatics/btu170
   Buenrostro JD, 2013, NAT METHODS, V10, P1213, DOI [10.1038/NMETH.2688, 10.1038/nmeth.2688]
   Crosson CE, 2010, INVEST OPHTH VIS SCI, V51, P3639, DOI 10.1167/iovs.09-4538
   Denny SK, 2016, CELL, V166, P328, DOI 10.1016/j.cell.2016.05.052
   Eisenberg E, 2013, TRENDS GENET, V29, P569, DOI 10.1016/j.tig.2013.05.010
   Fan J, 2013, INVEST OPHTH VIS SCI, V54, P4072, DOI 10.1167/iovs.12-11529
   Fan J, 2015, ACS CHEM BIOL, V10, P95, DOI 10.1021/cb500846u
   Feinberg AP, 2007, NATURE, V447, P433, DOI 10.1038/nature05919
   Freund CL, 1998, NAT GENET, V18, P311, DOI 10.1038/ng0498-311
   Fritsche LG, 2016, NAT GENET, V48, P134, DOI 10.1038/ng.3448
   Fritsche LG, 2013, NAT GENET, V45, P433, DOI 10.1038/ng.2578
   Gorisch SM, 2005, J CELL SCI, V118, P5825, DOI 10.1242/jcs.02689
   Grant CE, 2011, BIOINFORMATICS, V27, P1017, DOI 10.1093/bioinformatics/btr064
   Hao H, 2012, PLOS GENET, V8, P380, DOI 10.1371/journal.pgen.1002649
   Hunter A, 2012, INVEST OPHTH VIS SCI, V53, P2089, DOI 10.1167/iovs.11-8449
   Irizarry RA, 2009, NAT GENET, V41, P178, DOI 10.1038/ng.298
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Kim D, 2008, NEURON, V60, P803, DOI 10.1016/j.neuron.2008.10.015
   Kim HJ, 2007, J PHARMACOL EXP THER, V321, P892, DOI 10.1124/jpet.107.120188
   Kim HJ, 2011, AM J TRANSL RES, V3, P166
   Koppenol WH, 2011, NAT REV CANCER, V11, P325, DOI 10.1038/nrc3038
   Krzywinski M, 2009, GENOME RES, V19, P1639, DOI 10.1101/gr.092759.109
   Langmead B, 2012, NAT METHODS, V9, P357, DOI [10.1038/NMETH.1923, 10.1038/nmeth.1923]
   Li H, 2009, BIOINFORMATICS, V25, P1754, DOI 10.1093/bioinformatics/btp324
   Li MY, 2014, HUM MOL GENET, V23, P4001, DOI 10.1093/hmg/ddu114
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Lin MT, 2006, NATURE, V443, P787, DOI 10.1038/nature05292
   Lu J, 2013, P NATL ACAD SCI USA, V110, P10747, DOI 10.1073/pnas.1308950110
   Macosko EZ, 2015, CELL, V161, P1202, DOI 10.1016/j.cell.2015.05.002
   Maruotti J, 2015, P NATL ACAD SCI USA, V112, P10950, DOI 10.1073/pnas.1422818112
   Maruotti J, 2013, STEM CELL TRANSL MED, V2, P341, DOI 10.5966/sctm.2012-0106
   Matsuda T, 2004, P NATL ACAD SCI USA, V101, P16, DOI 10.1073/pnas.2235688100
   Matys V, 2003, NUCLEIC ACIDS RES, V31, P374, DOI 10.1093/nar/gkg108
   Newman AM, 2012, GENOME MED, V4, DOI [10.1186/PREACCEPT-1418491035586234, 10.1186/gm315]
   Nishida A, 2003, NAT NEUROSCI, V6, P1255, DOI 10.1038/nn1155
   Oliver VF, 2015, EPIGENETICS-US, V10, P698, DOI 10.1080/15592294.2015.1060388
   Oliver VF, 2013, CELL REP, V5, P1527, DOI 10.1016/j.celrep.2013.11.042
   Robinson MD, 2010, BIOINFORMATICS, V26, P139, DOI 10.1093/bioinformatics/btp616
   Roesch K, 2008, J COMP NEUROL, V509, P225, DOI 10.1002/cne.21730
   Sancho-Pelluz J, 2010, CELL DEATH DIS, V1, DOI 10.1038/cddis.2010.4
   Sancho-Pelluz J, 2012, ADV EXP MED BIOL, V723, P107, DOI 10.1007/978-1-4614-0631-0_15
   Schultz MD, 2015, NATURE, V523, P212, DOI 10.1038/nature14465
   Seddon JM, 2006, HUM HERED, V61, P157, DOI 10.1159/000094141
   Seddon JM, 2010, MOL VIS, V16, P2412
   Siegert S, 2012, NAT NEUROSCI, V15, P487, DOI 10.1038/nn.3032
   Strunnikova NV, 2010, HUM MOL GENET, V19, P2468, DOI 10.1093/hmg/ddq129
   Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102
   Sung MH, 2014, MOL CELL, V56, P275, DOI 10.1016/j.molcel.2014.08.016
   Tan JSL, 2009, ARCH OPHTHALMOL-CHIC, V127, P656, DOI 10.1001/archophthalmol.2009.76
   Thurman RE, 2012, NATURE, V489, P75, DOI 10.1038/nature11232
   Trapnell C, 2012, NAT PROTOC, V7, P562, DOI 10.1038/nprot.2012.016
   Trimarchi JM, 2007, J COMP NEUROL, V502, P1047, DOI 10.1002/cne.21368
   van Leeuwen R, 2005, JAMA-J AM MED ASSOC, V294, P3101, DOI 10.1001/jama.294.24.3101
   Wang K, 2010, NUCLEIC ACIDS RES, V38, DOI 10.1093/nar/gkq603
   Wei L, 2012, CELL REP, V2, P1151, DOI 10.1016/j.celrep.2012.10.013
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Woodell A, 2014, ADV EXP MED BIOL, V801, P301, DOI 10.1007/978-1-4614-3209-8_38
   Wright AF, 2010, NAT REV GENET, V11, P273, DOI 10.1038/nrg2717
   Ying M, 2011, ONCOGENE, V30, P3454, DOI 10.1038/onc.2011.58
   Yu JY, 2007, SCIENCE, V318, P1917, DOI 10.1126/science.1151526
   Zhang Y, 2008, GENOME BIOL, V9, DOI 10.1186/gb-2008-9-9-r137
   Zhang ZZ, 2012, EXP EYE RES, V94, P98, DOI 10.1016/j.exer.2011.11.013
NR 68
TC 74
Z9 76
U1 2
U2 26
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2041-1723
J9 NAT COMMUN
JI Nat. Commun.
PD APR 10
PY 2018
VL 9
AR 1364
DI 10.1038/s41467-018-03856-y
PG 13
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA GC1ED
UT WOS:000429521300006
PM 29636475
OA Green Published, gold, Green Submitted
DA 2022-11-30
ER

PT J
AU Laude, A
   Tan, LE
   Wilson, CG
   Lascaratos, G
   Elashry, M
   Aslam, T
   Patton, N
   Dhillon, B
AF Laude, Augustinus
   Tan, Lay Ean
   Wilson, Clive G.
   Lascaratos, Gerassimos
   Elashry, Mohammed
   Aslam, Tariq
   Patton, Niall
   Dhillon, Baljean
TI Intravitreal therapy for neovascular age-related macular degeneration
   and inter-individual variations in vitreous pharmacokinetics
SO PROGRESS IN RETINAL AND EYE RESEARCH
LA English
DT Article
DE Intravitreal therapy; Age-related macular degeneration; Choroidal
   neovascularization; Pharmacokinetics; Vitreous; Injection
ID BLOOD-RETINA BARRIER; DRUG-DELIVERY; ACTIVE-TRANSPORT; TRIAMCINOLONE
   ACETONIDE; INTRAOCULAR-PRESSURE; DIFFUSIVE TRANSPORT; PEGAPTANIB SODIUM;
   VANCOMYCIN LEVELS; RHESUS-MONKEYS; GANGLION-CELLS
AB This article aims to provide an interpretation and perspective on current concepts and recent literature regarding the evidence for individualizing intravitreal therapy (IVT), particularly considering iatrogenic and patient factors in the management of neovascular age-related macular degeneration (AMD). As ocular parameters that govern IVT pharmacokinetics do vary between individuals with AMD, developing a personalized strategy could improve safety and efficacy. This has to be derived from clinical measurements and data from laboratory animals; however, it is recognized that the animal models used in the development of intraocular formulations differ in their vitreous geometry from humans. These factors may be of relevance to the design of ophthalmic formulations and optimizing treatment outcomes in AMD. Further studies are needed to drive improvements in clinical practice which are aimed at maximizing the efficacy profile in IVT for AMD by a more rigorous evaluation of patient and surgeon-related variables. (C) 2010 Elsevier Ltd. All rights reserved.
C1 [Laude, Augustinus] Tan Tock Seng Hosp, Natl Healthcare Grp Eye Inst, Singapore, Singapore.
   [Tan, Lay Ean; Wilson, Clive G.] Univ Strathclyde, Strathclyde Inst Pharm & Biomed Sci, Glasgow G1 1XQ, Lanark, Scotland.
   [Patton, Niall] Cent Manchester & Manchester Childrens Univ Hosp, Manchester Royal Eye Hosp, Manchester, Lancs, England.
C3 Tan Tock Seng Hospital; University of Strathclyde; Manchester Royal Eye
   Hospital
RP Dhillon, B (通讯作者)，Dept Ophthalmol, Chalmers St, Edinburgh EH3 9HA, Midlothian, Scotland.
EM bal.dhillon@luht.scot.nhs.uk
RI Lascaratos, Gerassimos/AAL-6344-2020; Aslam, Tariq/A-8532-2016
OI Aslam, Tariq/0000-0002-9739-7280
FU Tan Tock Seng Scholarship; Allergan Inc.
FX AL is supported by Tan Tock Seng Scholarship and LET is the recipient of
   an open educational grant from Allergan Inc.
CR ADELMAN R, 2009, AM AC OPHTH JOINT AN
   AGUILAR HE, 1995, RETINA-J RET VIT DIS, V15, P428
   Avci B, 2009, INVEST OPHTH VIS SCI, V50, P3438, DOI 10.1167/iovs.08-2871
   Bakri SJ, 2008, GRAEF ARCH CLIN EXP, V246, P955, DOI 10.1007/s00417-008-0819-2
   Bakri SJ, 2007, OPHTHALMOLOGY, V114, P855, DOI 10.1016/j.ophtha.2007.01.017
   BARZA M, 1983, INVEST OPHTH VIS SCI, V24, P1602
   BARZA M, 1982, INVEST OPHTH VIS SCI, V22, P720
   Benz MS, 2006, OPHTHALMOLOGY, V113, P1174, DOI 10.1016/j.ophtha.2005.10.061
   Boon CJF, 2008, OPHTHALMOLOGY, V115, P1268, DOI 10.1016/j.ophtha.2008.02.021
   Bressler NM, 2009, OPHTHALMOLOGY, V116, pS15, DOI 10.1016/j.ophtha.2009.06.048
   Cheng CK, 2009, RETINA-J RET VIT DIS, V29, P306, DOI 10.1097/IAE.0b013e3181909404
   Chin HS, 2005, RETINA-J RET VIT DIS, V25, P556, DOI 10.1097/00006982-200507000-00002
   Chuang GS, 2008, J AM ACAD DERMATOL, V59, P167, DOI 10.1016/j.jaad.2008.02.017
   COBO LM, 1981, AM J OPHTHALMOL, V92, P59, DOI 10.1016/S0002-9394(14)75908-2
   Dadgostar H, 2009, OPHTHALMOLOGY, V116, P1740, DOI 10.1016/j.ophtha.2009.05.033
   Drolet DW, 2000, PHARMACEUT RES, V17, P1503, DOI 10.1023/A:1007657109012
   ETER N, 2008, RANIBIZUMAB NEOVASCU
   Falavarjani KG, 2010, EYE, V24, P717, DOI 10.1038/eye.2009.94
   FICKER L, 1990, INVEST OPHTH VIS SCI, V31, P502
   FISHMAN GA, 1981, ARCH OPHTHALMOL-CHIC, V99, P1202
   FOULDS WS, 1985, BRIT J OPHTHALMOL, V69, P529, DOI 10.1136/bjo.69.7.529
   Foy JWD, 2007, J OCUL PHARMACOL TH, V23, P452, DOI 10.1089/jop.2006.0149
   Friedrich S, 1997, CURR EYE RES, V16, P663, DOI 10.1076/ceyr.16.7.663.5061
   Fung AE, 2006, BRIT J OPHTHALMOL, V90, P1344, DOI 10.1136/bjo.2006.099598
   Gan IM, 2005, GRAEF ARCH CLIN EXP, V243, P1186, DOI 10.1007/s00417-005-1182-1
   Gaudreault J, 2005, INVEST OPHTH VIS SCI, V46, P726, DOI 10.1167/iovs.04-0601
   Gisladottir S, 2009, GRAEF ARCH CLIN EXP, V247, P1677, DOI 10.1007/s00417-009-1141-3
   HEEGAARD S, 1986, GRAEF ARCH CLIN EXP, V224, P355, DOI 10.1007/BF02150029
   Heiduschka P, 2007, INVEST OPHTH VIS SCI, V48, P2814, DOI 10.1167/iovs.06-1171
   Hughes PM, 2005, ADV DRUG DELIVER REV, V57, P2010, DOI 10.1016/j.addr.2005.09.004
   HUGHES PM, 2008, ANG EX DEG M BASC PA
   Iriyama A, 2007, BRIT J OPHTHALMOL, V91, P1230, DOI 10.1136/bjo.2007.117309
   Jaffe NS, 1969, VITREOUS CLIN OPHTHA
   Jager RD, 2004, RETINA-J RET VIT DIS, V24, P676, DOI 10.1097/00006982-200410000-00002
   JONGEBLOED WL, 1987, DOC OPHTHALMOL, V67, P183, DOI 10.1007/BF00142712
   Kim JH, 2008, NEUROTOXICOLOGY, V29, P1131, DOI 10.1016/j.neuro.2008.06.006
   Kim JE, 2008, AM J OPHTHALMOL, V146, P930, DOI 10.1016/j.ajo.2008.07.007
   Knudsen LL, 2001, GRAEF ARCH CLIN EXP, V239, P832, DOI 10.1007/s004170100355
   Koeberle MJ, 2006, PHARM RES-DORDR, V23, P2781, DOI 10.1007/s11095-006-9106-2
   Lee SS, 2010, INVEST OPHTH VIS SCI, V51, P2135, DOI 10.1167/iovs.09-3582
   Lopez-Cortes LF, 2001, INVEST OPHTH VIS SCI, V42, P1024
   Lopez-Guajardo L, 2008, EYE, V22, P430, DOI 10.1038/sj.eye.6703054
   Lund-Anderson H, 2003, ADLERS PHYSL EYE, P293
   LUNT R, 1978, HDB ULTRASONIC B SCA, P18
   Majumdar S, 2006, J OCUL PHARMACOL TH, V22, P231, DOI 10.1089/jop.2006.22.231
   MANDELL BA, 1993, AM J OPHTHALMOL, V115, P770, DOI 10.1016/S0002-9394(14)73646-3
   Mannermaa E, 2006, ADV DRUG DELIVER REV, V58, P1136, DOI 10.1016/j.addr.2006.07.024
   Maurice D, 2001, J OCUL PHARMACOL TH, V17, P393, DOI 10.1089/108076801753162807
   Maurice D. M., 1984, HANDB EXP PHARM, P19
   MAURICE DM, 1976, S OCULAR THERAPY, P59
   Meredith T. A., 2006, INTRAOCULAR DRUG DEL, P85
   MEREDITH TA, 1995, AM J OPHTHALMOL, V119, P774, DOI 10.1016/S0002-9394(14)72784-9
   Missel PJ, 2002, PHARMACEUT RES, V19, P1636, DOI 10.1023/A:1020940927675
   Mitchell P, 2010, BRIT J OPHTHALMOL, V94, P2, DOI 10.1136/bjo.2009.159160
   Moldow B, 2001, BRIT J OPHTHALMOL, V85, P592, DOI 10.1136/bjo.85.5.592
   Moldow B, 1998, GRAEF ARCH CLIN EXP, V236, P881, DOI 10.1007/s004170050175
   Moldow B, 1999, INVEST OPHTH VIS SCI, V40, P1770
   MOSELEY H, 1984, BRIT J OPHTHALMOL, V68, P145, DOI 10.1136/bjo.68.3.145
   OGURA Y, 1985, INVEST OPHTH VIS SCI, V26, P969
   OGURA Y, 1989, RETINA-J RET VIT DIS, V9, P199, DOI 10.1097/00006982-198909030-00007
   Park J, 2005, J CONTROL RELEASE, V105, P279, DOI 10.1016/j.jconrel.2005.03.010
   Peeters L, 2005, INVEST OPHTH VIS SCI, V46, P3553, DOI 10.1167/iovs.05-0165
   PFLUGFELDER SC, 1987, ARCH OPHTHALMOL-CHIC, V105, P831, DOI 10.1001/archopht.1987.01060060117045
   Pitkanen Leena, 2004, AAPS J, V6, pe25
   PRAGER TC, 1982, ARCH OPHTHALMOL-CHIC, V100, P594
   Richtig E, 2004, EYE, V18, P619, DOI 10.1038/sj.eye.6700720
   Rodrigues EB, 2007, AM J OPHTHALMOL, V143, P1035, DOI 10.1016/j.ajo.2007.01.035
   Rosenfeld PJ, 2005, OPHTHALMOLOGY, V112, P1048, DOI 10.1016/j.ophtha.2005.01.043
   Sander B, 2001, INVEST OPHTH VIS SCI, V42, P433
   SCHINDLER RH, 1982, AM J OPHTHALMOL, V93, P415, DOI 10.1016/0002-9394(82)90130-1
   Short BG, 2008, TOXICOL PATHOL, V36, P49, DOI 10.1177/0192623307310955
   SINGH S, 2008, RETIN CASES BRIEF RE, V2, P253
   Spitzer MS, 2006, BRIT J OPHTHALMOL, V90, P1316, DOI 10.1136/bjo.2006.095190
   Stay MS, 2003, PHARM RES-DORDR, V20, P96, DOI 10.1023/A:1022207026982
   TAN LE, 2009, ARVO SUMM EYE RES C
   Wu L, 2008, GRAEF ARCH CLIN EXP, V246, P81, DOI 10.1007/s00417-007-0660-z
   Xu J, 2000, PHARMACEUT RES, V17, P664, DOI 10.1023/A:1007517912927
   YOSHIDA A, 1984, ARCH OPHTHALMOL-CHIC, V102, P857
   Zhu Q, 2008, OPHTHALMOLOGY, V115, P1750, DOI 10.1016/j.ophtha.2008.04.023
NR 79
TC 62
Z9 64
U1 0
U2 13
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 1350-9462
EI 1873-1635
J9 PROG RETIN EYE RES
JI Prog. Retin. Eye Res.
PD NOV
PY 2010
VL 29
IS 6
BP 466
EP 475
DI 10.1016/j.preteyeres.2010.04.003
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 683BJ
UT WOS:000284446400002
PM 20452456
DA 2022-11-30
ER

PT J
AU Pennington, KL
   DeAngelis, MM
AF Pennington, Katie L.
   DeAngelis, Margaret M.
TI Epidemiology of age-related macular degeneration (AMD): associations
   with cardiovascular disease phenotypes and lipid factors
SO EYE AND VISION
LA English
DT Review
DE Atherosclerosis; Hypertension; Retina; Statins; Stroke; Cholesterol;
   Obesity; BMI; Antioxidants; Genetic association
ID CORONARY-ARTERY-DISEASE; CHOROIDAL BLOOD-FLOW; CHOLESTEROL-LOWERING
   MEDICATIONS; PHOSPHOLIPID TRANSFER PROTEIN; REDUCTASE INHIBITORS
   STATINS; GENOME-WIDE ASSOCIATION; RISK-FACTORS; EYE DISEASE; OXIDATIVE
   STRESS; 5-YEAR INCIDENCE
AB Age-related macular degeneration (AMD) is the leading cause of irreversible blindness in adults over 50 years old. Genetic, epidemiological, and molecular studies are beginning to unravel the intricate mechanisms underlying this complex disease, which implicate the lipid-cholesterol pathway in the pathophysiology of disease development and progression. Many of the genetic and environmental risk factors associated with AMD are also associated with other complex degenerative diseases of advanced age, including cardiovascular disease (CVD). In this review, we present epidemiological findings associating AMD with a variety of lipid pathway genes, cardiovascular phenotypes, and relevant environmental exposures. Despite a number of studies showing significant associations between AMD and these lipid/cardiovascular factors, results have been mixed and as such the relationships among these factors and AMD remain controversial. It is imperative that researchers not only tease out the various contributions of such factors to AMD development but also the connections between AMD and CVD to develop optimal precision medical care for aging adults.
C1 [Pennington, Katie L.; DeAngelis, Margaret M.] Univ Utah, Dept Ophthalmol, John A Moran Eye Ctr, Salt Lake City, UT 84112 USA.
C3 Utah System of Higher Education; University of Utah
RP DeAngelis, MM (通讯作者)，Univ Utah, Dept Ophthalmol, John A Moran Eye Ctr, Salt Lake City, UT 84112 USA.
EM margaret.deangelis@utah.edu
OI Pennington, Katie/0000-0003-2883-0025
FU National Institutes of Health National Eye Institute [EY014800];
   National Institutes of Health National Eye Institute Ruth L. Kirschstein
   National Research Service Award T32 [EY024234]; Research to Prevent
   Blindness, Inc., New York, NY; ARVO Foundation for Eye Research; Skaggs
   Foundation for Research; Carl Marshall Reeves & Mildred Almen Reeves
   Foundation, Inc.; Center of Aging Pilot Award, Division of Geriatrics,
   University of Utah; Macular Degeneration Foundation, Inc.; NATIONAL EYE
   INSTITUTE [T32EY024234, P30EY014800] Funding Source: NIH RePORTER
FX This work was supported by the National Institutes of Health National
   Eye Institute (EY014800); the National Institutes of Health National Eye
   Institute Ruth L. Kirschstein National Research Service Award T32
   (EY024234); an Unrestricted Grant from Research to Prevent Blindness,
   Inc., New York, NY, to the Department of Ophthalmology & Visual
   Sciences, University of Utah; the ARVO Foundation for Eye Research; The
   Skaggs Foundation for Research; The Carl Marshall Reeves & Mildred Almen
   Reeves Foundation, Inc.; the Center of Aging Pilot Award, Division of
   Geriatrics, University of Utah; and the Macular Degeneration Foundation,
   Inc.
CR Abalain JH, 2002, CLIN CHIM ACTA, V326, P97, DOI 10.1016/S0009-8981(02)00288-7
   Age-Related Eye Dis Study Res Grp, 2001, AM J OPHTHALMOL, V132, P668
   AGELLON LB, 1991, J BIOL CHEM, V266, P10796
   Al-Holou SN, 2015, OPHTHALMOLOGY, V122, P2490, DOI 10.1016/j.ophtha.2015.08.028
   Albers JJ, 1996, INT J CLIN LAB RES, V26, P262, DOI 10.1007/BF02602960
   Amoaku WM, 2015, EYE, V29, P721, DOI 10.1038/eye.2015.48
   Anand R, 2000, OPHTHALMOLOGY, V107, P2224
   Armstrong Richard A, 2015, J Stem Cells, V10, P171
   Badimon L, 2014, J INTERN MED, V276, P618, DOI 10.1111/joim.12296
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   Berenberg TL, 2012, RETINA-J RET VIT DIS, V32, P25, DOI 10.1097/IAE.0b013e3182150483
   Berglind IA, 2015, MENOPAUSE, V22, P369, DOI [10.1097/GME.0000000000000345, 10.1097/gme.0000000000000345]
   Bhutto I, 2012, MOL ASPECTS MED, V33, P295, DOI 10.1016/j.mam.2012.04.005
   Black JRM, 2016, GENET MED, V18, P283, DOI 10.1038/gim.2015.70
   Blasiak J, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/768026
   Bonds DE, 2014, JAMA INTERN MED, V174, P763, DOI 10.1001/jamainternmed.2014.328
   Booij JC, 2010, PROG RETIN EYE RES, V29, P1, DOI 10.1016/j.preteyeres.2009.08.003
   Buch H, 2005, OPHTHALMOLOGY, V112, P787, DOI 10.1016/j.ophtha.2004.11.040
   Campagne MV, 2016, IMMUNOBIOLOGY, V221, P733, DOI 10.1016/j.imbio.2015.11.007
   Castellon X, 2016, AGING DIS, V7, DOI 10.14336/AD.2015.0803
   Chakravarthy U, 2010, BMC OPHTHALMOL, V10, DOI 10.1186/1471-2415-10-31
   Chang HS, 2004, AM J PATHOL, V165, P1535, DOI 10.1016/S0002-9440(10)63411-6
   Chen M, 2015, J LEUKOCYTE BIOL, V98, P713, DOI 10.1189/jlb.3RI0615-239R
   Chen W, 2010, P NATL ACAD SCI USA, V107, P7401, DOI 10.1073/pnas.0912702107
   Cheng CY, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7063
   Cheung CMG, 2014, OPHTHALMOLOGY, V121, P1598, DOI 10.1016/j.ophtha.2014.02.004
   Chew EY, 2014, JAMA OPHTHALMOL, V132, P142, DOI 10.1001/jamaophthalmol.2013.7376
   Chistiakov DA, 2015, ACTA PHYSIOL, V214, P33, DOI 10.1111/apha.12466
   Chistiakov DA, 2015, INT J CARDIOL, V184, P436, DOI 10.1016/j.ijcard.2015.03.055
   Clemons TE, 2004, ARCH OPHTHALMOL-CHIC, V122, P716
   Cook HL, 2008, BRIT MED BULL, V85, P127, DOI 10.1093/bmb/ldn012
   Cougnard-Gregoire A, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0090973
   Cougnard-Gregoire A, 2013, INVEST OPHTH VIS SCI, V54, P1905, DOI 10.1167/iovs.12-10192
   Curcio CA, 1996, INVEST OPHTH VIS SCI, V37, P1236
   Curcio CA, 2011, BRIT J OPHTHALMOL, V95, P1638, DOI 10.1136/bjophthalmol-2011-300344
   Davis MD, 2005, ARCH OPHTHALMOL-CHIC, V123, P1484
   DeAngelis MM, 2004, ARCH OPHTHALMOL-CHIC, V122, P575, DOI 10.1001/archopht.122.4.575
   Dehghan A, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0144997
   Delcourt C, 2001, Ophthalmic Epidemiol, V8, P237, DOI 10.1076/opep.8.4.237.1613
   Duan YK, 2007, OPHTHALMOLOGY, V114, P732, DOI 10.1016/j.ophtha.2006.07.045
   Erke MG, 2014, ACTA OPHTHALMOL, V92, P662, DOI 10.1111/aos.12346
   Fauser S, 2011, INVEST OPHTH VIS SCI, V52, P5525, DOI 10.1167/iovs.10-6827
   Feehan M, 2011, BMC MED GENET, V12, DOI 10.1186/1471-2350-12-83
   Fernandez AB, 2012, OPHTHALMOLOGY, V119, P765, DOI 10.1016/j.ophtha.2011.09.044
   FERRIS FL, 1984, ARCH OPHTHALMOL-CHIC, V102, P1640
   Ferris FL, 2005, ARCH OPHTHALMOL-CHIC, V123, P1570
   Fliesler SJ, 2010, J LIPID RES, V51, P3399, DOI 10.1194/jlr.R010538
   Fong DS, 2010, AM J OPHTHALMOL, V149, P955, DOI 10.1016/j.ajo.2009.12.037
   Fraser-Bell S, 2008, AM J OPHTHALMOL, V145, P308, DOI 10.1016/j.ajo.2007.10.007
   Friedman E, 2004, BRIT J OPHTHALMOL, V88, P161, DOI 10.1136/bjo.2003.036277
   Friedman E, 1997, AM J OPHTHALMOL, V124, P677, DOI 10.1016/S0002-9394(14)70906-7
   Friedman E, 2000, AM J OPHTHALMOL, V130, P658, DOI 10.1016/S0002-9394(00)00643-7
   Friedman E, 2008, AM J OPHTHALMOL, V146, P348, DOI 10.1016/j.ajo.2008.05.017
   Fritsche LG, 2016, NAT GENET, V48, P134, DOI 10.1038/ng.3448
   Fritsche LG, 2014, ANNU REV GENOM HUM G, V15, P151, DOI 10.1146/annurev-genom-090413-025610
   Fritsche LG, 2013, NAT GENET, V45, P433, DOI 10.1038/ng.2578
   Galis ZS, 2002, CIRC RES, V90, P251, DOI 10.1161/res.90.3.251
   Gehlbach P, 2016, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006927.pub5
   Gelfand BD, 2016, TRENDS MOL MED, V22, P656, DOI 10.1016/j.molmed.2016.06.009
   Gemenetzi M, 2016, EYE, V30, P1, DOI 10.1038/eye.2015.203
   Gemenetzi M, 2014, EYE, V28, P1407, DOI 10.1038/eye.2014.225
   Golan S, 2011, GRAEF ARCH CLIN EXP, V249, P179, DOI 10.1007/s00417-010-1489-4
   Gorin MB, 2012, MOL ASPECTS MED, V33, P467, DOI 10.1016/j.mam.2012.04.004
   Grassmann F, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0126636
   Grodstein F, 2006, J WOMENS HEALTH, V15, P35, DOI 10.1089/jwh.2006.15.35
   Grunin M, 2014, ADV EXP MED BIOL, V801, P199, DOI 10.1007/978-1-4614-3209-8_26
   Grunwald JE, 1998, INVEST OPHTH VIS SCI, V39, P385
   Grunwald JE, 2005, INVEST OPHTH VIS SCI, V46, P1033, DOI 10.1167/iovs.04-1050
   Guay SP, 2014, CLIN EPIGENETICS, V6, DOI 10.1186/1868-7083-6-14
   Guay SP, 2012, EPIGENETICS-US, V7, P464, DOI 10.4161/epi.19633
   Guymer RH, 2005, SURV OPHTHALMOL, V50, P194, DOI 10.1016/j.survophthal.2004.12.002
   Guymer RH, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0083759
   Guymer RH, 2008, CLIN INTERV AGING, V3, P581
   Hafiane A, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0131997
   Haines JL, 2006, INVEST OPHTH VIS SCI, V47, P329, DOI 10.1167/iovs.05-0116
   Hall NF, 2001, BRIT MED J, V323, P375, DOI 10.1136/bmj.323.7309.375
   Handa JT, 2017, BBA-MOL CELL BIOL L, V1862, P430, DOI 10.1016/j.bbalip.2016.07.013
   HANDELMAN GJ, 1988, INVEST OPHTH VIS SCI, V29, P850
   He F, 2015, INT J MOL SCI, V16, P27770, DOI 10.3390/ijms161126059
   Herrington DM, 2002, CIRCULATION, V105, P2962, DOI 10.1161/01.CIR.0000019406.74017.B2
   Hirvela H, 1996, OPHTHALMOLOGY, V103, P871, DOI 10.1016/S0161-6420(96)30593-9
   Hodis HN, 2012, CLIMACTERIC, V15, P217, DOI 10.3109/13697137.2012.656401
   Hodis HN, 2001, ANN INTERN MED, V135, P939, DOI 10.7326/0003-4819-135-11-200112040-00005
   Hu CC, 2010, STROKE, V41, P613, DOI 10.1161/STROKEAHA.109.571000
   Hussain AA, 2011, INVEST OPHTH VIS SCI, V52, P4459, DOI 10.1167/iovs.10-6678
   Hyman L, 2000, ARCH OPHTHALMOL-CHIC, V118, P351, DOI 10.1001/archopht.118.3.351
   HYMAN LG, 1983, AM J EPIDEMIOL, V118, P213, DOI 10.1093/oxfordjournals.aje.a113629
   Ikram MK, 2012, STROKE, V43, P1681, DOI 10.1161/STROKEAHA.112.654632
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Jans D. M., 2006, Cardiovascular & Hematological Disorders - Drug Targets, V6, P21
   Jarrett SG, 2012, MOL ASPECTS MED, V33, P399, DOI 10.1016/j.mam.2012.03.009
   Jiang XC, 1999, J CLIN INVEST, V103, P907, DOI 10.1172/JCI5578
   Joyce C, 2003, ARTERIOSCL THROM VAS, V23, P965, DOI 10.1161/01.ATV.0000055194.85073.FF
   Jun GG, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025775
   Kaarniranta K, 2012, NEUROSCI LETT, V513, P233, DOI 10.1016/j.neulet.2012.02.050
   KAHN HA, 1977, AM J EPIDEMIOL, V106, P33, DOI 10.1093/oxfordjournals.aje.a112429
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Kauppinen A, 2016, CELL MOL LIFE SCI, V73, P1765, DOI 10.1007/s00018-016-2147-8
   Khan KN, 2016, PROG RETIN EYE RES, V53, P70, DOI 10.1016/j.preteyeres.2016.04.008
   Kim WS, 2005, J BIOL CHEM, V280, P3989, DOI 10.1074/jbc.M412602200
   Klaver CCW, 1998, AM J HUM GENET, V63, P200, DOI 10.1086/301901
   Klein R, 1997, OPHTHALMOLOGY, V104, P7, DOI 10.1016/S0161-6420(97)30368-6
   Klein R, 2003, ARCH OPHTHALMOL-CHIC, V121, P1151, DOI 10.1001/archopht.121.8.1151
   Klein R, 2003, OPHTHALMOLOGY, V110, P25, DOI 10.1016/S0161-6420(02)01565-8
   KLEIN R, 1993, OPHTHALMOLOGY, V100, P406
   Klein R, 2007, ARCH OPHTHALMOL-CHIC, V125, P534, DOI 10.1001/archopht.125.4.534
   Klein R, 2007, AM J OPHTHALMOL, V143, P473, DOI 10.1016/j.ajo.2006.11.058
   Klein R, 2014, AM J OPHTHALMOL, V158, P513, DOI 10.1016/j.ajo.2014.05.027
   Klein Ronald, 2003, Ophthalmology, V110, P1273, DOI 10.1016/S0161-6420(03)00599-2
   Klein R, 2011, ARCH OPHTHALMOL-CHIC, V129, P75, DOI 10.1001/archophthalmol.2010.318
   Kloeckener-Gruissem B, 2011, INVEST OPHTH VIS SCI, V52, P4694, DOI 10.1167/iovs.10-6080
   Knickelbein Jared E, 2015, Int Ophthalmol Clin, V55, P63, DOI 10.1097/IIO.0000000000000073
   Laitinen A, 2010, ACTA OPHTHALMOL, V88, P463, DOI 10.1111/j.1755-3768.2009.01566.x
   Lambert NG, 2016, PROG RETIN EYE RES, V54, P64, DOI 10.1016/j.preteyeres.2016.04.003
   Lambert V, 2002, AM J PATHOL, V161, P1247, DOI 10.1016/S0002-9440(10)64401-X
   Lechanteur YTE, 2012, INVEST OPHTH VIS SCI, V53, P5846, DOI 10.1167/iovs.11-7731
   Liao DP, 2008, OPEN OPHTHALMOL J, V2, P37, DOI 10.2174/1874364100802010037
   Libby P, 2011, NATURE, V473, P317, DOI 10.1038/nature10146
   Linton MF, 2000, ENDOTEXT
   Liu K, 2014, OPHTHALMOLOGY, V121, P911, DOI 10.1016/j.ophtha.2013.10.042
   Logue MW, 2014, NEUROBIOL AGING, V35, DOI 10.1016/j.neurobiolaging.2013.12.007
   Lowe GDO, 2003, PATHOPHYSIOL HAEMO T, V33, P455, DOI 10.1159/000083845
   Fanjul-Moles ML, 2016, OXID MED CELL LONGEV, V2016, DOI 10.1155/2016/7420637
   Ma L, 2015, SCI REP-UK, V5, DOI 10.1038/srep18280
   Machalinska A, 2012, ACTA OPHTHALMOL, V90, P695, DOI 10.1111/j.1755-3768.2011.02295.x
   Machalinska A, 2011, INVEST OPHTH VIS SCI, V52, P93, DOI 10.1167/iovs.10-5756
   Maguire MG, 2009, OPHTHALMOLOGY, V116, P2381, DOI 10.1016/j.ophtha.2009.06.055
   MARTINI E, 1991, Annali di Ottalmologia e Clinica Oculistica, V117, P1121
   McCarty CA, 2001, MED J AUSTRALIA, V175, P340, DOI 10.5694/j.1326-5377.2001.tb143604.x
   McGwin G, 2006, ARCH OPHTHALMOL-CHIC, V124, P33, DOI 10.1001/archopht.124.1.33
   McGwin G, 2005, OPHTHALMOLOGY, V112, P488, DOI 10.1016/j.ophtha.2004.10.027
   McHarg S, 2015, MOL IMMUNOL, V67, P43, DOI 10.1016/j.molimm.2015.02.032
   McKay GJ, 2011, HUM MUTAT, V32, P1407, DOI 10.1002/humu.21577
   McNeish J, 2000, P NATL ACAD SCI USA, V97, P4245, DOI 10.1073/pnas.97.8.4245
   Merle BMJ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0079848
   Metelitsina TI, 2006, BRIT J OPHTHALMOL, V90, P342, DOI 10.1136/bjo.2005.082974
   Mitchell P, 2010, BRIT J OPHTHALMOL, V94, P2, DOI 10.1136/bjo.2009.159160
   Moreno PR, 2012, ANN NY ACAD SCI, V1254, P7, DOI 10.1111/j.1749-6632.2012.06497.x
   Morgan DJ, 2015, CSH PERSPECT MED, V5, DOI 10.1101/cshperspect.a017210
   Mulero J, 2014, CLIN HEMORHEOL MICRO, V58, P447, DOI 10.3233/CH-141807
   Mullins RF, 2000, FASEB J, V14, P835, DOI 10.1096/fasebj.14.7.835
   Munch IC, 2013, INVEST OPHTH VIS SCI, V54, P3932, DOI 10.1167/iovs.12-10785
   Naderi S, 2013, CLEV CLIN J MED, V80, P577, DOI 10.3949/ccjm.80a.13005
   Neale BM, 2010, P NATL ACAD SCI USA, V107, P7395, DOI 10.1073/pnas.0912019107
   Nguyen-Khoa BA, 2008, ARCH OPHTHALMOL-CHIC, V126, P1280, DOI 10.1001/archopht.126.9.1280
   Nowak JZ, 2014, ACTA POL PHARM, V71, P900
   Ohno-Matsui K, 2011, PROG RETIN EYE RES, V30, P217, DOI 10.1016/j.preteyeres.2011.02.004
   Orso E, 2000, NAT GENET, V24, P192, DOI 10.1038/72869
   Parmeggiani F, 2012, MEDIAT INFLAMM, V2012, DOI 10.1155/2012/546786
   Pascolini D, 2012, BRIT J OPHTHALMOL, V96, P614, DOI 10.1136/bjophthalmol-2011-300539
   Pennington KL, 2015, J EXP NEUROSCI, V9, P51, DOI 10.4137/JEN.S25513
   Pikuleva IA, 2014, PROG RETIN EYE RES, V41, P64, DOI 10.1016/j.preteyeres.2014.03.002
   Qiu Y, 2001, GENOMICS, V73, P66, DOI 10.1006/geno.2000.6467
   Querques G, 2014, OPHTHALMIC RES, V52, P107, DOI 10.1159/000363187
   Rastogi N, 2016, SURV OPHTHALMOL, V61, P422, DOI 10.1016/j.survophthal.2015.10.003
   Rein DB, 2009, ARCH OPHTHALMOL-CHIC, V127, P533, DOI 10.1001/archophthalmol.2009.58
   Restrepo NA, 2014, INVEST OPHTH VIS SCI, V55, DOI 10.1167/iovs.14-14246
   Reynolds R, 2010, OPHTHALMOLOGY, V117, P1989, DOI 10.1016/j.ophtha.2010.07.009
   Riaz M, 2016, DEV OPHTHALMOL, V55, P57, DOI 10.1159/000431142
   Roh MI, 2008, YONSEI MED J, V49, P931, DOI 10.3349/ymj.2008.49.6.931
   Rudnicka AR, 2012, OPHTHALMOLOGY, V119, P571, DOI 10.1016/j.ophtha.2011.09.027
   SanGiovanni JP, 2008, ARCH OPHTHALMOL-CHIC, V126, P1274, DOI 10.1001/archopht.126.9.1274
   SanGiovanni JP, 2007, ARCH OPHTHALMOL-CHIC, V125, P1225, DOI 10.1001/archopht.125.9.1225
   Sasaki M, 2013, ACTA OPHTHALMOL, V91, pE418, DOI 10.1111/aos.12114
   Schaumberg DA, 2010, ARCH OPHTHALMOL-CHIC, V128, P1462, DOI 10.1001/archophthalmol.2010.261
   Schwartz SG, 2016, CLIN OPHTHALMOL, V10, P1229, DOI 10.2147/OPTH.S109723
   Sene A, 2013, CELL METAB, V17, P549, DOI 10.1016/j.cmet.2013.03.009
   Shah AR, 2007, AM J OPHTHALMOL, V143, P83, DOI 10.1016/j.ajo.2006.09.043
   Shalev V, 2011, OPHTHAL EPIDEMIOL, V18, P83, DOI 10.3109/09286586.2011.560746
   Silveira AC, 2010, VISION RES, V50, P698, DOI 10.1016/j.visres.2009.09.016
   Siti HN, 2015, VASC PHARMACOL, V71, P40, DOI 10.1016/j.vph.2015.03.005
   SMITH JD, 1990, J BIOL CHEM, V265, P14709
   Smith W, 1997, AUST NZ J OPHTHALMOL, V25, pS13
   Smith W, 2001, OPHTHALMOLOGY, V108, P697, DOI 10.1016/S0161-6420(00)00580-7
   Snow KK, 2002, AM J OPHTHALMOL, V134, P842, DOI 10.1016/S0002-9394(02)01755-5
   Souied EH, 1998, AM J OPHTHALMOL, V125, P353, DOI 10.1016/S0002-9394(99)80146-9
   SPERDUTO RD, 1986, ARCH OPHTHALMOL-CHIC, V104, P216
   Stanton CM, 2014, ADV EXP MED BIOL, V801, P251, DOI 10.1007/978-1-4614-3209-8_32
   Stefansson E, 2011, PROG RETIN EYE RES, V30, P72, DOI 10.1016/j.preteyeres.2010.09.003
   Sun C, 2009, OPHTHALMOLOGY, V116, P1913, DOI 10.1016/j.ophtha.2009.03.046
   Sun Y, 2015, P NATL ACAD SCI USA, V112, P10401, DOI 10.1073/pnas.1504387112
   Tan JSL, 2008, BRIT J OPHTHALMOL, V92, P509, DOI 10.1136/bjo.2007.131706
   Tan JSL, 2007, OPHTHALMOLOGY, V114, P1143, DOI 10.1016/j.ophtha.2006.09.033
   Tan PL, 2016, HUM GENOMICS, V10, DOI 10.1186/s40246-016-0079-x
   Taniguchi H, 2015, OPHTHALMOLOGICA, V233, P128, DOI 10.1159/000371716
   Thomas J, 2015, SOUTH MED J, V108, P502, DOI 10.14423/SMJ.0000000000000329
   Tomany SC, 2004, OPHTHALMOLOGY, V111, P1280, DOI 10.1016/j.ophtha.2003.11.010
   Toy BC, 2013, AM J OPHTHALMOL, V156, P532, DOI 10.1016/j.ajo.2013.04.031
   Ulas F, 2013, INT OPHTHALMOL, V33, P485, DOI 10.1007/s10792-013-9728-4
   Van Leeuwen R, 2004, OPHTHALMOLOGY, V111, P1169, DOI 10.1016/j.ophtha.2003.10.024
   van Leeuwen R, 2003, INVEST OPHTH VIS SCI, V44, P3771, DOI 10.1167/iovs.03-0121
   Varma R, 2010, AM J OPHTHALMOL, V149, P741, DOI 10.1016/j.ajo.2010.01.009
   Vassilev ZP, 2015, INVEST OPHTH VIS SCI, V56, P1585, DOI 10.1167/iovs.14-16271
   Vavvas DG, 2016, EBIOMEDICINE, V5, P198, DOI 10.1016/j.ebiom.2016.01.033
   Vaya J, 2013, BIOCHEM PHARMACOL, V86, P15, DOI 10.1016/j.bcp.2013.01.025
   VIDAURRI JS, 1984, OPHTHALMOLOGICA, V188, P243, DOI 10.1159/000309370
   Vine AK, 2005, OPHTHALMOLOGY, V112, P2076, DOI 10.1016/j.ophtha.2005.07.004
   Vitale S, 2016, JAMA OPHTHALMOL, V134, P1041, DOI 10.1001/jamaophthalmol.2016.2383
   Vlaicu SI, 2016, IMMUNOL RES, V64, P1, DOI 10.1007/s12026-015-8669-6
   Vu TH, 1998, CELL, V93, P411, DOI 10.1016/S0092-8674(00)81169-1
   Wang D, 2015, OPHTHALMIC GENET, V36, P303, DOI 10.3109/13816810.2014.881506
   Wang SB, 2015, BRIT J OPHTHALMOL, V99, P365, DOI 10.1136/bjophthalmol-2014-305793
   Wang YF, 2015, SCI REP-UK, V5, DOI 10.1038/srep15711
   WARDEN CH, 1995, J CLIN INVEST, V95, P1545, DOI 10.1172/JCI117827
   Wieberdink RG, 2011, STROKE, V42, P2138, DOI 10.1161/STROKEAHA.111.616359
   Wilson HL, 2004, AM J OPHTHALMOL, V137, P615, DOI 10.1016/j.ajo.2003.10.025
   Wong TY, 2007, OPHTHALMOLOGY, V114, P86, DOI 10.1016/j.ophtha.2006.06.039
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Woodell A, 2014, ADV EXP MED BIOL, V801, P301, DOI 10.1007/978-1-4614-3209-8_38
   Wu J, 2015, JAMA OPHTHALMOL, V133, P1415, DOI 10.1001/jamaophthalmol.2015.3590
   Wu J, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0089600
   Yang K, 2014, RETINA-J RET VIT DIS, V34, P1539, DOI 10.1097/IAE.0000000000000118
   YANNUZZI LA, 1992, ARCH OPHTHALMOL-CHIC, V110, P1701
   Yip JLY, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0132565
   You QS, 2012, OPHTHALMOLOGY, V119, P2519, DOI 10.1016/j.ophtha.2012.06.043
   Yu Y, 2011, INVEST OPHTH VIS SCI, V52, P4663, DOI 10.1167/iovs.10-7070
   Zareparsi S, 2005, HUM MOL GENET, V14, P1449, DOI 10.1093/hmg/ddi154
   Zetterberg M, 2016, MATURITAS, V83, P19, DOI 10.1016/j.maturitas.2015.10.005
   Zhang QY, 2016, INVEST OPHTH VIS SCI, V57, P1276, DOI 10.1167/iovs.15-18637
   ZHANG SH, 1992, SCIENCE, V258, P468, DOI 10.1126/science.1411543
NR 220
TC 229
Z9 234
U1 7
U2 26
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2326-0254
J9 EYE VISION
JI Eye Vis.
PY 2016
VL 3
AR 34
DI 10.1186/s40662-016-0063-5
PG 20
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA VH8XA
UT WOS:000457297900006
PM 28032115
OA Green Published, gold
HC Y
HP N
DA 2022-11-30
ER

PT J
AU Wahl, HW
   Schilling, O
   Becker, S
AF Wahl, Hans-Werner
   Schilling, Oliver
   Becker, Stefanie
TI Age-related macular degeneration and change in psychological control:
   Role of time since diagnosis and functional ability
SO JOURNALS OF GERONTOLOGY SERIES B-PSYCHOLOGICAL SCIENCES AND SOCIAL
   SCIENCES
LA English
DT Article
ID SECONDARY CONTROL; OLDER-ADULTS; DISABILITY; PEOPLE; HEALTH; LIFE
AB We apply the life-span theory of control proposed by Heckhausen and Schulz to study the change in use of control strategies related to age-related macular degeneration (AMD). A mixed-model approach considers nonlinear relations of rate of change in the use of control strategies with time since diagnosis and functional ability. Data stem from a sample of 90 individuals with AMD (age, M = 79.5 years at Time 1), of whom 71 were assessed two times over 1 year. Compensatory primary control strategies increased shortly after the diagnosis, whereas the increase in compensatory secondary control strategies was related to functional loss in instrumental daily activities. Findings provide support for the critical role of compensatory control strategies in the event that individuals with AMD are faced with anticipated or real functional loss.
C1 [Wahl, Hans-Werner; Schilling, Oliver] Heidelberg Univ, Inst Psychol, Dept Psychol Aging Res, D-69115 Heidelberg, Germany.
   [Becker, Stefanie] Heidelberg Univ, Inst Gerontol, D-6900 Heidelberg, Germany.
C3 Ruprecht Karls University Heidelberg; Ruprecht Karls University
   Heidelberg
RP Wahl, HW (通讯作者)，Heidelberg Univ, Inst Psychol, Dept Psychol Aging Res, Bergheimer Str 58, D-69115 Heidelberg, Germany.
EM h.w.wahl@psychologie.uni-heidelberg.de
CR BRANCH LG, 1989, GERONTOLOGIST, V29, P359, DOI 10.1093/geront/29.3.359
   Burmedi D, 2002, VIS IMPAIR RES, V4, P15, DOI [10.1076/vimr.4.1.15.15633, DOI 10.1076/VIMR.4.1.15.15633]
   Chipperfield JG, 1999, J AGING HEALTH, V11, P517, DOI 10.1177/089826439901100403
   Fine SL, 2000, NEW ENGL J MED, V342, P483, DOI 10.1056/NEJM200002173420707
   Heckhausen J, 1997, DEV PSYCHOL, V33, P176, DOI 10.1037/0012-1649.33.1.176
   HECKHAUSEN J, 1995, PSYCHOL REV, V102, P284, DOI 10.1037/0033-295X.102.2.284
   Heckhausen J, 1998, MOTIVATION SELF REGU, P50, DOI [10.1017/CBO9780511527869.004, DOI 10.1017/CBO9780511527869.004]
   Heckhausen J., 1999, DEV REGULATION ADULT
   Heckhausen J., 1998, DEV REGULATION ADULT
   Hofer S. M., 2006, HDB PSYCHOL AGING, V6, P15, DOI [DOI 10.1016/B978-012101264-9/50005-7, 10.1016/B978-012101264-9/50005-7]
   HOLZ FG, 2003, AGE RELATED MACULAR
   KLEIN LE, 1985, J AM GERIATR SOC, V33, P483, DOI 10.1111/j.1532-5415.1985.tb05460.x
   KLEINSCHMIDT JJ, 1995, J HLTH ED, V26, P26, DOI DOI 10.1080/10556699.1995.10603073
   Lachman ME, 2004, MAC FDN MEN, P320
   LAWTON MP, 1969, GERONTOLOGIST, V9, P179, DOI 10.1093/geront/9.3_Part_1.179
   LAWTON MP, 1982, J GERONTOL, V37, P91, DOI 10.1093/geronj/37.1.91
   Molenberghs G., 2000, LINEAR MIXED MODELS
   Montada L., 1992, LIFE CRISES EXPERIEN
   Mroczek DK, 2006, HDB PSYCHOL AGING, P363
   ORR AL, 1992, VISION AGING CROSSRO, P3
   Rovner BW, 2001, J AM GERIATR SOC, V49, P1097, DOI 10.1046/j.1532-5415.2001.49215.x
   SAS, 1999, SAS STAT US GUID VER
   Schafer JL, 2002, PSYCHOL METHODS, V7, P147, DOI 10.1037//1082-989X.7.2.147
   Schilling OK, 2006, PSYCHOL AGING, V21, P703, DOI 10.1037/0882-7974.21.4.703
   Schulz R, 1999, J GERONTOL B-PSYCHOL, V54, pP139, DOI 10.1093/geronb/54B.3.P139
   SCHULZ R, 1985, J PERS SOC PSYCHOL, V48, P1162, DOI 10.1037/0022-3514.48.5.1162
   SCHWARTZ SD, 2000, LIGHTHOUSE HDB VISIO, V2, P83
   SNIJDERS TAB, 1999, MULTILEVEL ANAL AN I
   STEINHAGENTHIES. E, 1999, BERLIN AGING STUDY A, P131
   Travis LA, 2004, J VISUAL IMPAIR BLIN, V98, P534, DOI 10.1177/0145482X0409800905
   WAHL, 2002, VISUAL IMPAIRMENT RE, V4, P143
   WAHL, 2005, VISION 2005, V1282, P326
   Wahl HW, 2004, PSYCHOL AGING, V19, P235, DOI 10.1037/0882-7974.19.1.235
   WAHL HW, 1999, PSYCHOL SCIENCES, V54, pP304
   Wrosch C, 2002, HEALTH PSYCHOL, V21, P340, DOI 10.1037//0278-6133.21.4.340
NR 35
TC 14
Z9 14
U1 0
U2 5
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 1079-5014
EI 1758-5368
J9 J GERONTOL B-PSYCHOL
JI J. Gerontol. Ser. B-Psychol. Sci. Soc. Sci.
PD MAR
PY 2007
VL 62
IS 2
BP P90
EP P97
DI 10.1093/geronb/62.2.P90
PG 8
WC Geriatrics & Gerontology; Gerontology; Psychology; Psychology,
   Multidisciplinary
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC Geriatrics & Gerontology; Psychology
GA 272CG
UT WOS:000253835700004
PM 17379677
OA Bronze, Green Submitted
DA 2022-11-30
ER

PT J
AU Garcia-Delgado, AB
   Calado, SM
   Valdes-Sanchez, LM
   Montero-Sanchez, A
   Ponte-Zuniga, B
   de la Cerda, B
   Bhattacharya, SS
   Diaz-Corrales, FJ
AF Garcia-Delgado, Ana B.
   Calado, Sofia M.
   Valdes-Sanchez, Lourdes M.
   Montero-Sanchez, Adoracion
   Ponte-Zuniga, Beatriz
   de la Cerda, Berta
   Shanker Bhattacharya, Shom
   Diaz-Corrales, Francisco J.
TI Generation of a human iPS cell line (CABi003-A) from a patient with
   age-related macular degeneration carrying the CFH Y402H polymorphism
SO STEM CELL RESEARCH
LA English
DT Article
AB Age-related macular degeneration (AMD) is the leading cause of adult blindness in developed countries and is characterized by progressive degeneration of the macula, the central region of the retina. A human induced pluripotent stem cell (hiPSC) line was derived from peripheral blood mononuclear cells (PBMCs) from a patient with a clinical diagnosis of dry AMD carrying the CFH Y402H polymorphism. Sendai virus was using for reprogramming and the pluripotent and differentiation capacity of the cells were assessed by immunocytochemistry and RT-PCR.
C1 [Garcia-Delgado, Ana B.; Calado, Sofia M.; Valdes-Sanchez, Lourdes M.; Montero-Sanchez, Adoracion; de la Cerda, Berta; Shanker Bhattacharya, Shom; Diaz-Corrales, Francisco J.] Univ Pablo de Olavide, Univ Sevilla, Andalusian Mol Biol & Regenerat Med Ctr CABIMER, Dept Regenerat & Cell Therapy,CSIC,Junta Andaluci, Seville, Spain.
   [Ponte-Zuniga, Beatriz] Macarena Univ Hosp, Dept Ophthalmol, Seville, Spain.
   [Ponte-Zuniga, Beatriz] Carlos III Inst Hlth Spain, Minist Hlth RD16 0008 0010, RETICS Oftared, Seville, Spain.
C3 Consejo Superior de Investigaciones Cientificas (CSIC); Universidad
   Pablo de Olavide; University of Sevilla; CSIC - Centro Andaluz de
   Biologia Molecular y Medicina Regenerativa (CABIMER)
RP Diaz-Corrales, FJ (通讯作者)，Andalusian Mol Biol & Regenerat Med Ctr, Avda Amer Vespucio 24 Edif CABIMER, Seville 41092, Spain.
EM francisco.diaz@cabimer.es
RI Calado, Sofia M./K-2202-2016; Diaz-Corrales, Francisco J./L-7559-2014
OI Calado, Sofia M./0000-0001-5509-4145; Diaz-Corrales, Francisco
   J./0000-0002-5752-0205; Garcia Delgado, Ana Belen/0000-0002-9818-9336
FU ISCIII, Spain [Miguel Servet-I]; European Regional Development Fund
   (ERDF) [CP 15/00071]
FX This work was supported by ISCIII, Spain (Miguel Servet-I, 2015) and
   cofinanced by European Regional Development Fund (ERDF) (CP 15/00071).
CR Takahashi K, 2007, CELL, V131, P861, DOI 10.1016/j.cell.2007.11.019
   Toomey CB, 2018, PROG RETIN EYE RES, V62, P38, DOI 10.1016/j.preteyeres.2017.09.001
NR 2
TC 1
Z9 1
U1 0
U2 2
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 1873-5061
EI 1876-7753
J9 STEM CELL RES
JI Stem Cell Res.
PD JUL
PY 2019
VL 38
AR 101473
DI 10.1016/j.scr.2019.101473
PG 4
WC Cell & Tissue Engineering; Biotechnology & Applied Microbiology; Cell
   Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology; Biotechnology & Applied Microbiology
GA IM3BG
UT WOS:000477866100020
PM 31176916
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Mori, K
   Horie-Inoue, K
   Kohda, M
   Kawasaki, I
   Gehlbach, PL
   Awata, T
   Yoneya, S
   Okazaki, Y
   Inoue, S
AF Mori, Keisuke
   Horie-Inoue, Kuniko
   Kohda, Masakazu
   Kawasaki, Izumi
   Gehlbach, Peter L.
   Awata, Takuya
   Yoneya, Shin
   Okazaki, Yasushi
   Inoue, Satoshi
TI Association of the HTRA1 gene variant with age-related macular
   degeneration in the Japanese population
SO JOURNAL OF HUMAN GENETICS
LA English
DT Article
DE high-temperature requirement A-1 (HTRA1); age-related macular
   degeneration; single-nucleotide polymorphism; Japanese population;
   smoking
ID COMPLEMENT-FACTOR-H; POLYPOIDAL CHOROIDAL VASCULOPATHY; EYE DISEASE;
   GENOME SCAN; PROMOTER POLYMORPHISM; CHROMOSOME 10Q26; APOLIPOPROTEIN-E;
   NO ASSOCIATION; RISK-FACTORS; SUSCEPTIBILITY
AB The purpose of this investigation was to determine whether the high-temperature requirement A-1 (HTRA1) gene polymorphism is associated with age-related macular degeneration (AMD) in native, unrelated Japanese patients. A total of 123 patients with AMD and 133 control subjects without AMD were recruited for this study. The single-nucleotide polymorphism (SNP) rs11200638 in the HTRA1 gene was assessed using a TaqMan assay. The risk A allele frequencies in the AMD cases and control patients were 0.577 and 0.380, respectively, and were associated with a significant risk of developing AMD (p=7.75x10(-6)). The results were more significant in subtype analyses with wet AMD (p=5.96x10(-7)). We conclude that the rs11200638 variant in the HTRA1 gene is strongly associated with AMD in the Japanese population. This result supports the hypothesis that the HTRA1 gene may increase susceptibility to AMD development and can participate in a potential new molecular pathway for AMD pathogenesis by extending this association across diverse ethnicities.
C1 Saitama Med Univ, Fac Med, Dept Ophthalmol, Moroyama, Saitama 3500495, Japan.
   Saitama Med Univ, Fac Med, Div Gene Regulat & Signal Transduct, Iruma, Saitama, Japan.
   Saitama Med Univ, Fac Med, Res Ctr Genom Med, Div Translat Res, Iruma, Saitama, Japan.
C3 Saitama Medical University; Saitama Medical University; Saitama Medical
   University
RP Mori, K (通讯作者)，Saitama Med Univ, Fac Med, Dept Ophthalmol, 38 Morohongo, Moroyama, Saitama 3500495, Japan.
EM keisuke@saitama-med.ac.jp
OI KOHDA, Masakazu/0000-0001-5970-2224; Okazaki,
   Yasushi/0000-0003-3241-5502; Awata, Takuya/0000-0003-2622-8129
CR Abecasis GR, 2004, AM J HUM GENET, V74, P482, DOI 10.1086/382786
   Allikmets R, 2000, AM J HUM GENET, V67, P487, DOI 10.1086/303018
   Allikmets R, 1997, SCIENCE, V277, P1805, DOI 10.1126/science.277.5333.1805
   Anand R, 2000, OPHTHALMOLOGY, V107, P2224
   Bird AC, 2003, EYE, V17, P457, DOI 10.1038/sj.eye.6700562
   Bressler NM, 2003, ARCH OPHTHALMOL-CHIC, V121, P1621
   Chang TS, 1999, CAN J OPHTHALMOL, V34, P266
   Chen LJ, 2006, MOL VIS, V12, P1536
   Dewan A, 2006, SCIENCE, V314, P989, DOI 10.1126/science.1133807
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Fisher SA, 2005, HUM MOL GENET, V14, P2257, DOI 10.1093/hmg/ddi230
   Fuse N, 2006, AM J OPHTHALMOL, V142, P1074, DOI 10.1016/j.ajo.2006.07.030
   Gibbs RA, 2003, NATURE, V426, P789, DOI 10.1038/nature02168
   Gotoh N, 2006, HUM GENET, V120, P139, DOI 10.1007/s00439-006-0187-0
   Grassi MA, 2006, HUM MUTAT, V27, P921, DOI 10.1002/humu.20359
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Hamdi HK, 2002, BIOCHEM BIOPH RES CO, V295, P668, DOI 10.1016/S0006-291X(02)00728-3
   Jakobsdottir J, 2005, AM J HUM GENET, V77, P389, DOI 10.1086/444437
   Kenealy SJ, 2004, MOL VIS, V10, P57
   Klaver CCW, 1998, AM J HUM GENET, V63, P200, DOI 10.1086/301901
   Klein ML, 1998, ARCH OPHTHALMOL-CHIC, V116, P1082, DOI 10.1001/archopht.116.8.1082
   Klein R, 2004, AM J OPHTHALMOL, V137, P486, DOI 10.1016/j.ajo.2003.11.069
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Lau LI, 2006, INVEST OPHTH VIS SCI, V47, P3242, DOI 10.1167/iovs.05-1532
   Li M, 2006, NAT GENET, V38, P1049, DOI 10.1038/ng1871
   Magnusson KP, 2006, PLOS MED, V3, P109, DOI 10.1371/journal.pmed.0030005
   Majewski J, 2003, AM J HUM GENET, V73, P540, DOI 10.1086/377701
   Maller J, 2006, NAT GENET, V38, P1055, DOI 10.1038/ng1873
   Milton RC, 2005, OPHTHALMOLOGY, V112, P533, DOI 10.1016/j.ophtha.2004.10.047
   Mori M, 2005, J HUM GENET, V50, P264, DOI 10.1007/s10038-005-0246-8
   Okamoto H, 2006, MOL VIS, V12, P156
   Rivera A, 2005, HUM MOL GENET, V14, P3227, DOI 10.1093/hmg/ddi353
   Schmidt S, 2006, AM J HUM GENET, V78, P852, DOI 10.1086/503822
   Seddon JM, 2003, AM J HUM GENET, V73, P780, DOI 10.1086/378505
   Sho K, 2003, ARCH OPHTHALMOL-CHIC, V121, P1392, DOI 10.1001/archopht.121.10.1392
   Souied EH, 1998, AM J OPHTHALMOL, V125, P353, DOI 10.1016/S0002-9394(99)80146-9
   Stone EM, 2004, NEW ENGL J MED, V351, P346, DOI 10.1056/NEJMoa040833
   Uka J, 2006, RETINA-J RET VIT DIS, V26, P985, DOI 10.1097/01.iae.0000244068.18520.3e
   Uyama M, 2002, AM J OPHTHALMOL, V133, P639, DOI 10.1016/S0002-9394(02)01404-6
   Uyama M, 1999, ARCH OPHTHALMOL-CHIC, V117, P1035
   Weeks DE, 2000, HUM MOL GENET, V9, P1329, DOI 10.1093/hmg/9.9.1329
   Yang ZL, 2006, SCIENCE, V314, P992, DOI 10.1126/science.1133811
   Yoshida T, 2007, MOL VIS, V13, P545
   Zareparsi S, 2005, AM J HUM GENET, V77, P149, DOI 10.1086/431426
NR 45
TC 47
Z9 47
U1 0
U2 2
PU SPRINGER TOKYO
PI TOKYO
PA 3-3-13, HONGO, BUNKYO-KU, TOKYO, 113-0033, JAPAN
SN 1434-5161
J9 J HUM GENET
JI J. Hum. Genet.
PD JUN
PY 2007
VL 52
IS 7
BP 636
EP 641
DI 10.1007/s10038-007-0162-1
PG 6
WC Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Genetics & Heredity
GA 184PI
UT WOS:000247653600009
PM 17568988
OA Bronze
DA 2022-11-30
ER

PT J
AU Karri, SPK
   Chakraborty, D
   Chatterjee, J
AF Karri, S. P. K.
   Chakraborty, Debjani
   Chatterjee, Jyotirmoy
TI Transfer learning based classification of optical coherence tomography
   images with diabetic macular edema and dry age-related macular
   degeneration
SO BIOMEDICAL OPTICS EXPRESS
LA English
DT Article
ID RETINAL LAYER SEGMENTATION; AUTOMATIC SEGMENTATION; OCT IMAGES; AMD
AB We present an algorithm for identifying retinal pathologies given retinal optical coherence tomography (OCT) images. Our approach fine-tunes a pre-trained convolutional neural network (CNN), GoogLeNet, to improve its prediction capability (compared to random initialization training) and identifies salient responses during prediction to understand learned filter characteristics. We considered a data set containing subjects with diabetic macular edema, or dry age-related macular degeneration, or no pathology. The fine-tuned CNN could effectively identify pathologies in comparison to classical learning. Our algorithm aims to demonstrate that models trained on non-medical images can be fine-tuned for classifying OCT images with limited training data. (C) 2017 Optical Society of America
C1 [Karri, S. P. K.; Chatterjee, Jyotirmoy] IIT Kharagpur, Sch Med Sci & Technol, Kharagpur, W Bengal, India.
   [Chakraborty, Debjani] IIT Kharagpur, Dept Math, Kharagpur, W Bengal, India.
C3 Indian Institute of Technology System (IIT System); Indian Institute of
   Technology (IIT) - Kharagpur; Indian Institute of Technology System (IIT
   System); Indian Institute of Technology (IIT) - Kharagpur
RP Karri, SPK (通讯作者)，IIT Kharagpur, Sch Med Sci & Technol, Kharagpur, W Bengal, India.
EM pkkarri.mm@iitkgp.ac.in
RI Chakraborty, Debjani/AAL-1162-2021
OI Chakraborty, Debjani/0000-0002-6929-6036; karri, sri phani
   krishna/0000-0002-0083-0114
CR Albarrak A, 2013, P 2013 INT C MED IM, P59
   Anantrasirichai N, 2013, I S BIOMED IMAGING, P1332
   Bengio Y, 2013, IEEE T PATTERN ANAL, V35, P1798, DOI 10.1109/TPAMI.2013.50
   Boureau Y. L., 2008, ADV NEURAL INFORM PR, P1185
   Bourne RRA, 2014, BRIT J OPHTHALMOL, V98, P629, DOI 10.1136/bjophthalmol-2013-304033
   Carass A, 2014, BIOMED OPT EXPRESS, V5, P1062, DOI 10.1364/BOE.5.001062
   Chiu SJ, 2015, BIOMED OPT EXPRESS, V6, P1172, DOI 10.1364/BOE.6.001172
   Chiu SJ, 2012, INVEST OPHTH VIS SCI, V53, P53, DOI 10.1167/iovs.11-7640
   Ciulla TA, 2003, DIABETES CARE, V26, P2653, DOI 10.2337/diacare.26.9.2653
   Dabov K, 2007, IEEE T IMAGE PROCESS, V16, P2080, DOI 10.1109/TIP.2007.901238
   Ding SF, 2012, ARTIF INTELL REV, V37, P169, DOI 10.1007/s10462-011-9225-y
   Drexler W, 2008, PROG RETIN EYE RES, V27, P45, DOI 10.1016/j.preteyeres.2007.07.005
   Duchi J, 2011, J MACH LEARN RES, V12, P2121
   Dufour PA, 2013, IEEE T MED IMAGING, V32, P531, DOI 10.1109/TMI.2012.2225152
   Farsiu S, 2014, OPHTHALMOLOGY, V121, P162, DOI 10.1016/j.ophtha.2013.07.013
   Glorot X, 2010, P 13 INT C ART INT S, P249, DOI DOI 10.1177/1753193409103364.
   Gregori G, 2011, OPHTHALMOLOGY, V118, P1373, DOI 10.1016/j.ophtha.2010.11.013
   Kafieh R, 2013, MED IMAGE ANAL, V17, P907, DOI 10.1016/j.media.2013.05.006
   Kanamori A, 2003, AM J OPHTHALMOL, V135, P513, DOI 10.1016/S0002-9394(02)02003-2
   Karri SPK, 2016, BIOMED OPT EXPRESS, V7, P2888, DOI 10.1364/BOE.7.002888
   Krizhevsky A., 2012, ADV NEURAL INF PROCE, P1097, DOI DOI 10.1145/3065386
   Lecun Y, 1998, P IEEE, V86, P2278, DOI 10.1109/5.726791
   LeCun Y, 2015, NATURE, V521, P436, DOI 10.1038/nature14539
   Lee H., 2011, P 14 INT C ART INT S, P215, DOI DOI 10.1177/1753193410390845
   Lemaitre G, 2016, J OPHTHALMOL, V2016, DOI 10.1155/2016/3298606
   Mayer MA, 2012, BIOMED OPT EXPRESS, V3, P572, DOI 10.1364/BOE.3.000572
   Mesnil G., 2012, P ICML WORKSHOP UNSU, V27, P97
   Mwanza JC, 2011, INVEST OPHTH VIS SCI, V52, P8323, DOI 10.1167/iovs.11-7962
   Oquab M., 2014, ADV NEURAL INF PROCE, V2014, P1717
   Otani T, 1999, AM J OPHTHALMOL, V127, P688, DOI 10.1016/S0002-9394(99)00033-1
   Pan SJ, 2010, IEEE T KNOWL DATA EN, V22, P1345, DOI 10.1109/TKDE.2009.191
   Rathke F, 2014, MED IMAGE ANAL, V18, P781, DOI 10.1016/j.media.2014.03.004
   Rickman CB, 2013, INVEST OPHTH VIS SCI, V54, pORSF68, DOI 10.1167/iovs.13-12757
   Romero-Aroca P, 2013, WORLD J DIABETES, V4, P165, DOI 10.4239/wjd.v4.i5.165
   Simard PY, 2003, PROC INT CONF DOC, P958
   Srinivasan PP, 2014, BIOMED OPT EXPRESS, V5, P3568, DOI 10.1364/BOE.5.003568
   Srinivasan PP, 2014, BIOMED OPT EXPRESS, V5, P348, DOI 10.1364/BOE.5.000348
   Srivastava N, 2014, J MACH LEARN RES, V15, P1929
   Szegedy C., 2015, IEEE C COMP VIS PATT, P1, DOI DOI 10.1109/CVPR.2015.7298594
   Tatrai E, 2011, J BIOMED OPT, V16, DOI 10.1117/1.3573817
   Wang Y, 2016, BIOMED OPT EXPRESS, V7, P4928, DOI 10.1364/BOE.7.004928
   YOSINSKI J, 2014, ADV NEURAL INFORM PR, P3320, DOI DOI 10.1109/IJCNN.2016.7727519
   Zhang YG, 2014, EURASIP J ADV SIG PR, DOI 10.1186/1687-6180-2014-17
NR 43
TC 152
Z9 158
U1 3
U2 42
PU Optica Publishing Group
PI WASHINGTON
PA 2010 MASSACHUSETTS AVE NW, WASHINGTON, DC 20036 USA
SN 2156-7085
J9 BIOMED OPT EXPRESS
JI Biomed. Opt. Express
PD FEB 1
PY 2017
VL 8
IS 2
BP 579
EP 592
DI 10.1364/BOE.8.000579
PG 14
WC Biochemical Research Methods; Optics; Radiology, Nuclear Medicine &
   Medical Imaging
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Optics; Radiology, Nuclear Medicine &
   Medical Imaging
GA EK8OA
UT WOS:000394182100009
PM 28270969
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Hart, KM
   Abbott, C
   Ly, A
   Kalff, S
   Lek, JJ
   Milston, R
   Page, G
   Robertson, B
   Ayton, L
AF Hart, Kerryn M.
   Abbott, Carla
   Ly, Angelica
   Kalff, Susan
   Lek, Jia Jia
   Milston, Rebecca
   Page, Gary
   Robertson, Bill
   Ayton, Lauren
TI Optometry Australia's chairside reference for the diagnosis and
   management of age-related macular degeneration
SO CLINICAL AND EXPERIMENTAL OPTOMETRY
LA English
DT Article
DE age-related macular degeneration; chairside reference; diagnosis;
   imaging; management; optometry; treatment
ID FUNDUS AUTOFLUORESCENCE; GEOGRAPHIC-ATROPHY; CIGARETTE-SMOKING;
   PHYSICAL-ACTIVITY; CLINICAL-TRIAL; EYE DISEASE; PROGRESSION; RISK;
   RANIBIZUMAB; ASSOCIATION
AB Age-related macular degeneration (AMD) is the leading cause of irreversible vision loss in people over the age of 50 years in Australia. Optometry Australia has developed this AMD chairside reference in consultation with a member-based working group comprised of experienced practitioners. It provides an evidence-based approach to current best practice in the diagnosis and management of AMD. Optometrists should be competent in assessing patients with or at risk of developing AMD, so that they are able to provide evidence-based management including appropriate communication, diagnosis and referral when indicated. This AMD chairside reference covers risk factors for the development of AMD or progression to late-stage AMD; the current clinical classification of AMD; common signs and symptoms; optometric assessment including ocular imaging and biomarkers; differential diagnoses; and management of early, intermediate and late AMD. Optometry Australia's chairside reference is intended as a general guide for optometrists, and is not a formal management protocol.
C1 [Hart, Kerryn M.] Support & Optometry Adv, Optometry Australia, Melbourne, Vic, Australia.
   [Hart, Kerryn M.] Deakin Univ, Fac Hlth, Sch Med Optometry, Geelong, Vic, Australia.
   [Abbott, Carla] Royal Victorian Eye & Ear Hosp, Ctr Eye Res Australia, Melbourne, Vic, Australia.
   [Abbott, Carla] Univ Melbourne, Fac Med Dent & Hlth Sci, Dept Surg Ophthalmol, Melbourne, Vic, Australia.
   [Ly, Angelica; Milston, Rebecca] Univ New South Wales, Ctr Eye Hlth, Sydney, NSW, Australia.
   [Lek, Jia Jia; Ayton, Lauren] Univ Melbourne, Fac Med Dent & Hlth Sci, Dept Optometry & Vis Sci, Melbourne, Vic, Australia.
C3 Deakin University; Centre for Eye Research Australia; Royal Victorian
   Eye & Ear Hospital; University of Melbourne; University of New South
   Wales Sydney; University of Melbourne
RP Hart, KM (通讯作者)，Support & Optometry Adv, Optometry Australia, Melbourne, Vic, Australia.; Hart, KM (通讯作者)，Deakin Univ, Fac Hlth, Sch Med Optometry, Geelong, Vic, Australia.
EM k.hart@optometry.org.au
RI Hart, Kerryn/AAR-8926-2020; Ayton, Lauren/AAV-2977-2021; Abbott, Carla
   J/H-9510-2019
OI Hart, Kerryn/0000-0002-8298-9144; Ayton, Lauren/0000-0001-9907-084X;
   Abbott, Carla J/0000-0002-1432-8977; Ly, Angelica/0000-0001-7881-1522
FU 2018 NHMRC Next Generation Fellowship (Translating Research Into
   Practice) on AMD
FX Lauren Ayton is a recipient of a 2018 NHMRC Next Generation Fellowship
   (Translating Research Into Practice) on AMD.
CR Agarwal A, 2012, GASS ATLAS MACULAR D
   Al-Zamil WM, 2017, CLIN INTERV AGING, V12, P1313, DOI 10.2147/CIA.S143508
   [Anonymous], 2014, NUTR REF VAL AUSTR N
   Augustin AJ, 2005, RETINA-J RET VIT DIS, V25, P443, DOI 10.1097/00006982-200506000-00008
   Bearelly S, 2011, RETINA-J RET VIT DIS, V31, P81, DOI 10.1097/IAE.0b013e3181e0958b
   Brody BL, 2001, OPHTHALMOLOGY, V108, P1893, DOI 10.1016/S0161-6420(01)00754-0
   Brouwers MC, 2010, CAN MED ASSOC J, V182, pE839, DOI 10.1503/cmaj.090449
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   Chakravarthy U, 2010, BMC OPHTHALMOL, V10, DOI 10.1186/1471-2415-10-31
   Chew EY, 2014, JAMA OPHTHALMOL, V132, P1031, DOI 10.1001/jamaophthalmol.2014.2009
   Chew EY, 2013, JAMA-J AM MED ASSOC, V309, P2005, DOI 10.1001/jama.2013.4997
   Coscas G, 2015, OPHTHALMIC RES, V54, P57, DOI 10.1159/000433547
   Crossland M, 2007, BRIT J OPHTHALMOL, V91, P391, DOI 10.1136/bjo.2006.095315
   Downie LE, 2017, OPHTHAL PHYSL OPT, V37, P202, DOI 10.1111/opo.12353
   Downie LE, 2014, JAMA OPHTHALMOL, V132, P1031, DOI 10.1001/jamaophthalmol.2014.2007
   Elliott DB., 2014, CLIN PROCEDURES PRIM
   Evans JR, 2005, BRIT J OPHTHALMOL, V89, P550, DOI 10.1136/bjo.2004.049726
   Eye Health Council of Ontario, 2015, CAN J OPTOM, V77, P2
   Ferris FL, 2005, ARCH OPHTHALMOL-CHIC, V123, P1570
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Fineman MS, 2012, RETINA COLOR ATLAS S
   Finger RP, 2014, OPHTHALMOLOGY, V121, P1252, DOI 10.1016/j.ophtha.2013.12.034
   Finger RP, 2013, MED J AUSTRALIA, V198, P260, DOI 10.5694/mja12.11295
   Flaxman SR, 2017, LANCET GLOB HEALTH, V5, pE1221, DOI 10.1016/S2214-109X(17)30393-5
   Frisen L, 2009, BRIT J OPHTHALMOL, V93, P714, DOI 10.1136/bjo.2008.149088
   Gass JD., 1977, STEREOSCOPIC ATLAS M, V2
   Gopinath B, 2015, AGING MENT HEALTH, V19, P239, DOI 10.1080/13607863.2014.924477
   Haddad S, 2006, SURV OPHTHALMOL, V51, P316, DOI 10.1016/j.survophthal.2006.05.001
   Hassell JB, 2006, BRIT J OPHTHALMOL, V90, P593, DOI 10.1136/bjo.2005.086595
   Holz FG, 2007, AM J OPHTHALMOL, V143, P463, DOI 10.1016/j.ajo.2006.11.041
   Holz FG, 2017, OPHTHALMOLOGY, V124, P464, DOI 10.1016/j.ophtha.2016.12.002
   Howard KP, 2014, INVEST OPHTH VIS SCI, V55, P2592, DOI 10.1167/iovs.13-13763
   Hwang JC, 2006, INVEST OPHTH VIS SCI, V47, P2655, DOI 10.1167/iovs.05-1027
   Islam FMA, 2014, OPHTHALMOLOGY, V121, P1428, DOI 10.1016/j.ophtha.2014.01.002
   Joachim N, 2014, OPHTHALMOLOGY, V121, P917, DOI 10.1016/j.ophtha.2013.10.043
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Keel S, 2017, JAMA OPHTHALMOL, V135, P1242, DOI 10.1001/jamaophthalmol.2017.4182
   Khan JC, 2006, BRIT J OPHTHALMOL, V90, P75, DOI 10.1136/bjo.2005.073643
   Khan KN, 2018, RETINA-J RET VIT DIS, V38, P379, DOI 10.1097/IAE.0000000000001523
   Klein ML, 2011, ARCH OPHTHALMOL-CHIC, V129, P1543, DOI 10.1001/archophthalmol.2011.216
   Klein R, 2007, OPHTHALMOLOGY, V114, P253, DOI 10.1016/j.ophtha.2006.10.040
   Lechanteur YTE, 2012, INVEST OPHTH VIS SCI, V53, P5846, DOI 10.1167/iovs.11-7731
   Leibowitz H M, 1980, Surv Ophthalmol, V24, P335
   Luk S, 2015, ACTA OPHTHALMOL, V93, pE309, DOI 10.1111/aos.12567
   Ly A, 2018, CLIN EXP OPTOM, V101, P172, DOI 10.1111/cxo.12624
   Ly A, 2017, OPTOMETRY VISION SCI, V94, P246, DOI 10.1097/OPX.0000000000000997
   Ly A, 2016, OPHTHAL PHYSL OPT, V36, P303, DOI 10.1111/opo.12283
   Mantel I, 2015, TRANSL VIS SCI TECHN, V4, DOI 10.1167/tvst.4.3.6
   McGuinness MB, 2018, JAMA OPHTHALMOL, V136, P139, DOI 10.1001/jamaophthalmol.2017.4782
   Mitchell P, 2011, EYES FUTURE CLEAR OU
   Moshfeghi AA, 2002, OPHTHALMOLOGY, V2006, pe2001
   Myers CE, 2014, OPHTHALMOLOGY, V121, P1949, DOI 10.1016/j.ophtha.2014.04.040
   National Institute for Health and Care Excellence (NICE), 2018, NICE GUID NG82 AG RE
   Oliver Alejandro, 2005, Curr Opin Ophthalmol, V16, P160, DOI 10.1097/01.icu.0000161228.21797.d9
   Pang L, 2016, OPTOMETRY VISION SCI, V93, P1466, DOI 10.1097/OPX.0000000000000959
   Prenner JL, 2015, AM J OPHTHALMOL, V160, P725, DOI 10.1016/j.ajo.2015.06.023
   Reynolds R, 2013, OPHTHALMOLOGY, V120, P1020, DOI 10.1016/j.ophtha.2012.10.020
   Robison CD, 2011, BRIT J OPHTHALMOL, V95, P1419, DOI 10.1136/bjo.2010.194886
   Rofagha S, 2013, OPHTHALMOLOGY, V120, P2292, DOI 10.1016/j.ophtha.2013.03.046
   Rovner BW, 2002, ARCH OPHTHALMOL-CHIC, V120, P1041
   Royal Australian and New Zealand College of Ophthalmologists, 2016, RANZCO REF PATHW AMD
   Rudnicka AR, 2012, OPHTHALMOLOGY, V119, P571, DOI 10.1016/j.ophtha.2011.09.027
   Sadda SR, 2018, OPHTHALMOLOGY, V125, P537, DOI 10.1016/j.ophtha.2017.09.028
   Schwartz Roy, 2015, Int J Retina Vitreous, V1, P20, DOI 10.1186/s40942-015-0022-7
   Scilley K, 2002, OPHTHALMOLOGY, V109, P1235, DOI 10.1016/S0161-6420(02)01060-6
   Seddon JM, 2003, ARCH OPHTHALMOL-CHIC, V121, P1728, DOI 10.1001/archopht.121.12.1728
   Seddon JM, 2003, ARCH OPHTHALMOL-CHIC, V121, P785, DOI 10.1001/archopht.121.6.785
   Stone EM, 1999, NAT GENET, V22, P199, DOI 10.1038/9722
   Takeda AL, 2007, BRIT J OPHTHALMOL, V91, P1177, DOI 10.1136/bjo.2007.118562
   van Leeuwen R, 2005, JAMA-J AM MED ASSOC, V294, P3101, DOI 10.1001/jama.294.24.3101
   VONRUCKMANN A, 1995, BRIT J OPHTHALMOL, V79, P407, DOI 10.1136/bjo.79.5.407
   WELEBER RG, 1994, ARCH OPHTHALMOL-CHIC, V112, P752, DOI 10.1001/archopht.1994.01090180050033
   Williams PT, 2009, INVEST OPHTH VIS SCI, V50, P101, DOI 10.1167/iovs.08-2165
   Wu ZC, 2015, INVEST OPHTH VIS SCI, V56, P115, DOI 10.1167/iovs.14-15614
   Wu ZC, 2014, OPHTHALMOLOGY, V121, P2415, DOI 10.1016/j.ophtha.2014.06.034
   Wykoff CC, 2015, OPHTHALMOLOGY, V122, P2514, DOI 10.1016/j.ophtha.2015.08.009
   2008, OPHTHALMOLOGY, V115, P1474
NR 77
TC 5
Z9 5
U1 0
U2 2
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 0816-4622
EI 1444-0938
J9 CLIN EXP OPTOM
JI Clin. Exp. Optom.
PD MAY
PY 2020
VL 103
IS 3
BP 254
EP 264
DI 10.1111/cxo.12964
EA SEP 2019
PG 11
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA LH0NL
UT WOS:000488157100001
PM 31566818
OA Green Published
DA 2022-11-30
ER

PT J
AU Kim, Y
   Tarallo, V
   Kerur, N
   Yasuma, T
   Gelfand, BD
   Bastos-Carvalho, A
   Hirano, Y
   Yasuma, R
   Mizutani, T
   Fowler, BJ
   Li, SJ
   Kaneko, H
   Bogdanovich, S
   Ambati, BK
   Hinton, DR
   Hauswirth, WW
   Hakem, R
   Wright, C
   Ambati, J
AF Kim, Younghee
   Tarallo, Valeria
   Kerur, Nagaraj
   Yasuma, Tetsuhiro
   Gelfand, Bradley D.
   Bastos-Carvalho, Ana
   Hirano, Yoshio
   Yasuma, Reo
   Mizutani, Takeshi
   Fowler, Benjamin J.
   Li, Shengjian
   Kaneko, Hiroki
   Bogdanovich, Sasha
   Ambati, Balamurali K.
   Hinton, David R.
   Hauswirth, William W.
   Hakem, Razqallah
   Wright, Charles
   Ambati, Jayakrishna
TI DICER1/Alu RNA dysmetabolism induces Caspase-8-mediated cell death in
   age-related macular degeneration
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
   AMERICA
LA English
DT Article
DE macular degeneration; inflammasome; caspase
ID NLRP3 INFLAMMASOME; ACTIVATION; INTERLEUKIN-18; MECHANISMS; APOPTOSIS;
   IL-18; IL-1-BETA; INDUCTION; TRIGGERS; ROLES
AB Geographic atrophy, an advanced form of age-related macular degeneration (AMD) characterized by death of the retinal pigmented epithelium (RPE), causes untreatable blindness in millions worldwide. The RPE of human eyes with geographic atrophy accumulates toxic Alu RNA in response to a deficit in the enzyme DICER1, which in turn leads to activation of the NLRP3 inflammasome and elaboration of IL-18. Despite these recent insights, it is still unclear how RPE cells die during the course of the disease. In this study, we implicate the involvement of Caspase-8 as a critical mediator of RPE degeneration. Here we show that DICER1 deficiency, Alu RNA accumulation, and IL-18 up-regulation lead to RPE cell death via activation of Caspase-8 through a Fas ligand-dependent mechanism. Coupled with our observation of increased Caspase-8 expression in the RPE of human eyes with geographic atrophy, our findings provide a rationale for targeting this apoptotic pathway in this disease.
C1 [Kim, Younghee; Tarallo, Valeria; Kerur, Nagaraj; Yasuma, Tetsuhiro; Gelfand, Bradley D.; Bastos-Carvalho, Ana; Hirano, Yoshio; Yasuma, Reo; Mizutani, Takeshi; Fowler, Benjamin J.; Li, Shengjian; Kaneko, Hiroki; Bogdanovich, Sasha; Wright, Charles; Ambati, Jayakrishna] Univ Kentucky, Dept Ophthalmol & Visual Sci, Lexington, KY 40536 USA.
   [Gelfand, Bradley D.] Univ Kentucky, Dept Biomed Engn, Lexington, KY 40536 USA.
   [Gelfand, Bradley D.] Univ Kentucky, Dept Microbiol Immunol & Human Genet, Lexington, KY 40536 USA.
   [Fowler, Benjamin J.; Ambati, Jayakrishna] Univ Kentucky, Dept Physiol, Lexington, KY 40536 USA.
   [Tarallo, Valeria] CNR, Inst Genet & Biophys, Angiogenesis Lab, I-80131 Naples, Italy.
   [Ambati, Balamurali K.] Univ Utah, Sch Med, Moran Eye Ctr, Dept Ophthalmol & Visual Sci, Salt Lake City, UT 84132 USA.
   [Ambati, Balamurali K.] Vet Affairs Salt Lake City Healthcare Syst, Dept Ophthalmol, Salt Lake City, UT 84148 USA.
   [Hinton, David R.] Univ So Calif, Keck Sch Med, Dept Pathol, Los Angeles, CA 90033 USA.
   [Hinton, David R.] Univ So Calif, Keck Sch Med, Dept Ophthalmol, Los Angeles, CA 90033 USA.
   [Hauswirth, William W.] Univ Florida, Dept Ophthalmol, Gainesville, FL 32610 USA.
   [Hakem, Razqallah] Univ Hlth Network, Ontario Canc Inst, Toronto, ON M5G 2M9, Canada.
   [Hakem, Razqallah] Univ Toronto, Dept Med Biophys, Toronto, ON M5G 2M9, Canada.
C3 University of Kentucky; University of Kentucky; University of Kentucky;
   University of Kentucky; Consiglio Nazionale delle Ricerche (CNR);
   Istituto di Genetica e Biofisica "Adriano Buzzati-Traverso" (IGB-CNR);
   Utah System of Higher Education; University of Utah; US Department of
   Veterans Affairs; University of Southern California; University of
   Southern California; State University System of Florida; University of
   Florida; University of Toronto; University Toronto Affiliates;
   University Health Network Toronto; University of Toronto
RP Ambati, J (通讯作者)，Univ Kentucky, Dept Ophthalmol & Visual Sci, Lexington, KY 40536 USA.
EM jamba2@email.uky.edu
RI Kaneko, Hiroki/AHA-2461-2022; Kaneko, Hiroki/O-7695-2015; Gelfand,
   Brad/L-3926-2019
OI Kaneko, Hiroki/0000-0003-0731-6465; Kaneko, Hiroki/0000-0003-0731-6465;
   Hakem, Razqallah/0000-0001-5948-7931; Hirano,
   Yoshio/0000-0002-9173-0839; Tarallo, Valeria/0000-0002-6920-4402;
   hauswirth, william/0000-0002-3244-4947
FU National Institutes of Health (NIH) [DP1GM114862, R01EY018350,
   R01EY018836, R01EY020672, R01EY022238, R01EY024068]; Doris Duke
   Distinguished Clinical Scientist Award; Burroughs Wellcome Fund Clinical
   Scientist Award in Translational Research; Ellison Medical Foundation
   Senior Scholar in Aging Award; Dr. E. Vernon Smith and Eloise C. Smith
   Macular Degeneration Endowed Chair; Foundation Fighting Blindness
   Individual Investigator Research Award; Carl Reeves Foundation;
   Harrington Discovery Institute Scholar-Innovator Award; Alcon Japan
   Research award; Fight for Sight postdoctoral award; NIH [T32HL091812,
   UL1RR033173, K99EY024336, R01EY017182, R01EY017950, P30EY003040,
   R01EY001545, P30EY021721, R01EY17549]; Programme for Advanced Medical
   Education - Fundacao Calouste Gulbenkian; Programme for Advanced Medical
   Education - Fundacao Champalimaud; Programme for Advanced Medical
   Education - Ministerio da Saude; Programme for Advanced Medical
   Education - Fundacao para a Ciencia e Tecnologia, Portugal; Bayer Global
   Ophthalmology Research Award; Beckman Initiative for Macular Research;
   American Heart Association; International Retinal Research Foundation
   (IRRF); VA Merit Award; Department of Defense; Arnold and Mabel Beckman
   Foundation; Macular Vision Research Foundation, Overstreet Fund and
   Research to Prevent Blindness; Loris and David Rich Postdoctoral Scholar
   Award (IRRF); NATIONAL CENTER FOR RESEARCH RESOURCES [UL1RR033173]
   Funding Source: NIH RePORTER; NATIONAL EYE INSTITUTE [P30EY021721,
   P30EY003040, R01EY020672, R01EY017549, R01EY024068, R01EY017950,
   K99EY024336, R01EY018836, R01EY017182, R01EY018350, R01EY022238,
   R01EY001545] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND
   BLOOD INSTITUTE [T32HL091812] Funding Source: NIH RePORTER; NATIONAL
   INSTITUTE OF GENERAL MEDICAL SCIENCES [DP1GM114862] Funding Source: NIH
   RePORTER
FX We thank L. Toll, G. R. Pattison, R. King, L. Xu, M. McConnell, C.
   Payne, D. Robertson, G. Botzet, K. Ambati, and A. Uittenbogaard for
   technical assistance. J.A. was supported by National Institutes of
   Health (NIH) Grants DP1GM114862, R01EY018350, R01EY018836, R01EY020672,
   R01EY022238, and R01EY024068 and Doris Duke Distinguished Clinical
   Scientist Award, Burroughs Wellcome Fund Clinical Scientist Award in
   Translational Research, Ellison Medical Foundation Senior Scholar in
   Aging Award, Dr. E. Vernon Smith and Eloise C. Smith Macular
   Degeneration Endowed Chair, Foundation Fighting Blindness Individual
   Investigator Research Award, Carl Reeves Foundation, and Harrington
   Discovery Institute Scholar-Innovator Award. Y.H. was supported by an
   Alcon Japan Research award; T.Y. was supported by a Fight for Sight
   postdoctoral award; B.J.F. was supported by NIH Grants T32HL091812 and
   UL1RR033173; A. B.-C. was supported by the Programme for Advanced
   Medical Education (sponsored by Fundacao Calouste Gulbenkian, Fundacao
   Champalimaud, Ministerio da Saude and Fundacao para a Ciencia e
   Tecnologia, Portugal) and Bayer Global Ophthalmology Research Award;
   N.K. was supported by Beckman Initiative for Macular Research and NIH
   Grant K99EY024336; B. D. G. was supported by American Heart Association
   and International Retinal Research Foundation (IRRF); B. K. A. was
   supported by NIH Grants R01EY017182 and R01EY017950, VA Merit Award, and
   Department of Defense; D. R. H. was supported by NIH Grants P30EY003040
   and R01EY001545 and Arnold and Mabel Beckman Foundation; W. W. H. was
   supported by NIH Grants P30EY021721 and R01EY17549 and Macular Vision
   Research Foundation, Overstreet Fund and Research to Prevent Blindness;
   and C. W. was supported by The Loris and David Rich Postdoctoral Scholar
   Award (IRRF).
CR Ambati J, 2013, NAT REV IMMUNOL, V13, P438, DOI 10.1038/nri3459
   Ambati J, 2012, NEURON, V75, P26, DOI 10.1016/j.neuron.2012.06.018
   Antonopoulos C, 2013, J IMMUNOL, V191, P4789, DOI 10.4049/jimmunol.1300645
   Bernstein E, 2001, NATURE, V409, P363, DOI 10.1038/35053110
   Dinarello CA, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00289
   Doyle SL, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3007616
   Doyle SL, 2012, NAT MED, V18, P791, DOI 10.1038/nm.2717
   Dridi S, 2012, P NATL ACAD SCI USA, V109, P13781, DOI 10.1073/pnas.1206494109
   Gringhuis SI, 2012, NAT IMMUNOL, V13, P246, DOI 10.1038/ni.2222
   Gross O, 2011, IMMUNOL REV, V243, P136, DOI 10.1111/j.1600-065X.2011.01046.x
   Gurung P, 2014, J IMMUNOL, V192, P1835, DOI 10.4049/jimmunol.1302839
   Haneklaus M, 2013, CURR OPIN IMMUNOL, V25, P40, DOI 10.1016/j.coi.2012.12.004
   Hinton DR, 1998, ARCH OPHTHALMOL-CHIC, V116, P203
   Hirano Y, 2014, NAT MED IN PRESS
   Ijima R, 2014, INVEST OPHTH VIS SCI, V55, DOI 10.1167/iovs.14-15367
   Kaneko H, 2011, NATURE, V471, P325, DOI 10.1038/nature09830
   Kang TB, 2013, IMMUNITY, V38, P27, DOI 10.1016/j.immuni.2012.09.015
   Kashiwamura S, 2002, J IMMUNOTHER, V25, pS4, DOI 10.1097/00002371-200203001-00002
   Kaufmann T, 2012, CELL DEATH DIFFER, V19, P42, DOI 10.1038/cdd.2011.121
   Kerur N, 2013, INVEST OPHTH VIS SCI, V54, P7395, DOI 10.1167/iovs.13-12500
   Ketting RF, 2001, GENE DEV, V15, P2654, DOI 10.1101/gad.927801
   Murakami Y, 2014, CELL DEATH DIFFER, V21, P270, DOI 10.1038/cdd.2013.109
   Ohnishi H, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0038423
   Ohtsuki T, 1997, ANTICANCER RES, V17, P3253
   Pierini R, 2012, CELL DEATH DIFFER, V19, P1709, DOI 10.1038/cdd.2012.51
   Salmena L, 2003, GENE DEV, V17, P883, DOI 10.1101/gad.1063703
   Shiose S, 2011, J BIOL CHEM, V286, P15543, DOI 10.1074/jbc.M111.228551
   Sun QM, 2006, IMMUNITY, V24, P633, DOI 10.1016/j.immuni.2006.04.004
   Tarallo V, 2012, CELL, V149, P847, DOI 10.1016/j.cell.2012.03.036
   Wen HT, 2013, IMMUNITY, V39, P432, DOI 10.1016/j.immuni.2013.08.037
   Yang ZL, 2008, NEW ENGL J MED, V359, P1456, DOI 10.1056/NEJMoa0802437
   Zhang HJ, 2011, AM J PHYSIOL-RENAL, V301, pF171, DOI 10.1152/ajprenal.00339.2010
   Zou J, 2013, IMMUNITY, V38, P717, DOI 10.1016/j.immuni.2012.12.007
NR 33
TC 67
Z9 69
U1 0
U2 10
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027-8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD NOV 11
PY 2014
VL 111
IS 45
BP 16082
EP 16087
DI 10.1073/pnas.1403814111
PG 6
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA AS8WW
UT WOS:000344526800058
PM 25349431
OA Green Published, Bronze
DA 2022-11-30
ER

PT J
AU Cheung, CMG
   Wong, TY
AF Cheung, C. M. G.
   Wong, T. Y.
TI Is age-related macular degeneration a manifestation of systemic disease?
   New prospects for early intervention and treatment
SO JOURNAL OF INTERNAL MEDICINE
LA English
DT Review
DE age-related macular degeneration; pathogenesis; risk factors; treatment
ID COMPLEMENT-FACTOR-H; ENDOTHELIAL GROWTH-FACTOR; C-REACTIVE PROTEIN;
   POLYPOIDAL CHOROIDAL VASCULOPATHY; LONG-TERM INCIDENCE; CARDIOVASCULAR
   RISK-FACTORS; CORONARY-HEART-DISEASE; MYOCARDIAL-INFARCTION;
   ATHEROSCLEROSIS RISK; 10-YEAR INCIDENCE
AB Age-related macular degeneration (AMD) is a common vision-threatening condition affecting the elderly. AMD shares common risk factors and processes, including vascular and inflammatory pathways, with many systemic disorders. Associations have been reported between AMD and hypertension, cardiovascular disease, cerebrovascular disease, dyslipidaemia, chronic kidney disease and neurodegenerative disorders. An increasing amount of evidence suggests that individuals with AMD are also at risk of systemic diseases such as stroke. In this review, we summarize the latest evidence to support the notion that AMD is an ocular manifestation of systemic disease processes, and discuss the potential systemic side effects of ocular AMD therapy of which general physicians should be aware. Recent genetic discoveries and understanding of the pathogenic pathways in AMD in relation to systemic disorders are also highlighted.
C1 [Cheung, C. M. G.; Wong, T. Y.] Singapore Natl Eye Ctr, Singapore 168751, Singapore.
   [Cheung, C. M. G.; Wong, T. Y.] Singapore Eye Res Inst, Singapore, Singapore.
   [Cheung, C. M. G.; Wong, T. Y.] Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Ophthalmol, Singapore 117595, Singapore.
   [Wong, T. Y.] Duke NUS Grad Med Sch, Ophthalmol Acad Clin Program, Singapore, Singapore.
C3 Singapore National Eye Center; National University of Singapore;
   Singapore National Eye Center; National University of Singapore;
   National University of Singapore
RP Wong, TY (通讯作者)，Singapore Natl Eye Ctr, 11 Third Hosp Ave, Singapore 168751, Singapore.
EM ophwty@nus.edu.sg
RI Wong, Tien Yin/AAC-9724-2020
OI Wong, Tien Yin/0000-0002-8448-1264; Cheung, Chui Ming
   Gemmy/0000-0003-3358-3516
CR Ambati J, 2003, SURV OPHTHALMOL, V48, P257, DOI 10.1016/S0039-6257(03)00030-4
   Anand R, 2000, OPHTHALMOLOGY, V107, P2224
   Baird PN, 2014, CLIN EXP OPHTHALMOL, V42, P53, DOI 10.1111/ceo.12235
   Bakri SJ, 2007, OPHTHALMOLOGY, V114, P855, DOI 10.1016/j.ophtha.2007.01.017
   Belkin M, 2013, AM J OPHTHALMOL, V155, P404, DOI 10.1016/j.ajo.2012.09.017
   Bloch SB, 2012, AM J OPHTHALMOL, V153, P209, DOI 10.1016/j.ajo.2011.10.016
   Borger PH, 2003, OPHTHALMOLOGY, V110, P1292, DOI 10.1016/S0161-6420(03)00450-0
   Bourne RRA, 2013, LANCET GLOB HEALTH, V1, pE339, DOI 10.1016/S2214-109X(13)70113-X
   Bressler NM, 2012, RETINA-J RET VIT DIS, V32, P1821, DOI 10.1097/IAE.0b013e31825db6ba
   Bromfield S, 2012, CURR EYE RES, V37, P549, DOI 10.3109/02713683.2011.647223
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Buch H, 2005, OPHTHALMOLOGY, V112, P787, DOI 10.1016/j.ophtha.2004.11.040
   Buitendijk GHS, 2013, OPHTHALMOLOGY, V120, P2644, DOI 10.1016/j.ophtha.2013.07.053
   Cackett P, 2008, AM J OPHTHALMOL, V146, P960, DOI 10.1016/j.ajo.2008.06.026
   Cackett P, 2011, OPHTHALMOLOGY, V118, P846, DOI 10.1016/j.ophtha.2010.09.026
   Campagne MV, 2014, J PATHOL, V232, P151, DOI 10.1002/path.4266
   Campbell RJ, 2012, OPHTHALMOLOGY, V119, P1604, DOI 10.1016/j.ophtha.2012.05.028
   Chakravarthy U, 2013, LANCET, V382, P1258, DOI 10.1016/S0140-6736(13)61501-9
   Chakravarthy U, 2010, BMC OPHTHALMOL, V10, DOI 10.1186/1471-2415-10-31
   Chen SJ, 2008, INVEST OPHTH VIS SCI, V49, P3126, DOI 10.1167/iovs.08-1803
   Cheung CMG, 2012, CLIN EXP OPHTHALMOL, V40, P727, DOI 10.1111/j.1442-9071.2012.02765.x
   Cheung CMG, 2013, LANCET, V382, P1230, DOI 10.1016/S0140-6736(13)61580-9
   Cheung CMG, 2013, AM J OPHTHALMOL, V155, P764, DOI 10.1016/j.ajo.2012.10.013
   Cheung N, 2013, BRIT J OPHTHALMOL, V97, P785, DOI 10.1136/bjophthalmol-2012-302253
   Chew EY, 2013, OPHTHALMOLOGY, V120, P1604, DOI 10.1016/j.ophtha.2013.01.021
   Chew EY, 2013, JAMA-J AM MED ASSOC, V309, P2005, DOI 10.1001/jama.2013.4997
   Chew EY, 2012, OPHTHALMOLOGY, V119, P2282, DOI 10.1016/j.ophtha.2012.05.027
   Cho BJ, 2014, INVEST OPHTH VIS SCI, V55, P1101, DOI 10.1167/iovs.13-13096
   Choudhury F, 2011, AM J OPHTHALMOL, V152, P385, DOI 10.1016/j.ajo.2011.02.025
   Christen WG, 2012, OPHTHALMOLOGY, V119, P1642, DOI 10.1016/j.ophtha.2012.01.053
   Christen WG, 2009, OPHTHALMOLOGY, V116, P2386, DOI 10.1016/j.ophtha.2009.05.031
   Ciulla TA, 2009, CURR OPIN OPHTHALMOL, V20, P158, DOI 10.1097/ICU.0b013e32832d25b3
   Clemons TE, 2004, ARCH OPHTHALMOL-CHIC, V122, P716
   Cong RH, 2008, ANN EPIDEMIOL, V18, P647, DOI 10.1016/j.annepidem.2008.04.002
   Conley YP, 2006, HUM MOL GENET, V15, P3206, DOI 10.1093/hmg/ddl396
   Cougnard-Gregoire A, 2013, INVEST OPHTH VIS SCI, V54, P1905, DOI 10.1167/iovs.12-10192
   Cugati S, 2007, ARCH OPHTHALMOL-CHIC, V125, P917, DOI 10.1001/archopht.125.7.917
   Curtis LH, 2010, ARCH OPHTHALMOL-CHIC, V128, P1273, DOI 10.1001/archophthalmol.2010.223
   de Jong PTVM, 2012, OPHTHALMOLOGY, V119, P112, DOI 10.1016/j.ophtha.2011.06.025
   Duan YK, 2007, OPHTHALMOLOGY, V114, P732, DOI 10.1016/j.ophtha.2006.07.045
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Erke MG, 2012, OPHTHALMOLOGY, V119, P1737, DOI 10.1016/j.ophtha.2012.03.016
   Fernandez AB, 2012, OPHTHALMOLOGY, V119, P765, DOI 10.1016/j.ophtha.2011.09.044
   Fraser-Bell S, 2006, AM J OPHTHALMOL, V141, P79, DOI 10.1016/j.ajo.2005.08.024
   Fritsche LG, 2013, NAT GENET, V45, P433, DOI 10.1038/ng.2578
   Gehlbach P, 2012, COCHRANE DB SYST REV, V3
   Geirsdottir A, 2007, AM J OPHTHALMOL, V143, P889, DOI 10.1016/j.ajo.2006.11.057
   Gillies MC, 2007, NEW ENGL J MED, V356, P748
   Girgis RAM, 2004, AM J OPHTHALMOL, V138, P697, DOI 10.1016/j.ajo.2004.05.063
   Gorin MB, 2012, MOL ASPECTS MED, V33, P467, DOI 10.1016/j.mam.2012.04.004
   Grosso A, 2007, AM J OPHTHALMOL, V143, P157, DOI 10.1016/j.ajo.2006.07.040
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Hahn P, 2013, RETINA-J RET VIT DIS, V33, P911, DOI 10.1097/IAE.0b013e3182831248
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Hogg RE, 2008, OPHTHALMOLOGY, V115, P1046, DOI 10.1016/j.ophtha.2007.07.031
   Hu CC, 2010, STROKE, V41, P613, DOI 10.1161/STROKEAHA.109.571000
   Hyman L, 2000, ARCH OPHTHALMOL-CHIC, V118, P351, DOI 10.1001/archopht.118.3.351
   Ikram MK, 2012, STROKE, V43, P1681, DOI 10.1161/STROKEAHA.112.654632
   Kabasawa S, 2011, OPHTHALMOLOGY, V118, P1082, DOI 10.1016/j.ophtha.2010.10.012
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Kawasaki R, 2008, OPHTHALMOLOGY, V115, P1376, DOI 10.1016/j.ophtha.2007.11.015
   Kawasaki R, 2010, OPHTHALMOLOGY, V117, P921, DOI 10.1016/j.ophtha.2009.10.007
   Keenan TDL, 2014, JAMA OPHTHALMOL, V132, P63, DOI 10.1001/jamaophthalmol.2013.5696
   Keilhauer CN, 2013, EUR J MED GENET, V56, P72, DOI 10.1016/j.ejmg.2012.10.005
   Kemp A, 2013, RETINA-J RET VIT DIS, V33, P920, DOI 10.1097/IAE.0b013e318276e07b
   Khandhadia S, 2012, MOL VIS, V18, P29
   Kikuchi M, 2007, OPHTHALMOLOGY, V114, P1722, DOI 10.1016/j.ophtha.2006.12.021
   Klein BEK, 2012, JAMA-J AM MED ASSOC, V308, P2469, DOI 10.1001/jama.2012.65406
   Klein R, 2004, AM J OPHTHALMOL, V137, P486, DOI 10.1016/j.ajo.2003.11.069
   Klein R, 2003, OPHTHALMOLOGY, V110, P636, DOI 10.1016/S0161-6420(02)01448-3
   KLEIN R, 1995, OPHTHALMOLOGY, V102, P371
   Klein R, 2003, OPHTHALMOLOGY, V110, P25, DOI 10.1016/S0161-6420(02)01565-8
   Klein R, 2002, OPHTHALMOLOGY, V109, P1767, DOI 10.1016/S0161-6420(02)01146-6
   KLEIN R, 1993, OPHTHALMOLOGY, V100, P406
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Klein R, 2008, OPHTHALMOLOGY, V115, P1742, DOI 10.1016/j.ophtha.2008.03.021
   Klein R, 2007, AM J OPHTHALMOL, V144, P1, DOI 10.1016/j.ajo.2007.02.047
   Klein R, 2007, AM J OPHTHALMOL, V143, P473, DOI 10.1016/j.ajo.2006.11.058
   Klein R, 2007, OPHTHALMOLOGY, V114, P253, DOI 10.1016/j.ophtha.2006.10.040
   Klein R, 2013, OPHTHALMOLOGY, V120, P1012, DOI 10.1016/j.ophtha.2012.11.003
   Klein R, 2011, ARCH OPHTHALMOL-CHIC, V129, P1605, DOI 10.1001/archophthalmol.2011.372
   Klein R, 2009, ARCH OPHTHALMOL-CHIC, V127, P193, DOI 10.1001/archophthalmol.2008.551
   La Torre G, 2013, EUR J EPIDEMIOL, V28, P445, DOI 10.1007/s10654-013-9798-7
   Liao DP, 2008, OPEN OPHTHALMOL J, V2, P37, DOI 10.2174/1874364100802010037
   Liew G, 2008, J AM SOC NEPHROL, V19, P806, DOI 10.1681/ASN.2007080844
   Liew G, 2013, JAMA INTERN MED, V173, P258, DOI 10.1001/jamainternmed.2013.1583
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Lim LS, 2011, AM J OPHTHALMOL, V152, P329, DOI 10.1016/j.ajo.2011.05.040
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Matsuyama K, 2010, BRIT J OPHTHALMOL, V94, P1215, DOI 10.1136/bjo.2008.156810
   McGwin G, 2005, OPHTHALMOLOGY, V112, P488, DOI 10.1016/j.ophtha.2004.10.027
   Merle BMJ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0079848
   Milton RC, 2005, OPHTHALMOLOGY, V112, P533, DOI 10.1016/j.ophtha.2004.10.047
   Mitta VP, 2013, JAMA OPHTHALMOL, V131, P507, DOI 10.1001/jamaophthalmol.2013.2303
   Moriarty-Craige SE, 2007, AM J OPHTHALMOL, V143, P206, DOI 10.1016/j.ajo.2006.09.056
   Musch DC, 2014, JAMA OPHTHALMOL, V132, P139, DOI 10.1001/jamaophthalmol.2013.7443
   Nalluri SR, 2008, JAMA-J AM MED ASSOC, V300, P2277, DOI 10.1001/jama.2008.656
   Neale BM, 2010, P NATL ACAD SCI USA, V107, P7395, DOI 10.1073/pnas.0912019107
   Ohno-Matsui K, 2011, PROG RETIN EYE RES, V30, P217, DOI 10.1016/j.preteyeres.2011.02.004
   Pan CW, 2013, OPHTHALMOLOGY, V120, P2058, DOI 10.1016/j.ophtha.2013.03.028
   Parmeggiani F, 2013, MEDIAT INFLAMM, V2013, DOI 10.1155/2013/435607
   Priya RR, 2012, OPHTHALMOLOGY, V119, P2526, DOI 10.1016/j.ophtha.2012.06.042
   Ratnapriya R, 2013, CLIN GENET, V84, P160, DOI 10.1111/cge.12206
   Rennie CA, 2012, EYE, V26, P109, DOI 10.1038/eye.2011.256
   Reynolds R, 2013, OPHTHALMOLOGY, V120, P1020, DOI 10.1016/j.ophtha.2012.10.020
   Reynolds R, 2010, OPHTHALMOLOGY, V117, P1989, DOI 10.1016/j.ophtha.2010.07.009
   Rivera A, 2005, HUM MOL GENET, V14, P3227, DOI 10.1093/hmg/ddi353
   Robman L, 2007, INVEST OPHTH VIS SCI, V48, P4007, DOI 10.1167/iovs.06-1434
   Robman L, 2010, OPHTHALMOLOGY, V117, P1982, DOI 10.1016/j.ophtha.2010.02.003
   Rochtchina E, 2007, AM J OPHTHALMOL, V143, P344, DOI 10.1016/j.ajo.2006.08.032
   de Cordoba SR, 2012, IMMUNOBIOLOGY, V217, P1034, DOI 10.1016/j.imbio.2012.07.021
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rudnicka AR, 2012, OPHTHALMOLOGY, V119, P571, DOI 10.1016/j.ophtha.2011.09.027
   Sakurada Y, 2013, RETINA-J RET VIT DIS, V33, P841, DOI 10.1097/IAE.0b013e31826ffe9d
   Schmidt S, 2006, AM J HUM GENET, V78, P852, DOI 10.1086/503822
   Schmucker C, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0042701
   Seddon JM, 2005, ARCH OPHTHALMOL-CHIC, V123, P774, DOI 10.1001/archopht.123.6.774
   Seddon JM, 2003, ARCH OPHTHALMOL-CHIC, V121, P785, DOI 10.1001/archopht.121.6.785
   Seddon JM, 2006, ARCH OPHTHALMOL-CHIC, V124, P995, DOI 10.1001/archopht.124.7.995
   Seddon JM, 2013, JAMA OPHTHALMOL, V131, P448, DOI 10.1001/jamaophthalmol.2013.2578
   Seddon JM, 2010, OPHTHALMOLOGY, V117, P1560, DOI 10.1016/j.ophtha.2009.11.020
   Shankar A, 2007, AM J EPIDEMIOL, V165, P375, DOI 10.1093/aje/kwk022
   Sin HPY, 2013, ACTA OPHTHALMOL, V91, P6, DOI 10.1111/j.1755-3768.2011.02357.x
   Sivak JM, 2013, INVEST OPHTH VIS SCI, V54, P871, DOI 10.1167/iovs.12-10827
   Souied EH, 2013, OPHTHALMOLOGY, V120, P1619, DOI 10.1016/j.ophtha.2013.01.005
   Stone EM, 2012, OPHTHALMOLOGY, V119, P2408, DOI 10.1016/j.ophtha.2012.05.047
   Tan JSL, 2008, OPHTHALMOLOGY, V115, P334, DOI 10.1016/j.ophtha.2007.03.083
   Tan JSL, 2007, OPHTHALMOLOGY, V114, P1143, DOI 10.1016/j.ophtha.2006.09.033
   Tan JSL, 2007, AM J OPHTHALMOL, V143, P685, DOI 10.1016/j.ajo.2006.11.021
   Tolentino M, 2011, SURV OPHTHALMOL, V56, P95, DOI 10.1016/j.survophthal.2010.08.006
   Tomany SC, 2004, OPHTHALMOLOGY, V111, P1280, DOI 10.1016/j.ophtha.2003.11.010
   Ueta T, 2009, OPHTHALMOLOGY, V116, P2400, DOI 10.1016/j.ophtha.2009.06.013
   Van Leeuwen R, 2004, OPHTHALMOLOGY, V111, P1169, DOI 10.1016/j.ophtha.2003.10.024
   van Leeuwen R, 2004, AM J OPHTHALMOL, V137, P750, DOI 10.1016/S0002-9394(03)01089-4
   van Leeuwen R, 2003, INVEST OPHTH VIS SCI, V44, P3771, DOI 10.1167/iovs.03-0121
   Velez-Montoya R, 2013, RETINA-J RET VIT DIS, V33, P1487, DOI 10.1097/IAE.0b013e318271f265
   Vine AK, 2005, OPHTHALMOLOGY, V112, P2076, DOI 10.1016/j.ophtha.2005.07.004
   Wang JJ, 2008, OPHTHALMOLOGY, V115, P693, DOI 10.1016/j.ophtha.2007.05.038
   Wang JJ, 2007, OPHTHALMOLOGY, V114, P92, DOI 10.1016/j.ophtha.2006.07.017
   Wang JJ, 2009, AM J EPIDEMIOL, V169, P633, DOI 10.1093/aje/kwn358
   Wang JJ, 2001, ARCH OPHTHALMOL-CHIC, V119, P1186, DOI 10.1001/archopht.119.8.1186
   Weiner DE, 2011, NEPHROL DIAL TRANSPL, V26, P3159, DOI 10.1093/ndt/gfr022
   Wilson HL, 2004, AM J OPHTHALMOL, V137, P615, DOI 10.1016/j.ajo.2003.10.025
   Wong CW, 2014, KIDNEY INT, V85, P1290, DOI 10.1038/ki.2013.491
   Wong T, 2008, OPHTHALMOLOGY, V115, P116, DOI 10.1016/j.ophtha.2007.03.008
   Wong T, 2007, LANCET, V369, P425, DOI 10.1016/S0140-6736(07)60198-6
   Wong TY, 2008, AM J OPHTHALMOL, V146, P656, DOI 10.1016/j.ajo.2008.07.048
   Wong TY, 2007, AM J OPHTHALMOL, V144, P117, DOI 10.1016/j.ajo.2007.04.018
   Wong TY, 2007, LANCET, V370, P204, DOI 10.1016/S0140-6736(07)61104-0
   Wong TY, 2010, STROKE, V41, P575, DOI 10.1161/STROKEAHA.109.574475
   Wong TY, 2009, AM J OPHTHALMOL, V148, P327, DOI 10.1016/j.ajo.2009.05.012
   Wong TY, 2007, OPHTHALMOLOGY, V114, P86, DOI 10.1016/j.ophtha.2006.06.039
   Wong TY, 2006, ANN INTERN MED, V145, P98, DOI 10.7326/0003-4819-145-2-200607180-00007
   Wong TY, 2002, STROKE, V33, P1487, DOI 10.1161/01.STR.0000016789.56668.43
   Woo SJ, 2012, OPHTHALMOLOGY, V119, P2094, DOI 10.1016/j.ophtha.2012.04.026
   Xing C, 2008, GENES IMMUN, V9, P231, DOI 10.1038/gene.2008.10
   Yang ZL, 2006, SCIENCE, V314, P992, DOI 10.1126/science.1133811
   Yasuda M, 2009, OPHTHALMOLOGY, V116, P2135, DOI 10.1016/j.ophtha.2009.04.017
   You QS, 2012, OPHTHALMOLOGY, V119, P2519, DOI 10.1016/j.ophtha.2012.06.043
   Zhang XZ, 2013, EXP EYE RES, V108, P16, DOI 10.1016/j.exer.2012.12.005
NR 160
TC 70
Z9 71
U1 0
U2 16
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0954-6820
EI 1365-2796
J9 J INTERN MED
JI J. Intern. Med.
PD AUG
PY 2014
VL 276
IS 2
BP 140
EP 153
DI 10.1111/joim.12227
PG 14
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA AN3OS
UT WOS:000340498400005
PM 24581182
DA 2022-11-30
ER

PT J
AU Gehrs, KM
   Anderson, DH
   Johnson, LV
   Hageman, GS
AF Gehrs, Karen M.
   Anderson, Don H.
   Johnson, Lincoln V.
   Hageman, Gregory S.
TI Age-related macular degeneration - emerging pathogenetic and therapeutic
   concepts
SO ANNALS OF MEDICINE
LA English
DT Review
DE age-related macular degeneration (AMD); basal laminar deposit (BLamD);
   Bruch's membrane; choroidal neovascularization; complement Factor B
   (BF); complement Factor H (CFH); drusen; epidemiology; genetics;
   geographic atrophy; inflammation; surgery
ID COMPLEMENT FACTOR-H; HEMOLYTIC-UREMIC SYNDROME; SUBFOVEAL CHOROIDAL
   NEOVASCULARIZATION; RETINAL-PIGMENT EPITHELIUM; BASAL LAMINAR DEPOSIT;
   BRUCHS MEMBRANE; INTRAVITREAL INJECTION; MORPHOMETRIC-ANALYSIS;
   ALTERNATIVE PATHWAY; SUSCEPTIBILITY LOCI
AB Today, the average life expectancy in developed nations is over 80 years and climbing. And yet, the quality of life during those additional years is often significantly diminished by the effects of age-related, degenerative diseases, including age-related macular degeneration (AMD), the leading cause of blindness in the elderly worldwide. AMD is characterized by a progressive loss of central vision attributable to degenerative and neovascular changes in the macula, a highly specialized region of the ocular retina responsible for fine visual acuity. Estimates gathered from the most recent World Health Organization (WHO) global eye disease survey conservatively indicate that 14 million persons are blind or severely visually impaired because of AMD. The disease has a tremendous impact on the physical and mental health of the geriatric population and their families and is becoming a major public health burden. Currently, there is neither a cure nor a means to prevent AMD. Palliative treatment options for the less prevalent, late-stage 'wet' form of the disease include anti-neovascular agents, photodynamic therapy and thermal laser. There are no current therapies for the more common 'dry' AMD, except for the use of antioxidants that delay progression in 20%-25% of eyes. New discoveries, however, are beginning to provide a much clearer picture of the relevant cellular events, genetic factors, and biochemical processes associated with early AMD. Recently, compelling evidence has emerged that the innate immune system and, more specifically, uncontrolled regulation of the complement alternative pathway plays a central role in the pathobiology of AMD. The complement Factor H gene-which encodes the major inhibitor of the complement alternative pathway-is the first gene identified in multiple independent studies that confers a significant genetic risk for the development of AMD. The emergence of this new paradigm of AMD pathogenesis should hasten the development of novel diagnostic and therapeutic approaches for this disease that will dramatically improve the quality of our prolonged lifespan.
C1 Univ Iowa, Dept Ophthalmol & Visual Sci, Cell Biol & Funct Gen Lab, Iowa City, IA 52240 USA.
   Univ Calif Santa Barbara, Ctr Study Macular Degenerat, Santa Barbara, CA 93106 USA.
   Univ Calif Santa Barbara, Neurosci Res Inst, Santa Barbara, CA 93106 USA.
C3 University of Iowa; University of California System; University of
   California Santa Barbara; University of California System; University of
   California Santa Barbara
RP Hageman, GS (通讯作者)，Univ Iowa, Dept Ophthalmol & Visual Sci, Cell Biol & Funct Gen Lab, 11190E PFP,200 Hawkins Dr, Iowa City, IA 52240 USA.
EM gregory-hageman@uiowa.edu
OI Gehrs, Karen/0000-0003-4510-9678
FU NATIONAL EYE INSTITUTE [R01EY011527, R01EY011515, R01EY011521] Funding
   Source: NIH RePORTER; NEI NIH HHS [R01 EY011515, EY11521, EY11515, R01
   EY011521, R01 EY011527, EY11527] Funding Source: Medline
CR Abecasis GR, 2004, AM J HUM GENET, V74, P482, DOI 10.1086/382786
   Abrera-Abeleda MA, 2006, J MED GENET, V43, P582, DOI 10.1136/jmg.2005.038315
   Abugreen S, 2003, BRIT J OPHTHALMOL, V87, P307, DOI 10.1136/bjo.87.3.307
   Abyad A, 1997, GERIATRICS-US, V52, P45
   Allikmets R, 1997, SCIENCE, V277, P1805, DOI 10.1126/science.277.5333.1805
   Andersen Nis, 2004, Int J Circumpolar Health, V63 Suppl 2, P320
   Anderson DH, 2004, EXP EYE RES, V78, P243, DOI 10.1016/j.exer.2003.10.011
   Anderson DH, 2002, AM J OPHTHALMOL, V134, P411, DOI 10.1016/S0002-9394(02)01624-0
   Anderson DH, 2001, AM J OPHTHALMOL, V131, P767, DOI 10.1016/S0002-9394(00)00961-2
   [Anonymous], 1991, Arch Ophthalmol, V109, P1220
   [Anonymous], 1998, Ophthalmology, V105, P1364
   Appel GB, 2005, J AM SOC NEPHROL, V16, P1392, DOI 10.1681/ASN.2005010078
   Arnold J, 2001, AM J OPHTHALMOL, V131, P541
   Arnold Jennifer, 2004, Clin Evid, P819
   Atkinson JP, 2005, ANN NY ACAD SCI, V1056, P144, DOI 10.1196/annals.1352.032
   Avery RL, 2006, OPHTHALMOLOGY, V113, P363, DOI 10.1016/j.ophtha.2005.11.019
   Baird PN, 2004, INVEST OPHTH VIS SCI, V45, P1311, DOI 10.1167/iovs.03-1121
   BERMAN K, 2006, INT PSYCHOGERIATR, V8, P1
   BIRD A, 1992, AGE RELATED MACULAR, pCH3
   BIRD AC, 1992, BRIT J OPHTHALMOL, V76, P166, DOI 10.1136/bjo.76.3.166
   Bressler NM, 2002, ARCH OPHTHALMOL-CHIC, V120, P1443
   Bressler NM, 2004, OPHTHALMOLOGY, V111, P1993, DOI 10.1016/j.ophtha.2004.07.023
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   Caprioli J, 2003, HUM MOL GENET, V12, P3385, DOI 10.1093/hmg/ddg363
   Caprioli J, 2006, BLOOD, V108, P1267, DOI 10.1182/blood-2005-10-007252
   Chong NHV, 2005, AM J PATHOL, V166, P241, DOI 10.1016/S0002-9440(10)62248-1
   Complications of Age-Related Macular Degeneration Prevention Trial Study Group, 2004, Clin Trials, V1, P91
   Conley YP, 2005, HUM MOL GENET, V14, P1991, DOI 10.1093/hmg/ddi204
   Curcio CA, 2005, EXP EYE RES, V80, P761, DOI 10.1016/j.exer.2004.09.017
   Curcio CA, 1996, INVEST OPHTH VIS SCI, V37, P1236
   Curcio CA, 2001, INVEST OPHTH VIS SCI, V42, P265
   DAMICO DJ, 2003, OPHTHALMOLOGY, V110, P84
   DASTGHEIB K, 1994, ARCH OPHTHALMOL-CHIC, V112, P813, DOI 10.1001/archopht.1994.01090180111045
   Davis MD, 2005, ARCH OPHTHALMOL-CHIC, V123, P1484
   de Cordoba SR, 2004, MOL IMMUNOL, V41, P355, DOI 10.1016/j.molimm.2004.02.005
   de Juan E, 1998, AM J OPHTHALMOL, V125, P635, DOI 10.1016/S0002-9394(98)00018-X
   Donoso LA, 2006, SURV OPHTHALMOL, V51, P137, DOI 10.1016/j.survophthal.2005.12.001
   DOREY CK, 1989, INVEST OPHTH VIS SCI, V30, P1691
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   EISNER A, 1991, INVEST OPHTH VIS SCI, V32, P8
   EISNER A, 1992, INVEST OPHTH VIS SCI, V33, P3091
   ERKKILA H, 1983, ACTA OPHTHALMOL, V61, P589
   Esparza-Gordillo J, 2005, HUM MOL GENET, V14, P703, DOI 10.1093/hmg/ddi066
   FARKAS TG, 1971, AM J OPHTHALMOL, V71, P1206, DOI 10.1016/0002-9394(71)90964-0
   Fearon DT, 1996, SCIENCE, V272, P50, DOI 10.1126/science.272.5258.50
   FEENEYBURNS L, 1985, AM J OPHTHALMOL, V100, P686, DOI 10.1016/0002-9394(85)90625-7
   FEENEYBURNS L, 1984, INVEST OPHTH VIS SCI, V25, P195
   Feher J, 1967, Albrecht Von Graefes Arch Klin Exp Ophthalmol, V173, P162, DOI 10.1007/BF00405719
   Ferris FL, 2005, ARCH OPHTHALMOL-CHIC, V123, P1570
   Fisher SA, 2005, HUM MOL GENET, V14, P2257, DOI 10.1093/hmg/ddi230
   FREUND KB, 1993, AM J OPHTHALMOL, V115, P786, DOI 10.1016/S0002-9394(14)73649-9
   Friberg TR, 2006, OPHTHALMOLOGY, V113, P612, DOI 10.1016/j.ophtha.2005.10.066
   FRIBERG TR, 2006, INVEST OPHTH VIS SCI, P47
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Gerard NP, 2002, CURR OPIN IMMUNOL, V14, P705, DOI 10.1016/S0952-7915(02)00410-7
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   Goverdhan SV, 2005, EYE, V19, P1137, DOI 10.1038/sj.eye.6701744
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   GREEN WR, 1993, OPHTHALMOLOGY, V100, P1519
   GREEN WR, 1985, OPHTHALMOLOGY, V92, P615
   GRINDLE CFJ, 1978, T OPHTHAL SOC UK, V98, P172
   Guymer R, 1999, PROG RETIN EYE RES, V18, P59, DOI 10.1016/S1350-9462(98)00012-3
   Guymer R., 1998, RETINAL PIGMENT EPIT, P693
   Guymer RH, 2005, SURV OPHTHALMOL, V50, P194, DOI 10.1016/j.survophthal.2004.12.002
   Hageman GS, 1999, MOL VIS, V5
   Hageman GS, 1999, FASEB J, V13, P477, DOI 10.1096/fasebj.13.3.477
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haimovici R, 2001, INVEST OPHTH VIS SCI, V42, P1592
   Haines JL, 2006, INVEST OPHTH VIS SCI, V47, P329, DOI 10.1167/iovs.05-0116
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   HALSTENSEN TS, 1989, GUT, V30, P361, DOI 10.1136/gut.30.3.361
   Hammond CJ, 2002, OPHTHALMOLOGY, V109, P730, DOI 10.1016/S0161-6420(01)01049-1
   HAN DP, 1988, OPHTHALMOLOGY, V95, P1380
   Handa JT, 1999, INVEST OPHTH VIS SCI, V40, P775
   HAWKINS BS, 1990, ARCH OPHTHALMOL-CHIC, V108, P816
   HAWKINS BS, 1986, ARCH OPHTHALMOL-CHIC, V104, P694
   Hawkins BS, 2004, OPHTHALMOLOGY, V111, P1967, DOI 10.1016/j.ophtha.2004.07.021
   HEIBA IM, 1994, GENET EPIDEMIOL, V11, P51, DOI 10.1002/gepi.1370110106
   HEIER JS, 2006, INVEST OPHTHALMOL VI, V47
   Heinen Stefan, 2006, Hum Mutat, V27, P292, DOI 10.1002/humu.9408
   HERIOT WJ, 1984, OPHTHALMOLOGY, V91, P1603
   HEWITT AT, 1989, INVEST OPHTH VIS SCI, V30, P478
   HOGAN M J, 1972, Transactions of the American Academy of Ophthalmology and Oto-Laryngology, V76, P64
   HOGAN MJ, 1967, ARCH OPHTHALMOL-CHIC, V77, P410, DOI 10.1001/archopht.1967.00980020412022
   Holers VM, 2004, MOL IMMUNOL, V41, P147, DOI 10.1016/j.molimm.2004.03.012
   Holers VM, 2003, CLIN IMMUNOL, V107, P140, DOI 10.1016/S1521-6616(03)00034-2
   Holz FG, 2001, INVEST OPHTH VIS SCI, V42, P1051
   HOLZ FG, 1994, ARCH OPHTHALMOL-CHIC, V112, P402, DOI 10.1001/archopht.1994.01090150132035
   Hussain AA, 2002, J OPT SOC AM A, V19, P166, DOI 10.1364/JOSAA.19.000166
   Ishibashi T, 1998, ARCH OPHTHALMOL-CHIC, V116, P1629, DOI 10.1001/archopht.116.12.1629
   Iyengar SK, 2004, AM J HUM GENET, V74, P20, DOI 10.1086/380912
   Jackson GR, 2004, INVEST OPHTH VIS SCI, V45, P3271, DOI 10.1167/iovs.04-0019
   Jackson GR, 2002, AGEING RES REV, V1, P381, DOI 10.1016/S1568-1637(02)00007-7
   Jackson GR, 2003, NEUROL CLIN, V21, P709, DOI 10.1016/S0733-8619(02)00107-X
   Jakobsdottir J, 2005, AM J HUM GENET, V77, P389, DOI 10.1086/444437
   Johnson LV, 2000, EXP EYE RES, V70, P441, DOI 10.1006/exer.1999.0798
   Johnson LV, 2001, EXP EYE RES, V73, P887, DOI 10.1006/exer.2001.1094
   Johnson LV, 2002, P NATL ACAD SCI USA, V99, P11830, DOI 10.1073/pnas.192203399
   JOHNSON LV, 2003, INVEST OPHTHALMOL VI, V44
   Johnson PT, 2005, INVEST OPHTH VIS SCI, V46, P4788, DOI 10.1167/iovs.05-0767
   Johnson PT, 2003, INVEST OPHTH VIS SCI, V44, P4481, DOI 10.1167/iovs.03-0436
   Jonas JB, 2006, AM J OPHTHALMOL, V141, P579, DOI 10.1016/j.ajo.2005.10.007
   Jonasson F, 2005, OPHTHALMOLOGY, V112, P132, DOI 10.1016/j.ophtha.2004.07.020
   Kamei M, 1999, INVEST OPHTH VIS SCI, V40, P2367
   Kamisato S, 1997, J BIOCHEM-TOKYO, V121, P862
   KARWATOWSKI WSS, 1995, BRIT J OPHTHALMOL, V79, P944, DOI 10.1136/bjo.79.10.944
   Kassoff A, 1999, CONTROL CLIN TRIALS, V20, P573
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Katz ML, 2002, ARCH GERONTOL GERIAT, V34, P359, DOI 10.1016/S0167-4943(02)00012-2
   KATZ ML, 1984, EXP EYE RES, V38, P137, DOI 10.1016/0014-4835(84)90098-8
   KILLINGSWORTH MC, 1990, EYE, V4, P613, DOI 10.1038/eye.1990.86
   Klaver CCW, 1998, AM J HUM GENET, V63, P200, DOI 10.1086/301901
   Klein ML, 1998, ARCH OPHTHALMOL-CHIC, V116, P1082, DOI 10.1001/archopht.116.8.1082
   KLEIN ML, 1994, ARCH OPHTHALMOL-CHIC, V112, P932, DOI 10.1001/archopht.1994.01090190080025
   Klein R, 2004, AM J OPHTHALMOL, V137, P486, DOI 10.1016/j.ajo.2003.11.069
   Klein R, 1997, OPHTHALMOLOGY, V104, P7, DOI 10.1016/S0161-6420(97)30368-6
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   KLEINER RC, 1988, ARCH OPHTHALMOL-CHIC, V106, P55
   KLIFFEN M, 1994, INVEST OPHTH VIS SCI, V35, P2901
   Kliffen M, 1997, MICROSC RES TECHNIQ, V36, P106, DOI 10.1002/(SICI)1097-0029(19970115)36:2<106::AID-JEMT4>3.0.CO;2-N
   Kliffen M, 1996, ARCH OPHTHALMOL-CHIC, V114, P1009, DOI 10.1001/archopht.1996.01100140217021
   Knupp C, 2002, J STRUCT BIOL, V139, P181, DOI 10.1016/S1047-8477(02)00534-8
   Krishnaiah S, 2005, INVEST OPHTH VIS SCI, V46, P4442, DOI 10.1167/iovs.05-0853
   Lassmann H, 2004, J NEUROL, V251, P2, DOI 10.1007/s00415-004-1402-3
   Leske MC, 2006, OPHTHALMOLOGY, V113, P29, DOI 10.1016/j.ophtha.2005.08.012
   Li CM, 2005, INVEST OPHTH VIS SCI, V46, P2576, DOI 10.1167/iovs.05-0034
   Li J, 2001, BRIT J OPHTHALMOL, V85, P287, DOI 10.1136/bjo.85.3.287
   Lin MY, 2004, J AM GERIATR SOC, V52, P1996, DOI 10.1111/j.1532-5415.2004.52554.x
   LOFFLER KU, 1986, GRAEF ARCH CLIN EXP, V224, P493, DOI 10.1007/BF02154735
   LOKKI ML, 1991, IMMUNOGENETICS, V34, P242, DOI 10.1007/BF00215259
   MACHEMER R, 1993, GRAEF ARCH CLIN EXP, V231, P635, DOI 10.1007/BF00921957
   Magnusson KP, 2006, PLOS MED, V3, P109, DOI 10.1371/journal.pmed.0030005
   Majewski J, 2003, AM J HUM GENET, V73, P540, DOI 10.1086/377701
   Malek G, 2003, AM J PATHOL, V162, P413, DOI 10.1016/S0002-9440(10)63836-9
   Marcus D, 2004, AM J OPHTHALMOL, V138, P818, DOI 10.1016/j.ajo.2004.06.081
   Marshall J., 1998, RETINAL PIGMENT EPIT, P669
   MARSHALL J, 1998, RETINAL PIGMENT EPIT
   Mastellos D, 2005, CLIN IMMUNOL, V115, P225, DOI 10.1016/j.clim.2005.03.012
   MASTELLOS D, 2005, CURR DRUG TARGETS IN, P125
   McConnell V, 2005, Ulster Med J, V74, P82
   McLeod DS, 2002, INVEST OPHTH VIS SCI, V43, P1986
   MEYERS SM, 1995, AM J OPHTHALMOL, V120, P757, DOI 10.1016/S0002-9394(14)72729-1
   MIDENA E, 1994, DOC OPHTHALMOL, V88, P179, DOI 10.1007/BF01204616
   Milam AH, 2000, OPHTHALMOLOGY, V107, P2256, DOI 10.1016/S0161-6420(00)00419-X
   Miller DM, 2004, AM J OPHTHALMOL, V138, P323, DOI 10.1016/j.ajo.2004.03.018
   Milton RC, 2005, OPHTHALMOLOGY, V112, P533, DOI 10.1016/j.ophtha.2004.10.047
   Mitchell P, 2002, OPHTHALMOLOGY, V109, P1092, DOI 10.1016/S0161-6420(02)01055-2
   MITCHELL P, 1995, OPHTHALMOLOGY, V102, P1450
   MOORE DJ, 1995, INVEST OPHTH VIS SCI, V36, P1290
   Moore DJ, 2001, INVEST OPHTH VIS SCI, V42, P2970
   Muller M, 2001, SCHMERZ, V15, P3, DOI 10.1007/s004820170042
   Mullins RF, 1997, OPHTHALMOLOGY, V104, P288, DOI 10.1016/S0161-6420(97)30322-4
   Mullins RF, 2000, FASEB J, V14, P835, DOI 10.1096/fasebj.14.7.835
   Munoz B, 2005, ARCH OPHTHALMOL-CHIC, V123, P1575, DOI 10.1001/archopht.123.11.1575
   Nackman GB, 1997, SURGERY, V122, P39, DOI 10.1016/S0039-6060(97)90262-2
   Neumann E, 2002, ARTHRITIS RHEUM, V46, P934, DOI 10.1002/art.10183
   NEWSOME DA, 1987, CURR EYE RES, V6, P1211, DOI 10.3109/02713688709025231
   Okamoto H, 2006, MOL VIS, V12, P156
   Okubo A, 1999, INVEST OPHTH VIS SCI, V40, P443
   Owsley C, 2000, INVEST OPHTH VIS SCI, V41, P267
   Owsley C, 2006, INVEST OPHTH VIS SCI, V47, P1310, DOI 10.1167/iovs.05-1292
   Owsley C, 2001, OPHTHALMOLOGY, V108, P1196, DOI 10.1016/S0161-6420(01)00580-2
   Pangburn MK, 2000, J IMMUNOL, V164, P4742, DOI 10.4049/jimmunol.164.9.4742
   PAULEIKHOFF D, 1990, OPHTHALMOLOGY, V97, P171
   Pauleikhoff D., 1994, Ophthalmologe, V91, P730
   PENFOLD P, 1984, AUST J OPHTHALMOL, V12, P23
   Penfold PL, 2001, PROG RETIN EYE RES, V20, P385, DOI 10.1016/S1350-9462(00)00025-2
   PETO T, 2005, INVEST OPHTHALMOL VI, V46
   Pio R, 2001, J BIOL CHEM, V276, P12292, DOI 10.1074/jbc.M007822200
   Prenner JL, 2003, RETINA-J RET VIT DIS, V23, P307, DOI 10.1097/00006982-200306000-00004
   Provis Jan M, 2005, Clin Exp Optom, V88, P269
   Quiram PA, 2006, AM J OPHTHALMOL, V141, P580, DOI 10.1016/j.ajo.2005.10.004
   RAMRATTAN RS, 1994, INVEST OPHTH VIS SCI, V35, P2857
   Resnikoff S, 2004, B WORLD HEALTH ORGAN, V82, P844
   Rivera A, 2005, HUM MOL GENET, V14, P3227, DOI 10.1093/hmg/ddi353
   Robman L, 2005, AM J EPIDEMIOL, V161, P1013, DOI 10.1093/aje/kwi130
   Rosenfeld PJ, 2005, OPHTHAL SURG LAS IM, V36, P331, DOI 10.3928/1542-8877-20050701-14
   Rovner BW, 2002, ARCH OPHTHALMOL-CHIC, V120, P1041
   ROZANOWSKA M, 1995, J BIOL CHEM, V270, P18825, DOI 10.1074/jbc.270.32.18825
   Russell S, 2003, OPHTHALMOLOGY, V110, P2372, DOI 10.1016/j.ophtha.2003.08.020
   Russell SR, 2000, AM J OPHTHALMOL, V129, P205, DOI 10.1016/S0002-9394(99)00345-1
   SANDBERG MA, 1995, RETINA-J RET VIT DIS, V15, P407, DOI 10.1097/00006982-199515050-00006
   SARKS JP, 1994, EYE, V8, P269, DOI 10.1038/eye.1994.57
   SARKS SH, 1976, BRIT J OPHTHALMOL, V60, P324, DOI 10.1136/bjo.60.5.324
   Sarks SH, 1999, BRIT J OPHTHALMOL, V83, P358, DOI 10.1136/bjo.83.3.358
   SARKS SH, 1980, T OPHTHAL SOC UK, V100, P414
   Sarraf D, 1999, RETINA-J RET VIT DIS, V19, P513, DOI 10.1097/00006982-199911000-00006
   Saunders RE, 2006, HUM MUTAT, V27, P21, DOI 10.1002/humu.20268
   Schick JH, 2003, AM J HUM GENET, V72, P1412, DOI 10.1086/375500
   Schmidt S, 2006, AM J HUM GENET, V78, P852, DOI 10.1086/503822
   Schmidt-Erfurth U, 2000, SURV OPHTHALMOL, V45, P195, DOI 10.1016/S0039-6257(00)00158-2
   Schultz DW, 2003, HUM MOL GENET, V12, P3315, DOI 10.1093/hmg/ddg348
   Seddon JM, 2003, AM J HUM GENET, V73, P780, DOI 10.1086/378505
   Seddon JM, 1997, AM J OPHTHALMOL, V123, P199, DOI 10.1016/S0002-9394(14)71036-0
   Sepp T, 2006, INVEST OPHTH VIS SCI, V47, P536, DOI 10.1167/iovs.05-1143
   Sivaprasad S, 2005, CLIN EXP OPHTHALMOL, V33, P518, DOI 10.1111/j.1442-9071.2005.01074.x
   Smith W, 2001, OPHTHALMOLOGY, V108, P697, DOI 10.1016/S0161-6420(00)00580-7
   Song WC, 2004, CURR DIRECT AUTOIMMU, V7, P181
   Sospedra M, 2005, ANNU REV IMMUNOL, V23, P683, DOI 10.1146/annurev.immunol.23.021704.115707
   Souied EH, 1998, AM J OPHTHALMOL, V125, P353, DOI 10.1016/S0002-9394(99)80146-9
   Souied EH, 2005, MOL VIS, V11, P1135
   Spaide RF, 2005, OPHTHALMOLOGY, V112, P301, DOI 10.1016/j.ophtha.2004.08.012
   Sparrow JR, 2005, EXP EYE RES, V80, P595, DOI 10.1016/j.exer.2005.01.007
   Spraul CW, 1997, ARCH OPHTHALMOL-CHIC, V115, P267, DOI 10.1001/archopht.1997.01100150269022
   Spraul CW, 1996, INVEST OPHTH VIS SCI, V37, P2724
   STANGOS N, 1995, OPHTHALMOLOGICA, V209, P194, DOI 10.1159/000310612
   Starita C, 1996, EXP EYE RES, V62, P565, DOI 10.1006/exer.1996.0066
   Stevenson MR, 2005, BRIT J OPHTHALMOL, V89, P1045, DOI 10.1136/bjo.2003.030445
   Stone EM, 2004, NEW ENGL J MED, V351, P346, DOI 10.1056/NEJMoa040833
   Sunness JS, 1999, MOL VIS, V5
   SUNNESS JS, 1989, OPHTHALMOLOGY, V96, P375, DOI 10.1016/S0161-6420(89)32883-1
   Tang S, 2005, NEPHROLOGY, V10, P174, DOI 10.1111/j.1440-1797.2005.00392.x
   TAYLOR H, 2006, IMPACT AGE RELATED M, P1
   Taylor HR, 2005, MED J AUSTRALIA, V182, P565, DOI 10.5694/j.1326-5377.2005.tb06815.x
   Thornton J, 2005, EYE, V19, P935, DOI 10.1038/sj.eye.6701978
   Thurman JM, 2006, J IMMUNOL, V176, P1305, DOI 10.4049/jimmunol.176.3.1305
   Turnberg D, 2005, CURR OPIN NEPHROL HY, V14, P223, DOI 10.1097/01.mnh.0000165887.75501.24
   UHLMANN RF, 1991, J GEN INTERN MED, V6, P126, DOI 10.1007/BF02598307
   VANDERSCHAFT TL, 1992, OPHTHALMOLOGY, V99, P278
   VANDERSCHAFT TL, 1994, GRAEF ARCH CLIN EXP, V232, P40, DOI 10.1007/BF00176436
   VANDERSCHAFT TL, 1991, ARCH OPHTHALMOL-CHIC, V109, P420, DOI 10.1001/archopht.1991.01080030122052
   VanNewkirk MR, 2000, OPHTHALMOLOGY, V107, P1593, DOI 10.1016/S0161-6420(00)00175-5
   VINGERLING JR, 1995, OPHTHALMOLOGY, V102, P205
   Vinores SA, 2005, IDRUGS, V8, P327
   Walport MJ, 2001, NEW ENGL J MED, V344, P1058, DOI 10.1056/NEJM200104053441406
   Walport MJ, 2001, NEW ENGL J MED, V344, P1140, DOI 10.1056/NEJM200104123441506
   Warwicker P, 1998, KIDNEY INT, V53, P836, DOI 10.1046/j.1523-1755.1998.00824.x
   Weeks DE, 2000, HUM MOL GENET, V9, P1329, DOI 10.1093/hmg/9.9.1329
   Weeks DE, 2004, AM J HUM GENET, V75, P174, DOI 10.1086/422476
   Weeks DE, 2001, AM J OPHTHALMOL, V132, P682, DOI 10.1016/S0002-9394(01)01214-4
   *WHO, 282 WHO
   WING G, 1978, INVEST OPHTH VIS SCI, V7, P601
   Wolfs RCW, 2000, INVEST OPHTH VIS SCI, V41, P3309
   Wong TY, 2006, BRIT J OPHTHALMOL, V90, P506, DOI 10.1136/bjo.2005.083733
   WRAY SH, 1976, INVEST OPHTH VISUAL, V15, P128
   Zarbin MA, 2004, ARCH OPHTHALMOL-CHIC, V122, P598, DOI 10.1001/archopht.122.4.598
   Zareparsi S, 2005, AM J HUM GENET, V77, P149, DOI 10.1086/431426
   Zareparsi S, 2005, HUM MOL GENET, V14, P1449, DOI 10.1093/hmg/ddi154
   Zee RYL, 2006, ATHEROSCLEROSIS, V187, P332, DOI 10.1016/j.atherosclerosis.2005.09.009
   Zipfel PF, 2006, MOL IMMUNOL, V43, P97, DOI 10.1016/j.molimm.2005.06.015
   Zipfel PF, 2001, SEMIN THROMB HEMOST, V27, P191, DOI 10.1055/s-2001-15248
   1990, ARCH OPHTHALMOLOGY, V108, P825
NR 244
TC 433
Z9 454
U1 0
U2 59
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 0785-3890
EI 1365-2060
J9 ANN MED
JI Ann. Med.
PY 2006
VL 38
IS 7
BP 450
EP 471
DI 10.1080/07853890600946724
PG 22
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA 111YN
UT WOS:000242491900001
PM 17101537
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Khurana, RN
   Fujii, GY
   Walsh, AC
   Humayun, MS
   de Juan, E
   Sadda, SR
AF Khurana, RN
   Fujii, GY
   Walsh, AC
   Humayun, MS
   de Juan, E
   Sadda, SR
TI Rapid recurrence of geographic atrophy after full macular translocation
   for nonexudative age-related macular degeneration
SO OPHTHALMOLOGY
LA English
DT Article
ID EYES
AB Objective: To report the recurrence of geographic atrophy (GA) in a patient with nonexudative age-related macular degeneration (AMD) after full macular translocation. Design: Observational case report.
   Methods: Review of the clinical, photographic, and angiographic records of a patient with GA who underwent full macular translocation.
   Main Outcome Measures: Progression of GA.
   Results: A 73-year-old man with GA secondary to nonexudative AMD underwent a macular translocation with 360 peripheral retinectomy (MT 360) in his left eye. On postoperative month 4, funclus photography showed subtle alterations of the pigment underneath the translocated foveal region. On postoperative month 9, the visual acuity worsened to preoperative levels and there was frank retinal pigment epithelium atrophy involving the new macular region.
   Conclusions: The rapid recurrence and development of GA in the translocated fovea after MT360 raise new questions regarding the pathogenesis of GA. They also raise concerns regarding the use of MT 360 in the management of nonexudative AMD.
C1 Univ So Calif, Keck Sch Med, Doheny Eye Inst, Doheny Retina Inst,Dept Ophthalmol, Los Angeles, CA USA.
C3 Doheny Eye Institute; University of Southern California
RP Sadda, SR (通讯作者)，1450 San Pablo St,Room 3610, Los Angeles, CA 90033 USA.
EM SSadda@doheny.org
OI Khurana, Rahul/0000-0001-5198-1353
CR Cahill MT, 2003, ARCH OPHTHALMOL-CHIC, V121, P132
   Eckardt C, 2002, RETINA-J RET VIT DIS, V22, P786, DOI 10.1097/00006982-200212000-00017
   Fujii GY, 2002, OPHTHALMOLOGY, V109, P1737, DOI 10.1016/S0161-6420(02)01120-X
   Fujii GY, 2001, RETINA-J RET VIT DIS, V21, P380, DOI 10.1097/00006982-200108000-00017
   Kim SY, 2002, RETINA-J RET VIT DIS, V22, P471, DOI 10.1097/00006982-200208000-00012
   Medeiros NE, 2001, INVEST OPHTH VIS SCI, V42, P795
   SCHATZ H, 1989, OPHTHALMOLOGY, V96, P1541
   Sunness JS, 1999, MOL VIS, V5
   Sunness JS, 1997, OPHTHALMOLOGY, V104, P1677, DOI 10.1016/S0161-6420(97)30079-7
NR 9
TC 23
Z9 23
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0161-6420
EI 1549-4713
J9 OPHTHALMOLOGY
JI Ophthalmology
PD SEP
PY 2005
VL 112
IS 9
BP 1586
EP 1591
DI 10.1016/j.ophtha.2005.04.016
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 959UG
UT WOS:000231544200019
PM 16051364
DA 2022-11-30
ER

PT J
AU Butt, AL
   Lee, ET
   Klein, R
   Russell, D
   Ogola, G
   Warn, A
   Kingsley, RM
   Yeh, JL
AF Butt, Amir L.
   Lee, Elisa T.
   Klein, Ronald
   Russell, Dana
   Ogola, Gerald
   Warn, Ann
   Kingsley, Ronald M.
   Yeh, Jeunliang
TI Prevalence and Risks Factors of Age-Related Macular Degeneration in
   Oklahoma Indians The Vision Keepers Study
SO OPHTHALMOLOGY
LA English
DT Article
ID BLUE-MOUNTAINS-EYE; BEAVER DAM EYE; VISUAL IMPAIRMENT; AMERICAN-INDIANS;
   CARDIOVASCULAR-DISEASE; ALCOHOL-CONSUMPTION; CIGARETTE-SMOKING; POOLED
   FINDINGS; SUN EXPOSURE; 3 CONTINENTS
AB Objective: To determine the prevalence of age-related macular degeneration (AMD) and to identify its risk factors in an Oklahoma Indian population.
   Design: Cross-sectional study design.
   Participants: Included 1019 Oklahoma Indians who participated in baseline and second examinations of the Strong Heart Study.
   Methods: Retinal photographs of at least 1 eye were obtained and graded for AMD by the University of Wisconsin Ocular Epidemiology Reading Center. Retinal photographs of 986 participants were considered gradable and were included in the study.
   Main Outcome Measures: Age-related macular degeneration (early and late).
   Results: The overall prevalence of AMD in the study was 35.2%, including a prevalence of 0.81% for late AMD. The prevalence of early AMD increased from 30.6% in those aged 48 to 59 years to 46.1% in those 70 to 82 years of age. When potential risk factors were analyzed individually (univariate analyses), men with hypertension had a significantly higher prevalence of AMD (P = 0.02) than those without hypertension. In women, high-density lipoprotein cholesterol and sun exposure were associated positively with the prevalence of AMD (P = 0.01), whereas a history of using multivitamins was associated with lower AMD prevalence (P = 0.005). When multiple risk factors were analyzed simultaneously using logistic regression, only age showed significant association with AMD in both men (P = 0.02) and women (P<0.0001) and was the only significant risk factor in men. In women, multivitamin use and total cholesterol had a significant inverse association with AMD, whereas sun exposure and high-density lipoprotein cholesterol had a positive association. When men and women were combined, age and high-density lipoprotein cholesterol had significant positive associations, whereas total cholesterol, multivitamin use, and current alcohol use showed a significant inverse association with AMD.
   Conclusions: This study was the first to report a detailed prevalence of AMD in Oklahoma Indians and its risk factors. The prevalence seemed to be relatively high compared with that in other ethnic groups. Some of the modifiable risk factors identified confirmed previous findings and can be used to design preventive programs to reduce the burden of AMD, although longitudinal data are still needed.
C1 [Butt, Amir L.; Lee, Elisa T.; Russell, Dana; Ogola, Gerald; Yeh, Jeunliang] Univ Oklahoma, Hlth Sci Ctr, Coll Publ Hlth, Ctr Amer Indian Hlth Res, Oklahoma City, OK 73126 USA.
   [Klein, Ronald] Univ Wisconsin, Sch Med & Publ Hlth, Dept Ophthalmol & Visual Sci, Madison, WI USA.
   [Warn, Ann] Dean A McGee Eye Inst, Lawton, OK USA.
   [Kingsley, Ronald M.] Dean A McGee Eye Inst, Oklahoma City, OK USA.
C3 University of Oklahoma System; University of Oklahoma Health Sciences
   Center; University of Wisconsin System; University of Wisconsin Madison
RP Lee, ET (通讯作者)，Univ Oklahoma, Hlth Sci Ctr, Coll Publ Hlth, Ctr Amer Indian Hlth Res, POB 26901, Oklahoma City, OK 73126 USA.
EM elisa-lee@ouhsc.edu
OI Klein, Ronald/0000-0002-4428-6237
FU National Eye Institute, National Institutes of Health, Bethesda,
   Maryland [EY-09898]; National Heart, Lung, and Blood Institute, National
   Institutes of Health, Bethesda, Maryland [U01-HL041654]; NATIONAL EYE
   INSTITUTE [U10EY009898] Funding Source: NIH RePORTER; NATIONAL HEART,
   LUNG, AND BLOOD INSTITUTE [U01HL041654] Funding Source: NIH RePORTER
FX The Vision Keeper Study was supported by the National Eye Institute,
   National Institutes of Health, Bethesda, Maryland (grant no.: EY-09898).
   The Strong Heart Study was supported by the National Heart, Lung, and
   Blood Institute, National Institutes of Health, Bethesda, Maryland
   (grant no.: U01-HL041654).
CR BRESSLER NM, 1995, OPHTHALMOLOGY, V102, P1206, DOI 10.1016/S0161-6420(95)30889-5
   Cho EY, 2004, ARCH OPHTHALMOL-CHIC, V122, P883, DOI 10.1001/archopht.122.6.883
   Cho EY, 2000, ARCH OPHTHALMOL-CHIC, V118, P681, DOI 10.1001/archopht.118.5.681
   Curcio CA, 2010, J LIPID RES, V51, P451, DOI 10.1194/jlr.R002238
   Darzins P, 1997, OPHTHALMOLOGY, V104, P770, DOI 10.1016/S0161-6420(97)30235-8
   Dashti N, 2006, BRIT J OPHTHALMOL, V90, P1028, DOI 10.1136/bjo.2006.093856
   Evans JR, 2001, PROG RETIN EYE RES, V20, P227, DOI 10.1016/S1350-9462(00)00023-9
   Evans JR, 2005, BRIT J OPHTHALMOL, V89, P550, DOI 10.1136/bjo.2004.049726
   Fletcher AE, 2008, ARCH OPHTHALMOL-CHIC, V126, P1396, DOI 10.1001/archopht.126.10.1396
   Guymer RH, 2006, MED J AUSTRALIA, V184, P455, DOI 10.5694/j.1326-5377.2006.tb00318.x
   HOWARD BV, 1995, AM J EPIDEMIOL, V142, P254, DOI 10.1093/oxfordjournals.aje.a117632
   HYMAN L, 1992, INVEST OPHTH VIS SCI, V33, P801
   Khan JC, 2006, BRIT J OPHTHALMOL, V90, P29, DOI 10.1136/bjo.2005.073825
   Khan JC, 2006, BRIT J OPHTHALMOL, V90, P75, DOI 10.1136/bjo.2005.073643
   Klein R, 2003, OPHTHALMOLOGY, V110, P25, DOI 10.1016/S0161-6420(02)01565-8
   Klein R, 2002, AM J EPIDEMIOL, V156, P589, DOI 10.1093/aje/kwf092
   Klein R, 1999, ARCH OPHTHALMOL-CHIC, V117, P1203
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   Klein R, 1999, PROG RETIN EYE RES, V18, P371, DOI 10.1016/S1350-9462(98)00025-1
   Klein R, 2007, ARCH OPHTHALMOL-CHIC, V125, P534, DOI 10.1001/archopht.125.4.534
   Klein Ronald, 2003, Ophthalmology, V110, P1273, DOI 10.1016/S0161-6420(03)00599-2
   LEE ET, 1990, AM J EPIDEMIOL, V132, P1141, DOI 10.1093/oxfordjournals.aje.a115757
   Lee ET, 2005, ARCH OPHTHALMOL-CHIC, V123, P1699, DOI 10.1001/archopht.123.12.1699
   Mansberger SL, 2005, AM J PUBLIC HEALTH, V95, P881, DOI 10.2105/AJPH.2004.054221
   Mitchell P, 1998, OPHTHALMOLOGY, V105, P1359, DOI 10.1016/S0161-6420(98)98013-7
   Mitchell P, 2003, ASIA PAC J CLIN NU S, V12, pS5
   Miyazaki M, 2003, BRIT J OPHTHALMOL, V87, P469, DOI 10.1136/bjo.87.4.469
   Moss SE, 1998, OPHTHALMOLOGY, V105, P789, DOI 10.1016/S0161-6420(98)95016-3
   Obisesan TO, 1998, J AM GERIATR SOC, V46, P1
   SanGiovanni JP, 2007, ARCH OPHTHALMOL-CHIC, V125, P1225, DOI 10.1001/archopht.125.9.1225
   Seddon JM, 2006, ARCH OPHTHALMOL-CHIC, V124, P995, DOI 10.1001/archopht.124.7.995
   Smith W, 1998, ARCH OPHTHALMOL-CHIC, V116, P583, DOI 10.1001/archopht.116.5.583
   Smith W, 2001, OPHTHALMOLOGY, V108, P697, DOI 10.1016/S0161-6420(00)00580-7
   Taylor HR, 2002, BMJ-BRIT MED J, V325, P11, DOI 10.1136/bmj.325.7354.11
   Tomany SC, 2004, OPHTHALMOLOGY, V111, P1280, DOI 10.1016/j.ophtha.2003.11.010
   van Leeuwen R, 2003, INVEST OPHTH VIS SCI, V44, P3771, DOI 10.1167/iovs.03-0121
   van Leeuwen R, 2003, EUR J EPIDEMIOL, V18, P845, DOI 10.1023/A:1025643303914
   van Leeuwen R, 2003, ARCH OPHTHALMOL-CHIC, V121, P519, DOI 10.1001/archopht.121.4.519
   VanNewkirk MR, 2000, OPHTHALMOLOGY, V107, P1593, DOI 10.1016/S0161-6420(00)00175-5
   Wang JJ, 2003, ARCH OPHTHALMOL-CHIC, V121, P658, DOI 10.1001/archopht.121.5.658
   YOUNG RW, 1988, SURV OPHTHALMOL, V32, P252, DOI 10.1016/0039-6257(88)90174-9
   YOUNG RW, 1987, SURV OPHTHALMOL, V31, P291, DOI 10.1016/0039-6257(87)90115-9
   YOUNG RW, 1992, J NATL MED ASSOC, V84, P353
NR 43
TC 32
Z9 36
U1 0
U2 6
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0161-6420
J9 OPHTHALMOLOGY
JI Ophthalmology
PD JUL
PY 2011
VL 118
IS 7
BP 1380
EP 1385
DI 10.1016/j.ophtha.2010.11.007
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 786JL
UT WOS:000292303000022
PM 21310490
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Subhi, Y
   Sorensen, TL
AF Subhi, Yousif
   Sorensen, Torben Lykke
TI New neovascular age-related macular degeneration is associated with
   systemic leucocyte activity
SO ACTA OPHTHALMOLOGICA
LA English
DT Article
DE age-related macular degeneration; blood; granulocytes; leucocytes;
   lymphocytes; monocytes
ID EXPERIMENTAL CHOROIDAL NEOVASCULARIZATION; ENDOTHELIAL GROWTH-FACTOR;
   C-REACTIVE PROTEIN; PERIPHERAL-BLOOD; RISK-FACTORS; T-CELLS;
   CARDIOVASCULAR-DISEASE; INFLAMMATORY MARKERS; LYMPHOCYTE RATIO;
   BRAIN-INJURY
AB PurposeTo investigate systemic leucocyte activity in subtypes of age-related macular degeneration (AMD) and onset of neovascular AMD.
   MethodsPatients with early and late AMD and age-matched control individuals were recruited consecutively, and venous blood was sampled for differential leucocyte counts. Patients with neovascular AMD were grouped based on time of blood sampling in relation to diagnosis of neovascular AMD: diagnosis of new neovascular AMD more than 30days before blood sampling, within 30days of blood sampling and more than 30days after blood sampling.
   ResultsOf 347 recruited participants, 330 fulfilled the eligibility criteria (77 age-matched controls, 33 with early AMD, 56 with geographic atrophy and 164 with neovascular AMD). We did not find any differences in the differential counts between patients at different stages of AMD and age-matched control individuals. However, lymphocyte and monocytes-basophils-eosinophils mixed (MXD) counts were both significantly increased in patients with new neovascular AMD. Among these patients; higher MXD correlated with lower BCVA, larger central foveal thickness and larger total lesion size; higher lymphocytes correlated with smaller total lesion size; higher neutrophils correlated with CNV lesion size; and higher neutrophil-to-lymphocyte ratio correlated with larger lesion size.
   ConclusionsSystemic leucocyte activity is associated with onset of CNV in patients with AMD and correlate with lesion size and BCVA, which suggest that acute systemic immune activity may play a role in neovascular flaring of AMD.
C1 [Subhi, Yousif; Sorensen, Torben Lykke] Zealand Univ Hosp, Clin Eye Res Unit, Dept Ophthalmol, Vestermarksvej 23, DK-4000 Roskilde, Denmark.
   [Subhi, Yousif; Sorensen, Torben Lykke] Univ Copenhagen, Fac Hlth & Med Sci, Copenhagen, Denmark.
C3 University of Copenhagen
RP Subhi, Y (通讯作者)，Zealand Univ Hosp, Clin Eye Res Unit, Dept Ophthalmol, Vestermarksvej 23, DK-4000 Roskilde, Denmark.
EM ysubhi@gmail.com
RI Subhi, Yousif/ABG-6330-2020
OI Subhi, Yousif/0000-0001-6620-5365
FU University of Copenhagen; Fight for Sight Denmark; Danish Eye Research
   Foundation; Velux Foundation; Novartis; Bayer
FX Parts of this study will be presented at Euretina, September 2016 in
   Copenhagen, Denmark. Support for the study was obtained by a Faculty
   Scholarship grant from University of Copenhagen, a research grant from
   Fight for Sight Denmark, a research grant from The Danish Eye Research
   Foundation and a research grant from the Velux Foundation. The funding
   bodies had no influence on the design of the study, analysis of the
   data, preparation of the manuscript or the decision to publish. Author
   YS has previously received travel grant for conferences from Novartis
   and Bayer.
CR Achiron A, 2015, ACTA OPHTHALMOL, V93, pE649, DOI 10.1111/aos.12735
   Ambati J, 2003, NAT MED, V9, P1390, DOI 10.1038/nm950
   Anderson DH, 2010, PROG RETIN EYE RES, V29, P95, DOI 10.1016/j.preteyeres.2009.11.003
   Bloch SB, 2012, AM J OPHTHALMOL, V153, P209, DOI 10.1016/j.ajo.2011.10.016
   Bodnar RJ, 2006, CIRC RES, V98, P617, DOI 10.1161/01.RES.0000209968.66606.10
   Bora NS, 2010, J BIOL CHEM, V285, P33826, DOI 10.1074/jbc.M110.153130
   Buljevac D, 2002, BRAIN, V125, P952, DOI 10.1093/brain/awf098
   Campbell JJ, 2001, J IMMUNOL, V166, P6477, DOI 10.4049/jimmunol.166.11.6477
   Chen M, 2016, CURR MOL MED, V16, P412, DOI 10.2174/1566524016666160324130031
   Combadiere C, 2007, J CLIN INVEST, V117, P2920, DOI 10.1172/JCI31692
   Erlandsen EJ, 2000, SCAND J CLIN LAB INV, V60, P37
   Espinosa-Heidmann DG, 2003, INVEST OPHTH VIS SCI, V44, P3586, DOI 10.1167/iovs.03-0038
   Faber C, 2015, ACTA OPHTHALMOL, V93, P242, DOI 10.1111/aos.12581
   Faber C, 2013, OPHTHALMOLOGY, V120, P2310, DOI 10.1016/j.ophtha.2013.04.014
   Falk MK, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0112473
   Falk MK, 2014, INVEST OPHTH VIS SCI, V55, P4050, DOI 10.1167/iovs.14-14107
   Fauser S, 2015, ACTA OPHTHALMOL, V93, P734, DOI 10.1111/aos.12770
   Fong TG, 2009, NEUROLOGY, V72, P1570, DOI 10.1212/WNL.0b013e3181a4129a
   Freedman ND, 2008, LANCET ONCOL, V9, P649, DOI 10.1016/S1470-2045(08)70154-2
   Haas P, 2015, ACTA OPHTHALMOL, V93, P533, DOI 10.1111/aos.12670
   Hautamaki A, 2015, ACTA OPHTHALMOL, V93, P726, DOI 10.1111/aos.12799
   Herz J, 2015, STROKE, V46, P2916, DOI 10.1161/STROKEAHA.115.010620
   Hu CC, 2017, ACTA OPHTHALMOL, V95, pE587, DOI 10.1111/aos.13204
   Ilhan N, 2015, OCUL IMMUNOL INFLAMM, V23, P287, DOI 10.3109/09273948.2014.921715
   INHOFFEN W, 1990, GRAEF ARCH CLIN EXP, V228, P316, DOI 10.1007/BF00920054
   Juel HB, 2012, INVEST OPHTH VIS SCI, V53, P8472, DOI 10.1167/iovs.12-9963
   Juel HB, 2011, EXP EYE RES, V92, P180, DOI 10.1016/j.exer.2011.01.003
   Kaiser Peter K, 2009, Trans Am Ophthalmol Soc, V107, P311
   Kao LT, 2015, J AM ACAD DERMATOL, V72, P1090, DOI 10.1016/j.jaad.2015.03.002
   Kataru RP, 2009, BLOOD, V113, P5650, DOI 10.1182/blood-2008-09-176776
   Klein R, 2003, OPHTHALMOLOGY, V110, P25, DOI 10.1016/S0161-6420(02)01565-8
   Klein R, 1999, ARCH OPHTHALMOL-CHIC, V117, P1203
   Klein R, 1999, OPHTHALMOLOGY, V106, P1056, DOI 10.1016/S0161-6420(99)90255-5
   KLEIN R, 1993, OPHTHALMOLOGY, V100, P406
   Klein R, 2007, AM J OPHTHALMOL, V143, P473, DOI 10.1016/j.ajo.2006.11.058
   Klein R, 2007, OPHTHALMOLOGY, V114, P253, DOI 10.1016/j.ophtha.2006.10.040
   Klein R, 2010, ARCH OPHTHALMOL-CHIC, V128, P750, DOI 10.1001/archophthalmol.2010.92
   Kubicka-Trzaska A, 2016, ACTA OPHTHALMOL, V94, pE617, DOI 10.1111/aos.13033
   Lechner J, 2015, SCI REP-UK, V5, DOI 10.1038/srep16754
   Liesz A, 2009, NAT MED, V15, P192, DOI 10.1038/nm.1927
   Lindekleiv H, 2013, ACTA OPHTHALMOL, V91, P307, DOI 10.1111/j.1755-3768.2012.02399.x
   Lip PL, 2001, OPHTHALMOLOGY, V108, P705, DOI 10.1016/S0161-6420(00)00663-1
   Luhmann UFO, 2009, INVEST OPHTH VIS SCI, V50, P5934, DOI 10.1167/iovs.09-3462
   Lyzogubov V, 2014, AM J PATHOL, V184, P2537, DOI 10.1016/j.ajpath.2014.06.001
   Ma YY, 2016, J NEUROINFLAMM, V13, DOI 10.1186/s12974-016-0504-z
   Mitchell P, 2002, OPHTHALMOLOGY, V109, P1092, DOI 10.1016/S0161-6420(02)01055-2
   Moulding DA, 1999, J LEUKOCYTE BIOL, V65, P875, DOI 10.1002/jlb.65.6.875
   Perry VH, 2010, ACTA NEUROPATHOL, V120, P277, DOI 10.1007/s00401-010-0722-x
   Pillay J, 2012, J CLIN INVEST, V122, P327, DOI 10.1172/JCI57990
   Rasmussen A, 2015, ACTA OPHTHALMOL, V93, P616, DOI 10.1111/aos.12781
   Rembach A, 2014, J NEUROIMMUNOL, V273, P65, DOI 10.1016/j.jneuroim.2014.05.005
   Rifai N, 2001, CLIN CHEM, V47, P28
   Sakurai E, 2003, INVEST OPHTH VIS SCI, V44, P3578, DOI 10.1167/iovs.03-0097
   Seddon JM, 2006, OPHTHALMOLOGY, V113, P260, DOI 10.1016/j.ophtha.2005.11.001
   Singh A, 2013, OPHTHALMOLOGY, V120, P1029, DOI 10.1016/j.ophtha.2012.11.002
   Singh A, 2012, AM J OPHTHALMOL, V154, P193, DOI 10.1016/j.ajo.2012.01.036
   Steelman AJ, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00520
   Subhi Y, 2016, AGEING RES REV, V29, P42, DOI 10.1016/j.arr.2016.05.013
   Subhi Y, 2014, CLIN OPHTHALMOL, V8, P15, DOI 10.2147/OPTH.S55080
   Subhi Y, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0091227
   Tamhane UU, 2008, AM J CARDIOL, V102, P653, DOI 10.1016/j.amjcard.2008.05.006
   Tegeler C, 2016, NEUROBIOL AGING, V38, P112, DOI 10.1016/j.neurobiolaging.2015.10.039
   Templeton AJ, 2014, JNCI-J NATL CANCER I, V106, DOI 10.1093/jnci/dju124
   Tsutsumi-Miyahara C, 2004, BRIT J OPHTHALMOL, V88, P1217, DOI 10.1136/bjo.2003.036392
   Wang JJ, 2008, OPHTHALMOLOGY, V115, P693, DOI 10.1016/j.ophtha.2007.05.038
   Wong T, 2008, OPHTHALMOLOGY, V115, P116, DOI 10.1016/j.ophtha.2007.03.008
   Yates-Binder CC, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0040812
   Yilmaz G, 2006, CIRCULATION, V113, P2105, DOI 10.1161/CIRCULATIONAHA.105.593046
   Zhou JH, 2005, MOL VIS, V11, P414
   Zlateva GP, 2007, RETINA-J RET VIT DIS, V27, P1292, DOI 10.1097/01.iae.0000300915.81866.b8
NR 70
TC 21
Z9 21
U1 0
U2 3
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1755-375X
EI 1755-3768
J9 ACTA OPHTHALMOL
JI Acta Ophthalmol.
PD AUG
PY 2017
VL 95
IS 5
BP 472
EP 480
DI 10.1111/aos.13330
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA FA4BJ
UT WOS:000405388500024
PM 27860298
OA Bronze
DA 2022-11-30
ER

PT J
AU Smiddy, WE
AF Smiddy, William E.
TI Economic Implications of Current Age-Related Macular Degeneration
   Treatments
SO OPHTHALMOLOGY
LA English
DT Article
ID INTRAVITREAL BEVACIZUMAB AVASTIN; VERTEPORFIN PHOTODYNAMIC THERAPY;
   SUBFOVEAL CHOROIDAL NEOVASCULARIZATION; TRIAMCINOLONE ACETONIDE;
   RANIBIZUMAB; COMBINATION; COST; INJECTION; LUCENTIS; EFFICACY
AB Purpose: To measure the cost versus benefit of age-related macular degeneration (AMD) treatment strategies, existing and proposed, in the postranibizumab era.
   Design: Cost-effectiveness model.
   Participants: None.
   Methods: University with hospital-based practice modeling of clinical examination, imaging, and treatment schedules were constructed considering published protocols where available, or by estimating usual practices. Medicare-allowable reimbursement schedules for a hospital-based, south Florida practice in 2007 were used to calculate costs of treatment. The lines of vision saved were deduced from published reports or using identified assumptions. This information was used to calculate cost per lines saved and, using actuarial tables data, costs per line-year saved were calculated.
   Main Outcome Measure: Cost ($US) per line-year.
   Results: Consensus control values of expected lines loss if untreated (natural history) were established from published reports (2.5 lines at 1 year; 3.5 at 2 years) and photodynamic therapy (2.0 lines at 1 year; 3.0 at 2 years) for use in calculating lines of vision saved in studies without untreated control groups. The cost per line-year for 1 year of treatment ranged from a low of $84 with as-needed bevacizumab to $766 for protocol-style use of ranibizumab. Combination treatment regimens yielded a range of $71 to $269. The pharmaceutical proportion of treatment costs is higher than professional or facility costs, ranging to 83% for protocol-style ranibizumab.
   Conclusions: Pharmaceutical-based treatments of AMD have markedly improved visual outcomes, but also have escalated costs markedly. Treatment regimens involving as-needed dosing, alternate medications, and combination therapy may preserve benefit for substantially lower costs. Disparate safety profiles would require consideration in choosing treatment regimens. Cost-benefit issues must be considered in AMD treatment regimens.
   Financial Disclosure(s): Proprietary or commercial disclosure may be found after the references. Ophthalmology 2009; 116:481-487 (C) 2009 by the American Academy of Ophthalmology.
C1 Univ Miami, Miller Sch Med, Dept Ophthalmol, Bascom Palmer Eye Inst, Miami, FL 33136 USA.
C3 Bascom Palmer Eye Institute; University of Miami
RP Smiddy, WE (通讯作者)，Univ Miami, Miller Sch Med, Dept Ophthalmol, Bascom Palmer Eye Inst, 900 NW 17th St, Miami, FL 33136 USA.
CR Antoszyk AN, 2008, AM J OPHTHALMOL, V145, P862, DOI 10.1016/j.ajo.2007.12.029
   Arnold J, 2001, AM J OPHTHALMOL, V131, P541
   Augustin AJ, 2006, AM J OPHTHALMOL, V141, P638, DOI 10.1016/j.ajo.2005.11.058
   Augustin AJ, 2007, RETINA-J RET VIT DIS, V27, P133, DOI 10.1097/IAE.0b013e3180323de7
   Avery RL, 2006, OPHTHALMOLOGY, V113, P363, DOI 10.1016/j.ophtha.2005.11.019
   Bashshur ZF, 2008, AM J OPHTHALMOL, V145, P249, DOI 10.1016/j.ajo.2007.09.031
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Brown MM, 2008, OPHTHALMOLOGY, V115, P1039, DOI 10.1016/j.ophtha.2007.08.033
   Brown MM, 2008, CURR OPIN OPHTHALMOL, V19, P202, DOI 10.1097/ICU.0b013e3282fc9c35
   CIULLA T, VEGF TRAP CLIN TRIAL
   Costa RA, 2007, GRAEF ARCH CLIN EXP, V245, P1273, DOI 10.1007/s00417-007-0557-x
   *CURR CONTR TIRALS, VERITAS SAF EFF STUD
   Dhalla MS, 2006, RETINA-J RET VIT DIS, V26, P988, DOI 10.1097/01.iae.0000247164.70376.91
   Emerson MV, 2007, RETINA-J RET VIT DIS, V27, P439, DOI 10.1097/IAE.0b013e31804b3e15
   *FCSOS FLOR MED PR, 2007 PHYS NONPH PRAC
   Fung AE, 2007, AM J OPHTHALMOL, V143, P566, DOI 10.1016/j.ajo.2007.01.028
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Gupta OP, 2008, AM J OPHTHALMOL, V145, P923, DOI 10.1016/j.ajo.2007.12.037
   Heier JS, 2006, ARCH OPHTHALMOL-CHIC, V124, P1532, DOI 10.1001/archopht.124.11.1532
   HEIER JS, 2007, OPHTHALMOLOGY REPORT, V1, P5
   Husain D, 2005, ARCH OPHTHALMOL-CHIC, V123, P509, DOI 10.1001/archopht.123.4.509
   Kaiser PK, 2006, GRAEF ARCH CLIN EXP, V244, P1132, DOI 10.1007/s00417-005-0199-9
   Klein RM, 2007, RETINA-J RET VIT DIS, V27, P1163, DOI 10.1097/IAE.0b013e31815e9322
   Lazic R, 2007, OPHTHALMOLOGY, V114, P1179, DOI 10.1016/j.ophtha.2007.03.006
   Regillo CD, 2008, AM J OPHTHALMOL, V145, P239, DOI 10.1016/j.ajo.2007.10.004
   Reich S, 2003, MOL VIS, V9, P210
   Rich RM, 2006, RETINA-J RET VIT DIS, V26, P495, DOI 10.1097/01.iae.0000225766.75009.3a
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rosenfeld PJ, 2006, AM J OPHTHALMOL, V142, P141, DOI 10.1016/j.ajo.2006.03.036
   Smiddy WE, 2007, OPHTHALMOLOGY, V114, P847, DOI 10.1016/j.ophtha.2006.10.038
   Smith BT, 2008, RETINA-J RET VIT DIS, V28, P675, DOI 10.1097/IAE.0b013e31816b316e
   *SOC SEC ONL, 2004, STAT TABL PER LIV TA
   Spaide RF, 2006, AM J OPHTHALMOL, V141, P149, DOI 10.1016/j.ajo.2005.07.025
   Spaide RF, 2005, OPHTHALMOLOGY, V112, P301, DOI 10.1016/j.ophtha.2004.08.012
   Spaide R, 2007, AM J OPHTHALMOL, V143, P679, DOI 10.1016/j.ajo.2007.02.024
   Spaide RF, 2006, RETINA-J RET VIT DIS, V26, P383, DOI 10.1097/00006982-200604000-00001
   Spaide RF, 2005, RETINA-J RET VIT DIS, V25, P685, DOI 10.1097/00006982-200509000-00001
   Wong T, 2008, OPHTHALMOLOGY, V115, P116, DOI 10.1016/j.ophtha.2007.03.008
NR 39
TC 25
Z9 26
U1 0
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0161-6420
J9 OPHTHALMOLOGY
JI Ophthalmology
PD MAR
PY 2009
VL 116
IS 3
BP 481
EP 487
DI 10.1016/j.ophtha.2008.10.029
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 416KQ
UT WOS:000264005400019
PM 19157562
DA 2022-11-30
ER

PT J
AU Kaarniranta, K
   Uusitalo, H
   Blasiak, J
   Felszeghy, S
   Kannan, R
   Kauppinen, A
   Salminen, A
   Sinha, D
   Ferrington, D
AF Kaarniranta, Kai
   Uusitalo, Hannu
   Blasiak, Janusz
   Felszeghy, Szabolcs
   Kannan, Ram
   Kauppinen, Anu
   Salminen, Antero
   Sinha, Debasish
   Ferrington, Deborah
TI Mechanisms of mitochondrial dysfunction and their impact on age-related
   macular degeneration
SO PROGRESS IN RETINAL AND EYE RESEARCH
LA English
DT Review
DE Age-related macular degeneration; Aggregation; Aging; Autophagy;
   Clearance; Degeneration; Mitochondria; Mitophagy; Retina; Retinal
   pigment epithelium
ID RETINAL-PIGMENT EPITHELIUM; TRANSCRIPTION FACTOR NRF2; LYSOSOMAL
   DEGRADATIVE FUNCTIONS; DNA-REPAIR ENZYMES; NF-KAPPA-B; OXIDATIVE STRESS;
   RPE CELLS; INFLAMMASOME ACTIVATION; ARPE-19 CELLS; GEOGRAPHIC ATROPHY
AB Oxidative stress-induced damage to the retinal pigment epithelium (RPE) is considered to be a key factor in age-related macular degeneration (AMD) pathology. RPE cells are constantly exposed to oxidative stress that may lead to the accumulation of damaged cellular proteins, lipids, nucleic acids, and cellular organelles, including mitochondria. The ubiquitin-proteasome and the lysosomal/autophagy pathways are the two major proteolytic systems to remove damaged proteins and organelles. There is increasing evidence that proteostasis is disturbed in RPE as evidenced by lysosomal lipofuscin and extracellular drusen accumulation in AMD. Nuclear factor-erythroid 2-related factor-2 (NFE2L2) and peroxisome proliferator-activated receptor gamma coactivator-1 alpha (PGC-1 alpha) are master transcription factors in the regulation of antioxidant enzymes, clearance systems, and biogenesis of mitochondria. The precise cause of RPE degeneration and the onset and progression of AMD are not fully understood. However, mitochondria dysfunction, increased reactive oxygen species (ROS) production, and mitochondrial DNA (mtDNA) damage are observed together with increased protein aggregation and inflammation in AMD. In contrast, functional mitochondria prevent RPE cells damage and suppress inflammation. Here, we will discuss the role of mitochondria in RPE degeneration and AMD pathology focused on mtDNA damage and repair, autophagy/mitophagy signaling, and regulation of inflammation. Mitochondria are putative therapeutic targets to prevent or treat AMD.
C1 [Kaarniranta, Kai] Univ Eastern Finland, Inst Clin Med, Dept Ophthalmol, POB 1627, FI-70211 Kuopio, Finland.
   [Kaarniranta, Kai] Kuopio Univ Hosp, POB 1627, FI-70211 Kuopio, Finland.
   [Uusitalo, Hannu] Tampere Univ, Fac Med & Hlth Technol, POB 2000, Tampere, Finland.
   [Uusitalo, Hannu] Tampere Univ Hosp, Tays Eye Ctr, POB 2000, Tampere, Finland.
   [Blasiak, Janusz] Univ Lodz, Fac Biol & Environm Protect, Dept Mol Genet, PL-90236 Lodz, Poland.
   [Felszeghy, Szabolcs] Univ Eastern Finland, Dept Biomed, Fac Hlth Sci, POB 1627, FI-70211 Kuopio, Finland.
   [Kannan, Ram] Stephen J Ryan Initiat Macular Res RIMR, Doheny Eye Inst, 1355 San Pablo St, Los Angeles, CA 90033 USA.
   [Kauppinen, Anu] Univ Eastern Finland, Sch Pharm, Fac Hlth Sci, POB 1627, FI-70211 Kuopio, Finland.
   [Salminen, Antero] Univ Eastern Finland, Inst Clin Med, Dept Neurol, POB 1627, FI-70211 Kuopio, Finland.
   [Sinha, Debasish] Univ Pittsburgh, Dept Ophthalmol, Glia Res Lab, 4401 Penn Ave, Pittsburgh, PA 15224 USA.
   [Sinha, Debasish] Johns Hopkins Univ, Wilmer Eye Inst, Sch Med, Room M035 Robert & Clarice Smith Bldg, Baltimore, MD 21287 USA.
   [Ferrington, Deborah] Univ Minnesota, Dept Ophthalmol & Visual Neurosci, 2001 6th St SE, Minneapolis, MN 55455 USA.
C3 University of Eastern Finland; Kuopio University Hospital; University of
   Eastern Finland; Tampere University; Tampere University; Tampere
   University Hospital; University of Lodz; University of Eastern Finland;
   Doheny Eye Institute; University of Eastern Finland; University of
   Eastern Finland; Pennsylvania Commonwealth System of Higher Education
   (PCSHE); University of Pittsburgh; Johns Hopkins University; Johns
   Hopkins Medicine; University of Minnesota System; University of
   Minnesota Twin Cities
RP Kaarniranta, K (通讯作者)，Univ Eastern Finland, Dept Ophthalmol, Yliopistonranta 1 C, Kuopio 70211, Finland.; Kaarniranta, K (通讯作者)，Kuopio Univ Hosp, Yliopistonranta 1 C, Kuopio 70211, Finland.
EM kai.kaarniranta@uef.fi
OI Blasiak, Janusz/0000-0001-9539-9584; Ferrington,
   Deborah/0000-0003-2561-7464
FU Kuopio University Hospital; Finnish Eye Foundation; Sigrid Juselius
   Foundation; Health Research Council of the Academy of Finland [AK
   297267, 307341, 328443, KK 296840]; Paivikki and Sakari Sohlberg
   Foundation; National Institutes of Health/National Eye Institute [R01
   EY028554, EY026012]; Lindsay Family Foundation; National Science Centre,
   Poland [2017/27/B/NZ3/00872]; RBF/IRRF Catalyst Award
FX This work was supported by the Kuopio University Hospital (KK), the
   Finnish Eye Foundation (KK), The Sigrid Juselius Foundation (KK), the
   Health Research Council of the Academy of Finland (AK 297267, 307341,
   328443, KK 296840), the Paivikki and Sakari Sohlberg Foundation (AK,
   KK), the National Institutes of Health/National Eye Institute (R01
   EY028554 and EY026012), the Lindsay Family Foundation and an anonymous
   benefactor for AMD research (DAF), National Science Centre, Poland (JB,
   Grant number 2017/27/B/NZ3/00872). RBF/IRRF Catalyst Award for
   Innovative Research Approaches for AMD (DS) and the Jennifer Salvitti
   Davis Chair in Ophthalmology (DS). We thank Iswariyaraja Sridevi
   Gurubaran, Ali Koskela and Johanna Viiri for technical assistance in
   preparing figures.
CR Ach T, 2015, INVEST OPHTH VIS SCI, V56, P3242, DOI 10.1167/iovs.14-16274
   Ach T, 2014, INVEST OPHTH VIS SCI, V55, P4832, DOI 10.1167/iovs.14-14802
   Alaimo A, 2019, ARCH TOXICOL, V93, P1401, DOI 10.1007/s00204-019-02409-6
   Allio R, 2017, MOL BIOL EVOL, V34, P2762, DOI 10.1093/molbev/msx197
   AMES A, 1992, J NEUROSCI, V12, P840, DOI 10.1523/jneurosci.12-03-00840.1992
   AMES BN, 1992, ANN NY ACAD SCI, V663, P85, DOI 10.1111/j.1749-6632.1992.tb38652.x
   Anderson DH, 2010, PROG RETIN EYE RES, V29, P95, DOI 10.1016/j.preteyeres.2009.11.003
   Armento A., 2020, LOSS COMPLEMENT FACT, V2020, DOI [10.1101/2020.01.08.898551, DOI 10.1101/2020.01.08.898551]
   Arselin G, 2004, J BIOL CHEM, V279, P40392, DOI 10.1074/jbc.M404316200
   Atilano SR, 2015, HUM MOL GENET, V24, P4491, DOI 10.1093/hmg/ddv173
   Azad MB, 2009, ANTIOXID REDOX SIGN, V11, P777, DOI [10.1089/ars.2008.2270, 10.1089/ARS.2008.2270]
   Bader V, 2019, SEMIN CELL DEV BIOL
   Baldelli S, 2013, BBA-GEN SUBJECTS, V1830, P4137, DOI 10.1016/j.bbagen.2013.04.006
   Ban N, 2018, JCI INSIGHT, V3, DOI 10.1172/jci.insight.120824
   Barot M, 2011, CURR EYE RES, V36, P1069, DOI 10.3109/02713683.2011.607536
   Barreau E, 1996, INVEST OPHTH VIS SCI, V37, P384
   Barron MJ, 2001, INVEST OPHTH VIS SCI, V42, P3016
   Bermann M, 2001, EXP EYE RES, V72, P191
   Blasiak J, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20010210
   Blasiak J, 2013, INT J MOL SCI, V14, P2996, DOI 10.3390/ijms14022996
   Bornhovd C, 2006, J BIOL CHEM, V281, P13990, DOI 10.1074/jbc.M512334200
   Boya P, 2016, PROG RETIN EYE RES, V55, P206, DOI 10.1016/j.preteyeres.2016.08.001
   Brown EE, 2019, REDOX BIOL, V24, DOI 10.1016/j.redox.2019.101201
   Cannizzo ES, 2011, J PROTEOMICS, V74, P2313, DOI 10.1016/j.jprot.2011.06.005
   Canter JA, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002091
   Caston RA, 2017, FREE RADICAL BIO MED, V107, P146, DOI 10.1016/j.freeradbiomed.2016.11.025
   Chen M, 2019, PROG RETIN EYE RES, V69, P159, DOI 10.1016/j.preteyeres.2018.10.003
   Chen M, 2016, AGING CELL, V15, P436, DOI 10.1111/acel.12447
   Chen Q, 2003, J BIOL CHEM, V278, P36027, DOI 10.1074/jbc.M304854200
   Chen QM, 2018, PHYSIOL GENOMICS, V50, P77, DOI 10.1152/physiolgenomics.00041.2017
   Chinnery PF, 2002, LANCET, V360, P1323, DOI 10.1016/S0140-6736(02)11310-9
   Choudhary M, 2016, AGING-US, V8, P1952, DOI 10.18632/aging.101031
   Ciechanover A, 2012, BBA-PROTEINS PROTEOM, V1824, P3, DOI 10.1016/j.bbapap.2011.03.007
   Datta S, 2017, PROG RETIN EYE RES, V60, P201, DOI 10.1016/j.preteyeres.2017.03.002
   Decanini A, 2007, AM J OPHTHALMOL, V143, P607, DOI 10.1016/j.ajo.2006.12.006
   del Amo EM, 2017, PROG RETIN EYE RES, V57, P134, DOI 10.1016/j.preteyeres.2016.12.001
   Di Malta C, 2019, FRONT CELL DEV BIOL, V7, DOI 10.3389/fcell.2019.00114
   Dikic I, 2017, ANNU REV BIOCHEM, V86, P193, DOI 10.1146/annurev-biochem-061516-044908
   Doktor F, 2018, PURINERG SIGNAL, V14, P471, DOI 10.1007/s11302-018-9631-6
   Dysli C, 2017, PROG RETIN EYE RES, V60, P120, DOI 10.1016/j.preteyeres.2017.06.005
   Eells J.T., 2019, BIOLOGY-BASEL, V8, pE31
   Egger A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031272
   Fann DYW, 2018, MOL NEUROBIOL, V55, P1082, DOI 10.1007/s12035-017-0394-9
   Feher J, 2006, NEUROBIOL AGING, V27, P983, DOI 10.1016/j.neurobiolaging.2005.05.012
   Felszeghy S, 2019, REDOX BIOL, V20, P1, DOI 10.1016/j.redox.2018.09.011
   Ferrington DA, 2017, REDOX BIOL, V13, P255, DOI 10.1016/j.redox.2017.05.015
   Ferrington DA, 2016, EXP EYE RES, V145, P269, DOI 10.1016/j.exer.2016.01.018
   Ferrington DA, 2016, PROG RETIN EYE RES, V51, P69, DOI 10.1016/j.preteyeres.2015.09.002
   Fisher CR, 2018, INVEST OPHTH VIS SCI, V59, pAMD41, DOI 10.1167/iovs.18-24289
   Fleckenstein M, 2018, OPHTHALMOLOGY, V125, P369, DOI 10.1016/j.ophtha.2017.08.038
   Frede K, 2017, J AGR FOOD CHEM, V65, P5944, DOI 10.1021/acs.jafc.7b01929
   Fritsche LG, 2013, NAT GENET, V45, P433, DOI 10.1038/ng.2578
   Gambril JA, 2019, INVEST OPHTH VIS SCI, V60, P2481, DOI 10.1167/iovs.19-26949
   Gao JY, 2015, MEDIAT INFLAMM, V2015, DOI 10.1155/2015/690243
   Geisler S, 2010, NAT CELL BIOL, V12, P119, DOI 10.1038/ncb2012
   Giorgi C, 2018, INT REV CEL MOL BIO, V340, P209, DOI 10.1016/bs.ircmb.2018.05.006
   Golestaneh N, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2016.453
   Golestaneh N, 2016, J TRANSL MED, V14, DOI 10.1186/s12967-016-1101-8
   Gomez-Sintes R, 2017, CELLS-BASEL, V6, DOI 10.3390/cells6040037
   Gong ZW, 2018, J CELL BIOL, V217, P635, DOI 10.1083/jcb.201606095
   Guha S, 2014, EXP EYE RES, V126, P68, DOI 10.1016/j.exer.2014.05.013
   Gureev AP, 2019, NEUROCHEM RES, V44, P2273, DOI 10.1007/s11064-018-02711-2
   Gurubaran IS, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21061976
   Handa JT, 2012, MOL ASPECTS MED, V33, P418, DOI 10.1016/j.mam.2012.03.006
   He HJ, 2019, J CELL MOL MED, V23, P3495, DOI 10.1111/jcmm.14246
   Holley AK, 2011, INT J MOL SCI, V12, P7114, DOI 10.3390/ijms12107114
   Holz FG, 1999, INVEST OPHTH VIS SCI, V40, P737
   Holz FG, 2007, AM J OPHTHALMOL, V143, P463, DOI 10.1016/j.ajo.2006.11.041
   Huang YH, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0193175
   Hurley JB, 2015, J NEUROSCI RES, V93, P1079, DOI 10.1002/jnr.23583
   Hytti M, 2017, J NUTR BIOCHEM, V42, P37, DOI 10.1016/j.jnutbio.2016.12.014
   Hytti M, 2015, SCI REP-UK, V5, DOI 10.1038/srep17645
   Hyttinen JMT, 2018, CELL MOL LIFE SCI, V75, P2991, DOI 10.1007/s00018-018-2843-7
   Hyttinen JMT, 2017, AGEING RES REV, V36, P64, DOI 10.1016/j.arr.2017.03.006
   Hyttinen JMT, 2013, BBA-MOL CELL RES, V1833, P503, DOI 10.1016/j.bbamcr.2012.11.018
   Iacovelli J, 2016, INVEST OPHTH VIS SCI, V57, P1038, DOI 10.1167/iovs.15-17758
   Ichimura Y, 2018, FRONT ONCOL, V8, DOI 10.3389/fonc.2018.00210
   Jager S, 2007, P NATL ACAD SCI USA, V104, P12017, DOI 10.1073/pnas.0705070104
   Jain A, 2010, J BIOL CHEM, V285, P22576, DOI 10.1074/jbc.M110.118976
   Jarrett SG, 2012, MOL ASPECTS MED, V33, P399, DOI 10.1016/j.mam.2012.03.009
   Jarrett SG, 2008, PROG RETIN EYE RES, V27, P596, DOI 10.1016/j.preteyeres.2008.09.001
   Jezek P, 2018, ANTIOXID REDOX SIGN, V29, P667, DOI 10.1089/ars.2017.7225
   Jin GF, 2001, CURR EYE RES, V23, P11, DOI 10.1076/ceyr.23.1.11.5423
   Joachim N, 2015, OPHTHALMOLOGY, V122, P2482, DOI 10.1016/j.ophtha.2015.08.002
   Johansen T, 2020, J MOL BIOL, V432, P80, DOI 10.1016/j.jmb.2019.07.016
   Johansson I, 2015, AUTOPHAGY, V11, P1636, DOI 10.1080/15548627.2015.1061170
   Jones MM, 2007, ARCH OPHTHALMOL-CHIC, V125, P1235, DOI 10.1001/archopht.125.9.1235
   Juuti-Uusitalo K, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18051089
   Kaarniranta K, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20102374
   Kaarniranta K, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19082317
   Kaarniranta K, 2019, BIOCHIMIE, V159, P49, DOI 10.1016/j.biochi.2018.07.010
   Kaarniranta K, 2018, ADV DRUG DELIVER REV, V126, P177, DOI 10.1016/j.addr.2018.04.016
   Kaarniranta K, 2017, CELL BIOL TOXICOL, V33, P113, DOI 10.1007/s10565-016-9371-8
   Kaarniranta K, 2013, AUTOPHAGY, V9, P973, DOI 10.4161/auto.24546
   Kaarniranta Kai, 2010, Front Biosci (Elite Ed), V2, P1374
   Kaarniranta K, 2009, AGEING RES REV, V8, P128, DOI 10.1016/j.arr.2009.01.001
   Kageyama Y, 2012, J CELL BIOL, V197, P535, DOI 10.1083/jcb.201110034
   Karlsson M, 2013, EXP EYE RES, V116, P359, DOI 10.1016/j.exer.2013.10.014
   Karunadharma PP, 2010, INVEST OPHTH VIS SCI, V51, P5470, DOI 10.1167/iovs.10-5429
   Kauppinen A, 2016, CELL MOL LIFE SCI, V73, P1765, DOI 10.1007/s00018-016-2147-8
   Kauppinen A, 2012, IMMUNOL LETT, V147, P29, DOI 10.1016/j.imlet.2012.05.005
   Kay P, 2014, INVEST OPHTH VIS SCI, V55, P926, DOI 10.1167/iovs.13-13239
   Kenney MC, 2014, HUM MOL GENET, V23, P3537, DOI 10.1093/hmg/ddu065
   Kenney MC, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0054339
   Kenney MC, 2010, INVEST OPHTH VIS SCI, V51, P4289, DOI 10.1167/iovs.09-4778
   Kerur N, 2018, NAT MED, V24, P50, DOI 10.1038/nm.4450
   Kim JY, 2013, CELL, V155, P725, DOI 10.1016/j.cell.2013.10.013
   Klionsky DJ, 2012, AUTOPHAGY, V8, P445, DOI 10.4161/auto.19496
   Kobayashi A, 2004, MOL CELL BIOL, V24, P7130, DOI 10.1128/MCB.24.16.7130-7139.2004
   Komatsu M, 2010, NAT CELL BIOL, V12, P213, DOI 10.1038/ncb2021
   Korovila I, 2017, REDOX BIOL, V13, P550, DOI 10.1016/j.redox.2017.07.008
   Koskela A, 2014, MOL VIS, V20, P760
   Krohne TU, 2010, EXP EYE RES, V90, P465, DOI 10.1016/j.exer.2009.12.011
   Lakkaraju A, 2007, P NATL ACAD SCI USA, V104, P11026, DOI 10.1073/pnas.0702504104
   Lambros ML, 2016, ADV EXP MED BIOL, V854, P67, DOI 10.1007/978-3-319-17121-0_10
   Lastres-Becker I, 2016, ANTIOXID REDOX SIGN, V25, P61, DOI 10.1089/ars.2015.6549
   Lau A, 2010, MOL CELL BIOL, V30, P3275, DOI 10.1128/MCB.00248-10
   Lazarou M, 2015, NATURE, V524, P309, DOI 10.1038/nature14893
   Lee J, 2012, BIOCHEM J, V441, P523, DOI 10.1042/BJ20111451
   Lee SY, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.266
   Lemasters JJ, 2005, REJUV RES, V8, P3, DOI 10.1089/rej.2005.8.3
   Li XF, 2018, BIOCHEM BIOPH RES CO, V501, P293, DOI 10.1016/j.bbrc.2018.05.003
   Li ZR, 2013, MOL VIS, V19, P1656
   Liang FQ, 2003, EXP EYE RES, V76, P397, DOI 10.1016/S0014-4835(03)00023-X
   Lin HJ, 2011, INVEST OPHTH VIS SCI, V52, P3521, DOI 10.1167/iovs.10-6163
   Liu J, 2016, SCI REP-UK, V6, DOI 10.1038/srep20639
   Liu J, 2015, NUCLEIC ACIDS RES, V43, P5476, DOI 10.1093/nar/gkv472
   Liu XB, 2016, REDOX BIOL, V8, P98, DOI 10.1016/j.redox.2015.12.005
   Liu YX, 2016, J AGR FOOD CHEM, V64, P416, DOI 10.1021/acs.jafc.5b05436
   Lu W, 2018, FRONT PHARMACOL, V9, DOI 10.3389/fphar.2018.00242
   Lu ZB, 2010, ANTIOXID REDOX SIGN, V13, P1011, DOI 10.1089/ars.2009.2940
   Malik D, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0099003
   Mao HY, 2014, INVEST OPHTH VIS SCI, V55, P4613, DOI 10.1167/iovs.14-14633
   Marchesi N., 2018, OXID MED CELL LONGEV, V2018, P1, DOI DOI 10.1155/2018/4956080
   Marie M, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-0331-5
   Matsumoto G, 2011, MOL CELL, V44, P279, DOI 10.1016/j.molcel.2011.07.039
   Matsunaga D, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0165150
   McWilliams TG, 2019, AUTOPHAGY, V15, P1296, DOI 10.1080/15548627.2019.1580509
   MEDRANO CJ, 1995, EXP EYE RES, V61, P273, DOI 10.1016/S0014-4835(05)80122-8
   Melis JPM, 2013, ANTIOXID REDOX SIGN, V18, P2409, DOI 10.1089/ars.2012.5036
   Miceli MV, 2005, INVEST OPHTH VIS SCI, V46, P1765, DOI 10.1167/iovs.04-1327
   Minasyan L, 2017, OXID MED CELL LONGEV, V2017, DOI 10.1155/2017/1675230
   Minauro-Sanmiguel F, 2005, P NATL ACAD SCI USA, V102, P12356, DOI 10.1073/pnas.0503893102
   Mitter SK, 2014, AUTOPHAGY, V10, P1989, DOI 10.4161/auto.36184
   Moldogazieva NT, 2019, OXID MED CELL LONGEV, V2019, DOI 10.1155/2019/3085756
   Mullins RF, 2000, FASEB J, V14, P835, DOI 10.1096/fasebj.14.7.835
   Murata H, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0142438
   Murphy MP, 2009, BIOCHEM J, V417, P1, DOI 10.1042/BJ20081386
   Murray D, 2018, RADIAT RES, V190, P331, DOI 10.1667/RR15101.1
   Myeku N, 2011, J BIOL CHEM, V286, P22426, DOI 10.1074/jbc.M110.149252
   Naidu SD, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-11262-5
   Nakamura S, 2017, J CELL SCI, V130, P1209, DOI 10.1242/jcs.196352
   Nashine S, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-33290-5
   Nie HR, 2016, MITOCHONDRION, V26, P104, DOI 10.1016/j.mito.2015.12.001
   Nordgaard CL, 2006, INVEST OPHTH VIS SCI, V47, P815, DOI 10.1167/iovs.05-0976
   Nordgaard CL, 2008, INVEST OPHTH VIS SCI, V49, P2848, DOI 10.1167/iovs.07-1352
   Nunez-Alvarez C, 2019, ACTA OPHTHALMOL, V97, pE103, DOI 10.1111/aos.13812
   O'Mealey GB, 2017, REDOX BIOL, V11, P103, DOI 10.1016/j.redox.2016.11.007
   Osborne NN, 2014, DRUG DISCOV TODAY, V19, P1613, DOI 10.1016/j.drudis.2014.05.010
   Pajares M, 2016, AUTOPHAGY, V12, P1902, DOI 10.1080/15548627.2016.1208889
   Piippo N, 2018, CELL PHYSIOL BIOCHEM, V49, P359, DOI 10.1159/000492886
   Piippo N, 2014, BBA-MOL CELL RES, V1843, P3038, DOI 10.1016/j.bbamcr.2014.09.015
   Popov LD, 2019, CELL TISSUE RES, V377, P161, DOI 10.1007/s00441-019-03049-z
   Prager P, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0165653
   Rao SR, 2018, AUTOPHAGY, V14, P1796, DOI 10.1080/15548627.2018.1490851
   Ratnayaka A, 2007, EXP EYE RES, V84, P1135, DOI 10.1016/j.exer.2006.01.030
   Rodriguez-Muela N, 2013, AGING CELL, V12, P478, DOI 10.1111/acel.12072
   Roggia MF, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0134870
   Rosales M.A.B., 2019, LIFE SCI ALLIANCE, V2
   Rottenberg H, 2017, AGING CELL, V16, P943, DOI 10.1111/acel.12650
   Rozing MP, 2020, PROG RETIN EYE RES, V76, DOI 10.1016/j.preteyeres.2019.100825
   Rudolf M, 2013, OPHTHALMOLOGY, V120, P821, DOI 10.1016/j.ophtha.2012.10.007
   Sachdeva MM, 2014, EXP EYE RES, V119, P111, DOI 10.1016/j.exer.2013.10.024
   Saito Y, 2018, REDOX BIOL, V19, P354, DOI 10.1016/j.redox.2018.09.004
   Salminen A, 2012, AGING-US, V4, P166, DOI 10.18632/aging.100444
   SanGiovanni JP, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005508
   Scherz-Shouval R, 2007, EMBO J, V26, P1749, DOI 10.1038/sj.emboj.7601623
   Schottler J, 2018, EXP EYE RES, V171, P1, DOI 10.1016/j.exer.2018.03.002
   Schutt F, 2003, INVEST OPHTH VIS SCI, V44, P3663, DOI 10.1167/iovs.03-0172
   Schutt F, 2002, GRAEF ARCH CLIN EXP, V240, P983, DOI 10.1007/s00417-002-0558-8
   Seibenhener ML, 2004, MOL CELL BIOL, V24, P8055, DOI 10.1128/MCB.24.18.8055-8068.2004
   Shadrach KG, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0067983
   Shah SZA, 2018, FRONT MOL NEUROSCI, V11, DOI 10.3389/fnmol.2018.00310
   Sharif U, 2019, J CELL MOL MED, V23, P405, DOI 10.1111/jcmm.13944
   Sharma A, 2018, THERANOSTICS, V8, P5529, DOI 10.7150/thno.29039
   Shi HQ, 2015, BIOCHEM BIOPH RES CO, V463, P1071, DOI 10.1016/j.bbrc.2015.06.060
   Sihvola V, 2017, ARCH BIOCHEM BIOPHYS, V617, P94, DOI 10.1016/j.abb.2016.10.010
   Silva-Palacios A, 2018, AGEING RES REV, V47, P31, DOI 10.1016/j.arr.2018.06.003
   Sinha D, 2016, EXP EYE RES, V144, P46, DOI 10.1016/j.exer.2015.08.018
   Song CJ, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0171940
   Sreekumar PG, 2016, INVEST OPHTH VIS SCI, V57, P1238, DOI 10.1167/iovs.15-17053
   St-Pierre J, 2006, CELL, V127, P397, DOI 10.1016/j.cell.2006.09.024
   Stefansson E, 2019, PROG RETIN EYE RES, V70, P1, DOI 10.1016/j.preteyeres.2019.04.001
   Stefansson E, 2011, PROG RETIN EYE RES, V30, P72, DOI 10.1016/j.preteyeres.2010.09.003
   Strauss O, 2005, PHYSIOL REV, V85, P845, DOI 10.1152/physrev.00021.2004
   Strom J, 2016, FASEB J, V30, P66, DOI 10.1096/fj.14-268904
   Su CC, 2014, INT J MOL SCI, V15, P13755, DOI 10.3390/ijms150813755
   Szatmari-Toth M, 2016, CELL DEATH DIS, V7, DOI 10.1038/cddis.2016.133
   Szatmari-Toth M, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20040926
   Tadi SK, 2016, MOL BIOL CELL, V27, P223, DOI 10.1091/mbc.E15-05-0260
   Tan LX, 2016, P NATL ACAD SCI USA, V113, P8789, DOI 10.1073/pnas.1523061113
   Tarallo V, 2012, CELL, V149, P847, DOI 10.1016/j.cell.2012.03.036
   Terluk MR, 2015, J NEUROSCI, V35, P7304, DOI 10.1523/JNEUROSCI.0190-15.2015
   Tokarz P, 2013, BIOGERONTOLOGY, V14, P461, DOI 10.1007/s10522-013-9463-2
   Twig G, 2011, ANTIOXID REDOX SIGN, V14, P1939, DOI 10.1089/ars.2010.3779
   Udar N, 2009, INVEST OPHTH VIS SCI, V50, P2966, DOI 10.1167/iovs.08-2646
   Valapala M, 2014, AUTOPHAGY, V10, P480, DOI 10.4161/auto.27292
   Viiri J, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0069563
   Viiri J, 2010, MOL VIS, V16, P1399
   Vives-Bauza C, 2008, J BIOL CHEM, V283, P24770, DOI 10.1074/jbc.M800706200
   Wang AL, 2008, MOL VIS, V14, P644
   Wang AL, 2010, NEUROBIOL AGING, V31, P2002, DOI 10.1016/j.neurobiolaging.2008.10.019
   Wang AL, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004160
   Wang J, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-03856-y
   Wang JY, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17101601
   Wang K., 2017, J BIOCHEM MOL TOXIC, V31, P6
   Wang L, 2016, ADV EXP MED BIOL, V854, P17, DOI 10.1007/978-3-319-17121-0_3
   Wang L, 2014, BBA-MOL CELL RES, V1843, P1248, DOI 10.1016/j.bbamcr.2014.03.016
   Wang L, 2014, FREE RADICAL BIO MED, V70, P155, DOI 10.1016/j.freeradbiomed.2014.01.015
   Wang SB, 2019, OXID MED CELL LONGEV, V2019, DOI 10.1155/2019/3632169
   Wang X., 2007, HUM MOL GENET, V1188, P1200
   West AP, 2015, NATURE, V520, P553, DOI 10.1038/nature14156
   Woodell A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0067894
   Wu R, 2018, BIOCHEM CELL BIOL, V96, P44, DOI 10.1139/bcb-2017-0149
   Xu L, 2018, P NATL ACAD SCI USA, V115, P10475, DOI 10.1073/pnas.1802724115
   Yang J, 2014, HUM MOL GENET, V23, P3445, DOI 10.1093/hmg/ddu053
   Yang PM, 2016, LIFE SCI, V155, P94, DOI 10.1016/j.lfs.2016.05.006
   Ye FX, 2016, FREE RADICAL BIO MED, V94, P121, DOI 10.1016/j.freeradbiomed.2016.02.027
   Yong CQY, 2018, CELLS-BASEL, V7, DOI 10.3390/cells7080105
   Yu DY, 2005, EXP EYE RES, V80, P745, DOI 10.1016/j.exer.2005.01.018
   Zaffagnini G, 2016, J MOL BIOL, V428, P1714, DOI 10.1016/j.jmb.2016.02.004
   Zhang J, 2015, CELL DEATH DIS, V6, DOI 10.1038/cddis.2015.330
   Zhang M., 2018, DIS MODEL MECH, V211, P9
   Zhou RB, 2011, NATURE, V469, P221, DOI 10.1038/nature09663
   Zinovkina LA, 2018, BIOCHEMISTRY-MOSCOW+, V83, P233, DOI 10.1134/S0006297918030045
   Zou X, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.190
NR 236
TC 106
Z9 108
U1 26
U2 81
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 1350-9462
EI 1873-1635
J9 PROG RETIN EYE RES
JI Prog. Retin. Eye Res.
PD NOV
PY 2020
VL 79
DI 10.1016/j.preteyeres.2020.100858
PG 19
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA PH4OZ
UT WOS:000600395400002
PM 32298788
OA hybrid, Green Accepted
HC Y
HP N
DA 2022-11-30
ER

PT J
AU Romano, MR
   Valldeperas, X
   Vinciguerra, P
   Wong, D
AF Romano, Mario R.
   Valldeperas, Xavier
   Vinciguerra, Paolo
   Wong, David
TI Sub-Macular Surgery: Is Still an Option for Age-Related Macular
   Degeneration?
SO CURRENT DRUG TARGETS
LA English
DT Review
DE Submacular surgery; age-related macular degeneration; choroidal
   transplant; retinal pigment epithelium
ID SUBFOVEAL CHOROIDAL NEOVASCULARIZATION; RETINAL-PIGMENT EPITHELIUM;
   QUALITY-OF-LIFE; RANDOMIZED CLINICAL-TRIAL; SUBMACULAR SURGERY;
   SUBRETINAL HEMORRHAGE; SURGICAL REMOVAL; AUTOLOGOUS TRANSLOCATION;
   PHOTODYNAMIC THERAPY; OPHTHALMIC FINDINGS
AB Purpose: This review summarizes the data reported in peer-reviewed literature on the effects of submacular surgery for age-related macular degeneration (AMD) associated with choriodal neovascularization (CNV). Methods: A review of the MEDLINE database has been performed in order to examine the therapeutic effects of submacular surgical treatments in patients affected by AMD. Results: The multicenter studies conducted by the Submacular Surgery Trials Research Group compare the removal of the CNV complex, both with (336) and without blood (454), with observation in patients affected by AMD. At a 1-year follow-up, no benefit in preventing visual loss had been shown. Furthermore, complications occurred in the surgery arm such as retinal detachment and lens opacification. No differences have been found between submacular surgery and laser photocoagulation in terms of visual acuity and quality of life. As yet, there are no randomized controlled trials concerning retinal pigment epithelium and choroid translocation or macular translocation, but only prospective, non-controlled case series with low quality of evidence. Conclusions: No evidence of potential benefit from submacular removal of the CNV complex due to AMD has been shown. Randomized clinical trails (RCT) concerning other submacular surgical approaches are not available. There are sufficient non-comparative data on retinal pigment epithelium (RPE) graft to warrant an RCT especially in patients with large subretinal haemorrhages, RPE rip or in Anti-VEGF non-responders.
C1 [Romano, Mario R.] Univ Molise, Dept Hlth Sci, I-86100 Campobasso, Italy.
   [Romano, Mario R.; Vinciguerra, Paolo] Ist Clin Humanitas, Dept Ophthalmol, Milan, Italy.
   [Valldeperas, Xavier] Hosp Badalona Germans Trias & Pujol, Dept Ophthalmol, Barcelona, Spain.
   [Wong, David] Univ Hong Kong, Li Ka Shing Fac Med, Hong Kong, Hong Kong, Peoples R China.
C3 University of Molise; IRCCS Humanitas Research Hospital; Hospital
   Germans Trias i Pujol; University of Hong Kong
RP Romano, MR (通讯作者)，Univ Molise, Dept Hlth Sci, Via F De Sanctis SNC, I-86100 Campobasso, Italy.
EM romanomario@email.it
RI Romano, Mario R/I-8320-2012; VINCIGUERRA, PAOLO/AAF-5775-2019
OI Vinciguerra, Paolo/0000-0002-3864-8246; Valldeperas,
   Xavier/0000-0002-6343-6405
CR Aisenbrey S, 2002, ARCH OPHTHALMOL-CHIC, V120, P451
   Aisenbrey S, 2007, ARCH OPHTHALMOL-CHIC, V125, P1367, DOI 10.1001/archopht.125.10.1367
   ALGVERE PV, 1994, GRAEF ARCH CLIN EXP, V232, P707, DOI 10.1007/BF00184273
   [Anonymous], 1993, Arch Ophthalmol, V111, P1200
   [Anonymous], 1984, Am J Ophthalmol, V98, P376
   Avery RL, 1996, RETINA-J RET VIT DIS, V16, P183, DOI 10.1097/00006982-199616030-00001
   Bass E, 2000, AM J OPHTHALMOL, V130, P408
   BLINDER KJ, 1991, INT OPHTHALMOL, V15, P215
   Bressler NM, 2000, AM J OPHTHALMOL, V130, P387
   Bressler NM, 2004, OPHTHALMOLOGY, V111, P1993, DOI 10.1016/j.ophtha.2004.07.023
   Bressler NM, 2001, OPHTHALMOLOGY, V108, P435, DOI 10.1016/S0161-6420(00)00666-7
   Bressler NM, 1997, ARCH OPHTHALMOL-CHIC, V115, P1071, DOI 10.1001/archopht.1997.01100160241017
   Bunce C, 2006, BMC PUBLIC HEALTH, V6, DOI 10.1186/1471-2458-6-58
   Cahill MT, 2005, OPHTHALMOLOGY, V112, P144, DOI 10.1016/j.ophtha.2004.06.035
   Chang TS, 2007, ARCH OPHTHALMOL-CHIC, V125, P1460, DOI 10.1001/archopht.125.11.1460
   Childs AL, 2004, OPHTHALMOLOGY, V111, P2007, DOI 10.1016/j.ophtha.2004.07.024
   Colquitt JL, 2008, HEALTH TECHNOL ASSES, V12, P1
   Complications of Age-Related Macular Degeneration Prevention Trial Study Group, 2004, Clin Trials, V1, P91
   DEJUAN E, 1988, AM J OPHTHALMOL, V105, P25, DOI 10.1016/0002-9394(88)90116-X
   Fan H, 2005, ACTA OPHTHALMOL SCAN, V83, P622, DOI 10.1111/j.1600-0420.2005.00493.x
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Fujikado T, 2002, AM J OPHTHALMOL, V134, P849, DOI 10.1016/S0002-9394(02)01756-7
   Gamulescu MA, 2007, GRAEF ARCH CLIN EXP, V245, P1037, DOI 10.1007/s00417-007-0551-3
   Gibran SK, 2007, BRIT J OPHTHALMOL, V91, P602, DOI 10.1136/bjo.2006.108795
   Gibran S, 2009, GRAEF ARCH CLIN EXP, V247, P187, DOI 10.1007/s00417-008-0958-5
   Hawkins BS, 2004, ARCH OPHTHALMOL-CHIC, V122, P1616, DOI 10.1001/archopht.122.11.1616
   Hawkins BS, 2004, OPHTHALMOLOGY, V111, P1967, DOI 10.1016/j.ophtha.2004.07.021
   Hubbard GB, 2004, ARCH OPHTHALMOL-CHIC, V122, P1597, DOI 10.1001/archopht.122.11.1597
   HUDSON HL, 1995, BRIT J OPHTHALMOL, V79, P417, DOI 10.1136/bjo.79.5.417
   Jeganathan VSE, 2009, CURR OPIN OPHTHALMOL, V20, P223, DOI 10.1097/ICU.0b013e328329b656
   Joussen AM, 2010, EYE, V24, P284, DOI 10.1038/eye.2009.107
   Joussen AM, 2007, OPHTHALMOLOGY, V114, P551, DOI 10.1016/j.ophtha.2006.08.016
   Joussen AM, 2006, AM J OPHTHALMOL, V142, P17, DOI 10.1016/j.ajo.2006.01.090
   Kaplan H, 1996, BRIT J OPHTHALMOL, V80, P101, DOI 10.1136/bjo.80.2.101
   Klein R, 2002, OPHTHALMOLOGY, V109, P1767, DOI 10.1016/S0161-6420(02)01146-6
   Lantry LE, 2007, CURR OPIN MOL THER, V9, P592
   Luke M, 2009, GRAEF ARCH CLIN EXP, V247, P745, DOI 10.1007/s00417-009-1050-5
   Lux A, 2007, BRIT J OPHTHALMOL, V91, P1318, DOI 10.1136/bjo.2006.113902
   Maaijwee K, 2007, GRAEF ARCH CLIN EXP, V245, P1681, DOI 10.1007/s00417-007-0607-4
   Machemer R, 1998, AM J OPHTHALMOL, V125, P698, DOI 10.1016/S0002-9394(98)00020-8
   Mejico LJ, 2004, AM J OPHTHALMOL, V137, P908, DOI 10.1016/j.ajo.2003.12.038
   Meyer CH, 2008, ACTA OPHTHALMOL, V86, P490, DOI 10.1111/j.1600-0420.2007.01125.x
   Miskala PH, 2004, OPHTHALMOLOGY, V111, P1981, DOI 10.1016/j.ophtha.2004.07.022
   Mitchell P, 2010, BRIT J OPHTHALMOL, V94, P2, DOI 10.1136/bjo.2009.159160
   Mruthyunjaya P, 2005, RETINA-J RET VIT DIS, V25, P597, DOI 10.1097/00006982-200507000-00010
   Neugebauer A, 2002, OPHTHALMOLOGE, V99, P10, DOI 10.1007/PL00007108
   Pertile G, 2002, AM J OPHTHALMOL, V134, P560, DOI 10.1016/S0002-9394(02)01641-0
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Ruiz-Moreno JM, 2007, RETINA-J RET VIT DIS, V27, P458, DOI 10.1097/IAE.0b013e318030c77c
   Smith TC, 2007, AUST FAM PHYSICIAN, V36, P359
   Solomon SD, 2007, ARCH OPHTHALMOL-CHIC, V125, P1323
   STERNBERG P, 1991, ARCH OPHTHALMOL-CHIC, V109, P1242
   THOMAS MA, 1991, AM J OPHTHALMOL, V111, P1, DOI 10.1016/S0002-9394(14)76888-6
   TOTH CA, 1995, OPHTHALMOLOGY, V102, P272
   VALENTINO TL, 1995, ARCH OPHTHALMOL-CHIC, V113, P932, DOI 10.1001/archopht.1995.01100070106033
   VANDER JF, 1991, OPHTHALMOLOGY, V98, P23
   WADE EC, 1990, ARCH OPHTHALMOL-CHIC, V108, P973, DOI 10.1001/archopht.1990.01070090075043
   Wong D, 2004, BRIT J OPHTHALMOL, V88, P186, DOI 10.1136/bjo.2003.019273
   Wong D, 2007, CLIN EXP OPHTHALMOL, V35, P167, DOI 10.1111/j.1442-9071.2006.01410.x
   Zhang TR, 2009, INVEST OPHTH VIS SCI, V50, P2982, DOI 10.1167/iovs.08-2131
NR 60
TC 1
Z9 2
U1 0
U2 3
PU BENTHAM SCIENCE PUBL LTD
PI SHARJAH
PA EXECUTIVE STE Y-2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB
   EMIRATES
SN 1389-4501
EI 1873-5592
J9 CURR DRUG TARGETS
JI Curr. Drug Targets
PD FEB
PY 2011
VL 12
IS 2
BP 190
EP 198
PG 9
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA 720RX
UT WOS:000287299000006
PM 20887243
DA 2022-11-30
ER

PT J
AU Zhao, C
   Zhang, Z
   Chen, L
   Wang, F
   Xu, D
AF Zhao, Chun
   Zhang, Zhen
   Chen, Lei
   Wang, Fang
   Xu, Ding
TI Effectiveness of Intravitreal Injection of Ranibizumab for Neovascular
   Age-Related Macular Degeneration with Serous Pigment Epithelial
   Detachment
SO MEDICAL SCIENCE MONITOR
LA English
DT Article
DE Intravitreal Injections; Macular Degeneration; Retinal Pigment
   Epithelium
ID CHOROIDAL NEOVASCULARIZATION; EXTRACELLULAR-MATRIX; BEVACIZUMAB;
   SECONDARY; TRIAL
AB Background: We sought to observe the effectiveness of intravitreal injection of ranibizumab in treating neovascular age-related macular degeneration (nAMD) with serous pigment epithelial detachment (sPED).
   Material/Methods: A retrospective, noncomparative case series was performed. Twenty-3 eyes of 23 patients with sPED secondary to nAMD who had received intravitreal injections of ranibizumab were included in this study. All patients underwent best-corrected visual acuity (BCVA), synchronous fluorescein fundus angiography (FFA), indocyanine green angiography (ICGA), and optical coherence tomography (OCT) examinations. All patients were treated with pro re nata intravitreal injections after 3 loading doses of ranibizumab and were followed up for 12 months. The differences in the BCVAs, maximum PED heights, PED volumes and CFTs of the affected eyes were compared between the baseline and last visit.
   Results: Twelve months after the first injection, improved visual acuity was observed in 16 of the 23 eyes. 4 eyes exhibited stable visual acuity, and 3 eyes exhibited impaired visual acuity. The mean post-injection logMAR BCVA was 0.58 +/- 0.05, which was much better than that at baseline (0.76 +/- 0.08; t=1.751, P=0.0869). The mean maximum PED height at baseline was 350.17 +/- 35.73 mu m and it was decreased to 238.87 +/- 36.87 mu m (t=2.192, P=0.0337) at the last visit. The mean PED volume after injection was 0.34 +/- 0.1 mm(3), which was significantly decreased compared with that at baseline (0.81 +/- 0.21 mm(3); t=2.021, P=0.0494). The mean CFT decreased, but this difference was not statistically significant (t=1.003, P=0.3211). None of the patients exhibited endophthalmitis, uveitis or RPE tears.
   Conclusions: Intravitreal injection of ranibizumab for the treatment of neovascular age-related macular degeneration with serous pigment epithelial detachment safely and effectively improved the patients' visual acuities and decreased their PED heights volumes.
C1 [Zhao, Chun; Zhang, Zhen; Wang, Fang] Nanjing Med Univ, Affiliated Shanghai Clin Med Coll 10, Dept Ophthalmol, Nanjing, Jiangsu, Peoples R China.
   [Zhao, Chun; Chen, Lei; Wang, Fang; Xu, Ding] Tongji Univ, Peoples Hosp 10, Dept Ophthalmol, Shanghai 200092, Peoples R China.
C3 Nanjing Medical University; Tongji University
RP Wang, F (通讯作者)，Nanjing Med Univ, Affiliated Shanghai Clin Med Coll 10, Dept Ophthalmol, Nanjing, Jiangsu, Peoples R China.; Wang, F; Xu, D (通讯作者)，Tongji Univ, Peoples Hosp 10, Dept Ophthalmol, Shanghai 200092, Peoples R China.
EM daisyxu70@hotmail.com
CR Ach T, 2010, RETINA-J RET VIT DIS, V30, P1420, DOI 10.1097/IAE.0b013e3181d87e97
   Arias L, 2010, CLIN OPHTHALMOL, V4, P369
   Arora S, 2011, EYE, V25, P1034, DOI 10.1038/eye.2011.115
   Baumal CR, 1997, OPHTHALMOLOGY, V104, P761, DOI 10.1016/S0161-6420(97)30236-X
   Chang TS, 2007, ARCH OPHTHALMOL-CHIC, V125, P1460, DOI 10.1001/archopht.125.11.1460
   Das UN, 2012, MED SCI MONITOR, V18, pLE1, DOI 10.12659/MSM.882187
   Figurska M, 2011, MED SCI MONITOR, V17, pCR485, DOI 10.12659/MSM.881934
   Funk M, 2009, OPHTHALMOLOGY, V116, P2393, DOI 10.1016/j.ophtha.2009.05.039
   Inoue M, 2013, RETINA-J RET VIT DIS, V33, P990, DOI 10.1097/IAE.0b013e3182755793
   Kaiser PK, 2007, AM J OPHTHALMOL, V144, P850, DOI 10.1016/j.ajo.2007.08.012
   Klein R, 2013, INVEST OPHTH VIS SCI, V54, DOI 10.1167/iovs.13-12789
   Larsen M, 2012, OPHTHALMOLOGY, V119, P992, DOI 10.1016/j.ophtha.2012.02.002
   Menke MN, 2014, BRIT J OPHTHALMOL, V98, P1197, DOI 10.1136/bjophthalmol-2013-304775
   Nita M, 2014, MED SCI MONITOR, V20, P1003, DOI 10.12659/MSM.889887
   Nita M, 2014, MED SCI MONITOR, V20, P875, DOI 10.12659/MSM.890031
   Panos GD, 2013, DRUG DES DEV THER, V7, P565, DOI 10.2147/DDDT.S46610
   Pauleikhoff D, 2002, GRAEF ARCH CLIN EXP, V240, P533, DOI 10.1007/s00417-002-0505-8
   Pepple K, 2011, SEMIN OPHTHALMOL, V26, P198, DOI 10.3109/08820538.2011.570850
   Regillo CD, 2008, AM J OPHTHALMOL, V145, P239, DOI 10.1016/j.ajo.2007.10.004
   Rosenfeld Philip J, 2006, Ophthalmol Clin North Am, V19, P361
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Schmidt-Erfurth U, 2011, OPHTHALMOLOGY, V118, P831, DOI 10.1016/j.ophtha.2010.09.004
   Shima C, 2009, GRAEF ARCH CLIN EXP, V247, P899, DOI 10.1007/s00417-009-1067-9
NR 23
TC 5
Z9 5
U1 0
U2 4
PU INT SCIENTIFIC LITERATURE, INC
PI SMITHTOWN
PA 361 FOREST LANE, SMITHTOWN, NY 11787 USA
SN 1643-3750
J9 MED SCI MONITOR
JI Med. Sci. Monitor
PD MAR 14
PY 2016
VL 22
BP 833
EP 839
DI 10.12659/MSM.895528
PG 7
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine
GA DG4TC
UT WOS:000372064500001
PM 26972376
OA Green Published
DA 2022-11-30
ER

PT J
AU Kim, JH
   Chang, YS
   Kim, JW
   Lee, DW
   Han, JI
   Kim, CG
AF Kim, Jae Hui
   Chang, Young Suk
   Kim, Jong Woo
   Lee, Dong Won
   Han, Jung Il
   Kim, Chul Gu
TI Self-recognition of recurrences among patients with exudative
   age-related macular degeneration
SO CLINICAL AND EXPERIMENTAL OPTOMETRY
LA English
DT Article
DE age-related macular degeneration; macula; retina
ID CHOROIDAL NEOVASCULARIZATION SECONDARY; OPTICAL COHERENCE TOMOGRAPHY;
   REFRACTIVE ERROR; DOSING REGIMEN; RANIBIZUMAB; BEVACIZUMAB; SINGAPORE;
   DEVICE; TREAT; DELAY
AB PurposeThe aim was to investigate factors influencing a patient's self-recognition of the recurrence of exudative changes secondary to age-related macular degeneration (AMD).
   MethodsIn this retrospective study, we reviewed medical records for patients with exudative AMD who were diagnosed with a recurrence of exudation. Various parameters were compared, including age, sex, diagnosis, spectacle use, visual acuity before and after the recurrence and the extent of the decrease in visual acuity. In addition, visual acuity and unaided vision before the recurrence were compared in patients who did not use eyeglasses.
   ResultsForty-eight eyes from 48 patients were included in the analysis. Twenty-seven patients (56.3 per cent) identified a decrease in visual acuity. These patients had better visual acuity before the recurrence (p=0.023) and reported a greater decrease in visual acuity (p=0.005) than patients who did not identify a visual change. Patients who wore spectacles were also more likely to notice the change in their visual acuity (p=0.027). Visual acuity was significantly better than uncorrected vision (p<0.001).
   ConclusionsPatients who do not use eyeglasses or who have relatively poor vision tend not to promptly recognise visual deterioration caused by the recurrence of exudation. Prescribing eyeglasses may facilitate accurate self-recognition of the recurrence of exudation in cases where vision can be improved with correction.
C1 [Kim, Jae Hui; Kim, Jong Woo; Lee, Dong Won; Han, Jung Il; Kim, Chul Gu] Konyang Univ, Coll Med, Kims Eye Hosp, Dept Ophthalmol, Seoul, South Korea.
   [Chang, Young Suk] Konyang Univ, Coll Med, Dept Ophthalmol, Daejeon, South Korea.
C3 Konyang University; Konyang University Hospital; Konyang University;
   Konyang University Hospital
RP Kim, CG (通讯作者)，Konyang Univ, Coll Med, Kims Eye Hosp, Dept Ophthalmol, Seoul, South Korea.
EM chulgukim@kimeye.com
CR Arias L, 2009, EYE, V23, P326, DOI 10.1038/sj.eye.6703053
   Berg K, 2015, OPHTHALMOLOGY, V122, P146, DOI 10.1016/j.ophtha.2014.07.041
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Chan A, 2006, ARCH OPHTHALMOL-CHIC, V124, P193, DOI 10.1001/archopht.124.2.193
   Chew EY, 2014, CONTEMP CLIN TRIALS, V37, P294, DOI 10.1016/j.cct.2014.02.003
   Cohen SY, 2009, AM J OPHTHALMOL, V148, P409, DOI 10.1016/j.ajo.2009.04.001
   Engelbert M, 2010, RETINA-J RET VIT DIS, V30, P1368, DOI 10.1097/IAE.0b013e3181d50cbf
   Faes L, 2014, EYE, V28, P788, DOI 10.1038/eye.2014.104
   FINE SL, 1985, OPHTHALMOLOGY, V92, P603
   Fung AE, 2007, AM J OPHTHALMOL, V143, P566, DOI 10.1016/j.ajo.2007.01.028
   He MG, 2014, JAMA OPHTHALMOL, V132, P978, DOI 10.1001/jamaophthalmol.2014.1011
   He MG, 2009, INVEST OPHTH VIS SCI, V50, P5130, DOI 10.1167/iovs.09-3455
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Hessellund A, 2012, ACTA OPHTHALMOL, V90, P471, DOI 10.1111/j.1755-3768.2010.02074.x
   Koh V, 2014, OPHTHAL EPIDEMIOL, V21, P247, DOI 10.3109/09286586.2014.928824
   Lavanya R, 2010, INVEST OPHTH VIS SCI, V51, P6247, DOI 10.1167/iovs.10-5229
   Loewenstein A, 2010, RETINA-J RET VIT DIS, V30, P1058, DOI 10.1097/IAE.0b013e3181d1a75e
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Moschos MM, 2011, CLIN EXP OPTOM, V94, P268, DOI 10.1111/j.1444-0938.2011.00589.x
   Muether PS, 2013, GRAEF ARCH CLIN EXP, V251, P453, DOI 10.1007/s00417-012-2038-0
   Oliver-Fernandez M, 2005, CAN J OPHTHALMOL, V40, P313, DOI 10.1016/S0008-4182(05)80074-2
   Rauch R, 2012, RETINA-J RET VIT DIS, V32, P1260, DOI 10.1097/IAE.0b013e3182018df6
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Schmid-Kubista KE, 2011, CURR EYE RES, V36, P958, DOI 10.3109/02713683.2011.597536
   Shona O, 2011, CLIN EXP OPHTHALMOL, V39, P5, DOI 10.1111/j.1442-9071.2010.02424.x
   Spaide RF, 2006, RETINA-J RET VIT DIS, V26, P383, DOI 10.1097/00006982-200604000-00001
   Tao Y, 2010, EYE, V24, P648, DOI 10.1038/eye.2009.160
   Wang YZ, 2013, INVEST OPHTH VIS SCI, V54, P5497, DOI 10.1167/iovs.13-12037
   You JY, 2012, CURR EYE RES, V37, P438, DOI 10.3109/02713683.2011.647227
NR 29
TC 1
Z9 1
U1 0
U2 0
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 0816-4622
EI 1444-0938
J9 CLIN EXP OPTOM
JI Clin. Exp. Optom.
PD JAN
PY 2016
VL 99
IS 1
BP 56
EP 60
DI 10.1111/cxo.12315
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA DE2VR
UT WOS:000370485800008
PM 26875854
OA Bronze
DA 2022-11-30
ER

PT J
AU Guthoff, R
   Schrader, W
AF Guthoff, R
   Schrader, W
TI Longterm results in surgical removal of subfoveal choroidal
   neovascularization in age-related macular degeneration
SO ACTA OPHTHALMOLOGICA SCANDINAVICA
LA English
DT Article
DE submacular surgery; subfoveal choroidal neovascularization; age-related
   macular degeneration; visual acuity
ID LASER PHOTOCOAGULATION; SUBMACULAR SURGERY; CLINICAL-TRIALS; NATURAL
   COURSE; MEMBRANES; EXCISION; OUTCOMES; LESIONS
AB Purpose: This study aimed to analyse visual outcome, surgical complications and recurrence rates 3 years after removal of subretinal choroidal neovascularization (CNV) in patients with age-related macular degeneration (AMD).
   Methods: The study involved a retrospective analysis of 50 eyes of 50 patients who underwent surgical removal of CNV in AMD between February 1996 and June 1998. The minimum follow-up period was 36 months. Improvement or worsening of visual acuity (VA) was defined as a change of more than two lines.
   Results: The mean reduction in VA was 2.2 +/- 6.9 lines. Visual acuity improved in 12 eyes, remained stable in 16 eyes and worsened in 22 eyes. Recurrence of CNV occurred in three eyes.
   Conclusion: After surgical excision of age-related subfoveal CNV, VA improved or stabilized in a large group of patients. Considering the development of VA and the low recurrence rate, surgical treatment seems to be beneficial compared to the natural course of CNV over a longterm follow-up of more than 3 years.
C1 Univ Wurzburg, Dept Ophthalmol, Wurzburg, Germany.
C3 University of Wurzburg
RP Guthoff, R (通讯作者)，Univ Hosp Wurzburg, Dept Ophthalmol, Josef Schneider Str 11, D-97080 Wurzburg, Germany.
EM r.guthoff@mail.uni-wuerzburg.de
CR Berglin L, 2001, ACTA OPHTHALMOL SCAN, V79, P580, DOI 10.1034/j.1600-0420.2001.790607.x
   Blumenkranz MS, 2001, ARCH OPHTHALMOL-CHIC, V119, P198
   Bottoni F, 1996, GRAEF ARCH CLIN EXP, V234, pS42, DOI 10.1007/BF02343047
   Bressler NM, 2000, AM J OPHTHALMOL, V130, P387
   BRESSLER NM, 1988, ARCH OPHTHALMOL-CHIC, V106, P1537, DOI 10.1001/archopht.1988.01060140705039
   BRESSLER SB, 1982, AM J OPHTHALMOL, V93, P157, DOI 10.1016/0002-9394(82)90410-X
   DEJUAN E, 1988, AM J OPHTHALMOL, V105, P25, DOI 10.1016/0002-9394(88)90116-X
   Eckardt Claus, 1996, Ophthalmologe, V93, P688, DOI 10.1007/s003470050059
   HAWKINS BS, 1993, ARCH OPHTHALMOL-CHIC, V111, P1200
   Lewis H, 1997, OPHTHALMOLOGY, V104, P1847, DOI 10.1016/S0161-6420(97)30018-9
   Lit ES, 2001, RETINA-J RET VIT DIS, V21, P317, DOI 10.1097/00006982-200108000-00004
   MAGUIRE MG, 1994, ARCH OPHTHALMOL-CHIC, V112, P489
   Merrill PT, 1999, OPHTHALMOLOGY, V106, P782, DOI 10.1016/S0161-6420(99)90167-7
   ORMEROD LD, 1994, OPHTHALMOLOGY, V101, P1201
   Roth DB, 1997, OPHTHALMIC SURG LAS, V28, P920
   Scheider A, 1999, GRAEF ARCH CLIN EXP, V237, P10, DOI 10.1007/s004170050187
   STERNBERG P, 1991, ARCH OPHTHALMOL-CHIC, V109, P1220
   THOMAS MA, 1994, OPHTHALMOLOGY, V101, P1384
   THOMAS MA, 1992, OPHTHALMOLOGY, V99, P952
   THOMAS MA, 1991, AM J OPHTHALMOL, V15, P111
NR 20
TC 6
Z9 6
U1 0
U2 0
PU BLACKWELL MUNKSGAARD
PI COPENHAGEN
PA 35 NORRE SOGADE, PO BOX 2148, DK-1016 COPENHAGEN, DENMARK
SN 1395-3907
J9 ACTA OPHTHALMOL SCAN
JI Acta Ophthalmol. Scand.
PD DEC
PY 2004
VL 82
IS 6
BP 686
EP 690
DI 10.1111/j.1600-0420.2004.00338.x
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 884NT
UT WOS:000226093000009
PM 15606464
DA 2022-11-30
ER

PT J
AU Faria-Correia, F
   Barros-Pereira, R
   Queiros-Mendanha, L
   Fonseca, S
   Mendonca, L
   Falcao, MS
   Brandao, E
   Falcao-Reis, F
   Carneiro, AM
AF Faria-Correia, F.
   Barros-Pereira, R.
   Queiros-Mendanha, L.
   Fonseca, S.
   Mendonca, L.
   Falcao, M. S.
   Brandao, E.
   Falcao-Reis, F.
   Carneiro, A. M.
TI Characterization of Neovascular Age-Related Macular Degeneration
   Patients with Outer Retinal Tubulations
SO OPHTHALMOLOGICA
LA English
DT Article
DE Neovascular age-related macular degeneration; Spectral-domain optical
   coherence tomography; Outer retinal tubulations
ID RANIBIZUMAB; BEVACIZUMAB
AB Purpose: To characterize the neovascular lesions of patients with age-related macular degeneration (AMD) and outer retinal tubulations (ORTs). Methods: A retrospective study of 377 eyes with exudative AMD, submitted to intravitreal anti-angiogenic treatment. Patients were divided into 2 groups according to the presence or absence of ORTs on spectral-domain optical coherence tomography (SD-OCT; group 1 - with ORTs; group 2 - without ORTs). Age, best corrected visual acuity (BCVA), fluorescein angiography characteristics, presence of subretinal fibrosis and subfoveal photoreceptor integrity on SD-OCT were analyzed. Results: Although both groups had a BCVA gain during the follow-up period, initial and final BCVA were lower in group 1 (p = 0.020 and p = 0.042, respectively). There was no statistically significant difference in the BCVA variation between the 2 groups (p = 0.907). Regarding the initial angiographic lesion type, there was a statistically significant difference between the 2 groups (p = 0.008): group 1 had more lesions with a classic component and group 2 had more occult lesions with no classic component. There was a statistically significant difference concerning the loss of subfoveal photoreceptor integrity (p = 0.0007). Conclusions: Even though AMD patients with ORTs were associated with poor visual outcomes, we reported BCVA improvement. AMD patients with a classical component in their lesions are prone to develop ORTs. Copyright (C) 2013 S. Karger AG, Basel
C1 [Faria-Correia, F.; Barros-Pereira, R.; Queiros-Mendanha, L.; Fonseca, S.; Mendonca, L.; Falcao, M. S.; Brandao, E.; Falcao-Reis, F.; Carneiro, A. M.] Hosp Sao Joao, Dept Ophthalmol, Oporto, Portugal.
   [Barros-Pereira, R.; Falcao, M. S.; Falcao-Reis, F.; Carneiro, A. M.] Univ Porto, Fac Med, P-4100 Oporto, Portugal.
C3 Sao Joao Hospital; Universidade do Porto
RP Faria-Correia, F (通讯作者)，Ave Bessa,Ed Boapor 2 216 7 Frente, P-4100 Oporto, Portugal.
EM f.faria.correia@gmail.com
RI Carneiro, Angela/N-9680-2013; Falcao/AAQ-8509-2020
OI Carneiro, Angela/0000-0002-3370-7243; Falcao/0000-0003-4718-0910;
   Falcao-Reis, Fernando/0000-0002-5995-9430; Faria-Correia,
   Fernando/0000-0002-8824-7862
CR Cukras C, 2010, EYE, V24, P775, DOI 10.1038/eye.2009.211
   Forte R, 2009, EYE, V23, P2071, DOI 10.1038/eye.2008.363
   Fung AE, 2007, AM J OPHTHALMOL, V143, P566, DOI 10.1016/j.ajo.2007.01.028
   Gass JD, 1997, STEREOSCOPIC ATLAS M, P1067
   Grossniklaus HE, 1998, AM J OPHTHALMOL, V126, P59, DOI 10.1016/S0002-9394(98)00145-7
   Grossniklaus HE, 2004, AM J OPHTHALMOL, V137, P496, DOI 10.1016/j.ajo.2003.09.042
   Hayashi H, 2009, AM J OPHTHALMOL, V148, P83, DOI 10.1016/j.ajo.2009.01.017
   Lalwani GA, 2009, AM J OPHTHALMOL, V148, P43, DOI 10.1016/j.ajo.2009.01.024
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Mitchell P, 2010, BRIT J OPHTHALMOL, V94, P2, DOI 10.1136/bjo.2009.159160
   Oishi A, 2010, AM J OPHTHALMOL, V150, P27, DOI 10.1016/j.ajo.2010.02.012
   Resnikoff S, 2004, B WORLD HEALTH ORGAN, V82, P844
   Rosenfeld PJ, 2011, NEW ENGL J MED, V364, P1966, DOI 10.1056/NEJMe1103334
   Sayanagi K, 2009, OPHTHALMOLOGY, V116, P947, DOI 10.1016/j.ophtha.2008.11.002
   Spaide RF, 2011, RETINA-J RET VIT DIS, V31, P1609, DOI 10.1097/IAE.0b013e3182247535
   Zweifel SA, 2009, ARCH OPHTHALMOL-CHIC, V127, P1596, DOI 10.1001/archophthalmol.2009.326
NR 16
TC 21
Z9 25
U1 0
U2 7
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 0030-3755
EI 1423-0267
J9 OPHTHALMOLOGICA
JI Ophthalmologica
PY 2013
VL 229
IS 3
BP 147
EP 151
DI 10.1159/000346854
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 126RT
UT WOS:000317639600004
PM 23485655
DA 2022-11-30
ER

PT J
AU Woo, SJ
   Veith, M
   Hamouz, J
   Ernest, J
   Zalewski, D
   Studnicka, J
   Vajas, A
   Papp, A
   Gabor, V
   Luu, J
   Matuskova, V
   Yoon, YH
   Pregun, T
   Kim, T
   Shin, D
   Bressler, NM
AF Woo, Se Joon
   Veith, Miroslav
   Hamouz, Jan
   Ernest, Jan
   Zalewski, Dominik
   Studnicka, Jan
   Vajas, Attila
   Papp, Andras
   Gabor, Vogt
   Luu, James
   Matuskova, Veronika
   Yoon, Young Hee
   Pregun, Tamas
   Kim, Taehyung
   Shin, Donghoon
   Bressler, Neil M.
TI Efficacy and Safety of a Proposed Ranibizumab Biosimilar Product vs a
   Reference Ranibizumab Product for Patients With Neovascular Age-Related
   Macular Degeneration A Randomized Clinical Trial
SO JAMA OPHTHALMOLOGY
LA English
DT Article
ID ENDOTHELIAL GROWTH-FACTOR; VERTEPORFIN PHOTODYNAMIC THERAPY
AB QUESTION Does SB11, a proposed ranibizumab biosimilar product, have equivalent best-corrected visual acuity (BCVA) and optical coherence tomography central subfield thickness (CST) outcomes and a similar safety profile to the reference ranibizumab product in patients with neovascular age-related macular degeneration?
   FINDINGS This randomized clinical equivalence trial found that SB11 demonstrated equivalence in efficacy for both primary end points: adjusted treatment differences between groups were within predefined equivalence margins for mean changes from baseline in both BCVA at week 8 and CST at week 4. Safety and immunogenicity profiles were similar between SB11 and ranibizumab.
   MEANING These results indicate that SB11 is similar to its reference product, ranibizumab.
   This randomized clinical trial compares the efficacy, safety, and immunogenicity of SB11, a ranibizumab biosimilar product, with that of the reference ranibizumab for patients with neovascular age-related macular degeneration (AMD).
   IMPORTANCE Neovascular age-related macular degeneration is the leading cause of blindness in individuals 50 years or older. The availability of a ranibizumab biosimilar product (SB11) may facilitate access to an effective alternative to this treatment.
   OBJECTIVE To demonstrate equivalence of efficacy, similar safety, and similar immunogenicity of SB11 compared with the reference ranibizumab.
   DESIGN, SETTING, AND PARTICIPANTS This randomized, double-masked, parallel-group phase 3 equivalence study was conducted in 75 centers in 9 countries from March 14, 2018, to December 9, 2019, among 705 participants 50 years or older with neovascular age-related macular degeneration with active subfoveal choroidal neovascularization lesions. Analysis was performed on an intent-to-treat basis.
   INTERVENTIONS Intravitreous injection of SB11 or ranibizumab, 0.5 mg, every 4 weeks through week 48.
   MAIN OUTCOMES AND MEASURES Preplanned interim analysis after all participants completed the week 24 assessment of primary efficacy end points at week 8 for change from baseline in best-corrected visual acuity (BCVA) and week 4 for central subfield thickness (CST), with predefined equivalence margins for adjusted treatment differences of -3 letters to 3 letters for BCVA and -36 mu m to 36 mu m for CST.
   RESULTS Baseline and disease characteristics among 705 randomized participants (403 women [57.2%]; mean [SD] age, 74.1 [8.5] years) were comparable between treatment groups (SB11, 351; ranibizumab, 354). Least-squares mean (SE) changes in BCVA from baseline at week 8 were 6.2 (0.5) letters in the SB11 group vs 7.0 (0.5) letters in the ranibizumab group, with an adjusted treatment difference of -0.8 letter (90% CI, -1.8 to 0.2 letters). Least-squares mean (SE) changes in CST from baseline at week 4 were -108 (5) mu m in the SB11 group vs -100 (5) mu m in the ranibizumab group, with an adjusted treatment difference of -8 mu m (95% CI, -19 to 3 mu m). Incidences of treatment-emergent adverse events (231 of 350 [66.0%] vs 237 of 354 [66.9%]), including serious treatment-emergent adverse events (44 of 350 [12.6%] vs 44 of 354 [12.4%]) and treatment-emergent adverse events leading to study drug discontinuation (8 of 350 [2.3%] vs 5 of 354 [1.4%]), were similar in the SB11 and ranibizumab groups. Immunogenicity was low, with a cumulative incidence of antidrug antibodies up to week 24 of 3.0% (10 of 330) in the SB11 group and 3.1% (10 of 327) in the ranibizumab group.
   CONCLUSIONS AND RELEVANCE These findings of equivalent efficacy and similar safety and immunogenicity profiles compared with ranibizumab support the use of SB11 for patients with neovascular age-related macular degeneration.
C1 [Woo, Se Joon] Seoul Natl Univ, Coll Med, Bundang Hosp, Dept Ophthalmol, Seongnam, South Korea.
   [Veith, Miroslav; Hamouz, Jan] Charles Univ Prague, Fac Med 3, Dept Ophthalmol, Prague, Czech Republic.
   [Veith, Miroslav; Hamouz, Jan] Univ Hosp Kralovske Vinohrady, Dept Ophthalmol, Prague, Czech Republic.
   [Ernest, Jan] Cent Mil Hosp, Dept Ophthalmol, Prague, Czech Republic.
   [Zalewski, Dominik] Diagnost & Microsurgery Ctr Eye LENS, Olsztyn, Poland.
   [Studnicka, Jan] Charles Univ Prague, Fac Med Hradec Kralove, Dept Ophthalmol, Prague, Czech Republic.
   [Studnicka, Jan] Univ Hosp Hradec Kralove, Dept Ophthalmol, Hradec Kralove, Czech Republic.
   [Vajas, Attila] Univ Debrecen, Dept Ophthalmol, Debrecen, Hungary.
   [Papp, Andras] Semmelweis Univ, Dept Ophthalmol, Budapest, Hungary.
   [Gabor, Vogt] Hungarian Def Forces, Dept Ophthalmol, Med Ctr, Budapest, Hungary.
   [Luu, James] Retina Consultants Southern Colorado, Colorado Springs, CO USA.
   [Matuskova, Veronika] Univ Hosp Brno, Dept Ophthalmol, Brno, Czech Republic.
   [Matuskova, Veronika] Masaryk Univ, Fac Med, Brno, Czech Republic.
   [Yoon, Young Hee] Univ Ulsan, Coll Med, Asan Med Ctr, Dept Ophthalmol, Seoul, South Korea.
   [Pregun, Tamas] Bajcsy Zsilinszky Hosp, Dept Ophthalmol, Budapest, Hungary.
   [Kim, Taehyung; Shin, Donghoon] Samsung Bioepis, Med Team, Incheon, South Korea.
   [Bressler, Neil M.] Johns Hopkins Univ, Sch Med, Wilmer Eye Inst, Baltimore, MD 21205 USA.
C3 Seoul National University (SNU); Charles University Prague; University
   Hospital Vinohrady; Military University Hospital Prague; Charles
   University Prague; University of Debrecen; Semmelweis University;
   University Hospital Brno; Masaryk University Brno; University of Ulsan;
   Asan Medical Center; Samsung; Johns Hopkins University; Johns Hopkins
   Medicine
RP Bressler, NM (通讯作者)，Johns Hopkins Univ Hosp, Maumenee 752,600 N Wolfe St, Baltimore, MD 21287 USA.
EM nmboffice@jhmi.edu
RI Matuskova, Veronika/ABE-1154-2020; Vajas, Attila/AAA-3014-2021;
   Matuskova, Veronika/AAD-7189-2021; Studnička, Jan/AAC-4127-2022
OI Matuskova, Veronika/0000-0002-3308-463X; 
FU Samsung Bioepis, Incheon, Republic of Korea
FX Planning, conduct, and analysis of the study was funded by Samsung
   Bioepis, Incheon, Republic of Korea.
CR Agarwal A, 2016, MIDDLE EAST AFR J OP, V23, P27, DOI 10.4103/0974-9233.173133
   [Anonymous], 2018, LANCET, V392, P1090, DOI 10.1016/S0140-6736(18)32291-8
   [Anonymous], BIOS EU INF GUID HEA
   Antoszyk AN, 2008, AM J OPHTHALMOL, V145, P862, DOI 10.1016/j.ajo.2007.12.029
   Bakri SJ, 2019, OPHTHALMOLOGY, V126, P55, DOI 10.1016/j.ophtha.2018.07.028
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   Bui LA, 2015, DRUG DISCOV TODAY, V20, P3, DOI 10.1016/j.drudis.2015.03.011
   Busbee BG, 2013, OPHTHALMOLOGY, V120, P1046, DOI 10.1016/j.ophtha.2012.10.014
   Chong V, 2016, EYE, V30, P270, DOI 10.1038/eye.2015.217
   Dutta B, 2020, BIODRUGS, V34, P159, DOI 10.1007/s40259-019-00395-w
   European Federation of Pharmaceutical Industries and Associations, 2016, PROM SAF EFF BIOS CA
   European Medicines Agency, 2014, GUID SIM BIOL MED PR
   European Medicines Agency, LUC
   Fung AE, 2007, AM J OPHTHALMOL, V143, P566, DOI 10.1016/j.ajo.2007.01.028
   Grisanti S, 2008, PROG RETIN EYE RES, V27, P372, DOI 10.1016/j.preteyeres.2008.05.002
   Holz FG, 2020, RETINA-J RET VIT DIS, V40, P1673, DOI 10.1097/IAE.0000000000002670
   Holz FG, 2015, BRIT J OPHTHALMOL, V99, P220, DOI 10.1136/bjophthalmol-2014-305327
   Holz FG, 2013, BRIT J OPHTHALMOL, V97, P1161, DOI 10.1136/bjophthalmol-2013-303232
   Hussain RM, 2017, EXPERT OPIN EMERG DR, V22, P235, DOI 10.1080/14728214.2017.1362390
   Jensen TB, 2020, EUR J CLIN PHARMACOL, V76, P35, DOI 10.1007/s00228-019-02765-3
   Lalwani GA, 2009, AM J OPHTHALMOL, V148, P43, DOI 10.1016/j.ajo.2009.01.024
   Lee JF, 2012, CURR MED RES OPIN, V28, P1053, DOI 10.1185/03007995.2012.686902
   Lucentis, PRESCR INF
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   MedDRA, 2017, WHATS NEW MEDDRA VER
   Mitchell P, 2018, LANCET, V392, P1147, DOI 10.1016/S0140-6736(18)31550-2
   Regillo CD, 2008, AM J OPHTHALMOL, V145, P239, DOI 10.1016/j.ajo.2007.10.004
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Sacconi Riccardo, 2019, F1000Res, V8, DOI 10.12688/f1000research.19198.1
   Shao J, 2016, DEV OPHTHALMOL, V55, P125, DOI 10.1159/000438969
   Sharma A, 2018, CLIN OPHTHALMOL, V12, P2137, DOI 10.2147/OPTH.S180393
   US Food and Drug Administration, BIOS INT PROD
   US Food and Drug Administration, BIOS DEV REV APPR
   US Food and Drug Administration,, 2015, SCI CONSIDERATIONS D
   US Food and Drug Administration, DRUGS FDA FDA APPR D
   Wadhwa M, 2015, BIOLOGICALS, V43, P298, DOI 10.1016/j.biologicals.2015.06.004
   World Medical Association, 2013, JAMA-J AM MED ASSOC, V310, P2191, DOI [DOI 10.1001/JAMA.2013.281053, 10.1001/jama.2013.281053]
NR 37
TC 21
Z9 21
U1 0
U2 16
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 2168-6165
EI 2168-6173
J9 JAMA OPHTHALMOL
JI JAMA Ophthalmol.
PD JAN
PY 2021
VL 139
IS 1
BP 68
EP 76
DI 10.1001/jamaophthalmol.2020.5053
EA NOV 2020
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA PX1MC
UT WOS:000592736300002
PM 33211076
OA Green Published, hybrid
DA 2022-11-30
ER

PT J
AU Ferris, FL
   Maguire, MG
   Glassman, AR
   Ying, GS
   Martin, DF
AF Ferris, Frederick L., III
   Maguire, Maureen G.
   Glassman, Adam R.
   Ying, Gui-shuang
   Martin, Daniel F.
TI Evaluating Effects of Switching Anti-Vascular Endothelial Growth Factor
   Drugs for Age-Related Macular Degeneration and Diabetic Macular Edema
SO JAMA OPHTHALMOLOGY
LA English
DT Article
ID RANIBIZUMAB; AFLIBERCEPT
AB IMPORTANCE When a patient with neovascular age-related macular degeneration or diabetic macular edema does not respond to an initial anti-vascular endothelial growth factor agent, usually after several injections, ophthalmologists may switch to another anti-vascular endothelial growth factor agent. Authors of case series have suggested beneficial effects from switching. However, to our knowledge, there are no studies with an appropriate control group to evaluate how such patients would do without switching agents.
   OBJECTIVE To assess outcomes in patients who have a poor initial response but continue treatment without switching agents.
   DESIGN, SETTING, AND PARTICIPANTS We obtained data from 2 multicenter clinical trials, the Comparison of Age-Related Macular Degeneration Treatments Trials (CATT) and the Diabetic Retinopathy Clinical Research Network (DRCR. net). Based on typical clinical reasons for switching agents, we developed "switching rules" at both 3 and 6 months after initiation of treatment. Using these switching rules, we identified a 3-month and a 6-month cohort of "treatment failures" from both CATT and DRCR. net studies.
   INTERVENTIONS Although the cohorts from each study met criteria for switching, they were treated with the initial agent throughout the study (bevacizumab or ranibizumab in CATT and ranibizumab in DRCR. net).
   MAIN OUTCOMES AND MEASURES Primary outcomeswere change in visual acuity and change in central retinal thickness on optical coherence tomography from the 3-or 6-month visit at which switching rules were met.
   RESULTS The 126 patients from CATT and the 59 patients from DRCR. net who were selected for the switching analysis were similar in age, sex and race/ethnicity to the overall study populations. Among the participants who met the criteria for switching, the CATT participants were a mean (SD) of 79.7 (7.8) years of age, 65.9% women, and 97.6% white, while the DRCR. net participants were a mean (SD) of 65.5 (9.3) years of age, 44.1% women, and 76.3% white In all 4 cohorts, there was a 3-to 5-letter improvement in mean visual acuity over the 3 months after the switching rules were met, although all patients continued on their originally assigned treatment. Mean central retinal thickness also improved by 40 to 70 mu M.
   CONCLUSIONS AND RELEVANCE These results demonstrate the importance of having a comparison group to evaluate the effect of switching anti-vascular endothelial growth factor agents for treatment of neovascular age-related macular degeneration or diabetic macular edema. Without a comparison group, it is impossible to know whether any improvement observed after switching was related to the new treatment or was related to regression to the mean and time effects as observed in the 4 cohorts presented here. Randomization to switching or not switching drugs would provide a basis for valid conclusions about the effects of switching.
C1 [Ferris, Frederick L., III] NEI, NIH, Bethesda, MD 20892 USA.
   [Maguire, Maureen G.; Ying, Gui-shuang] Univ Penn, Dept Ophthalmol, Philadelphia, PA 19104 USA.
   [Glassman, Adam R.] Jaeb Ctr Hlth Res, 15310 Amberly Dr,Ste 350, Tampa, FL 33647 USA.
   [Martin, Daniel F.] Cleveland Clin, Cole Eye Inst, Cleveland, OH 44106 USA.
C3 National Institutes of Health (NIH) - USA; NIH National Eye Institute
   (NEI); University of Pennsylvania; JAEB Center For Health Research;
   Cleveland Clinic Foundation
RP Glassman, AR (通讯作者)，Jaeb Ctr Hlth Res, 15310 Amberly Dr,Ste 350, Tampa, FL 33647 USA.
EM drcrstat2@jaeb.org
OI Glassman, Adam/0000-0003-0173-1684; Ferris,
   Frederick/0000-0002-4933-0639
FU National Eye Institute, National Institutes of Health, and the US
   Department of Health and Human Services [EY017823, EY017825, EY017826,
   EY017828, EY023689]; National Eye Institute and the National Institute
   of Diabetes, Digestive and Kidney Diseases, National Institutes of
   Health [EY14231, EY23207, EY18817]
FX Comparison of Age-Related Macular Degeneration Treatments Trials was
   supported by cooperative agreements EY017823, EY017825, EY017826,
   EY017828, EY023689, and R21EY023689 from the National Eye Institute,
   National Institutes of Health, and the US Department of Health and Human
   Services. Diabetic Retinopathy Clinical Research Network was supported
   by cooperative agreements EY14231, EY23207, and EY18817 from the
   National Eye Institute and the National Institute of Diabetes, Digestive
   and Kidney Diseases, National Institutes of Health, and the US
   Department of Health and Human Services.
CR Ciulla TA, 2016, RETINA-J RET VIT DIS, V36, P1292, DOI 10.1097/IAE.0000000000000876
   Elman MJ, 2010, OPHTHALMOLOGY, V117, P1064, DOI 10.1016/j.ophtha.2010.02.031
   Heussen FM, 2014, GRAEF ARCH CLIN EXP, V252, P909, DOI 10.1007/s00417-013-2553-7
   Lim LS, 2015, CLIN OPHTHALMOL, V9, P1715, DOI 10.2147/OPTH.S81523
   Moisseiev E, 2015, RETINA-J RET VIT DIS, V35, P1323, DOI 10.1097/IAE.0000000000000500
   Ying GS, 2015, OPHTHALMOLOGY, V122, P2523, DOI 10.1016/j.ophtha.2015.08.015
NR 6
TC 43
Z9 43
U1 0
U2 2
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 2168-6165
EI 2168-6173
J9 JAMA OPHTHALMOL
JI JAMA Ophthalmol.
PD FEB 1
PY 2017
VL 135
IS 2
BP 145
EP 149
DI 10.1001/jamaophthalmol.2016.4820
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA EM9PE
UT WOS:000395642800017
PM 28006042
DA 2022-11-30
ER

PT J
AU Emerson, GG
   Ghazi, NG
AF Emerson, GG
   Ghazi, NG
TI Spontaneous rip of the retinal pigment epithelium with a macular hole in
   neovascular age-related macular degeneration
SO AMERICAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID TEARS
AB PURPOSE: To report a case of retinal pigment epithelial tear associated with a macular hole in a patient with neovascular age,related macular degeneration (AMD).
   DESIGN: Observational case report.
   METHODS: An 87,year,old woman with AMD,related fibrovascular pigment epithelial detachment associated with vision loss was followed with sequential fundus photography, fluorescein angiography, and optical coherence tomography for 8 months.
   RESULTS: The detachment developed into a retinal pigment epithelium tear with macular hole formation. The temporal evolution of the lesion and optical coherence tomography findings suggested that the retinal pigment epithelium tear led to stretching forces along the posterior surface of the neurosensory retina with secondary foveal dehiscence.
   CONCLUSION: Macular hole formation is one mechanism by which retinal pigment epithelium tears may cause vision loss in AMD.
C1 Wilmer Eye Inst, Gen Eye Serv, Baltimore, MD 21287 USA.
   Univ Virginia, Dept Ophthalmol, Charlottesville, VA USA.
C3 Johns Hopkins University; Johns Hopkins Medicine; University of Virginia
RP Emerson, GG (通讯作者)，Wilmer Eye Inst, Gen Eye Serv, Room B-10,600 N Wolfe St, Baltimore, MD 21287 USA.
EM gemerso1@jhmi.edu
RI Ghazi, Nicola/AAH-4169-2020
OI Ghazi, Nicola/0000-0001-9255-8025
CR GASS JDM, 1984, BRIT J OPHTHALMOL, V68, P513, DOI 10.1136/bjo.68.8.513
   Giovannini A, 2000, RETINA-J RET VIT DIS, V20, P37, DOI 10.1097/00006982-200001000-00007
   HOSKIN A, 1981, BRIT J OPHTHALMOL, V65, P417, DOI 10.1136/bjo.65.6.417
   YEO JH, 1988, OPHTHALMOLOGY, V95, P8
NR 4
TC 7
Z9 8
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0002-9394
J9 AM J OPHTHALMOL
JI Am. J. Ophthalmol.
PD AUG
PY 2005
VL 140
IS 2
BP 316
EP 318
DI 10.1016/j.ajo.2005.01.028
PG 3
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 955OW
UT WOS:000231236600025
PM 16086957
DA 2022-11-30
ER

PT J
AU Butt, T
   Tufail, A
   Rubin, G
AF Butt, Thomas
   Tufail, Adnan
   Rubin, Gary
TI Health State Utility Values for Age-Related Macular Degeneration: Review
   and Advice
SO APPLIED HEALTH ECONOMICS AND HEALTH POLICY
LA English
DT Review
ID QUALITY-OF-LIFE; VERTEPORFIN PHOTODYNAMIC THERAPY; INCREMENTAL
   COST-EFFECTIVENESS; TIME TRADE-OFF; DIABETIC-RETINOPATHY; CONTRAST
   SENSITIVITY; LASER PHOTOCOAGULATION; PEGAPTANIB SODIUM; VISUAL-ACUITY;
   RANIBIZUMAB
AB Health state utility values are a major source of uncertainty in economic evaluations of interventions for age-related macular degeneration (AMD). This review identifies and critiques published utility values and methods for eliciting de novo utility values in AMD. We describe how utility values have been used in healthcare decision making and provide guidance on the choice of utility values for future economic evaluations for AMD. Literature was searched using PubMed, and health technology assessments (HTA) were searched using HTA agency websites to identify articles reporting utility values or approaches to derive utility values in AMD and articles applying utilities for use in healthcare decision making relating to treatments for AMD. A total of 70 studies qualified for data extraction, 22 of which were classified as containing utility values and/or elicitation methods, and 48 were classified as using utility values in decision making. A large number of studies have elicited utility values for AMD, although those applied to decision making have focused on a few of these. There is an appreciation of the challenges in the measurement and valuation of health states, with recent studies addressing challenges such as the insensitivity of generic health-related quality of life (HRQoL) questionnaires and utility in the worse-seeing eye. We would encourage careful consideration when choosing utility values in decision making and an explicit critique of their applicability to the decision problem.
C1 [Butt, Thomas; Tufail, Adnan; Rubin, Gary] UCL, Inst Ophthalmol, 11-43 Bath St, London EC1V 9EL, England.
   [Tufail, Adnan] Moorfields Eye Hosp, London, England.
C3 University of London; University College London; University of London;
   University College London; Moorfields Eye Hospital NHS Foundation Trust
RP Butt, T (通讯作者)，UCL, Inst Ophthalmol, 11-43 Bath St, London EC1V 9EL, England.
EM thomas.butt.10@ucl.ac.uk
RI Butt, Thomas/AAH-7882-2019
OI Butt, Thomas/0000-0002-0387-4550; Tufail, Adnan/0000-0001-6131-7640
CR Albrecht GL, 1999, SOC SCI MED, V48, P977, DOI 10.1016/S0277-9536(98)00411-0
   [Anonymous], 2008, RAN PEG TREATM AG RE
   Aspinall A, 2007, BRIT J OPHTHALMOL, V91, P766, DOI 10.1136/bjo.2006.104679
   Athanasakis K, 2012, CLIN THER, V34, P446, DOI 10.1016/j.clinthera.2012.01.005
   Bansback N, 2007, EYE, V21, P1455, DOI 10.1038/sj.eye.6702636
   Bansback N, 2007, QUAL LIFE RES, V16, P533, DOI 10.1007/s11136-006-9126-8
   Bojke L, 2008, MED DECIS MAKING, V28, P33, DOI 10.1177/0272989X07309638
   Brazier J., 2016, MEASURING VALUING HL, V2, DOI 10.1093/med/9780198725923.001.0001
   Brown G C, 1999, Trans Am Ophthalmol Soc, V97, P473
   Brown GC, 2007, OPHTHALMOLOGY, V114, P1170, DOI 10.1016/j.ophtha.2006.09.019
   Brown Gary C, 2005, Trans Am Ophthalmol Soc, V103, P173
   Brown GC, 2011, OPHTHALMOLOGY, V118, P1834, DOI 10.1016/j.ophtha.2011.02.012
   Brown GC, 2000, ARCH OPHTHALMOL-CHIC, V118, P47
   Brown GC, 2000, OPHTHALMOLOGY, V107, P1374, DOI 10.1016/S0161-6420(00)00169-X
   Brown GC, 2000, CAN J OPHTHALMOL, V35, P127, DOI 10.1016/S0008-4182(00)80005-8
   Brown Melissa M., 2001, International Ophthalmology, V24, P123, DOI 10.1023/A:1021171000838
   Brown MM, 1999, AM J OPHTHALMOL, V128, P324, DOI 10.1016/S0002-9394(99)00146-4
   Brown MM, 2005, CAN J OPHTHALMOL, V40, P277, DOI 10.1016/S0008-4182(05)80070-5
   Brown MM, 2003, SURV OPHTHALMOL, V48, P204, DOI 10.1016/S0039-6257(02)00457-5
   Brown MM, 2002, ARCH OPHTHALMOL-CHIC, V120, P481
   Brown MM, 2001, OPHTHALMOLOGY, V108, P643, DOI 10.1016/S0161-6420(00)00635-7
   Brown MM, 2001, BRIT J OPHTHALMOL, V85, P327, DOI 10.1136/bjo.85.3.327
   Busbee BG, 2003, RETINA-J RET VIT DIS, V23, P279, DOI 10.1097/00006982-200306000-00001
   Butt T, 2015, BMJ OPEN, V5, DOI 10.1136/bmjopen-2014-006535
   Butt T, 2015, BRIT J OPHTHALMOL, V99, P540, DOI 10.1136/bjophthalmol-2014-305802
   Butt T, 2014, APPL HEALTH ECON HEA, V12, P289, DOI 10.1007/s40258-014-0090-0
   Butt T, 2013, OPTOMETRY VISION SCI, V90, P855, DOI 10.1097/OPX.0b013e3182962318
   Chan CKW, 2015, OPHTHALMOLOGY, V122, P2278, DOI 10.1016/j.ophtha.2015.06.050
   Czoski-Murray C, 2009, VALUE HEALTH, V12, P793, DOI 10.1111/j.1524-4733.2009.00527.x
   Dakin HA, 2014, BMJ OPEN, V4, DOI 10.1136/bmjopen-2014-005094
   Earnshaw SR, 2007, CLIN THER, V29, P2096, DOI 10.1016/j.clinthera.2007.09.001
   Elshout M, 2014, GRAEF ARCH CLIN EXP, V252, P1911, DOI 10.1007/s00417-014-2641-3
   Eong KGA, 2012, EYE, V26, P379, DOI 10.1038/eye.2011.218
   Espallargues M, 2005, INVEST OPHTH VIS SCI, V46, P4016, DOI 10.1167/iovs.05-0072
   Finger R, 2012, BRIT J OPHTHALMOL, V96, P997, DOI 10.1136/bjophthalmol-2011-301201
   Fletcher EC, 2008, OPHTHALMOLOGY, V115, P2192, DOI 10.1016/j.ophtha.2008.07.018
   Freeman JV, 2011, ANN INTERN MED, V154, P1, DOI 10.7326/0003-4819-154-1-201101040-00289
   Gower EW, 2010, RETINA-J RET VIT DIS, V30, P212, DOI 10.1097/IAE.0b013e3181babd8e
   Grieve R, 2009, OPHTHALMOLOGY, V116, P2471, DOI 10.1016/j.ophtha.2009.10.023
   Hodge W, 2010, CAN J OPHTHALMOL, V45, P223, DOI 10.3129/i10-047
   Hollands H, 2001, CAN J OPHTHALMOL, V36, P202, DOI 10.1016/S0008-4182(01)80041-7
   Hopley C, 2004, BRIT J OPHTHALMOL, V88, P982, DOI 10.1136/bjo.2003.039131
   Hopley C, 2004, BRIT J OPHTHALMOL, V88, P450, DOI 10.1136/bjo.2003.035279
   Hunter RM, 2015, PHARMACOECONOMICS, V33, P355, DOI 10.1007/s40273-014-0247-6
   Hurley Susan F, 2008, Cost Eff Resour Alloc, V6, P12, DOI 10.1186/1478-7547-6-12
   Hurley Susan F, 2008, Cost Eff Resour Alloc, V6, P18, DOI 10.1186/1478-7547-6-18
   Hernandez-Pastor LJ, 2008, CLIN THER, V30, P2436, DOI 10.1016/j.clinthera.2008.12.025
   Javitt JC, 2008, VALUE HEALTH, V11, P563, DOI 10.1111/j.1524-4733.2007.00283.x
   Karnon J, 2008, HEALTH TECHNOL ASSES, V12, p[iii, ix, 124]
   Kim J, 2010, JPN J OPHTHALMOL, V54, P325, DOI 10.1007/s10384-010-0825-x
   Kymes SV, 2009, ROLE PHARMACOLOGIC S
   Lee BS, 2008, OPHTHALMOLOGY, V115, P898, DOI 10.1016/j.ophtha.2007.06.008
   Longworth L, 2014, HEALTH TECHNOL ASSES, V18, P1, DOI 10.3310/hta18090
   Ma YY, 2016, OPTOMETRY VISION SCI, V93, P165, DOI 10.1097/OPX.0000000000000772
   Meads C, 2003, HEALTH TECHNOL ASSES, V7, p[v, 1], DOI [10.3310/hta7090, DOI 10.3310/hta7090]
   Mitchell J, 2006, HEALTH QUAL LIFE OUT, V4, DOI 10.1186/1477-7525-4-97
   Mowatt G, 2014, HEALTH TECHNOL ASSES, V18, P1, DOI 10.3310/hta18690
   Neubauer AS, 2010, INT J OPHTHALMOL-CHI, V3, P228, DOI 10.3980/j.issn.2222-3959.2010.03.11
   Neubauer AS, 2010, CLIN THER, V32, P1343, DOI 10.1016/j.clinthera.2010.07.010
   Patel JJ, 2012, J EVAL CLIN PRACT, V18, P247, DOI 10.1111/j.1365-2753.2010.01546.x
   Payakachat N, 2009, QUAL LIFE RES, V18, P801, DOI 10.1007/s11136-009-9499-6
   Pearson Isobel, 2013, J Med Econ, V16, P1307, DOI 10.3111/13696998.2013.839946
   Poku E, 2013, BMC OPHTHALMOL, V13, DOI 10.1186/1471-2415-13-74
   Raftery J, 2007, BRIT J OPHTHALMOL, V91, P1244, DOI 10.1136/bjo.2007.116616
   Real FJ, 2008, BRIT J OPHTHALMOL, V92, P770, DOI 10.1136/bjo.2007.127407
   Reeves BC, 2009, OPHTHALMOLOGY, V116, P2463, DOI 10.1016/j.ophtha.2009.10.031
   Rein DB, 2007, OPHTHALMOLOGY, V114, P1319, DOI 10.1016/j.ophtha.2006.10.041
   Sahel JA, 2007, ARCH OPHTHALMOL-CHIC, V125, P945, DOI 10.1001/archopht.125.7.945
   Schmier JK, 2016, PHARMACOECONOMICS, V34, P259, DOI 10.1007/s40273-015-0347-y
   Sharma S, 2005, CAN J OPHTHALMOL, V40, P369, DOI 10.1016/S0008-4182(05)80079-1
   Sharma S, 2002, BRIT J OPHTHALMOL, V86, P493, DOI 10.1136/bjo.86.5.493
   Sharma S, 2001, OPHTHALMOLOGY, V108, P2051, DOI 10.1016/S0161-6420(01)00764-3
   Sharma S, 2000, CAN J OPHTHALMOL, V35, P267, DOI 10.1016/S0008-4182(00)80077-0
   Skalicky SE, 2016, CLIN EXP OPHTHALMOL, V44, P377, DOI 10.1111/ceo.12672
   Smith DH, 2004, BRIT J OPHTHALMOL, V88, P1107, DOI 10.1136/bjo.2003.023986
   Stein JD, 2003, BRIT J OPHTHALMOL, V87, P8, DOI 10.1136/bjo.87.1.8
   Stein JD, 2014, OPHTHALMOLOGY, V121, P936, DOI 10.1016/j.ophtha.2013.10.037
   Tamura H, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0133628
   Tosh J, 2012, VALUE HEALTH, V15, P118, DOI 10.1016/j.jval.2011.08.002
   Trevithick JR, 2004, OPHTHAL EPIDEMIOL, V11, P337, DOI 10.1080/09286580490888780
   Weinstein MC, 1996, JAMA-J AM MED ASSOC, V276, P1253, DOI 10.1001/jama.276.15.1253
   Wolowacz SE, 2007, PHARMACOECONOMICS, V25, P863, DOI 10.2165/00019053-200725100-00005
   Yanagi Y, 2011, JPN J OPHTHALMOL, V55, P35, DOI 10.1007/s10384-010-0893-y
NR 83
TC 9
Z9 9
U1 1
U2 7
PU SPRINGER INTERNATIONAL PUBLISHING AG
PI CHAM
PA GEWERBESTRASSE 11, CHAM, CH-6330, SWITZERLAND
SN 1175-5652
EI 1179-1896
J9 APPL HEALTH ECON HEA
JI Appl. Health Econ. Health Policy
PD FEB
PY 2017
VL 15
IS 1
BP 23
EP 32
DI 10.1007/s40258-016-0275-9
PG 10
WC Economics; Health Care Sciences & Services; Health Policy & Services
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC Business & Economics; Health Care Sciences & Services
GA EP2WQ
UT WOS:000397244700004
PM 27637920
OA Green Submitted
DA 2022-11-30
ER

PT J
AU Sandhu, HS
   Lambert, J
   Xu, Y
   Kaplan, HJ
AF Sandhu, Harpal S.
   Lambert, Joshua
   Xu, Yan
   Kaplan, Henry J.
TI Systemic immunosuppression and risk of age-related macular degeneration
SO PLOS ONE
LA English
DT Article
ID CHOROIDAL NEOVASCULARIZATION; INTRAVITREAL TRIAMCINOLONE;
   MYCOPHENOLATE-MOFETIL; INHIBITION; MEMBRANE; SUSCEPTIBILITY;
   INFLAMMATION; COMPLEMENT; INCREASES; FEATURES
AB A local immune response has been implicated in the pathogenesis of age-related macular degeneration (AMD), but it is unclear if systemic immunosuppressive/immunomodulatory therapy (IMT) protects against the onset and/or progression of AMD. We performed a retrospective cohort study using a Cox proportional hazards model of two cohorts. Cohort 1 included patients with stage V chronic kidney disease (CKD) status post kidney transplantation, on at least one IMT agent, and older than 50. Cohort 2 included patients with stage IV or V CKD who had not undergone kidney transplantation, were not on IMT, and were older than 50. The main outcomes were hazard ratios of a new diagnosis of dry AMD, wet AMD, or conversion from dry to wet. There were 10,813 patients in cohort 1, and 217,081 patients in cohort 2. After controlling for sex and age, there was no significant difference in the hazard of developing a new diagnosis of dry AMD (HR = 0.95, 95% CI 0.87-1.05, p = 0.32), developing a new diagnosis of wet AMD without any prior diagnosis of dry AMD (HR = 0.85, 95% CI 0.66-1.08, p = 0.18), or converting from dry to wet AMD (HR 1.24, 95% CI 0.94-1.62, p = 0.12). For patients over 70 on mycophenolate mofetil, there was a reduced hazard of converting from dry to wet AMD (HR = 0.92, 95% CI = 0.85-0.99, p = 0.02). In contrast, everolimus had an increased hazard of dry AMD (HR = 2.14, 95% CI 1.24-3.69, p < 0.01). Most systemic IMT does not affect the risk of onset or progression of AMD in patients with CKD. However, mycophenolate mofetil may confer some degree of protection against the conversion of dry AMD to wet AMD, suggesting that modulation of the immune response may prevent progression of the disease.
C1 [Sandhu, Harpal S.; Kaplan, Henry J.] Univ Louisville, Dept Ophthalmol & Visual Sci, Louisville, KY 40292 USA.
   [Lambert, Joshua; Xu, Yan] Univ Kentucky, Appl Stat Lab, Louisville, KY USA.
C3 University of Louisville; University of Kentucky
RP Sandhu, HS (通讯作者)，Univ Louisville, Dept Ophthalmol & Visual Sci, Louisville, KY 40292 USA.
EM harpal.sandhu@louisville.edu
OI Lambert, Joshua/0000-0002-4513-8156
FU Kentucky Biomedical Research Infrastructure Network, NIGMS
   [8P20GM103436]
FX This work was supported by the Kentucky Biomedical Research
   Infrastructure Network, NIGMS grant # 8P20GM103436
   (http://louisville.edu/research/kbrin/) to Harpal S. Sandhu. I proposal
   was submitted to them which proposed this study, and they then provided
   the funds to purchase the dataset. They had no other influence on any
   decision.
CR Anderson DH, 2002, AM J OPHTHALMOL, V134, P411, DOI 10.1016/S0002-9394(02)01624-0
   Anderson OA, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0067263
   Apte RS, 2006, PLOS MED, V3, P1371, DOI 10.1371/journal.pmed.0030310
   Bacchiega BC, 2017, J AM HEART ASSOC, V6, DOI 10.1161/JAHA.116.005038
   Bak M, 2017, JAMA OPHTHALMOL, V135, P835, DOI 10.1001/jamaophthalmol.2017.2011
   Bora PS, 2005, J IMMUNOL, V174, P491, DOI 10.4049/jimmunol.174.1.491
   Challa JK, 1998, AUST NZ J OPHTHALMOL, V26, P277, DOI 10.1111/j.1442-9071.1998.tb01330.x
   Chen HY, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002339
   Chen W, 2010, P NATL ACAD SCI USA, V107, P7401, DOI 10.1073/pnas.0912702107
   Curcio CA, 2009, PROG RETIN EYE RES, V28, P393, DOI 10.1016/j.preteyeres.2009.08.001
   Dalmarco EM, 2011, EXP LUNG RES, V37, P399, DOI 10.3109/01902148.2011.570416
   Datta S, 2017, PROG RETIN EYE RES, V60, P201, DOI 10.1016/j.preteyeres.2017.03.002
   Dehghani F, 2010, NEUROPATH APPL NEURO, V36, P598, DOI 10.1111/j.1365-2990.2010.01104.x
   Dejneka NS, 2004, MOL VIS, V10, P964
   Doyle SL, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3007616
   Doyle SL, 2012, NAT MED, V18, P791, DOI 10.1038/nm.2717
   Espinosa-Heidmann DG, 2003, INVEST OPHTH VIS SCI, V44, P3586, DOI 10.1167/iovs.03-0038
   Espinosa-Heidmann DG, 2003, INVEST OPHTH VIS SCI, V44, P4914, DOI 10.1167/iovs.03-0371
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P532
   Gillies MC, 2015, OPHTHALMOLOGY, V122, P1837, DOI 10.1016/j.ophtha.2015.05.010
   Gonzalez-Juanatey C, 2006, ARTHRIT RHEUM-ARTHR, V55, P150, DOI 10.1002/art.21707
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Heier JS, 2017, AAO SUBSP DAYS NOV 1
   Hirano Y, 2014, NAT MED, V20, P1372, DOI 10.1038/nm.3671
   Kao LT, 2015, J AM ACAD DERMATOL, V72, P1090, DOI 10.1016/j.jaad.2015.03.002
   Kaplan HJ, 1999, NAT MED, V5, P292, DOI 10.1038/6509
   Kato S, 2008, CLIN J AM SOC NEPHRO, V3, P1526, DOI 10.2215/CJN.00950208
   Krause D, 2000, ARTHRITIS RHEUM-US, V43, P14, DOI 10.1002/1529-0131(200001)43:1<14::AID-ANR3>3.0.CO;2-7
   Lains I, 2018, OPHTHALMOLOGY, V125, P245, DOI 10.1016/j.ophtha.2017.08.008
   Lavalette S, 2011, AM J PATHOL, V178, P2416, DOI 10.1016/j.ajpath.2011.01.013
   Lee J, 2007, RETINA-J RET VIT DIS, V27, P1205, DOI 10.1097/IAE.0b013e31815ec367
   LOPEZ PF, 1991, AM J OPHTHALMOL, V112, P647, DOI 10.1016/S0002-9394(14)77270-8
   Malek G, 2003, AM J PATHOL, V162, P413, DOI 10.1016/S0002-9440(10)63836-9
   Micha R, 2011, AM J CARDIOL, V108, P1362, DOI 10.1016/j.amjcard.2011.06.054
   NAGY SE, 1993, IMMUNOPHARMACOLOGY, V26, P11, DOI 10.1016/0162-3109(93)90062-U
   Nakamura R, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8847
   Nussenblatt RB, 2010, RETINA-J RET VIT DIS, V30, P1579, DOI 10.1097/IAE.0b013e3181e7978e
   Olson JL, 2009, OCUL IMMUNOL INFLAMM, V17, P195, DOI 10.1080/09273940802710705
   Packard RRS, 2009, SEMIN IMMUNOPATHOL, V31, P5, DOI 10.1007/s00281-009-0153-8
   Petrou PA, 2015, INVEST OPHTH VIS SCI, V56, P330, DOI 10.1167/iovs.14-15877
   Ranson NT, 2002, BRIT J OPHTHALMOL, V86, P527, DOI 10.1136/bjo.86.5.527
   Ridker PM, 2017, NEW ENGL J MED, V377, P1119, DOI 10.1056/NEJMoa1707914
   Rofagha S, 2013, OPHTHALMOLOGY, V120, P2292, DOI 10.1016/j.ophtha.2013.03.046
   Rudolf M, 2018, CURR EYE RES, V43, P135, DOI 10.1080/02713683.2017.1370118
   Sachdeva MM, 2014, EXP EYE RES, V119, P111, DOI 10.1016/j.exer.2013.10.024
   Sakurai E, 2003, INVEST OPHTH VIS SCI, V44, P3578, DOI 10.1167/iovs.03-0097
   Sengupta N, 2003, INVEST OPHTH VIS SCI, V44, P4908, DOI 10.1167/iovs.03-0342
   Shapouri-Moghaddam A, 2018, J CELL PHYSIOL, V233, P6425, DOI 10.1002/jcp.26429
   Tarallo V, 2012, CELL, V149, P847, DOI 10.1016/j.cell.2012.03.036
   Tomita M, 2004, STEM CELLS, V22, P21, DOI 10.1634/stemcells.22-1-21
   Ursini F, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-05759-2
   Vavvas DG, 2016, EBIOMEDICINE, V5, P198, DOI 10.1016/j.ebiom.2016.01.033
   Venegas C, 2017, NATURE, V552, P355, DOI 10.1038/nature25158
   Yang ZL, 2006, SCIENCE, V314, P992, DOI 10.1126/science.1133811
   Zou YH, 2006, J OCUL PHARMACOL TH, V22, P19, DOI 10.1089/jop.2006.22.19
NR 55
TC 4
Z9 4
U1 0
U2 0
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD SEP 20
PY 2018
VL 13
IS 9
AR e0203492
DI 10.1371/journal.pone.0203492
PG 13
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA GU8XH
UT WOS:000445626400025
PM 30235234
OA gold, Green Published, Green Submitted
DA 2022-11-30
ER

PT J
AU Sun, HJ
   Jin, XM
   Xu, J
   Xiao, Q
AF Sun, Hong-Jing
   Jin, Xiu-Ming
   Xu, Jia
   Xiao, Qing
TI Baicalin Alleviates Age-Related Macular Degeneration via
   miR-223/NLRP3-Regulated Pyroptosis
SO PHARMACOLOGY
LA English
DT Article
DE miR-223; NOD-like receptor family pyrin domain-containing 3; Pyroptosis;
   Age-related macular degeneration; Baicalin
ID NLRP3 INFLAMMASOME; CELL-DEATH; OXIDATIVE STRESS; WOGONIN; SUPPRESSION;
   EXPRESSION; MIR-223; PATHWAY; DISEASE
AB Background: Age-related macular degeneration (AMD), a major eye degenerative disease, ultimately causes irreversible vision loss. Baicalin was identified to attenuate laser-induced chorodial neovascularization, indicating a therapeutic role in AMD. However, the exact mechanisms for baicalin in AMD remain unknown. Methods: MTT assay was performed to access the suitable concentration of baicalin or A beta for treating ARPE-19 cells. CCK-8, morphology, and flow cytometry analysis were performed to evaluate cell viability and pyroptosis of baicalin in A beta-envoked ARPE-19 cells. Quantitative real-time polymerase chain reaction and western blot analysis were subjected to measure the correlation between miR-223 and NLRP3. Luciferase reporter assay was performed to determine their direct relationship. Western blot analysis was subjected to determine pyroptosis-related proteins. Results: Baicalin inhibited A beta-envoked pyroptosis in ARPE-19 cells. Mechanistically, baicalin significantly induced upregulation of miR-223 and downregulation of NLRP3, thus suppressing pyroptosis triggered by NLRP3 inflammasome signaling, yet such beneficial effects were reversed by miR-223 knockdown. Additionally, MCC950, a NLRP3 inhibitor, restored anti-pyroptosis activity of baicalin under miR-223 silencing. Conclusion: Baicalin alleviates intracellular pyroptosis and viability damage resulted from A beta inducement in human retinal pigment epithelium cells via negative crosstalk of miR-223/NLRP3 inflammasome signaling, indicating that baicalin may be considered as a potential candidate for AMD therapy.
C1 [Sun, Hong-Jing; Jin, Xiu-Ming; Xu, Jia; Xiao, Qing] Zhejiang Univ, Sch Med, Affiliated Hosp 2, Dept Ophthalmol, 88 Jiefang Rd, Hangzhou 310009, Zhejiang, Peoples R China.
C3 Zhejiang University
RP Xiao, Q (通讯作者)，Zhejiang Univ, Sch Med, Affiliated Hosp 2, Dept Ophthalmol, 88 Jiefang Rd, Hangzhou 310009, Zhejiang, Peoples R China.
EM xiaoqing2017@zju.edu.cn
RI Jin, Xiuming/AGO-9685-2022
OI Jin, Xiuming/0000-0001-7492-5143
FU Zhejiang Provincial Science and Technology program of Traditional
   Chinese Medicine [2019ZA072]
FX This work was supported by Zhejiang Provincial Science and Technology
   program of Traditional Chinese Medicine (No. 2019ZA072).
CR Aachoui Y, 2013, CURR OPIN MICROBIOL, V16, P319, DOI 10.1016/j.mib.2013.04.004
   Bauernfeind F, 2012, J IMMUNOL, V189, P4175, DOI 10.4049/jimmunol.1201516
   Bergsbaken T, 2009, NAT REV MICROBIOL, V7, P99, DOI 10.1038/nrmicro2070
   Chen HG, 2015, INT J CLIN EXP PATHO, V8, P10139
   Chen QY, 2012, PLOS ONE, V7, DOI [10.1371/journal.pone.0042971, 10.1371/journal.pone.0037149]
   Cookson BT, 2001, TRENDS MICROBIOL, V9, P113, DOI 10.1016/S0966-842X(00)01936-3
   Dick AD, 2017, EYE, V31, P87, DOI 10.1038/eye.2016.177
   Ding JD, 2011, P NATL ACAD SCI USA, V108, pE279, DOI 10.1073/pnas.1100901108
   Franchi L, 2009, NAT IMMUNOL, V10, P241, DOI 10.1038/ni.1703
   Fu SL, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-19293-2
   Fukao T, 2007, CELL, V129, P617, DOI 10.1016/j.cell.2007.02.048
   Gao JY, 2018, J NEUROINFLAMM, V15, DOI 10.1186/s12974-018-1062-3
   Gottesman S, 2004, CELL, V118, P1, DOI 10.1016/j.cell.2004.06.024
   Haneklaus M, 2013, J INTERN MED, V274, P215, DOI 10.1111/joim.12099
   Haneklaus M, 2012, J IMMUNOL, V189, P3795, DOI 10.4049/jimmunol.1200312
   Ildefonso CJ, 2016, ADV EXP MED BIOL, V854, P59, DOI 10.1007/978-3-319-17121-0_9
   Jia Y, 2016, J VET MED SCI, V78, P819, DOI 10.1292/jvms.15-0572
   Jorgensen I, 2015, IMMUNOL REV, V265, P130, DOI 10.1111/imr.12287
   Jung SH, 2008, NEUROCHEM INT, V53, P325, DOI 10.1016/j.neuint.2008.09.004
   Kauppinen A, 2016, CELL MOL LIFE SCI, V73, P1765, DOI 10.1007/s00018-016-2147-8
   Klein R, 2011, ARCH OPHTHALMOL-CHIC, V129, P75, DOI 10.1001/archophthalmol.2010.318
   Liu RT, 2013, INVEST OPHTH VIS SCI, V54, P2225, DOI 10.1167/iovs.12-10849
   Mehta S, 2015, PRIMARY CARE, V42, P377, DOI 10.1016/j.pop.2015.05.009
   Nagaki Y, 2001, JPN J OPHTHALMOL, V45, P216, DOI 10.1016/S0021-5155(01)00330-6
   Nakamura N, 2003, EXP EYE RES, V77, P195, DOI 10.1016/S0014-4835(03)00116-7
   Nita Malgorzata, 2016, Oxid Med Cell Longev, V2016, P3164734, DOI 10.1155/2016/3164734
   Shao BZ, 2015, FRONT PHARMACOL, V6, DOI 10.3389/fphar.2015.00262
   Shaw PX, 2016, AIMS MOL SCI, V3, P196, DOI 10.3934/molsci.2016.2.196
   Soifer HS, 2007, MOL THER, V15, P2070, DOI 10.1038/sj.mt.6300311
   Srinivas NR, 2010, XENOBIOTICA, V40, P357, DOI 10.3109/00498251003663724
   Wang HB, 2016, MOL VIS, V22, P189
   Wang H, 2018, IUBMB LIFE, V70, P479, DOI 10.1002/iub.1747
   Wang Y, 2016, INT J MOL SCI, V17, P17
   Xiao JR, 2014, J OCUL PHARMACOL TH, V30, P605, DOI 10.1089/jop.2014.0074
   Yang SJ, 2014, CURR EYE RES, V39, P745, DOI 10.3109/02713683.2013.868908
   Yao J, 2016, PHARMACOGN MAG, V12, P225, DOI 10.4103/0973-1296.186342
   Ye C, 2016, INNATE IMMUN-LONDON, V22, P196, DOI 10.1177/1753425916631032
   Zhou WQ, 2018, CELL REP, V22, P1810, DOI 10.1016/j.celrep.2018.01.058
NR 38
TC 22
Z9 25
U1 2
U2 13
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 0031-7012
EI 1423-0313
J9 PHARMACOLOGY
JI Pharmacology
PD JAN
PY 2020
VL 105
IS 1-2
BP 28
EP 38
DI 10.1159/000502614
PG 11
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA KE9ET
UT WOS:000508853800005
PM 31578016
OA Bronze
DA 2022-11-30
ER

PT J
AU Cong, RH
   Zhou, B
   Sun, QM
   Gu, HJ
   Tang, NP
   Wang, B
AF Cong, Rihong
   Zhou, Bo
   Sun, Qingmin
   Gu, Haijuan
   Tang, Naping
   Wang, Bin
TI Smoking and the risk of age-related macular degeneration: A
   meta-analysis
SO ANNALS OF EPIDEMIOLOGY
LA English
DT Article
DE age-related macular degeneration; geographic atrophy; smoking;
   meta-analysis
ID BODY-MASS INDEX; CIGARETTE-SMOKING; ENVIRONMENTAL ASSOCIATIONS; VISUAL
   IMPAIRMENT; 5-YEAR INCIDENCE; POOLED FINDINGS; MACULOPATHY; POPULATION;
   PLASMA; EYE
AB PURPOSE: Some studies were undertaken to evaluate the association between cigarette smoking and age-related macular degeneration (AMD). This meta-analysis summarized the risk estimate of smoking and AMD and provided robust evidence for the association.
   METHODS: Relevant studies were identified by searching PubMed and MEDLINE (from 1966 to June 2007) and reviewing the reference lists of key articles. The summary relative risk ratio (RR) or odds ratio (OR) and 95% confidence interval (CI) were calculated. Study-specific risk estimates were pooled using a random-effects model.
   RESULTS: Five prospective cohort and eight case-control studies met our inclusion criteria. Ever smoking was statistically significant associated with increased risk of AMD among cohort studies (RR, 1.61; 95% CI, 1.01-2.57) or case-control studies (RR, 1.76; 95% CI, 1.56-1.99). Current smokers were at higher risk of AMD than past smokers. Both geographic atrophy (GA) and neovascular AMD (NV) are subtypes of AMD. A significant relationship was found between smoking and GA risk. Smoking increased the risk of NV, with marginal nonsignificance (RR, 1.47; 95% CI, 0.92-2.37) in cohort studies and significance in case-control studies (RR, 1.96; 95% CI, 1.69-2-27).
   CONCLUSIONS: This meta-analysis indicated smoking, especially current smoking, was significantly associated with increased risks of AMD and its subtypes.
C1 [Cong, Rihong; Zhou, Bo; Sun, Qingmin; Gu, Haijuan; Tang, Naping; Wang, Bin] Nanjing Med Univ, Dept Pharmacol, Key Lab Reprod Med, Nanjing 210029, Jiangsu, Peoples R China.
C3 Nanjing Medical University
RP Wang, B (通讯作者)，Nanjing Med Univ, Dept Pharmacol, Key Lab Reprod Med, 140 Hanzhong Rd, Nanjing 210029, Jiangsu, Peoples R China.
EM binwang@njmu.edu.cn
FU National Natural Science Foundation of China [30672486]; Natural Science
   Foundation of Jiangsu Province [BK2006525]; Young Academic Leader of
   Jiangsu Province
FX This project was supported by grants from the National Natural Science
   Foundation of China (No 30672486), the Natural Science Foundation of
   Jiangsu Province (No. BK2006525), "333 Project" and "Qinglan Project"
   Funding for the Young Academic Leader of Jiangsu Province (to B.W.).
CR Anand R, 2000, OPHTHALMOLOGY, V107, P2224
   Arnarsson A, 2006, AM J OPHTHALMOL, V142, P419, DOI 10.1016/j.ajo.2006.04.015
   BETTMAN JW, 1958, ARCH OPHTHALMOL-CHIC, V59, P481
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   BLUMENKRANZ MS, 1986, OPHTHALMOLOGY, V93, P552
   Bressler Neil M, 2002, J Am Board Fam Pract, V15, P142
   Chaine G, 1998, BRIT J OPHTHALMOL, V82, P996, DOI 10.1136/bjo.82.9.996
   Chakravarthy U, 2007, OPHTHALMOLOGY, V114, P1157, DOI 10.1016/j.ophtha.2006.09.022
   CHOW CK, 1986, J AM COLL NUTR, V5, P305
   Christen WG, 1996, JAMA-J AM MED ASSOC, V276, P1147, DOI 10.1001/jama.276.14.1147
   CHURCH DF, 1985, ENVIRON HEALTH PERSP, V64, P111, DOI 10.2307/3430003
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   Dandekar SS, 2006, BRIT J OPHTHALMOL, V90, P724, DOI 10.1136/bjo.2005.086355
   DeAngelis MM, 2004, ARCH OPHTHALMOL-CHIC, V122, P575, DOI 10.1001/archopht.122.4.575
   Delcourt C, 1998, ARCH OPHTHALMOL-CHIC, V116, P1031, DOI 10.1001/archopht.116.8.1031
   DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2
   Evans JR, 2005, BRIT J OPHTHALMOL, V89, P550, DOI 10.1136/bjo.2004.049726
   Francis PJ, 2007, HUM HERED, V63, P212, DOI 10.1159/000100046
   Fraser-Bell S, 2006, AM J OPHTHALMOL, V141, P79, DOI 10.1016/j.ajo.2005.08.024
   Hammond BR, 1996, VISION RES, V36, P3003, DOI 10.1016/0042-6989(96)00008-9
   Hammond BR, 2000, INVEST OPHTH VIS SCI, V41, P1492
   Hirvela H, 1996, OPHTHALMOLOGY, V103, P871, DOI 10.1016/S0161-6420(96)30593-9
   HYMAN LG, 1983, AM J EPIDEMIOL, V118, P213, DOI 10.1093/oxfordjournals.aje.a113629
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Khan JC, 2006, BRIT J OPHTHALMOL, V90, P29, DOI 10.1136/bjo.2005.073825
   Klaver CCW, 2001, INVEST OPHTH VIS SCI, V42, P2237
   KLEIN R, 1993, AM J EPIDEMIOL, V137, P190, DOI 10.1093/oxfordjournals.aje.a116659
   Klein R, 1998, AM J EPIDEMIOL, V147, P103
   Klein R, 2002, AM J EPIDEMIOL, V156, P589, DOI 10.1093/aje/kwf092
   Krishnaiah S, 2005, INVEST OPHTH VIS SCI, V46, P4442, DOI 10.1167/iovs.05-0853
   MALTZMAN BA, 1979, ANN OPHTHALMOL, V11, P1197
   McCarty CA, 2001, ARCH OPHTHALMOL-CHIC, V119, P1455
   Milton RC, 2005, OPHTHALMOLOGY, V112, P533, DOI 10.1016/j.ophtha.2004.10.047
   Mitchell P, 2002, ARCH OPHTHALMOL-CHIC, V120, P1357, DOI 10.1001/archopht.120.10.1357
   Miyazaki M, 2005, INVEST OPHTH VIS SCI, V46, P1907, DOI 10.1167/iovs.04-0923
   Mooijaart SP, 2007, EXP GERONTOL, V42, P1116, DOI 10.1016/j.exger.2007.08.001
   Neuner B, 2007, ANN EPIDEMIOL, V17, P615, DOI 10.1016/j.annepidem.2007.03.005
   Pauleikhoff D, 1992, Ger J Ophthalmol, V1, P12
   Resnikoff S, 2004, B WORLD HEALTH ORGAN, V82, P844
   SCHALCH W, 1999, CRC MOD NUT, P215
   Schmidt S, 2006, AM J HUM GENET, V78, P852, DOI 10.1086/503822
   Scott WK, 2007, OPHTHALMOLOGY, V114, P1151, DOI 10.1016/j.ophtha.2006.08.054
   Seddon JM, 1996, JAMA-J AM MED ASSOC, V276, P1141, DOI 10.1001/jama.276.14.1141
   Seddon JM, 2006, HUM HERED, V61, P157, DOI 10.1159/000094141
   Seddon JM, 2006, ARCH OPHTHALMOL-CHIC, V124, P995, DOI 10.1001/archopht.124.7.995
   Smith W, 1998, ARCH OPHTHALMOL-CHIC, V116, P583, DOI 10.1001/archopht.116.5.583
   Smith W, 1996, ARCH OPHTHALMOL-CHIC, V114, P1518, DOI 10.1001/archopht.1996.01100140716016
   Smith W, 2001, OPHTHALMOLOGY, V108, P697, DOI 10.1016/S0161-6420(00)00580-7
   SNODDERLY DM, 1995, AM J CLIN NUTR, V62, P1448
   Tamakoshi A, 1997, BRIT J OPHTHALMOL, V81, P901, DOI 10.1136/bjo.81.10.901
   Tan JSL, 2007, ARCH OPHTHALMOL-CHIC, V125, P1089, DOI 10.1001/archopht.125.8.1089
   Thylefors B, 1998, AM J OPHTHALMOL, V125, P90, DOI 10.1016/S0002-9394(99)80239-6
   Tomany SC, 2004, OPHTHALMOLOGY, V111, P1280, DOI 10.1016/j.ophtha.2003.11.010
   VINDING T, 1992, ACTA OPHTHALMOL, V70, P66
   Vingerling JR, 1996, ARCH OPHTHALMOL-CHIC, V114, P1193, DOI 10.1001/archopht.1996.01100140393005
   Wang B, 2006, ATHEROSCLEROSIS, V184, P425, DOI 10.1016/j.atherosclerosis.2005.05.008
   Wang B, 2005, CLIN CHEM, V51, P1541, DOI 10.1373/clinchem.2005.050955
   WEST SK, 1989, ARCH OPHTHALMOL-CHIC, V107, P875, DOI 10.1001/archopht.1989.01070010897038
   Xu L, 2006, BRIT J OPHTHALMOL, V90, P1087, DOI 10.1136/bjo.2006.096123
   YANNUZZI LA, 1992, ARCH OPHTHALMOL-CHIC, V110, P1701
   Zhou B, 2007, AM J OBSTET GYNECOL, V197, DOI 10.1016/j.ajog.2007.05.027
   Zhou B, 2006, EXP EYE RES, V83, P615, DOI 10.1016/j.exer.2006.02.010
   Zhu HJ, 2006, CARCINOGENESIS, V27, P2491, DOI 10.1093/carcin/bgl121
NR 63
TC 66
Z9 67
U1 0
U2 14
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1047-2797
EI 1873-2585
J9 ANN EPIDEMIOL
JI Ann. Epidemiol.
PD AUG
PY 2008
VL 18
IS 8
BP 647
EP 656
DI 10.1016/j.annepidem.2008.04.002
PG 10
WC Public, Environmental & Occupational Health
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Public, Environmental & Occupational Health
GA 349KC
UT WOS:000259278700008
PM 18652983
DA 2022-11-30
ER

PT J
AU Bibiloni, MD
   Zapata, ME
   Aragon, JA
   Pons, A
   Olea, JL
   Tur, JA
AF del Mar Bibiloni, Maria
   Elisa Zapata, Maria
   Aragon, Juan A.
   Pons, Antoni
   Luis Olea, Jose
   Tur, Josep A.
TI Estimation of antioxidants dietary intake in wet age-related macular
   degeneration patients
SO NUTRICION HOSPITALARIA
LA English
DT Article
DE Antioxidants; Wet age-related macular degeneration; Lutein; Zeaxanthin
ID WEIGHT-LOSS; MACULOPATHY; PREVALENCE; RISK; POPULATION; GUIDELINES;
   OVERWEIGHT; ZEAXANTHIN; PERCENTAGE; CATARACT
AB Aims: The aim of this study was to estimate the intake of antioxidant nutrients in wet age-related macular degeneration (AND) patients, a degenerative and progressive disorder of the macula, which is the central part of the retina, associated with central vision loss.
   Methods: A sample (n = 52, 78.9 +/- 6.6 years old, 40.4% females and 59.6% males) of patients diagnosed of AMD was interviewed. Anthropometric measurements, two 24-h recalls, a semi-quantitative food frequency questionnaire and a general questionnaire incorporating questions related to socio-demographic and lifestyle variables were used.
   Results: Most of wet AMID patients showed inadequate antioxidant nutrient intake (< 2/3 of Recommended Dietary Intake, RDI), and more than 60% of patients showed serious deficient intake (< 1/3 RDI) of lutein and zeaxanthin. Most consumed antioxidant rich foods only represented low contributions to antioxidant intake. Although adiposity is a factor risk for AMID progression; the fat and saturated fatty acids (SPA) intake of study participants were higher than the recommendations; the prevalence of overweight was 61.9% men and 58.1% in women; and 83% of patients (90.5% men and 77.4% women) showed fat mass over the cut-off limits.
   Conclusions: The food pattern of wet AMD patients should be improved by means of an increase in the consumption of antioxidant rich foods, and a decrease in SFA rich foods.
C1 [del Mar Bibiloni, Maria; Elisa Zapata, Maria; Pons, Antoni; Tur, Josep A.] Univ Balearic Isl, Res Grp Community Nutr & Oxidat Stress, Palma De Mallorca 07122, Spain.
   [del Mar Bibiloni, Maria; Elisa Zapata, Maria; Pons, Antoni; Tur, Josep A.] CIBERobn Physiopathol Obes & Nutr, Palma De Mallorca, Spain.
   [Aragon, Juan A.; Luis Olea, Jose] Son Espases Hosp, Ophthalmol Serv, Palma De Mallorca, Spain.
C3 Universitat de les Illes Balears; CIBER - Centro de Investigacion
   Biomedica en Red; CIBEROBN; Hospital Universitari Son Espases
RP Tur, JA (通讯作者)，Univ Balearic Isl, Res Grp Community Nutr & Oxidat Stress, Guillem Colom Bldg Campus, Palma De Mallorca 07122, Spain.
EM pep.tur@uib.es
RI Bibiloni, Maria del Mar/H-9734-2015; Pons, Antoni/L-4844-2014; Tur,
   Josep/AAE-5748-2020; del Mar Bibiloni, Maria/M-3123-2014; Tur, Josep
   Antoni/F-5576-2014
OI Pons, Antoni/0000-0003-2447-3868; Tur, Josep/0000-0002-6940-0761; del
   Mar Bibiloni, Maria/0000-0001-8926-9206; Tur, Josep
   Antoni/0000-0002-6940-0761; OLEA, JOSE LUIS/0000-0002-3645-8262; Zapata,
   Maria Elisa/0000-0002-4853-4998
FU Balearic Islands Regional Ministry of Health [DGAVAL PI 033/09, IB
   1148/09]; CIBERobn [CB 12/03/30038]; Balearic Islands Gov. [35/2011]; EU
   FEDER funds; Spanish Ministry of Education and Science; Bank of
   Santander
FX The study was supported by the Balearic Islands Regional Ministry of
   Health (project DGAVAL PI 033/09; IB 1148/09), CIBERobn (CB
   12/03/30038), Grant of support to research groups no. 35/2011 (Balearic
   Islands Gov. and EU FEDER funds), Spanish Ministry of Education and
   Science (FPU Programme, PhD fellowship to Maria del Mar Bibiloni), Bank
   of Santander (PhD Programme Santander-Iberoamerica, PhD fellowship to
   Maria Elisa Zapata). The Research Group on Community Nutrition and
   Oxidative Stress, University of Balearic Islands belongs to the Centre
   Catala de la Nutricio (IEC) and Exernet Network.
CR Aranceta J, 2003, MED CLIN-BARCELONA, V120, P608, DOI 10.1157/13046926
   Aranceta J., 2003, 150 N INVESTIG ARTER, V15, P196, DOI [10.1016/S0214-9168(03)78933-5, DOI 10.1016/S0214-9168(03)78933-5]
   Aranceta J, 2010, REV ESP NUTR COMUNIT, V16, P173
   Aranceta-Bartrina J, 2005, MED CLIN-BARCELONA, V125, P460, DOI 10.1157/13079612
   Cangemi Francis E, 2007, BMC Ophthalmol, V7, P3, DOI 10.1186/1471-2415-7-3
   Carpentier S, 2009, CRIT REV FOOD SCI, V49, P313, DOI 10.1080/10408390802066979
   Casado J, 2009, ANN OFTALMOLOGIA, V17, P264
   Chiu CJ, 2009, OPHTHALMOLOGY, V116, P939, DOI 10.1016/j.ophtha.2008.12.025
   Coleman H, 2007, CURR OPIN OPHTHALMOL, V18, P220, DOI 10.1097/ICU.0b013e32814a586b
   Delcourt C, 1999, ARCH OPHTHALMOL-CHIC, V117, P1384, DOI 10.1001/archopht.117.10.1384
   Delcourt C, 2006, INVEST OPHTH VIS SCI, V47, P2329, DOI 10.1167/iovs.05-1235
   Deurenberg P, 2001, EUR J CLIN NUTR, V55, P973, DOI 10.1038/sj.ejcn.1601254
   ESQUIUS M, 1993, MED CLIN-BARCELONA, V100, P692
   Evans JR, 2004, BRIT J OPHTHALMOL, V88, P365, DOI 10.1136/bjo.2003.019927
   Fernandez-Ballarth JD, 2010, BRIT J NUTR, V103, P1808, DOI 10.1017/S0007114509993837
   Frisancho AR., 1990, ANTHROPOMETRIC STAND
   Gomez-Ulla De Irazazabal F, 2001, Arch Soc Esp Oftalmol, V76, P633
   Gomez-Ulla F, 1993, MACULA SENIL, P97
   Gutierrez-Fisac JL, 2004, OBES RES, V12, P710, DOI 10.1038/oby.2004.83
   HOLM S, 1979, SCAND J STAT, V6, P65
   KLEIN R, 1995, INVEST OPHTH VIS SCI, V36, P182
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Kondrup J, 2003, CLIN NUTR, V22, P415, DOI 10.1016/S0261-5614(03)00098-0
   Krakoff LR, 2009, BLOOD PRESS MONIT, V14, P172, DOI 10.1097/MBP.0b013e328330056a
   Mataix J, 2004, TABLAS COMPOSICION A
   Montgomery MP, 2010, OPHTHAL EPIDEMIOL, V17, P58, DOI 10.3109/09286580903450353
   Nolan J, 2004, INVEST OPHTH VIS SCI, V45, P3940, DOI 10.1167/iovs.04-0273
   Nowjack-Raymer RE, 2007, J DENT RES, V86, P1171, DOI 10.1177/154405910708601206
   Olea JL, 2009, DEGENERACION MACULAR
   Olmedilla B, 1996, CONTENIDO CAROTENOID
   Ortega-Anta RM, 2004, COMPOSICION ALIMENTO
   Pi-Sunyer FX, 1998, OBES RES, V6, p51S
   Sahyoun Nadine R., 2005, Journal of Nutrition for the Elderly, V24, P5, DOI 10.1300/J052v24n04_03
   Seddon JM, 2003, ARCH OPHTHALMOL-CHIC, V121, P1728, DOI 10.1001/archopht.121.12.1728
   Strauss RS, 2001, INT J OBESITY, V25, P1381, DOI 10.1038/sj.ijo.0801683
   THOMPSON MP, 1991, J AM GERIATR SOC, V39, P497, DOI 10.1111/j.1532-5415.1991.tb02496.x
   Tur JA, 2005, PUBLIC HEALTH NUTR, V8, P275, DOI 10.1079/PHN2004693
   van Leeuwen R, 2005, JAMA-J AM MED ASSOC, V294, P3101, DOI 10.1001/jama.294.24.3101
   WALKER D, 1991, J AM DIET ASSOC, V91, P300
   Wanden-Berghe C, 2007, NUTR ASSESSMENT ELDE, P77
   Wearne SJ, 1999, BRIT J NUTR, V81, pS119, DOI 10.1017/S0007114599000963
NR 41
TC 3
Z9 3
U1 0
U2 15
PU ARAN EDICIONES, S L
PI MADRID
PA C/ CASTELLO, 128, 1O, MADRID, 28006, SPAIN
SN 0212-1611
EI 1699-5198
J9 NUTR HOSP
JI Nutr. Hosp.
PD APR
PY 2014
VL 29
IS 4
BP 880
EP 888
DI 10.3305/nh.2014.29.4.7078
PG 9
WC Nutrition & Dietetics
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Nutrition & Dietetics
GA AE8NR
UT WOS:000334259100022
PM 24679031
DA 2022-11-30
ER

PT J
AU Perez-Rico, C
   Benitez-Herreros, J
   Castro-Rebollo, M
   Gomez-SanGil, Y
   Germain, F
   Montes-Mollon, MA
   Teus, MA
AF Perez-Rico, Consuelo
   Benitez-Herreros, Javier
   Castro-Rebollo, Maria
   Gomez-SanGil, Yanira
   Germain, Francisco
   Angeles Montes-Mollon, Maria
   Angel Teus, Miguel
TI Effect of Intravitreal Ranibizumab on Corneal Endothelium in Age-Related
   Macular Degeneration
SO CORNEA
LA English
DT Article
DE age-related macular degeneration; corneal endothelium; ranibizumab;
   specular microscopy; vascular endothelial growth factor A
ID GROWTH-FACTOR; BEVACIZUMAB AVASTIN; IN-VITRO; VEGF; NEOVASCULARIZATION;
   PHARMACOKINETICS; PROFILE; CELLS
AB Purpose: To determine the effect of intravitreal injection of ranibizumab on the corneal endothelium in patients with choroidal neovascularization in age-related macular degeneration.
   Methods: Observational prospective case series study. Fifty-two eyes of 52 consecutive patients (29 men, 23 women; age range, 61-80 years) were evaluated. All participants received monthly intravitreal injections of (0.05 mL, 0.5 mg) ranibizumab for 3 consecutive months; the follow-up period was 6 months. Central corneal specular microscopy was performed before injection and at 7 days and 6 months after the first intravitreal injection. The endothelial cell density, coefficient of variation of cell size, and percentage of hexagonal cells were analyzed, and the central corneal thickness was measured.
   Results: There were no significant differences in the endothelial cell densities, coefficient of variation of cell sizes, and percentage of hexagonal cells values before injection and at 7 days and 6 months after the first intravitreal ranibizumab injection (P = 0.987, P = 0.822, and P = 0.918, respectively). There was also no significant difference in central corneal thickness measurements before injection and at 7 days and 6 months after the first intravitreal ranibizumab injection (P = 0.325).
   Conclusion: Repeated intravitreal injections of 0.5 mg of ranibizumab do not seem to cause substantial changes in the corneal endothelium at 6 months.
C1 [Perez-Rico, Consuelo; Benitez-Herreros, Javier; Castro-Rebollo, Maria; Gomez-SanGil, Yanira; Angeles Montes-Mollon, Maria; Angel Teus, Miguel] Univ Alcala, Univ Hosp Principe Asturias, Dept Ophthalmol, Alcala De Henares 28805, Madrid, Spain.
   [Germain, Francisco] Univ Alcala, Univ Hosp Principe Asturias, Dept Physiol, Sch Med, Alcala De Henares 28805, Madrid, Spain.
C3 Prince of Asturias University Hospital; Universidad de Alcala; Prince of
   Asturias University Hospital; Universidad de Alcala
RP Perez-Rico, C (通讯作者)，Univ Alcala, Univ Hosp Principe Asturias, Dept Ophthalmol, Carretera Alcala Meco S-N, Alcala De Henares 28805, Madrid, Spain.
EM cinta.perezrico@gmail.com
RI Teus, Miguel A./AAW-1835-2020; Germain, Francisco/J-7152-2019; herreros,
   javier benitez/ABC-4598-2020
OI Teus, Miguel A./0000-0002-3835-9882; 
FU Fundacion de Investigacion del Hospital Universitario Principe de
   Asturias; Fundacion para la Investigacion Biomedica del Hospital
   Universitario Principe de Asturias; Instituto de Salud Carlos III
   [RD07/0062/0008]
FX Supported by the Fundacion de Investigacion del Hospital Universitario
   Principe de Asturias, Fundacion para la Investigacion Biomedica del
   Hospital Universitario Principe de Asturias, and Instituto de Salud
   Carlos III (RD07/0062/0008).
CR Adamis AP, 2005, RETINA-J RET VIT DIS, V25, P111, DOI 10.1097/00006982-200502000-00001
   Ambati BK, 2006, NATURE, V443, P993, DOI 10.1038/nature05249
   Bakri SJ, 2007, OPHTHALMOLOGY, V114, P2179, DOI 10.1016/j.ophtha.2007.09.012
   Chiang CC, 2008, AM J OPHTHALMOL, V146, P688, DOI 10.1016/j.ajo.2008.06.002
   Gan LS, 2004, ACTA OPHTHALMOL SCAN, V82, P557, DOI 10.1111/j.1600-0420.2004.00312.x
   Gaudreault J, 2005, INVEST OPHTH VIS SCI, V46, P726, DOI 10.1167/iovs.04-0601
   GEROSKI DH, 1989, INVEST OPHTH VIS SCI, V30, P254
   Iriyama A, 2007, BRIT J OPHTHALMOL, V91, P1230, DOI 10.1136/bjo.2007.117309
   Kernt M, 2007, OPHTHALMOLOGE, V104, P965, DOI 10.1007/s00347-007-1569-y
   Lowe J, 2007, EXP EYE RES, V85, P425, DOI 10.1016/j.exer.2007.05.008
   Luke M, 2006, BRIT J OPHTHALMOL, V90, P1178, DOI 10.1136/bjo.2006.094995
   Luthra S, 2006, RETINA-J RET VIT DIS, V26, P512, DOI 10.1097/01.iae.0000222547.35820.52
   Manzano RPA, 2006, RETINA-J RET VIT DIS, V26, P257, DOI 10.1097/00006982-200603000-00001
   Maturi RK, 2006, RETINA-J RET VIT DIS, V26, P270, DOI 10.1097/00006982-200603000-00003
   PEREZRICO C, 2009, BR J OPHTHALMOL, V94, P1
   Philipp W, 2000, INVEST OPHTH VIS SCI, V41, P2514
   Rainer G, 2002, J CATARACT REFR SURG, V28, P2142, DOI 10.1016/S0886-3350(02)01533-X
   SCHULTZ RO, 1984, AM J OPHTHALMOL, V98, P401, DOI 10.1016/0002-9394(84)90120-X
   Shahar J, 2006, RETINA-J RET VIT DIS, V26, P262, DOI 10.1097/00006982-200603000-00002
   Spitzer MS, 2006, BRIT J OPHTHALMOL, V90, P1316, DOI 10.1136/bjo.2006.095190
   Spitzer MS, 2007, GRAEF ARCH CLIN EXP, V245, P1837, DOI 10.1007/s00417-007-0568-7
   van Wijngaarden P, 2005, JAMA-J AM MED ASSOC, V293, P1509, DOI 10.1001/jama.293.12.1509
   Yoeruek E, 2007, CORNEA, V26, P977, DOI 10.1097/ICO.0b013e3180de1d0a
NR 23
TC 15
Z9 15
U1 0
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0277-3740
EI 1536-4798
J9 CORNEA
JI Cornea
PD AUG
PY 2010
VL 29
IS 8
BP 849
EP 852
DI 10.1097/ICO.0b013e3181ca33d2
PG 4
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 630ED
UT WOS:000280254500002
PM 20508510
DA 2022-11-30
ER

PT J
AU Yodoi, Y
   Sasahara, M
   Kameda, T
   Yoshimura, N
   Otani, A
AF Yodoi, Yuko
   Sasahara, Manabu
   Kameda, Takanori
   Yoshimura, Nagahisa
   Otani, Atsushi
TI Circulating hematopoietic stem cells in patients with neovascular
   age-related macular degeneration
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
ID ENDOTHELIAL PROGENITOR CELLS; EXPERIMENTAL CHOROIDAL NEOVASCULARIZATION;
   RETINAL-PIGMENT EPITHELIUM; VASCULAR REPAIR; RISK-FACTORS;
   ERYTHROPOIETIN; ANGIOGENESIS; MIGRATION; MOBILIZATION; ENUMERATION
AB PURPOSE. Circulating hematopoietic stem cells (HSCs) appear to have roles in the formation of choroidal neovascularization (CNV) in age-related macular degeneration (AMD). This study was conducted to investigate whether the number or function of HSCs plays a role in neovascular AMD.
   METHODS. Eighty-one patients with neovascular AMD who underwent comprehensive fundus examinations every 3 months were included. The number of CD34(+) HSCs isolated from peripheral blood was counted by flow cytometry. Serum cytokine levels were assessed by enzyme-linked immunosorbent assay. To examine the function of circulating HSCs, mononuclear cells were cultured and then colony forming unit (CFU-EC) and migration were measured.
   RESULTS. The number of circulating CD34(+) HSCs was significantly increased in the patients with active CNV without major systemic diseases (stable: 3.8 +/- 0.3 cells/mu L, active: 5.5 +/- 0.7 cells/mu L, stable versus active: P < 0.05). The number of HSCs correlated positively with the erythropoietin serum level (r = 0.47, P = 0.002). Although there was no significant difference in the CFU-EC between the patients with CNV and the control subjects, a significant decrease of CFU-EC was observed in the patients with bilateral or larger CNV.
   CONCLUSIONS. The findings suggest that CD34(+) HSCs may be recruited from bone marrow through a signal from active CNV. Furthermore, HSCs may play a role in the severity of CNV.
C1 Kyoto Univ, Grad Sch Med, Dept Ophthalmol & Visual Sci, Kyoto 6068386, Japan.
C3 Kyoto University
RP Otani, A (通讯作者)，Kyoto Univ, Grad Sch Med, Dept Ophthalmol & Visual Sci, 54 Shogoin-Kawahara-cho, Kyoto 6068386, Japan.
EM otan@kuhp.kyoto-u.ac.jp
CR Ambati J, 2003, SURV OPHTHALMOL, V48, P257, DOI 10.1016/S0039-6257(03)00030-4
   Asahara T, 1997, SCIENCE, V275, P964, DOI 10.1126/science.275.5302.964
   Asahara T, 1999, EMBO J, V18, P3964, DOI 10.1093/emboj/18.14.3964
   Atmaca-Sonmez P, 2006, EXP EYE RES, V83, P1295, DOI 10.1016/j.exer.2006.07.013
   Bahlmann FH, 2004, BLOOD, V103, P921, DOI 10.1182/blood-2003-04-1284
   Caicedo A, 2005, EXP EYE RES, V81, P38, DOI 10.1016/j.exer.2005.01.013
   Chan-Ling T, 2006, AM J PATHOL, V168, P1031, DOI 10.2353/ajpath.2006.050697
   Chen C H, 1994, J Hematother, V3, P3, DOI 10.1089/scd.1.1994.3.3
   Crane IJ, 2000, J IMMUNOL, V165, P4372, DOI 10.4049/jimmunol.165.8.4372
   Dimmeler S, 2004, J MOL MED, V82, P671, DOI 10.1007/s00109-004-0580-x
   Espinosa-Heidmann DG, 2005, EXP EYE RES, V80, P369, DOI 10.1016/j.exer.2004.10.005
   Espinosa-Heidmann DG, 2003, INVEST OPHTH VIS SCI, V44, P4914, DOI 10.1167/iovs.03-0371
   George J, 2005, CARDIOVASC RES, V68, P299, DOI 10.1016/j.cardiores.2005.06.022
   Grant MB, 2002, NAT MED, V8, P607, DOI 10.1038/nm0602-607
   Gratama JW, 1998, CYTOMETRY, V34, P128, DOI 10.1002/(SICI)1097-0320(19980615)34:3<128::AID-CYTO3>3.0.CO;2-D
   Harris JR, 2006, INVEST OPHTH VIS SCI, V47, P2108, DOI 10.1167/iovs.05-0928
   Hattori K, 2001, J EXP MED, V193, P1005, DOI 10.1084/jem.193.9.1005
   Heeschen C, 2003, BLOOD, V102, P1340, DOI 10.1182/blood-2003-01-0223
   Hill JM, 2003, NEW ENGL J MED, V348, P593, DOI 10.1056/NEJMoa022287
   Kawamoto A, 2001, CIRCULATION, V103, P634
   Kent D, 2003, MOL VIS, V9, P747
   Lagasse E, 2000, NAT MED, V6, P1229, DOI 10.1038/81326
   Leone AM, 2006, INT J CARDIOL, V111, P202, DOI 10.1016/j.ijcard.2005.06.043
   Li Y, 2006, INVEST OPHTH VIS SCI, V47, P1646, DOI 10.1167/iovs.05-1092
   Lyden D, 2001, NAT MED, V7, P1194, DOI 10.1038/nm1101-1194
   Maliakal JC, 2002, METHOD ENZYMOL, V352, P175
   Michaud SE, 2006, ATHEROSCLEROSIS, V187, P423, DOI 10.1016/j.atherosclerosis.2005.10.009
   Orlic D, 2001, P NATL ACAD SCI USA, V98, P10344, DOI 10.1073/pnas.181177898
   Priller J, 2001, NAT MED, V7, P1356, DOI 10.1038/nm1201-1356
   Schmidt-Lucke C, 2005, CIRCULATION, V111, P2981, DOI 10.1161/CIRCULATIONAHA.104.504340
   Sengupta N, 2003, INVEST OPHTH VIS SCI, V44, P4908, DOI 10.1167/iovs.03-0342
   Sengupta N, 2005, INVEST OPHTH VIS SCI, V46, P343, DOI 10.1167/iovs.04-0153
   Shyu WC, 2006, J NEUROSCI, V26, P3444, DOI 10.1523/JNEUROSCI.5165-05.2006
   Smith W, 2001, OPHTHALMOLOGY, V108, P697, DOI 10.1016/S0161-6420(00)00580-7
   Vasa M, 2001, CIRC RES, V89, pE1, DOI 10.1161/hh1301.093953
   Werner N, 2005, NEW ENGL J MED, V353, P999, DOI 10.1056/NEJMoa043814
   Yoder MC, 2007, BLOOD, V109, P1801, DOI 10.1182/blood-2006-08-043471
   2005, RETINA, V25, P119
NR 38
TC 36
Z9 41
U1 0
U2 1
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD DEC
PY 2007
VL 48
IS 12
BP 5464
EP 5472
DI 10.1167/iovs.07-0093
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 238MB
UT WOS:000251450800017
PM 18055794
OA Green Submitted
DA 2022-11-30
ER

PT J
AU Seddon, JM
   Cote, J
   Page, WF
   Aggen, SH
   Neale, MC
AF Seddon, JM
   Cote, J
   Page, WF
   Aggen, SH
   Neale, MC
TI The US twin study of age-related macular degeneration - Relative roles
   of genetic and environmental influences
SO ARCHIVES OF OPHTHALMOLOGY
LA English
DT Article
ID DIETARY-FAT; MACULOPATHY; ASSOCIATION; RISK; DISEASE; SCAN;
   HYPERTENSION; PROGRESSION; DIAGNOSIS; HEREDITY
AB Context: Age-related macular degeneration (AMD) is the leading cause of irreversible blindness among older individuals in many parts of the world. The relative importance of genes and environment in the etiology of this major public health problem is not well understood.
   Objective: To investigate the impact of genetic and environmental factors.
   Participants: Living twins in the National Academy of Sciences-National Research Council World War 11 Veteran Twin Registry born between 1917 and 1927.
   Methods: Twins were surveyed for the known presence of macular degeneration. Enrolled twins underwent a standardized examination and fundus photography. Age-related macular degeneration evaluation was completed for 840 elderly male twins, 2 10 monozygotic and 181 dizygotic complete twin pairs, both concordant and discordant for presence or absence of AMD, and 58 singletons. A bivariate twin model incorporating initial screening ascertainment and age effects was employed to partition variation in liability to AMD and signs of maculopathy into additive genetic, common environment, and unique environment components.
   Main Outcome Measure: Heritability of AMD grade and signs of maculopathy based on clinical examination and fundus photographs.
   Results: Of the 840 twins, 331 had no signs of maculopathy and 241 had early signs, while 162 had intermediate AMD and 106 had advanced AMD. Heritability (additive genetic) estimates were significant for overall AMD grade (0.46) and for intermediate (0.67) and advanced (0.71) AMD. Significant unique environmental proportions of variance were also observed for these AMD variables (0.37, 0.19, and 0.24, respectively). Shared or common environmental contributions were not significant (0.05-0.17). For specific macular drusen and retinal pigment epithelial characteristics, significant genetic (0.26-0.71) and unique environmental (0.28-0.64) proportions of variance were detected.
   Conclusions: Genetic factors play a substantial role in the etiology of AMD and associated macular characteristics, explaining 46% to 71% of the variation in the overall severity of the disease. Environmental factors unique to each twin also contribute to the occurrence of this disease. This quantification of relative genetic and environmental contributions to the development of AMD should guide future research on this important cause of blindness.
C1 Massachusetts Eye & Ear Infirm, Epidemiol Unit, Boston, MA 02114 USA.
   Harvard Univ, Sch Med, Dept Ophthalmol, Boston, MA 02115 USA.
   Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA.
   Natl Acad Sci, Natl Res Council, Vet Twin Registry World War 2, Washington, DC 20418 USA.
   Virginia Commonwealth Univ, Dept Psychiat, Richmond, VA USA.
   Virginia Commonwealth Univ, Dept Human Genet, Richmond, VA USA.
   Virginia Commonwealth Univ, Virginia Inst Psychiat & Behav Genet, Richmond, VA USA.
C3 Harvard University; Massachusetts Eye & Ear Infirmary; Harvard
   University; Harvard Medical School; Harvard University; Harvard T.H.
   Chan School of Public Health; National Academies of Sciences,
   Engineering & Medicine; Virginia Commonwealth University; Virginia
   Commonwealth University; Virginia Commonwealth University
RP Seddon, JM (通讯作者)，Massachusetts Eye & Ear Infirm, Epidemiol Unit, 243 charles St, Boston, MA 02114 USA.
EM Johanna_Seddon@meei.harvard.edu
RI Neale, Michael C/B-1418-2008; Neale, Michael/AAD-5056-2020
FU NEI NIH HHS [EY10012, R01 EY011309] Funding Source: Medline; NIMH NIH
   HHS [MH65322, MH01458] Funding Source: Medline; NATIONAL EYE INSTITUTE
   [R01EY010012] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL
   HEALTH [R01MH065322, K02MH001458] Funding Source: NIH RePORTER
CR ADELMAN R, 2000, ANN M AM AC OPHTH OC
   Age-Related Eye Dis Study Res Grp, 2001, AM J OPHTHALMOL, V132, P668
   Allikmets R, 2000, AM J HUM GENET, V67, P487, DOI 10.1086/303018
   Allikmets R, 1997, SCIENCE, V277, P1805, DOI 10.1126/science.277.5333.1805
   BREITNER JCS, 1993, NEUROLOGY, V43, P261, DOI 10.1212/WNL.43.2.261
   CEDERLOEF R, 1961, ACTA GENET STAT MED, V11, P338
   Cho E, 2001, AM J CLIN NUTR, V73, P209
   CHYLACK LT, 1989, ARCH OPHTHALMOL-CHIC, V107, P991, DOI 10.1001/archopht.1989.01070020053028
   Delcourt C, 1998, ARCH OPHTHALMOL-CHIC, V116, P1031, DOI 10.1001/archopht.116.8.1031
   Duggirala R, 1997, GENET EPIDEMIOL, V14, P987, DOI 10.1002/(SICI)1098-2272(1997)14:6<987::AID-GEPI71>3.0.CO;2-G
   FALCONER DS, 1965, ANN HUM GENET, V29, P51, DOI 10.1111/j.1469-1809.1965.tb00500.x
   FERRIS FL, 1982, AM J OPHTHALMOL, V94, P91, DOI 10.1016/0002-9394(82)90197-0
   Gottfredsdottir MS, 1999, ACTA OPHTHALMOL SCAN, V77, P422, DOI 10.1034/j.1600-0420.1999.770413.x
   Hammond CJ, 2002, OPHTHALMOLOGY, V109, P730, DOI 10.1016/S0161-6420(01)01049-1
   HRUBEC Z, 1984, NEW ENGL J MED, V310, P435, DOI 10.1056/NEJM198402163100706
   Hyman L, 2000, ARCH OPHTHALMOL-CHIC, V118, P351, DOI 10.1001/archopht.118.3.351
   JABLON S, 1967, AM J HUM GENET, V19, P133
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Klaver CCW, 1998, ARCH OPHTHALMOL-CHIC, V116, P1646, DOI 10.1001/archopht.116.12.1646
   KLEIN ML, 1994, ARCH OPHTHALMOL-CHIC, V112, P932, DOI 10.1001/archopht.1994.01090190080025
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   Little RJA, 1987, STAT ANAL MISSING DA
   Majewski J, 2003, AM J HUM GENET, V73, P540, DOI 10.1086/377701
   MARESPERLMAN JA, 1995, ARCH OPHTHALMOL-CHIC, V113, P743, DOI 10.1001/archopht.1995.01100060069034
   MELROSE MA, 1985, OPHTHALMIC SURG LAS, V16, P648
   MEYERS SM, 1995, AM J OPHTHALMOL, V120, P757, DOI 10.1016/S0002-9394(14)72729-1
   Neale M.C., 1992, METHODOLOGY GENETIC
   NEALE MC, 1989, BEHAV GENET, V19, P163, DOI 10.1007/BF01065901
   NEALE MC, 1993, BEHAV GENET, V23, P271, DOI 10.1007/BF01082466
   NEALE MC, 1994, BEHAV GENET, V24, P239, DOI 10.1007/BF01067191
   PIGUET B, 1993, BRIT J OPHTHALMOL, V77, P400, DOI 10.1136/bjo.77.7.400
   *PREV BLIND AM, 2002, VIS PROBL US PREV AD
   Reed T, 2003, TWIN RES, V6, P227, DOI 10.1375/136905203765693889
   Schick JH, 2003, AM J HUM GENET, V72, P1412, DOI 10.1086/375500
   Schultz DW, 2003, HUM MOL GENET, V12, P3315, DOI 10.1093/hmg/ddg348
   SEDDON J, 1994, INVEST OPHTH VIS SCI, V3454, pS2003
   Seddon J, 2001, RETINA-J RET VIT DIS, P1039
   Seddon J. M., 1997, Investigative Ophthalmology and Visual Science, V38, pS676
   SEDDON JM, 1990, INVEST OPHTH VIS SCI, V31, P1592
   Seddon JM, 2004, JAMA-J AM MED ASSOC, V291, P704, DOI 10.1001/jama.291.6.704
   Seddon JM, 2003, ARCH OPHTHALMOL-CHIC, V121, P1728, DOI 10.1001/archopht.121.12.1728
   Seddon JM, 2003, AM J HUM GENET, V73, P780, DOI 10.1086/378505
   Seddon JM, 2003, ARCH OPHTHALMOL-CHIC, V121, P785, DOI 10.1001/archopht.121.6.785
   Seddon JM, 1996, JAMA-J AM MED ASSOC, V276, P1141, DOI 10.1001/jama.276.14.1141
   Seddon JM, 1997, AM J OPHTHALMOL, V123, P199, DOI 10.1016/S0002-9394(14)71036-0
   SEDDON JM, 1994, JAMA-J AM MED ASSOC, V272, P1413, DOI 10.1001/jama.272.18.1413
   Seddon JM, 2001, ARCH OPHTHALMOL-CHIC, V119, P1191, DOI 10.1001/archopht.119.8.1191
   Smith W, 2001, OPHTHALMOLOGY, V108, P697, DOI 10.1016/S0161-6420(00)00580-7
   Snow K K, 1999, Ophthalmic Epidemiol, V6, P125, DOI 10.1076/opep.6.2.125.1558
   SPERDUTO RD, 1986, ARCH OPHTHALMOL-CHIC, V104, P216
   Stone EM, 2004, NEW ENGL J MED, V351, P346, DOI 10.1056/NEJMoa040833
   Tanner CM, 1999, JAMA-J AM MED ASSOC, V281, P341, DOI 10.1001/jama.281.4.341
   VandenLangenberg GM, 1998, AM J EPIDEMIOL, V148, P204, DOI 10.1093/oxfordjournals.aje.a009625
   Wade T, 1999, BEHAV GENET, V29, P1, DOI 10.1023/A:1021429604095
   Weeks DE, 2001, AM J OPHTHALMOL, V132, P682, DOI 10.1016/S0002-9394(01)01214-4
   YANNUZZI LA, 1992, ARCH OPHTHALMOL-CHIC, V110, P1701
NR 56
TC 297
Z9 306
U1 0
U2 19
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 0003-9950
EI 1538-3601
J9 ARCH OPHTHALMOL-CHIC
JI Arch. Ophthalmol.
PD MAR
PY 2005
VL 123
IS 3
BP 321
EP 327
DI 10.1001/archopht.123.3.321
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 903SV
UT WOS:000227446800002
PM 15767473
OA Bronze
DA 2022-11-30
ER

PT J
AU Uno, K
   Bhutto, IA
   McLeod, DS
   Merges, C
   Lutty, GA
AF Uno, K
   Bhutto, IA
   McLeod, DS
   Merges, C
   Lutty, GA
TI Impaired expression of thrombospondin-1 in eyes with age related macular
   degeneration
SO BRITISH JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID THROMBIN-SENSITIVE PROTEIN; BRUCHS MEMBRANE; HUMAN RETINA; TGF-BETA;
   ANGIOGENESIS; LOCALIZATION; INHIBITION; DRUSEN
AB Aims: This study investigated the expression and localisation of thrombospondin-1 ( TSP-1), a known antiangiogenic extracellular matrix protein, in normal aged control human eyes and eyes with age related macular degeneration ( AMD).
   Methods: Immunohistochemical analysis with mouse anti-human TSP-1 antibody and mouse anti-human CD 34 antibody, as a blood vessel marker, was performed on frozen sections from macular and peripheral blocks of aged control donor eyes ( n = 12; mean age 78.8 years), and eyes with AMD ( n = 12; mean age 83.9 years). Pigment in retinal pigment epithelium ( RPE) and choroidal melanocytes was bleached. Three independent observers scored the immunohistochemical reaction product.
   Results: In the macular region, TSP-1 expression was observed intensely in Bruch's membrane and weakly in RPE basement membrane, choriocapillaris, and the wall of large choroidal blood vessels in the aged control eyes. In eyes with AMD, TSP-1 immunoreactivity was significantly lower in all structures except RPE basement membrane ( p < 0.01). There was significantly lower TSP-1 in the far periphery than the equator and submacular regions in all eyes. TSP-1 immunoreactivity was low in choroidal neovascularisation ( CNV), but it was high and diffuse in adjacent scar tissue.
   Conclusion: These findings suggest that decreased TSP-1 in Bruch's membrane and choroidal vessels during AMD may permit the formation of CNV.
C1 Johns Hopkins Univ Hosp, Wilmer Ophthalmol Inst, Dept Ophthalmol, Baltimore, MD 21287 USA.
   Fukuoka Univ, Dept Ophthalmol, Sch Med, Jonan Ku, Fukuoka 8140180, Japan.
C3 Johns Hopkins University; Johns Hopkins Medicine; Fukuoka University
RP Lutty, GA (通讯作者)，Johns Hopkins Univ Hosp, Wilmer Ophthalmol Inst, Dept Ophthalmol, Woods Res Bldg,600 N Wolfe St, Baltimore, MD 21287 USA.
EM galutty@jhmi.edu
FU NATIONAL EYE INSTITUTE [R01EY016151, P30EY001765] Funding Source: NIH
   RePORTER; NEI NIH HHS [EY-01765, R01 EY016151] Funding Source: Medline
CR ARBEILLE BB, 1991, J HISTOCHEM CYTOCHEM, V39, P1367, DOI 10.1177/39.10.1940308
   BAENZIGE.NL, 1971, P NATL ACAD SCI USA, V68, P240, DOI 10.1073/pnas.68.1.240
   BAENZIGER NL, 1972, J BIOL CHEM, V247, P2723
   Bhutto IA, 2004, INVEST OPHTH VIS SCI, V45, P1544, DOI 10.1167/iovs.03-0862
   BHUTTO IA, 2005, IN PRESS EXP EYE RES
   Chong NHV, 2005, AM J PATHOL, V166, P241, DOI 10.1016/S0002-9440(10)62248-1
   Curcio CA, 1999, ARCH OPHTHALMOL-CHIC, V117, P329, DOI 10.1001/archopht.117.3.329
   DAS A, 1990, ARCH OPHTHALMOL-CHIC, V108, P421, DOI 10.1001/archopht.1990.01070050119045
   Dawson DW, 1997, J CELL BIOL, V138, P707, DOI 10.1083/jcb.138.3.707
   GREEN WR, 1993, OPHTHALMOLOGY, V100, P1519
   GREEN WR, 1985, OPHTHALMOLOGY, V92, P615
   Guymer R, 1999, PROG RETIN EYE RES, V18, P59, DOI 10.1016/S1350-9462(98)00012-3
   Handa JT, 1999, INVEST OPHTH VIS SCI, V40, P775
   Harman AM, 1997, INVEST OPHTH VIS SCI, V38, P2016
   HEWITT AT, 1989, INVEST OPHTH VIS SCI, V30, P478
   Iruela-Arispe ML, 1999, CIRCULATION, V100, P1423, DOI 10.1161/01.CIR.100.13.1423
   JAFFE EA, 1985, BLOOD, V65, P79
   Jimenez B, 2000, NAT MED, V6, P41, DOI 10.1038/71517
   Klein R, 1997, OPHTHALMOLOGY, V104, P7, DOI 10.1016/S0161-6420(97)30368-6
   LUTTY GA, 1993, INVEST OPHTH VIS SCI, V34, P477
   MCLEOD DS, 1995, AM J PATHOL, V147, P642
   Mimura Y, 2005, AM J PATHOL, V166, P1451, DOI 10.1016/S0002-9440(10)62362-0
   Miyajima-Uchida H, 2000, INVEST OPHTH VIS SCI, V41, P561
   Nakagawa T, 2004, KIDNEY INT, V66, P605, DOI 10.1111/j.1523-1755.2004.00780.x
   RAUGI GJ, 1982, J CELL BIOL, V95, P351, DOI 10.1083/jcb.95.1.351
   REED MJ, 1995, AM J PATHOL, V147, P1068
   Roth F, 2004, GRAEF ARCH CLIN EXP, V242, P710, DOI 10.1007/s00417-004-0976-x
   SARKS SH, 1976, BRIT J OPHTHALMOL, V60, P324, DOI 10.1136/bjo.60.5.324
   Sheibani N, 2000, BIOCHEM BIOPH RES CO, V267, P257, DOI 10.1006/bbrc.1999.1903
   Spraul CW, 1997, ARCH OPHTHALMOL-CHIC, V115, P267, DOI 10.1001/archopht.1997.01100150269022
   Stenina OI, 2003, CIRCULATION, V107, P3209, DOI 10.1161/01.CIR.0000074223.56882.97
   TOLSMA SS, 1993, J CELL BIOL, V122, P497, DOI 10.1083/jcb.122.2.497
   Uchida H, 2005, EXP EYE RES, V80, P23, DOI 10.1016/j.exer.2004.08.004
   WIGHT TN, 1985, J HISTOCHEM CYTOCHEM, V33, P295, DOI 10.1177/33.4.3884704
   Witmer AN, 2003, PROG RETIN EYE RES, V22, P1, DOI 10.1016/S1350-9462(02)00043-5
   Zarbin MA, 2004, ARCH OPHTHALMOL-CHIC, V122, P598, DOI 10.1001/archopht.122.4.598
NR 36
TC 50
Z9 52
U1 0
U2 1
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0007-1161
EI 1468-2079
J9 BRIT J OPHTHALMOL
JI Br. J. Ophthalmol.
PD JAN
PY 2006
VL 90
IS 1
BP 48
EP 54
DI 10.1136/bjo.2005.074005
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 993YD
UT WOS:000233994900016
PM 16361667
OA Green Published, Bronze
DA 2022-11-30
ER

PT J
AU van Leeuwen, R
   Klaver, CCW
   Vingerling, JR
   Hofman, A
   de Jong, PTVM
AF van Leeuwen, R
   Klaver, CCW
   Vingerling, JR
   Hofman, A
   de Jong, PTVM
TI Epidemiology of age-related maculopathy: a review
SO EUROPEAN JOURNAL OF EPIDEMIOLOGY
LA English
DT Review
DE age-related macular degeneration; age-related maculopathy; epidemiology;
   review
ID BEAVER-DAM-EYE; BLUE-MOUNTAINS-EYE; SENILE MACULAR DEGENERATION;
   APOLIPOPROTEIN-E GENE; NUTRITION EXAMINATION SURVEY; RISK-FACTORS;
   5-YEAR INCIDENCE; CARDIOVASCULAR-DISEASE; ALCOHOL-CONSUMPTION;
   CIGARETTE-SMOKING
AB Age-related maculopathy (ARM) is a degenerative disease of the retina and the leading cause of incurable blindness and visual impairment in industrialized countries. By definition, ARM is confined to the age-category above 50 years. The aetiology of ARM is still unknown, despite intensive research on many fronts. In this paper, we provide a review of the epidemiology of ARM. The most prominent findings were an exponential increase in frequency with age, a significant familial and genetic component, and a strong association with smoking. Other risk factors that were found less consistently were atherosclerosis, low intake of antioxidant nutrients, and cataract extraction. Future studies, both observational and experimental, will hopefully identify more risk factors that are amenable to prevention.
C1 Netherlands Ophthalm Res Inst, KNAW, NL-1105 BA Amsterdam, Netherlands.
   Erasmus Med Ctr, Dept Epidemiol & Biostat, Rotterdam, Netherlands.
   Erasmus Med Ctr, Dept Ophthalmol, Rotterdam, Netherlands.
   Univ Amsterdam, Acad Med Ctr, Dept Ophthalmol, NL-1105 AZ Amsterdam, Netherlands.
C3 Royal Netherlands Academy of Arts & Sciences; Netherlands Institute for
   Neuroscience (NIN-KNAW); Erasmus University Rotterdam; Erasmus MC;
   Erasmus University Rotterdam; Erasmus MC; University of Amsterdam;
   Academic Medical Center Amsterdam
RP de Jong, PTVM (通讯作者)，Netherlands Ophthalm Res Inst, KNAW, Meibergdreef 47, NL-1105 BA Amsterdam, Netherlands.
RI Klaver, Caroline C.W./A-2013-2016
OI Klaver, Caroline/0000-0002-2355-5258
CR Ajani UA, 1999, ANN EPIDEMIOL, V9, P172, DOI 10.1016/S1047-2797(98)00053-2
   Allikmets R, 2000, AM J HUM GENET, V67, P487, DOI 10.1086/303018
   Allikmets R, 1997, SCIENCE, V277, P1805, DOI 10.1126/science.277.5333.1805
   Ambati J, 2003, SURV OPHTHALMOL, V48, P257, DOI 10.1016/S0039-6257(03)00030-4
   Anand R, 2000, OPHTHALMOLOGY, V107, P2224
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   Berendschot TTJM, 2002, INVEST OPHTH VIS SCI, V43, P1928
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   BORGER PH, 2003, IN PRESS OPHTHALMOLO, V110
   BRESSLER NM, 1995, ARCH OPHTHALMOL-CHIC, V113, P301, DOI 10.1001/archopht.1995.01100030055022
   BRESSLER NM, 1989, ARCH OPHTHALMOL-CHIC, V107, P847, DOI 10.1001/archopht.1989.01070010869032
   Cai J, 2002, EYE, V16, P242, DOI 10.1038/sj.eye.6700133
   Cai JY, 2000, PROG RETIN EYE RES, V19, P205, DOI 10.1016/S1350-9462(99)00009-9
   Cho EY, 2001, ANN EPIDEMIOL, V11, P328, DOI 10.1016/S1047-2797(01)00217-4
   Cho EY, 2000, ARCH OPHTHALMOL-CHIC, V118, P681, DOI 10.1001/archopht.118.5.681
   Christen WG, 1999, AM J EPIDEMIOL, V149, P476, DOI 10.1093/oxfordjournals.aje.a009836
   Christen WG, 1996, JAMA-J AM MED ASSOC, V276, P1147, DOI 10.1001/jama.276.14.1147
   CRUICKSHANKS KJ, 1993, ARCH OPHTHALMOL-CHIC, V111, P514, DOI 10.1001/archopht.1993.01090040106042
   Cruickshanks KJ, 1997, ARCH OPHTHALMOL-CHIC, V115, P242, DOI 10.1001/archopht.1997.01100150244015
   Cruickshanks KJ, 2001, ARCH OPHTHALMOL-CHIC, V119, P246
   de Jong PTVM, 2001, EYE, V15, P396, DOI 10.1038/eye.2001.143
   Delcourt C, 1999, ARCH OPHTHALMOL-CHIC, V117, P1384, DOI 10.1001/archopht.117.10.1384
   Delcourt C, 1998, ARCH OPHTHALMOL-CHIC, V116, P1031, DOI 10.1001/archopht.116.8.1031
   Delcourt C, 2001, Ophthalmic Epidemiol, V8, P237, DOI 10.1076/opep.8.4.237.1613
   Evans JR, 2001, PROG RETIN EYE RES, V20, P227, DOI 10.1016/S1350-9462(00)00023-9
   Flood V, 2002, OPHTHALMOLOGY, V109, P2272, DOI 10.1016/S0161-6420(02)01263-0
   GOLDBERG J, 1988, AM J EPIDEMIOL, V128, P700, DOI 10.1093/oxfordjournals.aje.a115023
   Hammond CJ, 2001, INVEST OPHTH VIS SCI, V42, pS310
   HEIBA IM, 1994, GENET EPIDEMIOL, V11, P51, DOI 10.1002/gepi.1370110106
   HOLZ FG, 1994, AM J OPHTHALMOL, V117, P19, DOI 10.1016/S0002-9394(14)73010-7
   HOLZ FG, 1994, ARCH OPHTHALMOL-CHIC, V112, P402, DOI 10.1001/archopht.1994.01090150132035
   Hyman L, 2000, ARCH OPHTHALMOL-CHIC, V118, P351, DOI 10.1001/archopht.118.3.351
   HYMAN LG, 1983, AM J EPIDEMIOL, V118, P213, DOI 10.1093/oxfordjournals.aje.a113629
   Ikeda T, 2001, AM J OPHTHALMOL, V132, P191, DOI 10.1016/S0002-9394(01)00975-8
   IKRAM MK, IN PRESS INVEST OPHT
   JAMPOL LM, 1992, ARCH OPHTHALMOL-CHIC, V110, P1699, DOI 10.1001/archopht.1992.01080240039024
   Jonasson F, 2003, ARCH OPHTHALMOL-CHIC, V121, P379, DOI 10.1001/archopht.121.3.379
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Kimura K, 2000, AM J OPHTHALMOL, V130, P769, DOI 10.1016/S0002-9394(00)00552-3
   Klaver CCW, 1998, AM J HUM GENET, V63, P200, DOI 10.1086/301901
   Klaver CCW, 1998, ARCH OPHTHALMOL-CHIC, V116, P1646, DOI 10.1001/archopht.116.12.1646
   Klaver CCW, 1999, AM J EPIDEMIOL, V150, P963
   Klein B E, 1994, Trans Am Ophthalmol Soc, V92, P289
   Klein BEK, 2000, AM J OPHTHALMOL, V130, P322, DOI 10.1016/S0002-9394(00)00474-8
   KLEIN ML, 1994, ARCH OPHTHALMOL-CHIC, V112, P932, DOI 10.1001/archopht.1994.01090190080025
   Klein R, 1998, AM J EPIDEMIOL, V147, P103
   Klein R, 1998, ARCH OPHTHALMOL-CHIC, V116, P506, DOI 10.1001/archopht.116.4.506
   Klein R, 1997, OPHTHALMOLOGY, V104, P7, DOI 10.1016/S0161-6420(97)30368-6
   Klein R, 2003, OPHTHALMOLOGY, V110, P25, DOI 10.1016/S0161-6420(02)01565-8
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Klein R, 1997, OPHTHALMOLOGY, V104, P1804, DOI 10.1016/S0161-6420(97)30023-2
   Klein R, 2002, ARCH OPHTHALMOL-CHIC, V120, P1551, DOI 10.1001/archopht.120.11.1551
   Klein R, 2002, AM J EPIDEMIOL, V156, P589, DOI 10.1093/aje/kwf092
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P1527
   Klein R, 1998, ARCH OPHTHALMOL-CHIC, V116, P360, DOI 10.1001/archopht.116.3.360
   Klein R, 1999, OPHTHALMOLOGY, V106, P1056, DOI 10.1016/S0161-6420(99)90255-5
   KLEIN R, 1994, ARCH OPHTHALMOL-CHIC, V112, P191, DOI 10.1001/archopht.1994.01090140067025
   Klein R, 1999, PROG RETIN EYE RES, V18, P371, DOI 10.1016/S1350-9462(98)00025-1
   KLEIN R, 1993, OPHTHALMOLOGY, V100, P406
   Maguire MG, 1997, ARCH OPHTHALMOL-CHIC, V115, P741
   MALEK G, 2003, INVEST OPHTHALMOL VI, V44
   MALTZMAN BA, 1979, ANN OPHTHALMOL, V11, P1197
   MaresPerlman JA, 1996, ARCH OPHTHALMOL-CHIC, V114, P991, DOI 10.1001/archopht.1996.01100140199014
   MARESPERLMAN JA, 1995, ARCH OPHTHALMOL-CHIC, V113, P743, DOI 10.1001/archopht.1995.01100060069034
   MARESPERLMAN JA, 1995, ARCH OPHTHALMOL-CHIC, V113, P1518, DOI 10.1001/archopht.1995.01100120048007
   McCarty CA, 2001, ARCH OPHTHALMOL-CHIC, V119, P1455
   Mitchell P, 2002, OPHTHALMOLOGY, V109, P1092, DOI 10.1016/S0161-6420(02)01055-2
   Mitchell P, 1998, OPHTHALMOLOGY, V105, P1359, DOI 10.1016/S0161-6420(98)98013-7
   MITCHELL P, 1995, OPHTHALMOLOGY, V102, P1450
   Moss SE, 1998, OPHTHALMOLOGY, V105, P789, DOI 10.1016/S0161-6420(98)95016-3
   Mullins RF, 2000, FASEB J, V14, P835, DOI 10.1096/fasebj.14.7.835
   NEWSOME DA, 1988, ARCH OPHTHALMOL-CHIC, V106, P192
   Ong JM, 2001, INVEST OPHTH VIS SCI, V42, P1891
   PAETKAU ME, 1978, CAN J OPHTHALMOL, V13, P67
   Pang CP, 2000, OPHTHALMOLOGICA, V214, P289, DOI 10.1159/000027506
   Pollack A, 1996, OPHTHALMOLOGY, V103, P1546, DOI 10.1016/S0161-6420(96)30464-8
   RITTER LL, 1995, AM J OPHTHALMOL, V120, P190, DOI 10.1016/S0002-9394(14)72607-8
   ROSENTHAL FS, 1991, HEALTH PHYS, V61, P77, DOI 10.1097/00004032-199107000-00008
   SANDBERG MA, 1993, OPHTHALMOLOGY, V100, P1009
   SANDERS TAB, 1993, AM J CLIN NUTR, V57, P428, DOI 10.1093/ajcn/57.3.428
   SCHACHAT AP, 1995, ARCH OPHTHALMOL-CHIC, V113, P728, DOI 10.1001/archopht.1995.01100060054032
   Schick JH, 2003, AM J HUM GENET, V72, P1412, DOI 10.1086/375500
   Schmidt S, 2000, MOL VIS, V6, P287
   Schultz DW, 2003, ARCH OPHTHALMOL-CHIC, V121, P679, DOI 10.1001/archopht.121.5.679
   SCHULTZ DW, 2003, INVEST OPHTHALMOL VI, V44
   Seddon JM, 1996, JAMA-J AM MED ASSOC, V276, P1141, DOI 10.1001/jama.276.14.1141
   Seddon JM, 1997, AM J OPHTHALMOL, V123, P199, DOI 10.1016/S0002-9394(14)71036-0
   SEDDON JM, 1994, JAMA-J AM MED ASSOC, V272, P1413, DOI 10.1001/jama.272.18.1413
   Seddon JM, 2001, ARCH OPHTHALMOL-CHIC, V119, P1191, DOI 10.1001/archopht.119.8.1191
   Simonelli F, 2001, OPHTHALMIC RES, V33, P325, DOI 10.1159/000055688
   Smith W, 1999, OPHTHALMOLOGY, V106, P761, DOI 10.1016/S0161-6420(99)90164-1
   Smith W, 1998, ARCH OPHTHALMOL-CHIC, V116, P583, DOI 10.1001/archopht.116.5.583
   Smith W, 1997, AUST NZ J OPHTHALMOL, V25, pS13
   Smith W, 1996, ARCH OPHTHALMOL-CHIC, V114, P1518, DOI 10.1001/archopht.1996.01100140716016
   Smith W, 2001, OPHTHALMOLOGY, V108, P697, DOI 10.1016/S0161-6420(00)00580-7
   Smith W, 1996, AM J OPHTHALMOL, V122, P743, DOI 10.1016/S0002-9394(14)70503-3
   Smith W, 1997, AM J OPHTHALMOL, V124, P838, DOI 10.1016/S0002-9394(14)71702-7
   Smith W, 2000, ARCH OPHTHALMOL-CHIC, V118, P401, DOI 10.1001/archopht.118.3.401
   Solberg Y, 1998, SURV OPHTHALMOL, V42, P535, DOI 10.1016/S0039-6257(98)00002-2
   Souied EH, 1998, AM J OPHTHALMOL, V125, P353, DOI 10.1016/S0002-9394(99)80146-9
   SPERDUTO RD, 1990, ARCH OPHTHALMOL-CHIC, V108, P1403, DOI 10.1001/archopht.1990.01070120051026
   SPERDUTO RD, 1993, ARCH OPHTHALMOL-CHIC, V111, P104
   SPERDUTO RD, 1986, ARCH OPHTHALMOL-CHIC, V104, P216
   Stone EM, 1998, NAT GENET, V20, P328, DOI 10.1038/3798
   Stur M, 1996, INVEST OPHTH VIS SCI, V37, P1225
   Taylor H R, 1990, Trans Am Ophthalmol Soc, V88, P163
   Taylor HR, 2002, BMJ-BRIT MED J, V325, P11, DOI 10.1136/bmj.325.7354.11
   van Leeuwen R, 2003, ARCH OPHTHALMOL-CHIC, V121, P519, DOI 10.1001/archopht.121.4.519
   VandenLangenberg GM, 1998, AM J EPIDEMIOL, V148, P204, DOI 10.1093/oxfordjournals.aje.a009625
   VANDERSCHAFT TL, 1994, BRIT J OPHTHALMOL, V78, P441, DOI 10.1136/bjo.78.6.441
   VANLEEUWEN R, IN PRESS INVEST OPHT
   VINDING T, 1990, ACTA OPHTHALMOL, V68, P53
   VINGERLING JR, 1995, AM J EPIDEMIOL, V142, P404, DOI 10.1093/oxfordjournals.aje.a117648
   VINGERLING JR, 1995, OPHTHALMOLOGY, V102, P205
   VINGERLING JR, 1995, BRIT MED J, V310, P1570, DOI 10.1136/bmj.310.6994.1570
   Vingerling JR, 1996, ARCH OPHTHALMOL-CHIC, V114, P1193, DOI 10.1001/archopht.1996.01100140393005
   Wang JJ, 1998, INVEST OPHTH VIS SCI, V39, P2167
   Weeks DE, 2000, HUM MOL GENET, V9, P1329, DOI 10.1093/hmg/9.9.1329
   Weeks DE, 2001, AM J OPHTHALMOL, V132, P682, DOI 10.1016/S0002-9394(01)01214-4
   WEITER JJ, 1985, AM J OPHTHALMOL, V99, P185, DOI 10.1016/0002-9394(85)90230-2
   Weng J, 1999, CELL, V98, P13, DOI 10.1016/S0092-8674(00)80602-9
   WEST S, 1994, ARCH OPHTHALMOL-CHIC, V112, P222, DOI 10.1001/archopht.1994.01090140098031
   WEST SK, 1989, ARCH OPHTHALMOL-CHIC, V107, P875, DOI 10.1001/archopht.1989.01070010897038
   YANNUZZI LA, 1992, ARCH OPHTHALMOL-CHIC, V110, P1701
   YOUNG RW, 1988, SURV OPHTHALMOL, V32, P252, DOI 10.1016/0039-6257(88)90174-9
NR 125
TC 152
Z9 163
U1 0
U2 12
PU KLUWER ACADEMIC PUBL
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0393-2990
J9 EUR J EPIDEMIOL
JI Eur. J. Epidemiol.
PD SEP
PY 2003
VL 18
IS 9
BP 845
EP 854
DI 10.1023/A:1025643303914
PG 10
WC Public, Environmental & Occupational Health
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Public, Environmental & Occupational Health
GA 718CP
UT WOS:000185127800003
PM 14561043
DA 2022-11-30
ER

PT J
AU Ma, L
   Wang, YF
   Du, JH
   Wang, MX
   Zhang, R
   Fu, YH
AF Ma, Le
   Wang, Yafeng
   Du, Junhui
   Wang, Mingxu
   Zhang, Rui
   Fu, Yihao
TI The association between statin use and risk of age-related macular
   degeneration
SO SCIENTIFIC REPORTS
LA English
DT Article
ID A REDUCTASE INHIBITORS; CARDIOVASCULAR-DISEASE; INFLAMMATION;
   METAANALYSIS; PROGRESSION; HEALTH; COHORT
AB The aim of the present study was to evaluate the association between statin use and the risk of age-related macular degeneration (AMD). A systematic search of the PubMed, EMBASE and ISI web of science databases was used to identify eligible published literatures without language restrictions up to April 2015. Summary relative ratios (RRs) and 95% CIs were estimated using a fixed-effect or random-effects model. A total of 14 studies met the inclusion criteria and were included in this meta-analysis. No significant association was observed between statin use and the risk of any AMD (RR, 0.95; 95% CI, 0.74-1.15); and stratified analysis showed that statins had a significantly different effects on early and late stages of AMD. For early AMD, statin use significantly reduced the risk approximately 17% (RR, 0.83; 95% CI, 0.66-0.99). At the late stage, we observed a significant protective association of statin use with exudative AMD (RR, 0.90; 95% CI, 0.80-0.99), in contrast with the absent association between statins and geographic atrophy (RR, 1.16; 95% CI, 0.77-1.56). These results demonstrated that statin use was protective for early and exudative AMD. Additional large prospective cohort studies and RCTs are required to determine the potential effect of statins on AMD prevention.
C1 [Ma, Le; Wang, Yafeng; Wang, Mingxu; Zhang, Rui] Xi An Jiao Tong Univ, Hlth Sci Ctr, Sch Publ Hlth, Xian 710049, Peoples R China.
   [Ma, Le] Xi An Jiao Tong Univ, Key Lab Environm & Genes Related Dis, Minist Educ China, Xian 710049, Peoples R China.
   [Du, Junhui] Xi An Jiao Tong Univ, Xian Hosp 9, Hlth Sci Ctr, Xian 710049, Peoples R China.
   [Fu, Yihao] Univ New S Wales, Australian Sch Business, Sydney, NSW, Australia.
C3 Xi'an Jiaotong University; Ministry of Education, China; Xi'an Jiaotong
   University; Xi'an Jiaotong University; University of New South Wales
   Sydney
RP Ma, L (通讯作者)，Xi An Jiao Tong Univ, Hlth Sci Ctr, Sch Publ Hlth, Xian 710049, Peoples R China.
EM male@mail.xjtu.edu.cn; wangmx601@mail.xjtu.edu.cn
RI Du, junhui/P-3183-2019; wang, yafeng/J-4829-2017
OI Du, junhui/0000-0001-6692-3877; ma, le/0000-0001-7592-9779
FU National Natural Science Foundation of China [NSFC-81202198,
   NSFC-81473059]; Natural Science Foundation of Shaanxi Province of China
   [2013JQ4008]; New-star Plan of Science and Technology of Shaanxi
   Province [2015LJXX-07]; China Postdoctoral Science Special Foundation
   [2015T81036]; China Postdoctoral Science Foundation [2014M560790]
FX This study was partially supported by grants from the National Natural
   Science Foundation of China (NSFC-81202198, NSFC-81473059); the Natural
   Science Foundation of Shaanxi Province of China (2013JQ4008); New-star
   Plan of Science and Technology of Shaanxi Province (2015LJXX-07); the
   China Postdoctoral Science Special Foundation (2015T81036); and the
   China Postdoctoral Science Foundation Funded Project (2014M560790).
CR Abu-Asab MS, 2013, J OPHTHALMOL, V2013, DOI 10.1155/2013/453934
   Ardeljan CP, 2014, J CLIN MED, V3, P1542, DOI 10.3390/jcm3041542
   Barbosa DTQ, 2014, EYE, V28, P472, DOI 10.1038/eye.2014.8
   BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   Beri A, 2009, AM J CARDIOVASC DRUG, V9, P361, DOI 10.2165/11315710-000000000-00000
   Cackett P, 2008, AM J OPHTHALMOL, V146, P960, DOI 10.1016/j.ajo.2008.06.026
   Campagne MV, 2014, J PATHOL, V232, P151, DOI 10.1002/path.4266
   Chen J, 2007, J CLIN INVEST, V117, P2758, DOI 10.1172/JCI33513
   Chinwong D, 2015, THER CLIN RISK MANAG, V11, P127, DOI 10.2147/TCRM.S75608
   Chuo JY, 2007, OPHTHAL EPIDEMIOL, V14, P367, DOI 10.1080/09286580701421684
   Colak E, 2012, BIOCHEM MEDICA, V22, P39
   Collins R, 2002, LANCET, V360, P7, DOI 10.1016/S0140-6736(02)09327-3
   Cougnard-Gregoire A, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0090973
   Curcio CA, 2013, RETINA-J RET VIT DIS, V33, P265, DOI 10.1097/IAE.0b013e31827e25e0
   Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   Erke MG, 2014, ACTA OPHTHALMOL, V92, P662, DOI 10.1111/aos.12346
   Etminan M, 2008, CURR DRUG SAF, V3, P24, DOI 10.2174/157488608783333952
   Fong DS, 2010, AM J OPHTHALMOL, V149, P955, DOI 10.1016/j.ajo.2009.12.037
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Kim SY, 2002, RETINA-J RET VIT DIS, V22, P471, DOI 10.1097/00006982-200208000-00012
   Klein R, 2003, ARCH OPHTHALMOL-CHIC, V121, P1151, DOI 10.1001/archopht.121.8.1151
   Klein R, 2007, ARCH OPHTHALMOL-CHIC, V125, P534, DOI 10.1001/archopht.125.4.534
   Klein R, 2014, AM J OPHTHALMOL, V158, P513, DOI 10.1016/j.ajo.2014.05.027
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Maguire MG, 2009, OPHTHALMOLOGY, V116, P2381, DOI 10.1016/j.ophtha.2009.06.055
   McGwin G, 2006, ARCH OPHTHALMOL-CHIC, V124, P33, DOI 10.1001/archopht.124.1.33
   McGwin G, 2003, BRIT J OPHTHALMOL, V87, P1121, DOI 10.1136/bjo.87.9.1121
   Moher D, 1999, LANCET, V354, P1896, DOI 10.1016/S0140-6736(99)04149-5
   Ridker PM, 1999, CIRCULATION, V100, P230, DOI 10.1161/01.CIR.100.3.230
   Seddon JM, 2004, JAMA-J AM MED ASSOC, V291, P704, DOI 10.1001/jama.291.6.704
   Seddon JM, 2011, OPHTHALMOLOGY, V118, P2203, DOI 10.1016/j.ophtha.2011.04.029
   Smeeth L, 2005, BRIT J OPHTHALMOL, V89, P1171, DOI 10.1136/bjo.2004.064477
   Smeeth L, 2009, BRIT J CLIN PHARMACO, V67, P99, DOI 10.1111/j.1365-2125.2008.03308.x
   Stroup DF, 2000, JAMA-J AM MED ASSOC, V283, P2008, DOI 10.1001/jama.283.15.2008
   Tan JSL, 2007, AM J OPHTHALMOL, V143, P685, DOI 10.1016/j.ajo.2006.11.021
   Vine AK, 2005, OPHTHALMOLOGY, V112, P2076, DOI 10.1016/j.ophtha.2005.07.004
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Wu J, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0089600
   Xu Y, 2014, PHARMACOL RES, V87, P18, DOI 10.1016/j.phrs.2014.06.006
NR 39
TC 20
Z9 21
U1 0
U2 11
PU NATURE PORTFOLIO
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
SN 2045-2322
J9 SCI REP-UK
JI Sci Rep
PD DEC 14
PY 2015
VL 5
AR 18280
DI 10.1038/srep18280
PG 8
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA CY3FE
UT WOS:000366293100002
PM 26658620
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Anand, A
   Sharma, NK
   Gupta, A
   Prabhakar, S
   Sharma, SK
   Singh, R
AF Anand, Akshay
   Sharma, Neel K.
   Gupta, Amod
   Prabhakar, Sudesh
   Sharma, Suresh K.
   Singh, Ramandeep
TI Superoxide Dismutase1 Levels in North Indian Population with Age-Related
   Macular Degeneration
SO OXIDATIVE MEDICINE AND CELLULAR LONGEVITY
LA English
DT Article
ID ENDOTHELIAL GROWTH-FACTOR; OXIDATIVE STRESS; ROC CURVE; OVEREXPRESSION;
   ANTIOXIDANTS; SPECIFICITY; SENSITIVITY; RESISTANCE; MECHANISM; DISEASE
AB Aim. The aim of the study was to estimate the levels of superoxide dismutase1 (SOD1) in patients of age-related macular degeneration (AMD) and examine the role of oxidative stress, smoking, hypertension, and other factors involved in the pathogenesis of AMD. Methods. 115 AMD patients and 61 healthy controls were recruited for this study. Serum SOD1 levels were determined by ELISA and were correlated to various risk factors. Logistic regression model of authenticity, by considering SOD1 as independent variable, has been developed along with ROC curve. Results. The SOD1 levels were significantly higher in AMD patients as compared to those of the controls. The difference was not significant for wet and dry AMD. However, the difference was significant between wet AMD subtypes. Nonsignificance of the Hosmer-Lemeshow goodness of fit statistic (chi(2) = 10.516, df = 8, P = 0.231) indicates the appropriateness of logistic regression model to predict AMD. Conclusion. Oxidative stress in AMD patients may mount compensatory response resulting in increased levels of SOD1 in AMD patients. To predict the risk of AMD on the basis of SOD1, a logistic regression model shows authenticity of 78%, and area under the ROC curve (0.827, P = .0001) with less standard error of 0.033 coupled with 95% confidence interval of 0.762-0.891 further validates the model.
C1 [Anand, Akshay; Sharma, Neel K.; Prabhakar, Sudesh] Postgrad Inst Med Educ & Res PGIMER, Dept Neurol, Chandigarh 160012, India.
   [Gupta, Amod; Singh, Ramandeep] Postgrad Inst Med Educ & Res PGIMER, Dept Ophthalmol, Chandigarh 160012, India.
   [Sharma, Suresh K.] Panjab Univ, Dept Stat, Chandigarh 160014, India.
C3 Post Graduate Institute of Medical Education & Research (PGIMER),
   Chandigarh; Post Graduate Institute of Medical Education & Research
   (PGIMER), Chandigarh; Panjab University
RP Anand, A (通讯作者)，Postgrad Inst Med Educ & Res PGIMER, Dept Neurol, Chandigarh 160012, India.
EM akshay1anand@rediffmail.com
RI anand, Akshay/AAI-1586-2019; Gupta, Amod/V-7633-2017
OI Gupta, Amod/0000-0001-8427-5738
FU Indian Council of Medical research, India [45/11/2010-HUM/BMS]
FX The study was carried out at the Department of Neurology, PGIMER,
   Chandigarh, India. We acknowledge Indian Council of Medical research,
   India for providing funds (45/11/2010-HUM/BMS). The funders had no role
   in study design, data collection and analysis, decision to publish, or
   preparation of the paper.
CR Anand A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0049905
   Andersen JK, 2004, NAT MED, V10, pS18, DOI 10.1038/nrn1434
   [Anonymous], 1997, DIAGNOSIS TREATMENT
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   Behndig A, 1998, INVEST OPHTH VIS SCI, V39, P471
   Bloch SB, 2012, AM J OPHTHALMOL, V153, P209, DOI 10.1016/j.ajo.2011.10.016
   CASTORINA C, 1992, NEUROCHEM RES, V17, P599, DOI 10.1007/BF00968789
   Coudray C, 1997, BIOL TRACE ELEM RES, V57, P183, DOI 10.1007/BF02778201
   Danis RP, 2013, INVEST OPHTH VIS SCI, V54, P4548, DOI 10.1167/iovs.13-11804
   Danulescu R., 2007, REV MEDICOCHIRURGICA, V116, P1136
   Dastjerdi MN, 2013, RES PHARM SCI, V8, P79
   Davies S., 1998, IOVS, V39, pS129
   Dhalla NS, 2000, J HYPERTENS, V18, P655, DOI 10.1097/00004872-200018060-00002
   El-Remessy AB, 2005, J CELL SCI, V118, P243, DOI 10.1242/jcs.01612
   Ellis EA, 1998, FREE RADICAL BIO MED, V24, P111, DOI 10.1016/S0891-5849(97)00202-5
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Finkel T, 2000, NATURE, V408, P239, DOI 10.1038/35041687
   Freund KB, 2013, EXPERT OPIN PHARMACO, V14, P1017, DOI 10.1517/14656566.2013.787410
   Harrison DG, 2009, MED CLIN N AM, V93, P621, DOI 10.1016/j.mcna.2009.02.015
   He Yuan, 2010, J Ocul Biol Dis Infor, V3, P92, DOI 10.1007/s12177-011-9061-y
   Jia LH, 2011, AGING CLIN EXP RES, V23, P264, DOI 10.1007/BF03324965
   Justilien V, 2007, INVEST OPHTH VIS SCI, V48, P4407, DOI 10.1167/iovs.07-0432
   Kalariya NM, 2008, EXP EYE RES, V86, P70, DOI 10.1016/j.exer.2007.09.010
   King A, 2004, PHOTOCHEM PHOTOBIOL, V79, P470, DOI 10.1562/LE-03-17.1
   Kowald A, 2006, J THEOR BIOL, V238, P828, DOI 10.1016/j.jtbi.2005.06.034
   Mak CM, 2008, CLIN CHEM, V54, P1356, DOI 10.1373/clinchem.2008.103432
   Marin-Castano ME, 2005, INVEST OPHTH VIS SCI, V46, P3331, DOI 10.1167/iovs.04-1224
   Medinas DB, 2010, FREE RADICAL BIO MED, V49, P682, DOI 10.1016/j.freeradbiomed.2010.04.040
   Ndrepepa G, 2007, CLIN RES CARDIOL, V96, P763, DOI 10.1007/s00392-007-0562-4
   Obrosova IG, 2001, DIABETOLOGIA, V44, P1102, DOI 10.1007/s001250100631
   ORR WC, 1992, ARCH BIOCHEM BIOPHYS, V297, P35, DOI 10.1016/0003-9861(92)90637-C
   REVEILLAUD I, 1991, MOL CELL BIOL, V11, P632, DOI 10.1128/MCB.11.2.632
   RIKANS LE, 1988, BIOCHIM BIOPHYS ACTA, V966, P269, DOI 10.1016/0304-4165(88)90076-1
   Samiec PS, 1998, FREE RADICAL BIO MED, V24, P699, DOI 10.1016/S0891-5849(97)00286-4
   Sharma NK, 2009, ANN NEUROSCI, V16, P62, DOI 10.5214/ans.0972.7531.2009.160208
   Sharma NK, 2012, CURR NEUROVASC RES, V9, P256
   Sharma NK, 2012, DNA CELL BIOL, V31, P1618, DOI 10.1089/dna.2012.1786
   Shen JK, 2007, HISTOL HISTOPATHOL, V22, P1301, DOI 10.14670/HH-22.1301
   Silverio SC, 2012, ANAL BIOCHEM, V421, P719, DOI 10.1016/j.ab.2011.12.020
   Takahashi A, 2004, BRAIN RES BULL, V62, P497, DOI 10.1016/j.brainresbull.2003.07.009
   Tin LL, 2002, J HUM HYPERTENS, V16, P147, DOI 10.1038/sj.jhh.1001373
   Ushio-Fukai M, 2002, CIRC RES, V91, P1160, DOI 10.1161/01.RES.0000046227.65158.F8
   Valentine JS, 2005, ANNU REV BIOCHEM, V74, P563, DOI 10.1146/annurev.biochem.72.121801.161647
   Wan QL, 2013, ASIAN PAC J CANCER P, V14, P2919, DOI 10.7314/APJCP.2013.14.5.2919
   Ying X, 2013, DIAGN PATHOL, V8, DOI 10.1186/1746-1596-8-130
   Zafrilla P, 2013, J NUTR HEALTH AGING, V17, P219, DOI 10.1007/s12603-012-0095-z
NR 46
TC 5
Z9 5
U1 0
U2 2
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 1942-0900
EI 1942-0994
J9 OXID MED CELL LONGEV
JI Oxidative Med. Cell. Longev.
PY 2013
VL 2013
AR 365046
DI 10.1155/2013/365046
PG 7
WC Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology
GA 265XG
UT WOS:000327985200001
PM 24363822
OA Green Published, Green Submitted, gold
DA 2022-11-30
ER

PT J
AU Gopalakrishnan, S
   Velu, S
   Raman, R
AF Gopalakrishnan, Sarika
   Velu, Saranya
   Raman, Rajiv
TI Low-vision intervention in individuals with age-related macular
   degeneration
SO INDIAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE Age-related macular degeneration; dome magnifier; low-vision; spectacle
   magnifier
ID PREVALENCE; PROGRESSION; IMPAIRMENT; DEVICES; IMPACT
AB Purpose: The objective of this study was to estimate the level of visual impairment in patients diagnosed to have age-related macular degeneration (ARMD) who presented to low-vision care (LVC) clinic at a tertiary eye care center in India, to analyze the type of distant and near devices prescribed to them and to compare the visual benefit in different age groups among patients with ARMD. Methods: A retrospective review was done for 91 patients with low-vision secondary to ARMD who were referred to the LVC clinic from 2016 to 2017. Demographic profile: age, gender, occupation, ocular history, visual acuity status, and type of low-vision device (LVD) preferred were documented. The details of LVDs and subsequent improvements were noted. Result: Of the 91 patients, 64 (70.3%) were men and 27 (29.7%) were women. Of the cases which were referred, 36.26% had a severe visual impairment (VI), 32.96% had moderate VI, 28.57% had mild VI, and 5.49% had profound VI. The majority of the patients had myopia 57 (62.63%), followed by hyperopia in 25 (27.47%) subjects. The subjects were divided into three groups based on age 40-65 years, 66-75 years, and above 75 years for the analysis of VI. There was a statistically significant improvement (P < 0.01) in near vision with the help of LVDs in all three groups. SEE TV binocular telescope was the most commonly prescribed LVD for viewing distant objects. The most commonly preferred magnifier for near work was half-eye spectacle (56%) followed by stand magnifier (9.9%) and portable video magnifier (9.9%). Conclusion: The use of LVDs can help these patients with ARMD in cases where medical and surgical treatment have no or a limited role in restoring useful vision.
C1 [Gopalakrishnan, Sarika] SASTRA Univ, Shanmugha Arts Sci Technol & Res Acad, Thanjavur, India.
   [Gopalakrishnan, Sarika] Sankara Nethralaya, Dept Optometry, Low Vis Care Clin, Chennai, Tamil Nadu, India.
   [Velu, Saranya; Raman, Rajiv] Sankara Nethralaya, Shri Bhagwan Mahavir Vitreoretinal Serv, 18 Coll Rd, Chennai 600006, Tamil Nadu, India.
C3 Shanmugha Arts, Science, Technology & Research Academy (SASTRA)
RP Raman, R (通讯作者)，Sankara Nethralaya, Shri Bhagwan Mahavir Vitreoretinal Serv, 18 Coll Rd, Chennai 600006, Tamil Nadu, India.
EM rajivpgraman@gmail.com
OI Saranya, V/0000-0002-5659-8326
CR Dandona L, 2006, BMC MED, V4, DOI 10.1186/1741-7015-4-7
   Das K, 2019, CLIN EXP OPTOM, V102, P426, DOI 10.1111/cxo.12867
   Elliott DB, 1997, INVEST OPHTH VIS SCI, V38, P2566
   Gopalakrishnan S, 2017, INDIAN J OPHTHALMOL, V65, P995, DOI 10.4103/ijo.IJO_52_17
   Hatef E, 2008, RETINA-J RET VIT DIS, V28, P755, DOI 10.1097/IAE.0b013e3181613463
   Hazin R, 2009, J NATL MED ASSOC, V101, P134, DOI 10.1016/S0027-9684(15)30825-7
   Holz FG, 2007, AM J OPHTHALMOL, V143, P463, DOI 10.1016/j.ajo.2006.11.041
   Keeffe JE, 1998, AUST NZ J OPHTHALMOL, V26, pS16, DOI 10.1111/j.1442-9071.1998.tb01360.x
   Klein R, 2002, OPHTHALMOLOGY, V109, P1767, DOI 10.1016/S0161-6420(02)01146-6
   Kulkarni SR, 2013, INDIAN J OPHTHALMOL, V61, P196, DOI 10.4103/0301-4738.99870
   Platform, CHANGE DEFINITION BL
   Roh MI, 2008, YONSEI MED J, V49, P931, DOI 10.3349/ymj.2008.49.6.931
   Singer MA, 2012, CLIN OPHTHALMOL, V6, P33, DOI 10.2147/OPTH.S15028
   World Health Organization, P WHO PBL CONS BANGK
   World Health Organization, 1992, P WHO PBL CONS
NR 15
TC 5
Z9 5
U1 0
U2 1
PU WOLTERS KLUWER MEDKNOW PUBLICATIONS
PI MUMBAI
PA WOLTERS KLUWER INDIA PVT LTD , A-202, 2ND FLR, QUBE, C T S  NO 1498A-2
   VILLAGE MAROL, ANDHERI EAST, MUMBAI, Maharashtra, INDIA
SN 0301-4738
EI 1998-3689
J9 INDIAN J OPHTHALMOL
JI Indian J. Ophthalmol.
PD MAY
PY 2020
VL 68
IS 5
BP 886
EP 889
AR PMID 32317472
DI 10.4103/ijo.IJO_1093_19
PG 4
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA RM1MM
UT WOS:000639424400047
PM 32317472
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Law, SK
   Sohn, YH
   Hoffman, D
   Small, K
   Coleman, AL
   Caprioli, J
AF Law, SK
   Sohn, YH
   Hoffman, D
   Small, K
   Coleman, AL
   Caprioli, J
TI Optic disk appearance in advanced age-related macular degeneration
SO AMERICAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID GLUTAMATE TRANSPORTER; NITRIC-OXIDE; GLAUCOMA; MONKEYS; PRESSURE; CELLS
AB PURPOSE: To describe and quantify the appearance of the optic disk in patients with advanced age-related macular degeneration (ARMD).
   DESIGN: Retrospective comparative study.
   METHODS: A total of 316 charts were reviewed. From these, 45 subjects with advanced ARMD (defined as geographic atrophy or disciform scar) in at least one eye were enrolled. Patients with glaucoma or glaucoma visual field defects were excluded. The probability of glaucomatous optic nerve damage was scored by evaluation of stereoscopic optic disk photographs in a masked fashion, according to a predefined evaluation scale and measured with confocal ophthalmoscopy (Heidelberg Retinal Tomograph; HRT). The area of macular involvement was measured in units of disk area. The optic disk evaluation scores and HRT measurements of a group of eyes with a large area of ARMD were compared with their fellow eyes with smaller areas of ARMD. The correlations between the area of macular involvement with the optic disk evaluation scores and HRT measurements were analyzed.
   MAIN OUTCOME MEASURES: The optic disk evaluation scores and the HRT measurements between study groups. 0
   RESULTS: Eyes with larger areas of ARMD had optic disks that were more likely to be classified as glaucomatous by clinical evaluation (3.45 +/- 0.23 vs 3.05 +/- 0.18, P = .015) and by HRT imaging analysis (-0.995 +/- 0.423 vs -0.376 +/- 0.249, P = .030) than the fellow eyes with smaller areas of ARMD. For eyes with six or more disk areas of ARMD, larger areas of ARMD correlated with a higher cup/disk ratio (P = .022), smaller neuroretinal rim area (P = .022), and glaucomatous classification (P = .040) with HRT discriminant function analysis.
   CONCLUSIONS: Eyes with large areas of geographic or diskiform ARMD have optic disk structural alterations that resemble glaucomatous optic neuropathy. This should be taken into consideration when evaluating patients with ARMD for glaucomatous damage. (C) 2004 by Elsevier Inc. All rights reserved.
C1 Jules Stein Eye Inst, Los Angeles, CA 90095 USA.
RP Law, SK (通讯作者)，Jules Stein Eye Inst, 100 Stein Plaza 2-235, Los Angeles, CA 90095 USA.
EM law@jsei.ucla.edu
OI Caprioli, Joseph/0000-0002-2383-7263
CR Bowd C, 2001, INVEST OPHTH VIS SCI, V42, P1993
   CAPRIOLI J, 1996, AM ACAD OPHTHALMOL, V1, P1
   Carter-Dawson L, 2002, INVEST OPHTH VIS SCI, V43, P2633
   Chiou GCY, 2001, J OCUL PHARMACOL TH, V17, P189, DOI 10.1089/10807680151125555
   Ciulla TA, 2002, BRIT J OPHTHALMOL, V86, P209, DOI 10.1136/bjo.86.2.209
   DREHER AW, 1991, AM J OPHTHALMOL, V111, P221, DOI 10.1016/S0002-9394(14)72263-9
   Dreyer EB, 1996, ARCH OPHTHALMOL-CHIC, V114, P299, DOI 10.1001/archopht.1996.01100130295012
   Dreyer EB, 1998, J GLAUCOMA, V7, P62
   Dunaief JL, 2002, ARCH OPHTHALMOL-CHIC, V120, P1435, DOI 10.1001/archopht.120.11.1435
   Harris A, 1999, PROG RETIN EYE RES, V18, P669
   Hirvela H, 1996, OPHTHALMOLOGY, V103, P871, DOI 10.1016/S0161-6420(96)30593-9
   Honkanen RA, 2003, ARCH OPHTHALMOL-CHIC, V121, P183
   Jonas JB, 2000, INVEST OPHTH VIS SCI, V41, P2972
   Kawasaki A, 2000, INVEST OPHTH VIS SCI, V41, P3444
   LEIBOWITZ H, 1973, SURV OPHTHALMOL, V24, P335
   Medeiros NE, 2001, INVEST OPHTH VIS SCI, V42, P795
   Mikelberg F S, 1995, J Glaucoma, V4, P242
   MIYAMOTO Y, 1994, INVEST OPHTH VIS SCI, V35, P3589
   QUIGLEY HA, 1990, ARCH OPHTHALMOL-CHIC, V108, P51, DOI 10.1001/archopht.1990.01070030057028
   Ryan S. J., 1989, RETINA, V2, P170
   SARKS SH, 1976, BRIT J OPHTHALMOL, V60, P324, DOI 10.1136/bjo.60.5.324
   SOMMER A, 1991, ARCH OPHTHALMOL-CHIC, V109, P1090, DOI 10.1001/archopht.1991.01080080050026
   STERNBERG P, 1991, ARCH OPHTHALMOL-CHIC, V109, P1242
   Uchida H, 1996, INVEST OPHTH VIS SCI, V37, P2393
   VARMA R, 1989, ARCH OPHTHALMOL-CHIC, V107, P526, DOI 10.1001/archopht.1989.01070010540027
   Vorwerk CK, 2000, INVEST OPHTH VIS SCI, V41, P3615
NR 26
TC 16
Z9 16
U1 0
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0002-9394
J9 AM J OPHTHALMOL
JI Am. J. Ophthalmol.
PD JUL
PY 2004
VL 138
IS 1
BP 38
EP 45
DI 10.1016/j.ajo.2004.02.021
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 836PO
UT WOS:000222568200005
PM 15234280
DA 2022-11-30
ER

PT J
AU Chen, ZL
   Li, DB
   Shen, HL
   Mo, YF
   Wei, H
   Ouyang, PB
AF Chen, Zailiang
   Li, Dabao
   Shen, Hailan
   Mo, Yufang
   Wei, Hao
   Ouyang, Pingbo
TI Automated retinal layer segmentation in OCT images of age-related
   macular degeneration
SO IET IMAGE PROCESSING
LA English
DT Article
DE image segmentation; medical image processing; optical tomography;
   diseases; eye; vision defects; biomedical optical imaging; dynamic
   programming; graph theory; feature extraction; automated retinal layer
   segmentation; OCT images; age-related macular degeneration; common eye
   disease; progressive degeneration; abundant drusen; optical coherence
   tomography; physiological structure; retinal epithelium; drusen
   quantification; automatic method; BM layer boundaries; image patches;
   boundary probability maps; dynamic programming method; layer boundary;
   DF-LS method; AMD dataset; Bruch membrane; inner limiting membrane;
   deep-forest model; graph theory
ID BOUNDARIES
AB Age-related macular degeneration (AMD) is a common eye disease that causes progressive degeneration of the central vision. The presence of abundant drusen is a common early feature of AMD. Optical coherence tomography (OCT) can provide detailed structure information on drusen. The physiological structure of the retinal epithelium and drusen complex (RPEDC) and the Bruch's membrane (BM) layer boundaries will be influenced by the presence of drusen with AMD. Therefore, drusen quantification is important to diagnose and cure AMD. The authors proposed an automatic method to segment the inner limiting membrane, the retinal pigment epithelium and drusen complex (RPEDC) and BM layer boundaries from OCT images with AMD (termed as deep forest for layer segmentation (DF-LS)). In their method, image patches are extracted and used to train a deep-forest model to predict three boundary probability maps. In addition, they modify grapy theory and dynamic programming method to find the layer boundary. Finally, the layer boundary is smoothed by using a smoothing operation. The proposed DF-LS method is evaluated on three publicly available datasets (one healthy dataset and two AMD dataset). The proposed DF-LS method can yield superior mean unsigned error with an average error of 0.81 pixel on Tian et al.'s dataset, and 1.35, 1.23 pixel on Chiu et al.'s and Farisu et al.'s dataset, respectively.
C1 [Chen, Zailiang; Li, Dabao; Shen, Hailan; Mo, Yufang; Wei, Hao; Ouyang, Pingbo] Cent S Univ, Sch Informat Sci & Engn, Changsha 410083, Hunan, Peoples R China.
   [Chen, Zailiang; Li, Dabao; Mo, Yufang; Wei, Hao] Minist Educ & China Mobile, Joint Lab Mobile Hlth, Changsha 410083, Hunan, Peoples R China.
   [Ouyang, Pingbo] Cent S Univ, Xiangya Hosp 2, Changsha 410011, Hunan, Peoples R China.
C3 Central South University; Central South University
RP Shen, HL (通讯作者)，Cent S Univ, Sch Informat Sci & Engn, Changsha 410083, Hunan, Peoples R China.
EM hn_shl@126.com
FU National Natural Science Foundation of China [61672542, 61573380]
FX =This research was supported by the National Natural Science Foundation
   of China under grant nos. 61672542 and 61573380.
CR Bellman R., 1958, Q APPL MATH, V16, P87, DOI 10.1090/qam/102435
   Chakravarty A, 2017, COMM COM INF SC, V723, P3, DOI 10.1007/978-3-319-60964-5_1
   Chakravarty A, 2018, COMPUT METH PROG BIO, V165, P235, DOI 10.1016/j.cmpb.2018.09.004
   Chen ZL, 2019, MED BIOL ENG COMPUT, V57, P953, DOI 10.1007/s11517-018-1927-8
   Chiu SJ, 2012, INVEST OPHTH VIS SCI, V53, P53, DOI 10.1167/iovs.11-7640
   Chiu SJ, 2010, OPT EXPRESS, V18, P19413, DOI 10.1364/OE.18.019413
   de Sisternes L, 2017, BIOMED OPT EXPRESS, V8, P1926, DOI 10.1364/BOE.8.001926
   DeBuc C., 2011, IMAGE SEG, V1, P15, DOI DOI 10.5772/628
   Dijkstra E. W., 1959, NUMER MATH, V1, P269, DOI [10.1007/BF01386390, DOI 10.1007/BF01386390]
   Dufour PA, 2013, IEEE T MED IMAGING, V32, P531, DOI 10.1109/TMI.2012.2225152
   Esmaeili M, 2012, IET IMAGE PROCESS, V6, P1005, DOI 10.1049/iet-ipr.2011.0333
   Fang LY, 2017, BIOMED OPT EXPRESS, V8, P2732, DOI 10.1364/BOE.8.002732
   Farsiu S, 2014, OPHTHALMOLOGY, V121, P162, DOI 10.1016/j.ophtha.2013.07.013
   Gopinath K, 2017, PROCEEDINGS 2017 4TH IAPR ASIAN CONFERENCE ON PATTERN RECOGNITION (ACPR), P888, DOI 10.1109/ACPR.2017.121
   HUANG D, 1991, SCIENCE, V254, P1178, DOI 10.1126/science.1957169
   Hussain MA, 2017, IEEE T BIO-MED ENG, V64, P1638, DOI 10.1109/TBME.2016.2619120
   Mayer M., OCTSEG VERSION V0 4
   Mayer MA, 2010, BIOMED OPT EXPRESS, V1, P1358, DOI 10.1364/BOE.1.001358
   Novosel J., 2016, MED IMAGING 2016 IMA, P97842
   Novosel J, 2015, MED IMAGE ANAL, V26, P146, DOI 10.1016/j.media.2015.08.008
   Oliveira J, 2017, BIOMED OPT EXPRESS, V8, P281, DOI 10.1364/BOE.8.000281
   Oliveira J, 2015, IEEE ENG MED BIO, P2952, DOI 10.1109/EMBC.2015.7319011
   Pearl J., 1984, HEURISTICS INTELLIGE
   Rathke Fabian, 2017, Medical Image Computing and Computer Assisted Intervention - MICCAI 2017. 20th International Conference. Proceedings: LNCS 10433, P177, DOI 10.1007/978-3-319-66182-7_21
   Schuman SG, 2009, OPHTHALMOLOGY, V116, P488, DOI 10.1016/j.ophtha.2008.10.006
   Shah A, 2018, BIOMED OPT EXPRESS, V9, P4509, DOI 10.1364/BOE.9.004509
   Shah A, 2017, LECT NOTES COMPUT SC, V10553, P3, DOI 10.1007/978-3-319-67558-9_1
   Shah A, 2015, LECT NOTES COMPUT SC, V9351, P97, DOI 10.1007/978-3-319-24574-4_12
   Tian J, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0133908
   Zhang TQ, 2015, J BIOMED OPT, V20, DOI 10.1117/1.JBO.20.9.096014
   Zhou Z.-H., 2017, P IJCAI, P3553
NR 31
TC 4
Z9 4
U1 1
U2 16
PU INST ENGINEERING TECHNOLOGY-IET
PI HERTFORD
PA MICHAEL FARADAY HOUSE SIX HILLS WAY STEVENAGE, HERTFORD SG1 2AY, ENGLAND
SN 1751-9659
EI 1751-9667
J9 IET IMAGE PROCESS
JI IET Image Process.
PD SEP 19
PY 2019
VL 13
IS 11
BP 1824
EP 1834
DI 10.1049/iet-ipr.2018.5304
PG 11
WC Computer Science, Artificial Intelligence; Engineering, Electrical &
   Electronic; Imaging Science & Photographic Technology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Computer Science; Engineering; Imaging Science & Photographic Technology
GA JA4HM
UT WOS:000487789000002
DA 2022-11-30
ER

PT J
AU Chirco, KR
   Potempa, LA
AF Chirco, Kathleen R.
   Potempa, Lawrence A.
TI C-Reactive Protein As a Mediator of Complement Activation and
   inflammatory Signaling in Age-Related Macular Degeneration
SO FRONTIERS IN IMMUNOLOGY
LA English
DT Review
DE C-reactive protein; age-related macular degeneration; inflammation;
   complement; complement factor H; membrane attack complex
ID FACTOR-H POLYMORPHISM; CHOROIDAL ENDOTHELIAL-CELLS; MEMBRANE ATTACK
   COMPLEX; HUMAN CHORIOCAPILLARIS; PENTAMERIC SYMMETRY; GENE-EXPRESSION;
   BRUCHS MEMBRANE; HUMAN EYES; RISK; BINDING
AB Age-related macular degeneration (AMD) is a devastating neurodegenerative disease affecting millions worldwide. Complement activation, inflammation, and the loss of choroidal endothelial cells have been established as key factors in both normal aging and AMD; however, the exact mechanisms for these events have yet to be fully uncovered. Herein, we provide evidence that the prototypic acute phase reactant, C-reactive protein (CRP), contributes to AMD pathogenesis. We discuss serum CRP levels as a risk factor for disease, immunolocalization of distinct forms of CRP in the at-risk and diseased retina, and direct effects of CRP on ocular tissue. Furthermore, we discuss the complement system as it relates to AMD pathophysiology, provide a model for the role of CRP in this disease, and outline current therapies being developed and tested to treat AMD patients.
C1 [Chirco, Kathleen R.] Buck Inst Res Aging, Novato, CA 94945 USA.
   [Potempa, Lawrence A.] Roosevelt Univ, Coll Pharm, Schaumburg, IL USA.
C3 Buck Institute for Research on Aging
RP Chirco, KR (通讯作者)，Buck Inst Res Aging, Novato, CA 94945 USA.
EM kchirco@buckinstitute.org
CR BERMAN S, 1986, J IMMUNOL, V136, P1354
   Bhutto IA, 2011, BRIT J OPHTHALMOL, V95, P1323, DOI 10.1136/bjo.2010.199216
   Biesemeier A, 2014, NEUROBIOL AGING, V35, P2562, DOI 10.1016/j.neurobiolaging.2014.05.003
   Biro A, 2007, IMMUNOLOGY, V121, P40, DOI 10.1111/j.1365-2567.2007.02535.x
   Braig D, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms14188
   Cashman SM, 2015, J GENE MED, V17, P229, DOI 10.1002/jgm.2865
   Chew EY, 2013, JAMA-J AM MED ASSOC, V309, P2005, DOI 10.1001/jama.2013.4997
   Chirco KR, 2016, J PATHOL, V240, P173, DOI 10.1002/path.4766
   Chirco KR, 2016, EXP EYE RES, V146, P393, DOI 10.1016/j.exer.2015.09.003
   Cipriani V, 2017, JAMA OPHTHALMOL, V135, P909, DOI 10.1001/jamaophthalmol.2017.2191
   Clark SJ, 2006, J BIOL CHEM, V281, P24713, DOI 10.1074/jbc.M605083200
   Clark SJ, 2010, J BIOL CHEM, V285, P30192, DOI 10.1074/jbc.M110.103986
   Crabb JW, 2002, P NATL ACAD SCI USA, V99, P14682, DOI 10.1073/pnas.222551899
   Despriet DDG, 2006, JAMA-J AM MED ASSOC, V296, P301, DOI 10.1001/jama.296.3.301
   Devaraj S, 2011, ARTERIOSCL THROM VAS, V31, P1397, DOI 10.1161/ATVBAHA.111.225508
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Eisenhardt SU, 2009, CIRC RES, V105, P128, DOI 10.1161/CIRCRESAHA.108.190611
   Folk JC, 2010, NEW ENGL J MED, V363, P1648, DOI 10.1056/NEJMct1000495
   Fritsche LG, 2013, NAT GENET, V45, P433, DOI 10.1038/ng.2578
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Johnson LV, 2001, EXP EYE RES, V73, P887, DOI 10.1006/exer.2001.1094
   Johnson PT, 2006, P NATL ACAD SCI USA, V103, P17456, DOI 10.1073/pnas.0606234103
   Kelly U, 2010, J IMMUNOL, V185, P5486, DOI 10.4049/jimmunol.0903596
   Khreiss T, 2004, CIRCULATION, V109, P2016, DOI 10.1161/01.CIR.0000125527.41598.68
   Khreiss T, 2002, J BIOL CHEM, V277, P40775, DOI 10.1074/jbc.M205378200
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Lauer N, 2011, J IMMUNOL, V187, P4374, DOI 10.4049/jimmunol.1002488
   Liu GQ, 2011, ARTERIOSCL THROM VAS, V31, P1342, DOI 10.1161/ATVBAHA.110.222208
   McHarg S, 2015, MOL IMMUNOL, V67, P43, DOI 10.1016/j.molimm.2015.02.032
   Mold C, 1999, IMMUNOPHARMACOLOGY, V42, P23, DOI 10.1016/S0162-3109(99)00007-7
   Molins B, 2017, AM J PHYSIOL-CELL PH, V312, pC244, DOI 10.1152/ajpcell.00057.2016
   Molins B, 2016, SCI REP-UK, V6, DOI 10.1038/srep22889
   Molins B, 2011, CARDIOVASC RES, V92, P328, DOI 10.1093/cvr/cvr226
   Mullins RF, 2006, MOL VIS, V12, P224
   Mullins RF, 2000, FASEB J, V14, P835, DOI 10.1096/fasebj.14.7.835
   Mullins RE, 2011, INVEST OPHTH VIS SCI, V52, P1606, DOI 10.1167/iovs.10-6476
   Mullins RF, 2017, HUM MOL GENET, V26, pR51, DOI 10.1093/hmg/ddx181
   Mullins RF, 2014, AM J PATHOL, V184, P3142, DOI 10.1016/j.ajpath.2014.07.017
   Mullins RF, 2011, EXP EYE RES, V93, P565, DOI 10.1016/j.exer.2011.06.015
   Okemefuna AI, 2010, J BIOL CHEM, V285, P1053, DOI 10.1074/jbc.M109.044529
   Pennington KL, 2016, EYE VISION, V3, DOI 10.1186/s40662-016-0063-5
   POTEMPA LA, 1983, MOL IMMUNOL, V20, P1165, DOI 10.1016/0161-5890(83)90140-2
   POTEMPA LA, 1987, MOL IMMUNOL, V24, P531, DOI 10.1016/0161-5890(87)90028-9
   Prosser BE, 2007, J EXP MED, V204, P2277, DOI 10.1084/jem.20071069
   SARKS SH, 1976, BRIT J OPHTHALMOL, V60, P324, DOI 10.1136/bjo.60.5.324
   Schaumberg DA, 2006, INVEST OPHTH VIS SCI, V47, P2336, DOI 10.1167/iovs.05-1456
   Schnabolk G, 2018, MOL THER-METH CLIN D, V9, P1, DOI 10.1016/j.omtm.2017.11.003
   Seddon JM, 2005, ARCH OPHTHALMOL-CHIC, V123, P774, DOI 10.1001/archopht.123.6.774
   Seddon JM, 2004, JAMA-J AM MED ASSOC, V291, P704, DOI 10.1001/jama.291.6.704
   Seddon JM, 2010, OPHTHALMOLOGY, V117, P1560, DOI 10.1016/j.ophtha.2009.11.020
   Skeie JM, 2010, INVEST OPHTH VIS SCI, V51, P5336, DOI 10.1167/iovs.10-5322
   Slevin M, 2010, BRAIN PATHOL, V20, P151, DOI 10.1111/j.1750-3639.2008.00256.x
   Sohn EH, 2014, INVEST OPHTH VIS SCI, V55, P1352, DOI 10.1167/iovs.13-13754
   Taskintuna I, 2016, MIDDLE EAST AFR J OP, V23, P13, DOI 10.4103/0974-9233.173134
   Wang Y, 2010, EXP EYE RES, V91, P135, DOI 10.1016/j.exer.2010.02.008
   Whitmore SS, 2013, MOL VIS, V19, P2274
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Wu Y, 2015, BIOL CHEM, V396, P1181, DOI 10.1515/hsz-2015-0149
   Xu HP, 2016, EUR J PHARMACOL, V787, P94, DOI 10.1016/j.ejphar.2016.03.001
   Yang P, 2009, INVEST OPHTH VIS SCI, V50, P3473, DOI 10.1167/iovs.08-3202
   YING SC, 1989, J IMMUNOL, V143, P221
   Yu JM, 2007, BIOCHEMISTRY-US, V46, P8451, DOI 10.1021/bi700459a
   Yuan XL, 2010, MOL CELL PROTEOMICS, V9, P1031, DOI 10.1074/mcp.M900523-MCP200
   Zeng SM, 2016, J PATHOL, V238, P446, DOI 10.1002/path.4669
   Zouki C, 2001, J IMMUNOL, V167, P5355, DOI 10.4049/jimmunol.167.9.5355
NR 66
TC 14
Z9 14
U1 0
U2 7
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 1664-3224
J9 FRONT IMMUNOL
JI Front. Immunol.
PD MAR 15
PY 2018
VL 9
AR 539
DI 10.3389/fimmu.2018.00539
PG 7
WC Immunology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Immunology
GA FZ3WU
UT WOS:000427522700001
PM 29599782
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Guven, A
AF Guven, Aysegul
TI Automatic detection of age-related macular degeneration pathologies in
   retinal fundus images
SO COMPUTER METHODS IN BIOMECHANICS AND BIOMEDICAL ENGINEERING
LA English
DT Article
DE fundus image analysis; optic disc; macula and age-related macular
   degeneration; automatic determination
ID OPTIC-NERVE DISEASE; CLASSIFICATION; SEGMENTATION; DISC; VESSELS; FOVEA;
   MODEL
AB Advanced techniques in image processing and analysis are being extensively studied to assist clinical diagnoses. Digital colour retinal fundus images are widely utilised to investigate various eye diseases. In this paper, we describe the detection of optic disc (OD), macula and age-related macular degeneration (ARMD) pathologies of the macular regions in colour fundus images. ARMD causes the loss of central vision in older adults. If the disease is detected early and treated promptly, much of the vision loss can be prevented. Eighty colour retinal fundus images were tested using our proposed algorithm. The Hough transform was employed for OD determination. A fundus coordinate system was established based on the macula location. An ARMD pathology detection methodology using a subtraction process after contrast-limited adaptive histogram equalisation operations was proposed. The accuracies of the automated segmentations of the OD, macula and ARMD pathologies obtained were 100%, 100% and 95.49%, respectively. These results show that our algorithm is a useful tool for detecting ARMD in retinal fundus images. The application of our method may reduce the time needed by ophthalmologists to diagnose ARMD pathology while providing dependable detection precision. Integration of our technique into traditional software could be used in clinical implementations as an aid in disease diagnosis and as a tool for quantitative evaluation of treatment effectiveness.
C1 Erciyes Univ, Dept Biomed Engn, TR-38039 Kayseri, Turkey.
C3 Erciyes University
RP Guven, A (通讯作者)，Erciyes Univ, Dept Biomed Engn, TR-38039 Kayseri, Turkey.
EM aguven@erciyes.edu.tr
RI Güven, Ayşegül/AAP-1277-2021
OI Güven, Ayşegül/0000-0001-8517-3530
CR [Anonymous], 1991, OPHTHALMOLOGY, V98, P786
   Bartlett H, 2007, SURV OPHTHALMOL, V52, P655, DOI 10.1016/j.survophthal.2007.08.022
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Coscas G, 2009, ANN REP FRENCH OPHTA
   Demirkaya O., 2008, IMAGE PROCESSING MAT
   Foracchia M, 2004, IEEE T MED IMAGING, V23, P1189, DOI 10.1109/TMI.2004.829331
   Haar FT, 2005, THESIS U UTRECHT UTR
   Hoover A, 2003, IEEE T MED IMAGING, V22, P951, DOI 10.1109/TMI.2003.815900
   Ibanez MV, 1999, PATTERN RECOGN LETT, V20, P229, DOI 10.1016/S0167-8655(98)00137-8
   Kara S, 2007, J MED SYST, V31, P391, DOI 10.1007/s10916-007-9081-0
   Kara S, 2007, COMPUT BIOL MED, V37, P836, DOI 10.1016/j.compbiomed.2006.08.024
   Kose C, 2008, COMPUT BIOL MED, V38, P611, DOI 10.1016/j.compbiomed.2008.02.008
   Kose C, 2010, J MED SYST, V34, P1, DOI 10.1007/s10916-008-9210-4
   Lam HK, 2003, ICICS-PCM 2003, VOLS 1-3, PROCEEDINGS, P1437
   Law SK, 2004, AM J OPHTHALMOL, V138, P38, DOI 10.1016/j.ajo.2004.02.021
   Lee S. S., 2006, The 2nd International Conference on Distributed Frameworks for Multimedia Applications (IEEE Cat. No. 06EX1389), P37
   Li HQ, 2004, IEEE T BIO-MED ENG, V51, P246, DOI 10.1109/TBME.2003.820400
   Li HQ, 2003, NINTH IEEE INTERNATIONAL CONFERENCE ON COMPUTER VISION, VOLS I AND II, PROCEEDINGS, P394
   Narasimha-Iyer H, 2006, IEEE T BIO-MED ENG, V53, P1084, DOI 10.1109/TBME.2005.863971
   Osareh A., 2004, THESIS U BRISTOL BRI
   Patton N, 2006, PROG RETIN EYE RES, V25, P99, DOI 10.1016/j.preteyeres.2005.07.001
   Rapantzikos K, 2003, MED IMAGE ANAL, V7, P95, DOI 10.1016/S1361-8415(02)00093-2
   Saleh MD, 2008, INT S 26 28 AUG, V2, P1
   Sinthanayothin C, 1999, BRIT J OPHTHALMOL, V83, P902, DOI 10.1136/bjo.83.8.902
   Sivaramakrishna R, 2000, AM J ROENTGENOL, V175, P45, DOI 10.2214/ajr.175.1.1750045
   Smith RT, 2005, ARCH OPHTHALMOL-CHIC, V123, P200, DOI 10.1001/archopht.123.2.200
   Youssif AA, 2006, CAIR INT BIOM ENG C, P1
   Youssif AAHAR, 2008, IEEE T MED IMAGING, V27, P11, DOI 10.1109/TMI.2007.900326
NR 28
TC 10
Z9 10
U1 0
U2 14
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 1025-5842
EI 1476-8259
J9 COMPUT METHOD BIOMEC
JI Comput. Methods Biomech. Biomed. Eng.
PD APR 1
PY 2013
VL 16
IS 4
BP 425
EP 434
DI 10.1080/10255842.2011.623677
PG 10
WC Computer Science, Interdisciplinary Applications; Engineering,
   Biomedical
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Computer Science; Engineering
GA 127TT
UT WOS:000317722400008
PM 22372623
DA 2022-11-30
ER

PT J
AU Basile, AS
   Hutmacher, M
   Nickens, D
   Nielsen, J
   Kowalski, K
   Whitfield, L
   Masayo, O
   Nakane, M
AF Basile, Anthony S.
   Hutmacher, Matt
   Nickens, Dana
   Nielsen, Jace
   Kowalski, Ken
   Whitfield, Lloyd
   Masayo, Oishi
   Nakane, Masami
TI Population Pharmacokinetics of Pegaptanib in Patients With Neovascular,
   Age-Related Macular Degeneration
SO JOURNAL OF CLINICAL PHARMACOLOGY
LA English
DT Article
DE Pegaptanib; age-related macular degeneration; renal function; population
   pharmacokinetics; clearance
ID ENDOTHELIAL GROWTH-FACTOR; QUANTIFICATION LIMIT; APTAMER NX1838;
   RHESUS-MONKEYS; BIODISTRIBUTION; ANGIOGENESIS; MACULOPATHY; VESSEL
AB The anti-vascular endothelial growth factor (VEGF) aptamer pegaptanib is eliminated primarily by renal clearance. Because renal function declines with age, pegaptanib exposure in patients with age-related macular degeneration (AMD) may increase. Therefore, a population pharmacokinetic (PK) analysis of pegaptanib was undertaken in Western and Asian AMD patients to determine the influence of renal function on apparent pegaptanib clearance (CL). Pegaptanib (0.3-3 mg per eye) was administered every 4 to 6 weeks to 262 AMD patients in 4 studies. Pegaptanib exposures (area under the concentration-time curve [AUC] and maximum plasma concentration) after 8 doses were similar to exposures following the first dose, consistent with the absence of plasma accumulation. A 1-compartment model parameterized in terms of the absorption rate constant, apparent volume of distribution, and CL was used to describe the pegaptanib plasma concentration data. Creatinine clearance (CLCR), body weight (WT), and age influenced pegaptanib PK. Decreasing CLCR from 70 to 30 mL/min doubled AUC. After adjustment for CLCR, WT, and age, the model predicted no race differences in CL or AUC. Given that the therapeutic 0.3 mg per eye dose of pegaptanib results in exposures one-tenth of those observed following the well-tolerated 3-mg dose, these results suggest that no dose adjustment is warranted for AMD patients with moderate renal insufficiency (CLCR > 30 mL/min).
C1 [Basile, Anthony S.; Nickens, Dana] Pfizer Global Res & Dev, San Diego, CA USA.
   [Hutmacher, Matt; Nielsen, Jace; Kowalski, Ken] Ann Arbor Pharmacometr Grp, Ann Arbor, MI USA.
   [Whitfield, Lloyd] LW Solut LLC, Saline, MI USA.
   [Masayo, Oishi; Nakane, Masami] Pfizer Japan Inc, Clin Res, Tokyo, Japan.
C3 Pfizer; Pfizer
RP Basile, AS (通讯作者)，Allergan LLC, T1-115,2525 Dupont Dr, Irvine, CA 92612 USA.
EM basile_anthony@allergan.com
FU Pfizer Global Research and Development
FX Pfizer Global Research and Development funded all the studies in this
   report. Dana Nickens performed the work associated with this study as a
   full-time employee of Pfizer Inc. Oishi Masayo and Masami Nakane are
   full-time employees of Pfizer Japan Inc. Anthony S. Basile, Matt
   Hutmacher, Ken Kowalski, and Lloyd Whitfield were full-time employees of
   Pfizer at the time the original work was completed for this study.
CR Ahn JE, 2008, J PHARMACOKINET PHAR, V35, P401, DOI 10.1007/s10928-008-9094-4
   Beal S, 2009, NONMEM USERS GUIDES
   Beal SL, 2001, J PHARMACOKINET PHAR, V28, P481, DOI 10.1023/A:1012299115260
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Blau HM, 2001, NAT MED, V7, P532, DOI 10.1038/87850
   Bressler Neil M, 2004, JAMA, V291, P1900, DOI 10.1001/jama.291.15.1900
   Carmeliet P, 2000, NATURE, V407, P249, DOI 10.1038/35025220
   Ciulla TA, 2009, CURR OPIN OPHTHALMOL, V20, P158, DOI 10.1097/ICU.0b013e32832d25b3
   COCKCROFT DW, 1976, NEPHRON, V16, P31, DOI 10.1159/000180580
   Drolet DW, 2000, PHARMACEUT RES, V17, P1503, DOI 10.1023/A:1007657109012
   Ferrara N, 2001, AM J PHYSIOL-CELL PH, V280, pC1358, DOI 10.1152/ajpcell.2001.280.6.C1358
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Geary RS, 2009, EXPERT OPIN DRUG MET, V5, P381, DOI [10.1517/17425250902877680, 10.1517/17425250902877680 ]
   Healy JM, 2004, PHARM RES-DORDR, V21, P2234, DOI 10.1007/s11095-004-7676-4
   KECK PJ, 1989, SCIENCE, V246, P1309, DOI 10.1126/science.2479987
   Klein R, 2004, AM J OPHTHALMOL, V137, P486, DOI 10.1016/j.ajo.2003.11.069
   Kliffen M, 1997, BRIT J OPHTHALMOL, V81, P154, DOI 10.1136/bjo.81.2.154
   Kowalski KG, 2001, J PHARMACOKINET PHAR, V28, P253, DOI 10.1023/A:1011579109640
   LEVY AP, 1995, J BIOL CHEM, V270, P13333, DOI 10.1074/jbc.270.22.13333
   MathSoft Inc., 2005, S PLUS WIND
   Ng EWM, 2006, NAT REV DRUG DISCOV, V5, P123, DOI 10.1038/nrd1955
   Nimjee SM, 2005, ANNU REV MED, V56, P555, DOI 10.1146/annurev.med.56.062904.144915
   Reyderman L, 1998, PHARMACEUT RES, V15, P904, DOI 10.1023/A:1011980716659
   STRATFORD RE, 1988, J PHARM SCI, V77, P838, DOI 10.1002/jps.2600771005
   Tucker CE, 1999, J CHROMATOGR B, V732, P203, DOI 10.1016/S0378-4347(99)00285-6
   WINTERS ME, 1994, BASIC CLIN PHARMACOK
   Yancopoulos GD, 2000, NATURE, V407, P242, DOI 10.1038/35025215
NR 27
TC 19
Z9 19
U1 0
U2 8
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 0091-2700
J9 J CLIN PHARMACOL
JI J. Clin. Pharmacol.
PD AUG
PY 2012
VL 52
IS 8
BP 1186
EP 1199
DI 10.1177/0091270011412961
PG 14
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA 979UD
UT WOS:000306844400006
PM 21947371
DA 2022-11-30
ER

PT J
AU Guymer, RH
   Wu, ZC
   Hodgson, LAB
   Caruso, E
   Brassington, KH
   Tindill, N
   Aung, KZ
   McGuinness, MB
   Fletcher, EL
   Chen, FK
   Chakravarthy, U
   Arnold, JJ
   Heriot, WJ
   Durkin, SR
   Lek, JJ
   Harper, CA
   Wickremasinghe, SS
   Sandhu, SS
   Baglin, EK
   Sharangan, P
   Braat, S
   Luu, CD
AF Guymer, Robyn H.
   Wu, Zhichao
   Hodgson, Lauren A. B.
   Caruso, Emily
   Brassington, Kate H.
   Tindill, Nicole
   Aung, Khin Zaw
   McGuinness, Myra B.
   Fletcher, Erica L.
   Chen, Fred K.
   Chakravarthy, Usha
   Arnold, Jennifer J.
   Heriot, Wilson J.
   Durkin, Shane R.
   Lek, Jia Jia
   Harper, Colin A.
   Wickremasinghe, Sanjeewa S.
   Sandhu, Sukhpal S.
   Baglin, Elizabeth K.
   Sharangan, Pyrawy
   Braat, Sabine
   Luu, Chi D.
CA Laser Intervention Early Stages
TI Subthreshold Nanosecond Laser Intervention in Age-Related Macular
   Degeneration The LEAD Randomized Controlled Clinical Trial
SO OPHTHALMOLOGY
LA English
DT Article
ID OPTICAL COHERENCE TOMOGRAPHY; VISION LOSS; DRUSEN; AUTOFLUORESCENCE;
   PSEUDODRUSEN; ATROPHY; EYES
AB Purpose: There is an urgent need for a more effective intervention to slow or prevent progression of age-related macular degeneration (AMD) from its early stages to vision-threatening late complications. Subthreshold nanosecond laser (SNL) treatment has shown promise in preclinical studies and a pilot study in intermediate AMD (iAMD) as a potential treatment. We aimed to evaluate the safety of SNL treatment in iAMD and its efficacy for slowing progression to late AMD.
   Design: The Laser Intervention in Early Stages of Age-Related Macular Degeneration (LEAD) study is a 36-month, multicenter, randomized, sham-controlled trial.
   Participants: Two hundred ninety-two participants with bilateral large drusen and without OCT signs of atrophy.
   Methods: Participants were assigned randomly to receive Retinal Rejuvenation Therapy (2RT (R) ; Ellex Pty Ltd, Adelaide, Australia) SNL or sham treatment to the study eye at 6-monthly intervals.
   Main Outcome Measures: The primary efficacy outcome was the time to development of late AMD defined by multimodal imaging (MMI). Safety was assessed by adverse events.
   Results: Overall, progression to late AMD was not slowed significantly with SNL treatment compared with sham treatment (adjusted hazard ratio [HR], 0.61; 95% confidence interval [CI], 0.33-1.14; P = 0.122). However, a post hoc analysis showed evidence of effect modification based on the coexistence of reticular pseudodrusen (RPD; adjusted interaction P = 0.002), where progression was slowed for the 222 participants (76.0%) without coexistent RPD at baseline (adjusted HR, 0.23; 95% CI, 0.09-0.59; P = 0.002), whereas an increased progression rate (adjusted HR, 2.56; 95% CI, 0.80-8.18; P = 0.112) was observed for the 70 participants (24.0%) with RPD with SNL treatment. Differences between the groups in serious adverse events were not significant.
   Conclusions: In participants with iAMD without MMI-detected signs of late AMD, no significant difference in the overall progression rate to late AMD between those receiving SNL and sham treatment were observed. However, SNL treatment may have a role in slowing progression for those without coexistent RPD and may be inappropriate in those with RPD, warranting caution when considering treatment in clinical phenotypes with RPD. Our findings provide compelling evidence for further trials of the 2RT (R) laser, but they should not be extrapolated to other short-pulse lasers. (C) 2018 by the American Academy of Ophthalmology.
C1 [Guymer, Robyn H.; Wu, Zhichao; Hodgson, Lauren A. B.; Caruso, Emily; Brassington, Kate H.; Tindill, Nicole; Aung, Khin Zaw; McGuinness, Myra B.; Harper, Colin A.; Wickremasinghe, Sanjeewa S.; Sandhu, Sukhpal S.; Baglin, Elizabeth K.; Sharangan, Pyrawy; Luu, Chi D.] Univ Melbourne, Royal Victorian Eye & Ear Hosp, Dept Surg, Ctr Eye Res Australia, Melbourne, Vic, Australia.
   [Fletcher, Erica L.] Univ Melbourne, Dept Anat & Neurosci, Melbourne, Vic, Australia.
   [Chen, Fred K.] Univ Western Australia, Ctr Ophthalmol & Visual Sci, Lions Eye Inst, Perth, WA, Australia.
   [Chen, Fred K.] Royal Perth Hosp, Dept Ophthalmol, Perth, WA, Australia.
   [Chakravarthy, Usha] Belfast Hlth & Social Care Trust, Belfast, Antrim, North Ireland.
   [Arnold, Jennifer J.] Marsden Eye Res, Sydney, NSW, Australia.
   [Heriot, Wilson J.] Retinol Inst Victoria, Glen Iris, Australia.
   [Durkin, Shane R.] Adelaide Eye & Retina Ctr, Adelaide, SA, Australia.
   [Lek, Jia Jia] Univ Melbourne, Dept Optometry & Vis Sci, Melbourne, Vic, Australia.
   [Braat, Sabine] Univ Melbourne, Ctr Epidemiol & Biostat, Melbourne Sch Populat & Global Hlth, Melbourne, Vic, Australia.
   [Braat, Sabine] Univ Melbourne, Melbourne Clin & Translat Sci, Melbourne, Vic, Australia.
C3 Centre for Eye Research Australia; Royal Victorian Eye & Ear Hospital;
   University of Melbourne; University of Melbourne; Lions Eye Institute;
   University of Western Australia; Royal Perth Hospital; University of
   Western Australia; University of Melbourne; University of Melbourne;
   University of Melbourne
RP Guymer, RH (通讯作者)，Ctr Eye Res Australia, Locked Bag 8, East Melbourne, Vic 3002, Australia.
EM rhg@unimelb.edu.au
RI McGuinness, Myra/G-4900-2017; Braat, Sabine/AAQ-3753-2021; Fletcher,
   Erica/E-6364-2012
OI McGuinness, Myra/0000-0002-5422-040X; Fletcher,
   Erica/0000-0001-9412-9523; BRAAT, SABINE/0000-0003-1997-3999; Chen,
   Fred/0000-0003-2809-9930
FU National Health & Medical Research Council of Australia [APP1027624,
   GNT1103013, APP1104985, APP1054712, APP1142962]; Bupa Health Foundation,
   Australia; Ellex R&D Pty Ltd, Adelaide, Australia; Centre for Eye
   Research Australia
FX Supported by the National Health & Medical Research Council of Australia
   (project grant no.: APP1027624 [R.H.G., C.D.L.]; and fellowship grant
   nos.: GNT1103013 [R.H.G.], APP1104985 [Z.W.], APP1054712 [F.K.C.], and
   APP1142962 [F.K.C.]); and Bupa Health Foundation, Australia (R.H.G.,
   C.D.L.). The Centre for Eye Research Australia receives operational
   infrastructure support from the Victorian Government. Ellex R&D Pty Ltd,
   Adelaide, Australia, provided partial funding of the central
   coordinating center and the in-kind provision of Ellex 2RT (R) laser
   systems, ongoing support of those systems, and the Macular Integrity
   Assessment microperimeters for the duration of the study. The web-based
   Research Electronic Data Capture application and open-source platform
   OpenClinica allowed secure electronic data capture. The study is
   sponsored by the Centre for Eye Research Australia, an independent
   medical research institute and a not-for-profit company. The funders of
   this study had no role in the design and conduct of the study;
   collection, management, analysis, and interpretation of the data;
   preparation, review, or approval of the manuscript; or decision to
   submit the manuscript for publication. All authors had full access to
   all the data in the study and approved the final version and the
   corresponding author had the final responsibility for the decision to
   submit for publication.
CR Aleman TS, 2013, DOC OPHTHALMOL, V127, P239, DOI 10.1007/s10633-013-9403-0
   Alten F, 2015, BRIT J OPHTHALMOL, V99, P717, DOI 10.1136/bjophthalmol-2014-305339
   Bhisitkul RB, 2015, AM J OPHTHALMOL, V159, P915, DOI 10.1016/j.ajo.2015.01.032
   Booij JC, 2010, PROG RETIN EYE RES, V29, P1, DOI 10.1016/j.preteyeres.2009.08.003
   Chehade L, 2016, CLIN EXP OPHTHALMOL, V44, P714, DOI 10.1111/ceo.12754
   Chew EY, 2013, JAMA-J AM MED ASSOC, V309, P2005, DOI 10.1001/jama.2013.4997
   Curcio CA, 2017, INVEST OPHTH VIS SCI, V58
   Curcio CA, 2013, RETINA-J RET VIT DIS, V33, P265, DOI 10.1097/IAE.0b013e31827e25e0
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Friberg TR, 2006, OPHTHALMOLOGY, V113, P612, DOI 10.1016/j.ophtha.2005.10.066
   Gal A, 2000, NAT GENET, V26, P270, DOI 10.1038/81555
   Gass J D, 1971, Trans Am Acad Ophthalmol Otolaryngol, V75, P580
   Genead MA, 2010, OPHTHALMIC GENET, V31, P66, DOI 10.3109/13816810903584971
   Greferath U, 2016, OPHTHALMOLOGY, V123, P1320, DOI 10.1016/j.ophtha.2016.02.009
   Guymer RH, 2014, CLIN EXP OPHTHALMOL, V42, P466, DOI 10.1111/ceo.12247
   Jobling AI, 2015, FASEB J, V29, P696, DOI 10.1096/fj.14-262444
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Lek JJ, 2017, OPHTHALMOL RETINA, V1, P227, DOI 10.1016/j.oret.2016.12.001
   Meyers KJ, 2015, OPHTHALMOLOGY, V122, P2286, DOI 10.1016/j.ophtha.2015.07.029
   Owens SL, 2006, AM J OPHTHALMOL, V141, P276, DOI 10.1016/j.ajo.2005.08.019
   Paavo M, 2017, INVEST OPHTH VIS SCI, V58, P4769, DOI 10.1167/iovs.17-22338
   Querques G, 2018, GRAEF ARCH CLIN EXP, V256, P1, DOI 10.1007/s00417-017-3848-x
   Robman LD, 2015, OPHTHAL EPIDEMIOL, V22, P75, DOI 10.3109/09286586.2015.1010688
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Sadda SR, 2018, OPHTHALMOLOGY, V125, P537, DOI 10.1016/j.ophtha.2017.09.028
   Schmitz-Valckenberg S, 2011, INVEST OPHTH VIS SCI, V52, P5009, DOI 10.1167/iovs.11-7235
   Spaide RF, 2018, SURV OPHTHALMOL, V63, P782, DOI 10.1016/j.survophthal.2018.05.005
   Sternberg P, 2003, OPHTHALMOLOGY, V110, P971, DOI 10.1016/S0161-6420(03)00098-8
   Vessey KA, 2018, INVEST OPHTH VIS SCI, V59, P731, DOI 10.1167/iovs.17-23098
   Virgili G, 2015, LASER TREATMENT DRUS, V10
   Wood JPM, 2011, LASER SURG MED, V43, P499, DOI 10.1002/lsm.21087
   Wu ZC, 2014, OPHTHALMOLOGY, V121, P2415, DOI 10.1016/j.ophtha.2014.06.034
   Zhang JJ, 2012, INVEST OPHTH VIS SCI, V53, P2928, DOI 10.1167/iovs.11-8585
   Zhou Q, 2016, OPHTHALMOLOGY, V123, P1530, DOI 10.1016/j.ophtha.2016.02.043
NR 34
TC 91
Z9 93
U1 1
U2 6
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0161-6420
EI 1549-4713
J9 OPHTHALMOLOGY
JI Ophthalmology
PD JUN
PY 2019
VL 126
IS 6
BP 829
EP 838
DI 10.1016/j.ophtha.2018.09.015
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA HY6YD
UT WOS:000468275600017
PM 30244144
OA hybrid
DA 2022-11-30
ER

PT J
AU Scotti, F
   Maestroni, A
   Palini, A
   Introini, U
   Setaccioli, M
   Lorenzi, M
   Zerbini, G
AF Scotti, Fabrizio
   Maestroni, Anna
   Palini, Alessio
   Introini, Ugo
   Setaccioli, Marco
   Lorenzi, Mara
   Zerbini, Gianpaolo
TI ENDOTHELIAL PROGENITOR CELLS AND RESPONSE TO RANIBIZUMAB IN AGE-RELATED
   MACULAR DEGENERATION
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE age-related macular degeneration; choroidal neovascularization;
   endothelial progenitor cells; ranibizumab
ID HEMATOPOIETIC STEM-CELLS; CHOROIDAL NEOVASCULARIZATION; GROWTH-FACTOR;
   TUMOR ANGIOGENESIS; BEVACIZUMAB; DISEASE; ATHEROSCLEROSIS; OUTCOMES;
   THERAPY; CANCER
AB Background: Choroidal neovascularization (CNV) is the main cause of vision loss in age-related macular degeneration (AMD). In experimental CNV, endothelial progenitor cells (EPCs) contribute to the formation of new vessels. The aim of this study was to investigate whether the behavior of EPCs in patients with AMD supports a role for EPCs in human CNV.
   Methods: The number of circulating EPCs that are considered pure endothelial precursors and EPCs with monocytic characteristics, and the plasma levels of regulatory cytokines were evaluated in 23 patients with AMD with active CNV and 20 matched controls. In the patients, this profile was re-evaluated after ranibizumab.
   Results: When compared with controls, the patients with AMD showed a lower number of both EPC types (P = 0.03) and higher plasma levels (P = 0.03) of stromal cell-derived factor 1. Three monthly injections of ranibizumab returned to control levels the number of circulating EPCs considered pure endothelial precursors and of stromal cell-derived factor 1, but not of monocytic EPCs.
   Conclusion: The observations indicate responsiveness of circulating EPCs to the CNV process in AMD. They suggest the hypothesis that increased stromal cell-derived factor 1 production at the CNV site (reflected in higher plasma levels) recruits EPCs from the circulation, and that antivascular endothelial growth factor therapy selectively decreases the recruitment of cells to be incorporated into new vessels.
C1 [Scotti, Fabrizio; Introini, Ugo; Setaccioli, Marco] Ist Sci San Raffaele, Dept Ophthalmol, I-20132 Milan, Italy.
   [Maestroni, Anna; Zerbini, Gianpaolo] Ist Sci San Raffaele, Diabet Complicat Unit, I-20132 Milan, Italy.
   [Palini, Alessio] Ist Sci San Raffaele, Flow Cytometry Resource Lab, I-20132 Milan, Italy.
   [Lorenzi, Mara] Harvard Univ, Sch Med, Dept Ophthalmol, Schepens Eye Res Inst Massachusetts Eye & Ear, Boston, MA USA.
C3 Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele;
   Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele;
   Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele;
   Harvard University; Harvard Medical School
RP Zerbini, G (通讯作者)，Ist Sci San Raffaele, Complicat Diabet Unit, Div Metab & Cardiovasc Sci, Olgettina 60, I-20132 Milan, Italy.
EM g.zerbini@hsr.it
RI Zerbini, Gianpaolo/K-6723-2016
OI Setaccioli, Marco/0000-0002-0500-8728
FU International Agency for the Prevention of Blindness, Italian Section;
   George and Frances Levin Endowment
FX Supported by a grant from the International Agency for the Prevention of
   Blindness, Italian Section (F. S.); and by the George and Frances Levin
   Endowment (M. L.).
CR [Anonymous], 1999, Arch Ophthalmol, V117, P1329
   Bertolini F, 2006, NAT REV CANCER, V6, P833, DOI 10.1039/nrc1971
   Bhisitkul RB, 2006, BRIT J OPHTHALMOL, V90, P1542, DOI 10.1136/bjo.2006.098426
   Bhutto IA, 2006, BRIT J OPHTHALMOL, V90, P906, DOI 10.1136/bjo.2006.090357
   Bogoslovsky T, 2011, STROKE, V42, P618, DOI 10.1161/STROKEAHA.110.596007
   Carneiro AM, 2012, ACTA OPHTHALMOL, V90, pE25, DOI 10.1111/j.1755-3768.2011.02240.x
   de Gonzalez AB, 2010, NEW ENGL J MED, V363, P2211, DOI 10.1056/NEJMoa1000367
   de Jong PTVM, 2006, NEW ENGL J MED, V355, P1474, DOI 10.1056/NEJMra062326
   Fernandez AB, 2012, OPHTHALMOLOGY, V119, P765, DOI 10.1016/j.ophtha.2011.09.044
   Folk JC, 2010, NEW ENGL J MED, V363, P1648, DOI 10.1056/NEJMct1000495
   Foresta C, 2011, J TRAUMA, V70, P459, DOI 10.1097/TA.0b013e3181fcf83c
   Ghadge SK, 2011, PHARMACOL THERAPEUT, V129, P97, DOI 10.1016/j.pharmthera.2010.09.011
   Guerin E, 2008, MICROVASC RES, V75, P302, DOI 10.1016/j.mvr.2007.12.001
   Hill JM, 2003, NEW ENGL J MED, V348, P593, DOI 10.1056/NEJMoa022287
   Hristov M, 2007, THROMB HAEMOSTASIS, V98, P274, DOI 10.1160/TH07-03-0181
   Kerbel RS, 2008, NEW ENGL J MED, V358, P2039, DOI 10.1056/NEJMra0706596
   KLEIN ML, 1989, OPHTHALMOLOGY, V96, P1416
   Machalinska A, 2011, J OCUL PHARMACOL TH, V27, P471, DOI 10.1089/jop.2011.0091
   Machalinska A, 2011, INVEST OPHTH VIS SCI, V52, P93, DOI 10.1167/iovs.10-5756
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Mitchell P, 2010, BRIT J OPHTHALMOL, V94, P2, DOI 10.1136/bjo.2009.159160
   Prater DN, 2007, LEUKEMIA, V21, P1141, DOI 10.1038/sj.leu.2404676
   Roodhart JML, 2009, BBA-REV CANCER, V1796, P41, DOI 10.1016/j.bbcan.2009.04.006
   Sasahara M, 2009, INVEST OPHTH VIS SCI, V50, P1575, DOI 10.1167/iovs.08-1900
   Schmidt-Erfurth U, 2011, OPHTHALMOLOGY, V118, P831, DOI 10.1016/j.ophtha.2010.09.004
   Sengupta N, 2003, INVEST OPHTH VIS SCI, V44, P4908, DOI 10.1167/iovs.03-0342
   Sengupta N, 2005, INVEST OPHTH VIS SCI, V46, P343, DOI 10.1167/iovs.04-0153
   Sheridan CM, 2006, INVEST OPHTH VIS SCI, V47, P1642, DOI 10.1167/iovs.05-0779
   Silva RLE, 2007, FASEB J, V21, P3219, DOI 10.1096/fj.06-7359com
   Sun C, 2009, OPHTHALMOLOGY, V116, P1913, DOI 10.1016/j.ophtha.2009.03.046
   Timmermans F, 2007, ARTERIOSCL THROM VAS, V27, P1572, DOI 10.1161/ATVBAHA.107.144972
   Tomita M, 2004, STEM CELLS, V22, P21, DOI 10.1634/stemcells.22-1-21
   Werner N, 2005, NEW ENGL J MED, V353, P999, DOI 10.1056/NEJMoa043814
   Willett CG, 2004, NAT MED, V10, P145, DOI 10.1038/nm988
   Wong TY, 2007, OPHTHALMOLOGY, V114, P86, DOI 10.1016/j.ophtha.2006.06.039
   Yamani MH, 2005, J AM COLL CARDIOL, V46, P1029, DOI 10.1016/j.jacc.2005.04.059
   Ying GS, 2013, OPHTHALMOLOGY, V120, P122, DOI 10.1016/j.ophtha.2012.07.042
   Yoder MC, 2007, BLOOD, V109, P1801, DOI 10.1182/blood-2006-08-043471
   Yodoi Y, 2007, INVEST OPHTH VIS SCI, V48, P5464, DOI 10.1167/iovs.07-0093
   Zehetner C, 2013, BRIT J OPHTHALMOL, V97, P454, DOI 10.1136/bjophthalmol-2012-302451
   Zerbini G, 2008, NEW ENGL J MED, V359, P763, DOI 10.1056/NEJMc081278
   Zerbini G, 2012, DIABETES, V61, P908, DOI 10.2337/db11-1197
   Zhang ZX, 2011, CURR EYE RES, V36, P838, DOI 10.3109/02713683.2011.593107
NR 43
TC 6
Z9 6
U1 0
U2 6
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD SEP
PY 2014
VL 34
IS 9
BP 1802
EP 1810
DI 10.1097/IAE.0000000000000147
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA AO8UL
UT WOS:000341630400016
PM 24736462
DA 2022-11-30
ER

PT J
AU Campa, C
   Harding, SP
AF Campa, C.
   Harding, S. P.
TI Anti-VEGF Compounds in the Treatment of Neovascular Age Related Macular
   Degeneration
SO CURRENT DRUG TARGETS
LA English
DT Review
DE Vascular endothelial growth factor; age related macular degeneration;
   choroidal neovascularization; ranibizumab; bevacizumab; pegaptanib;
   VEGD-trap; small interfering RNA; tyrosine kinase inhibitors
ID ENDOTHELIAL GROWTH-FACTOR; VERTEPORFIN PHOTODYNAMIC THERAPY;
   VASCULAR-PERMEABILITY FACTOR; EXPERIMENTAL CHOROIDAL NEOVASCULARIZATION;
   RETINAL-PIGMENT EPITHELIUM; INTRAVITREAL BEVACIZUMAB; TYROSINE KINASE;
   FACTOR RECEPTORS; BINDING-SITES; RANIBIZUMAB
AB Age-related macular degeneration (AMD) is the leading cause of blindness among elderly patients in developed countries. Although the pathogenesis of AMD is still largely unknown, it is now well known that vascular endothelial growth factor (VEGF) plays a pivotal role in the growth of the abnormal blood vessels (i.e. choroidal neovascularization, CNV) which characterizes the "wet form" of this ocular disease. Therefore, inhibiting VEGF has turned out to be a good way of more effectively controlling neovascular AMD. VEGF is a heparin-binding glycoprotein with potent angiogenic, mitogenic and vascular permeability-enhancing activities specific for endothelial cells. Currently two anti-VEGF compounds have been approved by the US Food and Drug Administration (FDA) for the treatment of neovascular AMD: pegaptanib and ranibizumab. Off-label usage of bevacizumab, an anti-VEGF agent similar to ranibizumab, has also become fairly common. The substantial improvement of visual acuity noticed in patients treated with ranibizumab has made this drug the gold standard for AMD therapy. However, as with many new therapies, there are unresolved issues, including safety, cost, and dosing frequency.
   This review describes in details the properties and efficacy of the three anti-VEGF agents in use in clinical practice. Promising emerging anti-VEGF strategies (VEGF-trap, small interfering RNA, tyrosine kinase inhibitors) which aim to improve outcomes, safety and treatment burden through novel mechanisms of action are also discussed.
C1 [Campa, C.; Harding, S. P.] Univ Liverpool, Ophthalmol Res Unit, Sch Clin Sci, Liverpool L69 3BX, Merseyside, England.
C3 University of Liverpool
RP Campa, C (通讯作者)，Royal Liverpool Univ Hosp, St Pauls Eye Unit, Prescot St, Liverpool L7 8XP, Merseyside, England.
EM claudio.campa@yahoo.com
OI Harding, Simon/0000-0003-4676-1158
CR AIELLO LP, 1994, NEW ENGL J MED, V331, P1480, DOI 10.1056/NEJM199412013312203
   Alitalo K, 2005, NATURE, V438, P946, DOI 10.1038/nature04480
   ALON T, 1995, NAT MED, V1, P1024, DOI 10.1038/nm1095-1024
   [Anonymous], SAFETY EFFICACY ORAL
   [Anonymous], OPEN LABEL PILOT STU
   [Anonymous], SAFETY EFFICACY STUD
   [Anonymous], STUDY EVALUATE PHARM
   Antoszyk AN, 2008, AM J OPHTHALMOL, V145, P862, DOI 10.1016/j.ajo.2007.12.029
   Apte RS, 2008, EYE, V22, P734, DOI 10.1038/sj.eye.6702941
   Asahara T, 1999, EMBO J, V18, P3964, DOI 10.1093/emboj/18.14.3964
   Avery RL, 2006, OPHTHALMOLOGY, V113, P363, DOI 10.1016/j.ophtha.2005.11.019
   Barleon B, 1996, BLOOD, V87, P3336, DOI 10.1182/blood.V87.8.3336.bloodjournal8783336
   Benjamin LE, 1999, J CLIN INVEST, V103, P159, DOI 10.1172/JCI5028
   Bian ZM, 1999, CURR EYE RES, V18, P349, DOI 10.1076/ceyr.18.5.349.5353
   BINGAMAN D, 2007, INVEST OPHTHALMOL VI, V48
   Blaauwgeers HGT, 1999, AM J PATHOL, V155, P421, DOI 10.1016/S0002-9440(10)65138-3
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   Carmeliet P, 2005, NATURE, V438, P932, DOI 10.1038/nature04478
   Chakravarthy U, 2006, OPHTHALMOLOGY, V113, P1508, DOI 10.1016/j.ophtha.2006.02.064
   Chappelow AV, 2008, DRUGS, V68, P1029, DOI 10.2165/00003495-200868080-00002
   CHEN Z, 2007, OPHTHALMOL VIS SCI, V48
   Ciulla TA, 2009, CURR OPIN OPHTHALMOL, V20, P158, DOI 10.1097/ICU.0b013e32832d25b3
   CLAUSS M, 1990, J EXP MED, V172, P1535, DOI 10.1084/jem.172.6.1535
   Csaky KG, 2004, EXP EYE RES, V78, P1107, DOI 10.1016/j.exer.2004.01.010
   DEVRIES C, 1992, SCIENCE, V255, P989, DOI 10.1126/science.1312256
   Doukas J, 2008, J CELL PHYSIOL, V216, P29, DOI 10.1002/jcp.21426
   Dvorak HF, 2002, J CLIN ONCOL, V20, P4368, DOI 10.1200/JCO.2002.10.088
   ELDEM MB, 2009, OPHTHALMOL VIS SCI, V50
   Ferrara N, 2004, ENDOCR REV, V25, P581, DOI 10.1210/er.2003-0027
   Ferrara N, 2003, NAT MED, V9, P669, DOI 10.1038/nm0603-669
   Ferrara N, 2007, ANNU REV MED, V58, P491, DOI 10.1146/annurev.med.58.061705.145635
   Ferrara N, 2006, RETINA-J RET VIT DIS, V26, P859, DOI 10.1097/01.iae.0000242842.14624.e7
   Finger RP, 2008, BRIT J OPHTHALMOL, V92, P483, DOI 10.1136/bjo.2007.129916
   Frank RN, 1996, AM J OPHTHALMOL, V122, P393, DOI 10.1016/S0002-9394(14)72066-5
   FRANK RN, 2006, RETINA, P1240
   Fung AE, 2007, AM J OPHTHALMOL, V143, P566, DOI 10.1016/j.ajo.2007.01.028
   Gerber HP, 1998, J BIOL CHEM, V273, P13313, DOI 10.1074/jbc.273.21.13313
   Gerber HP, 1998, J BIOL CHEM, V273, P30336, DOI 10.1074/jbc.273.46.30336
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   GROSSNIKLAUS HE, 1992, AM J OPHTHALMOL, V114, P464, DOI 10.1016/S0002-9394(14)71859-8
   Grossniklaus HE, 2002, MOL VIS, V8, P119
   Heier JS, 2006, ARCH OPHTHALMOL-CHIC, V124, P1532, DOI 10.1001/archopht.124.11.1532
   Hera R, 2005, AM J OPHTHALMOL, V139, P589, DOI 10.1016/j.ajo.2004.11.064
   HOUCK KA, 1992, J BIOL CHEM, V267, P26031
   Ishibashi T, 1997, GRAEF ARCH CLIN EXP, V235, P159, DOI 10.1007/BF00941723
   JAKEMAN LB, 1992, J CLIN INVEST, V89, P244, DOI 10.1172/JCI115568
   JAKEMAN LB, 1993, ENDOCRINOLOGY, V133, P848, DOI 10.1210/en.133.2.848
   Jin KL, 2002, P NATL ACAD SCI USA, V99, P11946, DOI 10.1073/pnas.182296499
   Kaiser PK, 2007, OPHTHALMOLOGY, V114, P1868, DOI 10.1016/j.ophtha.2007.04.030
   Karkkainen MJ, 2002, NAT CELL BIOL, V4, pE2, DOI 10.1038/ncb0102-e2
   Keyt BA, 1996, J BIOL CHEM, V271, P7788, DOI 10.1074/jbc.271.13.7788
   Kim IB, 1999, INVEST OPHTH VIS SCI, V40, pS233
   KIRCHHOFL B, 2009, INVEST OPHTHALMOL VI, V50
   Krzystolik MG, 2002, ARCH OPHTHALMOL-CHIC, V120, P338
   Kvanta A, 1996, INVEST OPHTH VIS SCI, V37, P1929
   Lalwani GA, 2009, AM J OPHTHALMOL, V148, P43, DOI 10.1016/j.ajo.2009.01.024
   Lamoreaux WJ, 1998, MICROVASC RES, V55, P29, DOI 10.1006/mvre.1997.2056
   Lee S, 2005, J CELL BIOL, V169, P681, DOI 10.1083/jcb.200409115
   LEUNG DW, 1989, SCIENCE, V246, P1306, DOI 10.1126/science.2479986
   Lopez PF, 1996, INVEST OPHTH VIS SCI, V37, P855
   Maier P, 2005, GRAEF ARCH CLIN EXP, V243, P593, DOI 10.1007/s00417-004-1021-9
   MATTHEWS W, 1991, P NATL ACAD SCI USA, V88, P9026, DOI 10.1073/pnas.88.20.9026
   Michaelson I.C., 1948, T OPHTHALMOL SOC, V68, P137
   Michels M, 2008, 26 ANN M AM SOC RET
   MILLER JW, 1994, AM J PATHOL, V145, P574
   Mitchell P, 2010, BRIT J OPHTHALMOL, V94, P2, DOI 10.1136/bjo.2009.159160
   Monsky WL, 1999, CANCER RES, V59, P4129
   Noda K, 2008, FASEB J, V22, P2928, DOI 10.1096/fj.07-105346
   Otani A, 2002, MICROVASC RES, V64, P162, DOI 10.1006/mvre.2002.2407
   PAJUSOLA K, 1992, CANCER RES, V52, P5738
   PLOUET J, 1990, J BIOL CHEM, V265, P22071
   RAMRATTAN RS, 1994, INVEST OPHTH VIS SCI, V35, P2857
   Regillo CD, 2008, AM J OPHTHALMOL, V145, P239, DOI 10.1016/j.ajo.2007.10.004
   Roberts WG, 1997, CANCER RES, V57, P765
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rosenfeld PJ, 2005, OPHTHAL SURG LAS IM, V36, P331, DOI 10.3928/1542-8877-20050701-14
   Rosenstein JM, 2004, EXP NEUROL, V187, P246, DOI 10.1016/j.expneurol.2004.01.022
   Saishin Y, 2003, J CELL PHYSIOL, V195, P241, DOI 10.1002/jcp.10246
   Schadlu R, 2008, AM J OPHTHALMOL, V145, P875, DOI 10.1016/j.ajo.2007.12.030
   Schmidt-Erfurth U, 2008, BRIT J OPHTHALMOL, V92, P1628, DOI 10.1136/bjo.2007.135277
   SHEN H, 1993, BLOOD, V81, P2767
   Shibuya M., 1993, ONCOGENE, V8, P519
   SINGER M, 2009, INVEST OPHTHALMOL VI, V50
   Singerman LJ, 2008, BRIT J OPHTHALMOL, V92, P1606, DOI 10.1136/bjo.2007.132597
   SLAKTER S, 2009, INVEST OPHTHALMOL VI, V50
   Spilsbury K, 2000, AM J PATHOL, V157, P135, DOI 10.1016/S0002-9440(10)64525-7
   Steinbrook R, 2006, NEW ENGL J MED, V355, P1409, DOI 10.1056/NEJMp068185
   Takahashi K, 2009, ARCH OPHTHALMOL-CHIC, V127, P494, DOI 10.1001/archophthalmol.2009.27
   Tatar O, 2008, ARCH OPHTHALMOL-CHIC, V126, P782, DOI 10.1001/archopht.126.6.782
   TERMAN BI, 1991, ONCOGENE, V6, P1677
   Tolentino MJ, 1996, ARCH OPHTHALMOL-CHIC, V114, P964, DOI 10.1001/archopht.1996.01100140172010
   VAISMAN N, 1990, J BIOL CHEM, V265, P19461
   Venkatesh P, 2008, CAN J OPHTHALMOL, V43, P245, DOI 10.3129/i08-028
   Wada M, 1999, CURR EYE RES, V18, P203, DOI 10.1076/ceyr.18.3.203.5368
   Wells JA, 1996, BRIT J OPHTHALMOL, V80, P363, DOI 10.1136/bjo.80.4.363
   Witmer AN, 2003, PROG RETIN EYE RES, V22, P1, DOI 10.1016/S1350-9462(02)00043-5
   Wu L, 2008, GRAEF ARCH CLIN EXP, V246, P81, DOI 10.1007/s00417-007-0660-z
   LUCENTIS ONE YEAR
NR 99
TC 74
Z9 75
U1 1
U2 17
PU BENTHAM SCIENCE PUBL LTD
PI SHARJAH
PA EXECUTIVE STE Y-2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB
   EMIRATES
SN 1389-4501
EI 1873-5592
J9 CURR DRUG TARGETS
JI Curr. Drug Targets
PD FEB
PY 2011
VL 12
IS 2
BP 173
EP 181
DI 10.2174/138945011794182674
PG 9
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA 720RX
UT WOS:000287299000004
PM 20887245
DA 2022-11-30
ER

PT J
AU Sng, CCA
   Cackett, PD
   Yeo, IY
   Thalamuthu, A
   Venkatraman, A
   Venkataraman, D
   Koh, AH
   Tai, ES
   Wong, TY
   Aung, T
   Vithana, EN
AF Sng, Chelvin C. A.
   Cackett, Peter D.
   Yeo, Ian Y.
   Thalamuthu, Anbupalam
   Venkatraman, Anandalakshmi
   Venkataraman, Divya
   Koh, Adrian H.
   Tai, E-Shyong
   Wong, Tien Y.
   Aung, Tin
   Vithana, Eranga N.
TI Toll-Like Receptor 3 Polymorphism rs3775291 Is Not Associated with
   Choroidal Neovascularization or Polypoidal Choroidal Vasculopathy in
   Chinese Subjects
SO OPHTHALMIC RESEARCH
LA English
DT Article
DE Age-related macular degeneration; Genetics; Choroidal
   neovascularization; Toll-like receptor
ID COMPLEMENT FACTOR-H; MACULAR DEGENERATION; GENE POLYMORPHISMS; CLINICAL
   CHARACTERISTICS; JAPANESE POPULATION; GEOGRAPHIC ATROPHY; RISK;
   PREVALENCE; VARIANT; CFH
AB Background/Aims: Age-related macular degeneration (AMD) is a leading cause of visual impairment. A single-nucleotide polymorphism (SNP; rs3775291) in the Toll-like receptor 3 (TLR3) gene has recently been implicated in the pathogenesis of AMD in Caucasian populations. The aim of this study was to examine this association in Chinese persons with choroidal neovascularization (CNV) secondary to AMD and polypoidal choroidal vasculopathy (PCV). Methods: This was an observational cross-sectional study in Singapore. Study subjects were of Chinese ethnicity and included patients with exudative maculopathy and normal control subjects. The diagnoses of CNV and PCV were made based on fundus examination, fluorescein angiography and indocyanine green angiography findings. Genomic DNA was extracted, and genotypes were determined by bidirectional DNA sequencing. We compared the allele and genotype frequencies between subjects with CNV and PCV with controls using the software PLINK. Results: A total of 246 subjects with exudative maculopathy (consisting of 126 with CNV and 120 with PCV) and 274 normal control subjects were recruited. The distribution of rs3775291 SNP genotypes for CNV and PCV was not significantly different from that for normal controls. Conclusion: This study indicates that the TLR3 rs3775291 gene polymorphism is not associated with CNV and PCV in Singaporean Chinese patients. Copyright (C) 2010 S. Karger AG, Basel
C1 [Sng, Chelvin C. A.; Cackett, Peter D.; Yeo, Ian Y.; Venkatraman, Anandalakshmi; Venkataraman, Divya; Wong, Tien Y.; Aung, Tin; Vithana, Eranga N.] Natl Univ Singapore, Singapore Eye Res Inst, Singapore 168751, Singapore.
   [Cackett, Peter D.; Yeo, Ian Y.; Koh, Adrian H.; Wong, Tien Y.; Aung, Tin] Natl Univ Singapore, Singapore Natl Eye Ctr, Singapore 168751, Singapore.
   [Sng, Chelvin C. A.] Natl Univ Singapore, Dept Ophthalmol, Natl Univ Hlth Syst, Singapore 168751, Singapore.
   [Thalamuthu, Anbupalam] Natl Univ Singapore, Genome Inst Singapore, Singapore 168751, Singapore.
   [Tai, E-Shyong] Natl Univ Singapore, Dept Med, Natl Univ Hlth Syst, Singapore 168751, Singapore.
   [Wong, Tien Y.; Aung, Tin] Natl Univ Singapore, Yong Loo Lin Sch Med, Singapore 168751, Singapore.
   [Wong, Tien Y.] Univ Melbourne, Ctr Eye Res Australia, Melbourne, Vic, Australia.
C3 National University of Singapore; Singapore National Eye Center;
   National University of Singapore; Singapore National Eye Center;
   National University of Singapore; Agency for Science Technology &
   Research (A*STAR); A*STAR - Genome Institute of Singapore (GIS);
   National University of Singapore; National University of Singapore;
   National University of Singapore; Centre for Eye Research Australia;
   University of Melbourne
RP Vithana, EN (通讯作者)，Natl Univ Singapore, Singapore Eye Res Inst, 11 3rd Hosp Ave, Singapore 168751, Singapore.
EM eranga.n.v@seri.com.sg
RI Wong, Tien Yin/AAC-9724-2020; Thalamuthu, Anbupalam/Z-5545-2019; Tai, E
   Shyong/J-9831-2013
OI Wong, Tien Yin/0000-0002-8448-1264; Thalamuthu,
   Anbupalam/0000-0002-7114-1260; Sng, Chelvin/0000-0002-9837-6019; Tai, E
   Shyong/0000-0003-2929-8966
FU Singhealth [SHF/FG391P/2007]
FX This study was supported by Singhealth Grant SHF/FG391P/2007.
CR Allikmets R, 2009, NEW ENGL J MED, V360, P2252
   Cackett P, 2010, EYE, V24, P789, DOI 10.1038/eye.2009.214
   Cackett P, 2009, RETINA-J RET VIT DIS, V29, P187, DOI 10.1097/IAE.0b013e318188c839
   Cameron DJ, 2007, CELL CYCLE, V6, P1122, DOI 10.4161/cc.6.9.4157
   Cho YE, 2009, INVEST OPHTH VIS SCI, V50, P5614, DOI 10.1167/iovs.09-3688
   Churchill AJ, 2006, HUM MOL GENET, V15, P2955, DOI 10.1093/hmg/ddl238
   Ciardella Antonio P, 2002, Ophthalmol Clin North Am, V15, P537, DOI 10.1016/S0896-1549(02)00053-6
   Edwards AO, 2008, INVEST OPHTH VIS SCI, V49, P1652, DOI 10.1167/iovs.07-1378
   Edwards AO, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003813
   Evans J, 1996, BRIT J OPHTHALMOL, V80, P9, DOI 10.1136/bjo.80.1.9
   FERRIS FL, 1984, ARCH OPHTHALMOL-CHIC, V102, P1640
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   GAUDERMAN WJ, 2006, QUANTO 1 1 COMPUTER
   GOLD B, 2006, AM J HUM GENET, V77, P389
   Grossniklaus HE, 2004, AM J OPHTHALMOL, V137, P496, DOI 10.1016/j.ajo.2003.09.042
   Hageman GS, 2006, ANN MED, V38, P592, DOI 10.1080/07853890601097030
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   *JAP STUD GROUP PO, 2005, NIPPON GANKA GAKKAI, V109, P412
   Kawasaki R, 2008, OPHTHALMOLOGY, V115, P1735, DOI 10.1016/j.ophtha.2008.02.012
   Kawasaki R, 2008, OPHTHALMOLOGY, V115, P1376, DOI 10.1016/j.ophtha.2007.11.015
   Kawasaki R, 2010, OPHTHALMOLOGY, V117, P921, DOI 10.1016/j.ophtha.2009.10.007
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Kondo N, 2008, INVEST OPHTH VIS SCI, V49, P1101, DOI 10.1167/iovs.07-1145
   Kondo N, 2007, AM J OPHTHALMOL, V144, P608, DOI 10.1016/j.ajo.2007.06.003
   Laude A, 2010, PROG RETIN EYE RES, V29, P19, DOI 10.1016/j.preteyeres.2009.10.001
   Lee KY, 2008, INVEST OPHTH VIS SCI, V49, P2613, DOI 10.1167/iovs.07-0860
   Liew G, 2009, NEW ENGL J MED, V360, P2252
   Lin JM, 2008, AM J OPHTHALMOL, V145, P1045, DOI 10.1016/j.ajo.2008.01.027
   Liu Y, 2007, GRAEF ARCH CLIN EXP, V245, P1441, DOI 10.1007/s00417-007-0575-8
   Magnusson KP, 2006, PLOS MED, V3, P109, DOI 10.1371/journal.pmed.0030005
   Maller JB, 2007, NAT GENET, V39, P1200, DOI 10.1038/ng2131
   Maruko I, 2007, AM J OPHTHALMOL, V144, P15, DOI 10.1016/j.ajo.2007.03.047
   Owen CG, 2003, BRIT J OPHTHALMOL, V87, P312, DOI 10.1136/bjo.87.3.312
   Purcell S, 2007, AM J HUM GENET, V81, P559, DOI 10.1086/519795
   R Development Core Team, R LANG ENV STAT COMP
   Rivera A, 2005, HUM MOL GENET, V14, P3227, DOI 10.1093/hmg/ddi353
   Scassellati-Sforzolini B, 2001, RETINA-J RET VIT DIS, V21, P121, DOI 10.1097/00006982-200104000-00004
   Schroder M, 2005, TRENDS IMMUNOL, V26, P462, DOI 10.1016/j.it.2005.07.002
   Sho K, 2003, ARCH OPHTHALMOL-CHIC, V121, P1392, DOI 10.1001/archopht.121.10.1392
   Wong T, 2008, OPHTHALMOLOGY, V115, P116, DOI 10.1016/j.ophtha.2007.03.008
   Wong TY, 2007, LANCET, V370, P204, DOI 10.1016/S0140-6736(07)61104-0
   Yang ZL, 2008, NEW ENGL J MED, V359, P1456, DOI 10.1056/NEJMoa0802437
   Yannuzzi LA, 1999, ARCH OPHTHALMOL-CHIC, V117, P1503
   Yates JRW, 2007, NEW ENGL J MED, V357, P553, DOI 10.1056/NEJMoa072618
NR 44
TC 13
Z9 13
U1 0
U2 4
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 0030-3747
J9 OPHTHALMIC RES
JI Ophthalmic Res.
PY 2011
VL 45
IS 4
BP 191
EP 196
DI 10.1159/000321387
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 758IF
UT WOS:000290157100005
PM 21079408
DA 2022-11-30
ER

PT J
AU Sato, E
   Feke, GT
   Appelbaum, EY
   Menke, MN
   Trempe, CL
   McMeel, JW
AF Sato, Eiichi
   Feke, Gilbert T.
   Appelbaum, Ephraim Y.
   Menke, Marcel N.
   Trempe, Clement L.
   McMeel, J. Wallace
TI Association between systemic arterial stiffness and age-related macular
   degeneration
SO GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Article
DE age-related macular degeneration; systemic arterial stiffness; arterial
   pulse wave velocity; central aortic blood pressure waveform
ID PULSE-WAVE VELOCITY; CHOROIDAL NEOVASCULAR MEMBRANES; ENDOTHELIAL
   GROWTH-FACTOR; RISK-FACTORS; CARDIOVASCULAR-DISEASE; ADVANCED GLYCATION;
   AORTIC PRESSURE; POOLED FINDINGS; MACULOPATHY; ATHEROSCLEROSIS
AB Background: A number of epidemiological studies suggest that age-related macular degeneration (AMD) and cardiovascular disease share the same risk factors. Systemic arterial stiffness is a clear indicator of cardiovascular disease. We investigated whether there is an association between directly measured systemic arterial stiffness and the presence of AMD. Methods: We used a SphygmoCor 2000 system to noninvasively measure two indicators of the systemic arterial stiffness, the arterial pulse wave velocity (PWV) and the central aortic blood pressure waveform, from which the augmentation pressure is determined. We studied 50 patients with AMD (12 men, 38 women, aged 60 to 91 years, mean 77 years) and 11 age-matched control subjects (3 men, 8 women, aged 66 to 92 years, mean 75 years). All study subjects received a complete ophthalmic examination including digital fundus photography. All of the patients with AMD were classified as stage 3 or worse in at least one eye according to the AREDS system. Results: Pulse wave velocity was significantly higher in the patients with AMD (8.2 +/- 1.1 m/s, mean +/- SD) compared with controls (7.1 +/- 0.8 m/s, p=0.0025), indicating increased arterial stiffness. There was no significant difference in PWV in AMD patients with and without choroidal neovascularization. There was no association between PWV and the presence of hypertension in either the patients or the controls. The central aortic augmentation pressure was significantly higher in the AMD patients than in the controls (p=0.040), also indicating increased arterial stiffness. Conclusions: Patients with AMD have increased systemic arterial stiffness compared with age-matched controls. Treatments aimed at preventing or reversing systemic arterial stiffness may also be effective in preventing the onset or slowing the progression of AMD.
C1 Schepens Retina Associates Fdn, Boston, MA 02215 USA.
RP Feke, GT (通讯作者)，Schepens Retina Associates Fdn, 6th Floor,1 Autumn St, Boston, MA 02215 USA.
EM feke@schepens.com
OI Menke, Marcel/0000-0002-6561-6178
CR Age-Related Eye Dis Study Res Grp, 2001, AM J OPHTHALMOL, V132, P668
   AMIN R, 1994, INVEST OPHTH VIS SCI, V35, P3178
   [Anonymous], 1991, Arch Ophthalmol, V109, P1109
   *AR RES GROUP, 2004, ARCH OPHTHALMOL-CHIC, V122, P716
   Blacher J, 1999, HYPERTENSION, V33, P1111, DOI 10.1161/01.HYP.33.5.1111
   Blumenkranz MS, 2001, ARCH OPHTHALMOL-CHIC, V119, P198
   Bouck N, 2002, TRENDS MOL MED, V8, P330, DOI 10.1016/S1471-4914(02)02362-6
   Bramwell JC, 1922, P R SOC LOND B-CONTA, V93, P298, DOI 10.1098/rspb.1922.0022
   Chaine G, 1998, BRIT J OPHTHALMOL, V82, P996, DOI 10.1136/bjo.82.9.996
   Chirinos JA, 2005, HYPERTENSION, V45, P980, DOI 10.1161/01.HYP.0000165025.16381.44
   Chong NHV, 2005, AM J PATHOL, V166, P241, DOI 10.1016/S0002-9440(10)62248-1
   Hall NF, 2001, BRIT MED J, V323, P375, DOI 10.1136/bmj.323.7309.375
   Hollyfield JG, 2003, ADV EXP MED BIOL, V533, P83
   HUSSAIN AA, 2005, OPHTHALMOL VIS SCI E, V46
   Hyman L, 2000, ARCH OPHTHALMOL-CHIC, V118, P351, DOI 10.1001/archopht.118.3.351
   Imanishi R, 2004, HYPERTENS RES, V27, P71, DOI 10.1291/hypres.27.71
   KARAMANOGLU M, 1993, EUR HEART J, V14, P160, DOI 10.1093/eurheartj/14.2.160
   Kass DA, 2001, CIRCULATION, V104, P1464, DOI 10.1161/hc3801.097806
   Klein R, 2003, OPHTHALMOLOGY, V110, P636, DOI 10.1016/S0161-6420(02)01448-3
   Klein R, 1997, OPHTHALMOLOGY, V104, P1804, DOI 10.1016/S0161-6420(97)30023-2
   Klein R, 1999, ARCH OPHTHALMOL-CHIC, V117, P1203
   Konova E, 2004, EXP GERONTOL, V39, P249, DOI 10.1016/j.exger.2003.10.003
   Lim HE, 2004, BLOOD PRESSURE, V13, P369, DOI 10.1080/08037050410004800
   Lopez PF, 1996, INVEST OPHTH VIS SCI, V37, P855
   Martyn CN, 1997, LANCET, V350, P953, DOI 10.1016/S0140-6736(96)10508-0
   Matsuoka M, 2004, BRIT J OPHTHALMOL, V88, P809, DOI 10.1136/bjo.2003.032466
   McGwin G, 2005, OPHTHALMOLOGY, V112, P488, DOI 10.1016/j.ophtha.2004.10.027
   McGwin G, 2003, BRIT J OPHTHALMOL, V87, P1121, DOI 10.1136/bjo.87.9.1121
   Morgan T, 2004, AM J HYPERTENS, V17, P118, DOI 10.1016/j.amjhyper.2003.09.012
   Pauca AL, 2001, HYPERTENSION, V38, P932, DOI 10.1161/hy1001.096106
   SATO E, 2005, RETINAL HAEMODYNAMIC, DOI DOI 10.1038/SJ.EYE.6701951
   Savage MT, 2002, CLIN SCI, V103, P59
   Smith W, 2001, OPHTHALMOLOGY, V108, P697, DOI 10.1016/S0161-6420(00)00580-7
   Snow K K, 1999, Ophthalmic Epidemiol, V6, P125, DOI 10.1076/opep.6.2.125.1558
   Stitt AW, 2001, BRIT J OPHTHALMOL, V85, P746, DOI 10.1136/bjo.85.6.746
   Tomany SC, 2004, OPHTHALMOLOGY, V111, P1280, DOI 10.1016/j.ophtha.2003.11.010
   van Leeuwen R, 2003, INVEST OPHTH VIS SCI, V44, P3771, DOI 10.1167/iovs.03-0121
   Vasan S, 2003, ARCH BIOCHEM BIOPHYS, V419, P89, DOI 10.1016/j.abb.2003.08.016
   Verbeke F, 2005, HYPERTENSION, V46, P244, DOI 10.1161/01.HYP.0000166723.07809.7e
   VINGERLING JR, 1995, AM J EPIDEMIOL, V142, P404, DOI 10.1093/oxfordjournals.aje.a117648
   Waddell TK, 2001, HYPERTENSION, V38, P927, DOI 10.1161/hy1001.096107
   Weber T, 2004, CIRCULATION, V109, P184, DOI 10.1161/01.CIR.0000105767.94169.E3
   Wilkinson IB, 1998, J CARDIOVASC PHARM, V32, pS33
   Wilkinson IB, 1998, J HYPERTENS, V16, P2079, DOI 10.1097/00004872-199816121-00033
   Wilson HL, 2004, AM J OPHTHALMOL, V137, P615, DOI 10.1016/j.ajo.2003.10.025
   Zarbin MA, 2004, ARCH OPHTHALMOL-CHIC, V122, P598, DOI 10.1001/archopht.122.4.598
NR 46
TC 24
Z9 26
U1 0
U2 2
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 0721-832X
EI 1435-702X
J9 GRAEF ARCH CLIN EXP
JI Graefes Arch. Clin. Exp. Ophthalmol.
PD AUG
PY 2006
VL 244
IS 8
BP 963
EP 971
DI 10.1007/s00417-005-0201-6
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 070XE
UT WOS:000239559000009
PM 16411106
DA 2022-11-30
ER

PT J
AU Rovner, BW
   Casten, RJ
   Massof, RW
   Leiby, BE
   Tasman, WS
AF Rovner, Barry W.
   Casten, Robin J.
   Massof, Robert W.
   Leiby, Benjamin E.
   Tasman, William S.
TI Psychological and Cognitive Determinants of Vision Function in
   Age-Related Macular Degeneration
SO ARCHIVES OF OPHTHALMOLOGY
LA English
DT Article
ID VISUAL-FUNCTION-QUESTIONNAIRE; OLDER-ADULTS; NEI VFQ-25; IMPAIRMENT;
   DEPRESSION; REHABILITATION; RANIBIZUMAB; RESPONSIVENESS; POPULATION;
   VALIDITY
AB Objective: To investigate the effect of coping strategies, depression, physical health, and cognition on National Eye Institute Visual Function Questionnaire scores obtained at baseline in a sample of older patients with age-related macular degeneration (AMD) enrolled in the Improving Function in AMD Trial, a randomized controlled clinical trial that compares the efficacy of problem-solving therapy with that of supportive therapy to improve vision function in patients with AMD.
   Methods: Baseline evaluation of 241 older outpatients with advanced AMD who were enrolled in a clinical trial testing the efficacy of a behavioral intervention to improve vision function. Vision function was characterized as an interval-scaled, latent variable of visual ability based on the near-vision subscale of the National Eye Institute Vision Function Questionnaire-25 plus Supplement.
   Results: Visual ability was highly correlated with visual acuity. However, amultivariate model revealed that patient coping strategies and cognitive function contributed to their ability to perform near-vision activities independent of visual acuity.
   Conclusions: Patients with AMD vary in their coping strategies and cognitive function and in their visual acuity, and that variability determines patients' self-report of vision function. Understanding patient coping mechanisms and cognition may help increase the precision of vision rating scales and suggest new interventions to improve vision function and quality of life in patients with AMD.
C1 [Rovner, Barry W.] Jefferson Hosp Neurosci, Jefferson Med Coll, Dept Psychiat, Philadelphia, PA 19107 USA.
   [Rovner, Barry W.] Jefferson Hosp Neurosci, Jefferson Med Coll, Dept Neurol, Philadelphia, PA 19107 USA.
   [Casten, Robin J.] Jefferson Hosp Neurosci, Jefferson Med Coll, Dept Psychiat & Human Behav, Philadelphia, PA 19107 USA.
   [Massof, Robert W.] Johns Hopkins Univ, Sch Med, Wilmer Eye Inst, Lions Vis Res & Rehabil Ctr, Baltimore, MD 21205 USA.
   [Leiby, Benjamin E.] Jefferson Med Coll, Div Biostat, Dept Pharmacol & Expt Therapeut, Philadelphia, PA USA.
   [Tasman, William S.] Jefferson Med Coll, Wills Eye Inst, Dept Ophthalmol, Philadelphia, PA USA.
C3 Jefferson University; Jefferson University; Jefferson University; Johns
   Hopkins University; Johns Hopkins Medicine; Jefferson University;
   Jefferson University
RP Rovner, BW (通讯作者)，Jefferson Hosp Neurosci, Jefferson Med Coll, Dept Psychiat, 900 Walnut St, Philadelphia, PA 19107 USA.
EM barry.rovner@jefferson.edu
FU NEI [U01 EY 015839]; Farber Institute for Neurosciences of Thomas
   Jefferson University; NATIONAL EYE INSTITUTE [U01EY015839] Funding
   Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND
   KIDNEY DISEASES [T32DK060455] Funding Source: NIH RePORTER
FX This work was supported by grant U01 EY 015839 from the NEI and by the
   Farber Institute for Neurosciences of Thomas Jefferson University.
CR Ardila A, 2008, BRAIN COGNITION, V68, P92, DOI 10.1016/j.bandc.2008.03.003
   Baker ML, 2009, ARCH OPHTHALMOL-CHIC, V127, P667, DOI 10.1001/archophthalmol.2009.30
   Borkovec TD, 2002, J CONSULT CLIN PSYCH, V70, P288, DOI 10.1037//0022-006X.70.2.288
   BRENNAN M, 2004, ANN M GER SOC AM NOV
   BRESSLER SB, 2006, OPHTHALMOL TIMES, V31, P10
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Campbell RJ, 2010, ARCH OPHTHALMOL-CHIC, V128, P359, DOI 10.1001/archophthalmol.2010.19
   Chang TS, 2007, ARCH OPHTHALMOL-CHIC, V125, P1460, DOI 10.1001/archopht.125.11.1460
   Clemons TE, 2006, ARCH OPHTHALMOL-CHIC, V124, P537
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   Cuijpers P, 2007, EUR PSYCHIAT, V22, P9, DOI 10.1016/j.eurpsy.2006.11.001
   Dandona L, 1998, ARCH OPHTHALMOL-CHIC, V116, P545, DOI 10.1001/archopht.116.4.514
   Heckhausen J, 2010, PSYCHOL REV, V117, P32, DOI 10.1037/a0017668
   Horowitz A, 2005, AM J GERIAT PSYCHIAT, V13, P180, DOI 10.1176/appi.ajgp.13.3.180
   Kroenke K, 2001, J GEN INTERN MED, V16, P606, DOI 10.1046/j.1525-1497.2001.016009606.x
   LAWTON MP, 1982, J GERONTOL, V37, P91, DOI 10.1093/geronj/37.1.91
   Lindblad AS, 2005, ARCH OPHTHALMOL-CHIC, V123, P1207
   Lucas JA, 2005, CLIN NEUROPSYCHOL, V19, P243, DOI 10.1080/13854040590945337
   Mangione CM, 1998, ARCH OPHTHALMOL-CHIC, V116, P227
   Mangione CM, 2001, ARCH OPHTHALMOL-CHIC, V119, P1050, DOI 10.1001/archopht.119.7.1050
   Marella M, 2010, INVEST OPHTH VIS SCI, V51, P2878, DOI 10.1167/iovs.09-4494
   Massof RW, 2001, VISION RES, V41, P397, DOI 10.1016/S0042-6989(00)00249-2
   Massof RW, 1998, OPTOMETRY VISION SCI, V75, P349, DOI 10.1097/00006324-199805000-00025
   Miskala PH, 2007, OPHTHAL EPIDEMIOL, V14, P205, DOI 10.1080/09286580701502970
   Miskala PH, 2004, ARCH OPHTHALMOL-CHIC, V122, P758, DOI 10.1001/archopht.122.5.758
   Miskala PH, 2003, ARCH OPHTHALMOL-CHIC, V121, P531
   Moustaki I, 2003, BRIT J MATH STAT PSY, V56, P337, DOI 10.1348/000711003770480075
   Muthen LK., 2017, MPLUS USERS GUIDE VE, V8
   Owsley C, 2004, OPHTHALMOLOGY, V111, P2259, DOI 10.1016/j.ophtha.2004.06.026
   Pesudovs K, 2010, J CATARACT REFR SURG, V36, P718, DOI 10.1016/j.jcrs.2009.11.019
   Rees G, 2010, INVEST OPHTH VIS SCI, V51, P2891, DOI 10.1167/iovs.09-5080
   Rein DB, 2009, ARCH OPHTHALMOL-CHIC, V127, P533, DOI 10.1001/archophthalmol.2009.58
   Reischies FM, 1997, BRIT J PSYCHIAT, V171, P449, DOI 10.1192/bjp.171.5.449
   Rosenfeld Philip J, 2006, Ophthalmol Clin North Am, V19, P361
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rovner BW, 2009, ALZHEIMERS DEMENT, V5, P12, DOI 10.1016/j.jalz.2008.06.001
   Rovner BW, 2002, ARCH OPHTHALMOL-CHIC, V120, P1041
   Ryan B, 2008, OPTOMETRY VISION SCI, V85, P112, DOI 10.1097/OPX.0b013e31816225dc
   Skrondal A, 2004, GEN LATENT VARIABLE, V1st, DOI DOI 10.1201/9780203489437
   Stelmack JA, 2002, INVEST OPHTH VIS SCI, V43, P2859
   VONKORFF M, 1992, J CLIN EPIDEMIOL, V45, P197, DOI 10.1016/0895-4356(92)90016-G
   Wahl HW, 2007, J GERONTOL B-PSYCHOL, V62, pP90, DOI 10.1093/geronb/62.2.P90
   WEINTRAUB S, 2000, PRINCIPLES BEHAV COG, P121
   Whitson HE, 2007, J AM GERIATR SOC, V55, P885, DOI 10.1111/j.1532-5415.2007.01093.x
NR 44
TC 25
Z9 25
U1 0
U2 17
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 0003-9950
EI 1538-3601
J9 ARCH OPHTHALMOL-CHIC
JI Arch. Ophthalmol.
PD JUL
PY 2011
VL 129
IS 7
BP 885
EP 890
DI 10.1001/archophthalmol.2011.146
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC Ophthalmology
GA 790QJ
UT WOS:000292604000008
PM 21746979
OA Green Accepted, Green Submitted, Bronze
DA 2022-11-30
ER

PT J
AU Wittes, J
   Downs, M
AF Wittes, Janet
   Downs, Matthew
TI Outcome Measures to Assess Efficacy of Treatments for Age-Related
   Macular Degeneration
SO OPHTHALMOLOGY
LA English
DT Article
ID INTRAVITREAL BEVACIZUMAB AVASTIN; PHOTODYNAMIC THERAPY; CLINICAL-TRIALS;
   RANIBIZUMAB; VERTEPORFIN
AB In a clinical trial of age-related macular degeneration (AMD), the outcome measure chosen to assess the efficacy of treatment should reflect the purpose of the trial and the stage of development of the treatment. This article considers 3 classes of outcomes: continuous variables, such as mean change in best visual acuity; binary (2-category) variables, such as experiencing a 15-letter loss; or 3-category variables, such as experiencing either a 15-letter loss or 15-letter gain. Each type of outcome has advantages and disadvantages. Trials using outcomes based on means require much smaller sample sizes than trials based on 2- or 3-category variables, but means do not address the experience of individuals. Two- and 3-category variables show what happens to individuals, but they are subject to misclassification and are statistically inefficient. The authors recommend considering continuous measures for early stage trials and for trials studying various dose regimens when a treatment has been well characterized. However, 2- and 3-category outcomes are particularly useful in confirmatory phase 3 trials of a new therapy. A new graphical method is proposed to provide insight into the distribution of the time course of changes in acuity on an individual patient basis.
   Financial Disclosure(s): Proprietary or commercial disclosure may be found in the CME frontmatter. Ophthalmology 2009;116:S8-S14 (C) 2009 by the American Academy of Ophthalmology.
C1 [Wittes, Janet; Downs, Matthew] Stat Collaborat Inc, Washington, DC 20036 USA.
RP Wittes, J (通讯作者)，Stat Collaborat Inc, 1625 Massachusetts Ave NW,Suite 600, Washington, DC 20036 USA.
EM janet@statcollab.com
RI Downs, Matt/S-7646-2019
CR Arnold J, 2001, AM J OPHTHALMOL, V131, P541
   Avery RL, 2006, OPHTHALMOLOGY, V113, P363, DOI 10.1016/j.ophtha.2005.11.019
   Beck RW, 2007, OPHTHALMOLOGY, V114, P1804, DOI 10.1016/j.ophtha.2007.06.047
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Cleland JGF, 2006, EUR J HEART FAIL, V8, P105, DOI 10.1016/j.ejheart.2005.12.003
   EVANS JR, 2006, COCHRANE DB SYST REV, P2
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Nicolo M, 2006, GRAEF ARCH CLIN EXP, V244, P1336, DOI 10.1007/s00417-006-0306-6
   Regillo CD, 2008, AM J OPHTHALMOL, V145, P239, DOI 10.1016/j.ajo.2007.10.004
   Rich RM, 2006, RETINA-J RET VIT DIS, V26, P495, DOI 10.1097/01.iae.0000225766.75009.3a
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Verbeke G., 1997, LECT NOTES STAT, V126
   Walters Stephen J, 2004, Health Qual Life Outcomes, V2, P26, DOI 10.1186/1477-7525-2-26
   Whitt W., 1993, Telecommunication Systems - Modeling, Analysis, Design and Management, V2, P71, DOI 10.1007/BF02109851
   Wittes J, 2002, EPIDEMIOL REV, V24, P39, DOI 10.1093/epirev/24.1.39
NR 16
TC 6
Z9 6
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0161-6420
J9 OPHTHALMOLOGY
JI Ophthalmology
PD OCT
PY 2009
VL 116
IS 10
BP S8
EP S14
DI 10.1016/j.ophtha.2009.06.050
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 506RY
UT WOS:000270794700002
PM 19800537
DA 2022-11-30
ER

PT J
AU Wu, ZC
   Guymer, RH
   Jung, CJ
   Goh, JK
   Ayton, LN
   Luu, CD
   Lawson, DJ
   Turpin, A
   McKendrick, AM
AF Wu, Zhichao
   Guymer, Robyn H.
   Jung, Chang J.
   Goh, Jonathan K.
   Ayton, Lauren N.
   Luu, Chi D.
   Lawson, David J.
   Turpin, Andrew
   McKendrick, Allison M.
TI Measurement of Retinal Sensitivity on Tablet Devices in Age-Related
   Macular Degeneration
SO TRANSLATIONAL VISION SCIENCE & TECHNOLOGY
LA English
DT Article
DE iPad; visual function; microperimetry; age-related macular degeneration
ID TEST-RETEST VARIABILITY; VISUAL-ACUITY; MICROPERIMETRY; PERIMETRY;
   DYSFUNCTION; THRESHOLD
AB Purpose: We compared measurements of central retinal sensitivity on a portable, lowcost tablet device to the established method of microperimetry in age-related macular degeneration (AMD).
   Methods: A customized test designed to measure central retinal sensitivity (within the central 1 degrees radius) on a tablet device was developed using an open-source platform called PsyPad. A total of 30 participants with AMD were included in this study, and all participants performed a practice test on PsyPad, followed by four tests of one eye and one test of the other eye. Participants then underwent standardized microperimetry examinations in both eyes.
   Results: The average test duration on PsyPad was 53.9 +/- 7.5 seconds, and no significant learning effect was observed over the examinations performed (P = 1.000). The coefficient of repeatability of central retinal sensitivity between the first two examinations on PsyPad was +/- 1.76 dB. The mean central retinal sensitivity was not significantly different between PsyPad (25.7 +/- 0.4 dB) and microperimetry (26.1 +/- 0.4 dB, P = 0.094), and the 95% limits of agreement between the two measures were between -4.12 and 4.92 dB.
   Conclusions: The measurements of central retinal sensitivity can be performed effectively using a tablet device, displaying reasonably good agreement with those obtained using the established method of microperimetry.
C1 [Wu, Zhichao; Guymer, Robyn H.; Jung, Chang J.; Goh, Jonathan K.; Ayton, Lauren N.; Luu, Chi D.] Univ Melbourne, Royal Victorian Eye & Ear Hosp, Ctr Eye Res Australia, Melbourne, Vic, Australia.
   [Lawson, David J.; Turpin, Andrew] Univ Melbourne, Dept Comp & Informat Syst, Melbourne, Vic, Australia.
   [McKendrick, Allison M.] Univ Melbourne, Dept Optometry & Vis Sci, Melbourne, Vic, Australia.
C3 Centre for Eye Research Australia; Royal Victorian Eye & Ear Hospital;
   University of Melbourne; University of Melbourne; University of
   Melbourne
RP Wu, ZC (通讯作者)，Ctr Eye Res Australia, Macular Res Unit, Level 1,32 Gisborne St, East Melbourne, Vic 3002, Australia.
EM wu.z@unimelb.edu.au
RI Ayton, Lauren/AAV-2977-2021; McKendrick, Allison M/A-2114-2008
OI Ayton, Lauren/0000-0001-9907-084X; McKendrick,
   Allison/0000-0003-1972-1222; , Jun/0000-0003-1041-9588; Guymer,
   Robyn/0000-0002-9441-4356
FU Australian Research Council [FT0990930, FT0991326]; National Health and
   Medical Research Council (NHMRC) [1027624]; Macular Disease Foundation
   Australia (MDFA) Research Grant; Bupa Health Foundation (Australia);
   Macular Vision Loss Support Society of Australia, Inc.; NHMRC Centre for
   Clinical Research Excellence Award [529923]
FX Supported by the Australian Research Council (AMM, FT0990930 and AT,
   FT0991326), the National Health and Medical Research Council (NH&MRC)
   Project Grant (1027624), Macular Disease Foundation Australia (MDFA)
   Research Grant, Bupa Health Foundation (Australia) and The Macular
   Vision Loss Support Society of Australia, Inc. CERA receives Operational
   Infrastructure Support from the Victorian Government and is supported by
   a NHMRC Centre for Clinical Research Excellence Award (#529923).
CR Aslam TM, 2013, J R SOC INTERFACE, V10, DOI 10.1098/rsif.2013.0239
   Black JM, 2013, BMJ OPEN, V3, DOI 10.1136/bmjopen-2013-002730
   Bland JM, 2007, J BIOPHARM STAT, V17, P571, DOI 10.1080/10543400701329422
   BLAND JM, 1986, LANCET, V1, P307, DOI 10.1016/s0140-6736(86)90837-8
   Chen FK, 2009, INVEST OPHTH VIS SCI, V50, P3464, DOI 10.1167/iovs.08-2926
   Crossland M, 2012, OPTOMETRY REPORTS 20, V2, pe2
   Dorr M, 2013, INVEST OPHTH VIS SCI, V54, P7266, DOI 10.1167/iovs.13-11743
   EISNER A, 1992, INVEST OPHTH VIS SCI, V33, P3091
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Fishman GA, 2005, RETINA-J RET VIT DIS, V25, P772, DOI 10.1097/00006982-200509000-00014
   FLAMMER J, 1984, ARCH OPHTHALMOL-CHIC, V102, P876, DOI 10.1001/archopht.1984.01040030696021
   Hogg RE, 2006, PROG RETIN EYE RES, V25, P249, DOI 10.1016/j.preteyeres.2005.11.002
   Johnson CA, 2001, SURV OPHTHALMOL, V45, pS313, DOI 10.1016/S0039-6257(01)00201-6
   KLEIN R, 1995, INVEST OPHTH VIS SCI, V36, P182
   Kollbaum PS, 2014, OPTOMETRY VISION SCI, V91, P291, DOI 10.1097/OPX.0000000000000158
   Luu CD, 2012, ARCH OPHTHALMOL-CHIC, V130, P690, DOI 10.1001/archophthalmol.2012.277
   Monhart M, 2007, SURV OPHTHALMOL, V52, pS127, DOI 10.1016/j.survophthal.2007.08.007
   Neelam K, 2009, SURV OPHTHALMOL, V54, P167, DOI 10.1016/j.survophthal.2008.12.003
   Roman AJ, 2005, EXP EYE RES, V80, P259, DOI 10.1016/j.exer.2004.09.008
   Sandberg MA, 1998, OPHTHALMOLOGY, V105, P441, DOI 10.1016/S0161-6420(98)93025-1
   Sunness JS, 2008, OPHTHALMOLOGY, V115, P1480, DOI 10.1016/j.ophtha.2008.03.009
   Sunness JS, 1999, MOL VIS, V5
   Tahir HJ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0095074
   Turpin A, 2014, J VISION, V14, DOI 10.1167/14.3.16
   WOOD JM, 1988, OPHTHAL PHYSL OPT, V8, P26, DOI 10.1111/j.1475-1313.1988.tb01078.x
   Wu ZC, 2014, OPHTHALMOLOGY, V121, P1612, DOI 10.1016/j.ophtha.2014.02.005
   Wu ZC, 2013, INVEST OPHTH VIS SCI, V54, P7378, DOI 10.1167/iovs.13-12617
   Zhang ZT, 2013, J TELEMED TELECARE, V19, P55, DOI 10.1177/1357633X12474964
NR 28
TC 16
Z9 16
U1 0
U2 2
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 2164-2591
J9 TRANSL VIS SCI TECHN
JI Transl. Vis. Sci. Technol.
PD MAY
PY 2015
VL 4
IS 3
AR 13
DI 10.1167/tvst.4.3.13
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA ED2FM
UT WOS:000388659300013
PM 26175959
OA Green Published
DA 2022-11-30
ER

PT J
AU Haymes, SA
   Lee, J
AF Haymes, SA
   Lee, J
TI Effects of task lighting on visual function in age-related macular
   degeneration
SO OPHTHALMIC AND PHYSIOLOGICAL OPTICS
LA English
DT Article
DE contrast sensitivity; illuminance; low vision; optimal print size;
   reading speed; spectral power distribution; spectral sensitivity; visual
   function
ID LOW-VISION; READING SPEED; CONTRAST SENSITIVITY; COLOR-VISION; PUPIL
   SIZE; ACUITY; PSYCHOPHYSICS; PERFORMANCE; LUMINANCE; ILLUMINATION
AB The purpose was to investigate the effects of the spectral power distribution (SPD) and illuminance of task lighting on visual function in age-related macular degeneration (ARMD) compared to normal healthy eyes. Twenty-eight subjects with ARMD and 18 age-matched normal subjects were studied. The effects on visual function were determined for four common task light sources: standard pearl coat incandescent (SP), daylight blue incandescent (DL), warm white fluorescent (WW) and cool white fluorescent (CW). Apart from a small, statistically significant improvement in contrast sensitivity with DL compared to SP lighting (0.5 dB, p = 0.01), there were no significant effects of SPD on other visual functions and no differences in the effects for subjects with ARMD and those with normal vision. Thus, for task lighting typically used in low vision rehabilitation, the SPD would seem to be of minimal clinical importance to visual function. However, increasing the task illuminance had a greater effect on visual function, in particular for subjects with ARMD (p < 0.01). For an increase in illuminance from 300 to 3000 lux, the mean increase in contrast sensitivity and near visual acuity was 1.5 dB and 0.13 log MAR, respectively. Although this effect is not large, we suggest that it is clinically relevant and supports the provision of additional task illuminance as an important part of low vision rehabilitation for patients with ARMD.
C1 Univ Melbourne, Dept Optometry & Vis Sci, Parkville, Vic 3052, Australia.
C3 University of Melbourne
RP Haymes, SA (通讯作者)，Dalhousie Univ, Dept Ophthalmol & Visual Sci, 1278 Tower Rd, Halifax, NS, Canada.
EM haymesdomain@eastlink.ca
OI Bentley, Sharon/0000-0003-0146-4248
CR ABRAMOV I, 1977, J OPT SOC AM, V67, P195, DOI 10.1364/JOSA.67.000195
   Adrian Werner, 2003, Clin Exp Optom, V86, P235
   ATCHISON DA, 1979, AM J OPTOM PHYS OPT, V56, P315
   BAILEY IL, 1980, AM J OPTOM PHYS OPT, V57, P378
   BAILEY IL, 1991, INVEST OPHTH VIS SCI, V32, P422
   Berman SM, 1996, J ILLUM ENG SOC, V25, P42, DOI 10.1080/00994480.1996.10748132
   BERMAN SM, 1993, J ILLUM ENG SOC, V22, P150, DOI 10.1080/00994480.1993.10748048
   BERMAN SM, 1994, J ILLUM ENG SOC, V23, P123, DOI 10.1080/00994480.1994.10748086
   BERMAN SM, 1992, J ILLUM ENG SOC, V21, P3
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   BLACKWELL HR, 1985, ANN NY ACAD SCI, V453, P340, DOI 10.1111/j.1749-6632.1985.tb11822.x
   Blackwell O. M., 1971, Journal of the Illuminating Engineering Society, V1, P3
   Bowers Alex R, 2001, Clin Exp Optom, V84, P139
   Bowman K J, 1978, Mod Probl Ophthalmol, V19, P71
   Boyce P. R., 2003, Lighting Research & Technology, V35, P141, DOI 10.1191/1477153503li075oa
   Boyce P. R., 1973, Lighting Research and Technology, V5, P125
   BROWN B, 1983, AM J OPTOM PHYS OPT, V60, P788
   CAMPBELL CJ, 1971, MOD PROBL OPHTHAL, V11, P98
   CAMPBELL FW, 1965, J PHYSIOL-LONDON, V181, P576, DOI 10.1113/jphysiol.1965.sp007784
   Chung STL, 2002, INVEST OPHTH VIS SCI, V43, P1270
   Cohen JM, 1988, J VISION REHABIL, V2, P15
   CORNELISSEN FW, 1991, DOC OPHTHALMOL, V78, P195, DOI 10.1007/BF00165681
   ELDRED KB, 1992, OPTOMETRY VISION SCI, V69, P46, DOI 10.1097/00006324-199201000-00007
   Elliott DB, 2001, INVEST OPHTH VIS SCI, V42, P1945
   Elliott DB, 1997, INVEST OPHTH VIS SCI, V38, P2566
   FISCHER ML, 1996, FUNCTIONAL ASSESSMEN, P105
   Fosse P, 2001, OPTOMETRY VISION SCI, V78, P162, DOI 10.1097/00006324-200103000-00009
   Fotios S. A., 1995, Lighting Research and Technology, V27, P173
   *INT COMM ILL, 1978, SD41 CIE INT COMM IL
   John JA, 2003, J STAT PLAN INFER, V113, P259, DOI 10.1016/S0378-3758(01)00304-4
   Julian WG, 1984, LIGHTING RES TECHNOL, V16, P34
   LEGGE GE, 1985, VISION RES, V25, P239, DOI 10.1016/0042-6989(85)90117-8
   LEGGE GE, 1985, VISION RES, V25, P253, DOI 10.1016/0042-6989(85)90118-X
   LEGGE GE, 1992, INVEST OPHTH VIS SCI, V33, P677
   LEGGE GE, 1986, J OPT SOC AM A, V3, P40, DOI 10.1364/JOSAA.3.000040
   Lewis AL, 1999, J ILLUM ENG SOC, V28, P37, DOI 10.1080/00994480.1999.10748250
   LIE I, 1977, AM J OPTOM PHYS OPT, V54, P528
   LINDNER W, 1989, CHIRALITY, V1, P10, DOI 10.1002/chir.530010105
   Mansfield JS, 1996, INVEST OPHTH VIS SCI, V37, P1492
   McCabe P, 2000, Ophthalmic Epidemiol, V7, P259, DOI 10.1076/opep.7.4.259.4173
   MILOVA A, 1971, P 17 SESS COMM ECL B, P84
   Oshika T, 1999, INVEST OPHTH VIS SCI, V40, P1351
   Rea, 1993, LIGHTING HDB REFEREN
   Rea M. S., 1991, Lighting Research and Technology, V23, P135
   ROWLANDS E, 1971, P 17 SESS COMM ECL B, P86
   Russell W, 2001, OPHTHAL PHYSL OPT, V21, P36, DOI 10.1046/j.1475-1313.2001.00569.x
   SHEEDY JE, 1984, AM J OPTOM PHYS OPT, V61, P595
   SIMONSON E, 1948, J OPT SOC AM, V38, P830, DOI 10.1364/JOSA.38.000830
   SLOAN LL, 1973, AM J OPHTHALMOL, V76, P745, DOI 10.1016/0002-9394(73)90572-2
   SLOAN LL, 1968, VISION RES, V8, P901, DOI 10.1016/0042-6989(68)90139-9
   SLOAN LL, 1969, DOC OPHTHALMOL, V26, P384, DOI 10.1007/BF00943999
   SLOSSON RL, 1994, SLOSSON ORAL READING
   SOLDATOVA AM, 1990, OFTALMOL ZH, V7, P403
   *STAND ASS AUSTR, 1990, 16801 AS STAND ASS 1
   TAYLOR HR, 1989, AUST NZ J OPHTHALMOL, V17, P81, DOI 10.1111/j.1442-9071.1989.tb00492.x
   TUCKER J, 1975, AM J OPTOM PHYS OPT, V52, P3
   Veitch J. A., 1995, Lighting Research and Technology, V27, P243
   VERBAKEN JH, 1986, AM J OPTOM PHYS OPT, V63, P724
   VERRIEST G, 1963, J OPT SOC AM, V53, P185, DOI 10.1364/JOSA.53.000185
   VINGRYS AJ, 1988, INVEST OPHTH VIS SCI, V29, P50
   Virgili G, 2004, INVEST OPHTH VIS SCI, V45, P3418, DOI 10.1167/iovs.04-0390
   Vrabel PL, 1995, J ILLUM ENG SOC, V24, P69, DOI 10.1080/00994480.1995.10748099
   WEALE RA, 1953, J PHYSIOL-LONDON, V119, P170, DOI 10.1113/jphysiol.1953.sp004837
   Wolffsohn JS, 1999, OPTOMETRY VISION SCI, V76, P747, DOI 10.1097/00006324-199911000-00023
NR 64
TC 27
Z9 27
U1 1
U2 10
PU BLACKWELL PUBLISHING
PI OXFORD
PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND
SN 0275-5408
J9 OPHTHAL PHYSL OPT
JI Ophthalmic Physiol. Opt.
PD MAR
PY 2006
VL 26
IS 2
BP 169
EP 179
DI 10.1111/j.1475-1313.2006.00367.x
PG 11
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 010EB
UT WOS:000235168600006
PM 16460317
DA 2022-11-30
ER

PT J
AU Forshaw, TRJ
   Ahmed, HJ
   Kjaer, TW
   Andreasson, S
   Sorensen, TL
AF Forshaw, Thomas Richard Johansen
   Ahmed, Hassan Javed
   Kjaer, Troels Wesenberg
   Andreasson, Sten
   Sorensen, Torben Lykke
TI Full-field Electroretinography in Age-related Macular Degeneration: can
   retinal electrophysiology predict the subjective visual outcome of
   cataract surgery?
SO ACTA OPHTHALMOLOGICA
LA English
DT Article
DE age-related macular degeneration; cataract surgery; full-field
   electroretinography; visual function questionnaire
ID ACUITY
AB Purpose Predicting the visual gain from cataract surgery when the main cause of vision loss is age-related macular degeneration may be difficult and warrants the need for an objective predictor of subjective outcome. Full-field electroretinography is an objective measure of overall retinal function. We therefore wanted to study if full-field electroretinography can predict subjective visual outcome using visual function questionnaire. Methods Thirty-one patients with age-related macular degeneration operated for bilateral cataract underwent full-field electroretinography preoperatively. Full-field electroretinography was performed according to International Society for the Clinical Electrophysiology of Vision standards using a Ganzfeld bowl (RETI-port/scan 21, Roland, Berlin) and Dawson-Trick-Litzkow fibre electrodes. Vision-related quality of life was measured using the National Eye Institute Visual Function Questionnaire-39 before first-eye surgery and 4.12 +/- 2.11 months after second-eye surgery. Results Mean change in composite visual function questionnaire score after cataract surgery was 9.2 +/- 11.9. The patients were divided into three groups: visual function questionnaire composite score increase >10 (n = 17); no change (n = 8); and decrease (n = 6). In the dark-adapted full-field electroretinography responses, we found a significant difference between the three groups in the 0.01 b-wave amplitude (p = 0.05), the 10.0 b-wave amplitude (p = 0.04) and a near-significant difference in 3.0 a-wave amplitude (p = 0.09). Other dark-adapted responses (the 3.0 b-wave and 10.0 a-wave) did not show any significant differences between the three groups, and neither did the light-adapted responses. Conclusion Patients with low dark-adapted responses on full-field electroretinography preoperatively experience a decrease in subjective vision-related quality of life, suggesting that maintained rod function before cataract surgery may be important.
C1 [Forshaw, Thomas Richard Johansen; Sorensen, Torben Lykke] Zealand Univ Hosp, Dept Ophthalmol, Vestermarksvej 23, DK-4000 Roskilde, Denmark.
   [Forshaw, Thomas Richard Johansen; Kjaer, Troels Wesenberg; Sorensen, Torben Lykke] Univ Copenhagen, Fac Hlth & Med Sci, Copenhagen, Denmark.
   [Ahmed, Hassan Javed] Zealand Univ Hosp, Dept Ophthalmol, Naestved, Denmark.
   [Kjaer, Troels Wesenberg] Zealand Univ Hosp, Dept Neurophysiol, Roskilde, Denmark.
   [Andreasson, Sten] Lund Univ, Dept Ophthalmol, Lund, Sweden.
C3 University of Copenhagen; Lund University
RP Forshaw, TRJ (通讯作者)，Zealand Univ Hosp, Dept Ophthalmol, Vestermarksvej 23, DK-4000 Roskilde, Denmark.
EM forshawthomas@yahoo.co.uk
RI Forshaw, Thomas Richard Johansen/AGF-9674-2022
OI Forshaw, Thomas Richard Johansen/0000-0003-0667-6514; Kjaer, Troels
   W/0000-0002-2105-6199
FU Danish Eye Research Foundation; Synoptik Foundation; Fight for Sight
   Denmark; Jascha Fund
FX The authors wish to thank Hassan Hamoudi, Gitte Henningsen, Charlotte
   Larsen, Marie Krogh Nielsen and Vlasios Safarikas who referred patients
   to this study. This study was supported by the Danish Eye Research
   Foundation, Synoptik Foundation, Fight for Sight Denmark, and the Jascha
   Fund. The funding bodies had no influence on the design of the study,
   analysis of the data, preparation of the manuscript, or the decision to
   publish. Authors declare that no potential conflicts of interest exist
   in relation to this work.
CR Black AA, 2008, OPTOMETRY VISION SCI, V85, P489, DOI 10.1097/OPX.0b013e31817882db
   Casparis H, 2017, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006757.pub4
   Curcio CA, 1996, INVEST OPHTH VIS SCI, V37, P1236
   Daien V, 2018, AM J OPHTHALMOL, V190, P50, DOI 10.1016/j.ajo.2018.03.012
   Forshaw TRJ, 2019, OPHTHALMOL RETINA, V3, P734, DOI 10.1016/j.oret.2019.04.014
   Gerth C, 2009, DOC OPHTHALMOL, V118, P63, DOI 10.1007/s10633-008-9133-x
   Grixti A, 2014, ISRN OPHTHALMOL, V2014, DOI DOI 10.1155/2014/417603.
   Huestegge Lynn, 2016, J Vis, V16, P11, DOI 10.1167/16.2.11
   Jakobsson G, 2015, INVEST OPHTH VIS SCI, V56, P3407, DOI 10.1167/iovs.15-16837
   Kessel L, 2016, ACTA OPHTHALMOL, V94, P755, DOI 10.1111/aos.13120
   Kessel L, 2011, ACTA OPHTHALMOL, V89, pe289, DOI 10.1111/j.1755-3768.2009.01839.x
   Lamoureux EL, 2007, OPTOMETRY VISION SCI, V84, P683, DOI 10.1097/OPX.0b013e31812f755f
   Lamoureux EL, 2011, CURR OPIN OPHTHALMOL, V22, P19, DOI 10.1097/ICU.0b013e3283414284
   Lundstrom M, 2002, BRIT J OPHTHALMOL, V86, P1330, DOI 10.1136/bjo.86.12.1330
   Ma YY, 2015, J CATARACT REFR SURG, V41, P1248, DOI 10.1016/j.jcrs.2014.09.046
   Marigold DS, 2008, EXERC SPORT SCI REV, V36, P145, DOI 10.1097/JES.0b013e31817bff72
   McCulloch DL, 2015, DOC OPHTHALMOL, V130, P1, DOI 10.1007/s10633-014-9473-7
   NAKAYAMA K, 1985, VISION RES, V25, P625, DOI 10.1016/0042-6989(85)90171-3
   Pedersen KB, 2016, GRAEF ARCH CLIN EXP, V254, P1897, DOI 10.1007/s00417-016-3323-0
   Pedersen KB, 2010, RETINA-J RET VIT DIS, V30, P1025, DOI 10.1097/IAE.0b013e3181cafc8f
   Peli E, 2016, J VISION, V16, DOI 10.1167/16.15.5
   Pham TQ, 2007, EYE, V21, P324, DOI 10.1038/sj.eye.6702171
   Quinn N, 2019, PROG RETIN EYE RES, V68, P83, DOI 10.1016/j.preteyeres.2018.10.001
   Sedeh FB, 2017, DAN MED J, V64
   Sorensen MS, 2011, DAN MED BULL, V58
   Sundhedstyrelsen, 2019, NAT CLIN GUID TREATM
   SUNNESS JS, 1985, ARCH OPHTHALMOL-CHIC, V103, P811
   Taipale C, 2018, ACTA OPHTHALMOL, V96, pE1039, DOI 10.1111/aos.13792
   Tuuminen R, 2020, ACTA OPHTHALMOL, V98, P7, DOI 10.1111/aos.14329
   Vargas-Martin F, 2006, INVEST OPHTH VIS SCI, V47, P5295, DOI 10.1167/iovs.05-1043
   Walter P, 1999, GRAEF ARCH CLIN EXP, V237, P962, DOI 10.1007/s004170050331
   Whitcup SM, 2013, INT J INFLAM, V2013, P1
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   World Health Organization Cataract Grading Group, 2002, SIMPL CAT GRAD SYST
NR 34
TC 3
Z9 3
U1 0
U2 1
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1755-375X
EI 1755-3768
J9 ACTA OPHTHALMOL
JI Acta Ophthalmol.
PD NOV
PY 2020
VL 98
IS 7
BP 693
EP 700
DI 10.1111/aos.14430
EA APR 2020
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA OC4CH
UT WOS:000563987600001
PM 32275357
DA 2022-11-30
ER

PT J
AU Morohoshi, K
   Ohbayashi, M
   Patel, N
   Chong, V
   Bird, AC
   Ono, SJ
AF Morohoshi, Kei
   Ohbayashi, Masaharu
   Patel, Nishal
   Chong, Victor
   Bird, Alan C.
   Ono, Santa J.
TI Identification of anti-retinal antibodies in patients with age-related
   macular degeneration
SO EXPERIMENTAL AND MOLECULAR PATHOLOGY
LA English
DT Article
DE Age-related macular degeneration; Anti-retinal antibody; Autoantibody
   profile; Pyruvate kinase; Aldolase
ID PYRUVATE-KINASE M2; REDOX PROTEOMICS; PATHOGENESIS; INFLAMMATION;
   INVOLVEMENT; BIOMARKERS; PROTEINS; ETIOLOGY; DRUSEN; MARKER
AB Age-related macular degeneration (AMD) is the leading cause of irreversible blindness in industrial counties. Recent findings indicate that the autoimmunity is involved in the pathogenesis of the disease. However, there is no autoantibody biomarker applied in a clinical setting for diagnosis and prognosis of AMD.
   In order to reveal retinal antigens targeted by serum IgG from AMD patients, mouse retinal tissue proteins were separated by 2-dimensional electrophoresis and the proteins in the immunoblots that were specific for dry and wet AMD patients IgG were identified by LC-MS/MS.
   Retinol-binding protein 3 and aldolase C (ALDOC) were mainly recognized by IgG form wet AMD patients. Pyruvate kinase M2 (PKM2) was targeted by both dry and wet AMD and level of anti-PKM2 IgG antibody was correlated best with the stage of AMD. Expression of ALDOC and PKM2 was decreased in mouse retina from aging whereas PKM2 deposit on RPE was increased in aged mice.
   Our data demonstrate that sera of AMD patients contain autoantibodies against retinal proteins and anti-PKM2 IgG serves as a biomarker for diagnosis and prognosis of AMD. Further investigation of the association of anti-retinal antibody level with expression level of antigens in retina will be needed to reveal the disease pathogenesis. (C) 2012 Elsevier Inc. All rights reserved.
C1 [Morohoshi, Kei; Ono, Santa J.] Univ Cincinnati, Coll Med, Cincinnati Childrens Hosp, Div Allergy & Immunol,Dept Pediat,Med Ctr, Cincinnati, OH 45221 USA.
   [Morohoshi, Kei] Tokyo Med & Dent Univ, Dept Ophthalmol, Tokyo, Japan.
   [Morohoshi, Kei; Ohbayashi, Masaharu; Ono, Santa J.] Emory Univ, Sch Med, Dept Ophthalmol, Atlanta, GA 30322 USA.
   [Morohoshi, Kei; Ohbayashi, Masaharu; Ono, Santa J.] Emory Eye Ctr, Dobbs Ocular Immunol Labs, Atlanta, GA USA.
   [Patel, Nishal] UCL, Inst Ophthalmol, London, England.
   [Chong, Victor] Kings Coll Hosp London, Laser & Retinal Res Unit, London, England.
   [Bird, Alan C.] Moorfields Eye Hosp, Med Retina Serv, London, England.
C3 Cincinnati Children's Hospital Medical Center; University System of
   Ohio; University of Cincinnati; Tokyo Medical & Dental University
   (TMDU); Emory University; University of London; University College
   London; King's College Hospital NHS Foundation Trust; King's College
   Hospital; University of London; University College London; Moorfields
   Eye Hospital NHS Foundation Trust
RP Ono, SJ (通讯作者)，Univ Cincinnati, Coll Med, Cincinnati Childrens Hosp, Div Allergy & Immunol,Dept Pediat,Med Ctr, 2614 McMicken Circle,210 Van Wormer Hall,POB 2100, Cincinnati, OH 45221 USA.
EM santa.ono@uc.edu
RI Chong, Victor/Q-6565-2018
OI Chong, Victor/0000-0002-7693-522X; Morohoshi, Kei/0000-0002-2891-9073
FU R. Howard Dobbs, Jr. Foundation; Special Trustees of Moorfields Eye
   Hospital
FX This work was supported by the R. Howard Dobbs, Jr. Foundation and the
   Special Trustees of Moorfields Eye Hospital. We are grateful to Anne
   Goodwin for manuscript editing.
CR Ahn BY, 2006, PROTEOMICS, V6, P1200, DOI 10.1002/pmic.200500457
   Ambati J, 2003, SURV OPHTHALMOL, V48, P257, DOI 10.1016/S0039-6257(03)00030-4
   ASHIZAWA K, 1991, J BIOL CHEM, V266, P16842
   Avichezer D, 2000, INVEST OPHTH VIS SCI, V41, P127
   Braus BK, 2008, VET IMMUNOL IMMUNOP, V124, P177, DOI 10.1016/j.vetimm.2008.02.020
   Butterfield DA, 2006, NEUROBIOL DIS, V22, P223, DOI 10.1016/j.nbd.2005.11.002
   CAFFE AR, 1994, J COMP NEUROL, V348, P291, DOI 10.1002/cne.903480210
   Cano M, 2010, VISION RES, V50, P652, DOI 10.1016/j.visres.2009.08.018
   Crabb JW, 2002, P NATL ACAD SCI USA, V99, P14682, DOI 10.1073/pnas.222551899
   Deeg CA, 2007, CLIN DEV IMMUNOL, DOI 10.1155/2007/39245
   Donoso LA, 2006, SURV OPHTHALMOL, V51, P137, DOI 10.1016/j.survophthal.2005.12.001
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Gu JY, 2010, ADV EXP MED BIOL, V664, P411, DOI 10.1007/978-1-4419-1399-9_47
   Gu XR, 2003, J BIOL CHEM, V278, P42027, DOI 10.1074/jbc.M305460200
   Gupta V, 2010, PROTEIN SCI, V19, P2031, DOI 10.1002/pro.505
   Heckenlively JR, 1999, AM J OPHTHALMOL, V127, P565, DOI 10.1016/S0002-9394(98)00446-2
   Hollyfield JG, 2008, NAT MED, V14, P194, DOI 10.1038/nm1709
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Joachim S.C., 2006, GRAEFES ARCH CLIN EX
   Kaarniranta K, 2011, J ALZHEIMERS DIS, V24, P615, DOI 10.3233/JAD-2011-101908
   Liao WL, 2009, INVEST OPHTH VIS SCI, V50, P4992, DOI 10.1167/iovs.09-3671
   Mamczur P, 2010, CELL TISSUE RES, V341, P213, DOI 10.1007/s00441-010-1008-2
   Milton RC, 2005, OPHTHALMOLOGY, V112, P533, DOI 10.1016/j.ophtha.2004.10.047
   Morohoshi K, 2012, EXP MOL PATHOL, V92, P64, DOI 10.1016/j.yexmp.2011.09.017
   Morohoshi K, 2009, J AUTOIMMUN, V33, P247, DOI 10.1016/j.jaut.2009.09.003
   Ohguro H, 2004, AM J OPHTHALMOL, V137, P1117, DOI 10.1016/j.ajo.2004.01.010
   Ohno-Matsui K, 2011, PROG RETIN EYE RES, V30, P217, DOI 10.1016/j.preteyeres.2011.02.004
   Patel N, 2005, IMMUNOLOGY, V115, P422, DOI 10.1111/j.1365-2567.2005.02173.x
   Perluigi M, 2010, J NEUROSCI RES, V88, P3498, DOI 10.1002/jnr.22500
   Rein DB, 2009, ARCH OPHTHALMOL-CHIC, V127, P533, DOI 10.1001/archophthalmol.2009.58
   Seddon JM, 1997, AM J OPHTHALMOL, V123, P199, DOI 10.1016/S0002-9394(14)71036-0
   Stetak A, 2007, CANCER RES, V67, P1602, DOI 10.1158/0008-5472.CAN-06-2870
   Tanito M, 2006, FREE RADICAL BIO MED, V41, P1847, DOI 10.1016/j.freeradbiomed.2006.09.012
   Thornton J, 2005, EYE, V19, P935, DOI 10.1038/sj.eye.6701978
   Umeda S, 2005, FASEB J, V19, P1683, DOI 10.1096/fj.04-3525fje
NR 35
TC 50
Z9 53
U1 0
U2 3
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0014-4800
EI 1096-0945
J9 EXP MOL PATHOL
JI Exp. Mol. Pathol.
PD OCT
PY 2012
VL 93
IS 2
BP 193
EP 199
DI 10.1016/j.yexmp.2012.03.007
PG 7
WC Pathology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pathology
GA 990DL
UT WOS:000307611100003
PM 22465421
DA 2022-11-30
ER

PT J
AU Choudhary, M
   Ding, JD
   Qi, XP
   Boulton, ME
   Yao, PL
   Peters, JM
   Malek, G
AF Choudhary, Mayur
   Ding, Jin-dong
   Qi, Xiaoping
   Boulton, Michael E.
   Yao, Pei-Li
   Peters, Jeffrey M.
   Malek, Goldis
TI PPAR beta/delta selectively regulates phenotypic features of age-related
   macular degeneration
SO AGING-US
LA English
DT Article
DE age-related macular degeneration; PPAR beta/delta; nuclear receptors;
   inflammation; angiogenesis; choroidal neovascularization
ID ACTIVATED-RECEPTOR-BETA/DELTA; OPTICAL COHERENCE TOMOGRAPHY; NUCLEAR
   RECEPTORS; BRUCHS MEMBRANE; CHOROIDAL NEOVASCULARIZATION;
   INSULIN-RESISTANCE; GENE-EXPRESSION; DELTA; MODULATORS; GROWTH
AB Peroxisome proliferator-activated receptor-beta/delta (PPAR beta/delta) is a nuclear receptor that regulates differentiation, inflammation, lipid metabolism, extracellular matrix remodeling, and angiogenesis in multiple tissues. These pathways are also central to the pathogenesis of age-related macular degeneration (AMD), the leading cause of vision loss globally. With the goal of identifying signaling pathways that may be important in the development of AMD, we investigated the impact of PPAR beta/delta activation on ocular tissues affected in the disease. PPAR beta/delta is expressed and can be activated in AMD vulnerable cells, including retinal pigment epithelial (RPE) and choroidal endothelial cells. Further, PPAR beta/delta knockdown modulates AMD-related pathways selectively. Specifically, genetic ablation of Ppar beta/delta in aged mice resulted in exacerbation of several phenotypic features of early dry AMD, but attenuation of experimentally induced choroidal neovascular (CNV) lesions. Antagonizing PPAR beta/delta in both in vitro angiogenesis assays and in the in vivo experimentally induced CNV model, inhibited angiogenesis and angiogenic pathways, while ligand activation of PPAR beta/delta, in vitro, decreased RPE lipid accumulation, characteristic of dry AMD. This study demonstrates for the first time, selective regulation of a nuclear receptor in the eye and establishes that selective targeting of PPAR beta/delta may be a suitable strategy for treatment of different clinical sub-types of AMD.
C1 [Choudhary, Mayur; Ding, Jin-dong; Malek, Goldis] Duke Univ, Sch Med, Dept Ophthalmol, Durham, NC 27703 USA.
   [Qi, Xiaoping; Boulton, Michael E.] Indiana Univ Sch Med, Dept Ophthalmol, Indianapolis, IN 46202 USA.
   [Yao, Pei-Li; Peters, Jeffrey M.] Penn State Univ, Dept Vet & Biomed Sci, University Pk, PA 16802 USA.
   [Malek, Goldis] Duke Univ, Sch Med, Dept Pathol, Durham, NC 27703 USA.
C3 Duke University; Indiana University System; Indiana University
   Bloomington; Pennsylvania Commonwealth System of Higher Education
   (PCSHE); Pennsylvania State University; Pennsylvania State University -
   University Park; Duke University
RP Malek, G (通讯作者)，Duke Univ, Sch Med, Dept Ophthalmol, Durham, NC 27703 USA.; Malek, G (通讯作者)，Duke Univ, Sch Med, Dept Pathol, Durham, NC 27703 USA.
EM gmalek@duke.edu
RI Choudhary, Mayur/AAU-3497-2021
OI Choudhary, Mayur/0000-0001-8056-011X; Peters,
   Jeffrey/0000-0003-2782-2998; Yao, Pei-Li/0000-0003-0832-3771; Malek,
   Goldis/0000-0003-0026-2388
FU National Eye Institute [EY02868]; NEI [P30 EY005722]; Research to
   Prevent Blindness Core Grant; NATIONAL EYE INSTITUTE [R01EY020868,
   P30EY005722] Funding Source: NIH RePORTER
FX This work was supported by the National Eye Institute grant EY02868
   (GM), NEI P30 EY005722 (Duke Eye Center) and Research to Prevent
   Blindness Core Grant (Duke Eye Center).
CR Algvere PV, 2008, ACTA OPHTHALMOL, V86, P482, DOI 10.1111/j.1600-0420.2007.01113.x
   Ambati J, 2003, SURV OPHTHALMOL, V48, P257, DOI 10.1016/S0039-6257(03)00030-4
   Ambati J, 2013, NAT REV IMMUNOL, V13, P438, DOI 10.1038/nri3459
   Ambati J, 2012, NEURON, V75, P26, DOI 10.1016/j.neuron.2012.06.018
   Anderson DH, 2010, PROG RETIN EYE RES, V29, P95, DOI 10.1016/j.preteyeres.2009.11.003
   Arnaoutova I, 2009, ANGIOGENESIS, V12, P267, DOI 10.1007/s10456-009-9146-4
   Bojic LA, 2014, ARTERIOSCL THROM VAS, V34, P52, DOI 10.1161/ATVBAHA.113.301830
   Bojic LA, 2012, ARTERIOSCL THROM VAS, V32, P2919, DOI 10.1161/ATVBAHA.112.255208
   Burdick AD, 2006, CELL SIGNAL, V18, P9, DOI 10.1016/j.cellsig.2005.07.009
   Cai J, 2012, EMBO MOL MED, V4, P980, DOI 10.1002/emmm.201101084
   Capozzi ME, 2013, INVEST OPHTH VIS SCI, V54, P4197, DOI 10.1167/iovs.13-11608
   Channa R, 2015, AM J OPHTHALMOL, V159, P9, DOI 10.1016/j.ajo.2014.09.012
   Chen YL, 2009, OPT EXPRESS, V17, P4046, DOI 10.1364/OE.17.004046
   Choudhary M, 2016, ADV EXP MED BIOL, V854, P45, DOI 10.1007/978-3-319-17121-0_7
   Choudhary M, 2015, J PATHOL, V235, P101, DOI 10.1002/path.4433
   CLARK RAF, 1982, J EXP MED, V156, P646, DOI 10.1084/jem.156.2.646
   Curcio CA, 2010, J LIPID RES, V51, P451, DOI 10.1194/jlr.R002238
   Curcio CA, 2009, PROG RETIN EYE RES, V28, P393, DOI 10.1016/j.preteyeres.2009.08.001
   Davis George E., 2007, Birth Defects Research, V81, P270, DOI 10.1002/bdrc.20107
   Ebrahimi KB, 2011, J LIPIDS, V2011, DOI 10.1155/2011/802059
   Feldman PL, 2008, CURR TOP MED CHEM, V8, P728, DOI 10.2174/156802608784535084
   Galuppo M, 2010, INT J IMMUNOPATH PH, V23, P1033, DOI 10.1177/039463201002300408
   Graham TL, 2005, ATHEROSCLEROSIS, V181, P29, DOI 10.1016/j.atherosclerosis.2004.12.028
   GREEN WR, 1985, OPHTHALMOLOGY, V92, P615
   GROSSNIKLAUS HE, 1992, AM J OPHTHALMOL, V114, P464, DOI 10.1016/S0002-9394(14)71859-8
   Guo SZ, 2014, METHODS MOL BIOL, V1135, P393, DOI 10.1007/978-1-4939-0320-7_32
   Gupta N, 2003, EXP EYE RES, V76, P463, DOI 10.1016/S0014-4835(02)00332-9
   Hageman GS, 1999, FASEB J, V13, P477, DOI 10.1096/fasebj.13.3.477
   Hall JM, 2007, MOL ENDOCRINOL, V21, P1756, DOI 10.1210/me.2007-0060
   Hao NB, 2012, CLIN DEV IMMUNOL, DOI 10.1155/2012/948098
   Hee MR, 1996, OPHTHALMOLOGY, V103, P1260, DOI 10.1016/S0161-6420(96)30512-5
   Hollingshead HE, 2007, CARCINOGENESIS, V28, P2641, DOI 10.1093/carcin/bgm183
   Hu P, 2013, P NATL ACAD SCI USA, V110, pE4069, DOI 10.1073/pnas.1307574110
   Huang JD, 2007, EXP EYE RES, V85, P202, DOI 10.1016/j.exer.2007.03.011
   Kang K, 2008, CELL METAB, V7, P485, DOI 10.1016/j.cmet.2008.04.002
   Kilgore KS, 2008, CURR OPIN INVEST DR, V9, P463
   Lee CH, 2006, P NATL ACAD SCI USA, V103, P2434, DOI 10.1073/pnas.0510815103
   Li CM, 2005, INVEST OPHTH VIS SCI, V46, P2576, DOI 10.1167/iovs.05-0034
   Liu G, 2013, BIOMED RES INT, V2013, DOI [10.1155/2013/903947, DOI 10.1155/2013/903947]
   Luquet S, 2005, BBA-MOL BASIS DIS, V1740, P313, DOI 10.1016/j.bbadis.2004.11.011
   Malek G, 2014, CELL MOL LIFE SCI, V71, P4617, DOI 10.1007/s00018-014-1709-x
   Malek G, 2014, ADV EXP MED BIOL, V801, P317, DOI 10.1007/978-1-4614-3209-8_40
   Martinkovich S, 2014, CLIN INTERV AGING, V9, P1437, DOI 10.2147/CIA.S66690
   Matsushita Y, 2011, DIABETES, V60, P960, DOI 10.2337/db10-1361
   Maximov PY, 2013, CURR CLIN PHARMACOL, V8, P135, DOI 10.2174/1574884711308020006
   Murray PJ, 2011, NAT REV IMMUNOL, V11, P723, DOI 10.1038/nri3073
   NEWSOME DA, 1987, AM J OPHTHALMOL, V104, P373, DOI 10.1016/0002-9394(87)90227-3
   Ng EWM, 2005, CAN J OPHTHALMOL, V40, P352, DOI 10.1016/S0008-4182(05)80078-X
   Odegaard JI, 2008, CELL METAB, V7, P496, DOI 10.1016/j.cmet.2008.04.003
   Paterniti I, 2012, SURGERY, V152, P90, DOI 10.1016/j.surg.2012.02.004
   Peters JM, 2011, CANCER METAST REV, V30, P619, DOI 10.1007/s10555-011-9320-1
   Peters JM, 2009, BBA-REV CANCER, V1796, P230, DOI 10.1016/j.bbcan.2009.06.002
   Peters JM, 2000, MOL CELL BIOL, V20, P5119, DOI 10.1128/MCB.20.14.5119-5128.2000
   Reale E, 2009, CELLS TISSUES ORGANS, V190, P170, DOI 10.1159/000187632
   Safi R, 2005, CANCER RES, V65, P11762, DOI 10.1158/0008-5472.CAN-05-2792
   Schnegg CI, 2011, PPAR RES, V2011, DOI 10.1155/2011/373560
   Strauss O., 1995, RETINAL PIGMENT EPIT
   Suarez S, 2014, INVEST OPHTH VIS SCI, V55, P8232, DOI 10.1167/iovs.14-14217
   Toral M, 2015, J HYPERTENS, V33, P1831, DOI 10.1097/HJH.0000000000000634
   Vazquez-Carrera M, 2016, TRENDS ENDOCRIN MET, V27, P319, DOI 10.1016/j.tem.2016.02.008
   Wagner KD, 2010, PHARMACOL THERAPEUT, V125, P423, DOI 10.1016/j.pharmthera.2009.12.001
   Whitmore SS, 2013, MOL VIS, V19, P2274
   Zarbin MA, 2004, ARCH OPHTHALMOL-CHIC, V122, P598, DOI 10.1001/archopht.122.4.598
   Zhou Z, 2016, HISTOCHEM CELL BIOL
NR 64
TC 26
Z9 27
U1 0
U2 6
PU IMPACT JOURNALS LLC
PI ORCHARD PARK
PA 6666 E QUAKER ST, STE 1, ORCHARD PARK, NY 14127 USA
SN 1945-4589
J9 AGING-US
JI Aging-US
PD SEP
PY 2016
VL 8
IS 9
BP 1952
EP 1978
DI 10.18632/aging.101031
PG 27
WC Cell Biology; Geriatrics & Gerontology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology; Geriatrics & Gerontology
GA EF4OY
UT WOS:000390311600012
PM 27622388
OA Green Published, Green Submitted, gold
DA 2022-11-30
ER

PT J
AU Wilson, HL
   Schwartz, DM
   Bhatt, HRF
   McCulloch, CE
   Duncan, JL
AF Wilson, HL
   Schwartz, DM
   Bhatt, HRF
   McCulloch, CE
   Duncan, JL
TI Statin and aspirin therapy are associated with decreased rates of
   choroidal neovascularization among patients with age-related macular
   degeneration
SO AMERICAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID CORONARY-ARTERY-DISEASE; COA REDUCTASE INHIBITOR; RISK-FACTORS;
   CARDIOVASCULAR-DISEASE; 5-YEAR INCIDENCE; APOLIPOPROTEIN-E; MATRIX
   METALLOPROTEINASE-7; RANDOMIZED TRIAL; BRUCHS MEMBRANE; DIETARY-FAT
AB PURPOSE: To investigate the relationship between statin and aspirin use and the risk of choroidal neovascularization (CNV) in patients with age-related macular degeneration (AMD).
   DESIGN: Retrospective consecutive case series.
   METHODS: All patients 60 years and older with AMD who were seen between January 1, 1990, and March 1, 2003, at the San Francisco Veterans Affairs Hospital Eye Clinic with fundus photographs were included. Patients with other diagnoses predisposing to CNV or incomplete medical records were excluded. The main outcome measure was angiographically evident CNV. Diagnosis was based on review of fundus photographs and fluorescein angiograms in masked fashion; medical records were reviewed for variables possibly predisposing to CNV or statin use. For patients with CNV, age of onset was recorded; those without CNV were treated as censored. Age related macular degeneration disease status and time of onset of CNV was compared between patients treated or not treated with statins for at least 6 months.
   RESULTS: Of 326 patients with AMD, 104 had CNV, 204 had dry AMD, and 18 had geographic atrophy (GA). Of CNV subjects, 21 (20%) used statins, compared with 77 (38%) of dry AMD subjects without GA and 6 (33%) of controls with GA (hazard ratio = 0.51, 95% confidence interval (CI) = 0.31-0.86, P =.01). Aspirin use was also significantly associated with decreased rates of CNV; 62 CNV subjects (60%) used aspirin, compared with 154 (75%) dry AMD subjects without GA or 12 (67%) with GA (hazard ratio = 0.63, 95% CI 0.40-0-98, P =.04).
   CONCLUSIONS: Therapy with statins or aspirin is associated with decreased rates of CNV among AMD patients. Additional study with a prospective and/or randomized trial of statin and aspirin use in AMD patients is warranted. (C) 2004 by Elsevier Inc. All rights reserved.
C1 Univ Calif San Francisco, Dept Ophthalmol, San Francisco, CA 94143 USA.
   Univ Calif San Francisco, Sch Med, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA.
   Vet Affairs Med Ctr, Dept Ophthalmol, San Francisco, CA 94121 USA.
   Vet Affairs Med Ctr, Dept Gen Internal Med, San Francisco, CA 94121 USA.
C3 University of California System; University of California San Francisco;
   University of California System; University of California San Francisco;
   US Department of Veterans Affairs; Veterans Health Administration (VHA);
   US Department of Veterans Affairs; Veterans Health Administration (VHA)
RP Duncan, JL (通讯作者)，Univ Calif San Francisco, Dept Ophthalmol, 10 Koret Way,K129, San Francisco, CA 94143 USA.
EM jduncan@itsa.ucsf.edu
FU NATIONAL EYE INSTITUTE [P30EY002162] Funding Source: NIH RePORTER; NEI
   NIH HHS [EY02162, EY00415] Funding Source: Medline
CR Abalain JH, 2002, CLIN CHIM ACTA, V326, P97, DOI 10.1016/S0009-8981(02)00288-7
   Albert MA, 2001, JAMA-J AM MED ASSOC, V286, P64, DOI 10.1001/jama.286.1.64
   Anand R, 2000, OPHTHALMOLOGY, V107, P2224
   Bestehorn HP, 1997, EUR HEART J, V18, P226
   BIRD AC, 1986, T OPHTHAL SOC UK, V105, P674
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Blanco-Colio LM, 2003, KIDNEY INT, V63, P12, DOI 10.1046/j.1523-1755.2003.00744.x
   BLANKENHORN DH, 1993, ANN INTERN MED, V119, P969, DOI 10.7326/0003-4819-119-10-199311150-00002
   Blumenthal RS, 2000, AM HEART J, V139, P577, DOI 10.1016/S0002-8703(00)90033-4
   BROWN BG, 1993, CIRCULATION, V87, P1781, DOI 10.1161/01.CIR.87.6.1781
   BROWN G, 1990, NEW ENGL J MED, V323, P1289, DOI 10.1056/NEJM199011083231901
   Byington RP, 2001, CIRCULATION, V103, P387
   Callahan AS, 2001, J NEUROIMAGING, V11, P202, DOI 10.1111/j.1552-6569.2001.tb00034.x
   Christen WG, 2001, ARCH OPHTHALMOL-CHIC, V119, P1143, DOI 10.1001/archopht.119.8.1143
   Collins R, 2002, LANCET, V360, P7, DOI 10.1016/S0140-6736(02)09327-3
   Corti R, 2001, CIRCULATION, V104, P249, DOI 10.1161/01.CIR.104.3.249
   Curcio CA, 2001, INVEST OPHTH VIS SCI, V42, P265
   DELACOURT C, 2001, OPHTHAL EPIDEMIOL, V8, P237
   Dithmar S, 2000, INVEST OPHTH VIS SCI, V41, P2035
   FERRIS FL, 1984, ARCH OPHTHALMOL-CHIC, V102, P1640
   Freeman DJ, 2001, CIRCULATION, V103, P357
   Furberg CD, 2002, JAMA-J AM MED ASSOC, V288, P2998, DOI 10.1001/jama.288.23.2998
   Gould K. Lance, 1998, American Journal of Medicine, V104, p2S, DOI 10.1016/S0002-9343(98)00140-5
   Hall NF, 2001, BRIT MED J, V323, P375, DOI 10.1136/bmj.323.7309.375
   Hattenbach LO, 2002, OPHTHALMOLOGICA, V216, P209, DOI 10.1159/000059634
   Herd JA, 1997, AM J CARDIOL, V80, P278, DOI 10.1016/S0002-9149(97)00346-9
   Holdaas H, 2001, KIDNEY INT, V60, P1990, DOI 10.1046/j.1523-1755.2001.00010.x
   HOLZ FG, 1994, ARCH OPHTHALMOL-CHIC, V112, P402, DOI 10.1001/archopht.1994.01090150132035
   Hyman L, 2000, ARCH OPHTHALMOL-CHIC, V118, P351, DOI 10.1001/archopht.118.3.351
   Jick H, 2000, LANCET, V356, P1627, DOI 10.1016/S0140-6736(00)03155-X
   Johnson BA, 2003, AM J RESP CRIT CARE, V167, P1271, DOI 10.1164/rccm.200205-410OC
   JUKEMA JW, 1995, CIRCULATION, V91, P2528, DOI 10.1161/01.CIR.91.10.2528
   Kadonosono K, 1999, AM J OPHTHALMOL, V128, P382, DOI 10.1016/S0002-9394(99)00135-X
   KAHN HA, 1977, AM J EPIDEMIOL, V106, P33, DOI 10.1093/oxfordjournals.aje.a112429
   Kasiske BL, 2001, TRANSPLANTATION, V72, P223, DOI 10.1097/00007890-200107270-00009
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   KILLINGSWORTH MC, 1990, EYE, V4, P613, DOI 10.1038/eye.1990.86
   Klaver CCW, 1998, AM J HUM GENET, V63, P200, DOI 10.1086/301901
   KLEIN BE, 1982, ARCH OPHTHALMOL-CHIC, V100, P571
   KLEIN ML, 1991, JAMA-J AM MED ASSOC, V266, P2279
   KLEIN R, 1993, AM J EPIDEMIOL, V137, P190, DOI 10.1093/oxfordjournals.aje.a116659
   Klein R, 2003, ARCH OPHTHALMOL-CHIC, V121, P1151, DOI 10.1001/archopht.121.8.1151
   Klein R, 2003, OPHTHALMOLOGY, V110, P636, DOI 10.1016/S0161-6420(02)01448-3
   Klein R, 1997, OPHTHALMOLOGY, V104, P1804, DOI 10.1016/S0161-6420(97)30023-2
   Klein R, 2001, ARCH OPHTHALMOL-CHIC, V119, P1354
   KLEIN R, 1993, OPHTHALMOLOGY, V100, P406
   KLEIN R, 1999, AGE RELATED MACULAR, P31
   KOBASHIGAWA JA, 1995, NEW ENGL J MED, V333, P621, DOI 10.1056/NEJM199509073331003
   Lawless, 2011, STAT MODELS METHODS
   Leung BP, 2003, J IMMUNOL, V170, P1524, DOI 10.4049/jimmunol.170.3.1524
   LOPEZ PF, 1991, AM J OPHTHALMOL, V112, P647, DOI 10.1016/S0002-9394(14)77270-8
   Maguire MG, 1997, ARCH OPHTHALMOL-CHIC, V115, P741
   MAGUIRE MG, 1990, ARCH OPHTHALMOL-CHIC, V108, P825
   MAGUIRE MG, 1986, ARCH OPHTHALMOL-CHIC, V104, P503
   MARESPERLMAN JA, 1995, ARCH OPHTHALMOL-CHIC, V113, P743, DOI 10.1001/archopht.1995.01100060069034
   McCarty CA, 2001, ARCH OPHTHALMOL-CHIC, V119, P1455
   McCarty CA, 2001, MED J AUSTRALIA, V175, P340, DOI 10.5694/j.1326-5377.2001.tb143604.x
   McGwin G, 2003, BRIT J OPHTHALMOL, V87, P1121, DOI 10.1136/bjo.87.9.1121
   Meroni PL, 2002, CLIN REV ALLERG IMMU, V23, P263, DOI 10.1385/CRIAI:23:3:263
   Mitchell P, 2002, ARCH OPHTHALMOL-CHIC, V120, P1357, DOI 10.1001/archopht.120.10.1357
   MITCHELL P, 1995, OPHTHALMOLOGY, V102, P1450
   Niffenegger J, 1998, OPHTHALMOLOGY, V105, P1364
   Oh H, 1999, INVEST OPHTH VIS SCI, V40, P1891
   OLIVER MF, 1994, LANCET, V344, P633
   Ong JM, 2001, INVEST OPHTH VIS SCI, V42, P1891
   PEDERSEN TR, 1994, LANCET, V344, P1383
   PENFOLD PL, 1985, GRAEF ARCH CLIN EXP, V223, P69, DOI 10.1007/BF02150948
   PITT B, 1995, J AM COLL CARDIOL, V26, P1133, DOI 10.1016/0735-1097(95)00301-0
   Qi JH, 2002, J BIOL CHEM, V277, P13394, DOI 10.1074/jbc.M110870200
   Sacks FM, 1996, NEW ENGL J MED, V335, P1001, DOI 10.1056/NEJM199610033351401
   Sahu KM, 2001, CLIN TRANSPLANT, V15, P173, DOI 10.1034/j.1399-0012.2001.150305.x
   SANDERS TAB, 1993, AM J CLIN NUTR, V57, P428, DOI 10.1093/ajcn/57.3.428
   Seddon JM, 2001, ARCH OPHTHALMOL-CHIC, V119, P1191, DOI 10.1001/archopht.119.8.1191
   Smith W, 1998, ARCH OPHTHALMOL-CHIC, V116, P583, DOI 10.1001/archopht.116.5.583
   Smith W, 2001, OPHTHALMOLOGY, V108, P697, DOI 10.1016/S0161-6420(00)00580-7
   Snow K K, 1999, Ophthalmic Epidemiol, V6, P125, DOI 10.1076/opep.6.2.125.1558
   Steen B, 1998, INVEST OPHTH VIS SCI, V39, P2194
   STERNBERG P, 1991, ARCH OPHTHALMOL-CHIC, V109, P1242
   Taylor HR, 2001, BRIT J OPHTHALMOL, V85, P261, DOI 10.1136/bjo.85.3.261
   van Leeuwen R, 2003, ARCH OPHTHALMOL-CHIC, V121, P519, DOI 10.1001/archopht.121.4.519
   van Leeuwen R, 2003, BRIT MED J, V326, P255, DOI 10.1136/bmj.326.7383.255
   van Leeuwen R, 2001, BRIT MED J, V323, P1308, DOI 10.1136/bmj.323.7324.1308a
   Vaughan CJ, 2000, J AM COLL CARDIOL, V35, P1, DOI 10.1016/S0735-1097(99)00525-2
   Vaughan CJ, 1996, LANCET, V348, P1079, DOI 10.1016/S0140-6736(96)05190-2
   VIDAURRI JS, 1984, OPHTHALMOLOGICA, V188, P243, DOI 10.1159/000309370
   VINGERLING JR, 1995, AM J EPIDEMIOL, V142, P404, DOI 10.1093/oxfordjournals.aje.a117648
   WATERS D, 1994, CIRCULATION, V89, P959, DOI 10.1161/01.CIR.89.3.959
   Willard NR, 2002, CELL MOL LIFE SCI, V59, P1771, DOI 10.1007/PL00012505
   Wolozin B, 2000, ARCH NEUROL-CHICAGO, V57, P1439, DOI 10.1001/archneur.57.10.1439
   YANNUZZI LA, 1992, ARCH OPHTHALMOL-CHIC, V110, P1701
   Yazama F, 2002, J ELECTRON MICROSC, V51, P127, DOI 10.1093/jmicro/51.2.127
   Youssef S, 2002, NATURE, V420, P78, DOI 10.1038/nature01158
NR 92
TC 116
Z9 121
U1 0
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0002-9394
EI 1879-1891
J9 AM J OPHTHALMOL
JI Am. J. Ophthalmol.
PD APR
PY 2004
VL 137
IS 4
BP 615
EP 624
DI 10.1016/j.ajo.2003.10.025
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 811HK
UT WOS:000220762800002
PM 15059698
DA 2022-11-30
ER

PT J
AU Ying, GS
   Kim, BJ
   Maguire, MG
   Huang, JY
   Daniel, E
   Jaffe, GJ
   Grunwald, JE
   Blinder, KJ
   Flaxel, CJ
   Rahhal, F
   Regillo, C
   Martin, DF
AF Ying, Gui-shuang
   Kim, Benjamin J.
   Maguire, Maureen G.
   Huang, Jiayan
   Daniel, Ebenezer
   Jaffe, Glenn J.
   Grunwald, Juan E.
   Blinder, Kevin J.
   Flaxel, Christina J.
   Rahhal, Firas
   Regillo, Carl
   Martin, Daniel F.
CA CATT Res Grp
TI Sustained Visual Acuity Loss in the Comparison of Age-Related Macular
   Degeneration Treatments Trials
SO JAMA OPHTHALMOLOGY
LA English
DT Article
ID RANIBIZUMAB; BEVACIZUMAB
AB IMPORTANCE Although anti-vascular endothelial growth factor treatment of neovascular age-related macular degeneration (AMD) results in improved vision overall, loss of substantial vision can occur. Understanding the processes that lead to loss of vision may lead to preventive strategies.
   OBJECTIVE To determine the incidence, characteristics, causes, and baseline predictors of sustained visual acuity loss after 2 years of treatment with ranibizumab or bevacizumab for neovascular AMD.
   DESIGN, SETTING, AND PARTICIPANTS A cohort study within a randomized clinical trial of participants in the Comparison of Age-Related Macular Degeneration Treatments Trials (CATT).
   INTERVENTIONS Participants were randomly assigned to treatment with ranibizumab or bevacizumab and to 2 years of monthly or as needed injections or monthly injections for 1 year and as needed injections the following year.
   MAIN OUTCOMES AND MEASURES Sustained visual acuity loss, defined as loss of 15 or more letters from baseline at weeks 88 and 104.
   RESULTS Among 1030 participants, 61 eyes (5.9%) developed sustained visual acuity loss in 2 years. Within this group, visual acuity decreased gradually over time, with a mean decrease of 2, 19, and 33 letters from baseline at 4 weeks, 1 year, and 2 years, respectively. At 2 years, eyes with sustained visual acuity loss had more scarring (60.0% vs 41.4%, P = .007), more geographic atrophy (GA) (31.6% vs 20.7%, P = .004), larger lesions (16 vs 8 mm(2), P < .001), and higher proportions of intraretinal fluid (82.5% vs 51.0%, P < .001), subretinal hyperreflective material (84.5% vs 44.2%, P < .001), retinal thinning (43.3% vs 23.0%, P < .001), and thickening (20.0% vs 12.1%, P < .001). Likely causes of sustained visual acuity loss included foveal scarring (44.3%), pigmentary abnormalities (27.9%), and foveal GA (11.5%). Baseline factors independently associated with a higher incidence of sustained visual acuity loss were the presence of nonfoveal GA (odds ratio [OR], 2.86; 95% CI, 1.35-6.08; P = .006), larger area of choroidal neovascularization (OR for a >4-disc area vs <= 1-disc area, 3.91; 95% CI, 1.70-9.03; P = .007), and bevacizumab treatment (OR, 1.83; 95% CI, 1.07-3.14; P = .03).
   CONCLUSIONS AND RELEVANCE Sustained visual acuity loss was relatively rare in CATT. The development of foveal scar, pigmentary abnormalities, or GA contributed to most of the sustained visual acuity loss. Risk was 3% higher among eyes treated with bevacizumab. Treatment that targeted the prevention of scarring or GA may improve vision outcomes. Copyright 2014 American Medical Association. All rights reserved.
C1 [Ying, Gui-shuang; Kim, Benjamin J.; Maguire, Maureen G.; Huang, Jiayan; Daniel, Ebenezer; Grunwald, Juan E.] Univ Penn, Dept Ophthalmol, Perelman Sch Med, Philadelphia, PA 19104 USA.
   [Jaffe, Glenn J.] Duke Univ, Med Ctr, Duke Eye Ctr, Durham, NC USA.
   [Blinder, Kevin J.] Barnes Retina Inst, St Louis, MO USA.
   [Flaxel, Christina J.] Oregon Hlth & Sci Univ, Casey Eye Inst, Portland, OR 97201 USA.
   [Rahhal, Firas] Retina Vitreous Associates Med Grp, Beverly Hills, CA USA.
   [Regillo, Carl] Thomas Jefferson Univ, Wills Eye Hosp, Wills Eye Retina Serv, Philadelphia, PA 19107 USA.
   [Martin, Daniel F.] Cleveland Clin, Cole Eye Inst, Cleveland, OH 44106 USA.
C3 University of Pennsylvania; Pennsylvania Medicine; Duke University;
   Washington University (WUSTL); Oregon Health & Science University;
   Retina Vitreous Associates Medical Group; Jefferson University;
   Cleveland Clinic Foundation
RP Ying, GS (通讯作者)，Univ Penn, Scheie Eye Inst, 3535 Market St,Ste 700, Philadelphia, PA 19104 USA.
EM gsying@mail.med.upenn.edu
RI Kim, Benjamin/AAG-3786-2019
OI Kim, Benjamin/0000-0003-0230-3868; Stinnett, Sandra/0000-0001-7192-0195
FU National Eye Institute, National Institutes of Health, US Department of
   Health and Human Services [U10 EY017823, U10 EY017825, U10 EY017826, U10
   EY017828]; NATIONAL EYE INSTITUTE [U10EY017828, U10EY017826,
   U10EY017825, U10EY017823] Funding Source: NIH RePORTER
FX This study was supported by cooperative agreements U10 EY017823, U10
   EY017825, U10 EY017826, and U10 EY017828 from the National Eye
   Institute, National Institutes of Health, US Department of Health and
   Human Services.
CR Avery RL, 2006, OPHTHALMOLOGY, V113, P363, DOI 10.1016/j.ophtha.2005.11.019
   Avery RL, 2006, OPHTHALMOLOGY, V113, pe5, DOI DOI 10.1016/J.OPHTHA.2005.11.019
   Beck RW, 2003, AM J OPHTHALMOL, V135, P194, DOI 10.1016/S0002-9394(02)01825-1
   Brechner RJ, 2011, AM J OPHTHALMOL, V151, P887, DOI 10.1016/j.ajo.2010.11.017
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Chakravarthy U, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.04.015
   Curtis LH, 2012, AM J OPHTHALMOL, V153, P1116, DOI 10.1016/j.ajo.2011.11.032
   DeCroos FC, 2012, OPHTHALMOLOGY, V119, P2549, DOI 10.1016/j.ophtha.2012.06.040
   Grunwald JE, 2012, OPHTHALMOLOGY, V119, P1634, DOI 10.1016/j.ophtha.2012.02.013
   Jaffe GJ, 2013, OPHTHALMOLOGY, V120, P1860, DOI 10.1016/j.ophtha.2013.01.073
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rosenfeld PJ, 2011, OPHTHALMOLOGY, V118, P523, DOI 10.1016/j.ophtha.2010.07.011
   Rosenfeld PJ, 2005, OPHTHAL SURG LAS IM, V36, P331, DOI 10.3928/1542-8877-20050701-14
   Ying GS, 2013, OPHTHALMOLOGY, V120, P122, DOI 10.1016/j.ophtha.2012.07.042
NR 16
TC 65
Z9 65
U1 0
U2 6
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 2168-6165
EI 2168-6173
J9 JAMA OPHTHALMOL
JI JAMA Ophthalmol.
PD AUG
PY 2014
VL 132
IS 8
BP 915
EP 921
DI 10.1001/jamaophthalmol.2014.1019
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA AQ8EX
UT WOS:000343058000001
PM 24875610
OA Green Accepted, Bronze
DA 2022-11-30
ER

PT J
AU Wang, JJ
   Fong, CSU
   Rochtchina, E
   Cugati, S
   de Loryn, T
   Kaushik, S
   Tan, JSL
   Arnold, J
   Smith, W
   Mitchell, P
AF Wang, Jie Jin
   Fong, Calvin Sze-un
   Rochtchina, Elena
   Cugati, Sudha
   de Loryn, Tania
   Kaushik, Shweta
   Tan, Jennifer S. L.
   Arnold, Jennifer
   Smith, Wayne
   Mitchell, Paul
TI Risk of Age-related Macular Degeneration 3 Years after Cataract Surgery:
   Paired Eye Comparisons
SO OPHTHALMOLOGY
LA English
DT Article
ID BLUE MOUNTAINS EYE; CAUSE-SPECIFIC PREVALENCE; LONG-TERM INCIDENCE;
   VISUAL IMPAIRMENT; CLINICAL-OUTCOMES; 10-YEAR INCIDENCE; 5-YEAR
   INCIDENCE; GRADING SYSTEM; BEAVER DAM; MACULOPATHY
AB Objective: To clarify possible associations between cataract surgery and progression of age-related macular degeneration (AMD).
   Design: Clinic-based cohort.
   Participants: We followed cataract surgical patients aged 65+ years in the Australian Cataract Surgery and Age-related Macular Degeneration (CSAMD) study. Patients who remained unilaterally phakic for at least 24 months after recruitment were included.
   Methods: We performed annual examinations with retinal photography. We assessed AMD using side-by-side grading of images from all visits. Paired comparisons between operated and nonoperated fellow eyes (defined as nonoperated or operated <12 months previously) were made using generalized estimating equation models.
   Main Outcome Measures: Incident early AMD was defined as the new appearance of soft indistinct/reticular drusen or coexisting retinal pigmentary abnormality and soft distinct drusen in eyes at risk of early AMD. Incident late AMD was defined as the new appearance of neovascular AMD or geographic atrophy (GA) in eyes at risk of late AMD.
   Results: Among 2029 recruited, eligible participants, 1851 had cataract surgery performed at Westmead Hospital, Sydney, and 1244 (70.7%) had 36-month postoperative visits. Of these participants, 1178 had gradable photographs at baseline and at least 1 follow-up visit. Of 308 unilaterally operated participants at risk of late AMD, this developed in 4 (1.3%) operated and 7 (2.3%) nonoperated fellow eyes (odds ratio [OR], 0.74; 95% confidence interval [CI], 0.23-2.36) after adjusting for the presence of early AMD at baseline. Of 217 unilaterally operated participants at risk of early AMD, this developed in 23 (10.6%) operated and 21 (9.7%) nonoperated fellow eyes (OR, 1.07; 95% CI, 0.74-1.65). Incident retinal pigment abnormalities were more frequent in operated than nonoperated fellow eyes (15.3% vs. 9.9%; OR, 1.64; 95% CI, 1.07-2.52). There was no difference in the 3-year incidence of large soft indistinct or reticular drusen between the 2 eyes (8.8% vs. 7.9%; OR, 1.12; 95% CI, 0.79-1.60).
   Conclusions: Prospective follow-up data and paired eye comparisons of this older surgical cohort showed no increased risk of developing late AMD, early AMD, or soft/reticular drusen over 3 years. There was a 60% increased detection of retinal pigmentary changes in surgical eyes.
   Financial Disclosure(s): The author(s) have no proprietary or commercial interest in any materials discussed in this article. Ophthalmology 2012;119:2298-2303 (C) 2012 by the American Academy of Ophthalmology.
C1 [Wang, Jie Jin; Fong, Calvin Sze-un; Rochtchina, Elena; Cugati, Sudha; de Loryn, Tania; Kaushik, Shweta; Tan, Jennifer S. L.; Mitchell, Paul] Univ Sydney, Ctr Vis Res, Dept Ophthalmol, Sydney, NSW 2006, Australia.
   [Wang, Jie Jin; Fong, Calvin Sze-un; Rochtchina, Elena; Cugati, Sudha; de Loryn, Tania; Kaushik, Shweta; Tan, Jennifer S. L.; Mitchell, Paul] Univ Sydney, Westmead Millennium Inst, Sydney, NSW 2006, Australia.
   [Wang, Jie Jin] Univ Melbourne, Ctr Eye Res Australia, Melbourne, Vic, Australia.
   [Arnold, Jennifer] Marsden Eye Specialists, Parramatta, NSW, Australia.
   [Smith, Wayne] Univ Newcastle, Ctr Clin Epidemiol & Biostat, Newcastle, NSW 2300, Australia.
C3 University of Sydney; University of Sydney; Westmead Institute for
   Medical Research; Centre for Eye Research Australia; University of
   Melbourne; University of Newcastle
RP Wang, JJ (通讯作者)，Univ Sydney, Westmead Hosp, Ctr Vis Res, Dept Ophthalmol,Westmead Millennium Inst, Hawkesbury Rd, Westmead, NSW 2145, Australia.
EM jiejin.wang@sydney.edu.au
RI Cugati, Sudha/ABB-1331-2021; wang, jie/GRS-0942-2022; Mitchell,
   Paul/P-1498-2014; Wang, Jie Jin/P-1499-2014
OI Wang, Jie Jin/0000-0001-9491-4898
FU Australian National Health & Medical Research Council, Canberra
   Australia [302010]; Retina Australia; National Health & Medical Research
   Council Senior Research Fellowship [358702, 632909]
FX The study was supported by the Australian National Health & Medical
   Research Council, Canberra Australia (Grant ID 302010, 2004-2006) and
   Retina Australia (2005). JJW is funded by a National Health & Medical
   Research Council Senior Research Fellowship (Grant IDs 358702,
   2005-2009, and 632909, 2010-2014).
CR Armbrecht AM, 2003, J CATARACT REFR SURG, V29, P686, DOI 10.1016/S0886-3350(02)01650-4
   Baatz H, 2008, INVEST OPHTH VIS SCI, V49, P1079, DOI 10.1167/iovs.07-0557
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Bockelbrink A, 2008, SURV OPHTHALMOL, V53, P359, DOI 10.1016/j.survophthal.2008.04.001
   Buch H, 2005, ACTA OPHTHALMOL SCAN, V83, P400, DOI [10.1111/j.1600-0420.2005.00474.x, 10.1111/j.1600-0420.2005.thesis.x]
   Chakravarthy U, 2010, BMC OPHTHALMOL, V10, DOI 10.1186/1471-2415-10-31
   Chew EY, 2009, OPHTHALMOLOGY, V116, P297, DOI 10.1016/j.ophtha.2008.09.019
   Cugati S, 2007, OPHTHAL EPIDEMIOL, V14, P408, DOI 10.1080/09286580701316124
   Cugati S, 2006, OPHTHALMOLOGY, V113, P2020, DOI 10.1016/j.ophtha.2006.05.047
   Desai P, 1999, BRIT J OPHTHALMOL, V83, P1336, DOI 10.1136/bjo.83.12.1336
   Dong LM, 2009, ARCH OPHTHALMOL-CHIC, V127, P1412, DOI 10.1001/archophthalmol.2009.152
   Fraser-Bell S, 2008, AM J OPHTHALMOL, V145, P308, DOI 10.1016/j.ajo.2007.10.007
   Freeman EE, 2003, AM J OPHTHALMOL, V135, P849, DOI 10.1016/S0002-9394(02)02253-5
   GILVARRY A, 1982, T OPHTHAL SOC UK, V102, P502
   Ho L, 2008, INVEST OPHTH VIS SCI, V49, P4795, DOI 10.1167/iovs.08-2066
   Javitt JC, 1996, ANNU REV PUBL HEALTH, V17, P159
   Kaiserman I, 2007, OPHTHALMOLOGY, V114, P278, DOI 10.1016/j.ophtha.2006.10.019
   Klaver CCW, 1998, ARCH OPHTHALMOL-CHIC, V116, P653, DOI 10.1001/archopht.116.5.653
   Klein BEK, 2009, ARCH OPHTHALMOL-CHIC, V127, P1528, DOI 10.1001/archophthalmol.2009.258
   KLEIN R, 1995, INVEST OPHTH VIS SCI, V36, P182
   Klein R, 2002, ARCH OPHTHALMOL-CHIC, V120, P1551, DOI 10.1001/archopht.120.11.1551
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   Klein R, 2007, AM J OPHTHALMOL, V143, P473, DOI 10.1016/j.ajo.2006.11.058
   Krishnaiah S, 2005, INVEST OPHTH VIS SCI, V46, P4442, DOI 10.1167/iovs.05-0853
   McKibbin M, 1996, EYE, V10, P138, DOI 10.1038/eye.1996.25
   Mitchell P, 2002, OPHTHALMOLOGY, V109, P1092, DOI 10.1016/S0161-6420(02)01055-2
   MITCHELL P, 1995, OPHTHALMOLOGY, V102, P1450
   Pham TQ, 2004, CLIN EXP OPHTHALMOL, V32, P383, DOI 10.1111/j.1442-9071.2004.00842.x
   Pollack A, 1997, EYE, V11, P523, DOI 10.1038/eye.1997.138
   Pollack A, 1996, OPHTHALMOLOGY, V103, P1546, DOI 10.1016/S0161-6420(96)30464-8
   Rahmani B, 1996, OPHTHALMOLOGY, V103, P1721, DOI 10.1016/S0161-6420(96)30435-1
   Reeves SW, 2003, AM J OPHTHALMOL, V135, P599, DOI 10.1016/S0002-9394(02)02236-5
   Riley AF, 2002, BRIT J OPHTHALMOL, V86, P185, DOI 10.1136/bjo.86.2.185
   Sutter FKP, 2007, INVEST OPHTH VIS SCI, V48, P1472, DOI 10.1167/iovs.06-0766
   Tan JSL, 2007, OPHTHALMOLOGY, V114, P1143, DOI 10.1016/j.ophtha.2006.09.033
   Wang JJ, 2007, OPHTHALMOLOGY, V114, P92, DOI 10.1016/j.ophtha.2006.07.017
   Wang JJ, 2003, OPHTHALMOLOGY, V110, P1960, DOI 10.1016/S0161-6420(03)00816-9
   Wong TY, 2007, OPHTHALMOLOGY, V114, P86, DOI 10.1016/j.ophtha.2006.06.039
NR 38
TC 26
Z9 28
U1 0
U2 8
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0161-6420
J9 OPHTHALMOLOGY
JI Ophthalmology
PD NOV
PY 2012
VL 119
IS 11
BP 2298
EP 2303
DI 10.1016/j.ophtha.2012.07.003
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 030OH
UT WOS:000310579500016
PM 22959104
DA 2022-11-30
ER

PT J
AU Hawkins, BS
AF Hawkins, BS
CA Submacular Surg Trials Res Grp
TI Surgery for subfoveal choroidal neovascularization in age-related
   macular degeneration: Ophthalmic findings - SST report no. 11
SO OPHTHALMOLOGY
LA English
DT Article
ID MEMBRANES
AB Purpose: To present visual acuity (VA) and related findings from patients enrolled in one of the Submacular Surgery Trials (SST) evaluating surgical removal versus observation of subfoveal choroidal neovascularization secondary to age-related macular degeneration (SST Group N Trial).
   Design: Randomized clinical trial.
   Participants: Eligible patients had age-related macular degeneration with subfoveal choroidal neovascularization, some with a classic pattern on fluorescein angiography, and best-corrected VA (BCVA) of 20/100 to 20/800 in one eye (study eye) that had received no treatment in the macula. Any contiguous blood had to account for <50% of the total area occupied by the subfoveal lesion (maximum size, 9.0 disc areas [22.9 mm(2)]).
   Methods: Randomization was stratified by VA and by clinical center. All patients were scheduled for study examinations at 3, 6, 12, and 24 months after enrollment for assessment of study outcomes.
   Main Outcome Measure: A successful outcome was defined a priori to be either improvement of BCVA or VA no more than 1 line (7 letters) worse than baseline at the 24-month examination.
   Results: Of 454 patients enrolled, 228 study eyes were assigned to observation and 226 to surgery. The percentages of eyes that had successful outcomes were similar in the 2 arms: 44% assigned to observation and 41% assigned to surgery. Median VA losses from baseline to the 24-month examination were 2.1 lines (10.5 letters) in the observation arm and 2.0 lines (10 letters) in the surgery arm. Median VA declined from 20/100 at baseline to 20/400 at 24 months in both arms. No subgroup of patients was identified in which submacular surgery led to better VA outcomes. In the surgery arm, 55 (39%) of 142 initially phakic eyes had cataract surgery by the 24-month examination, compared with 6 (5%) of 133 eyes in the observation arm. Rhegmatogenous retinal detachment occurred in 12 surgery eyes (5%) and 1 observation eye.
   Conclusions: Submacular surgery, as performed in this clinical trial, did not improve or preserve VA for 24 months in more eyes than observation and is not recommended for patients with similar lesions. (C) 2004 by the American Academy of Ophthalmology.
C1 Wilmer Clin Trials & Biometry, SST Coordinating Ctr, Baltimore, MD 21205 USA.
   Emory Univ, Ctr Eye, Atlanta, GA 30322 USA.
   Wilmer Ophthalmol Inst, Baltimore, MD USA.
   Massachusetts Eye & Ear Infirm, Boston, MA 02114 USA.
   Illinois Retina Associates, Chicago, IL USA.
   Northwestern Univ, Sch Med, Chicago, IL USA.
   Cole Eye Inst, Cleveland, OH USA.
   Retina Associates Cleveland, Cleveland, OH USA.
   Ohio State Univ, Columbus, OH 43210 USA.
   Texas Retina Associates, Dallas, TX USA.
   Duke Univ, Ctr Eye, Durham, NC 27706 USA.
   Retina Associates Hawaii, Honolulu, HI USA.
   Mid Amer Retina Consultants, Kansas City, MO USA.
   SE Retina Associates, Knoxville, TN USA.
   Retina & Vitreous Associates Kentucky, Lexington, KY USA.
   Jules Stein Eye Inst, Los Angeles, CA 90024 USA.
   Calif vitreoretinal Associates, Menlo Pk, CA USA.
   Vitreoretinal Surg, OA, Minneapolis, MN USA.
   McGee Eye Inst, Oklahoma City, OK USA.
   Retinal Consultants Arizona, Phoenix, AZ USA.
   Retina Vitreous Consultants, Pittsburgh, PA USA.
   Oregon Hlth & Sci Univ, Portland, OR 97201 USA.
   Associated Retinal Consultants, Royal Oak, MI USA.
   Barnes Retina Inst, St Louis, MO USA.
   W Coast Retina Med Grp Inc, San Francisco, CA USA.
   St Vincent Mercy Med Ctr, Retina Vitreous Associates, Toledo, OH USA.
   Wilmer Ophthalmol Inst, Retinal Vasc Ctr, Chairmans Off, Baltimore, MD USA.
   Wilmer Ophthalmol Inst, Wilmer Photog Reading Ctr, Baltimore, MD USA.
C3 Emory University; Johns Hopkins University; Johns Hopkins Medicine;
   Harvard University; Massachusetts Eye & Ear Infirmary; Northwestern
   University; Retina Associates of Cleveland, Inc.; University System of
   Ohio; Ohio State University; Duke University; Oregon Health & Science
   University; Washington University (WUSTL); Johns Hopkins University;
   Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Medicine
RP Hawkins, BS (通讯作者)，Wilmer Clin Trials & Biometry, SST Coordinating Ctr, 550 N Broadway,9th Floor, Baltimore, MD 21205 USA.
EM bhawkins@jhmi.edu
FU NEI NIH HHS [U10 EY011558-07, EY11557, U10 EY011547-07, EY11558, U10
   EY011558, U10 EY011547, U10 EY011557, U10 EY011557-08, U10 EY11547]
   Funding Source: Medline; NATIONAL EYE INSTITUTE [U10EY011557,
   U10EY011558, U10EY011547] Funding Source: NIH RePORTER
CR [Anonymous], 1994, Arch Ophthalmol, V112, P489
   [Anonymous], 1991, Arch Ophthalmol, V109, P1109
   [Anonymous], 1991, Arch Ophthalmol, V109, P1220
   ARMITAGE P, 1987, STATISTICAL METHODS, P372
   Arnold J, 2001, AM J OPHTHALMOL, V131, P541
   BERGER AS, 1992, OPHTHALMOLOGY, V99, P969
   Bermig J, 2002, GRAEF ARCH CLIN EXP, V240, P169, DOI 10.1007/s00417-001-0378-2
   Blumenkranz MS, 2001, ARCH OPHTHALMOL-CHIC, V119, P198
   Bressler NM, 2000, AM J OPHTHALMOL, V130, P387
   Bressler NM, 2004, OPHTHALMOLOGY, V111, P1993, DOI 10.1016/j.ophtha.2004.07.023
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   BURGESS DB, 1993, ARCH OPHTHALMOL-CHIC, V111, P1189
   CHAKRAVARTHY U, 1993, BRIT J OPHTHALMOL, V77, P265, DOI 10.1136/bjo.77.5.265
   Childs AL, 2004, OPHTHALMOLOGY, V111, P2007, DOI 10.1016/j.ophtha.2004.07.024
   Complications of Age-Related Macular Degeneration Prevention Trial Study Group, 2004, Clin Trials, V1, P91
   FERRIS FL, 1982, AM J OPHTHALMOL, V94, P91, DOI 10.1016/0002-9394(82)90197-0
   FINE SL, 1982, ARCH OPHTHALMOL-CHIC, V100, P912
   Guyer DR, 1997, ARCH OPHTHALMOL-CHIC, V115, P865
   HAWKINS BS, 1993, ARCH OPHTHALMOL-CHIC, V111, P1200
   HAWKINS BS, 1990, ARCH OPHTHALMOL-CHIC, V108, P816
   HILLIS A, 1986, J CHRON DIS, V39, P595, DOI 10.1016/0021-9681(86)90184-0
   Holz FG, 1999, OPHTHALMOLOGY, V106, P2239
   JAMPOL LM, 1992, ARCH OPHTHALMOL-CHIC, V110, P1699, DOI 10.1001/archopht.1992.01080240039024
   KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   KATZ D, 1978, BIOMETRICS, V34, P469, DOI 10.2307/2530610
   LAMBERT HM, 1992, AM J OPHTHALMOL, V113, P257, DOI 10.1016/S0002-9394(14)71576-4
   LAN KKG, 1983, BIOMETRIKA, V70, P659, DOI 10.2307/2336502
   Maguire MG, 1997, ARCH OPHTHALMOL-CHIC, V115, P741
   MAGUIRE MG, 1994, ARCH OPHTHALMOL-CHIC, V112, P480
   MAGUIRE MG, 1990, ARCH OPHTHALMOL-CHIC, V108, P825
   MAGUIRE MG, 1986, ARCH OPHTHALMOL-CHIC, V104, P503
   Miskala PH, 2004, OPHTHALMOLOGY, V111, P1981, DOI 10.1016/j.ophtha.2004.07.022
   Olsen TW, 2004, OPHTHALMOLOGY, V111, P250, DOI 10.1016/j.ophtha.2003.05.030
   PELLI DG, 1988, CLIN VISION SCI, V2, P187
   RUBIN GS, 1988, CLIN VISION SCI, V2, P169
   SADDA SR, IN PRESS RETINA
   SCHACHAT AP, 1994, ARCH OPHTHALMOL-CHIC, V112, P500
   SNEDECOR GW, 1980, STATISTICAL METHODS, P144
   SOMMER A, 1991, NEW ENGL J MED, V325, P1412, DOI 10.1056/NEJM199111143252004
   *SST, 1998, PB98159445 NTIS SST
   *SST, 1998, PB98166648 NTIS SST
   STERNBERG P, 1991, ARCH OPHTHALMOL-CHIC, V109, P1242
   STERNBERG P, 1991, ARCH OPHTHALMOL-CHIC, V109, P1232
   Talic I, 2022, LEARN INSTR, V81, DOI [10.1016/j.learninstruc.2022.101594, 10.1016/j.ajo.2004.02.011]
   THOMAS MA, 1992, OPHTHALMOLOGY, V99, P952
NR 46
TC 127
Z9 133
U1 0
U2 5
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0161-6420
EI 1549-4713
J9 OPHTHALMOLOGY
JI Ophthalmology
PD NOV
PY 2004
VL 111
IS 11
BP 1967
EP 1980
DI 10.1016/j.ophtha.2004.07.021
PG 14
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 866JZ
UT WOS:000224771100002
PM 15522362
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Wan, L
   Lin, HJ
   Tsai, YS
   Lee, CC
   Tsai, CH
   Tsai, FJ
AF Wan, Lei
   Lin, Hui-Ju
   Tsai, Yushin
   Lee, Cheng-Chun
   Tsai, Chang-Hai
   Tsai, Fuu-Jen
TI TUMOR NECROSIS FACTOR-alpha GENE POLYMORPHISMS IN AGE-RELATED MACULAR
   DEGENERATION
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE tumor necrosis factor; polymorphism; age-related macular degeneration;
   Taiwan Chinese population
ID TNF-ALPHA; PROMOTER POLYMORPHISMS; 5'-FLANKING REGION; ASSOCIATION;
   DISEASE; SUSCEPTIBILITY; TRANSCRIPTION; LYMPHOTOXIN; MACULOPATHY;
   INFLIXIMAB
AB Purpose: The purpose of this study was to investigate tumor necrosis factor-alpha gene polymorphisms in unrelated Taiwan Chinese patients with wet age-related macular degeneration (AMD) and controls.
   Methods: In this retrospective case-control study, we enrolled 190 wet AMD patients and 180 age-and gender-matched controls. Genomic DNA was extracted from the peripheral blood obtained from wet AMD patients and control subjects. Polymerase chain reaction was performed to analyze 6 candidate single nucleotide polymorphisms in the tumor necrosis factor-alpha gene: -238 G/A, -308 G/A, +489 G/A, -857 C/T, -863 C/A, and -1031 T/C.
   Results: Among the 6 candidate single nucleotide polymorphisms of the tumor necrosis factor-a gene, only -1031 T/C was significantly associated with wet AMD. The distribution of the -1031 T/C genotypes was significantly different between wet AMD patients (homozygous T [TT], 64%; TC heterozygous [TC], 36%; homozygous C [CC] 0%) and controls (TT, 66%; TC, 28%; CC, 7%; P = 7 x 10(-4)). The genotype CC of -1031 T/C was significantly lower than that in controls (0 vs. 7%, P = 1.45 x 10(-4), odds ratio = 14.70, 95% confidence interval = 1.90-33.59). No single haplotype was found to be significantly associated with either wet AMD patients or controls.
   Conclusion: Our data indicate that the tumor necrosis factor-alpha -1031 T/C polymorphism may be associated with wet AMD in the Taiwan Chinese population. RETINA 30:1595-1600, 2010
C1 [Wan, Lei; Tsai, Chang-Hai; Tsai, Fuu-Jen] China Med Univ Hosp, Dept Med Genet, Taichung 404, Taiwan.
   [Lin, Hui-Ju] China Med Univ Hosp, Dept Ophthalmol, Taichung 404, Taiwan.
   [Wan, Lei; Lee, Cheng-Chun; Tsai, Chang-Hai; Tsai, Fuu-Jen] China Med Univ Hosp, Dept Med Res, Taichung 404, Taiwan.
   [Wan, Lei; Tsai, Yushin] China Med Univ, Grad Inst Chinese Med Sci, Taichung, Taiwan.
   [Tsai, Chang-Hai; Tsai, Fuu-Jen] Asia Univ, Dept Biotechnol & Bioinformat, Taichung, Taiwan.
C3 China Medical University Taiwan; China Medical University Hospital -
   Taiwan; China Medical University Taiwan; China Medical University
   Hospital - Taiwan; China Medical University Taiwan; China Medical
   University Hospital - Taiwan; China Medical University Taiwan; Asia
   University Taiwan
RP Tsai, FJ (通讯作者)，China Med Univ Hosp, Dept Med Genet, 2 Yuh Der Rd, Taichung 404, Taiwan.
EM d0704@mail.cmuh.org.tw
RI Wan, Lei/F-4719-2010; Tsai, Fuu-Jen/J-4140-2015
OI Wan, Lei/0000-0002-9525-3232
CR Akman A, 2006, BRIT J DERMATOL, V155, P350, DOI 10.1111/j.1365-2133.2006.07348.x
   Armstrong D, 1998, OPHTHALMOLOGICA, V212, P410, DOI 10.1159/000027378
   Bashshur ZF, 2006, AM J OPHTHALMOL, V142, P1, DOI 10.1016/j.ajo.2006.02.037
   Bird AC, 2003, EYE, V17, P457, DOI 10.1038/sj.eye.6700562
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Bouma G, 1996, SCAND J IMMUNOL, V43, P456, DOI 10.1046/j.1365-3083.1996.d01-65.x
   Chakravarthy U, 2006, OPHTHALMOLOGY, V113, P1508, DOI 10.1016/j.ophtha.2006.02.064
   Chapman JA, 2006, ANN PHARMACOTHER, V40, P1322, DOI 10.1345/aph.1G604
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   D'Aiuto F, 2004, CYTOKINE, V28, P29, DOI 10.1016/j.cyto.2004.06.005
   Day CP, 1998, DIABETOLOGIA, V41, P430, DOI 10.1007/s001250050926
   de Jong PTVM, 2006, NEW ENGL J MED, V355, P1474, DOI 10.1056/NEJMra062326
   Fraunfelder FW, 2005, DRUG TODAY, V41, P703, DOI 10.1358/dot.2005.41.11.917340
   Higuchi T, 1998, TISSUE ANTIGENS, V51, P605, DOI 10.1111/j.1399-0039.1998.tb03002.x
   Huizinga TWJ, 1997, J NEUROIMMUNOL, V72, P149, DOI 10.1016/S0165-5728(96)00182-8
   Kaijzel EL, 2001, GENES IMMUN, V2, P135, DOI 10.1038/sj.gene.6363747
   Kamizono S, 2000, CLIN ENDOCRINOL, V52, P759, DOI 10.1046/j.1365-2265.2000.01011.x
   Kamizono S, 2000, TISSUE ANTIGENS, V55, P449, DOI 10.1034/j.1399-0039.2000.550508.x
   Kesarwani P, 2009, J UROLOGY, V182, P2938, DOI 10.1016/j.juro.2009.08.016
   Li N, 2008, CLIN BIOCHEM, V41, P881, DOI 10.1016/j.clinbiochem.2008.04.014
   Louis E, 1998, CLIN EXP IMMUNOL, V113, P401
   Majka S, 2002, INVEST OPHTH VIS SCI, V43, P260
   Markomichelakis NN, 2005, AM J OPHTHALMOL, V139, P537, DOI 10.1016/j.ajo.2004.09.058
   Marx J, 2006, SCIENCE, V311, P1704, DOI 10.1126/science.311.5768.1704
   NEDWIN GE, 1985, NUCLEIC ACIDS RES, V13, P6361, DOI 10.1093/nar/13.17.6361
   Oh H, 1999, INVEST OPHTH VIS SCI, V40, pS230
   Olson JL, 2007, ARCH OPHTHALMOL-CHIC, V125, P1221, DOI 10.1001/archopht.125.9.1221
   Park K, 2006, J KOREAN MED SCI, V21, P596, DOI 10.3346/jkms.2006.21.4.596
   Richardson A, 2001, GENES IMMUN, V2, P343, DOI 10.1038/sj.gene.6363789
   Rosenfeld PJ, 2006, OPHTHALMOLOGY, V113, P623, DOI 10.1016/j.ophtha.2006.01.027
   Shi X, 2006, EXP EYE RES, V83, P1325, DOI 10.1016/j.exer.2006.07.007
   Skoog T, 1999, HUM MOL GENET, V8, P1443, DOI 10.1093/hmg/8.8.1443
   Theodossiadis PG, 2009, AM J OPHTHALMOL, V147, P825, DOI 10.1016/j.ajo.2008.12.004
   Udalova IA, 2000, MOL CELL BIOL, V20, P9113, DOI 10.1128/MCB.20.24.9113-9119.2000
   Ueda Toshihiko, 1998, Angiogenesis, V1, P174
   van Heel DA, 2002, HUM MOL GENET, V11, P1281, DOI 10.1093/hmg/11.11.1281
   van Krugten MV, 1999, GENES IMMUN, V1, P91, DOI 10.1038/sj.gene.6363632
   van Leeuwen R, 2003, ARCH OPHTHALMOL-CHIC, V121, P519, DOI 10.1001/archopht.121.4.519
   Zimmerman PA, 1996, IMMUNOGENETICS, V44, P485, DOI 10.1007/s002510050158
NR 39
TC 13
Z9 14
U1 1
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD NOV-DEC
PY 2010
VL 30
IS 10
BP 1595
EP 1600
DI 10.1097/IAE.0b013e3181dc58a6
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 678HL
UT WOS:000284064600006
PM 21060270
DA 2022-11-30
ER

PT J
AU Al-khersan, H
   Kwong, A
   Grassi, MA
AF Al-khersan, Hasenin
   Kwong, Alan
   Grassi, Michael A.
TI Mutations in MERTK are not associated with age-related macular
   degeneration
SO INTERNATIONAL OPHTHALMOLOGY
LA English
DT Article
DE Retina; Genetics; Age-related macular degeneration
ID VARIANTS; GENE
AB PurposeTo assess whether mutations in Mer tyrosine kinase (MERTK) are associated with age-related macular degeneration (AMD).MethodsAn association study using whole-genome sequencing was performed to determine whether rare variants in MERTK are associated with AMD. The data set included 4787 propensity score-matched case-control samples: 2394 AMD cases and 2393 controls. Whole-genome sequencing was performed and variants in MERTK were identified. Combined annotation-dependent depletion (CADD) scores and allele frequencies were calculated for each variant identified in MERTK. Student's t-test was used to assess the mean number of MERTK variants per subject between case and control cohorts (Bonferroni adjusted =0.0125). The number of subjects carrying at least one high CADD score loss-of-function or nonsynonymous mutation in each cohort was compared using Fisher's exact test (p<0.05).ResultsNo significant difference was found in the mean number of MERTK variants in AMD versus control subjects (p=0.0502). Additionally, there was no significant difference between cohorts in the number of subjects with at least one high CADD score loss-of-function or nonsynonymous variant (p=0.15 at CADD>10 and p=0.91 at CADD>20).ConclusionsThe present study provides a meaningfully negative result demonstrating that rare variants in MERTK are not associated with AMD. The study also demonstrates the role of large sample size genetic studies utilizing whole-genome sequencing as a powerful tool that can resolve clinically relevant questions regarding the genetic basis of ophthalmic disease.
C1 [Al-khersan, Hasenin] Univ Chicago, Pritzker Sch Med, Chicago, IL 60637 USA.
   [Kwong, Alan] Univ Michigan, Dept Biostat, Ann Arbor, MI 48109 USA.
   [Kwong, Alan] Univ Michigan, Ctr Stat Genet, Ann Arbor, MI 48109 USA.
   [Grassi, Michael A.] Grassi Retina, 1012 95th St,Suite 9, Naperville, IL 60564 USA.
   [Grassi, Michael A.] Univ Illinois, Dept Ophthalmol & Visual Sci, Chicago, IL USA.
C3 University of Chicago; University of Michigan System; University of
   Michigan; University of Michigan System; University of Michigan;
   University of Illinois System; University of Illinois Chicago;
   University of Illinois Chicago Hospital
RP Grassi, MA (通讯作者)，Grassi Retina, 1012 95th St,Suite 9, Naperville, IL 60564 USA.
EM mag@grassiretina.com
FU Search for Vision (Chicago, IL); National Eye Institute (Bethesda, MD)
   [R01EY023644, EY001792]; Research to Prevent Blindness (New York, NY);
   NATIONAL EYE INSTITUTE [P30EY001792, R01EY023644] Funding Source: NIH
   RePORTER
FX This report was supported by funding from Search for Vision (Chicago,
   IL), National Eye Institute (Bethesda, MD) R01EY023644 and Core Grant
   EY001792, and Research to Prevent Blindness (New York, NY) (departmental
   support). The funding organizations had no role in the design or conduct
   of this research.
CR Al-Khersan Hasenin, 2017, Graefes Arch Clin Exp Ophthalmol, V255, P1613, DOI 10.1007/s00417-017-3679-9
   Black JRM, 2016, GENET MED, V18, P283, DOI 10.1038/gim.2015.70
   Boye SE, 2013, MOL THER, V21, P509, DOI 10.1038/mt.2012.280
   Boyle EA, 2017, CELL, V169, P1177, DOI 10.1016/j.cell.2017.05.038
   Chen W, 2010, P NATL ACAD SCI USA, V107, P7401, DOI 10.1073/pnas.0912702107
   Fritsche LG, 2013, NAT GENET, V45, P433, DOI 10.1038/ng.2578
   Kassoff A, 1999, CONTROL CLIN TRIALS, V20, P573
   Kircher M, 2014, NAT GENET, V46, P310, DOI 10.1038/ng.2892
   Linger RMA, 2008, ADV CANCER RES, V100, P35, DOI 10.1016/S0065-230X(08)00002-X
   Marouli E, 2017, NATURE, V542, P186, DOI 10.1038/nature21039
   McHenry CL, 2004, INVEST OPHTH VIS SCI, V45, P1456, DOI 10.1167/iovs.03-0909
   Parinot C, 2016, ADV EXP MED BIOL, V854, P259, DOI 10.1007/978-3-319-17121-0_35
   WELLS J, 1993, NAT GENET, V3, P213, DOI 10.1038/ng0393-213
   Yu Y, 2011, HUM MOL GENET, V20, P3699, DOI 10.1093/hmg/ddr270
NR 14
TC 0
Z9 0
U1 0
U2 0
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0165-5701
EI 1573-2630
J9 INT OPHTHALMOL
JI Int. Ophthalmol.
PD JAN
PY 2019
VL 39
IS 1
BP 63
EP 67
DI 10.1007/s10792-017-0789-7
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA HN3IV
UT WOS:000460077900008
PM 29299721
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Shen, D
   Tuo, J
   Patel, M
   Herzlich, AA
   Ding, X
   Chew, EY
   Chan, CC
AF Shen, D.
   Tuo, J.
   Patel, M.
   Herzlich, A. A.
   Ding, X.
   Chew, E. Y.
   Chan, C-C
TI Chlamydia pneumoniae infection, complement factor H variants and
   age-related macular degeneration
SO BRITISH JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID NEOVASCULAR MEMBRANES; MULTIPLE-SCLEROSIS; POLYMORPHISM; ASSOCIATION;
   EXPOSURE; RISK; IDENTIFICATION; METAANALYSIS; PROGRESSION; GENE
AB Background/aims: Impaired inhibition of the alternative complement pathway by complement factor H (CFH) is linked to age-related macular degeneration (AMD) based on the strong association between CFH variant and AMD. Chlamydia pneumoniae (C pneumoniae) infection can trigger the alternative pathway, but the evidence for an association between C pneumoniae and AMD is contradictory. This study investigated whether C pneumoniae infection is associated with AMD and whether the presence of C pneumonia modulates AMD risk conferred by CFH variants.
   Methods: Genomic DNA extracted from peripheral blood of 148 advanced AMD patients and 162 controls was subjected to Taqman and PCR-RFLP for the CFH polymorphism and PCR for the C pneumoniae gene. Genomic DNA was also examined from microdissected macular cells from 59 AMD and 16 age-matched non-AMD archived slides. chi(2) testing was performed for case-control analysis.
   Results: C pneumoniae infection was associated with increased risk of AMD (OR = 2.17, p < 0.017). A CFH variant was also linked to increased risk of AMD (OR = 1.98, p < 0.0001). However, no relationship was found between risk-conferring CFH variant and C pneumoniae (OR = 1.81, p = 0.08).
   Conclusion: There is a possible association between AMD and C pneumoniae infection, although CFH may not be directly involved in the pathogenesis of C pneumoniae infection-mediated AMD.
C1 [Chan, C-C] NEI, Immunopathol Sect, Immunol Lab, NIH, Bethesda, MD 20892 USA.
   [Patel, M.] NIH, Howard Hughes Med Inst, Res Scholars Program, Chevy Chase, MD USA.
   [Chew, E. Y.] NEI, Div Epidemiol & Clin Res, NIH, Bethesda, MD 20892 USA.
C3 National Institutes of Health (NIH) - USA; NIH National Eye Institute
   (NEI); Howard Hughes Medical Institute; National Institutes of Health
   (NIH) - USA; National Institutes of Health (NIH) - USA; NIH National Eye
   Institute (NEI)
RP Chan, CC (通讯作者)，NEI, Immunopathol Sect, Immunol Lab, NIH, 10 Ctr Dr,10-10N103, Bethesda, MD 20892 USA.
EM chanc@nei.nih.gov
FU National Eye Institute Intramural Research Program; NATIONAL EYE
   INSTITUTE [ZIAEY000222, ZICEY000461, ZIAEY000418] Funding Source: NIH
   RePORTER
FX The study is funded by the National Eye Institute Intramural Research
   Program.
CR AbdelRahman YM, 2005, FEMS MICROBIOL REV, V29, P949, DOI 10.1016/j.femsre.2005.03.002
   Baird PN, 2008, HUM MOL GENET, V17, P1299, DOI 10.1093/hmg/ddn018
   Blasi F, 2004, EUR RESPIR J, V24, P171, DOI 10.1183/09031936.04.00135703
   Bojanowski CM, 2006, ENVIRON MOL MUTAGEN, V47, P594, DOI 10.1002/em.20233
   Bojanowski Christine M, 2005, Trans Am Ophthalmol Soc, V103, P37
   Chan CC, 2005, HISTOL HISTOPATHOL, V20, P857, DOI 10.14670/HH-20.857
   Chan Chi-Chao, 2007, Trans Am Ophthalmol Soc, V105, P92
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Fainardi E, 2008, CURR NEUROVASC RES, V5, P60, DOI 10.2174/156720208783565609
   Fisher SA, 2005, HUM MOL GENET, V14, P2257, DOI 10.1093/hmg/ddi230
   Guymer R, 2007, CLIN EXP OPHTHALMOL, V35, P89, DOI 10.1111/j.1442-9071.2006.01392.x
   Haddad S, 2006, SURV OPHTHALMOL, V51, P316, DOI 10.1016/j.survophthal.2006.05.001
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Haines JL, 2007, JAMA-J AM MED ASSOC, V297, P401, DOI 10.1001/jama.297.4.401
   Hammerschlag MR, 2005, J INFECT DIS, V192, P1305, DOI 10.1086/466533
   Ishida O, 2003, BRIT J OPHTHALMOL, V87, P523, DOI 10.1136/bjo.87.5.523
   Kalayoglu MV, 2005, GRAEF ARCH CLIN EXP, V243, P1080, DOI 10.1007/s00417-005-1169-y
   Kalayoglu MV, 2003, ARCH OPHTHALMOL-CHIC, V121, P478, DOI 10.1001/archopht.121.4.478
   Kessler W, 2006, ACTA OPHTHALMOL SCAN, V84, P333, DOI 10.1111/j.1600-0420.2005.00591.x
   Klein R, 2004, AM J OPHTHALMOL, V137, P486, DOI 10.1016/j.ajo.2003.11.069
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   KUO CC, 1995, CLIN MICROBIOL REV, V8, P451, DOI 10.1128/CMR.8.4.451
   MacIntyre A, 2003, J NEUROSCI RES, V71, P740, DOI 10.1002/jnr.10519
   Madico G, 2000, J CLIN MICROBIOL, V38, P1085, DOI 10.1128/JCM.38.3.1085-1093.2000
   Patel M, 2008, SEMIN IMMUNOPATHOL, V30, P97, DOI 10.1007/s00281-008-0112-9
   Robman L, 2005, AM J EPIDEMIOL, V161, P1013, DOI 10.1093/aje/kwi130
   Robman L, 2007, INVEST OPHTH VIS SCI, V48, P4007, DOI 10.1167/iovs.06-1434
   Ross RJ, 2007, EXPERT REV OPHTHALMO, V2, P443, DOI 10.1586/17469899.2.3.443
   Ross RJ, 2007, INVEST OPHTH VIS SCI, V48, P1128, DOI 10.1167/iovs.06-0999
   Sutherland ER, 2007, CHEST, V132, P1962, DOI 10.1378/chest.06-2415
   Swaroop A, 2007, HUM MOL GENET, V16, pR174, DOI 10.1093/hmg/ddm212
   Thakkinstian A, 2006, HUM MOL GENET, V15, P2784, DOI 10.1093/hmg/ddl220
   Tou JS, 2004, FASEB J, V18, P1297, DOI 10.1096/fj.04-1862fje
   Tuo JS, 2006, P NATL ACAD SCI USA, V103, P9256, DOI 10.1073/pnas.0603485103
   Tuo JS, 2004, PROG RETIN EYE RES, V23, P229, DOI 10.1016/j.preteyeres.2004.02.001
   Watson C, 2008, CLIN SCI, V114, P509, DOI 10.1042/CS20070298
   Zhou M, 2007, T AM OPHTHAL SOC, V105, P7
NR 38
TC 16
Z9 19
U1 0
U2 1
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0007-1161
EI 1468-2079
J9 BRIT J OPHTHALMOL
JI Br. J. Ophthalmol.
PD MAR
PY 2009
VL 93
IS 3
BP 405
EP 408
DI 10.1136/bjo.2008.145383
PG 4
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 411NH
UT WOS:000263655800029
PM 18996904
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Glotin, AL
   Debacq-Chainiaux, F
   Brossas, JY
   Faussat, AM
   Treton, J
   Zubielewicz, A
   Toussaint, O
   Mascarelli, F
AF Glotin, Anne-Lise
   Debacq-Chainiaux, Florence
   Brossas, Jean-Yves
   Faussat, Anne-Marie
   Treton, Jacques
   Zubielewicz, Anna
   Toussaint, Olivier
   Mascarelli, Frederic
TI Prematurely senescent ARPE-19 cells display features of age-related
   macular degeneration
SO FREE RADICAL BIOLOGY AND MEDICINE
LA English
DT Article
DE aging; retina; transcriptome; tight junction; amyloid beta;
   angiogenesis; free radicals
ID RETINAL-PIGMENT EPITHELIUM; HUMAN FORESKIN FIBROBLASTS; AMYLOID
   PRECURSOR PROTEIN; OXIDATIVE STRESS; REPLICATIVE SENESCENCE; CELLULAR
   SENESCENCE; GENE-EXPRESSION; DOWN-REGULATION; BETA; PATHOGENESIS
AB The etiology of age-related macular degeneration (AMD), the leading cause of blindness in the developed world, remains poorly understood, but may be related to cumulative oxidative stress. The prime target of the disease is the retinal pigmented epithelium (RPE). To study the molecular mechanisms underlying RPE degeneration, we investigated whether repetitive oxidative stress induced premature senescence in RPE cells from the human ARPE-19 cell line. After exposure to 8 mM tert-butylhydroperoxide (tert-BHP) for I h daily for 5 days, the cells showed four well-known senescence biomarkers: hypertrophy, senescence-associated p-galactosidase activity, growth arrest, and cell cycle arrest in G1. A specific low-density array followed by qRT-PCR validation allowed us to identify 36 senescence-associated genes differentially expressed in the prematurely senescent cells. Functional analysis demonstrated that premature senescence induced amyloid beta secretion, resistance to acute stress by tert-BHP and amyloid, and defects in adhesion and transepithelial permeability. Coculture assays with choroidal endothelial cells showed the proangiogenic properties of the senescent RPE cells. These results demonstrate that chronic oxidative stress induces premature senescence in RPE cells that modifies the transcriptome and substantially alters cell processes involved in the pathophysiology of AMD. Oxidative stress-induced premature senescence may represent an in vitro model for screening therapeutics against AMD and other retinal degeneration disorders. (C) 2007 Elsevier Inc. All rights reserved.
C1 [Glotin, Anne-Lise; Brossas, Jean-Yves; Faussat, Anne-Marie; Treton, Jacques; Mascarelli, Frederic] Univ Paris 06, Ctr Rech Cordeliers, UMR S 872, F-75006 Paris, France.
   [Glotin, Anne-Lise; Brossas, Jean-Yves; Treton, Jacques; Mascarelli, Frederic] Univ Paris 05, UMR S 872, F-75006 Paris, France.
   [Glotin, Anne-Lise; Brossas, Jean-Yves; Treton, Jacques; Mascarelli, Frederic] INSERM, U872, F-75006 Paris, France.
   [Debacq-Chainiaux, Florence; Toussaint, Olivier] Univ Namur FUNDP, Dept Biol, Lab Biochem & Cellular Biol, B-5000 Namur, Belgium.
   [Faussat, Anne-Marie] Sch Med, Dept Ophthalmol, Lublin, Poland.
C3 Institut National de la Sante et de la Recherche Medicale (Inserm);
   UDICE-French Research Universities; Sorbonne Universite; Universite
   Paris Cite; UDICE-French Research Universities; Universite Paris Cite;
   Institut National de la Sante et de la Recherche Medicale (Inserm);
   UDICE-French Research Universities; Universite Paris Cite; University of
   Namur; Medical University of Lublin
RP Mascarelli, F (通讯作者)，Univ Paris 06, Ctr Rech Cordeliers, UMR S 872, F-75006 Paris, France.
EM frederic.mascarelli@idf.inserm.fr
RI Mascarelli, Frederic/L-8916-2018
OI Debacq-Chainiaux, Florence/0000-0003-3949-395X
CR Ambati J, 2003, SURV OPHTHALMOL, V48, P257, DOI 10.1016/S0039-6257(03)00030-4
   Bailey TA, 2004, INVEST OPHTH VIS SCI, V45, P675, DOI 10.1167/iovs.03-0351
   Bani-Yaghoub M, 2000, EXP NEUROL, V162, P13, DOI 10.1006/exnr.2000.7294
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   Boulton M, 2004, GRAEF ARCH CLIN EXP, V242, P76, DOI 10.1007/s00417-003-0812-8
   Campochiaro PA, 2000, J CELL PHYSIOL, V184, P301, DOI 10.1002/1097-4652(200009)184:3<301::AID-JCP3>3.0.CO;2-H
   Chondrogianni N, 2005, EXP GERONTOL, V40, P931, DOI 10.1016/j.exger.2005.09.004
   Chong NHV, 2005, AM J PATHOL, V166, P241, DOI 10.1016/S0002-9440(10)62248-1
   Choo KW, 2007, FRONT BIOSCI-LANDMRK, V12, P1845, DOI 10.2741/2192
   de Magalhaes JP, 2004, EXP GERONTOL, V39, P1379, DOI 10.1016/j.exger.2004.06.004
   de Magalhaes JP, 2002, FEBS LETT, V523, P157, DOI 10.1016/S0014-5793(02)02973-3
   Debacq-Chainlaux F, 2005, J CELL SCI, V118, P743, DOI 10.1242/jcs.01651
   Decanini A, 2007, AM J OPHTHALMOL, V143, P607, DOI 10.1016/j.ajo.2006.12.006
   Dewachter I, 2000, J NEUROSCI, V20, P6452, DOI 10.1523/JNEUROSCI.20-17-06452.2000
   Dirmi G. P., 1995, P NATL ACAD SCI USA, V92, P9363
   Dumont P, 2000, FREE RADICAL BIO MED, V28, P361, DOI 10.1016/S0891-5849(99)00249-X
   FLOOD MT, 1980, INVEST OPHTH VIS SCI, V19, P1309
   Frippiat C, 2001, J BIOL CHEM, V276, P2531, DOI 10.1074/jbc.M006809200
   FUKAMI J, 1995, MECH AGEING DEV, V81, P139, DOI 10.1016/0047-6374(95)93703-6
   Glotin AL, 2006, INVEST OPHTH VIS SCI, V47, P4614, DOI 10.1167/iovs.06-0297
   Grune T, 2005, FREE RADICAL BIO MED, V39, P1208, DOI 10.1016/j.freeradbiomed.2005.06.009
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   HAMEL CP, 1993, J BIOL CHEM, V268, P15751
   Hecquet C, 2003, INVEST OPHTH VIS SCI, V44, P1320, DOI 10.1167/iovs.02-0519
   Hoffmann S, 1998, GRAEF ARCH CLIN EXP, V236, P779, DOI 10.1007/s004170050158
   Ida H, 2003, PHYSIOL GENOMICS, V15, P258, DOI 10.1152/physiolgenomics.00126.2003
   Johnson LV, 2002, P NATL ACAD SCI USA, V99, P11830, DOI 10.1073/pnas.192203399
   Kern A, 2006, J BIOL CHEM, V281, P2405, DOI 10.1074/jbc.M505625200
   Kimura N, 2007, J NEUROSCI RES, V85, P2909, DOI 10.1002/jnr.21408
   Liang FQ, 2003, EXP EYE RES, V76, P397, DOI 10.1016/S0014-4835(03)00023-X
   LUCIBELLO FC, 1993, J CELL SCI, V105, P123
   Luibl V, 2006, J CLIN INVEST, V116, P378, DOI 10.1172/JCI25843
   Marcotte R, 2004, MECH AGEING DEV, V125, P777, DOI 10.1016/j.mad.2004.07.007
   Matsunaga H, 1999, INVEST OPHTH VIS SCI, V40, P197
   Matsunaga H, 1999, MOL VIS, V5, pU6
   Medina MG, 2005, EMBO J, V24, P1706, DOI 10.1038/sj.emboj.7600650
   Mignatti P, 1996, ENZYME PROTEIN, V49, P117, DOI 10.1159/000468621
   Mishima K, 1999, INVEST OPHTH VIS SCI, V40, P1590
   Pitkanen L, 2005, INVEST OPHTH VIS SCI, V46, P641, DOI 10.1167/iovs.04-1051
   Rakoczy PE, 1999, EXP EYE RES, V69, P367, DOI 10.1006/exer.1999.0700
   Rizzolo LJ, 1997, HISTOL HISTOPATHOL, V12, P1057
   Rothhammer T, 2005, CANCER RES, V65, P448
   Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9
   Shen JK, 2007, HISTOL HISTOPATHOL, V22, P1301, DOI 10.14670/HH-22.1301
   Smith CP, 2007, EXP EYE RES, V84, P75, DOI 10.1016/j.exer.2006.08.018
   STEIN GH, 1995, BIOESSAYS, V17, P537, DOI 10.1002/bies.950170610
   Tomany SC, 2004, OPHTHALMOLOGY, V111, P1280, DOI 10.1016/j.ophtha.2003.11.010
   Trougakos IP, 2006, BIOGERONTOLOGY, V7, P375, DOI 10.1007/s10522-006-9052-8
   VOJTA PJ, 1995, BBA-REV CANCER, V1242, P29, DOI 10.1016/0304-419X(95)00002-W
   WANG E, 1995, CANCER RES, V55, P2284
   Wang XF, 2004, EXP EYE RES, V79, P209, DOI 10.1016/j.exer.2004.03.013
   Welling TH, 1996, J SURG RES, V66, P36, DOI 10.1006/jsre.1996.0369
   Wu ZH, 2007, J BIOL CHEM, V282, P22414, DOI 10.1074/jbc.M702321200
   Yerbury JJ, 2007, FASEB J, V21, P2312, DOI 10.1096/fj.06-7986com
   Yoshida T, 2005, J CLIN INVEST, V115, P2793, DOI 10.1172/JCI24635
NR 55
TC 55
Z9 54
U1 3
U2 13
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0891-5849
EI 1873-4596
J9 FREE RADICAL BIO MED
JI Free Radic. Biol. Med.
PD APR 1
PY 2008
VL 44
IS 7
BP 1348
EP 1361
DI 10.1016/j.freeradbiomed.2007.12.023
PG 14
WC Biochemistry & Molecular Biology; Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Endocrinology & Metabolism
GA 287IK
UT WOS:000254910600013
PM 18226607
DA 2022-11-30
ER

PT J
AU Cipriani, V
   Matharu, BK
   Khan, JC
   Shahid, H
   Stanton, CM
   Hayward, C
   Wright, AF
   Bunce, C
   Clayton, DG
   Moore, AT
   Yates, JRW
AF Cipriani, Valentina
   Matharu, Baljinder K.
   Khan, Jane C.
   Shahid, Humma
   Stanton, Chloe M.
   Hayward, Caroline
   Wright, Alan F.
   Bunce, Catey
   Clayton, David G.
   Moore, Anthony T.
   Yates, John R. W.
TI Genetic variation in complement regulators and susceptibility to
   age-related macular degeneration
SO IMMUNOBIOLOGY
LA English
DT Article
DE Age-related macular degeneration; Complement; Complement regulators;
   Genetic association; Genetic variation; Single nucleotide polymorphism
ID FACTOR-H POLYMORPHISM; ASSOCIATION; RISK; PROTEINS; ACTIVATION;
   HAPLOTYPE; DISEASE; SYSTEM; COMMON; ROLES
AB Objectives: Age-related macular degeneration (AMD) is the commonest cause of blindness in Western populations. Risk is influenced by age, genetic and environmental factors. Complement activation appears to be important in the pathogenesis and associations have been found between AMD and genetic variations in complement regulators such as complement factor H. We therefore investigated other complement regulators for association with AMD.
   Methods: We carried out a case-control study to test for association between AMD and single nucleotide polymorphisms (SNPs) spanning the genes encoding complement factor P (CFP, properdin), CD46 (membrane cofactor protein, MCP), CD55 (decay accelerating factor, OAF) and CD59 (protectin). All cases and controls were examined by an ophthalmologist and had independent grading of fundus photographs to confirm their disease status.
   Results: 20 SNPs were genotyped in 446 cases and 262 controls. For two SNPs with p-values approaching significance additional subjects were genotyped to increase the numbers to 622 cases and 359 controls. There was no evidence of association between AMD and any of the SNPs typed in CFP, CD46, CD55 or CD59.
   Conclusions: In a case-control sample that has shown the well established associations between AMD and variants in CFH, CFB and C3 there was absence of association with SNPs in CFP, CD46, CD55 and CD59. This suggests that these are not important susceptibility genes for AMD. (C) 2011 Elsevier GmbH. All rights reserved.
C1 [Cipriani, Valentina] UCL, Inst Ophthalmol, Dept Genet, London EC1V 9EL, England.
   [Cipriani, Valentina; Bunce, Catey; Moore, Anthony T.; Yates, John R. W.] Moorfields Eye Hosp, London, England.
   [Matharu, Baljinder K.; Khan, Jane C.; Shahid, Humma; Clayton, David G.; Yates, John R. W.] Univ Cambridge, Cambridge Inst Med Res, Dept Med Genet, Cambridge CB2 1TN, England.
   [Hayward, Caroline; Wright, Alan F.] Inst Genet & Mol Med, MRC, Human Genet Unit, Edinburgh, Midlothian, Scotland.
C3 University of London; University College London; University of London;
   University College London; Moorfields Eye Hospital NHS Foundation Trust;
   University of Cambridge; University of Edinburgh
RP Cipriani, V (通讯作者)，UCL, Inst Ophthalmol, Dept Genet, 11-43 Bath St, London EC1V 9EL, England.
EM v.cipriani@ucl.ac.uk
RI Mohammed, Imran/J-8271-2012; Hayward, Caroline/M-8818-2016; Cipriani,
   Valentina/A-8549-2012
OI Mohammed, Imran/0000-0002-8412-0768; Hayward,
   Caroline/0000-0002-9405-9550; Cipriani, Valentina/0000-0002-0839-9955;
   Bunce, Catey/0000-0002-0935-3713
FU Medical Research Council, United Kingdom; Macular Disease Society; Guide
   Dogs for the Blind Association; Wellcome Trust; Juvenile Diabetes
   Research Foundation; Macula Vision Research Foundation; Chief Scientist
   Office, Scotland; Department of Health's NIHR Biomedical Research Centre
   for Ophthalmology at Moorfields Eye Hospital; UCL Institute of
   Ophthalmology; MRC [MC_U127584475, G0000067] Funding Source: UKRI;
   Medical Research Council [MC_PC_U127584475, MC_U127584475, G0000067]
   Funding Source: researchfish
FX This work has received funding from the Medical Research Council, United
   Kingdom (JRWY, ATM, and DGC), the Macular Disease Society (JRWY, ATM),
   Guide Dogs for the Blind Association (ATM, JRWY, DGC, and CB), the
   Wellcome Trust (DGC), the Juvenile Diabetes Research Foundation (DGC),
   the Macula Vision Research Foundation (AFW), the Chief Scientist Office,
   Scotland (AFW, CH), and the Department of Health's NIHR Biomedical
   Research Centre for Ophthalmology at Moorfields Eye Hospital and UCL
   Institute of Ophthalmology (JRWY). The views expressed in the
   publication are those of the authors and not necessarily those of the
   Department of Health.
CR Anderson DH, 2010, PROG RETIN EYE RES, V29, P95, DOI 10.1016/j.preteyeres.2009.11.003
   Barrett JC, 2005, BIOINFORMATICS, V21, P263, DOI 10.1093/bioinformatics/bth457
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Cipriani V, 2012, EUR J HUM GENET, V20, P1, DOI 10.1038/ejhg.2011.118
   de Bakker PIW, 2005, NAT GENET, V37, P1217, DOI 10.1038/ng1669
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Fagerness JA, 2009, EUR J HUM GENET, V17, P100, DOI 10.1038/ejhg.2008.140
   Gibbs RA, 2003, NATURE, V426, P789, DOI 10.1038/nature02168
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Hecker LA, 2010, HUM MOL GENET, V19, P209, DOI 10.1093/hmg/ddp472
   Hughes AE, 2006, NAT GENET, V38, P1173, DOI 10.1038/ng1890
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Kemper C, 2008, MOL IMMUNOL, V45, P4048, DOI 10.1016/j.molimm.2008.06.034
   Khandhadia S, 2012, IMMUNOBIOLOGY, V217, P127, DOI 10.1016/j.imbio.2011.07.019
   Kim DD, 2006, CLIN IMMUNOL, V118, P127, DOI 10.1016/j.clim.2005.10.014
   Kimberley FC, 2007, MOL IMMUNOL, V44, P73, DOI 10.1016/j.molimm.2006.06.019
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Li M, 2006, NAT GENET, V38, P1049, DOI 10.1038/ng1871
   Mullins RF, 2000, FASEB J, V14, P835, DOI 10.1096/fasebj.14.7.835
   Purcell S, 2007, AM J HUM GENET, V81, P559, DOI 10.1086/519795
   Reynolds R, 2009, INVEST OPHTH VIS SCI, V50, P5818, DOI 10.1167/iovs.09-3928
   Scholl HPN, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002593
   Seitsonen S, 2010, MOL IMMUNOL, V47, P1334, DOI 10.1016/j.molimm.2010.01.001
   Sepp T, 2006, INVEST OPHTH VIS SCI, V47, P536, DOI 10.1167/iovs.05-1143
   Swaroop A, 2009, ANNU REV GENOM HUM G, V10, P19, DOI 10.1146/annurev.genom.9.081307.164350
   Thakkinstian A, 2006, HUM MOL GENET, V15, P2784, DOI 10.1093/hmg/ddl220
   Walport MJ, 2001, NEW ENGL J MED, V344, P1058, DOI 10.1056/NEJM200104053441406
   Zipfel PF, 2009, NAT REV IMMUNOL, V9, P729, DOI 10.1038/nri2620
NR 29
TC 19
Z9 21
U1 0
U2 3
PU ELSEVIER GMBH, URBAN & FISCHER VERLAG
PI JENA
PA OFFICE JENA, P O BOX 100537, 07705 JENA, GERMANY
SN 0171-2985
J9 IMMUNOBIOLOGY
JI Immunobiology
PD FEB
PY 2012
VL 217
IS 2
SI SI
BP 158
EP 161
DI 10.1016/j.imbio.2011.09.002
PG 4
WC Immunology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Immunology
GA 902GI
UT WOS:000301026200004
PM 22024702
OA Green Published, hybrid
DA 2022-11-30
ER

PT J
AU Bucan, K
   Lukic, M
   Bosnar, D
   Kopic, A
   Jukic, T
   Konjevoda, S
   Glavadanovic, S
   Antunica, AG
AF Bucan, Kajo
   Lukic, Marko
   Bosnar, Damir
   Kopic, Andrijana
   Jukic, Tomislav
   Konjevoda, Suzana
   Glavadanovic, Sergio
   Gverovic Antunica, Antonela
TI Analysis of association of risk factors for age-related macular
   degeneration
SO EUROPEAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE Age-related macular degeneration; retina; anatomy; biochemistry;
   physiology; preventive medicine; screening; socioeconomics and education
   in medicine; ophthalmology; practice management; genetics
ID CIGARETTE-SMOKING; GLOBAL PREVALENCE; BEAVER DAM; EYE; DISEASE;
   MACULOPATHY; IMPAIRMENT; BLINDNESS
AB Purpose: To evaluate the significance of risk factors and analyze their interrelationship in developing age-related macular degeneration (AMD). Materials and design: This is a multicenter, cross-sectional study conducted in eight ophthalmology centers in Europe. The STARS (Simplified Thea AMD Risk-Assessment Scale) questionnaire was used to assess 12 risk factors grouped in four major categories. We used Welch's t-test/F ratios to determine statistically significant changes. The principal component analysis was done to investigate the association between risk factors. Results: There were 3297 participants included in our data analysis. Nineteen percent of patients had a high risk of developing AMD, whilst 45.92% and 34.85% had moderate and small risk, respectively. Atherosclerosis appeared as the most relevant risk indicator for AMD development (Cohen's d = 0.861). Tukey's post hoc analysis of the smoking variable showed that ex-smokers (p < 0.001) have a significantly high risk of developing AMD. The Welch's t-test showed pseudophakic patients have a higher risk of developing AMD than phakic ones. Then, we conducted the principal component analysis, which revealed a significant connection between smoking and male gender and between smoking and atherosclerosis. Pseudophakic patients were generally older and had more often myocardial infarction as compared to phakic patients. We showed that higher BMI, history of arterial hypertension, hypercholesterolemia, and atherosclerosis tend to occur together as risk factors for AMD. Conclusion: Risk factors evaluated in our study should be considered for the development of AMD.
C1 [Bucan, Kajo] Univ Hosp Ctr Split, Ophthalmol Dept, Split, Croatia.
   [Lukic, Marko] Moorfields Eye Hosp NHS Fdn Trust, NIHR Biomed Res Ctr, 162 City Rd, London EC1V 2PD, England.
   [Lukic, Marko] UCL Inst Ophthalmol, 162 City Rd, London EC1V 2PD, England.
   [Bosnar, Damir] Univ Clin Ctr Sveti Duh, Dept Ophthalmol, Zagreb, Croatia.
   [Kopic, Andrijana] Univ Hosp Ctr Osijek, Ophthalmol Dept, Osijek, Croatia.
   [Kopic, Andrijana] JJ Strossmayer Univ Osijek, Fac Med Osijek, Osijek, Croatia.
   [Jukic, Tomislav] Univ Hosp Ctr Zagreb, Ophthalmol Dept, Zagreb, Croatia.
   [Konjevoda, Suzana] Gen Hosp Zadar, Ophthalmol Unit, Zadar, Croatia.
   [Glavadanovic, Sergio] Gen Hosp Sibenik, Ophthalmol Unit, Shibenik, Croatia.
   [Gverovic Antunica, Antonela] Gen Hosp Dubrovnik, Ophthalmol Unit, Dubrovnik, Croatia.
C3 University of Split; University of London; University College London;
   Moorfields Eye Hospital NHS Foundation Trust; University of London;
   University College London; University of JJ Strossmayer Osijek;
   University of Zagreb; University of Zadar
RP Lukic, M (通讯作者)，Moorfields Eye Hosp NHS Fdn Trust, NIHR Biomed Res Ctr, 162 City Rd, London EC1V 2PD, England.; Lukic, M (通讯作者)，UCL Inst Ophthalmol, 162 City Rd, London EC1V 2PD, England.
EM markolukic.md@gmail.com
RI Konjevoda, Suzana/GQQ-1812-2022
OI Konjevoda, Suzana/0000-0003-3979-6790; Lukic, Marko/0000-0002-7636-8368
CR [Anonymous], 2020, BLINDNESS VISION IMP, V8
   Bourne RRA, 2017, LANCET GLOB HEALTH, V5, pE888, DOI 10.1016/S2214-109X(17)30293-0
   Bressler Neil M, 2004, JAMA, V291, P1900, DOI 10.1001/jama.291.15.1900
   Chakravarthy U, 2007, OPHTHALMOLOGY, V114, P1157, DOI 10.1016/j.ophtha.2006.09.022
   Chakravarthy U, 2010, BMC OPHTHALMOL, V10, DOI 10.1186/1471-2415-10-31
   Chew EY, 2013, JAMA-J AM MED ASSOC, V309, P2005, DOI 10.1001/jama.2013.4997
   Christen WG, 1996, JAMA-J AM MED ASSOC, V276, P1147, DOI 10.1001/jama.276.14.1147
   Cohen J., 1988, STAT POWER ANAL SOCI, V2nd
   Delcourt C, 1998, ARCH OPHTHALMOL-CHIC, V116, P1031, DOI 10.1001/archopht.116.8.1031
   Delcourt C, 2017, INVEST OPHTH VIS SCI, V58, P6399, DOI 10.1167/iovs.17-21819
   Friedman DS, 1999, OPHTHALMOLOGY, V106, P1049, DOI 10.1016/S0161-6420(99)90267-1
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Jonas JB, 2014, AM J OPHTHALMOL, V158, P808, DOI 10.1016/j.ajo.2014.06.012
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Kortuem K, 2018, BRIT J OPHTHALMOL, V102, P1391, DOI 10.1136/bjophthalmol-2017-311494
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rudnicka AR, 2012, OPHTHALMOLOGY, V119, P571, DOI 10.1016/j.ophtha.2011.09.027
   Seddon JM, 1996, JAMA-J AM MED ASSOC, V276, P1141, DOI 10.1001/jama.276.14.1141
   Solberg Y, 1998, SURV OPHTHALMOL, V42, P535, DOI 10.1016/S0039-6257(98)00002-2
   Thornton J, 2005, EYE, V19, P935, DOI 10.1038/sj.eye.6701978
   Wang JJ, 2003, OPHTHALMOLOGY, V110, P1960, DOI 10.1016/S0161-6420(03)00816-9
   Wilde C, 2017, EYE, V31, P1042, DOI 10.1038/eye.2017.30
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Wright AF, 2018, OPHTHALMOLOGY, V125, P962, DOI 10.1016/j.ophtha.2018.03.034
NR 24
TC 1
Z9 1
U1 1
U2 3
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 1120-6721
EI 1724-6016
J9 EUR J OPHTHALMOL
JI Eur. J. Ophthalmol.
PD JAN
PY 2022
VL 32
IS 1
BP 410
EP 416
AR 1120672121998900
DI 10.1177/1120672121998900
EA MAR 2021
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA YK3MJ
UT WOS:000678250000001
PM 33660548
DA 2022-11-30
ER

PT J
AU Singer, MA
   del Cid, MR
   Stelton, CR
   Boord, T
AF Singer, Michael A.
   del Cid, Mario R.
   Stelton, Christopher R.
   Boord, Terry
TI Pars Plana Posterior Capsulotomy in a Patient With a Telescope
   Prosthesis for Age-Related Macular Degeneration
SO ARCHIVES OF OPHTHALMOLOGY
LA English
DT Article
ID IMPLANTABLE MINIATURE TELESCOPE; VISUAL-ACUITY; SAFETY
AB Objective: To demonstrate a surgical technique for visualization and removal of visually significant posterior capsule pacification (PCO) in a patient with a telescope prosthesis for end-stage age-related macular degeneration, in what is to our knowledge the first reported case of visually significant PCO associated with the use of this device.
   Methods: A pars plana capsulotomy using a 25-gauge vitrector was performed to remove PCO.
   Results: Pars plana capsulotomy was performed and visual acuity improved to pre-PCO levels. Challenges associated with the management of this condition are discussed.
   Conclusions: The development of visually significant PCO in patients with a telescope prosthesis is a rare occurrence that poses a unique treatment dilemma. Given the risks of damaging the device with Nd:YAG laser, a method for pars plana capsulotomy using a 25-gauge vitrectomy instrument was determined and successfully performed to remove PCO in a telescope-implanted eye.
C1 [Singer, Michael A.; Boord, Terry] Med Ctr Ophthalmol Associates, San Antonio, TX 78240 USA.
   [del Cid, Mario R.; Stelton, Christopher R.] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA.
C3 University of Texas System; University of Texas Health San Antonio
RP Singer, MA (通讯作者)，Med Ctr Ophthalmol Associates, 9157 Huebner Rd, San Antonio, TX 78240 USA.
EM msinger1@earthlink.net
CR Hudson HL, 2008, AM J OPHTHALMOL, V146, P664, DOI 10.1016/j.ajo.2008.07.003
   Hudson HL, 2006, OPHTHALMOLOGY, V113, P1987, DOI 10.1016/j.ophtha.2006.07.010
   Rosner M, 2003, J CATARACT REFR SURG, V29, P1005, DOI 10.1016/S0886-3350(02)01647-4
NR 3
TC 2
Z9 3
U1 0
U2 1
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 515 N STATE ST, CHICAGO, IL 60610-0946 USA
SN 0003-9950
J9 ARCH OPHTHALMOL-CHIC
JI Arch. Ophthalmol.
PD AUG
PY 2010
VL 128
IS 8
BP 1065
EP 1067
DI 10.1001/archophthalmol.2010.156
PG 3
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 638QJ
UT WOS:000280909700017
PM 20697010
OA Bronze
DA 2022-11-30
ER

PT J
AU Tanaka, K
   Nakayama, T
   Mori, R
   Sato, N
   Kawamura, A
   Yuzawa, M
AF Tanaka, Koji
   Nakayama, Tomohiro
   Mori, Ryusaburo
   Sato, Naoyuki
   Kawamura, Akiyuki
   Yuzawa, Mitsuko
TI Associations of complement factor B and complement component 2 genotypes
   with subtypes of polypoidal choroidal vasculopathy
SO BMC OPHTHALMOLOGY
LA English
DT Article
DE Subtypes of PCV; C2; CFB; Genetic variants
ID AGE-RELATED MACULOPATHY; HTRA1 PROMOTER POLYMORPHISM; FACTOR-H CFH;
   MACULAR DEGENERATION; GENE POLYMORPHISMS; LESION SIZE; ARMS2; JAPANESE;
   CLASSIFICATION; ACTIVATION
AB Background: We previously reported on subtypes of polypoidal choroidal vasculopathy (PCV), and categorized PCV as polypoidal choroidal neovascularization (CNV) and typical PCV. The aim of this study was to clarify whether complement component 2 (C2) and complement factor B (CFB) genotypes are associated with subtypes of polypoidal choroidal vasculopathy, such as polypoidal CNV and typical PCV.
   Methods: First, we categorized 677 patients into typical age-related macular degeneration (tAMD; 250 patients), PCV (376) and retinal angiomatous proliferation (RAP; 51). Second, we categorized 282 patients with PCV as having polypoidal CNV (84 patients) or typical PCV (198) based on indocyanine green angiographic findings. In total, 274 subjects without AMD, such as PCV and CNV, served as controls. A SNP (rs547154) in the C2 gene and three SNPs (rs541862, rs2072633, rs4151667) in the CFB gene were genotyped, and case-control studies were performed in subjects with these PCV subtypes.
   Results: In tAMD, no SNPs were associated with allele distributions. In PCV, rs547154 and rs2072633 were associated with allele distributions. RAP was only associated with rs2072633. After logistic regression analysis with adjustment for confounding factors, tAMD, PCV and RAP were found to be associated with rs2072633.
   As to PCV subtypes, there were significant differences in the distributions of rs547154, rs541862 and rs2072633 in the case-control studies for polypoidal CNV, but not between the typical PCV and control groups. Logistic regression analysis with adjustment for confounding factors showed the distributions of rs547154, rs541862 and rs2072633 to differ significantly between the controls and polypoidal CNV cases and that these SNPs were protective. The A/A genotype of rs2072633 was significantly more common in the polypoidal CNV than in the typical PCV group (p = 0.03), even with adjustment for polyp number and greatest linear dimension.
   Conclusions: PCV might be genetically divisible into polypoidal CNV and typical PCV. The C2 and CFB gene variants were shown to be associated with polypoidal CNV. Typical PCV was not associated with variants in these genes.
C1 [Tanaka, Koji; Mori, Ryusaburo; Kawamura, Akiyuki; Yuzawa, Mitsuko] Nihon Univ, Sch Med, Dept Ophthalmol, Chiyoda Ku, Tokyo 1018309, Japan.
   [Nakayama, Tomohiro; Sato, Naoyuki] Nihon Univ, Sch Med, Dept Pathol & Microbiol, Tokyo, Japan.
C3 Nihon University; Nihon University
RP Nakayama, T (通讯作者)，Nihon Univ, Sch Med, Dept Pathol & Microbiol, Tokyo, Japan.
EM nakayama.tomohiro@nihon-u.ac.jp
RI Nakayama, Tomohiro/GYU-0303-2022; Tanaka, Koji/H-3119-2019
OI Tanaka, Koji/0000-0003-3323-4148
FU Research Committee on Chorioretinal Degenerations and Optic Atrophy;
   Ministry of Health and Welfare of Japan (Mitsuko Yuzawa)
FX We would like to thank all patients who participated in this study. This
   work was funded in part by the Research Committee on Chorioretinal
   Degenerations and Optic Atrophy, and by The Ministry of Health and
   Welfare of Japan (Mitsuko Yuzawa).
CR Dewan A, 2006, SCIENCE, V314, P989, DOI 10.1126/science.1133807
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   Gotoh N, 2009, AM J OPHTHALMOL, V147, P1037, DOI 10.1016/j.ajo.2008.12.036
   Hayashi H, 2010, INVEST OPHTH VIS SCI, V51, P5914, DOI 10.1167/iovs.10-5554
   Kawamura A, 2013, ACTA OPHTHALMOL, V91, pe474, DOI 10.1111/aos.12110
   KLEIN R, 1993, AM J EPIDEMIOL, V137, P190, DOI 10.1093/oxfordjournals.aje.a116659
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Kondo N, 2009, OPHTHALMOLOGY, V116, P1502, DOI 10.1016/j.ophtha.2009.03.004
   Lee KY, 2008, INVEST OPHTH VIS SCI, V49, P2613, DOI 10.1167/iovs.07-0860
   Lima LH, 2010, OPHTHALMOLOGY, V117, P1567, DOI 10.1016/j.ophtha.2009.12.018
   Liu K, 2013, OPHTHALMOLOGY, V120, P837, DOI 10.1016/j.ophtha.2012.10.003
   Loyet KM, 2012, INVEST OPHTH VIS SCI, V53, P6628, DOI 10.1167/iovs.12-9587
   Miki A, 2013, OPHTHALMIC GENET, V34, P146, DOI 10.3109/13816810.2012.749288
   Mizutani Y, 2006, INT J BIOMED SCI, V2, P9
   Nakashizuka H, 2008, INVEST OPHTH VIS SCI, V49, P4729, DOI 10.1167/iovs.08-2134
   Nakata I, 2012, INVEST OPHTH VIS SCI, V53, P794, DOI 10.1167/iovs.11-8468
   Okubo A, 2008, GRAEF ARCH CLIN EXP, V246, P491, DOI 10.1007/s00417-007-0680-8
   Rivera A, 2005, HUM MOL GENET, V14, P3227, DOI 10.1093/hmg/ddi353
   Sato N, 2009, BIOCHEM BIOPH RES CO, V380, P548, DOI 10.1016/j.bbrc.2009.01.117
   Scholl HPN, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002593
   Smailhodzic D, 2012, OPHTHALMOLOGY, V119, P339, DOI 10.1016/j.ophtha.2011.07.056
   SPAIDE RF, 1995, RETINA-J RET VIT DIS, V15, P100, DOI 10.1097/00006982-199515020-00003
   SPERDUTO RD, 1986, ARCH OPHTHALMOL-CHIC, V104, P216
   Sun C, 2012, CURR EYE RES, V37, P259, DOI 10.3109/02713683.2011.635401
   Takahashi Kanji, 2008, Nippon Ganka Gakkai Zasshi, V112, P1076
   Tanaka K, 2011, INVEST OPHTH VIS SCI, V52, P7441, DOI 10.1167/iovs.11-7546
   Tsujikawa A, 2011, AM J OPHTHALMOL, V151, P961, DOI 10.1016/j.ajo.2011.01.002
   Yasuda M, 2009, OPHTHALMOLOGY, V116, P2135, DOI 10.1016/j.ophtha.2009.04.017
   Yoshida T, 2007, MOL VIS, V13, P545
   Yuzawa M, 2005, BRIT J OPHTHALMOL, V89, P602, DOI 10.1136/bjo.2004.049296
NR 30
TC 14
Z9 18
U1 0
U2 5
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1471-2415
J9 BMC OPHTHALMOL
JI BMC Ophthalmol.
PD JUN 25
PY 2014
VL 14
AR 83
DI 10.1186/1471-2415-14-83
PG 12
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA AK4EH
UT WOS:000338376300002
PM 24965207
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Bressler, NM
AF Bressler, Neil M.
TI Antiangiogenic Approaches to Age-Related Macular Degeneration Today
SO OPHTHALMOLOGY
LA English
DT Article
ID ENDOTHELIAL GROWTH-FACTOR; SUBFOVEAL CHOROIDAL NEOVASCULARIZATION;
   VISION-RELATED FUNCTION; PHOTODYNAMIC THERAPY; VISUAL-ACUITY;
   INTRAVITREAL BEVACIZUMAB; CLINICAL-TRIALS; RANIBIZUMAB; VERTEPORFIN;
   AVASTIN(R)
AB Intravitreal ranibizumab reduces the risk of visual acuity loss and increases the chance of visual acuity gain compared with no treatment or photodynamic therapy for selected cases of subfoveal choroidal neovascularization (CNV) in age-related macular degeneration (AMD). Although intravitreal ranibizumab did not result in substantial improvement (15 or more letters on an ETDRs chart) in the majority of cases treated in the MARINA (Minimally classic/occult trial of the Anti-VEGF antibody Ranibizumab in the treatment of Neovascular AMD) or ANCHOR (Anti-VEGF Antibody for the Treatment of Predominantly Classic CHORoidal Neovascularization in AMD) trials, few cases experienced substantial visual acuity loss. The most serious known risk of treatment, endophthalmitis, although rare, is always a possibility. Intravitreal bevacizumab might be considered when ranibizumab is not available because of regulatory or financial constraints, and it might be considered in place of ranibizumab even without financial constraints if noninferiority trials show that bevacizumab is almost as good as-or is better than-ranibizumab. Systemic risks of intravitreal ranibizumab or bevacizumab are unknown, although trials have ruled out moderate or large systemic risks for ranibizumab. This therapy should be considered when initiating therapy for lesions that are subfoveal, and predominantly CNV when the lesion composition on fluorescein angiography (FA) is predominantly classic, or when there is presumed recent disease progression and the lesion composition is minimally classic or occult with no classic. Optical coherence tomography, FA, or both also might be of value to assist with decisions regarding continuation of treatment after it has been initiated. However, to date, there is little consistent information to suggest that utilizing these imaging modalities to consider withholding treatment before 2 years has been shown confidently to result in outcomes as good as monthly treatment. Extrapolation of these recommendations should be done with caution when considering the treatment of subfoveal CNV that is not predominantly CNV, such as predominantly blood lesions or lesions that are predominantly scar, as well as lesions associated with very low levels of visual acuity or those owing to causes other than AMD. A subsequent review in this series discusses other therapies for CNV being considered in the future.
   Financial Disclosure(s): Proprietary or commercial disclosure may be found in the CME frontmatter. Ophthalmology 2009;116:S15-S23 (C) 2009 by the American Academy of Ophthalmology.
C1 Johns Hopkins Univ, Sch Med, Wilmer Eye Inst, Baltimore, MD 21287 USA.
C3 Johns Hopkins University; Johns Hopkins Medicine
RP Bressler, NM (通讯作者)，Johns Hopkins Univ, Sch Med, Wilmer Eye Inst, 600 N Wolfe St, Baltimore, MD 21287 USA.
EM nbressler@jhmi.edu
CR Alexander SL, 2007, OPHTHALMOLOGY, V114, P2174, DOI 10.1016/j.ophtha.2007.09.017
   [Anonymous], 1991, Arch Ophthalmol, V109, P1109
   [Anonymous], 1991, Arch Ophthalmol, V109, P1220
   [Anonymous], 1995, Arch Ophthalmol, V113, P190
   Arnold JJ, 2004, AM J OPHTHALMOL, V137, P683, DOI 10.1016/j.ajo.2003.11.059
   Avery RL, 2006, OPHTHALMOLOGY, V113, P363, DOI 10.1016/j.ophtha.2005.11.019
   Bashshur ZF, 2006, AM J OPHTHALMOL, V142, P1, DOI 10.1016/j.ajo.2006.02.037
   Beck RW, 2007, OPHTHALMOLOGY, V114, P1804, DOI 10.1016/j.ophtha.2007.06.047
   BLACKHURST DW, 1989, RETINA-J RET VIT DIS, V9, P163, DOI 10.1097/00006982-198909030-00001
   Bressler NM, 2009, ARCH OPHTHALMOL-CHIC, V127, P13, DOI 10.1001/archophthalmol.2008.562
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   Bressler SB, 2005, RETINA-J RET VIT DIS, V25, P253
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   Carmeliet P, 1999, NAT MED, V5, P495, DOI 10.1038/8379
   Chang LK, 2007, RETINA-J RET VIT DIS, V27, P523, DOI 10.1097/IAE.0b013e3180a032db
   Chang TS, 2007, ARCH OPHTHALMOL-CHIC, V125, P1460, DOI 10.1001/archopht.125.11.1460
   Cohen SY, 2009, AM J OPHTHALMOL, V148, P409, DOI 10.1016/j.ajo.2009.04.001
   Ferrara N, 2006, RETINA-J RET VIT DIS, V26, P859, DOI 10.1097/01.iae.0000242842.14624.e7
   Fung AE, 2007, AM J OPHTHALMOL, V143, P566, DOI 10.1016/j.ajo.2007.01.028
   *GEN INC, 2007, LUC RAN INJ
   *GEN INC, DEAR DOCT LETT
   GILLIES A, 1983, ANN OPHTHALMOL, V15, P1068
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Hawkins BS, 2004, OPHTHALMOLOGY, V111, P1967, DOI 10.1016/j.ophtha.2004.07.021
   Kvanta A, 1996, INVEST OPHTH VIS SCI, V37, P1929
   Lauer G, 2000, J INVEST DERMATOL, V115, P12, DOI 10.1046/j.1523-1747.2000.00036.x
   Marcus D, 2004, AM J OPHTHALMOL, V138, P818, DOI 10.1016/j.ajo.2004.06.081
   Miskala PH, 2004, OPHTHALMOLOGY, V111, P1981, DOI 10.1016/j.ophtha.2004.07.022
   Regillo CD, 2008, AM J OPHTHALMOL, V145, P239, DOI 10.1016/j.ajo.2007.10.004
   Rosamond W, 2007, CIRCULATION, V115, pE69, DOI 10.1161/CIRCULATIONAHA.106.179918
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rosenfeld PJ, 2005, OPHTHALMOLOGY, V112, P1048, DOI 10.1016/j.ophtha.2005.01.043
   Rosenfeld PJ, 2005, OPHTHAL SURG LAS IM, V36, P331, DOI 10.3928/1542-8877-20050701-14
   Scott IU, 2007, OPHTHALMOLOGY, V114, P1860, DOI 10.1016/j.ophtha.2007.05.062
   Shams Naveed, 2006, Ophthalmol Clin North Am, V19, P335
   STERNBERG P, 1991, ARCH OPHTHALMOL-CHIC, V109, P1242
   STERNBERG P, 1991, ARCH OPHTHALMOL-CHIC, V109, P1232
   Ta CN, 2004, RETINA-J RET VIT DIS, V24, P699, DOI 10.1097/00006982-200410000-00003
   Wu L, 2008, GRAEF ARCH CLIN EXP, V246, P81, DOI 10.1007/s00417-007-0660-z
NR 40
TC 102
Z9 103
U1 0
U2 8
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0161-6420
EI 1549-4713
J9 OPHTHALMOLOGY
JI Ophthalmology
PD OCT
PY 2009
VL 116
IS 10
SU S
BP S15
EP S23
DI 10.1016/j.ophtha.2009.06.048
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 506RY
UT WOS:000270794700003
PM 19800535
DA 2022-11-30
ER

PT J
AU Caljkusic-Mance, T
   Kovacevic, D
   Novak-Stroligo, M
   Alpeza-Dunato, Z
AF Caljkusic-Mance, Tea
   Kovacevic, Damir
   Novak-Stroligo, Maja
   Alpeza-Dunato, Zvjezdana
TI Distribution of Age-Related Macular Degeneration in Primorsko-Goranska
   County
SO COLLEGIUM ANTROPOLOGICUM
LA English
DT Article
DE age-related macular degeneration; distribution; Croatia
ID SOLAR ULTRAVIOLET-RADIATION
AB The aim of this study is to show what part of our County has the most population with age-related macular degeneration (ARMD) and how some types frequently appear in same parts. The County includes 3 different geographic areas: Gorski Kotar, Coast and Islands. ARMD is the leading cause of visual impairment and blindness in developed countries. There are two categories of ARMD: atrophic or "dry" ARMD and exudative or "wet" ARMD. Our epidemiological study group includes 60 patients (33 females, 27 males) with both types of ARMD and they mostly spent their life times in our County. Patients were examined and treated in our Clinic during 2008 and 2009. We also examined which contribution factor (age, genetics, UV-exposure, diet, iris and macular pigment) is more common and found a links with occupation, residence and habits. Our study shows that ARMD in our County is most frequent in interval of 61-80 years. Incidence of ARMD is mild increased in female (55%). Significant incidence of ARMD is connected with patients who work outdoor more than 5 hours daily (70 %). There were no significant difference between patients in different areas-Gorski Kotar andCoast (p=0.9260), Gorski Kotar and Islands (p=0.8382) and Coast and Islands (p=0.8546) connected with occupations. Regions Coast and Islands had more cases of ARMD than Gorski Kotar, but in Gorski Kotar patients had greater percent of "wet" type. Difference is statistically significant between areas Gorski Kotar and Islands (chi(2)=4.675, p=0.0306). Also, there were statistically significant difference in nutrition between Gorski Kotar and Islands (chi(2)=4.17, p=0.0411). Incidence of ARMD is related with less iris and macular pigment-47 patients (77%). There was an increased risk for exudative type in Trsce and Cabar in Gorski Kotar.
C1 [Caljkusic-Mance, Tea; Kovacevic, Damir; Novak-Stroligo, Maja; Alpeza-Dunato, Zvjezdana] Rijeka Univ Hosp, Dept Ophtalmol, Rijeka 51000, Croatia.
C3 University of Rijeka
RP Caljkusic-Mance, T (通讯作者)，Rijeka Univ Hosp, Dept Ophtalmol, Kresimirova 42, Rijeka 51000, Croatia.
EM tea.caljkusic-mance1@ri.t-com.hr
CR Kovacevic D, 2008, COLLEGIUM ANTROPOL, V32, P5
   Njiric S, 2007, COLLEGIUM ANTROPOL, V31, P107
   NOELL WK, 1980, VISION RES, V20, P1163, DOI 10.1016/0042-6989(80)90055-3
   Plestina-Borjan I, 2007, COLLEGIUM ANTROPOL, V31, P33
   TSO MOM, 1983, OPHTHALMOLOGY, V90, P952
   Vojnikovic B, 2007, COLLEGIUM ANTROPOL, V31, P43
   WAXLER M, 1988, OPHTHALMIC RES, V20, P179, DOI 10.1159/000266583
NR 7
TC 4
Z9 4
U1 0
U2 2
PU COLLEGIUM ANTROPOLOGICUM
PI ZAGREB
PA INST ANTHROPOLOGICAL RES, P O BOX 290, ULICA GRADA VUKOVARA 72/IV, 10000
   ZAGREB, CROATIA
SN 0350-6134
J9 COLLEGIUM ANTROPOL
JI Coll. Anthropol.
PD APR
PY 2010
VL 34
SU 2
BP 109
EP 111
PG 3
WC Anthropology
WE Social Science Citation Index (SSCI)
SC Anthropology
GA 677AI
UT WOS:000283961100023
PM 21302709
DA 2022-11-30
ER

PT J
AU Oca, AI
   Perez-Sala, A
   Pariente, A
   Ochoa, R
   Velilla, S
   Pelaez, R
   Larrayoz, IM
AF Oca, Ana I.
   Perez-Sala, Alvaro
   Pariente, Ana
   Ochoa, Rodrigo
   Velilla, Sara
   Pelaez, Rafael
   Larrayoz, Ignacio M.
TI Predictive Biomarkers of Age-Related Macular Degeneration Response to
   Anti-VEGF Treatment
SO JOURNAL OF PERSONALIZED MEDICINE
LA English
DT Article
DE RNA-Seq; PBMC; retina; ranibizumab; machine learning
ID ENDOTHELIAL GROWTH-FACTOR; RANIBIZUMAB THERAPY; PRECISION MEDICINE;
   NEOVASCULAR AMD; EXTEND REGIMEN; GENES; ASSOCIATION; BEVACIZUMAB;
   OUTCOMES; RISK
AB Age-related macular degeneration (AMD) is an incurable disease associated with aging that destroys sharp and central vision. Increasing evidence implicates both systemic and local inflammation in the pathogenesis of AMD. Intravitreal injection of anti-vascular endothelial growth factor (VEGF) agents is currently the first-line therapy for choroidal neovascularization in AMD patients. However, a high number of patients do not show satisfactory responses to anti-VEGF treatment after three injections. Predictive treatment response models are one of the most powerful tools for personalized medicine. Therefore, the application of these models is very helpful to predict the optimal treatment for an early application on each patient. We analyzed the transcriptome of peripheral blood mononuclear cells (PBMCs) from AMD patients before treatment to identify biomarkers of response to ranibizumab. A classification model comprised of four mRNAs and one miRNA isolated from PBMCs was able to predict the response to ranibizumab with high accuracy (Area Under the Curve of the Receiver Operating Characteristic curve = 0.968), before treatment. We consider that our classification model, based on mRNA and miRNA from PBMCs allows a robust prediction of patients with insufficient response to anti-VEGF treatment. In addition, it could be used in combination with other methods, such as specific baseline characteristics, to identify patients with poor response to anti-VEGF treatment to establish patient-specific treatment plans at the first visit.
C1 [Oca, Ana I.; Perez-Sala, Alvaro; Pariente, Ana; Ochoa, Rodrigo; Velilla, Sara; Pelaez, Rafael; Larrayoz, Ignacio M.] Fdn Rioja Salud, Biomarkers & Mol Signaling Grp, Ctr Biomed Res La Rioja CIBIR, Logrono 26006, La Rioja, Spain.
   [Larrayoz, Ignacio M.] Univ La Rioja UR, Unidad Predept Enfermeria, Logrono 26006, La Rioja, Spain.
RP Larrayoz, IM (通讯作者)，Fdn Rioja Salud, Biomarkers & Mol Signaling Grp, Ctr Biomed Res La Rioja CIBIR, Logrono 26006, La Rioja, Spain.; Larrayoz, IM (通讯作者)，Univ La Rioja UR, Unidad Predept Enfermeria, Logrono 26006, La Rioja, Spain.
EM aioca@riojasalud.es; aperez@riojaslud.es; apariente@riojaslud.es;
   rochoaf@riojasalud.es; svelillaoses@gmail.com; rpelaez@riojasalud.es;
   ilarrayoz@riojasalud.es
RI Larrayoz, Ignacio M/I-5613-2012
OI Larrayoz, Ignacio M/0000-0003-1629-152X; Pariente Delgado,
   Ana/0000-0001-9046-6629; Pelaez, Rafael/0000-0002-4047-6017
FU Instituto de Salud Carlos III [PI19/01805]; European Regional
   Development Fund (ERDF) "A way to build Europe"; Fundacion Rioja Salud;
   Miguel Servet contract from the Instituto de Salud Carlos III
   [CPII20/00029]; European Social fund (ESF) "Investing in your future"
FX This research was funded in part by a grant (PI19/01805) from the
   Instituto de Salud Carlos III, co-funded by European Regional
   Development Fund (ERDF) "A way to build Europe" and by Fundacion Rioja
   Salud. I.M.L. is supported by a Miguel Servet contract (CPII20/00029)
   from the Instituto de Salud Carlos III, co-funded by European Social
   fund (ESF) "Investing in your future".
CR Akiyama M, 2018, J HUM GENET, V63, P1083, DOI 10.1038/s10038-018-0493-0
   Amoaku WM, 2015, EYE, V29, P721, DOI 10.1038/eye.2015.48
   Amoaku W, 2018, CLIN OPHTHALMOL, V12, P1731, DOI 10.2147/OPTH.S174560
   Anand A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0049905
   Behnke V, 2020, CELL MOL LIFE SCI, V77, P781, DOI 10.1007/s00018-019-03419-4
   Blasiak J, 2019, J CELL MOL MED, V23, P8464, DOI 10.1111/jcmm.14731
   Cascella R, 2018, PROG RETIN EYE RES, V63, P132, DOI 10.1016/j.preteyeres.2017.11.004
   Cascella Raffaella, 2018, Oncotarget, V9, P7812, DOI 10.18632/oncotarget.23241
   Chang W, 2013, MOL VIS, V19, P702
   Chen S, 2020, CLIN CHIM ACTA, V500, P220, DOI 10.1016/j.cca.2019.10.021
   Cinici E, 2021, BIOMED RES INT, V2021, DOI 10.1155/2021/6620900
   Curcio Christine A, 2018, Invest Ophthalmol Vis Sci, V59, pAMD160, DOI 10.1167/iovs.18-24882
   Daftarian N, 2020, FASEB J, V34, P8001, DOI 10.1096/fj.201901902RR
   Diack C, 2021, TRANSL VIS SCI TECHN, V10, DOI 10.1167/tvst.10.6.11
   Dilley J, 2016, INVEST OPHTH VIS SCI, V57
   Dobin A, 2013, BIOINFORMATICS, V29, P15, DOI 10.1093/bioinformatics/bts635
   Farrar GJ, 2017, HUM MOL GENET, V26, pR2, DOI 10.1093/hmg/ddx185
   Fleckenstein M, 2021, NAT REV DIS PRIMERS, V7, DOI 10.1038/s41572-021-00265-2
   Frank E, 2004, BIOINFORMATICS, V20, P2479, DOI 10.1093/bioinformatics/bth261
   Friedlander MR, 2012, NUCLEIC ACIDS RES, V40, P37, DOI 10.1093/nar/gkr688
   Fritsche LG, 2010, HUM MOL GENET, V19, P4694, DOI 10.1093/hmg/ddq399
   Gadd VL, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0157771
   Gallardo M, 2021, OPHTHALMOL RETINA, V5, P604, DOI 10.1016/j.oret.2021.05.002
   Grassmann F, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0107461
   Greenberg E, 2014, OPEN BIOL, V4, DOI 10.1098/rsob.140030
   Grunin M, 2016, SCI REP-UK, V6, DOI 10.1038/srep29046
   Guo Y, 2021, BIOCHEM CELL BIOL, V99, P414, DOI 10.1139/bcb-2020-0357
   Hagstrom SA, 2013, OPHTHALMOLOGY, V120, P593, DOI 10.1016/j.ophtha.2012.11.037
   Hofmans M, 2021, SCI REP-UK, V11, DOI 10.1038/s41598-021-82509-5
   Huang C, 2013, MOL VIS, V19, P1211
   Indaram M, 2015, SCI REP-UK, V5, DOI 10.1038/srep09144
   Bonyadi MHJ, 2020, OPHTHALMIC GENET, V41, P301, DOI 10.1080/13816810.2020.1765396
   Jaffe GJ, 2019, OPHTHALMOLOGY, V126, P252, DOI 10.1016/j.ophtha.2018.08.035
   Kanehisa M, 2000, NUCLEIC ACIDS RES, V28, P27, DOI 10.1093/nar/28.1.27
   Kanehisa M, 2014, NUCLEIC ACIDS RES, V42, pD199, DOI 10.1093/nar/gkt1076
   Khanna S, 2019, BMJ OPEN OPHTHALMOL, V4, DOI 10.1136/bmjophth-2019-000398
   Larrayoz IM, 2014, INVEST OPHTH VIS SCI, V55, P7553, DOI 10.1167/iovs.14-14951
   Larrayoz IM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0039359
   Lederman M, 2010, INVEST OPHTH VIS SCI, V51, P53, DOI 10.1167/iovs.08-3019
   Li S, 2014, NAT IMMUNOL, V15, P195, DOI 10.1038/ni.2789
   Li Y, 2016, NAT MED, V22, P952, DOI 10.1038/nm.4139
   Litwinska Z, 2019, FRONT AGING NEUROSCI, V11, DOI 10.3389/fnagi.2019.00286
   Lores-Motta L, 2018, MOL DIAGN THER, V22, P315, DOI 10.1007/s40291-018-0332-1
   Lux A, 2007, BRIT J OPHTHALMOL, V91, P1318, DOI 10.1136/bjo.2006.113902
   Ma BF, 2015, INT J CLIN EXP PATHO, V8, P9592
   Ma L, 2016, SCI REP-UK, V6, DOI 10.1038/srep19718
   Mansoor Naima, 2019, Curr Mol Med, V19, P705, DOI 10.2174/1566524019666190828150625
   Martinez-Barricarte R, 2012, INVEST OPHTH VIS SCI, V53, P1087, DOI 10.1167/iovs.11-8709
   McDonel P, 2019, CSH PERSPECT BIOL, V11, DOI 10.1101/cshperspect.a032151
   Menard C, 2016, ONCOTARGET, V7, P19171, DOI 10.18632/oncotarget.8280
   Nguyen CL, 2018, BMC OPHTHALMOL, V18, DOI 10.1186/s12886-018-0785-3
   Pariente A, 2020, CELLS-BASEL, V9, DOI 10.3390/cells9051187
   Piermarocchi S, 2015, ACTA OPHTHALMOL, V93, pE451, DOI 10.1111/aos.12587
   Pin AL, 2012, ANGIOGENESIS, V15, P593, DOI 10.1007/s10456-012-9283-z
   Rickman CB, 2013, INVEST OPHTH VIS SCI, V54, pORSF68, DOI 10.1167/iovs.13-12757
   Romero-Vazquez S, 2021, BIOMEDICINES, V9, DOI 10.3390/biomedicines9070763
   Rua O, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0052696
   Rutar M, 2016, ADV EXP MED BIOL, V854, P11, DOI 10.1007/978-3-319-17121-0_2
   Schmidt-Erfurth U, 2014, BRIT J OPHTHALMOL, V98, P1144, DOI 10.1136/bjophthalmol-2014-305702
   Schmit K, 2018, FRONT PHARMACOL, V9, DOI 10.3389/fphar.2018.01345
   Sharma S, 2021, JHEP REP, V3, DOI 10.1016/j.jhepr.2021.100283
   Singh RP, 2016, OPHTHALMOLOGY, V123, P1581, DOI 10.1016/j.ophtha.2016.03.038
   Skalsky RL, 2012, PLOS PATHOG, V8, DOI 10.1371/journal.ppat.1002484
   Ulanczyk Z, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20225750
   Vlachos IS, 2015, NUCLEIC ACIDS RES, V43, pW460, DOI 10.1093/nar/gkv403
   Wang M, 2013, EUR J CANCER, V49, P2010, DOI 10.1016/j.ejca.2012.12.017
   Wang VM, 2012, MOL VIS, V18, P2578
   Wang YS, 2020, MOL MED REP, V22, P494, DOI 10.3892/mmr.2020.11082
   Xue CC, 2021, AM J OPHTHALMOL, V227, P143, DOI 10.1016/j.ajo.2021.03.010
   Yamaguchi M, 2008, DEVELOPMENT, V135, P1247, DOI 10.1242/dev.011015
   Yang Y, 2015, MOL VIS, V21, P1307
   Ying GS, 2015, JAMA OPHTHALMOL, V133, P726, DOI 10.1001/jamaophthalmol.2015.0502
   Ying GS, 2013, OPHTHALMOLOGY, V120, P122, DOI 10.1016/j.ophtha.2012.07.042
   Yu Y, 2011, HUM MOL GENET, V20, P3699, DOI 10.1093/hmg/ddr270
   Zhang XY, 2018, BIOMED RES INT, V2018, DOI 10.1155/2018/9640131
   Zhao L, 2013, CURR MOL MED, V13, P929, DOI 10.2174/15665240113139990048
   Ziemssen F, 2015, OPHTHALMOLOGE, V112, P246, DOI 10.1007/s00347-014-3217-7
NR 77
TC 3
Z9 3
U1 1
U2 1
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2075-4426
J9 J PERS MED
JI J. Pers. Med.
PD DEC
PY 2021
VL 11
IS 12
AR 1329
DI 10.3390/jpm11121329
PG 16
WC Health Care Sciences & Services; Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Health Care Sciences & Services; General & Internal Medicine
GA YA1AA
UT WOS:000738073700001
PM 34945801
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU McLeod, DS
   Grebe, R
   Bhutto, I
   Merges, C
   Baba, T
   Lutty, GA
AF McLeod, D. Scott
   Grebe, Rhonda
   Bhutto, Imran
   Merges, Carol
   Baba, Takayuki
   Lutty, Gerard A.
TI Relationship between RPE and Choriocapillaris in Age-Related Macular
   Degeneration
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
ID ENDOTHELIAL GROWTH-FACTOR; RETINAL-PIGMENT EPITHELIUM; BRUCH MEMBRANE
   CHANGE; CHOROIDAL BLOOD-FLOW; CARDIOVASCULAR-DISEASE; NEOVASCULAR
   MEMBRANES; OXIDATIVE DAMAGE; SURVIVAL FACTOR; IN-VITRO; PATHOGENESIS
AB PURPOSE. The purpose of this study was to examine the relationships between choriocapillaris (CC) and retinal pigment epithelial changes in age-related macular degeneration (AMD). Morphologic changes in the retinal pigment epithelium (RPE)/choriocapillaris complex were quantified in dry and wet forms of AMD, and the results were compared with those in aged control eyes without maculopathy.
   METHODS. Postmortem choroids from three aged control subjects, five subjects with geographic atrophy (GA), and three subjects with wet AMD were analyzed using a semiquantitative computer-assisted morphometric technique developed to measure the percentages of retinal pigment epithelial and CC areas in choroidal wholemounts incubated for alkaline phosphatase activity. The tissues were subsequently embedded in methacrylate and were sectioned so that structural changes could be examined.
   RESULTS. There was a linear relationship between the loss of RPE and CC in GA. A 50% reduction in vascular area was found in regions of complete retinal pigment epithelial atrophy. Extreme constriction of remaining viable capillaries was found in areas devoid of RPE. Adjacent to active choroidal neovascularization (CNV) in wet AMD, CC dropout was evident in the absence of retinal pigment epithelial atrophy, resulting in a 50% decrease in vascular area. Lumenal diameters of the remaining capillaries in wet AMD eyes were similar to those in control eyes.
   CONCLUSIONS. The primary insult in GA appears to be at the level of the RPE, and there is an intimate relationship between retinal pigment epithelial atrophy and secondary CC degeneration. CC degeneration occurs in the presence of viable RPE in wet AMD. The RPE in regions of vascular dropout are presumably hypoxic, which may result in an increase in VEGF production by the RPE and stimulation of CNV. (Invest Ophthalmol Vis Sci. 2009;50:4982-4991) DOI: 10.1167/iovs.09-3639
C1 [McLeod, D. Scott; Grebe, Rhonda; Bhutto, Imran; Merges, Carol; Baba, Takayuki; Lutty, Gerard A.] Johns Hopkins Univ Hosp, Wilmer Ophthalmol Inst, Baltimore, MD 21287 USA.
C3 Johns Hopkins University; Johns Hopkins Medicine
RP Lutty, GA (通讯作者)，Johns Hopkins Univ Hosp, Wilmer Ophthalmol Inst, M041 Smith Bldg,400 N Broadway, Baltimore, MD 21287 USA.
EM galutty@jhmi.edu
RI Mitchell, Paul/P-1498-2014
FU National Institutes of Health [EY016151, EY01765]; Altsheler-Durell
   Foundation; Foundation Fighting Blindness; Research to Prevent Blindness
   Unrestricted; NATIONAL EYE INSTITUTE [R01EY016151, P30EY001765] Funding
   Source: NIH RePORTER
FX Supported by National Institutes of Health Grants EY016151 (GAL) and
   EY01765 (Wilmer), the Altsheler-Durell Foundation, Foundation Fighting
   Blindness, and a Research to Prevent Blindness Unrestricted Grant
   (Wilmer). GAL is the recipient of an RPB Senior Scientific Investigator
   Award.
CR ADAMIS AP, 1993, BIOCHEM BIOPH RES CO, V193, P631, DOI 10.1006/bbrc.1993.1671
   ALON T, 1995, NAT MED, V1, P1024, DOI 10.1038/nm1095-1024
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   Benjamin LE, 1997, P NATL ACAD SCI USA, V94, P8761, DOI 10.1073/pnas.94.16.8761
   Blaauwgeers HGT, 1999, AM J PATHOL, V155, P421, DOI 10.1016/S0002-9440(10)65138-3
   Cai JY, 2000, PROG RETIN EYE RES, V19, P205, DOI 10.1016/S1350-9462(99)00009-9
   CHEN JC, 1992, INVEST OPHTH VIS SCI, V33, P334
   DelPriore LV, 1996, AM J OPHTHALMOL, V122, P629, DOI 10.1016/S0002-9394(14)70481-7
   Duan YK, 2007, OPHTHALMOLOGY, V114, P732, DOI 10.1016/j.ophtha.2006.07.045
   DUKEELDER S, 1966, SYSTEM OPHTHALMOLOGY, P608
   Dunaief JL, 2006, INVEST OPHTH VIS SCI, V47, P4660, DOI 10.1167/iovs.06-0568
   Espinosa-Heidmann DG, 2006, INVEST OPHTH VIS SCI, V47, P729, DOI 10.1167/iovs.05-0719
   Esser S, 1998, J CELL BIOL, V140, P947, DOI 10.1083/jcb.140.4.947
   Feigl B, 2009, PROG RETIN EYE RES, V28, P63, DOI 10.1016/j.preteyeres.2008.11.004
   FRIEDMAN E, 1995, OPHTHALMOLOGY, V102, P640, DOI 10.1016/S0161-6420(95)30974-8
   Friedman E, 2004, BRIT J OPHTHALMOL, V88, P161, DOI 10.1136/bjo.2003.036277
   Friedman E, 1997, AM J OPHTHALMOL, V124, P677, DOI 10.1016/S0002-9394(14)70906-7
   Friedman E, 2008, AM J OPHTHALMOL, V146, P348, DOI 10.1016/j.ajo.2008.05.017
   GASS JD, 1997, STEREOSCOPIC ATLAS M, P80
   Grunwald JE, 1998, ARCH OPHTHALMOL-CHIC, V116, P150
   Grunwald JE, 1998, INVEST OPHTH VIS SCI, V39, P385
   Grunwald JE, 2005, INVEST OPHTH VIS SCI, V46, P1033, DOI 10.1167/iovs.04-1050
   Harris A, 1999, PROG RETIN EYE RES, V18, P669
   Hayashi A, 1999, GRAEF ARCH CLIN EXP, V237, P668, DOI 10.1007/s004170050295
   HAYASHI K, 1985, OPHTHALMOLOGICA, V190, P30, DOI 10.1159/000309489
   HENKIND P, 1983, T OPHTHAL SOC UK, V103, P444
   HERIOT WJ, 1992, GRAEF ARCH CLIN EXP, V230, P91, DOI 10.1007/BF00166769
   Hogg RE, 2008, OPHTHALMOLOGY, V115, P1046, DOI 10.1016/j.ophtha.2007.07.031
   Hyman L, 2000, ARCH OPHTHALMOL-CHIC, V118, P351, DOI 10.1001/archopht.118.3.351
   Ivert L, 2003, GRAEF ARCH CLIN EXP, V241, P656, DOI 10.1007/s00417-003-0653-5
   Karsan A, 1997, AM J PATHOL, V151, P1775
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   KORNZWEIG AL, 1977, ANN OPHTHALMOL, V9, P753
   KORTE GE, 1984, INVEST OPHTH VIS SCI, V25, P1135
   Leonard DS, 1997, INVEST OPHTH VIS SCI, V38, P1094
   Leonard DS, 2003, EXP EYE RES, V76, P473, DOI 10.1016/S0014-4835(02)00331-7
   Liu XP, 1997, EXP EYE RES, V65, P117, DOI 10.1006/exer.1997.0317
   LUTTY GA, 1992, ARCH OPHTHALMOL-CHIC, V110, P267, DOI 10.1001/archopht.1992.01080140123039
   Margrain TH, 2004, PROG RETIN EYE RES, V23, P523, DOI 10.1016/j.preteyeres.2004.05.001
   MCLEOD DS, 1994, INVEST OPHTH VIS SCI, V35, P3799
   McLeod DS, 2002, INVEST OPHTH VIS SCI, V43, P1986
   MELROSE MA, 1987, ANN OPHTHALMOL, V19, P396
   PAULEIKHOFF D, 1990, AM J OPHTHALMOL, V109, P211, DOI 10.1016/S0002-9394(14)75989-6
   RAMRATTAN RS, 1994, INVEST OPHTH VIS SCI, V35, P2857
   ROBERTS WG, 1995, J CELL SCI, V108, P2369
   SARKS JP, 1988, EYE, V2, P552, DOI 10.1038/eye.1988.106
   Shichiri M, 1997, HYPERTENSION, V30, P1198, DOI 10.1161/01.HYP.30.5.1198
   Snow K K, 1999, Ophthalmic Epidemiol, V6, P125, DOI 10.1076/opep.6.2.125.1558
   Spaide RF, 2003, RETINA-J RET VIT DIS, V23, P595, DOI 10.1097/00006982-200310000-00001
   Tian J, 2005, P NATL ACAD SCI USA, V102, P11846, DOI 10.1073/pnas.0504759102
   Tolentino MJ, 2002, AM J OPHTHALMOL, V133, P373, DOI 10.1016/S0002-9394(01)01381-2
   van Leeuwen R, 2003, INVEST OPHTH VIS SCI, V44, P3771, DOI 10.1167/iovs.03-0121
   VINGERLING JR, 1995, AM J EPIDEMIOL, V142, P404, DOI 10.1093/oxfordjournals.aje.a117648
   Watanabe Y, 1997, EXP CELL RES, V233, P340, DOI 10.1006/excr.1997.3583
   Wong TY, 2006, ANN INTERN MED, V145, P98, DOI 10.7326/0003-4819-145-2-200607180-00007
   Yamada Y, 2006, EXP EYE RES, V82, P840, DOI 10.1016/j.exer.2005.10.005
NR 56
TC 383
Z9 393
U1 0
U2 23
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD OCT
PY 2009
VL 50
IS 10
BP 4982
EP 4991
DI 10.1167/iovs.09-3639
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 497XE
UT WOS:000270097200060
PM 19357355
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Zhu, W
   Wu, Y
   Xu, D
   Li, YH
   Ba, J
   Zhang, XL
   Wang, F
   Yu, J
AF Zhu, Wei
   Wu, Yan
   Xu, Ding
   Li, Yan-Hong
   Ba, Jun
   Zhang, Xiao-Long
   Wang, Fang
   Yu, Jing
TI Aspirin Use and Risk of Age-Related Macular Degeneration: A
   Meta-Analysis
SO PLOS ONE
LA English
DT Article
ID LOW-DOSE ASPIRIN; CHOROIDAL NEOVASCULARIZATION; INTRAOCULAR HEMORRHAGE;
   CARDIOVASCULAR-DISEASE; RANDOMIZED-TRIAL; 5-YEAR INCIDENCE; DECREASED
   RATES; MEDICATION USE; MACULOPATHY; EYE
AB Background: Age-related macular degeneration (AMD) is the main cause of blindness and the curative options are limited. The objective of this meta-analysis was to determine the association between aspirin use and risk of AMD.
   Methods: A comprehensive literature search was performed in PubMed, Embase, Web of Science, and reference lists. A meta-analysis was performed by STATA software.
   Results: Ten studies involving 171729 individuals examining the association between aspirin use and risk of AMD were included. Among the included studies, 2 were randomized-controlled trials (RCTs), 4 were case-control studies and 4 were cohort studies. The relative risks (RRs) were pooled using a random-effects model. Relative risks with 95% confidence intervals (CIs) of aspirin use as a risk for AMD. The pooled RR of 10 included studies between the use of aspirin and risk of AMD was 1.09 (95% CI, 0.96-1.24). The same result was detected in early and late stage AMD subgroup analysis. In the subgroup analyses, the pooled RR of RCTs, case-control studies and cohort studies were 0.81 (95% CI, 0.64-1.02), 1.02 (95% CI, 0.92-1.14) and 1.08 (95% CI, 0.91-1.28), respectively.
   Conclusions: The use of aspirin was not associated with the risk of AMD.
C1 [Zhu, Wei; Wu, Yan; Xu, Ding; Li, Yan-Hong; Ba, Jun; Wang, Fang; Yu, Jing] Tongji Univ, Affiliated Peoples Hosp 10, Dept Ophthalmol, Shanghai 200092, Peoples R China.
   [Zhu, Wei; Wu, Yan; Zhang, Xiao-Long] Nanjing Med Univ, Dept Clin Med Coll 1, Nanjing, Jiangsu, Peoples R China.
C3 Tongji University; Nanjing Medical University
RP Yu, J (通讯作者)，Tongji Univ, Affiliated Peoples Hosp 10, Dept Ophthalmol, Shanghai 200092, Peoples R China.
EM dryujing@yahoo.com.cn
RI li, yan/GTI-4638-2022
FU National Nature Science Foundation [30901643]; Shanghai Science
   Committee Biology Department Pilot Project [10411964900]; New Excellence
   Project of Shanghai Health Bureau [XYQ2011067]
FX This work was supported in whole or in part, by National Nature Science
   Foundation Project (30901643), Shanghai Science Committee Biology
   Department Pilot Project (10411964900) and The New Excellence Project of
   Shanghai Health Bureau (XYQ2011067). The funders had no role in study
   design, data collection and analysis, decision to publish, or
   preparation of the manuscript.
CR Anand R, 2000, OPHTHALMOLOGY, V107, P2224
   [Anonymous], 1991, Ophthalmology, V98, P757
   Ayyadevara S, 2012, ANTIOXID REDOX SIGNA
   Baron JA, 2012, JNCI-J NATL CANCER I, V104, P1199, DOI 10.1093/jnci/djs338
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   Becker RC, 2008, CHEST, V133, p776S, DOI 10.1378/chest.08-0685
   BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   Chew EY, 2012, OPHTHALMOLOGY, V119, P2282, DOI 10.1016/j.ophtha.2012.05.027
   Chopdar A, 2003, BRIT MED J, V326, P485, DOI 10.1136/bmj.326.7387.485
   Christen WG, 2001, ARCH OPHTHALMOL-CHIC, V119, P1143, DOI 10.1001/archopht.119.8.1143
   Christen WG, 2009, OPHTHALMOLOGY, V116, P2386, DOI 10.1016/j.ophtha.2009.05.031
   Clemons Traci E, 2005, Ophthalmology, V112, P533
   Coleman AL, 2010, AM J OPHTHALMOL, V149, P160, DOI 10.1016/j.ajo.2009.07.025
   de Jong PTVM, 2012, OPHTHALMOLOGY, V119, P112, DOI 10.1016/j.ophtha.2011.06.025
   de Jong PTVM, 2010, OPHTHALMOLOGY, V117, P1279, DOI 10.1016/j.ophtha.2010.03.011
   DeAngelis MM, 2004, ARCH OPHTHALMOL-CHIC, V122, P575, DOI 10.1001/archopht.122.4.575
   Delcourt C, 1998, ARCH OPHTHALMOL-CHIC, V116, P1031, DOI 10.1001/archopht.116.8.1031
   DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2
   Diehl AK, 2012, ANN INTERN MED, V157, pJC1
   Douglas IJ, 2007, OPHTHALMOLOGY, V114, P1164, DOI 10.1016/j.ophtha.2006.09.018
   Downs SH, 1998, J EPIDEMIOL COMMUN H, V52, P377, DOI 10.1136/jech.52.6.377
   Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   ELBABA F, 1986, OPHTHALMOLOGY, V93, P1581
   Fine SL, 2000, NEW ENGL J MED, V342, P483, DOI 10.1056/NEJM200002173420707
   Gagne JJ, 2010, NEUROLOGY, V74, P995, DOI 10.1212/WNL.0b013e3181d5a4a3
   Gaynes BI, 2004, AM J OPHTHALMOL, V138, P1089, DOI 10.1016/j.ajo.2004.08.048
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Hirvela H, 1996, OPHTHALMOLOGY, V103, P871, DOI 10.1016/S0161-6420(96)30593-9
   Kiernan DF, 2010, RETINA-J RET VIT DIS, V30, P1573, DOI 10.1097/IAE.0b013e3181e2266d
   KINGHAM JD, 1988, NEW ENGL J MED, V318, P1126
   Klein BEK, 2012, JAMA-J AM MED ASSOC, V308, P2469, DOI 10.1001/jama.2012.65406
   KLEIN ML, 1991, JAMA-J AM MED ASSOC, V266, P2279
   Klein R, 2001, AM J OPHTHALMOL, V132, P128, DOI 10.1016/S0002-9394(00)00931-4
   Klein R, 2001, ARCH OPHTHALMOL-CHIC, V119, P1354
   LeLorier J, 1997, NEW ENGL J MED, V337, P536, DOI 10.1056/NEJM199708213370806
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Mascitelli L, 2010, MED HYPOTHESES, V74, P754, DOI 10.1016/j.mehy.2009.11.009
   McCarty CA, 2001, ARCH OPHTHALMOL-CHIC, V119, P1455
   Millen AE, 2011, ARCH OPHTHALMOL-CHIC, V129, P481, DOI 10.1001/archophthalmol.2011.48
   Mitchell P, 2002, OPHTHALMOLOGY, V109, P1092, DOI 10.1016/S0161-6420(02)01055-2
   Moher David, 2009, BMJ, V339, pb2535, DOI [10.1016/j.ijsu.2010.02.007, 10.1136/bmj.b2535]
   Moon BG, 2012, J KOREAN MED SCI, V27, P537, DOI 10.3346/jkms.2012.27.5.537
   Nandish S, 2011, AM J CARDIOL, V108, p42B, DOI 10.1016/j.amjcard.2011.03.015
   Olea JL, 2012, EUR J OPHTHALMOL, V22, P404, DOI 10.5301/ejo.5000023
   Ridker PM, 2005, NEW ENGL J MED, V352, P1293, DOI 10.1056/NEJMoa050613
   Rudnicka AR, 2010, EYE, V24, P1199, DOI 10.1038/eye.2010.8
   Samoocha David, 2010, J Med Internet Res, V12, pe23, DOI 10.2196/jmir.1286
   Schaumberg DA, 2001, ARCH OPHTHALMOL-CHIC, V119, P1259
   Sperduto RD, 2001, OPHTHALMOLOGY, V108, P1400
   Tilanus MAD, 2000, GRAEF ARCH CLIN EXP, V238, P482, DOI 10.1007/PL00007887
   Van Leeuwen R, 2004, OPHTHALMOLOGY, V111, P1169, DOI 10.1016/j.ophtha.2003.10.024
   Wang JJ, 2003, OPHTHALMIC EPIDEMIOL, V10, P37, DOI 10.1076/opep.10.1.37.13776
   Wilson HL, 2004, AM J OPHTHALMOL, V137, P615, DOI 10.1016/j.ajo.2003.10.025
   Wong TY, 2006, BRIT J OPHTHALMOL, V90, P506, DOI 10.1136/bjo.2005.083733
   Yoshinaga N, 2011, LAB INVEST, V91, P1277, DOI 10.1038/labinvest.2011.101
NR 55
TC 31
Z9 31
U1 0
U2 9
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD MAR 14
PY 2013
VL 8
IS 3
AR e58821
DI 10.1371/journal.pone.0058821
PG 7
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA 109YM
UT WOS:000316407400066
PM 23516561
OA Green Published, gold, Green Submitted
DA 2022-11-30
ER

PT J
AU Kaiserman, N
   Vinker, S
   Kaiserman, I
AF Kaiserman, Nadia
   Vinker, Shlomo
   Kaiserman, Igor
TI Statins Do Not Decrease the Risk for Wet Age-Related Macular
   Degeneration
SO CURRENT EYE RESEARCH
LA English
DT Article
DE age-related macular degeneration; atherosclerosis; choroidal
   neovascularization; photodynamic therapy; statins
ID BEAVER DAM EYE; SUBFOVEAL CHOROIDAL NEOVASCULARIZATION;
   CHOLESTEROL-LOWERING MEDICATIONS; 5-YEAR INCIDENCE;
   CARDIOVASCULAR-DISEASE; PHOTODYNAMIC THERAPY; POOLED FINDINGS; 3
   CONTINENTS; MACULOPATHY; PREVALENCE
AB Purpose: To investigate the effect of statins on the risk for age-related macular degeneration (AMD) treated with photodynamic therapy (PDT). Methods: All members in one district of a health maintenance organization in Israel, older than 50 years (n = 139,894), were included. PDT procedures for AMD (775 procedures; 283 patients) and filled statin prescriptions between 1999 and 2002 (471,232 prescriptions; 29,417 patients) were documented. Results: For all age groups, PDT was more prevalent in statin users. Among statin users, the age adjusted proportion of patients undergoing PDT for wet AMD was 0.27% (95% confidence interval (CI): 0.20-0.34%), compared to 0.16% (95% CI: 0.14-0.18%) among non-users (p = 0.002, 2test, relative risk = 1.66 (95% CI: 1.29-2.19)). After correction for age, gender, socioeconomic status, place of birth, place of residence, hyperlipidemia, hypertension, ischemic heart disease, diabetes, and congestive heart failure, statins did not have any additional effect on the risk for undergoing PDT for wet AMD. In a case control analysis, statin use in PDT patients was similar to their use by matched controls (odds ratio = 1.0; 95% CI = 0.8-1.3). Conclusions: This study does not support a beneficial effect of statin use for reducing the risk for wet AMD requiring PDT.
C1 [Kaiserman, Nadia] Hebrew Univ Jerusalem, Sch Med, Jerusalem, Israel.
   [Vinker, Shlomo] Clalit Hlth Serv, Dept Family Med, Rehovot, Israel.
   [Vinker, Shlomo] Tel Aviv Univ, Sackler Fac Med, Dept Family Med, IL-69978 Tel Aviv, Israel.
   [Kaiserman, Igor] Ben Gurion Univ Negev, Fac Hlth Sci, Beer Sheva, Israel.
   [Kaiserman, Igor] Barzilai Govt Hosp, Dept Ophthalmol, Ashqelon, Israel.
C3 Hebrew University of Jerusalem; Clalit Health Services; Tel Aviv
   University; Sackler Faculty of Medicine; Ben Gurion University; Ben
   Gurion University; Barzilai Medical Center
RP Kaiserman, N (通讯作者)，Lea Porat St 1-1 Givat Massuah, IL-96408 Jerusalem, Israel.
EM nadia.kaiserman@gmail.com
OI Kaiserman, Igor/0000-0003-0130-8819
CR Anand R, 2000, OPHTHALMOLOGY, V107, P2224
   Barbazetto I, 2003, ARCH OPHTHALMOL-CHIC, V121, P1253
   Bauer DC, 2004, ARCH INTERN MED, V164, P146, DOI 10.1001/archinte.164.2.146
   Belda Sanchis J I, 2001, Arch Soc Esp Oftalmol, V76, P13
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   Cruickshanks KJ, 2001, ARCH OPHTHALMOL-CHIC, V119, P246
   Curcio CA, 2001, INVEST OPHTH VIS SCI, V42, P265
   Delcourt C, 2001, Ophthalmic Epidemiol, V8, P237, DOI 10.1076/opep.8.4.237.1613
   GENEST JJ, 1991, AM J CARDIOL, V67, P1185, DOI 10.1016/0002-9149(91)90924-A
   Hall NF, 2001, BRIT MED J, V323, P375, DOI 10.1136/bmj.323.7309.375
   HENNEKENS CH, 2001, CLIN CARDIOL S, V24, P2
   Hogg RE, 2008, OPHTHALMOLOGY, V115, P1046, DOI 10.1016/j.ophtha.2007.07.031
   Hyman L, 2000, ARCH OPHTHALMOL-CHIC, V118, P351, DOI 10.1001/archopht.118.3.351
   Kaiserman I, 2006, AM J OPHTHALMOL, V142, P441, DOI 10.1016/j.ajo.2006.04.031
   Klein R, 2003, ARCH OPHTHALMOL-CHIC, V121, P1151, DOI 10.1001/archopht.121.8.1151
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Klein R, 1997, OPHTHALMOLOGY, V104, P1804, DOI 10.1016/S0161-6420(97)30023-2
   Klein R, 2001, ARCH OPHTHALMOL-CHIC, V119, P1354
   Leibowitz H M, 1980, Surv Ophthalmol, V24, P335
   Malek G, 2003, AM J PATHOL, V162, P413, DOI 10.1016/S0002-9440(10)63836-9
   McCarty CA, 2001, ARCH OPHTHALMOL-CHIC, V119, P1455
   McCarty CA, 2001, MED J AUSTRALIA, V175, P340, DOI 10.5694/j.1326-5377.2001.tb143604.x
   McGwin G, 2005, OPHTHALMOLOGY, V112, P488, DOI 10.1016/j.ophtha.2004.10.027
   McGwin G, 2003, BRIT J OPHTHALMOL, V87, P1121, DOI 10.1136/bjo.87.9.1121
   Miller LJ, 2004, ANN PHARMACOTHER, V38, P91, DOI 10.1345/aph.1D104
   Milton RC, 2005, OPHTHALMOLOGY, V112, P533, DOI 10.1016/j.ophtha.2004.10.047
   Miyazaki M, 2005, INVEST OPHTH VIS SCI, V46, P1907, DOI 10.1167/iovs.04-0923
   Rennert G, 2001, ISR MED ASSOC J, V3, P404
   Schaumberg DA, 2001, ARCH OPHTHALMOL-CHIC, V119, P1259
   Smeeth L, 2005, BRIT J OPHTHALMOL, V89, P1171, DOI 10.1136/bjo.2004.064477
   Tomany SC, 2004, OPHTHALMOLOGY, V111, P1280, DOI 10.1016/j.ophtha.2003.11.010
   Van Leeuwen R, 2004, OPHTHALMOLOGY, V111, P1169, DOI 10.1016/j.ophtha.2003.10.024
   van Leeuwen R, 2003, INVEST OPHTH VIS SCI, V44, P3771, DOI 10.1167/iovs.03-0121
   van Leeuwen R, 2003, BRIT MED J, V326, P255, DOI 10.1136/bmj.326.7383.255
   Wachter A, 2004, OPHTHALMOLOGE, V101, P50, DOI 10.1007/s00347-003-0868-1
   Werner N, 2002, BASIC RES CARDIOL, V97, P105, DOI 10.1007/s003950200000
   Wilson HL, 2004, AM J OPHTHALMOL, V137, P615, DOI 10.1016/j.ajo.2003.10.025
   2005, DIABETES CARE S1, V28, pS1
NR 38
TC 17
Z9 17
U1 0
U2 0
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 325 CHESTNUT ST, SUITE 800, PHILADELPHIA, PA 19106 USA
SN 0271-3683
J9 CURR EYE RES
JI Curr. Eye Res.
PY 2009
VL 34
IS 4
BP 304
EP 310
AR PII 910507952
DI 10.1080/02713680902741670
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 434RT
UT WOS:000265292500008
PM 19373579
DA 2022-11-30
ER

PT J
AU Abraham-Marin, ML
   Cortes-Luna, CF
   Alvarez-Rivera, G
   Hernandez-Rojas, M
   Quiroz-Mercado, H
   Morales-Canton, V
AF Abraham-Marin, Maura Lucy
   Cortes-Luna, Carlos Fernando
   Alvarez-Rivera, Griselda
   Hernandez-Rojas, Myriam
   Quiroz-Mercado, Hugo
   Morales-Canton, Virgilio
TI Intravitreal bevacizumab therapy for neovascular age-related macular
   degeneration: a pilot study
SO GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Article
DE choroidal neovascularisation; macular degeneration; antibodies;
   angiogenesis inhibitors
ID GROWTH-FACTORS; ANGIOGENESIS
AB Purpose To evaluate the efficacy and safety of intravitreal bevacizumab therapy for neovascular age-related macular degeneration (ARMD). Methods Patients with diagnosis of neovascular ARMD without any other ocular pathology were injected with 2.5 mg of intravitreal bevacizumab. A complete ophthalmic examination was undertaken in all patients, including best corrected visual acuity (BCVA), slit lamp biomicroscopy and ocular fundus examination. Ophthalmic follow-up evaluations included visual acuity measurements, optical coherence tomography (OCT) imaging, and fluorescein angiography at first, second and fourth week post injection. Results 39 eyes of 39 patients were injected. The median age was 76 years-old (range 65-90), median visual acuity was 1.18 logMAR (range 0.18-3.00) and median retinal thickness was 388 microns (range 157-1237). By the fourth week of treatment, the median visual acuity was 0.88 (range 0.18-2.78) and median retinal thickness was 247 microns (range 108-1262). Statistically significant differences were found in visual acuity and retinal thickness before and after intravitreal injection (p=0.002, p < 0.001, Wilcoxon rank test). Conclusions Our results suggest that intravitreal bevacizumab is well tolerated and is associated with improvement in BCVA and decreased mean retinal thickness by OCT. Further controlled and long term evaluation of intravitreal bevacizumab for the treatment of neovascular ARMD is warranted.
C1 Hosp Luis Sanchez Bulnes, Asociac Evitar Ceguera Mexico, Mexico City 04030, DF, Mexico.
   Clin Ojos, Bogota, Colombia.
   Univ Nacl Autonoma Mexico, Mexico City 04510, DF, Mexico.
C3 Universidad Nacional Autonoma de Mexico
RP Abraham-Marin, ML (通讯作者)，Hosp Luis Sanchez Bulnes, Asociac Evitar Ceguera Mexico, Vicente Garcia Torres 46,Colonia San Lucas Coyoac, Mexico City 04030, DF, Mexico.
EM maura.abraham@gmail.com; carlos.cortes.luna@gmail.com
RI Canton, Virgilio/AAF-7047-2021
CR Adamis AP, 2005, RETINA-J RET VIT DIS, V25, P111, DOI 10.1097/00006982-200502000-00001
   [Anonymous], 1991, Arch Ophthalmol, V109, P1109
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Gryziewicz L, 2005, ADV DRUG DELIVER REV, V57, P2092, DOI 10.1016/j.addr.2005.09.009
   Holekamp NM, 2002, AM J OPHTHALMOL, V134, P220, DOI 10.1016/S0002-9394(02)01549-0
   Hurwitz HI, 2005, J CLIN ONCOL, V23, P3502, DOI 10.1200/JCO.2005.10.017
   Michels S, 2005, OPHTHALMOLOGY, V112, P1035, DOI 10.1016/j.ophtha.2005.02.007
   Michels S, 2005, KLIN MONATSBL AUGENH, V222, P480, DOI 10.1055/s-2005-858315
   Miller DW, 2003, OPHTHALMOLOGE, V100, P92, DOI 10.1007/s00347-002-0760-4
   Miller LS, 1999, J CLIN CHILD PSYCHOL, V28, P2, DOI 10.1207/s15374424jccp2801_1
   Mordenti J, 1999, TOXICOL PATHOL, V27, P536, DOI 10.1177/019262339902700507
   Ng EWM, 2005, CAN J OPHTHALMOL, V40, P352, DOI 10.1016/S0008-4182(05)80078-X
   Otani A, 1999, INVEST OPHTH VIS SCI, V40, P1912
   Pauleikhoff D, 2005, RETINA-J RET VIT DIS, V25, P1065, DOI 10.1097/00006982-200512000-00016
   Rosenfeld PJ, 2005, OPHTHALMOLOGY, V112, P1048, DOI 10.1016/j.ophtha.2005.01.043
   Rosenfeld PJ, 2005, OPHTHAL SURG LAS IM, V36, P331, DOI 10.3928/1542-8877-20050701-14
   Schlingemann RO, 2004, GRAEF ARCH CLIN EXP, V242, P91, DOI 10.1007/s00417-003-0828-0
   Shah MA, 2005, J CLIN ONCOL, V23, P2574, DOI 10.1200/JCO.2005.81.908
   Ta CN, 2004, RETINA-J RET VIT DIS, V24, P699, DOI 10.1097/00006982-200410000-00003
   Waheed Nadia K., 2004, International Ophthalmology Clinics, V44, P11, DOI 10.1097/00004397-200404430-00004
   Witmer AN, 2003, PROG RETIN EYE RES, V22, P1, DOI 10.1016/S1350-9462(02)00043-5
NR 21
TC 28
Z9 33
U1 0
U2 3
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 0721-832X
EI 1435-702X
J9 GRAEF ARCH CLIN EXP
JI Graefes Arch. Clin. Exp. Ophthalmol.
PD MAY
PY 2007
VL 245
IS 5
BP 651
EP 655
DI 10.1007/s00417-006-0411-6
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 163SK
UT WOS:000246183300005
PM 17006681
DA 2022-11-30
ER

PT J
AU Varadaraj, V
   Lesche, S
   Ramulu, PY
   Swenor, BK
AF Varadaraj, Varshini
   Lesche, Stephen
   Ramulu, Pradeep Y.
   Swenor, Bonnielin K.
TI Reading Speed and Reading Comprehension in Age-related Macular
   Degeneration
SO AMERICAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID LOW-VISION; EYE-MOVEMENTS; PSYCHOPHYSICS
AB PURPOSE: To evaluate the impact of age-related macular degeneration (AMD) on short out-loud and sustained silent reading speeds, and reading comprehension.
   DESIGN: Prospective, cross-sectional.
   METHODS: Setting: Wilmer Eye Institute. POPULATION: Literate, native-English speakers with and without AMD. AMD participants had better-eye visual acuity (VA) <20/32 and >20/100, while controls had binocular VA >20/32. PROCEDURES: MNRead was used to assess short-duration out-loud reading speed. Sustained silent reading test was used to evaluate sustained silent reading speeds, while reading comprehension was assessed based on silent reading test text. OUTCOME MEASURES: MNRead maximum reading speed, sustained-silent reading speed, and comprehension score.
   RESULTS: Analyses included 24 AMD patients and 22 controls. In age-adjusted regressions, AMD participants, compared to controls, read 46 words per minute (wpm) slower on MNRead (95% confidence interval [CI]: -66, -26, P < .001), but there was no difference in sustained reading speeds between groups (beta = 0.99, 95% CI: -41.8, 43.8, P = .96). In other models, there was a decrement of 12.6 wpm on MNRead per 0.1 worsening logMAR (95% CI: -18.7, -6.6, P < .001), but VA was not associated with a decrement in sustained reading speed (beta = -10.1, 95% CI: -22.4, 2.1, P = .10). However, AMD participants had substantially lower comprehension scores than controls (53% vs 85% correct, P < .001), and each 1-line VA decrement was associated with 5.9% lower comprehension score (95% CI: -9.1, -2.7, P = .001).
   CONCLUSIONS: AMD patients read slower than controls when forced to read out loud. When asked to read silently over a longer duration, both groups read at similar speeds, though AMD patients demonstrated substantially lower comprehension scores, suggesting that they chose to sacrifice comprehension for speed. (C) 2017 Elsevier Inc. All rights reserved.
C1 [Varadaraj, Varshini; Lesche, Stephen; Ramulu, Pradeep Y.; Swenor, Bonnielin K.] Johns Hopkins Univ, Sch Med, Wilmer Eye Inst, 600 N Wolfe St, Baltimore, MD 21287 USA.
C3 Johns Hopkins University; Johns Hopkins Medicine
RP Swenor, BK (通讯作者)，Johns Hopkins Univ, Sch Med, Wilmer Eye Inst, 600 N Wolfe St, Baltimore, MD 21287 USA.
EM bswenor@jhmi.edu
RI Swenor, Bonnie/ABH-1542-2021
OI Swenor, Bonnie/0000-0002-6044-0951; Varadaraj,
   Varshini/0000-0003-2060-1316
FU RESEARCH TO PREVENT BLINDNESS (NEW YORK, NY)
FX RESEARCH TO PREVENT BLINDNESS (NEW YORK, NY) SUPPORTED THIS WORK.
CR AKUTSU H, 1991, J GERONTOL, V46, pP325, DOI 10.1093/geronj/46.6.P325
   Bowers AR, 2004, OPTOMETRY VISION SCI, V81, P205, DOI 10.1097/00006324-200403000-00013
   Brown JC, 2014, OPHTHALMOLOGY, V121, P1655, DOI 10.1016/j.ophtha.2014.02.030
   BULLIMORE MA, 1995, OPTOMETRY VISION SCI, V72, P125, DOI 10.1097/00006324-199502000-00011
   Carver RP, 1990, READING RATE REV RES
   Chung STL, 1998, VISION RES, V38, P2949, DOI 10.1016/S0042-6989(98)00072-8
   Chung STL, 2007, VISION RES, V47, P3150, DOI 10.1016/j.visres.2007.08.017
   FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6
   Giacomelli G, 2010, EUR J OPHTHALMOL, V20, P389, DOI 10.1177/112067211002000220
   Kartha AG, 2010, INVEST OPHTH VIS SCI, V51
   LEGGE GE, 1985, VISION RES, V25, P253, DOI 10.1016/0042-6989(85)90118-X
   LEGGE GE, 1992, INVEST OPHTH VIS SCI, V33, P677
   LEGGE GE, 1989, OPTOMETRY VISION SCI, V66, P843, DOI 10.1097/00006324-198912000-00008
   Lovie-Kitchin JE, 2000, OPHTHAL PHYSL OPT, V20, P360
   Radner T, 1998, KLIN MONATSBL AUGENH, V213, P174, DOI 10.1055/s-2008-1034969
   Ramulu PY, 2013, INVEST OPHTH VIS SCI, V54, P673, DOI 10.1167/iovs.12-10617
   Ramulu PY, 2013, INVEST OPHTH VIS SCI, V54, P666, DOI 10.1167/iovs.12-10618
   Rubin GS, 2009, NEURO-OPHTHALMOLOGY, V33, P120, DOI 10.1080/01658100902998732
   Seiple W, 2005, INVEST OPHTH VIS SCI, V46, P2886, DOI 10.1167/iovs.04-1296
   Seiple W, 2011, INVEST OPHTH VIS SCI, V52, P2938, DOI 10.1167/iovs.10-6137
   STANGLERZUSCHROTT E, 1990, KLIN MONATSBL AUGENH, V196, P150, DOI 10.1055/s-2008-1046145
   TRAUZETTELKLOSINSKI S, 1994, NEURO-OPHTHALMOLOGY, V14, P15, DOI 10.3109/01658109409019482
   WHITTAKER SG, 1993, OPTOMETRY VISION SCI, V70, P54, DOI 10.1097/00006324-199301000-00010
NR 23
TC 14
Z9 14
U1 3
U2 11
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0002-9394
EI 1879-1891
J9 AM J OPHTHALMOL
JI Am. J. Ophthalmol.
PD FEB
PY 2018
VL 186
BP 138
EP 143
DI 10.1016/j.ajo.2017.11.026
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA FX8FF
UT WOS:000426326200020
PM 29246579
DA 2022-11-30
ER

PT J
AU Mammo, Z
   Guo, M
   Maberley, D
   Matsubara, J
   Etminan, M
AF Mammo, Zaid
   Guo, Michael
   Maberley, David
   Matsubara, Joanne
   Etminan, Mahyar
TI Oral Bisphosphonates and Risk of Wet Age-Related Macular Degeneration
SO AMERICAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID ACUTE-PHASE RESPONSE; C-REACTIVE PROTEIN; CASE SERIES; CYTOKINES;
   INFLAMMATION; CELLS; EYE
AB PURPOSE: To examine the risk of age-related macular degeneration (AMD) with oral bisphosphonates.
   DESIGN: Three study designs were used: (1) disproportionality analysis; (2) case-control study; (3) self-controlled case series (SCCS).
   METHODS: SETTING: (1) Food and Drug Administration (FDA) Adverse Event Reporting System (FAERS) Database; (2) 2 patient cohorts from British Columbia, Canada. STUDY POPULATION: (1) All reports of AMD to the FDA with oral bisphosphoantes; (2) patients with wet AMD in British Columbia (2009-2013) and 1 million controls (2000-2007). INTERVENTION: Oral bisphosphonates. MAIN OUTCOME MEASURES: (1) Reports of AMD to the FDA; (2) first diagnosis of wet AMD verified by a retina specialist in British Columbia.
   RESULTS: In the disproportionality analysis there were 133 cases of AMD reported with alendronate, 20 with ibandronate, and 14 with risedronate. The reported odds ratios (RORs) for alendronate, ibandronate, and risedronate were 3.82 (95% CI: 2.94-4.96), 2.40 (95% CI: 1.49-3.86), and 2.87 (95% CI: 1.58-5.19), respectively. In the case-control analysis there were 6367 cases and 6370 corresponding controls. The adjusted OR for wet AMD among regular users of bisphosphonates in the 1, 2, and 3 years prior to the index date were 1.24 (1.12-1.38), 1.38 (1.22-1.56), and 1.59 (1.38-1.82), respectively. In the SCCS analysis there were 198 caies of wet AMD on continuous bisphosphonate therapy. The rate ratio for wet AMD for continuous bisphosphonate use was 1.99 (95% CI: 1.41-2.79). We did not have information on intravenous bisphosphonates.
   CONCLUSIONS: Continuous users of oral bisphosphonates are at a higher risk of developing wet AMD. Given the observational nature of this study and limitation of the data, future studies are needed to confirm these findings. ((C) 2016 Elsevier Inc. All rights reserved.).
C1 [Mammo, Zaid; Maberley, David; Matsubara, Joanne; Etminan, Mahyar] Univ British Columbia, Dept Ophthalmol & Visual Sci, Vancouver, BC, Canada.
   [Guo, Michael; Etminan, Mahyar] Univ British Columbia, Dept Pharmacol & Therapeut, Vancouver, BC, Canada.
   [Maberley, David; Etminan, Mahyar] Univ British Columbia, Collaborat Epidemiol Ocular Dis CEPOD, Dept Ophthalmol & Visual Sci, Vancouver, BC, Canada.
C3 University of British Columbia; University of British Columbia;
   University of British Columbia
RP Etminan, M (通讯作者)，Univ British Columbia, Ophthalmol & Visual Sci, Fac Med, Eye Care Ctr, Room 323-2550 Willow St, Vancouver, BC V5Z 3N9, Canada.; Etminan, M (通讯作者)，Univ British Columbia, Pharmacol & Therapeut, Eye Care Ctr, Room 323-2550 Willow St, Vancouver, BC V5Z 3N9, Canada.
EM etminanm@mail.ubc.ca
FU FOUNDATION FIGHTING BLINDNESS; Alcon; Roche (Mississauga, Ontario,
   Canada); Ophthotech (New York, New York); Novartis (Dorval, Quebec,
   Canada); AbbVie (Saint-Laurent, Quebec, Canada); Bayer (Mississauga,
   Ontario, Canada)
FX FUNDING/SUPPORT: THE STUDY WAS FUNDED BY THE FOUNDATION FIGHTING
   BLINDNESS. THE FUNDING AGENCY DID NOT have any role in the design,
   analysis or interpretation of the data; or in preparation or approval of
   the manuscript. Financial disclosures: David Maberley has been on the
   following advisory boards in the last 3 years: Novartis (Quebec,
   Canada), Bayer (Mississauga, Ontario, Canada), Allergan (Markham,
   Ontario, Canada), and Alcon (Forth Worth, Texas). He is being
   compensated financially for the conduct of studies with the following
   companies: Alcon, Roche (Mississauga, Ontario, Canada), Ophthotech (New
   York, New York), Novartis (Dorval, Quebec, Canada), AbbVie
   (Saint-Laurent, Quebec, Canada), and Bayer (Mississauga, Ontario,
   Canada). Mahyar Etminan has consulted in the Mirena and intracranial
   hypertension litigation. The following authors have no financial
   disclosures: Zaid Mammo, Michael Guo and Joanne Matsubara. All authors
   attest that they meet the current ICMJE criteria for authorship.
CR Ambati J, 2003, SURV OPHTHALMOL, V48, P257, DOI 10.1016/S0039-6257(03)00030-4
   Anand R, 2000, OPHTHALMOLOGY, V107, P2224
   Anderson DH, 2002, AM J OPHTHALMOL, V134, P411, DOI 10.1016/S0002-9394(02)01624-0
   Bohm R, 2012, NAT BIOTECHNOL, V30, P137, DOI 10.1038/nbt.2113
   Brulinski P, 2013, CLIN ONCOL-UK, V25, P328, DOI 10.1016/j.clon.2012.12.006
   Colucci A, 2009, OCUL IMMUNOL INFLAMM, V17, P267, DOI 10.1080/09273940902916111
   Etminan M, 2012, CAN MED ASSOC J, V184, pE431, DOI 10.1503/cmaj.111752
   GHOSE K, 1994, AUST NZ J MED, V24, P320, DOI 10.1111/j.1445-5994.1994.tb02186.x
   Hauben Manfred, 2005, Expert Opin Drug Saf, V4, P929, DOI 10.1517/14740338.4.5.929
   Hewitt RE, 2005, CLIN EXP IMMUNOL, V139, P101, DOI 10.1111/j.1365-2249.2005.02665.x
   Honda S, 2010, J OPHTHALMOL, V2010, DOI 10.1155/2010/206837
   Kassi G, 2014, IMMUNOL INVEST, V43, P544, DOI 10.3109/08820139.2014.892510
   Lefebvre DR, 2016, OCUL IMMUNOL INFLAMM, V24, P134, DOI 10.3109/09273948.2014.942747
   Miao H, 2012, MOL VIS, V18, P574
   Mitta VP, 2013, JAMA OPHTHALMOL, V131, P507, DOI 10.1001/jamaophthalmol.2013.2303
   Nourinia R, 2013, J OPHTHALMIC VIS RES, V9, P44
   Nussenblatt RB, 2014, AM J OPHTHALMOL, V158, P5, DOI 10.1016/j.ajo.2014.03.014
   Or C, 2013, BRIT J OPHTHALMOL, V97, P1074, DOI 10.1136/bjophthalmol-2013-303355
   Sakaeda T, 2013, INT J MED SCI, V10, P796, DOI 10.7150/ijms.6048
   SAS Institute Inc, 2002, SAS R 9 4 HELP DOC
   Schneeweiss S, 2002, NEW ENGL J MED, V346, P822, DOI 10.1056/NEJMsa003087
   Seddon JM, 2004, JAMA-J AM MED ASSOC, V291, P704, DOI 10.1001/jama.291.6.704
   Seddon JM, 1996, JAMA-J AM MED ASSOC, V276, P1141, DOI 10.1001/jama.276.14.1141
   Whitaker HJ, 2006, STAT MED, V25, P1768, DOI 10.1002/sim.2302
   Zhang TT, 2013, EUR J CLIN PHARMACOL, V69, P581, DOI 10.1007/s00228-012-1343-1
NR 25
TC 8
Z9 8
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0002-9394
EI 1879-1891
J9 AM J OPHTHALMOL
JI Am. J. Ophthalmol.
PD AUG
PY 2016
VL 168
BP 62
EP 67
DI 10.1016/j.ajo.2016.04.022
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA DT0IG
UT WOS:000381166600007
PM 27163238
DA 2022-11-30
ER

PT J
AU Zhao, YH
   Bhattacharjee, S
   Jones, BM
   Hill, JM
   Clement, C
   Sambamurti, K
   Dua, P
   Lukiw, WJ
AF Zhao, Yuhai
   Bhattacharjee, Surjyadipta
   Jones, Brandon M.
   Hill, James M.
   Clement, Christian
   Sambamurti, Kumar
   Dua, Prerna
   Lukiw, Walter J.
TI Beta-Amyloid Precursor Protein (beta APP) Processing in Alzheimer's
   Disease (AD) and Age-Related Macular Degeneration (AMD)
SO MOLECULAR NEUROBIOLOGY
LA English
DT Article
DE 42 amino acid amyloid-beta (A beta 42); Age-related macular degeneration
   (AMD); Alzheimer's disease (AD); Beta-amyloid precursor protein (beta
   APP); beta APP processing; CNS inflammation; Drusen; Micro RNA (miRNA);
   Neurological disease; Senile plaques; Transmissibility; sAPP alpha
ID COMPLEMENT FACTOR-H; MICRO RNAS MIRNAS; PHYSIOLOGICAL-FUNCTION;
   INFLAMMATORY GENES; RETINAL PATHOLOGY; MOUSE MODELS; RISK-FACTORS;
   EXPRESSION; TREM2; DRUSEN
AB Amyloid is a generic term for insoluble, often intensely hydrophobic, fibrous protein aggregates that arise from inappropriately folded versions of naturally-occurring polypeptides. The abnormal generation and accumulation of amyloid, often referred to as amyloidogenesis, has been associated with the immune and pro-inflammatory pathology of several progressive age-related diseases of the human central nervous system (CNS) including Alzheimer's disease (AD) and age-related macular degeneration (AMD). This 'research perspective' paper reviews some of the research history, biophysics, molecular-genetics and environmental factors concerning the contribution of amyloid beta (A beta) peptides, derived from beta-amyloid precursor protein (beta APP), to AD and AMD that suggests an extensive similarity in immune and inflammatory degenerative mechanisms between these two CNS diseases.
C1 [Zhao, Yuhai; Bhattacharjee, Surjyadipta; Jones, Brandon M.; Hill, James M.; Lukiw, Walter J.] Louisiana State Univ, Hlth Sci Ctr, LSU Neurosci Ctr, New Orleans, LA 70112 USA.
   [Hill, James M.; Lukiw, Walter J.] Louisiana State Univ, Dept Ophthalmol, Hlth Sci Ctr, New Orleans, LA 70112 USA.
   [Hill, James M.] Louisiana State Univ, Dept Microbiol, Hlth Sci Ctr, New Orleans, LA 70112 USA.
   [Hill, James M.] Louisiana State Univ, Dept Pharmacol, Hlth Sci Ctr, New Orleans, LA 70112 USA.
   [Hill, James M.; Lukiw, Walter J.] Louisiana State Univ, Dept Neurol, Hlth Sci Ctr, New Orleans, LA 70112 USA.
   [Clement, Christian] Southern Univ New Orleans, Expt Therapeut & Human Toxicol Lab, Dept Nat Sci, Infect Dis, New Orleans, LA 70126 USA.
   [Sambamurti, Kumar] Med Univ S Carolina, Charleston, SC 29425 USA.
   [Dua, Prerna] Louisiana State Univ, Dept Hlth Informat Management, Ruston, LA 71272 USA.
C3 Louisiana State University System; Louisiana State University Health
   Sciences Center New Orleans; Louisiana State University System;
   Louisiana State University Health Sciences Center New Orleans; Louisiana
   State University System; Louisiana State University Health Sciences
   Center New Orleans; Louisiana State University System; Louisiana State
   University Health Sciences Center New Orleans; Louisiana State
   University System; Louisiana State University Health Sciences Center New
   Orleans; Southern University System; Southern University New Orleans;
   Medical University of South Carolina; Louisiana State University System;
   Louisiana State University
RP Lukiw, WJ (通讯作者)，Louisiana State Univ, Hlth Sci Ctr, LSU Neurosci Ctr, 2020 Gravier St,Suite 904, New Orleans, LA 70112 USA.
EM wlukiw@lsuhsc.edu
RI Bhattacharjee, Surjyadipta/I-5354-2016; Bhattacharjee,
   Surjyadipta/AAD-7586-2021; Sambamurti, Kumar/J-6102-2013
OI Bhattacharjee, Surjyadipta/0000-0003-0185-553X; Bhattacharjee,
   Surjyadipta/0000-0003-0185-553X; Sambamurti, Kumar/0000-0001-9507-9214
FU COBRE III Pilot Project NIH/NIGMS [P30-GM103340]; Research to Prevent
   Blindness (RPB); Louisiana Biotechnology Research Network (LBRN); NIH
   [NEI EY006311, NIA AG18031, NIA AG038834]; Alzheimer's Association [IIRG
   10-173180]; NIH NIA [AG046200]; NATIONAL EYE INSTITUTE [R01EY006311]
   Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL
   SCIENCES [P30GM103340] Funding Source: NIH RePORTER; NATIONAL INSTITUTE
   ON AGING [R01AG018031, P50AG016573, R01AG038834, R21AG046200] Funding
   Source: NIH RePORTER
FX The work in this research perspective was presented in part at the
   Alzheimer Association International Conference 2013 (AAIC 2013) Annual
   Meeting held in Boston MA, USA and at the AAIC 2014 held in Copenhagen,
   Denmark. Sincere thanks are extended to Drs. PN Alexandrov, F Culicchia,
   C Eicken, and C Hebel for the short postmortem interval (PMI) human
   brain tissues or extracts, miRNA array work, and initial data
   interpretation and to D Guillot and J Lockwood for the expert technical
   assistance. Additional thanks are extended to the physicians and
   neuropathologists of Canada and the USA who have provided high-quality,
   short postmortem interval human brain and retinal tissues for study.
   Additional human control and AD brain tissues were provided by the
   Memory Impairments and Neurological Disorders (MIND) Institute and the
   University of California, Irvine Alzheimer's Disease Research Center
   (UCI-ADRC; NIA P50 AG16573). Research on miRNA in the Lukiw laboratory
   involving the innate-immune response in AD, amyloidogenesis, and
   neuro-inflammation was supported through a COBRE III Pilot Project
   NIH/NIGMS Grant P30-GM103340, an unrestricted grant to the LSU Eye
   Center from Research to Prevent Blindness (RPB); the Louisiana
   Biotechnology Research Network (LBRN); and NIH grants NEI EY006311, NIA
   AG18031, and NIA AG038834. Research on AD, Down's syndrome, and
   amyloidosis in the Sambamurti laboratory are supported by the
   Alzheimer's Association IIRG 10-173180 and NIH NIA AG046200.
CR Alexandrov PN, 2013, J INORG BIOCHEM, V128, P267, DOI 10.1016/j.jinorgbio.2013.05.010
   Alexandrov Peter N, 2012, Int J Biochem Mol Biol, V3, P365
   Alexandrov PN, 2011, NEUROREPORT, V22, P623, DOI 10.1097/WNR.0b013e3283497334
   Allsop D, 1989, Prog Clin Biol Res, V317, P893
   Alzheimer A, 1995, Clin Anat, V8, P429
   Ambros V, 2001, CELL, V107, P823, DOI 10.1016/S0092-8674(01)00616-X
   Anderson DH, 2004, EXP EYE RES, V78, P243, DOI 10.1016/j.exer.2003.10.011
   Anderson DH, 2010, PROG RETIN EYE RES, V29, P95, DOI 10.1016/j.preteyeres.2009.11.003
   Armstrong RA, 2008, FOLIA NEUROPATHOL, V46, P241
   Aruoma OI, 2009, TOXICOLOGY, V256, P92, DOI 10.1016/j.tox.2008.11.007
   Baker ML, 2009, ARCH OPHTHALMOL-CHIC, V127, P667, DOI 10.1001/archophthalmol.2009.30
   Barnham KJ, 2003, J BIOL CHEM, V278, P17401, DOI 10.1074/jbc.M300629200
   Bhattacharjee S, 2014, FRONT AGING NEUROSCI, V6, DOI 10.3389/fnagi.2014.00062
   Buda O, 2009, NEUROLOGY, V72, P88, DOI 10.1212/01.wnl.0000338626.93425.74
   Buschini E, 2011, PROG NEUROBIOL, V95, P14, DOI 10.1016/j.pneurobio.2011.05.011
   Cai J, 2012, EMBO MOL MED, V4, P980, DOI 10.1002/emmm.201101084
   Chen YN, 2006, BIOCHEM BIOPH RES CO, V341, P1, DOI 10.1016/j.bbrc.2005.12.150
   Chiu K, 2012, AGE, V34, P633, DOI 10.1007/s11357-011-9260-2
   Chow VW, 2010, NEUROMOL MED, V12, P1, DOI 10.1007/s12017-009-8104-z
   Crabb JW, 2002, P NATL ACAD SCI USA, V99, P14682, DOI 10.1073/pnas.222551899
   Cui JG, 2004, NEUROREPORT, V15, P2025, DOI 10.1097/00001756-200409150-00006
   Cui JG, 2007, NEUROREPORT, V18, P115, DOI 10.1097/WNR.0b013e32801198bc
   Dawkins E, 2014, J NEUROCHEM, V129, P756, DOI 10.1111/jnc.12675
   Dentchev T, 2003, MOL VIS, V9, P184
   Ding JD, 2008, VISION RES, V48, P339, DOI 10.1016/j.visres.2007.07.025
   Ding JD, 2011, P NATL ACAD SCI USA, V108, pE279, DOI 10.1073/pnas.1100901108
   Dorey E, 2014, NEUROSCI BULL, V30, P317, DOI 10.1007/s12264-013-1422-z
   Duce JA, 2010, CELL, V142, P857, DOI 10.1016/j.cell.2010.08.014
   Dutescu RM, 2009, GRAEF ARCH CLIN EXP, V247, P1213, DOI 10.1007/s00417-009-1060-3
   Ermilov V. V., 2013, Arkhiv Patologii, V75, P37
   Exley C, 2005, SUB CELL BIOCHEM, V38, P225
   Forabosco P, 2013, NEUROBIOL AGING, V34, P2699, DOI 10.1016/j.neurobiolaging.2013.05.001
   Fritsche LG, 2014, ANNU REV GENOM HUM G, V15, P151, DOI 10.1146/annurev-genom-090413-025610
   Frost S, 2013, TRANSL PSYCHIAT, V3, DOI 10.1038/tp.2012.150
   Furumoto S, 2007, CURR TOP MED CHEM, V7, P1773, DOI 10.2174/156802607782507402
   Ghavami S, 2014, PROG NEUROBIOL, V112, P24, DOI 10.1016/j.pneurobio.2013.10.004
   GLENNER GG, 1989, J NEUROL SCI, V94, P1, DOI 10.1016/0022-510X(89)90214-1
   GLENNER GG, 1981, ANN PATHOL, V1, P120
   GLENNER GG, 1984, BIOCHEM BIOPH RES CO, V425, P534, DOI DOI 10.1016/J.BBRC.2012.08.020
   Goldstein LSB, 2001, P NATL ACAD SCI USA, V98, P6999, DOI 10.1073/pnas.111145298
   Griciuc A, 2013, NEURON, V78, P631, DOI 10.1016/j.neuron.2013.04.014
   Guo HL, 2010, NATURE, V466, P835, DOI 10.1038/nature09267
   HARDY J, 1991, TRENDS PHARMACOL SCI, V12, P383, DOI 10.1016/0165-6147(91)90609-V
   Hickman SE, 2013, BIOCHEM PHARMACOL, V88, P495
   Hickman SE, 2014, BIOCHEM PHARMACOL, V88, P495, DOI 10.1016/j.bcp.2013.11.021
   Hoe HS, 2012, CNS NEUROSCI THER, V18, P47, DOI 10.1111/j.1755-5949.2010.00221.x
   Hu N, 2014, NEUROSCI LETT, V563, P51, DOI 10.1016/j.neulet.2014.01.004
   Huang EJC, 2014, EYE, V28, P705, DOI 10.1038/eye.2014.55
   Jellinger KA, 2012, J CELL MOL MED, V16, P1166, DOI 10.1111/j.1582-4934.2011.01507.x
   Jiang T, 2014, NEUROBIOL AGING, V35, P1243, DOI 10.1016/j.neurobiolaging.2013.11.026
   Jiang T, 2013, MOL NEUROBIOL, V48, P180, DOI 10.1007/s12035-013-8424-8
   Johnson LV, 2002, P NATL ACAD SCI USA, V99, P11830, DOI 10.1073/pnas.192203399
   Jones BM, 2014, FRONT CELL NEUROSCI, V8, DOI 10.3389/fncel.2014.00094
   Kondo N, 2011, OPHTHALMOLOGY, V118, P339, DOI 10.1016/j.ophtha.2010.06.040
   Kruck TP, 2004, CELL MOL NEUROBIOL, V24, P443, DOI 10.1023/B:CEMN.0000022773.70722.b2
   Lagos-Quintana M, 2001, SCIENCE, V294, P853, DOI 10.1126/science.1064921
   Le Fur I, 2010, NEUROBIOL AGING, V31, P165, DOI 10.1016/j.neurobiolaging.2008.03.003
   Lengyel I, 2004, INVEST OPHTH VIS SCI, V45, P2886, DOI 10.1167/iovs.03-1083
   Li YY, 2011, NEUROSCI LETT, V499, P109, DOI 10.1016/j.neulet.2011.05.044
   Liu MM, 2012, HUM GENOMICS, V6, DOI 10.1186/1479-7364-6-13
   Logue MW, 2014, NEUROBIOL AGING, V35, DOI 10.1016/j.neurobiolaging.2013.12.007
   Luibl V, 2006, J CLIN INVEST, V116, P378, DOI 10.1172/JCI25843
   Lukiw WJ, 2008, J BIOL CHEM, V283, P31315, DOI 10.1074/jbc.M805371200
   Lukiw WJ, 2013, FRONT CELL NEUROSCI, V7, DOI 10.3389/fncel.2013.00133
   Lukiw Walter J., 2013, Frontiers in Genetics, V4, P77, DOI [10.3389/fgene.2013.00077, 10.3389/fgene.2013.00307]
   Lukiw WJ, 2013, FRONT PHYSIOL, V4, DOI 10.3389/fphys.2013.00024
   Lukiw WJ, 2012, MOL NEUROBIOL, V46, P11, DOI 10.1007/s12035-012-8234-4
   Lukiw WJ, 2012, EXP NEUROL, V235, P484, DOI 10.1016/j.expneurol.2011.11.022
   Lukiw Walter J, 2012, Int J Biochem Mol Biol, V3, P105
   Lukiw WJ, 2012, EXPERT OPIN EMERG DR, V17, P43, DOI 10.1517/14728214.2012.672559
   Mathis CA, 2012, SEMIN NUCL MED, V42, P423, DOI 10.1053/j.semnuclmed.2012.07.001
   Mattson MP, 1997, PHYSIOL REV, V77, P1081, DOI 10.1152/physrev.1997.77.4.1081
   MCLACHLAN DRC, 1991, LANCET, V337, P1304, DOI 10.1016/0140-6736(91)92978-B
   Moon BG, 2012, J KOREAN MED SCI, V27, P537, DOI 10.3346/jkms.2012.27.5.537
   Muller T, 2013, BBA-PROTEINS PROTEOM, V1834, P387, DOI 10.1016/j.bbapap.2012.07.017
   Nalivaeva NN, 2013, FEBS LETT, V587, P2046, DOI 10.1016/j.febslet.2013.05.010
   Neumann H, 2013, NEW ENGL J MED, V368, P182, DOI 10.1056/NEJMe1213157
   Nimmerjahn A, 2005, SCIENCE, V308, P1314, DOI 10.1126/science.1110647
   Ohno-Matsui K, 2011, PROG RETIN EYE RES, V30, P217, DOI 10.1016/j.preteyeres.2011.02.004
   Olson MV, 2012, ANNU REV GENOM HUM G, V13, P1, DOI 10.1146/annurev-genom-090711-163825
   Percy ME, 2011, J INORG BIOCHEM, V105, P1505, DOI 10.1016/j.jinorgbio.2011.08.001
   Porayette P, 2007, BIOCHEM BIOPH RES CO, V364, P522, DOI 10.1016/j.bbrc.2007.10.021
   Prakasam A, 2010, J ALZHEIMERS DIS, V20, P1243, DOI 10.3233/JAD-2010-100210
   Priller C, 2006, J NEUROSCI, V26, P7212, DOI 10.1523/JNEUROSCI.1450-06.2006
   Proitsi P, 2012, NEUROBIOL AGING, V33, P1843, DOI DOI 10.1016/J.NEUR0BI0LAGING.2011.12.036
   Quan YL, 2012, INT J OPHTHALMOL-CHI, V5, P242, DOI 10.3980/j.issn.2222-3959.2012.02.25
   Raj A, 2010, NATURE, V463, P913, DOI 10.1038/nature08781
   Rossjohn J, 1999, NAT STRUCT BIOL, V6, P327
   Satpute-Krishnan P, 2006, P NATL ACAD SCI USA, V103, P16532, DOI 10.1073/pnas.0607527103
   Selkoe DJ, 1998, TRENDS CELL BIOL, V8, P447, DOI 10.1016/S0962-8924(98)01363-4
   Sheng BY, 2009, NEUROSCI LETT, V450, P327, DOI 10.1016/j.neulet.2008.11.046
   Sieber MW, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0052982
   Sivak JM, 2013, INVEST OPHTH VIS SCI, V54, P871, DOI 10.1167/iovs.12-10827
   Skerka C, 2013, MOL IMMUNOL, V56, P170, DOI 10.1016/j.molimm.2013.06.001
   Sorrentino P, 2014, FEBS LETT, V588, P641, DOI 10.1016/j.febslet.2013.12.038
   SWOMLEY AM, 2013, BIOCHIM BIOPHYS ACTA, V1842, P1248, DOI DOI 10.1016/j.bbadis.2013.09.015
   Taru H, 2009, J ALZHEIMERS DIS, V18, P253, DOI 10.3233/JAD-2009-1148
   Tharp WG, 2013, BMC GENOMICS, V14, DOI 10.1186/1471-2164-14-290
   Turner PR, 2003, PROG NEUROBIOL, V70, P1, DOI 10.1016/S0301-0082(03)00089-3
   Tyan SH, 2012, MOL CELL NEUROSCI, V51, P43, DOI 10.1016/j.mcn.2012.07.009
   Walton JR, 2013, J ALZHEIMERS DIS, V35, P7, DOI 10.3233/JAD-121909
   Wang ZL, 2012, CURR ALZHEIMER RES, V9, P217, DOI 10.2174/156720512799361691
   Waring SC, 2008, ARCH NEUROL-CHICAGO, V65, P329, DOI 10.1001/archneur.65.3.329
   Woo SJ, 2012, OPHTHALMOLOGY, V119, P2094, DOI 10.1016/j.ophtha.2012.04.026
   Yang XG, 2014, MOL NEUROBIOL, V50, P119, DOI 10.1007/s12035-014-8652-6
   Yin RH, 2015, MOL NEUROBIOL, V51, P909, DOI 10.1007/s12035-014-8742-5
   Zetterberg M, 2008, AM J MED GENET B, V147B, P720, DOI 10.1002/ajmg.b.30668
   Zhao YH, 2013, FRONT CELL NEUROSCI, V7, DOI 10.3389/fncel.2013.00131
   Zhao YH, 2013, NEUROREPORT, V24, P318, DOI 10.1097/WNR.0b013e32835fb6b0
   Zhao YH, 2011, PLOS ONE, V6, DOI [10.1371/journal.pone.0015816, 10.1371/journal.pone.0016470]
NR 110
TC 40
Z9 43
U1 1
U2 34
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0893-7648
EI 1559-1182
J9 MOL NEUROBIOL
JI Mol. Neurobiol.
PD AUG
PY 2015
VL 52
IS 1
BP 533
EP 544
DI 10.1007/s12035-014-8886-3
PG 12
WC Neurosciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Neurosciences & Neurology
GA CN3QO
UT WOS:000358341600047
PM 25204496
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Chiras, D
   Kitsos, G
   Petersen, MB
   Skalidakis, I
   Kroupis, C
AF Chiras, Dimitrios
   Kitsos, George
   Petersen, Michael B.
   Skalidakis, Iosif
   Kroupis, Christos
TI Oxidative stress in dry age-related macular degeneration and exfoliation
   syndrome
SO CRITICAL REVIEWS IN CLINICAL LABORATORY SCIENCES
LA English
DT Review
DE Aging; antioxidant defenses; glaucoma; mitochondrial damage; reactive
   oxygen species; smoking; ultraviolet irradiation; vision loss
ID RETINAL-PIGMENT EPITHELIUM; LONG-TERM INCIDENCE; MITOCHONDRIAL-DNA
   DAMAGE; COMPLEMENT FACTOR-H; AQUEOUS-HUMOR; PSEUDOEXFOLIATION SYNDROME;
   CIGARETTE-SMOKING; LYSYL OXIDASE; PLASMA HOMOCYSTEINE; POTENTIAL
   MECHANISM
AB Oxidative stress refers to cellular or molecular damage caused by reactive oxygen species, which especially occurs in age-related conditions as a result of an imbalance between the production of reactive oxygen species and the antioxidant defense response. Dry age-related macular degeneration (AMD) and exfoliation syndrome (XFS) are two common and complex age-related conditions that can cause irreversible vision loss. Two subtypes of AMD, which is the leading cause of blindness in the Western world, exist: the most prevalent dry type and the most severe wet type. Early dry AMD is characterized by formation of drusen, which are sub-retinal deposits, in the macular area and may progress to geographic atrophy with more dramatic manifestation. XFS is a systemic disorder of the extracellular matrix characterized by the accumulation of elastic fibrils that leads, in most cases, to glaucoma development with progressive and irreversible vision loss. Due to the aging population, the prevalence of these already-widespread conditions is increasing and is resulting in significant economic and psychological costs for individuals and for society. The exact composition of the abnormal drusen and XFS material as well as the mechanisms responsible for their production and accumulation still remain elusive, and consequently treatment for both diseases is lacking. However, recent epidemiologic, genetic and molecular studies support a major role for oxidative stress in both dry AMD and XFS development. Understanding the early molecular events in their pathogenesis and the exact role of oxidative stress may provide novel opportunities for therapeutic intervention for the prevention of progression to advanced disease.
C1 [Chiras, Dimitrios; Kitsos, George] Univ Hosp Ioannina, Dept Ophthalmol, Ioannina, Greece.
   [Petersen, Michael B.; Skalidakis, Iosif] Aalborg Univ Hosp, Dept Clin Genet, Aalborg, Denmark.
   [Skalidakis, Iosif; Kroupis, Christos] Attikon Univ Gen Hosp, Dept Clin Biochem & Mol Diagnost, Athens, Greece.
C3 University Hospital Ioannina; Aalborg University; Aalborg University
   Hospital; University Hospital Attikon
RP Kroupis, C (通讯作者)，Attikon Univ, Gen Hosp, Dept Clin Biochem & Mol Diagnost, 1 Rimini St, Haidari 12462, Greece.
EM ckroupis@med.uoa.gr
RI Petersen, Michael Bjørn B/D-1483-2017; Kroupis, Christos/K-2725-2013
OI Petersen, Michael Bjørn B/0000-0003-0316-8207; Kroupis,
   Christos/0000-0002-5876-2599
CR Abu-Amero KK, 2011, MOL VIS, V17, P2769
   Amini Heydar, 2012, J Ophthalmic Vis Res, V7, P190
   Anand R, 2000, OPHTHALMOLOGY, V107, P2224
   Arnarsson A, 2010, BRIT J OPHTHALMOL, V94, P831, DOI 10.1136/bjo.2009.157636
   Aslan M, 2013, REDOX REP, V18, P76, DOI 10.1179/1351000212Y.0000000033
   Bamonti F, 2006, CLIN CHEM LAB MED, V44, P391, DOI 10.1515/CCLM.2006.084
   Barnett BR, 2013, GERONTOLOGY, V59, P297, DOI 10.1159/000346169
   Bazan NG, 2006, TRENDS NEUROSCI, V29, P263, DOI 10.1016/j.tins.2006.03.005
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   Belovay GW, 2010, CURR OPIN OPHTHALMOL, V21, P25, DOI 10.1097/ICU.0b013e328332f814
   Beyazyildiz E, 2014, JPN J OPHTHALMOL, V58, P353, DOI 10.1007/s10384-014-0325-5
   Bialasiewicz AA, 2005, OPHTHALMOLOGE, V102, P1064, DOI 10.1007/s00347-005-1226-2
   Blasiak J, 2013, INT J MOL SCI, V14, P2996, DOI 10.3390/ijms14022996
   Borazan M, 2010, J GLAUCOMA, V19, P207, DOI 10.1097/IJG.0b013e3181aae93e
   Boulton M, 2001, EYE, V15, P384, DOI 10.1038/eye.2001.141
   Browne JG, 2011, INVEST OPHTH VIS SCI, V52, P3660, DOI 10.1167/iovs.10-5209
   Bruno Richard S, 2006, Pathophysiology, V13, P143, DOI 10.1016/j.pathophys.2006.05.003
   Cai JY, 2000, PROG RETIN EYE RES, V19, P205, DOI 10.1016/S1350-9462(99)00009-9
   Cano M, 2010, VISION RES, V50, P652, DOI 10.1016/j.visres.2009.08.018
   Canter JA, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002091
   Chalam KV, 2011, EYE CONTACT LENS, V37, P225, DOI 10.1097/ICL.0b013e31821fbd3e
   Chew EY, 2013, JAMA-J AM MED ASSOC, V309, P2005, DOI 10.1001/jama.2013.4997
   Chiras Dimitrios, 2013, Mol Vis, V19, P1006
   Chou MY, 2008, J INTERN MED, V263, P479, DOI 10.1111/j.1365-2796.2008.01968.x
   Christensen B, 2001, AM J CLIN NUTR, V74, P302
   Chrysostomou V, 2013, CURR OPIN PHARMACOL, V13, P12, DOI 10.1016/j.coph.2012.09.008
   Crabb JW, 2002, P NATL ACAD SCI USA, V99, P14682, DOI 10.1073/pnas.222551899
   Cumurcu T, 2010, OPHTHALMIC RES, V43, P169, DOI 10.1159/000272019
   Demirdogen BC, 2014, CLIN LAB, V60, P79, DOI 10.7754/Clin.Lab.2013.121229
   Dhubhghaill SSN, 2010, ADV EXP MED BIOL, V664, P437, DOI 10.1007/978-1-4419-1399-9_50
   Djordjevic-Jocic J, 2012, VOJNOSANIT PREGL, V69, P231, DOI 10.2298/VSP1203231D
   Drobek-Slowik Monika, 2007, Postepy Hig Med Dosw (Online), V61, P28
   Dudek EJ, 2005, FASEB J, V19, P1707, DOI 10.1096/fj.05-4049fje
   Ferreira SM, 2009, EYE, V23, P1691, DOI 10.1038/eye.2008.352
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Fritsche LG, 2008, NAT GENET, V40, P892, DOI 10.1038/ng.170
   Fujihara M, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003119
   Galli A, 2005, HEPATOLOGY, V41, P1074, DOI 10.1002/hep.20683
   Gao XQ, 2004, P NATL ACAD SCI USA, V101, P10446, DOI 10.1073/pnas.0403886101
   Gartaganis SP, 2007, EYE, V21, P1406, DOI 10.1038/sj.eye.6702596
   Gartaganis SP, 2005, CURR EYE RES, V30, P647, DOI 10.1080/02713680590968367
   Gorgun E, 2010, INVEST OPHTH VIS SCI, V51, P4732, DOI 10.1167/iovs.09-4842
   Grodum K, 2005, OPHTHALMOLOGY, V112, P386, DOI 10.1016/j.ophtha.2004.09.024
   Gu XR, 2003, J BIOL CHEM, V278, P42027, DOI 10.1074/jbc.M305460200
   Ha KN, 2006, INVEST OPHTH VIS SCI, V47, P2709, DOI 10.1167/iovs.05-1322
   Hollyfield JG, 2008, NAT MED, V14, P194, DOI 10.1038/nm1709
   Hunter JJ, 2012, PROG RETIN EYE RES, V31, P28, DOI 10.1016/j.preteyeres.2011.11.001
   Izzotti A, 2006, MUTAT RES-REV MUTAT, V612, P105, DOI 10.1016/j.mrrev.2005.11.001
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Justilien V, 2007, INVEST OPHTH VIS SCI, V48, P4407, DOI 10.1167/iovs.07-0432
   Kaarniranta Kai, 2010, Front Biosci (Elite Ed), V2, P1374
   Kanda A, 2007, P NATL ACAD SCI USA, V104, P16227, DOI 10.1073/pnas.0703933104
   Kang JH, 2012, OPHTHALMOLOGY, V119, P27, DOI 10.1016/j.ophtha.2011.06.018
   Kanthan GL, 2013, AM J OPHTHALMOL, V155, P83, DOI 10.1016/j.ajo.2012.07.002
   Karunadharma PP, 2010, INVEST OPHTH VIS SCI, V51, P5470, DOI 10.1167/iovs.10-5429
   Kasahara E, 2005, INVEST OPHTH VIS SCI, V46, P3426, DOI 10.1167/iovs.05-0344
   Kenney MC, 2013, BMC MED GENET, V14, DOI 10.1186/1471-2350-14-4
   Khan JC, 2006, BRIT J OPHTHALMOL, V90, P75, DOI 10.1136/bjo.2005.073643
   Khandhadia S, 2010, EXPERT REV MOL MED, V12, DOI 10.1017/S146239941000164X
   Kinnunen K, 2012, ACTA OPHTHALMOL, V90, P299, DOI 10.1111/j.1755-3768.2011.02179.x
   Klein ML, 2008, OPHTHALMOLOGY, V115, P1019, DOI 10.1016/j.ophtha.2008.01.036
   Klein R, 2007, OPHTHAL EPIDEMIOL, V14, P184, DOI 10.1080/09286580701344381
   Kliment CR, 2010, FREE RADICAL BIO MED, V49, P707, DOI 10.1016/j.freeradbiomed.2010.04.036
   Kokotas H, 2011, CLIN CHEM LAB MED, V49, P601, DOI 10.1515/CCLM.2011.091
   Kokotas H, 2012, CLIN CHEM LAB MED, V50, P2107, DOI 10.1515/cclm-2012-0048
   Koliakos GG, 2008, GRAEF ARCH CLIN EXP, V246, P1477, DOI 10.1007/s00417-008-0871-y
   Koliakos GG, 2003, BRIT J OPHTHALMOL, V87, P353, DOI 10.1136/bjo.87.3.353
   Komur B, 2013, SEMIN OPHTHALMOL, V28, P256, DOI 10.3109/08820538.2013.771194
   Kong L, 2007, J NEUROCHEM, V101, P1041, DOI 10.1111/j.1471-4159.2007.04481.x
   Konstas AGP, 1997, ARCH OPHTHALMOL-CHIC, V115, P1063, DOI 10.1001/archopht.1997.01100160233014
   Kowalski M, 2010, MED SCI MONITOR, V16, pCR190
   Kroupis C., 2013, J GENET SYNDR GENE T, V4, DOI [10.4172/2157-7412.1000e118, DOI 10.4172/2157-7412.1000E118]
   Li GY, 2008, BRAIN RES, V1188, P35, DOI 10.1016/j.brainres.2007.10.073
   Liang FQ, 2003, EXP EYE RES, V76, P397, DOI 10.1016/S0014-4835(03)00023-X
   Lin T, 2013, CYTOKINE, V62, P369, DOI 10.1016/j.cyto.2013.03.027
   Liu RM, 2010, FREE RADICAL BIO MED, V48, P1, DOI 10.1016/j.freeradbiomed.2009.09.026
   Liu XQ, 2004, NAT GENET, V36, P178, DOI 10.1038/ng1297
   Lois N, 2008, BRIT J OPHTHALMOL, V92, P1304, DOI 10.1136/bjo.2008.141168
   Majora M, 2009, AM J PATHOL, V175, P1019, DOI 10.2353/ajpath.2009.080832
   Malhotra D, 2008, AM J RESP CRIT CARE, V178, P592, DOI 10.1164/rccm.200803-380OC
   Maron Bradley A, 2007, Curr Atheroscler Rep, V9, P375, DOI 10.1007/s11883-007-0048-x
   Medicherla B, 2008, J CELL BIOL, V182, P663, DOI 10.1083/jcb.200803022
   Mikropoulos DG, 2013, CURR EYE RES, V38, P266, DOI 10.3109/02713683.2012.757325
   Moriarty-Craige SE, 2005, AM J OPHTHALMOL, V140, P1020, DOI 10.1016/j.ajo.2005.06.043
   Nickel A, 2014, J MOL CELL CARDIOL, V73, P26, DOI 10.1016/j.yjmcc.2014.03.011
   Nordgaard CL, 2008, INVEST OPHTH VIS SCI, V49, P2848, DOI 10.1167/iovs.07-1352
   Oleggini R, 2007, MATRIX BIOL, V26, P494, DOI 10.1016/j.matbio.2007.02.003
   Osburn WO, 2008, MUTAT RES-REV MUTAT, V659, P31, DOI 10.1016/j.mrrev.2007.11.006
   Park Cheul Ho, 2012, Korean J Ophthalmol, V26, P123, DOI 10.3341/kjo.2012.26.2.123
   Pasquale LR, 2012, INVEST OPHTH VIS SCI, V53, P6427, DOI 10.1167/iovs.12-10085
   Pinar-Sueiro Sergio, 2011, Arch Soc Esp Oftalmol, V86, P275, DOI 10.1016/j.oftal.2011.06.014
   Plafker SM, 2010, ADV EXP MED BIOL, V664, P447, DOI 10.1007/978-1-4419-1399-9_51
   Purnomo Yudi, 2013, Cardiovascular & Hematological Disorders - Drug Targets, V13, P165
   Puska P, 1999, GRAEF ARCH CLIN EXP, V237, P457, DOI 10.1007/s004170050261
   Quigley HA, 2011, LANCET, V377, P1367, DOI 10.1016/S0140-6736(10)61423-7
   Rao A, 2013, SEMIN OPHTHALMOL, V28, P28, DOI 10.3109/08820538.2012.730099
   Ringvold A, 1999, ACTA OPHTHALMOL SCAN, V77, P371, DOI 10.1034/j.1600-0420.1999.770401.x
   Ritch R, 2003, PROG RETIN EYE RES, V22, P253, DOI 10.1016/S1350-9462(02)00014-9
   Rivera A, 2005, HUM MOL GENET, V14, P3227, DOI 10.1093/hmg/ddi353
   Diez GR, 2013, EXP EYE RES, V113, P172, DOI 10.1016/j.exer.2013.05.019
   Rozanowska M, 2005, PHOTOCHEM PHOTOBIOL, V81, P1305, DOI 10.1562/2004-11-13-IR-371
   Rozanowski B, 2008, INVEST OPHTH VIS SCI, V49, P2838, DOI 10.1167/iovs.08-1700
   Schlotzer-Schrehardt U, 2012, OPHTHALMOLOGE, V109, P944, DOI 10.1007/s00347-012-2531-1
   Schlotzer-Schrehardt U, 2010, KLIN MONATSBL AUGENH, V227, P108, DOI 10.1055/s-0028-1109977
   Schlotzer-Schrehardt U, 2006, AM J OPHTHALMOL, V141, P921, DOI 10.1016/j.ajo.2006.01.047
   Schlotzer-Schrehardt U, 2011, MIDDLE EAST AFR J OP, V18, P30, DOI 10.4103/0974-9233.75882
   Schmidt S, 2006, AM J HUM GENET, V78, P852, DOI 10.1086/503822
   Schutt F, 2003, INVEST OPHTH VIS SCI, V44, P3663, DOI 10.1167/iovs.03-0172
   Schutt F, 2002, FEBS LETT, V528, P217, DOI 10.1016/S0014-5793(02)03312-4
   Shadrach KG, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0067983
   Sharma RK, 2009, ACTA OPHTHALMOL, V87, P82, DOI 10.1111/j.1755-3768.2008.01170.x
   Sies H, 1997, EXP PHYSIOL, V82, P291, DOI 10.1113/expphysiol.1997.sp004024
   Stein JD, 2011, ARCH OPHTHALMOL-CHIC, V129, P1053, DOI 10.1001/archophthalmol.2011.191
   Strzalka-Mrozik B, 2013, MOL VIS, V19, P1341
   Sun MJ, 2006, J BIOL CHEM, V281, P4222, DOI 10.1074/jbc.M509769200
   Suzuki M, 2007, MOL VIS, V13, P772
   Synowiec E, 2013, FRONT BIOSCI-LANDMRK, V18, P80, DOI 10.2741/4088
   Synowiec E, 2012, EXP EYE RES, V98, P58, DOI 10.1016/j.exer.2012.02.008
   Tan JSL, 2008, OPHTHALMOLOGY, V115, P334, DOI 10.1016/j.ophtha.2007.03.083
   Tan JSL, 2007, ARCH OPHTHALMOL-CHIC, V125, P1089, DOI 10.1001/archopht.125.8.1089
   Tanito M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0049680
   Tezel G, 2005, INVEST OPHTH VIS SCI, V46, P3177, DOI 10.1167/iovs.05-0208
   Tezel G, 2004, INVEST OPHTH VIS SCI, V45, P4049, DOI 10.1167/iovs.04-0490
   Tezel G, 2009, INVEST OPHTH VIS SCI, V50, P1001, DOI 10.1167/iovs.08-2717
   Thorleifsson G, 2007, SCIENCE, V317, P1397, DOI 10.1126/science.1146554
   Tolleson William H, 2005, Int J Environ Res Public Health, V2, P147, DOI 10.3390/ijerph2005010147
   Tosun M, 2012, BRIT J OPHTHALMOL, V96, P1137, DOI 10.1136/bjophthalmol-2012-301901
   Tyagi N, 2005, AM J PHYSIOL-HEART C, V289, pH2649, DOI 10.1152/ajpheart.00548.2005
   Ucakhan OO, 2006, J CATARACT REFR SURG, V32, P618, DOI 10.1016/j.jcrs.2006.01.018
   Vives-Bauza C, 2008, J BIOL CHEM, V283, P24770, DOI 10.1074/jbc.M800706200
   Voloshenyuk TG, 2011, BIOCHEM BIOPH RES CO, V413, P370, DOI 10.1016/j.bbrc.2011.08.109
   Wang HJ, 2005, FREE RADICAL BIO MED, V38, P890, DOI 10.1016/j.freeradbiomed.2004.12.005
   Weismann D, 2011, NATURE, V478, P76, DOI 10.1038/nature10449
   Wielgus AR, 2010, PHOTOCH PHOTOBIO SCI, V9, P1505, DOI 10.1039/c0pp00133c
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Woodell A, 2014, ADV EXP MED BIOL, V801, P301, DOI 10.1007/978-1-4614-3209-8_38
   Wu YL, 2010, P NATL ACAD SCI USA, V107, P7275, DOI 10.1073/pnas.0913112107
   Xu F, 2012, GRAEF ARCH CLIN EXP, V250, P1067, DOI 10.1007/s00417-011-1877-4
   Yagci R, 2008, EYE, V22, P128, DOI 10.1038/sj.eye.6702751
   Yagci R, 2006, CURR EYE RES, V31, P1029, DOI 10.1080/02713680601001319
   Yagci R, 2009, OPHTHALMIC RES, V42, P155, DOI 10.1159/000229306
   Yang JJ, 2013, FOOD CHEM TOXICOL, V59, P421, DOI 10.1016/j.fct.2013.06.018
   Yildirim Z, 2007, ANN NY ACAD SCI, V1100, P207, DOI 10.1196/annals.1395.020
   Yilmaz A, 2005, CLIN EXP OPHTHALMOL, V33, P63, DOI 10.1111/j.1442-9071.2005.00944.x
   Yilmaz A, 2011, AM J OPHTHALMOL, V151, P272, DOI 10.1016/j.ajo.2010.08.032
   Yu X, 2005, MUTAT RES-FUND MOL M, V591, P93, DOI 10.1016/j.mrfmmm.2005.04.017
   Yuksel B, 2005, ACTA OPHTHALMOL SCAN, V83, P626, DOI 10.1111/j.1600-0420.2005.00508.x
   Zanon-Moreno V, 2008, J GLAUCOMA, V17, P263, DOI 10.1097/IJG.0b013e31815c3a7f
   Zenkel M, 2007, INVEST OPHTH VIS SCI, V48, P5558, DOI 10.1167/iovs.07-0750
   Zenkel M, 2011, INVEST OPHTH VIS SCI, V52, P8488, DOI 10.1167/iovs.11-8361
   Zhao ZY, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019456
   Zoric L, 2006, EUR J OPHTHALMOL, V16, P268, DOI 10.1177/112067210601600212
NR 152
TC 40
Z9 42
U1 0
U2 42
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 1040-8363
EI 1549-781X
J9 CRIT REV CL LAB SCI
JI Crit. Rev. Clin. Lab. Sci.
PD FEB
PY 2015
VL 52
IS 1
BP 12
EP 27
DI 10.3109/10408363.2014.968703
PG 16
WC Medical Laboratory Technology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Medical Laboratory Technology
GA AZ3IX
UT WOS:000348121800002
PM 25319011
DA 2022-11-30
ER

PT J
AU Maberley, DAL
   Isbister, C
   MacKenzie, P
   Aralar, A
AF Maberley, DAL
   Isbister, C
   MacKenzie, P
   Aralar, A
TI An evaluation of photographic screening for neovascular age-related
   macular degeneration
SO EYE
LA English
DT Review
DE age-related macular degeneration; screening; sensitivity; specificity;
   interobserver agreement
ID COST-EFFECTIVENESS
AB Background Photographic screening for neovascular age-related macular degeneration (AMD) is not commonly employed because the prevalence of treatable disease is low and fluorescein angiography is considered necessary for the diagnosis of this form of AMD. However, there may be a role for colour retinal imaging in assisting with the diagnosis and triage of subjects with neovascular AMD. The purpose of this study was to evaluate the utility of colour fundus photographs for identifying subjects with potentially treatable neovascular AMD.
   Methods A total of 74 stereo pairs of Kodachrome colour slides of subjects with AMD were evaluated (i) nonstereoscopically, (ii) stereoscopically, and (iii) stereoscopically with visual acuity and visual symptom data. Two retina specialists read the images to identify active exudative lesions.
   Results The kappa statistic comparing the retinal specialists diagnosis of treatable neovascular AMD from color slides was excellent. The sensitivity and specificity of nonstereo images for the appropriate categorization of lesions was 0.95 and 0.90 respectively. The evaluation of stereo pairs was more sensitive, but less specific, 0.98, 0.83, as was the evaluation of stereo-pairs with clinical histories and visual acuities, 1.00, 0.77.
   Conclusions The evaluation of colour images for subjects with suspected exudative macular degeneration can be diagnostic for neovascular AMD and may expedite the appropriate referral of patients for more timely angiography and treatment. Incorporating more clinical information for the image evaluators (( i) stereo image pairs and/or ( ii) presenting symptomatology and visual acuity data) led to a decrease in the false-negative rate, but also decreased the screening specificity.
C1 Univ British Columbia, Dept Ophthalmol, Vancouver, BC, Canada.
C3 University of British Columbia
RP Maberley, DAL (通讯作者)，2550 Willow, Vancouver, BC V5Z 3N9, Canada.
EM dmaberle@vanhosp.bc.ca
CR Age-Related Eye Dis Study Res Grp, 2001, AM J OPHTHALMOL, V132, P668
   [Anonymous], 1981, OPHTHALMOLOGY, V88, P583
   Ariyasu RG, 1996, OPHTHALMOLOGY, V103, P1751, DOI 10.1016/S0161-6420(96)30431-4
   BRESSLER NM, 1989, ARCH OPHTHALMOL-CHIC, V107, P847, DOI 10.1001/archopht.1989.01070010869032
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   *EARL TREATM DIAB, 1985, ARCH OPHTHALMOL-CHIC, V26, P983
   Haddad WM, 2002, GRAEF ARCH CLIN EXP, V240, P31, DOI 10.1007/s00417-001-0404-4
   Hennekens CH, 1987, EPIDEMIOLOGY MED
   JAVITT JC, 1989, OPHTHALMOLOGY, V96, P255
   Javitt JC, 1996, ANN INTERN MED, V124, P164, DOI 10.7326/0003-4819-124-1_Part_2-199601011-00017
   Kassoff A, 2001, AM J OPHTHALMOL, V131, P167
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Kiess R D, 1984, Ohio State Med J, V80, P235
   KINYOUN J, 1989, OPHTHALMOLOGY, V96, P746
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   MOSS SE, 1985, OPHTHALMOLOGY, V92, P62
   SINGER DE, 1992, ANN INTERN MED, V116, P660, DOI 10.7326/0003-4819-116-8-660
   SUSSMAN EJ, 1982, JAMA-J AM MED ASSOC, V247, P3231, DOI 10.1001/jama.247.23.3231
   WHITMORE WG, 1989, OPHTHALMOLOGY, V96, P393, DOI 10.1016/S0161-6420(89)32880-6
   2002, RETINA, V26, P6
NR 20
TC 10
Z9 10
U1 0
U2 0
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0950-222X
EI 1476-5454
J9 EYE
JI Eye
PD JUN
PY 2005
VL 19
IS 6
BP 611
EP 616
DI 10.1038/sj.eye.6701584
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 932NZ
UT WOS:000229561700002
PM 15184945
OA Bronze
DA 2022-11-30
ER

PT J
AU Haddad, WM
   Seres, A
   Coscas, G
   Soubrane, G
AF Haddad, WM
   Seres, A
   Coscas, G
   Soubrane, G
TI Presentation delay in patients affected with exudative age-related
   macular degeneration
SO GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Article
ID CHOROIDAL NEOVASCULAR MEMBRANES; FEATURES; VESSELS
AB Background: Presentation delay (i.e. duration of visual symptoms before initial presentation) is an established critical parameter for visual prognosis in patients with exudative age-related macular degeneration (ARMD) considering the natural history of the disease and the limitations of current treatments. The purpose of this study was to determine the duration of presentation delay and its evolution in two periods 4 years apart. Methods: Presentation delay in 1598 patients affected with exudative ARMD was retrospectively reviewed during two similar 8-month periods in 1994 and 1998 in a tertiary referral center. Results: The proportions of patients examined either within 1 month, between 1 and 3 months, and between 3 and 6 months after onset of symptoms, respectively, increased between 1994 and 1998 from 23% to 33%, from 27% to 32.5%, and from 14% to 18.5%. The proportions of patients examined between 6 and 12 months and after 12 months decreased from 16% to 12% and from 20% to 4%, respectively. Furthermore, the proportion of patients presenting with a first eye involvement during the first month following the onset of symptoms rose from 42% in 1994 to 52% in 1998. All these differences were statistically significant. Conclusion: This first specific review of presentation delay in exudative ARMD showed a significant decrease in this parameter between 1994 and 1998 that should be taken into account when assessing the overall evolution of visual outcome. Further studies are warranted to ascertain that these findings reflect a global improvement in the management of macular diseases.
C1 Univ Paris 12, Dept Ophthalmol, F-94010 Creteil, France.
   Semmelweis Univ, Sch Med, Dept Ophthalmol 1, Budapest, Hungary.
C3 Universite Paris-Est-Creteil-Val-de-Marne (UPEC); Semmelweis University
RP Soubrane, G (通讯作者)，Univ Paris 12, Dept Ophthalmol, 40 Ave Verdun, F-94010 Creteil, France.
EM gisele.soubrane@chicreteil.fr
CR [Anonymous], 1982, Br J Ophthalmol, V66, P745
   [Anonymous], 1991, Arch Ophthalmol, V109, P1109
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   BRESSLER SB, 1982, AM J OPHTHALMOL, V93, P157, DOI 10.1016/0002-9394(82)90410-X
   BRESSLER SB, 1983, RETINA-J RET VIT DIS, V3, P7, DOI 10.1097/00006982-198300310-00002
   COSCAS G, 1991, ARCH OPHTHALMOL-CHIC, V109, P1258, DOI 10.1001/archopht.1991.01080090082028
   Coscas G, 1982, Bull Mem Soc Fr Ophtalmol, V94, P149
   FERRIS FL, 1984, ARCH OPHTHALMOL-CHIC, V102, P1640
   FINE AM, 1986, ARCH OPHTHALMOL-CHIC, V104, P513
   FINE SL, 1982, ARCH OPHTHALMOL-CHIC, V100, P912
   FREUND KB, 1993, AM J OPHTHALMOL, V115, P786, DOI 10.1016/S0002-9394(14)73649-9
   GASS JDM, 1973, ARCH OPHTHALMOL-CHIC, V90, P206
   GREY RHB, 1979, BRIT J OPHTHALMOL, V63, P85, DOI 10.1136/bjo.63.2.85
   GUYER DR, 1986, ARCH OPHTHALMOL-CHIC, V104, P702, DOI 10.1001/archopht.1986.01050170092029
   HAWKINS BS, 1990, ARCH OPHTHALMOL-CHIC, V108, P816
   KLEIN ML, 1989, OPHTHALMOLOGY, V96, P1416
   Pauleikhoff D, 1996, KLIN MONATSBL AUGENH, V209, P309, DOI 10.1055/s-2008-1035324
   SOUBRANE G, 1990, OPHTHALMOLOGY, V97, P649
   STERNBERG P, 1991, ARCH OPHTHALMOL-CHIC, V109, P1242
   *TAP STUD GROUP, 1993, ARCH OPHTHALMOL-CHIC, V117, P1329
   VANDER JF, 1989, OPHTHALMOLOGY, V96, P1422
NR 21
TC 7
Z9 7
U1 0
U2 5
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0721-832X
EI 1435-702X
J9 GRAEF ARCH CLIN EXP
JI Graefes Arch. Clin. Exp. Ophthalmol.
PD JAN
PY 2002
VL 240
IS 1
BP 31
EP 34
DI 10.1007/s00417-001-0404-4
PG 4
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 528CJ
UT WOS:000174226300007
PM 11954778
DA 2022-11-30
ER

PT J
AU Tarallo, V
   Hirano, Y
   Gelfand, BD
   Dridi, S
   Kerur, N
   Kim, Y
   Cho, WG
   Kaneko, H
   Fowler, BJ
   Bogdanovich, S
   Albuquerque, RJC
   Hauswirth, WW
   Chiodo, VA
   Kugel, JF
   Goodrich, JA
   Ponicsan, SL
   Chaudhuri, G
   Murphy, MP
   Dunaief, JL
   Ambati, BK
   Ogura, Y
   Yoo, JW
   Lee, DK
   Provost, P
   Hinton, DR
   Nunez, G
   Baffi, JZ
   Kleinman, ME
   Ambati, J
AF Tarallo, Valeria
   Hirano, Yoshio
   Gelfand, Bradley D.
   Dridi, Sami
   Kerur, Nagaraj
   Kim, Younghee
   Cho, Won Gil
   Kaneko, Hiroki
   Fowler, Benjamin J.
   Bogdanovich, Sasha
   Albuquerque, Romulo J. C.
   Hauswirth, William W.
   Chiodo, Vince A.
   Kugel, Jennifer F.
   Goodrich, James A.
   Ponicsan, Steven L.
   Chaudhuri, Gautam
   Murphy, Michael P.
   Dunaief, Joshua L.
   Ambati, Balamurali K.
   Ogura, Yuichiro
   Yoo, Jae Wook
   Lee, Dong-ki
   Provost, Patrick
   Hinton, David R.
   Nunez, Gabriel
   Baffi, Judit Z.
   Kleinman, Mark E.
   Ambati, Jayakrishna
TI DICER1 Loss and Alu RNA Induce Age-Related Macular Degeneration via the
   NLRP3 Inflammasome and MyD88
SO CELL
LA English
DT Article
ID RETINAL-PIGMENT EPITHELIUM; ENDOTHELIAL GROWTH-FACTOR; INNATE
   IMMUNE-RESPONSES; DOUBLE-STRANDED-RNA; CELL-DEATH; ACTIVATION;
   RECOGNITION; CASPASE-1; PROTEIN; IL-1
AB Alu RNA accumulation due to DICER1 deficiency in the retinal pigmented epithelium (RPE) is implicated in geographic atrophy (GA), an advanced form of age-related macular degeneration that causes blindness in millions of individuals. The mechanism of Alu RNA-induced cytotoxicity is unknown. Here we show that DICER1 deficit or Alu RNA exposure activates the NLRP3 inflammasome and triggers TLR-independent MyD88 signaling via IL18 in the RPE. Genetic or pharmacological inhibition of inflammasome components (NLRP3, Pycard, Caspase-1), MyD88, or IL18 prevents RPE degeneration induced by DICER1 loss or Alu RNA exposure. These findings, coupled with our observation that human GA RPE contains elevated amounts of NLRP3, PYCARD, and IL18 and evidence of increased Caspase-1 and MyD88 activation, provide a rationale for targeting this pathway in GA. Our findings also reveal a function of the inflammasome outside the immune system and an immunomodulatory action of mobile elements.
C1 [Tarallo, Valeria; Hirano, Yoshio; Gelfand, Bradley D.; Dridi, Sami; Kerur, Nagaraj; Kim, Younghee; Cho, Won Gil; Kaneko, Hiroki; Fowler, Benjamin J.; Bogdanovich, Sasha; Albuquerque, Romulo J. C.; Baffi, Judit Z.; Kleinman, Mark E.; Ambati, Jayakrishna] Univ Kentucky, Dept Ophthalmol & Visual Sci, Lexington, KY 40506 USA.
   [Fowler, Benjamin J.; Ambati, Jayakrishna] Univ Kentucky, Dept Physiol, Lexington, KY 40506 USA.
   [Cho, Won Gil] Yonsei Univ, Wonju Coll Med, Dept Anat, Wonju 220701, South Korea.
   [Hauswirth, William W.; Chiodo, Vince A.] Univ Florida, Dept Ophthalmol, Gainesville, FL 32610 USA.
   [Kugel, Jennifer F.; Goodrich, James A.; Ponicsan, Steven L.] Univ Colorado, Dept Chem & Biochem, Boulder, CO 80309 USA.
   [Chaudhuri, Gautam] Meharry Med Coll, Dept Microbiol & Immunol, Nashville, TN 37208 USA.
   [Murphy, Michael P.] MRC, Mitochondrial Biol Unit, Cambridge CB2 0XY, England.
   [Dunaief, Joshua L.] Univ Penn, Scheie Eye Inst, FM Kirby Ctr Mol Ophthalmol, Philadelphia, PA 19104 USA.
   [Ambati, Balamurali K.] Univ Utah, Sch Med, Moran Eye Ctr, Dept Ophthalmol & Visual Sci, Salt Lake City, UT 84132 USA.
   [Ambati, Balamurali K.] Vet Affairs Salt Lake City Healthcare Syst, Dept Ophthalmol, Salt Lake City, UT 84148 USA.
   [Ogura, Yuichiro] Nagoya City Univ, Grad Sch Med Sci, Dept Ophthalmol & Visual Sci, Nagoya, Aichi 4678601, Japan.
   [Yoo, Jae Wook; Lee, Dong-ki] Sungkyunkwan Univ, Global Res Lab RNAi Med, Suwon 440746, South Korea.
   [Yoo, Jae Wook; Lee, Dong-ki] Sungkyunkwan Univ, Sch Chem Mat Sci BK21, Suwon 440746, South Korea.
   [Yoo, Jae Wook; Lee, Dong-ki] Sungkyunkwan Univ, Dept Chem, Suwon 440746, South Korea.
   [Provost, Patrick] Univ Laval, CHUL Res Ctr, CHUQ, Quebec City, PQ G1K 7P4, Canada.
   [Provost, Patrick] Univ Laval, Fac Med, Quebec City, PQ G1K 7P4, Canada.
   [Hinton, David R.] Univ So Calif, Doheny Eye Inst, Arnold & Mabel Beckman Macular Res Ctr, Los Angeles, CA 90033 USA.
   [Nunez, Gabriel] Univ Michigan, Sch Med, Dept Pathol, Ann Arbor, MI 48109 USA.
   [Nunez, Gabriel] Univ Michigan, Sch Med, Ctr Comprehens Canc, Ann Arbor, MI 48109 USA.
C3 University of Kentucky; University of Kentucky; Yonsei University; State
   University System of Florida; University of Florida; University of
   Colorado System; University of Colorado Boulder; Meharry Medical
   College; University of Pennsylvania; Pennsylvania Medicine; Utah System
   of Higher Education; University of Utah; US Department of Veterans
   Affairs; Nagoya City University; Sungkyunkwan University (SKKU);
   Sungkyunkwan University (SKKU); Sungkyunkwan University (SKKU); Laval
   University; Laval University; Doheny Eye Institute; University of
   Southern California; University of Michigan System; University of
   Michigan; University of Michigan System; University of Michigan
RP Ambati, J (通讯作者)，Univ Kentucky, Dept Ophthalmol & Visual Sci, Lexington, KY 40506 USA.
EM jamba2@email.uky.edu
RI Gelfand, Brad/L-3926-2019; Kaneko, Hiroki/O-7695-2015; Provost,
   Patrick/G-2786-2010; Nuñez, Gabriel/A-7160-2014; Kaneko,
   Hiroki/AHA-2461-2022; Dridi, Sami/Q-8207-2019; Murphy, Michael
   P/C-2120-2009; Fowler, Benjamin/F-4987-2012
OI Kaneko, Hiroki/0000-0003-0731-6465; Provost,
   Patrick/0000-0002-6099-6562; Kaneko, Hiroki/0000-0003-0731-6465; Murphy,
   Michael P/0000-0003-1115-9618; Tarallo, Valeria/0000-0002-6920-4402;
   hauswirth, william/0000-0002-3244-4947; Hirano,
   Yoshio/0000-0002-9173-0839; Kleinman, Mark/0000-0001-8557-7949
FU NEI/NIH [R01EY018350, R01EY018836, R01EY020672, R01EY022238,
   R21EY019778, RC1EY020442]; Doris Duke Distinguished Clinical Scientist
   Award; Burroughs Wellcome Fund Clinical Scientist Award in Translational
   Research; Research to Prevent Blindness, RPB; NIH [K08EY021521,
   K08EY021757, T32HL091812, UL1RR033173, R01AI063331, R01AR052756,
   P30EY021721, R01EY017182, R01EY017950, P30EY003040, R01EY001545,
   R01GM068414]; International Retinal Research Foundation; American Health
   Assistance Foundation; Alcon Japan Research award; VA Merit Award;
   Department of Defense; MEST, Korea; RPB; University of Kentucky; Fonds
   de la Recherche en Sante du Quebec (FRSQ); MRC [MC_U105663142] Funding
   Source: UKRI; Medical Research Council [MC_U105663142] Funding Source:
   researchfish; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES
   [TL1TR000115, UL1TR001998, UL1TR000117] Funding Source: NIH RePORTER;
   NATIONAL CENTER FOR RESEARCH RESOURCES [UL1RR033173, TL1RR033172]
   Funding Source: NIH RePORTER; NATIONAL EYE INSTITUTE [R01EY001545,
   R01EY018836, R21EY019778, R01EY022238, R01EY018350, P30EY021721,
   K08EY021757, R01EY020672, R01EY017950, K08EY021521, P30EY003040,
   R01EY017182, RC1EY020442] Funding Source: NIH RePORTER; NATIONAL HEART,
   LUNG, AND BLOOD INSTITUTE [T32HL091812] Funding Source: NIH RePORTER;
   NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI063331]
   Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND
   MUSCULOSKELETAL AND SKIN DISEASES [R01AR052756] Funding Source: NIH
   RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM068414]
   Funding Source: NIH RePORTER
FX We thank S. Akira, Z. Chen, M. Chrenek, J. Garcia-Perez, T. Heidmann,
   and J. V. Moran for providing mice, reagents, or tissues; R. King, L.
   Xu, M. McConnell, C. Payne, D. Robertson, G. Botzet, G. R. Pattison, and
   C. Spee for technical assistance; and S. Bondada, M. E. Boulton, R. A.
   Brekken, R. Kannan, K. Kariko, T. S. Khurana, R. Mohan, M. L. Peterson,
   V. Rangnekar, A. Sinai, A. M. Rao, G. S. Rao, and K. Ambati for
   discussions. J. A. was supported by NEI/NIH grants R01EY018350,
   R01EY018836, R01EY020672, R01EY022238, R21EY019778, and RC1EY020442,
   Doris Duke Distinguished Clinical Scientist Award, Burroughs Wellcome
   Fund Clinical Scientist Award in Translational Research, Dr. E. Vernon
   Smith and Eloise C. Smith Macular Degeneration Endowed Chair, and Senior
   Scientist Investigator Award (Research to Prevent Blindness, RPB);
   J.Z.B. by NIH K08EY021521, International Retinal Research Foundation,
   and American Health Assistance Foundation; M. E. K. by NIH K08EY021757;
   B. J. F., S. B., and M. E. K. by NIH T32HL091812 and UL1RR033173; G.N.
   by NIH R01AI063331 and R01AR052756; Y.H. by Alcon Japan Research award;
   W. W. H. by NIH P30EY021721; B. K. A. by NIH R01EY017182 and
   R01EY017950, VA Merit Award, and Department of Defense; D. R. H. by NIH
   P30EY003040 and R01EY001545; J. F. K. and J. A. G. by NIH R01GM068414;
   J.W.Y. and D.-k.L. by Global Research Laboratory grant from MEST, Korea.
   Departmental unrestricted grants from RPB supported J. A. and W. W. H.
   University of Kentucky Physician Scientist Awards supported J.Z.B. and
   M. E. K. P. P. is a Senior Scholar from the Fonds de la Recherche en
   Sante du Quebec (FRSQ). Several authors are named as inventors on patent
   applications filed by their universities relating to described
   technologies. V. T., Y.H., B. D. G., S. D., Y.K., W. G. C., J.Z.B., H.
   K., N.K., B. J. F., S. B., and M. E. K. performed experiments. W. W. H.,
   V. A. C, S. L. P., J. F. K., J. A. G., M. P. M., J.W.Y., D.-k.L, D. R.
   H., P. P., and G.N. provided reagents. J. A. conceived and directed the
   project and wrote the paper with assistance from B. K. A., B. J. F., and
   B. D. G. All authors had the opportunity to discuss the results and
   comment on the manuscript.
CR Adachi O, 1998, IMMUNITY, V9, P143, DOI 10.1016/S1074-7613(00)80596-8
   Akira S, 2006, CELL, V124, P783, DOI 10.1016/j.cell.2006.02.015
   Alexopoulou L, 2001, NATURE, V413, P732, DOI 10.1038/35099560
   Allensworth JJ, 2011, J LEUKOCYTE BIOL, V90, P1159, DOI 10.1189/jlb.0511249
   Ambati J, 2003, SURV OPHTHALMOL, V48, P257, DOI 10.1016/S0039-6257(03)00030-4
   Batzer MA, 2002, NAT REV GENET, V3, P370, DOI 10.1038/nrg798
   Bauernfeind F, 2011, J IMMUNOL, V187, P613, DOI 10.4049/jimmunol.1100613
   Bernstein E, 2001, NATURE, V409, P363, DOI 10.1038/35053110
   Blaauwgeers HGT, 1999, AM J PATHOL, V155, P421, DOI 10.1016/S0002-9440(10)65138-3
   Cao ZD, 1996, SCIENCE, V271, P1128, DOI 10.1126/science.271.5252.1128
   Diebold SS, 2004, SCIENCE, V303, P1529, DOI 10.1126/science.1093616
   Feher J, 2006, NEUROBIOL AGING, V27, P983, DOI 10.1016/j.neurobiolaging.2005.05.012
   Feldmeyer L, 2007, CURR BIOL, V17, P1140, DOI 10.1016/j.cub.2007.05.074
   Fernandes-Alnemri T, 2007, CELL DEATH DIFFER, V14, P1590, DOI 10.1038/sj.cdd.4402194
   Fink SL, 2008, P NATL ACAD SCI USA, V105, P4312, DOI 10.1073/pnas.0707370105
   Fink SL, 2006, CELL MICROBIOL, V8, P1812, DOI 10.1111/j.1462-5822.2006.00751.x
   Ghayur T, 1997, NATURE, V386, P619, DOI 10.1038/386619a0
   Gu Y, 1997, SCIENCE, V275, P206, DOI 10.1126/science.275.5297.206
   Guarda G, 2011, IMMUNITY, V34, P213, DOI 10.1016/j.immuni.2011.02.006
   Guarda G, 2009, NATURE, V460, P269, DOI 10.1038/nature08100
   Halle A, 2008, NAT IMMUNOL, V9, P857, DOI 10.1038/ni.1636
   Heil F, 2004, SCIENCE, V303, P1526, DOI 10.1126/science.1093620
   Hoebe K, 2003, NATURE, V424, P743, DOI 10.1038/nature01889
   Hornung V, 2006, SCIENCE, V314, P994, DOI 10.1126/science.1132505
   Kanakaraj P, 1999, J EXP MED, V189, P1129, DOI 10.1084/jem.189.7.1129
   Kaneko H, 2011, NATURE, V471, P325, DOI 10.1038/nature09830
   Kanneganti TD, 2006, NATURE, V440, P233, DOI 10.1038/nature04517
   Kato H, 2006, NATURE, V441, P101, DOI 10.1038/nature04734
   Keller M, 2008, CELL, V132, P818, DOI 10.1016/j.cell.2007.12.040
   Kleinman ME, 2008, NATURE, V452, P591, DOI 10.1038/nature06765
   Kleinman ME, 2012, MOL THER, V20, P101, DOI 10.1038/mt.2011.212
   Kumar H, 2006, J EXP MED, V203, P1795, DOI 10.1084/jem.20060792
   Kumar MV, 2004, J NEUROIMMUNOL, V153, P7, DOI 10.1016/j.jneuroim.2004.04.018
   Lander ES, 2001, NATURE, V409, P860, DOI 10.1038/35057062
   Latz E, 2010, BLOOD, V116, P1393, DOI 10.1182/blood-2010-06-287342
   Li YB, 1998, BIOCHEM BIOPH RES CO, V253, P295, DOI 10.1006/bbrc.1998.9729
   Lin HJ, 2011, INVEST OPHTH VIS SCI, V52, P3521, DOI 10.1167/iovs.10-6163
   Loiarro M, 2005, J BIOL CHEM, V280, P15809, DOI 10.1074/jbc.C400613200
   Lopez PF, 1996, INVEST OPHTH VIS SCI, V37, P855
   Mariathasan S, 2006, NATURE, V440, P228, DOI 10.1038/nature04515
   Martinez FO, 2009, ANNU REV IMMUNOL, V27, P451, DOI 10.1146/annurev.immunol.021908.132532
   Masters SL, 2010, NAT IMMUNOL, V11, P897, DOI 10.1038/ni.1935
   McLeod DS, 2009, INVEST OPHTH VIS SCI, V50, P4982, DOI 10.1167/iovs.09-3639
   Meissner F, 2010, BLOOD, V116, P1570, DOI 10.1182/blood-2010-01-264218
   Miao EA, 2010, NAT IMMUNOL, V11, P1136, DOI 10.1038/ni.1960
   Murphy MP, 2007, ANNU REV PHARMACOL, V47, P629, DOI 10.1146/annurev.pharmtox.47.120505.105110
   Murphy MP, 2009, BIOCHEM J, V417, P1, DOI 10.1042/BJ20081386
   Muruve DA, 2008, NATURE, V452, P103, DOI 10.1038/nature06664
   Muzio M, 1997, SCIENCE, V278, P1612, DOI 10.1126/science.278.5343.1612
   Nakahira K, 2011, NAT IMMUNOL, V12, P222, DOI 10.1038/ni.1980
   Ngo VN, 2011, NATURE, V470, P115, DOI 10.1038/nature09671
   Nordgaard CL, 2008, INVEST OPHTH VIS SCI, V49, P2848, DOI 10.1167/iovs.07-1352
   O'Neill LAJ, 2007, NAT REV IMMUNOL, V7, P353, DOI 10.1038/nri2079
   Picard C, 2010, MEDICINE, V89, P403, DOI 10.1097/MD.0b013e3181fd8ec3
   Pichlmair A, 2011, NAT IMMUNOL, V12, P624, DOI 10.1038/ni.2048
   Puente XS, 2011, NATURE, V475, P101, DOI 10.1038/nature10113
   QURESHI N, 1991, INFECT IMMUN, V59, P441, DOI 10.1128/IAI.59.1.441-444.1991
   Rey FE, 2001, CIRC RES, V89, P408, DOI 10.1161/hh1701.096037
   Savina A, 2006, CELL, V126, P205, DOI 10.1016/j.cell.2006.05.035
   Schroder K, 2010, SCIENCE, V327, P296, DOI 10.1126/science.1184003
   SINNETT D, 1991, J BIOL CHEM, V266, P8675
   Smith W, 2001, OPHTHALMOLOGY, V108, P697, DOI 10.1016/S0161-6420(00)00580-7
   Streilein JW, 2003, NAT REV IMMUNOL, V3, P879, DOI 10.1038/nri1224
   Sun DX, 2006, NAT IMMUNOL, V7, P375, DOI 10.1038/ni1308
   Sun QM, 2006, IMMUNITY, V24, P633, DOI 10.1016/j.immuni.2006.04.004
   Suzuki N, 2003, J IMMUNOL, V170, P4031, DOI 10.4049/jimmunol.170.8.4031
   Suzuki N, 2002, NATURE, V416, P750, DOI 10.1038/nature736
   Tabeta K, 2006, NAT IMMUNOL, V7, P156, DOI 10.1038/ni1297
   Takeda A, 2009, NATURE, V460, P225, DOI 10.1038/nature08151
   THORNBERRY NA, 1992, NATURE, V356, P768, DOI 10.1038/356768a0
   Tschopp J, 2003, NAT REV MOL CELL BIO, V4, P95, DOI 10.1038/nrm1019
   Tschopp J, 2010, NAT REV IMMUNOL, V10, P210, DOI 10.1038/nri2725
   van Bruggen R, 2010, BLOOD, V115, P5398, DOI 10.1182/blood-2009-10-250803
   Vandenabeele Peter, 2006, Sci STKE, V2006, ppe44, DOI 10.1126/stke.3582006pe44
   Verhoef PA, 2005, J IMMUNOL, V175, P7623, DOI 10.4049/jimmunol.175.11.7623
   Vogt SD, 2011, EXP EYE RES, V93, P413, DOI 10.1016/j.exer.2011.06.002
   von Bernuth H, 2008, SCIENCE, V321, P691, DOI 10.1126/science.1158298
   Wen HT, 2011, NAT IMMUNOL, V12, P408, DOI 10.1038/ni.2022
   Yamamoto M, 2003, SCIENCE, V301, P640, DOI 10.1126/science.1087262
   Yang YL, 1995, EMBO J, V14, P6095, DOI 10.1002/j.1460-2075.1995.tb00300.x
   Zaki MH, 2010, IMMUNITY, V32, P379, DOI 10.1016/j.immuni.2010.03.003
   Zhou RB, 2011, NATURE, V469, P221, DOI 10.1038/nature09663
NR 82
TC 420
Z9 452
U1 3
U2 38
PU CELL PRESS
PI CAMBRIDGE
PA 50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA
SN 0092-8674
EI 1097-4172
J9 CELL
JI Cell
PD MAY 11
PY 2012
VL 149
IS 4
BP 847
EP 859
DI 10.1016/j.cell.2012.03.036
PG 13
WC Biochemistry & Molecular Biology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology
GA 941AR
UT WOS:000303934700017
PM 22541070
OA Bronze, Green Accepted
DA 2022-11-30
ER

PT J
AU Cascella, R
   Strafella, C
   Caputo, V
   Errichiello, V
   Zampatti, S
   Milano, F
   Potenza, S
   Mauriello, S
   Novelli, G
   Ricci, F
   Cusumano, A
   Giardina, E
AF Cascella, Raffaella
   Strafella, Claudia
   Caputo, Valerio
   Errichiello, Valeria
   Zampatti, Stefania
   Milano, Filippo
   Potenza, Saverio
   Mauriello, Silvestro
   Novelli, Giuseppe
   Ricci, Federico
   Cusumano, Andrea
   Giardina, Emiliano
TI Towards the application of precision medicine in Age-Related Macular
   Degeneration
SO PROGRESS IN RETINAL AND EYE RESEARCH
LA English
DT Review
DE Macular degeneration; Genetics; Populations; Gene interactions;
   Susceptibility
ID COMPLEMENT FACTOR-H; GROWTH-FACTOR TREATMENT; ANTI-VEGF THERAPY;
   RANIBIZUMAB TREATMENT; GENE POLYMORPHISM; INTRAVITREAL RANIBIZUMAB;
   NUTRITIONAL SUPPLEMENTS; AREDS SUPPLEMENTS; OXIDATIVE STRESS; ARMS2
   LOC387715
AB The review essentially describes genetic and non-genetic variables contributing to the onset and progression of exudative Age-related Macular Degeneration (AMD) in Italian population. In particular, AMD susceptibility within Italian population is contributed to by genetic variants, accounting for 23% of disease and non-genetic variants, accounting for 10% of AMD. Our data highlighted prominent differences concerning genetic and non genetic contributors to AMD in our cohort with respect to worldwide populations. Among genetic variables, SNPs of CFH, ARMS2, IL-8, TIMP3, SLC16A8, RAD51B, VEGFA and COL8A1 were significantly associated with the risk of AMD in the Italian cohort. Surprisingly, other susceptibility variants described in European, American and Asiatic populations, did not reach the significance threshold in our cohort. As expected, advanced age, smoking and dietary habits were associated with the disease. In addition, we also describe a number of gene gene and gene-phenotype interactions. In fact, AMD-associated genes may be involved in the alteration of Bruch's membrane and induction of angiogenesis, contributing to exacerbate the damage caused by aging and environmental factors.
   Our review provides an overview of genetic and non-genetic factors characterizing AMD susceptibility in Italian population, outlining the differences with respect to the worldwide populations. Altogether, these data reflect historical, geographic, demographic and lifestyle peculiarities of Italian population. The role of epigenetics, pharmacogenetics, comorbities and genetic counseling in the management of AMD patients have been described, in the perspective of the application of a "population-specific precision medicine" approach addressed to prevent AMD onset and improve patients' quality of life.
C1 [Cascella, Raffaella; Zampatti, Stefania; Giardina, Emiliano] Santa Lucia Fdn, Mol Genet Lab UILDM, Via Ardeatina 354, I-00142 Rome, Italy.
   [Cascella, Raffaella] Catholic Univ Our Lady Good Counsel Laprake, Dept Chem Pharmaceut & Biomol Technol, Rruga Dritan Hoxha 1000, Tirane, Albania.
   [Strafella, Claudia; Caputo, Valerio; Errichiello, Valeria; Milano, Filippo; Potenza, Saverio; Mauriello, Silvestro; Novelli, Giuseppe; Giardina, Emiliano] Tor Vergata Univ, Dept Biomed & Prevent, Via Montpellier 1, I-00133 Rome, Italy.
   [Strafella, Claudia] Emotest Lab, Via Patria Montenuovo Licola 60, I-80078 Pozzuoli, Italy.
   [Zampatti, Stefania] Neuromed IRCCS, Via Atinense 18, I-86077 Pozzuoli, Italy.
   [Ricci, Federico; Cusumano, Andrea] UOSD Retinal Pathol PTV Fdn Policlin Tor Vergata, Viale Oxford 81, I-00133 Rome, Italy.
C3 IRCCS Santa Lucia; University of Rome Tor Vergata; IRCCS Neuromed
RP Giardina, E (通讯作者)，Univ Roma Tor Vergata, Via Montpellier 1, I-00133 Rome, Italy.
EM emiliano.giardina@uniroma2.it
RI ricci, federico/AAC-3836-2020; Zampatti, Stefania/AAC-4589-2022;
   Novelli, Giuseppe/T-8822-2019; Giardina, Emiliano/J-1965-2012; Novelli,
   Giuseppe/A-5195-2013; Cascella, Raffaella/G-9040-2019; Strafella,
   Claudia/AAA-5929-2019; Novelli, Giuseppe/GQB-3329-2022; Caputo,
   Valerio/AAB-6481-2019
OI ricci, federico/0000-0002-4224-9280; Zampatti,
   Stefania/0000-0003-2502-7157; Novelli, Giuseppe/0000-0002-7781-602X;
   Cascella, Raffaella/0000-0002-2148-0758; Strafella,
   Claudia/0000-0003-1334-0920; Novelli, Giuseppe/0000-0002-7781-602X;
   Caputo, Valerio/0000-0002-3503-3318; POTENZA,
   SAVERIO/0000-0002-1671-779X
FU Macula Foundation Onlus; National Health Ministry [E82F16003700001]
FX This work was kindly supported by Macula Foundation Onlus and the
   National Health Ministry E82F16003700001 (General Board of Medical
   Devices and of Pharmaceutical Service).
CR Abedi F, 2013, OPHTHALMOLOGY, V120, P1641, DOI 10.1016/j.ophtha.2013.01.014
   Abedi F, 2013, OPHTHALMOLOGY, V120, P115, DOI 10.1016/j.ophtha.2012.10.006
   Alexander SL, 2007, OPHTHALMOLOGY, V114, P2174, DOI 10.1016/j.ophtha.2007.09.017
   Altshuler DM, 2015, NATURE, V526, P68, DOI 10.1038/nature15393
   Augustin A, 2007, INVEST OPHTH VIS SCI, V48, P1498, DOI 10.1167/iovs.06-0761
   Awh CC, 2015, OPHTHALMOLOGY, V122, P162, DOI 10.1016/j.ophtha.2014.07.049
   Awh CC, 2013, OPHTHALMOLOGY, V120, P2317, DOI 10.1016/j.ophtha.2013.07.039
   Bailey JNC, 2014, GENES-BASEL, V5, P518, DOI 10.3390/genes5030518
   Barcia C, 2009, J NEURAL TRANSM-SUPP, P245, DOI 10.1007/978-3-211-92660-4_19
   Brantley MA, 2007, OPHTHALMOLOGY, V114, P2168, DOI 10.1016/j.ophtha.2007.09.008
   Buschini E, 2011, PROG NEUROBIOL, V95, P14, DOI 10.1016/j.pneurobio.2011.05.011
   Campagne MV, 2016, IMMUNOBIOLOGY, V221, P733, DOI 10.1016/j.imbio.2015.11.007
   Cascella R, 2018, EYE, V32, P446, DOI 10.1038/eye.2017.192
   Cascella R, 2015, J AM ACAD DERMATOL, V73, P528, DOI 10.1016/j.jaad.2015.06.022
   Cascella R, 2014, J OPHTHALMOL, V2014, DOI 10.1155/2014/582842
   Cascella R, 2011, J INVEST DERMATOL, V131, P982, DOI 10.1038/jid.2010.398
   Chen CY, 2017, MEDICINE, V96, DOI 10.1097/MD.0000000000006405
   Chen W, 2010, P NATL ACAD SCI USA, V107, P7401, DOI 10.1073/pnas.0912702107
   Chen YH, 2010, MOL INTERV, V10, P271, DOI 10.1124/mi.10.5.4
   Chew EY, 2015, OPHTHALMOLOGY, V122, P212, DOI 10.1016/j.ophtha.2014.10.012
   Chew EY, 2014, OPHTHALMOLOGY, V121, P2173, DOI 10.1016/j.ophtha.2014.05.008
   Chong EW, 2014, OPTOMETRY VISION SCI, V91, P860, DOI 10.1097/OPX.0000000000000288
   Choudhury A, 2014, BMC GENOMICS, V15, DOI 10.1186/1471-2164-15-437
   Chung SD, 2014, AM J OPHTHALMOL, V157, P464, DOI 10.1016/j.ajo.2013.09.026
   Collins FS, 2015, NEW ENGL J MED, V372, P793, DOI 10.1056/NEJMp1500523
   Dedania VS, 2015, RETINA-J RET VIT DIS, V35, P381, DOI 10.1097/IAE.0000000000000466
   Ehrlich R, 2008, CLIN INTERV AGING, V3, P473
   Feng XF, 2009, OPHTHALMOLOGY, V116, P1908, DOI 10.1016/j.ophtha.2009.03.011
   Francis Peter James, 2011, Trans Am Ophthalmol Soc, V109, P115
   Fritsche LG, 2008, NAT GENET, V40, P892, DOI 10.1038/ng.170
   Fritsche LG, 2016, NAT GENET, V48, P134, DOI 10.1038/ng.3448
   Fritsche LG, 2014, ANNU REV GENOM HUM G, V15, P151, DOI 10.1146/annurev-genom-090413-025610
   Fritsche LG, 2013, NAT GENET, V45, P433, DOI 10.1038/ng.2578
   Gemenetzi M, 2014, EYE, V28, P1407, DOI 10.1038/eye.2014.225
   Gervasini G, 2010, EUR J CLIN PHARMACOL, V66, P755, DOI 10.1007/s00228-010-0857-7
   Ginsburg G., 2013, GENOMIC PERSONALIZED
   Grassmann F, 2017, GENOME MED, V9, DOI 10.1186/s13073-017-0418-0
   Grishkevich V, 2013, TRENDS GENET, V29, P479, DOI 10.1016/j.tig.2013.05.006
   Hagstrom SA, 2013, OPHTHALMOLOGY, V120, P593, DOI 10.1016/j.ophtha.2012.11.037
   Hermann MM, 2014, OPHTHALMOLOGY, V121, P905, DOI 10.1016/j.ophtha.2013.10.047
   Horie-Inoue K, 2014, BIOCHEM BIOPH RES CO, V452, P263, DOI 10.1016/j.bbrc.2014.08.013
   Huang DW, 2009, NAT PROTOC, V4, P44, DOI 10.1038/nprot.2008.211
   Huang DW, 2009, NUCLEIC ACIDS RES, V37, P1, DOI 10.1093/nar/gkn923
   Hughes AE, 2007, PLOS MED, V4, P1993, DOI 10.1371/journal.pmed.0040355
   Jacob Louis, 2017, Ger Med Sci, V15, pDoc04, DOI 10.3205/000245
   Jarrett SG, 2012, MOL ASPECTS MED, V33, P399, DOI 10.1016/j.mam.2012.03.009
   Kawashima Y, 2015, GRAEF ARCH CLIN EXP, V253, P1471, DOI 10.1007/s00417-014-2838-5
   Kirchheiner J, 2005, NAT REV DRUG DISCOV, V4, P639, DOI 10.1038/nrd1801
   Klein ML, 2008, OPHTHALMOLOGY, V115, P1019, DOI 10.1016/j.ophtha.2008.01.036
   Kloeckener-Gruissem B, 2011, INVEST OPHTH VIS SCI, V52, P4694, DOI 10.1167/iovs.10-6080
   Lambert NG, 2016, PROG RETIN EYE RES, V54, P64, DOI 10.1016/j.preteyeres.2016.04.003
   Lazzeri S, 2016, PHARMACOGENOMICS, V17, P27, DOI 10.2217/pgs.15.153
   Lazzeri S, 2013, PHARMACOGENOMICS, V14, P623, DOI [10.2217/PGS.13.43, 10.2217/pgs.13.43]
   Lederman M, 2010, INVEST OPHTH VIS SCI, V51, P53, DOI 10.1167/iovs.08-3019
   Lee AY, 2009, BRIT J OPHTHALMOL, V93, P610, DOI 10.1136/bjo.2008.150995
   Lepre T, 2011, AM J OPHTHALMOL, V152, P325, DOI 10.1016/j.ajo.2011.04.021
   Liew G, 2008, J AM SOC NEPHROL, V19, P806, DOI 10.1681/ASN.2007080844
   Lukiw WJ, 2012, MOL NEUROBIOL, V46, P11, DOI 10.1007/s12035-012-8234-4
   Lukiw Walter J, 2012, Int J Biochem Mol Biol, V3, P105
   Majchrzak-Celinska A, 2017, EXPERT OPIN DRUG MET, V13, P387, DOI 10.1080/17425255.2017.1260546
   Marazita MC, 2016, REDOX BIOL, V7, P78, DOI 10.1016/j.redox.2015.11.011
   Matuskova V., 2017, OPHTHALMIC GENET, P1
   McKibbin M, 2012, BRIT J OPHTHALMOL, V96, P208, DOI 10.1136/bjo.2010.193680
   Medina FM, 2015, OPHTHALMIC RES, V54, P169, DOI 10.1159/000439172
   Meyers KJ, 2015, OPHTHALMOLOGY, V122, P2286, DOI 10.1016/j.ophtha.2015.07.029
   Newman AM, 2012, GENOME MED, V4, DOI [10.1186/PREACCEPT-1418491035586234, 10.1186/gm315]
   Nischler C, 2011, ACTA OPHTHALMOL, V89, pE344, DOI 10.1111/j.1755-3768.2010.02080.x
   Orlin A, 2012, RETINA-J RET VIT DIS, V32, P4, DOI 10.1097/IAE.0b013e31822a2c7c
   Parmeggiani F, 2015, INT J MOL SCI, V16, P19796, DOI 10.3390/ijms160819796
   Pinazo-Duran M. D., 2016, BIOMED RES INT, V2016
   Ricci F, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0066978
   Ricci F, 2009, ARCH OPHTHALMOL-CHIC, V127, P1368, DOI 10.1001/archophthalmol.2009.237
   SanGiovanni JP, 2017, CLIN CHEM LAB MED, V55, P763, DOI 10.1515/cclm-2016-0898
   Schmidl D, 2015, ACTA OPHTHALMOL, V93, P105, DOI 10.1111/aos.12650
   Schramm EC, 2014, MOL IMMUNOL, V61, P118, DOI 10.1016/j.molimm.2014.06.032
   Schwartz SG, 2005, OPHTHALMOLOGY, V112, P2131, DOI 10.1016/j.ophtha.2005.08.014
   Schwartz SG, 2017, CURR PHARM DESIGN, V23, P547, DOI 10.2174/1381612822666161208114847
   Seddon JM, 2016, BRIT J OPHTHALMOL, V100, P1731, DOI 10.1136/bjophthalmol-2016-308624
   Shen H, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0059494
   Smailhodzic D, 2012, OPHTHALMOLOGY, V119, P2304, DOI 10.1016/j.ophtha.2012.05.040
   Sobrin L, 2014, PROG RETIN EYE RES, V40, P1, DOI 10.1016/j.preteyeres.2013.12.004
   Sofat R, 2012, INT J EPIDEMIOL, V41, P250, DOI 10.1093/ije/dyr204
   Stone EM, 2012, OPHTHALMOLOGY, V119, P2408, DOI 10.1016/j.ophtha.2012.05.047
   Strunnikova NV, 2010, HUM MOL GENET, V19, P2468, DOI 10.1093/hmg/ddq129
   Sun C, 2007, OPHTHAL EPIDEMIOL, V14, P127, DOI 10.1080/09286580601186742
   Teper SJ, 2010, MOL VIS, V16, P2598
   Tian J, 2012, PHARMACOGENOMICS, V13, P779, DOI [10.2217/PGS.12.53, 10.2217/pgs.12.53]
   Vassilev ZP, 2015, INVEST OPHTH VIS SCI, V56, P1585, DOI 10.1167/iovs.14-16271
   WANG J, 2016, BIOMED RES INT, V2016, DOI DOI 10.1155/2016/8212063
   Wang J, 2013, NUCLEIC ACIDS RES, V41, pW77, DOI 10.1093/nar/gkt439
   Weikel KA, 2012, MOL ASPECTS MED, V33, P318, DOI 10.1016/j.mam.2012.03.005
   Weiner DE, 2011, NEPHROL DIAL TRANSPL, V26, P3159, DOI 10.1093/ndt/gfr022
   Wickremasinghe SS, 2011, INVEST OPHTH VIS SCI, V52, P4072, DOI 10.1167/iovs.10-6550
   Wieberdink RG, 2011, STROKE, V42, P2138, DOI 10.1161/STROKEAHA.111.616359
   Williams MA, 2015, AM J GERIAT PSYCHIAT, V23, P1290, DOI 10.1016/j.jagp.2015.06.005
   Wong TY, 2007, OPHTHALMOLOGY, V114, P86, DOI 10.1016/j.ophtha.2006.06.039
   Wong TY, 2006, ANN INTERN MED, V145, P98, DOI 10.7326/0003-4819-145-2-200607180-00007
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Woo SJ, 2012, OPHTHALMOLOGY, V119, P2094, DOI 10.1016/j.ophtha.2012.04.026
   Wray NR, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1000864
   Wu J., 2014, PLOS ONE, V3
   You Q. S., 2017, RETINA, DOI [10.1097/IAE, DOI 10.1097/IAE]
   Yu AM, 2016, DRUG METAB DISPOS, V44, P308, DOI 10.1124/dmd.115.067470
   Yu Y, 2011, HUM MOL GENET, V20, P3699, DOI 10.1093/hmg/ddr270
   Zaichuk TA, 2004, J EXP MED, V199, P1513, DOI 10.1084/jem.20040474
   Zampatti S, 2014, NUTR RES, V34, P95, DOI 10.1016/j.nutres.2013.10.011
   Zeng FX, 2013, GRAEF ARCH CLIN EXP, V251, P2539, DOI 10.1007/s00417-013-2442-0
   Zetterberg M, 2008, AM J MED GENET B, V147B, P720, DOI 10.1002/ajmg.b.30668
   Zhao L, 2013, CURR MOL MED, V13, P929, DOI 10.2174/15665240113139990048
NR 109
TC 45
Z9 46
U1 0
U2 8
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 1350-9462
EI 1873-1635
J9 PROG RETIN EYE RES
JI Prog. Retin. Eye Res.
PD MAR
PY 2018
VL 63
BP 132
EP 146
DI 10.1016/j.preteyeres.2017.11.004
PG 15
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA GD6UX
UT WOS:000430645100006
PM 29197628
DA 2022-11-30
ER

PT J
AU Vural, E
   Hazar, L
   Karakukcu, C
   Arslan, ME
   Sirem, MR
   Sirakaya, E
   Ozsaygili, C
   Cicek, A
AF Vural, Esra
   Hazar, Leyla
   Karakukcu, Cigdem
   Arslan, M. Erkam
   Sirem, M. Rasit
   Sirakaya, Ender
   Ozsaygili, Cemal
   Cicek, Ayse
TI Apelin-13: A Promising Biomarker for Age-Related Macular Degeneration?
SO OPHTHALMOLOGICA
LA English
DT Article
DE Apelin; Choroid; Macular degeneration; Retina
ID CHOROIDAL THICKNESS; APELIN/APJ SYSTEM; RECEPTOR; PEPTIDE; RETINA;
   TARGET; LIGAND; CELLS; GENE
AB Purpose: To investigate the value of serum apelin-13 levels in patients with age-related macular degeneration (AMD). Methods: Patients with dry-type AMD, patients with treatment-naive neovascular-type AMD, and healthy controls were included in this study. Diagnoses were confirmed on detailed fundus examination, optical coherence tomography (OCT), and fundus fluorescein angiography (FFA). Central foveal thickness and subfoveal choroidal thickness were evaluated. Both serum apelin-13 and vascular endothelial growth factor (VEGF) levels were measured by a competitive enzyme-linked immunosorbent assay (ELISA) principle. Results: A total of 84 subjects, i.e., 24 in the dry-type AMD group (group 1), 27 in the neovascular-type AMD group (group 2), and 33 in the control group (group 3) were included in the study. Mean best-corrected visual acuity (BCVA) was 76 +/- 4.5, 48.4 +/- 16.3, and 83.4 +/- 3.09 ETDRS letters in group 1, 2, and 3, respectively. The level of serum VEGF was 44.11 +/- 26.14, 56.53 +/- 53.77, and 61.47 +/- 41.62 pg/mL in groups 1, 2, and 3, respectively (p = 0.553, p = 0.286, and p = 0.896, respectively). The level of serum apelin-13 was 586.47 +/- 167.56, 622.18 +/- 324.52, and 379.31 +/- 171.96 pg/mL in groups 1, 2, and 3, respectively (p = 0.847, p = 0.04, and p <= 0.001, respectively). There was a negative correlation between the level of serum apelin and visual acuity (VA) and choroidal thickness. Conclusion: Serum apelin-13 levels were higher in both dry-type and neovascular-type AMD patients than in controls. Further studies demonstrating the relationship of the level of serum apelin-13 and AMD are needed.
C1 [Vural, Esra; Arslan, M. Erkam; Sirem, M. Rasit; Sirakaya, Ender; Ozsaygili, Cemal; Cicek, Ayse] Kayseri City Hosp, Dept Ophthalmol, TR-38010 Kayseri, Turkey.
   [Hazar, Leyla] Kiziltepe State Hosp, Clin Ophthalmol, Mardin, Turkey.
   [Karakukcu, Cigdem] Kayseri City Hosp, Dept Biochem, Kayseri, Turkey.
C3 Kiziltepe State Hospital
RP Vural, E (通讯作者)，Kayseri City Hosp, Dept Ophthalmol, TR-38010 Kayseri, Turkey.
EM vural_esra@yahoo.com
RI OZSAYGILI, CEMAL/AAH-3081-2019
OI OZSAYGILI, CEMAL/0000-0002-8236-1728
CR Anderson DH, 2002, AM J OPHTHALMOL, V134, P411, DOI 10.1016/S0002-9394(02)01624-0
   Du JH, 2014, INT J OPHTHALMOL-CHI, V7, P968, DOI 10.3980/j.issn.2222-3959.2014.06.10
   Han LJ, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0134543
   Hara C, 2013, INVEST OPHTH VIS SCI, V54, P4321, DOI 10.1167/iovs.13-11611
   Hu HL, 2016, MOL GENET METAB, V119, P20, DOI 10.1016/j.ymgme.2016.07.012
   Kalantaripour TP, 2016, BIOMED PHARMACOTHER, V84, P258, DOI 10.1016/j.biopha.2016.09.048
   Kasai A, 2004, BIOCHEM BIOPH RES CO, V325, P395, DOI 10.1016/j.bbrc.2004.10.042
   Kasai A, 2013, ANGIOGENESIS, V16, P723, DOI 10.1007/s10456-013-9349-6
   Kasai A, 2010, ARTERIOSCL THROM VAS, V30, P2182, DOI 10.1161/ATVBAHA.110.209775
   Kawamata Y, 2001, BBA-MOL CELL RES, V1538, P162, DOI 10.1016/S0167-4889(00)00143-9
   Kojima Y, 2008, ARTERIOSCL THROM VAS, V28, P1687, DOI 10.1161/ATVBAHA.108.174847
   Lee DK, 2000, J NEUROCHEM, V74, P34, DOI 10.1046/j.1471-4159.2000.0740034.x
   Lee DK, 2005, ENDOCRINOLOGY, V146, P231, DOI 10.1210/en.2004-0359
   Li LF, 2012, AM J PHYSIOL-HEART C, V303, pH605, DOI 10.1152/ajpheart.00366.2012
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Liu JH, 2000, J BIOL CHEM, V275, P29354, DOI 10.1074/jbc.M910191199
   Loewen N, 2009, EXP EYE RES, V88, P928, DOI 10.1016/j.exer.2008.11.037
   Lu Q, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0069703
   Masri B, 2004, FASEB J, V18, P1909, DOI 10.1096/fj.04-1930fje
   Masri Bernard, 2009, Journal de la Societe de Biologie, V203, P171, DOI 10.1051/jbio/2009021
   Mesmin C, 2010, RAPID COMMUN MASS SP, V24, P2875, DOI 10.1002/rcm.4718
   O'Donnell LA, 2007, J NEUROCHEM, V102, P1905, DOI 10.1111/j.1471-4159.2007.04645.x
   ODOWD BF, 1993, GENE, V136, P355, DOI 10.1016/0378-1119(93)90495-O
   Rezzola S, 2014, ANGIOGENESIS, V17, P429, DOI 10.1007/s10456-013-9398-x
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Saint-Geniez M, 2003, GENE EXPR PATTERNS, V3, P467, DOI 10.1016/S1567-133X(03)00062-0
   Simpkin JC, 2007, BASIC RES CARDIOL, V102, P518, DOI 10.1007/s00395-007-0671-2
   Tatemoto K, 1998, BIOCHEM BIOPH RES CO, V251, P471, DOI 10.1006/bbrc.1998.9489
   Vinel C, 2018, NAT MED, V24, P1360, DOI 10.1038/s41591-018-0131-6
   Vural E, 2018, RETINA-J RET VIT DIS, V38, P614, DOI 10.1097/IAE.0000000000001557
   Wu LL, 2017, CLIN CHIM ACTA, V466, P78, DOI 10.1016/j.cca.2016.12.023
   Yiu G, 2015, AM J OPHTHALMOL, V159, P617, DOI 10.1016/j.ajo.2014.12.010
   Zhao T, 2011, MOL VIS, V17, P1044
NR 33
TC 3
Z9 3
U1 2
U2 2
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 0030-3755
EI 1423-0267
J9 OPHTHALMOLOGICA
JI Ophthalmologica
PD MAY
PY 2021
VL 244
IS 2
BP 102
EP 109
DI 10.1159/000513050
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA RY0TU
UT WOS:000647629000002
PM 33197910
DA 2022-11-30
ER

PT J
AU Rickman, CB
   Farsiu, S
   Toth, CA
   Klingeborn, M
AF Rickman, Catherine Bowes
   Farsiu, Sina
   Toth, Cynthia A.
   Klingeborn, Mikael
TI Dry Age-Related Macular Degeneration: Mechanisms, Therapeutic Targets,
   and Imaging
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
DE drusen; complement; autophagy; functional imaging; therapeutic targets
ID RETINAL-PIGMENT EPITHELIUM; OPTICAL COHERENCE TOMOGRAPHY; FACTOR-H
   POLYMORPHISM; GEOGRAPHIC ATROPHY; OXIDATIVE STRESS; DRUSEN FORMATION;
   AUTOMATIC SEGMENTATION; COMPLEMENT ACTIVATION; BRUCHS MEMBRANE; EYE
   DISEASE
AB Age-related macular degeneration is the leading cause of irreversible visual dysfunction in individuals over 65 in Western Society. Patients with AMD are classified as having early stage disease (early AMD), in which visual function is affected, or late AMD (generally characterized as either "wet" neovascular AMD, "dry" atrophic AMD or both), in which central vision is severely compromised or lost. Until recently, there have been no therapies available to treat the disorder(s). Now, the most common wet form of late-stage AMD, choroidal neovascularization, generally responds to treatment with anti-vascular endothelial growth factor therapies. Nevertheless, there are no current therapies to restore lost vision in eyes with advanced atrophic AMD. Oral supplementation with the Age-Related Eye Disease Study (AREDS) or AREDS2 formulation (antioxidant vitamins C and E, lutein, zeaxanthin, and zinc) has been shown to reduce the risk of progression to advanced AMD, although the impact was in neovascular rather than atrophic AMD. Recent findings, however, have demonstrated several features of early AMD that are likely to be druggable targets for treatment. Studies have established that much of the genetic risk for AMD is associated with complement genes. Consequently, several complement-based therapeutic treatment approaches are being pursued. Potential treatment strategies against AMD deposit formation and protein and/or lipid deposition will be discussed, including anti-amyloid therapies. In addition, the role of autophagy in AMD and prevention of oxidative stress through modulation of the antioxidant system will be explored. Finally, the success of these new therapies in clinical trials and beyond relies on early detection, disease typing, and predicting disease progression, areas that are currently being rapidly transformed by improving imaging modalities and functional assays.
C1 [Rickman, Catherine Bowes; Farsiu, Sina; Toth, Cynthia A.; Klingeborn, Mikael] Duke Univ, Med Ctr, Dept Ophthalmol, Durham, NC 27706 USA.
   [Rickman, Catherine Bowes] Duke Univ, Med Ctr, Dept Cell Biol, Durham, NC 27706 USA.
   [Farsiu, Sina; Toth, Cynthia A.] Duke Univ, Med Ctr, Dept Biomed Engn, Durham, NC 27706 USA.
C3 Duke University; Duke University; Duke University
RP Rickman, CB (通讯作者)，Duke Eye Ctr, DUMC Box 3802,AERI Rm 5010, Durham, NC 27710 USA.
EM bowes007@duke.edu
RI Toth, Cynthia/L-5534-2019; Klingeborn, Mikael/AAC-2471-2019
OI Toth, Cynthia/0000-0002-2324-0854; Klingeborn,
   Mikael/0000-0003-2907-0371; Bowes Rickman,
   Catherine/0000-0002-8555-9596; Farsiu, Sina/0000-0003-4872-2902
FU National Institutes of Health [EY019038, P30 EY005722]; Edward N. &
   Della L. Thome Memorial Foundation Award; Genentech; NATIONAL EYE
   INSTITUTE [R01EY019038, P30EY005722] Funding Source: NIH RePORTER
FX Supported by National Institutes of Health Grants EY019038 (CBR), P30
   EY005722, and an Edward N. & Della L. Thome Memorial Foundation Award
   (CBR), Genentech Grant in support of AREDS2 Ancillary SDOCT Study (CAT).
CR Ahlers C, 2010, INVEST OPHTH VIS SCI, V51, P2149, DOI 10.1167/iovs.09-3817
   Al-Hussaini H, 2009, EXP EYE RES, V88, P610, DOI 10.1016/j.exer.2008.09.021
   Alers S, 2012, MOL CELL BIOL, V32, P2, DOI 10.1128/MCB.06159-11
   ALGVERE PV, 1994, GRAEF ARCH CLIN EXP, V232, P707, DOI 10.1007/BF00184273
   Ambati J, 2002, ARCH OPHTHALMOL-CHIC, V120, P997
   Ambati J, 2013, NAT REV IMMUNOL, V13, P438, DOI 10.1038/nri3459
   Anderson DH, 2002, AM J OPHTHALMOL, V134, P411, DOI 10.1016/S0002-9394(02)01624-0
   Anderson DH, 2001, AM J OPHTHALMOL, V131, P767, DOI 10.1016/S0002-9394(00)00961-2
   Anderson DH, 2010, PROG RETIN EYE RES, V29, P95, DOI 10.1016/j.preteyeres.2009.11.003
   [Anonymous], 1992, Arch Ophthalmol, V110, P1701
   [Anonymous], 1993, Arch Ophthalmol, V111, P104
   Armstrong RA, 2008, NEUROPATHOLOGY, V28, P351, DOI 10.1111/j.1440-1789.2008.00916.x
   Armstrong RA, 2009, FOLIA NEUROPATHOL, V47, P289
   Atmaca-Sonmez P, 2006, EXP EYE RES, V83, P1295, DOI 10.1016/j.exer.2006.07.013
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   Bergmann M, 2004, FASEB J, V18, P562, DOI 10.1096/fj.03-0289fje
   Binder S, 2007, PROG RETIN EYE RES, V26, P516, DOI 10.1016/j.preteyeres.2007.02.002
   Binder S, 2011, BRIT J OPHTHALMOL, V95, P441, DOI 10.1136/bjo.2009.171926
   Bird AC, 2010, J CLIN INVEST, V120, P3033, DOI 10.1172/JCI42437
   Boretsky A, 2012, LASER SURG MED, V44, P603, DOI 10.1002/lsm.22070
   Boulton M. E., 2009, FUNDUS AUTOFLUORESCE, P14
   Brader HS, 2011, INVEST OPHTH VIS SCI, V52, P9218, DOI 10.1167/iovs.11-7493
   Brar M, 2009, AM J OPHTHALMOL, V148, P439, DOI 10.1016/j.ajo.2009.04.022
   BRESSLER NM, 1989, ARCH OPHTHALMOL-CHIC, V107, P847, DOI 10.1001/archopht.1989.01070010869032
   Buschini E, 2011, PROG NEUROBIOL, V95, P14, DOI 10.1016/j.pneurobio.2011.05.011
   Cano M, 2010, VISION RES, V50, P652, DOI 10.1016/j.visres.2009.08.018
   Chan CC, 2005, HISTOL HISTOPATHOL, V20, P857, DOI 10.14670/HH-20.857
   Chang B, 2002, VISION RES, V42, P517, DOI 10.1016/S0042-6989(01)00146-8
   Cherepanoff S, 2010, BRIT J OPHTHALMOL, V94, P918, DOI 10.1136/bjo.2009.165563
   Chiu SJ, 2013, SPIE PHOT W OPHTH TE
   Chiu SJ, 2012, BIOMED OPT EXPRESS, V3, P1127, DOI 10.1364/BOE.3.001127
   Chiu SJ, 2012, INVEST OPHTH VIS SCI, V53, P53, DOI 10.1167/iovs.11-7640
   Chiu SJ, 2010, OPT EXPRESS, V18, P19413, DOI 10.1364/OE.18.019413
   Christenbury JG, 2013, OPHTHALMOLOGY, V120, P1038, DOI 10.1016/j.ophtha.2012.10.018
   Coffey PJ, 2007, P NATL ACAD SCI USA, V104, P16651, DOI 10.1073/pnas.0705079104
   Combadiere C, 2007, J CLIN INVEST, V117, P2920, DOI 10.1172/JCI31692
   Couch SM, 2011, SEMIN OPHTHALMOL, V26, P114, DOI 10.3109/08820538.2011.577130
   Cousins SW, 2004, ARCH OPHTHALMOL-CHIC, V122, P1013, DOI 10.1001/archopht.122.7.1013
   Crabb JW, 2002, P NATL ACAD SCI USA, V99, P14682, DOI 10.1073/pnas.222551899
   Cramer PE, 2012, SCIENCE, V335, P1503, DOI 10.1126/science.1217697
   Curcio CA, 2013, STRUCTURE FUNCTIONS
   Curcio CA, 2011, BRIT J OPHTHALMOL, V95, P1638, DOI 10.1136/bjophthalmol-2011-300344
   DASTGHEIB K, 1994, ARCH OPHTHALMOL-CHIC, V112, P813, DOI 10.1001/archopht.1994.01090180111045
   Davis MD, 2005, ARCH OPHTHALMOL-CHIC, V123, P1484
   de Jong PTVM, 2006, NEW ENGL J MED, V355, P1474, DOI 10.1056/NEJMra062326
   DeBuc C., 2011, IMAGE SEG, V1, P15, DOI DOI 10.5772/628
   Dimitrov PN, 2012, INVEST OPHTH VIS SCI, V53, P5213, DOI 10.1167/iovs.11-8958
   Dimitrov PN, 2011, INVEST OPHTH VIS SCI, V52, P9457, DOI 10.1167/iovs.10-7043
   Ding JD, 2008, VISION RES, V48, P339, DOI 10.1016/j.visres.2007.07.025
   Ding JD, 2011, P NATL ACAD SCI USA, V108, pE279, DOI 10.1073/pnas.1100901108
   Dorey K, 1993, RETINAL DEGENERATION, P3
   Du HJ, 2011, SEMIN OPHTHALMOL, V26, P216, DOI 10.3109/08820538.2011.577498
   Dubra A, 2011, BIOMED OPT EXPRESS, V2, P1864, DOI 10.1364/BOE.2.001864
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Eskelinen EL, 2008, INT REV CEL MOL BIO, V266, P207, DOI 10.1016/S1937-6448(07)66005-5
   Fang L, IEEE T MED IN PRESS
   Fang LY, 2012, BIOMED OPT EXPRESS, V3, P927, DOI 10.1364/BOE.3.000927
   Farsiu S, OPHTHALMOLO IN PRESS
   FEENEYBURNS L, 1984, INVEST OPHTH VIS SCI, V25, P195
   Ferris FL, 2005, ARCH OPHTHALMOL-CHIC, V123, P1570
   Ferris FL, 2002, ARCH OPHTHALMOL-CHIC, V120, P997
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Finnemann SC, 2002, P NATL ACAD SCI USA, V99, P3842, DOI 10.1073/pnas.052025899
   Fitz NF, 2013, SCIENCE, V340, DOI 10.1126/science.1235809
   FRIEDMAN E, 1968, ARCH OPHTHALMOL-CHIC, V79, P315, DOI 10.1001/archopht.1968.03850040317017
   Gestwicki JE, 2012, PROG MOL BIOL TRANSL, V107, P327, DOI 10.1016/B978-0-12-385883-2.00003-5
   Ghetti B, 1996, BRAIN PATHOL, V6, P127, DOI 10.1111/j.1750-3639.1996.tb00796.x
   Godara Pooja, 2010, Ophthalmic Surg Lasers Imaging, V41 Suppl, pS104, DOI 10.3928/15428877-20101031-07
   Godara P, 2010, OPTOMETRY VISION SCI, V87, P930, DOI 10.1097/OPX.0b013e3181ff9a8b
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   GOLDBERG J, 1988, AM J EPIDEMIOL, V128, P700, DOI 10.1093/oxfordjournals.aje.a115023
   Gonzalez-Cordero A, 2013, NAT BIOTECHNOL, V31, P741, DOI 10.1038/nbt.2643
   Green W R, 1999, Mol Vis, V5, P27
   Gregori G, 2011, OPHTHALMOLOGY, V118, P1373, DOI 10.1016/j.ophtha.2010.11.013
   Grossniklaus HE, 2002, MOL VIS, V8, P119
   Gupta N, 2003, EXP EYE RES, V76, P463, DOI 10.1016/S0014-4835(02)00332-9
   Hageman GS, 1999, MOL VIS, V5
   Hageman GS, 1999, FASEB J, V13, P477, DOI 10.1096/fasebj.13.3.477
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Handa JT, 2012, MOL ASPECTS MED, V33, P418, DOI 10.1016/j.mam.2012.03.006
   Hanisch UK, 2007, NAT NEUROSCI, V10, P1387, DOI 10.1038/nn1997
   Hendargo HC, 2013, BIOMED OPT EXPRESS, V4, P803, DOI 10.1364/BOE.4.000803
   Holz FG, 2001, INVEST OPHTH VIS SCI, V42, P1051
   Hu YT, 2012, OPHTHALMIC RES, V48, P186, DOI 10.1159/000338749
   HUANG D, 1991, SCIENCE, V254, P1178, DOI 10.1126/science.1957169
   Hwang JC, 2006, INVEST OPHTH VIS SCI, V47, P2655, DOI 10.1167/iovs.05-1027
   Isas JM, 2010, INVEST OPHTH VIS SCI, V51, P1304, DOI 10.1167/iovs.09-4207
   Jain N, 2010, INVEST OPHTH VIS SCI, V51, P4875, DOI 10.1167/iovs.09-4962
   Jampol LM, 2001, ARCH OPHTHALMOL-CHIC, V119, P1533
   Jarrett SG, 2012, MOL ASPECTS MED, V33, P399, DOI 10.1016/j.mam.2012.03.009
   Jiang Q, 2008, NEURON, V58, P681, DOI 10.1016/j.neuron.2008.04.010
   Jo N, 2006, AM J PATHOL, V168, P2036, DOI 10.2353/ajpath.2006.050588
   Johnson LV, 2011, P NATL ACAD SCI USA, V108, P18277, DOI 10.1073/pnas.1109703108
   Johnson LR, 2000, IEEE ANN HIST COMPUT, V22, P70
   Johnson LV, 2001, EXP EYE RES, V73, P887, DOI 10.1006/exer.2001.1094
   Johnson LV, 2002, P NATL ACAD SCI USA, V99, P11830, DOI 10.1073/pnas.192203399
   Kaarniranta K, 2013, AUTOPHAGY, V9, P973, DOI 10.4161/auto.24546
   Kaemmerer E, 2007, INVEST OPHTH VIS SCI, V48, P1342, DOI 10.1167/iovs.06-0549
   Kajic V, 2012, BIOMED OPT EXPRESS, V3, P86, DOI 10.1364/BOE.3.000086
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   King HW, 2012, BMC CANCER, V12, DOI 10.1186/1471-2407-12-421
   Klein ML, 2008, OPHTHALMOLOGY, V115, P1026, DOI 10.1016/j.ophtha.2007.08.030
   Klein R, 1997, OPHTHALMOLOGY, V104, P7, DOI 10.1016/S0161-6420(97)30368-6
   Klein R, 2002, OPHTHALMOLOGY, V109, P1767, DOI 10.1016/S0161-6420(02)01146-6
   KLEIN R, 1993, OPHTHALMOLOGY, V100, P406
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Klein R, 2010, ARCH OPHTHALMOL-CHIC, V128, P750, DOI 10.1001/archophthalmol.2010.92
   Klein T, 2013, BIOMED OPT EXPRESS, V4, P619, DOI 10.1364/BOE.4.000619
   Klevering BJ, 2013, ANN M ASS RES VIS OP
   Klionsky DJ, 2007, AUTOPHAGY, V3, P413, DOI 10.4161/auto.4377
   Klionsky DJ, 2006, NATURE, V441, P819, DOI 10.1038/441819a
   Krishna Y, 2011, BRIT J OPHTHALMOL, V95, P569, DOI 10.1136/bjo.2009.169953
   Lally DR, 2012, CURR OPIN OPHTHALMOL, V23, P182, DOI 10.1097/ICU.0b013e328352411c
   Landa G, 2011, RETINA-J RET VIT DIS, V31, P364, DOI 10.1097/IAE.0b013e3181e91132
   Landa G, 2008, CURR EYE RES, V33, P1011, DOI 10.1080/02713680802484637
   Landreth GE, 2013, SCIENCE, V340, DOI 10.1126/science.1234114
   Langmann T, 2007, J LEUKOCYTE BIOL, V81, P1345, DOI 10.1189/jlb.0207114
   Leuschen JN, 2013, OPHTHALMOLOGY, V120, P140, DOI 10.1016/j.ophtha.2012.07.004
   Li KY, 2007, J OPT SOC AM A, V24, P1358, DOI 10.1364/JOSAA.24.001358
   Li ST, 2012, IEEE T BIO-MED ENG, V59, P3450, DOI 10.1109/TBME.2012.2217493
   Li Y, 2006, INVEST OPHTH VIS SCI, V47, P1646, DOI 10.1167/iovs.05-1092
   Liu J, 2008, INVEST OPHTH VIS SCI, V49, P772, DOI 10.1167/iovs.07-0675
   Lombardo M, 2013, SENSORS-BASEL, V13, P334, DOI 10.3390/s130100334
   Loquin K, 2012, AUTOMATIC PHOTORECEP
   Luhmann UFO, 2013, EXP EYE RES, V107, P80, DOI 10.1016/j.exer.2012.11.015
   Maiese K, 2013, TRENDS MOL MED, V19, P51, DOI 10.1016/j.molmed.2012.11.001
   Mattapallil MJ, 2012, INVEST OPHTH VIS SCI, V53, P2921, DOI 10.1167/iovs.12-9662
   Mettu PS, 2012, MOL ASPECTS MED, V33, P376, DOI 10.1016/j.mam.2012.04.006
   Miller JW, 2013, AM J OPHTHALMOL, V155, P1, DOI 10.1016/j.ajo.2012.10.018
   Moeller SM, 2006, ARCH OPHTHALMOL-CHIC, V124, P1151, DOI 10.1001/archopht.124.8.1151
   Motaghiannezam R, 2012, INVEST OPHTH VIS SCI, V53, P2337, DOI 10.1167/iovs.11-7823
   Mullins RF, 2000, FASEB J, V14, P835, DOI 10.1096/fasebj.14.7.835
   Munch IC, 2007, INVEST OPHTH VIS SCI, V48, P833, DOI 10.1167/iovs.06-0529
   Owsley C, 2000, INVEST OPHTH VIS SCI, V41, P267
   Owsley C, 2001, OPHTHALMOLOGY, V108, P1196, DOI 10.1016/S0161-6420(01)00580-2
   Pastore N, 2013, EMBO MOL MED, V5, P397, DOI 10.1002/emmm.201202046
   Patryas L, 2013, GRAEF ARCH CLIN EXP, V251, P1821, DOI 10.1007/s00417-013-2324-5
   Pearson RA, 2012, NATURE, V485, P99, DOI 10.1038/nature10997
   Pickering MC, 2002, NAT GENET, V31, P424, DOI 10.1038/ng912
   Price AR, 2013, SCIENCE, V340, DOI 10.1126/science.1234089
   Puell MC, 2012, INVEST OPHTH VIS SCI, V53, P7310, DOI 10.1167/iovs.11-8649
   Ravikumar B, 2002, HUM MOL GENET, V11, P1107, DOI 10.1093/hmg/11.9.1107
   Revesz T, 2009, ACTA NEUROPATHOL, V118, P115, DOI 10.1007/s00401-009-0501-8
   Rogue RS, 1999, BRAIN RES, V836, P110, DOI 10.1016/S0006-8993(99)01625-X
   Roorda A, 2007, INVEST OPHTH VIS SCI, V48, P2297, DOI 10.1167/iovs.06-1450
   Rudolf M, 2008, INVEST OPHTH VIS SCI, V49, P1200, DOI 10.1167/iovs.07-1466
   Rudolf M, 2013, OPHTHALMOLOGY, V120, P821, DOI 10.1016/j.ophtha.2012.10.007
   Ryhanen T, 2008, EUR J PHARMACOL, V584, P229, DOI 10.1016/j.ejphar.2008.02.010
   Sakaguchi H, 2002, EXP EYE RES, V74, P547, DOI 10.1006/exer.2002.1186
   Salminen A, 2009, TRENDS MOL MED, V15, P217, DOI 10.1016/j.molmed.2009.03.004
   Schuman SG, 2009, OPHTHALMOLOGY, V116, P488, DOI 10.1016/j.ophtha.2008.10.006
   SEDDON JM, 1994, JAMA-J AM MED ASSOC, V272, P1413, DOI 10.1001/jama.272.18.1413
   Seigel D, 2002, ARCH OPHTHALMOL-CHIC, V120, P100
   Sene A, 2013, CELL METAB, V17, P549, DOI 10.1016/j.cmet.2013.03.009
   Sengupta N, 2009, MOL THER, V17, P1594, DOI 10.1038/mt.2009.145
   Spaide RF, 1999, RETINA-J RET VIT DIS, V19, P141, DOI 10.1097/00006982-199902000-00010
   Sparrow JR, 2005, EXP EYE RES, V80, P595, DOI 10.1016/j.exer.2005.01.007
   Sunness JS, 2008, J VISUAL IMPAIR BLIN, V102, P600
   Sunness JS, 2008, OPHTHALMOLOGY, V115, P1480, DOI 10.1016/j.ophtha.2008.03.009
   Tan JSL, 2008, OPHTHALMOLOGY, V115, P334, DOI 10.1016/j.ophtha.2007.03.083
   Tesseur I, 2013, SCIENCE, V340, DOI 10.1126/science.1233937
   Thurman JM, 2006, J IMMUNOL, V176, P1305, DOI 10.4049/jimmunol.176.3.1305
   Tomany SC, 2004, OPHTHALMOLOGY, V111, P1280, DOI 10.1016/j.ophtha.2003.11.010
   Tou JS, 2004, FASEB J, V18, P1297, DOI 10.1096/fj.04-1862fje
   TSO MOM, 1967, ARCH OPHTHALMOL-CHIC, V78, P641, DOI 10.1001/archopht.1967.00980030643016
   Tuo JS, 2007, INVEST OPHTH VIS SCI, V48, P3827, DOI 10.1167/iovs.07-0051
   VandenLangenberg GM, 1998, AM J EPIDEMIOL, V148, P204, DOI 10.1093/oxfordjournals.aje.a009625
   Veeraraghavalu K, 2013, SCIENCE, V340, DOI 10.1126/science.1235505
   Vessey KA, 2012, INVEST OPHTH VIS SCI, V53, P7833, DOI 10.1167/iovs.12-10650
   VINGERLING JR, 1995, OPHTHALMOLOGY, V102, P205
   Vishwanathan R, 2013, INVEST OPHTH VIS SCI, V54, P3985, DOI 10.1167/iovs.12-11552
   Waelter S, 2001, MOL BIOL CELL, V12, P1393, DOI 10.1091/mbc.12.5.1393
   Wang AL, 2009, AUTOPHAGY, V5, P563, DOI 10.4161/auto.5.4.8163
   Wang AL, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004160
   Wang AL, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005304
   Wang L, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010329
   Weismann D, 2011, NATURE, V478, P76, DOI 10.1038/nature10449
   Xue B, 2007, J OPT SOC AM A, V24, P1364, DOI 10.1364/JOSAA.24.001364
   Yates JRW, 2007, NEW ENGL J MED, V357, P553, DOI 10.1056/NEJMoa072618
   Yehoshua Z, 2011, OPHTHALMOLOGY, V118, P679, DOI 10.1016/j.ophtha.2010.08.018
   Zawadzki RJ, 2007, J BIOMED OPT, V12, DOI 10.1117/1.2772658
   Zhao C, 2011, J CLIN INVEST, V121, P369, DOI 10.1172/JCI44303
   Zotter S, 2012, BIOMED OPT EXPRESS, V3, P2720, DOI 10.1364/BOE.3.002720
NR 185
TC 162
Z9 164
U1 2
U2 25
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD DEC
PY 2013
VL 54
IS 14
SI SI
BP ORSF68
EP ORSF80
DI 10.1167/iovs.13-12757
PG 13
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 278IX
UT WOS:000328884600013
PM 24335072
OA Green Published
DA 2022-11-30
ER

PT J
AU Spencer, KL
   Olson, LM
   Anderson, BM
   Schnetz-Boutaud, N
   Scott, WK
   Gallins, P
   Agarwal, A
   Postel, EA
   Pericak-Vance, MA
   Haines, JL
AF Spencer, Kylee L.
   Olson, Lana M.
   Anderson, Brent M.
   Schnetz-Boutaud, Nathalie
   Scott, William K.
   Gallins, Paul
   Agarwal, Anita
   Postel, Eric A.
   Pericak-Vance, Margaret A.
   Haines, Jonathan L.
TI C3 R102G polymorphism increases risk of age-related macular degeneration
SO HUMAN MOLECULAR GENETICS
LA English
DT Article
ID MOLECULAR ANALYSIS; GENERAL PEDIGREES; ASSOCIATION; ALLOTYPES; GENETICS;
   DISEASE; VARIANT
AB Inflammation has long been suspected to play a role in the pathogenesis of age-related macular degeneration (AMD). Association of variants in the complement factor H (CFH) and complement factor B (CFB) genes has targeted the search for additional loci to the alternative complement cascade, of which C3 is a major component. Two non-synonymous coding polymorphisms within C3, R102G and L314P, have previously been strongly associated with increased risk. These variants are in strong linkage disequilibrium (LD), making the contribution of this locus to AMD even more difficult to ascertain. We sought to determine whether the C3 association resulted primarily from only one of these two variants or from a combined effect of both in 223 families and an independent dataset of 701 cases and 286 unrelated controls. The C3 polymorphisms were in strong LD (r (2) = 0.85), and both were associated in the family-based and case-control datasets (R102G genoPDT P = 0.02, case-control genotypic P = 0.004; L314P genoPDT P = 0.001, case-control genotypic P = 0.04). In conditional analyses in the case-control dataset, R102G remained associated with disease in the L314P risk allele carriers (P = 0.01), but there was no effect of L314P in the R102G risk allele carriers (P = 0.2). After adjusting for age, smoking, CFH Y402H, LOC387715 A69S, and CFB R32Q, the effect of R102G remained strong [P = 0.015, odds ratio = 1.55, 95% confidence interval 1.09 to 2.21, adjusted PAR(population attributable risk) = 0.17]. Therefore, while the strong LD between R102G and L314P makes it difficult to disentangle their individual effects on disease risk, the R102G polymorphism acting alone provides the best model for disease in our data.
C1 [Spencer, Kylee L.; Olson, Lana M.; Anderson, Brent M.; Schnetz-Boutaud, Nathalie; Haines, Jonathan L.] Vanderbilt Univ, Ctr Human Genet Res, Nashville, TN 37232 USA.
   [Agarwal, Anita] Vanderbilt Univ, Vanderbilt Eye Inst, Med Ctr, Nashville, TN 37232 USA.
   [Postel, Eric A.] Duke Univ, Med Ctr, Dept Ophthalmol, Durham, NC 27710 USA.
   [Postel, Eric A.] Duke Univ, Ctr Eye, Durham, NC USA.
   [Scott, William K.; Gallins, Paul; Pericak-Vance, Margaret A.] Univ Miami, Inst Human Genom, Miami, FL USA.
C3 Vanderbilt University; Vanderbilt University; Duke University; Duke
   University; University of Miami
RP Spencer, KL (通讯作者)，Vanderbilt Univ, Ctr Human Genet Res, 525 Light Hall,2215 Garland Ave, Nashville, TN 37232 USA.
EM kylee.spencer@vanderbilt.edu
RI Scott, William/A-7593-2009; Haines, Jonathan/C-3374-2012
OI Haines, Jonathan/0000-0002-4351-4728; Scott, William/0000-0001-9336-6404
FU NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000095] Funding Source: NIH
   RePORTER; NATIONAL EYE INSTITUTE [U10EY012118, R01EY012118] Funding
   Source: NIH RePORTER; NCRR NIH HHS [M01 RR-00095] Funding Source:
   Medline; NEI NIH HHS [EY12118] Funding Source: Medline
CR ARVILOMMI H, 1974, NATURE, V251, P740, DOI 10.1038/251740a0
   Barrett JC, 2005, BIOINFORMATICS, V21, P263, DOI 10.1093/bioinformatics/bth457
   BOTTO M, 1990, J EXP MED, V172, P1011, DOI 10.1084/jem.172.4.1011
   Dewan A, 2006, SCIENCE, V314, P989, DOI 10.1126/science.1133807
   FINN JE, 1993, CLIN EXP IMMUNOL, V91, P410
   FINN JE, 1994, NEPHROL DIAL TRANSPL, V9, P1564
   Horvath S, 2004, GENET EPIDEMIOL, V26, P61, DOI 10.1002/gepi.10295
   Kassoff A, 1999, CONTROL CLIN TRIALS, V20, P573
   Liu KJ, 2005, BIOINFORMATICS, V21, P2128, DOI 10.1093/bioinformatics/bti282
   Maller JB, 2007, NAT GENET, V39, P1200, DOI 10.1038/ng2131
   Martin ER, 2000, AM J HUM GENET, V67, P146, DOI 10.1086/302957
   Martin ER, 2003, GENET EPIDEMIOL, V25, P203, DOI 10.1002/gepi.10258
   MCLEAN RH, 1984, J PEDIATR-US, V105, P179, DOI 10.1016/S0022-3476(84)80110-9
   Nowak JZ, 2006, PHARMACOL REP, V58, P353
   RAMBAUSEK M, 1987, Nephrology Dialysis Transplantation, V2, P208
   Schmidt S, 2000, MOL VIS, V6, P287
   Scholl HPN, 2007, MOL VIS, V13, P196
   Spencer KL, 2007, HUM MOL GENET, V16, P1986, DOI 10.1093/hmg/ddm146
   Yang ZL, 2006, SCIENCE, V314, P992, DOI 10.1126/science.1133811
   Yates JRW, 2007, NEW ENGL J MED, V357, P553, DOI 10.1056/NEJMoa072618
NR 20
TC 101
Z9 104
U1 0
U2 2
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0964-6906
J9 HUM MOL GENET
JI Hum. Mol. Genet.
PD JUN 15
PY 2008
VL 17
IS 12
BP 1821
EP 1824
DI 10.1093/hmg/ddn075
PG 4
WC Biochemistry & Molecular Biology; Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Genetics & Heredity
GA 306VJ
UT WOS:000256275600013
PM 18325906
OA Green Published, Bronze
DA 2022-11-30
ER

PT J
AU Svendsen, SG
   Nilsson, LL
   Djurisic, S
   Funck, T
   Wu, CL
   Faber, C
   Falk, MK
   Singh, A
   Sorensen, TL
   Carosella, ED
   LeMaoult, J
   Hviid, TVF
   Nissen, MH
AF Svendsen, S. G.
   Nilsson, L. L.
   Djurisic, S.
   Funck, T.
   Wu, C. -L.
   Faber, C.
   Falk, M. K.
   Singh, A.
   Sorensen, T. L.
   Carosella, E. D.
   LeMaoult, J.
   Hviid, T. V. F.
   Nissen, M. H.
TI Extended HLA-G haplotypes in patients with age-related macular
   degeneration
SO HLA
LA English
DT Article
DE 3UTR; 5URR; age-related macular degeneration; AMD; haplotype; HLA-G
ID G GENE; REGION; POLYMORPHISMS; EXPRESSION; MACULOPATHY; POPULATION;
   PREVALENCE; EVOLUTION; DISEASE; PLASMA
AB This study aims to determine if genetic polymorphisms in the HLA-G gene are associated with age-related macular degeneration (AMD). HLA-G is important for immunological tolerance, and it is also known to have angiogenic effects. Polymorphisms in the 5-upstream regulatory region and 3-untranslated region (UTR) of HLA-G have been associated with a number of diseases, especially with respect to a 14 bp insertion/deletion (ins/del) polymorphism in the 3UTR. Full gene sequencing was performed on a cohort of 146 AMD patients and 63 healthy controls aged 60 and HLA-G haplotypes were determined. Analyses were performed on a publicly available gene expression dataset from the NCBI GEO database (accession number GSE29801) from which expression data for HLA-G, -C, and -A were extracted. Analysis of the GEO dataset showed that both HLA-G and -C were expressed in the back of the eye and that expression was upregulated in the macular area of AMD. No differences were observed between patients and controls when analyzing the distribution of haplotypes in the HLA-G promoter, coding region, 3UTR, or the 14 bp ins/del polymorphism of the 3UTR. The increased expression of HLA-G in the macula of AMD patients indicates a role of HLA-G in the micro environment as part of the AMD pathogenesis. This is supported by the expression of HLA-C, which has previously been shown to play a role in AMD. The HLA-G haplotype distribution did not display any differences between AMD patients and controls.
C1 [Svendsen, S. G.; Faber, C.; Nissen, M. H.] Univ Copenhagen, Dept Immunol & Microbiol, Blegdamsvej 3B, DK-2200 Copenhagen N, Denmark.
   [Nilsson, L. L.; Djurisic, S.; Funck, T.; Hviid, T. V. F.] Zealand Univ Hosp, Dept Clin Biochem, Ctr Immune Regulat & Reprod Immunol, Roskilde, Denmark.
   [Nilsson, L. L.; Djurisic, S.; Funck, T.; Sorensen, T. L.; Hviid, T. V. F.] Univ Copenhagen, Dept Clin Med, Fac Hlth Sci, Copenhagen, Denmark.
   [Wu, C. -L.; Carosella, E. D.; LeMaoult, J.] Hosp St Louis, Hematoimmunol Res Dept, CEA, Paris, France.
   [Faber, C.; Falk, M. K.] Rigshosp, Dept Ophthalmol, Glostrup, Denmark.
   [Falk, M. K.; Singh, A.; Sorensen, T. L.] Zealand Univ Hosp, Dept Ophthalmol, Clin Eye Res Unit, Roskilde, Denmark.
   [Singh, A.] Lund Univ, Skane Univ Hosp, Dept Ophthalmol, Lund, Sweden.
C3 University of Copenhagen; University of Copenhagen; Assistance Publique
   Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; CEA;
   UDICE-French Research Universities; Universite Paris Cite;
   Rigshospitalet; Lund University; Skane University Hospital
RP Svendsen, SG (通讯作者)，Univ Copenhagen, Dept Immunol & Microbiol, Blegdamsvej 3B, DK-2200 Copenhagen N, Denmark.; Hviid, TVF (通讯作者)，Univ Copenhagen, Zealand Univ Hosp, Dept Clin Biochem, Ctr Immune Regulat & Reprod Immunol, 10 Sygehusvej, DK-4000 Roskilde, Denmark.
EM signe_svendsen@hotmail.com; tvh@regionsjaelland.dk
RI Faber, Carsten/I-4150-2013; LeMaoult, Joel/E-9583-2011; Faber,
   Carsten/N-3210-2019
OI Faber, Carsten/0000-0002-2517-7270; Faber, Carsten/0000-0002-2517-7270;
   LeMaoult, Joel/0000-0002-4513-9482; WU, Ching-Lien/0000-0002-3254-6433
FU Faculty of Health and Medical Sciences, University of Copenhagen; Fight
   for Sight Denmark
FX Faculty of Health and Medical Sciences, University of Copenhagen; Fight
   for Sight Denmark
CR Ambati J, 2003, SURV OPHTHALMOL, V48, P257, DOI 10.1016/S0039-6257(03)00030-4
   Ambati J, 2013, NAT REV IMMUNOL, V13, P438, DOI 10.1038/nri3459
   Castelli EC, 2007, TISSUE ANTIGENS, V70, P62, DOI 10.1111/j.1399-0039.2007.00855.x
   Castelli EC, 2010, GENES IMMUN, V11, P134, DOI 10.1038/gene.2009.74
   Castelli EC, 2011, MOL BIOL EVOL, V28, P3069, DOI 10.1093/molbev/msr138
   Chen XY, 2008, TISSUE ANTIGENS, V72, P335, DOI 10.1111/j.1399-0039.2008.01107.x
   Coleman HR, 2008, LANCET, V372, P1835, DOI 10.1016/S0140-6736(08)61759-6
   Faber C, 2013, OPHTHALMOLOGY, V120, P2310, DOI 10.1016/j.ophtha.2013.04.014
   Favier B, 2007, TISSUE ANTIGENS, V69, P150, DOI 10.1111/j.1399-0039.2006.763_6.x
   Frederick Paul A, 2014, Curr Ophthalmol Rep, V2, P14
   Goverdhan SV, 2008, INVEST OPHTH VIS SCI, V49, P5077, DOI 10.1167/iovs.08-1837
   Goverdhan SV, 2005, INVEST OPHTH VIS SCI, V46, P1726, DOI 10.1167/iovs.04-0928
   Green W R, 1999, Mol Vis, V5, P27
   HARRISON GA, 1993, HUM MOL GENET, V2, P2200, DOI 10.1093/hmg/2.12.2200-a
   Hviid TVF, 2006, HUM REPROD UPDATE, V12, P209, DOI 10.1093/humupd/dmi048
   Jorgenson E, 2016, EUR J HUM GENET, V24, P1049, DOI 10.1038/ejhg.2015.247
   Katta S, 2009, J GENET, V88, P425, DOI 10.1007/s12041-009-0064-4
   Klein R, 1999, PROG RETIN EYE RES, V18, P371, DOI 10.1016/S1350-9462(98)00025-1
   la Cour M, 2002, DRUG AGING, V19, P101, DOI 10.2165/00002512-200219020-00003
   Larsen MH, 2009, HUM IMMUNOL, V70, P1026, DOI 10.1016/j.humimm.2009.07.015
   Menard C, 2016, ONCOTARGET, V7, P19171, DOI 10.18632/oncotarget.8280
   Newman AM, 2012, GENOME MED, V4, DOI [10.1186/PREACCEPT-1418491035586234, 10.1186/gm315]
   Nilsson LL, 2016, HLA, V88, P172, DOI 10.1111/tan.12871
   Nussenblatt RB, 2009, CURR OPIN INVEST DR, V10, P434
   Resnikoff S, 2004, B WORLD HEALTH ORGAN, V82, P844
   Rizzo Roberta, 2012, Inflammation & Allergy Drug Targets, V11, P448
   SARKS JP, 1994, EYE, V8, P269, DOI 10.1038/eye.1994.57
   Seddon JM, 2006, OPHTHALMOLOGY, V113, P260, DOI 10.1016/j.ophtha.2005.11.001
   Stephens M, 2005, AM J HUM GENET, V76, P449, DOI 10.1086/428594
   Stephens M, 2001, AM J HUM GENET, V68, P978, DOI 10.1086/319501
   Svendsen SG, 2017, HUM IMMUNOL, V78, P414, DOI 10.1016/j.humimm.2017.04.007
   Svendsen SG, 2013, HUM IMMUNOL, V74, P818, DOI 10.1016/j.humimm.2013.03.003
   Tan Z, 2005, HUM MOL GENET, V14, P3619, DOI 10.1093/hmg/ddi389
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
NR 34
TC 1
Z9 1
U1 0
U2 2
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 2059-2302
EI 2059-2310
J9 HLA
JI HLA
PD AUG
PY 2018
VL 92
IS 2
BP 83
EP 89
DI 10.1111/tan.13340
PG 7
WC Cell Biology; Immunology; Pathology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology; Immunology; Pathology
GA GR0MY
UT WOS:000442212800003
PM 30009537
DA 2022-11-30
ER

PT J
AU Wong, TY
   Cheung, CMG
   Lai, TYY
   Chen, SJ
   Lee, WK
   Yoon, YH
   Iida, T
   Tueckmantel, C
   Sowade, O
   Ogura, Y
AF Wong, Tien Yin
   Cheung, Chui Ming Gemmy
   Lai, Timothy Y. Y.
   Chen, Shih-Jen
   Lee, Won Ki
   Yoon, Young Hee
   Iida, Tomohiro
   Tueckmantel, Claudia
   Sowade, Olaf
   Ogura, Yuichiro
TI EFFICACY AND SAFETY OF INTRAVITREAL AFLIBERCEPT AND RANIBIZUMAB IN ASIAN
   PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION Subgroup
   Analyses From the VIEW Trials
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE aflibercept; age-related macular degeneration; anti-vascular endothelial
   growth factor; Asian patients
ID POLYPOIDAL CHOROIDAL VASCULOPATHY; JAPANESE; RISK; INJECTION; OUTCOMES
AB Purpose: To assess the treatment effect of intravitreal aflibercept and ranibizumab in Asian patients with neovascular age-related macular degeneration.
   Methods: We evaluated data from VIEW 1 and VIEW 2, comparing functional and morphologic outcomes at Week 96 between intravitreal aflibercept 2 mg monthly (2q4) or 2 mg bimonthly after 3 initial monthly doses (2q8) versus ranibizumab 0.5 mg monthly among Asian patients (n = 269) and between Asian and white patients (n = 2044).
   Results: In Asian patients, there were no significant differences between intravitreal aflibercept 2q4 and 2q8 compared with ranibizumab in mean gain in best-corrected visual acuity (10.23 and 8.35 vs. 8.51 letters). Reduction in central retinal thickness was greater for intravitreal aflibercept 2q4 (150.43 mu m, P = 0.0075) and 2q8 (148.15 mu m, P = 0.0126) than ranibizumab (119.46 mu m). The proportion of dry retinas was greater for intravitreal aflibercept 2q4 (65.7%, P < 0.01) than ranibizumab (41.7%). There were no differences in outcomes between Asian and white patients. Serious treatment-emergent ocular adverse events occurred in <8% of treated eyes, evenly distributed across subgroups.
   Conclusion: In Asian patients with neovascular age-related macular degeneration, functional and morphologic outcomes were largely similar between intravitreal aflibercept and ranibizumab groups, and to results seen in white patients.
C1 [Wong, Tien Yin; Cheung, Chui Ming Gemmy] The Academia, Singapore Natl Eye Ctr, Singapore Eye Res Inst, Singapore, Singapore.
   [Wong, Tien Yin; Cheung, Chui Ming Gemmy] Natl Univ Singapore, Duke NUS Grad Med Sch, Singapore, Singapore.
   [Lai, Timothy Y. Y.] Chinese Univ Hong Kong, Hong Kong Eye Hosp, Dept Ophthalmol & Visual Sci, Hong Kong, Peoples R China.
   [Chen, Shih-Jen] Taipei Vet Gen Hosp, Dept Ophthalmol, Taipei, Taiwan.
   [Chen, Shih-Jen] Natl Yang Ming Univ, Sch Med, Taipei, Taiwan.
   [Lee, Won Ki] Catholic Univ Korea, Dept Ophthalmol, Seoul St Marys Hosp, Coll Med, Seoul, South Korea.
   [Yoon, Young Hee] Univ Ulsan, Coll Med, Dept Ophthalmol, Ulsan, South Korea.
   [Yoon, Young Hee] Asan Med Ctr, Seoul, South Korea.
   [Iida, Tomohiro] Tokyo Womens Med Univ, Dept Ophthalmol, Tokyo, Japan.
   [Tueckmantel, Claudia; Sowade, Olaf] Bayer AG, Berlin, Germany.
   [Ogura, Yuichiro] Nagoya City Univ, Grad Sch Med Sci, Dept Ophthalmol & Visual Sci, Nagoya, Aichi, Japan.
C3 National University of Singapore; Singapore National Eye Center;
   National University of Singapore; Chinese University of Hong Kong;
   Taipei Veterans General Hospital; National Yang Ming Chiao Tung
   University; Catholic University of Korea; Seoul St. Mary's Hospital;
   University of Ulsan; Tokyo Women's Medical University; Bayer AG; Nagoya
   City University
RP Wong, TY (通讯作者)，Singapore Natl Eye Ctr, 11 Third Hosp Ave, Singapore 168751, Singapore.
EM wong.tien.yin@snec.com.sg
RI Wong, Tien Yin/AAC-9724-2020; Lai, Timothy Y Y/AAC-2120-2020
OI Wong, Tien Yin/0000-0002-8448-1264; Lai, Timothy Y
   Y/0000-0002-7832-6428; Cheung, Chui Ming Gemmy/0000-0003-3358-3516
FU Regeneron Pharmaceuticals, Inc.; Bayer
FX The VIEW 1 and VIEW 2 trials were supported by Bayer and Regeneron
   Pharmaceuticals, Inc.
CR Byeon SH, 2008, JPN J OPHTHALMOL, V52, P57, DOI 10.1007/s10384-007-0498-2
   Cheng CY, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7063
   Cheung CMG, 2017, OPHTHALMOLOGY, V124, P1305, DOI 10.1016/j.ophtha.2017.03.056
   Cheung CMG, 2017, SCI REP-UK, V7, DOI 10.1038/srep41386
   Cheung CMG, 2013, LANCET, V382, P1230, DOI 10.1016/S0140-6736(13)61580-9
   Congdon NG, 2003, JAMA-J AM MED ASSOC, V290, P2057, DOI 10.1001/jama.290.15.2057
   Coscas G, 2014, AM J OPHTHALMOL, V158, P309, DOI 10.1016/j.ajo.2014.05.004
   Fisher DE, 2016, OPHTHALMOLOGY, V123, P1297, DOI 10.1016/j.ophtha.2015.12.026
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Huang LL, 2016, NAT GENET, V48, P640, DOI 10.1038/ng.3546
   Kawasaki R, 2010, OPHTHALMOLOGY, V117, P921, DOI 10.1016/j.ophtha.2009.10.007
   Laude A, 2010, PROG RETIN EYE RES, V29, P19, DOI 10.1016/j.preteyeres.2009.10.001
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Lim LS, 2013, ASIA-PAC J OPHTHALMO, V2, P32, DOI 10.1097/APO.0b013e31827ff5bc
   Maruko I, 2007, AM J OPHTHALMOL, V144, P15, DOI 10.1016/j.ajo.2007.03.047
   Ogura Y, 2015, BRIT J OPHTHALMOL, V99, P92, DOI 10.1136/bjophthalmol-2014-305076
   Rim TH, 2017, BRIT J OPHTHALMOL, V101, P1367, DOI 10.1136/bjophthalmol-2016-309952
   Schmidt-Erfurth U, 2014, OPHTHALMOLOGY, V121, P193, DOI 10.1016/j.ophtha.2013.08.011
   Sho K, 2003, ARCH OPHTHALMOL-CHIC, V121, P1392, DOI 10.1001/archopht.121.10.1392
   Tsai ASH, 2017, SURV OPHTHALMOL, V62, P462, DOI 10.1016/j.survophthal.2017.01.008
   Wen F, 2004, GRAEF ARCH CLIN EXP, V242, P625, DOI 10.1007/s00417-003-0667-z
   Wong CW, 2016, PROG RETIN EYE RES, V53, P107, DOI 10.1016/j.preteyeres.2016.04.002
   Wong CW, 2015, J CLIN MED, V4, P782, DOI 10.3390/jcm4050782
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Yannuzzi LA, 1999, ARCH OPHTHALMOL-CHIC, V117, P1503
   Ying GS, 2013, OPHTHALMOLOGY, V120, P122, DOI 10.1016/j.ophtha.2012.07.042
NR 26
TC 7
Z9 7
U1 0
U2 2
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD MAR
PY 2019
VL 39
IS 3
BP 537
EP 547
DI 10.1097/IAE.0000000000001986
PG 11
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA IQ4SF
UT WOS:000480740100013
PM 29280937
OA Green Published
DA 2022-11-30
ER

PT J
AU Stenirri, S
   Santambrogio, P
   Setaccioli, M
   Erba, BG
   Manitto, MP
   Rovida, E
   Ferrari, M
   Levi, S
   Cremonesi, L
AF Stenirri, Stefania
   Santambrogio, Paolo
   Setaccioli, Marco
   Erba, Benedetta Gaia
   Manitto, Maria Pia
   Rovida, Ermanna
   Ferrari, Maurizio
   Levi, Sonia
   Cremonesi, Laura
TI Study of FTMT and ABCA4 genes in a patient affected by age-related
   macular degeneration: identification and analysis of new mutations
SO CLINICAL CHEMISTRY AND LABORATORY MEDICINE
LA English
DT Article
DE ABCA4; age-related macular degeneration; mitochondrial ferritin
ID HUMAN MITOCHONDRIAL FERRITIN; HANDLING PROTEINS FERRITIN;
   STARGARDT-DISEASE; IRON HOMEOSTASIS; OXIDATIVE DAMAGE; L-CHAIN;
   FERROPORTIN; METABOLISM; EXPRESSION; TOXICITY
AB Background: Age-related macular degeneration (AMD) is a multifactorial disease for which an involvement of alterations in the retinal ABC transporter gene (ABCA4) is still debated. Oxidative stress in retinal pigment epithelial cells has been postulated to contribute to the pathogenesis of the disease. Mitochondrial ferritin (FtMt), an iron-sequestering protein, is expressed in cell types characterized by high metabolic activity and oxygen consumption, including human retina, suggesting a role in protecting mitochondria from iron-dependent oxidative damage. Based on these findings we wanted to investigate whether mutations in this gene could be found in AMD patients.
   Methods: Mutational scanning of the FTMT gene was performed in a cohort of 50 patients affected by age-related macular degeneration. The ABCA4 gene was also scanned in one patient carrying an FtMt mutation. In silico analyses were carried out on the identified variants. The recombinant form of FtMt variant was expressed in Escherichia coli and biochemically characterized.
   Results: One patient was found to be heterozygous for two previously unreported genetic changes: a complex FtMt mutation (c.437_450delinsCT: delAGGACATCAAGAAGinsCT) and a missense p.Leu973Phe (c.2919G>T) mutation in exon 20 of ABCA4. Computational analyses predicted a severe structural impairment for FtMt variant and a mild destabilizing effect for ABCA4. E. coli expression of recombinant FtMt variant yielded a highly insoluble protein that could not be renatured under in vitro conditions suitable for wild-type ferritins.
   Conclusions: Our findings suggest that the FtMt mutation may determine a condition similar to haploinsufficiency resulting in a reduced protection from iron-dependent oxidative stress in mitochondria.
C1 [Stenirri, Stefania; Ferrari, Maurizio; Cremonesi, Laura] Ist Sci San Raffaele, Genom Unit Diag Human Pathol, Ctr Translat Genom & Bioinformat, I-20132 Milan, Italy.
   [Santambrogio, Paolo; Erba, Benedetta Gaia; Levi, Sonia] Ist Sci San Raffaele, Div Neurosci, Prote Iron Metab Unit, I-20132 Milan, Italy.
   [Setaccioli, Marco; Manitto, Maria Pia] Ist Sci San Raffaele, Dept Ophthalmol, I-20132 Milan, Italy.
   [Rovida, Ermanna] CNR, ITB, I-20133 Milan, Italy.
   [Ferrari, Maurizio; Levi, Sonia] Univ Vita Salute San Raffaele, Milan, Italy.
   [Ferrari, Maurizio] Diagnost & Ric San Raffaele SpA, Milan, Italy.
C3 Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele;
   Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele;
   Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele;
   Consiglio Nazionale delle Ricerche (CNR); Istituto di Tecnologie
   Biomediche (ITB-CNR); Vita-Salute San Raffaele University
RP Stenirri, S (通讯作者)，Ist Sci San Raffaele, Genom Unit Diag Human Pathol, Ctr Translat Genom & Bioinformat, Via Olgettina 60, I-20132 Milan, Italy.
EM stenirri.stefania@hsr.it
RI Santambrogio, Paolo/AAN-3837-2020; levi, sonia/A-3161-2015; Ferrari,
   Maurizio/D-9107-2013
OI Santambrogio, Paolo/0000-0002-5481-2130; levi,
   sonia/0000-0002-5092-0847; Setaccioli, Marco/0000-0002-0500-8728
FU Fondazione CARIPLO
FX We thank the patients and their families for participation. This work
   was partially supported by a Fondazione CARIPLO-2007 grant to SL.
CR Adzhubei IA, 2010, NAT METHODS, V7, P248, DOI 10.1038/nmeth0410-248
   Allikmets R, 1997, NAT GENET, V15, P236, DOI 10.1038/ng0397-236
   Allikmets R, 1997, SCIENCE, V277, P1805, DOI 10.1126/science.277.5333.1805
   Arosio P, 2010, BBA-GEN SUBJECTS, V1800, P783, DOI 10.1016/j.bbagen.2010.02.005
   Azarian SM, 1997, FEBS LETT, V409, P247, DOI 10.1016/S0014-5793(97)00517-6
   Bartnikas TB, 2010, AM J HEMATOL, V85, P958, DOI 10.1002/ajh.21872
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Campanella A, 2004, HUM MOL GENET, V13, P2279, DOI 10.1093/hmg/ddh232
   Campanella A, 2009, HUM MOL GENET, V18, P1, DOI 10.1093/hmg/ddn308
   Castiglioni E, 2010, GENET TEST MOL BIOMA, V14, P793, DOI 10.1089/gtmb.2010.0076
   Coleman HR, 2008, LANCET, V372, P1835, DOI 10.1016/S0140-6736(08)61759-6
   Corsi B, 2002, J BIOL CHEM, V277, P22430, DOI 10.1074/jbc.M105372200
   Cremonesi L, 2004, J MED GENET, V41, DOI 10.1136/jmg.2003.011718
   d'Estaintot BL, 2004, J MOL BIOL, V340, P277, DOI 10.1016/j.jmb.2004.04.036
   De La Paz MA, 1999, OPHTHALMOLOGY, V106, P1531, DOI 10.1016/S0161-6420(99)90449-9
   Dentchev T, 2005, ARCH OPHTHALMOL-CHIC, V123, P1745, DOI 10.1001/archopht.123.12.1745
   Ding XY, 2009, PROG RETIN EYE RES, V28, P1, DOI 10.1016/j.preteyeres.2008.10.001
   Drysdale J, 2002, BLOOD CELL MOL DIS, V29, P376, DOI 10.1006/bcmd.2002.0577
   Ferreira C, 2001, BLOOD, V98, P525, DOI 10.1182/blood.V98.3.525
   Guerois R, 2002, J MOL BIOL, V320, P369, DOI 10.1016/S0022-2836(02)00442-4
   Hahn P, 2004, MOL VIS, V10, P598
   He XN, 2007, PROG RETIN EYE RES, V26, P649, DOI 10.1016/j.preteyeres.2007.07.004
   Kumar P, 2009, NAT PROTOC, V4, P1073, DOI 10.1038/nprot.2009.86
   LEVI S, 1994, J BIOL CHEM, V269, P30334
   Levi S, 2004, INT J BIOCHEM CELL B, V36, P1887, DOI 10.1016/j.biocel.2003.10.020
   Levi S, 2001, J BIOL CHEM, V276, P24437, DOI 10.1074/jbc.C100141200
   Mullins RF, 2000, FASEB J, V14, P835, DOI 10.1096/fasebj.14.7.835
   Rocchia W, 2001, J PHYS CHEM B, V105, P6507, DOI 10.1021/jp010454y
   Santambrogio P, 1997, BIOCHEM J, V322, P461, DOI 10.1042/bj3220461
   SANTAMBROGIO P, 1993, J BIOL CHEM, V268, P12744
   Santambrogio P, 2000, PROTEIN EXPRES PURIF, V19, P212, DOI 10.1006/prep.2000.1212
   Santambrogio P, 2007, J HISTOCHEM CYTOCHEM, V55, P1129, DOI 10.1369/jhc.7A7273.2007
   Seddon Johanna M., 2004, International Ophthalmology Clinics, V44, P17, DOI 10.1097/00004397-200404440-00004
   Snyder AM, 2009, J NEUROPATH EXP NEUR, V68, P1193, DOI 10.1097/NEN.0b013e3181bdc44f
   Souied EH, 2000, INVEST OPHTH VIS SCI, V41, P244
   Stenirri S, 2004, CLIN CHEM, V50, P1336, DOI 10.1373/clinchem.2004.033241
   Stone EM, 1998, NAT GENET, V20, P328, DOI 10.1038/3798
   Ting AYC, 2009, CURR OPIN OPHTHALMOL, V20, P369, DOI 10.1097/ICU.0b013e32832f8016
   Tuncbag N, 2009, BIOINFORMATICS, V25, P1513, DOI 10.1093/bioinformatics/btp240
   Wong RW, 2007, RETINA-J RET VIT DIS, V27, P997, DOI 10.1097/IAE.0b013e318074c290
   Zhang Y, 2008, BMC BIOINFORMATICS, V9, DOI 10.1186/1471-2105-9-40
NR 41
TC 15
Z9 16
U1 2
U2 5
PU WALTER DE GRUYTER & CO
PI BERLIN
PA GENTHINER STRASSE 13, D-10785 BERLIN, GERMANY
SN 1434-6621
J9 CLIN CHEM LAB MED
JI Clin. Chem. Lab. Med.
PD JUN
PY 2012
VL 50
IS 6
BP 1021
EP 1029
DI 10.1515/cclm-2011-0854
PG 9
WC Medical Laboratory Technology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Medical Laboratory Technology
GA 963OO
UT WOS:000305631600009
PM 22706241
DA 2022-11-30
ER

PT J
AU Fine, SL
AF Fine, SL
TI Age-related macular degeneration 1969-2004: A 35-year personal
   perspective
SO AMERICAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID CHOROIDAL NEOVASCULAR MEMBRANES; RISK-FACTORS; LASER PHOTOCOAGULATION;
   CARDIOVASCULAR-DISEASE; PHOTODYNAMIC THERAPY; CIGARETTE-SMOKING;
   MACULOPATHY; PROGNOSIS; DRUSEN; VERTEPORFIN
AB PURPOSE: To provide a personal perspective concerning diagnosis, treatment, and evaluation of treatment for early and late stages of age-related macular degeneration (AMD) over a 35 year period, 1969-2004.
   DESIGN: Literature review, personal recollections, and conversations with investigators who participated in trials to evaluate treatments for AMD.
   METHODS: The author reviewed the literature pertaining to evaluation and treatment of patients with AMD and conversed with investigators who, over the past 35 years, designed, conducted and participated in trials to assess new and existing treatments for AMD.
   RESULTS: In 1969, patients with AMD constituted a small part of a typical ophthalmic practice. From 1969 to 2004, the prevalence of AMD has increased, and the methods of evaluation and treatment have changed dramatically. The emergence of fluorescein angiography and the development of laser photocoagulation and photodynamic therapy have substantially altered clinical practice. Several promising pharmacologic interventions are now being assessed in clinical trials. Nevertheless, AMD remains the leading cause of severe and irreversible vision loss in the United States because there are no highly effective treatments available for most patients.
   CONCLUSIONS: Because of an aging population and the lack of highly effective treatments, late AMD remains a major unsolved problem. However, there is extensive research being conducted with support from the National Eye Institute and from industry. There is also great interest in prevention trials. Accordingly, the author is optimistic that over the next 35 years there will be significant improvements in our ability to prevent severe vision loss from late AMD. (c) 2005 by Elsevier Inc. All rights reserved.
C1 Univ Penn, Dept Ophthalmol, Scheie Eye Inst, Philadelphia, PA USA.
   Univ Penn, Dept Ophthalmol, Scheie Eye Inst, Philadelphia, PA 19104 USA.
C3 University of Pennsylvania; University of Pennsylvania
RP Fine, SL (通讯作者)，Univ Penn, Dept Ophthalmol, Scheie Eye Inst, 51 N 39th St, Philadelphia, PA 19104 USA.
EM stuart.fine@uphs.upenn.edu
FU NATIONAL EYE INSTITUTE [U10EY012261] Funding Source: NIH RePORTER; NEI
   NIH HHS [U10-EY-012261] Funding Source: Medline
CR *AG REL MAC DEG RA, 2004, AM J OPHTHALMOL, V5, P818
   [Anonymous], 1982, Br J Ophthalmol, V66, P745
   [Anonymous], 1991, Arch Ophthalmol, V109, P1109
   [Anonymous], 1991, Arch Ophthalmol, V109, P1220
   [Anonymous], 1998, Ophthalmology, V105, P11
   [Anonymous], 1976, Am J Ophthalmol, V81, P383
   Arnold J, 2001, AM J OPHTHALMOL, V131, P541
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Blinder KJ, 2003, AM J OPHTHALMOL, V136, P407, DOI 10.1016/S0002-9394(03)00223-X
   Bressler NM, 2004, OPHTHALMOLOGY, V111, P1993, DOI 10.1016/j.ophtha.2004.07.023
   BRESSLER NM, 1989, ARCH OPHTHALMOL-CHIC, V107, P847, DOI 10.1001/archopht.1989.01070010869032
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   BRESSLER SB, 1982, AM J OPHTHALMOL, V93, P157, DOI 10.1016/0002-9394(82)90410-X
   CHAKRAVARTHY U, 1993, BRIT J OPHTHALMOL, V77, P265, DOI 10.1136/bjo.77.5.265
   CHAKRAVARTHY U, 1989, CURR EYE RES, V8, P337, DOI 10.3109/02713688908996381
   Chen L, 2003, MOL VIS, V9, P151
   Christen WG, 1996, JAMA-J AM MED ASSOC, V276, P1147, DOI 10.1001/jama.276.14.1147
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   Coscas G, 1982, Bull Mem Soc Fr Ophtalmol, V94, P149
   DAMATO RJ, 1994, P NATL ACAD SCI USA, V91, P4082, DOI 10.1073/pnas.91.9.4082
   Dentchev T, 2003, MOL VIS, V9, P184
   FIGUEROA MS, 1994, RETINA-J RET VIT DIS, V14, P391, DOI 10.1097/00006982-199414050-00001
   FINE SL, 1982, ARCH OPHTHALMOL-CHIC, V100, P912
   Fine SL, 2001, ARCH OPHTHALMOL-CHIC, V119, P275
   Frennesson CI, 2003, ACTA OPHTHALMOL SCAN, V81, P449, DOI 10.1034/j.1600-0420.2003.00143.x
   GASS JDM, 1967, AM J OPHTHALMOL, V64, P612
   Guyer DR, 1997, ARCH OPHTHALMOL-CHIC, V115, P865
   GUYER DR, 1986, ARCH OPHTHALMOL-CHIC, V104, P702, DOI 10.1001/archopht.1986.01050170092029
   Hahn P, 2004, P NATL ACAD SCI USA, V101, P13850, DOI 10.1073/pnas.0405146101
   Hahn P, 2003, ARCH OPHTHALMOL-CHIC, V121, P1099, DOI 10.1001/archopht.121.8.1099
   HAWKINS BS, 1990, ARCH OPHTHALMOL-CHIC, V108, P816
   Hawkins BS, 2004, OPHTHALMOLOGY, V111, P1967, DOI 10.1016/j.ophtha.2004.07.021
   Holz FG, 1999, OPHTHALMOLOGY, V106, P2239
   HOLZ FG, 1994, OPHTHALMOLOGY, V101, P1522
   HYMAN LG, 1983, AM J EPIDEMIOL, V118, P213, DOI 10.1093/oxfordjournals.aje.a113629
   JAMPOL LM, 1991, ARCH OPHTHALMOL-CHIC, V109, P789, DOI 10.1001/archopht.1991.01080060053022
   Johnson LV, 2002, P NATL ACAD SCI USA, V99, P11830, DOI 10.1073/pnas.192203399
   Kaiser RS, 2001, ARCH OPHTHALMOL-CHIC, V119, P826
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   KLEIN R, 1995, INVEST OPHTH VIS SCI, V36, P182
   Klein R, 1998, AM J EPIDEMIOL, V147, P103
   Klein R, 1997, OPHTHALMOLOGY, V104, P1804, DOI 10.1016/S0161-6420(97)30023-2
   KLEIN R, 1993, OPHTHALMOLOGY, V100, P406
   Lanchoney DM, 1998, ARCH OPHTHALMOL-CHIC, V116, P1045, DOI 10.1001/archopht.116.8.1045
   LEIBOWITZ H, 1973, SURV OPHTHALMOL, V24, P335
   Maguire MG, 1997, ARCH OPHTHALMOL-CHIC, V115, P741
   MAGUIRE MG, 1994, ARCH OPHTHALMOL-CHIC, V112, P480
   Miller JW, 1999, ARCH OPHTHALMOL-CHIC, V117, P1161
   MITCHELL P, 1995, OPHTHALMOLOGY, V102, P1450
   PATZ A, 1954, AM J OPHTHALMOL, V38, P291, DOI 10.1016/0002-9394(54)90845-4
   PATZ A, 1952, AM J OPHTHALMOL, V35, P1248, DOI 10.1016/0002-9394(52)91140-9
   Rodanant N, 2002, AM J OPHTHALMOL, V134, P577, DOI 10.1016/S0002-9394(02)01691-4
   Russell S, 2003, OPHTHALMOLOGY, V110, P2372, DOI 10.1016/j.ophtha.2003.08.020
   RYAN SJ, 1982, ARCH OPHTHALMOL-CHIC, V100, P1804, DOI 10.1001/archopht.1982.01030040784015
   SCHATZ H, 1977, T AM ACAD OPHTHALMOL, V83, P893
   Schmidt-Erfurth U, 1999, ARCH OPHTHALMOL-CHIC, V117, P1177
   SCHUMAN JS, 1996, OPTICAL COHERENCE TO
   Seddon JM, 1996, JAMA-J AM MED ASSOC, V276, P1141, DOI 10.1001/jama.276.14.1141
   SMIDDY WE, 1984, OPHTHALMOLOGY, V91, P271
   STERNBERG P, 1991, ARCH OPHTHALMOL-CHIC, V109, P1242
   STERNBERG P, 1991, ARCH OPHTHALMOL-CHIC, V109, P1232
   Sternberg P, 2003, OPHTHALMOLOGY, V110, P971, DOI 10.1016/S0161-6420(03)00098-8
   STRAHLMAN ER, 1984, ARCH OPHTHALMOL-CHIC, V91, P271
   VINDING T, 1992, ACTA OPHTHALMOL, V70, P66
   Vingerling JR, 1996, ARCH OPHTHALMOL-CHIC, V114, P1193, DOI 10.1001/archopht.1996.01100140393005
   WEST SK, 1989, ARCH OPHTHALMOL-CHIC, V107, P875, DOI 10.1001/archopht.1989.01070010897038
   YANNUZZI LA, 1992, ARCH OPHTHALMOL-CHIC, V110, P1701
   YANNUZZI LA, 1992, RETINA-J RET VIT DIS, V12, P191, DOI 10.1097/00006982-199212030-00003
   2003, OPHTHALMOLOGY, V110, P1534
NR 69
TC 26
Z9 27
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0002-9394
EI 1879-1891
J9 AM J OPHTHALMOL
JI Am. J. Ophthalmol.
PD MAR
PY 2005
VL 139
IS 3
BP 405
EP 420
DI 10.1016/j.ajo.2004.11.050
PG 16
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 907GO
UT WOS:000227704200001
PM 15767048
DA 2022-11-30
ER

PT J
AU Real, JP
   Granero, GE
   De Santis, MO
   Juarez, CP
   Palma, SD
   Kelly, SP
   Luna, JD
AF Real, Juan P.
   Granero, Gladys E.
   De Santis, Mariana O.
   Juarez, Claudio P.
   Palma, Santiago D.
   Kelly, Simon P.
   Luna, Jose D.
TI Rate of vision loss in neovascular age-related macular degeneration
   explored
SO GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Article
DE Age-related macular degeneration; Bevacizumab; Disease progression;
   Health systems; Patient safety; Ranibizumab
ID RANIBIZUMAB TREATMENT; BLINDNESS
AB To explore decline in visual acuity in patients with neovascular age-related macular degeneration (n-AMD) awaiting intravitreal bevacizumab or ranibizumab treatment following initial diagnosis and after disease reactivation.
   Retrospective analysis of 74 treatment-na < ve patients (84 eyes) in two centers in Crdoba, Argentina. The time between treatment indication and intravitreal injection, and the changes in BCVA produced during this delay were studied in both periods. A linear regression model to search the impact of time on progression visual impairment was conducted.
   In both periods, a significant reduction in vision occurred awaiting intravitreal injection. The longer the delay, the greater the vision loss (R2 = 0.55 p < 0.01) and the less improvement following treatment (Pearson coefficient -0.26). The result of the model shows that the change in vision as a function of initial delay were best described by a polynomic model with a mean loss of 5 letters in the first 3 weeks, a slowdown in the rate of change of VA, and a dependence of visual acuity at the moment of diagnosis . The loss of visual acuity after reactivation shows the same behavior as at the onset of the disease but independent of visual acuity prior to reactivation.
   Visual loss awaiting injection intravitreal anti-VEGF is clinically significant and with an asymptotic pattern, with early rapid loss of vision in both the onset of the disease and the reactivation. Initiation of anti-VEGF treatment must be undertaken urgently, as should retreatment of disease activation to reduce visual loss.
C1 [Real, Juan P.; Granero, Gladys E.; Palma, Santiago D.] Natl Univ Cordoba UNITEFA, CONICET, Fac Chem Sci, Dept Pharm, Cordoba, Argentina.
   [Juarez, Claudio P.; Luna, Jose D.] Fdn VER, Ctr Privado Ojos Romagosa SA, Vitreoretinal Dept, RA-5000 Cordoba, Argentina.
   [De Santis, Mariana O.] Natl Univ Cordoba, Sch Econ Sci, Inst Econ & Finance, Cordoba, Argentina.
   [Kelly, Simon P.] Royal Bolton Hosp, Dept Ophthalmol, Bolton, England.
C3 Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET);
   National University of Cordoba; Royal Bolton Hospital
RP Luna, JD (通讯作者)，Fdn VER, Ctr Privado Ojos Romagosa SA, Vitreoretinal Dept, Argentina Dean Funes 432, RA-5000 Cordoba, Argentina.
EM moonpintojd@outlook.com
FU Novartis
FX SPK declares attending advisory boards of Bayer and Novartis and
   conference travel from Alcon, Bayer, and Novartis and lecture fees from
   Novartis. The authors declare no conflict of interest.
CR Bloch SB, 2012, AM J OPHTHALMOL, V153, P209, DOI 10.1016/j.ajo.2011.10.016
   Cackett P, 2013, INVEST OPHTH VIS SCI, V54
   Chakravarthy U, 2013, LANCET, V382, P1258, DOI 10.1016/S0140-6736(13)61501-9
   Fung AE, 2007, AM J OPHTHALMOL, V143, P566, DOI 10.1016/j.ajo.2007.01.028
   Gerding H, 2011, GRAEF ARCH CLIN EXP, V249, P653, DOI 10.1007/s00417-011-1636-6
   Kelly SP, 2011, EYE, V25, P710, DOI 10.1038/eye.2011.89
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Ministry of Health Madrid Health Service, 2012, CRIT US BEV RAN PAT
   Muether PS, 2011, GRAEF ARCH CLIN EXP, V249, P633, DOI 10.1007/s00417-010-1520-9
   Real JP, 2013, EUR J OPHTHALMOL, V23, P857, DOI 10.5301/ejo.5000299
   Ruiz-Moreno J.M., 2009, Arch Soc Esp Oftalmol, V84, P333
   Shah AR, 2007, AM J OPHTHALMOL, V143, P83, DOI 10.1016/j.ajo.2006.09.043
   Skaat A, 2012, AM J OPHTHALMOL, V153, P214, DOI 10.1016/j.ajo.2011.08.035
   The Royal College of Ophthalmologists, 2013, AG REL MAC DEG GUID
   Wong T, 2008, OPHTHALMOLOGY, V115, P116, DOI 10.1016/j.ophtha.2007.03.008
NR 15
TC 13
Z9 13
U1 0
U2 7
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0721-832X
EI 1435-702X
J9 GRAEF ARCH CLIN EXP
JI Graefes Arch. Clin. Exp. Ophthalmol.
PD NOV
PY 2015
VL 253
IS 11
BP 1859
EP 1865
DI 10.1007/s00417-014-2885-y
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA CT8IE
UT WOS:000363057900004
PM 25491161
OA Green Submitted
DA 2022-11-30
ER

PT J
AU Ma, BF
   Dang, GF
   Yang, SY
   Duan, L
   Zhang, YW
AF Ma, Baofeng
   Dang, Guangfu
   Yang, Shaoyuan
   Duan, Lian
   Zhang, Yanwei
TI CX3CR1 polymorphisms and the risk of age-related macular degeneration
SO INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL PATHOLOGY
LA English
DT Article
DE Age-related macular degeneration; CX3CR1 gene; polymorphisms
ID FAMILY-HISTORY; HAN CHINESE; POPULATION; ASSOCIATION; MACULOPATHY;
   OBESITY; DISEASE; EYE
AB Background: Age-related macular degeneration (AMD), a most common eye disease, can lead to irreversible visual impairment. Age, genetic and environmental factors have been implicated in AMD. Chemokine (C-X3-C motif) receptor 1 (CX3CR1) gene polymorphisms could influence the susceptibility of AMD. Methods: We tested the association between AMD and single nocleotide polymorphisms (SNPs) of CX3CR1 gene (rs3732378 and rs3732379) in 102 cases and 115 controls from China. Genotypes were determined by MassArray genotyping assay method. Association between CX3CR1 gene polymorphisms and AMD were examined by chi(2) test and logistic regression. Results: Genotype distribution of CX3CR1 gene polymorphisms were in accordance with HWE examination. No obvious differences were observed in the genotypes of rs3732378 polymorphism between case and control groups (P > 0.05), but A allele of it could increase the risk of AMD (P = 0.025, OR = 2.391, 95% CI = 1.092-5.237). Both TT genotype and T allele of rs3732379 were significantly associated with the susceptibility of AMD (P = 8.663, OR = 8.663, 95% CI = 1.044-71.874; P = 0.021, OR = 2.076, 95% CI = 1.104-3.903). Age, gender and smoking status were used as common confounders to adjust the association between CX3CR1 gene polymorphism and AMD risk. Then we found that rs3732378 had no obvious association with AMD susceptibility. TT genotype of rs3732379 related to the occurrence of AMD, but the association was not significant (P = 0.050, OR = 8.274, 95% CI = 1.002-69.963). T allele of rs3732379 might increase the susceptibility of AMD (P = 0.029, OR = 2.033, 95% CI = 1.077-3.838). Conclusion: T allele of rs3732379 might have a positive association with the susceptibility of AMD.
C1 [Ma, Baofeng; Dang, Guangfu; Yang, Shaoyuan; Duan, Lian; Zhang, Yanwei] Shandong Univ, Shandong Prov Qianfoshan Hosp, Dept Ophthalmol, Jinan 250014, Shandong, Peoples R China.
C3 Shandong First Medical University & Shandong Academy of Medical
   Sciences; Shandong University
RP Ma, BF (通讯作者)，Shandong Univ, Shandong Prov Qianfoshan Hosp, Dept Ophthalmol, 16766 Jingshi Rd, Jinan 250014, Shandong, Peoples R China.
EM mabfeng@yeah.net
CR Adams MKM, 2011, AM J EPIDEMIOL, V173, P1246, DOI 10.1093/aje/kwr005
   Anastasopoulos E, 2012, CURR EYE RES, V37, P1148, DOI 10.3109/02713683.2012.705413
   Brion M, 2011, ACTA OPHTHALMOL, V89, pE12, DOI 10.1111/j.1755-3768.2010.02040.x
   Chen M, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0061381
   Cheung LK, 2013, PHARMACOTHERAPY, V33, P838, DOI 10.1002/phar.1264
   Chiras D, 2015, CRIT REV CL LAB SCI, V52, P12, DOI 10.3109/10408363.2014.968703
   Combadiere C, 2007, J CLIN INVEST, V117, P2920, DOI 10.1172/JCI31692
   de Jong PTVM, 2006, NEW ENGL J MED, V355, P1474, DOI 10.1056/NEJMra062326
   Ersoy L, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/413150
   Falk MK, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0112473
   Geirsdottir A, 2007, AM J OPHTHALMOL, V143, P889, DOI 10.1016/j.ajo.2006.11.057
   Hogg RE, 2006, PROG RETIN EYE RES, V25, P249, DOI 10.1016/j.preteyeres.2005.11.002
   Hsu MY, 2015, LAB CHIP, V15, P2357, DOI 10.1039/c4lc01052c
   Hu JY, 2011, OPHTHAL EPIDEMIOL, V18, P137, DOI 10.3109/09286586.2011.574335
   Jonasson F, 2011, OPHTHALMOLOGY, V118, P825, DOI 10.1016/j.ophtha.2010.08.044
   Kassoff A, 1999, CONTROL CLIN TRIALS, V20, P573
   Klein R, 2002, OPHTHALMOLOGY, V109, P1767, DOI 10.1016/S0161-6420(02)01146-6
   Margherio RR, 2000, RETINA-J RET VIT DIS, V20, P325, DOI 10.1097/00006982-200007000-00001
   Munch IC, 2013, INVEST OPHTH VIS SCI, V54, P3932, DOI 10.1167/iovs.12-10785
   Sakurada Y, 2015, OPHTHALMIC RES, V53, P2, DOI 10.1159/000365487
   Schaumberg DA, 2014, JAMA OPHTHALMOL, V132, P84, DOI 10.1001/jamaophthalmol.2013.5506
   Seddon JM, 2005, ARCH OPHTHALMOL-CHIC, V123, P321, DOI 10.1001/archopht.123.3.321
   Shahid H, 2012, BRIT J OPHTHALMOL, V96, P427, DOI 10.1136/bjophthalmol-2011-300193
   Tou JS, 2004, FASEB J, V18, P1297, DOI 10.1096/fj.04-1862fje
   Yang X, 2010, BRIT J OPHTHALMOL, V94, P1211, DOI 10.1136/bjo.2009.165811
NR 25
TC 9
Z9 9
U1 0
U2 0
PU E-CENTURY PUBLISHING CORP
PI MADISON
PA 40 WHITE OAKS LN, MADISON, WI 53711 USA
SN 1936-2625
J9 INT J CLIN EXP PATHO
JI Int. J. Clin. Exp. Pathol.
PY 2015
VL 8
IS 8
BP 9592
EP 9596
PG 5
WC Oncology; Pathology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Pathology
GA CW1TV
UT WOS:000364775400110
PM 26464724
DA 2022-11-30
ER

PT J
AU Akuffo, KO
   Nolan, J
   Stack, J
   Moran, R
   Feeney, J
   Kenny, RA
   Peto, T
   Dooley, C
   O'Halloran, AM
   Cronin, H
   Beatty, S
AF Akuffo, Kwadwo Owusu
   Nolan, John
   Stack, Jim
   Moran, Rachel
   Feeney, Joanne
   Kenny, Rose Anne
   Peto, Tunde
   Dooley, Cara
   O'Halloran, Aisling M.
   Cronin, Hilary
   Beatty, Stephen
TI Prevalence of age-related macular degeneration in the Republic of
   Ireland
SO BRITISH JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID BLUE MOUNTAINS EYE; CLINICAL-TRIAL; MACULOPATHY; POPULATION
AB Background Age-related macular degeneration (AMD) remains the most common cause of visual loss among subjects over 50 years of age in the developed world. The Irish Longitudinal study on Ageing (TILDA) is a population-based study of subjects aged 50 years or older, designed to investigate factors that influence ageing, and has enabled this investigation of the prevalence of AMD in the Republic of Ireland (ROI).
   Methods Data collected from a nationally representative sample of community-living older adults aged 50 years and over in ROI over the period November 2009 to July 2011. 5035 participants attended the TILDA health centre for assessment. Retinal photographs were obtained in 4859 of these participants. Retinal grading was performed in a masked fashion using a modified version of the International Classification and Grading System for AMD.
   Results Adjusting for lower response rates among older subjects, the estimated overall prevalence of any AMD was 7.2% (95% CI 6.5% to 7.9%) in the population aged 50 years or older. The estimated prevalence of early AMD was 6.6% (95% CI 5.9% to 7.3%), and the estimated prevalence of late AMD was 0.6% (95% CI 0.4% to 0.8%). Statistically significant associations with AMD included increasing age and family history of the condition.
   Conclusions This is the first study to provide prevalence estimates of AMD in ROI and will inform eye care professionals and policymakers involved in the delivery and planning of care for those afflicted with this condition.
C1 [Akuffo, Kwadwo Owusu; Nolan, John; Stack, Jim; Moran, Rachel; Beatty, Stephen] Waterford Inst Technol, Dept Chem & Life Sci, Macular Pigment Res Grp, Carriganore, Waterford, Ireland.
   [Feeney, Joanne; Kenny, Rose Anne; Dooley, Cara; O'Halloran, Aisling M.; Cronin, Hilary] Trinity Coll Dublin, Dept Med Gerontol, Irish Longitudinal Study Ageing, Dublin, Ireland.
   [Feeney, Joanne] Queens Univ Belfast, Ctr Publ Hlth, Belfast BT7 1NN, Antrim, North Ireland.
   [Peto, Tunde] Moorfields Eye Hosp, NIHR Biomed Res Ctr, London, England.
   [Peto, Tunde] UCL Inst Ophthalmol, London, England.
C3 South East Technological University (SETU); Trinity College Dublin;
   Queens University Belfast; University of London; University College
   London; Moorfields Eye Hospital NHS Foundation Trust; University of
   London; University College London
RP Akuffo, KO (通讯作者)，Waterford Inst Technol, Vis Res Ctr, Macular Pigment Res Grp, West Campus, Carriganore, Waterford, Ireland.
EM kakuffo@wit.ie
RI Peto, Tunde/G-8812-2018; Akuffo, Kwadwo Owusu/J-2036-2019; Nolan,
   John/N-4921-2014
OI Peto, Tunde/0000-0001-6265-0381; Akuffo, Kwadwo
   Owusu/0000-0001-6683-249X; Feeney, Joanne/0000-0001-9872-2025; Moran,
   Rachel/0000-0003-0501-5431; O'Halloran, Aisling/0000-0001-5498-4453;
   Nolan, John/0000-0002-5503-7084; Kenny, Rose Anne/0000-0002-9336-8124
FU An Roinn Slainte (Irish Department of Health); Atlantic Philanthropies;
   Irish Life; European Research Council (ERC); Howard Foundation,
   Cambridge, UK; NIHR Biomedical Research Centre at Moorfields Eye
   Hospital NHS Foundation Trust; UCL Institute of Ophthalmology
FX TILDA is funded by An Roinn Slainte (Irish Department of Health), The
   Atlantic Philanthropies and Irish Life. The sponsor had no role in the
   study design or in the collection, analysis and interpretation of the
   data or in the writing of the report or in the decision to submit the
   paper for publication. KOA and JN are funded by the European Research
   Council (ERC). JN is also funded by the Howard Foundation, Cambridge,
   UK. TP is funded by the NIHR Biomedical Research Centre at Moorfields
   Eye Hospital NHS Foundation Trust and UCL Institute of Ophthalmology.
CR Andersen MVN, 2008, OPHTHALMOLOGY, V115, P700, DOI 10.1016/j.ophtha.2007.12.013
   Augood CA, 2006, ARCH OPHTHALMOL-CHIC, V124, P529, DOI 10.1001/archopht.124.4.529
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Bloch SB, 2012, AM J OPHTHALMOL, V153, P209, DOI 10.1016/j.ajo.2011.10.016
   Brugiavini A, 2005, AGEING RETIREMENT EU
   Central Statistics Office, 2012, CENS 2011
   Chakravarthy U, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.04.015
   Chew EY, 2013, JAMA-J AM MED ASSOC, V309, P2005, DOI 10.1001/jama.2013.4997
   Cronin H, 2013, J AM GERIATR SOC, V61, pS269, DOI 10.1111/jgs.12197
   Friedman DS, 1999, OPHTHALMOLOGY, V106, P1049, DOI 10.1016/S0161-6420(99)90267-1
   Jonasson F, 2003, ARCH OPHTHALMOL-CHIC, V121, P379, DOI 10.1001/archopht.121.3.379
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Kearney PM, 2011, INT J EPIDEMIOL, V40, P877, DOI 10.1093/ije/dyr116
   Kelliher C, 2006, BRIT J OPHTHALMOL, V90, P367, DOI 10.1136/bjo.2005.075861
   Klein R, 2006, OPHTHALMOLOGY, V113, P373, DOI 10.1016/j.ophtha.2005.12.013
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Klein R, 2011, ARCH OPHTHALMOL-CHIC, V129, P75, DOI 10.1001/archophthalmol.2010.318
   LANDIS JR, 1977, BIOMETRICS, V33, P159, DOI 10.2307/2529310
   MITCHELL P, 1995, OPHTHALMOLOGY, V102, P1450
   Piermarocchi S, 2011, OPHTHAL EPIDEMIOL, V18, P129, DOI 10.3109/09286586.2011.574334
   Qualls LG, 2013, RETINA-J RET VIT DIS, V33, P854, DOI 10.1097/IAE.0b013e31826f065e
   R Development Core Team, 2008, R LANG ENV STAT COMP
   Rudnicka AR, 2012, OPHTHALMOLOGY, V119, P571, DOI 10.1016/j.ophtha.2011.09.027
   Schmidt-Erfurth U, 2014, OPHTHALMOLOGY, V121, P193, DOI 10.1016/j.ophtha.2013.08.011
   Seddon JM, 1997, AM J OPHTHALMOL, V123, P199, DOI 10.1016/S0002-9394(14)71036-0
   Slakter JS, 2005, SURV OPHTHALMOL, V50, P263, DOI 10.1016/j.survophthal.2005.02.007
   Smith W, 1998, AUST NZ J OPHTHALMOL, V26, P203, DOI 10.1111/j.1442-9071.1998.tb01311.x
   VanNewkirk MR, 2000, OPHTHALMOLOGY, V107, P1593, DOI 10.1016/S0161-6420(00)00175-5
   VINGERLING JR, 1995, OPHTHALMOLOGY, V102, P205
NR 29
TC 28
Z9 30
U1 0
U2 5
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0007-1161
EI 1468-2079
J9 BRIT J OPHTHALMOL
JI Br. J. Ophthalmol.
PD AUG
PY 2015
VL 99
IS 8
BP 1037
EP 1044
DI 10.1136/bjophthalmol-2014-305768
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA CN3BC
UT WOS:000358297200006
PM 25712825
OA hybrid, Green Published, Green Submitted, Green Accepted
DA 2022-11-30
ER

PT J
AU Rein, DB
   Saaddine, JB
   Wittenborn, JS
   Wirth, KE
   Hoerger, TJ
   Narayan, KMV
   Clemons, T
   Sorensen, SW
AF Rein, David B.
   Saaddine, Jinan B.
   Wittenborn, John S.
   Wirth, Kathleen E.
   Hoerger, Thomas J.
   Narayan, K. M. Venkat
   Clemons, Traci
   Sorensen, Stephen W.
TI Cost-effectiveness of vitamin therapy for age-related macular
   degeneration
SO OPHTHALMOLOGY
LA English
DT Article
ID PHOTODYNAMIC THERAPY; CHOROIDAL NEOVASCULARIZATION; VERTEPORFIN;
   MACULOPATHY; RETINOPATHY; UTILITY; EYES
AB Objective: To determine the cost-effectiveness of vitamin therapy (antioxidants plus zinc) for all indicated patients diagnosed with age-related macular degeneration (AMD).
   Design: We compared the impacts of vitamin therapy with those of no vitamin therapy using a computerized, stochastic, agent-based model. The model simulated the natural history of AMD and patterns of ophthalmic service use in the United States in a cohort from age 50 years until 100 or death.
   Participants and/or Controls: The model created 20 million simulated individuals. These individuals each received both the intervention (vitamin therapy after diagnosis) and the control (no vitamin therapy). Expected outcomes generated when vitamins were taken after diagnosis were compared with the expected outcomes generated when they were not.
   Methods: The model created individuals representative of patients in the U.S. Incidence of early AMD was based on published studies, as was vision loss and response to choroidal neovascularization therapies. Post-incident disease progression was governed by previously unpublished data drawn from the Age-Related Eye Disease Study.
   Main Outcome Measures: Extent of disease progression, years and severity of visual impairment, cost of ophthalmic care and nursing home services, and quality-adjusted life years (QALYs). Costs and benefits were considered from the health care perspective and discounted using a 3% rate. The analysis was run for 50 years starting in 2003.
   Results: Compared with no therapy, vitamin therapy yielded a cost-effectiveness ratio of $21 387 per QALY gained and lowered the percentage of patients with AMD who ever developed visual impairment in the better-seeing eye from 7.0% to 5.6%.
   Conclusions: Our model demonstrates that vitamin therapy for AMD improves quality of life at a reasonable cost.
C1 RTI Int, Res Triangle Pk, NC USA.
   Ctr Dis Control & Prevent, Div Diabet Translat, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA USA.
   Emmes Corp, Rockville, MD USA.
C3 Research Triangle Institute; Centers for Disease Control & Prevention -
   USA; Emmes Corporation
RP Rein, DB (通讯作者)，RTI Int, 2957 Flowers Rd,Suite 119, Atlanta, GA 30341 USA.
EM drein@rti.org
RI Narayan, K.M. Venkat/J-9819-2012
OI Narayan, K.M. Venkat/0000-0001-8621-5405; Hoerger,
   Thomas/0000-0003-4154-7806; Wirth, Kathleen/0000-0002-7468-851X; Rein,
   David/0000-0002-1271-5789
FU PHS HHS [200-2002-00776] Funding Source: Medline
CR Alpha-Tocopherol Beta Carotene Cancer Prevention Study Group, 1994, N Engl J Med, V330, P1029, DOI 10.1056/NEJM199404143301501
   American Academy of Ophthalmology Glaucoma Panel, 2005, PREF PRACT PATT AG R, P13
   [Anonymous], 1991, Arch Ophthalmol, V109, P1109
   Arnold J, 2001, AM J OPHTHALMOL, V131, P541
   Blumenkranz MS, 2001, ARCH OPHTHALMOL-CHIC, V119, P198
   Bressler NM, 2003, ARCH OPHTHALMOL-CHIC, V121, P1621
   Brown MM, 2003, SURV OPHTHALMOL, V48, P204, DOI 10.1016/S0039-6257(02)00457-5
   BURT CW, 2004, USING PAST VISIT INF
   Busbee BG, 2003, RETINA-J RET VIT DIS, V23, P279, DOI 10.1097/00006982-200306000-00001
   *CENT MED MED SERV, DUR MED EQU PROSTH O
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   COONEY JP, 2004, COMPARATIVE ASSESSME, P42
   EASTMAN RC, 1993, DIABETES CARE, V16, P1095, DOI 10.2337/diacare.16.8.1095
   Eter N, 2006, BIODRUGS, V20, P167, DOI 10.2165/00063030-200620030-00004
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   GOLD MR, 1996, COST EFFECTIVENESS H, V3, P82
   Hopley C, 2004, BRIT J OPHTHALMOL, V88, P450, DOI 10.1136/bjo.2003.035279
   JAVITT J, 1993, PEDIATRICS, V91, P859
   JAVITT JC, 1989, OPHTHALMOLOGY, V96, P255
   Kassoff A, 1999, CONTROL CLIN TRIALS, V20, P573
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Klein R, 2002, OPHTHALMOLOGY, V109, P1767, DOI 10.1016/S0161-6420(02)01146-6
   Lee PP, 2003, OPHTHALMOLOGY, V110, P1952, DOI 10.1016/S0161-6420(03)00817-0
   LENNIE P, 2002, VISUAL IMPAIRMENTS D, P111
   Maciosek MV, 2006, AM J PREV MED, V31, P52, DOI 10.1016/j.amepre.2006.03.012
   Mitchell P, 2002, OPHTHALMOLOGY, V109, P1092, DOI 10.1016/S0161-6420(02)01055-2
   Mitchell P, 2003, ASIA PAC J CLIN NU S, V12, pS5
   Ng WT, 2006, CLIN EXP OPHTHALMOL, V34, P9, DOI 10.1111/j.1442-9071.2006.01141.x
   Omenn GS, 1996, NEW ENGL J MED, V334, P1150, DOI 10.1056/NEJM199605023341802
   Rein DB, 2007, OPHTHALMOLOGY, V114, P1319, DOI 10.1016/j.ophtha.2006.10.041
   Rubin GS, 2002, RETINA-J RET VIT DIS, V22, P536, DOI 10.1097/00006982-200210000-00002
   SCHACHAT AP, 1994, ARCH OPHTHALMOL-CHIC, V112, P500
   Sharma S, 2001, OPHTHALMOLOGY, V108, P2051, DOI 10.1016/S0161-6420(01)00764-3
   Smith DH, 2004, BRIT J OPHTHALMOL, V88, P1107, DOI 10.1136/bjo.2003.023986
   Sunness JS, 1999, OPHTHALMOLOGY, V106, P910, DOI 10.1016/S0161-6420(99)00509-6
   van Leeuwen R, 2003, ARCH OPHTHALMOL-CHIC, V121, P519, DOI 10.1001/archopht.121.4.519
   Wang JJ, 2003, OPHTHALMIC EPIDEMIOL, V10, P3, DOI 10.1076/opep.10.1.3.13773
   Weinstein MC, 2003, VALUE HEALTH, V6, P9, DOI 10.1046/j.1524-4733.2003.00234.x
   2005, MMWR MORB MORTAL WKL, V54, P509
NR 39
TC 38
Z9 40
U1 0
U2 8
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0161-6420
EI 1549-4713
J9 OPHTHALMOLOGY
JI Ophthalmology
PD JUL
PY 2007
VL 114
IS 7
BP 1319
EP 1326
DI 10.1016/j.ophtha.2006.10.041
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 184GS
UT WOS:000247629700013
PM 17320962
DA 2022-11-30
ER

PT J
AU Wu, ZC
   Ayton, LN
   Guymer, RH
   Luu, CD
AF Wu, Zhichao
   Ayton, Lauren N.
   Guymer, Robyn H.
   Luu, Chi D.
TI Intrasession Test-Retest Variability of Microperimetry in Age-Related
   Macular Degeneration
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
DE age-related macular degeneration; microperimetry; test-retest;
   variability; repeatability
ID FUNDUS AUTOFLUORESCENCE; GEOGRAPHIC ATROPHY; PERIMETRY; DISEASE; FIELD;
   EYES; MP-1
AB PURPOSE. To determine the intrasession test-retest variability of microperimetry in participants with age-related macular degeneration (AMD).
   METHODS. This study consisted of two separate groups of subjects who had not performed microperimetry previously. In group 1, 30 AMD and 14 control participants performed three microperimetry examinations of a selected eye within one session (test 1 and 2, first pair; test 2 and 3, second pair). Follow-up examination at 6 months was available in 20 AMD participants in group 1, who performed two microperimetry examinations. In group 2, 71 AMD participants performed a short practice examination, then two microperimetry examinations of the right eye (test 1 and 2, first pair) and two of the left eye (test 3 and 4, second pair).
   RESULTS. There was a significant improvement in average point-wise sensitivity (PWS) between the first pair of examination in both groups (P < 0.001), but not in the subsequent pair (P >= 0.774). This improvement was not observed at the follow-up visit in the subset of AMD participants in group 1 (P = 0.433). The PWS coefficient of repeatability (CoR) for the second pair of examinations was +/-4.12 dB and +/-4.37 dB for AMD participants for group 1 and 2 respectively.
   CONCLUSIONS. A significant increase in sensitivity between the first and second test, but not in the subsequent tests, was found for participants who had not performed microperimetry previously. Intrasession test-retest variability can therefore be minimized by discarding the first examination to avoid the influence of a learning effect.
C1 [Wu, Zhichao; Ayton, Lauren N.; Guymer, Robyn H.; Luu, Chi D.] Univ Melbourne, Royal Victorian Eye & Ear Hosp, Ctr Eye Res Australia, Melbourne, Vic 3010, Australia.
C3 Centre for Eye Research Australia; Royal Victorian Eye & Ear Hospital;
   University of Melbourne
RP Luu, CD (通讯作者)，Ctr Eye Res Australia, Macular Res Unit, Level 1,32 Gisborne St, East Melbourne, Vic 3002, Australia.
EM cluu@unimelb.edu.au
RI Ayton, Lauren/AAV-2977-2021
OI Ayton, Lauren/0000-0001-9907-084X; Luu, Chi/0000-0002-7604-7097; Guymer,
   Robyn/0000-0002-9441-4356
FU National Health and Medical Research Council (NHMRC) [1027624]; NH&MRC
   Practitioner Fellowship [529905]; Macular Disease Foundation Research
   grant; Bupa Health Foundation (Australia); William Angliss (Victoria)
   Charitable Fund Research grant; Murray Redvers and Rodney Alastair
   Brownless Perpetual Charitable Trust; NH&MRC Centre for Clinical
   Research Excellence Award [529923]
FX Supported by National Health and Medical Research Council (NH&MRC)
   Project Grant 1027624, NH&MRC Practitioner Fellowship 529905 (RHG), a
   Macular Disease Foundation Research grant, the Bupa Health Foundation
   (Australia), a William Angliss (Victoria) Charitable Fund Research
   grant, and Murray Redvers and Rodney Alastair Brownless Perpetual
   Charitable Trust funding administered by the Trust Company. The Centre
   for Eye Research Australia receives operational infrastructure support
   from the Victorian Government and is supported by NH&MRC Centre for
   Clinical Research Excellence Award 529923.
CR Acton JH, 2012, INVEST OPHTH VIS SCI, V53, P7618, DOI 10.1167/iovs.12-10361
   Acton JH, 2011, OPTOMETRY VISION SCI, V88, P1288, DOI 10.1097/OPX.0b013e31822b3746
   Anastasakis A, 2011, EYE, V25, P245, DOI 10.1038/eye.2010.158
   Bland JM, 2007, J BIOPHARM STAT, V17, P571, DOI 10.1080/10543400701329422
   Chen FK, 2009, INVEST OPHTH VIS SCI, V50, P3464, DOI 10.1167/iovs.08-2926
   Cideciyan AV, 2012, INVEST OPHTH VIS SCI, V53, P841, DOI 10.1167/iovs.11-8415
   Evans JR, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000254.pub3
   Evans JR, 2012, COCHRANE DB SYST REV, V6, DOI DOI 10.1002/14651858.CD000253.PUB3
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Goldstein H, 2002, STAT MED, V21, P3291, DOI 10.1002/sim.1264
   Hartmann KI, 2011, RETINA-J RET VIT DIS, V31, P1323, DOI 10.1097/IAE.0b013e31820a6850
   Iwama D, 2010, CLIN EXP OPHTHALMOL, V38, P483, DOI 10.1111/j.1442-9071.2010.02294.x
   Jones A, 2011, P NATL ACAD SCI USA, V108, P14578, DOI 10.1073/pnas.1102853108
   KLEIN R, 1995, INVEST OPHTH VIS SCI, V36, P182
   Landa G, 2011, RETINA-J RET VIT DIS, V31, P364, DOI 10.1097/IAE.0b013e3181e91132
   Lesmes LA, DRUG DISCOV IN PRESS
   Luu CD, 2012, ARCH OPHTHALMOL-CHIC, V130, P690, DOI 10.1001/archophthalmol.2012.277
   Midena E, 2007, BRIT J OPHTHALMOL, V91, P1499, DOI 10.1136/bjo.2007.119685
   Parisi V, 2007, RETINA-J RET VIT DIS, V27, P879, DOI 10.1097/IAE.0b013e318042d6aa
   Pilotto E, 2013, BRIT J OPHTHALMOL, V97, P622, DOI 10.1136/bjophthalmol-2012-302633
   Pilotto E, 2011, BRIT J OPHTHALMOL, V95, P1140, DOI 10.1136/bjo.2010.187344
   Querques L, 2012, AM J OPHTHALMOL, V153, P1110, DOI 10.1016/j.ajo.2011.11.002
   Remky A, 2005, BRIT J OPHTHALMOL, V89, P464, DOI 10.1136/bjo.2004.050260
   STEWART WC, 1993, SURV OPHTHALMOL, V37, P353, DOI 10.1016/0039-6257(93)90065-F
   Vujosevic S, 2011, OPHTHALMOLOGICA, V225, P155, DOI 10.1159/000320340
   Weingessel B, 2009, EYE, V23, P1052, DOI 10.1038/eye.2008.237
   West BT, 2009, EVAL HEALTH PROF, V32, P207, DOI 10.1177/0163278709338554
NR 27
TC 85
Z9 85
U1 0
U2 4
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD NOV
PY 2013
VL 54
IS 12
BP 7378
EP 7385
DI 10.1167/iovs.13-12617
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 265KH
UT WOS:000327949700027
PM 24135753
DA 2022-11-30
ER

PT J
AU Jonas, JB
   Libondi, T
   Golubkina, L
   Spandau, UH
   Schlichtenbrede, F
   Rensch, F
AF Jonas, Jost B.
   Libondi, Teodosio
   Golubkina, Lidia
   Spandau, Ulrich H.
   Schlichtenbrede, Frank
   Rensch, Florian
TI Combined intravitreal bevacizumab and triamcinolone in exudative
   age-related macular degeneration
SO ACTA OPHTHALMOLOGICA
LA English
DT Article
DE Avastin; exudative age-related macular degeneration; intraocular
   anti-angiogenesis; intravitreal bevacizumab; intravitreal steroids;
   intravitreal triamcinolone
ID CHOROIDAL NEOVASCULARIZATION; PHOTODYNAMIC THERAPY; COMBINATION THERAPY;
   CLINICAL-TRIAL; ACETONIDE; INJECTION; EFFICACY; SAFETY; PROLIFERATION;
   VERTEPORFIN
AB Purpose:
   We report on the combined application of intravitreal bevacizumab and triamcinolone acetonide for treatment of exudative age-related macular degeneration (AMD).
   Methods:
   The clinical interventional case-series study included 16 patients (16 eyes) with exudative AMD who had previously received 3.5 +/- 1.8 mono-injections of bevacizumab (1.5 mg) without significant improvement in visual acuity (VA) or reduction in macular exudation. All patients underwent a combined intravitreal injection of bevacizumab (1.5 mg) and triamcinolone acetonide (about 20 mg). Main outcome measures were VA and macular thickness as determined by optical coherence tomography. All patients were re-examined at 2-3 months after the intervention.
   Results:
   Visual acuity improved significantly (p = 0.03) from 0.80 +/- 0.40 logMAR prior to the combined injection to 0.65 +/- 0.42 logMAR at 3 months after the injection. An improvement of >= 1 Snellen line was found in eight subjects, an increase of >= 2 lines in five subjects, and an improvement of >= 3 lines in two subjects. One patient lost 1 line and one patient lost 3 lines. Central retinal thickness decreased significantly from 272 +/- 62 mu m to 220 +/- 47 mu m (p = 0.03). At the 6-month follow-up examination, central retinal thickness had increased again to 319 +/- 142 mu m, which was not significantly (p = 0.30) different from baseline measurements.
   Conclusions:
   The combined intravitreal application of bevacizumab and triamcinolone may temporarily be helpful in the treatment of exudative AMD if previous intravitreal bevacizumab mono-injections have failed to improve vision and reduce macular oedema.
C1 [Jonas, Jost B.] Univ Heidelberg, Univ Augenklin, Med Fac Mannheim, Dept Ophthalmol, D-68167 Mannheim, Germany.
   [Libondi, Teodosio] Univ Naples 2, Fac Med & Surg, Dept Ophthalmol, Naples, Italy.
C3 Ruprecht Karls University Heidelberg; University of Hamburg; University
   Medical Center Hamburg-Eppendorf; Universita della Campania Vanvitelli
RP Jonas, JB (通讯作者)，Univ Heidelberg, Univ Augenklin, Med Fac Mannheim, Dept Ophthalmol, Theodor Kutzer Ufer 1-3, D-68167 Mannheim, Germany.
EM jost.jonas@augen.ma.uni-heidelberg.de
CR Algvere PV, 2008, ACTA OPHTHALMOL, V86, P482, DOI 10.1111/j.1600-0420.2007.01113.x
   Bakri SJ, 2008, EYE, V22, P978, DOI 10.1038/sj.eye.6703041
   Colucciello M, 2008, J OCUL PHARMACOL TH, V24, P15, DOI 10.1089/jop.2007.0080
   Cruess AF, 2009, ACTA OPHTHALMOL, V87, P118, DOI 10.1111/j.1755-3768.2008.01218.x
   Danis RP, 2000, RETINA-J RET VIT DIS, V20, P244, DOI 10.1097/00006982-200003000-00004
   Frimpong-Boateng A, 2009, ACTA OPHTHALMOL, V87, P183, DOI 10.1111/j.1755-3768.2008.01213.x
   Gillies MC, 2003, ARCH OPHTHALMOL-CHIC, V121, P667, DOI 10.1001/archopht.121.5.667
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Jonas JB, 2003, ARCH OPHTHALMOL-CHIC, V121, P57
   Jonas JB, 2001, AM J OPHTHALMOL, V132, P425, DOI 10.1016/S0002-9394(01)01010-8
   Jonas JB, 2005, AM J OPHTHALMOL, V139, P1073, DOI 10.1016/j.ajo.2005.01.032
   Jonas JB, 2003, BRIT J OPHTHALMOL, V87, P462, DOI 10.1136/bjo.87.4.462
   Jonas JB, 2009, OPHTHALMIC RES, V41, P21, DOI 10.1159/000162113
   Jonas JB, 2007, ACTA OPHTHALMOL SCAN, V85, P563, DOI 10.1111/j.1600-0420.2007.00891.x
   Kvanta A, 2000, CURR EYE RES, V21, P684, DOI 10.1076/0271-3683(200009)21:3;1-R;FT684
   Penfold PL, 1995, AUST NZ J OPHTHALMOL, V23, P293, DOI 10.1111/j.1442-9071.1995.tb00179.x
   Rechtman E, 2004, BRIT J OPHTHALMOL, V88, P344, DOI 10.1136/bjo.2003.027177
   Rich RM, 2006, RETINA-J RET VIT DIS, V26, P495, DOI 10.1097/01.iae.0000225766.75009.3a
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rosenfeld PJ, 2005, OPHTHAL SURG LAS IM, V36, P331, DOI 10.3928/1542-8877-20050701-14
   Schmidt-Erfurth UM, 2007, ACTA OPHTHALMOL SCAN, V85, P486, DOI 10.1111/j.1600-0420.2007.00979.x
   Spaide RF, 2005, OPHTHALMOLOGY, V112, P301, DOI 10.1016/j.ophtha.2004.08.012
   Spaide RF, 2006, RETINA-J RET VIT DIS, V26, P383, DOI 10.1097/00006982-200604000-00001
   Spandau UHM, 2005, BRIT J OPHTHALMOL, V89, P745, DOI 10.1136/bjo.2004.052563
   Steen B, 1998, INVEST OPHTH VIS SCI, V39, P2194
   Sutter FKP, 2004, OPHTHALMOLOGY, V111, P2044, DOI 10.1016/j.ophtha.2004.05.025
   Virgili G, 2007, ACTA OPHTHALMOL SCAN, V85, P6, DOI 10.1111/j.1600-0420.2006.00711.x
NR 27
TC 14
Z9 14
U1 0
U2 0
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 1755-375X
J9 ACTA OPHTHALMOL
JI Acta Ophthalmol.
PD SEP
PY 2010
VL 88
IS 6
BP 630
EP 634
DI 10.1111/j.1755-3768.2008.01502.x
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 643PI
UT WOS:000281310000012
PM 19432871
OA Bronze
DA 2022-11-30
ER

PT J
AU Mathew, RS
   Delbaere, K
   Lord, SR
   Beaumont, P
   Vaegan
   Madigan, MC
AF Mathew, Remy Sheena
   Delbaere, Kim
   Lord, Stephen R.
   Beaumont, Paul
   Vaegan
   Madigan, Michele C.
TI Depressive symptoms and quality of life in people with age-related
   macular degeneration
SO OPHTHALMIC AND PHYSIOLOGICAL OPTICS
LA English
DT Article
DE activities of daily living; ageing; depression; macular degeneration;
   physical activity; physical functioning
ID VISUAL IMPAIRMENT
AB Purpose: To examine quality of life and associated factors in people with Age-Related Macular Degeneration (AMD).
   Methods: One hundred and forty-five AMD participants (mean age 78.0 +/- 7.7 years) and 104 age- and gender- matched controls (mean age 78.1 +/- 5.8 years) comprised the study populations for this case-control study. Depressive symptoms were measured with the Goldberg Anxiety and Depression (GAD) scale; general health and daily functioning was assessed with the Medical Outcomes Study Short Form 36 (SF-36) and questions relating to assistance required for daily living activities.
   Results: People with AMD performed more poorly than controls on the GAD depression scale, and physical functioning subscale of SF-36. 44.4% of people with AMD had clinically significant depressive symptoms compared to 17.5% of controls (p < 0.001). Multiple regression analysis revealed that AMD was independently associated with depressive symptoms and a path model indicated that AMD led to depressive symptoms both directly and indirectly via reduced general health and social functioning.
   Conclusion: Psychological and functional outcome measures are reduced in people with AMD. Earlier recognition and treatment of depressive symptoms in people with AMD may be crucial to maintaining quality of life in this group.
C1 [Mathew, Remy Sheena; Vaegan; Madigan, Michele C.] Univ New S Wales, Sch Optometry & Vis Sci, Sydney, NSW, Australia.
   [Beaumont, Paul] Eye Res Inst, Sydney, NSW, Australia.
   [Delbaere, Kim; Lord, Stephen R.] Univ New S Wales, Neurosci Res Australia, Sydney, NSW, Australia.
C3 University of New South Wales Sydney; Neuroscience Research Australia;
   University of New South Wales Sydney
RP Mathew, RS (通讯作者)，Univ New S Wales, Sch Optometry & Vis Sci, Sydney, NSW, Australia.
EM fromrems@gmail.com
RI Lord, Stephen R/C-9612-2011; Delbaere, Kim/D-6370-2011
OI Delbaere, Kim/0000-0002-5655-0234; Lord, Stephen R/0000-0002-7111-8802
FU University of New South Wales
FX Dr Peter Herse provided input during the initial phase of the study. A
   PhD Completion Scholarship was provided by University of New South
   Wales.
CR Age-Related Eye Dis Study Res Grp, 2001, AM J OPHTHALMOL, V132, P668
   ALBERT A, 2007, INVEST OPHTH VIS SCI, V48, P1498
   Brody BL, 2002, ARCH OPHTHALMOL-CHIC, V120, P1477, DOI 10.1001/archopht.120.11.1477
   Brody BL, 2001, OPHTHALMOLOGY, V108, P1893, DOI 10.1016/S0161-6420(01)00754-0
   Byrne BM, 2004, STRUCT EQU MODELING, V11, P272, DOI 10.1207/s15328007sem1102_8
   Cahill MT, 2005, OPHTHALMOLOGY, V112, P152, DOI 10.1016/j.ophtha.2004.06.036
   Dandona L, 1998, ARCH OPHTHALMOL-CHIC, V116, P545, DOI 10.1001/archopht.116.4.514
   Delbaere K, 2010, BRIT J SPORT MED, V44, P1029, DOI 10.1136/bjsm.2009.060350
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   GOLDBERG D, 1988, BRIT MED J, V297, P897, DOI 10.1136/bmj.297.6653.897
   Holm J, 2001, SCAND J PRIM HEALTH, V19, P263
   MCCALLUM J, 1995, AUST J PUBLIC HEALTH, V19, P160
   Mitchell J, 2006, HEALTH QUAL LIFE OUT, V4, DOI 10.1186/1477-7525-4-97
   Moore LW, 2000, WESTERN J NURS RES, V22, P571, DOI 10.1177/01939450022044601
   Mukesh BN, 2004, OPHTHALMOLOGY, V111, P1176, DOI 10.1016/j.ophtha.2003.08.042
   Penninx BWJH, 1999, AM J PUBLIC HEALTH, V89, P1346, DOI 10.2105/AJPH.89.9.1346
   Pulska T, 1999, BRIT MED J, V318, P432, DOI 10.1136/bmj.318.7181.432
   Rovner BW, 1996, J AM GERIATR SOC, V44, P181, DOI 10.1111/j.1532-5415.1996.tb02436.x
   Rovner BW, 2002, ARCH OPHTHALMOL-CHIC, V120, P1041
   Rovner BW, 2002, AM J GERIAT PSYCHIAT, V10, P305
   TABACHNIK BG, 2007, TAB FID US MULT STAT, P60
   Ware JE., 1993, SCORING SF 36 SF 36
NR 22
TC 51
Z9 54
U1 0
U2 8
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0275-5408
EI 1475-1313
J9 OPHTHAL PHYSL OPT
JI Ophthalmic Physiol. Opt.
PD JUL
PY 2011
VL 31
IS 4
BP 375
EP 380
DI 10.1111/j.1475-1313.2011.00848.x
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC Ophthalmology
GA 789PZ
UT WOS:000292529100008
PM 21679317
OA Green Published
DA 2022-11-30
ER

PT J
AU Jiang, SN
   Moriarty-Craige, SE
   Li, C
   Lynn, MJ
   Cai, JJ
   Jones, DP
   Sternberg, P
AF Jiang, Shunai
   Moriarty-Craige, Siobhan E.
   Li, Chun
   Lynn, Michael J.
   Cai, Jiyang
   Jones, Dean P.
   Sternberg, Paul
TI Associations of plasma-soluble Fas ligand with aging and age-related
   macular degeneration
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
ID C-REACTIVE PROTEIN; BLOOD MONONUCLEAR-CELLS; FACTOR-H POLYMORPHISM;
   OXIDATIVE STRESS; T-LYMPHOCYTES; APOPTOSIS; EXPRESSION; CD95; RELEASE;
   DEATH
AB PURPOSE. To evaluate the associations between plasma-soluble Fas ligand (sFasL) and age-related macular degeneration (AMD).
   METHODS. Plasma samples were obtained from 230 individuals (age range, 45-85), with or without AMD. The concentrations of sFasL were determined by an enzyme-linked immunosorbent assay (ELISA). The measured sFasL levels were transformed into cubic roots and were fitted into linear regression models against AMD status, with adjustment for age and sex.
   RESULTS. Plasma sFasL increased with age and AMD. There was a linear correlation between age and the cubic roots of sFasL. The plasma sFasL concentrations in non-AMD subjects ranged from 0 to 1.63 ng/mL (median, 0.69 ng/mL), whereas in patients with AMD, sFasL ranged from 0 to 2.43 ng/mL (median, 0.18 ng/mL). Between the ages of 61 and 84, the subjects with AMD had significantly higher sFasL than did the non-AMD subjects. There was a sexual dimorphism of the plasma sFasL levels. In non-AMD subjects, sFasL was lower in the females. In patients with AMD, sFasL was higher in the females.
   CONCLUSIONS. An elevation of plasma sFasL with aging may play a role in the development of AMD and is a potential peripheral marker for monitoring disease progression.
C1 [Cai, Jiyang; Sternberg, Paul] Vanderbilt Univ, Med Ctr, Vanderbilt Eye Inst, Nashville, TN 37232 USA.
   [Lynn, Michael J.] Emory Univ, Rollins Sch Publ Hlth, Dept Biostat, Atlanta, GA 30322 USA.
   [Jiang, Shunai; Moriarty-Craige, Siobhan E.; Jones, Dean P.] Emory Univ, Sch Med, Dept Med, Atlanta, GA 30322 USA.
   [Jiang, Shunai] Univ Louisville, Dept Ophthalmol & Visual Sci, Louisville, KY 40292 USA.
   [Li, Chun] Vanderbilt Univ, Med Ctr, Dept Biostat, Nashville, TN 37232 USA.
C3 Vanderbilt University; Emory University; Rollins School Public Health;
   Emory University; University of Louisville; Vanderbilt University
RP Sternberg, P (通讯作者)，Vanderbilt Univ, Med Ctr, Vanderbilt Eye Inst, 2311 Pierce Ave, Nashville, TN 37232 USA.
EM paul.sternberg@vanderbilt.edu
RI Li, Chun/B-8388-2012; Li, Chun/R-1095-2019
OI Li, Chun/0000-0002-8819-2443
FU NEI NIH HHS [EY07892] Funding Source: Medline; NIEHS NIH HHS [ES09047,
   ES06360] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY007892,
   R29EY007892] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF
   ENVIRONMENTAL HEALTH SCIENCES [R01ES009047] Funding Source: NIH RePORTER
CR Aggarwal S, 1998, J IMMUNOL, V160, P1627
   Anand R, 2000, OPHTHALMOLOGY, V107, P2224
   Baran J, 2001, INFECT IMMUN, V69, P1287, DOI 10.1128/IAI.69.3.1287-1297.2001
   Bokov A, 2004, MECH AGEING DEV, V125, P811, DOI 10.1016/j.mad.2004.07.009
   Bruserud O, 2000, CANCER IMMUNOL IMMUN, V49, P377, DOI 10.1007/s002620000133
   Das H, 1999, BRIT J HAEMATOL, V104, P795, DOI 10.1046/j.1365-2141.1999.01246.x
   Dasch B, 2005, ARCH OPHTHALMOL-CHIC, V123, P1501, DOI 10.1001/archopht.123.11.1501
   Dockrell DH, 2003, CLIN MICROBIOL INFEC, V9, P766, DOI 10.1046/j.1469-0691.2003.00669.x
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Fas SC, 2006, CURR DIRECT AUTOIMMU, V9, P1
   Ferguson TA, 2006, IMMUNOL REV, V213, P228, DOI 10.1111/j.1600-065X.2006.00430.x
   Gaillard RC, 1998, DOMEST ANIM ENDOCRIN, V15, P345, DOI 10.1016/S0739-7240(98)00028-9
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Hashimoto H, 1998, ARTHRITIS RHEUM, V41, P657, DOI 10.1002/1529-0131(199804)41:4<657::AID-ART12>3.0.CO;2-N
   Hosaka N, 1998, J INFECT DIS, V178, P1030, DOI 10.1086/515700
   ITOH N, 1991, CELL, V66, P233, DOI 10.1016/0092-8674(91)90614-5
   Jiang SN, 2000, INVEST OPHTH VIS SCI, V41, P645
   Joseph JA, 2005, NEUROCHEM RES, V30, P927, DOI 10.1007/s11064-005-6967-4
   Kalayoglu MV, 2003, ARCH OPHTHALMOL-CHIC, V121, P478, DOI 10.1001/archopht.121.4.478
   Kaplan HJ, 1999, NAT MED, V5, P292, DOI 10.1038/6509
   KATSIKIS PD, 1995, J EXP MED, V181, P2029, DOI 10.1084/jem.181.6.2029
   KAYAGAKI N, 1995, J EXP MED, V182, P1777, DOI 10.1084/jem.182.6.1777
   Klein R, 2005, AM J OPHTHALMOL, V140, P35, DOI 10.1016/j.ajo.2005.01.051
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Lambooij AC, 2001, AM J OPHTHALMOL, V132, P437, DOI 10.1016/S0002-9394(01)01011-X
   Lapinski TW, 2005, HEPATO-GASTROENTEROL, V52, P1479
   McGwin G, 2005, BRIT J OPHTHALMOL, V89, P1166, DOI 10.1136/bjo.2005.067397
   Miller DM, 2004, AM J OPHTHALMOL, V138, P323, DOI 10.1016/j.ajo.2004.03.018
   Neff TA, 2005, AM J PATHOL, V166, P685, DOI 10.1016/S0002-9440(10)62290-0
   Okura T, 2002, J HYPERTENS, V20, P895, DOI 10.1097/00004872-200205000-00024
   Phelouzat MA, 1997, MECH AGEING DEV, V96, P35, DOI 10.1016/S0047-6374(97)01883-6
   Seddon JM, 2005, ARCH OPHTHALMOL-CHIC, V123, P774, DOI 10.1001/archopht.123.6.774
   Seddon JM, 2004, JAMA-J AM MED ASSOC, V291, P704, DOI 10.1001/jama.291.6.704
   Seddon JM, 2006, HUM HERED, V61, P157, DOI 10.1159/000094141
   Semkova I, 2006, FASEB J, V20, P1689, DOI 10.1096/fj.05-5653fje
   Serrao KL, 2001, AM J PHYSIOL-LUNG C, V280, pL298, DOI 10.1152/ajplung.2001.280.2.L298
   SUDA T, 1994, J EXP MED, V179, P873, DOI 10.1084/jem.179.3.873
   Sugimoto M, 1998, CLIN EXP IMMUNOL, V112, P120
   Suzuki Mayumi, 2006, J Inflamm (Lond), V3, P11, DOI 10.1186/1476-9255-3-11
   Wajant H, 2006, CANC TREAT, V130, P141
   Yu BP, 2006, MECH AGEING DEV, V127, P436, DOI 10.1016/j.mad.2006.01.023
   Zarbin MA, 2004, ARCH OPHTHALMOL-CHIC, V122, P598, DOI 10.1001/archopht.122.4.598
NR 43
TC 20
Z9 22
U1 0
U2 1
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD APR
PY 2008
VL 49
IS 4
BP 1345
EP 1349
DI 10.1167/iovs.07-0308
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 282ON
UT WOS:000254577200010
PM 18385048
DA 2022-11-30
ER

PT J
AU Guymer, RH
   Tan, RS
   Luu, CD
AF Guymer, Robyn H.
   Tan, Rose S.
   Luu, Chi D.
TI Comparison of Visual Function Tests in Intermediate Age-Related Macular
   Degeneration
SO TRANSLATIONAL VISION SCIENCE & TECHNOLOGY
LA English
DT Article
DE dark adaptation; scotopic sensitivity; age-related macular degeneration
ID MEDIATED DARK-ADAPTATION; ROD FUNCTION; CONE; MICROPERIMETRY; ACUITY
AB Purpose: Identifying the most sensitive functional measure in intermediate age-related macular degeneration (iAMD) could help select an appropriate test for monitoring disease progression and evaluating the efficacy of novel interventions for the early stages of AMD. The purpose of the study was to determine which commonly used visual function test is the most discriminatory when comparing individuals with iAMD to normal participants. Methods: In this prospective observational study, iAMD cases and healthy controls underwent visual function testing (best corrected visual acuity (BCVA), low luminance visual acuity (LLVA), mesopic microperimetry, dark adaptation, and scotopic perimetry following photobleach), clinical eye examination, and multimodal retinal imaging in a single study visit. The data of each functional parameter were converted into z-score so that all the parameters had a common scale to allow a direct comparison between different functional parameters. Results: Forty-eight subjects (23 normal control, 25 iAMD) participated. Although all five parameters showed a significant reduction in function in iAMD eyes compared to controls (P <= 0.003), the rod intercept time (RIT) detected the greatest reduction in function followed by the scotopic sensitivity, mesopic sensitivity, BCVA, and LLVA, with the absolute mean z-score of 4.5, 2.2, 1.0, 1.0, and 1.2, respectively. Conclusions: Among the five visual function parameters commonly used, RIT is the most discriminatory functional parameter in the early stages of AMD. Translational Relevance: The RIT could be considered for assessing visual function and evaluating efficacy of novel interventions aimed at improving retinal function in eyes with early stages of AMD.
C1 [Guymer, Robyn H.; Tan, Rose S.; Luu, Chi D.] Royal Victorian Eye & Ear Hosp, Ctr Eye Res Australia, Melbourne, Vic, Australia.
   [Guymer, Robyn H.; Tan, Rose S.; Luu, Chi D.] Univ Melbourne, Dept Surg, Ophthalmol, Melbourne, Vic, Australia.
C3 Centre for Eye Research Australia; Royal Victorian Eye & Ear Hospital;
   University of Melbourne
RP Luu, CD (通讯作者)，Ctr Eye Res Australia, Level 8 SFW,32 Gisborne St, Melbourne, Vic 3002, Australia.
EM cluu@unimelb.edu.au
OI Rose, Rose/0000-0002-7351-2774
FU Ryan Initiative for Macular Research, Australia Awards Scholarship
   (RST), National Health and Medical Research Council (NHMRC) Fellowship
   [GNT1103013]
FX Supported by Ryan Initiative for Macular Research, Australia Awards
   Scholarship (RST) , National Health and Medical Research Council (NHMRC)
   Fellowship (GNT1103013, RHG) . The Centre for Eye Research Australia
   (CERA) receives Operational Infrastructure Support from the Victorian
   Government.
CR Age-Related Eye Disease Study 2 Research Group, 2013, JAMA, V309, P2005, DOI 10.1001/jama.2013.4997
   Binns AM, 2018, INVEST OPHTH VIS SCI, V59, pAMD114, DOI 10.1167/iovs.18-24211
   Chen KG, 2019, OPHTHALMOLOGY, V126, P856, DOI 10.1016/j.ophtha.2018.09.039
   Dimitrov PN, 2008, INVEST OPHTH VIS SCI, V49, P55, DOI 10.1167/iovs.06-1048
   Dimitrov PN, 2012, INVEST OPHTH VIS SCI, V53, P5213, DOI 10.1167/iovs.11-8958
   Dimitrov PN, 2011, INVEST OPHTH VIS SCI, V52, P9457, DOI 10.1167/iovs.10-7043
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Flamendorf J, 2015, OPHTHALMOLOGY, V122, P2053, DOI 10.1016/j.ophtha.2015.06.023
   Fraser RG, 2016, INVEST OPHTH VIS SCI, V57, P5436, DOI 10.1167/iovs.16-19295
   Guymer RH, 2020, OPHTHALMOLOGY, V127, P394, DOI 10.1016/j.ophtha.2019.09.035
   Jackson GR, 2014, INVEST OPHTH VIS SCI, V55, DOI 10.1167/iovs.13-13745
   Lamb TD, 2004, PROG RETIN EYE RES, V23, P307, DOI 10.1016/j.preteyeres.2004.03.001
   Lamb TD, 2006, INVEST OPHTH VIS SCI, V47, P5138, DOI 10.1167/iovs.06-0849
   Owsley C, 2007, OPHTHALMOLOGY, V114, P1728, DOI 10.1016/j.ophtha.2006.12.023
   Owsley C, 2016, OPHTHALMOLOGY, V123, P344, DOI 10.1016/j.ophtha.2015.09.041
   Owsley C, 2014, INVEST OPHTH VIS SCI, V55, P4776, DOI 10.1167/iovs.14-14502
   Pfau M, 2018, EYE, V32, P1819, DOI 10.1038/s41433-018-0183-3
   Pondorfer SG, 2020, INVEST OPHTH VIS SCI, V61, DOI 10.1167/iovs.61.3.55
   Puell MC, 2012, INVEST OPHTH VIS SCI, V53, P7310, DOI 10.1167/iovs.11-8649
   Rodrigo-Diaz E, 2019, INVEST OPHTH VIS SCI, V60, P5070, DOI 10.1167/iovs.19-27971
   Sadda SR, 2018, OPHTHALMOLOGY, V125, P537, DOI 10.1016/j.ophtha.2017.09.028
   SanGiovanni JP, 2007, ARCH OPHTHALMOL-CHIC, V125, P1225, DOI 10.1001/archopht.125.9.1225
   Tan R, 2018, INVEST OPHTH VIS SCI, V59, P4154, DOI 10.1167/iovs.18-23970
   Tan RS, 2019, INVEST OPHTH VIS SCI, V60, P1511, DOI 10.1167/iovs.18-26385
   Thylefors B, 2002, OPHTHALMIC EPIDEMIOL, V9, P83, DOI 10.1076/opep.9.2.83.1523
   WALD G, 1945, SCIENCE, V101, P653, DOI 10.1126/science.101.2635.653
   Wu ZC, 2016, BRIT J OPHTHALMOL, V100, P395, DOI 10.1136/bjophthalmol-2015-306621
   Wu ZC, 2015, JAMA OPHTHALMOL, V133, P442, DOI 10.1001/jamaophthalmol.2014.5963
   Wu ZC, 2014, INVEST OPHTH VIS SCI, V55, P6431, DOI 10.1167/iovs.14-14407
   Wu ZC, 2014, OPHTHALMOLOGY, V121, P1612, DOI 10.1016/j.ophtha.2014.02.005
   ZEAVIN BH, 1956, AM J OPHTHALMOL, V42, P253, DOI 10.1016/0002-9394(56)90377-4
NR 31
TC 0
Z9 0
U1 0
U2 1
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 2164-2591
J9 TRANSL VIS SCI TECHN
JI Transl. Vis. Sci. Technol.
PD OCT
PY 2021
VL 10
IS 12
AR 14
DI 10.1167/tvst.10.12.14
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA XM9GY
UT WOS:000729127100001
PM 34636906
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Shahidi, M
   Blair, NP
   Mori, M
   Gieser, J
   Pulido, JS
AF Shahidi, M
   Blair, NP
   Mori, M
   Gieser, J
   Pulido, JS
TI Retinal topography and thickness mapping in atrophic age related macular
   degeneration
SO BRITISH JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID OPTICAL COHERENCE TOMOGRAPHY; LASER BIOMICROSCOPY; GEOGRAPHIC ATROPHY;
   POSTERIOR POLE; DRUSEN; DISEASES; AUTOFLUORESCENCE; VISUALIZATION;
   PATHOGENESIS; MACULOPATHY
AB Aim: To determine the relation between alterations in the retinal topography and thickness, visual acuity, and retinal pigment epithelium hypopigmentation in atrophic age related macular degeneration (AMD).
   Methods: 22 patients, mean age 74 (SID 8) years, with afrophic AMD were recruited. An optical imaging system based on the retinal thickness analyser (RTA) was applied to generate a series of 20 optical section images that encompass 2 mm x 2 mm retinal areas. The optical section images were digitised and analysed to provide topographic maps of the vitreoretinal and chorioretinal surfaces and the retinal thickness. Vitreorefinal and choriorefinal surface elevations and retinal thickness were determined.
   Results: Variation in the vitreoretinal surface height was iderately correlated with visual acuity (r = -0.4; p = 0.03; n = 22). Increase in variation of chorioretinal surface height was correlated with decrease in visual aculity (r = -0.5; p = 0.01; n = 22). The retinal thickness was not associated with visual acuity (r = 0.2; p = 0.2; n=22). Relative height of the vitreoretinal surface in eyes with retinal pigment epithelium (RPE) hypopigmentation was significantly less than eyes without RPE hypopigmentation (p=0.005). Eyes with and without RPE hypopigmentation relative height of the chorioretinal surface (p=0.4). Retinal thickness in eyes with RPE hypopigmentation was less than in eyes without RPE hypopigmentation (p=0.04).
   Conclusion: Mapping of chorloretinal and vitreoretinal topography and retinal thickness provides objective and quantitative measurements of retinal structural abnormalities and shows promise as an adjunct for the evaluation of retinal structural changes due to AMD.
C1 Univ Illinois, Dept Ophthalmol & Visual Sci, Chicago, IL 60612 USA.
C3 University of Illinois System; University of Illinois Chicago;
   University of Illinois Chicago Hospital
RP Shahidi, M (通讯作者)，Univ Illinois, Dept Ophthalmol & Visual Sci, 1855 W Taylor St, Chicago, IL 60612 USA.
EM mahnshah@uic.edu
FU NEI NIH HHS [EY1792, P30 EY001792, EY10314] Funding Source: Medline;
   NATIONAL EYE INSTITUTE [P30EY001792, R29EY010314] Funding Source: NIH
   RePORTER
CR Abdelsalam A, 1999, SURV OPHTHALMOL, V44, P1, DOI 10.1016/S0039-6257(99)00072-7
   Asrani S, 1997, OPHTHALMOLOGY, V104, P1145, DOI 10.1016/S0161-6420(97)30170-5
   Asrani S, 1999, OPHTHALMOLOGY, V106, P269, DOI 10.1016/S0161-6420(99)90057-X
   BARTSCH DU, 1989, AM J OPHTHALMOL, V108, P277, DOI 10.1016/0002-9394(89)90118-9
   BILLE JF, 1990, NONINVASIVE DIAGNOST, P528
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Born M, 1980, PRINCIPLES OPTICS EL
   BRESSLER NM, 1994, RETINA-J RET VIT DIS, V14, P130, DOI 10.1097/00006982-199414020-00006
   Delori FC, 2000, INVEST OPHTH VIS SCI, V41, P496
   FERRIS FL, 1983, AM J EPIDEMIOL, V118, P132, DOI 10.1093/oxfordjournals.aje.a113624
   Fitzke F. W., 1991, LASER LIGHT OPHTHALM, V4, P7
   Gieser JP, 1997, AM J OPHTHALMOL, V124, P648, DOI 10.1016/S0002-9394(14)70903-1
   Gieser JP, 2001, RETINA-J RET VIT DIS, V21, P352, DOI 10.1097/00006982-200108000-00010
   GREEN WR, 1993, OPHTHALMOLOGY, V100, P1519
   Hee MR, 1996, OPHTHALMOLOGY, V103, P1260, DOI 10.1016/S0161-6420(96)30512-5
   HEE MR, 1995, ARCH OPHTHALMOL-CHIC, V113, P325, DOI 10.1001/archopht.1995.01100030081025
   Holz FG, 1999, GRAEF ARCH CLIN EXP, V237, P145, DOI 10.1007/s004170050209
   HUANG D, 1991, SCIENCE, V254, P1178, DOI 10.1126/science.1957169
   KIRYU J, 1993, OPHTHALMOLOGY, V100, P1040
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Leibowitz H M, 1980, Surv Ophthalmol, V24, P335
   Mullins RF, 2000, FASEB J, V14, P835, DOI 10.1096/fasebj.14.7.835
   OGURA Y, 1991, ARCH OPHTHALMOL-CHIC, V109, P957, DOI 10.1001/archopht.1991.01080070069037
   PULIAFITO CA, 1995, OPHTHALMOLOGY, V102, P217
   Russell SR, 2000, AM J OPHTHALMOL, V129, P205, DOI 10.1016/S0002-9394(99)00345-1
   SORSBY A, 1972, INCIDENCE CAUSES BLI, P128
   Spraul CW, 1998, KLIN MONATSBL AUGENH, V212, P141, DOI 10.1055/s-2008-1034850
   Sunness JS, 1999, MOL VIS, V5
   Sunness JS, 1999, OPHTHALMOLOGY, V106, P1768, DOI 10.1016/S0161-6420(99)90340-8
   VINGERLING JR, 1995, OPHTHALMOLOGY, V102, P205
   WOON WH, 1992, BRIT J OPHTHALMOL, V76, P470, DOI 10.1136/bjo.76.8.470
   Zarbin MA, 1998, EUR J OPHTHALMOL, V8, P199, DOI 10.1177/112067219800800401
   Zeimer R, 1996, INVEST OPHTH VIS SCI, V37, P1994
NR 33
TC 13
Z9 18
U1 0
U2 1
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0007-1161
EI 1468-2079
J9 BRIT J OPHTHALMOL
JI Br. J. Ophthalmol.
PD JUN
PY 2002
VL 86
IS 6
BP 623
EP 626
DI 10.1136/bjo.86.6.623
PG 4
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 561WH
UT WOS:000176165700009
PM 12034682
OA Bronze, Green Submitted, Green Published
DA 2022-11-30
ER

PT J
AU Leveziel, N
   Puche, N
   Richard, F
   Somner, JEA
   Zerbib, J
   Bastuji-Garin, S
   Cohen, SY
   Korobelnik, JF
   Sahel, J
   Soubrane, G
   Benlian, P
   Souied, EH
AF Leveziel, Nicolas
   Puche, Nathalie
   Richard, Florence
   Somner, John E. A.
   Zerbib, Jennyfer
   Bastuji-Garin, Sylvie
   Cohen, Salomon Y.
   Korobelnik, Jean-Francois
   Sahel, Jose
   Soubrane, Gisele
   Benlian, Pascale
   Souied, Eric H.
TI Genotypic Influences on Severity of Exudative Age-Related Macular
   Degeneration
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
ID COMPLEMENT-FACTOR-H; CHOROIDAL NEOVASCULARIZATION; CIGARETTE-SMOKING;
   FRENCH POPULATION; Y402H VARIANT; LARGE FAMILY; GENE; PREVALENCE;
   ASSOCIATION; SUSCEPTIBILITY
AB PURPOSE. Major genetic risk factors have recently been identified for age-related macular degeneration (AMD), including the ARMS2/LOC387715 and CFH at-risk polymorphisms. The study was conducted to establish correlations between the AMD genotype and both the phenotype and severity of AMD.
   METHODS. In a prospective cohort of 1216 AMD patients, four genotypic homozygous groups were identified (n = 264): double homozygous for wild-type alleles (group 1, n = 49), homozygous for the at-risk allele of ARMS2/LOC387715 only (group 2, n = 57), homozygous for the at-risk allele of CFH only (group 3, n = 106), and double homozygous for both at-risk alleles (group 4, n = 52). The phenotypic classification of exudative AMD was based on fluorescein angiography.
   RESULTS. Mean age at presentation was significantly lower in group 4 than in group 1 (P < 0.014). Patients in group 4 presented more often with bilateral CNV and fibrovascular scars than did patients in group 1 (P < 0.001 and < 0.0031 respectively) and with significantly lower visual acuity (VA) in the first affected eye than did patients in group 1 (P < 0.02). Patients in group 2 presented with worse VA than did patients in group 3 (P < 0.003). Classic CNV was more commonly associated with the at-risk allele of the ARMS2/LOC387715 locus than with the at-risk allele of the CFH gene (P < 0.026).
   CONCLUSIONS. This study demonstrates an association between the at-risk allele of the ARMS2/LOC387715 locus and classic CNV, fibrovascular lesions, and poor VA. Individuals double homozygous for both at-risk alleles had a higher risk of being affected with a severe form of AMD at an earlier age. (Invest Ophthalmol Vis Sci. 2010;51:2620-2625) DOI:10.1167/iovs.09-4423
C1 [Leveziel, Nicolas; Puche, Nathalie; Zerbib, Jennyfer; Soubrane, Gisele; Souied, Eric H.] Univ Paris 12, Fac Med Henri Mondor, Dept Ophthalmol, Creteil, France.
   [Bastuji-Garin, Sylvie] Univ Paris 12, Dept Clin Res & Publ Hlth, AP HP, Grp Hosp Albert Chenevier Henri Mondor, Creteil, France.
   [Richard, Florence] Univ Lille 2, INSERM, UMR 744, Inst Pasteur, Lille, France.
   [Somner, John E. A.] Gartnavel Royal Hosp, Tennent Inst Ophthalmol, Glasgow, Lanark, Scotland.
   [Cohen, Salomon Y.] Ophthalmol Ctr Imaging & Laser, Paris, France.
   [Korobelnik, Jean-Francois] Univ Bordeaux 2, INSERM, U897, CHU Bordeaux,Dept Ophthalmol, F-33076 Bordeaux, France.
   [Sahel, Jose] Univ Paris 06, INSERM, Inst Vis, Paris, France.
   [Benlian, Pascale] CHU, UMRS 538, Paris, France.
C3 Assistance Publique Hopitaux Paris (APHP); Universite
   Paris-Est-Creteil-Val-de-Marne (UPEC); Hopital Universitaire
   Henri-Mondor - APHP; Assistance Publique Hopitaux Paris (APHP);
   Universite Paris-Est-Creteil-Val-de-Marne (UPEC); Hopital Universitaire
   Henri-Mondor - APHP; Institut National de la Sante et de la Recherche
   Medicale (Inserm); Le Reseau International des Instituts Pasteur (RIIP);
   Universite de Lille - ISITE; Institut Pasteur Lille; Universite de
   Lille; Gartnavel Royal Hospital; CHU Bordeaux; Institut National de la
   Sante et de la Recherche Medicale (Inserm); UDICE-French Research
   Universities; Universite de Bordeaux; Institut National de la Sante et
   de la Recherche Medicale (Inserm); UDICE-French Research Universities;
   Sorbonne Universite; Assistance Publique Hopitaux Paris (APHP)
RP Souied, EH (通讯作者)，Creteil Univ, Eye Clin, 40 Ave Verdun, F-94000 Creteil, France.
EM eric.souied@chicreteil.fr
RI Bastuji-Garin, Sylvie/R-3479-2018; Sahel, Jose-Alain/F-3172-2017;
   KOROBELNIK, Jean-Francois/A-5448-2016; Benlian, Pascale/I-7964-2016
OI Bastuji-Garin, Sylvie/0000-0001-9855-5183; Sahel,
   Jose-Alain/0000-0002-4831-1153; Benlian, Pascale/0000-0002-3423-8979;
   Nicolas, Leveziel/0000-0001-8533-9457
CR Allikmets R, 2000, AM J HUM GENET, V67, P487, DOI 10.1086/303018
   Boon CJF, 2009, MOL IMMUNOL, V46, P1573, DOI 10.1016/j.molimm.2009.02.013
   Brantley MA, 2007, AM J OPHTHALMOL, V144, P404, DOI 10.1016/j.ajo.2007.05.018
   Cohen SY, 2007, BRIT J OPHTHALMOL, V91, P354, DOI 10.1136/bjo.2006.101022
   Cohen SY, 2007, BRIT J OPHTHALMOL, V91, P1173, DOI 10.1136/bjo.2007.115501
   Conley YP, 2005, HUM MOL GENET, V14, P1991, DOI 10.1093/hmg/ddi204
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   Gotoh N, 2008, CLIN EXP OPHTHALMOL, V36, P437, DOI 10.1111/j.1442-9071.2008.01791.x
   Haddad S, 2006, SURV OPHTHALMOL, V51, P316, DOI 10.1016/j.survophthal.2006.05.001
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Hughes AE, 2007, PLOS MED, V4, P1993, DOI 10.1371/journal.pmed.0040355
   Jakobsdottir J, 2005, AM J HUM GENET, V77, P389, DOI 10.1086/444437
   KAHN HA, 1977, AM J EPIDEMIOL, V106, P17, DOI 10.1093/oxfordjournals.aje.a112428
   Kaur I, 2008, INVEST OPHTH VIS SCI, V49, P1771, DOI 10.1167/iovs.07-0560
   Khan JC, 2006, BRIT J OPHTHALMOL, V90, P75, DOI 10.1136/bjo.2005.073643
   Klaver CCW, 1998, ARCH OPHTHALMOL-CHIC, V116, P653, DOI 10.1001/archopht.116.5.653
   Klein ML, 1998, ARCH OPHTHALMOL-CHIC, V116, P1082, DOI 10.1001/archopht.116.8.1082
   Klein R, 2006, OPHTHALMOLOGY, V113, P373, DOI 10.1016/j.ophtha.2005.12.013
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Klein R, 2006, AM J OPHTHALMOL, V142, P539, DOI 10.1016/j.ajo.2006.06.015
   Leveziel N, 2008, INVEST OPHTH VIS SCI, V49, P3090, DOI 10.1167/iovs.07-1540
   Leveziel N, 2007, MOL VIS, V13, P2153
   Pai ASI, 2009, ARCH OPHTHALMOL-CHIC, V127, P1339, DOI 10.1001/archophthalmol.2009.239
   Penfold PL, 2001, PROG RETIN EYE RES, V20, P385, DOI 10.1016/S1350-9462(00)00025-2
   Recalde S, 2008, OPHTHALMOLOGY, V115, P916, DOI 10.1016/j.ophtha.2007.12.012
   Rivera A, 2005, HUM MOL GENET, V14, P3227, DOI 10.1093/hmg/ddi353
   Schmidt S, 2006, AM J HUM GENET, V78, P852, DOI 10.1086/503822
   Schultz DW, 2003, HUM MOL GENET, V12, P3315, DOI 10.1093/hmg/ddg348
   Seddon JM, 2005, ARCH OPHTHALMOL-CHIC, V123, P321, DOI 10.1001/archopht.123.3.321
   Seddon JM, 2007, JAMA-J AM MED ASSOC, V297, P1793, DOI 10.1001/jama.297.16.1793
   Seddon JM, 2009, INVEST OPHTH VIS SCI, V50, P2044, DOI 10.1167/iovs.08-3064
   Seitsonen SP, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003833
   SOUBRANE G, 1990, OPHTHALMOLOGY, V97, P649
   Souied EH, 1998, AM J OPHTHALMOL, V125, P353, DOI 10.1016/S0002-9394(99)80146-9
   Souied EH, 2005, MOL VIS, V11, P1135
   Thakkinstian A, 2006, HUM MOL GENET, V15, P2784, DOI 10.1093/hmg/ddl220
   Ting AYC, 2009, CURR OPIN OPHTHALMOL, V20, P369, DOI 10.1097/ICU.0b013e32832f8016
   Tomany SC, 2004, OPHTHALMOLOGY, V111, P1280, DOI 10.1016/j.ophtha.2003.11.010
   Varma R, 2004, OPHTHALMOLOGY, V111, P1288, DOI 10.1016/j.ophtha.2004.01.023
   VINGERLING JR, 1995, OPHTHALMOLOGY, V102, P205
   Wegscheider BJ, 2007, OPHTHALMOLOGY, V114, P738, DOI 10.1016/j.ophtha.2006.07.048
   Yang ZL, 2006, SCIENCE, V314, P992, DOI 10.1126/science.1133811
   Yannuzzi LA, 2001, RETINA-J RET VIT DIS, V21, P416, DOI 10.1097/00006982-200110000-00003
   Zareparsi S, 2005, AM J HUM GENET, V77, P149, DOI 10.1086/431426
   Zerbib J, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007341
NR 48
TC 23
Z9 25
U1 0
U2 1
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD MAY
PY 2010
VL 51
IS 5
BP 2620
EP 2625
DI 10.1167/iovs.09-4423
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 589UU
UT WOS:000277180500044
PM 20042647
DA 2022-11-30
ER

PT J
AU Rosenfeld, PJ
   Trivizki, OMER
   Gregori, GIOVANNI
   Wang, RK
AF Rosenfeld, Philip j.
   Trivizki, O. M. E. R.
   Gregori, G. I. O. V. A. N. N. I.
   Wang, Ruikang k.
TI An Update on the Hemodynamic Model of Age-Related Macular Degeneration
SO AMERICAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID CHOROIDAL BLOOD-FLOW; GEOGRAPHIC ATROPHY; RETICULAR PSEUDODRUSEN;
   HYPERREFLECTIVE FOCI; CHORIOCAPILLARIS; ASSOCIATION; DRUSEN; DISEASE;
   EYES; OCT
AB PURPOSE: To provide an update on the hemodynamic model of age-related macular degeneration (AMD).
   DESIGN: Evidence-based perspective.
   METHODS: Review of the literature and experience of the authors.
   RESULTS: Choroidal hemodynamics are not the primary cause of AMD as proposed by Ephraim Friedman in 1997. However, evidence is accumulating to suggest that choroidal perfusion is an important environmental influence that contributes to our understanding of disease progression in this complex genetic disorder. Although early and intermediate AMD seem to be influenced to a large extent by the underlying genetics, the asymmetry of disease progression to the later stages of AMD cannot be explained by genetics alone. The progression of disease and the asymmetry of this progression seem to correlate with abnormalities in choroidal perfusion that can be documented by optical coherence tomography. These perfusion abnormalities in the setting of a thickened Bruch's membrane are thought to exacerbate the impaired nutritional exchange between the retinal pigment epithelium and the choriocapillaris. We propose that the genetic susceptibility to develop AMD combined with age-related changes in macular choroidal hemodynamics, such as increasing choriocapillaris perfusion deficits and decreasing choroidal vascular densities, play an important role in disease progression and may help to explain the asymmetry between eyes, particularly in the later stages of AMD.
   CONCLUSIONS: This updated hemodynamic model of AMD focuses on disease progression and highlights the importance of age-related changes in the choroidal circulation as a major environmental influence on disease severity in eyes that are genetically susceptible to develop AMD. (C) 2021 Elsevier Inc. All rights reserved.
C1 [Rosenfeld, Philip j.; Trivizki, O. M. E. R.; Gregori, G. I. O. V. A. N. N. I.] Univ Miami, Dept Ophthalmol, Bascom Palmer Eye Insti tute, Miller Sch Med, Miami, FL USA.
   [Trivizki, O. M. E. R.] Tel Aviv Univ, Tel Aviv Med Ctr, Dept Ophthalmol, Tel Aviv, Israel.
   [Wang, Ruikang k.] Univ Washington, Dept Bioengn, Seattle, WA USA.
   [Wang, Ruikang k.] Univ Washington, Dept Ophthalmol, Seattle, WA USA.
   [Wang, Ruikang k.] Univ Washington, Dept Ophthalmol, Seattle, WA USA.
   [Rosenfeld, Philip j.] Bascom Palmer Eye Inst, 900 NW 17th St, Miami, FL 33136 USA.
C3 University of Miami; Tel Aviv University; Sackler Faculty of Medicine;
   University of Washington; University of Washington Seattle; University
   of Washington; University of Washington Seattle; University of
   Washington; University of Washington Seattle; Bascom Palmer Eye
   Institute
RP Rosenfeld, PJ (通讯作者)，Bascom Palmer Eye Inst, 900 NW 17th St, Miami, FL 33136 USA.
EM prosenfeld@miami.edu
RI Wang, Ruikang/L-3889-2019
OI Wang, Ruikang/0000-0001-5169-8822; Rosenfeld, Philip/0000-0002-4068-6671
FU Salah Foundation; Carl Zeiss Meditec; Research to Prevent Blindness,
   Inc. (New York, NY); National Eye Institute Center Core Grant
   [P30EY014801]; National Eye Institute [R01EY024158, R01EY028753]
FX Funding/Support: Dr Rosenfeld?s and Dr Gregori?s research is supported
   by grants from the Salah Foundation, Carl Zeiss Meditec, an unrestricted
   grant from the Research to Prevent Blindness, Inc. (New York, NY) , and
   the National Eye Institute Center Core Grant (P30EY014801) to the
   Department of Oph-thalmology, University of Miami Miller School of
   Medicine. Dr Wang?s research is supported by the National Eye Institute
   (R01EY024158, R01EY028753) . The funding organizations had no role in
   the design or conduct of this research.
CR Agrawal R, 2020, PROG RETIN EYE RES, V77, DOI 10.1016/j.preteyeres.2020.100829
   Alten F, 2016, GRAEF ARCH CLIN EXP, V254, P2165, DOI 10.1007/s00417-016-3375-1
   Anderson DH, 2010, PROG RETIN EYE RES, V29, P95, DOI 10.1016/j.preteyeres.2009.11.003
   Berenberg TL, 2012, RETINA-J RET VIT DIS, V32, P25, DOI 10.1097/IAE.0b013e3182150483
   Borrelli E, 2019, OPHTHALMOL RETINA, V3, P979, DOI 10.1016/j.oret.2019.05.026
   Borrelli E, 2018, RETINA-J RET VIT DIS, V38, P1968, DOI 10.1097/IAE.0000000000002198
   Cerniauskas E, 2020, STEM CELL TRANSL MED, V9, P1585, DOI 10.1002/sctm.20-0211
   Chakravarthy U, 2010, BMC OPHTHALMOL, V10, DOI 10.1186/1471-2415-10-31
   Chamberlain M, 2006, SURV OPHTHALMOL, V51, P576, DOI 10.1016/j.survophthal.2006.08.003
   Chatziralli I, 2018, INT OPHTHALMOL, V38, P1887, DOI 10.1007/s10792-017-0671-7
   Chavali VRM, 2015, J CLIN MED, V4, P304, DOI 10.3390/jcm4020304
   CHEN JC, 1992, INVEST OPHTH VIS SCI, V33, P334
   Chen SJ, 2001, BRIT J OPHTHALMOL, V85, P1411, DOI 10.1136/bjo.85.12.1411
   Cheung CMG, 2014, J INTERN MED, V276, P140, DOI 10.1111/joim.12227
   Chu ZD, 2021, AM J OPHTHALMOL, V222, P92, DOI 10.1016/j.ajo.2020.08.045
   Ciulla TA, 1999, AM J OPHTHALMOL, V128, P75, DOI 10.1016/S0002-9394(99)00061-6
   Corvi F, 2021, GRAEF ARCH CLIN EXP, V259, P2887, DOI 10.1007/s00417-021-05167-3
   Cymerman RM, 2016, CURR EYE RES, V41, P1482, DOI 10.3109/02713683.2015.1128552
   Garcia CAD, 2014, OSLI RETINA, V45, P18, DOI 10.3928/23258160-20131217-01
   Dutheil C, 2020, JAMA OPHTHALMOL, V138, P467, DOI 10.1001/jamaophthalmol.2020.0266
   Ebeling MC., CELLS-BASEL, V10, P789
   Ehrlich R, 2008, CLIN INTERV AGING, V3, P473
   Feigl B, 2009, PROG RETIN EYE RES, V28, P63, DOI 10.1016/j.preteyeres.2008.11.004
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Fleckenstein M, 2021, NAT REV DIS PRIMERS, V7, DOI 10.1038/s41572-021-00265-2
   FRIEDMAN E, 1995, OPHTHALMOLOGY, V102, P640, DOI 10.1016/S0161-6420(95)30974-8
   Friedman E, 1997, AM J OPHTHALMOL, V124, P677, DOI 10.1016/S0002-9394(14)70906-7
   Fritsche LG, 2016, NAT GENET, V48, P134, DOI 10.1038/ng.3448
   Fritsche LG, 2014, ANNU REV GENOM HUM G, V15, P151, DOI 10.1146/annurev-genom-090413-025610
   Fujioka S, 2006, JPN J OPHTHALMOL, V50, P224, DOI 10.1007/s10384-005-0312-y
   Gangnon RE, 2015, JAMA OPHTHALMOL, V133, P125, DOI 10.1001/jamaophthalmol.2014.4252
   Grassmann F, 2019, JAMA OPHTHALMOL, V137, P867, DOI 10.1001/jamaophthalmol.2019.1318
   Grebe R, 2019, EXP EYE RES, V181, P252, DOI 10.1016/j.exer.2019.02.018
   Grunwald JE, 1998, INVEST OPHTH VIS SCI, V39, P385
   Grunwald JE, 2005, INVEST OPHTH VIS SCI, V46, P1033, DOI 10.1167/iovs.04-1050
   Guymer RH, 2020, OPHTHALMOLOGY, V127, P394, DOI 10.1016/j.ophtha.2019.09.035
   Hallam D, 2017, STEM CELLS, V35, P2305, DOI 10.1002/stem.2708
   Hayreh SS, 2006, EYE, V20, P1130, DOI 10.1038/sj.eye.6702377
   Hayreh S S, 1962, Br J Ophthalmol, V46, P65, DOI 10.1136/bjo.46.2.65
   Hayreh SS, 2017, OPHTHALMOL RETINA, V1, P12, DOI 10.1016/j.oret.2016.08.003
   Hibert ML, 2021, AM J NEURORADIOL, V42, P1653, DOI 10.3174/ajnr.A7187
   Hoffman JD, 2016, INVEST OPHTH VIS SCI, V57, P2225, DOI 10.1167/iovs.15-18571
   Hyman L, 2000, ARCH OPHTHALMOL-CHIC, V118, P351, DOI 10.1001/archopht.118.3.351
   Ishii M, 2016, J OPHTHALMOL, V2016, DOI 10.1155/2016/2530914
   Jaffe GJ, 2021, OPHTHALMOLOGY, V128, P576, DOI 10.1016/j.ophtha.2020.08.027
   Keenan TD, 2020, RETINA-J RET VIT DIS, V40, P632, DOI 10.1097/IAE.0000000000002434
   Keenan TD, 2018, OPHTHALMOLOGY, V125, P1913, DOI 10.1016/j.ophtha.2018.05.028
   Keilhauer CN, 2011, OPHTHALMIC GENET, V32, P237, DOI 10.3109/13816810.2011.592177
   Kersten E, 2017, JAMA OPHTHALMOL, V135, P1037, DOI 10.1001/jamaophthalmol.2017.3195
   Klein ML, 2010, OPHTHALMOLOGY, V117, P1554, DOI 10.1016/j.ophtha.2009.12.012
   Klein Ronald, 2003, Ophthalmology, V110, P1273, DOI 10.1016/S0161-6420(03)00599-2
   Lambert NG, 2016, PROG RETIN EYE RES, V54, P64, DOI 10.1016/j.preteyeres.2016.04.003
   Lei JQ, 2017, GRAEF ARCH CLIN EXP, V255, P1551, DOI 10.1007/s00417-017-3693-y
   Liao DS, 2020, OPHTHALMOLOGY, V127, P186, DOI 10.1016/j.ophtha.2019.07.011
   Lutty GA, 2020, EXP EYE RES, V192, DOI 10.1016/j.exer.2020.107939
   Mann SS, 2011, GRAEF ARCH CLIN EXP, V249, P209, DOI 10.1007/s00417-010-1483-x
   Mano F, 2021, OPHTHALMOL RETINA, V5, P743, DOI 10.1016/j.oret.2020.11.011
   Marsiglia M, 2013, INVEST OPHTH VIS SCI, V54, P7362, DOI 10.1167/iovs.12-11073
   Mehdizadeh Morteza, 2012, J Ophthalmic Vis Res, V7, P295
   Merle BMJ, 2020, INVEST OPHTH VIS SCI, V61, DOI 10.1167/iovs.61.5.17
   Metelitsina TI, 2008, INVEST OPHTH VIS SCI, V49, P358, DOI 10.1167/iovs.07-0526
   Moult EM, 2020, AM J OPHTHALMOL, V214, P172, DOI 10.1016/j.ajo.2019.12.006
   Moult EM, 2020, RETINA-J RET VIT DIS, V40, P428, DOI 10.1097/IAE.0000000000002556
   Moult EM, 2016, RETINA-J RET VIT DIS, V36, pS2, DOI 10.1097/IAE.0000000000001287
   Mullins RE, 2011, INVEST OPHTH VIS SCI, V52, P1606, DOI 10.1167/iovs.10-6476
   Nassisi M, 2019, OPHTHALMOLOGY, V126, P1667, DOI 10.1016/j.ophtha.2019.05.016
   Nassisi M, 2019, GRAEF ARCH CLIN EXP, V257, P2079, DOI 10.1007/s00417-019-04403-1
   Nassisi M, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0207638
   Nassisi M, 2018, INVEST OPHTH VIS SCI, V59, P3431, DOI 10.1167/iovs.18-24143
   Nesper PL, 2017, AM J OPHTHALMOL, V174, P42, DOI 10.1016/j.ajo.2016.10.005
   Pennington KL, 2016, EYE VISION, V3, DOI 10.1186/s40662-016-0063-5
   Pietraszkiewicz A, 2018, OPHTHALMOLOGY, V125, P398, DOI 10.1016/j.ophtha.2017.10.027
   PIGUET B, 1992, AM J OPHTHALMOL, V113, P657, DOI 10.1016/S0002-9394(14)74790-7
   Pournaras CJ, 2006, INVEST OPHTH VIS SCI, V47, P1581, DOI 10.1167/iovs.05-0434
   Rastogi N, 2016, SURV OPHTHALMOL, V61, P422, DOI 10.1016/j.survophthal.2015.10.003
   Reiter GS, 2020, INVEST OPHTH VIS SCI, V61, DOI 10.1167/iovs.61.6.11
   Sacconi R, 2019, BRIT J OPHTHALMOL, V103, P1320, DOI 10.1136/bjophthalmol-2018-313004
   Sadda SR, 2018, OPHTHALMOLOGY, V125, P537, DOI 10.1016/j.ophtha.2017.09.028
   Sandhu R, 2007, EYE, V21, P506, DOI 10.1038/sj.eye.6702242
   Schmidt-Erfurth U, 2020, AM J OPHTHALMOL, V216, P257, DOI 10.1016/j.ajo.2020.03.042
   Seddon JM, 2019, INVEST OPHTH VIS SCI, V60, P4469, DOI 10.1167/iovs.19-27475
   Shi YY, 2021, AM J OPHTHALMOL, V224, P321, DOI 10.1016/j.ajo.2020.12.015
   Shi YY, 2020, AM J OPHTHALMOL, V209, P18, DOI 10.1016/j.ajo.2019.09.017
   Sobrin L, 2014, PROG RETIN EYE RES, V40, P1, DOI 10.1016/j.preteyeres.2013.12.004
   Sohn EH, 2019, AM J PATHOL, V189, P1473, DOI 10.1016/j.ajpath.2019.04.005
   Spaide RF, 2020, RETINA-J RET VIT DIS, V40, P1851, DOI 10.1097/IAE.0000000000002931
   Spaide RF, 2020, OPHTHALMOLOGY, V127, P616, DOI 10.1016/j.ophtha.2019.11.004
   Spaide RF, 2018, SURV OPHTHALMOL, V63, P782, DOI 10.1016/j.survophthal.2018.05.005
   Spaide RF, 2016, AM J OPHTHALMOL, V170, P58, DOI 10.1016/j.ajo.2016.07.023
   Sura AA, 2020, INVEST OPHTH VIS SCI, V61, DOI 10.1167/iovs.61.13.19
   TAMLER E, 1961, AM J OPHTHALMOL, V52, P381, DOI 10.1016/0002-9394(61)90738-3
   Tan ACS, 2018, SCI TRANSL MED, V10, DOI 10.1126/scitranslmed.aat4544
   Thiele S, 2021, BRIT J OPHTHALMOL, V105, P239, DOI 10.1136/bjophthalmol-2020-316004
   Thulliez M, 2019, OPHTHALMOL RETINA, V3, P478, DOI 10.1016/j.oret.2019.01.024
   VAN ALLEN M W, 1960, Arch Neurol, V2, P74
   van Asten F, 2018, OPHTHALMOLOGY, V125, P559, DOI 10.1016/j.ophtha.2017.09.023
   van Leeuwen R, 2003, INVEST OPHTH VIS SCI, V44, P3771, DOI 10.1167/iovs.03-0121
   Veerappan M, 2016, OPHTHALMOLOGY, V123, P2554, DOI 10.1016/j.ophtha.2016.08.047
   VINGERLING JR, 1995, AM J EPIDEMIOL, V142, P404, DOI 10.1093/oxfordjournals.aje.a117648
   Winkler TW, 2020, BMC MED GENOMICS, V13, DOI 10.1186/s12920-020-00760-7
   Xu W, 2010, AM J OPHTHALMOL, V150, P40, DOI 10.1016/j.ajo.2010.01.041
   Zheng F, 2019, AM J OPHTHALMOL, V200, P110, DOI 10.1016/j.ajo.2018.12.025
   Zhou H, 2020, OPHTHALMOL RETINA, V4, P204, DOI 10.1016/j.oret.2019.09.012
NR 103
TC 4
Z9 4
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0002-9394
EI 1879-1891
J9 AM J OPHTHALMOL
JI Am. J. Ophthalmol.
PD MAR
PY 2022
VL 235
BP 291
EP 299
DI 10.1016/j.ajo.2021.08.015
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 1Y4LB
UT WOS:000808112700018
PM 34509436
DA 2022-11-30
ER

PT J
AU Postel, EA
   Agarwal, A
   Caldwell, J
   Gallins, P
   Toth, C
   Schmidt, S
   Scott, WK
   Hauser, MA
   Haines, JL
   Pericak-Vance, MA
AF Postel, Eric A.
   Agarwal, Anita
   Caldwell, Jennifer
   Gallins, Paul
   Toth, Cynthia
   Schmidt, Silke
   Scott, William K.
   Hauser, Michael A.
   Haines, Jonathan L.
   Pericak-Vance, Margaret A.
TI Complement factor H increases risk for atrophic age-related macular
   degeneration
SO OPHTHALMOLOGY
LA English
DT Article
ID MACULOPATHY; POLYMORPHISM; ASSOCIATION; COMMON; GENES
AB Objective: To determine if the complement factor H gene (CFH) determines risk for development of geographic atrophy (GA).
   Design: Retrospective case-control study.
   Participants and Controls: The independent case-control data set contained 647 age-related macular degeneration (AMD) cases (grades 3, 4, or 5) and 163 controls (grades 1 or 2).
   Methods: To determine if CFH had any effect on determining risk for development of GA in an independent case-control data set of 647 AMD cases and 163 controls, the rs1061170 single-nucleotide polymorphism was tested for association, separating grades and analyzing them independently against the controls. Odds ratios were calculated using standard logistic regression models.
   Main Outcome Measures: The outcome variable was AMD affection status, and genotypes were coded according to a log-additive model.
   Results: There were 407 grade 5, 107 grade 4, 133 grade 3, 35 grade 2, and 128 grade 1 individuals. There was significant association with AMD when comparing grades 3, 4, and 5 versus the controls. The highest odds ratio was obtained when analyzing the grade-4 cases versus the grade-1 controls (OR = 3.217, P < 0.0001).
   Conclusions: Our results indicate that CFH increases the risk of developing GA (grade 4) as well as neovascular (grade 5) and milder (grade 3) disease. Although neovascular disease is responsible for the majority of severe vision loss with AMD, GA is also a significant cause of vision loss, and without effective treatment. Therefore, an attempt to clarify its pathogenesis is of the utmost importance.
C1 Duke Univ, Ctr Eye, Durham, NC 27710 USA.
   Vanderbilt Eye Inst, Nashville, TN USA.
   Duke Univ, Ctr Human Genet, Durham, NC USA.
   Vanderbilt Univ, Med Ctr, Ctr Human Genet Res, Nashville, TN USA.
C3 Duke University; Vanderbilt University; Duke University; Vanderbilt
   University
RP Postel, EA (通讯作者)，Duke Univ, Ctr Eye, Box 3802, Durham, NC 27710 USA.
EM poste002@mc.duke.edu
RI toth, cynthia a/F-5614-2011; Toth, Cynthia/L-5534-2019; Haines,
   Jonathan/C-3374-2012; Scott, William/A-7593-2009
OI Toth, Cynthia/0000-0002-2324-0854; Haines, Jonathan/0000-0002-4351-4728;
   Scott, William/0000-0001-9336-6404
FU NEI NIH HHS [U10 EY12118-05] Funding Source: Medline; NATIONAL EYE
   INSTITUTE [U10EY012118] Funding Source: NIH RePORTER
CR Age-Related Eye Dis Study Res Grp, 2001, AM J OPHTHALMOL, V132, P668
   Buch H, 2005, OPHTHALMOLOGY, V112, P787, DOI 10.1016/j.ophtha.2004.11.040
   Cahill MT, 2005, ARCH OPHTHALMOL-CHIC, V123, P935, DOI 10.1001/archopht.123.7.935
   DelaPaz MA, 1997, AM J OPHTHALMOL, V124, P331, DOI 10.1016/S0002-9394(14)70825-6
   Dunaief JL, 2002, ARCH OPHTHALMOL-CHIC, V120, P1435, DOI 10.1001/archopht.120.11.1435
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   GUME DH, 1991, OPHTHALMOLOGY, V98, P602
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2006, INVEST OPHTH VIS SCI, V47, P329, DOI 10.1167/iovs.05-0116
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Jakobsdottir J, 2005, AM J HUM GENET, V77, P389, DOI 10.1086/444437
   Kassoff A, 1999, CONTROL CLIN TRIALS, V20, P573
   KILLINGSWORTH MC, 1990, EYE, V4, P613, DOI 10.1038/eye.1990.86
   Klein R, 2005, AM J OPHTHALMOL, V140, P35, DOI 10.1016/j.ajo.2005.01.051
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Milton RC, 2005, OPHTHALMOLOGY, V112, P533, DOI 10.1016/j.ophtha.2004.10.047
   Mullins RF, 2000, FASEB J, V14, P835, DOI 10.1096/fasebj.14.7.835
   Postel EA, 2005, AM J OPHTHALMOL, V139, P820, DOI 10.1016/j.ajo.2004.12.029
   Rivera A, 2005, HUM MOL GENET, V14, P3227, DOI 10.1093/hmg/ddi353
   Schachat AP, 2005, OPHTHALMOLOGY, V112, P531, DOI 10.1016/j.ophtha.2005.01.018
   Seddon JM, 2004, JAMA-J AM MED ASSOC, V291, P704, DOI 10.1001/jama.291.6.704
   Tomany SC, 2004, OPHTHALMOLOGY, V111, P1280, DOI 10.1016/j.ophtha.2003.11.010
   Wang JJ, 2003, OPHTHALMIC EPIDEMIOL, V10, P37, DOI 10.1076/opep.10.1.37.13776
NR 23
TC 48
Z9 48
U1 0
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0161-6420
EI 1549-4713
J9 OPHTHALMOLOGY
JI Ophthalmology
PD SEP
PY 2006
VL 113
IS 9
BP 1504
EP 1507
DI 10.1016/j.ophtha.2006.02.049
PG 4
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 080TI
UT WOS:000240270900005
PM 16828512
DA 2022-11-30
ER

PT J
AU Rosen, R
   Hu, DN
   Perez, V
   Tai, K
   Yu, GP
   Chen, M
   Tone, P
   McCormick, SA
   Walsh, J
AF Rosen, Richard
   Hu, Dan-Ning
   Perez, Violete
   Tai, Katy
   Yu, Guo-Pei
   Chen, Min
   Tone, Paul
   McCormick, Steven A.
   Walsh, Joseph
TI Urinary 6-sulfatoxymelatonin level in age-related macular degeneration
   patients
SO MOLECULAR VISION
LA English
DT Article
ID RETINAL-PIGMENT EPITHELIUM; OXIDATIVE STRESS; MELATONIN RECEPTORS;
   LIPID-PEROXIDATION; ANTIOXIDANT ENZYMES; HUMAN-PLASMA;
   6-HYDROXYMELATONIN SULFATE; CELL-DEATH; VITAMIN-E; EXCRETION
AB Purpose: Melatonin is a potent antioxidant and free radical scavenger. It has been reported that serum melatonin level is relevant to certain aging diseases. The purpose of this study was to investigate melatonin levels in age-related macular degeneration (AMD) patients by measurement of 6-sulfatoxymelatonin levels (aMT6s), the major metabolite of melatonin in urine, and compare it with a group of age-and gender-matched controls.
   Methods: The first urine of the morning was collected from 43 AMD patients and 12 controls who did not have AMD. The level of aMT6s in specimens was measured by a commercial 6-sulfatoxymelatonin ELISA kit. The assay was performed by researchers, who were masked to the clinical information. To adjust for variation in the diluteness of urine, urinary creatinine level was measured and aMT6s levels were expressed as aMT6s/creatinine.
   Results: The level of urinary aMT6s/creatinine (mean+/-SD) in AMD (6.24+/-3.45 ng aMT6s/mg creatinine) was significantly lower than that of the controls (10.40+/-4.51, p=0.0128). After adjustment for various factors (age, smoking, cancer, and coronary heart disease) that may influence the aMT6s level, the odds-ratio of urinary aMT6s comparing AMD patients to controls was 0.65 (95% confidence interval=0.48-0.88, p=0.0036), indicating that urinary aMT6s level in AMD patients was lower than in controls even after multivariate adjustment.
   Conclusions: Urinary aMT6s level in AMD patients was 40% lower than in age-and gender-matched controls. This difference between AMD patients and controls is present after adjustment for the factors of age, smoking, and histories of cancer and coronary heart disease. The significance of this result and the role of melatonin in the occurrence of AMD require further investigation.
C1 [Rosen, Richard; Hu, Dan-Ning; Perez, Violete; Tai, Katy; Chen, Min; McCormick, Steven A.; Walsh, Joseph] New York Eye & Ear Infirm, Dept Ophthalmol, New York, NY 10003 USA.
   [Hu, Dan-Ning; Chen, Min; McCormick, Steven A.] New York Eye & Ear Infirm, Dept Pathol, New York, NY 10003 USA.
   [Yu, Guo-Pei] New York Eye & Ear Infirm, Dept Biostat, New York, NY 10003 USA.
   [Yu, Guo-Pei] New York Eye & Ear Infirm, Epidemiol Serv, New York, NY 10003 USA.
   [Rosen, Richard; Hu, Dan-Ning; Yu, Guo-Pei; Chen, Min; McCormick, Steven A.; Walsh, Joseph] New York Med Coll, Dept Ophthalmol, Valhalla, NY 10595 USA.
   [Rosen, Richard; Hu, Dan-Ning; Yu, Guo-Pei; Chen, Min; McCormick, Steven A.; Walsh, Joseph] New York Med Coll, Dept Otorhinolaryngol, Valhalla, NY 10595 USA.
   [Tone, Paul] Univ Richmond, Med Ctr, Dept Med, Staten Isl, NY USA.
C3 New York Eye & Ear Infirmary of Mount Sinai; New York Eye & Ear
   Infirmary of Mount Sinai; New York Eye & Ear Infirmary of Mount Sinai;
   New York Eye & Ear Infirmary of Mount Sinai; New York Medical College;
   New York Medical College
RP Hu, DN (通讯作者)，New York Eye & Ear Infirm, Dept Ophthalmol, 310 E 14th St, New York, NY 10003 USA.
EM hu2905@yahoo.com
FU Bendheim-Lowenstein Family Foundation, New York, NY; New York Eye and
   Ear Infirmary Pathology Research Funds
FX This study was supported by the Bendheim-Lowenstein Family Foundation,
   New York, NY and the New York Eye and Ear Infirmary Pathology Research
   Funds.
CR Ahmed SS, 2005, SURV OPHTHALMOL, V50, P183, DOI 10.1016/j.survophthal.2004.12.009
   Alarma-Estrany P, 2007, PHARMACOL THERAPEUT, V113, P507, DOI 10.1016/j.pharmthera.2006.11.003
   Allegra M, 2003, J PINEAL RES, V34, P1, DOI 10.1034/j.1600-079X.2003.02112.x
   ARENDT J, 1985, J CLIN ENDOCR METAB, V60, P1166, DOI 10.1210/jcem-60-6-1166
   Bartsch C, 1997, J PINEAL RES, V23, P53, DOI 10.1111/j.1600-079X.1997.tb00335.x
   Baskol G, 2006, OPHTHALMOLOGICA, V220, P12, DOI 10.1159/000089269
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   Benloucif S, 2008, J CLIN SLEEP MED, V4, P66
   BOJKOWSKI CJ, 1987, CLIN CHEM, V33, P1343
   BOWERS LD, 1980, CLIN CHEM, V26, P551
   Caballero B, 2009, J PINEAL RES, V46, P106, DOI 10.1111/j.1600-079X.2008.00637.x
   Chanut E, 1998, J CHROMATOGR B, V709, P11, DOI 10.1016/S0378-4347(98)00041-3
   Chetsawang B, 2009, J PINEAL RES, V46, P36, DOI 10.1111/j.1600-079X.2008.00605.x
   Chiquet C, 2006, AM J OPHTHALMOL, V142, P325, DOI 10.1016/j.ajo.2006.03.040
   COHEN SM, 1994, BRIT J OPHTHALMOL, V78, P791, DOI 10.1136/bjo.78.10.791
   Coral K, 2006, EYE, V20, P203, DOI 10.1038/sj.eye.6701853
   Curcio CA, 1999, ARCH OPHTHALMOL-CHIC, V117, P329, DOI 10.1001/archopht.117.3.329
   Das A, 2008, J PINEAL RES, V45, P117, DOI 10.1111/j.1600-079X.2008.00582.x
   Decanini A, 2007, AM J OPHTHALMOL, V143, P607, DOI 10.1016/j.ajo.2006.12.006
   Ekmekcioglu C, 2006, BIOMED PHARMACOTHER, V60, P97, DOI 10.1016/j.biopha.2006.01.002
   Esposito E, 2008, J PINEAL RES, V44, P78, DOI 10.1111/j.1600-079X.2007.00492.x
   Evereklioglu C, 2003, DOC OPHTHALMOL, V106, P129, DOI 10.1023/A:1022512402811
   Frank RN, 1999, AM J OPHTHALMOL, V127, P694, DOI 10.1016/S0002-9394(99)00032-X
   Girotti L, 2000, J PINEAL RES, V29, P138, DOI 10.1034/j.1600-079X.2000.290302.x
   Gogenur I, 2007, ACTA ANAESTH SCAND, V51, P1099, DOI 10.1111/j.1399-6576.2007.01387.x
   Graham C, 1998, J PINEAL RES, V24, P230, DOI 10.1111/j.1600-079X.1998.tb00538.x
   Hogg R, 2004, CURR EYE RES, V29, P387, DOI 10.1080/02713680490517890
   Ianas O, 1999, ADV EXP MED BIOL, V460, P321
   Jou MJ, 2004, J PINEAL RES, V37, P55, DOI 10.1111/j.1600-079X.2004.00140.x
   Kannan R, 2006, MOL VIS, V12, P1649
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Kennaway DJ, 1999, J PINEAL RES, V27, P210, DOI 10.1111/j.1600-079X.1999.tb00617.x
   Klante G, 1997, J PINEAL RES, V23, P191, DOI 10.1111/j.1600-079X.1997.tb00354.x
   Koh PO, 2008, J VET MED SCI, V70, P1219, DOI 10.1292/jvms.70.1219
   Liang FQ, 2004, EXP EYE RES, V78, P1069, DOI 10.1016/j.exer.2004.02.003
   Luboshitzky R, 2001, CHRONOBIOL INT, V18, P513, DOI 10.1081/CBI-100103973
   Marchiafava PL, 1999, J PINEAL RES, V26, P184, DOI 10.1111/j.1600-079X.1999.tb00582.x
   Marin-Castano ME, 2005, INVEST OPHTH VIS SCI, V46, P3331, DOI 10.1167/iovs.04-1224
   MARKEY SP, 1985, CLIN CHIM ACTA, V150, P221, DOI 10.1016/0009-8981(85)90247-5
   Molpeceres V, 2007, J GERONTOL A-BIOL, V62, P687, DOI 10.1093/gerona/62.7.687
   Montilla P, 2001, J PINEAL RES, V31, P138, DOI 10.1034/j.1600-079x.2001.310207.x
   Nagata C, 2005, CANCER EPIDEM BIOMAR, V14, P1333, DOI 10.1158/1055-9965.EPI-04-0915
   Nowak M, 2003, EUR J OPHTHALMOL, V13, P281, DOI 10.1177/112067210301300307
   NOWAK R, 1987, CLIN ENDOCRINOL, V27, P445, DOI 10.1111/j.1365-2265.1987.tb01172.x
   Paakkonen T, 2006, J PINEAL RES, V40, P110, DOI 10.1111/j.1600-079X.2005.00300.x
   Pandi-Perumal SR, 2006, FEBS J, V273, P2813, DOI 10.1111/j.1742-4658.2006.05322.x
   PARDUE HL, 1987, CLIN CHEM, V33, P278
   PRASHAR S, 1993, ACTA OPHTHALMOL, V71, P214
   Radogna F, 2007, J PINEAL RES, V43, P154, DOI 10.1111/j.1600-079X.2007.00455.x
   Rakoczy PE, 2002, AM J PATHOL, V161, P1515, DOI 10.1016/S0002-9440(10)64427-6
   Reiter RJ, 2003, ADV EXP MED BIOL, V527, P539
   Reiter RJ, 2000, J BIOMED SCI, V7, P444, DOI 10.1159/000025480
   REITER RJ, 1995, EXP GERONTOL, V30, P199, DOI 10.1016/0531-5565(94)00045-5
   Reiter RJ, 2003, ACTA BIOCHIM POL, V50, P1129
   Reiter RJ, 2001, CELL BIOCHEM BIOPHYS, V34, P237, DOI 10.1385/CBB:34:2:237
   Reiter RJ, 2007, ACTA BIOCHIM POL, V54, P1
   Richer Stuart, 2004, Optometry, V75, P216, DOI 10.1016/S1529-1839(04)70049-4
   Rodriguez C, 2004, J PINEAL RES, V36, P1, DOI 10.1046/j.1600-079X.2003.00092.x
   SACK RL, 1992, J CLIN ENDOCR METAB, V75, P127, DOI 10.1210/jc.75.1.127
   Sakotnik A, 1999, EUR HEART J, V20, P1314, DOI 10.1053/euhj.1999.1527
   Samiec PS, 1998, FREE RADICAL BIO MED, V24, P699, DOI 10.1016/S0891-5849(97)00286-4
   Schernhammer ES, 2006, J PINEAL RES, V40, P116, DOI 10.1111/j.1600-079X.2005.00285.x
   Schernhammer ES, 2005, J NATL CANCER I, V97, P1084, DOI 10.1093/jnci/dji190
   Sewerynek E, 2002, NEUROENDOCRINOL LETT, V23, P79
   Siu AW, 1998, J PINEAL RES, V24, P239, DOI 10.1111/j.1600-079X.1998.tb00539.x
   Tan Dun-Xian, 2002, Current Topics in Medicinal Chemistry, V2, P181, DOI 10.2174/1568026023394443
   Tan DX, 2000, BIOL SIGNAL RECEPT, V9, P137
   Tosini G, 2003, J NEUROENDOCRINOL, V15, P364, DOI 10.1046/j.1365-2826.2003.00973.x
   van Leeuwen R, 2005, JAMA-J AM MED ASSOC, V294, P3101, DOI 10.1001/jama.294.24.3101
   Vanecek J, 1998, PHYSIOL REV, V78, P687, DOI 10.1152/physrev.1998.78.3.687
   Venkataraman P, 2008, INT J DEV NEUROSCI, V26, P585, DOI 10.1016/j.ijdevneu.2008.05.002
   Wiechmann AF, 2008, EXP EYE RES, V86, P241, DOI 10.1016/j.exer.2007.10.015
   Winkler BS, 1999, MOL VIS, V5
   Witt-Enderby PA, 2003, LIFE SCI, V72, P2183, DOI 10.1016/S0024-3205(03)00098-5
   Witt-Enderby PA, 2006, J PINEAL RES, V41, P297, DOI 10.1111/j.1600-079X.2006.00369.x
   Wood AW, 2006, INT J RADIAT BIOL, V82, P69, DOI 10.1080/09553000600599775
   Yi CX, 2005, ANN NY ACAD SCI, V1057, P384, DOI 10.1196/annals.1356.029
NR 77
TC 47
Z9 47
U1 0
U2 4
PU MOLECULAR VISION
PI ATLANTA
PA C/O JEFF BOATRIGHT, LAB B, 5500 EMORY EYE CENTER, 1327 CLIFTON RD, N E,
   ATLANTA, GA 30322 USA
SN 1090-0535
J9 MOL VIS
JI Mol. Vis.
PD AUG 21
PY 2009
VL 15
IS 179-80
BP 1673
EP 1679
PG 7
WC Biochemistry & Molecular Biology; Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Ophthalmology
GA 501OK
UT WOS:000270391000001
PM 19710945
DA 2022-11-30
ER

PT J
AU Peng, YF
   Keenan, TD
   Chen, QY
   Agron, E
   Allot, A
   Wong, WT
   Chew, EY
   Lu, ZY
AF Peng, Yifan
   Keenan, Tiarnan D.
   Chen, Qingyu
   Agron, Elvira
   Allot, Alexis
   Wong, Wai T.
   Chew, Emily Y.
   Lu, Zhiyong
TI Predicting risk of late age-related macular degeneration using deep
   learning
SO NPJ DIGITAL MEDICINE
LA English
DT Article
ID PROGRESSION; DISEASE; MODEL
AB By 2040, age-related macular degeneration (AMD) will affect similar to 288 million people worldwide. Identifying individuals at high risk of progression to late AMD, the sight-threatening stage, is critical for clinical actions, including medical interventions and timely monitoring. Although deep learning has shown promise in diagnosing/screening AMD using color fundus photographs, it remains difficult to predict individuals' risks of late AMD accurately. For both tasks, these initial deep learning attempts have remained largely unvalidated in independent cohorts. Here, we demonstrate how deep learning and survival analysis can predict the probability of progression to late AMD using 3298 participants (over 80,000 images) from the Age-Related Eye Disease Studies AREDS and AREDS2, the largest longitudinal clinical trials in AMD. When validated against an independent test data set of 601 participants, our model achieved high prognostic accuracy (5-year C-statistic 86.4 (95% confidence interval 86.2-86.6)) that substantially exceeded that of retinal specialists using two existing clinical standards (81.3 (81.1-81.5) and 82.0 (81.8-82.3), respectively). Interestingly, our approach offers additional strengths over the existing clinical standards in AMD prognosis (e.g., risk ascertainment above 50%) and is likely to be highly generalizable, given the breadth of training data from 82 US retinal specialty clinics. Indeed, during external validation through training on AREDS and testing on AREDS2 as an independent cohort, our model retained substantially higher prognostic accuracy than existing clinical standards. These results highlight the potential of deep learning systems to enhance clinical decision-making in AMD patients.
C1 [Peng, Yifan; Chen, Qingyu; Allot, Alexis; Lu, Zhiyong] NIH, NCBI, NLM, Bldg 10, Bethesda, MD 20892 USA.
   [Keenan, Tiarnan D.; Agron, Elvira; Wong, Wai T.; Chew, Emily Y.] NEI, NIH, Bethesda, MD 20892 USA.
C3 National Institutes of Health (NIH) - USA; NIH National Library of
   Medicine (NLM); National Institutes of Health (NIH) - USA; NIH National
   Eye Institute (NEI)
RP Lu, ZY (通讯作者)，NIH, NCBI, NLM, Bldg 10, Bethesda, MD 20892 USA.; Chew, EY (通讯作者)，NEI, NIH, Bethesda, MD 20892 USA.
EM echew@nei.nih.gov; zhiyong.lu@nih.gov
RI Allot, Alexis/GWM-5716-2022; Chen, Qingyu/Q-8343-2019; Peng,
   Yifan/M-1605-2016
OI Allot, Alexis/0000-0002-2706-9054; Chen, Qingyu/0000-0002-6036-1516;
   Peng, Yifan/0000-0001-9309-8331; Chew, Emily/0000-0003-0999-9802;
   Keenan, Tiarnan/0000-0002-2253-1772
FU National Center for Biotechnology Information/National Library of
   Medicine/National Institutes of Health, the National Eye
   Institute/National Institutes of Health, Department of Health and Human
   Services, Bethesda Maryland [HHS-N260-2005-00007-C, NO1-EY-5-0007,
   K99LM013001]; National Institutes of Health: Office of Dietary
   Supplements, National Center for Complementary and Alternative Medicine;
   National Institutes of Health: National Institute on Aging; National
   Institutes of Health: National Heart, Lung, and Blood Institute;
   National Institutes of Health: National Institute of Neurological
   Disorders and Stroke
FX The work was supported by the intramural program funds and contracts
   from the National Center for Biotechnology Information/National Library
   of Medicine/National Institutes of Health, the National Eye
   Institute/National Institutes of Health, Department of Health and Human
   Services, Bethesda Maryland (Contract HHS-N260-2005-00007-C; ADB
   contract NO1-EY-5-0007; Grant No K99LM013001). Funds were generously
   contributed to these contracts by the following National Institutes of
   Health: Office of Dietary Supplements, National Center for Complementary
   and Alternative Medicine; National Institute on Aging; National Heart,
   Lung, and Blood Institute; and National Institute of Neurological
   Disorders and Stroke.
CR Abadi M, 2016, PROCEEDINGS OF OSDI'16: 12TH USENIX SYMPOSIUM ON OPERATING SYSTEMS DESIGN AND IMPLEMENTATION, P265
   Abramoff MD, 2018, NPJ DIGIT MED, V1, DOI 10.1038/s41746-018-0040-6
   Age-Related Eye Dis Study Res Grp, 2001, AM J OPHTHALMOL, V132, P668
   American Academy of Ophthalmology Retina/Vitreous Panel, 2015, PREF PRACT PATT GUID
   Arcadu F, 2019, NPJ DIGIT MED, V2, DOI 10.1038/s41746-019-0172-3
   Burlina PM, 2018, JAMA OPHTHALMOL, V136, P1359, DOI 10.1001/jamaophthalmol.2018.4118
   Calaprice-Whitty D, 2019, THER INNOV REGUL SCI, DOI [10.1177/2168479018815454, DOI 10.1177/2168479018815454]
   Chen Q, 2019, LECT NOTES COMPUT SC, V11922, P505, DOI 10.1007/978-3-030-34621-8_18
   Chew EY, 2014, OPHTHALMOLOGY, V121, P535, DOI 10.1016/j.ophtha.2013.10.027
   Chew EY, 2013, JAMA-J AM MED ASSOC, V309, P2005, DOI 10.1001/jama.2013.4997
   Chew EY, 2012, OPHTHALMOLOGY, V119, P2282, DOI 10.1016/j.ophtha.2012.05.027
   Ching T, 2018, J R SOC INTERFACE, V15, DOI 10.1098/rsif.2017.0387
   Cox D. R., 1992, STAT SPRINGER SERIES, P527
   Davis MD, 2005, ARCH OPHTHALMOL-CHIC, V123, P1484
   De Fauw J, 2018, NAT MED, V24, P1342, DOI 10.1038/s41591-018-0107-6
   Ding Y, 2017, GENETICS, V206, P119, DOI 10.1534/genetics.116.196998
   Domalpally A, 2019, OPHTHALMOL RETINA, V3, P326, DOI 10.1016/j.oret.2019.01.004
   Esteva A, 2017, NATURE, V542, P115, DOI 10.1038/nature21056
   Ferris FL, 2005, ARCH OPHTHALMOL-CHIC, V123, P1570
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Fleckenstein M, 2018, OPHTHALMOLOGY, V125, P369, DOI 10.1016/j.ophtha.2017.08.038
   Fritsche LG, 2016, NAT GENET, V48, P134, DOI 10.1038/ng.3448
   Gensheimer MF, 2019, PEERJ, V7, DOI 10.7717/peerj.6257
   Grassmann F, 2018, OPHTHALMOLOGY, V125, P1410, DOI 10.1016/j.ophtha.2018.02.037
   Gulshan V, 2016, JAMA-J AM MED ASSOC, V316, P2402, DOI 10.1001/jama.2016.17216
   Guymer RH, 2019, OPHTHALMOLOGY, V126, P829, DOI 10.1016/j.ophtha.2018.09.015
   Hannun AY, 2019, NAT MED, V25, P65, DOI 10.1038/s41591-018-0268-3
   Kassoff A, 1999, CONTROL CLIN TRIALS, V20, P573
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Katzman JL, 2018, BMC MED RES METHODOL, V18, DOI 10.1186/s12874-018-0482-1
   Kermany DS, 2018, CELL, V172, P1122, DOI 10.1016/j.cell.2018.02.010
   Klein ML, 2011, ARCH OPHTHALMOL-CHIC, V129, P1543, DOI 10.1001/archophthalmol.2011.216
   Lao JW, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-10649-8
   Lee CS, 2017, OPHTHALMOL RETINA, V1, P322, DOI 10.1016/j.oret.2016.12.009
   Liang HY, 2019, NAT MED, V25, P433, DOI 10.1038/s41591-018-0335-9
   Liao DS, 2020, OPHTHALMOLOGY, V127, P186, DOI 10.1016/j.ophtha.2019.07.011
   Olsen TW, 2020, OPHTHALMOLOGY, V127, pP1, DOI 10.1016/j.ophtha.2019.09.024
   Pencina MJ, 2004, STAT MED, V23, P2109, DOI 10.1002/sim.1802
   Peng YF, 2019, OPHTHALMOLOGY, V126, P565, DOI 10.1016/j.ophtha.2018.11.015
   Poplin R, 2018, NAT BIOMED ENG, V2, P158, DOI 10.1038/s41551-018-0195-0
   Quartilho A, 2016, EYE, V30, P602, DOI 10.1038/eye.2015.288
   Raumviboonsuk P, 2019, NPJ DIGIT MED, V2, DOI 10.1038/s41746-019-0099-8
   Rosner B., 2016, FUNDAMENTALS BIOSTAT
   Schmidt-Erfurth U, 2018, PROG RETIN EYE RES, V67, P1, DOI 10.1016/j.preteyeres.2018.07.004
   Simon J, 2011, NITROGEN CYCLING IN BACTERIA: MOLECULAR ANALYSIS, P39
   Simonyan K., 2013, DEEP INSIDE CONVOLUT
   Szegedy C., 2016, 2016 IEEE C COMPUTER, P2818, DOI DOI 10.1109/CVPR.2016.308
   Ting DSW, 2019, NPJ DIGIT MED, V2, DOI 10.1038/s41746-019-0097-x
   Ting DSW, 2019, PROG RETIN EYE RES, V72, DOI 10.1016/j.preteyeres.2019.04.003
   Ting DSW, 2017, JAMA-J AM MED ASSOC, V318, P2211, DOI 10.1001/jama.2017.18152
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Yandex Artem Babenko, 2015, 2015 IEEE International Conference on Computer Vision (ICCV). Proceedings, P1269, DOI 10.1109/ICCV.2015.150
NR 52
TC 13
Z9 13
U1 1
U2 2
PU NATURE PORTFOLIO
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
SN 2398-6352
J9 NPJ DIGIT MED
JI npj Digit. Med.
PD AUG 27
PY 2020
VL 3
IS 1
AR 111
DI 10.1038/s41746-020-00317-z
PG 10
WC Health Care Sciences & Services; Medical Informatics
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Health Care Sciences & Services; Medical Informatics
GA NL6ZF
UT WOS:000567560500002
OA Green Submitted, Green Published, gold
DA 2022-11-30
ER

PT J
AU Reale, E
   Groos, S
   Eckardt, U
   Eckardt, C
   Luciano, L
AF Reale, Enrico
   Groos, Stephanie
   Eckardt, Ute
   Eckardt, Claus
   Luciano, Liliana
TI New Components of 'Basal Laminar Deposits' in Age-Related Macular
   Degeneration
SO CELLS TISSUES ORGANS
LA English
DT Article
DE Choroidal neovascularization; Long-spacing collagen aggregates; Retinal
   pigment epithelium; Transmission electron microscopy
ID ENDOTHELIAL GROWTH-FACTOR; RETINAL-PIGMENT EPITHELIUM; CHOROIDAL
   NEOVASCULAR MEMBRANES; LONG-SPACING CRYSTALLITES; VI COLLAGEN;
   VASCULAR-PERMEABILITY; VESSEL FORMATION; FIBRILS; VEGF; PATHOGENESIS
AB Two new components of basal laminar deposit (BlamD) occurring in samples of submacular neovascular membranes surgically removed from patients with a wet (exudative) form of age-related macular degeneration are described. They are: (1) minute ribbon-like structures which occur singly and/or in a bunch and extend from the inner surface of the BlamD layer into the extracellular matrix (ECM) beneath the retinal pigment epithelium (RPE). The ribbons are composed of polarized molecules, aggregating in parallel, aligned transversally in register, morphologically similar to isolated collagen molecules of the short-chain type. Deeper in the BlamD but always close to its inner surface, aspects suggesting a transition between ribbons and (2) long-spacing collagen (LSC)-like aggregates characterized by periods bordered by a single dense band were observed. This band could arise from the globular domains of the polarized monomers, which assemble in parallel and display all their terminal extensions at the same end of each period resulting in the single dense band. The presence of ribbons and of LSC-like aggregates in the BlamD layer and the concomitant choroidal neovascularization (CNV) suggest that the events might be correlated. The newly formed vessels crossing Bruch's membrane and invading the BlamD layer could induce physicochemical changes in the ECM of the RPE, providing the required environmental conditions for the polymerization of collagen molecules into aggregates with the LSC-like pattern. With the deposition of new components, the thickness of BlamD increases and further impairs the supply of nutrients and oxygen, thus sustaining CNV. Copyright (C) 2008 S. Karger AG, Basel
C1 [Reale, Enrico; Groos, Stephanie; Luciano, Liliana] Hannover Med Sch, Zentrum Anat, Abt Zellbiol, DE-30625 Hannover, Germany.
   [Eckardt, Ute; Eckardt, Claus] Stadt Kliniken Frankfurt Main Hochst, Augenklin, Frankfurt, Germany.
C3 Hannover Medical School; University of Hamburg; University Medical
   Center Hamburg-Eppendorf
RP Luciano, L (通讯作者)，Hannover Med Sch, Zentrum Anat, Abt Zellbiol, Carl Neuberg Str 1, DE-30625 Hannover, Germany.
EM luciano.liliana@mh-hannover.de
CR Ball S, 2003, J BIOL CHEM, V278, P15326, DOI 10.1074/jbc.M209977200
   Blaauwgeers HGT, 1999, AM J PATHOL, V155, P421, DOI 10.1016/S0002-9440(10)65138-3
   BRESSLER NM, 1988, SURV OPHTHALMOL, V32, P375, DOI 10.1016/0039-6257(88)90052-5
   BRUNS RR, 1984, J ULTRA MOL STRUCT R, V89, P136, DOI 10.1016/S0022-5320(84)80010-6
   BRUNS RR, 1986, J CELL BIOL, V103, P393, DOI 10.1083/jcb.103.2.393
   BRUNS RR, 1979, P NATL ACAD SCI USA, V76, P313, DOI 10.1073/pnas.76.1.313
   Campochiaro P A, 1999, Mol Vis, V5, P34
   Campochiaro PA, 2004, EXPERT OPIN BIOL TH, V4, P1395, DOI 10.1517/14712598.4.9.1395
   Carmeliet P, 2005, ONCOLOGY-BASEL, V69, P4, DOI 10.1159/000088478
   CERVOSNAVARRO J, 1968, VIRCHOWS ARCH A, V345, P276, DOI 10.1007/BF00542684
   CHATTERJEE P, 1973, J ANAT, V115, P415
   Chopdar A, 2003, BRIT MED J, V326, P485, DOI 10.1136/bmj.326.7387.485
   CRAVIOTO H, 1968, J ULTRA MOL STRUCT R, V24, P70, DOI 10.1016/S0022-5320(68)80017-6
   DAMORE PA, 1994, INVEST OPHTH VIS SCI, V35, P3974
   Eckardt Claus, 1996, Ophthalmologe, V93, P688, DOI 10.1007/s003470050059
   ENGEL J, 1985, ANN NY ACAD SCI, V460, P25, DOI 10.1111/j.1749-6632.1985.tb51154.x
   FERRARA N, 1991, J CELL BIOCHEM, V47, P211, DOI 10.1002/jcb.240470305
   FURTHMAYR H, 1983, BIOCHEM J, V211, P303, DOI 10.1042/bj2110303
   GASS JDM, 1967, AM J OPHTHALMOL, V63, P617
   Ghadially F, 1988, ULTRASTRUCT PATHOL, V3, P1215
   Goerges AL, 2004, J BIOL CHEM, V279, P2307, DOI 10.1074/jbc.M308482200
   Green W R, 1977, Trans Am Ophthalmol Soc, V75, P180
   GREEN WR, 1993, OPHTHALMOLOGY, V100, P1519
   Green WR, 1999, AGE RELATED MACULAR, P81
   GROSS J, 1954, P NATL ACAD SCI USA, V40, P679, DOI 10.1073/pnas.40.8.679
   GROSSNIKLAUS HE, 1994, OPHTHALMOLOGY, V101, P1099
   GUYMER R, 2001, RETINA, V2, P1051
   He S, 2003, ARCH OPHTHALMOL-CHIC, V121, P1283, DOI 10.1001/archopht.121.9.1283
   Hera R, 2005, AM J OPHTHALMOL, V139, P589, DOI 10.1016/j.ajo.2004.11.064
   HILDING DA, 1965, J ULTRA MOL STRUCT R, V12, P611, DOI 10.1016/S0022-5320(65)80051-X
   HODGE AJ, 1960, P NATL ACAD SCI USA, V46, P186, DOI 10.1073/pnas.46.2.186
   HOGAN M J, 1972, Transactions of the American Academy of Ophthalmology and Oto-Laryngology, V76, P64
   Hogan M J, 1967, Trans Ophthalmol Soc U K, V87, P113
   Holz FG, 2004, AM J OPHTHALMOL, V137, P504, DOI 10.1016/j.ajo.2003.11.026
   HULMES DJS, 1983, P NATL ACAD SCI-BIOL, V80, P388, DOI 10.1073/pnas.80.2.388
   Karnovsky M.J., 1971, P 11 M AM SOC CELL B, P146
   KERENYI T., 1966, Z MIKROSKOPISCHANAT FORSCH, V74, P121
   Kielty Cay M., 1993, P103
   KIMURA K, 1975, LAB INVEST, V32, P279
   Kliffen M, 1997, BRIT J OPHTHALMOL, V81, P154, DOI 10.1136/bjo.81.2.154
   Knupp C, 2000, J STRUCT BIOL, V129, P38, DOI 10.1006/jsbi.1999.4202
   KUHN K, 1982, COLLAGEN REL RES, V2, P61
   LOFFLER KU, 1986, GRAEF ARCH CLIN EXP, V224, P493, DOI 10.1007/BF02154735
   Mousa SA, 1999, J CELL BIOCHEM, V74, P135, DOI 10.1002/(SICI)1097-4644(19990701)74:1<135::AID-JCB15>3.0.CO;2-#
   NAUMANN RA, 1963, NATURE, V198, P701, DOI 10.1038/198701a0
   Neufeld G, 1999, FASEB J, V13, P9, DOI 10.1096/fasebj.13.1.9
   PEER J, 1995, LAB INVEST, V72, P638
   Pugh CW, 2003, NAT MED, V9, P677, DOI 10.1038/nm0603-677
   Rauterberg J, 1986, FRONT MATRIX BIOL, V11, P90
   Reale E, 2001, MATRIX BIOL, V20, P37, DOI 10.1016/S0945-053X(00)00132-3
   RENTSCH FJ, 1977, A GRAEF ARCH KLIN EX, V203, P321, DOI 10.1007/BF00409837
   RENTSCH FJ, 1976, STRUCTURE EYE, V3, P19
   Ricard-Blum S, 2000, UNCONVENTIONAL COLLA
   SARKS JP, 1988, EYE, V2, P552, DOI 10.1038/eye.1988.106
   SARKS SH, 1973, BRIT J OPHTHALMOL, V57, P951, DOI 10.1136/bjo.57.12.951
   SARKS SH, 1976, BRIT J OPHTHALMOL, V60, P324, DOI 10.1136/bjo.60.5.324
   SARKS SH, 2001, RETINA, V2, P1064
   SCHMID TM, 1984, J ULTRA MOL STRUCT R, V86, P186, DOI 10.1016/S0022-5320(84)80057-X
   SCHMITT FO, 1953, P NATL ACAD SCI USA, V39, P459, DOI 10.1073/pnas.39.6.459
   SCHMITT FO, 1959, BIOPHYSICAL SCIENCE, P349
   SILBERBERG R, 1970, J ULTRA MOL STRUCT R, V32, P18, DOI 10.1016/S0022-5320(70)80034-X
   SZOLLOSI D, 1975, J ULTRA MOL STRUCT R, V53, P222, DOI 10.1016/S0022-5320(75)80138-9
   THOMAS MA, 1994, OPHTHALMOLOGY, V101, P1384
   VANDERSCHAFT TL, 1992, OPHTHALMOLOGY, V99, P278
   VANDERSCHAFT TL, 1991, ARCH OPHTHALMOL-CHIC, V109, P420, DOI 10.1001/archopht.1991.01080030122052
   von Bomhard K, 1974, Z Anat Entwicklungsgesch, V144, P101
   VONDERMARK H, 1984, EUR J BIOCHEM, V142, P493
   WEINSTOCK M, 1974, J CELL BIOL, V60, P92, DOI 10.1083/jcb.60.1.92
   Weis SM, 2005, NATURE, V437, P497, DOI 10.1038/nature03987
   WETZSTEIN R, 1963, Z ZELLFORSCH MIK ANA, V61, P493, DOI 10.1007/BF00343999
   Yancopoulos GD, 2000, NATURE, V407, P242, DOI 10.1038/35025215
   Zarbin MA, 2004, ARCH OPHTHALMOL-CHIC, V122, P598, DOI 10.1001/archopht.122.4.598
NR 72
TC 18
Z9 18
U1 0
U2 2
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 1422-6405
EI 1422-6421
J9 CELLS TISSUES ORGANS
JI Cells Tissues Organs
PY 2009
VL 190
IS 3
BP 170
EP 181
DI 10.1159/000187632
PG 12
WC Anatomy & Morphology; Cell Biology; Developmental Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Anatomy & Morphology; Cell Biology; Developmental Biology
GA 482DY
UT WOS:000268865700005
PM 19088465
DA 2022-11-30
ER

PT J
AU Ip, MS
   Scott, IU
   Brown, GC
   Brown, MM
   Ho, AC
   Huang, SS
   Recchia, FM
AF Ip, Michael S.
   Scott, Ingrid U.
   Brown, Gary C.
   Brown, Melissa M.
   Ho, Allen C.
   Huang, Suber S.
   Recchia, Franco M.
TI Anti-vascular endothelial growth factor pharmacotherapy for age-related
   macular degeneration
SO OPHTHALMOLOGY
LA English
DT Article
ID INTRAVITREAL BEVACIZUMAB AVASTIN; CHOROIDAL NEOVASCULARIZATION
   SECONDARY; PIGMENT EPITHELIAL TEAR; VERTEPORFIN PHOTODYNAMIC THERAPY;
   COHERENCE TOMOGRAPHY FINDINGS; RANIBIZUMAB LUCENTIS; VISUAL
   HALLUCINATIONS; SUBGROUP ANALYSIS; INJECTION; PEGAPTANIB
AB Objective: To examine the evidence about the safety and efficacy of anti-vascular endothelial growth factor (VEGF) pharmacotherapies for the treatment of neovascular age-related macular degeneration (AMD).
   Design: Literature searches were conducted in May and October 2007 in PubMed with no date restrictions, limited to articles published in English, and in the Cochrane Central Register of Controlled Trials without a language limitation and yielded 310 citations. The first author reviewed the abstracts of these articles and selected 73 articles of possible clinical relevance for review by the panel. The panel deemed 64 of these articles sufficiently clinically relevant to review in full text and assigned ratings of level of evidence to each of the selected articles with the guidance of the panel methodologists.
   Results: Eleven studies provided level I evidence for intravitreal pegaptanib and ranibizumab for neovascular AMD; there were no studies rated level I for bevacizumab for neovascular AMD. Five studies were rated as level II, which included studies of ranibizumab and bevacizumab, and the remaining 38 articles retrieved were rated as level III. The studies do not provide information about long-term results or the value (comparative effectiveness) and cost-effectiveness of combined therapies.
   Conclusions: Review of the available literature to date suggests that anti-VEGF pharmacotherapy, delivered by intravitreal injection, is a safe and effective treatment for neovascular AMD for up to 2 years. There is level I evidence to support this conclusion for pegaptanib and ranibizumab, but none for bevacizumab at this time.
   Financial Disclosure(s): Proprietary or commercial disclosure may be found after the references.
OI Ho, Allen/0000-0003-3921-608X; Scott, Ingrid/0000-0002-3908-7153
FU Michael S. Ip - Consultant/Advisor - Bausch Lomb. Inc.; Genentech, Inc.;
   OSI; Pfizer Ophthalmics; QLT Phototherapeutics, Inc.; Lecture Fees - Eli
   Lilly Co; Allergan, Inc; Allergan, Inc.; Alcon Laboratories, Inc.;
   Eyetech Ltd.; Novartis; Bausch Lomb, Inc.; Digital Healthcare, Inc.; i2i
   Innovative Ideas, Inc.; SurModics, Inc.; WMR Biomedical, Inc.; American
   Academy of Family Physicians; Synergetics, Inc.
FX Michael S. Ip - Consultant/Advisor - Bausch & Lomb. Inc.; Genentech,
   Inc.; OSI; Pfizer Ophthalmics; QLT Phototherapeutics, Inc.; Sirion.;
   Lecture Fees - Eli Lilly & Co.; Grant Support - Allergan, Inc.; Ingrid
   U. Scott - Consultant/Advisor, Lecture Fees - Eyetech (OSI); Genentech,
   Inc.; Pfizer Ophthalmics.; Gary C. Brown - Consultant/Advisor -
   NeoVista.; Consultant, Grant Support - Allergan, Inc.; Genentech, Inc.;
   Equity Owner - Center for Value Based Medicine.; Melissa M. Brown -
   Consultant/Advisor - Allergan, Inc.; Genentech, Inc.; NeoVista.; Equity
   Owner - Center for Value Based Medicine.; Allen C. Ho -
   Consultant/Advisor, Grant Support - Alcon Laboratories, Inc.; Eyetech
   Ltd.; Genentech. Inc.; Novartis; Occulogix; QLT Phototherapeutics, Inc.;
   Regeneron.; Lecture Fees - Alcon Laboratories. Inc.; Eyetech Ltd.:
   Genentech, Inc.; Suber S. Huang - Consultant/Advisor - Bausch & Lomb,
   Inc.; Digital Healthcare, Inc.; Genentech, Inc.; i2i Innovative Ideas,
   Inc.; Second Sight; SurModics, Inc.; WMR Biomedical, Inc.; Lecture Fees
   - Allergen, Inc.; American Academy of Family Physicians; Novartis;
   Synergetics, Inc.; Equity Owner - i2i Innovative Ideas, Inc.; SurModics,
   Inc.; WMR Biomedical. Inc.; Franco M. Recchia - Consultant/Advisor -
   Alcon Laboratories, Inc.; Genentech, Inc.
CR Abraham-Marin ML, 2007, GRAEF ARCH CLIN EXP, V245, P651, DOI 10.1007/s00417-006-0411-6
   Aggio FB, 2007, EYE, V21, P408, DOI 10.1038/sj.eye.6702683
   Aggio FB, 2007, GRAEF ARCH CLIN EXP, V245, P215, DOI 10.1007/s00417-006-0412-5
   Aggio FB, 2006, ACTA OPHTHALMOL SCAN, V84, P713, DOI 10.1111/j.1600-0420.2006.00759.x
   Aisenbrey S, 2007, GRAEF ARCH CLIN EXP, V245, P941, DOI 10.1007/s00417-006-0471-7
   *AM AC OPHTH RET V, 2008, PREF PRACT PATT AG R, P9
   Apte RS, 2007, OPHTHALMOLOGY, V114, P1702, DOI 10.1016/j.ophtha.2007.02.021
   Augustin AJ, 2007, RETINA-J RET VIT DIS, V27, P133, DOI 10.1097/IAE.0b013e3180323de7
   Avery RL, 2006, OPHTHALMOLOGY, V113, P363, DOI 10.1016/j.ophtha.2005.11.019
   Bakri SJ, 2007, OPHTHALMOLOGY, V114, P2179, DOI 10.1016/j.ophtha.2007.09.012
   Bakri SJ, 2007, AM J OPHTHALMOL, V143, P505, DOI 10.1016/j.ajo.2006.11.047
   Bashshur ZF, 2007, ARCH OPHTHALMOL-CHIC, V125, P1357, DOI 10.1001/archopht.125.10.1357
   Bashshur ZF, 2006, AM J OPHTHALMOL, V142, P1, DOI 10.1016/j.ajo.2006.02.037
   Bhisitkul RB, 2006, BRIT J OPHTHALMOL, V90, P1542, DOI 10.1136/bjo.2006.098426
   Boyer DS, 2007, OPHTHALMOLOGY, V114, P246, DOI 10.1016/j.ophtha.2006.10.045
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Brown MM, 2008, OPHTHALMOLOGY, V115, P1039, DOI 10.1016/j.ophtha.2007.08.033
   Chakravarthy U, 2006, OPHTHALMOLOGY, V113, P1508, DOI 10.1016/j.ophtha.2006.02.064
   Chan CK, 2007, RETINA-J RET VIT DIS, V27, P541, DOI 10.1097/IAE.0b013e3180cc2612
   Chang LK, 2007, RETINA-J RET VIT DIS, V27, P523, DOI 10.1097/IAE.0b013e3180a032db
   Chapman JA, 2006, ANN PHARMACOTHER, V40, P1322, DOI 10.1345/aph.1G604
   Chen CY, 2007, AM J OPHTHALMOL, V143, P510, DOI 10.1016/j.ajo.2006.10.004
   Chen E, 2007, RETINA-J RET VIT DIS, V27, P445, DOI 10.1097/01.iae.0000249574.89437.40
   Costa RA, 2007, GRAEF ARCH CLIN EXP, V245, P1273, DOI 10.1007/s00417-007-0557-x
   Costa RA, 2006, INVEST OPHTH VIS SCI, V47, P4569, DOI 10.1167/iovs.06-0433
   D'Amico DJ, 2006, OPHTHALMOLOGY, V113, P992, DOI 10.1016/j.ophtha.2006.02.027
   Emerson MV, 2007, RETINA-J RET VIT DIS, V27, P439, DOI 10.1097/IAE.0b013e31804b3e15
   Falkenstein IA, 2007, RETINA-J RET VIT DIS, V27, P701, DOI 10.1097/IAE.0b013e3180654240
   Ferrara N, 2006, RETINA-J RET VIT DIS, V26, P859, DOI 10.1097/01.iae.0000242842.14624.e7
   FERRIS FL, 1984, ARCH OPHTHALMOL-CHIC, V102, P1640
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Fung AE, 2006, BRIT J OPHTHALMOL, V90, P1344, DOI 10.1136/bjo.2006.099598
   Fung AE, 2007, AM J OPHTHALMOL, V143, P566, DOI 10.1016/j.ajo.2007.01.028
   Giansanti F, 2007, EUR J OPHTHALMOL, V17, P230, DOI 10.1177/112067210701700213
   Gillies MC, 2007, NEW ENGL J MED, V356, P748
   Goff MJ, 2007, RETINA-J RET VIT DIS, V27, P432, DOI 10.1097/IAE.0b013e318042b53f
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Hannan SR, 2007, BRIT J OPHTHALMOL, V91, P977, DOI 10.1136/bjo.2006.101899
   Heier JS, 2006, ARCH OPHTHALMOL-CHIC, V124, P1532, DOI 10.1001/archopht.124.11.1532
   Heier JS, 2006, OPHTHALMOLOGY, V113, P633, DOI 10.1016/j.ophtha.2005.10.052
   Hughes MS, 2006, OPHTHAL SURG LAS IM, V37, P446, DOI 10.3928/15428877-20061101-01
   Jonas JB, 2007, ACTA OPHTHALMOL SCAN, V85, P563, DOI 10.1111/j.1600-0420.2007.00891.x
   Jonas JB, 2007, J OCUL PHARMACOL TH, V23, P240, DOI 10.1089/jop.2006.0146
   KAHN HA, 1977, AM J EPIDEMIOL, V106, P17, DOI 10.1093/oxfordjournals.aje.a112428
   Kaiser PK, 2007, AM J OPHTHALMOL, V144, P850, DOI 10.1016/j.ajo.2007.08.012
   Kaiser PK, 2007, OPHTHALMOLOGY, V114, P1868, DOI 10.1016/j.ophtha.2007.04.030
   Kiss C, 2006, RETINA-J RET VIT DIS, V26, P877, DOI 10.1097/01.iae.0000237080.10627.b7
   KLEIN BE, 1982, ARCH OPHTHALMOL-CHIC, V100, P571
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Lazic R, 2007, OPHTHALMOLOGY, V114, P1179, DOI 10.1016/j.ophtha.2007.03.006
   Lazic R, 2007, GRAEF ARCH CLIN EXP, V245, P68, DOI 10.1007/s00417-006-0466-4
   Lee GKY, 2007, GRAEF ARCH CLIN EXP, V245, P1225, DOI 10.1007/s00417-007-0536-2
   Lucas RS, 2007, OPHTHALMOLOGY, V114, P400, DOI 10.1016/j.ophtha.2006.10.002
   Manzano RPA, 2006, RETINA-J RET VIT DIS, V26, P257, DOI 10.1097/00006982-200603000-00001
   Martin DF, 2002, RETINA-J RET VIT DIS, V22, P143
   Maturi RK, 2006, RETINA-J RET VIT DIS, V26, P270, DOI 10.1097/00006982-200603000-00003
   Meyer CH, 2007, AM J OPHTHALMOL, V144, P330, DOI 10.1016/j.ajo.2007.04.003
   Meyer CH, 2007, AM J OPHTHALMOL, V143, P169, DOI 10.1016/j.ajo.2006.08.003
   Michels S, 2005, OPHTHALMOLOGY, V112, P1035, DOI 10.1016/j.ophtha.2005.02.007
   Mones JM, 2007, OPHTHAL SURG LAS IM, V38, P226, DOI 10.3928/15428877-20070501-07
   Moshfeghi AA, 2006, OPHTHALMOLOGY, V113, P2002, DOI 10.1016/j.ophtha.2006.05.070
   *NAT EYE I, COMP AG REL MAC DEG
   Nguyen QD, 2006, OPHTHALMOLOGY, V113, P1522, DOI 10.1016/j.ophtha.2006.05.055
   Pedersen R, 2007, ACTA OPHTHALMOL SCAN, V85, P526, DOI 10.1111/j.1600-0420.2007.00895.x
   Quiram PA, 2007, RETINA-J RET VIT DIS, V27, P851, DOI 10.1097/IAE.0b013e31806458f0
   Raftery J, 2007, BRIT J OPHTHALMOL, V91, P1244, DOI 10.1136/bjo.2007.116616
   Regillo CD, 2008, AM J OPHTHALMOL, V145, P239, DOI 10.1016/j.ajo.2007.10.004
   Rich RM, 2006, RETINA-J RET VIT DIS, V26, P495, DOI 10.1097/01.iae.0000225766.75009.3a
   Ronan SM, 2007, RETINA-J RET VIT DIS, V27, P535, DOI 10.1097/IAE.0b013e3180cc2645
   Rosenfeld PJ, 2007, NEW ENGL J MED, V356, P749
   Rosenfeld Philip J, 2006, Ophthalmol Clin North Am, V19, P361
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rosenfeld PJ, 2005, OPHTHALMOLOGY, V112, P1048, DOI 10.1016/j.ophtha.2005.01.043
   Rosenfeld PJ, 2006, OPHTHALMOLOGY, V113, P623, DOI 10.1016/j.ophtha.2006.01.027
   Rosenfeld PJ, 2005, OPHTHAL SURG LAS IM, V36, P336, DOI 10.3928/1542-8877-20050701-15
   Rosenfeld PJ, 2005, OPHTHAL SURG LAS IM, V36, P331, DOI 10.3928/1542-8877-20050701-14
   Shah CP, 2006, AM J OPHTHALMOL, V142, P1070, DOI 10.1016/j.ajo.2006.07.037
   Shahar J, 2006, RETINA-J RET VIT DIS, V26, P262, DOI 10.1097/00006982-200603000-00002
   SOMMER A, 1991, NEW ENGL J MED, V325, P1412, DOI 10.1056/NEJM199111143252004
   Spaide RF, 2006, RETINA-J RET VIT DIS, V26, P383, DOI 10.1097/00006982-200604000-00001
   Spandau UHM, 2006, AM J OPHTHALMOL, V142, P1068, DOI 10.1016/j.ajo.2006.06.048
   Steffensmeier ACG, 2007, AM J OPHTHALMOL, V143, P512, DOI 10.1016/j.ajo.2006.10.007
   Tan CSH, 2007, AM J OPHTHALMOL, V144, P330, DOI 10.1016/j.ajo.2007.04.002
   *US FDA, BL125085145 US FOOD, P13
   *US FDA, 2008, 21756S006 NDA US FOO, V3, P21
   Web JA., 2008, OPHTHALMOL TIME 0115
   Wu L, 2008, GRAEF ARCH CLIN EXP, V246, P81, DOI 10.1007/s00417-007-0660-z
   Yoganathan P, 2006, RETINA-J RET VIT DIS, V26, P994, DOI 10.1097/01.iae.0000244380.34082.67
   Ziemssen F, 2006, BRIT J OPHTHALMOL, V90, P922, DOI 10.1136/bjo.2006.092262
NR 89
TC 122
Z9 130
U1 0
U2 8
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0161-6420
EI 1549-4713
J9 OPHTHALMOLOGY
JI Ophthalmology
PD OCT
PY 2008
VL 115
IS 10
BP 1837
EP 1846
DI 10.1016/j.ophtha.2008.08.012
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 357NJ
UT WOS:000259852200029
PM 18929163
OA Bronze
DA 2022-11-30
ER

PT J
AU Hyttinen, JMT
   Blasiak, J
   Felszeghy, S
   Kaarniranta, K
AF Hyttinen, Juha M. T.
   Blasiak, Janusz
   Felszeghy, Szabolcs
   Kaarniranta, Kai
TI MicroRNAs in the regulation of autophagy and their possible use in
   age-related macular degeneration therapy
SO AGEING RESEARCH REVIEWS
LA English
DT Review
DE Age-Related macular degeneration; Autophagy; Exosome; Extracellular
   vesicle; MicroRNA; Retinal pigment epithelium
AB Age-related macular degeneration (AMD) is a progressive sight-impairing disease of the elderly. The pathogenic mechanisms of AMD are not well understood although both genetic and many environmental factors have been associated with the development of AMD. One clinical hallmark of AMD is the detrimental aggregation of damaged proteins. Recently, it has been suggested that the weakening of autophagy clearance is an important mechanism in the pathogenesis of AMD. Autophagy is important in the removal of damaged or no longer needed cellular material and its recycling. A considerable number of autophagy-targeting microRNAs (miRNAs), small RNA molecules and epigenetic regulators have been found to be either up- or down-regulated in AMD patients and experimental models. The important role of autophagy-targeting miRNAs is supported by several studies and can open the prospect of the use of these miRNAs in the therapy for AMD.
C1 [Hyttinen, Juha M. T.; Kaarniranta, Kai] Univ Eastern Finland, Inst Clin Med, Dept Ophthalmol, POB 1627, FI-70211 Kuopio, Finland.
   [Blasiak, Janusz] Univ Lodz, Dept Mol Genet, Pomorska 141-143, PL-90236 Lodz, Poland.
   [Felszeghy, Szabolcs] Univ Eastern Finland, Inst Biomed, POB 1627, FI-70211 Kuopio, Finland.
   [Felszeghy, Szabolcs] Univ Eastern Finland, Inst Dent, POB 1627, FI-70211 Kuopio, Finland.
   [Kaarniranta, Kai] Kuopio Univ Hosp, Dept Ophthalmol, POB 100, FI-70029 Kys, Finland.
C3 University of Eastern Finland; University of Lodz; University of Eastern
   Finland; University of Eastern Finland; Kuopio University Hospital
RP Hyttinen, JMT (通讯作者)，Univ Eastern Finland, Inst Clin Med, Dept Ophthalmol, POB 1627, FI-70211 Kuopio, Finland.
EM Juha.Hyttinen@uef.fi
OI Hyttinen, Juha/0000-0002-3414-4032; Blasiak, Janusz/0000-0001-9539-9584
FU Kuopio University Hospital [5503743]; Finnish Eye Foundation; Finnish
   Funding Agency for Technology and Innovation; Health Research Council of
   the Academy of Finland [296840, 333302]; Paivikki and Sakari Sohlberg
   Foundation; Sigrid Juselius Foundation; University of Eastern Finland
FX This work was supported by Kuopio University Hospital (Grant Number
   5503743), the Finnish Eye Foundation, the Finnish Funding Agency for
   Technology and Innovation, the Health Research Council of the Academy of
   Finland (Grant Numbers 296840 and 333302), the Paivikki and Sakari
   Sohlberg Foundation, the Sigrid Juselius Foundation, and the University
   of Eastern Finland strategical support. The authors warmly thank Dr.
   Ewen MacDonald for revising the English language.
CR Abokyi S, 2020, OXID MED CELL LONGEV, V2020, DOI 10.1155/2020/7901270
   Alles J, 2019, NUCLEIC ACIDS RES, V47, P3353, DOI 10.1093/nar/gkz097
   Ambati J, 2012, NEURON, V75, P26, DOI 10.1016/j.neuron.2012.06.018
   Askou AL, 2018, ACTA OPHTHALMOL, V96, P9, DOI 10.1111/aos.13407
   Avery AW, 2007, CELL SIGNAL, V19, P177, DOI 10.1016/j.cellsig.2006.06.003
   Bales KL, 2016, EXP EYE RES, V150, P71, DOI 10.1016/j.exer.2015.11.007
   Bartel DP, 2018, CELL, V173, P20, DOI 10.1016/j.cell.2018.03.006
   Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5
   Bhattacharjee S, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0150211
   Bhattacharya S, 2017, INVEST OPHTH VIS SCI, V58, P2366, DOI 10.1167/iovs.16-21162
   Blasiak J, 2019, J CELL MOL MED, V23, P8464, DOI 10.1111/jcmm.14731
   Blasiak J, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/768026
   Boya P, 2016, PROG RETIN EYE RES, V55, P206, DOI 10.1016/j.preteyeres.2016.08.001
   Bratkovic T, 2020, NUCLEIC ACIDS RES, V48, P1627, DOI 10.1093/nar/gkz1140
   Bushweller JH, 2019, NAT REV CANCER, V19, P611, DOI 10.1038/s41568-019-0196-7
   Cai JJ, 2019, EXP CELL RES, V374, P231, DOI 10.1016/j.yexcr.2018.11.028
   Cai JJ, 2014, J NEUROINFLAMM, V11, DOI 10.1186/1742-2094-11-88
   Camussi G, 2013, BIOCHEM SOC T, V41, P283, DOI 10.1042/BST20120192
   Chai J, 2016, INT J CLIN EXP PATHO, V9, P464
   Chatterjee A, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0095716
   Chen DY, 2020, MBIO, V11, DOI 10.1128/mBio.03045-19
   Chen ZH, 2017, CELL DEATH DIFFER, V24, P212, DOI 10.1038/cdd.2016.111
   Chu-Tan JA, 2018, INVEST OPHTH VIS SCI, V59, P4094, DOI 10.1167/iovs.18-24623
   Cloonan N, 2008, GENOME BIOL, V9, DOI 10.1186/gb-2008-9-8-r127
   Clotaire DZJ, 2016, BIOCHEM BIOPH RES CO, V472, P194, DOI 10.1016/j.bbrc.2016.02.093
   Corso-Diaz X, 2018, PROG RETIN EYE RES, V65, P1, DOI 10.1016/j.preteyeres.2018.03.002
   Ding XY, 2009, PROG RETIN EYE RES, V28, P1, DOI 10.1016/j.preteyeres.2008.10.001
   Nguyen DD, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19010065
   Doherty J, 2018, NAT CELL BIOL, V20, P1110, DOI 10.1038/s41556-018-0201-5
   Du WW, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.305
   Duan XG, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0138011
   Ebert MS, 2007, NAT METHODS, V4, P721, DOI 10.1038/NMETH1079
   Ebert MS, 2012, CELL, V149, P515, DOI 10.1016/j.cell.2012.04.005
   Erke MG, 2014, ACTA OPHTHALMOL, V92, P662, DOI 10.1111/aos.12346
   Ertekin S, 2014, MOL VIS, V20, P1057
   Felszeghy S, 2019, REDOX BIOL, V20, P1, DOI 10.1016/j.redox.2018.09.011
   Hernandez-Zimbron LF, 2018, OXID MED CELL LONGEV, V2018, DOI 10.1155/2018/8374647
   Ferrington DA, 2016, PROG RETIN EYE RES, V51, P69, DOI 10.1016/j.preteyeres.2015.09.002
   Friedman RC, 2009, GENOME RES, V19, P92, DOI 10.1101/gr.082701.108
   Gao C, 2014, NEOPLASMA, V61, P680, DOI 10.4149/neo_2014_083
   Gao XL, 2018, CYTOKINE, V110, P466, DOI 10.1016/j.cyto.2018.05.016
   Ge QY, 2014, MOLECULES, V19, P1568, DOI 10.3390/molecules19021568
   Gong X, 2016, AM J TRANSL RES, V8, P2127
   Gong YJ, 2019, J CELL MOL MED, V23, P7664, DOI 10.1111/jcmm.14639
   Grassmann F, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0107461
   Griffiths-Jones S, 2006, NUCLEIC ACIDS RES, V34, pD140, DOI 10.1093/nar/gkj112
   Guo SB, 2014, TUMOR BIOL, V35, P7025, DOI 10.1007/s13277-014-1965-2
   Gurubaran IS, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21061976
   Gwak HS, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0047449
   Ha M, 2014, NAT REV MOL CELL BIO, V15, P509, DOI 10.1038/nrm3838
   Han YW, 2018, FEBS LETT, V592, P4051, DOI 10.1002/1873-3468.13282
   He L, 2004, NAT REV GENET, V5, P522, DOI 10.1038/nrg1379
   Heesterbeek TJ, 2020, OPHTHAL PHYSL OPT, V40, P140, DOI 10.1111/opo.12675
   Higashi K, 2015, AM J PHYSIOL-HEART C, V309, pH1813, DOI 10.1152/ajpheart.00709.2014
   Hou CF, 2014, BIOCHEM BIOPH RES CO, V453, P728, DOI 10.1016/j.bbrc.2014.10.002
   Hou WC, 2017, ONCOL RES, V25, P43, DOI 10.3727/096504016X14719078133285
   Huang J, 2018, J CELL BIOCHEM, V119, P3853, DOI 10.1002/jcb.26464
   Humphries B, 2015, ONCOTARGET, V6, P6472, DOI 10.18632/oncotarget.3052
   Hyttinen JMT, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20225800
   Hyttinen JMT, 2018, CELL MOL LIFE SCI, V75, P2991, DOI 10.1007/s00018-018-2843-7
   Hyttinen JMT, 2014, AGEING RES REV, V18, P16, DOI 10.1016/j.arr.2014.07.002
   Hyttinen JMT, 2013, BBA-MOL CELL RES, V1833, P503, DOI 10.1016/j.bbamcr.2012.11.018
   Jonas JB, 2017, ASIA-PAC J OPHTHALMO, V6, P493, DOI 10.22608/APO.2017251
   Kaarniranta K, 2020, PROG RETIN EYE RES, V79, DOI 10.1016/j.preteyeres.2020.100858
   Kaarniranta K, 2017, CELL BIOL TOXICOL, V33, P113, DOI 10.1007/s10565-016-9371-8
   Kato M, 2015, INT J ONCOL, V47, P710, DOI 10.3892/ijo.2015.3043
   Keeling E, 2018, CELLS-BASEL, V7, DOI 10.3390/cells7020016
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Kong F, 2019, BIOMED PHARMACOTHER, V109, P716, DOI 10.1016/j.biopha.2018.10.079
   Kozomara A, 2019, NUCLEIC ACIDS RES, V47, pD155, DOI 10.1093/nar/gky1141
   Kumar R, 2016, CELL MICROBIOL, V18, P679, DOI 10.1111/cmi.12540
   Kuo WT, 2016, ANTICANCER RES, V36, P5189, DOI 10.21873/anticanres.11089
   Lambert M, 2018, MOLECULES, V23, DOI 10.3390/molecules23061479
   Lambert NG, 2016, PROG RETIN EYE RES, V54, P64, DOI 10.1016/j.preteyeres.2016.04.003
   Lapierre LR, 2015, AUTOPHAGY, V11, P867, DOI 10.1080/15548627.2015.1034410
   LEE RC, 1993, CELL, V75, P843, DOI 10.1016/0092-8674(93)90529-Y
   Lewis BP, 2003, CELL, V115, P787, DOI 10.1016/S0092-8674(03)01018-3
   Li N, 2019, ARTIF CELL NANOMED B, V47, P2529, DOI 10.1080/21691401.2019.1628038
   Li SF, 2016, LIFE SCI, V147, P143, DOI 10.1016/j.lfs.2016.01.044
   Li SC, 2012, BMC GENOMICS, V13, DOI 10.1186/1471-2164-13-S1-S13
   Li Y, 2018, P NATL ACAD SCI USA, V115, pE10849, DOI 10.1073/pnas.1803377115
   Liao HQ, 2016, ONCOL REP, V35, P64, DOI 10.3892/or.2015.4331
   Lim LP, 2005, NATURE, V433, P769, DOI 10.1038/nature03315
   Lin H, 2014, MOL PHARMACOL, V85, P682, DOI 10.1124/mol.113.090092
   Ling ZX, 2017, ONCOL REP, V38, P1621, DOI 10.3892/or.2017.5852
   Liu HW, 2019, BIOMED PHARMACOTHER, V109, P957, DOI 10.1016/j.biopha.2018.10.123
   Liu L, 2017, ONCOGENE, V36, P5874, DOI 10.1038/onc.2017.193
   Liu T, 2019, EUR J PHARMACOL, V863, DOI 10.1016/j.ejphar.2019.172673
   Liu XL, 2016, TOXICOL LETT, V252, P1, DOI 10.1016/j.toxlet.2016.04.015
   Liu XJ, 2015, EXP CELL RES, V338, P64, DOI 10.1016/j.yexcr.2015.08.010
   Liu XJ, 2015, EXP CELL RES, V336, P192, DOI 10.1016/j.yexcr.2015.07.006
   Lu R, 2018, BIOMED PHARMACOTHER, V105, P633, DOI 10.1016/j.biopha.2018.06.024
   Lukiw Walter J, 2012, Int J Biochem Mol Biol, V3, P105
   Mead B, 2020, PROG RETIN EYE RES, V79, DOI 10.1016/j.preteyeres.2020.100849
   Meenhuis A, 2011, BLOOD, V118, P916, DOI 10.1182/blood-2011-02-336487
   Menard C, 2016, ONCOTARGET, V7, P19171, DOI 10.18632/oncotarget.8280
   Mitter SK, 2014, AUTOPHAGY, V10, P1989, DOI 10.4161/auto.36184
   Mizushima N, 2007, GENE DEV, V21, P2861, DOI 10.1101/gad.1599207
   Murad N, 2014, FEBS J, V281, P5251, DOI 10.1111/febs.13066
   Nicholson AW, 2014, WIRES RNA, V5, P31, DOI 10.1002/wrna.1195
   Ohno-Matsui K, 2011, PROG RETIN EYE RES, V30, P217, DOI 10.1016/j.preteyeres.2011.02.004
   Pal S, 2016, SCI ADV, V2, DOI 10.1126/sciadv.1600584
   Pan BZ, 2015, ONCOTARGET, V6, P317, DOI 10.18632/oncotarget.2787
   Pandi SPS, 2013, INVEST OPHTH VIS SCI, V54, P8140, DOI 10.1167/iovs.13-12631
   Pannuru P, 2014, CELL SIGNAL, V26, P2193, DOI 10.1016/j.cellsig.2014.06.014
   Paterson MR, 2017, PHYSIOL GENOMICS, V49, P243, DOI 10.1152/physiolgenomics.00133.2016
   Qu YL, 2019, CELL IMMUNOL, V337, P22, DOI 10.1016/j.cellimm.2019.01.004
   Ramalinga M, 2015, ONCOTARGET, V6, P34446, DOI 10.18632/oncotarget.5920
   Rao YM, 2013, J HUAZHONG U SCI-MED, V33, P567, DOI 10.1007/s11596-013-1160-5
   Rezzani R, 2012, AGEING RES REV, V11, P10, DOI 10.1016/j.arr.2011.09.001
   Riggs A. D., 1996, TORRENTS SPRING, P1
   Romano GL, 2017, FRONT PHARMACOL, V8, DOI 10.3389/fphar.2017.00168
   Rouquette-Jazdanian AK, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0131823
   Rupaimoole R, 2017, NAT REV DRUG DISCOV, V16, P203, DOI 10.1038/nrd.2016.246
   Salminen A, 2012, AGEING RES REV, V11, P230, DOI 10.1016/j.arr.2011.12.005
   Sarkar D, 2015, EPIGENETICS-US, V10, P103, DOI 10.1080/15592294.2014.1003746
   Seca H, 2013, CURR DRUG TARGETS, V14, P1135, DOI 10.2174/13894501113149990185
   Serva A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0052555
   Shi YP, 2020, NEOPLASMA, V67, P249, DOI 10.4149/neo_2019_190110N29
   Shimbo K, 2014, BIOCHEM BIOPH RES CO, V445, P381, DOI 10.1016/j.bbrc.2014.02.007
   Shu DY, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21124271
   Simonsen A, 2008, AUTOPHAGY, V4, P176, DOI 10.4161/auto.5269
   Strauss O, 2005, PHYSIOL REV, V85, P845, DOI 10.1152/physrev.00021.2004
   Su JL, 2017, FEBS OPEN BIO, V7, P645, DOI 10.1002/2211-5463.12199
   Su M, 2015, CELL DEATH DIFFER, V22, P986, DOI 10.1038/cdd.2014.187
   Sun KT, 2015, BONE, V73, P145, DOI 10.1016/j.bone.2014.11.026
   Sun LL, 2019, J CELL MOL MED, V23, P8493, DOI 10.1111/jcmm.14739
   Sun QQ, 2015, INT J CANCER, V136, P1003, DOI 10.1002/ijc.29065
   Sun WJ, 2019, MOL THER, V27, P1039, DOI 10.1016/j.ymthe.2019.02.010
   Szemraj M, 2015, MED SCI MONITOR, V21, P2734, DOI 10.12659/MSM.893697
   Tan DM, 2018, MOL MED REP, V17, P6319, DOI 10.3892/mmr.2018.8645
   Tang F, 2018, BIOCHEM BIOPH RES CO, V495, P1482, DOI 10.1016/j.bbrc.2017.12.001
   Thery C, 2018, J EXTRACELL VESICLES, V7, DOI 10.1080/20013078.2018.1535750
   Tian L, 2018, ONCOTARGET, V9, P4886, DOI 10.18632/oncotarget.23513
   Ucar A, 2012, NAT COMMUN, V3, DOI 10.1038/ncomms2090
   Verdoodt B, 2013, INT J ONCOL, V43, P307, DOI 10.3892/ijo.2013.1915
   Viiri J, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0069563
   Wan G, 2014, AUTOPHAGY, V10, P70, DOI 10.4161/auto.26534
   Wang L, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17060895
   Wang SS, 2018, MOL THER, V26, P2295, DOI 10.1016/j.ymthe.2018.06.015
   Wang XW, 2014, BIOINFORMATICS, V30, P1377, DOI 10.1093/bioinformatics/btu045
   Wei JW, 2017, ONCOL REP, V37, P3, DOI 10.3892/or.2016.5236
   Wu H, 2012, CELL SIGNAL, V24, P2179, DOI 10.1016/j.cellsig.2012.07.001
   Wu JY, 2019, BIOMATERIALS, V206, P87, DOI 10.1016/j.biomaterials.2019.03.022
   Xiao J, 2011, J BIOMED SCI, V18, DOI 10.1186/1423-0127-18-35
   Xin HQ, 2017, CELL TRANSPLANT, V26, P243, DOI 10.3727/096368916X693031
   Xu BB, 2020, GENE, V730, DOI 10.1016/j.gene.2019.144260
   Yang XD, 2016, ONCOTARGET, V7, P79603, DOI 10.18632/oncotarget.12873
   Yang YF, 2015, CIRC RES, V117, P450, DOI 10.1161/CIRCRESAHA.117.305962
   Yu FJ, 2020, MOL CELL BIOCHEM, V465, P115, DOI 10.1007/s11010-019-03672-y
   Zhang BH, 2007, DEV BIOL, V302, P1, DOI 10.1016/j.ydbio.2006.08.028
   Zhang E, 2015, CELL PHYSIOL BIOCHEM, V37, P1442, DOI 10.1159/000438513
   Zhang J, 2017, AUTOPHAGY, V13, P1004, DOI 10.1080/15548627.2017.1312041
   Zhang W, 2019, INVEST OPHTH VIS SCI, V60, P294, DOI 10.1167/iovs.18-25617
   Zhang Y, 2019, CELL BIOSCI, V9, DOI 10.1186/s13578-019-0282-2
   Zhao B, 2020, TRANSPL P, V52, P392, DOI 10.1016/j.transproceed.2019.09.010
   Zhao FK, 2018, EXP EYE RES, V170, P169, DOI 10.1016/j.exer.2018.02.026
   Zhou QB, 2011, P NATL ACAD SCI USA, V108, P8287, DOI 10.1073/pnas.1105254108
NR 158
TC 10
Z9 10
U1 2
U2 11
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 1568-1637
EI 1872-9649
J9 AGEING RES REV
JI Ageing Res. Rev.
PD MAY
PY 2021
VL 67
AR 101260
DI 10.1016/j.arr.2021.101260
EA FEB 2021
PG 14
WC Cell Biology; Geriatrics & Gerontology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology; Geriatrics & Gerontology
GA RF5FR
UT WOS:000634864600008
PM 33516915
DA 2022-11-30
ER

PT J
AU Chen, K
   Weiland, JD
AF Chen, Kinon
   Weiland, James D.
TI Discovery of Retinal Elastin and Its Possible Role in Age-Related
   Macular Degeneration
SO ANNALS OF BIOMEDICAL ENGINEERING
LA English
DT Article
DE Posterior eye; Atherosclerotic vascular disease; Atherosclerosis; Soft
   tissue; Blood vessel; Immunohistochemistry; Enzyme-linked immunosorbent
   assay; Biomechanics; Mechanical properties
ID MECHANICAL-PROPERTIES; ATHEROSCLEROSIS; PROTEINS; DISEASE; CAPILLARIES;
   TISSUES; CELLS; AORTA
AB Age-related macular degeneration (AMD) etiology is unknown, but its association to atherosclerotic vascular disease (ASVD) has been observed. Since elastin plays an important role in the atherosclerotic process, to understand ASVD and AMD's relationship we examined retinal elastin existence, elastin amount and vessel properties among normal subjects, mild AMD patients, moderate-to-severe AMD patients, and ASVD patients (n = 20). One eye per donor was assigned to enzyme-linked immunosorbent assay for quantifying the retinal elastin amount. The rest were assigned to mechanical test for examining the retinal vessel properties. Additionally, two normal human and two porcine eyes were acquired in immunohistochemistry for locating the retinal elastin. We found that elastin presented in the human and porcine retinal vessels at the basement membranes. 3.73 +/- 0.55% of the normal retinal tissues were elastin. Elastin decrease, tissue-weight increase, and vessel hardening and inelasticity (p< 0.05) were observed in the retina of patients with ASVD and only moderate-to-severe (i.e., not mild) AMD. Most moderate-to-severe AMD patients also happened to have ASVD. The results suggest that ASVD is unlikely the cause of AMD, but it is perhaps a factor that aggravates the condition through mechanism associated with retinal vessel abnormality.
C1 [Chen, Kinon; Weiland, James D.] Univ So Calif, Dept Biomed Engn, Denney Res Ctr 140, Los Angeles, CA 90089 USA.
   [Chen, Kinon; Weiland, James D.] Univ So Calif, Doheny Eye Inst, Dept Ophthalmol, Los Angeles, CA 90033 USA.
C3 University of Southern California; Doheny Eye Institute; University of
   Southern California
RP Chen, K (通讯作者)，Univ So Calif, Dept Biomed Engn, Denney Res Ctr 140, 1042 Downey Way, Los Angeles, CA 90089 USA.
EM chen0606@umn.edu; JWeiland@doheny.org
OI Weiland, James/0000-0003-3453-9074
FU Department of Energy's Office of Science [DE-FC02-04ER63735]; W.M. Keck
   Foundation; Clarence and Estelle Albaugh Trust
FX This work is financially supported by the Department of Energy's Office
   of Science (grant no. DE-FC02-04ER63735), W.M. Keck Foundation, and
   Clarence and Estelle Albaugh Trust. The authors would like to thank Ruth
   Phinney, Xiao Peng Wang, Douglas Hauser, and Ronald Pak Cheung Wong for
   their technical assistance on donor coordination, sectioning, electron
   microscope operation, and ELISA.
CR [Anonymous], 2012, EY COND MAC DEG
   ARMSTRONG ML, 1975, CIRC RES, V36, P256, DOI 10.1161/01.RES.36.2.256
   Astrand H, 2011, J APPL PHYSIOL, V110, P176, DOI 10.1152/japplphysiol.00579.2010
   BERNSTEIN EF, 1994, J INVEST DERMATOL, V103, P182, DOI 10.1111/1523-1747.ep12392693
   Brooke BS, 2003, TRENDS CARDIOVAS MED, V13, P176, DOI 10.1016/S1050-1738(03)00065-3
   Chen K, 2008, ANN BIOMED ENG, V36, P1668, DOI 10.1007/s10439-008-9541-9
   Chen KN, 2014, J BIOMED MATER RES A, V102, P2001, DOI 10.1002/jbm.a.34858
   Chen K, 2010, J BIOMECH, V43, P1417, DOI 10.1016/j.jbiomech.2009.09.056
   Chen K, 2010, J BIOMED MATER RES A, V93A, P634, DOI 10.1002/jbm.a.32571
   DAGAGORDINI D, 1987, HISTOCHEMISTRY, V87, P573, DOI 10.1007/BF00492473
   Debelle L, 1999, INT J BIOCHEM CELL B, V31, P261, DOI 10.1016/S1357-2725(98)00098-3
   DITZEL J, 1975, Acta Medica Scandinavica Supplement, V578, P59
   FARIS B, 1986, EXP MOL PATHOL, V45, P105, DOI 10.1016/0014-4800(86)90052-3
   Friedman E, 2000, AM J OPHTHALMOL, V130, P658, DOI 10.1016/S0002-9394(00)00643-7
   GERLI R, 1991, LYMPHOLOGY, V24, P105
   Giannoudis PV, 2006, INJURY, V37, pS3, DOI 10.1016/S0020-1383(07)70005-0
   Gosline J, 2002, PHILOS T R SOC B, V357, P121, DOI 10.1098/rstb.2001.1022
   Hirvela H, 1996, OPHTHALMOLOGY, V103, P871, DOI 10.1016/S0161-6420(96)30593-9
   HOGAN MJ, 1963, J ULTRA MOL STRUCT R, V9, P10, DOI 10.1016/S0022-5320(63)80033-7
   Hogan MJ, 1971, HISTOLOGY HUMAN EYE
   Klein R, 2004, AM J OPHTHALMOL, V137, P486, DOI 10.1016/j.ajo.2003.11.069
   MACSWEENEY STR, 1992, BRIT J SURG, V79, P1281, DOI 10.1002/bjs.1800791211
   MECHAM RP, 1983, J CELL PHYSIOL, V116, P282, DOI 10.1002/jcp.1041160304
   Mullins RF, 2000, FASEB J, V14, P835, DOI 10.1096/fasebj.14.7.835
   Murray CJL, 1997, LANCET, V349, P1498, DOI 10.1016/S0140-6736(96)07492-2
   NEUMAN RE, 1950, J BIOL CHEM, V186, P549
   Robert L, 1998, ATHEROSCLEROSIS, V140, P281, DOI 10.1016/S0021-9150(98)00171-3
   Sagaties M. J., 1988, CURR EYE RES, V8, P55
   Seifert P, 1998, BRIT J OPHTHALMOL, V82, P77, DOI 10.1136/bjo.82.1.77
   Sivaprasad S., 2005, INVESTIGATIONS POSSI
   VINGERLING JR, 1995, AM J EPIDEMIOL, V142, P404, DOI 10.1093/oxfordjournals.aje.a117648
   Wise G.N., 1975, RETINAL CIRCULATION
NR 32
TC 12
Z9 12
U1 0
U2 4
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0090-6964
EI 1573-9686
J9 ANN BIOMED ENG
JI Ann. Biomed. Eng.
PD MAR
PY 2014
VL 42
IS 3
BP 678
EP 684
DI 10.1007/s10439-013-0936-x
PG 7
WC Engineering, Biomedical
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Engineering
GA AD1RI
UT WOS:000333010700019
PM 24232693
DA 2022-11-30
ER

PT J
AU Zhang, JX
   Liang, Y
   Xie, J
   Li, D
   Hu, Q
   Li, XS
   Zheng, WY
   He, R
AF Zhang, Jiaxing
   Liang, Yi
   Xie, Juan
   Li, Dong
   Hu, Qian
   Li, Xiaosi
   Zheng, Wenyi
   He, Rui
TI Conbercept for patients with age-related macular degeneration: a
   systematic review
SO BMC OPHTHALMOLOGY
LA English
DT Review
DE Wet age-related macular degeneration; Vascular endothelial growth factor
   (VEGF) inhibitor; Conbercept; Ranibizumab; Systematic review
ID ENDOTHELIAL GROWTH-FACTOR; RANIBIZUMAB; DISEASES
AB Background: Conbercept is a novel vascular endothelial growth factor (VEGF) inhibitor for the treatment of wet age-related macular degeneration (AMD). This systematic review aims to assess the efficacy and safety of conbercept in the treatment of wet AMD.
   Methods: PubMed, Embase, Cochrane Library, China National Knowledge Infrastructure, VIP database, and Wanfang database were searched from their earliest records to June 2017. We included randomized controlled trials (RCTs) evaluating the efficacy and safety of conbercept in wet AMD patients. Outcomes included the mean changes from baseline in best-corrected visual acuity (BCVA) score (primary outcome), central retinal thickness (CRT), plasma level of vascular endothelial growth factor (VEGF) over time, and the incidence of adverse events (AEs).
   Results: Eighteen RCTs (1285 participants) were included in this systematic review. Conbercept might improve BCVA compared to triamcinolone acetonide [MD = 0.11, 95% CI (0.08, 0.15)], and reduce CRT compared to the other four therapies (conservative treatment, ranibizumab, transpupillary thermotherapy, and triamcinolone acetonide). The incidence of AEs in patients receiving conbercept was significantly lower than those receiving triamcinolone acetonide [RR = 0.25, 95% CI (0.09-0.72)], but was similar to the other therapies. Conbercept seemed to be more effective than ranibizumab in lowering the plasma level of VEGF [MD = -15.86, 95% CI (-23.17, -8.55)].
   Conclusions: Current evidence shows that conbercept is a promising option for the treatment of wet AMD. Nevertheless, further studies are required to compare the efficacy, long-term safety and cost-effectiveness between conbercept and other anti-VEGF agents in different populations.
C1 [Zhang, Jiaxing; Xie, Juan] Guizhou Prov Peoples Hosp, Dept Pharm, 83 Zhongshandong Rd, Guiyang, Guizhou, Peoples R China.
   [Liang, Yi] Univ Texas Austin, Coll Pharm, Hlth Outcomes & Pharm Practice, Austin, TX 78712 USA.
   [Li, Dong; Hu, Qian] Guizhou Prov Peoples Hosp, Dept Ophthalmol, Guiyang, Guizhou, Peoples R China.
   [Li, Xiaosi] Hosp Chengdu, Off Peoples Govt Tibetan Autonomous Reg, Dept Pharm, 20 Ximianqiaoheng St, Chengdu, Sichuan, Peoples R China.
   [Zheng, Wenyi; He, Rui] Karolinska Inst, Clin Res Ctr, Dept Lab Med, Expt Canc Med, S-14186 Stockholm, Sweden.
C3 University of Texas System; University of Texas Austin; Karolinska
   Institutet
RP Li, XS (通讯作者)，Hosp Chengdu, Off Peoples Govt Tibetan Autonomous Reg, Dept Pharm, 20 Ximianqiaoheng St, Chengdu, Sichuan, Peoples R China.
EM lixiaosiyyy@126.com
RI Zheng, Wenyi/AAZ-7475-2021
CR American academy of ophthalmology, AG REL MAC DEG PPP
   Cheng, 2016, INT EYE SCI, V16, P1310, DOI [10.3980/j.issn.1672-5123.2016.7.26, DOI 10.3980/J.ISSN.1672-5123.2016.7.26]
   Cui J, 2018, EYE, V32, P391, DOI 10.1038/eye.2017.187
   Ferrara N, 2003, NAT MED, V9, P669, DOI 10.1038/nm0603-669
   Ferrara N, 2006, RETINA-J RET VIT DIS, V26, P859, DOI 10.1097/01.iae.0000242842.14624.e7
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Friedman DS, 1999, OPHTHALMOLOGY, V106, P1049, DOI 10.1016/S0161-6420(99)90267-1
   He, 2015, INT J OPHTHALMOL, V15, P1603, DOI [10.3980/j.issn.1672-5123.2015.9.30, DOI 10.3980/J.ISSN.1672-5123.2015.9.30]
   Higgins JPT, 2011, COCHRANE HDB SYSTEMA
   Higgins JPT, 2011, BMJ-BRIT MED J, V343, DOI 10.1136/bmj.d5928
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Jin EZ, 2017, RETINA-J RET VIT DIS, V37, P971, DOI 10.1097/IAE.0000000000001274
   Jonas JB, 2014, AM J OPHTHALMOL, V158, P808, DOI 10.1016/j.ajo.2014.06.012
   Kawasaki R, 2010, OPHTHALMOLOGY, V117, P921, DOI 10.1016/j.ophtha.2009.10.007
   Laude A, 2010, PROG RETIN EYE RES, V29, P19, DOI 10.1016/j.preteyeres.2009.10.001
   Li, 2016, CHIN J CLIN PHARM, V25, P367, DOI [10.19577/j.cnki.issn10074406.2016.06.009, DOI 10.19577/J.CNKI.ISSN10074406.2016.06.009]
   Li L, 2017, STRAIT PHARM J, V29, P77
   Li XX, 2014, OPHTHALMOLOGY, V121, P1740, DOI 10.1016/j.ophtha.2014.03.026
   Li YY, 2017, FOR ALL HLTH, V11, P104
   Liang Y, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0036698
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   [刘瑞 Liu Rui], 2015, [中国中西医结合杂志, Chinese Journal of Integrated Traditional and Western Medicine], V35, P104
   Liu ZN, 2016, WORLD CLIN MED, V10, P120
   Lyu P, 2016, J COMMUNITY MED, V14, P30
   Mei HY, 2017, CHINESE FOREIGN MED, V15, P32
   Pan XL, 2017, CHIN J CONVALESCENT, V26, P212
   Schmidt-Erfurth U, 2014, BRIT J OPHTHALMOL, V98, P1144, DOI 10.1136/bjophthalmol-2014-305702
   Solomon SD, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005139.pub3
   Vos T, 2012, LANCET, V380, P2163, DOI 10.1016/S0140-6736(12)61729-2
   Wang J, 2017, INT EYE SCI, V17, P104, DOI [10.3980/j.issn.1672-5123.2017.1.27, DOI 10.3980/J.ISSN.1672-5123.2017.1.27]
   Wang NF., 2017, CHIN HLTH CARE NUTR, V27, P192
   Wang Q, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0070544
   Wang XX, 2015, WORLD MOTHER BABY, V24, P51
   Yue JL., 2017, J SHANDONG MED COLL, V39, P226
   Zhang CH., 2016, J CLIN MED, V3, P10428
   Zhang HX, 2016, CHIN J BIOCH PHARM, V36, P134
   Zhang X., 2015, CHINA PHARM, V24, P21
   Zhao M, 2015, VALUE HEALTH, V18, pA421, DOI 10.1016/j.jval.2015.09.558
   Zheng MW., 2017, J MATH MED, V30, P228
   Zhu Y, 2017, SHANXI MED J, V46, P262
NR 40
TC 26
Z9 29
U1 1
U2 14
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1471-2415
J9 BMC OPHTHALMOL
JI BMC Ophthalmol.
PD JUN 15
PY 2018
VL 18
AR 142
DI 10.1186/s12886-018-0807-1
PG 12
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA GJ7RW
UT WOS:000435587800001
PM 29902977
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Maruko, I
   Iida, T
   Saito, M
   Nagayama, D
   Saito, K
AF Maruko, Ichiro
   Iida, Tomohiro
   Saito, Masaaki
   Nagayama, Dai
   Saito, Kuniharu
TI Clinical characteristics of exudative age-related macular degeneration
   in Japanese patients
SO AMERICAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID POLYPOIDAL CHOROIDAL VASCULOPATHY; 5-YEAR INCIDENCE; MACULOPATHY;
   PREVALENCE; NEOVASCULARIZATION; PROGRESSION; POPULATION; FEATURES; RISK;
   EYE
AB PURPOSE: To clarify the clinical characteristics of exudative age-related macular degeneration (AMD) in Japanese patients.
   DESIGN: Retrospective, observational, consecutive case series.
   METHODS: Two hundred and eighty,nine patients with neovascular AMD were examined.
   RESULTS: The authors classified the patients into three subtypes of neovascular AMD: polypoidal choroidal vas, culopathy (PCV), retinal angiomatous proliferation (RAP), and typical AMD. One hundred and fifty,eight patients (54.7%) were diagnosed with PCV and 102 patients (35.3%) with typical AMD. RAP was observed in 13 patients (4.5%). In 16 patients (5.5%), one eye had PCV and the other eye had typical AMD. Most patients with PCV and typical AMD had unilateral disease (81.6% and 94.1%, respectively) with a male preponderance (77.8% and 71.6%, respectively). Nine of 13 patients with RAP were female (69.2%). Patients with RAP were older (mean, 80.3 years for men and 75.3 years for women) than patients with other subtypes. Serous and hemorrhagic pigment epithelial detachment developed in 69 patients (43.7%) with PCV, 22 patients (21.6%) with typical AMD, and nine patients (69.2%) with RAP. In the patients with unilateral disease in each subtype, large drusen in the unaffected eye were seen in 24.0% with PCV, 30.2% with typical AMD, and 77.8% with RAP.
   CONCLUSIONS: Neovascular AMD in Japanese pa- tients has different demographic features compared with that in White patients. In Japanese patients, there is a preponderance of PCV, male gender, unilaterality, and absence of drusen in the second eye, with the exception of RAP.
C1 Fukushima Med Coll, Sch Med, Dept Ophthalmol, Fukushima, Japan.
C3 Fukushima Medical University
RP Maruko, I (通讯作者)，Fukushima Med Coll, Sch Med, Dept Ophthalmol, 1 Hikarigaoka, Fukushima, Japan.
EM iidat@fmu.ac.jp
RI Maruko, Ichiro/AFP-1311-2022; Saito, Masaaki/ABI-2783-2020
OI Maruko, Ichiro/0000-0001-5647-6372; Saito, Masaaki/0000-0003-1494-6350
CR Ahuja RM, 2000, BRIT J OPHTHALMOL, V84, P479, DOI 10.1136/bjo.84.5.479
   Arai K, 2003, FOLIA OPHTHALMOL JPN, V54, P513
   Barbazetto I, 2003, ARCH OPHTHALMOL-CHIC, V121, P1253
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   Dewan A, 2006, SCIENCE, V314, P989, DOI 10.1126/science.1133807
   Ferris FL, 2005, ARCH OPHTHALMOL-CHIC, V123, P1570
   Gross NE, 2005, RETINA-J RET VIT DIS, V25, P713, DOI 10.1097/00006982-200509000-00005
   ISHIBASHI T, 1986, AM J OPHTHALMOL, V101, P342, DOI 10.1016/0002-9394(86)90830-5
   Japanese Study Group of Polypoidal Choroidal Vasculopathy, 2005, Nippon Ganka Gakkai Zasshi, V109, P417
   Klein R, 1997, OPHTHALMOLOGY, V104, P7, DOI 10.1016/S0161-6420(97)30368-6
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Klein R, 2002, OPHTHALMOLOGY, V109, P1767, DOI 10.1016/S0161-6420(02)01146-6
   Kwok AKH, 2002, BRIT J OPHTHALMOL, V86, P892, DOI 10.1136/bjo.86.8.892
   Lim JI, 1998, RETINA-J RET VIT DIS, V18, P435
   Maguire MG, 1997, ARCH OPHTHALMOL-CHIC, V115, P741
   Mitchell P, 2002, OPHTHALMOLOGY, V109, P1092, DOI 10.1016/S0161-6420(02)01055-2
   MITCHELL P, 2002, OPHTHALMOLOGY, V109, P1588
   Miyazaki M, 2003, BRIT J OPHTHALMOL, V87, P469, DOI 10.1136/bjo.87.4.469
   Oshima Y, 2001, BRIT J OPHTHALMOL, V85, P1153, DOI 10.1136/bjo.85.10.1153
   SCHACHAT AP, 1995, ARCH OPHTHALMOL-CHIC, V113, P728, DOI 10.1001/archopht.1995.01100060054032
   Sho K, 2003, ARCH OPHTHALMOL-CHIC, V121, P1392, DOI 10.1001/archopht.121.10.1392
   Singerman Lawrence J, 2005, Retina, V25, pS1
   SPAIDE RF, 1995, RETINA-J RET VIT DIS, V15, P100, DOI 10.1097/00006982-199515020-00003
   Uyama M, 2002, AM J OPHTHALMOL, V133, P639, DOI 10.1016/S0002-9394(02)01404-6
   Uyama M, 1999, ARCH OPHTHALMOL-CHIC, V117, P1035
   Uyama M, 2000, BRIT J OPHTHALMOL, V84, P1018, DOI 10.1136/bjo.84.9.1018
   VINGERLING JR, 1995, OPHTHALMOLOGY, V102, P205
   Wen F, 2004, GRAEF ARCH CLIN EXP, V242, P625, DOI 10.1007/s00417-003-0667-z
   Yang ZL, 2006, SCIENCE, V314, P992, DOI 10.1126/science.1133811
   Yannuzzi LA, 1999, ARCH OPHTHALMOL-CHIC, V117, P1503
   Yannuzzi LA, 2001, RETINA-J RET VIT DIS, V21, P416, DOI 10.1097/00006982-200110000-00003
   Yannuzzi LA, 1997, ARCH OPHTHALMOL-CHIC, V115, P478, DOI 10.1001/archopht.1997.01100150480005
   YOSHIMURA N, 2004, FOLIA OPHTHALMOL JPN, V55, P155
   Yuzawa M, 1997, INT OPHTHALMOL, V21, P1, DOI 10.1023/A:1005845521424
NR 35
TC 414
Z9 442
U1 0
U2 9
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0002-9394
EI 1879-1891
J9 AM J OPHTHALMOL
JI Am. J. Ophthalmol.
PD JUL
PY 2007
VL 144
IS 1
BP 15
EP 22
DI 10.1016/j.ajo.2007.03.047
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 187SD
UT WOS:000247867800003
PM 17509509
DA 2022-11-30
ER

PT J
AU Atmani, K
   Voigt, M
   Le Tien, V
   Querques, G
   Coscas, G
   Soubrane, G
   Souied, EH
AF Atmani, K.
   Voigt, M.
   Le Tien, V.
   Querques, G.
   Coscas, G.
   Soubrane, G.
   Souied, E. H.
TI Ranibizumab for retinal angiomatous proliferation in age-related macular
   degeneration
SO EYE
LA English
DT Article
DE age-related macular degeneration; retinal angiomatous proliferation;
   chorioretinal anastomosis; type 3 neovascularization; intravitreal
   ranibizumab
ID OCCULT CHOROIDAL NEOVASCULARIZATION; PHOTODYNAMIC THERAPY; SURGICAL
   ABLATION; INTRAVITREAL; DETACHMENTS; ANASTOMOSIS; DRUSEN; SIGN
AB Purpose To assess the 1-year functional outcome and to evaluate the morphological changes after intravitreal injections of ranibizumab in eyes affected with retinal angiomatous proliferation (RAP) due to age-related macular degeneration (AMD).
   Methods A prospective, non-randomized, interventional study was conducted on 26 consecutive patients with newly diagnosed RAP. All eyes were treatment naive and were randomized to receive intravitreal injections of ranibizumab for a 12-month period. After the first three monthly injections, re-treatment was performed in case of best-corrected visual acuity (BCVA) loss of at least five letters associated with fluid within the macula, central macular thickness (CMT) increase of at least 100 mu m, and/or persistence of fluid within the macula as evaluated by optical coherence tomography, new onset macular haemorrhages, persistence of leakage from the lesions on fluorescein angiography.
   Results All patients completed the 12-month follow-up: 25 of the 29 treated eyes (86.2%) were stabilized, with a loss of less than 15 letters. Nineteen eyes (65.5%) maintained or improved their BCVA, and three eyes (10.3%) gained three lines or more. Overall, mean BCVA remained stable at the 12-month follow-up (-0.07 letters; P>0.05). Mean CMT significantly decreased from 386 +/- 147 to 216 +/- 74 mu m at the 12-month follow-up. No significant adverse events were observed during the study. The mean number of injections was 5.8 +/- 1.7 during the follow-up period.
   Conclusion The 1-year follow-up outcomes in our series suggest that ranibizumab is an effective treatment for RAP in AMD, allowing stabilization of BCVA and reduction of CMT. Eye (2010) 24, 1193-1198; doi:10.1038/eye.2010.9; published online 12 February 2010
C1 [Atmani, K.; Voigt, M.; Le Tien, V.; Querques, G.; Coscas, G.; Soubrane, G.; Souied, E. H.] Univ Paris 12, Dept Ophthalmol, Ctr Hosp Intercommunal Creteil, F-94000 Creteil, France.
C3 Universite Paris-Est-Creteil-Val-de-Marne (UPEC); CHI Creteil
RP Querques, G (通讯作者)，Univ Paris 12, Dept Ophthalmol, Ctr Hosp Intercommunal Creteil, 40 Ave Verdun, F-94000 Creteil, France.
EM giuseppe.querques@hotmail.it
OI Querques, Giuseppe/0000-0002-3292-9581
CR Boscia F, 2004, AM J OPHTHALMOL, V138, P1077, DOI 10.1016/j.ajo.2004.06.072
   Boscia F, 2006, GRAEF ARCH CLIN EXP, V244, P1224, DOI 10.1007/s00417-005-0205-2
   Bottoni F, 2005, ARCH OPHTHALMOL-CHIC, V123, P1644, DOI 10.1001/archopht.123.12.1644
   Cohen SY, 2007, BRIT J OPHTHALMOL, V91, P1173, DOI 10.1136/bjo.2007.115501
   Freund KB, 2008, RETINA-J RET VIT DIS, V28, P201, DOI 10.1097/IAE.0b013e3181669504
   Fung AE, 2007, AM J OPHTHALMOL, V143, P566, DOI 10.1016/j.ajo.2007.01.028
   Gass JDM, 2003, RETINA-J RET VIT DIS, V23, P741, DOI 10.1097/00006982-200312000-00001
   GASS JDM, 1984, RETINA-J RET VIT DIS, V4, P205, DOI 10.1097/00006982-198400440-00001
   Gross NE, 2005, RETINA-J RET VIT DIS, V25, P713, DOI 10.1097/00006982-200509000-00005
   HARTNETT ME, 1992, GRAEF ARCH CLIN EXP, V230, P11, DOI 10.1007/BF00166756
   Holz FG, 2004, AM J OPHTHALMOL, V137, P504, DOI 10.1016/j.ajo.2003.11.026
   Konstantinidis L, 2009, GRAEF ARCH CLIN EXP, V247, P1165, DOI 10.1007/s00417-009-1089-3
   KUHN D, 1995, ARCH OPHTHALMOL-CHIC, V113, P1392, DOI 10.1001/archopht.1995.01100110052025
   Kuroiwa S, 2003, RETINA-J RET VIT DIS, V23, P417, DOI 10.1097/00006982-200306000-00027
   Lai TYY, 2007, GRAEF ARCH CLIN EXP, V245, P1877, DOI 10.1007/s00417-007-0679-1
   Leveziel N, 2008, INVEST OPHTH VIS SCI, V49, P3090, DOI 10.1167/iovs.07-1540
   Mahmood S, 2009, EYE, V23, P530, DOI 10.1038/eye.2008.101
   Meyerle CB, 2007, RETINA-J RET VIT DIS, V27, P451, DOI 10.1097/IAE.0b013e318030ea80
   Monson DM, 2008, ARCH OPHTHALMOL-CHIC, V126, P1664, DOI 10.1001/archopht.126.12.1664
   Montero JA, 2009, BRIT J OPHTHALMOL, V93, P166, DOI 10.1136/bjo.2008.141903
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Sakimoto S, 2005, AM J OPHTHALMOL, V139, P917, DOI 10.1016/j.ajo.2004.10.046
   SCHNEIDER U, 1995, ACTA OPHTHALMOL SCAN, V73, P450
   Shiragami C, 2007, RETINA-J RET VIT DIS, V27, P198, DOI 10.1097/01.iae.0000224938.61915.f0
   Soubrane G, 1987, DOC OPHTHALMOL P SER, V50, P219
   Yannuzzi LA, 2001, RETINA-J RET VIT DIS, V21, P416, DOI 10.1097/00006982-200110000-00003
NR 26
TC 26
Z9 30
U1 0
U2 0
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0950-222X
J9 EYE
JI Eye
PD JUL
PY 2010
VL 24
IS 7
BP 1193
EP 1198
DI 10.1038/eye.2010.9
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 626OT
UT WOS:000279976000011
PM 20150927
OA Bronze
DA 2022-11-30
ER

PT J
AU Cacho, I
   Dickinson, CM
   Reeves, BC
   Harper, RA
AF Cacho, Isabel
   Dickinson, Christine M.
   Reeves, Barnaby C.
   Harper, Robert A.
TI Visual acuity and fixation characteristics in age-related, macular
   degeneration
SO OPTOMETRY AND VISION SCIENCE
LA English
DT Article
DE visual acuity; crowding effect; AMD; PRL; fixation characteristics
ID PREFERRED RETINAL LOCI; CONTOUR INTERACTION; PERIPHERAL-VISION; FOVEA;
   DISEASE; RESOLUTION; SELECTION; SCOTOMAS; LOCATION; POSITION
AB Purpose. To compare "single letter" (SL) acuity, "crowded letter" (CL) acuity, and "repeated letter" (RL) acuity for patients with age-related macular degeneration (AMD) and investigate if differences between these visual acuities are associated with fixation characteristics.
   Methods. A total of 243 patients with AMD had their best-corrected visual acuity measured on an ETDRS chart. SL, CL, and RL acuities were measured using Landolt C targets on a monitor. Fifty-degree-field red-free funclus photographs were taken and a static target was used to calculate the Preferred Retinal Locus (PRL) distance and direction from the fovea. Quality of fixation (consistency and oculomotor response) was also assessed using a funclus camera and a dynamic target.
   Results. RL acuity was almost always better than CL acuity and SL acuity was almost always better than CL acuity. The mean (+/- SD) RL-CL and SL-CL acuity differences were -0.13 (+/- 0.15) logMAR and -0.11 (+/- 0.13) logMAR respectively. The median PRL distance was 3.73 degrees and the preferred retinal areas for the location of the PRL were the left (left quadrant of visual field; 39.5% of cases) and superior (inferior quadrant of visual field; 25.4%). Visual acuity was significantly associated with PRL distance but PRL distance only explained 10% of the variation in visual acuity. PRL distance was found to be a significant but weak predictor of the SL-CL acuity difference but fixation quality was not a good predictor of the RL-CL acuity difference.
   Conclusions. Although the acuity measured under different stimulus conditions varies, the absolute differences are small. This suggests that these techniques would not be helpful in determining fixation characteristics, or predicting the outcome of rehabilitation in individual patients with AMD.
C1 Univ Manchester, Fac Life Sci, Manchester M60 1QD, Lancs, England.
   Univ London, London Sch Hyg & Trop Med, London WC1E 7HU, England.
C3 University of Manchester; University of London; London School of Hygiene
   & Tropical Medicine
RP Dickinson, CM (通讯作者)，Univ Manchester, Fac Life Sci, Moffat Bldg,POB 88, Manchester M60 1QD, Lancs, England.
EM i.cacho@manchester.ac.uk; chris.dickinson@manchester.ac.uk
OI Harper, Robert/0000-0001-5437-2553
CR ANSTIS SM, 1974, VISION RES, V14, P589, DOI 10.1016/0042-6989(74)90049-2
   Chung STL, 2002, INVEST OPHTH VIS SCI, V43, P1270
   CROSSLAND MD, 2004, INVEST OPHTHALMOL VI, V45
   Fletcher DC, 1997, OPHTHALMOLOGY, V104, P632, DOI 10.1016/S0161-6420(97)30260-7
   FLOM MC, 1963, J OPT SOC AM, V53, P1026, DOI 10.1364/JOSA.53.001026
   GUEZ JE, 1993, VISION RES, V33, P1271, DOI 10.1016/0042-6989(93)90213-G
   HARRIS MJ, 1985, OPHTHALMOLOGY, V92, P1550
   Horiguchi M, 2001, INVEST OPHTH VIS SCI, V42, P2765
   Latham K, 1996, OPHTHAL PHYSL OPT, V16, P49, DOI 10.1016/0275-5408(95)00124-7
   Leat SJ, 1999, INVEST OPHTH VIS SCI, V40, P504
   Lei H, 1997, INVEST OPHTH VIS SCI, V38, P1812
   Ludvigh E, 1941, AM J OPHTHALMOL, V24, P303, DOI [10.1016/S0002-9394(41)90648-7, DOI 10.1016/S0002-9394(41)90648-7]
   Pardhan S, 1997, NEURO-OPHTHALMOLOGY, V18, P59, DOI 10.3109/01658109709044118
   Petre KL, 2000, OPTOMETRY VISION SCI, V77, P34, DOI 10.1097/00006324-200001000-00011
   Raasch TW, 2004, BRIT J OPHTHALMOL, V88, P443, DOI 10.1136/bjo.2003.034827
   RANDALL HG, 1966, ARCH OPHTHALMOL-CHIC, V75, P500
   REGAN D, 1992, OPHTHAL PHYSL OPT, V12, P425, DOI 10.1016/0275-5408(92)90171-R
   Smith HJ, 2005, ARCH OPHTHALMOL-CHIC, V123, P1042, DOI 10.1001/archopht.123.8.1042
   Stelmack JA, 2004, J REHABIL RES DEV, V41, P729, DOI 10.1682/JRRD.2003.08.0136
   SUNNESS JS, 1995, AM J OPHTHALMOL, V119, P143, DOI 10.1016/S0002-9394(14)73866-8
   TIMBERLAKE GT, 1986, INVEST OPHTH VIS SCI, V27, P1137
   TOET A, 1992, VISION RES, V32, P1349, DOI 10.1016/0042-6989(92)90227-A
   WEITER JJ, 1984, ANN OPHTHALMOL, V16, P174
   WHITE JM, 1990, INVEST OPHTH VIS SCI, V31, P1149
   WHITTAKER SG, 1991, VISION RES, V31, P2209, DOI 10.1016/0042-6989(91)90173-3
   WILLIAMS TD, 1992, OPTOMETRY VISION SCI, V69, P369, DOI 10.1097/00006324-199205000-00006
NR 26
TC 16
Z9 16
U1 0
U2 9
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1040-5488
J9 OPTOMETRY VISION SCI
JI Optom. Vis. Sci.
PD JUN
PY 2007
VL 84
IS 6
BP 487
EP 495
DI 10.1097/OPX.0b013e318073c2f2
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 179WS
UT WOS:000247321700005
PM 17568318
DA 2022-11-30
ER

PT J
AU Wong, D
   Stanga, P
   Briggs, M
   Lenfestey, P
   Lancaster, E
   Li, KK
   Lim, KS
   Groenewald, C
AF Wong, D
   Stanga, P
   Briggs, M
   Lenfestey, P
   Lancaster, E
   Li, KK
   Lim, KS
   Groenewald, C
TI Case selection in macular relocation surgery for age related macular
   degeneration
SO BRITISH JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID SUBFOVEAL CHOROIDAL NEOVASCULARIZATION; 360-DEGREES RETINOTOMY;
   TRANSLOCATION SURGERY; REGRESSION; FIELD
AB Background: To date there has been no randomised controlled trial demonstrating the safety and efficacy of macular relocation surgery (MRS) for age related macular degeneration (AMD). Vision can be improved in some patients and made worse in others despite successful surgery or because of complications.
   Purpose: To determine which patients would benefit from MRS.
   Methods: Twenty nine patients with exudative AMD took part in a prospective, non-comparative, interventional study. Macular relocation surgery involved phacoemulsification, vitrectomy, 360degrees retinotomy, excision of choroidal neovascular membrane, and macular relocation using an infusion of 5-fluorouracil and low molecular weight heparin as adjuvant to prevent proliferative vitreoretinopathy. Patients underwent protocol refraction preoperatively and six-monthly postoperatively by designated optometrists. Preoperative fundus fluorescein angiograms were read by masked observers and the lesions were classified according to a set protocol. The main outcome measures were visual improvement, final vision of better than 20/400, reading speed, critical print size. Logistic and multiple stepwise linear regressions were used to identify independent factors which predicted the main outcomes.
   Results: Preoperative visual acuity (20/120 or worse) and lesion type ( predominantly classic or submacular haemorrhage) were significantly associated with visual improvement ( coefficient of regression B = 26.8, p< 0.001 and B = 14.9 with p = 0.045 respectively). There were no significant independent factors which predicted a final distance logMAR visual acuity of 1.3 (20/400) or any arbitrary definition of blindness.
   Conclusions: The study showed that it was possible to select cases that were more likely to experience an improvement in vision following MRS.
C1 Royal Liverpool Univ Hosp, St Pauls Eye Unit, Liverpool L7 8XP, Merseyside, England.
   Univ Liverpool, Dept Med, Expt Ophthalmol Unit, Liverpool L69 3BX, Merseyside, England.
C3 Royal Liverpool & Broadgreen University Hospitals NHS Trust; Royal
   Liverpool University Hospital; University of Liverpool; University of
   Liverpool
RP Wong, D (通讯作者)，Royal Liverpool Univ Hosp, St Pauls Eye Unit, Prescot St, Liverpool L7 8XP, Merseyside, England.
EM shdwong@liverpool.ac.uk
RI Wong, Sai Hung David/D-8482-2015; Li, Kenneth/M-4140-2017
OI Li, Kenneth/0000-0001-9440-8063
CR Aisenbrey S, 2002, ARCH OPHTHALMOL-CHIC, V120, P451
   *AM AC OPHTH, 2000, OPHTHALMOLOGY, V107, P1015
   Asaria RHY, 2001, OPHTHALMOLOGY, V108, P1179, DOI 10.1016/S0161-6420(01)00589-9
   BLAND JM, 1994, BRIT MED J, V309, P780, DOI 10.1136/bmj.309.6957.780
   BLAND JM, 1994, BRIT MED J, V308, P1499, DOI 10.1136/bmj.308.6942.1499
   BLAND JM, 1986, LANCET, V1, P307, DOI 10.1016/s0140-6736(86)90837-8
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   Cekic O, 1999, LANCET, V354, P340, DOI 10.1016/S0140-6736(05)75249-1
   Eckardt C, 1999, GRAEF ARCH CLIN EXP, V237, P313, DOI 10.1007/s004170050239
   FRANK RN, 1975, ARCH OPHTHALMOL-CHIC, V93, P591
   Gelisken F, 2002, OPHTHALMOLOGE, V99, P144, DOI 10.1007/s00347-002-0607-z
   Kubota A, 2001, AM J OPHTHALMOL, V132, P581, DOI 10.1016/S0002-9394(01)01056-X
   Lai JC, 2002, ARCH OPHTHALMOL-CHIC, V120, P1317, DOI 10.1001/archopht.120.10.1317
   Lewis H, 1999, AM J OPHTHALMOL, V128, P135, DOI 10.1016/S0002-9394(99)00207-X
   MACHEMER R, 1993, GRAEF ARCH CLIN EXP, V231, P635, DOI 10.1007/BF00921957
   Machemer R, 1998, AM J OPHTHALMOL, V125, P698, DOI 10.1016/S0002-9394(98)00020-8
   *NAT I CLIN EXC, 2002, FIN APPR DET PHOT TH
   Neugebauer A, 2002, OPHTHALMOLOGE, V99, P10, DOI 10.1007/PL00007108
   Ohji M, 1998, Semin Ophthalmol, V13, P52, DOI 10.3109/08820539809066082
   Pertile G, 2002, AM J OPHTHALMOL, V134, P560, DOI 10.1016/S0002-9394(02)01641-0
   Pieramici DJ, 2000, AM J OPHTHALMOL, V130, P419, DOI 10.1016/S0002-9394(00)00533-X
   Sebag J, 2001, OPHTHALMOLOGY, V108, P1177, DOI 10.1016/S0161-6420(01)00621-2
   Stevens TS, 1997, ARCH OPHTHALMOL-CHIC, V115, P345, DOI 10.1001/archopht.1997.01100150347006
   Terasaki H, 2001, Nagoya J Med Sci, V64, P1
   Terasaki H, 2002, INVEST OPHTH VIS SCI, V43, P452
   Wong D, 2000, BRIT J OPHTHALMOL, V84, P352, DOI 10.1136/bjo.84.4.352
NR 26
TC 43
Z9 43
U1 0
U2 1
PU B M J PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0007-1161
J9 BRIT J OPHTHALMOL
JI Br. J. Ophthalmol.
PD FEB 1
PY 2004
VL 88
IS 2
BP 186
EP 190
DI 10.1136/bjo.2003.019273
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 765UT
UT WOS:000188302800010
PM 14736769
OA Bronze, Green Published, Green Submitted
DA 2022-11-30
ER

PT J
AU Mares, JA
   Voland, RP
   Sondel, SA
   Millen, AE
   LaRowe, T
   Moeller, SM
   Klein, ML
   Blodi, BA
   Chappell, RJ
   Tinker, L
   Ritenbaugh, C
   Gehrs, KM
   Sarto, GE
   Johnson, E
   Snodderly, DM
   Wallace, RB
AF Mares, Julie A.
   Voland, Rick P.
   Sondel, Sherie A.
   Millen, Amy E.
   LaRowe, Tara
   Moeller, Suzen M.
   Klein, Mike L.
   Blodi, Barbara A.
   Chappell, Richard J.
   Tinker, Lesley
   Ritenbaugh, Cheryl
   Gehrs, Karen M.
   Sarto, Gloria E.
   Johnson, Elizabeth
   Snodderly, D. Max
   Wallace, Robert B.
TI Healthy Lifestyles Related to Subsequent Prevalence of Age-Related
   Macular Degeneration
SO ARCHIVES OF OPHTHALMOLOGY
LA English
DT Article
ID 15-YEAR CUMULATIVE INCIDENCE; 3RD NATIONAL-HEALTH; LONG-TERM INCIDENCE;
   BODY-MASS INDEX; DIETARY-FAT; PHYSICAL-ACTIVITY; EYE DISEASE; VITAMIN-D;
   10-YEAR INCIDENCE; OPTICAL-DENSITY
AB Objective: To investigate the relationships between lifestyle behaviors of diet, smoking, and physical activity and the subsequent prevalence of age-related macular degeneration (AMD).
   Methods: The population included 1313 participants (aged 55-74 years) in the Carotenoids in Age-Related Eye Disease Study, an ancillary study of the Women's Health Initiative Observational Study. Scores on a modified 2005 Healthy Eating Index were assigned using responses to a food frequency questionnaire administered at baseline of the Women's Health Initiative Observational Study (1994-1998). Physical activity and lifetime smoking history were queried. An average of 6 years later, stereoscopic fundus photographs were taken to assess the presence and severity of AMD; it was present in 202 women, 94% of whom had early AMD, the primary outcome.
   Results: In multivariate models, women whose diets scored in the highest quintile compared with the lowest quintile on the modified 2005 Healthy Eating Index had 46% lower odds for early AMD. Women in the highest quintile compared with those in the lowest quintile for physical activity (in metabolic energy task hours per week) had 54% lower odds for early AMD. Although smoking was not independently associated with AMD on its own, having a combination of 3 healthy behaviors (healthy diet, physical activity, and not smoking) was associated with 71% lower odds for AMD compared with having high-risk scores (P < .001).
   Conclusion: Modifying lifestyles might reduce risk for early AMD as much as 3-fold, lowering the risk for advanced AMD in a person's lifetime and the social and economic costs of AMD to society.
C1 [Mares, Julie A.; Voland, Rick P.; Sondel, Sherie A.; Moeller, Suzen M.; Blodi, Barbara A.] Univ Wisconsin, Dept Ophthalmol & Visual Sci, Madison, WI 53726 USA.
   [LaRowe, Tara] Univ Wisconsin, Dept Family Med, Madison, WI 53726 USA.
   [Chappell, Richard J.] Univ Wisconsin, Dept Stat & Biostat, Madison, WI 53726 USA.
   [Sarto, Gloria E.] Univ Wisconsin, Ctr Womens Hlth Res, Dept Obstet & Gynecol, Madison, WI 53726 USA.
   [Millen, Amy E.] SUNY Buffalo, Dept Social & Prevent Med, Buffalo, NY 14260 USA.
   [Klein, Mike L.] Oregon Hlth & Sci Univ, Casey Eye Inst, Portland, OR USA.
   [Tinker, Lesley] Fred Hutchinson Canc Res Ctr, Div Publ Hlth Sci, Seattle, WA 98104 USA.
   [Ritenbaugh, Cheryl] Univ Arizona, Coll Med, Dept Family & Community Med, Tucson, AZ USA.
   [Gehrs, Karen M.] Ctr Retina & Macular Dis, Winter Haven, FL USA.
   [Johnson, Elizabeth] Tufts Univ, Jean Mayer USDA Human Nutr Res Ctr Aging, Boston, MA 02111 USA.
   [Snodderly, D. Max] Univ Texas Austin, Dept Nutr Sci, Austin, TX 78712 USA.
   [Wallace, Robert B.] Univ Iowa, Dept Epidemiol, Iowa City, IA USA.
C3 University of Wisconsin System; University of Wisconsin Madison;
   University of Wisconsin System; University of Wisconsin Madison;
   University of Wisconsin System; University of Wisconsin Madison;
   University of Wisconsin System; University of Wisconsin Madison; State
   University of New York (SUNY) System; State University of New York
   (SUNY) Buffalo; Oregon Health & Science University; Fred Hutchinson
   Cancer Center; University of Arizona; Tufts University; United States
   Department of Agriculture (USDA); University of Texas System; University
   of Texas Austin; University of Iowa
RP Mares, JA (通讯作者)，Univ Wisconsin, Dept Ophthalmol & Visual Sci, 610 N Walnut St,1063 WARF Bldg, Madison, WI 53726 USA.
EM jmarespe@wisc.edu
OI Gehrs, Karen/0000-0003-4510-9678; Ritenbaugh,
   Cheryl/0000-0002-3307-2727; Snodderly, Donald/0000-0002-3428-609X
FU National Eye Institute [EY013018, EY016886]; National Institutes of
   Health [N01WH22110, 24152, 32100-2, 32105-6, 32108-9, 32111-13, 32115,
   32118-32119, 32122, 42107-26, 42129-32, 44221]; Research to Prevent
   Blindness; National Heart, Lung, and Blood Institute; NATIONAL EYE
   INSTITUTE [R01EY016886, U10EY013018] Funding Source: NIH RePORTER;
   WOMEN&apos;S HEALTH INITIATIVE - OFFICE OF THE DIRECTOR NIH
   [N01WH032122, N01WH032113, N01WH032115, N01WH022110, N01WH042112,
   N01WH042126, N01WH032106, N01WH032108, N01WH042108, N01WH032109,
   N01WH042109, N01WH032100, N01WH032112, N01WH042115, N01WH042113,
   N01WH042132, N01WH032101, N01WH032102, N01WH042116, N01WH032119,
   N01WH042119, N01WH042110, N01WH032118, N01WH042123, N01WH042129,
   N01WH042130, N01WH042117, N01WH032105, N01WH042122, N01WH042107,
   N01WH032111, N01WH042121, N01WH042118, N01WH042125, N01WH042131,
   N01WH042114, N01WH042120, N01WH042124, N01WH042111] Funding Source: NIH
   RePORTER
FX This research was supported by grants EY013018 and EY016886 from the
   National Eye Institute, National Institutes of Health, and by Research
   to Prevent Blindness. The WHI program is funded by the National Heart,
   Lung, and Blood Institute, National Institutes of Health through
   contracts N01WH22110, 24152, 32100-2, 32105-6, 32108-9, 32111-13, 32115,
   32118-32119, 32122, 42107-26, 42129-32, and 44221.
CR Age-Related Eye Dis Study Res Grp, 2001, AM J OPHTHALMOL, V132, P668
   Anderson G, 1998, CONTROL CLIN TRIALS, V19, P61
   Appel LJ, 1997, NEW ENGL J MED, V336, P1117, DOI 10.1056/NEJM199704173361601
   Baird PN, 2008, HUM MOL GENET, V17, P1299, DOI 10.1093/hmg/ddn018
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Bone RA, 2003, J NUTR, V133, P992, DOI 10.1093/jn/133.4.992
   Bowen PE, 2002, J NUTR, V132, P3668, DOI 10.1093/jn/132.12.3668
   Cheung N, 2007, SURV OPHTHALMOL, V52, P180, DOI 10.1016/j.survophthal.2006.12.003
   Chiu CJ, 2009, OPHTHALMOLOGY, V116, P939, DOI 10.1016/j.ophtha.2008.12.025
   Cho E, 2001, AM J CLIN NUTR, V73, P209
   Cho EY, 2008, AM J CLIN NUTR, V87, P1837, DOI 10.1093/ajcn/87.6.1837
   Chong EWT, 2008, ARCH OPHTHALMOL-CHIC, V126, P826, DOI 10.1001/archopht.126.6.826
   Christen WG, 2009, ARCH INTERN MED, V169, P335, DOI 10.1001/archinternmed.2008.574
   Delcourt C, 2007, EUR J CLIN NUTR, V61, P1341, DOI 10.1038/sj.ejcn.1602685
   Ding XY, 2009, PROG RETIN EYE RES, V28, P1, DOI 10.1016/j.preteyeres.2008.10.001
   Elmer PJ, 2006, ANN INTERN MED, V144, P485, DOI 10.7326/0003-4819-144-7-200604040-00007
   Feke GT, 2007, AM J OPHTHALMOL, V144, P482, DOI 10.1016/j.ajo.2007.05.033
   Fung TT, 2005, AM J CLIN NUTR, V82, P163
   Gao X, 2006, J NUTR, V136, P1341, DOI 10.1093/jn/136.5.1341
   Guenther PM, 2007, DEV EVALUATION HLTH
   Hammond BR, 2002, INVEST OPHTH VIS SCI, V43, P47
   Hammond BR, 1997, INVEST OPHTH VIS SCI, V38, P1795
   Hoffmann K, 2004, AM J CLIN NUTR, V80, P633
   Ji Li Li, 2009, Infectious Disorders - Drug Targets, V9, P428
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Klein R, 2004, AM J OPHTHALMOL, V137, P486, DOI 10.1016/j.ajo.2003.11.069
   Klein R, 2002, OPHTHALMOLOGY, V109, P1767, DOI 10.1016/S0161-6420(02)01146-6
   Klein R, 2007, OPHTHALMOLOGY, V114, P253, DOI 10.1016/j.ophtha.2006.10.040
   Knudtson MD, 2006, BRIT J OPHTHALMOL, V90, P1461, DOI 10.1136/bjo.2006.103796
   Landrum JT, 2004, OXIDAT STRESS DIS, V13, P445
   MARES JA, 2008, NUTR PREVENTION TREA
   Mares JA, 2006, AM J CLIN NUTR, V84, P1107
   Mares-Perlman JA, 2001, AM J EPIDEMIOL, V153, P424, DOI 10.1093/aje/153.5.424
   MARESPERLMAN JA, 1995, ARCH OPHTHALMOL-CHIC, V113, P743, DOI 10.1001/archopht.1995.01100060069034
   Meyer AM, 2009, MED SCI SPORT EXER, V41, P530, DOI 10.1249/MSS.0b013e31818ace55
   Millen AE, 2011, ARCH OPHTHALMOL-CHIC, V129, P481, DOI 10.1001/archophthalmol.2011.48
   Millen AE, 2010, AM J CLIN NUTR, V91, P1324, DOI 10.3945/ajcn.2009.28908
   Moeller Suzen M., 2003, International Ophthalmology Clinics, V43, P47
   Moeller SM, 2006, ARCH OPHTHALMOL-CHIC, V124, P1151, DOI 10.1001/archopht.124.8.1151
   Moeller SM, 2009, J NUTR, V139, P1692, DOI 10.3945/jn.109.107748
   Montgomery MP, 2010, OPHTHAL EPIDEMIOL, V17, P58, DOI 10.3109/09286580903450353
   Nolan J, 2004, INVEST OPHTH VIS SCI, V45, P3940, DOI 10.1167/iovs.04-0273
   Parekh N, 2007, ARCH OPHTHALMOL-CHIC, V125, P661, DOI 10.1001/archopht.125.5.661
   Parekh N, 2009, ARCH OPHTHALMOL-CHIC, V127, P1483, DOI 10.1001/archophthalmol.2009.130
   Patterson RE, 1999, ANN EPIDEMIOL, V9, P178, DOI 10.1016/S1047-2797(98)00055-6
   Peeters A, 2008, ARCH OPHTHALMOL-CHIC, V126, P1554, DOI 10.1001/archopht.126.11.1554
   PRYOR WA, 1993, ANN NY ACAD SCI, V686, P12, DOI 10.1111/j.1749-6632.1993.tb39148.x
   SanGiovanni JP, 2007, ARCH OPHTHALMOL-CHIC, V125, P1225, DOI 10.1001/archopht.125.9.1225
   SanGiovanni JP, 2009, ARCH OPHTHALMOL-CHIC, V127, P110, DOI 10.1001/archophthalmol.2008.518
   Schaumberg DA, 2001, ARCH OPHTHALMOL-CHIC, V119, P1259
   Schaumberg DA, 2007, ARCH OPHTHALMOL-CHIC, V125, P55, DOI 10.1001/archopht.125.1.55
   SCHNEIDER EL, 1990, JAMA-J AM MED ASSOC, V263, P2335, DOI 10.1001/jama.263.17.2335
   Seddon JM, 2004, JAMA-J AM MED ASSOC, V291, P704, DOI 10.1001/jama.291.6.704
   Seddon JM, 2003, ARCH OPHTHALMOL-CHIC, V121, P1728, DOI 10.1001/archopht.121.12.1728
   Seddon JM, 2003, ARCH OPHTHALMOL-CHIC, V121, P785, DOI 10.1001/archopht.121.6.785
   SEDDON JM, 1994, JAMA-J AM MED ASSOC, V272, P1413, DOI 10.1001/jama.272.18.1413
   Seddon JM, 2007, JAMA-J AM MED ASSOC, V297, P1793, DOI 10.1001/jama.297.16.1793
   Seddon JM, 2009, INVEST OPHTH VIS SCI, V50, P2044, DOI 10.1167/iovs.08-3064
   Smiddy WE, 2007, OPHTHALMOLOGY, V114, P847, DOI 10.1016/j.ophtha.2006.10.038
   Snodderly DM, 2004, INVEST OPHTH VIS SCI, V45, P531, DOI 10.1167/iovs.03-0762
   Sparrow JR, 2005, EXP EYE RES, V80, P595, DOI 10.1016/j.exer.2005.01.007
   Stevens VJ, 2001, ANN INTERN MED, V134, P1, DOI 10.7326/0003-4819-134-1-200101020-00007
   Sun C, 2009, OPHTHALMOLOGY, V116, P1913, DOI 10.1016/j.ophtha.2009.03.046
   Tan JSL, 2008, OPHTHALMOLOGY, V115, P334, DOI 10.1016/j.ophtha.2007.03.083
   Tan JSL, 2007, OPHTHALMOLOGY, V114, P1143, DOI 10.1016/j.ophtha.2006.09.033
   Thornton J, 2005, EYE, V19, P935, DOI 10.1038/sj.eye.6701978
   Tomaszewski M, 2003, ARTERIOSCL THROM VAS, V23, P1640, DOI 10.1161/01.ATV.0000087036.75849.0B
   *USDA, KEY REC GEN POP
   van Leeuwen R, 2005, JAMA-J AM MED ASSOC, V294, P3101, DOI 10.1001/jama.294.24.3101
   VandenLangenberg GM, 1998, AM J EPIDEMIOL, V148, P204, DOI 10.1093/oxfordjournals.aje.a009625
   Vincent HK, 2007, DIABETES OBES METAB, V9, P813, DOI 10.1111/j.1463-1326.2007.00692.x
   Wang JJ, 2007, OPHTHALMOLOGY, V114, P92, DOI 10.1016/j.ophtha.2006.07.017
   Wang JJ, 2009, AM J EPIDEMIOL, V169, P633, DOI 10.1093/aje/kwn358
   Williams PT, 2009, INVEST OPHTH VIS SCI, V50, P101, DOI 10.1167/iovs.08-2165
   Yeum KJ, 1996, AM J CLIN NUTR, V64, P594, DOI 10.1093/ajcn/64.4.594
NR 75
TC 108
Z9 109
U1 0
U2 26
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 0003-9950
EI 1538-3601
J9 ARCH OPHTHALMOL-CHIC
JI Arch. Ophthalmol.
PD APR
PY 2011
VL 129
IS 4
BP 470
EP 480
DI 10.1001/archophthalmol.2010.314
PG 11
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 748GT
UT WOS:000289378900012
PM 21149749
OA Green Accepted, Bronze
DA 2022-11-30
ER

PT J
AU Wong, TY
   Klein, R
   Cong, S
   Mitchell, P
   Couper, DJ
   Hong, L
   Hubbard, LD
   Sharrett, AR
AF Wong, Tien Yin
   Klein, Ronald
   Cong Sun
   Mitchell, Paul
   Couper, David J.
   Hong Lai
   Hubbard, Larry D.
   Sharrett, A. Richey
CA Atherosclerosis Risk Communities S
TI Age-related macular degeneration and risk for stroke
SO ANNALS OF INTERNAL MEDICINE
LA English
DT Article
ID ATHEROSCLEROSIS RISK; CARDIOVASCULAR-DISEASE; MACULOPATHY; THERAPY;
   HYPERTENSION; ANTIOXIDANTS; ASSOCIATION; CHOLESTEROL; INFARCTION;
   ASPIRIN
AB Background: Age-related macular degeneration (AMD) affects 7 million persons 40 years of age and older in the United States. Risk factors for the disease are similar to those for stroke.
   Objective: To determine what relationship, if any, exists between AMD and incident clinical stroke.
   Design: Prospective cohort study.
   Setting: The population-based Atherosclerosis Risk in Communities Study, which was conducted in Minnesota, Maryland, Mississippi, and North Carolina.
   Patients: 10405 persons between 49 and 73 years of age who had no history of stroke or coronary heart disease.
   Measurements: Participants had retinal photographs taken between 1993 and 1995. A standardized protocol was used to evaluate the photographs for the presence of drusen and other signs of AMD. Incident stroke events were identified and validated by reviewing case records.
   Results: There were 498 early-stage and 10 late-stage cases of AMD in the cohort (n = 508). Over a 10-year period, 241 persons had an incident stroke event. After adjusting for age, sex, ethnicity, and site, the authors found that persons with early-stage AMD had a higher cumulative incidence of stroke than those without disease (4.08% vs. 2.14%). The presence of early-stage AMD was associated with a higher adjusted risk for stroke (hazard ratio, 1.87 [95% CI, 1.21 to 2.88]). Further adjustment for systolic blood pressure, diabetes, cigarette smoking, and use of anti hypertensive medications did not substantially alter this association (hazard ratio, 1.85 [CI, 1.19 to 2.87]). The authors found that the association between early-stage AMD and stroke varied by study site and patient ethnicity. Multivariable-adjusted hazard ratios were 3.15 and 1.07 in samples of white patients in Minnesota and Maryland, respectively; 3.77 in a sample of African-American patients in Mississippi; and 0.33 in a sample of mostly white patients (91 %) in North Carolina. No site included sufficient numbers of both African-American and white patients to determine whether ethnicity contributed to the observed differences by study site.
   Limitations: There were few cases of late-stage AMD, and the cohort assembly method prohibited full understanding of variation by ethnicity and site.
   Conclusion: Middle-aged persons with signs of early-stage AMD have a higher risk for stroke independent of traditional stroke risk factors.
C1 Univ Melbourne, Ctr Eye Res Australia, Melbourne, Vic 3002, Australia.
   Univ Wisconsin, Madison, WI 53706 USA.
   Univ Sydney, Sydney, NSW 2006, Australia.
   Univ N Carolina, Chapel Hill, NC 27515 USA.
   Johns Hopkins Univ, Baltimore, MD 21218 USA.
C3 Centre for Eye Research Australia; University of Melbourne; University
   of Wisconsin System; University of Wisconsin Madison; University of
   Sydney; University of North Carolina; University of North Carolina
   Chapel Hill; Johns Hopkins University
RP Wong, TY (通讯作者)，Univ Melbourne, Ctr Eye Res Australia, 32 Gisborne St, Melbourne, Vic 3002, Australia.
EM twong@unimelb.edu.au
RI Wong, Tien Yin/AAC-9724-2020; Mitchell, Paul/P-1498-2014
OI Wong, Tien Yin/0000-0002-8448-1264; Couper, David/0000-0002-4313-9235
FU NHLBI NIH HHS [N01-HC-55018, N01-HC-55016, N01-HC-55022, N01-HC-55015,
   N01-HC-55019, N01-HC-55020, N01-HC-55021] Funding Source: Medline;
   DIVISION OF EPIDEMIOLOGY AND CLINICAL APPLICATIONS [N01HC055016,
   N01HC055015, N01HC055019, N01HC055020, N01HC055018, N01HC055022,
   N01HC055021] Funding Source: NIH RePORTER
CR [Anonymous], 2004, HEART DIS STROK STAT
   Curcio CA, 2001, INVEST OPHTH VIS SCI, V42, P265
   Delcourt C, 2001, Ophthalmic Epidemiol, V8, P237, DOI 10.1076/opep.8.4.237.1613
   Di Napoli M, 2001, STROKE, V32, P1444, DOI 10.1161/01.STR.32.6.1443-a
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Fine SL, 2000, NEW ENGL J MED, V342, P483, DOI 10.1056/NEJM200002173420707
   Folsom AR, 1999, CIRCULATION, V100, P736, DOI 10.1161/01.CIR.100.7.736
   Friedman E, 2000, AM J OPHTHALMOL, V130, P658, DOI 10.1016/S0002-9394(00)00643-7
   GOTO I, 1975, STROKE, V6, P263, DOI 10.1161/01.STR.6.3.263
   Hyman L, 2000, ARCH OPHTHALMOL-CHIC, V118, P351, DOI 10.1001/archopht.118.3.351
   HYMAN LG, 1983, AM J EPIDEMIOL, V118, P213, DOI 10.1093/oxfordjournals.aje.a113629
   Jackson R, 1996, J CLIN EPIDEMIOL, V49, P1441, DOI 10.1016/0895-4356(95)00047-X
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Klaver CCW, 1998, AM J HUM GENET, V63, P200, DOI 10.1086/301901
   Klaver CCW, 1999, AM J EPIDEMIOL, V150, P963
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P1686
   Klein R, 2003, OPHTHALMOLOGY, V110, P25, DOI 10.1016/S0161-6420(02)01565-8
   Klein R, 1999, ARCH OPHTHALMOL-CHIC, V117, P1203
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   Klein R, 1999, OPHTHALMOLOGY, V106, P1056, DOI 10.1016/S0161-6420(99)90255-5
   Klein Ronald, 2003, Ophthalmology, V110, P1273, DOI 10.1016/S0161-6420(03)00599-2
   Lindsberg PJ, 1996, ANN NEUROL, V40, P587, DOI 10.1002/ana.410400408
   McCarron MO, 1999, NEUROLOGY, V53, P1308, DOI 10.1212/WNL.53.6.1308
   McGwin G, 2005, OPHTHALMOLOGY, V112, P488, DOI 10.1016/j.ophtha.2004.10.027
   *NAT HEART LUNG BL, 1988, ATH RISK COMM STUD O
   O'Leary DH, 1999, NEW ENGL J MED, V340, P14, DOI 10.1056/NEJM199901073400103
   PAULEIKHOFF D, 1990, AM J OPHTHALMOL, V109, P211, DOI 10.1016/S0002-9394(14)75989-6
   Ridker PM, 1997, NEW ENGL J MED, V336, P973, DOI 10.1056/NEJM199704033361401
   Rosamond WD, 1999, STROKE, V30, P736, DOI 10.1161/01.STR.30.4.736
   SCHNEIDER R, 1993, STROKE, V24, P1874, DOI 10.1161/01.STR.24.12.1874
   Seddon JM, 2004, JAMA-J AM MED ASSOC, V291, P704, DOI 10.1001/jama.291.6.704
   Smith W, 1998, ARCH OPHTHALMOL-CHIC, V116, P583, DOI 10.1001/archopht.116.5.583
   Snow K K, 1999, Ophthalmic Epidemiol, V6, P125, DOI 10.1076/opep.6.2.125.1558
   Snowdon DA, 1997, JAMA-J AM MED ASSOC, V277, P813, DOI 10.1001/jama.277.10.813
   SPERDUTO RD, 1986, ARCH OPHTHALMOL-CHIC, V104, P216
   van Leeuwen R, 2005, JAMA-J AM MED ASSOC, V294, P3101, DOI 10.1001/jama.294.24.3101
   van Leeuwen R, 2003, INVEST OPHTH VIS SCI, V44, P3771, DOI 10.1167/iovs.03-0121
   VINGERLING JR, 1995, AM J EPIDEMIOL, V142, P404, DOI 10.1093/oxfordjournals.aje.a117648
   Voko Z, 2003, NEUROLOGY, V61, P1273, DOI 10.1212/01.WNL.0000090458.67821.A3
   White AD, 1996, J CLIN EPIDEMIOL, V49, P223, DOI 10.1016/0895-4356(95)00041-0
   White HD, 2000, NEW ENGL J MED, V343, P317, DOI 10.1056/NEJM200008033430502
   WILLIAMS OD, 1989, AM J EPIDEMIOL, V129, P687, DOI 10.1093/oxfordjournals.aje.a115184
   Wilson HL, 2004, AM J OPHTHALMOL, V137, P615, DOI 10.1016/j.ajo.2003.10.025
   Wong TY, 2002, AM J OPHTHALMOL, V134, P828
   Wong TY, 2001, LANCET, V358, P1134, DOI 10.1016/S0140-6736(01)06253-5
NR 45
TC 111
Z9 114
U1 0
U2 4
PU AMER COLL PHYSICIANS
PI PHILADELPHIA
PA INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA
SN 0003-4819
EI 1539-3704
J9 ANN INTERN MED
JI Ann. Intern. Med.
PD JUL 18
PY 2006
VL 145
IS 2
BP 98
EP 106
DI 10.7326/0003-4819-145-2-200607180-00007
PG 9
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA 063WU
UT WOS:000239051400003
PM 16847292
DA 2022-11-30
ER

PT J
AU Pournaras, CJ
   Logean, E
   Riva, CE
   Petrig, BL
   Chamot, SR
   Coscas, G
   Soubrane, G
AF Pournaras, CJ
   Logean, E
   Riva, CE
   Petrig, BL
   Chamot, SR
   Coscas, G
   Soubrane, G
TI Regulation of subfoveal choroidal blood flow in age-related macular
   degeneration
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
ID SYSTEMIC VASCULAR-DISEASE; RETINAL PERICYTES; INTRACELLULAR PH;
   OPTIC-NERVE; NEOVASCULARIZATION; PATHOGENESIS; CIRCULATION; STIMULATION;
   RELAXATION; INCREASE
AB PURPOSE. To assess the capability of the subfoveal choroidal circulation to regulate its blood flow in response to an acute increase in ocular perfusion pressure in the eyes of health), elderly persons or of subjects with neovascular age-related macular degeneration (AMD).
   METHODS. Changes of subfoveal choroidal blood velocity (ChBVel), volume (ChBVol), and flow (ChBF) induced by isometric exercise were determined using laser Doppler flow-metry (LDF) in 19 young healthy volunteers (group 1), 24 elderly healthy volunteers with mild macular pigment distribution changes (group 2), and 23 subjects with subfoveal classic neovascularization caused by AMD (group 3).
   RESULTS. Isometric exercise induced significant increases ill mean ocular perfusion pressure (PPm) of 19.5% +/- 4.9%, 20.2% +/- 3.8%, and 23.2% +/- 4.2%, for groups 1, 2, and 3, respectively (mean 95% confidence interval). III groups I and 2, the increase in PPm did not induce significant changes in the mean values of the different LDF parameters. In group 3, however, ChBF increased significantly by 12.4% +/- 5.0%. No significant correlations were found between age and the changes of each of the LDF parameters and of PPm at the end of squatting for the young and elderly healthy groups.
   CONCLUSIONS. In response to all acute, moderate increase in PPm induced by isometric exercise, subfoveal choroidal blood flow behaves similarly in young and elderly health), persons and is not significantly different from its value at rest. In contrast, in patients with neovascular AMD, this flow increases, indicating altered regulation in response to the increase in PPm.
C1 Univ Geneva, Dept Ophthalmol, Geneva, Switzerland.
   Inst Rech Ophtalmol, Sion, Switzerland.
   Univ Lausanne, Lausanne, Switzerland.
   Univ Paris 12, Dept Ophthalmol, Paris, France.
C3 University of Geneva; University of Lausanne; Universite
   Paris-Est-Creteil-Val-de-Marne (UPEC)
RP Pournaras, CJ (通讯作者)，22 Rue Alcide Jentzer, CH-1211 Geneva 14, Switzerland.
EM constantin.pournaras@hcuge.ch
CR ALM A, 1973, ACTA PHYSIOL SCAND, V88, P84, DOI 10.1111/j.1748-1716.1973.tb05436.x
   ALM A, 1977, EXP EYE RES, V25, P19, DOI 10.1016/0014-4835(77)90241-X
   Chen Q, 1997, INVEST OPHTH VIS SCI, V38, P643
   Ciulla TA, 1999, AM J OPHTHALMOL, V128, P75, DOI 10.1016/S0002-9394(99)00061-6
   Ciulla TA, 2002, BRIT J OPHTHALMOL, V86, P209, DOI 10.1136/bjo.86.2.209
   Ciulla TA, 1998, AM J OPHTHALMOL, V126, P153
   DAS A, 1988, EXP EYE RES, V46, P349, DOI 10.1016/S0014-4835(88)80025-3
   DelPriore LV, 1996, AM J OPHTHALMOL, V122, P629, DOI 10.1016/S0002-9394(14)70481-7
   ERNEST JT, 1977, AM J OPHTHALMOL, V84, P341
   FRIEDMAN E, 1995, OPHTHALMOLOGY, V102, P640, DOI 10.1016/S0161-6420(95)30974-8
   Friedman E, 1997, AM J OPHTHALMOL, V124, P677, DOI 10.1016/S0002-9394(14)70906-7
   Friedman E, 2000, AM J OPHTHALMOL, V130, P658, DOI 10.1016/S0002-9394(00)00643-7
   Grossniklaus HE, 2004, AM J OPHTHALMOL, V137, P496, DOI 10.1016/j.ajo.2003.09.042
   Grunwald JE, 1998, ARCH OPHTHALMOL-CHIC, V116, P150
   Grunwald JE, 1998, INVEST OPHTH VIS SCI, V39, P385
   HAEFLIGER IO, 1994, SURV OPHTHALMOL, V39, P123, DOI 10.1016/0039-6257(94)90157-0
   Haefliger IO, 1997, INVEST OPHTH VIS SCI, V38, P1563
   HAEFLIGER IO, 1994, INVEST OPHTH VIS SCI, V35, P991
   ISHIBASHI T, 1995, ARCH OPHTHALMOL-CHIC, V113, P227, DOI 10.1001/archopht.1995.01100020111041
   Matsugi T, 1997, INVEST OPHTH VIS SCI, V38, P2695
   MILLER H, 1984, INVEST OPHTH VIS SCI, V25, P1338
   Movaffaghy A, 1998, EXP EYE RES, V67, P561, DOI 10.1006/exer.1998.0556
   Nuzzi R, 1996, J FR OPHTALMOL, V19, P89
   Petrig BL, 1996, OCULAR BLOOD FLOW, P120
   PETRIG BL, 1998, LASERS LIGHT, V8, P137
   Polska E, 2002, CURR EYE RES, V24, P318, DOI 10.1076/ceyr.24.4.318.8413
   Pournaras CJ, 1996, OCULAR BLOOD FLOW, P40
   Reber F, 2003, GRAEF ARCH CLIN EXP, V241, P140, DOI 10.1007/s00417-002-0560-1
   Riva CE, 1997, INVEST OPHTH VIS SCI, V38, P2338
   Riva CE, 2003, LASERS IN OPHTHALMOLOGY: BASIC, DIAGNOSTIC AND SURGICAL ASPECTS, P51
   RIVA CE, 1994, INVEST OPHTH VIS SCI, V35, P4273
   ROBINSON F, 1986, INVEST OPHTH VIS SCI, V27, P722
   Ross RD, 1998, AM J OPHTHALMOL, V125, P71, DOI 10.1016/S0002-9394(99)80237-2
   Sarks JP, 1997, EYE, V11, P515, DOI 10.1038/eye.1997.137
   Schmetterer L, 1998, GRAEF ARCH CLIN EXP, V236, P160, DOI 10.1007/s004170050058
   Schonfelder U, 1998, MICROVASC RES, V56, P22, DOI 10.1006/mvre.1998.2086
   Spraul CW, 1998, INVEST OPHTH VIS SCI, V39, P2201
   TAKEUCHI M, 1993, ACTA SOC OPHTHALMOL, V97, P17
NR 38
TC 51
Z9 51
U1 0
U2 4
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD APR
PY 2006
VL 47
IS 4
BP 1581
EP 1586
DI 10.1167/iovs.05-0434
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 029KI
UT WOS:000236560800042
PM 16565395
DA 2022-11-30
ER

PT J
AU Augustin, A
   Sahel, JA
   Bandello, F
   Dardennes, R
   Maurel, F
   Negrini, C
   Hieke, K
   Berdeaux, G
AF Augustin, Albert
   Sahel, Jose-Alain
   Bandello, Francesco
   Dardennes, Roland
   Maurel, Frederique
   Negrini, Cristina
   Hieke, Klaus
   Berdeaux, Gilles
CA MICMAC Study Grp
TI Anxiety and depression prevalence rates in age-related macular
   degeneration
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
ID QUALITY-OF-LIFE; SUBFOVEAL CHOROIDAL NEOVASCULARIZATION; HOSPITAL
   ANXIETY; BREAST-CANCER; OLDER-ADULTS; SURGERY; HEALTH; SCALE;
   CLASSIFICATION; SYMPTOMS
AB PURPOSE. To estimate the prevalence rates of depression and anxiety in patients with wet age-related macular degeneration (AMD) and the relationship with visual acuity and to develop a simple algorithm for depression screening.
   METHODS. This cross-sectional, prospective, observational, multicenter study was performed in France, Germany, and Italy. Retina specialists at 10 centers per country each enrolled 12 consecutive patients with wet ARMD. Patients were stratified into four severity groups by using best eye (BE) and worst eye (WE) visual acuity (VA) thresholds (BE:VA 20/40 and WE:VA 20/200). Patients rated themselves on the Hospital Anxiety and Depression Scale (HADS). Analysis of variance was performed to estimate the effect of VA severity levels on HADS scores adjusted on age, gender, and country.
   RESULTS. Patients (females 609/6) were recruited, with a mean age of 77 years and 2.3 years' disease duration. Mean BE:VA at inclusion was 0.49 logMar (logarithm of the minimum angled of resolution) and NW:VA 1.0 logMar. The prevalence of severe depression increased from 0% (BE:VA >= 20/40+WE:VA >= 20/200) to 7.6% (BE:VA < 20/40+)WE:VA < 20/200), whereas anxiety was unrelated to VA loss. Moreover, total depression scores were strongly associated with VA severity (P = 0.006), but not total anxiety scores (P = 0.840). Responses to two HADS items ("I still enjoy things I used to enjoy"; "I can enjoy a good book or radio or television program") identified 95% of severely to moderately depressed patients.
   CONCLUSIONS. Self-rated depression in patients with AMD was associated with VA severity level. It should, therefore, be relatively easy for ophthalmologists to implement the screening procedure and refer identified patients to psychiatrists for proper assessment and treatment.
C1 Alcon France, F-92563 Rueil Malmaison, France.
   Conservatoire Natl Arts & Metiers, Paris, France.
   Neos Hlth, Basel, Switzerland.
   PBE Consulting, Verona, Italy.
   Aremis Consultants, Neuilly Sur Seine, France.
   Univ Paris Descartes, Paris, France.
   Univ Udine, I-33100 Udine, Italy.
   Hop XV XX, Paris, France.
   Augenklin, Karlsruhe, Germany.
C3 Novartis; Alcon; heSam Universite; Conservatoire National Arts & Metiers
   (CNAM); UDICE-French Research Universities; Universite Paris Cite;
   University of Udine; CHNO des Quinze-Vingts; UDICE-French Research
   Universities; Sorbonne Universite; University of Hamburg; University
   Medical Center Hamburg-Eppendorf
RP Berdeaux, G (通讯作者)，Alcon France, 4 Rue Henri St Claire Deville, F-92563 Rueil Malmaison, France.
EM gilles.berdeaux@alconlabs.com
RI bandello, francesco/AAH-2405-2019; Warneck, Bérengère/G-2287-2010;
   Sahel, Jose-Alain/F-3172-2017; Dardennes, Roland/G-2237-2010
OI bandello, francesco/0000-0003-3238-9682; Sahel,
   Jose-Alain/0000-0002-4831-1153; Dardennes, Roland/0000-0002-8848-178X;
   Varano, Monica/0000-0002-6530-1563; Augustin, Prof. Dr. Albert
   J./0000-0003-1591-0536; Schiano Lomoriello,
   Domenico/0000-0001-6035-225X; Boscia, Francesco/0000-0002-5478-060X
CR *AM PSYCH ASS, 1994, DIAGN STAT MAN MENT, P317
   Barefoot JC, 2000, PSYCHOSOM MED, V62, P790, DOI 10.1097/00006842-200011000-00008
   Berdeaux GH, 2005, AM J OPHTHALMOL, V139, P271, DOI 10.1016/j.ajo.2004.09.028
   Bjelland I, 2002, J PSYCHOSOM RES, V52, P69, DOI 10.1016/S0022-3999(01)00296-3
   Blumenkranz MS, 2001, ARCH OPHTHALMOL-CHIC, V119, P198
   Brody BL, 2005, ARCH OPHTHALMOL-CHIC, V123, P46, DOI 10.1001/archopht.123.1.46
   Brody BL, 2001, OPHTHALMOLOGY, V108, P1893, DOI 10.1016/S0161-6420(01)00754-0
   Carney C, 1998, Depress Anxiety, V7, P149, DOI 10.1002/(SICI)1520-6394(1998)7:4<149::AID-DA2>3.0.CO;2-5
   Casten RJ, 2002, J VISUAL IMPAIR BLIN, V96, P399, DOI 10.1177/0145482X0209600603
   Casten Robin J, 2004, Curr Opin Ophthalmol, V15, P181, DOI 10.1097/01.icu.0000120710.35941.3f
   Childs AL, 2004, OPHTHALMOLOGY, V111, P2007, DOI 10.1016/j.ophtha.2004.07.024
   FRASURESMITH N, 1995, CIRCULATION, V91, P999, DOI 10.1161/01.CIR.91.4.999
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   GRAJSKI KA, 1986, IEEE T BIO-MED ENG, V33, P1076, DOI 10.1109/TBME.1986.325684
   Hinz Andreas, 2004, Psychosoc Med, V1, pDoc09
   Koenig HG, 1997, AM J PSYCHIAT, V154, P1376
   Mangione CM, 2001, ARCH OPHTHALMOL-CHIC, V119, P1050, DOI 10.1001/archopht.119.7.1050
   Miskala PH, 2004, OPHTHALMOLOGY, V111, P1981, DOI 10.1016/j.ophtha.2004.07.022
   Mitchell Jan, 2005, Health Qual Life Outcomes, V3, P25, DOI 10.1186/1477-7525-3-25
   MOOREY S, 1991, BRIT J PSYCHIAT, V158, P255, DOI 10.1192/bjp.158.2.255
   MURRAY CJL, 1994, B WORLD HEALTH ORGAN, V72, P495
   Nunnaly JimC., 1978, PSYCHOMETRIC THEORY, V2nd ed.
   Parker G, 1999, CURR OPIN PSYCHIATR, V12, P87, DOI 10.1097/00001504-199901000-00023
   Pasacreta JV, 1997, NURS RES, V46, P214, DOI 10.1097/00006199-199707000-00006
   RADLOFF L S, 1977, Applied Psychological Measurement, V1, P385, DOI 10.1177/014662167700100306
   Rovner BW, 2002, ARCH OPHTHALMOL-CHIC, V120, P1041
   Rovner BW, 2002, AM J GERIAT PSYCHIAT, V10, P305
   Russell S, 2003, OPHTHALMOLOGY, V110, P2372, DOI 10.1016/j.ophtha.2003.08.020
   Shumway M, 2004, J AFFECT DISORDERS, V83, P191, DOI 10.1016/j.jad.2004.08.007
   Slakter JS, 2005, SURV OPHTHALMOL, V50, P263, DOI 10.1016/j.survophthal.2005.02.007
   Talic I, 2022, LEARN INSTR, V81, DOI [10.1016/j.learninstruc.2022.101594, 10.1016/j.ajo.2004.02.011]
   Tasman W, 2005, CAN J OPHTHALMOL, V40, P389, DOI 10.1016/S0008-4182(05)80082-1
   Torrance GW, 1996, MED CARE, V34, P702, DOI 10.1097/00005650-199607000-00004
   Watson M, 1999, LANCET, V354, P1331, DOI 10.1016/S0140-6736(98)11392-2
   Wells KB, 1999, ARCH GEN PSYCHIAT, V56, P897, DOI 10.1001/archpsyc.56.10.897
   ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x
   [No title captured]
NR 37
TC 91
Z9 94
U1 1
U2 13
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD APR
PY 2007
VL 48
IS 4
BP 1498
EP 1503
DI 10.1167/iovs.06-0761
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC Ophthalmology
GA 153CB
UT WOS:000245408200010
PM 17389477
DA 2022-11-30
ER

PT J
AU Bashshur, ZF
   Schakal, AR
   El-Mollayess, GM
   Arafat, S
   Jaafar, D
   Salti, HI
AF Bashshur, Ziad F.
   Schakal, Alex R.
   El-Mollayess, Georges M.
   Arafat, Samer
   Jaafar, Dalida
   Salti, Haytham I.
TI RANIBIZUMAB MONOTHERAPY VERSUS SINGLE-SESSION VERTEPORFIN PHOTODYNAMIC
   THERAPY COMBINED WITH AS-NEEDED RANIBIZUMAB TREATMENT FOR THE MANAGEMENT
   OF NEOVASCULAR AGE-RELATED MACULAR DEGENERATION
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE age-related macular degeneration; anti-vascular endothelial growth
   factor; anti-VEGF; choroidal neovascular membrane; photodynamic therapy;
   ranibizumab
ID SUBFOVEAL CHOROIDAL NEOVASCULARIZATION; RANDOMIZED CLINICAL-TRIALS;
   OPTICAL COHERENCE TOMOGRAPHY; INTRAVITREAL BEVACIZUMAB; TRIPLE THERAPY;
   COMBINATION; TAP; DEXAMETHASONE
AB Purpose: To compare verteporfin photodynamic therapy combined with intravitreal ranibizumab (combination therapy) versus ranibizumab monotherapy for management of neovascular age-related macular degeneration.
   Methods: Thirty patients (40 eyes) with neovascular age-related macular degeneration were prospectively allocated to combination therapy or monotherapy. In monotherapy, the induction phase consisted of 3 consecutive monthly ranibizumab injections (0.5 mg), while the combination therapy had a single session of photodynamic therapy with intravitreal ranibizumab. Follow-up treatment for either group consisted only of additional as-needed ranibizumab injections. The main outcome measure was that a proportion of eyes losing,15 letters of visual acuity after 12 months.
   Results: Except for 1 eye in combination therapy, all eyes in both groups lost,15 letters of visual acuity. At 12 months, there was a mean gain of +12 letters and +3.2 letters for monotherapy and combination therapy, respectively (relative percent change of 32% vs. 7%, P = 0.03). Anatomical improvement was similar in both groups. After induction, the time until ranibizumab retreatment was longer for combination therapy (P = 0.002) while ranibizumab injections were required more frequently with monotherapy (P = 0.015).
   Conclusion: Ranibizumab monotherapy showed greater improvement in visual acuity versus combination therapy. However, combination therapy required fewer ranibizumab injections. Larger trials need to confirm the findings of this pilot study.
   RETINA 31: 636-644, 2011
C1 [Bashshur, Ziad F.] Amer Univ Beirut, Med Ctr, Dept Ophthalmol, Beirut, Lebanon.
   [Schakal, Alex R.] St Joseph Univ, Hotel Dieu France, Dept Ophthalmol, Beirut, Lebanon.
C3 American University of Beirut; American University of Beirut
RP Bashshur, ZF (通讯作者)，Amer Univ Beirut, Med Ctr, Dept Ophthalmol, POB 11-0236-B11, Beirut, Lebanon.
EM zb00@aub.edu.lb
FU Novartis, Basel, Switzerland
FX Supported by Novartis, Basel, Switzerland.
CR Antoszyk AN, 2008, AM J OPHTHALMOL, V145, P862, DOI 10.1016/j.ajo.2007.12.029
   Arnold J, 2001, AM J OPHTHALMOL, V131, P541
   Arnold JJ, 2004, AM J OPHTHALMOL, V137, P683, DOI 10.1016/j.ajo.2003.11.059
   Augustin AJ, 2007, RETINA-J RET VIT DIS, V27, P133, DOI 10.1097/IAE.0b013e3180323de7
   Azab M, 2004, RETINA-J RET VIT DIS, V24, P1
   Bakri SJ, 2009, RETINA-J RET VIT DIS, V29, P573, DOI 10.1097/IAE.0b013e3181a46a8a
   Barouch Fina C., 2004, International Ophthalmology Clinics, V44, P23, DOI 10.1097/00004397-200404430-00005
   Blumenkranz MS, 2001, ARCH OPHTHALMOL-CHIC, V119, P198
   Bressler NM, 2002, ARCH OPHTHALMOL-CHIC, V120, P1307
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   CONNOLLY BP, 2007, INVEST OPHTH VIS SCI, V48, P4555
   Dewi NA, 2008, JPN J OPHTHALMOL, V52, P277, DOI 10.1007/s10384-008-0551-9
   FERRIS FL, 1984, ARCH OPHTHALMOL-CHIC, V102, P1640
   Fung AE, 2007, AM J OPHTHALMOL, V143, P566, DOI 10.1016/j.ajo.2007.01.028
   Goff MJ, 2007, RETINA-J RET VIT DIS, V27, P432, DOI 10.1097/IAE.0b013e318042b53f
   Greve MDJ, 2005, ARCH OPHTHALMOL-CHIC, V123, P448
   Heier JS, 2006, OPHTHALMOLOGY, V113, P633, DOI 10.1016/j.ophtha.2005.10.052
   Husain D, 1999, INVEST OPHTH VIS SCI, V40, P2322
   Kaiser PK, 2007, CURR MED RES OPIN, V23, P477, DOI 10.1185/030079907X167624
   Kaiser PK, 2009, OPHTHALMOLOGY, V116, P747, DOI 10.1016/j.ophtha.2008.12.057
   Keane PA, 2008, INVEST OPHTH VIS SCI, V49, P3115, DOI 10.1167/iovs.08-1689
   Kiss CG, 2008, BRIT J OPHTHALMOL, V92, P1620, DOI 10.1136/bjo.2007.135335
   Kumar A, 2008, RETINA-J RET VIT DIS, V28, P1132, DOI 10.1097/IAE.0b013e318170d76d
   Lalwani GA, 2009, AM J OPHTHALMOL, V148, P43, DOI 10.1016/j.ajo.2009.01.024
   MCNEIL R, ANTI VEGF THERAPY NE
   Michels S, 2003, INVEST OPHTH VIS SCI, V44, P2147, DOI 10.1167/iovs.02-0604
   Ng EWM, 2005, CAN J OPHTHALMOL, V40, P352, DOI 10.1016/S0008-4182(05)80078-X
   *OPTH TIM STAFF RE, RAD STUD SHOWS POS 1
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Sacu S, 2008, BRIT J OPHTHALMOL, V92, P1347, DOI 10.1136/bjo.2008.137885
   Schmidt-Erfurth U, 2002, ARCH OPHTHALMOL-CHIC, V120, P835
   Schmidt-Erfurth U, 2008, BRIT J OPHTHALMOL, V92, P1628, DOI 10.1136/bjo.2007.135277
   Schmidt-Erfurth U, 2009, PROG RETIN EYE RES, V28, P145, DOI 10.1016/j.preteyeres.2009.01.001
   Shah GK, 2009, RETINA-J RET VIT DIS, V29, P133, DOI 10.1097/IAE.0b013e3181960a28
   SLAKTER JS, 2007, INVEST OPHTHALMOL VI, V48
   Stepien KE, 2009, RETINA-J RET VIT DIS, V29, P1067, DOI 10.1097/IAE.0b013e3181b1bb06
   Tatar O, 2007, RETINA-J RET VIT DIS, V27, P713, DOI 10.1097/IAE.0b013e318042d3b0
NR 37
TC 16
Z9 18
U1 0
U2 4
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0275-004X
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD APR
PY 2011
VL 31
IS 4
BP 636
EP 644
DI 10.1097/IAE.0b013e3181fe54ab
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 740HR
UT WOS:000288783200002
PM 21124254
DA 2022-11-30
ER

PT J
AU Arnault, E
   Barrau, C
   Nanteau, C
   Gondouin, P
   Bigot, K
   Vienot, F
   Gutman, E
   Fontaine, V
   Villette, T
   Cohen-Tannoudji, D
   Sahel, JA
   Picaud, S
AF Arnault, Emilie
   Barrau, Coralie
   Nanteau, Celine
   Gondouin, Pauline
   Bigot, Karine
   Vienot, Francoise
   Gutman, Emmanuel
   Fontaine, Valerie
   Villette, Thierry
   Cohen-Tannoudji, Denis
   Sahel, Jose-Alain
   Picaud, Serge
TI Phototoxic Action Spectrum on a Retinal Pigment Epithelium Model of
   Age-Related Macular Degeneration Exposed to Sunlight Normalized
   Conditions
SO PLOS ONE
LA English
DT Article
ID LIGHT-INDUCED APOPTOSIS; BLUE-LIGHT; LIPOFUSCIN FLUOROPHORE;
   PHOTOCHEMICAL DAMAGE; OPTICAL-DENSITY; RISK-FACTORS; PREVALENCE;
   BARRIER; CELLS; A2E
AB Among the identified risk factors of age-related macular degeneration, sunlight is known to induce cumulative damage to the retina. A photosensitive derivative of the visual pigment, N-retinylidene-N-retinylethanolamine (A2E), may be involved in this phototoxicity. The high energy visible light between 380 nm and 500 nm (blue light) is incriminated. Our aim was to define the most toxic wavelengths in the blue-green range on an in vitro model of the disease. Primary cultures of porcine retinal pigment epithelium cells were incubated for 6 hours with different A2E concentrations and exposed for 18 hours to 10 nm illumination bands centered from 380 to 520 nm in 10 nm increments. Light irradiances were normalized with respect to the natural sunlight reaching the retina. Six hours after light exposure, cell viability, necrosis and apoptosis were assessed using the Apotox-Glo Triplex (TM) assay. Retinal pigment epithelium cells incubated with A2E displayed fluorescent bodies within the cytoplasm. Their absorption and emission spectra were similar to those of A2E. Exposure to 10 nm illumination bands induced a loss in cell viability with a dose dependence upon A2E concentrations. Irrespective of A2E concentration, the loss of cell viability was maximal for wavelengths from 415 to 455 nm. Cell viability decrease was correlated to an increase in cell apoptosis indicated by caspase-3/7 activities in the same spectral range. No light-elicited necrosis was measured as compared to control cells maintained in darkness. Our results defined the precise spectrum of light retinal toxicity in physiological irradiance conditions on an in vitro model of age-related macular degeneration. Surprisingly, a narrow bandwidth in blue light generated the greatest phototoxic risk to retinal pigment epithelium cells. This phototoxic spectrum may be advantageously valued in designing selective photoprotection ophthalmic filters, without disrupting essential visual and non-visual functions of the eye.
C1 [Arnault, Emilie; Nanteau, Celine; Gondouin, Pauline; Bigot, Karine; Gutman, Emmanuel; Fontaine, Valerie; Sahel, Jose-Alain; Picaud, Serge] Univ Paris 06, Inst Vis, UMR S 968, Paris, France.
   [Arnault, Emilie; Nanteau, Celine; Gondouin, Pauline; Bigot, Karine; Gutman, Emmanuel; Fontaine, Valerie; Sahel, Jose-Alain; Picaud, Serge] INSERM, U968, Paris, France.
   [Arnault, Emilie; Nanteau, Celine; Gondouin, Pauline; Bigot, Karine; Gutman, Emmanuel; Fontaine, Valerie; Sahel, Jose-Alain; Picaud, Serge] CNRS, UMR 7210, Paris, France.
   [Barrau, Coralie; Villette, Thierry; Cohen-Tannoudji, Denis] Essilor Inc Corp, Charenton Le Pont, France.
   [Vienot, Francoise] Museum Natl Hist Nat, F-75231 Paris, France.
   [Sahel, Jose-Alain] INSERM DHOS CIC 503, Ctr Hosp Natl Ophtalmol Quinze Vingts, Paris, France.
   [Sahel, Jose-Alain] UCL, Inst Ophthalmol, London, England.
   [Sahel, Jose-Alain; Picaud, Serge] Fdn Ophtalmol Adolphe Rothschild, Paris, France.
   [Sahel, Jose-Alain] Acad Sci Inst France, Paris, France.
C3 UDICE-French Research Universities; Sorbonne Universite; Institut
   National de la Sante et de la Recherche Medicale (Inserm); Centre
   National de la Recherche Scientifique (CNRS); CNRS - National Institute
   for Biology (INSB); UDICE-French Research Universities; Universite Paris
   Cite; Essilor International; Museum National d'Histoire Naturelle
   (MNHN); CHNO des Quinze-Vingts; Institut National de la Sante et de la
   Recherche Medicale (Inserm); UDICE-French Research Universities;
   Sorbonne Universite; University of London; University College London;
   Fondation Adolphe de Rothschild
RP Picaud, S (通讯作者)，Univ Paris 06, Inst Vis, UMR S 968, Paris, France.
EM serge.picaud@inserm.fr
RI Picaud, Serge/H-4012-2014; Sahel, Jose-Alain/F-3172-2017
OI Picaud, Serge/0000-0002-0548-5145; Sahel,
   Jose-Alain/0000-0002-4831-1153; Villette, Thierry/0000-0003-3354-8155;
   CARNEIRO, Emilie/0000-0002-5235-6557
FU OSEO (DESCARTES project); INSERM; Universite Pierre et Marie Curie
   (Paris VI); CNRS; Fondation Ophtalmologique A. de Rothschild (Paris);
   Federation des Aveugles de France; City of Paris; Regional Council of
   Ile-de-France; ESSILOR International; French state funds
   [ANR-10-LABX-65, ANR-11-IDEX-0004-02]
FX This research programm received French public subsidies from OSEO
   (DESCARTES project) and was also supported by INSERM, Universite Pierre
   et Marie Curie (Paris VI), CNRS, the Fondation Ophtalmologique A. de
   Rothschild (Paris), the Federation des Aveugles de France, the City of
   Paris, the Regional Council of Ile-de-France and ESSILOR International.
   This work performed in the frame of the LABEX LIFESENSES [reference
   ANR-10-LABX-65] was also supported by French state funds managed by the
   ANR within the Investissements d'Avenir programme under reference
   ANR-11-IDEX-0004-02. The funders had no role in study design, data
   collection and analysis, decision to publish, or preparation of the
   manuscript.
CR Augood CA, 2006, ARCH OPHTHALMOL-CHIC, V124, P529, DOI 10.1001/archopht.124.4.529
   BAZAN HEP, 1990, INVEST OPHTH VIS SCI, V31, P1433
   Ben-Shabat S, 2002, ANGEW CHEM INT EDIT, V41, P814, DOI 10.1002/1521-3773(20020301)41:5<814::AID-ANIE814>3.0.CO;2-2
   Boettner EA, 1962, INVESTIGATIVE OPHTHA, V1
   Boettner EA, 1967, SPECTRAL TRANSMISSIO
   Butt AL, 2011, OPHTHALMOLOGY, V118, P1380, DOI 10.1016/j.ophtha.2010.11.007
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   Cruickshanks KJ, 2001, ARCH OPHTHALMOL-CHIC, V119, P246
   Davies S, 2001, FREE RADICAL BIO MED, V31, P256, DOI 10.1016/S0891-5849(01)00582-2
   Fletcher AE, 2008, ARCH OPHTHALMOL-CHIC, V126, P1396, DOI 10.1001/archopht.126.10.1396
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Gellermann W, 2002, J OPT SOC AM A, V19, P1172, DOI 10.1364/JOSAA.19.001172
   GORGELS TGMF, 1995, INVEST OPHTH VIS SCI, V36, P851
   Grimm C, 2000, NAT GENET, V25, P63, DOI 10.1038/75614
   Grimm C, 2001, INVEST OPHTH VIS SCI, V42, P497
   Hafezi F, 1997, EXP EYE RES, V64, P963, DOI 10.1006/exer.1997.0288
   Hunter JJ, 2012, PROG RETIN EYE RES, V31, P28, DOI 10.1016/j.preteyeres.2011.11.001
   Kaya S, 2012, ACTA OPHTHALMOL, V90, pe399, DOI 10.1111/j.1755-3768.2012.02423.x
   Klein R, 2010, ARCH OPHTHALMOL-CHIC, V128, P750, DOI 10.1001/archophthalmol.2010.92
   Lawwill T, 1982, Trans Am Ophthalmol Soc, V80, P517
   Le Grand Y, 1972, OPTIQUE PHYSL, V2
   Lund DJ, 2006, HEALTH PHYS, V90, P477, DOI 10.1097/01.HP.0000190115.83416.cb
   Maeda A, 2008, J BIOL CHEM, V283, P26684, DOI 10.1074/jbc.M804505200
   Maeda A, 2009, INVEST OPHTH VIS SCI, V50, P5435, DOI 10.1167/iovs.09-3944
   Maeda T, 2009, INVEST OPHTH VIS SCI, V50, P4917, DOI 10.1167/iovs.09-3581
   Mainster MA, 2010, SURV OPHTHALMOL, V55, P272, DOI 10.1016/j.survophthal.2009.07.006
   Maiti P, 2006, BIOCHEMISTRY-US, V45, P852, DOI 10.1021/bi0518545
   Mitchell P, 1998, OPHTHALMOLOGY, V105, P1359, DOI 10.1016/S0161-6420(98)98013-7
   Ng KP, 2008, MOL CELL PROTEOMICS, V7, P1397, DOI 10.1074/mcp.M700525-MCP200
   Parish CA, 1998, P NATL ACAD SCI USA, V95, P14609, DOI 10.1073/pnas.95.25.14609
   PUTTING BJ, 1993, GRAEF ARCH CLIN EXP, V231, P600, DOI 10.1007/BF00936526
   PUTTING BJ, 1992, EXP EYE RES, V54, P133, DOI 10.1016/0014-4835(92)90077-6
   PUTTING BJ, 1992, INVEST OPHTH VIS SCI, V33, P3385
   PUTTING BJ, 1994, EXP EYE RES, V58, P31, DOI 10.1006/exer.1994.1192
   Raman R, 2011, INVEST OPHTH VIS SCI, V52, P7910, DOI 10.1167/iovs.11-7636
   Rein DB, 2009, ARCH OPHTHALMOL-CHIC, V127, P533, DOI 10.1001/archophthalmol.2009.58
   Rezai KA, 2008, GRAEF ARCH CLIN EXP, V246, P671, DOI 10.1007/s00417-006-0484-2
   Sabour-Pickett S, 2012, MOL NUTR FOOD RES, V56, P270, DOI 10.1002/mnfr.201100219
   Sanchez-Ramos C, 2010, ADV EXP MED BIOL, V664, P159, DOI 10.1007/978-1-4419-1399-9_19
   Schutt F, 2000, INVEST OPHTH VIS SCI, V41, P2303
   Seddon JM, 2011, OPHTHALMOLOGY, V118, P2203, DOI 10.1016/j.ophtha.2011.04.029
   Smith W, 2001, OPHTHALMOLOGY, V108, P697, DOI 10.1016/S0161-6420(00)00580-7
   Sparrow JR, 2010, J LIPID RES, V51, P247, DOI 10.1194/jlr.R000687
   Sparrow JR, 1999, INVEST OPHTH VIS SCI, V40, P2988
   Sparrow JR, 2004, J CATARACT REFR SURG, V30, P873, DOI 10.1016/j.jcrs.2004.01.031
   Sparrow JR, 2002, INVEST OPHTH VIS SCI, V43, P1222
   Sparrow JR, 2001, INVEST OPHTH VIS SCI, V42, P1356
   Sparrow JR, 2000, INVEST OPHTH VIS SCI, V41, P1981
   Sui GY, 2013, BRIT J OPHTHALMOL, V97, P389, DOI 10.1136/bjophthalmol-2012-302281
   Tanito M, 2006, EXP EYE RES, V83, P1493, DOI 10.1016/j.exer.2006.08.006
   TAYLOR HR, 1992, ARCH OPHTHALMOL-CHIC, V110, P99, DOI 10.1001/archopht.1992.01080130101035
   Ueda T, 2009, EXP EYE RES, V89, P863, DOI 10.1016/j.exer.2009.07.018
   van Norren D, 2011, PHOTOCHEM PHOTOBIOL, V87, P747, DOI 10.1111/j.1751-1097.2011.00921.x
   vanBest JA, 1997, MICROSC RES TECHNIQ, V36, P77, DOI 10.1002/(SICI)1097-0029(19970115)36:2<77::AID-JEMT1>3.0.CO;2-S
   VANNORREN D, 1990, VISION RES, V30, P1517, DOI 10.1016/0042-6989(90)90032-G
   Vojnikovic B, 2010, COLLEGIUM ANTROPOL, V34, P57
   Weigert G, 2011, INVEST OPHTH VIS SCI, V52, P8174, DOI 10.1167/iovs.11-7522
   Westlund B, 2009, APOPTOSIS, V14, P31, DOI 10.1007/s10495-008-0285-7
   Wihlmark U, 1997, FREE RADICAL BIO MED, V22, P1229, DOI 10.1016/S0891-5849(96)00555-2
   YOUNG RW, 1992, J NATL MED ASSOC, V84, P353
   Zhou JL, 2011, OPTOMETRY VISION SCI, V88, P759, DOI 10.1097/OPX.0b013e3182158cdd
NR 61
TC 75
Z9 84
U1 0
U2 33
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD AUG 23
PY 2013
VL 8
IS 8
AR e71398
DI 10.1371/journal.pone.0071398
PG 12
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA 217ZW
UT WOS:000324403200007
PM 24058402
OA Green Published, Green Submitted, gold
DA 2022-11-30
ER

PT J
AU Lin, JB
   Serghiou, S
   Miller, JW
   Vavvas, DG
AF Lin, Jonathan B.
   Serghiou, Stylianos
   Miller, Joan W.
   Vavvas, Demetrios G.
TI Systemic Complement Activation Profiles in Nonexudative Age-Related
   Macular Degeneration: A Meta-Analysis
SO JOURNAL OF CLINICAL MEDICINE
LA English
DT Article
DE complement; age-related macular degeneration; meta-analysis; geographic
   atrophy
ID PROGRESSION
AB Although complement inhibition has emerged as a possible therapeutic strategy for age-related macular degeneration (AMD), there is not a clear consensus regarding what aspects of the complement pathway are dysregulated in AMD and when this occurs relative to disease stage. We recently published a systematic review describing systemic complement activation profiles in patients with early/intermediate AMD or geographic atrophy (GA) compared to non-AMD controls. Here, we sought to meta-analyze these results to estimate the magnitude of complement dysregulation in AMD using restricted maximum likelihood estimation. The seven meta-analyzed studies included 710 independent participants with 23 effect sizes. Compared with non-AMD controls, patients with early/intermediate nonexudative AMD (N = 246) had significantly higher systemic complement activation, as quantified by the levels of complement proteins generated by common final pathway activation, and significantly lower systemic complement inhibition. In contrast, there were no statistically significant differences in the systemic levels of complement common final pathway activation products or complement inhibition in patients with GA (N = 178) versus non-AMD controls. We provide evidence that systemic complement over-activation is a feature of early/intermediate nonexudative AMD; no such evidence was identified for patients with GA. These findings provide mechanistic insights and inform future clinical trials.
C1 [Lin, Jonathan B.; Miller, Joan W.; Vavvas, Demetrios G.] Mass Eye & Ear, Dept Ophthalmol, Boston, MA 02114 USA.
   [Lin, Jonathan B.; Miller, Joan W.; Vavvas, Demetrios G.] Harvard Med Sch, Boston, MA 02114 USA.
   [Serghiou, Stylianos] Google LLC, Mountain View, CA 94043 USA.
C3 Harvard University; Harvard Medical School
RP Vavvas, DG (通讯作者)，Mass Eye & Ear, Dept Ophthalmol, Boston, MA 02114 USA.; Vavvas, DG (通讯作者)，Harvard Med Sch, Boston, MA 02114 USA.
EM lin@meei.harvard.edu; stelios.serghiou@gmail.com;
   miller@meei.harvard.edu; demetrios_vavvas@meei.harvard.edu
OI Serghiou, Stylianos/0000-0002-2477-6060; Lin,
   Jonathan/0000-0002-2792-7821
FU VitreoRetinal Surgery Foundation; Monte J. Wallace Chair in Retina; Ines
   and Fred Yeatts Retina Research lab fund; MLS Foundation; American
   Macular Degeneration Foundation; NIH [R01 EY030088]
FX This research was funded by the VitreoRetinal Surgery Foundation
   (J.B.L.), the Monte J. Wallace Chair in Retina (D.G.V.), the Ines and
   Fred Yeatts Retina Research lab fund (D.G.V.), the MLS Foundation
   (D.G.V.), the American Macular Degeneration Foundation (D.G.V.), and NIH
   Grant R01 EY030088 (J.W.M.). S.S. is an employee of Google LLC and did
   not receive any funding for this study.
CR Age-Related Eye Disease Study 2 Research Group, 2013, JAMA, V309, P2005, DOI 10.1001/jama.2013.4997
   Altay L, 2019, EYE, V33, P1859, DOI 10.1038/s41433-019-0501-4
   Balduzzi S, 2019, EVID-BASED MENT HEAL, V22, P153, DOI 10.1136/ebmental-2019-300117
   Chew E.Y., 2013, AREDS REPORT NO 35 O, V120, P1611, DOI [10.1016/j.ophtha.2013.01.021, DOI 10.1016/J.OPHTHA.2013.01.021]
   Chew EY, 2014, JAMA OPHTHALMOL, V132, P142, DOI 10.1001/jamaophthalmol.2013.7376
   Cohen J., 1988, STAT POWER ANAL SOCI, V2nd
   Halawa OA, 2021, J CLIN MED, V10, DOI 10.3390/jcm10122580
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Lashkari K, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0236283
   Lashkari K, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0195751
   Lin Jonathan B, 2022, Ophthalmol Sci, V2, DOI 10.1016/j.xops.2022.100118
   Lin JB, 2021, J CLIN MED, V10, DOI 10.3390/jcm10132890
   Lin LF, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0204056
   Luo DH, 2018, STAT METHODS MED RES, V27, P1785, DOI 10.1177/0962280216669183
   Lynch AM, 2020, BMJ OPEN OPHTHALMOL, V5, DOI 10.1136/bmjophth-2019-000361
   Lynch AM, 2020, EUR J OPHTHALMOL, V30, P1061, DOI 10.1177/1120672119857896
   Machalinska A, 2009, OPHTHALMIC RES, V42, P54, DOI 10.1159/000219686
   Page MJ, 2021, PLOS MED, V18, DOI 10.1371/journal.pmed.1003583
   R Development Core Team, 2022, R LANG ENV STAT COMP
   Reynolds R, 2009, INVEST OPHTH VIS SCI, V50, P5818, DOI 10.1167/iovs.09-3928
   Sitnilska V, 2021, GRAEF ARCH CLIN EXP, V259, P623, DOI 10.1007/s00417-020-04910-6
   Sivaprasad S, 2007, ARCH OPHTHALMOL-CHIC, V125, P515, DOI 10.1001/archopht.125.4.515
   Stroup DF, 2000, JAMA-J AM MED ASSOC, V283, P2008, DOI 10.1001/jama.283.15.2008
   Vavvas DG, 2018, P NATL ACAD SCI USA, V115, pE696, DOI 10.1073/pnas.1718059115
   Viechtbauer W, 2010, J STAT SOFTW, V36, P1, DOI 10.18637/jss.v036.i03
   Wan X, 2014, BMC MED RES METHODOL, V14, DOI 10.1186/1471-2288-14-135
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
NR 27
TC 0
Z9 0
U1 2
U2 2
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2077-0383
J9 J CLIN MED
JI J. Clin. Med.
PD MAY
PY 2022
VL 11
IS 9
AR 2371
DI 10.3390/jcm11092371
PG 8
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA 1F5UN
UT WOS:000795234100001
PM 35566495
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Elbay, A
   Ercan,
   Akbas, F
   Bulut, H
   Ozdemir, H
AF Elbay, Ahmet
   Ercan, Cilem
   Akbas, Fahri
   Bulut, Huri
   Ozdemir, Hakan
TI Three new circulating microRNAs may be associated with wet age-related
   macular degeneration
SO SCANDINAVIAN JOURNAL OF CLINICAL & LABORATORY INVESTIGATION
LA English
DT Article
DE Age-related macular degeneration; apoptosis; exosome; microRNA;
   neovascularization
ID EXPRESSION; TARGETS; GROWTH; CANCER; IDENTIFICATION; INVOLVEMENT;
   BIOMARKERS; TRANSPORT; MIR-486
AB This study investigates the circulating microRNA (miRNA) expression profiles in patients with age-related macular degeneration (AMD) and the role of miRNA in wet AMD and its pathways. Exosomes were extracted from serum samples of AMD patients (n = 70) and a control group (n = 50). After isolating miRNA from the exosomes, miRNAs were transformed into cDNA. In the control and AMD samples, the expression was compared with a panel including 175 genes using the PCR array method. Target genes and pathways of miRNAs were detected by KEGG and Biocarta signaling pathway enrichments. Comparing the serum samples between groups revealed that the expression levels of 15 microRNAs within 175 genes had significantly changed. In the validation studies, miR-129-3p and miR-132-3p had no significant expression in AMD group compared to the controls. miR-486-5p and miR-626 had higher expression in AMD patients compared to the control group, while miR-885-5p showed significantly lower expression. Pathway analysis revealed that these miRNAs may have critical roles in the apoptosis and neovascularization pathways. The data suggest that some miRNAs within the serum may have a role in the pathogenesis of wet AMD. Further studies are needed to examine the use of these miRNAs as biomarkers.
C1 [Elbay, Ahmet; Ozdemir, Hakan] Bezmialem Vakif Univ, Fac Med, Dept Ophthalmol, Zumrutevler Mh Emek Cd 2, Istanbul, Turkey.
   [Ercan, Cilem; Akbas, Fahri] Bezmialem Vakif Univ, Fac Med, Dept Med Biol, Istanbul, Turkey.
   [Bulut, Huri] Bezmialem Vakif Univ, Fac Med, Dept Biochem, Istanbul, Turkey.
C3 Bezmialem Vakif University; Bezmialem Vakif University; Bezmialem Vakif
   University
RP Elbay, A (通讯作者)，Bezmialem Vakif Univ, Fac Med, Dept Ophthalmol, Zumrutevler Mh Emek Cd 2, Istanbul, Turkey.
EM elbayamd@gmail.com
RI Akbas, Fahri/AAQ-7015-2020
OI Akbas, Fahri/0000-0002-3837-250X
FU Bezmialem Vakif University Scientific Research Project Office
FX This study was funded by Bezmialem Vakif University Scientific Research
   Project Office.
CR Afanasyeva EA, 2011, CELL DEATH DIFFER, V18, P974, DOI 10.1038/cdd.2010.164
   Almeida MI, 2011, MUTAT RES-FUND MOL M, V717, P1, DOI 10.1016/j.mrfmmm.2011.03.009
   Ambati J, 2013, NAT REV IMMUNOL, V13, P438, DOI 10.1038/nri3459
   Anand A, 2014, CURR GENOMICS, V15, P266, DOI 10.2174/1389202915666140516204512
   Anand S, 2010, NAT MED, V16, P909, DOI 10.1038/nm.2186
   Ayaz L., 2017, CUTAN OCUL TOXICOL, P1
   Beveridge NJ, 2012, NEUROBIOL DIS, V46, P263, DOI 10.1016/j.nbd.2011.12.029
   de Jong PTVM, 2006, NEW ENGL J MED, V355, P1474, DOI 10.1056/NEJMra062326
   De S, 2007, ARCH OPHTHALMOL-CHIC, V125, P641, DOI 10.1001/archopht.125.5.641
   FERRIS FL, 1984, ARCH OPHTHALMOL-CHIC, V102, P1640
   Ha Tai-You, 2011, Immune Netw, V11, P11, DOI [10.4110/in.2011.11.3.135, 10.4110/in.2011.11.1.11]
   Hang TTN, 2011, J CLIN INVEST, V121, P1733, DOI 10.1172/JCI44631
   Hitachi K, 2014, INT J BIOCHEM CELL B, V47, P93, DOI 10.1016/j.biocel.2013.12.003
   Huang XP, 2015, FEBS J, V282, P579, DOI 10.1111/febs.13167
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Kido Y, 2001, J PHARM PHARMACOL, V53, P497, DOI 10.1211/0022357011775794
   Kim VN, 2005, MOL CELLS, V19, P1
   Lagos D, 2010, NAT CELL BIOL, V12, P513, DOI 10.1038/ncb2054
   Lambert NG, 2016, PROG RETIN EYE RES, V54, P64, DOI 10.1016/j.preteyeres.2016.04.003
   Lei ZY, 2015, J CELL MOL MED, V19, P1994, DOI 10.1111/jcmm.12586
   Li CM, 2018, BMC CANCER, V18, DOI 10.1186/s12885-017-3753-z
   Lin HJ, 2011, INVEST OPHTH VIS SCI, V52, P6308, DOI 10.1167/iovs.10-6632
   Liu BY, 2010, MOL VIS, V16, P184
   Lu TP, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0042390
   Machalinska A, 2012, ACTA OPHTHALMOL, V90, P695, DOI 10.1111/j.1755-3768.2011.02295.x
   Mees ST, 2009, ANN SURG ONCOL, V16, P2339, DOI 10.1245/s10434-009-0531-4
   Meier C, 2016, CANCER RES, V76, P197, DOI 10.1158/0008-5472.CAN-15-1228
   Menard C, 2016, ONCOTARGET, V7, P19171, DOI 10.18632/oncotarget.8280
   Mestdagh P, 2009, GENOME BIOL, V10, DOI 10.1186/gb-2009-10-6-r64
   Nakauchi T, 2003, INVEST OPHTH VIS SCI, V44, P5023, DOI 10.1167/iovs.03-0403
   Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45
   Rosenthal R, 2004, BIOCHEM BIOPH RES CO, V323, P1203, DOI 10.1016/j.bbrc.2004.08.219
   Shen JK, 2008, MOL THER, V16, P1208, DOI 10.1038/mt.2008.104
   Sinirlioglu ZA, 2017, CELL MOL BIOL, V63, P49, DOI 10.14715/cmb/2017.63.2.7
   Sun W, 2010, ANNU REV BIOMED ENG, V12, P1, DOI 10.1146/annurev-bioeng-070909-105314
   Szemraj M, 2015, MED SCI MONITOR, V21, P2734, DOI 10.12659/MSM.893697
   Tezel TH, 2004, TRENDS MOL MED, V10, P417, DOI 10.1016/j.molmed.2004.07.004
   Tili Esmerina, 2008, Int J Med Sci, V5, P73
   Tomi M, 2005, INVEST OPHTH VIS SCI, V46, P2522, DOI 10.1167/iovs.04-1175
   Usui T, 2013, EXP EYE RES, V113, P135, DOI 10.1016/j.exer.2013.06.002
   Vinas JL, 2016, KIDNEY INT, V90, P1238, DOI 10.1016/j.kint.2016.07.015
   Wang LS, 2015, BLOOD, V125, P1302, DOI 10.1182/blood-2014-06-581926
   Wang SS, 2012, FUTURE MED CHEM, V4, P277, DOI 10.4155/fmc.11.176
   Yan W, 2011, BRAIN RES, V1411, P108, DOI 10.1016/j.brainres.2011.07.002
   Zeringer Emily, 2013, World J Methodol, V3, P11, DOI 10.5662/wjm.v3.i1.11
   Zhang ZH, 2016, ONCOTARGET, V7, P75038, DOI 10.18632/oncotarget.12602
   Zhao C, 2011, J CLIN INVEST, V121, P369, DOI 10.1172/JCI44303
NR 47
TC 20
Z9 21
U1 1
U2 9
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 0036-5513
EI 1502-7686
J9 SCAND J CLIN LAB INV
JI Scand. J. Clin. Lab. Invest.
PD AUG 18
PY 2019
VL 79
IS 6
BP 388
EP 394
DI 10.1080/00365513.2019.1637931
EA JUL 2019
PG 7
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine
GA IZ4EX
UT WOS:000474243100001
PM 31277558
DA 2022-11-30
ER

PT J
AU Byun, YJ
   Lee, SJ
   Koh, HJ
AF Byun, Yeo Jue
   Lee, Sung Jun
   Koh, Hyoung Jun
TI Predictors of Response After Intravitreal Bevacizumab Injection for
   Neovascular Age-Related Macular Degeneration
SO JAPANESE JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE AMD; bevacizumab; nonresponders; OCT; responders
ID OPTICAL COHERENCE TOMOGRAPHY; SUBFOVEAL CHOROIDAL NEOVASCULARIZATION;
   PHOTODYNAMIC THERAPY; RANIBIZUMAB LUCENTIS; SECONDARY; AVASTIN
AB Purpose: To identify fluorescein angiography (FA) and optical coherence tomography (OCT) characteristics predicting responses to intravitreal bevacizumab therapy in patients with neovascular age-related macular degeneration (AMD).
   Methods: Results of 113 consecutive patients (113 eyes) treated with intravitreal bevacizumab injections for neovascular AMD were retrospectively reviewed. Patients were categorized into two groups according to visual acuity (VA) improvement 1 year after treatment: responders and nonresponders. Responders were defined as patients who achieved VA improvement >= 7 Early Treatment Diabetic Retinopathy Study (ETDRS) letters for occult choroidal neovascularization (CNV), and >= 11 ETDRS letters for classic CNV at month 12. Nonresponders were defined as patients who did not meet the above VA improvement at month 12.
   Results: Of the 113 eyes, 36 (31.9%) were categorized as responders and 77 (68.1%) as nonresponders. Nonresponders, compared with responders, had thicker subretinal tissue (SRT) (218.9 mu m versus 180.9 mu m, P = 0.040), and more frequent cystoid macular edema (CME) (42.9% versus 13.9%, P < 0.001).
   Conclusion: Thick SRT and CME on OCT may be characteristic of nonresponders and may be helpful for tailoring treatment for neovascular AMD. Jpn J Ophthalmol 2010;54:571-577 (C) Japanese Ophthalmological Society 2010
C1 [Byun, Yeo Jue; Koh, Hyoung Jun] Yonsei Univ, Coll Med, Dept Ophthalmol, Inst Vis Res, Seoul 120752, South Korea.
   [Lee, Sung Jun] Dongguk Univ, Sch Med, Dongguk Univ Ilsan Hosp, Dept Ophthalmol, Gyeonggido, South Korea.
C3 Yonsei University; Yonsei University Health System; Dongguk University
RP Koh, HJ (通讯作者)，Yonsei Univ, Coll Med, Dept Ophthalmol, Inst Vis Res, 134 Shinchon Dong, Seoul 120752, South Korea.
EM hjkoh@yuhs.ac
OI Koh, Hyoung Jun/0000-0002-5932-8516
CR Ahlers C, 2008, BRIT J OPHTHALMOL, V92, P197, DOI 10.1136/bjo.2007.120956
   Avery RL, 2006, OPHTHALMOLOGY, V113, P363, DOI 10.1016/j.ophtha.2005.11.019
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Dadgostar H, 2009, OPHTHALMOLOGY, V116, P1740, DOI 10.1016/j.ophtha.2009.05.033
   Fong DS, 2010, OPHTHALMOLOGY, V117, P298, DOI 10.1016/j.ophtha.2009.07.023
   Fung AE, 2007, AM J OPHTHALMOL, V143, P566, DOI 10.1016/j.ajo.2007.01.028
   Hee MR, 1996, OPHTHALMOLOGY, V103, P1260, DOI 10.1016/S0161-6420(96)30512-5
   Joeres S, 2007, INVEST OPHTH VIS SCI, V48, P4300, DOI 10.1167/iovs.07-0179
   Jyothi S, 2010, EYE, V24, P816, DOI 10.1038/eye.2009.219
   Klein R, 2004, AM J OPHTHALMOL, V137, P486, DOI 10.1016/j.ajo.2003.11.069
   Krebs I, 2005, BRIT J OPHTHALMOL, V89, P1184, DOI 10.1136/bjo.2005.067389
   Landa G, 2009, OPHTHALMOLOGICA, V223, P370, DOI 10.1159/000227783
   Moutray T, 2008, BRIT J OPHTHALMOL, V92, P361, DOI 10.1136/bjo.2007.123976
   PULIAFITO CA, 1995, OPHTHALMOLOGY, V102, P217
   Regillo CD, 2008, AM J OPHTHALMOL, V145, P239, DOI 10.1016/j.ajo.2007.10.004
   Rein DB, 2006, ARCH OPHTHALMOL-CHIC, V124, P1754, DOI 10.1001/archopht.124.12.1754
   Rogers AH, 2002, AM J OPHTHALMOL, V134, P566, DOI 10.1016/S0002-9394(02)01566-0
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Sahni J, 2005, BRIT J OPHTHALMOL, V89, P316, DOI 10.1136/bjo.2004.043364
   Salinas-Alaman A, 2005, AM J OPHTHALMOL, V140, P23, DOI 10.1016/j.ajo.2005.01.044
   Spaide RF, 2006, RETINA-J RET VIT DIS, V26, P383, DOI 10.1097/00006982-200604000-00001
   Subramanian ML, 2009, AM J OPHTHALMOL, V148, P875, DOI 10.1016/j.ajo.2009.07.009
   Voo Irene, 2004, Ophthalmol Clin North Am, V17, P21, DOI 10.1016/j.ohc.2003.12.002
NR 23
TC 23
Z9 23
U1 0
U2 1
PU SPRINGER JAPAN KK
PI TOKYO
PA CHIYODA FIRST BLDG EAST, 3-8-1 NISHI-KANDA, CHIYODA-KU, TOKYO, 101-0065,
   JAPAN
SN 0021-5155
EI 1613-2246
J9 JPN J OPHTHALMOL
JI Jpn. J. Ophthalmol.
PD NOV
PY 2010
VL 54
IS 6
BP 571
EP 577
DI 10.1007/s10384-010-0866-1
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 709VK
UT WOS:000286469300008
PM 21191718
DA 2022-11-30
ER

PT J
AU Misson, GP
   Anderson, SJ
   Armstrong, RA
   Gilett, M
   Reynolds, D
AF Misson, Gary P.
   Anderson, Stephen J.
   Armstrong, Richard A.
   Gilett, Mark
   Reynolds, David
TI The Effect of Age-Related Macular Degeneration on Polarization Pattern
   Perception
SO TRANSLATIONAL VISION SCIENCE & TECHNOLOGY
LA English
DT Article
DE polarized light; vision; haidinger's brushes; macula; macular pigment
ID HAIDINGER BRUSHES; CATARACT; PIGMENT; DISEASE
AB Purpose: The purpose of this study was to determine if a battery of polarization-modulated stimuli, quantified as a single metric, is effective in identifying macular disease in the presence/absence of cataract or pseudophakia.
   Methods: Using a modified liquid crystal display, polarization pattern perception (PPP) for a formulated battery of geometric and IogMAR stimuli was evaluated in participants that had either no eye pathology (healthy participants) or were grouped according to the presence of cataract, pseudophakia, and/or age-related macular degeneration (AMD). PPP was quantified as response frequencies to individual stimuli, and as a novel monocular polarization sensitivity score (Ps) based on perception of the stimulus battery set.
   Results: Stimulus response frequencies were pattern-dependent and, compared with healthy participants, reduced for cataract and AMD groups but not for subjects with pseudophakia. Compared with healthy eyes (n = 47, median Ps = 17), Ps was significantly reduced by AMD (n = 59, median Ps = 1, P < 0.001) and, to a lesser extent, by cataracts (n = 80, median Ps = 6, P < 0.001). There was no significant difference between Ps for healthy and pseudophakic eyes (n = 47, median Ps = 13, P = 0.323). There was no significant correlation between Ps and logMAR visual acuity.
   Conclusions: In the absence of significant cataract, or in pseudophakia, a set of polarization-modulated visual stimuli, quantified as the Ps score, distinguishes AMD from healthy maculae.
   Translational Relevance: Perception of polarization-modulated stimuli, previously shown to be macula-dependent in a laboratory setting, is effective as a test of macular function in health and disease in a clinic setting.
C1 [Misson, Gary P.; Anderson, Stephen J.; Armstrong, Richard A.] Aston Univ, Coll Life & Hlth Sci, Sch Optometry, Birmingham, W Midlands, England.
   [Misson, Gary P.; Gilett, Mark; Reynolds, David] South Warwickshire NHS Fdn Trust, Dept Ophthalmol, Lakin Rd, Warwick CV34 5BW, England.
C3 Aston University
RP Misson, GP (通讯作者)，South Warwickshire NHS Fdn Trust, Dept Ophthalmol, Lakin Rd, Warwick CV34 5BW, England.
EM g.misson@aston.ac.uk
OI Misson, Gary/0000-0001-8843-8389
FU European Society of Cataract and Refractive
FX G.P.M. is partly funded by a grant from the European Society of Cataract
   and Refractive
CR BONE RA, 1980, VISION RES, V20, P213, DOI 10.1016/0042-6989(80)90105-4
   Crossland M, 2007, BRIT J OPHTHALMOL, V91, P391, DOI 10.1136/bjo.2006.095315
   Davis MD, 2005, ARCH OPHTHALMOL-CHIC, V123, P1484
   FORSTER HW, 1954, AM J OPHTHALMOL, V38, P661, DOI 10.1016/0002-9394(54)90291-3
   Foster JJ, 2018, SCI NAT-HEIDELBERG, V105, DOI 10.1007/s00114-018-1551-3
   GOLDSCHMIDT M, 1950, ARCH OPHTHALMOL-CHIC, V44, P129
   Kessel L, 2015, ACTA OPHTHALMOL, V93, P593, DOI 10.1111/aos.12665
   Klein BEK, 2012, OPHTHALMOLOGY, V119, P1628, DOI 10.1016/j.ophtha.2012.01.050
   McGregor J, 2014, SPR SER VIS RES, V2, P303, DOI 10.1007/978-3-642-54718-8_14
   Misson GP, 2020, TRANSL VIS SCI TECHN, V9, DOI 10.1167/tvst.9.11.31
   Misson GP, 2018, J OPT SOC AM A, V35, P946, DOI 10.1364/JOSAA.35.000946
   Misson GP, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-16873-6
   Misson GP, 2015, VISION RES, V115, P48, DOI 10.1016/j.visres.2015.08.004
   Miura M, 2004, J CATARACT REFR SURG, V30, P1549, DOI 10.1016/j.jcrs.2003.12.029
   Muller PL, 2016, INVEST OPHTH VIS SCI, V57, P1448, DOI 10.1167/iovs.15-19004
   NAYLOR E J, 1955, Trans Ophthalmol Soc U K, V75, P67
   NAYLOR EJ, 1954, J PHYSIOL-LONDON, V124, P543, DOI 10.1113/jphysiol.1954.sp005127
   Royal College of Ophthalmologists UK, 2020, NAT OPHTH DAT AUD AN
   SCHUCHARD RA, 1993, ARCH OPHTHALMOL-CHIC, V111, P776, DOI 10.1001/archopht.1993.01090060064024
   SLOAN LL, 1955, AM J OPHTHALMOL, V40, P393, DOI 10.1016/0002-9394(55)91874-2
   Temple SE, 2019, J OPT SOC AM A, V36, pB123, DOI 10.1364/JOSAA.36.00B123
   Temple SE, 2015, P ROY SOC B-BIOL SCI, V282, DOI 10.1098/rspb.2015.0338
NR 22
TC 0
Z9 0
U1 0
U2 0
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 2164-2591
J9 TRANSL VIS SCI TECHN
JI Transl. Vis. Sci. Technol.
PD AUG
PY 2021
VL 10
IS 9
AR 8
DI 10.1167/tvst.10.9.8
PG 12
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA UW7XM
UT WOS:000700367100005
PM 34351366
OA Green Accepted, Green Published, gold
DA 2022-11-30
ER

PT J
AU Wykoff, CC
   Campochiaro, PA
   Pieramici, DJ
   Khanani, AM
   Gune, S
   Maia, M
   Kagedal, M
   Ding, HT
   Maass, KF
AF Wykoff, Charles C.
   Campochiaro, Peter A.
   Pieramici, Dante J.
   Khanani, Arshad M.
   Gune, Shamika
   Maia, Mauricio
   Kagedal, Matts
   Ding, Han Ting
   Maass, Katie F.
TI Pharmacokinetics of the Port Delivery System with Ranibizumab in the
   Ladder Phase 2 Trial for Neovascular Age-Related Macular Degeneration
SO OPHTHALMOLOGY AND THERAPY
LA English
DT Article
DE Age-related macular degeneration; Implant; Neovascular age-related
   macular degeneration; Pharmacokinetics; Port Delivery System with
   ranibizumab; Ranibizumab; Vascular endothelial growth factor
ID 2.0 MG RANIBIZUMAB; INTRAVITREAL RANIBIZUMAB; VISUAL-ACUITY; OUTCOMES;
   EFFICACY; THERAPY; SAFETY
AB Introduction Ladder was a phase 2 trial that evaluated the Port Delivery System with ranibizumab (PDS) for neovascular age-related macular degeneration. Serum and aqueous humor samples were collected to characterize the pharmacokinetics (PK) of ranibizumab delivered through the PDS. Methods Ladder was a multicenter, randomized, active treatment-controlled, phase 2 clinical trial. Patients with neovascular age-related macular degeneration (n = 220) were randomized (3:3:3:2) to PDS 10 mg/ml, PDS 40 mg/ml, PDS 100 mg/ml, or monthly intravitreal ranibizumab 0.5 mg. Serum PK samples were collected in all arms and analyzed for ranibizumab concentration using an enzyme-linked immunosorbent assay. The main PK analyses were conducted in the PK-evaluable population (n = 68), which excluded patients who received fellow eye intravitreal treatment, supplemental ranibizumab treatment, or had previous treatment with bevacizumab in either eye within 9 months of randomization. Results In the PDS 10 mg/ml arm, median serum ranibizumab concentrations were below the serum trough concentration (C-trough; 130 pg/ml) expected with monthly intravitreal ranibizumab 0.5 mg at all time points. In the PDS 40 mg/ml and 100 mg/ml arms, median serum ranibizumab concentrations were above the C-trough expected with monthly intravitreal ranibizumab 0.5 mg (130 pg/ml) through month 3 and month 12 after implantation, respectively, and remained above the lower limit of quantification through month 15 and month 16 after implantation, respectively. Conclusions These PK data indicate that the implant in the PDS 100 mg/ml arm maintained ranibizumab concentrations within the range of monthly intravitreal ranibizumab 0.5 mg injections (130-2220 pg/ml) through month 12 after implantation.
C1 [Wykoff, Charles C.] Retina Consultants Texas, 4460 Bissonnet St,Suite 200, Bellaire, TX 77401 USA.
   [Campochiaro, Peter A.] Johns Hopkins Univ, Sch Med, Wilmer Eye Inst, Dept Ophthalmol, Baltimore, MD 21205 USA.
   [Pieramici, Dante J.] Calif Retina Consultants, Santa Barbara, CA USA.
   [Khanani, Arshad M.] Sierra Eye Associates, Reno, NV USA.
   [Khanani, Arshad M.] Univ Nevada, Reno Sch Med, Reno, NV 89557 USA.
   [Gune, Shamika; Maia, Mauricio; Kagedal, Matts; Ding, Han Ting; Maass, Katie F.] Genentech Inc, San Francisco, CA 94080 USA.
C3 Johns Hopkins University; Johns Hopkins Medicine; Nevada System of
   Higher Education (NSHE); University of Nevada Reno; Roche Holding;
   Genentech
RP Wykoff, CC (通讯作者)，Retina Consultants Texas, 4460 Bissonnet St,Suite 200, Bellaire, TX 77401 USA.
EM charleswykoff@gmail.com
OI Wykoff, Charles/0000-0001-7756-5091
FU Genentech, Inc., a member of the Roche Group (South San Francisco, CA,
   USA)
FX Genentech, Inc., a member of the Roche Group (South San Francisco, CA,
   USA). The sponsor participated in the study design, conducting the
   study, and data collection, management, and interpretation; sponsored
   third-party writing assistance; and funded the journal's Rapid Service
   Fees.
CR [Anonymous], 2001, B WORLD HEALTH ORGAN, V79, P373
   [Anonymous], INT C HARMONISATION
   Avery RL, 2017, RETINA-J RET VIT DIS, V37, P1847, DOI 10.1097/IAE.0000000000001493
   Avery RL, 2014, BRIT J OPHTHALMOL, V98, P1636, DOI 10.1136/bjophthalmol-2014-305252
   Azadeh M, 2018, AAPS J, V20, DOI 10.1208/s12248-017-0159-4
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Busbee BG, 2013, OPHTHALMOLOGY, V120, P1046, DOI 10.1016/j.ophtha.2012.10.014
   Campochiaro PA, 2019, OPHTHALMOLOGY, V126, P1141, DOI 10.1016/j.ophtha.2019.03.036
   Center for Drug Evaluation and Research, 2020, GUID IND PHARM PAT I
   Chang DP, 2021, J PHARM SCI-US, V110, P860, DOI 10.1016/j.xphs.2020.09.043
   Ciulla TA, 2020, OPHTHALMOL RETINA, V4, P19, DOI 10.1016/j.oret.2019.05.017
   Cohen SY, 2013, RETINA-J RET VIT DIS, V33, P474, DOI 10.1097/IAE.0b013e31827b6324
   Ferrara N, 2006, RETINA-J RET VIT DIS, V26, P859, DOI 10.1097/01.iae.0000242842.14624.e7
   Finger RP, 2013, ACTA OPHTHALMOL, V91, P540, DOI 10.1111/j.1755-3768.2012.02493.x
   Ho AC, 2014, OPHTHALMOLOGY, V121, P2181, DOI 10.1016/j.ophtha.2014.05.009
   Holekamp NM, 2022, OPHTHALMOLOGY, V129, P295, DOI 10.1016/j.ophtha.2021.09.016
   Holz FG, 2015, BRIT J OPHTHALMOL, V99, P220, DOI 10.1136/bjophthalmol-2014-305327
   Julious S A, 2000, J Biopharm Stat, V10, P55, DOI 10.1081/BIP-100101013
   Khanani AM, 2021, OPHTHALMOL RETINA, V5, P775, DOI 10.1016/j.oret.2020.11.004
   Khanani AM, 2020, OPHTHALMOL RETINA, V4, P122, DOI 10.1016/j.oret.2019.09.009
   Kim LN, 2016, RETINA-J RET VIT DIS, V36, P1418, DOI 10.1097/IAE.0000000000001142
   Lowe J, 2018, J IMMUNOL METHODS, V461, P44, DOI 10.1016/j.jim.2018.05.007
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Olsen TW, 2020, OPHTHALMOLOGY, V127, pP1, DOI 10.1016/j.ophtha.2019.09.024
   Ozturk M, 2018, CLIN EXP OPHTHALMOL, V46, P407, DOI 10.1111/ceo.13085
   Ritschel WA., 2009, HDB BASIC PHARMACOKI, DOI [10.21019/9781582121260, DOI 10.21019/9781582121260]
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Xu L, 2013, INVEST OPHTH VIS SCI, V54, P1616, DOI 10.1167/iovs.12-10260
NR 28
TC 2
Z9 2
U1 0
U2 0
PU SPRINGER INT PUBL AG
PI CHAM
PA GEWERBESTRASSE 11, CHAM, CH-6330, SWITZERLAND
SN 2193-8245
EI 2193-6528
J9 OPHTHALMOL THER
JI OPHTHALMOL. THER.
PD OCT
PY 2022
VL 11
IS 5
BP 1705
EP 1717
DI 10.1007/s40123-022-00532-9
EA JUN 2022
PG 13
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 4I0YA
UT WOS:000817034100001
PM 35759124
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Tisi, A
   Passacantando, M
   Lozzi, L
   Maccarone, R
AF Tisi, A.
   Passacantando, M.
   Lozzi, L.
   Maccarone, R.
TI Cerium oxide nanoparticles reduce the accumulation of autofluorescent
   deposits in light-induced retinal degeneration: Insights for age-related
   macular degeneration
SO EXPERIMENTAL EYE RESEARCH
LA English
DT Article
DE Lipofuscin; Nanoceria; AMD; Nanomedicine; Retina; Eye
ID PIGMENT EPITHELIUM; A2E ACCUMULATE; LIPOFUSCIN; DAMAGE; MECHANISMS;
   PHOTORECEPTORS; AUTOPHAGY; COMPONENT; EXPOSURE
AB Accumulation of lipofuscin deposits in the retinal pigment epithelium (RPE) is one of the main events involved in age-related macular degeneration and its increase together with RPE dysfunction, blood retinal barrier disruption and photoreceptors death progressively leads to blindness. Lipofuscin is the main autofluorescent (AF) component of the retina and therapies to counteract its deposition are a main goal to be achieved, since effective treatments have not yet been identified. Here, we first investigated the spatio-temporal pattern of AF deposits accumulation in the light-damage model of age-related macular degeneration. Afterward, we tested the ability of cerium oxide nanoparticles, a well known anti-oxidant agent, to counteract AF granules accumulation. The treatment was performed both before and after the induction of the degeneration. AF granules were quantified by confocal microscopy on whole mounted retinas. We demonstrated that the acute light-damage increases the accumulation of AF deposits in the hot spot retina in terms of number of granules and percentage of occupied area, with a peak 7 days after the exposure. Remarkably, cerium oxide nanoparticles showed a strong efficacy in preventing the formation of AF deposits when they were injected 3 days before light exposure. Moreover, when the treatment was performed 7 days after light exposure, nanoceria activity was found to be effective also in reducing the amount of the AF granules still deposited up to 60 days. These important results represent the very first evidence about the ability of cerium oxide nanoparticles to counteract AF deposits accumulation in retinal degeneration, laying the foundations for the development of a new therapy possibly targeting lipofuscin in AMD.
C1 [Tisi, A.; Maccarone, R.] Univ Aquila, Dept Biotechnol & Appl Clin Sci, Via Vetoio,Coppito 2, I-67100 Laquila, Italy.
   [Passacantando, M.; Lozzi, L.] Univ Aquila, Dept Phys & Chem Sci, Via Vetoio,Coppito 1, I-67100 Laquila, Italy.
C3 University of L'Aquila; University of L'Aquila
RP Maccarone, R (通讯作者)，Univ Aquila, Dept Biotechnol & Appl Clin Sci, Via Vetoio,Coppito 2, I-67100 Laquila, Italy.
EM annamaria.tisi@graduate.univaq.it;
   maurizio.passacantando@aquila.infn.it; luca.lozzi@univaq.it;
   rita.maccarone@univaq.it
RI ; PASSACANTANDO, Maurizio/A-2122-2019
OI Lozzi, Luca/0000-0002-0150-5727; PASSACANTANDO,
   Maurizio/0000-0002-3680-5295
CR Bandello Francesco, 2017, F1000Res, V6, P245, DOI 10.12688/f1000research.10664.1
   Ben-Shabat S, 2002, J BIOL CHEM, V277, P7183, DOI 10.1074/jbc.M108981200
   Blasiak J, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20010210
   Boyer NP, 2012, PHOTOCHEM PHOTOBIOL, V88, P1373, DOI 10.1111/j.1751-1097.2012.01127.x
   Boyer NP, 2012, J BIOL CHEM, V287, P22276, DOI 10.1074/jbc.M111.329235
   Brunk UT, 2002, FREE RADICAL BIO MED, V33, P611, DOI 10.1016/S0891-5849(02)00959-0
   Cells E., 1981, LIPOFUSCIN ADV CELLU
   Dysli C, 2017, PROG RETIN EYE RES, V60, P120, DOI 10.1016/j.preteyeres.2017.06.005
   Fiorani L, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0140387
   Fleckenstein M, 2018, OPHTHALMOLOGY, V125, P369, DOI 10.1016/j.ophtha.2017.08.038
   Gray Douglas A, 2005, Sci Aging Knowledge Environ, V2005, pre1, DOI 10.1126/sageke.2005.5.re1
   Grimm Christian, 2013, Methods Mol Biol, V935, P87, DOI 10.1007/978-1-62703-080-9_6
   Iriyama A, 2009, J CELL PHYSIOL, V220, P469, DOI 10.1002/jcp.21792
   Jiao HH, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0143952
   Kast B, 2016, EXP EYE RES, V146, P60, DOI 10.1016/j.exer.2015.12.008
   Keeling E, 2018, CELLS-BASEL, V7, DOI 10.3390/cells7020016
   Klettner A, 2013, INT J BIOCHEM CELL B, V45, P1457, DOI 10.1016/j.biocel.2013.04.013
   Lamb LE, 2004, PHOTOCHEM PHOTOBIOL, V79, P127, DOI 10.1562/0031-8655(2004)079<0127:AACOOL>2.0.CO;2
   Lei L, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18040728
   Maccarone R, 2020, J OCUL PHARMACOL TH, V36, P376, DOI 10.1089/jop.2019.0105
   Moreno-Garcia A., 2018, FRONT NEUROSCI, V12, P1
   Natoli R, 2016, EXP EYE RES, V147, P114, DOI 10.1016/j.exer.2016.04.015
   Organisciak DT, 2010, PROG RETIN EYE RES, V29, P113, DOI 10.1016/j.preteyeres.2009.11.004
   Passacantando M, 2013, J NANOPART RES, V15, DOI 10.1007/s11051-013-1785-0
   Pichi F, 2018, ACTA OPHTHALMOL, V96, pE549, DOI 10.1111/aos.13602
   Riga S, 2006, ANN NY ACAD SCI, V1067, P383, DOI 10.1196/annals.1354.054
   Rozanowska M, 2005, PHOTOCHEM PHOTOBIOL, V81, P1305, DOI 10.1562/2004-11-13-IR-371
   Rutar M, 2015, J NEUROINFLAMM, V12, DOI 10.1186/s12974-014-0224-1
   Rutar M, 2011, INVEST OPHTH VIS SCI, V52, P2379, DOI 10.1167/iovs.10-6010
   Rutar M, 2010, CURR EYE RES, V35, P631, DOI 10.3109/02713681003682925
   Sparrow JR, 2014, J CLIN MED, V3, P1302, DOI 10.3390/jcm3041302
   Sparrow JR, 2003, VISION RES, V43, P2983, DOI 10.1016/S0042-6989(03)00475-9
   Terman A, 2004, INT J BIOCHEM CELL B, V36, P1400, DOI 10.1016/j.biocel.2003.08.009
   Tisi A, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-63449-y
   Tisi A, 2019, EXP EYE RES, V188, DOI 10.1016/j.exer.2019.107797
   Tisi A, 2019, EXP EYE RES, V182, P30, DOI 10.1016/j.exer.2019.03.003
   Tisi A, 2020, CELLS-BASEL, V9, DOI 10.3390/cells9071617
   Yung M, 2016, INT J RETIN VITR, V2, P1
   Zhang TZ, 2014, BIOCHEM BIOPH RES CO, V450, P966, DOI 10.1016/j.bbrc.2014.06.082
NR 39
TC 9
Z9 9
U1 1
U2 9
PU ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD
PI LONDON
PA 24-28 OVAL RD, LONDON NW1 7DX, ENGLAND
SN 0014-4835
EI 1096-0007
J9 EXP EYE RES
JI Exp. Eye Res.
PD OCT
PY 2020
VL 199
AR 108169
DI 10.1016/j.exer.2020.108169
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA OH0ED
UT WOS:000582245300030
PM 32758489
DA 2022-11-30
ER

PT J
AU Danner, M
   Vennedey, V
   Hiligsmann, M
   Fauser, S
   Gross, C
   Stock, S
AF Danner, Marion
   Vennedey, Vera
   Hiligsmann, Mickaeel
   Fauser, Sascha
   Gross, Christian
   Stock, Stephanie
TI Comparing Analytic Hierarchy Process and Discrete-Choice Experiment to
   Elicit Patient Preferences for Treatment Characteristics in Age-Related
   Macular Degeneration
SO VALUE IN HEALTH
LA English
DT Article
DE age-related macular degeneration; analytic hierarchy process; convergent
   validity; discrete choice experiment; patient preference(s)
ID MULTICRITERIA DECISION-ANALYSIS; ELDERLY OPHTHALMOLOGIC PATIENTS;
   OF-THE-LITERATURE; CONJOINT-ANALYSIS; HEALTH-CARE; TASK-FORCE; TUTORIAL;
   INSIGHTS
AB Background: In this study, we conducted an analytic hierarchy process (AHP) and a discrete choice experiment (DCE) to elicit the preferences of patients with age-related macular degeneration using identical attributes and levels. Objectives: To compare preference based weights for age-related macular degeneration treatment attributes and levels generated by two elicitation methods. The properties of both methods were assessed, including ease of instrument use. Methods: A DCE and an AHP experiment were designed on the basis of five attributes. Preference-based weights were generated using the matrix multiplication method for attributes and levels in AHP and a mixed multinomial logit model for levels in the DCE. Attribute importance was further compared using coefficient (DCE) and weight (AHP) level ranges. The questionnaire difficulty was rated on a qualitative scale. Patients were asked to think aloud while providing their judgments. Results: AHP and DCE generated similar results regarding levels, stressing a preference for visual improvement, frequent monitoring, on-demand and less frequent injection schemes, approved drugs, and mild side effects. Attribute weights derived on the basis of level ranges led to a ranking that was opposite to the AHP directly calculated attribute weights. For example, visual function ranked first in the AHP and last on the basis of level ranges. Conclusions: The results across the methods were similar, with one exception: the directly measured AHP attribute weights were different from the level-based interpretation of attribute importance in both DCE and AHP. The dependence/independence of attribute importance on level ranges in DCE and AHP, respectively, should be taken into account when choosing a method to support decision making.
C1 [Danner, Marion; Vennedey, Vera; Gross, Christian; Stock, Stephanie] Univ Hosp Cologne AoR, Inst Hlth Econ & Clin Epidemiol, Gleueler Str 176-178, D-50935 Cologne, Germany.
   [Hiligsmann, Mickaeel] Maastricht Univ, CAPHRI Sch Primary Care & Publ Hlth, Dept Hlth Serv Res, Maastricht, Netherlands.
   [Fauser, Sascha] Univ Hosp Cologne AoR, Ctr Ophthalmol, Cologne, Germany.
C3 University of Cologne; Maastricht University; University of Cologne
RP Danner, M (通讯作者)，Univ Hosp Cologne AoR, Inst Hlth Econ & Clin Epidemiol, Gleueler Str 176-178, D-50935 Cologne, Germany.
EM marion.danner@uk-koeln.de
FU Bayer Vital GmbH, Germany
FX This investigator-initiated study was funded by Bayer Vital GmbH,
   Germany. The funding agreement ensured the authors' independence in
   designing the study; collecting, analyzing, and interpreting the data;
   and writing and publishing the report.
CR Adunlin G, 2015, HEALTH EXPECT, V18, P1894, DOI 10.1111/hex.12287
   Baxter JM, 2016, EYE, V30, P698, DOI 10.1038/eye.2016.18
   Benaim C, 2010, REV EPIDEMIOL SANTE, V58, P59, DOI 10.1016/j.respe.2009.09.004
   Bridges JFP, 2011, VALUE HEALTH, V14, P403, DOI 10.1016/j.jval.2010.11.013
   Center for Devices and Radiological Health, 2016, PAT PREF INF VOL SUB
   Cheung KL, 2016, PHARMACOECONOMICS, V34, P1195, DOI 10.1007/s40273-016-0429-5
   Clark MD, 2014, PHARMACOECONOMICS, V32, P883, DOI 10.1007/s40273-014-0170-x
   Danner M, 2013, ANAL HIERARCHY PROCE
   Danner M, 2016, PATIENT, V9, P481, DOI 10.1007/s40271-016-0179-7
   Danner M, 2016, PATIENT, V9, P47, DOI 10.1007/s40271-015-0122-3
   Danner M, 2011, INT J TECHNOL ASSESS, V27, P369, DOI 10.1017/S0266462311000523
   DOLAN JG, 1989, MED DECIS MAKING, V9, P40, DOI 10.1177/0272989X8900900108
   Flynn TN, 2007, J HEALTH ECON, V26, P171, DOI 10.1016/j.jhealeco.2006.04.002
   Flynn TN, 2008, BMC MED RES METHODOL, V8, DOI 10.1186/1471-2288-8-76
   Gerber-Grote A, WAHLBASIERTE CONJOIN
   Hauber AB, 2016, VALUE HEALTH, V19, P300, DOI 10.1016/j.jval.2016.04.004
   Helm R, 2004, COMP EMPIRICAL STUDY
   Hensher DA., 2005, APPL CHOICE ANAL PRI, DOI 10.1017/CBO9780511610356
   Ho MP, 2015, SURG ENDOSC, V29, P2984, DOI 10.1007/s00464-014-4044-2
   Hollin IL, 2015, PATIENT, V8, P19, DOI 10.1007/s40271-014-0104-x
   Hummel JM, 2014, PATIENT, V7, P129, DOI 10.1007/s40271-014-0050-7
   IJzerman MJ, 2012, PATIENT, V5, P45, DOI 10.2165/11587140-000000000-00000
   IJzerman MJ, 2008, PATIENT, V1, P265, DOI [10.2165/01312067-200801040-00008, 10.2165/1312067-200801040-00008]
   Institute for Quality and Efficiency in Health Care, 2015, GEN METH VERS 4 2
   Kallas Z, 2011, FOOD QUAL PREFER, V22, P181, DOI 10.1016/j.foodqual.2010.09.010
   Lancsar E, 2007, SOC SCI MED, V64, P1738, DOI 10.1016/j.socscimed.2006.12.007
   Marsh K, 2014, PHARMACOECONOMICS, V32, P345, DOI 10.1007/s40273-014-0135-0
   Maruthur NM, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0126625
   Meissner M, 2008, DATA ANAL MACHINE LE
   Muhlbacher A, 2016, APPL HEALTH ECON HEA, V14, P253, DOI 10.1007/s40258-016-0232-7
   Mueller S, 2016, OPHTHALMOLOGY, V123, P876, DOI 10.1016/j.ophtha.2015.12.001
   Muhlbacher AC, 2016, GESUNDHEITSWESEN, V78, P326, DOI 10.1055/s-0034-1390474
   Orme BK, 2014, GETTING STARTED CONJ, V3rd
   Potoglou D, 2011, SOC SCI MED, V72, P1717, DOI 10.1016/j.socscimed.2011.03.027
   Reddy BP, 2014, PUBLIC HEALTH, V128, P896, DOI 10.1016/j.puhe.2014.07.003
   SAATY TL, 1994, EUR J OPER RES, V74, P426, DOI 10.1016/0377-2217(94)90222-4
   Scholl A, 2005, EUR J OPER RES, V164, P760, DOI 10.1016/j.ejor.2004.01.026
   van Dijk JD, 2016, VALUE HEALTH, V19, P316, DOI 10.1016/j.jval.2015.12.020
   Vennedey V, 2016, PATIENT PREFER ADHER, V10, P993, DOI 10.2147/PPA.S101584
   Whitty JA, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0090635
   Wijnen BFM, 2015, EXPERT REV PHARM OUT, V15, P721, DOI 10.1586/14737167.2015.1033406
NR 41
TC 13
Z9 14
U1 0
U2 12
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1098-3015
EI 1524-4733
J9 VALUE HEALTH
JI Value Health
PD SEP
PY 2017
VL 20
IS 8
BP 1166
EP 1173
DI 10.1016/j.jval.2017.04.022
PG 8
WC Economics; Health Care Sciences & Services; Health Policy & Services
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC Business & Economics; Health Care Sciences & Services
GA FI3CO
UT WOS:000411834200021
PM 28964450
OA Bronze
DA 2022-11-30
ER

PT J
AU Pardhan, S
   Scarfe, A
   Bourne, R
   Timmis, M
AF Pardhan, Shahina
   Scarfe, Amy
   Bourne, Rupert
   Timmis, Matthew
TI A Comparison of Reach-to-Grasp and Transport-to-Place Performance in
   Participants With Age-Related Macular Degeneration and Glaucoma
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
DE glaucoma; AMD; reach-to-grasp
ID CENTRAL VISUAL IMPAIRMENT; MANUAL PREHENSION; VISION; FIELD; DEFICITS;
   LEVEL; VIEW
AB PURPOSE. To compare visually guided manual prehension in participants with primarily central field loss (CFL) due to age-related macular degeneration and peripheral visual field loss (PFL) due to glaucoma. This study extends current literature by comparing directly ``reach-to-grasp'' performance, and presents a new task of ``transport-to-place'' the object accurately to a new location. Data were compared to age-matched controls.
   METHODS. Three-dimensional motion data were collected from 17 glaucoma participants with PFL, 17 participants with age-related macular degeneration CFL and 10 age-matched control participants. Participants reached toward and grasped a cylindrical object (reach-to-grasp), and then transported and placed (transport-to-place) it at a different (predefined) peripheral location. Various kinematic indices were measured. Correlation analyses explored relationships between visual function and kinematic data.
   RESULTS. In the reach-to-grasp phase, CFL patients exhibited significantly longer movement and reaction times when compared to PFL participants and controls. Central field loss participants also took longer to complete the movement and made more online movements in the latter part of the reach. During the transport-to-place phase, CFL participants showed increased deceleration times, longer movement trajectory, and increased vertical wrist displacement. Central field loss also showed higher errors in placing the object at a predefined location. A number of kinematic indices correlated significantly to central visual function indices (P < 0.05).
   CONCLUSIONS. Significant differences in performance exist between CFL and PFL participants. Various indices correlated significantly with loss in acuity and contrast sensitivity (CS), suggesting that performance is more dependent on central visual function irrespective of underlying pathology.
C1 [Pardhan, Shahina; Scarfe, Amy; Bourne, Rupert; Timmis, Matthew] Anglia Ruskin Univ, Postgrad Med Inst, VERU, YST 215,Young St, Cambridge CB1 2LZ, England.
   [Scarfe, Amy] Sheffield Teaching Hosp NHS Fdn Trust, Dept Clin Engn, Med Imaging & Med Phys Directorate, Sheffield, S Yorkshire, England.
   [Timmis, Matthew] Anglia Ruskin Univ, Sport & Exercise Sci, Cambridge, England.
C3 Anglia Ruskin University; University of Sheffield; Anglia Ruskin
   University
RP Pardhan, S (通讯作者)，Anglia Ruskin Univ, Postgrad Med Inst, VERU, YST 215,Young St, Cambridge CB1 2LZ, England.
EM shahina.pardhan@anglia.ac.uk
RI Pardhan, Shahina/AAZ-7509-2020
FU Fight for Sight; Fight for Sight [1538/1539] Funding Source:
   researchfish
FX Supported by Fight for Sight.
CR BECKER SW, 1985, INT J REHABIL RES, V8, P415, DOI 10.1097/00004356-198512000-00002
   Connolly JD, 1999, EXP BRAIN RES, V125, P281, DOI 10.1007/s002210050684
   CRUM RM, 1993, JAMA-J AM MED ASSOC, V269, P2386, DOI 10.1001/jama.269.18.2386
   De l'Aune WR, 1999, J REHABIL RES DEV, V36, P273
   Gonzalez-Alvarez C, 2007, OPHTHAL PHYSL OPT, V27, P265, DOI 10.1111/j.1475-1313.2007.00476.x
   Grant S, 2007, INVEST OPHTH VIS SCI, V48, P1139, DOI 10.1167/iovs.06-0976
   JAKOBSON LS, 1991, EXP BRAIN RES, V86, P199
   Jampel HD, 2002, INVEST OPHTH VIS SCI, V43, P1059
   Kotecha A, 2009, INVEST OPHTH VIS SCI, V50, P203, DOI 10.1167/iovs.08-2496
   Loftus A, 2004, EXP BRAIN RES, V158, P328, DOI 10.1007/s00221-004-1900-7
   Marotta JJ, 1998, EXP BRAIN RES, V120, P134, DOI 10.1007/s002210050386
   Massof RW, 2007, OPTOMETRY VISION SCI, V84, P689
   Melmoth DR, 2009, INVEST OPHTH VIS SCI, V50, P3711, DOI 10.1167/iovs.08-3229
   Neely KA, 2008, EXP BRAIN RES, V186, P375, DOI 10.1007/s00221-007-1238-z
   Nelson-Quigg JM, 2000, INVEST OPHTH VIS SCI, V41, P2212
   OLDFIELD RC, 1971, NEUROPSYCHOLOGIA, V9, P97, DOI 10.1016/0028-3932(71)90067-4
   Pardhan S, 2012, INVEST OPHTH VIS SCI, V54, P3281
   Pardhan S, 2012, INVEST OPHTH VIS SCI, V53, P6687, DOI 10.1167/iovs.12-9821
   Pardhan S, 2012, OPTOMETRY VISION SCI, V89, P426, DOI 10.1097/OPX.0b013e31824c1b89
   Pardhan S, 2011, OPHTHAL PHYSL OPT, V31, P233, DOI 10.1111/j.1475-1313.2010.00819.x
   Penta M, 1998, ARCH PHYS MED REHAB, V79, P1038, DOI 10.1016/S0003-9993(98)90167-8
   SERVOS P, 1994, EXP BRAIN RES, V98, P119
   SIVAK B, 1990, NEUROPSYCHOLOGIA, V28, P1095, DOI 10.1016/0028-3932(90)90143-C
   Tabrett DR, 2011, INVEST OPHTH VIS SCI, V52, P5293, DOI 10.1167/iovs.10-7055
   The International Agency for the Prevention of Blindness (IAPB), COURS 10 GLOB BURD D
   Timberlake GT, 2011, INVEST OPHTH VIS SCI, V52, P2540, DOI 10.1167/iovs.10-6062
   Timmis MA, 2012, INVEST OPHTH VIS SCI, V53, P2812, DOI 10.1167/iovs.11-8860
   Verghese P, 2016, INVEST OPHTH VIS SCI, V57, P1476, DOI 10.1167/iovs.15-18336
   Walker N, 1997, J GERONTOL B-PSYCHOL, V52, pP40, DOI 10.1093/geronb/52B.1.P40
   Watt SJ, 2000, EXP BRAIN RES, V135, P411, DOI 10.1007/s002210000545
NR 30
TC 9
Z9 9
U1 0
U2 3
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD MAR
PY 2017
VL 58
IS 3
BP 1560
EP 1569
DI 10.1167/iovs.16-20273
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC Ophthalmology
GA EQ4ZA
UT WOS:000398089000026
PM 28282488
OA Green Accepted, gold, Green Submitted
DA 2022-11-30
ER

PT J
AU Cruess, AF
   Zlateva, G
   Pleil, AM
   Wirostko, B
AF Cruess, Alan F.
   Zlateva, Gergana
   Pleil, Andreas M.
   Wirostko, Barbara
TI Photodynamic therapy with verteporfin in age-related macular
   degeneration: a systematic review of efficacy, safety, treatment
   modifications and pharmacoeconomic properties
SO ACTA OPHTHALMOLOGICA
LA English
DT Review
DE age-related macular degeneration; choroidal neovascularization;
   photodynamic therapy; verteporfin
ID SUBFOVEAL CHOROIDAL NEOVASCULARIZATION; OPTICAL COHERENCE TOMOGRAPHY;
   INTRAVITREAL TRIAMCINOLONE; COST-EFFECTIVENESS; VISUAL IMPAIRMENT;
   PEGAPTANIB SODIUM; RETINAL FUNCTION; TRIPLE THERAPY; SECONDARY;
   RANIBIZUMAB
AB Photodynamic therapy (PDT) with verteporfin has been used less comprehensively in the treatment of exudative age-related macular degeneration (AMD), and specifically of choroidal neovascularization (CNV), since the advent of antiangiogenic therapies. Recently, there has been a renewed interest in PDT as an adjunct to these and other agents in the treatment of neovascular AMD. In light of this new development and the European Medicines Evaluation Agency's (EMEA) recent labelling decision to rescind approval for the use of PDT in occult CNV lesions, the present systematic review was undertaken to revisit the evidence supporting its clinical application. Photodynamic therapy provided the first pharmacological treatment for patients suffering from subfoveal CNV, the major cause of severe vision loss in AMD. Key clinical trials evaluating efficacy and safety have examined patients with all lesion subtypes, with the primary labelled indication (i.e. lesions containing a classic component of >= 50% ) deriving from the results of the Treatment of Age-related Macular Degeneration with Photodynamic Therapy (TAP) Study. The subsequent TAP Study Group post hoc categorization of lesions as predominantly classic is open to question, however, as it appears that the overall efficacy in this group only may have reflected the especially strong response in 100% classic lesions. Based on a subgroup analysis of the Verteporfin in Photodynamic Therapy Study, the indication for PDT subsequently was expanded in some jurisdictions, including that of the EMEA, to include occult lesions with no classic component. However, the subsequent Visudyne in Occult Study found no benefit in 100% occult lesions, resulting in the EMEA rescinding its approval for this indication.
C1 [Cruess, Alan F.] Dalhousie Univ, Dept Ophthalmol & Visual Sci, Halifax, NS, Canada.
   [Zlateva, Gergana; Wirostko, Barbara] Pfizer Ophthalm, New York, NY USA.
   [Pleil, Andreas M.] Pfizer World Wide Outcomes Res, La Jolla, CA USA.
C3 Dalhousie University; Pfizer; Pfizer
RP Cruess, AF (通讯作者)，Dalhousie Univ, Dept Ophthalmol & Visual Sci, 2 W Victoria,Room 2035,1278 Tower Rd, Halifax, NS, Canada.
EM alan.cruess@dal.ca
FU Pfizer Inc., New York, NY, USA; (OSI) Eyetech, Inc., New York, NY, USA
FX Editorial support, including contributions to the literature review,
   manuscript development, revision of the paper based on author feedback
   and styling of the paper for journal submission, was provided by Dr
   Lauren Swenarchuk of Zola Associates, Englewood Cliffs, NJ, USA and was
   funded by Pfizer Inc., New York, NY, USA and (OSI) Eyetech, Inc., New
   York, NY, USA.
CR Ambati J, 2003, SURV OPHTHALMOL, V48, P257, DOI 10.1016/S0039-6257(03)00030-4
   Arias L, 2005, BRIT J OPHTHALMOL, V89, P312, DOI 10.1136/bjo.2004.050997
   Arnold J, 2001, AM J OPHTHALMOL, V131, P541
   Augustin AJ, 2006, EUR J OPHTHALMOL, V16, P824, DOI 10.1177/112067210601600607
   Augustin AJ, 2006, OPHTHALMOLOGY, V113, P14, DOI 10.1016/j.ophtha.2005.09.002
   Augustin AJ, 2007, RETINA-J RET VIT DIS, V27, P133, DOI 10.1097/IAE.0b013e3180323de7
   Axer-Siegel R, 2004, ARCH OPHTHALMOL-CHIC, V122, P453, DOI 10.1001/archopht.122.4.453
   Axer-Siegel R, 2004, AM J OPHTHALMOL, V137, P258, DOI 10.1016/j.ajo.2003.08.009
   Benjamin LE, 1999, J CLIN INVEST, V103, P159, DOI 10.1172/JCI5028
   Benjamin LE, 1998, DEVELOPMENT, V125, P1591
   Blinder KJ, 2003, AM J OPHTHALMOL, V136, P407, DOI 10.1016/S0002-9394(03)00223-X
   Blumenkranz MS, 2001, ARCH OPHTHALMOL-CHIC, V119, P198
   Borodoker N, 2002, AM J OPHTHALMOL, V133, P211, DOI 10.1016/S0002-9394(01)01341-1
   Bradley John, 2007, Angiogenesis, V10, P141, DOI 10.1007/s10456-007-9069-x
   Bressler NM, 2002, ARCH OPHTHALMOL-CHIC, V120, P1443
   Bressler NM, 2002, ARCH OPHTHALMOL-CHIC, V120, P1307
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   Bressler SB, 2004, ARCH OPHTHALMOL-CHIC, V122, P325, DOI 10.1001/archopht.122.3.325
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Brown GC, 2005, AM J OPHTHALMOL, V140, P679, DOI 10.1016/j.ajo.2005.04.061
   Buch H, 2001, ACTA OPHTHALMOL SCAN, V79, P441, DOI 10.1034/j.1600-0420.2001.790503.x
   Chan WM, 2006, BRIT J OPHTHALMOL, V90, P337, DOI 10.1136/bjo.2005.081299
   Comer GM, 2004, DRUG AGING, V21, P967, DOI 10.2165/00002512-200421150-00002
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   *EMEA, 2007, EMEAH3052AR
   Essex RW, 2003, CLIN EXP OPHTHALMOL, V31, P476, DOI 10.1046/j.1442-9071.2003.00714.x
   Feigl B, 2005, DOC OPHTHALMOL, V111, P135, DOI 10.1007/s10633-005-5319-7
   FERRIS FL, 1984, ARCH OPHTHALMOL-CHIC, V102, P1640
   Frennesson CI, 2004, ACTA OPHTHALMOL SCAN, V82, P645, DOI 10.1111/j.1600-0420.2004.00368.x
   Gaynes Bruce I, 2004, Expert Opin Drug Saf, V3, P345, DOI 10.1517/14740338.3.4.345
   Gelisken F, 2007, GRAEF ARCH CLIN EXP, V245, P1085, DOI 10.1007/s00417-006-0524-y
   GHANCHI FD, 2007, EYE ADVANCE ONLINE P, DOI DOI 10.1038/SJ.EYE.6702713
   Gonzales CR, 2005, RETINA-J RET VIT DIS, V25, P815
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Greiner R A, 2001, Semin Ophthalmol, V16, P218, DOI 10.1076/soph.16.4.218.10302
   Greve MDJ, 2005, ARCH OPHTHALMOL-CHIC, V123, P448
   Heier JS, 2006, ARCH OPHTHALMOL-CHIC, V124, P1532, DOI 10.1001/archopht.124.11.1532
   Holz FG, 2003, OPHTHALMOLOGY, V110, P400, DOI 10.1016/S0161-6420(02)01770-0
   Hopley C, 2004, BRIT J OPHTHALMOL, V88, P982, DOI 10.1136/bjo.2003.039131
   Huber G, 2001, Semin Ophthalmol, V16, P213, DOI 10.1076/soph.16.4.213.10294
   Ishikawa K, 2007, INVEST OPHTH VIS SCI, V48, P2254, DOI 10.1167/iovs.06-1277
   Jo N, 2006, AM J PATHOL, V168, P2036, DOI 10.2353/ajpath.2006.050588
   Jonas JB, 2006, OPHTHALMIC RES, V38, P218, DOI 10.1159/000093796
   Kaiser PK, 2006, GRAEF ARCH CLIN EXP, V244, P1132, DOI 10.1007/s00417-005-0199-9
   Kaiser PK, 2005, CURR MED RES OPIN, V21, P705, DOI 10.1185/030079905X43659
   Kaiser RS, 2002, RETINA-J RET VIT DIS, V22, P683, DOI 10.1097/00006982-200212000-00001
   Klais CM, 2005, ARCH OPHTHALMOL-CHIC, V123, P1149, DOI 10.1001/archopht.123.8.1149
   la Cour M, 2002, DRUG AGING, V19, P101, DOI 10.2165/00002512-200219020-00003
   Lafaut BA, 2000, BRIT J OPHTHALMOL, V84, P239, DOI 10.1136/bjo.84.3.239
   Lai TYY, 2004, AM J OPHTHALMOL, V137, P826, DOI 10.1016/j.ajo.2003.11.079
   Liggett PE, 2006, AM J OPHTHALMOL, V142, P1072, DOI 10.1016/j.ajo.2006.07.029
   Manku KK, 2007, CLIN EXP OPHTHALMOL, V35, P330, DOI 10.1111/j.1442-9071.2007.01482.x
   Meads C, 2004, BRIT J OPHTHALMOL, V88, P212, DOI 10.1136/bjo.2003.019471
   Meads C, 2003, HEALTH TECHNOL ASSES, V7, p[v, 1], DOI [10.3310/hta7090, DOI 10.3310/hta7090]
   MEADS C, 2001, CLIN EFFECTIVENESS C, P1
   Mennel S, 2005, GRAEF ARCH CLIN EXP, V243, P68, DOI 10.1007/s00417-004-0964-1
   Michels S, 2005, OPHTHALMOLOGY, V112, P2070, DOI 10.1016/j.ophtha.2005.06.034
   Michels S, 2006, INVEST OPHTH VIS SCI, V47, P371, DOI 10.1167/iovs.05-0354
   *NOV OPHTH AG, 2001, SUBM NAT I CLIN EXC
   Oner A, 2005, DOC OPHTHALMOL, V111, P107, DOI 10.1007/s10633-005-4608-5
   Ozdemir H, 2006, AM J OPHTHALMOL, V141, P574, DOI 10.1016/j.ajo.2005.09.031
   Pawlak D, 2004, AM J OPHTHALMOL, V137, P880, DOI 10.1016/j.ajo.2003.12.041
   Pece A, 2007, RETINA-J RET VIT DIS, V27, P342, DOI 10.1097/01.iae.0000239253.78495.8c
   Potter MJ, 2008, EYE, V22, P194, DOI 10.1038/sj.eye.6702547
   *QLT INC, 2005, RAND PLAC DOUBL MASK
   *QLT INC, 2005, QLT ANN 2 YEAR RES V
   Resnikoff S, 2004, B WORLD HEALTH ORGAN, V82, P844
   Rogers AH, 2002, AM J OPHTHALMOL, V134, P566, DOI 10.1016/S0002-9394(02)01566-0
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Russell SR, 2007, SURV OPHTHALMOL, V52, pS79, DOI 10.1016/j.survophthal.2006.11.005
   Sahni J, 2005, BRIT J OPHTHALMOL, V89, P316, DOI 10.1136/bjo.2004.043364
   Salinas-Alaman A, 2005, AM J OPHTHALMOL, V140, P23, DOI 10.1016/j.ajo.2005.01.044
   Schein OD, 2005, ARCH OPHTHALMOL-CHIC, V123, P58, DOI 10.1001/archopht.123.1.58
   Schlotzer-Schrehardt U, 2002, GRAEF ARCH CLIN EXP, V240, P748, DOI 10.1007/s00417-002-0517-4
   Schmidt-Erfurth U, 2002, INVEST OPHTH VIS SCI, V43, P830
   Sharma S, 2004, ARCH OPHTHALMOL-CHIC, V122, P853, DOI 10.1001/archopht.122.6.853
   Sharma S, 2001, OPHTHALMOLOGY, V108, P2051, DOI 10.1016/S0161-6420(01)00764-3
   Sharp DM, 2007, CLIN EXP OPHTHALMOL, V35, P24, DOI 10.1111/j.1442-9071.2007.01394.x
   Slakter JS, 2006, OPHTHALMOLOGY, V113, P3, DOI 10.1016/j.ophtha.2005.10.019
   Smith DH, 2004, BRIT J OPHTHALMOL, V88, P1107, DOI 10.1136/bjo.2003.023986
   STERNBERG P, 1991, ARCH OPHTHALMOL-CHIC, V109, P1242
   Sternberg P, 2004, AM J OPHTHALMOL, V137, P483, DOI 10.1016/j.ajo.2003.11.023
   Tano Y, 2003, AM J OPHTHALMOL, V136, P1049, DOI 10.1016/S0002-9394(03)00576-2
   *TAP VIP STUD GROU, 2004, RETINA, V24, P1
   Treatment Age Related Macular Dege, 2005, ARCH OPHTHALMOL-CHIC, V123, P1283
   *VAM STUD WRIT COM, 2004, RETINA, V24, P512
   Van de Moere A, 2006, BRIT J OPHTHALMOL, V90, P304, DOI 10.1136/bjo.2005.079947
   van Velthoven MEJ, 2006, GRAEF ARCH CLIN EXP, V244, P1119, DOI 10.1007/s00417-005-0209-y
   Wachtlin J, 2005, GRAEF ARCH CLIN EXP, V243, P438, DOI 10.1007/s00417-004-1071-z
   Wickens J, 2006, DRUG SAFETY, V29, P189, DOI 10.2165/00002018-200629030-00003
   WORMALD R, 2005, COCHRANE DB SYST REV, V19
   Yang N, 2006, EYE, V20, P523, DOI 10.1038/sj.eye.6701991
   Zarbin M, 2006, ARCH OPHTHALMOL-CHIC, V124, P563, DOI 10.1001/archopht.124.4.563
NR 93
TC 65
Z9 71
U1 1
U2 16
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1755-375X
EI 1755-3768
J9 ACTA OPHTHALMOL
JI Acta Ophthalmol.
PD MAR
PY 2009
VL 87
IS 2
BP 118
EP 132
DI 10.1111/j.1755-3768.2008.01218.x
PG 15
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 412SR
UT WOS:000263745000002
PM 18577193
DA 2022-11-30
ER

PT J
AU Daibert-Nido, M
   Patino, B
   Markowitz, M
   Markowitz, SN
AF Daibert-Nido, Monica
   Patino, Beatriz
   Markowitz, Michelle
   Markowitz, Samuel N.
TI Rehabilitation with biofeedback training in age-related macular
   degeneration for improving distance vision
SO CANADIAN JOURNAL OF OPHTHALMOLOGY-JOURNAL CANADIEN D OPHTALMOLOGIE
LA English
DT Article
AB Objectives: Biofeedback training (BT) is a modern method for enhancing the use of preferred retinal loci (PRL) retraining for new retinal loci (TRL), hence improving far and near vision. This article attempts to clarify the optimal methodology for BT and the types of patients who can benefit most from BT.
   Methods: This is a retrospective review of cases who received BT with the macular integrity assessment (MAIA) microperimetre. Outcome measures selected for analysis were visual acuity, PRL location, fixation stability, fixation pattern orientation, reading acuity, critical print size, and reading speed.
   Results: Out of 30 cases who received BT, only those with age-related macular degeneration and visual acuity of logMAR 0.8 (20/126) or poorer showed a visual acuity gain (statistically significant of 12 letters) after BT. Those with other diagnoses and those with residual Early Treatment Diabetic Retinopathy Study best-corrected visual acuity of logMAR of 0.7 (20/100) or better showed only positive trends for visual acuity and a negative trend for fixation stability. All subjects showed a shift in PRL location toward the superior quadrant of the retina (p < 0.02) in those who received BT.
   Conclusion: BT seems to offer patients a unique and efficient modality to improve distance vision outside of using optical devices.
C1 [Daibert-Nido, Monica; Markowitz, Samuel N.] Univ Toronto, Dept Ophthalmol & Vision Sci, Low Vision Serv, Univ Hlth Network Hosp, Toronto, ON, Canada.
C3 University of Toronto; University Health Network Toronto
RP Markowitz, SN (通讯作者)，1225 Davenport Rd, Toronto, ON M6H 2H1, Canada.
EM snm1@rogers.com
CR Cheung SH, 2005, VISUAL NEUROSCI, V22, P187, DOI 10.1017/S0952523805222071
   Chung STL, 1998, VISION RES, V38, P2949, DOI 10.1016/S0042-6989(98)00072-8
   Daibert-Nido M, 2018, CAN J OPHTHALMOL, V53, pe83
   Holocomb J G, 1976, J Am Optom Assoc, V47, P1438
   King AT., 1976, PROPOSED KING DEVICK
   Mansfield J, 1993, OSA NONINVASIVE ASSE
   Markowitz M, 2006, CAN J OPHTHALMOL, V41, P340, DOI 10.1139/I06-020
   Markowitz SN, 2006, CAN J OPHTHALMOL, V41, P289, DOI 10.1139/I06-027
   Markowitz SN, 2013, CAN J OPHTHALMOL, V48, P350, DOI 10.1016/j.jcjo.2012.03.004
   Markowitz SN, 2009, CAN J OPHTHALMOL, V44, P610, DOI 10.3129/i09-099
   Markowitz SN, 2013, MICROPERIMETRY MULTI, P185
   Pacella E, 2012, CLIN TER, V163, pE423
   Ramirez Estudillo Juan Abel, 2017, Int J Retina Vitreous, V3, P21, DOI 10.1186/s40942-017-0071-1
   Seiple W, 2005, INVEST OPHTH VIS SCI, V46, P2886, DOI 10.1167/iovs.04-1296
   Shima N, 2010, CAN J OPHTHALMOL, V45, P62, DOI 10.3129/i09-236
   Tarita-Nistor L, 2009, VISUAL NEUROSCI, V26, P487, DOI 10.1017/S0952523809990265
   Vingolo EM, 2007, APPL PSYCHOPHYS BIOF, V32, P185, DOI [10.1007/s10484-007-9038-6, 10.1007/sl0484-007-9038-6]
   Vingolo EM, 2009, APPL PSYCHOPHYS BIOF, V34, P127, DOI 10.1007/s10484-009-9083-4
   WARREN M, 1996, PREREADING WRITING E
   WATSON GR, 1995, LEARN USE YOUR VISIO
   WHITE JM, 1990, INVEST OPHTH VIS SCI, V31, P1149
NR 21
TC 10
Z9 10
U1 0
U2 4
PU CANADIAN OPHTHAL SOC
PI OTTAWA
PA 1525 CARLING AVE SUITE 610, OTTAWA, ONTARIO K1Z 8R9, CANADA
SN 0008-4182
EI 1715-3360
J9 CAN J OPHTHALMOL
JI Can. J. Opthalmol.-J. Can. Opthalmol.
PD JUN
PY 2019
VL 54
IS 3
BP 328
EP 334
DI 10.1016/j.jcjo.2018.10.016
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA HY5QZ
UT WOS:000468183900031
PM 31109472
DA 2022-11-30
ER

PT J
AU Coco, RM
   Sanabria, MR
   Castrejon, M
   Lopez-Galvez, MI
   Monje-Fernandez, L
   Fernandez-Munoz, M
   Anton, A
   de Juan-Marcos, L
   Villaron-Alvarez, S
   Fernandez, I
AF Coco, Rosa M.
   Sanabria, M. Rosa
   Castrejon, Melissa
   Lopez-Galvez, M. Isabel
   Monje-Fernandez, Laura
   Fernandez-Munoz, Marta
   Anton, Alejandro
   de Juan-Marcos, Lourdes
   Villaron-Alvarez, Sonia
   Fernandez, Itziar
TI Funduscopic results after 4-year follow-up treatment with ranibizumab
   for age-related macular degeneration in a region of Spain
SO BMC OPHTHALMOLOGY
LA English
DT Article
DE Age-related macular degeneration (AMD); Ranibizumab; Optical coherence
   tomography (OCT); Atrophy; Disciform scar; Outcome
ID VISUAL-ACUITY; CLINICAL-PRACTICE; OUTCOMES; TRIAL
AB Background: The study aims to survey longstanding funduscopic and functional outcomes of age-related macular degeneration (AMD) after ranibizumab treatment and verify the accuracy of a new method to compare the retinal thickness measured with different optical coherence tomography (OCT) tools.
   Methods: Case series included 314 eyes with 2-4 years of follow-up. Main Outcome Measures were visual acuity (VA), number of injections, retinal thickness, OCT morphology, and final macular funduscopic status.
   Results: One hundred twenty-two men and 177 women (mean age, 78.3 years) were included. The mean time to the first injection was 17.3 +/- 14.6 days. Initial VA was 0.8(20/125) +/- 0.5; 0.7(20/100) +/- 0.5 at 3 months; 0.8(20/125) +/- 0.5 at a year; 1(20/200) +/- 0.6 at year 2; 1(20/200) +/- 0.6 at year 3 and 1.1(20/250) +/- 0.6 at year 4. Number of visits at 3 months was 2.7 +/- 0.8; 7.3 +/- 2.1 at a year; 5.2 +/- 2.7 along the 2nd year; 3.9 +/- 2.3 at year 3 and 3.6 +/- 2.2 at year 4. Number of injections at 3 months was 2.6 +/- 0.5; 3.9 +/- 1.5 at a year; 1.1 +/- 1.5 along the 2nd year; 1.5 +/- 2.4 at year 3 and 1.8 +/- 3.1 at year 4. Patients with worse VA outcomes received more injections and were older. The formula to calculate changes in retinal thickness showed a 30% reduction in thickness, which correlated well with the OCT morphology. Patients with polypoidal choroidal vasculopathy (PCV) had a worse final outcome. The final disciform macular status (37%) was related to fewer injections and a greater decrease in thickness. Final well-preserved maculas (12.%) needed more injections and treatment changes; those that were atrophic at the final visit (30.8%) had a worse initial VA and greater decrease in thickness at the 3-month visit.
   Conclusions: Younger patients had better final outcomes. Our method to compare retinal thickness using different OCT tools worked well. The final visual outcome after a long follow-up was poor, which may be related to advanced age, poor initial VA, and the high incidence of final fibrosis or atrophy.
C1 [Coco, Rosa M.; Sanabria, M. Rosa; Castrejon, Melissa; Lopez-Galvez, M. Isabel; Fernandez, Itziar] Univ Valladolid, Inst Oftalmobiol Aplicada, E-47011 Valladolid, Spain.
   [Sanabria, M. Rosa; Fernandez-Munoz, Marta] Complejo Asistencial Palencia, Palencia, Spain.
   [Lopez-Galvez, M. Isabel] Hosp Univ Valladolid, Valladolid, Spain.
   [Monje-Fernandez, Laura] Univ Leon, E-24071 Leon, Spain.
   [Anton, Alejandro] Complejo Hosp Segovia, Segovia, Spain.
   [de Juan-Marcos, Lourdes] Hosp Univ Salamanca, Salamanca, Spain.
   [Villaron-Alvarez, Sonia] Complejo Asistencial Avila, Avila, Spain.
   [Fernandez, Itziar] Ciber BBN, Zaragoza, Spain.
C3 Universidad de Valladolid; Universidad de Valladolid; Universidad de
   Leon; University of Salamanca; CIBER - Centro de Investigacion Biomedica
   en Red; CIBERBBN
RP Coco, RM (通讯作者)，Univ Valladolid, Inst Oftalmobiol Aplicada, Campus Miguel Delibes,P Belen 17, E-47011 Valladolid, Spain.
EM rosa@ioba.med.uva.es
RI Martin, Rosa Maria Coco/H-4511-2015; Sanabria, Maribel/F-4785-2015;
   Sanabria, Maria Rosa/AAH-5766-2019; Fernández, Itziar/AAF-9590-2020
OI Martin, Rosa Maria Coco/0000-0002-1811-1417; Sanabria,
   Maribel/0000-0002-8686-6918; Fernández, Itziar/0000-0002-5077-4448;
   Sanabria, Maria Rosa/0000-0002-1818-9812
FU Novartis-Spain
FX Novartis-Spain funded this study. The views expressed are those of the
   authors and not necessarily the funding body. The researchers are
   independent of the funders.
CR Bermig J, 2002, GRAEF ARCH CLIN EXP, V240, P169, DOI 10.1007/s00417-001-0378-2
   Bressler Neil M, 2004, JAMA, V291, P1900, DOI 10.1001/jama.291.15.1900
   Cohen SY, 2013, RETINA-J RET VIT DIS, V33, P474, DOI 10.1097/IAE.0b013e31827b6324
   Cohen SY, 2012, RETINA-J RET VIT DIS, V32, P1480, DOI 10.1097/IAE.0b013e318240a516
   Daniel E, 2014, OPHTHALMOLOGY, V121, P656, DOI 10.1016/j.ophtha.2013.10.019
   Finger RP, 2013, ACTA OPHTHALMOL, V91, P540, DOI 10.1111/j.1755-3768.2012.02493.x
   Gregori NZ, 2010, RETINA-J RET VIT DIS, V30, P1046, DOI 10.1097/IAE.0b013e3181d87e04
   Hanout M, 2013, BIOMED RES INT, V2013, DOI 10.1155/2013/830837
   Hatz K, 2014, BRIT J OPHTHALMOL, V98, P188, DOI 10.1136/bjophthalmol-2013-303444
   Holz FG, 2013, BRIT J OPHTHALMOL, V97, P1161, DOI 10.1136/bjophthalmol-2013-303232
   KUIPERS EJ, 1994, GASTROENTEROLOGY, V106, P1398, DOI 10.1016/0016-5085(94)90047-7
   Malamos P, 2009, INVEST OPHTH VIS SCI, V50, P4926, DOI 10.1167/iovs.09-3610
   Mones J, 2011, OPHTHALMOLOGICA, V225, P112, DOI 10.1159/000319906
   Neal RE, 2005, EXP EYE RES, V80, P337, DOI 10.1016/j.exer.2004.09.015
   Olsen TW, 2004, OPHTHALMOLOGY, V111, P250, DOI 10.1016/j.ophtha.2003.05.030
   Rasmussen A, 2013, OPHTHALMOLOGY, V120, P2630, DOI 10.1016/j.ophtha.2013.05.018
   Ruiz-Moreno JM, 2009, GUIAS PRACTICA CLIN
   Silva R, 2013, OPHTHALMOLOGY, V120, P130, DOI 10.1016/j.ophtha.2012.07.026
   Singer MA, 2012, OPHTHALMOLOGY, V119, P1175, DOI 10.1016/j.ophtha.2011.12.016
   Wang JJ, 2007, OPHTHALMOLOGY, V114, P92, DOI 10.1016/j.ophtha.2006.07.017
   Weinberg DV, 2013, OPHTHALMOLOGY, V120, P1278, DOI 10.1016/j.ophtha.2012.11.042
NR 21
TC 5
Z9 5
U1 0
U2 2
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1471-2415
J9 BMC OPHTHALMOL
JI BMC Ophthalmol.
PD NOV 22
PY 2014
VL 14
AR 138
DI 10.1186/1471-2415-14-138
PG 12
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA AZ3ZX
UT WOS:000348163300001
PM 25416399
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Ooto, S
   Vongkulsiri, S
   Sato, T
   Suzuki, M
   Curcio, CA
   Spaide, RF
AF Ooto, Sotaro
   Vongkulsiri, Sritatath
   Sato, Taku
   Suzuki, Mihoko
   Curcio, Christine A.
   Spaide, Richard F.
TI Outer Retinal Corrugations in Age-Related Macular Degeneration
SO JAMA OPHTHALMOLOGY
LA English
DT Article
ID OPTICAL COHERENCE TOMOGRAPHY; PIGMENT-EPITHELIUM DEPOSITS; BASAL LAMINAR
   DEPOSIT; GEOGRAPHIC ATROPHY; MODEL; RANIBIZUMAB; MACULOPATHY; DRUSEN;
   EYES; AUTOFLUORESCENCE
AB IMPORTANCE Optical coherence tomography (OCT) abnormalities of age-related macular degeneration (AMD) have not been fully characterized because of the complex morphology and a lack of correlative histologic studies. Expansion of our ability to interpret increasing attributes brings us closer to the goal of in vivo histologic analysis of the eye by OCT.
   OBJECTIVE To describe a new outer retinal finding of AMD using spectral-domain (SD) OCT and suggest histopathologic correlates.
   DESIGN, SETTING, AND PARTICIPANTS Twenty-five eyes of 16 patients with AMD with severe atrophy due to either choroidal neovascularization (CNV) or geographic atrophy (GA) and 53 donor eyes of 53 patients with late AMD were included. Imaging studies were conducted at a referral retinal practice and histopathology was done at a university research laboratory.
   EXPOSURES Findings in the outer retina were evaluated in SD-OCT images in eyes with atrophy of the retinal pigment epithelium (RPE) and compared with histopathologic findings in eyes with GA or CNV that also showed loss of the RPE.
   MAIN OUTCOMES AND MEASURES Spectral-domain OCT and histologic characteristics of the outer retina.
   RESULTS The mean (SD) age of the 16 patients was 82.7 (7.9) years. Twenty eyes had CNV and 5 eyes had GA. The mean best-corrected visual acuity was 0.800 logMAR (interquartile range, 0.350-1.000 logMAR), a Snellen equivalent of 20/126. A curvilinear hyperreflective density was identified above the Bruch membrane line within the atrophic area in the SD-OCT images. At the internal border, the material was contiguous with the outer portion of the RPE band. Below the material was a relatively hyporeflective space. The material was thrown into folds in cases with atrophy following CNV or was seen as a sheet with numerous bumps in eyes with GA. Review of histopathologic findings of eyes with advanced GA and CNV revealed a rippled layer of basal laminar deposits in an area of RPE atrophy that was located in the same level as the curvilinear line seen in the OCT images.
   CONCLUSIONS AND RELEVANCE We have described a new entity, termed outer retinal corrugations, which may correspond to histological findings of basal laminar deposits, extracellular deposits that persist in eyes with late AMD. Observation of this undulating band does not necessarily mean there is exudation or leakage; as a consequence, these patients do not need treatment based on this solitary finding.
C1 [Ooto, Sotaro; Vongkulsiri, Sritatath; Sato, Taku; Suzuki, Mihoko; Spaide, Richard F.] LuEsther T Mertz Retinal Res Ctr, New York, NY USA.
   [Ooto, Sotaro; Vongkulsiri, Sritatath; Sato, Taku; Suzuki, Mihoko; Spaide, Richard F.] Vitreous Retina Macula Consultants New York, New York, NY 10022 USA.
   [Curcio, Christine A.] Univ Alabama Birmingham, Sch Med, Dept Ophthalmol, EyeSight Fdn Alabama Vis Res Labs, Birmingham, AL USA.
C3 Vitreous Retina Macula Consultants of New York; University of Alabama
   System; University of Alabama Birmingham
RP Spaide, RF (通讯作者)，Vitreous Retina Macula Consultants New York, 460 Pk Ave,5th Flr, New York, NY 10022 USA.
EM rick.spaide@gmail.com
RI Spaide, Richard/ABD-7368-2020
FU LuEsther T. Mertz Retinal Research Foundation; National Eye Institute
   [EY06109]; International Retinal Research Foundation; Beckman Initiative
   for Macular Research; Edward N. and Della L. Thorne Memorial Foundation
FX This work was supported by the LuEsther T. Mertz Retinal Research
   Foundation. Dr Curcio is supported by National Eye Institute grant
   EY06109 with institutional support from the EyeSight Foundation of
   Alabama and Research to Prevent Blindness Inc. She also reported
   receiving grants from the International Retinal Research Foundation,
   Beckman Initiative for Macular Research, and the Edward N. and Della L.
   Thorne Memorial Foundation.
CR Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   Chen L, 2003, BRIT J OPHTHALMOL, V87, P212, DOI 10.1136/bjo.87.2.212
   Curcio CA, 2005, EXP EYE RES, V81, P731, DOI 10.1016/j.exer.2005.04.012
   Curcio CA, 2005, EXP EYE RES, V80, P761, DOI 10.1016/j.exer.2004.09.017
   Curcio CA, 1999, ARCH OPHTHALMOL-CHIC, V117, P329, DOI 10.1001/archopht.117.3.329
   Curcio CA, 2013, RETINA-J RET VIT DIS, V33, P265, DOI 10.1097/IAE.0b013e31827e25e0
   Curcio CA, 2009, PROG RETIN EYE RES, V28, P393, DOI 10.1016/j.preteyeres.2009.08.001
   Fleckenstein M, 2008, INVEST OPHTH VIS SCI, V49, P4137, DOI 10.1167/iovs.08-1967
   Fleckenstein M, 2011, INVEST OPHTH VIS SCI, V52, P3761, DOI 10.1167/iovs.10-7021
   Garland DL, 2014, HUM MOL GENET, V23, P52, DOI 10.1093/hmg/ddt395
   GREEN WR, 1993, OPHTHALMOLOGY, V100, P1519
   Grossniklaus HE, 2005, ARCH OPHTHALMOL-CHIC, V123, P914
   Kanagasingam Y, 2014, PROG RETIN EYE RES, V38, P20, DOI 10.1016/j.preteyeres.2013.10.002
   Keane PA, 2012, SURV OPHTHALMOL, V57, P389, DOI 10.1016/j.survophthal.2012.01.006
   Klein ML, 2008, OPHTHALMOLOGY, V115, P1026, DOI 10.1016/j.ophtha.2007.08.030
   Knupp C, 2002, J STRUCT BIOL, V137, P31, DOI 10.1006/jsbi.2002.4449
   Knupp C, 2000, J STRUCT BIOL, V129, P38, DOI 10.1006/jsbi.1999.4202
   Kumar N, 2013, OPHTHALMOLOGY, V120, P334, DOI 10.1016/j.ophtha.2012.07.076
   Kuntz CA, 1996, INVEST OPHTH VIS SCI, V37, P1772
   Marmorstein LY, 2007, HUM MOL GENET, V16, P2423, DOI 10.1093/hmg/ddm199
   Milam AH, 2000, OPHTHALMOLOGY, V107, P2256, DOI 10.1016/S0161-6420(00)00419-X
   Moussa K, 2013, RETINA-J RET VIT DIS, V33, P1590, DOI 10.1097/IAE.0b013e31828d6052
   Reale E, 2009, CELLS TISSUES ORGANS, V190, P170, DOI 10.1159/000187632
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rudolf M, 2013, OPHTHALMOLOGY, V120, P821, DOI 10.1016/j.ophtha.2012.10.007
   SARKS JP, 1988, EYE, V2, P552, DOI 10.1038/eye.1988.106
   SARKS SH, 1976, BRIT J OPHTHALMOL, V60, P324, DOI 10.1136/bjo.60.5.324
   Sarks S, 2007, INVEST OPHTH VIS SCI, V48, P968, DOI 10.1167/iovs.06-0443
   Spaide RF, 2011, RETINA-J RET VIT DIS, V31, P1609, DOI 10.1097/IAE.0b013e3182247535
   VANDERSCHAFT TL, 1992, OPHTHALMOLOGY, V99, P278
   VANDERSCHAFT TL, 1994, GRAEF ARCH CLIN EXP, V232, P40, DOI 10.1007/BF00176436
   Vogt SD, 2011, EXP EYE RES, V93, P413, DOI 10.1016/j.exer.2011.06.002
   Wavre-Shapton ST, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0057769
NR 34
TC 42
Z9 42
U1 0
U2 3
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 2168-6165
EI 2168-6173
J9 JAMA OPHTHALMOL
JI JAMA Ophthalmol.
PD JUL
PY 2014
VL 132
IS 7
BP 806
EP 813
DI 10.1001/jamaophthalmol.2014.1871
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA AM1SY
UT WOS:000339629800002
PM 24801396
OA Bronze
DA 2022-11-30
ER

PT J
AU Pulido, JS
   Peterson, LM
   Mutapcic, L
   Bryant, S
   Highsmith, WE
AF Pulido, Jose S.
   Peterson, Lisa M.
   Mutapcic, Lejla
   Bryant, Sandra
   Highsmith, W. Edward
TI LOC387715/HTRA1 and complement factor H variants in patients with
   age-related macular degeneration seen at the Mayo Clinic
SO OPHTHALMIC GENETICS
LA English
DT Article
DE age-related macular degeneration; genetics; complement H; association
   study
ID FACTOR-V-LEIDEN; VENOUS THROMBOEMBOLISM; SUSCEPTIBILITY; POLYMORPHISM;
   ASSOCIATION; Y402H; GENE; RISK; MACULOPATHY; PREVALENCE
AB Purpose: To confirm association of the complement factor H allelic variant (CFH Y402H) and the LOC387715/HTRA1 (LOC387715 A69S) risk alleles with age-related macular degeneration (AMD). Study Population: Study of 89 Caucasian patients with neovascular (exudative) AMD and 232 Caucasian controls. Methods: The Y402H variant of CFH gene and A69S variant of LOC387715/HTRA1 gene locus were examined. Results: For CFH, the odds ratio for the homozygous variant was 4.97 (CI 2.52 to 9.79). For LOC387715/HTRA1 the odds ratio for the homozygous risk variant was 7.75 (CI 3.46 to 17.35). The odds ratio for heterozygous carriers was 3.35 (CI 1.91 to 5.90).
C1 [Peterson, Lisa M.; Bryant, Sandra; Highsmith, W. Edward] Mayo Clin, Coll Med, Lab Med & Pathol, Mol Genet Lab, Rochester, MN 55905 USA.
   [Pulido, Jose S.; Mutapcic, Lejla] Mayo Clin, Dept Ophthalmol, Rochester, MN USA.
C3 Mayo Clinic; Mayo Clinic
RP Highsmith, WE (通讯作者)，Mayo Clin, Coll Med, Lab Med & Pathol, Mol Genet Lab, 9-20 Hilton Bldg,200 1st St,SW, Rochester, MN 55905 USA.
EM highsmith.w@mayo.edu
RI Highsmith, William E/B-6175-2008
CR Antoniou A, 2003, AM J HUM GENET, V72, P1117, DOI 10.1086/375033
   Bureeva S, 2005, DRUG DISCOV TODAY, V10, P1535, DOI 10.1016/S1359-6446(05)03592-0
   Castoldi E, 2004, CURR OPIN HEMATOL, V11, P176, DOI 10.1097/01.moh.0000130315.41033.32
   Conley YP, 2006, HUM MOL GENET, V15, P3206, DOI 10.1093/hmg/ddl396
   DEANGELIS MM, 2007, ARCH OPHTHALMOL
   Dewan A, 2006, SCIENCE, V314, P989, DOI 10.1126/science.1133807
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Gotoh N, 2006, HUM GENET, V120, P139, DOI 10.1007/s00439-006-0187-0
   Grody WW, 2001, GENET MED, V3, P87, DOI 10.1097/00125817-200103000-00001
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Heit JA, 2006, J THROMB THROMBOLYS, V21, P23, DOI 10.1007/s11239-006-5572-y
   Heit JA, 2005, J THROMB HAEMOST, V3, P305, DOI 10.1111/j.1538-7836.2004.01117.x
   Jakobsdottir J, 2005, AM J HUM GENET, V77, P389, DOI 10.1086/444437
   Klein R, 2006, OPHTHALMOLOGY, V113, P373, DOI 10.1016/j.ophtha.2005.12.013
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Magnusson KP, 2006, PLOS MED, V3, P109, DOI 10.1371/journal.pmed.0030005
   Mizuno M., 2004, Current Drug Targets - Inflammation and Allergy, V3, P87, DOI 10.2174/1568010043483890
   Okamoto H, 2006, MOL VIS, V12, P156
   Rivera A, 2005, HUM MOL GENET, V14, P3227, DOI 10.1093/hmg/ddi353
   Schmidt S, 2006, AM J HUM GENET, V78, P852, DOI 10.1086/503822
   Seddon JM, 2005, ARCH OPHTHALMOL-CHIC, V123, P321, DOI 10.1001/archopht.123.3.321
   Sepp T, 2006, INVEST OPHTH VIS SCI, V47, P536, DOI 10.1167/iovs.05-1143
   Shuler RK, 2007, ARCH OPHTHALMOL-CHIC, V125, P63, DOI 10.1001/archopht.125.1.63
   SIMONELLI F, 2006, BR J OPHTHALMOL
   Souied EH, 2005, MOL VIS, V11, P1135
   Yang ZL, 2006, SCIENCE, V314, P992, DOI 10.1126/science.1133811
   YATES JRW, 2007, N ENGL J MED
   Zareparsi S, 2005, AM J HUM GENET, V77, P149, DOI 10.1086/431426
NR 30
TC 12
Z9 13
U1 0
U2 1
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 1381-6810
EI 1744-5094
J9 OPHTHALMIC GENET
JI Ophthalmic Genet.
PD DEC
PY 2007
VL 28
IS 4
BP 203
EP 207
DI 10.1080/13816810701649617
PG 5
WC Genetics & Heredity; Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Genetics & Heredity; Ophthalmology
GA 248JX
UT WOS:000252150700004
PM 18161619
DA 2022-11-30
ER

PT J
AU Tosi, GM
   Caldi, E
   Parolini, B
   Toti, P
   Neri, G
   Nardi, F
   Traversi, C
   Cevenini, G
   Marigliani, D
   Nuti, E
   Bacci, T
   Galvagni, F
   Orlandini, M
AF Tosi, Gian Marco
   Caldi, Elena
   Parolini, Barbara
   Toti, Paolo
   Neri, Giovanni
   Nardi, Federica
   Traversi, Claudio
   Cevenini, Gabriele
   Marigliani, Davide
   Nuti, Elisabetta
   Bacci, Tommaso
   Galvagni, Federico
   Orlandini, Maurizio
TI CD93 as a Potential Target in Neovascular Age-Related Macular
   Degeneration
SO JOURNAL OF CELLULAR PHYSIOLOGY
LA English
DT Article
ID OCULAR NEOVASCULARIZATION; ELEVATED EXPRESSION; ENDOTHELIAL-CELLS; VEGF;
   RECEPTOR; THERAPY; GROWTH; ANGIOGENESIS; MICROSCOPY; C1QR(P)
AB In patients with age-related macular degeneration (AMD), choroidal neovascularization is the major cause of severe visual loss. In these patients, the persistence of neovascular growth despite vascular endothelial growth factor-A blockage needs the discovery of new endothelial cell targets. The glycoprotein CD93, highly expressed in activated endothelial cells, has been recently involved in the regulation of the angiogenic process both as transmembrane and soluble protein. Choroidal neovascular membranes from patients affected by AMD were examined by immunofluorescence using anti-CD93 and anti-von Willebrand factor antibodies. Blood vessels within intraocular and extraocular neoplasias were used as controls for CD93 expression. All choroidal neovascular membranes displayed strong CD93 staining in the von Willebrand factor-positive endothelial cells, consistently with the analyses showing a high colocalization coefficient in the blood vessels. Intraocular and extraocular tumor vessels showed similar results, whereas the normal choroid displayed blood vessels with only faint CD93 staining. Additionally, the concentration of soluble CD93 was determined in the aqueous humor of patients affected by naive neovascular AMD by enzyme-linked immunosorbent assays. Age-matched cataract patients served as controls. Soluble CD93 was significantly increased in the aqueous humor of naive neovascular AMD patients and tended to decrease after treatment with an antiangiogenic drug. In conclusion, both transmembrane and soluble CD93 are overexpressed in patients with neovascular AMD, indicating that CD93 may represent a potential new antiangiogenic target in the treatment of choroidal neovascularization. J. Cell. Physiol. 232: 1767-1773, 2017. (c) 2016 Wiley Periodicals, Inc.
C1 [Tosi, Gian Marco; Neri, Giovanni; Traversi, Claudio; Marigliani, Davide; Nuti, Elisabetta; Bacci, Tommaso] Univ Siena, Dept Med Surg & Neurosci, Ophthalmol Unit, Siena, Italy.
   [Caldi, Elena; Nardi, Federica; Galvagni, Federico; Orlandini, Maurizio] Univ Siena, Dept Biotechnol Chem & Pharm, Via A Moro 2, I-53100 Siena, Italy.
   [Parolini, Barbara] St Anna Hosp, Vitreoretinal Unit, Brescia, Italy.
   [Toti, Paolo; Cevenini, Gabriele] Univ Siena, Dept Med Biotechnol, Siena, Italy.
C3 University of Siena; University of Siena; University of Ferrara;
   Arcispedale Sant'Anna; University of Siena
RP Galvagni, F; Orlandini, M (通讯作者)，Univ Siena, Dept Biotechnol Chem & Pharm, Via A Moro 2, I-53100 Siena, Italy.
EM federico.galvagni@unisi.it; maurizio.orlandini@unisi.it
RI Toti, Paolo/E-6358-2012; Orlandini, Maurizio/AAF-8247-2020; Bacci,
   Tommaso/GQA-8840-2022; Bacci, Tommaso/AAQ-5603-2020; Galvagni,
   Federico/F-9186-2013; Parolini, Barbara/AAH-9913-2019; CEVENINI,
   Gabriele/S-1973-2018
OI Toti, Paolo/0000-0002-1214-5886; Orlandini,
   Maurizio/0000-0002-6112-4889; Bacci, Tommaso/0000-0001-7477-2263;
   CEVENINI, Gabriele/0000-0002-7212-573X; Parolini,
   Barbara/0000-0002-7838-6834; Nardi, Federica/0000-0002-4155-1429
CR Balasubramanian SA, 2014, TRANSL RES, V164, P179, DOI 10.1016/j.trsl.2014.04.005
   Bao LL, 2016, BIOCHEM BIOPH RES CO, V476, P467, DOI 10.1016/j.bbrc.2016.05.146
   Behl T, 2015, PHARMACOL RES, V99, P137, DOI 10.1016/j.phrs.2015.05.013
   Bohlson SS, 2005, J IMMUNOL, V175, P1239, DOI 10.4049/jimmunol.175.2.1239
   Campochiaro PA, 2015, PROG RETIN EYE RES, V49, P67, DOI 10.1016/j.preteyeres.2015.06.002
   Campochiaro PA, 2013, J MOL MED, V91, P311, DOI 10.1007/s00109-013-0993-5
   Dong A, 2014, ANGIOGENESIS, V17, P553, DOI 10.1007/s10456-013-9402-5
   Dunn KW, 2011, AM J PHYSIOL-CELL PH, V300, pC723, DOI 10.1152/ajpcell.00462.2010
   Fonseca MI, 2001, J LEUKOCYTE BIOL, V70, P793
   Galvagni F, 2007, BIOCHEMISTRY-US, V46, P3998, DOI 10.1021/bi061400n
   Galvagni F, 2016, ONCOTARGET, V7, P10090, DOI 10.18632/oncotarget.7136
   Galvagni F, 2012, HISTOCHEM CELL BIOL, V138, P419, DOI 10.1007/s00418-012-0965-9
   Gao F, 2016, ANGIOGENESIS, V19, P107, DOI 10.1007/s10456-016-9497-6
   Greenlee MC, 2009, INFLAMM RES, V58, P909, DOI 10.1007/s00011-009-0064-0
   Kao YC, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0051647
   Kuehlewein L, 2015, EYE, V29, P932, DOI 10.1038/eye.2015.80
   Langenkamp E, 2015, CANCER RES, V75, P4504, DOI 10.1158/0008-5472.CAN-14-3636
   Malarstig A, 2011, J INTERN MED, V270, P229, DOI 10.1111/j.1365-2796.2011.02364.x
   MANDERS EMM, 1992, J CELL SCI, V103, P857
   Masiero M, 2013, CANCER CELL, V24, P229, DOI 10.1016/j.ccr.2013.06.004
   McGreal EP, 2002, J IMMUNOL, V168, P5222, DOI 10.4049/jimmunol.168.10.5222
   Miller JW, 2016, TRANSL VIS SCI TECHN, V5, DOI 10.1167/tvst.5.2.9
   Nepomuceno RR, 1997, IMMUNITY, V6, P119, DOI 10.1016/S1074-7613(00)80419-7
   Olsen RS, 2015, INT J COLORECTAL DIS, V30, P883, DOI 10.1007/s00384-015-2247-1
   Orlandini M, 2008, FEBS LETT, V582, P2542, DOI 10.1016/j.febslet.2008.06.025
   Orlandini M, 2014, ONCOTARGET, V5, P2750, DOI 10.18632/oncotarget.1887
   Petrenko O, 1999, IMMUNITY, V10, P691, DOI 10.1016/S1074-7613(00)80068-0
   Pusztaszeri MP, 2006, J HISTOCHEM CYTOCHEM, V54, P385, DOI 10.1369/jhc.4A6514.2005
   Schmidt-Erfurth U, 2014, BRIT J OPHTHALMOL, V98, P1144, DOI 10.1136/bjophthalmol-2014-305702
   Umeda N, 2006, MOL PHARMACOL, V69, P1820, DOI 10.1124/mol.105.020941
   Yang SQ, 2016, DRUG DES DEV THER, V10, P1857, DOI 10.2147/DDDT.S97653
NR 31
TC 15
Z9 17
U1 0
U2 12
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0021-9541
EI 1097-4652
J9 J CELL PHYSIOL
JI J. Cell. Physiol.
PD JUL
PY 2017
VL 232
IS 7
BP 1767
EP 1773
DI 10.1002/jcp.25689
PG 7
WC Cell Biology; Physiology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology; Physiology
GA ES1VB
UT WOS:000399314000023
PM 27859225
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Adams, MKM
   Chong, EW
   Williamson, E
   Aung, KZ
   Makeyeva, GA
   Giles, GG
   English, DR
   Hopper, J
   Guymer, RH
   Baird, PN
   Robman, LD
   Simpson, JA
AF Adams, Madeleine K. M.
   Chong, Elaine W.
   Williamson, Elizabeth
   Aung, Khin Zaw
   Makeyeva, Galina A.
   Giles, Graham G.
   English, Dallas R.
   Hopper, John
   Guymer, Robyn H.
   Baird, Paul N.
   Robman, Liubov D.
   Simpson, Julie A.
TI 20/20-Alcohol and Age-related Macular Degeneration: The Melbourne
   Collaborative Cohort Study
SO AMERICAN JOURNAL OF EPIDEMIOLOGY
LA English
DT Article
DE aging; alcohol drinking; macular degeneration
ID MODERATE ALCOHOL-CONSUMPTION; BEAVER DAM EYE; CORONARY-HEART-DISEASE;
   ANGELES LATINO EYE; LIPID-PEROXIDATION; VISUAL IMPAIRMENT; WINE
   CONSUMPTION; DRINKING PATTERN; RISK; MACULOPATHY
AB Little evidence exists regarding associations between age-related macular degeneration (AMD) and moderate alcohol consumption, patterns of consumption, or different types of alcoholic beverage. The authors examined associations between AMD prevalence and alcohol intake using 20,963 participants from the Melbourne Collaborative Cohort Study aged 4069 years at baseline (19901994). Participants alcohol consumption was determined from a structured interview at baseline. At follow-up from 2003 to 2007, digital macula photographs of both eyes were taken and evaluated for early and late AMD signs. Drinking more than 20 g of alcohol per day was associated with an approximate 20 increase in the odds of early AMD (odds ratio 1.21, 95 confidence interval: 1.06, 1.38; P 0.004) when compared with those who reported no alcohol intake at baseline, having adjusted for sex, age, smoking, country of birth, education, physical activity, and energy from food. This positive association was apparent for wine, beer, and spirits. The estimates were similar for both sexes. The odds ratio for those drinking more than 20 g of alcohol per day for late AMD was 1.44 (95 confidence interval: 0.85, 2.45; P 0.17). These results show a modest association between alcohol consumption and increased AMD risk.
C1 [Williamson, Elizabeth; Giles, Graham G.; English, Dallas R.; Simpson, Julie A.] Univ Melbourne, Ctr Mol Environm Genet & Analyt Epidemiol, Melbourne, Vic, Australia.
   [Giles, Graham G.; English, Dallas R.; Simpson, Julie A.] Canc Council Victoria, Canc Epidemiol Ctr, Melbourne, Vic, Australia.
   [Williamson, Elizabeth; Hopper, John] Monash Univ, Dept Epidemiol & Prevent Med, Clayton, Vic 3800, Australia.
   [Adams, Madeleine K. M.; Chong, Elaine W.; Aung, Khin Zaw; Makeyeva, Galina A.; Guymer, Robyn H.; Baird, Paul N.; Robman, Liubov D.] Univ Melbourne, Ctr Eye Res Australia, Royal Victorian Eye & Ear Hosp, Melbourne, Vic, Australia.
C3 University of Melbourne; Cancer Council Victoria; Monash University;
   Centre for Eye Research Australia; Royal Victorian Eye & Ear Hospital;
   University of Melbourne
RP Adams, MKM (通讯作者)，Univ Melbourne, Ctr Eye Res Australia, Royal Victorian Eye & Ear Hosp, 32 Gisborne St, Melbourne, Vic 3002, Australia.
EM madeleine.adams@bigpond.com
RI Williamson, Elizabeth/H-3876-2019; English, Dallas/AAH-5005-2019;
   Simpson, Julie A/P-7299-2014; Adams, Madeleine K M/B-7915-2016
OI Williamson, Elizabeth/0000-0001-6905-876X; English,
   Dallas/0000-0001-7828-8188; Adams, Madeleine K M/0000-0002-5277-5487;
   Simpson, Julie/0000-0002-2660-2013; Baird, Paul/0000-0002-1305-3502;
   Giles, Graham/0000-0003-4946-9099; Guymer, Robyn/0000-0002-9441-4356
FU VicHealth; Cancer Council Victoria; National Health and Medical Research
   Council of Australia (NHMRC) [209057, 251533, 396414]; Ophthalmic
   Research Institute of Australia; American Health Assistance Foundation;
   John Reid Charitable Trust; Perpetual Trustees; Royal Victorian Eye and
   Ear Hospital; NHMRC; Wagstaff Fellowship; Hugh Noel Puckle Scholarship
FX This work was supported by VicHealth; the Cancer Council Victoria
   (initial cohort recruitment); and the National Health and Medical
   Research Council of Australia (NHMRC) program grant 209057, capacity
   building grant 251533, and enabling grant 396414. The ophthalmic
   component was funded by the Ophthalmic Research Institute of Australia,
   American Health Assistance Foundation, John Reid Charitable Trust,
   Perpetual Trustees, and the Royal Victorian Eye and Ear Hospital. People
   support was provided through the NHMRC Practitioner Fellowship to R. H.
   G., Wagstaff Fellowship to L. D. R., and NHMRC PhD scholarship and Hugh
   Noel Puckle Scholarship to M. K. M. A. The Center for Eye Research
   Australia receives operational infrastructure support from the Victorian
   government.
CR Adams KF, 2006, NEW ENGL J MED, V355, P763, DOI 10.1056/NEJMoa055643
   Adams MKM, 2011, AM J EPIDEMIOL, V173, P1246, DOI 10.1093/aje/kwr005
   Agar E, 2003, INT J NEUROSCI, V113, P1643, DOI 10.1080/00207450390245207
   [Anonymous], 2006, NAT ALC STRAT 2006 2
   Arnarsson A, 2006, AM J OPHTHALMOL, V142, P419, DOI 10.1016/j.ajo.2006.04.015
   Aung KZ, 2009, OPHTHAL EPIDEMIOL, V16, P254, DOI [10.3109/09286580902864419, 10.1080/09286580902864419]
   Baglietto L, 2006, ALCOHOL ALCOHOLISM, V41, P664, DOI 10.1093/alcalc/agl087
   Bora PS, 2006, FEBS J, V273, P1403, DOI 10.1111/j.1742-4658.2006.05163.x
   Buch H, 2005, ACTA OPHTHALMOL SCAN, V83, P400, DOI [10.1111/j.1600-0420.2005.00474.x, 10.1111/j.1600-0420.2005.thesis.x]
   CEDERBAUM AI, 1989, FREE RADICAL BIO MED, V7, P537, DOI 10.1016/0891-5849(89)90029-4
   Cho EY, 2000, ARCH OPHTHALMOL-CHIC, V118, P681, DOI 10.1001/archopht.118.5.681
   Chong EWT, 2008, AM J OPHTHALMOL, V145, P707, DOI 10.1016/j.ajo.2007.12.005
   Chong EWT, 2009, ARCH OPHTHALMOL-CHIC, V127, P674, DOI 10.1001/archophthalmol.2009.60
   Chong EWT, 2007, BMJ-BRIT MED J, V335, P755, DOI 10.1136/bmj.39350.500428.47
   Coleman AL, 2010, AM J OPHTHALMOL, V149, P160, DOI 10.1016/j.ajo.2009.07.025
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   Corrao G, 2004, PREV MED, V38, P613, DOI 10.1016/j.ypmed.2003.11.027
   Dufour MC, 1999, ALCOHOL RES HEALTH, V23, P5
   Fillmore KM, 2007, ANN EPIDEMIOL, V17, pS16, DOI 10.1016/j.annepidem.2007.01.005
   Fraser-Bell S, 2006, AM J OPHTHALMOL, V141, P79, DOI 10.1016/j.ajo.2005.08.024
   Giles GG, 1990, P NUTR SOC AUST, V15, P61
   Hernan MA, 2002, AM J EPIDEMIOL, V155, P176, DOI 10.1093/aje/155.2.176
   HORTON A M JR, 1986, MMJ (Maryland Medical Journal), V35, P916
   Ireland P, 1994, Asia Pac J Clin Nutr, V3, P19
   KATZ ML, 1982, EXP EYE RES, V34, P339, DOI 10.1016/0014-4835(82)90082-3
   Klein R, 2002, AM J EPIDEMIOL, V156, P589, DOI 10.1093/aje/kwf092
   Knudtson MD, 2007, AM J OPHTHALMOL, V143, P1026, DOI 10.1016/j.ajo.2007.01.036
   Lewis J., 1995, NUTTAB95 NUTR DATA T
   Moss SE, 1998, OPHTHALMOLOGY, V105, P789, DOI 10.1016/S0161-6420(98)95016-3
   Mukamal KJ, 2003, NEW ENGL J MED, V348, P109, DOI 10.1056/NEJMoa022095
   National Health and Medical Research Council, 2009, AUSTR GUID RED HLTH
   Obisesan TO, 1998, J AM GERIATR SOC, V46, P1
   Orgogozo JM, 1997, REV NEUROL-FRANCE, V153, P185
   Rehm J, 2008, INT J METH PSYCH RES, V17, P141, DOI 10.1002/mpr.259
   Rimm EB, 1996, BRIT MED J, V312, P731, DOI 10.1136/bmj.312.7033.731
   RITTER LL, 1995, AM J OPHTHALMOL, V120, P190, DOI 10.1016/S0002-9394(14)72607-8
   Ronksley PE, 2011, BMJ-BRIT MED J, V342, DOI 10.1136/bmj.d671
   SHAPER AG, 1988, LANCET, V2, P1267
   Shrier I, 2008, BMC MED RES METHODOL, V8, DOI 10.1186/1471-2288-8-70
   Stampfer MJ, 2005, NEW ENGL J MED, V352, P245, DOI 10.1056/NEJMoa041152
   STAMPFER MJ, 1988, NEW ENGL J MED, V319, P267, DOI 10.1056/NEJM198808043190503
   Swaroop A, 2009, ANNU REV GENOM HUM G, V10, P19, DOI 10.1146/annurev.genom.9.081307.164350
   van Leeuwen R, 2003, ARCH OPHTHALMOL-CHIC, V121, P519, DOI 10.1001/archopht.121.4.519
   Varma R, 2004, OPHTHALMOLOGY, V111, P1288, DOI 10.1016/j.ophtha.2004.01.023
NR 44
TC 42
Z9 43
U1 0
U2 13
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 0002-9262
EI 1476-6256
J9 AM J EPIDEMIOL
JI Am. J. Epidemiol.
PD AUG 15
PY 2012
VL 176
IS 4
BP 289
EP 298
DI 10.1093/aje/kws004
PG 10
WC Public, Environmental & Occupational Health
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Public, Environmental & Occupational Health
GA 988ON
UT WOS:000307500500003
PM 22847604
OA Bronze
DA 2022-11-30
ER

PT J
AU Kondo, N
   Honda, S
   Kuno, S
   Negi, A
AF Kondo, Naoshi
   Honda, Shigeru
   Kuno, Shin-ichi
   Negi, Akira
TI Positive association of common variants in CD36 with neovascular
   age-related macular degeneration
SO AGING-US
LA English
DT Article
DE age-related macular degeneration; choroidal neovascularization; CD36;
   genetics; single nucleotide polymorphism; association
ID FACTOR-H POLYMORPHISM; FACTOR-B; RISK; SUSCEPTIBILITY; LIPOPROTEIN;
   INCREASES; HAPLOTYPE; HTRA1; CFH; PATHOGENESIS
AB Age-related macular degeneration (AMD) is a leading cause of legal blindness among older individuals of industrialized countries. In neovascular AMD, which is an advanced stage of AMD, choroidal neovascularization develops underneath the macula and destroys central vision. Oxidative stress is a hypothesized pathway for the pathophysiology of AMD. CD36 was chosen as a candidate gene for neovascular AMD because the protein plays an important role in this pathway as well as in angiogenesis and in maintaining chorioretinal homeostasis. We tested 19 tag single nucleotide polymorphisms (SNPs) across CD36 for their association with the disease in a Japanese population comprising 109 neovascular AMD subjects and 182 unrelated controls. Five of the 19 SNPs demonstrated a nominally significant association with neovascular AMD (P < 0.05), of which two (rs3173798 and rs3211883) withstood Bonferroni correction for multiple testing (rs3173798, nominal P = 9.96 x 10-4, allele-specific odds ratio = 0.55; rs3211883, nominal P = 2.09 x 10-4, allele-specific odds ratio = 0.50). Population structure analyses excluded stratification artifacts in our study cohort. This study supports the candidacy of CD36 as a novel susceptibility gene for neovascular AMD. Replication of our results in other populations will provide further convincing evidence for the genetic association.
C1 [Kondo, Naoshi; Honda, Shigeru; Negi, Akira] Kobe Univ, Grad Sch Med, Div Ophthalmol, Dept Surg,Chuo Ku, Kobe, Hyogo 6500017, Japan.
   [Kuno, Shin-ichi] Fdn Biomed Res & Innovat, Translat Res Informat Ctr, Chuo Ku, Kobe, Hyogo 6500047, Japan.
   [Kuno, Shin-ichi] Kobe Univ, Grad Sch Med, Clin Genome Informat Ctr, Chuo Ku, Kobe, Hyogo 6500017, Japan.
C3 Kobe University; Institute for Biomedical Research & Innovation (IBRI);
   Kobe University
RP Honda, S (通讯作者)，Kobe Univ, Grad Sch Med, Div Ophthalmol, Dept Surg,Chuo Ku, 7-5-2 Kusunoki Cho, Kobe, Hyogo 6500017, Japan.
EM sighonda@med.kobe-u.ac.jp
RI Honda, Shigeru/W-4761-2019
OI Kondo, Naoshi/0000-0001-6025-3876
FU Ministry of Education, Science, and Culture, Tokyo, Japan [20592042]
FX The authors thank all who participated in this study. This study was
   supported by a Grant-in Aid for (C) 20592042 from the Ministry of
   Education, Science, and Culture, Tokyo, Japan.
CR ANDERSON CR, 2008, AM J PATHOL IN PRESS
   Balding DJ, 2006, NAT REV GENET, V7, P781, DOI 10.1038/nrg1916
   Barrett JC, 2005, BIOINFORMATICS, V21, P263, DOI 10.1093/bioinformatics/bth457
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   de Bakker PIW, 2005, NAT GENET, V37, P1217, DOI 10.1038/ng1669
   Dewan A, 2006, SCIENCE, V314, P989, DOI 10.1126/science.1133807
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Falush D, 2003, GENETICS, V164, P1567
   Febbraio M, 2001, J CLIN INVEST, V108, P785, DOI 10.1172/JCI14006
   Frazer KA, 2007, NATURE, V449, P851, DOI 10.1038/nature06258
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Fritsche LG, 2008, NAT GENET, V40, P892, DOI 10.1038/ng.170
   Gabriel SB, 2002, SCIENCE, V296, P2225, DOI 10.1126/science.1069424
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   Gordiyenko N, 2004, INVEST OPHTH VIS SCI, V45, P2822, DOI 10.1167/iovs.04-0074
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Hoppe G, 2001, INVEST OPHTH VIS SCI, V42, P2714
   Houssier M, 2008, PLOS MED, V5, P323, DOI 10.1371/journal.pmed.0050039
   Hughes AE, 2006, NAT GENET, V38, P1173, DOI 10.1038/ng1890
   Kamei M, 2007, INVEST OPHTH VIS SCI, V48, P1801, DOI 10.1167/iovs.06-0699
   Kanda A, 2007, P NATL ACAD SCI USA, V104, P16227, DOI 10.1073/pnas.0703933104
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Kondo N, 2007, AM J OPHTHALMOL, V144, P608, DOI 10.1016/j.ajo.2007.06.003
   Kubo M, 2007, NAT GENET, V39, P212, DOI 10.1038/ng1945
   Kuniyasu A, 2003, FEBS LETT, V537, P85, DOI 10.1016/S0014-5793(03)00096-6
   Leveziel N, 2007, MOL VIS, V13, P2153
   Li M, 2006, NAT GENET, V38, P1049, DOI 10.1038/ng1871
   LI S, 1995, ARCH OPHTHALMOL-CHIC, V113, P521, DOI 10.1001/archopht.1995.01100040143041
   Maller J, 2006, NAT GENET, V38, P1055, DOI 10.1038/ng1873
   Maller JB, 2007, NAT GENET, V39, P1200, DOI 10.1038/ng2131
   Metelitsina TI, 2008, INVEST OPHTH VIS SCI, V49, P358, DOI 10.1167/iovs.07-0526
   Mwaikambo BR, 2006, INVEST OPHTH VIS SCI, V47, P4356, DOI 10.1167/iovs.05-1656
   Pritchard JK, 2000, GENETICS, V155, P945
   Purcell S, 2007, AM J HUM GENET, V81, P559, DOI 10.1086/519795
   Seddon JM, 2006, OPHTHALMOLOGY, V113, P260, DOI 10.1016/j.ophtha.2005.11.001
   Silverstein RL, 2000, CURR OPIN LIPIDOL, V11, P483, DOI 10.1097/00041433-200010000-00006
   Spencer KL, 2008, HUM MOL GENET, V17, P1821, DOI 10.1093/hmg/ddn075
   Spencer KL, 2007, HUM MOL GENET, V16, P1986, DOI 10.1093/hmg/ddm146
   Sun MJ, 2006, J BIOL CHEM, V281, P4222, DOI 10.1074/jbc.M509769200
   Yamada K, 2004, BIOL PSYCHIAT, V56, P683, DOI 10.1016/j.biopsych.2004.08.015
   Yamada K, 2007, P NATL ACAD SCI USA, V104, P2815, DOI 10.1073/pnas.0610765104
   Yamada Y, 2008, J NEUROCHEM, V105, P1187, DOI 10.1111/j.1471-4159.2008.05211.x
   Yang ZL, 2006, SCIENCE, V314, P992, DOI 10.1126/science.1133811
   Yates JRW, 2007, NEW ENGL J MED, V357, P553, DOI 10.1056/NEJMoa072618
   Yuan HY, 2006, NUCLEIC ACIDS RES, V34, pW635, DOI 10.1093/nar/gkl236
   Zarbin MA, 2004, ARCH OPHTHALMOL-CHIC, V122, P598, DOI 10.1001/archopht.122.4.598
NR 46
TC 22
Z9 25
U1 1
U2 5
PU IMPACT JOURNALS LLC
PI ORCHARD PARK
PA 6666 E QUAKER ST, STE 1, ORCHARD PARK, NY 14127 USA
SN 1945-4589
J9 AGING-US
JI Aging-US
PD FEB
PY 2009
VL 1
IS 2
BP 266
EP 274
DI 10.18632/aging.100006
PG 9
WC Cell Biology; Geriatrics & Gerontology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology; Geriatrics & Gerontology
GA 579UL
UT WOS:000276400900011
PM 20157514
OA Green Published, gold, Green Submitted
DA 2022-11-30
ER

PT J
AU Baker, ML
   Wang, JJ
   Rogers, S
   Klein, R
   Kuller, LH
   Larsen, EK
   Wong, TY
AF Baker, Michelle L.
   Wang, Jie Jin
   Rogers, Sophie
   Klein, Ronald
   Kuller, Lewis H.
   Larsen, Emily K.
   Wong, Tien Yin
TI Early Age-Related Macular Degeneration, Cognitive Function, and Dementia
   The Cardiovascular Health Study
SO ARCHIVES OF OPHTHALMOLOGY
LA English
DT Article
ID BEAVER DAM EYE; RETINAL MICROVASCULAR ABNORMALITIES; APOLIPOPROTEIN-E
   GENE; ALZHEIMERS-DISEASE; RISK-FACTORS; OLDER PERSONS; VISUAL
   IMPAIRMENT; BLOOD-PRESSURE; MACULOPATHY; POPULATION
AB Objective: To describe the association Of Cognitive function and dementia with early age-related macular degeneration (AMD) in older individuals.
   Methods: This population-based study included 2088 persons aged 69 to 97 years who participated in the Cardiovascular Health Study. The AMD was assessed from retinal photographs based on a modified Wisconsin AMD grading system. Cognitive function was assessed using the Digit Symbol Substitution Test (DSST) and the Modified Mini-Mental State Examination. Participants were also evaluated for dementia using detailed neuropsychological testing.
   Results: After controlling for age, sex, race, and stud), center, persons with low DSST scores (lowest quartile of scores, :530) were more likely to have cart), AMD (odds ratio, 1.38 95% confidence interval, 1.03-1.85) than were persons with higher DSST scores. In analyses further controlling for education, systolic blood pressure, total cholesterol level, diabetes mellitus, smoking status, and apolipoprotein E genotype, this association was stronger (odds ratio, 2.00; 95% confidence interval, 1.29-3.10). There was no association of low Modified Mini-Mental State Examination scores, dementia, or Alzheimer disease with early AMD.
   Conclusions: In this older population, cognitive impairment may share common age-related pathogenesis and risk factors with early AMD.
C1 [Baker, Michelle L.; Wang, Jie Jin; Rogers, Sophie; Wong, Tien Yin] Univ Melbourne, Ctr Eye Res Australia, Melbourne, Vic 3002, Australia.
   [Wang, Jie Jin] Univ Sydney, Ctr Vis Res, Sydney, NSW 2006, Australia.
   [Klein, Ronald] Univ Wisconsin, Sch Med & Publ Hlth, Dept Ophthalmol & Visual Sci, Madison, WI 53706 USA.
   [Kuller, Lewis H.] Univ Pittsburgh, Dept Epidemiol, Pittsburgh, PA 15261 USA.
   [Larsen, Emily K.] Univ Washington, Dept Biostat, Seattle, WA 98195 USA.
   [Wong, Tien Yin] Natl Univ Singapore, Singapore Eye Res Inst, Yong Loo Lin Sch Med, Singapore, Singapore.
C3 Centre for Eye Research Australia; University of Melbourne; University
   of Sydney; University of Wisconsin System; University of Wisconsin
   Madison; Pennsylvania Commonwealth System of Higher Education (PCSHE);
   University of Pittsburgh; University of Washington; University of
   Washington Seattle; National University of Singapore; Singapore National
   Eye Center
RP Wong, TY (通讯作者)，Univ Melbourne, Ctr Eye Res Australia, 32 Gisborne St, Melbourne, Vic 3002, Australia.
EM twong@unimelb.edu.au
RI Wang, Jie Jin/P-1499-2014; wang, jie/GRS-0942-2022; Wong, Tien
   Yin/AAC-9724-2020
OI Wang, Jie Jin/0000-0001-9491-4898; Wong, Tien Yin/0000-0002-8448-1264;
   Klein, Ronald/0000-0002-4428-6237
FU National Heart, Lung, and Blood Institute [N01-HC-35129, N01-HC-45133,
   N01-HC-75150, N01-HC-85079, N01-HC-85086, N01 HC-15103, N01 HC-55222,
   U01 HL080295, R21-HL077166]; National Institute of Neurological
   Disorders and Stroke; National Heart Foundation; DIVISION OF
   EPIDEMIOLOGY AND CLINICAL APPLICATIONS [N01HC085086, N01HC035129,
   N01HC085081, N01HC075150, N01HC085082, N01HC085080, N01HC015103,
   N01HC085079, N01HC085084, N01HC085083, N01HC055222, N01HC085085,
   N01HC045133] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND
   BLOOD INSTITUTE [R21HL077166, U01HL080295] Funding Source: NIH RePORTER
FX The research reported in this article was supported by contracts
   N01-HC-35129, N01-HC-45133, N01-HC-75150, N01-HC-85079 through
   N01-HC-85086, N01 HC-15103, N01 HC-55222, and U01 HL080295 from the
   National Heart, Lung, and Blood Institute, with additional contributions
   from the National Institute of Neurological Disorders and Stroke.
   Additional support was provided by grant R21-HL077166 from the National
   Heart, Lung, and Blood Institute and by the National Heart Foundation
   (Dr Wong).
CR Anstey KJ, 2007, AM J EPIDEMIOL, V166, P367, DOI 10.1093/aje/kwm116
   APA, 1994, DIAGNOSTIC STAT MANU
   Baker ML, 2007, STROKE, V38, P2041, DOI 10.1161/STROKEAHA.107.483586
   Blanks JC, 1996, NEUROBIOL AGING, V17, P377, DOI 10.1016/0197-4580(96)00010-3
   Blanks JC, 1996, NEUROBIOL AGING, V17, P385, DOI 10.1016/0197-4580(96)00009-7
   CHUI HC, 1992, NEUROLOGY, V42, P473, DOI 10.1212/WNL.42.3.473
   CURCIO CA, 1993, INVEST OPHTH VIS SCI, V34, P3278
   Dentchev T, 2003, MOL VIS, V9, P184
   Evans DA, 1997, JAMA-J AM MED ASSOC, V277, P822, DOI 10.1001/jama.277.10.822
   Fried Linda P., 1991, Annals of Epidemiology, V1, P263
   FURBERG CD, 1992, AM J CARDIOL, V69, P1329, DOI 10.1016/0002-9149(92)91231-R
   Giannakopoulos P, 1997, BRAIN RES REV, V25, P217, DOI 10.1016/S0165-0173(97)00023-4
   GREEN WR, 1993, OPHTHALMOLOGY, V100, P1519
   Haan MN, 1999, JAMA-J AM MED ASSOC, V282, P40, DOI 10.1001/jama.282.1.40
   HINTON DR, 1986, NEW ENGL J MED, V315, P485, DOI 10.1056/NEJM198608213150804
   HIXSON JE, 1990, J LIPID RES, V31, P545
   Ives Diane G., 1995, Annals of Epidemiology, V5, P278, DOI 10.1016/1047-2797(94)00093-9
   Klaver CCW, 1998, AM J HUM GENET, V63, P200, DOI 10.1086/301901
   Klaver CCW, 1998, ARCH OPHTHALMOL-CHIC, V116, P653, DOI 10.1001/archopht.116.5.653
   Klaver CCW, 1999, AM J EPIDEMIOL, V150, P963
   KLEIN R, 1993, AM J EPIDEMIOL, V137, P190, DOI 10.1093/oxfordjournals.aje.a116659
   Klein R, 2003, OPHTHALMOLOGY, V110, P25, DOI 10.1016/S0161-6420(02)01565-8
   Klein R, 1997, OPHTHALMOLOGY, V104, P1804, DOI 10.1016/S0161-6420(97)30023-2
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   KLEIN R, 1993, OPHTHALMOLOGY, V100, P406
   Kuller LH, 1998, STROKE, V29, P388, DOI 10.1161/01.STR.29.2.388
   Kuller LH, 2003, NEUROEPIDEMIOLOGY, V22, P13, DOI 10.1159/000067109
   Lopez OL, 2003, NEUROEPIDEMIOLOGY, V22, P1, DOI 10.1159/000067110
   MCKHANN G, 1984, NEUROLOGY, V34, P939, DOI 10.1212/WNL.34.7.939
   MITCHELL P, 1995, OPHTHALMOLOGY, V102, P1450
   Mrak RE, 1997, J NEUROPATH EXP NEUR, V56, P1269, DOI 10.1097/00005072-199712000-00001
   Ott A, 1998, LANCET, V351, P1840, DOI 10.1016/S0140-6736(97)07541-7
   Pham TQ, 2006, GERONTOLOGY, V52, P353, DOI 10.1159/000094984
   ROBBINS J, 1995, J AM GERIATR SOC, V43, P855, DOI 10.1111/j.1532-5415.1995.tb05526.x
   RUSSELL EW, 1972, J CONSULT CLIN PSYCH, V39, P133, DOI 10.1037/h0033212
   SALTHOUSE TA, 1978, J GERONTOL, V33, P232, DOI 10.1093/geronj/33.2.232
   Sarks SH, 1999, BRIT J OPHTHALMOL, V83, P358, DOI 10.1136/bjo.83.3.358
   Skoog I, 1996, LANCET, V347, P1141, DOI 10.1016/S0140-6736(96)90608-X
   Snowdon DA, 1997, JAMA-J AM MED ASSOC, V277, P813, DOI 10.1001/jama.277.10.813
   Souied EH, 1998, AM J OPHTHALMOL, V125, P353, DOI 10.1016/S0002-9394(99)80146-9
   Tell G S, 1993, Ann Epidemiol, V3, P358, DOI 10.1016/1047-2797(93)90062-9
   TENG EL, 1987, J CLIN PSYCHIAT, V48, P314
   TIELSCH JM, 1995, NEW ENGL J MED, V332, P1205, DOI 10.1056/NEJM199505043321806
   Tikellis G, 2007, ARCH OPHTHALMOL-CHIC, V125, P68, DOI 10.1001/archopht.125.1.68
   Vingerling JR, 1995, EPIDEMIOL REV, V17, P347, DOI 10.1093/oxfordjournals.epirev.a036198
   Wechsler D, 1958, MEASUREMENT APPRAISA
   Wechsler D., 1981, WAIS R MANUAL
   Wong TY, 2006, ANN INTERN MED, V145, P98, DOI 10.7326/0003-4819-145-2-200607180-00007
   Wong TY, 2003, OPHTHALMOLOGY, V110, P658, DOI 10.1016/S0161-6420(02)01931-0
   Wong TY, 2002, AM J OPHTHALMOL, V134, P828
   Wong TY, 2002, BRIT J OPHTHALMOL, V86, P1007, DOI 10.1136/bjo.86.9.1007
NR 51
TC 80
Z9 81
U1 0
U2 6
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 0003-9950
EI 1538-3601
J9 ARCH OPHTHALMOL-CHIC
JI Arch. Ophthalmol.
PD MAY
PY 2009
VL 127
IS 5
BP 667
EP 673
DI 10.1001/archophthalmol.2009.30
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 442NK
UT WOS:000265847700012
PM 19433718
OA Bronze, Green Accepted
DA 2022-11-30
ER

PT J
AU Klein, R
   Klein, BEK
AF Klein, Ronald
   Klein, Barbara E. K.
TI Vasodilators, Blood Pressure-Lowering Medications, and Age-Related
   Macular Degeneration
SO OPHTHALMOLOGY
LA English
DT Article
ID BEAVER-DAM-EYE; VISUAL-ACUITY; CARDIOVASCULAR-DISEASE; 5-YEAR INCIDENCE;
   RISK-FACTORS; MACULOPATHY; POPULATION; AMD; PERIOD; FLOW
AB Objective: To examine the association of vasodilator and antihypertensive medication use with the incidence of age-related macular degeneration (AMD).
   Design: Longitudinal population-based study.
   Participants: Persons 43 to 86 years of age living in Beaver Dam, Wisconsin, from 1988 through 1990.
   Methods: Examinations were performed every 5 years over a 20-year period. There were 9676 total person-visits over the course of the study. Status of AMD was determined from grading retinal photographs.
   Main Outcome Measures: Incidence of AMD.
   Results: The 5-year incidence of early AMD over the 20-year period was 8.4%; for late AMD, it was 1.4%; for pure geographic atrophy (GA), it was 0.6%; for exudative AMD, it was 0.9%; and for progression of AMD, it was 24.9%. While adjusting for age, gender, and other factors, using a vasodilator (hazard ratio [HR], 1.72; 95% confidence interval [CI], 1.25-2.38), particularly oral nitroglycerin (HR, 1.81; 95% CI, 1.14-2.90), was associated with an increased risk of early AMD. Using an oral beta-blocker was associated with an increased hazard of incident exudative AMD (HR, 1.71; 95% CI, 1.04-2.82), but not pure GA (HR, 0.51; 95% CI, 0.20-1.29) or progression of AMD (HR, 0.92; 95% CI, 0.67-1.28) over the 20-year period.
   Conclusions: Use of vasodilators is associated with a 72% increase in the hazard of incidence of early AMD, and use of oral beta-blockers is associated with a 71% increase in the hazard of incident exudative AMD. If these findings are replicated, it may have implications for care of older adults because vasodilators and oral beta-blockers are drugs that are used commonly by older persons. (C) 2014 by the American Academy of Ophthalmology.
C1 [Klein, Ronald; Klein, Barbara E. K.] Univ Wisconsin, Dept Ophthalmol & Visual Sci, Sch Med & Publ Hlth, Madison, WI 53726 USA.
C3 University of Wisconsin System; University of Wisconsin Madison
RP Klein, R (通讯作者)，Univ Wisconsin, Dept Ophthalmol & Visual Sci, Sch Med & Publ Hlth, 610 North Walnut St,4th Floor WARF, Madison, WI 53726 USA.
EM kleinr@epi.ophth.wisc.edu
FU National Institutes of Health, Bethesda, Maryland [EY06594]; Research to
   Prevent Blindness, Inc, New York, New York; National Eye Institute;
   NATIONAL EYE INSTITUTE [U10EY006594] Funding Source: NIH RePORTER
FX Supported by the National Institutes of Health, Bethesda, Maryland (
   grant no.: EY06594 (B.E.K.K., R.K.). The National Eye Institute provided
   funding for entire study, including collection and analyses of data.
   Additional support was provided by an unrestricted grant from Research
   to Prevent Blindness, Inc, New York, New York. Neither funding
   organization had any role in the design and conduct of the study;
   collection, management, analysis, or interpretation of the data; or
   preparation, review, or approval of the manuscript.
CR BETTMAN J W, 1962, Trans Am Acad Ophthalmol Otolaryngol, V66, P480
   Chaitman BR, 2005, CAN J CARDIOL, V21, P1031
   FRIEDMAN E, 1995, OPHTHALMOLOGY, V102, P640, DOI 10.1016/S0161-6420(95)30974-8
   Friedman E, 2004, BRIT J OPHTHALMOL, V88, P161, DOI 10.1136/bjo.2003.036277
   GRUNWALD JE, 1986, INVEST OPHTH VIS SCI, V27, P1713
   Grunwald JE, 1998, INVEST OPHTH VIS SCI, V39, P385
   Grunwald JE, 2005, INVEST OPHTH VIS SCI, V46, P1033, DOI 10.1167/iovs.04-1050
   Gu QP, 2006, CIRCULATION, V113, P213, DOI 10.1161/CIRCULATIONAHA.105.542290
   Hirvela H, 1996, OPHTHALMOLOGY, V103, P871, DOI 10.1016/S0161-6420(96)30593-9
   Hyman L, 2000, ARCH OPHTHALMOL-CHIC, V118, P351, DOI 10.1001/archopht.118.3.351
   Kaiserman I, 2005, J GLAUCOMA, V14, P157, DOI 10.1097/01.ijg.0000151889.59165.3d
   Klein R, 1997, OPHTHALMOLOGY, V104, P7, DOI 10.1016/S0161-6420(97)30368-6
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Klein R, 2001, OPHTHALMOLOGY, V108, P1757, DOI 10.1016/S0161-6420(01)00769-2
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1310
   Klein R, 1996, OPHTHALMOLOGY, V103, P1169, DOI 10.1016/S0161-6420(96)30526-5
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   Klein R, 2001, ARCH OPHTHALMOL-CHIC, V119, P1354
   Klein R, 1995, BEAVER DAY EYE STUDY, P59
   Klein R, 1991, NATL TECHNICAL INFOR, P1
   Klein R, 1991, BEAVER DAM EYE STUDY, P75
   Klein R, 2007, AM J OPHTHALMOL, V143, P473, DOI 10.1016/j.ajo.2006.11.058
   Klein R, 2006, AM J OPHTHALMOL, V142, P539, DOI 10.1016/j.ajo.2006.06.015
   Klein R, 2014, OPHTHAL EPIDEMIOL, V21, P14, DOI 10.3109/09286586.2013.867512
   Klein R, 2013, OPHTHALMOLOGY, V120, P1210, DOI 10.1016/j.ophtha.2012.11.041
   Klein R, 2013, JAMA OPHTHALMOL, V131, P383, DOI 10.1001/jamaophthalmol.2013.713
   KORNZWEIG AL, 1959, AM J OPHTHALMOL, V48, P22, DOI 10.1016/0002-9394(59)90238-7
   LAWS HW, 1964, CAN MED ASSOC J, V91, P325
   Marmor MF, 1999, SURV OPHTHALMOL, V44, P153, DOI 10.1016/S0039-6257(99)00079-X
   Masson P, 2005, UROL CLIN N AM, V32, P511, DOI 10.1016/j.ucl.2005.08.012
   Metelitsina TI, 2005, EXP EYE RES, V81, P159, DOI 10.1016/j.exer.2005.01.017
   NICHOLLS JVV, 1952, AM J OPHTHALMOL, V35, P1753, DOI 10.1016/0002-9394(52)92014-X
   Sato E, 2006, EYE, V20, P697, DOI 10.1038/sj.eye.6701951
   Van Leeuwen R, 2004, OPHTHALMOLOGY, V111, P1169, DOI 10.1016/j.ophtha.2003.10.024
NR 34
TC 20
Z9 25
U1 0
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0161-6420
EI 1549-4713
J9 OPHTHALMOLOGY
JI Ophthalmology
PD AUG
PY 2014
VL 121
IS 8
BP 1604
EP 1611
DI 10.1016/j.ophtha.2014.03.005
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA AO2KR
UT WOS:000341151100025
PM 24793737
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Osborn, MP
   Park, Y
   Parks, MB
   Burgess, LG
   Uppal, K
   Lee, KC
   Jones, DP
   Brantley, MA
AF Osborn, Melissa P.
   Park, Youngja
   Parks, Megan B.
   Burgess, L. Goodwin
   Uppal, Karan
   Lee, Kichun
   Jones, Dean P.
   Brantley, Milam A., Jr.
TI Metabolome-Wide Association Study of Neovascular Age-Related Macular
   Degeneration
SO PLOS ONE
LA English
DT Article
ID OXIDATIVE STRESS; VITAMIN-D; MARKERS; PATHOGENESIS; BIOMARKERS; DISEASE;
   PEPT2; ACID
AB Purpose: To determine if plasma metabolic profiles can detect differences between patients with neovascular age-related macular degeneration (NVAMD) and similarly-aged controls.
   Methods: Metabolomic analysis using liquid chromatography with Fourier-transform mass spectrometry (LC-FTMS) was performed on plasma samples from 26 NVAMD patients and 19 controls. Data were collected from mass/charge ratio (m/z) 85 to 850 on a Thermo LTQ-FT mass spectrometer, and metabolic features were extracted using an adaptive processing software package. Both non-transformed and log2 transformed data were corrected using Benjamini and Hochberg False Discovery Rate (FDR) to account for multiple testing. Orthogonal Partial Least Squares-Discriminant Analysis was performed to determine metabolic features that distinguished NVAMD patients from controls. Individual m/z features were matched to the Kyoto Encyclopedia of Genes and Genomes database and the Metlin metabolomics database, and metabolic pathways associated with NVAMD were identified using MetScape.
   Results: Of the 1680 total m/z features detected by LC-FTMS, 94 unique m/z features were significantly different between NVAMD patients and controls using FDR (q = 0.05). A comparison of these features to those found with log2 transformed data (n = 132, q = 0.2) revealed 40 features in common, reaffirming the involvement of certain metabolites. Such metabolites included di- and tripeptides, covalently modified amino acids, bile acids, and vitamin D-related metabolites. Correlation analysis revealed associations among certain significant features, and pathway analysis demonstrated broader changes in tyrosine metabolism, sulfur amino acid metabolism, and amino acids related to urea metabolism.
   Conclusions: These data suggest that metabolomic analysis can identify a panel of individual metabolites that differ between NVAMD cases and controls. Pathway analysis can assess the involvement of certain metabolic pathways, such as tyrosine and urea metabolism, and can provide further insight into the pathophysiology of AMD.
C1 [Osborn, Melissa P.; Parks, Megan B.; Burgess, L. Goodwin; Brantley, Milam A., Jr.] Vanderbilt Univ, Ctr Med, Vanderbilt Eye Inst, Nashville, TN 37232 USA.
   [Park, Youngja; Uppal, Karan; Jones, Dean P.] Emory Univ, Sch Med, Dept Med, Atlanta, GA USA.
   [Lee, Kichun] Hanyang Univ, Dept Ind Engn, Seoul 133791, South Korea.
C3 Vanderbilt University; Emory University; Hanyang University
RP Brantley, MA (通讯作者)，Vanderbilt Univ, Ctr Med, Vanderbilt Eye Inst, Nashville, TN 37232 USA.
EM milam.brantley@vanderbilt.edu
OI Uppal, Karan/0000-0001-5985-1668; Park, Youngja/0000-0002-1310-148X
FU National Institutes of Health [ES016731]; NIH [AG038746]; American
   Geriatrics Society; Carl M. & Mildred A. Reeves Foundation [P30
   EY08126]; Research to Prevent Blindness; NATIONAL EYE INSTITUTE
   [P30EY008126] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF
   ENVIRONMENTAL HEALTH SCIENCES [P01ES016731] Funding Source: NIH
   RePORTER; NATIONAL INSTITUTE ON AGING [R01AG038746] Funding Source: NIH
   RePORTER
FX Funding Sources: National Institutes of Health Grant ES016731 (DPJ), NIH
   Grant AG038746 (DPJ), Jahnigen Career Development Award from the
   American Geriatrics Society (MAB), Carl M. & Mildred A. Reeves
   Foundation (MAB), Core Grant P30 EY08126 to Vanderbilt University, and
   an unrestricted departmental grant to Vanderbilt University from
   Research to Prevent Blindness. The funders had no role in study design,
   data collection and analysis, decision to publish, or preparation of the
   manuscript.
CR Asiago VM, 2010, CANCER RES, V70, P8309, DOI 10.1158/0008-5472.CAN-10-1319
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   Beauchet O, 2011, J AM GERIATR SOC, V59, P568, DOI 10.1111/j.1532-5415.2010.03299.x
   Berger UV, 1999, ANAT EMBRYOL, V199, P439, DOI 10.1007/s004290050242
   Brantley MA, 2012, OXID STRESS APPL BAS, P367, DOI 10.1007/978-1-61779-606-7_18
   BRESSLER NM, 1988, SURV OPHTHALMOL, V32, P375, DOI 10.1016/0039-6257(88)90052-5
   Brito MA, 2008, NEUROTOXICOLOGY, V29, P259, DOI 10.1016/j.neuro.2007.11.002
   Brownlee M, 2005, DIABETES, V54, P1615, DOI 10.2337/diabetes.54.6.1615
   Caudle WM, 2010, EXPERT REV NEUROTHER, V10, P925, DOI 10.1586/ERN.10.54
   Chang CC, 2011, ACM T INTEL SYST TEC, V2, DOI 10.1145/1961189.1961199
   Chen QY, 2012, PLOS ONE, V7, DOI [10.1371/journal.pone.0042971, 10.1371/journal.pone.0037149]
   Chen YH, 2010, MOL INTERV, V10, P271, DOI 10.1124/mi.10.5.4
   Drack AV, 2012, INVEST OPHTH VIS SCI, V53, P100, DOI 10.1167/iovs.11-8544
   Dunn WB, 2007, METABOLOMICS, V3, P413, DOI 10.1007/s11306-007-0063-5
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Graffe A, 2012, J AM GERIATR SOC, V60, P1367, DOI 10.1111/j.1532-5415.2012.04015.x
   Gu XR, 2003, J BIOL CHEM, V278, P42027, DOI 10.1074/jbc.M305460200
   HYMAN LG, 1983, AM J EPIDEMIOL, V118, P213, DOI 10.1093/oxfordjournals.aje.a113629
   Johnson JM, 2010, ANALYST, V135, P2864, DOI 10.1039/c0an00333f
   Jones DP, 2012, ANNU REV NUTR, V32, P183, DOI 10.1146/annurev-nutr-072610-145159
   Kamal MA, 2008, DRUG METAB PHARMACOK, V23, P236, DOI 10.2133/dmpk.23.236
   Klein R, 2003, ARCH OPHTHALMOL-CHIC, V121, P674, DOI 10.1001/archopht.121.5.674
   Klein R, 2009, ARCH OPHTHALMOL-CHIC, V127, P193, DOI 10.1001/archophthalmol.2008.551
   Lin L, 2011, J PROTEOME RES, V10, P1396, DOI 10.1021/pr101161u
   Mantell DJ, 2000, CIRC RES, V87, P214, DOI 10.1161/01.RES.87.3.214
   Mantopoulos D, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024245
   Millen AE, 2011, ARCH OPHTHALMOL-CHIC, V129, P481, DOI 10.1001/archophthalmol.2011.48
   Mora JR, 2008, NAT REV IMMUNOL, V8, P685, DOI 10.1038/nri2378
   Oakman C, 2011, ANN ONCOL, V22, P1295, DOI 10.1093/annonc/mdq606
   OKAJIMA K, 1985, J LAB CLIN MED, V105, P132
   Parekh N, 2007, ARCH OPHTHALMOL-CHIC, V125, P661, DOI 10.1001/archopht.125.5.661
   Park S, 2012, PHARM BIOL, V50, P582
   Rochtchina E, 2007, AM J OPHTHALMOL, V143, P344, DOI 10.1016/j.ajo.2006.08.032
   Roede JR, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033020
   Soltow QA, 2013, METABOLOMICS, V9, pS132, DOI 10.1007/s11306-011-0332-1
   Staels B, 2009, DIABETES CARE, V32, pS237, DOI 10.2337/dc09-S355
   Uppal K, 2013, BMC BIOINFORMATICS, V14, DOI 10.1186/1471-2105-14-15
   Vapnik VN, 1999, IEEE T NEURAL NETWOR, V10, P988, DOI 10.1109/72.788640
   Wang TJ, 2011, NAT MED, V17, P448, DOI 10.1038/nm.2307
   Woo SJ, 2010, J OCUL PHARMACOL TH, V26, P223, DOI 10.1089/jop.2010.0012
   Xu L, 2013, INVEST OPHTH VIS SCI, V54, P1616, DOI 10.1167/iovs.12-10260
   Yu TW, 2009, BIOINFORMATICS, V25, P1930, DOI 10.1093/bioinformatics/btp291
NR 42
TC 85
Z9 89
U1 0
U2 25
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD AUG 27
PY 2013
VL 8
IS 8
AR e72737
DI 10.1371/journal.pone.0072737
PG 10
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA 210FR
UT WOS:000323815200055
PM 24015273
OA Green Submitted, gold, Green Published
DA 2022-11-30
ER

PT J
AU Wood, A
   Binns, A
   Margrain, T
   Drexler, W
   Povazay, B
   Esmaeelpour, M
   Sheen, N
AF Wood, Ashley
   Binns, Alison
   Margrain, Tom
   Drexler, Wolfgang
   Povazay, Boris
   Esmaeelpour, Marieh
   Sheen, Nik
TI Retinal and Choroidal Thickness in Early Age-Related Macular
   Degeneration
SO AMERICAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID OPTICAL COHERENCE TOMOGRAPHY; OCULAR BLOOD-FLOW; OCT; VISUALIZATION;
   PENETRATION; RESOLUTION; CHORIOCAPILLARIS; CLASSIFICATION; SUBANALYSIS;
   SYSTEM
AB PURPOSE: To compare retinal thickness and choroidal thickness at increasing retinal eccentricity in individuals with early age-related macular degeneration (AMD) and in healthy controls using enhanced choroidal penetration, 3-dimensional optical coherence tomography at 1060 nm.
   DESIGN: Cross-sectional study.
   METHODS: Individuals with early AMD (n = 16; mean age, 71.6 +/- 8.5 years) and a comparison group of healthy controls (n = 16; 67.6 +/- 5.4 years) were recruited. Three-dimensional (20 degrees x 20 degrees) long-wavelength optical coherence tomography (1060 nm) images (approximately 8-mu m axial resolution; 47 000 A scans/second, centered on the fovea) were obtained from all participants after pupil dilation. Retinal thickness was measured between the inner limiting membrane and the retinal pigment epithelium. Choroidal thickness was measured between the retinal pigment epithelium and the choroid-scleral interface. Thickness measurements were obtained subfoveally and at 0.5-mm intervals to a maximum of 2.0 mm nasally, temporally, superiorly, and inferiorly. The main outcome measures were retinal and choroidal thickness (measured in micrometers) at different eccentricities on vertical and horizontal meridians.
   RESULTS: Mean retinal thickness was reduced significantly in the group of participants with early AMD compared with the control group at multiple locations within 2.0 mm of the fovea. This difference was most significant at the fovea, where the mean retinal thickness of the early AMD group was 179 +/- 27 mu m and that of the control group was 202 +/- 18 mu m (P = .008). There was no significant difference in choroidal thickness between groups at any location.
   CONCLUSIONS: Retinal thickness is reduced in early AMD, but choroidal thickness seems to be unaffected by the early disease process. (Am J Ophthalmol 2011; 152:1030-1038. (C) 2011 by Elsevier Inc. All rights reserved.)
C1 [Wood, Ashley; Binns, Alison; Margrain, Tom; Drexler, Wolfgang; Povazay, Boris; Esmaeelpour, Marieh; Sheen, Nik] Cardiff Univ, Sch Optometry & Vis Sci, Cardiff CF24 4LU, S Glam, Wales.
C3 Cardiff University
RP Binns, A (通讯作者)，Cardiff Univ, Sch Optometry & Vis Sci, Cardiff CF24 4LU, S Glam, Wales.
EM binnsam@cardiff.ac.uk
RI Považay, Boris/F-6258-2012
OI Binns, Alison/0000-0001-8621-498X; Drexler,
   Wolfgang/0000-0002-3557-6398; Margrain, Tom/0000-0003-1280-0809; Sheen,
   Nik/0000-0003-2746-8626
FU Cardiff University, Cardiff, Wales [FP6-IST-NMP-2 STREPT (017128,
   NanoUB)]; Action Medical Research (AMR), West Sussex, United Kingdom
   [AP1110]
FX ALL AUTHORS HAVE COMPLETED AND SUBMITTED THE ICMJE FORM FOR DISCLOSURE
   OF POTENTIAL CONFLICTS OF INTEREST. The sponsor or funding organization
   had no role in the design or conduct of this research. The authors
   indicate no financial conflict of interest. Publication of this article
   was supported by Grant FP6-IST-NMP-2 STREPT (017128, NanoUB) from
   Cardiff University, Cardiff, Wales; and Grant AP1110 from Action Medical
   Research (AMR), West Sussex, United Kingdom. Involved in Design of study
   (A.W., A.B., T.M., N.S., B.P., W,D.); Conduct of study (A.W., T.M.,
   A.B., N.S.); Data collection (A.W.); Data analysis, management, and
   interpretation (A.W., T.M., N.S., A.B., M.E.); and Review and approval
   of manuscript (A.W., A.B., TM., W.D., B.P., ME., N.S.). The study
   adhered to the tenets of the Declaration of Helsinki, and institutional
   review board/ethics committee approval was obtained prospectively from
   the South East Wales Regional Ethics Committee Si. School of Optometry
   and Vision Sciences Research Ethics Committee. Informed consent was
   obtained from all participants.
CR Age-Related Eye Dis Study Res Grp, 2001, AM J OPHTHALMOL, V132, P668
   Altman D. G., 1991, PRACTICAL STAT MED R, P1
   ANSI, 2000, SAF US LAS SAF US OP, P168
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Blair MP, 2010, OPHTHAL SURG LAS IM, V41, P175, DOI 10.3928/15428877-20100303-04
   BLAND JM, 1995, BRIT MED J, V310, P170, DOI 10.1136/bmj.310.6973.170
   BLAND JM, 1986, LANCET, V1, P307, DOI 10.1016/s0140-6736(86)90837-8
   Bunce C, 2006, BMC PUBLIC HEALTH, V6, DOI 10.1186/1471-2458-6-58
   Cheng SCK, 2010, OPHTHAL PHYSL OPT, V30, P776, DOI 10.1111/j.1475-1313.2010.00788.x
   Chung SE, 2011, OPHTHALMOLOGY, V118, P840, DOI 10.1016/j.ophtha.2010.09.012
   CHYLACK LT, 1993, ARCH OPHTHALMOL-CHIC, V111, P831, DOI 10.1001/archopht.1993.01090060119035
   Ciulla TA, 1999, AM J OPHTHALMOL, V128, P75, DOI 10.1016/S0002-9394(99)00061-6
   Curcio CA, 1996, INVEST OPHTH VIS SCI, V37, P1236
   Drexler W, 2008, PROG RETIN EYE RES, V27, P45, DOI 10.1016/j.preteyeres.2007.07.005
   Esmaeelpour M, 2010, INVEST OPHTH VIS SCI, V51, P5260, DOI 10.1167/iovs.10-5196
   Ferris FL, 2005, ARCH OPHTHALMOL-CHIC, V123, P1570
   FRIEDMAN E, 1995, OPHTHALMOLOGY, V102, P640, DOI 10.1016/S0161-6420(95)30974-8
   Ghazi NG, 2009, AM J OPHTHALMOL, V148, P90, DOI 10.1016/j.ajo.2009.02.017
   Harris A, 1999, PROG RETIN EYE RES, V18, P669
   Ikuno Y, 2010, INVEST OPHTH VIS SCI, V51, P2173, DOI 10.1167/iovs.09-4383
   Ikuno Y, 2009, INVEST OPHTH VIS SCI, V50, P3876, DOI 10.1167/iovs.08-3325
   Joeres S, 2007, INVEST OPHTH VIS SCI, V48, P4300, DOI 10.1167/iovs.07-0179
   Kakinoki M, 2009, OPHTHAL SURG LAS IM, V40, P135, DOI 10.3928/15428877-20090301-09
   Kaluzny JJ, 2009, OPHTHAL SURG LAS IM, V40, P102, DOI 10.3928/15428877-20090301-10
   Kashani AH, 2009, INVEST OPHTH VIS SCI, V50, P3366, DOI 10.1167/iovs.08-2691
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Legarreta JE, 2008, OPHTHAL SURG LAS IM, V39, pS43, DOI 10.3928/15428877-20080715-02
   Malamos P, 2009, INVEST OPHTH VIS SCI, V50, P4926, DOI 10.1167/iovs.09-3610
   Manjunath V, 2010, AM J OPHTHALMOL, V150, P325, DOI 10.1016/j.ajo.2010.04.018
   Margolis R, 2009, AM J OPHTHALMOL, V147, P811, DOI 10.1016/j.ajo.2008.12.008
   Matthes R, 2000, HEALTH PHYS, V79, P431
   McLeod DS, 2009, INVEST OPHTH VIS SCI, V50, P4982, DOI 10.1167/iovs.09-3639
   Menke MN, 2005, OPHTHAL SURG LAS IM, V36, P310, DOI 10.3928/1542-8877-20050701-10
   Mitchell P, 2010, BRIT J OPHTHALMOL, V94, P2, DOI 10.1136/bjo.2009.159160
   Povazay B, 2003, OPT EXPRESS, V11, P1980, DOI 10.1364/OE.11.001980
   Povazay B, 2007, J BIOMED OPT, V12, DOI 10.1117/1.2773728
   Povazay B, 2009, OPT EXPRESS, V17, P4134, DOI 10.1364/OE.17.004134
   Povazay B, 2009, INVEST OPHTH VIS SCI, V50, P1856, DOI 10.1167/iovs.08-2869
   RAMRATTAN RS, 1994, INVEST OPHTH VIS SCI, V35, P2857
   Roquet W, 2004, BRIT J OPHTHALMOL, V88, P638, DOI 10.1136/bjo.2003.017632
   Sankoh AJ, 1997, STAT MED, V16, P2529, DOI 10.1002/(SICI)1097-0258(19971130)16:22<2529::AID-SIM692>3.0.CO;2-J
   SARKS SH, 1976, BRIT J OPHTHALMOL, V60, P324, DOI 10.1136/bjo.60.5.324
   Schuman SG, 2009, OPHTHALMOLOGY, V116, P488, DOI 10.1016/j.ophtha.2008.10.006
   Taban M, 2010, OPHTHAL SURG LAS IM, V41, P166, DOI 10.3928/15428877-20100303-03
   United Nations (UN), 2005, WORLD POP PROSP 2004
   Unterhuber A, 2005, OPT EXPRESS, V13, P3252, DOI 10.1364/OPEX.13.003252
   Yamaguchi Yumiko, 2000, Rinsho Ganka, V54, P941
   Yasuno Y, 2009, INVEST OPHTH VIS SCI, V50, P405, DOI 10.1167/iovs.08-2272
   Yuda K, 2010, GRAEF ARCH CLIN EXP, V248, P353, DOI 10.1007/s00417-009-1222-3
NR 49
TC 112
Z9 115
U1 0
U2 20
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0002-9394
EI 1879-1891
J9 AM J OPHTHALMOL
JI Am. J. Ophthalmol.
PD DEC
PY 2011
VL 152
IS 6
BP 1030
EP 1038
DI 10.1016/j.ajo.2011.05.021
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 857JN
UT WOS:000297714900018
PM 21851922
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Casparis, H
   Lindsley, K
   Bressler, NB
AF Casparis, Heather
   Lindsley, Kristina
   Bressler, Neil B.
TI Surgery for cataracts in people with age-related macular degeneration
SO COCHRANE DATABASE OF SYSTEMATIC REVIEWS
LA English
DT Review
ID QUALITY-OF-LIFE; INTRAOCULAR-LENS; CIGARETTE-SMOKING; RISK-FACTORS;
   BEAVER DAM; MACULOPATHY; RANIBIZUMAB; EXTRACTION
AB Background
   Cataract and age-related macular degeneration (AMD) are significant causes of decreased vision in the elderly that often occur simultaneously. Although cataract surgery is an effective treatment for cataract-induced visual loss, some clinicians suspect that such an intervention may increase the risk of progression of underlying AMD and thus have deleterious effects on vision.
   Objectives
   The objective of this review was to evaluate the effectiveness and safety of cataract surgery in eyes with AMD.
   Search strategy
   We searched the Cochrane Central Register of Controlled Trials (CENTRAL) (which contains the Cochrane Eyes and Vision Group Trials Register) (The Cochrane Library, Issue 4, 2008), MEDLINE (January 1966 to November 2008), EMBASE (January 1980 to November 2008) and Latin American and Caribbean Literature on Health Sciences (LILACS) (January 1982 to November 2008). There were no language or date restrictions in the search for trials. The electronic databases were last searched on 4 November 2008.
   Selection criteria
   We planned to include randomized controlled trials (RCTs) and quasi-randomized trials of eyes affected by both cataract and AMD in which cataract surgery would be compared to no surgery.
   Data collection and analysis
   Two authors independently evaluated the search results against the inclusion and exclusion criteria. Discrepancies were resolved by discussion.
   Main results
   We found no RCTs, thus no analysis was conducted. Evidence was limited to non-randomized clinical trials and prospective cohort and case-control studies.
   Authors' conclusions
   At this time, it is not possible to draw reliable conclusions from the available data to determine whether cataract surgery is beneficial or harmful in people with AMD. Physicians will have to make practice decisions based on best clinical judgement until controlled trials are conducted and their findings published.
C1 [Casparis, Heather] Jules Gonin Eye Hosp, Unites Chirurg Vitreoretinienne & Retine Med, CH-1004 Lausanne, Switzerland.
   [Lindsley, Kristina] Johns Hopkins Bloomberg Sch Publ Hlth, Baltimore, MD USA.
   [Bressler, Neil B.] Johns Hopkins Univ, Baltimore, MD USA.
C3 Johns Hopkins University; Johns Hopkins Bloomberg School of Public
   Health; Johns Hopkins University
RP Casparis, H (通讯作者)，Jules Gonin Eye Hosp, Unites Chirurg Vitreoretinienne & Retine Med, 15 Av France, CH-1004 Lausanne, Switzerland.
EM Heather.BartlettCasparis@fa2.ch
FU NATIONAL EYE INSTITUTE [N01EY021003] Funding Source: NIH RePORTER
CR *AG REL EY DIS STU, 2001, OPHTHALMOLOGY, V119, P1471
   *AM AC OPHTH, 2006, PREF PRACT PATT
   Anand R, 2000, OPHTHALMOLOGY, V107, P2224
   [Anonymous], 1991, Arch Ophthalmol, V109, P1109
   Armbrecht AM, 2003, J CATARACT REFR SURG, V29, P686, DOI 10.1016/S0886-3350(02)01650-4
   Armbrecht AM, 2000, BRIT J OPHTHALMOL, V84, P1343, DOI 10.1136/bjo.84.12.1343
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Blumenkranz MS, 2001, ARCH OPHTHALMOL-CHIC, V119, P198
   Bockelbrink A, 2008, SURV OPHTHALMOL, V53, P359, DOI 10.1016/j.survophthal.2008.04.001
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   BRUNNER S, 2001, SPEKTRUM AUGENHEILKU, V15, P178
   Buch H, 2005, ACTA OPHTHALMOL SCAN, V83, P409, DOI 10.1111/J.1600-0420.2005.00492.x
   Chew EY., 2001, EVIDENCE BASED EYE C, V2, P136
   Cugati S, 2006, OPHTHALMOLOGY, V113, P2020, DOI 10.1016/j.ophtha.2006.05.047
   D'Amico DJ, 2006, OPHTHALMOLOGY, V113, P992, DOI 10.1016/j.ophtha.2006.02.027
   Donoso LA, 2006, SURV OPHTHALMOL, V51, P137, DOI 10.1016/j.survophthal.2005.12.001
   Evans JR, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000254.pub2
   FERRIS FL, 1984, ARCH OPHTHALMOL-CHIC, V102, P1640
   FINE SL, 1982, ARCH OPHTHALMOL-CHIC, V100, P912
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Glanville JM, 2006, J MED LIBR ASSOC, V94, P130
   GRASSO CM, 2000, OPHTHALMOLOGY, V107, P2040
   Higgins JPT, 2008, COCHRANE HDB SYSTEMA
   Hiller R, 1997, ARCH OPHTHALMOL-CHIC, V115, P1113, DOI 10.1001/archopht.1997.01100160283003
   Jacques PF, 2005, ARCH OPHTHALMOL-CHIC, V123, P517, DOI 10.1001/archopht.123.4.517
   Kaiserman I, 2007, OPHTHALMOLOGY, V114, P278, DOI 10.1016/j.ophtha.2006.10.019
   Kertes PJ., 2003, EVIDENCE BASED EYE C, V4, P110
   KLEIN R, 1995, OPHTHALMOLOGY, V102, P371
   Klein R, 2002, ARCH OPHTHALMOL-CHIC, V120, P1551, DOI 10.1001/archopht.120.11.1551
   Lamoureux EL, 2007, OPTOMETRY VISION SCI, V84, P683, DOI 10.1097/OPX.0b013e31812f755f
   Lundstrom M, 2002, BRIT J OPHTHALMOL, V86, P1330, DOI 10.1136/bjo.86.12.1330
   Pollack A, 1998, OPHTHALMIC SURG LAS, V29, P286
   Pollack A, 1996, OPHTHALMOLOGY, V103, P1546, DOI 10.1016/S0161-6420(96)30464-8
   POWE NR, 1994, ARCH OPHTHALMOL-CHIC, V112, P239, DOI 10.1001/archopht.1994.01090140115033
   Prajna  NV, 1998, AM J OPHTHALMOL, V125, P14, DOI 10.1016/S0002-9394(99)80230-X
   Riaz Y, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001323.pub2
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Seddon JM, 2006, ARCH OPHTHALMOL-CHIC, V124, P995, DOI 10.1001/archopht.124.7.995
   Shuttleworth GN, 1998, BRIT J OPHTHALMOL, V82, P611, DOI 10.1136/bjo.82.6.611
   Siegfried N, 2009, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003362.pub2
   Sutter FKP, 2007, INVEST OPHTH VIS SCI, V48, P1472, DOI 10.1167/iovs.06-0766
   The Nordic Cochrane Centre The Cochrane Collaboration, 2008, COCHR COLL REV MAN R
   Wang JJ, 2003, OPHTHALMOLOGY, V110, P1960, DOI 10.1016/S0161-6420(03)00816-9
   WEST SK, 1989, ARCH OPHTHALMOL-CHIC, V107, P875, DOI 10.1001/archopht.1989.01070010897038
   World Health Organization, 2004, MAGN CAUS VIS IMP FA
NR 46
TC 7
Z9 7
U1 0
U2 4
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1469-493X
EI 1361-6137
J9 COCHRANE DB SYST REV
JI Cochrane Database Syst Rev.
PY 2009
IS 1
AR CD006757
DI 10.1002/14651858.CD006757.pub2
PG 16
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA 396KZ
UT WOS:000262591900082
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Shin, IH
   Lee, WH
   Lee, JJ
   Jo, YJ
   Kim, JY
AF Shin, Il-Hwan
   Lee, Woo-Hyuk
   Lee, Jong-Joo
   Jo, Young-Joon
   Kim, Jung-Yeul
TI THICKNESS OF THE MACULA, RETINAL NERVE FIBER LAYER, AND GANGLION
   CELL-INNER PLEXIFORM LAYER IN THE AGE-RELATED MACULAR DEGENERATION The
   Repeatability Study of Spectral Domain Optical Coherence Tomography
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE age-related macular degeneration; cirrus; ganglion cell-inner plexiform
   layer; optical coherence tomography; repeatability
ID EPIRETINAL MEMBRANE SURGERY; REPRODUCIBILITY; MACULOPATHY; PREVALENCE;
   PROGRESSION; GLAUCOMA; EYES; OCT
AB Purpose: To determine the repeatability of measuring the thickness of the central macula, retinal nerve fiber layer, and ganglion cell-inner plexiform layer (GC-IPL) using spectral domain optical coherence tomography (Cirrus HD-OCT) in eyes with age-related macular degeneration.
   Methods: One hundred and thirty-four eyes were included. The measurement repeatability was assessed by an experienced examiner who performed two consecutive measurements using a 512 x 128 macular cube scan and a 200 x 200 optic disk cube scan. To assess changes in macular morphology in patients with age-related macular degeneration, the patients were divided into the following three groups according to the central macular thickness (CMT): A group, CMT, 200 mm; B group, 200 mu m <= CMT, < 300 mu m; and C group, CMT > 300 mm.
   Results: Measurement repeatability was assessed using test-retest variability, a coefficient of variation, and an intraclass correlation coefficient. The mean measurement repeatability for the central macular, retinal nerve fiber layer, and GC-IPL thickness was high in the B group. The mean measurement repeatability for both the central macula and retinal nerve fiber layer thickness was high in the A and C groups, but was lower for the GCIPL thickness. The measurement repeatability for GC-IPL thickness was high in the B group, but low in the A group and in the C group.
   Conclusion: The automated measurement repeatability for GC-IPL thickness was significantly lower in patients with age-related macular degeneration with out of normal CMT range. The effect of changes in macular morphology should be considered when analyzing GC-IPL thicknesses in a variety of ocular diseases.
C1 [Shin, Il-Hwan; Lee, Woo-Hyuk; Lee, Jong-Joo; Jo, Young-Joon; Kim, Jung-Yeul] Chungnam Natl Univ, Coll Med, Dept Ophthalmol, Daejeon, South Korea.
   [Jo, Young-Joon; Kim, Jung-Yeul] Chungnam Natl Univ, Coll Med, Res Inst Med Sci, Daejeon, South Korea.
C3 Chungnam National University; Chungnam National University
RP Kim, JY (通讯作者)，Chungnam Natl Univ Hosp, Dept Ophthalmol, 640 Daesa Dong, Daejeon 301721, South Korea.
EM kimjy@cnu.ac.kr
OI Kim, Jung yeul/0000-0003-3679-1310
CR Abdelfattah NS, 2016, RETINA-J RET VIT DIS, V36, P1843, DOI 10.1097/IAE.0000000000001059
   Abdelfattah NS, 2016, INVEST OPHTH VIS SCI, V57, P1839, DOI 10.1167/iovs.15-18572
   Augood C, 2004, OPHTHAL EPIDEMIOL, V11, P117, DOI 10.1076/opep.11.2.117.28160
   Balducci N, 2015, BR J OPHTHALMOL
   Bland JM, 1996, BRIT MED J, V313, P744
   Blumenthal EZ, 2000, OPHTHALMOLOGY, V107, P2278, DOI 10.1016/S0161-6420(00)00341-9
   Bruyere E, 2015, AM J OPHTHALMOL, pS0002
   Vieira LMC, 2015, J NEURO-OPHTHALMOL, V35, P242, DOI 10.1097/WNO.0000000000000229
   Chen TC, 2005, ARCH OPHTHALMOL-CHIC, V123, P1715, DOI 10.1001/archopht.123.12.1715
   FERRIS FL, 1984, ARCH OPHTHALMOL-CHIC, V102, P1640
   Francoz M, 2014, BRIT J OPHTHALMOL, V98, P322, DOI 10.1136/bjophthalmol-2012-302242
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P532
   Fung AE, 2007, AM J OPHTHALMOL, V143, P566, DOI 10.1016/j.ajo.2007.01.028
   Gabriele ML, 2011, INVEST OPHTH VIS SCI, V52, P2425, DOI 10.1167/iovs.10-6312
   Garvin MK, 2009, IEEE T MED IMAGING, V28, P1436, DOI 10.1109/TMI.2009.2016958
   Giani A, 2012, RETINA-J RET VIT DIS, V32, P1007, DOI 10.1097/IAE.0b013e31822f5660
   Introini U, 2012, EYE, V26, P976, DOI 10.1038/eye.2012.75
   Kim JS, 2009, BRIT J OPHTHALMOL, V93, P1057, DOI 10.1136/bjo.2009.157875
   Kim JJ, 2014, BRIT J OPHTHALMOL, V98, P213, DOI 10.1136/bjophthalmol-2013-304349
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Kwon Yoon Hyung, 2014, Korean J Ophthalmol, V28, P386, DOI 10.3341/kjo.2014.28.5.386
   Lee EK, 2014, OPHTHALMOLOGY, V121, P1579, DOI 10.1016/j.ophtha.2014.02.010
   Lee HJ, 2015, INVEST OPHTH VIS SCI, V56, P4554, DOI 10.1167/iovs.15-16949
   Lee HJ, 2015, AM J OPHTHALMOL, V160, P283, DOI 10.1016/j.ajo.2015.05.015
   Leung CKS, 2009, OPHTHALMOLOGY, V116, P1257, DOI 10.1016/j.ophtha.2009.04.013
   Lim HB, 2015, INVEST OPHTH VIS SCI, V56, P6622, DOI 10.1167/iovs.15-17678
   MULLER R, 1994, STAT MED, V13, P2465, DOI 10.1002/sim.4780132310
   Mwanza JC, 2011, INVEST OPHTH VIS SCI, V52, P8323, DOI 10.1167/iovs.11-7962
   Nittala MG, 2012, INVEST OPHTH VIS SCI, V53, P8319, DOI 10.1167/iovs.12-10582
   Oberwahrenbrock T, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0137316
   Pron G, 2014, Ont Health Technol Assess Ser, V14, P1
   Resnikoff S, 2004, B WORLD HEALTH ORGAN, V82, P844
   Rickman CB, 2013, INVEST OPHTH VIS SCI, V54, pORSF68, DOI 10.1167/iovs.13-12757
   Song SJ, 2016, RETINA-J RET VIT DIS, V36, P305, DOI 10.1097/IAE.0000000000000705
   Tan CS, 2015, OSLI RETINA, V46, P172, DOI 10.3928/23258160-20150213-23
   VINGERLING JR, 1995, OPHTHALMOLOGY, V102, P205
   Zucchiatti I, 2015, AM J OPHTHALMOL, V160, P602, DOI 10.1016/j.ajo.2015.05.030
NR 37
TC 14
Z9 14
U1 1
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD FEB
PY 2018
VL 38
IS 2
BP 253
EP 262
DI 10.1097/IAE.0000000000001535
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA GB0KQ
UT WOS:000428735400011
PM 28141749
DA 2022-11-30
ER

PT J
AU Sitnilska, V
   Kersten, E
   Altay, L
   Schick, T
   Enders, P
   de Jong, EK
   Langmann, T
   Hoyng, CB
   den Hollander, AI
   Fauser, S
AF Sitnilska, Vasilena
   Kersten, Eveline
   Altay, Lebriz
   Schick, Tina
   Enders, Philip
   de Jong, Eiko K.
   Langmann, Thomas
   Hoyng, Carel B.
   den Hollander, Anneke, I
   Fauser, Sascha
TI Major Predictive Factors for Progression of Early to Late Age-Related
   Macular Degeneration
SO OPHTHALMOLOGICA
LA English
DT Article
DE Age-related macular degeneration; Progression; Risk factors;
   Hyperreflective foci; Genetic factors; Drusenoid pigment epithelial
   detachment
ID OPTICAL COHERENCE TOMOGRAPHY; COMPLEMENT ACTIVATION LEVELS; RETICULAR
   PSEUDODRUSEN; CHOROIDAL NEOVASCULARIZATION; DRUSEN VOLUME; RISK-FACTORS;
   FOLLOW-UP; FELLOW EYE; INTERMEDIATE; ASSOCIATION
AB Introduction: We present a prediction model for progression from early/intermediate to advanced age-related macular degeneration (AMD) within 5.9 years. Objectives: To evaluate the combined role of genetic, nongenetic, and phenotypic risk factors for conversion from early to late AMD over >= 5 years. Methods: Baseline phenotypic characteristics were evaluated based on color fundus photography, spectral-domain optical coherence tomography, and infrared images. Genotyping for 36 single-nucleotide polymorphisms as well as systemic lipid and complement measurements were performed. Multivariable backward logistic regression resulted in a final prediction model. Results and Conclusions: During a mean of 5.9 years of follow-up, 22.4% (n = 52) of the patients (n = 232) showed progression to late AMD. The multivariable prediction model included age, CFH variant rs1061170, pigment abnormalities, drusenoid pigment epithelial detachment (DPED), and hyperreflective foci (HRF). The model showed an area under the curve of 0.969 (95% confidence interval 0.948-0.990) and adequate calibration (Hosmer-Lemeshow test, p = 0.797). In addition to advanced age and carrying a CFH variant, pigment abnormalities, DPED, and HRF are relevant imaging biomarkers for conversion to late AMD. In clinical routine, an intensified monitoring of patients with a high-risk phenotypic profile may be suitable for the early detection of conversion to late AMD.
C1 [Sitnilska, Vasilena; Altay, Lebriz; Schick, Tina; Enders, Philip; Fauser, Sascha] Univ Cologne, Fac Med, Dept Ophthalmol, Cologne, Germany.
   [Sitnilska, Vasilena; Altay, Lebriz; Schick, Tina; Enders, Philip; Fauser, Sascha] Univ Hosp Cologne, Cologne, Germany.
   [Kersten, Eveline; de Jong, Eiko K.; Hoyng, Carel B.; den Hollander, Anneke, I] Radboud Univ Nijmegen, Med Ctr, Dept Ophthalmol, Donders Inst Brain Cognit & Behav, Nijmegen, Netherlands.
   [Langmann, Thomas] Univ Cologne, Dept Ophthalmol, Expt Immunol Eye, Cologne, Germany.
   [den Hollander, Anneke, I] Radboud Univ Nijmegen, Med Ctr, Dept Human Genet, Donders Inst Brain Cognit & Behav, Nijmegen, Netherlands.
   [Fauser, Sascha] Hoffmann La Roche AG, Basel, Switzerland.
C3 University of Cologne; University of Cologne; Radboud University
   Nijmegen; University of Cologne; Radboud University Nijmegen; Roche
   Holding
RP Altay, L (通讯作者)，Univ Hosp Cologne, Dept Ophthalmol, Kerpener Str 62, DE-50924 Cologne, Germany.
EM lebriz.altay@uk-koeln.de
RI Kersten, Eveline/P-8173-2015
OI Enders, Philip/0000-0002-9527-4957
FU European Union's Horizon 2020 research and innovation programme [634479]
FX This project received funding from the European Union's Horizon 2020
   research and innovation programme under grant agreement No. 634479
   (EYE-RISK).
CR Abdelfattah NS, 2016, INVEST OPHTH VIS SCI, V57, P1839, DOI 10.1167/iovs.15-18572
   Altay L, 2016, INVEST OPHTH VIS SCI, V57, P4315, DOI 10.1167/iovs.15-18855
   Anderson DH, 2002, AM J OPHTHALMOL, V134, P411, DOI 10.1016/S0002-9394(02)01624-0
   Cachulo L, 2011, OPHTHALMOLOGICA, V225, P144, DOI 10.1159/000321064
   Chan H, 2016, INVEST OPHTH VIS SCI, V57, P3058, DOI 10.1167/iovs.16-19487
   Christenbury JG, 2013, OPHTHALMOLOGY, V120, P1038, DOI 10.1016/j.ophtha.2012.10.018
   Colijn JM, 2017, OPHTHALMOLOGY, V124, P1753, DOI 10.1016/j.ophtha.2017.05.035
   Coscas G, 2013, OPHTHALMOLOGICA, V229, P32, DOI 10.1159/000342159
   de Sisternes L, 2014, INVEST OPHTH VIS SCI, V55, P7093, DOI 10.1167/iovs.14-14918
   Ding Y, 2017, GENETICS, V206, P119, DOI 10.1534/genetics.116.196998
   DOREY CK, 1989, INVEST OPHTH VIS SCI, V30, P1691
   Farwick A, 2010, INVEST OPHTH VIS SCI, V51, P731, DOI 10.1167/iovs.09-3953
   Ferrara D, 2017, INVEST OPHTH VIS SCI, V58, P3519, DOI 10.1167/iovs.17-21696
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Finger RP, 2016, OPHTHALMOLOGY, V123, P599, DOI 10.1016/j.ophtha.2015.10.029
   Folgar FA, 2016, OPHTHALMOLOGY, V123, P39, DOI 10.1016/j.ophtha.2015.09.016
   Fragiotta S, 2018, RETINA-J RET VIT DIS, V38, P245, DOI 10.1097/IAE.0000000000001540
   Framme C, 2010, INVEST OPHTH VIS SCI, V51, P5965, DOI 10.1167/iovs.10-5779
   Franceschi C, 2000, ANN NY ACAD SCI, V908, P244
   Fritsche LG, 2016, NAT GENET, V48, P134, DOI 10.1038/ng.3448
   Geerlings MJ, 2017, JAMA OPHTHALMOL, V135, P39, DOI 10.1001/jamaophthalmol.2016.4604
   Gliem M, 2015, OPHTHALMOLOGY, V122, P1555, DOI 10.1016/j.ophtha.2015.04.035
   Greferath U, 2016, OPHTHALMOLOGY, V123, P1320, DOI 10.1016/j.ophtha.2016.02.009
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Ho J, 2011, OPHTHALMOLOGY, V118, P687, DOI 10.1016/j.ophtha.2010.08.010
   Holz FG, 2017, OPHTHALMOLOGY, V124, P464, DOI 10.1016/j.ophtha.2016.12.002
   Hu XF, 2020, RETINA-J RET VIT DIS, V40, P1070, DOI 10.1097/IAE.0000000000002531
   Joachim N, 2015, OPHTHALMOLOGY, V122, P2482, DOI 10.1016/j.ophtha.2015.08.002
   Joachim NDL, 2015, JAMA OPHTHALMOL, V133, P698, DOI 10.1001/jamaophthalmol.2015.0498
   Jonasson F, 2014, OPHTHALMOLOGY, V121, P1766, DOI 10.1016/j.ophtha.2014.03.013
   Kaszubski PA, 2018, INT OPHTHALMOL, V38, P503, DOI 10.1007/s10792-017-0485-7
   Kersten E, 2018, SURV OPHTHALMOL, V63, P9, DOI 10.1016/j.survophthal.2017.05.003
   Klein ML, 2011, ARCH OPHTHALMOL-CHIC, V129, P1543, DOI 10.1001/archophthalmol.2011.216
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   Lauwen S, 2017, INVEST OPHTH VIS SCI, V58, pBIO88, DOI 10.1167/iovs.17-21809
   Nassisi M, 2019, OPHTHALMOLOGY, V126, P1667, DOI 10.1016/j.ophtha.2019.05.016
   Pang CE, 2015, OPHTHALMOLOGY, V122, P2316, DOI 10.1016/j.ophtha.2015.07.008
   Paun CC, 2016, SCI REP-UK, V6, DOI 10.1038/srep26568
   Paun CC, 2015, INVEST OPHTH VIS SCI, V56, P7766, DOI 10.1167/iovs.15-17035
   Perlee LT, 2013, OPHTHALMOLOGY, V120, P1880, DOI 10.1016/j.ophtha.2013.02.007
   Roquet W, 2004, BRIT J OPHTHALMOL, V88, P638, DOI 10.1136/bjo.2003.017632
   Sardell RJ, 2016, INVEST OPHTH VIS SCI, V57, P6107, DOI 10.1167/iovs.16-19519
   Schmidt-Erfurth U, 2018, INVEST OPHTH VIS SCI, V59, P3199, DOI 10.1167/iovs.18-24106
   Schreur V, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0206482
   Seddon JM, 2005, ARCH OPHTHALMOL-CHIC, V123, P321, DOI 10.1001/archopht.123.3.321
   Seddon JM, 2015, INVEST OPHTH VIS SCI, V56, P2192, DOI 10.1167/iovs.14-15841
   Silva R, 2011, OPHTHALMOLOGICA, V226, DOI 10.1159/000329473
   Thiele S, 2018, OPHTHALMOLOGICA, V239, P110, DOI 10.1159/000485260
   Veerappan M, 2016, OPHTHALMOLOGY, V123, P2554, DOI 10.1016/j.ophtha.2016.08.047
   Wilde C, 2016, EYE, V30, P817, DOI 10.1038/eye.2016.46
   Yu JJ, 2019, OPHTHALMOLOGY, V126, P261, DOI 10.1016/j.ophtha.2018.08.017
   Yu Y, 2012, INVEST OPHTH VIS SCI, V53, P1548, DOI 10.1167/iovs.11-8657
   Zweifel SA, 2010, OPHTHALMOLOGY, V117, P1775, DOI 10.1016/j.ophtha.2010.01.027
NR 53
TC 10
Z9 10
U1 0
U2 2
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 0030-3755
EI 1423-0267
J9 OPHTHALMOLOGICA
JI Ophthalmologica
PD DEC
PY 2020
VL 243
IS 6
BP 444
EP 452
DI 10.1159/000507196
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA PG4NP
UT WOS:000599714000007
PM 32172233
DA 2022-11-30
ER

PT J
AU Bouteleux, V
   Kodjikian, L
   Mendes, M
   Agard, E
   Machkour-Bentaleb, Z
   El-Chehab, H
   Denis, P
   Mathis, T
   Dot, C
AF Bouteleux, Victor
   Kodjikian, Laurent
   Mendes, Maud
   Agard, Emilie
   Machkour-Bentaleb, Zainab
   El-Chehab, Hussam
   Denis, Philippe
   Mathis, Thibaud
   Dot, Corinne
TI Increased choroidal thickness: a new feature to monitor age-related
   macular degeneration recurrence
SO GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Article
DE Choroidal thickness; Enhanced-depth imaging; Exudative recurrence;
   Intravitreal injection; Neovascular AMD
ID RETINAL ANGIOMATOUS PROLIFERATION; BLOOD-FLOW; INTRAVITREAL RANIBIZUMAB;
   PHOTODYNAMIC THERAPY; AFLIBERCEPT THERAPY; PIGMENT EPITHELIUM; EYES;
   REPRODUCIBILITY; AUTOREGULATION; CELLS
AB PurposeThe main objective of this study was to assess choroidal thickness (CT) changes during an exudative recurrence of age-related macular degeneration (AMD).MethodsA real-life prospective non-interventional 9-month study was conducted in two centers in consecutive patients with exudative AMD between November 2016 and July 2017. CT was measured manually in both eyes based on enhanced-depth imaging spectral-domain optical coherence tomography at different follow-up visits scheduled in the morning.ResultsA total of 134 patients were included. Ninety-five patients presented at least one episode, defined by a follow-up visit under controlled condition (dry retina) followed by a visit for exudative recurrence. A total of 119 episodes were analyzed. The mean CT change in the treated eye was +8.4513.52m (p<0.001) and +5.62 +/- 14.77m (p=0.009) respectively in the subfoveal area and nasal area. No significant change in CT was observed in the fellow eye. No significant association between CT changes and treatment, number of intravitreal injections, and blood pressure was observed.Conclusion p id=Par4 CT increased in case of exudative recurrence of neovascular AMD. The increase was mild but significant. Thus, CT could be used as a monitoring criterion, like the central retinal thickness, in AMD management.
C1 [Bouteleux, Victor; Mendes, Maud; Agard, Emilie; Dot, Corinne] Hop Instruct Armees Desgenettes, 108 Blvd Pinel, F-69003 Lyon, France.
   [Bouteleux, Victor; Kodjikian, Laurent; Mendes, Maud; Machkour-Bentaleb, Zainab; El-Chehab, Hussam; Denis, Philippe; Mathis, Thibaud] Hop Croix Rousse, HCL, 103 Grande Rue Croix Rousse, F-69004 Lyon, France.
   [Bouteleux, Victor] Hop Croix Rousse, Serv Ophtalmol, 103 Grande Rue Croix Rousse, F-69317 Lyon 04, France.
   [Mathis, Thibaud] CNRS, UMR 5510, Mateis, F-69621 Villeurbanne, France.
   [Dot, Corinne] Ecole Val De Grace, 74 Blvd Port Royal, F-75005 Paris, France.
C3 CHU Lyon; CHU Lyon; Centre National de la Recherche Scientifique (CNRS);
   CNRS - Institute for Engineering & Systems Sciences (INSIS); Institut
   National des Sciences Appliquees de Lyon - INSA Lyon
RP Bouteleux, V (通讯作者)，Hop Instruct Armees Desgenettes, 108 Blvd Pinel, F-69003 Lyon, France.; Bouteleux, V (通讯作者)，Hop Croix Rousse, HCL, 103 Grande Rue Croix Rousse, F-69004 Lyon, France.; Bouteleux, V (通讯作者)，Hop Croix Rousse, Serv Ophtalmol, 103 Grande Rue Croix Rousse, F-69317 Lyon 04, France.
EM victorbouteleux@hotmail.fr
RI Mathis, Thibaud/AAK-5745-2021
CR Adamis AP, 2005, RETINA-J RET VIT DIS, V25, P111, DOI 10.1097/00006982-200502000-00001
   Adhi M, 2014, RETINA-J RET VIT DIS, V34, P306, DOI 10.1097/IAE.0b013e3182993e09
   Branchini L, 2013, JAMA OPHTHALMOL, V131, P693, DOI 10.1001/jamaophthalmol.2013.692
   Branchini L, 2012, OPHTHALMOLOGY, V119, P119, DOI 10.1016/j.ophtha.2011.07.002
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Chhablani J, 2012, INVEST OPHTH VIS SCI, V53, P2274, DOI 10.1167/iovs.12-9435
   Chung SE, 2011, OPHTHALMOLOGY, V118, P840, DOI 10.1016/j.ophtha.2010.09.012
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   Grossniklaus HE, 2004, AM J OPHTHALMOL, V137, P496, DOI 10.1016/j.ajo.2003.09.042
   Grunwald JE, 1998, INVEST OPHTH VIS SCI, V39, P385
   Julien S, 2014, BRIT J OPHTHALMOL, V98, P813, DOI 10.1136/bjophthalmol-2013-304019
   Kaiser PK, 2007, OPHTHALMOLOGY, V114, P1868, DOI 10.1016/j.ophtha.2007.04.030
   Kano M, 2015, CLIN OPHTHALMOL, V9, P2049, DOI 10.2147/OPTH.S90932
   Kernt M, 2010, BRIT J OPHTHALMOL, V94, P1533, DOI 10.1136/bjo.2010.182162
   KIEL JW, 1992, INVEST OPHTH VIS SCI, V33, P2399
   KIEL JW, 1995, INVEST OPHTH VIS SCI, V36, P579
   Kiel JW, 1999, EXP EYE RES, V69, P413, DOI 10.1006/exer.1999.0717
   Kim JH, 2013, AM J OPHTHALMOL, V155, P743, DOI 10.1016/j.ajo.2012.11.001
   Kim YK, 2016, RETINA-J RET VIT DIS, V36, P1516, DOI 10.1097/IAE.0000000000000952
   Koizumi H, 2016, OPHTHALMOLOGY, V123, P617, DOI 10.1016/j.ophtha.2015.10.039
   Koizumi H, 2015, AM J OPHTHALMOL, V159, P627, DOI 10.1016/j.ajo.2014.12.025
   Kuroda Y, 2017, RETINA PHILA PA
   Manjunath V, 2011, AM J OPHTHALMOL, V152, P663, DOI 10.1016/j.ajo.2011.03.008
   Margolis R, 2009, AM J OPHTHALMOL, V147, P811, DOI 10.1016/j.ajo.2008.12.008
   Marneros AG, 2005, AM J PATHOL, V167, P1451, DOI 10.1016/S0002-9440(10)61231-X
   Maruko I, 2015, RETINA-J RET VIT DIS, V35, P648, DOI 10.1097/IAE.0000000000000486
   Maruko I, 2013, AM J OPHTHALMOL, V156, P548, DOI 10.1016/j.ajo.2013.03.041
   Mazaraki K, 2015, BRIT J OPHTHALMOL, V99, P1341, DOI 10.1136/bjophthalmol-2015-306636
   Michalewska Z, 2015, RETINA-J RET VIT DIS, V35, P244, DOI 10.1097/IAE.0000000000000281
   Mrejen S, 2014, RETINA-J RET VIT DIS, V34, P1560, DOI 10.1097/IAE.0000000000000139
   Nickla DL, 2010, PROG RETIN EYE RES, V29, P144, DOI 10.1016/j.preteyeres.2009.12.002
   Nishijima K, 2007, AM J PATHOL, V171, P53, DOI 10.2353/ajpath.2007.061237
   Peters S, 2007, AM J OPHTHALMOL, V143, P995, DOI 10.1016/j.ajo.2007.03.007
   Poukens V, 1998, INVEST OPHTH VIS SCI, V39, P1765
   Querques G, 2012, INVEST OPHTH VIS SCI, V53, P1258, DOI 10.1167/iovs.11-8907
   Reiner A, 2003, EXP EYE RES, V76, P273, DOI 10.1016/S0014-4835(02)00316-0
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Soubrane G, 2007, DMLAS RAPPORT SFO 20
   Spaide RF, 2008, AM J OPHTHALMOL, V146, P496, DOI 10.1016/j.ajo.2008.05.032
   Spaide RF, 2015, AM J OPHTHALMOL, V160, P1211, DOI 10.1016/j.ajo.2015.08.018
   Ting DSW, 2016, AM J OPHTHALMOL, V164, P128, DOI 10.1016/j.ajo.2015.12.024
   Usui S, 2012, INVEST OPHTH VIS SCI, V53, P2300, DOI 10.1167/iovs.11-8383
   Yamazaki T, 2014, RETINA-J RET VIT DIS, V34, P1316, DOI 10.1097/IAE.0000000000000086
   Yamazaki T, 2012, OPHTHALMOLOGY, V119, P1621, DOI 10.1016/j.ophtha.2012.02.022
   Zhang L, 2015, INVEST OPHTH VIS SCI, V56, P3202, DOI 10.1167/iovs.14-15669
NR 45
TC 9
Z9 9
U1 0
U2 1
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0721-832X
EI 1435-702X
J9 GRAEF ARCH CLIN EXP
JI Graefes Arch. Clin. Exp. Ophthalmol.
PD APR
PY 2019
VL 257
IS 4
BP 699
EP 707
DI 10.1007/s00417-018-04216-8
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA HR2CH
UT WOS:000462942600005
PM 30554268
DA 2022-11-30
ER

PT J
AU Balaskas, K
   Karampelas, M
   Horani, M
   Hotu, O
   Keane, P
   Aslam, T
AF Balaskas, Konstantinos
   Karampelas, Michael
   Horani, Mania
   Hotu, Oana
   Keane, Pearse
   Aslam, Tariq
TI QUANTITATIVE ANALYSIS OF PIGMENT EPITHELIAL DETACHMENT RESPONSE TO
   DIFFERENT ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR AGENTS IN WET
   AGE-RELATED MACULAR DEGENERATION
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE pigment epithelial detachment; image analysis; differential
   pharmacodynamics; optical coherence tomography
ID OPTICAL COHERENCE TOMOGRAPHY; VISUAL-ACUITY; RANIBIZUMAB; AFLIBERCEPT;
   INJECTION; THERAPY
AB Purpose: To assess whether best-corrected visual acuity and pigment epithelial detachment (PED) height, volume, and reflectivity in patients with wet age-related macular degeneration are influenced by baseline anatomical and functional parameters, including quantifiable metrics of PED morphology and choice of treatment.
   Methods: One hundred two consecutive, treatment-naive wet age-related macular degeneration patients with PED (. 50 mm) treated with aflibercept (52) or ranibizumab (50) were retrospectively included. Pigment epithelial detachment height, horizontal and vertical dimensions, and volume were recorded at baseline, 3 months, and 1 year, respectively. Bespoke image analysis software provided a quantifiable measure of reflectivity.
   Results: Best-corrected visual acuity at 3 months was influenced by baseline best-corrected visual acuity (P = 0.006). Pigment epithelial detachment height was influenced by baseline height (P = 0.009), subretinal fluid (P = 0.008), central macular thickness (P = 0.006), and use of aflibercept (P = 0.003) at 3 months and by baseline height (P = 0.018), volume (P = 0.017), vertical dimension (P = 0.0004), and aflibercept (P = 0.015) at 1 year. Pigment epithelial detachment reflectivity increased from 43.59 to 55.86 (3 months) and 57.35 (1 year) (P < 0.001) and was influenced by its baseline values and, interestingly, use of aflibercept at 3 months (P = 0.013).
   Conclusion: Quantifiable metrics of PED morphology improve with treatment, and PED content becomes hyperreflective, more so on aflibercept. Pigment epithelial detachments respond better in the context of more active disease. More hyporeflective PED content may predispose to better treatment response, especially with aflibercept.
C1 [Balaskas, Konstantinos; Horani, Mania; Hotu, Oana; Keane, Pearse; Aslam, Tariq] Cent Manchester Univ Hosp NHS Fdn Trust, Manchester Royal Eye Hosp, Oxford Rd, Manchester M13 9WL, Lancs, England.
   [Balaskas, Konstantinos; Aslam, Tariq] Univ Manchester, Ctr Vis & Hearing Res, Manchester, Lancs, England.
   [Balaskas, Konstantinos; Karampelas, Michael] Moorfields Eye Hosp NHS Fdn Trust, NIHR Biomed Res Ctr Ophthalmol, London, England.
   [Karampelas, Michael] West Hertfordshire NHS Trust, London, England.
   [Keane, Pearse] UCL, Inst Ophthalmol, London, England.
C3 Manchester Royal Eye Hospital; University of Manchester; University of
   Manchester; University of London; University College London; Moorfields
   Eye Hospital NHS Foundation Trust; University of London; University
   College London
RP Balaskas, K (通讯作者)，Cent Manchester Univ Hosp NHS Fdn Trust, Manchester Royal Eye Hosp, Oxford Rd, Manchester M13 9WL, Lancs, England.
EM Konstantinos.Balaskas@gmail.com
RI Keane, Pearse/AAE-5709-2019; Balaskas, Konstantinos/ABD-5979-2020;
   Aslam, Tariq/A-8532-2016
OI Keane, Pearse/0000-0002-9239-745X; Balaskas,
   Konstantinos/0000-0002-7690-6277; Aslam, Tariq/0000-0002-9739-7280
FU Bayer plc; National Institute for Health Research [CS-2014-14-023,
   CL-2010-18-004] Funding Source: researchfish
FX Supported by a grant from Bayer plc, only in terms of funding
   investigator's time spent on data collection.
CR Aslam T, 2014, ACTA OPHTHALMOL, V92, pe580, DOI 10.1111/aos.12390
   Baba T, 2012, OPHTHALMOLOGICA, V228, P102, DOI 10.1159/000337251
   Broadhead GK, 2015, RETINA-J RET VIT DIS, V35, P975, DOI 10.1097/IAE.0000000000000409
   Browning DJ, 2007, OPHTHALMOLOGY, V114, P525, DOI 10.1016/j.ophtha.2006.06.052
   Chan CK, 2012, EYE, V26, P882, DOI 10.1038/eye.2012.90
   Chan CK, 2007, RETINA-J RET VIT DIS, V27, P541, DOI 10.1097/IAE.0b013e3180cc2612
   Chan Clement K, 2014, Trans Am Ophthalmol Soc, V112, P160
   Dirani A, 2015, AM J OPHTHALMOL, V160, P732, DOI 10.1016/j.ajo.2015.06.025
   Hata M, 2014, INVEST OPHTH VIS SCI, V55, P7874, DOI 10.1167/iovs.14-14610
   Ho J, 2015, RETINA-J RET VIT DIS, V35, P467, DOI 10.1097/IAE.0000000000000355
   Inoue M, 2013, RETINA-J RET VIT DIS, V33, P990, DOI 10.1097/IAE.0b013e3182755793
   Keane PA, 2008, INVEST OPHTH VIS SCI, V49, P3115, DOI 10.1167/iovs.08-1689
   Keane PA, 2015, TRANSL VIS SCI TECHN, V4, DOI 10.1167/tvst.4.5.4
   Keane PA, 2012, INVEST OPHTH VIS SCI, V53, P1152, DOI 10.1167/iovs.11-8130
   Keane PA, 2008, OPHTHALMOLOGY, V115, P2206, DOI 10.1016/j.ophtha.2008.08.016
   Mrejen S, 2013, RETINA-J RET VIT DIS, V33, P1735, DOI 10.1097/IAE.0b013e3182993f66
   Pauleikhoff D, 2002, GRAEF ARCH CLIN EXP, V240, P533, DOI 10.1007/s00417-002-0505-8
   Penha FM, 2013, RETINA-J RET VIT DIS, V33, P459, DOI 10.1097/IAE.0b013e31827d2657
   Schmidt-Erfurth U, 2015, OPHTHALMOLOGY, V122, P822, DOI 10.1016/j.ophtha.2014.11.017
   Scott IU, 2011, OPHTHALMOLOGY, V118, P345, DOI 10.1016/j.ophtha.2010.06.034
   Veritti D, 2013, RETINA-J RET VIT DIS, V33, P982, DOI 10.1097/IAE.0b013e31826d8ff4
NR 21
TC 13
Z9 15
U1 0
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD JUL
PY 2017
VL 37
IS 7
BP 1297
EP 1304
DI 10.1097/IAE.0000000000001342
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA EY6ZG
UT WOS:000404133400014
PM 27755376
OA Green Submitted
DA 2022-11-30
ER

PT J
AU Evans, JR
   Sivagnanavel, V
   Chong, V
AF Evans, Jennifer R.
   Sivagnanavel, Vasuki
   Chong, Victor
TI Radiotherapy for neovascular age-related macular degeneration
SO COCHRANE DATABASE OF SYSTEMATIC REVIEWS
LA English
DT Review
DE Eye [radiation effects]; Macular Degeneration [radiotherapy]; Radiation
   Injuries [complications]; Randomized Controlled Trials as Topic; Humans
ID SUBFOVEAL CHOROIDAL NEOVASCULARIZATION; RADIATION-THERAPY; SR-90
   BRACHYTHERAPY; CLINICAL-TRIAL; MEMBRANES; SECONDARY
AB Background
   Radiotherapy has been proposed as a treatment to prevent new vessel growth in people with neovascular age-related macular degeneration (AMD).
   Objectives
   The aim of this review was to examine the effects of radiotherapy on neovascular AMD.
   Search strategy
   We searched the Cochrane Central Register of Controlled Trials (CENTRAL) (which contains the Cochrane Eyes and Vision Group Trials Register) in The Cochrane Library Issue 3, 2010, MEDLINE (January 1950 to March 2010), EMBASE (January 1980 to March 2010), Latin American and Caribbean Health Sciences Literature Database (LILACS) (January 1982 to March 2010), the m et a Register of Controlled Trials (mRCT) (www.controlled-trials.com) (March 2010) and ClinicalTrials.gov (http://clinicaltrials.gov) (March 2010). There were no language or date restrictions in the search for trials. The electronic databases were last searched on 23 March 2010. We also wrote to investigators of trials included in the review to ask if they were aware of any other studies.
   Selection criteria
   We included all randomised controlled trials in which radiotherapy was compared to another treatment, sham treatment, low dosage irradiation or no treatment in people with choroidal neovascularisation secondary to AMD.
   Data collection and analysis
   Two review authors independently extracted the data. We combined relative risks using a random-effects model. We estimated the percentage of the variability in effect estimates that was due to heterogeneity, rather than sampling error, using I-2.
   Main results
   Thirteen trials (n=1154) investigated external beam radiotherapy with dosages ranging from 7.5 to 24 Gy; one additional trial (n=88) used plaque brachytherapy (15Gy at 1.75mm for 54 minutes/12.6 Gy at 4mm for 11 minutes). Most studies found effects (not always significant) that favoured treatment. Overall there was a small statistically significant reduction in risk of visual acuity loss in the treatment group. There was considerable inconsistency between trials and the trials were considered to be at risk of bias, in particular because of the lack of masking of treatment group. Subgroup analyses did not reveal any significant interactions, however, there were small numbers of trials in each subgroup (range three to five). There was some indication that trials with no sham irradiation in the control group reported a greater effect of treatment. The incidence of adverse events was low in all trials; there were no reported cases of radiation retinopathy, optic neuropathy or malignancy. Three trials found non-significant higher rates of cataract progression in the treatment group.
   Authors' conclusions
   This review currently does not provide convincing evidence that radiotherapy is an effective treatment for neovascular AMD. If further trials are to be considered to evaluate radiotherapy in AMD then adequate masking of the control group must be considered.
C1 [Chong, Victor] Oxford Eye Hosp, Oxford OX3 9DU, England.
   [Evans, Jennifer R.] London Sch Hyg & Trop Med, ICEH, Cochrane Eyes & Vis Grp, London WC1, England.
   [Sivagnanavel, Vasuki] Moorfields Eye Hosp NHS Fdn Trust, London, England.
C3 University of London; London School of Hygiene & Tropical Medicine;
   University of London; University College London; Moorfields Eye Hospital
   NHS Foundation Trust
RP Chong, V (通讯作者)，Oxford Eye Hosp, Headley Way, Oxford OX3 9DU, England.
EM victor@eretina.org
RI Evans, Jennifer/F-4672-2012; Chong, Victor/Q-6565-2018; Chong, Ngaihang
   V/A-5141-2009
OI Evans, Jennifer/0000-0002-6137-2030; Chong, Victor/0000-0002-7693-522X; 
FU Guide Dogs for the Blind Association, UK
FX External sources; Guide Dogs for the Blind Association, UK.
CR Altman DG, 2003, BMJ-BRIT MED J, V326, P219, DOI 10.1136/bmj.326.7382.219
   Anders N, 1998, OPHTHALMOLOGE, V95, P760, DOI 10.1007/s003470050349
   [Anonymous], 2003, Nippon Ganka Gakkai Zasshi, V107, P326
   Avila MP, 2009, BRIT J OPHTHALMOL, V93, P305, DOI 10.1136/bjo.2008.145912
   Barak A, 2005, BRIT J RADIOL, V78, P827, DOI 10.1259/bjr/17631422
   Bergink GJ, 1998, GRAEF ARCH CLIN EXP, V236, P321, DOI 10.1007/s004170050085
   BERGINK GJ, 1995, DOC OPHTHALMOL, V90, P67, DOI 10.1007/BF01203296
   Bressler NM, 2002, AM J OPHTHALMOL, V133, P168, DOI 10.1016/S0002-9394(01)01237-5
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   Brown GC, 1997, INT J RADIAT ONCOL, V39, P332, DOI 10.1016/S0360-3016(97)80951-0
   Char DH, 1999, AM J OPHTHALMOL, V127, P574, DOI 10.1016/S0002-9394(99)00038-0
   Churei Hisahiko, 2004, Radiat Med, V22, P398
   Ciulla TA, 2002, AM J OPHTHALMOL, V134, P905, DOI 10.1016/S0002-9394(02)01821-4
   Eter N, 2001, GRAEF ARCH CLIN EXP, V239, P923, DOI 10.1007/s00417-001-0391-5
   Eter N, 2002, INT OPHTHALMOL, V24, P13
   Glanville JM, 2006, J MED LIBR ASSOC, V94, P130
   Hart PM, 2002, ARCH OPHTHALMOL-CHIC, V120, P1029
   Hart PM, 1999, BRIT J OPHTHALMOL, V83, P1115, DOI 10.1136/bjo.83.10.1115
   HEIER JS, 2008, MACULAR SOC, V186
   Higgins J.P.T, 2009, COCHRANE HDB SYSTEMA, P187
   Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557
   Holz FG, 1999, OPHTHALMOLOGY, V106, P2239
   Honjo M, 1997, JAPANESE J CLIN OPHT, V51, P1563
   Hoyng CB, 2002, GRAEF ARCH CLIN EXP, V240, P337, DOI 10.1007/s00417-002-0428-4
   Jaakkola A, 2005, OPHTHALMOLOGY, V112, P567, DOI 10.1016/j.ophtha.2004.11.029
   Kacperek A, 2001, PHYS MEDICA, V17, P7
   Kirkham JJ, 2010, BMJ-BRIT MED J, V340, DOI 10.1136/bmj.c365
   Kobayashi H, 2000, AM J OPHTHALMOL, V130, P617, DOI 10.1016/S0002-9394(00)00534-1
   Macdonald GM, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001930.pub2
   Mandai M, 2000, JPN J OPHTHALMOL, V44, P530, DOI 10.1016/S0021-5155(00)00217-3
   Mandai M, 1998, JAPANESE J CLIN OPHT, V52, P567
   Marcus D, 2004, AM J OPHTHALMOL, V138, P818, DOI 10.1016/j.ajo.2004.06.081
   Marcus DM, 2004, BRIT J OPHTHALMOL, V88, P114, DOI 10.1136/bjo.88.1.114
   Marcus DM, 1999, RETINA-J RET VIT DIS, V19, P525, DOI 10.1097/00006982-199911000-00008
   Marcus DM, 2001, ARCH OPHTHALMOL-CHIC, V119, P171
   Matsuhashi H, 2000, JPN J OPHTHALMOL, V44, P653, DOI 10.1016/S0021-5155(00)00280-X
   Matsuhashi Hideaki, 1996, Nippon Ganka Gakkai Zasshi, V100, P803
   Postgens H, 1997, GRAEF ARCH CLIN EXP, V235, P656, DOI 10.1007/BF00946943
   Saric B, 2001, COLLEGIUM ANTROPOL, V25, P89
   Sivagnanavel V, 2004, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD004004.PUB2
   Stevenson MR, 2005, BRIT J OPHTHALMOL, V89, P1045, DOI 10.1136/bjo.2003.030445
   Taniguchi T, 1996, JAPANESE J CLIN OPHT, V50, P1821
   Tholen AM, 2000, KLIN MONATSBL AUGENH, V216, P112, DOI 10.1055/s-2000-10528
   Tholen AM, 1998, OPHTHALMOLOGE, V95, P691, DOI 10.1007/s003470050337
   Vacha P, 2001, EUR J CANCER, V37, P275
   Valmaggia C, 2002, AM J OPHTHALMOL, V133, P521, DOI 10.1016/S0002-9394(02)01336-3
   Valmaggia Christophe, 2001, Documenta Ophthalmologica, V103, P201, DOI 10.1023/A:1013047722865
   White IR, 2008, STAT MED, V27, P711, DOI 10.1002/sim.3008
   Zambarakji HJ, 2006, OPHTHALMOLOGY, V113, P2012, DOI 10.1016/j.ophtha.2006.05.036
NR 49
TC 28
Z9 29
U1 0
U2 10
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1469-493X
EI 1361-6137
J9 COCHRANE DB SYST REV
JI Cochrane Database Syst Rev.
PY 2010
IS 5
AR CD004004
DI 10.1002/14651858.CD004004.pub3
PG 89
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA 595LD
UT WOS:000277611100042
PM 20464726
OA Green Accepted, Green Published
DA 2022-11-30
ER

PT J
AU Chan, WM
   Lai, TYY
   Chan, KP
   Li, HT
   Liu, DTL
   Lam, DSC
   Pang, CP
AF Chan, Wai-Man
   Lai, Timothy Y. Y.
   Chan, Kwok-Ping
   Li, Haitao
   Liu, David T. L.
   Lam, Dennis S. C.
   Pang, Chi-Pui
TI CHANGES IN AQUEOUS VASCULAR ENDOTHELIAL GROWTH FACTOR AND PIGMENT
   EPITHELIAL-DERIVED FACTOR LEVELS FOLLOWING INTRAVITREAL BEVACIZUMAB
   INJECTIONS FOR CHOROIDAL NEOVASCULARIZATION SECONDARY TO AGE-RELATED
   MACULAR DEGENERATION OR PATHOLOGIC MYOPIA
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE VEGF; PEDF; growth factor; choroidal neovascularization; age-related
   macular degeneration; pathologic myopia; bevacizumab
ID HUMOR LEVELS; EXPRESSION; AVASTIN; VEGF; PEDF; RANIBIZUMAB; VERTEPORFIN;
   MEMBRANES
AB Background: To evaluate the changes in aqueous vascular endothelial growth factor (VEGF) and pigment epithelium-derived factor (PEDF) following intravitreal bevacizumab injections for choroidal neovascularization (CNV) secondary to age-related macular degeneration or pathologic myopia.
   Methods: Aqueous samples were obtained at the time of injection from 51 eyes of 51 patients who underwent three monthly intravitreal bevacizumab (Avastin) injections at baseline, 1, and 2 months. Concentrations of VEGF and PEDF in the aqueous were evaluated using enzyme-linked immunosorbent assay and compared.
   Results: For the 34 eyes with age-related macular degeneration CNV, the mean +/- standard deviation aqueous VEGF level reduced from 102.6 mu g/mL +/- 90.6 pg/mL at baseline to 18.3 pg/mL +/- 22.5 pg/mL at 2 months (P < 0.001), whereas the mean PEDF level increased from 11.2 ng/mL +/- 10.4 ng/mL at baseline to 38.7 ng/mL +/- 47.9 ng/mL at 2 months (P = 0.001). For the 17 eyes with myopic CNV, the mean standard deviation aqueous VEGF level reduced from 20.1 pg/mL +/- 28.9 pg/mL at baseline to 3.8 pg/mL +/- 5.3 pg/mL at 2 months (P = 0.016), whereas the mean PEDF level increased from 20.0 ng/mL +/- 16.3 ng/mL at baseline to 126.0 ng/mL +/- 152.0 ng/mL at 2 months (P = 0.016).
   Conclusions: Intravitreal bevacizumab injections resulted in reduced aqueous VEGF and increased PEDF levels in patients with CNV secondary to age-related macular degeneration or pathologic myopia. These changes may be favorable for the inhibition of CNV angiogenesis. RETINA 28:1308-1313, 2008
C1 [Chan, Wai-Man; Lai, Timothy Y. Y.; Chan, Kwok-Ping; Li, Haitao; Liu, David T. L.; Lam, Dennis S. C.; Pang, Chi-Pui] Chinese Univ Hong Kong, Dept Ophthalmol & Visual Sci, Kowloon, Hong Kong, Peoples R China.
C3 Chinese University of Hong Kong
RP Chan, WM (通讯作者)，Chinese Univ Hong Kong, Dept Ophthalmol & Visual Sci, Hong Kong Eye Hosp, 147K Argyle St, Kowloon, Hong Kong, Peoples R China.
EM cwm6373@netvigator.com
RI Chan, Kwok Ping/E-6044-2016; Pang, Chi P/I-5388-2014; Lam,
   Dennis/AAL-1211-2020; Lai, Timothy Y Y/AAC-2120-2020
OI Chan, Kwok Ping/0000-0003-2416-1995; Lai, Timothy Y
   Y/0000-0002-7832-6428
CR Arnold J, 2001, OPHTHALMOLOGY, V108, P841
   Avery RL, 2006, OPHTHALMOLOGY, V113, P363, DOI 10.1016/j.ophtha.2005.11.019
   Blumenkranz MS, 2001, ARCH OPHTHALMOL-CHIC, V119, P198
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Chan WM, 2007, OPHTHALMOLOGY, V114, P2190, DOI 10.1016/j.ophtha.2007.03.043
   Cohen SY, 1996, OPHTHALMOLOGY, V103, P1241, DOI 10.1016/S0161-6420(96)30515-0
   Dawson DW, 1999, SCIENCE, V285, P245, DOI 10.1126/science.285.5425.245
   Funatsu H, 2005, GRAEF ARCH CLIN EXP, V243, P3, DOI 10.1007/s00417-004-0950-7
   Gao GQ, 2001, FEBS LETT, V489, P270, DOI 10.1016/S0014-5793(01)02110-X
   Grossniklaus HE, 2004, AM J OPHTHALMOL, V137, P496, DOI 10.1016/j.ajo.2003.09.042
   Matsuoka M, 2004, BRIT J OPHTHALMOL, V88, P809, DOI 10.1136/bjo.2003.032466
   Ohno-Matsui K, 2001, J CELL PHYSIOL, V189, P323, DOI 10.1002/jcp.10026
   Rich RM, 2006, RETINA-J RET VIT DIS, V26, P495, DOI 10.1097/01.iae.0000225766.75009.3a
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Sakaguchi H, 2007, BRIT J OPHTHALMOL, V91, P161, DOI 10.1136/bjo.2006.099887
   Sawada O, 2007, ARCH OPHTHALMOL-CHIC, V125, P1363, DOI 10.1001/archopht.125.10.1363
   Spaide RF, 2006, RETINA-J RET VIT DIS, V26, P383, DOI 10.1097/00006982-200604000-00001
   Tatar O, 2006, AM J OPHTHALMOL, V142, P95, DOI 10.1016/j.ajo.2006.01.085
   Tong HP, 2006, CLIN BIOCHEM, V39, P267, DOI 10.1016/j.clinbiochem.2005.11.013
   Tong JP, 2006, MOL VIS, V12, P1490
   Tong JP, 2006, AM J OPHTHALMOL, V141, P456, DOI 10.1016/j.ajo.2005.10.012
   Yamamoto I, 2007, BRIT J OPHTHALMOL, V91, P157, DOI 10.1136/bjo.2006.096776
NR 22
TC 71
Z9 78
U1 2
U2 6
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD OCT
PY 2008
VL 28
IS 9
BP 1308
EP 1313
DI 10.1097/IAE.0b013e31818358b2
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 366IM
UT WOS:000260474200021
PM 18728623
DA 2022-11-30
ER

PT J
AU Arya, M
   Sabrosa, AS
   Duker, JS
   Waheed, NK
AF Arya, Malvika
   Sabrosa, Almyr S.
   Duker, Jay S.
   Waheed, Nadia K.
TI Choriocapillaris changes in dry age-related macular degeneration and
   geographic atrophy: a review
SO EYE AND VISION
LA English
DT Review
DE Dry age related macular degeneration; Geographic atrophy;
   Choriocapillaris; Optical coherence tomography; Optical coherence
   tomography angiography
ID COHERENCE TOMOGRAPHY ANGIOGRAPHY; RISK-FACTORS; OCT ANGIOGRAPHY;
   SWEPT-SOURCE; CHOROIDAL NEOVASCULARIZATION; CARDIOVASCULAR-DISEASE;
   BRUCHS-MEMBRANE; DRUSEN; PREVALENCE; EYES
AB Age-related macular degeneration (AMD) is a leading cause of central vision loss worldwide. The progression of dry AMD from early to intermediate stages is primarily characterized by increasing drusen formation and adverse impact on outer retinal cells. Late stage AMD consists of either geographic atrophy (GA), the non-exudative (dry) AMD subtype, or choroidal neovascularization, the exudative (wet) AMD subtype. GA is characterized by outer retinal and choroidal atrophy, specifically the photoreceptor layer, RPE, and choriocapillaris. Much remains to be discovered regarding the pathogenesis of AMD progression and subsequent development of GA. As the functionality of all three layers is closely linked, the temporal sequence of events that end up in atrophy is important in the understanding of the pathogenic pathway of the disease. The advent of OCTA, and particularly of swept-source technology, has allowed for depth-resolved imaging of retinal vasculature and the choriocapillaris. With the use of OCTA, recent studies demonstrate that choriocapillaris flow alterations are closely associated with the development and progression of AMD. Such changes may even possibly offer predictive value in determining progression of GA. This article reviews studies demonstrating choriocapillaris changes in dry AMD and summarizes the existing literature on the potential role of the choriocapillaris as a key factor in the pathogenesis of AMD.
C1 [Sabrosa, Almyr S.; Duker, Jay S.; Waheed, Nadia K.] Tufts Med Ctr, New England Eye Ctr, Boston, MA 02111 USA.
   [Sabrosa, Almyr S.] Inst Ophthalmol, Rio De Janeiro, Brazil.
C3 Tufts Medical Center
RP Waheed, NK (通讯作者)，Tufts Med Ctr, New England Eye Ctr, Boston, MA 02111 USA.
EM nadiakwaheed@gmail.com
FU Macula Vision Research Foundation
FX This work was supported in part by a grant from the Macula Vision
   Research Foundation.
CR Alten F, 2017, GRAEF ARCH CLIN EXP, V255, P2347, DOI 10.1007/s00417-017-3813-8
   Alten F, 2016, GRAEF ARCH CLIN EXP, V254, P2165, DOI 10.1007/s00417-016-3375-1
   Anand R, 2000, OPHTHALMOLOGY, V107, P2224
   Bhisitkul RB, 2015, AM J OPHTHALMOL, V159, P915, DOI 10.1016/j.ajo.2015.01.032
   Bhutto I, 2012, MOL ASPECTS MED, V33, P295, DOI 10.1016/j.mam.2012.04.005
   Biesemeier A, 2014, NEUROBIOL AGING, V35, P2562, DOI 10.1016/j.neurobiolaging.2014.05.003
   Bird AC, 2014, JAMA OPHTHALMOL, V132, P338, DOI 10.1001/jamaophthalmol.2013.5799
   Borrelli E, 2017, INVEST OPHTH VIS SCI, V58, P4792, DOI 10.1167/iovs.17-22360
   Campbell JP, 2017, SCI REP-UK, V7, DOI 10.1038/srep42201
   Chatziralli I, 2017, J OPHTHALMOL, V2017, DOI 10.1155/2017/7612712
   Chirco KR, 2016, EXP EYE RES, V146, P393, DOI 10.1016/j.exer.2015.09.003
   Choi W, ULTRAHIGH SPEED SWEP
   Cicinelli MV, 2018, SURV OPHTHALMOL, V63, P236, DOI 10.1016/j.survophthal.2017.06.005
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   Corbelli E, 2017, INVEST OPHTH VIS SCI, V58, P5201, DOI 10.1167/iovs.17-22508
   Curcio CA, 2000, OPHTHALMOLOGY, V107, P334, DOI 10.1016/S0161-6420(99)00037-8
   Curcio CA, 2013, RETINA-J RET VIT DIS, V33, P265, DOI 10.1097/IAE.0b013e31827e25e0
   Daniel E, 2016, OPHTHALMOLOGY, V123, P609, DOI 10.1016/j.ophtha.2015.10.034
   de Carlo Talisa E, 2015, Int J Retina Vitreous, V1, P5
   Duan YK, 2007, OPHTHALMOLOGY, V114, P732, DOI 10.1016/j.ophtha.2006.07.045
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Espinosa-Heidmann DG, 2006, INVEST OPHTH VIS SCI, V47, P729, DOI 10.1167/iovs.05-0719
   Ferrara D, 2017, INVEST OPHTH VIS SCI, V58, P3519, DOI 10.1167/iovs.17-21696
   Ferrara D, 2016, PROG RETIN EYE RES, V52, P130, DOI 10.1016/j.preteyeres.2015.10.002
   Fleckenstein M, 2008, INVEST OPHTH VIS SCI, V49, P4137, DOI 10.1167/iovs.08-1967
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Hogg RE, 2008, OPHTHALMOLOGY, V115, P1046, DOI 10.1016/j.ophtha.2007.07.031
   Hyman L, 2000, ARCH OPHTHALMOL-CHIC, V118, P351, DOI 10.1001/archopht.118.3.351
   Jia YL, 2015, P NATL ACAD SCI USA, V112, pE2395, DOI 10.1073/pnas.1500185112
   Kaszubski P, 2016, OPHTHALMIC RES, V55, P185, DOI 10.1159/000443209
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Klein R, 2011, ARCH OPHTHALMOL-CHIC, V129, P75, DOI 10.1001/archophthalmol.2010.318
   Kochounian H, 2009, EXP EYE RES, V88, P1129, DOI 10.1016/j.exer.2009.01.019
   KORTE GE, 1984, INVEST OPHTH VIS SCI, V25, P1135
   Kvanta A, 2017, RETINA-J RET VIT DIS, V37, P936, DOI 10.1097/IAE.0000000000001248
   Lane M, 2016, INVEST OPHTH VIS SCI, V57, pOCT585, DOI 10.1167/iovs.15-18915
   Lauermann JL, 2018, OPHTHALMOLOGICA, V239, P74, DOI 10.1159/000485261
   Lengyel I, 2004, INVEST OPHTH VIS SCI, V45, P2886, DOI 10.1167/iovs.03-1083
   Lindner M, 2015, OPHTHALMOLOGY, V122, P1356, DOI 10.1016/j.ophtha.2015.03.027
   Lutty G, 1999, MOL VIS, V5
   Matsunaga D, 2014, OSLI RETINA, V45, P510, DOI 10.3928/23258160-20141118-04
   McLeod DS, 2009, INVEST OPHTH VIS SCI, V50, P4982, DOI 10.1167/iovs.09-3639
   Moult E, 2014, OSLI RETINA, V45, P496, DOI 10.3928/23258160-20141118-03
   Moult EM, 2016, RETINA-J RET VIT DIS, V36, pS2, DOI 10.1097/IAE.0000000000001287
   Mullins RE, 2011, INVEST OPHTH VIS SCI, V52, P1606, DOI 10.1167/iovs.10-6476
   Mullins RF, 2011, EXP EYE RES, V93, P565, DOI 10.1016/j.exer.2011.06.015
   Nesper PL, 2017, AM J OPHTHALMOL, V174, P42, DOI 10.1016/j.ajo.2016.10.005
   Pellegrini M, 2016, OPHTHALMOLOGY, V123, P1879, DOI 10.1016/j.ophtha.2016.05.041
   Pilgrim MG, 2017, INVEST OPHTH VIS SCI, V58, DOI 10.1167/iovs.16-21060
   Rudolf M, 2013, OPHTHALMOLOGY, V120, P821, DOI 10.1016/j.ophtha.2012.10.007
   Saade C, 2014, BRIT J OPHTHALMOL, V98, P1729, DOI 10.1136/bjophthalmol-2014-305005
   Sacconi R, 2018, RETINA-J RET VIT DIS, V38, P2350, DOI 10.1097/IAE.0000000000001873
   Sadda SR, 2018, OPHTHALMOLOGY, V125, P537, DOI 10.1016/j.ophtha.2017.09.028
   SARKS JP, 1988, EYE, V2, P552, DOI 10.1038/eye.1988.106
   Schmitz-Valckenberg S, 2011, INVEST OPHTH VIS SCI, V52, P5009, DOI 10.1167/iovs.11-7235
   Seddon JM, 2006, OPHTHALMOLOGY, V113, P260, DOI 10.1016/j.ophtha.2005.11.001
   Seddon JM, 2016, JAMA OPHTHALMOL, V134, P1272, DOI 10.1001/jamaophthalmol.2016.3519
   Spaide RF, 2016, AM J OPHTHALMOL, V170, P58, DOI 10.1016/j.ajo.2016.07.023
   Tomany SC, 2004, OPHTHALMOLOGY, V111, P1280, DOI 10.1016/j.ophtha.2003.11.010
   Uji A, 2017, JAMA OPHTHALMOL, V135, P1197, DOI 10.1001/jamaophthalmol.2017.3904
   van Leeuwen R, 2003, INVEST OPHTH VIS SCI, V44, P3771, DOI 10.1167/iovs.03-0121
   Velez-Montoya R, 2014, RETINA-J RET VIT DIS, V34, P423, DOI 10.1097/IAE.0000000000000036
   Waheed NK, 2016, DEV OPHTHALMOL, V56, P91, DOI 10.1159/000442784
   Whitmore SS, 2015, PROG RETIN EYE RES, V45, P1, DOI 10.1016/j.preteyeres.2014.11.005
   Wu ZC, 2014, OPHTHALMOLOGY, V121, P2415, DOI 10.1016/j.ophtha.2014.06.034
   YANNUZZI LA, 1992, ARCH OPHTHALMOL-CHIC, V110, P1701
   Zanzottera EC, 2016, RETINA-J RET VIT DIS, V36, pS12, DOI 10.1097/IAE.0000000000001276
   Zeng SM, 2016, J PATHOL, V238, P446, DOI 10.1002/path.4669
NR 68
TC 49
Z9 49
U1 0
U2 5
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2326-0254
J9 EYE VISION
JI Eye Vis.
PD SEP 15
PY 2018
VL 5
AR 22
DI 10.1186/s40662-018-0118-x
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA HJ6NY
UT WOS:000457308700001
PM 30238015
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Gibson, JM
   Gibson, SJ
AF Gibson, Jonathan Mark
   Gibson, Stewart James
TI A safety evaluation of ranibizumab in the treatment of age-related
   macular degeneration
SO EXPERT OPINION ON DRUG SAFETY
LA English
DT Review
DE aflibercept; age-related macular degeneration; bevacizumab; intravitreal
   injection; ranibizumab; safety
ID ENDOTHELIAL GROWTH-FACTOR; VERTEPORFIN PHOTODYNAMIC THERAPY;
   INTRAVITREAL INJECTION; CHOROIDAL NEOVASCULARIZATION; CLINICAL
   CHARACTERISTICS; INTRAOCULAR-PRESSURE; BEVACIZUMAB AVASTIN; VEGF-TRAP;
   ANTI-VEGF; RISK
AB Introduction: The use of intravitreal ranibizumab has transformed the outcomes for thousands of patients with wet age related macular degeneration (AMD), which is the leading cause of blindness in developed countries. Prior to its introduction, most patients with wet AMD would rapidly lose central vision. The use of intravitreal ranibizumab has been shown to reduce certifiable visual loss by about a half. Current treatment regimens with ranibizumab in wet AMD require multiple injections over several years and so it is highly relevant to review the safety record of this important drug.
   Areas covered: This review considers the important ocular and systemic adverse events (AE) that have been reported in the literature, particularly in the context of the pivotal clinical trials that have been performed. It also reviews the safety of other anti-VEGF drugs that are used in wet AMD, namely bevacizumab and aflibercept, and compares these drugs with ranibizumab.
   Expert opinion: Overall, intravitreal ranibizumab can be considered a safe and highly effective drug for patients with wet AMD. However recent concerns about retinal thinning following ranibizumab therapy, possible systemic AE associated with all anti-VEGF drugs and the occurrence of complications relating to drug preparation and delivery must be considered.
C1 [Gibson, Jonathan Mark] Aston Univ, Sch Life & Hlth Sci, Birmingham B4 7ET, W Midlands, England.
   [Gibson, Jonathan Mark] Heart England NHS Fdn Trust, Birmingham B9 5SS, W Midlands, England.
   [Gibson, Stewart James] St James Univ Hosp, Liver Unit, Dept Hepatol, Leeds LS9 7TF, W Yorkshire, England.
C3 Aston University; Heart of England NHS Foundation Trust; Saint James's
   University Hospital
RP Gibson, JM (通讯作者)，Aston Univ, Sch Life & Hlth Sci, Birmingham B4 7ET, W Midlands, England.
EM j.m.gibson@aston.ac.uk
OI Gibson, Jonathan M/0000-0002-9281-5244
FU Novartis Pharmaceuticals UK Ltd.; Alimera; Allergan; Bayer PLC
FX J Gibson has received travel honoraria and fees for attending advisory
   boards from Novartis Pharmaceuticals UK Ltd, Alimera, Allergan and Bayer
   PLC, and research funding from Novartis Pharmaceuticals UK Ltd. The
   authors have no other relevant affiliations or financial involvement
   with any organization or entity with a financial interest in or
   financial conflict with the subject matter or materials discussed in the
   manuscript apart from those disclosed.
CR Abraham P, 2010, AM J OPHTHALMOL, V150, P315, DOI 10.1016/j.ajo.2010.04.011
   Administration FaD, 2006, HIGHL PRESCR INF LUC
   Ahn SJ, 2014, INVEST OPHTH VIS SCI, V55, P567, DOI 10.1167/iovs.13-13054
   ALTMAN R, 1994, BMJ-BRIT MED J, V308, P81, DOI 10.1136/bmj.308.6921.81
   Anastasilakis K, 2011, CASE REP OPHTHALM, V2, P129, DOI 10.1159/000328385
   [Anonymous], 2014, EUR PUBL ASS REP EPA
   [Anonymous], 2012, EPAR EYLEA
   Bakri SJ, 2014, OPHTHALMOLOGY, V121, P1102, DOI 10.1016/j.ophtha.2013.11.029
   Beaumont PE, 2014, OPHTHALMOLOGY, V121, pE4, DOI 10.1016/j.ophtha.2013.09.020
   Bloch SB, 2012, AM J OPHTHALMOL, V153, P209, DOI 10.1016/j.ajo.2011.10.016
   Boyer DS, 2009, OPHTHALMOLOGY, V116, P1731, DOI 10.1016/j.ophtha.2009.05.024
   Brand CS, 2012, EYE, V26, pS1, DOI 10.1038/eye.2012.32
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   Bunce C, 2010, EYE, V24, P1692, DOI 10.1038/eye.2010.122
   Busbee BG, 2013, OPHTHALMOLOGY, V120, P1046, DOI 10.1016/j.ophtha.2012.10.014
   Campbell RJ, 2012, BMJ-BRIT MED J, V344, DOI 10.1136/bmj.e4203
   Chakravarthy U, 2013, LANCET, V382, P1258, DOI 10.1016/S0140-6736(13)61501-9
   Chakravarthy U, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.04.015
   Chang AA, 2014, OPHTHALMOLOGY, V121, P188, DOI 10.1016/j.ophtha.2013.08.035
   Cheung CMG, 2013, LANCET, V382, P1230, DOI 10.1016/S0140-6736(13)61580-9
   Chong V, 2012, OPHTHALMOLOGICA, V227, P2, DOI 10.1159/000337152
   Curtis LH, 2010, ARCH OPHTHALMOL-CHIC, V128, P1273, DOI 10.1001/archophthalmol.2010.223
   D'Agostino RB, 2000, AM HEART J, V139, P272, DOI 10.1016/S0002-8703(00)90236-9
   Ehlken C, 2012, ARCH OPHTHALMOL-CHIC, V130, P1226, DOI 10.1001/archophthalmol.2012.112
   Fung AE, 2006, BRIT J OPHTHALMOL, V90, P1344, DOI 10.1136/bjo.2006.099598
   Gaudreault J, 2005, INVEST OPHTH VIS SCI, V46, P726, DOI 10.1167/iovs.04-0601
   Gaudreault J, 2007, RETINA-J RET VIT DIS, V27, P1260, DOI 10.1097/IAE.0b013e318134eecd
   Gillies MC, 2007, NEW ENGL J MED, V356, P748
   Gillies MC, 2014, OPHTHALMOLOGY, V121, P676, DOI 10.1016/j.ophtha.2013.09.050
   Goldberg RA, 2012, AM J OPHTHALMOL, V153, P204, DOI 10.1016/j.ajo.2011.11.035
   Gordon MS, 2001, J CLIN ONCOL, V19, P843, DOI 10.1200/JCO.2001.19.3.843
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Grunwald JE, 2014, OPHTHALMOLOGY, V121, P150, DOI 10.1016/j.ophtha.2013.08.015
   Hayman SR, 2012, CURR ONCOL REP, V14, P285, DOI 10.1007/s11912-012-0242-z
   Heier JS, 2006, ARCH OPHTHALMOL-CHIC, V124, P1532, DOI 10.1001/archopht.124.11.1532
   Heier JS, 2014, OPHTHALMOLOGY, V121, pE5, DOI 10.1016/j.ophtha.2013.09.018
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Holash J, 2002, P NATL ACAD SCI USA, V99, P11393, DOI 10.1073/pnas.172398299
   Holz FG, 2013, BRIT J OPHTHALMOL, V97, P1161, DOI 10.1136/bjophthalmol-2013-303232
   Holz FG, 2011, OPHTHALMOLOGY, V118, P663, DOI 10.1016/j.ophtha.2010.12.019
   Hurwitz H, 2004, NEW ENGL J MED, V350, P2335, DOI 10.1056/NEJMoa032691
   Husain D, 2005, ARCH OPHTHALMOL-CHIC, V123, P509, DOI 10.1001/archopht.123.4.509
   Jackson TL, 2013, OPHTHALMOLOGY, V120, P1893, DOI 10.1016/j.ophtha.2013.02.016
   Kaiser RS, 2013, RETINA TODAY, P68
   Keenan TDL, 2013, BRIT J OPHTHALMOL, V97, P1168, DOI 10.1136/bjophthalmol-2013-303233
   Kim LA, 2012, AM J PATHOL, V181, P376, DOI 10.1016/j.ajpath.2012.06.006
   Lalwani GA, 2009, AM J OPHTHALMOL, V148, P43, DOI 10.1016/j.ajo.2009.01.024
   Lanzetta P, 2013, OPHTHALMOLOGICA, V230, P151, DOI 10.1159/000354549
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Castellanos MAM, 2013, BRIT J OPHTHALMOL, V97, P816, DOI 10.1136/bjophthalmol-2012-302276
   Mason JO, 2010, RETINA-J RET VIT DIS, V30, P1386, DOI 10.1097/IAE.0b013e3181e09739
   Menke MN, 2013, OPHTHALMOLOGICA, V229, P168, DOI 10.1159/000346397
   Meyer CH, 2011, EYE, V25, P661, DOI 10.1038/eye.2011.66
   Michels S, 2005, OPHTHALMOLOGY, V112, P1035, DOI 10.1016/j.ophtha.2005.02.007
   Mintz-Hittner HA, 2011, NEW ENGL J MED, V364, P603, DOI 10.1056/NEJMoa1007374
   Moon SW, 2013, J OCUL PHARMACOL TH, V29, P556, DOI 10.1089/jop.2012.0148
   National Institute of Clinical Excellence, 2008, RAN PEG TREATM AG RE
   Pelle G, 2011, AM J KIDNEY DIS, V57, P756, DOI 10.1053/j.ajkd.2010.11.030
   Regillo CD, 2008, AM J OPHTHALMOL, V145, P239, DOI 10.1016/j.ajo.2007.10.004
   Rofagha S, 2013, OPHTHALMOLOGY, V120, P2292, DOI 10.1016/j.ophtha.2013.03.046
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rosenfeld PJ, 2005, OPHTHAL SURG LAS IM, V36, P331, DOI 10.3928/1542-8877-20050701-14
   Scappaticci FA, 2007, JNCI-J NATL CANCER I, V99, P1232, DOI 10.1093/jnci/djm086
   Schmidt-Erfurth U, 2014, OPHTHALMOLOGY, V121, P193, DOI 10.1016/j.ophtha.2013.08.011
   Schmidt-Erfurth U, 2011, OPHTHALMOLOGY, V118, P831, DOI 10.1016/j.ophtha.2010.09.004
   Schmucker C, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0042701
   Scott AW, 2013, CURR OPIN OPHTHALMOL, V24, P190, DOI 10.1097/ICU.0b013e32835fefee
   Shahar J, 2006, RETINA-J RET VIT DIS, V26, P262, DOI 10.1097/00006982-200603000-00002
   Silva R, 2013, OPHTHALMOLOGY, V120, P130, DOI 10.1016/j.ophtha.2012.07.026
   Singer MA, 2012, OPHTHALMOLOGY, V119, P1175, DOI 10.1016/j.ophtha.2011.12.016
   Skaat A, 2012, AM J OPHTHALMOL, V153, P214, DOI 10.1016/j.ajo.2011.08.035
   Sullivan L, 2014, EYE, V28, P492, DOI 10.1038/eye.2013.311
   Sulzbacher F, 2013, INVEST OPHTH VIS SCI, V54, P1310, DOI 10.1167/iovs.12-11046
   Tan JSL, 2008, BRIT J OPHTHALMOL, V92, P509, DOI 10.1136/bjo.2007.131706
   Ueta T, 2014, OPHTHALMOLOGY, V121, pE5, DOI 10.1016/j.ophtha.2013.09.019
   Xu L, 2013, INVEST OPHTH VIS SCI, V54, P1616, DOI 10.1167/iovs.12-10260
   Zehetner C, 2013, BRIT J OPHTHALMOL, V97, P454, DOI 10.1136/bjophthalmol-2012-302451
NR 79
TC 14
Z9 15
U1 1
U2 30
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 1474-0338
EI 1744-764X
J9 EXPERT OPIN DRUG SAF
JI Expert Opin. Drug Saf.
PD SEP
PY 2014
VL 13
IS 9
BP 1259
EP 1270
DI 10.1517/14740338.2014.939951
PG 12
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA AN7IL
UT WOS:000340772900013
PM 25091039
DA 2022-11-30
ER

PT J
AU Chen, CZ
   Wu, LZ
   Wu, DZ
   Huang, SZ
   Wen, F
   Luo, GW
   Long, SX
AF Chen, CZ
   Wu, LZ
   Wu, DZ
   Huang, SZ
   Wen, F
   Luo, GW
   Long, SX
TI The local cone and rod system function in early age-related macular
   degeneration
SO DOCUMENTA OPHTHALMOLOGICA
LA English
DT Article
DE age-related macular degeneration; cone; multifocal electroretinogram;
   perimetry; rod
ID RETINITIS-PIGMENTOSA; SCOTOPIC SENSITIVITY; VISUAL FUNCTION;
   ELECTRORETINOGRAMS; MACULOPATHY
AB To compare cone and rod system function in patients with early age- related macular degeneration (ARMD) and control group using multifocal electroretinogram (MERG) and perimetry, to investigate whether there is rod system dysfunction in the central retina in ARMD. Cone-mediated MERG, photopic sensitivity, rod-mediated MERG, and scotopic sensitivity in 16 eyes of control subjects and 24 eyes of early dry-form ARMD were measured with VERIS Science(TM) 4.0 and Octopus 101 perimetry. The latencies and average response densities of the summed responses and five ring retinal regions, average sensitivity of all locus and eight ring retinal regions in control eyes were compared with those in ARMD. Mean scotopic and photopic sensitivity of ARMD patients were significantly lower than that of normal controls. Sotopic sensitivity reduced more than photopic sensitivity and the greatest deficit was 2.5-5.0degrees. The amplitudes of N-1 and P-1 wave in one ring (5.0degrees) of rod MERG were significantly lower of ARMD patients than that of normal subjects. Our results suggest that rod function decreased and the parafoveal rod cells were predominantly damaged in ARMD. The rod function testing in macula may be a useful tool to diagnose and measure the fundus dysfunction of ARMD.
C1 Wuhan Univ, Renmin Hosp, Wuhan 430060, Peoples R China.
   Sun Yet Sun Univ, Zhongshan Ophthalm Ctr, Guangzhou 510060, Peoples R China.
C3 Wuhan University
RP Chen, CZ (通讯作者)，Wuhan Univ, Renmin Hosp, Wuhan 430060, Peoples R China.
OI Chen, Changzheng/0000-0002-7281-552X
CR Ball SL, 2000, INVEST OPHTH VIS SCI, V41, P610
   Curcio CA, 2000, INVEST OPHTH VIS SCI, V41, P2015
   Curcio CA, 2001, EYE, V15, P376, DOI 10.1038/eye.2001.140
   EISNER A, 1992, INVEST OPHTH VIS SCI, V33, P3091
   Hicks D, 1999, INVEST OPHTH VIS SCI, V40, P3071
   Holopigian K, 2001, INVEST OPHTH VIS SCI, V42, P779
   Hood DC, 1998, INVEST OPHTH VIS SCI, V39, P1152
   Huang Shizhou, 2000, Documenta Ophthalmologica, V101, P115
   Jackson GR, 1998, VISION RES, V38, P3655, DOI 10.1016/S0042-6989(98)00044-3
   Jackson GR, 2000, VISION RES, V40, P2467, DOI 10.1016/S0042-6989(00)00108-5
   KLINE DW, 1992, J GERONTOL, V47, pP27, DOI 10.1093/geronj/47.1.P27
   Li J, 2001, BRIT J OPHTHALMOL, V85, P287, DOI 10.1136/bjo.85.3.287
   Mohand-Said S, 2000, ARCH OPHTHALMOL-CHIC, V118, P807, DOI 10.1001/archopht.118.6.807
   Nusinowitz S, 1999, INVEST OPHTH VIS SCI, V40, P2848
   Owsley C, 2000, INVEST OPHTH VIS SCI, V41, P267
   Seiple W, 2002, VISION RES, V42, P257, DOI 10.1016/S0042-6989(01)00276-0
   SUNNESS JS, 1989, OPHTHALMOLOGY, V96, P375, DOI 10.1016/S0161-6420(89)32883-1
   Sunness JS, 1997, OPHTHALMOLOGY, V104, P1677, DOI 10.1016/S0161-6420(97)30079-7
   Votruba M, 2001, EYE, V15, P424, DOI 10.1038/eye.2001.147
NR 19
TC 57
Z9 62
U1 1
U2 6
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0012-4486
EI 1573-2622
J9 DOC OPHTHALMOL
JI Doc. Ophthalmol.
PD JUL
PY 2004
VL 109
IS 1
BP 1
EP 8
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 888YR
UT WOS:000226411000001
PM 15675195
DA 2022-11-30
ER

PT J
AU van Asten, F
   Rovers, MM
   Lechanteur, YTE
   Smailhodzic, D
   Muether, PS
   Chen, J
   den Hollander, AI
   Fauser, S
   Hoyng, CB
   van der Wilt, GJ
   Klevering, BJ
AF van Asten, Freekje
   Rovers, Maroeska M.
   Lechanteur, Yara T. E.
   Smailhodzic, Dzenita
   Muether, Philipp S.
   Chen, John
   den Hollander, Anneke I.
   Fauser, Sascha
   Hoyng, Carel B.
   van der Wilt, Gert Jan
   Klevering, B. Jeroen
TI Predicting Non-response to Ranibizumab in Patients with Neovascular
   Age-related Macular Degeneration
SO OPHTHALMIC EPIDEMIOLOGY
LA English
DT Article
DE Age-related macular degeneration; anti-VEGF treatment; non-response;
   prediction model; response prediction
ID COMPLEMENT FACTOR-H; INTRAVITREAL RANIBIZUMAB; SUBGROUP ANALYSIS; POOLED
   FINDINGS; RISK-FACTORS; BEVACIZUMAB; ASSOCIATION; THERAPY; VERTEPORFIN;
   MACULOPATHY
AB Purpose: To validate known and determine new predictors of non-response to ranibizumab in patients with neovascular age-related macular degeneration (AMD) and to incorporate these factors into a prediction rule.
   Methods: This multicenter, observational cohort study included 391 patients treated with ranibizumab for neovascular AMD. We performed genetic analysis for single nucleotide polymorphisms in AMD-associated genes and collected questionnaires regarding environmental factors and disease history. The primary outcome was non-response to treatment, defined as a loss of visual acuity >= 30% of letters.
   Results: Of the 391 patients, 47 were classified as non-responsive. Independent predictors for non-response were age, baseline visual acuity, diabetes mellitus and accumulation of risk alleles in the CFH, ARMS2 and VEGF-A genes. The area under the receiver operating characteristic curve was 0.77 (95% confidence interval 0.70-0.84). We derived a clinical prediction rule, with possible total risk scores ranging from 0-19 points. The absolute risk of non-response varied from 3-52% between risk score groups.
   Conclusion: This is an important step towards a clinical prediction rule that can aid clinicians in identifying AMD patients with increased likelihood of non-response, and consequently contribute to making shared treatment decisions.
C1 [van Asten, Freekje; Lechanteur, Yara T. E.; Smailhodzic, Dzenita; den Hollander, Anneke I.; Hoyng, Carel B.; Klevering, B. Jeroen] Radboud Univ Nijmegen, Med Ctr, Dept Ophthalmol, NL-6525 EX Nijmegen, Netherlands.
   [Rovers, Maroeska M.; van der Wilt, Gert Jan] Radboud Univ Nijmegen, Med Ctr, Dept Hlth Evidence, NL-6525 EX Nijmegen, Netherlands.
   [Muether, Philipp S.; Fauser, Sascha] Univ Cologne, Dept Ophthalmol, D-50931 Cologne, Germany.
   [Chen, John] McGill Univ, Ctr Hlth, Dept Ophthalmol, Montreal, PQ, Canada.
   [den Hollander, Anneke I.] Radboud Univ Nijmegen, Med Ctr, Dept Human Genet, NL-6525 EX Nijmegen, Netherlands.
C3 Radboud University Nijmegen; Radboud University Nijmegen; University of
   Cologne; McGill University; Radboud University Nijmegen
RP Klevering, BJ (通讯作者)，Radboud Univ Nijmegen, Med Ctr, Dept Ophthalmol, Philips van Leydenlaan 15, NL-6525 EX Nijmegen, Netherlands.
EM Jeroen.Klevering@radboudumc.nl
RI Lechanteur, Yara/ABB-6875-2020; Klevering, B.J./L-4434-2015; Lehtimäki,
   Terho/AAD-1094-2022; van Asten, Freekje/P-6028-2015; van der Wilt, Gert
   Jan/H-8120-2014; Rovers, Maroeska/F-2969-2014
OI Lechanteur, Yara/0000-0003-0951-4625; Lehtimäki,
   Terho/0000-0002-2555-4427; van Asten, Freekje/0000-0002-8141-4234; van
   der Wilt, Gert Jan/0000-0002-5856-762X; Rovers,
   Maroeska/0000-0002-3095-170X
FU Nijmegen Center for Evidence Based Practice, Radboud University Nijmegen
   Medical Center; Netherlands Organization for Scientific Research
   [016.096.309]; MD fonds; Oogfonds; Landelijke Stichting voor Blinden en
   Slechtzienden; Algemene Nederlandse Vereniging ter Voorkoming van
   Blindheid; Stichting Blindenhulp; Gelderse Blindenstichting; Nijmeegse
   Oogonderzoek Stichting; Foundation Fighting Blindness Canada; Koln
   Fortune Program/Faculty of Medicine; University of Cologne
FX This study was supported by a grant awarded to the research project
   "Toward personalized medicine in patients with age-related macular
   degeneration'' by the Nijmegen Center for Evidence Based Practice,
   Radboud University Nijmegen Medical Center, the Netherlands Organization
   for Scientific Research [grant 016.096.309], the MD fonds, Oogfonds,
   Landelijke Stichting voor Blinden en Slechtzienden, Algemene Nederlandse
   Vereniging ter Voorkoming van Blindheid, Stichting Researchfonds
   Oogheelkunde, Stichting Nederlands Oogheelkundig Onderzoek, Stichting
   Blindenhulp, the Gelderse Blindenstichting, Nijmeegse Oogonderzoek
   Stichting, the Foundation Fighting Blindness Canada and the Koln Fortune
   Program/Faculty of Medicine, University of Cologne. The funding
   organizations had no role in the design or conduct of this research.
CR Altman DG, 2009, BMJ-BRIT MED J, V338, DOI 10.1136/bmj.b605
   Boyer DS, 2007, OPHTHALMOLOGY, V114, P246, DOI 10.1016/j.ophtha.2006.10.045
   Brantley MA, 2007, OPHTHALMOLOGY, V114, P2168, DOI 10.1016/j.ophtha.2007.09.008
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   Byun YJ, 2010, JPN J OPHTHALMOL, V54, P571, DOI 10.1007/s10384-010-0866-1
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Harrell FE, 1996, STAT MED, V15, P361, DOI 10.1002/(SICI)1097-0258(19960229)15:4<361::AID-SIM168>3.0.CO;2-4
   Kaiser PK, 2007, AM J OPHTHALMOL, V144, P850, DOI 10.1016/j.ajo.2007.08.012
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P1527
   Kloeckener-Gruissem B, 2011, INVEST OPHTH VIS SCI, V52, P4694, DOI 10.1167/iovs.10-6080
   Lee AY, 2009, BRIT J OPHTHALMOL, V93, P610, DOI 10.1136/bjo.2008.150995
   McKibbin M, 2012, BRIT J OPHTHALMOL, V96, P208, DOI 10.1136/bjo.2010.193680
   Menghini M, 2010, KLIN MONATSBL AUGENH, V227, P244, DOI 10.1055/s-0029-1245203
   Nischler C, 2011, ACTA OPHTHALMOL, V89, pE344, DOI 10.1111/j.1755-3768.2010.02080.x
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Royston P, 2009, BMJ-BRIT MED J, V338, P1373, DOI DOI 10.1136/BMJ.B604
   Schindelin J, 2012, NAT METHODS, V9, P676, DOI [10.1038/NMETH.2019, 10.1038/nmeth.2019]
   Singh RP, 2009, BRIT J OPHTHALMOL, V93, P1353, DOI 10.1136/bjo.2008.141879
   Smailhodzic D, 2012, OPHTHALMOLOGY, V119, P2304, DOI 10.1016/j.ophtha.2012.05.040
   Smith W, 2001, OPHTHALMOLOGY, V108, P697, DOI 10.1016/S0161-6420(00)00580-7
   STERNBERG P, 1991, ARCH OPHTHALMOL-CHIC, V109, P1242
   Steyerberg EW, 2001, MED DECIS MAKING, V21, P45, DOI 10.1177/0272989X0102100106
   Teper SJ, 2010, MOL VIS, V16, P2598
   Tian J, 2012, PHARMACOGENOMICS, V13, P779, DOI [10.2217/PGS.12.53, 10.2217/pgs.12.53]
   Tomany SC, 2004, OPHTHALMOLOGY, V111, P1280, DOI 10.1016/j.ophtha.2003.11.010
   Wong T, 2008, OPHTHALMOLOGY, V115, P116, DOI 10.1016/j.ophtha.2007.03.008
   Yamashiro K, 2012, AM J OPHTHALMOL, V154, P125, DOI 10.1016/j.ajo.2012.01.010
   Ying GS, 2013, OPHTHALMOLOGY, V120, P122, DOI 10.1016/j.ophtha.2012.07.042
NR 30
TC 23
Z9 25
U1 0
U2 6
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0928-6586
EI 1744-5086
J9 OPHTHAL EPIDEMIOL
JI Ophthalmic Epidemiol.
PD DEC
PY 2014
VL 21
IS 6
BP 347
EP 355
DI 10.3109/09286586.2014.949010
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA AT2NB
UT WOS:000344770300002
PM 25157998
DA 2022-11-30
ER

PT J
AU Geirsdottir, A
   Jonsson, O
   Thorisdottir, S
   Helgadottir, G
   Jonasson, F
   Stefansson, E
   Sigurdsson, H
AF Geirsdottir, Asbjorg
   Jonsson, Oskar
   Thorisdottir, Sigridur
   Helgadottir, Gudleif
   Jonasson, Fridbert
   Stefansson, Einar
   Sigurdsson, Haraldur
TI Population-based incidence of exudative age-related macular degeneration
   and ranibizumab treatment load
SO BRITISH JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID BLUE MOUNTAINS EYE; VISUAL IMPAIRMENT; 5-YEAR INCIDENCE; 10-YEAR
   INCIDENCE; REYKJAVIK EYE; MACULOPATHY; PREVALENCE; PROGRESSION;
   BLINDNESS; OLDER
AB Background/aims The use of intravitreal vascular endothelial growth factor antibodies for exudative age-related macular degeneration (AMD) has stressed ophthalmology services and drug budgets throughout the world. The authors study the population-based incidence of exudative AMD in Iceland and the use of intravitreal ranibizumab in a defined population.
   Methods This is a prospective study of 439 consecutive patients aged 60 years and older with exudative AMD starting intravitreal ranibizumab for exudative AMD in Iceland from March 2007 to December 2009. All patients initially received three consecutive ranibizumab injections, with regular follow-up visits and re-treatment as needed.
   Results In total, 517 eyes from 439 patients received treatment for exudative AMD (mean age 79 years). The annual incidence of exudative AMD in the population 60 years and older is 0.29%. The incidence increased with advancing age, double for patients 85 years and older compared with those 75-79 years. Approximately 2400 ranibizumab injections per 100 000 persons aged 60 years and older were given each year for exudative AMD.
   Conclusions These data allow an estimation of the incidence of exudative AMD in a Caucasian population and the treatment load with ranibizumab, which may help plan anti-vascular endothelial growth factor treatment programmes and estimate costs.
C1 [Geirsdottir, Asbjorg; Jonsson, Oskar; Thorisdottir, Sigridur; Helgadottir, Gudleif; Jonasson, Fridbert; Stefansson, Einar; Sigurdsson, Haraldur] Landspitali Natl Univ Hosp Iceland, Dept Ophthalmol, IS-101 Reykjavik, Iceland.
   [Jonasson, Fridbert; Stefansson, Einar; Sigurdsson, Haraldur] Univ Iceland, Fac Med, Dept Ophthalmol, Reykjavik, Iceland.
C3 University of Iceland
RP Sigurdsson, H (通讯作者)，Landspitali Natl Univ Hosp Iceland, Dept Ophthalmol, IS-101 Reykjavik, Iceland.
EM haraldsi@landspitali.is
RI Jonasson, Fridbert/ABA-9889-2021
CR Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   Finger RP, 2011, INVEST OPHTH VIS SCI, V52, P4381, DOI 10.1167/iovs.10-6987
   Fung AE, 2007, AM J OPHTHALMOL, V143, P566, DOI 10.1016/j.ajo.2007.01.028
   Geirsdottir A, 2007, AM J OPHTHALMOL, V143, P889, DOI 10.1016/j.ajo.2006.11.057
   Gunnlaugsdottir E, 2008, ACTA OPHTHALMOL, V86, P778, DOI 10.1111/j.1755-3768.2008.01191.x
   Jonasson F, 2005, OPHTHALMOLOGY, V112, P132, DOI 10.1016/j.ophtha.2004.07.020
   Jonasson F, 2011, OPHTHALMOLOGY, V118, P825, DOI 10.1016/j.ophtha.2010.08.044
   Klein R, 1997, OPHTHALMOLOGY, V104, P7, DOI 10.1016/S0161-6420(97)30368-6
   Klein R, 2002, OPHTHALMOLOGY, V109, P1767, DOI 10.1016/S0161-6420(02)01146-6
   Klein R, 2007, OPHTHALMOLOGY, V114, P253, DOI 10.1016/j.ophtha.2006.10.040
   Krishnan T, 2010, INVEST OPHTH VIS SCI, V51, P701, DOI 10.1167/iovs.09-4114
   Minassian DC, 2011, BRIT J OPHTHALMOL, V95, P1433, DOI 10.1136/bjo.2010.195370
   Mitchell P, 2002, OPHTHALMOLOGY, V109, P1092, DOI 10.1016/S0161-6420(02)01055-2
   Naegele G., 2011, GERMANY GROWS OLD
   National Institute for Health and Clinical Excellence, 2008, RAN PEG TREATM AG RE
   Neubauer AS, 2010, CLIN THER, V32, P1343, DOI 10.1016/j.clinthera.2010.07.010
   Owen CG, 2003, BRIT J OPHTHALMOL, V87, P312, DOI 10.1136/bjo.87.3.312
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Wang JJ, 2007, OPHTHALMOLOGY, V114, P92, DOI 10.1016/j.ophtha.2006.07.017
   Wang JJ, 2000, CLIN EXP OPHTHALMOL, V28, P268, DOI 10.1046/j.1442-9071.2000.00315.x
NR 21
TC 9
Z9 9
U1 0
U2 2
PU B M J PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0007-1161
J9 BRIT J OPHTHALMOL
JI Br. J. Ophthalmol.
PD MAR
PY 2012
VL 96
IS 3
BP 444
EP 447
DI 10.1136/bjophthalmol-2011-300304
PG 4
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 896XO
UT WOS:000300604900029
PM 21856691
DA 2022-11-30
ER

PT J
AU Dandekar, SS
   Jenkins, SA
   Peto, T
   Bird, AC
   Webster, AR
AF Dandekar, S. S.
   Jenkins, S. A.
   Peto, T.
   Bird, A. C.
   Webster, A. R.
TI Does smoking influence the type of age related macular degeneration
   causing visual impairment?
SO BRITISH JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID CIGARETTE-SMOKING; MACULOPATHY; ACCUMULATION; EYE
AB Aims: To assess the influence of smoking on the type of age related macular degeneration ( AMD) lesion causing visual impairment in a large cohort of patients with AMD at a tertiary referral UK centre.
   Methods: Prospective, observational, cross sectional study to analyse smoking data on 711 subjects, of western European origin, in relation to the type of AMD lesion present. Colour fundus photographs were graded according to a modified version of the international classification. Multiple logistic regression analysis was performed, adjusting for age and sex using the statistical package SPSS ver 9.0 for Windows. chi(2) tests were also used to assess pack year and ex-smoker data.
   Results: 578 subjects were graded with neovascular AMD and 133 with non-neovascular AMD. There was no statistically significant association found between smoking status or increasing number of pack years and type of AMD lesion. The odds of "current smokers'' compared to "non-smokers'' developing neovascular rather than non-neovascular AMD when adjusted for age and sex was 1.88 ( 95% CI: 0.91 to 3.89; p = 0.09).
   Conclusions: Smoking is known to be a risk factor for AMD and this study suggests that smokers are at no more risk of developing neovascular than atrophic lesions.
C1 Moorfields Eye Hosp, Professorial Unit, London EC1V 2PD, England.
   Inst Ophthalmol, London, England.
C3 University of London; University College London; Moorfields Eye Hospital
   NHS Foundation Trust; University of London; University College London
RP Dandekar, SS (通讯作者)，Moorfields Eye Hosp, Professorial Unit, 162 City Rd, London EC1V 2PD, England.
EM sam@hitbits.co.uk
RI Peto, Tunde/G-8812-2018
OI Peto, Tunde/0000-0001-6265-0381
CR Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Brunk UT, 2002, FREE RADICAL BIO MED, V33, P611, DOI 10.1016/S0891-5849(02)00959-0
   Delcourt C, 1998, ARCH OPHTHALMOL-CHIC, V116, P1031, DOI 10.1001/archopht.116.8.1031
   Evans JR, 2005, BRIT J OPHTHALMOL, V89, P550, DOI 10.1136/bjo.2004.049726
   Holz FG, 2001, INVEST OPHTH VIS SCI, V42, P1051
   KLEIN R, 1993, AM J EPIDEMIOL, V137, P190, DOI 10.1093/oxfordjournals.aje.a116659
   Okubo A, 2000, INVEST OPHTH VIS SCI, V41, P4305
   PAETKAU ME, 1978, CAN J OPHTHALMOL, V13, P67
   SANDERS TAB, 1993, AM J CLIN NUTR, V57, P428, DOI 10.1093/ajcn/57.3.428
   Scholl HPN, 2004, OPHTHALMOLOGY, V111, P125, DOI 10.1016/j.ophtha.2003.05.003
   Scholl HPN, 2003, GRAEF ARCH CLIN EXP, V241, P39, DOI 10.1007/s00417-002-0602-8
   Seddon JM, 1996, JAMA-J AM MED ASSOC, V276, P1141, DOI 10.1001/jama.276.14.1141
   Smith W, 1996, ARCH OPHTHALMOL-CHIC, V114, P1518, DOI 10.1001/archopht.1996.01100140716016
   STRYKER WS, 1988, AM J EPIDEMIOL, V127, P283, DOI 10.1093/oxfordjournals.aje.a114804
   Suner IJ, 2004, INVEST OPHTH VIS SCI, V45, P311, DOI 10.1167/iovs.03-0733
   Thornton J, 2005, EYE, V19, P935, DOI 10.1038/sj.eye.6701978
   VINDING T, 1992, ACTA OPHTHALMOL, V70, P66
   VINGERLING JR, 1995, AM J EPIDEMIOL, V142, P404, DOI 10.1093/oxfordjournals.aje.a117648
NR 19
TC 11
Z9 12
U1 0
U2 4
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0007-1161
EI 1468-2079
J9 BRIT J OPHTHALMOL
JI Br. J. Ophthalmol.
PD JUN
PY 2006
VL 90
IS 6
BP 724
EP 727
DI 10.1136/bjo.2005.086355
PG 4
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 044DX
UT WOS:000237653700019
PM 16597668
OA Green Published
DA 2022-11-30
ER

PT J
AU Tah, V
   Keane, PA
   Esposti, SD
   Allimuthu, J
   Chen, FK
   Da Cruz, L
   Tufail, A
   Patel, PJ
AF Tah, Vikas
   Keane, Pearce A.
   Esposti, Simona Degli
   Allimuthu, Joseph
   Chen, Fred K.
   Da Cruz, Lyndon
   Tufail, Adnan
   Patel, Praveen J.
TI Repeatability of retinal thickness and volume metrics in neovascular
   age-related macular degeneration using the topcon 3doct-1000
SO INDIAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE Imaging; optical coherence tomography; neovascular age-related macular
   degeneration
ID OPTICAL COHERENCE TOMOGRAPHY; REPRODUCIBILITY; OCT
AB Introduction: Optical coherence tomography (OCT) is a commonly used imaging modality that provides detailed cross-sectional retinal images. This has revolutionised management of neovascular age-related macular degeneration. The need for repeated anti-vascular endothelial growth factor injections has led to therapy being delivered using OCT-guided retreatment strategies with both qualitative OCT features of disease activity (e.g. macular fluid) and changes in retinal thickness as triggers for retreatment The purpose of this study is to determine the intra-session repeatability of retinal thickness and volume measurements using the Topcon 3DOCT-1000 spectral-domain optical coherence tomography (SDOCT) device in patients with neovascular age-related macular degeneration (nAMD). This is the largest study to date looking specifically at the Topcon 3DOCT-1000. Materials and Methods: Two SDOCT raster scans were performed by the same blinded observer in the same sitting in consecutive patients attending for nAMD treatment as part of standard validation of a new device. Retrospective analysis was undertaken, with retinal thickness and volume measurements automatically calculated by the onboard software for each Early Treatment of Diabetic Retinopathy Study subfield for each scan. Bland-Altman methods of analysis were used to assess repeatability. Results: Data from the 73 patients were analyzed with a mean age of 78 years (standard deviation 8). The 95% coefficient of repeatability (CR) was 64 mu m and 0.050 mm(3) for retinal thickness and volume respectively in the central 1 mm macular subfield. The CR did not exceed 85 mu m (0.30 mm(3)) in any subfield. The revised CR for retinal thickness and volume for the subgroup of 37 patients with no segmentation error in the central 1 mm subfield was 53 mu m and 0.050 mm(3) respectively. Discussion: We report relatively modest intra-sessional repeatability of SDOCT retinal thickness and volume metrics in patients with nAMD in a clinical setting. Though useful in detecting clinical change from measurement variability in clinical practice, these results suggest the precision of macular thickness measurement does not approach the theoretical resolution of SDOCT.
C1 [Tah, Vikas; Keane, Pearce A.; Esposti, Simona Degli; Allimuthu, Joseph; Da Cruz, Lyndon; Tufail, Adnan; Patel, Praveen J.] Moorfields Eye Hosp, NIHR Biomed Res Ctr Ophthalmol, London, England.
   [Tah, Vikas; Keane, Pearce A.; Esposti, Simona Degli; Allimuthu, Joseph; Da Cruz, Lyndon; Tufail, Adnan; Patel, Praveen J.] UCL Inst Ophthalmol, London, England.
   [Chen, Fred K.] Univ Western Australia, Ctr Ophthalmol & Visual Sci, Lions Eye Inst, Perth, WA 6009, Australia.
C3 University of London; University College London; Moorfields Eye Hospital
   NHS Foundation Trust; University of London; University College London;
   Lions Eye Institute; University of Western Australia
RP Patel, PJ (通讯作者)，Moorfields Eye Hosp, NIHR Biomed Res Ctr Ophthalmol, London, England.
EM praveen.patel@moorfields.nhs.uk
RI , Fred/B-8158-2013
OI , Fred/0000-0003-2809-9930; Keane, Pearse/0000-0002-9239-745X; Tufail,
   Adnan/0000-0001-6131-7640
FU Department of Health's NIHR Biomedical Research Centre for Ophthalmology
   at Moorfields Eye Hospital; UCL Institute of Ophthalmology; National
   Institute for Health Research [CL-2010-18-004] Funding Source:
   researchfish
FX Source of Support: This work was supported by the Department of Health's
   NIHR Biomedical Research Centre for Ophthalmology at Moorfields Eye
   Hospital and UCL Institute of Ophthalmology. The views expressed in the
   publication are those of the authors and not necessarily those of the
   Department of Health. Conflict of Interest: None declared.
CR Bland JM, 1996, BRIT MED J, V313, P744
   Giani A, 2010, AM J OPHTHALMOL, V150, P815, DOI 10.1016/j.ajo.2010.06.025
   Holz FG, 2011, OPHTHALMOLOGY, V118, P663, DOI 10.1016/j.ophtha.2010.12.019
   HUANG D, 1991, SCIENCE, V254, P1178, DOI 10.1126/science.1957169
   Keane PA, 2009, AM J OPHTHALMOL, V148, P242, DOI 10.1016/j.ajo.2009.03.004
   Krebs I, 2008, BRIT J OPHTHALMOL, V92, P933, DOI 10.1136/bjo.2007.128447
   Krebs I, 2011, INVEST OPHTH VIS SCI, V52, P6925, DOI 10.1167/iovs.10-6612
   Lalwani GA, 2009, AM J OPHTHALMOL, V148, P43, DOI 10.1016/j.ajo.2009.01.024
   Menke MN, 2011, ACTA OPHTHALMOL, V89, P346, DOI 10.1111/j.1755-3768.2009.01692.x
   Parravano M, 2010, INVEST OPHTH VIS SCI, V51, P4788, DOI 10.1167/iovs.09-4976
   Patel PJ, 2008, INVEST OPHTH VIS SCI, V49, P1084, DOI 10.1167/iovs.07-1203
   Patel PJ, 2009, INVEST OPHTH VIS SCI, V50, P399, DOI 10.1167/iovs.08-1697
   Tufail A, 2010, BMJ-BRIT MED J, V340, DOI 10.1136/bmj.c2459
   Wojtkowski M, 2004, AM J OPHTHALMOL, V138, P412, DOI 10.1016/j.ajo.2004.04.049
NR 14
TC 5
Z9 5
U1 0
U2 1
PU MEDKNOW PUBLICATIONS & MEDIA PVT LTD
PI MUMBAI
PA B-9, KANARA BUSINESS CENTRE, OFF LINK RD, GHAKTOPAR-E, MUMBAI, 400075,
   INDIA
SN 0301-4738
EI 1998-3689
J9 INDIAN J OPHTHALMOL
JI Indian J. Ophthalmol.
PD SEP
PY 2014
VL 62
IS 9
BP 941
EP 948
DI 10.4103/0301-4738.143936
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA AW8HK
UT WOS:000346502000010
PM 25370398
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Haas, P
   Aggermann, T
   Nagl, M
   Steindl-Kuscher, K
   Krugluger, W
   Binder, S
AF Haas, Paulina
   Aggermann, Tina
   Nagl, Manfred
   Steindl-Kuscher, Kerstin
   Krugluger, Walter
   Binder, Susanne
TI Implication of CD21, CD35, and CD55 in the Pathogenesis of Age-Related
   Macular Degeneration
SO AMERICAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID FACTOR-H POLYMORPHISM; COMPLEMENT-SYSTEM
AB PURPOSE: To determine a possible implication of CD21, CD35, and CD55 in the pathogenesis of age-related macular degeneration (AMD) by assessing the difference in expression rates of these factors on AMD patients and a control group.
   DESIGN: Case-control study.
   METHODS.: Fifty unrelated AMD patients and 48 unrelated sex- and age-matched control subjects participated in this case-control study. Samples of fresh EDTA-blood were stained and flow cytometry was chosen to measure fluorescence emissions. The association between exudative AMD and CD21, CD35, and CD55 was evaluated from all patients who completed the study.
   RESULTS: Our study shows CD35 to be expressed in a significantly higher frequency in AMD patients on monocytes (P = .00586), lymphocytes (P = .000605), and granulocytes (P < .000033). In contrast, the expression rate of CD21 (P > .05) and CD55 (P > .05) are similar in both groups.
   CONCLUSION: More regulative factors of the complement system are involved in pathogenesis of AMD. Our study underlines the key role of the complement system in AMD and shows the involvement of the whole immune system through more regulative factors. (Am J Ophthalmol 2011;152:396-399. (C) 2011 by Elsevier Inc. All rights reserved.)
C1 [Haas, Paulina] Rudolf Fdn Clin, Ludwig Boltzmann Inst Retinol & Biomicroscop Lase, Dept Ophthalmol, A-1030 Vienna, Austria.
   [Nagl, Manfred] Rudolf Fdn Clin, Karl Landsteiner Inst Cell Biol & Cell Therapy, A-1030 Vienna, Austria.
   [Krugluger, Walter] Social Med Ctr E, Dept Lab Med, Vienna, Austria.
C3 Ludwig Boltzmann Institute; Donauspital
RP Haas, P (通讯作者)，Rudolf Fdn Clin, Ludwig Boltzmann Inst Retinol & Biomicroscop Lase, Dept Ophthalmol, Juchgasse 25, A-1030 Vienna, Austria.
EM paulina.haas@wienkav.at
FU LUDWIG BOLTZMANN INSTITUTE FOR RETINOLOGY AND BIOMIcroscopic Laser
   Surgery, Vienna, Austria
FX PUBLICATION OF THIS ARTICLE WAS SUPPORTED BY THE LUDWIG BOLTZMANN
   INSTITUTE FOR RETINOLOGY AND BIOMIcroscopic Laser Surgery, Vienna,
   Austria. The authors report no financial disclosures or conflicts of
   interest. Involved in design of the study (PH., W.K.); conduct of the
   study (TA., M.N.); collection (PH., TA.), management S.B.), and analysis
   of the data (K.S.K., M.N.); interpretation of the data (K.S.K., W.K.);
   preparation of the manuscript (P.H.,T.A.); and review and approval of
   the manuscript (W.K., S.B.). The study was performed in accordance with
   the tenets of the Declaration of Helsinki and the guidelines of the
   local ethics committee of Vienna/Austria (Ethikkommission der Stadt
   Wien). Written informed consent was obtained prior to enrollment.
   Clinical Trials registration: http://www.clinicaltrials.gov
   (registration number NCT01174407).
CR Abbas A.K., 2007, BASIC IMMUNOLOGY FUN, V2nd
   Age-Related Eye Dis Study Res Grp, 2001, AM J OPHTHALMOL, V132, P668
   Bora NS, 2008, SEMIN IMMUNOPATHOL, V30, P85, DOI 10.1007/s00281-008-0110-y
   CHYLACK LT, 1993, ARCH OPHTHALMOL-CHIC, V111, P831, DOI 10.1001/archopht.1993.01090060119035
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Issa PC, 2005, OPHTHALMOLOGE, V102, P1036, DOI 10.1007/s00347-005-1269-4
   Jacobson AC, 2008, J IMMUNOL, V181, P2953, DOI 10.4049/jimmunol.181.5.2953
   Johnson LV, 2001, EXP EYE RES, V73, P887, DOI 10.1006/exer.2001.1094
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   LUBLIN DM, 1989, ANNU REV IMMUNOL, V7, P35, DOI 10.1146/annurev.immunol.7.1.35
   Nielsen CH, 2002, J LEUKOCYTE BIOL, V72, P249
   Odhiambo CO, 2008, BMC MED, V6, DOI 10.1186/1741-7015-6-23
   Robman L, 2005, AM J EPIDEMIOL, V161, P1013, DOI 10.1093/aje/kwi130
   Sivaprasad S, 2006, EYE, V20, P867, DOI 10.1038/sj.eye.6702176
   SPAIDE RF, 2003, RETINA, P595
   TERSTAPPEN LWMM, 1992, J LEUKOCYTE BIOL, V52, P652, DOI 10.1002/jlb.52.6.652
NR 18
TC 15
Z9 15
U1 0
U2 5
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0002-9394
EI 1879-1891
J9 AM J OPHTHALMOL
JI Am. J. Ophthalmol.
PD SEP
PY 2011
VL 152
IS 3
BP 396
EP 399
DI 10.1016/j.ajo.2011.02.017
PG 4
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 815IS
UT WOS:000294519900009
PM 21669404
DA 2022-11-30
ER

PT J
AU Nebbioso, M
   Barbato, A
   Pescosolido, N
AF Nebbioso, Marcella
   Barbato, Andrea
   Pescosolido, Nicola
TI Scotopic Microperimetry in the Early Diagnosis of Age-Related Macular
   Degeneration: Preliminary Study
SO BIOMED RESEARCH INTERNATIONAL
LA English
DT Article
ID BRUCHS MEMBRANE; DARK-ADAPTATION; MACULOPATHY; PREVALENCE; BIOFEEDBACK
AB Background. Recent clinical studies have shown that, in some degenerative retinal diseases, like age-related macular degeneration (AMD), the sensitivity of the rods decreases more rapidly than the sensitivity of the cones. The aim of this study was to evaluate if there is a correlation between the presence of hard drusen at the macular level and the rod damage responsible for the reduction in scotopic retinal sensitivity in subjects at risk for AMD. Methods. The authors selected 24 subjects (14 men and 10 women) with an average age of 67.25 + 5.7 years. Macular hard drusen were present in 50% of the subjects at the fundus oculi exam. The researchers evaluated the retinal sensitivity to light in mesopic and scotopic conditions of each subject with an MP-1 scotopic microperimeter (MP-1S). Results. In subjects with hard drusen in the fundus oculi examination, there was a statistically significant reduction in scotopic retinal sensitivity, while the mesopic retinal sensitivity was not compromised. Conclusion. This study revealed how the presence of hard drusen at the macular level is associated with a reduction in scotopic retinal sensitivity compared to a control group of healthy subjects. Retinal functionality in a scotopic setting examined with MP-1S could be useful in early diagnosis of AMD.
C1 [Nebbioso, Marcella; Barbato, Andrea] Univ Roma La Sapienza, Fac Med & Odontol, Dept Sense Organs, Policlin Umberto I, I-00185 Rome, Italy.
   [Nebbioso, Marcella] Univ Roma La Sapienza, Ocular Electrophysiol Ctr, Dept Sense Organs, I-00161 Rome, Italy.
   [Pescosolido, Nicola] Univ Roma La Sapienza, Fac Med & Odontol, Dept Cardiovasc Resp Nephrol Geriatr & Aesthet Sc, Policlin Umberto I, I-00185 Rome, Italy.
C3 Sapienza University Rome; University Hospital Sapienza Rome; Sapienza
   University Rome; Sapienza University Rome; University Hospital Sapienza
   Rome
RP Nebbioso, M (通讯作者)，Univ Roma La Sapienza, Fac Med & Odontol, Dept Sense Organs, Policlin Umberto I, Piazzale Aldo Moro 5, I-00185 Rome, Italy.
EM marcella.nebbioso@uniroma1.it
RI Nebbioso, Marcella/K-6878-2018
OI Nebbioso, Marcella/0000-0002-5512-0849
CR Birch DG, 2011, INVEST OPHTH VIS SCI, V52, P7141, DOI 10.1167/iovs.11-7509
   Bird A, 1996, BRIT J OPHTHALMOL, V80, P2, DOI 10.1136/bjo.80.1.2
   BIRD AC, 1992, BRIT J OPHTHALMOL, V76, P166, DOI 10.1136/bjo.76.3.166
   Blasiak J, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/768026
   BRESSLER NM, 1988, SURV OPHTHALMOL, V32, P375, DOI 10.1016/0039-6257(88)90052-5
   Cavallotti C, 2004, CAN J OPHTHALMOL, V39, P61, DOI 10.1016/S0008-4182(04)80054-1
   Cavallotti C, 2001, JPN J OPHTHALMOL, V45, P68, DOI 10.1016/S0021-5155(00)00294-X
   Crossland MD, 2011, BMC OPHTHALMOL, V11, DOI 10.1186/1471-2415-11-5
   Curcio CA, 2000, INVEST OPHTH VIS SCI, V41, P2015
   Curcio CA, 1996, INVEST OPHTH VIS SCI, V37, P1236
   Delori FC, 2001, INVEST OPHTH VIS SCI, V42, P1855
   FEENEYBURNS L, 1985, AM J OPHTHALMOL, V100, P686, DOI 10.1016/0002-9394(85)90625-7
   Feigl B, 2006, CURR EYE RES, V31, P635, DOI 10.1080/02713680600762739
   Isas JM, 2010, INVEST OPHTH VIS SCI, V51, P1304, DOI 10.1167/iovs.09-4207
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   MITCHELL P, 1995, OPHTHALMOLOGY, V102, P1450
   MOORE DJ, 1995, INVEST OPHTH VIS SCI, V36, P1290
   Murakami Kazuma, 2012, Commun Integr Biol, V5, P255, DOI 10.4161/cib.19548
   Nebbioso M, 2012, INT J EXP PATHOL, V93, P401, DOI 10.1111/j.1365-2613.2012.00832.x
   Nebbioso M, 2011, CLIN EXP OPTOM, V94, P276, DOI 10.1111/j.1444-0938.2010.00476.x
   Nebbioso M, 2009, J OCUL PHARMACOL TH, V25, P249, DOI 10.1089/jop.2008.0106
   Owsley C, 2000, INVEST OPHTH VIS SCI, V41, P267
   Owsley C, 2001, OPHTHALMOLOGY, V108, P1196, DOI 10.1016/S0161-6420(01)00580-2
   Pescosolido N., 2011, ELETTROFISIOLOGIA CL
   Pescosolido N., 1992, ACUITA VISIVA LUMINA
   RAMRATTAN RS, 1994, INVEST OPHTH VIS SCI, V35, P2857
   Scholl HPN, 2004, INVEST OPHTH VIS SCI, V45, P574, DOI 10.1167/iovs.03-0495
   Starita C, 1996, EXP EYE RES, V62, P565, DOI 10.1006/exer.1996.0066
   STEINMETZ RL, 1993, BRIT J OPHTHALMOL, V77, P549, DOI 10.1136/bjo.77.9.549
   van Leeuwen R, 2003, ARCH OPHTHALMOL-CHIC, V121, P519, DOI 10.1001/archopht.121.4.519
   Villanova L, 2013, J BIOL REG HOMEOS AG, V27, P497
   VINGERLING JR, 1995, OPHTHALMOLOGY, V102, P205
   Vingolo EM, 2007, APPL PSYCHOPHYS BIOF, V32, P185, DOI [10.1007/s10484-007-9038-6, 10.1007/sl0484-007-9038-6]
   Vingolo EM, 2013, APPL PSYCHOPHYS BIOF, V38, P11, DOI 10.1007/s10484-012-9203-4
   Wu ZC, 2014, OPHTHALMOLOGY, V121, P1612, DOI 10.1016/j.ophtha.2014.02.005
   Zarbin MA, 1998, EUR J OPHTHALMOL, V8, P199, DOI 10.1177/112067219800800401
NR 36
TC 7
Z9 7
U1 0
U2 4
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 2314-6133
EI 2314-6141
J9 BIOMED RES INT
JI Biomed Res. Int.
PY 2014
VL 2014
AR 671529
DI 10.1155/2014/671529
PG 7
WC Biotechnology & Applied Microbiology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biotechnology & Applied Microbiology; Research & Experimental Medicine
GA AY8GC
UT WOS:000347791400001
PM 25548774
OA gold, Green Published, Green Submitted
DA 2022-11-30
ER

PT J
AU Lem, DW
   Davey, PG
   Gierhart, DL
   Rosen, RB
AF Lem, Drake W.
   Davey, Pinakin Gunvant
   Gierhart, Dennis L.
   Rosen, Richard B.
TI A Systematic Review of Carotenoids in the Management of Age-Related
   Macular Degeneration
SO ANTIOXIDANTS
LA English
DT Review
DE carotenoids; macular pigment; macular pigment optical density; MPOD;
   lutein; zeaxanthin; meso-zeaxanthin; age-related macular degeneration;
   retinal neurodegeneration
ID PIGMENT OPTICAL-DENSITY; HETEROCHROMATIC FLICKER PHOTOMETRY; MEDIATED
   DARK-ADAPTATION; ENRICHMENT SUPPLEMENTATION TRIALS; DUAL-WAVELENGTH
   AUTOFLUORESCENCE; RESONANCE RAMAN MEASUREMENT; SIMPLIFIED SEVERITY
   SCALE; GANGLION-CELL COMPLEX; LONG-TERM INCIDENCE; OXIDATIVE STRESS
AB Age-related macular degeneration (AMD) remains a leading cause of modifiable vision loss in older adults. Chronic oxidative injury and compromised antioxidant defenses represent essential drivers in the development of retinal neurodegeneration. Overwhelming free radical species formation results in mitochondrial dysfunction, as well as cellular and metabolic imbalance, which becomes exacerbated with increasing age. Thus, the depletion of systemic antioxidant capacity further proliferates oxidative stress in AMD-affected eyes, resulting in loss of photoreceptors, neuroinflammation, and ultimately atrophy within the retinal tissue. The aim of this systematic review is to examine the neuroprotective potential of the xanthophyll carotenoids lutein, zeaxanthin, and meso-zeaxanthin on retinal neurodegeneration for the purpose of adjunctive nutraceutical strategy in the management of AMD. A comprehensive literature review was performed to retrieve 55 eligible publications, using four database searches from PubMed, Embase, Cochrane Library, and the Web of Science. Epidemiology studies indicated an enhanced risk reduction against late AMD with greater dietary consumption of carotenoids, meanwhile greater concentrations in macular pigment demonstrated significant improvements in visual function among AMD patients. Collectively, evidence strongly suggests that carotenoid vitamin therapies offer remarkable synergic protection in the neurosensory retina, with the potential to serve as adjunctive nutraceutical therapy in the management of established AMD, albeit these benefits may vary among different stages of disease.
C1 [Lem, Drake W.; Davey, Pinakin Gunvant] Western Univ Hlth Sci, Coll Optometry, Pomona, CA 91766 USA.
   [Gierhart, Dennis L.] ZeaVision LLC, Chesterfield, MO 63005 USA.
   [Rosen, Richard B.] Icahn Sch Med Mt Sinai, New York Eye & Ear Infirm Mt Sinai, Dept Ophthalmol, New York, NY 10029 USA.
C3 Western University of Health Sciences; Icahn School of Medicine at Mount
   Sinai; New York Eye & Ear Infirmary of Mount Sinai
RP Davey, PG (通讯作者)，Western Univ Hlth Sci, Coll Optometry, Pomona, CA 91766 USA.
EM drake.lem@westernu.edu; contact@pinakin-gunvant.com;
   dgierhart@zeavision.com; rrosen@nyee.edu
OI Davey, Pinakin/0000-0002-6683-7052
CR Abdel-Aal EM, 2013, NUTRIENTS, V5, P1169, DOI 10.3390/nu5041169
   Age-Related Eye Disease Study 2 Research Group, 2013, JAMA, V309, P2005, DOI 10.1001/jama.2013.4997
   Akuffo KO, 2015, EYE, V29, P902, DOI 10.1038/eye.2015.64
   Akuffo KO, 2017, INVEST OPHTH VIS SCI, V58, P5347, DOI 10.1167/iovs.16-21192
   Akuffo KO, 2014, OPHTHAL EPIDEMIOL, V21, P111, DOI 10.3109/09286586.2014.888085
   Al-Aubaidy HA, 2011, EUR J ENDOCRINOL, V164, P899, DOI 10.1530/EJE-11-0053
   Amissah-Arthur KN, 2012, EYE, V26, P394, DOI 10.1038/eye.2011.335
   Anand R, 2000, OPHTHALMOLOGY, V107, P2224
   [Anonymous], 2009, OPTOMETRY, V80, P592, DOI 10.1016/j.optm.2009.08.002
   [Anonymous], 1993, Arch Ophthalmol, V111, P104
   Armstrong JS, 2007, BRIT J PHARMACOL, V151, P1154, DOI 10.1038/sj.bjp.0707288
   Arnold C, 2013, NUTRITION, V29, P1412, DOI 10.1016/j.nut.2013.05.012
   Arnold C, 2013, JAMA OPHTHALMOL, V131, P564, DOI 10.1001/jamaophthalmol.2013.2851
   Arslan S, 2019, J AM COLL NUTR, V38, P424, DOI 10.1080/07315724.2018.1538830
   Azar G, 2017, J FR OPHTALMOL, V40, P303, DOI 10.1016/j.jfo.2016.11.009
   Barot M, 2011, CURR EYE RES, V36, P1069, DOI 10.3109/02713683.2011.607536
   Barreau E, 1996, INVEST OPHTH VIS SCI, V37, P384
   Bartlett HE, 2007, EUR J CLIN NUTR, V61, P1121, DOI 10.1038/sj.ejcn.1602626
   Bartlett H, 2007, SURV OPHTHALMOL, V52, P655, DOI 10.1016/j.survophthal.2007.08.022
   Bartlett H, 2011, BRIT J OPHTHALMOL, V95, P662, DOI 10.1136/bjo.2009.178137
   Bartlett H, 2010, CLIN EXP OPTOM, V93, P300, DOI 10.1111/j.1444-0938.2010.00499.x
   Beatty S, 1999, BRIT J OPHTHALMOL, V83, P867, DOI 10.1136/bjo.83.7.867
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   Beatty S, 2001, INVEST OPHTH VIS SCI, V42, P439
   Beatty S, 2013, OPHTHALMOLOGY, V120, P600, DOI 10.1016/j.ophtha.2012.08.040
   Berendschot TTJM, 2000, INVEST OPHTH VIS SCI, V41, P3322
   Berendschot TTJM, 2004, ARCH BIOCHEM BIOPHYS, V430, P149, DOI 10.1016/j.abb.2004.04.029
   Bernstein PS, 2016, PROG RETIN EYE RES, V50, P34, DOI 10.1016/j.preteyeres.2015.10.003
   Bernstein PS, 2010, VISION RES, V50, P716, DOI 10.1016/j.visres.2009.10.014
   Bernstein PS, 2004, ARCH BIOCHEM BIOPHYS, V430, P163, DOI 10.1016/j.abb.2004.07.004
   Bernstein PS, 2002, OPHTHALMOLOGY, V109, P1780, DOI 10.1016/S0161-6420(02)01173-9
   Berrow EJ, 2013, BRIT J NUTR, V109, P2008, DOI 10.1017/S0007114512004187
   Berrow EJ, 2010, DOC OPHTHALMOL, V121, P51, DOI 10.1007/s10633-010-9226-1
   Bhutto I, 2012, MOL ASPECTS MED, V33, P295, DOI 10.1016/j.mam.2012.04.005
   Biesemeier A, 2014, NEUROBIOL AGING, V35, P2562, DOI 10.1016/j.neurobiolaging.2014.05.003
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Bohn T, 2008, CURR NUTR FOOD SCI, V4, P240, DOI 10.2174/157340108786263685
   Bone RA, 2001, INVEST OPHTH VIS SCI, V42, P235
   BONE RA, 1993, INVEST OPHTH VIS SCI, V34, P2033
   Bone RA, 2007, NUTR METAB, V4, DOI 10.1186/1743-7075-4-12
   Bone RA, 2020, NUTRIENTS, V12, DOI 10.3390/nu12051321
   Bone RA, 2013, J BIOMED OPT, V18, DOI 10.1117/1.JBO.18.10.107003
   Bone RA, 2010, ARCH BIOCHEM BIOPHYS, V504, P50, DOI 10.1016/j.abb.2010.06.019
   Bonyadi MHJ, 2018, ACTA OPHTHALMOL, V96, pe105, DOI 10.1111/aos.13494
   Bonyadi M, 2016, ACTA OPHTHALMOL, V94, pE779, DOI 10.1111/aos.13143
   Bourne RRA, 2018, BRIT J OPHTHALMOL, V102, P575, DOI 10.1136/bjophthalmol-2017-311258
   Bovier ER, 2015, ARCH BIOCHEM BIOPHYS, V572, P54, DOI 10.1016/j.abb.2014.11.012
   Bovier ER, 2013, NUTRIENTS, V5, P750, DOI 10.3390/nu5030750
   Brandl C, 2019, INVEST OPHTH VIS SCI, V60, P1581, DOI 10.1167/iovs.18-25332
   Bray GA, 2004, AM J CLIN NUTR, V79, P537
   Broekmans WMR, 2002, AM J CLIN NUTR, V76, P595, DOI 10.1093/ajcn/76.3.595
   Buhren J, 2006, OPTOMETRY VISION SCI, V83, P290, DOI 10.1097/01.opx.0000216100.93302.2d
   Caban-Martinez AJ, 2011, PREV CHRONIC DIS, V8
   Cai JY, 2000, PROG RETIN EYE RES, V19, P205, DOI 10.1016/S1350-9462(99)00009-9
   Califf RM, 2018, EXP BIOL MED, V243, P213, DOI 10.1177/1535370217750088
   Cangemi Francis E, 2007, BMC Ophthalmol, V7, P3, DOI 10.1186/1471-2415-7-3
   Castenmiller JJM, 1998, ANNU REV NUTR, V18, P19, DOI 10.1146/annurev.nutr.18.1.19
   Castro A.M., 2017, REV MEDICA HOSP GEN, V80, P101, DOI [10.1016/j.hgmx.2016.06.011, DOI 10.1016/J.HGMX.2016.06.011]
   Chakrabarti M, 2020, KERALA J OPHTHALMOL, V32, P224, DOI [10.4103/kjo.kjo_114_20, DOI 10.4103/KJO.KJO_114_20]
   Chakravarthy U, 2007, OPHTHALMOLOGY, V114, P1157, DOI 10.1016/j.ophtha.2006.09.022
   Chen CZ, 2004, DOC OPHTHALMOL, V109, P1
   Chen M, 2015, J LEUKOCYTE BIOL, V98, P713, DOI 10.1189/jlb.3RI0615-239R
   Chen XP, 2012, NEUROSCI BULL, V28, P737, DOI 10.1007/s12264-012-1292-9
   Chew EY, 2014, JAMA OPHTHALMOL, V132, P142, DOI 10.1001/jamaophthalmol.2013.7376
   Chew EY, 2012, OPHTHALMOLOGY, V119, P2282, DOI 10.1016/j.ophtha.2012.05.027
   Cho EY, 2008, AM J CLIN NUTR, V87, P1837, DOI 10.1093/ajcn/87.6.1837
   Cho EY, 2004, ARCH OPHTHALMOL-CHIC, V122, P883, DOI 10.1001/archopht.122.6.883
   Choudhury F, 2011, AM J OPHTHALMOL, V152, P385, DOI 10.1016/j.ajo.2011.02.025
   Chous AP, 2016, BRIT J OPHTHALMOL, V100, P227, DOI 10.1136/bjophthalmol-2014-306534
   Christaras D, 2019, BIOMED OPT EXPRESS, V10, P3572, DOI 10.1364/BOE.10.003572
   Chung HY, 2009, AM J CLIN NUTR, V90, P533, DOI 10.3945/ajcn.2009.27712
   Connolly EE, 2010, CURR EYE RES, V35, P335, DOI 10.3109/02713680903521951
   Connor WE, 2007, INVEST OPHTH VIS SCI, V48, P4226, DOI 10.1167/iovs.06-1275
   Conti B, 1997, EUR J PHARM SCI, V5, P287, DOI 10.1016/S0928-0987(97)00023-7
   Corvi F, 2017, BRIT J OPHTHALMOL, V101, P770, DOI 10.1136/bjophthalmol-2016-309115
   Curcio CA, 1996, INVEST OPHTH VIS SCI, V37, P1236
   Curcio CA, 2011, INVEST OPHTH VIS SCI, V52, P3943, DOI 10.1167/iovs.10-6377
   Dasch B, 2005, GRAEF ARCH CLIN EXP, V243, P1028, DOI 10.1007/s00417-005-1176-z
   Davey PG, 2019, PROC SPIE, V10858, DOI 10.1117/12.2508723
   Davey PG, 2020, NUTRIENTS, V12, DOI 10.3390/nu12113271
   Davey PG, 2016, CLIN OPHTHALMOL, V10, P1671, DOI 10.2147/OPTH.S111708
   Davis MD, 2005, ARCH OPHTHALMOL-CHIC, V123, P1484
   Dawczynski J, 2013, GRAEF ARCH CLIN EXP, V251, P2711, DOI 10.1007/s00417-013-2376-6
   de Kinkelder R, 2011, EYE, V25, P105, DOI 10.1038/eye.2010.164
   Decanini A, 2007, AM J OPHTHALMOL, V143, P607, DOI 10.1016/j.ajo.2006.12.006
   Delcourt C, 2006, INVEST OPHTH VIS SCI, V47, P2329, DOI 10.1167/iovs.05-1235
   Delori FC, 2004, ARCH BIOCHEM BIOPHYS, V430, P156, DOI 10.1016/j.abb.2004.05.016
   Delori FC, 2001, J OPT SOC AM A, V18, P1212, DOI 10.1364/JOSAA.18.001212
   Dennison JL, 2013, EXP EYE RES, V116, P190, DOI 10.1016/j.exer.2013.08.014
   Dietzel M, 2011, INVEST OPHTH VIS SCI, V52, P3452, DOI 10.1167/iovs.10-6713
   Dimitrov PN, 2008, INVEST OPHTH VIS SCI, V49, P55, DOI 10.1167/iovs.06-1048
   Dong A, 2009, J CELL PHYSIOL, V219, P544, DOI 10.1002/jcp.21698
   Droge W, 2002, PHYSIOL REV, V82, P47, DOI 10.1152/physrev.00018.2001
   Dunaief JL, 2002, ARCH OPHTHALMOL-CHIC, V120, P1435, DOI 10.1001/archopht.120.11.1435
   Eisenhauer B, 2017, NUTRIENTS, V9, DOI 10.3390/nu9020120
   Fasler K, 2020, BRIT J OPHTHALMOL, V104, P684, DOI 10.1136/bjophthalmol-2019-314446
   FDA-NIH Biomarker Working Group, 2021, BEST BIOM ENDPOINTS
   Feher J, 2003, OPHTHALMOLOGICA, V217, P351, DOI 10.1159/000071351
   Feher J, 2006, NEUROBIOL AGING, V27, P983, DOI 10.1016/j.neurobiolaging.2005.05.012
   Feigl Beatrix, 2005, Clin Exp Optom, V88, P304
   Fernandez-Sanchez A, 2011, INT J MOL SCI, V12, P3117, DOI 10.3390/ijms12053117
   Ferrara D, 2017, INVEST OPHTH VIS SCI, V58, P3519, DOI 10.1167/iovs.17-21696
   Ferris FL, 2005, ARCH OPHTHALMOL-CHIC, V123, P1570
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Flammer J, 2013, EPMA J, V4, DOI 10.1186/1878-5085-4-14
   FRAYN KN, 1995, ADV ENZYME REGUL, V35, P163, DOI 10.1016/0065-2571(94)00011-Q
   Freund KB, 2008, RETINA-J RET VIT DIS, V28, P201, DOI 10.1097/IAE.0b013e3181669504
   Gale CR, 2003, INVEST OPHTH VIS SCI, V44, P2461, DOI 10.1167/iovs.02-0929
   Garcia-Layana A, 2021, NUTRIENTS, V13, DOI 10.3390/nu13041253
   Garcia-Layana A, 2013, NUTRIENTS, V5, P543, DOI 10.3390/nu5020543
   Garrity ST, 2018, INVEST OPHTH VIS SCI, V59, pAMD48, DOI 10.1167/iovs.18-24158
   Gellermann W, 2002, J OPT SOC AM A, V19, P1172, DOI 10.1364/JOSAA.19.001172
   Georgieva E, 2017, ANTICANCER RES, V37, P5373, DOI 10.21873/anticanres.11963
   Gerth C, 2006, ARCH OPHTHALMOL-CHIC, V124, P345, DOI 10.1001/archopht.124.3.345
   Gin TJ, 2011, INVEST OPHTH VIS SCI, V52, P9267, DOI 10.1167/iovs.11-8517
   Gorusupudi A, 2016, INVEST OPHTH VIS SCI, V57, P1853, DOI 10.1167/iovs.16-19111
   Gross LS, 2004, AM J CLIN NUTR, V79, P774
   GRUSZECKI WI, 1990, BIOCHIM BIOPHYS ACTA, V1023, P405, DOI 10.1016/0005-2736(90)90133-9
   Guymer R, 2020, CLIN EXP OPHTHALMOL, V48, P983, DOI 10.1111/ceo.13837
   Hammond BR, 2014, INVEST OPHTH VIS SCI, V55, P8583, DOI 10.1167/iovs.14-15573
   Hammond BR, 2013, INVEST OPHTH VIS SCI, V54, P476, DOI 10.1167/iovs.12-10411
   Hammond BR, 1996, VISION RES, V36, P2001, DOI 10.1016/0042-6989(95)00290-1
   Hammond BR, 1996, VISION RES, V36, P3003, DOI 10.1016/0042-6989(96)00008-9
   Hammond BR, 1996, EXP EYE RES, V62, P293, DOI 10.1006/exer.1996.0035
   Hammond BR, 2002, INVEST OPHTH VIS SCI, V43, P47
   Handa S, 2011, EYE, V25, P1170, DOI 10.1038/eye.2011.143
   HEINONEN OP, 1994, NEW ENGL J MED, V330, P1029
   Higgins JPT, 2011, BMJ-BRIT MED J, V343, DOI 10.1136/bmj.d5928
   Ho L, 2011, ARCH OPHTHALMOL-CHIC, V129, P758, DOI 10.1001/archophthalmol.2011.141
   Hof KHV, 2000, J NUTR, V130, P503
   Hood DC, 2003, J NEURO-OPHTHALMOL, V23, P225, DOI 10.1097/00041327-200309000-00008
   Hood DC, 2002, INVEST OPHTH VIS SCI, V43, P1673
   Howells O, 2013, GRAEF ARCH CLIN EXP, V251, P871, DOI 10.1007/s00417-012-2127-0
   Howells O, 2011, GRAEF ARCH CLIN EXP, V249, P315, DOI 10.1007/s00417-010-1577-5
   Huang CP, 2020, NUTRIENTS, V12, DOI 10.3390/nu12071950
   Huang HF, 2019, CURR EYE RES, V44, P324, DOI 10.1080/02713683.2018.1542735
   Huang Shizhou, 2000, Documenta Ophthalmologica, V101, P115
   Huang YM, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/564738
   Huang YM, 2015, BRIT J OPHTHALMOL, V99, P371, DOI 10.1136/bjophthalmol-2014-305503
   Huang YM, 2013, NUTRITION, V29, P387, DOI 10.1016/j.nut.2012.06.009
   Huisingh C, 2016, INVEST OPHTH VIS SCI, V57, P739, DOI 10.1167/iovs.15-18316
   Jackson GR, 2002, AGEING RES REV, V1, P381, DOI 10.1016/S1568-1637(02)00007-7
   Jaiswal M, 2015, 3 BIOTECH, V5, P123, DOI 10.1007/s13205-014-0214-0
   Jeganathan VSE, 2008, AM J OPHTHALMOL, V146, P954, DOI 10.1016/j.ajo.2008.07.006
   Johnson EJ, 2000, AM J CLIN NUTR, V71, P1555
   Johnson EJ, 2008, AM J CLIN NUTR, V87, P1521, DOI 10.1093/ajcn/87.5.1521
   Johnson EJ, 2021, EYE, V35, P1620, DOI 10.1038/s41433-020-01124-2
   Johnson EJ, 2014, NUTR REV, V72, P605, DOI 10.1111/nure.12133
   Johnson Elizabeth J, 2013, J Aging Res, V2013, P951786, DOI 10.1155/2013/951786
   Jonas JB, 2017, ASIA-PAC J OPHTHALMO, V6, P493, DOI 10.22608/APO.2017251
   Junghans A, 2001, ARCH BIOCHEM BIOPHYS, V391, P160, DOI 10.1006/abbi.2001.2411
   Kaarniranta K, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20102374
   Kaarniranta K, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19082317
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Kawasaki R, 2010, OPHTHALMOLOGY, V117, P921, DOI 10.1016/j.ophtha.2009.10.007
   Kennedy CJ, 1995, EYE, V9, P763, DOI 10.1038/eye.1995.192
   Khachik F, 1997, INVEST OPHTH VIS SCI, V38, P1802
   Khachik F, 2006, INVEST OPHTH VIS SCI, V47, P5234, DOI 10.1167/iovs.06-0504
   Kijlstra A, 2012, PROG RETIN EYE RES, V31, P303, DOI 10.1016/j.preteyeres.2012.03.002
   KILBRIDE PE, 1989, VISION RES, V29, P663, DOI 10.1016/0042-6989(89)90028-X
   Kim JH, 2020, J CLIN MED, V9, DOI 10.3390/jcm9041145
   Klein R, 2006, OPHTHALMOLOGY, V113, P373, DOI 10.1016/j.ophtha.2005.12.013
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   Klein R, 2014, OPHTHAL EPIDEMIOL, V21, P14, DOI 10.3109/09286586.2013.867512
   Klein R, 2011, ARCH OPHTHALMOL-CHIC, V129, P75, DOI 10.1001/archophthalmol.2010.318
   Koh HH, 2004, EXP EYE RES, V79, P21, DOI 10.1016/j.exer.2004.03.001
   Krinsky Norman I., 2005, Molecular Aspects of Medicine, V26, P459
   Krishnan T, 2010, INVEST OPHTH VIS SCI, V51, P701, DOI 10.1167/iovs.09-4114
   Kumari N, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0203868
   Kvansakul J, 2006, OPHTHAL PHYSL OPT, V26, P362, DOI 10.1111/j.1475-1313.2006.00387.x
   Kwon Hyokjoon, 2013, Front Endocrinol (Lausanne), V4, P71, DOI 10.3389/fendo.2013.00071
   Lambert NG, 2016, PROG RETIN EYE RES, V54, P64, DOI 10.1016/j.preteyeres.2016.04.003
   Lamin A, 2019, EYE, V33, P428, DOI 10.1038/s41433-018-0234-9
   Landrum J.T., 2004, MECHANISTIC EVIDENCE
   Landrum J, 2012, ACTA BIOCHIM POL, V59, P167
   Landrum JT, 1997, EXP EYE RES, V65, P57, DOI 10.1006/exer.1997.0309
   Lapierre-Landry M, 2018, J BIOL ENG, V12, DOI 10.1186/s13036-018-0124-5
   LaRowe TL, 2008, OPHTHALMOLOGY, V115, P876, DOI 10.1016/j.ophtha.2007.06.015
   LEE BB, 1988, J PHYSIOL-LONDON, V404, P323, DOI 10.1113/jphysiol.1988.sp017292
   Lee EK, 2015, INVEST OPHTH VIS SCI, V56, P3976, DOI 10.1167/iovs.15-17013
   Lem D.W., 2021, ANTIOXIDANTS BENEFIT
   Lem DW, 2021, NUTRIENTS, V13, DOI 10.3390/nu13072441
   Lem DW, 2021, NUTRIENTS, V13, DOI 10.3390/nu13061949
   Leung Ivan Y-F, 2008, Optometry, V79, P266, DOI 10.1016/j.optm.2007.03.017
   Li BX, 2020, P NATL ACAD SCI USA, V117, P12352, DOI 10.1073/pnas.1922793117
   Li J, 2001, BRIT J OPHTHALMOL, V85, P287, DOI 10.1136/bjo.85.3.287
   Li LH, 2020, NUTRIENTS, V12, DOI 10.3390/nu12061721
   Li SY, 2012, OXID MED CELL LONGEV, V2012, DOI 10.1155/2012/426769
   Liang FQ, 2003, EXP EYE RES, V76, P397, DOI 10.1016/S0014-4835(03)00023-X
   Liew G, 2016, OPHTHALMOLOGY, V123, P1874, DOI 10.1016/j.ophtha.2016.05.043
   Lim C, 2016, J DRUG DELIV SCI TEC, V36, P168, DOI 10.1016/j.jddst.2016.10.009
   Lima VC, 2010, INVEST OPHTH VIS SCI, V51, P5840, DOI 10.1167/iovs.09-4695
   Liu R, 2015, INVEST OPHTH VIS SCI, V56, P252, DOI 10.1167/iovs.14-15553
   Loane E, 2010, INVEST OPHTH VIS SCI, V51, P5897, DOI 10.1167/iovs.09-4878
   Loughman J, 2012, INVEST OPHTH VIS SCI, V53, P7871, DOI 10.1167/iovs.12-10690
   Loughman J, 2010, VISION RES, V50, P1249, DOI 10.1016/j.visres.2010.04.009
   Ludwig DS, 1999, PEDIATRICS, V103, DOI 10.1542/peds.103.3.e26
   Ma L, 2016, NUTRIENTS, V8, DOI 10.3390/nu8070426
   Ma L, 2012, OPHTHALMOLOGY, V119, P2290, DOI 10.1016/j.ophtha.2012.06.014
   Ma L, 2012, AM J OPHTHALMOL, V154, P625, DOI 10.1016/j.ajo.2012.04.014
   Ma L, 2012, BRIT J NUTR, V107, P350, DOI 10.1017/S0007114511004260
   Mageney V, 2016, J AGR FOOD CHEM, V64, P3251, DOI 10.1021/acs.jafc.6b00268
   Marazita MC, 2016, REDOX BIOL, V7, P78, DOI 10.1016/j.redox.2015.11.011
   Mares JA, 2006, AM J CLIN NUTR, V84, P1107
   Mares-Perlman JA, 2001, AM J EPIDEMIOL, V153, P424, DOI 10.1093/aje/153.5.424
   MARESPERLMAN JA, 1995, ARCH OPHTHALMOL-CHIC, V113, P1518, DOI 10.1001/archopht.1995.01100120048007
   Maugeri A, 2018, BIOMED RES INT, V2018, DOI 10.1155/2018/7532507
   McLeod DS, 2009, INVEST OPHTH VIS SCI, V50, P4982, DOI 10.1167/iovs.09-3639
   Meagher KA, 2013, BRIT J NUTR, V110, P289, DOI 10.1017/S0007114512004837
   Medeiros NE, 2001, INVEST OPHTH VIS SCI, V42, P795
   Medzhitov R, 2008, NATURE, V454, P428, DOI 10.1038/nature07201
   Meyers KJ, 2015, OPHTHALMOLOGY, V122, P2286, DOI 10.1016/j.ophtha.2015.07.029
   Meyers KJ, 2013, INVEST OPHTH VIS SCI, V54, P2333, DOI [10.1167/iovs.12-10867, 10.1167/iovs.13-13216]
   Michikawa T, 2009, ASIA PAC J CLIN NUTR, V18, P1
   Middha P, 2019, NICOTINE TOB RES, V21, P1045, DOI 10.1093/ntr/nty115
   Miller Joan W, 2017, US Ophthalmic Rev, V10, P119, DOI 10.17925/USOR.2017.10.02.119
   Milton RC, 2005, OPHTHALMOLOGY, V112, P533, DOI 10.1016/j.ophtha.2004.10.047
   Mitchell P, 2018, LANCET, V392, P1147, DOI 10.1016/S0140-6736(18)31550-2
   Moeller SM, 2006, ARCH OPHTHALMOL-CHIC, V124, P1151, DOI 10.1001/archopht.124.8.1151
   Moher David, 2009, BMJ, V339, pb2535, DOI [10.1016/j.ijsu.2010.02.007, 10.1136/bmj.b2535]
   Muftuoglu IK, 2018, RETINA-J RET VIT DIS, V38, P1478, DOI 10.1097/IAE.0000000000001759
   Mukhopadhyay A, 2007, ADV DRUG DELIVER REV, V59, P729, DOI 10.1016/j.addr.2007.06.004
   Murray IJ, 2013, INVEST OPHTH VIS SCI, V54, P1781, DOI 10.1167/iovs.12-10715
   Nagai N, 2020, J CLIN MED, V9, DOI 10.3390/jcm9051347
   Nagai N, 2020, NUTRIENTS, V12, DOI 10.3390/nu12040888
   Nagao A, 2011, BIOFACTORS, V37, P83, DOI 10.1002/biof.151
   National Eye Institute, AGE RELATED MACULAR
   Naysan J, 2016, RETINA-J RET VIT DIS, V36, P449, DOI 10.1097/IAE.0000000000000758
   Nazari Khanamiri Hossein, 2014, J Ophthalmic Vis Res, V9, P181
   Neroev VV, 2008, BIOCHEMISTRY-MOSCOW+, V73, P1317, DOI 10.1134/S0006297908120043
   Nieves DJ, 2003, DIABETES, V52, P172, DOI 10.2337/diabetes.52.1.172
   Nolan J, 2004, INVEST OPHTH VIS SCI, V45, P3940, DOI 10.1167/iovs.04-0273
   Nolan JM, 2007, EXP EYE RES, V84, P61, DOI 10.1016/j.exer.2006.08.016
   Nolan JM, 2016, INVEST OPHTH VIS SCI, V57, P3429, DOI 10.1167/iovs.16-19520
   Nolan JM, 2012, INVEST OPHTH VIS SCI, V53, P7855, DOI 10.1167/iovs.11-9367
   Nolan JM, 2011, VISION RES, V51, P459, DOI 10.1016/j.visres.2010.12.016
   Nordgaard CL, 2006, INVEST OPHTH VIS SCI, V47, P815, DOI 10.1167/iovs.05-0976
   Nozaki M, 2006, P NATL ACAD SCI USA, V103, P2328, DOI 10.1073/pnas.0408835103
   O'Connell OF, 2007, NUTR RES, V27, P258, DOI 10.1016/j.nutres.2007.04.002
   Obana A, 2008, OPHTHALMOLOGY, V115, P147, DOI 10.1016/j.ophtha.2007.02.028
   Obana A, 2018, JPN J OPHTHALMOL, V62, P473, DOI 10.1007/s10384-018-0588-3
   Obana A, 2014, GRAEF ARCH CLIN EXP, V252, P1221, DOI 10.1007/s00417-014-2574-x
   Obana A, 2011, OPHTHALMOLOGY, V118, P1852, DOI 10.1016/j.ophtha.2011.02.017
   Olk R Joseph, 2015, Int J Retina Vitreous, V1, P22, DOI 10.1186/s40942-015-0019-2
   Owsley C, 2001, OPHTHALMOLOGY, V108, P1196, DOI 10.1016/S0161-6420(01)00580-2
   Owsley C, 2007, OPHTHALMOLOGY, V114, P1728, DOI 10.1016/j.ophtha.2006.12.023
   Owsley C, 2016, CURR EYE RES, V41, P266, DOI 10.3109/02713683.2015.1011282
   Owsley C, 2016, OPHTHALMOLOGY, V123, P344, DOI 10.1016/j.ophtha.2015.09.041
   Ozawa Y, 2017, BMC OPHTHALMOL, V17, DOI 10.1186/s12886-017-0557-5
   Parisi V, 2008, OPHTHALMOLOGY, V115, P324, DOI 10.1016/j.ophtha.2007.05.029
   Parisi V, 2007, RETINA-J RET VIT DIS, V27, P879, DOI 10.1097/IAE.0b013e318042d6aa
   PARKER RS, 1989, J NUTR, V119, P101, DOI 10.1093/jn/119.1.101
   Perry A, 2009, J FOOD COMPOS ANAL, V22, P9, DOI 10.1016/j.jfca.2008.07.006
   Piermarocchi S, 2012, EUR J OPHTHALMOL, V22, P216, DOI 10.5301/ejo.5000069
   Pilotto E, 2013, CAN J OPHTHALMOL, V48, P386, DOI 10.1016/j.jcjo.2013.03.022
   Pinazo-Duran MD, 2015, PROG BRAIN RES, V220, P127, DOI 10.1016/bs.pbr.2015.06.001
   Priya RR, 2012, OPHTHALMOLOGY, V119, P2526, DOI 10.1016/j.ophtha.2012.06.042
   Raman R, 2012, EYE, V26, P950, DOI 10.1038/eye.2012.69
   Rein DB, 2009, ARCH OPHTHALMOL-CHIC, V127, P533, DOI 10.1001/archophthalmol.2009.58
   Resnikoff Serge, 2014, Community Eye Health, V27, P41
   Richer Stuart, 2004, Optometry, V75, P216, DOI 10.1016/S1529-1839(04)70049-4
   Richer Stuart, 2007, Optometry, V78, P213, DOI 10.1016/j.optm.2006.10.019
   Richer SP, 2011, OPTOMETRY, V82, P667, DOI 10.1016/j.optm.2011.08.008
   Rivera A, 2005, HUM MOL GENET, V14, P3227, DOI 10.1093/hmg/ddi353
   Robb MA, 2016, JAMA-J AM MED ASSOC, V315, P1107, DOI 10.1001/jama.2016.2240
   ROSEN BS, 1989, SCIENCE, V244, P1483, DOI 10.1126/science.2734615
   Rosen R, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/687386
   Rosenthal JM, 2006, INVEST OPHTH VIS SCI, V47, P5227, DOI 10.1167/iovs.05-1513
   Rozing MP, 2020, PROG RETIN EYE RES, V76, DOI 10.1016/j.preteyeres.2019.100825
   Rudolf M, 2013, OPHTHALMOLOGY, V120, P821, DOI 10.1016/j.ophtha.2012.10.007
   Sabour-Pickett S, 2014, RETINA-J RET VIT DIS, V34, P1757, DOI 10.1097/IAE.0000000000000174
   Sanabria JC, 2020, JOVE-J VIS EXP, DOI 10.3791/60429
   SanGiovanni JP, 2007, ARCH OPHTHALMOL-CHIC, V125, P1225, DOI 10.1001/archopht.125.9.1225
   Sarks S, 2007, INVEST OPHTH VIS SCI, V48, P968, DOI 10.1167/iovs.06-0443
   Savastano MC, 2014, INVEST OPHTH VIS SCI, V55, P560, DOI 10.1167/iovs.13-12172
   Savini I, 2013, INT J MOL SCI, V14, P10497, DOI 10.3390/ijms140510497
   Sawa M, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-62483-0
   Scripsema NK, 2015, J OPHTHALMOL, V2015, DOI 10.1155/2015/865179
   Seddon JM, 2005, ARCH OPHTHALMOL-CHIC, V123, P321, DOI 10.1001/archopht.123.3.321
   Seddon JM, 2003, ARCH OPHTHALMOL-CHIC, V121, P785, DOI 10.1001/archopht.121.6.785
   SEDDON JM, 1994, JAMA-J AM MED ASSOC, V272, P1413, DOI 10.1001/jama.272.18.1413
   Seddon JM, 2016, JAMA OPHTHALMOL, V134, P1272, DOI 10.1001/jamaophthalmol.2016.3519
   Sene A, 2015, TRENDS MOL MED, V21, P43, DOI 10.1016/j.molmed.2014.10.005
   Shyam R, 2017, P NATL ACAD SCI USA, V114, P10882, DOI 10.1073/pnas.1706332114
   Snellen ELM, 2002, ACTA OPHTHALMOL SCAN, V80, P368, DOI 10.1034/j.1600-0420.2002.800404.x
   Spaide RF, 2020, OPHTHALMOLOGY, V127, P616, DOI 10.1016/j.ophtha.2019.11.004
   Spaide RF, 2018, SURV OPHTHALMOL, V63, P782, DOI 10.1016/j.survophthal.2018.05.005
   Sparrow JR, 2005, EXP EYE RES, V80, P595, DOI 10.1016/j.exer.2005.01.007
   STANGOS N, 1995, OPHTHALMOLOGICA, V209, P194, DOI 10.1159/000310612
   STEINMETZ RL, 1993, BRIT J OPHTHALMOL, V77, P549, DOI 10.1136/bjo.77.9.549
   Stringham JM, 2008, OPTOMETRY VISION SCI, V85, P82, DOI 10.1097/OPX.0b013e318162266e
   Stringham JM, 2007, OPTOMETRY VISION SCI, V84, P859, DOI 10.1097/OPX.0b013e3181559c2b
   Stringham JM, 2017, FOODS, V6, DOI 10.3390/foods6070047
   Stringham JM, 2017, INVEST OPHTH VIS SCI, V58, P2291, DOI 10.1167/iovs.16-21087
   Stringham JM, 2016, EYE VISION, V3, DOI 10.1186/s40662-016-0060-8
   Stringham JM, 2015, INVEST OPHTH VIS SCI, V56, P2459, DOI 10.1167/iovs.14-15716
   Stringham JM, 2011, INVEST OPHTH VIS SCI, V52, P7406, DOI 10.1167/iovs.10-6699
   Suarez-Berumen K., 2014, JSM OPHTHALMOL, V3, P4
   Supanji, 2013, EXP EYE RES, V112, P79, DOI 10.1016/j.exer.2013.04.013
   SUTTER EE, 1992, VISION RES, V32, P433, DOI 10.1016/0042-6989(92)90235-B
   Tan JSL, 2008, OPHTHALMOLOGY, V115, P334, DOI 10.1016/j.ophtha.2007.03.083
   Terluk MR, 2015, J NEUROSCI, V35, P7304, DOI 10.1523/JNEUROSCI.0190-15.2015
   Terman A, 2006, ANTIOXID REDOX SIGN, V8, P197, DOI 10.1089/ars.2006.8.197
   Thurnham DI, 2015, GRAEF ARCH CLIN EXP, V253, P1231, DOI 10.1007/s00417-014-2811-3
   Tilg H, 2006, NAT REV IMMUNOL, V6, P772, DOI 10.1038/nri1937
   Toma C, 2021, ANTIOXIDANTS-BASEL, V10, DOI 10.3390/antiox10050653
   Trieschmann M, 2007, EXP EYE RES, V84, P718, DOI 10.1016/j.exer.2006.12.010
   van Leeuwen R, 2005, JAMA-J AM MED ASSOC, V294, P3101, DOI 10.1001/jama.294.24.3101
   VandenLangenberg GM, 1998, AM J EPIDEMIOL, V148, P204, DOI 10.1093/oxfordjournals.aje.a009625
   Vavvas DG, 2018, P NATL ACAD SCI USA, V115, pE696, DOI 10.1073/pnas.1718059115
   Wang JJ, 2014, OPHTHALMOLOGY, V121, P667, DOI 10.1016/j.ophtha.2013.10.017
   Wang L, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010329
   Wang W, 2007, AM J CLIN NUTR, V85, P762, DOI 10.1093/ajcn/85.3.762
   Weeks DE, 2004, AM J HUM GENET, V75, P174, DOI 10.1086/422476
   Weigert G, 2011, INVEST OPHTH VIS SCI, V52, P8174, DOI 10.1167/iovs.11-7522
   WHO World Health Organization, WORLD REP VIS 2019
   Wickstrom K, 2017, INVEST OPHTH VIS SCI, V58, pBIO27, DOI 10.1167/iovs.17-21778
   Wightman AJ, 2019, CLIN EXP OPTOM, V102, P455, DOI 10.1111/cxo.12842
   Wolf-Schnurrbusch UEK, 2015, INVEST OPHTH VIS SCI, V56, P8069, DOI 10.1167/iovs.15-17586
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Wu J, 2015, JAMA OPHTHALMOL, V133, P1415, DOI 10.1001/jamaophthalmol.2015.3590
   Wu MF, 2019, INT J NANOMED, V14, P2667, DOI 10.2147/IJN.S194068
   Xu HP, 2016, EUR J PHARMACOL, V787, P94, DOI 10.1016/j.ejphar.2016.03.001
   Xu HP, 2009, PROG RETIN EYE RES, V28, P348, DOI 10.1016/j.preteyeres.2009.06.001
   Yannuzzi LA, 2001, RETINA-J RET VIT DIS, V21, P416, DOI 10.1097/00006982-200110000-00003
   Yao Y, 2013, NUTRITION, V29, P958, DOI 10.1016/j.nut.2012.10.017
   Yenice E, 2015, EYE, V29, P1076, DOI 10.1038/eye.2015.86
   Yeo NJY, 2019, FRONT PHARMACOL, V10, DOI 10.3389/fphar.2019.01363
   You QS, 2016, RETINA-J RET VIT DIS, V36, P1381, DOI 10.1097/IAE.0000000000000893
   Yung Madeline, 2016, Int J Retina Vitreous, V2, P12, DOI 10.1186/s40942-016-0035-x
   Zhou HY, 2011, INVEST OPHTH VIS SCI, V52, P4338, DOI 10.1167/iovs.10-6519
   Zucchiatti I, 2015, AM J OPHTHALMOL, V160, P602, DOI 10.1016/j.ajo.2015.05.030
NR 332
TC 14
Z9 14
U1 6
U2 16
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2076-3921
J9 ANTIOXIDANTS-BASEL
JI Antioxidants
PD AUG
PY 2021
VL 10
IS 8
AR 1255
DI 10.3390/antiox10081255
PG 37
WC Biochemistry & Molecular Biology; Chemistry, Medicinal; Food Science &
   Technology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Pharmacology & Pharmacy; Food Science
   & Technology
GA UF5XX
UT WOS:000688647800001
PM 34439503
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Klein, R
   Klein, BEK
   Tomany, SC
   Cruickshanks, K
AF Klein, R
   Klein, BEK
   Tomany, SC
   Cruickshanks, K
TI Association of emphysema, gout and inflammatory markers with long-term
   incidence of age-related maculopathy
SO ARCHIVES OF OPHTHALMOLOGY
LA English
DT Article
ID BEAVER-DAM EYE; OBSTRUCTIVE PULMONARY-DISEASE; RISK-FACTORS;
   CARDIOVASCULAR-DISEASE; MACULAR DEGENERATION; 5-YEAR INCIDENCE;
   VISUAL-ACUITY; POPULATION; ATHEROSCLEROSIS; NEUTROPHILS
AB Objective: To examine the relationship of 2 diseases associated with systemic inflammatory response, emphysema and gout, and selected markers of systemic inflammation with the 10-year incidence of age-related maculopathy.
   Design: Population-based cohort study.
   Participants: We included persons aged 43 to 86 years at baseline examination from 1988 to 1990 living in Beaver Dam, Wis, of whom 3684 subjects participated in a 5-year follow-up examination and 2764 participate in a 10-year follow-up.
   Methods: Standardized protocols for physical examination, blood collection, administration of a questionnaire, and stereoscopic color fundus photography to determine the presence of age-related maculopathy. Standard univariate and multivariate analyses were performed.
   Main Outcome Measures: Incidence and progression of age-related maculopathy.
   Results: While controlling for age, sex, and other factors (history of heavy drinking or smoking, systolic blood pressure, and vitamin use), a higher white blood cell count at baseline was associated with the 10-year incidence of drusen 125 mum or greater in diameter (risk ratio [RR] per 10(6)/muL= 1.10; 95% confidence interval [CI], 1.03-1.17), retinal pigment epithelial depigmentation (RR = 2.08; 95% Cl, 1.01-1.16), and progression of age-related maculopathy (RR = 1.09; 95% Cl, 1.03-1.15). A lower serum albumin level was associated with the incidence of exudative macular degeneration (RR per grams per deciliter=0.31; 95% CI, 0.13-0.76). A history of emphysema at baseline was associated with the incidence of retinal pigment epithelial depigmentation (RR = 2.84; 95% CI, 1.40-5.78), increased retinal pigment (RR = 2.20; 95% Cl, 1.11-4.35), and exudative macular degeneration (RR = 5.12; 95% CI, 1.63-16.06); a history of gout was associated with the incidence of pure geographic atrophy (RR = 3.48; 95% Cl, 1.27-9.53).
   Conclusions: These findings indicate modest relationships between both increased white blood cell count and emphysema and the increased 10-year incidence of lesions defining early and late age-related maculopathy. Further investigation of these relationships in other studies is needed.
C1 Univ Wisconsin, Sch Med, Dept Ophthalmol & Visual Sci, Madison, WI 53726 USA.
   Univ Wisconsin, Sch Med, Dept Populat Hlth Sci, Madison, WI 53726 USA.
C3 University of Wisconsin System; University of Wisconsin Madison;
   University of Wisconsin System; University of Wisconsin Madison
RP Klein, R (通讯作者)，Univ Wisconsin, Sch Med, Dept Ophthalmol & Visual Sci, 610 N Walnut St,450 WARF, Madison, WI 53726 USA.
OI Klein, Ronald/0000-0002-4428-6237
FU NEI NIH HHS [EY06954] Funding Source: Medline; NATIONAL EYE INSTITUTE
   [F32EY006954] Funding Source: NIH RePORTER
CR Akiyama H, 2000, NEUROBIOL AGING, V21, P383, DOI 10.1016/S0197-4580(00)00124-X
   Anand R, 2000, OPHTHALMOLOGY, V107, P2224
   Barnes PJ, 2000, NEW ENGL J MED, V343, P269, DOI 10.1056/NEJM200007273430407
   BLUMENKRANZ MS, 1986, OPHTHALMOLOGY, V93, P552
   Christen WG, 2001, ARCH OPHTHALMOL-CHIC, V119, P1143, DOI 10.1001/archopht.119.8.1143
   DOWEIKO JP, 1991, JPEN-PARENTER ENTER, V15, P476, DOI 10.1177/0148607191015004476
   ERNST E, 1987, JAMA-J AM MED ASSOC, V257, P2318, DOI 10.1001/jama.257.17.2318
   FINKELSTEIN R, 1995, AM J RESP CRIT CARE, V152, P1666, DOI 10.1164/ajrccm.152.5.7582312
   GHEZZI P, 1991, CYTOKINE, V3, P189, DOI 10.1016/1043-4666(91)90015-6
   Gillies MC, 2001, INVEST OPHTH VIS SCI, V42, pS522
   HACHICHA M, 1995, J EXP MED, V182, P2019, DOI 10.1084/jem.182.6.2019
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Hosmer DW, 1989, APPL LOGISTIC REGRES, P238
   KANNEL WB, 1992, JAMA-J AM MED ASSOC, V267, P1253, DOI 10.1001/jama.267.9.1253
   KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868
   Klein R, 1997, OPHTHALMOLOGY, V104, P7, DOI 10.1016/S0161-6420(97)30368-6
   KLEIN R, 1995, ARCH OPHTHALMOL-CHIC, V113, P333, DOI 10.1001/archopht.1995.01100030089026
   Klein R, 2003, OPHTHALMOLOGY, V110, P25, DOI 10.1016/S0161-6420(02)01565-8
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Klein R, 2001, OPHTHALMOLOGY, V108, P1757, DOI 10.1016/S0161-6420(01)00769-2
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1310
   Klein R, 1996, OPHTHALMOLOGY, V103, P1169, DOI 10.1016/S0161-6420(96)30526-5
   Klein R, 1997, OPHTHALMOLOGY, V104, P1804, DOI 10.1016/S0161-6420(97)30023-2
   Klein R, 1999, ARCH OPHTHALMOL-CHIC, V117, P1203
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   Klein R, 1999, OPHTHALMOLOGY, V106, P1056, DOI 10.1016/S0161-6420(99)90255-5
   Klein R, 2001, ARCH OPHTHALMOL-CHIC, V119, P1354
   KLEIN R, 1993, OPHTHALMOLOGY, V100, P406
   Klein R, 1995, PB95273827
   Klein R, 1991, PB91149823
   KLEIN R, 1999, AGE RELATED MACULAR, P31
   KLEIN R, 1991, PB91184267AS
   PENFOLD PL, 1986, INVEST OPHTH VIS SCI, V27, P364
   Penfold PL, 2001, PROG RETIN EYE RES, V20, P385, DOI 10.1016/S1350-9462(00)00025-2
   Pickup JC, 1998, DIABETOLOGIA, V41, P1241, DOI 10.1007/s001250051058
   ROSEFF R, 1987, J RHEUMATOL, V14, P974
   Ross R, 1999, NEW ENGL J MED, V340, P115, DOI 10.1056/NEJM199901143400207
   Sarks S., 1985, RETINAL DIS, P87
   Schols AMWJ, 1999, AM J RESP CRIT CARE, V160, P1220, DOI 10.1164/ajrccm.160.4.9811033
   Smith W, 1998, ARCH OPHTHALMOL-CHIC, V116, P583, DOI 10.1001/archopht.116.5.583
   Snow K K, 1999, Ophthalmic Epidemiol, V6, P125, DOI 10.1076/opep.6.2.125.1558
   Stanescu D, 1996, THORAX, V51, P267, DOI 10.1136/thx.51.3.267
   YANNUZZI LA, 1992, ARCH OPHTHALMOL-CHIC, V110, P1701
NR 43
TC 49
Z9 52
U1 0
U2 0
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 515 N STATE ST, CHICAGO, IL 60610 USA
SN 0003-9950
J9 ARCH OPHTHALMOL-CHIC
JI Arch. Ophthalmol.
PD MAY
PY 2003
VL 121
IS 5
BP 674
EP 678
DI 10.1001/archopht.121.5.674
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 676XU
UT WOS:000182778500010
PM 12742845
OA Bronze
DA 2022-11-30
ER

PT J
AU Lin, MK
   Yang, J
   Hsu, CW
   Gore, A
   Bassuk, AG
   Brown, LM
   Colligan, R
   Sengillo, JD
   Mahajan, VB
   Tsang, SH
AF Lin, Michael K.
   Yang, Jin
   Hsu, Chun Wei
   Gore, Anuradha
   Bassuk, Alexander G.
   Brown, Lewis M.
   Colligan, Ryan
   Sengillo, Jesse D.
   Mahajan, Vinit B.
   Tsang, Stephen H.
TI HTRA1, an age-related macular degeneration protease, processes
   extracellular matrix proteins EFEMP1 and TSP1
SO AGING CELL
LA English
DT Article
DE age related macular degeneration; genetics; mass spectrometry;
   Neurodegenerative diseases
ID COMPLEMENT FACTOR-H; RETINAL-PIGMENT EPITHELIUM; SERINE-PROTEASE;
   MALATTIA LEVENTINESE; SUSCEPTIBILITY; MUTATION; RISK; GENE;
   POLYMORPHISM; ASSOCIATION
AB High-temperature requirement protein A1 (HTRA1) is a serine protease secreted by a number of tissues including retinal pigment epithelium (RPE). A promoter variant of the gene encoding HTRA1 is part of a mutant allele that causes increased HTRA1 expression and contributed to age-related macular degeneration (AMD) in genome-wide association studies. AMD is characterized by pathological development of drusen, extracellular deposits of proteins and lipids on the basal side of RPE. The molecular pathogenesis of AMD is not well understood, and understanding dysregulation of the extracellular matrix may be key. We assess the high-risk genotype at 10q26 by proteomic comparison of protein levels of RPE cells with and without the mutation. We show HTRA1 protein level is increased in high-risk RPE cells along with several extracellular matrix proteins, including known HTRA1 cleavage targets LTBP-1 and clusterin. In addition, two novel targets of HTRA1 have been identified: EFEMP1, an extracellular matrix protein mutated in Doyne honeycomb retinal dystrophy, a genetic eye disease similar to AMD, and thrombospondin 1 (TSP1), an inhibitor of angiogenesis. Our data support the role of RPE extracellular deposition with potential effects in compromised barrier to neovascularization in exudative AMD.
C1 [Lin, Michael K.] Columbia Univ, Coll Phys & Surg, New York, NY USA.
   [Lin, Michael K.; Yang, Jin; Hsu, Chun Wei; Sengillo, Jesse D.; Tsang, Stephen H.] New York Presbyterian Hosp, Edward S Harkness Eye Inst, New York, NY USA.
   [Lin, Michael K.; Yang, Jin; Hsu, Chun Wei; Sengillo, Jesse D.; Tsang, Stephen H.] Columbia Univ, Jonas Childrens Vis Care & Bernard & Shirlee Brow, Herbert Irving Comprehens Canc Ctr,Dept Ophthalmo, Inst Human Nutr,Columbia Stem Cell Initiat, New York, NY USA.
   [Lin, Michael K.; Yang, Jin; Hsu, Chun Wei; Sengillo, Jesse D.; Tsang, Stephen H.] Columbia Univ, Herbert Irving Comprehens Canc Ctr, Inst Human Nutr, Dept Pathol & Cell Biol, New York, NY USA.
   [Yang, Jin] Tianjin Med Univ, Eye Hosp, Tianjin, Peoples R China.
   [Gore, Anuradha; Mahajan, Vinit B.] Stanford Univ, Byers Eye Inst, Dept Ophthalmol, Omics Lab, Palo Alto, CA 94304 USA.
   [Bassuk, Alexander G.] Univ Iowa, Dept Pediat & Neurol, Iowa City, IA USA.
   [Brown, Lewis M.; Colligan, Ryan] Columbia Univ, Dept Biol Sci, Quantitat Prote & Metabol Ctr, New York, NY 10027 USA.
   [Mahajan, Vinit B.] Palo Alto Vet Adm, Palo Alto, CA USA.
C3 Columbia University; NewYork-Presbyterian Hospital; Columbia University;
   Columbia University; Tianjin Medical University; Stanford University;
   University of Iowa; Columbia University
RP Mahajan, VB (通讯作者)，Stanford Univ, Byers Eye Inst, Dept Ophthalmol, Omics Lab, Palo Alto, CA 94304 USA.; Tsang, SH (通讯作者)，Columbia Univ, Edward S Harkness Eye Inst, Dept Ophthalmol, New York, NY 10027 USA.; Tsang, SH (通讯作者)，Columbia Univ, Edward S Harkness Eye Inst, Dept Pathol & Cell Biol, New York, NY 10027 USA.
EM vinit.mahajan@stanford.com; sht2@columbia.edu
OI Mahajan, Vinit/0000-0003-1886-1741; Bassuk,
   Alexander/0000-0002-4067-2157; Dichgans, Martin/0000-0002-0654-387X
FU NIH [R01EY026682, R01EY024665, R01EY025225, R01EY024698, R21AG050437];
   Doris Duke Charitable Foundation [2013103]; Research to Prevent
   Blindness (RPB), New York, NY; National Institute of Health
   [5P30EY019007, R01EY018213]; National Cancer Institute [5P30CA013696];
   Research to Prevent Blindness (RPB) Physician-Scientist Award; RPB, New
   York, NY, USA; Tistou and Charlotte Kerstan Foundation; Schneeweiss Stem
   Cell Fund, New York State [C029572]; Foundation Fighting Blindness New
   York Regional Research Center Grant [C-NY05-0705-0312]; Joel Hoffman
   Fund; Professor Gertrude Rothschild Stem Cell Foundation; Edward N. and
   Della L. Thome Memorial Foundation Awards Program in Age Related Macular
   Degeneration Research; Gebroe Family Foundation; National Natural
   Science Foundation of China [81400412]; Natural Science Foundation of
   Tianjin, China [15JCZDJC34500]; NATIONAL EYE INSTITUTE [R01EY018213,
   R01EY026682, R01EY025225, R01EY024698, R01EY024665] Funding Source: NIH
   RePORTER; NATIONAL INSTITUTE ON AGING [R21AG050437] Funding Source: NIH
   RePORTER
FX VBM and AGB are supported by NIH grants [R01EY026682, R01EY024665,
   R01EY025225, R01EY024698, and R21AG050437], The Doris Duke Charitable
   Foundation Grant #2013103, and Research to Prevent Blindness (RPB), New
   York, NY. The Barbara & Donald Jonas Laboratory of Regenerative Medicine
   and Bernard & Shirlee Brown Glaucoma Laboratory are supported by the
   National Institute of Health [5P30EY019007 and R01EY018213], National
   Cancer Institute Core [5P30CA013696], the Research to Prevent Blindness
   (RPB) Physician-Scientist Award, unrestricted funds from RPB, New York,
   NY, USA. SHT is a member of the RD-CURE Consortium and is supported by
   the Tistou and Charlotte Kerstan Foundation, the Schneeweiss Stem Cell
   Fund, New York State [C029572], the Foundation Fighting Blindness New
   York Regional Research Center Grant [C-NY05-0705-0312], the Joel Hoffman
   Fund, the Professor Gertrude Rothschild Stem Cell Foundation, The Edward
   N. and Della L. Thome Memorial Foundation Awards Program in Age Related
   Macular Degeneration Research and the Gebroe Family Foundation. JY is
   supported by the National Natural Science Foundation of China [81400412]
   and the Natural Science Foundation of Tianjin, China [15JCZDJC34500].
CR Ambati J, 2013, NAT REV IMMUNOL, V13, P438, DOI 10.1038/nri3459
   Beaufort N, 2014, P NATL ACAD SCI USA, V111, P16496, DOI 10.1073/pnas.1418087111
   Chien J, 2004, ONCOGENE, V23, P1636, DOI 10.1038/sj.onc.1207271
   Crabb JW, 2002, P NATL ACAD SCI USA, V99, P14682, DOI 10.1073/pnas.222551899
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Fu L, 2007, HUM MOL GENET, V16, P2411, DOI 10.1093/hmg/ddm198
   Grau S, 2005, P NATL ACAD SCI USA, V102, P6021, DOI 10.1073/pnas.0501823102
   Grau S, 2006, J BIOL CHEM, V281, P6124, DOI 10.1074/jbc.M500361200
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Hara K, 2009, NEW ENGL J MED, V360, P1729, DOI 10.1056/NEJMoa0801560
   Iejima Daisuke, 2015, J Stem Cells, V10, P193
   Jones A, 2011, P NATL ACAD SCI USA, V108, P14578, DOI 10.1073/pnas.1102853108
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Li Y, 2012, MOL MED, V18, P1312, DOI 10.2119/molmed.2012.00242
   Liao JL, 2010, HUM MOL GENET, V19, P4229, DOI 10.1093/hmg/ddq341
   Magnusson KP, 2006, PLOS MED, V3, P109, DOI 10.1371/journal.pmed.0030005
   Marmorstein LHY, 2002, P NATL ACAD SCI USA, V99, P13067, DOI 10.1073/pnas.202491599
   Marmorstein LY, 2007, HUM MOL GENET, V16, P2423, DOI 10.1093/hmg/ddm199
   Nie GY, 2006, DEV DYNAM, V235, P3448, DOI 10.1002/dvdy.20999
   Oka C, 2004, DEVELOPMENT, V131, P1041, DOI 10.1242/dev.00999
   Rivera A, 2005, HUM MOL GENET, V14, P3227, DOI 10.1093/hmg/ddi353
   Schaumberg DA, 2007, ARCH OPHTHALMOL-CHIC, V125, P55, DOI 10.1001/archopht.125.1.55
   Stone EM, 1999, NAT GENET, V22, P199, DOI 10.1038/9722
   Vierkotten S, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022959
   Wang L, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010329
   Yang J, 2014, HUM MOL GENET, V23, P3445, DOI 10.1093/hmg/ddu053
   Yang ZL, 2006, SCIENCE, V314, P992, DOI 10.1126/science.1133811
NR 28
TC 44
Z9 46
U1 1
U2 8
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1474-9718
EI 1474-9726
J9 AGING CELL
JI Aging Cell
PD AUG
PY 2018
VL 17
IS 4
AR e12710
DI 10.1111/acel.12710
PG 9
WC Cell Biology; Geriatrics & Gerontology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology; Geriatrics & Gerontology
GA GO2AU
UT WOS:000439767700001
PM 29730901
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Jackson, TL
   Chakravarthy, U
   Slakter, JS
   Muldrew, A
   Shusterman, EM
   O'Shaughnessy, D
   Arnoldussen, M
   Gertner, ME
   Danielson, L
   Moshfeghi, DM
AF Jackson, Timothy L.
   Chakravarthy, Usha
   Slakter, Jason S.
   Muldrew, Alyson
   Shusterman, E. Mark
   O'Shaughnessy, Denis
   Arnoldussen, Mark
   Gertner, Michael E.
   Danielson, Linda
   Moshfeghi, Darius M.
CA INTREPID Study Grp
TI Stereotactic Radiotherapy for Neovascular Age-Related Macular
   Degeneration
SO OPHTHALMOLOGY
LA English
DT Article
ID EPIMACULAR BRACHYTHERAPY; EPIRETINAL BRACHYTHERAPY; BEVACIZUMAB;
   RANIBIZUMAB; VITRECTOMY; MERITAGE; CABERNET; SAFETY; EYE
AB Purpose: To determine the safety and efficacy of low-voltage, external-beam, stereotactic radiotherapy (SRT) for patients with neovascular age-related macular degeneration (AMD).
   Design: Randomized, double-masked, sham-controlled, multicenter, clinical trial.
   Participants: A total of 230 participants with neovascular AMD who received >= 3 ranibizumab or bevacizumab injections within the preceding year and requiring treatment at enrollment.
   Methods: Participants received 16 Gray, 24 Gray, or sham SRT. All arms received pro re nata (PRN) ranibizumab for 12 months, with PRN bevacizumab or ranibizumab thereafter.
   Main Outcome Measures: Mean number of PRN injections; best-corrected visual acuity (BCVA); loss of < 15 Early Treatment of Diabetic Retinopathy Study letters; change in optical coherence tomography central subfield thickness; and change in angiographic total lesion area and choroidal neovascularization (CNV) area.
   Results: At year 2, the 16 and 24 Gray arms received fewer PRN treatments compared with sham (mean 4.5, P = 0.008; mean 5.4, P = 0.09; and mean 6.6, respectively). Change in mean BCVA was -10.0, -7.5, and -6.7 letters for the 16 Gray, 24 Gray, and sham arms, respectively, with 46 (68%), 51 (75%), and 58 participants (79%), respectively, losing < 15 letters. Mean central subfield thickness decreased by 67.0 mu m, 55.4 mu m, and 33.3 mu m, respectively. Mean total active lesion area increased by 1.0, 4.2, and 2.7 mm(2), respectively. Mean CNV area decreased by 0.1 mm(2) in all groups. An independent reading center detected microvascular abnormalities in 6 control eyes and 29 SRT eyes, of which 18 were attributed to radiation; however, only 2 of these possibly affected vision. An exploratory subgroup analysis found that lesions with a greatest linear dimension <= 4 mm (the size of the treatment zone) and a macular volume greater than the median (7.4 mm(3)) were more responsive to SRT, with 3.9 PRN injections versus 7.1 in comparable sham-treated participants (P = 0.001) and mean BCVA 4.4 letters superior to sham (P = 0.24).
   Conclusions: A single dose of SRT significantly reduces intravitreal injections over 2 years. Radiation can induce microvascular change, but in only1% of eyes does this possibly affect vision. The best response occurs when AMD lesions fit within the treatment zone and they are actively leaking. (C) 2015 by the American Academy of Ophthalmology.
C1 [Jackson, Timothy L.] Kings Coll London, Sch Med, London SE5 9RS, England.
   [Chakravarthy, Usha] Belfast Hlth & Social Care Trust, Queens Univ Belfast, Belfast, Antrim, North Ireland.
   [Slakter, Jason S.] Digital Angiog Reading Ctr, Great Neck, NY USA.
   [Muldrew, Alyson] Queens Univ Belfast, Ctr Vis & Vasc Sci, Belfast, Antrim, North Ireland.
   [Shusterman, E. Mark; O'Shaughnessy, Denis; Arnoldussen, Mark] Oraya Therapeut Inc, Newark, CA USA.
   [Gertner, Michael E.] Stanford Univ, Dept Surg, Stanford, CA 94305 USA.
   [Danielson, Linda] Int Inst Drug Dev, Louvain La Neuve, Belgium.
   [Moshfeghi, Darius M.] Stanford Univ, Sch Med, Dept Ophthalmol, Byers Eye Inst,Horngren Family Vitreoretinal Ctr, Palo Alto, CA 94304 USA.
C3 University of London; King's College London; Queens University Belfast;
   Queens University Belfast; Stanford University; International Drug
   Development Institute; Stanford University
RP Jackson, TL (通讯作者)，Kings Coll London, Kings Coll Hosp London, Dept Ophthalmol, Sch Med, London SE5 9RS, England.
EM t.jackson1@nhs.net
RI Kousal, Bohdan/ABE-2741-2021; Kousal, Bohdan/B-9489-2017; Studnicka,
   Jan/K-2875-2017; Aslam, Tariq/A-8532-2016
OI Kousal, Bohdan/0000-0003-2824-2266; Kousal, Bohdan/0000-0003-2824-2266;
   Jackson, Timothy/0000-0001-7618-1555; Studnicka,
   Jan/0000-0002-9911-4379; Aslam, Tariq/0000-0002-9739-7280; Moshfeghi,
   Darius Mohammad/0000-0003-2254-292X; Chakravarthy,
   Usha/0000-0002-2606-3734
FU Oraya
FX The author(s) have made the following disclosure(s): T.L.J.: Employer
   received research funding from Oraya, and received a single advisory
   board payment and travel support from Oraya.; J.S.S.: Research Grant
   Support from Oraya.
CR Bunce C, 2010, EYE, V24, P1692, DOI 10.1038/eye.2010.122
   CHAKRAVARTHY U, 1993, BRIT J OPHTHALMOL, V77, P265, DOI 10.1136/bjo.77.5.265
   Christoforidis JB, 2013, CURR EYE RES, V38, P761, DOI 10.3109/02713683.2013.763988
   Dugel PU, 2013, OPHTHALMOLOGY, V120, P317, DOI 10.1016/j.ophtha.2012.07.068
   Dugel PU, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.01.014
   Finger RP, 2011, BRIT J OPHTHALMOL, V95, P1061, DOI 10.1136/bjo.2010.194712
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Jackson TL, 2014, RETINA-J RET VIT DIS, V34, P568, DOI 10.1097/IAE.0b013e3182a487be
   Jackson TL, 2013, OPHTHALMOLOGY, V120, P1893, DOI 10.1016/j.ophtha.2013.02.016
   Jackson TL, 2013, OPHTHALMOLOGY, V120, P1597, DOI 10.1016/j.ophtha.2013.01.074
   Jackson TL, 2014, RETINA
   Kakinoki M, 2012, INVEST OPHTH VIS SCI, V53, P5877, DOI 10.1167/iovs.12-10164
   Kirwan JF, 2003, EYE, V17, P207, DOI 10.1038/sj.eye.6700306
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Munoz B, 2000, ARCH OPHTHALMOL-CHIC, V118, P819, DOI 10.1001/archopht.118.6.819
   Owen CG, 2012, BRIT J OPHTHALMOL, V96, P752, DOI 10.1136/bjophthalmol-2011-301109
   Petrarca Robert, 2014, Retina, V34, P874, DOI 10.1097/IAE.0000000000000026
   Petrarca R, 2013, RETINA-J RET VIT DIS, V33, P1232, DOI 10.1097/IAE.0b013e3182794b22
   Petrarca R, 2013, OPHTHALMOLOGY, V120, P328, DOI 10.1016/j.ophtha.2012.07.091
   Petrarca R, 2011, CLIN OPHTHALMOL, V5, P57, DOI 10.2147/OPTH.S16444
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
NR 22
TC 29
Z9 31
U1 0
U2 13
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0161-6420
EI 1549-4713
J9 OPHTHALMOLOGY
JI Ophthalmology
PD JAN
PY 2015
VL 122
IS 1
BP 138
EP 145
DI 10.1016/j.ophtha.2014.07.043
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA AX1XK
UT WOS:000346737000030
PM 25208859
DA 2022-11-30
ER

PT J
AU Khan, JC
   Shahid, H
   Thurlby, DA
   Bradley, M
   Clayton, DG
   Moore, AT
   Bird, AC
   Yates, JRW
AF Khan, JC
   Shahid, H
   Thurlby, DA
   Bradley, M
   Clayton, DG
   Moore, AT
   Bird, AC
   Yates, JRW
CA Genetics Factors AMD Study
TI Age related macular degeneration and sun exposure, iris colour, and skin
   sensitivity to sunlight
SO BRITISH JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID RISK-FACTORS; MACULOPATHY; PREVALENCE; CLASSIFICATION
AB Background/aim: It has been suggested that sun exposure may be a risk factor for age related macular degeneration ( AMD) and that skin sensitivity to sunlight and iris colour could be confounding factors. The aim was to investigate this further in the white population.
   Methods: 446 cases with end stage AMD were compared with 283 spouse controls. Data on sun exposure, places of residence, iris colour, subjective assessment of change in iris colour, hair colour at age 20, and skin sensitivity were obtained using a questionnaire. Iris colour was graded clinically by comparison with standard photographs. AMD was graded using stereoscopic colour fundus photographs as well as clinical examination and was defined as the presence of geographic atrophy or choroidal neovascularisation. All variables were included in a multiple logistic regression model including age, sex, and smoking.
   Results: There was no association between AMD and sun exposure or related factors except for the suggestion of an association between sunburn prone skin type and geographic atrophy which reached borderline significance.
   Conclusions: No significant association between AMD and sun exposure, iris colour, change in iris colour, or hair colour was demonstrated.
C1 Univ Cambridge, Dept Med Genet, Cambridge, England.
   Univ Cambridge, Ctr Appl Med Stat, Inst Publ Hlth, Cambridge, England.
   UCL, Inst Ophthalmol, London, England.
   Moorfields Eye Hosp, London, England.
C3 University of Cambridge; University of Cambridge; University of London;
   University College London; University of London; University College
   London; Moorfields Eye Hospital NHS Foundation Trust
RP Yates, JRW (通讯作者)，Univ Cambridge, Addenbrookes Hosp, Dept Med Genet, Box 134, Cambridge CB2 2QQ, England.
EM jrwy1@cam.ac.uk
FU Medical Research Council [G0000067] Funding Source: Medline; MRC
   [G0000067] Funding Source: UKRI
CR *AG REL EYE DIS ST, 2000, OPHTHALMOLOGY, V107, P2224
   Bernaards CM, 2001, ADDICTION, V96, P1653, DOI 10.1046/j.1360-0443.2001.9611165311.x
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Chaine G, 1998, BRIT J OPHTHALMOL, V82, P996, DOI 10.1136/bjo.82.9.996
   CRUICKSHANKS KJ, 1993, ARCH OPHTHALMOL-CHIC, V111, P514, DOI 10.1001/archopht.1993.01090040106042
   Darzins P, 1997, OPHTHALMOLOGY, V104, P770, DOI 10.1016/S0161-6420(97)30235-8
   FITZPATRICK TB, 1988, ARCH DERMATOL, V124, P869, DOI 10.1001/archderm.124.6.869
   Frank R N, 2000, Trans Am Ophthalmol Soc, V98, P109
   GIBSON JM, 1985, T OPHTHAL SOC UK, V104, P196
   HOLZ FG, 1994, AM J OPHTHALMOL, V117, P19, DOI 10.1016/S0002-9394(14)73010-7
   HYMAN LG, 1983, AM J EPIDEMIOL, V118, P213, DOI 10.1093/oxfordjournals.aje.a113629
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   McCarty CA, 1996, B WORLD HEALTH ORGAN, V74, P353
   Mitchell P, 1998, OPHTHALMOLOGY, V105, P1359, DOI 10.1016/S0161-6420(98)98013-7
   SEDDON JM, 1990, INVEST OPHTH VIS SCI, V31, P1592
   VINDING T, 1989, ACTA OPHTHALMOL, V67, P609
   VINGERLING JR, 1995, OPHTHALMOLOGY, V102, P205
   WEITER JJ, 1985, AM J OPHTHALMOL, V99, P185, DOI 10.1016/0002-9394(85)90230-2
   WEST SK, 1989, ARCH OPHTHALMOL-CHIC, V107, P875, DOI 10.1001/archopht.1989.01070010897038
   YANNUZZI LA, 1992, ARCH OPHTHALMOL-CHIC, V110, P1701
NR 20
TC 68
Z9 70
U1 1
U2 15
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0007-1161
EI 1468-2079
J9 BRIT J OPHTHALMOL
JI Br. J. Ophthalmol.
PD JAN
PY 2006
VL 90
IS 1
BP 29
EP 32
DI 10.1136/bjo.2005.073825
PG 4
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 993YD
UT WOS:000233994900011
PM 16361662
OA Bronze, Green Published
DA 2022-11-30
ER

PT J
AU Joussen, AM
   Lehmacher, W
   Hilgers, RD
   Kirchhof, B
AF Joussen, Antonia M.
   Lehmacher, Walter
   Hilgers, Ralf-Dieter
   Kirchhof, Bernd
TI Is significant relevant? Validity and patient benefit of randomized
   controlled clinical trials on age-related macular degeneration
SO SURVEY OF OPHTHALMOLOGY
LA English
DT Review
DE ARMD; patient benefit; QoL; randomized controlled clinical trial;
   significance; validity; VFQ25
ID QUALITY-OF-LIFE; SUBFOVEAL CHOROIDAL NEOVASCULARIZATION; PHOTODYNAMIC
   THERAPY; INDUSTRY; SURGERY; VISION; SST; TRANSLOCATION; VERTEPORFIN;
   MACULOPATHY
AB A large variety of new treatment options for different forms of age-related macular degeneration (ARMD) are becoming available. Not all new therapies may meet the expectations of patients and ophthalmologists. Despite the given statistical significant priority of treatment investigations, the endpoints may not be relevant to the patient's requirements. Therefore, questions inevitably arise regarding patient's benefit and the validity of the randomized controlled trials. The randomized controlled trial is regarded as the "gold standard" in terms of evaluating the effectiveness of interventions. The external validity of randomized controlled trials may be compromised, if, for example, patients assigned to the study group are unrepresentative of the reference population. This review aims to analyze problems with external validity in the randomized controlled trials on ARMD and surveys the endpoints of clinical studies with respect to the patient benefit.
C1 Univ Dusseldorf, Dept Ophthalmol, D-40225 Dusseldorf, Germany.
   Univ Cologne, Dept Med Stat Informat & Epidemiol, Cologne, Germany.
   Rhein Westfal TH Aachen, Dept Med Stat, D-5100 Aachen, Germany.
   Univ Cologne, Dept Vitreoretinal Surg, Ctr Ophthalmol, Cologne, Germany.
C3 Heinrich Heine University Dusseldorf; University of Cologne; RWTH Aachen
   University; University of Cologne
RP Joussen, AM (通讯作者)，Univ Dusseldorf, Dept Ophthalmol, Mooren Str 5, D-40225 Dusseldorf, Germany.
RI Hilgers, Ralf-Dieter/C-7090-2013; Joussen, Antonia/AAA-6901-2022
OI Hilgers, Ralf-Dieter/0000-0002-5945-1119; 
CR Ambati J, 2003, SURV OPHTHALMOL, V48, P257, DOI 10.1016/S0039-6257(03)00030-4
   [Anonymous], 1991, Arch Ophthalmol, V109, P1109
   Arnold J, 2001, AM J OPHTHALMOL, V131, P541
   Arnold JJ, 2004, AM J OPHTHALMOL, V137, P683, DOI 10.1016/j.ajo.2003.11.059
   Barbazetto I, 2003, ARCH OPHTHALMOL-CHIC, V121, P1253
   Barden J, 2006, PAIN, V121, P207, DOI 10.1016/j.pain.2005.12.011
   Blinder K, 2003, RETINA-J RET VIT DIS, V23, P14
   Bodenheimer T, 2000, NEW ENGL J MED, V342, P1539, DOI 10.1056/NEJM200005183422024
   Boyd EA, 2000, JAMA-J AM MED ASSOC, V284, P2209, DOI 10.1001/jama.284.17.2209
   Bressler NM, 2004, ARCH OPHTHALMOL-CHIC, V122, P857
   Bressler NM, 2003, ARCH OPHTHALMOL-CHIC, V121, P1621
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   Britton A, 1999, J Health Serv Res Policy, V4, P112
   Cahill MT, 2005, OPHTHALMOLOGY, V112, P152, DOI 10.1016/j.ophtha.2004.06.036
   Cahill MT, 2005, OPHTHALMOLOGY, V112, P144, DOI 10.1016/j.ophtha.2004.06.035
   Childs AL, 2004, OPHTHALMOLOGY, V111, P2007, DOI 10.1016/j.ophtha.2004.07.024
   Constable LJ, 2004, MED J AUSTRALIA, V181, P471, DOI 10.5694/j.1326-5377.2004.tb06401.x
   Coyle SL, 2002, ANN INTERN MED, V136, P396, DOI 10.7326/0003-4819-136-5-200203050-00014
   Crossland MD, 2005, OPTOMETRY VISION SCI, V82, P11
   DiMasi JA, 2003, J HEALTH ECON, V22, P151, DOI 10.1016/S0167-6296(02)00126-1
   Dong LM, 2002, ARCH OPHTHALMOL-CHIC, V120, P1523, DOI 10.1001/archopht.120.11.1523
   FERRIS FL, 1982, AM J OPHTHALMOL, V94, P91, DOI 10.1016/0002-9394(82)90197-0
   Fine SL, 2005, AM J OPHTHALMOL, V139, P405, DOI 10.1016/j.ajo.2004.11.050
   Gelfand YA, 1997, OPHTHALMIC SURG LAS, V28, P823
   Gelijns AC, 2002, JAMA-J AM MED ASSOC, V287, P72, DOI 10.1001/jama.287.1.72
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   GRUNWALD H, 1999, TWILLIGHT LOSING SIG, P19
   Haegerstrom-Portnoy G, 2005, OPTOMETRY VISION SCI, V82, P87, DOI 10.1097/01.OPX.0000153162.05903.4C
   Hamdi HK, 2003, FRONT BIOSCI-LANDMRK, V8, pE305, DOI 10.2741/1019
   Hawkins BS, 2005, ARCH OPHTHALMOL-CHIC, V123, P78, DOI 10.1001/archopht.123.1.78
   Hawkins BS, 2004, OPHTHALMOLOGY, V111, P1967, DOI 10.1016/j.ophtha.2004.07.021
   Hooper CY, 2003, CLIN EXP OPHTHALMOL, V31, P376, DOI 10.1046/j.1442-9071.2003.00683.x
   Johns MME, 2003, JAMA-J AM MED ASSOC, V289, P741, DOI 10.1001/jama.289.6.741
   Joussen AM, 2006, AM J OPHTHALMOL, V142, P17, DOI 10.1016/j.ajo.2006.01.090
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Kim Rubin W., 2004, International Ophthalmology Clinics, V44, P41, DOI 10.1097/00004397-200404440-00005
   Klein R, 1997, OPHTHALMOLOGY, V104, P7, DOI 10.1016/S0161-6420(97)30368-6
   Lievre M, 2001, BRIT MED J, V322, P603, DOI 10.1136/bmj.322.7286.603
   Mangione CM, 2000, NEI VFQ 25 SCORING A
   MANGIONE CM, 1997, NEI VFQ 25 SCORING A
   Meyer CH, 2005, AM J OPHTHALMOL, V139, P214, DOI 10.1016/j.ajo.2004.07.034
   Mones J, 2005, EYE, V19, P1142, DOI 10.1038/sj.eye.6701717
   Montaner JSG, 2001, LANCET, V358, P1893, DOI 10.1016/S0140-6736(01)06891-X
   Moses LE, 2002, STAT MED, V21, P793, DOI 10.1002/sim.1098
   OLSCHEWSKI M, 1992, CONTROL CLIN TRIALS, V13, P226, DOI 10.1016/0197-2456(92)90005-K
   ORMEROD LD, 1994, OPHTHALMOLOGY, V101, P1201
   Porter T, 2001, Insight, V26, P40, DOI 10.1067/min.2001.113403
   Psaty BM, 2003, JAMA-J AM MED ASSOC, V289, P2128, DOI 10.1001/jama.289.16.2128
   Radner W, 2002, GRAEF ARCH CLIN EXP, V240, P461, DOI 10.1007/s00417-002-0443-5
   Rao JN, 2002, BRIT MED J, V325, P36, DOI 10.1136/bmj.325.7354.36
   Rechtman Ehud, 2002, Expert Opin Pharmacother, V3, P931, DOI 10.1517/14656566.3.7.931
   Relman AS, 2002, NEW REPUBLIC, V227, P27
   Rothwell PM, 2005, LANCET, V365, P82, DOI 10.1016/S0140-6736(04)17670-8
   Rothwell PM, 2005, LANCET, V365, P176, DOI 10.1016/S0140-6736(05)17709-5
   SCHACHAT AP, 1994, ARCH OPHTHALMOL-CHIC, V112, P500
   Scilley K, 2004, OPHTHAL EPIDEMIOL, V11, P131, DOI 10.1076/opep.11.2.131.28159
   Smith GCS, 2003, BRIT MED J, V327, P1459, DOI 10.1136/bmj.327.7429.1459
   STERNBERG P, 1991, ARCH OPHTHALMOL-CHIC, V109, P1232
   van Meurs JC, 2004, BRIT J OPHTHALMOL, V88, P110, DOI 10.1136/bjo.88.1.110
   World Med Assoc, 2013, JAMA-J AM MED ASSOC, V310, P2191, DOI 10.1001/jama.2013.281053
NR 60
TC 3
Z9 3
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0039-6257
EI 1879-3304
J9 SURV OPHTHALMOL
JI Surv. Ophthalmol.
PD MAY-JUN
PY 2007
VL 52
IS 3
BP 266
EP 278
DI 10.1016/j.survophthal.2007.02.010
PG 13
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 169QA
UT WOS:000246605500003
PM 17472802
DA 2022-11-30
ER

PT J
AU Simonett, JM
   Sohrab, MA
   Pacheco, J
   Armstrong, LL
   Rzhetskaya, M
   Smith, M
   Hayes, MG
   Fawzi, AA
AF Simonett, Joseph M.
   Sohrab, Mahsa A.
   Pacheco, Jennifer
   Armstrong, Loren L.
   Rzhetskaya, Margarita
   Smith, Maureen
   Hayes, M. Geoffrey
   Fawzi, Amani A.
TI A Validated Phenotyping Algorithm for Genetic Association Studies in
   Age-related Macular Degeneration
SO SCIENTIFIC REPORTS
LA English
DT Article
ID ELECTRONIC MEDICAL-RECORDS; POLYPOIDAL CHOROIDAL VASCULOPATHY;
   ENDOTHELIAL GROWTH-FACTOR; FACTOR-H POLYMORPHISM; EMERGE NETWORK; HEALTH
   RECORDS; RISK-FACTORS; PROGRESSION; SUSCEPTIBILITY; POPULATION
AB Age-related macular degeneration (AMD), a multifactorial, neurodegenerative disease, is a leading cause of vision loss. With the rapid advancement of DNA sequencing technologies, many AMD-associated genetic polymorphisms have been identified. Currently, the most time consuming steps of these studies are patient recruitment and phenotyping. In this study, we describe the development of an automated algorithm to identify neovascular (wet) AMD, non-neovascular (dry) AMD and control subjects using electronic medical record (EMR)-based criteria. Positive predictive value (91.7%) and negative predictive value (97.5%) were calculated using expert chart review as the gold standard to assess algorithm performance. We applied the algorithm to an EMR-linked DNA bio-repository to study previously identified AMD-associated single nucleotide polymorphisms (SNPs), using case/control status determined by the algorithm. Risk alleles of three SNPs, rs1061170 (CFH), rs1410996 (CFH), and rs10490924 (ARMS2) were found to be significantly associated with the AMD case/control status as defined by the algorithm. With the rapid growth of EMR-linked DNA biorepositories, patient selection algorithms can greatly increase the efficiency of genetic association study. We have found that stepwise validation of such an algorithm can result in reliable cohort selection and, when coupled within an EMR-linked DNA biorepository, replicates previously published AMD-associated SNPs.
C1 [Simonett, Joseph M.; Sohrab, Mahsa A.; Fawzi, Amani A.] Northwestern Univ, Dept Ophthalmol, Feinberg Sch Med, Chicago, IL 60611 USA.
   [Pacheco, Jennifer; Smith, Maureen; Hayes, M. Geoffrey] Northwestern Univ, Ctr Genet Med, Feinberg Sch Med, Chicago, IL 60611 USA.
   [Armstrong, Loren L.; Rzhetskaya, Margarita; Hayes, M. Geoffrey] Northwestern Univ, Dept Med, Feinberg Sch Med, Div Endocrinol Metab & Mol Med, Chicago, IL 60611 USA.
   [Hayes, M. Geoffrey] Northwestern Univ, Dept Anthropol, Evanston, IL 60208 USA.
   [Hayes, M. Geoffrey] Northwestern Univ, Northwestern Comprehens Ctr Obes, Feinberg Sch Med, Chicago, IL 60611 USA.
C3 Northwestern University; Feinberg School of Medicine; Northwestern
   University; Feinberg School of Medicine; Northwestern University;
   Feinberg School of Medicine; Northwestern University; Northwestern
   University; Feinberg School of Medicine
RP Fawzi, AA (通讯作者)，Northwestern Univ, Dept Ophthalmol, Feinberg Sch Med, Chicago, IL 60611 USA.
EM amani.fawzi@northwestern.edu
RI fawzi, amani/AAA-9199-2021
OI fawzi, amani/0000-0002-9568-3558; Pacheco, Jennifer/0000-0001-8021-5818;
   Hayes, M Geoffrey/0000-0002-4617-3981
FU Illinois society for the prevention of blindness; Research to Prevent
   Blindness; NY (Department of Ophthalmology, Northwestern University);
   NUgene Biobank (Center for Genetic Medicine, Northwestern University);
   NHGRI [U01HG004609, U01HG006388];  [NIH-EY021470]; NATIONAL CENTER FOR
   ADVANCING TRANSLATIONAL SCIENCES [UL1TR001422, UL1TR000150] Funding
   Source: NIH RePORTER; NATIONAL EYE INSTITUTE [R01EY021470] Funding
   Source: NIH RePORTER; NATIONAL HUMAN GENOME RESEARCH INSTITUTE
   [U01HG006388, U01HG004609] Funding Source: NIH RePORTER
FX We acknowledge NIH-EY021470 (AAF), Illinois society for the prevention
   of blindness (MAS), Research to Prevent Blindness, NY (Department of
   Ophthalmology, Northwestern University), The NUgene Biobank (Center for
   Genetic Medicine, Northwestern University), and U01HG004609 and
   U01HG006388 (NHGRI funded eMERGE I and II study, Northwestern University
   site).
CR Bonastre J, 2002, Eur J Health Econ, V3, P94, DOI 10.1007/s10198-002-0104-y
   Buitendijk GHS, 2013, OPHTHALMOLOGY, V120, P2644, DOI 10.1016/j.ophtha.2013.07.053
   Chen YK, 2013, J AM MED INFORM ASSN, V20, pE253, DOI 10.1136/amiajnl-2013-001945
   Chiu CJ, 2014, OPHTHALMOLOGY, V121, P1421, DOI 10.1016/j.ophtha.2014.01.016
   Courtenay M. D., 2014, INVEST OPHTHALMOL, DOI [10.1167/iovs.14-14494, DOI 10.1167/I0VS.14-14494]
   Crawford DC, 2014, FRONT GENET, V5, DOI 10.3389/fgene.2014.00184
   Day S, 2011, AM J OPHTHALMOL, V152, P266, DOI 10.1016/j.ajo.2011.01.053
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P532
   Fritsche LG, 2013, NAT GENET, V45, P433, DOI 10.1038/ng.2578
   Galan A, 2010, OPHTHALMOLOGY, V117, P1769, DOI 10.1016/j.ophtha.2010.01.030
   Gottesman O, 2013, GENET MED, V15, P761, DOI 10.1038/gim.2013.72
   Hadley D, 2010, INVEST OPHTH VIS SCI, V51, P2191, DOI 10.1167/iovs.09-3798
   Hageman Gregory S., 2011, Human Genomics, V5, P420
   Hagstrom SA, 2013, OPHTHALMOLOGY, V120, P593, DOI 10.1016/j.ophtha.2012.11.037
   Hennekam RCM, 2012, HUM MUTAT, V33, P884, DOI 10.1002/humu.22048
   Huang LZ, 2014, INVEST OPHTH VIS SCI, V55, P2534, DOI 10.1167/iovs.13-13437
   Imai Daisuke, 2010, J Ocul Biol Dis Infor, V3, P53, DOI 10.1007/s12177-010-9055-1
   Jonasson F, 2014, OPHTHALMOLOGY, V121, P1766, DOI 10.1016/j.ophtha.2014.03.013
   Kho AN, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3001807
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Li Dingcheng, 2012, AMIA Annu Symp Proc, V2012, P532
   Marchini J, 2007, NAT GENET, V39, P906, DOI 10.1038/ng2088
   Matsumiya W, 2014, PHARMACOGENOMICS, V15, P833, DOI [10.2217/PGS.14.51, 10.2217/pgs.14.51]
   McCarty CA, 2011, BMC MED GENOMICS, V4, DOI 10.1186/1755-8794-4-13
   Naj AC, 2013, ANN HUM GENET, V77, P215, DOI 10.1111/ahg.12011
   Nakata I, 2012, INVEST OPHTH VIS SCI, V53, P794, DOI 10.1167/iovs.11-8468
   Newton KM, 2013, J AM MED INFORM ASSN, V20, pE147, DOI 10.1136/amiajnl-2012-000896
   Oetjens M, 2014, BIOCOMPUT-PAC SYM, P253
   Pathak J, 2013, J AM MED INFORM ASSN, V20, pE341, DOI 10.1136/amiajnl-2013-001939
   Perlee LT, 2013, OPHTHALMOLOGY, V120, P1880, DOI 10.1016/j.ophtha.2013.02.007
   Purcell S, 2007, AM J HUM GENET, V81, P559, DOI 10.1086/519795
   Rea S, 2012, J BIOMED INFORM, V45, P763, DOI 10.1016/j.jbi.2012.01.009
   Ritchie MD, 2010, AM J HUM GENET, V86, P560, DOI 10.1016/j.ajhg.2010.03.003
   Seddon Johanna M., 2004, International Ophthalmology Clinics, V44, P17, DOI 10.1097/00004397-200404440-00004
   Seddon JM, 2013, JAMA OPHTHALMOL, V131, P448, DOI 10.1001/jamaophthalmol.2013.2578
   Seddon JM, 2011, OPHTHALMOLOGY, V118, P2203, DOI 10.1016/j.ophtha.2011.04.029
   Sofat R, 2012, INT J EPIDEMIOL, V41, P250, DOI 10.1093/ije/dyr204
   Stone E. M., 2015, JAMA OPHTHALMOLOGY, DOI [10.1001/jamaophthalmol.2015.0369, DOI 10.1001/JAMA0PHTHALM0L.2015.0369]
   Stone EM, 2012, OPHTHALMOLOGY, V119, P2408, DOI 10.1016/j.ophtha.2012.05.047
   Swaroop A, 2009, ANNU REV GENOM HUM G, V10, P19, DOI 10.1146/annurev.genom.9.081307.164350
   Thakkinstian A, 2012, AM J EPIDEMIOL, V176, P361, DOI 10.1093/aje/kws031
   Tong Y, 2010, MOL VIS, V16, P1958
   Verma SS, 2014, FRONT GENET, V5, DOI 10.3389/fgene.2014.00370
   Wilke RA, 2011, CLIN PHARMACOL THER, V89, P379, DOI 10.1038/clpt.2010.260
   Wilke RA, 2007, CLIN MED RES, V5, P1, DOI 10.3121/cmr.2007.726
   Williams SE, 2013, VACCINE, V31, pK88, DOI 10.1016/j.vaccine.2013.03.077
   Yates JRW, 2007, NEW ENGL J MED, V357, P553, DOI 10.1056/NEJMoa072618
   Yu Y, 2012, INVEST OPHTH VIS SCI, V53, P1548, DOI 10.1167/iovs.11-8657
NR 50
TC 3
Z9 3
U1 0
U2 3
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2045-2322
J9 SCI REP-UK
JI Sci Rep
PD AUG 10
PY 2015
VL 5
AR 12875
DI 10.1038/srep12875
PG 8
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA CO5KC
UT WOS:000359197000001
PM 26255974
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Ma, FY
   Yuan, MZ
   Kozak, I
   Zhang, Q
   Chen, YX
AF Ma, Feiyan
   Yuan, Mingzhen
   Kozak, Igor
   Zhang, Qing
   Chen, Youxin
TI SENSITIVITY AND SPECIFICITY OF MULTISPECTRAL IMAGING FOR POLYPOIDAL
   CHOROIDAL VASCULOPATHY
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE multispectral imaging; PCV; sensitivity; specificity
ID OPTICAL COHERENCE TOMOGRAPHY; INDOCYANINE GREEN ANGIOGRAPHY; MACULAR
   DEGENERATION
AB Purpose: To evaluate the sensitivity and specificity of multispectral imaging (MSI), a noninvasive imaging technique composed of a series of monochromatic scanning light, for polypoidal choroidal vasculopathy (PCV). Methods: This was a prospective observational study. Polypoidal lesions on MSI are defined by oval or lobular hyperreflective oval lesion with dark hyporeflective center. Branching vascular networks on MSI is featured by hyperreflective interlacing signal. Detection sensitivity and specificity of polypoidal lesions was compared with indocyanine green angiography, whereas sensitivity and specificity of branching vascular networks, subretinal fluid, and pigment epithelium detachment were compared with optical coherence tomography. Results: Among 67 eyes, 38 eyes (56.7%) were diagnosed with PCV, 7 eyes (10.4%) with neovascular age-related macular degeneration, 13 eyes (19.4%) with central serous chorioretinopathy, 6 eyes (9.0%) with pathological myopia, and 3 eyes (4.5%) with idiopathic choroidal neovascularization. Compared with indocyanine green angiography, the sensitivity and specificity for diagnosing PCV by MSI alone was 84.21% and 93.10%, respectively, and the positive predictive value and the negative predictive value for PCV by MSI was 94.12% and 81.82%, respectively. The sensitivity and specificity for detecting polypoidal lesions were 84.21% and 93.10% compared with indocyanine green angiography. Compared with optical coherence tomography, the sensitivity and specificity for detecting branching vascular networks were 95.83% and 88.37%, for the subretinal fluid were 76.92% and 86.67%, and for the pigment epithelium detachment were 91.11% and 90.91%, respectively. Conclusion: Multispectral imaging allowed noninvasive visualization of polypoidal lesions and branching vascular networks and may serve as a new diagnostic option for PCV.
C1 [Ma, Feiyan] Hebei Med Univ, Dept Ophthalmol, Hosp 2, Shijiazhuang, Hebei, Peoples R China.
   [Yuan, Mingzhen; Zhang, Qing; Chen, Youxin] Chinese Acad Med Sci, Peking Union Med Coll Hosp, Dept Ophthalmol, Beijing, Peoples R China.
   [Yuan, Mingzhen; Zhang, Qing; Chen, Youxin] Chinese Acad Med Sci & Peking Union Med Coll, Key Lab Ocular Fundus Dis, Beijing, Peoples R China.
   [Kozak, Igor] Moorfields Eye Hosp UAE, Dept Ophthalmol, Abu Dhabi, U Arab Emirates.
C3 Hebei Medical University; Chinese Academy of Medical Sciences - Peking
   Union Medical College; Peking Union Medical College Hospital; Chinese
   Academy of Medical Sciences - Peking Union Medical College; Peking Union
   Medical College
RP Chen, YX (通讯作者)，Chinese Acad Med Sci & Peking Union Med Coll, Chinese Acad Med Sci, Peking Union Med Coll Hosp, Dept Ophthalmol,Key Lab Ocular Fundus Dis, Beijing 100730, Peoples R China.
EM chenyx@pumch.cn
FU nonprofit Central Research Institute Fund of Chinese Academy of Medical
   Sciences [2018PT32029]; Scientific Research Project of Hebei Health
   Commission [20200069]
FX The nonprofit Central Research Institute Fund of Chinese Academy of
   Medical Sciences (2018PT32029). Scientific Research Project of Hebei
   Health Commission (Grant No. 20200069).
CR Baek J, 2018, GRAEF ARCH CLIN EXP, V256, P2309, DOI 10.1007/s00417-018-4143-1
   Calcagni A, 2011, EYE, V25, P1562, DOI 10.1038/eye.2011.202
   Chaikitmongkol V, 2018, AM J OPHTHALMOL, V192, P77, DOI 10.1016/j.ajo.2018.05.005
   Cheung CMG, 2021, OPHTHALMOLOGY, V128, P443, DOI 10.1016/j.ophtha.2020.08.006
   Cheung CMG, 2018, OPHTHALMOLOGY, V125, P708, DOI 10.1016/j.ophtha.2017.11.019
   De Salvo G, 2014, AM J OPHTHALMOL, V158, P1228, DOI 10.1016/j.ajo.2014.08.025
   DELORI FC, 1989, APPL OPTICS, V28, P1061, DOI 10.1364/AO.28.001061
   Dugel Pravin U, 2016, Am J Ophthalmol Case Rep, V2, P18, DOI 10.1016/j.ajoc.2016.04.003
   Dugel PU, 2016, OSLI RETINA, V47, P134, DOI 10.3928/23258160-20160126-06
   Everdell NL, 2010, REV SCI INSTRUM, V81, DOI 10.1063/1.3478001
   Ha SO, 2014, INTERN EMERG MED, V9, P325, DOI 10.1007/s11739-013-1019-6
   Hassenstein A, 2009, CLIN EXP OPHTHALMOL, V37, P130, DOI 10.1111/j.1442-9071.2009.02017.x
   Huang G, 2018, ACTA OPHTHALMOL, V96, P411, DOI 10.1111/aos.13606
   Inoue M, 2015, RETINA-J RET VIT DIS, V35, P2265, DOI 10.1097/IAE.0000000000000777
   Kang H, 2019, RETINA-J RET VIT DIS, V39, P1551, DOI 10.1097/IAE.0000000000002201
   Khan S, 2012, RETINA-J RET VIT DIS, V32, P1057, DOI 10.1097/IAE.0b013e31823beb14
   Koizumi H, 2011, GRAEF ARCH CLIN EXP, V249, P1123, DOI 10.1007/s00417-011-1620-1
   Li L, 2019, RETINA-J RET VIT DIS, V39, P1701, DOI 10.1097/IAE.0000000000002225
   Ma FY, 2020, INT OPHTHALMOL, V40, P3413, DOI 10.1007/s10792-020-01528-9
   Ojima Y, 2009, RETINA-J RET VIT DIS, V29, P52, DOI 10.1097/IAE.0b013e3181884fbf
   SPAIDE RF, 1995, RETINA-J RET VIT DIS, V15, P100, DOI 10.1097/00006982-199515020-00003
   Styles IB, 2006, MED IMAGE ANAL, V10, P578, DOI 10.1016/j.media.2006.05.007
   Takayama K, 2017, EYE, V31, P45, DOI 10.1038/eye.2016.232
   Treder M, 2018, GRAEF ARCH CLIN EXP, V256, P259, DOI 10.1007/s00417-017-3850-3
   Yanagi Y, 2018, RETINA-J RET VIT DIS, V38, P1509, DOI 10.1097/IAE.0000000000001758
   YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001
   Zhang J, 2018, OSLI RETINA, V49, pE249, DOI 10.3928/23258160-20181203-15
   Zhang J, 2018, INT J OPHTHALMOL-CHI, V11, P1071, DOI 10.18240/ijo.2018.06.29
   Zhang J, 2015, OPTOMETRY VISION SCI, V92, pE21, DOI 10.1097/OPX.0000000000000440
   Zhao XY, 2018, GRAEF ARCH CLIN EXP, V256, P1101, DOI 10.1007/s00417-018-3980-2
   Zhu XM, 2017, LASER SURG MED, V49, P498, DOI 10.1002/lsm.22619
NR 31
TC 3
Z9 3
U1 3
U2 5
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD SEP
PY 2021
VL 41
IS 9
BP 1921
EP 1929
DI 10.1097/IAE.0000000000003130
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA WN5QE
UT WOS:000711821200038
PM 33512897
DA 2022-11-30
ER

PT J
AU Li, YF
   Schon, C
   Chen, CC
   Yang, Z
   Liegl, R
   Murenu, E
   Schworm, B
   Klugbauer, N
   Grimm, C
   Wahl-Schott, C
   Michalakis, S
   Biel, M
AF Li, Yanfen
   Schoen, Christian
   Chen, Cheng-Chang
   Yang, Zhuo
   Liegl, Raffael
   Murenu, Elisa
   Schworm, Benedikt
   Klugbauer, Norbert
   Grimm, Christian
   Wahl-Schott, Christian
   Michalakis, Stylianos
   Biel, Martin
TI TPC2 promotes choroidal angiogenesis and inflammation in a mouse model
   of neovascular age-related macular degeneration
SO LIFE SCIENCE ALLIANCE
LA English
DT Article
ID IL-1-BETA SECRETION; 2-PORE CHANNELS; NAADP; INTERLEUKIN-1-BETA;
   RELEASE; ACTIVATION; MECHANISMS; EXOCYTOSIS; CALCIUM
AB Age-related macular degeneration (AMD) is the most common cause of blindness among the elderly and can be classified either as dry or as neovascular (or wet). Neovascular AMD is characterized by a strong immune response and the inadequate release of cytokines triggering angiogenesis and induction of photoreceptor death. The pathomechanisms of AMD are only partly understood. Here, we identify the endolysosomal two-pore cation channel TPC2 as a key factor of neovascularization and immune activation in the laser-induced choroidal neovascularization (CNV) mouse model of AMD. Block of TPC2 reduced retinal VEGFA and IL-1 beta levels and diminished neovascularization and immune activation. Mechanistically, TPC2 mediates cationic currents in endolysosomal organelles of immune cells and lack of TPC2 leads to reduced IL-1 beta levels in areas of choroidal neovascularization due to endolysosomal trapping. Taken together, our study identifies TPC2 as a promising novel therapeutic target for the treatment of AMD.
C1 [Li, Yanfen; Schoen, Christian; Chen, Cheng-Chang; Yang, Zhuo; Murenu, Elisa; Michalakis, Stylianos; Biel, Martin] Ludwig Maximilians Univ Munchen, Dept Pharm, Munich, Germany.
   [Chen, Cheng-Chang] Natl Taiwan Univ, Coll Med, Dept Clin Lab Sci & Med Biotechnol, Taipei, Taiwan.
   [Liegl, Raffael; Schworm, Benedikt; Michalakis, Stylianos] Ludwig Maximilians Univ Munchen, Dept Ophthalmol, Univ Hosp, Munich, Germany.
   [Klugbauer, Norbert] Albert Ludwigs Univ, Med Fac, Inst Expt & Clin Pharmacol & Toxicol, Freiburg, Germany.
   [Wahl-Schott, Christian] Hannover Med Sch, Inst Neurophysiol, Hannover, Germany.
   [Grimm, Christian] Ludwig Maximilians Univ Munchen, Walther Straub Inst Pharmacol & Toxicol, Munich, Germany.
C3 University of Munich; National Taiwan University; University of Munich;
   University of Freiburg; Hannover Medical School; University of Munich
RP Michalakis, S; Biel, M (通讯作者)，Ludwig Maximilians Univ Munchen, Dept Pharm, Munich, Germany.; Michalakis, S (通讯作者)，Ludwig Maximilians Univ Munchen, Dept Ophthalmol, Univ Hosp, Munich, Germany.
EM michalakis@lmu.de; biel@lmu.de
RI Michalakis, Stylianos/M-4677-2019; Grimm, Christian/ABF-9121-2020
OI Michalakis, Stylianos/0000-0001-5092-9238; Grimm,
   Christian/0000-0002-0177-5559; Klugbauer, Norbert/0000-0003-0553-9446;
   Chen, Cheng-Chang/0000-0003-1282-4026; Li, Yanfen/0000-0001-8244-7460;
   Murenu, Elisa/0000-0003-0209-5448
FU Chinese Scholarship Council; Deutsche Forschungsgemeinschaft (DFG,
   German Research Foundation) [TRR-152/2, KL 1119/6-1, EXC114]
FX We thank Maximilian Gerhardt (Eye Hospital, LMU Munich) , Olaf Strauss
   (Charite Berlin) , and Elisabeth Butz (Center for Genomic Medicine,
   Depart-ment of Neurology, Massachusetts General Hospital, Harvard
   Medical School, Boston, MA, USA) for scientific and/or experimental
   advice. Y Li was supported by a scholarship of the Chinese Scholarship
   Council. M Biel, S Michalakis, C Grimm, and C Wahl-Schott were supported
   by the Deutsche Forschungsgemeinschaft (DFG, German Research Foundation)
   TRR-152/2 Projects 12 (to M Biel) 4 (to C Grimm) and 6 (to C
   Wahl-Schott) , KL 1119/6-1 (to N Kligbauer) and EXC114 (to M Biel and S
   Michalakis) .
CR Al-Zamil WM, 2017, CLIN INTERV AGING, V12, P1313, DOI 10.2147/CIA.S143508
   Ambati J, 2013, NAT REV IMMUNOL, V13, P438, DOI 10.1038/nri3459
   Ambati J, 2012, NEURON, V75, P26, DOI 10.1016/j.neuron.2012.06.018
   Andrei C, 2004, P NATL ACAD SCI USA, V101, P9745, DOI 10.1073/pnas.0308558101
   Andrei C, 1999, MOL BIOL CELL, V10, P1463, DOI 10.1091/mbc.10.5.1463
   Arlt E, 2020, P NATL ACAD SCI USA, V117, P18068, DOI 10.1073/pnas.1920122117
   Balser C, 2019, J NEUROINFLAMM, V16, DOI 10.1186/s12974-019-1419-2
   Behnke V, 2020, CELL MOL LIFE SCI, V77, P781, DOI 10.1007/s00018-019-03419-4
   Brailoiu E, 2009, J CELL BIOL, V186, P201, DOI 10.1083/jcb.200904073
   Calcraft PJ, 2009, NATURE, V459, P596, DOI 10.1038/nature08030
   Cang CL, 2014, NAT CHEM BIOL, V10, P463, DOI 10.1038/nchembio.1522
   Cang CL, 2013, CELL, V152, P778, DOI 10.1016/j.cell.2013.01.023
   Charles-Messance H, 2020, J NEUROINFLAMM, V17, DOI 10.1186/s12974-019-1655-5
   Chen CC, 2017, NAT PROTOC, V12, P1639, DOI 10.1038/nprot.2017.036
   Crespo-Garcia S, 2015, EXP EYE RES, V139, P13, DOI 10.1016/j.exer.2015.07.012
   Davis LC, 2020, EMBO J, V39, DOI 10.15252/embj.2019104058
   Davis LC, 2012, CURR BIOL, V22, P2331, DOI 10.1016/j.cub.2012.10.035
   Eandi CM, 2016, ELIFE, V5, DOI 10.7554/eLife.16490
   Fahey E, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01426
   Favia A, 2014, P NATL ACAD SCI USA, V111, pE4706, DOI 10.1073/pnas.1406029111
   Ferrari D, 1997, J IMMUNOL, V159, P1451
   Grimm C, 2017, FRONT PHARMACOL, V8, DOI 10.3389/fphar.2017.00045
   Grimm C, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms5699
   Grisanti S, 2008, PROG RETIN EYE RES, V27, P372, DOI 10.1016/j.preteyeres.2008.05.002
   Hu SJ, 2015, J NEUROSCI, V35, P6987, DOI 10.1523/JNEUROSCI.3955-14.2015
   Jonas JB, 2014, AM J OPHTHALMOL, V158, P808, DOI 10.1016/j.ajo.2014.06.012
   Keckeis S, 2017, EXP EYE RES, V154, P139, DOI 10.1016/j.exer.2016.12.003
   Lambert V, 2013, NAT PROTOC, V8, P2197, DOI 10.1038/nprot.2013.135
   Lavalette S, 2011, AM J PATHOL, V178, P2416, DOI 10.1016/j.ajpath.2011.01.013
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Lopez-Castejon G, 2011, CYTOKINE GROWTH F R, V22, P189, DOI 10.1016/j.cytogfr.2011.10.001
   MATSUSHIMA K, 1986, J IMMUNOL, V136, P2883
   Natoli R, 2017, MOL NEURODEGENER, V12, DOI 10.1186/s13024-017-0175-y
   Naylor E, 2009, NAT CHEM BIOL, V5, P220, DOI 10.1038/nchembio.150
   Nguyen ONP, 2017, CANCER RES, V77, P1427, DOI 10.1158/0008-5472.CAN-16-0852
   Patel S, 2018, BBA-MOL CELL RES, V1865, P1678, DOI 10.1016/j.bbamcr.2018.05.004
   Plesch E, 2018, ELIFE, V7, DOI 10.7554/eLife.39720
   Qu Y, 2007, J IMMUNOL, V179, P1913, DOI 10.4049/jimmunol.179.3.1913
   Ruas Margarida, 2015, Messenger (Los Angel), V4, P4
   Ruas M, 2014, MOL CELL BIOL, V34, P3981, DOI 10.1128/MCB.00113-14
   Sakurai Y, 2015, SCIENCE, V347, P995, DOI 10.1126/science.1258758
   Shao Z, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0069552
   STEVENSON FT, 1992, J CELL PHYSIOL, V152, P223, DOI 10.1002/jcp.1041520202
   Weber K, 2014, J BIOL CHEM, V289, P9158, DOI 10.1074/jbc.M113.531202
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Wooff Y, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01618
   Xie CB, 2020, AM J PATHOL, V190, P1138, DOI 10.1016/j.ajpath.2020.02.006
   Zong XG, 2009, PFLUG ARCH EUR J PHY, V458, P891, DOI 10.1007/s00424-009-0690-y
NR 48
TC 4
Z9 4
U1 1
U2 3
PU LIFE SCIENCE ALLIANCE LLC
PI COLD SPRING HARBOR
PA 1 BUNGTOWN RD, COLD SPRING HARBOR, NY 11724 USA
EI 2575-1077
J9 LIFE SCI ALLIANCE
JI Life Sci. Alliance
PD AUG
PY 2021
VL 4
IS 8
AR e202101047
DI 10.26508/lsa.202101047
PG 13
WC Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Life Sciences & Biomedicine - Other Topics
GA WC5XC
UT WOS:000704330000008
PM 34183443
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Zhang, LJ
   Cui, X
   Han, YJ
   Park, KS
   Gao, XH
   Zhang, XM
   Yuan, ZG
   Hu, Y
   Hsu, CW
   Li, XR
   Bassuk, AG
   Mahajan, VB
   Wang, NK
   Tsang, SH
AF Zhang, Lijuan
   Cui, Xuan
   Han, Yangjun
   Park, Karen Sophia
   Gao, Xiaohong
   Zhang, Ximei
   Yuan, Zhigang
   Hu, Yong
   Hsu, Chun-Wei
   Li, Xiaorong
   Bassuk, Alexander G.
   Mahajan, Vinit B.
   Wang, Nan-Kai
   Tsang, Stephen H.
TI Hypoxic drive caused type 3 neovascularization in a preclinical model of
   exudative age-related macular degeneration
SO HUMAN MOLECULAR GENETICS
LA English
DT Article
ID ENDOTHELIAL GROWTH-FACTOR; DENSITY LIPOPROTEIN RECEPTOR; CHOROIDAL
   NEOVASCULARIZATION; MEDIATED EXPRESSION; ANIMAL-MODELS; RETINA; VEGF;
   OVEREXPRESSION; METABOLISM; SPARE
AB Hypoxia associated with the high metabolic demand of rods has been implicated in the pathology of age-related macular degeneration (AMD), the most common cause of adult blindness in the developed world. The majority of AMD-associated severe vision loss cases are due to exudative AMD, characterized by neovascularization. To further investigate the causes and histopathology of exudative AMD, we conditionally induced hypoxia in a novel preclinical AMD model (Pde6g(creERT2/+);Vhl(-/-)) by targeting Vhl and used multimodal imaging and immunohistochemistry to track the development of hypoxia-induced neovascularization. In addition to developing a preclinical model that phenocopies exudative AMD, our studies revealed that the photoreceptor hypoxic response initiates and drives type 3 neovascularization, mainly in the outer retina. Activation of the VHL-HIF1a-VEGF-EPO pathway in the adult retina led to long-term neovascularization, retinal hemorrhages and compromised retinal layers. Our novel preclinical model would accelerate the testing of therapies that use metabolomic approaches to ameliorate AMD.
C1 [Zhang, Lijuan; Gao, Xiaohong; Zhang, Ximei; Yuan, Zhigang] Shanxi Med Univ, Shanxi Eye Hosp, Fudong St 100, Taiyuan 030002, Shanxi, Peoples R China.
   [Cui, Xuan; Li, Xiaorong] Tianjin Med Univ, Inst Eye, Hosp Eye, Tianjin 300384, Peoples R China.
   [Cui, Xuan; Li, Xiaorong] Tianjin Med Univ, Sch Optometry & Ophthalmol, Tianjin 300384, Peoples R China.
   [Cui, Xuan; Park, Karen Sophia; Hsu, Chun-Wei; Wang, Nan-Kai; Tsang, Stephen H.] Jonas Childrens Vis Care, New York, NY 10032 USA.
   [Cui, Xuan; Park, Karen Sophia; Hsu, Chun-Wei; Wang, Nan-Kai; Tsang, Stephen H.] Herbert Irving Comprehens Canc Ctr, Bernard & Shirlee Brown Glaucoma Lab, New York, NY 10032 USA.
   [Cui, Xuan; Park, Karen Sophia; Hsu, Chun-Wei; Wang, Nan-Kai; Tsang, Stephen H.] New York Presbyterian Hosp, Edward S Harkness Eye Inst, New York, NY 10032 USA.
   [Han, Yangjun] Shanxi Cardiovasc Dis Hosp, Yifen St 18, Taiyuan 030024, Shanxi, Peoples R China.
   [Hu, Yong] Tongji Univ, Sch Med, Shanghai Tongji Hosp, Dept Neurol, Shanghai 200092, Peoples R China.
   [Bassuk, Alexander G.] Univ Iowa, Dept Pediat, Iowa City, IA 52242 USA.
   [Mahajan, Vinit B.] Stanford Univ, Sch Med, Dept Ophthalmol, Byers Eye Inst,Omics Lab, Palo Alto, CA 94303 USA.
   [Mahajan, Vinit B.] Vet Affairs Palo Alto Hlth Care Syst, Palo Alto, CA 94304 USA.
   [Tsang, Stephen H.] Columbia Univ, Dept Pathol & Cell Biol, Stem Cell Initiat CSCI, Inst Human Nutr,Coll Phys & Surg, New York, NY 10032 USA.
C3 Shanxi Medical University; Tianjin Medical University; Tianjin Medical
   University; NewYork-Presbyterian Hospital; Tongji University; University
   of Iowa; Stanford University; US Department of Veterans Affairs;
   Veterans Health Administration (VHA); VA Palo Alto Health Care System;
   Columbia University
RP Zhang, LJ (通讯作者)，Shanxi Med Univ, Shanxi Eye Hosp, Fudong St 100, Taiyuan 030002, Shanxi, Peoples R China.; Tsang, SH (通讯作者)，Columbia Univ, Edward S Harkness Eye Inst, New York Presbyterian Hosp, Med Ctr, 635 West 165th St,Box 112, New York, NY 10032 USA.
EM zhanglj2004@163.com; cuixuan2015@gmail.com; hanyj0618@163.com;
   ksp2117@columbia.edu; violetdaisynn@126.com; ximeizhang@sina.cn;
   yzg0158@163.com; myhuyong@gmail.com; cwheye2118@gmail.com;
   xiaorli@163.com; abassuk@gmail.com; mahajanlab@gmail.com;
   wang.nankai@gmail.com; gene.targeting@gmail.com
RI Wang, Nan-Kai/D-6608-2011; Wang, Nan-Kai/AAO-6559-2020
OI Wang, Nan-Kai/0000-0002-6277-9879; Wang, Nan-Kai/0000-0002-6277-9879;
   Bassuk, Alexander/0000-0002-4067-2157; Mahajan,
   Vinit/0000-0003-1886-1741
FU National Natural Science Foundation of China [81500750]; Shanxi Health
   and Family Planning Commission [2018088]; National Institutes of Health
   [P30EY019007, R01EY018213, R01EY024698]; National Cancer Institute Core
   [5P30CA013696]; NYSTEM IIRP Contract [C32590GG]; Edward N. & Della L.
   Thome Memorial Foundation; Foundation Fighting Blindness
   [TA-NMT0116-0692-COLU]; Kobi and Nancy Karp; Crowley Family Fund;
   Rosenbaum Family Foundation; Tistou and Charlotte Kerstan Foundation;
   Schneeweiss Stem Cell Fund, New York State [C029572]; Gebroe Family
   Foundation; Research to Prevent Blindness (RPB) Physician-Scientist
   Award; RPB, New York, NY, USA; NATIONAL EYE INSTITUTE [R01EY024698]
   Funding Source: NIH RePORTER
FX National Natural Science Foundation of China (81500750 to L.Z.); Shanxi
   Health and Family Planning Commission (2018088 to L.Z.); The Jonas
   Children's Vision Care and Bernard & Shirlee Brown Glaucoma Laboratory
   are supported by the National Institutes of Health (P30EY019007,
   R01EY018213 and R01EY024698), National Cancer Institute Core
   (5P30CA013696), NYSTEM IIRP Contract C32590GG, Edward N. & Della L.
   Thome Memorial Foundation, Foundation Fighting Blindness
   (TA-NMT0116-0692-COLU), Kobi and Nancy Karp, the Crowley Family Fund,
   the Rosenbaum Family Foundation, the Tistou and Charlotte Kerstan
   Foundation, the Schneeweiss Stem Cell Fund, New York State (C029572) and
   the Gebroe Family Foundation, Research to Prevent Blindness (RPB)
   Physician-Scientist Award and unrestricted funds from RPB, New York, NY,
   USA. S.H.T. is a member of the RD-CURE Consortium.
CR Arden GB, 2005, BRIT J OPHTHALMOL, V89, P764, DOI 10.1136/bjo.2004.062547
   Baffi J, 2000, INVEST OPHTH VIS SCI, V41, P3582
   Barben M, 2018, ADV EXP MED BIOL, V1074, P177, DOI 10.1007/978-3-319-75402-4_22
   Bressler Neil M, 2004, JAMA, V291, P1900, DOI 10.1001/jama.291.15.1900
   Chappelow AV, 2008, DRUGS, V68, P1029, DOI 10.2165/00003495-200868080-00002
   Chen Y, 2007, J BIOL CHEM, V282, P34420, DOI 10.1074/jbc.M611289200
   Country MW, 2017, BRAIN RES, V1672, P50, DOI 10.1016/j.brainres.2017.07.025
   Datta K, 2005, ONCOGENE, V24, P7850, DOI 10.1038/sj.onc.1208912
   Feigl B, 2009, PROG RETIN EYE RES, V28, P63, DOI 10.1016/j.preteyeres.2008.11.004
   Klein R, 2002, OPHTHALMOLOGY, V109, P1767, DOI 10.1016/S0161-6420(02)01146-6
   Koch SF, 2015, J CLIN INVEST, V125, P3704, DOI 10.1172/JCI82462
   Lin CZ, 2004, J ORTHOP RES, V22, P1175, DOI 10.1016/j.orthres.2004.03.002
   Lin Michael K, 2015, Taiwan J Ophthalmol, V5, P105, DOI 10.1016/j.tjo.2015.06.002
   Lynn SA, 2017, NEURAL REGEN RES, V12, P538, DOI 10.4103/1673-5374.205083
   Maxwell PH, 1999, NATURE, V399, P271, DOI 10.1038/20459
   Miller JW, 2013, OPHTHALMOLOGY, V120, P106, DOI 10.1016/j.ophtha.2012.07.038
   Pennesi ME, 2012, MOL ASPECTS MED, V33, P487, DOI 10.1016/j.mam.2012.06.003
   Qiu G, 2006, EXP EYE RES, V83, P141, DOI 10.1016/j.exer.2005.11.014
   Sancho-Pelluz J, 2012, MOL MED, V18, P549, DOI 10.2119/molmed.2011.00475
   Schmidt-Erfurth U, 2014, BRIT J OPHTHALMOL, V98, P1144, DOI 10.1136/bjophthalmol-2014-305702
   Seeliger MW, 2005, VISION RES, V45, P3512, DOI 10.1016/j.visres.2005.08.014
   Sivaprasad S, 2016, EYE, V30, P189, DOI 10.1038/eye.2015.254
   Spilsbury K, 2000, AM J PATHOL, V157, P135, DOI 10.1016/S0002-9440(10)64525-7
   Stewart MW, 2012, MAYO CLIN PROC, V87, P77, DOI 10.1016/j.mayocp.2011.10.001
   Tiebel O, 1999, ATHEROSCLEROSIS, V145, P239, DOI 10.1016/S0021-9150(99)00068-4
   Tobe T, 1998, INVEST OPHTH VIS SCI, V39, P180
   Tsai YT, 2018, OPHTHALMOLOGY, V125, P1421, DOI 10.1016/j.ophtha.2018.04.001
   Waisbourd M, 2007, DRUG AGING, V24, P643, DOI 10.2165/00002512-200724080-00003
   Wang F, 2003, INVEST OPHTH VIS SCI, V44, P781, DOI 10.1167/iovs.02-0281
   Wert KJ, 2016, SIGNAL TRANSDUCT TAR, V1, DOI 10.1038/sigtrans.2016.5
   Zhang LJ, 2018, MOL THER, V26, P1953, DOI 10.1016/j.ymthe.2018.06.014
   Zhang LJ, 2016, J CLIN INVEST, V126, P4659, DOI 10.1172/JCI86905
   Zylbermann R, 1997, EYE, V11, P872, DOI 10.1038/eye.1997.224
NR 33
TC 5
Z9 5
U1 2
U2 7
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0964-6906
EI 1460-2083
J9 HUM MOL GENET
JI Hum. Mol. Genet.
PD OCT 15
PY 2019
VL 28
IS 20
BP 3475
EP 3485
DI 10.1093/hmg/ddz159
PG 11
WC Biochemistry & Molecular Biology; Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Genetics & Heredity
GA KB9KN
UT WOS:000506805800009
PM 31518400
OA Green Published
DA 2022-11-30
ER

PT J
AU Matsuoka, M
   Ogata, N
   Otsuji, T
   Nishimura, T
   Takahashi, K
   Matsumura, M
AF Matsuoka, M
   Ogata, N
   Otsuji, T
   Nishimura, T
   Takahashi, K
   Matsumura, M
TI Expression of pigment epithelium derived factor and vascular endothelial
   growth factor in choroidal neovascular membranes and polypoidal
   choroidal vasculopathy
SO BRITISH JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID MACULAR DEGENERATION; MESSENGER-RNA; VEGF; ANGIOGENESIS; RETINOPATHY;
   MECHANISMS; RECEPTOR
AB Aims: To determine whether pigment epithelium derived factor (PEDF), a protein that inhibits angiogenesis, is expressed in human choroidal neovascular membranes (CNVMs) and in tissues from an eye with polypoidal choroidal vasculopathy (PCV). In addition, to compare the expression of PEDF with that of vascular endothelial growth factor (VEGF), a known stimulator of angiogenesis, in these tissues.
   Methods: CNVMs, associated with age related macular degeneration (AMD), angioid streaks, and PCV, were obtained during surgery. The expression of PEDF and VEGF in the excised subretinal fibrovascular membranes was determined by immunohistochemistry.
   Results: PEDF and VEGF were strongly expressed in the vascular endothelial cells and retinal pigment epithelial (RPE) cells in the CNVMs where numerous new vessels were prominent (clinically active CNVMs). On the other hand, immunoreactivity for PEDF and VEGF was weak in the new vessels where fibrosis was prominent (clinically quiescent CNVMs). However, the RPE cells were still positive for PEDF and VEGF. The specimens from the eye with PCV also showed strong expression of PEDF and VEGF in the vascular endothelial cells and the RPE cells.
   Conclusion: Because PEDF is an inhibitor of ocular angiogenesis and an inhibitor of ocular cell proliferation, our results suggest that PEDF along with VEGF may modulate the formation of subfoveal fibrovascular membranes.
C1 Kansai Med Univ, Dept Ophthalmol, Osaka 5708507, Japan.
C3 Kansai Medical University
RP Ogata, N (通讯作者)，Kansai Med Univ, Dept Ophthalmol, Fumizono Cho 10-15, Osaka 5708507, Japan.
EM ogata@takii.kmu.ac.jp
CR ADAMIS AP, 1993, BIOCHEM BIOPH RES CO, V193, P631, DOI 10.1006/bbrc.1993.1671
   AMIN R, 1994, INVEST OPHTH VIS SCI, V35, P3178
   AMIN RH, 1995, INVEST OPHTH VIS SCI, V36, pS2565
   BOUCK N, 1990, CANCER CELL-MON REV, V2, P179
   DAMORE PA, 1994, INVEST OPHTH VIS SCI, V35, P3974
   Dawson DW, 1999, SCIENCE, V285, P245, DOI 10.1126/science.285.5425.245
   Duh EJ, 2002, INVEST OPHTH VIS SCI, V43, P821
   Folkman J, 1995, NEW ENGL J MED, V333, P1757, DOI 10.1056/NEJM199512283332608
   Frank RN, 1996, AM J OPHTHALMOL, V122, P393, DOI 10.1016/S0002-9394(14)72066-5
   Gao GQ, 2002, J BIOL CHEM, V277, P9492, DOI 10.1074/jbc.M108004200
   Gao GQ, 2001, FEBS LETT, V489, P270, DOI 10.1016/S0014-5793(01)02110-X
   Green W R, 1977, Trans Am Ophthalmol Soc, V75, P180
   GREEN WR, 1985, OPHTHALMOLOGY, V92, P615
   Hanahan D, 1996, CELL, V86, P353, DOI 10.1016/S0092-8674(00)80108-7
   HERIOT WJ, 1984, OPHTHALMOLOGY, V91, P1603
   Holekamp NM, 2002, AM J OPHTHALMOL, V134, P220, DOI 10.1016/S0002-9394(02)01549-0
   Kvanta A, 1996, INVEST OPHTH VIS SCI, V37, P1929
   LAMBERT HM, 1992, AM J OPHTHALMOL, V113, P257, DOI 10.1016/S0002-9394(14)71576-4
   Lopez PF, 1996, INVEST OPHTH VIS SCI, V37, P855
   Matsushima M, 1996, JPN J OPHTHALMOL, V40, P329
   Miyagishi D, 2003, CANCER LETT, V196, P77, DOI 10.1016/S0304-3835(03)00185-X
   Ogata N, 1997, CURR EYE RES, V16, P9, DOI 10.1076/ceyr.16.1.9.5121
   Ogata N, 1996, CURR EYE RES, V15, P1008, DOI 10.3109/02713689609017649
   Ogata N, 2002, AM J OPHTHALMOL, V134, P348, DOI 10.1016/S0002-9394(02)01568-4
   Ogata N, 2002, INVEST OPHTH VIS SCI, V43, P1168
   Ogata N, 2002, AM J OPHTHALMOL, V133, P851, DOI 10.1016/S0002-9394(02)01406-X
   Ogata N, 2001, AM J OPHTHALMOL, V132, P378, DOI 10.1016/S0002-9394(01)01008-X
   Ogata N, 1998, CURR EYE RES, V17, P1087, DOI 10.1076/ceyr.17.11.1087.5234
   Ohno-Matsui K, 2003, BIOCHEM BIOPH RES CO, V303, P962, DOI 10.1016/S0006-291X(03)00446-7
   Ohno-Matsui K, 2001, J CELL PHYSIOL, V189, P323, DOI 10.1002/jcp.10026
   Okubo A, 2002, BRIT J OPHTHALMOL, V86, P1093, DOI 10.1136/bjo.86.10.1093
   REDDY VM, 1995, AM J OPHTHALMOL, V120, P291, DOI 10.1016/S0002-9394(14)72158-0
   Renno RZ, 2002, INVEST OPHTH VIS SCI, V43, P1574
   Stellmach V, 2001, P NATL ACAD SCI USA, V98, P2593, DOI 10.1073/pnas.031252398
   Terasaki H, 2002, BRIT J OPHTHALMOL, V86, P321, DOI 10.1136/bjo.86.3.321
   Uyama M, 1999, ARCH OPHTHALMOL-CHIC, V117, P1035
   Wada M, 1999, CURR EYE RES, V18, P203, DOI 10.1076/ceyr.18.3.203.5368
   Yannuzzi LA, 1999, ARCH OPHTHALMOL-CHIC, V117, P1503
   YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001
   YANNUZZI LA, 1982 MAC SOC M
   Yi XJ, 1997, GRAEF ARCH CLIN EXP, V235, P313, DOI 10.1007/BF01739641
   Yi XJ, 1998, EXP BRAIN RES, V118, P155, DOI 10.1007/s002210050267
NR 42
TC 162
Z9 189
U1 0
U2 5
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0007-1161
EI 1468-2079
J9 BRIT J OPHTHALMOL
JI Br. J. Ophthalmol.
PD JUN
PY 2004
VL 88
IS 6
BP 809
EP 815
DI 10.1136/bjo.2003.032466
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 821QS
UT WOS:000221478000019
PM 15148217
OA Bronze, Green Published, Green Submitted
DA 2022-11-30
ER

PT J
AU Yanagi, Y
   Mohla, A
   Lee, WK
   Lee, SY
   Mathur, R
   Chan, CM
   Yeo, I
   Wong, TY
   Cheung, CMG
AF Yanagi, Yasuo
   Mohla, Aditi
   Lee, Won-Ki
   Lee, Shu Yen
   Mathur, Ranjana
   Chan, Choi Mun
   Yeo, Ian
   Wong, Tien Yin
   Cheung, Chui Ming Gemmy
TI Prevalence and Risk Factors for Nonexudative Neovascularization in
   Fellow Eyes of Patients With Unilateral Age-Related Macular Degeneration
   and Polypoidal Choroidal Vasculopathy
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
DE age-related macular degeneration; nonexudative neovascularization;
   optical coherence tomography angiography
ID COHERENCE TOMOGRAPHY ANGIOGRAPHY; INDOCYANINE-GREEN VIDEOANGIOGRAPHY;
   PIGMENT EPITHELIAL DETACHMENTS; VASCULAR HYPERPERMEABILITY; THICKNESS;
   DISEASE; DRUSEN
AB PURPOSE. To determine the prevalence of subclinical nonexudative neovascularization and associated choroidal vascular changes in the fellow eyes of patients presenting with unilateral typical exudative AMD (tAMD) or polypoidal choroidal vasculopathy (PCV) using indocyanine green angiography (ICGA) and swept-source (SS) optical coherence tomography angiography (OCT-A).
   METHODS. We recruited patients presenting with tAMD or PCV in a prospective clinical study. The diagnosis in the presenting eye was determined based on clinical, fluorescein angiography (FA), and ICGA findings. We evaluated the contralateral eye for presence of nonexudative neovascularization, choroidal hyperpermeability, and pachyvessels in the outer choroid, based on multimodal imaging which included ICGA, spectral-domain (SD) OCT and OCT-A. We measured subfoveal choroidal thickness in both eyes for each patient.
   RESULTS. We included 76 fellow eyes of 76 patients who presented with unilateral tAMD (n = 33) or PCV (n = 43). Nonexudative neovascularization was present in 18% eyes (14 eyes, 8 in tAMD group, 6 in PCV group; 7 on ICGA, 4 on OCT-A, 3 on both ICGA and OCT-A). Pachychoroid pigment epitheliopathy was present in 13 eyes with nonexudative neovascularization, and was the only risk factor associated with nonexudative neovascularization.
   CONCLUSIONS. Approximately one in five fellow eyes with unilateral tAMD and PCV have features of nonexudative neovascularization. The use of multimodal imaging including ICGA and OCT-A can identify these features. The presence of pachychoroid epitheliopathy should alert clinicians to the possibility of underlying neovascularization.
C1 [Yanagi, Yasuo; Mohla, Aditi; Lee, Shu Yen; Mathur, Ranjana; Chan, Choi Mun; Yeo, Ian; Wong, Tien Yin; Cheung, Chui Ming Gemmy] Singapore Natl Eye Ctr, Singapore Eye Res Inst, 11 Third Hosp Ave, Singapore 168751, Singapore.
   [Yanagi, Yasuo; Lee, Shu Yen; Mathur, Ranjana; Chan, Choi Mun; Yeo, Ian; Wong, Tien Yin; Cheung, Chui Ming Gemmy] Natl Univ Singapore, Duke NUS Med Sch, Ophthalmol & Visual Sci Program, Singapore, Singapore.
   [Lee, Won-Ki] Catholic Univ Korea, Seoul St Marys Hosp, Dept Ophthalmol, Seoul, South Korea.
C3 National University of Singapore; Singapore National Eye Center;
   National University of Singapore; Catholic University of Korea; Seoul
   St. Mary's Hospital
RP Cheung, CMG (通讯作者)，Singapore Natl Eye Ctr, Singapore Eye Res Inst, 11 Third Hosp Ave, Singapore 168751, Singapore.
EM gemmy.cheung.c.m@snec.com.sg
RI Wong, Tien Yin/AAC-9724-2020; Yanagi, Yasuo/AAF-2670-2020; Yanagi,
   Yasuo/AAA-5441-2022
OI Wong, Tien Yin/0000-0002-8448-1264; Cheung, Chui Ming
   Gemmy/0000-0003-3358-3516; Yanagi, Yasuo/0000-0002-0362-7285
FU National Medical Research Council Grant (Singapore)
   [NMRC/NIG/1003/2009]; Biomedical Research Council Grant (Singapore)
   [10/1/35/19/671]
FX Supported by National Medical Research Council Grant NMRC/NIG/1003/2009
   (Singapore) and Biomedical Research Council Grant No. 10/1/35/19/671
   (Singapore).
CR Alasil T, 2015, AM J OPHTHALMOL, V159, P634, DOI 10.1016/j.ajo.2014.12.012
   Balaratnasingam C, 2016, RETINA-J RET VIT DIS, V36, P1, DOI 10.1097/IAE.0000000000000774
   Barbazetto IA, 2010, AM J OPHTHALMOL, V149, P939, DOI 10.1016/j.ajo.2010.01.007
   BOTTONI FG, 1994, GRAEF ARCH CLIN EXP, V232, P458, DOI 10.1007/BF00195354
   Carnevali A, OPHTHALMOLOGY RETINA, DOI [10.1016/j.oret.2017.01.003, DOI 10.1016/J.ORET.2017.01.003.]
   Carnevali A, 2016, AM J OPHTHALMOL, V169, P189, DOI 10.1016/j.ajo.2016.06.042
   Cheung CMG, 2012, CLIN EXP OPHTHALMOL, V40, P727, DOI 10.1111/j.1442-9071.2012.02765.x
   Cheung CMG, 2017, RETINA-J RET VIT DIS, V37, P1464, DOI 10.1097/IAE.0000000000001391
   Cheung CMG, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0101057
   Cho HJ, 2013, AM J OPHTHALMOL, V156, P1192, DOI 10.1016/j.ajo.2013.07.001
   Dansingani KK, 2016, RETINA-J RET VIT DIS, V36, P499, DOI 10.1097/IAE.0000000000000742
   Dansingani KK, 2015, AM J OPHTHALMOL, V160, P1243, DOI 10.1016/j.ajo.2015.08.028
   Gallego-Pinazo Roberto, 2014, Med Hypothesis Discov Innov Ophthalmol, V3, P111
   GREEN WR, 1985, OPHTHALMOLOGY, V92, P615
   Hage R, 2015, AM J OPHTHALMOL, V159, P890, DOI 10.1016/j.ajo.2015.02.002
   Hanutsaha P, 1998, OPHTHALMOLOGY, V105, P1632, DOI 10.1016/S0161-6420(98)99030-3
   Hong YJ, 2014, INVEST OPHTH VIS SCI, V55, P5016, DOI 10.1167/iovs.14-14005
   Japanese Study Group of Polypoidal Choroidal Vasculopathy, 2005, Nippon Ganka Gakkai Zasshi, V109, P417
   Jirarattanasopa P, 2012, INVEST OPHTH VIS SCI, V53, P3663, DOI 10.1167/iovs.12-9619
   Kim JH, 2015, INVEST OPHTH VIS SCI, V56, P1909, DOI 10.1167/iovs.14-16000
   Koizumi H, 2013, AM J OPHTHALMOL, V155, P305, DOI 10.1016/j.ajo.2012.07.018
   Lee W. K., 2016, RETINA, V36, P73
   Lim FP, 2015, BR J OPHTHALMOL, P918
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Maruko I, 2011, AM J OPHTHALMOL, V151, P594, DOI 10.1016/j.ajo.2010.10.030
   Miura M, 2015, INVEST OPHTH VIS SCI, V56, P3179, DOI 10.1167/iovs.14-16252
   Miyake M, 2014, INVEST OPHTH VIS SCI, V55, P3223, DOI 10.1167/iovs.14-14059
   Palejwala NV, 2015, RETINA-J RET VIT DIS, V35, P2204, DOI 10.1097/IAE.0000000000000867
   Pang CE, 2015, RETINA-J RET VIT DIS, V35, P1, DOI 10.1097/IAE.0000000000000331
   Quaranta-El Maftouhi M, 2015, AM J OPHTHALMOL, V160, P581, DOI 10.1016/j.ajo.2015.06.016
   Roisman L, 2016, OPHTHALMOLOGY, V123, P1309, DOI 10.1016/j.ophtha.2016.01.044
   Sasahara M, 2006, AM J OPHTHALMOL, V142, P601, DOI 10.1016/j.ajo.2006.05.051
   Sasaki M, 2014, OPTOMETRY VISION SCI, V91, P849, DOI 10.1097/OPX.0000000000000317
   Schmidt-Erfurth U, 2016, PROG RETIN EYE RES, V50, P1, DOI 10.1016/j.preteyeres.2015.07.007
   Sonoda S, 2013, BMC OPHTHALMOL, V13, DOI 10.1186/1471-2415-13-43
   Spraul CW, 1997, ARCH OPHTHALMOL-CHIC, V115, P267, DOI 10.1001/archopht.1997.01100150269022
   Takkar B, 2016, AM J OPHTHALMOL, V163, P193, DOI 10.1016/j.ajo.2015.12.016
   Ting DSW, 2016, AM J OPHTHALMOL, V164, P128, DOI 10.1016/j.ajo.2015.12.024
   Tsujikawa A, 2007, AM J OPHTHALMOL, V143, P102, DOI 10.1016/j.ajo.2006.08.025
   Warrow DJ, 2013, RETINA-J RET VIT DIS, V33, P1659, DOI 10.1097/IAE.0b013e3182953df4
   Wong CW, 2016, PROG RETIN EYE RES, V53, P107, DOI 10.1016/j.preteyeres.2016.04.002
   Wong T, 2008, OPHTHALMOLOGY, V115, P116, DOI 10.1016/j.ophtha.2007.03.008
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Yuzawa M, 2005, BRIT J OPHTHALMOL, V89, P602, DOI 10.1136/bjo.2004.049296
NR 44
TC 33
Z9 34
U1 0
U2 2
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD JUL
PY 2017
VL 58
IS 9
BP 3488
EP 3495
DI 10.1167/iovs.16-21167
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA FH1WU
UT WOS:000410931200024
PM 28702676
OA gold, Green Submitted
DA 2022-11-30
ER

PT J
AU Subramanian, ML
   Ness, S
   Abedi, G
   Ahmed, E
   Daly, M
   Feinberg, E
   Bhatia, S
   Patel, P
   Nguyen, M
   Houranieh, A
AF Subramanian, Manju L.
   Ness, Steven
   Abedi, Gelareh
   Ahmed, Ednan
   Daly, Mary
   Feinberg, Edward
   Bhatia, Sumit
   Patel, Payal
   Nguyen, Maileah
   Houranieh, Antoun
TI Bevacizumab vs Ranibizumab for Age-Related Macular Degeneration: Early
   Results of a Prospective Double-Masked, Randomized Clinical Trial
SO AMERICAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID ENDOTHELIAL GROWTH-FACTOR; INTRAVITREAL BEVACIZUMAB; CHOROIDAL
   NEOVASCULARIZATION; AVASTIN TREATMENT; EYE DISEASE; SHORT-TERM; THERAPY;
   SAFETY; VERTEPORFIN; PEGAPTANIB
AB PURPOSE: To report early outcomes of a prospective, double-masked, controlled trial comparing bevacizumab (Avastin; Genentech Inc, South San Francisco, California, USA) to ranibizumab (Lucentis; Genentech Inc) for the treatment of age-related macular degeneration.
   DESIGN: Prospective, double-Masked, randomized clinical trial.
   METHODS: This is a single-center, randomized clinical trial at the Boston Veterans Affairs Healthcare System. Patients who met inclusion criteria were randomized 2:1 to bevacizumab or ranibizumab. Each patient contributed 1 eye to the study. All subjects and investigators (except for the pharmacist responsible for study assignments) were masked to treatment arms. Visual acuity (VA) was checked on Early Treatment Diabetic Retinopathy Study (ETDRS) chart. Patients were given either bevacizumab or ranibizumab every month for the first 3 months, followed by optical coherence tomography-guided, variable-dosing schedule. Main outcomes measured were VA and foveal thickness.
   RESULTS: Twenty patients completed the 6 month follow up. Thirteen patients received bevacizumab and 7 patients received ranibizumab. No subjects in either group lost more than 15 letters on ETDRS chart. The average preoperative VA was 31.6 letters in the bevacizumab group and 30.4 letters in the ranibizumab group. At 6 months follow-up, mean vision was 46.4 letters in the bevacizumab group and 37.4 letters in the ranibizumab group. Two-tailed ttest failed to show statistical significance between the two groups. Patients in the bevacizumab group underwent an average of 5 injections, while patients in the ranibizumab group underwent a mean of 4 injections.
   CONCLUSION: Early results of a head-to,head, randomized, double-masked, prospective, single-center controlled trial between bevacizumab and ranibizumab show no difference in efficacy between the two treatments for choroidal neovascularizaton in the treatment of age-related macular degeneration. As this study conveys results of a small number of patients, further studies with larger sample sizes are needed in order to establish statistical significance. (Am J Ophthalmol 2009;148: 875-882. (C) 2009 by Elsevier Inc. All rights reserved.)
C1 [Subramanian, Manju L.; Ness, Steven; Abedi, Gelareh; Ahmed, Ednan; Daly, Mary; Feinberg, Edward; Bhatia, Sumit; Patel, Payal] Boston Univ, Sch Med, Dept Ophthalmol, Boston, MA 02118 USA.
   [Subramanian, Manju L.; Ness, Steven; Abedi, Gelareh; Ahmed, Ednan; Daly, Mary; Feinberg, Edward; Bhatia, Sumit; Nguyen, Maileah; Houranieh, Antoun] Vet Affairs Boston Healthcare Syst, Jamaica Plain, MA USA.
C3 Boston University; US Department of Veterans Affairs; Veterans Health
   Administration (VHA); Harvard University; VA Boston Healthcare System
RP Subramanian, ML (通讯作者)，Boston Univ, Sch Med, Dept Ophthalmol, 85 E Concord St,8th Fl, Boston, MA 02118 USA.
EM manju.subramanian@bmc.org
OI Daly, Mary/0000-0002-3298-8901; Ness, Steven/0000-0002-5843-9476;
   Subramanian, Manju/0000-0002-0061-098X
FU VETERANS AFFAIRS BOSTON HEALTHCARE SYSTEM, JAMAICA PLAIN, MASSACHUSETTS
FX THIS STUDY WAS SUPPORTED BY THE VETERANS AFFAIRS BOSTON HEALTHCARE
   SYSTEM, JAMAICA PLAIN, MASSACHUSETTS. The authors indicate no financial
   conflict of interest. Involved in design and conduct of study (M.S.,
   S.N., E.F., M.D., S.B., A.H.); collection, management, analysis, and
   interpretation of data (M.S., S.N., G.A., E.A., S.B., P.P., M.N.); and
   preparation, review, and/or approval of manuscript (M.S., G.A., E.F.,
   M.D., P.P., A.H., S.B.). The Veterans Affairs Boston Healthcare System
   Institutional Review Board approved this trial. The study is in
   accordance with HIPAA regulations. This clinical trial was registered
   with the International Standard Randomized Controlled Trial (trial
   number: ISRCTN73359806).
CR Abraham-Marin ML, 2007, GRAEF ARCH CLIN EXP, V245, P651, DOI 10.1007/s00417-006-0411-6
   Aisenbrey S, 2007, GRAEF ARCH CLIN EXP, V245, P941, DOI 10.1007/s00417-006-0471-7
   Avery RL, 2006, OPHTHALMOLOGY, V113, P363, DOI 10.1016/j.ophtha.2005.11.019
   Bashshur ZF, 2006, AM J OPHTHALMOL, V142, P1, DOI 10.1016/j.ajo.2006.02.037
   Bhutto IA, 2006, EXP EYE RES, V82, P99, DOI 10.1016/j.exer.2005.05.007
   BORENSTEIN M, 2004, POWER PRECISION 2 0, P4918
   Bressler NM, 2003, ARCH OPHTHALMOL-CHIC, V121, P1621
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   Brown MM, 2006, CURR OPIN OPHTHALMOL, V17, P257
   Chakravarthy U, 2006, OPHTHALMOLOGY, V113, P1508, DOI 10.1016/j.ophtha.2006.02.064
   Chen CY, 2007, AM J OPHTHALMOL, V143, P510, DOI 10.1016/j.ajo.2006.10.004
   Cleary CA, 2008, EYE, V22, P82, DOI 10.1038/sj.eye.6702936
   Emerson MV, 2007, RETINA-J RET VIT DIS, V27, P439, DOI 10.1097/IAE.0b013e31804b3e15
   Fung AE, 2006, BRIT J OPHTHALMOL, V90, P1344, DOI 10.1136/bjo.2006.099598
   Fung AE, 2007, AM J OPHTHALMOL, V143, P566, DOI 10.1016/j.ajo.2007.01.028
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Ho QT, 2007, INT J BIOCHEM CELL B, V39, P1349, DOI 10.1016/j.biocel.2007.04.010
   Holladay JT, 1997, J REFRACT SURG, V13, P388
   Kliffen M, 1997, BRIT J OPHTHALMOL, V81, P154, DOI 10.1136/bjo.81.2.154
   Lazic R, 2007, OPHTHALMOLOGY, V114, P1179, DOI 10.1016/j.ophtha.2007.03.006
   Madhusudhana KC, 2007, BRIT J OPHTHALMOL, V91, P1716, DOI 10.1136/bjo.2006.108639
   Michels S, 2005, OPHTHALMOLOGY, V112, P1035, DOI 10.1016/j.ophtha.2005.02.007
   Miller JW, 1997, AM J PATHOL, V151, P13
   Moshfeghi AA, 2006, OPHTHALMOLOGY, V113, P2002, DOI 10.1016/j.ophtha.2006.05.070
   Ng EWM, 2005, CAN J OPHTHALMOL, V40, P352, DOI 10.1016/S0008-4182(05)80078-X
   Penn JS, 2008, PROG RETIN EYE RES, V27, P331, DOI 10.1016/j.preteyeres.2008.05.001
   Regillo CD, 2008, AM J OPHTHALMOL, V145, P239, DOI 10.1016/j.ajo.2007.10.004
   Rich RM, 2006, RETINA-J RET VIT DIS, V26, P495, DOI 10.1097/01.iae.0000225766.75009.3a
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rosenfeld PJ, 2006, AM J OPHTHALMOL, V142, P141, DOI 10.1016/j.ajo.2006.03.036
   Spaide RF, 2006, RETINA-J RET VIT DIS, V26, P383, DOI 10.1097/00006982-200604000-00001
   Steinbrook R, 2006, NEW ENGL J MED, V355, P1409, DOI 10.1056/NEJMp068185
   Wu L, 2008, GRAEF ARCH CLIN EXP, V246, P81, DOI 10.1007/s00417-007-0660-z
   Yang JC, 2003, NEW ENGL J MED, V349, P427, DOI 10.1056/NEJMoa021491
   Ziemssen Focke, 2008, International Ophthalmology, V28, P101, DOI 10.1007/s10792-007-9122-1
NR 36
TC 51
Z9 57
U1 0
U2 5
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0002-9394
J9 AM J OPHTHALMOL
JI Am. J. Ophthalmol.
PD DEC
PY 2009
VL 148
IS 6
BP 875
EP 882
DI 10.1016/j.ajo.2009.07.009
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 530BP
UT WOS:000272564200011
PM 19800611
DA 2022-11-30
ER

PT J
AU Adamus, G
AF Adamus, Grazyna
TI Can innate and autoimmune reactivity forecast early and advance stages
   of age-related macular degeneration?
SO AUTOIMMUNITY REVIEWS
LA English
DT Review
DE Autoimmunity; Age-related macular degeneration; Autoantibodies;
   Complement factors; Factor H; Cytokines IL-17; Chemokines; Retina; Aging
ID FACTOR-H POLYMORPHISM; ANTI-RETINAL ANTIBODIES; ALPHA-B-CRYSTALLIN;
   COMPLEMENT COMPONENTS; SUBRETINAL MICROGLIA; AQUEOUS-HUMOR;
   ANIMAL-MODEL; BIOMARKERS; AUTOANTIBODIES; INFLAMMATION
AB Age-related macular degeneration (AMD) is a major cause of central vision loss in persons over 55 years of age in developed countries. AMD is a complex disease in which genetic, environmental and inflammatory factors influence its onset and progression. Elevation in serum anti-retinal autoantibodies, plasma and local activation of complement proteins of the alternative pathway, and increase in secretion of proinflammatory cytokines have been seen over the course of disease. Genetic studies of AMD patients confirmed that genetic variants affecting the alternative complement pathway have a major influence on AMD risk. Because the heterogeneity of this disease, there is no sufficient strategy to identify the disease onset and progression sole based eye examination, thus identification of reliable serological biomarkers for diagnosis, prognosis and response to treatment by sampling patient's blood is necessary. This review provides an outline of the current knowledge on possible serological (autoantibodies, complement factors, cytokines, chemokines) and related genetic biomarkers relevant to the pathology of AMD, and discusses their application for prediction of disease activity and prognosis in AMD. (C) 2017 Elsevier B.V. All rights reserved.
C1 [Adamus, Grazyna] Oregon Hlth & Sci Univ, Sch Med, Ocular Immunol Lab, Portland, OR 97201 USA.
C3 Oregon Health & Science University
RP Adamus, G (通讯作者)，Oregon Hlth & Sci Univ, Biomed Res Bldg,3181 SW Sam Jackson Pk Rd, Portland, OR 97239 USA.
EM adamusg@ohsu.edu
FU NIH [P30 EY010572]; Research to Prevent Blindness; NATIONAL EYE
   INSTITUTE [P30EY010572] Funding Source: NIH RePORTER
FX This work was supported by the NIH grant P30 EY010572 and unrestricted
   grant from Research to Prevent Blindness.
CR Adamus G, 1998, J AUTOIMMUN, V11, P671, DOI 10.1006/jaut.1998.0239
   Adamus Grazyna, 2004, BMC Ophthalmol, V4, P5, DOI 10.1186/1471-2415-4-5
   Adamus G, 2014, BMC OPHTHALMOL, V14, DOI 10.1186/1471-2415-14-154
   Adamus G, 2009, AUTOIMMUN REV, V8, P410, DOI 10.1016/j.autrev.2009.01.002
   Ambati J, 2003, NAT MED, V9, P1390, DOI 10.1038/nm950
   Ambati J, 2003, SURV OPHTHALMOL, V48, P257, DOI 10.1016/S0039-6257(03)00030-4
   Ambati J, 2013, NAT REV IMMUNOL, V13, P438, DOI 10.1038/nri3459
   Anderson DH, 2002, AM J OPHTHALMOL, V134, P411, DOI 10.1016/S0002-9394(02)01624-0
   Anderson DH, 2010, PROG RETIN EYE RES, V29, P95, DOI 10.1016/j.preteyeres.2009.11.003
   Ardeljan D, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0095900
   Ardeljan D, 2013, PROG RETIN EYE RES, V37, P68, DOI 10.1016/j.preteyeres.2013.07.003
   Bhutto IA, 2011, BR J OPHTHALMOL, V95
   Bhutto I, 2012, MOL ASPECTS MED, V33, P295, DOI 10.1016/j.mam.2012.04.005
   Bian ZM, 2004, INVEST OPHTH VIS SCI, V45, P1887, DOI 10.1167/iovs.03-0608
   BORA NS, 1993, INVEST OPHTH VIS SCI, V34, P3579
   Bromley SK, 2008, NAT IMMUNOL, V9, P970, DOI 10.1038/ni.f.213
   Buschini E, 2011, PROG NEUROBIOL, V95, P14, DOI 10.1016/j.pneurobio.2011.05.011
   Caicedo A, 2005, EXP EYE RES, V81, P38, DOI 10.1016/j.exer.2005.01.013
   Camelo S, 2014, AUTOIMMUN DIS, V2014, DOI 10.1155/2014/532487
   Celet B, 2000, J NEUROL, V247, P935, DOI 10.1007/s004150070049
   Chan CC, 2008, OPHTHALMIC RES, V40, P124, DOI 10.1159/000119862
   Chan CC, 2014, ADV EXP MED BIOL, V801, P193, DOI 10.1007/978-1-4614-3209-8_25
   Chen HY, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002339
   Chen M, 2010, INVEST OPHTH VIS SCI, V51, P5888, DOI 10.1167/iovs.09-5103
   Cherepanoff S, 2006, CLIN EXP OPHTHALMOL, V34, P590, DOI 10.1111/j.1442-9071.2006.01281.x
   Combadiere C, 2007, J CLIN INVEST, V117, P2920, DOI 10.1172/JCI31692
   Cousins SW, 2004, ARCH OPHTHALMOL-CHIC, V122, P1013, DOI 10.1001/archopht.122.7.1013
   Crabb JW, 2002, P NATL ACAD SCI USA, V99, P14682, DOI 10.1073/pnas.222551899
   Cruz-Guilloty F, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0088201
   Deane KD, 2014, CURR RHEUMATOL REP, V16, DOI 10.1007/s11926-014-0419-6
   Despriet DDG, 2006, JAMA-J AM MED ASSOC, V296, P301, DOI 10.1001/jama.296.3.301
   Diaz-Ramos A, 2012, J BIOMED BIOTECHNOL, DOI 10.1155/2012/156795
   Donoso LA, 2006, SURV OPHTHALMOL, V51, P137, DOI 10.1016/j.survophthal.2005.12.001
   Doycheva D, 2012, GRAEF ARCH CLIN EXP, V250, P297, DOI 10.1007/s00417-011-1758-x
   Ebrahimi KB, 2013, J PATHOL, V229, P729, DOI 10.1002/path.4128
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Ezzat MK, 2008, BRIT J OPHTHALMOL, V92, P976, DOI 10.1136/bjo.2007.129742
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Fritsche LG, 2016, NAT GENET, V48, P134, DOI 10.1038/ng.3448
   Gehrs KM, 2006, ANN MED, V38, P450, DOI 10.1080/07853890600946724
   Gemenetzi M, 2016, EYE, V30, P1, DOI 10.1038/eye.2015.203
   Gu XR, 2003, J BIOL CHEM, V278, P42027, DOI 10.1074/jbc.M305460200
   GURNE DH, 1991, OPHTHALMOLOGY, V98, P602
   Haddad S, 2006, SURV OPHTHALMOL, V51, P316, DOI 10.1016/j.survophthal.2006.05.001
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Hecker LA, 2010, HUM MOL GENET, V19, P209, DOI 10.1093/hmg/ddp472
   Iannaccone A, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0145323
   Issa PC, 2011, GRAEF ARCH CLIN EXP, V249, P163, DOI 10.1007/s00417-010-1568-6
   Joachim SC, 2007, CURR EYE RES, V32, P501, DOI 10.1080/02713680701375183
   Joachim SC, 2007, GRAEF ARCH CLIN EXP, V245, P619, DOI 10.1007/s00417-006-0429-9
   Jonas JB, 2010, ARCH OPHTHALMOL-CHIC, V128, P1281, DOI 10.1001/archophthalmol.2010.227
   Kauppinen A, 2016, CELL MOL LIFE SCI, V73, P1765, DOI 10.1007/s00018-016-2147-8
   Khandhadia S, 2012, IMMUNOBIOLOGY, V217, P127, DOI 10.1016/j.imbio.2011.07.019
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Klein R, 2014, JAMA OPHTHALMOL, V132, P446, DOI 10.1001/jamaophthalmol.2013.7671
   KUPPNER MC, 1995, IMMUNOLOGY, V84, P265
   Landeck L, 2016, EXP DERMATOL, V25, P333, DOI 10.1111/exd.12948
   Liu BY, 2011, J TRANSL MED, V9, DOI 10.1186/1479-5876-9-111
   Liu F, 2016, MOL VIS, V22, P352
   Lu B, 1998, J EXP MED, V187, P601, DOI 10.1084/jem.187.4.601
   Magrys A, 2007, J CLIN IMMUNOL, V27, P181, DOI 10.1007/s10875-006-9065-8
   Majka DS, 2008, ANN RHEUM DIS, V67, P801, DOI 10.1136/ard.2007.076679
   McHarg S, 2015, MOL IMMUNOL, V67, P43, DOI 10.1016/j.molimm.2015.02.032
   McLeod DS, 2009, INVEST OPHTH VIS SCI, V50, P4982, DOI 10.1167/iovs.09-3639
   Molins B, 2016, SCI REP-UK, V6, DOI 10.1038/srep22889
   Montezuma Sandra R, 2007, Semin Ophthalmol, V22, P229, DOI 10.1080/08820530701745140
   Morohoshi K, 2012, EXP MOL PATHOL, V93, P193, DOI 10.1016/j.yexmp.2012.03.007
   Morohoshi K, 2012, EXP MOL PATHOL, V92, P64, DOI 10.1016/j.yexmp.2011.09.017
   Nassar K, 2015, GRAEF ARCH CLIN EXP, V253, P699, DOI 10.1007/s00417-014-2738-8
   Nita M, 2014, MEDIAT INFLAMM, V2014, DOI 10.1155/2014/930671
   Nozaki M, 2006, P NATL ACAD SCI USA, V103, P2328, DOI 10.1073/pnas.0408835103
   Pan B, 2015, SCI REP-UK, V5, DOI 10.1038/srep16053
   Patel N, 2005, IMMUNOLOGY, V115, P422, DOI 10.1111/j.1365-2567.2005.02173.x
   Penfold PL, 2001, PROG RETIN EYE RES, V20, P385, DOI 10.1016/S1350-9462(00)00025-2
   Perez VL, 2015, TRENDS IMMUNOL, V36, P354, DOI 10.1016/j.it.2015.04.003
   PLANCK SR, 1993, CURR EYE RES, V12, P205, DOI 10.3109/02713689308999465
   Provis Jan M, 2005, Clin Exp Optom, V88, P269
   Ramkumar HL, 2010, PROG RETIN EYE RES, V29, P169, DOI 10.1016/j.preteyeres.2010.02.002
   Raoul W, 2010, J NEUROINFLAMM, V7, DOI 10.1186/1742-2094-7-87
   Reynolds R, 2009, INVEST OPHTH VIS SCI, V50, P5818, DOI 10.1167/iovs.09-3928
   Rudnicka AR, 2015, AM J OPHTHALMOL, V160, P85, DOI 10.1016/j.ajo.2015.04.003
   Saeed AM, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0106421
   Salomon RG, 2011, CHEM RES TOXICOL, V24, P1803, DOI 10.1021/tx200206v
   Schmidt-Erfurth U, 2016, PROG RETIN EYE RES, V50, P1, DOI 10.1016/j.preteyeres.2015.07.007
   Scholl HPN, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002593
   Seddon JM, 2011, OPHTHALMOLOGY, V118, P2203, DOI 10.1016/j.ophtha.2011.04.029
   Shin JI, 2013, NAT REV IMMUNOL, V13, DOI 10.1038/nri3459-c1
   Singh A, 2012, AM J OPHTHALMOL, V154, P193, DOI 10.1016/j.ajo.2012.01.036
   Skuljec J, 2011, CELL IMMUNOL, V270, P164, DOI 10.1016/j.cellimm.2011.05.001
   Strimbu K, 2010, CURR OPIN HIV AIDS, V5, P463, DOI 10.1097/COH.0b013e32833ed177
   van Lookeren CM, 2015, IMMUNOBIOLOGY, V221, P733
   Vogt SD, 2011, EXP EYE RES, V93, P413, DOI 10.1016/j.exer.2011.06.002
   Wei L, 2012, CELL REP, V2, P1151, DOI 10.1016/j.celrep.2012.10.013
   Xu HP, 2008, AGING CELL, V7, P58, DOI 10.1111/j.1474-9726.2007.00351.x
   Xu HP, 2009, PROG RETIN EYE RES, V28, P348, DOI 10.1016/j.preteyeres.2009.06.001
   Yonekawa Y, 2015, COLD SPRING HARB PER, V5
   Zarbin MA, 2004, ARCH OPHTHALMOL-CHIC, V122, P598, DOI 10.1001/archopht.122.4.598
NR 99
TC 11
Z9 11
U1 1
U2 9
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 1568-9972
EI 1873-0183
J9 AUTOIMMUN REV
JI Autoimmun. Rev.
PD MAR
PY 2017
VL 16
IS 3
BP 231
EP 236
DI 10.1016/j.autrev.2017.01.005
PG 6
WC Immunology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Immunology
GA EP7JD
UT WOS:000397553200003
PM 28137479
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Miller, JW
AF Miller, Joan W.
TI Age-Related Macular Degeneration Revisited - Piecing the Puzzle: The
   LXIX Edward Jackson Memorial Lecture
SO AMERICAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID COMPLEMENT FACTOR-H; RETINAL-PIGMENT EPITHELIUM; ORPHAN RECEPTOR-ALPHA;
   POLYPOIDAL CHOROIDAL VASCULOPATHY; DENSITY LIPOPROTEIN RECEPTOR;
   GENOME-WIDE ASSOCIATION; BRUCHS MEMBRANE; MOUSE MODEL; PHOTODYNAMIC
   THERAPY; GEOGRAPHIC ATROPHY
AB PURPOSE: To present the current understanding of age-related macular degeneration (AMD) pathogenesis, based on clinical evidence, epidemiologic data, histopathologic examination, and genetic data; to provide an update on current and emerging therapies; and to propose an integrated model of the pathogenesis of AMD.
   DESIGN: Review of published clinical and experimental studies.
   METHODS: Analysis and synthesis of clinical and experimental data.
   RESULTS: We are closer to a complete understanding of the pathogenesis of AMD, having progressed from clinical observations to epidemiologic observations and clinical pathologic correlation. More recently, modern genetic and genomic studies have facilitated the exploration of molecular pathways. It seems that AMD is a complex disease that results from the interaction of genetic susceptibility with aging and environmental factors. Disease progression also seems to be driven by a combination of genetic and environmental factors.
   CONCLUSIONS: Therapies based on pathophysiologic features have changed the paradigm for treating neovascular AMD. With improved understanding of the underlying genetic susceptibility, we can identify targets to halt early disease and to prevent progression and vision loss. (Am J Ophthalmol 2013;155:1-35. (c) 2013 by Elsevier Inc. All rights reserved.)
C1 Harvard Univ, Sch Med, Massachusetts Gen Hosp, Massachusetts Eye & Ear Infirm,Dept Ophthalmol, Boston, MA 02114 USA.
C3 Harvard University; Harvard Medical School; Massachusetts Eye & Ear
   Infirmary; Massachusetts General Hospital
RP Miller, JW (通讯作者)，Harvard Univ, Sch Med, Massachusetts Gen Hosp, Massachusetts Eye & Ear Infirm,Dept Ophthalmol, 243 Charles St, Boston, MA 02114 USA.
EM joan_miller@meei.harvard.edu
OI Miller, Joan/0000-0003-2046-3996
FU Neovascular Research Fund; Yeatts Retina Fund (Massachusetts Eye and Ear
   Foundation, Boston, Massachusetts)
FX THE AUTHOR COMPLETED AND SUBMITTED THE ICMJE FORM FOR DISCLOSURE OF
   POTENTIAL CONFLICTS OF INTEREST AND the following were reported. The
   Massachusetts Eye and Ear Infirmary has an ownership interest in 3
   United States patents directed to the use of verteporfin. In addition,
   the Massachusetts Eye and Ear Infirmary has ownership interest in
   certain patent applications directed to the selective destruction of
   subretinal choroidal neovasculature for the treatment of macular
   degeneration and other disorders. The Massachusetts Eye and Ear
   Infirmary receives royalties as a result of these patents and patent
   applications, and Dr Miller receives a share of the same in accordance
   with the Massachusetts Eye and Ear Infirmary's institutional Patent
   Policy and Procedures, which includes royalty-sharing provisions.
   Publication of this article was supported by the Neovascular Research
   Fund and Yeatts Retina Fund (Massachusetts Eye and Ear Foundation,
   Boston, Massachusetts). The author was involved in Design of study; Data
   collection; Analysis and interpretation of data; Provision of materials,
   patients, or resources; Obtaining funding; Literature search; Writing
   article and critical revision; and Final approval of article. Given the
   editorial perspective nature of this manuscript, there are no issues
   related to institutional review board approval, Clinical Trials
   registration, or Institutional Animal Care and Use Committee guidelines.
   Clinical images are used with proper informed consent and Health
   Insurance Portability and Accountability Act compliance. The author
   thanks the following individuals (all from the Department of
   Ophthalmology, Massachusetts Eye and Ear Infirmary and Harvard Medical
   School, unless otherwise noted): Wendy Chao for her unflagging support
   in data acquisition, critical review, and creative/technical input;
   Kimberley Fechtel for her critical input and review; Alexander Coster
   Scott (Boston, Massachusetts) for creative and technical help with
   figures; her mentors, Evangelos Gragoudas, Judah Folkman, (Department of
   Surgery, Boston Children's Hospital and Harvard Medical School,
   deceased), Simmons Lessell, and Ephraim Friedman (deceased), for their
   career-long advice and support; her colleagues Patricia D'Amore and
   Anthony Adamis (Genentech), for their collaboration and friendship; and
   her mentees, particularly Ivana Kim, Margaret DeAngelis, (Department of
   Ophthalmology and Visual Sciences, University of Utah School of
   Medicine, John A. Moran Eye Center), and Demetrios Vavvas, for their
   insight and critical review, and who are the generation who will lead
   the field forward.
CR Allikmets R, 1997, NAT GENET, V15, P236, DOI 10.1038/ng0397-236
   Amara U, 2010, J IMMUNOL, V185, P5628, DOI 10.4049/jimmunol.0903678
   Ambati J, 2003, NAT MED, V9, P1390, DOI 10.1038/nm950
   An E, 2006, J PROTEOME RES, V5, P2599, DOI 10.1021/pr060121j
   Anand R, 2000, OPHTHALMOLOGY, V107, P2224
   Anderson DH, 2004, EXP EYE RES, V78, P243, DOI 10.1016/j.exer.2003.10.011
   Anderson DH, 2002, AM J OPHTHALMOL, V134, P411, DOI 10.1016/S0002-9394(02)01624-0
   Anderson DH, 2010, PROG RETIN EYE RES, V29, P95, DOI 10.1016/j.preteyeres.2009.11.003
   [Anonymous], 1993, Arch Ophthalmol, V111, P104
   Appel GB, 2005, J AM SOC NEPHROL, V16, P1392, DOI 10.1681/ASN.2005010078
   Bagoly Z, 2012, THROMB RES, V129, pS77, DOI 10.1016/j.thromres.2012.02.040
   Barouch Fina C., 2007, International Ophthalmology Clinics, V47, P185, DOI 10.1097/IIO.0b013e3180377936
   Besnard S, 2001, CIRC RES, V89, P1209, DOI 10.1161/hh2401.101755
   Bindewald A, 2005, BRIT J OPHTHALMOL, V89, P874, DOI 10.1136/bjo.2004.057794
   Birch DG, 2001, EXP EYE RES, V73, P877, DOI 10.1006/exer.2001.1093
   Boker T, 1993, Ger J Ophthalmol, V2, P10
   Bonomini F, 2010, EXP GERONTOL, V45, P149, DOI 10.1016/j.exger.2009.11.006
   Bora NS, 2007, J IMMUNOL, V178, P1783, DOI 10.4049/jimmunol.178.3.1783
   Bora NS, 2006, J IMMUNOL, V177, P1872, DOI 10.4049/jimmunol.177.3.1872
   Bora PS, 2005, J IMMUNOL, V174, P491, DOI 10.4049/jimmunol.174.1.491
   Boukhtouche F, 2004, ARTERIOSCL THROM VAS, V24, P637, DOI 10.1161/01.ATV.0000119355.56036.de
   Brantley MA, 2007, OPHTHALMOLOGY, V114, P2168, DOI 10.1016/j.ophtha.2007.09.008
   BRESSLER NM, 1989, ARCH OPHTHALMOL-CHIC, V107, P847, DOI 10.1001/archopht.1989.01070010869032
   Cantsilieris S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035255
   Cashman SM, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019078
   Chakravarthy U, 2010, BMC OPHTHALMOL, V10, DOI 10.1186/1471-2415-10-31
   Chao W, 2008, CYTOKINE GROWTH F R, V19, P111, DOI 10.1016/j.cytogfr.2008.01.005
   Chau KY, 2007, EYE, V21, P1511, DOI [10.1038/sj.eye.6702722, 10.1038/sj.eye.6702722x]
   Chauvet C, 2004, BIOCHEM J, V384, P79, DOI 10.1042/BJ20040709
   Chen H, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0042464
   Chen HY, 2012, MOL VIS, V18, P816
   Chen Y, 2007, J BIOL CHEM, V282, P34420, DOI 10.1074/jbc.M611289200
   Chong NHV, 2005, AM J PATHOL, V166, P241, DOI 10.1016/S0002-9440(10)62248-1
   Churchill AJ, 2006, HUM MOL GENET, V15, P2955, DOI 10.1093/hmg/ddl238
   Clarke NE, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034747
   Clausen T, 2011, NAT REV MOL CELL BIO, V12, P152, DOI 10.1038/nrm3065
   Combadiere C, 2007, J CLIN INVEST, V117, P2920, DOI 10.1172/JCI31692
   Conley YP, 2005, HUM MOL GENET, V14, P1991, DOI 10.1093/hmg/ddi204
   Conley YP, 2006, HUM MOL GENET, V15, P3206, DOI 10.1093/hmg/ddl396
   Cortright DN, 2009, CURR EYE RES, V34, P57, DOI 10.1080/02713680802546658
   Crabb JW, 2002, P NATL ACAD SCI USA, V99, P14682, DOI 10.1073/pnas.222551899
   Curcio CA, 2001, EYE, V15, P376, DOI 10.1038/eye.2001.140
   Curcio CA, 1999, ARCH OPHTHALMOL-CHIC, V117, P329, DOI 10.1001/archopht.117.3.329
   Curcio CA, 2001, INVEST OPHTH VIS SCI, V42, P265
   Curcio CA, 2011, BRIT J OPHTHALMOL, V95, P1638, DOI 10.1136/bjophthalmol-2011-300344
   Davis MD, 2005, ARCH OPHTHALMOL-CHIC, V123, P1484
   Dawson DW, 1999, SCIENCE, V285, P245, DOI 10.1126/science.285.5425.245
   de Jong PTVM, 2006, NEW ENGL J MED, V355, P1474, DOI 10.1056/NEJMra062326
   DeAngelis MM, 2007, ARCH OPHTHALMOL-CHIC, V125, P49, DOI 10.1001/archopht.125.1.49
   DeAngelis MM, 2011, SEMIN OPHTHALMOL, V26, P77, DOI 10.3109/08820538.2011.577129
   Delerive P, 2001, EMBO REP, V2, P42, DOI 10.1093/embo-reports/kve007
   Dentchev T, 2003, MOL VIS, V9, P184
   Despriet DDG, 2006, JAMA-J AM MED ASSOC, V296, P301, DOI 10.1001/jama.296.3.301
   Dewan A, 2006, SCIENCE, V314, P989, DOI 10.1126/science.1133807
   Ding JD, 2011, P NATL ACAD SCI USA, V108, pE279, DOI 10.1073/pnas.1100901108
   Dorrell MI, 2009, J CLIN INVEST, V119, P611, DOI 10.1172/JCI35977
   Doyle SL, 2012, NAT MED, V18, P791, DOI 10.1038/nm.2717
   Duncan KG, 2009, BRIT J OPHTHALMOL, V93, P1116, DOI 10.1136/bjo.2008.144006
   Dunne A, 2011, BIOCHEM SOC T, V39, P669, DOI 10.1042/BST0390669
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Ennis S, 2008, LANCET, V372, P1828, DOI 10.1016/S0140-6736(08)61348-3
   Fariss RN, 1997, AM J PATHOL, V150, P323
   Fauser S, 2011, INVEST OPHTH VIS SCI, V52, P5525, DOI 10.1167/iovs.10-6827
   Feehan M, 2011, BMC MED GENET, V12, DOI 10.1186/1471-2350-12-83
   Ferris FL, 2005, ARCH OPHTHALMOL-CHIC, V123, P1570
   Finnemann SC, 2002, P NATL ACAD SCI USA, V99, P3842, DOI 10.1073/pnas.052025899
   Fiotti N, 2005, GENET MED, V7, P272, DOI 10.1097/01.GIM.0000159903.69597.73
   Fitzsimmons RL, 2012, J STEROID BIOCHEM, V130, P159, DOI 10.1016/j.jsbmb.2011.06.009
   Francis PJ, 2009, J MED GENET, V46, P300, DOI 10.1136/jmg.2008.062737
   Francis PJ, 2011, CLIN OPHTHALMOL, V5, P1127, DOI 10.2147/OPTH.S11627
   FRANCOIS J, 1977, OPHTHALMOLOGICA, V175, P67, DOI 10.1159/000308637
   Freund KB, 2008, RETINA-J RET VIT DIS, V28, P201, DOI 10.1097/IAE.0b013e3181669504
   Friedenwald J.S., 1937, AM J OPHTHALMOL, V20, P985, DOI [10.1016/s0002-9394(37)90425-2, DOI 10.1016/S0002-9394(37)90425-2, 10.1016/S0002-9394(37)90425-2]
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Friedman E, 1997, AM J OPHTHALMOL, V124, P677, DOI 10.1016/S0002-9394(14)70906-7
   FRIEDMAN E, 1968, ARCH OPHTHALMOL-CHIC, V79, P315, DOI 10.1001/archopht.1968.03850040317017
   Friedman E, 2008, AM J OPHTHALMOL, V146, P348, DOI 10.1016/j.ajo.2008.05.017
   Fritsche LG, 2008, NAT GENET, V40, P892, DOI 10.1038/ng.170
   Gass J D, 1972, Trans Am Ophthalmol Soc, V70, P409
   GOLDBERG J, 1988, AM J EPIDEMIOL, V128, P700, DOI 10.1093/oxfordjournals.aje.a115023
   Goverdhan SV, 2008, BRIT J OPHTHALMOL, V92, P537, DOI 10.1136/bjo.2007.123190
   Goverdhan SV, 2008, INVEST OPHTH VIS SCI, V49, P5077, DOI 10.1167/iovs.08-1837
   Goverdhan SV, 2005, INVEST OPHTH VIS SCI, V46, P1726, DOI 10.1167/iovs.04-0928
   GURNE DH, 1991, OPHTHALMOLOGY, V98, P602, DOI 10.1016/s0161-6420(91)32252-8
   Hadders MA, 2012, CELL REP, V1, P200, DOI 10.1016/j.celrep.2012.02.003
   Hageman GS, 2006, ANN MED, V38, P592, DOI 10.1080/07853890601097030
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2006, INVEST OPHTH VIS SCI, V47, P329, DOI 10.1167/iovs.05-0116
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Hamdi HK, 2002, BIOCHEM BIOPH RES CO, V295, P668, DOI 10.1016/S0006-291X(02)00728-3
   HARTNETT ME, 1992, GRAEF ARCH CLIN EXP, V230, P11, DOI 10.1007/BF00166756
   He XN, 2007, PROG RETIN EYE RES, V26, P649, DOI 10.1016/j.preteyeres.2007.07.004
   Heinen S, 2009, BLOOD, V114, P2439, DOI 10.1182/blood-2009-02-205641
   HOGAN M J, 1972, Transactions of the American Academy of Ophthalmology and Oto-Laryngology, V76, P64
   Hogg RE, 2006, PROG RETIN EYE RES, V25, P249, DOI 10.1016/j.preteyeres.2005.11.002
   Hoh Kam J, 2010, PLOS ONE, P10
   Holekamp NM, 2002, AM J OPHTHALMOL, V134, P220, DOI 10.1016/S0002-9394(02)01549-0
   Holz FG, 1999, INVEST OPHTH VIS SCI, V40, P737
   Hughes AE, 2006, NAT GENET, V38, P1173, DOI 10.1038/ng1890
   Ikram MK, 2003, INVEST OPHTH VIS SCI, V44, P3778, DOI 10.1167/iovs.03-0120
   Ishida S, 2003, J EXP MED, V198, P483, DOI 10.1084/jem.20022027
   Jackson GR, 1999, VISION RES, V39, P3975, DOI 10.1016/S0042-6989(99)00092-9
   Jackson Gregory R, 2008, J Ocul Biol Dis Infor, V1, P7, DOI 10.1007/s12177-008-9002-6
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Jakobsdottir J, 2005, AM J HUM GENET, V77, P389, DOI 10.1086/444437
   Jarrett SG, 2010, OPHTHALMIC RES, V44, P179, DOI 10.1159/000316480
   Johnson LV, 2011, P NATL ACAD SCI USA, V108, P18277, DOI 10.1073/pnas.1109703108
   Johnson LR, 2000, IEEE ANN HIST COMPUT, V22, P70
   Johnson LV, 2002, P NATL ACAD SCI USA, V99, P11830, DOI 10.1073/pnas.192203399
   Jonas JB, 2012, ACTA OPHTHALMOL, V90, pe381, DOI 10.1111/j.1755-3768.2012.02414.x
   Jones A, 2011, P NATL ACAD SCI USA, V108, P14578, DOI 10.1073/pnas.1102853108
   Jozsi M, 2008, TRENDS IMMUNOL, V29, P380, DOI 10.1016/j.it.2008.04.008
   Jun GG, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025775
   KAHN HA, 1977, AM J EPIDEMIOL, V106, P33, DOI 10.1093/oxfordjournals.aje.a112429
   KAHN HA, 1977, AM J EPIDEMIOL, V106, P17, DOI 10.1093/oxfordjournals.aje.a112428
   Kamei M, 1999, INVEST OPHTH VIS SCI, V40, P2367
   Kanda A, 2007, P NATL ACAD SCI USA, V104, P16227, DOI 10.1073/pnas.0703933104
   Kawasaki R, 2010, OPHTHALMOLOGY, V117, P921, DOI 10.1016/j.ophtha.2009.10.007
   Kessenbrock K, 2010, CELL, V141, P52, DOI 10.1016/j.cell.2010.03.015
   Kimura K, 2000, AM J OPHTHALMOL, V130, P769, DOI 10.1016/S0002-9394(00)00552-3
   Klaver CCW, 1998, ARCH OPHTHALMOL-CHIC, V116, P1646, DOI 10.1001/archopht.116.12.1646
   Klein ML, 2008, OPHTHALMOLOGY, V115, P1019, DOI 10.1016/j.ophtha.2008.01.036
   Klein ML, 2011, ARCH OPHTHALMOL-CHIC, V129, P1543, DOI 10.1001/archophthalmol.2011.216
   Klein ML, 1998, ARCH OPHTHALMOL-CHIC, V116, P1082, DOI 10.1001/archopht.116.8.1082
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Klein R, 2009, ARCH OPHTHALMOL-CHIC, V127, P193, DOI 10.1001/archophthalmol.2008.551
   Kondo N, 2011, OPHTHALMOLOGY, V118, P339, DOI 10.1016/j.ophtha.2010.06.040
   Kortvely E, 2010, INVEST OPHTH VIS SCI, V51, P79, DOI 10.1167/iovs.09-3850
   Krishnan AV, 2011, ANNU REV PHARMACOL, V51, P311, DOI 10.1146/annurev-pharmtox-010510-100611
   Kuny S, 2012, INVEST OPHTH VIS SCI, V53, P664, DOI 10.1167/iovs.11-8418
   Kurihara R, 2010, INFLAMM RES, V59, P659, DOI 10.1007/s00011-010-0178-4
   Lakkaraju A, 2007, P NATL ACAD SCI USA, V104, P11026, DOI 10.1073/pnas.0702504104
   Lamkanfi M, 2011, NAT REV IMMUNOL, V11, P213, DOI 10.1038/nri2936
   Landego I, 2012, EUR J IMMUNOL, V42, P2760, DOI 10.1002/eji.201242371
   Langer HF, 2010, BLOOD, V116, P4395, DOI 10.1182/blood-2010-01-261503
   Launay S, 2008, CELL DEATH DIFFER, V15, P1408, DOI 10.1038/cdd.2008.82
   Lechanteur YTE, 2012, INVEST OPHTH VIS SCI, V53, P5846, DOI 10.1167/iovs.11-7731
   Lee AY, 2009, BRIT J OPHTHALMOL, V93, P610, DOI 10.1136/bjo.2008.150995
   Leung KW, 2009, MOL IMMUNOL, V46, P1374, DOI 10.1016/j.molimm.2008.12.001
   Li C, 2007, ARCH OPHTHALMOL-CHIC, V125, P795, DOI 10.1001/archopht.125.6.795
   Liesegang TJ, 2005, AM J OPHTHALMOL, V139, P530, DOI 10.1016/j.ajo.2004.11.049
   Lin JM, 2008, AM J OPHTHALMOL, V145, P716, DOI 10.1016/j.ajo.2007.11.006
   Liu MM, 2011, INVEST OPHTH VIS SCI, V52, P3129, DOI 10.1167/iovs.10-6735
   Liu XQ, 2004, NAT GENET, V36, P178, DOI 10.1038/ng1297
   LOFFLER KU, 1995, INVEST OPHTH VIS SCI, V36, P24
   Luhmann UFO, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035551
   Luhmann UFO, 2009, INVEST OPHTH VIS SCI, V50, P5934, DOI 10.1167/iovs.09-3462
   Luo L, 2008, VISION RES, V48, P494, DOI 10.1016/j.visres.2007.11.013
   Ma WX, 2013, NEUROBIOL AGING, V34, P943, DOI 10.1016/j.neurobiolaging.2012.06.010
   Maeda A, 2008, J BIOL CHEM, V283, P26684, DOI 10.1074/jbc.M804505200
   Mahley RW, 2006, P NATL ACAD SCI USA, V103, P5644, DOI 10.1073/pnas.0600549103
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Mata NL, 2001, INVEST OPHTH VIS SCI, V42, P1685
   Mattapallil MJ, 2012, INVEST OPHTH VIS SCI, V53, P2921, DOI 10.1167/iovs.12-9662
   McKay GJ, 2011, HUM MUTAT, V32, P1407, DOI 10.1002/humu.21577
   MEYERS SM, 1995, AM J OPHTHALMOL, V120, P757, DOI 10.1016/S0002-9394(14)72729-1
   Miao L, 2009, FREE RADICAL BIO MED, V47, P344, DOI 10.1016/j.freeradbiomed.2009.05.018
   Miller JW, 2013, OPHTHALMOLOGY, V120, P106, DOI 10.1016/j.ophtha.2012.07.038
   Monson DM, 2008, ARCH OPHTHALMOL-CHIC, V126, P1664, DOI 10.1001/archopht.126.12.1664
   Morrison Margaux A., 2011, Human Genomics, V5, P538
   Mullins RF, 2000, FASEB J, V14, P835, DOI 10.1096/fasebj.14.7.835
   Mullins RF, 2007, EXP EYE RES, V84, P378, DOI 10.1016/j.exer.2006.09.021
   Mullins RF, 2009, EXP EYE RES, V89, P767, DOI 10.1016/j.exer.2009.07.001
   Munch IC, 2007, INVEST OPHTH VIS SCI, V48, P833, DOI 10.1167/iovs.06-0529
   Murakami Y, 2012, P NATL ACAD SCI USA, V109, P14598, DOI 10.1073/pnas.1206937109
   Nakamura T, 2002, NATURE, V415, P171, DOI 10.1038/415171a
   Nakata I, 2011, OPHTHALMOLOGY, V118, P1408, DOI 10.1016/j.ophtha.2010.12.011
   Newman AM, 2012, GENOME MED, V4, DOI [10.1186/PREACCEPT-1418491035586234, 10.1186/gm315]
   NEWSOME DA, 1987, AM J OPHTHALMOL, V104, P373, DOI 10.1016/0002-9394(87)90227-3
   Nozaki M, 2006, P NATL ACAD SCI USA, V103, P2328, DOI 10.1073/pnas.0408835103
   Owsley C, 2007, OPHTHALMOLOGY, V114, P1728, DOI 10.1016/j.ophtha.2006.12.023
   Paraoan L, 2010, VISION RES, V50, P737, DOI 10.1016/j.visres.2009.10.022
   Parekh N, 2007, ARCH OPHTHALMOL-CHIC, V125, P661, DOI 10.1001/archopht.125.5.661
   Parmeggiani F, 2008, INVEST OPHTH VIS SCI, V49, P3100, DOI 10.1167/iovs.07-1654
   Parmeggiani F, 2007, PHARMACOGENET GENOM, V17, P1039, DOI 10.1097/FPC.0b013e3282f12a4e
   Parmeggiani F, 2009, PHARMACOGENOMICS, V10, P81, DOI 10.2217/14622416.10.1.81
   Patel N, 2008, EYE, V22, P768, DOI 10.1038/sj.eye.6702844
   Patel N, 2005, IMMUNOLOGY, V115, P422, DOI 10.1111/j.1365-2567.2005.02173.x
   PAULEIKHOFF D, 1990, OPHTHALMOLOGY, V97, P171
   Penfold PL, 1997, INVEST OPHTH VIS SCI, V38, P2125
   PENFOLD PL, 1986, INVEST OPHTH VIS SCI, V27, P364
   PENFOLD PL, 1985, GRAEF ARCH CLIN EXP, V223, P69, DOI 10.1007/BF02150948
   PENFOLD PL, 1990, GRAEF ARCH CLIN EXP, V228, P270, DOI 10.1007/BF00920033
   Plenz GAM, 2003, ATHEROSCLEROSIS, V166, P1, DOI 10.1016/S0021-9150(01)00766-3
   Qiao H, 2007, J LEUKOCYTE BIOL, V81, P1012, DOI 10.1189/jlb.0506342
   Quan YL, 2012, INT J OPHTHALMOL-CHI, V5, P242, DOI 10.3980/j.issn.2222-3959.2012.02.25
   Quazi F, 2012, NAT COMMUN, V3, DOI 10.1038/ncomms1927
   Ramkumar HL, 2010, PROG RETIN EYE RES, V29, P169, DOI 10.1016/j.preteyeres.2010.02.002
   Raychaudhuri S, 2011, NAT GENET, V43, P1232, DOI 10.1038/ng.976
   Raychaudhuri S, 2010, NAT GENET, V42, P553, DOI 10.1038/ng0710-553
   Ricklin D, 2010, NAT IMMUNOL, V11, P785, DOI 10.1038/ni.1923
   Rohrer B, 2009, INVEST OPHTH VIS SCI, V50, P3056, DOI 10.1167/iovs.08-2222
   Rohrer Barbel, 2011, Mol Immunol, V48, pe1, DOI 10.1016/j.molimm.2010.12.016
   ROONEY P, 1993, J CELL SCI, V105, P213
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Ruberti JW, 2003, INVEST OPHTH VIS SCI, V44, P1753, DOI 10.1167/iovs.02-0496
   Ryu E, 2010, MOL VIS, V16, P2811
   SANDBERG MA, 1993, OPHTHALMOLOGY, V100, P1009
   Sarlos S, 2003, AM J PATHOL, V163, P879, DOI 10.1016/S0002-9440(10)63448-7
   Schaumberg DA, 2010, ARCH OPHTHALMOL-CHIC, V128, P1462, DOI 10.1001/archophthalmol.2010.261
   Schmitz-Valckenberg S, 2006, INVEST OPHTH VIS SCI, V47, P2648, DOI 10.1167/iovs.05-0892
   Schmitz-Valckenberg S, 2010, OPHTHALMOLOGY, V117, P1169, DOI 10.1016/j.ophtha.2009.10.044
   Schmitz-Valckenberg S, 2009, SURV OPHTHALMOL, V54, P96, DOI 10.1016/j.survophthal.2008.10.004
   Scholl HPN, 2001, GRAEF ARCH CLIN EXP, V239, P71, DOI 10.1007/s004170000232
   Schultz DW, 2003, HUM MOL GENET, V12, P3315, DOI 10.1093/hmg/ddg348
   Seddon JM, 1997, AM J OPHTHALMOL, V123, P199, DOI 10.1016/S0002-9394(14)71036-0
   SEDDON JM, 1994, JAMA-J AM MED ASSOC, V272, P1413, DOI 10.1001/jama.272.18.1413
   Seddon JM, 2011, OPHTHALMOLOGY, V118, P2203, DOI 10.1016/j.ophtha.2011.04.029
   Seddon JM, 2009, INVEST OPHTH VIS SCI, V50, P2044, DOI 10.1167/iovs.08-3064
   Sharma R, 2004, ANTIOXID REDOX SIGN, V6, P289, DOI 10.1089/152308604322899350
   Shastry BS, 2011, DISCOV MED, V12, P159
   Silveira AC, 2010, VISION RES, V50, P698, DOI 10.1016/j.visres.2009.09.016
   SILVESTRI G, 1994, EYE, V8, P564, DOI 10.1038/eye.1994.138
   Sobrin L, 2012, OPHTHALMOLOGY, V119, P1874, DOI 10.1016/j.ophtha.2012.03.014
   Sparrow JR, 2010, PHOTOCH PHOTOBIO SCI, V9, P1480, DOI 10.1039/c0pp00207k
   Sparrow JR, 2005, EXP EYE RES, V80, P595, DOI 10.1016/j.exer.2005.01.007
   Sparrow JR, 2001, INVEST OPHTH VIS SCI, V42, P1356
   Spencer JA, 2005, P NATL ACAD SCI USA, V102, P2946, DOI 10.1073/pnas.0500058102
   Spraul CW, 1999, SURV OPHTHALMOL, V44, pS10, DOI 10.1016/S0039-6257(99)00086-7
   Spraul CW, 1996, INVEST OPHTH VIS SCI, V37, P2724
   Stanton CM, 2011, INVEST OPHTH VIS SCI, V52, P8828, DOI 10.1167/iovs.11-7933
   Starita C, 1996, EXP EYE RES, V62, P565, DOI 10.1006/exer.1996.0066
   Steen B, 1998, INVEST OPHTH VIS SCI, V39, P2194
   Stone EM, 1999, NAT GENET, V22, P199, DOI 10.1038/9722
   Stone EM, 2004, NEW ENGL J MED, V351, P346, DOI 10.1056/NEJMoa040833
   Sun C, 2012, CURR EYE RES, V37, P259, DOI 10.3109/02713683.2011.635401
   Sun H, 2001, J BIOL CHEM, V276, P11766, DOI 10.1074/jbc.M010152200
   Tabas I, 2007, CIRCULATION, V116, P1832, DOI 10.1161/CIRCULATIONAHA.106.676890
   Takeuchi O, 2010, CELL, V140, P805, DOI 10.1016/j.cell.2010.01.022
   Tarallo V, 2012, CELL, V149, P847, DOI 10.1016/j.cell.2012.03.036
   TAYLOR HR, 1992, ARCH OPHTHALMOL-CHIC, V110, P99, DOI 10.1001/archopht.1992.01080130101035
   Tennstaedt A, 2012, J BIOL CHEM, V287, P20931, DOI 10.1074/jbc.M111.316232
   Thakkinstian A, 2006, HUM MOL GENET, V15, P2784, DOI 10.1093/hmg/ddl220
   Thakkinstian A, 2012, AM J EPIDEMIOL, V176, P361, DOI 10.1093/aje/kws031
   Thakkinstian A, 2011, AM J EPIDEMIOL, V173, P1365, DOI 10.1093/aje/kwr025
   Thompson CL, 2007, HUM MOL GENET, V16, P2135, DOI 10.1093/hmg/ddm164
   Tizon B, 2010, J ALZHEIMERS DIS, V19, P885, DOI 10.3233/JAD-2010-1291
   Tong Y, 2010, MOL VIS, V16, P1958
   Tou JS, 2004, FASEB J, V18, P1297, DOI 10.1096/fj.04-1862fje
   Trichonas G, 2010, P NATL ACAD SCI USA, V107, P21695, DOI 10.1073/pnas.1009179107
   Tserentsoodol N, 2006, MOL VIS, V12, P1319
   Tuo JS, 2007, INVEST OPHTH VIS SCI, V48, P3827, DOI 10.1167/iovs.07-0051
   Ufret-Vincenty RL, 2010, INVEST OPHTH VIS SCI, V51, P5878, DOI 10.1167/iovs.09-4457
   Verhoeff F H, 1937, Trans Am Ophthalmol Soc, V35, P262
   Vierkotten S, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022959
   Wang L, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010329
   Wang YJ, 2012, APOPTOSIS, V17, P1144, DOI 10.1007/s10495-012-0750-1
   Weng J, 1999, CELL, V98, P13, DOI 10.1016/S0092-8674(00)80602-9
   WEST SK, 1989, ARCH OPHTHALMOL-CHIC, V107, P875, DOI 10.1001/archopht.1989.01070010897038
   *WHO, PRIOR EYE DIS
   WING GL, 1978, INVEST OPHTH VIS SCI, V17, P601
   WOLTER JR, 1962, ARCH OPHTHALMOL-CHIC, V68, P219
   Wysokinski D, 2011, TOHOKU J EXP MED, V223, P253, DOI 10.1620/tjem.223.253
   Xu L, 2006, BRIT J OPHTHALMOL, V90, P1087, DOI 10.1136/bjo.2006.096123
   Yanagisawa H, 2002, NATURE, V415, P168, DOI 10.1038/415168a
   Yang ZL, 2008, NEW ENGL J MED, V359, P1456, DOI 10.1056/NEJMoa0802437
   Yang ZL, 2006, SCIENCE, V314, P992, DOI 10.1126/science.1133811
   YANNUZZI LA, 1992, ARCH OPHTHALMOL-CHIC, V110, P1701
   Yannuzzi LA, 1999, ARCH OPHTHALMOL-CHIC, V117, P1503
   Ying GS, 2011, OPHTHALMOLOGY, V118, P332, DOI 10.1016/j.ophtha.2010.06.030
   Yoshida T, 2005, J CLIN INVEST, V115, P2793, DOI 10.1172/JCI24635
   Yu Y, 2011, HUM MOL GENET, V20, P3699, DOI 10.1093/hmg/ddr270
   Yu Y, 2011, INVEST OPHTH VIS SCI, V52, P4663, DOI 10.1167/iovs.10-7070
   Yuan XL, 2010, MOL CELL PROTEOMICS, V9, P1031, DOI 10.1074/mcp.M900523-MCP200
   Zanke B, 2010, CAN J OPHTHALMOL, V45, P22, DOI 10.3129/i09-209
   Zareparsi S, 2005, AM J HUM GENET, V77, P149, DOI 10.1086/431426
   Zareparsi S, 2005, HUM MOL GENET, V14, P1449, DOI 10.1093/hmg/ddi154
   Zhang H, 2008, BMC MED GENET, V9, DOI 10.1186/1471-2350-9-51
   Zhang L, 2012, J BIOL CHEM, V287, P1520, DOI 10.1074/jbc.M111.275990
   Zhou J, 2009, INVEST OPHTH VIS SCI, V50, P1392, DOI 10.1167/iovs.08-2868
   Zhou YD, 2011, EXP EYE RES, V93, P636, DOI 10.1016/j.exer.2011.07.017
   Zhu Y, 2006, ONCOGENE, V25, P2901, DOI 10.1038/sj.onc.1209314
   Zumbrunn J, 1996, FEBS LETT, V398, P187, DOI 10.1016/S0014-5793(96)01229-X
   Zurdel J, 2002, BRIT J OPHTHALMOL, V86, P214, DOI 10.1136/bjo.86.2.214
   Zweifel SA, 2010, OPHTHALMOLOGY, V117, P303, DOI 10.1016/j.ophtha.2009.07.014
NR 277
TC 186
Z9 191
U1 0
U2 40
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0002-9394
EI 1879-1891
J9 AM J OPHTHALMOL
JI Am. J. Ophthalmol.
PD JAN
PY 2013
VL 155
IS 1
BP 1
EP 35
DI 10.1016/j.ajo.2012.10.018
PG 35
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 066ML
UT WOS:000313224800001
PM 23245386
DA 2022-11-30
ER

PT J
AU Sengul, EA
   Artunay, O
   Rasier, R
   Kockar, A
   Afacan, C
   Hancer, VS
   Yuzbasioglu, E
AF Sengul, Elvan Alper
   Artunay, Ozgur
   Rasier, Rifat
   Kockar, Alev
   Afacan, Ceyda
   Hancer, Veysel Sabri
   Yuzbasioglu, Erdal
TI Pharmacogenetic Aspect of Intravitreal Ranibizumab Treatment in
   Neovascular Age-Related Macular Degeneration: A Five-Year Follow-Up
SO OCULAR IMMUNOLOGY AND INFLAMMATION
LA English
DT Article
DE Age-related macular degeneration; complement factor H polymorphism;
   genetics; inflammation; intravitreal ranibizumab
ID COMPLEMENT FACTOR-H; HEMOLYTIC-UREMIC SYNDROME; GEOGRAPHIC ATROPHY;
   TREATMENTS TRIALS; RISK; GENE; POLYMORPHISMS; ASSOCIATION; ACTIVATION;
   Y402H
AB Purpose: This study aims to evaluate the role of complement factor H (CFH) in response to intravitreal ranibizumab (IVR) treatment, which is administered to patients with neovascular age-related macular degeneration (nAMD).Methods: In this retrospective study, 90 nAMD patients' 90 eyes were evaluated. IVR was injected once a month for three consecutive months, and then, patients were followed up for five years by using pro re nata method.Results: Average visual acuity (BCVA) values in TT group for the third, fourth and fifth years were found to be significantly higher than those in TC and CC groups, while average BCVA values in TC group were significantly higher than those in CC group (all p = .000 < .0167).Conclusion: Patients with CFH TT genotype responded significantly better to treatment after third year, while patients with CC genotype had a poorer response to IVR.
C1 [Sengul, Elvan Alper; Rasier, Rifat; Kockar, Alev; Yuzbasioglu, Erdal] TC Istanbul Bilim Univ, Med Fac, Ophthalmol Dept, Istanbul, Turkey.
   [Artunay, Ozgur] Haydarpasa Numune Training & Res Hosp, Ophthalmol Dept, Istanbul, Turkey.
   [Afacan, Ceyda] Mimar Sinan Fine Arts Univ, Dept Stat, Istanbul, Turkey.
   [Hancer, Veysel Sabri] Istinye Univ, Med Fac, Med Genet Dept, Istanbul, Turkey.
C3 Demiroglu Bilim University; Istanbul Haydarpasa Numune Training &
   Research Hospital; Mimar Sinan Guzel Sanatlar University; Istinye
   University
RP Sengul, EA (通讯作者)，Sisli Florence Nightingale Hastanesi 34381, Goz Hastaliklari Klinigi, Abidei Hurriyet Cad, Istanbul, Turkey.
EM ealper_sengul@yahoo.com
RI hancer, veysel sabri/X-8971-2018; Rasier, Rifat/AHB-8857-2022; Rasier,
   Rifat/AAK-4259-2021; Koçkar, Alev/GPX-8090-2022
OI hancer, veysel sabri/0000-0003-2994-1077; Rasier,
   Rifat/0000-0003-0963-7991; Koçkar, Alev/0000-0002-1457-8511; sengul,
   elvan alper/0000-0003-1313-6970
CR Brantley MA, 2007, OPHTHALMOLOGY, V114, P2168, DOI 10.1016/j.ophtha.2007.09.008
   Challis RC, 2016, J AM SOC NEPHROL, V27, P1617, DOI 10.1681/ASN.2015010100
   Clark SJ, 2015, J CLIN MED, V4, P18, DOI 10.3390/jcm4010018
   de Cordoba SR, 2008, CLIN EXP IMMUNOL, V151, P1, DOI 10.1111/j.1365-2249.2007.03574.x
   Dikmetas O, 2013, MOL VIS, V19, P2571
   Donoso LA, 2010, SURV OPHTHALMOL, V55, P227, DOI 10.1016/j.survophthal.2009.11.001
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P532
   Gotoh N, 2006, HUM GENET, V120, P139, DOI 10.1007/s00439-006-0187-0
   Grunwald JE, 2017, OPHTHALMOLOGY, V124, P97, DOI 10.1016/j.ophtha.2016.09.012
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Hagstrom SA, 2013, OPHTHALMOLOGY, V120, P593, DOI 10.1016/j.ophtha.2012.11.037
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Hao XF, 2015, INT J CLIN EXP PATHO, V8, P3186
   Hawkins BS, 1999, MOL VIS, V5
   Hecker LA, 2010, HUM MOL GENET, V19, P209, DOI 10.1093/hmg/ddp472
   Jabbarpoor Bonyadi MH, 2016, CURR EYE RES, V7, P1
   Klaver CCW, 1998, ARCH OPHTHALMOL-CHIC, V116, P1646, DOI 10.1001/archopht.116.12.1646
   Klein R, 2003, OPHTHALMOLOGY, V110, P25, DOI 10.1016/S0161-6420(02)01565-8
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Kloeckener-Gruissem B, 2011, INVEST OPHTH VIS SCI, V52, P4694, DOI 10.1167/iovs.10-6080
   Kumaramanickavel G, 2016, ASIA-PAC J OPHTHALMO, V5, P229, DOI 10.1097/APO.0000000000000223
   Lazreg S, 2016, OPHTHALMIC RES, V56, P145, DOI 10.1159/000446844
   Lee AY, 2009, BRIT J OPHTHALMOL, V93, P610, DOI 10.1136/bjo.2008.150995
   Loyet KM, 2012, INVEST OPHTH VIS SCI, V53, P6628, DOI 10.1167/iovs.12-9587
   McKibbin M, 2012, BRIT J OPHTHALMOL, V96, P208, DOI 10.1136/bjo.2010.193680
   Scholl HPN, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002593
   Sepp T, 2006, INVEST OPHTH VIS SCI, V47, P536, DOI 10.1167/iovs.05-1143
   Tan PL, 2016, HUM GENOMICS, V10, DOI 10.1186/s40246-016-0079-x
   van Doorn KJ, 2013, CLIN KIDNEY J, V6, P216, DOI 10.1093/ckj/sfs190
   Yildiz BK, 2016, OPHTHALMIC RES, V56, P132, DOI 10.1159/000446186
NR 31
TC 1
Z9 1
U1 0
U2 1
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0927-3948
EI 1744-5078
J9 OCUL IMMUNOL INFLAMM
JI Ocul. Immunol. Inflamm.
PY 2018
VL 26
IS 6
BP 971
EP 977
DI 10.1080/09273948.2017.1311925
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA GP3MI
UT WOS:000440751300024
PM 28471284
DA 2022-11-30
ER

PT J
AU Uzun, A
   Yalcindag, FN
   Demirel, S
   Batyodlu, F
   Ozmert, E
AF Uzun, Aslihan
   Yalcindag, Fatime Nilufer
   Demirel, Sibel
   Batyodlu, Figen
   Ozmert, Emin
TI Evaluation of Aqueous Flare Levels Following Intravitreal Ranibizumab
   Injection for Neovascular Age-related Macular Degeneration
SO OCULAR IMMUNOLOGY AND INFLAMMATION
LA English
DT Article
DE Age-related macular degeneration; anterior chamber; aqueous flare;
   intravitreal injection; ranibizumab
ID INTRAOCULAR INFLAMMATION; BEVACIZUMAB; OUTCOMES; ANCHOR
AB Purpose: To evaluate aqueous flare levels following intravitreal ranibizumab injection for neovascular age-related macular degeneration (AMD).
   Methods: In total, 81 eyes of 79 patients who underwent intravitreal ranibizumab injection for neovascular AMD were included. Aqueous flare was evaluated before pupillary dilatation with Kowa FM-600 laser flare meter at baseline, and 1 day, and 1 month after intravitreal administration of ranibizumab 0.5 mg (0.05 mL).
   Results: The mean anterior chamber flare was 10.7 +/- 6.8 (range: 1.5-35.4) ph/ms before the injection, 12.5 +/- 8.9 (range: 0.3-43) ph/ms on the first day, and 9.9 +/- 5.7 (range: 0.2-28.4) ph/ms in the first month. On the first day, a subtle increasing of flare was observed. However, the difference between the mean aqueous flare levels at baseline and postoperative first day and first month was not statistically different (p>0.05).
   Conclusions: No significant short-term intraocular inflammation was noted in these eyes receiving ranibizumab for the treatment of neovascular AMD.
C1 [Uzun, Aslihan] Ordu Univ, Training & Res Hosp, Dept Ophthalmol, TR-52100 Bucak Mahallesi, Ordu, Turkey.
   [Yalcindag, Fatime Nilufer; Demirel, Sibel; Batyodlu, Figen; Ozmert, Emin] Ankara Univ, Dept Ophthalmol, Fac Med, Ankara, Turkey.
C3 Ordu University; Ankara University
RP Uzun, A (通讯作者)，Ordu Univ, Training & Res Hosp, Dept Ophthalmol, TR-52100 Bucak Mahallesi, Ordu, Turkey.
EM draslihanuzun@gmail.com
RI Demirel, Sibel/AAQ-4282-2020; DEMIREL, SIBEL/GQH-3232-2022; Uzun,
   Aslihan/GQH-8653-2022; Uzun, Aslihan/AAV-1006-2021
OI Demirel, Sibel/0000-0002-6430-6565; DEMIREL, SIBEL/0000-0002-2477-9974;
   Uzun, Aslihan/0000-0002-5787-3879
CR Abouammoh M, 2011, CURR OPIN OPHTHALMOL, V22, P152, DOI 10.1097/ICU.0b013e32834595d0
   Bakri SJ, 2008, GRAEF ARCH CLIN EXP, V246, P779, DOI 10.1007/s00417-007-0754-7
   Biswas P, 2011, INDIAN J OPHTHALMOL, V59, P191, DOI 10.4103/0301-4738.81023
   Blaha GR, 2015, RETINA-J RET VIT DIS, V35, P577, DOI 10.1097/IAE.0000000000000334
   Bressler NM, 2010, OPHTHALMOLOGY, V117, P747, DOI 10.1016/j.ophtha.2009.09.002
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   Chong DY, 2010, RETINA-J RET VIT DIS, V30, P1432, DOI 10.1097/IAE.0b013e3181dc04da
   El-Harazi SM, 2002, OPHTHALMIC SURG LAS, V33, P379
   Georgopoulos M, 2009, BRIT J OPHTHALMOL, V93, P457, DOI 10.1136/bjo.2008.138479
   Goldberg RA, 2014, AM J OPHTHALMOL, V158, P733, DOI 10.1016/j.ajo.2014.06.019
   Johnson D, 2010, CAN J OPHTHALMOL, V45, P239, DOI 10.3129/i10-013
   Kiss C, 2006, RETINA-J RET VIT DIS, V26, P877, DOI 10.1097/01.iae.0000237080.10627.b7
   Kokotas H, 2011, CLIN CHEM LAB MED, V49, P601, DOI 10.1515/CCLM.2011.091
   Mitchell P, 2011, CURR MED RES OPIN, V27, P1465, DOI 10.1185/03007995.2011.585394
   Mozayan A, 2013, OPHTHAL SURG LAS IM, V44, P25, DOI 10.3928/23258160-20121221-08
   Rosenfeld Philip J, 2006, Ophthalmol Clin North Am, V19, P361
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rosenfeld PJ, 2005, OPHTHALMOLOGY, V112, P1048, DOI 10.1016/j.ophtha.2005.01.043
   Sato T, 2010, OPHTHALMOLOGY, V117, P512, DOI 10.1016/j.ophtha.2009.07.041
   Telander DG, 2011, SEMIN OPHTHALMOL, V26, P192, DOI 10.3109/08820538.2011.570849
   Tugal-Tutkun Ilknur, 2010, International Ophthalmology, V30, P453, DOI 10.1007/s10792-009-9310-2
   Yeniad B, 2011, EUR J OPHTHALMOL, V21, P156, DOI 10.5301/EJO.2010.5239
   Zhang XY, 2014, INT J OPHTHALMOL-CHI, V7, P355, DOI 10.3980/j.issn.2222-3959.2014.02.30
NR 23
TC 3
Z9 3
U1 0
U2 3
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0927-3948
EI 1744-5078
J9 OCUL IMMUNOL INFLAMM
JI Ocul. Immunol. Inflamm.
PD APR
PY 2017
VL 25
IS 2
BP 229
EP 232
DI 10.3109/09273948.2015.1108445
PG 4
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA ES7OX
UT WOS:000399740900013
PM 26828124
DA 2022-11-30
ER

PT J
AU Hirata, Y
   Oishi, A
   Maekawa, Y
   Tsuiki, E
   Machida, A
   Kurihara, J
   Kitaoka, T
AF Hirata, Yuki
   Oishi, Akio
   Maekawa, Yuki
   Tsuiki, Eiko
   Machida, Akira
   Kurihara, Junko
   Kitaoka, Takashi
TI Recurrence of neovascular age-related macular degeneration after
   cessation of treat and extend regimen
SO SCIENTIFIC REPORTS
LA English
DT Article
ID OUTCOMES
AB The appropriate timing of treatment cessation after treat and extend (TAE) regimen for age-related macular degeneration has not been established. This study aimed to investigate the incidence and risk factors of recurrence after cessation of the TAE regimen. We included patients who received and discontinued the TAE regimen, after extension of the treatment interval to >= 12 weeks. Forty-nine patients were included in the study. The estimated recurrence rates were 33% at 1 year and 48% at 2 years after treatment cessation, respectively. Good visual acuity at cessation and a large number of injections in the 6 months before cessation were significant risk factors. Higher chances of recurrence were associated with < 0.1 logarithm of the minimum angle of resolution (logMAR) at cessation (P < 0.002). Meanwhile, five patients with visual acuity >= 1.0 logMAR at cessation did not show recurrence. Among the 25 recurrences, two lines of vision loss were noted in only two cases after resumed treatment. This study confirmed the importance of the number of injections in reducing recurrence and the association between visual acuity and recurrence. Recurrence is generally well-controlled with resumed treatment.
C1 [Hirata, Yuki; Oishi, Akio; Maekawa, Yuki; Tsuiki, Eiko; Machida, Akira; Kitaoka, Takashi] Nagasaki Univ, Grad Sch Biomed Sci, Dept Ophthalmol & Visual Sci, Sakamoto 1-7-1, Nagasaki 8528102, Japan.
   [Kurihara, Junko] Japanese Red Cross Nagasaki Genbaku Hosp, Dept Ophthalmol, Mori Machi, Nagasaki 8528511, Japan.
C3 Nagasaki University
RP Oishi, A (通讯作者)，Nagasaki Univ, Grad Sch Biomed Sci, Dept Ophthalmol & Visual Sci, Sakamoto 1-7-1, Nagasaki 8528102, Japan.
EM akio.oishi@nagasaki-u.ac.jp
FU Japan Society for the Promotion of Science, Tokyo, Japan [22K09793]
FX This study was supported by a grant-in-aid for scientific research (No.
   22K09793) from the Japan Society for the Promotion of Science, Tokyo,
   Japan. A.O. received personal fees from Bayer (Tokyo, Japan), Santen
   (Tokyo, Japan), Novartis (Tokyo, Japan), Senju (Tokyo, Japan), and
   Chugai (Tokyo, Japan). Y.M. received personal fees from Novartis Pharma
   (Tokyo, Japan). Tsuiki Eiko received personal fees from Bayer
   Pharmaceutical (Tokyo, Japan), Novartis Pharma (Tokyo, Japan), and ALCON
   JAPAN (Tokyo, Japan). T.K. received fees from Bayer Pharmaceutical
   (Tokyo, Japan), Santen Pharmaceutical (Tokyo, Japan), Novartis Pharma
   (Tokyo, Japan), Senju Pharmaceutical (Tokyo, Japan), ALCON JAPAN (Tokyo,
   Japan), and Kowa Pharmaceutical (Tokyo, Japan).
CR Adrean SD, 2018, OPHTHALMOL RETINA, V2, P225, DOI 10.1016/j.oret.2017.07.009
   Aslanis S, 2022, OPHTHALMOL RETINA, V6, P15, DOI 10.1016/j.oret.2021.03.010
   Berg K, 2015, OPHTHALMOLOGY, V122, P146, DOI 10.1016/j.ophtha.2014.07.041
   Cruess AF, 2008, PHARMACOECONOMICS, V26, P57, DOI 10.2165/00019053-200826010-00006
   Daien V, 2018, OPHTHALMOLOGY, V125, P66, DOI 10.1016/j.ophtha.2017.07.005
   Flaxman SR, 2017, LANCET GLOB HEALTH, V5, pE1221, DOI 10.1016/S2214-109X(17)30393-5
   Garweg JG, 2022, EYE, V36, P862, DOI 10.1038/s41433-021-01562-6
   Gemenetzi M, 2017, EYE, V31, P1, DOI 10.1038/eye.2016.208
   Gillies MC, 2015, OPHTHALMOLOGY, V122, P1837, DOI 10.1016/j.ophtha.2015.05.010
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Jaggi D, 2022, BRIT J OPHTHALMOL, V106, P246, DOI 10.1136/bjophthalmol-2020-316514
   Kanda Y, 2013, BONE MARROW TRANSPL, V48, P452, DOI 10.1038/bmt.2012.244
   Kim S, 2019, BMC HEALTH SERV RES, V19, DOI 10.1186/s12913-019-4666-0
   Kinoshita T, 2021, CLIN OPHTHALMOL, V15, P4405, DOI 10.2147/OPTH.S334641
   Matsubara H, 2022, GRAEF ARCH CLIN EXP, V260, P1867, DOI 10.1007/s00417-021-05526-0
   Munk MR, 2018, OPHTHALMOL RETINA, V2, P288, DOI 10.1016/j.oret.2017.07.010
   Nguyen V, 2019, OPHTHALMOL RETINA, V3, P623, DOI 10.1016/j.oret.2019.05.013
   Obana A., 2021, J JPN OPHTHALMOL SOC, V125, P1055
   Oishi A, 2011, EUR J OPHTHALMOL, V21, P777, DOI 10.5301/EJO.2011.7430
   Singh R. P., 2019, GLOBAL TRENDS RETINA
   Spaide RF, 2020, OPHTHALMOLOGY, V127, P616, DOI 10.1016/j.ophtha.2019.11.004
   Traine PG, 2019, OPHTHALMOL RETINA, V3, P393, DOI 10.1016/j.oret.2019.01.018
NR 22
TC 0
Z9 0
U1 0
U2 0
PU NATURE PORTFOLIO
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
SN 2045-2322
J9 SCI REP-UK
JI Sci Rep
PD AUG 30
PY 2022
VL 12
IS 1
AR 14768
DI 10.1038/s41598-022-19062-2
PG 8
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA 4E4ND
UT WOS:000847803100081
PM 36042371
OA Green Published, Green Submitted, gold
DA 2022-11-30
ER

PT J
AU Kheitan, S
   Minuchehr, Z
   Soheil, ZS
AF Kheitan, Samira
   Minuchehr, Zarrin
   Soheil, Zahra-Soheila
TI Exploring the cross talk between ER stress and inflammation in
   age-related macular degeneration
SO PLOS ONE
LA English
DT Article
ID PIGMENT EPITHELIAL-CELLS; ENDOPLASMIC-RETICULUM STRESS; ACTIVATED
   PROTEIN-KINASE; OXIDATIVE STRESS; COMPLEMENT ACTIVATION;
   ALPHA-SYNUCLEIN; GENE; DRUSEN; EXPRESSION; SUSCEPTIBILITY
AB Increasing evidence demonstrates that inflammation and endoplasmic reticulum (ER) stress is implicated in the development and progression of age-related macular degeneration (AMD), a multifactorial neurodegenerative disease. However the cross talk between these cellular mechanisms has not been clearly and fully understood. The present study investigates a possible intersection between ER stress and inflammation in AMD. In this study, we recruited two collections of involved protein markers to retrieve their interaction information from IMEx-curated databases, which are the most well-known protein-protein interaction collections, allowing us to design an intersection network for AMD that is unprecedented. In order to find expression activated subnetworks, we utilized AMD expression profiles in our network. In addition, we studied topological characteristics of the most expressed active subnetworks to identify the hubs. With regard to topological quantifications and expressional activity, we reported a list of the most pivotal hubs which are potentially applicable as probable therapeutic targets. Furthermore, we introduced MAPK signaling pathway as a significantly involved pathway in the association between ER stress and inflammation, leading to promising new directions in discovering AMD formation mechanisms and possible treatments.
C1 [Kheitan, Samira; Minuchehr, Zarrin] Natl Inst Genet Engn & Biotechnol, Syst Biotechnol Dept, Tehran, Iran.
   [Soheil, Zahra-Soheila] Natl Inst Genet Engn & Biotechnol, Mol Med Dept, Tehran, Iran.
RP Minuchehr, Z (通讯作者)，Natl Inst Genet Engn & Biotechnol, Syst Biotechnol Dept, Tehran, Iran.
EM minuchehr@nigeb.ac.ir
RI Minuchehr, Zarrin/ABD-9983-2021; Soheili, Zahra-Soheila/W-8316-2018
OI Minuchehr, Zarrin/0000-0002-3734-745X; Soheili,
   Zahra-Soheila/0000-0003-1292-465X
FU Iran National Science Foundation (INSF) [93036935]
FX This work was supported by Iran National Science Foundation (INSF)
   (www.insf.org) under grant number: 93036935. ZM received the funding.
   The funders had no role in study design, data collection and analysis,
   decision to publish, or preparation of the manuscript.; This work was
   supported by Iran National Science Foundation (INSF) under grant number:
   93036935 and done at the Bioinformatics Lab of the National Institute of
   Genetic Engineering and Biotechnology.
CR Aranda B, 2011, NAT METHODS, V8, P528, DOI 10.1038/nmeth.1637
   Bader GD, 2003, BMC BIOINFORMATICS, V4, DOI 10.1186/1471-2105-4-2
   Barabasi AL, 2004, NAT REV GENET, V5, P101, DOI 10.1038/nrg1272
   Barrett T, 2013, NUCLEIC ACIDS RES, V41, pD991, DOI 10.1093/nar/gks1193
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   Berliner JA, 2001, TRENDS CARDIOVAS MED, V11, P142, DOI 10.1016/S1050-1738(01)00098-6
   Bian ZM, 2009, INVEST OPHTH VIS SCI, V50, P6006, DOI 10.1167/iovs.09-3628
   Bian ZM, 2008, INVEST OPHTH VIS SCI, V49, P5593, DOI 10.1167/iovs.08-2116
   Cano M, 2014, FREE RADICAL BIO MED, V69, P1, DOI 10.1016/j.freeradbiomed.2014.01.004
   Cooper AA, 2006, SCIENCE, V313, P324, DOI 10.1126/science.1129462
   Crabb JW, 2002, P NATL ACAD SCI USA, V99, P14682, DOI 10.1073/pnas.222551899
   DAVIS RJ, 1994, TRENDS BIOCHEM SCI, V19, P470, DOI 10.1016/0968-0004(94)90132-5
   DAVIS RJ, 1995, MOL REPROD DEV, V42, P459, DOI 10.1002/mrd.1080420414
   Deng L, 2000, CELL, V103, P351, DOI 10.1016/S0092-8674(00)00126-4
   Dugel PU, 2017, OPHTHALMOLOGY
   Enslen H, 2000, EMBO J, V19, P1301, DOI 10.1093/emboj/19.6.1301
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   Goverdhan SV, 2005, AGE, V1726, P1734
   Grek C, 2014, ENDOPLASMIC RETICULU, V1, P4, DOI 10.2478/ersc-2013-0001
   Grimm C, 2000, MOL VIS, V6, P252
   Hacker Hans, 2006, Sci STKE, V2006, pre13, DOI 10.1126/stke.3572006re13
   Hageman GS, 1999, FASEB J, V13, P477, DOI 10.1096/fasebj.13.3.477
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   HAI T, 1991, P NATL ACAD SCI USA, V88, P3720, DOI 10.1073/pnas.88.9.3720
   Hasnain SZ, 2014, NAT MED, V20, P1417, DOI 10.1038/nm.3705
   Heier JS, 2017, LANCET
   Huang DW, 2009, NAT PROTOC, V4, P44, DOI 10.1038/nprot.2008.211
   Hussien Y, 2014, GLIA, V62, P680, DOI 10.1002/glia.22634
   Ideker Trey, 2002, Bioinformatics, V18 Suppl 1, pS233
   JENTSCH S, 1991, BIOCHIM BIOPHYS ACTA, V1089, P127, DOI 10.1016/0167-4781(91)90001-3
   Johnson LV, 2001, EXP EYE RES, V73, P887, DOI 10.1006/exer.2001.1094
   Johnson LV, 2002, P NATL ACAD SCI USA, V99, P11830, DOI 10.1073/pnas.192203399
   Kalariya NM, 2009, EXP EYE RES, V89, P494, DOI 10.1016/j.exer.2009.05.011
   Komander D, 2009, BIOCHEM SOC T, V37, P937, DOI 10.1042/BST0370937
   Komurasaki R, 2010, DRUG METAB PHARMACOK, V25, P84, DOI 10.2133/dmpk.25.84
   Leung KW, 2009, MOL IMMUNOL, V46, P1374, DOI 10.1016/j.molimm.2008.12.001
   Li Y, 2014, REDOX BIOL, V2, P485, DOI 10.1016/j.redox.2014.01.023
   Libby RT, 2010, ADV EXP MED BIOL, V664, P403, DOI 10.1007/978-1-4419-1399-9_46
   Lu HY, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0087530
   Marnef A, 2010, BIOCHEM SOC T, V38, P1602, DOI 10.1042/BST0381602
   Merksamer PI, 2008, CELL, V135, P933, DOI 10.1016/j.cell.2008.10.011
   Moore P, 2010, MOL BIOL CELL, V21, P1305, DOI 10.1091/mbc.E09-09-0826
   Nakanishi T, 2013, J NEUROCHEM, V125, P111, DOI 10.1111/jnc.12116
   Newman AM, 2012, GENOME MED, V4, DOI [10.1186/PREACCEPT-1418491035586234, 10.1186/gm315]
   Orchard S, 2012, NAT METHODS, V9, P345, DOI [10.1038/NMETH.1931, 10.1038/nmeth.1931]
   Peng YT, 2017, BMC OPHTHALMOL, V17, DOI 10.1186/s12886-017-0481-8
   Pons M, 2011, AM J PATHOL, V178, P2665, DOI 10.1016/j.ajpath.2011.02.006
   Reynolds AD, 2008, J NEUROIMMUNE PHARM, V3, P59, DOI 10.1007/s11481-008-9100-z
   Ricci F, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0066978
   Diez GR, 2013, EXP EYE RES, V113, P172, DOI 10.1016/j.exer.2013.05.019
   Roduit R, 2008, APOPTOSIS, V13, P343, DOI 10.1007/s10495-008-0179-8
   Sakaguchi H, 2002, EXP EYE RES, V74, P547, DOI 10.1006/exer.2002.1186
   Salminen A, 2010, MOL MED, V16, P535, DOI 10.2119/molmed.2010.00070
   SanGiovanni JP, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0071239
   Santiago JA, 2014, TRENDS MOL MED, V20, P694, DOI 10.1016/j.molmed.2014.10.002
   Scardoni G., 2014, F1000RES, V3, P139, DOI [10.12688/f1000research.4477.1, DOI 10.12688/f1000research.4477.2]
   Schaumberg DA, 2007, ARCH OPHTHALMOL-CHIC, V125, P300, DOI 10.1001/archopht.125.3.300
   Schutt F, 2003, INVEST OPHTH VIS SCI, V44, P3663, DOI 10.1167/iovs.03-0172
   Schutt F, 2002, FEBS LETT, V528, P217, DOI 10.1016/S0014-5793(02)03312-4
   Shannon P, 2003, GENOME RES, V13, P2498, DOI 10.1101/gr.1239303
   Stahl A, 2013, ANGIOGENESIS, V16, P101, DOI 10.1007/s10456-012-9302-0
   Stanton CM, 2011, INVEST OPHTH VIS SCI, V52, P8828, DOI 10.1167/iovs.11-7933
   Supek F, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021800
   Tou JS, 2004, FASEB J, V18, P1297, DOI 10.1096/fj.04-1862fje
   Tsai B, 2001, CELL, V104, P937, DOI 10.1016/S0092-8674(01)00289-6
   Tsai YY, 2008, INVEST OPHTH VIS SCI, V49, P693, DOI 10.1167/iovs.07-0125
   Uehling DE, 2015, BIOORG MED CHEM LETT, V25, P4047, DOI 10.1016/j.bmcl.2015.07.093
   Watanabe Kenya, 2006, Fukushima J Med Sci, V52, P1
   Weber CK, 2010, RHEUMATOLOGY, V49, P2255, DOI 10.1093/rheumatology/keq272
   Widmann C, 1999, PHYSIOL REV, V79, P143, DOI 10.1152/physrev.1999.79.1.143
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Yamada Y, 2008, J NEUROCHEM, V105, P1187, DOI 10.1111/j.1471-4159.2008.05211.x
   Yang SQ, 2016, DRUG DES DEV THER, V10, P1857, DOI 10.2147/DDDT.S97653
   Zareparsi S, 2005, HUM MOL GENET, V14, P1449, DOI 10.1093/hmg/ddi154
   Zheng PZ, 1998, P NATL ACAD SCI USA, V95, P14745, DOI 10.1073/pnas.95.25.14745
   Zhong Y, 2012, PLOS ONE, V7
   Zotenko E, 2008, PLOS COMPUT BIOL, V4, DOI 10.1371/journal.pcbi.1000140
NR 78
TC 12
Z9 12
U1 1
U2 3
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JUL 24
PY 2017
VL 12
IS 7
AR e0181667
DI 10.1371/journal.pone.0181667
PG 17
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA FB8BB
UT WOS:000406362700060
PM 28742151
OA Green Published, gold, Green Submitted
DA 2022-11-30
ER

PT J
AU Barakat, MR
   Metelitsina, TI
   DuPont, JC
   Grunwald, JE
AF Barakat, M. R.
   Metelitsina, T. I.
   DuPont, J. C.
   Grunwald, J. E.
TI Effect of niacin on retinal vascular diameter in patients with
   age-related macular degeneration
SO CURRENT EYE RESEARCH
LA English
DT Article
DE niacin; retina; vessel
ID SUSTAINED-RELEASE
AB Purpose : Niacin is a B vitamin well-known for causing vasodilation and flushing. The purpose of this study was to investigate its effect on the retinal vasculature of patients with age-related macular degeneration (AMD). Methods : Twelve patients with AMD were enrolled in a double-blind, randomized, placebo-controlled, crossover trial. Fundus photographs of the posterior pole were taken at baseline, 30 min, and 90 min after a single dose of niacin or placebo. The protocol was repeated after a washout period using the alternate study drug. The diameters of two veins and one artery on each image were measured. Results : An analysis of variance for repeated measures comparing the effects of niacin with those of placebo demonstrated a significant increase in the inferior temporal retinal artery diameter (p = 0.01), with a 5.3 +/- 7.7% increase at 30 min (p = 0.05) and 5.8 5.0% increase at 90 min (p = 0.003). No significant changes were observed in the temporal retinal veins. Conclusions : Our results suggest that niacin produces vasodilatation of retinal arterioles. Further studies are needed to ascertain whether niacin treatment may be beneficial in retinal ischemic diseases.
C1 Univ Penn, Scheie Eye Inst, Dept Ophthalmol, Philadelphia, PA 19104 USA.
C3 University of Pennsylvania
RP Grunwald, JE (通讯作者)，Univ Penn, Scheie Eye Inst, Dept Ophthalmol, 51 N 39th St, Philadelphia, PA 19104 USA.
EM juangrun@mail.med.upenn.edu
CR Cheitlin MD, 1999, J AM COLL CARDIOL, V33, P273, DOI 10.1016/S0735-1097(98)00656-1
   GIBBONS LW, 1995, AM J MED, V99, P378, DOI 10.1016/S0002-9343(99)80185-5
   Grundy SM, 2002, CIRCULATION, V106, P3143, DOI 10.1161/circ.106.25.3143
   Grunwald JE, 1998, INVEST OPHTH VIS SCI, V39, P385
   Grunwald JE, 1999, BRIT J OPHTHALMOL, V83, P162, DOI 10.1136/bjo.83.2.162
   Grunwald JE, 1997, AM J OPHTHALMOL, V123, P753, DOI 10.1016/S0002-9394(14)71123-7
   MCKENNEY JM, 1994, JAMA-J AM MED ASSOC, V271, P672, DOI 10.1001/jama.271.9.672
   Metelitsina TI, 2004, BRIT J OPHTHALMOL, V88, P1568, DOI 10.1136/bjo.2004.046607
   MORROW JD, 1989, PROSTAGLANDINS, V38, P263, DOI 10.1016/0090-6980(89)90088-9
NR 9
TC 8
Z9 8
U1 0
U2 0
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0271-3683
EI 1460-2202
J9 CURR EYE RES
JI Curr. Eye Res.
PD JUL-AUG
PY 2006
VL 31
IS 7-8
BP 629
EP 634
DI 10.1080/02713680600760501
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 069MR
UT WOS:000239452200008
PM 16877271
DA 2022-11-30
ER

PT J
AU Iorga, RE
   Danulescu, RSM
   Ozturk, M
   Costin, D
AF Iorga, Raluca Eugenia
   Danulescu, Razvana Sorina Munteanu
   Ozturk, Manuela
   Costin, Danut
TI Use of Oxidative Stress Markers in Diagnosis and Evolution of
   Age-Related Macular Degeneration
SO REVISTA DE CHIMIE
LA English
DT Article
DE age related macular degeneration; oxidative stress; superoxide
   dismutase; thiobarbituric acid reactive substances; glutathione
   peroxidase
ID ENDOPLASMIC-RETICULUM STRESS; RETINAL-PIGMENT EPITHELIUM;
   GLUTATHIONE-PEROXIDASE; CHINESE PATIENTS; DAMAGE; INFLAMMATION;
   PROTECTS; DISEASE; DRUSEN; MICE
AB Age-related macular degeneration (AMD) is the most common cause of blindness in the elderly. Were monitored the evolution of oxidative stress markers before and after treatment. This is a case-control study, which included 59 patients diagnosed with AMD and 64 healthy controls. According to the AREDS classification, the patients were divided into two classes, moderate and severe form AMD and were treated with antioxidants, neurotrophic drugs, intravitreal injections with antiangiogenic factors. We followed the patients over a 12-month period and we evaluated the oxidative stress markers such as superoxide dismutase (SOD), thiobarbituric acid reactive substances (TBARS), glutathione peroxidase (GPx), before and after treatment. By comparing the mean values of SOD, TBARS in the two groups, we found that they were significantly higher in the study group compared to the control group, being higher in patients with severe disease. These values decreased after treatment, but they have remained higher than in controls. This research supports the role of oxidative stress in AMD. This paper opens the perspectives of possible elucidations of the AMD pathogenesis dilemma and supports the need to monitor the evolution by assessing the oxidative stress markers.
C1 [Iorga, Raluca Eugenia; Costin, Danut] Prof Dr Nicolae Oblu Emergency Hosp, Ophthalmol Clin 2nd, 2 Ateneului Str, Iasi 700309, Romania.
   [Danulescu, Razvana Sorina Munteanu] Grigore T Popa Univ Med & Pharm, Dept Gastroenterol, 6 Univ Str, Iasi 700115, Romania.
   [Ozturk, Manuela; Costin, Danut] Grigore T Popa Univ Med & Pharm, Dept Ophthalmol, 6 Univ Str, Iasi 700115, Romania.
C3 Grigore T Popa University of Medicine & Pharmacy; Grigore T Popa
   University of Medicine & Pharmacy
RP Iorga, RE (通讯作者)，Prof Dr Nicolae Oblu Emergency Hosp, Ophthalmol Clin 2nd, 2 Ateneului Str, Iasi 700309, Romania.
EM ralucadanulescu@yahoo.com
CR BASKOL G., 2004, ERCIYES MED J, V26, P7
   Bonne C, 2000, J FR OPHTALMOL, V23, P835
   Crabb JW, 2002, P NATL ACAD SCI USA, V99, P14682, DOI 10.1073/pnas.222551899
   de Haan JB, 1998, J BIOL CHEM, V273, P22528, DOI 10.1074/jbc.273.35.22528
   de Jong PTVM, 2006, NEW ENGL J MED, V355, P1474, DOI 10.1056/NEJMra062326
   Dong A, 2006, J CELL PHYSIOL, V208, P516, DOI 10.1002/jcp.20683
   Dong A, 2009, J CELL PHYSIOL, V219, P544, DOI 10.1002/jcp.21698
   Gosbell AD, 2006, INVEST OPHTH VIS SCI, V47, P2613, DOI 10.1167/iovs.05-0962
   Hollyfield JG, 2003, ADV EXP MED BIOL, V533, P83
   Hollyfield JG, 2008, NAT MED, V14, P194, DOI 10.1038/nm1709
   Hollyfield JG, 2010, INVEST OPHTH VIS SCI, V51, P1276, DOI 10.1167/iovs.09-4478
   Imamura Y, 2006, P NATL ACAD SCI USA, V103, P11282, DOI 10.1073/pnas.0602131103
   Janik-Papis Katarzyna, 2009, Klin Oczna, V111, P168
   Jia LH, 2011, AGING CLIN EXP RES, V23, P264, DOI 10.1007/BF03324965
   Kasahara E, 2005, INVEST OPHTH VIS SCI, V46, P3426, DOI 10.1167/iovs.05-0344
   Libby RT, 2010, ADV EXP MED BIOL, V664, P403, DOI 10.1007/978-1-4419-1399-9_46
   Ohira A, 2003, INVEST OPHTH VIS SCI, V44, P1230, DOI 10.1167/iovs.02-0191
   Salminen A, 2010, MOL MED, V16, P535, DOI 10.2119/molmed.2010.00070
   Shen XL, 2012, J NUTR HEALTH AGING, V16, P201, DOI 10.1007/s12603-011-0350-8
NR 19
TC 0
Z9 0
U1 0
U2 3
PU CHIMINFORM DATA S A
PI BUCHAREST
PA CALEA PLEVNEI NR 139, SECTOR 6, BUCHAREST R-77131, ROMANIA
SN 0034-7752
J9 REV CHIM-BUCHAREST
JI Rev. Chim.
PD FEB
PY 2019
VL 70
IS 2
BP 483
EP 486
PG 4
WC Chemistry, Multidisciplinary; Engineering, Chemical
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Chemistry; Engineering
GA HP8ZV
UT WOS:000461982200024
DA 2022-11-30
ER

PT J
AU Hu, ML
   Quinn, J
   Xue, KM
AF Hu, Monica L.
   Quinn, Joel
   Xue, Kanmin
TI Interactions between Apolipoprotein E Metabolism and Retinal
   Inflammation in Age-Related Macular Degeneration
SO LIFE-BASEL
LA English
DT Review
DE age-related macular degeneration; apolipoprotein E; amyloid-beta;
   retinal inflammation; drusen
ID COMPLEMENT FACTOR-H; AMYLOID PRECURSOR PROTEIN; NF-KAPPA-B;
   GEOGRAPHIC-ATROPHY; ALZHEIMERS-DISEASE; A-BETA; RETICULAR PSEUDODRUSEN;
   VISION LOSS; PIGMENTED EPITHELIUM; RECEPTOR-BINDING
AB Age-related macular degeneration (AMD) is a multifactorial retinal disorder that is a major global cause of severe visual impairment. The development of an effective therapy to treat geographic atrophy, the predominant form of AMD, remains elusive due to the incomplete understanding of its pathogenesis. Central to AMD diagnosis and pathology are the hallmark lipid and proteinaceous deposits, drusen and reticular pseudodrusen, that accumulate in the subretinal pigment epithelium and subretinal spaces, respectively. Age-related changes and environmental stressors, such as smoking and a high-fat diet, are believed to interact with the many genetic risk variants that have been identified in several major biochemical pathways, including lipoprotein metabolism and the complement system. The APOE gene, encoding apolipoprotein E (APOE), is a major genetic risk factor for AMD, with the APOE2 allele conferring increased risk and APOE4 conferring reduced risk, in comparison to the wildtype APOE3. Paradoxically, APOE4 is the main genetic risk factor in Alzheimer's disease, a disease with features of neuroinflammation and amyloid-beta deposition in common with AMD. The potential interactions of APOE with the complement system and amyloid-beta are discussed here to shed light on their roles in AMD pathogenesis, including in drusen biogenesis, immune cell activation and recruitment, and retinal inflammation.
C1 [Hu, Monica L.] Royal Victorian Eye & Ear Hosp, Ctr Eye Res Australia, East Melbourne, Vic 3002, Australia.
   [Quinn, Joel; Xue, Kanmin] Univ Oxford, Nuffield Dept Clin Neurosci, Nuffield Lab Ophthalmol, Oxford OX3 9DU, England.
   [Xue, Kanmin] Oxford Univ Hosp NHS Fdn Trust, Oxford Eye Hosp, Oxford OX3 9DU, England.
C3 Centre for Eye Research Australia; Royal Victorian Eye & Ear Hospital;
   University of Oxford; Oxford University Hospitals NHS Foundation Trust
RP Xue, KM (通讯作者)，Univ Oxford, Nuffield Dept Clin Neurosci, Nuffield Lab Ophthalmol, Oxford OX3 9DU, England.; Xue, KM (通讯作者)，Oxford Univ Hosp NHS Fdn Trust, Oxford Eye Hosp, Oxford OX3 9DU, England.
EM monica.hu.011@gmail.com; joel.quinn@ndcn.ox.ac.uk;
   enquiries@eye.ox.ac.uk
RI Xue, Kanmin/AIC-7111-2022
OI Xue, Kanmin/0000-0003-0065-9131; Quinn, Joel/0000-0002-7954-9201
FU University of Oxford Clarendon Fund [216593/Z/19/Z]
FX This research was funded by theWellcome Trust (K.X. & J.Q., grant no.
   216593/Z/19/Z), University of Oxford Clarendon Fund and Merton College
   Tira Wannamethee Graduate Scholarship (M.L.H.).
CR Adams MKM, 2012, AM J EPIDEMIOL, V175, P511, DOI 10.1093/aje/kwr329
   Albert R, 2015, BBA-GEN SUBJECTS, V1850, P435, DOI 10.1016/j.bbagen.2014.10.026
   Altay L, 2016, INVEST OPHTH VIS SCI, V57, P4315, DOI 10.1167/iovs.15-18855
   Anderson DH, 2004, EXP EYE RES, V78, P243, DOI 10.1016/j.exer.2003.10.011
   Anderson DH, 2001, AM J OPHTHALMOL, V131, P767, DOI 10.1016/S0002-9394(00)00961-2
   Anderson DH, 2010, PROG RETIN EYE RES, V29, P95, DOI 10.1016/j.preteyeres.2009.11.003
   Baird PN, 2004, INVEST OPHTH VIS SCI, V45, P1311, DOI 10.1167/iovs.03-1121
   Blum CB, 2016, PROG CARDIOVASC DIS, V59, P119, DOI 10.1016/j.pcad.2016.07.007
   Bourne RRA, 2013, LANCET GLOB HEALTH, V1, pE339, DOI 10.1016/S2214-109X(13)70113-X
   Bradt BM, 1998, J EXP MED, V188, P431, DOI 10.1084/jem.188.3.431
   Calippe B, 2017, IMMUNITY, V46, P261, DOI 10.1016/j.immuni.2017.01.006
   Cerf E, 2011, FASEB J, V25, P1585, DOI 10.1096/fj.10-175976
   Chew EY, 2014, JAMA OPHTHALMOL, V132, P142, DOI 10.1001/jamaophthalmol.2013.7376
   Christenbury JG, 2013, OPHTHALMOLOGY, V120, P1038, DOI 10.1016/j.ophtha.2012.10.018
   Clark SJ, 2010, J BIOL CHEM, V285, P30192, DOI 10.1074/jbc.M110.103986
   Colijn JM, 2017, OPHTHALMOLOGY, V124, P1753, DOI 10.1016/j.ophtha.2017.05.035
   Combadiere C, 2007, J CLIN INVEST, V117, P2920, DOI 10.1172/JCI31692
   Crabb JW, 2002, P NATL ACAD SCI USA, V99, P14682, DOI 10.1073/pnas.222551899
   Curcio CA, 1999, ARCH OPHTHALMOL-CHIC, V117, P329, DOI 10.1001/archopht.117.3.329
   Curcio Christine A, 2018, Invest Ophthalmol Vis Sci, V59, pAMD160, DOI 10.1167/iovs.18-24882
   DAVIGNON J, 1988, ARTERIOSCLEROSIS, V8, P1, DOI 10.1161/01.ATV.8.1.1
   de Guimaraes TAC, 2022, BRIT J OPHTHALMOL, V106, P297, DOI 10.1136/bjophthalmol-2020-318452
   Dentchev T, 2003, MOL VIS, V9, P184
   Ding JD, 2008, VISION RES, V48, P339, DOI 10.1016/j.visres.2007.07.025
   Ding JD, 2011, P NATL ACAD SCI USA, V108, pE279, DOI 10.1073/pnas.1100901108
   Dithmar S, 2000, INVEST OPHTH VIS SCI, V41, P2035
   Domalpally A, 2019, OPHTHALMOLOGY, V126, P1659, DOI 10.1016/j.ophtha.2019.07.022
   Dong LM, 1996, NAT STRUCT BIOL, V3, P718, DOI 10.1038/nsb0896-718
   Doyle SL, 2012, NAT MED, V18, P791, DOI 10.1038/nm.2717
   Ehrlich R, 2008, CLIN INTERV AGING, V3, P473
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Finger RP, 2014, OPHTHALMOLOGY, V121, P1252, DOI 10.1016/j.ophtha.2013.12.034
   Fritsche LG, 2016, NAT GENET, V48, P134, DOI 10.1038/ng.3448
   Greferath U, 2016, OPHTHALMOLOGY, V123, P1320, DOI 10.1016/j.ophtha.2016.02.009
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Hashimoto T, 2012, J NEUROSCI, V32, P15181, DOI 10.1523/JNEUROSCI.1542-12.2012
   Heesterbeek TJ, 2020, OPHTHAL PHYSL OPT, V40, P140, DOI 10.1111/opo.12675
   Holz FG, 2018, JAMA OPHTHALMOL, V136, P666, DOI 10.1001/jamaophthalmol.2018.1544
   Huang YWA, 2017, CELL, V168, P427, DOI 10.1016/j.cell.2016.12.044
   Indaram M, 2015, SCI REP-UK, V5, DOI 10.1038/srep09144
   Insel PS, 2021, JAMA NEUROL, V78, P229, DOI 10.1001/jamaneurol.2020.3780
   Isas JM, 2010, INVEST OPHTH VIS SCI, V51, P1304, DOI 10.1167/iovs.09-4207
   Ishida BY, 2004, J LIPID RES, V45, P263, DOI 10.1194/jlr.M300306-JLR200
   Jaffe GJ, 2021, OPHTHALMOLOGY, V128, P576, DOI 10.1016/j.ophtha.2020.08.027
   Jo DH, 2020, NEUROBIOL AGING, V95, P115, DOI 10.1016/j.neurobiolaging.2020.07.013
   Johnson LV, 2011, P NATL ACAD SCI USA, V108, P18277, DOI 10.1073/pnas.1109703108
   Johnson LV, 2002, P NATL ACAD SCI USA, V99, P11830, DOI 10.1073/pnas.192203399
   Johnson PT, 2006, P NATL ACAD SCI USA, V103, P17456, DOI 10.1073/pnas.0606234103
   Kam JH, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-49121-0
   Kam JH, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013127
   Kanekiyo T, 2014, NEURON, V81, P740, DOI 10.1016/j.neuron.2014.01.045
   Kang YH, 2012, IMMUNOBIOLOGY, V217, P455, DOI 10.1016/j.imbio.2011.10.008
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Klaver CCW, 1998, AM J HUM GENET, V63, P200, DOI 10.1086/301901
   Kliffen M, 2000, BRIT J OPHTHALMOL, V84, P1415, DOI 10.1136/bjo.84.12.1415
   Kopp A, 2012, BIOMOLECULES, V2, P46, DOI 10.3390/biom2010046
   LADU MJ, 1994, J BIOL CHEM, V269, P23403
   Landowski M, 2019, P NATL ACAD SCI USA, V116, P3703, DOI 10.1073/pnas.1814014116
   Levy O, 2015, J NEUROSCI, V35, P13568, DOI 10.1523/JNEUROSCI.2468-15.2015
   Levy O, 2015, EMBO MOL MED, V7, P211, DOI 10.15252/emmm.201404524
   Liu C, 2018, CELL DEATH DIFFER, V25, P661, DOI 10.1038/s41418-017-0005-3
   Liu RZT, 2014, EXP EYE RES, V127, P49, DOI 10.1016/j.exer.2014.07.003
   LOFFLER KU, 1995, INVEST OPHTH VIS SCI, V36, P24
   Luibl V, 2006, J CLIN INVEST, V116, P378, DOI 10.1172/JCI25843
   Lynn SA, 2017, NEURAL REGEN RES, V12, P538, DOI 10.4103/1673-5374.205083
   Ma WC, 2007, INVEST OPHTH VIS SCI, V48, P1355, DOI 10.1167/iovs.06-0738
   Malek G, 2005, P NATL ACAD SCI USA, V102, P11900, DOI 10.1073/pnas.0503015102
   Mattapallil MJ, 2017, IMMUNITY, V46, P167, DOI 10.1016/j.immuni.2017.02.008
   McKay GJ, 2011, HUM MUTAT, V32, P1407, DOI 10.1002/humu.21577
   Micklisch S, 2017, J NEUROINFLAMM, V14, DOI 10.1186/s12974-016-0776-3
   Mitchell P, 2018, LANCET, V392, P1147, DOI 10.1016/S0140-6736(18)31550-2
   Mitter SK, 2014, AUTOPHAGY, V10, P1989, DOI 10.4161/auto.36184
   Mrejen S, 2014, OPHTHALMOLOGY, V121, P545, DOI 10.1016/j.ophtha.2013.09.026
   Mullins RF, 2000, FASEB J, V14, P835, DOI 10.1096/fasebj.14.7.835
   Mullins RF, 2011, EXP EYE RES, V93, P565, DOI 10.1016/j.exer.2011.06.015
   O'Brien RJ, 2011, ANNU REV NEUROSCI, V34, P185, DOI 10.1146/annurev-neuro-061010-113613
   Ohno-Matsui K, 2011, PROG RETIN EYE RES, V30, P217, DOI 10.1016/j.preteyeres.2011.02.004
   Ong JM, 2001, INVEST OPHTH VIS SCI, V42, P1891
   Ormsby RJ, 2008, INVEST OPHTH VIS SCI, V49, P1763, DOI 10.1167/iovs.07-1297
   Pang CP, 2000, OPHTHALMOLOGICA, V214, P289, DOI 10.1159/000027506
   Panza F, 2019, NAT REV NEUROL, V15, P73, DOI 10.1038/s41582-018-0116-6
   Parsons CG, 2015, NEUROPHARMACOLOGY, V92, P158, DOI 10.1016/j.neuropharm.2014.12.038
   Petrlova J, 2011, PROTEINS, V79, P402, DOI 10.1002/prot.22891
   Phillips MC, 2014, IUBMB LIFE, V66, P616, DOI 10.1002/iub.1314
   Prasad T, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-03397-2
   Ratnayaka JA, 2015, EYE, V29, P1013, DOI 10.1038/eye.2015.100
   ROGERS J, 1992, P NATL ACAD SCI USA, V89, P10016, DOI 10.1073/pnas.89.21.10016
   Rosenfeld PJ, 2018, OPHTHALMOL RETINA, V2, P1028, DOI 10.1016/j.oret.2018.03.001
   SARKS JP, 1994, EYE, V8, P269, DOI 10.1038/eye.1994.57
   Schuman SG, 2009, OPHTHALMOLOGY, V116, P488, DOI 10.1016/j.ophtha.2008.10.006
   Seddon JM, 2005, ARCH OPHTHALMOL-CHIC, V123, P321, DOI 10.1001/archopht.123.3.321
   Shaw PX, 2012, P NATL ACAD SCI USA, V109, P13757, DOI 10.1073/pnas.1121309109
   Sun E, 2011, MOL VIS, V17, P997
   Thakkinstian A, 2006, AM J EPIDEMIOL, V164, P813, DOI 10.1093/aje/kwj279
   Tisi A, 2021, CELLS-BASEL, V10, DOI 10.3390/cells10010064
   Toomey CB, 2018, PROG RETIN EYE RES, V62, P38, DOI 10.1016/j.preteyeres.2017.09.001
   Wang JY, 2008, J IMMUNOL, V181, P712, DOI 10.4049/jimmunol.181.1.712
   Wang JY, 2009, J CELL PHYSIOL, V220, P119, DOI 10.1002/jcp.21742
   Wang L, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010329
   Warwick A, 2014, J CLIN MED, V3, P1234, DOI 10.3390/jcm3041234
   WEISGRABER KH, 1982, J BIOL CHEM, V257, P2518
   Wightman AJ, 2019, CLIN EXP OPTOM, V102, P455, DOI 10.1111/cxo.12842
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Yang P, 2017, INVEST OPHTH VIS SCI, V58, P3073, DOI 10.1167/iovs.16-20083
   Yehoshua Z, 2014, OPHTHALMOLOGY, V121, P693, DOI 10.1016/j.ophtha.2013.09.044
   Yin CJ, 2019, NAT MED, V25, P496, DOI 10.1038/s41591-018-0336-8
   Yoshida T, 2005, J CLIN INVEST, V115, P2793, DOI 10.1172/JCI24635
   Zarbin M, 2019, STEM CELL TRANSL MED, V8, P466, DOI 10.1002/sctm.18-0282
   Zweifel SA, 2010, OPHTHALMOLOGY, V117, P303, DOI 10.1016/j.ophtha.2009.07.014
NR 110
TC 8
Z9 8
U1 1
U2 4
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2075-1729
J9 LIFE-BASEL
JI Life-Basel
PD JUL
PY 2021
VL 11
IS 7
AR 635
DI 10.3390/life11070635
PG 15
WC Biology; Microbiology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Life Sciences & Biomedicine - Other Topics; Microbiology
GA TO0OT
UT WOS:000676623400001
PM 34210002
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Ruiz-Moreno, JM
   Montero, JA
   Barile, S
AF Ruiz-Moreno, J. M.
   Montero, J. A.
   Barile, S.
TI Triamcinolone and PDT to treat exudative age-related macular
   degeneration and submacular hemorrhage
SO EUROPEAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE age-related macular degeneration; intravitreous triamcinolone;
   photodynamic therapy; subretinal hemorrhage
ID TISSUE-PLASMINOGEN ACTIVATOR; SUBFOVEAL CHOROIDAL NEOVASCULARIZATION;
   INTRAVITREAL TRIAMCINOLONE; PHOTODYNAMIC THERAPY; SUBRETINAL HEMORRHAGE;
   INJECTION; ACETONIDE; VERTEPORFIN; INHIBITION; MANAGEMENT
AB PURPOSE. To evaluate the efficacy of photodynamic therapy (PDT) with verteporfin and intravitreal injection of triamcinolone to treat choroidal neovascularization (CNV) with flat submacular hemorrhage in age-related macular degeneration (ARMD).
   METHODS. A prospective, consecutive, noncomparative, interventional case series study was performed at the Instituto Oftalmologico de Alicante, Spain. Ten consecutive eyes from 10 patients with flat submacular hemorrhage secondary to ARMD were treated by PDT followed by intravitreal injection of 19.4 +/- 2.1 mg/0.1 mL triamcinolone 5 days later. PDT was repeated if leakage from the CNV appeared on fluorescein angiography (FA) at 3 months follow-up intervals. Main outcome measures were best-corrected visual acuity (BCVA) before and after treatment, post-treatment FA, results, and complications.
   RESULTS. Stable or improved BCVA was achieved in seven eyes at 6 months follow-up. Complete absence of leakage in FA was observed in five and in eight eyes at 3 and 6 months follow-up, respectively. Intraocular pressure rose in seven eyes.
   CONCLUSIONS. PDT followed by intravitreal triamcinolone seems useful to treat CNV with flat submacular hemorrhage in ARMD. However, further studies with longer follow-up and randomized controlled trials are necessary to assess its efficacy in the management of this difficult clinical problem.
C1 Univ Miguel Hernandez, Div Oftalmol, Sch Med, Alicante 03550, Spain.
   Inst Oftalmol Alicante, Vitreo Retinal Unit, Alicante, Spain.
C3 Universidad Miguel Hernandez de Elche
RP Ruiz-Moreno, JM (通讯作者)，Univ Miguel Hernandez, Div Oftalmol, Sch Med, Campus San Juan, Alicante 03550, Spain.
EM jm.ruiz@umh.es
RI Ruiz-Moreno, José M/E-4644-2016
OI Ruiz-Moreno, Jose M/0000-0001-9636-0788
CR ANTOSZYK AN, 1993, GRAEF ARCH CLIN EXP, V231, P34, DOI 10.1007/BF01681698
   Avery RL, 1996, RETINA-J RET VIT DIS, V16, P183, DOI 10.1097/00006982-199616030-00001
   BLOOM SM, 1997, LASER SURG POSTERIOR, P3
   Blumenkranz MS, 2001, ARCH OPHTHALMOL-CHIC, V119, P198
   Ciulla TA, 2003, BRIT J OPHTHALMOL, V87, P1032, DOI 10.1136/bjo.87.8.1032
   Daneshvar H, 1999, CAN J OPHTHALMOL, V34, P385
   Danis RP, 1996, OPHTHALMOLOGY, V103, P2099, DOI 10.1016/S0161-6420(96)30383-7
   Do DV, 2004, AM J OPHTHALMOL, V137, P558, DOI 10.1016/j.ajo.2003.08.001
   Dweik RA, 1997, IMMUNOPHARMACOLOGY, V37, P163, DOI 10.1016/S0162-3109(97)00043-X
   FUKUSHIMA K, 1990, J CLIN LAB IMMUNOL, V33, P117
   GLATT H, 1982, AM J OPHTHALMOL, V94, P762, DOI 10.1016/0002-9394(82)90301-4
   Handwerger BA, 2001, ARCH OPHTHALMOL-CHIC, V119, P28
   Hassan AS, 1999, OPHTHALMOLOGY, V106, P1900, DOI 10.1016/S0161-6420(99)90399-8
   Hattenbach LO, 2001, OPHTHALMOLOGY, V108, P1485, DOI 10.1016/S0161-6420(01)00648-0
   Hesse L, 1997, ADV THER, V14, P275
   Hesse L, 2000, RETINA-J RET VIT DIS, V20, P500, DOI 10.1097/00006982-200009000-00011
   Jonas JB, 2005, EYE, V19, P163, DOI 10.1038/sj.eye.6701438
   Jonas JB, 2002, EUR J OPHTHALMOL, V12, P534, DOI 10.1177/112067210201200614
   Krepler K, 2000, RETINA-J RET VIT DIS, V20, P251, DOI 10.1097/00006982-200003000-00005
   Leguay JM, 2000, J FR OPHTALMOL, V23, P797
   LeVine SM, 2004, ANN NY ACAD SCI, V1012, P252, DOI 10.1196/annals.1306.021
   LIM JI, 1995, OPHTHALMOLOGY, V102, P1393, DOI 10.1016/S0161-6420(95)30858-5
   Majori M, 1998, EUR RESPIR J, V11, P133, DOI 10.1183/09031936.98.11010133
   Massin P, 2004, OPHTHALMOLOGY, V111, P218, DOI 10.1016/j.ophtha.2003.05.037
   Merrill PT, 1999, OPHTHALMOLOGY, V106, P782, DOI 10.1016/S0161-6420(99)90167-7
   MILLER JW, 1995, ARCH OPHTHALMOL-CHIC, V113, P810, DOI 10.1001/archopht.1995.01100060136048
   Olivier S, 2004, OPHTHALMOLOGY, V111, P1201, DOI 10.1016/j.ophtha.2003.10.020
   Padeh S, 1998, ARTHRITIS RHEUM, V41, P1210, DOI 10.1002/1529-0131(199807)41:7<1210::AID-ART10>3.0.CO;2-5
   Rechtman E, 2004, BRIT J OPHTHALMOL, V88, P344, DOI 10.1136/bjo.2003.027177
   Scheider A, 1999, GRAEF ARCH CLIN EXP, V237, P10, DOI 10.1007/s004170050187
   Schmidt-Erfurth U, 2002, INVEST OPHTH VIS SCI, V43, P830
   Schmidt-Erfurth U, 2003, INVEST OPHTH VIS SCI, V44, P4473, DOI 10.1167/iovs.02-1115
   Schmidt-Erfurth UM, 2004, OPHTHALMOLOGY, V111, P931, DOI 10.1016/j.ophtha.2003.12.025
   Spaide RF, 2005, OPHTHALMOLOGY, V112, P301, DOI 10.1016/j.ophtha.2004.08.012
   Spaide RF, 2003, OPHTHALMOLOGY, V110, P1517, DOI 10.1016/S0161-6420(03)00544-X
   Steinhorst UH, 1997, OPHTHALMOLOGICA, V211, P399, DOI 10.1159/000310841
   TANO Y, 1980, AM J OPHTHALMOL, V90, P810, DOI 10.1016/S0002-9394(14)75196-7
   Wang YS, 2002, GRAEF ARCH CLIN EXP, V240, P42, DOI 10.1007/s00417-001-0398-y
   WEINER FR, 1987, J BIOL CHEM, V262, P6955
   WEISHAUPT KR, 1976, CANCER RES, V36, P2326
NR 40
TC 19
Z9 19
U1 0
U2 1
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 1120-6721
EI 1724-6016
J9 EUR J OPHTHALMOL
JI Eur. J. Ophthalmol.
PD MAY-JUN
PY 2006
VL 16
IS 3
BP 426
EP 434
DI 10.1177/112067210601600311
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 067MG
UT WOS:000239306400011
PM 16761245
DA 2022-11-30
ER

PT J
AU Yao, JQ
   Liu, XY
   Yang, Q
   Zhuang, M
   Wang, F
   Chen, X
   Hang, H
   Zhang, WW
   Liu, QH
AF Yao, Jiaqi
   Liu, Xiaoyi
   Yang, Qin
   Zhuang, Min
   Wang, Feng
   Chen, Xi
   Hang, Hui
   Zhang, Weiwei
   Liu, Qinghuai
TI Proteomic analysis of the aqueous humor in patients with wet age-related
   macular degeneration
SO PROTEOMICS CLINICAL APPLICATIONS
LA English
DT Article
DE Aqueous humor; MALDI-TOF MS; MS; Wet age-related macular degeneration
ID ALPHA-B-CRYSTALLIN; RETINAL-PIGMENT EPITHELIUM; ENDOTHELIAL
   GROWTH-FACTOR; A-CRYSTALLIN; OXIDATIVE-STRESS; PROTEINS; CELLS; VEGF;
   IDENTIFICATION; ANGIOGENESIS
AB PurposeA number of studies have shown that the levels of some proteins in the aqueous humor (AH) are altered and correlate with the mechanisms or prognosis of many eye diseases. To identify the possible mechanisms that lead to the development of wet age-related macular degeneration (AMD), a proteomic analysis of the AH composition from wet AMD patients was performed and compared with that from non-AMD cataract patients.
   Experimental designSix wet AMD and six non-AMD cataract patients were enrolled. A proteomic approach which included two-dimensional electrophoresis coupled with MS and bioinformatics methods were used to identify AH proteins with altered expression in wet AMD compared with non-AMD patients. An ELISA was used to validate the proteomic results.
   ResultsWe separated 78 protein spots and identified 68 that were differently expressed in the wet AMD group and controls. Numerous proteins identified in this study are implicated in inflammation, apoptosis, angiogenesis, and oxidative stress.
   Conclusions and clinical relevanceThe AH protein composition was significantly different between wet AMD and non-AMD patients. The proteins identified in this study may be potential biomarkers of wet AMD development and might play a role in the mechanisms of wet AMD.
C1 [Yao, Jiaqi] Nanjing Med Univ, Nanjing Childrens Hosp, Dept Ophthalmol, Nanjing 210029, Jiangsu, Peoples R China.
   [Liu, Xiaoyi; Yang, Qin; Zhuang, Min; Wang, Feng; Chen, Xi; Hang, Hui; Zhang, Weiwei; Liu, Qinghuai] Nanjing Med Univ, Affiliated Hosp 1, Dept Ophthalmol, Nanjing 210029, Jiangsu, Peoples R China.
C3 Nanjing Medical University; Nanjing Medical University
RP Liu, QH (通讯作者)，Nanjing Med Univ, Affiliated Hosp 1, Dept Ophthalmol, 300 Guangzhou Rd, Nanjing 210029, Jiangsu, Peoples R China.
EM liuqh@njmu.edu.cn
OI Liu, Qinghuai/0000-0003-1605-1964
FU National Basic Research Program of China (973 Program) [2011CB510200)];
   National Natural Science Foundation of China [30973257, 81170855]
FX This work was supported by grants from National Basic Research Program
   of China (973 Program, No. 2011CB510200), National Natural Science
   Foundation of China (No. 30973257 and No. 81170855).
CR Ahmad MF, 2008, J MOL BIOL, V382, P812, DOI 10.1016/j.jmb.2008.07.068
   Bennett KL, 2011, J PROTEOMICS, V74, P151, DOI 10.1016/j.jprot.2010.10.002
   Bevers LM, 2006, NEPHROL DIAL TRANSPL, V21, P3443, DOI 10.1093/ndt/gfl443
   Biswas A, 2008, BIOCHEM J, V409, P771, DOI 10.1042/BJ20071006
   Bouhenni RA, 2011, EXP EYE RES, V92, P67, DOI 10.1016/j.exer.2010.11.004
   Chien MH, 2009, CARCINOGENESIS, V30, P2005, DOI 10.1093/carcin/bgp244
   Chowdhury UR, 2010, INVEST OPHTH VIS SCI, V51, P4921, DOI 10.1167/iovs.10-5531
   Crabb JW, 2002, P NATL ACAD SCI USA, V99, P14682, DOI 10.1073/pnas.222551899
   Cryan LM, 2008, PROTEOM CLIN APPL, V2, P762, DOI 10.1002/prca.200780094
   De S, 2007, ARCH OPHTHALMOL-CHIC, V125, P641, DOI 10.1001/archopht.125.5.641
   Ding XY, 2009, PROG RETIN EYE RES, V28, P1, DOI 10.1016/j.preteyeres.2008.10.001
   Dinu V, 2007, GENET EPIDEMIOL, V31, P224, DOI 10.1002/gepi.20204
   Diz AP, 2009, ELECTROPHORESIS, V30, P2967, DOI 10.1002/elps.200900210
   Duan XM, 2008, MOL VIS, V14, P370
   Elsner J, 1998, EUR J IMMUNOL, V28, P2152, DOI 10.1002/(SICI)1521-4141(199807)28:07<2152::AID-IMMU2152>3.3.CO;2-7
   Ennis S, 2010, EUR J HUM GENET, V18, P15, DOI 10.1038/ejhg.2009.113
   Escoffier P, 2010, J PROTEOME RES, V9, P789, DOI 10.1021/pr9006602
   Funding M, 2005, ACTA OPHTHALMOL SCAN, V83, P31, DOI 10.1111/j.1600-0420.2005.00381.x
   Gong Y, 2009, NEPHROL DIAL TRANSPL, V24, P3108, DOI 10.1093/ndt/gfp231
   Hanash S, 2003, NATURE, V422, P226, DOI 10.1038/nature01514
   Isas JM, 2010, INVEST OPHTH VIS SCI, V51, P1304, DOI 10.1167/iovs.09-4207
   Izzotti A, 2010, J PROTEOME RES, V9, P4831, DOI 10.1021/pr1005372
   Kase S, 2010, BLOOD, V115, P3398, DOI 10.1182/blood-2009-01-197095
   Katta S, 2009, J GENET, V88, P425, DOI 10.1007/s12041-009-0064-4
   Kim TW, 2012, J PROTEOME RES, V11, P4034, DOI 10.1021/pr300080s
   Lambooij AC, 2003, INVEST OPHTH VIS SCI, V44, P2192, DOI 10.1167/iovs.02-0410
   Lechner M, 2001, BIOCHEM J, V356, P129, DOI 10.1042/0264-6021:3560129
   Liu AX, 2006, BIOL REPROD, V75, P414, DOI 10.1095/biolreprod.105.049379
   Meehan S, 2007, J MOL BIOL, V372, P470, DOI 10.1016/j.jmb.2007.06.060
   Nagaraj RH, 2005, ANN NY ACAD SCI, V1043, P158, DOI 10.1196/annals.1333.020
   Nakata K, 2005, EXP EYE RES, V80, P821, DOI 10.1016/j.exer.2004.12.011
   Nicolas MG, 1996, EXP EYE RES, V62, P211, DOI 10.1006/exer.1996.0026
   Noma H, 2008, EYE, V22, P42, DOI 10.1038/sj.eye.6702498
   Ousman SS, 2007, NATURE, V448, P474, DOI 10.1038/nature05935
   Richardson MR, 2010, MOL VIS, V16, P2376
   Richardson MR, 2009, MOL VIS, V15, P2740
   Roche M, 2008, FEBS LETT, V582, P1783, DOI 10.1016/j.febslet.2008.04.057
   Stahl A, 2009, GRAEF ARCH CLIN EXP, V247, P767, DOI 10.1007/s00417-009-1058-x
   Stastna M, 2011, PROTEOME SCI, V9, DOI 10.1186/1477-5956-9-8
   Su YY, 2012, DNA CELL BIOL, V31, P856, DOI 10.1089/dna.2011.1318
   Sun Hang, 2009, Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi, V25, P348
   Sun ZL, 2007, BBA-PROTEINS PROTEOM, V1774, P764, DOI 10.1016/j.bbapap.2007.04.001
   Takeda A, 2009, NATURE, V460, P225, DOI 10.1038/nature08151
   Tinahones F, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0008213
   Tong JP, 2006, AM J OPHTHALMOL, V141, P456, DOI 10.1016/j.ajo.2005.10.012
   Wu J, 2009, CHEM RES TOXICOL, V22, P668, DOI 10.1021/tx800406z
   Yao JQ, 2010, J BIOMED SCI, V17, DOI 10.1186/1423-0127-17-30
   Yaung J, 2007, MOL VIS, V13, P566
   Zou Hai-dong, 2005, Zhonghua Yan Ke Za Zhi, V41, P15
NR 49
TC 33
Z9 34
U1 1
U2 13
PU WILEY-V C H VERLAG GMBH
PI WEINHEIM
PA POSTFACH 101161, 69451 WEINHEIM, GERMANY
SN 1862-8346
EI 1862-8354
J9 PROTEOM CLIN APPL
JI Proteom. Clin. Appl.
PD AUG
PY 2013
VL 7
IS 7-8
SI SI
BP 550
EP 560
DI 10.1002/prca.201200012
PG 11
WC Biochemical Research Methods; Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology
GA 263FQ
UT WOS:000327792800009
PM 23418058
DA 2022-11-30
ER

PT J
AU Theodossiadis, GP
   Grigoropoulos, VG
   Emfietzoglou, I
   Nikolaidis, P
   Panagiotidis, D
   Vergados, I
   Theodossiadis, PG
AF Theodossiadis, G. P.
   Grigoropoulos, V. G.
   Emfietzoglou, I.
   Nikolaidis, P.
   Panagiotidis, D.
   Vergados, I.
   Theodossiadis, P. G.
TI Evolution of retinal pigment epithelium detachment after photodynamic
   therapy for choroidal neovascularization in age-related macular
   degeneration
SO EUROPEAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE age-related macular degeneration; choroidal neovascularization; pigment
   epithelium detachment; photodynamic therapy; fluorescein angiography;
   optical coherence tomography
ID VERTEPORFIN; TEAR
AB PURPOSE. To report a case of pigment epithelium detachment (PED) which appeared after photodynamic therapy (PDT) and was followed up for 50 months.
   METHODS. Case report.
   RESULTS. A 71-year-old woman with occult choroidal neovascular membrane due to age-related macular degeneration (ARMD) developed PED 48 hours after PDT. The patient was studied with fluorescein angiography (FA) and optical coherence tomography (OCT). Fluorescein angiographic evidence of PED remained essentially unchanged during the follow-up period of 50 months. Although OCT initially gave clear evidence of PED, in the last 12 months of follow-up the PED appears to have resolved.
   CONCLUSIONS. Photodynamic treatment could be involved in the occurrence of PED in occult choroidal neovascular membrane due to ARMD. In this particular case OCT could be considered since it offers useful information in the pretreatment and the post-treatment follow-up period.
C1 Henry Dunant Hosp, Dept Ophthalmol 2, Athens, Greece.
   Univ Athens, Dept Ophthalmol 2, GR-10679 Athens, Greece.
C3 Henry Dunant Hospital; National & Kapodistrian University of Athens
RP Theodossiadis, GP (通讯作者)，13 Likiou St, Athens, Greece.
EM george@hellasnet.gr
CR Arnold J, 2001, AM J OPHTHALMOL, V131, P541
   Miller JW, 1999, ARCH OPHTHALMOL-CHIC, V117, P1161
   Pece A, 2001, RETINA-J RET VIT DIS, V21, P661, DOI 10.1097/00006982-200112000-00017
   SAHEL J, 1986, KLIN MONATSBL AUGENH, V189, P123, DOI 10.1055/s-2008-1050768
   Schmidt-Erfurth U, 2000, SURV OPHTHALMOL, V45, P195, DOI 10.1016/S0039-6257(00)00158-2
   Srivastava SK, 2002, RETINA-J RET VIT DIS, V22, P669, DOI 10.1097/00006982-200210000-00027
   Theodossiadis GP, 2003, GRAEF ARCH CLIN EXP, V241, P13, DOI 10.1007/s00417-002-0579-3
NR 7
TC 1
Z9 1
U1 0
U2 0
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 1120-6721
EI 1724-6016
J9 EUR J OPHTHALMOL
JI Eur. J. Ophthalmol.
PD MAY-JUN
PY 2006
VL 16
IS 3
BP 491
EP 494
DI 10.1177/112067210601600325
PG 4
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 067MG
UT WOS:000239306400025
PM 16761259
DA 2022-11-30
ER

PT J
AU Wang, BW
   Wang, L
   Gu, SJ
   Yu, YK
   Huang, HX
   Mo, KL
   Xu, H
   Zeng, FZ
   Xiao, YC
   Peng, LL
   Liu, CQ
   Cao, N
   Liu, YZ
   Yuan, J
   Ouyang, H
AF Wang, Bowen
   Wang, Li
   Gu, Sijie
   Yu, Yankun
   Huang, Huaxing
   Mo, Kunlun
   Xu, He
   Zeng, Fanzhu
   Xiao, Yichen
   Peng, Lulu
   Liu, Chunqiao
   Cao, Nan
   Liu, Yizhi
   Yuan, Jin
   Ouyang, Hong
TI D609 protects retinal pigmented epithelium as a potential therapy for
   age-related macular degeneration
SO SIGNAL TRANSDUCTION AND TARGETED THERAPY
LA English
DT Article
ID AMYLOID BETA-PEPTIDE; OXIDATIVE STRESS; AUTOPHAGY; RPE; METALLOTHIONEIN;
   INACTIVATION; CONSUMPTION; MODELS; IMPACT; DAMAGE
AB Accumulated oxidative damage may lead to irreversible retinal pigmented epithelium (RPE) cell death, which is considered to be the primary cause of dry age-related macular degeneration (AMD), leading to blindness in the elderly. However, an effective therapy for this disease is lacking. Here, we described a robust high-content screening procedure with a library of 814 protective compounds and found that D609 strongly protected RPE cells from sodium iodate (SI)-induced oxidative cell death and prolonged their healthy survival. D609 effectively attenuated excessive reactive oxygen species (ROS) and prevented severe mitochondrial loss due to oxidative stress in the RPE cells. Surprisingly, the potent antioxidative effects of D609 were not achieved through its own reducibility but were primarily dependent on its ability to increase the expression of metallothionein. The injection of this small water-soluble molecule also showed an explicit protective effect of the RPE layer in an SI-induced AMD mouse model. These findings suggested that D609 could serve as a novel antioxidative protector of RPE cells both in vitro and in vivo and unveiled a novel antioxidative mechanism of D609, which may ultimately have clinical applications for the treatment of AMD.
C1 [Wang, Bowen; Wang, Li; Gu, Sijie; Yu, Yankun; Huang, Huaxing; Mo, Kunlun; Xiao, Yichen; Peng, Lulu; Liu, Chunqiao; Liu, Yizhi; Yuan, Jin; Ouyang, Hong] Sun Yat Sen Univ, Zhongshan Ophthalm Ctr, State Key Lab Ophthalmol, Guangzhou 510623, Peoples R China.
   [Xu, He; Zeng, Fanzhu; Cao, Nan] Sun Yat Sen Univ, Affiliated Hosp 5, Zhongshan Sch Med, Program Stem Cells & Regenerat Med, Guangzhou 5100809, Peoples R China.
C3 Sun Yat Sen University; Sun Yat Sen University
RP Liu, YZ; Yuan, J; Ouyang, H (通讯作者)，Sun Yat Sen Univ, Zhongshan Ophthalm Ctr, State Key Lab Ophthalmol, Guangzhou 510623, Peoples R China.
EM yizhi_liu@aliyun.com; yuanjincornea@126.com; ouyhong3@mail.sysu.edu.cn
RI liu, yi/GXE-9662-2022; Xiao, Yichen/GZS-8066-2022
OI Wang, Li/0000-0002-4007-6654; Ouyang, Hong/0000-0002-7622-7733
FU National Key Research and Development (R&D) Program of China
   [2016YFA0101700]; National Natural Science Foundation of China
   [81700805, 81622012, 81870633]; Fundamental Research Funds for the
   Central Universities [17ykjc28]; Guangdong Innovative and
   Entrepreneurial Research Team Program [2016ZT06S029]
FX The National Key Research and Development (R&D) Program of China
   (2016YFA0101700). National Natural Science Foundation of China
   (81700805, 81622012 and 81870633). Fundamental Research Funds for the
   Central Universities (17ykjc28). Fundamental Research Funds of the State
   Key Laboratory of Ophthalmology. Guangdong Innovative and
   Entrepreneurial Research Team Program (2016ZT06S029).
CR Adibhatla RM, 2012, NEUROCHEM RES, V37, P671, DOI 10.1007/s11064-011-0659-z
   Ambati J, 2012, NEURON, V75, P26, DOI 10.1016/j.neuron.2012.06.018
   Ansari MA, 2006, FREE RADICAL BIO MED, V41, P1694, DOI 10.1016/j.freeradbiomed.2006.09.002
   Bakhtiar R, 2002, J CHROMATOGR B, V768, P325, DOI 10.1016/S1570-0232(01)00611-0
   Bharti K, 2012, PLOS GENET, V8, DOI 10.1371/journal.pgen.1002757
   Bhutto I, 2012, MOL ASPECTS MED, V33, P295, DOI 10.1016/j.mam.2012.04.005
   Cai JY, 2000, PROG RETIN EYE RES, V19, P205, DOI 10.1016/S1350-9462(99)00009-9
   Cavalca E, 2018, ANN NEUROL, V83, P418, DOI 10.1002/ana.25161
   Chen DS, 2016, BBA-REV CANCER, V1865, P228, DOI 10.1016/j.bbcan.2016.03.003
   da Cruz L, 2018, NAT BIOTECHNOL, V36, P1, DOI 10.1038/nbt.4114
   Datta S, 2017, PROG RETIN EYE RES, V60, P201, DOI 10.1016/j.preteyeres.2017.03.002
   Dehghan E, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-02394-3
   Di Foggia V, 2014, J EXP MED, V211, P2617, DOI 10.1084/jem.20140317
   Eshaq RS, 2014, REDOX BIOL, V2, P661, DOI 10.1016/j.redox.2014.04.006
   Fields M, 2016, CELLS-BASEL, V5, DOI 10.3390/cells5040044
   Flaxman SR, 2017, LANCET GLOB HEALTH, V5, pE1221, DOI 10.1016/S2214-109X(17)30393-5
   Gulbins A, 2018, MOL PSYCHIATR, V23, P2324, DOI 10.1038/s41380-018-0090-9
   Handa JT, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-11262-1
   Hanus J, 2016, CELL DEATH DISCOV, V2, DOI 10.1038/cddiscovery.2016.54
   Hanus J, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.478
   Holz FG, 2014, J CLIN INVEST, V124, P1430, DOI 10.1172/JCI71029
   Iorio E, 2010, CANCER RES, V70, P2126, DOI 10.1158/0008-5472.CAN-09-3833
   Joshi G, 2005, FREE RADICAL BIO MED, V38, P1023, DOI 10.1016/j.freeradbiomed.2004.12.027
   Jung HS, 2013, J CONTROL RELEASE, V172, P1092, DOI 10.1016/j.jconrel.2013.09.031
   Kim JW, 2008, GENE DEV, V22, P3147, DOI 10.1101/gad.1700108
   Lopez-Otin C, 2013, CELL, V153, P1194, DOI 10.1016/j.cell.2013.05.039
   Lu L, 2006, J CELL PHYSIOL, V206, P119, DOI 10.1002/jcp.20439
   Macarron R, 2011, NAT REV DRUG DISCOV, V10, P188, DOI 10.1038/nrd3368
   Maminishkis Arvydas, 2010, J Vis Exp, DOI 10.3791/2032
   Mehat MS, 2018, OPHTHALMOLOGY, V125, P1765, DOI 10.1016/j.ophtha.2018.04.037
   Mitter SK, 2014, AUTOPHAGY, V10, P1989, DOI 10.4161/auto.36184
   Nie BM, 2017, CELL REP, V18, P624, DOI 10.1016/j.celrep.2016.12.062
   Nowak JZ, 2006, PHARMACOL REP, V58, P353
   Riazi-Esfahani Mohammad, 2017, J Ophthalmic Vis Res, V12, P424, DOI 10.4103/jovr.jovr_182_17
   Ruttkay-Nedecky B, 2013, INT J MOL SCI, V14, P6044, DOI 10.3390/ijms14036044
   Simo R, 2010, J BIOMED BIOTECHNOL, DOI 10.1155/2010/190724
   Spadaro F, 2006, EUR J IMMUNOL, V36, P3277, DOI 10.1002/eji.200635927
   Sultana R, 2004, FREE RADICAL RES, V38, P449, DOI 10.1080/1071576042000206478
   Tiwari BS, 2002, PLANT PHYSIOL, V128, P1271, DOI 10.1104/pp.010999
   Ueda M, 2019, J BIOL CHEM, V294, P11259, DOI 10.1074/jbc.RA119.007851
   Wang BW, 2019, INVEST OPHTH VIS SCI, V60, P2836, DOI 10.1167/iovs.19-27072
   Wang L, 2013, J PHYSIOL-LONDON, V591, P5005, DOI 10.1113/jphysiol.2013.262667
   Wang YB, 2013, J NEUROSCI, V33, P18880, DOI 10.1523/JNEUROSCI.3293-13.2013
   Wani A, 2019, AUTOPHAGY, V15, P1810, DOI 10.1080/15548627.2019.1596476
   Xia LM, 2017, CANCER CELL, V31, P653, DOI 10.1016/j.ccell.2017.04.005
   Yu DY, 2001, PROG RETIN EYE RES, V20, P175, DOI 10.1016/S1350-9462(00)00027-6
   Zhang C, 2018, ARTERIOSCL THROM VAS, V38, P2691, DOI 10.1161/ATVBAHA.118.311689
   Zhao C, 2011, J CLIN INVEST, V121, P369, DOI 10.1172/JCI44303
   Zheng SR, 2008, J AM SOC NEPHROL, V19, P2077, DOI 10.1681/ASN.2007080967
   Zhou DH, 2001, J PHARMACOL EXP THER, V298, P103
NR 50
TC 10
Z9 10
U1 2
U2 8
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2095-9907
EI 2059-3635
J9 SIGNAL TRANSDUCT TAR
JI Signal Transduct. Target. Ther.
PD MAR 4
PY 2020
VL 5
IS 1
AR 20
DI 10.1038/s41392-020-0122-1
PG 12
WC Biochemistry & Molecular Biology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology
GA KR9BM
UT WOS:000517908600001
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Christen, WG
   Chew, EY
AF Christen, William G.
   Chew, Emily Y.
TI Does long-term aspirin use increase the risk of neovascular age-related
   macular degeneration?
SO EXPERT OPINION ON DRUG SAFETY
LA English
DT Review
DE age-related macular degeneration; aspirin; observational studies;
   randomized trials
ID MASSIVE INTRAOCULAR HEMORRHAGE; BEAVER DAM EYE; CARDIOVASCULAR-DISEASE;
   UNITED-STATES; LASER PHOTOCOAGULATION; VISUAL IMPAIRMENT; MACULOPATHY;
   OLDER; ANTICOAGULANTS; ADULTS
AB Introduction: Aspirin is used regularly for rheumatoid pain management and cardioprotection. However, aspirin has also been associated with significant adverse events, such as cerebral and gastrointestinal bleeding. Recent findings from several observational epidemiologic studies indicate that regular aspirin use may also be associated with increased risks of some forms of age-related macular degeneration (AMD).
   Areas covered: In this report, we review recent findings from observational epidemiologic studies suggesting a possible adverse effect of regular aspirin use in AMD, and in particular, neovascular AMD. These findings are considered in light of the relative strengths and limitations of observational studies and randomized trials.
   Expert opinion: While the findings are important and warrant further investigation, the inherent limitations of observational studies, most notably uncontrolled confounding, preclude an interpretation of causality. Alternatively, the most reliable evidence with which to evaluate the effects of regular aspirin use in AMD will derive from well-designed randomized trials of sufficient size and duration. Such information is unlikely to alter current recommendations for persons at high risk of cardiovascular disease, but should help clarify the benefit-to-risk ratio of regular aspirin use in the large majority of individuals at low-to-moderate risk.
C1 [Christen, William G.] Harvard Univ, Brigham & Womens Hosp, Sch Med, Div Prevent Med,Dept Med, Boston, MA 02115 USA.
   [Chew, Emily Y.] NEI, NIH, Div Epidemiol & Clin Applicat, Bethesda, MD 20892 USA.
C3 Harvard University; Brigham & Women's Hospital; Harvard Medical School;
   National Institutes of Health (NIH) - USA; NIH National Eye Institute
   (NEI)
RP Christen, WG (通讯作者)，Harvard Univ, Brigham & Womens Hosp, Sch Med, Div Prevent Med,Dept Med, Boston, MA 02115 USA.
EM wchristen@rics.bwh.harvard.edu
FU NATIONAL EYE INSTITUTE [ZIAEY000485] Funding Source: NIH RePORTER
CR Ajani UA, 2006, AM J PREV MED, V30, P74, DOI 10.1016/j.amepre.2005.08.042
   Ambati J, 2012, NEURON, V75, P26, DOI 10.1016/j.neuron.2012.06.018
   Anand R, 2000, OPHTHALMOLOGY, V107, P2224
   Baigent C, 2002, BMJ-BRIT MED J, V324, P71, DOI 10.1136/bmj.324.7329.71
   BLOOME MA, 1978, AM J OPHTHALMOL, V86, P630, DOI 10.1016/0002-9394(78)90181-2
   BULLIMORE MA, 1991, INVEST OPHTH VIS SCI, V32, P2020
   Christen WG, 2001, ARCH OPHTHALMOL-CHIC, V119, P1143, DOI 10.1001/archopht.119.8.1143
   Christen WG, 2009, OPHTHALMOLOGY, V116, P2386, DOI 10.1016/j.ophtha.2009.05.031
   de Jong PTVM, 2012, OPHTHALMOLOGY, V119, P112, DOI 10.1016/j.ophtha.2011.06.025
   Duan YK, 2007, OPHTHALMOLOGY, V114, P732, DOI 10.1016/j.ophtha.2006.07.045
   ELBABA F, 1986, OPHTHALMOLOGY, V93, P1581
   FEMAN SS, 1972, J AMER MED ASSOC, V220, P1354, DOI 10.1001/jama.220.10.1354
   Fernandez AB, 2012, OPHTHALMOLOGY, V119, P765, DOI 10.1016/j.ophtha.2011.09.044
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P532
   Hennekens CH, 2013, AM J MED, V126, P373, DOI 10.1016/j.amjmed.2012.12.013
   Hirvela H, 1996, OPHTHALMOLOGY, V103, P871, DOI 10.1016/S0161-6420(96)30593-9
   Hu CC, 2010, STROKE, V41, P613, DOI 10.1161/STROKEAHA.109.571000
   Ikram MK, 2012, STROKE, V43, P1681, DOI 10.1161/STROKEAHA.112.654632
   Kiernan DF, 2010, RETINA-J RET VIT DIS, V30, P1573, DOI 10.1097/IAE.0b013e3181e2266d
   KINGHAM JD, 1988, NEW ENGL J MED, V318, P1126
   Klein BEK, 2012, JAMA-J AM MED ASSOC, V308, P2469, DOI 10.1001/jama.2012.65406
   Klein BEK, 2003, OPHTHALMOLOGY, V110, P644, DOI 10.1016/S0161-6420(02)01935-8
   KLEIN ML, 1991, JAMA-J AM MED ASSOC, V266, P2279
   Klein R, 2001, ARCH OPHTHALMOL-CHIC, V119, P1354
   LEWIS H, 1988, GRAEF ARCH CLIN EXP, V226, P59, DOI 10.1007/BF02172720
   Liew G, 2013, JAMA INTERN MED, V173, P258, DOI 10.1001/jamainternmed.2013.1583
   MAGUIRE MG, 1990, ARCH OPHTHALMOL-CHIC, V108, P825
   MAGUIRE MG, 1986, ARCH OPHTHALMOL-CHIC, V104, P503
   Pignone M, 2007, AM J PREV MED, V32, P403, DOI 10.1016/j.amepre.2007.01.010
   Popescu ML, 2011, INVEST OPHTH VIS SCI, V52, P7168, DOI 10.1167/iovs.11-7564
   Ramulu PY, 2009, OPHTHALMOLOGY, V116, P1846, DOI 10.1016/j.ophtha.2009.03.033
   Rothman KJ, 1986, MODERN EPIDEMIOLOGY
   Rothwell PM, 2012, LANCET, V379, P1602, DOI 10.1016/S0140-6736(11)61720-0
   Rudnicka AR, 2010, EYE, V24, P1199, DOI 10.1038/eye.2010.8
   Snow K K, 1999, Ophthalmic Epidemiol, V6, P125, DOI 10.1076/opep.6.2.125.1558
   STEVENSON L, 1992, SURV OPHTHALMOL, V37, P149, DOI 10.1016/0039-6257(92)90085-8
   Sun C, 2009, OPHTHALMOLOGY, V116, P1913, DOI 10.1016/j.ophtha.2009.03.046
   Tan JSL, 2008, BRIT J OPHTHALMOL, V92, P509, DOI 10.1136/bjo.2007.131706
   Tilanus MAD, 2000, GRAEF ARCH CLIN EXP, V238, P482, DOI 10.1007/PL00007887
   US FOOD and Drug Administration (FDA), ASP QUEST ANSW
   West SK, 2002, ARCH OPHTHALMOL-CHIC, V120, P774
   Willis JR, 2012, ARCH OPHTHALMOL-CHIC, V130, P329, DOI 10.1001/archopthalmol.2011.1773
   Wong TY, 2007, OPHTHALMOLOGY, V114, P86, DOI 10.1016/j.ophtha.2006.06.039
   Wong TY, 2006, ANN INTERN MED, V145, P98, DOI 10.7326/0003-4819-145-2-200607180-00007
NR 44
TC 13
Z9 13
U1 0
U2 18
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 1474-0338
EI 1744-764X
J9 EXPERT OPIN DRUG SAF
JI Expert Opin. Drug Saf.
PD APR
PY 2014
VL 13
IS 4
BP 421
EP 429
DI 10.1517/14740338.2014.889680
PG 9
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA AD2ET
UT WOS:000333047200003
PM 24547895
DA 2022-11-30
ER

PT J
AU Abalain, JH
   Carre, JL
   Leglise, D
   Robinet, A
   Legall, F
   Meskar, A
   Floch, HH
   Colin, J
AF Abalain, JH
   Carre, JL
   Leglise, D
   Robinet, A
   Legall, F
   Meskar, A
   Floch, HH
   Colin, J
TI Is age-related macular degeneration associated with serum lipoprotein
   and lipoparticle levels?
SO CLINICA CHIMICA ACTA
LA English
DT Article
DE retina; ARMD; lipoparticles; apolipoproteins; Apo E; Apo C-III
ID APOLIPOPROTEIN-E POLYMORPHISM; RISK-FACTORS; CARDIOVASCULAR-DISEASE;
   CIGARETTE-SMOKING; MACULOPATHY; PLASMA; CHOLESTEROL; GENE; PARTICLES;
   EYE
AB Objective: The etiology of age-related macular degeneration (ARMD) is poorly understood. Risk factors for cardiovascular disease have been thought to be associated with ARMD. Our purpose was to measure the concentration of atherogenic apolipoproteins (apo) and lipoparticles in serum from ARMD patients. Methods: We analyzed lipids, lipoparticles and apolipoproteins concentrations in 84 unrelated patients with ARMD and compared the results with those of age- and sex-matched control subjects (n = 62). Serum lipid concentrations were determined enzymatically; apolipoproteins levels by kinetic nephelometry and lipoparticles by electroimmunodiffusion. Results: No difference in total cholesterol, triglycerides, phospholipids, high- and low-density lipoprotein-cholesterol (IHDL-C and LDL-C) concentrations were observed between ARMD patients and controls. Apo E and LpE non-B concentrations were found to be higher in serum from patients than in serum from controls. In contrast, Apo C-III and LpC-III non-B concentrations were lower in serum from patients than in serum from controls. Conclusions: The main differences observed between ARMD patients and controls are in Apo E, Apo C-III, LpC-III non-B and LpE non-B concentrations. These lipoparticles belong to the HDL family, which is considered to consist of anti-atherogenic lipoproteins. These results raise the possibility that cardiovascular risk factors are not associated with ARMD. Furthermore, we can hypothesize that ARMD development is linked to perturbations of HDL metabolism. (C) 2002 Elsevier Science B.V. All rights reserved.
C1 Fac Med, Biochim Lab, F-29200 Brest, France.
   CHU Brest, Hop Morvan, Serv Ophthalmol, F-29200 Brest, France.
C3 Universite de Bretagne Occidentale; Universite de Franche-Comte; CHU
   Brest; Universite de Bretagne Occidentale
RP Abalain, JH (通讯作者)，Fac Med, Biochim Lab, 22 Ave Camille Desmoulins, F-29200 Brest, France.
EM jean-herve.abalain@univ-brest.fr
CR ALAUPOVI.P, 1972, BIOCHIM BIOPHYS ACTA, V260, P689, DOI 10.1016/0005-2760(72)90018-5
   ALBRINK MJ, 1963, AM J OPHTHALMOL, V55, P709, DOI 10.1016/0002-9394(63)92428-0
   Allikmets R, 1999, HUM GENET, V104, P449, DOI 10.1007/s004390050986
   Allikmets R, 1997, SCIENCE, V277, P1805, DOI 10.1126/science.277.5333.1805
   Bickeboller H, 1997, AM J HUM GENET, V60, P439
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   BLUMENKRANZ MS, 1986, OPHTHALMOLOGY, V93, P552
   BOERWINKLE E, 1988, AM J HUM GENET, V42, P104
   BRESSLER SB, 1992, ARCH OPHTHALMOL-CHIC, V110, P827, DOI 10.1001/archopht.1992.01080180099035
   CAZZOLATO G, 1983, CLIN CHIM ACTA, V135, P203, DOI 10.1016/0009-8981(83)90136-5
   Christen WG, 1996, JAMA-J AM MED ASSOC, V276, P1147, DOI 10.1001/jama.276.14.1147
   Delcourt C, 1999, OPHTHALMOLOGY, V106, P215, DOI 10.1016/S0161-6420(99)90059-3
   Egloff M, 1999, ANN BIOL CLIN-PARIS, V57, P561
   FERRIS FL, 1983, AM J EPIDEMIOL, V118, P132, DOI 10.1093/oxfordjournals.aje.a113624
   FRIEDEWALD WT, 1972, CLIN CHEM, V18, P499
   GILLERY P, 1993, CLIN CHEM, V39, P503
   HALLMAN DM, 1991, AM J HUM GENET, V49, P338
   HEIBA IM, 1994, GENET EPIDEMIOL, V11, P51, DOI 10.1002/gepi.1370110106
   HIXSON JE, 1990, J LIPID RES, V31, P545
   KAHN HA, 1977, AM J EPIDEMIOL, V106, P33, DOI 10.1093/oxfordjournals.aje.a112429
   Klaver CCW, 1998, AM J HUM GENET, V63, P200, DOI 10.1086/301901
   Klein R, 1997, OPHTHALMOLOGY, V104, P1804, DOI 10.1016/S0161-6420(97)30023-2
   KLEIN R, 1993, OPHTHALMOLOGY, V100, P406
   LANDOLFO V, 1978, OPHTHALMOLOGICA, V177, P248, DOI 10.1159/000308775
   Luc G, 1997, ATHEROSCLEROSIS, V131, P257, DOI 10.1016/S0021-9150(97)00053-1
   MAHLEY RW, 1984, J LIPID RES, V25, P1277
   PARRA HJ, 1992, ARTERIOSCLER THROMB, V12, P701, DOI 10.1161/01.ATV.12.6.701
   PARRA HJ, 1990, CLIN CHEM, V36, P1431
   PAULEIKHOFF D, 1990, OPHTHALMOLOGY, V97, P171
   PUCHOIS P, 1985, ANN BIOL CLIN-PARIS, V43, P831
   SANDERS TAB, 1993, AM J CLIN NUTR, V57, P428, DOI 10.1093/ajcn/57.3.428
   SCHACHTER F, 1994, NAT GENET, V6, P29, DOI 10.1038/ng0194-29
   Seddon JM, 1996, JAMA-J AM MED ASSOC, V276, P1141, DOI 10.1001/jama.276.14.1141
   Seddon JM, 1997, AM J OPHTHALMOL, V123, P199, DOI 10.1016/S0002-9394(14)71036-0
   Shachter NS, 2001, CURR OPIN LIPIDOL, V12, P297, DOI 10.1097/00041433-200106000-00009
   Smith W, 1998, ARCH OPHTHALMOL-CHIC, V116, P583, DOI 10.1001/archopht.116.5.583
   Souied EH, 1998, AM J OPHTHALMOL, V125, P353, DOI 10.1016/S0002-9394(99)80146-9
   SUGIUCHI H, 1995, CLIN CHEM, V41, P717
   TSANG NCK, 1992, DOC OPHTHALMOL, V81, P387
   Weisgraber Karl H., 1994, Current Opinion in Lipidology, V5, P110, DOI 10.1097/00041433-199404000-00007
   YANNUZZI LA, 1992, ARCH OPHTHALMOL-CHIC, V110, P1701
NR 41
TC 37
Z9 38
U1 0
U2 0
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0009-8981
EI 1873-3492
J9 CLIN CHIM ACTA
JI Clin. Chim. Acta
PD DEC
PY 2002
VL 326
IS 1-2
BP 97
EP 104
AR PII S0009-8981(02)00288-7
DI 10.1016/S0009-8981(02)00288-7
PG 8
WC Medical Laboratory Technology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Medical Laboratory Technology
GA 618TW
UT WOS:000179434200008
PM 12417100
DA 2022-11-30
ER

PT J
AU Aichi, R
   Nagai, N
   Ohkoshi, K
   Ozawa, Y
AF Aichi, Risa
   Nagai, Norihiro
   Ohkoshi, Kishiko
   Ozawa, Yoko
TI Impact of Treating Age-Related Macular Degeneration before Visual
   Function Is Impaired
SO JOURNAL OF CLINICAL MEDICINE
LA English
DT Article
DE age-related macular degeneration; anti-vascular endothelial growth
   factor treatment; visual outcome; Kaplan-Meier survival analysis
ID RANIBIZUMAB; HEMORRHAGE; OUTCOMES
AB Visual outcomes of age-related macular degeneration (AMD) have substantially improved via anti-vascular endothelial growth factor (anti-VEGF) therapy. However, the treatment effects vary among individuals. Medical charts of 104 eyes (104 patients) with AMD, treated with anti-VEGF drugs and followed up for 12-36 months, were retrospectively analyzed. Logistic regression analyses adjusted for age showed that eyes with an initial best-corrected visual acuity (BCVA) < 0.3 in the logarithm of the minimum angle of resolution (logMAR) were a positive predictor (odds ratio = 3.172; 95% confidence interval [CI] = 1.029-9.783; p = 0.045), and the presence of initial fibrovascular pigment epithelial detachment (PED) was a negative predictor (0.222; 0.078-0.637; p = 0.005) of maintained or improved BCVA at the final visit. Kaplan-Meier survival analysis showed that eyes with an initial BCVA < 0.3 (Cox hazard ratio = 2.947; 95% CI = 1.047-8.289; p = 0.041) had a better survival rate after adjusting for age when failure was defined as a BCVA reduction >= 0.2 of logMAR. Eyes with an initial BCVA < 0.3 belonged to younger patients; more frequently had subretinal fluid as an exudative change; and less frequently had intraretinal fluid, submacular hemorrhage, and fibrovascular PED. Initiating anti-VEGF treatment before BCVA declines and advanced lesions develop would afford better visual outcomes for AMD eyes in the real-world clinic, although further analyses are required.
C1 [Aichi, Risa; Nagai, Norihiro; Ohkoshi, Kishiko; Ozawa, Yoko] St Lukes Int Hosp, Dept Ophthalmol, Chuo Ku, 9-1 Akashi Cho, Tokyo 1048560, Japan.
   [Nagai, Norihiro; Ozawa, Yoko] St Lukes Int Univ, Chuo Ku, 9-1 Akashi Cho, Tokyo 1048560, Japan.
   [Nagai, Norihiro; Ozawa, Yoko] Keio Univ, Sch Med, Dept Ophthalmol, Shinjuku Ku, 35 Shinanomachi, Tokyo 1608582, Japan.
C3 St. Luke's International Hospital; St. Luke's International Hospital;
   Keio University
RP Ozawa, Y (通讯作者)，St Lukes Int Hosp, Dept Ophthalmol, Chuo Ku, 9-1 Akashi Cho, Tokyo 1048560, Japan.; Ozawa, Y (通讯作者)，St Lukes Int Univ, Chuo Ku, 9-1 Akashi Cho, Tokyo 1048560, Japan.; Ozawa, Y (通讯作者)，Keio Univ, Sch Med, Dept Ophthalmol, Shinjuku Ku, 35 Shinanomachi, Tokyo 1608582, Japan.
EM ozawa@a5.keio.jp
OI Ozawa, Yoko/0000-0003-4797-5705
CR [Anonymous], 2018, LANCET, V392, P1090, DOI 10.1016/S0140-6736(18)32291-8
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Fung AE, 2007, AM J OPHTHALMOL, V143, P566, DOI 10.1016/j.ajo.2007.01.028
   GLATT H, 1982, AM J OPHTHALMOL, V94, P762, DOI 10.1016/0002-9394(82)90301-4
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Gupta OP, 2010, OPHTHALMOLOGY, V117, P2134, DOI 10.1016/j.ophtha.2010.02.032
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Jacob J, 2017, INT J OPHTHALMOL-CHI, V10, P81, DOI 10.18240/ijo.2017.01.14
   Khanani AM, 2018, RETINA-J RET VIT DIS, V38, P2103, DOI 10.1097/IAE.0000000000002195
   Lalwani GA, 2009, AM J OPHTHALMOL, V148, P43, DOI 10.1016/j.ajo.2009.01.024
   Lee K, 2020, RETINA-J RET VIT DIS, V40, P2304, DOI 10.1097/IAE.0000000000002762
   Mattson MP, 2006, NAT REV NEUROSCI, V7, P278, DOI 10.1038/nrn1886
   Minami S, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-017-18255-4
   Nagai N, 2020, J CLIN MED, V9, DOI 10.3390/jcm9051391
   Nagai N, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-47738-9
   Nagai N, 2016, SCI REP-UK, V6, DOI 10.1038/srep29619
   Ohji M, 1998, ARCH OPHTHALMOL-CHIC, V116, P1326, DOI 10.1001/archopht.116.10.1326
   Rayess N, 2015, AM J OPHTHALMOL, V159, P3, DOI 10.1016/j.ajo.2014.09.011
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Schmidt-Erfurth U, 2016, PROG RETIN EYE RES, V50, P1, DOI 10.1016/j.preteyeres.2015.07.007
   Suzuki M, 2016, AM J OPHTHALMOL, V166, P52, DOI 10.1016/j.ajo.2016.03.024
   Suzuki M, 2014, BRIT J OPHTHALMOL, V98, P1186, DOI 10.1136/bjophthalmol-2013-304670
   Thoongsuwan S, 2022, OPHTHALMOL THER, V11, P739, DOI 10.1007/s40123-022-00471-5
   TOTH CA, 1991, ARCH OPHTHALMOL-CHIC, V109, P723, DOI 10.1001/archopht.1991.01080050139046
NR 24
TC 0
Z9 0
U1 0
U2 0
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2077-0383
J9 J CLIN MED
JI J. Clin. Med.
PD OCT
PY 2022
VL 11
IS 19
AR 5726
DI 10.3390/jcm11195726
PG 11
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA 5G3UE
UT WOS:000866926500001
PM 36233594
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Sacconi, R
   Vella, G
   Battista, M
   Borrelli, E
   Balasubramanian, S
   Querques, L
   Bandello, F
   Querques, G
AF Sacconi, Riccardo
   Vella, Giovanna
   Battista, Marco
   Borrelli, Enrico
   Balasubramanian, Siva
   Querques, Lea
   Bandello, Francesco
   Querques, Giuseppe
TI Choroidal Vascularity Index in Different Cohorts of Dry Age-Related
   Macular Degeneration
SO TRANSLATIONAL VISION SCIENCE & TECHNOLOGY
LA English
DT Article
DE age-related macular degeneration (AMD); choroidal vascularity index;
   CVI; geographic atrophy (GA); reticular pseudodrusen (RPD)
ID OPTICAL COHERENCE TOMOGRAPHY; RETICULAR PSEUDODRUSEN; GEOGRAPHIC
   ATROPHY; CHORIOCAPILLARIS; EYES; CLASSIFICATION; BINARIZATION; FLOW
AB Purpose: The purpose of this study was to investigate the choroidal luminal and interstitial stromal alterations using choroidal vascularity index (CVI) among different cohorts of dry age-related macular degeneration (dAMD) compared to healthy subjects. Methods: Four distinct cohorts were collected: three different cohorts of patients with dAMD (i.e. drusen, reticular pseudodrusen [RPD], and geographic atrophy [GA]) and an age-matched cohort of healthy subjects (controls). CVI (the ratio between the luminal choroidal area [LCA] and the total choroidal area [TCA]) was calculated in the subfoveal 1000 mu m area. Results: One hundred twenty eyes (from 120 patients) were included (30 eyes in each cohort). The mean age was 76.6 +/- 7.1 years. No statistical differences were disclosed in terms of age, axial length, and central macular thickness among study groups. TCA showed a different distribution among the four cohorts (P = 0.003), mainly due to the LCA changes (P = 0.001). Interestingly, CVI showed a different distribution among the four cohorts (P < 0.001). RPD showed a lower CVI in comparison to controls (P = 0.040), whereas GA showed a lower CVI in comparison to drusen, RPD, and controls (P = 0.001, P = 0.046, and P < 0.001, respectively). Conclusions: Different cohorts of dAMD are characterized by different impairments of the choroidal vascular and stromal components, reflecting different degrees of AMD severity. Translational Relevance: CVI provides insights for better understanding the pathogenesis of AMD.
C1 [Sacconi, Riccardo; Battista, Marco; Borrelli, Enrico; Bandello, Francesco; Querques, Giuseppe] Univ Vita Salute San Raffaele, Sch Med, Milan, Italy.
   [Sacconi, Riccardo; Vella, Giovanna; Battista, Marco; Borrelli, Enrico; Querques, Lea; Bandello, Francesco; Querques, Giuseppe] IRCCS San Raffaele Sci Inst, Div Head & Neck, Ophthalmol Unit, Milan, Italy.
   [Vella, Giovanna] Univ Pisa, Dept Surg Med Mol Pathol & Crit Area, Ophthalmol, Pisa, Italy.
   [Balasubramanian, Siva] Adv Clin, San Francisco, CA USA.
   [Balasubramanian, Siva] Genentech Inc, San Francisco, CA 94080 USA.
C3 Vita-Salute San Raffaele University; Vita-Salute San Raffaele
   University; IRCCS Ospedale San Raffaele; University of Pisa; Roche
   Holding; Genentech
RP Querques, G (通讯作者)，Univ Vita Salute, Dept Ophthalmol, IRCCS Osped San Raffaele, Via Olgettina 60, I-20132 Milan, Italy.
EM giuseppe.querques@hotmail.it
OI Sacconi, Riccardo/0000-0003-2891-2012
CR Anger EM, 2004, EXP EYE RES, V78, P1117, DOI 10.1016/j.exer.2004.01.011
   Berenberg TL, 2012, RETINA-J RET VIT DIS, V32, P25, DOI 10.1097/IAE.0b013e3182150483
   Biesemeier A, 2014, NEUROBIOL AGING, V35, P2562, DOI 10.1016/j.neurobiolaging.2014.05.003
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Borrelli E, 2018, AM J OPHTHALMOL, V196, P34, DOI 10.1016/j.ajo.2018.08.014
   Branchini LA, 2013, OPHTHALMOLOGY, V120, P1901, DOI 10.1016/j.ophtha.2013.01.066
   Breher K, 2020, TRANSL VIS SCI TECHN, V9, DOI 10.1167/tvst.9.11.8
   Chew EY, 2014, JAMA OPHTHALMOL, V132, P272, DOI 10.1001/jamaophthalmol.2013.6636
   Corbelli E, 2017, INVEST OPHTH VIS SCI, V58, P5201, DOI 10.1167/iovs.17-22508
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Friedman E, 2008, AM J OPHTHALMOL, V146, P348, DOI 10.1016/j.ajo.2008.05.017
   Giannaccare G, 2020, RETINA-J RET VIT DIS, V40, P960, DOI 10.1097/IAE.0000000000002459
   Iovino C, 2020, J CLIN MED, V9, DOI 10.3390/jcm9020595
   Li ML, 2018, RETINA-J RET VIT DIS, V38, P1937, DOI 10.1097/IAE.0000000000002182
   McLeod DS, 2009, INVEST OPHTH VIS SCI, V50, P4982, DOI 10.1167/iovs.09-3639
   Nassisi M, 2019, BRIT J OPHTHALMOL, V103, P911, DOI 10.1136/bjophthalmol-2018-312643
   Nesper PL, 2017, AM J OPHTHALMOL, V174, P42, DOI 10.1016/j.ajo.2016.10.005
   Querques G, 2014, RETINA-J RET VIT DIS, V34, P321, DOI 10.1097/IAE.0b013e3182993df1
   Rabiolo A, 2019, RETINA-J RET VIT DIS, V39, P2205, DOI 10.1097/IAE.0000000000002283
   Rabiolo A, 2017, CLIN OPHTHALMOL, V11, P1707, DOI 10.2147/OPTH.S130165
   Sacconi R, 2020, GRAEF ARCH CLIN EXP, V258, P2163, DOI 10.1007/s00417-020-04769-7
   Sacconi R, 2021, BRIT J OPHTHALMOL, V105, P222, DOI 10.1136/bjophthalmol-2020-316054
   Sacconi R, 2021, BRIT J OPHTHALMOL, V105, P97, DOI 10.1136/bjophthalmol-2019-315800
   Sacconi R, 2018, OPHTHALMOL RETINA, V2, P1097, DOI 10.1016/j.oret.2018.04.016
   Sacconi R, 2018, RETINA-J RET VIT DIS, V38, P2350, DOI 10.1097/IAE.0000000000001873
   Sacconi R, 2018, BRIT J OPHTHALMOL, V102, P1684, DOI 10.1136/bjophthalmol-2017-311240
   Sacconi R, 2017, OPHTHALMOL THER, V6, P69, DOI 10.1007/s40123-017-0086-6
   Sonoda S, 2015, AM J OPHTHALMOL, V159, P1123, DOI 10.1016/j.ajo.2015.03.005
   Sonoda S, 2014, INVEST OPHTH VIS SCI, V55, P3893, DOI 10.1167/iovs.14-14447
   Thulliez M, 2019, OPHTHALMOL RETINA, V3, P478, DOI 10.1016/j.oret.2019.01.024
   Velaga SB, 2020, RETINA-J RET VIT DIS, V40, P612, DOI 10.1097/IAE.0000000000002667
   Wei X, 2017, RETINA-J RET VIT DIS, V37, P1120, DOI 10.1097/IAE.0000000000001312
   Zhou H, 2020, OPHTHALMOL RETINA, V4, P204, DOI 10.1016/j.oret.2019.09.012
   Zweifel SA, 2010, OPHTHALMOLOGY, V117, P1775, DOI 10.1016/j.ophtha.2010.01.027
NR 34
TC 3
Z9 3
U1 0
U2 0
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 2164-2591
J9 TRANSL VIS SCI TECHN
JI Transl. Vis. Sci. Technol.
PD OCT
PY 2021
VL 10
IS 12
AR 26
DI 10.1167/tvst.10.12.26
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA XM9GY
UT WOS:000729127100003
PM 34665234
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Lee, SJ
   Lee, CS
   Koh, HJ
AF Lee, Sung Jun
   Lee, Christopher Seungkyu
   Koh, Hvoung Jun
TI Posterior Vitreomacular Adhesion and Risk of Exudative Age-related
   Macular Degeneration: Paired Eye Study
SO AMERICAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID VITREOUS DETACHMENT; CHOROIDAL NEOVASCULARIZATION; PHARMACOLOGICAL
   VITREOLYSIS; MICROPLASMIN; TRACTION; THERAPY; DISEASE
AB PURPOSE: To evaluate posterior vitreomacular adhesion as a risk factor for choroidal neovascularization (CNV) in age-related macular degeneration (AMD).
   DESIGN: Retrospective, observational case series.
   METHODS. We retrospectively reviewed optical coherence tomography (OCT) and fluorescein angiography (FA) of 251 consecutive patients with unilateral exudative AMD. Fellow eyes had no sign of exudative AMD. Vitreomacular adhesion was defined when posterior hyaloid line attached to inner retinal surface was seen in OCT. We compared the incidence of posterior vitreomacular adhesion between the 2 eyes and the association between CNV location and vitreomacular adhesion.
   RESULTS: We found posterior vitreomacular adhesion in 56 patients (22.3%), and 3 cases in which it was present in both eyes. CNV was mostly present in eyes with vitreomacular adhesion (44/53, 83%), and rarely found in eyes without vitreomacular adhesion (6/53, 11.3%; P = .0007). The location of vitreomacular adhesion was always observed over the area of the CNV in exudative eyes (50/50).
   CONCLUSIONS: Posterior vitreomacular adhesion is associated with CNV in AMD. Chronic vitreomacular traction may be a risk factor for the development of exudative AMD. (Am J Ophthalmol 2009;147:621-626. (C) 2009 by Elsevier Inc. All rights reserved.)
C1 [Lee, Sung Jun; Lee, Christopher Seungkyu; Koh, Hvoung Jun] Yonsei Univ, Coll Med, Dept Ophthalmol, Inst Vis Res, Seoul 120752, South Korea.
C3 Yonsei University; Yonsei University Health System
RP Koh, HJ (通讯作者)，Yonsei Univ, Coll Med, Dept Ophthalmol, Inst Vis Res, Seodaemungu Shinchondong 134, Seoul 120752, South Korea.
EM hjkoh@yuhs.ac
OI Koh, Hyoung Jun/0000-0002-5932-8516; Lee,
   Christopher/0000-0001-5054-9470
CR Anand R, 2000, OPHTHALMOLOGY, V107, P2224
   Chuo JY, 2006, AM J OPHTHALMOL, V142, P931, DOI 10.1016/j.ajo.2006.08.002
   Gross-Jendroska M, 1998, AUST NZ J OPHTHALMOL, V26, P311, DOI 10.1111/j.1442-9071.1998.tb01335.x
   Hayreh SS, 2004, OPHTHALMOLOGICA, V218, P333, DOI 10.1159/000079476
   Ikeda T, 2000, ACTA OPHTHALMOL SCAN, V78, P460, DOI 10.1034/j.1600-0420.2000.078004460.x
   Klein R, 2004, AM J OPHTHALMOL, V137, P486, DOI 10.1016/j.ajo.2003.11.069
   Krebs I, 2007, AM J OPHTHALMOL, V144, P741, DOI 10.1016/j.ajo.2007.07.024
   LAMBERT HM, 1992, AM J OPHTHALMOL, V113, P257, DOI 10.1016/S0002-9394(14)71576-4
   Meyer CH, 2001, GRAEF ARCH CLIN EXP, V239, P325, DOI 10.1007/s004170100259
   Mojana F, 2008, AM J OPHTHALMOL, V146, P218, DOI 10.1016/j.ajo.2008.04.027
   Nowak JZ, 2006, PHARMACOL REP, V58, P353
   Ondes F, 2000, JPN J OPHTHALMOL, V44, P91, DOI 10.1016/S0021-5155(99)00174-4
   Quaranta-El Maftouhi M, 2006, EUR J OPHTHALMOL, V16, P134
   Sakuma T, 2005, INVEST OPHTH VIS SCI, V46, P3295, DOI 10.1167/iovs.04-1517
   Schmidt JC, 2006, BRIT J OPHTHALMOL, V90, P1361, DOI 10.1136/bjo.2006.094201
   Schulze S, 2008, ACTA OPHTHALMOL, V86, P470, DOI 10.1111/j.1755-3768.2008.01210.x
   Sebag J, 2008, GRAEF ARCH CLIN EXP, V246, P329, DOI 10.1007/s00417-007-0743-x
   Sebag J, 2007, GRAEF ARCH CLIN EXP, V245, P576, DOI 10.1007/s00417-006-0394-3
   Sebag J, 2004, GRAEF ARCH CLIN EXP, V242, P690, DOI 10.1007/s00417-004-0980-1
   Weber-Krause Brigitte, 1996, Ophthalmologe, V93, P660, DOI 10.1007/s003470050054
NR 20
TC 82
Z9 87
U1 0
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0002-9394
EI 1879-1891
J9 AM J OPHTHALMOL
JI Am. J. Ophthalmol.
PD APR
PY 2009
VL 147
IS 4
BP 621
EP 626
DI 10.1016/j.ajo.2008.10.003
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 424KW
UT WOS:000264566600010
PM 19159862
DA 2022-11-30
ER

PT J
AU Melville, H
   Carpiniello, M
   Hollis, K
   Staffaroni, A
   Golestaneh, N
AF Melville, Heather
   Carpiniello, Matthew
   Hollis, Kia
   Staffaroni, Andrew
   Golestaneh, Nady
TI Stem cells: a new paradigm for disease modeling and developing therapies
   for age-related macular degeneration
SO JOURNAL OF TRANSLATIONAL MEDICINE
LA English
DT Review
DE Age-related macular degeneration; RPE; Stem cells
ID RETINAL-PIGMENT EPITHELIUM; ENDOTHELIAL GROWTH-FACTOR; MITOCHONDRIAL-DNA
   HAPLOGROUPS; GENE-EXPRESSION; BRUCHS MEMBRANE; CHOROIDAL
   NEOVASCULARIZATION; HUMAN RPE; FACTOR-B; TRANSPLANTATION; DRUSEN
AB Age-related macular degeneration (AMD) is the leading cause of blindness in people over age 55 in the U. S. and the developed world. This condition leads to the progressive impairment of central visual acuity. There are significant limitations in the understanding of disease progression in AMD as well as a lack of effective methods of treatment. Lately, there has been considerable enthusiasm for application of stem cell biology for both disease modeling and therapeutic application. Human embryonic stem cells and induced pluripotent stem cells (iPSCs) have been used in cell culture assays and in vivo animal models. Recently a clinical trial was approved by FDA to investigate the safety and efficacy of the human embryonic stem cell-derived retinal pigment epithelium (RPE) transplantation in sub-retinal space of patients with dry AMD These studies suggest that stem cell research may provide both insight regarding disease development and progression, as well as direction for therapeutic innovation for the millions of patients afflicted with AMD.
C1 [Melville, Heather; Carpiniello, Matthew; Hollis, Kia; Staffaroni, Andrew; Golestaneh, Nady] Georgetown Univ, Sch Med, Washington, DC 20057 USA.
   [Golestaneh, Nady] Georgetown Univ, Sch Med, Dept Ophthalmol, Washington, DC 20057 USA.
   [Golestaneh, Nady] Georgetown Univ, Sch Med, Dept Neurol, Washington, DC 20057 USA.
   [Golestaneh, Nady] Georgetown Univ, Sch Med, Dept Biochem & Mol & Cellular Biol, Washington, DC 20057 USA.
C3 Georgetown University; Georgetown University; Georgetown University;
   Georgetown University
RP Golestaneh, N (通讯作者)，Georgetown Univ, Sch Med, 3900 Reservoir Rd, Washington, DC 20057 USA.
EM Ncg8@georgetown.edu
RI Giannini, Heather/R-5176-2019
OI Giannini, Heather/0000-0002-8979-3806
CR Abdelsalam A, 1999, SURV OPHTHALMOL, V44, P1, DOI 10.1016/S0039-6257(99)00072-7
   AIELLO LP, 1994, NEW ENGL J MED, V331, P1480, DOI 10.1056/NEJM199412013312203
   Anderson DH, 2002, AM J OPHTHALMOL, V134, P411, DOI 10.1016/S0002-9394(02)01624-0
   Atala A, 2000, WORLD J UROL, V18, P364, DOI 10.1007/s003450000152
   Baird PN, 2004, INVEST OPHTH VIS SCI, V45, P1311, DOI 10.1167/iovs.03-1121
   Bessho K, 2005, RETINA-J RET VIT DIS, V25, P981, DOI 10.1097/00006982-200512000-00005
   Binder S, 2004, INVEST OPHTH VIS SCI, V45, P4151, DOI 10.1167/iovs.04-0118
   Binder S, 2007, PROG RETIN EYE RES, V26, P516, DOI 10.1016/j.preteyeres.2007.02.002
   Binder S, 2011, BRIT J OPHTHALMOL, V95, P441, DOI 10.1136/bjo.2009.171926
   BOK D, 1993, J CELL SCI, P189
   Boulton M, 2001, EYE, V15, P384, DOI 10.1038/eye.2001.141
   Buchholz DE, 2009, STEM CELLS, V27, P2427, DOI 10.1002/stem.189
   Bull ND, 2011, STEM CELLS, V29, P1170, DOI 10.1002/stem.676
   Buschini E, 2011, PROG NEUROBIOL, V95, P14, DOI 10.1016/j.pneurobio.2011.05.011
   Cai JY, 2000, PROG RETIN EYE RES, V19, P205, DOI 10.1016/S1350-9462(99)00009-9
   Carr AJ, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0008152
   Chen W, 2010, P NATL ACAD SCI USA, V107, P7401, DOI 10.1073/pnas.0912702107
   Cherry ABC, 2012, CELL, V148, P1110, DOI 10.1016/j.cell.2012.02.031
   Chin MH, 2009, CELL STEM CELL, V5, P111, DOI 10.1016/j.stem.2009.06.008
   Cideciyan AV, 2004, HUM MOL GENET, V13, P525, DOI 10.1093/hmg/ddh048
   Couch SM, 2011, SEMIN OPHTHALMOL, V26, P114, DOI 10.3109/08820538.2011.577130
   Crafoord S, 1999, ACTA OPHTHALMOL SCAN, V77, P247, DOI 10.1034/j.1600-0420.1999.770301.x
   Cvekl A, 2010, HEREDITY, V105, P135, DOI 10.1038/hdy.2010.16
   da Cruz L, 2007, PROG RETIN EYE RES, V26, P598, DOI 10.1016/j.preteyeres.2007.07.001
   DAVIS AA, 1995, INVEST OPHTH VIS SCI, V36, P955
   Del Priore LV, 2006, PROG RETIN EYE RES, V25, P539, DOI 10.1016/j.preteyeres.2006.08.001
   Dewan A, 2006, SCIENCE, V314, P989, DOI 10.1126/science.1133807
   Djojosubroto M, 2009, INVEST OPHTH VIS SCI, V50, P5975, DOI 10.1167/iovs.08-3091
   Doi A, 2009, NAT GENET, V41, P1350, DOI 10.1038/ng.471
   Du HJ, 2011, SEMIN OPHTHALMOL, V26, P216, DOI 10.3109/08820538.2011.577498
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   FARKAS TG, 1971, AM J OPHTHALMOL, V71, P1196, DOI 10.1016/0002-9394(71)90963-9
   FARKAS TG, 1971, AM J OPHTHALMOL, V71, P1206, DOI 10.1016/0002-9394(71)90964-0
   FEENEYBURNS L, 1987, INVEST OPHTH VIS SCI, V28, P1138
   Ferrara N, 2006, RETINA-J RET VIT DIS, V26, P859, DOI 10.1097/01.iae.0000242842.14624.e7
   Ferrara N, 2010, NAT MED, V16, P1107, DOI 10.1038/nm1010-1107
   FERRIS FL, 1984, ARCH OPHTHALMOL-CHIC, V102, P1640
   Fraga MF, 2009, CURR OPIN IMMUNOL, V21, P446, DOI 10.1016/j.coi.2009.04.003
   Gehrs KM, 2006, ANN MED, V38, P450, DOI 10.1080/07853890600946724
   Ghosh F, 2011, TISSUE ENG PT A, V17, P1675, DOI 10.1089/ten.tea.2008.0450
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   GOURAS P, 1984, AN ACAD BRAS CIENC, V56, P431
   Gullapalli VK, 2005, EXP EYE RES, V80, P235, DOI 10.1016/j.exer.2004.09.006
   Hageman GS, 1999, FASEB J, V13, P477, DOI 10.1096/fasebj.13.3.477
   Haines JL, 2006, INVEST OPHTH VIS SCI, V47, P329, DOI 10.1167/iovs.05-0116
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Hirami Y, 2009, NEUROSCI LETT, V458, P126, DOI 10.1016/j.neulet.2009.04.035
   Hjelmeland LM, 2011, INVEST OPHTH VIS SCI, V52, P1622, DOI 10.1167/iovs.10-6765
   Hu QR, 2010, STEM CELLS, V28, P1981, DOI 10.1002/stem.531
   Hughes AE, 2006, NAT GENET, V38, P1173, DOI 10.1038/ng1890
   Hunter A, 2012, INVEST OPHTH VIS SCI, V53, P2089, DOI 10.1167/iovs.11-8449
   Idelson M, 2009, CELL STEM CELL, V5, P396, DOI 10.1016/j.stem.2009.07.002
   ISHIBASHI T, 1986, AM J OPHTHALMOL, V101, P342, DOI 10.1016/0002-9394(86)90830-5
   Jakobsdottir J, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002199
   Johnson LR, 2000, IEEE ANN HIST COMPUT, V22, P70
   Jones MM, 2007, ARCH OPHTHALMOL-CHIC, V125, P1235, DOI 10.1001/archopht.125.9.1235
   Kaiser RS, 2001, ARCH OPHTHALMOL-CHIC, V119, P826
   Kam JH, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013127
   Kim K, 2010, NATURE, V467, P285, DOI 10.1038/nature09342
   Klimanskaya I, 2004, CLONING STEM CELLS, V6, P217, DOI 10.1089/1536230042323420
   Kokkinaki M, 2011, STEM CELLS, V29, P825, DOI 10.1002/stem.635
   Lamba DA, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008763
   Leu ST, 2002, EXP EYE RES, V74, P141, DOI 10.1006/exer.2001.1112
   Leveziel N, 2011, OPHTHALMOLOGICA, V226, DOI 10.1159/000328981
   Levine JP, 2009, RETINA-J RET VIT DIS, V29, P1074, DOI 10.1097/IAE.0b013e3181b09443
   Liao JL, 2010, HUM MOL GENET, V19, P4229, DOI 10.1093/hmg/ddq341
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Limb GA, 2008, BRIT MED BULL, V85, P47, DOI 10.1093/bmb/ldn008
   Lister R, 2011, NATURE, V471, P68, DOI 10.1038/nature09798
   Lu B, 2009, STEM CELLS, V27, P2126, DOI 10.1002/stem.149
   Luke M, 2009, GRAEF ARCH CLIN EXP, V247, P745, DOI 10.1007/s00417-009-1050-5
   Lund RD, 2006, CLONING STEM CELLS, V8, P189, DOI 10.1089/clo.2006.8.189
   MacLaren RE, 2007, EYE, V21, P1352, DOI 10.1038/sj.eye.6702842
   MacLaren RE, 2006, NATURE, V444, P203, DOI 10.1038/nature05161
   MacLaren RE, 2007, OPHTHALMOLOGY, V114, P561, DOI 10.1016/j.ophtha.2006.06.049
   MacNeil A, 2007, STEM CELLS, V25, P2430, DOI 10.1634/stemcells.2007-0035
   Maherali N, 2007, CELL STEM CELL, V1, P55, DOI 10.1016/j.stem.2007.05.014
   Maller JB, 2007, NAT GENET, V39, P1200, DOI 10.1038/ng2131
   Marchetti V, 2010, J CLIN INVEST, V120, P3012, DOI 10.1172/JCI42951
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Meyer JS, 2006, STEM CELLS, V24, P274, DOI 10.1634/stemcells.2005-0059
   Nakao S, 2012, INVEST OPHTH VIS SCI, V53, P4323, DOI 10.1167/iovs.11-9119
   Neale BM, 2010, P NATL ACAD SCI USA, V107, P7395, DOI 10.1073/pnas.0912019107
   Neeley WL, 2008, BIOMATERIALS, V29, P418, DOI 10.1016/j.biomaterials.2007.10.007
   NEGI A, 1984, ARCH OPHTHALMOL-CHIC, V102, P445
   Nowak JZ, 2006, PHARMACOL REP, V58, P353
   Ohi Y, 2011, NAT CELL BIOL, V13, P541, DOI 10.1038/ncb2239
   Ohji M, 2001, AM J OPHTHALMOL, V132, P888, DOI 10.1016/S0002-9394(01)01255-7
   Ohno-Matsui K, 2011, PROG RETIN EYE RES, V30, P217, DOI 10.1016/j.preteyeres.2011.02.004
   Ohta K, 2008, DEV GROWTH DIFFER, V50, P253, DOI [10.1111/j.1440-169x.2008.01006.x, 10.1111/j.1440-169X.2008.01006.x]
   Osakada F, 2008, NAT BIOTECHNOL, V26, P215, DOI 10.1038/nbt1384
   Osakada F, 2009, NAT PROTOC, V4, P811, DOI 10.1038/nprot.2009.51
   Parodi M, 2009, COCHRANE DATABASE SY, P3
   Polo JM, 2010, NAT BIOTECHNOL, V28, P848, DOI 10.1038/nbt.1667
   Redenti Stephen, 2008, J Ocul Biol Dis Infor, V1, P19, DOI 10.1007/s12177-008-9005-3
   Redenti S, 2009, BIOMATERIALS, V30, P3405, DOI 10.1016/j.biomaterials.2009.02.046
   Rein DB, 2009, ARCH OPHTHALMOL-CHIC, V127, P533, DOI 10.1001/archophthalmol.2009.58
   Robinton DA, 2012, NATURE, V481, P295, DOI 10.1038/nature10761
   Salero E, 2012, CELL STEM CELL, V10, P88, DOI 10.1016/j.stem.2011.11.018
   SanGiovanni JP, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005508
   Schmidt S, 2005, MOL VIS, V11, P941
   Schwartz SD, 2012, LANCET, V379, P713, DOI 10.1016/S0140-6736(12)60028-2
   Seddon JM, 2011, OPHTHALMOLOGY, V118, P1386, DOI 10.1016/j.ophtha.2010.12.020
   Sheridan C, 2004, GRAEF ARCH CLIN EXP, V242, P68, DOI 10.1007/s00417-003-0800-z
   Shin K, 2007, J BIOMED MATER RES A, V83A, P1076, DOI 10.1002/jbm.a.31437
   Sin HPY, 2012, ACTA OPHTHALMOL
   Spencer KL, 2008, HUM MOL GENET, V17, P971, DOI 10.1093/hmg/ddm369
   Spencer KL, 2007, HUM MOL GENET, V16, P1986, DOI 10.1093/hmg/ddm146
   Strauss O, 2005, PHYSIOL REV, V85, P845, DOI 10.1152/physrev.00021.2004
   Streilein JW, 2002, VISION RES, V42, P487, DOI 10.1016/S0042-6989(01)00185-7
   Suuronen T, 2007, BIOCHEM BIOPH RES CO, V357, P397, DOI 10.1016/j.bbrc.2007.03.135
   Swaroop A, 2009, ANNU REV GENOM HUM G, V10, P19, DOI 10.1146/annurev.genom.9.081307.164350
   Takahashi K, 2007, CELL, V131, P861, DOI 10.1016/j.cell.2007.11.019
   Takahashi K, 2006, CELL, V126, P663, DOI 10.1016/j.cell.2006.07.024
   Tamiya S, 2010, INVEST OPHTH VIS SCI, V51, P2755, DOI 10.1167/iovs.09-4725
   Tao S, 2007, LAB CHIP, V7, P695, DOI 10.1039/b618583e
   Tezel TH, 2004, INVEST OPHTH VIS SCI, V45, P3337, DOI 10.1167/iovs.04-0193
   Thomson JA, 1998, SCIENCE, V282, P1145, DOI 10.1126/science.282.5391.1145
   Tomita M, 2005, STEM CELLS, V23, P1579, DOI 10.1634/stemcells.2005-0111
   Treharne AJ, 2011, BRIT J OPHTHALMOL, V95, P768, DOI 10.1136/bjo.2010.184002
   Tucker BA, 2010, BIOMATERIALS, V31, P9, DOI 10.1016/j.biomaterials.2009.09.015
   Udar N, 2009, INVEST OPHTH VIS SCI, V50, P2966, DOI 10.1167/iovs.08-2646
   Van Meurs JC, 2003, AM J OPHTHALMOL, V136, P688, DOI 10.1016/S0002-9394(03)00384-2
   Velez-Montoya R, 2012, RETINA
   Veritti D, 2012, OPHTHALMOLOGICA, V227, P11, DOI 10.1159/000337154
   Vugler A, 2008, EXP NEUROL, V214, P347, DOI 10.1016/j.expneurol.2008.09.007
   Wang L, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010329
   Wei L, 2012, CELL REP, V2, P1151, DOI 10.1016/j.celrep.2012.10.013
   West EL, 2009, PROG BRAIN RES, V175, P3, DOI 10.1016/S0079-6123(09)17501-5
   Wimmers S, 2007, PROG RETIN EYE RES, V26, P263, DOI 10.1016/j.preteyeres.2006.12.002
   Yang ZL, 2006, SCIENCE, V314, P992, DOI 10.1126/science.1133811
   Yates JRW, 2007, NEW ENGL J MED, V357, P553, DOI 10.1056/NEJMoa072618
   Yoshida T, 2005, J CLIN INVEST, V115, P2793, DOI 10.1172/JCI24635
   Zhang XY, 1998, INVEST OPHTH VIS SCI, V39, P1021
NR 135
TC 24
Z9 24
U1 0
U2 45
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1479-5876
J9 J TRANSL MED
JI J. Transl. Med.
PD MAR 1
PY 2013
VL 11
AR 53
DI 10.1186/1479-5876-11-53
PG 9
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine
GA 109FZ
UT WOS:000316353100002
PM 23452406
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Williamson, JF
   McLure, CA
   Guymer, RH
   Baird, PN
   Millman, J
   Cantsilieris, S
   Dawkins, RL
AF Williamson, Joseph F.
   McLure, Craig A.
   Guymer, Robyn H.
   Baird, Paul N.
   Millman, John
   Cantsilieris, Stuart
   Dawkins, Roger L.
TI Almost total protection from age-related macular degeneration by
   haplotypes of the Regulators of Complement Activation
SO GENOMICS
LA English
DT Article
DE Age-related macular degeneration; Genetic predisposition to disease;
   Haplotypes; Ancestral haplotypes; Regulators of Complement Activation;
   Complement factor H
ID MAJOR HISTOCOMPATIBILITY COMPLEX; ANCESTRAL HAPLOTYPES; FACTOR-H; MHC
   HAPLOTYPES; RISK; GENES; AMD; VARIANTS; DISEASE; BLOCK
AB Age-related macular degeneration (AMD) is the leading cause of blindness in developed countries. It has been proposed that the polymorphism encoding Y402H (T1277C) in the complement factor H gene (CFH) is one of the main determinants of disease. We genotyped the polymorphism at a number of loci in the region encompassing the Regulators of Complement Activation (RCA) on chromosome 1, including T1277C SNP, in 187 patients and 146 controls. Haplotypes have been classified as protective (P) or susceptible (S) with respect to AMD. This included the identification of an S haplotype with a Tat 1277. The results show that no single locus should be assumed to be directly responsible for AMD, but rather argue for the existence of RCA haplotypes, which can be assigned meaningful predictive values for AMD. We conclude that the critical sequences are within a region 450 kb centromeric to 128 kb telomeric of CFH. (C) 2011 Elsevier Inc. All rights reserved.
C1 [Williamson, Joseph F.; McLure, Craig A.; Millman, John; Dawkins, Roger L.] CY OConnor ERADE Village Fdn, Canning Vale, WA, Australia.
   [Williamson, Joseph F.; McLure, Craig A.; Dawkins, Roger L.] Murdoch Univ, Div Hlth Sci, Murdoch, WA 6150, Australia.
   [McLure, Craig A.; Cantsilieris, Stuart] Genet Technol Ltd, Fitzroy, Vic, Australia.
   [McLure, Craig A.] Univ Melbourne, Dept Vet Sci, Melbourne, Vic 3000, Australia.
   [Guymer, Robyn H.; Baird, Paul N.] Univ Melbourne, Ctr Eye Res Australia, Melbourne, Vic 3000, Australia.
   [Dawkins, Roger L.] Univ Western Australia, Fac Med & Dent, Nedlands, WA 6009, Australia.
C3 Murdoch University; University of Melbourne; Centre for Eye Research
   Australia; University of Melbourne; University of Western Australia
RP Dawkins, RL (通讯作者)，CY OConnor ERADE Village, POB 5100, Canning Vale S, WA 6155, Australia.
EM rldawkins@cyo.edu.au
OI Guymer, Robyn/0000-0002-9441-4356; Baird, Paul/0000-0002-1305-3502
CR Alper CA, 2006, HUM IMMUNOL, V67, P73, DOI 10.1016/j.humimm.2005.11.006
   Anderson DH, 2010, PROG RETIN EYE RES, V29, P95, DOI 10.1016/j.preteyeres.2009.11.003
   Athanasiou Y, 2011, CLIN J AM SOC NEPHRO, V6, P1436, DOI 10.2215/CJN.09541010
   AWDEH ZL, 1983, P NATL ACAD SCI-BIOL, V80, P259, DOI 10.1073/pnas.80.1.259
   Baird PN, 2007, CLIN EXP OPHTHALMOL, V35, P194, DOI 10.1111/j.1442-9071.2007.01477.x
   Cattley SK, 2000, EUR J IMMUNOGENET, V27, P397, DOI 10.1046/j.1365-2370.2000.00226.x
   Dawkins R, 1999, IMMUNOL REV, V167, P275, DOI 10.1111/j.1600-065X.1999.tb01399.x
   DECORDOBA SR, 1985, J EXP MED, V161, P1189, DOI 10.1084/jem.161.5.1189
   DEGLIESPOSTI MA, 1992, HUM IMMUNOL, V34, P242, DOI 10.1016/0198-8859(92)90023-G
   DEGLIESPOSTI MA, 1992, IMMUNOGENETICS, V35, P355
   DEGLIESPOSTI MA, 1992, IMMUNOGENETICS, V36, P345
   Dinu V, 2007, GENET EPIDEMIOL, V31, P224, DOI 10.1002/gepi.20204
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Hughes AE, 2007, PLOS MED, V4, P1993, DOI 10.1371/journal.pmed.0040355
   Kaiser PK, 2007, INT J CLIN PRACT, V61, P501, DOI 10.1111/j.1742-1241.2007.01299.x
   Lester S, 2008, ANN RHEUM DIS, V67, P849, DOI 10.1136/ard.2007.075044
   Lotery A, 2007, HUM GENET, V122, P219, DOI 10.1007/s00439-007-0406-3
   Magnusson KP, 2006, PLOS MED, V3, P109, DOI 10.1371/journal.pmed.0030005
   Maller JB, 2007, NAT GENET, V39, P1200, DOI 10.1038/ng2131
   Milton RC, 2005, OPHTHALMOLOGY, V112, P533, DOI 10.1016/j.ophtha.2004.10.047
   RAUM D, 1984, J CLIN INVEST, V74, P449, DOI 10.1172/JCI111441
   Richardson AJ, 2007, MOL VIS, V13, P2148
   Romero V, 2007, BMC GENET, V8, DOI 10.1186/1471-2156-8-14
   Schaumberg DA, 2006, INVEST OPHTH VIS SCI, V47, P2336, DOI 10.1167/iovs.05-1456
   Spencer KL, 2007, HUM MOL GENET, V16, P1986, DOI 10.1093/hmg/ddm146
   Spencer KL, 2007, INVEST OPHTH VIS SCI, V48, P4277, DOI 10.1167/iovs.06-1427
   Williamson JF, 2008, HUM IMMUNOL, V69, P207, DOI 10.1016/j.humimm.2008.01.016
   Yunis EJ, 2003, TISSUE ANTIGENS, V62, P1, DOI 10.1034/j.1399-0039.2003.00098.x
NR 28
TC 3
Z9 3
U1 0
U2 4
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0888-7543
J9 GENOMICS
JI Genomics
PD DEC
PY 2011
VL 98
IS 6
BP 412
EP 421
DI 10.1016/j.ygeno.2011.08.002
PG 10
WC Biotechnology & Applied Microbiology; Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biotechnology & Applied Microbiology; Genetics & Heredity
GA 856SW
UT WOS:000297664700002
PM 21855625
OA Bronze, Green Published
DA 2022-11-30
ER

PT J
AU Yeung, L
   Lai, CC
   Chen, SN
   Cheng, CK
   Yang, CM
   Hsieh, YT
   Tsai, A
   Yang, CH
AF Yeung, Ling
   Lai, Chi-Chun
   Chen, San-Ni
   Cheng, Cheng-Kuo
   Yang, Chung-May
   Hsieh, Yi-Ting
   Tsai, Arslan
   Yang, Chang-Hao
TI Comparison of visual outcomes between therapy choices and subtypes of
   polypoidal choroidal vasculopathy (PCV) in Taiwan: a real-world study
SO SCIENTIFIC REPORTS
LA English
DT Article
AB Polypoidal choroidal vasculopathy (PCV) is a distinctive type of neovascular age-related macular degeneration prevalent in many Asian countries. However, there is still some controversy in how the subtypes of PCV are classified. This post-hoc study redefined the branching vascular network (BVN) and PCV subtypes through retrospective review of indocyanine green angiography (ICGA) and fluorescein angiography images from two observational studies (RENOWNED/REAL). Of the visual outcomes for each angiographic subtype and treatment pattern investigated, BVN was identified in 56.3% of PCV patients. The proportions and features of the re-defined PCV subtypes were 43.8%, 10.4%, and 45.8% for subtype A (without distinctive features of BVN), B (with BVN but no leakage), and C (with BVN and leakage), respectively. Subtype A had better visual outcomes when compared to subtype C. This possibly resulted from a better baseline visual acuity in subtype A. Moreover, combination therapy [photodynamic therapy plus anti-vascular endothelial growth factor (VEGF)] may lead to better visual improvement than mono-anti-VEGF treatment alone. This study provides the prevalence of PCV subtypes in Taiwan and may serve as a reference for PCV treatment strategies in a real-world setting, especially for the combination therapy and patients without distinctive features of BVN.
C1 [Yeung, Ling; Lai, Chi-Chun] Chang Gung Mem Hosp, Dept Ophthalmol, Keelung, Taiwan.
   [Lai, Chi-Chun] Chang Gung Mem Hosp, Dept Ophthalmol, Taoyuan, Taiwan.
   [Chen, San-Ni] Changhua Christian Hosp, Dept Ophthalmol, Changhua, Taiwan.
   [Cheng, Cheng-Kuo] Shin Kong Wu Ho Su Mem Hosp, Dept Ophthalmol, Taipei, Taiwan.
   [Tsai, Arslan] Novartis Taiwan, Clin Dev & Med Affairs, Taipei, Taiwan.
   [Yang, Chung-May; Hsieh, Yi-Ting; Yang, Chang-Hao] Natl Taiwan Univ Hosp, Sch Med, Dept Ophthalmol, 7 Zhongshan South Rd, Taipei 100, Taiwan.
C3 Chang Gung Memorial Hospital; Chang Gung Memorial Hospital; Changhua
   Christian Hospital; Shin Kong Wu Ho Su Memorial Hospital; National
   Taiwan University; National Taiwan University Hospital
RP Yang, CH (通讯作者)，Natl Taiwan Univ Hosp, Sch Med, Dept Ophthalmol, 7 Zhongshan South Rd, Taipei 100, Taiwan.
EM chyangoph@ntu.edu.tw
OI Lai, Chi-Chun/0000-0001-9547-7212; YANG, CHUNG-MAY/0000-0003-4082-420X;
   YANG, CHANG-HAO/0000-0002-4328-8716
FU Novartis Taiwan
FX Funding and support for this work was provided by Novartis Taiwan.
CR Cackett P, 2009, RETINA-J RET VIT DIS, V29, P187, DOI 10.1097/IAE.0b013e318188c839
   Chen SN, 2018, INT J OPHTHALMOL-CHI, V11, P1802, DOI 10.18240/ijo.2018.11.11
   Cheung CMG, 2018, OPHTHALMOLOGY, V125, P708, DOI 10.1016/j.ophtha.2017.11.019
   Cheung CMG, 2015, RETINA-J RET VIT DIS, V35, P1375, DOI 10.1097/IAE.0000000000000482
   Ciardella AP, 2004, SURV OPHTHALMOL, V49, P25, DOI 10.1016/j.survophthal.2003.10.007
   Coscas G, 2015, INVEST OPHTH VIS SCI, V56, P3187, DOI 10.1167/iovs.14-16236
   Coscas G, 2014, AM J OPHTHALMOL, V158, P309, DOI 10.1016/j.ajo.2014.05.004
   Honda S, 2014, OPHTHALMOLOGICA, V232, P92, DOI 10.1159/000360308
   Hsing-I Wang, 2018, 18 EURETINA C VIENN
   Huang CH, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-018-37384-y
   Inoue M, 2015, RETINA-J RET VIT DIS, V35, P2265, DOI 10.1097/IAE.0000000000000777
   Jang JW, 2019, RETINA-J RET VIT DIS, V39, P1995, DOI 10.1097/IAE.0000000000002259
   Jeong SY, 2017, BRIT J OPHTHALMOL, V101, P758, DOI 10.1136/bjophthalmol-2016-309144
   Kang HM, 2013, AM J OPHTHALMOL, V156, P652, DOI 10.1016/j.ajo.2013.05.038
   Kawamura A, 2013, ACTA OPHTHALMOL, V91, pe474, DOI 10.1111/aos.12110
   Koh A, 2017, JAMA OPHTHALMOL, V135, P1206, DOI 10.1001/jamaophthalmol.2017.4030
   Koh A, 2012, RETINA-J RET VIT DIS, V32, P1453, DOI 10.1097/IAE.0b013e31824f91e8
   Koh AHC, 2018, INVEST OPHTH VIS SCI, V59
   Lee WK, 2018, JAMA OPHTHALMOL, V136, P786, DOI 10.1001/jamaophthalmol.2018.1804
   Maruko I, 2007, AM J OPHTHALMOL, V144, P15, DOI 10.1016/j.ajo.2007.03.047
   Matsumiya W, 2013, BMC OPHTHALMOL, V13, DOI 10.1186/1471-2415-13-10
   Mori K, 2010, OPHTHALMOLOGY, V117, P928, DOI 10.1016/j.ophtha.2009.10.001
   Nakai S, 2017, OPHTHALMOLOGICA, V237, P123, DOI 10.1159/000455273
   Palkar AH, 2019, TAIWAN J OPHTHALMOL, V9, P72, DOI 10.4103/tjo.tjo_35_18
   Sho K, 2003, ARCH OPHTHALMOL-CHIC, V121, P1392, DOI 10.1001/archopht.121.10.1392
   SPAIDE RF, 1995, RETINA-J RET VIT DIS, V15, P100, DOI 10.1097/00006982-199515020-00003
   Tan CS, 2018, INVEST OPHTH VIS SCI, V59, P889, DOI 10.1167/iovs.17-22683
   Tan CSH, 2014, BRIT J OPHTHALMOL, V98, P1528, DOI 10.1136/bjophthalmol-2014-305059
   Tanaka K, 2017, BRIT J OPHTHALMOL, V101, P51, DOI 10.1136/bjophthalmol-2016-309264
   Tanaka K, 2011, INVEST OPHTH VIS SCI, V52, P7441, DOI 10.1167/iovs.11-7546
   Wakabayashi T, 2008, BRIT J OPHTHALMOL, V92, P936, DOI 10.1136/bjo.2007.132357
   Wong CW, 2016, PROG RETIN EYE RES, V53, P107, DOI 10.1016/j.preteyeres.2016.04.002
   YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001
   Yeung L, 2018, RETINA-J RET VIT DIS, V38, P263, DOI 10.1097/IAE.0000000000001556
   Yuzawa M, 2005, BRIT J OPHTHALMOL, V89, P602, DOI 10.1136/bjo.2004.049296
NR 35
TC 3
Z9 3
U1 1
U2 2
PU NATURE RESEARCH
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
SN 2045-2322
J9 SCI REP-UK
JI Sci Rep
PD JAN 11
PY 2021
VL 11
IS 1
AR 470
DI 10.1038/s41598-020-80731-1
PG 8
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA QV2UE
UT WOS:000627831200016
PM 33432090
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Kashani, AH
   Lebkowski, JS
   Hinton, DR
   Zhu, DH
   Faynus, MA
   Chen, SF
   Rahhal, FM
   Avery, RL
   Salehi-Had, H
   Chan, CT
   Palejwala, N
   Ingram, A
   Dang, W
   Lin, CM
   Mitra, D
   Martinez-Camarillo, JC
   Bailey, J
   Arnold, C
   Pennington, BO
   Rao, NA
   Johnson, LV
   Clegg, DO
   Humayun, MS
AF Kashani, Amir H.
   Lebkowski, Jane S.
   Hinton, David R.
   Zhu, Danhong
   Faynus, Mohamed A.
   Chen, Sanford
   Rahhal, Firas M.
   Avery, Robert L.
   Salehi-Had, Hani
   Chan, Clement
   Palejwala, Neal
   Ingram, April
   Dang, Wei
   Lin, Chih-Min
   Mitra, Debbie
   Martinez-Camarillo, Juan Carlos
   Bailey, Jeff
   Arnold, Cassidy
   Pennington, Britney O.
   Rao, Narsing
   Johnson, Lincoln, V
   Clegg, Dennis O.
   Humayun, Mark S.
TI Survival of an HLA-mismatched, bioengineered RPE implant in dry
   age-related macular degeneration
SO STEM CELL REPORTS
LA English
DT Article
ID RETINAL-PIGMENT EPITHELIUM; SUBRETINAL IMPLANTATION; TRANSPLANTATION;
   TRANSLOCATION; CELLS
AB Cell-based therapies face challenges, including poor cell survival, immune rejection, and integration into pathologic tissue. We conducted an open-label phase 1/2a clinical trial to assess the safety and preliminary efficacy of a subretinal implant consisting of a polarized monolayer of allogeneic human embryonic stem cell-derived retinal pigmented epithelium (RPE) cells in subjects with geographic atrophy (GA) secondary to dry age-related macular degeneration. Postmortem histology from one subject with very advanced disease shows the presence of donor RPE cells 2 years after implantation by immunoreactivity for RPE65 and donor-specific human leukocyte antigen (HLA) class I molecules. Markers of RPE cell polarity and phagocytosis suggest donor RPE function. Further histologic examination demonstrated CD34(+) structures beneath the implant and CD4(+), CD68(+), and FoxP3(+) cells in the tissue. Despite significant donor-host HLA mismatch, no clinical signs of retinitis, vitreitis, vasculitis, choroiditis, or serologic immune response were detected in the deceased subject or any other subject in the study. Subretinally implanted, HLA-mismatched donor RPE cells survive, express functional markers, and do not elicit clinically detectable intraocular inflammation or serologic immune responses even without long-term immunosuppression.
C1 [Kashani, Amir H.; Martinez-Camarillo, Juan Carlos] Johns Hopkins Univ, Wilmer Eye Inst, 600 N Wolfe St, Baltimore, MD 21087 USA.
   [Lebkowski, Jane S.; Faynus, Mohamed A.; Ingram, April; Bailey, Jeff; Arnold, Cassidy; Pennington, Britney O.; Johnson, Lincoln, V] Regenerat Patch Technol, 150 Gabarda Way, Portola Valley, CA 94028 USA.
   [Hinton, David R.; Zhu, Danhong] Univ Southern Calif, Keck Sch Med, Dept Pathol, 1441 Eastlake Ave,7503, Los Angeles, CA 90033 USA.
   [Faynus, Mohamed A.; Bailey, Jeff; Arnold, Cassidy; Pennington, Britney O.; Clegg, Dennis O.] Univ Calif Santa Barbara, Ctr Stem Cell Biol & Engn, Neurosci Res Inst, Mail Code 5060, Santa Barbara, CA 93016 USA.
   [Chen, Sanford] Orange Cty Retina Med Grp, 1200 N Tustin Ave,Suite 140, Santa Ana, CA 92705 USA.
   [Rahhal, Firas M.] Retina Vitreous Associates Med Grp, 9001 Wilshire Blvd,Suite 301, Beverly Hills, CA 90211 USA.
   [Avery, Robert L.] California Retina Consultants, 525 E Micheltorena St, Santa Barbara, CA 93103 USA.
   [Salehi-Had, Hani] Retina Associates Southern Calif, 7777 Edinger Ave,Suite 234, Huntington Beach, CA 92647 USA.
   [Chan, Clement] Southern Calif Desert Retina Consultants, 36-949 Cook St,Suite 101, Palm Desert, CA 92211 USA.
   [Palejwala, Neal] Retinal Consultants Arizona, 15401 North 29th Ave, Phoenix, AZ 85053 USA.
   [Dang, Wei; Lin, Chih-Min] City Hope Natl Med Ctr, Beckman Res Inst, Ctr Biomed & Genet, 1500 East Duarte Rd, Duarte, CA 91010 USA.
   [Hinton, David R.; Mitra, Debbie; Rao, Narsing; Humayun, Mark S.] Univ Southern Calif, Keck Sch Med, USC Roski Eye Inst, USC Ginsburg Inst Biomed Therapeut, 1450 San Pablo, Los Angeles, CA 90033 USA.
   [Hinton, David R.; Mitra, Debbie; Rao, Narsing; Humayun, Mark S.] Univ Southern Calif, Keck Sch Med, Dept Ophthalmol, 1450 San Pablo, Los Angeles, CA 90033 USA.
   [Humayun, Mark S.] Univ Southern Calif, Dept Biomed Engn, Denney Res Ctr DRB 140, 1042 Downey Way, Los Angeles, CA 90089 USA.
C3 Johns Hopkins University; Johns Hopkins Medicine; University of Southern
   California; University of California System; University of California
   Santa Barbara; Retina Vitreous Associates Medical Group; City of Hope;
   Beckman Research Institute of City of Hope; University of Southern
   California; University of Southern California; University of Southern
   California
RP Humayun, MS (通讯作者)，Univ Southern Calif, Keck Sch Med, USC Roski Eye Inst, USC Ginsburg Inst Biomed Therapeut, 1450 San Pablo, Los Angeles, CA 90033 USA.; Humayun, MS (通讯作者)，Univ Southern Calif, Keck Sch Med, Dept Ophthalmol, 1450 San Pablo, Los Angeles, CA 90033 USA.; Humayun, MS (通讯作者)，Univ Southern Calif, Dept Biomed Engn, Denney Res Ctr DRB 140, 1042 Downey Way, Los Angeles, CA 90089 USA.
EM humayun@usc.edu
FU California Institute for Regenerative Medicine, Regenerative Patch
   Technologies (RPT) LLC
FX This study was funded by The California Institute for Regenerative
   Medicine, Regenerative Patch Technologies (RPT) LLC, gifts from the Lori
   Mars Foundation, the William K. Bowes, Jr. Foundation, The Vermont
   Community Foundation, The Breaux Foundation, The Wilcox Family
   Foundation, Dennis and Michele Slivinski, and unrestricted departmental
   support to the University of Southern California (USC) Roski Eye
   Institute from Research to Prevent Blindness and the National Center for
   Advancing Translational Science (NCATS) of the National Institutes of
   Health. We sincerely thank the participants and their families for their
   altruism and participation. We would like to thank the
   sub-investigators, physicians, data safety monitoring board, and support
   staff at participating sites for their support of the ongoing study,
   including the Retina Vitreous Associates of Beverly Hills (CA, USA),
   California Retina Consultants of Santa Barbara (CA, USA), Retinal
   Consultants of Arizona (AZ, USA), Desert Retina (CA, USA), and Orange
   County Retina (CA, USA). We would also like to thank the support staff
   at California Institute for Regenerative Medicine, USC Roski Eye
   Institute, USC Ginsburg Institute for Biomedical Therapeutics, Leap
   Biomedical LLC, California Institute of Technology (Caltech),
   Regenerative Patch Technologies, the Center for Biomedicine and Genetics
   at the Beckman Research Institute of City of Hope, Uni-versity of
   California, Santa Barbara Center for Stem Cell Biology and Engineering,
   and UCLA's Immunogenetics Center for highresolution HLA class I and II
   molecular typing.
CR Algvere PV, 1997, GRAEF ARCH CLIN EXP, V235, P149, DOI 10.1007/BF00941722
   Benner JD, 2002, ARCH OPHTHALMOL-CHIC, V120, P586, DOI 10.1001/archopht.120.5.586
   Binder S, 2004, INVEST OPHTH VIS SCI, V45, P4151, DOI 10.1167/iovs.04-0118
   Cahill MT, 2005, ARCH OPHTHALMOL-CHIC, V123, P935, DOI 10.1001/archopht.123.7.935
   da Cruz L, 2018, NAT BIOTECHNOL, V36, P1, DOI 10.1038/nbt.4114
   Diniz B, 2013, INVEST OPHTH VIS SCI, V54, P5087, DOI 10.1167/iovs.12-11239
   Fernandes RAB, 2016, OSLI RETINA, V47, P342, DOI 10.3928/23258160-20160324-07
   Idelson M, 2018, STEM CELL REP, V11, P681, DOI 10.1016/j.stemcr.2018.07.009
   Kashani AH, 2021, TRANSL VIS SCI TECHN, V10, DOI 10.1167/tvst.10.10.13
   Kashani AH, 2020, OPHTHALMOL RETINA, V4, P264, DOI 10.1016/j.oret.2019.09.017
   Kashani AH, 2018, SCI TRANSL MED, V10, DOI 10.1126/scitranslmed.aao4097
   Kashani AH, 2016, INVEST OPHTH VIS SCI, V57, DOI 10.1167/iovs.15-17681
   Keino H, 2018, J IMMUNOL RES, V2018, DOI 10.1155/2018/1679197
   Kiser PD, 2010, PROG RETIN EYE RES, V29, P428, DOI 10.1016/j.preteyeres.2010.03.002
   Koss MJ, 2016, GRAEF ARCH CLIN EXP, V254, P1553, DOI 10.1007/s00417-016-3386-y
   Laiginhas R, 2020, OPHTHALMOL RETINA, V4, P651, DOI 10.1016/j.oret.2020.02.016
   Lambert NG, 2016, PROG RETIN EYE RES, V54, P64, DOI 10.1016/j.preteyeres.2016.04.003
   Mandai M, 2017, NEW ENGL J MED, V376, P1038, DOI 10.1056/NEJMoa1608368
   McGill TJ, 2018, INVEST OPHTH VIS SCI, V59, P1374, DOI 10.1167/iovs.17-22467
   Miller JW, 2013, AM J OPHTHALMOL, V155, P1, DOI 10.1016/j.ajo.2012.10.018
   Nazari H, 2015, PROG RETIN EYE RES, V48, P1, DOI 10.1016/j.preteyeres.2015.06.004
   PEYMAN GA, 1991, OPHTHALMIC SURG LAS, V22, P102
   Schachat AP., 2018, RYANS RETINA, V6
   Schultz H, 2019, EXP EYE RES, V186, DOI 10.1016/j.exer.2019.05.026
   Schwartz SD, 2016, INVEST OPHTH VIS SCI, V57, DOI 10.1167/iovs.15-18681
   Schwartz SD, 2015, LANCET, V385, P509, DOI 10.1016/S0140-6736(14)61376-3
   Schwartz SD, 2012, LANCET, V379, P713, DOI 10.1016/S0140-6736(12)60028-2
   Sohn EH, 2015, SCI REP-UK, V5, DOI 10.1038/srep11791
   Stark N., 1996, MED PLASTICS BIOMATE, V3, P30
   Van Meurs JC, 2003, AM J OPHTHALMOL, V136, P688, DOI 10.1016/S0002-9394(03)00384-2
   Wenkel H, 2000, INVEST OPHTH VIS SCI, V41, P3467
NR 31
TC 3
Z9 3
U1 0
U2 2
PU CELL PRESS
PI CAMBRIDGE
PA 50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA
SN 2213-6711
J9 STEM CELL REP
JI Stem Cell Rep.
PD MAR 8
PY 2022
VL 17
IS 3
BP 448
EP 458
DI 10.1016/j.stemcr.2022.01.001
PG 11
WC Cell & Tissue Engineering; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology
GA ZR2EJ
UT WOS:000767602800003
PM 35120620
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Garcia-Floriano, A
   Ferreira-Santiago, A
   Camacho-Nieto, O
   Yanez-Marquez, C
AF Garcia-Floriano, Andres
   Ferreira-Santiago, Angel
   Camacho-Nieto, Oscar
   Yanez-Marquez, Cornelio
TI A machine learning approach to medical image classification: Detecting
   age-related macular degeneration in fundus images
SO COMPUTERS & ELECTRICAL ENGINEERING
LA English
DT Article
DE Age-related macular degeneration; Mathematical morphology; Hu invariant
   moments; Feature selection; Support vector machines
ID RETINAL IMAGES; SEGMENTATION; TRANSFORM; DIAGNOSIS; VESSELS; DRUSEN
AB Age-Related Macular Degeneration (AMD) is a dangerous, chronic, and progressive illness that mostly affects people over 60 years old. This disease is related to the appearance of drusen: deposits of extracellular material located in the macular region. One way to effectively and non-invasively pre-diagnose AMD is by detecting the presence of drusen in fundus images. In this work we propose a new method that combines Digital Image Processing, Mathematical Morphology and a robust and powerful Machine Learning model: a Support Vector Machine (SVM). The enclosed macular region is subjected to a contrast enhancement method, followed by the application of basic morphological operations. We use invariant moments as the features of the processed image. The resulting vector is classified by an SVM as positive or negative for drusen. The proposed method is able to discriminate between healthy and afflicted cases with a classification accuracy that outperforms many well-regarded state-of-the-art methods. (C) 2017 Elsevier Ltd. All rights reserved.
C1 [Garcia-Floriano, Andres] Univ Mexiquense Bicentenario, UES Tepotzotlan, Ocoyoacac, Mexico.
   [Ferreira-Santiago, Angel; Yanez-Marquez, Cornelio] IPN, Ctr Invest Comp, Mexico City, DF, Mexico.
   [Camacho-Nieto, Oscar] IPN, Ctr Innovat & Desarrollo Tecnol Computo, Mexico City, DF, Mexico.
C3 Instituto Politecnico Nacional - Mexico; Instituto Politecnico Nacional
   - Mexico
RP Garcia-Floriano, A (通讯作者)，Univ Mexiquense Bicentenario, UES Tepotzotlan, Ocoyoacac, Mexico.
EM b130293@sagitario.cic.ipn.mx; b130078@sagitario.cic.ipn.mx;
   ocamacho@ipn.mx; cyanez@cic.ipn.mx
RI Floriano, Andrés García/G-7761-2018; Camacho-Nieto, Oscar/A-8820-2012;
   Yanez-Marquez, Cornelio/A-1411-2008
OI Floriano, Andrés García/0000-0002-9948-5954; Camacho-Nieto,
   Oscar/0000-0003-1142-5277; Yanez-Marquez, Cornelio/0000-0002-6250-4728
FU Institute Politecnico Nacional (Secretaria Academica) [20171530];
   CONACyT [1657]; SNI [26395]; Institute Politecnico Nacional (COFAA)
   [20171530]; Institute Politecnico Nacional (SIP) [20171530]; Institute
   Politecnico Nacional (CIDETEC) [20171530]; Institute Politecnico
   Nacional (CIC) [20171530]
FX The authors would like to thank the Institute Politecnico Nacional
   (grant no. 20171530) (Secretaria Academica, COFAA, SIP, CIDETEC, and
   CIC), the CONACyT (grant no. 1657) and SNI (grant no. 26395) for its
   financial and material support. Also, the authors would like to express
   their gratitude to Steven Cohen and Jason Calhoun for being the users of
   retgallery.com who uploaded some of the images that were used in this
   work.
CR [Anonymous], 2015, MATLAB R2015A
   Boser B. E., 1992, Proceedings of the Fifth Annual ACM Workshop on Computational Learning Theory, P144, DOI 10.1145/130385.130401
   Burger W, 2008, TEXTS COMPUT SCI, P173
   Burger W, 2008, TEXTS COMPUT SCI, P37
   Burlina P, 2017, COMPUT BIOL MED, V82, P80, DOI 10.1016/j.compbiomed.2017.01.018
   Chang CC, 2011, ACM T INTEL SYST TEC, V2, DOI 10.1145/1961189.1961199
   Chen Q, 2013, MED IMAGE ANAL, V17, P1058, DOI 10.1016/j.media.2013.06.003
   Cohen S, RETINA GALLERY FULL
   Franklin SW, 2014, APPL SOFT COMPUT, V22, P94, DOI 10.1016/j.asoc.2014.04.024
   Garcia Floriano, 2011, THESIS
   García-Floriano Andrés, 2015, Nova scientia, V7, P365
   Guerroudji MA, 2016, OPTIK, V127, P1251, DOI 10.1016/j.ijleo.2015.10.192
   Hall M, 2009, SIGKDD EXPLOR
   Hall M. A., 1999, Proceedings of the Twelfth International Florida AI Research Society Conference, P235
   Hoover A, 2000, IEEE T MED IMAGING, V19, P203, DOI 10.1109/42.845178
   HU M, 1962, IRE T INFORM THEOR, V8, P179, DOI 10.1109/TIT.1962.1057692
   Koh JEW, 2017, COMPUT BIOL MED, V84, P89, DOI 10.1016/j.compbiomed.2017.03.008
   Kovacs G, 2016, MED IMAGE ANAL, V29, P24, DOI 10.1016/j.media.2015.12.003
   Lee CS, 2017, OPHTHALMOL RETINA, V1, P322, DOI 10.1016/j.oret.2016.12.009
   Mary MCVS, 2015, BIOMED SIGNAL PROCES, V18, P19, DOI 10.1016/j.bspc.2014.11.003
   Mittal D, 2015, COMPUT ELECTR ENG, V47, P82, DOI 10.1016/j.compeleceng.2015.08.014
   Mookiah MRK, 2015, COMPUT BIOL MED, V66, P295, DOI 10.1016/j.compbiomed.2015.09.012
   OTSU N, 1979, IEEE T SYST MAN CYB, V9, P62, DOI 10.1109/TSMC.1979.4310076
   Rosas-Romero R, 2015, COMPUT MED IMAG GRAP, V44, P41, DOI 10.1016/j.compmedimag.2015.07.001
   Zhang XW, 2014, MED IMAGE ANAL, V18, P1026, DOI 10.1016/j.media.2014.05.004
NR 25
TC 21
Z9 23
U1 1
U2 13
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0045-7906
EI 1879-0755
J9 COMPUT ELECTR ENG
JI Comput. Electr. Eng.
PD MAY
PY 2019
VL 75
BP 218
EP 229
DI 10.1016/j.compeleceng.2017.11.008
PG 12
WC Computer Science, Hardware & Architecture; Computer Science,
   Interdisciplinary Applications; Engineering, Electrical & Electronic
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Computer Science; Engineering
GA HV8UI
UT WOS:000466259200018
DA 2022-11-30
ER

PT J
AU van de Ven, JPH
   Nilsson, SC
   Tan, PL
   Buitendijk, GHS
   Ristau, T
   Mohlin, FC
   Nabuurs, SB
   Schoenmaker-Koller, FE
   Smailhodzic, D
   Campochiaro, PA
   Zack, DJ
   Duvvari, MR
   Bakker, B
   Paun, CC
   Boon, CJF
   Uitterlinden, AG
   Liakopoulos, S
   Klevering, BJ
   Fauser, S
   Daha, MR
   Katsanis, N
   Klaver, CCW
   Blom, AM
   Hoyng, CB
   den Hollander, AI
AF van de Ven, Johannes P. H.
   Nilsson, Sara C.
   Tan, Perciliz L.
   Buitendijk, Gabrille H. S.
   Ristau, Tina
   Mohlin, Frida C.
   Nabuurs, Sander B.
   Schoenmaker-Koller, Frederieke E.
   Smailhodzic, Dzenita
   Campochiaro, Peter A.
   Zack, Donald J.
   Duvvari, Maheswara R.
   Bakker, Bjorn
   Paun, Codrut C.
   Boon, Camiel J. F.
   Uitterlinden, Andre G.
   Liakopoulos, Sandra
   Klevering, B. Jeroen
   Fauser, Sascha
   Daha, Mohamed R.
   Katsanis, Nicholas
   Klaver, Caroline C. W.
   Blom, Anna M.
   Hoyng, Carel B.
   den Hollander, Anneke I.
TI A functional variant in the CFI gene confers a high risk of age-related
   macular degeneration
SO NATURE GENETICS
LA English
DT Article
ID COMPLEMENT FACTOR-I; HEMOLYTIC-UREMIC SYNDROME; C4B-BINDING PROTEIN;
   MUTATIONS; ANGIOGENESIS; PREVALENCE; ZEBRAFISH; TIMP3; VEGFA; LOCI
AB Up to half of the heritability of age-related macular degeneration (AMD) is explained by common variants(1-5). Here, we report the identification of a rare, highly penetrant missense mutation in CFI encoding a p.Gly119Arg substitution that confers high risk of AMD (P = 3.79 x 10(-6); odds ratio (OR) = 22.20, 95% confidence interval (CI) = 2.98-164.49). Plasma and sera from cases carrying the p.Gly119Arg substitution mediated the degradation of C3b, both in the fluid phase and on the cell surface, to a lesser extent than those from controls. Recombinant protein studies showed that the Gly119Arg mutant protein is both expressed and secreted at lower levels than wild-type protein. Consistent with these findings, human CFI mRNA encoding Arg119 had reduced activity compared to wild-type mRNA encoding Gly119 in regulating vessel thickness and branching in the zebrafish retina. Taken together, these findings demonstrate that rare, highly penetrant mutations contribute to the genetic burden of AMD.
C1 [van de Ven, Johannes P. H.; Schoenmaker-Koller, Frederieke E.; Smailhodzic, Dzenita; Duvvari, Maheswara R.; Bakker, Bjorn; Paun, Codrut C.; Boon, Camiel J. F.; Klevering, B. Jeroen; Hoyng, Carel B.; den Hollander, Anneke I.] Radboud Univ Nijmegen, Med Ctr, Dept Ophthalmol, NL-6525 ED Nijmegen, Netherlands.
   [Nilsson, Sara C.; Mohlin, Frida C.; Blom, Anna M.] Lund Univ, Dept Lab Med Malmo, Sect Med Prot Chem, Malmo, Sweden.
   [Tan, Perciliz L.; Katsanis, Nicholas] Duke Univ, Ctr Human Dis Modeling, Durham, NC USA.
   [Tan, Perciliz L.; Katsanis, Nicholas] Duke Univ, Dept Cell Biol, Durham, NC USA.
   [Tan, Perciliz L.; Katsanis, Nicholas] Duke Univ, Dept Pediat, Durham, NC 27706 USA.
   [Buitendijk, Gabrille H. S.; Klaver, Caroline C. W.] Erasmus MC, Dept Ophthalmol, Rotterdam, Netherlands.
   [Buitendijk, Gabrille H. S.; Uitterlinden, Andre G.; Klaver, Caroline C. W.] Erasmus MC, Dept Epidemiol, Rotterdam, Netherlands.
   [Ristau, Tina; Liakopoulos, Sandra; Fauser, Sascha] Univ Cologne, Ctr Ophthalmol, Dept Vitreoretinal Surg, D-50931 Cologne, Germany.
   [Nabuurs, Sander B.] Radboud Univ Nijmegen, Med Ctr, Ctr Mol & Biomol Informat, NL-6525 ED Nijmegen, Netherlands.
   [Campochiaro, Peter A.; Zack, Donald J.] Johns Hopkins Sch Med, Dept Ophthalmol, Baltimore, MD USA.
   [Campochiaro, Peter A.; Zack, Donald J.] Johns Hopkins Sch Med, Dept Neurosci, Baltimore, MD USA.
   [Uitterlinden, Andre G.] Erasmus MC, Dept Internal Med, Genet Lab, Rotterdam, Netherlands.
   [Daha, Mohamed R.] Leiden Univ, Med Ctr, Dept Nephrol, Leiden, Netherlands.
   [den Hollander, Anneke I.] Radboud Univ Nijmegen, Med Ctr, Nijmegen Ctr Mol Life Sci, Dept Human Genet, NL-6525 ED Nijmegen, Netherlands.
   [den Hollander, Anneke I.] Radboud Univ Nijmegen, Med Ctr, Inst Genet & Metab Dis, NL-6525 ED Nijmegen, Netherlands.
C3 Radboud University Nijmegen; Lund University; Duke University; Duke
   University; Duke University; Erasmus University Rotterdam; Erasmus MC;
   Erasmus University Rotterdam; Erasmus MC; University of Cologne; Radboud
   University Nijmegen; Johns Hopkins University; Johns Hopkins Medicine;
   Johns Hopkins University; Johns Hopkins Medicine; Erasmus University
   Rotterdam; Erasmus MC; Leiden University; Leiden University Medical
   Center (LUMC); Leiden University - Excl LUMC; Radboud University
   Nijmegen; Radboud University Nijmegen
RP den Hollander, AI (通讯作者)，Radboud Univ Nijmegen, Med Ctr, Dept Ophthalmol, NL-6525 ED Nijmegen, Netherlands.
EM a.denhollander@ohk.umcn.nl
RI Bakker, Bjorn/E-2842-2016; Blom, Anna/AFS-7369-2022; Blom,
   Anna/B-9607-2009; Klevering, B.J./L-4434-2015; Boon, CJF/P-7534-2014
OI Blom, Anna/0000-0002-1348-1734; Klaver, Caroline/0000-0002-2355-5258;
   Katsanis, Nicholas/0000-0002-2480-0171; Boon, CJF/0000-0002-6737-7932;
   Zack, Don/0000-0002-7966-1973
FU Netherlands Organization for Scientific Research [016.096.309];
   Foundation Fighting Blindness [C-GE-0811-0548-RAD04]; Swedish Research
   Council [K2012-66X-14928-09-5]; Soderberg Foundation
FX We thank B. Janssen, A. Brucker, T. Janssen-van Kempen and M. Verbiest
   for excellent technical assistance. This study was supported by the
   Netherlands Organization for Scientific Research (Vidi Innovational
   Research Award 016.096.309 to A.I.d.H.), the Foundation Fighting
   Blindness (grant C-GE-0811-0548-RAD04 to A.I.d.H.), the Swedish Research
   Council (K2012-66X-14928-09-5 to A. M. B.) and the Soderberg Foundation
   (to A.M.B.).
CR Bahary N, 2007, BLOOD, V110, P3627, DOI 10.1182/blood-2006-04-016378
   Bienaime F, 2010, KIDNEY INT, V77, P339, DOI 10.1038/ki.2009.472
   Blom AM, 2003, MOL IMMUNOL, V39, P547, DOI 10.1016/S0161-5890(02)00213-4
   Boon CJE, 2008, AM J HUM GENET, V82, P516, DOI 10.1016/j.ajhg.2007.11.007
   Chen W, 2010, P NATL ACAD SCI USA, V107, P7401, DOI 10.1073/pnas.0912702107
   DAHLBACK B, 1983, BIOCHEM J, V209, P847, DOI 10.1042/bj2090847
   Despriet DDG, 2007, ARCH OPHTHALMOL-CHIC, V125, P1270, DOI 10.1001/archopht.125.9.1270
   Fagerness JA, 2009, EUR J HUM GENET, V17, P100, DOI 10.1038/ejhg.2008.140
   Fakhouri F, 2010, J AM SOC NEPHROL, V21, P859, DOI 10.1681/ASN.2009070706
   Fauser S, 2011, INVEST OPHTH VIS SCI, V52, P5525, DOI 10.1167/iovs.10-6827
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Ho L, 2011, ARCH OPHTHALMOL-CHIC, V129, P758, DOI 10.1001/archophthalmol.2011.141
   Hohenester E, 1999, NAT STRUCT BIOL, V6, P228, DOI 10.1038/6669
   Hooft RWW, 1997, COMPUT APPL BIOSCI, V13, P425
   Isogai S, 2001, DEV BIOL, V230, P278, DOI 10.1006/dbio.2000.9995
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Kleywegt GJ, 1996, STRUCTURE, V4, P1395, DOI 10.1016/S0969-2126(96)00147-5
   Krieger E, 2002, PROTEINS, V47, P393, DOI 10.1002/prot.10104
   Levey AS, 1999, ANN INTERN MED, V130, P461, DOI 10.7326/0003-4819-130-6-199903160-00002
   Maga TK, 2010, HUM MUTAT, V31, pE1445, DOI 10.1002/humu.21256
   Maller J, 2006, NAT GENET, V38, P1055, DOI 10.1038/ng1873
   Manolio TA, 2009, NATURE, V461, P747, DOI 10.1038/nature08494
   Nasevicius A, 2000, YEAST, V17, P294, DOI 10.1002/1097-0061(200012)17:4<294::AID-YEA54>3.0.CO;2-5
   Neale BM, 2010, P NATL ACAD SCI USA, V107, P7395, DOI 10.1073/pnas.0912019107
   Nilsson SC, 2007, MOL IMMUNOL, V44, P1835, DOI 10.1016/j.molimm.2006.10.005
   Nilsson SC, 2011, MOL IMMUNOL, V48, P1611, DOI 10.1016/j.molimm.2011.04.004
   Nilsson SC, 2009, EUR J IMMUNOL, V39, P310, DOI 10.1002/eji.200838702
   Raychaudhuri S, 2011, NAT GENET, V43, P1232, DOI 10.1038/ng.976
   Roversi P, 2011, P NATL ACAD SCI USA, V108, P12839, DOI 10.1073/pnas.1102167108
   Schultz DW, 2003, HUM MOL GENET, V12, P3315, DOI 10.1093/hmg/ddg348
   Seddon JM, 2009, INVEST OPHTH VIS SCI, V50, P2044, DOI 10.1167/iovs.08-3064
   Smailhodzic D, 2012, OPHTHALMOLOGY, V119, P339, DOI 10.1016/j.ophtha.2011.07.056
   Sobrin L, 2010, EUR J HUM GENET, V18, P496, DOI 10.1038/ejhg.2009.185
   van de Ven JPH, 2012, ARCH OPHTHALMOL-CHIC, V130, P1038, DOI 10.1001/archophthalmol.2012.265
   van Leeuwen R, 2003, OPHTHALMOLOGY, V110, P1540, DOI 10.1016/S0161-6420(03)00501-3
   Vingerling JR, 1995, EPIDEMIOL REV, V17, P347, DOI 10.1093/oxfordjournals.epirev.a036198
   Wang JY, 2008, J IMMUNOL, V181, P712, DOI 10.4049/jimmunol.181.1.712
   Weiner DE, 2011, NEPHROL DIAL TRANSPL, V26, P3159, DOI 10.1093/ndt/gfr022
   Yang ZL, 2008, NEW ENGL J MED, V359, P1456, DOI 10.1056/NEJMoa0802437
   Yang ZL, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1000836
   Yu Y, 2011, HUM MOL GENET, V20, P3699, DOI 10.1093/hmg/ddr270
   Zeng XXI, 2009, DEV BIOL, V328, P363, DOI 10.1016/j.ydbio.2009.01.035
NR 42
TC 137
Z9 143
U1 2
U2 15
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 1061-4036
EI 1546-1718
J9 NAT GENET
JI Nature Genet.
PD JUL
PY 2013
VL 45
IS 7
BP 813
EP +
DI 10.1038/ng.2640
PG 7
WC Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Genetics & Heredity
GA 172LQ
UT WOS:000321005200018
PM 23685748
DA 2022-11-30
ER

PT J
AU Ciulla, TA
   Oliver, A
   Comer, GM
AF Ciulla, TA
   Oliver, A
   Comer, GM
TI MV-6401, a potent photosensitizer in experimental animal models: a
   review of this agent and the current state of photosensitizing agents
   for the treatment of exudative age-related macular degeneration
SO DRUGS OF THE FUTURE
LA English
DT Review
ID CHLORIDE METHYL PYROPHEOPHORBIDE; DIODE-LASER PHOTOCOAGULATION;
   PHOTODYNAMIC THERAPY; CHOROIDAL NEOVASCULARIZATION; VISUAL IMPAIRMENT;
   PREVALENCE; MV6401; TUMOR; BLINDNESS
AB Age-related macular degeneration (AMD) is the leading cause of irreversible visual loss in developed countries, but therapeutic options available for treatment of this condition are limited. Intense research oriented towards halting progression of the exudative (wet) type of AMD is being conducted, and a number of therapeutic modalities have recently reached the stage of evaluation in a clinical setting. One very promising approach is that of photodynamic therapy, which in principle allows targeted and selective destruction of aberrant blood vessels affecting the macula with minimal damage to the surrounding retina. A number of photosensitizing agents have been developed to date and some of them are currently being evaluated in clinical and preclinical studies for their safety and efficacy. The photosensitizer MV-6401 has been studied in animal ocular models of neovascularization with promising results. The outcomes of studies evaluating this and other novel photosensitizing agents, and the potential of each agent to become an effective treatment for age-related macular degeneration are reviewed in this article.
C1 MW Eye Inst, Vitreoretinal Serv, Indianapolis, IN 46280 USA.
   Indiana Univ, Sch Med, Dept Ophthalmol, Indianapolis, IN 46202 USA.
C3 Indiana University System; Indiana University-Purdue University
   Indianapolis
RP Ciulla, TA (通讯作者)，MW Eye Inst, Vitreoretinal Serv, 201 Penn Pkwy, Indianapolis, IN 46280 USA.
EM thomasciulla@yahoo.com
RI Ciulla, Thomas/AAA-1299-2020
OI Ciulla, Thomas/0000-0001-5557-6777
CR ALLISON BA, 1991, PHOTOCHEM PHOTOBIOL, V54, P709, DOI 10.1111/j.1751-1097.1991.tb02079.x
   Arnold J, 2001, AM J OPHTHALMOL, V131, P541
   Attebo K, 1996, OPHTHALMOLOGY, V103, P357
   AVELINE B, 1994, PHOTOCHEM PHOTOBIOL, V59, P328, DOI 10.1111/j.1751-1097.1994.tb05042.x
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   BLUMENKRANZ M, 2000, INVEST OPHTHALMOL VI, V41
   Blumenkranz MS, 2001, ARCH OPHTHALMOL-CHIC, V119, P198
   BRESSLER N, 2003, INVEST OPHTHALMOL VI
   Bressler NM, 2002, ARCH OPHTHALMOL-CHIC, V120, P1307
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   Ciulla TA, 2005, BRIT J OPHTHALMOL, V89, P113, DOI 10.1136/bjo.2004.043075
   Ciulla TA, 2004, RETINA-J RET VIT DIS, V24, P521, DOI 10.1097/00006982-200408000-00004
   Dolmans DEJGJ, 2002, CANCER RES, V62, P2151
   Dolmans DEJGJ, 2002, CANCER RES, V62, P4289
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   GONZALEZ J, 2003, OCULAR SURG NEWS, P21
   Grisanti S, 2004, AM J OPHTHALMOL, V137, P914, DOI 10.1016/j.ajo.2003.12.049
   HOPEROSS MW, 1994, ACTA OPHTHALMOL, V72, P134
   Hunt DWC, 1999, IMMUNOPHARMACOLOGY, V41, P31, DOI 10.1016/S0162-3109(98)00051-4
   KAHN HA, 1977, AM J EPIDEMIOL, V106, P17, DOI 10.1093/oxfordjournals.aje.a112428
   Klaver CCW, 1998, ARCH OPHTHALMOL-CHIC, V116, P653, DOI 10.1001/archopht.116.5.653
   MORIARTY AP, 1994, BRIT J OPHTHALMOL, V78, P238, DOI 10.1136/bjo.78.3.238-b
   Nishiwaki H, 2002, PHOTOCHEM PHOTOBIOL, V75, P149, DOI 10.1562/0031-8655(2002)075<0149:LTPOOR>2.0.CO;2
   Obana A, 2000, ARCH OPHTHALMOL-CHIC, V118, P650
   Regillo C D, 2000, Curr Opin Ophthalmol, V11, P166, DOI 10.1097/00055735-200006000-00002
   REICHEL E, 1994, OPHTHALMIC SURG LAS, V25, P195
   Renno RZ, 2004, ARCH OPHTHALMOL-CHIC, V122, P1002, DOI 10.1001/archopht.122.7.1002
   RIDDLE J, 2003, JOBSONS REV OPHTHALM, V10, P40
   ROSENFELD PJ, 2004, INVEST OPHTHALMOL VI, V45
   SEDDON J, 2001, EPIDEMIOLOGY AGE REL, P1039
   SINGERMAN L, 2004, INVEST OPHTHALMOL VI, V4
   SLAKTER JS, 2003, INVEST OPHTHALMOL VI, V44
   STUR M, 2004, INVEST OPHTH VIS SCI, P45
   THOMAS EL, 2004, INVEST OPHTHALMOL VI, V45
   TIELSCH JM, 1995, NEW ENGL J MED, V332, P1205, DOI 10.1056/NEJM199505043321806
NR 35
TC 0
Z9 0
U1 1
U2 6
PU PROUS SCIENCE, SAU-THOMSON REUTERS
PI BARCELONA
PA 398 PROVENCA, 08025 BARCELONA, SPAIN
SN 0377-8282
EI 2013-0368
J9 DRUG FUTURE
JI Drug Future
PD OCT
PY 2005
VL 30
IS 10
BP 1031
EP 1037
DI 10.1358/dof.2005.030.10.923099
PG 7
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA 022QR
UT WOS:000236071300008
DA 2022-11-30
ER

PT J
AU van Nispen, RMA
   de Boer, MR
   van Rens, GHMB
AF van Nispen, Ruth M. A.
   de Boer, Michiel R.
   van Rens, Ger H. M. B.
TI Additional psychometric information and vision-specific questionnaires
   are available for age-related macular degeneration
SO QUALITY OF LIFE RESEARCH
LA English
DT Article
DE Age-related macular degeneration; Vision disorders; Low vision;
   Vision-related quality-of-life questionnaires; Item response theory;
   Differential item functioning
ID QUALITY-OF-LIFE; LVQOL
AB To present psychometric information and studies dealing with questionnaires for age-related macular degeneration (AMD) and visually impaired patients in addition to the study by Finger et al. "Quality of life in AMD: a review of available vision-specific psychometric tools". We propose that their literature search should not have focused solely on the specific eye disease AMD.
   The literature search was partly replicated (PubMed) by using "visual impairment" instead of "macular degeneration" as free text words. Psychometric information was obtained from the additional studies. Preliminary results from a differential item functioning (DIF) analysis used to examine the relationship between item responses on the Vision-related quality of life Core Measure (VCM1) of AMD patients versus patients with other eye conditions are discussed.
   Eight studies of visually impaired patient populations, including AMD patients, are discussed, with psychometric information from six vision-specific questionnaires. The VCM1 items did not present DIF, which means that the items were equally interpreted by all patients.
   The results on DIF and the additional studies presented here confirm that a specific eye disorder is of minor importance in the choice of a vision-specific questionnaire or, in this case, a literature search.
C1 [van Nispen, Ruth M. A.; van Rens, Ger H. M. B.] Vrije Univ Amsterdam, EMGO Inst, Dept Ophthalmol, Med Ctr Amsterdam, NL-1007 MB Amsterdam, Netherlands.
   [van Nispen, Ruth M. A.; van Rens, Ger H. M. B.] Vrije Univ Amsterdam, Med Ctr Amsterdam, Inst Res Extramural Med, NL-1007 MB Amsterdam, Netherlands.
   [de Boer, Michiel R.] Vrije Univ Amsterdam, Inst Hlth Sci, Amsterdam, Netherlands.
   [van Rens, Ger H. M. B.] Elkerliek Hosp, Dept Ophthalmol, Helmond, Netherlands.
C3 Vrije Universiteit Amsterdam; Vrije Universiteit Amsterdam; Vrije
   Universiteit Amsterdam
RP van Nispen, RMA (通讯作者)，Vrije Univ Amsterdam, EMGO Inst, Dept Ophthalmol, Med Ctr Amsterdam, POB 7057, NL-1007 MB Amsterdam, Netherlands.
EM r.vannispen@vumc.nl
RI van Rens, Ger/I-6247-2018
OI van Nispen, Ruth M.A./0000-0003-1227-1177; de Boer,
   Michiel/0000-0001-9240-0199
CR de Boer MR, 2006, QUAL LIFE RES, V15, P233, DOI 10.1007/s11136-005-1524-9
   de Boer MR, 2004, OPHTHAL PHYSL OPT, V24, P257, DOI 10.1111/j.1475-1313.2004.00187.x
   de Boer MR, 2005, J CLIN EPIDEMIOL, V58, P1260, DOI 10.1016/j.jclinepi.2005.04.007
   Finger RP, 2008, QUAL LIFE RES, V17, P559, DOI 10.1007/s11136-008-9327-4
   Langelaan M, 2007, OPTOMETRY VISION SCI, V84, P775, DOI 10.1097/OPX.0b013e3181334b98
   Massof RW, 2007, OPTOMETRY VISION SCI, V84, P689
   Pesudovs K, 2007, OPTOMETRY VISION SCI, V84, P663, DOI 10.1097/OPX.0b013e318141fe75
   SAMEJIMA F, 1969, PSYCHOMETRIC MONOG S, V17
   Teresi JA, 2007, QUAL LIFE RES, V16, P33, DOI 10.1007/s11136-007-9184-6
   Thissen D., 2001, IRTLRDIF V 2 0B SOFT
   Van Nispen RMA, 2007, OPTOMETRY VISION SCI, V84, P710, DOI 10.1097/OPX.0b013e31813375b8
   Wolffsohn JS, 2000, AM J OPHTHALMOL, V130, P793, DOI 10.1016/S0002-9394(00)00610-3
   Wolffsohn JS, 2000, BRIT J OPHTHALMOL, V84, P1035, DOI 10.1136/bjo.84.9.1035
   Zou H, 2005, QUAL LIFE RES, V14, P1633, DOI 10.1007/s11136-004-0026-5
NR 14
TC 6
Z9 6
U1 0
U2 6
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0962-9343
J9 QUAL LIFE RES
JI Qual. Life Res.
PD FEB
PY 2009
VL 18
IS 1
BP 65
EP 69
DI 10.1007/s11136-008-9425-3
PG 5
WC Health Care Sciences & Services; Health Policy & Services; Public,
   Environmental & Occupational Health
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC Health Care Sciences & Services; Public, Environmental & Occupational
   Health
GA 402PM
UT WOS:000263025600008
PM 19067235
OA Green Submitted, hybrid
DA 2022-11-30
ER

PT J
AU Kuo, SC
   Li, YX
   Cheng, KC
   Hsu, CC
   Cheng, JT
   Lau, HH
AF Kuo, Shu-Chun
   Li, Yingxiao
   Cheng, Kai-Chun
   Hsu, Chia-Chen
   Cheng, Juei-Tang
   Lau, Hui-Hsuan
TI Potassium bromate-induced cell model of age-related macular degeneration
   in vitro
SO MOLECULAR MEDICINE REPORTS
LA English
DT Article
DE age-related macular degeneration; antioxidant; reactive oxygen species;
   potassium bromate; retinal pigment epithelium cells
AB Age-related macular degeneration (AMD) progression occurs due to oxidative stress in retinal pigment epithelium (RPE) cells. To develop a new model of AMD, the present study investigated the effects of potassium bromate (KBrO3) on ARPE-19 cells. Incubation with KBrO3 for 24 h significantly decreased ARPE-19 cell viability in a concentration-dependent manner compared with the control group. The MTT and lactate dehydrogenase assay results indicated that KBrO3 induced cell apoptosis. Compared with the control group, KBrO3 treatment significantly decreased the Bcl2/Bax ratio, as determined via western blotting, and caspase-3 mRNA expression levels. Fluorescence microscopy indicated the increased ROS levels in cells treated with KBrO3. Endogenous antioxidant enzyme activities, including superoxide dismutase and glutathione peroxidase, were significantly inhibited by KBrO3 compared with the control group. Moreover, the antioxidants tiron and phloroglucinol inhibited KBrO3-mediated effects on ARPE-19 cells in a dose-dependent manner. Additionally, GPR109A is the binding site of 4-hydroxynonenal (4-HNE). KBrO3 displayed cytotoxic effects in 293 cells, which naturally lack the GPR109A gene, but these effects were not observed in 4-HNE-treated 293 cells, suggesting that KBrO3 induced apoptosis without increasing endogenous 4-HNE levels in cells. Moreover, the results suggested that KBrO3-induced oxidative stress may activate STAT3 to increase VEGF expression in ARPE-19 cells. Collectively, the results of the present study supported the potential use of KBrO3 to induce an in vitro model of AMD in ARPE-19 cells.
C1 [Kuo, Shu-Chun] Chung Hwa Univ Med Technol, Dept Optometry, Tainan 71701, Taiwan.
   [Kuo, Shu-Chun; Cheng, Juei-Tang] Chi Mei Med Ctr, Dept Ophthalmol, 901 Zhonghua Rd, Tainan 71003, Taiwan.
   [Li, Yingxiao] Tzu Chi Univ Sci & Technol, Dept Nursing, Hualien 97005, Taiwan.
   [Cheng, Kai-Chun] Kagoshima Univ, Dept Psychosomat Internal Med, Grad Sch Med & Dent Sci, Kagoshima 890, Japan.
   [Hsu, Chia-Chen] Chang Gung Univ Sci & Technol, Grad Inst Gerontol & Hlth Care Management, New Taipei 11049, Taiwan.
   [Hsu, Chia-Chen] Taipei City Hosp, Dept Otorhinolaryngol, Tainan 10413, Taiwan.
   [Lau, Hui-Hsuan] Mackay Mem Hosp, Dept Obstet & Gynecol, 92 Zhongshan North Rd, Taipei 10449, Taiwan.
C3 Chung Hua University; Chi Mei Hospital; Tzu Chi University of Science &
   Technology; Kagoshima University; Taipei City Hospital; Mackay Memorial
   Hospital
RP Cheng, JT (通讯作者)，Chi Mei Med Ctr, Dept Ophthalmol, 901 Zhonghua Rd, Tainan 71003, Taiwan.; Lau, HH (通讯作者)，Mackay Mem Hosp, Dept Obstet & Gynecol, 92 Zhongshan North Rd, Taipei 10449, Taiwan.
EM jtcheng5503@gmail.com; huihsuan1220@gmail.com
RI Kuo, Jesseanna/AAT-8331-2021; smile, chien/AAA-1053-2022
CR Abdel-Wahab Wessam Mohamad, 2014, Pak J Biol Sci, V17, P1152
   Bhutto I, 2012, MOL ASPECTS MED, V33, P295, DOI 10.1016/j.mam.2012.04.005
   Bonilha VL, 2018, ADV EXP MED BIOL, V1074, P3, DOI 10.1007/978-3-319-75402-4_1
   Calabrese A, 2011, INVEST OPHTH VIS SCI, V52, P2417, DOI 10.1167/iovs.09-5056
   Campagne MV, 2014, J PATHOL, V232, P151, DOI 10.1002/path.4266
   Chen YH, 2010, MOL INTERV, V10, P271, DOI 10.1124/mi.10.5.4
   Cia D, 2016, J CELL MOL MED, V20, P1651, DOI 10.1111/jcmm.12857
   Coleman HR, 2008, LANCET, V372, P1835, DOI 10.1016/S0140-6736(08)61759-6
   CUNNINGHAM DK, 1956, CEREAL CHEM, V33, P290
   Datta S, 2017, PROG RETIN EYE RES, V60, P201, DOI 10.1016/j.preteyeres.2017.03.002
   Ding XY, 2009, PROG RETIN EYE RES, V28, P1, DOI 10.1016/j.preteyeres.2008.10.001
   Dural E, 2020, MUTAGENESIS, V35, P479, DOI 10.1093/mutage/geaa024
   Ethen CM, 2007, INVEST OPHTH VIS SCI, V48, P3469, DOI 10.1167/iovs.06-1058
   Gautam J, 2018, BRIT J PHARMACOL, V175, P2581, DOI 10.1111/bph.14174
   Giri U, 1999, CANCER LETT, V135, P181, DOI 10.1016/S0304-3835(98)00290-0
   Hu X, 2019, J CELL BIOCHEM, V120, P4514, DOI 10.1002/jcb.27739
   Hytti M, 2015, EXP EYE RES, V132, P208, DOI 10.1016/j.exer.2015.02.001
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Khan RA, 2012, BMC COMPLEM ALTERN M, V12, DOI 10.1186/1472-6882-12-204
   Kuo SC, 2018, MOL MED REP, V18, P4700, DOI 10.3892/mmr.2018.9470
   KUROKAWA Y, 1990, ENVIRON HEALTH PERSP, V87, P309, DOI 10.2307/3431039
   Li CJ, 2012, CARDIOVASC DIABETOL, V11, DOI 10.1186/1475-2840-11-73
   Li G, 2010, J BIOL CHEM, V285, P22605, DOI 10.1074/jbc.M109.087213
   Li X, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0047600
   Liang FQ, 2003, EXP EYE RES, V76, P397, DOI 10.1016/S0014-4835(03)00023-X
   Liu WY, 2017, MOLECULES, V22, DOI 10.3390/molecules22122251
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Lores-Motta L, 2018, MOL DIAGN THER, V22, P315, DOI 10.1007/s40291-018-0332-1
   Lu L, 2006, J CELL PHYSIOL, V206, P119, DOI 10.1002/jcp.20439
   Oyewole AO, 2015, FASEB J, V29, P4766, DOI 10.1096/fj.15-275404
   Parsons JL, 2000, MUTAGENESIS, V15, P311, DOI 10.1093/mutage/15.4.311
   Raza H, 2006, TOXICOL APPL PHARM, V216, P309, DOI 10.1016/j.taap.2006.06.001
   Salakou S, 2007, IN VIVO, V21, P123
   Sharma A, 2008, ARCH BIOCHEM BIOPHYS, V480, P85, DOI 10.1016/j.abb.2008.09.016
   Shen CL, 2017, BMC OPHTHALMOL, V17, DOI 10.1186/s12886-017-0614-0
   Sheu SJ, 2015, ACTA OPHTHALMOL, V93, pE631, DOI 10.1111/aos.12745
   Ushio-Fukai M, 2008, CANCER LETT, V266, P37, DOI 10.1016/j.canlet.2008.02.044
   Wang XL, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-10124-4
   Wang YJ, 2012, APOPTOSIS, V17, P1144, DOI 10.1007/s10495-012-0750-1
   Watanabe S, 2002, BIOL PHARM BULL, V25, P1315, DOI 10.1248/bpb.25.1315
   Wei DY, 2003, ONCOGENE, V22, P319, DOI 10.1038/sj.onc.1206122
   Wihlmark U, 1996, APMIS, V104, P265, DOI 10.1111/j.1699-0463.1996.tb00716.x
   Zhang Y, 2011, CHEM-BIOL INTERACT, V189, P186, DOI 10.1016/j.cbi.2010.12.011
NR 43
TC 0
Z9 0
U1 1
U2 11
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1791-2997
EI 1791-3004
J9 MOL MED REP
JI Mol. Med. Rep.
PD MAR
PY 2021
VL 23
IS 3
AR 216
DI 10.3892/mmr.2021.11855
PG 9
WC Oncology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Research & Experimental Medicine
GA QA8ZX
UT WOS:000613732600001
PM 33495823
OA Bronze
DA 2022-11-30
ER

PT J
AU Supanji, S
   Perdamaian, ABI
   Romdhoniyyah, DF
   Sasongko, MB
   Agni, AN
   Wardhana, FS
   Widayanti, TW
   Prayogo, ME
   Oka, C
   Kawaichi, M
AF Supanji, Supanji
   Perdamaian, Ayudha Bahana Ilham
   Romdhoniyyah, Dewi Fathin
   Sasongko, Muhammad Bayu
   Agni, Angela Nurini
   Wardhana, Firman Setya
   Widayanti, Tri Wahyu
   Prayogo, Muhammad Eko
   Oka, Chio
   Kawaichi, Masashi
TI Association of the HtrA1 rs11200638 Polymorphism with Neovascular
   Age-Related Macular Degeneration in Indonesia
SO OPHTHALMOLOGY AND THERAPY
LA English
DT Article
DE Age-related macular degeneration; HtrA1; Polymorphism
ID GENE POLYMORPHISMS; ARMS2; RISK; CFH; VARIANTS; AMD; SUSCEPTIBILITY;
   LOC387715
AB Introduction The aim of this study was to investigate the association of the HtrA1 rs11200638 polymorphism with neovascular age-related macular degeneration (nAMD) in Indonesia. Methods This case-control study included 80 patients with nAMD and 85 controls. Demographic parameters and whole blood were collected from each participant. Genomic DNA was extracted and used to assess the rs11200638 genotype by PCR and restriction enzyme digestion. Associations between the HtrA1 rs11200638 polymorphism and other risk factors for susceptibility to nAMD were assessed using the logistic regression model. Results Significant allelic associations between the HtrA1 polymorphism and nAMD were detected (odds ratio [OR] 8.67; 95% confidence interval [CI] 4.88-15.41; P < 0.001). Genotype analysis showed a statistical difference between the nAMD group and the control group (P < 0.001). In the multiple adjusted logistic regression model, people with the AA genotype were more likely to have nAMD although there was a wide confidence interval (OR 19.65; 95% CI 4.52-85.38; P < 0.001). Conclusion Our findings show that the risk of nAMD increased in the presence of risk alleles of HtrA1 rs11200638.
C1 [Supanji, Supanji; Perdamaian, Ayudha Bahana Ilham; Romdhoniyyah, Dewi Fathin; Sasongko, Muhammad Bayu; Agni, Angela Nurini; Wardhana, Firman Setya; Widayanti, Tri Wahyu; Prayogo, Muhammad Eko] Univ Gadjah Mada, Fac Med Publ Hlth & Nursing, Dept Ophthalmol, Jalan Farmako Sekip Utara, Yogyakarta 55281, Indonesia.
   [Supanji, Supanji; Perdamaian, Ayudha Bahana Ilham; Romdhoniyyah, Dewi Fathin; Sasongko, Muhammad Bayu; Agni, Angela Nurini; Wardhana, Firman Setya; Widayanti, Tri Wahyu; Prayogo, Muhammad Eko] Dr Sardjito Gen Hosp, Yogyakarta, Indonesia.
   [Supanji, Supanji] Mil Air Force Cent Hosp Dr Suhardi Hardjolukito, Ophthalmol Clin, Yogyakarta, Indonesia.
   [Supanji, Supanji; Sasongko, Muhammad Bayu; Agni, Angela Nurini; Wardhana, Firman Setya; Widayanti, Tri Wahyu; Prayogo, Muhammad Eko] Dr YAP Eye Hosp, Ophthalmol Clin, Yogyakarta, Indonesia.
   [Oka, Chio; Kawaichi, Masashi] Nara Inst Sci & Technol, Lab Gene Funct Anim, Nara, Japan.
C3 Gadjah Mada University; Nara Institute of Science & Technology
RP Supanji, S (通讯作者)，Univ Gadjah Mada, Fac Med Publ Hlth & Nursing, Dept Ophthalmol, Jalan Farmako Sekip Utara, Yogyakarta 55281, Indonesia.
EM supanji@ugm.ac.id
RI Sasongko, Muhammad Bayu/GNP-0074-2022; Bahana, Ayudha/K-8858-2018
OI Sasongko, Muhammad Bayu/0000-0002-0366-8335; Bahana,
   Ayudha/0000-0002-5421-0105; Supanji, Supanji/0000-0001-6911-9382
FU Gadjah Mada University; Faculty of Medicine, Public Health, and Nurse
   (FK-KMK), Gadjah Mada University through the DAMAS research fund
   [269/UNI1/FKKMK/PPKE/PT/2021]
FX The journal's Rapid Service Fees, were financially supported by the
   Publishers and Publication Board (Badan Penerbit dan Publikasi; BPP) of
   Gadjah Mada University. The study was supported by Faculty of Medicine,
   Public Health, and Nurse (FK-KMK), Gadjah Mada University through the
   DAMAS research fund 2021 (No.: 269/UNI1/FKKMK/PPKE/PT/2021).
CR Abbas RO, 2013, OPHTHALMIC GENET, V34, P209, DOI 10.3109/13816810.2012.762934
   Chen CY, 2018, MATRIX BIOL, V70, P84, DOI 10.1016/j.matbio.2018.03.013
   Chen HY, 2008, VISION RES, V48, P690, DOI 10.1016/j.visres.2007.10.014
   DeAngelis MM, 2008, OPHTHALMOLOGY, V115, P1209, DOI 10.1016/j.ophtha.2007.10.032
   Dewan A, 2006, SCIENCE, V314, P989, DOI 10.1126/science.1133807
   Flaxman SR, 2017, LANCET GLOB HEALTH, V5, pE1221, DOI 10.1016/S2214-109X(17)30393-5
   Francis PJ, 2008, MOL VIS, V14, P1395
   Friedrich U, 2011, HUM MOL GENET, V20, P1387, DOI 10.1093/hmg/ddr020
   Fritsche LG, 2008, NAT GENET, V40, P892, DOI 10.1038/ng.170
   Fritsche LG, 2016, NAT GENET, V48, P134, DOI 10.1038/ng.3448
   Gibbs D, 2008, VISION RES, V48, P685, DOI 10.1016/j.visres.2007.10.022
   Gili P, 2022, EUR J OPHTHALMOL, V32, P651, DOI 10.1177/11206721211002698
   Gong Y, 2021, INT OPHTHALMOL, V41, P995, DOI 10.1007/s10792-020-01655-3
   Hazra A, 2017, J THORAC DIS, V9, P4125, DOI 10.21037/jtd.2017.09.14
   Kaur I, 2008, INVEST OPHTH VIS SCI, V49, P1771, DOI 10.1167/iovs.07-0560
   Lana TP, 2018, OPHTHALMIC GENET, V39, P46, DOI 10.1080/13816810.2017.1354382
   Lin JM, 2008, RETINA-J RET VIT DIS, V28, P309, DOI 10.1097/IAE.0b013e31814cef3a
   Lin MK, 2018, AGING CELL, V17, DOI 10.1111/acel.12710
   Matuskova V, 2020, ACTA OPHTHALMOL, V98, pE691, DOI 10.1111/aos.14357
   Mohamad NA, 2019, HUM GENOMICS, V13, DOI 10.1186/s40246-019-0197-3
   Mori K, 2007, J HUM GENET, V52, P636, DOI 10.1007/s10038-007-0162-1
   Nakayama M, 2014, INVEST OPHTH VIS SCI, V55, P6514, DOI 10.1167/iovs.14-14453
   Romanowska-Dixon B, 2019, KLIN OCZNA, V2019, P34, DOI [10.5114/ko.2019.84560, DOI 10.5114/KO.2019.84560]
   Supanji S, 2021, CLIN OPHTHALMOL, V15, P1101, DOI 10.2147/OPTH.S298310
   Tam POS, 2008, INVEST OPHTH VIS SCI, V49, P2357, DOI 10.1167/iovs.07-1520
   Tian J, 2012, INVEST OPHTH VIS SCI, V53, P4262, DOI 10.1167/iovs.11-8542
   Tong Y, 2010, MOL VIS, V16, P1958
   Tosi GM, 2017, INVEST OPHTH VIS SCI, V58, P162, DOI 10.1167/iovs.16-20922
   Vierkotten S, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022959
   Wang GF, 2010, HUM GENET, V127, P595, DOI 10.1007/s00439-010-0805-8
   Yang X, 2010, BRIT J OPHTHALMOL, V94, P1211, DOI 10.1136/bjo.2009.165811
   Yang ZL, 2006, SCIENCE, V314, P992, DOI 10.1126/science.1133811
   Zhou YL, 2017, BMC OPHTHALMOL, V17, DOI 10.1186/s12886-017-0487-2
NR 33
TC 0
Z9 0
U1 0
U2 1
PU SPRINGER INT PUBL AG
PI CHAM
PA GEWERBESTRASSE 11, CHAM, CH-6330, SWITZERLAND
SN 2193-8245
EI 2193-6528
J9 OPHTHALMOL THER
JI OPHTHALMOL. THER.
PD FEB
PY 2022
VL 11
IS 1
BP 125
EP 133
DI 10.1007/s40123-021-00402-w
EA NOV 2021
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA YJ5MU
UT WOS:000713914400001
PM 34727349
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Luu, J
   Kallestad, L
   Hoang, T
   Lewandowski, D
   Dong, ZQ
   Blackshaw, S
   Palczewski, K
AF Luu, Jennings
   Kallestad, Les
   Thanh Hoang
   Lewandowski, Dominik
   Dong, Zhiqian
   Blackshaw, Seth
   Palczewski, Krzysztof
TI Epigenetic hallmarks of age-related macular degeneration are
   recapitulated in a photosensitive mouse model
SO HUMAN MOLECULAR GENETICS
LA English
DT Article
ID RETINOPATHY; EXPRESSION; WIDE
AB Age-related macular degeneration (AMD) is a chronic, multifactorial disorder and a leading cause of blindness in the elderly. Characterized by progressive photoreceptor degeneration in the central retina, disease progression involves epigenetic changes in chromatin accessibility resulting from environmental exposures and chronic stress. Here, we report that a photosensitive mouse model of acute stress-induced photoreceptor degeneration recapitulates the epigenetic hallmarks of human AMD. Global epigenomic profiling was accomplished by employing an Assay for Transposase-Accessible Chromatin using Sequencing (ATAC-Seq), which revealed an association between decreased chromatin accessibility and stress-induced photoreceptor cell death in our mouse model. The epigenomic changes induced by light damage include reduced euchromatin and increased heterochromatin abundance, resulting in transcriptional and translational dysregulation that ultimately drives photoreceptor apoptosis and an inflammatory reactive gliosis in the retina. Of particular interest, pharmacological inhibition of histone deacetylase 11 (HDAC11) and suppressor of variegation 3-9 homolog 2 (SUV39H2), key histone-modifying enzymes involved in promoting reduced chromatin accessibility, ameliorated light damage in our mouse model, supporting a causal link between decreased chromatin accessibility and photoreceptor degeneration, thereby elucidating a potential new therapeutic strategy to combat AMD.
C1 [Luu, Jennings] Case Western Reserve Univ, Sch Med, Dept Pharmacol, 10900 Euclid Ave, Cleveland, OH 44106 USA.
   [Luu, Jennings; Kallestad, Les; Lewandowski, Dominik; Dong, Zhiqian; Palczewski, Krzysztof] Univ Calif Irvine, Gavin Herbert Eye Inst, 829 Hlth Sci Rd 2216, Irvine, CA 92697 USA.
   [Luu, Jennings; Kallestad, Les; Lewandowski, Dominik; Dong, Zhiqian; Palczewski, Krzysztof] Univ Calif Irvine, Dept Ophthalmol, 829 Hlth Sci Rd 2216, Irvine, CA 92697 USA.
   [Thanh Hoang; Blackshaw, Seth] Johns Hopkins Univ, Solomon H Snyder Dept Neurosci, Sch Med, Baltimore, MD 21205 USA.
   [Blackshaw, Seth] Johns Hopkins Univ, Ctr Human Syst Biol, Inst Cell Engn, Dept Ophthalmol,Dept Neurol,Sch Med, Baltimore, MD 21205 USA.
   [Palczewski, Krzysztof] Univ Calif Irvine, Sch Med, Dept Physiol & Biophys, Irvine, CA 92697 USA.
   [Palczewski, Krzysztof] Univ Calif Irvine, Dept Chem, Irvine, CA 92697 USA.
C3 Case Western Reserve University; University of California System;
   University of California Irvine; University of California System;
   University of California Irvine; Johns Hopkins University; Johns Hopkins
   University; University of California System; University of California
   Irvine; University of California System; University of California Irvine
RP Kallestad, L (通讯作者)，Univ Calif Irvine, Gavin Herbert Eye Inst, 829 Hlth Sci Rd 2216, Irvine, CA 92697 USA.; Kallestad, L (通讯作者)，Univ Calif Irvine, Dept Ophthalmol, 829 Hlth Sci Rd 2216, Irvine, CA 92697 USA.
EM lkallest@hs.uci.edu
OI Lewandowski, Dominik/0000-0002-2233-5501; Luu, Jennings
   C./0000-0001-7283-0335; DONG, ZHIQIAN/0000-0002-8748-4532
FU National Institutes of Health (NIH) [EY009339, EY027283, EY025451]; NIH
   MSTP training grant [T32 GM007250]; US Department of Veterans Affairs
   [IK2BX002683]
FX The National Institutes of Health (NIH) (EY009339, EY027283, EY025451);
   NIH MSTP training grant T32 GM007250; US Department of Veterans Affairs
   (IK2BX002683).
CR Atlasi Y, 2017, NAT REV GENET, V18, DOI 10.1038/nrg.2017.57
   Bahar R, 2006, NATURE, V441, P1011, DOI 10.1038/nature04844
   Bernstein BE, 2006, CELL, V125, P315, DOI 10.1016/j.cell.2006.02.041
   Bhutto I, 2012, MOL ASPECTS MED, V33, P295, DOI 10.1016/j.mam.2012.04.005
   Bolger AM, 2014, BIOINFORMATICS, V30, P2114, DOI 10.1093/bioinformatics/btu170
   Buenrostro J.D, 2015, CURR PROTOC MOL BIOL, V109
   Cascella R, 2014, J OPHTHALMOL, V2014, DOI 10.1155/2014/582842
   Chen H, 2011, BMC BIOINFORMATICS, V12, DOI 10.1186/1471-2105-12-35
   Chen Y, 2016, SCI SIGNAL, V9, DOI 10.1126/scisignal.aag0245
   Cheng H, 2006, HUM MOL GENET, V15, P2588, DOI 10.1093/hmg/ddl185
   Davis BK, 2011, ANNU REV IMMUNOL, V29, P707, DOI 10.1146/annurev-immunol-031210-101405
   Dobin A, 2013, BIOINFORMATICS, V29, P15, DOI 10.1093/bioinformatics/bts635
   Feinberg AP, 2007, NATURE, V447, P433, DOI 10.1038/nature05919
   Fournel M, 2008, MOL CANCER THER, V7, P759, DOI 10.1158/1535-7163.MCT-07-2026
   Fritsche LG, 2016, NAT GENET, V48, P134, DOI 10.1038/ng.3448
   Gu ZG, 2014, BIOINFORMATICS, V30, P2811, DOI 10.1093/bioinformatics/btu393
   Huang DW, 2009, NAT PROTOC, V4, P44, DOI 10.1038/nprot.2008.211
   Jiang K, 2013, J CLIN EXP OPHTHAL S, V2, P0071
   Jones PA, 2007, CELL, V128, P683, DOI 10.1016/j.cell.2007.01.029
   Klein HU, 2019, NAT NEUROSCI, V22, P37, DOI 10.1038/s41593-018-0291-1
   Klettner A, 2013, INT J BIOCHEM CELL B, V45, P1457, DOI 10.1016/j.biocel.2013.04.013
   Kohno H, 2013, J BIOL CHEM, V288, P15326, DOI 10.1074/jbc.M112.448712
   Langmead B, 2012, NAT METHODS, V9, P357, DOI [10.1038/NMETH.1923, 10.1038/nmeth.1923]
   Liao Y, 2013, NUCLEIC ACIDS RES, V41, DOI 10.1093/nar/gkt214
   Liddelow SA, 2017, IMMUNITY, V46, P957, DOI 10.1016/j.immuni.2017.06.006
   Luu J, 2018, P NATL ACAD SCI USA, V115, P2866, DOI 10.1073/pnas.1721033115
   Maeda A, 2008, J BIOL CHEM, V283, P26684, DOI 10.1074/jbc.M804505200
   Maeda A, 2009, J BIOL CHEM, V284, P15173, DOI 10.1074/jbc.M900322200
   McCarthy DJ, 2012, NUCLEIC ACIDS RES, V40, P4288, DOI 10.1093/nar/gks042
   Montana CL, 2013, P NATL ACAD SCI USA, V110, P1732, DOI 10.1073/pnas.1214387110
   Ordovas JM, 2010, NAT REV CARDIOL, V7, P510, DOI 10.1038/nrcardio.2010.104
   Ramirez F, 2016, NUCLEIC ACIDS RES, V44, pW160, DOI 10.1093/nar/gkw257
   Rando TA, 2012, CELL, V148, P46, DOI 10.1016/j.cell.2012.01.003
   Rivera CM, 2013, CELL, V155, P39, DOI 10.1016/j.cell.2013.09.011
   Robinson JT, 2011, NAT BIOTECHNOL, V29, P24, DOI 10.1038/nbt.1754
   Seto E, 2014, CSH PERSPECT BIOL, V6, DOI 10.1101/cshperspect.a018713
   Stuart T, 2019, CELL, V177, P1888, DOI 10.1016/j.cell.2019.05.031
   Talens RP, 2012, AGING CELL, V11, P694, DOI 10.1111/j.1474-9726.2012.00835.x
   Vougiouklakis Theodore, 2018, Oncotarget, V9, P31820, DOI 10.18632/oncotarget.25806
   Wang CXZ, 2012, EXP EYE RES, V102, P1, DOI 10.1016/j.exer.2012.06.003
   Wang J, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-017-02794-5
   Wang SK, 2019, P NATL ACAD SCI USA, V116, P10140, DOI 10.1073/pnas.1901787116
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Yang G, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms14941
   Zhang Y, 2008, GENOME BIOL, V9, DOI 10.1186/gb-2008-9-9-r137
NR 45
TC 6
Z9 6
U1 0
U2 3
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0964-6906
EI 1460-2083
J9 HUM MOL GENET
JI Hum. Mol. Genet.
PD AUG 1
PY 2020
VL 29
IS 15
BP 2611
EP 2624
DI 10.1093/hmg/ddaa158
PG 14
WC Biochemistry & Molecular Biology; Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Genetics & Heredity
GA OH6OE
UT WOS:000582711800012
PM 32691052
OA Green Published
DA 2022-11-30
ER

PT J
AU Tolentino, MJ
   Dennrick, A
   John, E
   Tolentino, MS
AF Tolentino, Michael John
   Dennrick, Abrahan
   John, Elizabeth
   Tolentino, Michael Steven
TI Drugs in Phase II clinical trials for the treatment of age-related
   macular degeneration
SO EXPERT OPINION ON INVESTIGATIONAL DRUGS
LA English
DT Review
DE aflibrecept; age related macular degeneration; bevacizumab; complement;
   fovista; gene therapy; geographic atrophy; ranibizumab; VEGF
ID ENDOTHELIAL GROWTH-FACTOR; COMPLEMENT FACTOR-H; RETINOL-BINDING-PROTEIN;
   SERUM AMYLOID P; ALTERNATIVE PATHWAY; VITREOMACULAR ADHESION; GEOGRAPHIC
   ATROPHY; FACTOR-B; DRUSEN; RANIBIZUMAB
AB Introduction: The clinical development of anti-VEGF therapies for the treatment of exudative age-related macular degeneration (wet AMD) has revolutionized ophthalmology. Indeed, it has provided clinicians and patients with treatments that lessen visual loss from in a disease that once was uniformly blinding. Although blindness is yet to be eradicated from AMD, repeated intraocular anti-VEGF injections are required to preserve a patient's vision. Therefore, further advances in this field are necessary.
   Areas covered: This review provides an overview of the agents that are in mid-stage phase trials for both exudative (wet AMD) and nonexudative macular degeneration (dry AMD). For wet AMD, new agents intend to enhance efficacy, develop alternative delivery such as eye drops, investigate alternate targets and construct sustained release strategies. For advanced dry AMD, the goal is to develop a strategy to slow or stop progressive loss of retinal tissue seen in geographic atrophy, the hallmark of advanced dry AMD.
   Expert opinion: It is important to develop better more sensitive biomarkers, validating different approvable clinical trial endpoints and stratifying patients on their genetic polymorphisms. These developments should help to progress the already rapidly developing field of macular degeneration therapy.
C1 [Tolentino, Michael John; Dennrick, Abrahan; John, Elizabeth] Univ Cent Florida, Coll Med, Orlando, FL 32827 USA.
   [Tolentino, Michael John; Tolentino, Michael Steven] Ctr Retina & Macular Dis, Winter Haven, FL 33880 USA.
C3 State University System of Florida; University of Central Florida
RP Tolentino, MJ (通讯作者)，Univ Cent Florida, Coll Med, 6850 Lake Nona Blvd, Orlando, FL 32827 USA.
EM Miket@crmd.net
FU Tolentino Eye Research Foundation; Regeneron; Bayer; Pfizer, Inc.;
   GlaxoSmithKline; Ophthotech; Panoptica; Genentech; Roche; Valeant;
   Alcon; Allergan
FX The authors were funded by a grant from the Tolentino Eye Research
   Foundation. MJ Tolentino has received grants from Regeneron, Bayer,
   Pfizer, Inc., GlaxoSmithKline, Ophthotech, Panoptica, Genentech, Roche,
   Valeant, Alcon, and Allergan and has received speaker honorarium from
   Regeneron. The authors have no other relevant affiliations or financial
   involvement with any organization or entity with a financial interest in
   or financial conflict with the subject matter or materials discussed in
   the manuscript apart from those disclosed.
CR Akuffo KO, 2014, OPHTHAL EPIDEMIOL, V21, P111, DOI 10.3109/09286586.2014.888085
   Anderson DH, 2004, EXP EYE RES, V78, P243, DOI 10.1016/j.exer.2003.10.011
   Anderson DH, 2002, AM J OPHTHALMOL, V134, P411, DOI 10.1016/S0002-9394(02)01624-0
   Anderson DH, 2010, PROG RETIN EYE RES, V29, P95, DOI 10.1016/j.preteyeres.2009.11.003
   Arons I., 2013, IRV ARONS JOURNAL
   Auricchio A, 2002, MOL THER, V6, P490, DOI 10.1006/mthe.2002.0702
   Awh CC, 2013, OPHTHALMOLOGY, V120, P2317, DOI 10.1016/j.ophtha.2013.07.039
   Baas DC, 2010, OPHTHALMOLOGY, V117, P500, DOI 10.1016/j.ophtha.2009.08.032
   Baglietto L, 2000, CANCER DETECT PREV, V24, P369
   Barouch Fina C., 2007, International Ophthalmology Clinics, V47, P185, DOI 10.1097/IIO.0b013e3180377936
   Bearelly S, 2011, RETINA-J RET VIT DIS, V31, P81, DOI 10.1097/IAE.0b013e3181e0958b
   Beatty S, 2001, INVEST OPHTH VIS SCI, V42, P439
   Binz HK, 2004, NAT BIOTECHNOL, V22, P575, DOI 10.1038/nbt962
   Binz HK, 2003, J MOL BIOL, V332, P489, DOI 10.1016/S0022-2836(03)00896-9
   Bora NS, 2006, J IMMUNOL, V177, P1872, DOI 10.4049/jimmunol.177.3.1872
   Bora PS, 2005, J IMMUNOL, V174, P491, DOI 10.4049/jimmunol.174.1.491
   Borras L, 2010, J BIOL CHEM, V285, P9054, DOI 10.1074/jbc.M109.072876
   Brafman A, 2004, INVEST OPHTH VIS SCI, V45, P3796, DOI 10.1167/iovs.04-0052
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   Caballero S, 2009, EXP EYE RES, V88, P367, DOI 10.1016/j.exer.2008.07.012
   Cao XG, 2011, PATHOL INT, V61, P528, DOI 10.1111/j.1440-1827.2011.02695.x
   Castano AP, 2009, SCI TRANSL MED, V1, DOI 10.1126/scitranslmed.3000111
   Chakravarthy U, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.04.015
   Chew EY, 2013, OPHTHALMOLOGY, V120, P1604, DOI 10.1016/j.ophtha.2013.01.021
   Chew EY, 2013, JAMA-J AM MED ASSOC, V309, P2005, DOI 10.1001/jama.2013.4997
   Choudhury P, 1997, INVEST OPHTH VIS SCI, V38, P824
   Connolly B, 2006, OPHTHALMOL CLIN N AM, V19, pvi
   Connolly Brian, 2006, Ophthalmol Clin North Am, V19, P381
   Corradetti MN, 2005, J BIOL CHEM, V280, P9769, DOI 10.1074/jbc.C400557200
   Crabb JW, 2002, P NATL ACAD SCI USA, V99, P14682, DOI 10.1073/pnas.222551899
   Csaky C, 2013, RETINA SUBSPECIALTY
   Dalkara D, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3005708
   Damico FM, 2012, ARQ BRAS OFTALMOL, V75, P71, DOI 10.1590/S0004-27492012000100016
   Danis R, 2014, BRIT J OPHTHALMOL, V98, P172, DOI 10.1136/bjophthalmol-2013-303117
   Davies S, 2001, FREE RADICAL BIO MED, V31, P256, DOI 10.1016/S0891-5849(01)00582-2
   de Smet MD, 2009, INVEST OPHTH VIS SCI, V50, P814, DOI 10.1167/iovs.08-2185
   Dentchev T, 2003, MOL VIS, V9, P184
   Dillingh MR, 2013, PULM PHARMACOL THER, V26, P672, DOI 10.1016/j.pupt.2013.01.008
   Ding JD, 2011, P NATL ACAD SCI USA, V108, pE279, DOI 10.1073/pnas.1100901108
   Dixon JA, 2009, EXPERT OPIN INV DRUG, V18, P1573, DOI 10.1517/13543780903201684
   DOREY CK, 1989, INVEST OPHTH VIS SCI, V30, P1691
   Duffield JS, 2013, ANNU REV PATHOL-MECH, V8, P241, DOI 10.1146/annurev-pathol-020712-163930
   Dugel P, 2012, RETINA SUBSPECIALTY
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Ferrara N, 2006, RETINA-J RET VIT DIS, V26, P859, DOI 10.1097/01.iae.0000242842.14624.e7
   Friberg TR, 2010, BRIT J OPHTHALMOL, V94, P1611, DOI 10.1136/bjo.2009.174946
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Gandorfer A, 2004, INVEST OPHTH VIS SCI, V45, P641, DOI 10.1167/iovs.03-0930
   Hageman GS, 1999, MOL VIS, V5
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Hecker LA, 2010, HUM MOL GENET, V19, P209, DOI 10.1093/hmg/ddp472
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Heinen S, 2009, BLOOD, V114, P2439, DOI 10.1182/blood-2009-02-205641
   Igarashi T, 2010, HUM GENE THER, V21, P631, DOI 10.1089/hum.2009.153
   Jansen RM, 2013, MED LAW, V32, P65
   Jo N, 2006, AM J PATHOL, V168, P2036, DOI 10.2353/ajpath.2006.050588
   Johnson LV, 2002, P NATL ACAD SCI USA, V99, P11830, DOI 10.1073/pnas.192203399
   Jozsi M, 2008, TRENDS IMMUNOL, V29, P380, DOI 10.1016/j.it.2008.04.008
   Kaiser PK, 2013, OPHTHALMOLOGY, V120, pS11, DOI 10.1016/j.ophtha.2013.01.061
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Katschke KJ, 2012, J BIOL CHEM, V287, P12886, DOI 10.1074/jbc.M112.345082
   Kawaguchi R, 2007, SCIENCE, V315, P820, DOI 10.1126/science.1136244
   Kernt M, 2012, RETINA-J RET VIT DIS, V32, P1652, DOI 10.1097/IAE.0b013e318240a558
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Krebs I, 2007, AM J OPHTHALMOL, V144, P741, DOI 10.1016/j.ajo.2007.07.024
   Kubota R, 2014, RETINA-J RET VIT DIS, V34, P603, DOI 10.1097/01.iae.0000434565.80060.f8
   Kumar R, 2007, MOL CANCER THER, V6, P2012, DOI 10.1158/1535-7163.MCT-07-0193
   Kuroki M, 1996, J CLIN INVEST, V98, P1667, DOI 10.1172/JCI118962
   Lamb LE, 2004, PHOTOCHEM PHOTOBIOL, V79, P127, DOI 10.1562/0031-8655(2004)079<0127:AACOOL>2.0.CO;2
   Li BX, 2010, ARCH BIOCHEM BIOPHYS, V504, P56, DOI 10.1016/j.abb.2010.07.024
   Lommatzsch A, 2008, GRAEF ARCH CLIN EXP, V246, P803, DOI 10.1007/s00417-007-0749-4
   Loyet KM, 2012, INVEST OPHTH VIS SCI, V53, P6628, DOI 10.1167/iovs.12-9587
   Maeda A, 2006, MOL PHARMACOL, V70, P1220, DOI 10.1124/mol.106.026823
   Margrain TH, 2004, PROG RETIN EYE RES, V23, P523, DOI 10.1016/j.preteyeres.2004.05.001
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Mata NL, 2013, RETINA-J RET VIT DIS, V33, P498, DOI 10.1097/IAE.0b013e318265801d
   Mayer G, 2004, BIODRUGS, V18, P351, DOI 10.2165/00063030-200418060-00002
   McLaughlin MM, 2013, JAMA OPHTHALMOL, V131, P1595, DOI 10.1001/jamaophthalmol.2013.5002
   Meagher KA, 2013, BRIT J NUTR, V110, P289, DOI 10.1017/S0007114512004837
   Miller JW, 2013, OPHTHALMOLOGY, V120, P106, DOI 10.1016/j.ophtha.2012.07.038
   Mojana F, 2008, AM J OPHTHALMOL, V146, P218, DOI 10.1016/j.ajo.2008.04.027
   Murdaugh LS, 2011, J MASS SPECTROM, V46, P90, DOI 10.1002/jms.1865
   Nguyen QD, 2012, EYE, V26, P1099, DOI 10.1038/eye.2012.106
   Nozaki M, 2006, P NATL ACAD SCI USA, V103, P2328, DOI 10.1073/pnas.0408835103
   Nunes RP, 2013, AGE RELATED MACULAR, P580
   PAULEIKHOFF D, 1990, AM J OPHTHALMOL, V109, P38, DOI 10.1016/S0002-9394(14)75576-X
   Quadro L, 2004, J LIPID RES, V45, P1975, DOI 10.1194/jlr.M400137-JLR200
   Nguyen QD, 2012, OPHTHALMOLOGY, V119, P1867, DOI 10.1016/j.ophtha.2012.03.043
   Raychaudhuri S, 2010, NAT GENET, V42, P553, DOI 10.1038/ng0710-553
   Reynolds R, 2009, INVEST OPHTH VIS SCI, V50, P5818, DOI 10.1167/iovs.09-3928
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rosenfeld PJ, 2011, OPHTHALMOLOGY, V118, P523, DOI 10.1016/j.ophtha.2010.07.011
   Seddon JM, 1996, JAMA-J AM MED ASSOC, V276, P1141, DOI 10.1001/jama.276.14.1141
   Shoshani T, 2002, MOL CELL BIOL, V22, P2283, DOI 10.1128/MCB.22.7.2283-2293.2002
   Smuc T, 2013, J PHARMACEUT BIOMED, V81-82, P210, DOI 10.1016/j.jpba.2013.03.014
   Sparrow JR, 2000, INVEST OPHTH VIS SCI, V41, P1981
   Stahl A, 2013, ANGIOGENESIS, V16, P101, DOI 10.1007/s10456-012-9302-0
   Stanton CM, 2011, INVEST OPHTH VIS SCI, V52, P8828, DOI 10.1167/iovs.11-7933
   Stumpp MT, 2008, DRUG DISCOV TODAY, V13, P695, DOI 10.1016/j.drudis.2008.04.013
   TAYLOR HR, 1992, ARCH OPHTHALMOL-CHIC, V110, P99, DOI 10.1001/archopht.1992.01080130101035
   Thakur A, 2011, MICROVASC RES, V82, P346, DOI 10.1016/j.mvr.2011.09.001
   Thurnham DI, 2013, FOOD CHEM TOXICOL, V59, P455, DOI 10.1016/j.fct.2013.06.002
   Tolentino M, 2011, SURV OPHTHALMOL, V56, P95, DOI 10.1016/j.survophthal.2010.08.006
   Tolentino MJ, 2009, CURR MOL MED, V9, P973, DOI 10.2174/156652409789712783
   Tsui I, 2012, J BIOMED BIOTECHNOL, DOI 10.1155/2012/354979
   van der Burght Barbro W, 2013, Acta Ophthalmol, V91, pe537, DOI 10.1111/aos.12146
   Vives-Bauza C, 2008, J BIOL CHEM, V283, P24770, DOI 10.1074/jbc.M800706200
   Wang Q, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0070544
   Whitehead KA, 2009, NAT REV DRUG DISCOV, V8, P129, DOI 10.1038/nrd2742
   Wilhelm SM, 2011, INT J CANCER, V129, P245, DOI 10.1002/ijc.25864
   Williams D, 2013, AMERICAN SOCIETY OF
   World Health Organization, 2014, PRIORITY EYE DISEASE
   Wu ZG, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0057642
   Xie B, 2009, J CELL PHYSIOL, V218, P192, DOI 10.1002/jcp.21588
   Xu YY, 2001, IMMUNOL REV, V180, P123, DOI 10.1034/j.1600-065X.2001.1800111.x
   Yehoshua Z, 2014, OPHTHALMOLOGY, V121, P693, DOI 10.1016/j.ophtha.2013.09.044
   Zareparsi S, 2005, AM J HUM GENET, V77, P149, DOI 10.1086/431426
NR 120
TC 36
Z9 46
U1 0
U2 39
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 1354-3784
EI 1744-7658
J9 EXPERT OPIN INV DRUG
JI Expert Opin. Investig. Drugs
PD FEB
PY 2015
VL 24
IS 2
BP 183
EP 199
DI 10.1517/13543784.2015.961601
PG 17
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA AY8MS
UT WOS:000347808500005
PM 25243494
DA 2022-11-30
ER

PT J
AU Jensen, EG
   Jakobsen, TS
   Thiel, S
   Askou, AL
   Corydon, TJ
AF Jensen, Emilie Grarup
   Jakobsen, Thomas Stax
   Thiel, Steffen
   Askou, Anne Louise
   Corydon, Thomas J.
TI Associations between the Complement System and Choroidal
   Neovascularization in Wet Age-Related Macular Degeneration
SO INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
LA English
DT Review
DE age-related macular degeneration; complement system; choroidal
   neovascularization; anti-complement therapy
ID PIGMENT EPITHELIAL-CELLS; MEMBRANE-ATTACK-COMPLEX; INDUCED
   HISTAMINE-RELEASE; GROWTH-FACTOR EXPRESSION; C-REACTIVE PROTEIN;
   FACTOR-H; BRUCHS MEMBRANE; ALTERNATIVE PATHWAY; APOPTOTIC CELLS;
   GENOMEWIDE-SCAN
AB Age-related macular degeneration (AMD) is the leading cause of blindness affecting the elderly in the Western world. The most severe form of AMD, wet AMD (wAMD), is characterized by choroidal neovascularization (CNV) and acute vision loss. The current treatment for these patients comprises monthly intravitreal injections of anti-vascular endothelial growth factor (VEGF) antibodies, but this treatment is expensive, uncomfortable for the patient, and only effective in some individuals. AMD is a complex disease that has strong associations with the complement system. All three initiating complement pathways may be relevant in CNV formation, but most evidence indicates a major role for the alternative pathway (AP) and for the terminal complement complex, as well as certain complement peptides generated upon complement activation. Since the complement system is associated with AMD and CNV, a complement inhibitor may be a therapeutic option for patients with wAMD. The aim of this review is to (i) reflect on the possible complement targets in the context of wAMD pathology, (ii) investigate the results of prior clinical trials with complement inhibitors for wAMD patients, and (iii) outline important considerations when developing a future strategy for the treatment of wAMD.
C1 [Jensen, Emilie Grarup; Thiel, Steffen; Askou, Anne Louise; Corydon, Thomas J.] Aarhus Univ, Dept Biomed, DK-8000 Aarhus C, Denmark.
   [Jakobsen, Thomas Stax; Corydon, Thomas J.] Aarhus Univ Hosp, Dept Ophthalmol, DK-8200 Aarhus N, Denmark.
C3 Aarhus University; Aarhus University
RP Corydon, TJ (通讯作者)，Aarhus Univ, Dept Biomed, DK-8000 Aarhus C, Denmark.; Corydon, TJ (通讯作者)，Aarhus Univ Hosp, Dept Ophthalmol, DK-8200 Aarhus N, Denmark.
EM egj@biomed.au.dk; thomasstaxjakobsen@gmail.com; st@biomed.au.dk;
   ala@biomed.au.dk; corydon@biomed.au.dk
RI Askou, Anne/AGW-2995-2022; Jakobsen, Thomas Stax/GVU-5079-2022
OI Corydon, Thomas Juhl/0000-0003-3588-6350; Jakobsen, Thomas
   Stax/0000-0002-5393-3918; Askou, Anne Louise/0000-0002-5512-1796; Thiel,
   Steffen/0000-0002-4817-155X; Jensen, Emilie Grarup/0000-0003-0502-5584
FU Danish Eye Research Foundation
FX This research was funded by The Danish Eye Research Foundation (T.J.C.).
CR Abecasis GR, 2004, AM J HUM GENET, V74, P482, DOI 10.1086/382786
   Alawieh A, 2015, J NEUROINFLAMM, V12, DOI 10.1186/s12974-015-0464-8
   ALPER CA, 1969, SCIENCE, V163, P286, DOI 10.1126/science.163.3864.286
   Altay L, 2019, EYE, V33, P1859, DOI 10.1038/s41433-019-0501-4
   Ambati J, 2003, SURV OPHTHALMOL, V48, P257, DOI 10.1016/S0039-6257(03)00030-4
   Anderson DH, 2002, AM J OPHTHALMOL, V134, P411, DOI 10.1016/S0002-9394(02)01624-0
   Anderson DH, 2010, PROG RETIN EYE RES, V29, P95, DOI 10.1016/j.preteyeres.2009.11.003
   Anderson NL, 2002, MOL CELL PROTEOMICS, V1, P845, DOI 10.1074/mcp.R200007-MCP200
   Askou AL, 2021, GENE THER, V28, P209, DOI 10.1038/s41434-020-0168-2
   Askou AL, 2019, MOL THER-NUCL ACIDS, V16, P38, DOI 10.1016/j.omtn.2019.01.012
   Askou AL, 2018, METHODS MOL BIOL, V1715, P47, DOI 10.1007/978-1-4939-7522-8_4
   Askou AL, 2015, MOL THER-METH CLIN D, V2, DOI 10.1038/mtm.2014.64
   Avery RL, 2006, OPHTHALMOLOGY, V113, P363, DOI 10.1016/j.ophtha.2005.11.019
   Bexborn F, 2008, MOL IMMUNOL, V45, P2370, DOI 10.1016/j.molimm.2007.11.003
   Bhutto IA, 2016, BRIT J OPHTHALMOL, V100, P720, DOI 10.1136/bjophthalmol-2015-308290
   Bhutto IA, 2011, BRIT J OPHTHALMOL, V95, P1323, DOI 10.1136/bjo.2010.199216
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Black JRM, 2016, GENET MED, V18, P283, DOI 10.1038/gim.2015.70
   Booij JC, 2010, PROG RETIN EYE RES, V29, P1, DOI 10.1016/j.preteyeres.2009.08.003
   Bora NS, 2007, J IMMUNOL, V178, P1783, DOI 10.4049/jimmunol.178.3.1783
   Bora NS, 2006, J IMMUNOL, V177, P1872, DOI 10.4049/jimmunol.177.3.1872
   Bora NS, 2015, MOL IMMUNOL, V63, P176, DOI 10.1016/j.molimm.2014.07.012
   Bora NS, 2010, J BIOL CHEM, V285, P33826, DOI 10.1074/jbc.M110.153130
   Bora PS, 2005, J IMMUNOL, V174, P491, DOI 10.4049/jimmunol.174.1.491
   Borras C, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-50420-9
   Brockmann C, 2015, GRAEF ARCH CLIN EXP, V253, P1695, DOI 10.1007/s00417-015-3041-z
   Campa C, 2010, MEDIAT INFLAMM, V2010, DOI 10.1155/2010/546826
   Campagne MV, 2016, IMMUNOBIOLOGY, V221, P733, DOI 10.1016/j.imbio.2015.11.007
   Cashman SM, 2015, J GENE MED, V17, P229, DOI 10.1002/jgm.2865
   Cashman SM, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019078
   Cashman SM, 2011, INVEST OPHTH VIS SCI, V52, P3436, DOI 10.1167/iovs.10-6002
   Chen M, 2007, EXP EYE RES, V84, P635, DOI 10.1016/j.exer.2006.11.015
   Chen M, 2008, EXP EYE RES, V87, P543, DOI 10.1016/j.exer.2008.09.005
   Cherepanoff S, 2010, BRIT J OPHTHALMOL, V94, P918, DOI 10.1136/bjo.2009.165563
   Chirco KR, 2018, EYE, V32, P1740, DOI 10.1038/s41433-018-0170-8
   Chong NHV, 2005, AM J PATHOL, V166, P241, DOI 10.1016/S0002-9440(10)62248-1
   Clark SJ, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01778
   Clark SJ, 2010, BIOCHEM SOC T, V38, P1342, DOI 10.1042/BST0381342
   Clark SJ, 2010, J BIOL CHEM, V285, P30192, DOI 10.1074/jbc.M110.103986
   Clinicaltrials.gov, ZIMURA COMB LUC PAT
   Colijn JM, 2017, OPHTHALMOLOGY, V124, P1753, DOI 10.1016/j.ophtha.2017.05.035
   Combadiere C, 2007, J CLIN INVEST, V117, P2920, DOI 10.1172/JCI31692
   Corporation O, OPHTH ANN RES PHAS 2
   Cortright DN, 2009, CURR EYE RES, V34, P57, DOI 10.1080/02713680802546658
   Corydon TJ, 2015, HUM GENE THER, V26, P777, DOI 10.1089/hum.2015.064.cxn
   Daien V, 2018, OPHTHALMOLOGY, V125, P66, DOI 10.1016/j.ophtha.2017.07.005
   Davis MD, 2005, ARCH OPHTHALMOL-CHIC, V123, P1484
   Dewan A, 2006, SCIENCE, V314, P989, DOI 10.1126/science.1133807
   Ding K, 2019, J CLIN INVEST, V129, P4901, DOI 10.1172/JCI129085
   Ebrahimi KB, 2013, J PATHOL, V229, P729, DOI 10.1002/path.4128
   El Sanharawi M, 2010, PROG RETIN EYE RES, V29, P443, DOI 10.1016/j.preteyeres.2010.04.001
   ELLATI SG, 1994, J INVEST DERMATOL, V102, P803, DOI 10.1111/1523-1747.ep12378589
   Fagerness JA, 2009, EUR J HUM GENET, V17, P100, DOI 10.1038/ejhg.2008.140
   Fajardo I, 2003, J IMMUNOL, V171, P1493, DOI 10.4049/jimmunol.171.3.1493
   Fakhouri F, 2010, KIDNEY INT, V78, P279, DOI 10.1038/ki.2010.132
   FEARON DT, 1975, J EXP MED, V142, P856, DOI 10.1084/jem.142.4.856
   Fernandez-Godino R, 2018, HUM MOL GENET, V27, P147, DOI 10.1093/hmg/ddx392
   Fritsche LG, 2016, NAT GENET, V48, P134, DOI 10.1038/ng.3448
   Fritsche LG, 2013, NAT GENET, V45, P433, DOI 10.1038/ng.2578
   GASS JDM, 1973, ARCH OPHTHALMOL-CHIC, V90, P206
   Gaudreault J, 2007, RETINA-J RET VIT DIS, V27, P1260, DOI 10.1097/IAE.0b013e318134eecd
   Geerlings MJ, 2017, MOL IMMUNOL, V84, P65, DOI 10.1016/j.molimm.2016.11.016
   Georgiannakis A, 2015, J IMMUNOL, V195, P3382, DOI 10.4049/jimmunol.1500937
   GREEN WR, 1986, OPHTHALMOLOGY, V93, P1169
   Grossniklaus HE, 2010, PROG RETIN EYE RES, V29, P500, DOI 10.1016/j.preteyeres.2010.05.003
   Grossniklaus HE, 2004, AM J OPHTHALMOL, V137, P496, DOI 10.1016/j.ajo.2003.09.042
   Gulati P, 1993, Behring Inst Mitt, P196
   Habot-Wilner Z, 2019, ACTA OPHTHALMOL, V97, P460, DOI 10.1111/aos.14042
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   HANSCH GM, 1987, INT ARCH ALLER A IMM, V82, P317, DOI 10.1159/000234216
   Hayashi M, 2019, J IMMUNOL, V203, P1411, DOI 10.4049/jimmunol.1900605
   Hecker LA, 2010, HUM MOL GENET, V19, P209, DOI 10.1093/hmg/ddp472
   Heesterbeek TJ, 2020, INVEST OPHTH VIS SCI, V61, DOI 10.1167/iovs.61.3.18
   Heiduschka P, 2007, INVEST OPHTH VIS SCI, V48, P2814, DOI 10.1167/iovs.06-1171
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Heier JS, 2006, OPHTHALMOLOGY, V113, P633, DOI 10.1016/j.ophtha.2005.10.052
   Herbert AP, 2007, J BIOL CHEM, V282, P18960, DOI 10.1074/jbc.M609636200
   Hom G.L., COMPLEMENT INHIBITOR
   HOOK WA, 1975, J IMMUNOL, V114, P1185
   Hourcade DE, 2006, J BIOL CHEM, V281, P2128, DOI 10.1074/jbc.M508928200
   ISHIBASHI T, 1986, AM J OPHTHALMOL, V101, P342, DOI 10.1016/0002-9394(86)90830-5
   Iyengar SK, 2004, AM J HUM GENET, V74, P20, DOI 10.1086/380912
   Jackson TL, 2003, INVEST OPHTH VIS SCI, V44, P2141, DOI 10.1167/iovs.02-1027
   Jakobsdottir J, 2005, AM J HUM GENET, V77, P389, DOI 10.1086/444437
   Johnson LV, 2000, EXP EYE RES, V70, P441, DOI 10.1006/exer.1999.0798
   Johnson LV, 2001, EXP EYE RES, V73, P887, DOI 10.1006/exer.2001.1094
   Kaplan HJ, 1999, NAT MED, V5, P292, DOI 10.1038/6509
   Kay P, 2013, J CELL MOL MED, V17, P833, DOI 10.1111/jcmm.12070
   Kevany BM, 2010, PHYSIOLOGY, V25, P8, DOI 10.1152/physiol.00038.2009
   Khandhadia S, 2013, OPHTHALMOLOGY, V120, P1612, DOI 10.1016/j.ophtha.2013.01.004
   Kim I, 1999, INVEST OPHTH VIS SCI, V40, P2115
   Kim LA, 2012, AM J PATHOL, V181, P376, DOI 10.1016/j.ajpath.2012.06.006
   Klaver CCW, 2001, INVEST OPHTH VIS SCI, V42, P2237
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Klein R, 2014, OPHTHAL EPIDEMIOL, V21, P14, DOI 10.3109/09286586.2013.867512
   Korb LC, 1997, J IMMUNOL, V158, P4525
   Krause TA, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0094313
   Kumar-Singh R, 2019, EXP EYE RES, V184, P266, DOI 10.1016/j.exer.2019.05.006
   Kumaran N, 2018, BRIT MED BULL, V126, P13, DOI 10.1093/bmb/ldy005
   Kunchithapautham K, 2011, J BIOL CHEM, V286, P23717, DOI 10.1074/jbc.M110.214593
   Kuraya M, 2005, IMMUNOBIOLOGY, V209, P689, DOI 10.1016/j.imbio.2004.11.001
   Kuroki M, 1996, J CLIN INVEST, V98, P1667, DOI 10.1172/JCI118962
   Kvanta A, 1996, INVEST OPHTH VIS SCI, V37, P1929
   Labardini CP, 2018, RAMBAM MAIMONIDES ME, V9, DOI 10.5041/RMMJ.10348
   Lambert V, 2003, FASEB J, V17, P2290, DOI 10.1096/fj.03-0113fje
   Langer HF, 2010, BLOOD, V116, P4395, DOI 10.1182/blood-2010-01-261503
   Leffler J, 2010, J BIOL CHEM, V285, P3766, DOI 10.1074/jbc.M109.045427
   Lenier S., APL 2 SLOWS GROWTH G
   Liszewski MK, 2017, MOL IMMUNOL, V84, P2, DOI 10.1016/j.molimm.2017.01.004
   Liu K, 2019, AM J OPHTHALMOL, V197, P156, DOI 10.1016/j.ajo.2018.08.026
   Long Q, 2016, BIOMED RES INT, V2016, DOI 10.1155/2016/6958752
   Lopez PF, 1996, INVEST OPHTH VIS SCI, V37, P855
   Lores-Motta L, 2018, OPHTHALMOLOGY, V125, P1064, DOI 10.1016/j.ophtha.2017.12.023
   Loyet KM, 2012, INVEST OPHTH VIS SCI, V53, P6628, DOI 10.1167/iovs.12-9587
   Lubbers R, 2017, CLIN EXP IMMUNOL, V188, P183, DOI 10.1111/cei.12952
   Lueck K, 2011, EYE, V25, P1074, DOI 10.1038/eye.2011.109
   Luo C, 2011, MOL VIS, V17, P1588
   Majewski J, 2003, AM J HUM GENET, V73, P540, DOI 10.1086/377701
   Martin M, 2016, CELL DEATH DIFFER, V23, P903, DOI 10.1038/cdd.2015.164
   McGrath FDG, 2006, J IMMUNOL, V176, P2950, DOI 10.4049/jimmunol.176.5.2950
   Morgan BP, 1997, CLIN EXP IMMUNOL, V107, P1, DOI 10.1046/j.1365-2249.1997.d01-890.x
   Moskovich O, 2012, J BIOL CHEM, V287, P19904, DOI 10.1074/jbc.M111.333039
   Mullins RF, 2001, EYE, V15, P390, DOI 10.1038/eye.2001.142
   Mullins RF, 2000, FASEB J, V14, P835, DOI 10.1096/fasebj.14.7.835
   Mullins RF, 2014, AM J PATHOL, V184, P3142, DOI 10.1016/j.ajpath.2014.07.017
   Mullins RF, 2011, EXP EYE RES, V93, P565, DOI 10.1016/j.exer.2011.06.015
   Natoli R, 2017, INVEST OPHTH VIS SCI, V58, P2977, DOI 10.1167/iovs.17-21672
   Nauta AJ, 2003, EUR J IMMUNOL, V33, P2853, DOI 10.1002/eji.200323888
   Nauta AJ, 2003, TRENDS IMMUNOL, V24, P148, DOI 10.1016/S1471-4906(03)00030-9
   Nishiguchi KM, 2012, INVEST OPHTH VIS SCI, V53, P508, DOI 10.1167/iovs.11-8425
   Nozaki M, 2006, P NATL ACAD SCI USA, V103, P2328, DOI 10.1073/pnas.0408835103
   Park DH, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01007
   Parsons N, 2019, MOL IMMUNOL, V108, P8, DOI 10.1016/j.molimm.2019.02.001
   Pauly D, 2019, CELL REP, V29, P2835, DOI 10.1016/j.celrep.2019.10.084
   PENFOLD PL, 1987, GRAEF ARCH CLIN EXP, V225, P70, DOI 10.1007/BF02155808
   Pennesi ME, 2012, MOL ASPECTS MED, V33, P487, DOI 10.1016/j.mam.2012.06.003
   Pepper MS, 2001, THROMB HAEMOSTASIS, V86, P346
   Poor SH, 2014, INVEST OPHTH VIS SCI, V55, P6525, DOI 10.1167/iovs.14-15067
   Punglia RS, 1997, DIABETES, V46, P1619, DOI 10.2337/diabetes.46.10.1619
   Ren XY, 2016, EXP EYE RES, V145, P352, DOI 10.1016/j.exer.2016.02.004
   Reynolds R, 2009, INVEST OPHTH VIS SCI, V50, P5818, DOI 10.1167/iovs.09-3928
   Ricklin D, 2010, NAT IMMUNOL, V11, P785, DOI 10.1038/ni.1923
   Rivera A, 2005, HUM MOL GENET, V14, P3227, DOI 10.1093/hmg/ddi353
   Rochowiak Aleksandra, 2010, Pol Merkur Lekarski, V28, P79
   Rohrer B, 2009, INVEST OPHTH VIS SCI, V50, P3056, DOI 10.1167/iovs.08-2222
   Rohrer Barbel, 2011, Mol Immunol, V48, pe1, DOI 10.1016/j.molimm.2010.12.016
   Sahu A, 1996, J IMMUNOL, V157, P884
   SALLO FB, 2003, INVEST OPHTH VIS S1, V44
   Schick T, 2017, EYE, V31, P810, DOI 10.1038/eye.2016.328
   Schnabolk G, 2018, MOL THER-METH CLIN D, V9, P1, DOI 10.1016/j.omtm.2017.11.003
   Schnabolk G, 2015, INVEST OPHTH VIS SCI, V56, P1850, DOI 10.1167/iovs.14-15910
   Scholl HPN, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002593
   Schramm EC, 2014, MOL IMMUNOL, V61, P118, DOI 10.1016/j.molimm.2014.06.032
   Schuman SG, 2009, OPHTHALMOLOGY, V116, P488, DOI 10.1016/j.ophtha.2008.10.006
   Seddon JM, 2003, AM J HUM GENET, V73, P780, DOI 10.1086/378505
   Simmons KT, 2020, MOL IMMUNOL, V118, P91, DOI 10.1016/j.molimm.2019.11.007
   SIRAGANIAN RP, 1976, J IMMUNOL, V116, P639
   Skattum L, 2011, MOL IMMUNOL, V48, P1643, DOI 10.1016/j.molimm.2011.05.001
   Sofat R, 2012, INT J EPIDEMIOL, V41, P250, DOI 10.1093/ije/dyr204
   Spaide RF, 2006, AM J OPHTHALMOL, V141, P149, DOI 10.1016/j.ajo.2005.07.025
   Sparrrow JR, 2010, CURR MOL MED, V10, P802
   Spraul CW, 1999, SURV OPHTHALMOL, V44, pS10, DOI 10.1016/S0039-6257(99)00086-7
   Spraul CW, 1997, ARCH OPHTHALMOL-CHIC, V115, P267, DOI 10.1001/archopht.1997.01100150269022
   STEIN I, 1995, MOL CELL BIOL, V15, P5363
   Sweigard JH, 2014, FASEB J, V28, P3171, DOI 10.1096/fj.14-251041
   Tan PL, 2016, HUM GENOMICS, V10, DOI 10.1186/s40246-016-0079-x
   Taylor PR, 2000, J EXP MED, V192, P359, DOI 10.1084/jem.192.3.359
   Thurman JM, 2009, J BIOL CHEM, V284, P16939, DOI 10.1074/jbc.M808166200
   VANDERSCHAFT TL, 1993, BRIT J OPHTHALMOL, V77, P657, DOI 10.1136/bjo.77.10.657
   VINGERLING JR, 1995, OPHTHALMOLOGY, V102, P205
   Volz C, 2015, EUR J PHARM BIOPHARM, V95, P158, DOI 10.1016/j.ejpb.2015.02.020
   Wang X, 2020, INT J OPHTHALMOL-CHI, V13, P382, DOI 10.18240/ijo.2020.03.03
   Weeks DE, 2004, AM J HUM GENET, V75, P174, DOI 10.1086/422476
   Wegscheider BJ, 2007, OPHTHALMOLOGY, V114, P738, DOI 10.1016/j.ophtha.2006.07.048
   Weismann D, 2011, NATURE, V478, P76, DOI 10.1038/nature10449
   Wijnsma KL, 2019, CLIN PHARMACOKINET, V58, P859, DOI 10.1007/s40262-019-00742-8
   Wirthmueller U, 1997, J IMMUNOL, V158, P4444
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Wu JL, 2019, DRUG DES DEV THER, V13, P2413, DOI 10.2147/DDDT.S206355
   Yang ZL, 2006, SCIENCE, V314, P992, DOI 10.1126/science.1133811
   Yates JRW, 2007, NEW ENGL J MED, V357, P553, DOI 10.1056/NEJMoa072618
   Yiu G, 2020, MOL THER-METH CLIN D, V16, P179, DOI 10.1016/j.omtm.2020.01.002
   Zhang YZ, 2013, J AM SOC NEPHROL, V24, P1820, DOI 10.1681/ASN.2013010045
NR 184
TC 5
Z9 5
U1 1
U2 3
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 1422-0067
J9 INT J MOL SCI
JI Int. J. Mol. Sci.
PD DEC
PY 2020
VL 21
IS 24
AR 9752
DI 10.3390/ijms21249752
PG 28
WC Biochemistry & Molecular Biology; Chemistry, Multidisciplinary
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry
GA PL2ZU
UT WOS:000602997100001
PM 33371261
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Zhang, XY
   Lai, TYY
AF Zhang, Xinyuan
   Lai, Timothy Y. Y.
TI Baseline Predictors of Visual Acuity Outcome in Patients with Wet
   Age-Related Macular Degeneration
SO BIOMED RESEARCH INTERNATIONAL
LA English
DT Review
ID ENDOTHELIAL GROWTH-FACTOR; POLYPOIDAL CHOROIDAL VASCULOPATHY;
   VERTEPORFIN PHOTODYNAMIC THERAPY; OUTER RETINAL TUBULATION; INTRAVITREAL
   RANIBIZUMAB; VITREOMACULAR ADHESION; AFLIBERCEPT TREATMENT; GEOGRAPHIC
   ATROPHY; SUBGROUP ANALYSIS; THICKNESS
AB Age-related macular degeneration (AMD) is one of the leading causes of severe vision loss in people over 60 years. Wet AMD (wAMD) causes more severe visual acuity (VA) loss compared with the dry form due to formation of choroidal neovascularization (CNV). Antivascular endothelial growth factor (anti-VEGF) agents such as ranibizumab and aflibercept are now the standard of care treatment for wAMD. Unfortunately, up to a quarter of anti-VEGF-treated wAMD patients might not fully benefit from intravitreal injections and CNV activity may not respond to the treatment and these patients are called anti-VEGF nonresponders. This article aims to discuss the baseline factors associated with VA outcome such as age, initial VA, lesion types, disease duration, optical coherence tomography (OCT) features, fundus autofluorescence findings, and the presence of particular genotype risk alleles in patients with wAMD. Recommendations are provided regarding when to consider discontinuation of therapy because of either success or futility. Understanding the predictive factors associated with VA outcome and treatment frequency response to anti-VEGF therapy may help retina specialists to manage patients' expectations and guide treatment decisions from the beginning of treatment on the basis of "personalized medicine."
C1 [Zhang, Xinyuan] Capital Med Univ, Beijing Inst Ophthalmol, Tongren Hosp, Beijing Tongren Eye Ctr, Beijing 100730, Peoples R China.
   [Lai, Timothy Y. Y.] Chinese Univ Hong Kong, Hong Kong Eye Hosp, Pao So Kok Macular Dis Treatment & Res Ctr, 4-F,147K Argyle St, Kowloon, Hong Kong, Peoples R China.
   [Lai, Timothy Y. Y.] Chinese Univ Hong Kong, Hong Kong Eye Hosp, Dept Ophthalmol & Visual Sci, 4-F,147K Argyle St, Kowloon, Hong Kong, Peoples R China.
   [Lai, Timothy Y. Y.] 2010 Retina & Macula Ctr, Kowloon, Hong Kong, Peoples R China.
C3 Capital Medical University; Chinese University of Hong Kong; Chinese
   University of Hong Kong
RP Zhang, XY (通讯作者)，Capital Med Univ, Beijing Inst Ophthalmol, Tongren Hosp, Beijing Tongren Eye Ctr, Beijing 100730, Peoples R China.
EM mmzxy2010@163.com
RI Lai, Timothy Y Y/AAC-2120-2020
OI Lai, Timothy Y Y/0000-0002-7832-6428; Zhang, Xinyuan/0000-0002-3372-0798
CR Amoaku WM, 2015, EYE, V29, P721, DOI 10.1038/eye.2015.48
   Antoszyk AN, 2008, AM J OPHTHALMOL, V145, P862, DOI 10.1016/j.ajo.2007.12.029
   Benjamin LE, 1998, DEVELOPMENT, V125, P1591
   Bergers G, 2008, NAT REV CANCER, V8, P592, DOI 10.1038/nrc2442
   Boyer DS, 2007, OPHTHALMOLOGY, V114, P246, DOI 10.1016/j.ophtha.2006.10.045
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   Brunk UT, 2002, FREE RADICAL BIO MED, V33, P611, DOI 10.1016/S0891-5849(02)00959-0
   Campochiaro PA, 2016, OPHTHALMOLOGY, V123, P1722, DOI 10.1016/j.ophtha.2016.04.025
   Carmeliet P, 2001, NAT MED, V7, P575, DOI 10.1038/87904
   Carmeliet P, 2011, NAT REV DRUG DISCOV, V10, P417, DOI 10.1038/nrd3455
   Chae B, 2015, INVEST OPHTH VIS SCI, V56, P5040, DOI 10.1167/iovs.15-16494
   Chang LK, 2008, RETINA-J RET VIT DIS, V28, P969, DOI 10.1097/IAE.0b013e3181744165
   Chen H, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0042464
   Chhablani J, 2015, INDIAN J OPHTHALMOL, V63, P384, DOI 10.4103/0301-4738.159861
   Chhablani J, 2014, INDIAN J OPHTHALMOL, V62, P1060, DOI 10.4103/0301-4738.146711
   Chhablani JK, 2011, GRAEF ARCH CLIN EXP, V249, P791, DOI 10.1007/s00417-010-1478-7
   Cho HJ, 2016, AM J OPHTHALMOL, V165, P1, DOI 10.1016/j.ajo.2016.02.019
   Coppens G, 2011, Bull Soc Belge Ophtalmol, P39
   Coscas F, 2015, INVEST OPHTH VIS SCI, V56, P4129, DOI 10.1167/iovs.15-16735
   Cuilla TA, 2015, OPHTHALMOLOGY, V122, P1203, DOI 10.1016/j.ophtha.2015.02.031
   Darland DC, 1999, J CLIN INVEST, V103, P157, DOI 10.1172/JCI6127
   Ehlken C, 2014, EYE, V28, P538, DOI 10.1038/eye.2014.64
   Faria-Correia F, 2013, OPHTHALMOLOGICA, V229, P147, DOI 10.1159/000346854
   FERCHER AF, 1993, AM J OPHTHALMOL, V116, P113, DOI 10.1016/S0002-9394(14)71762-3
   Friedlander M, 2007, J CLIN INVEST, V117, P576, DOI 10.1172/JCI31030
   Gerding H, 2011, GRAEF ARCH CLIN EXP, V249, P653, DOI 10.1007/s00417-011-1636-6
   Gharbiya M, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/273754
   Gomi F, 2008, CURR OPIN OPHTHALMOL, V19, P208, DOI 10.1097/ICU.0b013e3282fb7c33
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Grunwald JE, 2014, OPHTHALMOLOGY, V121, P150, DOI 10.1016/j.ophtha.2013.08.015
   Hariri A, 2015, OPHTHALMOLOGY, V122, P407, DOI 10.1016/j.ophtha.2014.08.035
   Heimes B, 2008, GRAEF ARCH CLIN EXP, V246, P1229, DOI 10.1007/s00417-008-0854-z
   Ho AC, 2014, OPHTHALMOLOGY, V121, P2181, DOI 10.1016/j.ophtha.2014.05.009
   Hua R, 2015, SCI REP-UK, V5, DOI 10.1038/srep07661
   Imamura Y, 2010, SURV OPHTHALMOL, V55, P501, DOI 10.1016/j.survophthal.2010.03.004
   Jaffe GJ, 2017, OPHTHALMOLOGY, V124, P224, DOI 10.1016/j.ophtha.2016.10.010
   Kaiser PK, 2007, AM J OPHTHALMOL, V144, P850, DOI 10.1016/j.ajo.2007.08.012
   Kang HM, 2014, AM J OPHTHALMOL, V157, P1013, DOI 10.1016/j.ajo.2014.01.019
   Kang S, 2009, JPN J OPHTHALMOL, V53, P389, DOI 10.1007/s10384-009-0670-y
   Kawashima Y, 2015, GRAEF ARCH CLIN EXP, V253, P1471, DOI 10.1007/s00417-014-2838-5
   Kim YT, 2011, EYE, V25, P1635, DOI 10.1038/eye.2011.258
   Kloeckener-Gruissem B, 2011, INVEST OPHTH VIS SCI, V52, P4694, DOI 10.1167/iovs.10-6080
   Koh A, 2012, RETINA-J RET VIT DIS, V32, P1453, DOI 10.1097/IAE.0b013e31824f91e8
   Koh L. H. L., 2017, ACTA OPHTHALMOLOGICA
   Kudelka MR, 2013, EXPERT REV OPHTHALMO, V8, P475, DOI 10.1586/17469899.2013.840095
   Kwok AKH, 2002, BRIT J OPHTHALMOL, V86, P892, DOI 10.1136/bjo.86.8.892
   Kwon Yoon Hyung, 2014, Korean J Ophthalmol, V28, P386, DOI 10.3341/kjo.2014.28.5.386
   Lafaut BA, 2000, GRAEF ARCH CLIN EXP, V238, P752, DOI 10.1007/s004170000180
   Larsen M, 2012, OPHTHALMOLOGY, V119, P992, DOI 10.1016/j.ophtha.2012.02.002
   Lee JY, 2013, INVEST OPHTH VIS SCI, V54, P7812, DOI 10.1167/iovs.13-12284
   Lee SJ, 2009, AM J OPHTHALMOL, V147, P621, DOI 10.1016/j.ajo.2008.10.003
   Lim JH, 2012, AM J OPHTHALMOL, V153, P678, DOI 10.1016/j.ajo.2011.09.013
   Lu Kan V, 2013, CNS Oncol, V2, P49
   Lucio-Eterovic AK, 2009, CLIN CANCER RES, V15, P4589, DOI 10.1158/1078-0432.CCR-09-0575
   Lux A, 2007, BRIT J OPHTHALMOL, V91, P1318, DOI 10.1136/bjo.2006.113902
   Manjunath V, 2011, AM J OPHTHALMOL, V152, P663, DOI 10.1016/j.ajo.2011.03.008
   Manjunath V, 2010, AM J OPHTHALMOL, V150, P325, DOI 10.1016/j.ajo.2010.04.018
   Mitamura Y, 2013, J OPHTHALMOL, V2013, DOI 10.1155/2013/518170
   Nagai N, 2016, SCI REP-UK, V6, DOI 10.1038/srep29619
   Nomura Y, 2014, JPN J OPHTHALMOL, V58, P443, DOI 10.1007/s10384-014-0333-5
   Oishi A, 2015, AM J OPHTHALMOL, V159, P853, DOI 10.1016/j.ajo.2015.01.018
   Ristau T, 2013, J CLIN EXP OPHTHALMO, V4, p264J, DOI DOI 10.4172/2155-9570.1000264
   Ritter M, 2014, BRIT J OPHTHALMOL, V98, P1629, DOI 10.1136/bjophthalmol-2014-305186
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Saitta A, 2015, INT OPHTHALMOL, V35, P441, DOI 10.1007/s10792-015-0059-5
   Schaal KB, 2015, RETINA-J RET VIT DIS, V35, P1339, DOI 10.1097/IAE.0000000000000471
   Sebag J, 2015, RETINA-J RET VIT DIS, V35, P1715, DOI 10.1097/IAE.0000000000000718
   Shin HJ, 2011, RETINA-J RET VIT DIS, V31, P1627, DOI 10.1097/IAE.0b013e31820d3d01
   Sun JK, 2014, JAMA OPHTHALMOL, V132, P1309, DOI 10.1001/jamaophthalmol.2014.2350
   Suzuki M, 2014, BRIT J OPHTHALMOL, V98, P1186, DOI 10.1136/bjophthalmol-2013-304670
   Tan CS, 2012, INVEST OPHTH VIS SCI, V53, P261, DOI 10.1167/iovs.11-8782
   Tong JP, 2006, AM J OPHTHALMOL, V141, P456, DOI 10.1016/j.ajo.2005.10.012
   Tranos P, 2013, DRUG DES DEV THER, V7, P485, DOI 10.2147/DDDT.S43470
   Waldstein SM, 2012, RETINA-J RET VIT DIS, V32, P424, DOI 10.1097/IAE.0b013e3182278b80
   Wickremasinghe SS, 2012, OPHTHALMOLOGY, V119, P2413, DOI 10.1016/j.ophtha.2012.06.056
   Yamashiro K, 2012, AM J OPHTHALMOL, V154, P125, DOI 10.1016/j.ajo.2012.01.010
   Ying GS, 2013, OPHTHALMOLOGY, V120, P122, DOI 10.1016/j.ophtha.2012.07.042
   Zweifel SA, 2009, ARCH OPHTHALMOL-CHIC, V127, P1596, DOI 10.1001/archophthalmol.2009.326
NR 78
TC 14
Z9 16
U1 0
U2 1
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 2314-6133
EI 2314-6141
J9 BIOMED RES INT
JI Biomed Res. Int.
PY 2018
VL 2018
AR 9640131
DI 10.1155/2018/9640131
PG 10
WC Biotechnology & Applied Microbiology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biotechnology & Applied Microbiology; Research & Experimental Medicine
GA FX5NA
UT WOS:000426125000001
PM 29682574
OA Green Published, Green Submitted, gold
DA 2022-11-30
ER

PT J
AU Gopinath, B
   Liew, G
   Burlutsky, G
   Mitchell, P
AF Gopinath, Bamini
   Liew, Gerald
   Burlutsky, George
   Mitchell, Paul
TI Age-related macular degeneration and 5-year incidence of impaired
   activities of daily living
SO MATURITAS
LA English
DT Article
DE Age-related macular degeneration; Activities of daily living; Blue
   Mountains Eye Study; Older adults
ID MACULOPATHY
AB Objectives: We aimed to assess the prospective association between age-related macular degeneration (AMD) and impaired activities of daily living (ADL) among a large cohort of older adults.
   Study design: Functional status was determined by the Older Americans Resources and Services ADL scale from 2002-2004 to 2007-2009 among 761 participants aged 60+ years. AMD was assessed from retinal photographs.
   Results: After adjusting for age, sex, living status, self-rated poor health, smoking, body mass index, visual impairment, hypertension, diabetes, hospital admissions in the past year, walking disability, probable depression, mini-mental state examination scores, having any AMD or late AMD increased the risk of incident impaired total ADL 5 years later, odds ratio, OR 2.87(95% confidence intervals, CI 1.44-5.71) and OR 12.95(95% CI 3.78-44.35), respectively. Having any AMD increased the risk of developing instrumental ADL disability over the 5 years, multivariable-adjusted OR 2.06(95% Cl 1.11-3.83).
   Conclusions: This study shows that the presence of AMD could independently signal an increased risk of functional disability, particularly in performing instrumental ADL tasks. (C) 2013 Elsevier Ireland Ltd. All rights reserved.
C1 Univ Sydney, Dept Ophthalmol, Ctr Vis Res, Westmead, NSW 2145, Australia.
   Univ Sydney, Westmead Millennium Inst, Westmead, NSW 2145, Australia.
C3 University of Sydney; University of Sydney; Westmead Institute for
   Medical Research
RP Gopinath, B (通讯作者)，Univ Sydney, Westmead Hosp, Ctr Vis Res, Hawkesbury Rd, Westmead, NSW 2145, Australia.
EM bamini.gopinath@sydney.edu.au
RI Liew, Gerald/AAB-6870-2022; Gopinath, Bamini/K-4286-2019; Mitchell,
   Paul/P-1498-2014
OI Gopinath, Bamini/0000-0003-3573-359X; 
FU Australian National Health; Medical Research Council [974159, 991407,
   211069, 262120]; Westmead Millennium Institute; Macular Degeneration
   Foundation and Blackmores Dr. Paul Beaumont Fellowship
FX The Blue Mountains Eye Study was supported by the Australian National
   Health and Medical Research Council (grant nos. 974159, 991407, 211069,
   262120), and Westmead Millennium Institute. Bamini Gopinath is supported
   by a Macular Degeneration Foundation and Blackmores Dr. Paul Beaumont
   Fellowship.
CR Afridi I, 2003, J HYPERTENS, V21, P1983, DOI 10.1097/01.hjh.0000084751-37215.d2
   ANDRESEN EM, 1994, AM J PREV MED, V10, P77, DOI 10.1016/S0749-3797(18)30622-6
   Attebo K, 1996, OPHTHALMOLOGY, V103, P64
   Duke University Centre for the Study of Aging and Human Development, 1975, OARS MULT FUNCT ASS
   FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6
   Foran S., 2003, OPHTHALMIC EPIDEMIOL, V10, P25
   Guymer RH, 2006, MED J AUSTRALIA, V184, P58
   Hochberg C., 2012, INVEST OPHTH VIS SCI, V53, P6
   Kemper P., 1992, HEALTH SERV RES, V27, P51
   Klein BE, 1989, INVEST OPHTH VIS SCI, V30, P9
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   McCusker J, 1999, J CLIN EPIDEMIOL, V52, P1023, DOI 10.1016/S0895-4356(99)00084-0
   MITCHELL P, 1995, OPHTHALMOLOGY, V102, P1450
   Timberlake GT, 2011, INVEST OPHTH VIS SCI, V52, P2540, DOI 10.1167/iovs.10-6062
   Wang JJ, 2007, OPHTHALMOLOGY, V114, P92, DOI 10.1016/j.ophtha.2006.07.017
   World Health Organization, 1999, DEF DIAGN CLASS DI 1
NR 16
TC 35
Z9 36
U1 0
U2 10
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0378-5122
EI 1873-4111
J9 MATURITAS
JI Maturitas
PD MAR
PY 2014
VL 77
IS 3
BP 263
EP 266
DI 10.1016/j.maturitas.2013.12.001
PG 4
WC Geriatrics & Gerontology; Obstetrics & Gynecology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Geriatrics & Gerontology; Obstetrics & Gynecology
GA AD8HP
UT WOS:000333507400011
PM 24388736
DA 2022-11-30
ER

PT J
AU Beguier, F
   Housset, M
   Roubeix, C
   Augustin, S
   Zagar, Y
   Nous, C
   Mathis, T
   Eandi, C
   Benchaboune, M
   Drame-Maigne, A
   Carpentier, W
   Chardonnet, S
   Touhami, S
   Blot, G
   Conart, JB
   Charles-Messance, H
   Potey, A
   Girmens, JF
   Paques, M
   Blond, F
   Leveillard, T
   Koertvely, E
   Roger, JE
   Sahel, JA
   Sapieha, P
   Delarasse, C
   Guillonneau, X
   Sennlaub, F
AF Beguier, Fanny
   Housset, Michael
   Roubeix, Christophe
   Augustin, Sebastien
   Zagar, Yvrick
   Nous, Caroline
   Mathis, Thibaud
   Eandi, Chiara
   Benchaboune, Mustapha
   Drame-Maigne, Adele
   Carpentier, Wassila
   Chardonnet, Solenne
   Touhami, Sara
   Blot, Guillaume
   Conart, Jean Baptiste
   Charles-Messance, Hugo
   Potey, Anais
   Girmens, Jean-Francois
   Paques, Michel
   Blond, Frederic
   Leveillard, Thierry
   Koertvely, Elod
   Roger, Jerome E.
   Sahel, Jose-Alain
   Sapieha, Przemyslaw
   Delarasse, Cecile
   Guillonneau, Xavier
   Sennlaub, Florian
TI The 10q26 Risk Haplotype of Age-Related Macular Degeneration Aggravates
   Subretinal Inflammation by Impairing Monocyte Elimination
SO IMMUNITY
LA English
DT Article
ID SERINE-PROTEASE HTRA1; RETINAL-PIGMENT EPITHELIUM; COMPLEMENT FACTOR-H;
   CHOROIDAL NEOVASCULARIZATION; CHROMOSOME 10Q26; UP-REGULATION;
   EXPRESSION; GENE; THROMBOSPONDIN-1; OSTEOPONTIN
AB A minor haplotype of the 10q26 locus conveys the strongest genetic risk for age-related macular degeneration (AMD). Here, we examined the mechanisms underlying this susceptibility. We found that monocytes from homozygous carriers of the 10q26 AMD-risk haplotype expressed high amounts of the serine peptidase HTRA1, and HTRA1 located to mononuclear phagocytes (MPs) in eyes of non-carriers with AMD. HTRA1 induced the persistence of monocytes in the subretinal space and exacerbated pathogenic inflammation by hydrolyzing thrombospondin 1 (TSP1), which separated the two CD47-binding sites within TSP1 that are necessary for efficient CD47 activation. This HTRA1-induced inhibition of CD47 signaling induced the expression of pro-inflammatory osteopontin (OPN). OPN expression increased in early monocyte-derived macrophages in 10q26 risk carriers. In models of subretinal inflammation and AMD, OPN deletion or pharmacological inhibition reversed HTRA1-induced pathogenic MP persistence. Our findings argue for the therapeutic potential of CD47 agonists and OPN inhibitors for the treatment of AMD.
C1 [Beguier, Fanny; Housset, Michael; Roubeix, Christophe; Augustin, Sebastien; Zagar, Yvrick; Nous, Caroline; Mathis, Thibaud; Drame-Maigne, Adele; Carpentier, Wassila; Touhami, Sara; Blot, Guillaume; Conart, Jean Baptiste; Charles-Messance, Hugo; Potey, Anais; Blond, Frederic; Leveillard, Thierry; Sahel, Jose-Alain; Delarasse, Cecile; Guillonneau, Xavier; Sennlaub, Florian] Sorbonne Univ, CNRS, Inst Vis, INSERM, 17 Rue Moreau, F-75012 Paris, France.
   [Chardonnet, Solenne] Sorbonne Univ, INSERM, Plateforme Postgen Pitie Salpetriere, P3S,UMS 37 PASS, F-75013 Paris, France.
   [Eandi, Chiara] Univ Torino, Dept Surg Sci, Turin, Italy.
   [Roger, Jerome E.] Univ Paris Saclay, CERTO Retina France, Univ Paris Sud, Paris Saclay Inst Neurosci,CNRS, F-91405 Orsay, France.
   [Benchaboune, Mustapha; Girmens, Jean-Francois; Paques, Michel; Sahel, Jose-Alain] INSERM, CHNO Quinze Vingts, DHU Sight Restore, DGOS,CIC 1423, 28 Rue Charenton, F-75012 Paris, France.
   [Koertvely, Elod] Roche Innovat Ctr Basel, Roche Pharma Res & Early Dev, 124 Grenzacherstr, CH-4070 Basel, Switzerland.
   [Sapieha, Przemyslaw] Univ Montreal, Dept Ophthalmol, Maisonneuve Rosemont Hosp, Res Ctr, Quebec City, PQ, Canada.
C3 Centre National de la Recherche Scientifique (CNRS); Institut National
   de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research
   Universities; Sorbonne Universite; Universite Paris Cite; Institut
   National de la Sante et de la Recherche Medicale (Inserm); UDICE-French
   Research Universities; Sorbonne Universite; University of Turin; Centre
   National de la Recherche Scientifique (CNRS); UDICE-French Research
   Universities; Universite Paris Saclay; CHNO des Quinze-Vingts; Institut
   National de la Sante et de la Recherche Medicale (Inserm); UDICE-French
   Research Universities; Sorbonne Universite; Roche Holding; Universite de
   Montreal
RP Sennlaub, F (通讯作者)，Sorbonne Univ, CNRS, Inst Vis, INSERM, 17 Rue Moreau, F-75012 Paris, France.
EM florian.sennlaub@inserm.fr
RI Delarasse, Cecile/K-8234-2017; Touhami, Sara/AAF-7836-2021; Léveillard,
   Thierry/AAR-1804-2020; Sennlaub, Florian/F-2756-2017; Guillonneau,
   xavier/E-3995-2017; roger, jerome/P-3670-2019; Mathis,
   Thibaud/AAK-5745-2021; Beguier, Fanny/AAY-8581-2020; guillonneau,
   xavier/AAF-9495-2021; Blot, Guillaume/AAK-5849-2021
OI Delarasse, Cecile/0000-0001-9739-4306; Léveillard,
   Thierry/0000-0001-5692-8770; Sennlaub, Florian/0000-0003-4412-1341;
   Guillonneau, xavier/0000-0001-7379-3935; roger,
   jerome/0000-0002-5061-230X; Beguier, Fanny/0000-0002-6123-2978;
   guillonneau, xavier/0000-0001-7379-3935; Blot,
   Guillaume/0000-0002-8955-6704; CHARLES-MESSANCE,
   Hugo/0000-0002-6627-2098; Blond, Frederic/0000-0002-2314-0570; Housset,
   Michael/0000-0002-3892-5696
FU Institut National de la Sante et de la Recherche Medicale (INSERM,
   France); Agence Nationale de la Recherche (ANR, France): ANR Geno 2009
   [R09099DS]; ANR MA-CLEAR [ANR-15-CE14-0015-01]; Programme
   Investissements d'Avenir LABEX LIFESENSES [ANR-10-LABX-65]; Carnot
   Institute (France); IHU FOReSIGHT (France) [ANR-18-IAHU-0001]
FX This work was supported by grants from Institut National de la Sante et
   de la Recherche Medicale (INSERM, France) and grants from the Agence
   Nationale de la Recherche (ANR, France): ANR Geno 2009 (R09099DS) and
   ANR MACLEAR (ANR-15-CE14-0015-01). The work was supported by the
   Programme Investissements d'Avenir LABEX LIFESENSES [ANR-10-LABX-65] and
   IHU FOReSIGHT [ANR-18-IAHU-0001] (France), the Carnot Institute
   (France), and a generous donation by Doris and Michael Bunte.
CR An E, 2010, INVEST OPHTH VIS SCI, V51, P3379, DOI 10.1167/iovs.09-4853
   Bruemmer D, 2003, J CLIN INVEST, V112, P1318, DOI 10.1172/JCI200318141
   Calippe B, 2017, IMMUNITY, V46, P261, DOI 10.1016/j.immuni.2017.01.006
   Chamberland A, 2009, J BIOL CHEM, V284, P27352, DOI 10.1074/jbc.M109.037051
   Chen CY, 2018, MATRIX BIOL, V70, P84, DOI 10.1016/j.matbio.2018.03.013
   Chen W, 2009, EXP EYE RES, V89, P292, DOI 10.1016/j.exer.2008.10.017
   Chowers I, 2008, MOL VIS, V14, P2263
   Clausen T, 2011, NAT REV MOL CELL BIO, V12, P152, DOI 10.1038/nrm3065
   Dobin A, 2013, BIOINFORMATICS, V29, P15, DOI 10.1093/bioinformatics/bts635
   Eigenbrot C, 2012, STRUCTURE, V20, P1040, DOI 10.1016/j.str.2012.03.021
   Fritsche LG, 2014, ANNU REV GENOM HUM G, V15, P151, DOI 10.1146/annurev-genom-090413-025610
   Fritsche LG, 2013, NAT GENET, V45, P433, DOI 10.1038/ng.2578
   Fujita N, 2011, INVEST OPHTH VIS SCI, V52, P9310, DOI 10.1167/iovs.10-7050
   Grau S, 2005, P NATL ACAD SCI USA, V102, P6021, DOI 10.1073/pnas.0501823102
   Guillonneau X, 2017, PROG RETIN EYE RES, V61, P98, DOI 10.1016/j.preteyeres.2017.06.002
   Hou YZ, 2014, J IMMUNOL, V193, P130, DOI 10.4049/jimmunol.1302700
   Hu SJ, 2015, J NEUROSCI, V35, P6987, DOI 10.1523/JNEUROSCI.3955-14.2015
   Hume DA, 2012, BLOOD, V119, P1810, DOI 10.1182/blood-2011-09-379214
   Iejima Daisuke, 2015, J Stem Cells, V10, P193
   Isenberg JS, 2009, J BIOL CHEM, V284, P1116, DOI 10.1074/jbc.M804860200
   Jones A, 2011, P NATL ACAD SCI USA, V108, P14578, DOI 10.1073/pnas.1102853108
   Kanda A, 2010, MOL VIS, V16, P1317
   Lavalette S, 2011, AM J PATHOL, V178, P2416, DOI 10.1016/j.ajpath.2011.01.013
   Lenzo JC, 2012, IMMUNOL CELL BIOL, V90, P429, DOI 10.1038/icb.2011.58
   Levy O, 2015, EMBO MOL MED, V7, P211, DOI 10.15252/emmm.201404524
   Liao SM, 2017, MOL VIS, V23, P318
   Liao Y, 2014, BIOINFORMATICS, V30, P923, DOI 10.1093/bioinformatics/btt656
   Lin MK, 2018, AGING CELL, V17, DOI 10.1111/acel.12710
   Liu JY, 2013, PLOS ONE, V8, DOI [10.1371/journal.pone.0050719, 10.1371/journal.pone.0064143, 10.1371/journal.pone.0057473]
   Lorenzi M, 2016, EXP GERONTOL, V81, P8, DOI 10.1016/j.exger.2016.03.019
   Luhmann UFO, 2009, INVEST OPHTH VIS SCI, V50, P5934, DOI 10.1167/iovs.09-3462
   Lund SA, 2009, J CELL COMMUN SIGNAL, V3, P311, DOI 10.1007/s12079-009-0068-0
   Manna PP, 2005, J BIOL CHEM, V280, P29637, DOI 10.1074/jbc.M500922200
   Martinez-Torres AC, 2015, PLOS MED, V12, DOI 10.1371/journal.pmed.1001796
   Mathis T, 2017, AGING CELL, V16, P173, DOI 10.1111/acel.12540
   Mattapallil MJ, 2012, INVEST OPHTH VIS SCI, V53, P2921, DOI 10.1167/iovs.12-9662
   McDonald JF, 2003, BIOCHEMISTRY-US, V42, P10001, DOI 10.1021/bi0341408
   Micklisch S, 2017, J NEUROINFLAMM, V14, DOI 10.1186/s12974-016-0776-3
   Milner JM, 2008, ARTHRITIS RHEUM-US, V58, P3644, DOI 10.1002/art.24046
   Newman AM, 2012, GENOME MED, V4, DOI [10.1186/PREACCEPT-1418491035586234, 10.1186/gm315]
   Ng TF, 2009, INVEST OPHTH VIS SCI, V50, P5472, DOI 10.1167/iovs.08-2877
   O'Koren EG, 2019, IMMUNITY, V50, P723, DOI 10.1016/j.immuni.2019.02.007
   Oura Y, 2018, AM J PATHOL, V188, P2729, DOI 10.1016/j.ajpath.2018.08.012
   Perez-Riverol Y, 2019, NUCLEIC ACIDS RES, V47, pD442, DOI 10.1093/nar/gky1106
   Quesada AJ, 2005, CELL DEATH DIFFER, V12, P649, DOI 10.1038/sj.cdd.4401615
   Rivera A, 2005, HUM MOL GENET, V14, P3227, DOI 10.1093/hmg/ddi353
   Robbie SJ, 2016, NEUROBIOL AGING, V40, P110, DOI 10.1016/j.neurobiolaging.2015.12.019
   Sakurai E, 2003, INVEST OPHTH VIS SCI, V44, P3578, DOI 10.1167/iovs.03-0097
   SARKS SH, 1976, BRIT J OPHTHALMOL, V60, P324, DOI 10.1136/bjo.60.5.324
   Sennlaub F, 2013, EMBO MOL MED, V5, P1775, DOI 10.1002/emmm.201302692
   Shi YY, 2011, GRAEF ARCH CLIN EXP, V249, P1667, DOI 10.1007/s00417-011-1699-4
   Spugnini EP, 2006, CLIN CANCER RES, V12, P6133, DOI 10.1158/1078-0432.CCR-06-1056
   Streilein JW, 2002, VISION RES, V42, P487, DOI 10.1016/S0042-6989(01)00185-7
   Tosi GM, 2017, INVEST OPHTH VIS SCI, V58, P162, DOI 10.1167/iovs.16-20922
   Truebestein L, 2011, NAT STRUCT MOL BIOL, V18, P386, DOI 10.1038/nsmb.2013
   Tsutsumi C, 2003, J LEUKOCYTE BIOL, V74, P25, DOI 10.1189/jlb.0902436
   van de Garde MDB, 2014, J IMMUNOL, V192, P1196, DOI 10.4049/jimmunol.1302138
   Wang SJ, 2012, ARCH OPHTHALMOL-CHIC, V130, P615, DOI 10.1001/archopthalmol.2011.1892
   Wang XL, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-10124-4
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Yang ZL, 2006, SCIENCE, V314, P992, DOI 10.1126/science.1133811
   Yehualaeshet T, 1999, AM J PATHOL, V155, P841, DOI 10.1016/S0002-9440(10)65183-8
NR 62
TC 27
Z9 27
U1 2
U2 6
PU CELL PRESS
PI CAMBRIDGE
PA 50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA
SN 1074-7613
EI 1097-4180
J9 IMMUNITY
JI Immunity
PD AUG 18
PY 2020
VL 53
IS 2
BP 429
EP +
DI 10.1016/j.immuni.2020.07.021
PG 21
WC Immunology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Immunology
GA NC4NX
UT WOS:000561190600019
PM 32814029
OA Green Submitted, Bronze
DA 2022-11-30
ER

PT J
AU Leinonen, MT
   Hyvarinen, L
AF Leinonen, Markku T.
   Hyvarinen, Lea
TI Documenting Fixation at an Extrafoveal Locus with a Modified Slit Lamp
   in Age-Related Macular Degeneration
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
ID PREFERRED RETINAL LOCI; CENTRAL SCOTOMA; PERFORMANCE; LOCATION; AMD
AB PURPOSE. To develop a simple and clinically useful technique for observing fixation at an extrafoveal locus (preferred retinal locus [PRL]) with different targets and texts in age-related macular degeneration (AMD).
   METHODS. A standard slit lamp was modified by adding several fixation targets in the illumination pathway for direct observation and documentation of fixation during fundus examination. Fixation patterns were analyzed in 30 subjects with AMD.
   RESULTS. The location and stability of fixation with various stimuli was possible to record in each subject. In 23 subjects, there was no difference between the fixations at star and wagon wheel stimuli; in seven subjects, they were in clearly different retinal locations. Fixation was unstable in three subjects. The PRL for reading words was detectable in all subjects.
   CONCLUSIONS. The present assessment technique seems to offer a simple, clinically available technique to record fixation patterns to different targets and texts. (Invest Ophthalmol Vis Sci. 2008; 49: 5274-5278) DOI: 10.1167/iovs.07-1120
C1 [Leinonen, Markku T.] Turku Univ Hosp, Dept Ophthalmol, Turku 20521, Finland.
   [Hyvarinen, Lea] Univ Helsinki, Fac Behav Sci, Helsinki, Finland.
C3 University of Turku; University of Helsinki
RP Leinonen, MT (通讯作者)，Turku Univ Hosp, Dept Ophthalmol, POB 52, Turku 20521, Finland.
EM leinonen@iki.fi
FU European Commission [QLK 6-CT-2002-00214]; De Blindas Vanner-Sokeain
   ystavat r.y.
FX Supported by European Commission, Key action No. 6, AMD-READ-Project,
   QLK 6-CT-2002-00214 and De Blindas Vanner-Sokeain ystavat r.y. (MTL).
CR *AD SYST INC, 2005, PHOT CS
   Altpeter E, 2000, VISION RES, V40, P1539, DOI 10.1016/S0042-6989(00)00059-6
   AULHORN E, 1962, P AUSTR OPHTH SOC, P80
   Deruaz A, 2002, VISION RES, V42, P2947, DOI 10.1016/S0042-6989(02)00354-1
   Deruaz Anouk, 2006, BMC Ophthalmol, V6, P35, DOI 10.1186/1471-2415-6-35
   Fletcher D. C., 1994, OPHTHALMOLOGY CLIN N, V7, P257
   Fletcher DC, 1997, OPHTHALMOLOGY, V104, P632, DOI 10.1016/S0161-6420(97)30260-7
   Fletcher DC, 1999, J REHABIL RES DEV, V36, P356
   Hahn GA, 2006, BRIT J OPHTHALMOL, V90, P480, DOI 10.1136/bjo.2005.087379
   LEINONEN M, 2003, OPHTHALMIC RES S1, V35, P44
   LEINONEN M, 2000, OPHTHALMIC RES S2, V32, P1
   Mackeben M., 2000, VISION REHABILITATIO, P158
   MACKEBEN M, 1998, PERIMETRY UPDATE, P307
   MESSIAS A, 2005, IMGMEM SOFTW VER 1 0
   *MOUNT VIEW, 2003, PINN LIQ ED VERS 5 5
   Nilsson UL, 1998, OPTOMETRY VISION SCI, V75, P873, DOI 10.1097/00006324-199812000-00009
   Nilsson UL, 2003, VISION RES, V43, P1777, DOI 10.1016/S0042-6989(03)00219-0
   NOORDEN GKV, 1962, AM J OPHTHALMOL, V53, P642, DOI 10.1016/0002-9394(62)91987-6
   NORTHCRAFT GB, 1994, HUM PERFORM, V7, P257, DOI DOI 10.1207/S15327043HUP0704_2
   Schuchard RA, 1999, J REHABIL RES DEV, V36, P294
   Schuchard RA, 1994, CLIN EYE VISION CARE, V6, P101
   Seiple W, 2005, INVEST OPHTH VIS SCI, V46, P2886, DOI 10.1167/iovs.04-1296
   Stelmack JA, 2004, J REHABIL RES DEV, V41, P729, DOI 10.1682/JRRD.2003.08.0136
   Sunness JS, 1996, OPHTHALMOLOGY, V103, P1458, DOI 10.1016/S0161-6420(96)30483-1
   TIMBERLAKE GT, 1987, INVEST OPHTH VIS SCI, V28, P1268
   TIMBERLAKE GT, 1986, INVEST OPHTH VIS SCI, V27, P1137
NR 26
TC 0
Z9 0
U1 0
U2 4
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD DEC
PY 2008
VL 49
IS 12
BP 5274
EP 5278
DI 10.1167/iovs.07-1120
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 376OW
UT WOS:000261193900015
PM 18676623
DA 2022-11-30
ER

PT J
AU Lim, RHF
   Gupta, B
   Simcock, P
AF Lim, Rachel Hui Fen
   Gupta, Bhaskar
   Simcock, Peter
TI Intravitreal aflibercept in neovascular age-related macular degeneration
   previously treated with ranibizumab
SO INTERNATIONAL JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE aflibercept; ranibizumab; neovascular age-related macular degeneration
ID OUTCOMES; FLUID; EYES
AB AIM: To report the change in visual acuity and central macular thickness (CMT) following treatment with intravitreal aflibercept injections in patients with neovascular age related macular degeneration (nAMD) with suboptimum response to ranibizumab.
   METHODS: This was a retrospective study. The inclusion criteria were patients with nAMD who responded poorly to ranibizumab. Patients then received either 3 consecutive aflibercept injections followed by pro re nata (PRN) treatment or PRN alone. Primary endpoints were mean change in best corrected visual acuity (BCVA) and CMT at 12mo. Secondary endpoints were number of injections and adverse events.
   RESULTS: Forty-nine eyes from 49 patients met the inclusion criteria and completed 12-month follow up on aflibercept. Thirty-eight eyes received 3 consecutive aflibercept injections followed by PRN treatment and 11 eyes received PRN injections alone. At 12mo, mean BCVA improved by one letters (logMAR 0.56 +/- 0.31 to 0.54 +/- 0.34) and mean CMT decreased from 303.9 +/- 82.1 to 259.2 +/- 108.3 mu m. Four percent of eyes gained 15 letters or more, 6% lost more than 15 letters and the remaining 90% had stable BCVA. The mean number of aflibercept injections was 6. There was one case of infectious endophthalmitis.
   CONCLUSION: Intravitreal aflibercept in patients with nAMD with a previous suboptimal response to ranibizumab resulted in an anatomical improvement in macular appearance at 12mo without a corresponding improvement in visual acuity.
C1 [Lim, Rachel Hui Fen; Gupta, Bhaskar; Simcock, Peter] Royal Devon & Exeter NHS Fdn Trust, Barrack Rd, Exeter EX2 5DW, Devon, England.
C3 University of Exeter
RP Gupta, B (通讯作者)，Royal Devon & Exeter NHS Fdn Trust, Barrack Rd, Exeter EX2 5DW, Devon, England.
EM Bhaskar.gupta@nhs.net
CR Barthelmes D, 2016, BRIT J OPHTHALMOL, V100, P1640, DOI 10.1136/bjophthalmol-2015-308090
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Chang AA, 2014, OPHTHALMOLOGY, V121, P188, DOI 10.1016/j.ophtha.2013.08.035
   Cho H, 2013, BRIT J OPHTHALMOL, V97, P1032, DOI 10.1136/bjophthalmol-2013-303344
   Griffin DR, 2014, J OPHTHALMOL, V2014, DOI 10.1155/2014/497178
   Hatz K, 2016, RETINA
   Ho VY, 2013, AM J OPHTHALMOL, V156, P23, DOI 10.1016/j.ajo.2013.02.009
   Julien S, 2014, BRIT J OPHTHALMOL, V98, P813, DOI 10.1136/bjophthalmol-2013-304019
   Kumar N, 2013, RETINA-J RET VIT DIS, V33, P1605, DOI 10.1097/IAE.0b013e31828e8551
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Messenger WB, 2014, BRIT J OPHTHALMOL, V98, P1205, DOI 10.1136/bjophthalmol-2013-304829
   Miki A, 2010, J CELL PHYSIOL, V224, P262, DOI 10.1002/jcp.22129
   National Institute for Health and Care Excellence, 2013, AFL SOL INJ TREAT WE
   National Institute for Health and Care Excellence, 2008, RAN PEG TEATM AG REL
   Rofagha S, 2013, OPHTHALMOLOGY, V120, P2292, DOI 10.1016/j.ophtha.2013.03.046
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Simcock P, 2014, EYE, V28, P1161, DOI 10.1038/eye.2014.153
   Stewart MW, 2012, RETINA-J RET VIT DIS, V32, P434, DOI 10.1097/IAE.0B013E31822C290F
   Tadayoni Ramin, 2014, J Ophthalmic Vis Res, V9, P405, DOI 10.4103/2008-322X.150799
   Wykoff CC, 2014, BRIT J OPHTHALMOL, V98, P951, DOI 10.1136/bjophthalmol-2013-304736
NR 20
TC 3
Z9 3
U1 0
U2 2
PU IJO PRESS
PI XI AN
PA NO 269 YOUYI EAST RD, XI AN, 710054, PEOPLES R CHINA
SN 2222-3959
EI 2227-4898
J9 INT J OPHTHALMOL-CHI
JI Int. J. Ophthalmol.
PD MAR 18
PY 2017
VL 10
IS 3
BP 423
EP 426
DI 10.18240/ijo.2017.03.15
PG 4
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA EO8WM
UT WOS:000396971200015
PM 28393034
OA gold, Green Published, Green Submitted
DA 2022-11-30
ER

PT J
AU Mei, L
   Yu, MZ
   Liu, YY
   Weh, E
   Pawar, M
   Li, L
   Besirli, CG
   Schwendeman, AA
AF Mei, Ling
   Yu, Minzhi
   Liu, Yayuan
   Weh, Eric
   Pawar, Mercy
   Li, Li
   Besirli, Cagri G.
   Schwendeman, Anna A.
TI Synthetic high-density lipoprotein nanoparticles delivering rapamycin
   for the treatment of age-related macular degeneration
SO NANOMEDICINE-NANOTECHNOLOGY BIOLOGY AND MEDICINE
LA English
DT Article
DE High-density lipoprotein; Drug delivery; Rapamycin; Autophagy; AMD
ID RETINAL-PIGMENT EPITHELIUM; CORONARY ATHEROSCLEROSIS; CHOLESTEROL
   EFFLUX; AUTOPHAGY; INFLAMMATION; FORMULATION; TOXICITY; DRUG; RPE
AB Synthetic high-density lipoprotein (sHDL) and rapamycin (Rap) have both been shown to be potential treatments for age-related macular degeneration (AMD). The low aqueous solubility of Rap, however, limits its therapeutic utility. Here we used an Apolipoprotein A-I mimetic peptide and phospholipid-based sHDL for the intravitreal delivery of Rap. By incorporation of Rap in sHDL nanoparticles (sHDL-Rap), we achieve 125-fold increase in drug aqueous concentration. When applied in vitro to retinal pigment epithelium cells, sHDL-Rap exhibited the abilities to efflux cholesterol, neutralize endotoxin, and suppress NF-kappa B activation. As an mTOR inhibitor, Rap induced autophagy and inhibited NF-kappa B-mediated pro-inflammatory signaling. Additionally, a greater reduction in lipofuscin accumulation and increased antiinflammatory effects were achieved by sHDL-Rap relative to free drug or sHDL alone. In vivo studies demonstrated that sHDL reached the target retina pigment epithelium (RPE) layer following intravitreal administration in rats. These results suggest that sHDL-Rap holds potential as a treatment for AMD. (C) 2022 Elsevier Inc. All rights reserved.
C1 [Mei, Ling; Yu, Minzhi; Liu, Yayuan; Schwendeman, Anna A.] Univ Michigan, Dept Pharmaceut Sci, Ann Arbor, MI 48109 USA.
   [Mei, Ling] Chengdu Univ, Sichuan Ind Inst Antibiot, Engn Res Ctr Pharmaceut & Equipments Sichuan Prov, Sch Pharm, Chengdu 610106, Peoples R China.
   [Weh, Eric; Pawar, Mercy; Besirli, Cagri G.] Univ Michigan, Kellogg Eye Ctr, Dept Ophthalmol & Visual Sci, Ann Arbor, MI 48109 USA.
   [Li, Li] Shenyang Pharmaceut Univ, Dept Pharmaceut Sci, Shenyang, Peoples R China.
   [Schwendeman, Anna A.] Univ Michigan, Biointerfaces Inst, Ann Arbor, MI 48109 USA.
C3 University of Michigan System; University of Michigan; Chengdu
   University; University of Michigan System; University of Michigan;
   Shenyang Pharmaceutical University; University of Michigan System;
   University of Michigan
RP Schwendeman, AA (通讯作者)，Univ Michigan, Dept Pharmaceut Sci, Ann Arbor, MI 48109 USA.; Schwendeman, AA (通讯作者)，Univ Michigan, Biointerfaces Inst, Ann Arbor, MI 48109 USA.
EM annaschw@umich.edu
OI Besirli, Cagri/0000-0001-7154-2024
FU NIH [R01 HL134569, R21 NS111191, R01 EY029675]; American Heart
   Association Postdoc-toral Fellowship [20POST35210818]
FX This work was supported by NIH R01 HL134569 and R21 NS111191 (A.S.) ,
   R01 EY029675 (C.G.B) , American Heart Association Postdoc-toral
   Fellowship 20POST35210818 (L.M.) .
CR Linares-Alba MA, 2016, J OCUL PHARMACOL TH, V32, P11, DOI 10.1089/jop.2015.0032
   Ban N, 2018, JCI INSIGHT, V3, DOI 10.1172/jci.insight.120824
   BOK D, 1993, J CELL SCI, P189
   Buschini E, 2011, PROG NEUROBIOL, V95, P14, DOI 10.1016/j.pneurobio.2011.05.011
   Cholkar K, 2015, AAPS PHARMSCITECH, V16, P610, DOI 10.1208/s12249-014-0244-2
   Dasseux J-l, 2001, GOOGLE PATENTS
   De Nardo D, 2014, NAT IMMUNOL, V15, P152, DOI 10.1038/ni.2784
   Demidenko ZN, 2009, CELL CYCLE, V8, P1888, DOI 10.4161/cc.8.12.8606
   Galvao J, 2014, FASEB J, V28, P1317, DOI 10.1096/fj.13-235440
   Guo YH, 2018, EBIOMEDICINE, V28, P225, DOI 10.1016/j.ebiom.2017.12.021
   Hands SL, 2009, AGING-US, V1, P586, DOI 10.18632/aging.100070
   Inana G, 2018, J TRANSL MED, V16, DOI 10.1186/s12967-018-1434-6
   Jun SJ, 2019, EXP EYE RES, V181, P346, DOI 10.1016/j.exer.2018.09.023
   Kaarniranta K, 2013, AUTOPHAGY, V9, P973, DOI 10.4161/auto.24546
   Kaarniranta Kai, 2010, Front Biosci (Elite Ed), V2, P1374
   Keyserling CH, 2017, CLIN DRUG INVEST, V37, P483, DOI 10.1007/s40261-017-0506-3
   Keyserling CH, 2011, CIRCULATION, V124
   Khan M, 2003, CIRCULATION 530 WALN
   Kuai R, 2017, NAT MATER, V16, P489, DOI [10.1038/NMAT4822, 10.1038/nmat4822]
   Kuai R, 2016, ACS NANO, V10, P3015, DOI 10.1021/acsnano.5b07522
   Lei L, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18040728
   Li J, 2014, CELL METAB, V19, P373, DOI 10.1016/j.cmet.2014.01.001
   Lyssenko NN, 2018, J LIPID RES, V59, P1927, DOI 10.1194/jlr.M087361
   Mathew R, 2007, NAT REV CANCER, V7, P961, DOI 10.1038/nrc2254
   Miles J, 2004, ARTERIOSCL THROM VAS, V24, pE19
   Mitter SK, 2014, AUTOPHAGY, V10, P1989, DOI 10.4161/auto.36184
   Mitter SK, 2012, ADV EXP MED BIOL, V723, P83, DOI 10.1007/978-1-4614-0631-0_12
   Mizushima N, 2007, AUTOPHAGY, V3, P542, DOI 10.4161/auto.4600
   Mudumba S, US PATENT ASSIGNEE L
   Mudumba S, US PATENT ASSIGNEE R
   Nissen SE, 2003, JAMA-J AM MED ASSOC, V290, P2292, DOI 10.1001/jama.290.17.2292
   Nofer JR, 2001, J BIOL CHEM, V276, P34480, DOI 10.1074/jbc.M103782200
   Nowak JZ, 2006, PHARMACOL REP, V58, P353
   Nuhrenberg TG, 2004, FASEB J, V18, P246, DOI 10.1096/fj.04-2431fje
   Okamoto T, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0146517
   Pan T, 2009, NEUROSCIENCE, V164, P541, DOI 10.1016/j.neuroscience.2009.08.014
   Patel S, 2016, J OCUL PHARMACOL TH, V32, P97, DOI 10.1089/jop.2015.0069
   Pikuleva IA, 2014, PROG RETIN EYE RES, V41, P64, DOI 10.1016/j.preteyeres.2014.03.002
   Rami A, 2009, NEUROPATH APPL NEURO, V35, P449, DOI 10.1111/j.1365-2990.2009.01034.x
   Riwanto M, 2013, J LIPID RES, V54, P3227, DOI 10.1194/jlr.R037762
   Rodriguez-Muela N, 2012, CELL DEATH DIFFER, V19, P162, DOI 10.1038/cdd.2011.88
   Rudolf M, 2018, CURR EYE RES, V43, P135, DOI 10.1080/02713683.2017.1370118
   Sakurai E, 2001, OPHTHALMIC RES, V33, P31, DOI 10.1159/000055638
   Salminen A, 2012, AGING-US, V4, P166, DOI 10.18632/aging.100444
   Schwendeman A, 2015, J LIPID RES, V56, P1727, DOI 10.1194/jlr.M060285
   Sene A, 2014, TRENDS ENDOCRIN MET, V25, P107, DOI 10.1016/j.tem.2013.10.007
   Storti F, 2017, EXP EYE RES, V165, P65, DOI 10.1016/j.exer.2017.09.008
   Strauss O, 2005, PHYSIOL REV, V85, P845, DOI 10.1152/physrev.00021.2004
   Suda K, 2017, J CONTROL RELEASE, V266, P301, DOI 10.1016/j.jconrel.2017.09.036
   Sun MH, 2011, DRUG DEV IND PHARM, V37, P986, DOI 10.3109/03639045.2011.553618
   Supino R, 1995, Methods Mol Biol, V43, P137, DOI 10.1385/0-89603-282-5:137
   Tardif JC, 2007, JAMA-J AM MED ASSOC, V297, P1675, DOI 10.1001/jama.297.15.jpc70004
   Wang S, 2019, OXID MED CELL LONGEV, V2019
   Wilkinson JE, 2012, AGING CELL, V11, P675, DOI 10.1111/j.1474-9726.2012.00832.x
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Wu W, 2016, INT J PHARMACEUT, V513, P238, DOI 10.1016/j.ijpharm.2016.09.013
   Wubben TJ, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-59999-w
   Xu QG, 2013, J CONTROL RELEASE, V167, P76, DOI 10.1016/j.jconrel.2013.01.018
   Xu QY, 2018, LIPIDS HEALTH DIS, V17, DOI 10.1186/s12944-017-0647-7
   Yuan WM, 2021, J CONTROL RELEASE, V329, P361, DOI 10.1016/j.jconrel.2020.11.016
   Yuan Y, 2016, INT J NANOMED, V11, P6229, DOI 10.2147/IJN.S112835
   Zhang J, 2015, CELL DEATH DIS, V6, DOI 10.1038/cddis.2015.330
   Zhu XW, 2010, J LIPID RES, V51, P3196, DOI 10.1194/jlr.M006486
NR 63
TC 1
Z9 1
U1 12
U2 12
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 1549-9634
EI 1549-9642
J9 NANOMED-NANOTECHNOL
JI Nanomed.-Nanotechnol. Biol. Med.
PD AUG
PY 2022
VL 44
AR 102571
DI 10.1016/j.nano.2022.102571
PG 12
WC Nanoscience & Nanotechnology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics; Research & Experimental Medicine
GA 2A8ZA
UT WOS:000809782700002
PM 35623563
DA 2022-11-30
ER

PT J
AU Tisi, A
   Feligioni, M
   Passacantando, M
   Ciancaglini, M
   Maccarone, R
AF Tisi, Annamaria
   Feligioni, Marco
   Passacantando, Maurizio
   Ciancaglini, Marco
   Maccarone, Rita
TI The Impact of Oxidative Stress on Blood-Retinal Barrier Physiology in
   Age-Related Macular Degeneration
SO CELLS
LA English
DT Review
DE blood retinal barrier; oxidative stress; physiology; age-related macular
   degeneration
ID PIGMENT EPITHELIAL-CELLS; SUBFOVEAL CHOROIDAL THICKNESS; ENDOTHELIAL
   GROWTH-FACTOR; BASAL LINEAR DEPOSIT; GEOGRAPHIC ATROPHY; FUNDUS
   AUTOFLUORESCENCE; MESENCHYMAL TRANSITION; SUNLIGHT EXPOSURE; POTENTIAL
   ROLE; LIGHT DAMAGE
AB The blood retinal barrier (BRB) is a fundamental eye component, whose function is to select the flow of molecules from the blood to the retina and vice-versa, and its integrity allows the maintenance of a finely regulated microenvironment. The outer BRB, composed by the choriocapillaris, the Bruch's membrane, and the retinal pigment epithelium, undergoes structural and functional changes in age-related macular degeneration (AMD), the leading cause of blindness worldwide. BRB alterations lead to retinal dysfunction and neurodegeneration. Several risk factors have been associated with AMD onset in the past decades and oxidative stress is widely recognized as a key factor, even if the exact AMD pathophysiology has not been exactly elucidated yet. The present review describes the BRB physiology, the BRB changes occurring in AMD, the role of oxidative stress in AMD with a focus on the outer BRB structures. Moreover, we propose the use of cerium oxide nanoparticles as a new powerful anti-oxidant agent to combat AMD, based on the relevant existing data which demonstrated their beneficial effects in protecting the outer BRB in animal models of AMD.
C1 [Tisi, Annamaria; Maccarone, Rita] Univ Aquila, Dept Biotechnol & Appl Clin Sci, I-67100 Laquila, Italy.
   [Feligioni, Marco] European Brain Res Inst, I-00161 Rome, Italy.
   [Feligioni, Marco] Casa Cura Policlin, Dept Neuroreabilitat Sci, I-20144 Milan, Italy.
   [Passacantando, Maurizio] Univ Aquila, Dept Phys & Chem Sci, I-67100 Laquila, Italy.
   [Ciancaglini, Marco] Univ Aquila, Dept Life Hlth & Environm Sci, I-67100 Laquila, Italy.
C3 University of L'Aquila; University of L'Aquila; University of L'Aquila
RP Maccarone, R (通讯作者)，Univ Aquila, Dept Biotechnol & Appl Clin Sci, I-67100 Laquila, Italy.
EM annamaria.tisi@graduate.univaq.it; m.feligioni@ebri.it;
   maurizio.passacantando@univaq.it; marco.ciancaglini@univaq.it;
   rita.maccarone@univaq.it
RI ; PASSACANTANDO, Maurizio/A-2122-2019
OI MACCARONE, Rita/0000-0003-0648-3771; PASSACANTANDO,
   Maurizio/0000-0002-3680-5295; Ciancaglini, Marco/0000-0001-5888-7976
CR Abokyi S, 2020, OXID MED CELL LONGEV, V2020, DOI 10.1155/2020/7901270
   Adams MKM, 2012, AM J EPIDEMIOL, V176, P289, DOI 10.1093/aje/kws004
   Adhi M, 2014, RETINA-J RET VIT DIS, V34, P306, DOI 10.1097/IAE.0b013e3182993e09
   Ambati J, 2012, NEURON, V75, P26, DOI 10.1016/j.neuron.2012.06.018
   Anderson DH, 2010, PROG RETIN EYE RES, V29, P95, DOI 10.1016/j.preteyeres.2009.11.003
   APPLE DJ, 1973, AM J OPHTHALMOL, V75, P595, DOI 10.1016/0002-9394(73)90812-X
   Arya M, 2018, EYE VISION, V5, DOI 10.1186/s40662-018-0118-x
   Domenech EB, 2020, ANTIOXIDANTS-BASEL, V9, DOI 10.3390/antiox9040347
   Balaiya S, 2013, MOL VIS, V19, P2385
   Balaiya S, 2012, MOL VIS, V18, P114
   Ben-Shabat S, 2002, J BIOL CHEM, V277, P7183, DOI 10.1074/jbc.M108981200
   Berrow EJ, 2010, DOC OPHTHALMOL, V121, P51, DOI 10.1007/s10633-010-9226-1
   Bhutto I, 2012, MOL ASPECTS MED, V33, P295, DOI 10.1016/j.mam.2012.04.005
   Biesemeier A, 2014, NEUROBIOL AGING, V35, P2562, DOI 10.1016/j.neurobiolaging.2014.05.003
   BIRCH DG, 1988, DOC OPHTHALMOL, V69, P211, DOI 10.1007/BF00154401
   BIRCH DG, 1992, ARCH OPHTHALMOL-CHIC, V110, P1571, DOI 10.1001/archopht.1992.01080230071024
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Biswal MR, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0203816
   Blasiak J, 2020, CELL MOL LIFE SCI, V77, P789, DOI 10.1007/s00018-019-03420-x
   Bodnar Z.M., 2016, SPECTRAL DOMAIN OPTI, P117
   BOK D, 1993, J CELL SCI, P189
   Booij JC, 2010, PROG RETIN EYE RES, V29, P1, DOI 10.1016/j.preteyeres.2009.08.003
   Borras C, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-50420-9
   Brandl C, 2019, INVEST OPHTH VIS SCI, V60, P1581, DOI 10.1167/iovs.18-25332
   Broadhead GK, 2019, GRAEF ARCH CLIN EXP, V257, P31, DOI 10.1007/s00417-018-4163-x
   Cabral T., 2017, INT J RETINA VITREOU, V3, P31, DOI [10.1186/s40942-017-0084-9, DOI 10.1186/S40942-017-0084-9]
   Cai X, 2016, MOL VIS, V22, P1176
   Checchin D, 2006, INVEST OPHTH VIS SCI, V47, P3595, DOI 10.1167/iovs.05-1522
   Chen JP, 2006, NAT NANOTECHNOL, V1, P142, DOI 10.1038/nnano.2006.91
   Chen M, 2019, PROG RETIN EYE RES, V69, P159, DOI 10.1016/j.preteyeres.2018.10.003
   Coorey NJ, 2012, CLIN EXP OPTOM, V95, P266, DOI 10.1111/j.1444-0938.2012.00741.x
   Country MW, 2017, BRAIN RES, V1672, P50, DOI 10.1016/j.brainres.2017.07.025
   Crane IJ, 2008, SEMIN IMMUNOPATHOL, V30, P165, DOI 10.1007/s00281-008-0106-7
   Crouch RK, 2015, PROG MOL BIOL TRANSL, V134, P449, DOI 10.1016/bs.pmbts.2015.06.005
   Cunha-Vaz J, 2011, EUR J OPHTHALMOL, V21, pS3, DOI 10.5301/EJO.2010.6049
   Curcio CA, 1999, ARCH OPHTHALMOL-CHIC, V117, P329, DOI 10.1001/archopht.117.3.329
   Datta S, 2017, PROG RETIN EYE RES, V60, P201, DOI 10.1016/j.preteyeres.2017.03.002
   Del Priore LV, 2002, CURR EYE RES, V25, P79
   Diaz-Coranguez M, 2017, VISION RES, V139, P123, DOI 10.1016/j.visres.2017.05.009
   Ding XY, 2009, PROG RETIN EYE RES, V28, P1, DOI 10.1016/j.preteyeres.2008.10.001
   Fardeau C, 2016, EYE, V30, P1277, DOI 10.1038/eye.2016.115
   Farecki ML, 2017, GRAEF ARCH CLIN EXP, V255, P913, DOI 10.1007/s00417-017-3588-y
   Ferguson TA, 2014, AUTOPHAGY, V10, P165, DOI 10.4161/auto.26735
   Hernandez-Zimbron LF, 2018, OXID MED CELL LONGEV, V2018, DOI 10.1155/2018/8374647
   Ferris FL, 2005, ARCH OPHTHALMOL-CHIC, V123, P1570
   Fields MA, 2020, PROG RETIN EYE RES, V76, DOI 10.1016/j.preteyeres.2019.100803
   Finkel T, 2011, J CELL BIOL, V194, P7, DOI 10.1083/jcb.201102095
   Fiorani L, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0140387
   Fisher CR, 2018, INVEST OPHTH VIS SCI, V59, pAMD41, DOI 10.1167/iovs.18-24289
   Fleckenstein M, 2018, OPHTHALMOLOGY, V125, P369, DOI 10.1016/j.ophtha.2017.08.038
   FRANK RN, 1990, INVEST OPHTH VIS SCI, V31, P999
   Frey T, 2011, ANTIOXID REDOX SIGN, V15, P1271, DOI 10.1089/ars.2011.3906
   Fritsche LG, 2016, NAT GENET, V48, P134, DOI 10.1038/ng.3448
   Fritsche LG, 2014, ANNU REV GENOM HUM G, V15, P151, DOI 10.1146/annurev-genom-090413-025610
   Garcia-Layana A, 2017, CLIN INTERV AGING, V12, P1579, DOI 10.2147/CIA.S142685
   Gardner TW, 1997, INVEST OPHTH VIS SCI, V38, P2423
   Gil-Martinez M, 2020, CURR MED CHEM, V27, P583, DOI 10.2174/0929867326666190726121711
   Gonzalez-Garcia E, 2016, DOC OPHTHALMOL, V133, P31, DOI 10.1007/s10633-016-9545-y
   Gorusupudi A, 2017, ADV NUTR, V8, P40, DOI 10.3945/an.116.013177
   Grebe R, 2019, EXP EYE RES, V181, P252, DOI 10.1016/j.exer.2019.02.018
   Guerra F, 2017, FRONT ONCOL, V7, DOI 10.3389/fonc.2017.00295
   Gugnoni M, 2016, CELL DEATH DIS, V7, DOI 10.1038/cddis.2016.415
   Guymer RH, 2004, INVEST OPHTH VIS SCI, V45, P1660, DOI 10.1167/iovs.03-0913
   Handa JT, 2012, MOL ASPECTS MED, V33, P418, DOI 10.1016/j.mam.2012.03.006
   Heesterbeek TJ, 2020, OPHTHAL PHYSL OPT, V40, P140, DOI 10.1111/opo.12675
   Hogan MJ, 1971, HISTOLOGY HUMAN EYE
   Hormel TT, 2021, PROG RETIN EYE RES, V80, DOI 10.1016/j.preteyeres.2020.100878
   Hussain AA, 2010, EXP EYE RES, V90, P703, DOI 10.1016/j.exer.2010.02.013
   Inan S, 2019, CURR EYE RES, V44, P908, DOI 10.1080/02713683.2019.1600195
   Iriyama A, 2009, J CELL PHYSIOL, V220, P469, DOI 10.1002/jcp.21792
   Ismayilov AS, 2019, CLIN EXP OPTOM, V102, P617, DOI 10.1111/cxo.12877
   Jaadane I, 2017, J CELL MOL MED, V21, P3453, DOI 10.1111/jcmm.13255
   Jones DP, 2015, REDOX BIOL, V5, P71, DOI 10.1016/j.redox.2015.03.004
   Ju Rui-Hong, 2017, Nan Fang Yi Ke Da Xue Xue Bao, V37, P933
   Jun SJ, 2019, EXP EYE RES, V181, P346, DOI 10.1016/j.exer.2018.09.023
   Justilien V, 2007, INVEST OPHTH VIS SCI, V48, P4407, DOI 10.1167/iovs.07-0432
   Kaarniranta K, 2020, PROG RETIN EYE RES, V79, DOI 10.1016/j.preteyeres.2020.100858
   Kaarniranta K, 2017, CELL BIOL TOXICOL, V33, P113, DOI 10.1007/s10565-016-9371-8
   Karampelas M, 2013, BRIT J OPHTHALMOL, V97, P1256, DOI 10.1136/bjophthalmol-2013-303219
   Karlstetter M, 2015, PROG RETIN EYE RES, V45, P30, DOI 10.1016/j.preteyeres.2014.11.004
   Kasprowska-Liskiewicz D, 2017, POSTEP HIG MED DOSW, V71, P825, DOI 10.5604/01.3001.0010.4672
   Kaszubski P, 2016, OPHTHALMIC RES, V55, P185, DOI 10.1159/000443209
   Khorrami MB, 2019, INT J NANOMED, V14, P2915, DOI 10.2147/IJN.S194192
   Kieffer J, 2020, CUREUS, V12, DOI 10.7759/cureus.9675
   Klaassen I, 2013, PROG RETIN EYE RES, V34, P19, DOI 10.1016/j.preteyeres.2013.02.001
   Klettner Alexa, 2012, Front Biosci (Schol Ed), V4, P392
   Kumar A, 2017, INT J OPHTHALMOL-CHI, V10, P1552, DOI 10.18240/ijo.2017.10.12
   Kunchithapautham K, 2014, J BIOL CHEM, V289, P14534, DOI 10.1074/jbc.M114.564674
   Kyosseva SV, 2013, EXP EYE RES, V116, P63, DOI 10.1016/j.exer.2013.08.003
   Lambert NG, 2016, PROG RETIN EYE RES, V54, P64, DOI 10.1016/j.preteyeres.2016.04.003
   Lee B, 2018, INVEST OPHTH VIS SCI, V59, P5246, DOI 10.1167/iovs.17-23600
   Lehmann GL, 2014, EXP EYE RES, V126, P5, DOI 10.1016/j.exer.2014.04.021
   Lei L, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18040728
   Lin W, 2019, OPHTHALMIC RES, V61, P65, DOI 10.1159/000487486
   Lipecz A, 2019, GEROSCIENCE, V41, P813, DOI 10.1007/s11357-019-00138-3
   Liu CQ, 2015, INT J MOL MED, V35, P169, DOI 10.3892/ijmm.2014.1993
   LOFFLER KU, 1986, GRAEF ARCH CLIN EXP, V224, P493, DOI 10.1007/BF02154735
   Maccarone R, 2020, J OCUL PHARMACOL TH, V36, P376, DOI 10.1089/jop.2019.0105
   MARSHALL GE, 1992, BRIT J OPHTHALMOL, V76, P607, DOI 10.1136/bjo.76.10.607
   MICELI MV, 1994, EXP CELL RES, V214, P242, DOI 10.1006/excr.1994.1254
   Mitchell P, 2002, ARCH OPHTHALMOL-CHIC, V120, P1357, DOI 10.1001/archopht.120.10.1357
   Mitchell P, 2018, LANCET, V392, P1147, DOI 10.1016/S0140-6736(18)31550-2
   Mitic LL, 1998, ANNU REV PHYSIOL, V60, P121, DOI 10.1146/annurev.physiol.60.1.121
   Mitra RN, 2017, ACS NANO, V11, P4669, DOI 10.1021/acsnano.7b00429
   Mitter SK, 2012, ADV EXP MED BIOL, V723, P83, DOI 10.1007/978-1-4614-0631-0_12
   Moreno ML, 2018, FRONT PHYSIOL, V9, DOI 10.3389/fphys.2018.01008
   Mullins RE, 2011, INVEST OPHTH VIS SCI, V52, P1606, DOI 10.1167/iovs.10-6476
   Murali A, 2020, EUR J OPHTHALMOL, V30, P1195, DOI 10.1177/1120672120919337
   Naylor A, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21010211
   Nishihara H, 2008, INVEST OPHTH VIS SCI, V49, P3121, DOI 10.1167/iovs.08-1835
   Organisciak DT, 2010, PROG RETIN EYE RES, V29, P113, DOI 10.1016/j.preteyeres.2009.11.004
   Orhan C, 2016, J OCUL PHARMACOL TH, V32, P631, DOI 10.1089/jop.2015.0154
   Park GB, 2018, MOL MED REP, V17, P3563, DOI 10.3892/mmr.2017.8355
   Passacantando M, 2013, J NANOPART RES, V15, DOI 10.1007/s11051-013-1785-0
   Prakash G, 2017, INDIAN J CLIN BIOCHE, V32, P3, DOI 10.1007/s12291-016-0560-2
   Ranjan R, 2020, BIOPHYS CHEM, V265, DOI 10.1016/j.bpc.2020.106430
   Rattner A, 2019, J CLIN INVEST, V129, P3807, DOI 10.1172/JCI126655
   Redmond TM, 1998, NAT GENET, V20, P344, DOI 10.1038/3813
   Rispoli M, 2018, OSLI RETINA, V49, P918, DOI 10.3928/23258160-20181203-02
   Robson AG, 2018, DOC OPHTHALMOL, V136, P1, DOI 10.1007/s10633-017-9621-y
   Russ PK, 1998, INVEST OPHTH VIS SCI, V39, P2479
   Scherz-Shouval R, 2019, EMBO J, V38, DOI 10.15252/embj.2019101812
   Schick T, 2016, RETINA-J RET VIT DIS, V36, P787, DOI 10.1097/IAE.0000000000000756
   Schwartsburd PM, 1995, GERONTOLOGY, V41, P29
   Seddon JM, 2016, JAMA OPHTHALMOL, V134, P1272, DOI 10.1001/jamaophthalmol.2016.3519
   Shao L, 2014, AM J OPHTHALMOL, V158, P702, DOI 10.1016/j.ajo.2014.05.023
   Shaw PX, 2012, P NATL ACAD SCI USA, V109, P13757, DOI 10.1073/pnas.1121309109
   Shen Y, 2016, INT J OPHTHALMOL-CHI, V9, P363, DOI 10.18240/ijo.2016.03.06
   SHEPRO D, 1993, FASEB J, V7, P1031, DOI 10.1096/fasebj.7.11.8370472
   Shu DY, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21124271
   Sivapathasuntharam C, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-018-37673-6
   Smith W, 2001, OPHTHALMOLOGY, V108, P697, DOI 10.1016/S0161-6420(00)00580-7
   Sparrow JR, 2014, J CLIN MED, V3, P1302, DOI 10.3390/jcm3041302
   Sparrow JR, 2012, MOL ASPECTS MED, V33, P436, DOI 10.1016/j.mam.2012.03.007
   STEELE FR, 1993, P NATL ACAD SCI USA, V90, P1526, DOI 10.1073/pnas.90.4.1526
   STEINBERG RH, 1970, NATURE, V227, P728, DOI 10.1038/227728a0
   STEINBERG RH, 1977, PHILOS T ROY SOC B, V277, P459, DOI 10.1098/rstb.1977.0028
   Strauss O, 2005, PHYSIOL REV, V85, P845, DOI 10.1152/physrev.00021.2004
   Sui GY, 2013, BRIT J OPHTHALMOL, V97, P389, DOI 10.1136/bjophthalmol-2012-302281
   Sun H, 2001, J BIOL CHEM, V276, P11766, DOI 10.1074/jbc.M010152200
   Sun Y, 2018, ANNU REV VIS SCI, V4, P101, DOI 10.1146/annurev-vision-091517-034018
   Tan ACS, 2018, SCI TRANSL MED, V10, DOI 10.1126/scitranslmed.aat4544
   Tisi A, 2020, EXP EYE RES, V199, DOI 10.1016/j.exer.2020.108169
   Tisi A, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-63449-y
   Tisi A, 2019, EXP EYE RES, V188, DOI 10.1016/j.exer.2019.107797
   Tisi A, 2019, EXP EYE RES, V182, P30, DOI 10.1016/j.exer.2019.03.003
   Tisi A, 2020, CELLS-BASEL, V9, DOI 10.3390/cells9071617
   TOUT S, 1993, NEUROSCIENCE, V55, P291, DOI 10.1016/0306-4522(93)90473-S
   Ugarte M, 2006, BRIT J OPHTHALMOL, V90, P621, DOI 10.1136/bjo.2005.086579
   van Norren D, 2016, EYE, V30, P169, DOI 10.1038/eye.2015.218
   Vatsyayan R, 2012, BIOCHEM BIOPH RES CO, V417, P346, DOI 10.1016/j.bbrc.2011.11.113
   Verzijl N, 2000, J BIOL CHEM, V275, P39027, DOI 10.1074/jbc.M006700200
   Wakatsuki Y, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0144156
   Wang HB, 2016, MOL VIS, V22, P116
   Wang K, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-51151-7
   Wang SB, 2019, OXID MED CELL LONGEV, V2019, DOI 10.1155/2019/3632169
   Wang XF, 2018, INVEST OPHTH VIS SCI, V59, P2808, DOI 10.1167/iovs.17-22069
   Weismann D, 2011, NATURE, V478, P76, DOI 10.1038/nature10449
   Wong LL, 2019, ADV EXP MED BIOL, V1185, P125, DOI 10.1007/978-3-030-27378-1_21
   Wong LL, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0058431
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Yamazaki T, 2012, OPHTHALMOLOGY, V119, P1621, DOI 10.1016/j.ophtha.2012.02.022
   Yannuzzi LA, 2008, RETINA-J RET VIT DIS, V28, P375, DOI 10.1097/IAE.0b013e3181619c55
   You GX, 2021, REV ENVIRON CONTAM T, V253, P155, DOI 10.1007/398_2020_42
   Zhang ZH, 2020, OXID MED CELL LONGEV, V2020, DOI 10.1155/2020/6579696
   Zhao ZY, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019456
   Zhdankina AA, 2008, B EXP BIOL MED+, V146, P455, DOI 10.1007/s10517-009-0298-4
   Zheng QQ, 2019, J MATER CHEM B, V7, P6759, DOI 10.1039/c9tb01066a
   Zhou RB, 2011, NATURE, V469, P221, DOI 10.1038/nature09663
   Zhou XH, 2011, PLOS ONE, V6, DOI [10.1371/journal.pone.0016733, 10.1371/journal.pone.0017812]
   Zhou YR, 2019, NANOSCALE, V11, P13126, DOI 10.1039/c9nr02350j
NR 171
TC 27
Z9 27
U1 5
U2 17
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2073-4409
J9 CELLS-BASEL
JI Cells
PD JAN
PY 2021
VL 10
IS 1
AR 64
DI 10.3390/cells10010064
PG 21
WC Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology
GA PV5HE
UT WOS:000610017800001
PM 33406612
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Aisenbrey, S
   Bartz-Schmidt, KU
   Walter, P
   Hilgers, RD
   Ayertey, H
   Szurman, P
   Thumann, G
AF Aisenbrey, Sabine
   Bartz-Schmidt, Karl Ulrich
   Walter, Peter
   Hilgers, Ralf Dieter
   Ayertey, Helen
   Szurman, Peter
   Thumann, Gabriele
TI Long-term follow-up of macular translocation with 360 retinotomy for
   exudative age-related macular degeneration
SO ARCHIVES OF OPHTHALMOLOGY
LA English
DT Article
ID SUBFOVEAL CHOROIDAL NEOVASCULARIZATION; RETINAL-PIGMENT EPITHELIUM;
   GEOGRAPHIC ATROPHY; SURGERY; RETINECTOMY; RECURRENCE; ROTATION
AB Objective: To assess long- term functional and morphological changes after macular translocation in patients with exudative age- related macular degeneration.
   Methods: Evaluation of a noncomparative cohort study of 90 patients with a follow- up of 14 to 79 months ( mean, 38.2 months).
   Results: Visual acuity increased by 3 or more lines in 15 patients, remained stable in 35 patients, and deteriorated in 40 patients at final examination. Pigment epithelium atrophy extending to the new fovea was detected in 44 patients; in 25 patients this new atrophy was associated with loss of visual function.
   Conclusions: Long- term follow- up of macular translocation with 360 retinotomy showed stabilization or improvement in half of the patients. Progressive atrophy of the pigment epithelium represented one major limiting factor of the beneficial effect of the treatment. Macular translocation may be an option for cases of exudative agerelated macular degeneration that are not eligible for or do not respond to alternative treatments.
C1 Univ Tubingen, Dept Ophthalmol, D-72076 Tubingen, Germany.
   BIOMAT, Interdisciplinary Ctr Clin Res IZKF, Dept Ophthalmol, Aachen, Germany.
   Rhein Westfal TH Aachen, Dept Med Stat, D-5100 Aachen, Germany.
   Univ Cologne, Dept Ophthalmol, Cologne, Germany.
C3 Eberhard Karls University of Tubingen; Eberhard Karls University
   Hospital; RWTH Aachen University; University of Cologne
RP Aisenbrey, S (通讯作者)，Univ Tubingen, Dept Ophthalmol, Schleichstr 12-16, D-72076 Tubingen, Germany.
EM sabine.aisenbrey@med.uni-tuebingen.de
RI Walter, Peter/L-5982-2018; Hilgers, Ralf-Dieter/C-7090-2013
OI Walter, Peter/0000-0001-8745-6593; Hilgers,
   Ralf-Dieter/0000-0002-5945-1119
CR Abdel-Meguid A, 2003, BRIT J OPHTHALMOL, V87, P615, DOI 10.1136/bjo.87.5.615
   Aisenbrey S, 2006, ARCH OPHTHALMOL-CHIC, V124, P183, DOI 10.1001/archopht.124.2.183
   Aisenbrey S, 2002, ARCH OPHTHALMOL-CHIC, V120, P451
   Akduman L, 1999, RETINA-J RET VIT DIS, V19, P418, DOI 10.1097/00006982-199909000-00009
   Binder S, 2004, INVEST OPHTH VIS SCI, V45, P4151, DOI 10.1167/iovs.04-0118
   Bressler NM, 2004, OPHTHALMOLOGY, V111, P1993, DOI 10.1016/j.ophtha.2004.07.023
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   Cahill MT, 2005, ARCH OPHTHALMOL-CHIC, V123, P935, DOI 10.1001/archopht.123.7.935
   D'Amico DJ, 2006, OPHTHALMOLOGY, V113, P992, DOI 10.1016/j.ophtha.2006.02.027
   Eckardt C, 1999, GRAEF ARCH CLIN EXP, V237, P313, DOI 10.1007/s004170050239
   HEIER JS, 2006, OPHTHALMOLOGY, V113, P642
   Joussen AM, 2006, AM J OPHTHALMOL, V142, P17, DOI 10.1016/j.ajo.2006.01.090
   Khurana RN, 2005, OPHTHALMOLOGY, V112, P1586, DOI 10.1016/j.ophtha.2005.04.016
   Lewis H, 1999, AM J OPHTHALMOL, V128, P135, DOI 10.1016/S0002-9394(99)00207-X
   MacLaren RE, 2005, OPHTHALMOLOGY, V112, P2081, DOI 10.1016/j.ophtha.2005.06.029
   MAGUIRE MG, 1994, ARCH OPHTHALMOL-CHIC, V112, P480
   Mruthyunjaya P, 2004, OPHTHALMOLOGY, V111, P1715, DOI 10.1016/j.ophtha.2004.03.022
   Ninomiya Y, 1996, AM J OPHTHALMOL, V122, P613, DOI 10.1016/S0002-9394(14)70479-9
   Wong D, 2004, BRIT J OPHTHALMOL, V88, P186, DOI 10.1136/bjo.2003.019273
NR 19
TC 33
Z9 34
U1 0
U2 2
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 515 N STATE ST, CHICAGO, IL 60610-0946 USA
SN 0003-9950
J9 ARCH OPHTHALMOL-CHIC
JI Arch. Ophthalmol.
PD OCT
PY 2007
VL 125
IS 10
BP 1367
EP 1372
DI 10.1001/archopht.125.10.1367
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 218EK
UT WOS:000249998600008
PM 17923545
DA 2022-11-30
ER

PT J
AU Tarau, IS
   Berlin, A
   Curcio, CA
   Ach, T
AF Tarau, Ioana-Sandra
   Berlin, Andreas
   Curcio, Christine A.
   Ach, Thomas
TI The Cytoskeleton of the Retinal Pigment Epithelium: from Normal Aging to
   Age-Related Macular Degeneration
SO INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
LA English
DT Review
DE retinal pigment epithelium; cytoskeleton; aging; age-related macular
   degeneration; actin; microfilament; microtubules; stress fiber
ID OPTICAL COHERENCE TOMOGRAPHY; ENDOTHELIAL GROWTH-FACTOR;
   PROTEIN-KINASE-C; MYOSIN-II; INTERMEDIATE-FILAMENTS; IN-VIVO; ACTIN
   CYTOSKELETON; STRESS FIBERS; HEAVY-CHAIN; MOLECULAR-STRUCTURE
AB The retinal pigment epithelium (RPE) is a unique epithelium, with major roles which are essential in the visual cycle and homeostasis of the outer retina. The RPE is a monolayer of polygonal and pigmented cells strategically placed between the neuroretina and Bruch membrane, adjacent to the fenestrated capillaries of the choriocapillaris. It shows strong apical (towards photoreceptors) to basal/basolateral (towards Bruch membrane) polarization. Multiple functions are bound to a complex structure of highly organized and polarized intracellular components: the cytoskeleton. A strong connection between the intracellular cytoskeleton and extracellular matrix is indispensable to maintaining the function of the RPE and thus, the photoreceptors. Impairments of these intracellular structures and the regular architecture they maintain often result in a disrupted cytoskeleton, which can be found in many retinal diseases, including age-related macular degeneration (AMD). This review article will give an overview of current knowledge on the molecules and proteins involved in cytoskeleton formation in cells, including RPE and how the cytoskeleton is affected under stress conditions-especially in AMD.
C1 [Tarau, Ioana-Sandra; Berlin, Andreas; Ach, Thomas] Univ Hosp Wurzburg, Dept Ophthalmol, D-97080 Wurzburg, Germany.
   [Curcio, Christine A.] Univ Alabama Birmingham, Dept Ophthalmol & Visual Sci, Birmingham, AL 35249 USA.
C3 University of Wurzburg; University of Alabama System; University of
   Alabama Birmingham
RP Ach, T (通讯作者)，Univ Hosp Wurzburg, Dept Ophthalmol, D-97080 Wurzburg, Germany.
EM ach_t@ukw.de
RI Ach, Thomas/AAE-7870-2021
OI Ach, Thomas/0000-0001-6583-8283; Curcio, Christine/0000-0001-9769-1538
FU NIH [1R01EY027948, 1R01EY06109]; Dr. Werner Jackstadt Foundation; German
   Research Foundation (DFG); University of Wurzburg; NATIONAL EYE
   INSTITUTE [R01EY027948] Funding Source: NIH RePORTER
FX The research was funded by NIH 1R01EY027948 (T.A., C.A.C.), 1R01EY06109
   (C.A.C.), Dr. Werner Jackstadt Foundation (T.A.). The publication was
   funded by the German Research Foundation (DFG) and the University of
   Wurzburg in the funding program Open Access Publishing.
CR Ablonczy Z, 2011, INVEST OPHTH VIS SCI, V52, P8614, DOI 10.1167/iovs.11-8021
   Ach T, 2015, INVEST OPHTH VIS SCI, V56, P3242, DOI 10.1167/iovs.14-16274
   Ach T, 2014, INVEST OPHTH VIS SCI, V55, P4832, DOI 10.1167/iovs.14-14802
   Achard V, 2010, CURR BIOL, V20, P423, DOI 10.1016/j.cub.2009.12.056
   ADAMIS AP, 1993, BIOCHEM BIOPH RES CO, V193, P631, DOI 10.1006/bbrc.1993.1671
   ADELSTEIN RS, 1980, ANNU REV BIOCHEM, V49, P921, DOI 10.1146/annurev.bi.49.070180.004421
   ANDERSON DH, 1978, INVEST OPHTH VIS SCI, V17, P117
   Andrianantoandro E, 2006, MOL CELL, V24, P13, DOI 10.1016/j.molcel.2006.08.006
   Balaratnasingam C, 2017, OPHTHALMOLOGY, V124, P644, DOI 10.1016/j.ophtha.2016.12.034
   Barral DC, 2004, PIGM CELL RES, V17, P111, DOI 10.1111/j.1600-0749.2004.00138.x
   Bendix PM, 2008, BIOPHYS J, V94, P3126, DOI 10.1529/biophysj.107.117960
   Blaauwgeers HGT, 1999, AM J PATHOL, V155, P421, DOI 10.1016/S0002-9440(10)65138-3
   Bonilha VL, 2014, EXP EYE RES, V126, P38, DOI 10.1016/j.exer.2013.09.015
   Bonilha VL, 1999, J CELL BIOL, V147, P1533, DOI 10.1083/jcb.147.7.1533
   Bonilha VL, 2001, INVEST OPHTH VIS SCI, V42, P3274
   Bressler S. B., 2005, MED RETINA, V2, P1041
   BRETSCHER A, 1978, EXP CELL RES, V116, P397, DOI 10.1016/0014-4827(78)90463-9
   BRETSCHER A, 1980, CELL, V20, P839, DOI 10.1016/0092-8674(80)90330-X
   Brown RA, 1996, J CELL PHYSIOL, V169, P439, DOI 10.1002/(SICI)1097-4652(199612)169:3<439::AID-JCP4>3.0.CO;2-P
   Bruban J, 2009, AGING CELL, V8, P162, DOI 10.1111/j.1474-9726.2009.00456.x
   Burgoyne T, 2015, J CELL SCI, V128, P1400, DOI 10.1242/jcs.164400
   Burnette DT, 2011, NAT CELL BIOL, V13, P371, DOI 10.1038/ncb2205
   BURNSIDE B, 1976, INVEST OPHTH VISUAL, V15, P570
   Burridge K, 2016, EXP CELL RES, V343, P14, DOI 10.1016/j.yexcr.2015.10.029
   CARSON NL, 1989, CYTOGENET CELL GENET, V51, P974
   Chang L, 2004, NAT REV MOL CELL BIO, V5, P601, DOI 10.1038/nrm1438
   Ciuba K, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-35948-6
   Cramer LP, 1997, J CELL BIOL, V136, P1287, DOI 10.1083/jcb.136.6.1287
   CURCIO CA, 1990, J COMP NEUROL, V292, P497, DOI 10.1002/cne.902920402
   Curcio CA, 2017, INVEST OPHTH VIS SCI, V58, P211, DOI 10.1167/iovs.17-21872
   DAVIES PF, 1993, CIRC RES, V72, P239, DOI 10.1161/01.RES.72.2.239
   Del Priore LV, 2002, INVEST OPHTH VIS SCI, V43, P3312
   DELORI FC, 1995, INVEST OPHTH VIS SCI, V36, P718
   Dhingra A, 2018, FRONT CELL NEUROSCI, V12, DOI 10.3389/fncel.2018.00351
   Ding JD, 2011, P NATL ACAD SCI USA, V108, pE279, DOI 10.1073/pnas.1100901108
   Elam WA, 2013, FEBS LETT, V587, P1215, DOI 10.1016/j.febslet.2013.01.062
   Elner SG, 1996, INVEST OPHTH VIS SCI, V37, P696
   Endlich N, 2009, KIDNEY INT, V75, P214, DOI 10.1038/ki.2008.486
   Etienne-Manneville S, 2018, ANNU REV CELL DEV BI, V34, P1, DOI 10.1146/annurev-cellbio-100617-062534
   Favre B, 2011, EUR J CELL BIOL, V90, P390, DOI 10.1016/j.ejcb.2010.11.013
   FEENEY L, 1978, INVEST OPHTH VIS SCI, V17, P583
   FINER JT, 1994, NATURE, V368, P113, DOI 10.1038/368113a0
   Fletcher DA, 2010, NATURE, V463, P485, DOI 10.1038/nature08908
   Friedl P, 2010, J CELL BIOL, V188, P11, DOI 10.1083/jcb.200909003
   Friedlander M, 1996, P NATL ACAD SCI USA, V93, P9764, DOI 10.1073/pnas.93.18.9764
   FUCHS U, 1991, INVEST OPHTH VIS SCI, V32, P3178
   Galbraith CG, 1998, CELL MOTIL CYTOSKEL, V40, P317, DOI 10.1002/(SICI)1097-0169(1998)40:4<317::AID-CM1>3.0.CO;2-8
   Gambril JA, 2019, INVEST OPHTH VIS SCI, V60, P2481, DOI 10.1167/iovs.19-26949
   GAO H, 1992, INVEST OPHTH VIS SCI, V33, P1
   Geisler F, 2016, CELLS-BASEL, V5, DOI 10.3390/cells5030029
   Gibbs D, 2004, J CELL SCI, V117, P6473, DOI 10.1242/jcs.01580
   Gibbs D, 2003, P NATL ACAD SCI USA, V100, P6481, DOI 10.1073/pnas.1130432100
   Girouard MP, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0168641
   Godsel LM, 2008, TRENDS CELL BIOL, V18, P28, DOI 10.1016/j.tcb.2007.11.004
   Gonzalez-Fernandez F, 2008, EXP EYE RES, V86, P169, DOI 10.1016/j.exer.2006.09.003
   GONZALEZFERNANDEZ F, 1993, J CELL SCI, V105, P7
   Granger CE, 2018, INVEST OPHTH VIS SCI, V59, P5705, DOI 10.1167/iovs.18-24677
   Greferath U, 2016, OPHTHALMOLOGY, V123, P1320, DOI 10.1016/j.ophtha.2016.02.009
   GRIERSON I, 1994, EYE, V8, P255, DOI 10.1038/eye.1994.54
   GRISANTI S, 1995, INVEST OPHTH VIS SCI, V36, P391
   Gungor-Ordueri NE, 2015, ASIAN J ANDROL, V17, P653, DOI 10.4103/1008-682X.146103
   Gunning P, 2008, PHYSIOL REV, V88, P1, DOI 10.1152/physrev.00001.2007
   Herrmann H, 2004, ANNU REV BIOCHEM, V73, P749, DOI 10.1146/annurev.biochem.73.011303.073823
   Hiscott P, 1999, PROG RETIN EYE RES, V18, P167, DOI 10.1016/S1350-9462(98)00024-X
   Hohmann T, 2019, CELLS-BASEL, V8, DOI 10.3390/cells8040362
   Holtkamp GM, 1998, CLIN EXP IMMUNOL, V112, P34
   Holtkamp GM, 2001, PROG RETIN EYE RES, V20, P29, DOI 10.1016/S1350-9462(00)00017-3
   Hotulainen P, 2006, J CELL BIOL, V173, P383, DOI 10.1083/jcb.200511093
   Hu SQ, 2017, NAT CELL BIOL, V19, P133, DOI 10.1038/ncb3466
   HUDSPETH AJ, 1973, INVEST OPHTH VISUAL, V12, P354
   Ingerman E, 2013, J CELL BIOL, V200, P619, DOI 10.1083/jcb.201211069
   Jiang M, 2015, J CELL BIOL, V210, P595, DOI 10.1083/jcb.201410112
   KAMM KE, 1985, ANNU REV PHARMACOL, V25, P593, DOI 10.1146/annurev.pharmtox.25.1.593
   Kang F, 1999, J BIOL CHEM, V274, P36963, DOI 10.1074/jbc.274.52.36963
   Kawska A, 2012, P NATL ACAD SCI USA, V109, P14440, DOI 10.1073/pnas.1117096109
   Kevany BM, 2010, PHYSIOLOGY, V25, P8, DOI 10.1152/physiol.00038.2009
   Kiser PD, 2016, ANNU REV VIS SCI, V2, P197, DOI 10.1146/annurev-vision-111815-114407
   Kivela T, 2000, CELL TISSUE RES, V301, P217, DOI 10.1007/s004410000225
   Kohler S, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023798
   Koenderink GH, 2018, CURR OPIN CELL BIOL, V50, P79, DOI 10.1016/j.ceb.2018.01.015
   Koenderink GH, 2009, P NATL ACAD SCI USA, V106, P15192, DOI 10.1073/pnas.0903974106
   Kovar DR, 2006, CELL, V124, P423, DOI 10.1016/j.cell.2005.11.038
   Kroger C, 2013, J CELL BIOL, V201, P681, DOI 10.1083/jcb.201208162
   Law AL, 2015, J BIOL CHEM, V290, P4941, DOI 10.1074/jbc.M114.628297
   LAZARIDES E, 1975, CELL, V6, P289, DOI 10.1016/0092-8674(75)90180-4
   Lee CF, 2005, ANN NY ACAD SCI, V1042, P246, DOI 10.1196/annals.1338.027
   Lehmann GL, 2014, EXP EYE RES, V126, P5, DOI 10.1016/j.exer.2014.04.021
   Leri A, 1998, J CLIN INVEST, V101, P1326, DOI 10.1172/JCI316
   Li ML, 2018, RETINA-J RET VIT DIS, V38, P1937, DOI 10.1097/IAE.0000000000002182
   Litts KM, 2015, JAMA OPHTHALMOL, V133, P609, DOI 10.1001/jamaophthalmol.2015.126
   Liu T, 2017, BIOMED OPT EXPRESS, V8, P4348, DOI 10.1364/BOE.8.004348
   Maekawa M, 1999, SCIENCE, V285, P895, DOI 10.1126/science.285.5429.895
   Mahajan RK, 1996, BIOCHEMISTRY-US, V35, P15504, DOI 10.1021/bi9618981
   MALAWISTA SE, 1975, ANN NY ACAD SCI, V253, P738, DOI 10.1111/j.1749-6632.1975.tb19242.x
   Marmorstein AD, 2001, TRAFFIC, V2, P867, DOI 10.1034/j.1600-0854.2001.21202.x
   MATSUMOTO B, 1990, INVEST OPHTH VIS SCI, V31, P879
   Matsumura F, 2005, TRENDS CELL BIOL, V15, P371, DOI 10.1016/j.tcb.2005.05.004
   Matthews BD, 2006, J CELL SCI, V119, P508, DOI 10.1242/jcs.02760
   Matveeva EA, 2015, BIOL OPEN, V4, P1290, DOI 10.1242/bio.011874
   Maw MA, 1997, NAT GENET, V17, P198, DOI 10.1038/ng1097-198
   Mazzitello K., 2016, ARXIV160904496
   MCKECHNIE NM, 1988, J CELL SCI, V91, P303
   MOOSEKER MS, 1975, J CELL BIOL, V67, P725, DOI 10.1083/jcb.67.3.725
   Muller C, 2018, STEM CELL REP, V10, P1075, DOI 10.1016/j.stemcr.2018.01.017
   Murakami N, 1998, BIOCHEMISTRY-US, V37, P1989, DOI 10.1021/bi971959a
   Murakami N, 2000, BIOCHEMISTRY-US, V39, P11441, DOI 10.1021/bi000347e
   Naumanen P, 2008, J MICROSC-OXFORD, V231, P446, DOI 10.1111/j.1365-2818.2008.02057.x
   Nawrot M, 2004, INVEST OPHTH VIS SCI, V45, P393, DOI 10.1167/iovs.03-0989
   Ngo KX, 2015, ELIFE, V4, DOI 10.7554/eLife.04806
   Nguyen Lan K, 2018, Small GTPases, V9, P316, DOI 10.1080/21541248.2016.1224399
   Noy N, 2000, BIOCHEM J, V348, P481, DOI 10.1042/0264-6021:3480481
   Ooto S, 2014, JAMA OPHTHALMOL, V132, P806, DOI 10.1001/jamaophthalmol.2014.1871
   Osterberg G, 1935, Acta Ophthalmol., V13, P11
   OWARIBE K, 1988, CELL TISSUE RES, V254, P301
   Parri M, 2010, CELL COMMUN SIGNAL, V8, DOI 10.1186/1478-811X-8-23
   Pekny M, 2007, EXP CELL RES, V313, P2244, DOI 10.1016/j.yexcr.2007.04.023
   Pollard T.D, 2016, COLD SPRING HARBOR P, V8
   Pollard TD, 2009, SCIENCE, V326, P1208, DOI 10.1126/science.1175862
   Pollreisz A, 2018, EXP EYE RES, V166, P131, DOI 10.1016/j.exer.2017.10.018
   Ramms L, 2013, P NATL ACAD SCI USA, V110, P18513, DOI 10.1073/pnas.1313491110
   Reymann AC, 2011, MOL BIOL CELL, V22, P2541, DOI 10.1091/mbc.E11-01-0052
   Rizzolo LJ, 2007, INT REV CYTOL, V258, P195, DOI 10.1016/S0074-7696(07)58004-6
   Rizzolo LJ, 2014, EXP EYE RES, V126, P16, DOI 10.1016/j.exer.2013.12.018
   Rizzolo LJ, 2011, PROG RETIN EYE RES, V30, P296, DOI 10.1016/j.preteyeres.2011.06.002
   Rosenberg M, 2006, MOL BIOL CELL, V17, P1364, DOI 10.1091/mbc.e05-07-0597
   Rotty Jeremy D, 2014, Bioarchitecture, V5, P27, DOI 10.1080/19490992.2015.1090670
   RUDOLPH R, 1978, ANAT REC, V191, P169, DOI 10.1002/ar.1091910204
   Sanghvi-Shah R, 2017, FRONT CELL DEV BIOL, V5, DOI 10.3389/fcell.2017.00081
   Schmidt K, 2004, BMC CELL BIOL, V5, DOI 10.1186/1471-2121-5-43
   Schmitz-Valckenberg S, 2008, RETINA-J RET VIT DIS, V28, P385, DOI 10.1097/IAE.0b013e318164a907
   SCHOLEY JM, 1980, NATURE, V287, P233, DOI 10.1038/287233a0
   Sept D, 1999, BIOPHYS J, V77, P2911, DOI 10.1016/S0006-3495(99)77124-9
   Simson J V, 1973, Int Rev Exp Pathol, V12, P79
   Sjoblom B, 2008, CELL MOL LIFE SCI, V65, P2688, DOI 10.1007/s00018-008-8080-8
   Sorkio A, 2014, TISSUE ENG PT A, V20, P622, DOI 10.1089/ten.TEA.2013.0049
   Spaide RF, 2011, RETINA-J RET VIT DIS, V31, P1609, DOI 10.1097/IAE.0b013e3182247535
   Sripathi SR, 2016, PROTEIN J, V35, P179, DOI 10.1007/s10930-016-9659-9
   Starnes AC, 2016, VISUAL NEUROSCI, V33, DOI 10.1017/S0952523815000310
   STEINBERG RH, 1977, PHILOS T ROY SOC B, V277, P459, DOI 10.1098/rstb.1977.0028
   STOSSEL TP, 1974, NEW ENGL J MED, V290, P717, DOI 10.1056/NEJM197403282901306
   Strauss O, 2005, PHYSIOL REV, V85, P845, DOI 10.1152/physrev.00021.2004
   Stricker J, 2010, J BIOMECH, V43, P9, DOI 10.1016/j.jbiomech.2009.09.003
   Tan ACS, 2017, INVEST OPHTH VIS SCI, V58, P2349, DOI 10.1167/iovs.16-21237
   Toivola DM, 2010, TRENDS CELL BIOL, V20, P79, DOI 10.1016/j.tcb.2009.11.004
   Toivola DM, 2005, TRENDS CELL BIOL, V15, P608, DOI 10.1016/j.tcb.2005.09.004
   Tojkander S, 2015, ELIFE, V4, DOI 10.7554/eLife.06126
   Tojkander S, 2012, J CELL SCI, V125, P1855, DOI 10.1242/jcs.098087
   Tojkander S, 2011, CURR BIOL, V21, P539, DOI 10.1016/j.cub.2011.03.007
   TOMASEK JJ, 1984, J CELL BIOL, V99, P536, DOI 10.1083/jcb.99.2.536
   Totsukawa G, 2000, J CELL BIOL, V150, P797, DOI 10.1083/jcb.150.4.797
   TSO MOM, 1967, ARCH OPHTHALMOL-CHIC, V78, P641, DOI 10.1001/archopht.1967.00980030643016
   Vasioukhin V, 2000, CELL, V100, P209, DOI 10.1016/S0092-8674(00)81559-7
   Vicente-Manzanares M, 2009, NAT REV MOL CELL BIO, V10, P778, DOI 10.1038/nrm2786
   Wagner B, 2006, P NATL ACAD SCI USA, V103, P13974, DOI 10.1073/pnas.0510190103
   Wang AL, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004160
   WANG N, 1993, SCIENCE, V260, P1124, DOI 10.1126/science.7684161
   Wang N, 2000, AM J PHYSIOL-CELL PH, V279, pC188, DOI 10.1152/ajpcell.2000.279.1.C188
   WEISSMANN G, 1975, ANN NY ACAD SCI, V253, P750, DOI 10.1111/j.1749-6632.1975.tb19243.x
   WING GL, 1978, INVEST OPHTH VIS SCI, V17, P601
   Wu S, 2017, BMC OPHTHALMOL, V17, DOI 10.1186/s12886-017-0606-0
   Yang X, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0191279
   Ruiz-Loredo AY, 2012, INT REV CEL MOL BIO, V293, P85, DOI 10.1016/B978-0-12-394304-0.00008-7
   Yumura S, 2005, MOL BIOL CELL, V16, P4256, DOI 10.1091/mbc.E05-03-0219
   Zanzottera EC, 2016, RETINA-J RET VIT DIS, V36, pS12, DOI 10.1097/IAE.0000000000001276
   Zanzottera EC, 2015, INVEST OPHTH VIS SCI, V56, P3253, DOI 10.1167/iovs.15-16431
   Zanzottera EC, 2015, INVEST OPHTH VIS SCI, V56, P3269, DOI 10.1167/iovs.15-16432
NR 166
TC 30
Z9 31
U1 2
U2 11
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 1422-0067
J9 INT J MOL SCI
JI Int. J. Mol. Sci.
PD JUL 2
PY 2019
VL 20
IS 14
AR 3578
DI 10.3390/ijms20143578
PG 19
WC Biochemistry & Molecular Biology; Chemistry, Multidisciplinary
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry
GA IQ0OB
UT WOS:000480449300202
PM 31336621
OA Green Published, Green Submitted, gold
DA 2022-11-30
ER

PT J
AU Goverdhan, SV
   Ennis, S
   Hannan, SR
   Madhusudhana, KC
   Cree, AJ
   Luff, AJ
   Lotery, AJ
AF Goverdhan, S. V.
   Ennis, S.
   Hannan, S. R.
   Madhusudhana, K. C.
   Cree, A. J.
   Luff, A. J.
   Lotery, A. J.
TI Interleukin-8 promoter polymorphism-251A/T is a risk factor for
   age-related macular degeneration
SO BRITISH JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID C-REACTIVE PROTEIN; CELLS IN-VITRO; ASSOCIATION; GENE; ANGIOGENESIS;
   INHIBITION; EXPRESSION; PIGMENT; GROWTH; MACULOPATHY
AB Background/aims: To determine whether four expression-related cytokine polymorphisms are associated with age-related macular degeneration (AMD).
   Methods: DNA from 478 cases with AMD and 555 normal controls was genotyped for the pro-inflammatory IL1 beta -511C/ T, IL6 -174C/ G, IL8 -251A/ T and anti-inflammatory IL10 -1082G/ A cytokine polymorphisms using the 59 nuclease TaqMan (R) assay for allelic discrimination. Associations with AMD were analysed using allelic frequencies.
   Results: The -251A allele of the IL8 promoter gene polymorphism was more prevalent in AMD patients than controls ( p= 0.037, OR= 1.21, 95% CI= 1.01 to 1.44). Adjusting for age, sex, body mass index ( BMI), current smoking and past smoking status did not alter the AMD association significantly ( corrected p value= 0.043, OR= 1.23, 95% CI= 1.0 to 1.50).
   Conclusion: The pro-inflammatory homozygous IL8 -251AA genotype is an important risk factor for AMD. This may have implications for future therapy with biological agents that could target this cytokine.
C1 [Goverdhan, S. V.; Cree, A. J.; Lotery, A. J.] Southampton Gen Hosp, Clin Neurosci Div, Southampton SO16 6YD, Hants, England.
   [Goverdhan, S. V.; Hannan, S. R.; Madhusudhana, K. C.; Luff, A. J.; Lotery, A. J.] Southampton Gen Hosp, Southampton Eye Unit, Southampton SO16 6YD, Hants, England.
   [Ennis, S.] Southampton Gen Hosp, Div Human Genet, Southampton SO16 6YD, Hants, England.
C3 University of Southampton; University of Southampton; University of
   Southampton
RP Lotery, AJ (通讯作者)，Southampton Gen Hosp, Clin Neurosci Div, Mailpoint 806, Southampton SO16 6YD, Hants, England.
EM a.j.lotery@soton.ac.uk
OI Lotery, Andrew/0000-0001-5541-4305; Cree, Angela/0000-0002-1987-8900
FU Intramural NIH HHS Funding Source: Medline; Wellcome Trust [076169]
   Funding Source: Medline
CR Baird PN, 2006, INVEST OPHTH VIS SCI, V47, P4194, DOI 10.1167/iovs.05-1285
   Berendschot TTJM, 2002, INVEST OPHTH VIS SCI, V43, P1928
   Chen LJ, 2006, MOL VIS, V12, P1536
   de Waal MR, 1991, J EXP MED, V174, P915, DOI DOI 10.1084/JEM.174.4.915
   ENK AH, 1993, J IMMUNOL, V151, P2390
   Enzmann V, 2002, OPHTHALMIC RES, V34, P232, DOI 10.1159/000063875
   Enzmann V, 2001, CURR EYE RES, V23, P98, DOI 10.1076/ceyr.23.2.98.5474
   Gabay C, 1999, NEW ENGL J MED, V340, P448, DOI 10.1056/NEJM199902113400607
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Higgins GT, 2003, INVEST OPHTH VIS SCI, V44, P1775, DOI 10.1167/iovs.02-0742
   Howell WM, 2001, GENES IMMUN, V2, P25, DOI 10.1038/sj.gene.6363726
   Hull J, 2000, THORAX, V55, P1023, DOI 10.1136/thorax.55.12.1023
   Infante J, 2005, J NEUROL SCI, V228, P11, DOI 10.1016/j.jns.2004.09.023
   ITO H, 2005, J HUM GENET
   Klaver CCW, 2001, INVEST OPHTH VIS SCI, V42, P2237
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   KOCH AE, 1992, SCIENCE, V258, P1798, DOI 10.1126/science.1281554
   Kohno T, 2003, CANCER RES, V63, P5091
   Lee WP, 2005, CLIN CANCER RES, V11, P6431, DOI 10.1158/1078-0432.CCR-05-0942
   MATSUDA M, 1994, J EXP MED, V180, P2371, DOI 10.1084/jem.180.6.2371
   MILLER SA, 1988, NUCLEIC ACIDS RES, V16, P1215, DOI 10.1093/nar/16.3.1215
   Radisavljevic Z, 2000, J BIOL CHEM, V275, P20770, DOI 10.1074/jbc.M002448200
   Sanchez E, 2006, BMC MED GENET, V7, DOI 10.1186/1471-2350-7-48
   Seddon JM, 2005, ARCH OPHTHALMOL-CHIC, V123, P774, DOI 10.1001/archopht.123.6.774
   Seddon JM, 2004, JAMA-J AM MED ASSOC, V291, P704, DOI 10.1001/jama.291.6.704
   SMITH DR, 1994, J EXP MED, V179, P1409, DOI 10.1084/jem.179.5.1409
   Stone EM, 2001, HUM MOL GENET, V10, P2285, DOI 10.1093/hmg/10.20.2285
   VAIRAKTARIS E, 2006, EUR J SURG ONCOL
NR 29
TC 54
Z9 57
U1 0
U2 6
PU B M J PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0007-1161
J9 BRIT J OPHTHALMOL
JI Br. J. Ophthalmol.
PD APR
PY 2008
VL 92
IS 4
BP 537
EP 540
DI 10.1136/bjo.2007.123190
PG 4
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 279XH
UT WOS:000254388200025
PM 18310311
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Virgili, G
   Do, DV
   Bressler, NM
   Menchini, U
AF Virgili, Gianni
   Do, Diana V.
   Bressler, Neil M.
   Menchini, Ugo
TI New therapies for neovascular age-related macular degeneration: critical
   appraisal of the current evidence
SO ACTA OPHTHALMOLOGICA SCANDINAVICA
LA English
DT Review
DE age-related macular degeneration; choroidal neovascularization;
   evidence-based medicine; laser photocoagulation; pegaptanib sodium;
   verteporfin therapy
ID SUBFOVEAL CHOROIDAL NEOVASCULARIZATION; INTRAVITREAL TRIAMCINOLONE
   ACETONIDE; PHOTODYNAMIC THERAPY; VISUAL IMPAIRMENT; OXIDATIVE STRESS;
   VERTEPORFIN; PREVALENCE; PHOTOCOAGULATION; TRANSLOCATION; MACULOPATHY
AB During the past 20 years, several multicentre clinical trials have investigated different therapies for neovascular age-related macular degeneration (AMD). These landmark studies have provided the scientific community with powerful data regarding the ability of laser photocoagulation, verteporfin therapy, pegaptanib sodium and submacular surgery to treat particular choroidal neovascular lesion types. Accurate interpretation of data from these trials is essential to enable clinicians to make informed decisions about therapeutic interventions. Furthermore, several new treatment options are likely to become available in the next few years and clinicians will have to decide how effective these therapies may be, and how ( or if) they should be used in clinical practice. It is therefore timely to review the strengths and weaknesses of the body of evidence for the currently available therapeutic options for patients with choroidal neovascularization due to AMD. Evaluation of the quality of reporting in past clinical trials will also enable critical review of new studies that will be published in the future. This review summarizes the design, reporting and results of key randomized clinical trials, in addition to evaluating the available evidence for new therapies and identifying the important issues that need to be considered when evaluating their efficacy.
C1 Univ Florence, Dept Otoneuroophthalmol Surg Sci, Florence, Italy.
   Johns Hopkins Univ, Sch Med, Wilmer Ophthalmol Inst, Retina Serv, Baltimore, MD 21205 USA.
C3 University of Florence; Johns Hopkins University; Johns Hopkins Medicine
RP Virgili, G (通讯作者)，Univ Florence, Dept Otoneuroophthalmol Surg Sci, Via le Morgagni 5, Florence, Italy.
EM gianni.virgili@unifi.it
RI Virgili, Gianni/P-6607-2014
OI Virgili, Gianni/0000-0002-9960-2989
CR ADAMIS AP, 1994, AM J OPHTHALMOL, V118, P445, DOI 10.1016/S0002-9394(14)75794-0
   Ahuja R M, 2001, Semin Ophthalmol, V16, P81, DOI 10.1076/soph.16.2.81.4215
   Algvere P V, 2001, Semin Ophthalmol, V16, P90, DOI 10.1076/soph.16.2.90.4210
   [Anonymous], 1991, Arch Ophthalmol, V109, P1109
   [Anonymous], 1991, Arch Ophthalmol, V109, P1220
   Arnold J, 2001, OPHTHALMOLOGY, V108, P841
   Arnold J, 2001, AM J OPHTHALMOL, V131, P541
   Arnold JJ, 2004, AM J OPHTHALMOL, V137, P683, DOI 10.1016/j.ajo.2003.11.059
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   Blinder KJ, 2003, AM J OPHTHALMOL, V136, P407, DOI 10.1016/S0002-9394(03)00223-X
   Blinder KJ, 2003, OPHTHALMOLOGY, V110, P667, DOI 10.1016/S0161-6420(02)01998-X
   Blumenkranz MS, 2001, ARCH OPHTHALMOL-CHIC, V119, P198
   Bressler NM, 2004, OPHTHALMOLOGY, V111, P1993, DOI 10.1016/j.ophtha.2004.07.023
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   Buch H, 2004, OPHTHALMOLOGY, V111, P53, DOI 10.1016/j.ophtha.2003.05.010
   CASTELLANI A, 1963, J Pathol Bacteriol, V86, P99, DOI 10.1002/path.1700860111
   Challa JK, 1998, AUST NZ J OPHTHALMOL, V26, P277, DOI 10.1111/j.1442-9071.1998.tb01330.x
   Ciulla TA, 2003, RETINA-J RET VIT DIS, V23, P808, DOI 10.1097/00006982-200312000-00011
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   Cook DI, 2004, MED J AUSTRALIA, V180, P289, DOI 10.5694/j.1326-5377.2004.tb05928.x
   DAMICO DJ, 2002, INVEST OPHTHALMOL VI, V43
   Danis RP, 2000, RETINA-J RET VIT DIS, V20, P244, DOI 10.1097/00006982-200003000-00004
   Desatnik H, 2000, RETINA-J RET VIT DIS, V20, P143, DOI 10.1097/00006982-200003000-00005
   Dimitrov PN, 2003, INVEST OPHTH VIS SCI, V44, P5075, DOI 10.1167/iovs.02-0457
   FINE SL, 1982, ARCH OPHTHALMOL-CHIC, V100, P912
   FOLKMAN J, 1971, NEW ENGL J MED, V285, P1182
   Foran S, 2003, OPHTHALMIC EPIDEMIOL, V10, P215, DOI 10.1076/opep.10.4.215.15906
   GARCIA GA, 2004, INVEST OPHTHALMOL VI, V45
   Gillies MC, 2003, ARCH OPHTHALMOL-CHIC, V121, P667, DOI 10.1001/archopht.121.5.667
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Greve MDJ, 2005, ARCH OPHTHALMOL-CHIC, V123, P448
   Harbour R, 2001, BRIT MED J, V323, P334, DOI 10.1136/bmj.323.7308.334
   HAWKINS BS, 1993, ARCH OPHTHALMOL-CHIC, V111, P1200
   HAWKINS BS, 1990, ARCH OPHTHALMOL-CHIC, V108, P816
   Hawkins BS, 2004, OPHTHALMOLOGY, V111, P1967, DOI 10.1016/j.ophtha.2004.07.021
   Hawkins BS, 1999, ARCH OPHTHALMOL-CHIC, V117, P677
   Heier JS, 2005, INVEST OPHTH VIS SCI, V46
   Heier JS, 2005, AM SOC RET SPEC 23 A
   HEIER JS, 2003, INVEST OPHTHALMOL VI, V44
   Higgins RD, 2000, INVEST OPHTH VIS SCI, V41, P1507
   Holz FG, 1999, OPHTHALMOLOGY, V106, P2239
   Hudson HL, 2005, INVEST OPHTH VIS SCI, V46
   Jonas JB, 2003, BRIT J OPHTHALMOL, V87, P462, DOI 10.1136/bjo.87.4.462
   JONAS JB, 2004, INVEST OPHTHALMOL VI, V45
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Kim J E, 2001, Semin Ophthalmol, V16, P86, DOI 10.1076/soph.16.2.86.4212
   Kim MY, 2004, J CLIN EPIDEMIOL, V57, P1253, DOI 10.1016/j.jclinepi.2004.05.005
   KLEIN R, 1995, INVEST OPHTH VIS SCI, V36, P182
   Kramer M, 1996, OPHTHALMOLOGY, V103, P427
   Lee W K, 2000, Korean J Ophthalmol, V14, P60
   Lewis H, 2001, AM J OPHTHALMOL, V132, P156, DOI 10.1016/S0002-9394(01)01088-1
   Liang FQ, 2003, EXP EYE RES, V76, P397, DOI 10.1016/S0014-4835(03)00023-X
   Lim L, 2004, CLIN EXP OPHTHALMOL, V32, P341, DOI 10.1111/j.1442-9071.2004.00832.x
   MAGUIRE MG, 1994, ARCH OPHTHALMOL-CHIC, V112, P480
   MILLER J, 2005, AM SOC RET SPEC 23 A
   MILLER JW, 1995, ARCH OPHTHALMOL-CHIC, V113, P810, DOI 10.1001/archopht.1995.01100060136048
   Moher David, 2003, Clin Oral Investig, V7, P2
   Pauleikhoff D, 2005, KLIN MONATSBL AUGENH, V222, P381, DOI 10.1055/s-2005-858225
   Penfold PL, 1995, AUST NZ J OPHTHALMOL, V23, P293, DOI 10.1111/j.1442-9071.1995.tb00179.x
   Pieramici DJ, 2000, AM J OPHTHALMOL, V130, P419, DOI 10.1016/S0002-9394(00)00533-X
   Ranson NT, 2002, BRIT J OPHTHALMOL, V86, P527, DOI 10.1136/bjo.86.5.527
   Rechtman E, 2004, BRIT J OPHTHALMOL, V88, P344, DOI 10.1136/bjo.2003.027177
   REICHEL E, 2004, AAO RET SUBSP DAY 22
   ROSENFELD PJ, 2005, AAO RET SUBSP DAY 15
   Russell S, 2003, OPHTHALMOLOGY, V110, P2372, DOI 10.1016/j.ophtha.2003.08.020
   Sanchez-Thorin JC, 2001, OPHTHALMOLOGY, V108, P410, DOI 10.1016/S0161-6420(00)00500-5
   SCHACHAT AP, 1994, ARCH OPHTHALMOL-CHIC, V112, P500
   Shiraga F, 1998, OPHTHALMOLOGY, V105, P662, DOI 10.1016/S0161-6420(98)94021-0
   Sivagnanavel V, 2004, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD004004.PUB2
   Slakter JS, 2006, OPHTHALMOLOGY, V113, P3, DOI 10.1016/j.ophtha.2005.10.019
   Spaide RF, 2005, OPHTHALMOLOGY, V112, P301, DOI 10.1016/j.ophtha.2004.08.012
   Spaide RF, 2003, OPHTHALMOLOGY, V110, P1517, DOI 10.1016/S0161-6420(03)00544-X
   Sternberg P, 1996, ARCH OPHTHALMOL-CHIC, V114, P400
   STERNBERG P, 1991, ARCH OPHTHALMOL-CHIC, V109, P1232
   THOMAS EL, 2004, AM AC OPHTH EUR SOC
   THOMAS EL, 2004, INVEST OPHTHALMOL VI, V45
   Tranos P, 2004, ACTA OPHTHALMOL SCAN, V82, P585, DOI 10.1111/j.1600-0420.2004.00327.x
   *TREATM AG REL MAC, 2006, 8 TAP
   *TREATM AG REL MAC, 2004, RETINA, V24, P1
   VINGERLING JR, 1995, OPHTHALMOLOGY, V102, P205
   WEISHAUPT KR, 1976, CANCER RES, V36, P2326
NR 81
TC 11
Z9 11
U1 0
U2 2
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1395-3907
J9 ACTA OPHTHALMOL SCAN
JI Acta Ophthalmol. Scand.
PD FEB
PY 2007
VL 85
IS 1
BP 6
EP 20
DI 10.1111/j.1600-0420.2006.00711.x
PG 15
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 128CJ
UT WOS:000243634100003
PM 17244204
OA Bronze
DA 2022-11-30
ER

PT J
AU Vingolo, EM
   Salvatore, S
   Limoli, PG
AF Vingolo, Enzo M.
   Salvatore, Serena
   Limoli, Paolo G.
TI MP-1 Biofeedback: Luminous Pattern Stimulus Versus Acoustic Biofeedback
   in Age Related Macular degeneration (AMD)
SO APPLIED PSYCHOPHYSIOLOGY AND BIOFEEDBACK
LA English
DT Article
DE Age related macular degeneration (AMD); Visual rehabilitation; MP-1
   microperimetry; Retina; Biofeedback; Pattern stimulus
ID VISION RESTORATION THERAPY; CIGARETTE-SMOKING; VISUAL-FIELD;
   DIETARY-FAT; RISK
AB In this study we evaluated the efficacy of visual rehabilitation by means of two different types of biofeedback techniques in patients with age related macular degeneration (AMD). Thirty patients, bilaterally affected by AMD, were randomly divided in two groups: one group was treated with an acoustic biofeedback (AB group), the other was treated with luminous biofeedback of a black and white checkerboard flickering during the examination (LB group). All patients underwent a complete ophthalmological examination. Rehabilitation consisted of 12 training sessions of 10 min for each eye performed once a week for both groups. Both groups showed better visual performance after rehabilitation and luminous flickering biofeedback stimulus showed a statistically significant improvement in training the patients to modify their preferred retinal locus in comparison to acoustic biofeedback. This suggests that it might be possible in the damaged retina to override dead photoreceptor and outer retinal layers and involve residual surviving cells, as well as amplify and integrate retinal and brain cortex plasticity by using other spared channels towards associative pathways.
C1 [Vingolo, Enzo M.; Salvatore, Serena] Univ Roma La Sapienza, A Fiorini Hosp, Dept Ophthalmol, Terracina, LT, Italy.
   [Vingolo, Enzo M.; Salvatore, Serena] AUSL Latina, Santa Maria Goretti Hosp, Dept Ophthalmol, Latina, Italy.
   [Limoli, Paolo G.] Low Vis Ctr, Milan, Italy.
C3 Sapienza University Rome
RP Salvatore, S (通讯作者)，Via Terni 38 E 13, I-00182 Rome, Italy.
EM serena.sal@hotmail.it
RI Limoli, Paolo/AAB-9828-2021; Vingolo, Enzo Maria/E-6674-2010
OI Vingolo, Enzo Maria/0000-0002-8363-5866
CR Baker CI, 2005, J NEUROSCI, V25, P614, DOI 10.1523/JNEUROSCI.3476-04.2005
   Bird A. C., 2005, SURV OPHTHALMOL, V39, P367
   CARTER TL, 1994, GERIATRICS, V49, P37
   Cho E, 2001, AM J CLIN NUTR, V73, P209
   Christen WG, 1996, JAMA-J AM MED ASSOC, V276, P1147, DOI 10.1001/jama.276.14.1147
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   Crossland MD, 2004, OPHTHAL PHYSL OPT, V24, P327, DOI 10.1111/j.1475-1313.2004.00213.x
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Fujii GY, 2002, OPHTHALMOLOGY, V109, P1737, DOI 10.1016/S0161-6420(02)01120-X
   Henriksson L, 2007, J NEUROL NEUROSUR PS, V78, P74, DOI 10.1136/jnnp.2006.099374
   Horton JC, 2005, BRIT J OPHTHALMOL, V89, P792, DOI 10.1136/bjo.2005.072967
   Kanabarou S. A., 2003, INVESTIGATIVE OPHTHA
   Kasten E, 1998, J CLIN EXP NEUROPSYC, V20, P581, DOI 10.1076/jcen.20.5.581.1129
   KASTEN E, 1995, RESTOR NEUROL NEUROS, V8, P113, DOI 10.3233/RNN-1995-8302
   Khan JC, 2006, BRIT J OPHTHALMOL, V90, P75, DOI 10.1136/bjo.2005.073643
   MAFFEI L, 1976, VISION RES, V16, P1131, DOI 10.1016/0042-6989(76)90253-4
   MARESPERLMAN JA, 1995, ARCH OPHTHALMOL-CHIC, V113, P743, DOI 10.1001/archopht.1995.01100060069034
   Nilsson UL, 2003, VISION RES, V43, P1777, DOI 10.1016/S0042-6989(03)00219-0
   Parisi V, 2010, CLIN NEUROPHYSIOL, V121, P380, DOI 10.1016/j.clinph.2009.09.032
   Poggel DA, 2004, NEUROLOGY, V63, P2069, DOI 10.1212/01.WNL.0000145773.26378.E5
   Raninen A, 2007, J NEUROL NEUROSUR PS, V78, P66, DOI 10.1136/jnnp.2006.099366
   Rovner BW, 2009, ALZHEIMERS DEMENT, V5, P12, DOI 10.1016/j.jalz.2008.06.001
   Sabel B A, 2000, Curr Opin Ophthalmol, V11, P430, DOI 10.1097/00055735-200012000-00008
   Sabel BA, 2004, RESTOR NEUROL NEUROS, V22, P399
   Seddon JM, 1996, JAMA-J AM MED ASSOC, V276, P1141, DOI 10.1001/jama.276.14.1141
   Shak G. K., 2009, RETINA, V29, P133
   Vingolo EM, 2007, APPL PSYCHOPHYS BIOF, V32, P185, DOI [10.1007/s10484-007-9038-6, 10.1007/sl0484-007-9038-6]
   Vingolo EM, 2009, APPL PSYCHOPHYS BIOF, V34, P127, DOI 10.1007/s10484-009-9083-4
   Vingolo EM, 2009, EYE VIS RES DEV, P313
   Wahl HW, 2008, OPHTHALMOLOGE, V105, P735, DOI 10.1007/s00347-008-1724-0
NR 30
TC 20
Z9 20
U1 0
U2 17
PU SPRINGER/PLENUM PUBLISHERS
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1090-0586
EI 1573-3270
J9 APPL PSYCHOPHYS BIOF
JI Appl. Psychophysiol. Biofeedback
PD MAR
PY 2013
VL 38
IS 1
BP 11
EP 16
DI 10.1007/s10484-012-9203-4
PG 6
WC Psychology, Clinical
WE Social Science Citation Index (SSCI)
SC Psychology
GA 092ZF
UT WOS:000315160800002
PM 22903517
DA 2022-11-30
ER

PT J
AU Seitsonen, S
   Onkamo, P
   Torniainen, S
   Ihalainen, M
   Immonen, I
   Meri, S
   Jarvela, I
AF Seitsonen, Sanna
   Onkamo, Paivi
   Torniainen, Suvi
   Ihalainen, Milla
   Immonen, Ilkka
   Meri, Seppo
   Jarvela, Irma
TI Screening of DNA-variants in the properdin gene (CFP) in age-related
   macular degeneration (AMD)
SO MOLECULAR IMMUNOLOGY
LA English
DT Article
DE Properdin; Age-related macular degeneration; Complement; Gene;
   Association
ID ASSOCIATION
AB Several variants in the complement cascade genes (complement factor H [CFH], C2, C3, CFB, and Serping1) have been reported to associate with age-related macular degeneration (AMD). Of these, a member of the complement alternative pathway, CFH, represents the highest risk. As properdin (P) is also an important protein in this pathway, we analysed whether variants in the properdin gene (CFP) at Xp11.4 are associated with AMD. Ten exons of CFP were sequenced in a total of 222 Finnish patients with AMD (150 sporadic cases and 72 familial cases). The controls were 86 age-matched non-AMD patients with no large drusen and no or minimal focal pigmentary abnormalities. A total of four single nucleotide polymorphisms (SNPs) were detected in CFP, three of them infrequent (in 5 patients and controls in total). The fourth SNP, rs1048118 in exon 10, was more frequent, but was not associated with AMD, either alone (p = 0.33) or in conjunction with other risk factors. Thus, CFP does not seem to confer any risk for AMD. (C) 2010 Elsevier Ltd. All rights reserved.
C1 [Seitsonen, Sanna; Immonen, Ilkka] Univ Helsinki, Dept Ophthalmol, Helsinki 00029, Finland.
   [Seitsonen, Sanna; Torniainen, Suvi; Ihalainen, Milla; Jarvela, Irma] Univ Helsinki, Haartman Inst, Dept Med Genet, FIN-00014 Helsinki, Finland.
   [Onkamo, Paivi] Univ Helsinki, Dept Biol & Environm Sci, FIN-00014 Helsinki, Finland.
   [Meri, Seppo] Univ Helsinki, Haartman Inst, Dept Bacteriol & Immunol, FIN-00014 Helsinki, Finland.
   [Jarvela, Irma] Univ Helsinki, Cent Hosp, Mol Genet Lab, Helsinki 00029, Finland.
C3 University of Helsinki; University of Helsinki; University of Helsinki;
   University of Helsinki; University of Helsinki; Helsinki University
   Central Hospital
RP Jarvela, I (通讯作者)，Univ Helsinki, Dept Med Genet, Box 63, Helsinki 00251, Finland.
EM irma.jarvela@kolumbus.fi
RI Mohammed, Imran/J-8271-2012; Jarvela, Irma E/L-5836-2013
OI Mohammed, Imran/0000-0002-8412-0768; Jarvela, Irma
   E/0000-0002-1770-6187; Meri, Seppo/0000-0001-9142-501X
FU Mary and Georg Ehrnrooth Foundation, Helsinki, Finland; Eye Foundation,
   Helsinki, Finland; Academy of Finland, Helsinki, Finland; Helsinki
   University Central Hospital, Helsinki, Finland [TLE82G0004, TYH5117,
   TYH2008235]; National Institutes of Health [EY11515]; National Eye
   Institute [R24EY017404]; NATIONAL EYE INSTITUTE [R01EY011515,
   R24EY017404] Funding Source: NIH RePORTER
FX We thank the patients for the participation in the study. This study was
   funded by grants from the Mary and Georg Ehrnrooth Foundation, Helsinki,
   Finland; The Eye Foundation, Helsinki, Finland; The Academy of Finland,
   Helsinki, Finland; Helsinki University Central Hospital Research Funds
   (TLE82G0004, TYH5117, and TYH2008235) Helsinki, Finland; and National
   Institutes of Health (EY11515) and National Institutes of Health
   (R24EY017404) from the National Eye Institute.
CR BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Botto M, 2009, MOL IMMUNOL, V46, P2774, DOI 10.1016/j.molimm.2009.04.029
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Ennis S, 2008, LANCET, V372, P1828, DOI 10.1016/S0140-6736(08)61348-3
   FEARON DT, 1975, J EXP MED, V142, P856, DOI 10.1084/jem.142.4.856
   Fijen CAP, 1999, MOL IMMUNOL, V36, P863, DOI 10.1016/S0161-5890(99)00107-8
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Kemper C, 2008, MOL IMMUNOL, V45, P4048, DOI 10.1016/j.molimm.2008.06.034
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Laine M, 2007, J IMMUNOL, V178, P3831, DOI 10.4049/jimmunol.178.6.3831
   NOLAN KF, 1992, BIOCHEM J, V287, P291, DOI 10.1042/bj2870291
   Purcell S, 2007, AM J HUM GENET, V81, P559, DOI 10.1086/519795
   Seitsonen SP, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003833
   SJOHOLM AG, 1990, APMIS, V98, P861
   van den Bogaard R, 2000, EUR J HUM GENET, V8, P513, DOI 10.1038/sj.ejhg.5200496
   Walport MJ, 2001, NEW ENGL J MED, V344, P1058, DOI 10.1056/NEJM200104053441406
   YATES JR, 2007, NEW ENGL J MED, V6, P553
NR 20
TC 4
Z9 6
U1 0
U2 1
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0161-5890
J9 MOL IMMUNOL
JI Mol. Immunol.
PD MAR
PY 2010
VL 47
IS 6
BP 1334
EP 1336
DI 10.1016/j.molimm.2010.01.001
PG 3
WC Biochemistry & Molecular Biology; Immunology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Immunology
GA 578NN
UT WOS:000276300600020
PM 20122735
DA 2022-11-30
ER

PT J
AU Carneiro, AM
   Silva, RM
   Veludo, MJ
   Barbosa, A
   Ruiz-Moreno, JM
   Falcao, MS
   Brandao, EM
   Falcao-Reis, FM
AF Carneiro, Angela M.
   Silva, Rufino M.
   Veludo, Maria J.
   Barbosa, Augusto
   Ruiz-Moreno, Jose M.
   Falcao, Manuel S.
   Brandao, Elisete M.
   Falcao-Reis, Fernando M.
TI Ranibizumab Treatment for Choroidal Neovascularization from Causes Other
   than Age-Related Macular Degeneration and Pathological Myopia
SO OPHTHALMOLOGICA
LA English
DT Article
DE Anti-VEGF therapy; Lucentis (R); Choroidal neovascularization; Angioid
   streaks; Inflammatory chorioretinal diseases; Idiopathic choroidal
   neovascularization
ID INTRAVITREAL BEVACIZUMAB AVASTIN; ANGIOID STREAKS; PHOTODYNAMIC THERAPY;
   PSEUDOXANTHOMA ELASTICUM; SECONDARY; VERTEPORFIN; MANAGEMENT; INJECTION
AB Aim: Evaluation of safety and efficacy of intravitreal ranibizumab in the treatment of choroidal neovascularization (CNV) secondary to causes other than age-related macular degeneration (AMD) or pathological myopia (PM). Methods: Retrospective and multicentric analysis of 21 eyes with CNV. Nine eyes had angioid streaks, 5 inflammatory chorioretinal diseases, 3 central serous chorioretinopathy and 4 idiopathic CNV. Follow-ups lasted 6 3 months. Best-corrected visual acuity (BCVA), ocular coherence tomography (OCT) and fundus examination were assessed monthly. Results: Sixteen eyes (76%) completed 180 days of follow-up. Overall BCVA increased by +9.8 letters with treatment (p = 0.015). Visual acuity improvements >= 15 letters occurred in 43%. A significant reduction in OCT central thickness was observed. No cases of severe visual acuity loss, systemic or ocular side effects were registered. Conclusion: Short-term results of intravitreal ranibizumab for CNV unrelated to AMD or PM are encouraging. This treatment may constitute the only option for some of these patients. Copyright (C) 2010 S. Karger AG, Basel
C1 [Falcao-Reis, Fernando M.] Univ Porto, Dept Ophthalmol, Hosp Sao Joao, Fac Med, PT-4200319 Porto, Portugal.
   [Carneiro, Angela M.; Falcao, Manuel S.; Falcao-Reis, Fernando M.] Univ Porto, Fac Med, PT-4200319 Porto, Portugal.
   [Silva, Rufino M.] Univ Hosp Coimbra, Dept Ophthalmol, Coimbra, Portugal.
   [Barbosa, Augusto] Ctr Hosp Coimbra, Dept Ophthalmol, Coimbra, Portugal.
   [Veludo, Maria J.] Hosp Sao Jose, Dept Ophthalmol, Lisbon, Portugal.
   [Ruiz-Moreno, Jose M.] Univ Castilla La Mancha, Albacete Med Sch, Dept Ophthalmol, Albacete, Spain.
   [Ruiz-Moreno, Jose M.] VISSUM, Alicante Inst Ophthalmol, Vitreo Retinal Unit, Alicante, Spain.
C3 Sao Joao Hospital; Universidade do Porto; Universidade do Porto;
   Universidade de Coimbra; Centro Hospitalar e Universitario de Coimbra
   (CHUC); Universidade de Coimbra; Centro Hospitalar e Universitario de
   Coimbra (CHUC); Universidad de Castilla-La Mancha
RP Falcao-Reis, FM (通讯作者)，Univ Porto, Dept Ophthalmol, Hosp Sao Joao, Fac Med, Al Prof Hernani Monteiro, PT-4200319 Porto, Portugal.
EM falcao@med.up.pt
RI Falcao/AAQ-8509-2020; Silva, Rufino M/J-2817-2012; Ruiz-Moreno, José
   M/E-4644-2016; Carneiro, Angela/N-9680-2013
OI Falcao/0000-0003-4718-0910; Silva, Rufino M/0000-0001-8676-0833;
   Carneiro, Angela/0000-0002-3370-7243; Falcao-Reis,
   Fernando/0000-0002-5995-9430; Ruiz-Moreno, Jose M/0000-0001-9636-0788
CR [Anonymous], 1997, DIAGNOSIS TREATMENT
   Arias L, 2006, GRAEF ARCH CLIN EXP, V244, P753, DOI 10.1007/s00417-005-0131-3
   Bhatnagar P, 2007, RETINA-J RET VIT DIS, V27, P897, DOI 10.1097/IAE.0b013e31809ff5df
   BLOCH SB, 2010, ACTA OPHTHALMOL
   Boyer DS, 2009, OPHTHALMOLOGY, V116, P1731, DOI 10.1016/j.ophtha.2009.05.024
   BRANCATO R, 1987, OPHTHALMOLOGICA, V195, P84, DOI 10.1159/000309793
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   Chan WM, 2007, AM J OPHTHALMOL, V143, P977, DOI 10.1016/j.ajo.2007.02.039
   Chang LK, 2008, ARCH OPHTHALMOL-CHIC, V126, P941, DOI 10.1001/archopht.126.7.941
   CLARKSON JG, 1982, SURV OPHTHALMOL, V26, P235, DOI 10.1016/0039-6257(82)90158-8
   Ferrara N, 2006, RETINA-J RET VIT DIS, V26, P859, DOI 10.1097/01.iae.0000242842.14624.e7
   Fung AE, 2007, AM J OPHTHALMOL, V143, P566, DOI 10.1016/j.ajo.2007.01.028
   Gomi F, 2007, AM J OPHTHALMOL, V143, P507, DOI 10.1016/j.ajo.2006.10.050
   Inoue M, 2010, RETINA-J RET VIT DIS, V30, P733, DOI 10.1097/IAE.0b013e3181c9699c
   Jurklies B, 2006, OPHTHALMIC RES, V38, P209, DOI 10.1159/000093071
   Kaiser PK, 2007, OPHTHALMOLOGY, V114, P1868, DOI 10.1016/j.ophtha.2007.04.030
   Klein R, 2004, AM J OPHTHALMOL, V137, P486, DOI 10.1016/j.ajo.2003.11.069
   KONSTANTINIDIS L, 2010, EUR J OPHTHALMOL
   Konstantinidis L, 2010, ACTA OPHTHALMOL, V88, pe100, DOI 10.1111/j.1755-3768.2009.01754.x
   Lalwani GA, 2009, AM J OPHTHALMOL, V148, P43, DOI 10.1016/j.ajo.2009.01.024
   Menchini U, 2004, RETINA-J RET VIT DIS, V24, P763, DOI 10.1097/00006982-200410000-00013
   Myung JS, 2010, RETINA-J RET VIT DIS, V30, P748, DOI 10.1097/IAE.0b013e3181c596b1
   Neri P, 2009, BRIT J OPHTHALMOL, V93, P155, DOI 10.1136/bjo.2008.145896
   Pece A, 1997, RETINA-J RET VIT DIS, V17, P12
   Regillo CD, 2008, AM J OPHTHALMOL, V145, P239, DOI 10.1016/j.ajo.2007.10.004
   Rinaldi M, 2007, ARCH OPHTHALMOL-CHIC, V125, P1422, DOI 10.1001/archopht.125.10.1422
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Sawa M, 2009, AM J OPHTHALMOL, V148, P584, DOI 10.1016/j.ajo.2009.04.026
   Shyong MP, 2006, EYE, V20, P1420, DOI 10.1038/sj.eye.6702278
   Silva RM, 2008, RETINA-J RET VIT DIS, V28, P1117, DOI 10.1097/IAE.0b013e31817eda41
   Silva RM, 2010, RETINA-J RET VIT DIS, V30, P407, DOI 10.1097/IAE.0b013e3181c9691e
   Wiegand TW, 2009, BRIT J OPHTHALMOL, V93, P47, DOI 10.1136/bjo.2008.143461
   Yannuzzi LA, 1995, THE RETINA ATLAS
NR 34
TC 28
Z9 30
U1 1
U2 8
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 0030-3755
EI 1423-0267
J9 OPHTHALMOLOGICA
JI Ophthalmologica
PY 2011
VL 225
IS 2
BP 81
EP 88
DI 10.1159/000317908
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 666QN
UT WOS:000283132200003
PM 20881442
DA 2022-11-30
ER

PT J
AU Sedeh, FB
   Scott, DAR
   Subhi, Y
   Sorensen, TL
AF Sedeh, Farnam Barati
   Scott, Daniel Andrew Richard
   Subhi, Yousif
   Sorensen, Torben Lykke
TI Prevalence of neovascular age-related macular degeneration and
   geographic atrophy in Denmark
SO DANISH MEDICAL JOURNAL
LA English
DT Article
ID EPIDEMIOLOGY; EYE
AB INTRODUCTION: In Denmark, age-related macular degeneration (AMD) is the most common cause of blindness. To better understand current and future challenges, we estimated and projected the annual number of patients with neovascular AMD and geographic atrophy in Denmark from 2016 to 2060.
   METHODS: Detailed age-and gender-stratified prevalence estimates of neovascular AMD and geographic atrophy in a Scandinavian population were identified and applied to age- and gender-stratified population numbers provided by Statistics Denmark. Prevalence estimates were calculated for each year from 2016 to 2060. Future forecasts were provided by Statistics Denmark and based on calculations by the Danish Institute for Economic Modelling and Forecasting.
   RESULTS: We estimated that there are currently similar to 30,000 patients with neovascular AMD and similar to 21,000 patients with geographic atrophy in Denmark. The majority of these patients are persons aged >= 85 years. For neovascular AMD, the number of patients will grow to similar to 33,000 in 2020, similar to 58,000 in 2040 and similar to 72,000 in 2060. For geographic atrophy, the number of patients will grow to similar to 23,000 in 2020, similar to 41,000 in 2040, and similar to 50,000 in 2060.
   CONCLUSIONS: We expect a steady growth in the prevalence of neovascular AMD and geographic atrophy in Denmark due to an ageing population. These numbers emphasise the importance of disease prevention, careful planning of health service activities and continuing research.
C1 [Sedeh, Farnam Barati; Scott, Daniel Andrew Richard; Subhi, Yousif; Sorensen, Torben Lykke] Zealand Univ Hosp, Dept Ophthalmol, Clin Eye Res Div, Roskilde, Denmark.
   [Sedeh, Farnam Barati; Subhi, Yousif; Sorensen, Torben Lykke] Univ Copenhagen, Fac Hlth & Med Sci, Copenhagen, Denmark.
   [Scott, Daniel Andrew Richard] Univ Otago, Wellington, New Zealand.
C3 University of Copenhagen; University of Otago
RP Subhi, Y (通讯作者)，Zealand Univ Hosp, Dept Ophthalmol, Clin Eye Res Div, Roskilde, Denmark.; Subhi, Y (通讯作者)，Univ Copenhagen, Fac Hlth & Med Sci, Copenhagen, Denmark.
EM ysubhi@gmail.com
RI Subhi, Yousif/ABG-6330-2020; Scott, Daniel/AAM-9983-2021
OI Subhi, Yousif/0000-0001-6620-5365; Scott, Daniel/0000-0002-0954-582X
CR [Anonymous], 2017, POPULATION POPULATIO
   Buch H, 2004, OPHTHALMOLOGY, V111, P53, DOI 10.1016/j.ophtha.2003.05.010
   Chew EY, 2013, JAMA-J AM MED ASSOC, V309, P2005, DOI 10.1001/jama.2013.4997
   Documentation of statistics, 2017, POP PROJ DENM
   Erke MG, 2012, OPHTHALMOLOGY, V119, P1737, DOI 10.1016/j.ophtha.2012.03.016
   Hoeg TB, 2016, OPHTHAL EPIDEMIOL, V23, P53, DOI 10.3109/09286586.2015.1066396
   Jonasson F, 2011, OPHTHALMOLOGY, V118, P825, DOI 10.1016/j.ophtha.2010.08.044
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Lindekleiv H, 2013, ACTA OPHTHALMOL, V91, P307, DOI 10.1111/j.1755-3768.2012.02399.x
   Radet for Anvendelse af Dyr Sygehusmedicin, 2016, BAGGR BEH VAD ALD MA
   Rasul A, 2016, DAN MED J, V63
   Singh A, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-00741-4
   Subhi Yousif, 2016, Dan Med J, V63
   Subhi Y, 2017, J OPHTHALMOL, V2017, DOI 10.1155/2017/7194927
   Subhi Y, 2017, ACTA OPHTHALMOL, V95, P472, DOI 10.1111/aos.13330
   Subhi Y, 2016, AGEING RES REV, V29, P42, DOI 10.1016/j.arr.2016.05.013
   Subhi Yousif, 2015, Ugeskr Laeger, V177, P1624
   Subhi Y, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0091227
   Yaspan BL, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aaf1443
NR 19
TC 20
Z9 20
U1 0
U2 2
PU DANISH MEDICAL ASSOC
PI COPENHAGEN
PA TRONDHJEMSGADE 9, DK-2100 COPENHAGEN, DENMARK
SN 2245-1919
J9 DAN MED J
JI Dan. Med. J.
PD NOV
PY 2017
VL 64
IS 11
AR A5422
PG 4
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA FP0XL
UT WOS:000417331800006
PM 29115208
DA 2022-11-30
ER

PT J
AU Grunin, M
   Shira-Hagbi-Levi
   Rinsky, B
   Smith, Y
   Chowers, I
AF Grunin, Michelle
   Shira-Hagbi-Levi
   Rinsky, Batya
   Smith, Yoav
   Chowers, Itay
TI Transcriptome Analysis on Monocytes from Patients with Neovascular
   Age-Related Macular Degeneration
SO SCIENTIFIC REPORTS
LA English
DT Article
ID BLOOD MONOCYTES; ALTERED EXPRESSION; DENDRITIC CELLS; DEFICIENT MICE;
   PROBE LEVEL; INFLAMMATION; MACROPHAGES; SUBSETS; GENOME; TOOLS
AB Mononuclear phagocytes (MPs), including monocytes/macrophages, play complex roles in age-related macular degeneration (AMD) pathogenesis. We reported altered gene-expression signature in peripheral blood mononuclear cells from AMD patients, and a chemokine receptor signature on AMD monocytes. To obtain comprehensive understanding of MP involvement, particularly in peripheral circulation in AMD, we performed global gene expression analysis in monocytes. We separated monocytes from treatment-naive neovascular AMD (nvAMD) patients (n = 14) and age-matched controls (n = 15), and performed microarray and bioinformatics analysis. Quantitative real-time PCR was performed on other sets of nvAMD (n = 25), atrophic AMD (n = 21), and controls (n = 28) for validation. This validated microarray genes (like TMEM176A/B and FOSB) tested, including differences between nvAMD and atrophic AMD. We identified 2,165 differentially-expressed genes (P < 0.05), including 79 genes with log2 fold change >= 1.5 between nvAMD and controls. Functional annotation using DAVID and TANGO demonstrated immune response alterations in AMD monocytes (FDR-P < 0.05), validated by randomized data comparison (P < 0.0001). GSEA, ISMARA, and MEME analysis found immune enrichment and specific involved microRNAs. Enrichment of differentially-expressed genes in monocytes was found in retina via SAGE data-mining. These genes were enriched in non-classical vs. classical monocyte subsets (P < 0.05). Therefore, global gene expression analysis in AMD monocytes reveals an altered immune-related signature, further implicating systemic MP activation in AMD.
C1 [Grunin, Michelle; Shira-Hagbi-Levi; Rinsky, Batya; Chowers, Itay] Hadassah Hebrew Univ Med Ctr, Dept Ophthalmol, Jerusalem, Israel.
   [Smith, Yoav] Hebrew Univ Jerusalem, Genom Data Anal Unit, Jerusalem, Israel.
C3 Hebrew University of Jerusalem; Hebrew University of Jerusalem
RP Chowers, I (通讯作者)，Hadassah Hebrew Univ Med Ctr, Dept Ophthalmol, Jerusalem, Israel.
EM chowers@hadassah.org.il
RI Grunin, Michelle/O-6044-2019
OI Grunin, Michelle/0000-0002-3155-2858
FU Israeli Ministry of Health [9184]; Israel Science Foundation [1006/13];
   Baroness Ariane de Rothschild scholarship program
FX Michelle Grunin would like to thank Eyal Ben-David for excellent advice
   with regards to R and Dr. Shahar Frankel for statistical help. This work
   was supported by a grant from the Israeli Ministry of Health [grant
   number 9184]; the Israel Science Foundation [grant number 1006/13]; and
   the Baroness Ariane de Rothschild scholarship program.
CR Ambati J, 2003, NAT MED, V9, P1390, DOI 10.1038/nm950
   Ashburner M, 2000, NAT GENET, V25, P25, DOI 10.1038/75556
   Bailey TL, 2009, NUCLEIC ACIDS RES, V37, pW202, DOI 10.1093/nar/gkp335
   Balwierz PJ, 2014, GENOME RES, V24, P869, DOI 10.1101/gr.169508.113
   BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x
   Bryne JC, 2008, NUCLEIC ACIDS RES, V36, pD102, DOI 10.1093/nar/gkm955
   Bustin SA, 2009, CLIN CHEM, V55, P611, DOI 10.1373/clinchem.2008.112797
   Carvalho BS, 2010, BIOINFORMATICS, V26, P2363, DOI 10.1093/bioinformatics/btq431
   Cavigelli M, 1996, EMBO J, V15, P6269, DOI 10.1002/j.1460-2075.1996.tb01017.x
   Chaum E, 2009, J CELL BIOCHEM, V108, P1280, DOI 10.1002/jcb.22358
   Chen EY, 2013, BMC BIOINFORMATICS, V14, DOI 10.1186/1471-2105-14-128
   Condamine T, 2010, J LEUKOCYTE BIOL, V88, P507, DOI 10.1189/jlb.1109738
   Cuajungco MP, 2012, ACTA HISTOCHEM, V114, P705, DOI 10.1016/j.acthis.2011.12.006
   Dennis G, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-9-r60
   Espinosa-Heidmann DG, 2003, INVEST OPHTH VIS SCI, V44, P3586, DOI 10.1167/iovs.03-0038
   Farkas MH, 2013, BMC GENOMICS, V14, DOI 10.1186/1471-2164-14-486
   Francis PJ, 2009, J MED GENET, V46, P300, DOI 10.1136/jmg.2008.062737
   Frankenberger M, 2012, EUR J IMMUNOL, V42, P957, DOI 10.1002/eji.201141907
   Fritsche LG, 2013, NAT GENET, V45, P433, DOI 10.1038/ng.2578
   Gautier L, 2004, BIOINFORMATICS, V20, P307, DOI 10.1093/bioinformatics/btg405
   Geissmann F, 2003, IMMUNITY, V19, P71, DOI 10.1016/S1074-7613(03)00174-2
   Grunin M, 2012, INVEST OPHTH VIS SCI, V53, P5292, DOI 10.1167/iovs.11-9165
   Guymer RH, 2011, INVEST OPHTH VIS SCI, V52, P4639, DOI 10.1167/iovs.10-7120
   Hearps AC, 2012, AGING CELL, V11, P867, DOI 10.1111/j.1474-9726.2012.00851.x
   Hong S, 2011, J LEUKOCYTE BIOL, V90, P643, DOI 10.1189/jlb.0111043
   Huang E, 2014, J IMMUNOL, V193, P13, DOI 10.4049/jimmunol.1303410
   Irizarry RA, 2003, NUCLEIC ACIDS RES, V31, DOI 10.1093/nar/gng015
   Italiani P, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0087680
   Karolchik D, 2004, NUCLEIC ACIDS RES, V32, pD493, DOI 10.1093/nar/gkh103
   Kassoff A, 1999, CONTROL CLIN TRIALS, V20, P573
   Kasukawa T, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023228
   Kent WJ, 2002, GENOME RES, V12, P996, DOI 10.1101/gr.229102
   Kozhevnikova OS, 2013, CELL CYCLE, V12, P1745, DOI 10.4161/cc.24825
   Kozomara A, 2011, NUCLEIC ACIDS RES, V39, pD152, DOI 10.1093/nar/gkq1027
   Kramer M, 2012, CLIN EXP OPHTHALMOL, V40, P617, DOI 10.1111/j.1442-9071.2011.02747.x
   Kyger M, 2013, J NEUROIMMUNOL, V254, P91, DOI 10.1016/j.jneuroim.2012.10.007
   Lederman M, 2010, INVEST OPHTH VIS SCI, V51, P53, DOI 10.1167/iovs.08-3019
   Lein ES, 2007, NATURE, V445, P168, DOI 10.1038/nature05453
   Liberzon A, 2011, BIOINFORMATICS, V27, P1739, DOI 10.1093/bioinformatics/btr260
   Liu YT, 2011, MOL VIS, V17, P885
   Luhmann UFO, 2009, INVEST OPHTH VIS SCI, V50, P5934, DOI 10.1167/iovs.09-3462
   Maeda Y, 2006, BRAIN RES, V1104, P18, DOI 10.1016/j.brainres.2006.05.068
   Melchior B, 2010, ASN NEURO, V2, P157, DOI 10.1042/AN20100010
   Merino A, 2011, J IMMUNOL, V186, P1809, DOI 10.4049/jimmunol.1001866
   Nakamura R, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8847
   Quackenbush J, 2002, NAT GENET, V32, P496, DOI 10.1038/ng1032
   Reese BE, 2011, VISION RES, V51, P613, DOI 10.1016/j.visres.2010.07.010
   Rickman CB, 2006, INVEST OPHTH VIS SCI, V47, P2305, DOI 10.1167/iovs.05-1437
   Riggins GJ, 2001, HUM MOL GENET, V10, P663, DOI 10.1093/hmg/10.7.663
   Rutar M, 2015, J NEUROINFLAMM, V12, DOI 10.1186/s12974-014-0224-1
   Rutella S, 2006, BLOOD, V108, P218, DOI 10.1182/blood-2005-08-3141
   Sanges R, 2007, BIOINFORMATICS, V23, P3406, DOI 10.1093/bioinformatics/btm469
   Seddon JM, 2013, NAT GENET, V45, P1366, DOI 10.1038/ng.2741
   Segovia M, 2014, AM J TRANSPLANT, V14, P1021, DOI 10.1111/ajt.12708
   Seidler S, 2010, BMC IMMUNOL, V11, DOI 10.1186/1471-2172-11-30
   Sene A, 2013, CELL METAB, V17, P549, DOI 10.1016/j.cmet.2013.03.009
   Sennlaub F, 2013, EMBO MOL MED, V5, P1775, DOI 10.1002/emmm.201302692
   Shamir R, 2005, BMC BIOINFORMATICS, V6, DOI 10.1186/1471-2105-6-232
   Shay T, 2013, TRENDS IMMUNOL, V34, P602, DOI 10.1016/j.it.2013.03.004
   Shi J, 2007, CURR BIOINFORM, V2, P133, DOI 10.2174/157489307780618231
   Singh A, 2013, OPHTHALMOLOGY, V120, P1029, DOI 10.1016/j.ophtha.2012.11.002
   Singh A, 2012, AM J OPHTHALMOL, V154, P193, DOI 10.1016/j.ajo.2012.01.036
   Smyth GK, 2005, STAT BIOL HEALTH, P397, DOI 10.1007/0-387-29362-0_23
   Strohacker K, 2012, J BIOSCIENCES, V37, P55, DOI 10.1007/s12038-011-9169-z
   Strunnikova NV, 2010, HUM MOL GENET, V19, P2468, DOI 10.1093/hmg/ddq129
   Syrovets T, 2001, BLOOD, V97, P3941, DOI 10.1182/blood.V97.12.3941
   Thornton MR, 2005, J ANAT, V206, P69, DOI 10.1111/j.0021-8782.2005.00369.x
   Vergoulis T, 2012, NUCLEIC ACIDS RES, V40, pD222, DOI 10.1093/nar/gkr1161
   Wenzel A, 2003, INVEST OPHTH VIS SCI, V44, P2798, DOI 10.1167/iovs.02-1134
   Wilson CL, 2005, BIOINFORMATICS, V21, P3683, DOI 10.1093/bioinformatics/bti605
   Wrigley BJ, 2011, EUR J HEART FAIL, V13, P1161, DOI 10.1093/eurjhf/hfr122
   Ziegler-Heitbrock HWL, 2000, J LEUKOCYTE BIOL, V67, P603, DOI 10.1002/jlb.67.5.603
   Ziegler-Heitbrock L, 2007, J LEUKOCYTE BIOL, V81, P584, DOI 10.1189/jlb.0806510
   Ziegler-Heitbrock L, 2014, CELL IMMUNOL, V289, P135, DOI 10.1016/j.cellimm.2014.03.019
   Zuccolo J, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009369
NR 75
TC 24
Z9 24
U1 1
U2 7
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2045-2322
J9 SCI REP-UK
JI Sci Rep
PD JUL 4
PY 2016
VL 6
AR 29046
DI 10.1038/srep29046
PG 13
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA DQ2DN
UT WOS:000379011800001
PM 27374485
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Ardeljan, D
   Chan, CC
AF Ardeljan, Daniel
   Chan, Chi-Chao
TI Aging is not a disease: Distinguishing age-related macular degeneration
   from aging
SO PROGRESS IN RETINAL AND EYE RESEARCH
LA English
DT Article
DE Age-related macular degeneration; Aging; Homeostasis; Para-inflammation;
   Oxidative stress; Retina
ID RETINAL-PIGMENT EPITHELIUM; GLYCATION END-PRODUCTS; COMPLEMENT FACTOR-H;
   HUMAN BRUCHS MEMBRANE; ENDOPLASMIC-RETICULUM STRESS; MITOCHONDRIAL-DNA
   DAMAGE; KAPPA-B ACTIVATION; C-REACTIVE PROTEIN; OXIDATIVE STRESS;
   GENE-EXPRESSION
AB Age-related macular degeneration (AMD) is a disease of the outer retina, characterized most significantly by atrophy of photoreceptors and retinal pigment epithelium accompanied with or without choroidal neovascularization. Development of AMD has been recognized as contingent on environmental and genetic risk factors, the strongest being advanced age. In this review, we highlight pathogenic changes that destabilize ocular homeostasis and promote AMD development. With normal aging, photoreceptors are steadily lost, Bruch's membrane thickens, the choroid thins, and hard drusen may form in the periphery. In AMD, many of these changes are exacerbated in addition to the development of disease-specific factors such as soft macular drusen. Para-inflammation, which can be thought of as an intermediate between basal and robust levels of inflammation, develops within the retina in an attempt to maintain ocular homeostasis, reflected by increased expression of the anti-inflammatory cytokine IL-10 coupled with shifts in macrophage plasticity from the pro-inflammatory M1 to the anti-inflammatory M2 polarization. In AMD, imbalances in the M1 and M2 populations together with activation of retinal microglia are observed and potentially contribute to tissue degeneration. Nonetheless, the retina persists in a state of chronic inflammation and increased expression of certain cytokines and inflammasomes is observed. Since not everyone develops AMD, the vital question to ask is how the body establishes a balance between normal age-related changes and the pathological phenotypes in AMD. Published by Elsevier Ltd.
C1 [Ardeljan, Daniel; Chan, Chi-Chao] NEI, Immunopathol Sect, Immunol Lab, NIH, Bethesda, MD 20892 USA.
   [Ardeljan, Daniel] Johns Hopkins Univ, Sch Med, Baltimore, MD 21205 USA.
C3 National Institutes of Health (NIH) - USA; NIH National Eye Institute
   (NEI); Johns Hopkins University
RP Chan, CC (通讯作者)，NEI, NIH, 10 Ctr Dr,10-10N103, Bethesda, MD 20892 USA.
EM dardelj1@jhu.edu; chanc@nei.nih.gov
OI Ardeljan, Daniel/0000-0002-5593-421X; Chan, Chi-Chao/0000-0001-9460-8049
FU NEI; NATIONAL EYE INSTITUTE [ZIAEY000418, ZICEY000461, ZIAEY000222]
   Funding Source: NIH RePORTER
FX The authors state no conflicts of interest. We appreciate Dr. Janet
   Sparrow's critical review of the manuscript. This work was supported by
   the NEI Intramural Fund.
CR Ablonczy Z, 2011, INVEST OPHTH VIS SCI, V52, P8614, DOI 10.1167/iovs.11-8021
   Ahonen M, 2003, ONCOGENE, V22, P2121, DOI 10.1038/sj.onc.1206292
   ALSENZ J, 1985, BIOCHEM J, V232, P841, DOI 10.1042/bj2320841
   Ambati J, 2003, NAT MED, V9, P1390, DOI 10.1038/nm950
   Anand R, 2000, OPHTHALMOLOGY, V107, P2224
   Anderson DH, 2010, PROG RETIN EYE RES, V29, P95, DOI 10.1016/j.preteyeres.2009.11.003
   Apte RS, 2006, PLOS MED, V3, P1371, DOI 10.1371/journal.pmed.0030310
   Ardeljan D, 2011, DRUG FUTURE, V36, P713, DOI 10.1358/dof.2011.36.9.1678338
   Ardeljan D., 2013, INTERLEUKIN 17 NEUTR
   Ardeljan D., 2013, EUR J HUM GENET
   Baas DC, 2010, OPHTHALMOLOGY, V117, P500, DOI 10.1016/j.ophtha.2009.08.032
   Ballinger SW, 1999, EXP EYE RES, V68, P765, DOI 10.1006/exer.1998.0661
   Barker FM, 2011, INVEST OPHTH VIS SCI, V52, P3934, DOI 10.1167/iovs.10-5898
   Barron MJ, 2001, INVEST OPHTH VIS SCI, V42, P3016
   Baynes JW, 2001, EXP GERONTOL, V36, P1527, DOI 10.1016/S0531-5565(01)00138-3
   Bazan NG, 2005, BRAIN PATHOL, V15, P159
   Bazan NG, 2009, J LIPID RES, V50, pS400, DOI 10.1194/jlr.R800068-JLR200
   Belayev L, 2009, STROKE, V40, P3121, DOI 10.1161/STROKEAHA.109.555979
   Berman DR, 2009, AM J OBSTET GYNECOL, V200, DOI 10.1016/j.ajog.2009.01.020
   Berra A, 2002, ARCH GERONTOL GERIAT, V34, P371, DOI 10.1016/S0167-4943(02)00013-4
   Bhutto I, 2012, MOL ASPECTS MED, V33, P295, DOI 10.1016/j.mam.2012.04.005
   Bhutto IA, 2011, BRIT J OPHTHALMOL, V95, P1323, DOI 10.1136/bjo.2010.199216
   Bhutto IA, 2010, EXP EYE RES, V90, P155, DOI 10.1016/j.exer.2009.10.004
   Blasiak J, 2012, INT J MOL SCI, V13, P13378, DOI 10.3390/ijms131013378
   Blasiak J, 2011, FRONT BIOSCI-LANDMRK, V16, P1291, DOI 10.2741/3789
   Boltz A, 2010, INVEST OPHTH VIS SCI, V51, P4220, DOI 10.1167/iovs.09-4968
   Brew K, 2010, BBA-MOL CELL RES, V1803, P55, DOI 10.1016/j.bbamcr.2010.01.003
   Bringmann A, 2003, CAN J OPHTHALMOL, V38, P464, DOI 10.1016/S0008-4182(03)80024-8
   Bringmann A, 2006, PROG RETIN EYE RES, V25, P397, DOI 10.1016/j.preteyeres.2006.05.003
   Bringmann A, 2012, OPHTHALMOLOGICA, V227, P1, DOI 10.1159/000328979
   Buch H, 2005, OPHTHALMOLOGY, V112, P787, DOI 10.1016/j.ophtha.2004.11.040
   Butcher MJ, 2012, FRONT PHYSIOL, V3, DOI 10.3389/fphys.2012.00044
   Cackett P, 2011, OPHTHALMOLOGY, V118, P846, DOI 10.1016/j.ophtha.2010.09.026
   Cai H, 2006, CURR EYE RES, V31, P181, DOI 10.1080/02713680500514628
   Cankova Z, 2011, EXP EYE RES, V93, P947, DOI 10.1016/j.exer.2011.10.016
   Cao XG, 2011, PATHOL INT, V61, P528, DOI 10.1111/j.1440-1827.2011.02695.x
   Cao XG, 2010, EXP EYE RES, V91, P15, DOI 10.1016/j.exer.2010.03.016
   Chan-Ling T, 2007, MICROCIRCULATION, V14, P63, DOI 10.1080/10739680601073451
   Chang LF, 2001, NATURE, V410, P37, DOI 10.1038/35065000
   Chen HY, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002339
   Chen M, 2007, EXP EYE RES, V84, P635, DOI 10.1016/j.exer.2006.11.015
   Chen M, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022818
   Chen M, 2010, INVEST OPHTH VIS SCI, V51, P5888, DOI 10.1167/iovs.09-5103
   Chen M, 2008, EXP EYE RES, V87, P543, DOI 10.1016/j.exer.2008.09.005
   Chen PM, 2011, CELL BIOSCI, V1, DOI 10.1186/2045-3701-1-10
   Chen W, 2010, P NATL ACAD SCI USA, V107, P7401, DOI 10.1073/pnas.0912702107
   Chen YH, 2010, MOL INTERV, V10, P271, DOI 10.1124/mi.10.5.4
   Cherepanoff S, 2010, BRIT J OPHTHALMOL, V94, P918, DOI 10.1136/bjo.2009.165563
   Chew EY, 2013, JAMA-J AM MED ASSOC, V309, P2005, DOI 10.1001/jama.2013.4997
   Chi ZL, 2010, ADV EXP MED BIOL, V703, P127, DOI 10.1007/978-1-4419-5635-4_9
   Chung HY, 2001, ANN NY ACAD SCI, V928, P327
   Coleman HR, 2008, LANCET, V372, P1835, DOI 10.1016/S0140-6736(08)61759-6
   Combadiere C, 2007, J CLIN INVEST, V117, P2920, DOI 10.1172/JCI31692
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   Coscas G, 2013, OPHTHALMOLOGICA, V229, P32, DOI 10.1159/000342159
   Crabb JW, 2002, P NATL ACAD SCI USA, V99, P14682, DOI 10.1073/pnas.222551899
   Curcio CA, 2005, EXP EYE RES, V81, P731, DOI 10.1016/j.exer.2005.04.012
   CURCIO CA, 1993, INVEST OPHTH VIS SCI, V34, P3278
   Curcio CA, 1996, INVEST OPHTH VIS SCI, V37, P1236
   Curcio CA, 2001, INVEST OPHTH VIS SCI, V42, P265
   Curcio CA, 2011, BRIT J OPHTHALMOL, V95, P1638, DOI 10.1136/bjophthalmol-2011-300344
   Curcio CA, 2010, J LIPID RES, V51, P451, DOI 10.1194/jlr.R002238
   Curcio CA, 2009, PROG RETIN EYE RES, V28, P393, DOI 10.1016/j.preteyeres.2009.08.001
   Damani MR, 2011, AGING CELL, V10, P263, DOI 10.1111/j.1474-9726.2010.00660.x
   DASTGHEIB K, 1994, ARCH OPHTHALMOL-CHIC, V112, P813, DOI 10.1001/archopht.1994.01090180111045
   DeGroot J, 2001, ARTHRITIS RHEUM, V44, P2562, DOI 10.1002/1529-0131(200111)44:11<2562::AID-ART437>3.0.CO;2-1
   Delori FC, 2001, INVEST OPHTH VIS SCI, V42, P1855
   Doyle SL, 2012, NAT MED, V18, P791, DOI 10.1038/nm.2717
   Dridi S, 2012, P NATL ACAD SCI USA, V109, P13781, DOI 10.1073/pnas.1206494109
   Ebihara N, 2007, OPHTHAL RES, V39, P155, DOI 10.1159/000103235
   Ebrahem Q, 2006, P NATL ACAD SCI USA, V103, P13480, DOI 10.1073/pnas.0601552103
   Ebrahimi KB, 2011, J LIPIDS, V2011, DOI 10.1155/2011/802059
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Eliasieh K, 2007, INVEST OPHTH VIS SCI, V48, P2824, DOI 10.1167/iovs.06-1228
   Ennis S, 2008, LANCET, V372, P1828, DOI 10.1016/S0140-6736(08)61348-3
   Espinosa-Heidmann DG, 2003, INVEST OPHTH VIS SCI, V44, P3586, DOI 10.1167/iovs.03-0038
   Eyerich S, 2010, TRENDS IMMUNOL, V31, P354, DOI 10.1016/j.it.2010.06.004
   Farboud B, 1999, MOL VIS, V5, pU1
   Fariss RN, 1997, AM J PATHOL, V150, P323
   FEENEY L, 1978, INVEST OPHTH VIS SCI, V17, P583
   FEENEYBURNS L, 1980, AM J OPHTHALMOL, V90, P783, DOI 10.1016/S0002-9394(14)75193-1
   Feher J, 2006, NEUROBIOL AGING, V27, P983, DOI 10.1016/j.neurobiolaging.2005.05.012
   Ferguson TA, 2008, SEMIN IMMUNOPATHOL, V30, P111, DOI 10.1007/s00281-008-0113-8
   Ferreira VP, 2010, MOL IMMUNOL, V47, P2187, DOI 10.1016/j.molimm.2010.05.007
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Fritsche LG, 2008, NAT GENET, V40, P892, DOI 10.1038/ng.170
   Fritsche LG, 2010, HUM MOL GENET, V19, P4694, DOI 10.1093/hmg/ddq399
   Fujihara M, 2009, EXP EYE RES, V88, P1115, DOI 10.1016/j.exer.2009.01.017
   Galehdar Z, 2010, J NEUROSCI, V30, P16938, DOI 10.1523/JNEUROSCI.1598-10.2010
   GAO H, 1992, INVEST OPHTH VIS SCI, V33, P1
   GEHRMANN J, 1995, BRAIN RES REV, V20, P269, DOI 10.1016/0165-0173(94)00015-H
   Gensler G, 2002, J NUTR, V132, P697
   Gibson J, 2012, IMMUNOBIOLOGY, V217, P251, DOI 10.1016/j.imbio.2011.07.015
   Glenn JV, 2012, GRAEF ARCH CLIN EXP, V250, P349, DOI 10.1007/s00417-011-1856-9
   Glenn JV, 2007, FASEB J, V21, P3542, DOI 10.1096/fj.06-7896com
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   Gorgani NN, 2008, J IMMUNOL, V181, P7902, DOI 10.4049/jimmunol.181.11.7902
   Goronzy JJ, 2012, CELL MOL LIFE SCI, V69, P1615, DOI 10.1007/s00018-012-0970-0
   Green W R, 1999, Mol Vis, V5, P27
   Grossniklaus HE, 2002, MOL VIS, V8, P119
   Gu JY, 2009, MOL CELL PROTEOMICS, V8, P1338, DOI 10.1074/mcp.M800453-MCP200
   Gu XR, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0038673
   Gu XR, 2003, J BIOL CHEM, V278, P42027, DOI 10.1074/jbc.M305460200
   Guidry C, 2002, INVEST OPHTH VIS SCI, V43, P267
   GULCAN HG, 1993, INVEST OPHTH VIS SCI, V34, P3187
   Guo L, 1999, INVEST OPHTH VIS SCI, V40, P2676
   Guven M, 2011, OPHTHALMIC RES, V46, P31, DOI 10.1159/000321940
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Hammes HP, 1999, INVEST OPHTH VIS SCI, V40, P1855
   Han YJ, 2001, NITRIC OXIDE-BIOL CH, V5, P504, DOI 10.1006/niox.2001.0367
   Handa JT, 1999, INVEST OPHTH VIS SCI, V40, P775
   Hein G, 2003, RHEUMATOLOGY, V42, P1242, DOI 10.1093/rheumatology/keg324
   Helmy KY, 2006, CELL, V124, P915, DOI 10.1016/j.cell.2005.12.039
   Herrero C, 2002, EXP GERONTOL, V37, P389, DOI 10.1016/S0531-5565(01)00205-4
   HOBBS MV, 1993, J IMMUNOL, V150, P3602
   Hodge WG, 2007, RETINA-J RET VIT DIS, V27, P216, DOI 10.1097/01.iae.0000233322.83713.2d
   Hodge WG, 2006, OPHTHALMOLOGY, V113, P1165, DOI 10.1016/j.ophtha.2006.02.043
   Hollyfield JG, 2008, NAT MED, V14, P194, DOI 10.1038/nm1709
   Hollyfield JG, 2010, MOL NEUROBIOL, V41, P290, DOI 10.1007/s12035-010-8110-z
   Horie K, 1997, BIOCHEM BIOPH RES CO, V236, P327, DOI 10.1006/bbrc.1997.6944
   Howes KA, 2004, INVEST OPHTH VIS SCI, V45, P3713, DOI 10.1167/iovs.04-0404
   Hu MJ, 2011, BRIT J OPHTHALMOL, V95, P1738, DOI 10.1136/bjophthalmol-2011-300235
   Huang JD, 2012, BBA-MOL CELL BIOL L, V1821, P637, DOI 10.1016/j.bbalip.2012.01.013
   Hughes AE, 2006, NAT GENET, V38, P1173, DOI 10.1038/ng1890
   Hunter A, 2012, INVEST OPHTH VIS SCI, V53, P2089, DOI 10.1167/iovs.11-8449
   Hussain AA, 2010, EXP EYE RES, V90, P703, DOI 10.1016/j.exer.2010.02.013
   Hussain AA, 2002, J OPT SOC AM A, V19, P166, DOI 10.1364/JOSAA.19.000166
   Hussain AA, 2011, INVEST OPHTH VIS SCI, V52, P4459, DOI 10.1167/iovs.10-6678
   Hussain AA, 2010, INVEST OPHTH VIS SCI, V51, P2363, DOI 10.1167/iovs.09-4259
   Isas JM, 2010, INVEST OPHTH VIS SCI, V51, P1304, DOI 10.1167/iovs.09-4207
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   JIANG B, 1994, J CELL SCI, V107, P2499
   JIANG B, 1995, GLIA, V15, P1, DOI 10.1002/glia.440150102
   Jing GJ, 2012, EXP DIABETES RES, DOI 10.1155/2012/589589
   Johnson LV, 2011, P NATL ACAD SCI USA, V108, P18277, DOI 10.1073/pnas.1109703108
   Jones M, 2004, AM J OPHTHALMOL, V138, P1051, DOI 10.1016/j.ajo.2004.06.026
   Jono T, 2002, PATHOL INT, V52, P563, DOI 10.1046/j.1320-5463.2002.01390.x
   Julien S, 2012, NEUROBIOL AGING, V33, P2390, DOI 10.1016/j.neurobiolaging.2011.12.009
   Kaarniranta Kai, 2010, Front Biosci (Elite Ed), V2, P1374
   Kaarniranta K, 2009, EXP GERONTOL, V44, P685, DOI 10.1016/j.exger.2009.09.002
   Kabasawa S, 2011, OPHTHALMOLOGY, V118, P1082, DOI 10.1016/j.ophtha.2010.10.012
   Kamei M, 1999, INVEST OPHTH VIS SCI, V40, P2367
   Kaneko H, 2011, NATURE, V471, P325, DOI 10.1038/nature09830
   Kannan R, 2011, INVEST OPHTH VIS SCI, V52, P9047, DOI 10.1167/iovs.11-8737
   Karlstetter M, 2010, IMMUNOBIOLOGY, V215, P685, DOI 10.1016/j.imbio.2010.05.010
   Karunadharma PP, 2010, INVEST OPHTH VIS SCI, V51, P5470, DOI 10.1167/iovs.10-5429
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Kawazoe Y, 2012, EXP EYE RES, V94, P32, DOI 10.1016/j.exer.2011.11.002
   Kelly J, 2007, J CLIN INVEST, V117, P3421, DOI 10.1172/JCI32430
   Kenney MC, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0054339
   Kenney MC, 2013, BMC MED GENET, V14, DOI 10.1186/1471-2350-14-4
   Kenney MC, 2010, INVEST OPHTH VIS SCI, V51, P4289, DOI 10.1167/iovs.09-4778
   Kim YH, 2009, GRAEF ARCH CLIN EXP, V247, P651, DOI 10.1007/s00417-009-1049-y
   Kimura T, 1998, PATHOL INT, V48, P575, DOI 10.1111/j.1440-1827.1998.tb03953.x
   Kindt T.J., 2007, KUBY IMMUNOLOGY
   Kinnunen K, 2012, ACTA OPHTHALMOL, V90, P299, DOI 10.1111/j.1755-3768.2011.02179.x
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Klein R, 2008, AM J OPHTHALMOL, V145, P317, DOI 10.1016/j.ajo.2007.09.008
   Knudtson MD, 2004, INVEST OPHTH VIS SCI, V45, P2135, DOI 10.1167/iovs.03-1085
   KORTE GE, 1984, INVEST OPHTH VIS SCI, V25, P1135
   Krohne TU, 2010, EXP EYE RES, V90, P465, DOI 10.1016/j.exer.2009.12.011
   KUBO M, 1990, EUR J IMMUNOL, V20, P1289, DOI 10.1002/eji.1830200614
   Kumar MV, 2004, J NEUROIMMUNOL, V153, P7, DOI 10.1016/j.jneuroim.2004.04.018
   Lewis GP, 1998, INVEST OPHTH VIS SCI, V39, P424
   Li CM, 2005, INVEST OPHTH VIS SCI, V46, P2576, DOI 10.1167/iovs.05-0034
   Li DY, 2012, CELL PHYSIOL BIOCHEM, V29, P9, DOI 10.1159/000337581
   Libby RT, 2010, ADV EXP MED BIOL, V664, P403, DOI 10.1007/978-1-4419-1399-9_46
   Lin HJ, 2011, INVEST OPHTH VIS SCI, V52, P3521, DOI 10.1167/iovs.10-6163
   Liu BY, 2011, J TRANSL MED, V9, DOI 10.1186/1479-5876-9-111
   Liu LX, 2012, J THORAC ONCOL, V7, P1091, DOI 10.1097/JTO.0b013e3182542752
   Lopes KO, 2008, GLIA, V56, P1048, DOI 10.1002/glia.20678
   Luibl V, 2006, J CLIN INVEST, V116, P378, DOI 10.1172/JCI25843
   Lutty G, 1999, MOL VIS, V5
   Ma WC, 2007, INVEST OPHTH VIS SCI, V48, P1355, DOI 10.1167/iovs.06-0738
   Ma WX, 2013, NEUROBIOL AGING, V34, P943, DOI 10.1016/j.neurobiolaging.2012.06.010
   Ma WX, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007945
   Macgregor AM, 2009, J HISTOCHEM CYTOCHEM, V57, P207, DOI 10.1369/jhc.2008.952531
   MADIGAN MC, 1994, RETINA-J RET VIT DIS, V14, P65, DOI 10.1097/00006982-199401000-00014
   Maeda A, 2005, BIOCHEMISTRY-US, V44, P480, DOI 10.1021/bi048016f
   Mandal MNA, 2006, INVEST OPHTH VIS SCI, V47, P5505, DOI 10.1167/iovs.06-0312
   Manning BD, 2007, CELL, V129, P1261, DOI 10.1016/j.cell.2007.06.009
   Mantovani A, 2005, IMMUNITY, V23, P344, DOI 10.1016/j.immuni.2005.10.001
   Mantovani A, 2004, TRENDS IMMUNOL, V25, P677, DOI 10.1016/j.it.2004.09.015
   Mantovani A, 2009, ARTERIOSCL THROM VAS, V29, P1419, DOI 10.1161/ATVBAHA.108.180497
   Margolis R, 2009, AM J OPHTHALMOL, V147, P811, DOI 10.1016/j.ajo.2008.12.008
   Mayurasakorn K, 2011, CURR OPIN CLIN NUTR, V14, P158, DOI 10.1097/MCO.0b013e328342cba5
   McCullough KD, 2001, MOL CELL BIOL, V21, P1249, DOI 10.1128/MCB.21.4.1249-1259.2001
   McLeod DS, 2009, INVEST OPHTH VIS SCI, V50, P4982, DOI 10.1167/iovs.09-3639
   McLeod DS, 2002, INVEST OPHTH VIS SCI, V43, P1986
   Medzhitov R, 2008, NATURE, V454, P428, DOI 10.1038/nature07201
   MILLER RA, 1991, INT REV CYTOL, V124, P187
   Miyata T, 1996, J CLIN INVEST, V98, P1088, DOI 10.1172/JCI118889
   Miyazaki M, 2011, HUM GENE THER, V22, P559, DOI 10.1089/hum.2010.132
   MOORE DJ, 1995, INVEST OPHTH VIS SCI, V36, P1290
   Moreira EF, 2009, INVEST OPHTH VIS SCI, V50, P523, DOI 10.1167/iovs.08-2373
   Mosser DM, 2008, NAT REV IMMUNOL, V8, P958, DOI 10.1038/nri2448
   Mrak RE, 2005, NEUROBIOL AGING, V26, P349, DOI 10.1016/j.neurobiolaging.2004.05.010
   Mueller EE, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030874
   Mukherjee PK, 2007, P NATL ACAD SCI USA, V104, P13158, DOI 10.1073/pnas.0705963104
   Mullins RF, 2000, FASEB J, V14, P835, DOI 10.1096/fasebj.14.7.835
   Mullins RE, 2011, INVEST OPHTH VIS SCI, V52, P1606, DOI 10.1167/iovs.10-6476
   Mullins RF, 2009, EXP EYE RES, V89, P767, DOI 10.1016/j.exer.2009.07.001
   Murakami Y, 2008, AM J PATHOL, V173, P1326, DOI 10.2353/ajpath.2008.080466
   Nag TC, 2011, ANN ANAT, V193, P205, DOI 10.1016/j.aanat.2011.02.004
   Ni JQ, 2009, MOL CELL PROTEOMICS, V8, P1921, DOI 10.1074/mcp.M900127-MCP200
   Njemini R, 2007, MECH AGEING DEV, V128, P450, DOI 10.1016/j.mad.2007.06.003
   Odetti P, 2005, ANN NY ACAD SCI, V1043, P710, DOI 10.1196/annals.1333.082
   Parapuram SK, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013885
   Park K, 2011, AM J PATHOL, V178, P688, DOI 10.1016/j.ajpath.2010.10.014
   Park KH, 2009, MOL VIS, V15, P200
   Park S., 2012, 1667 ARVO
   Pascolini D, 2004, OPHTHAL EPIDEMIOL, V11, P67, DOI 10.1076/opep.11.2.67.28158
   Pascolini D, 2012, BRIT J OPHTHALMOL, V96, P614, DOI 10.1136/bjophthalmol-2011-300539
   Patel M, 2008, SEMIN IMMUNOPATHOL, V30, P97, DOI 10.1007/s00281-008-0112-9
   PAULEIKHOFF D, 1990, OPHTHALMOLOGY, V97, P171
   PENFOLD PL, 1985, GRAEF ARCH CLIN EXP, V223, P69, DOI 10.1007/BF02150948
   Petrovski G, 2011, ACTA OPHTHALMOL, V89, pE30, DOI 10.1111/j.1755-3768.2010.02047.x
   Pillin A, 2007, Soud Lek, V52, P60
   Plackett TP, 2003, FASEB J, V17, P688, DOI 10.1096/fj.02-0452fje
   Prasad AS, 2009, CURR OPIN CLIN NUTR, V12, P646, DOI 10.1097/MCO.0b013e3283312956
   Prelog M, 2006, AUTOIMMUN REV, V5, P136, DOI 10.1016/j.autrev.2005.09.008
   Prosser BE, 2007, J EXP MED, V204, P2277, DOI 10.1084/jem.20071069
   Qi JH, 2003, NAT MED, V9, P407, DOI 10.1038/nm846
   Querques G, 2011, RETINA-J RET VIT DIS, V31, P518, DOI 10.1097/IAE.0b013e3181f04974
   Ramirez JM, 2001, EXP EYE RES, V73, P601, DOI 10.1006/exer.2001.1061
   RAMRATTAN RS, 1994, INVEST OPHTH VIS SCI, V35, P2857
   Reinoso MA, 2008, OCHSNER J, V8, P39
   RIANCHO JA, 1994, GERONTOLOGY, V40, P8
   Rodriguez IR, 2010, J LIPID RES, V51, P2847, DOI 10.1194/jlr.R004820
   Rogue RS, 1999, BRAIN RES, V836, P110, DOI 10.1016/S0006-8993(99)01625-X
   Rohrer B, 2012, J OCUL PHARMACOL TH, V28, P402, DOI 10.1089/jop.2011.0212
   Rohrer B, 2010, ADV EXP MED BIOL, V703, P137, DOI 10.1007/978-1-4419-5635-4_10
   Rosenbaum JT, 2012, NEW ENGL J MED, V367, P768, DOI 10.1056/NEJMcibr1204973
   Rudolf M, 2005, BRIT J OPHTHALMOL, V89, P1627, DOI 10.1136/bjo.2005.071183
   Rudolf M, 2008, INVEST OPHTH VIS SCI, V49, P1200, DOI 10.1167/iovs.07-1466
   Rudolf M, 2013, OPHTHALMOLOGY, V120, P821, DOI 10.1016/j.ophtha.2012.10.007
   Rutar M, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-221
   Salminen A, 2010, MOL MED, V16, P535, DOI 10.2119/molmed.2010.00070
   Sanchez A, 2012, NEUROSCI RES, V72, P1, DOI 10.1016/j.neures.2011.09.003
   SARKS SH, 1976, BRIT J OPHTHALMOL, V60, P324, DOI 10.1136/bjo.60.5.324
   Sauer T, 2008, EXPERT REV OPHTHALMO, V3, P29, DOI 10.1586/17469899.3.1.29
   SCHMIDT AM, 1994, P NATL ACAD SCI USA, V91, P8807, DOI 10.1073/pnas.91.19.8807
   SCHMIDT AM, 1995, J CLIN INVEST, V96, P1395, DOI 10.1172/JCI118175
   Schmitz-Valckenberg S, 2010, OPHTHALMOLOGY, V117, P1169, DOI 10.1016/j.ophtha.2009.10.044
   Scholl HPN, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002593
   Schutt F, 2012, INVEST OPHTH VIS SCI, V53, P5354, DOI 10.1167/iovs.12-9845
   Seddon JM, 2003, ARCH OPHTHALMOL-CHIC, V121, P1728, DOI 10.1001/archopht.121.12.1728
   Seddon JM, 2003, ARCH OPHTHALMOL-CHIC, V121, P785, DOI 10.1001/archopht.121.6.785
   Seddon JM, 1996, JAMA-J AM MED ASSOC, V276, P1141, DOI 10.1001/jama.276.14.1141
   Seddon JM, 2006, ARCH OPHTHALMOL-CHIC, V124, P995, DOI 10.1001/archopht.124.7.995
   Seddon JM, 2011, OPHTHALMOLOGY, V118, P1386, DOI 10.1016/j.ophtha.2010.12.020
   Sheikpranbabu S, 2011, DIABETES METAB, V37, P505, DOI 10.1016/j.diabet.2011.03.006
   Shelley EJ, 2009, ARCH OPHTHALMOL-CHIC, V127, P483, DOI 10.1001/archophthalmol.2008.622
   Shen DF, 2011, INVEST OPHTH VIS SCI, V52, P2897, DOI 10.1167/iovs.10-6114
   Sheng JG, 1998, ACTA NEUROPATHOL, V95, P229, DOI 10.1007/s004010050792
   Sieving PA, 2006, P NATL ACAD SCI USA, V103, P3896, DOI 10.1073/pnas.0600236103
   Skeie JM, 2009, EYE, V23, P747, DOI 10.1038/eye.2008.206
   Spaide RF, 1999, RETINA-J RET VIT DIS, V19, P141, DOI 10.1097/00006982-199902000-00010
   Spaide RF, 2010, RETINA-J RET VIT DIS, V30, P1441, DOI 10.1097/IAE.0b013e3181ee5ce8
   Sparrow JR, 2012, PROG RETIN EYE RES, V31, P121, DOI 10.1016/j.preteyeres.2011.12.001
   Sparrow JR, 2010, ADV EXP MED BIOL, V703, P63, DOI 10.1007/978-1-4419-5635-4_5
   Sparrow JR, 2000, INVEST OPHTH VIS SCI, V41, P1981
   Spencer KL, 2007, HUM MOL GENET, V16, P1986, DOI 10.1093/hmg/ddm146
   Spraul CW, 1999, SURV OPHTHALMOL, V44, pS10, DOI 10.1016/S0039-6257(99)00086-7
   Spraul CW, 1996, INVEST OPHTH VIS SCI, V37, P2724
   Starita C, 1997, INVEST OPHTH VIS SCI, V38, P762
   Starita C, 1996, EXP EYE RES, V62, P565, DOI 10.1006/exer.1996.0066
   STARITA C, 1995, AM J MED GENET, V57, P235, DOI 10.1002/ajmg.1320570224
   Streit WJ, 2004, GLIA, V45, P208, DOI 10.1002/glia.10319
   Sue CM, 1997, NEUROLOGY, V49, P1013, DOI 10.1212/WNL.49.4.1013
   Sugita S, 2010, INVEST OPHTH VIS SCI, V51, P5783, DOI 10.1167/iovs.09-5098
   Sullivan R, 2003, INVEST OPHTH VIS SCI, V44, P856, DOI 10.1167/iovs.02-0416
   Sullivan RKP, 2007, INVEST OPHTH VIS SCI, V48, P2782, DOI 10.1167/iovs.06-1283
   Tabas I, 2010, NAT REV IMMUNOL, V10, P36, DOI 10.1038/nri2675
   Tarallo V, 2012, CELL, V149, P847, DOI 10.1016/j.cell.2012.03.036
   Terzibasi E, 2009, NEUROBIOL AGING, V30, P819, DOI 10.1016/j.neurobiolaging.2007.08.017
   Thampi P, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034468
   Totan Y, 2009, CURR EYE RES, V34, P1089, DOI 10.3109/02713680903353772
   Tuo J., 2012, INFLUENCE TIMP3 SYN1
   Tuo JS, 2009, AM J PATHOL, V175, P799, DOI 10.2353/ajpath.2009.090089
   Ugarte M, 2006, BRIT J OPHTHALMOL, V90, P621, DOI 10.1136/bjo.2005.086579
   Unterlauft JD, 2012, NEUROCHEM RES, V37, P1524, DOI 10.1007/s11064-012-0747-8
   van Deemter M, 2009, EXP EYE RES, V88, P1043, DOI 10.1016/j.exer.2009.01.004
   Venza I, 2012, AGING CLIN EXP RES, V24, P21, DOI 10.3275/7659
   Wang AL, 2008, MOL VIS, V14, P644
   Wang AL, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004160
   Wang GF, 2009, INVEST OPHTH VIS SCI, V50, P3084, DOI 10.1167/iovs.08-3240
   Wang JJ, 2003, ARCH OPHTHALMOL-CHIC, V121, P658, DOI 10.1001/archopht.121.5.658
   Wang L, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010329
   Wang XF, 2004, EXP EYE RES, V79, P209, DOI 10.1016/j.exer.2004.03.013
   Wang Y, 2010, EXP EYE RES, V91, P135, DOI 10.1016/j.exer.2010.02.008
   Wang YJ, 2012, APOPTOSIS, V17, P1144, DOI 10.1007/s10495-012-0750-1
   Ward RE, 2010, J NEUROTRAUM, V27, P1769, DOI 10.1089/neu.2010.1348
   Wasmuth S, 2009, INVEST OPHTH VIS SCI, V50, P5304, DOI 10.1167/iovs.08-3326
   Wei L, 2012, CELL REP, V2, P1151, DOI 10.1016/j.celrep.2012.10.013
   West XZ, 2010, NATURE, V467, P972, DOI 10.1038/nature09421
   Wood A, 2011, AM J OPHTHALMOL, V152, P1030, DOI 10.1016/j.ajo.2011.05.021
   Wu KHC, 2003, BRIT J OPHTHALMOL, V87, P1159, DOI 10.1136/bjo.87.9.1159
   Wu WK, 2010, IMMUNOBIOLOGY, V215, P796, DOI 10.1016/j.imbio.2010.05.025
   Wu YL, 2011, J AM CHEM SOC, V133, P849, DOI 10.1021/ja107195u
   Xu HP, 2008, AGING CELL, V7, P58, DOI 10.1111/j.1474-9726.2007.00351.x
   Xu HP, 2007, GLIA, V55, P1189, DOI 10.1002/glia.20535
   Xu HP, 2009, PROG RETIN EYE RES, V28, P348, DOI 10.1016/j.preteyeres.2009.06.001
   Xu W, 2010, AM J OPHTHALMOL, V150, P40, DOI 10.1016/j.ajo.2010.01.041
   Yamada Y, 2006, EXP EYE RES, V82, P840, DOI 10.1016/j.exer.2005.10.005
   Yan SD, 1999, AM J PATHOL, V155, P1403, DOI 10.1016/S0002-9440(10)65452-1
   Yates JRW, 2007, NEW ENGL J MED, V357, P553, DOI 10.1056/NEJMoa072618
   Ye SM, 1999, J NEUROIMMUNOL, V93, P139, DOI 10.1016/S0165-5728(98)00217-3
   Yin LL, 2012, AM J PATHOL, V180, P541, DOI 10.1016/j.ajpath.2011.10.015
   Yoon KD, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0041309
   Yu Y, 2011, HUM MOL GENET, V20, P3699, DOI 10.1093/hmg/ddr270
   Zamiri Parisa, 2007, Chem Immunol Allergy, V92, P86, DOI 10.1159/000099259
   Zealley B, 2013, GERONTOLOGY, V59, P183, DOI 10.1159/000342197
   Zhang K, 2011, P NATL ACAD SCI USA, V108, P6241, DOI 10.1073/pnas.1018987108
   Zhao L, 2011, AM J PATHOL, V179, P1265, DOI 10.1016/j.ajpath.2011.05.042
   Zhou JL, 2006, P NATL ACAD SCI USA, V103, P16182, DOI 10.1073/pnas.0604255103
   Zhou J, 2009, INVEST OPHTH VIS SCI, V50, P1392, DOI 10.1167/iovs.08-2868
   Zweifel SA, 2010, OPHTHALMOLOGY, V117, P1775, DOI 10.1016/j.ophtha.2010.01.027
   Zweifel SA, 2010, OPHTHALMOLOGY, V117, P303, DOI 10.1016/j.ophtha.2009.07.014
NR 319
TC 149
Z9 153
U1 1
U2 39
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 1350-9462
EI 1873-1635
J9 PROG RETIN EYE RES
JI Prog. Retin. Eye Res.
PD NOV
PY 2013
VL 37
BP 68
EP 89
DI 10.1016/j.preteyeres.2013.07.003
PG 22
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 264VI
UT WOS:000327908700004
PM 23933169
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Sorbera, LA
   Leeson, PA
   Bayes, M
AF Sorbera, LA
   Leeson, PA
   Bayes, M
TI Pegaptanib sodium. Treatment of age-related macular degeneration,
   treatment of diabetic retinopathy, anti-VEGF aptamer
SO DRUGS OF THE FUTURE
LA English
DT Article
ID ENDOTHELIAL GROWTH-FACTOR; INHIBITION; NX1838; NEOVASCULARIZATION;
   PHARMACOKINETICS
AB Exudative age-related macular degeneration (AMD) and diabetic macular edema (DME) are the leading causes of vision loss in the elderly and diabetics, respectively, in the Western world. Although photocoagulation and photodynamic therapy are indicated for these pathologies, recurrence is exceptionally high. Thus, the search continues for a more effective treatment for these disorders. Vascular endothelial growth factor (VEGF) is a cytokine involved in angiogenesis and necessary for normal vascular development. However, it has also been implicated in several pathologies such as AMD, DME and choroidal neovascularization (CNV) where patients display high intraocular VEGF levels. Thus, anti-VEGF therapy is an attractive therapeutic option for these diseases. One such anti-VEGF agent is the pegylated aptamer pegaptanib sodium. Pegaptanib specifically binds with high affinity of VEGF(165,) the major soluble human VEGF isoform, and has been shown to potently inhibit blood vessel growth and block neovascularization in preclinical models. It has been chosen for further development for the treatment of AMD and DME and is the first aptamer to reach human clinical testing.
C1 Prous Sci, Barcelona 08080, Spain.
RP Sorbera, LA (通讯作者)，Prous Sci, POB 540, Barcelona 08080, Spain.
CR ADAMIS AP, 1994, AM J OPHTHALMOL, V118, P445, DOI 10.1016/S0002-9394(14)75794-0
   Adamis AP, 1996, ARCH OPHTHALMOL-CHIC, V114, P66, DOI 10.1001/archopht.1996.01100130062010
   AIELLO LP, 1995, P NATL ACAD SCI USA, V92, P10457, DOI 10.1073/pnas.92.23.10457
   AIELLO LP, 1994, NEW ENGL J MED, V331, P1480, DOI 10.1056/NEJM199412013312203
   Amano S, 1998, INVEST OPHTH VIS SCI, V39, P18
   [Anonymous], 1991, Arch Ophthalmol, V109, P1109
   [Anonymous], 1991, Arch Ophthalmol, V109, P1220
   Bell C, 1999, IN VITRO CELL DEV-AN, V35, P533
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   Carmeliet P, 1996, NATURE, V380, P435, DOI 10.1038/380435a0
   CARRASQUILLO KG, 2002, ANN M ASS RES VIS OP
   Drolet DW, 2000, PHARMACEUT RES, V17, P1503, DOI 10.1023/A:1007657109012
   ELLINGTON AD, 1990, NATURE, V346, P818, DOI 10.1038/346818a0
   FERRARA N, 1992, ENDOCR REV, V13, P18, DOI 10.1210/er.13.1.18
   HAWKINS BS, 1990, ARCH OPHTHALMOL-CHIC, V108, P816
   HYMAN L, 1987, EYE, V1, P330, DOI 10.1038/eye.1987.53
   KIM KJ, 1993, NATURE, V362, P841, DOI 10.1038/362841a0
   LEUNG DW, 1989, SCIENCE, V246, P1306, DOI 10.1126/science.2479986
   Martin DF, 2002, RETINA-J RET VIT DIS, V22, P143
   MONES J, 2002, 4 INT S OC PHARM PHA, P27
   Ruckman J, 1998, J BIOL CHEM, V273, P20556, DOI 10.1074/jbc.273.32.20556
   SMITH LEH, 1994, INVEST OPHTH VIS SCI, V35, P101
   TOMKINSON B, 1999, P AM ASS CANC RES, V40
   Tucker CE, 1999, J CHROMATOGR B, V732, P203, DOI 10.1016/S0378-4347(99)00285-6
   TUERK C, 1990, SCIENCE, V249, P505, DOI 10.1126/science.2200121
   2002, DAILYDRUGNEWS C 0812
NR 26
TC 4
Z9 4
U1 0
U2 8
PU PROUS SCIENCE, SAU-THOMSON REUTERS
PI BARCELONA
PA 398 PROVENCA, 08025 BARCELONA, SPAIN
SN 0377-8282
EI 2013-0368
J9 DRUG FUTURE
JI Drug Future
PD SEP
PY 2002
VL 27
IS 9
BP 841
EP 845
DI 10.1358/dof.2002.027.09.695013
PG 5
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA 620FK
UT WOS:000179523200003
DA 2022-11-30
ER

PT J
AU Nicolo, M
   Ghiglione, D
   Lai, S
   Calabria, G
AF Nicolo, M
   Ghiglione, D
   Lai, S
   Calabria, G
TI Intravitreal triamcinolone in the treatment of serous pigment epithelial
   detachment and occult choroidal neovascularization secondary to
   age-related macular degeneration
SO EUROPEAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE triamcinolone; occult CNV; pigment epithelial detachment
ID PHOTODYNAMIC THERAPY; VERTEPORFIN; ACETONIDE
AB PURPOSE. To report two cases of occult choroidal neovascularization (CNV) and serous pigment epithelial detachment (PED) treated with intravitreal triamcinolone (IVT) injections'.
   METHODS. Interventional case reports.
   RESULTS. Both patients showed an increase in visual acuity and a complete flattening of the PED at 10 months (Case 1) and 4 months (Case 2) after IVT injections. No complications or adverse effects are reported.
   CONCLUSIONS. Future studies should be designed to investigate if IVT can effectively influence the clinical and functional outcome of eyes with serous PED and occult CNV secondary to age-related macular degeneration, for which at the moment no treatment has been shown to be effective.
C1 Univ Genoa, Eye Clin, Genoa, Italy.
   1st Biosanites, Genoa, Italy.
C3 University of Genoa
RP Nicolo, M (通讯作者)，Univ Genoa, Eye Clin, Genoa, Italy.
EM massimo.nicolo@hsanmartino.it
OI Nicolo, Massimo/0000-0002-7824-3091
CR Axer-Siegel R, 2004, ARCH OPHTHALMOL-CHIC, V122, P453, DOI 10.1001/archopht.122.4.453
   BRESSLER NM, 1988, SURV OPHTHALMOL, V32, P375, DOI 10.1016/0039-6257(88)90052-5
   Bressler NM, 2002, ARCH OPHTHALMOL-CHIC, V120, P1307
   Gillies MC, 2003, ARCH OPHTHALMOL-CHIC, V121, P667, DOI 10.1001/archopht.121.5.667
   Jonas JB, 2004, ARCH OPHTHALMOL-CHIC, V122, P218, DOI 10.1001/archopht.122.2.218
   KLEIN ML, 1980, BRIT J OPHTHALMOL, V64, P412, DOI 10.1136/bjo.64.6.412
   Penfold PL, 2002, INVEST OPHTH VIS SCI, V43, P3125
   Perretti M, 2000, MICROCIRCULATION, V7, P147, DOI 10.1038/sj.mn.7300108
   SCHOLES GN, 1985, ARCH OPHTHALMOL-CHIC, V103, P1567
   Spaide RF, 2003, OPHTHALMOLOGY, V110, P1517, DOI 10.1016/S0161-6420(03)00544-X
NR 10
TC 21
Z9 21
U1 0
U2 0
PU WICHTIG EDITORE
PI MILAN
PA 72/74 VIA FRIULI, 20135 MILAN, ITALY
SN 1120-6721
J9 EUR J OPHTHALMOL
JI Eur. J. Ophthalmol.
PD MAY-JUN
PY 2005
VL 15
IS 3
BP 415
EP 419
DI 10.1177/112067210501500318
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 935WE
UT WOS:000229813300018
PM 15945015
DA 2022-11-30
ER

PT J
AU Ke, KM
AF Ke, Kathleen Melissa
TI The direct, indirect and intangible costs of visual impairment caused by
   neovascular age-related macular degeneration
SO EUROPEAN JOURNAL OF HEALTH ECONOMICS
LA English
DT Article
DE Economic costs; Neovascular age-related macular degeneration; Visual
   impairment
ID RESOURCE UTILIZATION; RISK-FACTORS; BURDEN; INDIVIDUALS; ILLNESS;
   COHORT; IMPACT
AB Neovascular age-related macular degeneration (nvAMD) is a chronic, progressive disease of the central retina, and its prevalence is expected to rise with the ageing population. Using a bottom-up approach based on retrospective data, this cross-sectional study estimated average annual direct costs of nvAMD to be A 4,047 pound, and average annual indirect costs to be A 449 pound. An attempt to measure intangible costs through willingness-to-pay yielded a lower response rate and estimated intangible costs to be 11.5% of monthly income. Direct costs were significantly higher for male participants, for those who have mild or moderate visual impairment in both eyes, and for those who have been diagnosed for a shorter time. The findings of this study suggest that the availability of early diagnosis, effective treatment, support services, and sustained research into the management of nvAMD may reduce the burden of visual impairment caused by nvAMD to affected individuals and the state.
C1 Univ Bristol, Bristol Dent Sch, Dept Oral & Dent Sci, Bristol BS1 2LY, Avon, England.
C3 University of Bristol
RP Ke, KM (通讯作者)，Univ Bristol, Bristol Dent Sch, Dept Oral & Dent Sci, Lower Maudlin St, Bristol BS1 2LY, Avon, England.
EM Melissa.Ke@bristol.ac.uk
RI de Lima, Andréia/G-8040-2014; Berryman, Katie/J-4236-2014
OI Ke, Kathleen Melissa/0000-0002-2670-2188
CR *AA MOT TRUST, 2006, COST MOT 2006
   AMOAKU WMK, 2007, ROYAL COLL OPHTHALMO
   Bonastre J, 2003, PHARMACOECONOMICS, V21, P181, DOI 10.2165/00019053-200321030-00003
   Coleman AL, 2008, OPHTHALMOLOGY, V115, P18, DOI 10.1016/j.ophtha.2007.04.016
   Cruess A, 2007, CAN J OPHTHALMOL, V42, P836, DOI 10.3129/i07-153
   Cruess AF, 2008, PHARMACOECONOMICS, V26, P57, DOI 10.2165/00019053-200826010-00006
   Curtis L, 2006, UNIT COSTS HLTH SOCI
   *DEP ENT TRAD INV, 2006, NO IR ANN SURV HOUS
   Evans JR, 2001, PROG RETIN EYE RES, V20, P227, DOI 10.1016/S1350-9462(00)00023-9
   Garattini Livio, 2004, Eur J Health Econ, V5, P22
   *GOV ACT DEP UK, 2007, PROJ POP MID AG LAST
   Gupta OP, 2007, CURR OPIN OPHTHALMOL, V18, P201, DOI 10.1097/ICU.0b013e32810c8df4
   Halpern MT, 2006, HEALTH CARE FINANC R, V27, P37
   Kahneman D, 1999, J RISK UNCERTAINTY, V19, P203, DOI 10.1023/A:1007835629236
   Ke KM, 2006, DRUG AGING, V23, P217, DOI 10.2165/00002512-200623030-00004
   Lamoureux EL, 2004, AM J OPHTHALMOL, V137, P265, DOI 10.1016/j.ajo.2003.08.003
   Lotery A, 2007, BRIT J OPHTHALMOL, V91, P1303, DOI 10.1136/bjo.2007.116939
   *NICE, 2003, TECHN APPR 68 GUID U
   Owen CG, 2003, BRIT J OPHTHALMOL, V87, P312, DOI 10.1136/bjo.87.3.312
   Resnikoff S, 2004, B WORLD HEALTH ORGAN, V82, P844
   ROMANS F, 2007, 972007 EUR
   Schmier JK, 2006, RETINA-J RET VIT DIS, V26, P1056, DOI 10.1097/01.iae.0000254890.48272.5a
   Schmier JK, 2006, DISABIL REHABIL, V28, P1331, DOI 10.1080/09638280600621436
   Smith W, 2001, OPHTHALMOLOGY, V108, P697, DOI 10.1016/S0161-6420(00)00580-7
   U.S. Department of Labor, 2007, LAB FORC STAT CURR P
   *VERT ROUNDT 2000, 2002, RETINA, V22, P6
NR 26
TC 16
Z9 18
U1 0
U2 12
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1618-7598
J9 EUR J HEALTH ECON
JI Eur. J. Health Econ.
PD DEC
PY 2010
VL 11
IS 6
BP 525
EP 531
DI 10.1007/s10198-009-0207-9
PG 7
WC Economics; Health Policy & Services
WE Social Science Citation Index (SSCI)
SC Business & Economics; Health Care Sciences & Services
GA 681LR
UT WOS:000284317400002
PM 19936811
DA 2022-11-30
ER

PT J
AU Forshaw, TRJ
   Kjaer, TW
   Andreasson, S
   Sorensen, TL
AF Forshaw, Thomas Richard Johansen
   Kjaer, Troels Wesenberg
   Andreasson, Sten
   Sorensen, Torben Lykke
TI Full-field electroretinography in age-related macular degeneration: an
   overall retinal response
SO ACTA OPHTHALMOLOGICA
LA English
DT Article
DE age-related macular degeneration; full-field electroretinography;
   functional testing; peripheral retina
ID MEDIATED DARK-ADAPTATION; IMPAIRMENT; VISION
AB Purpose Age-related macular degeneration (AMD) is generally considered a disease of the macula. However, recent studies show peripheral retinal lesions are prevalent in patients with AMD, indicative of a disease process that is more widespread. Full-field electroretinography (ffERG) measures an electrical response, not only from the macula, but from the entire retina. We wanted to study the ffERG response in eyes with AMD. Methods We performed full-field electroretinography (RETI-port/scan 21, Roland, Berlin) in 13 patients with early AMD, 25 patients with late AMD and 24 individuals without vitreoretinal disease as a control group. Dawson-Trick-Litzkow fibre electrodes were used. Statistical analysis was performed and a p-value After adjusting for multiple comparisons, both the light-adapted 3.0 a-wave implicit time (p < 0.001) and 30-Hertz flicker peak time (p = 0.012) showed significant difference between patients with late AMD and individuals without vitreoretinal disease. There was a significant difference in the light-adapted 3.0 a-wave implicit time (p = 0.011) between patients with early AMD and the control group, but the difference in 30 Hz flicker peak time was not significant (p = 0.256). Conclusion The difference in cone function measured by light-adapted 3.0 a-wave implicit time and 30-Hertz flicker peak time in early and late AMD when compared to healthy controls suggests a more diminished overall response when AMD has reached later stages.
C1 [Forshaw, Thomas Richard Johansen; Sorensen, Torben Lykke] Zealand Univ Hosp, Dept Ophthalmol, Vestermarksvej 23, DK-4000 Roskilde, Denmark.
   [Forshaw, Thomas Richard Johansen; Kjaer, Troels Wesenberg; Sorensen, Torben Lykke] Univ Copenhagen, Fac Hlth & Med Sci, Copenhagen, Denmark.
   [Kjaer, Troels Wesenberg] Zealand Univ Hosp, Dept Neurophysiol, Roskilde, Denmark.
   [Andreasson, Sten] Skane Univ Hosp, Dept Ophthalmol, Lund, Sweden.
C3 University of Copenhagen; Lund University; Skane University Hospital
RP Forshaw, TRJ (通讯作者)，Zealand Univ Hosp, Dept Ophthalmol, Vestermarksvej 23, DK-4000 Roskilde, Denmark.
EM forshawthomas@yahoo.co.uk
RI Forshaw, Thomas Richard Johansen/AGF-9674-2022
OI Forshaw, Thomas Richard Johansen/0000-0003-0667-6514; Kjaer, Troels
   W/0000-0002-2105-6199
CR BERSON EL, 1969, ARCH OPHTHALMOL-CHIC, V81, P207
   BIRCH DG, 1992, ARCH OPHTHALMOL-CHIC, V110, P1571, DOI 10.1001/archopht.1992.01080230071024
   Black AA, 2008, OPTOMETRY VISION SCI, V85, P489, DOI 10.1097/OPX.0b013e31817882db
   Chen KG, 2019, OPHTHALMOLOGY, V126, P856, DOI 10.1016/j.ophtha.2018.09.039
   CURCIO CA, 1993, INVEST OPHTH VIS SCI, V34, P3278
   Curcio CA, 1996, INVEST OPHTH VIS SCI, V37, P1236
   Dimopoulos IS, 2013, INVEST OPHTH VIS SCI, V54, P5186, DOI 10.1167/iovs.13-12194
   Domalpally A, 2017, OPHTHALMOLOGY, V124, P479, DOI 10.1016/j.ophtha.2016.12.004
   Eksandh L, 2001, Ophthalmic Genet, V22, P107, DOI 10.1076/opge.22.2.107.2226
   Evans JR, 2000, NEUROSCIENCE, V101, P229, DOI 10.1016/S0306-4522(00)00367-5
   Forshaw TRJ, 2019, OPHTHALMOL RETINA, V3, P734, DOI 10.1016/j.oret.2019.04.014
   Gerber DM, 2003, INVEST OPHTH VIS SCI, V44, P493, DOI 10.1167/iovs.01-0787
   Granit R, 1963, SENSORY MECH RETINA, P350
   Huestegge Lynn, 2016, J Vis, V16, P11, DOI 10.1167/16.2.11
   Jarrett SG, 2012, MOL ASPECTS MED, V33, P399, DOI 10.1016/j.mam.2012.03.009
   Lains I, 2017, OPHTHALMOLOGY, V124, P1340, DOI 10.1016/j.ophtha.2017.03.061
   Marigold DS, 2008, EXERC SPORT SCI REV, V36, P145, DOI 10.1097/JES.0b013e31817bff72
   McCannel CA., 2019, 2019 2020 BASIC CLIN, P41
   McCulloch DL, 2015, DOC OPHTHALMOL, V130, P1, DOI 10.1007/s10633-014-9473-7
   NAKAYAMA K, 1985, VISION RES, V25, P625, DOI 10.1016/0042-6989(85)90171-3
   Owsley C, 2007, OPHTHALMOLOGY, V114, P1728, DOI 10.1016/j.ophtha.2006.12.023
   Owsley C, 2017, TRANSL VIS SCI TECHN, V6, DOI 10.1167/tvst.6.3.15
   Owsley C, 2016, OPHTHALMOLOGY, V123, P344, DOI 10.1016/j.ophtha.2015.09.041
   Pedersen KB, 2010, RETINA-J RET VIT DIS, V30, P1025, DOI 10.1097/IAE.0b013e3181cafc8f
   Peli E, 2016, J VISION, V16, DOI 10.1167/16.15.5
   Pfau M, 2020, RETINA-J RET VIT DIS, V40, P169, DOI 10.1097/IAE.0000000000002337
   Prokofyeva E, 2012, OPHTHALMIC RES, V47, P171, DOI 10.1159/000329603
   Quinn N, 2019, PROG RETIN EYE RES, V68, P83, DOI 10.1016/j.preteyeres.2018.10.001
   Ratanapakorn Tanapat, 2010, Journal of the Medical Association of Thailand, V93, P1196
   Schaal KB, 2015, RETINA-J RET VIT DIS, V35, P1339, DOI 10.1097/IAE.0000000000000471
   Schroeder M, 2018, MOL VIS, V24, P1
   Sorensen MS, 2011, DAN MED BULL, V58
   Tan CS, 2013, OPHTHALMOLOGY, V120, P1271, DOI 10.1016/j.ophtha.2012.12.002
   Tsang SH, 2018, ADV EXP MED BIOL, V1085, P17, DOI 10.1007/978-3-319-95046-4_5
   Vargas-Martin F, 2006, INVEST OPHTH VIS SCI, V47, P5295, DOI 10.1167/iovs.05-1043
   Walter P, 1999, GRAEF ARCH CLIN EXP, V237, P962, DOI 10.1007/s004170050331
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Ying GS, 2008, OPHTHALMOLOGY, V115, P1876, DOI 10.1016/j.ophtha.2008.05.023
NR 38
TC 2
Z9 2
U1 0
U2 0
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1755-375X
EI 1755-3768
J9 ACTA OPHTHALMOL
JI Acta Ophthalmol.
PD MAR
PY 2021
VL 99
IS 2
BP E253
EP E259
DI 10.1111/aos.14571
EA AUG 2020
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA QT2FQ
UT WOS:000561932600001
PM 32833310
OA Bronze
DA 2022-11-30
ER

PT J
AU Toomey, CB
   Kelly, U
   Saban, DR
   Rickman, CB
AF Toomey, Christopher B.
   Kelly, Una
   Saban, Daniel R.
   Rickman, Catherine Bowes
TI Regulation of age-related macular degeneration-like pathology by
   complement factor H
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
   AMERICA
LA English
DT Article
DE age-related macular degeneration; retinal pigmented epithelium;
   complement; factor H; lipoprotein
ID RETINAL PIGMENTED EPITHELIUM; BRUCHS MEMBRANE IMPLICATIONS; BEAVER DAM
   EYE; APOLIPOPROTEIN-E; OXIDIZED PHOSPHOLIPIDS; ALTERNATIVE PATHWAY;
   ENDOTHELIAL-CELLS; DRUSEN FORMATION; HEPARAN-SULFATE; C5A RECEPTORS
AB Complement factor H (CFH) is a major susceptibility gene for age-related macular degeneration (AMD); however, its impact on AMD pathobiology is unresolved. Here, the role of CFH in the development of AMD pathology in vivo was interrogated by analyzing aged Cfh(+/-) and Cfh(-/-) mice fed a high-fat, cholesterol-enriched diet. Strikingly, decreased levels of CFH led to increased sub-retinal pigmented epithelium (sub-RPE) deposit formation, specifically basal laminar deposits, following high-fat diet. Mechanistically, our data show that deposits are due to CFH competition for lipoprotein binding sites in Bruch's membrane. Interestingly and despite sub-RPE deposit formation occurring in both Cfh(+/-) and Cfh(-/-) mice, RPE damage accompanied by loss of vision occurred only in old Cfh(+/-) mice. We demonstrate that such pathology is a function of excess complement activation in Cfh(+/-) mice versus complement deficiency in Cfh(-/-) animals. Due to the CFH-dependent increase in sub-RPE deposit height, we interrogated the potential of CFH as a previously unidentified regulator of Bruch's membrane lipoprotein binding and show, using human Bruch's membrane explants, that CFH removes endogenous human lipoproteins in aged donors. Thus, advanced age, high-fat diet, and decreased CFH induce sub-RPE deposit formation leading to complement activation, which contributes to RPE damage and visual function impairment. This new understanding of the complicated interactions of CFH in AMD-like pathology provides an improved foundation for the development of targeted therapies for AMD.
C1 [Toomey, Christopher B.; Kelly, Una; Saban, Daniel R.; Rickman, Catherine Bowes] Duke Univ, Ctr Eye, Dept Ophthalmol, Durham, NC 27710 USA.
   [Toomey, Christopher B.; Rickman, Catherine Bowes] Duke Univ, Dept Cell Biol, Durham, NC 27710 USA.
   [Saban, Daniel R.] Duke Univ, Dept Immunol, Durham, NC 27710 USA.
C3 Duke University; Duke University; Duke University
RP Rickman, CB (通讯作者)，Duke Univ, Ctr Eye, Dept Ophthalmol, Durham, NC 27710 USA.
EM bowes007@duke.edu
OI Bowes Rickman, Catherine/0000-0002-8555-9596
FU National Eye Institute [P30 EY005722, R01 EY019038, T32 GM007171];
   Research to Prevent Blindness; Edward N. and Della L. Thome Memorial
   Foundation; NATIONAL EYE INSTITUTE [R01EY019038, P30EY005722] Funding
   Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES
   [T32GM007171] Funding Source: NIH RePORTER
FX We thank Jindong Ding, Mikael Klingborn, Nikolai Skiba, Terry
   Singhapricha, and Marybeth Groelle for their expert technical
   assistance; Rose Matthews and Joan Kalnitsky for their assistance with
   flow cytometry; Scott Cousins, Dan Stamer, Christine Curcio, Lincoln
   Johnson, and Ekaterina Lobanova for their intellectual contributions to
   the manuscript; and Marina Botto for access to the Cfh-/- mice. This
   work was supported by funding grants from the National Eye Institute
   [P30 EY005722 (to V. Arshavsky), R01 EY019038 (to C.B.R.), and T32
   GM007171-Medical Scientist Training Program (to C.B.T.)], an
   unrestricted grant from Research to Prevent Blindness (to the Duke Eye
   Center), and a grant from the Edward N. and Della L. Thome Memorial
   Foundation (to C.B.R.).
CR Alexander JJ, 2007, MOL IMMUNOL, V44, P123, DOI 10.1016/j.molimm.2006.07.287
   Anand A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0049905
   Anand R, 2000, OPHTHALMOLOGY, V107, P2224
   Anderson DH, 2002, AM J OPHTHALMOL, V134, P411, DOI 10.1016/S0002-9394(02)01624-0
   Anderson DH, 2001, AM J OPHTHALMOL, V131, P767, DOI 10.1016/S0002-9394(00)00961-2
   Anderson DH, 2010, PROG RETIN EYE RES, V29, P95, DOI 10.1016/j.preteyeres.2009.11.003
   Anderson KG, 2014, NAT PROTOC, V9, P209, DOI 10.1038/nprot.2014.005
   Binder CJ, 2002, NAT MED, V8, P1218, DOI 10.1038/nm1102-1218
   Booij JC, 2010, PROG RETIN EYE RES, V29, P1, DOI 10.1016/j.preteyeres.2009.08.003
   CALL TW, 1990, EXP EYE RES, V51, P451, DOI 10.1016/0014-4835(90)90158-Q
   Carlin LM, 2013, CELL, V153, P362, DOI 10.1016/j.cell.2013.03.010
   Chakravarthy U, 2010, BMC OPHTHALMOL, V10, DOI 10.1186/1471-2415-10-31
   Chang MK, 2002, P NATL ACAD SCI USA, V99, P13043, DOI 10.1073/pnas.192399699
   Chen W, 2010, P NATL ACAD SCI USA, V107, P7401, DOI 10.1073/pnas.0912702107
   Cherepanoff S, 2010, BRIT J OPHTHALMOL, V94, P918, DOI 10.1136/bjo.2009.165563
   Clark SJ, 2006, J BIOL CHEM, V281, P24713, DOI 10.1074/jbc.M605083200
   Clark SJ, 2014, J IMMUNOL, V193, P4962, DOI 10.4049/jimmunol.1401613
   Clark SJ, 2013, J IMMUNOL, V190, P2049, DOI 10.4049/jimmunol.1201751
   Clark SJ, 2010, J BIOL CHEM, V285, P30192, DOI 10.1074/jbc.M110.103986
   Coffey PJ, 2007, P NATL ACAD SCI USA, V104, P16651, DOI 10.1073/pnas.0705079104
   Combadiere C, 2007, J CLIN INVEST, V117, P2920, DOI 10.1172/JCI31692
   Curcio C.A., 2013, RETINA-J RET VIT DIS, VVolume 1, P465
   Curcio CA, 1999, ARCH OPHTHALMOL-CHIC, V117, P329, DOI 10.1001/archopht.117.3.329
   Curcio CA, 2011, BRIT J OPHTHALMOL, V95, P1638, DOI 10.1136/bjophthalmol-2011-300344
   Curcio CA, 2009, PROG RETIN EYE RES, V28, P393, DOI 10.1016/j.preteyeres.2009.08.001
   Dashti N, 2006, BRIT J OPHTHALMOL, V90, P1028, DOI 10.1136/bjo.2006.093856
   Despriet DDG, 2008, INVEST OPHTH VIS SCI, V49, P364, DOI 10.1167/iovs.07-0656
   Dietzel M, 2014, GRAEF ARCH CLIN EXP, V252, P1273, DOI 10.1007/s00417-014-2690-7
   Ding JD, 2015, AM J PATHOL, V185, P29, DOI 10.1016/j.ajpath.2014.08.026
   Ding JD, 2011, P NATL ACAD SCI USA, V108, pE279, DOI 10.1073/pnas.1100901108
   Dithmar S, 2001, ARCH OPHTHALMOL-CHIC, V119, P1643, DOI 10.1001/archopht.119.11.1643
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Elner SG, 2003, LAB INVEST, V101, P89
   Elner Susan G, 2003, Trans Am Ophthalmol Soc, V101, P77
   Fritsche LG, 2013, NAT GENET, V45, P433, DOI 10.1038/ng.2578
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   GOURAS P, 1970, INVEST OPHTH VISUAL, V9, P557
   Green W R, 1999, Mol Vis, V5, P27
   Grunin M, 2012, INVEST OPHTH VIS SCI, V53, P5292, DOI 10.1167/iovs.11-9165
   Guo RF, 2005, ANNU REV IMMUNOL, V23, P821, DOI 10.1146/annurev.immunol.23.021704.115835
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Hanna RN, 2012, CIRC RES, V110, P416, DOI 10.1161/CIRCRESAHA.111.253377
   Hanna RN, 2011, NAT IMMUNOL, V12, P778, DOI 10.1038/ni.2063
   Herrmann R, 2010, J NEUROSCI, V30, P3239, DOI 10.1523/JNEUROSCI.4775-09.2010
   Hilgendorf I, 2014, CIRC RES, V114, P1611, DOI 10.1161/CIRCRESAHA.114.303204
   Hollyfield JG, 2008, NAT MED, V14, P194, DOI 10.1038/nm1709
   Horkko S, 2000, FREE RADICAL BIO MED, V28, P1771, DOI 10.1016/S0891-5849(00)00333-6
   Hu P, 2013, P NATL ACAD SCI USA, V110, pE4069, DOI 10.1073/pnas.1307574110
   Imamura Y, 2006, P NATL ACAD SCI USA, V103, P11282, DOI 10.1073/pnas.0602131103
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Johnson LR, 2000, IEEE ANN HIST COMPUT, V22, P70
   Johnson LV, 2001, EXP EYE RES, V73, P887, DOI 10.1006/exer.2001.1094
   Justilien V, 2007, INVEST OPHTH VIS SCI, V48, P4407, DOI 10.1167/iovs.07-0432
   Kam JH, 2013, AM J PATHOL, V183, P480, DOI 10.1016/j.ajpath.2013.04.008
   Keenan TDL, 2014, INVEST OPHTH VIS SCI, V55, P5370, DOI 10.1167/iovs.14-14126
   Kelly U, 2010, J IMMUNOL, V185, P5486, DOI 10.4049/jimmunol.0903596
   Klein BEK, 2002, OPHTHALMOLOGY, V109, P2052, DOI 10.1016/S0161-6420(02)01249-6
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Kliffen M, 2000, BRIT J OPHTHALMOL, V84, P1415, DOI 10.1136/bjo.84.12.1415
   Langford-Smith A, 2014, J INNATE IMMUN, V6, P407, DOI 10.1159/000356513
   Luhmann UFO, 2009, INVEST OPHTH VIS SCI, V50, P5934, DOI 10.1167/iovs.09-3462
   Malagon F, 2011, RNA BIOL, V8, P184, DOI 10.4161/rna.8.2.14822
   Malek G, 2005, P NATL ACAD SCI USA, V102, P11900, DOI 10.1073/pnas.0503015102
   Manthey HD, 2011, FASEB J, V25, P2447, DOI 10.1096/fj.10-174284
   Mattapallil MJ, 2012, INVEST OPHTH VIS SCI, V53, P2921, DOI 10.1167/iovs.12-9662
   McKay GJ, 2011, HUM MUTAT, V32, P1407, DOI 10.1002/humu.21577
   PANGBURN MK, 1983, ANN NY ACAD SCI, V421, P291, DOI 10.1111/j.1749-6632.1983.tb18116.x
   PAULEIKHOFF D, 1990, OPHTHALMOLOGY, V97, P171
   Pauleikhoff D., 1994, Ophthalmologe, V91, P730
   Penfold PL, 2001, PROG RETIN EYE RES, V20, P385, DOI 10.1016/S1350-9462(00)00025-2
   Pennesi ME, 2012, MOL ASPECTS MED, V33, P487, DOI 10.1016/j.mam.2012.06.003
   Picard E, 2010, AGING-US, V2, P981, DOI 10.18632/aging.100218
   Pickering MC, 2002, NAT GENET, V31, P424, DOI 10.1038/ng912
   Prosser BE, 2007, J EXP MED, V204, P2277, DOI 10.1084/jem.20071069
   Raoul W, 2010, J NEUROINFLAMM, V7, DOI 10.1186/1742-2094-7-87
   Rittirsch D, 2008, NAT MED, V14, P551, DOI 10.1038/nm1753
   Ruberti JW, 2003, INVEST OPHTH VIS SCI, V44, P1753, DOI 10.1167/iovs.02-0496
   SARKS SH, 1976, BRIT J OPHTHALMOL, V60, P324, DOI 10.1136/bjo.60.5.324
   Sarrazin S., 2011, COLD SPRING HARB PER, V3
   Sennlaub F, 2013, EMBO MOL MED, V5, P1775, DOI 10.1002/emmm.201302692
   Shaw PX, 2012, P NATL ACAD SCI USA, V109, P13757, DOI 10.1073/pnas.1121309109
   Skeie JM, 2010, INVEST OPHTH VIS SCI, V51, P5336, DOI 10.1167/iovs.10-5322
   Stephan AH, 2012, ANNU REV NEUROSCI, V35, P369, DOI 10.1146/annurev-neuro-061010-113810
   STRITTMATTER WJ, 1993, P NATL ACAD SCI USA, V90, P1977, DOI 10.1073/pnas.90.5.1977
   Swaroop A, 2009, ANNU REV GENOM HUM G, V10, P19, DOI 10.1146/annurev.genom.9.081307.164350
   Tserentsoodol N, 2006, MOL VIS, V12, P1306
   VINGERLING JR, 1995, OPHTHALMOLOGY, V102, P205
   Wang L, 2009, INVEST OPHTH VIS SCI, V50, P870, DOI 10.1167/iovs.08-2376
   Ward PA, 2009, J MOL MED, V87, P375, DOI 10.1007/s00109-009-0442-7
   Weismann D, 2011, NATURE, V478, P76, DOI 10.1038/nature10449
   Yamada Y, 2008, J NEUROCHEM, V105, P1187, DOI 10.1111/j.1471-4159.2008.05211.x
   Yang D, 2007, EXP EYE RES, V85, P462, DOI 10.1016/j.exer.2007.06.013
   Yang DL, 2011, INVEST OPHTH VIS SCI, V52, P6026, DOI 10.1167/iovs.10-7023
   Yates JRW, 2007, NEW ENGL J MED, V357, P553, DOI 10.1056/NEJMoa072618
   Yoshida A, 2003, LAB INVEST, V83, P1117, DOI 10.1097/01.LAB.0000082393.02727.B5
   Zeiss CJ, 2010, VET PATHOL, V47, P396, DOI 10.1177/0300985809359598
   Zhou HF, 2012, P NATL ACAD SCI USA, V109, pE415, DOI 10.1073/pnas.1119000109
   Zipfel PF, 2009, NAT REV IMMUNOL, V9, P729, DOI 10.1038/nri2620
NR 101
TC 90
Z9 93
U1 1
U2 9
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027-8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD JUN 9
PY 2015
VL 112
IS 23
BP E3040
EP E3049
DI 10.1073/pnas.1424391112
PG 10
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA CJ9LG
UT WOS:000355823200012
PM 25991857
OA Green Published, Bronze
DA 2022-11-30
ER

PT J
AU Michels, S
   Wachtlin, J
   Gamulescu, MA
   Heimann, H
   Prunte, C
   Inhoffen, W
   Krebs, I
   Schmidt-Erfurth, U
AF Michels, S
   Wachtlin, J
   Gamulescu, MA
   Heimann, H
   Prunte, C
   Inhoffen, W
   Krebs, I
   Schmidt-Erfurth, U
TI Comparison of early retreatment with the standard regimen in verteporfin
   therapy of neovascular age-related macular degeneration
SO OPHTHALMOLOGY
LA English
DT Article
ID PHOTODYNAMIC THERAPY; CHOROIDAL NEOVASCULARIZATION; MACULOPATHY;
   PREVALENCE
AB Purpose: To compare the efficacy and safety of early retreatment with verteporfin therapy with that of approved standard verteporfin therapy in neovascular age-related macular degeneration.
   Design: Prospective, randomized, multicenter clinical trial.
   Participants: Two hundred three patients with predominantly classic choroidal neovascularization secondary to age-related macular degeneration.
   Methods: Throughout the first 6 months of follow-up, patients received retreatment with verteporfin therapy either every 2 months (group A) or 3 months (group B). From 6 to 12 months, both groups received retreatment at 3-month intervals.
   Main Outcome Measures: The primary outcome of the study was best-corrected mean visual acuity as measured using the Early Treatment Diabetic Retinopathy Study protocol. The secondary outcomes were percentage of patients losing at least 3 lines of vision, percentage of patients gaining at least 1 line of vision, and lesion size based on the greatest linear dimension (GLD) documented by fluorescein angiography, impact of initial lesion size, and retreatment rate as well as safety.
   Results: Visual acuity was similar in both groups at baseline with a mean visual acuity of 20/100(-1). During the 12 months of follow-up, mean visual acuity was better in the early retreatment group at all intervals; however, no statistically significant benefit was seen in the overall population at anytime (P > 0.1). At month 12, mean visual acuity was 20/160(+1) in group A and 20/160(-1) in group B. There was a trend for better outcomes in the early retreatment group with regard to loss of less than 3 lines of vision at 12 months (61% vs. 51.7%). No statistically significant difference was seen with regard to lesion size for either group throughout follow-up with a final GLD of the lesion of 2790 mu m (group A) and 2996 mu m (group B). However, subgroup analysis indicated a statistically relevant benefit (P <= 0.004) for patients with small lesions (GLD < 2000 mu m) at baseline receiving early retreatment.
   Conclusions:. Early retreatment in 2-month intervals did not show a significant overall benefit at 1 year of follow-up compared with the standard regimen. However, smaller lesions seemed to benefit from early retreatment with verteporfin therapy in contrast to larger lesions.
C1 Med Univ Vienna, Klin Augenheilkunde & Optometrie, A-1090 Vienna, Austria.
   Univ Med Berlin, Charite, Augenklin, Berlin, Germany.
   Klinikum Univ Regensburg, Klin & Poliklin Augenheilkunde, Regensburg, Germany.
   Royal Liverpool Univ Hosp, St Pauls Eye Unit, Liverpool, Merseyside, England.
   Univ Basel, Augenklin, Basel, Switzerland.
   Univ Tubingen, Augenklin, D-7400 Tubingen, Germany.
   Augenklin Rudolfstiftung, Vienna, Austria.
C3 Medical University of Vienna; Free University of Berlin; Humboldt
   University of Berlin; Charite Universitatsmedizin Berlin; University of
   Hamburg; University Medical Center Hamburg-Eppendorf; University of
   Regensburg; Royal Liverpool & Broadgreen University Hospitals NHS Trust;
   Royal Liverpool University Hospital; University of Liverpool; University
   of Basel; Eberhard Karls University of Tubingen; Eberhard Karls
   University Hospital; University of Hamburg; University Medical Center
   Hamburg-Eppendorf; Rudolfstiftung Hospital
RP Schmidt-Erfurth, U (通讯作者)，Med Univ Vienna, Klin Augenheilkunde & Optometrie, Waehringer Guertel 18-20, A-1090 Vienna, Austria.
RI Heimann, Heinrich/AAP-8747-2020
OI Heimann, Heinrich/0000-0002-3298-4644
CR Arias L, 2005, BRIT J OPHTHALMOL, V89, P312, DOI 10.1136/bjo.2004.050997
   Arnold J, 2001, AM J OPHTHALMOL, V131, P541
   Blinder KJ, 2003, AM J OPHTHALMOL, V136, P407, DOI 10.1016/S0002-9394(03)00223-X
   Blumenkranz MS, 2001, ARCH OPHTHALMOL-CHIC, V119, P198
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   Eter N, 2003, OPHTHALMOLOGE, V100, P314, DOI 10.1007/s00347-002-0693-y
   Greve MDJ, 2005, ARCH OPHTHALMOL-CHIC, V123, P448
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Michels S, 2003, INVEST OPHTH VIS SCI, V44, P2147, DOI 10.1167/iovs.02-0604
   Schlotzer-Schrehardt U, 2002, GRAEF ARCH CLIN EXP, V240, P748, DOI 10.1007/s00417-002-0517-4
   Schmidt-Erfurth U, 1999, ARCH OPHTHALMOL-CHIC, V117, P1177
   Schmidt-Erfurth U, 2002, INVEST OPHTH VIS SCI, V43, P830
   Schmidt-Erfurth U, 2003, INVEST OPHTH VIS SCI, V44, P4473, DOI 10.1167/iovs.02-1115
   Tano Y, 2003, AM J OPHTHALMOL, V136, P1049, DOI 10.1016/S0002-9394(03)00576-2
   VINGERLING JR, 1995, OPHTHALMOLOGY, V102, P205
NR 15
TC 11
Z9 12
U1 0
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0161-6420
EI 1549-4713
J9 OPHTHALMOLOGY
JI Ophthalmology
PD DEC
PY 2005
VL 112
IS 12
BP 2070
EP 2075
DI 10.1016/j.ophtha.2005.06.034
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 991MS
UT WOS:000233818700003
PM 16225928
DA 2022-11-30
ER

PT J
AU McKay, GJ
   Young, IS
   McGinty, A
   Bentham, GCG
   Chakravarthy, U
   Rahu, M
   Seland, J
   Soubrane, G
   Tomazzoli, L
   Topouzis, F
   Vioque, J
   de Jong, PTVM
   Fletcher, AE
AF McKay, Gareth J.
   Young, Ian S.
   McGinty, Ann
   Bentham, Graham C. G.
   Chakravarthy, Usha
   Rahu, Mati
   Seland, Johan
   Soubrane, Gisele
   Tomazzoli, Laura
   Topouzis, Fotis
   Vioque, Jesus
   de Jong, Paulus T. V. M.
   Fletcher, Astrid E.
TI Associations between Serum Vitamin D and Genetic Variants in Vitamin D
   Pathways and Age-Related Macular Degeneration in the European Eye Study
SO OPHTHALMOLOGY
LA English
DT Article
ID RETINOID-X-RECEPTOR; D DEFICIENCY; COGNITIVE IMPAIRMENT; RISK-FACTORS;
   DISEASES; SYSTEM; HEALTH
AB Purpose: To study associations between early and late age-related macular degeneration (AMD) and neovascular AMD (nvAMD) with serum 25-hydroxy vitamin D (25(OH)D) and genetic variants in vitamin D pathway genes.
   Design: Population-based, cross-sectional study in a random sample aged 65 years or older from 7 European countries.
   Participants: Of 4753 participants, 4496 (2028 men and 2468 women), with a mean age of 73 years, provided a blood sample; 2137 had no signs of AMD, 2209 had early AMD, and 150 had late AMD, of whom 104 had nvAMD.
   Methods: Participants were interviewed to determine smoking and alcohol use, sunlight exposure, and diet; underwent fundus photography. Fundus images were graded using the International Classification System for Age-Related Maculopathy. The 25(OH)D was measured by liquid chromatography-tandem mass spectrometry and categorized as deficient (<30 nmol/l), insufficient (30-50 nmol/l), or adequate (>= 50 nmol/l). Genotyping was performed on a subsample of 1284 AMD cases and controls for 93 single nucleotide polymorphisms (SNPs) from 7 genes. Associations were investigated by linear or logistic regression adjusted for potential confounders.
   Main Outcome Measures: Adjusted odds ratio (OR) for 3 outcomes (early AMD, late AMD, nvAMD).
   Results: No linear association was found with 25(OH)D and early or late AMD or nvAMD. There was no association between insufficient or deficient status with early or late AMD. Deficient status was associated with nvAMD (adjusted OR, 1.27; 95% confidence interval, 1.1-1.45; P < 0.0001). Significant (P < 0.05) associations with 25(OH) D were found for SNPs in genes GC, VDR, CYP2R1, and CYP27B1. Two SNPs (VDR) were associated with early AMD, 4 SNPs (RXRA) and 1 SNP (VDR) were associated with nvAMD, and 1 SNP (RXRA), 2 SNPs (VDR), and 1 SNP (CYP2R1) were associated with late AMD. After Bonferroni correction, no SNPs were associated with early AMD, late AMD, or nvAMD.
   Conclusions: Deficiency in 25(OH) D was associated with nvAMD, but the adjusted OR was small, and we cannot exclude residual confounding. The hypothesis of a causal association of vitamin D with AMD is not supported by clear evidence for an association of vitamin D SNPs with early AMD, late AMD, or nvAMD. (C) 2016 by the American Academy of Ophthalmology
C1 [McKay, Gareth J.; Young, Ian S.; McGinty, Ann] Queens Univ Belfast, Ctr Publ Hlth, Belfast, Antrim, North Ireland.
   [Bentham, Graham C. G.] Univ East Anglia, Sch Environm Sci, Norwich, Norfolk, England.
   [Chakravarthy, Usha] Queens Univ Belfast, Inst Clin Sci, Ctr Med Expt, Belfast, Antrim, North Ireland.
   [Rahu, Mati] Natl Inst Hlth Dev, Dept Epidemiol & Biostat, Tallinn, Estonia.
   [Seland, Johan] Univ Bergen, Eye Dept, Bergen, Norway.
   [Soubrane, Gisele] Univ Paris Descartes 1, Dept Ophthalmol, Hotel Dieu Paris, Paris, France.
   [Tomazzoli, Laura] Univ Verona, Clin Oculist, Verona, Italy.
   [Topouzis, Fotis] Aristotle Univ Thessaloniki, Sch Med, Dept Ophthalmol, Thessaloniki, Greece.
   [Vioque, Jesus] Univ Miguel Hernandez, CIBER Epidemiol & Salud Publ, Alicante, Spain.
   [de Jong, Paulus T. V. M.] AMC, Netherlands Inst Neurosci, Amsterdam, Netherlands.
   [Fletcher, Astrid E.] London Sch Hyg & Trop Med, Fac Epidemiol & Populat Hlth, London WC1E 7HT, England.
C3 Queens University Belfast; University of East Anglia; Queens University
   Belfast; National Institute for Health Development - Estonia; University
   of Bergen; Assistance Publique Hopitaux Paris (APHP); Hopital
   Universitaire Hotel-Dieu - APHP; UDICE-French Research Universities;
   Universite Paris Cite; University of Verona; Aristotle University of
   Thessaloniki; CIBER - Centro de Investigacion Biomedica en Red;
   CIBERESP; Universidad Miguel Hernandez de Elche; Royal Netherlands
   Academy of Arts & Sciences; Netherlands Institute for Neuroscience
   (NIN-KNAW); University of Amsterdam; Academic Medical Center Amsterdam;
   University of London; London School of Hygiene & Tropical Medicine
RP Fletcher, AE (通讯作者)，London Sch Hyg & Trop Med, Fac Epidemiol & Populat Hlth, London WC1E 7HT, England.
EM astrid.fletcher@lshtm.ac.uk
RI McKay, Gareth/AAZ-2601-2020
OI McKay, Gareth/0000-0001-8197-6280; Young, Ian/0000-0003-3890-3152;
   Vioque, Jesus/0000-0002-2284-148X; Rahu, Mati/0000-0001-7172-8048;
   Chakravarthy, Usha/0000-0002-2606-3734; Topouzis,
   Fotis/0000-0002-8966-537X
FU Guide Dogs for the Blind UK; Novartis; European Union; Macula Disease
   Society UK; Thomas Pocklington Trust UK; Estonian Research Council
   [IUT5-1]; Fondo de Investigacion Sanitaria, Madrid, Spain [FIS 01/1692E,
   RCESP C 03/09]; Oficina de Ciencia y Tecnologia Generalitat Valenciana,
   Valencia, Spain [CTGCA/2002/06]; Medical Research Council [G0901530,
   MC_CF023241] Funding Source: researchfish; MRC [G0601354, G0901530]
   Funding Source: UKRI
FX A.M.: Grants - Guide Dogs for the Blind UK, during the conduct of the
   study.; F.T.: Consultant - Bayer; Grants/grants pending - Novartis.;
   A.E.F.: Grants - The European Union, Macula Disease Society UK, Thomas
   Pocklington Trust UK, and Guide Dogs for the Blind.; M.R.: Salaried by
   his home institute (grant IUT5-1 from the Estonian Research Council).
   Additional funding in Alicante was received from the Fondo de
   Investigacion Sanitaria, Madrid, Spain (grants FIS 01/1692E, RCESP C
   03/09), and Oficina de Ciencia y Tecnologia Generalitat Valenciana,
   Valencia, Spain (grant CTGCA/2002/06). The funding organizations had no
   role in the design or conduct of this research
CR Ahn J, 2010, HUM MOL GENET, V19, P2739, DOI 10.1093/hmg/ddq155
   Ahuja HS, 2003, J BIOL REG HOMEOS AG, V17, P29
   Anderson DH, 2010, PROG RETIN EYE RES, V29, P95, DOI 10.1016/j.preteyeres.2009.11.003
   Autier P, 2014, LANCET DIABETES ENDO, V2, P76, DOI 10.1016/S2213-8587(13)70165-7
   Bendik I, 2014, FRONT PHYSIOL, V5, DOI 10.3389/fphys.2014.00248
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Cashman KD, 2016, AM J CLIN NUTR, V103, P1033, DOI 10.3945/ajcn.115.120873
   Chakravarthy U, 2010, BMC OPHTHALMOL, V10, DOI 10.1186/1471-2415-10-31
   Chen W, 2010, P NATL ACAD SCI USA, V107, P7401, DOI 10.1073/pnas.0912702107
   Cimarolli VR, 2016, CLIN OPHTHALMOL, V10, P55, DOI 10.2147/OPTH.S80489
   Clemons TE, 2006, ARCH OPHTHALMOL-CHIC, V124, P537
   Cougnard-Greoire A, 2015, J NUTR, V145, P1865, DOI 10.3945/jn.115.214387
   Day S, 2012, ARCH OPHTHALMOL-CHIC, V130, P1070, DOI 10.1001/archophthalmol.2012.439
   Fletcher AE, 2008, ARCH OPHTHALMOL-CHIC, V126, P1396, DOI 10.1001/archopht.126.10.1396
   Golan S, 2011, EYE, V25, P1122, DOI 10.1038/eye.2011.174
   Graffe A, 2012, J AM GERIATR SOC, V60, P1367, DOI 10.1111/j.1532-5415.2012.04015.x
   Hibler EA, 2010, J STEROID BIOCHEM, V121, P438, DOI 10.1016/j.jsbmb.2010.03.052
   Holick MF, 2007, NEW ENGL J MED, V357, P266, DOI 10.1056/NEJMra070553
   Holland B., 1991, MCCANCE WIDDOWSONS C, V5
   Institute of Medicine, 2011, DIETARY REFERENCE IN
   Itty S, 2014, RETINA-J RET VIT DIS, V34, P1779, DOI 10.1097/IAE.0000000000000178
   Karami S, 2010, INT J ENDOCRINOL, V2010, DOI 10.1155/2010/879362
   Kim EC, 2014, INVEST OPHTH VIS SCI, V55, P4823, DOI 10.1167/iovs.14-14763
   Lengqvist J, 2004, MOL CELL PROTEOMICS, V3, P692, DOI 10.1074/mcp.M400003-MCP200
   Loprinzi PD, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0125394
   Millen AE, 2015, JAMA OPHTHALMOL, V133, P1171, DOI 10.1001/jamaophthalmol.2015.2715
   Millen AE, 2011, ARCH OPHTHALMOL-CHIC, V129, P481, DOI 10.1001/archophthalmol.2011.48
   Morrison Margaux A., 2011, Human Genomics, V5, P538
   Nitsch D, 2008, OPHTHALMOLOGY, V115, P1904, DOI 10.1016/j.ophtha.2008.06.035
   Parekh N, 2007, ARCH OPHTHALMOL-CHIC, V125, P661, DOI 10.1001/archopht.125.5.661
   Pham TQ, 2006, GERONTOLOGY, V52, P353, DOI 10.1159/000094984
   Purcell S, 2007, AM J HUM GENET, V81, P559, DOI 10.1086/519795
   Reins RY, 2015, EXP EYE RES, V134, P101, DOI 10.1016/j.exer.2015.02.019
   Singh A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0070948
   Theodoratou E, 2014, BMJ-BRIT MED J, V348, DOI 10.1136/bmj.g2035
   Wang TJ, 2010, LANCET, V376, P180, DOI 10.1016/S0140-6736(10)60588-0
   Willett WC, 1997, AM J CLIN NUTR, V65, P1220, DOI 10.1093/ajcn/65.4.1220S
   Williams RL, 2000, BIOMETRICS, V56, P645, DOI 10.1111/j.0006-341X.2000.00645.x
   Wong CW, 2014, KIDNEY INT, V85, P1290, DOI 10.1038/ki.2013.491
NR 39
TC 17
Z9 17
U1 1
U2 11
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0161-6420
EI 1549-4713
J9 OPHTHALMOLOGY
JI Ophthalmology
PD JAN
PY 2017
VL 124
IS 1
BP 90
EP 96
DI 10.1016/j.ophtha.2016.09.007
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA EK4KZ
UT WOS:000393896900027
PM 28029444
OA Green Submitted, Bronze, Green Accepted
DA 2022-11-30
ER

PT J
AU Frennesson, CI
   Nilsson, SEG
AF Frennesson, CI
   Nilsson, SEG
TI Encouraging results of photodynamic therapy with visudyne in a clinical
   patient material of age-related macular degeneration
SO ACTA OPHTHALMOLOGICA SCANDINAVICA
LA English
DT Article
DE photodynamic therapy; verteporfin; choroidal neovascularization;
   age-related macular degeneration
ID SUBFOVEAL CHOROIDAL NEOVASCULARIZATION; REPORT NO. 1; LASER
   PHOTOCOAGULATION; VERTEPORFIN THERAPY; PATHOLOGICAL MYOPIA; TRIAL;
   LESIONS; TAP
AB Purpose: To investigate the effects of photodynamic therapy (PDT) on subfoveal choroidal neovascularization (CNV) in age-related macular degeneration (AMD) in a Swedish patient material with smaller lesions than those investigated in the TAP (Treatment of Age-related Macular Degeneration with Photodynamic Therapy) and VIP (Verteporfin in Photodynamic Therapy) Studies.
   Methods: Photodynamic therapy with verteporfin was performed according to the results and recommendations of the TAP and VIP Studies. The patients were followed up for 12 months and retreatment was performed every 12 weeks when leakage from CNV was present. Of the 100 eyes in the first 100 patients with a follow-up period of 12 months, 59% had a predominantly classic lesion, 36% had an occult-only lesion and 5% had a minimally classic lesion. The greatest linear dimension (GLD) was less than or equal to3 MPS (Macular Photocoagulation Study) disc diameters (DD) in 73%, 39% and 20% of lesions, respectively, for the three groups. The actual lesion area was less than or equal to3 MPS disc areas (DA) in 85%, 50% and 40% of lesions, respectively. There was a positive correlation (p < 0.05) between the duration of symptoms and GLD, as well as between the duration of symptoms and the lesion area (p < 0.02).
   Results: At 12 months, visual acuity had remained stable or increased by greater than or equal to3 lines (ETDRS) in 61% of patients with predominantly classic lesions, in 61% of patients with occult-only lesions and in 60% of patients with minimally classic lesions. Leakage had stopped after 2.9 +/- 0.9 treatments in 77% of the total group of patients.
   Conclusion: The visual outcome was comparable to those of the TAP and VIP Studies (p > 0.3). Regarding the effect on leakage, however, our results are far better than those of the TAP and VIP Studies. The proportion of patients in which leakage had stopped was almost three times that of the TAP (27%) and VIP (26%) Studies. It seems likely that this difference was caused by the fact that the lesions in our study were much smaller, on average, than those in the TAP and VIP Studies.
C1 Linkoping Univ, Dept Ophthalmol, SE-58185 Linkoping, Sweden.
C3 Linkoping University
RP Frennesson, CI (通讯作者)，Linkoping Univ, Dept Ophthalmol, SE-58185 Linkoping, Sweden.
EM Christina.Frennesson@lio.se
CR Arnold J, 2001, OPHTHALMOLOGY, V108, P841
   Arnold J, 2001, AM J OPHTHALMOL, V131, P541
   Barbazetto I, 2003, ARCH OPHTHALMOL-CHIC, V121, P1253
   Blinder KJ, 2003, AM J OPHTHALMOL, V136, P407, DOI 10.1016/S0002-9394(03)00223-X
   Blinder KJ, 2003, OPHTHALMOLOGY, V110, P667, DOI 10.1016/S0161-6420(02)01998-X
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   HAWKINS BS, 1990, ARCH OPHTHALMOL-CHIC, V108, P816
   HAWKINS BS, 1991, ARCH OPHTHALMOL-CHIC, V109, P1109
   STERNBERG P, 1991, ARCH OPHTHALMOL-CHIC, V109, P1220
   TAP and VIP Study Group, 2002, RETINA, V22, P6
NR 10
TC 17
Z9 17
U1 0
U2 2
PU BLACKWELL MUNKSGAARD
PI COPENHAGEN
PA 35 NORRE SOGADE, PO BOX 2148, DK-1016 COPENHAGEN, DENMARK
SN 1395-3907
J9 ACTA OPHTHALMOL SCAN
JI Acta Ophthalmol. Scand.
PD DEC
PY 2004
VL 82
IS 6
BP 645
EP 650
DI 10.1111/j.1600-0420.2004.00368.x
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 884NT
UT WOS:000226093000003
PM 15606458
OA Bronze
DA 2022-11-30
ER

PT J
AU Ebeling, MC
   Fisher, CR
   Kapphahn, RJ
   Stahl, MR
   Shen, SC
   Qu, J
   Montezuma, SR
   Ferrington, DA
AF Ebeling, Mara C.
   Fisher, Cody R.
   Kapphahn, Rebecca J.
   Stahl, Madilyn R.
   Shen, Shichen
   Qu, Jun
   Montezuma, Sandra R.
   Ferrington, Deborah A.
TI Inflammasome Activation in Retinal Pigment Epithelium from Human Donors
   with Age-Related Macular Degeneration
SO CELLS
LA English
DT Article
DE age-related macular degeneration; complement factor H; inflammasome;
   inflammation; retinal pigment epithelium
ID COMPLEMENT FACTOR-H; NLRP3 INFLAMMASOME; Y402H POLYMORPHISM;
   MITOCHONDRIAL-DNA; CELLS; QUANTIFICATION; RECOGNITION; CYTOKINES;
   VARIANT; SYSTEM
AB Age-related macular degeneration (AMD), the leading cause of blindness in the elderly, is characterized by the death of retinal pigment epithelium (RPE) and photoreceptors. One of the risk factors associated with developing AMD is the single nucleotide polymorphism (SNP) found within the gene encoding complement factor H (CFH). Part of the innate immune system, CFH inhibits alternative complement pathway activation. Multi-protein complexes called inflammasomes also play a role in the innate immune response. Previous studies reported that inflammasome activation may contribute to AMD pathology. In this study, we used primary human adult RPE cell cultures from multiple donors, with and without AMD, that were genotyped for the Y402H CFH risk allele. We found complement and inflammasome-related genes and proteins at basal levels in RPE tissue and cell cultures. Additionally, treatment with rotenone, bafilomycin A, and ATP led to inflammasome activation. Overall, the response to priming and activation was similar, irrespective of disease state or CFH genotype. While these data show that the inflammasome is present and active in RPE, our results suggest that inflammasome activation may not contribute to early AMD pathology.
C1 [Ebeling, Mara C.; Fisher, Cody R.; Kapphahn, Rebecca J.; Stahl, Madilyn R.; Montezuma, Sandra R.; Ferrington, Deborah A.] Univ Minnesota, Dept Ophthalmol & Visual Neurosci, Minneapolis, MN 55455 USA.
   [Fisher, Cody R.; Ferrington, Deborah A.] Univ Minnesota, Grad Program Biochem Mol Biol & Biophys, Minneapolis, MN 55455 USA.
   [Shen, Shichen; Qu, Jun] SUNY Buffalo, Dept Pharmaceut Sci, Buffalo, NY 14203 USA.
   [Ferrington, Deborah A.] Doheny Eye Inst, Pasadena, CA 91103 USA.
C3 University of Minnesota System; University of Minnesota Twin Cities;
   University of Minnesota System; University of Minnesota Twin Cities;
   State University of New York (SUNY) System; State University of New York
   (SUNY) Buffalo; Doheny Eye Institute
RP Ferrington, DA (通讯作者)，Univ Minnesota, Dept Ophthalmol & Visual Neurosci, Minneapolis, MN 55455 USA.; Ferrington, DA (通讯作者)，Univ Minnesota, Grad Program Biochem Mol Biol & Biophys, Minneapolis, MN 55455 USA.; Ferrington, DA (通讯作者)，Doheny Eye Inst, Pasadena, CA 91103 USA.
EM ebeli017@umn.edu; fishe765@umn.edu; kapph001@umn.edu; stahl154@umn.edu;
   shichens@buffalo.edu; junqu@buffalo.edu; smontezu@umn.edu;
   dferrington@doheny.org
OI Ferrington, Deborah/0000-0003-2561-7464
FU National Institutes of Health (NIH) National Eye Institute [R01EY026012,
   R01EY028554, F31-EY031558, T32-EY025187]; NIH National Institute on
   Aging (NIA) [T32-AG029796]; Diana Jacobs Kalman/AFAR Scholarships for
   Research in the Biology of Aging; VitreoRetinal Surgery Foundation
   Fellowship; Elaine and Robert Larson Endowed Vision Chair; Winston and
   Maxine Wallin Neuroscience Discovery Fund Award; Lindsay Family
   Foundation
FX This research was funded by the National Institutes of Health (NIH)
   National Eye Institute; R01EY026012 and R01EY028554 (to D.A.F.),
   F31-EY031558 (to C.R.F.), T32-EY025187 (to C.R.F.), the NIH National
   Institute on Aging (NIA) T32-AG029796 (to C.R.F.), Diana Jacobs
   Kalman/AFAR Scholarships for Research in the Biology of Aging (to
   C.R.F.), VitreoRetinal Surgery Foundation Fellowship (to C.R.F.); the
   Elaine and Robert Larson Endowed Vision Chair (to D.A.F.); Winston and
   MaxineWallin Neuroscience Discovery Fund Award (to D.A.F.), an anonymous
   benefactor for Macular Degeneration Research; and the Lindsay Family
   Foundation. None of the funding agencies had a role in the study design,
   in the collection, analysis and interpretation of data, in writing the
   manuscript, or in the decision to submit the manuscript for publication.
CR An B, 2015, ANAL CHEM, V87, P4023, DOI 10.1021/acs.analchem.5b00350
   Anderson DH, 2010, PROG RETIN EYE RES, V29, P95, DOI 10.1016/j.preteyeres.2009.11.003
   Arbore G, 2016, EUR J IMMUNOL, V46, P1563, DOI 10.1002/eji.201546131
   Borras C, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-50420-9
   Brandstetter C, 2015, J BIOL CHEM, V290, P31189, DOI 10.1074/jbc.M115.671180
   Brandstetter C, 2015, J MOL MED, V93, P905, DOI 10.1007/s00109-015-1275-1
   Bronner Denise N, 2016, Bio Protoc, V6, DOI 10.21769/BioProtoc.1839
   Buschini E, 2015, CLIN OPHTHALMOL, V9, P563, DOI 10.2147/OPTH.S59724
   Cao SJ, 2016, BRIT J OPHTHALMOL, V100, P713, DOI 10.1136/bjophthalmol-2015-307213
   Cao SJ, 2013, AM J OPHTHALMOL, V156, P1176, DOI 10.1016/j.ajo.2013.08.003
   Cerniauskas E, 2020, STEM CELL TRANSL MED, V9, P1585, DOI 10.1002/sctm.20-0211
   Clark SJ, 2010, BIOCHEM SOC T, V38, P1342, DOI 10.1042/BST0381342
   Dib B, 2015, BBA-MOL CELL RES, V1853, P2897, DOI 10.1016/j.bbamcr.2015.08.012
   Doyle SL, 2012, NAT MED, V18, P791, DOI 10.1038/nm.2717
   Ebeling MC, 2021, CELLS-BASEL, V10, DOI 10.3390/cells10040789
   Ebeling MC, 2020, REDOX BIOL, V34, DOI 10.1016/j.redox.2020.101552
   Ferrington DA, 2017, REDOX BIOL, V13, P255, DOI 10.1016/j.redox.2017.05.015
   Fisher CR, 2022, ANTIOXIDANTS-BASEL, V11, DOI 10.3390/antiox11040605
   Gangnon RE, 2012, ARCH OPHTHALMOL-CHIC, V130, P1169, DOI 10.1001/archophthalmol.2012.693
   Garcia-Layana A, 2017, CLIN INTERV AGING, V12, P1579, DOI 10.2147/CIA.S142685
   Gnanaguru G, 2016, INVEST OPHTH VIS SCI, V57, P4704, DOI 10.1167/iovs.15-18663
   Golestaneh N, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2016.453
   Gong J, 2020, STEM CELL TRANSL MED, V9, P364, DOI 10.1002/sctm.19-0321
   Guha S, 2013, FASEB J, V27, P4500, DOI 10.1096/fj.13-236166
   Hallam D, 2017, STEM CELLS, V35, P2305, DOI 10.1002/stem.2708
   Hytti M, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22136800
   Kaneko H, 2011, NATURE, V471, P325, DOI 10.1038/nature09830
   Karunadharma PP, 2010, INVEST OPHTH VIS SCI, V51, P5470, DOI 10.1167/iovs.10-5429
   Kosmidou C, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-017-17634-1
   Kumar H, 2011, INT REV IMMUNOL, V30, P16, DOI 10.3109/08830185.2010.529976
   Latz E, 2013, NAT REV IMMUNOL, V13, P397, DOI 10.1038/nri3452
   Leffler J, 2010, J BIOL CHEM, V285, P3766, DOI 10.1074/jbc.M109.045427
   Liszewski MK, 2013, IMMUNITY, V39, P1143, DOI 10.1016/j.immuni.2013.10.018
   Martin M, 2016, CELL DEATH DIFFER, V23, P903, DOI 10.1038/cdd.2015.164
   Mitchell CH, 2001, J PHYSIOL-LONDON, V534, P193, DOI 10.1111/j.1469-7793.2001.00193.x
   Miyagishima KJ, 2016, STEM CELL TRANSL MED, V5, P1562, DOI 10.5966/sctm.2016-0037
   Mohr LKM, 2015, INVEST OPHTH VIS SCI, V56, P6404, DOI 10.1167/iovs.15-16898
   Olsen TW, 2004, INVEST OPHTH VIS SCI, V45, P4484, DOI 10.1167/iovs.04-0342
   Piippo N, 2014, BBA-MOL CELL RES, V1843, P3038, DOI 10.1016/j.bbamcr.2014.09.015
   Rickman CB, 2013, INVEST OPHTH VIS SCI, V54, pORSF68, DOI 10.1167/iovs.13-12757
   Ross RJ, 2007, EXPERT REV OPHTHALMO, V2, P443, DOI 10.1586/17469899.2.3.443
   Schafer N, 2020, ANTIOXIDANTS-BASEL, V9, DOI 10.3390/antiox9090793
   Shen SC, 2018, ANAL CHEM, V90, P10350, DOI 10.1021/acs.analchem.8b02172
   Shen XM, 2018, P NATL ACAD SCI USA, V115, pE4767, DOI 10.1073/pnas.1800541115
   Sofat R, 2012, INT J EPIDEMIOL, V41, P250, DOI 10.1093/ije/dyr204
   Strauss O, 2005, PHYSIOL REV, V85, P845, DOI 10.1152/physrev.00021.2004
   Tarallo V, 2012, CELL, V149, P847, DOI 10.1016/j.cell.2012.03.036
   Terluk MR, 2015, J NEUROSCI, V35, P7304, DOI 10.1523/JNEUROSCI.0190-15.2015
   Tseng WA, 2013, INVEST OPHTH VIS SCI, V54, P110, DOI 10.1167/iovs.12-10655
   Wang X, 2021, ANAL CHEM, V93, P4884, DOI 10.1021/acs.analchem.0c05002
   Wang YJ, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17010073
NR 51
TC 0
Z9 0
U1 0
U2 0
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2073-4409
J9 CELLS-BASEL
JI Cells
PD JUL
PY 2022
VL 11
IS 13
AR 2075
DI 10.3390/cells11132075
PG 18
WC Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology
GA 2X9LI
UT WOS:000825517900001
PM 35805159
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Patel, PJ
   Chen, FK
   Ikeji, F
   Richardson, M
   Da Cruz, L
   Tufail, A
AF Patel, Praveen J.
   Chen, Fred K.
   Ikeji, Felicia
   Richardson, Matthew
   Da Cruz, Lyndon
   Tufail, Adnan
TI Intrasession repeatability of optical coherence tomography measures in
   active neovascular age-related macular degeneration
SO ACTA OPHTHALMOLOGICA
LA English
DT Article
DE age-related macular degeneration; clinical methods; optical coherence
   tomography; repeatability
ID RETINAL THICKNESS MEASUREMENTS; REPRODUCIBILITY; RANIBIZUMAB
AB Objectives: To determine the repeatability of Stratus optical coherence tomography fast macular thickness map analysis in patients with active neovascular age-related macular degeneration (nAMD).
   Methods: Consecutive pairs of scans from 112 eyes of 112 consecutive patients with active nAMD were analyzed. The Bland-Altman coefficient of repeatability (CR) was calculated for each retinal thickness or volume measure.
   Results: The CR for the central 1 mm macular subfield was 59 mu m (18% of retinal thickness) and did not exceed 69 mu m in any subfield. There was much poorer repeatability for the center-point thickness (CPT) measure (CR of 78 mu m; 24%). However, in the subgroup of 38 patients with no Stratus software low analysis confidence message on either analysis map, the revised CR (42 mu m) for the CPT measure and the A1 subfield (40 mu m) were similar.
   Conclusion: Optical coherence tomography-derived retinal thickness measurements are subject to measurement variability in patients with active nAMD. The results suggest a change criterion of more than 59 mu m in central 1 mm (A1) subfield macular thickness is necessary to distinguish true clinical change from measurement variability in these patients.
C1 [Patel, Praveen J.; Chen, Fred K.; Ikeji, Felicia; Richardson, Matthew; Da Cruz, Lyndon; Tufail, Adnan] Moorfields Eye Hosp, London EC1V 2PD, England.
C3 University of London; University College London; Moorfields Eye Hospital
   NHS Foundation Trust
RP Patel, PJ (通讯作者)，Moorfields Eye Hosp, 162 City Rd, London EC1V 2PD, England.
EM praveen.patel@moorfields.nhs.uk
RI , Fred/B-8158-2013
OI , Fred/0000-0003-2809-9930; Tufail, Adnan/0000-0001-6131-7640
CR Bland JM, 1996, BRIT MED J, V313, P744
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Browning DJ, 2004, AM J OPHTHALMOL, V138, P477, DOI 10.1016/j.ajo.2004.03.014
   Danis RP, 2008, ARCH OPHTHALMOL-CHIC, V126, P45, DOI 10.1001/archopht.126.1.45
   Fung AE, 2007, AM J OPHTHALMOL, V143, P566, DOI 10.1016/j.ajo.2007.01.028
   Hammer DX, 2005, J BIOMED OPT, V10, DOI 10.1117/1.1896967
   HUANG D, 1991, SCIENCE, V254, P1178, DOI 10.1126/science.1957169
   Krzystolik MG, 2007, OPHTHALMOLOGY, V114, P1520, DOI 10.1016/j.ophtha.2006.10.055
   Massin P, 2001, ARCH OPHTHALMOL-CHIC, V119, P1135, DOI 10.1001/archopht.119.8.1135
   Patel PJ, 2008, INVEST OPHTH VIS SCI, V49, P1084, DOI 10.1167/iovs.07-1203
   Patel PJ, 2009, INVEST OPHTH VIS SCI, V50, P399, DOI 10.1167/iovs.08-1697
   Paunescu LA, 2004, INVEST OPHTH VIS SCI, V45, P1716, DOI 10.1167/iovs.03-0514
   Polito A, 2005, ARCH OPHTHALMOL-CHIC, V123, P1330, DOI 10.1001/archopht.123.10.1330
   Ray R, 2005, AM J OPHTHALMOL, V139, P18, DOI 10.1016/j.ajo.2004.07.050
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Sadda SR, 2006, OPHTHALMOLOGY, V113, P285, DOI 10.1016/j.ophtha.2005.10.005
   Sadda SR, 2007, INVEST OPHTH VIS SCI, V48, P839, DOI 10.1167/iovs.06-0554
   Wojtkowski M, 2004, AM J OPHTHALMOL, V138, P412, DOI 10.1016/j.ajo.2004.04.049
NR 18
TC 7
Z9 7
U1 0
U2 3
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 1755-375X
J9 ACTA OPHTHALMOL
JI Acta Ophthalmol.
PD SEP
PY 2011
VL 89
IS 6
BP 526
EP 532
DI 10.1111/j.1755-3768.2009.01761.x
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 812BE
UT WOS:000294261900022
PM 19900204
OA Bronze
DA 2022-11-30
ER

PT J
AU Warden, C
   Barnett, JM
   Brantley, MA
AF Warden, Cassandra
   Barnett, Joshua M.
   Brantley, Milam A., Jr.
TI Taurocholic acid inhibits features of age-related macular degeneration
   in vitro
SO EXPERIMENTAL EYE RESEARCH
LA English
DT Article
DE Age-related macular degeneration; Bile acids; Taurocholic acid; Retinal
   pigment epithelium; Choroidal endothelial cells
ID RETINAL-PIGMENT EPITHELIUM; TAUROURSODEOXYCHOLIC ACID; OXIDATIVE STRESS;
   TUDCA; PERMEABILITY; TRANSITION; MOUSE; BILE
AB Previous metabolomics studies from our lab found altered plasma levels of bile acids in patients with age-related macular degeneration (AMD) compared to controls. In this study, we investigated the ability of the bile acid taurocholic acid (TCA) to inhibit features of AMD modeled in vitro. Paraquat was used to induce oxidative stress in HRPEpiC primary retinal pigment epithelial (RPE) cells. Cells were treated with 300 mu M paraquat alone or with TCA (10, 50, 100, 200, or 500 mu M). RPE tight junction integrity was assessed via ZO-1 immunofluorescence and transepithelial electrical resistance (TEER) measurements. RF/6A macaque choroidal endothelial cells were treated with 100 ng/mL vascular endothelial growth factor (VEGF) to induce angiogenesis. The effect of TCA on VEGF-induced angiogenesis was evaluated with cell proliferation, cell migration, and tube formation assays. Addition of TCA at 100 (P = 8.6 x 10(-4)), 200 (P = 0.0035), and 500 (P = 2.1 x 10(-4)) mu M resulted in significant preservation of TEER in paraquat treated cells. In RF/6A cells, TCA did not significantly affect VEGF-induced cell proliferation. VEGF-induced migration of RF/6A cells was significantly inhibited at TCA concentrations of 100 (P = 0.010), 200 (P = 0.023) and 500 (P = 0.0049) mu M. VEGF-induced tube formation was significantly inhibited when treated with 200 (P = 0.014) and 500 (P = 7.1 x 10(-4)) mu M TCA. In vitro, TCA promoted RPE cell integrity and diminished VEGF-induced choroidal endothelial cell migration and tube formation. This suggests that TCA may have protective effects against both degenerative and neovascular AMD.
C1 [Warden, Cassandra; Barnett, Joshua M.; Brantley, Milam A., Jr.] Vanderbilt Univ, Med Ctr, Vanderbilt Eye Inst, 2311 Pierce Ave, Nashville, TN 37232 USA.
C3 Vanderbilt University
RP Brantley, MA (通讯作者)，Vanderbilt Univ, Med Ctr, Vanderbilt Eye Inst, 2311 Pierce Ave, Nashville, TN 37232 USA.
EM milam.brantley@vumc.org
OI Barnett, Joshua/0000-0003-1752-3599
FU National Institutes of Health [R01 EY022618, P30 EY008126]; Edward N. &
   Della L. Thome Memorial Foundation Awards Program in Age-Related Macular
   Degeneration Research; Research to Prevent Blindness
FX This work was supported by National Institutes of Health grants R01
   EY022618 and P30 EY008126, a grant from the Edward N. & Della L. Thome
   Memorial Foundation Awards Program in Age-Related Macular Degeneration
   Research, and an unrestricted departmental grant to Vanderbilt
   University Medical Center from Research to Prevent Blindness.
CR Boatright JH, 2006, MOL VIS, V12, P1706
   Boatright Jeffrey H, 2009, J Ocul Biol Dis Infor, V2, P149
   BOTLA R, 1995, J PHARMACOL EXP THER, V272, P930
   Carmeliet P, 2011, NATURE, V473, P298, DOI 10.1038/nature10144
   Chiang JYL, 2019, ANNU REV NUTR, V39, P175, DOI 10.1146/annurev-nutr-082018-124344
   Drack AV, 2012, INVEST OPHTH VIS SCI, V53, P100, DOI 10.1167/iovs.11-8544
   Drechsel DA, 2009, TOXICOL SCI, V112, P427, DOI 10.1093/toxsci/kfp223
   Fernandez-Sanchez L, 2011, INVEST OPHTH VIS SCI, V52, P4998, DOI 10.1167/iovs.11-7496
   Froger N, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0042017
   Garcia-Ramirez M, 2011, METHODS MOL BIOL, V763, P179, DOI 10.1007/978-1-61779-191-8_12
   Hanafi NI, 2018, BIOMOLECULES, V8, DOI 10.3390/biom8040159
   Huang M, 2019, ENVIRON TOXICOL, V34, P548, DOI 10.1002/tox.22723
   Husain N, 2020, AMINO ACIDS, V52, P35, DOI 10.1007/s00726-019-02807-1
   Kim KA, 2018, LARYNGOSCOPE, V128, pE393, DOI 10.1002/lary.27510
   Kim YS, 2017, ADV EXP MED BIOL, V975, P1165, DOI 10.1007/978-94-024-1079-2_93
   Kundu S, 2017, MEDCHEMCOMM, V8, P2248, DOI 10.1039/c7md00475c
   Lawson EC, 2016, ADV EXP MED BIOL, V854, P431, DOI 10.1007/978-3-319-17121-0_57
   Lee E, 2009, INT J CANCER, V124, P2755, DOI 10.1002/ijc.24239
   Li FT, 2015, OPHTHALMIC RES, V53, P109, DOI 10.1159/000369824
   Li SY, 2017, IND HEALTH, V55, P108, DOI 10.2486/indhealth.2016-0044
   Luu J, 2018, P NATL ACAD SCI USA, V115, P2866, DOI 10.1073/pnas.1721033115
   Mantopoulos D, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024245
   Mitchell SL, 2018, INVEST OPHTH VIS SCI, V59, P4978, DOI 10.1167/iovs.18-25137
   Murase H, 2015, INVEST OPHTH VIS SCI, V56, P2511, DOI 10.1167/iovs.14-15962
   Narimatsu T, 2013, INVEST OPHTH VIS SCI, V54, P4555, DOI 10.1167/iovs.12-11572
   Omura T, 2013, BIOCHEM BIOPH RES CO, V432, P689, DOI 10.1016/j.bbrc.2013.01.131
   Osborn MP, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0072737
   Oveson BC, 2011, J NEUROCHEM, V116, P144, DOI 10.1111/j.1471-4159.2010.07092.x
   Pardue MT, 2018, PROG RETIN EYE RES, V65, P50, DOI 10.1016/j.preteyeres.2018.02.002
   Pennington KL, 2016, EYE VISION, V3, DOI 10.1186/s40662-016-0063-5
   Phillips MJ, 2008, INVEST OPHTH VIS SCI, V49, P2148, DOI 10.1167/iovs.07-1012
   Wang CF, 2016, J ETHNOPHARMACOL, V185, P162, DOI 10.1016/j.jep.2016.03.026
   Woo SJ, 2010, J OCUL PHARMACOL TH, V26, P223, DOI 10.1089/jop.2010.0012
   Xie LS, 2016, EXP TOXICOL PATHOL, V68, P69, DOI 10.1016/j.etp.2015.09.010
   Yoon SY, 2013, CORNEA, V32, P1488, DOI 10.1097/ICO.0b013e3182a48009
   Zhu Y, 2016, J CELL MOL MED, V20, P688, DOI 10.1111/jcmm.12769
NR 36
TC 10
Z9 11
U1 1
U2 2
PU ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD
PI LONDON
PA 24-28 OVAL RD, LONDON NW1 7DX, ENGLAND
SN 0014-4835
EI 1096-0007
J9 EXP EYE RES
JI Exp. Eye Res.
PD APR
PY 2020
VL 193
AR 107974
DI 10.1016/j.exer.2020.107974
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA KZ8MD
UT WOS:000523511400017
PM 32067977
DA 2022-11-30
ER

PT J
AU Parodi, MB
   Da Pozzo, S
   Ravalico, G
AF Parodi, MB
   Da Pozzo, S
   Ravalico, G
TI Angiographic pattern of recurrent choroidal neovascularization in
   age-related macular degeneration
SO EYE
LA English
DT Article
DE age-related macular degeneration; recurrent choroidal
   neovascularization; fluorescein angiography; indocyanine green
   angiography
ID INDOCYANINE GREEN VIDEOANGIOGRAPHY; KRYPTON LASER PHOTOCOAGULATION;
   RANDOMIZED CLINICAL-TRIALS; LESIONS; MACULOPATHY; PERSISTENT
AB Purpose To evaluate the angiographic characteristics of recurrent choroidal neovascularization (R-CNV) in age-related macular degeneration (AMD).
   Methods A prospective investigation on 107 consecutive patients with exudative AMD and CNV not involving the fovea was conducted. Fluorescein angiography ( FA) and indocyanine green angiography (ICGA) were planned before krypton laser treatment, and after 3 weeks, 2, 3, 4, 6, 9, 12, 18, and 24 months from photocoagulation. Laser treatment was FA-guided in eyes with classic CNV, and ICGA-guided in eyes with occult CNV on FA.
   Results At baseline on FA, 23.3% had classic CNV, whereas, 76.6% showed occult CNV. On ICGA, CNV assumed a focal and a plaque pattern in 81.3 and 18.6% of cases, respectively. Overall, post-laser CNVs occurred in 56 eyes. FA identified well-defined and ill-defined R-CNV in 25 and 75% of cases, respectively. ICGA identified three different R-CNV patterns: focal, annular, and plaque. Focal R-CNV was defined as a single dot-like hyperfluorescence, which was detected in 69.6% of cases, with subfoveal location in half of them. Annular R-CNV was identified by a hyperfluorescent lesion, partially or completely encircling treated area, which was visible in 19.6% of cases, all with subfoveal involvement. Plaque R-CNV was defined as a hyperfluorescent lesion larger than 1 disc diameter in size, and was seen in 10.7% of cases, all with subfoveal location.
   Conclusions ICGA is able to improve R-CNV visualization identifying three different R-CNV patterns. Focal R-CNV is the most frequent pattern and can be re-treated in half of the cases.
C1 Univ Trieste, Eye Clin, I-34129 Trieste, Italy.
C3 University of Trieste
RP Parodi, MB (通讯作者)，Univ Trieste, Eye Clin, Piazza Osped 1, I-34129 Trieste, Italy.
EM maubp@yahoo.it
RI Parodi, Maurizio Battaglia/K-7876-2016
OI Battaglia Parodi, Maurizio/0000-0002-0385-7961
CR Chen CJ, 1999, OPHTHALMOLOGY, V106, P925, DOI 10.1016/S0161-6420(99)00511-4
   Da Pozzo Stefano, 2001, International Ophthalmology, V24, P187, DOI 10.1023/A:1022539204849
   HAWKINS BS, 1993, ARCH OPHTHALMOL-CHIC, V111, P1200
   HAWKINS BS, 1990, ARCH OPHTHALMOL-CHIC, V108, P816
   HAWKINS BS, 1991, ARCH OPHTHALMOL-CHIC, V109, P1109
   MAGUIRE MG, 1990, ARCH OPHTHALMOL-CHIC, V108, P825
   MAGUIRE MG, 1986, ARCH OPHTHALMOL-CHIC, V104, P503
   Parodi MB, 2001, GRAEF ARCH CLIN EXP, V239, P900, DOI 10.1007/s00417-001-0387-1
   Regillo CD, 1998, OPHTHALMOLOGY, V105, P1821, DOI 10.1016/S0161-6420(98)91022-3
   Reichel E, 1995, OPHTHALMIC SURG LAS, V26, P513
   SCHACHAT AP, 1994, ARCH OPHTHALMOL-CHIC, V112, P500
   SORENSON JA, 1994, ARCH OPHTHALMOL-CHIC, V112, P473, DOI 10.1001/archopht.1994.01090160049021
   SORENSON JA, 1985, OPHTHALMOLOGY, V92, P1059
   SORENSON JA, 1997, INDOCYANINE GREEN AN, P217
   YANNUZZI LA, 1992, RETINA-J RET VIT DIS, V12, P191, DOI 10.1097/00006982-199212030-00003
NR 15
TC 0
Z9 0
U1 0
U2 0
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0950-222X
EI 1476-5454
J9 EYE
JI Eye
PD JUL
PY 2004
VL 18
IS 7
BP 685
EP 690
DI 10.1038/sj.eye.6701316
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 835DC
UT WOS:000222459200005
PM 14739913
OA Bronze
DA 2022-11-30
ER

PT J
AU Liutkeviciene, R
   Vilkeviciute, A
   Slavinskaite, A
   Petrauskaite, A
   Tatarunas, V
   Kriauciuniene, L
AF Liutkeviciene, Rasa
   Vilkeviciute, Alvita
   Slavinskaite, Aiste
   Petrauskaite, Aiste
   Tatarunas, Vacis
   Kriauciuniene, Loresa
TI Evaluation of serum SLCO1B1 levels and genetic variants of SLCO1B1
   rs4149056 and rs2306283 in patients with early and exudative age-related
   macular degeneration
SO GENE
LA English
DT Article
DE Age-related macular degeneration; SLCO1B1; Gene polymorphisms; Serum
   SLCO1B1
ID CARDIOVASCULAR RISK-FACTORS; STATIN-INDUCED MYOPATHY; OATP-C;
   POLYMORPHISMS; DISEASE; ATORVASTATIN; EXPRESSION; ASSOCIATION;
   MACULOPATHY; TRANSPORTER
AB Purpose: To determine SLCOIBI rs4149056 and rs2306283 gene polymorphisms and SLCO1B1 serum levels in patients with early and exudative age-related macular degeneration.
   Materials and methods: The study enrolled 206 patients with exudative AMD, 253 patients with early AMD and 301 control subjects. DNA was extracted from peripheral venous blood leukocytes using commercial kits. Genotyping of SLCO1B1 rs4149056 and rs2306283 was carried out using a real-time polymerase chain reaction (RT-PCR) method. Serum SLCO1B1 levels were measured using SLCO1B1 ELISA kit.
   Results: We found statistically significant differences in genotype (T/T, T/C and C/C) distribution of SLCO1B1 rs4149056 variant between the patients with exudative AMD and control group (52.4%, 47.6% and 0% vs. 64.8%, 31.6% and 13.7%, respectively, p < 0.001). Univariate binary logistic regression analysis showed that age was a risk factor for exudative AMD development. Also, T/C variant was associated with 1.9-fold increased Odds ratio of exudative AMD development under a codominant model (OR = 1.863; 95% CI: 1.290;2.689; p < 0.001). The results remained of the same statistical significance after multivariate analysis. On the other hand, C allele was associated with 1.6-fold increased odds ratio of exudative AMD development (OR = 1.563; 95% CI: 1.035;2.359; p = 0.034) only after adjustment for age. No significant associations were found in analysis of genotypes and alleles at rs2306283.
   Serum SLCO1B1 concentration was significantly higher in early AMD patients than in healthy controls (median, IQR: 2.92 ng/ml, 5.01 ng/ml versus 1.26 ng/ml, 2.63 ng/ml, respectively, p = 0.025), as well as in exudative AMD patients than in controls (median, IQR: 2.72 ng/ml, 5.71 ng/ml versus 1.26 ng/ml, 2.63 ng/ml, respectively, p = 0.002). Furthermore, subjects with rs4149056 T/C genotype had higher SLCO1B1 serum levels than those with T/T genotype (median, IQR: 3.73 ng/ml, 3.14 ng/ml versus 1.23 ng/ml, 1.47 ng/ml, respectively, p = 0.037).
   Conclusion: Our study determined that SLCO1B1 (c.521 T > C) rs4149056 T/C genotype and C allele may be associated with exudative age-related macular degeneration, as well as with elevated serum SLCO1B1 levels. Also, higher serum SLCO1B1 levels were found to be associated with early and exudative age-related macular degeneration.
C1 [Liutkeviciene, Rasa; Kriauciuniene, Loresa] Lithuanian Univ Hlth Sci, Med Acad, Dept Ophthalmol, Eiveniu 2, LT-50161 Kaunas, Lithuania.
   [Liutkeviciene, Rasa; Vilkeviciute, Alvita; Kriauciuniene, Loresa] Lithuanian Univ Hlth Sci, Med Acad, Neurosci Inst, Eiveniu 2, LT-50161 Kaunas, Lithuania.
   [Slavinskaite, Aiste; Petrauskaite, Aiste] Lithuanian Univ Hlth Sci, Med Acad, LT-50009 Kaunas, Lithuania.
   [Tatarunas, Vacis] Lithuanian Univ Hlth Sci, Med Acad, Cardiol Inst, Eiveniu 2, LT-50161 Kaunas, Lithuania.
C3 Lithuanian University of Health Sciences; Lithuanian University of
   Health Sciences; Lithuanian University of Health Sciences; Lithuanian
   University of Health Sciences
RP Liutkeviciene, R (通讯作者)，Dept Ophthalmol, Eiveniu 2, Kaunas, Lithuania.
EM rasa.liutkeviciene@lsmuni.lt
CR [Anonymous], AM J OPHTHALMOL, P668
   [Anonymous], ARCH OPHTHALMOL, V110, P1701
   Brunham LR, 2012, PHARMACOGENOMICS J, V12, P233, DOI 10.1038/tpj.2010.92
   Butt AL, 2011, OPHTHALMOLOGY, V118, P1380, DOI 10.1016/j.ophtha.2010.11.007
   Cackett P, 2008, AM J OPHTHALMOL, V146, P960, DOI 10.1016/j.ajo.2008.06.026
   Carr DF, 2013, CLIN PHARMACOL THER, V94, P695, DOI 10.1038/clpt.2013.161
   Chakravarthy U, 2010, BMC OPHTHALMOL, V10, DOI 10.1186/1471-2415-10-31
   Chen CP, 2008, DRUG METAB DISPOS, V36, P1840, DOI 10.1124/dmd.108.020594
   Colijn JM, 2017, OPHTHALMOLOGY, V124, P1753, DOI 10.1016/j.ophtha.2017.05.035
   Cougnard-Gregoire A, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0090973
   Dahlin A, 2013, MOL PHARMACEUT, V10, P650, DOI 10.1021/mp300429e
   Danik JS, 2013, AM HEART J, V165, P1008, DOI 10.1016/j.ahj.2013.01.025
   de Cordoba SR, 2008, CLIN EXP IMMUNOL, V151, P1, DOI 10.1111/j.1365-2249.2007.03574.x
   de Jong PTVM, 2006, NEW ENGL J MED, V355, P1474, DOI 10.1056/NEJMra062326
   de Keyser CE, 2014, PHARMACOGENET GENOM, V24, P43, DOI 10.1097/FPC.0000000000000018
   Delcourt C, 2001, Ophthalmic Epidemiol, V8, P237, DOI 10.1076/opep.8.4.237.1613
   Donnelly LA, 2011, CLIN PHARMACOL THER, V89, P210, DOI 10.1038/clpt.2010.255
   Gao B, 2002, INVEST OPHTH VIS SCI, V43, P510
   Grigorova M, 2017, J ENDOCR SOC, V1, P560, DOI 10.1210/js.2017-00050
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Hagenbuch B, 2004, PFLUG ARCH EUR J PHY, V447, P653, DOI 10.1007/s00424-003-1168-y
   Hagenbuch B, 2013, MOL ASPECTS MED, V34, P396, DOI 10.1016/j.mam.2012.10.009
   Hyman L, 2000, ARCH OPHTHALMOL-CHIC, V118, P351, DOI 10.1001/archopht.118.3.351
   Joseph C., 2011, RETINA ITS DISORDERS, P830
   Santos PCJL, 2012, EUR J CLIN PHARMACOL, V68, P273, DOI 10.1007/s00228-011-1125-1
   Kameyama Y, 2005, PHARMACOGENET GENOM, V15, P513, DOI 10.1097/01.fpc.0000170913.73780.5f
   Klein R, 1997, OPHTHALMOLOGY, V104, P1804, DOI 10.1016/S0161-6420(97)30023-2
   KLEIN R, 1993, OPHTHALMOLOGY, V100, P406
   Klein Ronald, 2003, Ophthalmology, V110, P1273, DOI 10.1016/S0161-6420(03)00599-2
   Konig J, 2006, N-S ARCH PHARMACOL, V372, P432, DOI 10.1007/s00210-006-0040-y
   Li LM, 2012, MOL MED REP, V6, P75, DOI 10.3892/mmr.2012.900
   Link E, 2008, NEW ENGL J MED, V359, P789, DOI 10.1056/NEJMoa0801936
   Liutkeviciene R, 2017, GENE, V636, P30, DOI 10.1016/j.gene.2017.09.022
   Luo J., 2015, NAT SCI REP, V5, P1, DOI [10.1038/srep14214, DOI 10.1038/SREP14214, DOI 10.1038/SREP18556]
   Luo J.Q., 2015, STUDY SCI REP, V26, P17253
   Marciante KD, 2011, PHARMACOGENET GENOM, V21, P280, DOI 10.1097/FPC.0b013e328343dd7d
   Mendez L, 2013, REV MED CHILE, V141, P1266, DOI 10.4067/S0034-98872013001000005
   Neale BM, 2010, P NATL ACAD SCI USA, V107, P7395, DOI 10.1073/pnas.0912019107
   Niemi M, 2004, PHARMACOGENETICS, V14, P429, DOI 10.1097/01.fpc.0000114750.08559.32
   Niemi M, 2011, PHARMACOL REV, V63, P157, DOI 10.1124/pr.110.002857
   Nies AT, 2013, GENOME MED, V5, DOI 10.1186/gm405
   Nozawa T, 2002, J PHARMACOL EXP THER, V302, P804, DOI 10.1124/jpet.302.2.804
   Oshiro C, 2010, PHARMACOGENET GENOM, V20, P211, DOI 10.1097/FPC.0b013e328333b99c
   Pasanen MK, 2007, CLIN PHARMACOL THER, V82, P726, DOI 10.1038/sj.clpt.6100220
   Pasanen Marja, 2008, PHARMACOGENETICS SLC
   Pasanen MK, 2006, PHARMACOGENET GENOM, V16, P873, DOI 10.1097/01.fpc.0000230416.82349.90
   Prado Y, 2015, INT J MOL SCI, V16, P20609, DOI 10.3390/ijms160920609
   Reimer T, 2016, BMC CANCER, V16, DOI 10.1186/s12885-016-2373-3
   Romaine SPR, 2010, PHARMACOGENOMICS J, V10, P1, DOI 10.1038/tpj.2009.54
   Rudolf M, 2008, INVEST OPHTH VIS SCI, V49, P1200, DOI 10.1167/iovs.07-1466
   Santos PCJL, 2011, BMC MED GENET, V12, DOI 10.1186/1471-2350-12-136
   Smith W, 1998, ARCH OPHTHALMOL-CHIC, V116, P583, DOI 10.1001/archopht.116.5.583
   Sortica VA, 2012, CLIN CHEM LAB MED, V50, P441, DOI [10.1515/CCLM.2011.804, 10.1515/cclm.2011.804]
   Sortica VD, 2012, BASIC CLIN PHARMACOL, V110, P460, DOI 10.1111/j.1742-7843.2011.00838.x
   Spencer KL, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017784
   Thompson JF, 2005, PHARMACOGENOMICS J, V5, P352, DOI 10.1038/sj.tpj.6500328
   Tomany SC, 2004, OPHTHALMOLOGY, V111, P1280, DOI 10.1016/j.ophtha.2003.11.010
   Tomi M, 2004, J NEUROCHEM, V91, P1244, DOI 10.1111/j.1471-4159.2004.02842.x
   Ulvestad M, 2013, CLIN PHARMACOL THER, V93, P275, DOI 10.1038/clpt.2012.261
   van der Deure WM, 2008, ENDOCRINOLOGY, V149, P4695, DOI 10.1210/en.2008-0169
   van Leeuwen R, 2004, AM J OPHTHALMOL, V137, P750, DOI 10.1016/S0002-9394(03)01089-4
   Voora D, 2009, J AM COLL CARDIOL, V54, P1609, DOI 10.1016/j.jacc.2009.04.053
   Wang L, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010329
   Wilke RA, 2012, CLIN PHARMACOL THER, V92, P112, DOI 10.1038/clpt.2012.57
   Zarbin MA, 2004, ARCH OPHTHALMOL-CHIC, V122, P598, DOI 10.1001/archopht.122.4.598
NR 65
TC 4
Z9 4
U1 1
U2 9
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0378-1119
EI 1879-0038
J9 GENE
JI Gene
PD NOV 15
PY 2018
VL 676
BP 139
EP 145
DI 10.1016/j.gene.2018.07.031
PG 7
WC Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Genetics & Heredity
GA GV3JD
UT WOS:000445989300018
PM 30010042
DA 2022-11-30
ER

PT J
AU Luo, D
   Deng, TT
   Yuan, W
   Deng, H
   Jin, M
AF Luo, Dan
   Deng, Tingting
   Yuan, Wei
   Deng, Hui
   Jin, Ming
TI Plasma metabolomic study in Chinese patients with wet age-related
   macular degeneration
SO BMC OPHTHALMOLOGY
LA English
DT Article
DE Age-related macular degeneration; Metabolomic study; Amino acids;
   Metabolites
ID ASSOCIATION; IDENTIFICATION; METABOLITES; PREVALENCE; MECHANISM;
   THERAPY; RISK; EYE
AB Background: Age-related macular degeneration (AMD) is a leading disease associated with blindness. It has a high incidence and complex pathogenesis. We aimed to study the metabolomic characteristics in Chinese patients with wet AMD by analyzing the morning plasma of 20 healthy controls and 20 wet AMD patients for metabolic differences.
   Methods: We used ultra-high-pressure liquid chromatography and quadrupole-time-of-flight mass spectrometry for this analysis. The relationship of these differences with AMD pathophysiology was also assessed. Remaining data were normalized using Pareto scaling, and then valid data were handled using multivariate data analysis with MetaboAnalysis software, including unsupervised principal component analysis and supervised partial least squares-discriminate analysis. The purpose of the present work was to identify significant metabolites for the analyses. Hierarchical clustering was conducted to identify metabolites that differed between the two groups. Significant metabolites were then identified using the established database, and features were mapped on the Kyoto Encyclopedia of Genes and Genomes.
   Results: A total of 5443 ion peaks were detected, all of them attributable to the same 10 metabolites. These included some amino acids, isomaltose, hydrocortisone, and biliverdin. The heights of these peaks differed significantly between the two groups. The biosynthesis of amino acids pathways also differed profoundly between patients with wet AMD and controls.
   Conclusions: These findings suggested that metabolic profiles and and pathways differed between wet AMD and controls and may provide promising new targets for AMD-directed therapeutics and diagnostics.
C1 [Luo, Dan; Yuan, Wei; Deng, Hui; Jin, Ming] China Japan Friendship Hosp, Dept Ophthalmol, Beijing 100029, Peoples R China.
   [Luo, Dan] Beijing Changping Hosp Chinese Med, South Sect East Ring Rd, Beijing 102200, Peoples R China.
   [Deng, Tingting] China Japan Friendship Hosp, Inst Clin Med Sci, Beijing 100029, Peoples R China.
C3 China-Japan Friendship Hospital; China-Japan Friendship Hospital
RP Jin, M (通讯作者)，China Japan Friendship Hosp, Dept Ophthalmol, Beijing 100029, Peoples R China.
EM jinmingyk@163.com
OI Luo, Dan/0000-0002-6146-9529
FU National Natural Science Foundation of China [81373693]; Beijing Natural
   Science Foundation [7132196]; China-Japan Friendship Hospital Youth
   Science and Technology Excellence Project [2015-QNYC-B-01]
FX This study was supported by the National Natural Science Foundation of
   China (No. 81373693) and Beijing Natural Science Foundation (No.
   7132196) and China-Japan Friendship Hospital Youth Science and
   Technology Excellence Project (No. 2015-QNYC-B-01).
CR Aoki A, 2016, SCI REP-UK, V6, DOI 10.1038/srep20723
   Asai T, 2017, J BIOSCI BIOENG, V123, P376, DOI 10.1016/j.jbiosc.2016.09.013
   Barikian A, 2017, RETINA-J RET VIT DIS, V37, P1337, DOI 10.1097/IAE.0000000000001366
   Benton HP, 2015, ANAL CHEM, V87, P884, DOI 10.1021/ac5025649
   Bird AC, 2016, SURV OPHTHALMOL, V39, P367
   Brennan L, 2014, PROG NUCL MAG RES SP, V83, P42, DOI 10.1016/j.pnmrs.2014.09.001
   Cai YP, 2015, METABOLOMICS, V11, P1575, DOI 10.1007/s11306-015-0809-4
   de Raad M, 2016, CURR OPIN CHEM BIOL, V30, P7, DOI 10.1016/j.cbpa.2015.10.012
   Fischer T, 2015, ORVOSI HETILAP, V156, P1847, DOI 10.1556/650.2015.30207
   Ge J, 2013, OPHTHALMOLOGY, P314
   Kanan Y, 2015, EXP EYE RES, V133, P126, DOI 10.1016/j.exer.2014.07.007
   Kanan Y, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0105409
   Kersten E, 2018, SURV OPHTHALMOL, V63, P9, DOI 10.1016/j.survophthal.2017.05.003
   Kim IK, 2008, MOL VIS, V14, P1487
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Lains I, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0177749
   Lawrenson JG, 2013, BMC PUBLIC HEALTH, V13, DOI 10.1186/1471-2458-13-564
   Loboda A, 2016, CELL MOL LIFE SCI, V73, P3221, DOI 10.1007/s00018-016-2223-0
   Newman AM, 2012, GENOME MED, V4, DOI [10.1186/PREACCEPT-1418491035586234, 10.1186/gm315]
   Orban T, 2015, FASEB J, V29, P4579, DOI 10.1096/fj.15-275289
   Osborn MP, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0072737
   Ramautar R, 2013, CURR OPIN CHEM BIOL, V17, P841, DOI 10.1016/j.cbpa.2013.06.015
   Rowan S, 2017, P NATL ACAD SCI USA, V114, pE4472, DOI 10.1073/pnas.1702302114
   Shen JH, 2016, DISCOV MED, V22, P129
   Smith CA, 2006, ANAL CHEM, V78, P779, DOI 10.1021/ac051437y
   Tong Y, 2016, INT J OPHTHALMOL-CHI, V9, P1028, DOI 10.18240/ijo.2016.07.16
   Van Lancker L, 2017, EUR J OPHTHALMOL, V27, P342, DOI 10.5301/ejo.5000861
   Wang JH, 2016, PHILOS T R SOC A, V374, DOI 10.1098/rsta.2015.0376
   Wang YF, 2016, INT J ENV RES PUB HE, V13, DOI 10.3390/ijerph13101022
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Woo HJ, 2016, BMC GENOMICS, V17, DOI 10.1186/s12864-016-2871-3
   Zhang QH, 2016, TRAC-TREND ANAL CHEM, V80, P57, DOI 10.1016/j.trac.2016.02.017
   Zhou HD, 2005, CHIN J OPHTHALMOL, V41, P19
NR 33
TC 32
Z9 33
U1 3
U2 21
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1471-2415
J9 BMC OPHTHALMOL
JI BMC Ophthalmol.
PD SEP 6
PY 2017
VL 17
AR 165
DI 10.1186/s12886-017-0555-7
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA FG1JG
UT WOS:000409551000001
PM 28874192
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Lee, KK
   Markowitz, SN
AF Lee, Kevin K.
   Markowitz, Samuel N.
TI Scotoma size reduction as an adaptive strategy in age-related macular
   degeneration
SO CANADIAN JOURNAL OF OPHTHALMOLOGY-JOURNAL CANADIEN D OPHTALMOLOGIE
LA English
DT Article
DE scotoma size; adaptive strategies; age-related macular degeneration; low
   vision rehabilitation
ID ECCENTRIC FIXATION; VISUAL-ACUITY
AB Objective: Retinal areas with reduced sensitivity to light stimuli represent the true scotoma size in patients with age-related macular degeneration (AMD), whereas the perceived visual field defect area that covers a specific target of regard may represent an effective size of the same scotoma. This study was designed to highlight the conceptual difference between the "true scotoma size" and its "effective scotoma size" counterpart.
   Design: Prospective nonrandomized observational case series.
   Participants: Ten adults with documented AMD, low vision, and best-corrected visual acuity of 20/50-20/200 in the better eye.
   Methods: Effective scotoma size and true scotoma size were calculated from measurements with the macular grid test performed with automated perimetry and from microperimetry performed with the Nidek MP-1, respectively.
   Results: Ten patients aged 70-92 years (mean 81 years) met the inclusion criteria. Mean effective scotoma size measured with the macular grid test was 40.19 (SD 34.88) deg(2). Mean true scotoma size measured with microperimetry was 75.17 (SD 56.08) deg(2) (p <= 0.003). The log unit change in scotoma size, defined as scotoma utility score, was -55.91%. The effect size observed for the scotoma utility score was 0.74.
   Conclusions: Effective scotoma size experienced by patients with AM D is significantly smaller than true scotoma size. This reduction may be explained by adaptive variability in eye positions during any single fixation stability attempt, which ultimately results in enhanced visual field perception.
C1 [Lee, Kevin K.; Markowitz, Samuel N.] Univ Toronto, Univ Hlth Network Hosp, Dept Ophthalmol & Vis Sci, Low Vis Serv, Toronto, ON, Canada.
C3 University of Toronto; University Health Network Toronto
RP Markowitz, SN (通讯作者)，1225 Davenport Rd, Toronto, ON M6H 2H1, Canada.
EM snm1@rogers.com
FU Alcon Canada
FX The authors thank Luminita Tarita-Nistor, PhD, for help with MP-1 data
   collection. This work was supported with a research grant from Alcon
   Canada.
CR Al-Karmi R, 2006, CAN J OPHTHALMOL, V41, P313, DOI 10.1139/I06-016
   Cheung SH, 2005, VISUAL NEUROSCI, V22, P187, DOI 10.1017/S0952523805222071
   *CNIB, YOU YOUR VIS
   Cohen J., 1988, STAT POWER ANAL SOCI, V2nd
   Cohen SY, 2003, GRAEF ARCH CLIN EXP, V241, P785, DOI 10.1007/s00417-003-0744-3
   Crossland MD, 2002, OPTOMETRY VISION SCI, V79, P735, DOI 10.1097/00006324-200211000-00011
   Deruaz A, 2004, BRIT J OPHTHALMOL, V88, P461, DOI 10.1136/bjo.2003.025601
   FERRIS FL, 1982, AM J OPHTHALMOL, V94, P91, DOI 10.1016/0002-9394(82)90197-0
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Gonzalez EG, 2007, INVEST OPHTH VIS SCI, V48, P4838, DOI 10.1167/iovs.06-1240
   JONAS JB, 1995, OPHTHALMOLOGY, V102, P1102
   Kuyk TK, 2005, VISION RES, V45, P3224, DOI 10.1016/j.visres.2005.07.019
   Markowitz SN, 2004, CAN J OPHTHALMOL, V39, P56, DOI 10.1016/S0008-4182(04)80053-X
   Pidcoe PE, 2006, INVEST OPHTH VIS SCI, V47, P169, DOI 10.1167/iovs.04-0564
   Schuchard RA, 2005, CAN J OPHTHALMOL, V40, P303, DOI 10.1016/S0008-4182(05)80073-0
   SCHUCHARD RA, 1993, ARCH OPHTHALMOL-CHIC, V111, P776, DOI 10.1001/archopht.1993.01090060064024
   Seiple W, 2005, INVEST OPHTH VIS SCI, V46, P2886, DOI 10.1167/iovs.04-1296
   Tarita-Nistor L, 2008, RETINA-J RET VIT DIS, V28, P125, DOI 10.1097/IAE.0b013e3180ed4571
   Timberlake GT, 2005, OPTOMETRY VISION SCI, V82, P177
   WHITE JM, 1990, INVEST OPHTH VIS SCI, V31, P1149
   WHITTAKER SG, 1988, INVEST OPHTH VIS SCI, V29, P268
   *WHO, 2004, 282 WHO
NR 22
TC 7
Z9 7
U1 0
U2 3
PU CANADIAN OPHTHAL SOC
PI OTTAWA
PA 1525 CARLING AVE SUITE 610, OTTAWA, ONTARIO K1Z 8R9, CANADA
SN 0008-4182
EI 1715-3360
J9 CAN J OPHTHALMOL
JI Can. J. Opthalmol.-J. Can. Opthalmol.
PD AUG
PY 2010
VL 45
IS 4
BP 393
EP 398
DI 10.3129/i10-021
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 645MI
UT WOS:000281463000013
PM 20648088
DA 2022-11-30
ER

PT J
AU Ma, YB
   Ding, XQ
   Shao, MX
   Qiu, YC
   Li, SJ
   Cao, WJ
   Xu, GZ
AF Ma, Yingbo
   Ding, Xueqing
   Shao, Mingxi
   Qiu, Yichao
   Li, Shengjie
   Cao, Wenjun
   Xu, Gezhi
TI Association of Serum Complement C1q and C3 Level with Age-Related
   Macular Degeneration in Women
SO JOURNAL OF INFLAMMATION RESEARCH
LA English
DT Article
DE macular degeneration; complement classical pathway; complement
   component; peripheral blood; case-control study
ID HORMONE REPLACEMENT THERAPY; IMMUNOGLOBULIN IGG; ACTIVATION;
   INFLAMMATION; MODEL; ENDOTHELIUM; INDUCTION; DISEASES; RETINA; SYSTEM
AB Purpose: To investigate the association between serum complement components and age-related macular degeneration (AMD). Patients and Methods: A total of 118 AMD patients and age-and sex-matched 106 control subjects were included. Demographic data and the level of serum complement component (C)1q, C3 and C4 were evaluated. Based on sex, the subjects were stratified into male and female subgroups. Results: The level of C1q (226.31 +/- 45.33mg/dL) was significantly higher and C3 (121.14 +/- 15.76mg/dL) was significantly lower than that in control group (200.03 +/- 38.54mg/dL) (128.42 +/- 19.81mg/dL) in the female AMD patients (p = 0.005, p = 0.045). Logistic regres-sion showed that increased C1q (OR = 1.132, p = 0.016) and decreased C3 (OR = 0.960, p = 0.048) were independent risk factors for female AMD patients. No statistical significance was observed in the male. Conclusion: Increased C1q and decreased C3 were associated with increased risk of AMD, suggesting that the complement classical pathway probably be involved in AMD, especially in female.
C1 [Ma, Yingbo; Ding, Xueqing; Shao, Mingxi; Qiu, Yichao; Li, Shengjie; Cao, Wenjun] Fudan Univ, Dept Clin Lab, Eye & ENT Hosp, Fenyang Rd 83th, Shanghai, Peoples R China.
   [Cao, Wenjun; Xu, Gezhi] Fudan Univ, Dept Ophthalmol, Eye & ENT Hosp, Shanghai, Peoples R China.
   [Xu, Gezhi] Fudan Univ, Shanghai Key Lab Visual Impairment & Restorat, Shanghai, Peoples R China.
   [Xu, Gezhi] Fudan Univ, NHC Key Lab Myopia, Shanghai, Peoples R China.
C3 Fudan University; Fudan University; Fudan University; Fudan University
RP Li, SJ (通讯作者)，Fudan Univ, Dept Clin Lab, Eye & ENT Hosp, Fenyang Rd 83th, Shanghai, Peoples R China.
EM lishengjie6363020@163.com
OI Li, Shengjie/0000-0002-6443-740X
CR Acosta J, 2000, P NATL ACAD SCI USA, V97, P5450, DOI 10.1073/pnas.97.10.5450
   Anderson DH, 2010, PROG RETIN EYE RES, V29, P95, DOI 10.1016/j.preteyeres.2009.11.003
   Cascio C, 2015, STEROIDS, V103, P31, DOI 10.1016/j.steroids.2015.08.002
   Chen M, 2019, PROG RETIN EYE RES, V69, P159, DOI 10.1016/j.preteyeres.2018.10.003
   Demirs JT, 2021, INVEST OPHTH VIS SCI, V62, DOI 10.1167/iovs.62.7.26
   Despriet DDG, 2009, OPHTHALMOLOGY, V116, P474, DOI 10.1016/j.ophtha.2008.09.055
   Doyle SL, 2012, NAT MED, V18, P791, DOI 10.1038/nm.2717
   Du X, OXID MED CELL LONGEV, V2021
   Gibson J, 2012, IMMUNOBIOLOGY, V217, P251, DOI 10.1016/j.imbio.2011.07.015
   Golubnitschaja O, 2021, EPMA J, V12, P243, DOI 10.1007/s13167-021-00251-4
   Ho EXP, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0201768
   Horii N, 2018, FASEB J, V32, P3547, DOI 10.1096/fj.201700772RRR
   Javed F, 2021, ACTA OPHTHALMOL, V99, P351, DOI 10.1111/aos.14629
   Jiao HH, 2018, MOL NEURODEGENER, V13, DOI 10.1186/s13024-018-0278-0
   Johnson LV, 2011, P NATL ACAD SCI USA, V108, P18277, DOI 10.1073/pnas.1109703108
   Kaarniranta K, 2015, CURR EYE RES, V40, P226, DOI 10.3109/02713683.2014.925933
   Kauppinen A, 2016, CELL MOL LIFE SCI, V73, P1765, DOI 10.1007/s00018-016-2147-8
   Kim SY, 2021, EXP EYE RES, V203, DOI 10.1016/j.exer.2020.108391
   Kreutz R, 2007, J HYPERTENS, V25, P2308, DOI 10.1097/HJH.0b013e3282ef8611
   LaFon DC, 2020, IMMUN AGEING, V17, DOI 10.1186/s12979-020-00189-7
   Lechner J, 2016, IMMUN AGEING, V13, DOI 10.1186/s12979-016-0060-5
   Li SJ, 2021, EPMA J, V12, P659, DOI 10.1007/s13167-021-00260-3
   Li SJ, 2020, AM J OPHTHALMOL, V217, P55, DOI 10.1016/j.ajo.2020.04.033
   Li SJ, 2018, J GLAUCOMA, V27, P761, DOI 10.1097/IJG.0000000000001014
   Li SJ, 2017, INVEST OPHTH VIS SCI, V58, P682, DOI 10.1167/iovs.16-20675
   Liu Y, 2008, J HUAZHONG U SCI-MED, V28, P102, DOI 10.1007/s11596-008-0126-5
   Lynch AM, 2020, EUR J OPHTHALMOL, V30, P1061, DOI 10.1177/1120672119857896
   Matuskova V, 2020, ACTA OPHTHALMOL, V98, pE691, DOI 10.1111/aos.14357
   Merle NS, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00262
   Mitchell P, 2018, LANCET, V392, P1147, DOI 10.1016/S0140-6736(18)31550-2
   Monteiro R, 2014, MEDIAT INFLAMM, V2014, DOI 10.1155/2014/615917
   Morohoshi K, 2009, J AUTOIMMUN, V33, P247, DOI 10.1016/j.jaut.2009.09.003
   Naito AT, 2012, CELL, V149, P1298, DOI 10.1016/j.cell.2012.03.047
   Nitsch D, 2008, OPHTHALMOLOGY, V115, P1904, DOI 10.1016/j.ophtha.2008.06.035
   Nuzzi R, 2018, FRONT ENDOCRINOL, V9, DOI 10.3389/fendo.2018.00066
   Patel N, 2005, IMMUNOLOGY, V115, P422, DOI 10.1111/j.1365-2567.2005.02173.x
   Radu RA, 2011, J BIOL CHEM, V286, P18593, DOI 10.1074/jbc.M110.191866
   Reddy V, 2020, EPMA J, V11, P217, DOI 10.1007/s13167-020-00203-4
   Reynolds R, 2009, INVEST OPHTH VIS SCI, V50, P5818, DOI 10.1167/iovs.09-3928
   Robman L, 2005, AM J EPIDEMIOL, V161, P1013, DOI 10.1093/aje/kwi130
   Rudnicka AR, 2012, OPHTHALMOLOGY, V119, P571, DOI 10.1016/j.ophtha.2011.09.027
   Sasaki M, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-017-18487-4
   Shah D, 2015, J BIOL CHEM, V290, P29642, DOI 10.1074/jbc.M115.690784
   Shepherd R, 2021, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.604000
   Sivaprasad S, 2007, ARCH OPHTHALMOL-CHIC, V125, P515, DOI 10.1001/archopht.125.4.515
   Stasi K, 2006, INVEST OPHTH VIS SCI, V47, P1024, DOI 10.1167/iovs.05-0830
   Wang W, 2021, EPMA J, V12, P403, DOI 10.1007/s13167-021-00253-2
   Webster SD, 2000, EXP NEUROL, V161, P127, DOI 10.1006/exnr.1999.7260
   Whitcup SM, 2013, INT J INFLAMM, V2013, DOI 10.1155/2013/348092
   Yang P, 2017, INVEST OPHTH VIS SCI, V58, P3073, DOI 10.1167/iovs.16-20083
   Yates JRW, 2007, NEW ENGL J MED, V357, P553, DOI 10.1056/NEJMoa072618
   Yilmazer M, 2003, HUM REPROD, V18, P1531, DOI 10.1093/humrep/deg292
   Yin CJ, 2019, NAT MED, V25, P496, DOI 10.1038/s41591-018-0336-8
   Zetterberg M, 2016, MATURITAS, V83, P19, DOI 10.1016/j.maturitas.2015.10.005
   Zhou JL, 2006, P NATL ACAD SCI USA, V103, P16182, DOI 10.1073/pnas.0604255103
NR 55
TC 0
Z9 0
U1 2
U2 6
PU DOVE MEDICAL PRESS LTD
PI ALBANY
PA PO BOX 300-008, ALBANY, AUCKLAND 0752, NEW ZEALAND
EI 1178-7031
J9 J INFLAMM RES
JI J. Inflamm. Res.
PY 2022
VL 15
BP 285
EP 294
DI 10.2147/JIR.S348539
PG 10
WC Immunology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Immunology
GA YL0WE
UT WOS:000745620900003
PM 35058703
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Zisimopoulos, A
   Klavdianou, O
   Theodossiadis, P
   Chatziralli, I
AF Zisimopoulos, Athanasios
   Klavdianou, Olga
   Theodossiadis, Panagiotis
   Chatziralli, Irini
TI The Role of the Microbiome in Age-Related Macular Degeneration: A Review
   of the Literature
SO OPHTHALMOLOGICA
LA English
DT Review
DE Age-related macular degeneration; Diagnosis; Microbiome; Treatment
ID GUT-RETINA AXIS; OBESITY; INFLAMMATION; ASSOCIATION; DISEASE; DRUSEN;
   RISK
AB Background: Age-related macular degeneration (AMD) is a progressive, multifactorial, degenerative disease and the leading cause of severe visual loss in the elderly population. The exact pathogenesis of AMD remains elusive, being the combination of genetic, environmental, metabolic, and functional processes. A better understanding of the disease's pathophysiology can lead to new treatment targets. The human microbiome seems to be a potential therapeutic pathway for AMD, as it has been recently proven to play a role in its pathogenesis. Summary: This review sheds light on the association between the microbiome and AMD. Key Messages: The current evidence based on the existing literature shows that there are differences in taxonomical and functional profiles in the human microbiome between patients with AMD and controls, suggesting that the microbiome is implicated in AMD onset and progression, being a link between AMD and nutrition/diet. Additionally, specific bacterial classes have been proposed as potential biomarkers for AMD diagnosis. Further randomized clinical studies with a large sample are needed to elucidate the role of the microbiome in AMD and to draw more solid conclusions.
C1 [Zisimopoulos, Athanasios; Klavdianou, Olga] Natl & Kapodistrian Univ Athens, Sch Med, Athens, Greece.
   [Theodossiadis, Panagiotis; Chatziralli, Irini] Natl & Kapodistrian Univ Athens, Dept Ophthalmol 2, Attikon Univ Hosp, Athens, Greece.
C3 Athens Medical School; National & Kapodistrian University of Athens;
   National & Kapodistrian University of Athens; University Hospital
   Attikon
RP Chatziralli, I (通讯作者)，Attikon Univ Hosp, Dept Ophthalmol, 1 Rimini St, GR-12462 Haidari, Greece.
EM eirchat@yahoo.gr
CR Adams MKM, 2011, AM J EPIDEMIOL, V173, P1246, DOI 10.1093/aje/kwr005
   Andriessen EMMA, 2016, EMBO MOL MED, V8, P1366, DOI 10.15252/emmm.201606531
   Biesemeier A, 2014, NEUROBIOL AGING, V35, P2562, DOI 10.1016/j.neurobiolaging.2014.05.003
   Blum HE, 2017, ADV MED SCI-POLAND, V62, P414, DOI 10.1016/j.advms.2017.04.005
   Boon CJE, 2008, AM J HUM GENET, V82, P516, DOI 10.1016/j.ajhg.2007.11.007
   Cani PD, 2008, DIABETES, V57, P1470, DOI 10.2337/db07-1403
   Chaiwiang N, 2019, ACTA MICROBIOL IMM H, V66, P541, DOI 10.1556/030.66.2019.038
   Chakravarthy SK, 2018, INDIAN J MICROBIOL, V58, P457, DOI 10.1007/s12088-018-0746-9
   Chassaing B, 2014, TOXICOL PATHOL, V42, P49, DOI 10.1177/0192623313508481
   Chen M, 2015, J LEUKOCYTE BIOL, V98, P713, DOI 10.1189/jlb.3RI0615-239R
   de Jong PTVM, 2006, NEW ENGL J MED, V355, P1474, DOI 10.1056/NEJMra062326
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Floyd JL, 2020, OPHTHALMOL THER, V9, P499, DOI 10.1007/s40123-020-00278-2
   GREEN WR, 1985, OPHTHALMOLOGY, V92, P615
   Heesterbeek TJ, 2020, OPHTHAL PHYSL OPT, V40, P140, DOI 10.1111/opo.12675
   Ho EXP, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0201768
   Joachim N, 2014, OPHTHALMOLOGY, V121, P917, DOI 10.1016/j.ophtha.2013.10.043
   Kijlstra A, 2015, OPHTHALMIC RES, V54, P64, DOI 10.1159/000432401
   Klein R, 2004, AM J OPHTHALMOL, V137, P486, DOI 10.1016/j.ajo.2003.11.069
   Lin P, 2019, CLIN EXP OPHTHALMOL, V47, P418, DOI 10.1111/ceo.13493
   Lin P, 2018, CURR OPIN OPHTHALMOL, V29, P261, DOI 10.1097/ICU.0000000000000465
   Lloyd-Price J, 2017, NATURE, V550, P61, DOI 10.1038/nature23889
   Longhi MS, 2017, J MOL MED, V95, P915, DOI 10.1007/s00109-017-1545-1
   Rowan S, 2018, GUT MICROBES, V9, P452, DOI 10.1080/19490976.2018.1435247
   Rowan S, 2017, P NATL ACAD SCI USA, V114, pE4472, DOI 10.1073/pnas.1702302114
   Rullo J, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-60674-3
   Wang BH, 2017, ENGINEERING, V3, P71, DOI 10.1016/J.ENG.2017.01.008
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Wu JL, 2019, DRUG DES DEV THER, V13, P2413, DOI 10.2147/DDDT.S206355
   Zhang MX, 2015, GENET MOL RES, V14, P12567, DOI 10.4238/2015.October.16.24
   Zhang QY, 2016, INVEST OPHTH VIS SCI, V57, P1276, DOI 10.1167/iovs.15-18637
   Zinkernagel MS, 2017, SCI REP-UK, V7, DOI 10.1038/srep40826
   Zysset-Burri DC, 2020, NPJ GENOM MED, V5, DOI 10.1038/s41525-020-00141-0
NR 33
TC 2
Z9 2
U1 2
U2 6
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 0030-3755
EI 1423-0267
J9 OPHTHALMOLOGICA
JI Ophthalmologica
PD JUL
PY 2021
VL 244
IS 3
BP 173
EP 178
DI 10.1159/000515026
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA TF3RY
UT WOS:000670635600001
PM 33550293
OA Bronze
DA 2022-11-30
ER

PT J
AU Combadiere, C
   Feumi, C
   Raoul, W
   Keller, N
   Rodero, M
   Pezard, A
   Lavalette, S
   Houssier, M
   Jonet, L
   Picard, E
   Debre, P
   Sirinyan, M
   Deterre, P
   Ferroukhi, T
   Cohen, SY
   Chauvaud, D
   Jeanny, JC
   Chemtob, S
   Behar-Cohen, F
   Sennlaub, F
AF Combadiere, Christophe
   Feumi, Charles
   Raoul, William
   Keller, Nicole
   Rodero, Mathieu
   Pezard, Adeline
   Lavalette, Sophie
   Houssier, Marianne
   Jonet, Laurent
   Picard, Emilie
   Debre, Patrice
   Sirinyan, Mirna
   Deterre, Philippe
   Ferroukhi, Tania
   Cohen, Salomon-Yves
   Chauvaud, Dominique
   Jeanny, Jean-Claude
   Chemtob, Sylvain
   Behar-Cohen, Francine
   Sennlaub, Florian
TI CX3CR1-dependent subretinal microglia cell accumulation is associated
   with cardinal features of age-related macular degeneration
SO JOURNAL OF CLINICAL INVESTIGATION
LA English
DT Article
ID CHOROIDAL NEOVASCULARIZATION; FRACTALKINE RECEPTOR; RETINAL MICROGLIA;
   OUTER SEGMENTS; GLIAL-CELLS; RAT-BRAIN; DRUSEN; MICE; GENE; MACROPHAGES
AB The role of retinal microglial cells (MCs) in age-related macular degeneration (AMD) is unclear. Here we demonstrated that all retinal MCs express CX3C chemokine receptor 1 (CX3CR1) and that homozygosity for the CX3CR1 M280 allele, which is associated with impaired cell migration, increases the risk of AMD. In humans with AMD, MCs accumulated in the subretinal space at sites of retinal degeneration and choroidal neovascularization (CNV). In CX3CR1-deficient mice, MCs accumulated subretinally with age and albino background and after laser impact preceding retinal degeneration. Raising the albino mice in the dark prevented both events. The appearance of lipid-bloated subretinal MCs was drusen-like on funduscopy of senescent mice, and CX3CR1-dependent MC accumulation was associated with an exacerbation of experimental CNV These results show that CX3CR1-dependent accumulation of subretinal MCs evokes cardinal features of AMD. These findings reveal what we believe to be a novel pathogenic process with important implications for the development of new therapies for AMD.
C1 INSERM, U872, Ctr Rech Cordeliers, F-75006 Paris, France.
   INSERM, U543, Lab Immunol Cellularie, Paris, France.
   Univ Paris 06, Lab Informat Paris 6, Paris, France.
   Grp Hosp Pitie Salpetriere, AP HP, Serv Immunol, F-75634 Paris, France.
   Univ Paris 06, Ctr Rech Cordeliers, Lab Informat Paris 6, Paris, France.
   Univ Paris 05, UMR S 872, Paris, France.
   Hop St Justine, Res Ctr, Dept Pediat Opthalmol & Pharmacol, Montreal, PQ H3T 1C5, Canada.
   Ctr Angiograph & Laser, Paris, France.
   Ctr Rech Opthalmol, Serv Ophtalmol, Hotel Dieu, AP HP, Paris, France.
C3 Institut National de la Sante et de la Recherche Medicale (Inserm);
   UDICE-French Research Universities; Sorbonne Universite; Universite
   Paris Cite; Institut National de la Sante et de la Recherche Medicale
   (Inserm); UDICE-French Research Universities; Sorbonne Universite;
   Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire
   Pitie-Salpetriere - APHP; UDICE-French Research Universities; Sorbonne
   Universite; Institut National de la Sante et de la Recherche Medicale
   (Inserm); UDICE-French Research Universities; Sorbonne Universite;
   Universite Paris Cite; UDICE-French Research Universities; Universite
   Paris Cite; Universite de Montreal; Assistance Publique Hopitaux Paris
   (APHP); Hopital Universitaire Hotel-Dieu - APHP
RP Sennlaub, F (通讯作者)，INSERM, U872, Ctr Rech Cordeliers, 15 Rue Ecole Med, F-75006 Paris, France.
EM combad@ccr.jussieu.fr; sennlaub@idfinserm.fr
RI Deterre, Philippe/O-8984-2017; Sennlaub, Florian/F-2756-2017;
   Combadiere, Christophe/I-5639-2013; picard, Emilie/A-6919-2013; Raoul,
   William/H-2118-2018; rodero, mathieu/C-8083-2011
OI Deterre, Philippe/0000-0001-9303-0791; Sennlaub,
   Florian/0000-0003-4412-1341; Combadiere, Christophe/0000-0002-1755-4531;
   picard, Emilie/0000-0002-2689-0510; Raoul, William/0000-0002-5040-3372;
   rodero, mathieu/0000-0002-1300-0187; Houssier,
   Marianne/0000-0002-5329-4597
CR Ambati J, 2003, NAT MED, V9, P1390, DOI 10.1038/nm950
   Bellander BM, 2004, J NEUROTRAUM, V21, P605, DOI 10.1089/089771504774129937
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Caicedo A, 2005, EXP EYE RES, V81, P38, DOI 10.1016/j.exer.2005.01.013
   Cardona AE, 2006, NAT NEUROSCI, V9, P917, DOI 10.1038/nn1715
   Checchin D, 2006, INVEST OPHTH VIS SCI, V47, P3595, DOI 10.1167/iovs.05-1522
   Combadiere C, 2003, CIRCULATION, V107, P1009, DOI 10.1161/01.CIR.0000057548.68243.42
   Daoudi M, 2004, J BIOL CHEM, V279, P19649, DOI 10.1074/jbc.M313457200
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   FARKAS TG, 1971, AM J OPHTHALMOL, V71, P1196, DOI 10.1016/0002-9394(71)90963-9
   FARKAS TG, 1971, AM J OPHTHALMOL, V71, P1206, DOI 10.1016/0002-9394(71)90964-0
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Geissmann F, 2003, IMMUNITY, V19, P71, DOI 10.1016/S1074-7613(03)00174-2
   Georges JL, 2001, J MOL MED, V79, P300, DOI 10.1007/s001090100209
   Gupta N, 2003, EXP EYE RES, V76, P463, DOI 10.1016/S0014-4835(02)00332-9
   HAASS C, 1991, J NEUROSCI, V11, P3783
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Hatori K, 2002, J NEUROSCI RES, V69, P418, DOI 10.1002/jnr.10304
   Higgins GT, 2003, INVEST OPHTH VIS SCI, V44, P1775, DOI 10.1167/iovs.02-0742
   Johnson LV, 2002, P NATL ACAD SCI USA, V99, P11830, DOI 10.1073/pnas.192203399
   Jung S, 2000, MOL CELL BIOL, V20, P4106, DOI 10.1128/MCB.20.11.4106-4114.2000
   KANNEL WB, 1979, AM J EPIDEMIOL, V110, P281, DOI 10.1093/oxfordjournals.aje.a112813
   Kimura K, 2000, AM J OPHTHALMOL, V130, P769, DOI 10.1016/S0002-9394(00)00552-3
   KLEGERIS A, 1994, J NEUROIMMUNOL, V53, P83, DOI 10.1016/0165-5728(94)90067-1
   Lavergne E, 2004, J IMMUNOL, V173, P3755, DOI 10.4049/jimmunol.173.6.3755
   Lesnik P, 2003, J CLIN INVEST, V111, P333, DOI 10.1172/JCI200315555
   Luibl V, 2006, J CLIN INVEST, V116, P378, DOI 10.1172/JCI25843
   Margrain TH, 2004, PROG RETIN EYE RES, V23, P523, DOI 10.1016/j.preteyeres.2004.05.001
   Matsubara T, 1999, INVEST OPHTH VIS SCI, V40, P3186
   Mullins RF, 2000, FASEB J, V14, P835, DOI 10.1096/fasebj.14.7.835
   Ng TF, 2001, INVEST OPHTH VIS SCI, V42, P3301
   Nishiyori A, 1998, FEBS LETT, V429, P167, DOI 10.1016/S0014-5793(98)00583-3
   Rogue RS, 1999, BRAIN RES, V836, P110, DOI 10.1016/S0006-8993(99)01625-X
   SARKS SH, 1976, BRIT J OPHTHALMOL, V60, P324, DOI 10.1136/bjo.60.5.324
   Silverman MD, 2003, INVEST OPHTH VIS SCI, V44, P1608, DOI 10.1167/iovs.02-0233
   Souied EH, 1998, AM J OPHTHALMOL, V125, P353, DOI 10.1016/S0002-9394(99)80146-9
   TAMAI M, 1979, EXP EYE RES, V28, P399, DOI 10.1016/0014-4835(79)90115-5
   THANOS S, 1993, J NEUROSCI, V13, P455
   Tou JS, 2004, FASEB J, V18, P1297, DOI 10.1096/fj.04-1862fje
   Touboul PJ, 2000, CIRCULATION, V102, P313
   Tsutsumi C, 2003, J LEUKOCYTE BIOL, V74, P25, DOI 10.1189/jlb.0902436
   VANDERSCHAFT TL, 1993, BRIT J OPHTHALMOL, V77, P657, DOI 10.1136/bjo.77.10.657
   Xu Q, 2006, J NEUROSCI, V26, P4985, DOI 10.1523/JNEUROSCI.5476-05.2006
   Zeiss CJ, 2004, INVEST OPHTH VIS SCI, V45, P971, DOI 10.1167/iovs.03-0301
NR 45
TC 422
Z9 437
U1 0
U2 25
PU AMER SOC CLINICAL INVESTIGATION INC
PI ANN ARBOR
PA 2015 MANCHESTER RD, ANN ARBOR, MI 48104 USA
SN 0021-9738
EI 1558-8238
J9 J CLIN INVEST
JI J. Clin. Invest.
PD OCT
PY 2007
VL 117
IS 10
BP 2920
EP 2928
DI 10.1172/JCI31692
PG 9
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine
GA 216QP
UT WOS:000249894400023
PM 17909628
OA Bronze, Green Submitted, Green Published
DA 2022-11-30
ER

PT J
AU Errera, MH
   Girmens, JF
   Ayello-Scheer, S
   Nourry, H
   Warnet, JM
   Sahel, JA
   Barale, PO
AF Errera, M. -H.
   Girmens, J. -F.
   Ayello-Scheer, S.
   Nourry, H.
   Warnet, J. -M.
   Sahel, J. -A.
   Barale, P. -O.
TI Correlation between aqueous flare and chorioretinal neovascularization
   in age-related macular degeneration following intravitreal bevacizumab
   injections
SO JOURNAL FRANCAIS D OPHTALMOLOGIE
LA English
DT Article
DE Chorioretinal neovascularization; Age macular degeneration; Bevacizumab;
   Flare
ID RANIBIZUMAB
AB Purpose. - Prospective evaluation of aqueous flare following intravitreal bevacizumab (Avastin, Genentech Inc., San Francisco, CA, USA) injections in eyes with choroidal neovascularization due to age-related macular degeneration.
   Patients and methods. - Sixteen eyes of eight patients were recruited. Aqueous humor flare was determined by laser flare meter every month after one intravitreal injection of 1.25 mg of bevacizumab at baseline followed by a second injection at month 3 (day 100 +/- 21 days). Four patients received an injection at month 6 (+/- 10 days), and one patient received an injection at month 7.
   Results. - Two months after the first intravitreal bevacizumab injection, flare values decreased from 10 +/- 5.57 (mean +/- standard deviation) to 5.2 +/- 1.69 photon count/ms (P = 0.0207) and from 8.3 +/- 3.59 to 5.4 +/- 0 photon counts/ms, 2 months after the second injection (P = 0.02).
   Conclusion. - Significantly decreased aqueous humor flare levels were noted after repeated injections of bevacizumab. (C) 2013 Elsevier Masson SAS. All rights reserved.
C1 [Errera, M. -H.; Girmens, J. -F.; Ayello-Scheer, S.; Sahel, J. -A.; Barale, P. -O.] Ctr Hosp Natl Quinze Vingts, Dept Ophthalmol, F-75012 Paris, France.
   [Nourry, H.; Warnet, J. -M.] Univ Paris 06, Dept Pharm, Ctr Hosp Natl Quinze Vingts, F-75012 Paris, France.
C3 CHNO des Quinze-Vingts; UDICE-French Research Universities; Sorbonne
   Universite; CHNO des Quinze-Vingts; UDICE-French Research Universities;
   Sorbonne Universite
RP Errera, MH (通讯作者)，Ctr Hosp Natl Quinze Vingts, Dept Ophthalmol, 28 Rue Charenton, F-75012 Paris, France.
EM marie-helene.errera@orange.fr
RI Sahel, Jose-Alain/F-3172-2017
OI Sahel, Jose-Alain/0000-0002-4831-1153; GIRMENS,
   Jean-Francois/0000-0002-9102-8716
CR Ablonczy Z, 2007, EXP EYE RES, V85, P762, DOI 10.1016/j.exer.2007.08.010
   Bashshur ZF, 2008, AM J OPHTHALMOL, V145, P249, DOI 10.1016/j.ajo.2007.09.031
   Bates DO, 2002, J ANAT, V200, P581, DOI 10.1046/j.1469-7580.2002.00066.x
   Fung AE, 2006, BRIT J OPHTHALMOL, V90, P1344, DOI 10.1136/bjo.2006.099598
   Kiss C, 2006, RETINA-J RET VIT DIS, V26, P877, DOI 10.1097/01.iae.0000237080.10627.b7
   Kruger H, 1995, Ophthalmologe, V92, P26
   Kubota T, GREAFES ARCH CLIN EX, V234, P285
   Nakao S, 2012, INVEST OPHTH VIS SCI, V53, P4323, DOI 10.1167/iovs.11-9119
   Roh MI, 2010, GRAEF ARCH CLIN EXP, V248, P635, DOI 10.1007/s00417-009-1254-8
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Schneeberger EE, 2004, AM J PHYSIOL-CELL PH, V286, pC1213, DOI 10.1152/ajpcell.00558.2003
   Sharma S, 2012, CAN J OPHTHALMOL, V47, P275, DOI 10.1016/j.jcjo.2012.03.026
   Wickremasinghe SS, 2008, OPHTHALMOLOGY, V115, P1911, DOI 10.1016/j.ophtha.2008.05.007
   Wu L, 2008, GRAEF ARCH CLIN EXP, V248, P81
   Xu WQ, 2010, CAN J OPHTHALMOL, V45, P386, DOI 10.3129/i10-024
   Yeniad B, 2011, EUR J OPHTHALMOL, V21, P156, DOI 10.5301/EJO.2010.5239
   Zhu Q, 2008, OPHTHALMOLOGY, V115, P1750, DOI 10.1016/j.ophtha.2008.04.023
   Ziemssen F, 2006, BRIT J OPHTHALMOL, V90, P922, DOI 10.1136/bjo.2006.092262
NR 18
TC 1
Z9 1
U1 0
U2 3
PU MASSON EDITEUR
PI MOULINEAUX CEDEX 9
PA 21 STREET CAMILLE DESMOULINS, ISSY, 92789 MOULINEAUX CEDEX 9, FRANCE
SN 0181-5512
EI 1773-0597
J9 J FR OPHTALMOL
JI J. Fr. Ophthamol.
PD JAN
PY 2014
VL 37
IS 1
BP 30
EP 35
DI 10.1016/j.jfo.2013.02.008
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 293JP
UT WOS:000329967500009
PM 24209785
DA 2022-11-30
ER

PT J
AU Wu, ZC
   Ayton, LN
   Guymer, RH
   Luu, CD
AF Wu, Zhichao
   Ayton, Lauren N.
   Guymer, Robyn H.
   Luu, Chi D.
TI Comparison Between Multifocal Electroretinography and Microperimetry in
   Age-Related Macular Degeneration
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
DE age-related macular degeneration; microperimetry; multifocal
   electroretinography; retinal function
ID 2ND REFLECTIVE BAND; RETINAL FUNCTION; FLICKER PERIMETRY; VISUAL
   FUNCTION; MACULOPATHY; ABNORMALITIES; ADAPTATION; FIXATION; EYES
AB PURPOSE. To correlate and compare retinal function measured using multifocal electroretinography (mfERG) with microperimetry in intermediate age-related macular degeneration (AMD).
   METHODS. Sixty AMD participants underwent multifocal electroretinography (mfERG) and microperimetry testing in one eye, and 44 control participants were included to provide normative values for each test. Thirteen hexagons in the central three rings of a 103-hexagon stimulus grid for mfERG and retinotopically matched points on microperimetry were chosen and converted into standard deviations (SDs) away from that of normal participants (Z-score) to represent the magnitude of measured functional deficit and to allow a comparison of the two measures.
   RESULTS. For the average of all points on mfERG and microperimetry, mfERG N1 to P1 response amplitude and microperimetric retinal sensitivity was significantly lower (P = 0.013 and P < 0.001, respectively) and mfERG P1 implicit time was significantly increased (P < 0.001) in the AMD participants compared to those in the control participants. Considering retinotopically matched points, there was no significant correlation between the average Z-scores of the microperimetric retinal sensitivity and mfERG implicit time (correlation coefficient, R = 0.254, P = 0.051), nor response amplitudes (R = 0.006, P = 0.965), and the measured functional deficit with microperimetry was consistently greater than both mfERG parameters (P < 0.001).
   CONCLUSIONS. The measured functional deficit with microperimetry was greater than mfERG parameters in eyes with intermediate AMD. The absence of correlations between these two measures suggests that mfERG may be capturing unique aspects of retinal dysfunction. These findings are important when considering the use of these functional measures in intermediate AMD.
C1 [Wu, Zhichao; Ayton, Lauren N.; Guymer, Robyn H.; Luu, Chi D.] Univ Melbourne, Royal Victorian Eye & Ear Hosp, Ctr Eye Res Australia, Melbourne, Vic 3010, Australia.
C3 Centre for Eye Research Australia; Royal Victorian Eye & Ear Hospital;
   University of Melbourne
RP Luu, CD (通讯作者)，Ctr Eye Res Australia, Macular Res Unit, Level 1,32 Gisborne St, East Melbourne, Vic 3002, Australia.
EM cluu@unimelb.edu.au
RI Ayton, Lauren/AAV-2977-2021
OI Ayton, Lauren/0000-0001-9907-084X; Luu, Chi/0000-0002-7604-7097; Guymer,
   Robyn/0000-0002-9441-4356
FU National Health and Medical Research Council (NHMRC) [1027624]; NHMRC
   practitioner fellowship grant [529905]; Macular Disease Foundation
   research grant; Bupa Health Foundation (Australia); Macular Vision Loss
   Support Society of Australia Inc.; NHMRC Centre for Clinical Research
   Excellence award [529923]
FX Supported by National Health and Medical Research Council (NHMRC)
   project grant 1027624 and NHMRC practitioner fellowship grant 529905
   (RHG) and by a Macular Disease Foundation research grant, the Bupa
   Health Foundation (Australia), and the Macular Vision Loss Support
   Society of Australia Inc. Centre for Eye Research Australia receives
   operational infrastructure support from the Victorian government and is
   supported by NHMRC Centre for Clinical Research Excellence award 529923.
   The authors alone are responsible for the content and writing of the
   paper.
CR Acton JH, 2012, INVEST OPHTH VIS SCI, V53, P7618, DOI 10.1167/iovs.12-10361
   CHENG AS, 1993, OPTOMETRY VISION SCI, V70, P89, DOI 10.1097/00006324-199302000-00001
   Chisholm Jennifer A., 2001, Documenta Ophthalmologica, V102, P131, DOI 10.1023/A:1017536625847
   Chu PHW, 2006, GRAEF ARCH CLIN EXP, V244, P1273, DOI 10.1007/s00417-006-0304-8
   Csaky KG, 2008, INVEST OPHTH VIS SCI, V49, P479, DOI 10.1167/iovs.07-1132
   Dimitrov PN, 2011, INVEST OPHTH VIS SCI, V52, P9457, DOI 10.1167/iovs.10-7043
   Dinc UA, 2008, EUR J OPHTHALMOL, V18, P595, DOI 10.1177/112067210801800416
   Feigl B, 2005, INVEST OPHTH VIS SCI, V46, P4722, DOI 10.1167/iovs.05-0795
   Feigl B, 2005, EYE, V19, P1169, DOI 10.1038/sj.eye.6701711
   Feigl B, 2005, EYE, V19, P431, DOI 10.1038/sj.eye.6701503
   Feigl B, 2004, CURR EYE RES, V29, P327, DOI 10.1080/02713680490516198
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Gerth C, 2006, ARCH OPHTHALMOL-CHIC, V124, P345, DOI 10.1001/archopht.124.3.345
   Gerth C, 2003, ARCH OPHTHALMOL-CHIC, V121, P1404, DOI 10.1001/archopht.121.10.1404
   Gin TJ, 2011, INVEST OPHTH VIS SCI, V52, P9267, DOI 10.1167/iovs.11-8517
   Hartmann KI, 2011, RETINA-J RET VIT DIS, V31, P1323, DOI 10.1097/IAE.0b013e31820a6850
   Hogg RE, 2006, PROG RETIN EYE RES, V25, P249, DOI 10.1016/j.preteyeres.2005.11.002
   Hood DC, 2002, INVEST OPHTH VIS SCI, V43, P1673
   Hood DC, 2000, PROG RETIN EYE RES, V19, P607, DOI 10.1016/S1350-9462(00)00013-6
   Hood Donald C., 2000, Documenta Ophthalmologica, V100, P115, DOI 10.1023/A:1002727602212
   Jivrajka RV, 2013, EYE, V27, P1044, DOI 10.1038/eye.2013.112
   KLEIN R, 1995, INVEST OPHTH VIS SCI, V36, P182
   Landa G, 2011, RETINA-J RET VIT DIS, V31, P364, DOI 10.1097/IAE.0b013e3181e91132
   Lesmes Luis Andres, 2013, Drug Discov Today Ther Strateg, V10, pe43, DOI 10.1016/j.ddstr.2012.11.002
   Li J, 2001, BRIT J OPHTHALMOL, V85, P287, DOI 10.1136/bjo.85.3.287
   Luu CD, 2012, ARCH OPHTHALMOL-CHIC, V130, P690, DOI 10.1001/archophthalmol.2012.277
   Midena E, 1997, INVEST OPHTH VIS SCI, V38, P469
   Midena E, 2007, BRIT J OPHTHALMOL, V91, P1499, DOI 10.1136/bjo.2007.119685
   Neelam K, 2009, SURV OPHTHALMOL, V54, P167, DOI 10.1016/j.survophthal.2008.12.003
   Owsley C, 2000, INVEST OPHTH VIS SCI, V41, P267
   Parisi V, 2008, OPHTHALMOLOGY, V115, P324, DOI 10.1016/j.ophtha.2007.05.029
   Parisi V, 2007, RETINA-J RET VIT DIS, V27, P879, DOI 10.1097/IAE.0b013e318042d6aa
   Querques G, 2014, RETINA-J RET VIT DIS, V34, P330, DOI 10.1097/IAE.0b013e31829f7495
   Rudolph G, 2002, GRAEF ARCH CLIN EXP, V240, P874, DOI 10.1007/s00417-002-0549-9
   STEINMETZ RL, 1993, BRIT J OPHTHALMOL, V77, P549, DOI 10.1136/bjo.77.9.549
   Vujosevic S, 2011, OPHTHALMOLOGICA, V225, P155, DOI 10.1159/000320340
   Wu Z, 2014, OPHTHALMOLO IN PRESS
   Wu ZC, 2013, INVEST OPHTH VIS SCI, V54, P7378, DOI 10.1167/iovs.13-12617
   Wu ZC, 2013, OPHTHALMOLOGY, V120, P1307, DOI 10.1016/j.ophtha.2012.12.047
   Wu ZC, 2013, INVEST OPHTH VIS SCI, V54, P2800, DOI 10.1167/iovs.13-11613
NR 40
TC 32
Z9 34
U1 0
U2 9
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD OCT
PY 2014
VL 55
IS 10
BP 6431
EP 6439
DI 10.1167/iovs.14-14407
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA AQ9DY
UT WOS:000343147100040
PM 25159206
DA 2022-11-30
ER

PT J
AU Shuler, RK
   Hauser, MA
   Caldwell, J
   Gallins, P
   Schmidt, S
   Scott, WK
   Agarwal, A
   Haines, JL
   Pericak-Vance, MA
   Postel, EA
AF Shuler, R. Keith, Jr.
   Hauser, Michael A.
   Caldwell, Jennifer
   Gallins, Paul
   Schmidt, Silke
   Scott, William K.
   Agarwal, Anita
   Haines, Jonathan L.
   Pericak-Vance, Margaret A.
   Postel, Eric A.
TI Neovascular age-related macular degeneration and its association with
   LOC387715 and complement factor H polymorphism
SO ARCHIVES OF OPHTHALMOLOGY
LA English
DT Article
ID RISK; INCREASES
AB Objective: To compare phenotypes of 2 age-related macular degeneration (AMD) susceptibility genes: LOC387715 and complement factor H (CFH).
   Methods: Phenotypes of 755 AMD cases were characterized. The number of LOC387715 (T allele at rs10490924, or A69S) and CFH (T1277C at rs1061170, or Y402H) risk alleles were determined in each case. Individuals were divided into 5 groups by genotype: group 1, LOC-/-CFH-/-; group 2, LOC+/- CFH-/- or LOC+/+ CFH-/-; group 3, LOC-/- CFH+/- or LOC-/- CFH+/+; group 4, LOC+/- CFH+/-, LOC-/- CFH+/-, or LOC+/- CFH+/-; and group 5, LOC+/+ CFH+/+.
   Results: Signs of neovascular AMD including grade (P = .002), pigment epithelial detachment (P = .001), and subretinal hemorrhage (P < .001) demonstrated significant association with groups 2, 4, and 5 vs groups 1 and 3. Group 5 had a significantly younger mean age (72.3 years) compared with other groups ( P=. 002).
   Conclusions: The AMD cases possessing the LOC387715 (rs10490924) variant may have a higher risk of neovascular AMD. Individuals with AMD who are homozygous for both variants might be at greater risk for earlier onset of neovascular AMD.
C1 Duke Univ, Ctr Eye, Durham, NC 27710 USA.
   Duke Univ, Ctr Human Genet, Durham, NC 27710 USA.
   Vanderbilt Univ, Inst Eye, Nashville, TN USA.
   Vanderbilt Univ, Med Ctr, Ctr Human Genet Res, Nashville, TN USA.
C3 Duke University; Duke University; Vanderbilt University; Vanderbilt
   University
RP Postel, EA (通讯作者)，Duke Univ, Ctr Eye, Box 3802, Durham, NC 27710 USA.
EM poste002@mc.duke.edu
RI Haines, Jonathan/C-3374-2012; Scott, William/A-7593-2009
OI Haines, Jonathan/0000-0002-4351-4728; Scott, William/0000-0001-9336-6404
FU NATIONAL EYE INSTITUTE [U10EY012118] Funding Source: NIH RePORTER; NEI
   NIH HHS [U10 EY12118-05] Funding Source: Medline
CR Age-Related Eye Dis Study Res Grp, 2001, AM J OPHTHALMOL, V132, P668
   CHYLACK LT, 1993, ARCH OPHTHALMOL-CHIC, V111, P831, DOI 10.1001/archopht.1993.01090060119035
   DelaPaz MA, 1997, AM J OPHTHALMOL, V124, P331, DOI 10.1016/S0002-9394(14)70825-6
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Kassoff A, 1999, CONTROL CLIN TRIALS, V20, P573
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Klein R, 2004, AM J OPHTHALMOL, V137, P486, DOI 10.1016/j.ajo.2003.11.069
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Magnusson KP, 2006, PLOS MED, V3, P109, DOI 10.1371/journal.pmed.0030005
   Postel EA, 2005, AM J OPHTHALMOL, V139, P820, DOI 10.1016/j.ajo.2004.12.029
   Postel EA, 2006, OPHTHALMOLOGY, V113, P1504, DOI 10.1016/j.ophtha.2006.02.049
   Rivera A, 2005, HUM MOL GENET, V14, P3227, DOI 10.1093/hmg/ddi353
   Schmidt S, 2006, AM J HUM GENET, V78, P852, DOI 10.1086/503822
   Schmidt S, 2004, BMC GENET, V5, DOI 10.1186/1471-2156-5-18
   SHULER RK, 2006, 2006 JOINT M AM AC O
NR 16
TC 54
Z9 57
U1 0
U2 1
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 0003-9950
EI 1538-3601
J9 ARCH OPHTHALMOL-CHIC
JI Arch. Ophthalmol.
PD JAN
PY 2007
VL 125
IS 1
BP 63
EP 67
DI 10.1001/archopht.125.1.63
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 123ZQ
UT WOS:000243336800008
PM 17210853
OA Bronze
DA 2022-11-30
ER

PT J
AU Abu Asleh, S
   Lederman, M
   Weinstein, O
   Horowitz, S
   Meir, T
   Lahad, A
   Goldstein, N
   Sharon, D
   Israel, S
   Chowers, I
AF Abu Asleh, Saleh
   Lederman, Michal
   Weinstein, Orly
   Horowitz, Smadar
   Meir, Tal
   Lahad, Amnon
   Goldstein, Nurit
   Sharon, Dror
   Israel, Shoshana
   Chowers, Itay
TI Lack of association between the C2 allele of transferrin and age-related
   macular degeneration in the Israeli population
SO OPHTHALMIC GENETICS
LA English
DT Article
DE Transferrin; Hemochromatosis; Age-related macular degeneration
ID ALZHEIMERS-DISEASE; IRON; RISK; MUTATIONS; TOXICITY; BINDING; PROTEIN;
   VARIANT; GENES; ONSET
AB Background: Altered iron metabolism and transferrin expression were associated with neurodegen erations including age-related macular degeneration (AMD) and Alzheimer's disease (AD). Carriers of transferrin C2 allele alone or in combination with the hemochromatosis C282Y variant may have increased risk for developing AD. We aim to assess if these alleles also predispose to AMD.
   Methods: DNA was collected from 290 AMD patients and 157 unaffected, age-matched, controls. Genotyping was performed for transferrin C1/C2 alleles and hemochromatosis C282Y allele, and association with AMD was evaluated.
   Results: There was no association between the C1/C2 transferrin alleles and AMD. Hemochromatosis C282Y variant was identified in four individuals; one was an AMD patient and three were unaffected.
   Conclusion: Transferrin C2 and hemochromatosis C282Y alleles are not associated with increased risk for developing AMD in Israel.
C1 [Abu Asleh, Saleh; Lederman, Michal; Horowitz, Smadar; Meir, Tal; Sharon, Dror; Chowers, Itay] Hadassah Hebrew Univ Med Ctr, Dept Ophthalmol, IL-91120 Jerusalem, Israel.
   [Goldstein, Nurit; Israel, Shoshana] Hadassah Hebrew Univ Med Ctr, Tissue Typing Unit, IL-91120 Jerusalem, Israel.
   [Weinstein, Orly] Soroka Med Ctr, Dept Ophthalmol, IL-84101 Beer Sheva, Israel.
   [Lahad, Amnon] Hebrew Univ Jerusalem, Sch Med, Dept Family Med, IL-91010 Jerusalem, Israel.
C3 Hebrew University of Jerusalem; Hebrew University of Jerusalem; Ben
   Gurion University; Soroka Medical Center; Hebrew University of Jerusalem
RP Chowers, I (通讯作者)，Hadassah Hebrew Univ Med Ctr, Dept Ophthalmol, POB 12000, IL-91120 Jerusalem, Israel.
EM chowers@hadassah.org.il
RI Sharon, Dror/P-4539-2015
OI Sharon, Dror/0000-0002-1789-5811
FU Binational United States-Israel Science Fund (BSF); Hadassah-Hebrew
   University Medical Center
FX This study was supported in part by grants from the Binational United
   States-Israel Science Fund (BSF) and from the Hadassah-Hebrew University
   Medical Center. (I.C.)
CR Beckman L, 1986, Prog Clin Biol Res, V209B, P221
   Cabrera OEE, 1997, J NEUROSCI RES, V47, P603
   Chowers I, 2003, INVEST OPHTH VIS SCI, V44, P3732, DOI 10.1167/iovs.02-1080
   Chowers I, 2006, INVEST OPHTH VIS SCI, V47, P2135, DOI 10.1167/iovs.05-1135
   Dentchev T, 2005, ARCH OPHTHALMOL-CHIC, V123, P1745, DOI 10.1001/archopht.123.12.1745
   Dunaief JL, 2005, OPHTHALMOLOGY, V112, P1062, DOI 10.1016/j.ophtha.2004.12.029
   Edwards AO, 2008, ADV EXP MED BIOL, V613, P211, DOI 10.1007/978-0-387-74904-4_24
   Goland S, 2004, EUR J HEART FAIL, V6, P547, DOI 10.1016/j.ejheart.2003.11.003
   Hadziahmetovic M, 2008, INVEST OPHTH VIS SCI, V49, P2728, DOI 10.1167/iovs.07-1472
   Hahn P, 2003, ARCH OPHTHALMOL-CHIC, V121, P1099, DOI 10.1001/archopht.121.8.1099
   HAHN P, 2004, INVEST OPHTHALMOL VI, V45
   He XN, 2007, PROG RETIN EYE RES, V26, P649, DOI 10.1016/j.preteyeres.2007.07.004
   Hussain RI, 2002, NEUROSCI LETT, V317, P13, DOI 10.1016/S0304-3940(01)02403-X
   HYNDMAN AG, 1991, BRAIN RES, V561, P318, DOI 10.1016/0006-8993(91)91610-D
   Jouanolle AM, 1996, NAT GENET, V14, P251, DOI 10.1038/ng1196-251
   Kim KW, 2001, NEUROSCI LETT, V308, P45, DOI 10.1016/S0304-3940(01)01985-1
   Lehmann DJ, 2006, J MED GENET, V43, DOI 10.1136/jmg.2006.040519
   Lleo A, 2002, J NEUROL NEUROSUR PS, V72, P820, DOI 10.1136/jnnp.72.6.820-a
   Namekata K, 1997, HUM GENET, V101, P126, DOI 10.1007/s004390050600
   Picard E, 2008, MOL VIS, V14, P928
   Robson KJH, 2004, J MED GENET, V41, P261, DOI 10.1136/jmg.2003.015552
   Van Landeghem GF, 1998, NEUROREPORT, V9, P177
   van Rensburg SJ, 2000, ANN NY ACAD SCI, V903, P200, DOI 10.1111/j.1749-6632.2000.tb06369.x
   VANRENSBURG SJ, 1995, MED HYPOTHESES, V44, P268, DOI 10.1016/0306-9877(95)90178-7
   VANRENSBURG SJ, 1993, NEUROREPORT, V4, P1269, DOI 10.1097/00001756-199309000-00015
   Zambenedetti P, 2003, J ALZHEIMERS DIS, V5, P423, DOI 10.3233/JAD-2003-5601
   Zatta P, 2005, BBA-MOL BASIS DIS, V1741, P264, DOI 10.1016/j.bbadis.2005.04.009
   2001, ARCH OPHTHALMOL, V119, P1417
NR 28
TC 0
Z9 0
U1 1
U2 1
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 1381-6810
EI 1744-5094
J9 OPHTHALMIC GENET
JI Ophthalmic Genet.
PY 2009
VL 30
IS 4
BP 161
EP 164
DI 10.3109/13816810903147998
PG 4
WC Genetics & Heredity; Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Genetics & Heredity; Ophthalmology
GA 565UF
UT WOS:000275319600002
PM 19852572
DA 2022-11-30
ER

PT J
AU Jonas, JB
   Ihloff, AK
   Harder, B
   Kreissig, I
   Schlichtenbrede, F
   Libondi, T
   Spandau, UHM
   Vossmerbaeumer, U
AF Jonas, Jost B.
   Ihloff, Anna K.
   Harder, Bjoern
   Kreissig, Ingrid
   Schlichtenbrede, Frank
   Libondi, Teodosio
   Spandau, Ulrich H. M.
   Vossmerbaeumer, Urs
TI Intravitreal Bevacizumab versus Triamcinolone Acetonide for Exudative
   Age-Related Macular Degeneration
SO OPHTHALMIC RESEARCH
LA English
DT Article
DE Intravitreal bevacizumab; Intravitreal Avastin; Intravitreal
   triamcinolone; Age-related macular degeneration; Intraocular pressure;
   Intraocular steroids; Subfoveal neovascularization
ID COMBINED PHOTODYNAMIC THERAPY; CHOROIDAL NEOVASCULARIZATION SECONDARY;
   SUBRETINAL NEOVASCULARIZATION; SUBFOVEAL NEOVASCULARIZATION;
   INTRAOCULAR-PRESSURE; INJECTION; VERTEPORFIN; COMBINATION; AVASTIN;
   INHIBITION
AB Background: To compare an intravitreal high-dose injection of triamcinolone acetonide with an intravitreal injection of bevacizumab for the treatment of progressive exudative age-related macular degeneration (AMD). Method: The comparative nonrandomized retrospective clinical interventional study included 305 patients with progressive AMD, divided into a bevacizumab group of 36 patients (1.5 mg bevacizumab) and a triamcinolone group of 269 patients (about 20 mg triamcinolone). All patients were consecutively included, in the first phase of the study for triamcinolone, and in the second phase of the study for bevacizumab. The mean follow-up was 8.5 +/- 6.8 months (2-35.7 months). Results: In the bevacizumab group, best visual acuity increased significantly (p < 0.001) by 3.2 +/- 3.4 Snellen lines, with 25 (69%) eyes and 21 (58%) eyes, improving by at least 2 and 3 Snellen lines, respectively. In the triamcinolone group, the visual acuity change was not statistically significant for any specific follow-up examination within the first 3 months. The maximal increase in visual acuity, the visual acuity change at 2 months after injection and the percentage of patients with an improvement by at least 2 and 3 Snellen lines were significantly (p < 0.001) higher in the bevacizumab group than in the triamcinolone group. Intraocular pressure increased significantly (p < 0.001) in the triamcinolone group and did not change significantly (p = 0.47) in the bevacizumab group. Conclusion: In exudative AMD, intravitreal bevacizumab (1.5 mg) compared with intravitreal triamcinolone acetonide (about 20 mg) results in a higher improvement of visual acuity and does not markedly influence intraocular pressure within 2 months after injection. Copyright (C) 2008 S. Karger AG, Basel
C1 [Jonas, Jost B.; Ihloff, Anna K.; Harder, Bjoern; Kreissig, Ingrid; Schlichtenbrede, Frank; Libondi, Teodosio; Spandau, Ulrich H. M.; Vossmerbaeumer, Urs] Heidelberg Univ, Dept Ophthalmol, Med Fac Mannheim, Heidelberg, Germany.
C3 Ruprecht Karls University Heidelberg
RP Jonas, JB (通讯作者)，Univ Augenklin, Theodor Kutzer Ufer 1-3, DE-68167 Mannheim, Germany.
EM Jost.Jonas@ma.augen.uni-heidelberg.de
CR ANTOSZYK AN, 1993, GRAEF ARCH CLIN EXP, V231, P34, DOI 10.1007/BF01681698
   Arevalo JF, 2005, GRAEF ARCH CLIN EXP, V243, P1180, DOI 10.1007/s00417-005-1177-y
   Augustin AJ, 2006, AM J OPHTHALMOL, V141, P638, DOI 10.1016/j.ajo.2005.11.058
   Augustin AJ, 2006, OPHTHALMOLOGY, V113, P14, DOI 10.1016/j.ophtha.2005.09.002
   Avery RL, 2006, OPHTHALMOLOGY, V113, P363, DOI 10.1016/j.ophtha.2005.11.019
   Challa JK, 1998, AUST NZ J OPHTHALMOL, V26, P277, DOI 10.1111/j.1442-9071.1998.tb01330.x
   Ciulla TA, 2001, ARCH OPHTHALMOL-CHIC, V119, P399, DOI 10.1001/archopht.119.3.399
   Danis RP, 1996, OPHTHALMOLOGY, V103, P2099, DOI 10.1016/S0161-6420(96)30383-7
   Danis RP, 2000, RETINA-J RET VIT DIS, V20, P244, DOI 10.1097/00006982-200003000-00004
   Deckers V, 2005, Bull Soc Belge Ophtalmol, P69
   Degenring RF, 2005, ACTA OPHTHALMOL SCAN, V83, P621, DOI 10.1111/j.1600-0420.2005.00506.x
   Gillies MC, 2003, ARCH OPHTHALMOL-CHIC, V121, P667, DOI 10.1001/archopht.121.5.667
   Gillies MC, 2005, OPHTHALMOLOGY, V112, P139, DOI 10.1016/j.ophtha.2004.07.017
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   HEIER JS, 2006, OPHTHALMOLOGY, V113
   Hogan A, 2005, BRIT J OPHTHALMOL, V89, P1109, DOI 10.1136/bjo.2004.063024
   ISHIBASHI T, 1985, ARCH OPHTHALMOL-CHIC, V103, P708
   Iwama D, 2008, BRIT J OPHTHALMOL, V92, P1352, DOI 10.1136/bjo.2008.141754
   Jonas JB, 2006, EUR J OPHTHALMOL, V16, P566, DOI 10.1177/112067210601600411
   Jonas JB, 2005, ACTA OPHTHALMOL SCAN, V83, P645, DOI 10.1111/j.1600-0420.2005.00592.x
   Jonas JB, 2005, AM J OPHTHALMOL, V139, P1073, DOI 10.1016/j.ajo.2005.01.032
   Jonas JB, 2005, EUR J OPHTHALMOL, V15, P462, DOI 10.1177/112067210501500407
   Jonas JB, 2005, EYE, V19, P163, DOI 10.1038/sj.eye.6701438
   Jonas JB, 2004, BRIT J OPHTHALMOL, V88, P1557, DOI 10.1136/bjo.2003.039552
   Jonas JB, 2004, ARCH OPHTHALMOL-CHIC, V122, P218, DOI 10.1001/archopht.122.2.218
   Jonas JB, 2003, BRIT J OPHTHALMOL, V87, P462, DOI 10.1136/bjo.87.4.462
   Jonas JB, 2002, GRAEF ARCH CLIN EXP, V240, P872, DOI 10.1007/s00417-002-0547-y
   Jonas JB, 2005, OPHTHALMOLOGY, V112, P593, DOI 10.1016/j.ophtha.2004.10.042
   Jonas JB, 2006, J OCUL PHARMACOL TH, V22, P194, DOI 10.1089/jop.2006.22.194
   Ladewig MS, 2006, OPHTHALMOLOGE, V103, P463, DOI 10.1007/s00347-006-1352-5
   Larsson J, 2005, CLIN EXP OPHTHALMOL, V33, P544, DOI 10.1111/j.1442-9071.2005.01082.x
   Luke M, 2006, BRIT J OPHTHALMOL, V90, P1178, DOI 10.1136/bjo.2006.094995
   Manzano RPA, 2006, RETINA-J RET VIT DIS, V26, P257, DOI 10.1097/00006982-200603000-00001
   Maturi RK, 2006, RETINA-J RET VIT DIS, V26, P270, DOI 10.1097/00006982-200603000-00003
   Nicolo M, 2005, EUR J OPHTHALMOL, V15, P415, DOI 10.1177/112067210501500318
   Penfold PL, 1995, AUST NZ J OPHTHALMOL, V23, P293, DOI 10.1111/j.1442-9071.1995.tb00179.x
   Penfold PL, 2002, INVEST OPHTH VIS SCI, V43, P3125
   Penfold PL, 2002, BRIT J OPHTHALMOL, V86, P600, DOI 10.1136/bjo.86.6.600
   Penfold PL, 2001, CLIN EXP OPHTHALMOL, V29, P188, DOI 10.1046/j.1442-9071.2001.00407.x
   Potter MJ, 2006, GRAEF ARCH CLIN EXP, V244, P639, DOI 10.1007/s00417-005-0115-3
   Ranson NT, 2002, BRIT J OPHTHALMOL, V86, P527, DOI 10.1136/bjo.86.5.527
   Rechtman E, 2004, BRIT J OPHTHALMOL, V88, P344, DOI 10.1136/bjo.2003.027177
   Rich RM, 2006, RETINA-J RET VIT DIS, V26, P495, DOI 10.1097/01.iae.0000225766.75009.3a
   Rosenfeld PJ, 2005, OPHTHAL SURG LAS IM, V36, P331, DOI 10.3928/1542-8877-20050701-14
   Shahar J, 2006, RETINA-J RET VIT DIS, V26, P262, DOI 10.1097/00006982-200603000-00002
   Slakter JS, 2006, OPHTHALMOLOGY, V113, P3, DOI 10.1016/j.ophtha.2005.10.019
   Smithen LM, 2004, AM J OPHTHALMOL, V138, P884, DOI 10.1016/j.ajo.2004.05.073
   Spaide RF, 2005, OPHTHALMOLOGY, V112, P301, DOI 10.1016/j.ophtha.2004.08.012
   Spaide RF, 2003, OPHTHALMOLOGY, V110, P1517, DOI 10.1016/S0161-6420(03)00544-X
   Spaide RF, 2006, RETINA-J RET VIT DIS, V26, P383, DOI 10.1097/00006982-200604000-00001
   Spaide RF, 2005, RETINA-J RET VIT DIS, V25, P685, DOI 10.1097/00006982-200509000-00001
   TANO Y, 1980, AM J OPHTHALMOL, V89, P131, DOI 10.1016/0002-9394(80)90239-1
   TANO Y, 1980, AM J OPHTHALMOL, V90, P810, DOI 10.1016/S0002-9394(14)75196-7
   Weigert G, 2008, BRIT J OPHTHALMOL, V92, P356, DOI 10.1136/bjo.2007.125823
   Wingate RJB, 1999, AUST NZ J OPHTHALMOL, V27, P431
NR 55
TC 19
Z9 19
U1 0
U2 1
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 0030-3747
EI 1423-0259
J9 OPHTHALMIC RES
JI Ophthalmic Res.
PY 2009
VL 41
IS 1
BP 21
EP 27
DI 10.1159/000162113
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 372HC
UT WOS:000260891700004
PM 18849638
DA 2022-11-30
ER

PT J
AU Tsai, CY
   Chen, CT
   Wu, HH
   Liao, CC
   Hua, KT
   Hsu, CH
   Chen, CF
AF Tsai, Ching-Yao
   Chen, Chueh-Tan
   Wu, Hsin-Han
   Liao, Chen-Chung
   Hua, Kate
   Hsu, Chung-Hua
   Chen, Chian-Feng
TI Proteomic Profiling of Aqueous Humor Exosomes from Age-related Macular
   Degeneration Patients
SO INTERNATIONAL JOURNAL OF MEDICAL SCIENCES
LA English
DT Article
DE Aqueous Humor; Age-related macular degeneration; Exosome
ID ENDOTHELIAL GROWTH-FACTOR; CIGARETTE-SMOKING; OXIDATIVE STRESS; RISK;
   BIOMARKERS; CLUSTERIN; PROTEINS; C3
AB Purpose: The alteration of the exosomal proteins in the aqueous humor (AH) is linked to the development of eye diseases. The goal of this study was to examine the exosomal protein profile of patients with age-related macular degeneration (AMD) to better understand their role in the pathogenesis of AMD. Methods: Exosomes were isolated from the AH of 28 AMD and 25 control eyes. The quality, concentration, and size distribution of exosomes were measured using a nanoparticle tracking analysis system (NTA). Total exosomal proteins from each sample were purified and digested with trypsin for liquid chromatography-tandem mass spectrometry (LC-MS/MS) analysis. Results: Based on LC-MS/MS analysis, we got 105 exosomal peptides from AMD and control patients. Gene ontology (GO) analysis in the biology process revealed that exosomal proteins of AMD were enriched in the lipoprotein metabolic process. T-test analysis revealed six exosomal proteins in patients with AMD were significantly different from controls. Comparing the exosomal protein profile of AMD patients who were receiving anti-VEGF therapy, we observed the amount of two proteins decreased with the duration of the anti-VEGF treatment time. Conclusions: In this study, we successfully isolated and purified AH exosomes. Our results provide pioneering findings for the exosomal protein profile in AMD development and under therapy. These unique proteins could be the new targets for drug discovery or biological markers for evaluating therapeutic efficacy.
C1 [Tsai, Ching-Yao; Chen, Chueh-Tan] Taipei City Hosp, Zhongxing Branch, Dept Ophthalmol, Taipei, Taiwan.
   [Tsai, Ching-Yao] Natl Yang Ming Chiao Tung Univ, Inst Publ Hlth, Taipei, Taiwan.
   [Tsai, Ching-Yao] Fu Jen Catholic Univ, Dept Business Adm, New Taipei, Taiwan.
   [Chen, Chueh-Tan; Hsu, Chung-Hua] Natl Yang Ming Chiao Tung Univ, Inst Tradit Med, Taipei, Taiwan.
   [Wu, Hsin-Han; Hua, Kate; Chen, Chian-Feng] Natl Yang Ming Chiao Tung Univ, Canc Progress Res Ctr, Taipei, Taiwan.
   [Liao, Chen-Chung] Natl Yang Ming Chiao Tung Univ, Metabol Prote Res Ctr, Taipei, Taiwan.
   [Hsu, Chung-Hua] Taipei City Hosp, Linsen Chinese Med & Kunming Branch, Dept Chinese Med, Taipei, Taiwan.
C3 Taipei City Hospital; National Yang Ming Chiao Tung University; Fu Jen
   Catholic University; National Yang Ming Chiao Tung University; National
   Yang Ming Chiao Tung University; National Yang Ming Chiao Tung
   University; Taipei City Hospital
RP Chen, CF (通讯作者)，155,Sect 2,Linong St, Taipei 112, Taiwan.
EM cfchen@nycu.edu.tw
FU National Core Facility for Biopharmaceuticals (NCFB), Ministry of
   Science and Technology; Ministry of Science and Technology of Taiwan
   [MOST 108-2314-B-532-009-]; Taipei City Hospital [TPCH-110-]
FX We acknowledge the technical services provided by the Center for
   Clinical and Biotechnological Applications of National Yang Ming Chiao
   Tung University. The core facility is supported by the National Core
   Facility for Biopharmaceuticals (NCFB), Ministry of Science and
   Technology. This study was supported by grants from the Ministry of
   Science and Technology of Taiwan (MOST 108-2314-B-532-009-) and Taipei
   City Hospital (TPCH-110-) .
CR Apte RS, 2021, NEW ENGL J MED, V385, P539, DOI 10.1056/NEJMcp2102061
   Banks WA, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21124407
   Cao RY, 2019, J CELL PHYSIOL, V234, P17444, DOI 10.1002/jcp.28366
   Chen CF, 2019, TOHOKU J EXP MED, V249, P213, DOI 10.1620/tjem.249.213
   Cho YK, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms222111837
   Christen WG, 1996, JAMA-J AM MED ASSOC, V276, P1147, DOI 10.1001/jama.276.14.1147
   Colombo M, 2014, ANNU REV CELL DEV BI, V30, P255, DOI 10.1146/annurev-cellbio-101512-122326
   Comfort N, 2021, J VIS EXP, V169, P62447
   Cunha-Vaz J, 2011, EUR J OPHTHALMOL, V21, pS3, DOI 10.5301/EJO.2010.6049
   Davis MD, 2005, ARCH OPHTHALMOL-CHIC, V123, P1484
   Deng YH, 2022, GENES DIS, V9, P62, DOI 10.1016/j.gendis.2021.02.009
   Dismuke WM, 2015, EXP EYE RES, V132, P73, DOI 10.1016/j.exer.2015.01.019
   Gao C, 2021, INT J OPHTHALMOL-CHI, V14, P1484, DOI 10.18240/ijo.2021.10.03
   Ge SX, 2020, BIOINFORMATICS, V36, P2628, DOI 10.1093/bioinformatics/btz931
   Goel M, 2010, OPEN OPHTHALMOL J, V4, P52, DOI 10.2174/1874364101004010052
   Han XK, 2021, INT J EPIDEMIOL, V50, P325, DOI 10.1093/ije/dyaa178
   He CJ, 2018, THERANOSTICS, V8, P237, DOI 10.7150/thno.21945
   Helgason H, 2013, NAT GENET, V45, P1371, DOI 10.1038/ng.2740
   Hoeben A, 2004, PHARMACOL REV, V56, P549, DOI 10.1124/pr.56.4.3
   Ji ML, 2019, J CANCER, V10, P5557, DOI 10.7150/jca.35380
   Jiang LC, 2020, ONCOL LETT, V20, DOI 10.3892/ol.2020.12141
   Kang GY, 2014, J PROTEOME RES, V13, P581, DOI 10.1021/pr400751k
   Kelly UL, 2020, J BIOL CHEM, V295, P13601, DOI 10.1074/jbc.RA119.012305
   Kim BJ, 2021, PROG RETIN EYE RES, V83, DOI 10.1016/j.preteyeres.2020.100936
   Kim JH, 2010, INVEST OPHTH VIS SCI, V51, P561, DOI 10.1167/iovs.09-3774
   Kwon CH, 2014, BRIT J CANCER, V111, P1993, DOI 10.1038/bjc.2014.490
   Lu Ming, 2006, Ophthalmol Clin North Am, V19, P323
   Ma Ho Hin, 2021, Acta Med Litu, V28, P36, DOI 10.15388/Amed.2021.28.1.7
   MILLER JW, 1994, AM J PATHOL, V145, P574
   Nashine S, 2021, CELLS-BASEL, V10, DOI 10.3390/cells10092483
   Nordestgaard LT, 2021, J CLIN ENDOCR METAB, V106, pE2749, DOI 10.1210/clinem/dgab095
   Sakaguchi H, 2002, EXP EYE RES, V74, P547, DOI 10.1006/exer.2002.1186
   Scholl HPN, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002593
   Seddon JM, 2003, ARCH OPHTHALMOL-CHIC, V121, P785, DOI 10.1001/archopht.121.6.785
   Seddon JM, 1996, JAMA-J AM MED ASSOC, V276, P1141, DOI 10.1001/jama.276.14.1141
   Seddon JM, 2006, ARCH OPHTHALMOL-CHIC, V124, P995, DOI 10.1001/archopht.124.7.995
   Sivagurunathan S, 2021, INDIAN J OPHTHALMOL, V69, P647, DOI 10.4103/ijo.IJO_470_20
   Sivaprasad S, 2007, ARCH OPHTHALMOL-CHIC, V125, P515, DOI 10.1001/archopht.125.4.515
   Steinmetz JD, 2021, LANCET GLOB HEALTH, V9, pE144, DOI 10.1016/S2214-109X(20)30489-7
   Strunz T, 2020, CELLS-BASEL, V9, DOI 10.3390/cells9102267
   Trougakos IP, 2006, FREE RADICAL RES, V40, P1324, DOI 10.1080/10715760600902310
   Tsai CY, 2021, INT J MED SCI, V18, P2023, DOI 10.7150/ijms.51735
   van der Vorst Emiel P C, 2020, Subcell Biochem, V94, P399, DOI 10.1007/978-3-030-41769-7_16
   Wang L, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010329
   Wecker T, 2016, INVEST OPHTH VIS SCI, V57, P1706, DOI 10.1167/iovs.15-17828
   Yang SQ, 2016, DRUG DES DEV THER, V10, P1857, DOI 10.2147/DDDT.S97653
NR 46
TC 0
Z9 0
U1 3
U2 3
PU IVYSPRING INT PUBL
PI LAKE HAVEN
PA PO BOX 4546, LAKE HAVEN, NSW 2263, AUSTRALIA
SN 1449-1907
J9 INT J MED SCI
JI Int. J. Med. Sci.
PY 2022
VL 19
IS 5
BP 893
EP 900
DI 10.7150/ijms.73489
PG 8
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA 1U5DY
UT WOS:000805434500013
PM 35693737
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Stone, EM
   Braun, TA
   Russell, SR
   Kuehn, MH
   Lotery, AJ
   Moore, PA
   Eastman, CG
   Casavant, TL
   Sheffield, VC
AF Stone, EM
   Braun, TA
   Russell, SR
   Kuehn, MH
   Lotery, AJ
   Moore, PA
   Eastman, CG
   Casavant, TL
   Sheffield, VC
TI Missense variations in the fibulin 5 gene and age-related macular
   degeneration
SO NEW ENGLAND JOURNAL OF MEDICINE
LA English
DT Article
ID MALATTIA LEVENTINESE; ALLELIC VARIATION; VISUAL IMPAIRMENT;
   STARGARDT-DISEASE; MUTATION; ABCR; MACULOPATHY; POPULATION; PREVALENCE;
   BLINDNESS
AB Background: Age-related macular degeneration (AMD) is the most common cause of irreversible vision loss in the developed world. The study of a rare mendelian form of macular degeneration implicated fibulin genes in the pathogenesis of more common forms of this disease. We evaluated five fibulin genes in a large series of patients with AMD.
   Methods: We studied 402 patients with AMD and 429 control subjects from the same clinic population. Patients were examined by means of indirect ophthalmoscopy, slit-lamp microscopy, and fundus photography to establish the presence and phenotypic pattern of AMD. DNA samples were screened for sequence variations in five members of the fibulin gene family.
   Results: Amino acid-altering sequence variations were found in all five fibulin genes, many of which were observed only in patients with AMD. Several of the altered residues have been conserved during evolution. Seven of the 402 patients with AMD had amino acid-altering sequence variations in the fibulin 5 gene, whereas none were observed among 429 control subjects (P<0.01). In addition, these seven patients all had small, circular drusen, which are commonly referred to as basal laminar or cuticular drusen.
   Conclusions: Missense mutations in the fibulin 5 gene were found in 1.7 percent of patients with AMD. Many variations in other fibulin genes were also found in these patients, and the evolutionary conservation of the affected residues suggests that several of these variations may also be involved in AMD.
C1 Univ Iowa, Carver Coll Med, Ctr Macular Degenerat, Iowa City, IA 52242 USA.
   Univ Iowa, Howard Hughes Med Inst, Iowa City, IA 52242 USA.
   Univ Southampton, Dept Ophthalmol, Southampton, Hants, England.
C3 University of Iowa; Howard Hughes Medical Institute; University of Iowa;
   University of Southampton
RP Stone, EM (通讯作者)，Univ Iowa, Carver Coll Med, Ctr Macular Degenerat, 200 Hawkins Dr, Iowa City, IA 52242 USA.
EM edwin-stone@uiowa.edu
OI Sheffield, Val/0000-0002-6282-0835; Lotery, Andrew/0000-0001-5541-4305;
   Russell, Stephen/0000-0003-3776-1367; Kuehn, Markus/0000-0003-3940-198X;
   Stone, Edwin M./0000-0003-3343-4414
CR Allikmets R, 1997, NAT GENET, V17, P122, DOI 10.1038/ng0997-122b
   Allikmets R, 1997, NAT GENET, V15, P236, DOI 10.1038/ng0397-236
   Allikmets R, 1997, SCIENCE, V277, P1805, DOI 10.1126/science.277.5333.1805
   Attebo K, 1996, OPHTHALMOLOGY, V103, P357
   BUFFONE GJ, 1985, CLIN CHEM, V31, P164
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Gass JD., 1977, STEREOSCOPIC ATLAS M, V2
   GASS JDM, 1985, AM J OPHTHALMOL, V99, P445
   Hayward C, 2003, HUM MOL GENET, V12, P2657, DOI 10.1093/hmg/ddg289
   HEIBA IM, 1994, GENET EPIDEMIOL, V11, P51, DOI 10.1002/gepi.1370110106
   Heon E, 1996, ARCH OPHTHALMOL-CHIC, V114, P193, DOI 10.1001/archopht.1996.01100130187014
   Klaver CCW, 1998, ARCH OPHTHALMOL-CHIC, V116, P653, DOI 10.1001/archopht.116.5.653
   Klaver CCW, 1998, ARCH OPHTHALMOL-CHIC, V116, P1646, DOI 10.1001/archopht.116.12.1646
   Loeys B, 2002, HUM MOL GENET, V11, P2113, DOI 10.1093/hmg/11.18.2113
   Lotery AJ, 2000, INVEST OPHTH VIS SCI, V41, P1291
   Marmorstein LHY, 2002, P NATL ACAD SCI USA, V99, P13067, DOI 10.1073/pnas.202491599
   Nakamura T, 2002, NATURE, V415, P171, DOI 10.1038/415171a
   NICHOLS BE, 1993, NAT GENET, V3, P202, DOI 10.1038/ng0393-202
   Petrukhin K, 1998, NAT GENET, V19, P241, DOI 10.1038/915
   Schultz DW, 2003, HUM MOL GENET, V12, P3315, DOI 10.1093/hmg/ddg348
   Seddon JM, 1997, AM J OPHTHALMOL, V123, P199, DOI 10.1016/S0002-9394(14)71036-0
   Stone EM, 1999, NAT GENET, V22, P199, DOI 10.1038/9722
   Stone EM, 1998, NAT GENET, V20, P328, DOI 10.1038/3798
   TIELSCH JM, 1995, NEW ENGL J MED, V332, P1205, DOI 10.1056/NEJM199505043321806
   Timpl R, 2003, NAT REV MOL CELL BIO, V4, P479, DOI 10.1038/nrm1130
   Vogel BE, 2001, DEVELOPMENT, V128, P883
   WEBER BHF, 1994, NAT GENET, V8, P352, DOI 10.1038/ng1294-352
   Webster AR, 2001, INVEST OPHTH VIS SCI, V42, P1179
   Yanagisawa H, 2002, NATURE, V415, P168, DOI 10.1038/415168a
   Zhang K, 2001, NAT GENET, V27, P89, DOI 10.1038/83817
NR 30
TC 247
Z9 259
U1 0
U2 6
PU MASSACHUSETTS MEDICAL SOC
PI WALTHAM
PA WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA
SN 0028-4793
EI 1533-4406
J9 NEW ENGL J MED
JI N. Engl. J. Med.
PD JUL 22
PY 2004
VL 351
IS 4
BP 346
EP 353
DI 10.1056/NEJMoa040833
PG 8
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA 839RC
UT WOS:000222801200008
PM 15269314
DA 2022-11-30
ER

PT J
AU Phan, TV
   Seoud, L
   Chakor, H
   Cheriet, F
AF Thanh Van Phan
   Seoud, Lama
   Chakor, Hadi
   Cheriet, Farida
TI Automatic Screening and Grading of Age-Related Macular Degeneration from
   Texture Analysis of Fundus Images
SO JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID DRUSEN; SEGMENTATION; CLASSIFICATION
AB Age-related macular degeneration (AMD) is a disease which causes visual deficiency and irreversible blindness to the elderly. In this paper, an automatic classification method for AMD is proposed to perform robust and reproducible assessments in a telemedicine context. First, a study was carried out to highlight the most relevant features for AMD characterization based on texture, color, and visual context in fundus images. A support vector machine and a random forest were used to classify images according to the different AMD stages following the AREDS protocol and to evaluate the features' relevance. Experiments were conducted on a database of 279 fundus images coming from a telemedicine platform. The results demonstrate that local binary patterns in multiresolution are the most relevant for AMD classification, regardless of the classifier used. Depending on the classification task, our method achieves promising performances with areas under the ROC curve between 0.739 and 0.874 for screening and between 0.469 and 0.685 for grading. Moreover, the proposed automatic AMD classification system is robust with respect to image quality.
C1 [Thanh Van Phan] Ecole Polytech, Biomed Engn Inst, Montreal, PQ H3C 3A7, Canada.
   [Thanh Van Phan] Univ Libre Bruxelles, B-1050 Brussels, Belgium.
   [Seoud, Lama; Chakor, Hadi] Diagnos Inc, Brossard, PQ J4Z 1A7, Canada.
   [Cheriet, Farida] Ecole Polytech, Dept Comp & Software Engn, Montreal, PQ H3C 3A7, Canada.
C3 Universite de Montreal; Polytechnique Montreal; Universite Libre de
   Bruxelles; Universite de Montreal; Polytechnique Montreal
RP Seoud, L (通讯作者)，Diagnos Inc, Brossard, PQ J4Z 1A7, Canada.
EM lseoud@diagnos.ca
OI Phan, Thanh Van/0000-0002-1849-1368
FU Diagnos Inc.; Natural Sciences and Engineering Research Council of
   Canada
FX The authors would like to acknowledge the contribution of Philippe
   Debanne for revising this paper. This work was funded by Diagnos Inc.
   and Natural Sciences and Engineering Research Council of Canada.
CR Agurto C, 2011, INVEST OPHTH VIS SCI, V52, P5862, DOI 10.1167/iovs.10-7075
   Akram MU, 2013, 2013 INTERNATIONAL CONFERENCE ON ELECTRONICS, COMPUTER AND COMPUTATION (ICECCO), P17, DOI 10.1109/ICECCO.2013.6718217
   Barriga E. S., 2009, P 22 IEEE INT S COMP
   Bartling H, 2009, ACTA OPHTHALMOL, V87, P643, DOI 10.1111/j.1755-3768.2008.01321.x
   Brandon L, 2003, LECT NOTES COMPUT SC, V2878, P618
   BREIMAN L, 2001, MACH LEARN, V0045
   Breiman L., 2002, MANUAL SETING USING
   Dalal N, 2005, PROC CVPR IEEE, P886, DOI 10.1109/cvpr.2005.177
   Davis MD, 2005, ARCH OPHTHALMOL-CHIC, V123, P1484
   DELONG ER, 1988, BIOMETRICS, V44, P837, DOI 10.2307/2531595
   Duda R. O., 2009, PATTERN CLASSIFICATI, P84
   Fasih M., 2014, P SPIE
   Feeny AK, 2015, COMPUT BIOL MED, V65, P124, DOI 10.1016/j.compbiomed.2015.06.018
   Garnier M., 2014, P SPIE, V9035
   Guo ZH, 2010, IEEE T IMAGE PROCESS, V19, P1657, DOI 10.1109/TIP.2010.2044957
   Hanafi M., 2010, P SGAI INT C ART INT
   Kanagasingam Y, 2014, PROG RETIN EYE RES, V38, P20, DOI 10.1016/j.preteyeres.2013.10.002
   Kankanahalli S, 2013, INVEST OPHTH VIS SCI, V54, P1789, DOI 10.1167/iovs.12-10928
   Kasuga DT, 2011, AGE-RELATED MACULAR DEGENERATION DIAGNOSIS AND TREATMENT, P1, DOI 10.1007/978-1-4614-0125-4_1
   Kose C, 2010, J MED SYST, V34, P1, DOI 10.1007/s10916-008-9210-4
   Liang ZY, 2010, IEEE ENG MED BIO, P4100, DOI 10.1109/IEMBS.2010.5627289
   Meleth AD, 2011, AGE-RELATED MACULAR DEGENERATION DIAGNOSIS AND TREATMENT, P65, DOI 10.1007/978-1-4614-0125-4_5
   Mora AD, 2011, BIOMED ENG ONLINE, V10, DOI 10.1186/1475-925X-10-59
   MORGAN WH, 1994, AUST NZ J OPHTHALMOL, V22, P7, DOI 10.1111/j.1442-9071.1994.tb01688.x
   Ojala T, 2002, IEEE T PATTERN ANAL, V24, P971, DOI 10.1109/TPAMI.2002.1017623
   Oliveira CM, 2011, OPHTHALMOLOGICA, V226, P191, DOI 10.1159/000330285
   Parvathi SS, 2007, ICCIMA 2007: INTERNATIONAL CONFERENCE ON COMPUTATIONAL INTELLIGENCE AND MULTIMEDIA APPLICATIONS, VOL II, PROCEEDINGS, P377, DOI 10.1109/ICCIMA.2007.100
   Penha FM, 2011, AGE-RELATED MACULAR DEGENERATION DIAGNOSIS AND TREATMENT, P79, DOI 10.1007/978-1-4614-0125-4_6
   Phan T. V., 2015, P INT C IM AN REC NI
   Prasath AR, 2015, RES J INF TECHNOL, V7, P70
   Priya R., 2011, 2011 3rd International Conference on Electronics Computer Technology (ICECT 2011), P227, DOI 10.1109/ICECTECH.2011.5941690
   Quellec G, 2011, IEEE T MED IMAGING, V30, P523, DOI 10.1109/TMI.2010.2089383
   Rapantzikos K, 2003, MED IMAGE ANAL, V7, P95, DOI 10.1016/S1361-8415(02)00093-2
   Remeseiro B, 2009, LECT NOTES COMPUT SC, V5717, P187, DOI 10.1007/978-3-642-04772-5_25
   Seoud Lama, 2016, IEEE Trans Med Imaging, V35, P1116, DOI 10.1109/TMI.2015.2509785
   Smith RT, 2005, ARCH OPHTHALMOL-CHIC, V123, P200, DOI 10.1001/archopht.123.2.200
   Soliz P, 2002, P SOC PHOTO-OPT INS, V4681, P159, DOI 10.1117/12.466917
   Steinwart I., 2008, SUPPORT VECTOR MACHI
   Sundaresan V., 2015, P OPHTH MED IM AN 2, P81
   van Grinsven MJJP, 2013, I S BIOMED IMAGING, P1444
   Van Grinsven M. J. J. P., 2013, P SPIE MED IM 2013 C
   Viera AJ, 2005, FAM MED, V37, P360
   Walter T, 2007, MED IMAGE ANAL, V11, P555, DOI 10.1016/j.media.2007.05.001
   Webb AR, 2003, STAT PATTERN RECOGNI, V2
NR 44
TC 15
Z9 15
U1 0
U2 3
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 2090-004X
EI 2090-0058
J9 J OPHTHALMOL
JI J. Ophthalmol.
PY 2016
VL 2016
AR 5893601
DI 10.1155/2016/5893601
PG 11
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA DK4MN
UT WOS:000374892600001
PM 27190636
OA Green Published, Green Submitted, Green Accepted, gold
DA 2022-11-30
ER

PT J
AU Adams, MKM
   Simpson, JA
   Richardson, AJ
   Guymer, RH
   Williamson, E
   Cantsilieris, S
   English, DR
   Aung, KZ
   Makeyeva, GA
   Giles, GG
   Hopper, J
   Robman, LD
   Baird, PN
AF Adams, Madeleine K. M.
   Simpson, Julie A.
   Richardson, Andrea J.
   Guymer, Robyn H.
   Williamson, Elizabeth
   Cantsilieris, Stuart
   English, Dallas R.
   Aung, Khin Zaw
   Makeyeva, Galina A.
   Giles, Graham G.
   Hopper, John
   Robman, Liubov D.
   Baird, Paul N.
TI Can genetic associations change with age? CFH and age-related macular
   degeneration
SO HUMAN MOLECULAR GENETICS
LA English
DT Article
ID COMPLEMENT FACTOR-H; CIGARETTE-SMOKING; RISK; DISEASE; POLYMORPHISM;
   VARIANT; SUSCEPTIBILITY; HAPLOTYPES; MORTALITY; ADULTS
AB Genetic variation in the gene encoding complement factor H (CFH) on chromosome 1q31 has repeatedly been associated with an increased risk of age-related macular degeneration (AMD); however, previous studies have had inadequate numbers of participants across a sufficiently wide age range to determine whether the association varies by age. We conducted a genetic casecontrol study using data from 2294 cases and 2294 controls selected from the Melbourne Collaborative Cohort Study, matched on age, sex and region of origin. Four consistently replicated CFH single-nucleotide polymorphisms (SNPs) were genotyped: rs1061170 (Y402H), rs2274700, rs393955 and rs800292; their relationship with AMD prevalence was determined across the age range 4886. A difference in genotype frequencies was seen across age groups, where the low-risk homozygote prevalence rose with each increasing age group. Associations with early AMD were strongly modified by age for three of the four SNPs (interaction P-value: 0.010.00003). An inverse association between the high-risk homozygote for each SNP and early AMD was observed in the younger age groups [odds ratios (OR) range 0.370.48 for age 55], reversing to a positive association with increasing age (OR 1.872.8 for age 75). The direction of associations for this gene change was from inverse to risk with increasing age. These findings have important implications for predictive models for AMD and potentially other age-related diseases which extrapolate risks from older cohorts, as they assume homogeneity of association by age, which might not exist.
C1 [Adams, Madeleine K. M.; Richardson, Andrea J.; Guymer, Robyn H.; Cantsilieris, Stuart; Aung, Khin Zaw; Makeyeva, Galina A.; Robman, Liubov D.; Baird, Paul N.] Univ Melbourne, Royal Victorian Eye & Ear Hosp, Ctr Eye Res Australia, Melbourne, Vic 3002, Australia.
   [Simpson, Julie A.; Williamson, Elizabeth; English, Dallas R.; Giles, Graham G.; Hopper, John] Univ Melbourne, Melbourne Sch Populat Hlth, Ctr Mol Environm Genet & Analyt Epidemiol, Melbourne, Vic, Australia.
   [Simpson, Julie A.; English, Dallas R.; Giles, Graham G.] Canc Council Victoria, Canc Epidemiol Ctr, Melbourne, Vic, Australia.
C3 Centre for Eye Research Australia; Royal Victorian Eye & Ear Hospital;
   University of Melbourne; University of Melbourne; Cancer Council
   Victoria
RP Adams, MKM (通讯作者)，Univ Melbourne, Royal Victorian Eye & Ear Hosp, Ctr Eye Res Australia, 32 Gisborne St, Melbourne, Vic 3002, Australia.
EM madeleine.adams@bigpond.com
RI English, Dallas/AAH-5005-2019; Williamson, Elizabeth/H-3876-2019; Adams,
   Madeleine K M/B-7915-2016; Simpson, Julie A/P-7299-2014
OI English, Dallas/0000-0001-7828-8188; Williamson,
   Elizabeth/0000-0001-6905-876X; Adams, Madeleine K M/0000-0002-5277-5487;
   Simpson, Julie/0000-0002-2660-2013; Guymer, Robyn/0000-0002-9441-4356;
   Baird, Paul/0000-0002-1305-3502; Giles, Graham/0000-0003-4946-9099
FU VicHealth; Cancer Council Victoria; National Health and Medical Research
   Council of Australia (NHMRC) [209057, 251533, 396414]; Ophthalmic
   Research Institute of Australia; American Health Assistance Foundation;
   John Reid Charitable Trust; Perpetual Trustees; Royal Victorian Eye and
   Ear Hospital; NHMRC; Wagstaff Fellowship; Hugh Noel Puckle Scholarship
FX This work was supported by VicHealth, the Cancer Council Victoria
   (initial cohort recruitment) and the National Health and Medical
   Research Council of Australia (NHMRC) (program grant 209057, capacity
   building grant 251533 and enabling grant 396414). The ophthalmic
   component was funded by the Ophthalmic Research Institute of Australia,
   American Health Assistance Foundation, John Reid Charitable Trust,
   Perpetual Trustees and the Royal Victorian Eye and Ear Hospital. People
   support was provided through the NHMRC Practitioner Fellowship to R. H.
   G., Wagstaff Fellowship to L. D. R. and an NHMRC PhD. Scholarship and
   Hugh Noel Puckle Scholarship to M. K. M. A. NHMRC Research Fellowship to
   P.N.B. and J.H. The Centre for Eye Research Australia (CERA) receives
   operational infrastructure support from the Victorian Government. The
   funding organizations did not have any involvement in study design and
   data collection, analysis and interpretation.
CR Adams M. K., 2011, AM J EPIDEMIOL
   Appelboom G, 2011, J CLIN NEUROSCI, V18, P1439, DOI 10.1016/j.jocn.2011.04.001
   Atmon G, 2005, MECH AGEING DEV, V126, P341, DOI 10.1016/j.mad.2004.08.026
   Aung KZ, 2009, OPHTHAL EPIDEMIOL, V16, P254, DOI [10.3109/09286580902864419, 10.1080/09286580902864419]
   Baird PN, 2008, HUM MOL GENET, V17, P1299, DOI 10.1093/hmg/ddn018
   Baird PN, 2006, INVEST OPHTH VIS SCI, V47, P4194, DOI 10.1167/iovs.05-1285
   Bergeron-Sawitzke J, 2009, EUR J HUM GENET, V17, P1190, DOI 10.1038/ejhg.2009.23
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   BRENNER DE, 1993, NEUROLOGY, V43, P293, DOI 10.1212/WNL.43.2.293
   Chamberlain M, 2006, SURV OPHTHALMOL, V51, P576, DOI 10.1016/j.survophthal.2006.08.003
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   DeAngelis MM, 2007, ARCH OPHTHALMOL-CHIC, V125, P49, DOI 10.1001/archopht.125.1.49
   Duffy DL, 2010, AM J HUM GENET, V87, P6, DOI 10.1016/j.ajhg.2010.05.017
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Francis PJ, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0001197
   Francis PJ, 2011, CLIN OPHTHALMOL, V5, P1127, DOI 10.2147/OPTH.S11627
   Gehrs K. M., ARCH OPHTHALMOL, V128, P349
   Giles GG, 1990, P NUTR SOC AUST, V15, P61
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Jylhava J, 2010, PFLUG ARCH EUR J PHY, V459, P239, DOI 10.1007/s00424-009-0726-3
   Jylhava J, 2009, EXP GERONTOL, V44, P297, DOI 10.1016/j.exger.2008.10.006
   Kenyon CJ, 2010, NATURE, V464, P504, DOI 10.1038/nature08980
   Kim IK, 2008, MOL VIS, V14, P1487
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Klein R, 2008, OPHTHALMOLOGY, V115, P1742, DOI 10.1016/j.ophtha.2008.03.021
   Lescai F, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011876
   Leveziel N, 2011, OPHTHALMOLOGICA, V226, DOI 10.1159/000328981
   Li M, 2006, NAT GENET, V38, P1049, DOI 10.1038/ng1871
   Marshall Stephen W, 2007, Epidemiol Perspect Innov, V4, P4, DOI 10.1186/1742-5573-4-4
   Middelberg RP, 2012, HUM MOL GENET, V21, P446, DOI 10.1093/hmg/ddr478
   RIPOCHE J, 1988, BIOCHEM J, V249, P593, DOI 10.1042/bj2490593
   Rozing MP, 2009, AGING-US, V1, P714, DOI 10.18632/aging.100071
   Sambrooke J., 1989, MOL CLONING LAB MANU, pE3
   Slagboom PE, 2011, PHILOS T R SOC B, V366, P35, DOI 10.1098/rstb.2010.0284
   Swaroop A, 2009, ANNU REV GENOM HUM G, V10, P19, DOI 10.1146/annurev.genom.9.081307.164350
   Thakkinstian A, 2006, HUM MOL GENET, V15, P2784, DOI 10.1093/hmg/ddl220
   van Leeuwen R, 2003, ARCH OPHTHALMOL-CHIC, V121, P519, DOI 10.1001/archopht.121.4.519
   WeverlingRijnsburger AWE, 1997, LANCET, V350, P1119, DOI 10.1016/S0140-6736(97)04430-9
NR 39
TC 17
Z9 18
U1 0
U2 2
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0964-6906
EI 1460-2083
J9 HUM MOL GENET
JI Hum. Mol. Genet.
PD DEC 1
PY 2012
VL 21
IS 23
BP 5229
EP 5236
DI 10.1093/hmg/dds364
PG 8
WC Biochemistry & Molecular Biology; Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Genetics & Heredity
GA 035SE
UT WOS:000310967900018
PM 22936692
OA Bronze, Green Published
DA 2022-11-30
ER

PT J
AU Klein, R
   Knudtson, MD
   Klein, BEK
AF Klein, Ronald
   Knudtson, Michael D.
   Klein, Barbara E. K.
TI Pulmonary disease and age-related macular degeneration - The Beaver Dam
   Eye Study
SO ARCHIVES OF OPHTHALMOLOGY
LA English
DT Article
ID VISUAL-ACUITY; INFLAMMATORY MARKERS; GROWTH-FACTORS; MACULOPATHY;
   POPULATION; DRUSEN; ASSOCIATION; PROGRESSION; HYPOXIA; PERIOD
AB Objective: To examine the association of pulmonary symptoms, disease, and function with the incidence of age-related macular degeneration (AMD).
   Design: Population-based cohort study of persons aged 43 to 86 years at baseline (N=4926), of whom 3779 participated in 1 or more follow-up examinations.
   Methods: Stereoscopic photographs of the macula were graded to determine the presence of AMD. Existence of emphysema, asthma, and respiratory symptoms was determined from subjects' medical history questionnaires; the peak expiratory flow rate was measured using a Mini-Wright Peak Flow Meter (Clement Clarke International, Harlow, England). Discrete logistic hazard and logistic regression models were used.
   Main Outcome Measures: Incidence and progression of AMD.
   Results: While controlling for age, sex, and other factors, a history of emphysema at baseline was found to be associated with the 15-year cumulative incidence of increased retinal pigment (odds ratio, 2.08; 95% confidence interval, 1.06-4.06), retinal pigment epithelium depigmentation (2.40; 1.23-4.67), and exudative AMD (3.65; 1.24-10.73). Mild pulmonary symptoms were associated with the 5-year incidence of exudative AMD (odds ratio, 3.83; 95% confidence interval, 1.39-10.58), and the fourth (ie, highest) quartile of pulmonary expiratory flow rate showed a protective effect for progression of AMD among women (0.36; 0.15-0.86).
   Conclusion: Independent of smoking, a history of emphysema and respiratory symptoms and function are modestly but inconsistently associated with the incidence and progression of AMD.
C1 [Klein, Ronald; Knudtson, Michael D.; Klein, Barbara E. K.] Univ Wisconsin, Sch Med & Publ Hlth, Dept Ophthalmol & Visual Sci, Madison, WI 53726 USA.
C3 University of Wisconsin System; University of Wisconsin Madison
RP Klein, R (通讯作者)，Univ Wisconsin, Sch Med & Publ Hlth, Dept Ophthalmol & Visual Sci, 610 N Walnut St,417 WARF, Madison, WI 53726 USA.
EM kleinr@epi.ophth.wisc.edu
OI Klein, Ronald/0000-0002-4428-6237
FU NEI NIH HHS [EY06594, U10 EY006594] Funding Source: Medline
CR Ambati J, 2003, NAT MED, V9, P1390, DOI 10.1038/nm950
   Anderson DH, 2002, AM J OPHTHALMOL, V134, P411, DOI 10.1016/S0002-9394(02)01624-0
   [Anonymous], [No title captured]
   Anstey KJ, 1999, PSYCHOL AGING, V14, P605, DOI 10.1037/0882-7974.14.4.605
   Bok D, 2005, P NATL ACAD SCI USA, V102, P7053, DOI 10.1073/pnas.0502819102
   Castillo M, 2002, OPHTHALMIC RES, V34, P338, DOI 10.1159/000067050
   Crabb JW, 2002, P NATL ACAD SCI USA, V99, P14682, DOI 10.1073/pnas.222551899
   DELANEY WV, 1982, ANN OPHTHALMOL, V14, P21
   Despriet DDG, 2006, JAMA-J AM MED ASSOC, V296, P301, DOI 10.1001/jama.296.3.301
   Donoso LA, 2006, SURV OPHTHALMOL, V51, P137, DOI 10.1016/j.survophthal.2005.12.001
   DUBINA TL, 1984, EXP GERONTOL, V19, P133, DOI 10.1016/0531-5565(84)90016-0
   Hosmer DW., 1989, APPL LOGISTIC REGRES
   HYMAN LG, 1983, AM J EPIDEMIOL, V118, P213, DOI 10.1093/oxfordjournals.aje.a113629
   KAHN HA, 1977, AM J EPIDEMIOL, V106, P33, DOI 10.1093/oxfordjournals.aje.a112429
   KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868
   KILLINGSWORTH MC, 1990, EYE, V4, P613, DOI 10.1038/eye.1990.86
   Klein R, 1998, AM J EPIDEMIOL, V147, P103
   Klein R, 2005, AM J OPHTHALMOL, V140, P35, DOI 10.1016/j.ajo.2005.01.051
   Klein R, 1997, OPHTHALMOLOGY, V104, P7, DOI 10.1016/S0161-6420(97)30368-6
   Klein R, 2003, ARCH OPHTHALMOL-CHIC, V121, P674, DOI 10.1001/archopht.121.5.674
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Klein R, 2001, OPHTHALMOLOGY, V108, P1757, DOI 10.1016/S0161-6420(01)00769-2
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1310
   Klein R, 2005, AM J OPHTHALMOL, V140, P129, DOI 10.1016/j.ajo.2004.12.049
   Klein R, 1996, OPHTHALMOLOGY, V103, P1169, DOI 10.1016/S0161-6420(96)30526-5
   Klein R, 2002, OPHTHALMOLOGY, V109, P1767, DOI 10.1016/S0161-6420(02)01146-6
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   KLEIN R, 1995, BEAVER DAM EYE STUDY, V2
   KLEIN R, 1991, BEAVER DAM EYE STUDY
   KLEIN R, 1999, BEAVER DAM EYE STUDY, V3
   Klein R, 2007, OPHTHALMOLOGY, V114, P253, DOI 10.1016/j.ophtha.2006.10.040
   Klein R, 2006, AM J OPHTHALMOL, V142, P539, DOI 10.1016/j.ajo.2006.06.015
   Knudtson MD, 2006, ARCH OPHTHALMOL-CHIC, V124, P243, DOI 10.1001/archopht.124.2.243
   LINTON KLP, 1991, AM J EPIDEMIOL, V134, P1438, DOI 10.1093/oxfordjournals.aje.a116049
   Mousa SA, 1999, J CELL BIOCHEM, V74, P135, DOI 10.1002/(SICI)1097-4644(19990701)74:1<135::AID-JCB15>3.0.CO;2-#
   Mullins RF, 2000, FASEB J, V14, P835, DOI 10.1096/fasebj.14.7.835
   Penfold PL, 2001, PROG RETIN EYE RES, V20, P385, DOI 10.1016/S1350-9462(00)00025-2
   Schlingemann RO, 2004, GRAEF ARCH CLIN EXP, V242, P91, DOI 10.1007/s00417-003-0828-0
   Umeda S, 2005, FASEB J, V19, P1683, DOI 10.1096/fj.04-3525fje
   Wu KHC, 2007, INVEST OPHTH VIS SCI, V48, P1983, DOI 10.1167/iovs.06-0223
NR 40
TC 14
Z9 15
U1 0
U2 0
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 515 N STATE ST, CHICAGO, IL 60610-0946 USA
SN 0003-9950
J9 ARCH OPHTHALMOL-CHIC
JI Arch. Ophthalmol.
PD JUN
PY 2008
VL 126
IS 6
BP 840
EP 846
DI 10.1001/archopht.126.6.840
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 310RX
UT WOS:000256548900012
PM 18541850
OA Bronze
DA 2022-11-30
ER

PT J
AU Apte, RS
   Richter, J
   Herndon, J
   Ferguson, TA
AF Apte, Rajendra S.
   Richter, Jennifer
   Herndon, John
   Ferguson, Thomas A.
TI Macrophages inhibit neovascularization in a murine model of age-related
   macular degeneration
SO PLOS MEDICINE
LA English
DT Article
ID EXPERIMENTAL CHOROIDAL NEOVASCULARIZATION; SUBMACULAR SURGERY TRIALS;
   EPITHELIUM-DERIVED FACTOR; FACTOR-H POLYMORPHISM; PIGMENT EPITHELIUM;
   PHOTODYNAMIC THERAPY; FAS LIGAND; EPIDEMIOLOGY; PREVALENCE; LIPOSOMES
AB Background Age-related macular degeneration (AMD) is the leading cause of blindness in people over 50 y of age in at least three continents. Choroidal neovascularization (CNV) is the process by which abnormal blood vessels develop underneath the retina. CNV develops in 10% of patients with AMD but accounts for up to 90% of the blindness from AMD.
   Although the precise etiology of CNV in AMD remains unknown, the macrophage component of the inflammatory response, which has been shown to promote tumor growth and support atherosclerotic plaque formation, is thought to stimulate aberrant angiogenesis in blinding eye diseases. The current theory is that macrophage infiltration promotes the development of neovascularization in CNV.
   Methods and Findings We examined the role of macrophages in a mouse model of CNV. IL-10(-/-) mice, which have increased inflammation in response to diverse stimuli, have significantly reduced CNV with increased macrophage infiltrates compared to wild type. Prevention of macrophage entry into the eye promoted neovascularization while direct injection of macrophages significantly inhibited CNV. Inhibition by macrophages was mediated by the TNF family death molecule Fas ligand (CD95-ligand).
   Conclusions Immune vascular interactions can be highly complex. Normal macrophage function is critical in controlling pathologic neovascularization in the eye. IL-10 regulates macrophage activity in the eye and is an attractive therapeutic target in order to suppress or inhibit CNV in AMD that can otherwise lead to blindness.
C1 Washington Univ, Sch Med, Dept Ophthalmol, St Louis, MO 63110 USA.
C3 Washington University (WUSTL)
RP Apte, RS (通讯作者)，Washington Univ, Sch Med, Dept Ophthalmol, St Louis, MO 63110 USA.
EM apte@vision.wustl.edu; ferguson@vision.wustl.edu
RI Mohammed, Imran/J-8271-2012
OI Mohammed, Imran/0000-0002-8412-0768; Herndon, John/0000-0002-8378-9654
FU NEI NIH HHS [K08EY016139, R01 EY006765, EY06765, F32 EY006765, EY12826,
   EY08972, K08 EY016139, R01 EY012826] Funding Source: Medline; NIDDK NIH
   HHS [5 P60 DK20579, P60 DK020579] Funding Source: Medline; NATIONAL EYE
   INSTITUTE [K08EY016139, R01EY012826, R01EY008972] Funding Source: NIH
   RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY
   DISEASES [P60DK020579] Funding Source: NIH RePORTER
CR Adamis AP, 1996, ARCH OPHTHALMOL-CHIC, V114, P66, DOI 10.1001/archopht.1996.01100130062010
   Ambati J, 2003, NAT MED, V9, P1390, DOI 10.1038/nm950
   Apte RS, 2004, INVEST OPHTH VIS SCI, V45, P4491, DOI 10.1167/iovs.04-0172
   Blumenkranz MS, 2001, ARCH OPHTHALMOL-CHIC, V119, P198
   Bonastre J, 2002, Eur J Health Econ, V3, P94, DOI 10.1007/s10198-002-0104-y
   Brown SB, 1999, J IMMUNOL, V162, P480
   Campochiaro PA, 2006, HUM GENE THER, V17, P167, DOI 10.1089/hum.2006.17.167
   Diegelmann RF, 2004, FRONT BIOSCI-LANDMRK, V9, P283, DOI 10.2741/1184
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Espinosa-Heidmann DG, 2003, INVEST OPHTH VIS SCI, V44, P3586, DOI 10.1167/iovs.03-0038
   FERGUSON TA, 1994, J EXP MED, V179, P1597, DOI 10.1084/jem.179.5.1597
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Gomez CR, 2005, CURR OPIN IMMUNOL, V17, P457, DOI 10.1016/j.coi.2005.07.013
   GORDON EJ, 1995, J NEUROIMMUNOL, V62, P153, DOI 10.1016/0165-5728(95)00120-2
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Grossniklaus HE, 2006, AM J OPHTHALMOL, V141, P93, DOI 10.1016/j.ajo.2005.07.076
   Grossniklaus HE, 2005, ARCH OPHTHALMOL-CHIC, V123, P914
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Hansson GK, 2005, NEW ENGL J MED, V352, P1685, DOI 10.1056/NEJMra043430
   Hebert LE, 2003, ARCH NEUROL-CHICAGO, V60, P1119, DOI 10.1001/archneur.60.8.1119
   INABA K, 1992, J EXP MED, V176, P1693, DOI 10.1084/jem.176.6.1693
   Kaplan HJ, 1999, NAT MED, V5, P292, DOI 10.1038/6509
   Klein R, 2004, AM J OPHTHALMOL, V137, P486, DOI 10.1016/j.ajo.2003.11.069
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Krasnici S, 2003, INT J CANCER, V105, P561, DOI 10.1002/ijc.11108
   Kuo IC, 2000, INT OPHTHALMOL CLIN, V40, P111, DOI 10.1097/00004397-200004000-00009
   Lobov IB, 2005, NATURE, V437, P417, DOI 10.1038/nature03928
   Marmorstein AD, 2000, P NATL ACAD SCI USA, V97, P12758, DOI 10.1073/pnas.220402097
   MILLER JW, 1995, ARCH OPHTHALMOL-CHIC, V113, P810, DOI 10.1001/archopht.1995.01100060136048
   Miskala PH, 2004, ARCH OPHTHALMOL-CHIC, V122, P758, DOI 10.1001/archopht.122.5.758
   Moore KW, 2001, ANNU REV IMMUNOL, V19, P683, DOI 10.1146/annurev.immunol.19.1.683
   Mori K, 2002, INVEST OPHTH VIS SCI, V43, P1994
   Nakao S, 2005, J CLIN INVEST, V115, P2979, DOI 10.1172/JCI23298
   Papadimitriou E, 2000, J DRUG TARGET, V8, P335, DOI 10.3109/10611860008997910
   Park JE, 2004, AM J SURG, V187, p11S, DOI 10.1016/S0002-9610(03)00296-4
   Penfold PL, 2001, PROG RETIN EYE RES, V20, P385, DOI 10.1016/S1350-9462(00)00025-2
   Sakurai E, 2003, INVEST OPHTH VIS SCI, V44, P3578, DOI 10.1167/iovs.03-0097
   Taylor PR, 2005, ANNU REV IMMUNOL, V23, P901, DOI 10.1146/annurev.immunol.23.021704.115816
   van Leeuwen R, 2003, EUR J EPIDEMIOL, V18, P845, DOI 10.1023/A:1025643303914
   VanNewkirk MR, 2000, OPHTHALMOLOGY, V107, P2203, DOI 10.1016/S0161-6420(00)00459-0
   Wiley SR, 2001, IMMUNITY, V15, P837, DOI 10.1016/S1074-7613(01)00232-1
   2002, RETINA, V22, P6
NR 43
TC 190
Z9 205
U1 0
U2 9
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA
SN 1549-1277
J9 PLOS MED
JI PLos Med.
PD AUG
PY 2006
VL 3
IS 8
BP 1371
EP 1381
AR e310
DI 10.1371/journal.pmed.0030310
PG 11
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA 079YG
UT WOS:000240213200031
PM 16903779
OA Green Published, Green Submitted, gold
DA 2022-11-30
ER

PT J
AU Ho, J
   Jang, KH
   Koo, TS
   Park, C
   Kim, YH
   Lee, J
   Kim, E
AF Ho, Jeongmin
   Jang, Ki-Hong
   Koo, Tae-Sung
   Park, Changmin
   Kim, Young-Hoon
   Lee, Juhee
   Kim, Eunhee
TI Protective effects of PARP1-inhibitory compound in dry age-related
   macular degeneration
SO BIOMEDICINE & PHARMACOTHERAPY
LA English
DT Article
DE Dry AMD; PARP1; PARP1-inhibitory compound; RPE; Funduscopy;
   Electroretinogram
ID RETINAL-PIGMENT EPITHELIUM; SODIUM IODATE; GEOGRAPHIC ATROPHY; OXIDATIVE
   STRESS; POLY(ADP-RIBOSE) POLYMERASE; INDUCED APOPTOSIS; PARTHANATOS;
   MECHANISMS; PARP1; ACTIVATION
AB Poly (ADP-ribose) polymerase 1 (PARP1)-dependent cell death in the retinal pigment epithelium (RPE) is implicated in dry age-related macular degeneration (AMD). Although PARP1 inhibitors are available for treating dry AMD, their delivery route is not ideal for patients. The aim of this study was to test the efficacy of a novel PARP1-inhibitory compound (PIC) in vitro and in vivo. This study presents PIC, a novel small molecule, with superior efficacy to PARP1 inhibitors in the market. PIC demonstrated a distinctive inhibitory profile against PARP isotypes than the FDA-approved PARP1 inhibitors. PIC inhibited PARP1 activation at an IC50 of 0.41 +/- 0.15 nM in an enzyme-based assay in vitro and at IC50 and EC50 in ARPE-19 cells of 0.11 +/- 0.02 nM and 0.22 +/- 0.02 nM, respectively, upon H2O2 insult. PIC also moderated mitochondrial fission and depolarization and maintained cellular energy levels under oxidative stress in ARPE-19 cells. Furthermore, PIC demonstrated good corneal penetration in a rat model, presenting PIC as a promising candidate for eye drop therapeutics for dry AMD. When PIC was administered as an eye drop formulation, RPE morphology was preserved, maintaining the thickness of the outer nuclear layers under sodium iodate (SI) treatment in rats. In SI-treated rabbits, eye drop administration of PIC also retained the structural and functional integrity when analyzed using funduscopy and electroretinogram. Collectively, our data portray PIC as an attractive treatment measure for dry AMD.
C1 [Ho, Jeongmin; Jang, Ki-Hong; Kim, Eunhee] Chungnam Natl Univ, Dept Biol Sci, 99 Daehak Ro, Daejeon 34134, South Korea.
   [Koo, Tae-Sung] Chungnam Natl Univ, Grad Sch New Drug Discovery & Dev, Daejeon, South Korea.
   [Park, Changmin; Kim, Young-Hoon; Lee, Juhee] Kukjepharma R&D Ctr, Sanseong Ro 47, Ansan, Gyeonggi Do, South Korea.
C3 Chungnam National University; Chungnam National University
RP Kim, E (通讯作者)，Chungnam Natl Univ, Dept Biol Sci, 99 Daehak Ro, Daejeon 34134, South Korea.
EM eunhee@cnu.ac.kr
RI Jang, Ki-Hong/AAR-2399-2021
FU Bio & Medical Technology Development Program of the National Research
   Foundation (NRF) - Korean government (MSIP) [2017M3A9C8021844]
FX This work was supported by the Bio & Medical Technology Development
   Program of the National Research Foundation (NRF) funded by the Korean
   government (MSIP) (2017M3A9C8021844).
CR Ambati J, 2012, NEURON, V75, P26, DOI 10.1016/j.neuron.2012.06.018
   BAICH A, 1992, PIGM CELL RES, V5, P394, DOI 10.1111/j.1600-0749.1992.tb00568.x
   Bandello Francesco, 2017, F1000Res, V6, P245, DOI 10.12688/f1000research.10664.1
   Barkauskaite E, 2015, MOL CELL, V58, P935, DOI 10.1016/j.molcel.2015.05.007
   Basu B, 2012, DRUGS, V72, P1579, DOI 10.2165/11635510-000000000-00000
   Brunyanszki A, 2014, MOL PHARMACOL, V86, P450, DOI 10.1124/mol.114.094318
   Cai JY, 1999, INVEST OPHTH VIS SCI, V40, P959
   Carney B, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-017-02096-w
   Chakravarthy U, 2013, LANCET, V382, P1258, DOI 10.1016/S0140-6736(13)61501-9
   Cheung LK, 2013, PHARMACOTHERAPY, V33, P838, DOI 10.1002/phar.1264
   CLIFTON L, 1973, VISION RES, V13, P919, DOI 10.1016/0042-6989(73)90072-2
   Enzmann V, 2006, EXP EYE RES, V82, P441, DOI 10.1016/j.exer.2005.08.002
   Fatokun AA, 2014, BRIT J PHARMACOL, V171, P2000, DOI 10.1111/bph.12416
   Fletcher EL, 2014, OPTOMETRY VISION SCI, V91, P878, DOI 10.1097/OPX.0000000000000322
   Fong PC, 2009, NEW ENGL J MED, V361, P123, DOI 10.1056/NEJMoa0900212
   Gibson BA, 2012, NAT REV MOL CELL BIO, V13, P411, DOI 10.1038/nrm3376
   Greenwald SH, 2019, ADV EXP MED BIOL, V1185, P323, DOI 10.1007/978-3-030-27378-1_53
   Hanus J, 2016, CELL DEATH DISCOV, V2, DOI 10.1038/cddiscovery.2016.54
   Hanus J, 2015, AGEING RES REV, V24, P286, DOI 10.1016/j.arr.2015.09.002
   Jaffe GJ, 2015, AM J OPHTHALMOL, V160, P1226, DOI 10.1016/j.ajo.2015.08.024
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Jang KH, 2020, MOL CELLS, V43, P632, DOI 10.14348/molcells.2020.0078
   Jang KH, 2018, BBA-MOL CELL RES, V1865, P132, DOI 10.1016/j.bbamcr.2017.10.004
   Jang KH, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2016.437
   Kim JH, 2010, INVEST OPHTH VIS SCI, V51, P561, DOI 10.1167/iovs.09-3774
   Love S, 1999, BRAIN, V122, P247, DOI 10.1093/brain/122.2.247
   Luo X, 2012, GENE DEV, V26, P417, DOI 10.1101/gad.183509.111
   Machalinska A, 2010, NEUROCHEM RES, V35, P1819, DOI 10.1007/s11064-010-0248-6
   Mehta S, 2015, PRIMARY CARE, V42, P377, DOI 10.1016/j.pop.2015.05.009
   Mizota A, 1997, VISION RES, V37, P1859, DOI 10.1016/S0042-6989(97)00015-1
   Moja L, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD011230.pub2
   NILSSON SEG, 1977, ACTA OPHTHALMOL, V55, P994
   Patel HR, 2015, OSLI RETINA, V46, P8, DOI 10.3928/23258160-20150101-01
   Pennesi ME, 2012, MOL ASPECTS MED, V33, P487, DOI 10.1016/j.mam.2012.06.003
   ROBSON JG, 1995, VISUAL NEUROSCI, V12, P837, DOI 10.1017/S0952523800009408
   Smith S, 2001, TRENDS BIOCHEM SCI, V26, P174, DOI 10.1016/S0968-0004(00)01780-1
   Sparrrow JR, 2010, CURR MOL MED, V10, P802
   TIAN N, 1995, VISION RES, V35, P1359, DOI 10.1016/0042-6989(95)98715-L
   Wang XZ, 2020, NEUROSCIENCE, V449, P241, DOI 10.1016/j.neuroscience.2020.09.049
   Wong WT, 2010, INVEST OPHTH VIS SCI, V51, P6131, DOI 10.1167/iovs.10-5637
   Yelamos J, 2011, AM J CANCER RES, V1, P328
   Yu CS, 2016, CELL DEATH DIFFER, V23, P1873, DOI 10.1038/cdd.2016.99
   Zhou P, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0098275
NR 43
TC 2
Z9 2
U1 1
U2 3
PU ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER
PI ISSY-LES-MOULINEAUX
PA 65 RUE CAMILLE DESMOULINS, CS50083, 92442 ISSY-LES-MOULINEAUX, FRANCE
SN 0753-3322
EI 1950-6007
J9 BIOMED PHARMACOTHER
JI Biomed. Pharmacother.
PD JAN
PY 2021
VL 133
AR 111041
DI 10.1016/j.biopha.2020.111041
PG 11
WC Medicine, Research & Experimental; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine; Pharmacology & Pharmacy
GA PN6JO
UT WOS:000604583500001
PM 33378949
OA gold
DA 2022-11-30
ER

PT J
AU Yoshida, H
   Matsushita, T
   Kimura, E
   Fujita, Y
   Keany, R
   Ikeda, T
   Toshimori, M
   Imanaka, T
   Nakamura, M
AF Yoshida, Hiroyuki
   Matsushita, Tokiyoshi
   Kimura, Erika
   Fujita, Yukie
   Keany, Robert
   Ikeda, Toshihiro
   Toshimori, Masanao
   Imanaka, Takahiro
   Nakamura, Masatsugu
TI Systemic expression of Alu RNA in patients with geographic atrophy
   secondary to age-related macular degeneration
SO PLOS ONE
LA English
DT Article
ID FACTOR-H POLYMORPHISM; PROGRESSION; DISEASE
AB Geographic atrophy (GA) secondary to age-related macular degeneration (AMD) is characterized by irreversible loss of macular retinal tissue and retinal pigment epithelium (RPE) cells. Several studies have revealed that accumulation of Alu RNA in RPE cell causes RPE cell degeneration in AMD. In the present study, systemic Alu RNA expression levels were determined in 33 subjects with GA and 40 control subjects using a proprietary Alu RNA quantification method. It was observed that the expression level of Alu RNA was not significantly different between GA and Control groups (median = 21.3 in both GA and Control groups, P = 0.251). In addition, the systemic level of Alu RNA was not associated with subject characteristics, such as GA lesion size and SNP profiles of complement factors associated with increased risk of AMD. In conclusion, the usability of systemic Alu RNA expression level as a biomarker of GA secondary to AMD could not be established in this study.
C1 [Yoshida, Hiroyuki; Matsushita, Tokiyoshi; Kimura, Erika; Fujita, Yukie; Ikeda, Toshihiro; Toshimori, Masanao; Imanaka, Takahiro; Nakamura, Masatsugu] Santen Pharmaceut Co Ltd, Res & Dev Div, Osaka, Japan.
   [Keany, Robert] Santen Inc, Res & Dev Div, Emeryville, CA USA.
C3 Santen Pharmaceutical Co Ltd
RP Yoshida, H (通讯作者)，Santen Pharmaceut Co Ltd, Res & Dev Div, Osaka, Japan.
EM hiroyuki.yoshida@santen.com
OI Toshimori, Masanao/0000-0003-3869-7790; Yoshida,
   Hioryuki/0000-0002-2578-0782
FU Santen Pharmaceutical Co., Ltd.; Santen Inc.
FX This study was funded by Santen Pharmaceutical Co., Ltd. and Santen Inc.
   HY, TM, EK, YF, TI, MT, TI, and MN are employed by Santen Pharmaceutical
   Co., Ltd. RK is employed by Santen Inc. The funders provided support in
   the form of salary for the all the authors but did not have any
   additional role in the study design, data collection and analysis,
   decision to publish, or preparation of the manuscript. The specific
   roles of this author are mentioned in the "Author Contributions"
   section.
CR Ardeljan D, 2013, PROG RETIN EYE RES, V37, P68, DOI 10.1016/j.preteyeres.2013.07.003
   Black JRM, 2016, GENET MED, V18, P283, DOI 10.1038/gim.2015.70
   Boyer DS, 2017, RETINA-J RET VIT DIS, V37, P819, DOI 10.1097/IAE.0000000000001392
   Campagne MV, 2014, J PATHOL, V232, P151, DOI 10.1002/path.4266
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Hasler J, 2007, NUCLEIC ACIDS RES, V35, P1389, DOI 10.1093/nar/gkm044
   Holz FG, 2018, JAMA OPHTHALMOL, V136, P666, DOI 10.1001/jamaophthalmol.2018.1544
   Kaneko H, 2011, NATURE, V471, P325, DOI 10.1038/nature09830
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Klein R, 2008, AM J OPHTHALMOL, V146, P692, DOI 10.1016/j.ajo.2008.05.050
   Lindblad AS, 2009, ARCH OPHTHALMOL-CHIC, V127, P1168, DOI 10.1001/archophthalmol.2009.198
   Rosenfeld PJ, 2018, OPHTHALMOLOGY, V125, P1556, DOI 10.1016/j.ophtha.2018.03.059
   Schmitz-Valckenberg S, 2016, OPHTHALMOLOGY, V123, P361, DOI 10.1016/j.ophtha.2015.09.036
   Tarallo V, 2012, CELL, V149, P847, DOI 10.1016/j.cell.2012.03.036
   Yan YQ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0080029
   Yehoshua Z, 2015, OSLI RETINA, V46, P772, DOI 10.3928/23258160-20150730-15
NR 19
TC 2
Z9 2
U1 0
U2 0
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD AUG 19
PY 2019
VL 14
IS 8
AR e0220887
DI 10.1371/journal.pone.0220887
PG 10
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA IW5MK
UT WOS:000485022400018
PM 31425537
OA Green Published, gold, Green Submitted
DA 2022-11-30
ER

PT J
AU Nakamura, T
   Miyakoshi, A
   Fujita, K
   Yunoki, T
   Mitarai, K
   Yanagisawa, S
   Fuchizawa, C
   Hayashi, A
AF Nakamura, Tomoko
   Miyakoshi, Akio
   Fujita, Kazuya
   Yunoki, Tatsuya
   Mitarai, Keiichi
   Yanagisawa, Shuichiro
   Fuchizawa, Chiharu
   Hayashi, Atsushi
TI One-Year Results of Photodynamic Therapy Combined with Intravitreal
   Ranibizumab for Exudative Age-Related Macular Degeneration
SO JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID INNER/OUTER SEGMENT JUNCTION; OPTICAL COHERENCE IMAGES; SUBGROUP
   ANALYSIS; VISUAL RECOVERY; VERTEPORFIN; COMBINATION; EFFICACY; MARINA
AB Purpose. To evaluate the effects of photodynamic therapy (PDT) combined with intravitreal injection of ranibizumab (IVR) for exudative age-related macular degeneration (AMD). Methods. Retrospective case series. Thirty eight eyes of 38 patients with exudative AMD underwent combined therapy consisting first of IVR, followed by PDT within a week and the second IVR at 1 month. All patients were followed up for more than 12 months. The best corrected visual acuity (BCVA) and central macular thickness (CMT) were examined. Results. The mean number of IVR and PDT sessions were 2.9 +/- 1.3 and 1.1 +/- 0.3, respectively. The mean BCVA and CMT were significantly improved to 0.38 logMAR units (P < 0.01) and 240 mu m (P < 0.01) at 12 months, respectively. Thirty-six of 38 eyes (94.8%) improved or maintained BCVA at 12 months. Conclusion. PDT combined with IVR for exudative AMD was effective at improving visual acuity and CMT with a low recurrence rate for 12 months.
C1 [Nakamura, Tomoko; Miyakoshi, Akio; Fujita, Kazuya; Yunoki, Tatsuya; Mitarai, Keiichi; Yanagisawa, Shuichiro; Fuchizawa, Chiharu; Hayashi, Atsushi] Toyama Univ, Grad Sch Med & Pharmaceut Sci, Dept Ophthalmol, Toyama 9300194, Japan.
C3 University of Toyama
RP Hayashi, A (通讯作者)，Toyama Univ, Grad Sch Med & Pharmaceut Sci, Dept Ophthalmol, 2630 Sugitani, Toyama 9300194, Japan.
EM ahayashi@med.u-toyama.ac.jp
CR Arias L, 2005, BRIT J OPHTHALMOL, V89, P312, DOI 10.1136/bjo.2004.050997
   Baba T, 2008, RETINA-J RET VIT DIS, V28, P453, DOI 10.1097/IAE.0b013e3181571398
   Boyer DS, 2007, OPHTHALMOLOGY, V114, P246, DOI 10.1016/j.ophtha.2006.10.045
   Dadgostar H, 2009, OPHTHALMOLOGY, V116, P1740, DOI 10.1016/j.ophtha.2009.05.033
   Heier JS, 2006, ARCH OPHTHALMOL-CHIC, V124, P1532, DOI 10.1001/archopht.124.11.1532
   Husain D, 2005, ARCH OPHTHALMOL-CHIC, V123, P509, DOI 10.1001/archopht.123.4.509
   Iriyama A, 2008, GRAEF ARCH CLIN EXP, V246, P339, DOI 10.1007/s00417-007-0667-5
   Kaiser PK, 2007, AM J OPHTHALMOL, V144, P850, DOI 10.1016/j.ajo.2007.08.012
   Kaiser PK, 2007, OPHTHALMOLOGY, V114, P1868, DOI 10.1016/j.ophtha.2007.04.030
   Kaiser PK, 2009, OPHTHALMOLOGY, V116, P747, DOI 10.1016/j.ophtha.2008.12.057
   Kitaya N, 2004, AM J OPHTHALMOL, V138, P308, DOI 10.1016/j.ajo.2004.03.004
   Kumar A, 2008, RETINA-J RET VIT DIS, V28, P1296, DOI 10.1097/IAE.0b013e3181814482
   Kvanta A, 1996, INVEST OPHTH VIS SCI, V37, P1929
   Lai TYY, 2004, AM J OPHTHALMOL, V137, P826, DOI 10.1016/j.ajo.2003.11.079
   Mataix J, 2010, RETINA-J RET VIT DIS, V30, P1190, DOI 10.1097/IAE.0b013e3181d2f172
   Michels S, 2006, INVEST OPHTH VIS SCI, V47, P371, DOI 10.1167/iovs.05-0354
   Mitamura Y, 2009, BRIT J OPHTHALMOL, V93, P171, DOI 10.1136/bjo.2008.146381
   Moutray T, 2008, BRIT J OPHTHALMOL, V92, P361, DOI 10.1136/bjo.2007.123976
   Sato T, 2010, AM J OPHTHALMOL, V149, P947, DOI 10.1016/j.ajo.2009.12.038
   Schmidt-Erfurth U, 2003, INVEST OPHTH VIS SCI, V44, P4473, DOI 10.1167/iovs.02-1115
   Spielberg L, 2010, GRAEF ARCH CLIN EXP, V248, P943, DOI 10.1007/s00417-009-1256-6
   Tzekov R, 2006, INVEST OPHTH VIS SCI, V47, P377, DOI 10.1167/iovs.05-0838
   Zarbin MA, 2004, ARCH OPHTHALMOL-CHIC, V122, P598, DOI 10.1001/archopht.122.4.598
NR 23
TC 3
Z9 3
U1 0
U2 1
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 2090-004X
EI 2090-0058
J9 J OPHTHALMOL
JI J. Ophthalmol.
PY 2012
VL 2012
AR 154659
DI 10.1155/2012/154659
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 979CD
UT WOS:000306791600001
PM 22174997
OA gold, Green Published, Green Submitted
DA 2022-11-30
ER

PT J
AU Balatsoukas, DD
   Tsaousis, KT
   Boboridis, KG
   Konstas, AG
   Topouzis, F
AF Balatsoukas, Dionysis D.
   Tsaousis, Konstantinos T.
   Boboridis, Konstadinos G.
   Konstas, Anastasios G.
   Topouzis, Fotis
TI Emerging Treatment Modalities for Neovascular Age-Related Macular
   Degeneration: A Systematic Overview
SO ADVANCES IN THERAPY
LA English
DT Review
DE Anti-vascular endothelial growth factors (VEGF); nAMD therapy;
   Neovascular age-related macular degeneration
ID ENDOTHELIAL GROWTH-FACTOR; ABICIPAR PEGOL; GENE-THERAPY; REAL-WORLD;
   DISEASE BURDEN; OPEN-LABEL; FOLLOW-UP; PHASE-1; VEGF; RANIBIZUMAB
AB Introduction Neovascular age-related macular degeneration (nAMD) represents a leading cause of irreversible visual loss affecting the quality of life of millions of elderly patients worldwide. Although the introduction of intravitreal injections with anti-vascular endothelial growth factors (anti-VEGF) agents has revolutionized the management of nAMD, their effectiveness and ultimate success are limited by several therapeutic challenges. Consequently, real-world efficacy appears significantly inferior to that reported by randomized controlled trials. Therefore, further innovative, long-term treatment options are essential to improve the prognosis and outcome of nAMD therapy. Methods Emerging pharmacological therapies for nAMD and those currently in clinical trials are reviewed and their mechanism of action, safety, and efficacy are discussed. The evidence presented herein has been collected from online databases PubMed, Cochrane library, and the ClinicalTrials.gov site. Results A number of promising technologies and novel anti-VEGF therapies are currently being tested and some have already reached phase III trials. Anti-VEGF agents with enhanced durability and possibly efficacy, gene therapy, angiogenic targets, alternative drug delivery routes such as sustained delivery implants, drug carriers, and encapsulated cell technology are currently being explored. We briefly discuss the potential value of these options. Conclusion Several options may optimize future nAMD management. On the basis of current, albeit limited evidence, the most promising technology to reach clinical practice soon appears to be the sustained drug delivery options, which may improve visual outcome and reduce the socioeconomic burden of nAMD.
C1 [Balatsoukas, Dionysis D.; Boboridis, Konstadinos G.; Konstas, Anastasios G.; Topouzis, Fotis] Aristotle Univ Thessaloniki, Univ Dept Ophthalmol 1, Thessaloniki, Greece.
   [Tsaousis, Konstantinos T.] Gen Hosp Volos, Volos, Greece.
   [Boboridis, Konstadinos G.; Konstas, Anastasios G.] Aristotle Univ Thessaloniki, Univ Dept Ophthalmol 3, Thessaloniki, Greece.
C3 Aristotle University of Thessaloniki; Aristotle University of
   Thessaloniki
RP Konstas, AG (通讯作者)，Aristotle Univ Thessaloniki, Univ Dept Ophthalmol 1, Thessaloniki, Greece.; Konstas, AG (通讯作者)，Aristotle Univ Thessaloniki, Univ Dept Ophthalmol 3, Thessaloniki, Greece.
EM agkonstas@gmail.com
CR Abbey AM, 2019, RETINA SPECIALIST, V5, P38
   Al-Khersan H, 2019, EXPERT OPIN PHARMACO, V20, P1879, DOI 10.1080/14656566.2019.1636031
   Ambati J, 2012, NEURON, V75, P26, DOI 10.1016/j.neuron.2012.06.018
   [Anonymous], 2018, CLN0046
   [Anonymous], 2018, AAVCAGSCD59 TREATMEN
   [Anonymous], 2018, OPHTHOTECH ANNOUNCES
   [Anonymous], 2020, REGENXBIO ANN ADD PO
   [Anonymous], 2020, ROCHE PHASE 3 DATA S
   [Anonymous], 2019, STUDY ASSESS EFFICAC
   [Anonymous], 2015, SAFETY EFFICACY STUD
   [Anonymous], STUDY EVALUATE EFFIC
   [Anonymous], 2020, RET SOC ANN M AUG 25
   [Anonymous], 2017, SAFETY TOLERABILITY
   [Anonymous], 2015, SAFETY EFFICACY ABIC
   [Anonymous], 2018, STUDY EVALUATE ABICI
   [Anonymous], 2012, SAFETY EFFICACY INTR
   [Anonymous], 2019, OPHTH INN SUMM OCT 1
   [Anonymous], 2020, STUDY COMP SB11 PROP
   [Anonymous], 2013, PHASE 1 STUDY TOPICA
   Baldwin M., 2019, PHASE 2B CLIN RESULT
   Binley K, 2012, HUM GENE THER, V23, P980, DOI 10.1089/hum.2012.008
   Bressler NM, 2011, ARCH OPHTHALMOL-CHIC, V129, P709, DOI 10.1001/archophthalmol.2011.140
   Busse A, 2019, BREAST CARE, V14, P10, DOI 10.1159/000496834
   Callanan D, 2018, J OCUL PHARMACOL TH, V34, P700, DOI 10.1089/jop.2018.0062
   Campochiaro PA, 2019, OPHTHALMOLOGY, V126, P1141, DOI 10.1016/j.ophtha.2019.03.036
   Campochiaro PA, 2017, HUM GENE THER, V28, P99, DOI 10.1089/hum.2016.117
   Carrasco J, 2020, ADV THER, V37, P300, DOI 10.1007/s12325-019-01147-6
   Cashman SM, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019078
   Chen ER, 2020, CLIN OPHTHALMOL, V14, P1349, DOI 10.2147/OPTH.S194234
   Ciulla TA, 2020, OPHTHALMOL RETINA, V4, P19, DOI 10.1016/j.oret.2019.05.017
   Ciulla TA, 2018, OPHTHALMOL RETINA, V2, P645, DOI 10.1016/j.oret.2018.01.006
   Colijn JM, 2017, OPHTHALMOLOGY, V124, P1753, DOI 10.1016/j.ophtha.2017.05.035
   Constable IJ, 2017, AM J OPHTHALMOL, V177, P150, DOI 10.1016/j.ajo.2017.02.018
   Constable IJ, 2016, EBIOMEDICINE, V14, P168, DOI 10.1016/j.ebiom.2016.11.016
   Cousins SW, 2010, INVEST OPHTH VIS SCI, V51
   de Guimaraes TAC., 2020, BRIT J OPHTHALMOL, V2, P1
   Ding K, 2019, J CLIN INVEST, V129, P4901, DOI 10.1172/JCI129085
   Dugel PU, 2020, OPHTHALMOL RETINA, V4, P250, DOI 10.1016/j.oret.2019.10.008
   Dugel PU, 2020, OPHTHALMOLOGY, V127, P72, DOI 10.1016/j.ophtha.2019.04.017
   DUGEL PU, 2020, OPHTHALMOLOGY
   Desideri LF, 2020, EXPERT OPIN INV DRUG, V29, P651, DOI 10.1080/13543784.2020.1772754
   Garcia-Layana A, 2017, CLIN INTERV AGING, V12, P1579, DOI 10.2147/CIA.S142685
   Gonzales CR, 2017, INVEST OPHTH VIS SCI, V58
   Grishanin R, 2019, MOL THER, V27, P118, DOI 10.1016/j.ymthe.2018.11.003
   Heier J, 2019, AM ACAD OPHTHALMOLOG
   Heier JS, 2017, LANCET, V390, P50, DOI 10.1016/S0140-6736(17)30979-0
   Hsu J, 2020, OPHTHALMOLOGY, V127, P1189, DOI 10.1016/j.ophtha.2020.03.034
   Hussain RM, 2019, EXPERT OPIN INV DRUG, V28, P861, DOI 10.1080/13543784.2019.1667333
   Jeffords E., 2019, OIS ASRS
   Khanani AM, 2020, JAMA OPHTHALMOL, V138, P964, DOI 10.1001/jamaophthalmol.2020.2699
   KHURANA RN, 2020, OPHTHALMOLOGY
   Krebs I, 2013, BRIT J OPHTHALMOL, V97, P1443, DOI 10.1136/bjophthalmol-2013-303513
   Kunimoto D, 2020, OPHTHALMOLOGY, V127, P1331, DOI 10.1016/j.ophtha.2020.03.035
   Kunimoto D, 2019, OSLI RETINA, V50, pE10, DOI 10.3928/23258160-20190129-13
   Kwak N, 2000, INVEST OPHTH VIS SCI, V41, P3158
   Liu K, 2019, AM J OPHTHALMOL, V197, P156, DOI 10.1016/j.ajo.2018.08.026
   Mandal A, 2020, BIOENG TRANSL MED, V5, DOI 10.1002/btm2.10158
   Opthea, WET AMD TRIALS PHAS
   Park D, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01133
   Pravin U., 2020, RETINAL PHYS, V17, P16
   Prenner JL, 2015, AM J OPHTHALMOL, V160, P725, DOI 10.1016/j.ajo.2015.06.023
   Nguyen QD, 2020, OPHTHALMOLOGY, V127, P963, DOI 10.1016/j.ophtha.2019.12.031
   Raica M, 2010, PHARMACEUTICALS, V3, P572, DOI 10.3390/ph3030572
   Rakoczy EP, 2019, AM J OPHTHALMOL, V204, P113, DOI 10.1016/j.ajo.2019.03.006
   Rakoczy EP, 2015, LANCET, V386, P2395, DOI 10.1016/S0140-6736(15)00345-1
   Regillo CD, 2020, AM AC OPHTH VIRT M 1
   Rodrigues GA, 2018, PHARM RES-DORDR, V35, DOI 10.1007/s11095-018-2519-x
   Sahni J, 2020, JAMA OPHTHALMOL, V138, P955, DOI 10.1001/jamaophthalmol.2020.2685
   Samanta A, 2020, ASIA-PAC J OPHTHALMO, V9, P250, DOI 10.1097/APO.0000000000000291
   Sharma A, 2020, BRIT J OPHTHALMOL, V104, P2, DOI 10.1136/bjophthalmol-2019-314443
   Sharma A, 2018, CLIN OPHTHALMOL, V12, P2137, DOI 10.2147/OPTH.S180393
   Sharma S, 2020, OPHTHALMOL THER, V9, P103, DOI 10.1007/s40123-019-00228-7
   Souied EH, 2014, AM J OPHTHALMOL, V158, P724, DOI 10.1016/j.ajo.2014.05.037
   Spooner KL, 2018, CLIN OPHTHALMOL, V12, P2483, DOI 10.2147/OPTH.S185052
   Wang Q, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0070544
   Wells JA, 2018, OSLI RETINA, V49, P336, DOI 10.3928/23258160-20180501-07
   Wong CW, 2019, BRIT J OPHTHALMOL, V103, P14, DOI 10.1136/bjophthalmol-2018-313462
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Wu JL, 2019, DRUG DES DEV THER, V13, P2413, DOI 10.2147/DDDT.S206355
   Yannuzzi NA, 2019, CLIN OPHTHALMOL, V13, P1323, DOI 10.2147/OPTH.S184706
NR 80
TC 0
Z9 0
U1 2
U2 5
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 0741-238X
EI 1865-8652
J9 ADV THER
JI Adv. Ther.
PD JAN
PY 2022
VL 39
IS 1
BP 5
EP 32
DI 10.1007/s12325-021-01949-7
EA NOV 2021
PG 28
WC Medicine, Research & Experimental; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine; Pharmacology & Pharmacy
GA YO9TI
UT WOS:000713579400001
PM 34724151
DA 2022-11-30
ER

EF